FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Liu, WJ
   Xie, G
   Yuan, GX
   Xie, DT
   Lian, Z
   Lin, ZH
   Ye, JJ
   Zhou, WY
   Zhou, WJ
   Li, HH
   Wang, XJ
   Feng, HT
   Liu, Y
   Yao, GF
AF Liu, Wenjie
   Xie, Gang
   Yuan, Guixin
   Xie, Dantao
   Lian, Zhen
   Lin, Zihong
   Ye, Jiajie
   Zhou, Wenyun
   Zhou, Weijun
   Li, Henghui
   Wang, Xinjia
   Feng, Haotian
   Liu, Ying
   Yao, Guanfeng
TI 6′ O Galloylpaeoniflorin Attenuates Osteoclasto genesis and Relieves
   Ovariectomy Induced Osteoporosis by Inhibiting Reactive Oxygen Species
   and MAPKs/c Fos/NFATc1 Signaling Pathway
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE 6&#8242;  O galloylpaeoniflorin; osteoporosis; osteoclast; MAPKs;
   NFATc1; reactive oxygen species
AB Emerging evidence suggests bright prospects of some natural antioxidants in the treatment of osteoporosis. 6 ' O Galloylpaeoniflorin (GPF), an antioxidant isolated from peony roots (one of very widely used Oriental medicines, with various anti inflammatory, antitumor, and antioxidant activities), shows a series of potential clinical applications. However, its effects on osteoporosis remain poorly investigated. The current study aimed to explore whether GPF can attenuate osteoclastogenesis and relieve ovariectomy induced osteoporosis via attenuating reactive oxygen species (ROS), and investigate the possible mechanism. After the culture of primary murine bone marrow derived macrophages/monocytes were induced by the use of macrophage colony stimulating factor (M CSF) and the receptor activator of NF kappa B ligand (RANKL) and then treated with GPF. Cell proliferation and viability were assessed by Cell Counting Kit 8 (CCK 8) assay. Thereafter, the role of GPF in the production of osteoclasts and the osteogenic resorption of mature osteoclasts were evaluated by tartrate resistant acid phosphatase (TRAP) staining, podosome belt formation, and resorption pit assay. Western blotting and qRT PCR examination were performed to evaluate proteins' generation and osteoclast specific gene levels, respectively. The ROS generation in cells was measured in vitro by 2 ',7 ' Dichlorodi hydrofluorescein diacetate (DCFH DA). Ovariectomy induced osteoporosis mouse administered with GPF or vehicle was performed to explore the in vivo potential of GPF, then a micro CT scan was performed in combination with histological examination for further analysis. GPF suppressed the formation of osteoclasts and podosome belts, as well as bone resorption when induced by RANKL through affecting intracellular ROS activity, MAPKs signaling pathway, and subsequent NFATc1 translocation and expression, as well as osteoclast specific gene expression in vitro. In vivo study suggested that exposure to GPF prevented osteoporosis related bone loss in the ovariectomized mice. These findings indicate that GPF attenuates osteoclastogenesis and relieves ovariectomy induced osteoporosis by inhibiting ROS and MAPKs/c Fos/NFATc1 signaling pathway. This suggested that GPF may be potentially used to treat bone diseases like periodontitis, rheumatoid arthritis, and osteoporosis associated with osteoclasts.
C1 [Liu, Wenjie; Xie, Gang; Yuan, Guixin; Xie, Dantao; Lian, Zhen; Lin, Zihong; Ye, Jiajie; Zhou, Wenyun; Zhou, Weijun; Wang, Xinjia; Yao, Guanfeng] Shantou Univ, Coll Med, Affiliated Hosp 2, Dept Orthoped, Shantou, Peoples R China.
   [Li, Henghui; Liu, Ying] Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China.
   [Feng, Haotian] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Peoples R China.
   [Feng, Haotian] Guangxi Med Univ, Guangxi Collaborat Innovat Ctr Biomed, Nanning, Peoples R China.
   [Feng, Haotian] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
C3 Shantou University; Shanghai University; Guangxi Medical University;
   Guangxi Medical University; University of Western Australia
RP Yao, GF (通讯作者)，Shantou Univ, Coll Med, Affiliated Hosp 2, Dept Orthoped, Shantou, Peoples R China.; Liu, Y (通讯作者)，Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China.
EM liuchanger1984@163.com; gfyao@stu.edu.cn
RI Yao, Guanfeng/JPA 5741 2023
FU Guangdong Basic and Applied Basic Research Foundation [2018A030307025];
   Scientific research Program of Guangdong Bureau of Traditional Chinese
   Medicine [20201178]
FX This work was supported by grants from Guangdong Basic and Applied Basic
   Research Foundation (NO. 2018A030307025). Sponsored by Scientific
   research Program of Guangdong Bureau of Traditional Chinese Medicine
   (NO. 20201178).
CR Amcheslavsky A, 2007, J BONE MINER RES, V22, P1301, DOI 10.1359/JBMR.070501
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006 291X(05)80311 0
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Calabrese EJ, 2020, AGEING RES REV, V64, DOI 10.1016/j.arr.2020.101019
   Calabrese V, 2010, ANTIOXID REDOX SIGN, V13, P1763, DOI 10.1089/ars.2009.3074
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Datta Mannan A, 2019, DRUG METAB DISPOS, V47, P1100, DOI 10.1124/dmd.119.086488
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Gao JY, 2020, RESP RES, V21, DOI 10.1186/s12931 020 1277 6
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Jiao ZX, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16853 w
   KANG S S, 1991, Archives of Pharmacal Research (Seoul), V14, P52, DOI 10.1007/BF02857815
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Koo YK, 2010, PHARMAZIE, V65, P624, DOI 10.1691/ph.2010.9870
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01023
   Liao FY, 2018, J CHROMATOGR B, V1092, P320, DOI 10.1016/j.jchromb.2018.06.027
   Liao FY, 2018, TALANTA, V179, P490, DOI 10.1016/j.talanta.2017.11.018
   Lim SY, 2017, DRUG DES DEV THER, V11, P1221, DOI 10.2147/DDDT.S127568
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Lu YJ, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/6150357
   Ma JJ, 2015, BIOCHEM J, V469, P399, DOI 10.1042/BJ20150151
   Matsuda H, 2001, CHEM PHARM BULL, V49, P69, DOI 10.1248/cpb.49.69
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Okubo T, 2000, BIOL PHARM BULL, V23, P199, DOI 10.1248/bpb.23.199
   Pang MH, 2019, J CELL BIOCHEM, V120, P12382, DOI 10.1002/jcb.28504
   Park H, 2015, ANTIOXID REDOX SIGN, V22, P63, DOI 10.1089/ars.2013.5748
   Pazianas M, 2016, ANN NY ACAD SCI, V1376, P5, DOI 10.1111/nyas.13166
   Rivero Buceta E, 2015, EUR J MED CHEM, V92, P656, DOI 10.1016/j.ejmech.2015.01.033
   Shi YH, 2016, FITOTERAPIA, V108, P55, DOI 10.1016/j.fitote.2015.11.011
   Silva MM, 2002, FREE RADICAL RES, V36, P1219, DOI 10.1080/198 1071576021000016472
   Song WH, 2014, J NAT PROD, V77, P42, DOI 10.1021/np400571x
   Taguri T, 2006, BIOL PHARM BULL, V29, P2226, DOI 10.1248/bpb.29.2226
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Torres M, 2003, FRONT BIOSCI, V8, pD369, DOI 10.2741/999
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wagner EF, 2003, ANN RHEUM DIS, V62, P83, DOI 10.1136/ard.62.suppl_2.ii83
   Wang J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01175
   Wen ZM, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8678267
   Yao CW, 2013, BIOMOL THER, V21, P349, DOI 10.4062/biomolther.2013.064
   Zheng JH, 2018, CANCERS, V10, DOI 10.3390/cancers10110461
NR 61
TC 18
Z9 20
U1 0
U2 26
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD APR 7
PY 2021
VL 12
AR 641277
DI 10.3389/fphar.2021.641277
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA RP4RC
UT WOS:000641715800001
PM 33897430
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Huynh, NCN
   Ling, R
   Komagamine, M
   Shi, TS
   Tsukasaki, M
   Matsuda, K
   Okamoto, K
   Asano, T
   Muro, R
   Pluemsakunthai, W
   Kollias, G
   Kaneko, Y
   Takeuchi, T
   Tanaka, S
   Komatsu, N
   Takayanagi, H
AF Huynh, Nam Cong Nhat
   Ling, Rui
   Komagamine, Masatsugu
   Shi, Tianshu
   Tsukasaki, Masayuki
   Matsuda, Kotaro
   Okamoto, Kazuo
   Asano, Tatsuo
   Muro, Ryunosuke
   Pluemsakunthai, Warunee
   Kollias, George
   Kaneko, Yuko
   Takeuchi, Tsutomu
   Tanaka, Sakae
   Komatsu, Noriko
   Takayanagi, Hiroshi
TI Oncostatin M driven macrophage fibroblast circuits as a drug target in
   autoimmune arthritis
SO INFLAMMATION AND REGENERATION
LA English
DT Article
DE Rheumatoid arthritis; JAK inhibitor; Macrophage; Synovial fibroblast;
   Drug target
ID LEUKEMIA INHIBITORY FACTOR; IN VITRO; EXPRESSION; GENES; RESPONSES; TNF
AB BackgroundRecent single cell RNA sequencing (scRNA seq) analysis revealed the functional heterogeneity and pathogenic cell subsets in immune cells, synovial fibroblasts and bone cells in rheumatoid arthritis (RA). JAK inhibitors which ameliorate joint inflammation and bone destruction in RA, suppress the activation of various types of cells in vitro. However, the key cellular and molecular mechanisms underlying the potent clinical effects of JAK inhibitors on RA remain to be determined. Our aim is to identify a therapeutic target for JAK inhibitors in vivo.MethodsWe performed scRNA seq analysis of the synovium of collagen induced arthritis (CIA) mice treated with or without a JAK inhibitor, followed by a computational analysis to identify the drug target cells and signaling pathways. We utilized integrated human RA scRNA seq datasets and genetically modified mice administered with the JAK inhibitor for the confirmation of our findings.ResultsscRNA seq analysis revealed that oncostatin M (OSM) driven macrophage fibroblast interaction is highly activated under arthritic conditions. OSM derived from macrophages, acts on OSM receptor (OSMR) expressing synovial fibroblasts, activating both inflammatory and tissue destructive subsets. Inflammatory synovial fibroblasts stimulate macrophages, mainly through IL 6, to exacerbate inflammation. Tissue destructive synovial fibroblasts promote osteoclast differentiation by producing RANKL to accelerate bone destruction. scRNA seq analysis also revealed that OSM signaling in synovial fibroblasts is the main signaling pathway targeted by JAK inhibitors in vivo. Mice specifically lacking OSMR in synovial fibroblasts (Osmr triangle Fibro) displayed ameliorated inflammation and joint destruction in arthritis. The JAK inhibitor was effective on the arthritis of the control mice while it had no effect on the arthritis of Osmr triangle Fibro mice.ConclusionsOSM functions as one of the key cytokines mediating pathogenic macrophage fibroblast interaction. OSM signaling in synovial fibroblasts is one of the main signaling pathways targeted by JAK inhibitors in vivo. The critical role of fibroblast OSM signaling in autoimmune arthritis was shown by a combination of mice specifically deficient for OSMR in synovial fibroblasts and administration of the JAK inhibitor. Thus, the OSM driven synovial macrophage fibroblast circuit is proven to be a key driver of autoimmune arthritis, serving as a crucial drug target in vivo.
C1 [Huynh, Nam Cong Nhat; Ling, Rui; Komagamine, Masatsugu; Shi, Tianshu; Matsuda, Kotaro; Muro, Ryunosuke; Pluemsakunthai, Warunee; Komatsu, Noriko; Takayanagi, Hiroshi] Univ Tokyo, Grad Sch Med, Dept Immunol, Tokyo, Japan.
   [Huynh, Nam Cong Nhat; Ling, Rui; Komagamine, Masatsugu; Shi, Tianshu; Tsukasaki, Masayuki; Matsuda, Kotaro; Okamoto, Kazuo; Asano, Tatsuo; Muro, Ryunosuke; Pluemsakunthai, Warunee; Komatsu, Noriko; Takayanagi, Hiroshi] Univ Tokyo, Fac Med, Tokyo, Japan.
   [Huynh, Nam Cong Nhat] Univ Med & Pharm Ho Chi Minh City, Fac Odontostomatol, Unit Prosthodont, Ho Chi Minh City, Vietnam.
   [Komagamine, Masatsugu; Kaneko, Yuko; Takeuchi, Tsutomu] Keio Univ, Sch Med, Dept Internal Med, Div Rheumatol, Tokyo, Japan.
   [Tsukasaki, Masayuki; Okamoto, Kazuo; Asano, Tatsuo] Univ Tokyo, Grad Sch Med, Dept Osteoimmunol, Tokyo, Japan.
   [Okamoto, Kazuo] Kanazawa Univ, Div Immune Environm Dynam, Canc Res Inst, Kakuma Machi, Kanazawa, Japan.
   [Kollias, George] Biomed Sci Res Ctr BSRC, Inst Bioinnovat, Vari, Attika, Greece.
   [Kollias, George] Natl & Kapodistrian Univ Athens, Med Sch, Dept Physiol, Athens, Greece.
   [Takeuchi, Tsutomu] Saitama Med Univ, Saitama, Japan.
   [Tanaka, Sakae] Univ Tokyo, Fac Med, Dept Orthopaed Surg, Tokyo, Japan.
   [Komatsu, Noriko] Tokyo Med & Dent Univ TMDU, Med Res Inst, Dept Immune Regulat, Tokyo, Japan.
C3 University of Tokyo; University of Tokyo; Hochiminh City University of
   Medicine & Pharmacy; Keio University; University of Tokyo; Kanazawa
   University; National & Kapodistrian University of Athens; Saitama
   Medical University; University of Tokyo; Institute of Science Tokyo;
   Tokyo Medical & Dental University (TMDU)
RP Komatsu, N (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Immunol, Tokyo, Japan.; Komatsu, N (通讯作者)，Univ Tokyo, Fac Med, Tokyo, Japan.; Komatsu, N (通讯作者)，Tokyo Med & Dent Univ TMDU, Med Res Inst, Dept Immune Regulat, Tokyo, Japan.
EM komatsu.ire@tmd.ac.jp
RI ; Tanaka, Sakae/Y 3061 2019
OI Komagamine, Masatsugu/0009 0008 7898 9134; 
FU AMED
FX We thank T. Nitta, H. Takaba, K. Kusubata, S. Yin, A. Suematsu, K. Kubo,
   N. Takeda, I. Komuro, T. Saito, Y. Omata and A. Terashima and all the
   lab members for thoughtful discussion and technical assistance.
CR Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Alivernini S, 2020, NAT MED, V26, P1295, DOI 10.1038/s41591 020 0939 8
   Armaka M, 2008, J EXP MED, V205, P331, DOI 10.1084/jem.20070906
   Armaka M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 02935 4
   Burmester GR, 2018, LANCET, V391, P2503, DOI 10.1016/S0140 6736(18)31115 2
   Chen YL, 2009, ENDOCRINOLOGY, V150, P3645, DOI 10.1210/en.2009 0212
   Chen Y, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000540
   Choy EH, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4312
   Croft AP, 2019, NATURE, V570, P246, DOI 10.1038/s41586 019 1263 7
   Culemann S, 2019, NATURE, V572, P670, DOI 10.1038/s41586 019 1471 1
   Diller M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00541
   Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596 020 0292 x
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Garcia Alonso L, 2021, NAT GENET, V53, P1698, DOI 10.1038/s41588 021 00972 2
   Hui W, 1997, ANN RHEUM DIS, V56, P184, DOI 10.1136/ard.56.3.184
   Komagamine M, 2023, INFLAMM REGEN, V43, DOI 10.1186/s41232 023 00293 3
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Kubo S, 2014, ANN RHEUM DIS, V73, P2192, DOI 10.1136/annrheumdis 2013 203756
   Kurowska Stolarska M, 2022, NAT REV RHEUMATOL, V18, P384, DOI 10.1038/s41584 022 00790 8
   Lacey DC, 2012, J IMMUNOL, V188, P5752, DOI 10.4049/jimmunol.1103426
   Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253
   Langdon C, 2000, AM J PATHOL, V157, P1187, DOI 10.1016/S0002 9440(10)64634 2
   Le Goff B, 2014, CYTOKINE, V68, P101, DOI 10.1016/j.cyto.2014.04.001
   Le Saout C, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96228
   Maeshima K, 2012, ARTHRITIS RHEUM US, V64, P1790, DOI 10.1002/art.34329
   McGarry T, 2018, ARTHRITIS RHEUMATOL, V70, P1959, DOI 10.1002/art.40569
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   McLornan DP, 2021, LANCET, V398, P803, DOI 10.1016/S0140 6736(21)00438 4
   McNamara MJ, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/s40425 014 0028 y
   Migita K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3333
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Mori S, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen 2021 001601
   Murakami K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181126
   Nygaard G, 2020, NAT REV RHEUMATOL, V16, P316, DOI 10.1038/s41584 020 0413 5
   Ochi S, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02744 7
   Okamoto H, 1997, ARTHRITIS RHEUM, V40, P1096, DOI 10.1002/art.1780400614
   Parmentier JM, 2018, BMC RHEUMATOL, V2, DOI 10.1186/s41927 018 0031 x
   Plater Zyberk C, 2001, ARTHRITIS RHEUM, V44, P2697, DOI 10.1002/1529 0131(200111)44:11<2697::AID ART450>3.0.CO;2 #
   Rusinova I, 2013, NUCLEIC ACIDS RES, V41, pD1040, DOI 10.1093/nar/gks1215
   Sims NA, 2021, CYTOKINE, V146, DOI 10.1016/j.cyto.2021.155655
   Sivertsen EA, 2006, BRIT J HAEMATOL, V135, P117, DOI 10.1111/j.1365 2141.2006.06252.x
   Smith MH, 2023, NAT IMMUNOL, V24, P1200, DOI 10.1038/s41590 023 01527 9
   Sobotta S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00775
   Sonomoto K, 2014, RHEUMATOLOGY, V53, P914, DOI 10.1093/rheumatology/ket466
   Stephenson W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02659 x
   Street K, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864 018 4772 0
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tanaka Y, 2022, NAT REV RHEUMATOL, V18, P133, DOI 10.1038/s41584 021 00726 8
   Traves PG, 2021, ANN RHEUM DIS, V80, P865, DOI 10.1136/annrheumdis 2020 219012
   Tsukasaki M, 2020, NAT METAB, V2, DOI 10.1038/s42255 020 00318 y
   Tsukasaki M, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108124
   Van den Berge K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14766 3
   Vento Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586 018 0698 6
   Walker EC, 2016, J BIOL CHEM, V291, P21703, DOI 10.1074/jbc.M116.748483
   Wei KV, 2020, NATURE, V582, P259, DOI 10.1038/s41586 020 2222 z
   West NR, 2018, SCAND J IMMUNOL, V88, DOI 10.1111/sji.12694
   Weston S, 2022, CLIN EXP RHEUMATOL, V40, P1620, DOI 10.55563/clinexprheumatol/cfsajk
   Wu HX, 2016, JOINT BONE SPINE, V83, P525, DOI 10.1016/j.jbspin.2015.09.002
   Yan ML, 2022, NAT IMMUNOL, V23, P1330, DOI 10.1038/s41590 022 01285 0
   Yari S, 2023, INFLAMM REGEN, V43, DOI 10.1186/s41232 023 00268 4
   Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590 019 0378 1
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 62
TC 4
Z9 4
U1 1
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1880 8190
J9 INFLAMM REGEN
JI Inflamm. Regen.
PD JUL 31
PY 2024
VL 44
IS 1
AR 36
DI 10.1186/s41232 024 00347 0
PG 18
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Research & Experimental Medicine
GA A2M3F
UT WOS:001280917600001
PM 39080781
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Do, M
   Wu, CCN
   Sonavane, PR
   Juarez, EF
   Adams, SR
   Ross, J
   Baena, ARY
   Patel, C
   Mesirov, JP
   Carson, DA
   Advani, SJ
   Willert, K
AF Do, Myan
   Wu, Christina C. N.
   Sonavane, Pooja R.
   Juarez, Edwin F.
   Adams, Stephen R.
   Ross, Jason
   Baena, Alessandra Rodriguez Y.
   Patel, Charmi
   Mesirov, Jill P.
   Carson, Dennis A.
   Advani, Sunil J.
   Willert, Karl
TI A FZD7 specific Antibody Drug Conjugate Induces Ovarian Tumor Regression
   in Preclinical Models
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID WNT RECEPTOR; CANCER; CELLS; FZD7; EXPRESSION; OSTEOBLAST; FRIZZLED7;
   PATHWAY
AB Although WNT signaling is frequently dysregulated in solid tumors, drugging this pathway has been challenging due to off tumor effects. Current clinical pan WNT inhibitors are nonspe cific and lead to adverse effects, highlighting the urgent need for more specific WNT pathway targeting strategies. We identified elevated expression of the WNT receptor Frizzled class receptor 7 (FZD7) in multiple solid cancers in The Cancer Genome Atlas, particularly in the mesenchymal and proliferative subtypes of ovarian serous cystadenocarcinoma, which correlate with poorer median patient survival. Moreover, we observed increased FZD7 protein expression in ovarian tumors compared with normal ovarian tissue, indicating that FZD7 may be a tumor specific antigen. We therefore developed a novel antibody drug conjugate, septuximab vedotin (F7 ADC), which is composed of a chimeric human mouse antibody to human FZD7 conjugated to the microtubule inhibiting drug monomethyl auristatin E (MMAE). F7 ADC selectively binds human FZD7, potently kills ovarian cancer cells in vitro, and induces regression of ovarian tumor xenografts in murine models. To evaluate F7 ADC toxicity in vivo, we generated mice harboring a modified Fzd7 gene where the resulting Fzd7 protein is reactive with the human targeting F7 ADC. F7 ADC treatment of these mice did not induce acute toxicities, indicating a potentially favorable safety profile in patients. Overall, our data suggest that the antibody drug con jugate approach may be a powerful strategy to combat FZD7 expressing ovarian cancers in the clinic.
C1 [Do, Myan; Sonavane, Pooja R.; Willert, Karl] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
   [Wu, Christina C. N.; Juarez, Edwin F.; Mesirov, Jill P.; Carson, Dennis A.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Adams, Stephen R.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
   [Ross, Jason] Illumina Inc, Dept Global Creat Studio, San Diego, CA USA.
   [Baena, Alessandra Rodriguez Y.] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA.
   [Patel, Charmi] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.
   [Mesirov, Jill P.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
   [Advani, Sunil J.] Univ Calif San Diego, Dept Radiat Med & Appl Sci, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   Illumina; University of California System; University of California
   Santa Cruz; University of California System; University of California
   San Diego; University of California System; University of California San
   Diego; University of California System; University of California San
   Diego
RP Willert, K (通讯作者)，Univ Calif San Diego, 9500 Gilman Dr,MC 0695, La Jolla, CA 92093 USA.
EM kwillert@health.ucsd.edu
RI ; Mesirov, Jill/AGF 7626 2022; Sonavane, Pooja/ABD 6697 2021
OI Sonavane, Pooja/0000 0002 5716 6090; Rodriguez y Baena,
   Alessandra/0000 0003 2510 7173; , Myan/0000 0001 5892 6859; 
FU NIH (NIGMS) [R35GM134961]; Mary Kay Foundation Cancer Research Grant
   Program; NIH (NCI) [R37CA215081, U24CA248457]; Cancer Biology,
   Informatics, Omics Training Program from the NCI [T32CA067754]; NCI
   Cancer Center Support Grant (CCSG grant) [P30CA23100]; National Cancer
   Institute [U24CA220341, U24CA248457, R37CA215081] Funding Source: NIH
   RePORTER
FX We are grateful to UCSD Transgenic Mouse Services for technical
   assistance with generating Fzd7hF7/hF7 mice; UCSD Tissue Technology
   Shared Resource for performing H&E and IHC staining; Dr. Nissi Varki
   (UCSD) for IHC analyses; Jesus Olvera and Cody Fine (UCSD) for technical
   assistance with flow cytometry experiments; UCSD Nikon Imaging Center
   for technical assistance with confocal imaging; and Dr. Dina Hingorani
   and Maria Fernanda Camargo (UCSD) for initial help with F7 ADC synthesis
   and tumor xenograft mouse models. Research reported in this publication
   was supported by grants from the NIH (NIGMS, R35GM134961) and The Mary
   Kay Foundation Cancer Research Grant Program (to K. Willert); NIH (NCI,
   R37CA215081; to S. J. Advani); NIH (NCI, U24CA248457; to J.P. Mesirov).
   M. Do was supported in part by a Cancer Biology, Informatics, Omics
   Training Program from the NCI (T32CA067754). The UCSD Tissue Technology
   Shared Resource is supported by a NCI Cancer Center Support Grant (CCSG
   grant P30CA23100).
CR Adams SR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13019
   Asad M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.302
   Aysola K., 2013, Hered. Genet, V2013, P001, DOI DOI 10.4172/2161 1041.S2 001
   Baah S, 2021, MOLECULES, V26, DOI 10.3390/molecules26102943
   Chalcrabarti R, 2014, NAT CELL BIOL, V16, P1004, DOI 10.1038/ncb3040
   Choijamts B, 2011, STEM CELLS, V29, P1485, DOI 10.1002/stem.711
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Condello S, 2018, CANCER RES, V78, P2990, DOI 10.1158/0008 5472.CAN 17 2319
   Damelin M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2611
   Davis SL, 2020, INVEST NEW DRUG, V38, P821, DOI [10.1007/s10637 019 00824 1, 10.1038/s41564 019 0492 8]
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Deng BY, 2015, MED ONCOL, V32, DOI 10.1007/s12032 015 0552 8
   Fernandez A, 2014, P NATL ACAD SCI USA, V111, P1409, DOI 10.1073/pnas.1323697111
   Fischer MM, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700090
   Flanagan DJ, 2019, CANCER RES, V79, P970, DOI 10.1158/0008 5472.CAN 18 2095
   Flanagan DJ, 2015, STEM CELL REP, V4, P759, DOI 10.1016/j.stemcr.2015.03.003
   Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370
   Giraudet AL, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4544 x
   GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092 8674(81)90021 0
   Gumber D, 2020, ELIFE, V9, DOI 10.7554/eLife.63060
   Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109
   Hingorani DV, 2020, MOL CANCER THER, V19, P157, DOI 10.1158/1535 7163.MCT 18 1302
   Jain N, 2015, PHARM RES DORDR, V32, P3526, DOI 10.1007/s11095 015 1657 7
   Jimeno A, 2017, CLIN CANCER RES, V23, P7490, DOI 10.1158/1078 0432.CCR 17 2157
   Jin YM, 2022, PHARMACOL THERAPEUT, V229, DOI 10.1016/j.pharmthera.2021.107917
   Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276 020 0380 6
   Kim S, 2019, MOL CELLS, V42, P8, DOI 10.14348/molcells.2018.0436
   King TD, 2012, CELL SIGNAL, V24, P846, DOI 10.1016/j.cellsig.2011.12.009
   Kirikoshi H, 2001, INT J ONCOL, V19, P111
   Madan B, 2016, ONCOGENE, V35, P2197, DOI 10.1038/onc.2015.280
   Madan B, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0017 8
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018
   Merle P, 2005, J HEPATOL, V43, P854, DOI 10.1016/j.jhep.2005.05.018
   Merle P, 2004, GASTROENTEROLOGY, V127, P1110, DOI 10.1053/j.gastro.2004.07.009
   Mita MM, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.2516
   Moore KN, 2019, GYNECOL ONCOL, V154, P294, DOI 10.1016/j.ygyno.2019.04.001
   Ng M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2584
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Phesse T, 2016, CANCERS, V8, DOI 10.3390/cancers8050050
   Rahman M, 2015, BIOINFORMATICS, V31, P3666, DOI 10.1093/bioinformatics/btv377
   Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Smith DC, 2013, J CLIN ONCOL, V31
   Spit M, 2020, EMBO J, V39, DOI 10.15252/embj.2019103932
   Tan D., 2018, Ann. Oncol, V29, pix23, DOI DOI 10.1093/ANNONC/MDY430.002
   Tan M, 2019, MOL ONCOL, V13, P757, DOI 10.1002/1878 0261.12425
   Tiwary S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147638
   Ueno K, 2009, BRIT J CANCER, V101, P1374, DOI 10.1038/sj.bjc.6605307
   Vaisitti T, 2021, BLOOD, V137, P3365, DOI 10.1182/blood.2020008404
   Verhaak RGW, 2013, J CLIN INVEST, V123, P517, DOI 10.1172/JCI65833
   Vincan E, 2005, DIFFERENTIATION, V73, P142, DOI 10.1111/j.1432 0436.2005.00015.x
   Wang YN, 2021, CANCER RES, V81, P384, DOI 10.1158/0008 5472.CAN 20 1488
   Xie W, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 020 01800 x
   Yang L, 2011, ONCOGENE, V30, P4437, DOI 10.1038/onc.2011.145
   Yin P, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 00646 2
   Yu HM, 2012, DEVELOPMENT, V139, P4383, DOI 10.1242/dev.083352
   Zeng CM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051543
NR 58
TC 22
Z9 25
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JAN
PY 2022
VL 21
IS 1
BP 113
EP 124
DI 10.1158/1535 7163.MCT 21 0548
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA YX3TK
UT WOS:000754029300001
PM 34667113
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Geng, ZX
   Sun, TC
   Yu, J
   Wang, N
   Jiang, Q
   Wang, PG
   Yang, GY
   Li, YF
   Ding, Y
   Zhang, JG
   Lin, GQ
   Zhao, YF
AF Geng, Zixiang
   Sun, Tiancheng
   Yu, Jie
   Wang, Ning
   Jiang, Qiang
   Wang, Peige
   Yang, Guangyue
   Li, Yifei
   Ding, Yue
   Zhang, Jiange
   Lin, Guoqiang
   Zhao, Yongfang
TI Cinobufagin Suppresses Lipid Peroxidation and Inflammation in
   Osteoporotic Mice by Promoting the Delivery of miR 3102 5p by
   Macrophage Derived Exosomes
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE osteoporosis; cinobufagin; exosomes; miR 3102 5p
ID EXTRACELLULAR VESICLES; DIFFERENTIATION; OSTEOGENESIS
AB Background: Cinobufagin, the primary active compound in toad venom, is commonly used for anti tumor, anti inflammatory, and analgesic purposes. However, its specific bone protective effects remain uncertain. This research aims to ascertain the bone protective properties of cinobufagin and investigate underlying mechanisms. Methods: Mice were ovariectomized to establish an osteoporosis model, followed by intraperitoneal injections of cinobufagin and cinobufagin treated RAW.264.7 derived exosomes for therapy. MicroCT, HE staining, and TRAP staining were employed to evaluate bone mass and therapeutic outcomes, while mRNA sequencing and immunoblotting were utilized to assess markers of bone metabolism, inflammation, and lipid peroxidation. Osteoblast and osteoclast precursor cells were differentiated to observe the impact of cinobufagin treated exosomes derived from RAW264.7 cells on bone metabolism. Exosomes characteristics were studied using transmission electron microscopy and particle size analysis, and miRNA binding targets in exosomes were determined by luciferase reporting. Results: In ovariectomized mice, cinobufagin and cinobufagin treated exosomes from RAW264.7 cells increased trabecular bone density and mass in the femur, while also decreasing inflammation and lipid peroxidation. The effect was reversed by an exosomes inhibitor. In vitro experiments revealed that cinobufagin treated exosomes from RAW264.7 cells enhanced osteogenic and suppressed osteoclast differentiation, possibly linked to Upregulated miR 3102 5p in RAW derived exosomes. MiR 3102 5p targets the 3 ' UTR region of alox15, thereby suppressing its expression and reducing the lipid peroxidation process in osteoblasts. Conclusion: Overall, this study clarified cinobufagin's bone protective effects and revealed that cinobufagin can enhance the delivery of miR 3102 5p targeting alox15 through macrophage derived exosomes, demonstrating anti lipid peroxidation and anti inflammatory effects.
C1 [Geng, Zixiang; Sun, Tiancheng; Yu, Jie; Wang, Ning; Jiang, Qiang; Wang, Peige; Yang, Guangyue; Zhao, Yongfang] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shis Ctr Orthoped & Traumatol, Shanghai 201203, Peoples R China.
   [Geng, Zixiang; Sun, Tiancheng; Yu, Jie; Wang, Ning; Jiang, Qiang; Wang, Peige; Yang, Guangyue; Zhao, Yongfang] Shanghai Acad Tradit Chinese Med, Inst Traumatol & Orthoped, Shanghai 201203, Peoples R China.
   [Li, Yifei] Shanghai Univ Tradit Chinese Med, Shanghai 201203, Peoples R China.
   [Ding, Yue] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China.
   [Zhang, Jiange; Lin, Guoqiang] Shanghai Univ Tradit Chinese Med, Innovat Res Inst Tradit, Res Ctr Chiral Drugs, Chinese Med, Shanghai 201203, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine; Shanghai University of Traditional
   Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Geng, ZX; Zhao, YF (通讯作者)，Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shis Ctr Orthoped & Traumatol, Shanghai 201203, Peoples R China.; Geng, ZX; Zhao, YF (通讯作者)，Shanghai Acad Tradit Chinese Med, Inst Traumatol & Orthoped, Shanghai 201203, Peoples R China.
EM gengzx@foxmail.com; zhaoyongfang@shutcm.edu.cn
RI S, T.C./JEP 7261 2023; Zhang, Jiange/A 4465 2012; Geng,
   zixiang/AAC 9151 2022
OI Geng, Zixiang/0000 0002 6596 8456; 
FU Shanghai Science and Technology Development Fund from Central Leading
   Local Government [YDZX20223100001004]; National Natural Science
   Foundation of China [82174404]; Shanghai Chronic Bone and Joint Disease
   Clinical Research Center [20MC1920600]; Shanghai Municipal Science and
   Technology Commission [23010505000]
FX Funding This work was partially supported by Shanghai Science and
   Technology Development Fund from Central Leading Local Government
   (YDZX20223100001004) , National Natural Science Foundation of China
   (82174404) , Shanghai Chronic Bone and Joint Disease Clinical Research
   Center (20MC1920600) , Shanghai Municipal Science and Technology
   Commission (23010505000) .
CR Alibhai SMH, 2017, ANN INTERN MED, V167, P341, DOI 10.7326/M16 2577
   Apryani E, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974 019 1616 z
   Baek SH, 2015, IMMUNOPHARM IMMUNOT, V37, P265, DOI 10.3109/08923973.2015.1027916
   Body JJ, 2010, ANN ONCOL, V21, P180, DOI 10.1093/annonc/mdq422
   Della Torre S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27272 x
   Eisen A, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.21.02647
   Ensrud KE, 2024, ANN INTERN MED, V177, pNIL_40, DOI 10.7326/AITC202401160
   Fulzele S, 2019, AGING US, V11, P1791, DOI 10.18632/aging.101874
   Gao HY, 2023, PHARMACOL RES, V194, DOI 10.1016/j.phrs.2023.106841
   Geng ZX, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1090997
   Giannandrea D, 2024, J HAZARD MATER, V462, DOI 10.1016/j.jhazmat.2023.132717
   Hou RT, 2022, CANCER LETT, V531, P57, DOI 10.1016/j.canlet.2022.01.025
   Jiang LB, 2018, EUR REV MED PHARMACO, V22, P6221, DOI 10.26355/eurrev_201810_16028
   Jin SE, 2022, BIOACT MATER, V8, P559, DOI 10.1016/j.bioactmat.2021.06.028
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Koide T, 2023, CIRC RES, V132, P415, DOI 10.1161/CIRCRESAHA.122.321939
   Li WH, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0706 8
   Liang MM, 2021, MOL THER NUCL ACIDS, V23, P1191, DOI 10.1016/j.omtn.2021.01.031
   Liu T, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13089
   Liu Y, 2015, ADV COLLOID INTERFAC, V221, P60, DOI 10.1016/j.cis.2015.04.006
   Long Y, 2023, BIOMATERIALS, V303, DOI 10.1016/j.biomaterials.2023.122369
   Lorenzo J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146619
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mashouri L, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 0991 5
   Murphy C, 2018, MOL ASPECTS MED, V60, P123, DOI 10.1016/j.mam.2017.09.006
   Pegtel DM, 2019, ANNU REV BIOCHEM, V88, P487, DOI 10.1146/annurev biochem 013118 111902
   Song H, 2019, NANO LETT, V19, P3040, DOI 10.1021/acs.nanolett.9b00287
   Sun ZQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0831 z
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   Thummuri D, 2015, PHARMACOL RES, V99, P63, DOI 10.1016/j.phrs.2015.05.006
   Walters JLH, 2018, ANTIOXIDANTS BASEL, V7, DOI 10.3390/antiox7100132
   Wang J, 2023, AUTOPHAGY, V19, P2409, DOI 10.1080/15548627.2023.2186112
   Wang YL, 2023, BIOACT MATER, V28, P273, DOI 10.1016/j.bioactmat.2023.05.018
   Wei YK, 2021, AGING US, V13, P17190, DOI 10.18632/aging.203169
   Wu KR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25473 y
   Xie XD, 2024, SIGNAL TRANSDUCT TAR, V9, DOI 10.1038/s41392 023 01726 8
   Xu RY, 2021, THERANOSTICS, V11, P5491, DOI 10.7150/thno.55041
   Xu RY, 2018, AGING CELL, V17, DOI 10.1111/acel.12794
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
   Yin JQ, 2013, TOXICOL LETT, V218, P129, DOI 10.1016/j.toxlet.2012.11.006
   Yin PB, 2023, ADV SCI, V10, DOI 10.1002/advs.202207050
   Yu B, 2024, J NANOBIOTECHNOL, V22, DOI 10.1186/s12951 024 02412 9
   Yu G, 2018, BIOMATERIALS, V162, P71, DOI 10.1016/j.biomaterials.2018.02.003
   Yu LJ, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12056
   Zhan X, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.112178
   Zhang C, 2023, BIOMED PHARMACOTHER, V163, DOI 10.1016/j.biopha.2023.114834
   Zhang J, 2021, ADV DRUG DELIVER REV, V178, DOI 10.1016/j.addr.2021.113964
   Zhang L, 2022, CELL MOL BIOENG, V15, P87, DOI 10.1007/s12195 021 00699 4
   Zhao YZ, 2024, INT IMMUNOPHARMACOL, V131, DOI 10.1016/j.intimp.2024.111885
   Zheng X, 2023, J CONTROL RELEASE, V353, P675, DOI 10.1016/j.jconrel.2022.12.026
NR 51
TC 3
Z9 3
U1 6
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2024
VL 19
BP 10497
EP 10512
DI 10.2147/IJN.S483849
PG 16
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA J3T9U
UT WOS:001336332300001
PM 39439501
OA gold
DA 2025 08 17
ER

PT J
AU Paz, JERM
   Adolpho, LF
   Ramos, JIR
   Bighetti Trevisan, RL
   Calixto, RD
   Oliveira, FS
   Almeida, ALG
   Beloti, MM
   Rosa, AL
AF Paz, Jessica Emanuella Rocha Moura
   Adolpho, Leticia Faustino
   Ramos, Jaqueline Isadora Reis
   Bighetti Trevisan, Rayana Longo
   Calixto, Robson Diego
   Oliveira, Fabiola Singaretti
   Almeida, Adriana Luisa Goncalves
   Beloti, Marcio Mateus
   Rosa, Adalberto Luiz
TI Effect of Mesenchymal Stem Cells Overexpressing BMP 9 Primed with
   Hypoxia on BMP Targets, Osteoblast Differentiation and Bone Repair
SO BIOLOGY BASEL
LA English
DT Article
DE BMP 9; bone; cell therapy; HIF 1 alpha; hypoxia; stem cells
ID OSTEOGENIC DIFFERENTIATION; STROMAL CELLS; IN VITRO; EXPRESSION;
   THERAPY; GROWTH; PLAYS; ASSAY; BETA
AB Bone formation is driven by many signaling molecules including bone morphogenetic protein 9 (BMP 9) and hypoxia inducible factor 1 alpha (HIF 1 alpha). We demonstrated that cell therapy using mesenchymal stem cells (MSCs) overexpressing BMP 9 (MSCs+BMP 9) enhances bone formation in calvarial defects. Here, the effect of hypoxia on BMP components and targets of MSCs+BMP 9 and of these hypoxia primed cells on osteoblast differentiation and bone repair was evaluated. Hypoxia was induced with cobalt chloride (CoCl2) in MSCs+BMP 9, and the expression of BMP components and targets was evaluated. The paracrine effects of hypoxia primed MSCs+BMP 9 on cell viability and migration and osteoblast differentiation were evaluated using conditioned medium. The bone formation induced by hypoxia primed MSCs+BMP 9 directly injected into rat calvarial defects was also evaluated. The results demonstrated that hypoxia regulated BMP components and targets without affecting BMP 9 amount and that the conditioned medium generated under hypoxia favored cell migration and osteoblast differentiation. Hypoxia primed MSCs+BMP 9 did not increase bone repair compared with control MSCs+BMP 9. Thus, despite the lack of effect of hypoxia on bone formation, the enhancement of cell migration and osteoblast differentiation opens windows for further investigations on approaches to modulate the BMP 9 HIF 1 alpha circuit in the context of cell based therapies to induce bone regeneration.
C1 [Paz, Jessica Emanuella Rocha Moura; Adolpho, Leticia Faustino; Ramos, Jaqueline Isadora Reis; Bighetti Trevisan, Rayana Longo; Calixto, Robson Diego; Oliveira, Fabiola Singaretti; Almeida, Adriana Luisa Goncalves; Beloti, Marcio Mateus; Rosa, Adalberto Luiz] Univ Sao Paulo, Sch Dent Ribeirao Preto, Bone Res Lab, Ave Cafe S N, BR 14040904 Ribeirao Preto, SP, Brazil.
C3 Universidade de Sao Paulo
RP Rosa, AL (通讯作者)，Univ Sao Paulo, Sch Dent Ribeirao Preto, Bone Res Lab, Ave Cafe S N, BR 14040904 Ribeirao Preto, SP, Brazil.
EM jessicamourapaz@usp.br; leticia.adolpho@usp.br;
   jaqueline.isadora.ramos@usp.br; rayana.bighetti@usp.br;
   robsonzahaila@usp.br; oliveira@forp.usp.br; aalmeida@forp.usp.br;
   mmbeloti@usp.br; adalrosa@forp.usp.br
RI Calixto, Robson/AAN 6739 2020; Beloti, Marcio/E 7473 2012; Beloti,
   Marcio/AAX 4014 2020; Trevisan, Rayana/L 9482 2017; Longo Bighetti
   Trevisan, Rayana/L 9482 2017; Adolpho, Letícia/AAO 6338 2021; Rosa,
   Adalberto/A 6314 2008; Rosa, Adalberto Luiz/A 6314 2008
OI Beloti, Marcio/0000 0003 0149 7189; Adolpho,
   Leticia/0000 0002 1952 5136; Longo Bighetti Trevisan,
   Rayana/0000 0002 0228 3652; Rosa, Adalberto Luiz/0000 0002 6495 2778
FU The authors would like to thank Roger Rodrigo Fernandes for his
   technical assistance during the execution of the study.
FX The authors would like to thank Roger Rodrigo Fernandes for his
   technical assistance during the execution of the study.
CR Amir MS, 2022, J CELL PHYSIOL, V237, P2183, DOI 10.1002/jcp.30752
   Chan NT, 2022, SCI ADV, V8, DOI 10.1126/sciadv.adc9222
   Chen FG, 2018, CONNECT TISSUE RES, V59, P223, DOI 10.1080/03008207.2017.1353085
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Dai QY, 2021, BIOMATER SCI UK, V9, P5519, DOI 10.1039/d1bm00870f
   de Jong DS, 2004, J BONE MINER RES, V19, P947, DOI 10.1359/JBMR.040216
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Freitas GP, 2021, GENE THER, V28, P748, DOI 10.1038/s41434 021 00248 8
   Freitas GP, 2019, REGEN MED, V14, P1107, DOI 10.2217/rme 2019 0036
   Gaihre B, 2021, MAT SCI ENG C MATER, V127, DOI 10.1016/j.msec.2021.112252
   Gao XQ, 2014, FASEB J, V28, P3792, DOI 10.1096/fj.13 247965
   Ho SS, 2018, STEM CELLS, V36, P1393, DOI 10.1002/stem.2853
   Hsu SH, 2013, STEM CELLS, V31, P2779, DOI 10.1002/stem.1441
   Hu N, 2013, J CELL SCI, V126, P532, DOI 10.1242/jcs.114231
   Huang J, 2016, CELL PHYSIOL BIOCHEM, V39, P1177, DOI 10.1159/000447824
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Li YW, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/2475169
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Liu DD, 2022, J DENT RES, V101, P1227, DOI 10.1177/00220345221093518
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Niu XL, 2019, CYTOKINE, V113, P117, DOI 10.1016/j.cyto.2018.06.022
   Rezaei A, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 18067 1
   Rico Llanos GA, 2017, J BIOMED MATER RES A, V105, P1867, DOI 10.1002/jbm.a.36051
   Sachse A, 2023, J MATER SCI MATER M, V34, DOI 10.1007/s10856 023 06734 2
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Shen QR, 2009, J CRANIOFAC SURG, V20, P1561, DOI 10.1097/SCS.0b013e3181b09cc1
   Souza ATP, 2018, J CELL BIOCHEM, V119, P8441, DOI 10.1002/jcb.27060
   Stegen S, 2016, BONE, V87, P176, DOI 10.1016/j.bone.2016.03.014
   Tao JM, 2022, FASEB J, V36, DOI 10.1096/fj.202200329RR
   Teotia AK, 2021, ACS APPL BIO MATER, V4, P3716, DOI 10.1021/acsabm.1c00311
   Toberer F, 2021, J EUR ACAD DERMATOL, V35, P88, DOI 10.1111/jdv.16600
   Towler DA, 2007, J CLIN INVEST, V117, P1477, DOI 10.1172/JCI32518
   Usategui Martín R, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23063233
   Venkataiah VS, 2021, CELLS BASEL, V10, DOI 10.3390/cells10102687
   Wang B, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.102684
   Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955 2235(89)90015 X
   Yang YY, 2023, INT J BIOCHEM CELL B, V154, DOI 10.1016/j.biocel.2022.106341
   Yao XT, 2023, TISSUE ENG REGEN MED, V20, P705, DOI 10.1007/s13770 023 00526 z
   Yu X, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658 019 0191 8
   Yu X, 2018, CELL BIOL INT, V42, P1321, DOI 10.1002/cbin.11017
   Yuan ZN, 2017, BIOCHEM BIOPH RES CO, V491, P228, DOI 10.1016/j.bbrc.2017.07.083
   Zheng JJ, 2021, ANN NY ACAD SCI, V1485, P56, DOI 10.1111/nyas.14483
NR 45
TC 0
Z9 0
U1 0
U2 6
PU MDPI
PI BASEL
PA Gross peteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2079 7737
J9 BIOLOGY BASEL
JI Biology Basel
PD AUG
PY 2023
VL 12
IS 8
AR 1147
DI 10.3390/biology12081147
PG 17
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA Q2TI0
UT WOS:001056086700001
PM 37627031
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Magrey, MN
   Khan, MA
AF Magrey, Marina N.
   Khan, Muhammad A.
TI The Paradox of Bone Formation and Bone Loss in Ankylosing Spondylitis:
   Evolving New Concepts of Bone Formation and Future Trends in Management
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Ankylosing spondylitis; Axial spondyloarthritis; Osteoproliferation;
   Osteoporosis; Bone morphogenetic proteins; Wnt signaling pathways;
   MicroRNAs; TNF alpha inhibitors; Il 17 inhibitors; Syndesmophytes; New
   bone formation
ID MESENCHYMAL STEM CELLS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   NECROSIS FACTOR ALPHA; RADIOGRAPHIC PROGRESSION; AXIAL
   SPONDYLOARTHRITIS; OSTEOGENIC DIFFERENTIATION; RHEUMATOID ARTHRITIS;
   MOUSE MODEL; TNF ALPHA; INFLAMMATION
AB Purpose of Review The purpose of the study is to briefly review the molecular mechanisms that leads to structural damage in ankylosing spondylitis (AS), defined as new bone formation resulting in complete or incomplete ankylosis of the spine, and the impact of treatment with biologics to retard this process.
   Recent Findings The understanding of molecular mechanisms leading to new bone formation in AS has significantly improved but is still incomplete. Availability of biologics has greatly enhanced the treatment of patients with AS, but its impact on slowing the structural damage is still a matter of debate, although a few observational studies have shown that long term use of TNF a blockers may slow radiographic progression. The availability of newer biologics targeting IL 17/ 1L23 has shown some promising results in slowing radiographic progression in AS.
   Summary Although the availability of TNF inhibitors has greatly enhanced the treatment options for patients with AS, their impact on slowing the structural damage is still not clearly established. However, preliminary results using newer biologics targeting IL 17/1L23 axis are more encouraging but longer follow up is needed.
C1 [Magrey, Marina N.] Case Western Reserve Univ, Sch Med, Cleveland, OH 44109 USA.
   [Magrey, Marina N.] MetroHlth Med Ctr, Cleveland, OH 44109 USA.
   [Khan, Muhammad A.] Case Western Reserve Univ, Sch Med, Div Rheumatol, Cleveland, OH USA.
C3 University System of Ohio; Case Western Reserve University; MetroHealth
   System; University System of Ohio; Case Western Reserve University
RP Magrey, MN (通讯作者)，Case Western Reserve Univ, Sch Med, Cleveland, OH 44109 USA.; Magrey, MN (通讯作者)，MetroHlth Med Ctr, Cleveland, OH 44109 USA.
EM mmagrey@metrohealth.org; mkhan@metrohealth.org
RI Khan, Muhammad/AAJ 8391 2021; Magrey, Marina/AAX 4067 2020
CR González Chávez SA, 2016, JOINT BONE SPINE, V83, P394, DOI 10.1016/j.jbspin.2015.07.008
   Appel H, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3370
   Appel H, 2010, J RHEUMATOL, V37, P823, DOI 10.3899/jrheum.090986
   Appel H, 2009, ARTHRITIS RHEUM US, V60, P3257, DOI 10.1002/art.24888
   Baraliakos X, 2014, ANN RHEUM DIS, V73, P1819, DOI 10.1136/annrheumdis 2013 203425
   Baraliakos X, 2014, ANN RHEUM DIS, V73, P710, DOI 10.1136/annrheumdis 2012 202698
   Baraliakos X, 2012, RHEUMATOLOGY, V51, P1378, DOI 10.1093/rheumatology/kes026
   Biver E, 2013, CYTOKINE GROWTH F R, V24, P69, DOI 10.1016/j.cytogfr.2012.06.003
   Bleil J, 2016, ARTHRITIS RHEUMATOL, V68, P2456, DOI 10.1002/art.39715
   BOERSMA JW, 1976, SCAND J RHEUMATOL, V5, P60
   BRAUN J, 1995, ARTHRITIS RHEUM, V38, P499, DOI 10.1002/art.1780380407
   Braun J., 2016, ANN RHEUM DIS
   Chen HA, 2010, J RHEUMATOL, V37, P2126, DOI 10.3899/jrheum.100200
   Daoussis D, 2010, ARTHRITIS RHEUM US, V62, P150, DOI 10.1002/art.27231
   El Tamer MK, 2009, J TISSUE ENG REGEN M, V3, P327, DOI 10.1002/term.173
   Goldring SR, 2007, NAT MED, V13, P133, DOI 10.1038/nm0207 133
   Haroon N, 2013, ARTHRITIS RHEUM US, V65, P2645, DOI 10.1002/art.38070
   Heiland GR, 2012, ANN RHEUM DIS, V71, P572, DOI 10.1136/annrheumdis 2011 200216
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Huang H, 2011, CELL PROLIFERAT, V44, P420, DOI 10.1111/j.1365 2184.2011.00769.x
   Im CH, 2009, CLIN EXP RHEUMATOL, V27, P620
   Jacques P, 2014, ANN RHEUM DIS, V73, P437, DOI 10.1136/annrheumdis 2013 203643
   Joo YB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104966
   Khan MA, 2011, RHEUMATOLOGY, V50, P637, DOI 10.1093/rheumatology/keq433
   KRAMER I, 2015, ARTHRITIS RHEUMA S10, V67
   Krause C, 2011, INT J BIOCHEM CELL B, V43, P478, DOI 10.1016/j.biocel.2011.01.007
   Kwon SR, 2012, RHEUMATOL INT, V32, P2523, DOI 10.1007/s00296 011 1981 0
   Lories RJ, 2014, BEST PRACT RES CL RH, V28, P765, DOI 10.1016/j.berh.2014.10.008
   Lories RJU, 2007, ARTHRITIS RHEUM, V56, P489, DOI 10.1002/art.22372
   Lories RJU, 2012, RHEUM DIS CLIN N AM, V38, P555, DOI 10.1016/j.rdc.2012.08.003
   Lories RJU, 2005, J CLIN INVEST, V115, P1571, DOI 10.1172/JCI23738
   Maas F, 2017, ARTHRIT CARE RES, V69, P1011, DOI 10.1002/acr.23097
   Maas F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122693
   Maksymowych WP, 2013, ANN RHEUM DIS, V72, P23, DOI 10.1136/annrheumdis 2011 200859
   Maksymowych WP, 2009, ARTHRITIS RHEUM US, V60, P93, DOI 10.1002/art.24132
   McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698
   Mohanty ST, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3098
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Pedersen SJ, 2011, ARTHRITIS RHEUM US, V63, P3789, DOI 10.1002/art.30627
   Poddubnyy D, 2012, ANN RHEUM DIS, V71, P1616, DOI 10.1136/annrheumdis 2011 201252
   Poddubnyy D, 2012, ARTHRITIS RHEUM US, V64, P1388, DOI 10.1002/art.33465
   Rohekar S, 2015, J RHEUMATOL, V42, P665, DOI 10.3899/jrheum.141001
   Rudwaleit M, 2009, ANN RHEUM DIS, V68, P1520, DOI 10.1136/ard.2009.110767
   Shaw AT, 2016, SEMIN CELL DEV BIOL, V49, P2, DOI 10.1016/j.semcdb.2015.10.013
   Shen H, 2009, ARTHRITIS RHEUM US, V60, P1647, DOI 10.1002/art.24568
   Sherlock JP, 2012, NAT MED, V18, P1069, DOI 10.1038/nm.2817
   Sieper J, 2016, ANN RHEUM DIS, V75, P1438, DOI 10.1136/annrheumdis 2015 207897
   Sieper J, 2016, NAT REV RHEUMATOL, V12, P282, DOI 10.1038/nrrheum.2016.42
   Sieper J, 2014, ANN RHEUM DIS, V73, P1439, DOI 10.1136/annrheumdis 2014 205464
   Smith JA, 2014, ARTHRITIS RHEUMATOL, V66, P231, DOI 10.1002/art.38291
   Sun LY, 2007, LUPUS, V16, P121, DOI 10.1177/0961203306075793
   Tariq MN, 2016, CLIN RHEUMATOL, V35, P1323, DOI 10.1007/s10067 015 3123 7
   Taurog JD, 2016, NEW ENGL J MED, V374, P2563, DOI 10.1056/NEJMra1406182
   Uderhardt S, 2010, ANN RHEUM DIS, V69, P592, DOI 10.1136/ard.2008.102046
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P1324, DOI 10.1002/art.23471
   Van Der Heijde D, 2016, ARTHRITIS RHEUMA S10, V68
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P3063, DOI 10.1002/art.23901
   van der Heijde D, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2794
   van Duivenvoorde LM, 2012, ARTHRITIS RHEUM US, V64, P3210, DOI 10.1002/art.34600
   Walsh NC, 2009, J BONE MINER RES, V24, P1572, DOI [10.1359/JBMR.090320, 10.1359/jbmr.090320]
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
   Ward MM, 2016, ARTHRIT CARE RES, V68, P151, DOI [10.1002/acr.22708, 10.1002/art.39298]
   Wendling D, 2007, JOINT BONE SPINE, V74, P304, DOI 10.1016/j.jbspin.2006.11.005
   Xie WQ, 2016, ANN NY ACAD SCI, V1364, P25, DOI 10.1111/nyas.12968
   Xie ZY, 2016, ARTHRITIS RHEUMATOL, V68, P430, DOI 10.1002/art.39433
NR 65
TC 40
Z9 49
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523 3774
EI 1534 6307
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD APR
PY 2017
VL 19
IS 4
AR 17
DI 10.1007/s11926 017 0644 x
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA EQ4VD
UT WOS:000398076900003
PM 28361330
DA 2025 08 17
ER

PT J
AU Lafferty, MK
   Fantry, L
   Bryant, J
   Jones, O
   Hammoud, D
   Weitzmann, MN
   Lewis, GK
   Garzino Demo, A
   Reid, W
AF Lafferty, Mark K.
   Fantry, Lori
   Bryant, Joseph
   Jones, Odell
   Hammoud, Dima
   Weitzmann, M. Neale
   Lewis, George K.
   Garzino Demo, Alfredo
   Reid, William
TI Elevated suppressor of cytokine signaling 1 (SOCS 1): a mechanism for
   dysregulated osteoclastogenesis in HIV transgenic rats
SO PATHOGENS AND DISEASE
LA English
DT Article
DE SOCS 1; HIV 1; osteoclast; osteoporosis
ID BONE MINERAL DENSITY; VIRUS INFECTED WOMEN; B LIGAND RANKL;
   ANTIRETROVIRAL THERAPY; T CELLS; RECEPTOR ACTIVATOR; IFN GAMMA;
   OSTEOPROTEGERIN LIGAND; INHIBITORY FACTOR; CROSS TALK
AB Accelerated bone loss leading to osteopenia, osteoporosis, and bone fracture is a major health problem that is increasingly common in human immunodeficiency virus (HIV) infected patients. The underlying pathogenesis is unclear but occurs in both treatment naive and individuals receiving antiretroviral therapies. We developed an HIV 1 transgenic rat that exhibits many key features of HIV disease including HIV 1 induced changes in bone mineral density (BMD). A key determinant in the rate of bone loss is the differentiation of osteoclasts, the cells responsible for bone resorption. We found HIV 1 transgenic osteoclast precursors (OCP) express higher levels of suppressor of cytokine signaling 1 (SOCS 1) and TNF receptor associated factor 6 (TRAF6) and are resistant to interferon gamma (IFN ) mediated suppression of osteoclast differentiation. Our data suggest that dysregulated SOCS 1 expression by HIV 1 transgenic OCP promotes osteoclastogenesis leading to the accelerated bone loss observed in this animal model. We propose that elevated SOCS 1 expression in OCP antagonizes the inhibitory effects of IFN  and enhances receptor activator of NF kB ligand (RANKL) signaling that drives osteoclast differentiation and activation. Understanding the molecular mechanisms of HIV associated BMD changes has the potential to detect and treat bone metabolism disturbances early and improve the quality of life in patients.
C1 [Lafferty, Mark K.; Lewis, George K.; Garzino Demo, Alfredo; Reid, William] Univ Maryland, Sch Med, Inst Human Virol, Div Basic Sci & Vaccine Res, Baltimore, MD 21201 USA.
   [Lafferty, Mark K.; Lewis, George K.; Garzino Demo, Alfredo; Reid, William] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
   [Fantry, Lori] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
   [Fantry, Lori; Bryant, Joseph] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.
   [Bryant, Joseph] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA.
   [Bryant, Joseph; Jones, Odell] Univ Maryland, Sch Med, Anim Models Div, Inst Human Virol, Baltimore, MD 21201 USA.
   [Hammoud, Dima; Reid, William] NIH, Ctr Clin, Baltimore, MD 21201 USA.
   [Weitzmann, M. Neale] Emory Univ, Sch Med, Div Endocrinol & Metab & Lipids, Atlanta, GA 30322 USA.
   [Weitzmann, M. Neale] Atlanta Vet Affairs Med Ctr, Decatur, GA 30033 USA.
   [Weitzmann, M. Neale] Emory Univ, Winship Canc Inst, Sch Med, Atlanta, GA 30322 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   National Institutes of Health (NIH)   USA; NIH National Institute on
   Aging (NIA); Emory University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Atlanta VA Health Care System;
   Emory University
RP Reid, W (通讯作者)，NIH, Ctr Infect Dis Imaging Radiol & Imaging Sci, Ctr Clin, Baltimore, MD 21201 USA.
EM william.reid@nih.gov
RI ; Hammoud, Dima/C 2286 2015
OI Garzino Demo, Alfredo/0000 0002 4095 6950; Hammoud,
   Dima/0000 0001 7406 7871; 
FU National Institute of Allergy and Infectious Diseases, NIH [R01A1063171,
   R01AI087181]; National Institute of Neurological Disorders And Stroke,
   NIH [R01NS066842]
FX We thank Dr Marvin Reitz for his critical reading of this manuscript. We
   also thank Dr Bryan Taylor, manager of the Core facility at the
   Institute of Human Virology, for his technical assistance. This study
   was supported by National Institute of Allergy and Infectious Diseases,
   NIH grants R01A1063171 and R01AI087181 and National Institute of
   Neurological Disorders And Stroke, NIH grant R01NS066842. The authors
   declare no competing financial interests.
CR Amiel C, 2004, J BONE MINER RES, V19, P402, DOI 10.1359/JBMR.0301246
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Bolland MJ, 2007, CLIN ENDOCRINOL, V67, P270, DOI 10.1111/j.1365 2265.2007.02875.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown TT, 2007, AIDS, V21, P1830, DOI 10.1097/QAD.0b013e3282703837
   Carr A, 2001, AIDS, V15, P703, DOI 10.1097/00002030 200104130 00005
   CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167 5699(93)90208 3
   Dalpke AH, 2003, EUR J IMMUNOL, V33, P1776, DOI 10.1002/eji.200323621
   Deeks Steven G, 2009, Top HIV Med, V17, P118
   Dolan SE, 2006, J CLIN ENDOCR METAB, V91, P2938, DOI 10.1210/jc.2006 0127
   Fakruddin JM, 2005, ARCH VIROL, V150, P67, DOI 10.1007/s00705 004 0395 7
   Fakruddin JM, 2003, J BIOL CHEM, V278, P48251, DOI 10.1074/jbc.M304676200
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Gibellini D, 2007, J MED VIROL, V79, P1446, DOI 10.1002/jmv.20938
   Haskelberg H, 2011, AIDS REV, V13, P240
   Hayashi T, 2002, J BIOL CHEM, V277, P27880, DOI 10.1074/jbc.M203836200
   Hu XY, 2009, IMMUNITY, V31, P539, DOI 10.1016/j.immuni.2009.09.002
   Ji JD, 2009, J IMMUNOL, V183, P7223, DOI 10.4049/jimmunol.0900072
   Kamolmatyakul S, 2001, J DENT RES, V80, P351, DOI 10.1177/00220345010800011001
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Madeddu G, 2004, Q J NUCL MED MOL IM, V48, P39
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   McComsey GA, 2010, CLIN INFECT DIS, V51, P937, DOI 10.1086/656412
   Mondy K, 2003, CLIN INFECT DIS, V36, P482, DOI 10.1086/367569
   Nakashima T, 2008, ARCH BIOCHEM BIOPHYS, V473, P166, DOI 10.1016/j.abb.2008.04.004
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nolan D, 2001, AIDS, V15, P1275, DOI 10.1097/00002030 200107060 00009
   Ofotokun I, 2010, CURR OPIN ENDOCRINOL, V17, P523, DOI 10.1097/MED.0b013e32833f48d6
   Ohishi M, 2005, J IMMUNOL, V174, P3024, DOI 10.4049/jimmunol.174.5.3024
   Paton NIJ, 1997, CALCIFIED TISSUE INT, V61, P30, DOI 10.1007/s002239900288
   Prior J, 2007, OSTEOPOROSIS INT, V18, P1345, DOI 10.1007/s00198 007 0428 7
   Reid W, 2004, VIROLOGY, V321, P111, DOI 10.1016/j.virol.2003.12.010
   Reid W, 2001, P NATL ACAD SCI USA, V98, P9271, DOI 10.1073/pnas.161290298
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stone B, 2010, ARCH BIOCHEM BIOPHYS, V503, P66, DOI 10.1016/j.abb.2010.07.029
   TAKAHASHI N, 1986, J IMMUNOL, V137, P3544
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2005, IMMUNOL REV, V208, P181, DOI 10.1111/j.0105 2896.2005.00337.x
   Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030 200003100 00005
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Triant VA, 2008, J CLIN ENDOCR METAB, V93, P3499, DOI 10.1210/jc.2008 0828
   VantHof RJ, 1997, J BONE MINER RES, V12, P1797, DOI 10.1359/jbmr.1997.12.11.1797
   Vikulina T, 2010, P NATL ACAD SCI USA, V107, P13848, DOI 10.1073/pnas.1003020107
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Weitzmann MN, 2007, ANN NY ACAD SCI, V1116, P360, DOI 10.1196/annals.1402.068
   Womack JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017217
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yadav A, 2009, VIROLOGY, V385, P126, DOI 10.1016/j.virol.2008.11.039
   Yadav A, 2006, VIROLOGY, V353, P357, DOI 10.1016/j.virol.2006.05.026
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yin M, 2005, OSTEOPOROSIS INT, V16, P1345, DOI 10.1007/s00198 005 1845 0
   Yin MT, 2010, J CLIN ENDOCR METAB, V95, P620, DOI 10.1210/jc.2009 0708
   Young B, 2011, CLIN INFECT DIS, V52, P1061, DOI 10.1093/cid/ciq242
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 63
TC 8
Z9 9
U1 0
U2 3
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2049 632X
J9 PATHOG DIS
JI Pathog. Dis.
PD JUN
PY 2014
VL 71
IS 1
BP 81
EP 89
DI 10.1111/2049 632X.12117
PG 9
WC Immunology; Infectious Diseases; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases; Microbiology
GA AJ3PB
UT WOS:000337577900009
PM 24376119
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Manolagas, SC
AF Manolagas, Stavros C.
TI The Quest for Osteoporosis Mechanisms and Rational Therapies: How Far
   We've Come, How Much Further We Need to Go
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; DISEASES AND DISORDERS OF; RELATED TO BONE; SEX STEROIDS;
   CELL; TISSUE SIGNALING; ENDOCRINE PATHWAYS; AGING; MENOPAUSE
ID ESTROGEN RECEPTOR ALPHA; FOXO TRANSCRIPTION FACTORS; PREVENTS BONE LOSS;
   SENESCENT CELLS; CORTICAL BONE; ANDROGEN RECEPTOR; POSTMENOPAUSAL WOMEN;
   VERTEBRAL FRACTURES; HUMAN OSTEOCLASTS; OXIDATIVE STRESS
AB During the last 40 years, understanding of bone biology and the pathogenesis of osteoporosis, the most common and impactful bone disease of old age, has improved dramatically thanks to basic and clinical research advances, genetic insights from humans and rodents, and newer imaging technologies. Culprits of osteoporosis are no longer a matter of speculation based on in vitro observations. Instead, they can be identified and dissected at the cellular and molecular level using genetic approaches; and their effect on distinct bone envelopes and anatomic regions can be functionally assessed in vivo. The landscape of pharmacotherapies for osteoporosis has also changed profoundly with the emergence of several potent antiresorptive drugs as well as anabolic agents, displacing estrogen replacement as the treatment of choice. In spite of these major positive developments, the optimal duration of the available therapies and their long term safety remain matters of conjecture and some concern. Moreover, antiresorptive therapies are used indiscriminately for patients of all ages on the assumption that suppressing remodeling is always beneficial for bone, but rebound remodeling upon their discontinuation suggests otherwise. In this invited perspective, I highlight the latest state of knowledge of bone intrinsic and extrinsic mechanisms responsible for the development of osteoporosis in both sexes; differences between the mechanisms responsible for the effects of aging and estrogen deficiency; and the role of old osteocytes in the development of cortical porosity. In addition, I highlight advances toward the goal of developing drugs for several degenerative diseases of old age at once, including osteoporosis, by targeting shared mechanisms of aging. (c) 2018 American Society for Bone and Mineral Research.
C1 [Manolagas, Stavros C.] Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, Little Rock, AR 72205 USA.
   [Manolagas, Stavros C.] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Central Arkansas Veterans Healthcare System
RP Manolagas, SC (通讯作者)，4301 W Markham St 587, Little Rock, AR 72205 USA.
EM manolagasstavros@uams.edu
FU NIH [P01 AG013918, R01 AR056679]; Department of Veterans Affairs [I01
   BX001405]; University of Arkansas for Medical Sciences Tobacco Funds and
   Translational Research Institute [1UL1RR029884]
FX The author's research is supported by the NIH (P01 AG013918, R01
   AR056679), by the Department of Veterans Affairs (I01 BX001405), and by
   the University of Arkansas for Medical Sciences Tobacco Funds and
   Translational Research Institute (1UL1RR029884). The author thanks Katie
   H. Poe for help with the preparation of the manuscript; and his current
   and former co workers (the late Michael A Parfitt, Robert Jilka, Rob
   Weinstein, Maria Almeida, Charles O'Brien, Haibo Zhao, Elena Ambrogini,
   Teresita Bellido, Stavroula Kousteni, Beata Lecka Czernik, and Lilian
   Plotkin) for their invaluable contribution to the perspective and ideas
   discussed herein.
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Almeida M, 2013, J GERONTOL A BIOL, V68, P1197, DOI 10.1093/gerona/glt079
   Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   Almeida M, 2009, J BIOL CHEM, V284, P27438, DOI 10.1074/jbc.M109.023572
   Anastasilakis AD, 2017, EUR J ENDOCRINOL, V176, P677, DOI 10.1530/EJE 16 1027
   [Anonymous], 2017, PLOS ONE
   Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Bartell SM, 2013, MOL ENDOCRINOL, V27, P649, DOI 10.1210/me.2012 1368
   Bhatt NY, 2002, J IMMUNOL, V169, P6427, DOI 10.4049/jimmunol.169.11.6427
   Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93
   Chambliss KL, 2010, J CLIN INVEST, V120, P2319, DOI 10.1172/JCI38291
   Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010
   Chesi A, 2017, J BONE MINER RES, V32, P1274, DOI 10.1002/jbmr.3097
   Chiang C, 2009, J BONE MINER RES, V24, P621, DOI [10.1359/jbmr.081217, 10.1359/JBMR.081217]
   Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140 6736(09)61460 4
   Crescenzi E, 2003, BIOCHEM J, V375, P263, DOI 10.1042/BJ20030868
   Dai DF, 2010, AGING CELL, V9, P536, DOI 10.1111/j.1474 9726.2010.00581.x
   Dewson G, 2009, J CELL SCI, V122, P2801, DOI 10.1242/jcs.038166
   Droser ML, 2014, J PALEONTOL, V88, P145, DOI 10.1666/12 158
   Edwards JR, 2013, J BONE MINER RES, V28, P960, DOI 10.1002/jbmr.1824
   Emerton KB, 2010, BONE, V46, P577, DOI 10.1016/j.bone.2009.11.006
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   FROST HM, 1960, J BONE JOINT SURG AM, V42, P138, DOI 10.2106/00004623 196042010 00011
   Fu J, 2016, J CLIN INVEST, V126, P1759, DOI 10.1172/JCI80276
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Grassi F, 2004, J CELL PHYSIOL, V199, P244, DOI 10.1002/jcp.10445
   Grassi F, 2003, HISTOCHEM CELL BIOL, V120, P391, DOI 10.1007/s00418 003 0587 3
   Gronthos S, 2007, TRENDS ENDOCRIN MET, V18, P108, DOI 10.1016/j.tem.2007.02.002
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Halloran BP, 2002, J BONE MINER RES, V17, P1044, DOI 10.1359/jbmr.2002.17.6.1044
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Iyer S, 2014, J BIOL CHEM, V289, P24069, DOI 10.1074/jbc.M114.561803
   Iyer S, 2013, J CLIN INVEST, V123, P3409, DOI 10.1172/JCI68049
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Jilka RL, 2014, J BONE MINER RES, V29, P103, DOI 10.1002/jbmr.2007
   Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861
   Kaeberlein M, 2015, SCIENCE, V350, P1191, DOI 10.1126/science.aad3267
   Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Kim HN, 2018, CURR TOP DEV BIOL, V127, P149, DOI 10.1016/bs.ctdb.2017.10.004
   Kim HN, 2017, AGING CELL, V16, P693, DOI 10.1111/acel.12597
   Kim HN, 2015, MOL ENDOCRINOL, V29, P1498, DOI 10.1210/me.2015 1133
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Lee HY, 2010, CELL METAB, V12, P668, DOI 10.1016/j.cmet.2010.11.004
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li J, 2017, SCIENCE, V355, P1312, DOI 10.1126/science.aad8242
   Li Y, 2004, J MOL HISTOL, V35, P723, DOI 10.1007/s10735 004 6206 3
   Liu Y, 2016, AM J PHYSIOL ENDOC M, V310, pE762, DOI 10.1152/ajpendo.00501.2015
   Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093
   López Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Maatta Jorma A, 2013, Bonekey Rep, V2, P440, DOI 10.1038/bonekey.2013.174
   Madak Erdogan Z, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad8170
   Makovey J, 2009, BONE, V44, P208, DOI 10.1016/j.bone.2008.09.020
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007 0259
   Manolagas SC, 2014, MATURITAS, V78, P233, DOI 10.1016/j.maturitas.2014.04.013
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Manolagas SC, 2013, BONE, V54, P272, DOI 10.1016/j.bone.2012.09.017
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mao PZ, 2012, HUM MOL GENET, V21, P2973, DOI 10.1093/hmg/dds128
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nirody JA, 2015, BONE, V75, P88, DOI 10.1016/j.bone.2015.02.006
   Notini AJ, 2007, J BONE MINER RES, V22, P347, DOI 10.1359/JBMR.061117
   Nussey DH, 2013, AGEING RES REV, V12, P214, DOI 10.1016/j.arr.2012.07.004
   Ocampo A, 2016, CELL, V167, P1719, DOI 10.1016/j.cell.2016.11.052
   Onal M, 2013, J BIOL CHEM, V288, P17432, DOI 10.1074/jbc.M112.444190
   Parfitt A., 1992, Triangle, V31, P99
   PARFITT AM, 1981, ACTA ASTRONAUT, V8, P1083, DOI 10.1016/0094 5765(81)90082 5
   PARFITT AM, 1995, J BONE MINER RES, V10, P466
   Piemontese M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93771
   Pivetta E, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3047
   Popp AW, 2016, OSTEOPOROSIS INT, V27, P1917, DOI 10.1007/s00198 015 3458 6
   Ricklefs RE, 2010, AGING CELL, V9, P273, DOI 10.1111/j.1474 9726.2009.00542.x
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Schiltz C, 2008, J CELL BIOCHEM, V104, P1803, DOI 10.1002/jcb.21747
   Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092 8674(02)00734 1
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   Shanbhogue VV, 2016, J BONE MINER RES, V31, P1541, DOI 10.1002/jbmr.2817
   Simic P, 2013, EMBO MOL MED, V5, P430, DOI 10.1002/emmm.201201606
   Sinnesael M, 2012, J BONE MINER RES, V27, P2535, DOI 10.1002/jbmr.1713
   Steinberg D, 2010, ARTERIOSCL THROM VAS, V30, P2311, DOI 10.1161/ATVBAHA.108.179697
   Tintut Y, 2004, ARTERIOSCL THROM VAS, V24, pE6, DOI 10.1161/01.ATV.0000112023.62695.7f
   Tintut Y, 2014, TRENDS ENDOCRIN MET, V25, P53, DOI 10.1016/j.tem.2013.10.001
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Ucer S, 2017, J BONE MINER RES, V32, P560, DOI 10.1002/jbmr.3014
   Ucer S, 2015, J BONE MINER RES, V30, P1138, DOI 10.1002/jbmr.2485
   Vanderschueren D, 2014, ENDOCR REV, V35, P906, DOI 10.1210/er.2014 1024
   WAKAMATU.E, 1969, CALC TISS RES, V4, P147, DOI 10.1007/BF02279116
   WASSERMAN SHS, 1987, SEMIN NUCL MED, V17, P283
   Webb AE, 2014, TRENDS BIOCHEM SCI, V39, P159, DOI 10.1016/j.tibs.2014.02.003
   Witztum JL, 2014, ANNU REV PATHOL MECH, V9, P73, DOI 10.1146/annurev pathol 020712 163936
   Wright LM, 2005, BONE, V36, P840, DOI 10.1016/j.bone.2005.01.021
   Wronski TJ, 1999, BONE, V25, P465, DOI 10.1016/S8756 3282(99)00191 X
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
   Zannettino ACW, 2005, CANCER RES, V65, P1700, DOI 10.1158/0008 5472.CAN 04 1687
NR 103
TC 43
Z9 46
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2018
VL 33
IS 3
BP 371
EP 385
DI 10.1002/jbmr.3400
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FY3OT
UT WOS:000426731100002
PM 29405383
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Ito, R
   Matsumiya, T
   Kon, T
   Narita, N
   Kubota, K
   Sakaki, H
   Ozaki, T
   Imaizumi, T
   Kobayashi, W
   Kimura, H
AF Ito, Ryohei
   Matsumiya, Tomoh
   Kon, Takao
   Narita, Norihiko
   Kubota, Kosei
   Sakaki, Hirotaka
   Ozaki, Taku
   Imaizumi, Tadaatsu
   Kobayashi, Wataru
   Kimura, Hiroto
TI Periosteum derived cells respond to mechanical stretch and activate Wnt
   and BMP signaling pathways
SO BIOMEDICAL RESEARCH TOKYO
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; LEUKEMIA INHIBITORY FACTOR; INDUCIBLE
   GENE I; GINGIVAL FIBROBLASTS; EXPRESSION; INTERLEUKIN 1 BETA;
   DIFFERENTIATION; OSTEOPOROSIS; FAMILY; CSF 1
AB The periosteum supplies osteoblasts and nutrients for bone metabolism and is important for osteoblast differentiation and osteogenesis. Recently, periosteum derived cells have been used for orofacial bone regeneration therapy. However, little is known about the function of the periosteum in physiological bone remodeling. On our hypothesis that the periosteum senses a mechanical stress to induce bone remodeling, we subjected human jaw bone periosteum cells (HJBPCs) to uniaxial stretching for 24 h and characterized their gene expression profiles by microarray analysis. Of 62,976 genes detected, 550 genes related to bone metabolism were extracted, and 76 of these genes with large changes in gene expression were short listed. The results indicated that mechanical stretch in HJBPCs regulated the expression levels of genes involved in the Wingless type MMTV integration (Wnt) site, bone morphogenetic protein (BMP) signaling pathways, and inflammatory cytokines. We propose that periosteum derived cells sense mechanical stress and then activate and regulate signals for osteoblast differentiation and osteogenesis.
C1 [Ito, Ryohei; Kon, Takao; Narita, Norihiko; Kubota, Kosei; Sakaki, Hirotaka; Kobayashi, Wataru; Kimura, Hiroto] Hirosaki Univ, Grad Sch Med, Dept Dent & Oral Surg, Hirosaki, Aomori 0368562, Japan.
   [Matsumiya, Tomoh; Imaizumi, Tadaatsu] Hirosaki Univ, Grad Sch Med, Inst Brain Sci, Dept Vasc Biol, Hirosaki, Aomori 0368562, Japan.
   [Ozaki, Taku] Hirosaki Univ, Grad Sch Med, Dept Ophthalmol, Hirosaki, Aomori 0368562, Japan.
C3 Hirosaki University; Hirosaki University; Hirosaki University
RP Matsumiya, T (通讯作者)，Hirosaki Univ, Grad Sch Med, Inst Brain Sci, Dept Vasc Biol, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.
EM tomo1027@cc.hirosaki u.ac.jp
RI Kobayashi, Wataru/G 4186 2014; Matsumiya, Tomoh/ABA 5861 2021; Ozaki,
   Taku/E 8639 2013
OI Ozaki, Taku/0000 0001 8183 5453; 
FU Priority Research Grant for Young Scientists Designated; President of
   Hirosaki University; KAKENHI [23590560, 23592979]; Grants in Aid for
   Scientific Research [23592979, 23590560] Funding Source: KAKEN
FX This work was supported in part by Priority Research Grant for Young
   Scientists Designated by the President of Hirosaki University (to TM), a
   KAKENHI Grants in Aid for Scientific Research 23590560 (to TM) and by a
   KAKENHI Grant in Aid for Scientific Research 23592979 (to HK).
CR BASSEY EJ, 1994, OSTEOPOROSIS INT, V4, P72, DOI 10.1007/BF01623226
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Cheung WMW, 2006, BONE, V39, P470, DOI 10.1016/j.bone.2006.02.069
   Crane JL, 2014, J MOL MED, V92, P107, DOI 10.1007/s00109 013 1084 3
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   EISMAN JA, 1991, AM J MED, V91, pS5, DOI 10.1016/0002 9343(91)90239 T
   Gow DJ, 2012, CYTOKINE, V60, P793, DOI 10.1016/j.cyto.2012.08.008
   Hoffmann A, 2001, CRIT REV EUKAR GENE, V11, P23, DOI 10.1615/CritRevEukarGeneExpr.v11.i1 3.20
   Hopwood B, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2301
   Izumi M, 2006, J MOL CELL CARDIOL, V40, P224, DOI 10.1016/j.yjmcc.2005.11.007
   Katoh M, 2005, ONCOL REP, V14, P1583
   Kawase T, 2011, CRYOBIOLOGY, V62, P202, DOI 10.1016/j.cryobiol.2011.03.004
   Kawase T, 2009, J TISSUE ENG REGEN M, V3, P218, DOI 10.1002/term.156
   Kikuchi A, 2007, CELL SIGNAL, V19, P659, DOI 10.1016/j.cellsig.2006.11.001
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kubota K, 2006, ORAL MICROBIOL IMMUN, V21, P399, DOI 10.1111/j.1399 302X.2006.00326.x
   LEBLANC AD, 1990, J BONE MINER RES, V5, P843
   Lee GT, 2011, MOL IMMUNOL, V48, P1540, DOI 10.1016/j.molimm.2011.04.019
   Matsushima S, 2011, CELLS TISSUES ORGANS, V194, P320, DOI 10.1159/000324642
   Meeran Nazeer Ahmed, 2013, J Indian Soc Periodontol, V17, P16, DOI 10.4103/0972 124X.107468
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   Minami Y, 2010, DEV DYNAM, V239, P1, DOI 10.1002/dvdy.21991
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   Niu TH, 2005, GENE, V361, P38, DOI 10.1016/j.gene.2005.07.016
   Okamoto K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3323
   Qiang YW, 2008, BONE, V42, P669, DOI 10.1016/j.bone.2007.12.006
   Sakaki H, 2005, ORAL MICROBIOL IMMUN, V20, P47, DOI 10.1111/j.1399 302X.2005.00181.x
   Sato M, 1999, J BONE MINER RES, V14, P1084, DOI 10.1359/jbmr.1999.14.7.1084
   Sims NA, 2012, GROWTH FACTORS, V30, P76, DOI 10.3109/08977194.2012.656760
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Wang Q, 2011, BONE, V48, P524, DOI 10.1016/j.bone.2010.10.178
   Wei SW, 2010, J LEUKOCYTE BIOL, V88, P495, DOI 10.1189/jlb.1209822
   Wilson NH, 2012, VITAM HORM, V88, P173, DOI 10.1016/B978 0 12 394622 5.00008 0
   Xavier CP, 2014, CELL SIGNAL, V26, P94, DOI 10.1016/j.cellsig.2013.09.016
   Yadav VK, 2010, CALCIFIED TISSUE INT, V86, P382, DOI 10.1007/s00223 010 9350 7
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
NR 37
TC 16
Z9 17
U1 2
U2 16
PU BIOMEDICAL RESEARCH PRESS LTD
PI SAPPORO
PA HOKKAIDO UNIV, LAB HISTOLOGY & CYTOLOGY, C/O TOSHIHIKO IWANAGA, KITA
   15 NISHI 7, SAPPORO, 060 8638, JAPAN
SN 0388 6107
EI 1880 313X
J9 BIOMED RES TOKYO
JI Biomed. Res.
PD FEB
PY 2014
VL 35
IS 1
BP 69
EP 79
DI 10.2220/biomedres.35.69
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AC2SZ
UT WOS:000332355600008
PM 24573203
OA Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Shukla, RP
   Tiwari, P
   Sardar, A
   Urandur, S
   Gautam, S
   Marwaha, D
   Tripathi, AK
   Rai, N
   Trivedi, R
   Mishra, PR
AF Shukla, Ravi Prakash
   Tiwari, Pratiksha
   Sardar, Anirban
   Urandur, Sandeep
   Gautam, Shalini
   Marwaha, Disha
   Tripathi, Ashish Kumar
   Rai, Nikhil
   Trivedi, Ritu
   Mishra, Prabhat Ranjan
TI Alendronate functionalized porous nano crystalsomes mitigate osteolysis
   and consequent inhibition of tumor growth in a tibia induced metastasis
   model
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Crystalsomes; RANKL; Osteoclast; Osteoblast; Oleanolic acid; Alendronate
ID CONJUGATED MESOPOROUS SILICA; DRUG DELIVERY; ACID; NANOPARTICLES;
   EFFICACY; DOXORUBICIN; MECHANISMS
AB Bone is one of the most prevalent sites of metastases in various epithelial malignancies, including breast cancer and this metastasis to bone often leads to severe skeletal complications in women due to its osteolytic nature. To address this, we devised a novel drug delivery approach using an Alendronate (ALN) functionalized selfassembled porous crystalsomes for concurrent targeting of Oleanolic acid (OA) and ALN (ALN + OA@NCs) to bone metastasis. Initially, the conjugation of both PEG OA and OA PEG ALN with ALN and OA was achieved, and this conjugation was then self assembled into porous crystalsomes (ALN + OA@NCs) by nanoemulsion crystallization. The reconstruction of a 3D single particle using transmission electron microscopy ensured the crystalline porous structure of ALN + OA@NCs, was well aligned with characteristic nanoparticle attributes including size distribution, polydispersity, and zeta potential. Further, ALN + OA@NCs showed enhanced efficacy in comparison to OA@NCs suggesting the cytotoxic roles of ALN towards cancer cells, followed by augmentation ROS generation (40.81%), mitochondrial membrane depolarization (57.20%), and induction of apoptosis (40.43%). We found that ALN + OA@NCs facilitated inhibiting osteoclastogenesis and bone resorption followed by inhibited osteolysis. In vivo activity of ALN + OA@NCs in the 4 T1 cell induced tibia model rendered a reduced bone loss in the treated mice followed by restoring bone morphometric markers which were further corroborated bone targeting effects of ALN + OA@NCs to reduce RANKL stimulated osteoclastogenesis. Further, In vivo intravenous pharmacokinetics showed the improved therapeutic profile of the ALN + OA@NCs in comparison to the free drug, prolonging the levels of the drug in the systemic compartment by reducing the clearance culminating the higher accumulation at the tumor site. Our finding proposed that ALN + OA@NCs can effectively target and treat breast cancer metastasis to bone and its associated complications.
C1 [Shukla, Ravi Prakash; Tiwari, Pratiksha; Urandur, Sandeep; Gautam, Shalini; Marwaha, Disha; Rai, Nikhil; Mishra, Prabhat Ranjan] CSIR Cent Drug Res Inst, Div Pharmaceut & Pharmacokinet, Lucknow 226031, India.
   [Sardar, Anirban; Tripathi, Ashish Kumar; Trivedi, Ritu] CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, India.
   [Sardar, Anirban; Trivedi, Ritu; Mishra, Prabhat Ranjan] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Academy of Scientific & Innovative Research (AcSIR)
RP Mishra, PR (通讯作者)，CSIR Cent Drug Res Inst, Div Pharmaceut & Pharmacokinet, Lucknow 226031, India.; Trivedi, R (通讯作者)，CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, India.
EM ritu_trivedi@cdri.res.in; prabhat_mishra@cdri.res.in
RI SARDAR, ANIRBAN/GLV 3193 2022; marwaha, Disha/JZT 6903 2024; Shukla,
   Ravi Prakash/JVP 0271 2024; Urandur, Sandeep/GXA 0635 2022; Tripathi,
   Ashish/JXY 6318 2024; Mishra, Prabhat/KHY 3664 2024
OI Trivedi, Ritu/0000 0002 9524 2541; Tripathi, Ashish
   Kumar/0000 0002 0976 8476; Shukla, Ravi Prakash/0000 0001 7492 5848;
   SARDAR, ANIRBAN/0000 0002 7840 1862
FU CSIR CDRI; ICMR, New Delhi
FX The author would like to acknowledge CSIR CDRI and ICMR, New Delhi for
   the research fellowship. The authors thank the CSIR CDRI and DBT Govt.of
   India for providing the necessary research facilities. The authors would
   also like to thank Madhu Chaturvedi and A. L. Vishwakarma for their
   assistance with the flow cytometry studies. The authors thank Rima Ray
   Sarkar of the CSIR CDRI Division of Molecular and Structural Biology for
   her assistance in CLSM. Dr. Kalyan Mitra of the CSIR CDRI Division of
   Electron Microscopy provided the TEM and SEM images. The authors also
   thank NIPER Raebareli for providing the IVIVS system. The manuscript
   number allotted to this paper is 10804.
CR Adjei IM, 2016, J CONTROL RELEASE, V232, P83, DOI 10.1016/j.jconrel.2016.04.019
   Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037
   Asnani M, 2009, J PHARM SCI US, V98, P2113, DOI 10.1002/jps.21561
   Bakshi AK, 2022, DRUG DELIV TRANSL RE, V12, P2335, DOI 10.1007/s13346 021 01103 4
   Banala VT, 2019, BIOMATER SCI UK, V7, P2889, DOI 10.1039/c9bm00221a
   Banala VT, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800300
   Barley K, 2024, BLOOD ADV, V8, P1634, DOI 10.1182/bloodadvances.2023012304
   Blumer MJF, 2012, MECH DEVELOP, V129, P162, DOI 10.1016/j.mod.2012.04.003
   Cao X, 2015, MOL PHARMACEUT, V12, P274, DOI 10.1021/mp500637b
   Chen SH, 2020, J MATER CHEM B, V8, P3789, DOI 10.1039/d0tb00046a
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Damasco JA, 2023, TALANTA, V256, DOI 10.1016/j.talanta.2023.124308
   Ding XY, 2020, NANOSCALE RES LETT, V15, DOI 10.1186/s11671 020 03297 x
   Gautam S, 2023, MOL PHARMACEUT, DOI 10.1021/acs.molpharmaceut.2c00673
   Gdowski AS, 2017, NANOMEDICINE UK, V12, P2083, DOI 10.2217/nnm 2017 0190
   Green JR, 2002, AM J CLIN ONCOL CANC, V25, pS3, DOI 10.1097/00000421 200212001 00002
   Gunasekaran S, 2008, J CHEM SCI, V120, P315, DOI 10.1007/s12039 008 0054 8
   Ha H, 2011, BIOCHEM BIOPH RES CO, V406, P546, DOI 10.1016/j.bbrc.2011.02.085
   Hao WJ, 2017, RSC ADV, V7, P851, DOI 10.1039/c6ra25224a
   Jafari SH, 2018, J CELL PHYSIOL, V233, P5200, DOI 10.1002/jcp.26379
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kimura Y, 2017, SCI REP UK, V7, DOI 10.1038/srep44824
   Kothari P, 2023, BIOMED PHARMACOTHER, V163, DOI 10.1016/j.biopha.2023.114809
   Li L, 2015, INT J ONCOL, V47, P2247, DOI 10.3892/ijo.2015.3198
   Maeda H, 2013, ADV DRUG DELIVER REV, V65, P71, DOI 10.1016/j.addr.2012.10.002
   Marwaha D, 2023, COLLOID SURFACE B, V226, DOI 10.1016/j.colsurfb.2023.113316
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Mortezaee K, 2021, FUTURE ONCOL, V17, P1943, DOI 10.2217/fon 2020 1103
   Park SY, 2014, TOXICOL APPL PHARM, V275, P152, DOI 10.1016/j.taap.2014.01.009
   Pathan M, 2019, NUCLEIC ACIDS RES, V47, pD516, DOI 10.1093/nar/gky1029
   Phan TG, 2020, NAT REV CANCER, V20, P398, DOI 10.1038/s41568 020 0263 0
   Qi H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05396 x
   Rai Divya, 2022, Free Radic Biol Med, V190, P124, DOI 10.1016/j.freeradbiomed.2022.08.007
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sardar A, 2022, EUR J MED CHEM, V244, DOI 10.1016/j.ejmech.2022.114813
   Sardar A, 2022, LIFE SCI, V309, DOI 10.1016/j.lfs.2022.121020
   Schiffelers RM, 2003, J CONTROL RELEASE, V91, P115, DOI 10.1016/S0168 3659(03)00240 2
   Segal E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005233
   Sharma M, 2023, BIOMATER ADV, V155, DOI 10.1016/j.bioadv.2023.213672
   Sharma M, 2022, J CONTROL RELEASE, V346, P43, DOI 10.1016/j.jconrel.2022.04.007
   Sharma M, 2017, INT J BIOL MACROMOL, V104, P1345, DOI 10.1016/j.ijbiomac.2017.06.005
   Sharma S, 2016, ACS APPL MATER INTER, V8, P30407, DOI 10.1021/acsami.6b08958
   Sharma S, 2016, RSC ADV, V6, P73083, DOI 10.1039/c6ra11260a
   Shukla RP, 2021, BIOMATER SCI UK, V9, P1779, DOI 10.1039/d0bm01033b
   Shukla RP, 2020, BIOMATER SCI UK, V8, P1298, DOI 10.1039/c9bm01246j
   Singh N, 2023, BIOMACROMOLECULES, V24, P5780, DOI 10.1021/acs.biomac.3c00795
   Staub MC, 2022, ACS MACRO LETT, V11, P1022, DOI 10.1021/acsmacrolett.2c00347
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Tang G, 2007, J STRUCT BIOL, V157, P38, DOI 10.1016/j.jsb.2006.05.009
   Tang ZY, 2022, BIOMED PHARMACOTHER, V145, DOI 10.1016/j.biopha.2021.112397
   Thamake SI, 2012, BIOMATERIALS, V33, P7164, DOI 10.1016/j.biomaterials.2012.06.026
   Tiwari P, 2024, ARCH BIOCHEM BIOPHYS, V756, DOI 10.1016/j.abb.2024.110022
   Tiwari P, 2024, J MOL GRAPH MODEL, V128, DOI 10.1016/j.jmgm.2024.108702
   Tiwari P, 2024, J CONTROL RELEASE, V365, P43, DOI 10.1016/j.jconrel.2023.11.005
   Tiwari P, 2023, J CONTROL RELEASE, V363, P290, DOI 10.1016/j.jconrel.2023.09.016
   Urandur S, 2020, ACTA BIOMATER, V113, P522, DOI 10.1016/j.actbio.2020.06.023
   Urandur S, 2018, ACS APPL MATER INTER, V10, P12960, DOI 10.1021/acsami.7b19109
   Wang FF, 2014, J CONTROL RELEASE, V196, P222, DOI 10.1016/j.jconrel.2014.10.012
   Wang WD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10599
   Wen J, 2017, CHEM SOC REV, V46, P6024, DOI 10.1039/c7cs00219j
   Wu XQ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00076
   Yadav K, 2023, INT J BIOL MACROMOL, V241, DOI 10.1016/j.ijbiomac.2023.124582
   Yang XX, 2016, ASIAN J PHARM SCI, V11, P241, DOI 10.1016/j.ajps.2015.07.002
   Ye WL, 2015, SCI REP UK, V5, DOI 10.1038/srep14614
   Zhao QF, 2015, ACTA BIOMATER, V23, P147, DOI 10.1016/j.actbio.2015.05.010
   Zhao RR, 2017, BIOMATERIALS, V143, P1, DOI 10.1016/j.biomaterials.2017.07.030
NR 67
TC 4
Z9 4
U1 2
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD AUG
PY 2024
VL 372
BP 331
EP 346
DI 10.1016/j.jconrel.2024.06.009
EA JUN 2024
PG 16
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA XG5K1
UT WOS:001260540800001
PM 38844176
DA 2025 08 17
ER

PT J
AU Guo, JC
   Ren, RY
   Guo, Z
   Sun, K
   He, JP
   Shao, JF
   Wang, XL
AF Guo, Jiachao
   Ren, Ranyue
   Guo, Zhou
   Sun, Kai
   He, Jinpeng
   Shao, Jingfan
   Wang, Xiaolin
TI Probucol suppresses osteoclastogenesis via activating Nrf2 signaling and
   ameliorates ovariectomy induced bone loss
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Probucol; Osteoporosis; Osteoclast; RANKL; Nrf2
ID OSTEOPOROSIS; IDENTIFICATION; DYSFUNCTION; PROTECTS; DISEASE
AB Osteoporosis is a systemic and endocrine bone disorder distinguished by declined bone mineral density, compromised bone strength, and destruction of trabecular structure. The abnormally excessive osteoclasto genesis and bone erosion play imperative roles in the progression of osteoporosis. However, treatment of oste oporosis is far from satisfactory due to poor adherence to existing medications and adverse reactions, there is an urgent to develop novel therapies for osteoporosis. Probucol, a synthetic compound with two characteristic phenolic rings, owns anti inflammatory and antioxidant properties. Accumulating evidence have indicated that intracellular reactive oxygen species (ROS) is closely related to osteoclastogenesis. Hence, we investigated the potential effects of probucol on osteoclastogenesis in vivo and in vitro. In this study, TRAP staining and bone slice resorption assay showed that probucol suppressed RANKL induced osteoclast formation and function. The mRNA and protein levels of osteoclastogenesis marker genes were reduced by probucol in a concentration dependent manner. Besides, probucol suppressed osteoclast differentiation by inhibiting ROS production, MAPKs and NF Kappa B signaling pathways, while Nrf2 silencing reversed the inhibitory effect of probucol on osteoclast formation and function. Consistent with the above findings, in vivo experiments demonstrated that probucol visibly alle viated bone loss caused by estrogen deficiency. In brief, these results showed the potential of anti oxidant compound probucol in the treatment of osteoporosis, highlighting Nrf2 as a promising target in osteoclast related disease.
C1 [Guo, Jiachao; Shao, Jingfan; Wang, Xiaolin] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat Surg, Wuhan 430030, Hubei, Peoples R China.
   [Ren, Ranyue; Guo, Zhou; Sun, Kai] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430030, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology
RP Shao, JF; Wang, XL (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pediat Surg, Wuhan 430030, Hubei, Peoples R China.
EM guojcdoc@tjh.tjmu.edu.cn; renranyue@tjh.tjmu.edu.cn; 1178519539@qq.com;
   1085844308@qq.com; hejinpeng2006@126.com; shaojf65@126.com;
   olaf7819@163.com
RI Kai, Sun/AGH 0704 2022; He, Jinpeng/GQI 2034 2022
FU National Natural Science Foundation of China [82102625]
FX This study was supported by National Natural Science Foundation of China
   (grant number 82102625) .
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chen XR, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00128 8
   Colle D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067658
   Colle D, 2012, BRAIN RES BULL, V87, P397, DOI 10.1016/j.brainresbull.2012.01.003
   Derangula K, 2022, INT IMMUNOPHARMACOL, V102, DOI 10.1016/j.intimp.2021.108397
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Goettsch C, 2013, J CLIN INVEST, V123, P4731, DOI 10.1172/JCI67603
   Guo JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03046 z
   Guo JC, 2020, AGING US, V12, P3976, DOI 10.18632/aging.102866
   Guo JC, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00693
   Gyori DS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00507
   Ha YJ, 2021, MAR DRUGS, V19, DOI 10.3390/md19030132
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Jung YS, 2016, ACTA PHARMACOL SIN, V37, P1031, DOI 10.1038/aps.2016.51
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Krishnamurthy A, 2016, ANN RHEUM DIS, V75, P721, DOI 10.1136/annrheumdis 2015 208093
   Langdahl BL, 2021, BRIT J PHARMACOL, V178, P1891, DOI 10.1111/bph.15024
   Lau M, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14030502
   Liu Y, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03939 7
   Liu ZY, 2021, REDOX BIOL, V48, DOI 10.1016/j.redox.2021.102180
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Ni S, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12882
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raynaud Messina B, 2019, BONE, V127, P315, DOI 10.1016/j.bone.2019.06.023
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Ren RY, 2020, J CELL PHYSIOL, V235, P6204, DOI 10.1002/jcp.29549
   Sánchez de Diego C, 2021, REDOX BIOL, V40, DOI 10.1016/j.redox.2020.101845
   Santos DB, 2020, MOL NEUROBIOL, V57, P3245, DOI 10.1007/s12035 020 01963 w
   Schröder K, 2015, CELL MOL LIFE SCI, V72, P25, DOI 10.1007/s00018 014 1712 2
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev biochem 061516 045037
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Singer FR, 2015, NAT REV ENDOCRINOL, V11, P662, DOI 10.1038/nrendo.2015.138
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Sun K, 2019, AGING US, V11, P10513, DOI 10.18632/aging.102474
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Sun YX, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929 015 0212 5
   Takechi R, 2013, CLIN EXP PHARMACOL P, V40, P45, DOI 10.1111/1440 1681.12032
   Tao ZS, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00503 7
   Wang HR, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01788 3
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Witting PK, 2005, J BIOL CHEM, V280, P15612, DOI 10.1074/jbc.M414256200
   Zhang QB, 2016, CELL PHYSIOL BIOCHEM, V39, P89, DOI 10.1159/000445608
   Zucoloto AZ, 2017, EUR J PHARMACOL, V809, P52, DOI 10.1016/j.ejphar.2017.05.016
NR 47
TC 7
Z9 7
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD MAR
PY 2023
VL 116
AR 109820
DI 10.1016/j.intimp.2023.109820
EA FEB 2023
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 8T8QT
UT WOS:000929520200001
PM 36758295
OA hybrid
DA 2025 08 17
ER

PT J
AU Prawitt, J
   Beil, FT
   Marshall, RP
   Bartelt, A
   Ruether, W
   Heeren, J
   Amling, M
   Staels, B
   Niemeier, A
AF Prawitt, Janne
   Beil, F. Timo
   Marshall, Robert P.
   Bartelt, Alexander
   Ruether, Wolfgang
   Heeren, Joerg
   Amling, Michael
   Staels, Bart
   Niemeier, Andreas
TI Short term activation of liver X receptors inhibits osteoblasts but
   long term activation does not have an impact on murine bone in
   vivo
SO BONE
LA English
DT Article
DE Liver X receptor; Synthetic LXR ligand; Bone; Osteoblast
ID PANCREATIC BETA CELLS; MARROW STROMAL CELLS; NUCLEAR RECEPTOR;
   INSULIN SECRETION; GENE EXPRESSION; LXR ALPHA; PHARMACOLOGICAL
   ACTIVATION; CHOLESTEROL HOMEOSTASIS; RESPONSE PATHWAY; DEFICIENT MICE
AB Liver X receptors (LXRs) are nuclear receptors that play a crucial role in the transcriptional control of lipid metabolism. Pharmacological LXR activation is an attractive concept for the treatment of atherosclerosis. Genetic LXR deficiency in mice has been shown to have an effect on bone turnover and structure and LXR activation is known to influence the osteogenic differentiation of bone marrow stromal cells. Therefore, therapeutic pharmacological LXR activation may have relevant effects on bone.
   Here, using two synthetic LXR ligands, T0901317 and GW3965, we investigated the effect of LXR activation on murine osteoblasts and the influence of long term LXR activation on bone in vivo in mice. Short term (48 h) in vitro treatment of primary murine osteoblasts with T0901317.resulted in a dose dependent decrease of osteocalcin and alkaline phosphatase mRNA and protein. In vivo, a 6 day treatment of C57BL/6J mice with T0901317 led to a 40% reduction of serum osteocalcin concentrations. Long term (12 week) oral administration of T0901317 or GW3965 influenced the expression of established LXR target genes in liver and intestine, but did not alter trabecular and cortical bone structure or bone turnover as determined by total skeleton radiography, histomorphometric analysis of lumbar vertebral trabecular bone, micro CT analysis of femur cortical bone and biochemical determination of bone formation and resorption markers.
   We conclude that short term pharmacological LXR activation has the potential to profoundly influence osteoblast function, but that long term LXR activation in vivo has no adverse effects on the murine skeleton. 2010 Elsevier Inc. All rights reserved.
C1 [Beil, F. Timo; Ruether, Wolfgang; Niemeier, Andreas] Univ Med Ctr Hamburg Eppendorf, Dept Orthopaed, D 20246 Hamburg, Germany.
   [Prawitt, Janne; Staels, Bart] Univ Lille Nord France, INSERM, Inst Pasteur Lille, UMR1011,UDSL, Lille, France.
   [Beil, F. Timo; Marshall, Robert P.; Amling, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
   [Bartelt, Alexander; Heeren, Joerg; Niemeier, Andreas] Univ Med Ctr Hamburg Eppendorf, Dept Biochem & Mol Biol Mol Cell Biol 2, D 20246 Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   Universite de Lille; Pasteur Network; Institut Pasteur Lille; Institut
   National de la Sante et de la Recherche Medicale (Inserm); University of
   Hamburg; University Medical Center Hamburg Eppendorf; University of
   Hamburg; University Medical Center Hamburg Eppendorf
RP Niemeier, A (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Orthopaed, Martinistr 52, D 20246 Hamburg, Germany.
EM janne.prawitt@inserm.fr; t.beil@uke.de; r.marshall@uke.de;
   abartelt@uke.uni hamburg.de; ruether@uke.uni hamburg.de;
   heeren@uke.uni hamburg.de; amling@uke.de; Bart.Staels@pasteur lille.fr;
   niemeier@uke.uni hamburg.de
RI Marshall, Robert/AAD 5269 2022; Staels, Bart/N 9497 2016; Beil, Frank
   Timo/JBI 9771 2023; Bartelt, Alexander/ABC 2525 2020
OI Staels, Bart/0000 0002 3784 1503; Marshall, Robert
   Percy/0000 0003 4247 1006; Bartelt, Alexander/0000 0001 7840 3991
FU Deutsche Forschungsgemeinschaft [Ni 637/2 3]; Jurgen Rickertsen Stiftung
FX We thank Walter Tauscher and Sandra Ehret for expert technical
   assistance and Ulrike Beisiegel for continuous support and fruitful
   discussions. This study was supported by grants from the Deutsche
   Forschungsgemeinschaft (Ni 637/2 3) and the Jurgen Rickertsen Stiftung.
   AB is a fellow of the Ernst Schering Foundation.
CR Aghaloo TL, 2007, J ORTHOP RES, V25, P1488, DOI 10.1002/jor.20437
   Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982
   Bradley MN, 2007, J CLIN INVEST, V117, P2337, DOI 10.1172/JCI31909
   Cha JY, 2007, J BIOL CHEM, V282, P743, DOI 10.1074/jbc.M605023200
   Chen WL, 2007, CELL METAB, V5, P73, DOI 10.1016/j.cmet.2006.11.012
   Choe SS, 2007, DIABETES, V56, P1534, DOI 10.2337/db06 1059
   Collins JL, 2002, J MED CHEM, V45, P1963, DOI 10.1021/jm0255116
   Costet P, 2000, J BIOL CHEM, V275, P28240
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Dwyer JR, 2007, J BIOL CHEM, V282, P8959, DOI 10.1074/jbc.M611741200
   Eckert GP, 2007, NEUROSCI LETT, V423, P47, DOI 10.1016/j.neulet.2007.05.063
   Efanov AM, 2004, DIABETES, V53, pS75, DOI 10.2337/diabetes.53.suppl_3.S75
   Fiévet C, 2009, BIOCHEM PHARMACOL, V77, P1316, DOI 10.1016/j.bcp.2008.11.026
   Green CD, 2009, ENDOCRINOLOGY, V150, P2637, DOI 10.1210/en.2008 1039
   Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200
   Grey A, 2008, OSTEOPOROSIS INT, V19, P129, DOI 10.1007/s00198 007 0477 y
   Grey A, 2009, DIABETES OBES METAB, V11, P275, DOI 10.1111/j.1463 1326.2008.00931.x
   Hu BH, 2006, J MED CHEM, V49, P6151, DOI 10.1021/jm0609566
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200
   Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299
   Kalaany NY, 2005, CELL METAB, V1, P231, DOI 10.1016/j.cmet.2005.03.001
   Kha HT, 2004, J BONE MINER RES, V19, P830, DOI 10.1359/JBMR.040115
   Kim WK, 2007, J BONE MINER RES, V22, P1711, DOI 10.1359/JBMR.070710
   Kim WK, 2010, J BONE MINER RES, V25, P782, DOI 10.1359/jbmr.091024
   Kim WK, 2009, MOL ENDOCRINOL, V23, P1532, DOI 10.1210/me.2008 0453
   Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100
   Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137
   Levin N, 2005, ARTERIOSCL THROM VAS, V25, P135, DOI 10.1161/01.ATV.0000150044.84012.68
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Miao B, 2004, J LIPID RES, V45, P1410, DOI 10.1194/jlr.M300450 JLR200
   Naik SU, 2006, CIRCULATION, V113, P90, DOI 10.1161/CIRCULATIONAHA.105.560177
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Peng DC, 2008, J PHARMACOL EXP THER, V327, P332, DOI 10.1124/jpet.108.142687
   Quinet EM, 2004, J LIPID RES, V45, P1929, DOI 10.1194/jlr.M400257 JLR200
   Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459
   Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524
   Repa JJ, 2007, J NEUROSCI, V27, P14470, DOI 10.1523/JNEUROSCI.4823 07.2007
   Richardson JA, 2007, J CELL BIOCHEM, V100, P1131, DOI 10.1002/jcb.21112
   Robertson KM, 2006, J BONE MINER RES, V21, P1276, DOI 10.1359/JBMR.060503
   Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400
   Stenson BM, 2009, ENDOCRINOLOGY, V150, P4104, DOI 10.1210/en.2009 0676
   TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096
   Terasaka N, 2003, FEBS LETT, V536, P6, DOI 10.1016/S0014 5793(02)03578 0
   Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697
   WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033
   Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883
   Zitzer H, 2006, ENDOCRINOLOGY, V147, P3898, DOI 10.1210/en.2005 1483
NR 48
TC 18
Z9 20
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB 1
PY 2011
VL 48
IS 2
BP 339
EP 346
DI 10.1016/j.bone.2010.08.018
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 710UY
UT WOS:000286543700022
PM 20817130
DA 2025 08 17
ER

PT J
AU Ndong, JD
   Stephenson, Y
   Davis, ME
   García, AJ
   Goudy, S
AF Ndong, Jean De La Croix
   Stephenson, Yvonne
   Davis, Michael E.
   Garcia, Andres J.
   Goudy, Steven
TI Controlled JAGGED1 delivery induces human embryonic palate mesenchymal
   cells to form osteoblasts
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE JAGGED1; notch; bone; hydrogel
ID BONE MORPHOGENETIC PROTEIN 2; ALAGILLE SYNDROME PATIENTS; PULP
   STEM CELLS; REGENERATIVE MEDICINE; SIGNALING PATHWAYS; GROWTH FACTORS;
   NOTCH; HYDROGEL; DIFFERENTIATION; SCAFFOLDS
AB Osteoblast commitment and differentiation are controlled by multiple growth factors including members of the Notch signaling pathway. JAGGED1 is a cell surface ligand of the Notch pathway that is necessary for murine bone formation. The delivery of JAGGED1 to induce bone formation is complicated by its need to be presented in a bound form to allow for proper Notch receptor signaling. In this study, we investigate whether the sustained release of JAGGED1 stimulates human mesenchymal cells to commit to osteoblast cell fate using polyethylene glycol malemeide (PEG MAL) hydrogel delivery system. Our data demonstrated that PEG MAL hydrogel constructs are stable in culture for at least three weeks and maintain human mesenchymal cell viability with little cytotoxicity in vitro. JAGGED1 loaded on PEG MAL hydrogel (JAGGED1 PEG MAL) showed continuous release from the gel for up to three weeks, with induction of Notch signaling using a CHO cell line with a Notch1 reporter construct, and qPCR gene expression analysis in vitro. Importantly, JAGGED1 PEG MAL hydrogel induced mesenchymal cells towards osteogenic differentiation based on increased Alkaline phosphatase activity and osteoblast genes expression including RUNX2, ALP, COL1, and BSP. These results thus indicated that JAGGED1 delivery in vitro using PEG MAL hydrogel induced osteoblast commitment, suggesting that this may be a viable in vivo approach to bone regeneration. (c) 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 552 560, 2018.
C1 [Ndong, Jean De La Croix; Stephenson, Yvonne; Goudy, Steven] Emory Univ, Dept Otolaryngol, Atlanta, GA 30322 USA.
   [Goudy, Steven] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA.
   [Davis, Michael E.] Emory Univ, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA.
   [Garcia, Andres J.] Georgia Inst Technol, Atlanta, GA 30332 USA.
   [Garcia, Andres J.] Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA.
C3 Emory University; Emory University; Emory University; University System
   of Georgia; Georgia Institute of Technology; University System of
   Georgia; Georgia Institute of Technology
RP Ndong, JD (通讯作者)，Emory Univ, Dept Otolaryngol, Atlanta, GA 30322 USA.
EM delacroix.ndong@emory.edu
RI Davis, Michael/K 6300 2012
FU Oral Maxillofacial Surgery Foundation; Children's Healthcare of Atlanta
   Research Trust; NIH [HL127236]
FX We would like to thank Manvinder Kumar and Melissa Oh for their help on
   this project. This work was supported by grants from the Oral
   Maxillofacial Surgery Foundation and from Children's Healthcare of
   Atlanta Research Trust (SG) and NIH HL127236 (SG, AG, MD).
CR Bales CB, 2010, J PEDIATR GASTR NUTR, V51, P66, DOI 10.1097/MPG.0b013e3181cb9629
   Bodalia PN, 2016, BONE JOINT RES, V5, P145, DOI 10.1302/2046 3758.54.2000418
   Boopathy AV, 2015, TISSUE ENG PT A, V21, P2315, DOI [10.1089/ten.tea.2014.0622, 10.1089/ten.TEA.2014.0622]
   Boopathy AV, 2014, BIOMATERIALS, V35, P8103, DOI 10.1016/j.biomaterials.2014.05.082
   Bosetti M, 2007, BIOMOL ENG, V24, P613, DOI 10.1016/j.bioeng.2007.08.019
   Dishowitz MI, 2014, J BIOMED MATER RES A, V102, P1558, DOI 10.1002/jbm.a.34825
   Dong YF, 2014, STEM CELL TRANSL MED, V3, P1456, DOI 10.5966/sctm.2014 0034
   Dosier CR, 2015, TISSUE ENG PT A, V21, P156, DOI [10.1089/ten.tea.2014.0057, 10.1089/ten.TEA.2014.0057]
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   García AJ, 2014, ANN BIOMED ENG, V42, P312, DOI 10.1007/s10439 013 0870 y
   Habibovic P, 2007, J TISSUE ENG REGEN M, V1, P25, DOI 10.1002/term.5
   Hill CR, 2014, BONE, V62, P10, DOI 10.1016/j.bone.2014.01.019
   Howard D, 2008, J ANAT, V213, P66, DOI 10.1111/j.1469 7580.2008.00878.x
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Humphreys R, 2012, HUM MOL GENET, V21, P1374, DOI 10.1093/hmg/ddr575
   Im Jin Young, 2013, Lab Anim Res, V29, P196, DOI 10.5625/lar.2013.29.4.196
   Krantz ID, 1998, AM J HUM GENET, V62, P1361, DOI 10.1086/301875
   Krishnan L, 2015, CLIN ORTHOP RELAT R, V473, P2885, DOI 10.1007/s11999 015 4312 z
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Lin NY, 2016, ANN RHEUM DIS, V75, P2037, DOI 10.1136/annrheumdis 2015 208420
   Liu HC, 2011, TISSUE ENG PT A, V17, P2417, DOI [10.1089/ten.tea.2010.0620, 10.1089/ten.TEA.2010.0620]
   Liu P, 2016, P NATL ACAD SCI USA, V113, pE2152, DOI 10.1073/pnas.1603399113
   Ndong JD, 2015, J BONE MINER RES, V30, P55, DOI 10.1002/jbmr.2316
   Nooeaid P, 2012, J CELL MOL MED, V16, P2247, DOI 10.1111/j.1582 4934.2012.01571.x
   Perri B, 2007, SPINE J, V7, P235, DOI 10.1016/j.spinee.2006.04.010
   Phelps EA, 2013, BIOMATERIALS, V34, P4602, DOI 10.1016/j.biomaterials.2013.03.012
   Phelps EA, 2012, ADV MATER, V24, P64, DOI 10.1002/adma.201103574
   Ripamonti U, 2009, J CRANIOFAC SURG, V20, P1544, DOI 10.1097/SCS.0b013e3181b09ca6
   Rutz S, 2005, EUR J IMMUNOL, V35, P2443, DOI 10.1002/eji.200526294
   Shekaran A, 2014, BIOMATERIALS, V35, P5453, DOI 10.1016/j.biomaterials.2014.03.055
   Sprinzak D, 2010, NATURE, V465, P86, DOI 10.1038/nature08959
   Taichman DB, 2002, DEV DYNAM, V225, P166, DOI 10.1002/dvdy.10146
   TALLEYRONSHOLDT DJ, 1995, IN VITRO CELL DEV AN, V31, P274
   Tannoury CA, 2014, SPINE J, V14, P552, DOI 10.1016/j.spinee.2013.08.060
   Tollemar V, 2016, GENES DIS, V3, P56, DOI 10.1016/j.gendis.2015.09.004
   Tsukamoto J, 2017, TISSUE ENG PT A, V23, P1394, DOI [10.1089/ten.tea.2017.0025, 10.1089/ten.TEA.2017.0025]
   Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723
   Yuan X, 2016, TISSUE ENG PT A, V22, P928, DOI [10.1089/ten.tea.2016.0052, 10.1089/ten.TEA.2016.0052]
   Zeitouni S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003396
   Zhang SF, 2010, BIOMATERIALS, V31, P952, DOI 10.1016/j.biomaterials.2009.10.011
   Zhu JM, 2010, BIOMATERIALS, V31, P4639, DOI 10.1016/j.biomaterials.2010.02.044
NR 42
TC 10
Z9 11
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD FEB
PY 2018
VL 106
IS 2
BP 552
EP 560
DI 10.1002/jbm.a.36236
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA FR1MB
UT WOS:000418830200025
PM 28913955
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Mediero, A
   Ramkhelawon, B
   Perez Aso, M
   Moore, KJ
   Cronstein, BN
AF Mediero, Aranzazu
   Ramkhelawon, Bhama
   Perez Aso, Miguel
   Moore, Kathryn J.
   Cronstein, Bruce N.
TI Netrin 1 Is a Critical Autocrine/Paracrine Factor for Osteoclast
   Differentiation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE NETRIN 1; UNC5B; OSTEOCLAST DIFFERENTIATION; RHOA; FAK
ID RHEUMATOID ARTHRITIS; MACROPHAGE RETENTION; AXON OUTGROWTH; STEM CELLS;
   BONE CELLS; RECEPTOR; INFLAMMATION; UNC5B; MODULATION; ACTIVATION
AB Bone metabolism is a vital process that involves resorption by osteoclasts and formation by osteoblasts, which is closely regulated by immune cells. The neuronal guidance protein Netrin 1 regulates immune cell migration and inflammatory reactions, but its role in bone metabolism is unknown. During osteoclast differentiation, osteoclast precursors increase expression of Netrin 1 and its receptor Unc5b. Netrin 1 binds, in an autocrine and paracrine manner, to Unc5b to promote osteoclast differentiation in vitro, and absence of Netrin 1 or antibody mediated blockade of Netrin 1 or Unc5b prevents osteoclast differentiation of both murine and human precursors. We confirmed the functional relationship of Netrin 1 in osteoclast differentiation in vivo using Netrin 1 deficient (Ntn1( / )) or wild type (WT) bone marrow transplanted mice. Notably, Ntn1( / ) chimeras have markedly diminished osteoclasts, as well as increased cortical and trabecular bone density and volume compared with WT mice. Mechanistic studies revealed that Netrin 1 regulates osteoclast differentiation by altering cytoskeletal assembly. Netrin 1 increases regulator of Rho GEF subfamily (LARG) and repulsive guidance molecule (RGMa) association with Unc5b, which increases expression and activation of cytoskeletal regulators RhoA and focal adhesion kinase (FAK). Netrin 1 and its receptor Unc5b likely play a role in fusion of osteoclast precursors because Netrin 1 and DC STAMP are tightly linked. These results identify Netrin 1 as a key regulator of osteoclast differentiation that may be a new target for bone therapies. (c) 2015 American Society for Bone and Mineral Research.
C1 [Mediero, Aranzazu; Perez Aso, Miguel; Cronstein, Bruce N.] NYU, Sch Med, Dept Med, Div Translat Med, New York, NY 10016 USA.
   [Ramkhelawon, Bhama; Moore, Kathryn J.] NYU, Sch Med, Leon H Charney Div Cardiol, Dept Med, New York, NY 10016 USA.
C3 New York University; New York University
RP Cronstein, BN (通讯作者)，NYU, Sch Med, Dept Med, Div Translat Med, 550 First Ave,MSB251, New York, NY 10016 USA.
EM Bruce.Cronstein@nyumc.org
RI ; Moore, Kathryn/ABE 6416 2020; Mediero, Aranzazu/AAA 8362 2020;
   Cronstein, Bruce/JTD 2507 2023
OI Pintor, Jesus/0000 0002 9191 7679; Cronstein, Bruce/0000 0002 4295 7383;
   Mediero, Aranzazu/0000 0002 5368 574X; Moore,
   kathryn/0000 0003 2505 2547; Perez Aso, Miguel/0000 0002 4703 4182
FU National Institutes of Health [AR56672, AR54897, AR046121, RC1HL100815];
   NYU HHC Clinical and Translational Science Institute [UL1TR000038];
   NYUCI Center Support Grant [9NIH/NCI 5 P30CA16087 310]; Celgene;
   AstraZeneca; Gilead Pharmaceuticals
FX This work was supported by grants from the National Institutes of Health
   (AR56672, AR54897, AR046121, RC1HL100815), the NYU HHC Clinical and
   Translational Science Institute (UL1TR000038), the NYUCI Center Support
   Grant, 9NIH/NCI 5 P30CA16087 310, and grants from Celgene, AstraZeneca,
   and Gilead Pharmaceuticals.
CR Aherne CM, 2012, GUT, V61, P695, DOI 10.1136/gutjnl 2011 300012
   Ai LS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046287
   Awaya N, 2002, EXP HEMATOL, V30, P937, DOI 10.1016/S0301 472X(02)00821 4
   BJURHOLM A, 1991, INT ORTHOP, V15, P325
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Causeret F, 2004, DEVELOPMENT, V131, P2841, DOI 10.1242/dev.01162
   Chen J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046201
   Chitu V, 2005, MOL BIOL CELL, V16, P2947, DOI 10.1091/mbc.E04 10 0914
   Edwards Claire M, 2008, Int J Med Sci, V5, P263
   Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Grenz A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014812
   Halvorson KG, 2005, CANCER RES, V65, P9426, DOI 10.1158/0008 5472.CAN 05 0826
   Han Y, 2012, INVEST OPHTH VIS SCI, V53, P1285, DOI 10.1167/iovs.11 8722
   Hata K, 2009, J CELL BIOL, V184, P737, DOI 10.1083/jcb.200807029
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   He WJ, 2013, FASEB J, V27, P3446, DOI 10.1096/fj.13 231233
   HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059
   Kang SJ, 2013, SEMIN CELL DEV BIOL, V24, P163, DOI 10.1016/j.semcdb.2012.09.008
   Koç ON, 1999, EXP HEMATOL, V27, P1675, DOI 10.1016/S0301 472X(99)00101 0
   Li WQ, 2004, NAT NEUROSCI, V7, P1213, DOI 10.1038/nn1329
   Ly NP, 2005, P NATL ACAD SCI USA, V102, P14729, DOI 10.1073/pnas.0506233102
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mediero A, 2013, BRIT J PHARMACOL, V169, P1372, DOI 10.1111/bph.12227
   Mediero A, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003393
   Mediero A, 2012, AM J PATHOL, V180, P775, DOI 10.1016/j.ajpath.2011.10.017
   Mehlen P, 2005, CELL MOL LIFE SCI, V62, P2599, DOI 10.1007/s00018 005 5191 3
   Mirakaj V, 2011, J IMMUNOL, V186, P549, DOI 10.4049/jimmunol.1002671
   Mirakaj V, 2010, AM J RESP CRIT CARE, V181, P815, DOI 10.1164/rccm.200905 0717OC
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Nishiyama M, 2003, NATURE, V423, P990, DOI 10.1038/nature01751
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Ramkhelawon B, 2014, NAT MED, V20, P377, DOI 10.1038/nm.3467
   Ramkhelawon B, 2013, ARTERIOSCL THROM VAS, V33, P1180, DOI 10.1161/ATVBAHA.112.301008
   Reyes M, 2005, BLOOD, V106, P3646, DOI 10.1182/blood 2004 12 4603
   Rosenberger P, 2009, NAT IMMUNOL, V10, P195, DOI 10.1038/ni.1683
   Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105 2896.2005.00331.x
   Schubert T, 2009, INT J IMMUNOPATH PH, V22, P715, DOI 10.1177/039463200902200317
   Shahrara S, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2318
   SIMMONS PJ, 1987, NATURE, V328, P429, DOI 10.1038/328429a0
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sun CY, 2012, INT J CANCER, V130, P827, DOI 10.1002/ijc.26059
   Sun HL, 2009, CELLS TISSUES ORGANS, V190, P69, DOI 10.1159/000178020
   Tadagavadi RK, 2010, J IMMUNOL, V185, P3750, DOI 10.4049/jimmunol.1000435
   Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943
   Togari A, 2000, BRAIN RES, V878, P204, DOI 10.1016/S0006 8993(00)02700 1
   van Gils JM, 2012, NAT IMMUNOL, V13, P136, DOI 10.1038/ni.2205
   Wang WW, 2008, AM J PHYSIOL RENAL, V294, pF739, DOI 10.1152/ajprenal.00508.2007
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756 3282(99)00121 0
NR 52
TC 52
Z9 60
U1 2
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2015
VL 30
IS 5
BP 837
EP 854
DI 10.1002/jbmr.2421
PG 18
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CG2JQ
UT WOS:000353101100009
PM 25483983
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Fleischhacker, V
   Milosic, F
   Bricelj, M
   Kührer, K
   Wahl Figlash, K
   Heimel, P
   Diendorfer, A
   Nardini, E
   Fischer, I
   Stangl, H
   Pietschmann, P
   Hackl, M
   Foisner, R
   Grillari, J
   Hengstschläger, M
   Osmanagic Myers, S
AF Fleischhacker, Viviane
   Milosic, Filip
   Bricelj, Marko
   Kuehrer, Kristina
   Wahl Figlash, Katharina
   Heimel, Patrick
   Diendorfer, Andreas
   Nardini, Eleonora
   Fischer, Irmgard
   Stangl, Herbert
   Pietschmann, Peter
   Hackl, Matthias
   Foisner, Roland
   Grillari, Johannes
   Hengstschlaeger, Markus
   Osmanagic Myers, Selma
TI Aged vascular niche hinders osteogenesis of mesenchymal stem cells
   through paracrine repression of Wnt axis
SO AGING CELL
LA English
DT Article
DE aging; bone; cellular senescence; mesenchymal stem cells; microRNA;
   progeria; vascular
ID PROGERIA; BONE; EXPRESSION; OSTEOCYTES; MUTATION
AB Age induced decline in osteogenic potential of bone marrow mesenchymal stem cells (BMSCs) potentiates osteoporosis and increases the risk for bone fractures. Despite epidemiology studies reporting concurrent development of vascular and bone diseases in the elderly, the underlying mechanisms for the vascular bone cross talk in aging are largely unknown. In this study, we show that accelerated endothelial aging deteriorates bone tissue through paracrine repression of Wnt driven axis in BMSCs. Here, we utilize physiologically aged mice in conjunction with our transgenic endothelial progeria mouse model (Hutchinson Gilford progeria syndrome; HGPS) that displays hallmarks of an aged bone marrow vascular niche. We find bone defects associated with diminished BMSC osteogenic differentiation that implicate the existence of angiocrine factors with long term inhibitory effects. microRNA transcriptomics of HGPS patient plasma combined with aged vascular niche analyses in progeria mice reveal abundant secretion of Wnt repressive microRNA 31 5p. Moreover, we show that inhibition of microRNA 31 5p as well as selective Wnt activator CHIR99021 boosts the osteogenic potential of BMSCs through de repression and activation of the Wnt signaling, respectively. Our results demonstrate that the vascular niche significantly contributes to osteogenesis defects in aging and pave the ground for microRNA based therapies of bone loss in elderly.
   Aging of the vascular niche hinders osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) leading to a decline in osteogenesis and cortical bone thinning. Mechanistically, paracrine senescence associated microRNA 31 5p (miR 31) signals derived from the aged vascular niche inhibit pro osteogenic Wnt signaling. Targeting microRNA 31 5p may represent a promising strategy to combat bone loss in elderly.image
C1 [Fleischhacker, Viviane; Milosic, Filip; Bricelj, Marko; Kuehrer, Kristina; Nardini, Eleonora; Stangl, Herbert; Hengstschlaeger, Markus; Osmanagic Myers, Selma] Med Univ Vienna, Ctr Pathobiochem & Genet, Vienna, Austria.
   [Wahl Figlash, Katharina; Pietschmann, Peter] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Vienna, Austria.
   [Heimel, Patrick; Grillari, Johannes] Res Ctr Cooperat AUVA, Ludwig Boltzmann Inst Traumatol, Vienna, Austria.
   [Heimel, Patrick; Grillari, Johannes] Austrian Cluster Tissue Regenerat, Vienna, Austria.
   [Heimel, Patrick] Med Univ Vienna, Univ Clin Dent, Karl Donath Lab, Core Facil Hard Tissue & Biomat Res, Vienna, Austria.
   [Diendorfer, Andreas; Hackl, Matthias] TAmiRNA GmbH, Vienna, Austria.
   [Fischer, Irmgard; Foisner, Roland] Vienna Bioctr Campus VBC, Max Perutz Labs, Vienna, Austria.
   [Foisner, Roland] Med Univ Vienna, Max Perutz Labs, Vienna, Austria.
   [Grillari, Johannes] Univ Nat Resources & Life Sci, Inst Mol Biotechnol, Dept Biotechnol, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Ludwig
   Boltzmann Institute; Ludwig Boltzmann Institute for Experimental &
   Clinical Traumatology; Medical University of Vienna; Medical University
   of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz
   Laboratories (MFPL); Medical University of Vienna; University of Vienna;
   Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Vienna
   Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); BOKU
   University
RP Osmanagic Myers, S (通讯作者)，Med Univ Vienna, Ctr Pathobiochem & Genet, Vienna, Austria.
EM selma.osmanagic myers@meduniwien.ac.at
RI Grillari, Johannes/B 2967 2011; Stangl, Herbert/AAT 4379 2021; Hackl,
   Matthias/LSK 0315 2024; Osmanagic Myers, Selma/AAI 8921 2020
OI Grillari, Johannes/0000 0001 5474 6332; Nardini,
   Eleonora/0000 0001 7444 0488; Stangl, Herbert/0000 0002 7288 7320;
   Diendorfer, Andreas Bernhard/0000 0003 0331 9685; Osmanagic Myers,
   Selma/0000 0002 3834 1332; 
FU Austrian Science Fund (FWF); Progeria Research Foundation
FX We would like to thank The Progeria Research Foundation (PRF) Cell and
   Tissue Bank for providing us with plasma samples from HGPS patients and
   unaffected controls. In this respect, we especially want to acknowledge
   Leslie Gordon. We further thank Christina Troindl, Hyejin Hwang, Paula
   Erfurt, Christina Manakanatas, and Moritz Weigl for assistance in
   experiments. Moreover, we thank Vienna Biocenter Core Facilities (VBC,
   NGS Facilities) for miRNA sequencing, and Loredana Ionce and Dragana
   Peric for administrative and genotyping support. Drawings were created
   with (license holder: Viviane Fleischhacker).
CR Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784
   Biswas L, 2023, CELL, V186, P382, DOI 10.1016/j.cell.2022.12.031
   Brunet A, 2023, NAT REV MOL CELL BIO, V24, P45, DOI 10.1038/s41580 022 00510 w
   Cabral WA, 2023, AGING CELL, V22, DOI 10.1111/acel.13903
   Cenni V, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101073
   Chen JY, 2020, J BONE MINER RES, V35, P2103, DOI 10.1002/jbmr.4171
   Choi JY, 2018, J BONE MINER RES, V33, P2059, DOI 10.1002/jbmr.3549
   Doolittle ML, 2021, MECH AGEING DEV, V199, DOI 10.1016/j.mad.2021.111565
   Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629
   Ferguson VL, 2003, BONE, V33, P387, DOI 10.1016/S8756 3282(03)00199 6
   Galli C, 2012, EUR CELLS MATER, V24, P46, DOI 10.22203/eCM.v024a04
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Grillari J, 2021, BONE, V145, DOI 10.1016/j.bone.2020.115787
   Grunewald M, 2021, SCIENCE, V373, P533, DOI 10.1126/science.abc8479
   Hamczyk MR, 2018, CIRCULATION, V138, P266, DOI 10.1161/CIRCULATIONAHA.117.030856
   He NN, 2014, BONE MARROW RES, DOI 10.1155/2014/128436
   Heilmeier U, 2022, BONE, V158, DOI 10.1016/j.bone.2021.116308
   Hemmatian H, 2017, CURR OSTEOPOROS REP, V15, P401, DOI 10.1007/s11914 017 0402 z
   Hernandez L, 2010, DEV CELL, V19, P413, DOI 10.1016/j.devcel.2010.08.013
   Ho YH, 2019, CELL STEM CELL, V25, P407, DOI 10.1016/j.stem.2019.06.007
   Hofmann JW, 2014, AGE, V36, P1033, DOI 10.1007/s11357 014 9618 3
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lehmann J, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 021 04035 x
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   López Otin C, 2023, CELL, V186, P243, DOI 10.1016/j.cell.2022.11.001
   Manakanatas C, 2022, AGING US, V14, P195, DOI 10.18632/aging.203820
   Matsuzaki Y, 2014, CELL STEM CELL, V15, P112, DOI 10.1016/j.stem.2014.07.001
   Merideth MA, 2008, NEW ENGL J MED, V358, P592, DOI 10.1056/NEJMoa0706898
   Meshorer E, 2008, J CELL BIOL, V181, P9, DOI 10.1083/jcb.200802155
   Mo L, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.950030
   Mojiri A, 2021, EUR HEART J, V42, P4352, DOI 10.1093/eurheartj/ehab547
   Osmanagic Myers S, 2019, J CLIN INVEST, V129, P531, DOI 10.1172/JCI121297
   Primmer SR, 2022, AGING US, V14, P8150, DOI 10.18632/aging.204342
   Sagelius H, 2008, J CELL SCI, V121, P969, DOI 10.1242/jcs.022913
   Schmidt E, 2012, J BIOL CHEM, V287, P33512, DOI 10.1074/jbc.M112.366450
   Sun JF, 2005, P NATL ACAD SCI USA, V102, P128, DOI 10.1073/pnas.0403198102
   Wang ZX, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 29191 x
   Weigl M, 2021, J BONE MINER RES, V36, P1131, DOI 10.1002/jbmr.4276
   Weilner S, 2016, AGING CELL, V15, P744, DOI 10.1111/acel.12484
   Whitmarsh T, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 36299 y
   Wiley CD, 2017, AGING CELL, V16, P1043, DOI 10.1111/acel.12632
   Xu RY, 2018, AGING CELL, V17, DOI 10.1111/acel.12794
   Zhang L, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI158450
   Zhu SP, 2020, THERANOSTICS, V10, P5957, DOI 10.7150/thno.45422
NR 44
TC 7
Z9 7
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1474 9718
EI 1474 9726
J9 AGING CELL
JI Aging Cell
PD JUN
PY 2024
VL 23
IS 6
DI 10.1111/acel.14139
EA APR 2024
PG 16
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA TY4Y2
UT WOS:001197135400001
PM 38578073
OA gold
DA 2025 08 17
ER

PT J
AU Niu, YB
   Li, YH
   Kong, XH
   Zhang, R
   Sun, Y
   Li, Q
   Li, C
   Liu, L
   Wang, J
   Mei, QB
AF Niu, Y. B.
   Li, Y. H.
   Kong, X. H.
   Zhang, R.
   Sun, Y.
   Li, Q.
   Li, C.
   Liu, L.
   Wang, J.
   Mei, Q. B.
TI The beneficial effect of Radix Dipsaci total saponins on bone
   metabolism in vitro and in vivo and the possible mechanisms of action
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Osteoblast; Osteoclast; Osteoporosis; Ovariectomy; Radix Dipsaci total
   saponins
ID OVARIECTOMIZED RATS; ASPER WALL; HORMONE THERAPY; OSTEOPOROSIS; MASS;
   OSTEOBLASTS; EXTRACT; ROOTS; ARCHITECTURE; ENHANCEMENT
AB The purpose of this study is to investigate the anti osteoporotic effects of Radix Dipsaci total saponins (RTS). We showed that RTS was able to improve bone properties by either an increase of osteoblastic activity or a decrease in osteoclastic activity.
   Radix Dipsaci has long been used as an anti osteoporotic drug. The present study investigates the anti osteoporotic effects of RTS.
   Three month old female rats were randomly assigned into a sham operated group (sham) and five ovariectomy (OVX) subgroups, namely, OVX with vehicle (OVX), OVX with 17 beta ethinylestradiol (E 2), and OVX with graded doses of RTS (50, 100, or 200 mg/kg/d). RTS and E 2 were administered orally, daily from 1 week after OVX treatment for 4 months. Bone mass, turnover, and strength were evaluated by dual energy X ray absorptiometry, biochemical markers, and the three point bending test. The trabecular bone microarchitecture was assessed by microCT. In vitro experiments were performed to determine the potential molecular mechanisms of the anti osteoporotic effect of RTS.
   RTS prevented the loss of bone mass induced by OVX. The preventive effect on bone loss was primarily indicated by decreasing levels of bone turnover markers and confirmed by the changes in urinary calcium and phosphorus excretion. The treatment also enhanced the biomechanical strength of bone and prevented the deterioration of trabecular bone microarchitecture. RTS induced MC3T3 E1 and primary osteoblastic cell maturation and differentiation and increased bone formation by increasing BMP 2 synthesis. In addition, RTS inhibited osteoclastogenesis through an increase in osteoprotegrin and a decrease in NF kB ligand expression in vitro.
   RTS treatment can effectively suppress the loss of bone mass induced by OVX and in vitro evidence suggests this could be through actions on both osteoblasts and osteoclasts.
C1 [Niu, Y. B.; Kong, X. H.; Mei, Q. B.] NW Polytech Univ, Sch Life Sci, Xian 710072, Peoples R China.
   [Li, Y. H.] PLA, Dept Pharm, Hosp 422, Zhanjiang 524005, Peoples R China.
   [Zhang, R.; Sun, Y.; Li, Q.; Li, C.; Liu, L.; Mei, Q. B.] Fourth Mil Med Univ, Sch Pharm, Dept Pharmacol, Xian 710032, Peoples R China.
   [Wang, J.] Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China.
C3 Northwestern Polytechnical University; Air Force Medical University; Air
   Force Medical University
RP Mei, QB (通讯作者)，NW Polytech Univ, Sch Life Sci, Xian 710072, Peoples R China.
EM qbmei@nwpu.edu.cn
FU National Natural Science Foundation of China [81073037]; China
   Postdoctoral Science Foundation [2011M501482]
FX We would like to thank Dr. ZhenGuo Liu for providing the support in
   carrying out this study. This work was supported by the National Natural
   Science Foundation of China (grant no. 81073037) and the China
   Postdoctoral Science Foundation funded project (grant no. 2011M501482).
CR Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   Davison S, 2003, CLIN ENDOCRINOL, V58, P249, DOI 10.1046/j.1365 2265.2003.01774.x
   Devareddy L, 2006, BONE, V38, P686, DOI 10.1016/j.bone.2005.10.024
   Ederveen AGH, 2001, J BONE MINER RES, V16, P1674, DOI 10.1359/jbmr.2001.16.9.1674
   FERRETTI JL, 1990, BONE MINER, V11, P111, DOI 10.1016/0169 6009(90)90020 G
   Foidart JM, 2007, CLIMACTERIC, V10, P54, DOI 10.1080/13697130701598324
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hung TM, 2005, ARCH PHARM RES, V28, P1053, DOI 10.1007/BF02977401
   Hung TM, 2006, J ETHNOPHARMACOL, V108, P188, DOI 10.1016/j.jep.2006.04.029
   Iwasawa H, 2011, BIOL PHARM BULL, V34, P128, DOI 10.1248/bpb.34.128
   JUNG KY, 1993, J NAT PROD, V56, P1912, DOI 10.1021/np50101a007
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P399, DOI 10.1007/s00198 008 0560 z
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Laib A, 2001, OSTEOPOROSIS INT, V12, P936, DOI 10.1007/s001980170022
   Laib A, 2000, MED BIOL ENG COMPUT, V38, P326, DOI 10.1007/BF02347054
   Li YH, 2009, CANCER SCI, V100, P2451, DOI 10.1111/j.1349 7006.2009.01335.x
   Liu ZG, 2009, J ETHNOPHARMACOL, V123, P74, DOI 10.1016/j.jep.2009.02.025
   Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002 021496
   Morch LS, 2009, JAMA J AM MED ASSOC, V302, P298, DOI 10.1001/jama.2009.1052
   Müller R, 2004, J BONE MINER RES, V19, P1787, DOI 10.1359/JBMR.040809
   Oh SR, 1999, ARCH PHARM RES, V22, P317, DOI 10.1007/BF02976371
   Ono Y, 2008, BIOL PHARM BULL, V31, P1199, DOI 10.1248/bpb.31.1199
   PASTOUREAU P, 1995, OSTEOPOROSIS INT, V5, P143, DOI 10.1007/BF02106092
   Peng LH, 2010, J ETHNOPHARMACOL, V131, P282, DOI 10.1016/j.jep.2010.06.039
   Pérez Sayáns M, 2010, ORAL SURG ORAL MED O, V109, P679, DOI 10.1016/j.tripleo.2009.10.042
   Reginster JY, 2011, DRUGS, V71, P65, DOI 10.2165/11587570 000000000 00000
   Stevenson JC, 2005, MATURITAS, V51, P113, DOI 10.1016/j.maturitas.2005.01.012
   Suh HW, 2000, J ETHNOPHARMACOL, V71, P211, DOI 10.1016/S0378 8741(99)00204 4
   Sykaras Nikitas, 2003, J Oral Sci, V45, P57
   Tanaka T, 2000, CHEM PHARM BULL, V48, P201, DOI 10.1248/cpb.48.201
   Tang CH, 2003, J BONE MINER RES, V18, P502, DOI 10.1359/jbmr.2003.18.3.502
   Tang CH, 2008, EUR J PHARMACOL, V579, P40, DOI 10.1016/j.ejphar.2007.10.013
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   TURNER RT, 1987, J BONE MINER RES, V2, P115
   Ulrich D, 1999, BONE, V25, P55, DOI 10.1016/S8756 3282(99)00098 8
   Westerlind KC, 1997, P NATL ACAD SCI USA, V94, P4199, DOI 10.1073/pnas.94.8.4199
   Wong RWK, 2007, PHYTOTHER RES, V21, P596, DOI 10.1002/ptr.2126
   Xiao Y, 2004, CELL TRANSPLANT, V13, P15, DOI 10.3727/000000004772664851
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhang Y, 2011, OSTEOPOROSIS INT, V22, P703, DOI 10.1007/s00198 010 1240 3
   Zhang ZJ, 2003, LIFE SCI, V73, P2443, DOI 10.1016/S0024 3205(03)00649 0
NR 43
TC 53
Z9 63
U1 2
U2 20
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD NOV
PY 2012
VL 23
IS 11
BP 2649
EP 2660
DI 10.1007/s00198 012 1932 y
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 028MA
UT WOS:000310425200009
PM 22535190
DA 2025 08 17
ER

PT J
AU Fassio, A
   Gatti, D
   Biffi, A
   Ronco, R
   Porcu, G
   Adami, G
   Alvaro, R
   Bogini, R
   Caputi, AP
   Cianferotti, L
   Frediani, B
   Gonnelli, S
   Iolascon, G
   Lenzi, A
   Leone, S
   Michieli, R
   Migliaccio, S
   Nicoletti, T
   Paoletta, M
   Pennini, A
   Piccirilli, E
   Rossini, M
   Brandi, ML
   Corrao, G
   Tarantino, U
AF Fassio, Angelo
   Gatti, Davide
   Biffi, Annalisa
   Ronco, Raffaella
   Porcu, Gloria
   Adami, Giovanni
   Alvaro, Rosaria
   Bogini, Riccardo
   Caputi, Achille P.
   Cianferotti, Luisella
   Frediani, Bruno
   Gonnelli, Stefano
   Iolascon, Giovanni
   Lenzi, Andrea
   Leone, Salvatore
   Michieli, Raffaella
   Migliaccio, Silvia
   Nicoletti, Tiziana
   Paoletta, Marco
   Pennini, Annalisa
   Piccirilli, Eleonora
   Rossini, Maurizio
   Brandi, Maria Luisa
   Corrao, Giovanni
   Tarantino, Umberto
TI The sequential antifracturative treatment: a meta analysis of randomized
   clinical trials
SO THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
LA English
DT Article
DE anabolic; antiresorptive; fragility fracture; sequential therapy;
   systematic review
ID FRACTURE RISK REDUCTION; POSTMENOPAUSAL WOMEN; ANTIRESORPTIVE THERAPY;
   TERIPARATIDE TREATMENT; SUBSEQUENT FRACTURE; BONE DENSITY; ALENDRONATE;
   OSTEOPOROSIS; PREVENTION; BISPHOSPHONATE
AB Background: Subjects with a fragility fracture have an increased risk of a new fracture and should receive effective strategies to prevent new events. The medium term to long term strategy should be scheduled by considering the mechanisms of action in therapy and the estimated fracture risk.Objective: A systematic review was conducted to evaluate the sequential strategy in patients with or at risk of a fragility fracture in the context of the development of the Italian Guidelines.Design: Systematic review and meta analysis.Data sources and methods: PubMed, Embase, and the Cochrane Library were investigated up to February 2021 to update the search of a recent systematic review. Randomized clinical trials (RCTs) that analyzed the sequential therapy of antiresorptive, anabolic treatment, or placebo in patients with or at risk of a fragility fracture were eligible. Three authors independently extracted data and appraised the risk of bias in the included studies. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Effect sizes were pooled in a meta analysis using fixed effects models. The primary outcome was the risk of refracture, while the secondary outcome was the bone mineral density (BMD) change.Results: In all, 17 RCTs, ranging from low to high quality, met our inclusion criteria. A significantly reduced risk of fracture was detected at (i) 12 or 24 months after the switch from romosozumab to denosumab versus placebo to denosumab; (ii) 30 months from teriparatide to bisphosphonates versus placebo to bisphosphonates; and (iii) 12 months from romosozumab to alendronate versus the only alendronate therapy (specifically for vertebral fractures). In general, at 2 years after the switch from anabolic to antiresorptive drugs, a weighted BMD was increased at the lumbar spine, total hip, and femoral neck site.Conclusion: The Task Force formulated recommendations on sequential therapy, which is the first treatment with anabolic drugs or 'bone builders' in patients with very high or imminent risk of fracture.
   A systematic review to evaluate the sequential therapy of antiresorptive (denosumab and bisphosphonate, such as alendronate, minodronate, risedronate, and etidronate), anabolic treatment (such as romosozumab, teriparatide), or placebo in patients with or at risk of a fragility fracture in the context of the development of the Italian GuidelinesSubjects with previous fragility fractures should promptly receive effective strategies to prevent the risk of subsequent events. Indeed, patients with a fragility fracture have a doubled risk of a new fracture. For this reason, it is essential to provide adequate sequential therapy based on the mechanisms and the rapidity of action. A systematic review was performed to identify the sequential strategy in patients at high  or imminent risk of (re)fracture and to support the Panel of the Italian Fragility Fracture Guideline in formulating recommendations. Our systematic review included seventeen studies mostly focused on women and enabled us to strongly recommend the anabolic drugs as first line treatment. Specifically, for the sequential therapy from anabolic to antiresorptive treatment, there was a significant reduction in the risk of different types of fractures after the switch from romosozumab to denosumab versus placebo to denosumab. These findings were confirmed at 24 months after the switch. Considering the sequential treatment from antiresorptive to anabolic medications, there was a decreased risk of fracture 12 months after the switch from placebo to teriparatide versus bisphosphonate or antiresorptive to teriparatide. Moreover, a greater bone mineral density increase after the switch from anabolic to antiresorptive medications was shown in the lumbar spine, total hip, and femoral neck. The results of this systematic review and meta analysis confirm that initial treatment with anabolic drugs produces substantial bone mineral density improvements, and the transition to antiresorptive drugs can preserve or even amplify the acquired benefit. These findings support the choice to treat very high risk individuals with anabolic drugs first, followed by antiresorptive drugs.
C1 [Fassio, Angelo] Univ Verona, Rheumatol Unit, Policlin GB Rossi, Piazzale A Scuro, I 37134 Verona, Italy.
   [Gatti, Davide; Adami, Giovanni; Rossini, Maurizio] Univ Verona, Rheumatol Unit, Verona, Italy.
   [Biffi, Annalisa; Ronco, Raffaella; Porcu, Gloria; Corrao, Giovanni] Univ Milano Bicocca, Natl Ctr Healthcare Res & Pharmacoepidemiol, Dept Stat & Quantitat Methods, Milan, Italy.
   [Biffi, Annalisa; Ronco, Raffaella; Porcu, Gloria; Adami, Giovanni] Univ Milano Bicocca, Dept Stat & Quantitat Methods, Unit Biostat Epidemiol & Publ Hlth, Milan, Italy.
   [Alvaro, Rosaria; Pennini, Annalisa] Tor Vergata Univ Rome, Dept Biomed & Prevent, Rome, Italy.
   [Bogini, Riccardo] Local Hlth Unit Umbria, Perugia, Italy.
   [Caputi, Achille P.] Univ Messina, Sch Med, Dept Biomorphol, Messina, Italy.
   [Cianferotti, Luisella; Brandi, Maria Luisa] Italian Bone Dis Res Fdn, Florence, Italy.
   [Frediani, Bruno] Univ Siena, Dept Med Surg & Neurosci, Rheumatol Unit, Azienda Osped Univ Senese, Siena, Italy.
   [Gonnelli, Stefano] Univ Siena, Dept Med Surg & Neurosci, Policlin Scotte, Siena, Italy.
   [Iolascon, Giovanni; Paoletta, Marco] Univ Campania Luigi Vanvitelli, Dept Med & Surg Specialties & Dent, Naples, Italy.
   [Lenzi, Andrea] Sapienza Univ Rome, Dept Expt Med, Viale Policlin, Rome, Italy.
   [Leone, Salvatore] AM Onlus, Assoc Nazl Malattie Infiammatorie Cron Intestino, Milan, Italy.
   [Michieli, Raffaella] Italian Soc Gen Med & Primary Care, Florence, Italy.
   [Migliaccio, Silvia] Foro Ital Univ, Dept Movement Human & Hlth Sci, Rome, Italy.
   [Nicoletti, Tiziana] Coordinamento Nazl Assoc Malati Cron & rari Cittad, Rome, Italy.
   [Piccirilli, Eleonora; Tarantino, Umberto] Tor Vergata Univ Rome, Dept Clin Sci & Translat Med, Rome, Italy.
   [Piccirilli, Eleonora; Tarantino, Umberto] Policlin Tor Vergata Fdn, Dept Orthoped & Traumatol, Rome, Italy.
C3 University of Verona; Azienda Ospedaliera Universitaria Integrata
   Verona; University of Verona; University of Milano Bicocca; University
   of Milano Bicocca; University of Rome Tor Vergata; University of
   Messina; University of Siena; University Hospital of Siena; University
   of Siena; Universita della Campania Vanvitelli; Sapienza University
   Rome; Foro Italico University of Rome; University of Rome Tor Vergata
RP Fassio, A (通讯作者)，Univ Verona, Rheumatol Unit, Policlin GB Rossi, Piazzale A Scuro, I 37134 Verona, Italy.
EM angelo.fassio@univr.it
RI Adami, Giovanni/AAQ 2160 2021; Piccirilli, Eleonora/AIC 4365 2022;
   Fassio, Angelo/AAB 9767 2022; Gatti, Davide/Q 1140 2015; Paoletta,
   Marco/KHT 2720 2024; CIANFEROTTI, LUISELLA/LSK 2125 2024; Cianferotti,
   Luisella/LSK 2125 2024; Benetti, Elisa/AAI 6682 2021
OI Adami, Giovanni/0000 0002 8915 0755; Leone,
   Salvatore/0000 0003 1690 8147; Piccirilli, Eleonora/0000 0002 1570 6482;
   Fassio, Angelo/0000 0001 9187 232X; CIANFEROTTI,
   LUISELLA/0000 0001 7424 6212; 
FU ALTIS Omnia Pharma Service
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: The Italian
   guideline was funded by ALTIS Omnia Pharma Service, which did not affect
   the content of the document.
CR Anagnostis P, 2019, MATURITAS, V120, P1, DOI 10.1016/j.maturitas.2018.11.010
   Anastasilakis AD, 2020, EXPERT OPIN PHARMACO, V21, P477, DOI 10.1080/14656566.2020.1717468
   [Anonymous], 2019, Manuale metodologico per la produzione di linee guida di pratica clinica
   Balasubramanian A, 2019, OSTEOPOROSIS INT, V30, P79, DOI 10.1007/s00198 018 4732 1
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007 0711
   Borgström F, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 0706 y
   Bouxsein ML, 2019, J BONE MINER RES, V34, P632, DOI 10.1002/jbmr.3641
   Center JR, 2007, JAMA J AM MED ASSOC, V297, P387, DOI 10.1001/jama.297.4.387
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2020, J BONE MINER RES, V35, P1333, DOI 10.1002/jbmr.3996
   Cosman F, 2017, J BONE MINER RES, V32, P198, DOI 10.1002/jbmr.3051
   Curtis EM, 2022, AGING CLIN EXP RES, V34, P695, DOI 10.1007/s40520 022 02100 4
   Deeks JJ, 2022, COCHRANE HDB SYSTEMA
   Elbers LPB, 2021, DRUGS, V81, P1645, DOI 10.1007/s40265 021 01587 x
   Fahrleitner Pammer A, 2016, BONE, V89, P16, DOI 10.1016/j.bone.2016.05.004
   Fassio A, 2017, CURR PHARM DESIGN, V23, P6241, DOI 10.2174/1381612823666170713104431
   Gatti D, 2019, J POPUL THER CLIN PH, V26, pE1, DOI 10.15586/jptcp.v26.i4.646
   Gonnelli S, 2006, OSTEOPOROSIS INT, V17, P1524, DOI 10.1007/s00198 006 0157 3
   Gupta MJ, 2018, OSTEOPOROSIS INT, V29, P1861, DOI 10.1007/s00198 018 4559 9
   Hadji P, 2012, OSTEOPOROSIS INT, V23, P2141, DOI 10.1007/s00198 011 1856 y
   Higgins JPT, 2003, BMJ BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Johansson H, 2017, OSTEOPOROSIS INT, V28, P775, DOI 10.1007/s00198 016 3868 0
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kanis JA, 2004, BONE, V35, P375, DOI 10.1016/j.bone.2004.03.024
   Kendler DL, 2019, OSTEOPOROSIS INT, V30, P2437, DOI 10.1007/s00198 019 05146 9
   Keshishian A, 2017, OSTEOPOROSIS INT, V28, P2485, DOI 10.1007/s00198 017 4072 6
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Leder BZ, 2020, J CLIN ENDOCR METAB, V105, P938, DOI 10.1210/clinem/dgz162
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Lewiecki EM, 2019, J BONE MINER RES, V34, P419, DOI 10.1002/jbmr.3622
   Lewiecki EM, 2015, WOMENS HEALTH, V11, P269, DOI [10.2217/whe.15.5, 10.2217/WHE.15.5]
   Middleton ET, 2007, CALCIFIED TISSUE INT, V81, P335, DOI 10.1007/s00223 007 9066 5
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   Miyauchi A, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 019 0608 z
   Niimi R, 2018, JBMR PLUS, V2, P289, DOI 10.1002/jbm4.10054
   Obermayer Pietsch BM, 2008, J BONE MINER RES, V23, P1591, DOI 10.1359/JBMR.080506
   Page MJ, 2021, BMJ BRIT MED J, V372, DOI [10.1136/bmj.n160, 10.1136/bmj.n71]
   Page MJ, 2017, SYST REV LONDON, V6, DOI 10.1186/s13643 017 0663 8
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Roux C, 2017, OSTEOPOROSIS INT, V28, P1765, DOI 10.1007/s00198 017 3976 5
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Schünemann HJ, 2017, J CLIN EPIDEMIOL, V81, P101, DOI 10.1016/j.jclinepi.2016.09.009
   Shea BJ, 2017, BMJ BRIT MED J, V358, DOI 10.1136/bmj.j4008
   Sistema Nazionale Linee Guida (SNLG), 2021, Diagnosi, Stratificazione del rischio e continuita assistenziale delle Fratture da Fragilita
   SNLG ISS, 2019, Sistema nazionale per le linee guida  Istituto superiore di sanita. Come produrre
   van Geel Tineke A C M, 2010, Curr Osteoporos Rep, V8, P118, DOI 10.1007/s11914 010 0023 2
   Wang PW, 2019, AGING CLIN EXP RES, V31, P1525, DOI 10.1007/s40520 018 1094 7
NR 55
TC 1
Z9 1
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1759 720X
EI 1759 7218
J9 THER ADV MUSCULOSKEL
JI Ther. Adv. Musculoskelet. Dis.
PY 2024
VL 16
AR 1759720X241234584
DI 10.1177/1759720X241234584
PG 15
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA OG6O4
UT WOS:001206158800001
PM 38654732
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kaback, LA
   Soung, DY
   Naik, A
   Geneau, G
   Schwarz, EV
   Rosier, RN
   O'Keefe, RJ
   Drissi, H
AF Kaback, Lee A.
   Soung, Do Y.
   Naik, Amish
   Geneau, Graziello
   Schwarz, Edward V.
   Rosier, Randy N.
   O'Keefe, Regis J.
   Drissi, Hicham
TI Teriparatide (1 34 human PTH) regulation of osterix during fracture
   repair
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE teriparatide; PTH; osterix/sp7; Runx2; fractures
ID HUMAN PARATHYROID HORMONE; BONE MINERAL DENSITY; OSTEOBLAST
   DIFFERENTIATION; POSTMENOPAUSAL OSTEOPOROSIS; CELLS; PROLIFERATION;
   CHONDROCYTE; INHIBITION; MECHANISMS; STRENGTH
AB Based on remarkable success of PTH as an anabolic drug for osteoporosis, case reports of off label use of teriparatide (1 34 PTH) in patients with complicated fractures and non unions are emerging. We investigated the mechanisms underlying PTH accelerated fracture repair. Bone marrow cells from 7 days 40 mu g/kg of teriparatide treated or saline control mice were cultured and Osx and osteoblast phenotypic gene expression assessed by real time RT PCR in these cells. Fractured animals injected daily with either saline or 40 mu g/kg of teriparatide for up to 21 clays were X rayed and histological assessment performed, as well as immunohistochemical analyses of the Osx expression in the fracture callus. Osx, Runx2 and osteoblast or chondrocyte phenotypic gene expression was also assessed in fracture calluses. Our data shows that Osx and Runx2 are up regulated in marrow derived MSCs isolated from mice systemically treated with teriparatide. Furthermore, these MSCs undergo accelerated osteoblast maturation compared to saline injected controls. Systemic teriparatide treatments also accelerated fracture healing in these mice concomitantly with increased Osx expression in the PTH treated fracture calluses compared to controls. Collectively, these data suggest a mechanism for teriparatide mediated fracture healing possibly via Osx induction in MSCs.
C1 [Soung, Do Y.; Geneau, Graziello; Drissi, Hicham] Univ Connecticut Hlth Ctr, New England Musculoskeletal Inst, Dept Orthopaed Surg, Farmington, CT 06034 USA.
   [Kaback, Lee A.; Naik, Amish; Schwarz, Edward V.; Rosier, Randy N.; O'Keefe, Regis J.] Univ Rochester, Ctr Musculoskeletal Res, Rochester, NY USA.
C3 University of Connecticut; University of Rochester
RP Drissi, H (通讯作者)，Univ Connecticut Hlth Ctr, New England Musculoskeletal Inst, Dept Orthopaed Surg, 263 Farmington Ave, Farmington, CT 06034 USA.
EM drissi@uchc.edu
OI drissi, hicham/0000 0002 3322 281X
FU National Institutes of Health (NIH) RO1 [AR052674 01]; NIH CORT P50
   [AR05404]
FX Grant sponsor: National Institutes of Health (NIH) RO1; Grant number:
   AR052674 01; Grant sponsor: NIH CORT P50; Grant number: AR05404.
CR Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Andreassen TT, 2004, CALCIFIED TISSUE INT, V74, P351, DOI 10.1007/s00223 003 0093 6
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   ARNAUD CD, 1970, P NATL ACAD SCI USA, V67, P415, DOI 10.1073/pnas.67.1.415
   Bilezikian J P, 2005, J Endocrinol Invest, V28, P41
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Cranney A, 2002, ENDOCR REV, V23, P524, DOI 10.1210/er.2001 4002
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Drissi H, 1999, CANCER RES, V59, P3705
   Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925 4773(99)00142 2
   FINKELSTEIN JS, 2000, CECIL TXB MED
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Heaney Robert P, 2003, Clin Med Res, V1, P93
   HILTUNEN A, 1993, J ORTHOP RES, V11, P305, DOI 10.1002/jor.1100110219
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491
   Jiang YB, 2005, J BONE MINER METAB, V23, P122, DOI 10.1007/BF03026336
   Kaback LA, 2008, J CELL PHYSIOL, V214, P173, DOI 10.1002/jcp.21176
   Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002 0225
   Kulkarni NH, 2007, J CELL BIOCHEM, V102, P1504, DOI 10.1002/jcb.21374
   Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Nakazawa T, 2005, BONE, V37, P711, DOI 10.1016/j.bone.2005.06.013
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   NISHIDA S, 1994, BONE, V15, P717, DOI 10.1016/8756 3282(94)90322 0
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Potts JT, 2005, J ENDOCRINOL, V187, P311, DOI 10.1677/joe.1.06057
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Soung DY, 2007, J BONE MINER RES, V22, P1260, DOI 10.1359/JBMR.070502
   Thomas T, 2006, JOINT BONE SPINE, V73, P262, DOI 10.1016/j.jbspin.2005.11.007
   Tu QS, 2006, BIOCHEM BIOPH RES CO, V341, P1257, DOI 10.1016/j.bbrc.2006.01.092
   van der Horst G, 2005, J BONE MINER RES, V20, P2233, DOI 10.1359/JBMR.050821
   Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925 4773(97)00203 7
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 39
TC 70
Z9 82
U1 0
U2 5
PU WILEY LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0730 2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP 1
PY 2008
VL 105
IS 1
BP 219
EP 226
DI 10.1002/jcb.21816
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 346ZX
UT WOS:000259109200024
PM 18494002
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Niu, HM
   Wei, LC
   He, L
AF Niu, H. M.
   Wei, L. C.
   He, L.
TI A Systematic Expression Profile of circRNA miRNA mRNA in Osteoporosis
   upon Treatment with Denosumab
SO INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Osteoporosis; denosumab; micro ribonucleic acid; circular ribonucleic
   acids; messenger ribonucleic acid
ID DIFFERENTIATION; PATHWAY
AB The aim of this research was to discover microRNAs and circular RNAs with varying expression in osteoporosis patients who have been given denosumab and to explore the correlation between microRNAs, messenger RNAs and circular RNAs and the drugs. As a first finding, we found differential microRNA and circular RNA expression in patients treated with denosumab for osteoporosis. Our next step was to identify microRNA regulated genes and genes that correspond to circular RNAs and then to perform enrichment analysis on those genes. We explored the correlation between circular RNA, microRNA and messenger RNA for the drugs as a concluding step. Our findings revealed 18 microRNA and 239 circular RNAs that were increased, and 15 microRNAs and 316 circular RNAs that were reduced in osteoporosis patients treated with denosumab in comparison to those who had not been treated. Analysis of Kyoto encyclopedia of genes and genomes pathway revealed that pathways targeted by differentially expressed microRNAs were notably enriched and they are axon guidance, proteoglycans in cancer, sphingolipid signalling and erythroblastic oncogene B signalling. The gene ontology enrichment analysis, meanwhile, revealed that pathways targeted by differentially expressed microRNAs were notably enriched and they are wingless related integration site induced cell cell signalling, glutamatergic synapse and deoxyribonucleic acid binding transcription activator activity. Analysis of Kyoto encyclopedia of genes and genomes pathway revealed that pathways significantly enriched by differentially expressed circular RNA were Salmonella infection, endocytosis, Fc gamma R mediated phagocytosis and spinocerebellar ataxia; conversely, gene ontology enrichment analysis indicated that pathways significantly enriched by differentially expressed circular RNA were positive regulation of cellular catabolic process and cadherin binding. Considered to be the most important microRNAs involved the hsa miR 424 5p, hsa miR 1299, hsa miR 195 5, hsa miR 320d and hsa miR 548am 3p are in the functions of denosumab in osteoporosis. A number of critical circular RNAs have been identified, such as hsa_circ_0005044, hsa_circ_0005027, hsa_circ_0005657, hsa_circ_0005988 and hsa_circ_0013386.
C1 [Niu, H. M.; Wei, L. C.; He, L.] Nanjing Med Univ, Dept Orthoped, Guanyun Cty Peoples Hosp, Kangda Coll, Lianyungang 222200, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Niu, HM (通讯作者)，Nanjing Med Univ, Dept Orthoped, Guanyun Cty Peoples Hosp, Kangda Coll, Lianyungang 222200, Jiangsu, Peoples R China.
EM nhm197809@163.com
RI Niu, Huimin/IUM 8400 2023
FU Lianyungang city Aging Health Research Project [L202120]
FX This study was supported by Lianyungang city Aging Health Research
   Project (Grant project, No. L202120).
CR Bellavia D, 2019, CELL MOL LIFE SCI, V76, P3723, DOI 10.1007/s00018 019 03162 w
   Hammond SM, 2015, ADV DRUG DELIVER REV, V87, P3, DOI 10.1016/j.addr.2015.05.001
   Jin D, 2018, AM J TRANSL RES, V10, P1498
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Ma S, 2019, J CELL BIOCHEM, V120, P15429, DOI 10.1002/jcb.28810
   Pu MF, 2019, CELL MOL LIFE SCI, V76, P441, DOI 10.1007/s00018 018 2940 7
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Schuiling KD, 2011, J MIDWIFERY WOM HEAL, V56, P615, DOI 10.1111/j.1542 2011.2011.00135.x
   Wang F, 2016, J AGR FOOD CHEM, V64, P2875, DOI 10.1021/acs.jafc.5b06132
   Yang MF, 2014, FEBS LETT, V588, P4761, DOI 10.1016/j.febslet.2014.11.008
   Yang Y, 2020, BIOL RES, V53, DOI 10.1186/s40659 020 00309 z
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhao KW, 2018, CELL PHYSIOL BIOCHEM, V46, P2508, DOI 10.1159/000489657
NR 15
TC 0
Z9 0
U1 0
U2 1
PU INDIAN PHARMACEUTICAL ASSOC
PI MUMBAI
PA KALINA, SANTA CRUZ EAST, MUMBAI, 00000, INDIA
SN 0250 474X
EI 1998 3743
J9 INDIAN J PHARM SCI
JI Indian J. Pharm. Sci.
PY 2023
VL 85
IS 4
SI 4
BP 87
EP 92
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GT6U0
UT WOS:001154968900010
DA 2025 08 17
ER

PT J
AU Giraudel, JM
   Diquelou, A
   Lees, P
   Toutain, PL
AF Giraudel, JM
   Diquelou, A
   Lees, P
   Toutain, PL
TI Development and validation of a new model of inflammation in the cat and
   selection of surrogate endpoints for testing anti inflammatory drugs
SO JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID EXPERIMENTAL ORTHOPEDIC SURGERY; CUTANEOUS HYPERALGESIA; POSTOPERATIVE
   COURSE; HIND PAW; PHARMACODYNAMICS; RATS; DOGS; PHARMACOKINETICS; EDEMA;
   CYCLOOXYGENASE 2
AB In laboratory animals many models of inflammation have been developed for preclinical evaluation of the pharmacological profiles of nonsteroidal anti inflammatory drugs (NSAIDs). In contrast, in species of veterinary interest, including the cat, NSAIDs have been studied mainly using dose titration or dose confirmation studies in clinical subjects. This is due to the scarcity of appropriate animal models and to the associated lack of quantitative validated endpoints describing the magnitude and time course of drug response. Determination of pharmacokinetic/pharmacodynamic (PK/PD) relationships provides a powerful approach for the selection of effective and safe dosage regimens. In this study, a paw inflammation model in the cat was developed for the preclinical evaluation of NSAIDs using PK/PD modelling. Subcutaneous injection of 500 mg kaolin in the paw produced a well defined and reproducible inflammatory response that lasted 4 5 days. Several endpoints were assessed for their clinical relevance and for their metrological performance (accuracy and reproducibility). Body temperature, lameness scoring, locomotion tests and possibly skin temperature were the most appropriate endpoints for testing the antipyretic, analgesic and anti inflammatory effects of NSAIDs in the cat.
C1 Ecole Natl Vet Toulouse, INRA ENVT, UMR Physiopathol & Toxicol Expt 181, F 31076 Toulouse, France.
   Univ London Royal Vet Coll, Dept Vet Basic Sci, Hatfield, Herts, England.
C3 INRAE; Universite de Toulouse; Ecole Nationale Veterinaire de Toulouse;
   University of London; University of London Royal Veterinary College
RP Ecole Natl Vet Toulouse, INRA ENVT, UMR Physiopathol & Toxicol Expt 181, 23 Chemin Capelles,BP 87614, F 31076 Toulouse, France.
EM j.giraudel@envt.fr
RI Toutain, Pierre/G 4540 2011
OI lees, peter/0000 0002 8966 3737
CR BOTREL MA, 1994, J PHARMACOL TOXICOL, V32, P63, DOI 10.1016/1056 8719(94)90055 8
   BROOKS RR, 1991, J PHARMACOL METHOD, V25, P275, DOI 10.1016/0160 5402(91)90027 3
   Chan CC, 1999, J PHARMACOL EXP THER, V290, P551
   Colburn WA, 2000, J CLIN PHARMACOL, V40, P1419
   Dixon MJ, 2002, RES VET SCI, V72, P205, DOI 10.1053/rvsc.2001.0543
   GEMMELL DK, 1979, AGENTS ACTIONS, V9, P107, DOI 10.1007/BF02024141
   HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304 3959(88)90026 7
   HOLSAPPLE MP, 1984, INFLAMMATION, V8, P223, DOI 10.1007/BF00916412
   Holton LL, 1998, J AM VET MED ASSOC, V212, P61
   JACOBI H, 1980, ARZNEIMITTELFORSCH, V30 2, P1326
   KESSLER F, 1983, Z RHEUMATOL, V42, P337
   KILO S, 1995, PAIN, V62, P187, DOI 10.1016/0304 3959(94)00265 G
   LABRECQUE G, 1995, PHARMACOL THERAPEUT, V66, P285, DOI 10.1016/0163 7258(94)00082 E
   Lascelles BDX, 1998, VET SURG, V27, P568, DOI 10.1111/j.1532 950X.1998.tb00533.x
   Lees P, 2003, VET J, V165, P21, DOI 10.1016/S1090 0233(02)00168 5
   LEES P, 1991, BRIT VET J, V147, P298, DOI 10.1016/0007 1935(91)90002 5
   Lees Peter, 2003, Inflammopharmacology, V11, P385, DOI 10.1163/156856003322699564
   LEWIS AJ, 1976, EUR J PHARMACOL, V40, P1, DOI 10.1016/0014 2999(76)90347 2
   MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850
   MASSO JM, 1993, J PHARM PHARMACOL, V45, P959, DOI 10.1111/j.2042 7158.1993.tb05635.x
   MBUGUA SW, 1988, ACTA VET SCAND, V29, P43
   MBURU DN, 1988, J VET PHARMACOL THER, V11, P163, DOI 10.1111/j.1365 2885.1988.tb00137.x
   MCCANDLE.EL, 1967, P SOC EXP BIOL MED, V124, P1239
   Mukherjee A, 1996, INFLAMM RES, V45, P531, DOI 10.1007/BF02342223
   Nantel F, 1999, BRIT J PHARMACOL, V128, P853, DOI 10.1038/sj.bjp.0702866
   NOLAN A, 1988, J VET PHARMACOL THER, V11, P94, DOI 10.1111/j.1365 2885.1988.tb00126.x
   OKUDA K, 1984, PAIN, V18, P287, DOI 10.1016/0304 3959(84)90823 6
   OTTERNESS IG, 1988, J PHARM SCI, V77, P790, DOI 10.1002/jps.2600770915
   ROSA MD, 1971, J PHARM PHARMACOL, V23, P297, DOI 10.1111/j.2042 7158.1971.tb08661.x
   SHIROTA H, 1984, J PHARMACOL METHOD, V12, P35, DOI 10.1016/0160 5402(84)90004 4
   SOBANSKI H, 1974, EXPERIENTIA, V30, P1326
   TAYLOR PM, 1991, VET REC, V128, P258, DOI 10.1136/vr.128.11.258
   Taylor PM, 1996, RES VET SCI, V60, P144, DOI 10.1016/S0034 5288(96)90009 0
   TAYLOR PM, 1994, BRIT VET J, V150, P253, DOI 10.1016/S0007 1935(05)80005 3
   Toutain PL, 2002, AAPS PHARMSCI, V4
   Toutain PL, 2001, J VET PHARMACOL THER, V24, P43, DOI 10.1046/j.1365 2885.2001.00304.x
   VINEGAR R, 1968, J PHARMACOL EXP THER, V161, P389
   WELSH EM, 1993, AM J VET RES, V54, P976
   WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544
   Zhang Y, 1997, J PHARMACOL EXP THER, V283, P1069
NR 40
TC 29
Z9 30
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0140 7783
EI 1365 2885
J9 J VET PHARMACOL THER
JI J. Vet. Pharmacol. Ther.
PD JUN
PY 2005
VL 28
IS 3
BP 275
EP 285
DI 10.1111/j.1365 2885.2005.00639.x
PG 11
WC Pharmacology & Pharmacy; Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Veterinary Sciences
GA 934BD
UT WOS:000229680600006
PM 15953201
DA 2025 08 17
ER

PT J
AU Li, CJ
   Chang, JK
   Wang, GJ
   Ho, ML
AF Li, Ching Ju
   Chang, Je Ken
   Wang, Gwo Jaw
   Ho, Mei Ling
TI Constitutively expressed COX 2 in osteoblasts positively regulates Akt
   signal transduction via suppression of PTEN activity
SO BONE
LA English
DT Article
DE Cyclooxygenase 2; Cyclooxygenase 1; PTEN; Akt; Osteoblast
ID FOXO TRANSCRIPTION FACTORS; CHRONIC INFLAMMATORY PAIN; HUMAN
   PROSTATE CANCER; CELL CYCLE; MULTIPLE ROLES; MESSENGER RNA; RAT KIDNEY;
   CYCLOOXYGENASE 2; INHIBITION; GROWTH
AB Cyclooxygenase 2 (COX 2) is thought to be an inducible enzyme, but increasing reports indicate that COX 2 is constitutively expressed in several organs. The status of COX 2 expression in bone and its physiological role remains undefined. Non selective non steroidal anti inflammatory drugs (NSAIDs) and selective COX 2 inhibitors, which commonly suppress COX 2 activity, were reported to suppress osteoblast proliferation via Akt/FOX03a/p27(KiP1) signaling, suggesting that COX 2 may be the key factor of the suppressive effects of NSAIDs on proliferation. Although Akt activation correlates with PTEN deficiency and cell viability, the role of COX 2 on PTEN/Akt regulation remains unclear. In this study, we hypothesized that COX 2 may be constitutively expressed in osteoblasts and regulate PTEN/Akt related proliferation. We examined the localization and co expression of COX 2 and p Akt in normal mouse femurs and in cultured mouse (mOBs) and human osteoblasts (hOBs). Our results showed that osteoblasts adjacent to the trabeculae, periosteum and endosteum in mouse femurs constitutively expressed COX 2, while COX 2 co expressed with p Akt in osteoblasts sitting adjacent to trabeculae in vivo, and in mOBs and hOBs in vitro. We further used COX 2 siRNA to test the role of COX 2 in Akt signaling in hOBs; COX 2 silencing significantly inhibited PTEN phosphorylation, enhanced PTEN activity, and suppressed p Akt level and proliferation. However, replenishment of the COX 2 enzymatic product, PGE2, failed to reverse COX 2 dependent Akt phosphorylation. Furthermore, transfection with recombinant human COX 2 (rhCOX 2) significantly reversed COX 2 siRNA suppressed PTEN phosphorylation, but this effect was reduced when the enzymatic activity of rhCOX 2 was blocked. This finding indicated that the effect of COX 2 on PTEN/Akt signaling is not related to PGE2 but still dependent on COX 2 enzymatic activity. Conversely, COX 1 silencing did not affect PTEN/Akt signaling. Our findings provide new insight into bone physiology; namely, that COX 2 is constitutively expressed in osteoblasts in the dynamic bone growth area, which facilitates osteoblast proliferation via PTEN/Akt/p27(Kip1) signaling. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Li, Ching Ju; Ho, Mei Ling] Kaohsiung Med Univ, Dept Physiol, Coll Med, Kaohsiung 807, Taiwan.
   [Chang, Je Ken; Wang, Gwo Jaw] Kaohsiung Med Univ, Dept Orthopaed, Coll Med, Kaohsiung 807, Taiwan.
   [Li, Ching Ju; Ho, Mei Ling] Kaohsiung Med Univ, Fac Med, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan.
   [Li, Ching Ju; Chang, Je Ken; Wang, Gwo Jaw; Ho, Mei Ling] Kaohsiung Med Univ, Orthopaed Res Ctr, Coll Med, Kaohsiung 807, Taiwan.
   [Chang, Je Ken; Wang, Gwo Jaw] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthopaed, Kaohsiung 807, Taiwan.
   [Chang, Je Ken] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Orthopaed, Kaohsiung 807, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital; Kaohsiung Medical
   University; Kaohsiung Municipal Ta Tung Hospital
RP Ho, ML (通讯作者)，Kaohsiung Med Univ, Dept Physiol, Coll Med, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
EM homelin@cc.kmu.edu.tw
RI ; Ho, Mei Ling/D 5515 2009
OI Ho, Mei Ling/0000 0001 8064 8488; 
CR Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
   Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015
   Arpornmaeklong P, 2008, INT J ORAL MAX IMPL, V23, P1071
   Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699
   Chang JK, 2009, ARTHRITIS RHEUM US, V60, P3049, DOI 10.1002/art.24843
   Chang JK, 2009, TOXICOLOGY, V258, P148, DOI 10.1016/j.tox.2009.01.016
   Chang JK, 2005, CONNECT TISSUE RES, V46, P200, DOI 10.1080/03008200500344025
   Chikazu D, 2007, INT J ORAL MAX SURG, V36, P441, DOI 10.1016/j.ijom.2006.11.011
   Chu EC, 2004, BIOCHEM BIOPH RES CO, V320, P875, DOI 10.1016/j.bbrc.2004.06.036
   Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031
   Covey TM, 2007, ONCOGENE, V26, P5784, DOI 10.1038/sj.onc.1210391
   DEJONG RH, 1967, ANESTHESIOLOGY, V28, P382, DOI 10.1097/00000542 196703000 00021
   FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601
   FERREIRA SH, 1973, BRIT J PHARMACOL, V47, pP629
   Forwood MR, 1998, ANAT REC, V252, P580, DOI 10.1002/(SICI)1097 0185(199812)252:4<580::AID AR8>3.0.CO;2 S
   Fu YC, 2009, INT J ONCOL, V35, P583, DOI 10.3892/ijo_00000369
   Gu PQ, 2008, CANCER INVEST, V26, P822, DOI 10.1080/07357900801941860
   HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620
   Hétu PO, 2005, BIOCHEM J, V391, P561, DOI 10.1042/BJ20050451
   HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384
   Honjo S, 2005, DNA CELL BIOL, V24, P141, DOI 10.1089/dna.2005.24.141
   Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397
   Jacobshagen C, 2008, EUR J HEART FAIL, V10, P334, DOI 10.1016/j.ejheart.2008.02.013
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kis B, 2005, J PHARMACOL EXP THER, V315, P1, DOI 10.1124/jpet.105.085431
   Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380
   Leslie NR, 2008, ONCOGENE, V27, P5464, DOI 10.1038/onc.2008.243
   Li CJ, 2010, BIOCHEM PHARMACOL, V79, P926, DOI 10.1016/j.bcp.2009.10.019
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104
   Luo F, 2008, J PHARMACOL EXP THER, V325, P267, DOI 10.1124/jpet.107.132167
   Malviya Ajay, 2009, J Orthop Surg Res, V4, P17, DOI 10.1186/1749 799X 4 17
   Martin F, 2007, ANESTHESIOLOGY, V106, P1013, DOI 10.1097/01.anes.0000265162.39932.33
   Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014 5793(02)03274 X
   Morrison TB, 1998, BIOTECHNIQUES, V24, P954
   Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002 9440(10)62295 X
   Naik AA, 2009, J BONE MINER RES, V24, P251, DOI [10.1359/jbmr.081002, 10.1359/JBMR.081002]
   Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312
   Nielsen Preiss SM, 2003, J CELL BIOCHEM, V90, P964, DOI 10.1002/jcb.10709
   NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855
   Okada Y, 2000, J BONE MINER RES, V15, pS217
   ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014 5793(93)80263 T
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pham Marcou TA, 2008, PAIN, V140, P274, DOI 10.1016/j.pain.2008.08.010
   PILBEAM CC, 1995, J BONE MINER RES, V10, P406
   Reagan Shaw S, 2007, TOXICOL APPL PHARM, V224, P360, DOI 10.1016/j.taap.2006.12.003
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497 356
   Sunters A, 2010, J BIOL CHEM, V285, P8743, DOI 10.1074/jbc.M109.027086
   Tao F, 2008, MOL THER, V16, P1776, DOI 10.1038/mt.2008.192
   Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200
   Tsatsanis C, 2006, INT J BIOCHEM CELL B, V38, P1654, DOI 10.1016/j.biocel.2006.03.021
   Uddin S, 2010, INT J CANCER, V126, P382, DOI 10.1002/ijc.24757
   Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246
   WHITTLE BJR, 1980, NATURE, V284, P271, DOI 10.1038/284271a0
   Xia XC, 2010, MOL CELL BIOL, V30, P206, DOI 10.1128/MCB.01844 08
   Xie W, 1994, Hua Xi Yi Ke Da Xue Xue Bao, V25, P45
   Yar AS, 2010, MOL BIOL REP, V37, P2323, DOI 10.1007/s11033 009 9737 6
   Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006 8993(99)01389 X
   Yoon SH, 2002, LIFE SCI, V71, P2145, DOI 10.1016/S0024 3205(02)01997 5
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhang Y, 2007, BIOMED PHARMACOTHER, V61, P277, DOI 10.1016/j.biopha.2007.02.014
NR 61
TC 28
Z9 33
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB 1
PY 2011
VL 48
IS 2
BP 286
EP 297
DI 10.1016/j.bone.2010.09.020
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 710UY
UT WOS:000286543700016
PM 20854947
DA 2025 08 17
ER

PT J
AU Ali, D
   Chalisserry, EP
   Manikandan, M
   Hamam, R
   Alfayez, M
   Kassem, M
   Aldahmash, A
   Alajez, NM
AF Ali, Dalia
   Chalisserry, Elna P.
   Manikandan, Muthurangan
   Hamam, Rimi
   Alfayez, Musaad
   Kassem, Moustapha
   Aldahmash, Abdullah
   Alajez, Nehad M.
TI Romidepsin Promotes Osteogenic and Adipocytic Differentiation of Human
   Mesenchymal Stem Cells through Inhibition of Histondeacetylase Activity
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; HISTONE DEACETYLASE; TRANSCRIPTIONAL
   REGULATION; GENE EXPRESSION; VALPROIC ACID; TGF BETA; OSTERIX;
   ADIPOGENESIS; ACTIVATION; REGULATORS
AB Bone marrow mesenchymal stem cells (BMSCs) are adult multipotent stem cells that can differentiate into mesodermal lineage cells, including adipocytes and osteoblasts. However, the epigenetic mechanisms governing the lineage specific commitment of BMSCs into adipocytes or osteoblasts are under investigation. Herein, we investigated the epigenetic effect of romidepsin, a small molecule dual inhibitor targeting HDAC1 and HDAC2 identified through an epigenetic library functional screen. BMSCs exposed to romidepsin (5 nM) exhibited enhanced adipocytic and osteoblastic differentiation. Global gene expression and signaling pathway analyses of differentially expressed genes revealed a strong enrichment of genes involved in adipogenesis and osteogenesis in romidepsin treated BMSCs during induction into adipocytes or osteoblasts, respectively. Pharmacological inhibition of FAK signaling during adipogenesis or inhibition of FAK or TGF beta signaling during osteogenesis diminished the biological effects of romidepsin on BMSCs. The results of chromatin immunoprecipitation combined with quantitative polymerase chain reaction indicated a significant increase in H3K9Ac epigenetic markers in the promoter regions of peroxisome proliferator activated receptor gamma (PPAR gamma) and KLF15 (related to adipogenesis) or SP7 (Osterix) and alkaline phosphatase (ALP) (related to osteogenesis) in romidepsin treated BMSCs. Our data indicated that romidepsin is a novel in vitro modulator of adipocytic and osteoblastic differentiation of BMSCs.
C1 [Ali, Dalia; Chalisserry, Elna P.; Manikandan, Muthurangan; Hamam, Rimi; Alfayez, Musaad; Kassem, Moustapha; Aldahmash, Abdullah; Alajez, Nehad M.] King Saud Univ, Coll Med, Dept Anat, Stem Cell Unit, Riyadh 11461, Saudi Arabia.
   [Hamam, Rimi] Univ Montreal, Dept Med, Montreal, PQ, Canada.
   [Kassem, Moustapha] Univ Hosp Odense, Dept Endocrinol, Mol Endocrinol Unit KMEB, Odense, Denmark.
   [Kassem, Moustapha] Univ Southern Denmark, Odense, Denmark.
   [Kassem, Moustapha] Univ Copenhagen, Danish Stem Cell Ctr DanStem, Dept Cellular & Mol Med, DK 2200 Copenhagen, Denmark.
   [Aldahmash, Abdullah] King Saud Univ, Prince Naif Hlth Res Ctr, Riyadh 11461, Saudi Arabia.
C3 King Saud University; Universite de Montreal; University of Southern
   Denmark; Odense University Hospital; University of Southern Denmark;
   University of Copenhagen; King Saud University
RP Alajez, NM (通讯作者)，King Saud Univ, Coll Med, Dept Anat, Stem Cell Unit, Riyadh 11461, Saudi Arabia.
EM nalajez@ksu.edu.sa
RI Chalisserry, Elna/X 7930 2019; Chalisserry, Elna/E 9733 2017; Aldahmash,
   Abdullah/D 4693 2015; Ali, Dalia/KEH 0488 2024; Kassem,
   Moustapha/J 7688 2013; muthurangan, manikandan/GVU 5356 2022; Kassem,
   Moustapha/O 3819 2019
OI muthurangan, manikandan/0000 0003 3057 1851; Chalisserry,
   Elna/0000 0001 5024 2081; Kassem, Moustapha/0000 0003 1557 0869; Alajez,
   Nehad/0000 0002 1546 1091; Ali, Dalia/0000 0002 2852 5971; 
FU Deanship of Scientific Research at King Saud University [RG 1438 033];
   Novo Nordisk Foundation Section for Basic Stem Cell Biology [Petersen
   Group] Funding Source: researchfish
FX The authors would like to thank the Deanship of Scientific Research at
   King Saud University (Research Group no. RG 1438 033) for funding this
   work.
CR Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Al Nbaheen M, 2013, STEM CELL REV REP, V9, P32, DOI 10.1007/s12015 012 9365 8
   Alfayez M, 2016, ANTICANCER RES, V36, P5257, DOI 10.21873/anticanres.11096
   Ali AT, 2013, EUR J CELL BIOL, V92, P229, DOI 10.1016/j.ejcb.2013.06.001
   Ali D, 2017, STEM CELLS DEV, V26, P353, DOI 10.1089/scd.2016.0183
   Ali D, 2016, STEM CELL TRANSL MED, V5, P1036, DOI 10.5966/sctm.2015 0331
   Bug G, 2007, HAEMATOLOGICA, V92, P542, DOI 10.3324/haematol.10758
   Cao Y, 2005, CANCER RES, V65, P1124, DOI 10.1158/0008 5472.CAN 04 2128
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Christodoulides C, 2009, TRENDS ENDOCRIN MET, V20, P16, DOI 10.1016/j.tem.2008.09.002
   Davidson ENB, 2007, OSTEOARTHR CARTILAGE, V15, P597, DOI 10.1016/j.joca.2007.02.005
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Dünker N, 2002, ANAT EMBRYOL, V206, P73, DOI 10.1007/s00429 002 0273 6
   Eckschlager T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071414
   Eslaminejad MB, 2013, CELL J, V15, P1
   Furumai R, 2002, CANCER RES, V62, P4916
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Glemzaite M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6465307
   Heilig J, 2016, BONE, V83, P48, DOI 10.1016/j.bone.2015.10.007
   Hoshiba T, 2009, J BIOL CHEM, V284, P31164, DOI 10.1074/jbc.M109.054676
   Hu J, 2016, SCI REP UK, V6, DOI 10.1038/srep20875
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Karantzali E, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 4 r65
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luk CT, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14360
   Mathieu PS, 2012, TISSUE ENG PART B RE, V18, P436, DOI [10.1089/ten.teb.2012.0014, 10.1089/ten.TEB.2012.0014]
   Menssen A, 2011, BMC GENOMICS, V12, DOI 10.1186/1471 2164 12 461
   Mori T, 2005, J BIOL CHEM, V280, P12867, DOI 10.1074/jbc.M410515200
   Paino F, 2014, STEM CELLS, V32, P279, DOI 10.1002/stem.1544
   Pérez Campo FM, 2016, CALCIFIED TISSUE INT, V99, P302, DOI 10.1007/s00223 016 0144 4
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Rosen ED, 2000, GENE DEV, V14, P1293
   Salasznyk RM, 2007, J CELL BIOCHEM, V100, P499, DOI 10.1002/jcb.21074
   Samee N, 2008, AM J PATHOL, V173, P773, DOI 10.2353/ajpath.2008.080243
   Scotti E, 2010, MOL CELL BIOL, V30, P2076, DOI 10.1128/MCB.00171 10
   Seo HS, 2007, DEV BIOL, V310, P304, DOI 10.1016/j.ydbio.2007.07.040
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Tencerova M, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00127
   Wei Shengjuan, 2013, J Genomics, V1, P5, DOI 10.7150/jgen.3769
   Yoo EJ, 2006, J BIOL CHEM, V281, P6608, DOI 10.1074/jbc.M508982200
   Zvonic S, 2003, J BIOL CHEM, V278, P2228, DOI 10.1074/jbc.M205871200
NR 44
TC 7
Z9 7
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2018
VL 2018
AR 2379546
DI 10.1155/2018/2379546
PG 12
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GA5DS
UT WOS:000428352900001
PM 29731773
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Gozzetti, A
   Gennari, L
   Merlotti, D
   Salvadori, S
   De Paola, V
   Avanzati, A
   Franci, B
   Marchini, E
   Tozzi, M
   Campagna, MS
   Nuti, R
   Lauria, F
   Martini, G
AF Gozzetti, Alessandro
   Gennari, Luigi
   Merlotti, Daniela
   Salvadori, Stefania
   De Paola, Vincenzo
   Avanzati, Annalisa
   Franci, Beatrice
   Marchini, Elena
   Tozzi, Monica
   Campagna, Maria Stella
   Nuti, Ranuccio
   Lauria, Francesco
   Martini, Giuseppe
TI The effects of zoledronic acid on serum lipids in multiple myeloma
   patients
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE zoledronic acid; serum lipid; multiple myeloma
ID DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONATE PATHWAY; BONE DISEASE;
   BISPHOSPHONATES; CELLS; ATORVASTATIN; PRAVASTATIN; INHIBITION; EFFICACY
AB Nitrogen containing bisphosphonates (N BPs) inhibit osteoclast mediated bone resorption and are widely used for tumor associated osteolysis. The mechanism of action of these drugs has not been completely clarified, but it has been observed that N BPs may inhibit squalene synthase or farnesyl pyrophosphate synthase. Zoledronic acid (ZA) represents a novel N BP which also has antitumor activity. To explore the effects of ZA on serum lipids, we studied 26 patients with smoldering myeloma at diagnosis. Sixteen patients were treated with ZA (4 mg) at baseline and at months 1, 2, 4, and 6. The remaining 10 served as controls. In all subjects, total cholesterol (TC), triglycerides (TGs), high density lipoprotein cholesterol (HDL C), low density lipoprotein cholesterol (LDL C), and C terminal telopeptide of type I collagen (CTX) were measured at baseline and after 1, 3, and 6 months. In treated patients, we observed a progressive and significant reduction of TC, with a maximum decrease of 13% at 6 months. Moreover LDL C decreased by 21% at 6 months, while no significant difference was appreciated in HDL C and TGs. Also, the indexes of cardiovascular risk improved after ZA administration: TC/HDL C ratio progressively decreased by 17% and HDL C/LDL C ratio increased by 36%, showing an effect that appears to be cumulative. In conclusion, ZA given intravenously at high doses in patients with smoldering myeloma seems to be able to modify the lipid profile with an improvement of atherosclerotic risk index.
C1 [Gozzetti, Alessandro; Marchini, Elena; Tozzi, Monica; Lauria, Francesco] Univ Siena, Policlin Santa Maria Le Scotte, Div Hematol & Transplants, I 53100 Siena, Italy.
   [Gennari, Luigi; Merlotti, Daniela; Salvadori, Stefania; De Paola, Vincenzo; Avanzati, Annalisa; Franci, Beatrice; Campagna, Maria Stella; Nuti, Ranuccio; Martini, Giuseppe] Univ Siena, Dept Internal Med, I 53100 Siena, Italy.
C3 University of Siena; University of Siena
RP Gozzetti, A (通讯作者)，Univ Siena, Policlin Santa Maria Le Scotte, Div Hematol & Transplants, Via Laterina 8, I 53100 Siena, Italy.
EM gozzetti@unisi.it
RI Gennari, Luigi/J 7013 2016; Gozzetti, Alessandro/D 9055 2014; de paola,
   vincenzo/B 4900 2016; Merlotti, Daniela/J 8245 2016
OI Gozzetti, Alessandro/0000 0003 0769 6891; Merlotti,
   Daniela/0000 0002 3338 6339
CR Adami S, 2000, J BONE MINER RES, V15, P599, DOI 10.1359/jbmr.2000.15.3.599
   AMIN D, 1992, J LIPID RES, V33, P1657
   Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F
   Bevilacqua M, 2005, LUPUS, V14, P773, DOI 10.1191/0961203305lu2219oa
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132
   Derenne S, 1999, J BONE MINER RES, V14, P2048, DOI 10.1359/jbmr.1999.14.12.2048
   Fiore F, 2007, BLOOD, V110, P921, DOI 10.1182/blood 2006 09 044321
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002 9149(97)00965 X
   Jones PH, 2003, AM J CARDIOL, V92, P152, DOI 10.1016/S0002 9149(03)00530 7
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Martini G, 2006, HAEMATOLOGICA, V91, P1720
   Montagnani A, 2003, BONE, V32, P15, DOI 10.1016/S8756 3282(02)00924 9
   Nuti R, 2004, CLIN ORTHOP RELAT R, P208, DOI 10.1097/01.blo.0000129163.97988.06
   Persy V, 2006, KIDNEY INT, V70, P1537, DOI 10.1038/sj.ki.5001899
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   RUSSEL RGG, 2008, OSTEOPOROS INT   JAN
   Van Wagoner DR, 2000, J MOL CELL CARDIOL, V32, P1101, DOI 10.1006/jmcc.2000.1147
   Ylitalo R, 2002, GEN PHARMACOL, V35, P287
NR 29
TC 22
Z9 23
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD APR
PY 2008
VL 82
IS 4
BP 258
EP 262
DI 10.1007/s00223 008 9123 8
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 296HX
UT WOS:000255535200002
PM 18418538
DA 2025 08 17
ER

PT J
AU Qi, DH
   Liu, H
   Sun, XY
   Luo, DN
   Zhu, MP
   Tao, TH
   Gao, CH
   Zhou, CK
   Zhou, W
   Xiao, J
AF Qi, Dahu
   Liu, Hui
   Sun, Xuying
   Luo, Danni
   Zhu, Meipeng
   Tao, Tenghui
   Gao, Chenghao
   Zhou, Chuankun
   Zhou, Wei
   Xiao, Jun
TI Pristimerin Suppresses RANKL Induced Osteoclastogenesis and Ameliorates
   Ovariectomy Induced Bone Loss
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE pristimerin; osteoclastogenesis; MAPK; NF kappa B; Nrf2
ID NF KAPPA B; TRANSCRIPTION FACTOR; IN VITRO; INFLAMMATION; ROS;
   OSTEOIMMUNOLOGY; DIFFERENTIATION; OSTEOPOROSIS; INHIBITION; MECHANISMS
AB Osteoporosis is characterized by bone loss and destruction of trabecular architecture, which greatly increases the burden on the healthcare system. Excessive activation of osteoclasts is an important cause of osteoporosis, and suppression of osteoclastogenesis is helpful for the treatment of osteoporosis. Pristimerin, a natural compound, possesses numerous pharmacological effects via inactivating the NF kappa B and MAPK pathways, which are closely related to osteoclastogenesis process. However, the relationship between Pristimerin and osteoclastogenesis requires further investigation. In this research, we examined the effect of Pristimerin on osteoclastogenesis and investigated the related mechanisms. Our results showed Pristimerin inhibited RANKL induced osteoclast differentiation and osteoclastic bone resorption in vitro, with decreased expression of osteoclastogenesis related markers including c Fos, NFATc1, TRAP, Cathepsin K, and MMP 9 at both mRNA and protein levels. Furthermore, Pristimerin suppressed NF kappa B and MAPK signaling pathways, reduced reactive oxygen species (ROS) production and activated the nuclear factor erythroid 2 related factor 2/heme oxygenase 1 (Nrf2/HO 1) signaling during osteoclastogenesis. Our in vivo experiments showed that Pristimerin remarkably ameliorated ovariectomy induced bone loss, reduced serum levels of TNF alpha, IL 1 beta, IL 6, and RANKL, and increased serum level of osteoprotegerin (OPG). Therefore, our research indicated that Pristimerin is a potential chemical for the treatment of osteoporosis.
C1 [Qi, Dahu; Liu, Hui; Sun, Xuying; Luo, Danni; Zhu, Meipeng; Tao, Tenghui; Gao, Chenghao; Zhou, Chuankun; Xiao, Jun] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthoped, Tongji Med Coll, Wuhan, Peoples R China.
   [Liu, Hui] Wuhan Univ, Dept Orthoped, Zhongnan Hosp, Wuhan, Peoples R China.
   [Zhou, Wei] Wuhan Univ, Hubei Key Lab Med Technol Transplantat, Inst Hepatobiliary Dis, Transplant Ctr,Zhongnan Hosp, Wuhan, Peoples R China.
C3 Huazhong University of Science & Technology; Wuhan University; Wuhan
   University
RP Xiao, J (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthoped, Tongji Med Coll, Wuhan, Peoples R China.; Zhou, W (通讯作者)，Wuhan Univ, Hubei Key Lab Med Technol Transplantat, Inst Hepatobiliary Dis, Transplant Ctr,Zhongnan Hosp, Wuhan, Peoples R China.
EM zwxy66@whu.edu.cn; jun_xiao@hust.edu.cn
RI ZHOU, WEI/HNP 4799 2023; gao, chenghao/ABH 4408 2020
FU National Natural Science Foundation of China [81772396, 81974350]
FX This study was supported by National Natural Science Foundation of China
   (No.81772396; No.81974350).
CR Adamopoulos IE, 2018, CURR OPIN RHEUMATOL, V30, P59, DOI 10.1097/BOR.0000000000000449
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Baud'huin M, 2007, CELL MOL LIFE SCI, V64, P2334, DOI 10.1007/s00018 007 7104 0
   Baum R, 2016, CLIN REV ALLERG IMMU, V51, P1, DOI 10.1007/s12016 015 8515 6
   Bellezza I, 2018, BBA MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Coury F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00679
   D'Autréaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256
   Deeb D, 2014, INT J ONCOL, V44, P1707, DOI 10.3892/ijo.2014.2325
   Deng QD, 2015, INT IMMUNOPHARMACOL, V29, P302, DOI 10.1016/j.intimp.2015.11.001
   El Agamy DS, 2019, CANCER MANAG RES, V11, P47, DOI 10.2147/CMAR.S186696
   El Agamy DS, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00292
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Figueiredo JN, 1998, J NAT PROD, V61, P718, DOI 10.1021/np9704157
   dos Santos VADFM, 2010, MOLECULES, V15, P6956, DOI 10.3390/molecules15106956
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Gullo FP, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/340787
   Hui B, 2018, NEUROTOX RES, V33, P268, DOI 10.1007/s12640 017 9837 3
   Hui B, 2014, INT IMMUNOPHARMACOL, V21, P501, DOI 10.1016/j.intimp.2014.06.010
   Jin YL, 2016, IMMUNOPHARM IMMUNOT, V38, P221, DOI 10.3109/08923973.2016.1168435
   Kawai M, 2010, NAT REV ENDOCRINOL, V6, P629, DOI 10.1038/nrendo.2010.155
   Kim HJ, 2013, ARCH PHARM RES, V36, P495, DOI 10.1007/s12272 013 0054 1
   Li JJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00746
   Liu H, 2019, J CELL PHYSIOL, V234, P11009, DOI 10.1002/jcp.27924
   Luo DQ, 2005, PEST MANAG SCI, V61, P85, DOI 10.1002/ps.953
   Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Prasad S, 2017, CANCER LETT, V387, P95, DOI 10.1016/j.canlet.2016.03.042
   Rao SS, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0012 0
   Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281
   Shaaban AA, 2018, INT IMMUNOPHARMACOL, V59, P31, DOI 10.1016/j.intimp.2018.03.033
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Sun YX, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929 015 0212 5
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tonelli C, 2018, ANTIOXID REDOX SIGN, V29, P1727, DOI 10.1089/ars.2017.7342
   Tong L, 2014, CLIN IMMUNOL, V155, P220, DOI 10.1016/j.clim.2014.09.014
   Tu YQ, 2018, CELL BIOCHEM FUNCT, V36, P228, DOI 10.1002/cbf.3335
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Watanabe J, 2018, BIOMATERIALS, V185, P25, DOI 10.1016/j.biomaterials.2018.08.055
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Xie XS, 2019, J CELL MOL MED, V23, P7545, DOI 10.1111/jcmm.14623
   Yadav VR, 2010, TOXINS, V2, P2428, DOI 10.3390/toxins2102428
   Yousef BA, 2018, PHYTOMEDICINE, V40, P140, DOI 10.1016/j.phymed.2018.01.008
   Zhou M, 2019, CURR OSTEOPOROS REP, V17, P97, DOI 10.1007/s11914 019 00507 z
   Zupan J, 2013, BIOCHEM MEDICA, V23, P43, DOI 10.11613/BM.2013.007
NR 52
TC 9
Z9 9
U1 0
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 15
PY 2021
VL 11
AR 621110
DI 10.3389/fphar.2020.621110
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PZ4AQ
UT WOS:000612681900001
PM 33628184
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shi, LY
   Ren, LY
   Li, JP
   Liu, X
   Lu, JJ
   Jia, LJ
   Xie, BP
   Tang, SY
   Liu, W
   Zhang, J
AF Shi, Liying
   Ren, Liuyi
   Li, Jinping
   Liu, Xin
   Lu, Jingjing
   Jia, Lujuan
   Xie, Baoping
   Tang, Siyuan
   Liu, Wei
   Zhang, Jie
TI Ethanol extract of Cyathulae Radix inhibits osteoclast differentiation
   and bone loss
SO CHINESE JOURNAL OF NATURAL MEDICINES
LA English
DT Article
DE Osteoporosis; Osteoclast; BMMs; Cyathulae Radix; RANKL; ER/RANK/NFATc1
   signaling pathway
ID RECEPTOR ACTIVATOR; RANKL
AB Cyathulae Radix, a traditional Chinese medicine and a common vegetable, boasts a history spanning millennia. It enhances bone density, boosts metabolism, and effectively alleviates osteoporosis induced pain. Despite its historical use, the molecular mechanisms behind Cyathulae Radix's impact on osteoporosis remain unexplored. In this study, we investigated the effects and mechanisms of Cyathulae Radix ethanol extract (CEE) in inhibiting osteoporosis and osteoclastogenesis. Eight week old female mice underwent ovariectomy and were treated with CEE for eight weeks. Micro computed tomography (micro CT) assessed histomorphometric parameters, bone tissue staining observed distal femur histomorphology, and three point bending tests evaluated tibia mechanical properties. Enzyme linked immunosorbent assay (ELISA) measured serum estradiol (E 2 ), receptor activator for nuclear factor B ligand (RANKL), and osteoprotegerin (OPG) levels. Osteoclastogenesis related markers were analyzed via Western blotting (WB) and quantitative real  time polymerase chain reaction (qRT PCR). Additionally, CEE effects on RANKL induced osteoclast formation and bone resorption were investigated in vitro using tartrate resistant acid phosphatase (TRAP) staining, qRT PCR, and WB assay. Compared with the ovariectomy (OVX) group, CEE treatment enhanced trabecular bone density, maximal load bearing capacity, and various histomorphometric parameters. Serum E 2 and OPG levels significantly increased, while Receptor activator of nuclear factor  kappa B (RANK) decreased in the CEE group. CEE downregulated matrix metallopeptidase 9 (MMP 9), Cathepsin K (CTSK), and TRAP gene and protein expression. In bone marrow macrophages (BMMs), CEE reduced mature osteoclasts, bone resorption pit areas, and MMP9, CTSK, and TRAP expression during osteoclast differentiation. Compared with DMSO treatment, CEE markedly inhibited RANK, TNF receptor associated factor 6 (TRAF6), Proto oncogene c  Fos (c  Fos), Nuclear factor of activated T cells cytoplasmic 1 (NFATc1) expressions, and Extracellular regulated protein kinases (ERK), c  Jun N terminal kinase (JNK), NF kappa B  p65 (p65) phosphorylation in osteoclasts. In conclusion, CEE significantly inhibits OVX induced osteoporosis and RANKL induced osteoclastogenesis, potentially through modulating the Estrogen Receptor (ER)/RANK/NFATc1 signaling pathway.
C1 [Shi, Liying; Ren, Liuyi; Li, Jinping; Liu, Xin; Lu, Jingjing; Jia, Lujuan] Cent South Univ, Xiangya Sch Pharmaceut Sci, Dept Pharmachem, Changsha 410013, Peoples R China.
   [Li, Jinping] Cent South Univ, Hunan Key Lab Diagnost & Therapeut Drug Res Chron, Changsha 410013, Peoples R China.
   [Xie, Baoping; Tang, Siyuan] Gannan Med Univ, Key Lab Prevent & Treatment Cardiovasc & Cerebrova, Minist Educ, Ganzhou 341000, Peoples R China.
   [Liu, Wei] Cent South Univ, Xiangya Nursing Sch, Changsha 410013, Peoples R China.
   [Zhang, Jie] Cent South Univ, Xiangya Hosp 3, Changsha 410013, Peoples R China.
C3 Central South University; Central South University; Gannan Medical
   University; Central South University; Central South University
RP Li, JP (通讯作者)，Cent South Univ, Xiangya Sch Pharmaceut Sci, Dept Pharmachem, Changsha 410013, Peoples R China.; Li, JP (通讯作者)，Cent South Univ, Hunan Key Lab Diagnost & Therapeut Drug Res Chron, Changsha 410013, Peoples R China.
EM pjingli@163.com
CR Abdallah BM, 2005, CALCIFIED TISSUE INT, V76, P90, DOI 10.1007/s00223 004 0074 4
   Abdelmagid SM, 2015, J BIOL CHEM, V290, P20128, DOI 10.1074/jbc.M114.624270
   Amano S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125054
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   [Anonymous], 2017, Chin J Osteoporos Bone Miner Res, V10, P413, DOI 10.3969/j.issn.1674 2591.2017.05.002
   Basak S, 2012, IMMUNOL REV, V246, P221, DOI 10.1111/j.1600 065X.2011.01092.x
   Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chinese Pharmacopoeia Commission, 2020, Pharmacopoeia of the People's Republic of China, P39
   Choi SW, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 35
   De Vries TJ, 2015, J CELL PHYSIOL, V230, P210, DOI 10.1002/jcp.24702
   Feng HB, 2014, INT J BIOL MACROMOL, V65, P121, DOI 10.1016/j.ijbiomac.2014.01.017
   Hamidi A, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal4186
   He JB, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 016 0301 4
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Huang YL, 2019, CHIN MED UK, V14, DOI 10.1186/s13020 019 0237 x
   Ihn HJ, 2015, EXP BIOL MED, V240, P1690, DOI 10.1177/1535370215576310
   Ji QL, 2018, J Kunming Med Univ, V39, P21
   Kim HJ, 2016, CELL SIGNAL, V28, P1137, DOI 10.1016/j.cellsig.2016.05.018
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Li J, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829862
   Li M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01023
   Liu SB, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12613
   Liu W, 2015, MOL MED REP, V11, P3212, DOI 10.3892/mmr.2015.3152
   Meng JH, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113715
   Nagy V, 2015, GERONTOLOGY, V61, P534, DOI 10.1159/000371845
   Poblenz AT, 2007, BIOCHEM BIOPH RES CO, V359, P510, DOI 10.1016/j.bbrc.2007.05.151
   Sen B, 2009, J BIOL CHEM, V284, P34607, DOI 10.1074/jbc.M109.039453
   Shi XD, 2014, PSYCHOPHARMACOLOGY, V231, P3109, DOI 10.1007/s00213 014 3491 8
   Siddiqi MH, 2015, PHYTOTHER RES, V29, P1286, DOI 10.1002/ptr.5374
   Stemig M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123843
   Suvarna V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00981
   Swarnkar G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12707 7
   Tzeng HE, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29257 1
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   [王艳 Wang Yan], 2015, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V21, P918
   Wang Yan Wang Yan, 2015, Maternal and Child Health Care of China, V30, P5063
   Wang YY, 2018, J Jining Med Univ, V41, P132
   Xie BP, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109045
   Xie JC, 2022, Central South Pharm, V20, P2046
   Yan WJ, 2014, Pharm Clin Res, V22, P336
   [智信 Zhi Xin], 2018, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V24, P1510
NR 43
TC 2
Z9 3
U1 1
U2 13
PU CHINESE JOURNAL NATURAL MEDICINES
PI NANJING
PA 24, TONGJIA XIANG, NANJING, 210009, PEOPLES R CHINA
SN 2095 6975
EI 1875 5364
J9 CHIN J NAT MEDICINES
JI Chin. J. Nat. Med.
PD MAR
PY 2024
VL 22
IS 3
BP 212
EP 223
DI 10.1016/S1875 5364(24)60596 0
EA MAR 2024
PG 12
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA QY8B4
UT WOS:001224509800001
PM 38553189
DA 2025 08 17
ER

PT J
AU Zhou, C
   You, Y
   Shen, WX
   Zhu, YZ
   Peng, J
   Feng, HT
   Wang, Y
   Li, D
   Shao, WW
   Li, CX
   Li, WZ
   Xu, JK
   Shen, XY
AF Zhou, Chun
   You, Yan
   Shen, Weixing
   Zhu, Yi Zhun
   Peng, Jing
   Feng, Hao Tian
   Wang, Ying
   Li, Dong
   Shao, Wei Wei
   Li, Cui Xian
   Li, Wan Zhen
   Xu, Jiake
   Shen, Xiaoyan
TI Deficiency of sorting nexin 10 prevents bone erosion in collagen induced
   mouse arthritis through promoting NFATc1 degradation
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID MINERAL DENSITY; SEALING ZONE; OSTEOCLASTS; INTEGRIN; KINASE;
   OSTEOPETROSIS; TRAFFICKING; DIFFERENTIATION; ORGANIZATION; RESORPTION
AB Objective Periarticular and subchondral bone erosion in rheumatoid arthritis caused by osteoclast differentiation and activation is a critical index for diagnosis, therapy and monitoring of the disease. Sorting nexin (SNX) 10, a member of the SNX family which functions in regulation of endosomal sorting, has been implicated to play an important clinical role in malignant osteopetrosis. Here we studied the roles and precise mechanisms of SNX10 in the bone destruction of collagen induced arthritis (CIA) mice.
   Methods The role of SNX10 in bone destruction was evaluated by a CIA mice model which was induced in male SNX10( / ) mice and wild type littermates. The mechanism was explored in osteoclasts induced by receptor activator of nuclear factor kappa B ligand from bone marrow mononuclear cells of wild type and SNX10( / ) mice.
   Results SNX10 knockout prevented bone loss and joint destruction in CIA mice with reduced serum levels of TNF alpha, interleukin 1 beta and anticollagen IgG 2 alpha antibody. SNX10 deficiency did not block osteoclastogenesis, but significantly impaired osteoclast maturation and bone resorption function by disturbing the formation of actin belt. The production of TRAP, CtsK and MMP9 in SNX10( / ) osteoclasts was significantly inhibited, and partially restored by SNX10 overexpression. We further demonstrated that the degradation of NFATc1 was accelerated in SNX10( / ) osteoclasts causing an inhibition of integrin beta 3 Src PYK2 signalling.
   Conclusions Our study discloses a crucial role and novel mechanism for SNX10 in osteoclast function, and provides evidence for SNX10 as a promising novel therapeutic target for suppression of immune inflammation and bone erosion in rheumatoid arthritis.
C1 [Zhou, Chun; You, Yan; Peng, Jing; Wang, Ying; Li, Dong; Shao, Wei Wei; Li, Cui Xian; Li, Wan Zhen; Shen, Xiaoyan] Sun Yat Sen Univ, Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Guangzhou 510275, Guangdong, Peoples R China.
   [You, Yan; Zhu, Yi Zhun; Li, Dong; Li, Wan Zhen; Shen, Xiaoyan] Fudan Univ, Sch Pharm, Dept Pharmacol, Shanghai 201203, Peoples R China.
   [Feng, Hao Tian; Xu, Jiake] Univ Western Australia, Sch Pathol & Lab Med, 1st Floor M Block QEII Med Ctr, Perth, WA 6009, Australia.
   [Shen, Weixing] Nanjing Univ Tradit Chinese Med, Translat Med Res Ctr, Nanjing, Jiangsu, Peoples R China.
C3 Sun Yat Sen University; Fudan University; University of Western
   Australia; Nanjing University of Chinese Medicine
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Pathol & Lab Med, 1st Floor M Block QEII Med Ctr, Perth, WA 6009, Australia.; Shen, XY (通讯作者)，Fudan Univ, Sch Pharmaceut Sci, Dept Pharmacol, 826 Zhangheng Rd,Pudong New Area, Shanghai 201203, Peoples R China.
EM jiake.xu@uwa.edu.au; shxiaoy@fudan.edu.cn
RI Wang, Ying/T 9438 2018; Zhou, Chun/AGK 7203 2022; Zhu, Yi
   Zhun/ABG 8449 2021
OI Wang, Ying/0000 0002 1407 2668; , Xiaoyan/0000 0003 4828 3268; Xu,
   Jiake/0000 0003 2021 8309; ZHU, YI ZHUN/0000 0001 7700 8041; Zhou,
   Chun/0000 0001 7395 5842; 
FU National Natural Science Foundation of China [81371923, 81173056,
   81228013]; Natural Science Foundation of Guangdong Province
   [S2013010015313]
FX This study was supported by National Natural Science Foundation of China
   (No. 81371923, 81173056, and 81228013); Natural Science Foundation of
   Guangdong Province (S2013010015313).
CR Aker M, 2012, J MED GENET, V49, P221, DOI 10.1136/jmedgenet 2011 100520
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Braun T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3380
   Chen YQ, 2012, CELL RES, V22, P333, DOI 10.1038/cr.2011.134
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0
   Coxon FP, 2008, SEMIN CELL DEV BIOL, V19, P424, DOI 10.1016/j.semcdb.2008.08.004
   Crotti TN, 2008, J CELL PHYSIOL, V215, P636, DOI 10.1002/jcp.21344
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   Cullen PJ, 2012, NAT CELL BIOL, V14, P29, DOI 10.1038/ncb2374
   Deodhar A, 2010, ARTHRIT CARE RES, V62, P569, DOI 10.1002/acr.20004
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212
   Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200
   Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082
   Izawa T, 2012, MOL CELL BIOL, V32, P2943, DOI 10.1128/MCB.00077 12
   Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816
   Joosten LAB, 1997, ARTHRITIS RHEUM, V40, P249, DOI 10.1002/art.1780400209
   Kartner N, 2010, J BIOL CHEM, V285, P37476, DOI 10.1074/jbc.M110.123281
   Li YM, 2013, TRANSL RES, V161, P89, DOI 10.1016/j.trsl.2012.06.001
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Matsumoto T, 2013, J BONE MINER RES, V28, P1191, DOI 10.1002/jbmr.1844
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Mulari M, 2003, MICROSC RES TECHNIQ, V61, P496, DOI 10.1002/jemt.10371
   Pavlos NJ, 2011, MOL CELL BIOL, V31, P1551, DOI 10.1128/MCB.00834 10
   Qin BM, 2006, J BIOL CHEM, V281, P36891, DOI 10.1074/jbc.M608884200
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Saltel F, 2008, EUR J CELL BIOL, V87, P459, DOI 10.1016/j.ejcb.2008.01.001
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Stenbeck G, 2002, SEMIN CELL DEV BIOL, V13, P285, DOI 10.1016/S1084952102000587
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tsai CY, 2007, ARTHRITIS RHEUM US, V56, P544, DOI 10.1002/art.22401
   Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974
   Zhou C, 2013, NEUROSCIENCE, V254, P361, DOI 10.1016/j.neuroscience.2013.09.045
   Zhu C, 2012, J CELL BIOCHEM, V113, P1608, DOI 10.1002/jcb.24029
NR 39
TC 31
Z9 34
U1 0
U2 38
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003 4967
EI 1468 2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2016
VL 75
IS 6
BP 1211
EP 1218
DI 10.1136/annrheumdis 2014 207134
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA DM6DP
UT WOS:000376440900042
PM 26141367
DA 2025 08 17
ER

PT J
AU White, AD
   Peña, KA
   Clark, LJ
   Santa Maria, C
   Liu, S
   Jean Alphonse, FG
   Lee, JY
   Lei, SF
   Cheng, ZQ
   Tu, CL
   Fang, F
   Szeto, N
   Gardella, TJ
   Xiao, KH
   Gellman, SH
   Bahar, I
   Sutkeviciute, I
   Chang, WH
   Vilardaga, JP
AF White, Alex D.
   Pena, Karina A.
   Clark, Lisa J.
   Santa Maria, Christian
   Liu, Shi
   Jean Alphonse, Frederic G.
   Lee, Ji Young
   Lei, Saifei
   Cheng, Zhiqiang
   Tu, Chia Ling
   Fang, Fei
   Szeto, Nicholas
   Gardella, Thomas J.
   Xiao, Kunhong
   Gellman, Samuel H.
   Bahar, Ivet
   Sutkeviciute, Ieva
   Chang, Wenhan
   Vilardaga, Jean Pierre
TI Spatial bias in cAMP generation determines biological responses to PTH
   type 1 receptor activation
SO SCIENCE SIGNALING
LA English
DT Article
ID PARATHYROID HORMONE RECEPTOR; PROTEIN COUPLED RECEPTORS; DYNAMICS;
   SELECTIVITY; PATHOPHYSIOLOGY; MECHANISMS; RETROMER; COMPLEX; PRODY; PKA
AB The parathyroid hormone (PTH) type 1 receptor (PTHR) is a class B G protein coupled receptor (GPCR) that regulates mineral ion, vitamin D, and bone homeostasis. Activation of the PTHR by PTH induces both transient cell surface and sustained endosomal cAMP production. To address whether the spatial (location) or temporal (duration) dimension of PTHR induced cAMP encodes distinct biological outcomes, we engineered a biased PTHR ligand (PTH7d) that elicits cAMP production at the plasma membrane but not at endosomes. PTH7d stabilized a unique active PTHR conformation that mediated sustained cAMP signaling at the plasma membrane due to impaired beta arrestin coupling to the receptor. Experiments in cells and mice revealed that sustained cAMP production by cell surface PTHR failed to mimic the pharmacological effects of sustained endosomal cAMP production on the abundance of the rate limiting hydroxylase catalyzing the formation of active vitamin D, as well as increases in circulating active vitamin D and Ca2+ and in bone formation in mice. Thus, similar amounts of cAMP generated by PTHR for similar lengths of time in different cellular locations, plasma membrane and endosomes, mediate distinct physiological responses. These results unveil subcellular signaling location as a means to achieve specificity in PTHR mediated biological outcomes and raise the prospect of rational drug design based upon spatiotemporal manipulation of GPCR signaling.
C1 [White, Alex D.; Pena, Karina A.; Clark, Lisa J.; Jean Alphonse, Frederic G.; Lei, Saifei; Fang, Fei; Xiao, Kunhong; Sutkeviciute, Ieva; Vilardaga, Jean Pierre] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA.
   [White, Alex D.] Univ Pittsburgh, Sch Med, Grad Program Mol Pharmacol, Pittsburgh, PA 15261 USA.
   [Clark, Lisa J.] Univ Pittsburgh, Sch Med, Grad Program Mol Biol & Struct Biol, Pittsburgh, PA 15261 USA.
   [Santa Maria, Christian; Cheng, Zhiqiang; Tu, Chia Ling; Szeto, Nicholas; Chang, Wenhan] Dept Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA 94158 USA.
   [Santa Maria, Christian; Cheng, Zhiqiang; Tu, Chia Ling; Szeto, Nicholas; Chang, Wenhan] Univ Calif San Francisco, San Francisco, CA 94158 USA.
   [Liu, Shi; Gellman, Samuel H.] Univ Wisconsin, Dept Chem, Madison, WI 53706 USA.
   [Lee, Ji Young; Bahar, Ivet] Univ Pittsburgh, Dept Computat & Syst Biol, Sch Med, Pittsburgh, PA 15260 USA.
   [Gardella, Thomas J.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Gardella, Thomas J.] Harvard Med Sch, Boston, MA 02114 USA.
   [Clark, Lisa J.] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA.
   [Jean Alphonse, Frederic G.] Univ Tours, Ctr Natl Rech Sci CNRS, Inst Natl Rech Agr Alimentat & Environm INRAE, Physiol Reprod & Comportements PRC,Inst Francais, F 37380 Nouzilly, France.
   [Lei, Saifei] Univ Pittsburgh, Ctr Pharmacogenet, Sch Pharm, Pittsburgh, PA 15261 USA.
   [Fang, Fei] Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; University of
   California System; University of California San Francisco; University of
   Wisconsin System; University of Wisconsin Madison; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Harvard University; Harvard University Medical Affiliates;
   Massachusetts General Hospital; Harvard University; Harvard Medical
   School; University of California System; University of California Los
   Angeles; INRAE; Centre National de la Recherche Scientifique (CNRS);
   Universite de Tours; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Michigan State University
RP Vilardaga, JP (通讯作者)，Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA.; Chang, WH (通讯作者)，Dept Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA 94158 USA.; Chang, WH (通讯作者)，Univ Calif San Francisco, San Francisco, CA 94158 USA.
EM wenhan.chang@ucsf.edu; jpv@pitt.edu
RI ; Bahar, Ivet/AAH 2921 2020; Lei, Saifei/HLG 6767 2023; Fang,
   Fei/AHD 3579 2022; Xiao, Kunhong/AAG 4275 2020
OI Pena, Karina/0000 0001 6401 5269; Santa Maria,
   Christian/0000 0002 7842 1740; Chang, Wenhan/0000 0001 6583 7176; White,
   Alex/0000 0003 2180 2136; Clark, Lisa/0000 0003 0484 4596;
   JEAN ALPHONSE, Frederic/0000 0002 7380 5825; Liu,
   Shi/0000 0002 9113 6207
FU U.S. National Institutes of Health (NIH) [R01 DK111427, R01 DK116780,
   R01 DK122259, R01 AR067291, DK11794, AR066261, R01 GM 056414,
   P41 GM103712, R01 GM139297, F31 AR074843]; Department of Veterans
   Affairs [I0 BX003453 03, IK6BX004835]; National Cancer Institute
   [T32CA009120] Funding Source: NIH RePORTER; National Institute of Dental
   and Craniofacial Research [T32DE007306] Funding Source: NIH RePORTER;
   National Institute of General Medical Sciences [P41GM103712] Funding
   Source: NIH RePORTER
FX Research reported in this publication was supported by grants from the
   U.S. National Institutes of Health (NIH) (R01 DK111427 and R01 DK116780
   to J. P.V., R01 DK122259 to J. P.V. and W.C., R01 AR067291 to W.C.,
   DK11794 and AR066261 to T.J.G., R01 GM 056414 to S.H.G., P41 GM103712
   and R01 GM139297 to I.B., and F31 AR074843 to L.J.C.) and the Department
   of Veterans Affairs (I0 BX003453 03 and IK6BX004835 to W.C.).
CR Bahar I, 2010, CHEM REV, V110, P1463, DOI 10.1021/cr900095e
   Bakalarski CE, 2008, J PROTEOME RES, V7, P4756, DOI 10.1021/pr800333e
   Bakan A, 2014, BIOINFORMATICS, V30, P2681, DOI 10.1093/bioinformatics/btu336
   Bakan A, 2011, BIOINFORMATICS, V27, P1575, DOI 10.1093/bioinformatics/btr168
   Bock A, 2020, CELL, V182, P1519, DOI 10.1016/j.cell.2020.07.035
   Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723
   Boone M, 2008, PFLUG ARCH EUR J PHY, V456, P1005, DOI 10.1007/s00424 008 0498 1
   Brenza HL, 1998, P NATL ACAD SCI USA, V95, P1387, DOI 10.1073/pnas.95.4.1387
   Calebiro D, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000172
   Clark LJ, 2020, NAT CHEM BIOL, V16, P1096, DOI 10.1038/s41589 020 0567 0
   Dean T, 2006, MOL ENDOCRINOL, V20, P931, DOI 10.1210/me.2005 0349
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Feinstein TN, 2013, J BIOL CHEM, V288, P27849, DOI 10.1074/jbc.M112.445098
   Feinstein TN, 2011, NAT CHEM BIOL, V7, P278, DOI 10.1038/nchembio.545
   Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206
   Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001
   Galandrin S, 2007, TRENDS PHARMACOL SCI, V28, P423, DOI 10.1016/j.tips.2007.06.005
   Gardella TJ, 2015, PHARMACOL REV, V67, P310, DOI 10.1124/pr.114.009464
   Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043 2760(01)00409 X
   Gidon A, 2016, METHOD CELL BIOL, V132, P109, DOI 10.1016/bs.mcb.2015.10.007
   Gidon A, 2014, NAT CHEM BIOL, V10, P707, DOI [10.1038/nchembio.1589, 10.1038/NCHEMBIO.1589]
   GOLDMAN ME, 1988, ENDOCRINOLOGY, V123, P2597, DOI 10.1210/endo 123 5 2597
   Haas W, 2006, MOL CELL PROTEOMICS, V5, P1326, DOI 10.1074/mcp.M500339 MCP200
   Horwitz MJ, 2005, J BONE MINER RES, V20, P1792, DOI 10.1359/JBMR.050602
   Huang J, 2017, NAT METHODS, V14, P71, DOI [10.1038/NMETH.4067, 10.1038/nmeth.4067]
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263 7855(96)00018 5
   Irannejad R, 2017, NAT CHEM BIOL, V13, P799, DOI 10.1038/nchembio.2389
   Jean Alphonse FG, 2017, NAT CHEM BIOL, V13, P259, DOI [10.1038/NCHEMBIO.2267, 10.1038/nchembio.2267]
   Kahsai AW, 2014, NAT PROTOC, V9, P1301, DOI 10.1038/nprot.2014.075
   Kuna RS, 2013, AM J PHYSIOL ENDOC M, V305, pE161, DOI 10.1152/ajpendo.00551.2012
   Lee J, 2016, J CHEM THEORY COMPUT, V12, P405, DOI 10.1021/acs.jctc.5b00935
   Liggett SB, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002331
   Lomize MA, 2012, NUCLEIC ACIDS RES, V40, pD370, DOI 10.1093/nar/gkr703
   Lymperopoulos A, 2013, CIRC RES, V113, P739, DOI 10.1161/CIRCRESAHA.113.300308
   MacDonald PE, 2002, DIABETES, V51, pS434, DOI 10.2337/diabetes.51.2007.S434
   Maudsley S, 2005, J PHARMACOL EXP THER, V314, P485, DOI 10.1124/jpet.105.083121
   Mayer D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09204 y
   McElderry JDP, 2013, J BONE MINER RES, V28, P1846, DOI 10.1002/jbmr.1924
   McGarvey JC, 2016, J BIOL CHEM, V291, P10986, DOI 10.1074/jbc.M115.697045
   Nobles KN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001707
   Noda H, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10367
   Okazaki M, 2008, P NATL ACAD SCI USA, V105, P16525, DOI 10.1073/pnas.0808750105
   Oztan A, 2007, MOL BIOL CELL, V18, P3978, DOI 10.1091/mbc.E07 02 0097
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Sample V, 2012, NAT CHEM BIOL, V8, P375, DOI [10.1038/NCHEMBIO.799, 10.1038/nchembio.799]
   Scheerert P, 2017, CURR OPIN STRUC BIOL, V45, P160, DOI 10.1016/j.sbi.2017.05.001
   Shimizu M, 2016, J BONE MINER RES, V31, P1405, DOI 10.1002/jbmr.2811
   Stallaert W, 2017, MOL PHARMACOL, V91, P533, DOI 10.1124/mol.116.106419
   Staus DP, 2018, P NATL ACAD SCI USA, V115, P3834, DOI 10.1073/pnas.1722336115
   Sutkeviciute I, 2020, J BIOL CHEM, V295, P11626, DOI 10.1074/jbc.REV120.009348
   Sutkeviciute I, 2019, TRENDS ENDOCRIN MET, V30, P860, DOI 10.1016/j.tem.2019.07.011
   Vilardaga JP, 2014, NAT CHEM BIOL, V10, P700, DOI [10.1038/NCHEMBIO.1611, 10.1038/nchembio.1611]
   Vilardaga JP, 2012, TRENDS PHARMACOL SCI, V33, P423, DOI 10.1016/j.tips.2012.05.004
   Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838
   Vilardaga JP, 2002, J BIOL CHEM, V277, P8121, DOI 10.1074/jbc.M110433200
   Wakabayashi Y, 2007, HISTOCHEM CELL BIOL, V127, P463, DOI 10.1007/s00418 007 0274 x
   Wang B, 2012, J BIOL CHEM, V287, P24148, DOI 10.1074/jbc.M112.369405
   Wehbi VL, 2013, P NATL ACAD SCI USA, V110, P1530, DOI 10.1073/pnas.1205756110
   White AD, 2019, P NATL ACAD SCI USA, V116, P3294, DOI 10.1073/pnas.1814670116
   Wootten D, 2013, P NATL ACAD SCI USA, V110, P5211, DOI 10.1073/pnas.1221585110
   Wu EL, 2014, J COMPUT CHEM, V35, P1997, DOI 10.1002/jcc.23702
   Xiao KH, 2018, NAT PROTOC, V13, P1403, DOI 10.1038/nprot.2018.037
   Xiao KH, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.203091
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471 2105 9 40
   Zhao LH, 2019, SCIENCE, V364, P148, DOI 10.1126/science.aav7942
NR 67
TC 52
Z9 52
U1 1
U2 26
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945 0877
EI 1937 9145
J9 SCI SIGNAL
JI Sci. Signal.
PD OCT 5
PY 2021
VL 14
IS 703
AR eabc5944
DI 10.1126/scisignal.abc5944
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA WD0TT
UT WOS:000704660900001
PM 34609896
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Xiao, HX
   Yu, L
   Xia, Y
   Chen, K
   Li, WM
   Ge, GR
   Zhang, W
   Zhang, Q
   Zhang, HT
   Geng, DC
AF Xiao, Hai Xiang
   Yu, Lei
   Xia, Yu
   Chen, Kai
   Li, Wen Ming
   Ge, Gao Ran
   Zhang, Wei
   Zhang, Qing
   Zhang, Hong Tao
   Geng, De Chun
TI Sinomenine increases osteogenesis in mice with ovariectomy induced bone
   loss by modulating autophagy
SO WORLD JOURNAL OF STEM CELLS
LA English
DT Article
DE Sinomenine; Osteogenesis; Autophagy; Ovariectomy; Osteoporosis
ID MESENCHYMAL STEM CELLS; PI3K/AKT/MTOR; OSTEOPOROSIS; APOPTOSIS
AB BACKGROUND A decreased autophagic capacity of bone marrow mesenchymal stromal cells (BMSCs) has been suggested to be an important cause of decreased osteogenic differentiation. A pharmacological increase in autophagy of BMSCs is a potential therapeutic option to increase osteoblast viability and ameliorate osteoporosis. AIM To explore the effects of sinomenine (SIN) on the osteogenic differentiation of BMSCs and the underlying mechanisms. METHODS For in vitro experiments, BMSCs were extracted from sham treated mice and ovariectomized mice, and the levels of autophagy markers and osteogenic differentiation were examined after treatment with the appropriate concentrations of SIN and the autophagy inhibitor 3 methyladenine. In vivo, the therapeutic effect of SIN was verified by establishing an ovariectomy induced mouse model and by morphological and histological assays of the mouse femur. RESULTS SIN reduced the levels of AKT and mammalian target of the rapamycin (mTOR) phosphorylation in the phosphatidylinositol 3 kinase (PI3K)/AKT/mTOR signaling pathway, inhibited mTOR activity, and increased autophagy ability of BMSCs, thereby promoting the osteogenic differentiation of BMSCs and effectively alleviating bone loss in ovariectomized mice in vivo. CONCLUSION The Chinese medicine SIN has potential for the treatment of various types of osteoporosis, bone homeostasis disorders, and autophagy related diseases.
C1 [Xiao, Hai Xiang] Soochow Univ, Affiliated Hosp 4, Suzhou Dushu Lake Hosp, Dept Orthoped,Med Ctr, Suzhou 215006, Jiangsu, Peoples R China.
   [Xiao, Hai Xiang] Yangzhou Univ, Jingjiang Peoples Hosp, Dept Orthoped, Jingjiang 214500, Jingjiang, Jiangsu, Peoples R China.
   [Xiao, Hai Xiang; Yu, Lei; Xia, Yu; Li, Wen Ming; Ge, Gao Ran; Zhang, Wei; Geng, De Chun] Soochow Univ, Affiliated Hosp 1, Dept Orthoped, 188 Shizi Rd, Suzhou 215006, Jiangsu, Peoples R China.
   [Chen, Kai] Haian Peoples Hosp, Dept Orthoped, Haian 226600, Jiangsu, Peoples R China.
   [Zhang, Qing] Xuzhou Med Univ, Affiliated Huaian Hosp, Huaian Peoples Hosp 2, Dept Orthoped, Xuzhou 223002, Jiangsu, Peoples R China.
   [Zhang, Hong Tao] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou 215006, Jiangsu, Peoples R China.
C3 Soochow University   China; Yangzhou University; Soochow University  
   China; Xuzhou Medical University; Soochow University   China
RP Geng, DC (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthoped, 188 Shizi Rd, Suzhou 215006, Jiangsu, Peoples R China.; Zhang, HT (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou 215006, Jiangsu, Peoples R China.
EM szgengdc@suda.edu.cn
RI Zhang, Hongtao/MCY 2202 2025; Chen, Kai/MHQ 9454 2025; Geng,
   Dechun/LMO 1733 2024; Li, Wenming/JTU 5517 2023
OI Yu, Lei/0000 0002 7288 2458; 
FU National Natural Science Foundation of China [82072425]
FX National Natural Science Foundation of China, No. 82072425.
CR Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Deng F, 2018, BIOMED PHARMACOTHER, V97, P1269, DOI 10.1016/j.biopha.2017.11.064
   Ensrud Kristine E, 2021, JAMA, V325, P96, DOI 10.1001/jama.2020.2923
   Feng ZT, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.108759
   Hong HX, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1015035
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Jiang H, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 30922 3
   Jiang YM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030844
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kumariya S, 2021, AUTOPHAGY, V17, P2706, DOI 10.1080/15548627.2021.1938914
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Li HK, 2022, DRUG DES DEV THER, V16, P2949, DOI 10.2147/DDDT.S379468
   Li XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074274
   Liao KS, 2021, BIOMED PHARMACOTHER, V135, DOI 10.1016/j.biopha.2020.111195
   Lin Y, 2022, J CONTROL RELEASE, V348, P42, DOI 10.1016/j.jconrel.2022.05.016
   Liu F, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101963
   Liu WW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02228
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Miura M, 2006, ORAL DIS, V12, P514, DOI 10.1111/j.1601 0825.2006.01300.x
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Sun Z, 2018, DRUG DES DEV THER, V12, P2413, DOI 10.2147/DDDT.S155798
   Tong B, 2015, MOL IMMUNOL, V65, P94, DOI 10.1016/j.molimm.2015.01.014
   Tuckermann J, 2021, NAT REV RHEUMATOL, V17, P608, DOI 10.1038/s41584 021 00682 3
   Wang J, 2023, AUTOPHAGY, V19, P2409, DOI 10.1080/15548627.2023.2186112
   Wang SW, 2023, INT IMMUNOPHARMACOL, V119, DOI 10.1016/j.intimp.2023.110227
   Wang YL, 2019, EXP THER MED, V17, P3644, DOI 10.3892/etm.2019.7339
   Xu X., 2023, Cells, V12
   YAMASAKI H, 1976, ACTA MED OKAYAMA, V30, P1
   Yang C, 2022, AUTOPHAGY, V18, P2817, DOI 10.1080/15548627.2022.2048432
   Zhang YY, 2019, PHARMACOL RES, V142, P140, DOI 10.1016/j.phrs.2019.02.015
   Zheng XJ, 2021, ACTA PHARM SIN B, V11, P3465, DOI 10.1016/j.apsb.2021.05.027
   Zhou B, 2017, BIOMED PHARMACOTHER, V90, P835, DOI 10.1016/j.biopha.2017.03.084
   Zhu CY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.898634
NR 36
TC 3
Z9 3
U1 2
U2 6
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1948 0210
J9 WORLD J STEM CELLS
JI World J. Stem Cells
PD MAY 26
PY 2024
VL 16
IS 5
DI 10.4252/wjsc.v16.i5.486
PG 14
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA SV7V3
UT WOS:001237298700009
PM 38817333
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Liu, SP
   Wang, GD
   Du, XJ
   Wan, G
   Wu, JT
   Miao, LB
   Liang, QD
AF Liu, Shen Peng
   Wang, Guo Dong
   Du, Xue Jun
   Wan, Guang
   Wu, Jun Tao
   Miao, Lian Bao
   Liang, Qiu Dong
TI Triptolide inhibits the function of TNF α in osteoblast differentiation
   by inhibiting the NF κB signaling pathway
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE fracture healing; bone morphogenetic protein 1; triptolide; osteoblast
   differentiation
ID MESENCHYMAL STEM CELLS; NECROSIS FACTOR ALPHA; OSTEOCLAST
   DIFFERENTIATION; CHRONIC INFLAMMATION; BONE FORMATION; GENE THERAPY;
   APOPTOSIS; EXPRESSION; LPS
AB Chronic inflammation often delays fracture healing or leads to bone nonunion. Effectively suppressing pathological inflammation is crucial for fracture healing or bone remodeling. Triptolide, which is a diterpenoid epoxide, is the major active component of the Thunder God Vine, Tripterygium wilfordii. The aim of the present study was to investigate the role of triptolide in osteoblast differentiation and explore the molecular mechanisms of triptolide in fracture healing. Alkaline phosphatase (ALP) activity was used to evaluate osteoblast differentiation. ALP activity was measured via histochemical staining and western blotting was used to determine the expression of factors associated with inflammation. C2C12 cells were initially treated with 200 ng/ml bone morphogenetic protein (BMP) 2 alone for 3 days, which caused a significant increase in ALP activity (P<0.01). However, treatment with tumor necrosis factor (TNF) alpha significantly decreased the ALP activity (P<0.05). Notably, treatment with the chronic inflammatory cytokine TNF alpha significantly decreased the effect of BMP 2 in C2C12 cells compared with BMP 2 treatment alone (P<0.01). C2C12 cells were treated with increasing concentrations of BMP 2 or TNF alpha for 3 days. The results demonstrated that TNF alpha treatment significantly inhibited BMP 2 induced osteoblast differentiation in a dose dependent manner (P<0.01). The role of triptolide in BMP 2 induced osteoblast differentiation was also examined. Cells were treated with BMP 2, BMP 2 + TNF alpha alone, or BMP2 + TNF alpha with increasing concentrations of triptolide (4, 8 or 16 ng/ml). After 3 days, the results of ALP activity revealed that triptolide significantly reversed the TNF alpha associated inhibition of osteoblast differentiation (P<0.01). Western blotting analysis demonstrated that triptolide markedly inhibited the phosphorylation of nuclear factor kappa B, therefore suppressing the effects of TNF alpha. In summary, triptolide is able to reverse the TNF alpha associated suppression of osteoblast differentiation, suggesting that triptolide treatment may have a positive effect on bone remodeling and fracture repairing.
C1 [Liu, Shen Peng; Wang, Guo Dong; Du, Xue Jun; Wan, Guang; Liang, Qiu Dong] Xinxiang Med Univ, Affiliated Hosp 1, Dept Orthoped, 88 Jiankang Rd, Weihui 453100, Henan, Peoples R China.
   [Wu, Jun Tao] Xinxiang Med Univ, Affiliated Hosp 3, Dept Orthoped, Xinxiang 453003, Henan, Peoples R China.
   [Miao, Lian Bao] Huaxian Peoples Hosp Henan Prov, Dept Orthoped, Anyang 456400, Henan, Peoples R China.
C3 Henan Medical University; Henan Medical University
RP Liu, SP (通讯作者)，Xinxiang Med Univ, Affiliated Hosp 1, Dept Orthoped, 88 Jiankang Rd, Weihui 453100, Henan, Peoples R China.
EM liushenpenglsp@163.com
RI Wu, Juntao/G 4126 2015
CR Abbas S, 2003, CYTOKINE, V22, P33, DOI 10.1016/S1043 4666(03)00106 6
   Abou Khalil R, 2014, J BONE MINER RES, V29, P304, DOI 10.1002/jbmr.2038
   Akiyama T, 2014, J BIOL CHEM, V289, P15621, DOI 10.1074/jbc.M113.520510
   Crisostomo PR, 2008, AM J PHYSIOL CELL PH, V294, pC675, DOI 10.1152/ajpcell.00437.2007
   Dragoo JL, 2003, J ORTHOP RES, V21, P622, DOI 10.1016/S0736 0266(02)00238 3
   Eleftheriadis T, 2008, RENAL FAILURE, V30, P431, DOI 10.1080/08860220801964251
   Fürnrohr BG, 2015, INT J MOL SCI, V16, P18825, DOI 10.3390/ijms160818825
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Halai M, 2014, J TISSUE ENG, V5, DOI 10.1177/2041731414552114
   Han R, 2012, BRIT J CLIN PHARMACO, V74, P424, DOI 10.1111/j.1365 2125.2012.04221.x
   Hao ML, 2015, INFLAMMATION, V38, P1617, DOI 10.1007/s10753 015 0137 x
   Huang RL, 2014, STEM CELLS DEV, V23, P277, DOI 10.1089/scd.2013.0345
   Jin XQ, 2015, NEUROPSYCH DIS TREAT, V11, P1395, DOI 10.2147/NDT.S82052
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Kizelsztein P, 2009, J NEUROIMMUNOL, V217, P28, DOI 10.1016/j.jneuroim.2009.08.017
   Kobayashi K, 2016, EXP CELL RES, V340, P295, DOI 10.1016/j.yexcr.2015.10.030
   Kusunoki Natsuko, 2004, BMC Pharmacology, V4, P2, DOI 10.1186/1471 2210 4 2
   Kwon HY, 2013, INDIAN J BIOCHEM BIO, V50, P485
   Letourneau PA, 2011, J TISSUE SCI ENG S3
   Lieberman JR, 1998, J ORTHOP RES, V16, P330, DOI 10.1002/jor.1100160309
   Lorea CF, 2012, EUR J ENDOCRINOL, V167, P199, DOI 10.1530/EJE 12 0183
   Mehrara BJ, 1999, J BONE MINER RES, V14, P1290, DOI 10.1359/jbmr.1999.14.8.1290
   Mountziaris PM, 2011, TISSUE ENG PART B RE, V17, P393, DOI [10.1089/ten.teb.2011.0182, 10.1089/ten.TEB.2011.0182]
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Munisso MC, 2012, BIOCHIMIE, V94, P2360, DOI 10.1016/j.biochi.2012.05.031
   Ou CC, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/350239
   Rahman M, 2008, J CELL PHYSIOL, V214, P201, DOI 10.1002/jcp.21188
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321
   Sen C, 2004, J ORTHOP TRAUMA, V18, P150, DOI 10.1097/00005131 200403000 00005
   Shiotani A, 2002, ANAT REC, V268, P137, DOI 10.1002/ar.10121
   Straub RH, 2015, SEMIN ARTHRITIS RHEU, V45, P220, DOI 10.1016/j.semarthrit.2015.04.014
   Susperregui ARG, 2008, J CELL PHYSIOL, V216, P144, DOI 10.1002/jcp.21389
   Vestergaard RF, 2015, ANN THORAC SURG, V99, P1005, DOI 10.1016/j.athoracsur.2014.10.016
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu PJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142719
   Zhang T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974 015 0275 y
   Zhou H, 2015, BIOCHEM BIOPH RES CO, V456, P815, DOI 10.1016/j.bbrc.2014.12.023
   Zhou SH, 2015, SCI REP UK, V5, DOI 10.1038/srep10573
NR 39
TC 16
Z9 20
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD SEP
PY 2017
VL 14
IS 3
BP 2235
EP 2240
DI 10.3892/etm.2017.4749
PN A
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FF0MW
UT WOS:000408596800055
PM 28962148
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tabane, K
   Vorobiof, DA
AF Tabane, Keo
   Vorobiof, Daniel A.
TI Bone Targeted Therapies in Early Breast Cancer
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Article
ID PLUS ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; MINERAL DENSITY;
   RANDOMIZED TRIAL; TAMOXIFEN THERAPY; DOUBLE BLIND; FOLLOW UP;
   BISPHOSPHONATES; ANASTROZOLE; METASTASES
AB Bisphosphonates have emerged as an important tool in the supportive care of women with early breast cancer. Whereas traditionally, these drugs have been part of the treatment of osseous metastasis, the key role of bisphosphonates in preserving bone health in patients with early breast cancer cannot be overemphasised. Currently the most established use of bisphosphonates in early breast cancer patients is in women receiving hormonal blockade, mostly aromatase inhibitors (AI), with concomitant osteopenia. To that end, it is recommended that every woman undergo a Dual Energy X Ray absorptiometry (DEXA) scan before commencement of an AI and annually during the treatment duration. In addition, unless contraindicated, all women should receive calcium and Vitamin D supplementation. The use of bisphosphonates as part of the adjuvant therapy strategy, regardless of baseline bone density condition, has produced thought provoking results, although this is not yet considered standard clinical practise.
C1 [Tabane, Keo; Vorobiof, Daniel A.] Sandton Oncol Ctr, ZA 2121 Johannesburg, South Africa.
RP Tabane, K (通讯作者)，Sandton Oncol Ctr, 159 Rivonia Rd,POB 2059, ZA 2121 Johannesburg, South Africa.
EM sandtononcology@iafrica.com
RI Vorobiof, Daniel/LIG 6487 2024
CR Aebi S, 2010, ANN ONCOL, V21, pv9, DOI 10.1093/annonc/mdq159
   Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   [Anonymous], 2011, ST GALL BREAST CANC
   Baum M, 2003, Cancer, V98, P1802
   Bloomfield DJ, 1998, J CLIN ONCOL, V16, P1218, DOI 10.1200/JCO.1998.16.3.1218
   Brufsky A, 2009, CANC RES S, V69
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Chlebowski RT, 2010, J CLIN ONCOL, V28, P3582, DOI 10.1200/JCO.2010.28.2095
   Coleman R, 2009, CANC RES S3, V69
   Coleman RE, 2010, BRIT J CANCER, V102, P1099, DOI 10.1038/sj.bjc.6605604
   Coleman RE, 2010, ADJUVANT TREATMENT Z
   Coleman RE, 2007, LANCET ONCOL, V8, P119, DOI 10.1016/S1470 2045(07)70003 7
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Eastell R, 2011, ANN ONCOL, V22, P857, DOI 10.1093/annonc/mdq541
   Eastell R, 2008, J CLIN ONCOL, V26, P1051, DOI 10.1200/JCO.2007.11.0726
   Eidtmann H, 2010, ANN ONCOL, V21, P2188, DOI 10.1093/annonc/mdq217
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312
   Greenberg S, 2010, J CLIN ONCOL S, V28, p114s
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Hadji P, 2011, ANN ONCOL       0402
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Jakesz R, 2005, LANCET, V366, P455, DOI 10.1016/S0140 6736(05)67059 6
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lester JE, 2008, CLIN CANCER RES, V14, P6336, DOI 10.1158/1078 0432.CCR 07 5101
   Paget S., LANCET, V1, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Powles T, 2002, J CLIN ONCOL, V20, P19
   Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621
   Rack B, 2010, ANTICANCER RES, V30, P1807
   Rennert G, 2010, J CLIN ONCOL, V28, P3577, DOI 10.1200/JCO.2010.28.1113
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saarto T, 2004, ACTA ONCOL, V43, P650, DOI 10.1080/02841860410032885
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Thürlimann B, 2005, NEW ENGL J MED, V353, P2747
   Van Poznak C, 2005, CANCER AM CANCER SOC, V104, P443, DOI 10.1002/cncr.21201
   Van Poznak C, 2010, J CLIN ONCOL, V28, P967, DOI 10.1200/JCO.2009.24.5902
   Vorobiof DA, 1999, ANN ONCOL, V10, P1219, DOI 10.1023/A:1008308609325
NR 43
TC 6
Z9 6
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1527 2729
EI 1534 6277
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD DEC
PY 2011
VL 12
IS 4
BP 412
EP 423
DI 10.1007/s11864 011 0163 3
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 849HY
UT WOS:000297117800009
PM 21887503
DA 2025 08 17
ER

PT J
AU Hsu, SH
   Huang, GS
AF Hsu, Shan hui
   Huang, Guo shiang
TI Substrate dependent Wnt signaling in MSC differentiation within
   biomaterial derived 3D spheroids
SO BIOMATERIALS
LA English
DT Article
DE Mesenchymal stem cells (MSCs); Spheroids; Wnt signaling; Chitosan;
   Hyaluronan
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; CYTOSKELETAL
   TENSION; CHITOSAN SCAFFOLDS; STROMAL CELLS; SELF RENEWAL; CANCER CELLS;
   N CADHERIN; CHONDROGENESIS; CULTURE
AB A unique biomaterial based system was developed to generate dynamic three dimensional (3D) multicellular spheroids of mesenchymal stem cells (MSCs). MSCs were cultured on transparent membranes made of chitosan or those further grafted with hyaluronan (HA) in different densities. MSCs vigorously migrated and were self assembled into highly mobile 3D spheroids with substrate dependent upregulation of adhesion molecule N cadherin. MSC spheroids showed increased expression of Wnt genes/proteins and substrate dependent cell fate. The correlation of differentiation capacities with Wnt signaling and crosstalk with other pathways such as ERK1/2 or Smad2/3 were observed for MSC spheroids but not for the conventional 2D cultured cells. Wnt3a mediated canonical Wnt signaling was more active for MSC spheroids derived on chitosan, which were prone to osteogenesis. Wnt5a mediated non canonical Wnt signaling was more active for MSC spheroids derived on HA grafted chitosan, which were prone to chondrogenesis. In particular, the relative importance of Wnt5a mediated non canonical vs. Wnt3a mediated canonical Wnt signals in determining the cell fate was controlled by the grafting density of HA on chitosan. Treatment with the inhibitor of canonical Wnt associated signaling molecules suppressed the osteogenesis of MSC spheroids on chitosan. This study demonstrates that Wnt signaling of MSCs is distinct in 3D environment and is substrate dependent. The convenient 3D platform may be used to examine the role of Wnt signaling in controlling MSC fate under different extracellular environments, and potentially applied to study stem cell behavior in regenerative medicine, normal development, and cancer. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Hsu, Shan hui; Huang, Guo shiang] Natl Taiwan Univ, Inst Polymer Sci & Engn, Taipei 10617, Taiwan.
   [Hsu, Shan hui; Huang, Guo shiang] Natl Taiwan Univ, Res Ctr Dev Biol & Regenerat Med, Taipei 10617, Taiwan.
C3 National Taiwan University; National Taiwan University
RP Hsu, SH (通讯作者)，Natl Taiwan Univ, Inst Polymer Sci & Engn, 1,Sec 4 Roosevelt Rd, Taipei 10617, Taiwan.
EM shhsu@ntu.edu.tw
OI Hsu, Shan hui/0000 0003 3399 055X
FU Program for Stem Cell and Regenerative Medicine Frontier Research
   [NSC100 2321 B 002 077]; National Science Council, Taiwan, R.O.C.
FX This research was supported by the Program for Stem Cell and
   Regenerative Medicine Frontier Research (NSC100 2321 B 002 077)
   sponsored by the National Science Council, Taiwan, R.O.C.
CR Achilli TM, 2012, EXPERT OPIN BIOL TH, V12, P1347, DOI 10.1517/14712598.2012.707181
   Bartosh TJ, 2010, P NATL ACAD SCI USA, V107, P13724, DOI 10.1073/pnas.1008117107
   Bhadriraju K, 2007, EXP CELL RES, V313, P3616, DOI 10.1016/j.yexcr.2007.07.002
   Bhang SH, 2011, BIOMATERIALS, V32, P2734, DOI 10.1016/j.biomaterials.2010.12.035
   Chang TT, 2009, TISSUE ENG PT A, V15, P559, DOI 10.1089/ten.tea.2007.0434
   Chen YL, 2007, BIOMATERIALS, V28, P2294, DOI 10.1016/j.biomaterials.2007.01.027
   Cheng NC, 2012, BIOMATERIALS, V33, P1748, DOI 10.1016/j.biomaterials.2011.11.049
   Correia CR, 2011, TISSUE ENG PART C ME, V17, P717, DOI 10.1089/ten.tec.2010.0467
   Dakeng S, 2012, J CELL BIOCHEM, V113, P49, DOI 10.1002/jcb.23326
   Davidson KC, 2012, P NATL ACAD SCI USA, V109, P4485, DOI 10.1073/pnas.1118777109
   Di Benedetto A, 2010, J CELL SCI, V123, P2640, DOI 10.1242/jcs.067777
   Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652
   Griffon DJ, 2006, ACTA BIOMATER, V2, P313, DOI 10.1016/j.actbio.2005.12.007
   Haga T, 2008, APOPTOSIS, V13, P97, DOI 10.1007/s10495 007 0132 2
   Haÿ E, 2009, MOL CELL BIOL, V29, P953, DOI 10.1128/MCB.00349 08
   Hsu SH, 2012, TISSUE ENG PT A, V18, P67, DOI [10.1089/ten.TEA.2011.0157, 10.1089/ten.tea.2011.0157]
   Hsu SH, 2012, BIOMATERIALS, V33, P2642, DOI 10.1016/j.biomaterials.2011.12.032
   Huang GS, 2011, BIOMATERIALS, V32, P6929, DOI 10.1016/j.biomaterials.2011.05.092
   Ishida Takagishi M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1861
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Li BQ, 2011, J BIOMAT SCI POLYM E, V22, P505, DOI 10.1163/092050610X487800
   Liao HT, 2011, TISSUE ENG PART C ME, V17, P1139, DOI 10.1089/ten.tec.2011.0140
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Miyagawa Y, 2011, TISSUE ENG PT A, V17, P513, DOI [10.1089/ten.tea.2009.0810, 10.1089/ten.TEA.2009.0810]
   Papenburg BJ, 2010, SOFT MATTER, V6, P4377, DOI 10.1039/b927207k
   Park JS, 2011, BIOMATERIALS, V32, P3921, DOI 10.1016/j.biomaterials.2011.02.019
   Pittet P, 2008, J CELL SCI, V121, P877, DOI 10.1242/jcs.024877
   Quintana L, 2009, TISSUE ENG PART B RE, V15, P29, DOI 10.1089/ten.teb.2008.0329
   Singh AM, 2012, CELL STEM CELL, V10, P312, DOI 10.1016/j.stem.2012.01.014
   Sonoda T, 2003, CANCER LETT, V196, P229, DOI 10.1016/S0304 3835(03)00216 7
   Tuli R, 2003, J BIOL CHEM, V278, P41227, DOI 10.1074/jbc.M305312200
   Wang WJ, 2009, BIOMATERIALS, V30, P2705, DOI 10.1016/j.biomaterials.2009.01.030
   Zhou Y, 2010, BRIT J PHARMACOL, V161, P1542, DOI 10.1111/j.1476 5381.2010.00998.x
NR 34
TC 80
Z9 88
U1 3
U2 114
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 2013
VL 34
IS 20
BP 4725
EP 4738
DI 10.1016/j.biomaterials.2013.03.031
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 137UR
UT WOS:000318464200003
PM 23562051
DA 2025 08 17
ER

PT J
AU Zhang, LH
   Luo, Q
   Shu, Y
   Zeng, ZY
   Huang, B
   Feng, YX
   Zhang, B
   Wang, X
   Lei, Y
   Ye, ZY
   Zhao, L
   Cao, DG
   Yang, LJ
   Chen, X
   Liu, B
   Wagstaff, W
   Reid, RR
   Luu, HH
   Haydon, RC
   Lee, MJ
   Wolf, JM
   Fu, Z
   He, TC
   Kang, Q
AF Zhang, Linghuan
   Luo, Qing
   Shu, Yi
   Zeng, Zongyue
   Huang, Bo
   Feng, Yixiao
   Zhang, Bo
   Wang, Xi
   Lei, Yan
   Ye, Zhenyu
   Zhao, Ling
   Cao, Daigui
   Yang, Lijuan
   Chen, Xian
   Liu, Bin
   Wagstaff, William
   Reid, Russell R.
   Luu, Hue H.
   Haydon, Rex C.
   Lee, Michael J.
   Wolf, Jennifer Moriatis
   Fu, Zhou
   He, Tong Chuan
   Kang, Quan
TI Transcriptomic landscape regulated by the 14 types of bone morphogenetic
   proteins (BMPs) in lineage commitment and differentiation of mesenchymal
   stem cells (MSCs)
SO GENES & DISEASES
LA English
DT Article
DE Bone morphogenetic proteins (BMPs); MAP kinase signaling; Mesenchymal
   stem cells; Notch signaling; PI3K/AKT/mTOR pathway; Smad signaling; TGF
   beta superfamily; Wnt signaling
ID BMP9 INDUCED OSTEOGENIC DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION;
   OSTEO/ODONTOBLASTIC DIFFERENTIATION; SIGNALING PATHWAYS; GENE THERAPY;
   WNT; GROWTH; PLAYS; TUMORIGENESIS; AMPLIFICATION
AB Mesenchymal stem cells (MSCs) are ubiquitously existing multipotent progenitors that can self renew and differentiate into multiple lineages including osteocytes, chondrocytes, adipocytes, tenocytes and myocytes. MSCs represent one of the most commonly used adult progenitors and serve as excellent progenitor cell models for investigating lineagespecific differentiation regulated by various cellular signaling pathways, such as bone morphogenetic proteins (BMPs). As members of TGF beta superfamily, BMPs play diverse and important roles in development and adult tissues. At least 14 BMPs have been identified in mammals. Different BMPs exert distinct but overlapping biological functions. Through a comprehensive analysis of 14 BMPs in MSCs, we demonstrated that BMP9 is one of the most potent BMPs in inducing osteogenic differentiation of MSCs. Nonetheless, a global mechanistic view of BMP signaling in regulating the proliferation and differentiation of MSCs remains to be fully elucidated. Here, we conducted a comprehensive transcriptomic profiling in the MSCs stimulated by 14 types of BMPs. Hierarchical clustering analysis classifies 14 BMPs into three subclusters: an osteo/chondrogenic/adipogenic cluster, a tenogenic cluster, and BMP3 cluster. We also demonstrate that six BMPs (e.g., BMP2, BMP3, BMP4, BMP7, BMP8, and BMP9) can induce ISmads effectively, while BMP2, BMP3, BMP4, BMP7, and BMP11 up regulate Smad independent MAP kinase pathway. Furthermore, we show that many BMPs can upregulate the expression of the signal mediators of Wnt, Notch and PI3K/AKT/mTOR pathways. While the reported transcriptomic changes need to be further validated, our expression profiling represents the first of its kind to interrogate a comprehensive transcriptomic landscape regulated by the 14 types of BMPs in MSCs. Copyright (C) 2019, Chongqing Medical University. Production and hosting by Elsevier B.V.
C1 [Zhang, Linghuan; Luo, Qing; Shu, Yi; Fu, Zhou; Kang, Quan] Chongqing Med Univ, Childrens Hosp, Key Lab Child Dev & Disorders, Stem Cell Biol & Therapy Lab,Minist Educ, Chongqing 400014, Peoples R China.
   [Zhang, Linghuan; Luo, Qing; Shu, Yi; Zeng, Zongyue; Huang, Bo; Feng, Yixiao; Zhang, Bo; Wang, Xi; Lei, Yan; Ye, Zhenyu; Zhao, Ling; Cao, Daigui; Yang, Lijuan; Chen, Xian; Liu, Bin; Wagstaff, William; Reid, Russell R.; Luu, Hue H.; Haydon, Rex C.; Lee, Michael J.; Wolf, Jennifer Moriatis; He, Tong Chuan] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA.
   [Zeng, Zongyue; Huang, Bo; Feng, Yixiao; Wang, Xi; Lei, Yan; Zhao, Ling; Cao, Daigui] Sch Lab Med, Minist Educ, Key Lab Diagnost Med, Chicago, IL 60637 USA.
   [Zeng, Zongyue; Huang, Bo; Feng, Yixiao; Wang, Xi; Lei, Yan; Zhao, Ling; Cao, Daigui] Chongqing Med Univ, Affiliated Hosp, Chongqing 400016, Peoples R China.
   [Zhang, Bo] Nanchang Univ, Affiliated Hosp 2, Dept Clin Lab Med, Nanchang 330006, Jiangxi, Peoples R China.
   [Zhang, Bo] Lanzhou Univ, First & Second Hosp, Dept Orthopaed Surg, Key Lab Orthopaed Surg Gansu Prov, Lanzhou 730030, Gansu, Peoples R China.
   [Ye, Zhenyu] Lanzhou Univ, First & Second Hosp, Dept Obstet & Gynecol, Key Lab Orthopaed Surg Gansu Prov, Lanzhou 730030, Gansu, Peoples R China.
   [Chen, Xian] Soochow Univ, Affiliated Hosp 2, Dept Gen Surg, Suzhou 215004, Peoples R China.
C3 Chongqing Medical University; University of Chicago; University of
   Chicago Medical Center; Chongqing Medical University; Nanchang
   University; Lanzhou University; Lanzhou University; Soochow University  
   China
RP He, TC (通讯作者)，Chongqing Med Univ, Childrens Hosp, Dept Pediat Surg, Chongqing 400016, Peoples R China.; Kang, Q (通讯作者)，Univ Chicago, Med Ctr, Mol Oncol Lab, 5841 South Maryland Ave,MC3079, Chicago, IL 60637 USA.
EM tche@uchicago.edu; quan kang@boneandcancer.org
RI Wang, Yujie/L 9676 2017; Reid, Russell/LIF 6227 2024; Liu,
   Bin/KLZ 8961 2024
FU National Key Research and Development Program of China [2016YFC1000803];
   National Institutes of Health [CA226303, DE020140]; U.S. Department of
   Defense [OR130096]; Chicago Community Trust; Brinson Foundation;
   Scoliosis Research Society; University of Chicago Cancer Center Support
   Grant [P30CA014599]; National Center for Advancing Translational
   Sciences of the National Institutes of Health [UL1 TR000430]; Mabel
   Green Myers Research Endowment Fund; University of Chicago Orthopaedic
   Surgery Alumni Fund; Chicago Biomedical Consortium
FX The reported work was supported in part by research grants from the
   National Key Research and Development Program of China (2016YFC1000803),
   the National Institutes of Health (CA226303, DE020140 to TCH and RRR),
   the U.S. Department of Defense (OR130096 to JMW), the Chicago Biomedical
   Consortium with support from the Searle Funds at The Chicago Community
   Trust (RRR, TCH), the Brinson Foundation (TCH), and the Scoliosis
   Research Society (TCH and MJL). This project was also supported in part
   by The University of Chicago Cancer Center Support Grant (P30CA014599)
   and the National Center for Advancing Translational Sciences of the
   National Institutes of Health through Grant Number UL1 TR000430. TCH was
   supported by the Mabel Green Myers Research Endowment Fund and The
   University of Chicago Orthopaedic Surgery Alumni Fund. Funding sources
   were not involved in the study design; in the collection, analysis and
   interpretation of data; in the writing of the report; and in the
   decision to submit the paper for publication.
CR Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Aubin J, 2004, GENE DEV, V18, P1482, DOI 10.1101/gad.1202604
   Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254
   Bianco P, 2014, ANNU REV CELL DEV BI, V30, P677, DOI 10.1146/annurev cellbio 100913 013132
   Bolt P, 2007, J BONE JOINT SURG AM, V89A, P1315, DOI 10.2106/JBJS.F.00257
   Broege A, 2013, J BIOL CHEM, V288, P37230, DOI 10.1074/jbc.M113.496950
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Chen JQ, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0004 5
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810
   Denduluri SK, 2015, GENES DIS, V2, P13, DOI 10.1016/j.gendis.2014.10.004
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Fan JM, 2017, ONCOTARGET, V8, P27105, DOI 10.18632/oncotarget.15637
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Hu N, 2013, J CELL SCI, V126, P532, DOI 10.1242/jcs.114231
   Hu X, 2017, ONCOTARGET, V8, P111847, DOI 10.18632/oncotarget.22915
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032428
   Huang JY, 2009, LIVER INT, V29, P1569, DOI 10.1111/j.1478 3231.2009.02111.x
   Jena N, 1997, EXP CELL RES, V230, P28, DOI 10.1006/excr.1996.3411
   Jo A, 2014, GENES DIS, V1, P149, DOI 10.1016/j.gendis.2014.09.004
   Kakoi H, 2014, J BIOL CHEM, V289, P8135, DOI 10.1074/jbc.M113.509331
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Lamplot JD, 2013, AM J STEM CELLS, V2, P1
   Lampot JD, 2015, CELL TRANSPLANT, V24, P1053, DOI 10.3727/096368914X681054
   Lee CS, 2017, GENES DIS, V4, P43, DOI 10.1016/j.gendis.2017.04.001
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Lee MY, 2009, STEM CELLS, V27, P1858, DOI 10.1002/stem.124
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Li RD, 2014, CURR CANCER DRUG TAR, V14, P274, DOI 10.2174/1568009614666140305105805
   Liao J, 2017, GENE THER, V24, P333, DOI 10.1038/gt.2017.24
   Liao JY, 2017, ONCOTARGET, V8, P53581, DOI 10.18632/oncotarget.18655
   Liao JY, 2017, CELL PHYSIOL BIOCHEM, V41, P1905, DOI 10.1159/000471945
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo XJ, 2008, INT J ONCOL, V32, P975, DOI 10.1007/978 3 540 77385 6
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luther G, 2011, CURR GENE THER, V11, P229
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Noel Daniele, 2002, Curr Opin Investig Drugs, V3, P1000
   Paul R, 2003, SPINE, V28, P755, DOI 10.1097/00007632 200304150 00006
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rastegar Farbod, 2010, World J Stem Cells, V2, P67, DOI 10.4252/wjsc.v2.i4.67
   Ricard N, 2012, BLOOD, V119, P6162, DOI 10.1182/blood 2012 01 407593
   Rocher C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084009
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Shenaq DS, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/519028
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Song DZ, 2017, J CELL MOL MED, V21, P2782, DOI 10.1111/jcmm.13193
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Teven CM, 2014, GENES DIS, V1, P199, DOI 10.1016/j.gendis.2014.09.005
   Tillet E, 2018, J BIOL CHEM, V293, P10963, DOI 10.1074/jbc.RA118.002968
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   Wagner Eric R, 2011, Curr Mol Pharmacol, V4, P14
   Wang J, 2017, CELL PHYSIOL BIOCHEM, V41, P484, DOI 10.1159/000456885
   Wang JH, 2014, STEM CELLS DEV, V23, P1405, DOI 10.1089/scd.2013.0580
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wang YYE, 2017, CANCER RES, V77, pE11, DOI 10.1158/0008 5472.CAN 17 0802
   Wang Y, 2013, J ORTHOP RES, V31, P1796, DOI 10.1002/jor.22427
   Wei Q, 2017, CELL PHYSIOL BIOCHEM, V41, P2383, DOI 10.1159/000475909
   Wen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094397
   Wu N, 2014, GENE THER, V21, P629, DOI 10.1038/gt.2014.40
   Yan SJ, 2018, GENES DIS, V5, P172, DOI 10.1016/j.gendis.2018.04.006
   Yang K, 2016, LAB INVEST, V96, P116, DOI 10.1038/labinvest.2015.144
   Yu XY, 2018, GENES DIS, V5, P137, DOI 10.1016/j.gendis.2018.04.003
   Yu XY, 2018, CELL PHYSIOL BIOCHEM, V47, P957, DOI 10.1159/000490140
   Zeng Zongyue, 2018, Genes Dis, V5, P62, DOI 10.1016/j.gendis.2018.02.001
   Zhang FG, 2016, GENES DIS, V3, P263, DOI 10.1016/j.gendis.2016.09.004
   Zhang HM, 2015, BIOMATERIALS, V39, P145, DOI 10.1016/j.biomaterials.2014.11.007
   Zhang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132666
   Zhao C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092908
   Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167
   Zhu GH, 2009, DIFFERENTIATION, V78, P195, DOI 10.1016/j.diff.2009.06.001
NR 82
TC 70
Z9 77
U1 2
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 4820
EI 2352 3042
J9 GENES DIS
JI Genes Dis.
PD SEP
PY 2019
VL 6
IS 3
BP 258
EP 275
DI 10.1016/j.gendis.2019.03.008
PG 18
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA IY0QB
UT WOS:000486096700005
PM 32042865
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kang, HR
   Fernandes, CJD
   da Silva, RA
   Constantino, VRL
   Koh, IHJ
   Zambuzzi, WF
AF Kang, Ha Ram
   da Costa Fernandes, Celio Junior
   da Silva, Rodrigo Augusto
   Leopoldo Constantino, Vera Regina
   Jun Koh, Ivan Hong
   Zambuzzi, Willian F.
TI Mg Al and Zn Al Layered Double Hydroxides Promote Dynamic Expression of
   Marker Genes in Osteogenic Differentiation by Modulating
   Mitogen Activated Protein Kinases
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE differentiation; double metal hydroxides; hydrotalcite like materials;
   layered double hydroxides; nanoparticles; osteoblasts
ID OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR; SKELETAL DEVELOPMENT;
   BONE; ULCER; RUNX2; PHOSPHORYLATION; NANOPARTICLES; INDUCTION; MECHANISM
AB The effect of LDH samples comprised of chloride anions intercalated between positive layers of magnesium/aluminum (Mg Al LDH) or zinc/aluminum (Zn Al LDH) chemical composition on pre osteoblast performance is investigated. Non cytotoxic concentrations of both LDHs modulated pre osteoblast adhesion by triggering cytoskeleton rearrangement dependent on recruiting of Cofilin, which is modulated by the inhibition of the Protein Phosphatase 2A (PP2A), culminating in osteoblast differentiation with a significant increase of osteogenic marker genes. The alkaline phosphatase (ALP) and bone sialoprotein (BSP) are significantly up modulated by both LDHs; however, Mg Al LDH nanomaterial promoted even more significance than both experimental controls, while the phosphorylations of mitogen activated protein kinase (MAPKs)  extracellular signal regulated kinases (ERK) and c Jun N terminal kinase (JNK) significantly increased. MAPK signaling is necessary to activate Runt related transcription factor 2 (RUNX2) gene. Concomitantly, it is also investigated whether challenged osteoblasts are able to modulate osteoclastogenesis by investigating both osteoprotegerin (OPG) and Receptor activator of nuclear factor kappa ligand (RANKL) in this model; a dynamic reprogramming of both these genes is found, suggesting LDHs in modulating osteoclastogenesis. These results suggest that LDHs interfere in bone remodeling, and they can be considered as nanomaterials in graft based bone healing or drug delivery materials for bone disorders.
C1 [Kang, Ha Ram; da Costa Fernandes, Celio Junior; da Silva, Rodrigo Augusto; Zambuzzi, Willian F.] Univ Estadual Paulista, UNESP, Lab Bioensaios & Dinam Celular, Dept Quim & Bioquim,Inst Biociencias, Campus Botucatu, BR 18618970 Sao Paulo, Brazil.
   [Leopoldo Constantino, Vera Regina] Univ Sao Paulo, USP, Inst Quim, Dept Quim Fundamental, Av Prof Lineu Prestes 748, BR 05508000 Sao Paulo, Brazil.
   [Jun Koh, Ivan Hong] Univ Fed Sao Paulo, UNIFESP, Dept Cirurgia, Rua Botucatu 740, BR 04023900 Sao Paulo, Brazil.
C3 Universidade Estadual Paulista; Universidade de Sao Paulo; Universidade
   Federal de Sao Paulo (UNIFESP)
RP Zambuzzi, WF (通讯作者)，Univ Estadual Paulista, UNESP, Lab Bioensaios & Dinam Celular, Dept Quim & Bioquim,Inst Biociencias, Campus Botucatu, BR 18618970 Sao Paulo, Brazil.
EM wzambuzzi@ibb.unesp.br
RI Koh, ivan/ABB 2084 2021; Leopoldo Constantino, Vera Regina/B 9202 2012;
   da Silva, Rodrigo/G 1222 2012; Constantino, Vera/B 9202 2012; Fernandes,
   Célio/L 3873 2018; Junior da Costa Fernandes, Celio/L 3873 2018;
   Zambuzzi, Willian/F 9519 2012; da Silva, Rodrigo Augusto/G 1222 2012;
   Zambuzzi, Willian/ABD 8339 2020
OI Leopoldo Constantino, Vera Regina/0000 0001 9276 7329; Junior da Costa
   Fernandes, Celio/0000 0003 1009 3127; KOH, IVAN/0000 0001 5076 789X;
   Zambuzzi, Willian/0000 0002 4149 5965; da Silva, Rodrigo
   Augusto/0000 0002 7754 1855; 
FU FAPESP [2014/22689 3, 2011/50318 1]; CNPq
FX The authors would like to thank the FAPESP (Proc. 2014/22689 3;
   2011/50318 1) and the CNPq for the financial support. The authors are
   thankful to Dr. Vanessa R. R. Cunha for preparation of samples.
CR Aubin J E, 2000, Medscape Womens Health, V5, P5
   Baek WY, 2009, J BONE MINER RES, V24, P1055, DOI [10.1359/JBMR.081248, 10.1359/jbmr.081248]
   Bertazzo S, 2010, CLIN ORAL IMPLAN RES, V21, P1411, DOI 10.1111/j.1600 0501.2010.01968.x
   Bertazzo S, 2010, COLLOID SURFACE B, V78, P177, DOI 10.1016/j.colsurfb.2010.02.027
   Bezerra F, 2017, BIOTECHNOL BIOENG, V114, P1888, DOI 10.1002/bit.26310
   Blangy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045909
   Buo AM, 2017, J BONE MINER RES, V32, P1727, DOI 10.1002/jbmr.3152
   Demarchi ACCD, 2010, CELL TISSUE RES, V340, P61, DOI 10.1007/s00441 010 0931 6
   Chen YX, 2017, J MATER CHEM B, V5, P2245, DOI 10.1039/c6tb02730j
   Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498
   Choi SJ, 2011, NANOMEDICINE UK, V6, P803, DOI [10.2217/NNM.11.86, 10.2217/nnm.11.86]
   Cunha VRR, 2016, MAT SCI ENG C MATER, V58, P629, DOI 10.1016/j.msec.2015.08.037
   Cunha VRR, 2012, CHEM MATER, V24, P1415, DOI 10.1021/cm202953y
   Del Fattore Andrea, 2012, Front Biosci (Elite Ed), V4, P2302
   Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Gemini Piperni S, 2014, ARCH BIOCHEM BIOPHYS, V561, P88, DOI 10.1016/j.abb.2014.06.019
   Gemini Piperni S, 2014, BIOTECHNOL BIOENG, V111, P1900, DOI 10.1002/bit.25246
   Gil OM, 2016, VIB SPECTROSC, V87, P60, DOI 10.1016/j.vibspec.2016.09.010
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Gu Z, 2015, CHEM COMMUN, V51, P3024, DOI 10.1039/c4cc07715f
   Habibovic P, 2007, J TISSUE ENG REGEN M, V1, P25, DOI 10.1002/term.5
   HOLTERMULLER KH, 1992, Z GASTROENTEROL, V30, P717
   Kapusetti G, 2013, J MATER CHEM B, V1, P2275, DOI 10.1039/c3tb00004d
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Kobayashi Y, 2009, CRIT REV EUKAR GENE, V19, P61, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.30
   Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420
   Kuthati Y, 2015, APPL CLAY SCI, V112, P100, DOI 10.1016/j.clay.2015.04.018
   Liang RZ, 2014, CHEM COMMUN, V50, P14071, DOI 10.1039/c4cc03118k
   LOWRY E C, 1951, U S Armed Forces Med J, V2, P265
   Lu JL, 2016, ONCOTARGET, V7, P37471, DOI 10.18632/oncotarget.9650
   Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058
   Marumoto A, 2017, BONE, V103, P55, DOI 10.1016/j.bone.2017.06.012
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Oleinik NV, 2010, ONCOGENE, V29, P6233, DOI 10.1038/onc.2010.356
   Rocha MA, 2016, RSC ADV, V6, P16419, DOI 10.1039/c5ra25814f
   Cunha VRR, 2016, SCI REP UK, V6, DOI 10.1038/srep30547
   Saifullah B, 2015, INT J NANOMED, V10, P5609, DOI 10.2147/IJN.S72330
   SERNA CJ, 1978, J PHARM SCI, V67, P324, DOI 10.1002/jps.2600670312
   Paiva KBS, 2009, J MOL HISTOL, V40, P201, DOI 10.1007/s10735 009 9231 4
   Tarnawski A, 1999, DIGESTION, V60, P449, DOI 10.1159/000007690
   Tarnawski AS, 2000, J PHYSIOL PARIS, V94, P93, DOI 10.1016/S0928 4257(00)00149 2
   Teti Anna, 2011, Curr Osteoporos Rep, V9, P264, DOI 10.1007/s11914 011 0078 8
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Yazar S, 2004, PLAST RECONSTR SURG, V114, P1457, DOI 10.1097/01.PRS.0000138811.88807.65
   Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704
   Zambuzzi WF, 2011, J BIOMED MATER RES A, V97A, P193, DOI 10.1002/jbm.a.32933
   Zambuzzi WF, 2009, MOL CELL BIOCHEM, V322, P143, DOI 10.1007/s11010 008 9951 x
   Zambuzzi WF, 2009, J CELL BIOCHEM, V108, P134, DOI 10.1002/jcb.22236
NR 50
TC 54
Z9 55
U1 4
U2 101
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD FEB 21
PY 2018
VL 7
IS 4
AR 1700693
DI 10.1002/adhm.201700693
PG 12
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA FW8YF
UT WOS:000425622200002
PM 29280352
DA 2025 08 17
ER

PT J
AU Shen, XF
   Sun, XC
   Chen, H
   Lu, BJ
   Qin, YY
   Zhang, CX
   Liang, GQ
   Wang, JP
   Yu, PF
   Su, L
   Ma, QH
   Li, YW
AF Shen, Xiaofeng
   Sun, Xiaochen
   Chen, Hua
   Lu, Binjie
   Qin, Yuanyuan
   Zhang, Chenxi
   Liang, Guoqiang
   Wang, Jiangping
   Yu, Pengfei
   Su, Li
   Ma, Qihan
   Li, Yuwei
TI Demethoxycucumin protects MDA MB 231 cells induced bone destruction
   through JNK and ERK pathways inhibition
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Demethoxycucumin; MDA MB 231; JNK; ERK; Bone destruction
ID BREAST CANCER METASTASIS; OSTEOCLAST DIFFERENTIATION; KAPPA B;
   MECHANISMS; HOMEOSTASIS; BIOMARKERS; INVASION
AB Bone is the most common late metastasis of breast cancer. Bone metastasis causes not only severe bone pain, but also bone related diseases such as pathological fractures, which are closely related to osteoclasts. The effects of demethoxycurcumin (DMC) on osteoclast biology has not been investigated. In this study, we explored the effects of DMC on MDA MB 231 cells, MCF 7 cells, and osteoclasts induced by RANKL in vitro, as well as the protective effect on bone destruction of tumor bone metastasis in vivo. DMC showed inhibitory effect on the migration and promotes the apoptosis of MDA MB 231 and MCF 7 cells. At the same time, DMC inhibited osteoclast maturation and mature osteoclast bone resorption in a dose dependent manner, and suppressed the expression of osteoclast marker genes TRAP, CTSK, MMP9, V ATPase d2 and DC STAMP significantly. Biochemical data showed that DMC inhibited tumor cells and osteoclasts by inhibiting the early activation of ERK and JNK MAPK pathway. Consistent with the results in vitro, we confirmed that DMC protects bone destruction caused by tumor metastasis in vivo. In short, our study confirmed that DMC could be used as a potential drug for the treatment of tumor bone destruction.
C1 [Shen, Xiaofeng; Chen, Hua; Lu, Binjie; Qin, Yuanyuan; Liang, Guoqiang; Wang, Jiangping; Yu, Pengfei; Ma, Qihan; Li, Yuwei] Nanjing Univ Chinese Med, Suzhou TCM Hosp, Nanjing, Peoples R China.
   [Sun, Xiaochen] Shanghai Univ, Sch Med, Shanghai, Peoples R China.
   [Sun, Xiaochen] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Zhang, Chenxi; Su, Li] Shanghai Univ, Inst Translat Med, Shanghai, Peoples R China.
C3 Nanjing University of Chinese Medicine; Shanghai University; Guangxi
   Medical University; Shanghai University
RP Ma, QH; Li, YW (通讯作者)，Nanjing Univ Chinese Med, Suzhou TCM Hosp, Nanjing, Peoples R China.
EM ma_zyy@126.com; lyw97538@hotmail.com
RI Liang, Guoqiang/JUF 0287 2023; jin, ziliang/JTU 2764 2023; qin,
   yuanyuan/G 4351 2010; Lu, Binjie/JCP 3303 2023
FU Science and Technology Project of Suzhou Science and Technology Bureau
   [sys2018091, SS2019070]; Key Project of Jiangsu Science and Technology
   Development Program of Traditional Chinese Medicine [ZD201910]
FX This project is supported by grants from Science and Technology Project
   of Suzhou Science and Technology Bureau (sys2018091, SS2019070), and Key
   Project of Jiangsu Science and Technology Development Program of
   Traditional Chinese Medicine (ZD201910).
CR Ahmed T, 2014, PHYTOTHER RES, V28, P517, DOI 10.1002/ptr.5030
   Anbarasu K, 2018, 3 BIOTECH, V8, DOI 10.1007/s13205 018 1239 6
   Arshad L, 2017, FUTURE MED CHEM, V9, P605, DOI 10.4155/fmc 2016 0223
   Bennett CL, 2018, ACTA NEUROPATHOL, V136, P425, DOI 10.1007/s00401 018 1852 9
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Currey JD, 2017, BIOL REV, V92, P1702, DOI 10.1111/brv.12302
   Du ZH, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694302
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Fecher LA, 2008, CURR OPIN ONCOL, V20, P183, DOI 10.1097/CCO.0b013e3282f5271c
   dos Santos PDF, 2019, FOOD FUNCT, V10, P573, DOI [10.1039/c8fo02431f, 10.1039/C8FO02431F]
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   Hatamipour M, 2019, J CELL PHYSIOL, V234, P19320, DOI 10.1002/jcp.28626
   Hatamipour M, 2018, J CELL PHYSIOL, V233, P9247, DOI 10.1002/jcp.27029
   Hayder M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002212
   Huang SS, 2017, CANCER CHEMOTH PHARM, V80, P685, DOI 10.1007/s00280 017 3393 7
   Ibrahim MFK, 2015, ANN ONCOL, V26, P2205, DOI 10.1093/annonc/mdv284
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Jules J, 2015, J BIOL CHEM, V290, P23738, DOI 10.1074/jbc.M115.667535
   Karsenty G, 2016, CELL, V164, P1248, DOI 10.1016/j.cell.2016.02.043
   Kim BJ, 2019, CELL MOL LIFE SCI, V76, P1243, DOI 10.1007/s00018 018 2981 y
   Kim SB, 2017, LANCET ONCOL, V18, P1360, DOI 10.1016/S1470 2045(17)30450 3
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Lin CC, 2018, ANTICANCER RES, V38, P2761, DOI 10.21873/anticanres.12519
   Mensah KA, 2010, J CELL PHYSIOL, V223, P76, DOI 10.1002/jcp.22012
   Min YF, 2010, CANCER RES, V70, P2819, DOI 10.1158/0008 5472.CAN 09 1915
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Niikura K, 2007, CANCER CHEMOTH PHARM, V60, P555, DOI 10.1007/s00280 006 0401 8
   Pattarawat P, 2020, CANCER CHEMOTH PHARM, V85, P141, DOI 10.1007/s00280 019 04013 y
   Quayle L, 2015, CURR CANCER DRUG TAR, V15, P469, DOI 10.2174/1568009615666150506092443
   Ramkumar M, 2018, PHARMACOGN MAG, V14, P9, DOI 10.4103/pm.pm_113_17
   Roodman GD, 2008, CANCER TREAT REV, V34, P92, DOI 10.1016/j.ctrv.2007.09.002
   Srirod S, 2019, J ETHNOPHARMACOL, V238, DOI 10.1016/j.jep.2019.111828
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   Tanaka R, 2016, ONCOLOGIST, V21, P508, DOI 10.1634/theoncologist.2015 0377
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tibullo D, 2020, CANCERS, V12, DOI 10.3390/cancers12020323
   Torre LA, 2015, CA CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang LH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1424 4
   Wood SL, 2014, CANCER TREAT REV, V40, P139, DOI 10.1016/j.ctrv.2013.07.006
   Wuerzberger Davis SM, 2011, IMMUNITY, V34, P188, DOI 10.1016/j.immuni.2011.01.014
   Yahara Y, 2020, NAT CELL BIOL, V22, P49, DOI 10.1038/s41556 019 0437 8
   Yao Y, 2012, CANCER GENE THER, V19, P601, DOI 10.1038/cgt.2012.38
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Yuan FL, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00628
NR 51
TC 12
Z9 13
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0344 5704
EI 1432 0843
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD APR
PY 2021
VL 87
IS 4
BP 487
EP 499
DI 10.1007/s00280 020 04198 7
EA JAN 2021
PG 13
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA QU6NG
UT WOS:000605153200001
PM 33403398
DA 2025 08 17
ER

PT J
AU Yu, SF
   Huang, WF
   Zhang, H
   Guo, YF
   Zhang, BT
   Zhang, G
   Lei, JP
AF Yu, Sifan
   Huang, Weifeng
   Zhang, Hao
   Guo, Yinfeng
   Zhang, Baoting
   Zhang, Ge
   Lei, Jinping
TI Discovery of the small molecular inhibitors against sclerostin loop3 as
   potential anti osteoporosis agents by structural based virtual screening
   and molecular design
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Sclerostin; Anti osteoporosis; Structural based virtual screening;
   Selective; Small molecular inhibitors
ID POSTMENOPAUSAL WOMEN; ACCURATE DOCKING; BONE; ROMOSOZUMAB; DATABASE;
   WNT; CHALLENGES; THERAPY; PATHWAY; CATENIN
AB Sclerostin is a secreted glycoprotein that expresses predominantly in osteocytes and inhibits bone formation by antagonizing the Wnt/beta catenin signaling pathway, and the loop3 region of sclerostin has recently discovered as novel therapeutic target for bone anabolic treatment without increasing cardiovascular risk. Herein, we used a structural based virtual screening to search for small molecular inhibitors selectively targeting sclerostin loop3. A novel natural product hit ZINC4228235 (THFA) was identified as the sclerostin loop3 selective inhibitor with a Kd value of 42.43 nM against sclerostin loop3. The simplification and derivation of THFA using molecular modeling guided modification allowed the discovery of an effective and loop3 selective small molecular inhibitor, compound (4 (3 acetamidoprop 1 yn 1 yl)benzoyl)glycine (AACA), with improved binding affinity (Kd = 15.4 nM) compared to the hit THFA. Further in vitro experiment revealed that compound AACA could attenuate the suppressive effect of transfected sclerostin on Wnt signaling and bone formation. These results make AACA as potential candidate for development of anti osteoporosis agents without increasing cardiovascular risk.
C1 [Huang, Weifeng; Zhang, Hao; Guo, Yinfeng; Lei, Jinping] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangdong Key Lab Chiral Mol & Drug Discovery, Guangzhou 510006, Peoples R China.
   [Yu, Sifan; Zhang, Ge] Hong Kong Baptist Univ, Law Sau Fai Inst Adv Translat Med Bone & Joint Dis, Hong Kong, Peoples R China.
   [Zhang, Baoting] Chinese Univ Hong Kong, Sch Chinese Med, Hong Kong, Peoples R China.
   [Lei, Jinping] Sun Yat Sen Univ, Sch Pharmaceut Sci, State Key Lab Antiinfect Drug Discovery & Dev, Guangzhou 510006, Peoples R China.
C3 Sun Yat Sen University; Hong Kong Baptist University; Chinese University
   of Hong Kong; Sun Yat Sen University
RP Lei, JP (通讯作者)，Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangdong Key Lab Chiral Mol & Drug Discovery, Guangzhou 510006, Peoples R China.; Yu, SF; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Law Sau Fai Inst Adv Translat Med Bone & Joint Dis, Hong Kong, Peoples R China.
EM sifanyu@cuhk.edu.hk; zhangge@hkbu.edu.hk; leijp@mail.sysu.edu.cn
RI Zhang, Ge/N 4150 2013; Zhang, Hao/LXU 3441 2024; Zhang,
   Baoting/B 6273 2015; YU, Sifan/HSG 0139 2023
FU Guangdong Hong Kong Technology Cooperation Funding Scheme
   [2023A0505010015, GHP/149/21GD]; National Key Research and Development
   Program of China [2023YFF1204902, 2018YFA0800802]; Young Scientists Fund
   of the National Natural Science Foundation of China [82304378]; Hong
   Kong General Research Fund [CUHK 14108322, CUHK 14109721, HKBU 12102223,
   HKBU 12114416, HKBU 12100921]; CUHK Direct Grant [4054714]; Theme based
   Research Scheme [T12 201 20R]
FX This work has been supported by the Guangdong Hong Kong Technology
   Cooperation Funding Scheme (2023A0505010015, GHP/149/21GD) , the
   National Key Research and Development Program of China (2023YFF1204902,
   2018YFA0800802) , the Young Scientists Fund of the National Natural
   Science Foundation of China (82304378) , Theme based Research Scheme
   (T12 201 20R) , Hong Kong General Research Fund (CUHK 14108322, CUHK
   14109721, HKBU 12102223, HKBU 12114416, HKBU 12100921) , CUHK Direct
   Grant (4054714) .
CR Bandeira L, 2017, EXPERT OPIN BIOL TH, V17, P255, DOI 10.1080/14712598.2017.1280455
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bartlett JA, 2002, J ACQ IMMUN DEF SYND, V29, pS2, DOI 10.1097/00126334 200202011 00002
   Beggs LA, 2015, J BONE MINER RES, V30, P681, DOI 10.1002/jbmr.2396
   Bilia AR, 2019, CURR MED CHEM, V26, P4631, DOI 10.2174/0929867325666181101110050
   Chen LH, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/7902046
   Choi J, 2018, BIOORG MED CHEM LETT, V28, P1116, DOI 10.1016/j.bmcl.2018.01.050
   Cooper C, 2006, OSTEOPOROSIS INT, V17, P337, DOI 10.1007/s00198 005 2039 5
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   DeLano W. L., 2002, CCP4 Newsletter on protein crystallography, V40, P82
   Eberhardt J, 2021, J CHEM INF MODEL, V61, P3891, DOI 10.1021/acs.jcim.1c00203
   Fixen C, 2021, CURR OSTEOPOROS REP, V19, P15, DOI 10.1007/s11914 020 00652 w
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Gao S, 2010, MINI REV MED CHEM, V10, P550, DOI 10.2174/138955710791384081
   Gao YX, 2021, J PHARM ANAL, V11, P472, DOI 10.1016/j.jpha.2020.08.005
   Goodsell DS, 2020, PROTEIN SCI, V29, P52, DOI 10.1002/pro.3730
   Gubu A, 2024, MOL THER NUCL ACIDS, V35, DOI 10.1016/j.omtn.2024.102146
   Guglielmi G, 2011, RADIOGRAPHICS, V31, P1343, DOI 10.1148/rg.315105712
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399 0004.2003.00036.x
   Holdsworth G, 2019, J MOL ENDOCRINOL, V62, pR167, DOI 10.1530/JME 18 0176
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Irwin JJ, 2020, J CHEM INF MODEL, V60, P6065, DOI 10.1021/acs.jcim.0c00675
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kim J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19155 4
   Koblan LW, 2021, NATURE, V589, P608, DOI 10.1038/s41586 020 03086 7
   König R, 2007, NAT METHODS, V4, P847, DOI 10.1038/NMETH1089
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Landrum G., 2013, Greg Landrum, V8, P5281
   Lewiecki EM, 2011, DISCOV MED, V12, P263
   Lim SY, 2022, WOMENS HEALTH, V18, DOI 10.1177/17455057221125577
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Lin JH, 2009, CURR DRUG METAB, V10, P661, DOI 10.2174/138920009789895499
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169 409X(96)00423 1
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   MacNabb C, 2016, J OSTEOPOROS, V2016, DOI 10.1155/2016/6217286
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007 0259
   Marini JC, 2018, GENETICS OF BONE BIOLOGY AND SKELETAL DISEASE, 2ND EDITION, P397, DOI 10.1016/B978 0 12 804182 6.00023 X
   Markham A, 2019, DRUGS, V79, P471, DOI 10.1007/s40265 019 01072 6
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Moreno SE, 2021, EUR J CELL BIOL, V100, DOI 10.1016/j.ejcb.2021.151168
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muthusamy K, 2016, PHYSIOL RES, V65, P871, DOI 10.33549/physiolres.933267
   Nathubhai A, 2017, J MED CHEM, V60, P814, DOI 10.1021/acs.jmedchem.6b01574
   Ni SJ, 2021, ACS APPL MATER INTER, V13, P9500, DOI 10.1021/acsami.0c05750
   Prather C, 2020, AM J HEALTH SYST PH, V77, P1949, DOI 10.1093/ajhp/zxaa285
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ralston SH, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00924
   RDKit, Open source cheminformatics
   Reginster JY, 2006, BONE, V38, pS2, DOI 10.1016/j.bone.2006.01.150
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Shah AD, 2015, INT J WOMENS HEALTH, V7, P565, DOI 10.2147/IJWH.S73244
   Shahrezaee M, 2018, NANOMED NANOTECHNOL, V14, P2061, DOI 10.1016/j.nano.2018.06.007
   Shivanyuk AN., 2007, Chem. Today, V25, P58
   Suen PK, 2016, J ORTHOP TRANSL, V4, P1, DOI 10.1016/j.jot.2015.08.004
   Sugatani T, 2015, BONE, V81, P168, DOI 10.1016/j.bone.2015.07.018
   Sun LS, 2022, MOL CANCER, V21, DOI 10.1186/s12943 022 01697 4
   Takeuchi Y, 2021, OSTEOPORO SARCOPENIA, V7, P89, DOI 10.1016/j.afos.2021.09.002
   Tominaga A, 2021, OSTEOPOROSIS INT, V32, P653, DOI 10.1007/s00198 020 05639 y
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Veverka V, 2009, J BIOL CHEM, V284, P10890, DOI 10.1074/jbc.M807994200
   Wang LY, 2022, THERANOSTICS, V12, P5645, DOI 10.7150/thno.63177
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005
   Yan SF, 2005, J CHEM INF MODEL, V45, P1784, DOI 10.1021/ci0502808
   Yooin W, 2020, J BIOMOL STRUCT DYN, V38, P1272, DOI 10.1080/07391102.2019.1599427
   Yu SF, 2022, ACTA PHARM SIN B, V12, P2150, DOI 10.1016/j.apsb.2022.01.012
   Yu YY, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 31997 8
   Yu YY, 2020, J BONE MINER RES, V35, P252
   Zhang H., 2023, Mol. Ther. Nucleic Acids, V34
   Zhang YH, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.1048148
   Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199
NR 74
TC 2
Z9 2
U1 5
U2 22
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD MAY 5
PY 2024
VL 271
AR 116414
DI 10.1016/j.ejmech.2024.116414
EA APR 2024
PG 9
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA SN2D6
UT WOS:001235057000001
PM 38677061
DA 2025 08 17
ER

PT J
AU Kutaish, H
   Bengtsson, L
   Tscholl, PM
   Marteyn, A
   Braunersreuther, V
   Guérin, A
   Béna, F
   Gimelli, S
   Longet, D
   Ilmjärv, S
   Dietrich, PY
   Gerstel, E
   Jaquet, V
   Menetrey, J
   Assal, M
   Krause, KH
   Cosset, E
   Tieng, V
AF Kutaish, Halah
   Bengtsson, Laura
   Tscholl, Philippe Matthias
   Marteyn, Antoine
   Braunersreuther, Vincent
   Guerin, Alexandre
   Bena, Frederique
   Gimelli, Stefania
   Longet, David
   Ilmjaerv, Sten
   Dietrich, Pierre Yves
   Gerstel, Eric
   Jaquet, Vincent
   Menetrey, Jacques
   Assal, Mathieu
   Krause, Karl Heinz
   Cosset, Erika
   Tieng, Vannary
TI Hyaline Cartilage Microtissues Engineered from Adult Dedifferentiated
   Chondrocytes: Safety and Role of WNT Signaling
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE articular cartilage; hyaline cartilage; tissue engineering;
   microtissues; dedifferentiation; re differentiation; WNT signaling
ID MESENCHYMAL STEM CELLS; CHROMOSOME LOSS; TISSUE; DIFFERENTIATION;
   CHONDROGENESIS; HYPERTROPHY; OSTEOBLASTS; MODELS; REPAIR
AB The repair of damaged articular cartilage is an unmet medical need. Chondrocyte based cell therapy has been used to repair cartilage for over 20 years despite current limitations. Chondrocyte dedifferentiation upon expansion in monolayer is well known and is the main obstacle to their use as cell source for cartilage repair. Consequently, current approaches often lead to fibrocartilage, which is biomechanically different from hyaline cartilage and not effective as a long lasting treatment. Here, we describe an innovative 3 step method to engineer hyaline like cartilage microtissues, named Cartibeads, from high passage dedifferentiated chondrocytes. We show that WNT5A/5B/7B genes were highly expressed in dedifferentiated chondrocytes and that a decrease of the WNT signaling pathway was instrumental for full re differentiation of chondrocytes, enabling production of hyaline matrix instead of fibrocartilage matrix. Cartibeads showed hyaline like characteristics based on GAG quantity and type II collagen expression independently of donor age and cartilage quality. In vivo, Cartibeads were not tumorigenic when transplanted into SCID mice. This simple 3 step method allowed a standardized production of hyaline like cartilage microtissues from a small cartilage sample, making Cartibeads a promising candidate for the treatment of cartilage lesions.
C1 [Kutaish, Halah; Marteyn, Antoine; Guerin, Alexandre; Longet, David; Ilmjaerv, Sten; Jaquet, Vincent; Krause, Karl Heinz] Univ Geneva, Med Sch, Dept Pathol & Immunol, Geneva, Switzerland.
   [Kutaish, Halah; Tscholl, Philippe Matthias; Marteyn, Antoine; Guerin, Alexandre; Longet, David; Ilmjaerv, Sten; Gerstel, Eric; Jaquet, Vincent; Menetrey, Jacques; Assal, Mathieu; Krause, Karl Heinz] Univ Geneva, Univ Med Ctr, Geneva, Switzerland.
   [Kutaish, Halah; Assal, Mathieu] Clin La Colline, Ctr Assal, Foot & Ankle Surg Ctr, Hirslanden Geneva, Switzerland.
   [Bengtsson, Laura; Tieng, Vannary] Vanarix SA, Ave Mon Repos 14, CH 1005 Lausanne, Switzerland.
   [Tscholl, Philippe Matthias] Geneva Univ Hosp, Dept Orthopaed Surg, Geneva, Switzerland.
   [Braunersreuther, Vincent] Geneva Univ Hosp, Diagnost Dept, Serv Clin Pathol, Geneva, Switzerland.
   [Bena, Frederique; Gimelli, Stefania] Geneva Univ Hosp, Diagnost Dept, Serv Genet Med, Geneva, Switzerland.
   [Dietrich, Pierre Yves; Cosset, Erika] Univ Geneva, Geneva Univ Hosp, Ctr Translat Res Oncohematol, Lab Tumor Immunol Oncol,Dept Ctr, Geneva, Switzerland.
   [Gerstel, Eric] Clin la Colline, Geneva, Switzerland.
   [Jaquet, Vincent] Univ Geneva, Med Sch, READS Unit, Geneva, Switzerland.
   [Menetrey, Jacques] Clin la Colline, Ctr Sports Med & Exercise, Geneva, Switzerland.
   [Cosset, Erika] Canc Res Ctr Lyon CRCL, Team Glimmer IIght, GLIoblastoma Metab HetERogene & Organolds, Lyon, France.
C3 University of Geneva; University of Geneva; University of Geneva;
   University of Geneva; University of Geneva; University of Geneva;
   University of Geneva; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite Claude Bernard Lyon 1; UNICANCER; Centre
   Leon Berard; Centre de Recherche en cancerologie (CRCL)
RP Tieng, V (通讯作者)，Vanarix SA, Ave Mon Repos 14, CH 1005 Lausanne, Switzerland.
EM vannary.tieng@vanarix sa.ch
RI ; COSSET, erika/Y 2469 2018; Krause, Karl Heinz/E 8030 2011; cosset,
   Erika/Y 2469 2018
OI Tscholl, Philippe Matthias/0000 0003 1702 7114; Jaquet,
   Vincent/0000 0003 2229 2406; Gerstel, Eric/0000 0003 0754 1873; COSSET,
   erika/0000 0001 5481 6556; KUTAISH, Halah/0000 0001 5016 4466; Marteyn,
   Antoine/0000 0003 2176 3595; 
FU Vanarix SA
FX This work was sponsored by Vanarix SA.
CR Bartz C, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 1065 8
   BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092 8674(78)90056 9
   BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092 8674(82)90027 7
   Bosurgi L, 2017, SCIENCE, V356, P1072, DOI 10.1126/science.aai8132
   Brittberg M, 2018, AM J SPORT MED, V46, P1343, DOI 10.1177/0363546518756976
   Buchtova M, 2015, BBA MOL BASIS DIS, V1852, P839, DOI 10.1016/j.bbadis.2014.12.020
   Chen Yunshun, 2016, F1000Res, V5, P1438, DOI 10.12688/f1000research.8987.2
   CO.DON AG, 2017, EMEAHC002736 CODON A
   Cosset E, 2016, BIOMATERIALS, V107, P74, DOI 10.1016/j.biomaterials.2016.08.009
   Darling EM, 2005, J ORTHOP RES, V23, P425, DOI 10.1016/j.orthres.2004.08.008
   Davies RL, 2019, BIOENGINEERING BASEL, V6, DOI 10.3390/bioengineering6010022
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Du WJ, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0418 9
   Fox AJS, 2009, SPORTS HEALTH, V1, P461, DOI 10.1177/1941738109350438
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 10 r80
   Gobbi A, 2014, KNEE SURG SPORT TR A, V22, P1986, DOI 10.1007/s00167 013 2676 8
   GUTTENBACH M, 1995, AM J HUM GENET, V57, P1143
   Hartmann C, 2007, MOL CELLS, V24, P177
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Huang BJ, 2016, BIOMATERIALS, V98, P1, DOI 10.1016/j.biomaterials.2016.04.018
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Huber W, 2015, INTENS CARE MED, V41, P2034, DOI 10.1007/s00134 015 4022 8
   Hwang Nathaniel S, 2009, J Knee Surg, V22, P60
   Johnson CI, 2016, VET J, V209, P40, DOI 10.1016/j.tvjl.2015.07.011
   Karin M, 2016, NATURE, V529, P307, DOI 10.1038/nature17039
   Kondo M, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00173 9
   Kwon H, 2021, BIOFABRICATION, V13, DOI 10.1088/1758 5090/abd9d9
   Laschober GT, 2011, REJUV RES, V14, P119, DOI 10.1089/rej.2010.1077
   Le HX, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420943839
   Liu YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033225
   Lotz M, 2012, BONE, V51, P241, DOI 10.1016/j.bone.2012.03.023
   Madeira C, 2015, TRENDS BIOTECHNOL, V33, P35, DOI 10.1016/j.tibtech.2014.11.003
   Martín AR, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536 019 0074 7
   Merimi M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.661532
   Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138
   Mueller MB, 2008, ARTHRITIS RHEUM US, V58, P1377, DOI 10.1002/art.23370
   MUIR H, 1995, BIOESSAYS, V17, P1039, DOI 10.1002/bies.950171208
   Mumme M, 2016, LANCET, V388, P1985, DOI 10.1016/S0140 6736(16)31658 0
   Munirah S, 2010, TISSUE CELL, V42, P282, DOI 10.1016/j.tice.2010.07.002
   Negoro T, 2018, NPJ REGEN MED, V3, DOI 10.1038/s41536 018 0055 2
   Orthocell LTD, 2022, ORTHOACI
   Park MS, 2015, CELL TRANSPLANT, V24, P1067, DOI 10.3727/096368914X681018
   Park Y, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 62580 0
   Pathak S, 2022, INT ORTHOP, V46, P1313, DOI 10.1007/s00264 022 05369 2
   Pelttari K, 2006, ARTHRITIS RHEUM US, V54, P3254, DOI 10.1002/art.22136
   Ramezankhani R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.547653
   Richter W, 2009, J INTERN MED, V266, P390, DOI 10.1111/j.1365 2796.2009.02153.x
   Scotti C, 2012, TISSUE ENG PT A, V18, P362, DOI [10.1089/ten.TEA.2011.0234, 10.1089/ten.tea.2011.0234]
   Sewon Collontech CO. LTD, 2016, CHONDR
   Stumm M, 2012, OSTEOARTHR CARTILAGE, V20, P1039, DOI 10.1016/j.joca.2012.05.012
   Thompson DJ, 2019, NATURE, V575, P652, DOI 10.1038/s41586 019 1765 3
   Vericel Denmark ApS, 2013, EMEAHC002522 EMA VER
   Vonk LA, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0086 1
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wu L, 2014, TISSUE ENG PART C ME, V20, P160, DOI [10.1089/ten.tec.2013.0056, 10.1089/ten.TEC.2013.0056]
   Zscharnack M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0517 x
NR 57
TC 9
Z9 9
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2157 6564
EI 2157 6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD DEC 30
PY 2022
VL 11
IS 12
BP 1219
EP 1231
DI 10.1093/stcltm/szac074
EA NOV 2022
PG 13
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 7L2HW
UT WOS:000877874200001
PM 36318262
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Back, J
   Nguyen, MN
   Li, L
   Lee, S
   Lee, I
   Chen, FC
   Gillinov, L
   Chung, YH
   Alder, KD
   Kwon, HK
   Yu, KE
AF Back, Jungho
   Nguyen, Minh Nam
   Li, Lu
   Lee, Saelim
   Lee, Inkyu
   Chen, Fancheng
   Gillinov, Lauren
   Chung, Yeon Ho
   Alder, Kareme D.
   Kwon, Hyuk Kwon
   Yu, Kristin E.
TI Inflammatory conversion of quiescent osteoblasts by metastatic breast
   cancer cells through pERK1/2 aggravates cancer induced bone destruction
SO BONE RESEARCH
LA English
DT Article
ID DIFFERENTIATION; MELANOMA; SURVIVAL; BRAF; OSTEOCLASTOGENESIS;
   MICROENVIRONMENT; INHIBITION; RESORPTION; MUTATIONS; FRACTURES
AB Disruption of bone homeostasis caused by metastatic osteolytic breast cancer cells increases inflammatory osteolysis and decreases bone formation, thereby predisposing patients to pathological fracture and cancer growth. Alteration of osteoblast function induces skeletal diseases due to the disruption of bone homeostasis. We observed increased activation of pERK1/2 in osteolytic breast cancer cells and osteoblasts in human pathological specimens with aggressive osteolytic breast cancer metastases. We confirmed that osteolytic breast cancers with high expression of pERK1/2 disrupt bone homeostasis via osteoblastic ERK1/2 activation at the bone breast cancer interface. The process of inflammatory osteolysis modulates ERK1/2 activation in osteoblasts and breast cancer cells through dominant negative MEK1 expression and constitutively active MEK1 expression to promote cancer growth within bone. Trametinib, an FDA approved MEK inhibitor, not only reduced breast cancer induced bone destruction but also dramatically reduced cancer growth in bone by inhibiting the inflammatory skeletal microenvironment. Taken together, these findings suggest that ERK1/2 activation in both breast cancer cells and osteoblasts is required for osteolytic breast cancer induced inflammatory osteolysis and that ERK1/2 pathway inhibitors may represent a promising adjuvant therapy for patients with aggressive osteolytic breast cancers by altering the shared cancer and bone microenvironment.
RI ; kwon, hyuk kwon/AAS 4154 2021; Nguyen, Minh/AFP 4984 2022
OI Alder, Kareme/0000 0002 7796 4188; Flores, Michael/0000 0002 6842 3152;
   Munger, Alana/0000 0002 3950 8923; kwon, hyuk kwon/0000 0002 4723 4061;
   Kim, Yoseph/0009 0009 2344 234X; Chung, Yeon Ho/0009 0000 9035 7932;
   Gillinov, Lauren/0000 0002 1720 3504; 
FU  [AR056246];  [AR068353];  [CA203011]
FX The authors thank the Orthopaedic Histology and Histomorphometry
   Laboratory for their excellent assistance. We also thank Dr. Jong Woo
   Lee for critically discussing this study. This work was supported by
   AR056246 (F.Y.L.), AR068353 (F.Y.L.), and CA203011 (F.Y.L.).
CR Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Bhullar KS, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0804 2
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000
   Chambard JC, 2007, BBA MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010
   Chandhanayingyong Chandhanarat, 2012, Sarcoma, V2012, P404810, DOI 10.1155/2012/404810
   Coleman RE, 2013, NAT REV RHEUMATOL, V9, P365, DOI 10.1038/nrrheum.2013.36
   David JM, 2016, VACCINES BASEL, V4, DOI 10.3390/vaccines4030022
   Deng ZY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036739
   Dogan S, 2012, CLIN CANCER RES, V18, P6169, DOI 10.1158/1078 0432.CCR 11 3265
   Dutka Julian, 2003, Ortop Traumatol Rehabil, V5, P276
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
   Ford JA, 2012, EXPERT REV CLIN PHAR, V5, P271, DOI [10.1586/ECP.12.21, 10.1586/ecp.12.21]
   Giltnane JM, 2014, DISCOV MED, V17, P275
   Gnant M, 2012, BREAST CARE, V7, P92, DOI 10.1159/000338650
   Gorden A, 2003, CANCER RES, V63, P3955
   Gross S, 2015, J CLIN INVEST, V125, P1780, DOI 10.1172/JCI76094
   Hagiwara May, 2014, J Med Econ, V17, P223, DOI 10.3111/13696998.2014.890937
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008 5472.CAN 06 2355
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Kaminska B, 2005, BBA PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017
   Khalili JS, 2012, CLIN CANCER RES, V18, P5329, DOI 10.1158/1078 0432.CCR 12 1632
   Krishnamurthy A, 2016, ANN RHEUM DIS, V75, P721, DOI 10.1136/annrheumdis 2015 208093
   Lee HG, 2011, BIOMATERIALS, V32, P9197, DOI 10.1016/j.biomaterials.2011.08.059
   Lee YM, 2010, INT IMMUNOL, V22, P805, DOI 10.1093/intimm/dxq431
   Lipton A, 2009, J NATL COMPR CANC NE, V7, pS1
   Liu FF, 2018, ACTA PHARM SIN B, V8, P552, DOI 10.1016/j.apsb.2018.01.008
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Long GV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6694
   Luo G, 2018, MOL MED REP, V17, P6605, DOI 10.3892/mmr.2018.8698
   Mathew A, 2015, INT J CANCER, V137, P753, DOI 10.1002/ijc.28965
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   McGreevy C, 2011, THER ADV DRUG SAF, V2, P159, DOI 10.1177/2042098611411012
   Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Olechnowicz SWZ, 2014, CANCER RES, V74, P1625, DOI 10.1158/0008 5472.CAN 13 2645
   Park Wyllie LY, 2011, JAMA J AM MED ASSOC, V305, P783, DOI 10.1001/jama.2011.190
   Parker MJ, 2011, HIP INT, V21, P526, DOI 10.5301/HIP.2011.8654
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690
   Seo SW, 2010, BONE, V46, P695, DOI 10.1016/j.bone.2009.10.032
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Shandala T, 2012, J CELL PHYSIOL, V227, P2889, DOI 10.1002/jcp.23034
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sounni NE, 2013, CLIN CHEM, V59, P85, DOI 10.1373/clinchem.2012.185363
   Sullivan RJ, 2019, NAT MED, V25, P929, DOI 10.1038/s41591 019 0474 7
   Theriault RL, 2012, CANCER CONTROL, V19, P92, DOI 10.1177/107327481201900203
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Weitzmann MN, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/125705
   Wissing MD, 2015, CURR OSTEOPOROS REP, V13, P140, DOI 10.1007/s11914 015 0266 z
   Wortzel Inbal, 2011, Genes Cancer, V2, P195, DOI 10.1177/1947601911407328
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549 011 1475 5
   Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599
   Zirlik K, 2018, ONCOL RES TREAT, V41, P166, DOI 10.1159/000488087
NR 58
TC 15
Z9 18
U1 1
U2 15
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD SEP 29
PY 2021
VL 9
IS 1
AR 43
DI 10.1038/s41413 021 00158 w
PG 14
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA UY9FZ
UT WOS:000701822300001
PM 34588427
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Weffort, D
   Adolpho, LF
   Souza, ATP
   Freitas, GP
   Lopes, HB
   Oliveira, FS
   Bighetti Trevisan, RL
   Pitol Palin, L
   Matsushita, DH
   Okamoto, R
   Beloti, MM
   Rosa, AL
AF Weffort, Denise
   Adolpho, Leticia F.
   Souza, Alann T. P.
   Freitas, Gileade P.
   Lopes, Helena B.
   Oliveira, Fabiola S.
   Bighetti Trevisan, Rayana L.
   Pitol Palin, Leticia
   Matsushita, Doris H.
   Okamoto, Roberta
   Beloti, Marcio M.
   Rosa, Adalberto L.
TI Normoglycemia partially recovers the disrupted osteoblast
   differentiation of mesenchymal stem cells induced by type 1 but not type
   2 diabetes mellitus
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE bone; diabetes mellitus; hyperglycemia; mesenchymal stem cells;
   osteoblasts
ID HIGH FAT DIET; OSTEOGENIC DIFFERENTIATION; BONE FRAGILITY; STROMAL
   CELLS; STREPTOZOTOCIN; EXPRESSION; RAT; REGENERATION; COMBINATION;
   ACTIVATION
AB Type 1 (T1DM) and type 2 (T2DM) diabetes mellitus are characterized by changes in glucose metabolism and cause bone damage via a variety of mechanisms, including effects on osteoblasts. We aimed to evaluate the osteoblast differentiation of mesenchymal stem cells (MSCs) from rats with T1DM or T2DM and the effects of removing the hyperglycemic stimulus on the osteogenic potential of these cells. MSCs from healthy rats were cultured in normoglycemic medium, whereas MSCs from rats with T1DM or T2DM were cultured in hyperglycemic or normoglycemic medium. T1DM and T2DM reduced osteoblast differentiation of MSCs grown in hyperglycemic media, with T1DM having a more pronounced effect, as evidenced by alkaline phosphatase activity, RUNX2 protein expression, and extracellular matrix mineralization, and modulated the gene expression of several components of the bone morphogenetic protein signaling pathway. The restoration of the normoglycemic environment partially recovers the osteogenic potential of MSCs from rats with T1DM but not with T2DM. Our findings highlight the need for specific therapies to treat T1DM  or T2DM induced bone loss, as both disrupt osteoblast differentiation at distinct levels and likely through different mechanisms.
C1 [Weffort, Denise; Adolpho, Leticia F.; Souza, Alann T. P.; Freitas, Gileade P.; Lopes, Helena B.; Oliveira, Fabiola S.; Bighetti Trevisan, Rayana L.; Beloti, Marcio M.; Rosa, Adalberto L.] Univ Sao Paulo, Sch Dent Ribeira~o Preto, Bone Res Lab, Ribeiraao Preto, Brazil.
   [Freitas, Gileade P.] Univ Fed Goias, Sch Dent, Goiania, Brazil.
   [Pitol Palin, Leticia; Matsushita, Doris H.; Okamoto, Roberta] Sao Paulo State Univ Julio Mesquita Filho, Aracatuba Dent Sch, Dept Basic Sci, Aracatuba, Brazil.
   [Rosa, Adalberto L.] Univ Sao Paulo, Sch Dent Ribeirao Preto, Bone Res Lab, Av Prof Doutor Zeferino Vaz S N, BR 14040904 Ribeirao Preto, SP, Brazil.
C3 Universidade de Sao Paulo; Universidade Federal de Goias; Universidade
   Estadual Paulista; Universidade de Sao Paulo
RP Rosa, AL (通讯作者)，Univ Sao Paulo, Sch Dent Ribeirao Preto, Bone Res Lab, Av Prof Doutor Zeferino Vaz S N, BR 14040904 Ribeirao Preto, SP, Brazil.
EM adalrosa@forp.usp.br
RI Longo Bighetti Trevisan, Rayana/L 9482 2017; Adolpho,
   Letícia/AAO 6338 2021; Lopes, Helena/G 8090 2016; Palin,
   Letícia/AAY 4320 2020; Beloti, Marcio/E 7473 2012; Rosa,
   Adalberto/A 6314 2008; Pereira Freitas, Gileade/G 8468 2016; Trevisan,
   Rayana/L 9482 2017; Oliveira, Fabíola/J 6915 2014; Rosa, Adalberto
   Luiz/A 6314 2008; Matsushita, Doris/C 8540 2012; Okamoto,
   Roberta/C 4562 2012; Souza, Alann/E 4194 2018; Freitas,
   Gileade/G 8468 2016
OI Longo Bighetti Trevisan, Rayana/0000 0002 0228 3652; Pitol Palin,
   Leticia/0000 0003 4765 3765; Pereira Freitas,
   Gileade/0000 0002 1674 4667; Rosa, Adalberto Luiz/0000 0002 6495 2778; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2017/12622 7,
   2019/18711 7]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico [307698/2021 1]
FX Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Grant/Award
   Numbers: 2017/12622 7, 2019/18711 7; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico, Grant/Award Number:
   307698/2021 1
CR AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871
   Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc14 S081, 10.2337/dc11 S011, 10.2337/dc13 S067, 10.2337/dc13 S011, 10.2337/dc11 S062, 10.2337/dc10 S062, 10.2337/dc10 S011, 10.2337/dc12 s064, 10.2337/dc12 s011]
   Asharani PV, 2012, AM J HUM GENET, V90, P661, DOI 10.1016/j.ajhg.2012.02.026
   Aswamenakul K, 2020, MOL BIOL REP, V47, P7505, DOI 10.1007/s11033 020 05811 x
   Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419
   BOUILLON R, 1991, CALCIFIED TISSUE INT, V49, P155, DOI 10.1007/BF02556109
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Caddy JC, 2020, J CELL BIOCHEM, V121, P3266, DOI 10.1002/jcb.29595
   Cao BR, 2016, BIOMED PHARMACOTHER, V84, P544, DOI 10.1016/j.biopha.2016.09.058
   Chen FL, 2019, NUTR METAB, V16, DOI 10.1186/s12986 019 0393 0
   Chen SX, 2020, J CELL PHYSIOL, V235, P1480, DOI 10.1002/jcp.29068
   Chinipardaz Z, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116176
   Dai F, 2023, BIOTECH HISTOCHEM, V98, P20, DOI 10.1080/10520295.2022.2083685
   Deng XQ, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/5765478
   Erdal N, 2012, DIABETES RES CLIN PR, V97, P461, DOI 10.1016/j.diabres.2012.03.005
   Figeac F, 2022, STEM CELLS, V40, P149, DOI 10.1093/stmcls/sxab011
   Gong FZ, 2021, BMC MOL CELL BIOL, V22, DOI 10.1186/s12860 021 00365 7
   Hamann C, 2011, AM J PHYSIOL ENDOC M, V301, pE1220, DOI 10.1152/ajpendo.00378.2011
   Hie M, 2011, INT J MOL MED, V28, P455, DOI 10.3892/ijmm.2011.697
   Hofbauer LC, 2022, LANCET DIABETES ENDO, V10, P207, DOI 10.1016/S2213 8587(21)00347 8
   Huang KC, 2019, INT J MED SCI, V16, P696, DOI 10.7150/ijms.32707
   JUNOD A, 1969, J CLIN INVEST, V48, P2129, DOI 10.1172/JCI106180
   Limirio PHJO, 2022, CURR DIABETES REV, V18, DOI 10.2174/1573399818666211130142153
   Kalyanaraman H, 2018, DIABETES, V67, P607, DOI 10.2337/db17 0965
   KRAKAUER JC, 1995, DIABETES, V44, P775, DOI 10.2337/diabetes.44.7.775
   LEBOVITZ HE, 1984, PEDIATR CLIN N AM, V31, P521
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Londzin P, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110342
   Ma LL, 2012, EUR J EPIDEMIOL, V27, P319, DOI 10.1007/s10654 012 9674 x
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Nissen Meyer LSH, 2007, J CELL SCI, V120, P2785, DOI 10.1242/jcs.003855
   Phimphilai M, 2017, J BONE MINER METAB, V35, P631, DOI 10.1007/s00774 016 0800 9
   Picke AK, 2016, BONE, V82, P108, DOI 10.1016/j.bone.2015.06.001
   Pitol Palin L, 2020, BIOLOGY BASEL, V9, DOI 10.3390/biology9120471
   Rubin MR, 2015, CURR OSTEOPOROS REP, V13, P186, DOI 10.1007/s11914 015 0265 0
   Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223 003 0023 7
   Silva JC, 2015, J CELL BIOCHEM, V116, P1658, DOI 10.1002/jcb.25126
   Skovso S, 2014, J DIABETES INVEST, V5, P349, DOI 10.1111/jdi.12235
   Srinivasan K, 2005, PHARMACOL RES, V52, P313, DOI 10.1016/j.phrs.2005.05.004
   Stolzing A, 2010, CELLS TISSUES ORGANS, V191, P453, DOI 10.1159/000281826
   Takeno A, 2021, DIABETOL INT, V12, P171, DOI 10.1007/s13340 020 00463 5
   Wang RZ, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420 019 0223 1
   Wutzl A, 2010, J ORTHOP RES, V28, P1431, DOI 10.1002/jor.21144
   Yin DP, 2006, DIABETES, V55, P3256, DOI 10.2337/db05 1275
   Zeng Q, 2007, BONE, V40, P374, DOI 10.1016/j.bone.2006.09.022
NR 45
TC 2
Z9 4
U1 3
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUL
PY 2023
VL 124
IS 7
BP 1050
EP 1063
DI 10.1002/jcb.30434
EA JUN 2023
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA M9TA9
UT WOS:001004523000001
PM 37293736
DA 2025 08 17
ER

PT J
AU Arthur, A
   Panagopoulos, RA
   Cooper, L
   Menicanin, D
   Parkinson, IH
   Codrington, JD
   Vandyke, K
   Zannettino, ACW
   Koblar, SA
   Sims, NA
   Matsuo, K
   Gronthos, S
AF Arthur, Agnieszka
   Panagopoulos, Romana A.
   Cooper, Lachlan
   Menicanin, Danijela
   Parkinson, Ian H.
   Codrington, John D.
   Vandyke, Kate
   Zannettino, Andrew C. W.
   Koblar, Simon A.
   Sims, Natalie A.
   Matsuo, Koichi
   Gronthos, Stan
TI EphB4 enhances the process of endochondral ossification and inhibits
   remodeling during bone fracture repair
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE EPHB4; BONE REPAIR; ENDOCHONDRAL OSSIFICATION; OSTEOBLASTS; MESENCHYMAL
   STEM CELLS
ID EPHRIN B2; CARDIOVASCULAR DEVELOPMENT; RECEPTOR EPHB4; CML PATIENTS;
   IN VIVO; MICE; CELL; ANGIOGENESIS; OSTEOBLASTS; ACTIVATION
AB Previous reports have identified a role for the tyrosine kinase receptor EphB4 and its ligand, ephrinB2, as potential mediators of both bone formation by osteoblasts and bone resorption by osteoclasts. In the present study, we examined the role of EphB4 during bone repair after traumatic injury. We performed femoral fractures with internal fixation in transgenic mice that overexpress EphB4 under the collagen type 1 promoter (Col1 EphB4) and investigated the bone repair process up to 12 weeks postfracture. The data indicated that Col1 EphB4 mice exhibited stiffer and stronger bones after fracture compared with wild type mice. The fractured bones of Col1 EphB4 transgenic mice displayed significantly greater tissue and bone volume 2 weeks postfracture compared with that of wild type mice. These findings correlated with increased chondrogenesis and mineral formation within the callus site at 2 weeks postfracture, as demonstrated by increased safranin O and von Kossa staining, respectively. Interestingly, Col1 EphB4 mice were found to possess significantly greater numbers of clonogenic mesenchymal stromal progenitor cells (CFU F), with an increased capacity to form mineralized nodules in vitro under osteogenic conditions, when compared with those of the wild type control mice. Furthermore, Col1 EphB4 mice had significantly lower numbers of TRAP positive multinucleated osteoclasts within the callus site. Taken together, these observations suggest that EphB4 promotes endochondral ossification while inhibiting osteoclast development during callus formation and may represent a novel drug target for the repair of fractured bones. (c) 2013 American Society for Bone and Mineral Research.
C1 [Arthur, Agnieszka; Panagopoulos, Romana A.; Cooper, Lachlan; Menicanin, Danijela; Gronthos, Stan] Univ Adelaide, Dept Haematol, SA Pathol Adelaide, Mesenchymal Stem Cell Grp, Adelaide, SA, Australia.
   [Arthur, Agnieszka; Panagopoulos, Romana A.; Cooper, Lachlan; Menicanin, Danijela; Vandyke, Kate; Zannettino, Andrew C. W.; Gronthos, Stan] Univ Adelaide, Ctr Stem Cell Res, Robinson Inst, Adelaide, SA, Australia.
   [Parkinson, Ian H.; Codrington, John D.] SA Pathol, Bone & Joint Res Lab, Adelaide, SA, Australia.
   [Codrington, John D.] Univ Adelaide, Sch Mech Engn, Adelaide, SA, Australia.
   [Vandyke, Kate; Zannettino, Andrew C. W.] Univ Adelaide, Dept Haematol, Ctr Canc Biol, Myeloma Res Program,SA Pathol, Adelaide, SA, Australia.
   [Koblar, Simon A.] Univ Adelaide, Sch Med, Sch Mol & Biomed Sci, Ctr Stem Cell Res,Robinson Inst, Adelaide, SA, Australia.
   [Sims, Natalie A.] Univ Melbourne, St Vincents Inst Med Res, Bone Cell Biol & Dis Unit, Melbourne, Vic, Australia.
   [Sims, Natalie A.] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia.
   [Matsuo, Koichi] Keio Univ, Sch Med, Lab Cell & Tissue Biol, Shinjuku Ku, Tokyo, Japan.
   [Gronthos, Stan] Univ Adelaide, Sch Med Sci, Adelaide, SA, Australia.
C3 SA Pathology; University of Adelaide; Robinson Research Institute;
   University of Adelaide; SA Pathology; University of Adelaide; Centre for
   Cancer Biology; SA Pathology; University of Adelaide; Robinson Research
   Institute; University of Adelaide; University of Melbourne; St.
   Vincent's Institute of Medical Research; St Vincent's Health; St
   Vincent's Hospital Melbourne; University of Melbourne; NSW Health; St
   Vincents Hospital Sydney; Keio University; University of Adelaide
RP Gronthos, S (通讯作者)，Inst Med & Vet Sci, Dept Haematol, Frome Rd, Adelaide, SA 5000, Australia.
EM stan.gronthos@health.sa.gov.au
RI ; Gronthos, Stan/Y 4419 2019; Matsuo, Koichi/K 5695 2012; Sims,
   Natalie/A 7192 2012; Matsuo, Koichi/AFP 4369 2022; Vandyke,
   Kate/G 6280 2010
OI Zannettino, Andrew/0000 0002 6646 6167; Matsuo,
   Koichi/0000 0002 1490 8955; Sims, Natalie/0000 0003 1421 8468; Arthur,
   Agnes/0000 0002 0539 8797; Koblar, Simon/0000 0002 8667 203X; Gronthos,
   Stan/0000 0002 6225 3084; Vandyke, Kate/0000 0002 1033 849X
FU NHMRC [565176, 1023390]
FX This work was supported by the NH&MRC project grants 565176 and 1023390.
CR Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295
   Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Arthur A, 2009, J DENT RES, V88, P829, DOI 10.1177/0022034509342363
   Arthur A, 2011, BONE, V48, P533, DOI 10.1016/j.bone.2010.10.180
   Das A, 2010, AM J PHYSIOL GASTR L, V298, pG908, DOI 10.1152/ajpgi.00510.2009
   Diercke K, 2011, J BIOL CHEM, V286, P37651, DOI 10.1074/jbc.M110.166900
   Duvall CL, 2007, J BONE MINER RES, V22, P286, DOI 10.1359/JBMR.061103
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Fitter S, 2008, BLOOD, V111, P2538, DOI 10.1182/blood 2007 07 104281
   Fitter S, 2010, J CLIN ENDOCR METAB, V95, P3763, DOI 10.1210/jc.2010 0086
   Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097 2765(00)80342 1
   Manigrasso MB, 2004, J ORTHOP TRAUMA, V18, P687, DOI 10.1097/00005131 200411000 00006
   Mao YJ, 2011, INT J MOL MED, V27, P669, DOI 10.3892/ijmm.2011.639
   Martin TJ, 2010, ADV EXP MED BIOL, V658, P51, DOI 10.1007/978 1 4419 1050 9_6
   Noberini R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028611
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   Pennisi A, 2009, BLOOD, V114, P1803, DOI 10.1182/blood 2009 01 201954
   Schriefer JL, 2005, J BIOMECH, V38, P467, DOI 10.1016/j.jbiomech.2004.04.020
   Silva MJ, 2002, J BONE MINER RES, V17, P1597, DOI 10.1359/jbmr.2002.17.9.1597
   Tat SK, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2782
   Tat SK, 2008, ARTHRITIS RHEUM US, V58, P3820, DOI 10.1002/art.24029
   Vandyke K, 2009, LEUKEMIA, V23, P2155, DOI 10.1038/leu.2009.150
   Vandyke K, 2010, J BONE MINER RES, V25, P1759, DOI 10.1002/jbmr.85
   Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092 8674(00)81436 1
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 26
TC 38
Z9 40
U1 0
U2 12
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2013
VL 28
IS 4
BP 926
EP 935
DI 10.1002/jbmr.1821
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 112EB
UT WOS:000316573900023
PM 23165754
DA 2025 08 17
ER

PT J
AU Ehrenmann, J
   Schöppe, J
   Klenk, C
   Plückthun, A
AF Ehrenmann, Janosch
   Schoeppe, Jendrik
   Klenk, Christoph
   Plueckthun, Andreas
TI New views into class B GPCRs from the crystal structure of PTH1R
SO FEBS JOURNAL
LA English
DT Article
DE crystal structure; G protein coupled receptor; osteoporosis; parathyroid
   hormone 1 receptor; protein engineering
ID HUMAN PARATHYROID HORMONE; CRYO EM STRUCTURE; PROTEIN COUPLED RECEPTOR;
   GLP 1 RECEPTOR; DIRECTED EVOLUTION; EXPRESSION; BINDING; RECOGNITION;
   STABILITY; ANALOGS
AB The parathyroid hormone 1 receptor (PTH1R) is a major regulator of mineral ion homeostasis and bone metabolism and is thus considered an attractive drug target for the treatment of disorders in calcium metabolism and bone related diseases such as osteoporosis. PTH1R is a member of the class B of GPCRs, which all share a dynamic multidomain binding mechanism to the peptide hormone. For a long time, these complexes have been recalcitrant to structural studies despite their great therapeutic relevance. Through extensive engineering of both the receptor and the peptide agonist ligand, we were able to determine the first high resolution structure of a PTH1R agonist complex. Comparisons of the PTH1R crystal structure with subsequently reported cryo electron microscopy structures of the same receptor in complex with a G protein, as well as with other class B GPCR structures bound to antagonists, reveal new insights into the two step activation mechanism of class B GPCRs and extend our understanding of the precise molecular rearrangements during receptor activation.
C1 [Ehrenmann, Janosch; Schoeppe, Jendrik; Klenk, Christoph; Plueckthun, Andreas] Univ Zurich, Dept Biochem, Winterthurerstr 190, CH 8057 Zurich, Switzerland.
C3 University of Zurich
RP Plückthun, A (通讯作者)，Univ Zurich, Dept Biochem, Winterthurerstr 190, CH 8057 Zurich, Switzerland.
EM plueckthun@bioc.uzh.ch
RI Klenk, Christoph/E 5158 2014; Pluckthun, Andreas/C 2746 2009; Plückthun,
   Andreas/C 2746 2009
OI Klenk, Christoph/0000 0001 5199 7144; Pluckthun,
   Andreas/0000 0003 4191 5306; Schoppe, Jendrik/0000 0002 2689 5549
FU Schweizerischer Nationalfonds [31003A_153143, 31003A_182334]; KTI Grant
   [18022.1 PFLS LS]; German Academy of Sciences Leopoldina [LPDS 2009 48];
   Marie Curie fellowship of the European Commission (FP7 PEOPLE 2011 IEF)
   [299208]; Swiss National Science Foundation (SNF) [31003A_153143,
   31003A_182334] Funding Source: Swiss National Science Foundation (SNF)
FX This work was supported by Schweizerischer Nationalfonds Grants
   31003A_153143 and 31003A_182334 and KTI Grant 18022.1 PFLS LS, all to
   A.P.; C.K. is the recipient of a fellowship of the German Academy of
   Sciences Leopoldina (LPDS 2009 48) and a Marie Curie fellowship of the
   European Commission (FP7 PEOPLE 2011 IEF #299208).
CR Castro M, 2005, P NATL ACAD SCI USA, V102, P16084, DOI 10.1073/pnas.0503942102
   Condon SM, 2000, J AM CHEM SOC, V122, P3007, DOI 10.1021/ja994033u
   Dodevski I, 2011, J MOL BIOL, V408, P599, DOI 10.1016/j.jmb.2011.02.051
   Egloff P, 2014, P NATL ACAD SCI USA, V111, pE655, DOI 10.1073/pnas.1317903111
   Ehrenmann J, 2018, NAT STRUCT MOL BIOL, V25, P1086, DOI 10.1038/s41594 018 0151 4
   Hollenstein K, 2014, TRENDS PHARMACOL SCI, V35, P12, DOI 10.1016/j.tips.2013.11.001
   Jazayeri A, 2017, NATURE, V546, P254, DOI 10.1038/nature22800
   LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488
   Liang YL, 2018, NATURE, V555, P121, DOI 10.1038/nature25773
   Liang YL, 2017, NATURE, V546, P118, DOI 10.1038/nature22327
   NEUGEBAUER W, 1995, BIOCHEMISTRY US, V34, P8835, DOI 10.1021/bi00027a035
   Pal K, 2012, ACTA PHARMACOL SIN, V33, P300, DOI 10.1038/aps.2011.170
   Pioszak AA, 2008, P NATL ACAD SCI USA, V105, P5034, DOI 10.1073/pnas.0801027105
   Pratley R, 2019, LANCET, V394, P39, DOI 10.1016/S0140 6736(19)31271 1
   Rasmussen SGF, 2011, NATURE, V469, P175, DOI 10.1038/nature09648
   Rosenbaum DM, 2011, NATURE, V469, P236, DOI 10.1038/nature09665
   ROSENBLATT M, 1976, J BIOL CHEM, V251, P159
   Sarkar CA, 2008, P NATL ACAD SCI USA, V105, P14808, DOI 10.1073/pnas.0803103105
   Schlinkmann KM, 2012, J MOL BIOL, V422, P414, DOI 10.1016/j.jmb.2012.05.039
   Schöppe J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 07939 8
   Schütz M, 2016, SCI REP UK, V6, DOI 10.1038/srep21508
   Selye H, 1932, ENDOCRINOLOGY, V16, P547, DOI 10.1210/endo 16 5 547
   Shimizu N, 2004, J BONE MINER RES, V19, P2078, DOI 10.1359/JBMR.040914
   Stewart AF, 2005, NEW ENGL J MED, V352, P373, DOI 10.1056/NEJMcp042806
   Vilardaga JP, 2011, CELL MOL LIFE SCI, V68, P1, DOI 10.1007/s00018 010 0465 9
   Weaver RE, 2017, BIOCHEM PHARMACOL, V127, P71, DOI 10.1016/j.bcp.2016.12.013
   Wootten D, 2013, P NATL ACAD SCI USA, V110, P5211, DOI 10.1073/pnas.1221585110
   Yang LL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8859
   Zhang HN, 2018, NATURE, V553, P106, DOI 10.1038/nature25153
   Zhang HN, 2017, NATURE, V546, P259, DOI 10.1038/nature22363
   Zhang Y, 2017, NATURE, V546, P248, DOI 10.1038/nature22394
   Zhao LH, 2019, SCIENCE, V364, P148, DOI 10.1126/science.aav7942
NR 32
TC 5
Z9 5
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1742 464X
EI 1742 4658
J9 FEBS J
JI FEBS J.
PD DEC
PY 2019
VL 286
IS 24
BP 4852
EP 4860
DI 10.1111/febs.15115
EA NOV 2019
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA OB9NK
UT WOS:000496816800001
PM 31670461
OA Bronze
DA 2025 08 17
ER

PT J
AU Raux, S
   Bouhamama, A
   Gaspar, N
   Brugières, L
   Entz Werlé, N
   Mallet, C
   Dijoud, F
   Gouin, F
   Marec Bérard, P
AF Raux, Sebastien
   Bouhamama, Amine
   Gaspar, Nathalie
   Brugieres, Laurence
   Entz Werle, Natacha
   Mallet, Cindy
   Dijoud, Frederique
   Gouin, Francois
   Marec Berard, Perrine
TI Denosumab for treating aneurysmal bone cysts in children
SO ORTHOPAEDICS & TRAUMATOLOGY SURGERY & RESEARCH
LA English
DT Article
DE Aneurysmal bone cyst; Denosumab; RANKL antagonist
ID GIANT CELL TUMOR; THERAPY; SPINE
AB Background: Aneurysmal bone cyst (ABC) is a benign tumour whose progression involves the RANK/RANKL signalling pathway. Surgery is the reference standard treatment but carries risks that vary with the site of the tumour. Denosumab is a human monoclonal IgG2 antibody that targets the RANK/RANKL pathway and may therefore hold promise for inhibiting ABC progression. The objective of this study was to evaluate denosumab use in paediatric patients (younger than 18 years) with ABC and to describe the clinical and radiological outcomes, as well as the side effect profile. Hypothesis: Denosumab is a viable option in children with ABC refractory to standard treatments.
   Material and methods: We retrospectively reviewed the medical files of paediatric patients given denosumab to treat ABC in any of 32 centres affiliated with the French Paediatric Cancer Society (Societe Francaise du Cancer de l'Enfant, SFCE) and French Sarcoma Group (Groupe Sarcome Francais, GSF GETO). We identified 5 patients treated between March 2015 and June 2018. Median age was 8 years (range, 7 17 years). Pain was a symptom in all 5 patients and neurological deficits were present in 3 patients. Surgery was performed in 4 patients, either before (n = 3) or after (n = 1) denosumab therapy; the remaining patient had no surgery. Denosumab was given as monthly injections in a dosage of 70 mg/m(2) for a median of 12 months (range, 4 23 months). The clinical outcomes and changes in computed tomography and/or magnetic resonance imaging findings were evaluated.
   Results: Abnormalities in calcium and phosphate levels secondary to the ABC occurred in 2 patients. At median of 24 months (range, 0 28 months) after denosumab initiation, all 5 patients were free of pain, and the neurological deficits in 3 patients had improved. Central remineralisation and cortical reconstitution were demonstrated consistently by the imaging studies.
   Discussion: Denosumab is a viable treatment option in selected paediatric patients with inoperable ABC. The immediate adverse effect profile is acceptable. A larger study with a longer follow up would be welcome to further assess the contribution of denosumab to the treatment of ABC. (C) 2019 Elsevier Masson SAS. All rights reserved.
C1 [Raux, Sebastien; Dijoud, Frederique] HFME, Dept Chirurg Infantile, 59 Blvd Pinel, F 69677 Bron, France.
   [Bouhamama, Amine; Marec Berard, Perrine] IHOP, 1 Pl Prof Joseph Renaut, F 69008 Lyon, France.
   [Gaspar, Nathalie; Brugieres, Laurence] IGR, 114 Rue Edouard Vaillant, F 94800 Villejuif, France.
   [Entz Werle, Natacha] Hop Mere Enfant Hautepierre, 1 Ave Moliere, F 67200 Strasbourg, France.
   [Mallet, Cindy] Hop Univ Robert Debre, 48 Blvd Serurier, F 75019 Paris, France.
   [Gouin, Francois] Ctr Leon Berard, F 69008 Lyon, France.
C3 CHU Lyon; CHU Lyon; UNICANCER; Gustave Roussy; Assistance Publique
   Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire
   Robert Debre   APHP; UNICANCER; Centre Leon Berard
RP Raux, S (通讯作者)，HFME, Dept Chirurg Infantile, 59 Blvd Pinel, F 69677 Bron, France.
EM sebastien.raux@chu lyon.fr
RI Gaspar, Nathalie/JRW 5505 2023; Marec Berard, Perrine/HZL 6119 2023
CR Amendola L, 2013, EUR SPINE J, V22, P533, DOI 10.1007/s00586 012 2566 7
   CAPANNA R, 1985, J BONE JOINT SURG AM, V67A, P527, DOI 10.2106/00004623 198567040 00004
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Cornelis F, 2014, BONE, V58, P11, DOI 10.1016/j.bone.2013.10.004
   Cottalorda J, 2005, J PEDIATR ORTHOPED, V25, P471, DOI 10.1097/01.bpo.0000158002.30800.8f
   Dubory A, 2016, SPINE, V41, pE654, DOI 10.1097/BRS.0000000000001350
   Gossai N, 2015, PEDIATR BLOOD CANCER, V62, P1078, DOI 10.1002/pbc.25393
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kurucu N, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26926
   Lange T, 2013, EUR SPINE J, V22, P1417, DOI 10.1007/s00586 013 2715 7
   Müller DA, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957 016 1034 y
   Papagelopoulos PJ, 1998, SPINE, V23, P621, DOI 10.1097/00007632 199803010 00018
   Pelle DW, 2014, TRANSL RES, V164, P139, DOI 10.1016/j.trsl.2014.03.005
   Rekhi B, 2017, PATHOL ONCOL RES, V23, P157, DOI 10.1007/s12253 016 0123 0
   Rutkowski P, 2018, EJSO EUR J SURG ONC, V44, P1384, DOI 10.1016/j.ejso.2018.03.020
NR 15
TC 33
Z9 34
U1 0
U2 2
PU ELSEVIER MASSON, CORPORATION OFFICE
PI PARIS
PA 65 CAMILLE DESMOULINS CS50083 ISSY LES MOULINEAUX, 92442 PARIS, FRANCE
SN 1877 0568
J9 ORTHOP TRAUMATOL SUR
JI Orthop. Traumatol. Surg. Res.
PD OCT
PY 2019
VL 105
IS 6
BP 1181
EP 1185
DI 10.1016/j.otsr.2019.04.028
PG 5
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA IY5JQ
UT WOS:000486428600025
PM 31358461
OA Bronze
DA 2025 08 17
ER

PT J
AU Costessi, A
   Pines, A
   D'Andrea, P
   Romanello, M
   Damante, G
   Cesaratto, L
   Quadrifoglio, F
   Moro, L
   Tell, G
AF Costessi, A
   Pines, A
   D'Andrea, P
   Romanello, M
   Damante, G
   Cesaratto, L
   Quadrifoglio, F
   Moro, L
   Tell, G
TI Extracellular nucleotides activate Runx2 in the osteoblast like HOBIT
   cell line: a possible molecular link between mechanical stress and
   osteoblasts' response
SO BONE
LA English
DT Article
DE Runx2; HOBIT cell line; mechanical stress
ID FOCAL ADHESION KINASE; INDUCED ATP RELEASE; PROTEIN KINASE;
   SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR; BONE FORMATION;
   GENE EXPRESSION; BINDING; DIFFERENTIATION; GALECTIN 3
AB Dynamic mechanical loading increases bone density and strength and promotes osteoblast proliferation, differentiation and matrix production, by acting at the gene expression level. Molecular mechanisms through which mechanical forces are conversed into biochemical signalling in bone are still poorly understood. A growing body of evidence point to extracellular nucleotides (i.e., ATP and UTP) as soluble factors released in response to mechanical stimulation in different cell systems. Runx2, a fundamental transcription factor involved in controlling osteoblasts differentiation, has been recently identified as a target of mechanical signals in osteoblastic cells. We tested the hypothesis that these extracellular nucleotides could be able to activate Runx2 in the human osteoblastic HOBIT cell line. We found that ATP and UTP treatments, as well as hypotonic stress, promote a significant stimulation of Runx2 DNA binding activity via a mechanism involving PKC and distinct mitogen activated protein kinase cascades. In fact, by using the specific inhibitors SB203580 (specific for p38 MAPK) and PD98059 (specific for ERK 1/2 MAPK), we found that ERK 1/2, but not p38, play a major role in Runx2 activation. On the contrary, another important transcription factor, i.e., Egr 1, that we previously demonstrated being activated by extracellular released nucleotides in this osteoblastic cell line, demonstrated to be susceptible to both ERK 1/2 and p38 kinases. These data suggest a possible differential involvement of these two transcription factors in response to extracellularly released nucleotides.
   The biological relevance of our data is strengthened by the finding that a target gene of Runx2, i.e., Galectin 3, is up regulated by ATP stimulation of HOBIT cells with a comparable kinetic of that found for Runx2. Since it is known that osteocytes are the primary mechanosensory cells of the bone, we hypothesize that they may signal mechanical loading to osteoblasts through release of extracellular nucleotides.
   Altogether, these data suggest a molecular mechanism explaining the purinoreceptors mediated activation of specific gene expression in osteoblasts and could be of help in setting up new pharmacological strategies for the intervention in bone loss pathologies. (c) 2004 Elsevier Inc. All rights reserved.
C1 Univ Udine, Dept Biomed Sci & Technol, I 33100 Udine, Italy.
   Univ Trieste, Dept Biochem Biophys & Macromol Chem, I 34127 Trieste, Italy.
   Univ Udine, Interdept Ctr Regenerat Med, I 33100 Udine, Italy.
C3 University of Udine; University of Trieste; University of Udine
RP Univ Udine, Dept Biomed Sci & Technol, P Le Kolbe 4, I 33100 Udine, Italy.
EM gtell@mail.dstb.uniud.it
RI ; Cesaratto, Laura/AAA 7577 2019; Damante, Giuseppe/AAC 5200 2022
OI Damante, Giuseppe/0000 0003 2312 4009; Cesaratto,
   Laura/0000 0002 7815 2544; Tell, Gianluca/0000 0001 8845 6448
CR Aubin JE, 1996, J CELL PHYSIOL, V169, P468, DOI 10.1002/(SICI)1097 4652(199612)169:3<468::AID JCP7>3.0.CO;2 M
   BAO Q, 1995, J CELL SCI, V108, P2791
   Berenbaum F, 2003, J BIOL CHEM, V278, P13680, DOI 10.1074/jbc.M211570200
   BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092 8674(91)90098 J
   Bowler WB, 1999, J BIOL CHEM, V274, P14315, DOI 10.1074/jbc.274.20.14315
   Bowler WB, 1998, BONE, V22, P195, DOI 10.1016/S8756 3282(97)00280 9
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101
   Collet P, 1997, BONE, V20, P547, DOI 10.1016/S8756 3282(97)00052 5
   *COMM ENZ SOC FRAN, 1982, ANN BIOL CLIN, V40, P291
   Crute BE, 1996, J BIOL CHEM, V271, P26251, DOI 10.1074/jbc.271.42.26251
   DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973
   Gerasimovskaya EV, 2002, J BIOL CHEM, V277, P44638, DOI 10.1074/jbc.M203012200
   Grygorczyk R, 1997, AM J PHYSIOL CELL PH, V272, pC1058
   HARTER LV, 1995, ENDOCRINOLOGY, V136, P528, DOI 10.1210/en.136.2.528
   Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200
   HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460 2075.1994.tb06517.x
   Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165 6147(03)00123 8
   HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904
   Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925
   Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891 2905.2001
   KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168 9525(93)90026 E
   Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444
   Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756 3282(02)00979 1
   KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Koyama T, 2001, J PHYSIOL LONDON, V532, P759, DOI 10.1111/j.1469 7793.2001.0759e.x
   Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348
   LEFFLER H, 1989, BIOCHEMISTRY US, V28, P9222, DOI 10.1021/bi00449a039
   Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092 8674(02)00690 6
   Liu FT, 1996, BIOCHEMISTRY US, V35, P6073, DOI 10.1021/bi952716q
   Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839
   Malmsjo Malin, 2003, BMC Pharmacol, V3, P4, DOI 10.1186/1471 2210 3 4
   Marotti G, 1996, Ital J Anat Embryol, V101, P25
   Miyauchi A, 2000, J BIOL CHEM, V275, P3335, DOI 10.1074/jbc.275.5.3335
   Oike M, 2000, AM J PHYSIOL HEART C, V279, pH630, DOI 10.1152/ajpheart.2000.279.2.H630
   Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092 8674(00)80986 1
   Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Palumbo C, 2004, ANAT REC PART A, V278A, P474, DOI 10.1002/ar.a.20032
   Paron I, 2004, BIOCHEM J, V378, P929, DOI 10.1042/BJ20031190
   Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232
   Pines A, 2003, BIOCHEM J, V373, P815, DOI 10.1042/BJ20030208
   Ping PP, 1999, AM J PHYSIOL HEART C, V276, pH1468, DOI 10.1152/ajpheart.1999.276.5.H1468
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274
   Rezzonico R, 2003, J BONE MINER RES, V18, P1863, DOI 10.1359/jbmr.2003.18.10.1863
   Romanello M, 2001, BIOCHEM BIOPH RES CO, V289, P1275, DOI 10.1006/bbrc.2001.6124
   Romanello M, 2001, J BONE MINER RES, V16, P1465, DOI 10.1359/jbmr.2001.16.8.1465
   Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647
   Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383
   Stock M, 2003, J BIOL CHEM, V278, P17360, DOI 10.1074/jbc.M207631200
   Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309
   Taylor AL, 1998, AM J PHYSIOL CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391
   Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062
   Tornquist K, 1996, J CELL PHYSIOL, V166, P241
   TOULLEC D, 1991, J BIOL CHEM, V266, P15771
   Turner C H, 1998, J Orthop Sci, V3, P346, DOI 10.1007/s007760050064
   Vertegaal ACO, 2000, CELL SIGNAL, V12, P759, DOI 10.1016/S0898 6568(00)00133 9
   Wang FS, 2002, J BIOL CHEM, V277, P10931, DOI 10.1074/jbc.M104587200
   Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444
   Webb BLJ, 1997, BIOCHEM PHARMACOL, V54, P199, DOI 10.1016/S0006 2952(97)00165 2
   Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   You J, 2002, J BIOL CHEM, V277, P48724, DOI 10.1074/jbc.M209245200
   Zimmerman D, 2000, DEV BIOL, V220, P2, DOI 10.1006/dbio.2000.9633
   Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200
NR 74
TC 68
Z9 83
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2005
VL 36
IS 3
BP 418
EP 432
DI 10.1016/j.bone.2004.10.016
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 914AN
UT WOS:000228196900006
PM 15777650
DA 2025 08 17
ER

PT J
AU de Campaigno, EP
   Kebir, I
   Montastruc, JL
   Rueter, M
   Maret, D
   Lapeyre Mestre, M
   Sallerin, B
   Despas, F
AF de Campaigno, Emilie Patras
   Kebir, Ines
   Montastruc, Jean Louis
   Rueter, Manuela
   Maret, Delphine
   Lapeyre Mestre, Maryse
   Sallerin, Brigitte
   Despas, Fabien
TI Drug Induced Dental Caries: A Disproportionality Analysis Using Data
   from VigiBase
SO DRUG SAFETY
LA English
DT Article
ID INDUCED HYPERGLYCEMIA; PHARMACOVIGILANCE DATABASE; PHOSPHATE DEPLETION;
   DIABETES MELLITUS; INSULIN; RISK; PERIODONTITIS; OSTEOMALACIA; DISEASE;
   HEALTH
AB Dental caries is defined as a pathological breakdown of the tooth. It is an infectious phenomenon involving a multifactorial aetiology. The impact of drugs on cariogenic risk has been poorly investigated.
   In this study, we identified drugs suspected to induce dental caries as adverse drug reactions (ADRs) and then studied a possible pathogenic mechanism for each drug that had a statistically significant disproportionality.
   We extracted individual case safety reports of dental caries associated with drugs from VigiBase(A (R)) (the World Health Organization global individual case safety report database). We calculated disproportionality for each drug with a reporting odds ratio (ROR) and 99% confidence interval. We analysed the pharmacodynamics of each drug that had a statistically significant disproportionality.
   In VigiBase(A (R)), 5229 safety reports for dental caries concerning 733 drugs were identified. Among these drugs, 88 had a significant ROR, and for 65 of them (73.9%), no information about dental caries was found in the summaries of the product characteristics, the Micromedex(A (R)) DRUGDEX, or the Martindale databases. Regarding the pharmacological classes of drugs involved in dental caries, we identified bisphosphonates, atropinic drugs, antidepressants, corticoids, immunomodulating drugs, antipsychotics, antiepileptics, opioids and beta(2) adrenoreceptor agonist drugs. Regarding possible pathogenic mechanisms for these drugs, we identified changes in salivary flow/composition for 54 drugs (61.4%), bone metabolism changes for 31 drugs (35.2%), hyperglycaemia for 32 drugs (36.4%) and/or immunosuppression for 23 drugs (26.1%). For nine drugs (10.2%), the mechanism was unclear.
   We identified 88 drugs with a significant positive disproportionality for dental caries. Special attention has to be paid to bisphosphonates, atropinic drugs, immunosuppressants and drugs causing hyperglycaemia.
C1 [de Campaigno, Emilie Patras; Kebir, Ines; Montastruc, Jean Louis; Rueter, Manuela; Lapeyre Mestre, Maryse; Despas, Fabien] Ctr Hosp Univ Toulouse, Serv Pharmacol Med, F 31000 Toulouse, France.
   [Montastruc, Jean Louis; Lapeyre Mestre, Maryse; Despas, Fabien] Univ Paul Sabatier, Lab Pharmacol Med & Clin, Fac Med, 37 Allee Jules Guesde, F 31000 Toulouse, France.
   [Montastruc, Jean Louis; Lapeyre Mestre, Maryse; Despas, Fabien] Univ Toulouse, INSERM, Fac Med, UMR 1027, Toulouse, France.
   [Montastruc, Jean Louis; Lapeyre Mestre, Maryse; Despas, Fabien] Univ Toulouse, CIC INSERM 1436, Toulouse, France.
   [Montastruc, Jean Louis; Lapeyre Mestre, Maryse; Despas, Fabien] Ctr Hosp Univ Toulouse, Toulouse, France.
   [Montastruc, Jean Louis] Ctr Hosp Univ Toulouse, Ctr Midi Pyrenees PharmacoVigilance Pharmacoepide, Toulouse, France.
   [Maret, Delphine] CNRS, Lab AMIS, UMR 5288, F 31000 Toulouse, France.
   [Maret, Delphine] Univ Toulouse III, Serv Odontol Conservatrice, Endodontie, F 31000 Toulouse, France.
   [Maret, Delphine] CHU Toulouse, Serv Odontol Conservatrice, F 31000 Toulouse, France.
   [Sallerin, Brigitte] Ctr Hosp Univ Toulouse, Serv Pharmacie Hosp, F 31000 Toulouse, France.
   [Sallerin, Brigitte] Fac Pharmacie Toulouse, Lab Pharmacie Clin, F 31000 Toulouse, France.
C3 CHU de Toulouse; Universite de Toulouse; Universite Toulouse III   Paul
   Sabatier; Universite de Toulouse; Universite Toulouse III   Paul
   Sabatier; Universite de Toulouse; Universite Toulouse III   Paul
   Sabatier; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Toulouse; Universite de Toulouse; Universite
   Toulouse III   Paul Sabatier; CHU de Toulouse; Universite de Toulouse;
   Universite Toulouse III   Paul Sabatier; CHU de Toulouse; Centre
   National de la Recherche Scientifique (CNRS); CNRS   Institute of
   Ecology & Environment (INEE); Universite de Toulouse; Universite
   Toulouse III   Paul Sabatier; Universites de Strasbourg Etablissements
   Associes; Universite de Strasbourg; Universite de Toulouse; Universite
   Toulouse III   Paul Sabatier; CHU de Toulouse; Universite de Toulouse;
   Universite Toulouse III   Paul Sabatier; CHU de Toulouse; Universite de
   Toulouse; Universite Toulouse III   Paul Sabatier; Universite de
   Toulouse; Universite Toulouse III   Paul Sabatier
RP Despas, F (通讯作者)，Ctr Hosp Univ Toulouse, Serv Pharmacol Med, F 31000 Toulouse, France.; Despas, F (通讯作者)，Univ Paul Sabatier, Lab Pharmacol Med & Clin, Fac Med, 37 Allee Jules Guesde, F 31000 Toulouse, France.; Despas, F (通讯作者)，Univ Toulouse, INSERM, Fac Med, UMR 1027, Toulouse, France.; Despas, F (通讯作者)，Univ Toulouse, CIC INSERM 1436, Toulouse, France.; Despas, F (通讯作者)，Ctr Hosp Univ Toulouse, Toulouse, France.
EM fabien.despas@univ tlse3.fr
RI ; Maret, Delphine/AFT 1061 2022; Lapeyre Mestre, Maryse/C 8710 2012
OI despas, fabien/0000 0002 3116 9963; Lapeyre Mestre,
   Maryse/0000 0002 5494 5873; Maret, Delphine/0000 0002 0727 7745
FU Toulouse University Hospital, Toulouse (France)
FX This work was supported by the Toulouse University Hospital, 31000
   Toulouse (France).
CR Abou Neel EA, 2016, INT J NANOMED, V11, P4743, DOI 10.2147/IJN.S107624
   [Anonymous], 2015, PRESCRIRE INT, V24, P44
   BAKER LRI, 1974, BRIT MED J, V3, P150, DOI 10.1136/bmj.3.5924.150
   Baroffio M, 2013, RESP PHYSIOL NEUROBI, V185, P281, DOI 10.1016/j.resp.2012.10.001
   Bate A, 2008, FUND CLIN PHARMACOL, V22, P127, DOI 10.1111/j.1472 8206.2007.00552.x
   Benderli Y, 2000, ORAL SURG ORAL MED O, V89, P588, DOI 10.1067/moe.2000.105144
   Chebane L, 2010, THERAPIE, V65, P447, DOI 10.2515/therapie/2010051
   CHRISTOFFERSEN J, 1991, J DENT RES, V70, P123, DOI 10.1177/00220345910700020501
   Ciancio S., 1995, COMPEND CONTIN ED DE, V2001, P24
   CLARKSON BH, 1986, J ORAL PATHOL MED, V15, P423, DOI 10.1111/j.1600 0714.1986.tb00651.x
   Davies AN, 2005, J PAIN SYMPTOM MANAG, V30, P496, DOI 10.1016/j.jpainsymman.2005.11.006
   DENT CE, 1974, BRIT MED J, V1, P551, DOI 10.1136/bmj.1.5907.551
   Donaldson M, 1939, J AM DENT ASSOC, V2015, P129
   Fathallah N, 2015, DRUG SAFETY, V38, P1153, DOI 10.1007/s40264 015 0339 z
   Featherstone JDB, 2006, MG ORAL SCI, V20, P66, DOI 10.1159/000093351
   Featherstone J D B, 2004, J Dent Res, V83 Spec No C, pC39
   Fouda N, 1991, J Biol Buccale, V19, P106
   Glare Paul, 2006, Am J Hosp Palliat Care, V23, P229, DOI 10.1177/1049909106289068
   Hellwig E, 2014, MONOGR ORAL SCI, V25, P155, DOI 10.1159/000359942
   Information Product, 2009, ONSOLIS TM BUCC SOL
   Information Product, 2009, ACTIQ R OR TRANSM LO
   IPP E, 1980, ENDOCRINOLOGY, V107, P461, DOI 10.1210/endo 107 2 461
   Jawed M, 2011, J DIABETES COMPLICAT, V25, P183, DOI 10.1016/j.jdiacomp.2010.07.001
   Lehner T, 1977, Ciba Found Symp, P135
   Lindquist M, 2008, DRUG INF J, V42, P409, DOI 10.1177/009286150804200501
   Mandel ID, 1939, J AM DENT ASSOC, V1989, P298
   Martínez Abundis E, 2007, ARCH DERMATOL RES, V299, P461, DOI 10.1007/s00403 007 0784 3
   Montastruc JL, 2011, BRIT J CLIN PHARMACO, V72, P905, DOI 10.1111/j.1365 2125.2011.04037.x
   Nakahara Y, 2013, TOXICOL PATHOL, V41, P761, DOI 10.1177/0192623312464307
   Nakahara Y, 2012, HISTOL HISTOPATHOL, V27, P1297, DOI 10.14670/HH 27.1297
   Olczak Kowalczyk D, 2012, ANN TRANSPL, V17, P72
   Park YS, 2014, BONE ABSTR
   Peeters FPML, 1998, GEN HOSP PSYCHIAT, V20, P150, DOI 10.1016/S0163 8343(98)00017 6
   Rabenda V, 2013, OSTEOPOROSIS INT, V24, P121, DOI 10.1007/s00198 012 2015 9
   SCHAMSCHULA RG, 1981, ANNU REV NUTR, V1, P427, DOI 10.1146/annurev.nu.01.070181.002235
   Schwan S, 2009, EUR NEUROPSYCHOPHARM, V19, P683, DOI 10.1016/j.euroneuro.2009.05.001
   Selwitz RH, 2007, LANCET, V369, P51, DOI 10.1016/S0140 6736(07)60031 2
   Shen CH, 2014, BONE, V64, P246, DOI 10.1016/j.bone.2014.04.018
   Singh Mabi L, 2014, Dent Clin North Am, V58, P783, DOI 10.1016/j.cden.2014.07.004
   SUTTON RBO, 1983, J CLIN PERIODONTOL, V10, P317, DOI 10.1111/j.1600 051X.1983.tb01280.x
   TOAGARI A, 1991, JPN J PHARMACOL, V56, P177, DOI 10.1254/jjp.56.177
   van Puijenbroek EP, 2002, PHARMACOEPIDEM DR S, V11, P3, DOI 10.1002/pds.668
   World Health Organization, 2010, JOIN WHO PROGR INT D
   Xavier AFC, 2013, BMC ORAL HEALTH, V13, DOI 10.1186/1472 6831 13 71
NR 44
TC 8
Z9 8
U1 0
U2 20
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114 5916
EI 1179 1942
J9 DRUG SAFETY
JI Drug Saf.
PD DEC
PY 2017
VL 40
IS 12
BP 1249
EP 1258
DI 10.1007/s40264 017 0575 5
PG 10
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA FM9MS
UT WOS:000415595100009
PM 28744845
DA 2025 08 17
ER

PT J
AU Shao, L
   Gou, Y
   Fang, J
   Hu, Y
   Lian, Q
   Zhang, Y
   Wang, Y
   Tian, F
   Zhang, L
AF Shao, L.
   Gou, Y.
   Fang, J.
   Hu, Y.
   Lian, Q.
   Zhang, Y.
   Wang, Y.
   Tian, F.
   Zhang, L.
TI Parathyroid hormone (1 34) ameliorates cartilage degeneration and
   subchondral bone deterioration in collagenase induced osteoarthritis
   model in mice
SO BONE & JOINT RESEARCH
LA English
DT Article
DE Cartilage; Osteoarthritis
ID MESENCHYMAL STEM CELLS; JANUS KINASE/SIGNAL TRANSDUCER; PROTEIN KINASE;
   TERMINAL DIFFERENTIATION; CHONDROCYTES; PROGRESSION; DESTRUCTION;
   MECHANISMS; EXPRESSION; APOPTOSIS
AB Aims
   Parathyroid hormone (PTH) (1 34) exhibits potential in preventing degeneration in both cartilage and subchondral bone in osteoarthritis (OA) development. We assessed the effects of PTH (1 34) at different concentrations on bone and cartilage metabolism in a collagenase induced mouse model of OA and examined whether PTH (1 34) affects the JAK2/STAT3 signalling pathway in this process.
   Methods
   Collagenase induced OA was established in C57131/6 mice. Therapy with PTH (1 34) (10 mu g/kg/day or 40 mu g/kg/day) was initiated immediately after surgery and continued for six weeks. Cartilage pathology was evaluated by gross visual, histology, and immunohistochemical assessments. Cell apoptosis was analyzed by TUNEL staining. Microcomputed tomography (micro CT) was used to evaluate the bone mass and the microarchitecture in subchondral bone.
   Results
   Enhanced matrix catabolism, increased apoptosis of chondrocytes in cartilage, and over expressed JAK2/STAT3 and p JAK2/p STAT3 were observed in cartilage in this model. All of these changes were prevented by PTH (1 34) treatment, with no significant difference between the low dose and high dose groups. Micro CT analysis indicated that bone mineral density (BMD), bone volume/trabecular volume (BV/TV), and trabecular thickness (Tb.Th) levels were significantly lower in the OA group than those in the Sham, PTH 10 mu g, and PTH 40 mu g groups, but these parameters were significantly higher in the PTH 40 mu g group than in the PTH 10 mu g group.
   Conclusion
   Intermittent administration of PTH (1 34) exhibits protective effects on both cartilage and subchondral bone in a dose dependent manner on the latter in a collagenase induced OA mouse model, which may be involved in regulating the JAK2/STAT3 signalling pathway.
C1 [Gou, Y.; Fang, J.; Hu, Y.; Lian, Q.; Zhang, Y.; Wang, Y.; Tian, F.] Hebei Med Univ, Shijiazhuang, Hebei, Peoples R China.
   [Shao, L.; Zhang, L.] Hebei Med Univ, Dept Orthoped Surg, Shijiazhuang, Hebei, Peoples R China.
   [Shao, L.; Fang, J.; Hu, Y.; Lian, Q.; Zhang, Y.; Wang, Y.; Tian, F.] North China Univ Sci & Technol, Med Res Ctr, Hebei Key Lab Organ Fibrosis, Tangshan, Peoples R China.
   [Gou, Y.] Tianjin Univ, Tianjin Hosp, Dept Orthopaed Surg, Tianjin, Peoples R China.
   [Zhang, L.] Emergency Gen Hosp, Dept Orthoped Surg, Beijing, Peoples R China.
C3 Hebei Medical University; Hebei Medical University; North China
   University of Science & Technology; Tianjin University
RP Zhang, L (通讯作者)，Hebei Med Univ, Dept Orthoped Surg, Shijiazhuang, Hebei, Peoples R China.; Zhang, L (通讯作者)，Emergency Gen Hosp, Dept Orthoped Surg, Beijing, Peoples R China.
EM zhliu130@sohu.com
OI , Gou Yu/0000 0002 4110 5736
FU Natural Science Foundation of Hebei Province [H2016209176, H2019209550];
   National Natural Science Foundation of China [NSFC 31671235, 81874029];
   Youth Talent Support Program of Hebei Province [JI 2016 10]; One Hundred
   Innovative Talents Support Fundation of Hebei Province [JJK 2019 14]
FX The study was supported by the Natural Science Foundation of Hebei
   Province (H2016209176; H2019209550), the National Natural Science
   Foundation of China (NSFC 31671235 and 81874029), the Youth Talent
   Support Program of Hebei Province (JI 2016 10), and the One Hundred
   Innovative Talents Support Fundation of Hebei Province (JJK 2019 14). No
   benefits in any form have been received or will be received from a
   commercial party related directly or indirectly to the subject of this
   article.
CR Becher C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 28
   Behera AK, 2004, INFECT IMMUN, V72, P2864, DOI 10.1128/IAI.72.5.2864 2871.2004
   Bei MJ, 2019, MED SCI MONITOR, V25, P2702, DOI 10.12659/MSM.915018
   Bellido M, 2011, OSTEOARTHR CARTILAGE, V19, P1228, DOI 10.1016/j.joca.2011.07.003
   Bellido M, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3103
   Blom AB, 2007, ARTHRITIS RHEUM, V56, P147, DOI 10.1002/art.22337
   Botter SM, 2008, OSTEOARTHR CARTILAGE, V16, P506, DOI 10.1016/j.joca.2007.08.005
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chang JK, 2009, ARTHRITIS RHEUM US, V60, P3049, DOI 10.1002/art.24843
   Chang LH, 2016, TOXICOLOGY, V368, P116, DOI 10.1016/j.tox.2016.09.002
   Chen CH, 2018, J APPL PHYSIOL, V124, P1177, DOI 10.1152/japplphysiol.00871.2017
   Chen QZ, 2012, FOLIA HISTOCHEM CYTO, V50, P137, DOI [10.5603/FHC.2012.0020, 10.2478/18709]
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Dai MW, 2016, OSTEOARTHR CARTILAGE, V24, P1103, DOI 10.1016/j.joca.2016.01.007
   Ebihara G, 2012, BIOMATERIALS, V33, P3846, DOI 10.1016/j.biomaterials.2012.01.056
   Fu Xiaoxia, 2011, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V25, P299
   Gou Y, 2019, BONE, V127, P17, DOI 10.1016/j.bone.2019.02.024
   Gou Y, 2018, MED SCI MONITOR, V24, P2849, DOI 10.12659/MSM.910012
   Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917
   GUNNESSHEY M, 1984, METAB BONE DIS RELAT, V5, P177, DOI 10.1016/0221 8747(84)90026 2
   Harrington EK, 2010, ANAT REC, V293, P225, DOI 10.1002/ar.21072
   Hayashi S, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0828 6
   Henak CR, 2014, BIOMECH MODEL MECHAN, V13, P387, DOI 10.1007/s10237 013 0504 1
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   HOCK JM, 1988, ENDOCRINOLOGY, V122, P2899, DOI 10.1210/endo 122 6 2899
   Huang CY, 2011, RHEUMATOLOGY, V50, P1379, DOI 10.1093/rheumatology/ker134
   Iijima H, 2015, OSTEOARTHR CARTILAGE, V23, P1563, DOI 10.1016/j.joca.2015.04.015
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Komatsu DE, 2009, ENDOCRINOLOGY, V150, P1570, DOI 10.1210/en.2008 0814
   Latourte A, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 209757
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Lin EA, 2010, PROTEIN CELL, V1, P33, DOI 10.1007/s13238 010 0002 5
   Little CB, 2010, OSTEOARTHR CARTILAGE, V18, pS80, DOI 10.1016/j.joca.2010.04.016
   Lu JS, 2018, J BONE MINER RES, V33, P909, DOI 10.1002/jbmr.3388
   Orth P, 2013, OSTEOARTHR CARTILAGE, V21, P614, DOI 10.1016/j.joca.2013.01.008
   Osagie Clouard L, 2019, BONE JOINT RES, V8, P397, DOI 10.1302/2046 3758.88.BJR 2019 0018.R1
   Osagie Clouard L, 2017, BONE JOINT RES, V6, P14, DOI 10.1302/2046 3758.61.BJR 2016 0085.R1
   Portal Núñez S, 2018, BONE JOINT RES, V7, P58, DOI 10.1302/2046 3758.71.BJR 2016 0242.R2
   Qiao ZG, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2673 7
   Rubin MR, 2003, CLIN GERIATR MED, V19, P415, DOI 10.1016/S0749 0690(02)00074 5
   Salvesen GS, 2002, CELL DEATH DIFFER, V9, P3, DOI 10.1038/sj.cdd.4400963
   Sampson ER, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002214
   Sun Y, 2018, BONE JOINT RES, V7, P157, DOI 10.1302/2046 3758.72.BJR 2017 0253
   Tang ZL, 2016, PLAST RECONSTR SURG, V137, p347E, DOI 10.1097/01.prs.0000475780.68585.cc
   ter Huurne M, 2012, ARTHRITIS RHEUM US, V64, P3604, DOI 10.1002/art.34626
   Tsunori K, 2015, IMPLANT DENT, V24, P142, DOI 10.1097/ID.0000000000000228
   van Dalen SCM, 2018, OSTEOARTHR CARTILAGE, V26, P1722, DOI 10.1016/j.joca.2018.08.014
   Van Dalen SCM, 2017, OSTEOARTHR CARTILAGE, V25, P385, DOI 10.1016/j.joca.2016.09.009
   van den Berg WB, 2011, OSTEOARTHR CARTILAGE, V19, P338, DOI 10.1016/j.joca.2011.01.022
   Verma P, 2011, J CELL BIOCHEM, V112, P3507, DOI 10.1002/jcb.23298
   Wu XF, 2018, AM J TRANSL RES, V10, P1143
   Xue HM, 2015, CELL PHYSIOL BIOCHEM, V36, P2456, DOI 10.1159/000430206
   Yan JY, 2014, OSTEOARTHR CARTILAGE, V22, P1869, DOI 10.1016/j.joca.2014.07.013
   Zhang MC, 2015, INT J BIOCHEM CELL B, V67, P101, DOI 10.1016/j.biocel.2015.04.019
NR 55
TC 27
Z9 28
U1 0
U2 8
PU BRITISH EDITORIAL SOC BONE & JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 2046 3758
J9 BONE JOINT RES
JI Bone Jt. Res.
PD OCT
PY 2020
VL 9
IS 10
BP 675
EP 688
DI 10.1302/2046 3758.910.BJR 2020 0018.R1
PG 14
WC Cell & Tissue Engineering; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA OL2ZR
UT WOS:000585211100005
PM 33101657
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sun, HF
   Feng, Y
   Tu, SQ
   Zhou, JW
   Wang, YX
   Wei, JM
   Zhang, S
   Hou, YL
   Shao, YT
   Ai, H
   Chen, Z
AF Sun, Hanfei
   Feng, Yi
   Tu, Shaoqin
   Zhou, Jianwu
   Wang, Yuxuan
   Wei, Jiaming
   Zhang, Sai
   Hou, Yuluan
   Shao, Yiting
   Ai, Hong
   Chen, Zheng
TI Dopamine promotes osteogenic differentiation of PDLSCs by activating
   DRD1 and DRD2 during orthodontic tooth movement via ERK1/2 signaling
   pathway
SO REGENERATIVE THERAPY
LA English
DT Article
DE Orthodontic tooth movement; Bone remodeling; Dopamine; Periodontal
   ligament stem cells; Osteogenesis; ERK1/2 signaling pathway
ID PRIMARY OSTEOBLASTS; PARKINSONS DISEASE; BONE; METABOLISM; OSTEOPENIA;
   INDUCTION; BIOLOGY; FORCES
AB Introduction: Orthodontic tooth movement (OTM) involves complex interactions between mechanical forces and periodontal tissue adaptation, mainly mediated by periodontal ligament cells, including periodontal ligament stem cells (PDLSCs), osteoblasts, and osteoclasts. Dopamine (DA), a neurotransmitter known for its critical role in bone metabolism, is investigated in this study for its potential to enhance osteogenic differentiation in PDLSCs, which are pivotal in OTM. This study examined the potential of DA to facilitate OTM by binding to DA receptors (D1R and D2R) and activating the ERK1/2 signaling pathway. We propose that DA's interaction with these receptors on PDLSCs could enhance osteogenic differentiation, thereby accelerating bone remodeling and reducing the duration of orthodontic treatments, which offering a novel approach to improve clinical outcomes in orthodontic care. Methods: This study utilized a rat OTM model, micro CT, histological analyses, and in vitro assays to investigate dopamine's effect on osteogenesis. PDLSCs were cultured and treated with DA, and cytotoxicity, osteogenic differentiation, gene and protein expression assessed. Results: Dopamine administration signi ficantly increased trabecular bone density and osteogenic marker expression in an OTM rat model. In vitro , DA at 10 nM optimally promoted human PDLSCs osteogenesis without affecting proliferation. Blocking DA receptors or inhibiting the ERK1/2 pathway attenuated these effects, underscoring the importance of dopaminergic signaling in tension induced osteogenesis during OTM. Conclusion: Taken together, our study reveals that local dopamine administration at a concentration of 10 nM not only enhances tension induced osteogenesis in vivo but also signi ficantly promotes osteogenic differentiation of PDLSCs in vitro through D1 and D2 receptor mediated ERK1/2 signaling pathway activation. (c) 2024, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/ 4.0/).
C1 [Sun, Hanfei; Feng, Yi; Tu, Shaoqin; Zhou, Jianwu; Wang, Yuxuan; Wei, Jiaming; Zhang, Sai; Hou, Yuluan; Shao, Yiting; Ai, Hong; Chen, Zheng] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Stomatol, Guangzhou 510630, Peoples R China.
C3 Sun Yat Sen University
RP Ai, H; Chen, Z (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 3, Dept Stomatol, Guangzhou 510630, Peoples R China.
EM aihong@mail.sysu.edu.cn; chenzh68@mail.sysu.edu.cn
RI Shao, Yiting/KSM 9514 2024; jianwu, Zhou/GQQ 1113 2022
OI tu, shaoqin/0000 0003 4391 8025; 
FU Fundamental Research Funds for the Central Universities; Sun Yat sen
   University [23qnpy143]; China Post doctoral Science Foundation
   [2021M703690]
FX This work is supported by the National Natural Science Foundation of
   China (No. 82271021), the GuangDong Basic and Applied Basic Research
   Foundation, China (No. 2021A1515111099), the Science and Technology
   Projects in Guangzhou, China (No. 2024A03J0098), the Fundamental
   Research Funds for the Central Universities, Sun Yat sen University
   (23qnpy143), and the Project funded by China Post doctoral Science
   Foundation (No. 2021M703690).r Fundamental Research Funds for the
   Central Universities, Sun Yat sen University (23qnpy143) , and the
   Project funded by China Post doctoral Science Foundation (No.
   2021M703690) .
CR Alikhani M, 2015, ORTHOD CRANIOFAC RES, V18, P8, DOI 10.1111/ocr.12090
   Beaulieu JM, 2015, BRIT J PHARMACOL, V172, P1, DOI 10.1111/bph.12906
   Bliziotes M, 2000, BONE, V26, P15, DOI 10.1016/S8756 3282(99)00232 X
   Bystrytska M, 2020, J OSTEOPOROS, V2020, DOI 10.1155/2020/5027973
   Cha Y, 2015, J ENDODONT, V41, P1462, DOI 10.1016/j.joen.2015.04.010
   Cheong PU, 2018, INT J CLIN EXP MED, V11, P1765
   Chiang TI, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70262 0
   Choi EY, 1999, BIOCHEM BIOPH RES CO, V256, P33, DOI 10.1006/bbrc.1999.0286
   Comi C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020242
   Dab S, 2019, ORTHOD CRANIOFAC RES, V22, P61, DOI 10.1111/ocr.12272
   Glavaski Joksimovic A, 2009, CELL TRANSPLANT, V18, P801, DOI 10.3727/096368909X470801
   Hanami K, 2013, BONE, V56, P1, DOI 10.1016/j.bone.2013.04.019
   Handa K, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50336 4
   Huang HM, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6531216
   Kamal AT, 2019, INT ORTHOD, V17, P193, DOI 10.1016/j.ortho.2019.03.006
   Kim JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081803
   Kunimatsu T, 2010, REGUL TOXICOL PHARM, V58, P360, DOI 10.1016/j.yrtph.2010.08.001
   Lee DJ, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.20
   Li Q, 2014, FRONT BIOSCI LANDMRK, V19, P1411, DOI 10.2741/4291
   Li YN, 2018, KAOHSIUNG J MED SCI, V34, P207, DOI 10.1016/j.kjms.2018.01.007
   Liu XB, 2022, AM J ORTHOD DENTOFAC, V162, P881, DOI 10.1016/j.ajodo.2021.07.025
   Liu Y, 2021, BLOOD, V138, P2051, DOI 10.1182/blood.2020010419
   Lu WX, 2021, J PERIODONTAL RES, V56, P885, DOI 10.1111/jre.12885
   Magistrelli L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073781
   Masella RS, 2006, AM J ORTHOD DENTOFAC, V129, P458, DOI 10.1016/j.ajodo.2005.12.013
   Motyl KJ, 2017, BONE, V103, P168, DOI 10.1016/j.bone.2017.07.008
   Mühlenfeld N, 2021, EUR J TRAUMA EMERG S, V47, P573, DOI 10.1007/s00068 019 01240 z
   Noble E P, 2000, Pharmacogenomics, V1, P309, DOI 10.1517/14622416.1.3.309
   Oortgiesen DAW, 2014, J TISSUE ENG REGEN M, V8, P202, DOI 10.1002/term.1514
   Park OJ, 2010, J BIOL CHEM, V285, P3568, DOI 10.1074/jbc.M109.055053
   Roof AK, 2018, ENDOCRINOLOGY, V159, P2421, DOI 10.1210/en.2017 03135
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320 344.2004
   Takeno A, 2016, AM J CASE REP, V17, P160, DOI 10.12659/AJCR.894712
   Trubiani O, 2019, STEM CELLS DEV, V28, P995, DOI 10.1089/scd.2019.0025
   Ullah I, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150025
   van den Bos F, 2013, AGE AGEING, V42, P156, DOI 10.1093/ageing/afs161
   Vâta LI, 2020, INT J MED DENT, V24, P45
   Wang CH, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1265 2
   Wang Y, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180448
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Zaniboni E, 2019, CLIN ORAL INVEST, V23, P4083, DOI 10.1007/s00784 019 02845 9
   Zhang DW, 2014, MAT SCI ENG C MATER, V42, P70, DOI 10.1016/j.msec.2014.04.042
   Zhang MJ, 2022, J WORLD FED ORTHOD, V11, P139, DOI 10.1016/j.ejwf.2022.08.003
   Zhao Y, 2013, BONE, V52, P498, DOI 10.1016/j.bone.2012.09.013
   Zhou YL, 2019, J CELL BIOCHEM, V120, P15952, DOI 10.1002/jcb.28872
   Zhu J, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00453 0
NR 46
TC 7
Z9 7
U1 5
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD DEC
PY 2024
VL 27
BP 268
EP 278
DI 10.1016/j.reth.2024.03.025
EA APR 2024
PG 11
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA RJ3U0
UT WOS:001227263900001
PM 38617443
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hu, ST
   Hu, YY
   Tan, ZL
   Zhou, CY
   Zhang, C
   Yin, S
   Chen, XJ
   Chen, K
   Wang, L
   Chen, L
AF Hu, Sitao
   Hu, Yangyang
   Tan, Zenglin
   Zhou, Chengyu
   Zhang, Cheng
   Yin, Sheng
   Chen, Xiaojun
   Chen, Kai
   Wang, Lu
   Chen, Lei
TI Repurposing the multiple sclerosis drug Siponimod for osteoporosis
   treatment
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Siponimod; Osteoclast; Osteoporosis; MAPK
ID OSTEOCLAST DIFFERENTIATION; SPHINGOSINE 1 PHOSPHATE; LYSOPHOSPHATIDIC
   ACID; SPHINGOSINE 1 PHOSPHATE; RECEPTOR
AB Osteoporosis is the most common bone disorder, in which an imbalance between osteoclastic bone resorption and osteoblastic bone formation disrupts bone homeostasis. Osteoporosis management using anti osteoclastic agents is a promising strategy; however, this remains an unmet need. Sphingosine 1 phosphate (S1P) and its receptors (S1PRs) are essential for maintaining bone homeostasis. Here, we identified that Siponimod, a Food and Drug Administration approved S1PR antagonist for the treatment of multiple sclerosis, shows promising therapeutic effects against osteoporosis by inhibiting osteoclast formation and function. We found that Siponimod inhibited osteoclast formation in a dose dependent manner without causing cytotoxicity. Podosome belt staining and bone resorption assays indicated that Siponimod treatment impaired osteoclast function. Western blot and qPCR assays demonstrated that Siponimod suppressed the expression of osteoclast specific markers, including C Fos, Nftac1, and Ctsk. Mechanistically, we validated that Siponimod downregulated receptor activator of nuclear factor kappa B ligand (RANKL) induced Mitogen activated protein kinases (MAPKs) and nuclear factor kappa B (NF kappa B) signaling pathways during osteoclastogenesis. Moreover, in a preclinical mouse model, Siponimod prevented ovariectomy induced bone loss by suppressing osteoclast activity in vivo. Collectively, these results suggest that Siponimod could serve as an alternative therapeutic agent for the treatment of osteoporosis.
C1 [Hu, Sitao; Hu, Yangyang; Tan, Zenglin; Zhou, Chengyu; Zhang, Cheng; Wang, Lu; Chen, Lei] Wenzhou Med Univ, Affiliated Hosp 1, Dept Orthoped, Wenzhou, Peoples R China.
   [Yin, Sheng; Chen, Xiaojun; Chen, Kai] Univ Western Australia, Sch Mol Sci, Perth, Australia.
   [Yin, Sheng] Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China.
C3 Wenzhou Medical University; University of Western Australia; Central
   South University
RP Wang, L; Chen, L (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 1, Dept Orthoped, Wenzhou, Peoples R China.
EM wanglu@wmu.edu.cn; chenlei689595@wmu.edu.cn
RI Lu, Wang/JVO 0416 2024; Zhou, Chengyu/LKK 4482 2024
OI Zhang, Cheng/0009 0003 0167 5296
FU Natural Science Foundation of Zhejiang Province [LGF22H060014]; Wenzhou
   Science & Technology Bureau [Y2020413]; National Natural Science
   Foundation of China [82002279]
FX This study was supported by Natural Science Foundation of Zhejiang
   Province (LGF22H060014) , Wenzhou Science & Technology Bureau (Y2020413)
   , and National Natural Science Foundation of China (82002279) .
CR Aarthi JJ, 2011, J DENT RES, V90, P841, DOI 10.1177/0022034510389178
   Behrangi N, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2204509119
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Duru EA, 2012, J SURG RES, V177, pE75, DOI 10.1016/j.jss.2011.12.012
   Dziak R, 2003, PROSTAG LEUKOTR ESS, V68, P239, DOI 10.1016/S0952 3278(02)00277 6
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Everts V, 2006, J BONE MINER RES, V21, P1399, DOI 10.1359/JBMR.060614
   Gergely P, 2012, BRIT J PHARMACOL, V167, P1035, DOI 10.1111/j.1476 5381.2012.02061.x
   Grewe JM, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00205 0
   Grey A, 2002, ENDOCRINOLOGY, V143, P4755, DOI 10.1210/en.2002 220347
   Hearn AP, 2010, MULT SCLER J, V16, P1031, DOI 10.1177/1352458510368985
   Hsu LC, 2019, CELLS BASEL, V8, DOI 10.3390/cells8010017
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Maraka S, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h3783
   McGinley MP, 2021, LANCET, V398, P1184, DOI 10.1016/S0140 6736(21)00244 0
   Nelson HD, 2002, ANN INTERN MED, V137, P529, DOI 10.7326/0003 4819 137 6 200209170 00015
   PIPER K, 1992, ANAT EMBRYOL, V186, P291
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Sartawi Z, 2020, INT J PHARMACEUT, V590, DOI 10.1016/j.ijpharm.2020.119956
   Sartawi Z, 2020, EUR J PHARMACOL, V882, DOI 10.1016/j.ejphar.2020.173262
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Valis M, 2023, DRUGS R&D, V23, P331, DOI 10.1007/s40268 023 00434 6
   Veis DJ, 2023, ANNU REV PATHOL MECH, V18, P257, DOI 10.1146/annurev pathmechdis 031521 040919
   Yang CC, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.569802
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Yu H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156303
   Yu H, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944 015 0057 7
NR 35
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JUL 5
PY 2024
VL 974
AR 176630
DI 10.1016/j.ejphar.2024.176630
EA MAY 2024
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA YA7X4
UT WOS:001265840300001
PM 38692426
OA hybrid
DA 2025 08 17
ER

PT J
AU Delion, M
   Braux, J
   Jourdain, ML
   Guillaume, C
   Bour, C
   Gangloff, S
   Le Pimpec Barthes, F
   Sermet Gaudelus, I
   Jacquot, J
   Velard, F
AF Delion, Martial
   Braux, Julien
   Jourdain, Marie Laure
   Guillaume, Christine
   Bour, Camille
   Gangloff, Sophie
   Le Pimpec Barthes, Francoise
   Sermet Gaudelus, Isabelle
   Jacquot, Jacky
   Velard, Frederic
TI Overexpression of RANKL in osteoblasts: a possible mechanism of
   susceptibility to bone disease in cystic fibrosis
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE cystic fibrosis; bone disease; osteoblasts; RANKL; OPG; F508del CFTR;
   CFTR correctors
ID TRANSMEMBRANE CONDUCTANCE REGULATOR; NF KAPPA B; MINERAL DENSITY;
   PSEUDOMONAS AERUGINOSA; OPG/RANKL/RANK SYSTEM; RHEUMATOID ARTHRITIS;
   F508DEL MUTATION; CFTR; ACTIVATION; CELLS
AB Bone fragility and loss are a significant cause of morbidity in patients with cystic fibrosis (CF), and the lack of effective therapeutic options means that treatment is more often palliative rather than curative. A deeper understanding of the pathogenesis of CF related bone disease (CFBD) is necessary to develop new therapies. Defective CF transmembrane conductance regulator (CFTR) protein and chronic inflammation in bone are important components of the CFBD development. The receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) drive the regulation of bone turnover. To investigate their roles in CFBD, we evaluated the involvement of defective CFTR in their production level in CF primary human osteoblasts with and without inflammatory stimulation, in the presence or not of pharmacological correctors of the CFTR. No major difference in cell ultrastructure was noted between cultured CF and non CF osteoblasts, but a delayed bone matrix mineralization was observed in CF osteoblasts. Strikingly, resting CF osteoblasts exhibited strong production of RANKL protein, which was highly localized at the cell membrane and was enhanced in TNF (TNF ) or IL 17 stimulated conditions. Under TNF stimulation, a defective response in OPG production was observed in CF osteoblasts in contrast to the elevated OPG production of non CF osteoblasts, leading to an elevated RANKL to OPG protein ratio in CF osteoblasts. Pharmacological inhibition of CFTR chloride channel conductance in non CF osteoblasts replicated both the decreased OPG production and the enhanced RANKL to OPG ratio. Interestingly, using CFTR correctors such as C18, we significantly reduced the production of RANKL by CF osteoblasts, in both resting and TNF stimulated conditions. In conclusion, the overexpression of RANKL and high membranous RANKL localization in osteoblasts are related to defective CFTR, and may worsen bone resorption, leading to bone loss in patients with CF. Targeting osteoblasts with CFTR correctors may represent an effective strategy to treat CFBD. Copyright (c) 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Delion, Martial; Braux, Julien; Jourdain, Marie Laure; Guillaume, Christine; Bour, Camille; Gangloff, Sophie; Jacquot, Jacky; Velard, Frederic] Univ Reims, SFR CAP Sante FED 4231, Biomat & Inflammat Site Osseux, EA 4691, 1 Ave Marechal Juin, Reims, France.
   [Le Pimpec Barthes, Francoise] Hop Europeen Georges Pompidou, Dept Chirurg Thorac, 20 40 Rue Leblanc, Paris, France.
   [Sermet Gaudelus, Isabelle] Univ Paris 04, Inserm U1551, Hop Necker, Unite Pneumopediat Allergol, Paris, France.
C3 Universite de Reims Champagne Ardenne; Assistance Publique Hopitaux
   Paris (APHP); Universite Paris Cite; Hopital Universitaire Europeen
   Georges Pompidou   APHP; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Sorbonne Universite; Assistance Publique
   Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire
   Necker Enfants Malades   APHP
RP Jacquot, J; Velard, F (通讯作者)，Univ Reims, SFR CAP Sante FED 4231, Biomat & Inflammat Site Osseux BIOS, EA 4691, 1 Ave Marechal Juin, F 51095 Reims, France.
EM jacky.jacquot@inserm.fr; frederic.velard@univ reims.fr
RI ; Braux, Julien/HTP 1983 2023; Jacquot, Jacky/L 9060 2018; Velard,
   Frédéric/AAG 6783 2020; Le+Pimpec Barthes, Francoise/ABD 1300 2021
OI VELARD, Frederic/0000 0002 4826 2160; Braux, Julien/0000 0002 1927 9801;
   Sermet Gaudelus, Isabelle/0000 0001 5537 9482; gangloff,
   sophie/0000 0003 2651 9372; BOUR, camille/0000 0002 6587 6201
CR Ambroszkiewicz J, 2013, ADV MED SCI POLAND, V58, P338, DOI 10.2478/ams 2013 0011
   [Anonymous], JOURNAL OF OSTEOPORO, DOI DOI 10.4061/2011/926045
   Aris RM, 2005, J CLIN ENDOCR METAB, V90, P1888, DOI 10.1210/jc.2004 1629
   Aris RM, 1998, ANN INTERN MED, V128, P186, DOI 10.7326/0003 4819 128 3 199802010 00004
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baudouin Legros M, 2012, INT J BIOCHEM CELL B, V44, P1009, DOI 10.1016/j.biocel.2012.03.010
   Birault V, 2013, CURR OPIN CHEM BIOL, V17, P353, DOI 10.1016/j.cbpa.2013.04.020
   Bitam Sara, 2015, F1000Res, V4, P218, DOI 10.12688/f1000research.6683.2
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyle MP, 2006, CURR OPIN PULM MED, V12, P453, DOI 10.1097/01.mcp.0000245708.59138.a4
   Boyle MP, 2013, LANCET RESP MED, V1, P158, DOI 10.1016/S2213 2600(12)70057 7
   Buntain HM, 2004, THORAX, V59, P149, DOI 10.1136/thorax.2003.006726
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Conwell LS, 2014, COCHRANE DB SYST REV, V3
   Dif F, 2004, BONE, V35, P595, DOI 10.1016/j.bone.2004.05.021
   DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865
   Eckford PDW, 2014, CHEM BIOL, V21, P666, DOI 10.1016/j.chembiol.2014.02.021
   Haston CK, 2008, AM J RESP CRIT CARE, V177, P309, DOI 10.1164/rccm.200705 659OC
   Haworth CS, 2010, CURR OPIN PULM MED, V16, P616, DOI 10.1097/MCP.0b013e32833e2e94
   Haworth CS, 2004, THORAX, V59, P613, DOI 10.1136/thx.2003.012047
   Jacquot J, 2016, OSTEOPOROSIS INT, V27, P1401, DOI 10.1007/s00198 015 3343 3
   Javier RM, 2011, JOINT BONE SPINE, V78, P445, DOI 10.1016/j.jbspin.2010.11.015
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim KR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122764
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Le Henaff C, 2014, AM J PATHOL, V184, P1132, DOI 10.1016/j.ajpath.2013.12.027
   Le Henaff C, 2012, AM J PATHOL, V180, P2068, DOI 10.1016/j.ajpath.2012.01.039
   Le Heron L, 2010, J CYST FIBROS, V9, P69, DOI 10.1016/j.jcf.2009.11.005
   Liu XH, 2006, ANN NY ACAD SCI, V1068, P225, DOI 10.1196/annals.1346.047
   Mori G, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/108451
   Napimoga MH, 2013, INT IMMUNOPHARMACOL, V16, P131, DOI 10.1016/j.intimp.2013.03.035
   Ousingsawat J, 2015, J BIOL CHEM, V290, P6270, DOI 10.1074/jbc.M114.602979
   Paccou J, 2010, CALCIFIED TISSUE INT, V86, P1, DOI 10.1007/s00223 009 9316 9
   Pashuck TD, 2009, PEDIATR RES, V65, P311, DOI 10.1203/PDR.0b013e3181961e80
   Plant BJ, 2013, LANCET RESP MED, V1, P164, DOI 10.1016/S2213 2600(13)70025 0
   Putman MS, 2016, OSTEOPOROSIS INT, V27, P2497, DOI 10.1007/s00198 016 3557 z
   Putman MS, 2014, J CLIN ENDOCR METAB, V99, P3399, DOI 10.1210/jc.2014 1982
   Riordan JR, 2008, ANNU REV BIOCHEM, V77, P701, DOI 10.1146/annurev.biochem.75.103004.142532
   RIORDAN JR, 1989, SCIENCE, V245, P1066
   Sermet Gaudelus I, 2007, AM J RESP CRIT CARE, V175, P951, DOI 10.1164/rccm.200606 776OC
   Sermet Gaudelus I, 2011, J CYST FIBROS, V10, pS16, DOI 10.1016/S1569 1993(11)60004 0
   Sermet Gaudelus I, 2009, PAEDIATR RESPIR REV, V10, P134, DOI 10.1016/j.prrv.2009.05.001
   Shead EF, 2007, THORAX, V62, P650, DOI 10.1136/thx.2006.075887
   Shead EF, 2006, AM J RESP CRIT CARE, V174, P306, DOI 10.1164/rccm.200512 1943OC
   Shead EF, 2010, J CYST FIBROS, V9, P93, DOI 10.1016/j.jcf.2009.11.007
   Shmarina G, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 19
   Stalvey MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080098
   Stalvey MS, 2013, CURR OPIN ENDOCRINOL, V20, P547, DOI 10.1097/01.med.0000436191.87727.ec
   Stoltz DA, 2015, NEW ENGL J MED, V372, P351, DOI 10.1056/NEJMra1300109
   Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844
   Tabary O, 1999, AM J PATHOL, V155, P473, DOI 10.1016/S0002 9440(10)65143 7
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Tiringer K, 2013, AM J RESP CRIT CARE, V187, P621, DOI 10.1164/rccm.201206 1150OC
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Van Goor F, 2009, P NATL ACAD SCI USA, V106, P18825, DOI 10.1073/pnas.0904709106
   Velard F, 2015, EUR RESPIR J, V45, P845, DOI 10.1183/09031936.00174014
   Velard F, 2014, AM J RESP CRIT CARE, V189, P746, DOI 10.1164/rccm.201312 2144LE
   Verkman Alan S, 2002, Methods Mol Med, V70, P187
   Vij N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004664
   Wainwright CE, 2015, NEW ENGL J MED, V373, P220, DOI 10.1056/NEJMoa1409547
   Wei S, 2008, PATHOL RES PRACT, V204, P695, DOI 10.1016/j.prp.2008.07.002
   Xie C, 2009, AM J PATHOL, V175, P772, DOI 10.2353/ajpath.2009.081099
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 68
TC 21
Z9 22
U1 0
U2 8
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3417
EI 1096 9896
J9 J PATHOL
JI J. Pathol.
PD SEP
PY 2016
VL 240
IS 1
BP 50
EP 60
DI 10.1002/path.4753
PG 11
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA DW4EO
UT WOS:000383595500005
PM 27235726
DA 2025 08 17
ER

PT J
AU Fromigué, O
   Brun, J
   Marty, C
   Da Nascimento, S
   Sonnet, P
   Marie, PJ
AF Fromigue, Olivia
   Brun, Julia
   Marty, Caroline
   Da Nascimento, Sophie
   Sonnet, Pascal
   Marie, Pierre J.
TI Peptide based activation of alpha5 integrin for promoting osteogenesis
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE INTEGRIN ALPHA5; SIGNALING; OSTEOBLAST; BONE FORMATION
ID OSTEOBLAST DIFFERENTIATION; EXTRACELLULAR MATRIX; LIGAND BINDING;
   CELL SURVIVAL; STEM CELLS; FIBRONECTIN; APOPTOSIS; MECHANISMS; BCL 2;
   ALPHA(5)BETA(1)
AB Promoting osteoblastogenesis remains a major challenge in disorders characterized by defective bone formation. We recently showed that the alpha 5 integrin subunit (ITGA5) is critically involved in human mesenchymal cell osteoblast differentiation. In this study, we determined the potential of pharmacological ITGA5 activation by a synthetic cyclic peptide (GA CRRETAWAC GA) on murine osteoblast differentiation and function in vitro and bone formation in vivo. Peptide mediated activation of ITGA5 in murine C3H10T1/2 mesenchymal cells resulted in the generation of the integrin mediated cell signals FAK and ERK1/2 MAPKs. In vitro, peptide based activation of ITGA5 protected from cell apoptosis but did not affect cell adhesion or replication, while it enhanced the expression of the osteoblast marker genes Runx2 and type I collagen and increased extracellular matrix (ECM) mineralization as also found with bone morphogenetic protein 2 (BMP2), a standard bone anabolic factor. When injected on adult mouse cranial bone for 3 weeks, the peptide mediated activation of ITGA5 increased bone thickness by twofold, an effect also induced by BMP2. Histomorphometric analysis showed that this anabolic effect resulted from decreased cell apoptosis and increased bone forming surfaces and bone formation rate (BFR). We conclude that pharmacological activation of ITGA5 in mesenchymal cells is effective in promoting de novo bone formation as a result of increased osteoprogenitor cell differentiation into osteoblasts and increased cell protection from apoptosis. This peptide based approach could be used therapeutically to promote the osteogenic capacity of osteoblast progenitor cells and to induce de novo bone formation in conditions where osteoblastogenesis is compromised. J. Cell. Biochem. 113: 30293038, 2012. (C) 2012 Wiley Periodicals, Inc.
C1 [Fromigue, Olivia; Brun, Julia; Marty, Caroline; Marie, Pierre J.] INSERM, Lab Osteoblast Biol & Pathol, UMR 606, F 75475 Paris, France.
   [Fromigue, Olivia; Brun, Julia; Marty, Caroline; Marie, Pierre J.] Univ Paris Diderot, UMR 606, F 75475 Paris, France.
   [Da Nascimento, Sophie; Sonnet, Pascal] Univ Picardie, UFR Pharm, Equipe Thera, Lab Glucides,UMR CNRS 6219, F 80037 Amiens, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite; Centre National de la Recherche Scientifique
   (CNRS); Universite de Picardie Jules Verne (UPJV)
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, U606, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@inserm.fr
RI Fromigue, Olivia/B 8225 2013; sonnet, pascal/AAM 3308 2021
OI Fromigue, Olivia/0000 0002 3050 6155; 
FU Fondation de l'Avenir pour la Recherche Appliquee, Paris, France
   [ET9 521]; DIM Stem Pole Region Ile de France
FX Grant sponsor: Fondation de l'Avenir pour la Recherche Appliquee, Paris,
   France; Grant number: ET9 521; Grant sponsor: The DIM Stem Pole Region
   Ile de France (2009).
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<73::AID JCB11>3.0.CO;2 L
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Cao ZJ, 1998, J BIOL CHEM, V273, P31670, DOI 10.1074/jbc.273.48.31670
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Dufour C, 2008, BONE, V42, P1032, DOI 10.1016/j.bone.2008.02.009
   Dufour C, 2008, AM J PHYSIOL ENDOC M, V294, pE794, DOI 10.1152/ajpendo.00791.2007
   Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955 0674(97)80123 8
   Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693
   Hamidouche Z, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 44
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959 437X(01)00260 X
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kaabeche K, 2005, J CELL SCI, V118, P1223, DOI 10.1242/jcs.01679
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kassem M, 2004, CLONING STEM CELLS, V6, P369, DOI 10.1089/clo.2004.6.369
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marie PJ, 2009, OSTEOPOROSIS INT, V20, P1037, DOI 10.1007/s00198 009 0856 7
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Marie PJ, 2011, J CLIN ENDOCR METAB, V96, P600, DOI 10.1210/jc.2010 2113
   Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200
   MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953
   Mould AP, 2009, BIOCHEM J, V424, P179, DOI 10.1042/BJ20090992
   Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200
   Mould AP, 1998, J BIOL CHEM, V273, P25664, DOI 10.1074/jbc.273.40.25664
   Moursi AM, 1997, J CELL SCI, V110, P2187
   Moursi AM, 1996, J CELL SCI, V109, P1369
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Prockop DJ, 2009, MOL THER, V17, P939, DOI 10.1038/mt.2009.62
   Pulai JI, 2002, ARTHRITIS RHEUM, V46, P1528, DOI 10.1002/art.10334
   Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092 8674(94)90209 7
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Srouji S, 2012, HUM GENE THER, V23, P167, DOI 10.1089/hum.2011.059
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161
NR 48
TC 42
Z9 44
U1 1
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP
PY 2012
VL 113
IS 9
BP 3029
EP 3038
DI 10.1002/jcb.24181
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 972QQ
UT WOS:000306292700024
PM 22566152
DA 2025 08 17
ER

PT J
AU Jang, HY
   Kim, JM
   Kim, JS
   Kim, BS
   Lee, YR
   Bae, JS
AF Jang, Hye Yeon
   Kim, Jeong Mi
   Kim, Jong Suk
   Kim, Byeong Soo
   Lee, Young Rae
   Bae, Jun Sang
TI Protaetia brevitarsis Extract Attenuates RANKL Induced
   Osteoclastogenesis by Inhibiting the JNK/NF ?B/PLC?<SUP>2</SUP>
   Signaling Pathway
SO NUTRIENTS
LA English
DT Article
DE Protaetia brevitarsis; edible insect; osteoclast differentiation; JNK;
   NF & kappa;B; PLC & gamma;2
ID NF KAPPA B; RECEPTOR ACTIVATOR; NUCLEAR FACTOR; FATTY ACIDS;
   BONE RESORPTION; UP REGULATION; C FOS; DIFFERENTIATION; EXPRESSION;
   LIGAND
AB Protaetia brevitarsis (PB) derived bioactive substances have been used as food and medicine in many Asian countries because of their antioxidant, antidiabetic, anti cancer, and hepatoprotective properties. However, the effect of PB extracts (PBE) on osteoclast differentiation is unclear. In this study, we investigated the effect of PBE on RANKL induced osteoclastogenesis in mouse bone marrow derived macrophages (BMMs). To investigate the cytotoxicity of PBE, the viability of BMMs was confirmed via MTT assay. Tartrate resistant acid phosphatase (TRAP) staining and pit assays were performed to confirm the inhibitory effect of PBE on osteoclast differentiation and bone resorption. The expression levels of osteoclast differentiation related genes and proteins were evaluated using quantitative real time PCR and Western blotting. PBE attenuated osteoclastogenesis in BMMs in TRAP and pit assays without cytotoxicity. The expression levels of osteoclast marker genes and proteins induced by RANKL were decreased after PBE treatment. PBE suppressed osteoclastogenesis by inhibiting the RANKL induced activated JNK/NF ?B/PLC?2 signaling pathway and the expression of NFATc1 and c Fos. Collectively, these results suggest that PBE could be a potential therapeutic strategy or functional product for osteoclast related bone disease.
C1 [Jang, Hye Yeon] Korea Res Inst Chem Technol KRICT, Infect Dis Therapeut Res Ctr, Daejeon 34114, South Korea.
   [Kim, Jeong Mi; Kim, Jong Suk] Jeonbuk Natl Univ, Med Sch, Dept Biochem, 20 Geonji Ro, Jeonju 54907, South Korea.
   [Kim, Jong Suk] Jeonbuk Natl Univ, BK21FOUR Century Med Sci Creat Human Resource Dev, 567 Baekje Daero, Jeonju 54896, South Korea.
   [Kim, Byeong Soo] Kongju Natl Univ, Dept Compan & Lab Anim Sci, Yesan 32439, South Korea.
   [Lee, Young Rae] Wonkwang Univ, Inst Biomat Implant, Sch Dent, Dept Oral Biochem, 460, Iksan 54538, South Korea.
   [Bae, Jun Sang] Wonkwang Univ, Coll Korean Med, Dept Pathol, 460, Iksan 54538, South Korea.
C3 Korea Research Institute of Chemical Technology (KRICT); Jeonbuk
   National University; Jeonbuk National University; Kongju National
   University; Wonkwang University; Wonkwang University
RP Lee, YR (通讯作者)，Wonkwang Univ, Inst Biomat Implant, Sch Dent, Dept Oral Biochem, 460, Iksan 54538, South Korea.; Bae, JS (通讯作者)，Wonkwang Univ, Coll Korean Med, Dept Pathol, 460, Iksan 54538, South Korea.
EM janghyeyeon@naver.com; wjdal4219@daum.net; jsukim@jbnu.ac.kr;
   bskim@kongju.ac.kr; mindyr@wku.ac.kr; jsbae78@wku.ac.kr
RI Kim, Jae Hong/B 2530 2009
FU Wonkwang University
FX This paper was supported by Wonkwang University in 2021.
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Aguilar Toalá JE, 2022, INSECTS, V13, DOI 10.3390/insects13111007
   Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535 7163.MCT 08 0530
   Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Barasch A, 2013, Tex Dent J, V130, P299, DOI 10.1177/0022034510397196
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Calder PC, 2015, JPEN PARENTER ENTER, V39, p18S, DOI 10.1177/0148607115595980
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Cardoso GBC, 2017, EXP BIOL MED, V242, P1765, DOI 10.1177/1535370217731104
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Choi RY, 2023, BIOMED PHARMACOTHER, V165, DOI 10.1016/j.biopha.2023.115112
   Deng W, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1015693
   Dong MM, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829741
   Fonolla Joya J, 2016, J AM COLL NUTR, V35, P529, DOI 10.1080/07315724.2014.1003114
   Fontana A, 2013, BBA PROTEINS PROTEOM, V1834, P1125, DOI 10.1016/j.bbapap.2013.02.041
   Ganguly K, 2020, MOLECULES, V25, DOI 10.3390/molecules25246056
   Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140 6736(96)07308 4
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Hanley DA, 2017, AM J MED, V130, DOI 10.1016/j.amjmed.2017.03.002
   Hedvicakova V, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11030438
   Hirose Y, 2013, J NAT PROD, V76, P554, DOI 10.1021/np300713c
   Huh JE, 2014, J NAT PROD, V77, P2423, DOI 10.1021/np500417d
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Jang HY, 2021, ARCH ORAL BIOL, V122, DOI 10.1016/j.archoralbio.2020.105029
   Jeong DH, 2020, J NAT PROD, V83, P1174, DOI 10.1021/acs.jnatprod.9b01212
   Kang M, 2012, ENTOMOL RES, V42, P111, DOI 10.1111/j.1748 5967.2012.00444.x
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee W, 2016, SCI REP UK, V6, DOI 10.1038/srep21956
   Li SS, 2014, J CLIN INVEST, V124, P5057, DOI 10.1172/JCI71882
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756 3282(95)00180 L
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Nam HH, 2022, FOOD SCI NUTR, V10, P3969, DOI 10.1002/fsn3.2992
   Narod SA, 2011, NAT REV CLIN ONCOL, V8, P669, DOI 10.1038/nrclinonc.2011.110
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park JH, 2017, MOL CELLS, V40, P706
   Park YM, 2021, EUR REV MED PHARMACO, V25, P7508, DOI 10.26355/eurrev_202112_27450
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Shi LP, 2018, MOL MED REP, V17, P7947, DOI 10.3892/mmr.2018.8835
   Shi YN, 2014, BIOORG MED CHEM LETT, V24, P5164, DOI 10.1016/j.bmcl.2014.09.083
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Trouvin AP, 2010, CLIN INTERV AGING, V5, P345, DOI 10.2147/CIA.S10153
   Van Itterbeeck J, 2012, J ETHNOBIOL ETHNOMED, V8, DOI 10.1186/1746 4269 8 3
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yeo Hyelim, 2013, Prev Nutr Food Sci, V18, P150, DOI 10.3746/pnf.2013.18.2.150
   Yoo YC, 2007, ARCH PHARM RES, V30, P361, DOI 10.1007/BF02977619
NR 57
TC 3
Z9 3
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD JUL
PY 2023
VL 15
IS 14
AR 3193
DI 10.3390/nu15143193
PG 16
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA N8VC5
UT WOS:001039715000001
PM 37513611
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Scotece, M
   Gómez, R
   Conde, J
   Lopez, V
   Gómez Reino, JJ
   Lago, F
   Smith, AB
   Gualillo, O
AF Scotece, M.
   Gomez, R.
   Conde, J.
   Lopez, V.
   Gomez Reino, J. J.
   Lago, F.
   Smith, A. B., III
   Gualillo, O.
TI Oleocanthal Inhibits Proliferation and MIP 1α Expression in Human
   Multiple Myeloma Cells
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Apoptosis; chemokines; multiple myeloma; natural drugs; nutraceuticals;
   oleocanthal; proliferation
ID FACTOR KAPPA B; MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA; CONSTITUTIVE
   ACTIVATION; BONE MARROW; KINASE; APOPTOSIS; PHENOLS
AB Multiple myeloma (MM) is a plasma cell malignancy that causes devastating bone destruction by activating osteoclasts in the bone marrow milieu. MM is the second of all hematological malignancies. Thus, the search for new pharmacological weapons is under intensive investigation being MM a critically important public health goal. Recently, it has been demonstrated that macrophage inflammatory protein 1   alpha (MIP 1 alpha) is crucially involved in the development of osteolytic bone lesions in MM. Phenolic components of extra virgin olive oil are reported to have anti tumor activity. However, the underlying mechanisms and specific targets of extra virgin olive oil remain to be elucidated. In the present study, we investigated the effects of a recently isolated novel extra virgin olive oil polyphenol, oleocanthal, on the human multiple myeloma cell line ARH 77. Here we report that this natural compound has a remarkable in vitro activity by inhibiting MIP 1 alpha expression and secretion in MM cells. In addition, we also demonstrated that oleocanthal inhibits MM cells proliferation by inducing the activation of apoptosis mechanisms and by down regulating ERK1/2 and AKT signal transduction pathways. This in vitro study suggests a therapeutic potential of oleocanthal in treating multiple myeloma.
C1 [Scotece, M.; Gomez, R.; Conde, J.; Lopez, V.; Gomez Reino, J. J.; Gualillo, O.] Santiago Univ Clin Hosp, SERGAS,Res Lab 9, NEIRID LAB Lab Neuroendocrine Interact Rheumatol, Inst Med Res IDIS, Santiago De Compostela 15706, Spain.
   [Lago, F.] Santiago Univ Clin Hosp, SERGAS, Inst Med Res IDIS, Res Lab Mol & Cellular Cardiol 7, Santiago De Compostela 15706, Spain.
   [Smith, A. B., III] Univ Penn, Dept Chem, Monell Chem Senses Ctr, Philadelphia, PA 19104 USA.
   [Smith, A. B., III] Univ Penn, Res Struct Matter Lab, Philadelphia, PA 19104 USA.
C3 Complexo Hospitalario Universitario de Santiago de Compostela; Complexo
   Hospitalario Universitario de Santiago de Compostela; Monell Chemical
   Senses Center; University of Pennsylvania; University of Pennsylvania
RP Gualillo, O (通讯作者)，Santiago Univ Clin Hosp, SERGAS,Res Lab 9, NEIRID LAB Lab Neuroendocrine Interact Rheumatol, Inst Med Res IDIS, Santiago De Compostela 15706, Spain.
EM oreste.gualillo@sergas.es
RI ; GUALILLO, ORESTE/B 8223 2008; Gomez Bahamonde, Rodolfo/B 4642 2012;
   Gomez, Rodolfo/B 4642 2012; Aranda, Javier/P 5537 2015; Scotece,
   Morena/ABI 6561 2020; López, Verónica/K 5472 2014; Gualillo,
   Oreste/B 8223 2008; Gomez Reino, Juan/ABI 2853 2020; Conde Aranda,
   Javier/P 5537 2015
OI Gomez Reino, Juan/0000 0001 5229 6294; GUALILLO,
   ORESTE/0000 0002 7154 1328; Scotece, Morena/0000 0002 1150 2933; Gomez
   Bahamonde, Rodolfo/0000 0002 1309 1023; Conde Aranda,
   Javier/0000 0002 2187 479X
FU Instituto de Salud Carlos III; "FPU" programme of the Spanish Ministry
   of Education; "Sara Borell Programme" of the Spanish National Institute
   of Health "Carlos III."; Fundacion Ramon Dominguez of the Santiago
   University Clinical Hospital; Xunta de Galicia; Xunta de Galicia
   (SERGAS)
FX The work of Oreste Gualillo and Francisca Lago is funded by Instituto de
   Salud Carlos III and Xunta de Galicia (SERGAS) through a research staff
   stabilization contract. Morena Scotece is a recipient of the "FPU"
   programme of the Spanish Ministry of Education. Rodolfo Gomez is a
   recipient of the "Sara Borell Programme" of the Spanish National
   Institute of Health "Carlos III." Javier Conde is a recipient of a
   pre doctoral fellowship funded by Fundacion Ramon Dominguez of the
   Santiago University Clinical Hospital Veronica Lopez is a recipient of a
   grant from Xunta de Galicia.
CR Beauchamp GK, 2005, NATURE, V437, P45, DOI 10.1038/437045a
   Berenson JR, 2001, SEMIN ONCOL, V28, P626, DOI 10.1053/sonc.2001.29542
   Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood 2002 05 1320
   Catlett Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074 7613(00)80011 4
   Choi SJ, 2000, BLOOD, V96, P671
   Cives M, 2012, EUR J HAEMATOL, V88, P279, DOI 10.1111/j.1600 0609.2011.01735.x
   Colomer Ramon, 2006, Clin Transl Oncol, V8, P15, DOI 10.1007/s12094 006 0090 0
   Ferrarini M, 2011, CURR MED CHEM, V18, P5185, DOI 10.2174/092986711798184316
   FULLER K, 1995, J IMMUNOL, V154, P6065
   Gill CIR, 2005, INT J CANCER, V117, P1, DOI 10.1002/ijc.21083
   Giuliani N, 2004, LEUKEMIA, V18, P628, DOI 10.1038/sj.leu.2403269
   Han J, 2009, CYTOTECHNOLOGY, V59, P45, DOI 10.1007/s10616 009 9191 2
   Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853
   Iacono A, 2010, ARTHRITIS RHEUM US, V62, P1675, DOI 10.1002/art.27437
   Kagoya Y., LEUK RES, V36, P1016
   Kukita T, 1997, LAB INVEST, V76, P399
   Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood 2002 08 2383
   Ocio EM, 2009, BLOOD, V113, P3781, DOI 10.1182/blood 2008 09 177774
   Ogata A, 1996, LEUKEMIA RES, V20, P303, DOI 10.1016/0145 2126(95)00085 2
   Ogata A, 1997, CLIN CANCER RES, V3, P1017
   Owen RW, 2000, FOOD CHEM TOXICOL, V38, P647, DOI 10.1016/S0278 6915(00)00061 2
   Pitt J, 2009, TOXICOL APPL PHARM, V240, P189, DOI 10.1016/j.taap.2009.07.018
   Rödel F, 2011, CURR MED CHEM, V18, P191, DOI 10.2174/092986711794088362
   Scotece M, 2012, LIFE SCI, V91, P1229, DOI 10.1016/j.lfs.2012.09.012
   Silva MT, 2008, APOPTOSIS, V13, P463, DOI 10.1007/s10495 008 0187 8
   Tsubaki M, 2007, MOL CELL BIOCHEM, V304, P53, DOI 10.1007/s11010 007 9485 7
   Vallet S, 2011, LEUKEMIA, V25, P1174, DOI 10.1038/leu.2011.43
   Zangari M, 2012, CANCER TREAT REV, V38, P968, DOI 10.1016/j.ctrv.2011.12.007
NR 28
TC 55
Z9 59
U1 0
U2 15
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929 8673
EI 1875 533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD JUN
PY 2013
VL 20
IS 19
BP 2467
EP 2475
DI 10.2174/0929867311320190006
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 138CU
UT WOS:000318486900006
PM 23521677
DA 2025 08 17
ER

PT J
AU Bissinger, O
   Kreutzer, K
   Götz, C
   Hapfelmeier, A
   Pautke, C
   Vogt, S
   Wexel, G
   Wolff, KD
   Tischer, T
   Prodinger, PM
AF Bissinger, Oliver
   Kreutzer, Kilian
   Goetz, Carolin
   Hapfelmeier, Alexander
   Pautke, Christoph
   Vogt, Stephan
   Wexel, Gabriele
   Wolff, Klaus Dietrich
   Tischer, Thomas
   Prodinger, Peter Michael
TI A biomechanical, micro computertomographic and histological analysis of
   the influence of diclofenac and prednisolone on fracture healing in vivo
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Fracture healing; Bone regeneration; Bone remodelling; Micro; CT (mu
   CT); Histology; Biomechanics; Bone volume (BV); Tissue mineral density
   (TMD)
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GLUCOCORTICOID INDUCED
   OSTEOPOROSIS; SHORT TERM TREATMENT; COMPUTED TOMOGRAPHY;
   PARATHYROID HORMONE; TRABECULAR BONE; INHIBITION; REPAIR; RATS;
   MECHANISMS
AB Background: Non steroidal anti inflammatory drugs (NSAIDs) have long been suspected of negatively affecting fracture healing, although numerous disputes still exist and little data are available regarding diclofenac. Glucocorticoids interfere in this process over a similar and even broader mechanism of action. As many previously conducted studies evaluated either morphological changes or biomechanical properties of treated bones, the conjunction of both structural measures is completely missing. Therefore, it was our aim to evaluate the effects of diclofenac and prednisolone on the fracture callus biomechanically, morphologically and by 3 dimensional (3D) microstructural analysis.
   Methods: Femura of diclofenac , prednisolone  or placebo treated rats were pinned and a closed transverse fracture was generated. After 21 days, biomechanics, micro CT (mu CT) and histology were examined.
   Results: The diclofenac group showed significantly impaired fracture healing compared with the control group by biomechanics and mu CT (e.g. stiffness: 57.31 +/  31.11 N/mm vs. 122.44 +/  81.16 N/mm, p = 0.030; callus volume: 47.05 +/  15. 67 mm3 vs. 67.19 +/  14.90 mm3, p = 0.037, trabecular thickness: 0.0937 mm +/  0.003 vs. 0.0983 mm +/  0.003, p = 0.023), as confirmed by histology. Biomechanics of the prednisolone group showed obviously lower absolute values than the control group. These alterations were confirmed in conjunction with mu CT and histology.
   Conclusions: The inhibiting effects of both substances were not only mediated by absolute parameters (e.g. breaking load, BV), but we have shown, for the first time, that additional changes occurred in the microstructural bony network. Especially in patients at risk for delayed bone healing (arteriosclerosis, diabetes mellitus, smoking), the administration of these drugs should be weighed carefully.
C1 [Bissinger, Oliver; Kreutzer, Kilian; Goetz, Carolin; Pautke, Christoph; Wolff, Klaus Dietrich] Tech Univ Munich, Klinikum Rechts Isar, Dept Oral & Maxillofacial Surg, Ismaninger Str 22, D 81675 Munich, Germany.
   [Hapfelmeier, Alexander] Tech Univ Munich, Klinikum Rechts Isar, Inst Med Stat & Epidemiol, Ismaninger Str 22, D 81675 Munich, Germany.
   [Vogt, Stephan; Wexel, Gabriele; Tischer, Thomas; Prodinger, Peter Michael] Tech Univ Munich, Klinikum Rechts Isar, Dept Orthopaed & Orthopaed Sports Med, Ismaninger Str 22, D 81675 Munich, Germany.
   [Vogt, Stephan] Hessing Stiftung Augsburg, Dept Orthopaed Sports Med, Hessingstr 17, D 86199 Augsburg, Germany.
   [Tischer, Thomas] Univ Rostock, Dept Orthopaed Surg, Doberanerstr 142, D 18057 Rostock, Germany.
C3 Technical University of Munich; Technical University of Munich;
   Technical University of Munich; University of Rostock
RP Bissinger, O (通讯作者)，Tech Univ Munich, Klinikum Rechts Isar, Dept Oral & Maxillofacial Surg, Ismaninger Str 22, D 81675 Munich, Germany.
EM oliver.bissinger@tum.de
RI ; Hapfelmeier, Alexander/I 9966 2019; Tischer, Thomas/H 4524 2019;
   Prodinger, Peter/AAL 3665 2021; Vogt, Stephan/AAQ 7434 2021
OI Tischer, Thomas/0000 0002 3942 0235; Hapfelmeier,
   Alexander/0000 0001 6765 6352; Kreutzer, Kilian/0000 0003 0581 4137; 
FU Komission fur Klinische Forschung (KKF) [C78 08]; Faculty of Medicine
   (Technische Universitat Munchen)
FX The authors thank Dr. Andres Laib (Scanco Medical AG, Brittisellen,
   Switzerland) for providing technical support and image analysis.
   Furthermore, we are grateful to Professor Karl Heinz Kunzelmann,
   Department of Restorative Dentistry, LMU University, Munich, Germany,
   for providing the mu Ct 40. Finally, we also thank Dr. Eduardo Grande
   Garcia, Department of Orthopaedic Sports Medicine, Technische
   Universitat Munchen, for the biomechanical support. This work was
   supported by the "Komission fur Klinische Forschung" at the Faculty of
   Medicine (Technische Universitat Munchen), KKF grant no. C78 08.
CR Aslan M, 2005, DENT TRAUMATOL, V21, P222, DOI 10.1111/j.1600 9657.2005.00300.x
   Bauer JS, 2007, CALCIFIED TISSUE INT, V80, P366, DOI 10.1007/s00223 007 9021 5
   Beck A, 2003, ARCH ORTHOP TRAUM SU, V123, P327, DOI 10.1007/s00402 003 0537 5
   Bevill G, 2006, BONE, V39, P1218, DOI 10.1016/j.bone.2006.06.016
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Bostrom MPG, 2000, BONE, V26, P437, DOI 10.1016/S8756 3282(00)00251 9
   Brändström H, 2001, BIOCHEM BIOPH RES CO, V280, P831, DOI 10.1006/bbrc.2000.4223
   Chen MR, 2013, KNEE SURG SPORT TR A, V21, P540, DOI 10.1007/s00167 012 2095 2
   Doyon A, 2010, CALCIFIED TISSUE INT, V87, P68, DOI 10.1007/s00223 010 9370 3
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Gerstenfeld LC, 2006, J HISTOCHEM CYTOCHEM, V54, P1215, DOI 10.1369/jhc.6A6959.2006
   Geusens P, 2013, CURR OPIN RHEUMATOL, V25, P524, DOI 10.1097/BOR.0b013e32836200b8
   Ghalayani Parichehr, 2014, Dent Res J (Isfahan), V11, P357
   Gilley RS, 2009, CLIN ORTHOP RELAT R, V467, P3104, DOI 10.1007/s11999 009 0782 1
   Histing T, 2011, BONE, V49, P591, DOI 10.1016/j.bone.2011.07.007
   HO ML, 1995, CLIN ORTHOP RELAT R, P270
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   HOGEVOLD HE, 1992, ACTA ORTHOP SCAND, V63, P607
   HUO MH, 1991, J ORTHOPAED RES, V9, P383, DOI 10.1002/jor.1100090310
   Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822
   Iwamoto J, 2010, CALCIFIED TISSUE INT, V86, P234, DOI 10.1007/s00223 010 9333 8
   Jeno L, 1975, Mikroskopie, V31, P1
   Kitazawa R, 1999, BBA GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167 4781(99)00032 9
   Krischak GD, 2007, ARCH ORTHOP TRAUM SU, V127, P453, DOI 10.1007/s00402 007 0288 9
   Krischak G D, 2007, J Wound Care, V16, P76
   Krischak GD, 2007, ARCH ORTHOP TRAUM SU, V127, P3, DOI 10.1007/s00402 006 0202 x
   Leppänen OV, 2008, J BIOMECH, V41, P1623, DOI 10.1016/j.jbiomech.2008.03.017
   Luppen CA, 2002, J BONE MINER RES, V17, P301, DOI 10.1359/jbmr.2002.17.2.301
   Morgan EF, 2009, BONE, V44, P335, DOI 10.1016/j.bone.2008.10.039
   Musumeci G, 2013, J BONE MINER METAB, V31, P274, DOI 10.1007/s00774 012 0414 9
   NEWMAN RJ, 1987, CLIN ORTHOP RELAT R, P253
   Pichler K, 2013, HISTOL HISTOPATHOL, V28, P1185, DOI 10.14670/HH 28.1185
   Reifenrath J, 2014, J BIOMED MATER RES A, V102, P2884, DOI 10.1002/jbm.a.34920
   Sandberg O, 2015, ACTA ORTHOP, V86, P243, DOI 10.3109/17453674.2014.973328
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Spies CM, 2011, BEST PRACT RES CL RH, V25, P891, DOI 10.1016/j.berh.2011.11.002
   Su B, 2013, J APPL PHYSIOL, V115, P892, DOI 10.1152/japplphysiol.00053.2013
   Tiseo Bruno C., 2006, Clinics, V61, P223, DOI 10.1590/S1807 59322006000300007
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Waters RV, 2000, ACTA ORTHOP SCAND, V71, P316, DOI 10.1080/000164700317411951
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wingerter S, 2007, J INVEST SURG, V20, P149, DOI 10.1080/08941930701364732
NR 43
TC 19
Z9 20
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD SEP 5
PY 2016
VL 17
AR 383
DI 10.1186/s12891 016 1241 2
PG 11
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA EM0QV
UT WOS:000395023700002
PM 27596101
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhou, L
   Kuai, F
   Shi, Q
   Yang, HL
AF Zhou, Liang
   Kuai, Feng
   Shi, Qin
   Yang, Huilin
TI Doxorubicin restrains osteogenesis and promotes osteoclastogenesis in
   vitro
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Doxorubicin; mesenchymal stem cells; osteoporosis; smadl/5/9; Bmp 2;
   RANKL/OPG
ID MESENCHYMAL STEM CELLS; RUNX2 EXPRESSION; DIFFERENTIATION; BETA;
   OSTEOBLAST; GENE; ACTIVATION; P38; CHEMOTHERAPY; INDUCTION
AB Clinical evidence suggests that doxorubicin (DOX), as a chemotherapeutic drug, can induce severe bone damage in cancer patients. However, the effect of DOX on osteoporosis has not been fully elucidated. Therefore our study aims to investigate the effect and mechanism of DOX in osteoporosis. In our study, we co cultured rat BMSCs with different concentrations of DOX solution, then the osteogenic differentiation markers and proliferation ability were analyzed. The results indicated that a certain concentration of the DOX solution may restrain the osteogenic differentiation of rat BMSCs by bmp 2/smads signalling pathway. Also, we found DOX promoted the receptor activator of nuclear factor KB (NF KB) ligand (RANKL) induced osteoclast formation. Our research explains excellently the induce osteoporotic mechanism of DOX in vitro, which maybe contributing to the exploration of a new way to prevent osteoporosis caused by chemotherapy.
C1 [Zhou, Liang; Shi, Qin; Yang, Huilin] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed Surg, 188 Shizi St, Suzhou 215006, Peoples R China.
   [Zhou, Liang] Lianshui Cty Hosp, Dept Orthopaed Surg, Huaian 223001, Peoples R China.
   [Kuai, Feng] Yancheng 1 Peoples Hosp, Dept Geriatr, Yancheng 224001, Jiangsu, Peoples R China.
C3 Soochow University   China
RP Shi, Q; Yang, HL (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthopaed Surg, 188 Shizi St, Suzhou 215006, Peoples R China.
CR Anampa J, 2015, BMC MED, V13, DOI 10.1186/s12916 015 0439 8
   Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Cai BZ, 2009, J MOL CELL CARDIOL, V47, P41, DOI 10.1016/j.yjmcc.2009.03.002
   Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   Eliseev RA, 2008, ONCOGENE, V27, P3605, DOI 10.1038/sj.onc.1211020
   Feng X, 2005, GENE, V350, P1, DOI 10.1016/j.gene.2005.01.014
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gersbach CA, 2004, EXP CELL RES, V300, P406, DOI 10.1016/j.yexcr.2004.07.031
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Ito Y, 2001, J BONE MINER METAB, V19, P188, DOI 10.1007/s007740170041
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Liu H, 2019, J CELL PHYSIOL, V234, P11009, DOI 10.1002/jcp.27924
   Massagué J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Mathis KM, 2018, MED HYPOTHESES, V118, P36, DOI 10.1016/j.mehy.2018.06.013
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Rho J, 2002, DNA CELL BIOL, V21, P541, DOI 10.1089/104454902320308915
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rosen CJ, 2009, CRIT REV EUKAR GENE, V19, P109, DOI 10.1615/CritRevEukarGeneExpr.v19.i2.20
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Sledge GW, 2003, J CLIN ONCOL, V21, P588, DOI 10.1200/JCO.2003.08.013
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Trudeau M, 2005, LANCET ONCOL, V6, P886, DOI 10.1016/S1470 2045(05)70424 1
   Van Damme An, 2002, Current Gene Therapy, V2, P195
   Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327
   Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012
   Yang F, 2013, CELL PHYSIOL BIOCHEM, V32, P1072, DOI 10.1159/000354507
   Yang K, 2016, AM J CANCER RES, V6, P1302
NR 39
TC 14
Z9 15
U1 0
U2 4
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2020
VL 12
IS 9
BP 5640
EP 5654
PG 15
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA NZ0TG
UT WOS:000576805000013
PM 33042445
DA 2025 08 17
ER

PT J
AU Gu, H
   Boonanantanasarn, K
   Kang, M
   Kim, I
   Woo, KM
   Ryoo, HM
   Baek, JH
AF Gu, Hanna
   Boonanantanasarn, Kanitsak
   Kang, Moonkyu
   Kim, Ikhwi
   Woo, Kyung Mi
   Ryoo, Hyun Mo
   Baek, Jeong Hwa
TI Morinda citrifolia Leaf Extract Enhances Osteogenic
   Differentiation Through Activation of Wnt/β Catenin Signaling
SO JOURNAL OF MEDICINAL FOOD
LA English
DT Article
DE Morinda citrifolia; Noni; osteogenic differentiation; Wnt/beta catenin
   signaling
ID PERIODONTAL TISSUE; OSTEOBLASTIC DIFFERENTIATION; NONI FRUIT; CELL LINE;
   REGENERATION; MINERALIZATION; BONE; PROLIFERATION; THERAPY; PATHWAY
AB Morinda citrifolia (Noni) leaf is an herbal medicine with application in the domestic treatment of a broad range of conditions, including bone fracture and luxation. However, the basic mechanism underlying the stimulation of osteogenic differentiation by Noni leaf extract remains poorly understood. This study aimed to examine the effect of this extract on osteogenic differentiation and the mechanism by which Noni leaf extract enhances osteogenic differentiation. Aqueous extract of Noni leaves was prepared, and rutin and kaempferol 3 O rutinoside were identified to be two of its major components. C2C12 and human periodontal ligament (hPDL) cells were used to study the effect of Noni. Noni did not show cytotoxicity at a concentration range of 0.015% 1.0% (w/v%) and significantly enhanced the activity of alkaline phosphatase (ALP) and expression levels of osteoblast differentiation markers, including Runx2, ALP, osterix, and osteocalcin, bone morphogenetic protein 2, Wnt3a, and  catenin. In addition, Noni enhanced the matrix mineralization of hPDL cells. In the signaling pathways, Noni increased the phosphorylation levels of Akt and GSK3 and nuclear translocation and transcriptional activity of  catenin, which were attenuated by the addition of Dkk 1, a Wnt inhibitor, or LY294002, a PI3K inhibitor. These results suggest that Noni leaf extract enhances osteogenic differentiation through the PI3K/Akt dependent activation of Wnt/ catenin signaling. Noni leaf extract might be a novel alternative medicine for bone and periodontal regeneration in patients with periodontal diseases.
C1 [Gu, Hanna; Boonanantanasarn, Kanitsak; Woo, Kyung Mi; Ryoo, Hyun Mo; Baek, Jeong Hwa] Seoul Natl Univ, Sch Dent, Dept Mol Genet, 1 Gwanak Ro, Seoul 08826, South Korea.
   [Gu, Hanna; Boonanantanasarn, Kanitsak; Woo, Kyung Mi; Ryoo, Hyun Mo; Baek, Jeong Hwa] Seoul Natl Univ, Dent Res Inst, Seoul, South Korea.
   [Kang, Moonkyu] MAYJUNE Life & Hlth Co Inc, R&D Ctr, Seoul, South Korea.
   [Kim, Ikhwi] Elcubio Co Ltd, Daejeon, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU)
RP Baek, JH (通讯作者)，Seoul Natl Univ, Sch Dent, Dept Mol Genet, 1 Gwanak Ro, Seoul 08826, South Korea.
EM baekjh@snu.ac.kr
RI ; Woo, Kyung/A 2793 2009; Kang, Moonkyu/AAR 8974 2021; Ryoo,
   Hyun Mo/D 5839 2012; Baek, Jeong Hwa/A 8628 2012
OI Ryoo, Hyun Mo/0000 0001 6769 8341; Kang, Moonkyu/0000 0002 2039 4866; 
FU NRF grant through Oromaxillofacial Dysfunction Research Center for the
   Elderly at Seoul National University in Korea [2014 050477]
FX This study was supported by an NRF grant through the Oromaxillofacial
   Dysfunction Research Center for the Elderly (No. 2014 050477) at Seoul
   National University in Korea.
CR Aggarwal P, 2012, ORAL DIS, V18, P48, DOI 10.1111/j.1601 0825.2011.01850.x
   Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   [Anonymous], 2014, EVID BASED COMPL ALT, DOI DOI 10.1155/2014/925069
   Bayan L, 2014, AVICENNA J PHYTOMEDI, V4, P1
   Boonanantanasarn K, 2015, J CELL BIOCHEM, V116, P2849, DOI 10.1002/jcb.25231
   Boonanantanasarn K, 2014, DENT MATER J, V33, P157, DOI 10.4012/dmj.2012 053 r
   Chan Blanco Y, 2006, J FOOD COMPOS ANAL, V19, P645, DOI 10.1016/j.jfca.2005.10.001
   Chen FM, 2010, TISSUE ENG PART B RE, V16, P219, DOI [10.1089/ten.teb.2009.0562, 10.1089/ten.TEB.2009.0562]
   Choi MH, 2011, J PERIODONTAL IMPLAN, V41, P167, DOI 10.5051/jpis.2011.41.4.167
   Cortellini P, 2015, PERIODONTOL 2000, V68, P282, DOI 10.1111/prd.12048
   Ding Y, 2009, PLANTA MED, V75, P158, DOI 10.1055/s 0028 1088373
   Fujii S, 2008, J CELL PHYSIOL, V215, P743, DOI 10.1002/jcp.21359
   Gavanji S, 2014, INTEGR MED RES, V3, P83, DOI 10.1016/j.imr.2014.03.001
   Gupta S, 2015, INT J PREVENTIVE MED, V6, DOI 10.4103/2008 7802.162311
   Han PP, 2015, J BONE MINER RES, V30, P1160, DOI 10.1002/jbmr.2445
   Heo JS, 2010, MOL CELLS, V30, P449, DOI 10.1007/s10059 010 0139 3
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Howes MJR, 2012, CURR ALZHEIMER RES, V9, P67
   Hyun H, 2014, KOREAN J PHYSIOL PHA, V18, P347, DOI 10.4196/kjpp.2014.18.4.347
   Irfan U M, 2001, J Int Acad Periodontol, V3, P14
   Izumi Y, 2011, PERIODONTOL 2000, V56, P166, DOI 10.1111/j.1600 0757.2010.00366.x
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Kao Solon T, 2007, Oral Maxillofac Surg Clin North Am, V19, P513, DOI 10.1016/j.coms.2007.06.002
   Khanna Jain R, 2010, GROWTH FACTORS, V28, P437, DOI 10.3109/08977194.2010.495719
   Kook SH, 2015, MOL CELL BIOCHEM, V402, P213, DOI 10.1007/s11010 015 2329 y
   Koop R, 2012, J PERIODONTOL, V83, P707, DOI 10.1902/jop.2011.110266
   Kornman KS, 2008, J PERIODONTOL, V79, P1560, DOI 10.1902/jop.2008.080213
   Kwon A, 2012, J DENT RES, V91, P506, DOI 10.1177/0022034512443367
   Lee HL, 2014, EXP CELL RES, V323, P276, DOI 10.1016/j.yexcr.2014.03.004
   Lee HL, 2013, J CELL PHYSIOL, V228, P87, DOI 10.1002/jcp.24106
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104
   McClatchey Will, 2002, Integr Cancer Ther, V1, P110, DOI 10.1177/1534735402001002002
   Murakami S, 2011, PERIODONTOL 2000, V56, P188, DOI 10.1111/j.1600 0757.2010.00365.x
   Nayak BS, 2009, EVID BASED COMPL ALT, V6, P351, DOI 10.1093/ecam/nem127
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756 3282(02)00826 8
   Offenbacher S, 2008, J PERIODONTOL, V79, P1577, DOI 10.1902/jop.2008.080220
   Potterat O, 2007, PLANTA MED, V73, P191, DOI 10.1055/s 2007 967115
   Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323
   Costa CRR, 2016, PHYTOTHER RES, V30, P519, DOI 10.1002/ptr.5568
   Rheu GB, 2011, J ADV PROSTHODONT, V3, P25
   Saito Y, 2002, J CELL SCI, V115, P4191, DOI 10.1242/jcs.00098
   Sculean A, 2015, PERIODONTOL 2000, V68, P182, DOI 10.1111/prd.12086
   Serafini MR, 2011, J MED FOOD, V14, P1159, DOI 10.1089/jmf.2010.0254
   Steele ML, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/724258
   Tradtrantip L, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002674
   Wang MY, 2002, ACTA PHARMACOL SIN, V23, P1127
   West BJ, 2009, J NAT MED TOKYO, V63, P351, DOI 10.1007/s11418 009 0327 7
NR 49
TC 17
Z9 17
U1 0
U2 43
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096 620X
EI 1557 7600
J9 J MED FOOD
JI J. Med. Food
PD JAN
PY 2018
VL 21
IS 1
BP 57
EP 69
DI 10.1089/jmf.2017.3933
PG 13
WC Chemistry, Medicinal; Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Food Science & Technology; Nutrition &
   Dietetics
GA FX3NU
UT WOS:000425979500008
PM 28981378
DA 2025 08 17
ER

PT J
AU Hiasa, M
   Teramachi, J
   Oda, A
   Amachi, R
   Harada, T
   Nakamura, S
   Miki, H
   Fujii, S
   Kagawa, K
   Watanabe, K
   Endo, I
   Kuroda, Y
   Yoneda, T
   Tsuji, D
   Nakao, M
   Tanaka, E
   Hamada, K
   Sano, S
   Itoh, K
   Matsumoto, T
   Abe, M
AF Hiasa, M.
   Teramachi, J.
   Oda, A.
   Amachi, R.
   Harada, T.
   Nakamura, S.
   Miki, H.
   Fujii, S.
   Kagawa, K.
   Watanabe, K.
   Endo, I.
   Kuroda, Y.
   Yoneda, T.
   Tsuji, D.
   Nakao, M.
   Tanaka, E.
   Hamada, K.
   Sano, S.
   Itoh, K.
   Matsumoto, T.
   Abe, M.
TI Pim 2 kinase is an important target of treatment for tumor progression
   and bone loss in myeloma
SO LEUKEMIA
LA English
DT Article
ID MARROW STROMAL CELLS; GROWTH IN VIVO; MULTIPLE MYELOMA; OSTEOBLAST
   DIFFERENTIATION; BISPHOSPHONATE THERAPY; PARATHYROID HORMONE; OSTEOLYTIC
   LESIONS; WNT INHIBITOR; DISEASE; DKK1
AB Pim 2 kinase is overexpressed in multiple myeloma (MM) cells to enhance their growth and survival, and regarded as a novel therapeutic target in MM. However, the impact of Pim 2 inhibition on bone disease in MM remains unknown. We demonstrated here that Pim 2 expression was also upregulated in bone marrow stromal cells and MC3T3 E1 preosteoblastic cells in the presence of cytokines known as the inhibitors of osteoblastogenesis in MM, including interleukin 3 (IL 3), IL 7, tumor necrosis factor alpha, transforming growth factor beta (TGF beta) and activin A, as well as MM cell conditioned media. The enforced expression of Pim 2 abrogated in vitro osteoblastogenesis by BMP 2, which suggested Pim 2 as a negative regulator for osteoblastogenesis. Treatment with Pim 2 short interference RNA as well as the Pim inhibitor SMI 16a successfully restored osteoblastogenesis suppressed by all the above inhibitory factors and MM cells. The SMI 16a treatment potentiated BMP 2 mediated anabolic signaling while suppressing TGF beta signaling. Furthermore, treatment with the newly synthesized thiazolidine 2,4 dione congener, 12a OH, as well as its prototypic SMI 16a effectively prevented bone destruction while suppressing MM tumor growth in MM animal models. Thus, Pim 2 may have a pivotal role in tumor progression and bone loss in MM, and Pim 2 inhibition may become an important therapeutic strategy to target the MM cell bone marrow interaction.
C1 [Hiasa, M.; Oda, A.; Harada, T.; Nakamura, S.; Miki, H.; Fujii, S.; Kagawa, K.; Endo, I.; Matsumoto, T.; Abe, M.] Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, Inst Hlth Biosci, Tokushima 7708503, Japan.
   [Hiasa, M.] Univ Tokushima, Grad Sch Med, Dept Biomat & Bioengn, Inst Hlth Biosci, Tokushima 7708503, Japan.
   [Hiasa, M.; Amachi, R.; Watanabe, K.; Tanaka, E.] Univ Tokushima, Grad Sch Med, Dept Orthodont & Dentofacial Orthoped, Inst Hlth Biosci, Tokushima 7708503, Japan.
   [Teramachi, J.] Univ Tokushima, Grad Sch Med, Dept Histol & Oral Histol, Inst Hlth Biosci, Tokushima 7708503, Japan.
   [Kuroda, Y.] Hiroshima Univ, RIRBM, Dept Hematol & Oncol, Hiroshima, Japan.
   [Yoneda, T.] Indiana Univ, Dept Med, Indianapolis, IN USA.
   [Tsuji, D.; Itoh, K.] Univ Tokushima, Grad Sch Med, Inst Hlth Biosci, Dept Med Biotechnol, Tokushima 7708503, Japan.
   [Nakao, M.; Sano, S.] Univ Tokushima, Grad Sch Med, Inst Hlth Biosci, Dept Mol Med Chem, Tokushima 7708503, Japan.
C3 Tokushima University; Tokushima University; Tokushima University;
   Tokushima University; Hiroshima University; Indiana University System;
   Indiana University Indianapolis; Tokushima University; Tokushima
   University
RP Abe, M (通讯作者)，Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, 3 18 15 Kuramoto Cho, Tokushima 7708503, Japan.
EM masabe@clin.med.tokushima u.ac.jp
RI Tsuji, Daisuke/F 7085 2013; Tanaka, Eiji/E 7105 2015; Nakamura,
   Shingen/GPX 5438 2022; 日浅, 雅博/S 1537 2019; Abe, Masahiro/AAJ 3032 2021
OI Tsuji, Daisuke/0000 0002 1528 7820; Tanaka, Eiji/0000 0002 2707 1613;
   HIASA, MASAHIRO/0000 0002 4830 6274; 
FU Ministry of Education, Science, Sport, and Culture of Japan [23591390];
   National Cancer Center Research and Development Fund [21 8 5];
   Grants in Aid for Scientific Research [25460389, 26670269, 23591390,
   26293120, 25861745] Funding Source: KAKEN
FX This work was supported in part by a Grants in aid for Scientific
   Research (C) (23591390) from the Ministry of Education, Science, Sport,
   and Culture of Japan, a National Cancer Center Research and Development
   Fund (21 8 5) from the Ministry of Health, Labor and Welfare of Japan,
   and A STEP from Japan Science and Technology Agency (AS242Z02068Q) to
   MA, and a Japan Leukemia Research Fund, IMF Japan Aki Horinouchi
   Research Grant, and a Grant in Aid for Scientific Research (21792077,
   23659946 and 25463087) from the Ministry of Education, Science, Sport
   and Culture of Japan to MH. The funders had no role in the study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Asano J, 2011, LEUKEMIA, V25, P1182, DOI 10.1038/leu.2011.60
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chantry AD, 2010, J BONE MINER RES, V25, P2357, DOI 10.1002/jbmr.142
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282 06
   D'Souza S, 2011, BLOOD, V118, P6871, DOI 10.1182/blood 2011 04 346775
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008 5472.CAN 08 4135
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Ehrlich LA, 2005, BLOOD, V106, P1407, DOI 10.1182/blood 2005 03 1080
   Fowler JA, 2012, CANCER RES, V72, P2183, DOI 10.1158/0008 5472.CAN 11 2067
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hiasa M, 2009, BLOOD, V114, P4517, DOI 10.1182/blood 2009 04 215020
   Hideshima T, 2001, CANCER RES, V61, P3071
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Hosen N, 2012, LEUKEMIA, V26, P2135, DOI 10.1038/leu.2012.80
   Jain N, 2009, NAT REV RHEUMATOL, V5, P341, DOI 10.1038/nrrheum.2009.87
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood 2007 10 116129
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   LeBlanc R, 2002, CANCER RES, V62, P4996
   Lentzsch S, 2012, BLOOD, V119, P4608, DOI 10.1182/blood 2011 12 395715
   Li BZ, 2007, STEM CELLS DEV, V16, P921, DOI 10.1089/scd.2007.0074
   Mitra A, 2010, J BIOL CHEM, V285, P24686, DOI 10.1074/jbc.M109.094847
   Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   MORI KJ, 1978, GANN, V69, P689
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   Ozaki S, 2007, INT J HEMATOL, V86, P180, DOI 10.1532/IJH97.07030
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Podar K, 2009, LEUKEMIA, V23, P10, DOI 10.1038/leu.2008.259
   Pozzi S, 2013, BONE, V53, P487, DOI 10.1016/j.bone.2013.01.012
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   Takeuchi K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009870
   Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Wu P, 2011, CLIN CANCER RES, V17, P6347, DOI 10.1158/1078 0432.CCR 11 0994
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yata K, 2004, LEUKEMIA, V18, P1891, DOI 10.1038/sj.leu.2403513
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
NR 50
TC 52
Z9 54
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887 6924
EI 1476 5551
J9 LEUKEMIA
JI Leukemia
PD JAN
PY 2015
VL 29
IS 1
BP 207
EP 217
DI 10.1038/leu.2014.147
PG 11
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA AY6JX
UT WOS:000347673700022
PM 24787487
DA 2025 08 17
ER

PT J
AU Liu, XX
   Cao, FY
   Liu, S
   Mi, YH
   Liu, JH
AF Liu, Xiaoxiao
   Cao, Fangying
   Liu, Shuang
   Mi, Yuhong
   Liu, Jinghua
TI BMP2/Smad signaling pathway is involved in the inhibition function of
   fibroblast growth factor 21 on vascular calcification
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Fibroblast growth factor21; Vascular calcification; BMP2/Smad signaling
   pathway; Osteoblast differentiation; Noggin
ID SMOOTH MUSCLE CELLS; OSTEOBLAST DIFFERENTIATION; IN VITRO; RECEPTOR
   COMPLEX; PROTEIN; TRANSCRIPTION; MECHANISMS; MUTATION; THERAPY; FGF 21
AB Vascular calcification is extremely common and associated with major adverse cardiovascular events. Fibroblast growth factor (FGF) 21 has been identified as a potent metabolic regulator and a protector of the cardiovascular system. In this study, we aimed to investigate the effect of FGF21 on calcification of vascular smooth muscle cell (VSMC) and its mechanism. FGF21 inhibited beta glycerophosphate (BGP) induced mineralization in VSMCs as determined by calcium concentration and Alizarin Red S. FGF21 suppressed BGP induced BMP2/Smad signaling pathway components as well as osteoblast differentiation markers. FGF21 and Noggin could synergistically inhibit BGP induced BMP2/Smad pathway expressions and calcification. Taken together, FGF21 inhibits vascular calcification in vitro by modulating BMP2/Smad signaling pathway. (C) 2018 Published by Elsevier Inc.
C1 [Liu, Xiaoxiao; Mi, Yuhong] Capital Med Univ, Beijing Anzhen Hosp, Emergency & Crit Care Ctr, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China.
   [Cao, Fangying] Nanchang Univ, Affiliated Hosp 2, Dept Cardiol, Nanchang, Jiangxi, Peoples R China.
   [Liu, Shuang] Peking Univ, Int Hosp, Dept Pulm & Crit Care Med, Beijing, Peoples R China.
   [Liu, Jinghua] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China.
C3 Capital Medical University; Nanchang University; Peking University;
   Capital Medical University
RP Liu, JH (通讯作者)，Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China.
EM liujinghua@vip.sina.com
RI Liu, Xiaoxiao/HNI 6180 2023
FU National Natural Science Fund of China [81570388]
FX This work was supported by National Natural Science Fund of China
   (No.81570388).
CR Adams AC, 2012, CURR DIABETES REV, V8, P285, DOI 10.2174/157339912800840505
   Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258
   Cai J, 2012, FEBS LETT, V586, P1993, DOI 10.1016/j.febslet.2012.04.030
   Cao FY, 2017, J PHARM PHARMACOL, V69, P1802, DOI 10.1111/jphp.12826
   Cao FY, 2017, BIOCHEM BIOPH RES CO, V491, P578, DOI 10.1016/j.bbrc.2017.07.160
   CARCAMO J, 1995, MOL CELL BIOL, V15, P1573
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161
   Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092 8674(00)81250 7
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606
   Leopold JA, 2015, TRENDS CARDIOVAS MED, V25, P267, DOI 10.1016/j.tcm.2014.10.021
   Li Baojie, 2008, Endocrine Metabolic & Immune Disorders Drug Targets, V8, P208, DOI 10.2174/187153008785700127
   Li L, 2008, DIABETES RES CLIN PR, V82, P209, DOI 10.1016/j.diabres.2008.07.012
   Li XW, 2008, ATHEROSCLEROSIS, V199, P271, DOI 10.1016/j.atherosclerosis.2007.11.031
   Liu SQ, 2013, SCI REP UK, V3, DOI 10.1038/srep02767
   Lu Y, 2010, CHINESE MED J PEKING, V123, P3417, DOI 10.3760/cma.j.issn.0366 6999.2010.23.008
   Matuszek B, 2010, ENDOKRYNOL POL, V61, P50
   Minamizato T, 2007, BIOCHEM BIOPH RES CO, V354, P567, DOI 10.1016/j.bbrc.2007.01.029
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nishide Y, 2015, INT J ENV RES PUB HE, V12, P13750, DOI 10.3390/ijerph121113750
   Ong KL, 2012, J CLIN ENDOCR METAB, V97, P4701, DOI 10.1210/jc.2012 2267
   Planavila A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3019
   Potthoff MJ, 2012, GENE DEV, V26, P312, DOI 10.1101/gad.184788.111
   Shen T, 2016, METHODS MOL BIOL, V1344, P111, DOI [10.1007/978 1 4939 2966 5_6, 10.1007/978 1 4939 2966 5_6,]
   Sheu TJ, 2014, MOL CELL BIOCHEM, V397, P67, DOI 10.1007/s11010 014 2173 5
   Suzuki M, 2008, MOL ENDOCRINOL, V22, P1006, DOI 10.1210/me.2007 0313
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166
   WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460 2075.1995.tb07214.x
   Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092 8674(00)00211 7
   Yoshikawa Y, 2015, ARCH ORAL BIOL, V60, P1319, DOI 10.1016/j.archoralbio.2015.06.001
   Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597
NR 34
TC 16
Z9 18
U1 1
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 5
PY 2018
VL 503
IS 2
BP 930
EP 937
DI 10.1016/j.bbrc.2018.06.098
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GR5VY
UT WOS:000442711200080
PM 29932916
DA 2025 08 17
ER

PT J
AU Zuo, H
   Yang, DB
   Yang, QW
   Tang, HD
   Fu, YX
   Wan, YH
AF Zuo, Hao
   Yang, Dengbao
   Yang, Qiwen
   Tang, Haidong
   Fu, Yang Xin
   Wan, Yihong
TI Differential regulation of breast cancer bone metastasis by PARP1 and
   PARP2
SO NATURE COMMUNICATIONS
LA English
DT Article
ID NF KAPPA B; DNA REPAIR; CELLS; BETA; OSTEOCLASTOGENESIS; MECHANISMS;
   REVEALS; PROGRAM; TARGETS; C/EBP
AB PARP1 and PARP2 dual inhibitors, such as olaparib, have been recently FDA approved for the treatment of advanced breast and ovarian cancers. However, their effects on bone mass and bone metastasis are unknown. Here we show that olaparib increases breast cancer bone metastasis through PARP2, but not PARP1, specifically in the myeloid lineage, but not in the cancer cells. Olaparib treatment or PARP1/2 deletion promotes osteoclast differentiation and bone loss. Intriguingly, myeloid deletion of PARP2, but not PARP1, increases the population of immature myeloid cells in bone marrow, and impairs the expression of chemokines such as CCL3 through enhancing the transcriptional repression by beta  catenin. Compromised CCL3 production in turn creates an immune suppressive milieu by altering T cell subpopulations. Our findings warrant careful examination of current PARP inhibitors on bone metastasis and bone loss, and suggest cotreatment with CCL3, beta  catenin inhibitors, anti RANKL or bisphosphonates as potential combination therapy for PARP inhibitors. The effect of PARP inhibitors on bone mass and bone metastasis are unclear. Here, the authors show that PARP1/2 dual inhibitors may increase cancer bone metastasis through PARP2 dependent regulation of immature myeloid cells, and cause bone loss through PARP1/2 dependent regulation of osteoclasts.
C1 [Zuo, Hao; Yang, Dengbao; Yang, Qiwen; Wan, Yihong] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
   [Tang, Haidong; Fu, Yang Xin] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
   [Wan, Yihong] Univ Texas Southwestern Med Ctr Dallas, Simmons Canc Ctr, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center; University of Texas System; University of Texas Southwestern
   Medical Center; University of Texas System; University of Texas
   Southwestern Medical Center
RP Wan, YH (通讯作者)，Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.; Wan, YH (通讯作者)，Univ Texas Southwestern Med Ctr Dallas, Simmons Canc Ctr, Dallas, TX 75390 USA.
EM yihong.wan@utsouthwestern.edu
RI Wan, Yihong/J 8681 2012; fu, yang xin/AFF 1084 2022; yang,
   dengbao/KIG 4663 2024; Tang, Haidong/P 1729 2019; Zuo, Hao/KCL 0405 2024
OI yang, dengbao/0000 0001 7475 0320; Zuo, Hao/0000 0002 8812 7385; Wan,
   Yihong/0000 0003 0556 7017; fu, yang xin/0000 0001 8441 6617; Tang,
   Haidong/0000 0002 1512 2655; 
FU Harold C. Simmons Cancer Center through an NCI Cancer Center Support
   Grant [1P30 CA142543 01]; NIH/NCI [R01CA229487, R01CA236802]; CPRIT
   [RP180047]; DOD [W81XWH 18 1 0014]; Welch Foundation [I 1751]; UTSW
   Endowed Scholar Startup Fund; National Institutes of Health American
   Recovery and Reinvestment Act stimulus funds [1S10RR02564801]
FX We thank University of Texas Southwestern histology pathology core, flow
   cytometry core, and next generation sequencing core for their assistance
   in our studies; F. Dantzer and W. L. Kraus for the PARP1 and PARP2 KO,
   and flox mice; W. L. Kraus for the plasmids for human and mouse PARP1
   and PARP2, and shPARP1 and shPARP2; S. Morrison, P. Dechow, J. Feng, and
   C. Qin for assistance with mu CT, histomorphometry, and X ray analysis.
   We also thank University of Texas Southwestern Small Animal Imaging
   Resource, which is supported in part by the Harold C. Simmons Cancer
   Center through an NCI Cancer Center Support Grant, 1P30 CA142543 01 and
   The Department of Radiology. Y.W. is Lawrence Raisz Professor in Bone
   Cell Metabolism and a Virginia Murchison Linthicum Scholar in Medical
   Research. This work was in part supported by NIH/NCI (R01CA229487,
   R01CA236802, Y.W.), CPRIT (RP180047, Y.W.), and DOD (W81XWH 18 1 0014,
   Y.W.), The Welch Foundation (I 1751, Y.W.) and UTSW Endowed Scholar
   Startup Fund (Y.W.). The VisualSonics Vevo 770 was purchased with
   National Institutes of Health American Recovery and Reinvestment Act
   stimulus funds 1S10RR02564801.
CR Benchoua A, 2002, J BIOL CHEM, V277, P34217, DOI 10.1074/jbc.M203941200
   Biswas T, 2014, CANCER LETT, V346, P129, DOI 10.1016/j.canlet.2013.12.018
   Bognar MK, 2016, ONCOGENE, V35, P4269, DOI 10.1038/onc.2015.493
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Carey Michael F, 2009, Cold Spring Harb Protoc, V2009, DOI 10.1101/pdb.prot5279
   Carter O'Connell I, 2014, J AM CHEM SOC, V136, P5201, DOI 10.1021/ja412897a
   Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159, DOI 10.1615/CritRevEukarGeneExpr.v10.i2.50
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206
   deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303
   Eckhardt BL, 2005, MOL CANCER RES, V3, P1
   Ell B, 2012, CELL, V151, DOI 10.1016/j.cell.2012.10.005
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Gibby K, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3174
   Gibson BA, 2016, SCIENCE, V353, P45, DOI 10.1126/science.aaf7865
   GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kishi Y, 2015, INT J MOL SCI, V16, P24820, DOI 10.3390/ijms161024820
   Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092 8674(03)00433 1
   Krzeszinski JY, 2015, TRENDS PHARMACOL SCI, V36, P360, DOI [10.1016/J.tips.2015.04.006, 10.1016/j.tips.2015.04.006]
   Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505
   Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344
   Lu X, 2009, GENE DEV, V23, P1882, DOI 10.1101/gad.1824809
   Luo X, 2017, MOL CELL, V65, P260, DOI 10.1016/j.molcel.2016.11.015
   Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005
   Menten P, 2002, CYTOKINE GROWTH F R, V13, P455, DOI 10.1016/S1359 6101(02)00045 X
   Navarro J, 2017, SCI REP UK, V7, DOI 10.1038/srep41962
   Robaszkiewicz A, 2016, SCI REP UK, V6, DOI 10.1038/srep21131
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wang C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.58
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
NR 34
TC 31
Z9 35
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR 27
PY 2020
VL 11
IS 1
AR 1578
DI 10.1038/s41467 020 15429 z
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA KY2XX
UT WOS:000522436700005
PM 32221289
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Skarzynska, J
   Damulewicz, M
   Filipowska, J
   Madej, W
   Leboy, PS
   Osyczka, AM
AF Skarzynska, Joanna
   Damulewicz, Milena
   Filipowska, Joanna
   Madej, Wojciech
   Leboy, Phoebe S.
   Osyczka, Anna M.
TI Modification of Smad1 Linker Modulates BMP Mediated Osteogenesis of
   Adult Human MSC
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE bone marrow; mesenchymal stem cells (MSCs); bone morphogenetic protein
   (BMP); osteogenesis; Smad signaling
ID BONE MORPHOGENETIC PROTEINS; MESENCHYMAL STEM CELLS; SIGNAL REGULATED
   KINASE; MARROW STROMAL CELLS; RAT BONE; CLINICAL APPLICATIONS;
   GROWTH FACTOR; DIFFERENTIATION; PATHWAYS; INDUCTION
AB We examined whether bone morphogenetic protein (BMP) mediated osteogenesis of adult human mesenchymal stem cells (MSCs) is regulated by extracellular signal regulated kinase phosphorylation of Smad1. Adenoviral constructs carrying either unmodified human Smad1 or Smad1 mutated in the linker region to preclude extracellular signal regulated kinase phosphorylation were expressed in human and rodent cells. Unlike unmodified Smad1, expression of mutated Smad1 facilitated BMP stimulated expression of osteoblast markers in human MSC but had no effect on either rat MSC or mouse pre osteoblastic MC3T3 E1 cells. Expression of mutated Smad1 in adult human MSC cultures also resulted in increased nuclear accumulation of BMP activated Smads and elevated gene transcripts characteristic of differentiating osteoblasts. These results may partly explain the poor efficacy of BMP in some human bone therapies and indicate an important mechanism regulating BMP mediated bone formation in adults.
C1 [Skarzynska, Joanna; Damulewicz, Milena; Filipowska, Joanna; Madej, Wojciech; Osyczka, Anna M.] Jagiellonian Univ, Dept Cytol & Histol, Fac Biol & Earth Sci, PL 30060 Krakow, Poland.
   [Leboy, Phoebe S.] Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA.
C3 Jagiellonian University; University of Pennsylvania
RP Osyczka, AM (通讯作者)，Jagiellonian Univ, Dept Cytol & Histol, Fac Biol & Earth Sci, Ingardena 6, PL 30060 Krakow, Poland.
EM a.m.osyczka@uj.edu.pl
RI ; Damulewicz, Milena/AAK 2606 2020; Osyczka, Anna/AEQ 9499 2022
OI Osyczka, Anna/0000 0003 2423 5114; Damulewicz,
   Milena/0000 0002 1766 8328; 
FU NIH [AG026047]; EC [MIRG CT 2007 046479]; Polish Ministry of Science and
   Education [465/6.PRUE/2007/7]; Polish State Committee for Scientific
   Research [NN401 006135]
FX The authors thank Prof. Dr. hab. Tadeusz Niedzwiedzki from the
   Department of Orthopedic Surgery of the L. Rydygier's Hospital in Krakow
   for procuring bone marrow samples. Funding for this study was provided
   in part by NIH AG026047; MIRG CT 2007 046479 grant within EC 6FP,
   465/6.PRUE/2007/7 matching funds from Polish Ministry of Science and
   Education, and grant no. NN401 006135 from Polish State Committee for
   Scientific Research.
CR Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264 007 0424 8
   DE BP, 2005, INJURY S3, V36, pS43
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Eivers E, 2008, CURR OPIN GENET DEV, V18, P304, DOI 10.1016/j.gde.2008.06.001
   Forte A, 2007, J CELL BIOCHEM, V100, P293, DOI 10.1002/jcb.21025
   Friedman MS, 2006, J CELL BIOCHEM, V98, P538, DOI 10.1002/jcb.20719
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445 2197.2007.04175.x
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Hanada K, 1997, J BONE MINER RES, V12, P1606, DOI 10.1359/jbmr.1997.12.10.1606
   Herpin A, 2007, FEBS J, V274, P2977, DOI 10.1111/j.1742 4658.2007.05840.x
   Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827
   Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005 0303
   Osyczka AM, 2004, CELLS TISSUES ORGANS, V176, P109, DOI 10.1159/000075032
   RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022
   Sapkota G, 2007, MOL CELL, V25, P441, DOI 10.1016/j.molcel.2007.01.006
   Suzawa M, 2002, J BONE MINER RES, V17, P240, DOI 10.1359/jbmr.2002.17.2.240
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
NR 21
TC 9
Z9 10
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD OCT
PY 2011
VL 52
IS 5
BP 408
EP 414
DI 10.3109/03008207.2010.551568
PG 7
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA 819LM
UT WOS:000294827400006
PM 21405981
DA 2025 08 17
ER

PT J
AU Cortellini, A
   Cocciolone, V
   Irelli, A
   Pavese, F
   Sidoni, T
   Parisi, A
   Baldi, PL
   Venditti, O
   D'Orazio, C
   Bonfili, P
   Franzese, P
   Zugaro, L
   Verna, L
   Porzio, G
   Santini, D
   Cannita, K
   Ficorella, C
AF Cortellini, Alessio
   Cocciolone, Valentina
   Irelli, Azzurra
   Pavese, Francesco
   Sidoni, Tina
   Parisi, Alessandro
   Baldi, Paola Lanfiuti
   Venditti, Olga
   D'Orazio, Carla
   Bonfili, Pierluigi
   Franzese, Pietro
   Zugaro, Luigi
   Verna, Lucilla
   Porzio, Giampiero
   Santini, Daniele
   Cannita, Katia
   Ficorella, Corrado
TI The possible different roles of denosumab in prevention and cure breast
   cancer bone metastases: A "hypothesis generator' study from clinical
   practice
SO ONCOLOGY LETTERS
LA English
DT Article
DE denosumab; bone; breast cancer; aromatase inhibitors; bone recurrence
ID HORMONE RELATED PROTEIN; ZOLEDRONIC ACID; DOUBLE BLIND;
   PROGNOSTIC FACTORS; ADJUVANT THERAPY; FOLLOW UP; MECHANISMS; PLACEBO;
   WOMEN; RECURRENCE
AB The most frequent site of recurrence in breast cancer (BC) is the bone, particularly in patients with 'luminal like' disease. Denosumab has been shown to prevent aromatase inhibitors (AIs) induced bone resorption in postmenopausal early BC patients and reduce skeletal related events (SREs) in bone metastatic breast cancer (BMBC). A 'real life' analysis of 90 BMBC patients treated with denosumab was performed. Eighty six patients (95.6%) had 'luminal like' disease, 72 (80%) had bone metastases at the time of first recurrence of disease. Among 50 patients with metachronous 'luminal like' disease, 40 (80%) had first recurrence to the bone. Among these patients median time to skeletal recurrence (TSkR) was shorter for patients who were previously exposed to AIs compared to those who were not (53.0 vs. 102.0 months, respectively; P=0.0300) and longer for patients previously treated with tamoxifen compared to those who were not (102.0 vs. 59.0 months, respectively; P=0.0466). Both of them were not confirmed at multivariate analysis. In the overall population, 17 first SREs were observed (16 radiation therapy) and median time to first SRE was not reached. A statistically significant difference in the incidence of SREs was detected only between patients with exclusively osteolytic bone metastases vs. those without (P=0.013). The presence of exclusively osteolytic bone metastases was the only factor significantly associated with a shorter time to first SRE (P=0.011). The only G3 toxicity reported was hypocalcemia in one patient. No osteonecrosis of the jaw events (ONJ) occurred. This study demonstrated that a pro active attitude enables the treatment of the majority of patients with denosumab without significant class related toxicities. The majority of SREs were from radiation therapy, so pain still remains the clinical hallmark of bone metastases, particularly for osteolytic ones. The suggestion that estrogen deprivation with AIs can favor a 'bone related' risk conditions for developing bone metastases must be considered with caution and surely needs further validations.
C1 [Cortellini, Alessio; Cocciolone, Valentina; Irelli, Azzurra; Pavese, Francesco; Parisi, Alessandro; D'Orazio, Carla; Verna, Lucilla; Porzio, Giampiero; Ficorella, Corrado] St Salvatore Hosp, Med Oncol, Via Vetoio, I 67100 Laquila, Italy.
   [Cortellini, Alessio; Cocciolone, Valentina; Irelli, Azzurra; Pavese, Francesco; Sidoni, Tina; Parisi, Alessandro; Baldi, Paola Lanfiuti; Venditti, Olga; D'Orazio, Carla; Porzio, Giampiero; Cannita, Katia; Ficorella, Corrado] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio, I 67100 Laquila, Italy.
   [Bonfili, Pierluigi; Franzese, Pietro] St Salvatore Hosp, Dept Radiat Oncol, I 67100 Laquila, Italy.
   [Zugaro, Luigi] St Salvatore Hosp, Div Emergency Radiol, I 67100 Laquila, Italy.
   [Santini, Daniele] Campus Biomed Univ, Med Oncol, I 00128 Rome, Italy.
C3 University of L'Aquila; University Campus Bio Medico   Rome Italy
RP Cortellini, A (通讯作者)，St Salvatore Hosp, Med Oncol, Via Vetoio, I 67100 Laquila, Italy.; Cannita, K (通讯作者)，Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio, I 67100 Laquila, Italy.
EM alessiocortellini@gmail.com; kcannita@gmail.com
RI Venditti, Olga/AAA 4321 2019; Parisi, Alessandro/AAB 9728 2019;
   Cortellini, Alessio/AAB 8609 2019
OI Irelli, Azzurra/0000 0003 4724 6297; Cortellini,
   Alessio/0000 0002 1209 5735; Parisi, Alessandro/0000 0003 4629 7762;
   Cocciolone, Valentina/0009 0007 1460 1391; Pavese,
   Francesco/0000 0002 4218 6726
CR Ahn SG, 2013, YONSEI MED J, V54, P1168, DOI 10.3349/ymj.2013.54.5.1168
   BRIASOULIS E, 2014, CANCER, V101, P1524
   BUNDRED NJ, 1992, EUR J CANCER, V28A, P690, DOI 10.1016/S0959 8049(05)80127 3
   Chin AR, 2016, CLIN CANCER RES, V22, P3725, DOI 10.1158/1078 0432.CCR 16 0028
   Cleeland CS, 2013, CANCER AM CANCER SOC, V119, P832, DOI 10.1002/cncr.27789
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 1998, BRIT J CANCER, V77, P336, DOI 10.1038/bjc.1998.52
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   COX DR, 1972, J R STAT SOC B, V34, P187
   Falk S, 2014, J CLIN ONCOL, V32, P1647, DOI 10.1200/JCO.2013.51.7219
   Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521
   Geisler J, 2006, EUR J CANCER, V42, P2968, DOI 10.1016/j.ejca.2006.07.005
   Gnant M, 2011, CANCER RES, V71, DOI 10.1158/0008 5472.SABCS1151 2
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gobbini E, 2018, EUR J CANCER, V96, P17, DOI 10.1016/j.ejca.2018.03.015
   Ignatov A, 2018, J CANCER RES CLIN, V144, P1347, DOI 10.1007/s00432 018 2644 2
   Jacobson AF, 2001, CANCER AM CANCER SOC, V91, P17, DOI 10.1002/1097 0142(20010101)91:1<17::AID CNCR3>3.0.CO;2 K
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Karrison TG, 1999, JNCI J NATL CANCER I, V91, P80, DOI 10.1093/jnci/91.1.80
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   LEONE BA, 1988, AM J CLIN ONCOL CANC, V11, P618, DOI 10.1097/00000421 198812000 00004
   Lipton A, 2017, CANCER AM CANCER SOC, V123, P2444, DOI 10.1002/cncr.30682
   Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011
   MANTEL N, 1963, J AM STAT ASSOC, V58, P690
   Niikura N, 2011, ONCOLOGIST, V16, P155, DOI 10.1634/theoncologist.2010 0350
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Parkes A, 2018, NPJ BREAST CANCER, V4, DOI 10.1038/s41523 018 0054 x
   PARMELEE PA, 1995, J AM GERIATR SOC, V43, P130, DOI 10.1111/j.1532 5415.1995.tb06377.x
   Perez EA, 2006, J CLIN ONCOL, V24, P3629, DOI 10.1200/JCO.2005.05.4882
   PEREZ JE, 1990, AM J CLIN ONCOL CANC, V13, P294, DOI 10.1097/00000421 199008000 00005
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197 2456(96)00075 X
   SHERRY MM, 1986, AM J MED, V81, P381, DOI 10.1016/0002 9343(86)90286 X
   Steger Guenther G, 2011, Ther Adv Med Oncol, V3, P233, DOI 10.1177/1758834011412656
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tesarova P, 2013, REP PRACT ONCOL RADI, V18, P26, DOI 10.1016/j.rpor.2012.05.005
   Van Poznak CH, 2011, J CLIN ONCOL, V29, P1221, DOI 10.1200/JCO.2010.32.5209
   VARGAS SJ, 1992, J BONE MINER RES, V7, P971
   Yan TT, 2012, EUR J CANCER, V48, P187, DOI 10.1016/j.ejca.2011.10.021
NR 43
TC 2
Z9 2
U1 1
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD DEC
PY 2018
VL 16
IS 6
BP 7195
EP 7203
DI 10.3892/ol.2018.9561
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HB9GV
UT WOS:000451400400038
PM 30546457
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU De Ponte, FS
   Favaloro, A
   Siniscalchi, EN
   Centofanti, A
   Runci, M
   Cutroneo, G
   Catalfamo, L
AF De Ponte, Francesco Saverio
   Favaloro, Angelo
   Siniscalchi, Enrico Nastro
   Centofanti, Antonio
   Runci, Michele
   Cutroneo, Giuseppina
   Catalfamo, Luciano
TI Sarcoglycans and integrins in bisphosphonate treatment:
   Immunohistochemical and scanning electron microscopy study
SO ONCOLOGY REPORTS
LA English
DT Article
DE gingival mucosa; bisphosphonates; bone tissue; osteonecrosis;
   sarcoglycans; integrins; scanning electron microscopy;
   immunohistochemistry
ID HUMAN SKELETAL MUSCLE; NITROGEN CONTAINING BISPHOSPHONATES; INDUCE
   APOPTOSIS; CACO 2 CELLS; IN VITRO; OSTEONECROSIS; JAWS; PAMIDRONATE;
   LOCALIZATION; FEMUR
AB Osteonecrosis of the jaw is an adverse outcome associated with bisphosphonate treatment. Bisphosphonates are used in conjunction with antineoplastic chemotherapy for the treatment of hypercalcaemia associated with malignancy, lytic bone metastasis and multiple myeloma. However, it is not known if the osteonecrosis of the jaw lesion originates in the bone or whether it initiates in the gingival epithelium. Two bisphosphonates are commonly used in cancer treatment. One of these is pamidronate disodium, a second generation bisphosphonate that differs from the first generation drug because it inhibits bone resorption at a dose that does not affect bone mineralization. The other widely used BP, zoledronate, is a third generation drug that is the most potent bisphosphonate in clinical use, showing strong anti osteoclastic activity, similar to pamidronate. The aim of the present study was to evaluate the modifications of human oral mucosa and underlying bone in patients after treatment with these nitrogen containing bisphosphonates for 24 and 36 months. We analyzed the structural damage of the oral mucosa and damage of the perilesional mandibular bone observing possible correlations from them. Our results allow to express two hypotheses about the mechanism responsible for these results relating to mandible matrix necrosis; first, an increased skeletal microdamage associated with turnover suppression occurred early in treatment and progress with longer treatment duration, second, opening damage in osteonecrosis of the jaw modifies structural morphology of gingival epithelium.
C1 [De Ponte, Francesco Saverio; Siniscalchi, Enrico Nastro; Runci, Michele; Catalfamo, Luciano] Univ Messina, Dept Expt Med Surg & Odontostomatol Sci, I 98125 Messina, Italy.
   [Favaloro, Angelo; Centofanti, Antonio; Cutroneo, Giuseppina] Univ Messina, Dept Biomed Sci & Morphofunct Imaging, I 98125 Messina, Italy.
   [Favaloro, Angelo; Centofanti, Antonio; Cutroneo, Giuseppina] Ctr Neurolesi Bonino Pulejo, IRCCS, Messina, Italy.
C3 University of Messina; University of Messina; IRCCS Bonino Pulejo
RP Cutroneo, G (通讯作者)，Univ Messina, Dept Biomed Sci & Morphofunct Imaging, Via Consolare Valeria 1, I 98125 Messina, Italy.
EM gcutroneo@unime.it
RI ; centofanti, antonio/AAG 3641 2021; Catalfamo, Luciano/G 1856 2011; de
   Rosa, Francesco/AAC 5935 2022
OI NASTRO SINISCALCHI, Enrico/0000 0002 4424 0917; FAVALORO,
   Angelo/0000 0002 2283 2321; Centofanti, Antonio/0000 0002 8801 8285; DE
   PONTE, FRANCESCO SAVERIO/0000 0002 9255 4152; CUTRONEO,
   Giuseppina/0000 0002 3919 9630; 
CR Allegra A, 2007, HEMATOL ONCOL, V25, P164, DOI 10.1002/hon.819
   Anastasi G, 2006, EUR J HISTOCHEM, V50, P327
   Anastasi G, 2004, EUR J HISTOCHEM, V48, P245
   Anastasi G, 2003, CELLS TISSUES ORGANS, V175, P151, DOI 10.1159/000074631
   Anastasi G, 2008, J ANAT, V213, P284, DOI 10.1111/j.1469 7580.2008.00921.x
   Bauss F, 2008, CURR CLIN PHARMACOL, V3, P1, DOI 10.2174/157488408783329904
   Cheng A, 2005, AUST DENT J, V50, pS4, DOI 10.1111/j.1834 7819.2005.tb00384.x
   Ficarra G, 2005, J CLIN PERIODONTOL, V32, P1123, DOI 10.1111/j.1600 051X.2005.00842.x
   FLEISCH H, 1994, BRIT J CLIN PRACT, V48, P323
   Gutta R, 2007, ORAL SURG ORAL MED O, V103, P197, DOI 10.1016/j.tripleo.2006.05.006
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Idris AI, 2008, DRUG NEWS PERSPECT, V21, P533, DOI 10.1358/dnp.2008.21.10.1314055
   Iwata K, 2006, BONE, V39, P1053, DOI 10.1016/j.bone.2006.05.006
   Kapitola J, 1998, PHYSIOL RES, V47, P237
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mehrotra B, 2006, HEMATOL AM SOC HEMAT, V356 360, P515
   Merigo Elisabetta, 2006, Acta Biomed, V77, P109
   Migliorati CA, 2005, J AM DENT ASSOC, V136, P1658, DOI 10.14219/jada.archive.2005.0108
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Siniscalchi EN, 2010, ONCOL REP, V24, P129, DOI 10.3892/or_00000837
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
   TOBIAS JH, 1993, BONE, V14, P619, DOI 10.1016/8756 3282(93)90083 M
   TWISS IM, 1994, J PHARM SCI, V83, P699, DOI 10.1002/jps.2600830521
   Twiss IM, 1999, J BONE MINER RES, V14, P784, DOI 10.1359/jbmr.1999.14.5.784
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Wang CJ, 2003, J BONE JOINT SURG AM, V85A, P2121, DOI 10.2106/00004623 200311000 00009
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 34
TC 13
Z9 15
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021 335X
EI 1791 2431
J9 ONCOL REP
JI Oncol. Rep.
PD DEC
PY 2013
VL 30
IS 6
BP 2639
EP 2646
DI 10.3892/or.2013.2766
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 297AE
UT WOS:000330226200013
PM 24100935
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, YM
   Yu, P
   Gao, YY
   Ma, ZT
   Wang, H
   Long, YT
   Ma, ZA
   Liu, RH
AF Li, Yuman
   Yu, Ping
   Gao, Yingying
   Ma, Zitong
   Wang, Han
   Long, Yuting
   Ma, Zaina
   Liu, Renhui
TI Effects of the combination of Epimedii Folium and Ligustri Lucidi
   Fructus on apoptosis and autophagy in SOP rats and osteoblasts via
   PI3K/AKT/ mTOR pathway
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE UPLC Q TOF MS; Senile osteoporosis; Osteoblast; Autophagy / apoptosis;
   PI3K/Akt/mTOR; Epimedii Folium / Ligustri Lucidi Fructus
ID OXIDATIVE STRESS; CELL DEATH; OSTEOPOROSIS; ICARIIN; PRESERVES
AB Background: This study aimed to investigate the effects of the combination of Epimedii Folium (EF) and Ligustri Lucidi Fructus (LLF) on regulating apoptosis and autophagy in senile osteoporosis (SOP) rats. Methods: Firstly, we identified the components in the decoction and drug containing serum of EL (EF&LLF) by Ultra performance liquid chromatography quadrupole time of flight mass spectrometry (UPLC Q TOF MS). Secondly, SOP rats were treated with EF, LLF, EL and caltrate to evaluate the advantages of EL. Finally, H2O2 , chloroquine , and MHY1485 induced osteoblasts were treated with different doses of EL to reveal the molecular mechanism of EL. We detected bone microstructure, oxidative stress levels, ALP activity and the expressions of Bax, Bcl 2, caspase3, P53, Beclin 1, p PI3K, PI3K, p Akt, Akt, p mTOR, mTOR, and LC3 in vivo and in vitro. Results: 36 compounds in EL decoction and 23 in EL containing serum were identified, including flavonoids, iridoid terpenoids, phenylethanoid glycosides, polyols and triterpenoids. EL could inhibit apoptosis activity and increase ALP activity. In SOP rats and chloroquine inhibited osteoblasts, EL could improve bone tissue microstructure and osteoblasts functions by upregulating Bcl 2, Beclin1, and LC3 II/LC3 I, while downregulating p53 in all treatment groups. In H2O2 induced osteoblasts, EL could upregulate the protein and mRNA expressions of Bcl 2 while downregulate LC3 II/LC3 I, p53 and Beclin1. Besides, EL was able to down regulate PI3K/AKT/ mTOR pathway which activated in SOP rats and MHY1485 induced osteoblasts. Conclusions: These findings demonstrate that EL with bone protective effects on SOP rats by regulating autophagy and apoptosis via PI3K/Akt/mTOR signaling pathway, which might be an alternative medicine for the treatment of SOP.
C1 [Li, Yuman; Yu, Ping; Gao, Yingying; Ma, Zitong; Wang, Han; Long, Yuting; Ma, Zaina; Liu, Renhui] Capital Med Univ, Sch Tradit Chinese Med, 10 Xitoutiao, Beijing 100069, Peoples R China.
C3 Capital Medical University
RP Liu, RH (通讯作者)，Capital Med Univ, Sch Tradit Chinese Med, 10 Xitoutiao, Beijing 100069, Peoples R China.
EM gzblrh45@ccmu.edu.cn
RI Long, Yuting/MFJ 5300 2025; zitong, Ma/LFS 4594 2024
OI Li, Yuman/0000 0001 5415 3713; ma, zitong/0000 0003 3922 6472; 
FU Natural Science Foundation of Beijing China [7202014]; National Natural
   Science Foundation of China [81673993, 81873115]
FX <BOLD>Funding</BOLD> This work was supported by grants from Natural
   Science Foundation of Beijing China (No.7202014) , and National Natural
   Science Foun  dation of China (No. 81673993 and 81873115) .
CR Barnett A, 2011, J ALZHEIMERS DIS, V25, P385, DOI 10.3233/JAD 2011 101989
   Cai J, 2012, NEURAL REGEN RES, V7, P413, DOI 10.3969/j.issn.1673 5374.2012.06.002
   Chandra A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073553
   Chen XF, 2018, EUR J PHARMACOL, V819, P281, DOI 10.1016/j.ejphar.2017.12.025
   Chen YH, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/1596951
   Cheung ZH, 2011, J NEUROCHEM, V118, P317, DOI 10.1111/j.1471 4159.2011.07314.x
   Chew KCM, 2011, J BIOL CHEM, V286, P33380, DOI 10.1074/jbc.M111.268409
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Feng RJ, 2013, CELL BIOCHEM BIOPHYS, V67, P189, DOI 10.1007/s12013 013 9533 8
   Gunaratnam K, 2013, BIOL OPEN, V2, P1382, DOI 10.1242/bio.20136700
   Guo YY, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101915
   Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580 019 0110 x
   Hasty P, 2013, CELL CYCLE, V12, P20, DOI 10.4161/cc.22912
   Heras Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Ji D., 2021, J. Anhui Sci. Technol. Univ., V35, P54, DOI [10.11842/wst.20190730006, DOI 10.11842/WST.20190730006]
   Jiang YX, 2020, LIFE SCI, V246, DOI 10.1016/j.lfs.2020.117422
   Kaminskyy VO, 2014, ANTIOXID REDOX SIGN, V21, P86, DOI 10.1089/ars.2013.5746
   Kang Xue, 2013, Zhongguo Zhong Yao Za Zhi, V38, P4124
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Li H, 2017, MOLECULES, V22, DOI 10.3390/molecules22050689
   Li L, 2019, AGING US, V11, P9348, DOI 10.18632/aging.102376
   Li L, 2016, SCI REP UK, V6, DOI 10.1038/srep32131
   Li X, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101098
   Liang XX, 2019, J CELL BIOCHEM, V120, P13121, DOI 10.1002/jcb.28585
   Liu RH, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/184802
   Long YT, 2023, J ETHNOPHARMACOL, V314, DOI 10.1016/j.jep.2023.116547
   Luo D, 2016, OSTEOPOROSIS INT, V27, P1093, DOI 10.1007/s00198 015 3325 5
   Luo N, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI152868
   Ma HP, 2014, CELL PROLIFERAT, V47, P527, DOI 10.1111/cpr.12147
   Ma ZT, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/2319409
   Moriishi T, 2016, J BONE MINER RES, V31, P1366, DOI 10.1002/jbmr.2808
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Rossini M, 2016, EXPERT OPIN DRUG SAF, V15, P321, DOI 10.1517/14740338.2016.1136287
   Sfeir JG, 2022, MAYO CLIN PROC, V97, P1194, DOI 10.1016/j.mayocp.2022.03.011
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Sun K, 2020, OSTEOARTHR CARTILAGE, V28, P400, DOI 10.1016/j.joca.2020.02.027
   Suzuki R, 2020, J BONE MINER RES, V35, P1992, DOI 10.1002/jbmr.4053
   Tang XF, 2020, CHIN MED UK, V15, DOI 10.1186/s13020 020 00368 0
   Tang XF, 2019, FOOD FUNCT, V10, P8026, DOI [10.1039/c9fo01322a, 10.1039/C9FO01322A]
   Vatner SF, 2020, AGEING RES REV, V64, DOI 10.1016/j.arr.2020.101194
   Wang YF, 2022, PHYTOMEDICINE, V99, DOI 10.1016/j.phymed.2022.154020
   Wang Y, 2019, ADV EXP MED BIOL, V1206, P67, DOI 10.1007/978 981 15 0602 4_3
   Wen Y., 2012, Mod. Chin. Med., V14, P15, DOI [10.3969/j.issn.1673 4890.2012.05.004, DOI 10.3969/J.ISSN.1673 4890.2012.05.004]
   Wu Yan Wu Yan, 2014, Journal of Yunnan Agricultural University, V29, P701
   Wu Y, 2021, VET SCI, V8, DOI 10.3390/vetsci8090198
   Xi YH, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108850
   Xia J, 2022, PHYTOMEDICINE, V104, DOI 10.1016/j.phymed.2022.154331
   [肖然 Xiao Ran], 2020, [世界科学技术：中医药现代化, Modernization of Traditional Chinese Medicine and Materia Medica  World Science and Technology], V22, P392
   Xu G., 2019, J. Cell Biol., V41, P1127, DOI [10.11844/cjcb.2019.06.0016, DOI 10.11844/CJCB.2019.06.0016]
   Xu YX, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.894832
   Yang Y, 2017, J ETHNOPHARMACOL, V201, P91, DOI 10.1016/j.jep.2017.02.033
   [杨宗林 Yang Zonglin], 2017, [质谱学报, Journal of Chinese Mass Spectrometry Society], V38, P19
   Ye W, 2013, CONNECT TISSUE RES, V54, P22, DOI 10.3109/03008207.2012.715702
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
   余州, 2019, [细胞与分子免疫学杂志, Chinese Journal of Cellular and Molecular Immunology], V35, P849
   Zhai Yuan yuan, 2020, Yaoxue Xuebao, V55, P1222, DOI 10.16438/j.0513 4870.2020 0027
   Zhang Hao Jie, 2020, Zhongguo Zhong Yao Za Zhi, V45, P3871, DOI 10.19540/j.cnki.cjcmm.20200424.302
   Zhang M., 2022, J. Liaoning Univ. TCM, V24, P55, DOI [10.13194/j.issn.1673 842x.2022.05.013, DOI 10.13194/J.ISSN.1673 842X.2022.05.013]
   Zheng HX, 2018, MOLECULES, V23, DOI 10.3390/molecules23092398
   Zhou QZ, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/7067984
   Zhu SY, 2018, AGING CELL, V17, DOI 10.1111/acel.12764
NR 61
TC 5
Z9 7
U1 4
U2 14
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD APR
PY 2024
VL 173
AR 116346
DI 10.1016/j.biopha.2024.116346
EA MAR 2024
PG 17
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OR9X4
UT WOS:001209131300001
PM 38428312
OA gold
DA 2025 08 17
ER

PT J
AU Tang, XD
   Zhang, QZ
   Shi, SH
   Yen, Y
   Li, XY
   Zhang, YF
   Zhou, KY
   Le, AD
AF Tang, Xudong
   Zhang, Qunzhou
   Shi, Shihong
   Yen, Yun
   Li, Xiangyong
   Zhang, Yuefei
   Zhou, Keyuan
   Le, Anh D.
TI Bisphosphonates suppress insulin like growth factor 1 induced
   angiogenesis via the HIF 1α/VEGF signaling pathways in human
   breast cancer cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE bisphosphonates; breast cancer; IGF 1; HIF 1 alpha; VEGF; PI 3K/Akt;
   angiogenesis
ID HYPOXIA INDUCIBLE FACTOR 1 ALPHA; FACTOR I ACTIVITY; ZOLEDRONIC ACID;
   FACTOR EXPRESSION; TUMOR ANGIOGENESIS; INDUCED APOPTOSIS;
   PROSTATE CANCER; CARCINOMA CELLS; FACTOR RECEPTOR; FACTOR 1 ALPHA
AB Adjunctive chemotherapy with bisphosphonates has been reported to delay bone metastasis and improve overall survival in breast cancer. Aside from its antiresorptive effect, bisphosphonates exhibit antitumor activities, in vitro and in vivo, via several mechanisms, including antiangiogenesis. In this study, we investigated the potential molecular mechanisms underlying the antiangiogenic effect of non nitrogen containing and nitrogen containing bisphosphonates, clodronate and pamidronate, respectively, in insulin like growth factor (IGF) 1 responsive human breast cancer cells. We tested whether bisphosphonates had any effects on hypoxia inducible factor (HIF) 1 alpha/vascular endothelial growth factor (VEGF) axis that plays a pivotal role in tumor angiogenesis, and our results showed that both pamidronate and clodronate significantly suppressed IGF 1 induced HIF 1 alpha protein accumulation and VEGF expression in MCF 7 cells. Mechanistically, we found that either pamidronate or clodronate did not affect mRNA expression of HIF 1 alpha, but they apparently promoted the degradation of IGF 1 induced HIF 1 alpha protein. Meanwhile, we found that the presence of pamidronate and clodronate led to a dose dependent decease in the newly synthesized HIF 1 alpha protein induced by IGF 1 in breast cancer cells after proteasomal inhibition, thus, indirectly reflecting the inhibition of protein synthesis. In addition, our results indicated that the inhibitory effects of bisphosphonates on the HIF 1 alpha/VEGF axis are associated with the inhibition of the phosphoinositide 3 kinase/AKT/ mammalian target of rapamycin signaling pathways. Consistently, we demonstrated that pamidronate and clodronate functionally abrogated both in vitro and in vivo tumor angiogenesis induced by IGF 1 stimulated MCF 7 cells. These findings have highlighted an important mechanism of the pharmacological action of bisphosphonates in the inhibition of tumor angiogenesis in breast cancer cells.
C1 [Le, Anh D.] Univ So Calif, Div Surg Therapeut & Bioengn Sci, Ctr Craniofacial Mol Biol, Sch Dent, Los Angeles, CA 90033 USA.
   [Tang, Xudong; Li, Xiangyong; Zhou, Keyuan] Guangdong Med Coll, Inst Biochem & Mol Biol, Zhanjiang 524023, Guangdong, Peoples R China.
   [Yen, Yun] City Hope Natl Med Ctr, Dept Clin & Mol Pharmacol, Duarte, CA 91010 USA.
   [Zhang, Yuefei] Guangdong Med Coll, Affiliated Hosp 1, Dept Otorhinolaryngol, Zhanjiang 524023, Guangdong, Peoples R China.
C3 University of Southern California; Guangdong Medical University; City of
   Hope; Guangdong Medical University
RP Le, AD (通讯作者)，Univ So Calif, Div Surg Therapeut & Bioengn Sci, Ctr Craniofacial Mol Biol, Sch Dent, Hlth Sci Campus,2250 Alcazar St,CSA103, Los Angeles, CA 90033 USA.
EM kyz@gdmc.edu.cn; anhle@usc.edu
RI Zhang, Qunzhou/X 4504 2019; Zhou, Ke/HJY 3699 2023
FU National Institute of Health Research [IS11 AR47359, R03 CA128099]; Oral
   and Maxillofacial Surgery Foundation Research Support [OMSF002894];
   National Natural Science Foundation of China [30672741, 30872944]
FX Grant sponsor: National Institute of Health Research; Grant numbers:
   IS11 AR47359, R03 CA128099; Grant sponsor: Oral and Maxillofacial
   Surgery Foundation Research Support; Grant number: OMSF002894; Grant
   sponsor: National Natural Science Foundation of China; Grant numbers:
   30672741, 30872944
CR Akakura N, 2001, CANCER RES, V61, P6548
   Bäckman U, 2008, ANTICANCER RES, V28, P1551
   Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440 1711.2000.00928.x
   CARBONARE LD, 2005, MOL CELL ENDOCRINOL, V240, P23
   Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008 5472.CAN 05 2519
   Cascio S, 2008, ONCOGENE, V27, P540, DOI 10.1038/sj.onc.1210660
   Catrina SB, 2006, CLIN CANCER RES, V12, P4506, DOI 10.1158/1078 0432.CCR 05 2473
   Chen HHW, 2007, BREAST CANCER RES TR, V103, P167, DOI 10.1007/s10549 006 9360 3
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Clézardin P, 2003, CURR MED CHEM, V10, P173, DOI 10.2174/0929867033368529
   Coleman RE, 2005, ANN ONCOL, V16, P687, DOI 10.1093/annonc/mdi162
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984
   de Ostrovich KK, 2008, AM J PATHOL, V173, P824, DOI 10.2353/ajpath.2008.071005
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Duyndam MCA, 2007, BIOCHEM PHARMACOL, V74, P191, DOI 10.1016/j.bcp.2007.04.003
   Fang Y, 2007, EXP CELL RES, V313, P867, DOI 10.1016/j.yexcr.2006.12.004
   Ferretti G, 2005, ONCOLOGY BASEL, V69, P35, DOI 10.1159/000087286
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996 150
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Fromigue O, 2003, BRIT J CANCER, V89, P178, DOI 10.1038/sj.bjc.6601009
   Fu BB, 2007, MOL CANCER THER, V6, P220, DOI 10.1158/1535 7163.MCT 06 0526
   Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200
   Garcia Maceira P, 2009, ONCOGENE, V28, P313, DOI 10.1038/onc.2008.398
   Generali D, 2006, CLIN CANCER RES, V12, P4562, DOI 10.1158/1078 0432.CCR 05 2690
   Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201
   Greenberger LM, 2008, MOL CANCER THER, V7, P3598, DOI 10.1158/1535 7163.MCT 08 0510
   Haddad JJ, 2005, INT IMMUNOPHARMACOL, V5, P461, DOI 10.1016/j.intimp.2004.11.009
   Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805
   Han JY, 2005, JNCI J NATL CANCER I, V97, P1272, DOI 10.1093/jnci/dji251
   Hashimoto K, 2007, BIOCHEM BIOPH RES CO, V354, P478, DOI 10.1016/j.bbrc.2007.01.014
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008 5472.CAN 06 2355
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kimbro KS, 2006, ENDOCR RELAT CANCER, V13, P739, DOI 10.1677/erc.1.00728
   Kondo S, 2006, CANCER RES, V66, P9870, DOI 10.1158/0008 5472.CAN 06 1679
   Li YM, 2005, CANCER RES, V65, P3257, DOI 10.1158/0008 5472.CAN 04 1284
   Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008 5472.CAN 06 2701
   Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008
   Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Ottewell PD, 2008, CLIN CANCER RES, V14, P4658, DOI 10.1158/1078 0432.CCR 07 1545
   Pagé EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200
   Peng XH, 2006, J BIOL CHEM, V281, P25903, DOI 10.1074/jbc.M603414200
   Piret JP, 2002, ANN NY ACAD SCI, V973, P443, DOI 10.1111/j.1749 6632.2002.tb04680.x
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603 677
   Ribatti D, 2008, ONCOL REP, V19, P1109
   Riby JE, 2008, BIOCHEM PHARMACOL, V75, P1858, DOI 10.1016/j.bcp.2008.01.017
   Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535 7163.MCT 06 0080
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Saxena NK, 2008, CANCER RES, V68, P9712, DOI 10.1158/0008 5472.CAN 08 1952
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Senaratne SG, 2002, BREAST CANCER RES, V4, P18, DOI 10.1186/bcr412
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Slomiany MG, 2006, BIOCHEM BIOPH RES CO, V342, P851, DOI 10.1016/j.bbrc.2006.02.043
   Soltau J, 2008, ANTICANCER RES, V28, P933
   Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014 5793(02)02247 0
   Sutton KM, 2007, ONCOGENE, V26, P3920, DOI 10.1038/sj.onc.1210168
   Tan C, 2005, CANCER RES, V65, P605
   Tanaka H, 2006, CANCER RES, V66, P11263, DOI 10.1158/0008 5472.CAN 06 1699
   Tang XD, 2007, CLIN CANCER RES, V13, P2568, DOI 10.1158/1078 0432.CCR 06 2704
   Trastour C, 2007, INT J CANCER, V120, P1451, DOI 10.1002/ijc.22436
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619
   Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501
   Zhang QZ, 2004, INT J CANCER, V111, P849, DOI 10.1002/ijc.20334
   Zhong H, 1999, CANCER RES, V59, P5830
NR 72
TC 79
Z9 84
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
EI 1097 0215
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 1
PY 2010
VL 126
IS 1
BP 90
EP 103
DI 10.1002/ijc.24710
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 529DS
UT WOS:000272496700011
PM 19569175
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Yun, HM
   Park, KR
   Hong, JT
   Kim, EC
AF Yun, Hyung Mun
   Park, Kyung Ran
   Hong, Jin Tae
   Kim, Eun Cheol
TI Peripheral serotonin mediated system suppresses bone development and
   regeneration via serotonin 6 G protein coupled receptor
SO SCIENTIFIC REPORTS
LA English
DT Article
ID 5 HT6 RECEPTOR; REUPTAKE INHIBITORS; ALZHEIMERS DISEASE; ACTIVATION;
   MECHANISM; JAB1
AB Serotonin is important in brain functions and involved in neurological diseases. It is also drawn considerable attention in bone disease since it mainly produced by the gut. Serotonin 6 G protein coupled receptor (5 HT6R) is clinical targets for the treatment of neurological diseases. However, 5 HT6R as a therapeutic target in bone has not been reported. Herein, we found that 5 HT6R showed higher expression in bone, and its expression was increased during bone remodeling and osteoblast differentiation. The activation of 5 HT6R by ST1936 caused the inhibition of ALP activity and mineralization in primary osteoblast cultures, which was antagonized by SB258585, an antagonist and by the knockdown of 5 HT6R. Further investigation indicated that 5 HT6R inhibited osteoblast differentiation via Jab1 in BMP2 signaling but not PKA and ERK1/2. In vivo studies showed that the activation of 5 HT6R inhibited bone regeneration in the calvarial defect mice and also delayed bone development in newborn mice; this response was antagonized by SB258585. Therefore, our findings indicate a key role of 5 HT6R in bone formation through serotonin originating in the peripheral system, and suggest that it is a novel therapeutic target for drug development in the bone repair and bone diseases.
C1 [Yun, Hyung Mun; Kim, Eun Cheol] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 130701, South Korea.
   [Park, Kyung Ran] Kyung Hee Univ, Grad Sch, Dept Oral & Maxillofacial Regenerat, Seoul 130701, South Korea.
   [Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, 12 Gaesin Dong, Cheongju 361763, Chungbuk, South Korea.
   [Hong, Jin Tae] Chungbuk Natl Univ, MRC, 12 Gaesin Dong, Cheongju 361763, Chungbuk, South Korea.
   [Kim, Eun Cheol] Kyung Hee Univ, Res Ctr Tooth & Periodontal Regenerat MRC, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University; Chungbuk National
   University; Chungbuk National University; Kyung Hee University
RP Kim, EC (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 130701, South Korea.; Kim, EC (通讯作者)，Kyung Hee Univ, Res Ctr Tooth & Periodontal Regenerat MRC, Seoul 130701, South Korea.
EM eckim@khu.ac.kr
RI Kim, Cheorl Ho/T 6753 2019
FU National Research Foundation of Korea (NRF) grant   Korea government
   (MEST) [2012R1A5A2051384, 2015R1D1A1A01059240]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MEST) (Nos 2012R1A5A2051384,
   2015R1D1A1A01059240).
CR Asaoka N, 2015, NEUROPHARMACOLOGY, V95, P261, DOI 10.1016/j.neuropharm.2015.03.032
   Bornstein JC, 2012, FRONT NEUROSCI SWITZ, V6, DOI 10.3389/fnins.2012.00016
   Chen DX, 2013, J CELL SCI, V126, P234, DOI 10.1242/jcs.113795
   Côté F, 2003, P NATL ACAD SCI USA, V100, P13525, DOI 10.1073/pnas.2233056100
   Deckelbaum RA, 2006, DEVELOPMENT, V133, P63, DOI 10.1242/dev.02171
   Duhr F, 2014, NAT CHEM BIOL, V10, P590, DOI [10.1038/nchembio.1547, 10.1038/NCHEMBIO.1547]
   Eom CS, 2012, J BONE MINER RES, V27, P1186, DOI 10.1002/jbmr.1554
   Gershon MD, 2007, GASTROENTEROLOGY, V132, P397, DOI 10.1053/j.gastro.2006.11.002
   Haag J, 2006, ARTHRITIS RHEUM, V54, P3878, DOI 10.1002/art.22261
   Jonason JH, 2014, METHODS MOL BIOL, V1130, P295, DOI 10.1007/978 1 62703 989 5_22
   Kohen R, 1996, J NEUROCHEM, V66, P47
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   MANN JJ, 1992, ARCH GEN PSYCHIAT, V49, P442
   Meffre J, 2012, EMBO MOL MED, V4, P1043, DOI 10.1002/emmm.201201410
   Opperman LA, 2000, DEV DYNAM, V219, P472, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1073>3.0.CO;2 F
   Riccioni T, 2011, EUR J PHARMACOL, V661, P8, DOI 10.1016/j.ejphar.2011.04.028
   Rosen CJ, 2009, NAT MED, V15, P145, DOI 10.1038/nm0209 145
   Seo J, 2014, NAT CHEM BIOL, V10, P488, DOI 10.1038/nchembio.1557
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Svenningsson P, 2002, P NATL ACAD SCI USA, V99, P3188, DOI 10.1073/pnas.052712699
   Sykaras Nikitas, 2003, J Oral Sci, V45, P57
   Warden SJ, 2005, ENDOCRINOLOGY, V146, P685, DOI 10.1210/en.2004 1259
   Wilkinson D, 2014, LANCET NEUROL, V13, P1092, DOI 10.1016/S1474 4422(14)70198 X
   Woolley ML, 2004, CNS NEUROL DISORD DR, V3, P59, DOI 10.2174/1568007043482561
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yun HM, 2007, J BIOL CHEM, V282, P5496, DOI 10.1074/jbc.M606215200
   Yun HM, 2015, ONCOTARGET, V6, P26716, DOI 10.18632/oncotarget.5777
   Yun Hyung Mun, 2011, Exp Neurobiol, V20, P159, DOI 10.5607/en.2011.20.4.159
   Yun HM, 2010, J BIOL CHEM, V285, P10016, DOI 10.1074/jbc.M109.068759
NR 30
TC 25
Z9 30
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 1
PY 2016
VL 6
AR 30985
DI 10.1038/srep30985
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DU7BN
UT WOS:000382368400001
PM 27581523
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wu, HB
   Hu, B
   Zhou, XP
   Zhou, CH
   Meng, JH
   Yang, YT
   Zhao, X
   Shi, ZL
   Yan, SG
AF Wu, Haobo
   Hu, Bin
   Zhou, Xiaopeng
   Zhou, Chenhe
   Meng, Jiahong
   Yang, Yute
   Zhao, Xiang
   Shi, Zhongli
   Yan, Shigui
TI Artemether attenuates LPS induced inflammatory bone loss by inhibiting
   osteoclastogenesis and bone resorption via suppression of MAPK signaling
   pathway
SO CELL DEATH & DISEASE
LA English
DT Article
ID INDUCED OSTEOLYSIS; IN VIVO; PERIPROSTHETIC OSTEOLYSIS;
   ANTIMALARIAL DRUG; PARTICLE DISEASE; TNF ALPHA; DIFFERENTIATION;
   MECHANISMS; LIPOPOLYSACCHARIDE; ENDOTOXIN
AB Osteolysis is an osteolytic lesion featured by enhanced osteoclast formation and potent bone erosion. Lacking of effective regimen for treatment of the pathological process highlights the importance of identifying agents that can suppress the differentiation and function of osteoclast. Artemether is a natural compound derived from Artemisia annua L. and it is popularized for the treatment of malaria. In present study, we demonstrated that artemether could suppress RANKL induced osteoclastogenesis and expression of osteoclast marker genes such as tartrate resistant acid phosphatase, cathepsin K, matrix metalloproteinase 9, nuclear factor of activated T cell cytoplasmic 1, and dendritic cell specific transmembrane protein. It inhibited the osteoclastic bone resorption in a dose dependent manner in vitro. Furthermore, artemether attenuated RANKL induced MAPKs (ERK, JNK, p 38) activity. In addition, we have showed that artemether was able to mitigate bone erosion in a murine model of LPS induced inflammatory bone loss. Taken together, these findings suggest that artemether reduces inflammatory bone loss via inhibition of MAPKs activation during osteoclast differentiation, and it might be a potential candidate for the treatment of osteoclast related disorders.
C1 [Wu, Haobo; Hu, Bin; Zhou, Xiaopeng; Zhou, Chenhe; Meng, Jiahong; Yang, Yute; Zhao, Xiang; Shi, Zhongli; Yan, Shigui] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthoped Surg, Hangzhou 310009, Zhejiang, Peoples R China.
   [Wu, Haobo; Hu, Bin; Zhou, Xiaopeng; Zhou, Chenhe; Meng, Jiahong; Yang, Yute; Zhao, Xiang; Shi, Zhongli; Yan, Shigui] Zhejiang Univ, Orthoped Res Inst, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Yan, SG (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthoped Surg, Hangzhou 310009, Zhejiang, Peoples R China.; Yan, SG (通讯作者)，Zhejiang Univ, Orthoped Res Inst, Hangzhou 310009, Zhejiang, Peoples R China.
EM zrjwsj@zju.edu.cn
RI ; Zhou, Chenhe/AAI 9226 2020
OI Yan, Shigui/0000 0001 9096 2868; 
FU National Natural Science Foundation of China [81772360, 81371954,
   81401785]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81772360, 81371954, 81401785).
CR Angel NZ, 2000, J BONE MINER RES, V15, P103, DOI 10.1359/jbmr.2000.15.1.103
   Bi YM, 2001, J BONE MINER RES, V16, P2082, DOI 10.1359/jbmr.2001.16.11.2082
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Chen X, 2017, FASEB J, V31, P4855, DOI 10.1096/fj.201700316R
   Cuzzocrea S, 2005, IMMUNOPHARM IMMUNOT, V27, P615, DOI 10.1080/08923970500418786
   Gallo J, 2013, INNATE IMMUN LONDON, V19, P213, DOI 10.1177/1753425912451779
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Greenfield EM, 2005, J BIOMED MATER RES B, V72B, P179, DOI 10.1002/jbm.b.30150
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Holt G, 2007, CLIN ORTHOP RELAT R, P240, DOI 10.1097/BLO.0b013e31804b4147
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Hu XY, 2017, ACTA BIOMATER, V48, P479, DOI 10.1016/j.actbio.2016.11.022
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim HA, 2006, ARTHRITIS RHEUM US, V54, P2152, DOI 10.1002/art.21951
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim KJ, 2015, BONE, V81, P208, DOI 10.1016/j.bone.2015.07.023
   KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Maitz MF, 2009, J BIOMED MATER RES B, V90B, P18, DOI 10.1002/jbm.b.31247
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mwaiswelo R, 2017, AM J TROP MED HYG, V97, P526, DOI 10.4269/ajtmh.16 0780
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Nalepka JL, 2006, CLIN ORTHOP RELAT R, P229, DOI 10.1097/01.blo.0000224050.94248.38
   Okorji UP, 2016, MOL NEUROBIOL, V53, P6426, DOI 10.1007/s12035 015 9543 1
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Rasmussen SA, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01516 17
   Segawa H, 1999, J BONE JOINT SURG AM, V81A, P1434, DOI 10.2106/00004623 199910000 00008
   Skoglund B, 2002, J BONE JOINT SURG BR, V84B, P767, DOI 10.1302/0301 620X.84B5.11775
   Stevenson DA, 2011, CLIN GENET, V80, P566, DOI 10.1111/j.1399 0004.2010.01619.x
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tanaka S, 2006, ANN NY ACAD SCI, V1068, P180, DOI 10.1196/annals.1346.020
   Wagner EF, 2010, ANN RHEUM DIS, V69, P86, DOI 10.1136/ard.2009.119396
   Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597
   Wasko MK, 2016, J ORTHOP RES, V34, P1497, DOI 10.1002/jor.23292
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhu X, 2016, J BONE MINER RES, V31, P560, DOI 10.1002/jbmr.2710
NR 48
TC 66
Z9 70
U1 1
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD APR 27
PY 2018
VL 9
AR 498
DI 10.1038/s41419 018 0540 y
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GF2QG
UT WOS:000431784200002
PM 29703893
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xue, LM
   Jiao, L
   Wang, Y
   Nie, Y
   Han, T
   Jiang, YP
   Rahman, K
   Zhang, QY
   Qin, LP
AF Xue, Liming
   Jiao, Lei
   Wang, Yin
   Nie, Yan
   Han, Ting
   Jiang, Yiping
   Rahman, Khalid
   Zhang, Qiaoyan
   Qin, Luping
TI Effects and Interaction of Icariin, Curculigoside, and Berberine in
   Er Xian Decoction, a Traditional Chinese Medicinal Formula, on
   Osteoclastic Bone Resorption
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID FACTOR KAPPA B; RECEPTOR ACTIVATOR; HERBAL FORMULA; IN VITRO;
   DIFFERENTIATION; RANKL; SYNERGY; DAMAGE; NFAT2
AB Er Xian decoction (EXD), a traditional Chinese medicine, has been reported to have a protective effect against bone loss in ovariectomized osteoporotic rats, and the inclusion of icariin (I), curculigoside (C), and berberine (B) in EXD displays inhibitory effects on osteoclastic bone resorption. In the present paper, we investigated the interaction and effects of I, C, B, and their combination on bone resorption activity in vitro on osteoclasts derived from rat bone marrow cells. ICB synergistically decreased the formation of bone resorption pits, the number of multinucleated osteoclasts, and the activity of tartrate resistant acid phosphatase (TRAP) and showed antagonistic or additive effects on cathepsin K activity in the coculture system of osteoblasts and bone marrow cells in the presence of 1, 25 dihydroxyvitamin D 3 and dexamethasone. The combination of ICB also enhanced the inhibitory effects on the formation of F actin ring, a cytoskeleton structure of osteoclasts induced from bone marrow cells with macrophage colony stimulation factor (M CSF) and receptor activator of NF kappa B ligand (RANKL). In addition, ICB synergistically improved the ratio of protein expression of osteoprotegerin (OPG) and RANKL in osteoblasts and interfered with the mitogen activated protein kinases (MAPKs) pathway in osteoclast. These results clearly show that I, C, B, and their combination in EXD exert effects of mutual reinforcement. However, IBC does not show an intensified adverse effect in the ovariectomized murine model, as revealed by change in body and uterine weight, confirming the safety of EXD. These observations are in agreement with the rationality of the formula used in this paper.
C1 [Xue, Liming; Jiao, Lei; Nie, Yan; Han, Ting; Jiang, Yiping; Zhang, Qiaoyan; Qin, Luping] Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
   [Wang, Yin] PLA 455 Hosp, Dept Pharmaceut, Shanghai 200052, Peoples R China.
   [Rahman, Khalid] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Liverpool L3 3AF, Merseyside, England.
C3 Naval Medical University; Liverpool John Moores University
RP Zhang, QY (通讯作者)，Second Mil Med Univ, Sch Pharm, 325 Guohe Rd, Shanghai 200433, Peoples R China.
EM zqy1965@163.com; lpqin@smmu.edu.cn
RI HAN, TINGTING/GQZ 8692 2022; Xue, Liming/LMP 0982 2024
FU National Natural Science Foundation of China [81173191]; Shanghai
   Committee of Science and Technology, China [12401900702]
FX The work was supported by National Natural Science Foundation of China (
   81173191) and Shanghai Committee of Science and Technology, China
   (12401900702).
CR BLAZEJ M, 2009, GINEKOL POL, V80, P213
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen HY, 2008, AM J CHINESE MED, V36, P233, DOI 10.1142/S0192415X08005746
   Cheng KF, 2003, AM J CHINESE MED, V31, P163, DOI 10.1142/S0192415X0300093X
   Cicek M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017522
   Cole Z, 2008, BRIT MED BULL, V86, P129, DOI 10.1093/bmb/ldn017
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Han P, 2009, J CELL MOL MED, V13, P726, DOI 10.1111/j.1582 4934.2008.00365.x
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Jiao L, 2009, PHYTOMEDICINE, V16, P874, DOI 10.1016/j.phymed.2009.01.005
   Jin Z J, 1980, Zhongguo Yao Li Xue Bao, V1, P70
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li JJ, 2007, CHIN J INTEGR MED, V13, P67, DOI 10.1007/s11655 007 0067 z
   Li XJ, 2008, TRENDS PHARMACOL SCI, V29, P331, DOI 10.1016/j.tips.2008.04.002
   Liu XH, 2005, ENDOCRINOLOGY, V146, P1991, DOI 10.1210/en.2004 1167
   Liu Z., 1995, Acta Anatomic Sin, V26, P157
   Ma CJ, 2011, PHYTOTHER RES, V25, P922, DOI 10.1002/ptr.3449
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476 5381.2009.00593.x
   Nian H, 2006, J ETHNOPHARMACOL, V108, P96, DOI 10.1016/j.jep.2006.04.020
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   Qiu J, 2007, NATURE, V448, P126, DOI 10.1038/448126a
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytogfr.2003.10.005
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Wang Y, 2012, ACTA BIOCH BIOPH SIN, V44, P431, DOI 10.1093/abbs/gms014
   Williamson EM, 2001, PHYTOMEDICINE, V8, P401, DOI 10.1078/0944 7113 00060
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
NR 38
TC 25
Z9 25
U1 0
U2 27
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2012
VL 2012
AR 490843
DI 10.1155/2012/490843
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 035BW
UT WOS:000310918200001
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU He, LH
   Xiao, E
   An, JG
   He, Y
   Chen, S
   Zhao, L
   Zhang, T
   Zhang, Y
AF He, L. H.
   Xiao, E.
   An, J. G.
   He, Y.
   Chen, S.
   Zhao, L.
   Zhang, T.
   Zhang, Y.
TI Role of Bone Marrow Stromal Cells in Impaired Bone Repair from BRONJ
   Osseous Lesions
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE osteonecrosis; osteogenesis; bone resorption; osteoblast; osteoclast;
   cell differentiation
ID BISPHOSPHONATE RELATED OSTEONECROSIS; MESENCHYMAL STEM CELLS; JAW;
   THERAPY; ANGIOGENESIS; EXPRESSION; PATHWAYS; MULTIPLE; RANKL; MICE
AB Treatment of bisphosphonate related osteonecrosis of the jaw (BRONJ) has posed significant challenges to maxillofacial surgeons because of the poor repair of BRONJ bone defects. Moreover, the pathological mechanisms remain unclear. Bone marrow stromal cells (BMSCs) play key roles during bone repair and bone regeneration. However, the activities of BMSCs derived from BRONJ lesions and the BRONJ lesion boundary, as well as the roles of BMSCs in BRONJ defect repair, are poorly defined. In this study, we found that BMSCs from the central area of the osteonecrotic BRONJ region (center BRONJ BMSCs) and the peripheral area at the recommended debridement boundary (peri BRONJ BMSCs) had decreased proliferative ability, self renewal capacity, and multidifferentiation capacities compared with control BMSCs. Osteoclast inducing ability was also impaired in BRONJ BMSCs. All of these results suggested that the decreased activities of BRONJ BMSCs, even the BMSCs derived from the BRONJ lesion boundary, might be an important factor leading to insufficient bone repair of BRONJ lesions. This study offers early stage evidence for the use of marrow stromal cells in the treatment of BRONJ.
C1 [He, L. H.; Xiao, E.; An, J. G.; He, Y.; Chen, S.; Zhao, L.; Zhang, Y.] Peking Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, 22 Zhongguancun Nandajie, Beijing 100081, Peoples R China.
   [He, L. H.; Xiao, E.; An, J. G.; He, Y.; Chen, S.; Zhao, L.; Zhang, T.; Zhang, Y.] Beijing Key Lab Digital Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol, Beijing, Peoples R China.
   [Zhang, T.] Peking Univ, Dept Orthodont, Ctr Craniofacial Stem Cell Res & Regenerat, Sch & Hosp Stomatol, Beijing, Peoples R China.
C3 Peking University; Peking University
RP Zhang, Y (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, 22 Zhongguancun Nandajie, Beijing 100081, Peoples R China.
EM zhangyi2000@263.net
RI ; XIAO, E/AAA 7719 2020
OI Chen, Shuo/0000 0002 1087 9974; Xiao, E/0000 0002 0527 1542; He,
   Linhai/0000 0002 2157 0630
FU National Natural Science Foundation of China [81371117]; Beijing Natural
   Science Foundation [7152155]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (No. 81371117) and the Beijing Natural Science
   Foundation (No. 7152155). The funding agencies had no role in the
   project design, experimental execution, analysis of the results, or
   preparation of the manuscript. The authors declare no potential
   conflicts of interest with respect to the authorship and/or publication
   of this article.
CR Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Cella L, 2011, HEAD FACE MED, V7, DOI 10.1186/1746 160X 7 16
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Dougall WC, 2012, CLIN CANCER RES, V18, P326, DOI 10.1158/1078 0432.CCR 10 2507
   Fernández M, 2010, J CELL BIOCHEM, V111, P130, DOI 10.1002/jcb.22676
   Fliefel R, 2015, INT J ORAL MAX SURG, V44, P568, DOI 10.1016/j.ijom.2015.01.026
   Fournier P, 2002, CANCER RES, V62, P6538
   Gallagher JC, 2010, MATURITAS, V65, P301, DOI 10.1016/j.maturitas.2010.01.002
   Granero Moltó F, 2011, STEM CELLS, V29, P1537, DOI 10.1002/stem.697
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   He LH, 2015, J DENT RES, V94, P1392, DOI 10.1177/0022034515599149
   Hernigou P, 1999, J BONE JOINT SURG BR, V81B, P349, DOI 10.1302/0301 620X.81B2.8818
   Houdek MT, 2016, J ARTHROPLASTY, V31, P893, DOI 10.1016/j.arth.2015.08.017
   Kikuiri T, 2010, J BONE MINER RES, V25, P1668, DOI 10.1002/jbmr.37
   Lesclous P, 2009, BONE, V45, P843, DOI 10.1016/j.bone.2009.07.011
   Li YS, 2013, STEM CELLS DEV, V22, P2047, DOI 10.1089/scd.2012.0615
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Mücke T, 2011, J CANCER RES CLIN, V137, P907, DOI 10.1007/s00432 010 0953 1
   Nishida S, 2005, BIOCHEM BIOPH RES CO, V328, P91, DOI 10.1016/j.bbrc.2004.12.145
   Parfitt AM, 2000, BONE, V26, P319, DOI 10.1016/S8756 3282(00)80937 0
   Ruggiero SL, 2007, J DENT RES, V86, P1013, DOI 10.1177/154405910708601101
   Suh KT, 2005, CLIN ORTHOP RELAT R, P220, DOI 10.1097/01.blo.0000150568.16133.3c
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Wilde F, 2011, ORAL SURG ORAL MED O, V111, P153, DOI 10.1016/j.tripleo.2010.04.015
   Xiao CW, 2011, BIOMED MATER, V6, DOI 10.1088/1748 6041/6/1/015013
   Xiao E, 2013, J DENT RES, V92, P450, DOI 10.1177/0022034513483471
   Yamada T, 2013, BONE, V57, P343, DOI 10.1016/j.bone.2013.08.028
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhu XF, 2014, J ENDODONT, V40, P1573, DOI 10.1016/j.joen.2014.05.010
NR 30
TC 18
Z9 22
U1 1
U2 24
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD MAY
PY 2017
VL 96
IS 5
BP 539
EP 546
DI 10.1177/0022034517691507
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA ES9YM
UT WOS:000399917900009
PM 28199140
DA 2025 08 17
ER

PT J
AU Cao, Y
   Tan, XJ
   Shen, JW
   Liu, FB
   Xu, YK
   Chen, YZ
   Zhou, SR
   Qiu, TX
   Li, DX
   Zhao, Q
   Zhao, KW
AF Cao, Yue
   Tan, Xuejun
   Shen, Jiawen
   Liu, Fubin
   Xu, Yukun
   Chen, Yuzhen
   Zhou, Sirui
   Qiu, Tianxin
   Li, Dongxiao
   Zhao, Qing
   Zhao, Kewei
TI Morinda Officinalis derived extracellular vesicle like
   particles: Anti osteoporosis effect by regulating MAPK signaling pathway
SO PHYTOMEDICINE
LA English
DT Article
DE Morinda Officinalis; Extracellular vesicle like particles;
   Postmenopausal osteoporosis; MAPK signaling pathway
ID MECHANISMS; GROWTH
AB Background: Postmenopausal osteoporosis (PMOP) is a systemic bone disease characterized by low bone mass and microstructural damage. Morinda Officinalis (MO) contains various components with anti PMOP activities. Morinda Officinalis derived extracellular vesicle like particles (MOEVLPs) are new active components isolated from MO, and no relevant studies have investigated their anti osteoporosis effect and mechanism. Purpose: To investigate the alleviating effect of MOEVLPs on PMOP and the underlying mechanism. Methods: Differential centrifugation and ultracentrifugation were used to isolate MOEVLPs from MO. Transmission electron microscopy (TEM), flow nano analyzer, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE), agarose gel electrophoresis, and thin layer chromatography were employed to characterize MOEVLPs. PMOP mouse models were utilized to examine the anti PMOP effect of MOEVLPs. H&E and immunohistochemical staining were used for drug safety and osteogenic effect assessment. Mouse embryo osteoblast precursor cells (MC3T3 E1) were used in vitro experiments. CCK 8 kit, alizarin red staining, proteomic, bioinformatic analyses, and western blot were used to explore the mechanism of MOEVLPs. Results: In this study, MOEVLPs from MO were successfully isolated and characterized. Animal experiments demonstrated that MOEVLPs exhibited specific femur targeting, were non toxic to the heart, liver, spleen, lung, kidney, and aorta, and possessed anti PMOP properties. The ability of MOEVLPs to strengthen bone formation was better than that of alendronate. In vitro experiments, results revealed that MOEVLPs did not significantly enhance osteogenic differentiation in MC3T3 E1 cells. Instead, MOEVLPs promoted the proliferation of MC3T3E1 cells. Proteomic and bioinformatic analyses suggested that the proliferative effect of MOEVLPs was closely associated with the mitogen activated protein kinase (MAPK) signaling pathway, particularly the altered expression of cAMP response element binding protein (CREB) and ribosomal S6 kinase 1 (RSK1). Western blot results further confirmed these findings. Conclusion: Our studies successfully isolated high  quality MOEVLPs and demonstrated that MOEVLPs can alleviate PMOP by promoting osteoblast proliferation through the MAPK pathway. MOEVLPs have the potential to become a novel and natural anti PMOP drug.
C1 [Cao, Yue; Tan, Xuejun; Shen, Jiawen; Liu, Fubin; Xu, Yukun; Chen, Yuzhen; Zhou, Sirui; Qiu, Tianxin; Li, Dongxiao] Guangzhou Univ Chinese Med, Clin Med Coll 3, 261 & 263,Longxi Ave, Guangzhou 510375, Guangdong, Peoples R China.
   [Cao, Yue] Shaoguan Univ, Dept Med Technol, Med Coll, 288 Univ Rd, Shaoguan 512005, Guangdong, Peoples R China.
   [Zhao, Qing; Zhao, Kewei] Guangzhou Univ Chinese Med, Guangdong Engn Res Ctr Chinese Herbal Vesicles, 261 & 263,Longxi Ave, Guangzhou 510378, Guangdong, Peoples R China.
   [Zhao, Qing; Zhao, Kewei] Guangzhou Univ Chinese Med, Affiliated Hosp 3, Guangzhou Key Lab Chinese Med Res Prevent & Treatm, 261 & 263 Longxi Ave, Guangzhou 510378, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Shaoguan University; Guangzhou
   University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Zhao, Q; Zhao, KW (通讯作者)，Guangzhou Univ Chinese Med, Guangdong Engn Res Ctr Chinese Herbal Vesicles, 261 & 263,Longxi Ave, Guangzhou 510378, Guangdong, Peoples R China.
EM zhaoqing900116@126.com; zkw2011@gzucm.edu.cn
RI zheng, Huanquan/G 4739 2011; Zhao, Kewei/ADY 6907 2022; Zhao,
   Qing/MXK 4616 2025; 李, 冬筱/IAP 2721 2023; Zhou, sirui/JTS 9855 2023; xu,
   yukun/JQV 7789 2023
OI Xu, Yukun/0009 0008 1639 4901; 
FU National Natural Science Foundation of China [82174119]; Young Talent
   Support Project of Guangzhou Association for Science and Technology
   [QT20230101268]; Science and Technology Projects in Liwan District,
   Guangzhou [202201009, 20230710]; Special focus areas for general
   universities in Guangdong Province [2022ZDZX2016]; Guangdong Engineering
   Research Center of Chinese herbal vesicles
FX This work was supported by the National Natural Science Foundation of
   China [Grant number: 82174119] ; Young Talent Support Project of
   Guangzhou Association for Science and Technology [Grant number:
   QT20230101268] ; Science and Technology Projects in Liwan District,
   Guangzhou [Grant number: 202201009 and 20230710] ; Special focus areas
   for general universities in Guangdong Province [Grant number:
   2022ZDZX2016] ; Guangdong Engineering Research Center of Chinese herbal
   vesicles.
CR Bokka R, 2020, FOODS, V9, DOI 10.3390/foods9121852
   Cao M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425 019 0817 4
   Cui WW, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.864188
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fu SQ, 2020, CHEM BIODIVERS, V17, DOI 10.1002/cbdv.202000056
   Huang WW, 2023, ASIAN J SURG, V46, P1332, DOI 10.1016/j.asjsur.2022.08.100
   Jiang KM, 2018, INT J BIOL MACROMOL, V120, P170, DOI 10.1016/j.ijbiomac.2018.08.082
   Kim WS, 2022, CELLS BASEL, V11, DOI 10.3390/cells11182805
   Manolagas SC, 2014, MATURITAS, V78, P233, DOI 10.1016/j.maturitas.2014.04.013
   Nemati M, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964 022 00889 1
   Qi MS, 2005, J CELL SCI, V118, P3569, DOI 10.1242/jcs.02470
   Qiao F, 2022, INDIAN J PHARM SCI, V84, P58, DOI 10.36468/pharmaceutical sciences.895
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Raimondo S, 2022, J CELL MOL MED, V26, P4195, DOI 10.1111/jcmm.17404
   Rong K, 2022, J ORTHOP SURG HONG K, V30, DOI 10.1177/10225536221130824
   Wang YC, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15060708
   Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184
   Wu PY, 2022, KAOHSIUNG J MED SCI, V38, P675, DOI 10.1002/kjm2.12544
   Wu PY, 2022, PHARM BIOL, V60, P1303, DOI 10.1080/13880209.2022.2093385
   Yan CY, 2019, INT J BIOL MACROMOL, V133, P446, DOI 10.1016/j.ijbiomac.2019.04.084
   Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704
   Zhang CD, 2022, METABOLITES, V12, DOI 10.3390/metabo12100958
   Zhang C, 2019, EXP THER MED, V17, P3155, DOI 10.3892/etm.2019.7310
   Zhang DD, 2022, J PHARMACEUT BIOMED, V207, DOI 10.1016/j.jpba.2021.114422
   Zhang DW, 2020, J ETHNOPHARMACOL, V261, DOI 10.1016/j.jep.2020.113113
   Zhang JH, 2018, J ETHNOPHARMACOL, V213, P230, DOI 10.1016/j.jep.2017.10.028
   Zhao Q, 2024, CHIN HERB MED, V16, P3, DOI 10.1016/j.chmed.2023.11.002
   Zhong D, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03586 y
   Zhu Y, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1076348
NR 29
TC 12
Z9 13
U1 13
U2 58
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUL
PY 2024
VL 129
AR 155628
DI 10.1016/j.phymed.2024.155628
EA APR 2024
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA PT7B2
UT WOS:001216389700001
PM 38663117
OA hybrid
DA 2025 08 17
ER

PT J
AU Lian, Z
   Han, JS
   Huang, L
   Wei, CM
   Fan, YY
   Xu, JK
   Zhou, MY
   Feng, HT
   Liu, Q
   Chen, LZ
   Li, ZN
   Cheng, HC
   Yuan, GX
   Lin, XX
   Song, FM
   Su, YJ
   Wang, C
   Huang, GP
   Qin, A
   Song, YL
   Yao, GF
AF Lian, Zhen
   Han, Jinsong
   Huang, Lin
   Wei, Chengming
   Fan, Yongyong
   Xu, Jiake
   Zhou, Mengyu
   Feng, Haotian
   Liu, Qian
   Chen, Lingzi
   Li, Zhaoning
   Cheng, Haichun
   Yuan, Guixin
   Lin, Xixi
   Song, Fangming
   Su, Yiji
   Wang, Chao
   Huang, Guopeng
   Qin, An
   Song, Yunlong
   Yao, Guanfeng
TI 被撤回的出版物: A005, a novel inhibitor of phosphatidylinositol
   3 kinase/mammalian target of rapamycin, prevents osteosarcoma induced
   osteolysis (Retraction Article, 2017) (Retracted Article)
SO CARCINOGENESIS
LA English
DT Article; Retracted Publication
ID NF KAPPA B; MTOR; BONE; PHOSPHORYLATION; ACTIVATION; RESISTANCE; POTENT;
   LEADS; PI3K
AB Osteosarcoma is the most frequent primary bone tumor in children and adolescents. The phosphatidylinositol 3 kinase (PI3K)/ mammalian target of rapamycin (mTOR) signaling pathway is an attractive anticancer target because it plays key roles in the regulation of cell growth, division and differentiation. In this study, we demonstrated high expression of PI3K/mTOR signaling pathway related genes in patients with osteosarcoma. We thus investigated the effects of A005, a newly synthesized dual PI3K/mTOR inhibitor, on osteosarcoma cells and in a mouse xenograft tumor model. The results confirmed that A005 inhibited the proliferation, migration and invasion of human osteosarcoma cells. In addition, A005 also inhibited receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation and bone resorption in vitro. Therefore, A005 was further applied to a SaOS 2 osteosarcoma induced mouse osteolysis model. A005 inhibited tumor growth and prevented osteosarcoma associated osteolysis via modulation of the PI3K/AKT/mTOR pathway. Overall, our results showed that A005 inhibited osteoclastogenesis and prevented osteosarcoma induced bone osteolysis by suppressing PI3K/AKT/mTOR signaling. These findings indicated that A005 may be a promising candidate drug for the treatment of human osteosarcoma.
C1 [Lian, Zhen; Chen, Lingzi; Li, Zhaoning; Yuan, Guixin; Huang, Guopeng] Shantou Univ, Affiliated Hosp 2, Dept Orthoped, Med Coll, Shantou 515041, Guangdong, Peoples R China.
   [Han, Jinsong; Song, Yunlong] Second Mil Med Univ, Sch Pharm, Dept Med Chem, Shanghai 200433, Peoples R China.
   [Han, Jinsong] Heidelberg Univ, Organ Chem Inst, Dept Med Chem, Neuenheimer Feld 270, D 69120 Heidelberg, Germany.
   [Huang, Lin] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Spine Surg, Dept Orthoped,Res Ctr Spinal & Pelv Tumor, Guangzhou 510120, Guangdong, Peoples R China.
   [Wei, Chengming] Guangxi Med Univ, Dept Orthoped, Collaborat Innovat Ctr Guangxi Biol Med, Guangxi 530021, Peoples R China.
   [Fan, Yongyong] Wenzhou Med Univ, Taizhou Hosp, Orthoped Dept, Linhai 317000, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Pathol & Lab Med, Dept Orthoped, Perth, WA 6009, Australia.
   [Zhou, Mengyu] Haicheng Cent Hosp, Dept Stomatol, Anshan 114200, Liaoning, Peoples R China.
   [Feng, Haotian; Liu, Qian; Lin, Xixi] Guangxi Med Univ, Dept Orthoped, Res Ctr Regenerat Med, Guangxi 530021, Peoples R China.
   [Cheng, Haichun] Guangzhou Med Univ, Shenzhen Shajing Affiliated Hosp, Dept Gen Surg, Shenzhen 518104, Guangdong, Peoples R China.
   [Su, Yiji] Guangxi Med Univ, Affiliated Hosp 1, Dept Rehabil, Guangxi 530021, Peoples R China.
   [Qin, An] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthoped Implants, Sch Med,Dept Orthoped, Shanghai 200011, Peoples R China.
C3 Shantou University; Naval Medical University; Ruprecht Karls University
   Heidelberg; Sun Yat Sen University; Guangxi Medical University; Wenzhou
   Medical University; University of Western Australia; Guangxi Medical
   University; Guangzhou Medical University; Guangxi Medical University;
   Shanghai Jiao Tong University
RP Song, YL (通讯作者)，Second Mil Med Univ, Sch Pharm, Dept Med Chem, Shanghai 200433, Peoples R China.; Qin, A (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthoped Implants, Sch Med,Dept Orthoped, Shanghai 200011, Peoples R China.
EM dr_qinan@163.com; ylsong@smmu.edu.cn; yao_guanfeng@hotmail.com
RI ; Huang, Lin/X 5137 2019; Han, Jinsong/D 3892 2015; Qin, An/J 2518 2019;
   xi, lin/JOK 1026 2023; Li, Zhaoning/O 9768 2014
OI Xu, Jiake/0000 0003 2021 8309; 
FU Institutions of Higher Education Doctoral Special Funding
   [20124402120004]; Municipal Nature and Science Funding of Shantou
   [E201100393]; Shanghai Pujiang Program [14pj1406200]; National Natural
   Science Foundation of China [81572167]; Sun Yat Sen University Clinical
   Research 5010 Program
FX This work was supported by the Institutions of Higher Education Doctoral
   Special Funding (20124402120004); Municipal Nature and Science Funding
   of Shantou (E201100393), Shanghai Pujiang Program (14pj1406200);
   National Natural Science Foundation of China (81572167); and Sun Yat Sen
   University Clinical Research 5010 Program.
CR Ahmad A, 2013, ANTI CANCER AGENT ME, V13, P1002, DOI 10.2174/18715206113139990078
   Branstetter D, 2015, J BONE ONCOL, V4, P59, DOI 10.1016/j.jbo.2015.06.002
   Divakar SKA, 2016, LEUKEMIA, V30, P86, DOI 10.1038/leu.2015.185
   Elkabets M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005747
   Gobin B, 2014, CANCER LETT, V344, P291, DOI 10.1016/j.canlet.2013.11.017
   Gupte A, 2015, CLIN CANCER RES, V21, P3216, DOI 10.1158/1078 0432.CCR 14 3026
   Han JS, 2016, EUR J MED CHEM, V122, P684, DOI 10.1016/j.ejmech.2016.06.030
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kolev VN, 2015, CANCER RES, V75, P446, DOI 10.1158/0008 5472.CAN 14 1223
   Kuliwaba JS, 2005, BBA MOL BASIS DIS, V1740, P1, DOI 10.1016/j.bbadis.2005.03.005
   Lee DF, 2007, CELL CYCLE, V6, P3011, DOI 10.4161/cc.6.24.5085
   Li ZP, 2016, ONCOTARGET, V7, P31892, DOI 10.18632/oncotarget.7441
   LIAN Z, 2017, CARCINOGENESIS
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535 7163.MCT 08 0017
   Marion A, 2012, INT J CANCER, V130, P2514, DOI 10.1002/ijc.26246
   McKinnon BD, 2016, HUM REPROD UPDATE, V22, P382, DOI 10.1093/humupd/dmv060
   Meng LH, 2015, ACTA PHARMACOL SIN, V36, P1163, DOI 10.1038/aps.2015.68
   Mohan S, 2015, CLIN CANCER RES, V21, P3946, DOI 10.1158/1078 0432.CCR 14 3377
   Ozes ON, 1999, NATURE, V401, P82
   Shaikh AB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040506
   Sizemore N, 1999, MOL CELL BIOL, V19, P4798
   Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183
   Ta H, 2009, CANCER METAST REV, V28, P247, DOI 10.1007/s10555 009 9186 7
   Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882
   Wang Y, 2014, INT IMMUNOPHARMACOL, V23, P77, DOI 10.1016/j.intimp.2014.07.028
   Xi YM, 2015, J CELL BIOCHEM, V116, P1837, DOI 10.1002/jcb.25159
   Zang CB, 2013, CANCER LETT, V339, P288, DOI 10.1016/j.canlet.2012.11.013
   Zhang J, 2015, CLIN CHIM ACTA, V444, P182, DOI 10.1016/j.cca.2014.12.041
   Zhou WY, 2014, DISCOV MED, V17, P301
NR 32
TC 6
Z9 7
U1 3
U2 28
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143 3334
EI 1460 2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD FEB
PY 2019
VL 40
IS 2
BP E1
EP E13
DI 10.1093/carcin/bgy036
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA IF0UG
UT WOS:000472792800001
PM 29635391
OA Bronze
DA 2025 08 17
ER

PT J
AU Pohl, S
   Angermann, A
   Jeschke, A
   Hendrickx, G
   Yorgan, TA
   Makrypidi Fraune, G
   Steigert, A
   Kuehn, SC
   Rolvien, T
   Schweizer, M
   Koehne, T
   Neven, M
   Winter, O
   Velho, RV
   Albers, J
   Streichert, T
   Pestka, JM
   Baldauf, C
   Breyer, S
   Stuecker, R
   Muschol, N
   Cox, TM
   Saftig, P
   Paganini, C
   Rossi, A
   Amling, M
   Braulke, T
   Schinke, T
AF Pohl, Sandra
   Angermann, Alexandra
   Jeschke, Anke
   Hendrickx, Gretl
   Yorgan, Timur A.
   Makrypidi Fraune, Georgia
   Steigert, Anita
   Kuehn, Sonja C.
   Rolvien, Tim
   Schweizer, Michaela
   Koehne, Till
   Neven, Mona
   Winter, Olga
   Velho, Renata Voltolini
   Albers, Joachim
   Streichert, Thomas
   Pestka, Jan M.
   Baldauf, Christina
   Breyer, Sandra
   Stuecker, Ralf
   Muschol, Nicole
   Cox, Timothy M.
   Saftig, Paul
   Paganini, Chiara
   Rossi, Antonio
   Amling, Michael
   Braulke, Thomas
   Schinke, Thorsten
TI The Lysosomal Protein Arylsulfatase B Is a Key Enzyme Involved in
   Skeletal Turnover
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ARYLSULFATASE B; LYSOSOMAL STORAGE DISORDERS; MUCOPOLYSACCHARIDOSIS TYPE
   VI; TARTRATE RESISTANT ACID PHOSPHATASE
ID REPLACEMENT THERAPY; BONE FORMATION; CATHEPSIN K; MICE; DEFICIENT;
   STORAGE; OSTEOPETROSIS; DISEASE; VI; OSTEOCLASTOGENESIS
AB Skeletal pathologies are frequently observed in lysosomal storage disorders, yet the relevance of specific lysosomal enzymes in bone remodeling cell types is poorly defined. Two lysosomal enzymes, ie, cathepsin K (Ctsk) and Acp5 (also known as tartrate resistant acid phosphatase), have long been known as molecular marker proteins of differentiated osteoclasts. However, whereas the cysteine protease Ctsk is directly involved in the degradation of bone matrix proteins, the molecular function of Acp5 in osteoclasts is still unknown. Here we show that Acp5, in concert with Acp2 (lysosomal acid phosphatase), is required for dephosphorylation of the lysosomal mannose 6 phosphate targeting signal to promote the activity of specific lysosomal enzymes. Using an unbiased approach we identified the glycosaminoglycan degrading enzyme arylsulfatase B (Arsb), mutated in mucopolysaccharidosis type VI (MPS VI), as an osteoclast marker, whose activity depends on dephosphorylation by Acp2 and Acp5. Similar to Acp2/Acp5( / ) mice, Arsb deficient mice display lysosomal storage accumulation in osteoclasts, impaired osteoclast activity, and high trabecular bone mass. Of note, the most prominent lysosomal storage accumulation was observed in osteocytes from Arsb deficient mice, yet this pathology did not impair production of sclerostin (Sost) and Fgf23. Because the influence of enzyme replacement therapy (ERT) on bone remodeling in MPS VI is still unknown, we additionally treated Arsb deficient mice by weekly injection of recombinant human ARSB from 12 to 24 weeks of age. We found that the high bone mass phenotype of Arsb deficient mice and the underlying bone cell deficits were fully corrected by ERT in the trabecular compartment. Taken together, our results do not only show that the function of Acp5 in osteoclasts is linked to dephosphorylation and activation of lysosomal enzymes, they also provide an important proof of principle for the feasibility of ERT to correct bone cell pathologies in lysosomal storage disorders. (c) 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
C1 [Pohl, Sandra; Makrypidi Fraune, Georgia; Velho, Renata Voltolini; Braulke, Thomas] Univ Med Ctr Hamburg Eppendorf, Dept Biochem, Childrens Hosp, Hamburg, Germany.
   [Angermann, Alexandra; Jeschke, Anke; Hendrickx, Gretl; Yorgan, Timur A.; Steigert, Anita; Kuehn, Sonja C.; Rolvien, Tim; Koehne, Till; Neven, Mona; Winter, Olga; Albers, Joachim; Pestka, Jan M.; Baldauf, Christina; Amling, Michael; Schinke, Thorsten] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Martinistr 52, D 20246 Hamburg, Germany.
   [Schweizer, Michaela; Muschol, Nicole] Univ Med Ctr Hamburg Eppendorf, Dept Electron Microscopy, Ctr Mol Neurobiol, Hamburg, Germany.
   [Koehne, Till] Univ Med Ctr Hamburg Eppendorf, Dept Orthodont, Hamburg, Germany.
   [Streichert, Thomas] Univ Hosp Cologne, Dept Clin Chem, Cologne, Germany.
   [Breyer, Sandra; Stuecker, Ralf] Childrens Hosp Hamburg Altona, Dept Orthoped, Hamburg, Germany.
   [Cox, Timothy M.] Univ Cambridge, Dept Med, Cambridge, England.
   [Saftig, Paul] Univ Kiel, Inst Biochem, Kiel, Germany.
   [Paganini, Chiara; Rossi, Antonio] Univ Pavia, Dept Mol Med, Pavia, Italy.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Cologne; University of Hamburg; University Medical Center
   Hamburg Eppendorf; University of Cambridge; University of Kiel;
   University of Pavia
RP Schinke, T (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Martinistr 52, D 20246 Hamburg, Germany.
EM schinke@uke.de
RI Saftig, Paul/A 7966 2010; Pohl, Sandra/AAF 1943 2020; Braulke,
   Thomas/AAV 9121 2020; Paganini, Chiara/AAB 5170 2022; Koehne,
   Till/AAC 4458 2020; Voltolini Velho, Renata/IYJ 4372 2023; Hendrickx,
   Gretl/HHC 1170 2022
OI Paganini, Chiara/0000 0003 1709 6339; Kohne, Till/0009 0000 8830 1964;
   Hendrickx, Gretl/0000 0001 6715 9241; Albers,
   Joachim/0000 0003 0582 1863; Pohl, Sandra/0000 0001 7409 7042; Braulke,
   Thomas/0000 0002 2336 8532
FU European Community [602300]; European Union [794386]; Deutsche
   Forschungsgemeinschaft [AM 103/25 1, SCHI 504/8 1, PO 1539/1 1, SFB877];
   Marie Curie Actions (MSCA) [794386] Funding Source: Marie Curie Actions
   (MSCA)
FX The research leading to these results has received funding from the
   European Community's Seventh Framework Programme under grant agreement
   no 602300 (SYBIL), from the European Union's Horizon 2020 research and
   innovation program under the Marie Sklodowska Curie grant agreement No
   794386, and from grants by the Deutsche Forschungsgemeinschaft (AM
   103/25 1, SCHI 504/8 1, PO 1539/1 1, SFB877). We thank Johannes Brand,
   Nicole Lueder, Andrea Nitsche, Gudrun Arndt, Chuda mani Raithore,
   Emanuela Szpotowicz, and Sandra Perkovic for expert technical
   assistance.
CR Balemans W., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P355
   Bergwitz C, 2012, ADV EXP MED BIOL, P72841
   Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969 2126(97)00185 8
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Braulke T, 2009, BBA MOL CELL RES, V1793, P605, DOI 10.1016/j.bbamcr.2008.10.016
   Briggs TA, 2011, NAT GENET, V43, P127, DOI 10.1038/ng.748
   Bune AJ, 2001, IMMUNOLOGY, V102, P103, DOI 10.1046/j.1365 2567.2001.01145.x
   Busse B, 2009, BONE, V45, P1034, DOI 10.1016/j.bone.2009.08.002
   Byers S, 1997, BONE, V21, P425, DOI 10.1016/S8756 3282(97)00175 0
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Cimaz R, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926 013 0389 0
   Clarke LA, 2015, BEST PRACT RES CL EN, V29, P219, DOI 10.1016/j.beem.2014.08.010
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Dhami R, 2004, J BIOL CHEM, V279, P1526, DOI 10.1074/jbc.M309465200
   Di Lorenzo G, 2018, MOL CELL PROTEOMICS, V17, P1612, DOI 10.1074/mcp.RA118.000720
   Esfandiari E, 2006, J BONE MINER RES, V21, P1367, DOI 10.1359/JBMR.060611
   Evers M, 1996, P NATL ACAD SCI USA, V93, P8214, DOI 10.1073/pnas.93.16.8214
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Ferla R, 2014, HUM GENE THER, V25, P609, DOI 10.1089/hum.2013.213
   Ferron M, 2013, GENE DEV, V27, P955, DOI 10.1101/gad.213827.113
   Frohbergh M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100882
   Gilkes JA, 2014, PEDIATR ENDOCR REV P, V12, P133
   Giugliani R, 2016, EXPERT OPIN EMERG DR, V21, P9, DOI 10.1517/14728214.2016.1123690
   Harmatz PR, 2017, FRONT BIOSCI LANDMRK, V22, P385, DOI 10.2741/4490
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hayman AR, 1996, DEVELOPMENT, V122, P3151
   Hinton RJ, 2017, J DENT RES, V96, P23, DOI 10.1177/0022034516668321
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Kollmann K, 2012, BRAIN, V135, P2661, DOI 10.1093/brain/aws209
   Kollmann K, 2013, EMBO MOL MED, V5, P1871, DOI 10.1002/emmm.201302979
   Kollmann K, 2010, EUR J CELL BIOL, V89, P117, DOI 10.1016/j.ejcb.2009.10.008
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Lachmann RH, 2011, CURR OPIN PEDIATR, V23, P588, DOI 10.1097/MOP.0b013e32834c20d9
   Lausch E, 2011, NAT GENET, V43, P132, DOI 10.1038/ng.749
   Litjens T, 2001, HUM MUTAT, V18, P282, DOI 10.1002/humu.1190
   Liu SG, 2006, AM J PHYSIOL ENDOC M, V291, pE38, DOI 10.1152/ajpendo.00008.2006
   Makrypidi G, 2012, MOL CELL BIOL, V32, P774, DOI 10.1128/MCB.06195 11
   MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306
   Müllerr Loennies S, 2010, AM J PATHOL, V177, P240, DOI 10.2353/ajpath.2010.090954
   Muenzer J, 2014, MOL GENET METAB, V111, P63, DOI 10.1016/j.ymgme.2013.11.015
   Niedzwiedzki T, 2015, J MOL ENDOCRINOL, V55, pR23, DOI 10.1530/JME 15 0067
   Parenti G, 2015, ANNU REV MED, V66, P471, DOI 10.1146/annurev med 122313 085916
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Peck SH, 2016, MOL GENET METAB, V118, P232, DOI 10.1016/j.ymgme.2016.06.002
   Priemel M, 2010, J BONE MINER RES, V25, P305, DOI 10.1359/jbmr.090728
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Saftig P, 1997, J BIOL CHEM, V272, P18628, DOI 10.1074/jbc.272.30.18628
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Schinke T, 2009, NAT MED, V15, P674, DOI 10.1038/nm.1963
   Schulze J, 2011, J BONE MINER RES, V26, P704, DOI 10.1002/jbmr.269
   Solanki GA, 2016, MOL GENET METAB, V118, P310, DOI 10.1016/j.ymgme.2016.06.001
   Sun PL, 2008, P NATL ACAD SCI USA, V105, P16590, DOI 10.1073/pnas.0807472105
   Suter A, 2001, DEVELOPMENT, V128, P4899
   Tekoah Y, 2013, BIOSCIENCE REP, V33, P771, DOI 10.1042/BSR20130081
   Vairo F, 2015, APPL CLIN GENET, V8, P245, DOI 10.2147/TACG.S68650
   van Meel E, 2011, TRAFFIC, V12, P912, DOI 10.1111/j.1600 0854.2011.01203.x
   Wraith JE, 2014, PEDIATR ENDOCR REV P, V12, P102
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zachos C, 2012, TRAFFIC, V13, P1113, DOI 10.1111/j.1600 0854.2012.01372.x
NR 60
TC 27
Z9 27
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2018
VL 33
IS 12
BP 2186
EP 2201
DI 10.1002/jbmr.3563
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HD1WB
UT WOS:000452301800012
PM 30075049
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Che, JM
   Chen, X
   Ren, WH
   Shang, P
AF Che, Jingmin
   Chen, Xin
   Ren, Weihao
   Shang, Peng
TI PTH 1 34 reduced apoptosis of MLO Y4 osteocyte like cells by activating
   autophagy and inhibiting ER stress under RPM conditions
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Osteocyte; Autophagy; PTH 1 34; Apoptosis; RPM
ID OSTEOBLAST APOPTOSIS; BONE FORMATION; WEIGHTLESSNESS
AB Osteocytes, as mechanosensitive cells residing within bone tissue, hold a pivotal role in averting the occurrence and progression of osteoporosis. The apoptosis of osteocytes induced by unloading is one of the contributing factors to osteoporosis, although the underlying molecular mechanisms have not been fully elucidated. PTH 1 34 is known to promote bone formation and inhibit bone loss by targeting osteoblasts and osteocytes. However, it is not known whether PTH 1 34 can inhibit osteocyte apoptosis under unloading conditions and the molecular mechanisms involved. In this study, we employed a Random Positioning Machine (RPM) to emulate unloading conditions and cultured MLO Y4 osteocyte like cells, in order to unravel the mechanisms through which PTH 1 34 constrains osteocyte apoptosis amidst unloading circumstances. Our findings revealed that PTH 1 34 activated autophagy while suppressing endoplasmic reticulum stress by curtailing the generation of reactive oxygen species (ROS) in MLO Y4 osteocyte like cells during unloading conditions. By shedding light on the osteoporosis triggered by skeletal unloading, this study contributes vital insights that may pave the way for the development of pharmacological interventions.
C1 [Che, Jingmin] Shaanxi Prov Peoples Hosp, Shaanxi Prov Key Lab Infect & Immune Dis, Xian, Shaanxi, Peoples R China.
   [Che, Jingmin; Chen, Xin; Ren, Weihao; Shang, Peng] Northwestern Polytech Univ Shenzhen, Res & Dev Inst, Shenzhen, Guangdong, Peoples R China.
   [Chen, Xin; Ren, Weihao] Northwestern Polytech Univ, Sch Life Sci, Xian, Shaanxi, Peoples R China.
   [Che, Jingmin; Chen, Xin; Ren, Weihao; Shang, Peng] Northwestern Polytech Univ, Key Lab Space Biosci & Biotechnol, Xian, Shaanxi, Peoples R China.
C3 Xi'an Medical University; Northwestern Polytechnical University;
   Northwestern Polytechnical University; Northwestern Polytechnical
   University
RP Che, JM (通讯作者)，Shaanxi Prov Peoples Hosp, Shaanxi Prov Key Lab Infect & Immune Dis, Xian, Shaanxi, Peoples R China.; Che, JM; Shang, P (通讯作者)，Northwestern Polytech Univ Shenzhen, Res & Dev Inst, Shenzhen, Guangdong, Peoples R China.
EM jm.che1123@mail.nwpu.edu.cn; shangpeng@nwpu.edu.cn
RI 车, 景敏/GYA 3521 2022
FU Shenzhen Science and Technology Program [JCYJ20210324141414034];
   Technology Talent Support Program of Shaanxi Provincial People's
   Hospital [2022JY 60]; Science and Technology Incubation Fund Project of
   Shaanxi Provincial People's Hospital [2022YJY 40]; Space Medical
   Experiment Project of China Manned Space Program [HYZHXM01008]; Space
   Utilization Project of China Manned Space Program [YYWT 0901 EXP 04]
FX This work was supported by the Shenzhen Science and Technology Program
   [grant number JCYJ20210324141414034] , the Technology Talent Support
   Program of Shaanxi Provincial People's Hospital [grant number 2022JY 60]
   , the Science and Technology Incubation Fund Project of Shaanxi
   Provincial People's Hospital [grant number 2022YJY 40] , the Space
   Medical Experiment Project of China Manned Space Program [grant number
   HYZHXM01008] , and the Space Utilization Project of China Manned Space
   Program [grant number YYWT 0901 EXP 04] .
CR Agas D, 2020, J CELL PHYSIOL, V235, P7516, DOI 10.1002/jcp.29654
   Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Brown M, 2016, J CELL SCI, V129, P2317, DOI 10.1242/jcs.179127
   Capriani C, 2012, J BONE MINER RES, V27, P2419, DOI 10.1002/jbmr.1800
   Chandra A, 2015, J BIOL CHEM, V290, P157, DOI 10.1074/jbc.M114.608158
   Chandra A, 2014, BONE, V67, P33, DOI 10.1016/j.bone.2014.06.030
   Che JM, 2023, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1048818
   Chen CH, 2018, J APPL PHYSIOL, V124, P1177, DOI 10.1152/japplphysiol.00871.2017
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Ezzat S, 2019, J CELL BIOCHEM, V120, P2560, DOI 10.1002/jcb.27552
   Gorman AM, 2012, PHARMACOL THERAPEUT, V134, P306, DOI 10.1016/j.pharmthera.2012.02.003
   Guo YF, 2021, J CELL PHYSIOL, V236, P4152, DOI 10.1002/jcp.30111
   Hotamisligil GS, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a006072
   Infanger M, 2006, CELL TISSUE RES, V324, P267, DOI 10.1007/s00441 005 0142 8
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kennedy OD, 2014, BONE, V64, P132, DOI 10.1016/j.bone.2014.03.049
   Kim JM, 2022, ELIFE, V11, DOI 10.7554/eLife.78069
   Kurihara M, 2021, CELLS TISSUES ORGANS, V210, P326, DOI 10.1159/000519086
   Lee S, 2018, MOL CELLS, V41, P1000
   Liu W, 2016, SCI REP UK, V6, DOI 10.1038/srep20404
   Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438
   Luo MZ, 2013, ADV SPACE RES, V51, P2058, DOI 10.1016/j.asr.2013.01.009
   Luo TW, 2018, TOXICOL IN VITRO, V52, P60, DOI 10.1016/j.tiv.2018.06.001
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Nishitoh H, 2012, J BIOCHEM, V151, P217, DOI 10.1093/jb/mvr143
   Piemontese M, 2016, SCI REP UK, V6, DOI 10.1038/srep24262
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Schnoke M, 2009, BONE, V45, P590, DOI 10.1016/j.bone.2009.05.006
   Sorice M, 2022, CELLS BASEL, V11, DOI 10.3390/cells11091479
   Tanaka KI, 2015, BIOCHEM BIOPH RES CO, V461, P193, DOI 10.1016/j.bbrc.2015.02.091
   van Loon JJWA, 2007, ADV SPACE RES, V39, P1161, DOI 10.1016/j.asr.2007.02.016
   Vashishth D, 2000, BONE, V26, P375, DOI 10.1016/S8756 3282(00)00236 2
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang XY, 2018, MOL MED REP, V18, P2681, DOI 10.3892/mmr.2018.9229
   Wang XY, 2020, EUR J PHARMACOL, V880, DOI 10.1016/j.ejphar.2020.173212
   Wei LW, 2023, CELL DEATH DISCOV, V9, DOI 10.1038/s41420 023 01331 2
   Weinstein RS, 2010, ENDOCRINOLOGY, V151, P2641, DOI 10.1210/en.2009 1488
   Yang JC, 2018, BONE, V114, P235, DOI 10.1016/j.bone.2018.06.012
   Yue JC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072346
   Zhu L, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.903432
NR 42
TC 0
Z9 3
U1 2
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAR 15
PY 2024
VL 967
AR 176364
DI 10.1016/j.ejphar.2024.176364
EA FEB 2024
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA LK6L8
UT WOS:001186732900001
PM 38316249
DA 2025 08 17
ER

PT J
AU Huang, YJ
   Cao, DY
   Zhang, MX
   Yang, Y
   Niu, GM
   Tang, LA
   Shen, Z
   Zhang, ZC
   Bai, YQ
   Min, DL
   He, AA
AF Huang, Yujing
   Cao, Dongyan
   Zhang, Manxue
   Yang, Yue
   Niu, Gengming
   Tang, Lina
   Shen, Zan
   Zhang, Zhichang
   Bai, Yueqing
   Min, Daliu
   He, Aina
TI Exploring the impact of PDGFD in osteosarcoma metastasis through
   single cell sequencing analysis
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Osteosarcoma; Metastasis; scRNA seq; PDGFD; Organoid
ID GROWTH FACTOR D; HIGH GRADE OSTEOSARCOMA; SOFT TISSUE SARCOMA;
   E CADHERIN; PHASE II; IFOSFAMIDE; ETOPOSIDE; CHILDREN; INVASION; BONE
AB Purpose The overall survival rate for metastatic osteosarcoma hovers around 20%. Responses to second line chemotherapy, targeted therapies, and immunotherapies have demonstrated limited efficacy in metastatic osteosarcoma. Our objective is to validate differentially expressed genes and signaling pathways between non metastatic and metastatic osteosarcoma, employing single cell RNA sequencing (scRNA seq) and additional functional investigations. We aim to enhance comprehension of metastatic mechanisms and potentially unveil a therapeutic target.Methods scRNA seq was performed on two primary osteosarcoma lesions (1 non metastatic and 1 metastatic). Seurat package facilitated dimensionality reduction and cluster identification. Copy number variation (CNV) was predicted using InferCNV. CellChat characterized ligand receptor based intercellular communication networks. Differentially expressed genes underwent GO function enrichment analysis and GSEA. Validation was achieved through the GSE152048 dataset, which identified PDGFD PDGFRB as a common ligand receptor pair with significant contribution. Immunohistochemistry assessed PDGFD and PDGFRB expression, while multicolor immunofluorescence and flow cytometry provided insight into spatial relationships and the tumor immune microenvironment. Kaplan Meier survival analysis compared metastasis free survival and overall survival between high and low levels of PDGFD and PDGFRB. Manipulation of PDGFD expression in primary osteosarcoma cells examined invasion abilities and related markers.Results Ten clusters encompassing osteoblasts, osteoclasts, osteocytes, fibroblasts, pericytes, endothelial cells, myeloid cells, T cells, B cells, and proliferating cells were identified. Osteoblasts, osteoclasts, and osteocytes exhibited heightened CNV levels. Ligand receptor based communication networks exposed significant fibroblast crosstalk with other cell types, and the PDGF signaling pathway was activated in non metastatic osteosarcoma primary lesion. These results were corroborated by the GSE152048 dataset, confirming the prominence of PDGFD PDGFRB as a common ligand receptor pair. Immunohistochemistry demonstrated considerably greater PDGFD expression in non metastatic osteosarcoma tissues and organoids, correlating with extended metastasis free and overall survival. PDGFRB expression showed no significant variation between non metastatic and metastatic osteosarcoma, nor strong correlations with survival times. Multicolor immunofluorescence suggested co localization of PDGFD with PDGFRB. Flow cytometry unveiled a highly immunosuppressive microenvironment in metastatic osteosarcoma. Manipulating PDGFD expression demonstrated altered invasive abilities and marker expressions in primary osteosarcoma cells from both non metastatic and metastatic lesions.Conclusions scRNA seq illuminated the activation of the PDGF signaling pathway in primary lesion of non metastatic osteosarcoma. PDGFD displayed an inhibitory effect on osteosarcoma metastasis, likely through the suppression of the EMT signaling pathway.
C1 [Huang, Yujing; Tang, Lina; Shen, Zan; Min, Daliu; He, Aina] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Oncol, Sch Med, Shanghai, Peoples R China.
   [Cao, Dongyan; Zhang, Manxue] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Syst Med Canc, Shanghai, Peoples R China.
   [Cao, Dongyan; Zhang, Manxue] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Biliary Pancreat Surg, Shanghai, Peoples R China.
   [Yang, Yue] Lanzhou Univ, Inst Toxicol, Sch Publ Hlth, Lanzhou 730000, Gansu, Peoples R China.
   [Niu, Gengming] Shanghai OneTar Biomed, Shanghai, Peoples R China.
   [Zhang, Zhichang] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Orthopaed, Sch Med, Shanghai, Peoples R China.
   [Bai, Yueqing] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Pathol, Sch Med, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Lanzhou University; Shanghai Jiao Tong University;
   Shanghai Jiao Tong University
RP He, AA (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Oncol, Sch Med, Shanghai, Peoples R China.
EM docmin1969@sjtu.edu.cn; ainahe@sjtu.edu.cn
RI NIU, NIU/AAA 1523 2022; cao, dongyan/KIK 2881 2024
FU China Postdoctoral Science Foundation
FX No Statement Available
CR Bacci G, 2003, ANN ONCOL, V14, P1126, DOI 10.1093/annonc/mdg286
   Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588
   Borkham Kamphorst E, 2015, BIOCHEM BIOPH RES CO, V457, P307, DOI 10.1016/j.bbrc.2014.12.106
   Brahmi M, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2020.100037
   Cadamuro M, 2019, J HEPATOL, V70, P700, DOI 10.1016/j.jhep.2018.12.004
   Corre I, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040976
   Dhupkar P, 2018, CANCER MED US, V7, P2654, DOI 10.1002/cam4.1518
   Duggan MA, 2016, AM J SURG PATHOL, V40, pE94, DOI 10.1097/PAS.0000000000000749
   Ehnman M, 2013, CANCER RES, V73, P2139, DOI 10.1158/0008 5472.CAN 12 1646
   Gao X, 2020, J CELL PHYSIOL, V235, P9834, DOI 10.1002/jcp.29796
   Gentet JC, 1997, EUR J CANCER, V33, P232, DOI 10.1016/S0959 8049(96)00439 X
   Goorin AM, 2002, J CLIN ONCOL, V20, P426, DOI 10.1200/JCO.20.2.426
   Gorlick R, 2003, CLIN CANCER RES, V9, P5442
   Grignani G, 2012, ANN ONCOL, V23, P508, DOI 10.1093/annonc/mdr151
   Grignani G, 2015, LANCET ONCOL, V16, P98, DOI 10.1016/S1470 2045(14)71136 2
   Han Y, 2019, CANCER LETT, V440, P116, DOI 10.1016/j.canlet.2018.10.011
   He LJ, 2021, BMC CANCER, V21, DOI 10.1186/s12885 021 08328 z
   Hu C, 2020, BMC CANCER, V20, DOI 10.1186/s12885 020 07216 2
   Hu JY, 2022, BMC CANCER, V22, DOI 10.1186/s12885 022 10264 5
   Jin K, 2021, AGING US, V13, P1859, DOI 10.18632/aging.103787
   Köksal H, 2019, SCAND J IMMUNOL, V89, DOI 10.1111/sji.12741
   Kong D, 2008, CANCER RES, V68, P1927, DOI 10.1158/0008 5472.CAN 07 3241
   Kourtidis A, 2017, EXP CELL RES, V358, P78, DOI 10.1016/j.yexcr.2017.04.006
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593
   Le Cesne A, 2019, EUR J CANCER, V119, P151, DOI 10.1016/j.ejca.2019.07.018
   Lee HW, 2020, GENOME MED, V12, DOI 10.1186/s13073 020 00741 6
   Li JJ, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/5940049
   Li XR, 2003, CYTOKINE GROWTH F R, V14, P91, DOI 10.1016/S1359 6101(02)00090 4
   Lin WH, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1137013
   Liu JQ, 2011, CLIN CANCER RES, V17, P3638, DOI 10.1158/1078 0432.CCR 10 2456
   Liu W, 2016, MOL MED REP, V13, P315, DOI 10.3892/mmr.2015.4515
   Lu MH, 2017, EUR REV MED PHARMACO, V21, P928
   Lu WS, 2022, ANGIOGENESIS, V25, P517, DOI 10.1007/s10456 022 09847 4
   Ma S., 2022, P NATL ACAD SCI US, V119
   McCarty JH, 2023, CANCER RES, V83, P1167, DOI 10.1158/0008 5472.CAN 23 0151
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Mu K., 2023, Ann Pancreat Cancer, V6
   Mulder K, 2021, IMMUNITY, V54, P1883, DOI 10.1016/j.immuni.2021.07.007
   Navid F, 2008, CANCER, V113, P419, DOI 10.1002/cncr.23586
   Noman MZ, 2019, CELLS BASEL, V8, DOI 10.3390/cells8091083
   Olsen RS, 2019, CANCER INVEST, V37, P99, DOI 10.1080/07357907.2019.1576191
   Palmerini E, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2312 3
   PosthumaDeBoer J, 2011, CLIN EXP METASTAS, V28, P493, DOI 10.1007/s10585 011 9384 x
   Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556
   Saraf AJ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00004
   Saylors RL, 2001, J CLIN ONCOL, V19, P3463, DOI 10.1200/JCO.2001.19.15.3463
   Sethi S, 2011, TRANSL ONCOL, V4, P212, DOI 10.1593/tlo.10244
   Shen AD, 2012, J SURG ONCOL, V105, P830, DOI 10.1002/jso.23012
   Suehara Y, 2019, CLIN CANCER RES, V25, P6346, DOI 10.1158/1078 0432.CCR 18 4032
   Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470 2045(17)30624 1
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501
   Ustach CV, 2004, CANCER RES, V64, P1722, DOI 10.1158/0008 5472.CAN 03 3047
   Uutela M, 2004, BLOOD, V104, P3198, DOI 10.1182/blood 2004 04 1485
   Van Winkle P, 2005, PEDIATR BLOOD CANCER, V44, P338, DOI 10.1002/pbc.20227
   Wang D, 2019, CANCER RES, V79, P7, DOI 10.1158/0008 5472.CAN 18 1086
   WARD WG, 1994, J CLIN ONCOL, V12, P1849, DOI 10.1200/JCO.1994.12.9.1849
   Wensman H, 2009, BREAST CANCER RES TR, V118, P333, DOI 10.1007/s10549 008 0243 7
   Wolf Dennen K, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1747677
   Xie L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc 2020 000798
   Xu L, 2005, CANCER RES, V65, P5711, DOI 10.1158/0008 5472.CAN 04 4313
   Yang HG, 2014, ONCOL LETT, V8, P193, DOI 10.3892/ol.2014.2079
   Yang QK, 2020, CANCER MANAG RES, V12, P4193, DOI 10.2147/CMAR.S251814
   Yang Y, 2022, J ONCOL, V2022, DOI 10.1155/2022/2214686
   Yuan Q, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935 020 01174 2
   Zhang C, 2020, AGING US, V12, P3486, DOI 10.18632/aging.102824
   Zhang H, 2016, BIOCHEM BIOPH RES CO, V478, P845, DOI 10.1016/j.bbrc.2016.08.035
   Zhu BR, 2018, CANCER BIOL THER, V19, P198, DOI 10.1080/15384047.2017.1416275
NR 69
TC 7
Z9 7
U1 5
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211 3428
EI 2211 3436
J9 CELL ONCOL
JI Cell. Oncol.
PD OCT
PY 2024
VL 47
IS 5
BP 1715
EP 1733
DI 10.1007/s13402 024 00949 3
EA APR 2024
PG 19
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology; Pathology
GA I4L3B
UT WOS:001207088100002
PM 38652223
OA hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Giatagana, EM
   Berdiaki, A
   Gaardlos, M
   Tsatsakis, AM
   Samsonov, SA
   Nikitovic, D
AF Giatagana, Eirini Maria
   Berdiaki, Aikaterini
   Gaardlos, Margrethe
   Tsatsakis, Aristidis M.
   Samsonov, Sergey A.
   Nikitovic, Dragana
TI Rapamycin induced autophagy in osteosarcoma cells is mediated via the
   biglycan/Wnt/b catenin signaling axis
SO AMERICAN JOURNAL OF PHYSIOLOGY CELL PHYSIOLOGY
LA English
DT Article
DE autophagy; b  catenin; biglycan; osteosarcoma; Wnt signaling pathway
ID WNT BETA CATENIN; LRP6 ECTODOMAIN; CHEMOTHERAPY; DECORIN; CANCER;
   EXPRESSION; APOPTOSIS; PROTEINS; BINDING; PROTEOGLYCANS
AB Biglycan is a class I secreted small leucine rich proteoglycan (SLRP), which regulates signaling pathways connected to bone pathologies. Autophagy is a vital catabolic process with a dual role in cancer progression. Here, we show that biglycan inhibits autophagy in two osteosarcoma cell lines (P < 0.001), while rapamycin induced autophagy decreases biglycan expression in MG63 osteosarcoma cells and abrogates the biglycan induced cell growth increase (P < 0.001). Rapamycin also inhibits I3 catenin translocation to the nucleus, inhibiting the Wnt pathway (P < 0.001) and reducing biglycan's colocalization with the Wnt coreceptor LRP6 (P < 0.05). Furthermore, biglycan exhibits protective effects against the chemotherapeutic drug doxorubicin in MG63 OS cells through an autophagy dependent manner (P < 0.05). Cotreatment of these cells with rapamycin and doxorubicin enhances cells response to doxorubicin by decreasing biglycan (P < 0.001) and I3 catenin (P < 0.05) expression. Biglycan deficiency leads to increased caspase 3 activation (P < 0.05), suggesting increased apoptosis of biglycan deficient cells treated with doxorubicin. Computational models of LRP6 and biglycan complexes suggest that biglycan changes the receptor's ability to interact with other signaling molecules by affecting the interdomain bending angles in the receptor structure. Biglycan binding to LRP6 activates the Wnt pathway and I3 catenin nuclear translocation by disrupting I3 catenin degradation complex (P < 0.01 and P < 0.05). Interestingly, this mechanism is not followed in moderately differentiated, biglycan nonexpressing U 2OS OS cells. To sum up, biglycan exhibits protective effects against the doxorubicin in MG63 OS cells by activating the Wnt signaling pathway and inhibiting autophagy.
C1 [Giatagana, Eirini Maria; Berdiaki, Aikaterini; Nikitovic, Dragana] Univ Crete, Med Sch, Lab Histol Embryol, Heraklion Greece, Iraklion, Greece.
   [Gaardlos, Margrethe; Samsonov, Sergey A.] Univ Gdansk, Fac Chem, Dept Theoret Chem, Gdansk, Poland.
   [Tsatsakis, Aristidis M.] Univ Crete, Sch Med, Lab Toxicol, Iraklion, Greece.
C3 University of Crete; Fahrenheit Universities; University of Gdansk;
   University of Crete
RP Nikitovic, D (通讯作者)，Univ Crete, Med Sch, Lab Histol Embryol, Heraklion Greece, Iraklion, Greece.
EM nikitovic@uoc.gr
RI Tsatsakis, Aristidis/H 2890 2013; Nikitovic, Dragana/AAS 6215 2020
OI Nikitovic, Dragana/0000 0003 3882 7399
FU Research Committee of the University of Crete (ELKE) [KA: 10028, KA:
   10648]; National Science Center of Poland (Narodowe Centrum Nauki)
   [UMO 2018/31/G/ST4/00246]
FX D.N. was funded by the Research Committee of the University of Crete
   (ELKE) , Grant Nos. KA: 10028 and KA: 10648. E. M.G. received a
   scholarship from the Research Committee of the University of Crete
   (ELKE) , Grant No. KA:10648. S.A.S. was funded by the National Science
   Center of Poland (Narodowe Centrum Nauki, Grant number
   UMO 2018/31/G/ST4/00246) .
CR Abdullah CS, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 37862 3
   Aggelidakis J, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00470
   Ando T, 2020, CANCERS, V12, DOI 10.3390/cancers12113097
   Antoniak A, 2021, J MOL GRAPH MODEL, V108, DOI 10.1016/j.jmgm.2021.108008
   Appunni S, 2019, CLIN CHIM ACTA, V491, P1, DOI 10.1016/j.cca.2019.01.003
   Baksh D, 2007, J CELL BIOCHEM, V101, P1109, DOI 10.1002/jcb.21097
   Beagle B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011821
   Berendsen AD, 2011, P NATL ACAD SCI USA, V108, P17022, DOI 10.1073/pnas.1110629108
   BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616
   Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065
   Buraschi S, 2013, P NATL ACAD SCI USA, V110, pE2582, DOI 10.1073/pnas.1305732110
   Cai Y, 2014, J CELL BIOCHEM, V115, P625, DOI 10.1002/jcb.24708
   Carrle D, 2006, INT ORTHOP, V30, P445, DOI 10.1007/s00264 006 0192 x
   Case D., 2022, Amber 2022
   Chang ZQ, 2014, SCI WORLD J, DOI 10.1155/2014/794756
   Chen JH, 2015, AUTOPHAGY, V11, P239, DOI 10.1080/15548627.2015.1009767
   Chen S, 2011, DEV CELL, V21, P848, DOI 10.1016/j.devcel.2011.09.007
   Chen SS, 2018, J LEUKOCYTE BIOL, V103, P377, DOI 10.1002/JLB.2CE1117 453RR
   Chen YY, 2019, ARTIF CELL NANOMED B, V47, P1971, DOI 10.1080/21691401.2019.1593853
   Cheng ZH, 2011, NAT STRUCT MOL BIOL, V18, P1204, DOI 10.1038/nsmb.2139
   Chu CW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030473
   Cortini M, 2017, CANCER LETT, V405, P90, DOI 10.1016/j.canlet.2017.07.024
   Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265
   Cui JC, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046 020 01685 w
   Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170
   Diehl V, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.801801
   Giatagana EM, 2022, CANCERS, V14, DOI 10.3390/cancers14051196
   Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200
   Gubbiotti MA, 2016, MATRIX BIOL, V55, P7, DOI 10.1016/j.matbio.2016.09.009
   Guo XG, 2019, J CELL PHYSIOL, V234, P3478, DOI 10.1002/jcp.26828
   Nguyen H, 2014, J AM CHEM SOC, V136, P13959, DOI 10.1021/ja5032776
   Hattinger CM, 2017, FUTURE ONCOL, V13, P673, DOI 10.2217/fon 2016 0519
   Hattinger CM, 2021, CANCERS, V13, DOI 10.3390/cancers13122878
   Holdsworth G, 2012, J BIOL CHEM, V287, P26464, DOI 10.1074/jbc.M112.350108
   Hosseini F, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114758
   Hoverter NP, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.139pe43
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263 7855(96)00018 5
   Iozzo RV, 2015, MATRIX BIOL, V42, P11, DOI 10.1016/j.matbio.2015.02.003
   Iozzo RV, 2011, BIOL EXTRACELL MATR, P197, DOI 10.1007/978 3 642 16555 9_6
   Islam M, 2013, J BIOL CHEM, V288, P35526, DOI 10.1074/jbc.M113.504530
   Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586 021 03819 2
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kram V, 2020, J HISTOCHEM CYTOCHEM, V68, P747, DOI 10.1369/0022155420937371
   Kühn K, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.31
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li CJ, 2013, FRONT BIOSCI LANDMRK, V18, P1385, DOI 10.2741/4187
   Li J, 2019, ONCOL LETT, V18, P2694, DOI 10.3892/ol.2019.10589
   Li J, 2016, ONCOTARGET, V7, P44763, DOI 10.18632/oncotarget.8206
   Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Lorzadeh S, 2021, BBA MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2020.118926
   Luo XM, 2018, INT J ONCOL, V53, P904, DOI 10.3892/ijo.2018.4442
   Lv MC, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935 021 02397 7
   Ma YM, 2013, BIOCHEM BIOPH RES CO, V431, P274, DOI 10.1016/j.bbrc.2012.12.118
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Martin Broto J, 2017, ANN ONCOL, V28, P2994, DOI 10.1093/annonc/mdx536
   Matoba K, 2017, CELL REP, V18, P32, DOI 10.1016/j.celrep.2016.12.017
   Mavrogonatou E, 2021, CANCERS, V13, DOI 10.3390/cancers13081987
   McEwan PA, 2006, J STRUCT BIOL, V155, P294, DOI 10.1016/j.jsb.2006.01.016
   Messerschmitt PJ, 2009, J AM ACAD ORTHOP SUR, V17, P515, DOI 10.5435/00124635 200908000 00005
   Mi KH, 2007, J NEUROCHEM, V101, P517, DOI 10.1111/j.1471 4159.2007.04447.x
   Mi KH, 2006, J BIOL CHEM, V281, P4787, DOI 10.1074/jbc.M508657200
   Mi KH, 2005, J CELL BIOCHEM, V95, P328, DOI 10.1002/jcb.20400
   Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008 5472.CAN 04 2463
   Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003 0034
   Nàger M, 2018, AUTOPHAGY, V14, P619, DOI 10.1080/15548627.2017.1423439
   Nehme G, 2020, ADV EXP MED BIOL, V1258, P167, DOI 10.1007/978 3 030 43085 6_11
   Nikitovic D, 2008, FEBS J, V275, P350, DOI 10.1111/j.1742 4658.2007.06205.x
   Onorati AV, 2018, CANCER AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Onufriev A, 2000, J PHYS CHEM B, V104, P3712, DOI 10.1021/jp994072s
   Pan S, 2009, OMICS, V13, P345, DOI 10.1089/omi.2009.0008
   Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741
   Pérez Plasencia C, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01037
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Poluzzi C, 2019, KIDNEY INT, V95, P540, DOI 10.1016/j.kint.2018.10.037
   Roedig H, 2019, FEBS J, V286, P2965, DOI 10.1111/febs.14791
   Sakamoto Y, 2011, CANCER SCI, V102, P799, DOI 10.1111/j.1349 7006.2011.01857.x
   Schaefer L, 2008, J BIOL CHEM, V283, P21305, DOI 10.1074/jbc.R800020200
   Schaefer L, 2017, FEBS J, V284, P10, DOI 10.1111/febs.13963
   Scherz Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Schrodinger L, 2018, Version
   Schulz M, 2021, MATRIX BIOL, V100, P150, DOI 10.1016/j.matbio.2021.06.001
   Scott PG, 2006, J BIOL CHEM, V281, P13324, DOI 10.1074/jbc.M513470200
   Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735
   Tamaddoni A, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104798
   TRAUPE H, 1992, GENOMICS, V13, P481, DOI 10.1016/0888 7543(92)90279 2
   Tzanakakis G, 2020, CANCERS, V12, DOI 10.3390/cancers12092401
   Unni N, 2019, JAMA ONCOL, V5, P1564, DOI 10.1001/jamaoncol.2019.2525
   Varadi M, 2022, NUCLEIC ACIDS RES, V50, pD439, DOI 10.1093/nar/gkab1061
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Xie WP, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/4857814
   Yang Q, 2017, MOL MED REP, V16, P1347, DOI 10.3892/mmr.2017.6729
   Yokoyama Noriko, 2007, J Mol Signal, V2, P11, DOI 10.1186/1750 2187 2 11
   Yu WX, 2020, EUR REV MED PHARMACO, V24, P915, DOI 10.26355/eurrev_202001_20076
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540
   Zhang XL, 2019, NEUROL RES, V41, P52, DOI 10.1080/01616412.2018.1531199
NR 99
TC 7
Z9 7
U1 1
U2 8
PU AMER PHYSIOLOGICAL SOC
PI Rockville
PA 6120 Executive Blvd, Suite 600, Rockville, MD, UNITED STATES
SN 0363 6143
EI 1522 1563
J9 AM J PHYSIOL CELL PH
JI Am. J. Physiol. Cell Physiol.
PD DEC
PY 2022
VL 323
IS 6
BP C1740
EP C1756
DI 10.1152/ajpcell.00368.2022
PG 17
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 7W2ZF
UT WOS:000913382000010
PM 36280393
DA 2025 08 17
ER

PT J
AU Kushwaha, P
   Tripathi, AK
   Gupta, S
   Kothari, P
   Upadhyay, A
   Ahmad, N
   Sharma, T
   Siddiqi, MI
   Trivedi, R
   Sashidhara, KV
AF Kushwaha, Pragati
   Tripathi, Ashish Kumar
   Gupta, Sampa
   Kothari, Priyanka
   Upadhyay, Akanksha
   Ahmad, Naseer
   Sharma, Tanuj
   Siddiqi, M. I.
   Trivedi, Ritu
   Sashidhara, Koneni V.
TI Synthesis and study of benzofuran pyran analogs as BMP 2 targeted
   osteogenic agents
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Benzofuran pyran hybrids; Molecular hybridization; Alkaline phosphatase
   (ALP); Osteoblast differentiation; Gene expression; Osteoporosis
ID DIHYDROPYRIDINE HYBRIDS; BONE RESORPTION; OSTEOPOROSIS; DERIVATIVES;
   COUMARIN; PROTEIN; BETA; MODEL; RISK; BISPHOSPHONATES
AB Twenty four novel benzofuran pyran derivatives were synthesized and evaluated for their anti osteoporotic activity in primary cultures of rat calvarial osteoblasts in vitro. Among all the compounds screened for the alkaline phosphatase activity, three compounds 4e, 4j and 4k showed potent activity at picomolar concentrations in osteoblast differentiating stimulation. Additionally, these compounds were found effective in mineralization, assessed by alizarin red S staining assay. Compounds were again validated through a series of other in vitro experiments. Moreover, molecular dynamics simulations demonstrated that both benzofuran and pyran moieties are requisite to fit into the active site of BMP 2 receptor, a key target of the osteogenic agents. The obtained results strongly convey that compound 4e is a potential bone anabolic agent among synthesized series, which can be further explored as a drug lead for treating osteoporosis. (C) 2018 Elsevier Masson SAS. All rights reserved.
C1 [Kushwaha, Pragati; Gupta, Sampa; Upadhyay, Akanksha; Sashidhara, Koneni V.] CSIR Cent Drug Res Inst, Med & Proc Chem Div, BS 10 1,Sect 10,Jankipuram Extens,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
   [Tripathi, Ashish Kumar; Kothari, Priyanka; Ahmad, Naseer; Trivedi, Ritu] CSIR Cent Drug Res Inst, Div Endocrinol, BS 10 1,Sect 10,Jankipuram Extens,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
   [Sharma, Tanuj; Siddiqi, M. I.] CSIR Cent Drug Res Inst, Mol & Struct Biol Div, BS 10 1,Sect 10,Jankipuram Extens,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Council of Scientific & Industrial Research (CSIR)  
   India; CSIR   Central Drug Research Institute (CDRI)
RP Sashidhara, KV (通讯作者)，CSIR Cent Drug Res Inst, Med & Proc Chem Div, BS 10 1,Sect 10,Jankipuram Extens,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.; Trivedi, R (通讯作者)，CSIR Cent Drug Res Inst, Div Endocrinol, BS 10 1,Sect 10,Jankipuram Extens,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
EM ritu_trivedi@cdri.res.in; kv_sashidhara@cdri.res.in
RI Kothari, Priyanka/AAE 3770 2021; Koneni, Sashidhara/B 7845 2009; Gupta,
   Sampa/V 7503 2019; Tripathi, Ashish/JXY 6318 2024; AHMAD,
   NASEER/MAH 2950 2025
OI SHARMA, TANUJ/0000 0003 0054 6153; Trivedi, Ritu/0000 0002 9524 2541;
   Tripathi, Ashish Kumar/0000 0002 0976 8476
FU UGC; CSIR, New Delhi, India
FX We are thankful to Director, CSIR CDRI for his support and encouragement
   in drug development program, Dr. S.P. Singh for technical support, SAIF
   for NMR, IR, and Mass spectral data. P.K., A.K.T., S.G., P.K., A.U. N.A.
   and T.S. are thankful to UGC and CSIR, New Delhi, India for financial
   support. This is CSIR CDRI communication number 9706.
CR Adler RA, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.1
   [Anonymous], 2016, SCHROD REL 2016 2 MA
   [Anonymous], 2016, SCHROD REL 2016 2 SC
   [Anonymous], 2016, SCHROD REL 2016 2 LI
   Burford NT, 2015, J MED CHEM, V58, P4220, DOI 10.1021/acs.jmedchem.5b00007
   Cardwell CR, 2010, JAMA J AM MED ASSOC, V304, P657, DOI 10.1001/jama.2010.1098
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen PC, 2017, J MED CHEM, V60, P4062, DOI 10.1021/acs.jmedchem.7b00376
   Coskun D, 2017, EUR J MED CHEM, V136, P212, DOI 10.1016/j.ejmech.2017.05.017
   Fontana S. A., 1996, US, Patent No. [5489587 A 19960206, 5489587]
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gupta A, 2016, EUR J MED CHEM, V121, P82, DOI 10.1016/j.ejmech.2016.05.023
   Gupta A, 2016, J STEROID BIOCHEM, V158, P63, DOI 10.1016/j.jsbmb.2016.01.010
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Hardwicke MA, 2014, NAT CHEM BIOL, V10, P774, DOI [10.1038/NCHEMBIO.1603, 10.1038/nchembio.1603]
   Hussain MK, 2014, RSC ADV, V4, P8828, DOI 10.1039/c3ra45749d
   Kaufman JM, 2013, BONE, V53, P134, DOI 10.1016/j.bone.2012.11.018
   Khanam H, 2015, EUR J MED CHEM, V97, P483, DOI 10.1016/j.ejmech.2014.11.039
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Kushwaha P, 2016, EUR J PHARMACOL, V788, P65, DOI 10.1016/j.ejphar.2016.06.003
   Kushwaha P, 2016, J BIOL CHEM, V291, P3959, DOI 10.1074/jbc.M115.687152
   Lewiecki EM, 2009, CLEV CLIN J MED, V76, P457, DOI 10.3949/ccjm.76a.09019
   Li KR, 2012, HEART, V98, P920, DOI 10.1136/heartjnl 2011 301345
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Modukuri RK, 2017, BIOORGAN MED CHEM, V25, P6450, DOI 10.1016/j.bmc.2017.10.018
   Mulder JE, 2006, NAT CLIN PRACT ENDOC, V2, P670, DOI 10.1038/ncpendmet0325
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Rio D.C., 2010, COLD SPRING HARBOR P, V6, DOI [10.1101/pdb.prot5439, DOI 10.1101/PDB.PROT5439]
   ROWE DW, 1982, J BIOL CHEM, V257, P8009
   SAMPATH TK, 1990, J BIOL CHEM, V265, P13198
   Sánchez Duffhues G, 2015, BONE, V80, P43, DOI 10.1016/j.bone.2015.05.025
   Sashidhara KV, 2016, MEDCHEMCOMM, V7, P2349, DOI 10.1039/c6md00447d
   Sashidhara KV, 2013, EUR J MED CHEM, V70, P802, DOI 10.1016/j.ejmech.2013.10.060
   Sashidhara KV, 2013, J MED CHEM, V56, P109, DOI 10.1021/jm301281e
   Sashidhara KV, 2012, BIOORG MED CHEM LETT, V22, P3926, DOI 10.1016/j.bmcl.2012.04.100
   Siris ES, 2001, JAMA J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815
   Stille JR, 1996, TETRAHEDRON LETT, V37, P9267, DOI 10.1016/S0040 4039(97)82938 3
   Sun JS, 2007, J BIOMED MATER RES A, V81A, P214, DOI 10.1002/jbm.a.30929
   Tang CH, 2008, EUR J PHARMACOL, V579, P40, DOI 10.1016/j.ejphar.2007.10.013
   van den Bergh JP, 2012, NAT REV RHEUMATOL, V8, P163, DOI 10.1038/nrrheum.2011.217
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Weber D, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472 6807 7 6
   Woo JT, 2006, P NATL ACAD SCI USA, V103, P4729, DOI 10.1073/pnas.0505663103
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Wu CJ, 2008, J DENT SCI, V3, P13
NR 49
TC 22
Z9 22
U1 0
U2 11
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD AUG 5
PY 2018
VL 156
BP 103
EP 117
DI 10.1016/j.ejmech.2018.06.062
PG 15
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA GS4YG
UT WOS:000443663200009
PM 30006156
DA 2025 08 17
ER

PT J
AU He, L
   Lee, J
   Jang, JH
   Lee, SH
   Nan, MH
   Oh, BC
   Lee, SG
   Kim, HH
   Soung, NK
   Ahn, JS
   Kim, BY
AF He, Long
   Lee, Junwon
   Jang, Jae Hyuk
   Lee, Sung Hoon
   Nan, Mei Hua
   Oh, Byung Chul
   Lee, Sang Gu
   Kim, Hong Hee
   Soung, Nak Kyun
   Ahn, Jong Seog
   Kim, Bo Yeon
TI Ginsenoside Rh2 inhibits osteoclastogenesis through down regulation of
   NF κB, NFATc1 and c Fos
SO BONE
LA English
DT Article
DE Ginsenoside Rh2; Osteoclast; NF kappa B; NFATc1; Osteoporosis
ID RECEPTOR ACTIVATOR; PANAX GINSENG; TRANSCRIPTION FACTOR; SIGNALING
   PATHWAY; LIGAND RANKL; DIFFERENTIATION; CELLS; CYTOTOXICITY; EXPRESSION;
   INDUCTION
AB Ginsenoside Rh2 is one of the most active components of red ginseng, controlling cancer and other metabolic diseases including osteoclast differentiation. However, the molecular mechanism underlying the inhibition of osteoclast differentiation by ginsenoside Rh2 remains poorly understood. In the present study, it was found that ginsenoside Rh2 suppressed osteoclast differentiation from bone marrow macrophages (BMMs) treated with receptor activator of nuclear factor kappa B ligand (RANKL) without any cytotoxicity. Ginsenoside Rh2 significantly reduced RANKL induced expression of transcription factors, c Fos and nuclear factor of activated T cells (NFATc1), as well as osteoclast markers, TRAP and OSCAR. In defining the signaling pathways, ginsenoside Rh2 was shown to moderately inhibit NF kappa B activation and ERK phosphorylation in response to RANKL stimulation in BMM cells without any effect on p38 and c Jun N terminal kinase (iNK). Finally, ginsenoside Rh2 blocked osteoporosis in vivo as confirmed by restored bone mineral density (BMD) and other markers associated osteoclast differentiation. Hence, it is suggested that ginsenoside Rh2 could suppress RANKL induced osteoclast differentiation in vitro and in vivo through the regulation of c Fos and NFATc1 expressions, not excluding the involvement of NF kappa B and ERK. Ginsenoside Rh2 is also suggested to be developed as a therapeutic drug for prevention and treatment of osteoporosis. (C) 2012 Elsevier Inc. All rights reserved.
C1 [He, Long; Jang, Jae Hyuk; Nan, Mei Hua; Lee, Sang Gu; Soung, Nak Kyun; Ahn, Jong Seog; Kim, Bo Yeon] KRIBB, Ochang 363883, Cheongwon, South Korea.
   [Lee, Junwon; Lee, Sung Hoon] Pai Chai Univ, Dept Biomed Sci & Biotechnol, Taejon 302735, South Korea.
   [Oh, Byung Chul] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Dept Mol Med, Inchon 406840, South Korea.
   [Kim, Hong Hee; Kim, Bo Yeon] Seoul Natl Univ, Sch Dent, Seoul 110749, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Pai Chai
   University; Gachon University; Seoul National University (SNU)
RP Ahn, JS (通讯作者)，KRIBB, Ochang 363883, Cheongwon, South Korea.
EM jsahn@kribb.re.kr; bykim@kribb.re.kr
RI ; lee, Jaeho/KEH 5184 2024
OI Oh, Byung Chul/0000 0002 4277 7083; Lee, junwon/0009 0006 9313 3612; He,
   Long/0000 0003 4721 9221; 
FU World Class Institute (WCI) [WCI 2009 002]; Global R&D Center (GRDC) of
   the National Research Foundation of Korea (NRF); Ministry of Education,
   Science and Technology (MEST); Ministry for Agriculture, Forestry and
   Fisheries; KRIBB Research Initiative
FX This work was supported by the World Class Institute (WCI) Program (WCI
   2009 002), Global R&D Center (GRDC) Program of the National Research
   Foundation of Korea (NRF) funded by the Ministry of Education, Science
   and Technology (MEST), Technology Development Program for Agriculture
   and Forestry, Ministry for Agriculture, Forestry and Fisheries, and also
   supported by KRIBB Research Initiative Program.
CR Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hwang JT, 2007, BIOCHEM BIOPH RES CO, V364, P1002, DOI 10.1016/j.bbrc.2007.10.125
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kiefer D, 2003, AM FAM PHYSICIAN, V68, P1539
   Kim DY, 2011, INT J MOL MED, V28, P753, DOI 10.3892/ijmm.2011.750
   Kim HJ, 2007, MOL PHARMACOL, V72, P418, DOI 10.1124/mol.107.034173
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee WK, 2007, HORM METAB RES, V39, P347, DOI 10.1055/s 2007 976537
   Lee WK, 2006, CLIN EXP PHARMACOL P, V33, P27, DOI 10.1111/j.1440 1681.2006.04319.x
   Li BH, 2011, CANCER LETT, V301, P185, DOI 10.1016/j.canlet.2010.11.015
   Liu J, 2009, BIOORG MED CHEM LETT, V19, P3320, DOI 10.1016/j.bmcl.2009.04.054
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   MARASCO AC, 1996, CLIN RES, V22, P323
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Nakata H, 1998, JPN J CANCER RES, V89, P733, DOI 10.1111/j.1349 7006.1998.tb03278.x
   Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432 1327.1998.2570242.x
   PIERALISI G, 1991, CLIN THER, V13, P373
   Popovich DG, 2004, J BIOCHEM MOL TOXIC, V18, P143, DOI 10.1002/jbt.20019
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Wang CZ, 2008, AM J CHINESE MED, V36, P1019, DOI 10.1142/S0192415X08006545
   Wang W, 2007, CANCER CHEMOTH PHARM, V59, P589, DOI 10.1007/s00280 006 0300 z
   Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
NR 36
TC 48
Z9 58
U1 0
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD JUN
PY 2012
VL 50
IS 6
BP 1207
EP 1213
DI 10.1016/j.bone.2012.03.022
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 948LC
UT WOS:000304503700001
PM 22484180
DA 2025 08 17
ER

PT J
AU He, DC
   Xiao, JJ
   Zhang, Y
   Lin, H
   Ding, XJ
AF He, Dong Chu
   Xiao, Jing Jing
   Zhang, Yong
   Lin, Hui
   Ding, Xiao Juan
TI Effect of the Jianpi Bushen prescription on the expression profiles of
   genes associated with bone marrow hematopoiesis in radiation damaged
   mice
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Jianpi Bushen prescription; radiation damage; gene expression profile;
   bone marrow hematopoietic; molecular mechanisms
ID PPAR GAMMA EXPRESSION; IONIZING RADIATION; ANGELICA SINENSIS;
   ADIPOGENESIS; WNT3A; SHP 1
AB The effects of the traditional Chinese drug Jianpi Bushen prescription (JBP) on the expression profiles of genes associated with bone marrow hematopoiesis in radiation damaged mice were examined. A radiation damage model was induced in mice by single total body irradiation. Total RNA in bone marrow mononuclear cells of radiation damaged mice was collected after treatment with JBP for 9 days. Gene expression profiles were detected using a whole genome chip. The gene expression profile revealed 261 significantly different genes, 108 of which were upregulated and 153 were down regulated, in the radiation damage model group as compared to those in the control group. High dose (200%) and low dose (100%) JBP reversed 35 and 42 differential genes, respectively, induced by radiation. Gene Ontology (GO) analysis showed that these reversed differentially regulated genes were related mainly to cell adhesion, material transport, cell growth, proliferation, differentiation, signal transduction, substance metabolism, immunity, and stimulation. Pathway analysis revealed that there were 34 differentially regulated genes in 10 signaling pathways related to hematopoietic processes, with the Wnt signaling pathway showing the best results. JBP improved bone marrow hematopoietic function in radiation  damaged mice by regulating multiple genes, functions, and signaling pathways.
C1 [He, Dong Chu; Xiao, Jing Jing; Zhang, Yong; Lin, Hui; Ding, Xiao Juan] Chinese Peoples Liberat Army, Wuhan Gen Hosp, Dept Integrated Chinese & Western Med, Wuhan 430000, Hubei, Peoples R China.
RP He, DC (通讯作者)，Chinese Peoples Liberat Army, Wuhan Gen Hosp, Dept Integrated Chinese & Western Med, Wuhan 430000, Hubei, Peoples R China.
EM dongchuhe@126.com
RI Zhang, Yin/E 6547 2015
FU National Natural Science Foundation of China [8127 3905]
FX This research was supported by the National Natural Science Foundation
   of China (#8127 3905).
CR Chen XP, 2013, CHIN J NAT MEDICINES, V11, P577, DOI [10.3724/SP.J.1009.2013.00577, 10.1016/S1875 5364(13)60067 9]
   Chen YZ, 2011, CHIN J INTEGR MED, V17, P453, DOI 10.1007/s11655 011 0634 1
   Dai Jun, 2012, Zhonghua Yi Xue Za Zhi, V92, P351
   He DC, 2014, GENET MOL RES, V13, P5957, DOI 10.4238/2014.August.7.11
   He DC, 2014, GENET MOL RES, V13, P3201, DOI 10.4238/2014.April.25.5
   He DC, 2013, GENET MOL RES, V12, P4137, DOI 10.4238/2013.October.3.1
   Jiang Q, 2013, BLOOD, V122, P4216
   Kamiya Kenji, 2012, Nihon Rinsho, V70, P367
   Kim ES, 2015, CANCER RES, V75, P3992, DOI 10.1158/0008 5472.CAN 15 1599
   Lee JE, 2014, CELL BIOSCI, V4, DOI 10.1186/2045 3701 4 29
   Lee KF, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/834087
   Li QF, 2014, INT J RADIAT BIOL, V90, P36, DOI 10.3109/09553002.2014.847294
   Liu Y, 2014, INT J BIOL MACROMOL, V68, P209, DOI 10.1016/j.ijbiomac.2014.05.001
   Ma Hui rong, 2015, Zhonghua Nan Ke Xue, V21, P737
   Ma Zengchun, 2012, Zhongguo Zhong Yao Za Zhi, V37, P1289
   Oh IH, 2010, EXPERT OPIN BIOL TH, V10, P1315, DOI 10.1517/14712598.2010.504705
   Okamura H, 2014, BBA MOL CELL RES, V1843, P2376, DOI 10.1016/j.bbamcr.2014.06.008
   Wang CS, 2013, INT J RADIAT BIOL, V89, P132, DOI 10.3109/09553002.2013.734947
   Zhang Xian Ping, 2013, Zhongguo Zhong Yao Za Zhi, V38, P407
   Zhao L, 2012, FITOTERAPIA, V83, P1712, DOI 10.1016/j.fitote.2012.09.029
   Zhu Min, 2011, Zhongguo Zhong Yao Za Zhi, V36, P2543
NR 21
TC 0
Z9 0
U1 0
U2 6
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2017
VL 10
IS 2
BP 2460
EP 2468
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EO2HZ
UT WOS:000396518500072
DA 2025 08 17
ER

PT J
AU Spiro, AS
   Beil, FT
   Baranowsky, A
   Barvencik, F
   Schilling, AF
   Nguyen, K
   Khadem, S
   Seitz, S
   Rueger, JM
   Schinke, T
   Amling, M
AF Spiro, Alexander S.
   Beil, F. Timo
   Baranowsky, Anke
   Barvencik, Florian
   Schilling, Arndt F.
   Nguyen, Khoa
   Khadem, Shahram
   Seitz, Sebastian
   Rueger, Johannes M.
   Schinke, Thorsten
   Amling, Michael
TI BMP 7 Induced Ectopic Bone Formation and Fracture Healing Is Impaired by
   Systemic NSAID Application in C57BL/6 Mice
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE BMP 7 (OP 1); NSAIDs; fracture healing; ectopic bone formation;
   histology
ID HUMAN OSTEOGENIC PROTEIN 1; MORPHOGENETIC PROTEIN 2; CYCLOOXYGENASE 2
   INHIBITION; FAMILY MEMBERS; SEGMENTAL BONE; DIFFERENTIATION; DEFECTS;
   OP 1; REGENERATION; EXPRESSION
AB Nonsteroidal antiinflammatory drugs (NSAIDs) are known to potentially impair the fracture healing process. The aim of the present study was to determine if the impairment of bone healing by systemic NSAID application is, at least in part, due to an interaction of NSAIDs with the bone anabolic BMP 7 pathway. Therefore, we first analyzed fracture healing in control and diclofenac treated mice, where we not only found a significant impairment of fracture healing due to diclofenac treatment as assessed by biomechanical testing and mu CT imaging, but also found high coexpression of bone morphogenetic protein 7 (BMP 7) and cyclooxygenase 2 (COX 2) within the fracture callus of both groups. To experimentally address the possible interaction between BMP 7 and COX 2, we then induced ectopic bone formation in control (n = 10) and diclofenac treated mice (n = 10) by application of BMP 7 (recombinant human OP 1, rhOP 1) into the hamstring muscles. After 20 days of treatment, each ectopic hone nodule was analyzed by contact radiography, mu CT, histology, and histomorphometry. Diclofenac application decreased the trabecular number and bone mass in the ectopic bone nodules significantly due to reduced osteoblast number and activity. These data demonstrate that the bone anabolic effect of BMP 7 and fracture healing is impaired by diclofenac application, and suggest that the potential negative impact of NSAIDs on fracture healing is, at least in part, due to interference with BMP 7 signaling. (C) 2010 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 28:785 791, 2010
C1 [Spiro, Alexander S.; Beil, F. Timo; Baranowsky, Anke; Barvencik, Florian; Schilling, Arndt F.; Nguyen, Khoa; Khadem, Shahram; Seitz, Sebastian; Rueger, Johannes M.; Schinke, Thorsten; Amling, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, D 20246 Hamburg, Germany.
   [Spiro, Alexander S.; Beil, F. Timo; Baranowsky, Anke; Barvencik, Florian; Schilling, Arndt F.; Nguyen, Khoa; Khadem, Shahram; Seitz, Sebastian; Rueger, Johannes M.; Schinke, Thorsten; Amling, Michael] Univ Med Ctr Hamburg Eppendorf, Ctr Biomech & Skeletal Biol, D 20246 Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf
RP Amling, M (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, Martinistr 52, D 20246 Hamburg, Germany.
EM amling@uke.uni hamburg.de
RI Beil, Frank Timo/JBI 9771 2023; Barvencik, Florian/NTR 6013 2025
FU German Research Foundation
FX The authors thank Stryker Biotech (Natick, MA) for providing the
   recombinant human Osteogenic Protein 1 powder. No funds were received in
   support of this work. F.T.B. is a fellow of the German Research
   Foundation.
CR Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982
   Arikawa T, 2004, J CELL PHYSIOL, V200, P400, DOI 10.1002/jcp.20031
   Beck A, 2003, ARCH ORTHOP TRAUM SU, V123, P327, DOI 10.1007/s00402 003 0537 5
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   BOSTROM MPG, 1995, J ORTHOPAED RES, V13, P357, DOI 10.1002/jor.1100130309
   CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843
   Chikazu D, 2002, J BONE MINER RES, V17, P1430, DOI 10.1359/jbmr.2002.17.8.1430
   Cook SD, 2002, J INVEST SURG, V15, P69, DOI 10.1080/08941930290085822
   Damrongsri D, 2006, CLIN ORAL IMPLAN RES, V17, P38, DOI 10.1111/j.1600 0501.2005.01187.x
   DAVIES P, 1984, ANNU REV IMMUNOL, V2, P335, DOI 10.1146/annurev.iy.02.040184.002003
   den Boer FC, 2003, J ORTHOP RES, V21, P521, DOI 10.1016/S0736 0266(02)00205 X
   FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151
   Geesink RGT, 1999, J BONE JOINT SURG BR, V81B, P710, DOI 10.1302/0301 620X.81B4.9311
   Gerstenfeld LC, 2007, J BONE JOINT SURG AM, V89A, P114, DOI 10.2106/JBJS.F.00495
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Gregory LS, 2007, CALCIFIED TISSUE INT, V80, P176, DOI 10.1007/s00223 006 0170 8
   Kloen P, 2003, BONE, V33, P362, DOI 10.1016/S8756 3282(03)00191 1
   Koide M, 1999, BIOCHEM BIOPH RES CO, V259, P97, DOI 10.1006/bbrc.1999.0715
   Lind M, 2000, J ARTHROPLASTY, V15, P339, DOI 10.1016/S0883 5403(00)90693 4
   Ma T, 2006, J BIOMED MATER RES A, V79A, P740, DOI 10.1002/jbm.a.30949
   McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272
   Onishi T, 1998, BONE, V22, P605, DOI 10.1016/S8756 3282(98)00056 8
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Ripamonti U, 1996, GROWTH FACTORS, V13, P273, DOI 10.3109/08977199609003228
   Salkeld SL, 2001, J BONE JOINT SURG AM, V83A, P803, DOI 10.2106/00004623 200106000 00001
   SAMPATH TK, 1992, J BIOL CHEM, V267, P20352
   Schilling AF, 2005, J BONE MINER RES, V20, P274, DOI 10.1359/JBMR.041101
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Steinmeyer J, 2000, ARTHRITIS RES, V2, P379, DOI 10.1186/ar116
   Takigami H, 2007, J ORTHOP RES, V25, P1333, DOI 10.1002/jor.20411
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
   Zhang RW, 2004, J BIOMED MATER RES A, V71A, P412, DOI 10.1002/jbm.a.30151
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 35
TC 61
Z9 65
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD JUN
PY 2010
VL 28
IS 6
BP 785
EP 791
DI 10.1002/jor.21044
PG 7
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 592BI
UT WOS:000277349400013
PM 20063306
DA 2025 08 17
ER

PT J
AU Junankar, S
   Shay, G
   Jurczyluk, J
   Ali, N
   Down, J
   Pocock, N
   Parker, A
   Nguyen, A
   Sun, ST
   Kashemirov, B
   McKenna, CE
   Croucher, PI
   Swarbrick, A
   Weilbaecher, K
   Phan, TG
   Rogers, MJ
AF Junankar, Simon
   Shay, Gemma
   Jurczyluk, Julie
   Ali, Naveid
   Down, Jenny
   Pocock, Nicholas
   Parker, Andrew
   Nguyen, Akira
   Sun, Shuting
   Kashemirov, Boris
   McKenna, Charles E.
   Croucher, Peter I.
   Swarbrick, Alexander
   Weilbaecher, Katherine
   Phan, Tri Giang
   Rogers, Michael J.
TI Real Time Intravital Imaging Establishes Tumor Associated Macrophages as
   the Extraskeletal Target of Bisphosphonate Action in Cancer
SO CANCER DISCOVERY
LA English
DT Article
ID BREAST CANCER; ZOLEDRONIC ACID; IN VIVO; POSTMENOPAUSAL WOMEN;
   INHIBITION; LOCALIZATION; PROGRESSION; MECHANISMS; MONOCYTES; THERAPY
AB Recent clinical trials have shown that bisphosphonate drugs improve breast cancer patient survival independent of their antiresorptive effects on the skeleton. However, because bisphosphonates bind rapidly to bone mineral, the exact mechanisms of their antitumor action, particularly on cells outside of bone, remain unknown. Here, we used real time intravital two photon microscopy to show extensive leakage of fluorescent bisphosphonate from the vasculature in 4T1 mouse mammary tumors, where it initially binds to areas of small, granular microcalcifications that are engulfed by tumor associated macrophages (TAM), but not tumor cells. Importantly, we also observed uptake of radiolabeled bisphosphonate in the primary breast tumor of a patient and showed the resected tumor to be infiltrated with TAMs and to contain similar granular microcalcifications. These data represent the first compelling in vivo evidence that bisphosphonates can target cells in tumors outside the skeleton and that their antitumor activity is likely to be mediated via TAMs.
   SIGNIFICANCE: Bisphosphonates are assumed to act solely in bone. However, mouse models and clinical trials show that they have surprising antitumor effects outside bone. We provide unequivocal evidence that bisphosphonates target TAMs, but not tumor cells, to exert their extraskeletal effects, offering a rationale for use in patients with early disease. (C)2014 AACR.
C1 [Junankar, Simon; Jurczyluk, Julie; Ali, Naveid; Down, Jenny; Pocock, Nicholas; Nguyen, Akira; Croucher, Peter I.; Swarbrick, Alexander; Phan, Tri Giang; Rogers, Michael J.] UNSW Australia, Garvan Inst Med Res, Fac Med, Sydney, NSW, Australia.
   [Junankar, Simon; Jurczyluk, Julie; Ali, Naveid; Down, Jenny; Pocock, Nicholas; Nguyen, Akira; Croucher, Peter I.; Swarbrick, Alexander; Phan, Tri Giang; Rogers, Michael J.] UNSW Australia, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia.
   [Shay, Gemma] Univ Aberdeen, Div Appl Med, Aberdeen, Scotland.
   [Pocock, Nicholas] St Vincents Hosp, Dept Nucl Med, Sydney, NSW 2010, Australia.
   [Parker, Andrew] St Vincents Hosp, Dept Pathol, Sydney, NSW 2010, Australia.
   [Sun, Shuting; Kashemirov, Boris; McKenna, Charles E.] Univ So Calif, Los Angeles, CA USA.
   [Weilbaecher, Katherine] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
C3 University of New South Wales Sydney; Garvan Institute of Medical
   Research; University of New South Wales Sydney; University of Aberdeen;
   NSW Health; St Vincents Hospital Sydney; NSW Health; St Vincents
   Hospital Sydney; University of Southern California; Washington
   University (WUSTL)
RP Rogers, MJ (通讯作者)，Garvan Inst Med Res, 384 Victoria St, Sydney, NSW 2010, Australia.
EM m.rogers@garvan.org.au
RI ; Phan, Tri/G 3937 2012; Swarbrick, Alexander/E 6107 2010; Sun,
   Shuting/N 1807 2014; Junankar, Simon/B 7677 2019
OI Shay, Gemma/0000 0001 6126 7049; Croucher, Peter/0000 0002 7102 2413;
   Rogers, Michael/0000 0002 1818 9249; Down, Jenny/0009 0006 5378 8999;
   Phan, Tri/0000 0002 4909 2984; Junankar, Simon/0000 0002 3965 8278; Sun,
   Shuting/0000 0002 3635 9029; Swarbrick, Alexander/0000 0002 3051 5676
FU Cancer Council NSW [RG 14 12]; Career Development Fellowship [APP
   1005097]; National Health and Medical Research Council of Australia
   (NHMRC) [APP 1004632]; Fraserburgh Moonlight Prowl; National Health and
   Medical Research Council of Australia; Cancer Institute NSW; National
   Breast Cancer Foundation;  [RO1 CA097250]
FX This work was funded by project grant RG 14 12 from the Cancer Council
   NSW (to M.J. Rogers and T. G. Phan). T. G. Phan was also supported by a
   Career Development Fellowship (APP 1005097) and Project Grant APP
   1004632 from the National Health and Medical Research Council of
   Australia (NHMRC). The contents of this article are solely the
   responsibility of the administering institution, a participating
   institution, or individual authors and do not reflect the views of
   NHMRC. K. Weilbaecher was supported by RO1 CA097250. G. Shay was funded
   by a studentship from the Fraserburgh Moonlight Prowl, facilitated by
   Prof. S. Heys, University of Aberdeen. Tissues and samples were received
   from the Australia Breast Cancer Tissue Bank, which is generously
   supported by the National Health and Medical Research Council of
   Australia, The Cancer Institute NSW, and the National Breast Cancer
   Foundation.
CR Benzaïd I, 2012, CLIN CANCER RES, V18, P6249, DOI 10.1158/1078 0432.CCR 12 0918
   BERG GR, 1973, RADIOLOGY, V109, P393, DOI 10.1148/109.2.393
   Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027
   Chlebowski RT, 2010, J CLIN ONCOL, V28, P3582, DOI 10.1200/JCO.2010.28.2095
   Chtanova T, 2014, J BIOPHOTONICS, V7, P425, DOI 10.1002/jbio.201200175
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Grigorova IL, 2009, NAT IMMUNOL, V10, P58, DOI 10.1038/ni.1682
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   McDonald DM, 2002, CANCER RES, V62, P5381
   Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008 5472.CAN 07 1882
   Ottewell PD, 2010, INT J CANCER, V126, P522, DOI 10.1002/ijc.24756
   PICCOLO S, 1995, J NUCL MED, V36, P718
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   WORSLEY DF, 1993, J NUCL MED, V34, P1612
NR 25
TC 118
Z9 128
U1 2
U2 48
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 2159 8274
EI 2159 8290
J9 CANCER DISCOV
JI Cancer Discov.
PD JAN
PY 2015
VL 5
IS 1
BP 35
EP 42
DI 10.1158/2159 8290.CD 14 0621
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AY9NK
UT WOS:000347877500009
PM 25312016
OA Green Submitted, Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Yang, SH
   Zhang, WH
   Cai, MX
   Zhang, YX
   Jin, FJ
   Yan, S
   Baloch, Z
   Fang, ZH
   Xue, SR
   Tang, RP
   Xiao, J
   Huang, QS
   Sun, Y
   Wang, XG
AF Yang, Shihua
   Zhang, Wenhui
   Cai, Mingxiang
   Zhang, Yuanxu
   Jin, Fujun
   Yan, Sen
   Baloch, Zulqurain
   Fang, Zhihao
   Xue, Senren
   Tang, Rongping
   Xiao, Jia
   Huang, Qunshan
   Sun, Yao
   Wang, Xiaogang
TI Suppression of Bone Resorption by miR 141 in Aged Rhesus Monkeys
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; PRIMATES; miR 141; BONE RESORPTION; OSTEOCLAST TARGETING
   DELIVERY
ID CELL GROWTH; IN VIVO; CANCER; DIFFERENTIATION; OSTEOPOROSIS; METASTASIS;
   EXPRESSION; DELIVERY; SIRNA; OSTEOCLASTOGENESIS
AB Aging related osteoporosis (OP) is considered a serious public health concern. Approximately 30% of postmenopausal women suffer from OP; more than 40% of them risk fragility fractures. Multiple drugs have been prescribed to treat OP, but they are not ideal because of low cure rates and adverse side effects. miRNA based gene therapy is a rapidly developing strategy in disease treatment that presents certain advantages, such as large scale production capability, genetic safety, and rapid effects. miRNA drugs have been used primarily in cancer treatments; they have not yet been reported as candidates for osteoclast targeted OP treatment in primates. Their therapeutic efficacy has been limited by several shortcomings, such as low efficiency of selective delivery, insufficient expression levels in targeting cells, and unexpected side effects. Here, we identify miR 141 as a critical suppressor of osteoclastogenesis and bone resorption. The expression levels of miR 141 are positively correlated with BMD and negatively correlated with the aging of bones in both aged rhesus monkeys (Macaca mulatta) and osteoporotic patients. Selective delivery of miR 141 into the osteoclasts of aged rhesus monkeys via a nucleic acid delivery system allowed for a gradual increase in bone mass without significant effects on the health and function of primary organs. Furthermore, we found that the functional mechanism of miR 141 resides in its targeting of two osteoclast differentiation players, Calcr (calcitonin receptors) and EphA2 (ephrin type A receptor 2 precursor). Our study suggests that miRNAs, such as miR 141, could play a crucial role in suppressing bone resorption in primates and provide reliable experimental evidence for the clinical application of miRNA in OP treatment. (c) 2018 American Society for Bone and Mineral Research.
C1 [Yang, Shihua; Zhang, Wenhui; Baloch, Zulqurain; Fang, Zhihao; Xue, Senren; Huang, Qunshan] South China Agr Univ, Coll Vet Med, 483 Wushan Rd, Guangzhou 510642, Guangdong, Peoples R China.
   [Yang, Shihua; Zhang, Wenhui; Baloch, Zulqurain; Fang, Zhihao; Xue, Senren; Huang, Qunshan] South China Agr Univ, Key Lab Comprehens Prevent & Control Severe Clin, 483 Wushan Rd, Guangzhou 510642, Guangdong, Peoples R China.
   [Yang, Shihua; Zhang, Wenhui; Baloch, Zulqurain; Fang, Zhihao; Xue, Senren; Huang, Qunshan] Tongji Univ, Sch & Hosp Stomatol, Shanghai, Peoples R China.
   [Zhang, Yuanxu; Jin, Fujun; Yan, Sen; Xiao, Jia; Wang, Xiaogang] Jinan Univ, Dept Cell Biol, Coll Life Sci & Technol, Guangzhou, Guangdong, Peoples R China.
   [Zhang, Yuanxu; Jin, Fujun; Yan, Sen; Xiao, Jia; Wang, Xiaogang] Jinan Univ, Inst Biomed, Coll Life Sci & Technol, Guangzhou, Guangdong, Peoples R China.
   [Wang, Xiaogang] Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100083, Peoples R China.
   [Tang, Rongping] WinconTheraCells Biotechnol Co Ltd, Nanning, Peoples R China.
C3 South China Agricultural University; South China Agricultural
   University; Tongji University; Jinan University; Jinan University;
   Beihang University
RP Yang, SH (通讯作者)，South China Agr Univ, Coll Vet Med, 483 Wushan Rd, Guangzhou 510642, Guangdong, Peoples R China.; Yang, SH (通讯作者)，South China Agr Univ, Key Lab Comprehens Prevent & Control Severe Clin, 483 Wushan Rd, Guangzhou 510642, Guangdong, Peoples R China.; Sun, Y (通讯作者)，Sch & Hosp Stomatol, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, 399 Middle Yanchang Rd, Shanghai, Peoples R China.; Wang, XG (通讯作者)，Jinan Univ, Dept Cell Biol, 601 Huangpu Ave West, Guangzhou 510632, Guangdong, Peoples R China.; Wang, XG (通讯作者)，Jinan Univ, Inst Biomed, 601 Huangpu Ave West, Guangzhou 510632, Guangdong, Peoples R China.
EM yangsh@scau.edu.cn; yaosun@tongji.edu.cn; txg_wang@jnu.edu.cn
RI wang, Xiaogang/J 5003 2017; baloch, Dr. Zulqarnain/A 8455 2017; sun,
   yao/MEP 9275 2025; cai, mingxiang/IYT 1913 2023; Baloch,
   Zulqarnain/A 8455 2017; Zhang, Wenhui/LFR 9194 2024
OI baloch, Dr. Zulqarnain/0000 0002 7873 1343; Jin,
   Fujun/0000 0002 7314 0085; Wang, Xiaogang/0000 0001 9798 834X
FU Science and Technology Major Project of Guangdong Province
   [2014B020225007]; National Natural Science Foundation [81370971,
   81470715]; Guangdong Natural Science Funds for Distinguished Young
   Scholar [S2013050013880]; Recruitment Program of Global Experts 1000
   Plan; Key Project of Chinese National Programs for Research and
   Development [2016YFC1102705]; National Natural Science Foundation of
   China (NSFC); SFC [81770873]; NSFC [81470715, 81722031, 81771043]
FX This work was supported by grants from Science and Technology Major
   Project of Guangdong Province (2014B020225007) and National Natural
   Science Foundation Projects (81370971, 81470715) and Guangdong Natural
   Science Funds for Distinguished Young Scholar (S2013050013880),
   Recruitment Program of Global Experts 1000 Plan (YS), SFC 81770873, NSFC
   81722031 (XW), Key Project of Chinese National Programs for Research and
   Development (2016YFC1102705), National Natural Science Foundation of
   China (NSFC), NSFC 81470715 81771043 (YS), National Natural Science
   Foundation of China (NSFC). The funders played no role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. We'd like to thank Dr. Gong Zhang (Jinan
   University) for valuable advice. We especially thank the anonymous
   reviewers for constructive and useful comments.
CR Aalaei Andabili SH, 2013, IMMUNOTHERAPY UK, V5, P1127, DOI 10.2217/imt.13.112
   Abedi N, 2015, TUMOR BIOL, V36, P9895, DOI 10.1007/s13277 015 3738 y
   Akhtar N, 2016, PROG LIPID RES, V64, P192, DOI 10.1016/j.plipres.2016.08.005
   Allen RM, 2014, CIRC RES, V115, P10, DOI 10.1161/CIRCRESAHA.115.303100
   Annoni A, 2009, BLOOD, V114, P5152, DOI 10.1182/blood 2009 04 214569
   Belaya ZE, 2018, OSTEOPOROSIS INT, V29, P211, DOI 10.1007/s00198 017 4241 7
   Bouchie A, 2013, NAT BIOTECHNOL, V31, P577, DOI 10.1038/nbt0713 577
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Chen C, 2014, J BONE MINER RES, V29, P338, DOI 10.1002/jbmr.2032
   Chen JL, 2016, INT J MOL MED, V37, P1601, DOI 10.3892/ijmm.2016.2553
   Chen Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058104
   Choi KY, 2014, NAT PROTOC, V9, P1900, DOI 10.1038/nprot.2014.128
   Dacquin R, 2004, J CELL BIOL, V164, P509, DOI 10.1083/jcb.200312135
   Dong S, 2016, AM J TRANSL RES, V8, P1471
   Dou C, 2014, BBA GENE REGUL MECH, V1839, P1084, DOI 10.1016/j.bbagrm.2014.08.002
   Eastell R, 2010, OSTEOPOROSIS INT, V21, P1277, DOI 10.1007/s00198 009 1077 9
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Erdem Y, 2016, Case Rep Orthop, V2016
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Gao AC, 2016, IN VITRO CELL DEV AN, V52, P228, DOI 10.1007/s11626 015 9965 0
   Golan M, 2016, EUR J PHARM BIOPHARM, V109, P103, DOI 10.1016/j.ejpb.2016.09.017
   Golob AL, 2015, MED CLIN N AM, V99, P587, DOI 10.1016/j.mcna.2015.01.010
   Guo E, 2016, EUR REV MED PHARMACO, V20, P3385
   Horvath JE, 2007, TRENDS GENET, V23, P173, DOI 10.1016/j.tig.2007.02.007
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Itoh T, 2009, J BIOL CHEM, V284, P19272, DOI 10.1074/jbc.M109.014001
   Kittivanichkul D, 2016, MENOPAUSE, V23, P87, DOI 10.1097/GME.0000000000000556
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Leidinger P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143321
   Lespessailles E, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.59
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li Y, 2015, MOL THER, V23, P1349, DOI 10.1038/mt.2015.101
   Liu HQ, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752 0509 4 51
   Lorenzen JM, 2011, NAT REV NEPHROL, V7, P286, DOI 10.1038/nrneph.2011.26
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Mastaglia SR, 2016, EUR J RHEUMATOL, V3, P87, DOI 10.5152/eurjrheum.2015.0010
   Mehta N. M., 2003, Current Pharmaceutical Design, V9, P2659, DOI 10.2174/1381612033453622
   Mizoguchi F, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4282
   Molina PE, 2014, AIDS RES HUM RETROV, V30, P567, DOI [10.1089/aid.2013.0182, 10.1089/AID.2013.0182]
   Peng T, 2016, AM J TRANSL RES, V8, P3513
   Qiu WM, 2014, BBA MOL CELL RES, V1843, P2114, DOI 10.1016/j.bbamcr.2014.06.004
   Reid G, 2016, EPIGENOMICS UK, V8, P1079, DOI 10.2217/epi 2016 0035
   Shafei AE, 2017, J GENE MED, V19, DOI 10.1002/jgm.2995
   Singh B, 2014, J NANOSCI NANOTECHNO, V14, P564, DOI 10.1166/jnn.2014.9079
   Smith SY, 2015, J BONE MINER METAB, V33, P161, DOI 10.1007/s00774 014 0580 z
   Tsukamoto M, 2016, BONE, V85, P70, DOI 10.1016/j.bone.2016.01.025
   Varacallo MA, 2014, MED CLIN N AM, V98, P817, DOI 10.1016/j.mcna.2014.03.007
   Zhong R, 2016, EUR SPINE J, V25, P2705, DOI 10.1007/s00586 016 4593 2
   Zhou XY, 2015, DIGEST DIS SCI, V60, P3271, DOI 10.1007/s10620 015 3782 x
NR 50
TC 22
Z9 31
U1 4
U2 34
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD OCT
PY 2018
VL 33
IS 10
BP 1799
EP 1812
DI 10.1002/jbmr.3479
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GX8XF
UT WOS:000448078300008
PM 29852535
OA Bronze
DA 2025 08 17
ER

PT J
AU Yorgan, TA
   Peters, S
   Amling, M
   Schinke, T
AF Yorgan, Timur A.
   Peters, Stephanie
   Amling, Michael
   Schinke, Thorsten
TI Osteoblast specific expression of Panx3 is dispensable for
   postnatal bone remodeling
SO BONE
LA English
DT Article
DE Osteoblast; Expression analysis; Panx3; Mouse model
ID PANNEXIN 3; SKELETAL DEVELOPMENT; GENE EXPRESSION; SCLEROSTIN;
   DIFFERENTIATION; DELETION; OSTEOPOROSIS; PATHOGENESIS; GUIDELINES;
   MUTATION
AB Since cost effective osteoarrabolic treatment options remain to be established, it is relevant to identify specific molecules physiologically regulating osteoblast differentiation and/or activity that are principally accessible as drug targets. Specific or predominant gene expression in a given cell type often predicts a relevant function in the respective tissue. Thus, we aimed to identify genes encoding membrane associated proteins with selective expression in differentiated osteoblasts. We therefore applied an unbiased approach, i.e. Affymetrix Gene Chip hybridization, to compare global gene expression in primary murine osteoblasts at two stages of differentiation. For the most strongly induced genes we analyzed their expression pattern in different tissues, which led us to identify known and unknown osteoblast differentiation markers with predominant expression in bone. One of these genes was Panx3, encoding a transmembrane hemichannel with ill defined function in skeletal remodeling. To decipher the role of Panx3 in osteoblasts we first generated Panx3 fl/fl mice carrying a Runx2 Cre transgene. Using undecalcified histology followed by bone specific histomorphometry we did not observe any significant difference between 24 weeks old Cre negative and Cre positive littermates. We additionally generated and analyzed mice with ubiquitous Panx3 deletion, where a delay of endochondral ossification did not translate into a detectable skeletal phenotype after weaning, possibly explained by compensatory induction of Panx1. Of note, newborn Panx3 deficient mice displayed significantly reduced serum glucose levels, which was not the case in older animals. Our findings demonstrate that Panx3 expression in osteoblasts is not required for postnatal bone remodeling, which essentially rules out its suitability as a target protein for osteoanabolic medication.
C1 [Yorgan, Timur A.; Peters, Stephanie; Amling, Michael; Schinke, Thorsten] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf
RP Schinke, T (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
EM schinke@uke.de
CR Abitbol JM, 2019, J MOL MED, V97, P723, DOI 10.1007/s00109 019 01779 9
   Aggarwal S, 2013, GENE, V528, P41, DOI 10.1016/j.gene.2013.04.069
   Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bartelt A, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0006 3
   Beck L, 1997, J CLIN INVEST, V99, P1200, DOI 10.1172/JCI119276
   Bond SR, 2011, J BONE MINER RES, V26, P2911, DOI 10.1002/jbmr.509
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Caskenette D, 2016, J ANAT, V228, P746, DOI 10.1111/joa.12437
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Hanagata N, 2011, J BONE MINER METAB, V29, P279, DOI 10.1007/s00774 010 0221 0
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Ishikawa M, 2016, J CELL SCI, V129, P1018, DOI 10.1242/jcs.176883
   Ishikawa M, 2011, J CELL BIOL, V193, P1257, DOI 10.1083/jcb.201101050
   Iwamoto T, 2010, J BIOL CHEM, V285, P18948, DOI 10.1074/jbc.M110.127027
   Jeschke A, 2015, J IMMUNOL, V195, P3675, DOI 10.4049/jimmunol.1402392
   Karsenty G, 2012, NATURE, V481, P314, DOI 10.1038/nature10763
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Leder BZ, 2018, JBMR PLUS, V2, P62, DOI 10.1002/jbm4.10041
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lewiecki EM, 2018, J BONE MINER RES, V33, P410
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lohman AW, 2012, J VASC RES, V49, P405, DOI 10.1159/000338758
   Luther J, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau7137
   McClung MR, 2017, THER ADV MUSCULOSKEL, V9, P263, DOI 10.1177/1759720X17726744
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Moon PM, 2015, J MOL MED, V93, P845, DOI 10.1007/s00109 015 1311 1
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Oh SK, 2015, FASEB J, V29, P4473, DOI 10.1096/fj.15 273722
   Penuela S, 2014, J INVEST DERMATOL, V134, P2026, DOI 10.1038/jid.2014.86
   Pietrzyk B, 2017, ADV CLIN EXP MED, V26, P1283, DOI 10.17219/acem/68739
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Seitz S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050301
   Sims NA, 1997, MOL ENDOCRINOL, V11, P1695, DOI 10.1210/me.11.11.1695
   Stains JP, 2016, SEMIN CELL DEV BIOL, V50, P31, DOI 10.1016/j.semcdb.2015.12.017
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tu Kristie N, 2018, P T, V43, P92
   Vollersen N, 2018, J BONE MINER RES, V33, P70, DOI 10.1002/jbmr.3283
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Weivoda MM, 2017, BONE, V96, P45, DOI 10.1016/j.bone.2016.11.024
   Whyte Fagundes P, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00135
   Yorgan T, 2016, BONE, V87, P136, DOI 10.1016/j.bone.2016.04.012
   Yorgan TA, 2015, J BONE MINER RES, V30, P1175, DOI 10.1002/jbmr.2461
NR 49
TC 8
Z9 9
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2019
VL 127
BP 155
EP 163
DI 10.1016/j.bone.2019.06.008
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IU2ZR
UT WOS:000483449000019
PM 31202927
OA hybrid
DA 2025 08 17
ER

PT J
AU Yang, X
   Liu, J
   Liu, ZJ
   Xia, QJ
   He, M
   Liu, R
   Liu, W
   Wang, W
   Liu, J
   Zhou, XF
   Zhang, YH
   Wang, TH
AF Yang, Xu
   Liu, Jia
   Liu, Zun Jing
   Xia, Qing Jie
   He, Mu
   Liu, Ran
   Liu, Wei
   Wang, Wei
   Liu, Jin
   Zhou, Xin Fu
   Zhang, Yun Hui
   Wang, Ting Hua
TI Reversal of Bone Cancer Pain by HSV 1 Mediated Silencing of CNTF in an
   Afferent Area of the Spinal Cord Associated with AKT ERK Signal
   Inhibition
SO CURRENT GENE THERAPY
LA English
DT Article
DE Bone cancer pain; CNTF; gene therapy; HSV 1; intrathecal catheterization
ID CILIARY NEUROTROPHIC FACTOR; PRIMARY SENSORY NEURONS; MEDIATED
   GENE TRANSFER; RAT MODEL; PHOSPHATIDYLINOSITOL 3 KINASE; SKELETAL
   COMPLICATIONS; CENTRAL SENSITIZATION; REGIONAL DISTRIBUTION; MECHANICAL
   ALLODYNIA; THERMAL HYPERALGESIA
AB Pain induced by bone metastases has a strong impact on the quality of life of patients with cancer, but current therapies for bone cancer pain cannot attain a satisfactory therapeutic goal because of various adverse reactions. Currently, advanced monitoring is required to clarify pathogenic mechanisms, so as to develop more effective treatments. We constructed herpes simplex virus carrying small interference RNA for CNTF (HSV siCNTF) and established cancer induced bone cancer pain models with intra tibial injection of MRMT 1 cells. At different time points after treatment, sensory function indicated by thermal hyperalgesia and mechanical allodynia was measured. The mechanism underlying sensory function regulated by CNTF was also determined. There was apparent mechanical and thermal hyperalgesia in rats injected with bone cancer cells. Bone destruction was detected in the area of tibia injected with tumor cells by the plain radiography. MRMT 1 cells and the increased number of osteoclasts were found in tibia sections stained with hematoxylin and eosin. Intrathecal injection of morphine or HSV siCNTF significantly reduced the mechanical allodynia and thermal hyperalgesia, which was accompanied by astrocyte hypertrophy. The number of nerve fibers positive for substance P (SP) and calcitonin gene related peptide (CGRP) was significantly decreased, which was consistent with the decrease of CNTF, ERK/pERK, AKT/pAKT and c fos expression. These results demonstrate that the HSV siCNTF gene therapy appears beneficial for the treatment of pain induced by bone cancer via blocking the AKT ERK signaling pathway. Our data suggest that CNTF interference may be considered a new target to develop an effective management for bone cancer pain.
C1 [Yang, Xu; Liu, Ran; Liu, Wei; Wang, Wei; Liu, Jin; Wang, Ting Hua] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Translat Neurosci Ctr,Dept Anesthesiol, Chengdu 610041, Peoples R China.
   [Yang, Xu; Xia, Qing Jie; He, Mu; Liu, Ran; Liu, Wei; Wang, Wei; Liu, Jin; Wang, Ting Hua] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Translat Neurosci Ctr,Inst Neurol Dis, Chengdu 610041, Peoples R China.
   [Liu, Jia; Zhou, Xin Fu; Wang, Ting Hua] Kunming Med Univ, Inst Neurosci, Kunming 650031, Peoples R China.
   [Liu, Zun Jing] China Japan Friendship, Dept Neurol, Beijing 100029, Peoples R China.
   [Zhang, Yun Hui] First Peoples Hosp Yunnan Prov, Dept Respirat, Kunming 65000, Peoples R China.
   [Zhou, Xin Fu] Univ S Australia, Sansom Inst, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia.
C3 Sichuan University; Sichuan University; Kunming Medical University;
   Kunming University of Science & Technology; University of South
   Australia
RP Wang, TH (通讯作者)，Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Translat Neurosci Ctr,Dept Anesthesiol, Chengdu 610041, Peoples R China.
EM yunhuizhang3188@126.com; tinghua_neuron@263.net
RI ; Zhou, Xin Fu/F 4119 2013; li, jizhou/ABC 4650 2020; Liu,
   Jie/JCP 1070 2023; zhou, xin fu/F 4119 2013; Li, Jianqi/R 3908 2018;
   Wang, Wei/L 4562 2019
OI Wang, Wei/0000 0002 8450 9773; Liu, Jin/0000 0002 2026 2513; Zhou,
   Xin Fu/0000 0002 8687 0175; 
FU China National Science Foundation [81271358, 81070991, 81173595]
FX This research was supported by a grant from the China National Science
   Foundation (No. 81271358; NO. 81070991; No. 81173595).
CR [Anonymous], Revue Medicale Suisse
   Bastami S, 2013, ACTA ONCOL, V52, P1022, DOI 10.3109/0284186X.2012.737932
   Berto E, 2005, GENE THER, V12, pS98, DOI 10.1038/sj.gt.3302623
   Calcutt NA, 2004, DIABETOLOGIA, V47, P718, DOI 10.1007/s00125 004 1354 2
   Chandler LJ, 2005, ALCOHOL CLIN EXP RES, V29, P672, DOI 10.1097/01.ALC.0000158935.53360.5F
   Chattopadhyay M, 2013, CURR GENE THER, V13, P315, DOI 10.2174/156652321305131212123237
   Colburn RW, 1999, EXP NEUROL, V157, P289, DOI 10.1006/exnr.1999.7065
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Currie GL, 2013, PAIN, V154, P917, DOI 10.1016/j.pain.2013.02.033
   Davies Jeannette E, 2008, J Biol, V7, P24, DOI 10.1186/jbiol85
   de Almeida LP, 2001, NEUROBIOL DIS, V8, P433, DOI 10.1006/nbdi.2001.0388
   De Gregori S, 2012, METAB BRAIN DIS, V27, P1, DOI 10.1007/s11011 011 9274 6
   de Wit R, 2001, PAIN, V91, P339, DOI 10.1016/S0304 3959(00)00455 3
   Doré Savard L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013774
   Doyle CA, 1999, NEUROSCIENCE, V89, P17, DOI 10.1016/S0306 4522(98)00276 0
   Fang M, 2012, ANTIMICROB AGENTS CH, V56, P5253, DOI 10.1128/AAC.00304 12
   Fillingim RB, 2009, J PAIN, V10, P447, DOI 10.1016/j.jpain.2008.12.001
   Fink DJ, 2011, ANN NEUROL, V70, P207, DOI 10.1002/ana.22446
   FRIEDMANN T, 1972, SCIENCE, V175, P949, DOI 10.1126/science.175.4025.949
   Galasko C., 1981, Bone metastases, P49
   Gao Yong Jing, 2009, Open Pain J, V2, P11
   GARRISON CJ, 1991, BRAIN RES, V565, P1, DOI 10.1016/0006 8993(91)91729 K
   Goins WF, 2012, NEUROBIOL DIS, V48, P255, DOI 10.1016/j.nbd.2012.05.005
   Hald A, 2009, CELL MOL NEUROBIOL, V29, P609, DOI 10.1007/s10571 009 9390 6
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Horvath RJ, 2010, NEUROSCIENCE, V169, P843, DOI 10.1016/j.neuroscience.2010.05.030
   Hu S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742 2094 9 278
   HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0
   Ikeda H, 2003, SCIENCE, V299, P1237, DOI 10.1126/science.1080659
   Ip NY, 1996, ANNU REV NEUROSCI, V19, P491
   Ji RR, 2002, J NEUROSCI, V22, P478, DOI 10.1523/JNEUROSCI.22 02 00478.2002
   Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017
   Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011
   Karimi Abdolrezaee S, 2010, J NEUROSCI, V30, P1657, DOI 10.1523/JNEUROSCI.3111 09.2010
   Kawamata T, 2008, NEUROSCIENCE, V154, P1067, DOI 10.1016/j.neuroscience.2008.04.010
   Ke CB, 2012, NEUROSCIENCE, V227, P80, DOI 10.1016/j.neuroscience.2012.09.046
   Kim HN, 2012, BRAIN RES BULL, V87, P199, DOI 10.1016/j.brainresbull.2011.11.010
   Kimple RJ, 2012, ONCOLOGIST, V17, P1496, DOI 10.1634/theoncologist.2012 0256
   Krames E, 1999, NEUROMODULATION, V2, P133, DOI 10.1046/j.1525 1403.1999.00133.x
   Laughlin TM, 2001, J PHARMACOL EXP THER, V299, P6
   Le Bars D, 2001, PHARMACOL REV, V53, P597
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Lu ZQ, 2009, J NEUROIMMUNOL, V206, P58, DOI 10.1016/j.jneuroim.2008.10.014
   Montiel Ruiz RM, 2013, GAC MED MEX, V149, P204
   Mata M, 2003, EXP NEUROL, V184, pS25, DOI 10.1016/S0014 4886(03)00357 1
   Mata M, 2008, CURR GENE THER, V8, P42, DOI 10.2174/156652308783688527
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304 3959(01)00437 7
   MELLERICK DM, 1987, VIROLOGY, V158, P265, DOI 10.1016/0042 6822(87)90198 X
   Melzack R, 2001, ANN NY ACAD SCI, V933, P157
   Menéndez L, 2003, N S ARCH PHARMACOL, V367, P28, DOI 10.1007/s00210 002 0655 6
   Merighi S, 2013, BIOCHEM PHARMACOL, V86, P487, DOI 10.1016/j.bcp.2013.05.027
   Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304 3959(01)00324 4
   Miller RG, 1996, ANN NEUROL, V39, P256, DOI 10.1002/ana.410390215
   Motta EM, 2006, EXP BIOL MED, V231, P1141
   Obata K, 2004, LIFE SCI, V74, P2643, DOI 10.1016/j.lfs.2004.01.007
   Pezet S, 2008, J NEUROSCI, V28, P4261, DOI 10.1523/JNEUROSCI.5392 07.2008
   Poon YY, 2011, J NEUROSCI METH, V200, P36, DOI 10.1016/j.jneumeth.2011.06.010
   Qi ML, 2003, NEUROSCI RES, V45, P181, DOI 10.1016/S0168 0102(02)00224 9
   Rivera FJ, 2008, J NEUROCHEM, V107, P832, DOI 10.1111/j.1471 4159.2008.05674.x
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   Shang FF, 2013, J PROTEOMICS, V91, P188, DOI 10.1016/j.jprot.2012.12.002
   Smith HS, 2012, ANN PALLIAT MED, V1, P14, DOI 10.3978/j.issn.2224 5820.2012.02.03
   STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0
   STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447
   Suzumori N, 2003, GYNECOL OBSTET INVES, V56, P51, DOI 10.1159/000072694
   Urch CE, 2005, J PAIN, V6, P837, DOI 10.1016/j.jpain.2005.08.005
   Vidal Torres A, 2013, EUR J PHARMACOL, V711, P63, DOI 10.1016/j.ejphar.2013.04.018
   Wang JY, 2012, J ETHNOPHARMACOL, V143, P905, DOI 10.1016/j.jep.2012.08.026
   Wang XW, 2012, NEUROSCIENCE, V217, P172, DOI 10.1016/j.neuroscience.2012.04.065
   Wolfe D, 2009, GENE THER, V16, P455, DOI 10.1038/gt.2009.17
   Wolfe D, 2012, NEUROSCI LETT, V527, P85, DOI 10.1016/j.neulet.2012.04.047
   Xu QH, 2011, J NEUROSCI, V31, P2113, DOI 10.1523/JNEUROSCI.2139 10.2011
   YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031 9384(76)90029 9
   Yu LN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040930
   Zhang YL, 2007, NEUROSCI LETT, V419, P153, DOI 10.1016/j.neulet.2007.04.040
   Zhuang ZY, 2005, PAIN, V114, P149, DOI 10.1016/j.pain.2004.12.022
   Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290 05.2006
   Zhuang ZY, 2004, J NEUROSCI, V24, P8300, DOI 10.1523/JNEUROSCI.2893 04.2004
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304 3959(83)90201 4
NR 80
TC 6
Z9 6
U1 0
U2 29
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566 5232
EI 1875 5631
J9 CURR GENE THER
JI Curr. Gene Ther.
PY 2014
VL 14
IS 5
BP 377
EP 388
DI 10.2174/156652321405140926162236
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA AQ8WV
UT WOS:000343120300005
PM 25687503
DA 2025 08 17
ER

PT J
AU Lu, ZF
   Roohani Esfahani, SI
   Li, JJ
   Zreiqat, H
AF Lu, ZuFu
   Roohani Esfahani, Seyed Iman
   Li, JiaoJiao
   Zreiqat, Hala
TI Synergistic effect of nanomaterials and BMP 2 signalling in inducing
   osteogenic differentiation of adipose tissue derived mesenchymal stem
   cells
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Osteogensis; Wnt; beta 1 integrin; BMP 2; Bioglass
ID BONE FORMATION; ALPHA 2 BETA 1 INTEGRIN; REGENERATIVE MEDICINE;
   GENE EXPRESSION; SCAFFOLDS; PATHWAY; OSTEOBLASTS; OSTEOCONDUCTIVITY;
   BIOMATERIALS; REPAIR
AB The lack of complete understanding in the signalling pathways that control the osteogenic differentiation of mesenchymal stem cells hinders their clinical application in the reconstruction of large bone defects and non union bone fractures. The aim of this study is to gain insight into the interactions of bone morphogenetic protein 2 (BMP 2) and bone biomimetic scaffolds in directing osteogenic differentiation of adipose tissue derived mesenchymal stem cells (ASCs) and the underlying signalling pathways involved. We demonstrated that bioactive glass nanoparticles (nBG) incorporated polycaprolactone (PCL) coating on hydroxyapatite/beta tricalcium phosphate (HA/ TCP) scaffold exerted a synergistic effect with 3 days of BMP 2 treatment in promoting osteogenic gene expression levels (Runx 2, collagen I, osteopontin and bone sialoprotein) and alkaline phosphatase activity in ASCs. Furthermore, we revealed that the synergistic effect was mediated through a mechanism of activating beta 1 integrin and induction of Wnt 3a autocrine signalling pathways by nBG incorporated scaffold.
   From the Clinical Editor: The aim of this study was to gain insight into the interactions of bone morphogenetic protein 2 and bone biomimetic scaffolds in directing osteogenic differentiation of adipose tissue derived mesenchymal stem cells and the underlying signaling pathways involved. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Lu, ZuFu; Roohani Esfahani, Seyed Iman; Li, JiaoJiao; Zreiqat, Hala] Univ Sydney, Sch AMME, Biomat & Tissue Engn Res Unit, Sydney, NSW 2006, Australia.
C3 University of Sydney
RP Lu, ZF (通讯作者)，Univ Sydney, Sch AMME, Biomat & Tissue Engn Res Unit, Sydney, NSW 2006, Australia.
EM zufu.lu@sydney.edu.au; hala.zreiqat@sydney.edu.au
RI Roohani, Iman/JMR 3441 2023; Li, Jiao Jiao/W 3268 2019
OI , Iman Roohani/0009 0000 3678 3455; Zreiqat, Hala/0000 0003 0521 7711;
   Roohani, Iman/0000 0001 6618 8577; Li, Jiao Jiao/0000 0002 3584 6765;
   Lu, ZuFu/0000 0003 4843 4441
FU Australian National Health and Medical Research Council (NHMRC); Faculty
   of Engineering and IT at University of Sydney
FX The authors acknowledge the Australian National Health and Medical
   Research Council (NHMRC) and the Faculty of Engineering and IT at
   University of Sydney, for funding this project. The authors also
   acknowledge the Rebecca Cooper Foundation, and the facilities provided
   by School of AMME and the Bosch Institute at the University of Sydney.
CR Ambikaipalan A, 2013, CURR STEM CELL RES T, V8, P210, DOI 10.2174/1574888X11308030005
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Chalazonitis A, 2012, DEV NEUROBIOL, V72, P843, DOI 10.1002/dneu.22002
   Chao MM, 2006, J CRANIOFAC SURG, V17, P405, DOI 10.1097/00001665 200605000 00004
   Goulet JA, 1997, CLIN ORTHOP RELAT R, P76
   Haidar ZS, 2009, BIOTECHNOL LETT, V31, P1825, DOI 10.1007/s10529 009 0100 8
   Haidar ZS, 2009, BIOTECHNOL LETT, V31, P1817, DOI 10.1007/s10529 009 0099 x
   He XN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060473
   Higuchi A, 2013, CHEM REV, V113, P3297, DOI 10.1021/cr300426x
   Honda T, 2010, MOL BIOL CELL, V21, P3269, DOI 10.1091/mbc.E10 02 0117
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Khanna R, 2011, ACTA BIOMATER, V7, P1173, DOI 10.1016/j.actbio.2010.10.028
   Kidd LJ, 2010, BONE, V46, P369, DOI 10.1016/j.bone.2009.10.009
   Leu A, 2008, PHARM RES DORDR, V25, P1222, DOI 10.1007/s11095 007 9508 9
   Li JJ, 2011, BONE, V48, P321, DOI 10.1016/j.bone.2010.09.033
   Liu HH, 2013, BIOMATERIALS, V34, P4404, DOI 10.1016/j.biomaterials.2013.02.048
   Liu WT, 2013, ACS NANO, V7, P6928, DOI 10.1021/nn402118s
   LORD CF, 1988, J BONE JOINT SURG AM, V70A, P369, DOI 10.2106/00004623 198870030 00008
   Lu ZF, 2011, TISSUE ENG PT A, V17, P1651, DOI 10.1089/ten.tea.2010.0567
   Lu ZF, 2012, NANOMED NANOTECHNOL, V8, P507, DOI 10.1016/j.nano.2011.07.012
   Lu ZL, 2010, TISSUE ENG PT A, V16, P3075, DOI 10.1089/ten.tea.2010.0204
   Lu ZF, 2010, BIOCHEM BIOPH RES CO, V394, P323, DOI 10.1016/j.bbrc.2010.02.178
   Marie PJ, 2013, NAT REV ENDOCRINOL, V9, P288, DOI 10.1038/nrendo.2013.4
   Marsh D, 1998, CLIN ORTHOP RELAT R, pS22
   Martino S, 2012, BIOTECHNOL ADV, V30, P338, DOI 10.1016/j.biotechadv.2011.06.015
   Miao CG, 2013, CELL SIGNAL, V25, P2069, DOI 10.1016/j.cellsig.2013.04.002
   Olszta MJ, 2007, MAT SCI ENG R, V58, P77, DOI 10.1016/j.mser.2007.05.001
   Park SY, 2013, TISSUE ENG PT A, V19, P2495, DOI 10.1089/ten.tea.2012.0648
   Regard JB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007997
   Rodríguez Carballo E, 2011, J BONE MINER RES, V26, P718, DOI 10.1002/jbmr.260
   Roohani Esfahani SI, 2013, ACTA BIOMATER, V9, P7014, DOI 10.1016/j.actbio.2013.02.039
   Roohani Esfahani SI, 2012, MAT SCI ENG C MATER, V32, P830, DOI 10.1016/j.msec.2012.01.034
   Roohani Esfahani SI, 2011, ACTA BIOMATER, V7, P1307, DOI 10.1016/j.actbio.2010.10.015
   Roohani Esfahani SI, 2010, BIOMATERIALS, V31, P5498, DOI 10.1016/j.biomaterials.2010.03.058
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Sawada R, 2013, J BIOMED MATER RES A, V101, P2573, DOI 10.1002/jbm.a.34566
   Tay CY, 2013, NANOMEDICINE UK, V8, P623, DOI [10.2217/NNM.13.31, 10.2217/nnm.13.31]
   Thorfve A, 2014, ACTA BIOMATER, V10, P1451, DOI 10.1016/j.actbio.2013.12.012
   Tuan RS, 2003, J BONE JOINT SURG AM, V85A, P137, DOI 10.2106/00004623 200300002 00019
   Xynos ID, 2001, J BIOMED MATER RES, V55, P151, DOI 10.1002/1097 4636(200105)55:2<151::AID JBM1001>3.0.CO;2 D
   Yao X, 2013, ADV MATER, V25, P5257, DOI 10.1002/adma.201301762
   Zhang ZY, 2012, BIOMATERIALS, V33, P2656, DOI 10.1016/j.biomaterials.2011.12.025
   Zimmerman D, 2000, DEV BIOL, V220, P2, DOI 10.1006/dbio.2000.9633
NR 45
TC 26
Z9 30
U1 0
U2 54
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD JAN
PY 2015
VL 11
IS 1
BP 219
EP 228
DI 10.1016/j.nano.2014.09.008
PG 10
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA AX3NQ
UT WOS:000346846500022
PM 25262582
DA 2025 08 17
ER

PT J
AU Takayama, S
   Rogatsky, I
   Schwarcz, LE
   Darimont, BD
AF Takayama, Sachiko
   Rogatsky, Inez
   Schwarcz, Leslie E.
   Darimont, Beatrice D.
TI The glucocorticoid receptor represses cyclin D1 by targeting the
   Tcf β catenin complex
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID T CELL FACTOR; ANDROGEN RECEPTOR; C MYC; TRANSCRIPTIONAL ACTIVITY;
   GENE EXPRESSION; DIFFERENTIATING OSTEOBLASTS; LYMPHOBLASTIC LEUKEMIA;
   NUCLEAR RECEPTORS; RESPONSE ELEMENT; SIGNALING AXIS
AB The ability of glucocorticoids (GCs) to regulate cell proliferation plays an important role in their therapeutic use. The canonical Wnt pathway, which promotes the proliferation of many cancers and differentiated tissues, is an emerging target for the actions of GCs, albeit existing links between these signaling pathways are indirect. By screening known Wnt target genes for their ability to respond differently to GCs in cells whose proliferation is either positively or negatively regulated by GCs, we identified c myc, c jun, and cyclin D1, which encode rate limiting factors for G(1) progression of the cell cycle. Here we show that in U2OS/GR cells, which are growth arrested by GCs, the glucocorticoid receptor (GR) represses cyclin D1 via Tcf beta catenin, the transcriptional effector of the canonical Wnt pathway. We demonstrate that GR can bind beta catenin in vitro, suggesting that GC and Wnt signaling pathways are linked directly through their effectors. Down regulation of beta catenin by RNA interference impeded the expression of cyclin D1 but not of c myc or c jun and had no significant effect on the proliferation of U2OS/GR cells. Although these results revealed that beta catenin and cyclin D1 are not essential for the regulation of U2OS/GR cell proliferation, considering the importance of the Wnt pathway for proliferation and differentiation of other cells, the repression of Tcf beta catenin activity by GR could open new possibilities for tissue selective GC therapies.
C1 Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
   Univ Oregon, Dept Chem, Eugene, OR 97403 USA.
   Cornell Univ, Weill Med Coll, Hosp Special Surg, New York, NY 10021 USA.
   Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.
C3 University of Oregon; University of Oregon; Cornell University; Weill
   Cornell Medicine; Cornell University; Weill Cornell Medicine
RP Darimont, BD (通讯作者)，Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
EM bead@molbio.uoregon.edu
FU NCI NIH HHS [R01 CA 20535] Funding Source: Medline; NIGMS NIH HHS [5T32
   GM 07413] Funding Source: Medline
CR Amir AL, 2003, J BIOL CHEM, V278, P30828, DOI 10.1074/jbc.M301208200
   Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269
   Ausserlechner MJ, 2004, CELL DEATH DIFFER, V11, P165, DOI 10.1038/sj.cdd.4401328
   Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935
   Barrett TJ, 1998, J CELL BIOCHEM, P185
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049
   Cheskis BJ, 2004, J CELL BIOCHEM, V93, P20, DOI 10.1002/jcb.20180
   Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075
   Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343
   Fernandes D, 1999, AM J RESP CELL MOL, V21, P77, DOI 10.1165/ajrcmb.21.1.3396
   FROST GH, 1994, J STEROID BIOCHEM, V50, P109, DOI 10.1016/0960 0760(94)90017 5
   Glass CK, 2000, GENE DEV, V14, P121
   Guan Y, 2004, MOL ENDOCRINOL, V18, P214, DOI 10.1210/me.2003 0014
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo reports/kvd012
   IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149
   Kauppi B, 2003, J BIOL CHEM, V278, P22748, DOI 10.1074/jbc.M212711200
   King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601
   Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200
   Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860
   Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603
   Masiello D, 2004, MOL ENDOCRINOL, V18, P2388, DOI 10.1210/me.2003 0436
   Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003 0034
   Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802
   Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200
   Natsume H, 2003, BIOCHEM BIOPH RES CO, V309, P408, DOI 10.1016/j.bbrc.2003.08.019
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   OBANION MK, 1992, MOL ENDOCRINOL, V6, P1371, DOI 10.1210/me.6.9.1371
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735
   Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200
   PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Poy F, 2001, NAT STRUCT BIOL, V8, P1053, DOI 10.1038/nsb720
   Renner K, 2003, CURR MOL MED, V3, P707, DOI 10.2174/1566524033479357
   RHEE K, 1995, CANCER RES, V55, P4188
   Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181
   Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100
   Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071
   Ryves W Jonathan, 2003, Prog Cell Cycle Res, V5, P489
   Saag KG, 2003, ENDOCRIN METAB CLIN, V32, P135, DOI 10.1016/S0889 8529(02)00064 6
   Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200
   Smith E, 2002, J BIOL CHEM, V277, P18191, DOI 10.1074/jbc.M109708200
   Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674 1687.2003
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Truica CI, 2000, CANCER RES, V60, P4709
   Wei P, 1998, MOL ENDOCRINOL, V12, P1322, DOI 10.1210/me.12.9.1322
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200
   Zhu ZJ, 2003, CARCINOGENESIS, V24, P1225, DOI 10.1093/carcin/bgg077
NR 51
TC 55
Z9 65
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 30
PY 2006
VL 281
IS 26
BP 17856
EP 17863
DI 10.1074/jbc.M602290200
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 055ZO
UT WOS:000238490300035
PM 16644723
OA hybrid
DA 2025 08 17
ER

PT J
AU Chen, PY
   Sun, JS
   Tsuang, YH
   Chen, MH
   Weng, PW
   Lin, FH
AF Chen, Pei Yu
   Sun, Jui Sheng
   Tsuang, Yang Hwei
   Chen, Ming Hong
   Weng, Pei Wei
   Lin, Feng Huei
TI Simvastatin promotes osteoblast viability and differentiation via
   Ras/Smad/Erk/BMP 2 signaling pathway
SO NUTRITION RESEARCH
LA English
DT Article
DE Simvastatin; Osteoblasts; GAPs; GEFs; Ras/Smad/Erk/BMP 2; Alkaline
   phosphatase; Collagen type1
ID BONE MORPHOGENETIC PROTEIN 2; ENDOTHELIAL GROWTH FACTOR; MINERAL
   DENSITY; IN VITRO; EXPRESSION; STATINS; CELLS; STIMULATION; OSTEOCALCIN;
   FLUVASTATIN
AB Statins inhibit 3 hydroxy 3 methylglutaryl coenzyme A reductase, which catalyzes the conversion of 3 hydroxy 3 methylglutaryl coenzyme A to mevalonate, a rate limiting step in cholesterol synthesis. Statins are able to reduce cardiovascular risk in hypercholesterolemic patients. In recent years, the possible effect of statins on bone tissue has received particular attention. The present study was undertaken to understand the events of osteoblast differentiation induced by statins. Our hypothesis is that simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/bone morphogenic protein (BMP) 2 signaling pathway. The viability and differentiation of osteoblasts were examined by mitochondrial activity assay, alkaline phosphatase (ALP) activity, and gene expression. The associated signaling pathways were analyzed by cytoplasmic and membrane proteins manifestation. After administration of 10( 6) M simvastatin, the ALP activity was significantly enhanced, and the expression of BMP 2, ALP, sialoprotein, and type I collagen genes were up regulated. After simvastatin treatment, both the RasGRF1 and phospho RasGRF1 in the cytoplasm decreased significantly, whereas those on the plasma membrane increased. A marked increase in membranous GAP associated protein (P190) and the activated form of both phospho extracellular signal regulated kinase1/2 and phospho Smad I were also noted. In conclusion, this study shows that statins pose a positive effect on the metabolism of osteoblasts. Simvastatin can promote osteoblast viability and differentiation via membrane bound Ras/Smad/Erk/BMP 2 pathway. Statins stimulate osteoblast differentiation in vitro and may be a promising drug for the treatment of osteoporosis in the future. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Sun, Jui Sheng] Taipei Med Univ, Grad Inst Clin Med, Taipei 11031, Taiwan.
   [Chen, Pei Yu; Lin, Feng Huei] Natl Taiwan Univ, Grad Inst Biomed Engn, Taipei 10764, Taiwan.
   [Sun, Jui Sheng] Hsin Chu Gen Hosp, Dept Orthoped Surg, Dept Hlth, Hsinchu, Taiwan.
   [Tsuang, Yang Hwei] Taipei City Hosp, Dept Orthoped Surg, Taipei, Taiwan.
   [Chen, Ming Hong] Natl Yang Ming Univ, Inst Biomed Engn, Taipei 112, Taiwan.
   [Weng, Pei Wei] Taipei Med Univ, Shuang Ho Hosp, Dept Orthoped Surg, Taipei, Taiwan.
C3 Taipei Medical University; National Taiwan University; Taipei City
   Hospital; National Yang Ming Chiao Tung University; Taipei Medical
   University; Shuang Ho Hospital
RP Sun, JS (通讯作者)，Taipei Med Univ, Grad Inst Clin Med, 250 Wusing St, Taipei 11031, Taiwan.
EM drjssun@tmu.edu.tw
RI ; SUN, Jus Sheng/ITU 1253 2023; Huang, Chen/I 2304 2019
OI Chen, Ming Hong/0000 0001 6306 0818; SUN, JUI SHENG/0000 0001 5142 8777;
   Chen, Pei yu/0000 0003 2793 2361
FU Department of Health, Taipei City Government (Taiwan, ROC)
   [95003 62 141]
FX This work was supported by Grants in Aid for Scientific Research from
   the Department of Health, Taipei City Government (Taiwan, ROC) (Grant
   No: 95003 62 141).
CR Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289
   CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843
   Choudhury GG, 1997, AM J PHYSIOL RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   Coutant KD, 1998, BIOCHEM BIOPH RES CO, V245, P307, DOI 10.1006/bbrc.1998.8429
   Delahoy PJ, 2009, CLIN THER, V31, P236, DOI 10.1016/j.clinthera.2009.02.017
   Downs JR, 1998, JAMA J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615
   DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014 5793(94)80346 3
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Ghosh Choudhury N, 2007, J BIOL CHEM, V282, P4983, DOI 10.1074/jbc.M606706200
   Goad DL, 1996, ENDOCRINOLOGY, V137, P2262, DOI 10.1210/en.137.6.2262
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Hamelin BA, 1998, TRENDS PHARMACOL SCI, V19, P26, DOI 10.1016/S0165 6147(97)01147 4
   Heinke Stephan, 2004, BMC Cardiovasc Disord, V4, P4, DOI 10.1186/1471 2261 4 4
   Ho ML, 2009, EUR J CLIN INVEST, V39, P296, DOI 10.1111/j.1365 2362.2009.02092.x
   HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671
   Kaji H, 2008, HORM METAB RES, V40, P746, DOI 10.1055/s 0028 1082051
   Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Liantonio A, 2007, J PHARMACOL EXP THER, V321, P626, DOI 10.1124/jpet.106.118331
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo 124 1 301
   McFarlane SI, 2002, J CLIN ENDOCR METAB, V87, P1451, DOI 10.1210/jc.87.4.1451
   MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240
   Montagnani A, 2003, BONE, V32, P427, DOI 10.1016/S8756 3282(03)00034 6
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo 124 6 2991
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Rajalingam K, 2007, BBA MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012
   Robinson KN, 2005, J BIOL CHEM, V280, P225, DOI 10.1074/jbc.M410454200
   Ruiz Gaspa S, 2007, J CELL BIOCHEM, V101, P1430, DOI 10.1002/jcb.21259
   Spelsberg TC, 1999, MOL ENDOCRINOL, V13, P819, DOI 10.1210/me.13.6.819
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Uzzan B, 2007, BONE, V40, P1581, DOI 10.1016/j.bone.2007.02.019
   Yamashita M, 2008, J ENDOCRINOL, V196, P601, DOI 10.1677/JOE 07 0532
   Yazawa H, 2005, J PERIODONTOL, V76, P295, DOI 10.1902/jop.2005.76.2.295
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 38
TC 154
Z9 174
U1 0
U2 30
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271 5317
EI 1879 0739
J9 NUTR RES
JI Nutr. Res.
PD MAR
PY 2010
VL 30
IS 3
BP 191
EP 199
DI 10.1016/j.nutres.2010.03.004
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 594IB
UT WOS:000277529000005
PM 20417880
DA 2025 08 17
ER

PT J
AU Li, H
   Li, T
   Fan, J
   Li, T
   Fan, L
   Wang, S
   Weng, X
   Han, Q
   Zhao, RC
AF Li, H.
   Li, T.
   Fan, J.
   Li, T.
   Fan, L.
   Wang, S.
   Weng, X.
   Han, Q.
   Zhao, R. C.
TI miR 216a rescues dexamethasone suppression of osteogenesis, promotes
   osteoblast differentiation and enhances bone formation, by regulating
   c Cbl mediated PI3K/AKT pathway
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID MESENCHYMAL STEM CELLS; HUMAN ADIPOSE TISSUE; IN VIVO; ADIPOGENIC
   DIFFERENTIATION; CBL PI3K INTERACTION; OSTEOCLAST SURVIVAL; PROTEIN
   EXPRESSION; GROWTH FACTOR; MICRORNA; PROLIFERATION
AB Osteoporosis is a disease marked by reduced bone mass, leading to an increased risk of fractures or broken bones. Bone formation is mediated by recruiting mesenchymal stem cells (MSCs). Elucidation of the molecular mechanisms that regulate MSC differentiation into osteoblasts is of great importance for the development of anabolic therapies for osteoporosis and other bone metabolism related diseases. microRNAs (miRNAs) have been reported to have crucial roles in bone development, osteogenic differentiation and osteoporosis pathophysiology. However, to date, only a few miRNAs have been reported to enhance osteogenesis and regulate the suppressive effect of glucocorticoids on osteogenic differentiation. In this study, we discovered that miR 216a, a pancreatic specific miRNA, was significantly upregulated during osteogenic differentiation in human adipose derived MSCs (hAMSCs). The expression of miR 216a was positively correlated with the expression of bone formation marker genes in clinical osteoporosis samples. Functional analysis demonstrated that miR 216a can markedly promote osteogenic differentiation of hAMSCs, rescue the suppressive effect of dexamethasone (DEX) on osteogenic differentiation in vitro and enhance bone formation in vivo. c Cbl, a gene that encodes a RING finger E3 ubiquitin ligase, was identified as a direct target of miR 216a. Downregulation of c Cbl by short hairpin RNAs can mimic the promotion effects of miR 216a and significantly rescue the suppressive effects of DEX on osteogenesis. Pathway analysis indicated that miR 216a regulation of osteogenic differentiation occurs via the c Cbl mediated phosphatidylinositol 3 kinase (PI3K)/AKT pathway. The recovery effects of miR 216a on the inhibition of osteogenesis by DEX were attenuated after blocking the PI3K pathway. Thus, our findings suggest that miR 216a may serve as a novel therapeutic agent for the prevention and treatment of osteoporosis and other bone metabolism related diseases.
C1 [Li, H.; Li, T.; Fan, J.; Fan, L.; Wang, S.; Han, Q.; Zhao, R. C.] Chinese Acad Med Sci, Inst Basic Med Sci, Sch Basic Med,Ctr Excellence Tissue Engn, Dept Cell Biol,Peking Union Med Coll,Peking Union, Beijing 100005, Peoples R China.
   [Li, T.; Weng, X.] Chinese Acad Med Sci, Dept Orthopaed Surg, Peking Union Med Coll Hosp, Peking Union Med Coll, Beijing 100005, Peoples R China.
C3 Institute of Basic Medical Sciences   CAMS; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Peking Union Medical College;
   Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College Hospital; Peking Union Medical College
RP Han, Q (通讯作者)，Chinese Acad Med Sci, Inst Basic Med Sci, Sch Basic Med, Peking Union Med Coll,Ctr Excellence Tissue Engn, Beijing 100005, Peoples R China.
EM hanqinhanqin@126.com; zhaochunhua@vip.163.com
RI Weng, Xiaoyu/J 4899 2019; zhao, chunhua/MZR 1130 2025
OI Weng, Xisheng/0000 0002 6021 1462; 
FU National Natural Science Foundation of China [81370466, 81272009];
   National Key Scientific Program of China [2011CB964901]; National
   Collaborative Innovation Program; Program for Cheung Kong Scholars and
   Innovative Research Team in University PCSIRT [IRT0909]; National
   Science and Technology Major Projects for 'Drug Research and
   Development' [2014ZX09101042]
FX This work was supported by grants from the National Natural Science
   Foundation of China (no. 81370466 and no. 81272009), the National Key
   Scientific Program of China (no. 2011CB964901), National Collaborative
   Innovation Program, and Program for Cheung Kong Scholars and Innovative
   Research Team in University PCSIRT (no. IRT0909), and the National
   Science and Technology Major Projects for 'Drug Research and
   Development' (2014ZX09101042).
CR Abdallah Basem M., 2008, V455, P89, DOI 10.1007/978 1 59745 104 8_6
   Adapala NS, 2014, BONE, V67, P1, DOI 10.1016/j.bone.2014.06.013
   Adapala NS, 2014, J CELL BIOCHEM, V115, P1277, DOI 10.1002/jcb.24779
   Adapala NS, 2010, J BIOL CHEM, V285, P36745, DOI 10.1074/jbc.M110.124628
   Addison WN, 2007, J BIOL CHEM, V282, P15872, DOI 10.1074/jbc.M701116200
   Ahmed SF, 2009, ENDOCR DEV, V16, P170, DOI 10.1159/000223695
   Brennan T, 2011, CALCIFIED TISSUE INT, V89, P396, DOI 10.1007/s00223 011 9531 z
   Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092 8674(03)00231 9
   Can A, 2011, METHODS MOL BIOL, V698, P51, DOI 10.1007/978 1 60761 999 4_5
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chen L, 2014, STEM CELLS, V32, P902, DOI 10.1002/stem.1615
   Cheung KSC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098063
   Dieudonne FX, 2013, STEM CELLS, V31, P1340, DOI 10.1002/stem.1380
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Fink T, 2011, STEM CELL RES, V7, P89, DOI 10.1016/j.scr.2011.03.003
   GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 12
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Huang S, 2012, STEM CELLS DEV, V21, P2531, DOI 10.1089/scd.2012.0014
   Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936
   Kang IH, 2015, J CELL PHYSIOL, V230, P911, DOI 10.1002/jcp.24822
   Kato M, 2009, NAT CELL BIOL, V11, P881, DOI 10.1038/ncb1897
   Ko JY, 2013, BONE, V57, P468, DOI 10.1016/j.bone.2013.09.019
   Kureel J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.4
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Li HL, 2013, STEM CELL RES, V10, P313, DOI 10.1016/j.scr.2012.11.007
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   LIPS P, 1978, CALC TISS RES, V26, P13, DOI 10.1007/BF02013227
   Mori M, 2014, CELL, V156, P893, DOI 10.1016/j.cell.2013.12.043
   Mosna F, 2010, STEM CELLS DEV, V19, P1449, DOI 10.1089/scd.2010.0140
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Overman RA, 2014, ARTHRIT CARE RES, V66, P1644, DOI 10.1002/acr.22346
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076
   Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100
   Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53
   Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019
   Wang FS, 2013, ARTHRITIS RHEUM US, V65, P1530, DOI 10.1002/art.37948
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Yang M, 2014, MOL CELLS, V37, P873, DOI 10.14348/molcells.2014.0147
   Yu S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.363
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774 008 0019 5
   Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444
   Zhang J, 2015, DIGEST DIS SCI, V60, P127, DOI 10.1007/s10620 014 3261 9
   Zhang JF, 2011, MOL BIOL CELL, V22, P3955, DOI 10.1091/mbc.E11 04 0356
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zuo B, 2015, J BONE MINER RES, V30, P330, DOI 10.1002/jbmr.2352
NR 56
TC 129
Z9 155
U1 2
U2 56
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350 9047
EI 1476 5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD DEC
PY 2015
VL 22
IS 12
BP 1935
EP 1945
DI 10.1038/cdd.2015.99
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CW2UU
UT WOS:000364849400005
PM 26206089
OA Green Published
DA 2025 08 17
ER

PT J
AU Poon, M
   Zeng, L
   Zhang, LY
   Hsiao, J
   Wong, E
   Lam, H
   Bedard, G
   Chow, E
AF Poon, Michael
   Zeng, Liang
   Zhang, Liying
   Hsiao, Janey
   Wong, Erin
   Lam, Henry
   Bedard, Gillian
   Chow, Edward
TI Incidence of skeletal morbidity rates over time in patients with
   multiple myeloma related bone disease as reported in randomized trials
   employing bone modifying agents
SO JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
LA English
DT Article
DE bisphosphonates; bone metastases; multiple myeloma; skeletal morbidity
   rates; skeletal related events; time trend
ID STEM CELL TRANSPLANTATION; PLACEBO CONTROLLED TRIAL; ZOLEDRONIC ACID;
   DOUBLE BLIND; BREAST CARCINOMA; CLODRONIC ACID; PAMIDRONATE; BORTEZOMIB;
   THERAPY; COMPLICATIONS
AB Aim: The purpose of this review was to investigate if advances in bone targeted therapies have decreased the incidence of skeletal morbidity rates over time in patients with multiple myeloma related bone disease. Methods: A literature search was conducted over the OvidSP platform in MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials to identify Phase III results from bone targeted therapy trials in patients with multiple myeloma. The skeletal morbidity rate was the end point of interest, and for each study, a mean year of enrollment ([start of enrollment + end of enrollment]/2) was calculated. Results: A total of eight study arms were identified, with only two placebo arms; therefore, a weighted linear regression was not feasible and only intervention treatment arms were analyzed. A statistically significant downward trend in the skeletal morbidity rate was observed in all intervention arms. Conclusion: The incidence of skeletal morbidity rates has decreased significantly over time in patients with multiple myeloma.
C1 [Poon, Michael; Zeng, Liang; Zhang, Liying; Hsiao, Janey; Wong, Erin; Lam, Henry; Bedard, Gillian; Chow, Edward] Univ Toronto, Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Dept Radiat Oncol, Toronto, ON M4N 3M5, Canada.
C3 University of Toronto; Sunnybrook Research Institute; Sunnybrook Health
   Science Center
RP Chow, E (通讯作者)，Univ Toronto, Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Dept Radiat Oncol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM edward.chow@sunnybrook.ca
FU Bratty Family Fund; Michael and Karyn Goldstein Cancer Research Fund;
   Joseph and Silvana Melara Cancer Research Fund; Ofelia Cancer Research
   Fund
FX The authors thank the generous support of Bratty Family Fund, Michael
   and Karyn Goldstein Cancer Research Fund, Joseph and Silvana Melara
   Cancer Research Fund, and Ofelia Cancer Research Fund. The authors have
   no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Abildgaard N, 2004, HAEMATOLOGICA, V89, P567
   Bäuerle T, 2009, RADIOLOGY, V252, P477, DOI 10.1148/radiol.2522081756
   Berenson JR, 2011, AM J HEMATOL, V86, P25, DOI 10.1002/ajh.21912
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Bradwell AR, 2001, CLIN CHEM, V47, P673
   Brincker H, 1998, BRIT J HAEMATOL, V101, P280, DOI 10.1046/j.1365 2141.1998.00695.x
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Gimsing P, 2010, LANCET ONCOL, V11, P973, DOI 10.1016/S1470 2045(10)70198 4
   Harousseau JL, 2010, CL LYMPH MYELOM LEUK, V10, P424, DOI 10.3816/CLML.2010.n.076
   Hecht M, 2008, EXP CELL RES, V314, P1082, DOI 10.1016/j.yexcr.2007.10.021
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Kraj M, 2000, Acta Pol Pharm, V57 Suppl, P113
   LAHTINEN R, 1992, LANCET, V340, P1049, DOI 10.1016/0140 6736(92)93075 X
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Mateos MV, 2010, J CLIN ONCOL, V28, P2259, DOI 10.1200/JCO.2009.26.0638
   McCloskey EV, 2001, BRIT J HAEMATOL, V113, P1035, DOI 10.1046/j.1365 2141.2001.02851.x
   Menssen HD, 2002, J CLIN ONCOL, V20, P2353, DOI 10.1200/JCO.2002.02.032
   Morgan GJ, 2012, BLOOD, V119, P5374, DOI 10.1182/blood 2011 11 392522
   Morgan GJ, 2011, LANCET ONCOL, V12, P743, DOI 10.1016/S1470 2045(11)70157 7
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Musto P, 2008, CANCER AM CANCER SOC, V113, P1588, DOI 10.1002/cncr.23783
   Palumbo A, 2011, CLIN CANCER RES, V17, P1253, DOI 10.1158/1078 0432.CCR 10 1925
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Richardson P, 2009, BLOOD, V114, P772, DOI 10.1182/blood 2008 12 196238
   Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rosiñol L, 2012, BLOOD, V120, P1589, DOI 10.1182/blood 2012 02 408922
   San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479
   Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102
   Terpos E, 2004, LEUKEMIA, V18, P1420, DOI 10.1038/sj.leu.2403423
   Terpos E, 2010, ANN ONCOL, V21, P1561, DOI 10.1093/annonc/mdq259
   Terpos E, 2009, ANN ONCOL, V20, P1303, DOI 10.1093/annonc/mdn796
   Terpos E, 2011, CRIT REV ONCOL HEMAT, V77, pS13, DOI 10.1016/S1040 8428(11)70004 X
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
NR 35
TC 1
Z9 1
U1 1
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 2042 6305
EI 2042 6313
J9 J COMP EFFECT RES
JI J. Comp. Eff. Res.
PD JAN
PY 2013
VL 2
IS 1
BP 69
EP 76
DI 10.2217/CER.12.69
PG 8
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services
GA 299CG
UT WOS:000330372000016
PM 24236523
DA 2025 08 17
ER

PT J
AU Ma, ZG
   Lv, XD
   Zhan, LL
   Chen, L
   Zou, QY
   Xiang, JQ
   Qin, JL
   Zhang, WW
   Zeng, ZJ
   Jin, H
   Jiang, HX
   Lv, XP
AF Ma, Zhi Gang
   Lv, Xiao Dan
   Zhan, Ling Ling
   Chen, Lan
   Zou, Qi Yuan
   Xiang, Ji Qiao
   Qin, Jiao Li
   Zhang, Wei Wei
   Zeng, Zhao Jing
   Jin, Hui
   Jiang, Hai Xing
   Lv, Xiao Ping
TI Human urokinase type plasminogen activator gene modified bone
   marrow derived mesenchymal stem cells attenuate liver fibrosis in rats
   by down regulating the Wnt signaling pathway
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE bone marrow derived mesenchymal stem cells; liver fibrosis; urokinase
   plasminogen activator; Wnt signaling pathway
ID HEPATIC STELLATE CELLS; EXPRESSION PROFILE; IN VITRO; MICE; CATENIN;
   INJURY; TRANSPLANTATION; REORGANIZATION; CIRRHOSIS; MECHANISM
AB AIM: To evaluate the therapeutic effects of bone marrow derived mesenchymal stem cells (BMSCs) with human urokinase type plasminogen activator (uPA) on liver fibrosis, and to investigate the mechanism of gene therapy.
   METHODS: BMSCs transfected with adenovirus mediated human urokinase plasminogen activator (AduPA) were transplanted into rats with CCl4 induced liver fibrosis. All rats were sacrificed after 8 wk, and their serum and liver tissue were collected for biochemical, histopathologic, and molecular analyzes. The degree of liver fibrosis was assessed by hematoxylin and eosin or Masson's staining. Western blot and quantitative reverse transcription polymerase chain reaction were used to determine protein and mRNA expression levels.
   RESULTS: Serum levels of alanine aminotransferase, aminotransferase, total bilirubin, hyaluronic acid, laminin, and procollagen type. were markedly decreased, whereas the levels of serum albumin were increased by uPA gene modified BMSCs treatment. Histopathology revealed that chronic CCl4 treatment resulted in significant fibrosis while uPA gene modified BMSCs treatment significantly reversed fibrosis. By quantitatively analysing the fibrosis area of liver tissue using Masson staining in different groups of animals, we found that model animals with CCl4 induced liver fibrosis had the largest fibrotic area (16.69% +/  1.30%), while fibrotic area was significantly decreased by BMSCs treatment (12.38% +/  2.27%) and was further reduced by uPA BMSCs treatment (8.31% +/  1.21%). Both protein and mRNA expression of beta catenin, Wnt4 and Wnt5a was down regulated in liver tissues following uPA gene modified BMSCs treatment when compared with the model animals.
   CONCLUSION: Transplantation of uPA gene modified BMSCs suppressed liver fibrosis and ameliorated liver function and may be a new approach to treating liver fibrosis. Furthermore, treatment with uPA gene modified BMSCs also resulted in a decrease in expression of molecules of the Wnt signaling pathway.
C1 [Ma, Zhi Gang; Chen, Lan; Zou, Qi Yuan; Xiang, Ji Qiao; Qin, Jiao Li; Zhang, Wei Wei; Zeng, Zhao Jing; Jin, Hui; Jiang, Hai Xing; Lv, Xiao Ping] Guangxi Med Univ, Affiliated Hosp 1, Dept Gastroenterol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Lv, Xiao Dan; Zhan, Ling Ling] Guangxi Med Univ, Affiliated Hosp 1, Dept Clin Expt Med, Nanning 530021, Guangxi Zhuang, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University
RP Lv, XP (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Dept Gastroenterol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.
EM lxxp58@hotmail.com
RI ; zou, qiyuan/GVU 7494 2022; zhan, lingling/OAJ 4542 2025
OI Zou, Qi Yuan/0000 0001 9497 847X; 
FU National Natural Science Foundation of China [81460114]; Natural Science
   Foundation of Guangxi Zhuang Autonomous Region [1355005 3 2,
   2012GXNSFAA053143]; Chinese Traditional Medicine Science Foundation of
   Guangxi Zhuang Autonomous Region [GZPT1238]; Science Foundation of
   Guangxi Department of Education [201203YB036, 2013LX031]
FX Supported by National Natural Science Foundation of China, No. 81460114;
   Natural Science Foundation of Guangxi Zhuang Autonomous Region, No.
   1355005 3 2 and No. 2012GXNSFAA053143; Chinese Traditional Medicine
   Science Foundation of Guangxi Zhuang Autonomous Region, No. GZPT1238;
   and Science Foundation of Guangxi Department of Education, No.
   201203YB036 and No. 2013LX031.
CR Andersen P, 2012, TRENDS CELL BIOL, V22, P257, DOI 10.1016/j.tcb.2012.02.003
   Baron C, 2007, PLOS MED, V4, P69, DOI 10.1371/journal.pmed.0040023
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Bezerra JA, 2001, AM J PATHOL, V158, P921, DOI 10.1016/S0002 9440(10)64039 4
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bueno M, 2006, J GENE MED, V8, P1291, DOI 10.1002/jgm.961
   CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0
   Carvalho AB, 2008, STEM CELLS, V26, P1307, DOI 10.1634/stemcells.2007 0941
   Cheng JH, 2008, AM J PHYSIOL GASTR L, V294, pG39, DOI 10.1152/ajpgi.00263.2007
   CHEVALLIER M, 1994, HEPATOLOGY, V20, P349, DOI 10.1002/hep.1840200213
   Clark CEJ, 2012, NEUROSIGNALS, V20, P202, DOI 10.1159/000332153
   Di Bonzo LV, 2008, GUT, V57, P223, DOI 10.1136/gut.2006.111617
   Dong S, 2014, J INTEGR MED JIM, V12, P147, DOI 10.1016/S2095 4964(14)60022 4
   Fang BJ, 2004, TRANSPLANTATION, V78, P83, DOI 10.1097/01.TP.0000128326.95294.14
   Fiegel HC, 2003, STEM CELLS, V21, P98, DOI 10.1634/stemcells.21 1 98
   Forbes SJ, 2004, GASTROENTEROLOGY, V126, P955, DOI 10.1053/j.gastro.2004.02.025
   Friedman SL, 2008, PHYSIOL REV, V88, P125, DOI 10.1152/physrev.00013.2007
   Ge WS, 2014, MOL MED REP, V9, P2145, DOI 10.3892/mmr.2014.2099
   Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004
   Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009
   Jiang F, 2006, J HEPATOL, V45, P401, DOI 10.1016/j.jhep.2006.03.016
   Jiao JJ, 2009, CURR OPIN GASTROEN, V25, P223, DOI 10.1097/MOG.0b013e3283279668
   Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978 0 12 386035 4.00002 1
   Kim MD, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.49
   Kordes C, 2008, BIOCHEM BIOPH RES CO, V367, P116, DOI 10.1016/j.bbrc.2007.12.085
   Kumar S, 2008, GENE THER, V15, P711, DOI 10.1038/gt.2008.35
   Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003
   Leyland H, 1996, HEPATOLOGY, V24, P1172, DOI 10.1002/hep.510240532
   Li WT, 2011, DIGEST LIVER DIS, V43, P559, DOI 10.1016/j.dld.2011.02.016
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Mercadal BA, 2015, HUM REPROD, V30, P1196, DOI 10.1093/humrep/dev042
   Mondino A, 2004, TRENDS IMMUNOL, V25, P450, DOI 10.1016/j.it.2004.06.004
   Parekkadan B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000941
   Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168
   Piotrowski WJ, 2011, MED SCI MONITOR, V17, pCR598, DOI 10.12659/MSM.881987
   Pohl JF, 2001, AM J PATHOL, V159, P2179, DOI 10.1016/S0002 9440(10)63069 6
   Sakaida I, 2004, HEPATOLOGY, V40, P1304, DOI 10.1002/hep.20452
   Salgado S, 2000, MOL THER, V2, P545, DOI 10.1006/mthe.2000.0210
   Sato K, 2007, BLOOD, V109, P228, DOI 10.1182/blood 2006 02 002246
   Shanmukhappa K, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471 230X 6 40
   Shao CH, 2014, J SURG RES, V186, P408, DOI 10.1016/j.jss.2013.08.016
   Sun C, 2008, J GENE MED, V10, P855, DOI 10.1002/jgm.1206
   Wang BCC, 2012, MED SCI MONITOR, V18, pBR394, DOI 10.12659/MSM.883479
   Xiong WJ, 2012, WORLD J GASTROENTERO, V18, P1745, DOI 10.3748/wjg.v18.i15.1745
   Yao XL, 2014, BIOCHEM BIOPH RES CO, V447, P383, DOI 10.1016/j.bbrc.2014.03.142
   Zhang YN, 2006, HEPATOLOGY, V44, P612, DOI 10.1002/hep.21315
NR 46
TC 29
Z9 31
U1 0
U2 10
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007 9327
EI 2219 2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD FEB 14
PY 2016
VL 22
IS 6
BP 2092
EP 2103
DI 10.3748/wjg.v22.i6.2092
PG 12
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA DB5MX
UT WOS:000368559400014
PM 26877613
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Tao, SY
   Yu, H
   You, T
   Kong, XX
   Wei, XA
   Zheng, ZY
   Zheng, L
   Feng, ZH
   Huang, B
   Zhang, XY
   Chen, F
   Chen, X
   Song, HX
   Li, J
   Chen, BH
   Chen, J
   Yao, QQ
   Zhao, FD
AF Tao, Siyue
   Yu, Hao
   You, Tao
   Kong, Xiangxi
   Wei, Xiaoan
   Zheng, Zeyu
   Zheng, Lin
   Feng, Zhenhua
   Huang, Bao
   Zhang, Xuyang
   Chen, Feng
   Chen, Xiao
   Song, Haixin
   Li, Jie
   Chen, Binhui
   Chen, Jian
   Yao, Qingqing
   Zhao, Fengdong
TI A Dual Targeted Metal Organic Framework Based Nanoplatform for the
   Treatment of Rheumatoid Arthritis by Restoring the Macrophage Niche
SO ACS NANO
LA English
DT Article
DE metal organic framework; pH responsive materials; rheumatoid arthritis;
   macrophage niche; complementsystem; osteoclast
ID RECEPTOR; PATHWAY; PATHOGENESIS; INFLAMMATION; ANTAGONIST; INSIGHTS;
   BEHAVIOR; PROTEIN; IMMUNE; INJURY
AB Inflammatory infiltration and bone destruction are importantpathologicalfeatures of rheumatoid arthritis (RA), which originate from the disturbedniche of macrophages. Here, we identified a niche disrupting processin RA: due to overactivation of complement, the barrier function of VSIg4 (+) lining macrophages is disrupted and mediatesinflammatory infiltration within the joint, thereby activating excessiveosteoclastogenesis and bone resorption. However, complement antagonistshave poor biological applications due to superphysiologic dose requirementsand inadequate effects on bone resorption. Therefore, we developeda dual targeted therapeutic nanoplatform based on the MOF frameworkto achieve bone targeted delivery of the complement inhibitor CRIg CD59and pH responsive sustained release. The surface mineralized zoledronicacid (ZA) of ZIF8@CRIg CD59@HA@ZA targets the skeletal acidicmicroenvironment in RA, and the sustained release of CRIg CD59can recognize and prevent the complement membrane attack complex (MAC)from forming on the surface of healthy cells. Importantly, ZA caninhibit osteoclast mediated bone resorption, and CRIg CD59can promote the repair of the VSIg4 (+) liningmacrophage barrier to achieve sequential niche remodeling. This combinationtherapy is expected to treat RA by reversing the core pathologicalprocess, circumventing the pitfalls of traditional therapy.
C1 [Tao, Siyue; Kong, Xiangxi; Wei, Xiaoan; Zheng, Zeyu; Zheng, Lin; Feng, Zhenhua; Huang, Bao; Zhang, Xuyang; Song, Haixin; Chen, Jian; Zhao, Fengdong] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Orthoped Surg, Hangzhou 310016, Zhejiang, Peoples R China.
   [Tao, Siyue; Kong, Xiangxi; Wei, Xiaoan; Zheng, Zeyu; Zheng, Lin; Feng, Zhenhua; Huang, Bao; Zhang, Xuyang; Song, Haixin; Chen, Jian; Zhao, Fengdong] Key Lab Musculoskeletal Syst Degenerat & Regenerat, Hangzhou 310016, Zhejiang, Peoples R China.
   [Yu, Hao; Yao, Qingqing] Wenzhou Med Univ, Eye Hosp, Natl Engn Res Ctr Ophthalmol & Optometry, Sch Ophthalmol & Optometry, Wenzhou 325027, Zhejiang, Peoples R China.
   [You, Tao; Chen, Feng; Chen, Xiao] Univ Sci & Technol China, Affiliated Hosp USTC 1, Sch Chem & Mat Sci, Div Life Sci & Med, Hefei 230026, Anhui, Peoples R China.
   [You, Tao; Chen, Feng; Chen, Xiao] Univ Sci & Technol China, Sch Chem & Mat Sci, Dept Polymer Sci & Engn, CAS Key Lab Soft Matter Chem, Hefei 230026, Anhui, Peoples R China.
   [Li, Jie; Chen, Binhui] Li Huili Hosp, Ningbo Med Ctr, Dept Orthopaed Surg, Ningbo 315100, Zhejiang, Peoples R China.
   [Chen, Jian; Zhao, Fengdong] Wenzhou Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Wenzhou 325000, Zhejiang, Peoples R China.
C3 Zhejiang University; Wenzhou Medical University; Chinese Academy of
   Sciences; University of Science & Technology of China, CAS; Chinese
   Academy of Sciences; University of Science & Technology of China, CAS;
   Wenzhou Medical University
RP Chen, J; Zhao, FD (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Orthoped Surg, Hangzhou 310016, Zhejiang, Peoples R China.; Chen, J; Zhao, FD (通讯作者)，Key Lab Musculoskeletal Syst Degenerat & Regenerat, Hangzhou 310016, Zhejiang, Peoples R China.; Yao, QQ (通讯作者)，Wenzhou Med Univ, Eye Hosp, Natl Engn Res Ctr Ophthalmol & Optometry, Sch Ophthalmol & Optometry, Wenzhou 325027, Zhejiang, Peoples R China.; Chen, J; Zhao, FD (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Wenzhou 325000, Zhejiang, Peoples R China.
EM chenjian bio@zju.edu.cn; qingqingyao@wmu.edu.cn; zhaofengdong@zju.edu.cn
RI zheng, zeyu/A 3867 2013; Kong, Xiangxi/KFA 7573 2024; song,
   haixin/NZO 0362 2025; Zheng, Lin/AAE 8093 2021; zhang,
   xuyang/GQH 3712 2022
OI Zheng, Lin/0000 0002 7585 6968; 
FU Zhejiang Provincial Natural Science Foundation of China [LQ20H170002];
   National Natural Scientific Foundation of China (NNSFC) Projects
   [82072466, 82272521, 82272520]; Key Ramp;D and Development Projects in
   Anhui Province [201904a07020107]
FX We gratefully acknowledge the financial support of Zhejiang Provincial
   Natural Science Foundation of China (Z23H060004), the National Natural
   Scientific Foundation of China (NNSFC) Projects (82072466, 82272521,
   82272520), Zhejiang Provincial Natural Science Foundation of China
   (LQ20H170002), and Key R&D and Development Projects in Anhui Province
   (201904a07020107). All animal experiments in this study were approved by
   the Animal Ethics Review Committee of Sir Run Run Shaw Hospital
   affiliated with Zhejiang University.
CR Adamopoulos IE, 2015, NAT REV RHEUMATOL, V11, P189, DOI 10.1038/nrrheum.2014.198
   Ames RS, 2001, J IMMUNOL, V166, P6341, DOI 10.4049/jimmunol.166.10.6341
   Andreatta M, 2021, COMPUT STRUCT BIOTEC, V19, P3796, DOI 10.1016/j.csbj.2021.06.043
   Barilla LaBarca ML, 2013, CLIN IMMUNOL, V148, P313, DOI 10.1016/j.clim.2013.02.014
   Bashiri G, 2021, INT J BIOL MACROMOL, V170, P222, DOI 10.1016/j.ijbiomac.2020.12.150
   Beh CY, 2021, J COLLOID INTERF SCI, V600, P187, DOI 10.1016/j.jcis.2021.03.158
   Blom AM, 2009, ANN RHEUM DIS, V68, P136, DOI 10.1136/ard.2007.085753
   Bonnet CS, 2015, ANN RHEUM DIS, V74, P242, DOI 10.1136/annrheumdis 2013 203670
   Boutet MA, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102758
   BRODEUR JP, 1991, ARTHRITIS RHEUM, V34, P1531
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Cai W, 2019, ADV SCI, V6, DOI 10.1002/advs.201801526
   Catrina AI, 2017, NAT REV RHEUMATOL, V13, P79, DOI 10.1038/nrrheum.2016.200
   Cheer SM, 2001, DRUGS, V61, P799, DOI 10.2165/00003495 200161060 00010
   Cortal A, 2021, NAT BIOTECHNOL, V39, P1095, DOI 10.1038/s41587 021 00896 6
   Culemann S, 2019, NATURE, V572, P670, DOI 10.1038/s41586 019 1471 1
   Delgado Calle J, 2022, PHYSIOL REV, V102, DOI 10.1152/physrev.00043.2020
   Deng CF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22454 z
   Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140 6736(05)71086 2
   Dura B, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gky1173
   Durigutto P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058696
   Fujii T, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00120 2
   Goodfellow RM, 2000, CLIN EXP IMMUNOL, V119, P210, DOI 10.1046/j.1365 2249.2000.01129.x
   Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039
   Hornum L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189017
   Jung K, 2012, HEPATOLOGY, V56, P1838, DOI 10.1002/hep.25906
   Kameda Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041889
   Katschke KJ, 2007, J EXP MED, V204, P1319, DOI 10.1084/jem.20070432
   Katz JN, 2021, JAMA J AM MED ASSOC, V325, P568, DOI 10.1001/jama.2020.22171
   Koivisto K, 2019, DIAGNOSTICS, V9, DOI 10.3390/diagnostics9040212
   Laha D, 2019, AUTOPHAGY, V15, P2063, DOI 10.1080/15548627.2019.1596491
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lu KD, 2018, ADV MATER, V30, DOI 10.1002/adma.201707634
   Mannes M, 2021, BLOOD, V137, P443, DOI 10.1182/blood.2020005959
   Marshall KM, 2014, J EXP MED, V211, P1793, DOI 10.1084/jem.20131902
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Michaelson MD, 2005, J CLIN ONCOL, V23, P8219, DOI 10.1200/JCO.2005.02.9579
   Munawara U, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02892
   Murayama MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9483
   Nguyen THP, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0264628
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Parsons ES, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10058 7
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Romero V, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006869
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Tai TW, 2017, SCI REP UK, V7, DOI 10.1038/srep44245
   Trouw LA, 2017, NAT REV RHEUMATOL, V13, DOI 10.1038/nrrheum.2017.125
   Vergunst CE, 2007, RHEUMATOLOGY, V46, P1773, DOI 10.1093/rheumatology/kem222
   Vogt L, 2006, J CLIN INVEST, V116, P2817, DOI 10.1172/JCI25673
   Wang Y, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119619
   Wei PF, 2019, CHEM ENG J, V368, P577, DOI 10.1016/j.cej.2019.02.202
   Wei XA, 2022, EMBO MOL MED, V14, DOI 10.15252/emmm.202115373
   Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263
   Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059 017 1382 0
   Woodruff TM, 2002, ARTHRITIS RHEUM US, V46, P2476, DOI 10.1002/art.10449
   Wu MX, 2017, ADV MATER, V29, DOI 10.1002/adma.201606134
   Wu T, 2016, MAT SCI ENG C MATER, V62, P888, DOI 10.1016/j.msec.2016.01.012
   Wu XL, 2017, BIORESOUR BIOPROCESS, V4, DOI 10.1186/s40643 017 0154 8
   Yang J, 2020, SMALL, V16, DOI 10.1002/smll.201906846
   Yin ZT, 2022, J COLLOID INTERF SCI, V607, P1300, DOI 10.1016/j.jcis.2021.09.027
   Zhang LY, 2020, J MATER CHEM B, V8, P1739, DOI 10.1039/c9tb02621e
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zhou YH, 2021, ADV MATER, V33, DOI 10.1002/adma.202102044
NR 65
TC 24
Z9 26
U1 13
U2 134
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD JUL 10
PY 2023
VL 17
IS 14
BP 13917
EP 13937
DI 10.1021/acsnano.3c03828
EA JUL 2023
PG 21
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA M6YD2
UT WOS:001025907800001
PM 37429012
DA 2025 08 17
ER

PT J
AU Inoue, R
   Matsuki, N
   Jing, G
   Kanematsu, T
   Abe, K
   Hirata, M
AF Inoue, R
   Matsuki, N
   Jing, G
   Kanematsu, T
   Abe, K
   Hirata, M
TI The inhibitory effect of alendronate, a nitrogen containing
   bisphosphonate on the PI3K Akt NFκB pathway in osteosarcoma cells
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Akt; apoptosis; bisphosphonate; cell survival pathway; NF kappa B;
   osteosarcoma; phosphoinositides
ID NF KAPPA B; PROTEIN KINASE KINASE; MEVALONATE PATHWAY; IN VITRO;
   OSTEOCLAST FORMATION; INDUCE APOPTOSIS; BONE RESORPTION; ACTIVATION;
   TUMOR; MECHANISMS
AB 1 Bisphosphonates are inhibitors of tumor cell growth as well as of bone resorption by inducing cell apoptosis. However, little is known regarding the mechanisms by which the drug induces cell apoptosis. The aim of the present study was to determine the effect of alendronate, one of the nitrogen containing bisphosphonates on the phoshoinositide 3 kinase (PI3K) Akt NF kappa B pathway, the major cell survival pathway.
   2 The PI3K Akt NF kappa B pathway was activated in the osteosarcoma cell line MG 63 treated with tumor necrosis factor alpha or insulin. Saos 2 was also used in some experiments. This was assessed by the production of phosphatidylinositol 3,4,5 trisphosphate (PtdIns(3,4,5)P 3), increased PI3K activity, phosphorylation of Akt at serine 473 and threonine 308, increase in activity of the inhibitor of nuclear factor kappa B (I kappa B) kinase (IKK) and finally phosphorylation of I kappa B and its subsequent degradation.
   3 Pretreatment with alendronate at 100 mu M for 24 h prior to the stimulation with tumor necrosis factor alpha or insulin partially inhibited the I kappa B phosphorylation and degradation. These events were more clearly observed in the presence of inhibitors of proteasomes, which are responsible for the degradation of I kappa B. The drug also partially inhibited the activity of IKK, but almost fully inhibited the phosphorylation of Akt and the production of PtdIns(3,4,5)P3.
   4 The inhibitory effect of alendronate on I kappa B phosphorylation and degradation was not attenuated by the exogenous addition of geranylgeraniol to replenish the cytosolic isoprenyl lipid substrate.
   5 The present findings demonstrate that alendronate inhibited the PI3K Akt NF kappa B cell survival pathway at the point of PI3K activation, thus indicating the presence of new targets of alendronate.
C1 Kyushu Univ, Fac Dent Sci, Lab Mol & Cellular Biochem, Fukuoka 8128582, Japan.
   Kyushu Univ, Stn Collaborat Res, Fukuoka 8128582, Japan.
   Kyushu Univ Hosp, Special Patient Oral Care Unit, Fukuoka 8128582, Japan.
   Kyushu Univ, Fac Dent Sci, Dept Oral & Maxillofacial Oncol, Fukuoka 8128582, Japan.
C3 Kyushu University; Kyushu University; Kyushu University; Kyushu
   University
RP Hirata, M (通讯作者)，Kyushu Univ, Fac Dent Sci, Lab Mol & Cellular Biochem, Fukuoka 8128582, Japan.
EM hirata1@dent.kyushu u.ac.jp
CR Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460 2075.1996.tb01045.x
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Binderman I, 2000, J PERIODONTOL, V71, P1236, DOI 10.1902/jop.2000.71.8.1236
   Cheng YY, 2004, CALCIFIED TISSUE INT, V75, P71, DOI 10.1007/s00223 004 0120 2
   Clement EVP, 2002, J BONE MINER RES, V17, P2247, DOI 10.1359/jbmr.2002.17.12.2247
   Coxon FP, 1998, MOL PHARMACOL, V54, P631
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Ebetino FH, 1998, REV CONTEMP PHARMACO, V9, P233
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Foo SY, 1999, TRENDS GENET, V15, P229
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kaynak D, 2003, J PERIODONTOL, V74, P1348, DOI 10.1902/jop.2003.74.9.1348
   Lallena MJ, 1999, MOL CELL BIOL, V19, P2180
   Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319
   Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092 8674(00)81842 5
   Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839
   Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933 2940.2000
   Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899
   Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074 7613(00)80027 8
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0
   Mansell A, 2001, J BIOL CHEM, V276, P43597, DOI 10.1074/jbc.M105202200
   Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336
   Ozes ON, 1999, NATURE, V401, P82
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0
   Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Sandra F, 2002, CELL SIGNAL, V14, P771, DOI 10.1016/S0898 6568(02)00025 6
   SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495
   Shipman CM, 1998, CANCER RES, V58, P5294
   SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201
   Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49
   Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009
   SUBHA P, 2003, J BIOL CHEM, V278, P14487
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
   Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699
   Zhou LM, 2003, AM J RESP CELL MOL, V28, P762, DOI 10.1165/rcmb.2002 0261OC
NR 50
TC 54
Z9 59
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD NOV
PY 2005
VL 146
IS 5
BP 633
EP 641
DI 10.1038/sj.bjp.0706373
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 984ZO
UT WOS:000233346100002
PM 16100524
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Wang, ZQ
   Zhan, CY
   Zeng, F
   Wu, SZ
AF Wang, Ziqian
   Zhan, Chenyue
   Zeng, Fang
   Wu, Shuizhu
TI A biopolymer based and inflammation responsive nanodrug for rheumatoid
   arthritis treatment via inhibiting JAK STAT and JNK signalling
   pathways
SO NANOSCALE
LA English
DT Article
ID HYBRID MICELLES; GENE EXPRESSION; BONE EROSION; TOFACITINIB;
   METHOTREXATE; ACTIVATION; INDUCTION; DELIVERY; NANOPARTICLES;
   MACROPHAGES
AB Rheumatoid arthritis (RA) is a common chronic autoimmune disease associated with progressive disability, systemic complications, and poor prognosis. The improved understanding of the roles of immune signaling pathway inhibitors has shed light on designing new and more effective approaches for RA treatment. In this work, an inflammation responsive and molecularly targeted drug system has been developed for RA therapy. The drug carrier was synthesized by covalently grafting hydrophobic cholesterol (Chol) molecules onto a hydrophilic chondroitin sulfate (CS) chain via the inflammation responsive diselenide bonds (SeSe). The resultant amphiphilic polymer CSSeSeChol readily forms nanoparticles (NPs) and encapsulates two kinase inhibitors tofacitinib and SP600125 in aqueous media. Upon administration into the RA mouse model, the nanodrug accumulates in RA lesions and releases the inhibitors for regulating the JAK STAT and JNK pathways. As a result, the nanodrug exhibits satisfactory efficacy in RA treatment by suppressing the expression of relevant pro inflammatory cytokines, blocking the activation of osteoclasts and providing protection for cartilage and joints.
C1 [Wang, Ziqian; Zhan, Chenyue; Zeng, Fang; Wu, Shuizhu] South China Univ Technol, Coll Mat Sci & Engn, Guangdong Prov Key Lab Luminescence Mol Aggregate, Biomed Div,State Key Lab Luminescent Mat & Device, Wushan Rd 381, Guangzhou 510640, Peoples R China.
C3 South China University of Technology
RP Zeng, F; Wu, SZ (通讯作者)，South China Univ Technol, Coll Mat Sci & Engn, Guangdong Prov Key Lab Luminescence Mol Aggregate, Biomed Div,State Key Lab Luminescent Mat & Device, Wushan Rd 381, Guangzhou 510640, Peoples R China.
EM mcfzeng@scut.edu.cn; shzhwu@scut.edu.cn
OI Wang, Ziqian/0000 0001 7787 9621; Wu, Shuizhu/0000 0002 6739 0694
FU NSFC [21875069, 51673066, 21574044]; Natural Science Foundation of
   Guangdong Province [2016A030312002]; Fund of Guangdong Provincial Key
   Laboratory of Luminescence from Molecular Aggregates [2019B030301003]
FX This work was supported by the NSFC (21875069, 51673066 and 21574044),
   the Natural Science Foundation of Guangdong Province (2016A030312002)
   and the Fund of Guangdong Provincial Key Laboratory of Luminescence from
   Molecular Aggregates (2019B030301003).
CR Ahamad N, 2020, NANOSCALE, V12, P12673, DOI 10.1039/d0nr01648a
   Aletaha D, 2018, JAMA J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103
   Bissonnette R, 2016, BRIT J DERMATOL, V175, P902, DOI 10.1111/bjd.14871
   Chauhan AS, 2004, J DRUG TARGET, V12, P575, DOI 10.1080/10611860400010655
   Cheng CC, 2019, NANOSCALE, V11, P10393, DOI 10.1039/c8nr09537j
   Chistiakov DA, 2017, LAB INVEST, V97, P4, DOI 10.1038/labinvest.2016.116
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Croft AP, 2019, NATURE, V570, P246, DOI 10.1038/s41586 019 1263 7
   Daginakatte GC, 2008, CANCER RES, V68, P10358, DOI 10.1158/0008 5472.CAN 08 2506
   Davignon JL, 2013, RHEUMATOLOGY, V52, P590, DOI 10.1093/rheumatology/kes304
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   du Souich P, 2009, J CELL MOL MED, V13, P1451, DOI 10.1111/j.1582 4934.2009.00826.x
   Fahmy RG, 2006, NAT BIOTECHNOL, V24, P856, DOI 10.1038/nbt1225
   FALCIANI F, 1992, BIOCHEM J, V285, P1001, DOI 10.1042/bj2851001
   Firestein GS, 2017, IMMUNITY, V46, P183, DOI 10.1016/j.immuni.2017.02.006
   Fleischmann R, 2012, NEW ENGL J MED, V367, P495, DOI 10.1056/NEJMoa1109071
   Gao W, 2016, ANN RHEUM DIS, V75, P311, DOI 10.1136/annrheumdis 2014 207201
   Guenthoer P, 2019, INFLAMMOPHARMACOLOGY, V27, P1217, DOI 10.1007/s10787 019 00593 6
   Guo ZQ, 2014, CHEM SOC REV, V43, P16, DOI 10.1039/c3cs60271k
   Hammaker DR, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2215
   Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466
   Hao F, 2019, THERANOSTICS, V9, P5282, DOI 10.7150/thno.32268
   Hemmerle T, 2014, P NATL ACAD SCI USA, V111, P12008, DOI 10.1073/pnas.1402783111
   Heo R, 2017, BIOMATERIALS, V131, P15, DOI 10.1016/j.biomaterials.2017.03.044
   Hofkens W, 2011, J CONTROL RELEASE, V152, P363, DOI 10.1016/j.jconrel.2011.03.001
   Hu YH, 2019, NANO LETT, V19, P2731, DOI 10.1021/acs.nanolett.9b01093
   Inglis JJ, 2008, NAT PROTOC, V3, P612, DOI 10.1038/nprot.2008.19
   Joshi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03691 1
   Kim J, 2019, ACS NANO, V13, P3206, DOI 10.1021/acsnano.8b08785
   Kinne RW, 2000, ARTHRITIS RES, V2, P189, DOI 10.1186/ar86
   Kubo S, 2014, ANN RHEUM DIS, V73, P2192, DOI 10.1136/annrheumdis 2013 203756
   LaBranche TP, 2012, ARTHRITIS RHEUM US, V64, P3531, DOI 10.1002/art.34649
   Lee EB, 2014, NEW ENGL J MED, V370, P2377, DOI 10.1056/NEJMoa1310476
   Lee H, 2014, ACS NANO, V8, P4790, DOI 10.1021/nn500685h
   Legendre F, 2008, OSTEOARTHR CARTILAGE, V16, P105, DOI 10.1016/j.joca.2007.05.020
   Li MH, 2018, ADV SCI, V5, DOI 10.1002/advs.201800155
   Li P, 2020, J CONTROL RELEASE, V319, P87, DOI 10.1016/j.jconrel.2019.12.025
   Liu JY, 2012, BIOMATERIALS, V33, P7765, DOI 10.1016/j.biomaterials.2012.07.003
   Lovu M, 2008, OSTEOARTHR CARTILAGE, V16, pS14, DOI 10.1016/j.joca.2008.06.008
   Maruotti N, 2007, HISTOL HISTOPATHOL, V22, P581, DOI 10.14670/HH 22.581
   Miklossy G, 2013, NAT REV DRUG DISCOV, V12, P611, DOI 10.1038/nrd4088
   Mooney J, 2014, RHEUMATOLOGY, V53, P1414, DOI 10.1093/rheumatology/keu026
   Ni S, 2019, J CELL PHYSIOL, V234, P454, DOI 10.1002/jcp.26580
   Nograles KE, 2009, NAT CLIN PRACT RHEUM, V5, P83, DOI 10.1038/ncprheum0987
   O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev med 051113 024537
   Oh J, 2012, J BIOL CHEM, V287, P11629, DOI 10.1074/jbc.M111.338673
   Ouchi N, 2010, SCIENCE, V329, P454, DOI 10.1126/science.1188280
   Ouyang J, 2020, ANGEW CHEM INT EDIT, V59, P10111, DOI 10.1002/anie.201913149
   Pizzolla A, 2011, EUR J IMMUNOL, V41, P403, DOI 10.1002/eji.201040598
   Qi Y, 2018, ANAL CHEM, V90, P1014, DOI 10.1021/acs.analchem.7b04407
   RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827
   Revu S, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4398
   Sandborn WJ, 2017, NEW ENGL J MED, V376, P1723, DOI 10.1056/NEJMoa1606910
   Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201
   Schwarzenböck C, 2018, NANOSCALE, V10, P16062, DOI 10.1039/c8nr04760j
   Shao D, 2018, ADV MATER, V30, DOI 10.1002/adma.201801198
   Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226
   Smolen JS, 2016, LANCET, V388, P1984
   Sun TB, 2013, MACROMOL CHEM PHYS, V214, P2875, DOI 10.1002/macp.201300579
   Sweeney SE, 2004, INT J BIOCHEM CELL B, V36, P372, DOI 10.1016/S1357 2725(03)00259 0
   Tan XX, 2015, POLYM CHEM UK, V6, P681, DOI 10.1039/c4py01440e
   te Boekhorst BCM, 2012, J CONTROL RELEASE, V161, P772, DOI 10.1016/j.jconrel.2012.05.004
   Thalhamer T, 2008, RHEUMATOLOGY, V47, P409, DOI 10.1093/rheumatology/kem297
   Tian Y, 2019, ANAL CHEM, V91, P10901, DOI 10.1021/acs.analchem.9b02857
   van Vollenhoven RF, 2012, NEW ENGL J MED, V367, P508, DOI 10.1056/NEJMoa1112072
   Vangsness CT, 2009, ARTHROSCOPY, V25, P86, DOI 10.1016/j.arthro.2008.07.020
   Volpi Nicola, 2011, Inflammopharmacology, V19, P299, DOI 10.1007/s10787 011 0098 0
   Wang L, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02217 y
   Wang Q, 2017, BIOMATERIALS, V122, P10, DOI 10.1016/j.biomaterials.2017.01.008
   Wang WX, 2020, SENSOR ACTUAT B CHEM, V320, DOI 10.1016/j.snb.2020.128296
   Weissmann G, 2006, BULL HOSP JT DIS, V64, P12
   Wu YL, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201807960
   Wu YL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06499 1
   Xu XL, 2018, NANOSCALE, V10, P2923, DOI 10.1039/c7nr08430g
   Yuan Q, 2019, THERANOSTICS, V9, P1825, DOI 10.7150/thno.31893
   Zhou WQ, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201605465
   Zhou YY, 2015, CELL PHYSIOL BIOCHEM, V36, P631, DOI 10.1159/000430126
   Zhu HJ, 2019, J MATER CHEM B, V7, P384, DOI 10.1039/c8tb03069c
NR 78
TC 24
Z9 25
U1 2
U2 62
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040 3364
EI 2040 3372
J9 NANOSCALE
JI Nanoscale
PD DEC 7
PY 2020
VL 12
IS 45
BP 23013
EP 23027
DI 10.1039/d0nr05551d
PG 15
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA OW6VH
UT WOS:000593021300012
PM 33191426
DA 2025 08 17
ER

PT J
AU Joo, MK
   Park, JJ
   Lee, BJ
   Kim, JH
   Yeon, JE
   Kim, JS
   Byun, KS
   Bak, YT
AF Joo, Moon Kyung
   Park, Jong Jae
   Lee, Beom Jae
   Kim, Ji Hoon
   Yeon, Jong Eun
   Kim, Jae Seon
   Byun, Kwan Soo
   Bak, Young Tae
TI The effect of a proton pump inhibitor on bone metabolism in
   ovariectomized rats
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE proton pump inhibitor; bone metabolism; osteoclast
ID B LIGAND RANKL; OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; REFLUX
   DISEASE; NUCLEAR FACTOR; C FOS; OMEPRAZOLE; GUIDELINES; RESORPTION;
   THERAPY
AB Recent studies revealed that long term intake of proton pump inhibitor (PPI) increases the risk of vertebral or hip fracture; however, the exact mechanism for this is not known. To evaluate the effect of long term PPI therapy on bone turnover, we analyzed the signaling pathway involved in osteoclast differentiation and bone resorption/formation markers using ovariectomized rats. Six week old Sprague Dawley (S D) rats were ovariectomized, and two weeks later they were divided into four groups (group A, normal diet + placebo; group B, low calcium diet + placebo; group C, normal diet + PPI; and group D, low calcium diet + PPI). Omeprazole, at a concentration of 30 mg/kg, was administered orally for eight weeks and the rats were sacrificed when they were 16 weeks old. The relative expression levels of the receptor activator of NF kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio, c Fos, nuclear factor of activated T cells c1 (NFATc1) and osteocalcin in femoral bone marrow cells were compared, and serum C terminal cross linking telopeptide of type I (CTX 1) levels were determined. The relative ratio of RANKL/OPG was increased in group D, and gene expression levels of c Fos and NFATc1 were upregulated in groups B and D, which are involved in differentiation and activation of osteoclasts. Furthermore, expression levels of osteocalcin, a bone formation marker, were decreased and levels of serum CTX 1, a bone resorption marker, were increased in group D. Taken together, a low calcium diet and PPI administration are thought to collaborate in order to alter osteoclast activity and bone resorption signaling.
C1 [Joo, Moon Kyung; Park, Jong Jae; Lee, Beom Jae; Kim, Ji Hoon; Yeon, Jong Eun; Kim, Jae Seon; Byun, Kwan Soo; Bak, Young Tae] Korea Univ, Coll Med, Guro Hosp, Div Gastroenterol,Dept Internal Med, Seoul 152703, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine)
RP Park, JJ (通讯作者)，Korea Univ, Coll Med, Guro Hosp, Div Gastroenterol,Dept Internal Med, 148 Gurodong Ro, Seoul 152703, South Korea.
EM gi7pjj@yahoo.co.kr
RI Kim, Sun/L 4239 2013; Kim, Jeong/AAO 6927 2021; Kim, Ji
   Hwan/JKJ 3785 2023
OI Bak, Young Tae/0000 0002 3242 2836; KIM, JI HOON/0000 0003 3924 0434;
   Joo, Moon Kyung/0000 0001 6050 3695
CR Becker V, 2007, ALIMENT PHARM THER, V26, P1355, DOI 10.1111/j.1365 2036.2007.03529.x
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Cadir FO, 2008, PEDIATR SURG INT, V24, P809, DOI 10.1007/s00383 008 2157 1
   Chonan O, 1998, J NUTR SCI VITAMINOL, V44, P473, DOI 10.3177/jnsv.44.473
   Dent J, 1999, GUT, V44, pS1, DOI 10.1136/gut.44.2008.S1
   DeVault KR, 2005, AM J GASTROENTEROL, V100, P190, DOI 10.1111/j.1572 0241.2005.41217.x
   Diogo Filho A, 2006, ACTA CIR BRAS, V21, P279
   Elseweidy MM, 2008, DIGEST DIS SCI, V53, P1774, DOI 10.1007/s10620 008 0246 6
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Jacobson BC, 2003, AM J GASTROENTEROL, V98, P51, DOI 10.1111/j.1572 0241.2003.07186.x
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Kocsis I, 2002, CALCIFIED TISSUE INT, V71, P129, DOI 10.1007/s00223 001 2068 9
   Lee BJ, 2008, J GASTROEN HEPATOL, V23, pA10
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   MIZUNASHI K, 1993, CALCIFIED TISSUE INT, V53, P21, DOI 10.1007/BF01352010
   Niikura K, 2005, J BONE MINER RES, V20, P1579, DOI 10.1359/JBMR.050517
   Niikura K, 2005, J TOXICOL SCI, V30, P297
   O'Connell MB, 2005, AM J MED, V118, P778, DOI 10.1016/j.amjmed.2005.02.007
   Otomo H, 2004, J BONE MINER METAB, V22, P404, DOI 10.1007/s00774 004 0502 6
   Soll Andrew H., 1996, JAMA (Journal of the American Medical Association), V275, P622, DOI 10.1001/jama.275.8.622
   Song YH, 2007, KOREAN J ORAL MAXILL, V37, P27
   Sorensen MG, 2007, BIOMARKERS, V12, P266, DOI 10.1080/13547500601070842
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Talley NJ, 2005, AM J GASTROENTEROL, V100, P2324, DOI 10.1111/j.1572 0241.2005.00225.x
   Targownik LE, 2008, CAN MED ASSOC J, V179, P319, DOI 10.1503/cmaj.071330
   Tat SK, 2008, CLIN EXP RHEUMATOL, V26, P295
   van Zanten SV, 2006, AM J GASTROENTEROL, V101, P2096, DOI 10.1111/j.1572 0241.2006.00751.x
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang YX, 2006, JAMA J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947
NR 31
TC 18
Z9 20
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD APR
PY 2013
VL 7
IS 4
BP 1267
EP 1272
DI 10.3892/mmr.2013.1327
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 178SG
UT WOS:000321467100034
PM 23426758
OA Bronze
DA 2025 08 17
ER

PT J
AU Meng, LX
   Ma, WL
   Jiang, YP
   Li, XZ
   Zhang, ML
   Yuan, RD
   Fu, YQ
   Ma, HH
   Lu, X
   Han, L
   Liu, HR
   Li, MQ
AF Meng, Lingxiao
   Ma, Wanli
   Jiang, Yuping
   Li, Xiaozhuang
   Zhang, Minglei
   Yuan, Rundong
   Fu, Yaqiu
   Ma, Haohua
   Lu, Xiong
   Han, Lu
   Liu, Hongrui
   Li, Minqi
TI Bone Targeting and Multishelled Oral Eldecalcitol Nanoparticles Improve
   Osteoporosis by Reconstruction of Osteogenic Osteoclastic Homeostasis
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE bone targeting; bone metabolic homeostasis; eldecalcitol; nanoparticle;
   osteoporosis
ID VITAMIN D ANALOG; MESENCHYMAL STEM CELLS; DIFFERENTIATION; REGENERATION;
   THERAPY; CALCIUM; MARROW; ED 71
AB Current treatment of postmenopausal osteoporosis (PMOP) focuses on systemic administration of medication, neglecting to proactively modulate the local microenvironment of skeletal system for superior therapeutic performance. Eldecalcitol (ED 71), a novel drug for treating osteoporosis, still requires research to overcome high frequency delivery and low utilization. Here, a bone targeting and multishelled nanoparticles are developed for step wise release of ED 71. The nanoparticles are achieved by using the chitosan/alginate outer layer as protective barrier against gastric acid, pectin middle layer as adhesive agent that improved intestinal penetration, and ethylene diamine tetraacetic acid grafted mesoporous silica nanomaterials core as bone targeting nanocarriers. After oral administration, the ED 71 loaded nanoparticles (ME ED 71@PCA) promotes osteogenic differentiation of bone marrow mesenchymal stem cells by reducing intracellular oxidative stress, and inhibits the osteoclast differentiation. ME ED 71@PCA improves bone mass in ovariectomized mice by promoting osteogenesis and inhibiting osteoclastogenesis, and the efficacy is more pronounced than ED 71 alone. ME ED 71@PCA exhibits satisfactory therapeutic performance due to its step wise drug release and bone targeting compared to ED 71 administration, providing a new approach to re establish bone metabolic homeostasis in PMOP.
   The step wise eldecalcitol delivery nanoparticles (ME ED 71@PCA) with bone targeting ability, gastrointestinal protection, and good intestinal penetration properties is established to improve postmenopausal osteoporosis (PMOP). The ME ED 71@PCA exerted superior therapeutic efficacy in re establishing osteogenic osteoclastic homeostasis in PMOP mice by promoting osteogenic differentiation of bone marrow mesenchymal stem cells as well as inhibiting the osteoclast differentiation, without side effects. image
C1 [Meng, Lingxiao; Zhang, Minglei; Yuan, Rundong; Fu, Yaqiu; Liu, Hongrui; Li, Minqi] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Bone Metab, Jinan 250000, Peoples R China.
   [Meng, Lingxiao; Zhang, Minglei; Yuan, Rundong; Fu, Yaqiu; Liu, Hongrui; Li, Minqi] Shandong Key Lab Oral Tissue Regenerat, Jinan 250000, Peoples R China.
   [Meng, Lingxiao; Zhang, Minglei; Yuan, Rundong; Fu, Yaqiu; Liu, Hongrui; Li, Minqi] Shandong Engn Res Ctr Dent Mat & Oral Tissue Regen, Jinan 250000, Peoples R China.
   [Meng, Lingxiao; Zhang, Minglei; Yuan, Rundong; Fu, Yaqiu; Liu, Hongrui; Li, Minqi] Shandong Prov Clin Res Ctr Oral Dis, Jinan 250000, Peoples R China.
   [Meng, Lingxiao; Zhang, Minglei; Yuan, Rundong; Fu, Yaqiu; Liu, Hongrui; Li, Minqi] Shandong Univ, Ctr Osteoporosis & Bone Mineral Res, Jinan 250000, Peoples R China.
   [Ma, Wanli] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Orthoped, Jinan 250033, Peoples R China.
   [Jiang, Yuping; Li, Xiaozhuang; Ma, Haohua; Han, Lu] Ocean Univ China, Sch Med & Pharm, Key Lab Marine Drugs, Minist Educ, Qingdao 266003, Shandong, Peoples R China.
   [Lu, Xiong] Southwest Jiaotong Univ, Inst Biomed Engn, Coll Med, Chengdu 610031, Sichuan, Peoples R China.
   [Li, Minqi] Jining Med Univ, Sch Clin Med, Jining 272013, Peoples R China.
C3 Shandong University; Shandong University; Shandong University; Ocean
   University of China; Southwest Jiaotong University; Jining Medical
   University
RP Liu, HR; Li, MQ (通讯作者)，Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Bone Metab, Jinan 250000, Peoples R China.; Liu, HR; Li, MQ (通讯作者)，Shandong Key Lab Oral Tissue Regenerat, Jinan 250000, Peoples R China.; Liu, HR; Li, MQ (通讯作者)，Shandong Engn Res Ctr Dent Mat & Oral Tissue Regen, Jinan 250000, Peoples R China.; Liu, HR; Li, MQ (通讯作者)，Shandong Prov Clin Res Ctr Oral Dis, Jinan 250000, Peoples R China.; Liu, HR; Li, MQ (通讯作者)，Shandong Univ, Ctr Osteoporosis & Bone Mineral Res, Jinan 250000, Peoples R China.; Han, L (通讯作者)，Ocean Univ China, Sch Med & Pharm, Key Lab Marine Drugs, Minist Educ, Qingdao 266003, Shandong, Peoples R China.; Li, MQ (通讯作者)，Jining Med Univ, Sch Clin Med, Jining 272013, Peoples R China.
EM hanlu@ouc.edu.cn; liuhongrui@sdu.edu.cn; liminqi@sdu.edu.cn
RI ; Liu, Zhiying/KYQ 2869 2024
OI meng, lingxiao/0009 0006 3604 0356; 
FU National Natural Science Foundation of China; TaiShan Scholars of China
   [tstp20221160]; Construction Engineering Special Fund of "Taishan Young
   Scholars" of Shandong Province [tsqn202103177]; Natural Science
   Foundation of Shandong Province [ZR202210210042];  [81800982]
FX L.M. and W.M. contributed equally to this work. This work was supported
   by the National Natural Science Foundation of China (No. 81972072);
   TaiShan Scholars of China (No. tstp20221160); National Natural Science
   Foundation of China (No. 81800982); Construction Engineering Special
   Fund of "Taishan Young Scholars" of Shandong Province (No.
   tsqn202103177) and Natural Science Foundation of Shandong Province (No.
   ZR202210210042).
CR Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Brown AJ, 2011, CALCIFIED TISSUE INT, V89, P372, DOI 10.1007/s00223 011 9528 7
   Bunpetch V, 2019, BIOMATERIALS, V192, P323, DOI 10.1016/j.biomaterials.2018.11.025
   Cai GQ, 2023, ADV SCI, V10, DOI 10.1002/advs.202206540
   Chen GH, 2022, FREE RADICAL BIO MED, V180, P95, DOI 10.1016/j.freeradbiomed.2022.01.012
   Chen L, 2023, ACS NANO, V17, P3153, DOI 10.1021/acsnano.2c12440
   Chen MH, 2022, BIOMATERIALS, V291, DOI 10.1016/j.biomaterials.2022.121878
   Chen S, 2019, ACS APPL MATER INTER, V11, P38103, DOI 10.1021/acsami.9b11782
   Chen XT, 2020, THERANOSTICS, V10, P3281, DOI 10.7150/thno.37599
   Chen XR, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00128 8
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Dang RZ, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974 022 02400 6
   Dosunmu Ogunbi A, 2022, BLOOD, V139, P1760, DOI 10.1182/blood.2021013350
   Fang CY, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/1949718
   Foessl I, 2023, NAT REV ENDOCRINOL, V19, P520, DOI 10.1038/s41574 023 00866 9
   Guan H., 2024, Adv. Mater, V36
   Haddadzadegan S, 2022, ADV DRUG DELIVER REV, V182, DOI 10.1016/j.addr.2021.114097
   Han L, 2012, BIOMATERIALS, V33, P8517, DOI 10.1016/j.biomaterials.2012.07.034
   Harada S, 2012, J BONE MINER RES, V27, P461, DOI 10.1002/jbmr.555
   Hasegawa T, 2019, J HISTOCHEM CYTOCHEM, V67, P169, DOI 10.1369/0022155418806865
   Hu Y, 2021, BIOACT MATER, V6, P2905, DOI 10.1016/j.bioactmat.2021.02.014
   Jiang Y, 2019, J BONE MINER METAB, V37, P1036, DOI 10.1007/s00774 019 01009 9
   Jiang YX, 2020, LIFE SCI, V246, DOI 10.1016/j.lfs.2020.117422
   Kikuta J, 2013, P NATL ACAD SCI USA, V110, P7009, DOI 10.1073/pnas.1218799110
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Kou YY, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1067085
   Lee SE, 2020, J PINEAL RES, V68, DOI 10.1111/jpi.12638
   Lee YC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205015
   Li H, 2023, PHYTOTHER RES, V37, P231, DOI 10.1002/ptr.7609
   Li JJ, 2023, ADV SCI, V10, DOI 10.1002/advs.202207381
   Li X. T., 2022, BIOL MED PARIS, V193, P459
   Li XQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb7135
   Li YY, 2016, PART PART SYST CHAR, V33, P896, DOI 10.1002/ppsc.201600166
   Liang H., 2023, SMALL, V19
   Lin W, 2023, SMALL, V19, DOI 10.1002/smll.202207093
   Lin ZJ, 2021, BIOACT MATER, V6, P2315, DOI 10.1016/j.bioactmat.2021.01.018
   Liu RX, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00296 3
   Liu XL, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adf3329
   Lu YP, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02800 8
   de Freitas PHL, 2011, BONE, V49, P335, DOI 10.1016/j.bone.2011.05.022
   Ma SX, 2023, CELL METAB, V35, P2028, DOI 10.1016/j.cmet.2023.10.013
   Ono Y, 2014, J STEROID BIOCHEM, V139, P88, DOI 10.1016/j.jsbmb.2013.10.007
   Plum LA, 2020, J BONE MINER RES, V35, P623, DOI 10.1002/jbmr.3838
   Qin ZY, 2023, PHYTOMEDICINE, V118, DOI 10.1016/j.phymed.2023.154945
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Ren HW, 2020, MOL CELL ENDOCRINOL, V500, DOI 10.1016/j.mce.2019.110628
   Rong X, 2022, DRUG DES DEV THER, V16, P3929, DOI 10.2147/DDDT.S377001
   Saito H, 2014, J STEROID BIOCHEM, V144, P189, DOI 10.1016/j.jsbmb.2013.11.013
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Sun H, 2023, BIOACT MATER, V24, P477, DOI 10.1016/j.bioactmat.2022.12.021
   Suo JL, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00202 3
   Tang FQ, 2012, ADV MATER, V24, P1504, DOI 10.1002/adma.201104763
   Uenishi K, 2018, OSTEOPOROSIS INT, V29, P723, DOI 10.1007/s00198 017 4351 2
   Vatner SF, 2020, AGEING RES REV, V64, DOI 10.1016/j.arr.2020.101194
   Wang QQ, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abn3333
   Wang SY, 2021, J BONE MINER RES, V36, P1850, DOI 10.1002/jbmr.4328
   Wang T, 2020, BIOMATERIALS, V257, DOI 10.1016/j.biomaterials.2020.120264
   Wu JH, 2023, ADV SCI, V10, DOI 10.1002/advs.202301300
   Xiao PL, 2022, OSTEOPOROSIS INT, V33, P2137, DOI 10.1007/s00198 022 06454 3
   Xiong J, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 32435 5
   Xu MZ, 2023, ACS NANO, V17, P20825, DOI 10.1021/acsnano.3c05853
   Yamamoto T, 2021, BIOMED RES TOKYO, V42, P161, DOI 10.2220/biomedres.42.161
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yuan Y, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13194
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhang Y, 2022, CELL SIGNAL, V96, DOI 10.1016/j.cellsig.2022.110376
   Zhang ZH, 2022, INT IMMUNOPHARMACOL, V110, DOI 10.1016/j.intimp.2022.109017
   Zhao X, 2024, SMALL, V20, DOI 10.1002/smll.202400273
   Zheng LM, 2022, BIOACT MATER, V14, P250, DOI 10.1016/j.bioactmat.2021.11.012
   Zhou J, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 31171 0
   Zhou Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abl6432
NR 71
TC 3
Z9 3
U1 30
U2 84
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD OCT
PY 2024
VL 34
IS 44
DI 10.1002/adfm.202404549
EA MAY 2024
PG 18
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA K0E3E
UT WOS:001229564300001
DA 2025 08 17
ER

PT J
AU Jun, AY
   Kim, HJ
   Park, KK
   Son, KH
   Lee, DH
   Woo, MH
   Chung, WY
AF Jun, Ah Young
   Kim, Hyun Jeong
   Park, Kwang Kyun
   Son, Kun Ho
   Lee, Dong Hwa
   Woo, Mi Hee
   Chung, Won Yoon
TI Tetrahydrofurofuran type lignans inhibit breast cancer mediated bone
   destruction by blocking the vicious cycle between cancer cells,
   osteoblasts and osteoclasts
SO INVESTIGATIONAL NEW DRUGS
LA English
DT Article
DE Tetrahydrofurofuran type lignans; Breast cancer; Cancer induced bone
   destruction; PTHrP; RANKL/OPG; Osteoclast
ID HORMONE RELATED PROTEIN; FLOS MAGNOLIAE; THERAPEUTIC TARGET; FLOWER
   BUDS; METASTASIS; MECHANISMS; METALLOPROTEINASES; OSTEOPOROSIS;
   OSTEOLYSIS; RESORPTION
AB Breast cancer frequently spreads to bone. The interaction between bone metastases and microenvironment, referred as the "vicious cycle", increases both tumor burden and bone destruction. Therefore, inhibition at any point in this "vicious cycle" can reduce malignant osteolytic lesions in patients with advanced breast cancer. In this study, we evaluated whether tetrahydrofurofuran type lignans derived from Magnoliae Flos, commonly used in traditional Asian medicine to treat inflammatory diseases, could block breast cancer mediated bone loss. Aschatin, fargesin, lirioresinol B dimethyl ether, and magnolin at noncytotoxic concentrations suppressed mRNA expression and secretion of osteolytic factor PTHrP in MDA MB 231 metastatic human breast cancer cells. Fargesin inhibited TGF beta stimulated cell viability, migration, and invasion and decreased TGF beta induced PTHrP production in MDA MB 231 cells. In addition, these lignans reduced RANKL/OPG ratio in PTHrP treated hFOB1.19 human osteoblastic cells and inhibited RANKL mediated osteoclast differentiation in mouse bone marrow macrophages. Aschatin, fargesin, lirioresinol B dimethyl ether, and magnolin substantially reduced bone resorbing activity of osteoclasts by inhibiting MMP 9 and cathepsin K activities. Furthermore, orally administered fargesin inhibited tumor growth and cancer mediated bone destruction in mice with MDA MB 231 cells injected into calvarial tissues. Aschatin, fargesin, lirioresinol B dimethyl ether, and magnolin blocked initiation and progression of the "vicious cycle" between breast cancer metastases and bone microenvironment by inhibiting PTHrP production in breast cancer cells and osteoclastic bone resorption. Therefore, these tetrahydrofurofuran type lignans have the potential to serve as beneficial agents to prevent and treat cancer induced bone destruction in breast cancer patients.
C1 [Jun, Ah Young; Kim, Hyun Jeong; Park, Kwang Kyun; Chung, Won Yoon] Yonsei Univ, Grad Sch, Dept Appl Life Sci, Seoul 120749, South Korea.
   [Jun, Ah Young; Kim, Hyun Jeong; Park, Kwang Kyun; Chung, Won Yoon] Yonsei Univ, Coll Dent, Oral Canc Res Inst, Dept Oral Biol, Seoul 120752, South Korea.
   [Jun, Ah Young; Kim, Hyun Jeong; Park, Kwang Kyun; Chung, Won Yoon] Yonsei Univ, Coll Dent, Brain Korea Project 21, Seoul 120752, South Korea.
   [Son, Kun Ho; Lee, Dong Hwa] Andong Natl Univ, Dept Life Sci, Andong 760740, South Korea.
   [Woo, Mi Hee] Catholic Univ Daegu, Coll Pharm, Gyongsan 712702, South Korea.
   [Chung, Won Yoon] Yonsei Univ, Coll Dent, Dept Oral Biol, Seodaemoon Ku, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University; Yonsei University Health System;
   Yonsei University; Yonsei University Health System; Gyeongkuk National
   University; Catholic University of Daegu; Yonsei University; Yonsei
   University Health System
RP Chung, WY (通讯作者)，Yonsei Univ, Coll Dent, Dept Oral Biol, Seodaemoon Ku, 50 Yonsei Ro, Seoul 120752, South Korea.
EM wychung@yuhs.ac
OI Kim, Hyun Jeong/0000 0003 4608 2120; Chung, Won Yoon/0000 0001 8428 9005
FU National Research Foundation of Korea (NRF); Ministry of Education,
   Science and Technology [2010 0026040]
FX This work was supported by the National Research Foundation of Korea
   (NRF) funded by the Ministry of Education, Science and Technology
   (2010 0026040).
CR Andersen TL, 2004, BONE, V35, P1107, DOI 10.1016/j.bone.2004.06.019
   Clezardin P, 2007, CLIN EXP METASTAS, V24, P599, DOI 10.1007/s10585 007 9112 8
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2001, SEMIN ONCOL, V28, P11, DOI 10.1053/sonc.2001.24155
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Guise TA, 2009, GENE DEV, V23, P2117, DOI 10.1101/gad.1854909
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Javelaud D, 2011, CANCER RES, V71, P5606, DOI 10.1158/0008 5472.CAN 11 1194
   Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008 5472.CAN 10 2993
   Jun AY, 2012, FITOTERAPIA, V83, P1523, DOI 10.1016/j.fitote.2012.08.020
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Kim EK, 2008, INT J MOL MED, V22, P481, DOI 10.3892/ijmm_00000046
   Kim JS, 2010, PHYTOTHER RES, V24, P748, DOI 10.1002/ptr.3028
   Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657
   Kohno N, 2008, INT J CLIN ONCOL, V13, P18, DOI 10.1007/s10147 007 0726 2
   Lee J, 2007, CHEM PHARM BULL, V55, P137, DOI 10.1248/cpb.55.137
   Lim H, 2009, PHYTOTHER RES, V23, P1489, DOI 10.1002/ptr.2783
   McGrath EE, 2011, J THORAC ONCOL, V6, P1468, DOI 10.1097/JTO.0b013e318229421f
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Saito H, 2005, ANTICANCER RES, V25, P3817
   Santini D, 2010, CANCER TREAT REV, V36, pS6, DOI 10.1016/S0305 7372(10)70013 X
   Schühly W, 2009, NAT PROD COMMUN, V4, P231
   Shen Y, 2008, CURR MED CHEM, V15, P1616, DOI 10.2174/092986708784911515
   Soki FN, 2012, FUTURE ONCOL, V8, P803, DOI [10.2217/fon.12.76, 10.2217/FON.12.76]
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   Watts NB, 1999, CLIN CHEM, V45, P1359
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zhang YF, 2010, CANCER LETT, V292, P1, DOI 10.1016/j.canlet.2009.11.003
   Zheng Y, 2007, BONE, V40, P471, DOI 10.1016/j.bone.2006.09.016
NR 34
TC 23
Z9 25
U1 0
U2 22
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167 6997
EI 1573 0646
J9 INVEST NEW DRUG
JI Invest. New Drugs
PD FEB
PY 2014
VL 32
IS 1
BP 1
EP 13
DI 10.1007/s10637 013 9969 0
PG 13
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA AA3BY
UT WOS:000330969100001
PM 23673814
DA 2025 08 17
ER

PT J
AU Wang, F
   Wang, YM
   Zhao, YL
   Zhan, QP
   Yu, P
   Wang, JF
   Xue, CH
AF Wang, Fei
   Wang, Yiming
   Zhao, Yanlei
   Zhan, Qiping
   Yu, Peng
   Wang, Jingfeng
   Xue, Changhu
TI Sialoglycoprotein Isolated from Eggs of Carassius auratus
   Ameliorates Osteoporosis: An Effect Associated with Regulation of the
   Wnt/β Catenin Pathway in Rodents
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE Carassius auratus eggs; sialoglycoprotein; OVX; SAMP6; Wnt/beta catenin
ID BONE TURNOVER; OVARIECTOMIZED RATS; GUT MICROBIOTA; DENSITY; WNT;
   OSTEOGENESIS; EXPRESSION; PROTEINS; DRUGS
AB In the current study, ovariectomized (OVX) rats and the senescence accelerated mouse strain P6 (SAMP6) were employed to establish models of postmenopausal osteoporosis and senile osteoporosis, respectively. The effects of treatment with sialoglycoprotein isolated from the eggs of Carassius auratus (Ca SGP) on these two types of osteoporosis were investigated in vivo. Results showed that Ca SGP significantly increased bone mineral density, ameliorated trabecular bone microstructure, and improved bone biomechanical properties in both OVX rats and SAMP6. The osteogenesis related Wnt/beta catenin pathway was targeted to study the underlying mechanism of Ca SGP activity. In postmenopausal osteoporosis, Ca SGP suppressed the activation of Wnt/beta catenin signal via down regulating the expression of key genes including LRPS, beta catenin, and Runx2, suggesting that overactive osteogenesis was controlled by Ca SGP. The bone formation was sharply weakened in senile osteoporosis, whereas Ca SGP treatment promoted osteoblast activity by stimulating the Wnt/beta catenin signal. In conclusion, Ca SGP ameliorated these two types of osteoporosis by normalizing bone anabolism.
C1 [Wang, Fei; Wang, Yiming; Zhao, Yanlei; Zhan, Qiping; Yu, Peng; Wang, Jingfeng; Xue, Changhu] Ocean Univ China, Coll Food Sci & Engn, Qingdao 266003, Shandong, Peoples R China.
C3 Ocean University of China
RP Wang, JF (通讯作者)，Ocean Univ China, Coll Food Sci & Engn, Qingdao 266003, Shandong, Peoples R China.
EM jfwang@ouc.edu.cn
RI 于, 鹏/GVS 6791 2022; yuming, wang/K 8179 2012
FU National Natural Science Foundation of China [31371876, 31571771,
   U1406402]
FX This study is financially supported by the National Natural Science
   Foundation of China (No. 31371876, 31571771, and U1406402).
CR Alonso Bouzon Cristina, 2011, Rev Esp Geriatr Gerontol, V46, P223, DOI 10.1016/j.regg.2011.02.010
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Brewer L, 2011, EUR J CLIN PHARMACOL, V67, P321, DOI 10.1007/s00228 011 0999 2
   Britton RA, 2014, J CELL PHYSIOL, V229, P1822, DOI 10.1002/jcp.24636
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Chung SL, 2014, J ORTHOP RES, V32, P1572, DOI 10.1002/jor.22715
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   de Paula FJA, 2010, EXPERT OPIN PHARMACO, V11, P867, DOI 10.1517/14656560903575662
   Fu SW, 2014, NUTR RES, V34, P467, DOI 10.1016/j.nutres.2014.05.003
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hu SW, 2014, J FUNCT FOODS, V10, P128, DOI 10.1016/j.jff.2014.05.012
   INOUE S, 1997, N COMP BIOC B, V29, P143
   Karsenty G, 2012, NATURE, V481, P314, DOI 10.1038/nature10763
   Khajuria DK, 2011, REV BRAS REUMATOL, V51, P365
   Kim HK, 2011, MENOPAUSE, V18, P307, DOI 10.1097/gme.0b013e3181f31b1f
   Kim Jung Hoon, 2013, Lab Anim Res, V29, P70, DOI 10.5625/lar.2013.29.2.70
   Kushwaha P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.350
   Leem KH, 2004, BIOSCI BIOTECH BIOCH, V68, P2388, DOI 10.1271/bbb.68.2388
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   Ma J, 2013, J AGR FOOD CHEM, V61, P339, DOI 10.1021/jf300651d
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   Marcellini S, 2012, BIOESSAYS, V34, P953, DOI 10.1002/bies.201200061
   Mccabe LR, 2013, J CELL PHYSIOL, V228, P1793, DOI 10.1002/jcp.24340
   Ohlsson C, 2015, TRENDS ENDOCRIN MET, V26, P69, DOI 10.1016/j.tem.2014.11.004
   Ohlsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092368
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Seeman E, 2008, OSTEOPOROSIS INT, V19, P1676
   Seeman E, 2008, J BONE MINER METAB, V26, P1, DOI 10.1007/s00774 007 0793 5
   Sjogren K, 2012, BONE, V50, pS91, DOI [10.1016/j.bone.2012.02.272, 10.1002/jbmr.1588]
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Tan S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/814057
   Tulipano G, 2010, REGUL PEPTIDES, V160, P168, DOI 10.1016/j.regpep.2009.11.018
   Uehara K, 2014, NUTRITION, V30, P719, DOI 10.1016/j.nut.2013.11.005
   Westerlind KC, 1997, P NATL ACAD SCI USA, V94, P4199, DOI 10.1073/pnas.94.8.4199
   Wu XY, 2014, BMC ENDOCR DISORD, V14, DOI 10.1186/1472 6823 14 8
   Xia GH, 2015, J AGR FOOD CHEM, V63, P9550, DOI 10.1021/acs.jafc.5b04263
   Xia GH, 2015, J FUNCT FOODS, V15, P137, DOI 10.1016/j.jff.2015.03.021
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zou ZY, 2009, EUR J NUTR, V48, P301, DOI 10.1007/s00394 009 0014 1
NR 42
TC 24
Z9 26
U1 1
U2 32
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021 8561
EI 1520 5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD APR 13
PY 2016
VL 64
IS 14
BP 2875
EP 2882
DI 10.1021/acs.jafc.5b06132
PG 8
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA DJ5UH
UT WOS:000374275100009
PM 27023001
DA 2025 08 17
ER

PT J
AU Suominen, MI
   Rissanen, JP
   Käkönen, R
   Fagerlund, KM
   Alhoniemi, E
   Mumberg, D
   Ziegelbauer, K
   Halleen, JM
   Käkönen, SM
   Scholz, A
AF Suominen, Mari I.
   Rissanen, Jukka P.
   Kakonen, Rami
   Fagerlund, Katja M.
   Alhoniemi, Esa
   Mumberg, Dominik
   Ziegelbauer, Karl
   Halleen, Jussi M.
   Kakonen, Sanna Maria
   Scholz, Arne
TI Survival Benefit With Radium 223 Dichloride in a Mouse Model of Breast
   Cancer Bone Metastasis
SO JNCI JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID SKELETAL METASTASES; PROSTATE CANCER; PHASE II; RA 223; CELLS;
   MULTICENTER; THERAPY; MARROW
AB Bone metastases are associated with increased morbidity and poor prognosis in breast cancer patients. Radium 223 dichloride is a calcium mimetic that localizes to bone, providing targeted therapy for skeletal metastasis.
   We investigated the mode of action of radium 223 dichloride using breast cancer cell, osteoclast, and osteoblast cultures as well as a mouse model of breast cancer bone metastasis. A single dose of radium 223 dichloride was used in three different settings mimicking the prevention or treatment of bone metastasis. Disease progression was monitored using fluorescence and radiographic imaging and histological analyses. The effect of radium 223 dichloride alone and in combination with doxorubicin or zoledronic acid on survival of mice was analyzed by Kaplan Meier methods. All statistical tests used were two sided.
   Radium 223 dichloride incorporated into bone matrix and inhibited proliferation of breast cancer cells and differentiation of osteoblasts and osteoclasts (all P values < .001) in vitro. In an established bone metastasis setting, radium 223 dichloride prevented tumor induced cachexia (0/14 vs 7/14 control mice) and decreased osteolysis by 56% and tumor growth by 43% (all P values < .05). Radium 223 dichloride induced double strand DNA breaks in cancer cells in vivo. Finally, radium 223 dichloride extended survival as a monotherapy (29.2 days, 95% confidence interval [CI] 26.6 to 31.8 days, P .039) and in combination with zoledronic acid (31.4 days, 95% CI 28.8 to 34.0 days, P .004) or doxorubicin (31.5 days, 95% CI 29.5 to 33.5 days, P < .001) compared to the vehicle group (24.9 days, 95% CI 23.4 to 26.4 days). Similar but even more pronounced effects were observed when radium 223 dichloride was administered in a preventive or micrometastatic setting.
   Our findings strongly support the development of radium 223 dichloride for the treatment of breast cancer patients with or at high risk of developing bone metastases.
C1 [Suominen, Mari I.; Rissanen, Jukka P.; Kakonen, Rami; Fagerlund, Katja M.; Alhoniemi, Esa; Halleen, Jussi M.] Pharmatest Serv Ltd, Turku, Finland.
   [Mumberg, Dominik; Ziegelbauer, Karl; Scholz, Arne] Bayer HealthCare, Global Drug Discovery, Berlin, Germany.
   [Kakonen, Sanna Maria] Univ Turku, Inst Biomed, Dept Cell Biol & Anat, SF 20500 Turku, Finland.
C3 Pharmatest Services; Bayer AG; Bayer Healthcare Pharmaceuticals;
   University of Turku
RP Scholz, A (通讯作者)，Bayer Pharma AG, Global Drug Discovery, Therapeut Res Grp Oncol, Mullerstr 178,S107,6,103, D 13353 Berlin, Germany.
EM arne.scholz@bayer.com
RI ; Suominen, Mari/KHZ 4938 2024
OI Kakonen, Sanna Maria/0000 0001 9393 6235; Suominen,
   Mari/0000 0002 8760 6595; 
FU Bayer Pharma AG
FX The authors are solely responsible for the study design, data
   collection, analysis and interpretation of the data, writing the
   manuscript, and decision to submit the manuscript for publication. Bayer
   has paid Pharmatest for the execution of the experiments. DM, KZ, and AS
   are employees of Bayer, and MIS, JPR, RK, KMF, EA, and JMH are employees
   of Pharmatest. We thank Riikka Kytomaa, Anniina Luostarinen, Jani
   Seppanen, Suvi Suutari, and Johanna Rantanen for their skillful
   technical assistance. We are grateful to Dr Sirkku Pollari at Aurexel
   Consulting Ltd for editorial support funded by Bayer Pharma AG; to
   Professor Theresa A. Guise at Indiana University for generously
   providing the MDA MB 231(SA) cell line; and to Gro Salberg at Algeta ASA
   for supplying the radium 223 dichloride compound.
CR Ahlstrom M, 2008, BONE, V42, P483, DOI 10.1016/j.bone.2007.10.025
   ARGUELLO F, 1988, CANCER RES, V48, P6876
   Bruland OS, 2006, CLIN CANCER RES, V12, p6250S, DOI 10.1158/1078 0432.CCR 06 0841
   Coleman R, 2011, SAN ANT BREAST CANC
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Dang ZC, 2002, J BONE MINER RES, V17, P394, DOI 10.1359/jbmr.2002.17.3.394
   Elgqvist J, 2011, CURR RADIOPHARM, V4, P176, DOI 10.2174/1874471011104030176
   Fagerlund KM, 2011, ASBMR ANN M SEPT SAN
   Gonzalez Angulo AM, 2007, ADV EXP MED BIOL, V608, P1
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Henriksen G, 2002, CANCER RES, V62, P3120
   Kassis AI, 2005, J NUCL MED, V46, p4S
   Larsen RH, 2006, IN VIVO, V20, P325
   Nilsson S, 2005, CLIN CANCER RES, V11, P4451, DOI 10.1158/1078 0432.CCR 04 2244
   Nilsson S, 2012, EUR J CANCER, V48, P678, DOI 10.1016/j.ejca.2011.12.023
   Nilsson S, 2007, LANCET ONCOL, V8, P587, DOI 10.1016/S1470 2045(07)70147 X
   Parker C, 2012, ASCO ANN M JUN CHIC
   Redon CE, 2011, METHODS MOL BIOL, V682, P249, DOI 10.1007/978 1 60327 409 8_18
   Rissanen JP, 2009, J BONE MINER METAB, V27, P105, DOI 10.1007/s00774 008 0002 1
   Salmon PL, 1999, RADIAT RES, V152, pS43, DOI 10.2307/3580112
NR 20
TC 70
Z9 75
U1 1
U2 17
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027 8874
J9 JNCI J NATL CANCER I
JI JNCI . Natl. Cancer Inst.
PD JUN
PY 2013
VL 105
IS 12
BP 908
EP 916
DI 10.1093/jnci/djt116
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 170MZ
UT WOS:000320857800014
PM 23682134
OA hybrid
DA 2025 08 17
ER

PT J
AU Shim, KS
   Ma, JY
AF Shim, Ki Shuk
   Ma, Jin Yeul
TI Pine needles attenuate receptor activator for nuclear factor B ligand
   (RANKL) induced trabecular bone loss by inhibiting osteoclast
   differentiation
SO INTEGRATIVE MEDICINE RESEARCH
LA English
DT Article
DE Pinus densiflora; Osteoclast; Receptor activator for nuclear
   factor kappa B ligand; Nuclear factor of activated T cells cytoplasmic 1
ID POSTMENOPAUSAL WOMEN; ANTIOXIDANT ACTIVITY; C FOS; RANKL; NFATC1;
   PREVENTION; OSTEOPOROSIS; MECHANISMS; EXPRESSION; INDUCTION
AB Background: The leaf of Pinus densiflora known as pine needles has been used to treat vascular disease, gastrointestinal diseases, and urinary diseases in traditional medicine. We evaluated anti osteoporotic effect of water extract of Pinus densiflora (WEPN) on acute bone loss and osteoclastogenesis induced by receptor activator for nuclear factor kappa B ligand (RANKL).
   Methods: After oral administration of WEPN (0.25 g/kg) for 5 days, femora were collected, and bone parameter [trabecular bone volume/tissue volume (BV/TV), trabecular thickness (Tb. Th), trabecular separation (Tb. Sp), trabecular number (Tb. N), and bone mineral density (BMD)] were analyzed by micro CT analysis. Anti osteoclastic effect of WEPN was examined using tartrate resistant acid phosphatase activity and activation of RANKL signaling pathway.
   Results: We found that WEPN significantly attenuated RANKL induced decrease of BV/TV, Tb.Th., Tb.N, and BMD but increase of Tb.Sp in femora. WEPN dose dependently decreased osteoclastogenesis accompanied by inhibiting the activation of RANKL signaling components (JNK, p38, and p65) and mRNA expression level of osteoclast specific genes (NFATc1, c Fos, TRAP, cathepsin K, DC STAMP, and carbonic anhydrate).
   Conclusion: WEPN inhibition on osteoclastogenesis could contribute to attenuate RANKL induced trabecular bone loss in vivo. Therefore, it might suggest that WEPN could be prescribed in traditional medicine or used in health functional food to prevent or treat osteoporotic bone diseases. (C) 2018 Korea Institute of Oriental Medicine. Publishing services by Elsevier B.V.
C1 [Shim, Ki Shuk] Korea Inst Oriental Med, Herbal Med Res Div, Daejeon, South Korea.
   [Ma, Jin Yeul] Korea Inst Oriental Med, Clin Med Div, 70 Cheomdanro, Daegu, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); Korea Institute of Oriental
   Medicine (KIOM)
RP Ma, JY (通讯作者)，Korea Inst Oriental Med, Clin Med Div, 70 Cheomdanro, Daegu, South Korea.
EM jyma@kiom.re.kr
FU Korea Institute of Oriental Medicine, Ministry of Science, ICT and
   Future Planning, Korea [K17281]
FX This work was supported by grants (K17281) from the Korea Institute of
   Oriental Medicine, Ministry of Science, ICT and Future Planning, Korea.
   We thank to Dr. Hyunil Ha and Dr. Taesoo Kim for in vivo experiments.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Barrett Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Busserolles J, 2006, INT J VITAM NUTR RES, V76, P22, DOI 10.1024/0300 9831.76.1.22
   Cornelius C, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00120
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cummings SR, 2016, J BONE MINER RES, V31, P2069, DOI 10.1002/jbmr.3030
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Iwata H, 1997, BIOL PHARM BULL, V20, P656, DOI 10.1248/bpb.20.656
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Kim KY, 2000, J AGR FOOD CHEM, V48, P1269, DOI 10.1021/jf9900229
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Kuribara H, 2001, PHYTOTHER RES, V15, P142, DOI 10.1002/ptr.698
   전민희, 2011, [Journal of the Korean Society of Food Science and Nutrition, 한국식품영양과학회지], V40, P525
   전민희, 2010, [Journal of Life Science, 생명과학회지], V20, P607
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Miller PD, 2008, J BONE MINER RES, V23, P525, DOI 10.1359/JBMR.071206
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Ono K, 2005, J BONE MINER RES, V20, P23, DOI 10.1359/JBMR.041027
   Pasqualini V, 2003, CHEMOSPHERE, V52, P239, DOI 10.1016/S0045 6535(03)00268 6
   Poulsen RC, 2008, NUTR REV, V66, P359, DOI 10.1111/j.1753 4887.2008.00046.x
   Pradère JP, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aab2820
   Roitto M, 2005, ENVIRON POLLUT, V137, P603, DOI 10.1016/j.envpol.2005.01.046
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Touriño S, 2005, J AGR FOOD CHEM, V53, P4728, DOI 10.1021/jf050262q
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yen GC, 2008, FOOD CHEM TOXICOL, V46, P175, DOI 10.1016/j.fct.2007.07.012
   Zeng WC, 2012, J FOOD SCI, V77, pC824, DOI 10.1111/j.1750 3841.2012.02767.x
NR 37
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213 4220
EI 2213 4239
J9 INTEGR MED RES
JI Integr. Med. Res.
PD DEC
PY 2018
VL 7
IS 4
BP 374
EP 380
DI 10.1016/j.imr.2018.06.006
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA HE5PY
UT WOS:000453437300011
PM 30591892
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, LY
   Shao, L
   Li, B
   Zong, C
   Li, JH
   Zheng, Q
   Tong, XM
   Gao, CY
   Wang, JF
AF Liu, Liyue
   Shao, Lan
   Li, Bo
   Zong, Chen
   Li, Jianhu
   Zheng, Qiang
   Tong, Xiangming
   Gao, Changyou
   Wang, Jinfu
TI Extracellular signal regulated kinase1/2 activated by fluid shear stress
   promotes osteogenic differentiation of human bone marrow derived
   mesenchymal stem cells through novel signaling pathways
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Human mesenchymal stem cells; Extracellular signal regulated kinase1/2;
   Osteogenic differentiation; Fluid shear stress; Molecular signaling
   network
ID STROMAL CELLS; INTEGRIN EXPRESSION; OSTEOBLAST DIFFERENTIATION;
   MECHANICAL STIMULATION; TRANSDUCTION PATHWAYS; PERFUSION CULTURE;
   PROTEIN KINASE; FLOW; PROLIFERATION; MECHANOTRANSDUCTION
AB It is a classical signaling pathway that the activation of extracellular signal regulated kinase1/2 (ERK1/2) results in the phosphorylation of runt related transcription factor 2 (Runx2) and thereby initiates the transcription of osteogenic genes. Recently, it is found that the activation of ERK1/2 resulted from fluid shear stress (FSS) also increased the expression of Runx2 and beta 1 integrins, and finally enhanced osteogenic differentiation. However, it has been remained largely unknown how ERK1/2 regulates the expression of Runx2 and beta 1 integrins. We use the perfusion culture system to produce FSS exerting on human bone marrow derived mesenchymal stem cells (hMSCs) and thus activate ERK1/2. Our study demonstrated that FSS activated ERK1/2 mediated the expression of osteogenic genes via two novel signaling pathways except for the classical signaling pathway: feedback up regulation of beta 1 integrins expression via activating nuclear factor kappa B (NF kappa B), and activation of bone morphogenesis proteins (BMPs)/mothers against decapentaplegic (Smad) pathway via activating NF kappa B and thereby regulating Runx2 expression. These signaling pathways combined with the classical signaling pathway, with ERK1/2 as a hub node molecule, form a molecular signaling cross talking network to induce the osteogenic differentiation of hMSCs. The understanding on the mechanism of FSS inducing the osteogenic differentiation of hMSCs will not only be helpful to develop the bone tissue engineering but also provide new targets for drug discovery for treatment of osteoporosis and other related bone wasting diseases. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Liu, Liyue; Shao, Lan; Zong, Chen; Wang, Jinfu] Zhejiang Univ, Inst Cell Biol, Coll Life Sci, Hangzhou 310058, Zhejiang, Peoples R China.
   [Li, Bo; Gao, Changyou] Zhejiang Univ, Inst Mat Med, Coll Mat & Chem, Hangzhou 310028, Zhejiang, Peoples R China.
   [Li, Jianhu; Tong, Xiangming] Zhejiang Univ, Lab Bone Manow, Hosp 1, Hangzhou 310006, Zhejiang, Peoples R China.
   [Zheng, Qiang] Zhejiang Univ, Inst Orthoped, Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang
   University
RP Wang, JF (通讯作者)，Zhejiang Univ, Inst Cell Biol, Coll Life Sci, Zijingang Campus, Hangzhou 310058, Zhejiang, Peoples R China.
EM wjfu@zju.edu.cn
RI Gao, Changyou/HDO 7162 2022; Zhang, Yunyi/JHS 3626 2023; Zong,
   Chen/HMV 2527 2023
OI Gao, Changyou/0000 0001 5084 7208; 
FU scientific research from scientific Fund of Zhejiang [2009C13020];
   National Natural Science Fund of China [30971460]
FX The authors thank the health donors of the First People's Hospital of
   Zhejiang for kindly providing bone marrow and Dr. Erik form USA to check
   the manuscript. This study was financially supported by scientific
   research from scientific Fund of Zhejiang (2009C13020) and National
   Natural Science Fund of China (30971460).
CR Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Bancroft GN, 2002, P NATL ACAD SCI USA, V99, P12600, DOI 10.1073/pnas.202296599
   CARVALHO RS, 1995, ARCH ORAL BIOL, V40, P257, DOI 10.1016/0003 9969(95)98814 F
   Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393
   Communal C, 2003, J CELL BIOCHEM, V89, P381, DOI 10.1002/jcb.10520
   DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365 2141.1999.01715.x
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fan JG, 2006, J CELL PHYSIOL, V207, P499, DOI 10.1002/jcp.20593
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Glossop JR, 2009, GENE EXPR PATTERNS, V9, P381, DOI 10.1016/j.gep.2009.01.001
   Grellier M, 2009, J TISSUE ENG REGEN M, V3, P302, DOI 10.1002/term.166
   Hsu CJ, 2010, J CELL BIOCHEM, V111, P138, DOI 10.1002/jcb.22677
   Kanno T, 2007, J CELL BIOCHEM, V101, P1266, DOI 10.1002/jcb.21249
   Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756 3282(02)00979 1
   Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200
   Kim SH, 2007, J BIOMED MATER RES A, V80A, P826, DOI 10.1002/jbm.a.30945
   Kleiveland CR, 2008, EXP CELL RES, V314, P1831, DOI 10.1016/j.yexcr.2008.02.004
   Kundu AK, 2009, TISSUE ENG PT A, V15, P273, DOI 10.1089/ten.tea.2008.0055
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Laser M, 2000, J BIOL CHEM, V275, P35624, DOI 10.1074/jbc.M006124200
   Lavery K, 2008, J BIOL CHEM, V283, P20948, DOI 10.1074/jbc.M800850200
   Lee DY, 2008, J BONE MINER RES, V23, P1140, DOI 10.1359/JBMR.080302
   Lee HS, 2000, J BONE MINER RES, V15, P1501, DOI 10.1359/jbmr.2000.15.8.1501
   Liu J, 2009, J CELL BIOCHEM, V107, P224, DOI 10.1002/jcb.22118
   Liu LY, 2010, BIOMECH MODEL MECHAN, V9, P659, DOI 10.1007/s10237 010 0206 x
   Manton KJ, 2007, STEM CELLS, V25, P2845, DOI 10.1634/stemcells.2007 0065
   McAllister TN, 2000, BIOCHEM BIOPH RES CO, V270, P643, DOI 10.1006/bbrc.2000.2467
   Musa H, 2006, J CELL SCI, V119, P4322, DOI 10.1242/jcs.03198
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Orciani M, 2009, ACTA HISTOCHEM, V111, P15, DOI 10.1016/j.acthis.2008.02.005
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Pavalko FM, 1998, AM J PHYSIOL CELL PH, V275, pC1591
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Rangaswami H, 2004, J BIOL CHEM, V279, P38921, DOI 10.1074/jbc.M404674200
   Riddle RC, 2006, AM J PHYSIOL CELL PH, V290, pC776, DOI 10.1152/ajpcell.00082.2005
   Scaglione S, 2008, J BIOMED MATER RES A, V86A, P411, DOI 10.1002/jbm.a.31607
   Sharp LA, 2009, ANN BIOMED ENG, V37, P445, DOI 10.1007/s10439 008 9632 7
   Soghomonians A, 2002, BBA MOL CELL RES, V1589, P233, DOI 10.1016/S0167 4889(02)00179 9
   Stephens JS, 2007, BIOTECHNOL BIOENG, V97, P952, DOI 10.1002/bit.21252
   Stiehler M, 2009, J BIOMED MATER RES A, V89A, P96, DOI 10.1002/jbm.a.31967
   Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325
   Yang JF, 2010, J BIOMED MATER RES A, V92A, P817, DOI 10.1002/jbm.a.32378
   Young SRL, 2009, J BONE MINER RES, V24, P411, DOI 10.1359/JBMR.081102
NR 43
TC 33
Z9 37
U1 0
U2 34
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357 2725
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD NOV
PY 2011
VL 43
IS 11
BP 1591
EP 1601
DI 10.1016/j.biocel.2011.07.008
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 837QZ
UT WOS:000296219600007
PM 21810479
DA 2025 08 17
ER

PT J
AU Qi, SQ
   Sun, XM
   Choi, HK
   Yao, JF
   Wang, L
   Wu, GM
   He, Y
   Pan, J
   Guan, JL
   Liu, F
AF Qi, Shuqun
   Sun, Xiumei
   Choi, Han Kyoung
   Yao, Jinfeng
   Wang, Li
   Wu, Guomin
   He, Yun
   Pan, Jian
   Guan, Jun Lin
   Liu, Fei
TI FAK Promotes Early Osteoprogenitor Cell Proliferation by Enhancing
   mTORC1 Signaling
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE FAK; mTORC1; OSTEOBLAST; OSTEOPROGENITOR; PYK2
ID FOCAL ADHESION KINASE; CONDITIONAL INACTIVATION; CANCER; MICE; SURVIVAL;
   GROWTH; DIFFERENTIATION; INHIBITION; DEFICIENCY; EXPRESSION
AB Focal adhesion kinase (FAK) has important functions in bone homeostasis but its role in early osteoprogenitor cells is unknown. We show herein that mice lacking FAK in Dermo1 expressing cells exhibited low bone mass and decreased osteoblast number. Mechanistically, FAK deficient early osteoprogenitor cells had decreased proliferation and significantly reduced mammalian/mechanistic target of rapamycin complex 1 (mTORC1) signaling, a central regulator of cell growth and proliferation. Furthermore, our data showed that the pharmacological inhibition of FAK kinase dependent function alone was sufficient to decrease the proliferation and compromise the mineralization of early osteoprogenitor cells. In contrast to the Fak deletion in early osteoprogenitor cells, FAK loss in Col3.6 Cre targeted osteoblasts did not cause bone loss, and Fak deletion in osteoblasts did not affect proliferation, differentiation, and mTORC1 signaling but increased the level of active proline rich tyrosine kinase 2 (PYK2), which belongs to the same non receptor tyrosine kinase family as FAK. Importantly, mTORC1 signaling in bone marrow stromal cells (BMSCs) was reduced if FAK kinase was inhibited at the early osteogenic differentiation stage. In contrast, mTORC1 signaling in BMSCs was not affected if FAK kinase was inhibited at a later osteogenic differentiation stage, in which, however, the concomitant inhibition of both FAK kinase and PYK2 kinase reduced mTORC1 signaling. In summary, our data suggest that FAK promotes early osteoprogenitor cell proliferation by enhancing mTORC1 signaling via its kinase dependent function and the loss of FAK in osteoblasts can be compensated by the upregulated active PYK2. (c) 2020 American Society for Bone and Mineral Research.
C1 [Qi, Shuqun; Pan, Jian] Sichuan Univ, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Qi, Shuqun; Pan, Jian] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.
   [Qi, Shuqun; Pan, Jian] Sichuan Univ, West China Hosp Stomatol, Dept Oral & Maxillofacial Surg, Chengdu, Sichua, Peoples R China.
   [Qi, Shuqun; Sun, Xiumei; Choi, Han Kyoung; Yao, Jinfeng; Wang, Li; Wu, Guomin; He, Yun; Liu, Fei] Univ Michigan, Sch Dent, Dept Biol & Mat Sci & Prosthodont, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
   [Sun, Xiumei; Wu, Guomin] Jilin Univ, Dept Orthodont, Sch & Hosp Stomatol, Changchun, Peoples R China.
   [Yao, Jinfeng] Second Peoples Hosp Shenzhen, Dept Stomatol, Shenzhen, Peoples R China.
   [He, Yun] Chengdu Univ, Coll Med, Dent Dept, Chengdu, Peoples R China.
   [Guan, Jun Lin] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH USA.
C3 Sichuan University; Sichuan University; Sichuan University; University
   of Michigan System; University of Michigan; Jilin University; Second
   People's Hospital of Shenzhen; Chengdu University; University System of
   Ohio; University of Cincinnati
RP Liu, F (通讯作者)，Univ Michigan, Sch Dent, Dept Biol & Mat Sci & Prosthodont, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM feiliu@umich.edu
RI ; Pan, Jian/E 5700 2013; Liu, Fei/AAR 6464 2021
OI Wang, Li/0000 0002 4007 6654; , fei/0000 0002 2646 3009; Wu,
   Guomin/0000 0002 2277 1442; 
FU NIH/NIAMS [AR 69620]; Department of Biologic and Materials Sciences &
   Prosthodontics, University of Michigan School of Dentistry; National
   Institute of Arthritis and Musculoskeletal and Skin Diseases
   [P30AR069620] Funding Source: NIH RePORTER
FX The mu CT work was partly supported by a P30 Core Center award to the
   University of Michigan from NIH/NIAMS (AR 69620). FL was supported by
   the Department of Biologic and Materials Sciences & Prosthodontics,
   University of Michigan School of Dentistry. We thank Ms. Andrea Clark
   for mu CT scanning and reconstruction, and Dr. Laurie McCauley for
   valuable discussion.
CR Beggs HE, 2003, NEURON, V40, P501, DOI 10.1016/S0896 6273(03)00666 4
   Cary Leslie A., 1999, Frontiers in Bioscience, V4, pD102, DOI 10.2741/Cary
   Chandhoke TK, 2008, BONE, V43, P101, DOI 10.1016/j.bone.2008.03.012
   Choi HK, 2018, J BONE MINER RES, V33, P2021, DOI 10.1002/jbmr.3530
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Elefteriou F, 2011, BONE, V49, P1242, DOI 10.1016/j.bone.2011.08.021
   Fang F, 2015, J BONE MINER RES, V30, P1195, DOI 10.1002/jbmr.2447
   Golubovskaya VM, 2014, FRONT BIOSCI LANDMRK, V19, P687, DOI 10.2741/4236
   Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945 053X(97)90008 1
   GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0
   Guan JL, 2010, IUBMB LIFE, V62, P268, DOI 10.1002/iub.303
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Hsiao YH, 2016, ENDOCR RELAT CANCER, V23, P651, DOI 10.1530/ERC 16 0122
   ILLC D, 1995, NATURE, V377, P539
   Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839
   Kim JB, 2007, BONE, V41, P39, DOI 10.1016/j.bone.2007.01.024
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031
   Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Luo M, 2013, CANCER RES, V73, P5591, DOI 10.1158/0008 5472.CAN 13 1351
   Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097 2765(02)00568 3
   Nawroth R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027509
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Perinpanayagam H, 2001, J ORTHOPAED RES, V19, P993, DOI 10.1016/S0736 0266(01)00045 6
   Rajshankar D, 2017, FASEB J, V31, P937, DOI 10.1096/fj.201600645R
   Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112
   Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079 6107(98)00052 2
   Shekaran A, 2014, BONE, V68, P131, DOI 10.1016/j.bone.2014.08.008
   Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155
   Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022
   Slack Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200
   Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566
   Stokes JB, 2011, MOL CANCER THER, V10, P2135, DOI 10.1158/1535 7163.MCT 11 0261
   Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792
   Sun CH, 2016, J BONE MINER RES, V31, P2227, DOI 10.1002/jbmr.2908
   VanKoevering KK., 2008, IBMS BoneKEy, V5, P151, DOI DOI 10.1138/20080312
   Yamamoto D, 2003, CELL SIGNAL, V15, P575, DOI 10.1016/S0898 6568(02)00142 0
   Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491
   Zhao XF, 2010, J CELL BIOL, V189, P955, DOI 10.1083/jcb.200912094
NR 42
TC 12
Z9 13
U1 1
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2020
VL 35
IS 9
BP 1798
EP 1811
DI 10.1002/jbmr.4029
EA JUN 2020
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA NL6ZL
UT WOS:000537901400001
PM 32286710
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Lei, SS
   Li, B
   Huang, XW
   Wang, XP
   Xiong, S
   Duan, R
   Li, LZ
AF Lei, Shan shan
   Li, Bo
   Huang, Xiao wen
   Wang, Xu pin
   Xiong, Shan
   Duan, Rui
   Li, Lin zi
TI Structural identification of an polysaccharide isolated from
   Epimedium brevicornum and its beneficial effect on promoting
   osteogenesis in osteoblasts induced by high glucose
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Diabetes osteoporosis; Epimedium brevicornum polysaccharide; Structural
   resolution; Pharmacological mechanisms
AB Aim: Diabetes osteoporosis (DOP) is a chronic bone metabolic disease induced by diabetes, whose morbidity continues to increase. Epimedium brevicornum Maxim (EB), a popular Chinese traditional medicine, has been used to treat bone diseases in China for thousands of years. But its material basis and specific mechanism of action are not clear. Methods: Epimedium brevicornum crude polysaccharide (EPE) is the main component, in this research the characterized the structure of EBPC1 purified from EPE was detected and its effects on cell proliferation, differentiation, and cytoskeletal in osteoblasts induced by high glucose. Results: The molecular weight of EBPC1 was 10.5 kDa. It was mainly comprised of glucose and galactose, and the backbone of EBPC1 was  > 4) alpha D Galp (1  > 4) alpha D Galp (1  > 6) beta D Galp (1  > 6) beta D Galp (1  > 4) alpha D Glcp (1  > 4)alpha D Glcp (1  >. The results from in vitro experiments revealed that EBPC1 significantly increased alkaline phosphatase (ALP) activity and mineralized nodule formation in primary osteoblasts, also significantly upregulated expression of Alp mRNA and Runx2 mRNA in the presence of EBPC1 pretreatment. Moreover, EBPC1 modulated apoptosis via the regulation of Bax/Bcl2. Conclusion: These results indicate that EBPC1 treatment can promote osteogenesis during DOP, which can ameliorate apoptosis by regulating Bax/Bcl2 and accelerating osteogenesis in osteoblasts.
C1 [Lei, Shan shan; Huang, Xiao wen; Wang, Xu pin] Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou 310007, Zhejiang, Peoples R China.
   [Li, Bo] Zhejiang Univ Technol, Hangzhou 310014, Zhejiang, Peoples R China.
   [Xiong, Shan] Shandong First Med Univ, Sch Pharmaceut Sci, Jinan 250117, Shandong, Peoples R China.
   [Xiong, Shan] Shandong First Med Univ, Inst Mat Med, Jinan 250117, Shandong, Peoples R China.
   [Xiong, Shan] Shandong Acad Med Sci, Natl Key Lab Adv Drug Delivery Syst, Key Lab Biotechnol Drugs Natl Hlth Commiss, Key Lab Rare & Uncommon Dis Shandong Prov, Jinan 250117, Shandong, Peoples R China.
   [Duan, Rui; Li, Lin zi] Jingmen Cent Hosp, Jingmen 448000, Hubei, Peoples R China.
C3 Zhejiang University of Technology; Shandong First Medical University &
   Shandong Academy of Medical Sciences; Shandong First Medical University
   & Shandong Academy of Medical Sciences; Shandong First Medical
   University & Shandong Academy of Medical Sciences; University of Jinan
RP Xiong, S (通讯作者)，Shandong First Med Univ, Sch Pharmaceut Sci, Jinan 250117, Shandong, Peoples R China.; Xiong, S (通讯作者)，Shandong First Med Univ, Inst Mat Med, Jinan 250117, Shandong, Peoples R China.; Xiong, S (通讯作者)，Shandong Acad Med Sci, Natl Key Lab Adv Drug Delivery Syst, Key Lab Biotechnol Drugs Natl Hlth Commiss, Key Lab Rare & Uncommon Dis Shandong Prov, Jinan 250117, Shandong, Peoples R China.; Duan, R; Li, LZ (通讯作者)，Jingmen Cent Hosp, Jingmen 448000, Hubei, Peoples R China.
EM shanxiong83@sohu.com; duanrui@sina.com; lilinzi1989@163.com
OI Lei, Shan shan/0000 0002 5324 3984
FU National Science Foundation of China [82004022, 81803760]; Traditional
   Chinese Medicine Science and technology Project of Zhejiang Province
   [2022ZQ023, 2023ZL342]; Natural Science Foundation of Zhejiang Province
   [Q23H280031]; Medical and health science and technology program of
   Zhejiang Province [2020KY507]; Huadong Medicine Joint Funds of the
   Zhejiang Provincial Natural Science Foundation of China
   [LHDMZ22H280002]; Big Health Project of Science and Technology Program
   of Hubei Province [2022BCE060]; Public Health Project of Hubei Province
   [WJ2023M173]
FX The research work was financially supported by the National Science
   Foundation of China (Nos. 82004022, 81803760) , Traditional Chinese
   Medicine Science and technology Project of Zhejiang Province (Nos.
   2022ZQ023, 2023ZL342) , Natural Science Foundation of Zhejiang Province
   (No. Q23H280031) , Medical and health science and technology program of
   Zhejiang Province (No. 2020KY507) , Huadong Medicine Joint Funds of the
   Zhejiang Provincial Natural Science Foundation of China (No.
   LHDMZ22H280002) , Big Health Project of Science and Technology Program
   of Hubei Province (No. 2022BCE060) , and the Public Health Project of
   Hubei Province (No. WJ2023M173) .
CR Huang XW, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109345
   Khosla S, 2021, NAT REV ENDOCRINOL, V17, P685, DOI 10.1038/s41574 021 00555 5
   Lei SS, 2021, INT J BIOL MACROMOL, V193, P1996, DOI 10.1016/j.ijbiomac.2021.11.030
   Lei SS, 2019, J FUNCT FOODS, V61, DOI 10.1016/j.jff.2019.103458
   Li B, 2018, CARBOHYD POLYM, V196, P246, DOI 10.1016/j.carbpol.2018.05.037
   Li XJ, 2022, INT J BIOL MACROMOL, V211, P441, DOI 10.1016/j.ijbiomac.2022.05.036
   Li YZ, 2020, BMJ BRIT MED J, V369, DOI 10.1136/bmj.m997
   Liu W., 2017, Preliminary structural characterization and hypoglycemic effects of an acidic polysaccharide SERP1 from the residue of Sarcandra glabra, Patent No. 0144861717309475
   Miyoshi A, 2021, J DIABETES INVEST, V12, P1293, DOI 10.1111/jdi.13458
   Nakagami H, 2001, DIABETES, V50, P1472, DOI 10.2337/diabetes.50.6.1472
   Qin T, 2019, INT IMMUNOPHARMACOL, V70, P56, DOI 10.1016/j.intimp.2019.02.009
   Si YH, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019762
   Song LG, 2020, DIABETES, V69, DOI 10.2337/db20 183 LB
   Wang NN, 2021, CARBOHYD POLYM, V271, DOI 10.1016/j.carbpol.2021.118438
   Wang NN, 2021, FREE RADICAL BIO MED, V171, P112, DOI 10.1016/j.freeradbiomed.2021.05.014
   Wang NN, 2020, PHYTOMEDICINE, V75, DOI 10.1016/j.phymed.2020.153247
   Wu Y, 2016, CARBOHYD POLYM, V138, P134, DOI 10.1016/j.carbpol.2015.11.014
   Xiang Y., 2017, Rejuvenation Res, V20, P1
   Yang K, 2020, INT J BIOL MACROMOL, V149, P320, DOI 10.1016/j.ijbiomac.2020.01.026
   Zhao LG, 2014, CARBOHYD POLYM, V111, P714, DOI 10.1016/j.carbpol.2014.05.001
   Zheng H, 2020, INT J BIOL MACROMOL, V156, P1135, DOI 10.1016/j.ijbiomac.2019.11.145
   Zz A., 2021, Biomed. Pharmacother, V138
NR 22
TC 8
Z9 8
U1 8
U2 23
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC 31
PY 2023
VL 169
AR 115893
DI 10.1016/j.biopha.2023.115893
EA NOV 2023
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AG1G4
UT WOS:001117214900001
PM 37979377
OA gold
DA 2025 08 17
ER

PT J
AU Aljabban, J
   Syed, S
   Syed, S
   Rohr, M
   Mukhtar, M
   Aljabban, H
   Cottini, F
   Mohammed, M
   Hughes, T
   Gonzalez, T
   Panahiazr, M
   Hadley, D
   Benson, D
AF Aljabban, Jihad
   Syed, Sharjeel
   Syed, Saad
   Rohr, Michael
   Mukhtar, Mohamed
   Aljabban, Hisham
   Cottini, Francesca
   Mohammed, Mohammed
   Hughes, Tiffany
   Gonzalez, Taylor
   Panahiazr, Maryam
   Hadley, Dexter
   Benson, Don
TI Characterization of monoclonal gammopathy of undetermined significance
   progression to multiple myeloma through meta analysis of GEO data
SO HELIYON
LA English
DT Article
DE Multiple myeloma; Monoclonal gammopathy; Interferon gamma;
   Bioinformatics; Gene expression omnibus
ID MARROW STROMAL CELLS; INTERFERON GAMMA; C KIT; EXPRESSION; ACTIVATION;
   PROMOTES; LEUKEMIA; PATHWAY; GROWTH; PROLIFERATION
AB The etiology of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) is still obscure as are the processes that enable the progression of MGUS to MM. Understanding the unique vs. shared transcriptomes can potentially elucidate why individuals develop one or the other. Furthermore, highlighting key pathways and genes involved in the pathogenesis of MM or the development of MGUS to MM may allow the discovery of novel drug targets and therapies. We employed STARGEO platform to perform three separate meta analysis to compare MGUS and MM transcriptomes. For these analyses we tagged (1) 101 MGUS patient plasma cells from bone marrow samples and 64 plasma cells from healthy controls (2) 383 MM patient CD138+ cells from bone marrow and the 101 MGUS samples in the first analysis as controls (3) 517 MM patient peripheral blood samples and 97 peripheral blood samples from healthy controls. We then utilized Ingenuity Pathway Analysis (IPA) to analyze the unique genomic signatures within and across these samples. Our study identified genes that may have unique roles in MGUS (GADD45RA and COMMD3), but also newly identified signaling pathways (EIF2, JAK/STAT, and MYC) and gene activity (NRG3, RBFOX2, and PARP15) in MGUS that have previously been shown to be involved in MM suggesting a spectrum of molecular overlap. On the other hand, genes such as DUSP4, RN14, LAMP5, differentially upregulated in MM, may be seen as tipping the scales from benignity to malignancy and could serve as drug targets or novel biomarkers for risk of progression. Furthermore, our analysis of MM identified newly associated gene/pathway activity such as inhibition of Wnt signaling and defective B cell development. Finally, IPA analysis, suggests the multifactorial, oncogenic qualities of IFN & gamma; signaling in MM may be a unifying pathway for these diverse mechanisms and prompts the need for further studies.
C1 [Aljabban, Jihad] Univ Wisconsin, Hosp & Clin, Dept Med, Madison, WI 53705 USA.
   [Syed, Sharjeel] Univ Chicago, Dept Med, Med Ctr, Chicago, IL USA.
   [Syed, Saad] Northwestern Mem Hosp, Dept Med, Chicago, IL USA.
   [Rohr, Michael; Hadley, Dexter] Univ Cent Florida, Coll Med, Orlando, FL USA.
   [Mukhtar, Mohamed] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA.
   [Aljabban, Hisham] Regis Univ, Denver, CO USA.
   [Cottini, Francesca; Hughes, Tiffany; Gonzalez, Taylor; Benson, Don] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA.
   [Cottini, Francesca; Benson, Don] James Canc Hosp, Solove Res Inst, Columbus, OH USA.
   [Mohammed, Mohammed] Windsor Univ, Sch Med, Frankfort, IL USA.
   [Panahiazr, Maryam] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
   [Hadley, Dexter] Univ Cent Florida, Dept Artificial Intelligence, Orlando, FL USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Chicago; University of Chicago Medical Center;
   Northwestern Memorial Hospital; State University System of Florida;
   University of Central Florida; Michigan State University; Michigan State
   University College of Human Medicine; Regis University; University
   System of Ohio; Ohio State University; James Cancer Hospital & Solove
   Research Institute; University System of Ohio; Ohio State University;
   University of California System; University of California San Francisco;
   State University System of Florida; University of Central Florida
RP Aljabban, J (通讯作者)，Univ Wisconsin, Hosp & Clin, Dept Med, Madison, WI 53705 USA.
EM jihadal1992@gmail.com
RI ; Hadley, Dexter/ABB 7568 2021; Cottini, Francesca/JOZ 3952 2023
OI Aljabban, Jihad/0000 0003 4999 9372; Syed, Sharjeel/0000 0001 9381 0456;
   
CR Aguiar RCT, 2005, J BIOL CHEM, V280, P33756, DOI 10.1074/jbc.M505408200
   Alessandrini F, 2017, SEMIN ONCOL, V44, P239, DOI 10.1053/j.seminoncol.2017.10.013
   Asaf S., 2014, MOL CELL ONCOL, V2
   Babel N, 2004, TRANSPLANT P, V36, P2679, DOI 10.1016/j.transproceed.2004.09.046
   Barbarulo A, 2013, ONCOGENE, V32, P4231, DOI 10.1038/onc.2012.448
   Barreto G, 2007, NATURE, V445, P671, DOI 10.1038/nature05515
   Bataille R, 2008, LEUKEMIA RES, V32, P379, DOI 10.1016/j.leukres.2007.07.016
   Beldi Ferchiou A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174835
   Borlido J, 2018, EMBO REP, V19, P3, DOI 10.15252/embr.201745497
   Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287
   Calvanese V, 2019, NATURE, V576, P281, DOI 10.1038/s41586 019 1790 2
   Campbell AJ, 2010, BRIT J HAEMATOL, V149, P221, DOI 10.1111/j.1365 2141.2009.08070.x
   Carafa V, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00038
   Cayrol C, 2007, BLOOD, V109, P584, DOI 10.1182/blood 2006 03 012013
   Chandra P, 2010, AM J CLIN PATHOL, V133, P686, DOI 10.1309/AJCPGII1TT4NYOGI
   Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104
   Christina C., 1998, IMMUNITY, V9, P25
   Doidge R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051331
   Dorina U., 2018, BIOCHEM BIOPH RES CO, V498, P502
   Fairfield H, 2016, ANN NY ACAD SCI, V1364, P32, DOI 10.1111/nyas.13038
   Frassanito MA, 2015, EUR J HAEMATOL, V95, P65, DOI 10.1111/ejh.12481
   Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074 7613(00)80591 9
   Gambella M, 2015, EXPERT REV MOL DIAGN, V15, P881, DOI 10.1586/14737159.2015.1046436
   Giuliani N, 2006, HAEMATOLOGICA, V91, P1489
   Grudzien Nogalska E, 2016, RNA, V22, P773, DOI 10.1261/rna.055699.115
   Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295
   Hadley D, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.125
   Harousseau Jean Luc, 2004, Hematology Am Soc Hematol Educ Program, P237
   Hedvat CV, 2003, BRIT J HAEMATOL, V122, P728, DOI 10.1046/j.1365 2141.2003.04481.x
   Heo SK, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15492 5
   Iwata H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12849
   Jackson SW, 2016, J EXP MED, V213, P733, DOI 10.1084/jem.20151724
   Jovanovic KK, 2019, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00665
   Karlenius Therese Christina, 2010, Cancers (Basel), V2, P209, DOI 10.3390/cancers2020209
   Krämer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   Ledergor G, 2018, NAT MED, V24, P1867, DOI 10.1038/s41591 018 0269 2
   Ledergor G, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.8026
   Lee MK, 2016, GENET TEST MOL BIOMA, V20, P696, DOI 10.1089/gtmb.2016.0007
   Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200
   Li YX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058809
   Liu T, 2017, EXP THER MED, V14, P5251, DOI 10.3892/etm.2017.5209
   Liu X, 2018, MOL MED REP, V18, P1377, DOI 10.3892/mmr.2018.9107
   López Corral L, 2014, HAEMATOLOGICA, V99, P1365, DOI 10.3324/haematol.2013.087809
   Mahtouk K, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 198
   Marinac CR, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408 020 0284 7
   Matsumoto T, 2011, BONE, V48, P129, DOI 10.1016/j.bone.2010.05.036
   Mikulasova A, 2017, HAEMATOLOGICA, V102, P1617, DOI 10.3324/haematol.2017.163766
   Miura Y, 2006, ANTICANCER RES, V26, P4115
   Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257
   Musolino C, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/1852517
   Noonan K, 2011, CANCER MICROENVIRON, V4, P313, DOI 10.1007/s12307 011 0086 3
   Olmos G, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/861231
   PALUMBO A, 1995, LEUKEMIA LYMPHOMA, V18, P215, DOI 10.3109/10428199509059610
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Pawlyn C, 2016, CLIN CANCER RES, V22, P5783, DOI 10.1158/1078 0432.CCR 15 1790
   Pearse RN, 2005, BLOOD, V105, P4429, DOI 10.1182/blood 2004 08 3096
   Perez Peña J, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17836 7
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Roy P, 2017, ONCOGENE, V36, P1417, DOI 10.1038/onc.2016.309
   Shilo A, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.970955
   Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035
   Siegel R., 2020, CANC J CLIN, V2020
   Tagde A, 2016, BLOOD, V127, P2587, DOI 10.1182/blood 2015 07 659151
   Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365 2443.1998.00206.x
   Thomas JJ, 2016, CELL REP, V16, P3388, DOI 10.1016/j.celrep.2016.08.024
   Tian X., 2018, EXPRESSION DUAL SPEC, V78, P2498, DOI [10.1158/1538 7445.AM2018 2498, DOI 10.1158/1538 7445.AM2018 2498]
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Tricot G, 2000, LANCET, V355, P248, DOI 10.1016/S0140 6736(00)00019 2
   Udina IG, 2001, RUSS J GENET+, V37, P105, DOI 10.1023/A:1009087029511
   Wang J, 2016, GENE, V586, P41, DOI 10.1016/j.gene.2016.03.051
   Wang JH, 2014, BLOOD, V124, P555, DOI 10.1182/blood 2014 03 562439
   Wen MX, 2015, ONCOTARGET, V6, P25226, DOI 10.18632/oncotarget.4712
   Xiang Y, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117971
   Xiao RB, 2014, AM J SURG PATHOL, V38, P776, DOI 10.1097/PAS.0000000000000213
   Xie Y, 2020, ONCOGENE, V39, P922, DOI 10.1038/s41388 019 1037 6
   Yilmaz M, 2014, LEUKEMIA RES, V38, pS7, DOI 10.1016/S0145 2126(14)70019 0
   Yu WG, 1997, J LEUKOCYTE BIOL, V62, P450, DOI 10.1002/jlb.62.4.450
   Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745
   Zhan X, 2017, ONCOTARGET, V8, P111213, DOI 10.18632/oncotarget.22740
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
   Zhou FL, 2013, BLOOD REV, V27, P261, DOI 10.1016/j.blre.2013.08.002
   Zhou P, 2005, BRIT J HAEMATOL, V128, P636, DOI 10.1111/j.1365 2141.2005.05369.x
NR 83
TC 1
Z9 1
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405 8440
J9 HELIYON
JI Heliyon
PD JUL
PY 2023
VL 9
IS 7
AR e17298
DI 10.1016/j.heliyon.2023.e17298
EA JUL 2023
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA Q2JX9
UT WOS:001055842300001
PM 37539132
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zheng, C
   Liu, H
   Zhao, PP
   Lu, WG
   Song, SJ
   He, T
   Fan, J
   Wang, D
   Yang, PF
   Jie, Q
   Zheng, HF
   Luo, ZJ
   Yang, L
AF Zheng, Chao
   Liu, He
   Zhao, Pianpian
   Lu, Weiguang
   Song, Shiju
   He, Ting
   Fan, Jing
   Wang, Di
   Yang, Pengfei
   Jie, Qiang
   Zheng, Hou Feng
   Luo, Zhuojing
   Yang, Liu
TI Targeting sulfation dependent mechanoreciprocity between matrix and
   osteoblasts to mitigate bone loss
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID PERICELLULAR MATRIX; SLC26A2; MOUSE; SUPPRESSES; ROLES; MICE
AB Sulfation is a widespread modification of biomolecules that has been incompletely explored to date. Through cross phenotype meta analysis of bone mineral density in up to 426,824 genotyped human participants along with phenotypic characterization of multiple mutant mouse lines, we identified a causative role for sulfate transporter solute carrier family 26 member A2 (SLC26A2) deficiency in osteoporosis. Ablation of SLC26A2 in osteoblasts caused severe bone loss and accumulation of immature bone cells and elicited peculiar pericellular matrix (PCM) production characterized by undersulfation coupled with decreased stiffness. These altered chemophysical properties of the PCM disrupted the formation of focal adhesions in osteoblasts. Bulk RNA sequencing and functional assays revealed that the mechanoreciprocal inhibition of focal adhesion kinase (FAK) and Yes1 associated transcriptional regulator (YAP)/WW domain containing transcription regulator 1 (TAZ) signaling impinged osteoblast maturation upon SLC26A2 deficiency. Moreover, pharmacological abrogation of the Hippo kinases and forced wheel running ameliorated SLC26A2 deficient osteoporosis by promoting YAP/TAZ activity. Analysis of mouse single cell RNA sequencing data suggested coordination among sulfate metabolism, focal adhesion, and YAP/TAZ activity during osteoblast to osteocyte transition. In addition to the SLC26A2 deficient setting, altered FAK and YAP/TAZ signaling was also observed in bone cells of ovariectomized mice and patients with osteoporosis, and pharmacological enforcing of YAP/TAZ activity ameliorated bone loss in ovariectomized mice. Collectively, these data unveil a role for sulfation in the developmental mechanoreciprocity between matrix and osteoblasts, which could be leveraged to prevent bone loss.
C1 [Zheng, Chao; Liu, He; Lu, Weiguang; Song, Shiju; He, Ting; Fan, Jing; Wang, Di; Luo, Zhuojing; Yang, Liu] Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, Xian 710032, Peoples R China.
   [Zhao, Pianpian; Zheng, Hou Feng] Westlake Univ, Sch Life Sci, Dis & Populat DaP Geninfo Lab, Hangzhou 310024, Peoples R China.
   [Zhao, Pianpian; Zheng, Hou Feng] Westlake Lab Life Sci & Biomed, Hangzhou 310024, Peoples R China.
   [Yang, Pengfei] Northwestern Polytech Univ, Sch Life Sci, Inst Special Environm Biophys, Key Lab Space Biosci & Biotechnol, Xian 710072, Peoples R China.
   [Jie, Qiang] Xi An Jiao Tong Univ, Hong Hui Hosp, Coll Med, Dept Spine Surg, Xian 710049, Peoples R China.
   [Jie, Qiang] Northwest Univ, Coll Life Sci & Med, Res Ctr Skeletal Dev Deform & Injury Repair, Xian 710069, Peoples R China.
   [Luo, Zhuojing; Yang, Liu] Northwestern Polytech Univ, Med Res Inst, Xian 710072, Peoples R China.
C3 Air Force Medical University; Westlake University; Westlake Laboratory;
   Northwestern Polytechnical University; Xi'an Jiaotong University;
   Northwest University Xi'an; Northwestern Polytechnical University
RP Luo, ZJ; Yang, L (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, Xian 710032, Peoples R China.; Zheng, HF (通讯作者)，Westlake Univ, Sch Life Sci, Dis & Populat DaP Geninfo Lab, Hangzhou 310024, Peoples R China.; Zheng, HF (通讯作者)，Westlake Lab Life Sci & Biomed, Hangzhou 310024, Peoples R China.; Luo, ZJ; Yang, L (通讯作者)，Northwestern Polytech Univ, Med Res Inst, Xian 710072, Peoples R China.
EM zhenghoufeng@westlake.edu.cn; zjluo@fmmu.edu.cn; yangliu@fmmu.edu.cn
RI ; He, Ting/HHZ 5004 2022; Zheng, Houfeng/K 4424 2012; Lu,
   Weiguang/HJA 2546 2022
OI Wang, Di/0000 0001 5036 7909; Yang, Liu/0000 0002 6498 4702; Zheng,
   Chao/0000 0001 8530 0923; Zhao, Pianpian/0009 0009 1676 1748
FU National Natural Science Foundation of China [81972032, 82002261,
   82130070, 82272442]; Key Industrial Chain Program of Shaanxi
   [2021SF 022]; Key Research and Development Program of Shaanxi; 
   [2022ZDLSF02 12]
FX This work was funded by the National Natural Science Foundation of China
   (81972032 to L.Y., 82002261 to C.Z., 82130070 to L.Y., and 82272442 to
   Q.J.); the Key Industrial Chain Program of Shaanxi 2022ZDLSF02 12 (to
   L.Y.); and the Key Research and Development Program of Shaanxi
   2021SF 022 (to C.Z.).
CR Atsawasuwan P, 2011, CONNECT TISSUE RES, V52, P479, DOI 10.3109/03008207.2011.564337
   Bai WY, 2020, BONE, V133, DOI 10.1016/j.bone.2020.115247
   Batoon L, 2019, BIOMATERIALS, V196, P51, DOI 10.1016/j.biomaterials.2017.10.033
   Brenig B, 2003, GENE, V319, P161, DOI 10.1016/S0378 1119(03)00806 0
   Burridge K, 2017, FEBS J, V284, P3355, DOI 10.1111/febs.14195
   Cai T, 2015, P NATL ACAD SCI USA, V112, P8064, DOI 10.1073/pnas.1502454112
   Chen CH, 2020, J BONE MINER RES, V35, P1812, DOI 10.1002/jbmr.4036
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Chery DR, 2020, ACTA BIOMATER, V111, P267, DOI 10.1016/j.actbio.2020.05.005
   Dasgupta I, 2019, J BIOL CHEM, V294, P17693, DOI 10.1074/jbc.REV119.007963
   de Leeuw CA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004219
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dzamukova M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30618 8
   Elosegui Artola A, 2016, NAT CELL BIOL, V18, P540, DOI 10.1038/ncb3336
   Fan FQ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2304
   Feng XD, 2019, CANCER CELL, V35, P457, DOI 10.1016/j.ccell.2019.01.009
   Forlino A, 2005, HUM MOL GENET, V14, P859, DOI 10.1093/hmg/ddi079
   Gallardo T, 2007, GENESIS, V45, P413, DOI 10.1002/dvg.20310
   Gualeni B, 2013, BONE, V54, P83, DOI 10.1016/j.bone.2013.01.036
   Gualeni B, 2010, MATRIX BIOL, V29, P453, DOI 10.1016/j.matbio.2010.05.001
   Günal S, 2019, J BIOL CHEM, V294, P12293, DOI 10.1074/jbc.REV119.007422
   Hammal F, 2022, NUCLEIC ACIDS RES, V50, pD316, DOI 10.1093/nar/gkab996
   Hellewell AL, 2017, JOVE J VIS EXP, DOI 10.3791/55051
   Heneghan JF, 2010, AM J PHYSIOL CELL PH, V298, pC1363, DOI 10.1152/ajpcell.00004.2010
   Hua R, 2020, MATRIX BIOL, V94, DOI 10.1016/j.matbio.2020.09.002
   Jacobs CR, 2010, ANNU REV BIOMED ENG, V12, P369, DOI 10.1146/annurev bioeng 070909 105302
   Keenan AB, 2019, NUCLEIC ACIDS RES, V47, pW212, DOI 10.1093/nar/gkz446
   Li XH, 2021, CURR OSTEOPOROS REP, V19, P101, DOI 10.1007/s11914 020 00650 y
   Li XH, 2019, ELIFE, V8, DOI 10.7554/eLife.49631
   Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl
   Liu Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   Lü SY, 2015, ACS APPL MATER INTER, V7, P13029, DOI 10.1021/acsami.5b03143
   Mattinzoli D, 2012, EUR CELLS MATER, V24, P403, DOI 10.22203/eCM.v024a29
   Meng ZP, 2018, NATURE, V560, P655, DOI 10.1038/s41586 018 0444 0
   Monigatti F, 2002, BIOINFORMATICS, V18, P769, DOI 10.1093/bioinformatics/18.5.769
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Mortier GR, 2019, AM J MED GENET A, V179, P2393, DOI 10.1002/ajmg.a.61366
   Mueller JW, 2015, ENDOCR REV, V36, P526, DOI 10.1210/er.2015 1036
   Paganini C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082710
   Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010
   Park M, 2014, J BIOL CHEM, V289, P1993, DOI 10.1074/jbc.M113.503466
   Qian Y, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003 021 02861 0
   Qin L, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0099 y
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Randilini A, 2021, ANAT SCI INT, V96, P265, DOI 10.1007/s12565 020 00588 2
   Ransom RC, 2018, NATURE, V563, P514, DOI 10.1038/s41586 018 0650 9
   Rawat SJ, 2015, TRENDS BIOCHEM SCI, V40, P149, DOI 10.1016/j.tibs.2015.01.001
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rosell García T, 2019, J BIOL CHEM, V294, P11087, DOI 10.1074/jbc.RA119.007806
   Sladitschek Martens HL, 2022, NATURE, V607, P790, DOI 10.1038/s41586 022 04924 6
   Smith AJ, 1997, HISTOCHEM J, V29, P1, DOI 10.1023/A:1026406932452
   St John HC, 2014, MOL ENDOCRINOL, V28, P1150, DOI 10.1210/me.2014 1091
   Sun WJ, 2019, ELIFE, V8, DOI 10.7554/eLife.47454
   Takagi Minoru, 1997, Journal of Nihon University School of Dentistry, V39, P156
   Taylor Scott, 2018, Bone Rep, V8, P95, DOI 10.1016/j.bonr.2018.03.002
   Totaro A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15206
   Vrahnas C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11373 9
   Wang CJ, 2008, J BONE MINER RES, V23, P837, DOI 10.1359/JBMR.080214
   Wang JLS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 26571 7
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wilusz RE, 2012, J R SOC INTERFACE, V9, P2997, DOI 10.1098/rsif.2012.0314
   Xia JW, 2022, BMC MED, V20, DOI 10.1186/s12916 022 02531 w
   Xia JW, 2020, ANN RHEUM DIS, V79, P1460, DOI 10.1136/annrheumdis 2020 217892
   Yang PF, 2018, J MECH BEHAV BIOMED, V79, P115, DOI 10.1016/j.jmbbm.2017.12.015
   Youlten SE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22517 1
   Yue R, 2016, ELIFE, V5, DOI 10.7554/eLife.18782
   Zeng Y, 2022, CELL BIOSCI, V12, DOI 10.1186/s13578 022 00929 w
   Zheng C, 2020, FASEB J, V34, P720, DOI 10.1096/fj.201901040RR
   Zheng C, 2019, EBIOMEDICINE, V40, P695, DOI 10.1016/j.ebiom.2019.01.010
   Zheng HF, 2015, NATURE, V526, P112, DOI 10.1038/nature14878
   Zhou TF, 2020, ELIFE, V9, DOI 10.7554/eLife.52779
   Zhou ZX, 2018, BIOTECHNOL BIOENG, V115, P1561, DOI 10.1002/bit.26577
   Zhu XW, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.104466
   Zhu XF, 2015, AM J HUM GENET, V96, P21, DOI 10.1016/j.ajhg.2014.11.011
   Zhu ZH, 2016, NAT GENET, V48, P481, DOI 10.1038/ng.3538
NR 75
TC 12
Z9 14
U1 9
U2 51
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD AUG 23
PY 2023
VL 15
IS 710
AR eadg3983
DI 10.1126/scitranslmed.adg3983
PG 17
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA Q4JZ4
UT WOS:001057210400003
PM 37611084
DA 2025 08 17
ER

PT J
AU Park, KR
   Lee, H
   Cho, M
   Yun, HM
AF Park, Kyung Ran
   Lee, Hanna
   Cho, MyoungLae
   Yun, Hyung Mun
TI A Phytochemical Constituent, (E) Methyl Cinnamate Isolated from
   Alpinia katsumadai Hayata Suppresses Cell Survival, Migration,
   and Differentiation in Pre Osteoblasts
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE phytomedicine; Alpinia katsumadai Hayata; (E) methyl cinnamate;
   osteoblast; apoptosis; MAPKs
ID METHYL CINNAMATE; ALKALINE PHOSPHATASE; APOPTOSIS; INHIBITION; REPAIR
AB Background: (E) methyl cinnamate (EMC), a phytochemical constituent isolated from Alpinia katsumadai Hayata, is a natural flavor compound with anti inflammatory properties, which is widely used in the food and commodity industry. However, the pharmacological effects of methyl cinnamate on pre osteoblasts remain unknown. This study aimed to investigate the pharmacological effects and mechanisms of EMC in pre osteoblast MC3T3 E1 cells (pre osteoblasts). Methods: Cell viability and apoptosis were evaluated using the MTT assay and TUNEL staining. Cell migration and osteoblast differentiation were examined using migration assays, as well as alkaline phosphatase activity and staining assays. Western blot analysis was used to examine intracellular signaling pathways and apoptotic proteins. Results: EMC decreased cell viability with morphological changes and increased apoptosis in pre osteoblasts. EMC also induced the cleavage of Poly (ADP ribose) polymerase (PARP) and caspase 3 and reduced the expression of anti apoptotic proteins. In addition, EMC increased TUNEL positive cells in pre osteoblasts, decreased the activation of mitogen activated protein kinases, and suppressed cell migration rate in pre osteoblasts. Subsequently, EMC inhibited the osteoblast differentiation of pre osteoblasts, as assessed by alkaline phosphatase staining and activity assays. Conclusion: These findings demonstrate that EMC has a pharmacological and biological role in cell survival, migration, and osteoblast differentiation. It suggests that EMC might be a potential phytomedicine for treating abnormalities of osteoblast function in bone diseases.
C1 [Park, Kyung Ran; Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02453, South Korea.
   [Lee, Hanna; Cho, MyoungLae] Natl Dev Inst Korean Med, Gyongsan 38540, South Korea.
C3 Kyung Hee University
RP Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02453, South Korea.
EM rudfks282@naver.com; iiihanna@nikom.or.kr; meanglae@nikom.or.kr;
   yunhm@khu.ac.kr
FU National Research Foundation of Korea [NRF]   Korean government (MSIP)
   [NRF 2018R1D1A1B07043282]
FX This work was supported by the National Research Foundation of Korea
   [NRF] grant funded by the Korean government (MSIP)
   (NRF 2018R1D1A1B07043282).
CR Bhatia SP, 2007, FOOD CHEM TOXICOL, V45, pS113, DOI 10.1016/j.fct.2007.09.077
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   CHANG YM, 2011, EVID BASED COMPL ALT, P1, DOI DOI 10.1093/ECAM/NEP131
   Chen YY, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/378415
   Chen YY, 2012, J AGR FOOD CHEM, V60, P955, DOI 10.1021/jf203981x
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   GOLUB EE, 1992, BONE MINER, V17, P273, DOI 10.1016/0169 6009(92)90750 8
   Gui YL, 2018, EUR J PHARMACOL, V833, P183, DOI 10.1016/j.ejphar.2018.05.033
   Huang QS, 2009, J AGR FOOD CHEM, V57, P2565, DOI 10.1021/jf8036227
   Huang WF, 2018, DIABET METAB SYND OB, V11, P357, DOI 10.2147/DMSO.S166728
   Hughes DE, 1997, J CLIN PATHOL MOL PA, V50, P132, DOI 10.1136/mp.50.3.132
   Ichida M, 2011, FEBS LETT, V585, P4018, DOI 10.1016/j.febslet.2011.11.014
   Iguchi M, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/3979606
   Iwaki A, 1997, J BONE MINER RES, V12, P96, DOI 10.1359/jbmr.1997.12.1.96
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Lee SE, 2003, PHYTOTHER RES, V17, P1041, DOI 10.1002/ptr.1291
   Liao XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042709
   Lima FJB, 2014, EUR J PHARMACOL, V740, P192, DOI 10.1016/j.ejphar.2014.07.016
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427
   Mollazadeh S, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018 015 0152 5
   Nam JW, 2012, NAT PROD COMMUN, V7, P795
   Numan MS, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S88845
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Park KR, 2020, INT J BIOL SCI, V16, P330, DOI 10.7150/ijbs.37781
   Park KR, 2019, TOXICOLOGY, V422, P95, DOI 10.1016/j.tox.2019.05.010
   Park KR, 2018, THERANOSTICS, V8, P3087, DOI 10.7150/thno.24426
   Park KR, 2017, ARCH PHARM RES, V40, P933, DOI 10.1007/s12272 017 0932 z
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097 4644(199701)64:1<50::AID JCB8>3.0.CO;2 Z
   Sequeira DB, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9040074
   SHIMOI K, 1985, MUTAT RES, V146, P15, DOI 10.1016/0167 8817(85)90050 1
   Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113 8133.2004
   Yun HM, 2016, SCI REP UK, V6, DOI 10.1038/srep30985
   Zhang C, 2019, PHYTOCHEMISTRY, V164, P50, DOI 10.1016/j.phytochem.2019.04.013
   Zheng XG, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20187574, 10.1590/1414 431x20187574]
NR 39
TC 19
Z9 19
U1 0
U2 16
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2020
VL 21
IS 10
AR 3700
DI 10.3390/ijms21103700
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LW7GO
UT WOS:000539312100296
PM 32456334
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kawasaki, Y
   Sekiguchi, M
   Kawasaki, M
   Hirakura, Y
AF Kawasaki, Yuko
   Sekiguchi, Mitsuhiro
   Kawasaki, Masashi
   Hirakura, Yutaka
TI Thermodynamic Evaluation of the Binding of Bisphosphonates to Human
   Farnesyl Pyrophosphate Synthase
SO CHEMICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE isothermal titration calorimetry; thermodynamics; drug discovery;
   enthalpy; differential scanning calorimetry
ID NITROGEN CONTAINING BISPHOSPHONATES; DIPHOSPHATE SYNTHASE; IN VIVO;
   BONE RESORPTION; MOLECULAR MECHANISM; STRUCTURAL BASIS; INHIBITION;
   OSTEOCLAST; DISCOVERY; PROTEINS
AB Bisphosphonates (BPs) are the drug of choice for treating bone diseases such as osteoporosis, Paget's disease, and metastatic bone disease. BPs with nitrogen containing side chains (N BPs) are known to act as inhibitors for farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway. In this study, we evaluated the effect of different side chains on the binding affinity of BPs to human FPPS using calorimetric techniques. Differential scanning calorimetry (DSC) was used to determine the thermal unfolding of FPPS in the presence of BPs. The addition of a series of clinically available BPs increased the structural stability of human FPPS by preferential binding, as indicated by an increase in the FPPS unfolding temperature. The magnitude of the increase was correlated with in vivo antiresorptive efficacy, suggesting that the stabilization of FPPS underlies the inhibitory effect of the BPs. Isothermal titration calorimetry (ITC) experiments were performed to evaluate the binding thermodynamics of BPs against human FPPS. Analysis of the binding energetics revealed that over 30 years of optimization practiced by different pharmaceutical companies has enhanced the enthalpic contribution as well as binding affinity of BPs. The larger enthalpic contribution observed for newer, more potent BPs derives from both improved hydrogen bonding interactions and shape complementarity based on comparisons of our results with available structure information.
C1 [Kawasaki, Yuko; Sekiguchi, Mitsuhiro; Kawasaki, Masashi; Hirakura, Yutaka] Astellas Pharma Inc, Inst Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan.
C3 Astellas Pharmaceuticals
RP Kawasaki, Y (通讯作者)，Astellas Pharma Inc, Inst Drug Discovery Res, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan.
EM yuko.kusuzaki@astellas.com
CR Aripirala S, 2012, J MED CHEM, V55, P6445, DOI 10.1021/jm300425y
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   BRANDTS JF, 1990, BIOCHEMISTRY US, V29, P6927, DOI 10.1021/bi00481a024
   Cao R, 2008, PROTEINS, V73, P431, DOI 10.1002/prot.22066
   Carbonell T, 2005, BIOCHEMISTRY US, V44, P11741, DOI 10.1021/bi050905v
   Dunford JE, 2010, CURR PHARM DESIGN, V16, P2961
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Edink E, 2011, J AM CHEM SOC, V133, P5363, DOI 10.1021/ja110571r
   Ferenczy GG, 2010, DRUG DISCOV TODAY, V15, P919, DOI 10.1016/j.drudis.2010.08.013
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Freire E, 2008, DRUG DISCOV TODAY, V13, P869, DOI 10.1016/j.drudis.2008.07.005
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   Glickman JF, 2007, ASSAY DRUG DEV TECHN, V5, P205, DOI 10.1089/adt.2007.057
   Holdgate GA, 2005, DRUG DISCOV TODAY, V10, P1543, DOI 10.1016/S1359 6446(05)03610 X
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Huang CH, 2010, PROTEINS, V78, P888, DOI 10.1002/prot.22614
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kawasaki Y, 2011, DRUG DISCOV TODAY, V16, P985, DOI 10.1016/j.drudis.2011.07.010
   Kawasaki Y, 2010, CHEM BIOL DRUG DES, V75, P143, DOI 10.1111/j.1747 0285.2009.00921.x
   Kobashigawa Y, 2009, J BIOMOL NMR, V43, P145, DOI 10.1007/s10858 008 9296 5
   Ladbury JE, 2010, NAT REV DRUG DISCOV, V9, P23, DOI 10.1038/nrd3054
   Lafont V, 2007, CHEM BIOL DRUG DES, V69, P413, DOI 10.1111/j.1747 0285.2007.00519.x
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mukherjee S, 2009, J AM CHEM SOC, V131, P8374, DOI 10.1021/ja902895p
   Ohno K, 2011, CURR MED CHEM, V18, P220, DOI 10.2174/092986711794088335
   Ohtaka H, 2005, PROG BIOPHYS MOL BIO, V88, P193, DOI 10.1016/j.pbiomolbio.2004.07.005
   Olsson TSG, 2008, J MOL BIOL, V384, P1002, DOI 10.1016/j.jmb.2008.09.073
   ©Prous Science Tomson Reuters business, THOMS REUT INT
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Scott AD, 2009, CHEMMEDCHEM, V4, P1985, DOI 10.1002/cmdc.200900386
   Sun ST, 2011, EXPERT OPIN THER PAT, V21, P1433, DOI 10.1517/13543776.2011.593511
   Takeuchi M, 1998, CHEM PHARM BULL, V46, P1703
   Todd MJ, 1999, PROTEINS, V36, P147, DOI 10.1002/(SICI)1097 0134(19990801)36:2<147::AID PROT2>3.0.CO;2 3
   Velazquez Campoy A., 2004, Curr. Protoc. Cell Biol, V23, p17.8.1
   Waldron TT, 2003, BIOCHEMISTRY US, V42, P5058, DOI 10.1021/bi034212v
   Yin FL, 2006, J AM CHEM SOC, V128, P3524, DOI 10.1021/ja0601639
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 43
TC 6
Z9 6
U1 0
U2 13
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0009 2363
J9 CHEM PHARM BULL
JI Chem. Pharm. Bull.
PD JAN
PY 2014
VL 62
IS 1
BP 77
EP 83
DI 10.1248/cpb.c13 00710
PG 7
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA 280AY
UT WOS:000329002300011
PM 24172032
OA gold
DA 2025 08 17
ER

PT J
AU Duan, J
   Hu, XT
   Li, T
   Wu, G
   Dou, PC
   Ouyang, ZX
AF Duan, Juan
   Hu, Xuantao
   Li, Tao
   Wu, Gen
   Dou, Pengcheng
   Ouyang, Zhengxiao
TI Cimifugin Suppresses NF κB Signaling to Prevent Osteoclastogenesis and
   Periprosthetic Osteolysis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE osteoclast; NF kappa B; p38; MAPK; aseptic prosthetic loosening;
   periprosthetic osteolysis; cimifugin
ID PARTICLE INDUCED OSTEOLYSIS; POLYETHYLENE; ARTHROPLASTY; INFLAMMATION;
   RESPONSES; FAMILY; WEAR
AB Background: Aseptic loosening of prosthesis (ALP) is one of the most common long term complications of knee and hip arthroplasty. Wear particle induced osteoclastogenesis and subsequent periprosthetic osteolysis account for the morbidity of ALP. Here, we investigate the potential of cimifugin (CIM), a natural extract from Cimicifuga racemosa and Saposhnikovia divaricata, as a bone protective drug in the treatment of ALP.
   Method: First, we performed cell viability and osteoclast formation assays to assess the effect of noncytotoxic CIM on osteoclast differentiation in vitro. Bone slice resorption and F actin ring immunofluorescence assays were adopted to assess the effects of CIM on bone resorption function. Then, quantitative real time polymerase chain reaction (qRT PCR) analysis was performed to further assess the repressive effects of CIM on osteoclastogenesis at the gene expression level. To elucidate the mechanisms underlying the above findings, Western blot and luciferase reporter gene assays were used to assess the regulatory effects of CIM on the NF kappa B and MAPK signaling pathways. Moreover, a Ti particle induced murine calvarial osteolysis model and subsequent histomorphometric analysis via micro CT and immunohistochemical staining were used to elucidate the effect of CIM on periprosthetic osteolysis in vivo.
   Result: CIM dose dependently inhibited both bone marrow derived macrophage (BMM)  and RAW264.7 cell derived osteoclastogenesis and bone resorption pit formation in vitro, which was further supported by the reduced expression of F actin and osteoclast specific genes. According to the Western blot analysis, inhibition of I kappa B alpha phosphorylation in the NF kappa B signaling pathway, not the phosphorylation of MAPKs, was responsible for the suppressive effect of CIM on osteoclastogenesis. Animal experiments demonstrated that CIM alleviated Ti particle induced bone erosion and osteoclast accumulation in murine calvaria.
   Conclusion: The current study suggested for the first time that CIM can inhibit RANKL induced osetoclastogenesis by suppressing the NF kappa B signaling pathway in vitro and prevent periprosthetic osteolysis in vivo. These findings suggest the potential of CIM as a therapeutic in ALP.
C1 [Duan, Juan] Cent South Univ, Xiangya Hosp 2, Dept Geriatr Internal Med, Changsha, Peoples R China.
   [Hu, Xuantao; Li, Tao; Wu, Gen; Dou, Pengcheng; Ouyang, Zhengxiao] Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Dou, PC; Ouyang, ZX (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Hunan, Peoples R China.
EM doupengcheng@csu.edu.cn; ouyangzhengxiao@csu.edu.cn
RI 窦, 鹏程/HJH 2386 2023; Ouyang, Zhengxiao/Q 1461 2019
FU Excellent Youth Foundation of Hunan Provincial Natural Science
   Foundation [2021JJ20086]; Science and Technology Department of Hunan
   Province [2019JJ50845, 2019JJ50883, 2020JJ5802]; Health Commission of
   Hunan Province [202104070969]
FX This work was supported by the Excellent Youth Foundation of Hunan
   Provincial Natural Science Foundation Committee (grant number
   2021JJ20086), the Science and Technology Department of Hunan Province
   (grant number 2019JJ50845; 2019JJ50883; 2020JJ5802) and the Health
   Commission of Hunan Province (grant number 202104070969).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Dyskova T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01026
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Gibon E, 2017, J BIOMED MATER RES B, V105, P1685, DOI 10.1002/jbm.b.33676
   Goodman SB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122091
   Granholm S, 2011, J CELL BIOCHEM, V112, P3300, DOI 10.1002/jcb.23256
   Han B, 2019, MED SCI MONITOR, V25, P409, DOI 10.12659/MSM.912042
   He K, 2000, PLANTA MED, V66, P635, DOI 10.1055/s 2000 8619
   Holliday LS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010158
   Howie DW, 2013, INFLAMMOPHARMACOLOGY, V21, P389, DOI 10.1007/s10787 013 0192 6
   Hu XT, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00385
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jia ZX, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00264
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kodama J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165685
   Lin TH, 2014, ACTA BIOMATER, V10, P1, DOI 10.1016/j.actbio.2013.09.034
   Liu AM, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200471
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Nemeth B, 2021, J THROMB HAEMOST, V19, P41, DOI 10.1111/jth.15132
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Panegrossi G, 2014, INT ORTHOP, V38, P419, DOI 10.1007/s00264 013 2262 1
   Park JH, 2017, MOL CELLS, V40, P706
   Prock Gibbs H, 2021, J BONE JOINT SURG AM, V103, P728, DOI 10.2106/JBJS.20.01086
   Sun GJ, 2019, ORTHOP SURG, V11, P770, DOI 10.1111/os.12496
   Sun ZY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00389
   Taki N, 2005, J ORTHOP RES, V23, P376, DOI 10.1016/j.orthres.2004.08.023
   Visgauss JD, 2020, J ARTHROPLASTY, V35, P1333, DOI 10.1016/j.arth.2019.12.032
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Walia B, 2018, ANN NY ACAD SCI, V1415, P57, DOI 10.1111/nyas.13629
   Walsh MC, 2015, IMMUNOL REV, V266, P72, DOI 10.1111/imr.12302
   Wang XY, 2017, J CELL MOL MED, V21, P2926, DOI 10.1111/jcmm.13204
   Wooley PH, 2014, CLIN ORTHOP RELAT R, V472, P3699, DOI 10.1007/s11999 014 3725 4
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Wu LQ, 2016, BIOMOL THER, V24, P418, DOI 10.4062/biomolther.2015.168
   Yang DS, 2020, BIOCHEM BIOPH RES CO, V533, P510, DOI 10.1016/j.bbrc.2020.09.054
   Yao L, 2019, PHYTOMEDICINE, V64, DOI 10.1016/j.phymed.2019.153076
   Zhai ZJ, 2014, BREAST CANCER RES TR, V144, P33, DOI 10.1007/s10549 014 2844 7
   Zhang L, 2020, INT J NANOMED, V15, P6705, DOI 10.2147/IJN.S248848
   Zhang Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01028
   Zhu W, 2019, BIOCHEM BIOPH RES CO, V509, P294, DOI 10.1016/j.bbrc.2018.12.125
NR 40
TC 15
Z9 19
U1 1
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 29
PY 2021
VL 12
AR 724256
DI 10.3389/fphar.2021.724256
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WV4TH
UT WOS:000717230300001
PM 34658863
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Lv, F
   Cai, XL
   Yang, WJ
   Gao, LL
   Chen, L
   Wu, J
   Ji, LN
AF Lv, Fang
   Cai, Xiaoling
   Yang, Wenjia
   Gao, Leili
   Chen, Ling
   Wu, Jing
   Ji, Linong
TI Denosumab or romosozumab therapy and risk of cardiovascular events in
   patients with primary osteoporosis: Systematic review and meta  analysis
SO BONE
LA English
DT Article
DE Osteoporosis; Denosumab; Romosozumab; Cardiovascular events;
   Meta analysis
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; ZOLEDRONIC ACID; FRACTURE
   RISK; ALENDRONATE; OSTEOPROTEGERIN; CALCIFICATION; SAFETY;
   ATHEROSCLEROSIS; BISPHOSPHONATES
AB Background: Osteoporosis and cardiovascular (CV) diseases are closely correlated. RANKL/RANK/OPG pathway and Wnt signalling pathway both implicated in the pathogenesis of osteoporosis and cardiovascular diseases. We aimed to investigate the effect of denosumab or romosozumab therapy on cardiovascular outcomes in patients with primary osteoporosis.
   Methods: PubMed, Cochrane library, and EMBASE databases were systematically searched from the inception dates to June 4, 2019. Randomized clinical trials evaluating the effect of denosumab or romosozumab versus active comparators or placebo for at least 6 months in patients with primary osteoporosis or osteopenia were included. Two investigators independently extracted data for study characteristics, outcomes of interest, and risk of bias in accordance with PRISMA guidelines.
   Results: 17 relevant studies (denosumab: n = 11, 13615 participants; romosozumab: n = 6, 12219 participants) were included. No associations between denosumab therapy and risk of a composite cardiovascular outcome (1.06 [95 % CI, 0.88 1.28], p = 0.54), three point major adverse cardiovascular event (3P MACE, 1.01 [95 % CI, 0.83 1.23], p = 0.93), and four point major adverse cardiovascular event (4P MACE, 0.99 [95 % CI, 0.83 1.18], p = 0.89) were identified. Romosozumab therapy did not increase the risk of composite cardiovascular outcome (1.26 [95 % CI, 0.95 1.68], p = 0.11), and 3P MACE (1.41 [95 % CI, 0.99 2.02], p = 0.06), while increased the risk of 4P MACE (1.39 [95 % CI, 1.01 1.90], p = 0.04) among elderly men and postmenopausal woman with osteoporosis over a period of 12 36 months. Denosumab or romosozumab did not increase or reduce specific cardiovascular outcomes, including CV death or death, myocardial infarction, stroke, atrial fibrillation, heart failure, aortic and intracranial aneurysm, aortic dissection, aortic valve disease and hypertension (all p > 0.05). Sensitivity analysis conducted by random effects model altered the result of 4 P MACE in romosozumab (1.36 [0.99 1.87], p = 0.06). No other significant difference was detected in the sensitivity analyses and subgroup analyses.
   Conclusions: Denosumab therapy was not associated with any risk of composite and specific cardiovascular outcomes among patients with primary osteoporosis than active comparators or placebo, while romosozumab therapy might increase the risk of 4 P MACE.
C1 [Lv, Fang; Cai, Xiaoling; Yang, Wenjia; Gao, Leili; Chen, Ling; Wu, Jing; Ji, Linong] Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, 11 Xizhimen South St, Beijing 100044, Peoples R China.
C3 Peking University
RP Cai, XL; Ji, LN (通讯作者)，Peking Univ, Peoples Hosp, Dept Endocrinol & Metab, 11 Xizhimen South St, Beijing 100044, Peoples R China.
EM dr_junel@sina.com; jiln@bjmu.edu.cn
RI ; Linong, Ji/AAB 6543 2020; 吕, 芳/GRY 1152 2022; Cai,
   Xiaoling/AFR 4880 2022
OI Cai, Xiaoling/0000 0002 7881 0543; Lv, Fang/0000 0002 1872 781X; 
FU National Key Research and Development Program [2016YFC1304901]
FX This work was supported by National Key Research and Development Program
   (No. 2016YFC1304901) of China. The funding agency had no role in the
   study design, data collection or analysis, decision to publish or
   preparation of the manuscript.
CR Anastasilakis AD, 2009, HORM METAB RES, V41, P721, DOI 10.1055/s 0029 1224109
   [Anonymous], AM SOC BON MIN RES A
   Bagger YZ, 2006, J INTERN MED, V259, P598, DOI 10.1111/j.1365 2796.2006.01640.x
   Baldini V, 2005, J Endocrinol Invest, V28, P69
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Browner WS, 2001, J CLIN ENDOCR METAB, V86, P631, DOI 10.1210/jc.86.2.631
   Chen ZD, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0743 z
   Choi NK, 2017, J BONE MINER RES, V32, P611, DOI 10.1002/jbmr.3019
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Gay A, 2017, CURR OPIN LIPIDOL, V28, P387, DOI 10.1097/MOL.0000000000000445
   Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
   Ishibashi H, 2017, BONE, V103, P209, DOI 10.1016/j.bone.2017.07.005
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kendler DL, 2011, OSTEOPOROSIS INT, V22, P1725, DOI 10.1007/s00198 010 1378 z
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Khosla S, 2017, NAT REV ENDOCRINOL, V13, P697, DOI 10.1038/nrendo.2017.136
   Kiechl S, 2004, CIRCULATION, V109, P2175, DOI 10.1161/01.CIR.0000127957.43874.BB
   Kiechl Stefan, 2006, Expert Rev Cardiovasc Ther, V4, P801, DOI 10.1586/14779072.4.6.801
   Kim A, 2017, DIAGNOSIS AND CONTROL OF DISEASES OF FISH AND SHELLFISH, P109
   Kranenburg G, 2016, ATHEROSCLEROSIS, V252, P106, DOI 10.1016/j.atherosclerosis.2016.06.039
   Krishna SM, 2017, ARTERIOSCL THROM VAS, V37, P553, DOI 10.1161/ATVBAHA.116.308723
   Lampropoulos CE, 2012, NAT REV RHEUMATOL, V8, P587, DOI 10.1038/nrrheum.2012.120
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Lewiecki EM, 2018, J CLIN ENDOCR METAB, V103, P3183, DOI 10.1210/jc.2017 02163
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lin T, 2012, INT J CLIN PRACT, V66, P399, DOI 10.1111/j.1742 1241.2011.02806.x
   Liu D, 2019, OSTEOPOROSIS INT, V30, P1807, DOI 10.1007/s00198 019 05031 5
   Liu Y, 2018, CLIMACTERIC, V21, P189, DOI 10.1080/13697137.2018.1433655
   Lyu HC, 2019, J CLIN ENDOCR METAB, V104, P1753, DOI 10.1210/jc.2018 02236
   Markham A, 2019, DRUGS, V79, P471, DOI 10.1007/s40265 019 01072 6
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Miller PD, 2016, J CLIN ENDOCR METAB, V101, P3163, DOI 10.1210/jc.2016 1801
   Morony S, 2008, CIRCULATION, V117, P411, DOI 10.1161/CIRCULATIONAHA.107.707380
   Nakamura T, 2012, OSTEOPOROSIS INT, V23, P1131, DOI 10.1007/s00198 011 1786 8
   Nakamura T, 2014, J CLIN ENDOCR METAB, V99, P2599, DOI 10.1210/jc.2013 4175
   Orwoll E, 2012, J CLIN ENDOCR METAB, V97, P3161, DOI 10.1210/jc.2012 1569
   PECK WA, 1993, AM J MED, V94, P646
   Recknor C, 2013, OBSTET GYNECOL, V121, P1291, DOI 10.1097/AOG.0b013e318291718c
   Rosen CJ, 2017, NEW ENGL J MED, V377, P1479, DOI 10.1056/NEJMe1711298
   Roux C, 2014, BONE, V58, P48, DOI 10.1016/j.bone.2013.10.006
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Samelson EJ, 2014, J BONE MINER RES, V29, P450, DOI 10.1002/jbmr.2043
   Tankó LB, 2005, J BONE MINER RES, V20, P1912, DOI 10.1359/JBMR.050711
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
NR 49
TC 83
Z9 91
U1 1
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2020
VL 130
AR 115121
DI 10.1016/j.bone.2019.115121
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA JW8UD
UT WOS:000503321100014
PM 31678488
DA 2025 08 17
ER

PT J
AU Ghallab, DS
   Shawky, E
   Khalifa, AA
   Ibrahim, RS
AF Ghallab, Dina S.
   Shawky, Eman
   Khalifa, Asmaa A.
   Ibrahim, Reham S.
TI Insights into the molecular mechanisms of Spirulina platensis against
   rheumatoid arthritis through integrative serum pharmacochemistry and
   network pharmacology analysis
SO FOOD BIOSCIENCE
LA English
DT Article
DE Rheumatoid arthritis; S . platensis; Network pharmacology; Serum
   pharmacochemistry; Mechanistic study
ID SUBCHRONIC TOXICITY; INFLAMMATION; RANDOMIZATION; METABOLOMICS;
   IONIZATION
AB Spirulina platensis traditionally and increasingly consumed as a premium food and complementary medicine in many Asian countries on account of its nutritive and pharmacological attributes. So far, Spirulina holds promise as a potential therapeutic agent for RA alleviation. However, the mechanistic basis of S. platensis against RA remains poorly clarified. The research strategy featuring serum pharmacochemistry and network pharmacology was constructed to pinpoint the potential bioactive components and efficiency mechanisms of S. platensis against RA. Firstly, a rat model of RA was established using Complete Freund 's Adjuvant (CFA). Secondly, serum migrating components following Spirulina administration were profiled and relatively quantified as monitoring indexes for Spirulina bioavailability. Using network pharmacology strategy, potential target genes of transitional components and associated pathways were predicted. Lastly, the control mechanisms of S. platensis in CFA model were verified through a series of serum and synovial biochemical markers along with master RA  related pathways by western blotting. Nineteen circulating compounds, including four prototypes and fifteen metabolites were profiled and selected as candidate efficacy compounds successfully absorbed and maintained considerable concentrations in Spirulina  treated sera creating a great opportunity to exert the anti  RA potential. Among which, fatty acids and their conjugated metabolites represented the most relevant and abundant circulating metabolites. Regarding network pharmacology findings, the top predictive targets highly correlated with RA were NFKB, NLRP3, TNF, MMP 9, TLR4 and VEGFA. Relatedly, KEGG analysis dissected PI3K Akt signaling pathway, MAPK signaling pathway, osteoclasts (OCs) differentiation and VEGF signaling pathway as the top  ranked RA pathways. Our efficacy experimental findings emphasized that Spirulina markedly downregulated the inflammatory mediators (IL  1, IL  6, IL  17, TNF  alpha and MMP 9) levels. Following Spirulina treatment, western blotting detected significant alterations in RA master proteins as TLR4, NLRP3, VEGF, Pro caspases 1, Caspase 1, and NF  kappa B p65. This integrated work illuminates the molecular mechanisms and efficacy constituents of S. platensis as referenced templates against RA. In the light of the above, systematized information on the metabolic fate of the absorbable Spirulina metabolites should be expanded through in depth pharmacokinetics research for highly targeted drugs. In a broader sense, future investigations and adequate evidence should be explored to broaden the therapeutic strategies scenario in the era of personalized medicine to achieve a comprehensive "treat  to  target " approach which, undoubtedly, is of a great significance in the clinical settings.
C1 [Ghallab, Dina S.; Shawky, Eman; Ibrahim, Reham S.] Alexandria Univ, Fac Pharm, Dept Pharmacognosy, Alkhartoom Sq, Alexandria 21521, Egypt.
   [Khalifa, Asmaa A.] Pharos Univ Alexandria, Fac Pharm, Dept Pharmacol & Therapeut, Alexandria, Egypt.
C3 Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge
   Bank (EKB); Pharos University in Alexandria
RP Shawky, E (通讯作者)，Alexandria Univ, Fac Pharm, Dept Pharmacognosy, Alkhartoom Sq, Alexandria 21521, Egypt.
EM shawkyeman@yahoo.com
RI Shawky, Eman/R 5917 2018; Ibrahim, Reham/AAY 7424 2021
CR Ali EAI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121523
   Azizan A, 2020, MAR DRUGS, V18, DOI 10.3390/md18080403
   Babar MM., 2017, PLANT BIOINFORMATICS, P375, DOI [10.1007/978 3 319 67156 7_15, DOI 10.1007/978 3 319 67156 7_15]
   Banoth B, 2015, ELIFE, V4, DOI 10.7554/eLife.05648
   Bello S, 2014, J CLIN EPIDEMIOL, V67, P973, DOI 10.1016/j.jclinepi.2014.04.008
   Bilal M, 2021, MAR DRUGS, V19, DOI 10.3390/md19010010
   Buhrmann C, 2011, J BIOL CHEM, V286, P28556, DOI 10.1074/jbc.M111.256180
   Castello F, 2018, ARCH BIOCHEM BIOPHYS, V646, P1, DOI 10.1016/j.abb.2018.03.021
   Chi G, 2018, MOL IMMUNOL, V99, P171, DOI 10.1016/j.molimm.2018.05.005
   Chu W. L., 2012, IeJSME, V6, pS24, DOI DOI 10.56026/IMU.6.SUPPL1.S24
   Della Corte A, 2015, TALANTA, V140, P52, DOI 10.1016/j.talanta.2015.03.003
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Ding Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01331 9
   Divito EB, 2012, ANAL CHEM, V84, P2388, DOI 10.1021/ac203158u
   Doig GS, 2005, J CRIT CARE, V20, P187, DOI 10.1016/j.jcrc.2005.04.005
   Du HY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01620
   Duarte Delgado NP, 2022, J TRANSL AUTOIMMUN, V5, DOI 10.1016/j.jtauto.2022.100150
   Elbandy M, 2023, MOLECULES, V28, DOI 10.3390/molecules28010002
   Elkhawaga SY, 2021, CLIN RHEUMATOL, V40, P2927, DOI 10.1007/s10067 021 05584 z
   Fadel NA, 2024, EGYPT RHEUMATOL, V46, P38, DOI 10.1016/j.ejr.2023.12.001
   Farhadi F, 2023, BIOFACTORS, V49, P478, DOI 10.1002/biof.1929
   Fernando IPS, 2022, CRIT REV BIOTECHNOL, V42, P23, DOI 10.1080/07388551.2021.1922351
   Ghallab DS, 2022, FOOD BIOSCI, V50, DOI 10.1016/j.fbio.2022.102091
   Ghallab DS, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 12265 7
   Ghallab DS, 2021, LWT FOOD SCI TECHNOL, V136, DOI 10.1016/j.lwt.2020.110298
   Hamed I, 2015, COMPR REV FOOD SCI F, V14, P446, DOI 10.1111/1541 4337.12136
   Han JW, 2020, DRUG DES DEV THER, V14, P5235, DOI 10.2147/DDDT.S282112
   Harlow E., 1988, A laboratory manual, V579
   Huang CC, 2021, CELLS BASEL, V10, DOI 10.3390/cells10082168
   Huang Qi Quan, 2009, Curr Rheumatol Rep, V11, P357
   Hutadilok Towatana N, 2008, FOOD SCI TECHNOL RES, V14, P351, DOI 10.3136/fstr.14.351
   Kadian N, 2016, J PHARMACEUT BIOMED, V126, P83, DOI 10.1016/j.jpba.2016.03.052
   Karkos PD, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen058
   KATO R, 1977, XENOBIOTICA, V7, P25, DOI 10.3109/00498257709036242
   Khan Z, 2005, CURR PHARM BIOTECHNO, V6, P373, DOI 10.2174/138920105774370607
   Kumar Narendra, 2009, Inflammopharmacology, V17, P181, DOI 10.1007/s10787 009 0004 1
   Laine L, 2003, J PAIN SYMPTOM MANAG, V25, pS32
   Lao MX, 2016, J IMMUNOL, V196, P596, DOI 10.4049/jimmunol.1403254
   Lauritano C, 2016, FRONT MAR SCI, V3, DOI 10.3389/fmars.2016.00068
   Leonarduzzi G, 2012, FREE RADICAL BIO MED, V52, P19, DOI 10.1016/j.freeradbiomed.2011.09.031
   Li S, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/138460
   Lin B, 2014, J ETHNOPHARMACOL, V155, P248, DOI 10.1016/j.jep.2014.05.023
   Liu RZ, 2022, BIOMED PHARMACOTHER, V153, DOI 10.1016/j.biopha.2022.113362
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Maryati M., 2020, Food Res, V4, P1018, DOI [10.26656/fr.2017.4(4).389, DOI 10.26656/FR.2017.4(4).389]
   Mateen S, 2016, CLIN CHIM ACTA, V455, P161, DOI 10.1016/j.cca.2016.02.010
   Mena P, 2016, MOLECULES, V21, DOI 10.3390/molecules21111576
   Mizushima T, 2010, PHARMACEUTICALS, V3, P1614, DOI 10.3390/ph3051614
   Munro BA, 2022, VET ANAESTH ANALG, V49, P18, DOI 10.1016/j.vaa.2021.09.004
   Natl Res Council, 2011, SUCCESSFUL K 12 STEM EDUCATION: IDENTIFYING EFFECTIVE APPROACHES IN SCIENCE, TECHNOLOGY, ENGINEERING, AND MATHEMATICS, P1
   Navarini L, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944 017 0586 3
   Niu Q, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1034050
   Okada Y, 2004, J NAT PROD, V67, P103, DOI 10.1021/np030323j
   Paulos CM, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1944
   Peña Blanco A, 2018, FEBS J, V285, P416, DOI 10.1111/febs.14186
   Robert M, 2019, FRONT MED LAUSANNE, V5, DOI 10.3389/fmed.2018.00364
   Robinson PC, 2020, MED CAMBRIDGE, V1, P90, DOI 10.1016/j.medj.2020.11.005
   Salazar M, 1998, J ETHNOPHARMACOL, V62, P235, DOI 10.1016/S0378 8741(98)00080 4
   Schlotterbeck J, 2018, J SEP SCI, V41, P4286, DOI 10.1002/jssc.201800780
   Shih CM, 2009, ANESTH ANALG, V108, P1303, DOI 10.1213/ane.0b013e318193e919
   Shikov AN, 2020, MAR DRUGS, V18, DOI 10.3390/md18110557
   Tekeoglu Ibrahim, 2020, Reumatologia (Warsaw), V58, P265, DOI 10.5114/reum.2020.99764
   Thalhamer T, 2008, RHEUMATOLOGY, V47, P409, DOI 10.1093/rheumatology/kem297
   Tian DM, 2023, J PHARMACEUT BIOMED, V227, DOI 10.1016/j.jpba.2023.115271
   van der Doelen GA, 1998, J CHROMATOGR A, V809, P21, DOI 10.1016/S0021 9673(98)00186 1
   Veras KS, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14122663
   Costa JAV, 2019, BIORESOURCE TECHNOL, V292, DOI 10.1016/j.biortech.2019.121946
   Waldner MJ, 2010, J EXP MED, V207, P2855, DOI 10.1084/jem.20100438
   Wang J, 2023, PHYTOMEDICINE, V108, DOI 10.1016/j.phymed.2022.154507
   Wang L, 2021, J ETHNOPHARMACOL, V273, DOI 10.1016/j.jep.2021.113988
   Wang X., 2017, Serum pharmacochemistry of traditional Chinese medicine, P7
   Wang YJ, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110519
   Weckwerth W, 2003, ANNU REV PLANT BIOL, V54, P669, DOI 10.1146/annurev.arplant.54.031902.135014
   Wu YH, 2021, J ETHNOPHARMACOL, V276, DOI 10.1016/j.jep.2021.114200
   Xu LX, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.961708
   Yang JH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03038 z
   Zhang AH, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00553
   Zhang AH, 2019, ENGINEERING PRC, V5, P60, DOI 10.1016/j.eng.2018.11.008
   Zhang RZ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00123
   Zheng ZJ, 2018, J AGR FOOD CHEM, V66, P3975, DOI 10.1021/acs.jafc.7b06015
   Zhong BM, 2020, MAR DRUGS, V18, DOI 10.3390/md18060331
NR 81
TC 5
Z9 6
U1 0
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212 4292
EI 2212 4306
J9 FOOD BIOSCI
JI Food Biosci.
PD JUN
PY 2024
VL 59
AR 103902
DI 10.1016/j.fbio.2024.103902
EA MAR 2024
PG 14
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA QA6R5
UT WOS:001218204000001
DA 2025 08 17
ER

PT J
AU Xue, H
   Feng, ZH
   Yuan, PT
   Qiao, L
   Lou, QL
   Zhao, XD
   Ma, QL
   Wang, SY
   Shen, Y
   Ye, HL
   Cheng, J
   Wang, JY
   Wan, SL
   Zhang, BY
   Shi, PH
   Sun, XW
AF Xue, Hong
   Feng, Zhenhua
   Yuan, Putao
   Qiao, Li
   Lou, Qiliang
   Zhao, Xiangde
   Ma, Qingliang
   Wang, Shiyu
   Shen, Yang
   Ye, Huali
   Cheng, Jiao
   Wang, Jiying
   Wan, Shuanglin
   Zhang, Boya
   Shi, Peihua
   Sun, Xuewu
TI Restrained Mitf associated autophagy by Mulberroside A ameliorates
   osteoclastogenesis and counteracts OVX Induced osteoporosis in mice
SO CELL DEATH DISCOVERY
LA English
DT Article
ID TRANSCRIPTION FACTOR; MORUS ALBA; IN VIVO; DIFFERENTIATION; RECEPTOR;
   MELANOMA; TARGET; RANK; BIOGENESIS; EXPRESSION
AB Bone and mineral metabolism homeostasis accounts for the maintenance of normal skeletal remodeling. However, with aging and changes in hormone levels, over activated osteoclasts disrupt homeostasis, induce osteoporosis, and even cause osteoporotic fractures, leading to an enormous economic burden. Despite the rapid development of pharmacological therapy for osteoporosis, safer and more effective treatments remain to be explored. Here, we demonstrate that Mulberroside A (Mul A), a natural component extracted from mulberry bark and branches, effectively suppresses osteoclastogenesis in vitro and counteracts bone loss caused by ovariectomy (OVX). The mechanism underlying this effect involves the repression of autophagic flux during osteoclastogenesis by Mul A, which can be attributed to the restrained expression of microphthalmia related transcription factor (Mitf) and its nuclear translocation. Importantly, Mitf overexpression partially reverses the inhibitory effects of Mul A on autophagy and osteoclastogenesis. Moreover, applying two autophagy agonizts, rapamycin and Torin 1, attenuates the osteoclastogenic regulatory role of Mul A. Collectively, our study demonstrates that Mul A damages osteoclast differentiation and ameliorates osteoporosis caused by estrogen deficiency by modulation of Mitf associated autophagy, indicating its therapeutic potential against osteoporosis.
C1 [Xue, Hong; Feng, Zhenhua; Yuan, Putao; Qiao, Li; Lou, Qiliang; Zhao, Xiangde; Ma, Qingliang; Wang, Shiyu; Shen, Yang; Ye, Huali; Cheng, Jiao; Wang, Jiying; Wan, Shuanglin; Zhang, Boya; Shi, Peihua; Sun, Xuewu] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Sch Med, Hangzhou, Peoples R China.
   [Xue, Hong; Feng, Zhenhua; Yuan, Putao; Qiao, Li; Lou, Qiliang; Zhao, Xiangde; Ma, Qingliang; Wang, Shiyu; Shen, Yang; Ye, Huali; Cheng, Jiao; Wang, Jiying; Wan, Shuanglin; Zhang, Boya; Shi, Peihua; Sun, Xuewu] Key Lab Musculoskeletal Syst Degenerat & Regenerat, Hangzhou, Peoples R China.
C3 Zhejiang University
RP Shi, PH; Sun, XW (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Sch Med, Hangzhou, Peoples R China.; Shi, PH; Sun, XW (通讯作者)，Key Lab Musculoskeletal Syst Degenerat & Regenerat, Hangzhou, Peoples R China.
EM peihua_shi@zju.edu.cn; xuewu_sun@zju.edu.cn
RI Wang, Yijun/GXW 1763 2022; Wang, Shiyu/LTE 7491 2024; Zhang,
   Boya/AAZ 3093 2021
OI Shi, Peihua/0000 0002 2063 0419; 
FU National Natural Science Foundation of China (National Science
   Foundation of China); National Natural Science Foundation of China;
   Zhejiang Provincial Natural Science Foundation of China; Analysis Center
   of Agrobiology and Environmental Sciences, Zhejiang Univ
FX Thanks to the National Natural Science Foundation of China and the
   Zhejiang Provincial Natural Science Foundation of China for financial
   support. Thanks to the Bio ultrastructure Analysis Lab. of the Analysis
   Center of Agrobiology and Environmental Sciences, Zhejiang Univ for
   technical support. Thanks to Hanbio Biotechnology Co., Ltd. in Shanghai,
   China for the reagents supplied.
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Bento CF, 2016, ANNU REV BIOCHEM, V85, P685, DOI 10.1146/annurev biochem 060815 014556
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chitu V, 2012, BLOOD, V120, P3126, DOI 10.1182/blood 2012 04 425595
   Chung KO, 2003, J PHARM PHARMACOL, V55, P1695, DOI 10.1211/0022357022313
   Chung YH, 2012, INT J BIOCHEM CELL B, V44, P989, DOI 10.1016/j.biocel.2012.03.007
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Gai DZ, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI159527
   Goding CR, 2000, GENE DEV, V14, P1712
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Huynh H, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003 018 0028 4
   HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092 8674(93)90429 T
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jo SP, 2014, FOOD CHEM TOXICOL, V65, P213, DOI 10.1016/j.fct.2013.12.040
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P897, DOI 10.1007/s00198 004 1627 0
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Lauss M, 2015, J INVEST DERMATOL, V135, P1820, DOI 10.1038/jid.2015.61
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754
   Martina JA, 2013, J CELL BIOL, V200, P475, DOI 10.1083/jcb.201209135
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963
   Olson Karin, 2007, J Oncol Pharm Pract, V13, P223, DOI 10.1177/1078155207080806
   Park KT, 2011, FOOD CHEM TOXICOL, V49, P3038, DOI 10.1016/j.fct.2011.09.008
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Ploper D, 2015, P NATL ACAD SCI USA, V112, pE420, DOI 10.1073/pnas.1424576112
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Raja DA, 2020, EMBO REP, V21, DOI 10.15252/embr.201948333
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Reid IR, 2010, J CLIN ENDOCR METAB, V95, P4380, DOI 10.1210/jc.2010 0597
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Sambandam Y, 2014, BONE, V61, P125, DOI 10.1016/j.bone.2014.01.004
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092 8674(85)80047 7
   Shi YW, 2012, J ETHNOPHARMACOL, V143, P896, DOI 10.1016/j.jep.2012.08.023
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang BT, 2011, P NATL ACAD SCI USA, V108, P15201, DOI 10.1073/pnas.1103746108
   Wang CP, 2014, J NEUROSCI RES, V92, P944, DOI 10.1002/jnr.23374
   Wang KK, 2011, J MOL CELL BIOL, V3, P360, DOI 10.1093/jmcb/mjr021
   Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097 2765(01)00360 4
   Yang MH, 2006, BLOOD, V107, P2262, DOI 10.1182/blood 2005 08 3365
   Yu R, 2021, J NEUROCHEM, V157, P1979, DOI 10.1111/jnc.15242
   Zhang LS, 2010, J BONE MINER RES, V25, P1572, DOI 10.1002/jbmr.36
   Zhao Y, 2012, J CELL PHYSIOL, V227, P639, DOI 10.1002/jcp.22768
NR 51
TC 3
Z9 3
U1 2
U2 9
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2058 7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PD FEB 15
PY 2024
VL 10
IS 1
AR 80
DI 10.1038/s41420 024 01847 1
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HY5F0
UT WOS:001163077100003
PM 38360705
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tsourdi, E
   Lademann, F
   Ominsky, MS
   Rijntjes, E
   Köhrle, J
   Misof, BM
   Roschger, P
   Klaushofer, K
   Hofbauer, LC
   Rauner, M
AF Tsourdi, Elena
   Lademann, Franziska
   Ominsky, Michael S.
   Rijntjes, Eddy
   Koehrle, Josef
   Misof, Barbara M.
   Roschger, Paul
   Klaushofer, Klaus
   Hofbauer, Lorenz C.
   Rauner, Martina
TI Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength
   in Male Mice With Exogenous Hyperthyroidism
SO ENDOCRINOLOGY
LA English
DT Article
ID ANTIBODY TREATMENT; PARATHYROID HORMONE; THYROID HORMONES; CHONDROCYTE
   DIFFERENTIATION; POSTMENOPAUSAL WOMEN; OSTEOBLAST LINEAGE;
   GENE EXPRESSION; CORTICAL BONE; FRACTURE RISK; TRIIODOTHYRONINE
AB Hyperthyroidism in mice is associated with low bone mass, high bone turnover, and high concentrations of sclerostin, a potent Wnt inhibitor. Here, we explored the effects of either increasing bone formation with sclerostin antibodies (Scl Ab) or reducing bone turnover with bisphosphonates on bone mass and strength in hyperthyroid mice. Twelve week old C57BL/6 male mice were rendered hyperthyroid using L thyroxine (T4; 1.2 mg/mL added to the drinking water) and treated with 20 mg/kg Scl Ab twice weekly or 100 mg/kg zoledronic acid (ZOL) once weekly or phosphate buffered saline for 4 weeks. Hyperthyroid mice displayed a lower trabecular bone volume at the spine (242%, P < 0.05) and the distal femur (255%, P < 0.05) compared with euthyroid controls. Scl Ab and ZOL treatment of hyperthyroid mice increased trabecular bone volume at the spine by threefold and twofold, respectively. Serum bone formation and resorption markers were increased in hyperthyroid mice and suppressed by treatment with ZOL but not Scl Ab. Trabecular bone stiffness at the lumbar vertebra was 63% lower in hyperthyroid mice (P < 0.05) and was increased fourfold by Sci Ab (P < 0.001) and threefold by ZOL treatment (P < 0.01). Bone strength based on ultimate load, which was 10% lower in hyperthyroidism, was increased by Scl Ab by 71% and ZOL by 22% (both P < 0.001). Increased proportion of low mineralized bone seen in hyperthyroid mice was restored by treatmentwith Scl Ab and ZOL. Thus, bone forming and antiresorptive drugs prevent bone loss in hyperthyroid mice via different mechanisms.
C1 [Tsourdi, Elena; Lademann, Franziska; Hofbauer, Lorenz C.; Rauner, Martina] Tech Univ Dresden, Dept Med 3, Med Ctr, D 01307 Dresden, Germany.
   [Tsourdi, Elena; Lademann, Franziska; Hofbauer, Lorenz C.; Rauner, Martina] Tech Univ Dresden, Ctr Hlth Aging, Med Ctr, D 01307 Dresden, Germany.
   [Ominsky, Michael S.] Radius Hlth Inc, Waltham, MA 02451 USA.
   [Rijntjes, Eddy; Koehrle, Josef] Charite, Inst Expt Endokrinol, D 10117 Berlin, Germany.
   [Misof, Barbara M.; Roschger, Paul; Klaushofer, Klaus] Hanusch Hosp WGKK, Ludwig Boltzmann Inst Osteol, A 1140 Vienna, Austria.
   [Misof, Barbara M.; Roschger, Paul; Klaushofer, Klaus] Hanusch Hosp, Trauma Ctr Meidling AUVA, Med Dept 1, A 1140 Vienna, Austria.
   [Hofbauer, Lorenz C.] Ctr Regenerat Therapies Dresden, D 01307 Dresden, Germany.
C3 Technische Universitat Dresden; Technische Universitat Dresden; Radius
   Health, Inc.; Free University of Berlin; Humboldt University of Berlin;
   Charite Universitatsmedizin Berlin; WGKK   Hanusch Hospital; Ludwig
   Boltzmann Institute; Ludwig Boltzmann Institute for Osteology; WGKK  
   Hanusch Hospital; Technische Universitat Dresden
RP Rauner, M (通讯作者)，Tech Univ Dresden, Med Ctr, Div Endocrinol Diabet & Metabol Bone Dis, Dept Med 3, Fetscherstr 74, D 01307 Dresden, Germany.
EM martina.rauner@uniklinikum dresden.de
RI ; Tsourdi, Elena/W 9970 2019; Rauner, Martina/A 1665 2015; Misof,
   Barbara/AAG 5051 2020; Köhrle, Josef/AAH 6438 2020; Hofbauer,
   Lorenz/G 2490 2010; Hofbauer, Lorenz C./G 2490 2010
OI Rijntjes, Eddy/0000 0001 8870 8545; Kohrle, Josef/0000 0002 9187 9078;
   Rauner, Martina/0000 0002 4067 6799; Brinkmann,
   Franziska/0000 0003 1059 5506; Misof, Barbara/0000 0001 9923 4920;
   Hofbauer, Lorenz C./0000 0002 8691 8423
FU MedDrive Starting Grant of Technische Universitat Dresden; Deutsche
   Forschungsgemeinschaft [Sonderforschungsbereich/Transregio 67,
   Schwerpunktprogramm 1629]
FX This work was supported by the MedDrive Starting Grant of Technische
   Universitat Dresden (to E.T.), the Deutsche Forschungsgemeinschaft
   Sonderforschungsbereich/Transregio 67 (to E.T. and L.C.H.), and the
   Deutsche Forschungsgemeinschaft Schwerpunktprogramm 1629 Thyroid Trans
   Act (to L.C.H., J.K., and M.R.).
CR Achiou Z, 2015, BONE, V81, P691, DOI 10.1016/j.bone.2015.09.010
   Allain TJ, 1996, EUR J CLIN INVEST, V26, P418, DOI 10.1046/j.1365 2362.1996.160289.x
   Banovac K, 2000, CALCIFIED TISSUE INT, V67, P460, DOI 10.1007/s002230001171
   Baschant U, 2016, J BONE MINER RES, V31, P1787, DOI 10.1002/jbmr.2988
   Bassett JHD, 2016, ENDOCR REV, V37, P135, DOI 10.1210/er.2015 1106
   Blum MR, 2015, JAMA J AM MED ASSOC, V313, P2055, DOI 10.1001/jama.2015.5161
   Boskey Adele L, 2013, Bonekey Rep, V2, P447, DOI 10.1038/bonekey.2013.181
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brouwers JEM, 2008, CALCIFIED TISSUE INT, V83, P186, DOI 10.1007/s00223 008 9160 3
   Canalis E, 2004, BONE, V34, P593, DOI 10.1016/j.bone.2003.11.026
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Gouveia CH, 2001, J ENDOCRINOL, V170, P667, DOI 10.1677/joe.0.1700667
   Hamann C, 2014, ENDOCRINOLOGY, V155, P1197, DOI 10.1210/en.2013 1960
   Karga H, 2011, ENDOCR J, V58, P969, DOI 10.1507/endocrj.EJ11 0039
   Kiper POS, 2016, NEW ENGL J MED, V374, P2553, DOI 10.1056/NEJMoa1509342
   LAKATOS P, 1991, ACTA ENDOCRINOL COP, V125, P603, DOI 10.1530/acta.0.1250603
   Li XD, 2014, ENDOCRINOLOGY, V155, P4785, DOI 10.1210/en.2013 1905
   Marenzana M, 2011, ARTHRITIS RHEUM US, V63, P2385, DOI 10.1002/art.30385
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Miura M, 2002, J BONE MINER RES, V17, P443, DOI 10.1359/jbmr.2002.17.3.443
   Monfoulet LE, 2011, J BONE MINER RES, V26, P2036, DOI 10.1002/jbmr.432
   MUNDY GR, 1976, J CLIN INVEST, V58, P529, DOI 10.1172/JCI108497
   O'Shea PJ, 2012, J BIOL CHEM, V287, P17812, DOI 10.1074/jbc.M111.311464
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Pereira RC, 1999, AM J PHYSIOL ENDOC M, V277, pE496, DOI 10.1152/ajpendo.1999.277.3.E496
   Rauner M, 2014, BONE, V64, P281, DOI 10.1016/j.bone.2014.04.022
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Roschger A, 2014, BONE, V66, P182, DOI 10.1016/j.bone.2014.06.015
   Roschger P, 2008, BONE, V42, P456, DOI 10.1016/j.bone.2007.10.021
   Roschger P, 2014, CURR OSTEOPOROS REP, V12, P338, DOI 10.1007/s11914 014 0218 z
   Segni M, 1999, THYROID, V9, P871, DOI 10.1089/thy.1999.9.871
   Siddiqi A, 1998, J ENDOCRINOL, V157, P453, DOI 10.1677/joe.0.1570453
   Siddiqi A, 2002, J CLIN ENDOCR METAB, V87, P906, DOI 10.1210/jc.87.2.906
   Skowronska Jozwiak E, 2012, THYROID RES, V5, DOI 10.1186/1756 6614 5 14
   Stevens DA, 2000, J BONE MINER RES, V15, P2431, DOI 10.1359/jbmr.2000.15.12.2431
   Stolina M, 2014, BONE, V67, P305, DOI 10.1016/j.bone.2014.07.031
   Taylor S, 2016, BONE, V84, P148, DOI 10.1016/j.bone.2015.12.013
   Tsourdi E, 2015, ENDOCRINOLOGY, V156, P3517, DOI 10.1210/en.2015 1073
   Varga F, 2004, CALCIFIED TISSUE INT, V74, P382, DOI 10.1007/s00223 003 0033 5
   Vestergaard P, 2003, THYROID, V13, P585, DOI 10.1089/105072503322238854
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Williams GR, 2013, EUR THYROID J, V2, P3, DOI 10.1159/000345548
   Yao W, 2016, OSTEOPOROSIS INT, V27, P283, DOI 10.1007/s00198 015 3308 6
   Zhang QH, 2013, MOL MED REP, V8, P1195, DOI 10.3892/mmr.2013.1630
NR 47
TC 19
Z9 20
U1 1
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD NOV
PY 2017
VL 158
IS 11
BP 3765
EP 3777
DI 10.1210/en.2017 00247
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FL6AN
UT WOS:000414327700008
PM 28973221
OA Bronze
DA 2025 08 17
ER

PT J
AU Foreman, MA
   Gu, YC
   Howl, JD
   Jones, S
   Publicover, SJ
AF Foreman, MA
   Gu, YC
   Howl, JD
   Jones, S
   Publicover, SJ
TI Group III metabotropic glutamate receptor activation inhibits
   Ca<SUP>2+</SUP> influx and nitric oxide synthase activity in bone marrow
   stromal cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID OSTEOBLAST LIKE CELLS; PRIMARY RAT OSTEOBLASTS; PHARMACOLOGICAL
   CHARACTERIZATION; PARATHYROID HORMONE; IN VITRO; FUNCTIONAL ROLE;
   EXPRESSION; DIFFERENTIATION; RELEASE; PROSTAGLANDINS
AB Nitric oxide (NO) is pivotal to bone physiology. In the central nervous system constitutive, Ca2+ calmodulin regulated NO synthase activity and glutamate signalling are intimately linked. Since L glutamate signalling occurs in bone and is implicated in bone regulation, we have investigated the effect Of L glutamate on NO synthase in bone derived cells. Treatment of marrow stromal cells with L glutamate reduced basal NO synthase activity by 40%. Imaging showed that L glutamate caused a rapid, usually localised and slowly reversible fall in [Ca2+]. This effect was resistant to disruption of intracellular Ca2+ stores but sensitive to extracellular La3+ or omission of extracellular Ca2+, demonstrating that glutamate acts by inhibition of membrane Ca2+ influx. The only previous description Of Such an effect Of L glutamate is via activation of the group 111 receptor, mGluR6, in the retina. Using Western blotting and RT PCR we detected mGIuR6 protein and transcripts in marrow stromal cells. The effects Of L glutamate on NOS activity and [Ca2+] in marrow stromal cells were abolished by a group III mGIuR inhibitor, (S) 2 amino 2 methyl 4 phosphonobutyric acid. Recording of membrane potential showed that, similarly to the effects of retinal mGIuR6 activation, L glutamate induced membrane hyperpolarisation ( 16 +/  2 mV), which was also sensitive to group III mGIuR inhibition. L glutamate had no effect on cAMP levels. We conclude that activation of a group III mGIuR in bone marrow stromal cells inhibits a Ca2+ permeable plasma membrane channel, reducing [Ca2+](i) and suppressing generation of NO. These observations directly link bone L glutamate signalling to processes central to bone growth and regulation. (c) 2005 Wiley Liss, Inc.
C1 Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.
   Univ Cambridge, Dept Anat, Cambridge, England.
   Wolverhampton Univ, RIHS, Mol Pharmacol Grp, Wolverhampton, England.
C3 University of Birmingham; University of Cambridge; University of
   Wolverhampton
RP Publicover, SJ (通讯作者)，Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.
EM s.j.publicover@bham.ac.uk
RI Publicover, Steve/E 7970 2018
OI gu, yuchun/0000 0002 7558 0447; Howl, John/0000 0001 9341 3717; Foreman,
   Megan Anne/0009 0000 9019 9858; Jones, Sarah/0000 0003 4951 8647
CR Afzal F, 2004, J PATHOL, V202, P503, DOI 10.1002/path.1536
   Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   BERESFORD JN, 1998, MARROW STROMAL CELL, P26
   Bhangu PS, 2001, BONE, V29, P16, DOI 10.1016/S8756 3282(01)00482 3
   Bianchi G, 2001, WOUND REPAIR REGEN, V9, P460, DOI 10.1046/j.1524 475x.2001.00460.x
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   BIDWELL JP, 1991, ENDOCRINOLOGY, V129, P2993, DOI 10.1210/endo 129 6 2993
   Birch MA, 1997, J BONE MINER RES, V12, pO10
   BIZZARRI C, 1994, ENDOCRINOLOGY, V134, P133, DOI 10.1210/en.134.1.133
   Brenman JE, 1997, CURR OPIN NEUROBIOL, V7, P374, DOI 10.1016/S0959 4388(97)80065 7
   Brown J, 2000, LAB INVEST, V80, P37, DOI 10.1038/labinvest.3780006
   Chambers TJ, 1999, OSTEOARTHR CARTILAGE, V7, P422, DOI 10.1053/joca.1998.0231
   Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756 3282(97)00295 0
   Chow JWM, 1998, J BONE MINER RES, V13, P1039, DOI 10.1359/jbmr.1998.13.6.1039
   Fleming I, 2003, AM J PHYSIOL REG I, V284, pR1, DOI 10.1152/ajpregu.00323.2002
   Fox SW, 1998, BONE, V23, P1, DOI 10.1016/S8756 3282(98)00070 2
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343
   Genever PG, 1999, BLOOD, V93, P2876
   Genever PG, 2001, FASEB J, V15, P1586, DOI 10.1096/fj.00 0594fje
   Ghosh PK, 1997, DEV BRAIN RES, V102, P1, DOI 10.1016/S0165 3806(97)00066 7
   Gronthos S, 1999, J BONE MINER RES, V14, P47, DOI 10.1359/jbmr.1999.14.1.47
   Gu Y, 2002, CALCIFIED TISSUE INT, V70, P194, DOI 10.1007/s00223 001 2004 z
   Gu YC, 2000, J BIOL CHEM, V275, P34252, DOI 10.1074/jbc.M004520200
   Helfrich MH, 1997, J BONE MINER RES, V12, P1108, DOI 10.1359/jbmr.1997.12.7.1108
   Hinoi E, 2001, BIOCHEM BIOPH RES CO, V281, P341, DOI 10.1006/bbrc.2001.4355
   Hinoi E, 2003, FASEB J, V17, P1532, DOI 10.1096/fj.02 0820fje
   Hinoi E, 2004, EUR J BIOCHEM, V271, P1, DOI 10.1046/j.1432 1033.2003.03907.x
   Hinoi E, 2002, BIOCHEM BIOPH RES CO, V297, P452, DOI 10.1016/S0006 291X(02)02223 4
   Huggett J, 2000, FEBS LETT, V485, P13, DOI 10.1016/S0014 5793(00)02175 X
   JOLY C, 1995, J NEUROSCI, V15, P3970
   Kane MD, 1998, NEUROSCI LETT, V252, P1, DOI 10.1016/S0304 3940(98)00484 4
   Kiss JP, 2001, TRENDS NEUROSCI, V24, P211, DOI 10.1016/S0166 2236(00)01745 8
   KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822
   KNOPFEL T, 1995, NEUROPHARMACOLOGY, V34, P1099, DOI 10.1016/0028 3908(95)00111 I
   Koyama A, 2000, EUR J PHARMACOL, V391, P225, DOI 10.1016/S0014 2999(00)00100 X
   Laketic Ljubojevic I, 1999, BONE, V25, P631, DOI 10.1016/S8756 3282(99)00224 0
   MacPherson H, 1999, BONE, V24, P179, DOI 10.1016/S8756 3282(98)00173 2
   Mancini L, 2000, BIOCHEM BIOPH RES CO, V274, P477, DOI 10.1006/bbrc.2000.3164
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   Mason Deborah J, 2004, Eur Cell Mater, V7, P12
   Mason DJ, 1997, BONE, V20, P199, DOI 10.1016/S8756 3282(96)00386 9
   Muraglia A, 2000, J CELL SCI, V113, P1161
   NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868
   Nawy S, 2000, J NEUROSCI, V20, P4471, DOI 10.1523/JNEUROSCI.20 12 04471.2000
   NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0
   PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0
   Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756 3282(98)00061 1
   Peet NM, 1999, FASEB J, V13, P2179, DOI 10.1096/fasebj.13.15.2179
   PUBLICOVER SJ, 1994, CALCIFIED TISSUE INT, V54, P125, DOI 10.1007/BF00296063
   RALSTON SH, 1994, ENDOCRINOLOGY, V135, P330, DOI 10.1210/en.135.1.330
   Ralston SH, 1997, BRIT J RHEUMATOL, V36, P831
   RIANCHO JA, 1995, J BONE MINER RES, V10, P439
   SANTI MR, 1994, J NEUROCHEM, V63, P1207
   SIMMONS PJ, 1991, BLOOD, V78, P55
   Skerry TM, 2001, CURR PHARM DESIGN, V7, P737, DOI 10.2174/1381612013397771
   Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165 6147(00)01642 4
   THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186
   Turner CH, 1997, BONE, V21, P487, DOI 10.1016/S8756 3282(97)00202 0
   Valerio A, 1997, NEUROREPORT, V8, P2695, DOI 10.1097/00001756 199708180 00012
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   WILTINK A, 1993, CELL CALCIUM, V14, P591, DOI 10.1016/0143 4160(93)90059 F
   Zaman G, 1999, J BONE MINER RES, V14, P1123, DOI 10.1359/jbmr.1999.14.7.1123
NR 65
TC 29
Z9 37
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD AUG
PY 2005
VL 204
IS 2
BP 704
EP 713
DI 10.1002/jcp.20353
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 941TT
UT WOS:000230237800041
PM 15799084
DA 2025 08 17
ER

PT J
AU Curtis, RC
   Custis, JT
   Ehrhart, NP
   Ehrhart, EJ
   Condon, KW
   Gookin, SE
   Donahue, SW
AF Curtis, Ryan C.
   Custis, James T.
   Ehrhart, Nicole P.
   Ehrhart, E. J.
   Condon, Keith W.
   Gookin, Sara E.
   Donahue, Seth W.
TI Combination Therapy with Zoledronic Acid and Parathyroid Hormone
   Improves Bone Architecture and Strength following a Clinically Relevant
   Dose of Stereotactic Radiation Therapy for the Local Treatment of Canine
   Osteosarcoma in Athymic Rats
SO PLOS ONE
LA English
DT Article
ID APPENDICULAR OSTEOSARCOMA; PALLIATIVE RADIOTHERAPY; POSTMENOPAUSAL
   WOMEN; MINERAL DENSITY; OSTEOPOROSIS; DOGS; TERIPARATIDE; FRACTURE; PTH;
   BISPHOSPHONATES
AB Clinical studies using definitive intent stereotactic radiation therapy (SRT) for the local treatment of canine osteosarcoma (OSA) have shown canine patients achieving similar median survival times as the current standard of care (amputation and adjuvant chemotherapy). Despite this, there remains an unacceptable high risk of pathologic fracture following radiation treatment. Zoledronic acid (ZA) and parathyroid hormone (PTH) are therapeutic candidates for decreasing this fracture risk post irradiation. Due to differing mechanisms, we hypothesized that the combined treatment with ZA and PTH would significantly improve bone healing more than ZA or PTH treatment alone. Using an orthotopic model of canine osteosarcoma in athymic rats, we evaluated bone healing following clinically relevant doses of radiation therapy (12 Gy x 3 fractions, 36 Gy total). Groups included 36 Gy SRT only, 36 Gy SRT plus ZA, 36 Gy SRT plus ZA and PTH, 36 Gy SRT plus PTH, and 36 Gy SRT plus localized PTH treatment. Our study showed significant increases in bone volume and increased polar moments of inertia (in the distal femoral metaphysis) 8 weeks after radiation in the combined (ZA/PTH) treatment group as compared to radiation treatment alone. Histomorphometric analysis revealed evidence of active mineralization at the study endpoint as well as successful tumor cell kill across all treatment groups. This work provides further evidence for the expanding potential indications for ZA and PTH therapy, including post irradiated bone disease due to osteosarcoma.
C1 [Curtis, Ryan C.; Ehrhart, E. J.] Colorado State Univ, Coll Vet Med & Biomed Sci, Microbiol Immunol & Pathol Dept, Ft Collins, CO 80523 USA.
   [Custis, James T.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA.
   [Ehrhart, Nicole P.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Clin Sci, Ft Collins, CO 80523 USA.
   [Condon, Keith W.] Indiana Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA.
   [Gookin, Sara E.; Donahue, Seth W.] Colorado State Univ, Dept Mech Engn, Coll Engn, Ft Collins, CO 80523 USA.
C3 Colorado State University System; Colorado State University Fort
   Collins; Colorado State University System; Colorado State University
   Fort Collins; Colorado State University System; Colorado State
   University Fort Collins; Indiana University System; Indiana University
   Bloomington; Colorado State University System; Colorado State University
   Fort Collins
RP Curtis, RC (通讯作者)，Colorado State Univ, Coll Vet Med & Biomed Sci, Microbiol Immunol & Pathol Dept, Ft Collins, CO 80523 USA.; Curtis, RC (通讯作者)，Oklahoma State Univ, Ctr Vet Hlth Sci, 101 McElroy Hall Annex, Stillwater, OK 74078 USA.
EM Ryan.Curtis@okstate.edu
FU Cancer Supercluster Grant from Colorado State University's Flint Animal
   Cancer Center
FX Supported by a Cancer Supercluster Grant from Colorado State
   University's Flint Animal Cancer Center.
CR Alcaraz M, 2013, CLIN TRANSL ONCOL, V15, P300, DOI 10.1007/s12094 012 0917 9
   Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768
   Arrington SA, 2010, CALCIFIED TISSUE INT, V87, P263, DOI 10.1007/s00223 010 9390 z
   Bagi CM, 2006, BONE, V38, P136, DOI 10.1016/j.bone.2005.07.028
   Bielack S, 2008, ANN ONCOL, V19, P94, DOI 10.1093/annonc/mdn102
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Chandra A, 2013, BONE, V55, P449, DOI 10.1016/j.bone.2013.02.023
   Donahue SW, 2006, J EXP BIOL, V209, P1630, DOI 10.1242/jeb.02185
   Fan TM, 2008, J VET INTERN MED, V22, P380, DOI 10.1111/j.1939 1676.2008.0046.x
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Gao Y, 2008, CELL METAB, V8, P132, DOI 10.1016/j.cmet.2008.07.001
   Gasser J. A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P53
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Gray S.K., 2012, Treatment of Osteoporosis in a Mouse Model of Duchenne Muscular Dystrophy Using Black Bear Parathyroid Hormone, P111
   Gray SK, 2012, BONE, V51, P578, DOI 10.1016/j.bone.2012.05.003
   Green EM, 2002, J AM ANIM HOSP ASSOC, V38, P445, DOI 10.5326/0380445
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jing D., 2014, J BONE MINER RES
   Kijima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064615
   Lane AE, 2012, AUST VET J, V90, P69, DOI 10.1111/j.1751 0813.2011.00878.x
   Li YF, 2012, OSTEOPOROSIS INT, V23, P1463, DOI 10.1007/s00198 011 1751 6
   Liptak JM, 2004, COMP CONT EDUC PRACT, V26, P172
   Mayer MN, 2006, CAN VET J, V47, P707
   Mueller F, 2007, ANTICANCER RES, V27, P155
   Mueller F, 2005, IN VIVO, V19, P713
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   O'Donoghue LE, 2011, J VET DIAGN INVEST, V23, P780, DOI 10.1177/1040638711408064
   POWERS BE, 1991, CANCER, V67, P126, DOI 10.1002/1097 0142(19910101)67:1<126::AID CNCR2820670123>3.0.CO;2 7
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Ramirez O III, 1999, VET RADIOL ULTRASOUN, V40, P517, DOI 10.1111/j.1740 8261.1999.tb00385.x
   Recker RR, 2009, BONE, V44, P113, DOI 10.1016/j.bone.2008.09.019
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Samadfam R, 2007, ENDOCRINOLOGY, V148, P2778, DOI 10.1210/en.2006 1475
   Schwartz AL, 2013, AM J VET RES, V74, P452, DOI 10.2460/ajvr.74.3.452
   Spugnini EP, 2009, J SMALL ANIM PRACT, V50, P44, DOI 10.1111/j.1748 5827.2008.00635.x
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Vegger J.B., 2014, Bone
   Walter C U, 2005, Vet Comp Oncol, V3, P1, DOI 10.1111/j.1476 5810.2005.00062.x
NR 41
TC 8
Z9 8
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 22
PY 2016
VL 11
IS 6
AR e0158005
DI 10.1371/journal.pone.0158005
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DP0WX
UT WOS:000378212800066
PM 27332712
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Sato, T
   Takakura, A
   Lee, JW
   Tokunaga, K
   Matsumori, H
   Takao Kawabata, R
   Iimura, T
AF Sato, Takanori
   Takakura, Aya
   Lee, Ji Won
   Tokunaga, Kazuaki
   Matsumori, Haruka
   Takao Kawabata, Ryoko
   Iimura, Tadahiro
TI A quantitative analysis of bone lamellarity and bone collagen linearity
   induced by distinct dosing and frequencies of teriparatide
   administration in ovariectomized rats and monkeys
SO MICROSCOPY
LA English
DT Article
DE bone lamellarity; collagen linearity; multi photon microscopy; SHG
   (second harmonic generation); semi automatic recognition; teriparatide
ID PARATHYROID HORMONE; MECHANICAL PROPERTIES; ARCHITECTURE; FRACTURE;
   MATRIX
AB The lamellar structure of bone, which endows biomechanical rigidity to support the host organism, is observed in mammals, including humans. It is therefore essential to develop a quantitative analysis to evaluate the lamellarity of bone, which would especially be useful for the pharmacological evaluation of anti osteoporotic drugs. This study applied a current system for the semi automatic recognition of fluorescence signals to the analysis of un decalcified bone sections from rat and monkey specimens treated with teriparatide (TPTD). Our analyses on bone formation pattern and collagen topology indicated that TPTD augmented bone lamellarity and bone collagen linearity, which were possibly associated with the recovery of collagen cross linking, thus endowing bone rigidity.
C1 [Sato, Takanori; Takakura, Aya; Lee, Ji Won; Iimura, Tadahiro] Hokkaido Univ, Fac & Grad Sch Dent Med, Dept Pharmacol, N13 W7, Sapporo, Hokkaido 0608586, Japan.
   [Takakura, Aya; Takao Kawabata, Ryoko] Asahi Kasei Pharma Corp, Pharmaceut Res Ctr, 632 1 Mifuku, Shizuoka 4102321, Japan.
   [Tokunaga, Kazuaki; Matsumori, Haruka] Nikon Inc, Minato Ku, 2 15 3 Konan, Tokyo 1086290, Japan.
C3 Hokkaido University; Asahi Kasei Pharma Corporation; Nikon Corporation
RP Takakura, A; Iimura, T (通讯作者)，Hokkaido Univ, Fac & Grad Sch Dent Med, Dept Pharmacol, N13 W7, Sapporo, Hokkaido 0608586, Japan.; Takakura, A; Takao Kawabata, R (通讯作者)，Asahi Kasei Pharma Corp, Pharmaceut Res Ctr, 632 1 Mifuku, Shizuoka 4102321, Japan.
EM shimomura.ac@om.asahi kasei.co.jp; takao.rb@om.asahi kasei.co.jp;
   iimura@den.hokudai.ac.jp
RI Takao Kawabata, Ryoko/AGF 7646 2022; Lee, Ji Won/M 8265 2016; Iimura,
   Tadahiro/P 3550 2018
OI Iimura, Tadahiro/0000 0002 1431 0689
FU Japan Society for the Promotion of Science (JSPS KAKENHI) [18H02983,
   18K19649]; Japan Society for the Promotion of Science [19K10044]; Takeda
   Science Foundation; Grants in Aid for Scientific Research [19K10044,
   18H02983, 18K19649] Funding Source: KAKEN
FX This work was partly supported by Grant in Aids for Scientific Research
   from the Japan Society for the Promotion of Science (JSPS KAKENHI) grant
   numbers 18H02983 and 18K19649 to T.I. J.W.L. was supported by
   Grant in Aids for Scientific Research from the Japan Society for the
   Promotion of Science (19K10044) and a grant from Takeda Science
   Foundation.
CR Bonewald Lynda F., 2009, P277
   Bromage TG, 2009, CALCIFIED TISSUE INT, V84, P388, DOI 10.1007/s00223 009 9221 2
   Buehler MJ, 2008, J MECH BEHAV BIOMED, V1, P59, DOI 10.1016/j.jmbbm.2007.04.001
   Chou SH, 2016, J CLIN DENSITOM, V19, P48, DOI 10.1016/j.jocd.2015.08.005
   Cicchi R, 2013, J BIOPHOTONICS, V6, P129, DOI 10.1002/jbio.201200092
   Cosman F, 2017, J BONE MINER RES, V32, P198, DOI 10.1002/jbmr.3051
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Depalle B, 2015, J MECH BEHAV BIOMED, V52, P1, DOI 10.1016/j.jmbbm.2014.07.008
   Glinkowski WM, 2017, EUR J RADIOL, V94, P195, DOI 10.1016/j.ejrad.2017.06.027
   Gorski JP, 1998, CRIT REV ORAL BIOL M, V9, P201, DOI 10.1177/10454411980090020401
   Hamed E, 2013, J MECH BEHAV BIOMED, V28, P94, DOI 10.1016/j.jmbbm.2013.05.025
   Hamed E, 2012, J R SOC INTERFACE, V9, P1654, DOI 10.1098/rsif.2011.0814
   KIMMEL DB, 1980, CALCIFIED TISSUE INT, V32, P113, DOI 10.1007/BF02408530
   Kiyomatsu H, 2015, BIOMED OPT EXPRESS, V6, P405, DOI 10.1364/BOE.6.000405
   Kolb C, 2015, PEERJ, V3, DOI 10.7717/peerj.1358
   MAROTTI G, 1993, CALCIFIED TISSUE INT, V53, pS47, DOI 10.1007/BF01673402
   Marotti G, 2013, J MORPHOL, V274, P543, DOI 10.1002/jmor.20114
   McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617
   Moen MD, 2006, DRUGS, V66, P2371, DOI 10.2165/00003495 200666180 00008
   Nakano T, 2014, J BONE MINER METAB, V32, P441, DOI 10.1007/s00774 013 0505 2
   Odin C, 2008, OPT EXPRESS, V16, P16151, DOI 10.1364/OE.16.016151
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pijanka JK, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800376
   Potts JT, 2005, J ENDOCRINOL, V187, P311, DOI 10.1677/joe.1.06057
   Razi H, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115102
   RUBEN JA, 1987, EVOLUTION, V41, P1187, DOI 10.1111/j.1558 5646.1987.tb02460.x
   Sabet FA, 2016, INTERFACE FOCUS, V6, DOI 10.1098/rsfs.2015.0055
   Saito M, 2011, OSTEOPOROSIS INT, V22, P2373, DOI 10.1007/s00198 010 1454 4
   Silva BC, 2011, J ENDOCRINOL INVEST, V34, P801, DOI 10.3275/7925
   Suarez Bregua P, 2017, DEV DYNAM, V246, P992, DOI [10.1002/DVDY.24591, 10.1002/dvdy.24591]
   Suarez Bregua P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186444
   Suarez Bregua P, 2017, FASEB J, V31, P569, DOI 10.1096/fj.201600815R
   Sugimoto T, 2019, OSTEOPOROSIS INT, V30, P2321, DOI 10.1007/s00198 019 05111 6
   Takakura A, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.2
   Wang X, 2008, BONE, V42, P1184, DOI 10.1016/j.bone.2008.01.022
   Weiner S, 1999, J STRUCT BIOL, V126, P241, DOI 10.1006/jsbi.1999.4107
   Willett TL, 2019, BONE, V120, P187, DOI 10.1016/j.bone.2018.10.024
   Wu JP, 2017, J MICROSC OXFORD, V266, P273, DOI 10.1111/jmi.12537
   Yamane H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175329
   Yoshitake S, 2019, CALCIFIED TISSUE INT, V104, P402, DOI 10.1007/s00223 018 0500 7
NR 40
TC 4
Z9 4
U1 1
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2050 5698
EI 2050 5701
J9 MICROSCOPY JPN
JI Microscopy
PD DEC
PY 2021
VL 70
IS 6
BP 498
EP 509
DI 10.1093/jmicro/dfab020
EA JUN 2021
PG 12
WC Microscopy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microscopy
GA YJ4UQ
UT WOS:000744529300003
PM 34100544
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Liang, D
   Ren, H
   Qiu, T
   Shen, GY
   Xie, B
   Wei, QS
   Yao, ZS
   Tang, JJ
   Zhang, ZD
   Jiang, XB
AF Liang, De
   Ren, Hui
   Qiu, Ting
   Shen, Gengyang
   Xie, Bo
   Wei, Qiushi
   Yao, Zhensong
   Tang, Jingjing
   Zhang, Zhida
   Jiang, Xiaobing
TI Extracts from plastrum testudinis reverse glucocorticoid induced spinal
   osteoporosis of rats via targeting osteoblastic and osteoclastic markers
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Glucocorticoid induced osteoporosis; Extracts from plastrum testudinis;
   Prevention; Management; Rat; Mechanism
ID CORTICOSTEROID INDUCED OSTEOPOROSIS; MESENCHYMAL STEM CELLS;
   BONE RESORPTION; OSTEOPROTEGERIN; PROLIFERATION; EXPRESSION; PREVENTION;
   MANAGEMENT; THERAPY; MICE
AB Extracts from plastrum testudinis (PTE), an important traditional Chinese medicine, have been demonstrated promotion of osteoblastic function in vitro. This study aims to investigate the protective effect of PTE on glucocorticoid induced osteoporosis(GIOP) in vivo and analyze therapeutic targets of PTE on GIOP. SD rats were randomly assigned to two experiments: preventive and therapeutic experiments, in which rats respectively received oral PTE at the same time of glucocorticoid injection or after glucocorticoid injection inducing osteoporosis. BMD, microarchitecture, biomechanics, bone metabolism markers and histomorphology were evaluated. mRNA and protein expression of OPG, Runx2, CTSK and MMP9 were examined. Results showed bone quality and bone quantity were significantly elevated by PTE. Histomorphometry showed thicker and denser bone trabecularsand more osteoblasts and less osteoclasts in group of PTE intervention. The mRNA expression of OPG was significantly upregulated whereas expression of CTSK was significantly downregulatedin different groups of PTE intervention. Stronger immunostaining for Runx2 and weaker immunostaining for CTSK were observed in groups of PTE intervention. This demonstrated that PTE may reverse GIOP in prevention and management via targeting OPG, Runx2 and CTSK in mRNA and protein levels. (C) 2016 Published by Elsevier Masson SAS.
C1 [Liang, De; Yao, Zhensong; Tang, Jingjing; Jiang, Xiaobing] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Spinal Surg, Guangzhou 510405, Guangdong, Peoples R China.
   [Ren, Hui; Qiu, Ting; Shen, Gengyang; Xie, Bo; Zhang, Zhida] Guangzhou Univ Chinese Med, Sch Clin Med 1, Guangzhou 510405, Guangdong, Peoples R China.
   [Wei, Qiushi] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510405, Guangdong, Peoples R China.
   [Liang, De; Jiang, Xiaobing] Guangzhou Univ Chinese Med, Lab Affiliated Natl Key Discipline Orthopaed & Tr, Guangzhou 510405, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou
   University of Chinese Medicine
RP Jiang, XB (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Spinal Surg, Guangzhou 510405, Guangdong, Peoples R China.; Jiang, XB (通讯作者)，Guangzhou Univ Chinese Med, Lab Affiliated Natl Key Discipline Orthopaed & Tr, Guangzhou 510405, Guangdong, Peoples R China.
EM 513469239@qq.com; renhuispine@163.com; spinedrjxb@sina.com
RI ; Zhida, Zhang/HME 3183 2023
OI Shen, Gengyang/0000 0001 8940 7912; 
FU Natural Science Foundation of China [81503591]; Science and Technology
   projects of Guangdong province [2014A020221021]; Natural Science
   Foundation of Guangdong Province [2014A030310082]; Guangzhou University
   of Chinese Medicine for excellent Young Scholars Project [KAB110133K04];
   Disciplinary Construction fund of Education Department in Guangdong
   Province for Young Researcher Project [2013LYM 0012]; Excellent doctor
   project of the first school of clinic medicine of Guangzhou University
   of Chinese Medicine [YB201501]
FX This study is supported by Natural Science Foundation of China
   [81503591], Science and Technology projects of Guangdong province
   [2014A020221021], Natural Science Foundation of Guangdong Province
   [2014A030310082], a grant from Guangzhou University of Chinese Medicine
   for excellent Young Scholars Project [KAB110133K04] and Disciplinary
   Construction fund of Education Department in Guangdong Province for
   Young Researcher Project [2013LYM 0012]. Excellent doctor project of the
   first school of clinic medicine of Guangzhou University of Chinese
   Medicine[YB201501].
CR Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603
   Chen DF, 2007, CELL PROLIFERAT, V40, P196, DOI 10.1111/j.1365 2184.2007.00431.x
   Feng R., 2013, Int. J. Distrib. Sens. Netw., V9, P1
   Lucinda LMF, 2013, PHYTOTHER RES, V27, P515, DOI 10.1002/ptr.4747
   Garnero P, 2014, BONE, V66, P46, DOI 10.1016/j.bone.2014.05.016
   Grossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295
   Gürgül S, 2008, BONE, V42, P74, DOI 10.1016/j.bone.2007.08.040
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Humphrey EL, 2006, BONE, V38, P652, DOI 10.1016/j.bone.2005.10.004
   Kalpakcioglu BB, 2011, BONE, V48, P1221, DOI 10.1016/j.bone.2011.02.005
   Kostenuik PJ, 2001, CURR PHARM DESIGN, V7, P613, DOI 10.2174/1381612013397807
   Li MH, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0626 6
   Liu H, 2015, BIOMATERIALS, V49, P103, DOI 10.1016/j.biomaterials.2015.01.017
   Logar DB, 2007, J BONE MINER METAB, V25, P219, DOI 10.1007/s00774 007 0753 0
   McGee Lawrence ME, 2014, BONE, V66, P277, DOI 10.1016/j.bone.2014.06.022
   Nawata H, 2005, J BONE MINER METAB, V23, P105, DOI 10.1007/s00774 004 0596 x
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Ren H, 2015, STEROIDS, V102, P65, DOI 10.1016/j.steroids.2015.07.006
   Sambrook PN, 2007, NEW ENGL J MED, V357, P2084, DOI 10.1056/NEJMe0706770
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Suzuki Y, 2014, J BONE MINER METAB, V32, P337, DOI 10.1007/s00774 014 0586 6
   Turner CH, 2002, OSTEOPOROSIS INT, V13, P97, DOI 10.1007/s001980200000
   van Brussel MS, 2009, EXPERT OPIN PHARMACO, V10, P997, DOI [10.1517/14656560902868225 , 10.1517/14656560902868225]
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Wang TT, 2012, CHEM BIOL DRUG DES, V79, P1049, DOI 10.1111/j.1747 0285.2012.01361.x
   Yoon HY, 2012, J BONE MINER METAB, V30, P509, DOI 10.1007/s00774 012 0350 8
   Zheng D, 2012, BONE, V51, P85, DOI 10.1016/j.bone.2012.04.006
NR 27
TC 20
Z9 27
U1 3
U2 24
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD AUG
PY 2016
VL 82
BP 151
EP 160
DI 10.1016/j.biopha.2016.04.068
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DT7PP
UT WOS:000381679000020
PM 27470350
DA 2025 08 17
ER

PT J
AU Berry, SD
   Dufour, AB
   Travison, TG
   Zhu, H
   Yehoshua, A
   Barron, R
   Recknor, C
   Samelson, EJ
AF Berry, S. D.
   Dufour, A. B.
   Travison, T. G.
   Zhu, H.
   Yehoshua, A.
   Barron, R.
   Recknor, C.
   Samelson, E. J.
TI Changes in bone mineral density (BMD): a longitudinal study of
   osteoporosis patients in the real world setting
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE Bone mineral density (BMD); T score target; Osteoporosis; Medications
ID FUNCTIONAL MOTION TEST; POSTMENOPAUSAL WOMEN; FRACTURES; ALENDRONATE;
   THERAPY; DENSITOMETRY; PREVENTION; EFFICACY; SCORES; TRIAL
AB In clinical practice, the frequency of patients achieving improved T scores and the expected change in bone mineral density (BMD) according to osteoporosis drugs is unknown. We found that osteoporosis medications infrequently achieve improved femoral neck T scores over 1.2years. BMD increases were more often seen with IV bisphosphonates and denosumab.
   Purpose: To determine the frequency of osteoporosis patients achieving improvement in T scores and quantify the change in bone mineral density (BMD) over time according to osteoporosis medication use.
   Methods: The study included all patients receiving clinical care at United Osteoporosis Centers, Gainesville, GA, 1995 2015, who had at least two measures of femoral neck BMD (N=1232). We evaluated successive pairs of BMD tests to describe the distribution of transitions between T score categories. Generalized estimating equations were used to estimate %BMD change between successive pairs of BMD tests according to osteoporosis medication, adjusted for age, sex, height, weight, baseline BMD, previous fracture, and follow up time.
   Results: Mean (SD) age was 68 (+/  10) years, and 90% of patients were women. Mean baseline T score was  2.04 (+/  0.85). In total, 1232 patients had 4918 pairs of successive BMD tests, with a mean 1.2years (+/  0.9) between assessments. Frequency of transition to an improved T score category was 41% when prior T score  3.5, and 15% when prior T score  1.99 to  1.50. Most individuals (69%) remained in the same T score category. BMD increased 0.54% (95% CI 0.23 0.85%) with IV bisphosphonates and 1.23% (95% CI 0.56 1.90%) with denosumab, whereas no significant change was seen with oral bisphosphonates, teriparatide, or raloxifene.
   Conclusions: Osteoporosis patients are unlikely to improve femoral neck T scores over 1.2years. Additional studies are needed to determine the optimal time to repeat BMD testing while receiving osteoporosis treatment and to determine whether fracture risk is reduced in patients who achieve target T scores.
C1 [Berry, S. D.; Dufour, A. B.; Travison, T. G.; Zhu, H.; Samelson, E. J.] Hebrew SeniorLife, Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA.
   [Berry, S. D.; Dufour, A. B.; Travison, T. G.; Samelson, E. J.] Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
   [Yehoshua, A.; Barron, R.] amg, Thousand Oaks, CA USA.
   [Recknor, C.] United Osteoporosis Ctr, Gainesville, GA USA.
C3 Harvard University; Harvard University Medical Affiliates; Hebrew
   SeniorLife; Harvard University; Harvard Medical School; Harvard
   University Medical Affiliates; Beth Israel Deaconess Medical Center
RP Berry, SD (通讯作者)，Hebrew SeniorLife, Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA.; Berry, SD (通讯作者)，Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
EM sarahberry@hsl.harvard.edu
OI Travison, Thomas/0000 0002 1030 7175
FU Amgen
FX This work was funded in part by an investigator initiated grant from
   Amgen. Investigators at Amgen did not have access to the data.
CR [Anonymous], 2017, WHAT IS OSTEOPOROSIS
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM., 2015, J BONE MINER RES, V30, pS49
   Burden AM, 2012, OSTEOPOROSIS INT, V23, P1075, DOI 10.1007/s00198 011 1645 7
   Camacho PM, 2016, ENDOCR PRACT, V22, P1, DOI 10.4158/EP161435.GL
   Chapurlat RD, 2005, OSTEOPOROSIS INT, V16, P842, DOI 10.1007/s00198 004 1770 7
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cosman F, 2017, J BONE MINER RES, V32, P198, DOI 10.1002/jbmr.3051
   Cummings SR, 2000, JAMA J AM MED ASSOC, V283, P1318, DOI 10.1001/jama.283.10.1318
   Cummings SR, 2017, J BONE MINER RES, V32, P3, DOI 10.1002/jbmr.3039
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
   Ferrari S, 2014, ACR ARHP ANN M OCT 2
   Fischer S, 2017, OSTEOPOROSIS INT, V28, P2843, DOI 10.1007/s00198 017 4110 4
   Genant HK, 2000, J CLIN DENSITOM, V3, P281, DOI 10.1385/JCD:3:3:281
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   Leslie WD, 2016, OSTEOPOROSIS INT, V27, P203, DOI 10.1007/s00198 015 3259 y
   Leslie WD, 2015, J CLIN ENDOCR METAB, V100, P679, DOI 10.1210/jc.2014 3777
   Lewiecki EM, 2018, OSTEOPOROSIS INT, V29, P717, DOI 10.1007/s00198 017 4345 0
   Lewiecki EM, 2017, CURR OSTEOPOROS REP, V15, P103, DOI 10.1007/s11914 017 0350 7
   MacIntyre NJ, 2014, OSTEOPOROSIS INT, V25, P543, DOI 10.1007/s00198 013 2449 8
   Morden NE, 2014, OSTEOPOROSIS INT, V25, P2307, DOI 10.1007/s00198 014 2725 2
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Orford NR, 2017, CRIT CARE, V21, DOI 10.1186/s13054 017 1657 6
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   Recknor CP, 2013, PHYSIOTHER CAN, V65, P75, DOI 10.3138/ptc.2011 25BH
   Schousboe JT, 2017, J BONE MINER RES, V32, P1783, DOI 10.1002/jbmr.3216
   Schwartz AV, 2010, J BONE MINER RES, V25, P976, DOI 10.1002/jbmr.11
   Wade SW, 2012, BONE, V50, P870, DOI 10.1016/j.bone.2011.12.021
   Wasnich RD, 2000, J CLIN ENDOCR METAB, V85, P231, DOI 10.1210/jc.85.1.231
   Weycker Derek, 2016, Bone Rep, V5, P186, DOI 10.1016/j.bonr.2016.07.005
NR 33
TC 9
Z9 10
U1 0
U2 7
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862 3522
EI 1862 3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD NOV 12
PY 2018
VL 13
IS 1
AR 124
DI 10.1007/s11657 018 0528 3
PG 9
WC Endocrinology & Metabolism; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Orthopedics
GA HA2NB
UT WOS:000450074500002
PM 30421141
DA 2025 08 17
ER

PT J
AU Segar, CE
   Ogle, ME
   Botchwey, EA
AF Segar, Claire E.
   Ogle, Molly E.
   Botchwey, Edward A.
TI Regulation of Angiogenesis and Bone Regeneration with Natural and
   Synthetic Small Molecules
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Angiogenesis; osteogenesis; small molecules; regenerative medicine
ID ENDOTHELIAL GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR; SPHINGOSINE
   1 PHOSPHATE RECEPTOR; PROTEIN COUPLED RECEPTOR; COLONY STIMULATING
   FACTOR; MESENCHYMAL STEM CELLS; BETA TRICALCIUM PHOSPHATE;
   LYSOPHOSPHATIDIC ACID LPA; MESSENGER RNA EXPRESSION; BLOOD VESSEL
   FORMATION
AB Regeneration of bone requires the coordinated processes of angiogenesis and osteogenesis. These repair mechanisms are closely linked through both direct cell cell contact and indirect paracrine signaling among osteoblasts, endothelial cells, and other cell types. The vasculature provides a source of nutrients, oxygen, metabolic substrates, and access for circulating cells that help to support new bone formation. The complexity of the endogenous signaling axis that promotes angiogenesis provides numerous opportunities for therapeutic intervention ranging from progenitor cell mobilization to endothelial proliferation and sprouting. Small molecules are particularly appealing for regenerative medicine applications because many exhibit extended in vivo stability, low cost, and scalable production. Innovative techniques for developing small molecules such as high throughput functional assays and broad spectrum database analysis techniques have led to the development of new compounds and the identification of novel applications of existing drugs. In addition, rapid advances in biomaterials design and synthesis provide platforms to deliver therapeutic small molecules to sites of bone injury. This review presents an overview of current strategies for harnessing endogenous healing mechanisms using small molecules by targeting angiogenesis, osteogenesis, or both.
C1 [Botchwey, Edward A.] Georgia Inst Technol, Atlanta, GA 30322 USA.
   [Botchwey, Edward A.] Emory Univ, Dept Biomed Engn, Atlanta, GA 30322 USA.
C3 University System of Georgia; Georgia Institute of Technology; Emory
   University
RP Botchwey, EA (通讯作者)，Georgia Inst Technol, 315 Ferst Dr,IBB1311, Atlanta, GA 30322 USA.
EM edward.botchwey@bme.gatech.edu
FU NSF [R01DE019935, R01AR056445, NSF0933643]
FX Funding sources: R01DE019935, R01AR056445, NSF0933643, NSF Graduate
   Research Award to Claire Segar.
CR Costa MA, 2011, J CELL PHYSIOL, V226, P1353, DOI 10.1002/jcp.22458
   Ader I, 2009, CANCER RES, V69, P3723, DOI 10.1158/0008 5472.CAN 09 0389
   Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood 2003 02 0460
   Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997
   Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Aronin CEP, 2010, BIOMATERIALS, V31, P6417, DOI 10.1016/j.biomaterials.2010.04.061
   Aronin CEP, 2010, TISSUE ENG PT A, V16, P1801, DOI [10.1089/ten.tea.2009.0539, 10.1089/ten.TEA.2009.0539]
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Blackburn J, 2012, BONE, V50, P756, DOI 10.1016/j.bone.2011.12.002
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Bodine PVN, 2009, BONE, V44, P1063, DOI 10.1016/j.bone.2009.02.013
   Bodine PVN, 2005, J CELL BIOCHEM, V96, P1212, DOI 10.1002/jcb.20599
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534 200206000 00033
   Bowers DT, 2011, TRANSPL P, V43, P3285, DOI 10.1016/j.transproceed.2011.09.008
   Brecht K, 2011, FASEB J, V25, P2408, DOI 10.1096/fj.10 179473
   Brey DM, 2011, BIOTECHNOL BIOENG, V108, P163, DOI 10.1002/bit.22925
   Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248
   Brownlow HC, 2002, INJURY, V33, P145, DOI 10.1016/S0020 1383(01)00153 X
   Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373
   Brunner S, 2008, EXP HEMATOL, V36, P695, DOI 10.1016/j.exphem.2008.01.011
   Butcher RA, 2005, CURR OPIN CHEM BIOL, V9, P25, DOI 10.1016/j.cbpa.2004.10.009
   Butler J, 2004, PROSTAG OTH LIPID M, V73, P29, DOI 10.1016/j.prostaglandins.2003.11.003
   Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575
   Capoccia BJ, 2006, BLOOD, V108, P2438, DOI 10.1182/blood 2006 04 013755
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Chiba K, 1998, J IMMUNOL, V160, P5037
   Chikazu D, 2002, J BONE MINER RES, V17, P1430, DOI 10.1359/jbmr.2002.17.8.1430
   Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753
   Chow A, 2011, J EXP MED, V208, P261, DOI 10.1084/jem.20101688
   Christopher MJ, 2008, J BONE MINER RES, V23, P1765, DOI 10.1359/JBMR.080612
   Christopher MJ, 2011, J EXP MED, V208, P251, DOI 10.1084/jem.20101700
   Clark AN, 2007, CIRC RES, V101, P1130, DOI 10.1161/CIRCRESAHA.107.150110
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200
   Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628
   Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106
   Das A, 2011, TISSUE ENG PART B RE, V17, P403, DOI [10.1089/ten.teb.2011.0190, 10.1089/ten.TEB.2011.0190]
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   DICKSON K, 1994, CLIN ORTHOP RELAT R, P189
   Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152
   Donneys A, 2012, PLAST RECONSTR SURG, V129, P850, DOI 10.1097/PRS.0b013e31824422f2
   Donneys A, 2012, J CRANIOFAC SURG, V23, P328, DOI 10.1097/SCS.0b013e318241db26
   Doorn J, 2011, BIOMATERIALS, V32, P6089, DOI 10.1016/j.biomaterials.2011.05.010
   Dragusin M, 2006, FASEB J, V20, P1930, DOI 10.1096/fj.05 5518fje
   DUSSEAU JW, 1986, CIRC RES, V59, P163, DOI 10.1161/01.RES.59.2.163
   Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200
   Ernens I, 2010, BIOCHEM BIOPH RES CO, V392, P351, DOI 10.1016/j.bbrc.2010.01.023
   Fan W, 2010, BIOMATERIALS, V31, P3580, DOI 10.1016/j.biomaterials.2010.01.083
   Feoktistov I, 2003, CIRC RES, V92, P485, DOI 10.1161/01.RES.0000061572.10929.2D
   Feoktistov I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FORM DM, 1983, P SOC EXP BIOL MED, V172, P214
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Fredholm BB, 2010, EXP CELL RES, V316, P1284, DOI 10.1016/j.yexcr.2010.02.004
   Gelse K, 2011, ARTHRITIS RHEUM US, V63, P871, DOI 10.1002/art.30153
   Gennero I, 2011, BONE, V49, P395, DOI 10.1016/j.bone.2011.04.018
   Gidley J, 2006, PROSTAG OTH LIPID M, V80, P46, DOI 10.1016/j.prostaglandins.2006.04.001
   Golan K, 2012, BLOOD, V119, P2478, DOI 10.1182/blood 2011 06 358614
   Golfier S, 2010, FASEB J, V24, P4701, DOI 10.1096/fj.09 141473
   Grey A, 2002, ENDOCRINOLOGY, V143, P4755, DOI 10.1210/en.2002 220347
   Grey A, 2001, ENDOCRINOLOGY, V142, P1098, DOI 10.1210/en.142.3.1098
   Gwak J, 2012, CELL RES, V22, P237, DOI 10.1038/cr.2011.127
   Hait NC, 2006, BBA BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Han Y, 2010, STEM CELLS, V28, P799, DOI 10.1002/stem.316
   HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258
   Haralson RH, 2009, JAMA J AM MED ASSOC, V302, P1586, DOI 10.1001/jama.2009.1489
   Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471 4906(01)02154 8
   Hart ML, 2011, J IMMUNOL, V186, P4367, DOI 10.4049/jimmunol.0903617
   Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003
   Herr B, 2009, BLOOD, V114, P2140, DOI 10.1182/blood 2009 01 201889
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Ho MH, 2011, J ORTHOP RES, V29, P1504, DOI 10.1002/jor.21421
   Hoang MV, 2011, BLOOD, V117, P1751, DOI 10.1182/blood 2010 05 286831
   Hoggatt J, 2009, BLOOD, V113, P5444, DOI 10.1182/blood 2009 01 201335
   Honold J, 2006, ARTERIOSCL THROM VAS, V26, P2238, DOI 10.1161/01.ATV.0000240248.55172.dd
   Huang C, 2012, CELL TISSUE RES, V347, P553, DOI 10.1007/s00441 011 1217 3
   Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100
   Ikeda Y, 2011, ATHEROSCLEROSIS, V215, P339, DOI 10.1016/j.atherosclerosis.2011.01.009
   Inoki I, 2006, BIOCHEM BIOPH RES CO, V346, P293, DOI 10.1016/j.bbrc.2006.05.119
   Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200
   Ishii M, 2010, J EXP MED, V207, P2793, DOI 10.1084/jem.20101474
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Jaeblon T, 2010, J AM ACAD ORTHOP SUR, V18, P297, DOI 10.5435/00124635 201005000 00006
   Jaillard C, 2005, J NEUROSCI, V25, P1459, DOI 10.1523/JNEUROSCI.4645 04.2005
   Jiang BH, 1996, AM J PHYSIOL CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172
   Juarez JG, 2012, BLOOD, V119, P707, DOI 10.1182/blood 2011 04 348904
   Jujo K, 2010, P NATL ACAD SCI USA, V107, P11008, DOI 10.1073/pnas.0914248107
   Kamolratanakul P, 2011, ARTHRITIS RHEUM US, V63, P1021, DOI 10.1002/art.30151
   Kara FM, 2010, FASEB J, V24, P2325, DOI 10.1096/fj.09 147447
   Kasten P, 2003, BIOMATERIALS, V24, P2593, DOI 10.1016/S0142 9612(03)00062 0
   Kato N, 2007, J CELL BIOCHEM, V101, P1063, DOI 10.1002/jcb.21160
   Keila S, 2001, J ENDOCRINOL, V168, P131, DOI 10.1677/joe.0.1680131
   Kim HK, 2006, BLOOD, V108, P812, DOI 10.1182/blood 2005 10 4162
   Kimura T, 2004, BLOOD, V103, P4478, DOI 10.1182/blood 2003 03 0875
   Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264 6021:3480071
   Kimura T, 2011, CARDIOVASC RES, V92, P149, DOI 10.1093/cvr/cvr154
   Kitaori T, 2009, ARTHRITIS RHEUM US, V60, P813, DOI 10.1002/art.24330
   Kluk MJ, 2001, CIRC RES, V89, P496, DOI 10.1161/hh1801.096338
   Knowles HJ, 2010, FASEB J, V24, P4648, DOI 10.1096/fj.10 162230
   Kobayashi Y, 2005, J BIOL CHEM, V280, P11395, DOI 10.1074/jbc.M411189200
   Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200
   Kono M, 2007, J BIOL CHEM, V282, P10690, DOI 10.1074/jbc.M700370200
   Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253
   Kovarik JM, 2004, BRIT J CLIN PHARMACO, V57, P586, DOI 10.1111/j.1365 2125.2003.02065.x
   Kubota T, 2008, J BONE MINER RES, V23, P1661, DOI 10.1359/JBMR.080512
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Kumar S, 2012, BONE, V50, P1012, DOI 10.1016/j.bone.2012.01.027
   Lapierre DM, 2010, J BIOL CHEM, V285, P25792, DOI 10.1074/jbc.M110.109322
   Lee K, 2011, J R SOC INTERFACE, V8, P153, DOI 10.1098/rsif.2010.0223
   Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272
   Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092 8674(00)81661 X
   Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097 2765(01)00324 0
   Leger AJ, 2010, J BONE MINER METAB, V28, P510, DOI 10.1007/s00774 010 0171 6
   Leibovich SJ, 2002, AM J PATHOL, V160, P2231, DOI 10.1016/S0002 9440(10)61170 4
   Lichterfeld M, 2000, BRIT J HAEMATOL, V110, P71, DOI 10.1046/j.1365 2141.2000.02130.x
   Lin CI, 2008, CELL SIGNAL, V20, P1804, DOI 10.1016/j.cellsig.2008.06.008
   Liu FL, 2000, BLOOD, V95, P3025, DOI 10.1182/blood.V95.10.3025.010k32_3025_3031
   Liu GW, 2010, NAT IMMUNOL, V11, P1047, DOI 10.1038/ni.1939
   Liu JB, 2011, INJURY, V42, P742, DOI 10.1016/j.injury.2010.08.028
   Liu LZ, 2012, BONE, V51, P633, DOI 10.1016/j.bone.2012.06.010
   Liu YB, 2010, J CELL BIOCHEM, V109, P794, DOI 10.1002/jcb.22471
   Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905
   Liu Z, 2009, J CELL SCI, V122, P3294, DOI 10.1242/jcs.048942
   Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131
   Lo KWH, 2012, J TISSUE ENG REGEN M, V6, P40, DOI 10.1002/term.395
   Lü JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15
   Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36
   MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953 816x.2001.01634.x
   Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002 220682
   Malek RL, 2001, J BIOL CHEM, V276, P5692, DOI 10.1074/jbc.M003964200
   Mansell JP, 2012, BIOCH BIOPHYSICA ACT
   Marsell R, 2012, BONE, V50, P619, DOI 10.1016/j.bone.2011.11.007
   Masiello LM, 2006, BONE, V39, P72, DOI 10.1016/j.bone.2005.12.013
   Mayr Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756 3282(01)00690 1
   McLaughlin SW, 2012, J MAT SCI MAT MED
   Mediero A, 2012, AM J PATHOL, V180, P775, DOI 10.1016/j.ajpath.2011.10.017
   Michaud MD, 2009, ARTERIOSCL THROM VAS, V29, P902, DOI 10.1161/ATVBAHA.109.185280
   MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240
   Montesinos MC, 2004, AM J PATHOL, V164, P1887, DOI 10.1016/S0002 9440(10)63749 2
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nakagawa K, 2007, BONE, V41, P543, DOI 10.1016/j.bone.2007.06.013
   Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014 5793(00)01520 9
   Namkoong S, 2005, EXP MOL MED, V37, P588, DOI 10.1038/emm.2005.72
   Neal RA, 2009, TISSUE ENG PART C ME, V15, P11, DOI 10.1089/ten.tec.2007.0366
   Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293
   Niida S, 2005, P NATL ACAD SCI USA, V102, P14016, DOI 10.1073/pnas.0503544102
   Nyan M, 2010, J BIOMED MATER RES B, V93B, P65, DOI 10.1002/jbm.b.31559
   OHGUSHI H, 1990, J BIOMED MATER RES, V24, P1563, DOI 10.1002/jbm.820241202
   Ohno T, 2003, TRANSPLANTATION, V76, P869, DOI 10.1097/01.TP.0000074992.49236.58
   Ono K, 2005, J BONE MINER RES, V20, P23, DOI 10.1359/JBMR.041027
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006 291X(02)02671 2
   Oyama O, 2008, CARDIOVASC RES, V78, P301, DOI 10.1093/cvr/cvn002
   Özec I, 2007, J CRANIOFAC SURG, V18, P546
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Pelletier JC, 2009, J MED CHEM, V52, P6962, DOI 10.1021/jm9014197
   Peters A, 2009, TISSUE ENG PART B RE, V15, P225, DOI [10.1089/ten.teb.2009.0049, 10.1089/ten.TEB.2009.0049]
   Priestley GV, 2007, BLOOD, V109, P109, DOI 10.1182/blood 2006 06 026427
   Qi X, 2010, EUR J PHARMACOL, V634, P121, DOI 10.1016/j.ejphar.2010.02.038
   Rankin EB, 2012, CELL, V149, P63, DOI 10.1016/j.cell.2012.01.051
   Rao R, 2007, J BIOL CHEM, V282, P16959, DOI 10.1074/jbc.M701214200
   Ratajczak MZ, 2010, LEUKEMIA, V24, P976, DOI 10.1038/leu.2010.53
   Ren B, 2011, BLOOD, V117, P6036, DOI 10.1182/blood 2010 12 326017
   Rettig MP, 2012, LEUKEMIA, V26, P34, DOI 10.1038/leu.2011.197
   Rezwan K, 2006, BIOMATERIALS, V27, P3413, DOI 10.1016/j.biomaterials.2006.01.039
   Rivera Lopez CM, 2008, ANGIOGENESIS, V11, P301, DOI 10.1007/s10456 008 9113 5
   Rojbani H, 2011, J BIOMED MATER RES A, V98A, P488, DOI 10.1002/jbm.a.33117
   Ruiz Gaspa S, 2007, J CELL BIOCHEM, V101, P1430, DOI 10.1002/jcb.21259
   Ryser MF, 2008, MOL IMMUNOL, V46, P166, DOI 10.1016/j.molimm.2008.07.016
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Ryzhov S, 2007, J PHARMACOL EXP THER, V320, P565, DOI 10.1124/jpet.106.114850
   Saba JD, 2004, CIRC RES, V94, P724, DOI 10.1161/01.RES.0000122383.60368.24
   Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127
   Sato C, 2012, BIOCHEM BIOPH RES CO, V423, P200, DOI 10.1016/j.bbrc.2012.05.130
   Schipani E, 2001, GENE DEV, V15, P2865
   Scott EA, 2010, ACTA BIOMATER, V6, P29, DOI 10.1016/j.actbio.2009.07.009
   Sefcik LS, 2008, BIOMATERIALS, V29, P2869, DOI 10.1016/j.biomaterials.2008.03.017
   Sefcik LS, 2011, TISSUE ENG PT A, V17, P617, DOI 10.1089/ten.TEA.2010.0404
   Semenza GL, 2000, CANCER METAST REV, V19, P59, DOI 10.1023/A:1026544214667
   Semenza GL, 2002, P NATL ACAD SCI USA, V99, P11570, DOI 10.1073/pnas.192442299
   SEMENZA GL, 1994, J BIOL CHEM, V269, P23757
   Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186
   Semenza GL, 2007, J BIOENERG BIOMEMBR, V39, P231, DOI 10.1007/s10863 007 9081 2
   Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood 2004 01 0272
   Shao HW, 2008, STEM CELLS, V26, P1376, DOI 10.1634/stemcells.2007 0785
   Shen X, 2009, J ORTHOP RES, V27, P1298, DOI 10.1002/jor.20886
   Shepherd RM, 2006, BLOOD, V108, P3662, DOI 10.1182/blood 2006 06 030577
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Sims SM, 2013, BBA MOL CELL BIOL L, V1831, P109, DOI 10.1016/j.bbalip.2012.08.001
   Singh P, 2012, LEUKEMIA, V26, P2375, DOI 10.1038/leu.2012.117
   Skoura A, 2011, ARTERIOSCL THROM VAS, V31, P81, DOI 10.1161/ATVBAHA.110.213496
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Subramanian P, 2010, CIRC RES, V107, P96, DOI 10.1161/CIRCRESAHA.109.212647
   Sugama R, 2006, BONE, V38, P206, DOI 10.1016/j.bone.2005.08.006
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337
   Szpalski C, 2012, TISSUE ENG PART B RE, V18, P246, DOI [10.1089/ten.teb.2011.0427, 10.1089/ten.TEB.2011.0427]
   Szpalski C, 2012, J CRANIOFAC SURG, V23, P638, DOI 10.1097/SCS.0b013e31824db8d4
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Take I, 2005, ENDOCRINOLOGY, V146, P5204, DOI 10.1210/en.2005 0451
   Takenaka M, 2003, BIOCHEM BIOPH RES CO, V301, P198, DOI 10.1016/S0006 291X(02)03014 0
   Tanaka M, 2004, BONE, V34, P940, DOI 10.1016/j.bone.2004.01.002
   Tanaka M, 2006, J BIOL CHEM, V281, P25822, DOI 10.1074/jbc.M605142200
   Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200
   Taylor PA, 2012, BIOL BLOOD MARROW TR, V18, P1341, DOI 10.1016/j.bbmt.2012.06.007
   Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200
   Toyoda H, 2005, BONE, V37, P555, DOI 10.1016/j.bone.2005.04.042
   Uchida S, 2003, BONE, V32, P491, DOI 10.1016/S8756 3282(03)00053 X
   van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419 05
   Vandenburgh H, 2010, TISSUE ENG PART B RE, V16, P55, DOI 10.1089/ten.TEB.2009.0445
   Wacker BK, 2006, BIOMACROMOLECULES, V7, P1335, DOI 10.1021/bm050948r
   Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55
   Walter DH, 2007, ARTERIOSCL THROM VAS, V27, P275, DOI 10.1161/01.ATV.0000254669.12675.70
   Wamhoff BR, 2008, ARTERIOSCL THROM VAS, V28, P1454, DOI 10.1161/ATVBAHA.107.159392
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   Wang DS, 1996, J BONE MINER RES, V11, P472
   WANG GL, 1993, BLOOD, V82, P3610
   WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230
   Wang XX, 2011, PLAST RECONSTR SURG, V128, P395, DOI 10.1097/PRS.0b013e31821e6e10
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02 1062fje
   Waters KM, 2007, BONE, V41, P833, DOI 10.1016/j.bone.2007.06.029
   Wieghaus KA, 2008, BIOINFORMATICS, V24, P2384, DOI 10.1093/bioinformatics/btn451
   Winkler IG, 2010, BLOOD, V116, P4815, DOI 10.1182/blood 2009 11 253534
   Wise JK, 2012, TISSUE ENG PT A, V18, P861, DOI [10.1089/ten.tea.2011.0187, 10.1089/ten.TEA.2011.0187]
   Yang D, 2008, P NATL ACAD SCI USA, V105, P792, DOI 10.1073/pnas.0705563105
   Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090 6980(01)00103 4
   Yonezawa T, 2011, BIOCHEM BIOPH RES CO, V409, P260, DOI 10.1016/j.bbrc.2011.05.001
   Yoon DS, 2010, STEM CELLS DEV, V19, P1523, DOI 10.1089/scd.2009.0393
   Yoshii T., 2012, J Tissue Eng Regen Med
   Zaman K, 1999, J NEUROSCI, V19, P9821
   Zelzer E, 2002, DEVELOPMENT, V129, P1893
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhou FF, 2012, PROTEIN CELL, V3, P311, DOI 10.1007/s13238 012 2027 4
NR 240
TC 49
Z9 54
U1 1
U2 66
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381 6128
EI 1873 4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD JUN
PY 2013
VL 19
IS 19
BP 3403
EP 3419
DI 10.2174/1381612811319190007
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 133RN
UT WOS:000318157300007
PM 23432670
DA 2025 08 17
ER

PT J
AU Schmeel, LC
   Schmeel, FC
   Kim, Y
   Endo, T
   Lu, DS
   Schmidt Wolf, IGH
AF Schmeel, Leonard Christopher
   Schmeel, Frederic Carsten
   Kim, Young
   Endo, Tomoyuki
   Lu, Desheng
   Schmidt Wolf, Ingo G. H.
TI Targeting the Wnt/Beta Catenin Pathway in Multiple Myeloma
SO ANTICANCER RESEARCH
LA English
DT Article
DE Myeloma; Wnt pathway; Wnt inhibitors; beta catenin; signaling therapies;
   MPC 11; OPM 2; RPMI 8226; U 266 cell lines
ID IN VIVO EFFICACY; ETHACRYNIC ACID; BETA CATENIN; BONE MARROW;
   PICEATANNOL; INHIBITION; CELLS; PROLIFERATION; PROGRESSION; ACTIVATION
AB Background/Aim: Recent investigations have shown that the Wnt signaling pathway is constitutively activated in multiple myeloma (MM), thereby promoting an exaggerated cell proliferation. Thus, influencing the Wnt pathway might represent a promising target in myeloma treatment. Materials and Methods: The present study investigated whether a combination of ethacrynic acid (EA) and ciclopirox olamine (CIC) with piceatannol (PIC) would influence the Wnt pathway and viability of human and murine myeloma cell lines by using DiOC(6) and propidium iodide (PI) staining, flow cytometry and immunoblotting. Results: The combination of EA with PIC as well as the combination of CIC with PIC had a significant additive effect on the vitality of myeloma cells compared to single agent application, while healthy cells remained mainly unaffected. Additionally, EA and CIC altered the expression of beta catenin itself and its downstream factors. Conclusion: A combination of Wnt inhibitors could lead to novel treatment options for MM patients.
C1 [Schmeel, Leonard Christopher; Schmeel, Frederic Carsten; Kim, Young; Schmidt Wolf, Ingo G. H.] Univ Hosp Bonn, Ctr Integrated Oncol, Dept Internal Med 3, D 53105 Bonn, Germany.
   [Endo, Tomoyuki] Univ Grad Sch Med, Dept Hematol, Sapporo, Hokkaido, Japan.
   [Lu, Desheng] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
C3 University of Bonn; University of California System; University of
   California San Diego
RP Schmidt Wolf, IGH (通讯作者)，Univ Hosp Bonn, Ctr Integrated Oncol, Dept Internal Med 3, Sigmund Freud Str 25, D 53105 Bonn, Germany.
EM Ingo.Schmidt Wolf@ukb.uni bonn.de
RI ; Lu, Deheng/AAK 5216 2020
OI Schmeel, Frederic/0000 0003 0985 1517; Schmeel,
   Christopher/0000 0002 3901 4122; Lu, Desheng/0000 0002 0314 5649; 
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Aizawa S, 2003, CANCER SCI, V94, P886, DOI 10.1111/j.1349 7006.2003.tb01371.x
   Alas S, 2003, CLIN CANCER RES, V9, P316
   [Anonymous], ISRN UROL
   Ashihara E, 2009, CLIN CANCER RES, V15, P2731, DOI 10.1158/1078 0432.CCR 08 1350
   Belenky P, 2013, CELL REP, V3, P350, DOI 10.1016/j.celrep.2012.12.021
   Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Coombs GS, 2012, ONCOGENE, V31, P213, DOI 10.1038/onc.2011.228
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   Dutta Simmons J, 2009, BLOOD, V114, P2699, DOI 10.1182/blood 2008 12 194290
   Eberhard Y, 2009, BLOOD, V114, P3064, DOI 10.1182/blood 2009 03 209965
   Fowler JA, 2012, CANCER RES, V72, P2183, DOI 10.1158/0008 5472.CAN 11 2067
   Han YS, 2005, SHOCK, V23, P45, DOI 10.1097/01.shk.0000150629.53699.3f
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Howlader N., 2013, SEER CANC STAT REV
   Kim EJ, 2009, J MED FOOD, V12, P943, DOI 10.1089/jmf.2008.1341
   Kim Y, 2012, LEUKEMIA RES, V36, P598, DOI 10.1016/j.leukres.2012.01.025
   Kim Y, 2011, IN VIVO, V25, P887
   Ko HS, 2012, J AGR FOOD CHEM, V60, P4083, DOI 10.1021/jf205171g
   Kocemba KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030359
   Lu DS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008294
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Polakis P, 2000, GENE DEV, V14, P1837
   Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239
   Schmidt M, 2011, IN VIVO, V25, P325
   Siegel R, 2012, CA CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Song SJ, 2011, J MECH SCI TECHNOL, V25, P3
   Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104
   Takada Y, 2004, J IMMUNOL, V173, P1066, DOI 10.4049/jimmunol.173.2.1066
   TEW KD, 1988, CANCER RES, V48, P3622
   Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006
   Wolter F, 2002, J NUTR, V132, P298
   Zhou HY, 2010, INT J CANCER, V127, P2467, DOI 10.1002/ijc.25255
NR 36
TC 44
Z9 47
U1 0
U2 8
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD NOV
PY 2013
VL 33
IS 11
BP 4719
EP 4726
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 257CW
UT WOS:000327362200005
PM 24222106
DA 2025 08 17
ER

PT J
AU McGee Lawrence, ME
   Pierce, JL
   Yu, KL
   Culpepper, NR
   Bradley, EW
   Westendorf, JJ
AF McGee Lawrence, Meghan E.
   Pierce, Jessica L.
   Yu, Kanglun
   Culpepper, Natasha R.
   Bradley, Elizabeth W.
   Westendorf, Jennifer J.
TI Loss of Hdac3 in osteoprogenitors increases bone expression of
   osteoprotegerin, improving systemic insulin sensitivity
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE energy metabolism; histone deacetylase 3; insulin sensitivity; mellitus;
   osteoblast; osteoprotegerin; type 2 diabetes
ID HISTONE DEACETYLASE 3; GLUCOSE METABOLISM; RECEPTOR ACTIVATOR;
   BETA CELL; OSTEOBLASTS; INHIBITION; PROTEIN; ENERGY; MAINTENANCE;
   RESORPTION
AB Type 2 diabetes is an emerging global health epidemic. Foundations for new therapies are arising from understanding interactions between body systems. Bone derived factors that reduce RANKL (receptor activator of NF kappa B ligand) signaling in the liver may prevent insulin resistance and the onset of type 2 diabetes. Here we demonstrate that deletion of the epigenetic regulator, Hdac3, in Osx1 expressing osteoprogenitors prevents insulin resistance induced by high fat diet by increasing serum and skeletal gene expression levels of osteoprotegerin (Opg), a natural inhibitor of RANKL signaling. Removal of one Opg allele in mice lacking Hdac3 in Osx1+ osteoprogenitors increases the insulin resistance of the Hdac3 deficient mice on a high fat diet. Thus, Hdac3 depletion in osteoblasts increases expression of Opg, subsequently preserving insulin sensitivity. The Hdac inhibitor vorinostat also increased Opg transcription and histone acetylation of the Opg locus. These results define a new mechanism by which bone regulates systemic insulin sensitivity.
C1 [McGee Lawrence, Meghan E.; Pierce, Jessica L.; Yu, Kanglun; Culpepper, Natasha R.] Augusta Univ, Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA USA.
   [McGee Lawrence, Meghan E.] Augusta Univ, Dept Orthopaed Surg, Med Coll Georgia, Augusta, GA USA.
   [Bradley, Elizabeth W.; Westendorf, Jennifer J.] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA.
   [Westendorf, Jennifer J.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; Mayo Clinic; Mayo Clinic
RP McGee Lawrence, ME (通讯作者)，Augusta Univ, Med Coll Georgia, Dept Cellular Biol & Anat, Dept Orthopaed Surg, 1120 15th St, Augusta, GA 30912 USA.
EM mmcgeelawrence@augusta.edu
OI Bradley, Elizabeth/0000 0002 8814 5524; McGee Lawrence,
   Meghan/0000 0002 2728 5849
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [AR056950, AR60140]; National Institute of Diabetes and Digestive and
   Kidney Diseases [H412621701, P30DK050456 18]; Mayo Clinic Center for
   Regenerative Medicine; American Diabetes Association [1 16 JDF 062]
FX National Institute of Arthritis and Musculoskeletal and Skin Diseases,
   Grant numbers: AR056950, AR60140; National Institute of Diabetes and
   Digestive and Kidney Diseases, Grant numbers: Subaward H412621701,
   P30DK050456 18; Mayo Clinic Center for Regenerative Medicine; American
   Diabetes Association, Grant number: 1 16 JDF 062
CR Alenghat T, 2008, NATURE, V456, P997, DOI 10.1038/nature07541
   [Anonymous], ASBMR ANNUAL MEETING
   [Anonymous], CURRENT DIABETES REP
   Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359 6446(04)03309 4
   Bock G, 2006, DIABETES, V55, P3536, DOI 10.2337/db06 0319
   Brennan Speranza TC, 2012, J CLIN INVEST, V122, P4172, DOI 10.1172/JCI63377
   Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166
   Carpio LR, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf3273
   Chou DHC, 2012, CHEM BIOL, V19, P669, DOI 10.1016/j.chembiol.2012.05.010
   Clemens TL, 2011, J BONE MINER RES, V26, P677, DOI 10.1002/jbmr.321
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Diabetes Prevention Progam, 2005, DIABETES, V54, P1150
   Dinneen SF, 1998, DIABETES CARE, V21, P1408, DOI 10.2337/diacare.21.9.1408
   Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732
   Farr JN, 2016, BONE, V82, P28, DOI 10.1016/j.bone.2015.07.027
   Farr JN, 2014, J BONE MINER RES, V29, P787, DOI 10.1002/jbmr.2106
   Feng D, 2011, SCIENCE, V331, P1315, DOI 10.1126/science.1198125
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Ferron M, 2014, ARCH BIOCHEM BIOPHYS, V561, P137, DOI 10.1016/j.abb.2014.05.022
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Galmozzi A, 2013, DIABETES, V62, P732, DOI 10.2337/db12 0548
   GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Jia HQ, 2012, NEUROBIOL DIS, V46, P351, DOI 10.1016/j.nbd.2012.01.016
   Kiechl S, 2013, NAT MED, V19, P358, DOI 10.1038/nm.3084
   Knutson SK, 2008, EMBO J, V27, P1017, DOI 10.1038/emboj.2008.51
   Kode A, 2012, J BIOL CHEM, V287, P8757, DOI 10.1074/jbc.M111.282897
   Kondegowda NG, 2015, CELL METAB, V22, P77, DOI 10.1016/j.cmet.2015.05.021
   Lacombe J, 2013, MOL METAB, V2, P498, DOI 10.1016/j.molmet.2013.08.004
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204
   McGee Lawrence ME, 2015, MOL CELL ENDOCRINOL, V410, P42, DOI 10.1016/j.mce.2015.02.001
   McGee Lawrence ME, 2013, J BIOL CHEM, V288, P5291, DOI 10.1074/jbc.M112.414995
   McGee Lawrence ME, 2013, BONE, V52, P296, DOI 10.1016/j.bone.2012.10.015
   McGee Lawrence ME, 2011, BONE, V48, P1117, DOI 10.1016/j.bone.2011.01.007
   Medrikova D, 2012, INT J OBESITY, V36, P262, DOI 10.1038/ijo.2011.87
   Melton LJ, 2008, J BONE MINER RES, V23, P1334, DOI 10.1359/JBMR.080323
   Minami J, 2014, LEUKEMIA, V28, P680, DOI 10.1038/leu.2013.231
   Montgomery RL, 2008, J CLIN INVEST, V118, P3588, DOI 10.1172/JCI35847
   Niu YX, 2015, BMC ENDOCR DISORD, V15, DOI 10.1186/s12902 015 0067 5
   O'Sullivan EP, 2013, METABOLISM, V62, P34, DOI 10.1016/j.metabol.2012.06.005
   Ominsky MS, 2009, J BONE MINER RES, V24, P1234, DOI [10.1359/JBMR.090215, 10.1359/jbmr.090215]
   Passeri E, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/352858
   Pettersson US, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046057
   Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200
   Razidlo DF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011492
   Schwartz AV, 2013, J BONE MINER RES, V28, P1348, DOI 10.1002/jbmr.1865
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Subramaniam M, 2010, BIOCHEM BIOPH RES CO, V392, P72, DOI 10.1016/j.bbrc.2009.12.171
   Sun Z, 2012, NAT MED, V18, P934, DOI 10.1038/nm.2744
   Toffoli B, 2011, MOL CELL ENDOCRINOL, V331, P136, DOI 10.1016/j.mce.2010.08.019
   Wang L, 2015, CALCIFIED TISSUE INT, V96, P129, DOI 10.1007/s00223 014 9945 5
   Wells CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068915
   Wiech NL, 2009, CURR TOP MED CHEM, V9, P257, DOI 10.2174/156802609788085241
   Yoshikawa Y, 2011, J BONE MINER RES, V26, P2012, DOI 10.1002/jbmr.417
NR 55
TC 10
Z9 11
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD APR
PY 2018
VL 233
IS 4
BP 2671
EP 2680
DI 10.1002/jcp.26148
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FR0AL
UT WOS:000418723200001
PM 28840938
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Trotter, TN
   Gibson, JT
   Sherpa, TL
   Gowda, PS
   Peker, D
   Yang, Y
AF Trotter, Timothy N.
   Gibson, Justin T.
   Sherpa, Tshering Lama
   Gowda, Pramod S.
   Peker, Deniz
   Yang, Yang
TI Adipocyte Lineage Cells Support Growth and Dissemination of Multiple
   Myeloma in Bone
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID SIGNALING CASCADES; DRUG RESISTANCE; MARROW; INHIBITION; EXPRESSION;
   NICHE; MIGRATION; CANCER; SIZE; MICROENVIRONMENT
AB Multiple myeloma (MM) cells reside in the bone marrow microenvironment and form complicated interactions with nonneoplastic, resident stromal cells. We previously found that aggressive MM cells shift osteoblast progenitors toward adipogenesis. In addition, adipocytes are among the most common cell types in the adult skeleton; both mature adipocytes and preadipocytes serve as endocrine cells that secrete a number of soluble molecules into the microenvironment. Therefore, we used a combination of in vivo and in vitro methods to test the hypothesis that an increase in adipocyte lineage cells feeds back to promote MM progression. The results of this study revealed that bone marrow from patients with MM indeed contains increased preadipocytes and significantly larger mature adipocytes than normal bone marrow. We also found that preadipocytes and mature adipocytes secrete many molecules important for supporting MM cells in the bone marrow and directly recruit MM cells through both monocyte chemotactic protein 1 and stromal cell derived factor 1 alpha. Co culture experiments found that preadipocytes activate Wnt signaling and decrease cleaved caspase 3, whereas mature adipocytes activate ERK signaling in MM cells. Furthermore, mature adipocyte conditioned medium promotes MM growth, whereas co culture with preadipocytes results in enhanced MM cell chemotaxis in vitro and increased tumor growth in bone in vivo. Combined, these data reveal the importance of preadipocytes and mature adipocytes on MM progression and represent a unique target in the bone marrow microenvironment.
C1 [Trotter, Timothy N.; Gibson, Justin T.; Sherpa, Tshering Lama; Gowda, Pramod S.; Peker, Deniz; Yang, Yang] Univ Alabama Birmingham, Dept Pathol, WTI 320A,1824 Sixth Ave S, Birmingham, AL 35294 USA.
   [Yang, Yang] Univ Alabama Birmingham, Ctr Comprehens Canc, WTI 320A,1824 Sixth Ave S, Birmingham, AL 35294 USA.
   [Yang, Yang] Univ Alabama Birmingham, Ctr Metab Bone Dis, WTI 320A,1824 Sixth Ave S, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Yang, Y (通讯作者)，Univ Alabama Birmingham, Dept Pathol, WTI 320A,1824 Sixth Ave S, Birmingham, AL 35294 USA.
EM yangyang@uabmc.edu
RI ; Lama Sherpa, Tshering/ABG 5957 2020
OI Gibson, Justin/0000 0003 2967 5338; Lama Sherpa,
   Tshering/0000 0003 2057 1962
FU NIH [R01CA151538]; International Myeloma Foundation Senior Award;
   University of Alabama at Birmingham Center for Metabolic Bone Disease
   pilot grant; Carmichael Scholarship Award
FX Supported by NIH grant R01CA151538 (Y.Y.), an International Myeloma
   Foundation Senior Award (Y.Y.), University of Alabama at Birmingham
   Center for Metabolic Bone Disease pilot grant (Y.Y.), and a Carmichael
   Scholarship Award (T.N.T.).
CR Asosingh K, 2000, Hematol J, V1, P351, DOI 10.1038/sj.thj.6200052
   Broek IV, 2008, CLIN EXP METASTAS, V25, P325, DOI 10.1007/s10585 007 9108 4
   Broek IV, 2004, LEUKEMIA, V18, P976, DOI 10.1038/sj.leu.2403331
   Broek IV, 2003, BRIT J CANCER, V88, P855, DOI 10.1038/sj.bjc.6600833
   Dallas SL, 1999, BLOOD, V93, P1697, DOI 10.1182/blood.V93.5.1697.405a17_1697_1706
   Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630
   de Haart SJ, 2013, CLIN CANCER RES, V19, P5591, DOI 10.1158/1078 0432.CCR 12 3676
   Fischer Posovszky P, 2007, HORM METAB RES, V39, P314, DOI 10.1055/s 2007 976539
   Fujiwara S, 2015, EXP HEMATOL ONCOL, V4, DOI 10.1186/s40164 015 0008 z
   Fulda S, 2015, SEMIN CANCER BIOL, V31, P84, DOI 10.1016/j.semcancer.2014.05.002
   Gao D, 2013, INT J OBESITY, V37, P357, DOI 10.1038/ijo.2012.53
   Ge NL, 2000, BLOOD, V96, P2856
   Gilbert CA, 2013, ANNU REV MED, V64, P45, DOI 10.1146/annurev med 121211 091527
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Hardaway AL, 2014, CANCER METAST REV, V33, P527, DOI 10.1007/s10555 013 9484 y
   Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170
   JACOBSSON B, 1972, J LIPID RES, V13, P651
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kawano Y, 2015, IMMUNOL REV, V263, P160, DOI 10.1111/imr.12233
   Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116
   Lentzsch S, 2004, LEUKEMIA, V18, P1883, DOI 10.1038/sj.leu.2403486
   Tirado Vélez JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046484
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Müller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630
   Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924
   Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492
   Parlee SD, 2014, METHOD ENZYMOL, V537, P93, DOI 10.1016/B978 0 12 411619 1.00006 9
   Parmo Cabañas M, 2004, EXP CELL RES, V294, P571, DOI 10.1016/j.yexcr.2003.12.003
   Pellegrino A, 2005, BRIT J HAEMATOL, V129, P248, DOI 10.1111/j.1365 2141.2005.05443.x
   Purushothaman A, 2008, J BIOL CHEM, V283, P32628, DOI 10.1074/jbc.M806266200
   RADL J, 1979, J IMMUNOL, V122, P609
   Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood 2002 03 0996
   Roccaro AM, 2014, CELL REP, V9, P118, DOI 10.1016/j.celrep.2014.08.042
   Ruan J, 2013, BONE, V57, P10, DOI 10.1016/j.bone.2013.07.024
   Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555 013 9420 1
   Skurk T, 2007, J CLIN ENDOCR METAB, V92, P1023, DOI 10.1210/jc.2006 1055
   Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404
   Tagde A, 2016, BLOOD, V127, P2587, DOI 10.1182/blood 2015 07 659151
   Takeshita S, 2014, J BIOL CHEM, V289, P16699, DOI 10.1074/jbc.M114.547919
   Takeuchi K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009870
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   Toscani D, 2015, ANN NY ACAD SCI, V1335, P45, DOI 10.1111/nyas.12578
   Trotter TN, 2015, BLOOD, V125, P3598, DOI 10.1182/blood 2014 12 613968
   Wang YH, 2006, J NUTR, V136, P2953, DOI 10.1093/jn/136.12.2953
   Wang YH, 2006, MOL CELL BIOL, V26, P5421, DOI 10.1128/MCB.02437 05
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yang Y, 2010, CANCER RES, V70, P8329, DOI 10.1158/0008 5472.CAN 10 2179
NR 48
TC 72
Z9 76
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002 9440
EI 1525 2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD NOV
PY 2016
VL 186
IS 11
BP 3054
EP 3063
DI 10.1016/j.ajpath.2016.07.012
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA EA9TG
UT WOS:000386987000023
PM 27648615
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Zhou, J
   Zhou, FR
   Yang, L
   Liang, HH
   Zhu, QY
   Guo, FH
   Yin, XS
   Li, J
AF Zhou, Jian
   Zhou, Fanru
   Yang, Liu
   Liang, Haihui
   Zhu, Qinyao
   Guo, Fenghua
   Yin, Xiushan
   Li, Jian
TI Original Morinda officinalis saponins promote osteogenic differentiation
   of human umbilical cord derived mesenchymal stem cells via the BMP SMAD
   signaling pathway
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Morinda officinalis saponins; human umbilical cord derived mesenchymal
   stem cells; osteogenic differentiation; RNA sequencing; stem cell
   therapy
ID MARROW STROMAL CELLS; OSTEOBLAST DIFFERENTIATION; TGF BETA;
   PROLIFERATION; EXPRESSION; THERAPY; MODEL
AB Background: Morinda officinalis saponins (MOS), a traditional Chinese medicine extracted from M. officinalis roots, have been used as a health supplement. Existing evidence suggests that extracts from this plant can be used for osteoporosis treatment. However, the molecular mechanisms underlying the anti osteoporotic effects of M. officinalis remain poorly understood. Methods and Results: In this study, we investigated the osteogenesispromoting effects of MOS on human umbilical cord derived mesenchymal stem cells (HUC MSCs). Alkaline phosphatase staining, alizarin red staining, and quantitative reverse transcription PCR demonstrated that MOS promoted the osteogenic differentiation of HUC MSCs in a concentration dependent manner. RNA sequencing results showed that the expression of key osteogenic differentiation related genes, including BMP4, as well as the activity of transforming growth factor beta and calcium signaling pathways increased following MOS treatment. Furthermore, treatment with the bone morphogenetic protein (BMP) antagonist Noggin reversed the MOS induced pro osteogenic differentiation effects and the upregulation of osteoblast specific markers. Conclusions: Overall, the results indicate that MOS can partially promote osteogenic differentiation of HUC MSCs by regulating the BMP SMAD signaling pathway. These findings indicate the potential utility of MOS as a therapeutic agent for osteoporosis, particularly in the context of stem cell therapy.
C1 [Zhou, Jian; Zhou, Fanru; Yang, Liu; Liang, Haihui; Zhu, Qinyao; Yin, Xiushan] Shenyang Univ Chem Technol, Coll Pharmaceut & Biol Engn, Appl Biol Lab, 13 Rd, Shenyang 110142, Peoples R China.
   [Zhou, Jian; Li, Jian] Gannan Med Univ, Coll Pharmaceut Sci, 1 Med Coll Rd, Ganzhou 341000, Peoples R China.
   [Guo, Fenghua] Glabiolus Biotech Xuzhou Co Ltd, Xuzhou 221000, Jiangsu, Peoples R China.
   [Li, Jian] Glabiolus Biotech Jiangxi Co Ltd, Ganzhou 341005, Jiangxi, Peoples R China.
C3 Shenyang University of Chemical Technology; Gannan Medical University
RP Yin, XS (通讯作者)，Shenyang Univ Chem Technol, Coll Pharmaceut & Biol Engn, Appl Biol Lab, 13 Rd, Shenyang 110142, Peoples R China.; Li, J (通讯作者)，Gannan Med Univ, Coll Pharmaceut Sci, 1 Med Coll Rd, Ganzhou 341000, Peoples R China.
EM xiush anyin@me.com; lijian@gmu.edu.cn
RI Guo, Fenghua/KDO 4690 2024
FU Jiangxi Natural Science Foundation for distinguished young scholars
   [20212ACB216001]; Startup Foundation for Advanced Talents [QD201910];
   Jiangxi key research and development program [20203BBG73063]; Jiangxi
   Double Thousand Plan [jxsq2019101064]; Graduate Innovation Special Fund
   project of Jiangxi Education Department [YC2021 S804]; Liaoning
   Revitalization Talents Program [XLYC2002027]; Construction of Liaoning
   technological innovation center [1590826279052]; Scientific Research
   Fund of Education Department of Liaoning Province in 2021 [LJKZ0464];
   Young Scientists Nurturing Program from Department of Education of
   Liaoning Province [LQ2020022]; Central government funds for guiding
   local scientific and Technological Development [2021JH6/10500225]
FX This work was supported by Jiangxi Natural Science Foundation for
   distinguished young scholars (20212ACB216001) , Startup Foundation for
   Advanced Talents (QD201910) , Jiangxi key research and development
   program (20203BBG73063) , Jiangxi Double Thousand Plan (jxsq2019101064)
   , Graduate Innovation Special Fund project of Jiangxi Education
   Department (YC2021 S804) , Liaoning Revitalization Talents Program
   (XLYC2002027) , Construction of Liaoning technological innovation center
   (1590826279052) , Central government funds for guiding local scientific
   and Technological Development (2021JH6/10500225) , Scientific Research
   Fund of Education Department of Liaoning Province in 2021 (LJKZ0464) ,
   and Young Scientists Nurturing Program from Department of Education of
   Liaoning Province (LQ2020022) .
CR Almalki SG, 2016, DIFFERENTIATION, V92, P41, DOI 10.1016/j.diff.2016.02.005
   Barreto AEA, 2021, EUR J PHARMACOL, V911, DOI 10.1016/j.ejphar.2021.174515
   Carlier A, 2011, ACTA BIOMATER, V7, P3573, DOI 10.1016/j.actbio.2011.06.021
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gong ZM, 2018, GENE, V673, P251, DOI 10.1016/j.gene.2018.05.043
   Grafe I, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022202
   Han BL, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5868745
   Harrell CR, 2019, BIOMED PHARMACOTHER, V109, P2318, DOI 10.1016/j.biopha.2018.11.099
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 12
   He SW, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2148 2
   He YQ, 2018, BIOCHEM BIOPH RES CO, V506, P927, DOI 10.1016/j.bbrc.2018.10.100
   Hendrijantini Nike, 2019, Acta Inform Med, V27, P72, DOI 10.5455/aim.2019.27.72 77
   Jiang KM, 2018, INT J BIOL MACROMOL, V120, P170, DOI 10.1016/j.ijbiomac.2018.08.082
   Kokabu S, 2012, MOL ENDOCRINOL, V26, P87, DOI 10.1210/me.2011 1168
   Krause C, 2011, INT J BIOCHEM CELL B, V43, P478, DOI 10.1016/j.biocel.2011.01.007
   Li T, 2015, EXPERT OPIN BIOL TH, V15, P1293, DOI 10.1517/14712598.2015.1051528
   Li ZF, 2021, CNS NEUROSCI THER, V27, P1570, DOI 10.1111/cns.13732
   Liu DD, 2022, J DENT RES, V101, P1227, DOI 10.1177/00220345221093518
   Liu DD, 2013, J CELL BIOCHEM, V114, P1105, DOI 10.1002/jcb.24451
   Liu QC, 2020, CURR MOL MED, V20, P79, DOI 10.2174/1566524019666191007104816
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mei Y, 2013, J CELL BIOCHEM, V114, P1374, DOI 10.1002/jcb.24479
   Minina E, 2001, DEVELOPMENT, V128, P4523
   Oshimori N, 2012, CELL STEM CELL, V11, P751, DOI 10.1016/j.stem.2012.11.001
   Park GC, 2016, STEM CELLS DEV, V25, P1149, DOI 10.1089/scd.2016.0061
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Seeherman HJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar4953
   Seo BI, 2005, PHYTOTHER RES, V19, P231, DOI 10.1002/ptr.1683
   Shu L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01875 5
   Sun Q, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.929510
   Viti F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148173
   Wang C, 2019, BONE JOINT RES, V8, P550, DOI 10.1302/2046 3758.811.BJR 2018 0251.R1
   Wu YB, 2009, MOLECULES, V14, P573, DOI 10.3390/molecules14010573
   Xia TS, 2019, J PHARMACEUT BIOMED, V166, P336, DOI 10.1016/j.jpba.2019.01.019
   Xu JW, 2022, CYTOTECHNOLOGY, V74, P17, DOI 10.1007/s10616 021 00502 2
   Yan CY, 2019, INT J BIOL MACROMOL, V133, P446, DOI 10.1016/j.ijbiomac.2019.04.084
   YANG Y J, 1992, Yaoxue Xuebao, V27, P358
   Zhang DW, 2020, J ETHNOPHARMACOL, V261, DOI 10.1016/j.jep.2020.113113
   Zhang JH, 2018, J ETHNOPHARMACOL, V213, P230, DOI 10.1016/j.jep.2017.10.028
   Zhang LB, 2019, PULM PHARMACOL THER, V54, P39, DOI 10.1016/j.pupt.2018.11.007
   Zhang LH, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10570
   Zhu JY, 2020, FASEB J, V34, P13376, DOI 10.1096/fj.201902546RR
NR 48
TC 2
Z9 2
U1 5
U2 7
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2024
VL 16
IS 10
DI 10.62347/KNRS3234
PG 16
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA W7A3A
UT WOS:001420050400019
PM 39544743
OA Green Published
DA 2025 08 17
ER

PT J
AU Anastasilakis, AD
   Polyzos, SA
   Avramidis, A
   Toulis, KA
   Papatheodorou, A
   Terpos, E
AF Anastasilakis, Athanasios D.
   Polyzos, Stergios A.
   Avramidis, Avraam
   Toulis, Konstantinos A.
   Papatheodorou, Athanasios
   Terpos, Evangelos
TI The effect of teriparatide on serum Dickkopf 1 levels in postmenopausal
   women with established osteoporosis
SO CLINICAL ENDOCRINOLOGY
LA English
DT Article
ID BONE MINERAL DENSITY; PARATHYROID HORMONE; OSTEOBLAST DIFFERENTIATION;
   WNT; EXPRESSION; DKK 1; CELLS; GENE; ANTAGONISTS; SCLEROSTIN
AB Objective Parathyroid hormone increases the differentiation of osteoblast precursors through canonical wingless (Wnt) signalling, resulting in an osteoanabolic effect. We aimed to evaluate serum levels of the Wnt inhibitor Dickkopf 1 (Dkk 1) in postmenopausal women with established osteoporosis and their changes with teriparatide (TPTD human recombinant PTH 1 34).
   Design and patients A total of 31 postmenopausal Caucasian women with established osteoporosis (mean age 66.3 +/  1.4 years) received daily injections of 20 mu g TPTD for 18 months. Follow up was continued for another 6 months after treatment discontinuation (total duration of treatment 24 months).
   Measurements Serum samples for total calcium (Ca), intact PTH (iPTH), bone specific alkaline phosphatase, C terminal cross linking telopeptide of type 1 collagen (CTx) and Dkk 1 were obtained at baseline, and at 6, 18 and 24 months after TPTD initiation. Lumbar spine bone mineral density (BMD) was measured before and after 18 months of TPTD treatment. A total of 16 age and gender matched healthy controls were also analysed at baseline.
   Results Serum Dkk 1 levels at baseline were significantly higher in osteoporotic women compared with that in controls (P < 0 002). Dkk 1 increased significantly during TPTD administration (P < 0 044) and decreased to baseline 6 months after TPTD discontinuation. Dkk 1 change was positively correlated to Ca (r = 0.530, P = 0.004) and negatively correlated to iPTH change (r = 0.398, P = 0.040). There was no correlation between Dkk 1 and BMD changes.
   Conclusions Our data suggest that Dkk 1 levels are increased in women with postmenopausal osteoporosis. TPTD therapy results in further increase of Dkk 1 that may be compensative to TPTD induced enhanced Wnt signalling.
C1 [Anastasilakis, Athanasios D.; Toulis, Konstantinos A.] 424 Gen Mil Hosp, Dept Endocrinol, Thessaloniki, Greece.
   [Polyzos, Stergios A.] Aristotle Univ Thessaloniki, Dept Internal Med 2, Hippokrat Gen Hosp, GR 54006 Thessaloniki, Greece.
   [Avramidis, Avraam] Hippokrateion Hosp, Dept Endocrinol, Thessaloniki, Greece.
   [Papatheodorou, Athanasios; Terpos, Evangelos] 251 Gen AF Hosp, Dept Med Res, Athens, Greece.
C3 Aristotle University of Thessaloniki
RP Anastasilakis, AD (通讯作者)，Soulini 4, Sykies 56625, Greece.
EM anastath@endo.gr
RI ; Toulis, Konstantinos/E 7951 2012; Anastasilakis,
   Athanasios/AAF 7669 2020; Terpos, Evangelos/AAD 3667 2019; Polyzos,
   Stergios/H 2844 2019
OI Polyzos, Stergios/0000 0001 9232 4042; Anastasilakis,
   Athanasios/0000 0002 9624 6296; Terpos, Evangelos/0000 0001 5133 1422; 
CR Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094
   Amantea CM, 2008, J CELL BIOCHEM, V105, P424, DOI 10.1002/jcb.21840
   Anastasilakis AD, 2008, INT J CLIN PRACT, V62, P919, DOI 10.1111/j.1742 1241.2008.01768.x
   Anastasilakis AD, 2008, ENDOCR J, V55, P613, DOI 10.1507/endocrj.K07E 123
   Anastasilakis AD, 2008, EUR J ENDOCRINOL, V158, P411, DOI 10.1530/EJE 07 0528
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bodine PVN, 2007, J CELL PHYSIOL, V210, P352, DOI 10.1002/jcp.20834
   Body JJ, 2002, J CLIN ENDOCR METAB, V87, P4528, DOI 10.1210/jc.2002 020334
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Delmas PD, 2006, BONE, V39, P237, DOI 10.1016/j.bone.2006.02.003
   Dobnig H, 2005, J CLIN ENDOCR METAB, V90, P3970, DOI 10.1210/jc.2003 1703
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lane NE, 2007, ARTHRITIS RHEUM US, V56, P3319, DOI 10.1002/art.22867
   Lee N, 2007, BRIT J CANCER, V97, P1552, DOI 10.1038/sj.bjc.6604069
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Qiang YW, 2008, BONE, V42, P669, DOI 10.1016/j.bone.2007.12.006
   Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Schwaninger R, 2007, AM J PATHOL, V170, P160, DOI 10.2353/ajpath.2007.051276
   Sheikh SS, 2001, J BONE MINER RES, V16, pS368
   Suzuki A, 2008, J CELL BIOCHEM, V104, P304, DOI 10.1002/jcb.21626
   Terpos E, 2007, LEUKEMIA, V21, P1875, DOI 10.1038/sj.leu.2404843
   van Bezooijen RL, 2007, J BONE MINER RES, V22, P19, DOI 10.1359/JBMR.061002
   van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Voorzanger Rousselot N, 2009, CALCIFIED TISSUE INT, V84, P348, DOI 10.1007/s00223 009 9225 y
   Voskaridou E, 2009, HAEMATOL HEMATOL J, V94, P725, DOI [10.3324/haematol.2008.000893, 10.3324/haema tol.2008.000893]
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Wang FS, 2007, BONE, V40, P485, DOI 10.1016/j.bone.2006.09.004
   Withold W, 1996, CLIN CHEM, V42, P210
   Zegels B, 2001, BONE, V28, P108, DOI 10.1016/S8756 3282(00)00410 5
NR 38
TC 46
Z9 53
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0300 0664
EI 1365 2265
J9 CLIN ENDOCRINOL
JI Clin. Endocrinol.
PD JUN
PY 2010
VL 72
IS 6
BP 752
EP 757
DI 10.1111/j.1365 2265.2009.03728.x
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 598VD
UT WOS:000277866200006
PM 19832854
DA 2025 08 17
ER

PT J
AU Vandyke, K
   Dewar, AL
   Diamond, P
   Fitter, S
   Schultz, CG
   Sims, NA
   Zannettino, ACW
AF Vandyke, Kate
   Dewar, Andrea L.
   Diamond, Peter
   Fitter, Stephen
   Schultz, Christopher G.
   Sims, Natalie A.
   Zannettino, Andrew C. W.
TI The Tyrosine Kinase Inhibitor Dasatinib Dysregulates Bone Remodeling
   Through Inhibition of Osteoclasts In Vivo
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE DASATINIB; OSTEOCLASTS; OSTEOBLASTS; BONE RESORPTION; TRABECULAR
   MORPHOMETRY
ID COLONY STIMULATING FACTOR; CHRONIC MYELOID LEUKEMIA; IMATINIB MESYLATE;
   CHRONIC PHASE; C SRC; MICRODAMAGE ACCUMULATION; BIOMECHANICAL
   PROPERTIES; TARGETED DISRUPTION; RECEPTOR BETA; ALTERED BONE
AB Dasatinib is a potent tyrosine kinase inhibitor that is used to treat chronic myeloid leukemia in patients resistant or intolerant to imatinib mesylate. While designed to inhibit Abl and Src kinases, dasatinib shows multitarget effects, including inhibition of the macrophage colony stimulating factor (M CSF) receptor c fms. We have shown previously that dasatinib abrogates osteoclast formation and activity in vitro owing, in part, to its specificity for c fms. In this study we examined whether dasatinib could significantly alter bone volume in a model of physiologic bone turnover. Sprague Dawley rats were administered dasatinib (5 mg/kg/day) or vehicle by gavage or zoledronic acid (ZOL; 100 mu g/kg/6 weeks) subcutaneously. Following 4, 8, and 12 weeks of treatment, serum biochemical, bone morphometric, and histologic analyses were performed. Whole body bone mineral density and tibial cortical thickness where unchanged in the dasatinib  or ZOL treated animals relative to controls. However, micro computed tomographic (mu CT) analysis of cancellous bone at the proximal tibias showed that trabecular volume (BV/TV) and thickness (Tb.Th) were increased in dasatinib treated animals at levels comparable with those of the ZOL treated group. These changes were associated with a decrease in osteoclast numbers (N.Oc/B.Pm) and surface (Oc.S/BS) and decreased serum levels of the osteoclast marker c terminal collagen crosslinks (CTX 1). Mineral apposition rate (MAR), bone formation rate (BFR), and levels of the serum osteoblast markers osteocalcin and N terminal propeptide of type I procollagen (P1NP) were not altered significantly in the dasatinib treated animals relative to controls. These studies show that dasatinib increases trabecular bone volume at least in part by inhibiting osteoclast activity, suggesting that dasatinib therapy may result in dysregulated bone remodeling. (c) 2010 American Society for Bone and Mineral Research.
C1 [Zannettino, Andrew C. W.] Inst Med & Vet Sci, Dept Haematol, Hanson Inst,Myeloma Res Lab,Ctr Canc Biol, Myeloma Res Program,Bone & Canc Res Labs, Adelaide, SA 5000, Australia.
   [Vandyke, Kate; Zannettino, Andrew C. W.] Univ Adelaide, Sch Med, Adelaide, SA, Australia.
   [Schultz, Christopher G.] Royal Adelaide Hosp, Dept Nucl Med, Adelaide, SA 5000, Australia.
   [Sims, Natalie A.] St Vincents Inst, Melbourne, Vic, Australia.
C3 Institute Medical & Veterinary Science Australia; Centre for Cancer
   Biology; Hanson Institute; University of Adelaide; Royal Adelaide
   Hospital; St. Vincent's Institute of Medical Research
RP Zannettino, ACW (通讯作者)，Inst Med & Vet Sci, Dept Haematol, Hanson Inst,Myeloma Res Lab,Ctr Canc Biol, Myeloma Res Program,Bone & Canc Res Labs, GPO Box 14, Adelaide, SA 5000, Australia.
EM andrew.zannettino@imvs.sa.gov.au
RI Sims, Natalie/A 7192 2012; Vandyke, Kate/G 6280 2010
OI Sims, Natalie/0000 0003 1421 8468; Zannettino,
   Andrew/0000 0002 6646 6167; Vandyke, Kate/0000 0002 1033 849X; Fitter,
   Stephen/0000 0003 1663 6807
FU Leukemia and Lymphoma Society
FX We are grateful to Behzad Baradaran and the staff at Veterinary
   Services, IMVS, for their assistance with the animal experiments. We
   wish to thank Lee Anne Griffiths, Francis Lee, Richard Smykla, and Kate
   Church from Bristol Myers Squibb for providing the dasatinib and helpful
   discussions. This work is supported by a grant from the Leukemia and
   Lymphoma Society Translational Research Program (awarded to ACWZ).
CR Bentolila V, 1998, BONE, V23, P275, DOI 10.1016/S8756 3282(98)00104 5
   Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Brownlow N, 2009, LEUKEMIA, V23, P590, DOI 10.1038/leu.2008.237
   Burr DB, 1997, J BONE MINER RES, V12, P6, DOI 10.1359/jbmr.1997.12.1.6
   Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200
   Carpiuc KT, 2007, J CLIN ONCOL, V25
   CECCHINI MG, 1994, DEVELOPMENT, V120, P1357
   Chaudhary LR, 2004, BONE, V34, P402, DOI 10.1016/j.bone.2003.11.014
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood 2004 10 3967
   Fierro F, 2007, CELL PROLIFERAT, V40, P355, DOI 10.1111/j.1365 2184.2007.00438.x
   Fitter S, 2008, BLOOD, V111, P2538, DOI 10.1182/blood 2007 07 104281
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Grey A, 2000, ENDOCRINOLOGY, V141, P2129, DOI 10.1210/en.141.6.2129
   Grey A, 2006, NEW ENGL J MED, V355, P2494, DOI 10.1056/NEJMc062388
   Hochhaus A, 2007, BLOOD, V109, P2303, DOI 10.1182/blood 2006 09 047266
   HOCK JM, 1994, ENDOCRINOLOGY, V134, P1423, DOI 10.1210/en.134.3.1423
   Ikeda S, 2003, BONE, V33, P779, DOI 10.1016/S8756 3282(03)00263 1
   Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790
   Joensuu H, 2006, NEW ENGL J MED, V355, P628
   Jönsson S, 2008, HAEMATOL HEMATOL J, V93, P1101, DOI 10.3324/haematol.12373
   KLEEREKOPER M, 1985, CALCIFIED TISSUE INT, V37, P594, DOI 10.1007/BF02554913
   Komatsubara S, 2003, J BONE MINER RES, V18, P512, DOI 10.1359/jbmr.2003.18.3.512
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   Labrinidis A, 2009, CLIN CANCER RES, V15, P3451, DOI 10.1158/1078 0432.CCR 08 1616
   Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   McNeil PJ, 1997, J HISTOTECHNOL, V20, P307
   Melnick JS, 2006, P NATL ACAD SCI USA, V103, P3153, DOI 10.1073/pnas.0511292103
   MORI S, 1993, BONE, V14, P103, DOI 10.1016/8756 3282(93)90235 3
   O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008 5472.CAN 05 0259
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   O'Sullivan S, 2009, J CLIN ENDOCR METAB, V94, P1131, DOI 10.1210/jc.2008 2324
   Osorio S, 2007, AM J HEMATOL, V82, P394, DOI 10.1002/ajh.20778
   Owen S, 2006, NEW ENGL J MED, V355, P627
   Perilli E, 2006, J MICROSC OXFORD, V222, P124, DOI 10.1111/j.1365 2818.2006.01580.x
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706
   Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Teo JCM, 2007, MAT SCI ENG C BIO S, V27, P333, DOI 10.1016/j.msec.2006.05.003
   Tibullo D, 2009, EXP HEMATOL, V37, P461, DOI 10.1016/j.exphem.2008.12.008
   Tokarski JS, 2006, CANCER RES, V66, P5790, DOI 10.1158/0008 5472.CAN 05 4187
   Tokunaga A, 2008, J BONE MINER RES, V23, P1519, DOI 10.1359/JBMR.080409
   Vanderkerken Karin, 2005, V113, P191, DOI 10.1385/1 59259 916 8:191
   Vandyke K, 2009, LEUKEMIA, V23, P2155, DOI 10.1038/leu.2009.150
   Vandyke K, 2009, LEUKEMIA, V23, P994, DOI 10.1038/leu.2008.356
   VANDYKE K, 2009, BLOOD, DOI DOI 10.1182/BL00D 2009 08 237404
   Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927
   Wihlidal P, 2008, LEUKEMIA RES, V32, P437, DOI 10.1016/j.leukres.2007.07.020
   WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828
   Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301
   Yang MH, 2006, BLOOD, V107, P2262, DOI 10.1182/blood 2005 08 3365
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
NR 58
TC 81
Z9 88
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2010
VL 25
IS 8
BP 1759
EP 1770
DI 10.1002/jbmr.85
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 643UO
UT WOS:000281325000007
PM 20225261
DA 2025 08 17
ER

PT J
AU Li, SY
   Li, Y
   Jiang, ZX
   Hu, C
   Gao, Y
   Zhou, QS
AF Li, Shuyuan
   Li, Yue
   Jiang, Zexin
   Hu, Cheng
   Gao, Ya
   Zhou, Qishi
TI Original Efficacy of total flavonoids of Rhizoma drynariae on the blood
   vessels and the bone graft in the induced membrane
SO PHYTOMEDICINE
LA English
DT Article
DE Total flavonoids of Rhizoma drynariae; Induced membrane; Vessel; Bone
   defect; BMP SMAD pathway
ID MARROW STROMAL CELLS; OSTEOGENIC DIFFERENTIATION; OSTEOBLAST
   DIFFERENTIATION; SKELETAL DEVELOPMENT; STEM CELLS; TGF BETA; NARINGIN;
   EXPRESSION; PROMOTES; PROLIFERATION
AB Background: Total flavonoids of Rhizoma drynariae (TFRD), a Chinese medicine, is widely used in the treatment of orthopedic diseases. However, there are few basic and clinical studies on the effect of TFRD on induced membrane technique (Masquelet technique).Purpose: This trial is to explore effects of TFRD on vascularization of the induced membrane, and mineralization of the bone graft in rats with femoral bone defects.Study design and methods: Forty eight Sprague Dawley rats were randomly divided into high dose group (HTFRD), medium dose group (M TFRD), low dose group (L TFRD) and control group (control). The segmental bone defects were established with 12 rats in per group. The polymethyl methacrylate (PMMA) spacer was implanted into the femoral bone defect of rats in the first stage surgery. About 4 weeks after first stage surgery, induced membranes of 6 rats in each group were selected. The blood vessels and angiogenesis related factors in the induced membrane were analyzed by hematoxylin eosin (HE) and masson staining, western blot, qPCR and immunohistostaining. The remaining rats in per group underwent second stage surgery (bone grafting). Twelve weeks after the bone grafting, the bone tissues was examined by X ray, micro computed tomography (Micro CT), HE staining and enzyme linked immunosorbent assay (ELISA) to evaluate the growth of the bone graft. Meanwhile, the TFRD containing serum was collected from rats to culture osteoblasts in vitro. Cell Counting Kit 8 (CCK 8) method, Alizarin Red S (ARS) staining, western blot and immunofluorescence were used to detect effects of TFRD on the osteoblasts' proliferation and BMP SMAD signaling pathway.Results: Compared with the L TFRD and control groups, the number of blood vessels and the expression of angiogenesis related factors (VEGF, TGF 81, BMP 2, PDGF BB and CD31) were higher in the H TFRD and MTFRD groups. The Lane Sandhu X ray score, bone mass and growth rate of the bone graft in the H TFRD and MTFRD groups were significantly better than those in the L TFRD and control groups. In addition, medium and high doses of TFRD significantly increased the expression of BMP SMAD pathway proteins (BMP 2, SMAD1, SMAD4, SMAD5 and RUNX2) in rat serum and bone graft. In vitro, after osteoblasts were intervened with TFRDcontaining serum from the H TFRD and M TFRD groups, the cell viability, the number of mineralized nodules and the phosphorylation of BMP SMAD pathway proteins were markedly increased.Conclusion: TFRD could promote the formation of blood vessels and the expression of angiogenesis related factors during the formation of the induced membrane. During the growing period of bone graft, it could facilitate the growth and mineralization of bone graft in a dose dependent manner, which is partly related to the activation and phosphorylation of BMP SMAD signaling pathway.
C1 [Li, Shuyuan; Jiang, Zexin; Hu, Cheng; Gao, Ya] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
   [Li, Yue; Zhou, Qishi] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine
RP Zhou, QS (通讯作者)，Baiyun Dist Airport Rd 16, Guangzhou, Guangdong, Peoples R China.
EM zhouqishi@139.com
FU National Natural Science Foundation of China [81674001]
FX Acknowledgements This work was supported by the National Natural Science
   Foundation of China (No. 81674001) .
CR Alford AI, 2021, J ORTHOP RES, V39, P707, DOI 10.1002/jor.24978
   Azi ML, 2019, JBJS ESSENT SURG TEC, V9, DOI 10.2106/JBJS.ST.18.00099
   Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097 4644(19980201)68:2<269::AID JCB13>3.0.CO;2 A
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen Shun Qing, 2021, Zhongguo Zhong Yao Za Zhi, V46, P2737, DOI 10.19540/j.cnki.cjcmm.20210222.602
   Chim SM, 2013, CYTOKINE GROWTH F R, V24, P297, DOI 10.1016/j.cytogfr.2013.03.008
   Chu CY, 2019, MAT SCI ENG C MATER, V100, P505, DOI 10.1016/j.msec.2019.03.007
   Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479
   Dirckx N, 2013, BIRTH DEFECTS RES C, V99, P170, DOI 10.1002/bdrc.21047
   Gaio N, 2018, J BIOMECH, V72, P53, DOI 10.1016/j.jbiomech.2018.02.026
   Giannoudis PV, 2008, INJURY, V39, pS5, DOI 10.1016/S0020 1383(08)70010 X
   Giannoudis PV, 2007, INJURY, V38, pS3, DOI 10.1016/S0020 1383(08)70003 2
   Gohel N, 2020, J ORTHOP RES, V38, P2120, DOI 10.1002/jor.24676
   Gouron R, 2017, J TISSUE ENG REGEN M, V11, P382, DOI 10.1002/term.1921
   Han ZH, 2018, TISSUE ENG PART C ME, V24, P272, DOI [10.1089/ten.TEC.2017.0497, 10.1089/ten.tec.2017.0497]
   He XN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060473
   Huang J, 2020, POULTRY SCI, V99, P5047, DOI 10.1016/j.psj.2020.06.057
   Huang ST, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00979
   Kang SN, 2014, NUTRIENTS, V6, P1737, DOI 10.3390/nu6041737
   Kong YY, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1493 5
   LANE JM, 1987, ORTHOP CLIN N AM, V18, P213
   Li H, 2018, RSC ADV, V8, P15547, DOI 10.1039/c8ra00750k
   Li LN, 2011, PHYTOMEDICINE, V18, P985, DOI 10.1016/j.phymed.2011.03.002
   Li SY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.675470
   Li YT, 2018, CHEM BIOL INTERACT, V283, P51, DOI 10.1016/j.cbi.2018.02.005
   Lin FX, 2016, AM J TRANSL RES, V8, P5098
   Luangphakdy V, 2017, CLIN ORTHOP RELAT R, V475, P2575, DOI 10.1007/s11999 017 5420 8
   Luo K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022137
   Lv WX, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.11984
   Masquelet A C, 2000, Ann Chir Plast Esthet, V45, P346
   Masquelet AC, 2019, ORTHOP TRAUMATOL SUR, V105, P159, DOI 10.1016/j.otsr.2018.11.012
   Masquelet AC, 2010, ORTHOP CLIN N AM, V41, P27, DOI 10.1016/j.ocl.2009.07.011
   Mathieu L, 2020, EUR J TRAUMA EMERG S, V46, P1099, DOI 10.1007/s00068 019 01217 y
   Ming LG, 2012, CELL PROLIFERAT, V45, P508, DOI 10.1111/j.1365 2184.2012.00844.x
   Mu PY, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.10050
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   [单宇 Shan Yu], 2017, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V23, P954
   Sharmin F, 2019, J BIOMED MATER RES B, V107, P1002, DOI 10.1002/jbm.b.34193
   Shu X., 2013, ZHONGGUO ZHONG YAO Z, V35, P2760, DOI [10.4268/cjcmm20102027, DOI 10.4268/CJCMM20102027]
   Song Shuang Hong, 2016, Bone Rep, V5, P262, DOI 10.1016/j.bonr.2016.09.001
   Sun WP, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.739503
   Susperregui ARG, 2008, J CELL PHYSIOL, V216, P144, DOI 10.1002/jcp.21389
   Toth Z, 2019, ANN BIOMED ENG, V47, P174, DOI 10.1007/s10439 018 02137 5
   Wang W, 2019, MAT SCI ENG C MATER, V100, P297, DOI 10.1016/j.msec.2019.02.067
   Wu JB, 2008, EUR J PHARMACOL, V588, P333, DOI 10.1016/j.ejphar.2008.04.030
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Yang JH, 2016, EUR J PHARMACOL, V783, P92, DOI 10.1016/j.ejphar.2016.04.042
   Yilmaz O, 2018, INJURY, V49, P1497, DOI 10.1016/j.injury.2018.06.011
   Yu G.Y., 2017, IRAN J BASIC MED SCI, V20, P408, DOI [10.22038/IJBMS.2017.8582, DOI 10.22038/IJBMS.2017.8582]
   Zhang X, 2003, CURR OPIN RHEUMATOL, V15, P387, DOI 10.1097/00002281 200307000 00004
   Zhao K, 2021, BIOMED PHARMACOTHER, V138, DOI 10.1016/j.biopha.2021.111466
   Zhao ZH, 2018, CHEM BIOL INTERACT, V286, P45, DOI 10.1016/j.cbi.2018.03.002
   Zou ML, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.593310
NR 54
TC 8
Z9 8
U1 2
U2 37
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD MAY
PY 2022
VL 99
AR 153995
DI 10.1016/j.phymed.2022.153995
EA MAR 2022
PG 14
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 1B0JT
UT WOS:000792132200002
PM 35278899
DA 2025 08 17
ER

PT J
AU Jang, HD
   Shin, JH
   Park, DR
   Hong, JH
   Yoon, K
   Ko, R
   Ko, CY
   Kim, HS
   Jeong, D
   Kim, N
   Lee, SY
AF Jang, Hyun Duk
   Shin, Ji Hye
   Park, Doo Ri
   Hong, Jin Hee
   Yoon, Kwiyeom
   Ko, Ryeojin
   Ko, Chang Yong
   Kim, Han Sung
   Jeong, Daewon
   Kim, Nacksung
   Lee, Soo Young
TI Inactivation of Glycogen Synthase Kinase 3β Is Required for Osteoclast
   Differentiation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID KAPPA B ACTIVATION; BONE HOMEOSTASIS; RANKL; GSK3; EXPRESSION; NFATC1;
   KINASE; MICE; PHOSPHORYLATION; CALCINEURIN
AB Glycogen synthase kinase 3 beta (GSK 3 beta is a serine/threonine kinase originally identified as a regulator of glycogen deposition. Although the role of GSK 3 beta in osteoblasts is well characterized as a negative regulator of beta catenin, its effect on osteoclast formation remains largely unidentified. Here, we show that the GSK 3 beta inactivation upon receptor activator of NF kappa B ligand (RANKL) stimulation is crucial for osteoclast differentiation. Regulation of GSK 3 beta activity in bone marrow macrophages by retroviral expression of the constitutively active GSK 3 beta (GSK3 beta S9A) mutant inhibits RANKL induced osteoclastogenesis, whereas expression of the catalytically inactive GSK 3 beta (GSK3 beta K85R) or small interfering RNA (siRNA) mediated GSK 3 beta silencing enhances osteoclast formation. Pharmacological inhibition of GSK 3 beta further confirmed the negative role of GSK 3 beta in osteoclast formation. We also show that overexpression of the GSK3 beta S9A mutant in bone marrow macrophages inhibits RANKL mediated NFATc1 induction and Ca2+ oscillations. Remarkably, transgenic mice expressing the GSK3 beta S9A mutant show an osteopetrotic phenotype due to impaired osteoclast differentiation. Further, osteoclast precursor cells from the transgenic mice show defects in expression and nuclear localization of NFATc1. These findings demonstrate a novel role for GSK 3 beta in the regulation of bone remodeling through modulation of NFATc1 in RANKL signaling.
C1 [Lee, Soo Young] Ewha Womans Univ, Div Life & Pharmaceut Sci, Dept Bioinspired Sci, Ctr Cell Signaling & Drug Discovery Res,Dept Life, Seoul 120750, South Korea.
   [Hong, Jin Hee] Korea Univ, Ctr Cell Dynam, Seoul 136701, South Korea.
   [Hong, Jin Hee] Korea Univ, Dept Phys, Seoul 136701, South Korea.
   [Ko, Chang Yong; Kim, Han Sung] Yonsei Univ, Dept Biomed Engn, Coll Hlth Sci, Inst Med Engn, Wonju 220701, South Korea.
   [Jeong, Daewon] Yeungnam Univ, Coll Med, Dept Microbiol, Taegu 705717, South Korea.
   [Jeong, Daewon] Yeungnam Univ, Coll Med, Aging Associated Dis Res Ctr, Taegu 705717, South Korea.
   [Kim, Nacksung] Chonnam Natl Univ, Sch Med, Med Res Ctr Gene Regulat, Kwangju 501746, South Korea.
C3 Ewha Womans University; Korea University; Korea University; Yonsei
   University; Yeungnam University; Yeungnam University; Chonnam National
   University
RP Lee, SY (通讯作者)，Ewha Womans Univ, Div Life & Pharmaceut Sci, Dept Bioinspired Sci, Ctr Cell Signaling & Drug Discovery Res,Dept Life, Seoul 120750, South Korea.
EM leesy@ewha.ac.kr
RI Ko, Chang Yong/JHS 9349 2023
OI ko, chang yong/0000 0002 8164 5120
FU National Research Foundation of Korea (NRF); Korea Government (Ministry
   of Education, Science, and Technology) [R0A 2008 000 20001 0,
   R31 2008 000 10010 0, 2011 0006244, 2010 0020577]; Ewha Womans
   University; Brain Korea 21 Project
FX This work was supported by National Research Foundation of Korea (NRF)
   grants funded by the Korea Government (Ministry of Education, Science,
   and Technology; Grants R0A 2008 000 20001 0; R31 2008 000 10010 0;
   2011 0006244; and 2010 0020577). Supported by Research Professor Grant
   2010 of Ewha Womans University. Supported by the second stage of the
   Brain Korea 21 Project.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415
   Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092 8674(00)80571 1
   Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092 8674(02)00699 2
   Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384
   Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097 2765(01)00253 2
   Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264 6021:3590001
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hikata T, 2009, BLOOD, V113, P2202, DOI 10.1182/blood 2008 06 162594
   Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004
   Kim JH, 2010, CELL SIGNAL, V22, P1341, DOI 10.1016/j.cellsig.2010.05.001
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184 4195.2004
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835
   Suda T, 1997, METHOD ENZYMOL, V282, P223
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sugden PH, 2008, BRIT J PHARMACOL, V153, pS137, DOI 10.1038/sj.bjp.0707659
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460 2075.1990.tb07419.x
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892 3904.2002
   Yoon K, 2008, CELL DEATH DIFFER, V15, P730, DOI 10.1038/sj.cdd.4402304
NR 39
TC 72
Z9 81
U1 0
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 11
PY 2011
VL 286
IS 45
BP 39043
EP 39050
DI 10.1074/jbc.M111.256768
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 844PO
UT WOS:000296759800023
PM 21949120
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Hu, XT
   Yin, ZQ
   Chen, X
   Jiang, GY
   Yang, DS
   Cao, ZQ
   Li, S
   Liu, ZC
   Peng, D
   Dou, PC
AF Hu, Xuantao
   Yin, Ziqing
   Chen, Xia
   Jiang, Guangyao
   Yang, Daishui
   Cao, Ziqin
   Li, Shuai
   Liu, Zicheng
   Peng, Dan
   Dou, Pengcheng
TI Tussilagone Inhibits Osteoclastogenesis and Periprosthetic Osteolysis by
   Suppressing the NF κB and P38 MAPK Signaling Pathways
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE tussilagone; osteoclast; NF kappa B; p38; MAPK; aseptic prosthetic
   loosening; periprosthetic osteolysis
ID PARTICLE INDUCED OSTEOLYSIS; INFLAMMATORY BONE RESORPTION; PERI IMPLANT
   OSTEOLYSIS; WEAR DEBRIS; FARFARA; POLYETHYLENE; EXPRESSION; RAT;
   SESQUITERPENOIDS; DIFFERENTIATION
AB Background: Aseptic prosthetic loosening is one of the main factors causing poor prognosis of limb function after joint replacement and requires troublesome revisional surgery. It is featured by wear particle induced periprosthetic osteolysis mediated by excessive osteoclasts activated in inflammatory cell context. Some natural compounds show antiosteoclast traits with high cost efficiency and few side effects. Tussilagone (TUS), which is the main functional extract from Tussilago farfara generally used for relieving cough, asthma, and eliminating phlegm in traditional medicine has been proven to appease several RAW264.7 mediated inflammatory diseases via suppressing osteoclast related signaling cascades. However, whether and how TUS can improve aseptic prosthetic loosening via modulating osteoclast mediated bone resorption still needs to be answered.
   Methods: We established a murine calvarial osteolysis model to detect the preventative effect of TUS on osteolysis in vivo. Micro CT scanning and histomorphometric analysis were used to determine the variation of bone resorption and osteoclastogenesis. The anti osteoclast differentiation and anti bone resorption bioactivities of TUS in vitro were investigated using bone slice resorption pit evaluation, and interference caused by cytotoxicity of TUS was excluded according to the CCK 8 assay results. Quantitative polymerase chain reaction (qPCR) analysis was applied to prove the decreased expression of osteoclast specific genes after TUS treatment. The inhibitory effect of TUS on NF kappa B and p38 MAPK signaling pathways was testified by Western blot and NF kappa B linked luciferase reporter gene assay.
   Results: TUS better protected bones against osteolysis in murine calvarial osteolysis model with reduced osteoclasts than those in the control group. In vitro studies also showed that TUS exerted antiosteoclastogenesis and anti bone resorption effects in both bone marrow macrophages (BMMs) and RAW264.7 cells, as evidenced by the decline of osteoclast specific genes according to qPCR. Western blotting revealed that TUS treatment inhibited I kappa B alpha degradation and p38 phosphorylation.
   Conclusions: Collectively, our studies proved for the first time that TUS inhibits osteoclastogenesis by suppressing the NF kappa B and p38 MAPK signaling pathways, therefore serving as a potential natural compound to treat periprosthetic osteolysis induced aseptic prosthetic loosening.
C1 [Hu, Xuantao; Yin, Ziqing; Chen, Xia; Jiang, Guangyao; Yang, Daishui; Cao, Ziqin; Li, Shuai; Liu, Zicheng; Peng, Dan; Dou, Pengcheng] Cent South Univ, Dept Orthoped, Xiangya Hosp 2, Changsha, Peoples R China.
C3 Central South University
RP Peng, D; Dou, PC (通讯作者)，Cent South Univ, Dept Orthoped, Xiangya Hosp 2, Changsha, Peoples R China.
EM xyeypd@163.com; doupengcheng@csu.edu.cn
RI 窦, 鹏程/HJH 2386 2023; yin, ziqing/HSF 9216 2023
OI Peng, Dan/0009 0006 3825 5270
FU Science & Technology Department of Hunan Province [2017WK2062]; Natural
   Science Foundation of Hunan Province for Youths [2019JJ50845]
FX This work was funded by the Science & Technology Department of Hunan
   Province (Grant number 2017WK2062) and the Natural Science Foundation of
   Hunan Province for Youths (Grant number 2019JJ50845).
CR Adelani MA, 2014, J BONE JOINT SURG AM, V96A, P1015, DOI 10.2106/JBJS.L.01177
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyer B, 2018, J ARTHROPLASTY, V33, P908, DOI 10.1016/j.arth.2017.10.005
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao HL, 2010, J CLIN INVEST, V120, P2755, DOI 10.1172/JCI42106
   Chen J, 2017, OSTEOPOROSIS INT, V28, P517, DOI 10.1007/s00198 016 3755 8
   Cheng LL, 2018, ARCH TOXICOL, V92, P469, DOI 10.1007/s00204 017 2048 0
   Cheng XY, 2018, BIOMED CHROMATOGR, V32, DOI 10.1002/bmc.4047
   Cheon HJ, 2018, CHEM BIOL INTERACT, V294, P74, DOI 10.1016/j.cbi.2018.08.022
   Choi BS, 2018, KOREAN J PHYSIOL PHA, V22, P671, DOI 10.4196/kjpp.2018.22.6.671
   Crotti TN, 2004, BIOMATERIALS, V25, P565, DOI 10.1016/S0142 9612(03)00556 8
   Du Z, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0736 y
   Edwards BJ, 2008, LANCET ONCOL, V9, P1166, DOI 10.1016/S1470 2045(08)70305 X
   Eger M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02963
   Endo M, 2002, P I MECH ENG H, V216, P111, DOI 10.1243/0954411021536333
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Futosi K, 2013, INT IMMUNOPHARMACOL, V17, P1185, DOI 10.1016/j.intimp.2013.11.010
   Gibon E, 2017, J BIOMED MATER RES B, V105, P1685, DOI 10.1002/jbm.b.33676
   Goodman SB, 2010, BIOMATERIALS, V31, P5045, DOI 10.1016/j.biomaterials.2010.03.046
   Granchi D, 2005, BIOMATERIALS, V26, P2371, DOI 10.1016/j.biomaterials.2004.07.045
   Helming L, 2009, TRENDS CELL BIOL, V19, P514, DOI 10.1016/j.tcb.2009.07.005
   Hwang JH, 2018, CHIN J INTEGR MED, V24, P844, DOI 10.1007/s11655 018 2936 4
   HWANG SB, 1987, EUR J PHARMACOL, V141, P269, DOI 10.1016/0014 2999(87)90272 X
   Hwangbo C, 2009, INT IMMUNOPHARMACOL, V9, P1578, DOI 10.1016/j.intimp.2009.09.016
   Iqbal Jameel, 2010, Curr Osteoporos Rep, V8, P163, DOI 10.1007/s11914 010 0034 z
   Iwase M, 2002, J ORTHOPAED RES, V20, P499, DOI 10.1016/S0736 0266(01)00155 3
   Kim JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189702
   Kim YK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122744
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lee J, 2016, INT IMMUNOPHARMACOL, V34, P155, DOI 10.1016/j.intimp.2016.02.026
   Li H, 2014, BIOCHEM BIOPH RES CO, V443, P132, DOI 10.1016/j.bbrc.2013.11.062
   Li J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00764
   LI YP, 1988, GEN PHARMACOL VASC S, V19, P261, DOI 10.1016/0306 3623(88)90072 9
   Lim HJ, 2008, ARCH PHARM RES, V31, P645, DOI 10.1007/s12272 001 1207 4
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Liu YF, 2008, BIOMED CHROMATOGR, V22, P1194, DOI 10.1002/bmc.1042
   Lv SM, 2016, INT ORTHOP, V40, P1545, DOI 10.1007/s00264 015 3021 2
   MARGEVICIUS KJ, 1994, J BONE JOINT SURG AM, V76A, P1664, DOI 10.2106/00004623 199411000 00010
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Meng JH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01053
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Ormsby RT, 2019, ACTA BIOMATER, V87, P296, DOI 10.1016/j.actbio.2019.01.047
   Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007
   Ouyang ZX, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00584
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Park HR, 2008, J AGR FOOD CHEM, V56, P10493, DOI 10.1021/jf801978r
   Park Y, 2014, INT IMMUNOPHARMACOL, V22, P400, DOI 10.1016/j.intimp.2014.07.023
   Peter R, 2004, BMJ BRIT MED J, V328, P335, DOI 10.1136/bmj.328.7435.335
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Qin ZB, 2014, PLANTA MED, V80, P703, DOI 10.1055/s 0034 1368567
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Shin DK, 2012, ACTA BIOMATER, V8, P3524, DOI 10.1016/j.actbio.2012.05.002
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tsutsumi R, 2008, J ORTHOP RES, V26, P1340, DOI 10.1002/jor.20620
   Wang LJ, 2018, FASEB J, V32, P875, DOI 10.1096/fj.201700672RR
   Wang ZH, 2015, AUTOPHAGY, V11, P2358, DOI 10.1080/15548627.2015.1106779
   Xiao F, 2015, EXP CELL RES, V330, P91, DOI 10.1016/j.yexcr.2014.07.005
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Zhang Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01028
   Zhang XS, 2015, RAPID COMMUN MASS SP, V29, P1641, DOI 10.1002/rcm.7262
   Zhao S, 2016, INT IMMUNOPHARMACOL, V40, P458, DOI 10.1016/j.intimp.2016.09.031
   Zhou F, 2017, BIOCHEM BIOPH RES CO, V484, P820, DOI 10.1016/j.bbrc.2017.01.179
   Zhu W, 2019, BIOCHEM BIOPH RES CO, V509, P294, DOI 10.1016/j.bbrc.2018.12.125
NR 65
TC 17
Z9 17
U1 1
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD APR 3
PY 2020
VL 11
AR 385
DI 10.3389/fphar.2020.00385
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA LG2OL
UT WOS:000527946600001
PM 32317967
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Schafer, PH
   Kivitz, AJ
   Ma, JL
   Korish, S
   Sutherland, D
   Li, L
   Azaryan, A
   Kosek, J
   Adams, M
   Capone, L
   Hur, EM
   Hough, DR
   Ringheim, GE
AF Schafer, Peter H.
   Kivitz, Alan J.
   Ma, Jianglin
   Korish, Shimon
   Sutherland, Donna
   Li, Li
   Azaryan, Ada
   Kosek, Jolanta
   Adams, Mary
   Capone, Lori
   Hur, Eun Mi
   Hough, Douglas R.
   Ringheim, Garth E.
TI Spebrutinib (CC 292) Affects Markers of B Cell Activation, Chemotaxis,
   and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a
   Mechanistic Study
SO RHEUMATOLOGY AND THERAPY
LA English
DT Article
DE Background methotrexate therapy; Bruton's tyrosine kinase inhibitor;
   CC 292; Rheumatoid arthritis; Spebrutinib
ID BRUTONS TYROSINE KINASE; INHIBITOR IBRUTINIB; MIGRATION; RECEPTOR;
   CXCL13; BTK
AB Introduction Spebrutinib (CC 292) is an orally administered, covalent, small molecule inhibitor of Bruton's tyrosine kinase (BTK), part of the B cell and Fc receptor signaling pathways. This study evaluated spebrutinib pharmacology and mechanism of action over a 4 week treatment period in patients with active rheumatoid arthritis (RA). Methods Primary human B cells, T cells, natural killer cells, macrophages, dendritic cells, basophils, and osteoclasts were treated with spebrutinib in vitro. Clinical pharmacodynamics were studied in 47 patients with active RA on background methotrexate therapy randomized to oral spebrutinib 375 mg/day or placebo. Results In vitro, spebrutinib inhibited B cell proliferation more potently than T cell proliferation and reduced both lymphoid and myeloid cytokine production and degranulation, as well as osteoclastogenesis. Clinical efficacy trended higher in spebrutinib treated RA patients, with 41.7% (10/24) achieving >= 20% improvement in ACR response criteria (ACR20) versus 21.7% (5/23) of placebo patients at week 4 (P = 0.25). Treatment emergent adverse events were comparable between treatment groups. In spebrutinib treated patients, median BTK occupancy in peripheral blood was 83%, and significant increases in total CD19(+) and mature naive CD27( )CD38( )IgD(+) B cells and decreases in transitional CD27( )CD38(+) B cells were observed. Spebrutinib significantly reduced serum chemokines chemokine ligand 13 (CXCL13), macrophage inflammatory protein 1 beta (MIP 1 beta), and the bone resorption biomarker carboxy terminal collagen cross linking telopeptide (CTX I) (P < 0.05). Clinical response to spebrutinib was associated with lower increases in CD19(+) B cells and greater decreases in CXCL13 and MIP 1 beta from baseline to week 4. High CD19(+) B cells and low CTX I at baseline were associated with better spebrutinib clinical response. Conclusions Spebrutinib inhibited various leukocyte responses in vitro, including those of B cells and osteoclasts. In this small study in RA patients, spebrutinib was well tolerated, showed a downward trend for symptoms, significantly modulated B cell populations, and reduced markers of chemotaxis and osteoclast activity.
C1 [Schafer, Peter H.; Ma, Jianglin; Korish, Shimon; Sutherland, Donna; Li, Li; Azaryan, Ada; Kosek, Jolanta; Adams, Mary; Capone, Lori; Hur, Eun Mi; Hough, Douglas R.; Ringheim, Garth E.] Celgene Corp, 86 Morris Ave,L Bldg, Summit, NJ 07901 USA.
   [Kivitz, Alan J.] Altoona Ctr Clin Res, Duncansville, PA USA.
C3 Bristol Myers Squibb; Celgene Corporation; Altoona Center for Clinical
   Research
RP Schafer, PH (通讯作者)，Celgene Corp, 86 Morris Ave,L Bldg, Summit, NJ 07901 USA.
EM pschafer@celgene.com
FU Celgene Corporation
FX This study and the Rapid Service Fee were funded by Celgene Corporation.
CR Brown JR, 2016, HAEMATOLOGICA, V101, P295, DOI 10.3324/haematol.2015.140806
   Bugatti S, 2014, RHEUMATOLOGY, V53, P1886, DOI 10.1093/rheumatology/keu163
   Chang BY, 2013, BLOOD, V122, P2412, DOI 10.1182/blood 2013 02 482125
   Chang BY, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3400
   de Gorter DJJ, 2007, IMMUNITY, V26, P93, DOI 10.1016/j.immuni.2006.11.012
   de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood 2011 11 390989
   Dennis G, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4555
   Eda H, 2014, LEUKEMIA, V28, P1892, DOI 10.1038/leu.2014.69
   Evans EK, 2013, J PHARMACOL EXP THER, V346, P219, DOI 10.1124/jpet.113.203489
   Folkersen L, 2016, MOL MED, V22, P322, DOI 10.2119/molmed.2016.00078
   Hobbs K, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064 015 0895 9
   Khan WN, 2001, IMMUNOL RES, V23, P147, DOI 10.1385/IR:23:2 3:147
   Kivitz A, 2016, ANN M AM COLL RHEUM
   Nakayama Y, 2017, J IMMUNOL, V199, P2388, DOI 10.4049/jimmunol.1601725
   Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955
   Ping LY, 2017, ONCOTARGET, V8, P39218, DOI 10.18632/oncotarget.16836
   van de Putte BA, 2004, ANN RHEUM DIS, V63, P508, DOI 10.1136/ard.2003.013052
   Vos JM, 2017, HAEMATOLOGICA, V102, pE452, DOI 10.3324/haematol.2017.172627
   Weinblatt ME, 2012, RHEUMATOLOGY, V51, P2204, DOI 10.1093/rheumatology/kes150
NR 19
TC 56
Z9 57
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2198 6576
EI 2198 6584
J9 RHEUMATOL THER
JI Rheumatol. Ther.
PD MAR
PY 2020
VL 7
IS 1
BP 101
EP 119
DI 10.1007/s40744 019 00182 7
EA NOV 2019
PG 19
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA KL3UZ
UT WOS:000496197000001
PM 31721017
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tarapore, RS
   Siddiqui, IA
   Saleem, M
   Adhami, VM
   Spiegelman, VS
   Mukhtar, H
AF Tarapore, Rohinton S.
   Siddiqui, Imtiaz A.
   Saleem, Mohammad
   Adhami, Vaqar M.
   Spiegelman, Vladimir S.
   Mukhtar, Hasan
TI Specific targeting of Wnt/β catenin signaling in human melanoma cells by
   a dietary triterpene lupeol
SO CARCINOGENESIS
LA English
DT Article
ID BETA CATENIN; CYCLIN D1; TRANSCRIPTION FACTOR; MALIGNANT MELANOMA;
   MATRIX METALLOPROTEINASES; MESSENGER RNA; TUMOR GROWTH; CRD BP; C MYC;
   CANCER
AB Wingless (Wnt) signaling pathway regulates a variety of cellular processes including proliferation, differentiation, survival, apoptosis and cell motility. Aberrant activation of Wnt/beta catenin pathway has been observed in approximately one third of melanomas and this subset has very poor prognosis suggesting that targeting Wnt signaling could be a promising strategy against this subtype. Mel 928 and Mel 1241 melanoma cells representative of cells with constitutive activation of Wnt/beta catenin signaling pathway and Mel 1011 representative of cells that lack this pathway were treated with a dietary triterpene lupeol and its effects on growth, proliferation, beta catenin transcriptional activity and Wnt target genes were determined both in vitro and in vivo. Lupeol treatment to Mel 928 and Mel 1241 but not Mel 1011 cells resulted in a dose dependent (i) decrease in cell viability, (ii) induction of apoptosis, (iii) decrease in colonogenic potential, (iv) decrease in beta catenin transcriptional activity and (v) decrease in the expression of Wnt target genes. Most importantly, lupeol restricted the translocation of beta catenin from the cytoplasm to the nucleus. Lupeol also decreased the growth of Mel 928 but not Mel 1011 derived tumors implanted in the athymic nude mice. The decrease in Mel 928 derived tumor growth was associated with a decrease in the expression of Wnt target genes c myc, cyclin D1, proliferation markers proliferating cell nuclear antigen and Ki 67 and invasion marker osteopontin. We suggest that lupeol alone or as an adjuvant to current therapies could be developed as an agent for the management of human melanomas harboring constitutive Wnt/beta catenin signaling.
C1 [Mukhtar, Hasan] Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Sch Med & Publ Hlth, Madison, WI 53706 USA.
   [Tarapore, Rohinton S.; Spiegelman, Vladimir S.; Mukhtar, Hasan] Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Mukhtar, H (通讯作者)，Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Sch Med & Publ Hlth, Room 4385,1300 Univ Ave, Madison, WI 53706 USA.
EM hmukhtar@wisc.edu
RI Siddiqui, Imtiaz/B 6587 2009; Adhami, Vaqar/AAY 2837 2020; Bhat,
   Mohammad Saleem/GVS 9221 2022; Tarapore, Rohinton/J 8300 2012
OI Bhat, Mohammad Saleem/0000 0002 7422 7967; Spiegelman, Vladimir
   S/0000 0003 4847 155X; 
FU National Institutes of Health [R01 120451]
FX National Institutes of Health (R01 120451).
CR Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008 5472.CAN 04 2840
   Afaq F, 2002, FRONT BIOSCI LANDMRK, V7, pD784, DOI 10.2741/afaq
   Becker JC, 2006, CANCER AM CANCER SOC, V107, P2317, DOI 10.1002/cncr.22273
   Beveridge THJ, 2002, J AGR FOOD CHEM, V50, P744, DOI 10.1021/jf010701v
   Bilechele Travis L., 2008, V468, P99, DOI 10.1007/978 1 59745 249 6_8
   Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206
   Cmoch P, 2008, CARBOHYD RES, V343, P995, DOI 10.1016/j.carres.2008.02.011
   Dorsky RI, 2000, GENE DEV, V14, P158
   Elcheva I, 2008, ONCOGENE, V27, P5069, DOI 10.1038/onc.2008.141
   Fecher LA, 2009, HEMATOL ONCOL CLIN N, V23, P599, DOI 10.1016/j.hoc.2009.03.004
   Fernández A, 2001, FARMACO, V56, P335, DOI 10.1016/S0014 827X(01)01080 1
   Fernández MA, 2001, J PHARM PHARMACOL, V53, P1533, DOI 10.1211/0022357011777909
   Florenes VA, 2000, CLIN CANCER RES, V6, P3614
   Giles RH, 2003, BBA REV CANCER, V1653, P1, DOI 10.1016/S0304 419X(03)00005 2
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hofmann UB, 2005, BIOCHIMIE, V87, P307, DOI 10.1016/j.biochi.2005.01.013
   Hu J, 2009, CANCER RES, V69, P6951, DOI 10.1158/0008 5472.CAN 09 0541
   Imam S, 2007, PAK J PHARM SCI, V20, P125
   Jemal A, 2009, CA CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Khan N, 2008, ANTIOXID REDOX SIGN, V10, P475, DOI 10.1089/ars.2007.1740
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Latha RM, 2001, PROSTAG LEUKOTR ESS, V64, P81, DOI 10.1054/plef.2001.0245
   Lima LM, 2007, J PHARM PHARMACOL, V59, P1151, DOI 10.1211/jpp.59.8.0014
   Lira WD, 2008, J MED FOOD, V11, P111, DOI 10.1089/jmf.2007.553
   López Otín C, 2009, CELL CYCLE, V8, P3657, DOI 10.4161/cc.8.22.9956
   Marneros AG, 2009, HEMATOL ONCOL CLIN N, V23, P431, DOI 10.1016/j.hoc.2009.03.007
   Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166
   Moon Randall T, 2005, Sci STKE, V2005, pcm1
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Nichenametla SN, 2006, CRIT REV FOOD SCI, V46, P161, DOI 10.1080/10408390591000541
   Nigam N, 2007, FOOD CHEM TOXICOL, V45, P2331, DOI 10.1016/j.fct.2007.06.002
   Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839
   Philchenkov A, 2004, J CELL MOL MED, V8, P432, DOI 10.1111/j.1582 4934.2004.tb00468.x
   Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002 9440(10)65278 9
   Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790
   Saito H, 2003, PIGM CELL RES, V16, P261, DOI 10.1034/j.1600 0749.2003.00039.x
   Saito H, 2002, J BIOL CHEM, V277, P28787, DOI 10.1074/jbc.M203719200
   Saleem M, 2004, ONCOGENE, V23, P5203, DOI 10.1038/sj.onc.1207641
   Saleem M, 2008, CLIN CANCER RES, V14, P2119, DOI 10.1158/1078 0432.CCR 07 4413
   Saleem M, 2009, CANCER LETT, V285, P109, DOI 10.1016/j.canlet.2009.04.033
   Sauter ER, 2002, CANCER GENE THER, V9, P807, DOI 10.1038/sj.cgt.7700492
   Sauter ER, 2002, CANCER RES, V62, P3200
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Siddiqui IA, 2008, ONCOGENE, V27, P2055, DOI 10.1038/sj.onc.1210840
   Siddiqui IA, 2006, CARCINOGENESIS, V27, P833, DOI 10.1093/carcin/bgi323
   Sultana Sarwat, 2003, Indian Journal of Experimental Biology, V41, P827
   Vachtenheim J, 2004, Prague Med Rep, V105, P318
   Vasconcelos JF, 2008, INT IMMUNOPHARMACOL, V8, P1216, DOI 10.1016/j.intimp.2008.04.011
   Weeraratna AT, 2005, CANCER METAST REV, V24, P237, DOI 10.1007/s10555 005 1574 z
   Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703
   You YJ, 2003, PHYTOTHER RES, V17, P341, DOI 10.1002/ptr.1140
   Zhang ZY, 2009, J MOL CELL CARDIOL, V46, P370, DOI 10.1016/j.yjmcc.2008.11.016
NR 52
TC 73
Z9 80
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143 3334
EI 1460 2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 2010
VL 31
IS 10
BP 1844
EP 1853
DI 10.1093/carcin/bgq169
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 661TD
UT WOS:000282750100019
PM 20732907
OA Green Published
DA 2025 08 17
ER

PT J
AU Güemes, M
   Garcia, AJ
   Rigueur, D
   Runke, S
   Wang, WG
   Zhao, GX
   Mayorga, VH
   Atti, E
   Tetradis, S
   Péault, B
   Lyons, K
   Miranda Carboni, GA
   Krum, SA
AF Gueemes, Miriam
   Garcia, Alejandro J.
   Rigueur, Diana
   Runke, Stephanie
   Wang, Weiguang
   Zhao, Gexin
   Mayorga, Victor Hugo
   Atti, Elisa
   Tetradis, Sotirios
   Peault, Bruno
   Lyons, Karen
   Miranda Carboni, Gustavo A.
   Krum, Susan A.
TI GATA4 is Essential for Bone Mineralization via ERα and TGFβ/BMP Pathways
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE GATA4; ESTROGEN; TGF BETA; BMP; OSTEOBLAST
ID HEART TUBE FORMATION; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTORS;
   ESTROGEN RECEPTOR; VENTRAL MORPHOGENESIS; GENE EXPRESSION; STEM CELLS;
   REQUIREMENT; TRANSGENES; ACTIVATION
AB Osteoporosis is a disease characterized by low bone mass, leading to an increased risk of fragility fractures. GATA4 is a zinc finger transcription factor that is important in several tissues, such as the heart and intestines, and has recently been shown to be a pioneer factor for estrogen receptor alpha (ER) in osteoblast like cells. Herein, we demonstrate that GATA4 is necessary for estrogen mediated transcription and estrogen independent mineralization in vitro. In vivo deletion of GATA4, driven by Cre recombinase in osteoblasts, results in perinatal lethality, decreased trabecular bone properties, and abnormal bone development. Microarray analysis revealed GATA4 suppression of TGF signaling, necessary for osteoblast progenitor maintenance, and concomitant activation of BMP signaling, necessary for mineralization. Indeed, pSMAD1/5/8 signaling, downstream of BMP signaling, is decreased in the trabecular region of conditional knockout femurs, and pSMAD2/3, downstream of TGF signaling, is increased in the same region. Together, these experiments demonstrate the necessity of GATA4 in osteoblasts. Understanding the role of GATA4 to regulate the tissue specificity of estrogen mediated osteoblast gene regulation and estrogen independent bone differentiation may help to develop therapies for postmenopausal osteoporosis. (c) 2014 American Society for Bone and Mineral Research.
C1 [Gueemes, Miriam; Garcia, Alejandro J.; Rigueur, Diana; Wang, Weiguang; Zhao, Gexin; Peault, Bruno; Lyons, Karen; Krum, Susan A.] Univ Calif Los Angeles, Orthopaed Hosp, Dept Orthopaed Surg, Los Angeles, CA USA.
   [Gueemes, Miriam; Garcia, Alejandro J.; Rigueur, Diana; Wang, Weiguang; Zhao, Gexin; Peault, Bruno; Lyons, Karen; Krum, Susan A.] Univ Calif Los Angeles, David Geffen Sch Med, Orthopaed Hosp, Res Ctr, Los Angeles, CA 90095 USA.
   [Rigueur, Diana; Lyons, Karen] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA USA.
   [Runke, Stephanie; Mayorga, Victor Hugo; Miranda Carboni, Gustavo A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Atti, Elisa; Tetradis, Sotirios] UCLA Sch Dent, Div Diagnost & Surg Sci, Los Angeles, CA USA.
   [Peault, Bruno] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland.
   [Peault, Bruno] Univ Edinburgh, Ctr Regenerat Med, Edinburgh, Midlothian, Scotland.
   Univ Tennessee, Ctr Hlth Sci, Dept Orthopaed Surg & Biomed Engn, Memphis, TN 38163 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; UCLA Jonsson Comprehensive Cancer Center;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of Edinburgh; University of Edinburgh;
   University of Tennessee System; University of Tennessee Health Science
   Center
RP Krum, SA (通讯作者)，19 S Mansassas, Memphis, TN 38163 USA.
EM smirand5@uthsc.edu
RI Zhao, Gexin/O 8269 2019; Krum, Susan/D 7282 2013; wang,
   weiguang/KMX 8511 2024
OI Krum, Susan/0000 0002 6414 6397; 
FU ASBMR Junior Faculty Osteoporosis Research Award;  [1R56DK090231 01]; 
   [AR044528];  [JCCC/P30 CA016042];  [CURE/P30 DK041301]; National Cancer
   Institute [P30CA016042] Funding Source: NIH RePORTER; National Institute
   of Arthritis and Musculoskeletal and Skin Diseases [T32AR059033] Funding
   Source: NIH RePORTER
FX This work was supported by an ASBMR Junior Faculty Osteoporosis Research
   Award and 1R56DK090231 01 to SAK and AR044528 to KL. The UCLA Vector
   Core is supported by JCCC/P30 CA016042 and CURE/P30 DK041301. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Almeida M, 2010, J BONE MINER RES, V25, P769, DOI 10.1359/jbmr.091017
   American Academy Of Orthopaedic Surgeons, 2008, US BON JOINT DEC BUR
   Anttonen M, 2006, J MOL ENDOCRINOL, V36, P557, DOI 10.1677/jme.1.01962
   Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216
   Battle MA, 2008, GASTROENTEROLOGY, V135, P1676, DOI 10.1053/j.gastro.2008.07.074
   Belaguli NS, 2007, AM J PHYSIOL GASTR L, V292, pG1520, DOI 10.1152/ajpgi.00236.2006
   Brown CO, 2004, J BIOL CHEM, V279, P10659, DOI 10.1074/jbc.M301648200
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Gaur T, 2010, DEV BIOL, V340, P10, DOI 10.1016/j.ydbio.2010.01.008
   Hartung S, 2013, STEM CELLS DEV, V22, P1112, DOI 10.1089/scd.2012.0351
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Krum SA, 2008, MOL ENDOCRINOL, V22, P2393, DOI 10.1210/me.2008 0100
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Krum SA, 2011, J CELL BIOCHEM, V112, P401, DOI 10.1002/jcb.22970
   Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048
   Kyrönlahti A, 2011, MOL CELL ENDOCRINOL, V333, P85, DOI 10.1016/j.mce.2010.12.019
   Kyrönlahti A, 2011, BIOL REPROD, V84, P1033, DOI 10.1095/biolreprod.110.086850
   Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl
   Miranda Carboni GA, 2011, MOL ENDOCRINOL, V25, P1126, DOI 10.1210/me.2010 0463
   Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200
   Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061
   Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858
   Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012 1606(02)00026 X
   Oka T, 2006, CIRC RES, V98, P837, DOI 10.1161/01.RES.0000215985.18538.c4
   READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend 3 2 295
   Retting KN, 2009, DEVELOPMENT, V136, P1093, DOI 10.1242/dev.029926
   Rojas A, 2005, DEVELOPMENT, V132, P3405, DOI 10.1242/dev.01913
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Sanford LP, 1997, DEVELOPMENT, V124, P2659
   Song B, 2009, CYTOKINE GROWTH F R, V20, P379, DOI 10.1016/j.cytogfr.2009.10.010
   VanKoevering KK., 2008, IBMS BoneKEy, V5, P151, DOI DOI 10.1138/20080312
   Wang M, 2011, OSTEOARTHR CARTILAGE, V19, P751, DOI 10.1016/j.joca.2011.03.004
   Watt AJ, 2004, P NATL ACAD SCI USA, V101, P12573, DOI 10.1073/pnas.0400752101
   Xuan SH, 2012, J CLIN INVEST, V122, P3516, DOI 10.1172/JCI63352
NR 42
TC 36
Z9 37
U1 0
U2 14
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2014
VL 29
IS 12
BP 2676
EP 2687
DI 10.1002/jbmr.2296
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AW4UB
UT WOS:000346274700019
PM 24932701
OA Green Accepted, Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Tang, CH
   Lu, DY
   Tan, TW
   Fu, WM
   Yang, RS
AF Tang, Chih Hsin
   Lu, Dah Yuu
   Tan, Tzu Wei
   Fu, Wen Mei
   Yang, Rong Sen
TI Ultrasound induces hypoxia inducible factor 1 activation and inducible
   nitric oxide synthase expression through the integrin/integrin linked
   kinase/Akt/mammalian target of rapamycin pathway in osteoblasts
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INTENSITY PULSED ULTRASOUND; CYCLIC RGD PEPTIDES; SIGNALING PATHWAY;
   PROTEIN KINASE; CYCLOOXYGENASE 2 EXPRESSION; ACTIN CYTOSKELETON;
   BONE FORMATION; CELL ADHESION; SHEAR STRESS; INTEGRIN
AB It has been shown that ultrasound (US) stimulation accelerates fracture healing in the animal models and clinical studies. Nitric oxide (NO) is a crucial early mediator in mechanically induced bone formation. Here we found that US stimulation increased NO formation and the protein level of inducible nitric oxide synthase (iNOS). US mediated iNOS expression was attenuated by anti integrin alpha 5 beta 1 or beta 1 antibodies but not anti integrin alpha v beta 3 or beta 3 antibodies or focal adhesion kinase mutant. Integrin linked kinase (ILK) inhibitor (KP 392), Akt inhibitor (1L 6 hydroxymethyl chiro inositol2 [(R) 2 O methyl 3 O octadecylcarbonate]) or mammalian target of rapamycin (mTOR) inhibitor (rapamycin) also inhibited the potentiating action of US. US stimulation increased the kinase activity of ILK and phosphorylation of Akt and mTOR. Furthermore, US stimulation also increased the stability and activity of HIF 1 protein. The binding of HIF 1 alpha to the HRE elements on the iNOS promoter was enhanced by US stimulation. Moreover, the use of pharmacological inhibitors or genetic inhibition revealed that both ILK/Akt and mTOR signaling pathway were potentially required for US induced HIF 1 alpha activation and subsequent iNOS up regulation. Taken together, our results provide evidence that US stimulation up regulates iNOS expression in osteoblasts by an HIF 1 alpha dependent mechanism involving the activation of ILK/Akt and mTOR pathways via integrin receptor.
C1 Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei 100, Taiwan.
   Natl Taiwan Univ, Coll Med, Dept Orthopaed, Taipei 100, Taiwan.
   China Med Univ, Coll Med, Dept Pharmacol, Taichung 404, Taiwan.
C3 National Taiwan University; National Taiwan University; China Medical
   University Taiwan
RP Fu, WM (通讯作者)，Natl Taiwan Univ, Coll Med, Inst Pharmacol, 7 Chung shan S Rd, Taipei 100, Taiwan.
EM wenmei@ntu.edu.tw; rsyang@ntuh.gov.tw
RI Tang, Chih/O 5212 2015; Lu, Dah Yuu/P 2563 2015
OI FU, WEN MEI/0000 0003 4157 8987; Yang, Rong Sen/0000 0002 0553 4779
CR Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092 8674(00)81235 0
   Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955 0674(98)80145 2
   Cook SD, 1997, CLIN ORTHOP RELAT R, P198
   Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g
   Deng WG, 2006, BLOOD, V108, P518, DOI 10.1182/blood 2005 09 3691
   Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334
   DUARTE LR, 1983, ARCH ORTHOP TRAUM SU, V101, P153, DOI 10.1007/BF00436764
   Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592 6602.2005
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092 8674(92)90115 S
   Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771
   Klein Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270
   Lee HS, 2000, J BONE MINER RES, V15, P1501, DOI 10.1359/jbmr.2000.15.8.1501
   Lu DY, 2006, BIOCHEM PHARMACOL, V72, P992, DOI 10.1016/j.bcp.2006.06.038
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236
   Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200
   Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200
   PFAFF M, 1994, J BIOL CHEM, V269, P20233
   PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349
   Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756 3282(02)00789 5
   RUBIN CT, 1995, J BONE MINER RES, V10, P488
   Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975
   Saito M, 2004, BONE, V35, P644, DOI 10.1016/j.bone.2004.04.024
   Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642
   SCHULTZ JF, 1995, J BIOL CHEM, V270, P11522, DOI 10.1074/jbc.270.19.11522
   Sharp FR, 2004, NAT REV NEUROSCI, V5, P437, DOI 10.1038/nrn1408
   Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200
   Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535 6108(03)00281 2
   Tang CH, 2005, J BIOL CHEM, V280, P22907, DOI 10.1074/jbc.M500130200
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200
   Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   WANG SJ, 1994, J ORTHOP RES, V12, P40, DOI 10.1002/jor.1100120106
   Warden SJ, 2001, BIOCHEM BIOPH RES CO, V286, P443, DOI 10.1006/bbrc.2001.5412
   Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
   Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008 5472.CAN 04 2940
NR 43
TC 66
Z9 74
U1 0
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 31
PY 2007
VL 282
IS 35
BP 25406
EP 25415
DI 10.1074/jbc.M701001200
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 204AB
UT WOS:000249014100026
PM 17588951
DA 2025 08 17
ER

PT J
AU Li, JL
   Mai, JL
   Zhang, M
   Ma, YH
   He, Q
   Gong, DW
   Xiao, JC
   Li, M
   Chen, WJ
   Li, Z
   Chen, S
   Pan, ZF
   Li, SC
   Wang, HB
AF Li, Jianliang
   Mai, Jiale
   Zhang, Meng
   Ma, Yanhuai
   He, Qi
   Gong, Dawei
   Xiao, Jiacong
   Li, Miao
   Chen, Weijian
   Li, Zhen
   Chen, Shuai
   Pan, Zhaofeng
   Li, Shaocong
   Wang, Haibin
TI Myricitrin promotes osteogenesis and prevents ovariectomy bone mass loss
   via the PI3K/AKT signalling pathway
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE bone marrow mesenchymal stem cells; myricitrin; osteoporosis; PI3K; AKT
   signalling pathway
ID MESENCHYMAL STEM CELLS; DIARYLHEPTANOID GLYCOSIDES; POSTMENOPAUSAL
   WOMEN; MYRICA RUBRA; OSTEOPOROSIS; DIFFERENTIATION; CONSTITUENTS;
   ACTIVATION; INHIBITORS; BARK
AB This study aimed to explore the effect of myricitrin on osteoblast differentiation in mice immortalised bone marrow mesenchymal stem cells (imBMSCs). Additionally, ovariectomy (OVX) mice were employed to examine the effect of myricitrin on bone trabecular loss in vivo. The effect of myricitrin on the proliferation of imBMSCs was evaluated using a cell counting kit 8 assay. Alizarin red staining, alkaline phosphatase staining were performed to elucidate osteogenesis. Furthermore, qRT PCR and western blot determined the expression of osteo specific genes and proteins. To screen for candidate targets, mRNA transcriptome genes were sequenced using bioinformatics analyses. Western blot and molecular docking analysis were used to examine target signalling markers. Moreover, rescue experiments were used to confirm the effect of myricitrin on the osteogenic differentiation of imBMSCs. OVX mice were also used to estimate the delay capability of myricitrin on bone trabecular loss in vivo using western blot, micro CT, tartaric acid phosphatase (Trap) staining, haematoxylin and eosin staining, Masson staining and immunochemistry. In vitro, myricitrin significantly enhanced osteo specific genes and protein expression and calcium deposition. Moreover, mRNA transcriptome gene sequencing and molecular docking analysis revealed that this enhancement was accompanied by an upregulation of the PI3K/AKT signalling pathway. Furthermore, copanlisib, a PI3K inhibitor, partially reversed the osteogenesis promotion induced by myricitrin. In vivo, western blot, micro CT, hematoxylin and eosin staining, Masson staining, Trap staining and immunochemistry revealed that bone trabecular loss rate was significantly alleviated in the myricitrin low  and high dose groups, with an increased expression of osteopontin, osteoprotegerin, p PI3K and p AKT compared to the OVX group. Myricitrin enhances imBMSC osteoblast differentiation and attenuate bone mass loss partly through the upregulation of the PI3K/AKT signalling pathway. Thus, myricitrin has therapeutic potential as an antiosteoporosis drug.
C1 [Li, Jianliang; Ma, Yanhuai; He, Qi; Gong, Dawei; Xiao, Jiacong; Li, Miao; Chen, Shuai; Pan, Zhaofeng; Li, Shaocong; Wang, Haibin] Guangzhou Univ Chinese Med, Sch Clin Med 1, Guangzhou, Peoples R China.
   [Li, Jianliang; Mai, Jiale; Ma, Yanhuai; He, Qi; Gong, Dawei; Xiao, Jiacong; Li, Miao; Chen, Weijian; Li, Zhen; Chen, Shuai; Pan, Zhaofeng; Li, Shaocong; Wang, Haibin] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Lab Orthopaed & Traumatol, Guangzhou, Peoples R China.
   [Li, Jianliang] South China Univ Technol, Guangzhou Peoples Hosp 1, Affiliated Hosp 2, Guangzhou, Peoples R China.
   [Mai, Jiale] Guangzhou Univ Chinese Med, Foshan Hosp Tradit Chinese Med, Clin Sch 8, Foshan, Peoples R China.
   [Zhang, Meng] Zhengzhou Univ, Henan Univ, Peoples Hosp, Dept Orthoped,Sch Clin Med, Zhengzhou, Peoples R China.
   [Gong, Dawei] Wendeng Orthoped & Traumatol Hosp Shandong Prov, Dept Orthopaed Surg, Weihai, Peoples R China.
   [Chen, Weijian] Guangzhou Univ Chinese Med, Clin Sch 5, Guangdong Tradmonal Chinese Med Hostpital 2, Guangzhou, Peoples R China.
   [Li, Zhen] Guangzhou Univ Chinese Med, Sch Clin Med 2, Guangzhou, Peoples R China.
   [Chen, Shuai] Guangzhou Hosp Integrated Tradit & West Med, Dept Orthopaed Surg, Guangzhou, Peoples R China.
   [Wang, Haibin] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Orthopaed Surg, Guangzhou, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; South China University of Technology; Guangzhou
   University of Chinese Medicine; Zhengzhou University; Henan University;
   Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine
RP Wang, HB (通讯作者)，Guangzhou Univ Chinese Med, Sch Clin Med 1, Guangzhou, Peoples R China.; Wang, HB (通讯作者)，Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Lab Orthopaed & Traumatol, Guangzhou, Peoples R China.; Wang, HB (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Orthopaed Surg, Guangzhou, Guangdong, Peoples R China.
EM hipman@163.com
RI Wang, Qianghu/HJI 9741 2023; zhang, zhizhong/KRP 4408 2024
FU Guangzhou University of Chinese Medicine [2021xk53]; National Natural
   Science Foundation of China [82074462]
FX Major Research Project of Guangzhou University of Chinese Medicine,
   Grant/Award Number: 2021xk53; National Natural Science Foundation of
   China, Grant/Award Number: 82074462
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Bustin SA, 2005, CLIN SCI, V109, P365, DOI 10.1042/CS20050086
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Cardiff Robert D, 2014, Cold Spring Harb Protoc, V2014, P655, DOI 10.1101/pdb.prot073411
   Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659
   Cheng HY, 2003, PLANTA MED, V69, P953, DOI 10.1055/s 2003 45108
   Chotiyarnwong P, 2020, J BONE MINER RES, V35, P1014, DOI 10.1002/jbmr.3972
   Clark DP, 2021, PHYS MEDICA, V88, P175, DOI 10.1016/j.ejmp.2021.07.005
   Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301 472X(00)00482 3
   Domitrovic R, 2015, CHEM BIOL INTERACT, V230, P21, DOI 10.1016/j.cbi.2015.01.030
   Dong J, 2020, EXP CELL RES, V394, DOI 10.1016/j.yexcr.2020.112137
   Duan HXY, 2021, PHARMACOL RES, V168, DOI 10.1016/j.phrs.2021.105599
   Fan SL, 2018, LIFE SCI, V207, P205, DOI 10.1016/j.lfs.2018.06.006
   Filgueira L, 2004, J HISTOCHEM CYTOCHEM, V52, P411, DOI 10.1177/002215540405200312
   Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313
   Gan DH, 2019, MED SCI MONITOR, V25, P5700, DOI 10.12659/MSM.915170
   Gao SQ, 2023, STEM CELL RES, V66, DOI 10.1016/j.scr.2022.103010
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Grey A, 2017, CAN MED ASSOC J, V189, pE1130, DOI 10.1503/cmaj.161207
   Han YY, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 00932 0
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004
   Hnasko TS, 2015, METHODS MOL BIOL, V1318, P87, DOI 10.1007/978 1 4939 2742 5_9
   Hobbs CA, 2015, FOOD CHEM TOXICOL, V83, P283, DOI 10.1016/j.fct.2015.06.016
   Hofman Florence, 2002, Curr Protoc Immunol, VChapter 21, DOI 10.1002/0471142735.im2104s49
   Hu X, 2017, ONCOTARGET, V8, P111847, DOI 10.18632/oncotarget.22915
   Hu ZP, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110726
   Huang JL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030422
   Huang Q, 2014, TOXICOL APPL PHARM, V280, P550, DOI 10.1016/j.taap.2014.08.004
   Iglesias Ara A, 2018, METHODS MOL BIOL, V1726, P153, DOI 10.1007/978 1 4939 7565 5_14
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Jing WB, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02690 1
   Kendler DL, 2018, LANCET, V391, P1896, DOI 10.1016/S0140 6736(18)30756 6
   Kim HH, 2013, ARCH PHARM RES, V36, P1533, DOI 10.1007/s12272 013 0147 x
   Kukurba Kimberly R, 2015, Cold Spring Harb Protoc, V2015, P951, DOI 10.1101/pdb.top084970
   Li HB, 2020, CHEM BIOL DRUG DES, V95, P451, DOI 10.1111/cbdd.13659
   Li RQ, 2020, INT UROL NEPHROL, V52, P187, DOI 10.1007/s11255 019 02334 8
   Liang X, 2020, J TRADIT CHIN MED, V40, P690, DOI 10.19852/j.cnki.jtcm.2020.04.019
   Ma HY, 2021, HORM METAB RES, V53, P730, DOI 10.1055/a 1655 4362
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Martiniakova M, 2022, NUTRIENTS, V14, DOI 10.3390/nu14030523
   Matsuda H, 2002, CHEM PHARM BULL, V50, P208, DOI 10.1248/cpb.50.208
   Odell ID, 2013, J INVEST DERMATOL, V133, pE1, DOI 10.1038/jid.2012.455
   QI SM, 2017, OXID MED CELL LONGEV, V2017, DOI DOI 10.1155/2017/9738745
   Shen CY, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.905376
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Sleeman A, 2019, AM J HEALTH SYST PH, V76, P130, DOI 10.1093/ajhp/zxy022
   Sridharan D, 2022, METHOD PROTOCOL, V5, DOI 10.3390/mps5010013
   Tao J, 2002, BIOORGAN MED CHEM, V10, P4005, DOI 10.1016/S0968 0896(02)00314 0
   Tariq Kamran, 2021, Explor Neuroprotective Ther, V1, P86, DOI 10.37349/ent.2021.00008
   Vidal Limon A, 2022, J AGR FOOD CHEM, V70, P934, DOI 10.1021/acs.jafc.1c06110
   Wang B, 2018, J CELL MOL MED, V22, P4236, DOI 10.1111/jcmm.13703
   Wang HC, 2017, IRAN J BASIC MED SCI, V20, P408, DOI 10.22038/IJBMS.2017.8582
   Wang N, 2021, PHYTOTHER RES, V35, P2639, DOI 10.1002/ptr.7010
   Xu Chang, 2020, Zhongguo Zhong Yao Za Zhi, V45, P3575, DOI 10.19540/j.cnki.cjcmm.20200426.605
   Xu H., 2021, J N CHINA U SCI TECH, V23, P444
   Yeh CB, 2016, OSTEOPOROSIS INT, V27, P3355, DOI 10.1007/s00198 016 3652 1
   Yen BL, 2023, FEBS J, V290, P2833, DOI 10.1111/febs.16438
   Ying XZ, 2014, EUR J PHARMACOL, V738, P22, DOI 10.1016/j.ejphar.2014.04.049
   Zheng D, 2022, INT WOUND J, V19, P1023, DOI 10.1111/iwj.13699
   Zhu Y, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1143 y
NR 60
TC 3
Z9 3
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG
PY 2023
VL 124
IS 8
BP 1155
EP 1172
DI 10.1002/jcb.30439
EA JUN 2023
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FP1B7
UT WOS:001015954000001
PM 37357411
DA 2025 08 17
ER

PT J
AU McLeod, NMH
   Moutasim, KA
   Brennan, PA
   Thomas, G
   Jenei, V
AF McLeod, Niall M. H.
   Moutasim, Karwan A.
   Brennan, Peter A.
   Thomas, Gareth
   Jenei, Veronika
TI In Vitro Effect of Bisphosphonates on Oral Keratinocytes and Fibroblasts
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID ENDOTHELIAL CELLS; OSTEONECROSIS; ALENDRONATE; TISSUE; JAW; MECHANISMS;
   MODEL; BONE
AB Purpose: Osteonecrosis of the jaws is a potential complication of bisphosphonate (BP) therapy. The underlying mechanisms remain unclear. Although most research has concentrated on the effects of BPs on osteoclast and osteoblast functions, the disease is diagnosed and classified based on of mucosal breakdown, suggesting that oral soft tissues may be involved in its pathogenesis. The aim of this study was to determine the effect of 3 different BP drugs (alendronate, zoledronate, and clodronate) on the function of oral keratinocytes and fibroblasts.
   Materials and Methods: Human oral keratinocytes (OKF6) and fetal foreskin fibroblasts (HFFF2) were exposed to each drug at several concentrations and the effect on cell proliferation was assessed by counting the viable cells after different lengths of treatment. The effect on cell migration was examined using Transwell migration assays. An organotypic coculture model using keratinocytes and fibroblasts, which recapitulated the morphology of the oral mucosa, was used to assess the effect of the drugs on epithelial stratification and differentiation.
   Results: The 3 BPs affected the viability and proliferation of OKF6 and HFFF2 cells at concentrations in keeping with their known relative in vitro potencies. There was no effect on cell migration or tissue architecture in organotypic cultures at subtoxic concentrations.
   Conclusion: The lack of effect of these drugs on cell migration below concentrations known to affect cell viability suggests that BP related osteonecrosis is not caused through suppression of keratinocyte or fibroblast motility. (C) 2014 American Association of Oral and Maxillofacial Surgeons
C1 [McLeod, Niall M. H.; Moutasim, Karwan A.; Brennan, Peter A.; Thomas, Gareth; Jenei, Veronika] John Radcliffe, Dept Oral & Maxillofacial Surg, Oxford OX3 9DU, England.
RP McLeod, NMH (通讯作者)，John Radcliffe, Dept Oral & Maxillofacial Surg, Headley Way, Oxford OX3 9DU, England.
EM niall.mcleod@nhs.net
RI ; McLeod, Niall/AAO 9623 2020
OI McLeod, Niall/0000 0001 5795 6482; 
FU British Association of Oral and Maxillofacial Surgeons; National
   Institute for Health Research [CL 2011 26 003] Funding Source:
   researchfish
FX This study was supported by a grant from the British Association of Oral
   and Maxillofacial Surgeons.
CR Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   McLeod NMH, 2012, SURG J R COLL SURG E, V10, P36, DOI 10.1016/j.surge.2011.09.002
   Moreira MS, 2005, DENT TRAUMATOL, V21, P329, DOI 10.1111/j.1600 9657.2005.00370.x
   Nyström ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716
   Correia VDP, 2006, DENT TRAUMATOL, V22, P312, DOI 10.1111/j.1600 9657.2005.00434.x
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Ringe JD, 1998, CLIN THER, V20, P648, DOI 10.1016/S0149 2918(98)80128 8
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Santini D, 2003, ANN ONCOL, V14, P1468, DOI 10.1093/annonc/mdg401
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Scheper MA, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755 1536 3 6
   Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365 2141.2008.07504.x
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Stefanik D, 2008, ORAL DIS, V14, P465, DOI 10.1111/j.1601 0825.2007.01402.x
   Twiss IM, 1999, J BONE MINER RES, V14, P784, DOI 10.1359/jbmr.1999.14.5.784
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 21
TC 23
Z9 24
U1 0
U2 11
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0278 2391
EI 1531 5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD MAR
PY 2014
VL 72
IS 3
BP 503
EP 509
DI 10.1016/j.joms.2013.08.007
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AA5OZ
UT WOS:000331150800010
PM 24342576
DA 2025 08 17
ER

PT J
AU Lee, HG
   Hur, J
   Won, JP
   Seo, HG
AF Lee, Hyuk Gyoon
   Hur, Jinwoo
   Won, Jun Pil
   Seo, Han Geuk
TI Ginseng (Panax ginseng) leaf extract modulates the
   expression of heme oxygenase 1 to attenuate osteoclast differentiation
SO FITOTERAPIA
LA English
DT Article
DE Ginseng leaf extract; HMGB1; HO 1; Osteoclast differentiation; ROS
ID BONE MINERAL DENSITY; RED GINSENG; IN VITRO; RANKL; OSTEOPOROSIS;
   GINSENOSIDES; ACTIVATOR; PATHWAYS; RELEASE
AB Osteoporosis is an aging disease characterized by an imbalance between bone formation and resorption. However, drugs that inhibit bone resorption have various adverse effects. Ginseng (Panax ginseng), a prominent herbal medicine in East Asia for >2000 years, is renowned for its manifold beneficial properties, including antioxidant, anti cancer, anti diabetic, and anti adipogenic activities. Despite its long history of use, the pharmacological functions of ginseng leaves are not yet fully comprehended. In this study, we evaluated the potential effects of ginseng leaf extract (GLE) on receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation in RAW264.7 macrophage cells. Tartrate resistant acid phosphatase (TRAP) staining revealed that GLE had significant anti osteoclastogenic activity. GLE significantly reduced mRNA levels of osteoclast differentiation markers including TRAP, nuclear factor of activated T cell cytoplasmic 1, and cathepsin K. It also suppressed the production of reactive oxygen species (ROS) and secretion of high mobility group box 1 (HMGB1) in RANKL treated RAW264.7 cells. In addition, GLE upregulated dose  and time dependently the expression of heme oxygenase 1 (HO 1), eventually suppressing ROS production and HMGB1 secretion. This effects of GLE were significantly reversed by Tin Protoporphyrin IX dichloride, an inhibitor of HO 1, and HO 1 shRNA, indicating that HO 1 potently inhibits RANKL induced osteoclast differentiation by inhibiting ROS production and HMGB1 secretion. Taken together, these observations suggest that GLE could have therapeutic potential as a natural product derived medicine for the treatment of bone disorders.
C1 [Lee, Hyuk Gyoon; Hur, Jinwoo; Won, Jun Pil; Seo, Han Geuk] Konkuk Univ, Coll Sang Huh Life Sci, Dept Anim Food Resources, 120 Neungdong Ro, Seoul 05029, South Korea.
C3 Konkuk University
RP Seo, HG (通讯作者)，Konkuk Univ, Coll Sang Huh Life Sci, Dept Anim Food Resources, 120 Neungdong Ro, Seoul 05029, South Korea.
EM hgseo@konkuk.ac.kr
FU National Research Foundation of Korea (NRF)   Korean government (MSIT)
   [2021R1A2C1007526]
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant funded by the Korean government (MSIT) (2021R1A2C1007526) .
CR Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Altindag O, 2008, RHEUMATOL INT, V28, P317, DOI 10.1007/s00296 007 0452 0
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Blangy A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.244798
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Chen LX, 2019, MOLECULES, V24, DOI 10.3390/molecules24061096
   Cheng BB, 2012, FOOD CHEM TOXICOL, V50, P1610, DOI 10.1016/j.fct.2012.02.019
   Choi YS, 2013, RHEUMATOL INT, V33, P1981, DOI 10.1007/s00296 013 2664 9
   Cong F, 2017, BIOMED PHARMACOTHER, V92, P927, DOI 10.1016/j.biopha.2017.05.115
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   He FL, 2019, J CELL PHYSIOL, V234, P17314, DOI 10.1002/jcp.28351
   Hur J, 2021, J FOOD BIOCHEM, V45, DOI 10.1111/jfbc.13805
   Hwang JS, 2020, BRIT J PHARMACOL, V177, P4601, DOI 10.1111/bph.15060
   Jeon Hyun Ook, 2018, J Dent Anesth Pain Med, V18, P9, DOI 10.17245/jdapm.2018.18.1.9
   Kang B, 2019, FOOD SCI BIOTECHNOL, V28, P1819, DOI 10.1007/s10068 019 00611 x
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim J, 2015, J GINSENG RES, V39, P46, DOI 10.1016/j.jgr.2014.06.001
   Kim MR, 2014, APPL BIOCHEM BIOTECH, V173, P933, DOI 10.1007/s12010 014 0886 2
   Lee HJ, 2012, PROCESS BIOCHEM, V47, P538, DOI 10.1016/j.procbio.2011.12.004
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Liu MQ, 2021, J ETHNOPHARMACOL, V275, DOI 10.1016/j.jep.2021.114129
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Muraki S, 2006, J BONE MINER METAB, V24, P100, DOI 10.1007/s00774 005 0654 z
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nguyen ND, 2007, J BONE MINER RES, V22, P1147, DOI [10.1359/jbmr.070412, 10.1359/JBMR.070412]
   Nishioku T, 2020, BIOCHEM BIOPH RES CO, V530, P455, DOI 10.1016/j.bbrc.2020.05.088
   Park CM, 2016, MOL CELLS, V39, P855, DOI 10.14348/molcells.2016.0111
   Patel S, 2017, BIOMED PHARMACOTHER, V85, P120, DOI 10.1016/j.biopha.2016.11.112
   Ratan ZA, 2021, J GINSENG RES, V45, P199, DOI 10.1016/j.jgr.2020.02.004
   Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372
   Sendur OF, 2009, JOINT BONE SPINE, V76, P514, DOI 10.1016/j.jbspin.2009.02.005
   Shi W, 2007, FOOD CHEM, V102, P664, DOI 10.1016/j.foodchem.2006.05.053
   Siddiqi MH, 2015, PHYTOTHER RES, V29, P1286, DOI 10.1002/ptr.5374
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Suzuki T, 2010, OSTEOPOROSIS INT, V21, P71, DOI 10.1007/s00198 009 0970 6
   Wang CZ, 2006, J AGR FOOD CHEM, V54, P2261, DOI 10.1021/jf052993w
   Wang Hongwei, 2009, Chin Med, V4, P20, DOI 10.1186/1749 8546 4 20
   Yamaguchi Y, 2014, J APPL TOXICOL, V34, P49, DOI 10.1002/jat.2827
   Yamashiro K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01461
   Zhang B, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00271
   Zhou Z, 2008, J BONE MINER RES, V23, P1084, DOI 10.1359/JBMR.080234
NR 45
TC 6
Z9 6
U1 1
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0367 326X
EI 1873 6971
J9 FITOTERAPIA
JI Fitoterapia
PD MAR
PY 2024
VL 173
AR 105831
DI 10.1016/j.fitote.2024.105831
EA JAN 2024
PG 8
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA JY9L9
UT WOS:001176836600001
PM 38278423
DA 2025 08 17
ER

PT J
AU Sun, JF
   Gao, Y
   Yao, YX
   Li, Y
   Feng, MG
   Bai, L
   Chen, XY
   Ge, YC
   Lin, YF
   Cai, XX
AF Sun, Jiafei
   Gao, Yang
   Yao, Yangxue
   Li, Yong
   Feng, Maogeng
   Bai, Long
   Chen, Xingyu
   Ge, Yichen
   Lin, Yunfeng
   Cai, Xiaoxiao
TI Bone tissue engineering based on sustained release of MiR29c modified
   framework nucleic acids from an injectable hydrogel
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE GelMA; MiR29c; Framework nucleic acids; Cranial defects; Critical size
   bone defects
ID SCAFFOLDS
AB Bone defects affect the daily activities of patients and are prevalent complications of various skeletal disorders. The miR29 family regulates bone physiology and pathological processes. MiR29c can inhibit Dickkopf 1 (DKK1) expression, up regulate the Wnt signaling pathway, and modify the intracellular microenvironment. However, its application is hindered by poor stability and low bioavailability. This study sought to optimize the nano miR29c delivery system, enable enhanced drug effects, stable drug in situ retention, and sustained drug release. Tetrahedral framework nucleic acids (tFNAs), which have excellent drug loading ability, endocytic capacity, and stability, were used with sticky ends to deliver miR29c (i.e., stFNAs miR29c). Porous gelatin methacryloyl (GelMA) was selected as a scaffold for the in situ sustained release of stFNAs miR29c and to provide a growth environment for bone marrow mesenchymal stem cells (BMSCs). This research developed a miR29c sustainedrelease system in situ : GelMA stFNAs miR29c and demonstrated its osteogenesis in vitro and in vivo . GelMA, stFNAs, and miR29c can function synergistically at nano , micro , and macroscales that achieves high stability and efficiency on microRNA nano delivery, regulates the local microenvironment, maintains the macroosteogenic space, accelerates the osteogenic process, and ensures excellent osteogenesis effects, contributing to the broader application of miRNAs in biomedicine and improved bone regeneration in situ .
C1 [Sun, Jiafei; Gao, Yang; Yao, Yangxue; Li, Yong; Chen, Xingyu; Ge, Yichen; Lin, Yunfeng; Cai, Xiaoxiao] Sichuan Univ, State Key Lab Oral Dis, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,West China Hosp Stomato, Chengdu 610041, Peoples R China.
   [Sun, Jiafei; Gao, Yang; Yao, Yangxue; Li, Yong; Chen, Xingyu; Ge, Yichen; Lin, Yunfeng; Cai, Xiaoxiao] Sichuan Prov Engn Res Ctr Oral Biomat, Chengdu 610041, Sichuan, Peoples R China.
   [Feng, Maogeng; Bai, Long] Southwest Med Univ, Affiliated Stomatol Hosp, Dept Oral Implantol, Luzhou 646000, Peoples R China.
C3 Sichuan University; Southwest Medical University
RP Cai, XX (通讯作者)，Sichuan Univ, State Key Lab Oral Dis, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,West China Hosp Stomato, Chengdu 610041, Peoples R China.
EM xcai@scu.edu.cn
RI Xingyu, Chen/IYS 8727 2023; Long, Bai/JDC 3687 2023; 林,
   云峰/HSH 4987 2023; Cai, Xiaoxiao/C 4868 2018; Lin, Yunfeng/H 3393 2011
OI Cai, Xiaoxiao/0000 0002 5654 7414; Lin, Yunfeng/0000 0003 1224 6561
FU National Natural Science Foundation of China [82322015, 82171006];
   Sichuan Province Youth Science and Technology Innovation Team
   [2022JDTD0021]; West China Hospital of Stomatology Sichuan University
   [RCDWJS2024 3]
FX This paper was supported by various funding sources, including the
   National Natural Science Foundation of China (82322015, 82171006) ,
   Sichuan Province Youth Science and Technology Innovation Team
   (2022JDTD0021) , West China Hospital of Stomatology Sichuan University
   (RCDWJS2024 3) . The author would like to express gratitude to Liying
   Hao (State Key Laboratory of Oral Diseases, National Clinical Research
   Center for Oral Diseases, West China Hospital of Stomatology, Sichuan
   University) for the help with AFM characterization and Bomiao Cui (State
   Key Laboratory of Oral Diseases, National Clinical Research Center for
   Oral Diseases, West China Hospital of Stomatology, Sichuan University)
   for the support with confocal microscopy.
CR Ban E, 2014, BIOMACROMOLECULES, V15, P143, DOI 10.1021/bm401425k
   Bellavia D, 2019, BONE, V122, P52, DOI 10.1016/j.bone.2019.02.013
   Bothe F, 2018, ACTA BIOMATER, V76, P135, DOI 10.1016/j.actbio.2018.06.026
   Chen L, 2019, BRIEF BIOINFORM, V20, P1836, DOI 10.1093/bib/bby054
   Chen RQ, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13206
   Chen YH, 2019, INT J BIOL MACROMOL, V126, P159, DOI 10.1016/j.ijbiomac.2018.12.199
   Chen Y, 2024, SIGNAL TRANSDUCT TAR, V9, DOI 10.1038/s41392 024 01736 0
   Cui WT, 2020, NANOSCALE, V12, P17196, DOI 10.1039/d0nr03731a
   Gao SJY, 2021, NANO LETT, V21, P4437, DOI 10.1021/acs.nanolett.1c01131
   Gao Y, 2022, ADV MATER, V34, DOI 10.1002/adma.202201731
   Horita M, 2021, J CELL BIOCHEM, V122, P696, DOI 10.1002/jcb.29896
   Hu B, 2018, ACTA BIOMATER, V76, P275, DOI 10.1016/j.actbio.2018.06.017
   Huang EE, 2022, BIOENGINEERING BASEL, V9, DOI 10.3390/bioengineering9040171
   Kapinas K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3325
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kara G, 2022, ADV DRUG DELIVER REV, V182, DOI 10.1016/j.addr.2022.114113
   Koushik TM, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202202766
   Kurian AG, 2022, BIOACT MATER, V8, P267, DOI 10.1016/j.bioactmat.2021.06.027
   Laird NZ, 2021, ADV DRUG DELIVER REV, V174, P613, DOI 10.1016/j.addr.2021.05.009
   Li DH, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202101412
   Li JJ, 2022, ADV MATER, V34, DOI 10.1002/adma.202202513
   Li JJ, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202104141
   Li J, 2022, CHEM ENG J, V435, DOI 10.1016/j.cej.2022.134855
   Li SH, 2022, ADV MATER, V34, DOI 10.1002/adma.202204287
   Li SH, 2021, SMALL, V17, DOI 10.1002/smll.202104359
   Li SH, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12708
   Li Y, 2024, BONE RES, V12, DOI 10.1038/s41413 024 00319 7
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liu DD, 2022, J DENT RES, V101, P1227, DOI 10.1177/00220345221093518
   Liu MT, 2021, ACS APPL MATER INTER, V13, P25825, DOI 10.1021/acsami.1c07297
   Liu NX, 2019, SMALL, V15, DOI 10.1002/smll.201901907
   Liu R, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202108378
   Ma WJ, 2022, ADV MATER, V34, DOI 10.1002/adma.202109609
   Newman H, 2021, BIOMATERIALS, V277, DOI 10.1016/j.biomaterials.2021.121114
   Nguyen MK, 2018, ACTA BIOMATER, V75, P105, DOI 10.1016/j.actbio.2018.06.007
   Potyondy T, 2021, BIOFABRICATION, V13, DOI 10.1088/1758 5090/abc8de
   Qi JQ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910233
   Qin X, 2022, BIOACT MATER, V14, P134, DOI 10.1016/j.bioactmat.2021.11.031
   Sassi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01737 4
   Saunders WB, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.921486
   Schmidt AH, 2021, INJURY, V52, pS18, DOI 10.1016/j.injury.2021.01.043
   Shi SR, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202305558
   Sun H, 2023, BIOACT MATER, V24, P477, DOI 10.1016/j.bioactmat.2022.12.021
   Tan BW, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 021 00113 9
   Tan JL, 2019, ACS NANO, V13, P5616, DOI 10.1021/acsnano.9b00788
   Tao J, 2022, MATER TODAY BIO, V17, DOI 10.1016/j.mtbio.2022.100487
   Tian TR, 2023, NAT PROTOC, V18, P1028, DOI 10.1038/s41596 022 00791 7
   Tian TR, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00212 1
   Tresguerres FGF, 2020, ANN ANAT, V227, DOI 10.1016/j.aanat.2019.151422
   Turnbull G, 2018, BIOACT MATER, V3, P278, DOI 10.1016/j.bioactmat.2017.10.001
   Wang QG, 2024, ADV SCI, V11, DOI 10.1002/advs.202306622
   Wang Y, 2022, NANO LETT, V22, P1759, DOI 10.1021/acs.nanolett.1c05003
   Wubneh A, 2018, ACTA BIOMATER, V80, P1, DOI 10.1016/j.actbio.2018.09.031
   Xiao SN, 2019, STEM CELL REV REP, V15, P664, DOI 10.1007/s12015 019 09893 4
   Xie Y, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202303580
   Xin TW, 2020, ACS APPL MATER INTER, V12, P6840, DOI 10.1021/acsami.9b18496
   Xu C, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202101911
   Xue K, 2019, ADV THER GERMANY, V2, DOI 10.1002/adtp.201800088
   Yan R, 2023, ACS NANO, V17, P8767, DOI 10.1021/acsnano.3c02102
   Yu XG, 2022, CHEM ENG J, V433, DOI 10.1016/j.cej.2021.132799
   Zeng H, 2020, BIOFABRICATION, V12, DOI 10.1088/1758 5090/ab78ed
   Zhang BW, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202109728
   Zhang H, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.989648
   Zhang JF, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0046 1
   Zhang M, 2022, BIOACT MATER, V8, P368, DOI 10.1016/j.bioactmat.2021.06.003
   Zhang T, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202213401
   Zhang T, 2022, ADV MATER, DOI 10.1002/adma.202107820
   Zhang T, 2020, NAT PROTOC, V15, P2728, DOI 10.1038/s41596 020 0355 z
   Zhang TX, 2022, ADV SCI, V9, DOI 10.1002/advs.202202058
   Zhang XZ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 32868 y
   Zhang XX, 2022, MATTER US, V5, P666, DOI 10.1016/j.matt.2021.11.017
   Zhang YD, 2022, ACS APPL MATER INTER, V14, P47052, DOI 10.1021/acsami.2c13557
   Zhou H, 2021, BIOMACROMOLECULES, V22, P4552, DOI 10.1021/acs.biomac.1c00842
   Zhou M, 2021, BIOACT MATER, V6, P1676, DOI 10.1016/j.bioactmat.2020.11.018
   Zhu GY, 2021, BIOACT MATER, V6, P4110, DOI 10.1016/j.bioactmat.2021.03.043
NR 75
TC 19
Z9 20
U1 21
U2 76
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD MAY 1
PY 2024
VL 487
AR 150706
DI 10.1016/j.cej.2024.150706
EA MAR 2024
PG 12
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA QC5T7
UT WOS:001218700500001
DA 2025 08 17
ER

PT J
AU Yoshida, H
   Okamoto, K
   Iwamoto, T
   Sakai, E
   Kanaoka, K
   Hu, JP
   Shibata, M
   Hotokezaka, H
   Nishishita, K
   Mizuno, A
   Kato, Y
AF Yoshida, H
   Okamoto, K
   Iwamoto, T
   Sakai, E
   Kanaoka, K
   Hu, JP
   Shibata, M
   Hotokezaka, H
   Nishishita, K
   Mizuno, A
   Kato, Y
TI Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL induced
   osteoclast differentiation
SO JOURNAL OF BIOCHEMISTRY
LA English
DT Article
DE aspartic proteinase; cathepsin; osteoclast; pepstatin A
ID NF KAPPA B; NECROSIS FACTOR RECEPTOR; BONE RESORPTION; KEY REGULATOR;
   IMMUNOCYTOCHEMICAL LOCALIZATION; OSTEOPROTEGERIN LIGAND; MACROPHAGE
   LINEAGE; GENE EXPRESSION; RAT OSTEOCLAST; CATHEPSIN D
AB Pepstatin A is well known to be an inhibitor of aspartic proteinases such as pepsin, cathepsins D and E. Except for its role as a proteinase inhibitor, however, the pharmacological action of pepstatin A upon cells remain unclear. In this study, we found that pepstatin A suppressed receptor activator of NF kappa B ligand (RANKL) induced osteoclast differentiation. Pepstatin A suppressed the formation of multinuclear osteoclasts dose dependently. This inhibition of the formation only affected osteoclast cells, i.e., not osteoblast like cells. Furthermore, pepstatin A also suppressed differentiation from pre osteoclast cells to mononuclear osteoclast cells dose dependently. This inhibition seems to be independent of the activities of proteinases such as cathepsin D, because the formation of osteoclasts was not suppressed with the concentration that inhibited the activity of cathepsin D. Cell signaling analysis indicated that the phosphorylation of ERK was inhibited in pepstatin A treated cells, while the phosphorylation of I kappa B and Akt showed almost no change. Furthermore, pepstatin A decreased the expression of nuclear factor of activated T cells c1 (NFATc1). These results suggest that pepstatin A suppresses the differentiation of osteoclasts through the blockade of ERK signaling and the inhibition of NFATc1 expression.
C1 Nagasaki Univ, Grad Sch Biomed Sci, Div Oral Mol Pharmacol, Nagasaki 8528588, Japan.
   Nagasaki Univ, Grad Sch Biomed Sci, Div Oral & Maxillofacial Surg, Nagasaki 8528588, Japan.
   Nagasaki Univ, Grad Sch Biomed Sci, Div Orthodont & Biomed Engn, Dep Dev & Reconstruct Med, Nagasaki 8528588, Japan.
C3 Nagasaki University; Nagasaki University; Nagasaki University
RP Nagasaki Univ, Grad Sch Biomed Sci, Div Oral Mol Pharmacol, Nagasaki 8528588, Japan.
EM k oka@net.nagasaki u.ac.jp
RI ; Iwamoto, Tsutomu/AAI 8952 2021
OI sakai, eiko/0000 0002 6776 6540; Iwamoto, Tsutomu/0000 0001 8472 605X; 
CR Annunziata CM, 2000, BLOOD, V96, P2841
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brage M, 2004, BONE, V34, P412, DOI 10.1016/j.bone.2003.11.018
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Chen CS, 2000, J BIOCHEM BIOPH METH, V42, P137, DOI 10.1016/S0165 022X(00)00048 8
   Collin Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   GOTO T, 1992, HISTOCHEMISTRY, V97, P13, DOI 10.1007/BF00271276
   GOTO T, 1994, HISTOCHEMISTRY, V101, P33, DOI 10.1007/BF00315829
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Iwamoto T, 2001, J BIOL CHEM, V276, P46031, DOI 10.1074/jbc.M104464200
   Jimi E, 1999, J IMMUNOL, V163, P434
   Khapli SM, 2003, J IMMUNOL, V171, P142, DOI 10.4049/jimmunol.171.1.142
   Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554
   Takasu Junichiro, 2002, BMC Blood Disord, V2, P3, DOI 10.1186/1471 2326 2 3
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   YAMAMOTO K, 1984, BIOCHIM BIOPHYS ACTA, V790, P208, DOI 10.1016/0167 4838(84)90024 4
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888
   YOSHIMINE Y, 1995, CELL TISSUE RES, V281, P85, DOI 10.1007/BF00307961
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 44
TC 16
Z9 17
U1 1
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0021 924X
EI 1756 2651
J9 J BIOCHEM
JI J. Biochem.
PD MAR
PY 2006
VL 139
IS 3
BP 583
EP 590
DI 10.1093/jb/mvj066
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 040BY
UT WOS:000237355200030
PM 16567424
DA 2025 08 17
ER

PT J
AU Lau, YS
   Adamopoulos, IE
   Sabokbar, A
   Giele, H
   Gibbons, CLMH
   Athanasou, NA
AF Lau, Y. S.
   Adamopoulos, I. E.
   Sabokbar, A.
   Giele, H.
   Gibbons, C. L. M. H.
   Athanasou, N. A.
TI Cellular and humoral mechanisms of osteoclast formation in Ewing's
   sarcoma
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE Ewing's sarcoma; macrophage; osteoclast; bone resorption
ID TUMOR ASSOCIATED MACROPHAGES; BONE RESORBING CELLS; COLONY STIMULATING
   FACTOR; STROMAL CELLS; TNF ALPHA; RESORPTION; OSTEOLYSIS; MONOCYTE;
   GROWTH; DIFFERENTIATION
AB Cellular mechanisms that account for tumour osteolysis associated with Ewing's sarcoma are uncertain. Osteoclasts are marrow derived multinucleated cells (MNCs) that effect tumour osteolysis. Osteoclasts are known to form from macrophages by both receptor activator for nuclear factor kappa B (RANK) ligand (RANKL) dependent and  independent mechanisms. In this study, our aim has been to determine whether tumour associated macrophages (TAMs) isolated from Ewing's sarcoma are capable of differentiating into osteoclasts and to characterise the cellular and humoral mechanisms whereby this occurs. Tumour associated macrophages were isolated from two Ewing's sarcomas and cultured on both coverslips and dentine slices for up to 21 days with soluble RANKL and macrophage colony stimulating factor (M CSF). Osteoclast formation from TAMs (CD14(+)) was evidenced by the formation of tartrate resistant acid phosphatase (TRAP) and vitronectin receptor (VNR) positive MNCs, which were capable of carrying out lacunar resorption. This osteoclast formation was inhibited by the addition of bisphosphonates. Both Ewing's sarcoma derived fibroblasts and some bone stromal cells expressed RANKL and supported osteoclast formation by a contact dependent mechanism. We also found that osteoclast differentiation occurred when Ewing's TAMs were cultured with tumour necrosis factor (TNF) alpha in the presence of M CSF and that TC71 Ewing's sarcoma cells stimulated osteoclast formation through the release of a soluble factor, the action of which was abolished by an antibody to TNF alpha. These results indicate that TAMs in Ewing's sarcoma are capable of osteoclast differentiation by both RANKL dependent and TNF alpha dependent mechanisms and that Ewing's sarcoma cells produce osteoclastogenic factor(s). Our findings suggest that anti resorptive and anti osteoclastogenic therapies may be useful in inhibiting the osteolysis of Ewing's sarcoma.
C1 Univ Oxford, Nuffield Orthopaed Ctr, Dept Orthopaed Surg, Dept Pathol, Oxford OX3 7LD, England.
   Univ Oxford, Nuffield Orthopaed Ctr, Nuffield Dept Surg, Oxford OX3 7LD, England.
C3 Nuffield Orthopaedic Centre; University of Oxford; Nuffield Orthopaedic
   Centre; University of Oxford
RP Athanasou, NA (通讯作者)，Univ Oxford, Nuffield Orthopaed Ctr, Dept Orthopaed Surg, Dept Pathol, Oxford OX3 7LD, England.
EM nick.athanasou@noc.anglox.nhs.uk
RI ; Adamopoulos, Iannis/AAE 5624 2022
OI Giele, Henk/0000 0003 2017 5193; Adamopoulos, Iannis/0000 0002 3708 2965
CR Adamopoulos IE, 2006, J PATHOL, V208, P35, DOI 10.1002/path.1891
   Athanasou NA, 1996, J BONE JOINT SURG AM, V78A, P1096, DOI 10.2106/00004623 199607000 00016
   ATHANASOU NA, 1990, J CLIN PATHOL, V43, P997, DOI 10.1136/jcp.43.12.997
   BUGELSKI PJ, 1987, CANCER RES, V47, P4141
   CLAASEN HHV, 1992, LAB INVEST, V67, P166
   Clohisy DR, 1998, J ORTHOPAED RES, V16, P660, DOI 10.1002/jor.1100160606
   Clohisy DR, 1996, J ORTHOPAED RES, V14, P2, DOI 10.1002/jor.1100140103
   CLOHISY DR, 2000, CLIN ORTHOP RELAT R, V373, P104
   Dorfman H.D., 1998, Bone tumors
   FELIX R, 1994, J CELL BIOCHEM, V55, P340, DOI 10.1002/jcb.240550311
   Flanagan A M, 1998, Curr Opin Hematol, V5, P181, DOI 10.1097/00062752 199805000 00006
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   Gatter KC., 1984, RECENT ADV HISTOPATH, V12, P35
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   GUNDLE R, 1995, CALCIFIED TISSUE INT, V56, pS8, DOI 10.1007/BF03354640
   Holzer G, 2003, ANTICANCER RES, V23, P3057
   HORTON MA, 1985, CANCER RES, V45, P5663
   Kudo O, 2002, J PATHOL, V198, P220, DOI 10.1002/path.1190
   Kwon BS, 1998, FASEB J, V12, P845, DOI 10.1096/fasebj.12.10.845
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lau YS, 2006, BRIT J CANCER, V94, P1496, DOI 10.1038/sj.bjc.6603103
   Lau YS, 2005, HUM PATHOL, V36, P945, DOI 10.1016/j.humpath.2005.07.005
   MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167 5699(92)90008 U
   MCBRIDE WH, 1986, BIOCHIM BIOPHYS ACTA, V865, P27, DOI 10.1016/0304 419X(86)90011 9
   MICHIGAMI T, 2001, CANCER RES, V61
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Mirra JM, 1989, BONE TUMORS CLIN RAD, P1087
   QUINN JMW, 1994, LAB INVEST, V71, P465
   Quinn JMW, 1998, J PATHOL, V184, P31, DOI 10.1002/(SICI)1096 9896(199801)184:1<31::AID PATH962>3.0.CO;2 V
   Quinn JMW, 2002, BONE, V30, P164, DOI 10.1016/S8756 3282(01)00654 8
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rübe CE, 2003, INT J RADIAT ONCOL, V56, P1414, DOI 10.1016/S0360 3016(03)00418 8
   Sabokbar A, 2003, J ORTHOP RES, V21, P73, DOI 10.1016/S0736 0266(02)00106 7
   Sterling H, 1998, J CELL BIOL, V143, P837, DOI 10.1083/jcb.143.3.837
   Sun SG, 2006, J PATHOL, V209, P114, DOI 10.1002/path.1953
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   WALTER S, 1991, INT J CANCER, V49, P431, DOI 10.1002/ijc.2910490321
   Yang TT, 2002, J BONE JOINT SURG BR, V84B, P452, DOI 10.1302/0301 620X.84B3.11945
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhou ZC, 2005, CANCER AM CANCER SOC, V104, P1713, DOI 10.1002/cncr.21383
NR 41
TC 33
Z9 35
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007 0920
EI 1532 1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD JUN 4
PY 2007
VL 96
IS 11
BP 1716
EP 1722
DI 10.1038/sj.bjc.6603774
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 172PL
UT WOS:000246816200015
PM 17533390
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Wang, CF
   Wang, L
   Li, QS
   Wu, WQ
   Yuan, JC
   Wang, HB
   Lu, XH
AF Wang, Chenfeng
   Wang, Liang
   Li, Qisheng
   Wu, Weiqing
   Yuan, Jincan
   Wang, Haibin
   Lu, Xuhua
TI Computational Drug Discovery in Ankylosing Spondylitis Induced
   Osteoporosis Based on Data Mining and Bioinformatics Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ankylosing spondylitis; Drug discovery; Osteoporosis; Text mining
ID BONE MINERAL DENSITY; MONOCLONAL ANTIBODY; BISPHOSPHONATES; METABOLISM;
   INFLIXIMAB; FRACTURES; CARLUMAB; MARKERS; CCL2
AB  BACKGROUND: Ankylosing spondylitis (AS) and osteo porosis (OP) are both prevalent illnesses in spine surgery, with OP being a possible consequence of AS. However, the mechanism of AS induced OP (AS OP) remains unknown, limiting etiologic research and therapy of the illness. To mine targetable medicine for the prevention and treatment of AS OP, this study analyzes public data sets using bio informatics to identify genes and biological pathways relevant to AS OP.  METHODS: First, text mining was used to identify com mon genes associated with AS and OP, after which func tional analysis was carried out. The STRING database and Cytoscape software were used to create protein  protein interaction networks. Hub genes and potential drugs were discovered using drug gene interaction analysis and transcription factors gene interaction analysis.  RESULTS: The results of text mining showed 241 genes common to AS and OP, from which 115 key symbols were sorted out by functional analysis. As options for treating AS OP, protein  protein interaction analysis yielded 20 genes, which may be targeted by 13 medications.  CONCLUSIONS: Carlumab, bermekimab, rilonacept, rilo tumumab, and ficlatuzumab were first identified as the potential drugs for the treatment of AS OP, proving the value of text mining and pathway analysis in drug discovery.
C1 [Wang, Chenfeng; Wang, Liang; Li, Qisheng; Wu, Weiqing; Yuan, Jincan; Wang, Haibin; Lu, Xuhua] Naval Med Univ, Shanghai Changzheng Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Wang, Liang; Lu, Xuhua] Univ Shanghai Sci & Technol, Sch Hlth Sci & Engn, Shanghai, Peoples R China.
C3 Naval Medical University; University of Shanghai for Science &
   Technology
RP Lu, XH (通讯作者)，Naval Med Univ, Shanghai Changzheng Hosp, Dept Orthoped, Shanghai, Peoples R China.; Lu, XH (通讯作者)，Univ Shanghai Sci & Technol, Sch Hlth Sci & Engn, Shanghai, Peoples R China.
EM xuhualu@hotmail.com
OI wang, chenfeng/0000 0001 5476 4565
CR Aarts P, 2021, DRUGS, V81, P1397, DOI 10.1007/s40265 021 01566 2
   Al Daghri NM, 2017, MEDICINE, V96, P5780
   An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Bal A, 2007, CLIN RHEUMATOL, V26, P211, DOI 10.1007/s10067 006 0283 5
   Brana I, 2015, TARGET ONCOL, V10, P111, DOI 10.1007/s11523 014 0320 2
   Carter Shea, 2011, Curr Osteoporos Rep, V9, P112, DOI 10.1007/s11914 011 0058 z
   Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470 2045(17)30566 1
   Davey Ranasinghe N, 2013, CURR OPIN RHEUMATOL, V25, P509, DOI 10.1097/BOR.0b013e3283620777
   Fatehi F, 2017, J BIOMED RES, V31, P468, DOI 10.7555/JBR.31.20150166
   Feng XZ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4918239
   Franck H, 2004, J RHEUMATOL, V31, P2236
   Gorgulla C, 2020, NATURE, V580, P663, DOI 10.1038/s41586 020 2117 z
   Gottlieb A, 2020, J INVEST DERMATOL, V140, P1538, DOI 10.1016/j.jid.2019.10.024
   Harmer D, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00788
   He B, 2013, BIOORG MED CHEM LETT, V23, P630, DOI 10.1016/j.bmcl.2012.12.005
   Hinze Alicia M, 2016, Curr Treatm Opt Rheumatol, V2, P271, DOI 10.1007/s40674 016 0055 6
   Kim HJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061467
   Klein AL, 2021, NEW ENGL J MED, V384, P31, DOI 10.1056/NEJMoa2027892
   Klingberg E, 2014, J RHEUMATOL, V41, P1349, DOI 10.3899/jrheum.131199
   Knowles HJ, 2009, HISTOL HISTOPATHOL, V24, P337, DOI 10.14670/HH 24.337
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Lee JH, 2012, CANCER RES, V72, P3175, DOI 10.1158/0008 5472.CAN 12 0481
   Liang T, 2022, BMC IMMUNOL, V23, DOI 10.1186/s12865 022 00476 6
   Liu P, 2017, CELL DEATH DIFFER, V24, P672, DOI 10.1038/cdd.2016.165
   Llorente I, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.601618
   Magrey Marina, 2010, Curr Rheumatol Rep, V12, P332, DOI 10.1007/s11926 010 0122 1
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Pienta KJ, 2013, INVEST NEW DRUG, V31, P760, DOI 10.1007/s10637 012 9869 8
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Sambrook PN, 2012, THER ADV MUSCULOSKEL, V4, P287, DOI 10.1177/1759720X12441276
   Scagliotti GV, 2013, CANCER TREAT REV, V39, P793, DOI 10.1016/j.ctrv.2013.02.001
   Schumacher HR, 2012, ARTHRIT CARE RES, V64, P1462, DOI 10.1002/acr.21690
   Singh P, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18030972
   Torres L, 2019, OSTEOPOROSIS INT, V30, P441, DOI 10.1007/s00198 018 4721 4
   Viapiana O, 2014, RHEUMATOLOGY, V53, P90, DOI 10.1093/rheumatology/ket321
   Visvanathan S, 2009, ANN RHEUM DIS, V68, P175, DOI 10.1136/ard.2007.084426
   Wang CF, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm 21 6900
   Wang W, 2022, CLIN EXP PHARMACOL P, V49, P113, DOI 10.1111/1440 1681.13591
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Zhang J, 2021, THER ADV CHRONIC DIS, V12, DOI 10.1177/2040622321995685
   Zhou J, 2016, OSTEOPOROSIS INT, V27, P3289, DOI 10.1007/s00198 016 3654 z
   Zhu LX, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw6143
NR 43
TC 2
Z9 3
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878 8750
EI 1878 8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUN
PY 2023
VL 174
BP E8
EP E16
DI 10.1016/j.wneu.2023.01.092
EA JUN 2023
PG 9
WC Clinical Neurology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Surgery
GA J8MM0
UT WOS:001012109900001
PM 36716856
DA 2025 08 17
ER

PT J
AU Tortora, C
   Punzo, F
   Argenziano, M
   Di Paola, A
   Tolone, C
   Strisciuglio, C
   Rossi, F
AF Tortora, Chiara
   Punzo, Francesca
   Argenziano, Maura
   Di Paola, Alessandra
   Tolone, Carlo
   Strisciuglio, Caterina
   Rossi, Francesca
TI The Role of Cannabinoid Receptor Type 2 in the Bone Loss Associated With
   Pediatric Celiac Disease
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
DE cannabinoid receptor type 2; celiac disease; children; osteoclasts;
   osteoporosis
ID LONG TERM TREATMENT; GLUTEN FREE DIET; MINERAL DENSITY; VITAMIN D; RISK;
   CB2; OSTEOPOROSIS; METABOLISM; CHILDREN; MASS
AB Objectives: In this study, we investigated the role of the cannabinoid receptor type 2 (CB2) in the bone loss associated with celiac disease (CD) evaluating the effect of its pharmacological modulation on osteoclast activity. We previously demonstrated a significant association between the CB2 Q63R variant and CD, suggesting it as a possible disease biomarker. Moreover, CB2 stimulation is beneficial for reducing osteoclast activity in several bone pathologic conditions. Methods: In vitro osteoclasts (OCs) were differentiated from peripheral blood mononuclear cells of healthy donors, CD children at diagnosis and after 1 year of gluten free diet (GFD) and characterized by real time PCR and western blot for the expression of CB2 and specific osteoclastic markers, TRAP and Cathepsin K. TRAP assay and Bone Resorption assay were performed to evaluate osteoclast activity before and after 48 h exposure to CB2 selective drugs (JWH 133 and AM630) and Vitamin D. Results: We found in CD patients an osteoclast hyperactivation and low levels of CB2. CB2 stimulation with JWH 133 agonist is more effective than Vitamin D in reducing osteoclast activity whereas CB2 blockade with AM630 increases osteoclast activation. The anti osteoporotic effect of JWH 133 decreases when used in co treatment with vitamin D. GFD reduces osteoclast activity without restore CB2 expression. Conclusions: CB2 could be a molecular marker to predict the risk of bone alterations in CD and a pharmacological target to reduce bone mass loss in patients who need a direct intervention on bone metabolism, in addition to the GFD.
C1 [Tortora, Chiara; Punzo, Francesca; Tolone, Carlo; Strisciuglio, Caterina; Rossi, Francesca] Univ Campania Luigi Vanvitelli, Dept Woman Child & Gen & Specialist Surg, Via Crecchio 4, I 80138 Naples, Italy.
   [Argenziano, Maura; Di Paola, Alessandra] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.
C3 Universita della Campania Vanvitelli; Universita della Campania
   Vanvitelli
RP Rossi, F (通讯作者)，Univ Campania Luigi Vanvitelli, Dept Woman Child & Gen & Specialist Surg, Via Crecchio 4, I 80138 Naples, Italy.
EM francesca.rossi@unicampania.it
RI Rossi, Francesca/HTP 5870 2023; Strisciuglio, Caterina/ABD 2466 2020; Di
   Paola, Alessandra/LUA 0359 2024
OI Rossi, Francesca/0000 0003 2879 6277; Argenziano,
   Maura/0000 0003 4457 1318; Di Paola, Alessandra/0000 0001 5634 3967;
   STRISCIUGLIO, Caterina/0000 0002 9005 6571
FU Fondazione Celiachia Onlus (FC) [009_FC_2017]
FX This work was supported by Fondazione Celiachia Onlus (FC) Grant no
   009_FC_2017 "The role of CB2 receptor in the pathogenesis of celiac
   disease and associated bone loss''.
CR Ahlawat R, 2017, CURR OPIN PEDIATR, V29, P122, DOI 10.1097/MOP.0000000000000451
   Garrote JA, 2008, J PEDIATR GASTR NUTR, V47, pS27, DOI 10.1097/MPG.0b013e3181818fb9
   Zanchetta MB, 2016, CURR OSTEOPOROS REP, V14, P43, DOI 10.1007/s11914 016 0304 5
   Bellini G, 2017, PHARMACOL RES, V115, P267, DOI 10.1016/j.phrs.2016.11.039
   Caio G, 2019, BMC MED, V17, DOI 10.1186/s12916 019 1380 z
   Chellan D, 2019, JGH OPEN, V3, P388, DOI 10.1002/jgh3.12172
   Choung RS, 2020, J CLIN GASTROENTEROL, V54, P620, DOI 10.1097/MCG.0000000000001277
   Corazza GR, 1997, GASTROENTEROLOGY, V113, P67, DOI 10.1016/S0016 5085(97)70081 7
   Czaja Bulsa G, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101424
   Di Nardo G, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071588
   Di Stefano M, 2019, J CLIN GASTROENTEROL, V53, pE221, DOI 10.1097/MCG.0000000000001032
   Di Stefano M, 2013, NUTRIENTS, V5, P4786, DOI 10.3390/nu5114786
   Drummond FJ, 2003, BONE, V33, P970, DOI 10.1016/j.bone.2003.07.002
   Duerksen D, 2018, CAN FAM PHYSICIAN, V64, P433
   Fedewa MV, 2020, J CLIN DENSITOM, V23, P200, DOI 10.1016/j.jocd.2019.02.003
   Fiore CE, 2006, HORM METAB RES, V38, P417, DOI 10.1055/s 2006 944548
   Fornari MC, 1998, AM J GASTROENTEROL, V93, P413, DOI 10.1016/S0002 9270(97)00115 9
   Hossein nezhad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058725
   Husby S, 2020, J PEDIATR GASTR NUTR, V70, P141, DOI 10.1097/MPG.0000000000002497
   Jericho H, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060755
   Kogawa M, 2010, ENDOCRINOLOGY, V151, P4613, DOI 10.1210/en.2010 0334
   Krupa Kozak U, 2016, FOODS, V5, DOI 10.3390/foods5030051
   Krupa Kozak U, 2014, NUTRITION, V30, P16, DOI 10.1016/j.nut.2013.05.027
   Ligresti A, 2016, PHYSIOL REV, V96, P1593, DOI 10.1152/physrev.00002.2016
   Lu HC, 2016, BIOL PSYCHIAT, V79, P516, DOI 10.1016/j.biopsych.2015.07.028
   Ludvigsson JF, 2007, ALIMENT PHARM THER, V25, P273, DOI 10.1111/j.1365 2036.2006.03203.x
   Margulies SL, 2015, J DIGEST DIS, V16, P617, DOI 10.1111/1751 2980.12283
   Micic D, 2020, J CLIN DENSITOM, V23, P190, DOI 10.1016/j.jocd.2019.06.005
   Nardecchia S, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00056
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Pantaleoni S, 2014, SCI WORLD J, V2014
   Pazianas M, 2005, OSTEOPOROSIS INT, V16, P56, DOI 10.1007/s00198 004 1641 2
   Pike JW, 2017, ENDOCRIN METAB CLIN, V46, P815, DOI 10.1016/j.ecl.2017.07.001
   Punzo F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208102
   Ramagopalan SV, 2010, GENOME RES, V20, P1352, DOI 10.1101/gr.107920.110
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Rossi F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081919
   Rossi F, 2015, PHARMACOL RES, V99, P194, DOI 10.1016/j.phrs.2015.06.010
   Rossi F, 2014, HAEMATOLOGICA, V99, P1876, DOI 10.3324/haematol.2014.104463
   Rossi F, 2013, PHARMACOL RES, V68, P7, DOI 10.1016/j.phrs.2012.10.017
   Rossi F, 2012, PHARMACOL RES, V66, P88, DOI 10.1016/j.phrs.2012.03.011
   Rossi F, 2011, BONE, V48, P997, DOI 10.1016/j.bone.2011.01.001
   Serena G, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882 019 0871 5
   Silva I, 2011, ACTA REUMATOL PORT, V36, P209
   Taranta A, 2004, J BONE MINER RES, V19, P1112, DOI 10.1359/JBMR.040319
   Tilg H, 2008, GUT, V57, P684, DOI 10.1136/gut.2006.117382
   Verlinden L, 2019, J STEROID BIOCHEM, V195, DOI 10.1016/j.jsbmb.2019.105478
   Volkan B, 2018, TURK J GASTROENTEROL, V29, P215, DOI 10.5152/tjg.2018.17451
   Vukic M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124339
   Webster J, 2019, CLIN GASTROENTEROL H, V17, P1509, DOI 10.1016/j.cgh.2018.10.035
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Wood CL, 2015, CURR GENOMICS, V16, P411, DOI 10.2174/1389202916666150817202217
   Zarei A, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.30
   Zimmer Andreas, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P229, DOI 10.1515/jbcpp 2015 0125
   Zingone F, 2018, DIGEST LIVER DIS, V50, P757, DOI 10.1016/j.dld.2018.04.005
   Zylberberg HM, 2018, ENDOCRINE, V59, P311, DOI 10.1007/s12020 017 1488 x
NR 56
TC 11
Z9 11
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277 2116
EI 1536 4801
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD NOV
PY 2020
VL 71
IS 5
BP 633
EP 640
DI 10.1097/MPG.0000000000002863
PG 8
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA OR9XW
UT WOS:000589820000013
PM 33093370
OA Bronze
DA 2025 08 17
ER

PT J
AU Roberts, BM
   Geddis, AV
   Matheny, RW Jr
AF Roberts, Brandon M.
   Geddis, Alyssa V.
   Matheny Jr, Ronald W.
TI The dose response effects of flurbiprofen, indomethacin, ibuprofen, and
   naproxen on primary skeletal muscle cells
SO JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION
LA English
DT Article
DE Myogenesis; anabolic signaling; skeletal muscle; AKT; muscle growth
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LOCAL NSAID INFUSION; SATELLITE
   CELLS; HUMAN PLASMA; PHARMACOKINETICS; PROSTAGLANDINS; PROLIFERATION;
   MEDICATION; CYCLOOXYGENASE 1; DIFFERENTIATION
AB Background: Non steroidal anti inflammatory drugs (NSAIDs) like ibuprofen, flurbiprofen, naproxen sodium, and indomethacin are commonly employed for their pain relieving and inflammation reducing qualities. NSAIDs work by blocking COX 1 and/or COX 2, enzymes which play roles in inflammation, fever, and pain. The main difference among NSAIDs lies in their affinity to these enzymes, which in turn, influences prostaglandin secretion, and skeletal muscle growth and regeneration. The current study investigated the effects of NSAIDs on human skeletal muscle cells, focusing on myoblast proliferation, differentiation, and muscle protein synthesis signaling.Methods: Using human primary muscle cells, we examined the dose response impact of flurbiprofen (25 200 mu M), indomethacin (25 200 mu M), ibuprofen (25 200 mu M), and naproxen sodium (25 200 mu M), on myoblast viability, myotube area, fusion, and prostaglandin production.Results: We found that supraphysiological concentrations of indomethacin inhibited myoblast proliferation ( 74 +/  2% with 200 mu M;  53 +/  3% with 100 mu M; both p < 0.05) compared to control cells and impaired protein synthesis signaling pathways in myotubes, but only attenuated myotube fusion at the highest concentrations ( 18 +/  2% with 200 <mu>M, p < 0.05) compared to control myotubes. On the other hand, ibuprofen had no such effects. Naproxen sodium only increased cell proliferation at low concentrations (+36 +/  2% with 25 <mu>M, p < 0.05), and flurbiprofen exhibited divergent impacts depending on the concentration whereby low concentrations improved cell proliferation (+17 +/  1% with 25 <mu>M, p < 0.05) but high concentrations inhibited cell proliferation ( 32 +/  1% with 200 <mu>M, p < 0.05).Conclusion: Our findings suggest that indomethacin, at high concentrations, may detrimentally affect myoblast proliferation and differentiation via an AKT dependent mechanism, and thus provide new understanding of NSAIDs' effects on skeletal muscle cell development.
C1 [Roberts, Brandon M.; Geddis, Alyssa V.; Matheny Jr, Ronald W.] US Army Res Inst Environm Med, Mil Performance Div, Natick, MA USA.
   [Matheny Jr, Ronald W.] Mil Operat Med Res Program, Detrick, MD USA.
   [Roberts, Brandon M.] US Army Res Inst Environm Med, Mil Performance Div, 10 Gen Greene Ave,Bldg 42, Natick, MA 01760 USA.
C3 United States Department of Defense; United States Army; United States
   Department of Defense; United States Army; United States Army Medical
   Research & Development Command (USAMRDC); Military Operational Medicine
   Research Program (MOMRP); United States Department of Defense; United
   States Army
RP Roberts, BM (通讯作者)，US Army Res Inst Environm Med, Mil Performance Div, 10 Gen Greene Ave,Bldg 42, Natick, MA 01760 USA.
EM robertsb21@gmail.com
RI ; Roberts, Brandon/H 4504 2019
OI Roberts, Brandon M./0000 0003 0395 6967; 
FU Military Operational Medicine Research Program
FX Funding for this project was received from the Military Operational
   Medicine Research Program.
CR Abu Risha M, 2021, GENES BASEL, V12, DOI 10.3390/genes12020192
   Bondesen BA, 2006, AM J PHYSIOL CELL PH, V290, pC1651, DOI 10.1152/ajpcell.00518.2005
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   Brewer CB, 2014, J STRENGTH COND RES, V28, P74, DOI 10.1519/JSC.0b013e318291ba98
   Bushra Rabia, 2010, Oman Med J, V25, P155, DOI 10.5001/omj.2010.49
   Christopher S, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03581 y
   Cornu C, 2020, SPORTS MED OPEN, V6, DOI 10.1186/s40798 020 00247 w
   Davies NM, 1997, CLIN PHARMACOKINET, V32, P268, DOI 10.2165/00003088 199732040 00002
   Davis JS, 2017, OPEN HEART, V4, DOI 10.1136/openhrt 2016 000550
   Dittrich P, 1984, Eur J Rheumatol Inflamm, V7, P45
   FINCH WR, 1986, AM J MED, V80, P16, DOI 10.1016/0002 9343(86)90105 1
   Ho ATV, 2017, P NATL ACAD SCI USA, V114, P6675, DOI 10.1073/pnas.1705420114
   Kaufman DW, 2002, JAMA J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337
   Lee JH, 2009, LIFE SCI, V84, P415, DOI 10.1016/j.lfs.2009.01.004
   Lees P, 2004, J VET PHARMACOL THER, V27, P479, DOI 10.1111/j.1365 2885.2004.00617.x
   Liao CH, 2019, SKELET MUSCLE, V9, DOI 10.1186/s13395 019 0208 z
   Lucas S, 2016, HEADACHE, V56, P436, DOI 10.1111/head.12769
   Mackey AL, 2012, SCAND J MED SCI SPOR, V22, pE8, DOI 10.1111/j.1600 0838.2012.01463.x
   Mackey AL, 2007, J APPL PHYSIOL, V103, P425, DOI 10.1152/japplphysiol.00157.2007
   Mackey AL, 2016, FASEB J, V30, P2266, DOI 10.1096/fj.201500198R
   Mackey AL, 2013, J APPL PHYSIOL, V115, P900, DOI 10.1152/japplphysiol.00044.2013
   Manvelian G, 2012, POSTGRAD MED, V124, P197, DOI 10.3810/pgm.2012.07.2580
   Markworth JF, 2014, J APPL PHYSIOL, V117, P20, DOI 10.1152/japplphysiol.01299.2013
   Markworth JF, 2013, AM J PHYSIOL CELL PH, V304, pC56, DOI 10.1152/ajpcell.00038.2012
   Matheny RW, 2022, PHYSIOL REP, V10, DOI 10.14814/phy2.15481
   Matheny RW, 2017, GROWTH HORM IGF RES, V32, P14, DOI 10.1016/j.ghir.2016.09.002
   Matheny RW, 2015, MOL CELL BIOL, V35, P1182, DOI 10.1128/MCB.00550 14
   Mehlisch DR, 2013, INT J CLIN PRACT, V67, P3, DOI 10.1111/ijcp.12053
   Mendias CL, 2004, MUSCLE NERVE, V30, P497, DOI 10.1002/mus.20102
   Mikkelsen UR, 2011, SCAND J MED SCI SPOR, V21, P630, DOI 10.1111/j.1600 0838.2010.01170.x
   Mikkelsen UR, 2009, J APPL PHYSIOL, V107, P1600, DOI 10.1152/japplphysiol.00707.2009
   MISHRA DK, 1995, J BONE JOINT SURG AM, V77, P1510, DOI 10.2106/00004623 199510000 00005
   MOYER S, 1986, CEPHALALGIA, V6, P77, DOI 10.1177/03331024860060S409
   MUCKLE DS, 1977, RHEUMATOL REHABIL, V16, P58, DOI 10.1093/rheumatology/16.1.58
   Munjal A, 2023, InStatPearls Internet
   Novak ML, 2009, AM J PHYSIOL REG I, V296, pR1132, DOI 10.1152/ajpregu.90874.2008
   Paulsen G, 2010, SCAND J MED SCI SPOR, V20, pE195, DOI 10.1111/j.1600 0838.2009.00947.x
   Prisk V, 2003, HISTOL HISTOPATHOL, V18, P1243, DOI 10.14670/HH 18.1243
   Rainsford K. D., 1999, American Journal of Medicine, V107, p27S
   Reynoso M, 2023, FEBS LETT, V597, P1225, DOI 10.1002/1873 3468.14616
   Roberts BM, 2023, J INT SOC SPORT NUTR, V20, DOI 10.1080/15502783.2022.2164209
   RODEMANN HP, 1982, J BIOL CHEM, V257, P8716
   RUILOPE LM, 1986, HYPERTENSION, V8, P677, DOI 10.1161/01.HYP.8.8.677
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Semark A, 1999, J SPORT SCI, V17, P197, DOI 10.1080/026404199366091
   Simmons DL, 2000, CLIN INFECT DIS, V31, pS211, DOI 10.1086/317517
   Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3
   Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313
   Sugár D, 2019, CURR THER RES CLIN E, V90, P33, DOI 10.1016/j.curtheres.2019.01.004
   Sultan A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007358.pub2
   Trappe RA, 2002, AM J PHYSIOL ENDOC M, V282, pE551, DOI 10.1152/ajpendo.00352.2001
   Trappe TA, 2013, J APPL PHYSIOL, V115, P909, DOI 10.1152/japplphysiol.00061.2013
   Walker LA, 2017, MIL MED, V182, pE1709, DOI 10.7205/MILMED D 16 00183
   Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563
   Wongrakpanich S, 2018, AGING DIS, V9, P143, DOI 10.14336/AD.2017.0306
   Yilmaz B, 2015, J CHROMATOGR SCI, V53, P1443, DOI 10.1093/chromsci/bmv032
   Yilmaz B, 2014, J AOAC INT, V97, P415, DOI 10.5740/jaoacint.11 414
   ZALIN RJ, 1977, DEV BIOL, V59, P241, DOI 10.1016/0012 1606(77)90258 5
NR 58
TC 9
Z9 10
U1 0
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
EI 1550 2783
J9 J INT SOC SPORT NUTR
JI J. Int. Soc. Sport Nutr.
PD DEC 31
PY 2024
VL 21
IS 1
AR 2302046
DI 10.1080/15502783.2024.2302046
PG 16
WC Nutrition & Dietetics; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics; Sport Sciences
GA EQ7G6
UT WOS:001140449100001
PM 38198469
OA gold
DA 2025 08 17
ER

PT J
AU Garimella, MG
   Kour, S
   Piprode, V
   Mittal, M
   Kumar, A
   Rani, L
   Pote, ST
   Mishra, GC
   Chattopadhyay, N
   Wani, MR
AF Garimella, Manasa G.
   Kour, Supinder
   Piprode, Vikrant
   Mittal, Monika
   Kumar, Anil
   Rani, Lekha
   Pote, Satish T.
   Mishra, Gyan C.
   Chattopadhyay, Naibedya
   Wani, Mohan R.
TI Adipose Derived Mesenchymal Stem Cells Prevent Systemic Bone Loss in
   Collagen Induced Arthritis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID REGULATORY B CELLS; OSTEOCLAST DIFFERENTIATION; OSTEOBLAST FUNCTION;
   T CELLS; CYTOKINES; DISEASE; MARROW; MICE; MECHANISMS; PRECURSORS
AB Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammatory synovitis leading to joint destruction and systemic bone loss. The inflammation induced bone loss is mediated by increased osteoclast formation and function. Current antirheumatic therapies primarily target suppression of inflammatory cascade with limited or no success in controlling progression of bone destruction. Mesenchymal stem cells (MSCs) by virtue of their tissue repair and immunomodulatory properties have shown promising results in various autoimmune and degenerative diseases. However, the role of MSCs in prevention of bone destruction in RA is not yet understood. In this study, we investigated the effect of adipose derived MSCs (ASCs) on in vitro formation of bone resorbing osteoclasts and pathological bone loss in the mouse collagen induced arthritis (CIA) model of RA. We observed that ASCs significantly inhibited receptor activator of NF kappa B ligand (RANKL) induced osteoclastogenesis in both a contact dependent and  independent manner. Additionally, ASCs inhibited RANKL induced osteoclastogenesis in the presence of proinflammatory cytokines such as TNF alpha, IL 17, and IL 1 beta. Furthermore, treatment with ASCs at the onset of CIA significantly reduced clinical symptoms and joint pathology. Interestingly, ASCs protected periarticular and systemic bone loss in CIA mice by maintaining trabecular bone structure. We further observed that treatment with ASCs reduced osteoclast precursors in bone marrow, resulting in decreased osteoclastogenesis. Moreover, ASCs suppressed autoimmune T cell responses and increased the percentages of peripheral regulatory T and B cells. Thus, we provide strong evidence that ASCs ameliorate inflammation induced systemic bone loss in CIA mice by reducing osteoclast precursors and promoting immune tolerance.
C1 [Garimella, Manasa G.; Kour, Supinder; Piprode, Vikrant; Kumar, Anil; Rani, Lekha; Pote, Satish T.; Mishra, Gyan C.; Wani, Mohan R.] Natl Ctr Cell Sci, Pune 411007, Maharashtra, India.
   [Mittal, Monika; Chattopadhyay, Naibedya] CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
C3 Department of Biotechnology (DBT) India; National Centre for Cell
   Science, Pune (NCCS); Council of Scientific & Industrial Research (CSIR)
     India; CSIR   Central Drug Research Institute (CDRI)
RP Wani, MR (通讯作者)，Natl Ctr Cell Sci, Savitribai Phule Pune Univ Campus,Ganeshkhind Rd, Pune 411007, Maharashtra, India.
EM mohanwani@nccs.res.in
RI ; Piprode, Vikrant/AAP 6951 2021; Kumar, Anil/AAC 9216 2022; Wani,
   Mohan/AAK 8516 2020; Chattopadhyay, Naibedya/AAQ 3213 2021
OI KUMAR, ANIL/0000 0003 2287 5388; Mittal, Monika/0000 0002 3328 7787;
   Chattopadhyay, Naibedya/0000 0003 2473 0246; Garimella, Manasa
   Gayatri/0000 0002 9879 4480
FU Department of Biotechnology, India [BT/HRD/34/01/2009]; Council of
   Scientific and Industrial Research, New Delhi, India [BSC0201]
FX This work was supported by Department of Biotechnology, India Grant
   BT/HRD/34/01/2009 (to M.R.W.), as well as Council of Scientific and
   Industrial Research, New Delhi, India Grant BSC0201 (to N.C.). M.G.G. is
   the recipient of a senior research fellowship from the Council for
   Scientific and Industrial Research, New Delhi, India.
CR Augello A, 2007, ARTHRITIS RHEUM US, V56, P1175, DOI 10.1002/art.22511
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Carter NA, 2011, J IMMUNOL, V186, P5569, DOI 10.4049/jimmunol.1100284
   Chen HY, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/213234
   Chen MG, 2013, ARTHRITIS RHEUM US, V65, P1181, DOI 10.1002/art.37894
   Cho YG, 2007, AUTOIMMUN REV, V7, P65, DOI 10.1016/j.autrev.2007.08.001
   Choi JJ, 2008, CLIN EXP IMMUNOL, V153, P269, DOI 10.1111/j.1365 2249.2008.03683.x
   Dimitroulas T, 2013, AUTOIMMUN REV, V12, P958, DOI 10.1016/j.autrev.2013.03.015
   Djouad F, 2005, ARTHRITIS RHEUM US, V52, P1595, DOI 10.1002/art.21012
   English K, 2013, IMMUNOL CELL BIOL, V91, P19, DOI 10.1038/icb.2012.56
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   González MA, 2009, ARTHRITIS RHEUM US, V60, P1006, DOI 10.1002/art.24405
   Guo YW, 2013, NEUROIMMUNOMODULAT, V20, P294, DOI 10.1159/000351450
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kelchtermans H, 2009, ANN RHEUM DIS, V68, P744, DOI 10.1136/ard.2007.086066
   Khan MP, 2015, DIABETES, V64, P2609, DOI 10.2337/db14 1611
   Khapli SM, 2003, J IMMUNOL, V171, P142, DOI 10.4049/jimmunol.171.1.142
   Lacey DC, 2009, OSTEOARTHR CARTILAGE, V17, P735, DOI 10.1016/j.joca.2008.11.011
   Lee SK, 2006, CURR OPIN RHEUMATOL, V18, P411, DOI 10.1097/01.bor.0000231911.42666.78
   Matsushita T, 2008, J CLIN INVEST, V118, P3420, DOI 10.1172/JCI36030
   Mbalaviele G, 1999, ENDOCRINOLOGY, V140, P3736, DOI 10.1210/endo.140.8.6880
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Orbay H, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/461718
   Oshita K, 2011, ARTHRITIS RHEUM US, V63, P1658, DOI 10.1002/art.30309
   Park MJ, 2011, ARTHRITIS RHEUM US, V63, P1668, DOI 10.1002/art.30326
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Schurgers E, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2939
   Shi YF, 2010, CELL RES, V20, P510, DOI 10.1038/cr.2010.44
   Sung JH, 2008, TRANSPL P, V40, P2649, DOI 10.1016/j.transproceed.2008.08.009
   Swarnkar G, 2012, BRIT J PHARMACOL, V165, P1526, DOI 10.1111/j.1476 5381.2011.01637.x
   Tanaka K, 2014, CLIN EXP IMMUNOL, V175, P172, DOI 10.1111/cei.12201
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tomar GB, 2010, BIOCHEM BIOPH RES CO, V393, P377, DOI 10.1016/j.bbrc.2010.01.126
   Varin A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072831
   Villeneuve E, 2013, ANN RHEUM DIS, V72, P1, DOI 10.1136/annrheumdis 2012 202650
   Walsh NC, 2009, J BONE MINER RES, V24, P1572, DOI [10.1359/JBMR.090320, 10.1359/jbmr.090320]
   Wang SH, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 19
   Wei X, 2013, ACTA PHARMACOL SIN, V34, P747, DOI 10.1038/aps.2013.50
   Yanaba K, 2007, J IMMUNOL, V179, P1369, DOI 10.4049/jimmunol.179.2.1369
   Yang M, 2013, CELL MOL IMMUNOL, V10, P122, DOI 10.1038/cmi.2012.60
   Yogesha SD, 2009, J IMMUNOL, V182, P361, DOI 10.4049/jimmunol.182.1.361
   Zaiss MM, 2010, J IMMUNOL, V184, P7238, DOI 10.4049/jimmunol.0903841
   Zhou B, 2011, CLIN IMMUNOL, V141, P328, DOI 10.1016/j.clim.2011.08.014
   Zhu H, 2009, STEM CELLS DEV, V18, P1473, DOI 10.1089/scd.2009.0021
NR 46
TC 49
Z9 57
U1 0
U2 9
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
EI 1550 6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 1
PY 2015
VL 195
IS 11
BP 5136
EP 5148
DI 10.4049/jimmunol.1500332
PG 13
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA CX3NP
UT WOS:000365606100010
PM 26538398
OA Green Published
DA 2025 08 17
ER

PT J
AU Kamal, KC
   Alexandru, DO
   Rogoveanu, OC
   Panus, C
   Kamal, D
   Maria, DT
   Traistaru, MR
AF Kamal, Kamal Constantin
   Alexandru, Dragos Ovidiu
   Rogoveanu, Otilia Constantina
   Panus, Camelia
   Kamal, Diana
   Maria, Daniela Teodora
   Traistaru, Magdalena Rodica
TI Immunohistochemical analysis of bone metabolism in osteonecrosis of the
   femoral head
SO ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY
LA English
DT Article
DE osteonecrosis; repair phase; osteoblasts; osteoclasts
ID AVASCULAR NECROSIS; NATURAL HISTORY; OSTEOPROTEGERIN; RANKL
AB Osteonecrosis of the femoral head occurs because of the suppression of blood circulation. At the level of the area affected by the ischemic phenomenon, there are two types of events, in the first stage there is necrosis of the cellular elements, followed by a reparatory phase of the spongy bone tissue. The objective of the study was the histological and immunohistochemical (INC) analysis of bone metabolism in the repair phase. We observed the action of the main cells involved in the remodeling, the osteoblasts and the osteoclasts, following the reaction of the markers of their activity: osteoprotegerin, osteonectin, osteopontin. We included 23 patients diagnosed with femoral head osteonecrosis, stage II, Ficat and Arlet classification, biological material required for histological and IHC analysis being obtained during hip arthroplasty. Regardless of the age or presence of risk factors, the reaction to osteoprotegerin was mildly positive, being only highlighted at the level of the reactive dividing line, being absent in the other areas, indicating a reduced activity of inhibiting differentiation and activation of osteoclasts, also highlighted with classical histology methods, the affected area being well defined and we could observe the necrotic tissue resorption by osteoclasts. The intense positive reaction of osteopontin and osteonectin, especially at the line of demarcation, is due to the increase in the number of osteoblasts required for the synthesis of neoformation bone tissue. We believe that the aspects revealed by our study can be a track in finding new targeted therapies useful in stopping the development of the disease.
C1 [Kamal, Kamal Constantin] Univ Med & Pharm Craiova, Dept Family Med, Craiova, Romania.
   [Alexandru, Dragos Ovidiu] Univ Med & Pharm Craiova, Dept Med Informat & Biostat, 2 Petru Rares St, Craiova 200349, Romania.
   [Rogoveanu, Otilia Constantina; Traistaru, Magdalena Rodica] Univ Med & Pharm Craiova, Dept Phys Med & Rehabil, Craiova, Romania.
   [Panus, Camelia] Urodiamed Clin, 35 Gheorghe Chitu St, Craiova 200541, Romania.
   [Kamal, Diana] Elga Clin, Craiova, Romania.
   [Maria, Daniela Teodora] Univ Med & Pharm Craiova, Dept Nephrol, Craiova, Romania.
C3 University of Medicine & Pharmacy of Craiova; University of Medicine &
   Pharmacy of Craiova; University of Medicine & Pharmacy of Craiova;
   University of Medicine & Pharmacy of Craiova
RP Alexandru, DO (通讯作者)，Univ Med & Pharm Craiova, Dept Med Informat & Biostat, 2 Petru Rares St, Craiova 200349, Romania.; Panus, C (通讯作者)，Urodiamed Clin, 35 Gheorghe Chitu St, Craiova 200541, Romania.
EM dragosado@yahoo.com; campanus@hotmail.com
RI Constantin, Kamal/S 6668 2019; Traistaru, Rodica/ABF 6052 2020; Teodora,
   Maria/ABF 7232 2020; Alexandru, Dragos/AAM 8276 2020
OI MARIA, DANIELA TEODORA/0009 0000 3410 1334; 
CR [Anonymous], TECH ORTHOP
   Assouline Dayan Y, 2002, SEMIN ARTHRITIS RHEU, V32, P94, DOI 10.1053/sarh.2002.33724
   Boechat MI, 2001, RADIOLOGY, V218, P411, DOI 10.1148/radiology.218.2.r01fe03411
   Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980
   Fondi C, 2007, CLIN CASES MINER BON, V4, P21
   Kamal D, 2015, ROM J MORPHOL EMBRYO, V56, P163
   Kamal D, 2012, ROM J MORPHOL EMBRYO, V53, P557
   Kaushik AP, 2012, WORLD J ORTHOP, V3, P49, DOI 10.5312/wjo.v3.i5.49
   Lafforgue P, 2006, JOINT BONE SPINE, V73, P500, DOI 10.1016/j.jbspin.2006.01.025
   Lieberman Jay R, 2003, Instr Course Lect, V52, P337
   Malizos KN, 2007, EUR J RADIOL, V63, P16, DOI 10.1016/j.ejrad.2007.03.019
   Narayanan A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10817 w
   Rosset EM, 2016, MATRIX BIOL, V52 54, P78, DOI 10.1016/j.matbio.2016.02.001
   Samara S, 2014, EXP MOL PATHOL, V96, P9, DOI 10.1016/j.yexmp.2013.10.014
   Santori F.S., 2004, AVASCULAR NECROSIS F, P1
   Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101
   Tingart M, 2008, CALCIFIED TISSUE INT, V82, P300, DOI 10.1007/s00223 008 9111 z
   Traistaru MR, 2015, ROM J MORPHOL EMBRYO, V56, P1447
   Wang Jianzhong, 2009, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V23, P777
   Wright HL, 2009, CURR REV MUSCULOSKE, V2, P56, DOI 10.1007/s12178 009 9046 7
   Zalavras C, 2000, EUR J CLIN INVEST, V30, P215, DOI 10.1046/j.1365 2362.2000.00621.x
NR 21
TC 13
Z9 17
U1 0
U2 7
PU EDITURA ACAD ROMANE
PI BUCURESTI
PA CALEA 13 SEPTEMBRIE NR 13, SECTOR 5, BUCURESTI 050711, ROMANIA
SN 1220 0522
EI 2066 8279
J9 ROM J MORPHOL EMBRYO
JI Rom. J. Morphol. Embryol.
PY 2018
VL 59
IS 3
BP 819
EP 824
PG 6
WC Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology
GA HI0CB
UT WOS:000456108600020
PM 30534821
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Zhang, L
   Yan, M
   Zheng, XX
AF Zhang, Yun
   Zhang, Le
   Yan, Ming
   Zheng, Xiaoxiang
TI Inhibition of phosphatidylinositol 3 kinase causes cell death in rat
   osteoblasts through inactivation of Akt
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE osteoblasts; LY294002; PI3 kinase/Akt pathway
ID GROWTH FACTOR I; ENDOTHELIAL CELLS; SIGNALING PATHWAY; INDUCED
   APOPTOSIS; MC3T3 E1 CELLS; SURVIVAL; INVOLVEMENT; KINASE;
   PHOSPHORYLATION; LY294002
AB Previous evidences indicated that phosphatidylinositol 3 kinase (PI3 kinase) is an important regulatory molecule that is involved in the cell growth and survival, and inhibition of the PI3 kinase activity enhances apoptotic cell death. However, the relationship between PI3 kinase activity and osteoblasts, capable of new bone formation, remained unknown. In the present study, pharmacological inhibitor of PI3 kinase LY294002 was used to observe the role of the PI3 kinase in the growth of rat osteoblasts. To identify its molecular mechanism, Western blots analysis and immunocytochemistry were applied to examine changes of Akt phosphorylation and its distribution. Our data showed that inhibition of PI3 kinase activity significantly triggered the decrease of cell growth, cell apoptosis and. loss of mitochondrial membrane potential (Delta Psi(m)). Osteoblastic dysfunction stimulated by LY294002 was accompanied by inactivation of Akt and its redistribution. In all these results demonstrated that inhibition of PI3 kinase induced apoptotic cell death, which was mediated by inactivation of Akt pathway in rat osteoblasts. (c) 2007 Elsevier Masson SAS. All rights reserved.
C1 Zhejiang Univ, Dept Biomed Engn, Key Lab Biomed Engn, Minist Educ, Hangzhou 310027, Peoples R China.
C3 Zhejiang University
RP Zheng, XX (通讯作者)，Zhejiang Univ, Dept Biomed Engn, Key Lab Biomed Engn, Minist Educ, Zheda Rd 38, Hangzhou 310027, Peoples R China.
EM zxx@mail.hz.zj.cn
CR Agrawala PK, 2004, BIOMED PHARMACOTHER, V58, P129, DOI 10.1016/j.biopha.2003.10.002
   Atencia R, 2000, VITAM HORM, V58, P267, DOI 10.1016/S0083 6729(00)58028 5
   Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960 9822(99)80186 9
   Borgatti P, 2000, FEBS LETT, V477, P27, DOI 10.1016/S0014 5793(00)01758 0
   Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092 8674(00)80595 4
   Bursch W, 2000, J CELL SCI, V113, P1189
   Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318
   Ceneviva GD, 1998, AM J PHYSIOL LUNG C, V275, pL717, DOI 10.1152/ajplung.1998.275.4.L717
   Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014 5793(03)00055 3
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092 8674(00)80405 5
   Fujita H, 2005, BIOCHEM PHARMACOL, V69, P1773, DOI 10.1016/j.bcp.2005.03.006
   Gottschalk AR, 2005, INT J RADIAT ONCOL, V61, P1183, DOI 10.1016/j.ijrobp.2004.12.024
   Grzanka A, 2003, BIOCHEM PHARMACOL, V66, P1611, DOI 10.1016/S0006 2952(03)00532 X
   Gu Q, 2002, ACTA PHARMACOL SIN, V23, P808
   Harada Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681
   Kang HY, 2004, J BONE MINER RES, V19, P1181, DOI 10.1359/JBMR.040306
   Krasilnikov MA, 2000, BIOCHEMISTRY MOSCOW+, V65, P59
   KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017
   Lee SB, 2005, LIFE SCI, V78, P91, DOI 10.1016/j.lfs.2005.04.035
   Luo HR, 2003, P NATL ACAD SCI USA, V100, P11712, DOI 10.1073/pnas.1634990100
   Martelli AM, 2000, J BONE MINER RES, V15, P1716, DOI 10.1359/jbmr.2000.15.9.1716
   Neri LM, 2002, BBA MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388 1981(02)00300 1
   Nicholson KM, 2003, CANCER LETT, V190, P31, DOI 10.1016/S0304 3835(02)00615 8
   Noda T, 2005, HORM METAB RES, V37, P270, DOI 10.1055/s 2005 861468
   Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474
   Uddin S, 2004, BIOCHEM BIOPH RES CO, V320, P932, DOI 10.1016/j.bbrc.2004.06.038
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264 6021:3460561
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Yip Schneider MT, 2003, J GASTROINTEST SURG, V7, P354, DOI 10.1016/S1091 255X(02)00156 7
NR 31
TC 14
Z9 16
U1 0
U2 3
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JUN
PY 2007
VL 61
IS 5
BP 277
EP 284
DI 10.1016/j.biopha.2007.02.014
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 190EZ
UT WOS:000248042100007
PM 17433610
DA 2025 08 17
ER

PT J
AU Tang, LJ
   Chen, Y
   Pei, FX
   Zhang, H
AF Tang, Linjun
   Chen, Yu
   Pei, Fuxing
   Zhang, Hui
TI Lithium Chloride Modulates Adipogenesis and Osteogenesis of Human Bone
   Marrow Derived Mesenchymal Stem Cells
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Lithium Chloride; Adipogenesis; Osteogenesis; Human bone meshenchymal
   stem cells; Wnt signaling; Hedgehog signaling
ID BETA CATENIN; WNT; DIFFERENTIATION; OSTEOPOROSIS; HEDGEHOG; PATHWAY;
   ACTIVATION; DEPRESSION; DENSITY; DISEASE
AB Background/Aims: Lithium chloride (LiCI) has long been used as a psychiatric medication; however, its role in the differentiation of bone marrow derived mesenchymal stem cells (BMSCs) remains largely unknown. The aim of this study is to explore the effect of LiCI on the differentiation of BMSCs. Methods: The roles of LiCI in osteogenic and adipogenic processes were observed using alizarin red staining and oil red O staining, respectively. The effects of LiCI on the Wnt and Hedgehog (Hh) pathways were investigated. Results: Our data showed that LiCI effectively promoted osteogenesis and inhibited adipogenesis by simultaneously affecting the Wnt and Hh pathways. Conclusion: These results suggest that LiCI influences the differentiation of BMSCs directly through the Wnt and Hh pathways and thus may be a candidate drug for the treatment of osteoporosis. Copyright (C) 2015 S. Karger AG, Basel
C1 [Tang, Linjun; Chen, Yu; Pei, Fuxing; Zhang, Hui] Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu 610041, Peoples R China.
C3 Sichuan University
RP Zhang, H (通讯作者)，Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu 610041, Peoples R China.
EM hxgk123@126.com; caesarzh@163.com
FU National Natural Science Foundation of China [81071506]
FX This work was supported by the grant from National Natural Science
   Foundation of China (Grant No. 81071506).
CR Armiñán A, 2009, STEM CELLS DEV, V18, P907, DOI 10.1089/scd.2008.0292
   Bilezikian JP, 2009, J BONE MINER RES, V24, P373, DOI [10.1359/JBMR.090105, 10.1359/jbmr.090105]
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chen YP, 2013, CELL PHYSIOL BIOCHEM, V32, P755, DOI 10.1159/000354477
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Davis LA, 2008, CELL MOL LIFE SCI, V65, P2658, DOI 10.1007/s00018 008 8042 1
   Day TF, 2008, J BONE JOINT SURG AM, V90A, P19, DOI 10.2106/JBJS.G.01174
   Fontaine C, 2008, STEM CELLS, V26, P1037, DOI 10.1634/stemcells.2007 0974
   Funck Brentano T, 2014, ARTHRITIS RHEUMATOL
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Guo J, 2014, CELL PHYSIOL BIOCHEM, V33, P1087, DOI 10.1159/000358678
   Han YF, 2013, CELL PHYSIOL BIOCHEM, V31, P795, DOI 10.1159/000350097
   Ho JE, 2007, J BIOMED MATER RES A, V83A, P1200, DOI 10.1002/jbm.a.31355
   Ito Masako, 2011, Clin Calcium, V21, P1067, DOI CliCa110710671073
   Kawai M, 2007, BIOCHEM BIOPH RES CO, V363, P276, DOI 10.1016/j.bbrc.2007.08.088
   Kishimoto T, 2012, CURR OPIN PSYCHIATR, V25, P415, DOI 10.1097/YCO.0b013e328355e1ac
   Kong YH, 2013, CELL PHYSIOL BIOCHEM, V32, P1187, DOI 10.1159/000354518
   Li MM, 2014, CELL PHYSIOL BIOCHEM, V33, P1988, DOI 10.1159/000362975
   Lim JY, 2006, EXP NEUROL, V199, P416, DOI 10.1016/j.expneurol.2006.01.015
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Loebel A, 2014, AM J PSYCHIAT, V171, P169, DOI 10.1176/appi.ajp.2013.13070985
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   Noort WA, 2002, EXP HEMATOL, V30, P870, DOI 10.1016/S0301 472X(02)00820 2
   Ohba S, 2008, DEV CELL, V14, P689, DOI 10.1016/j.devcel.2008.03.007
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rong S, 2014, CELL PHYSIOL BIOCHEM, V34, P2049, DOI 10.1159/000366400
   Schousboe JT, 2014, J CLIN DENSITOM, V17, P301, DOI 10.1016/j.jocd.2013.09.008
   Shahnazari Mohammad, 2008, Curr Osteoporos Rep, V6, P142, DOI 10.1007/s11914 008 0025 5
   Suppes T, 2008, J AFFECT DISORDERS, V111, P334, DOI 10.1016/j.jad.2008.02.004
   Wang Y, 2014, CELL PHYSIOL BIOCHEM, V33, P1225, DOI 10.1159/000358692
   Zamani A, 2009, BONE, V44, P331, DOI 10.1016/j.bone.2008.10.001
   Zhang Na, 2012, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V20, P654
NR 35
TC 63
Z9 69
U1 0
U2 27
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2015
VL 37
IS 1
BP 143
EP 152
DI 10.1159/000430340
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA CQ9JK
UT WOS:000360930400013
PM 26303458
OA gold
DA 2025 08 17
ER

PT J
AU Xia, TS
   Xu, SY
   Lai, LY
   Jiang, YP
   Wang, NN
   Xin, HL
AF Xia, Tian Shuang
   Xu, Sheng Yan
   Lai, Li Yong
   Jiang, Yi Ping
   Wang, Na Ni
   Xin, Hai Liang
TI Bitter acids from Humulus lupulus L. alleviate D galactose
   induced osteoblastic senescence and bone loss via regulating
   AKT/mTOR mediated autophagy
SO JOURNAL OF FOOD AND DRUG ANALYSIS
LA English
DT Article
DE AKT/mTOR pathway; Autophagy; Bitter acids; D galactose; Senior
   osteoporosis
ID HOP; DEPOSITION; MICE
AB Bitter acids (BA) are main component of Humulus lupulus L. (hops). They are known for beer brewing and have various biological and pharmacological properties, especially the bone protective effect confirmed by our previous in vivo study. Here we aimed to elucidate the anti senior osteoporosis (SOP) effect of BA on osteoblasts and explore its underlying mechanism. In vitro SOP model was established by D galactose (D gal) injured osteoblasts, and the bone formation markers and apoptosis level were measured. mCherry EGFP LC3 adenovirus infection and autophagic markers including beclin1 and LC3 proteins were detected to investigate the autophagy level in osteoblasts. To further verify whether BA play the bone protective role through regulating autophagy, the autophagy inhibitor 3 MA was used, and the cell proliferation, ALP activity, bone mineralization, apoptosis rate and SA b  gal staining areas were measured. Finally, the protein expressions of AKT/mTOR signaling pathway were detected by Western blotting, and AKT agonist SC79 and mTOR agonist MHY1485 were used to further study the mechanism of BA on AKT/mTOR mediated autophagy. The results showed that BA stimulated osteoblastic differentiation and inhibited apoptosis proteins Bcl 2/Bax in D gal treated osteoblasts. BA also increased the expression of autophagic markers beclin1 and LC3 II/LC3 I in D gal  treated osteoblasts. mCherry EGFP LC3 autophagic double fl uorescent adenovirus showed BA promoted the generation of autolysosomes and autophagosomes in D gal injured osteoblasts, indicating that BA might prevent osteoblastic bone loss through activating autophagy. Autophagy inhibitor 3 MA was used to further verify whether BA played the bone  protective role via regulating autophagy. The results revealed the promotion effects of BA on proliferation, ALP activity, and mineralized nodule formation in D gal injured osteoblasts were eliminated after autophagy blocking with 3 MA, and the inhibitory effects of BA on apoptosis rate and SA b  gal staining areas were also eliminated. Moreover, BA reduced the phosphorylation levels of AKT, mTOR, p70S6K, and 4EBP in AKT/mTOR pathway, and the promotion of BA on the autophagic markers was blocked after the activation of AKT and mTOR by SC79 and MHY1485. In conclusion, it was the fi rst time to demonstrate that BA improved cell activities and bone formation in aging osteoblasts, and revealed the mechanism of BA against SOP in osteoblasts was activating AKT/mTOR mediated autophagy.
C1 [Xia, Tian Shuang; Xu, Sheng Yan; Lai, Li Yong; Jiang, Yi Ping; Xin, Hai Liang] Naval Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
   [Wang, Na Ni] Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou 310007, Zhejiang, Peoples R China.
C3 Naval Medical University
RP Xin, HL (通讯作者)，Naval Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
EM hailiangxin@163.com
FU National Natural Science Foundation of China [82174079, U1603283]
FX Acknowledgments This work was supported by the National Natural Science
   Foundation of China (82174079, U1603283) .
CR Aghamiri V, 2016, COMPLEMENT THER CLIN, V23, P130, DOI 10.1016/j.ctcp.2015.05.001
   Chen WJ, 2004, J AGR FOOD CHEM, V52, P55, DOI 10.1021/jf034737u
   Colón Emeric CS, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 021 01050 0
   Debnath J, 2023, NAT REV MOL CELL BIO, V24, P560, DOI 10.1038/s41580 023 00585 z
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580 018 0003 4
   Fang SH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 020 03357 1
   Gong W, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/5410377
   Hsu YY, 2019, J FOOD SCI TECH MYS, V56, P1939, DOI 10.1007/s13197 019 03660 6
   Huang B, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005426
   Huang LT, 2022, CELL BIOL INT, V46, P829, DOI 10.1002/cbin.11783
   Hung YT, 2014, CHINESE J PHYSIOL, V57, P121, DOI 10.4077/CJP.2014.BAC199
   Kao TH, 2013, FOOD CHEM, V141, P1218, DOI 10.1016/j.foodchem.2013.04.032
   Kim JM, 2022, ELIFE, V11, DOI 10.7554/eLife.78069
   Li WW, 2019, MOL MED REP, V19, P3676, DOI 10.3892/mmr.2019.10040
   Li X, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101098
   Ma L, 2021, CHEM BIOL INTERACT, V349, DOI 10.1016/j.cbi.2021.109659
   Ma YP, 2022, GENES DIS, V9, P549, DOI 10.1016/j.gendis.2021.02.010
   Maupin KA, 2019, BONE, V127, P452, DOI 10.1016/j.bone.2019.07.010
   Prerna K, 2022, INT J BIOL MACROMOL, V204, P258, DOI 10.1016/j.ijbiomac.2022.02.005
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Sasaoka N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087185
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Shi Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109566
   Siegel L, 2008, ANTICANCER RES, V28, P289
   Sun XL, 2021, J PHARM PHARMACOL, V73, P1230, DOI 10.1093/jpp/rgab052
   Sun XL, 2022, J BONE MINER METAB, V40, P375, DOI 10.1007/s00774 021 01295 2
   Thomas N, 2019, CALCIFIED TISSUE INT, V105, P518, DOI 10.1007/s00223 019 00593 2
   Van Cleemput M, 2009, MOL NUTR FOOD RES, V53, P1143, DOI 10.1002/mnfr.200800493
   Vardiyan R, 2020, CLIN EXP REPROD MED, V47, P155, DOI 10.5653/cerm.2019.03440
   Vasto S, 2023, NUTRIENTS, V15, DOI 10.3390/nu15041022
   Wang S, 2020, INT J BIOL SCI, V16, P2675, DOI 10.7150/ijbs.46627
   Wei WZ, 2020, GENE, V749, DOI 10.1016/j.gene.2020.144703
   Wu KC, 2022, J BONE MINER RES, V37, P171, DOI 10.1002/jbmr.4499
   Xia TS, 2023, MOLECULES, V28, DOI 10.3390/molecules28020583
   Xia TianShuang Xia TianShuang, 2019, Academic Journal of Second Military Medical University, V40, P25
   Xu SY, 2022, J FUNCT FOODS, V94, DOI 10.1016/j.jff.2022.105099
   Yu Q, 2023, CELL COMMUN SIGNAL, V21, DOI 10.1186/s12964 022 00954 9
   Yuan YF, 2022, AGING US, V14, P892, DOI 10.18632/aging.203848
   Yue C, 2021, J CELL MOL MED, V25, P10175, DOI 10.1111/jcmm.16954
NR 40
TC 2
Z9 2
U1 1
U2 2
PU DIGITAL COMMONS BEPRESS
PI BERKELEY
PA 2100 MILVIA ST, STE 300, BERKELEY, CA 94704 USA
SN 1021 9498
J9 J FOOD DRUG ANAL
JI J. Food Drug Anal.
PY 2024
VL 32
IS 4
DI 10.38212/2224 6614.3508
PG 15
WC Food Science & Technology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Pharmacology & Pharmacy
GA P9I8U
UT WOS:001380963800009
PM 39752859
DA 2025 08 17
ER

PT J
AU Wang, D
   Gu, JH
   Feng, LL
   Tong, XS
   Song, RL
   Zhao, HY
   Bian, JC
   Liu, XZ
   Yuan, Y
   Liu, ZP
AF Wang, Dong
   Gu, Jian Hong
   Feng, Ling Ling
   Tong, Xi Shuai
   Song, Rui Long
   Zhao, Hong Yan
   Bian, Jian Chun
   Liu, Xue Zhong
   Yuan, Yan
   Liu, Zong Ping
TI 1 α,25 dihydroxyvitamin D3 potentiates avian osteoclast
   activation by increasing the formation of zipper like structure via
   Src/Rac1 signaling
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoclast; 1 alpha,25 (OH)(2)D 3; Src; Rac1; Activation; Zipper like
   structure
ID VITAMIN D; BONE RESORPTION; IN VITRO; DIFFERENTIATION; OSTEOPROTEGERIN;
   CYTOSKELETON; APOPTOSIS; RECEPTOR; CALCIUM; FUSION
AB Avian bone metabolism diseases affect the development and production of chickens, and many of these diseases can be prevented and controlled by balanced nutrition and hormone medicine. The steroid hormone 1 alpha,25 dihydroxyvitamin D 3 plays a key role in maintaining the balance of avian bone metabolism. Clinically, 1 alpha,25 (OH)(2)D 3 has been used to treat several bone diseases. Although several previous studies have investigated the effects of 1 alpha,25 (OH)(2)D 3 on osteoclastogenesis, the mechanisms underpinning osteoclast (OC) activity remain largely unknown. Herein, we used molecular and cell biology approaches to demonstrate that 1 alpha,25 (OH)(2)D 3 increases avian OC formation and activity, and upregulates bone resorption related genes. Moreover, 1 alpha,25 (OH)(2)D 3 regulates the OC cytoskeleton by increasing the formation of zipper like structure in OC precursor cells to potentiate OC activity via the Src/Racl signaling pathway. These findings provide new insight into the role of 1 alpha,25 (OH)(2)D 3 in OC activity. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Wang, Dong; Gu, Jian Hong; Tong, Xi Shuai; Song, Rui Long; Zhao, Hong Yan; Bian, Jian Chun; Liu, Xue Zhong; Yuan, Yan; Liu, Zong Ping] Yangzhou Univ, Coll Vet Med, 88 Daxuenanlu Rd, Yangzhou 225009, Jiangsu, Peoples R China.
   [Wang, Dong; Gu, Jian Hong; Tong, Xi Shuai; Song, Rui Long; Zhao, Hong Yan; Bian, Jian Chun; Liu, Xue Zhong; Yuan, Yan; Liu, Zong Ping] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China.
   [Wang, Dong; Gu, Jian Hong; Tong, Xi Shuai; Song, Rui Long; Zhao, Hong Yan; Bian, Jian Chun; Liu, Xue Zhong; Yuan, Yan; Liu, Zong Ping] Jiangsu Key Lab Zoonosis, Yangzhou 225009, Jiangsu, Peoples R China.
   [Wang, Dong; Gu, Jian Hong; Tong, Xi Shuai; Song, Rui Long; Zhao, Hong Yan; Bian, Jian Chun; Liu, Xue Zhong; Yuan, Yan; Liu, Zong Ping] Yangzhou Univ, Joint Int Res Lab Agr & Agriprod Safety, Minist Educ China, Yangzhou 225009, Jiangsu, Peoples R China.
   [Feng, Ling Ling] Yangzhou Univ, Affiliated Hosp, Dept Pediat, Yangzhou 225009, Jiangsu, Peoples R China.
C3 Yangzhou University; Yangzhou University; Yangzhou University; Yangzhou
   University
RP Gu, JH; Liu, ZP (通讯作者)，Yangzhou Univ, Coll Vet Med, 88 Daxuenanlu Rd, Yangzhou 225009, Jiangsu, Peoples R China.
EM jhgu@yzu.edu.cn; liuzongping@yzu.edu.cn
RI Gu, Jianhong/B 5316 2011
FU National Key Research and Development Program of China [2016YFD0501208];
   National Natural Science Foundation of China [31372495, 31672620,
   31502128, 31702304, 31702204]; Natural Science Foundation of Jiangsu
   Province [BK20150447]; China Postdoctoral Science Foundation
   [2017M611932]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions; Graduate Innovation Project of Jiangsu Province
   [KYLX15 1385]; Project of the Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD)
FX This work was supported by the National Key Research and Development
   Program of China [grant number 2016YFD0501208], the National Natural
   Science Foundation of China [grant numbers 31372495, 31672620, 31502128,
   31702304, 31702204], the Natural Science Foundation of Jiangsu Province
   [grant number BK20150447], the China Postdoctoral Science Foundation
   [grant number 2017M611932], the Priority Academic Program Development of
   Jiangsu Higher Education Institutions and the Graduate Innovation
   Project of Jiangsu Province[grant number KYLX15 1385], and the Project
   of the Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD). We thank the China Scholarship Council and the
   Testing Center of Yangzhou University for their technical assistance.
CR Albiges Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704
   Ang ESM, 2007, J CELL PHYSIOL, V212, P787, DOI 10.1002/jcp.21076
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Fu YX, 2013, POULTRY SCI, V92, P1613, DOI 10.3382/ps.2012 02756
   Gu JH, 2009, VET J, V181, P321, DOI 10.1016/j.tvjl.2008.03.006
   Gu JH, 2015, J STEROID BIOCHEM, V152, P25, DOI 10.1016/j.jsbmb.2015.04.003
   Kagiya T, 2015, J CLIN MED, V4, P1741, DOI 10.3390/jcm4091741
   Kim TH, 2013, JOINT BONE SPINE, V80, P307, DOI 10.1016/j.jbspin.2012.09.011
   Kogawa M, 2010, J STEROID BIOCHEM, V121, P277, DOI 10.1016/j.jsbmb.2010.03.048
   Lieben L, 2013, BONE, V54, P237, DOI 10.1016/j.bone.2012.10.007
   Lieben L, 2011, BEST PRACT RES CL EN, V25, P561, DOI 10.1016/j.beem.2011.05.008
   Liu W, 2014, TOXICOL LETT, V224, P1, DOI 10.1016/j.toxlet.2013.10.009
   Nakamichi Y, 2017, J BONE MINER RES, V32, P1297, DOI 10.1002/jbmr.3096
   PRICE CP, 1995, CLIN CHEM, V41, P641
   Qu XH, 2014, BIOCHEM BIOPH RES CO, V443, P658, DOI 10.1016/j.bbrc.2013.12.029
   Suda T, 2012, ARCH BIOCHEM BIOPHYS, V523, P22, DOI 10.1016/j.abb.2011.11.011
   Takahashi Naoyuki, 2007, V135, P285
   Takasu H, 2006, J CLIN INVEST, V116, P528, DOI 10.1172/JCI24742
   Takito J, 2015, J CELL PHYSIOL, V230, P395, DOI 10.1002/jcp.24723
   Takito Jiro, 2012, Commun Integr Biol, V5, P453, DOI 10.4161/cib.20980
   Takito J, 2012, J CELL SCI, V125, P662, DOI 10.1242/jcs.090886
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Wang D. F., 2015, CHINESE PHYS B, V25
   Yang MX, 2012, INFLAMM RES, V61, P511, DOI 10.1007/s00011 012 0441 y
   Zhang Y, 2018, J BONE MINER RES, V33, P1114, DOI 10.1002/jbmr.3398
NR 25
TC 5
Z9 6
U1 1
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 22
PY 2018
VL 501
IS 2
BP 576
EP 583
DI 10.1016/j.bbrc.2018.05.048
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GH9KM
UT WOS:000433988300037
PM 29753745
DA 2025 08 17
ER

PT J
AU Chang, EJ
   Ha, J
   Oerlemans, F
   Lee, YJ
   Lee, SW
   Ryu, J
   Kim, HJ
   Lee, Y
   Kim, HM
   Choi, JY
   Kim, JY
   Shin, CS
   Pak, YK
   Tanaka, S
   Wieringa, B
   Lee, ZH
   Kim, HH
AF Chang, Eun Ju
   Ha, Jeongim
   Oerlemans, Frank
   Lee, You Jin
   Lee, Soo Woong
   Ryu, Jiyoon
   Kim, Hyung Joon
   Lee, Youngkyun
   Kim, Hyun Man
   Choi, Je Yong
   Kim, Jin Young
   Shin, Chan Soo
   Pak, Youngmi Kim
   Tanaka, Sakae
   Wieringa, Be
   Lee, Zang Hee
   Kim, Hong Hee
TI Brain type creatine kinase has a crucial role in osteoclast mediated
   bone resorption
SO NATURE MEDICINE
LA English
DT Article
ID VACUOLAR PROTON PUMP; IN VIVO; MICE; DIFFERENTIATION; ATPASE;
   OSTEOPETROSIS; PROTEOMICS; DEFICIENT; SUBUNIT; SYSTEM
AB Osteoclasts differentiate from precursor cells of the monocyte macrophage lineage and subsequently become activated to be competent for bone resorption through programs primarily governed by receptor activator of nuclear factor kappa B ligand in cooperation with macrophage colony stimulating factor(1 3). Proteins prominently expressed at late phases of osteoclastogenesis and with a supportive role in osteoclast function are potential therapeutic targets for bone remodeling disorders. In this study, we used a proteomics approach to show that abundance of the brain type cytoplasmic creatine kinase (Ckb) is greatly increased during osteoclastogenesis. Decreasing Ckb abundance by RNA interference or blocking its enzymatic activity with a pharmacological inhibitor, cyclocreatine, suppressed the bone resorbing activity of osteoclasts grown in vitro via combined effects on actin ring formation, RhoA GTPase activity and vacuolar ATPase function. Activities of osteoclasts derived from Ckb( / ) mice were similarly affected. In vivo studies showed that Ckb( / ) mice were better protected against bone loss induced by ovariectomy, lipopolysaccharide challenge or interleukin 1 treatment than wild type controls. Furthermore, administration of cyclocreatine or adenoviruses harboring Ckb small hairpin RNA attenuated bone loss in rat and mouse models. Our findings establish an important role for Ckb in the bone resorbing function of osteoclasts and underscore its potential as a new molecular target for antiresorptive drug development.
C1 [Chang, Eun Ju; Ha, Jeongim; Ryu, Jiyoon; Kim, Hyung Joon; Lee, Youngkyun; Kim, Hyun Man; Lee, Zang Hee; Kim, Hong Hee] Seoul Natl Univ, Sch Dent, Dept Cell & Dev Biol, Seoul 110749, South Korea.
   [Oerlemans, Frank] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Cell Biol, NL 6500 HB Nijmegen, Netherlands.
   [Lee, You Jin] Jeonnam Biotechnol Res Ctr, Div Res, Hwasun Gun 519801, Jeollanamdo, South Korea.
   [Lee, Soo Woong] Inje Univ, Coll Med, Ctr Viral Dis Res, Dept Microbiol, Pusan 614735, South Korea.
   [Choi, Je Yong] Kyungpook Natl Univ, Skeletal Dis Genome Res Ctr, Taegu 700422, South Korea.
   [Choi, Je Yong] Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Taegu 700422, South Korea.
   [Kim, Jin Young] Korea Basic Sci Inst, Taejon 305333, South Korea.
   [Shin, Chan Soo] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea.
   [Pak, Youngmi Kim] Kyung Hee Univ, Dept Nanopharmaceut & Life Sci, Agerelated & Brain Dis Res Ctr, Seoul 130701, South Korea.
   [Tanaka, Sakae] Univ Tokyo, Fac Med, Dept Orthopaed Surg, Tokyo 1130033, Japan.
C3 Seoul National University (SNU); Radboud University Nijmegen; Inje
   University; Kyungpook National University (KNU); Kyungpook National
   University (KNU); Korea Basic Science Institute (KBSI); Seoul National
   University (SNU); Kyung Hee University; University of Tokyo
RP Kim, HH (通讯作者)，Seoul Natl Univ, Sch Dent, Dept Cell & Dev Biol, 28 Yeongon Dong, Seoul 110749, South Korea.
EM b.wieringa@ncmls.ru.nl; hhbkim@snu.ac.kr
RI ; Lee, Jeong Eun/R 8689 2019; Tanaka, Sakae/Y 3061 2019; Kim, Hyung
   Joon/ABD 3143 2020; Kim, Dae/AAJ 7518 2021; Lee, Youngkyun/D 2667 2011;
   Wieringa, Berend/A 5346 2011; Ryu, Jiyoon/M 8573 2019; Shin,
   Chan/I 7320 2012; Kim, Young/C 9839 2015
OI Kim, Hyung Joon/0000 0002 2962 9553; Tanaka, Sakae/0000 0001 9210 9414;
   Pak, Youngmi/0000 0001 7424 3484; 
FU 21C Frontier Functional Proteomics Project [FPR08B1 170, FPR08A1 070];
   Research Program for New Drug Target Discovery
   [M10748000257 07N4800 25710]; Ministry of Education, Science &
   Technology, Korea; NKB KWF [2002 2763]
FX We thank S. I. Kim, H. B. Kwak, J. Y. Yang, T. K. Yu and J. S. Ko for
   technical help and discussion. We also thank T. Kitamura (University of
   Tokyo) for Plat E cells. This work was supported by the 21C Frontier
   Functional Proteomics Project grants FPR08B1 170 (to H. H. K.) and
   FPR08A1 070 (to Y. K. P.), the Research Program for New Drug Target
   Discovery grant M10748000257 07N4800 25710 (to H. H. K.) from the
   Ministry of Education, Science & Technology, Korea and NKB KWF grant
   2002 2763 (to B. W.).
CR BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang EJ, 2004, FEBS LETT, V564, P166, DOI 10.1016/S0014 5793(04)00338 2
   Chang EJ, 2007, J CELL SCI, V120, P166, DOI 10.1242/jcs.03310
   Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200
   Crozatier B, 2002, FASEB J, V16, DOI 10.1096/fj.01 0652com
   Dzeja PP, 2004, MOL CELL BIOCHEM, V256, P13, DOI 10.1023/B:MCBI.0000009856.23646.38
   Fernández R, 1998, J MEMBRANE BIOL, V163, P137, DOI 10.1007/s002329900378
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Grey A, 1999, ENDOCRINOLOGY, V140, P4683, DOI 10.1210/en.140.10.4683
   Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Jost CR, 2002, EUR J NEUROSCI, V15, P1692, DOI 10.1046/j.1460 9568.2002.02001.x
   Kaasik A, 2001, CIRC RES, V89, P153, DOI 10.1161/hh1401.093440
   Kuiper JWP, 2008, PLOS BIOL, V6, P568, DOI 10.1371/journal.pbio.0060051
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lee Y, 2008, BLOOD, V111, P885, DOI 10.1182/blood 2007 03 082941
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Mahajan VB, 2000, P NATL ACAD SCI USA, V97, P12062, DOI 10.1073/pnas.97.22.12062
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   SISTERMANS EA, 1995, BIOCHEM J, V311, P445, DOI 10.1042/bj3110445
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Vaananen Kalervo, 1996, P103
   VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092 8674(93)90510 W
   Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107
   ZHANG D, 1995, J CELL SCI, V108, P2285
NR 27
TC 89
Z9 94
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD SEP
PY 2008
VL 14
IS 9
BP 966
EP 972
DI 10.1038/nm.1860
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 345IB
UT WOS:000258988600030
PM 18724377
DA 2025 08 17
ER

PT J
AU Sinder, BP
   Salemi, JD
   Ominsky, MS
   Caird, MS
   Marini, JC
   Kozloff, KM
AF Sinder, Benjamin P.
   Salemi, Joseph D.
   Ominsky, Michael S.
   Caird, Michelle S.
   Marini, Joan C.
   Kozloff, Kenneth M.
TI Rapidly growing Brtl/ plus mouse model of osteogenesis imperfecta
   improves bone mass and strength with sclerostin antibody treatment
SO BONE
LA English
DT Article
DE Osteogenesis imperfecta; Sclerostin antibody; Collagen; Bone mass;
   Anabolic therapy; Dynamic histomorphometry
ID GROWTH HORMONE TREATMENT; ALENDRONATE TREATMENT; MINERAL DENSITY; MURINE
   MODEL; CHILDREN; MICE; HISTOMORPHOMETRY; OSTEOPOROSIS; PERIOSTEAL;
   RESORPTION
AB Osteogenesis imperfecta (OI) is a heritable collagen related bone dysplasia, characterized by brittle bones with increased fracture risk that presents most severely in children. Anti resorptive bisphosphonates are frequently used to treat pediatric OI and controlled clinical trials have shown that bisphosphonate therapy improves vertebral outcomes but has little benefit on long bone fracture rate. New treatments which increase bone mass throughout the pediatric OI skeleton would be beneficial. Sclerostin antibody (Scl Ab) is a potential candidate anabolic therapy for pediatric OI and functions by stimulating osteoblastic bone formation via the canonical Wnt signaling pathway. To explore the effect of Scl Ab on the rapidly growing OI skeleton, we treated rapidly growing 3 week old Brtl/+ mice, harboring a typical heterozygous OI causing Gly   > Cys substitution on col1a1, for 5 weeks with Scl Ab. Scl Ab had anabolic effects in Brtl/+ and led to new cortical bone formation and increased cortical bone mass. This anabolic action resulted in improved mechanical strength to WTVeh levels without altering the underlying brittle nature of the material. While Scl Ab was anabolic in trabecular bone of the distal femur in both genotypes, the effect was less strong in these rapidly growing Brtl/+ mice compared to WT. In conclusion, Scl Ab was able to stimulate bone formation in a rapidly growing Brtl/+ murine model of OI, and represents a potential new therapy to improve bone mass and reduce fracture risk in pediatric OI. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Sinder, Benjamin P.; Salemi, Joseph D.; Caird, Michelle S.; Kozloff, Kenneth M.] Univ Michigan, Dept Orthopaed Surg, Orthopaed Res Labs, Ann Arbor, MI 48109 USA.
   [Sinder, Benjamin P.; Salemi, Joseph D.; Kozloff, Kenneth M.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Ominsky, Michael S.] Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91320 USA.
   [Marini, Joan C.] NICHHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Amgen; National Institutes of
   Health (NIH)   USA; NIH Eunice Kennedy Shriver National Institute of
   Child Health & Human Development (NICHD)
RP Kozloff, KM (通讯作者)，2015 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.
EM kenkoz@umich.edu
RI Salemi, Jason/IUO 0313 2023
FU NIH [R01AR062522]
FX The authors thank Bonnie Nolan, Kathy Sweet and Logan White for their
   contributions. Scl Ab was provided by Amgen and UCB Pharma. Funding
   support from NIH to KMK (R01AR062522) is gratefully acknowledged. Study
   designed and conducted by BPS and KMK. Data collected by BPS and JDS.
   Data analyzed and interpreted by BPS, JDS, MSO, MSC, JCM, and KMK.
   Manuscript was written by BPS and KMK and revised and approved by all
   authors. KMK takes responsibility for the integrity of the data
   analysis. MSO is an employee and stock owner of Amgen Inc. All others
   state that they have no conflicts of interest.
CR Agholme F, 2011, ACTA ORTHOP, V82, P125, DOI [10.3109/17453674.2011.572252, 10.3109/17453674.2011.625539]
   Antoniazzi F, 1996, J PEDIATR US, V129, P432, DOI 10.1016/S0022 3476(96)70077 X
   BEIGHTON P, 1988, J MED GENET, V25, P200, DOI 10.1136/jmg.25.3.200
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Davis MS, 2012, BONE, V50, P784, DOI 10.1016/j.bone.2011.12.007
   EPSTEIN S, 1979, S AFR MED J, V55, P1105
   Forlino A, 1999, J BIOL CHEM, V274, P37923, DOI 10.1074/jbc.274.53.37923
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Gatti D, 2005, J BONE MINER RES, V20, P758, DOI 10.1359/JBMR.041232
   Hauge E, 1999, BONE, V25, P389, DOI 10.1016/S8756 3282(99)00194 5
   Jepsen KJ, 2009, WIRES SYST BIOL MED, V1, P73, DOI 10.1002/wsbm.15
   Kozloff KM, 2004, J BONE MINER RES, V19, P614, DOI 10.1359/JBMR.040111
   Letocha AD, 2005, J BONE MINER RES, V20, P977, DOI 10.1359/JBMR.050109
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2011, ENDOCRINOLOGY, V152, P3312, DOI 10.1210/en.2011 0252
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Marenzana M, 2011, ARTHRITIS RHEUM US, V63, P2385, DOI 10.1002/art.30385
   Marini JC, 2003, J BONE MINER RES, V18, P237, DOI 10.1359/jbmr.2003.18.2.237
   Marini JC, 2009, NAT REV ENDOCRINOL, V5, P241, DOI 10.1038/nrendo.2009.58
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Meganck JA, 2013, BONE, V56, P204, DOI 10.1016/j.bone.2013.06.003
   Meganck JA, 2009, BONE, V45, P1104, DOI 10.1016/j.bone.2009.07.078
   Misof BM, 2005, BONE, V36, P150, DOI 10.1016/j.bone.2004.10.006
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Panaroni C, 2009, BLOOD, V114, P459, DOI 10.1182/blood 2008 12 195859
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   PATERSON CR, 1984, NEW ENGL J MED, V310, P1694, DOI 10.1056/NEJM198406283102602
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Rauch F, 2009, J BONE MINER RES, V24, P1282, DOI [10.1359/jbmr.090213, 10.1359/JBMR.090213]
   Sakkers R, 2004, LANCET, V363, P1427, DOI 10.1016/S0140 6736(04)16101 1
   Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717
   Sinder BP, 2014, OSTEOPOROSIS INT, V7, P1
   SONTAG W, 1986, BONE, V7, P55, DOI 10.1016/8756 3282(86)90152 3
   Uveges TE, 2009, J BONE MINER RES, V24, P849, DOI [10.1359/jbmr.081238, 10.1359/JBMR.081238]
   Uveges TE, 2008, J BONE MINER RES, V23, P1983, DOI 10.1359/JBMR.080804
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Ward LM, 2011, J CLIN ENDOCR METAB, V96, P355, DOI 10.1210/jc.2010 0636
NR 40
TC 73
Z9 82
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2015
VL 71
BP 115
EP 123
DI 10.1016/j.bone.2014.10.012
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AY7XU
UT WOS:000347770000015
PM 25445450
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Shu, X
   Liu, WF
   Liu, HQ
   Qi, H
   Wu, CG
   Ran, YL
AF Shu, Xiong
   Liu, Weifeng
   Liu, Huiqi
   Qi, Hui
   Wu, Chengai
   Ran, Yu Liang
TI Analysis of microRNA expression in CD133 positive cancer stem like cells
   of human osteosarcoma cell line MG 63
SO PEERJ
LA English
DT Article
DE Osteosarcoma; Cancer stem cells; CD133; microRNA; miR 4284
ID PROLIFERATION; CHEMORESISTANCE; PROGRESSION; BIOMARKER; SERVES; GROWTH;
   MODEL; MIRNA
AB Osteosarcoma (OS) is a primary malignant tumor of bone occurring in young adults. OS stem cells (OSCs) play an important role in the occurrence, growth, metastasis, drug resistance and recurrence of OS. CD133 is an integral membrane glycoprotein, which has been identified as an OSC marker. However, the mechanisms of metastasis, chemoresistance, and progression in CD133(+) OSCs need to be further explored. In this study, we aim to explore differences in miRNA levels between CD133(+) and CD133( ) cells from the MG 63 cell line. We found 20 differentially expressed miRNAs (DEmiRNAs) (16 upregulated and 4 downregulated) in CD133(+) cells compared with CD133( ) cells. Hsa miR 4485 3p, hsa miR 4284 and hsa miR 3656 were the top three upregulated DEmiRNAs, while hsa miR 487b 3p, hsa miR 493 5p and hsa miR 431 5p were the top three downregulated DEmiRNAs. In addition, RT PCR analysis confirmed that the expression levels of hsa miR 4284, hsa miR 4485 3p and hsa miR 3656 were significantly increased, while the expression levels of hsa miR 487b 3p, hsa miR 493 5p, and hsa miR 431 5p were significantly decreased in CD133(+) cells compared with CD133( ) cells. Moreover, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis revealed that predicted or validated target genes for all 20 DEmiRNAs or the selected 6 DEmiRNAs participated in the "PI3K Akt signaling pathway," "Wnt signaling pathway," "Rap1 signaling pathway," "Cell cycle" and "MAPK signaling pathway". Among the selected six DEmiRNAs, miR 4284 was especially interesting. MiR 4284 knockdown significantly reduced the sphere forming capacity of CD133(+) OS cells. The number of invasive CD133(+) OS cells was markedly decreased after miR 4284 knockdown. In addition, miR 4284 knockdown increased the p beta catenin levels in CD133(+) OS cells. In conclusion, RNA seq analysis revealed DEmiRNAs between CD133(+) and CD133( ) cells. MiRNAs might play significant roles in the function of OSCs and could serve as targets for OS treatment. MiR 4284 prompted the self renewal and invasion of OSCs. The function of miR 4284 might be associated with the Wnt signaling pathway.
C1 [Shu, Xiong; Qi, Hui; Wu, Chengai] Beijing JiShuiTan Hosp, Beijing Res Inst Traumatol & Orthopaed, Beijing, Peoples R China.
   [Liu, Weifeng] Peking Univ, Beijing Jishuitan Hosp, Dept Orthopaed Oncol Surg, Beijing, Peoples R China.
   [Liu, Huiqi] Qinghai Univ, Med Coll, Xining, Peoples R China.
   [Ran, Yu Liang] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China.
C3 Peking University; Qinghai University; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Peking Union Medical College;
   Cancer Institute & Hospital   CAMS
RP Wu, CG (通讯作者)，Beijing JiShuiTan Hosp, Beijing Res Inst Traumatol & Orthopaed, Beijing, Peoples R China.; Ran, YL (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China.
EM wuchengai@jst hosp.com.cn; ran_yuliang@126.com
OI Liu, Weifeng/0000 0001 6935 3064
FU National Natural Science Foundation of China [81330043, 81071499];
   Beijing Municipal Health Commission [BMHC 2019 9, BMHC 2018 4]; Natural
   Science Foundation of Beijing JiShuiTan Hospital [ZR 201906]; CAMS
   Innovation Fund for Medical Sciences [2017 2M 3 005]; Independent Issue
   of State Key Laboratory of Molecular Oncology [SKL 2019 17]
FX This work was supported by the National Natural Science Foundation of
   China (81330043, 81071499) , the Beijing Municipal Health Commission
   (BMHC 2019 9, BMHC 2018 4) , the Natural Science Foundation of Beijing
   JiShuiTan Hospital (ZR 201906) , the CAMS Innovation Fund for Medical
   Sciences (2017 2M 3 005) , and the Independent Issue of State Key
   Laboratory of Molecular Oncology (SKL 2019 17) . The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008 5472.CAN 09 3463
   Bao ZQ, 2018, INT J CLIN EXP PATHO, V11, P3656
   Camuzard O, 2020, CANCERS, V12, DOI 10.3390/cancers12123675
   Chang YW, 2015, CELL PHYSIOL BIOCHEM, V36, P1186, DOI 10.1159/000430289
   Chen CB, 2015, ONCOTARGET, V6, P17570, DOI 10.18632/oncotarget.4100
   Chen R, 2019, MOL MED REP, V19, P1571, DOI 10.3892/mmr.2018.9774
   Cheng M, 2020, ONCOL REP, V44, P2691, DOI 10.3892/or.2020.7814
   Czarnecka AM, 2020, CANCERS, V12, DOI 10.3390/cancers12082130
   Dai JL, 2021, HUM CELL, V34, P624, DOI 10.1007/s13577 020 00468 x
   Feng XT, 2021, J BIOL REG HOMEOS AG, V35, P151, DOI 10.23812/20 695 A
   Gong YB, 2021, ONCOTARGETS THER, V14, P15, DOI 10.2147/OTT.S282485
   Guo A, 2019, MED SCI MONITOR, V25, P8403, DOI 10.12659/MSM.920364
   Guo Y, 2007, J ORTHOP RES, V25, P964, DOI 10.1002/jor.20356
   Huang CW, 2019, INT J CLIN ONCOL, V24, P976, DOI 10.1007/s10147 019 01433 x
   Li J, 2013, MOL MED REP, V7, P577, DOI 10.3892/mmr.2012.1231
   Li K, 2016, ONCOL REP, V36, P1973, DOI 10.3892/or.2016.4991
   Li YS, 2018, MOL MED REP, V17, P6569, DOI 10.3892/mmr.2018.8671
   Liang K, 2021, CLIN TRANSL ONCOL, V23, P2350, DOI 10.1007/s12094 021 02633 6
   Lin JL, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12478
   Liu HW, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935 021 01909 9
   Luo X, 2020, NEUROSCI BULL, V36, P1171, DOI 10.1007/s12264 020 00532 4
   Ni MZ, 2015, INT J NANOMED, V10, P2537, DOI 10.2147/IJN.S78498
   Pinczewski J, 2021, PATHOL RES PRACT, V224, DOI 10.1016/j.prp.2021.153527
   Ren ZN, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03621 y
   Saini V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041401
   Shu X, 2020, ONCOL REP, V44, P313, DOI 10.3892/or.2020.7597
   Singla A, 2020, ADV EXP MED BIOL, V1258, P125, DOI 10.1007/978 3 030 43085 6_8
   Sun SL, 2020, CANCER MANAG RES, V12, P8159, DOI 10.2147/CMAR.S260149
   Taciak B, 2018, J PHYSIOL PHARMACOL, V69, DOI 10.26402/jpp.2018.2.07
   Tamaddon G, 2016, IRAN J MED SCI, V41, P334
   Tian P, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9983
   Tornín J, 2021, FREE RADICAL BIO MED, V164, P107, DOI 10.1016/j.freeradbiomed.2020.12.437
   Wang JH, 2020, INT J MOL MED, V46, P2251, DOI 10.3892/ijmm.2020.4764
   Wang LL, 2020, INT J GEN MED, V13, P1685, DOI 10.2147/IJGM.S274641
   Wang T, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1195 y
   Yao JZ, 2020, GENE, V726, DOI 10.1016/j.gene.2019.144224
   Yin CD, 2021, BIOENGINEERED, V12, P172, DOI 10.1080/21655979.2020.1864096
   Yu T, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.10024
   Zhang C, 2019, J CANCER, V10, P6511, DOI 10.7150/jca.29931
   Zhang HW, 2021, BIOENGINEERED, V12, P162, DOI 10.1080/21655979.2020.1863014
   Zhang J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0864 6
   Zhang L, 2020, NEOPLASMA, V67, P519, DOI 10.4149/neo_2020_190711N624
   Zhang ZQ, 2019, J CELL PHYSIOL, V234, P13525, DOI 10.1002/jcp.28030
   Zhao D, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705341
   Zhao FY, 2015, INT J CLIN EXP PATHO, V8, P1451
   Zhou JH, 2015, EXP BIOL MED, V240, P867, DOI 10.1177/1535370214563893
   Zhou W, 2016, MOL MED REP, V13, P713, DOI 10.3892/mmr.2015.4597
   Zhu MS, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2020.12413
   Zou YG, 2017, MOL MED REP, V15, P1631, DOI 10.3892/mmr.2017.6187
NR 49
TC 5
Z9 5
U1 0
U2 15
PU PEERJ INC
PI LONDON
PA 341 345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167 8359
J9 PEERJ
JI PeerJ
PD SEP 3
PY 2021
VL 9
AR e12115
DI 10.7717/peerj.12115
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA UR9LS
UT WOS:000697061900002
PM 34557357
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Park, CK
   Kim, HJ
   Kwak, HB
   Lee, TH
   Bang, MH
   Kim, CM
   Lee, Y
   Chung, DK
   Baek, NI
   Kim, J
   Lee, ZH
   Kim, HH
AF Park, Cheol Kyu
   Kim, Hyung Joon
   Kwak, Han Bok
   Lee, Tae Hoon
   Bang, Myun Ho
   Kim, Chul Min
   Lee, Youngkyun
   Chung, Dae Kyun
   Baek, Nam In
   Kim, Jiyoung
   Lee, Zang Hee
   Kim, Hong Hee
TI Inhibitory effects of Stewartia koreana on osteoclast
   differentiation and bone resorption
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Stewartia koreana; RANKL; osteoclast; NFATc1; bone resorption
ID NF KAPPA B; NECROSIS FACTOR RECEPTOR; TOLL LIKE RECEPTORS; LACKING
   C FOS; NUCLEAR FACTOR; RHEUMATOID ARTHRITIS; KEY REGULATOR;
   PHOSPHATIDYLINOSITOL 3 KINASE; ACTIVATION; INVOLVEMENT
AB Osteoclasts are responsible for bone lysis in several bone diseases such as osteoporosis and rheumatoid arthritis. Natural products from plants have been invaluable source in discovery of compounds for new therapies. In this study, we screened plant products for potential application to therapy for bone loss using a primary osteoclastogenesis culture system and found that extract of Stewartia koreana (SKE) had a strong inhibitory effect on osteoclast formation. To gain molecular insights, we examined the effect of SKE on signaling pathways and transcription factors stimulated by the osteoclast differentiation factor RANKL. SKE suppressed the induction of c Fos and NFATc I by RANKL. However, SKE did not inhibit NF kappa B activation by RANKL. Among the MAPKs stimulated by RANKL, SKE significantly reduced the activation of ERK and p38. Therefore, the anti osteoclastogenic effect of SKE is likely to be elicited by interference with RANKL signaling to ERK and p38, which mediate the induction of c Fos and subsequently that of NFATcl. Consistent with the in vitro effect on osteoclast differentiation, SKE showed a great inhibitory effect on in vivo bone loss in LPS challenged mice. Taken together, we demonstrated that SKE has inhibitory effects on osteoclast differentiation in vitro and confirmed its in vivo efficacy in prevention of inflammatory bone loss. (C) 2007 Elsevier B.V. All rights reserved.
C1 Seoul Natl Univ, Sch Dent, Inst Dent Res, Dept Cell & Dev Biol,Program BK21, Seoul 110749, South Korea.
   Kyung Hee Univ, Grad Sch Biotechnol, Yongin 446701, South Korea.
   Kyung Hee Univ, Inst Life Sci & Resources, Yongin 446701, South Korea.
   Kyung Hee Univ, RNA Inc, Coll Life Sci, Yongin 449701, South Korea.
C3 Seoul National University (SNU); Kyung Hee University; Kyung Hee
   University; Kyung Hee University
RP Kim, HH (通讯作者)，Seoul Natl Univ, Sch Dent, Inst Dent Res, Dept Cell & Dev Biol,Program BK21, 28 Yeongon Dong, Seoul 110749, South Korea.
EM hhbkim@snu.ae.kr
RI ; Lee, Youngkyun/D 2667 2011; Baek, Nam In/AAK 7447 2020; Lee,
   Tae/B 1160 2013; Park, Cheol Kyu/AAT 9872 2021; chung,
   dae/AAG 1058 2021; Kim, Hyung Joon/ABD 3143 2020
OI Kim, Hyung Joon/0000 0002 2962 9553; 
CR Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Chang EJ, 2007, J CELL SCI, V120, P166, DOI 10.1242/jcs.03310
   Coffer PJ, 1998, BIOCHEM J, V335, P1
   Feldmann M, 1995, ANN NY ACAD SCI, V766, P272, DOI 10.1111/j.1749 6632.1995.tb26675.x
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Isomäki P, 1997, ANN MED, V29, P499, DOI 10.3109/07853899709007474
   Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee SE, 2001, J BIOL CHEM, V276, P49343, DOI 10.1074/jbc.M103642200
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   LOTSOVA V, 1997, NAT MED, V3, P1285
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015
   PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092 8674(94)90482 0
   Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9
   Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483
   Sakuma Y, 2000, J BONE MINER RES, V15, P218, DOI 10.1359/jbmr.2000.15.2.218
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeda S, 1999, ENDOCRINOLOGY, V140, P1005, DOI 10.1210/en.140.2.1005
   Usui T, 2006, ENDOCR J, V53, P7, DOI 10.1507/endocrj.53.7
   Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959 437X(00)00228 8
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612
NR 35
TC 27
Z9 28
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC 5
PY 2007
VL 7
IS 12
BP 1507
EP 1516
DI 10.1016/j.intimp.2007.07.016
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 226LG
UT WOS:000250590000002
PM 17920527
DA 2025 08 17
ER

PT J
AU Liang, GH
   Liu, N
   He, MT
   Yang, J
   Liang, ZJ
   Gao, XJ
   Rahhal, AH
   He, QY
   Zhang, HT
   Zha, ZG
AF Liang, Gui Hong
   Liu, Ning
   He, Ming Tang
   Yang, Jie
   Liang, Zu Jian
   Gao, Xue Juan
   Rahhal, Ali Hasan
   He, Qing Yu
   Zhang, Huan Tian
   Zha, Zhen Gang
TI Transcriptional regulation of Runx2 by HSP90 controls osteosarcoma
   apoptosis via the AKT/GSK 3/ catenin signaling
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE 17 AAG;  catenin; apoptosis; heat shock protein 90; osteosarcoma; RUNX2
ID OSTEOBLAST DIFFERENTIATION; TARGETED THERAPY; GENE EXPRESSION;
   CANCER THERAPY; BETA CATENIN; CELL GROWTH; WNT; DEGRADATION;
   OSTEOGENESIS; PATHWAY
AB Osteosarcoma (OS) is the most malignant primary bone tumor in children and adolescents with limited treatment options and poor prognosis. Recently, aberrant expression of Runx2 has been found in OS, thereby contributing to the development, and progression of OS. However, the upstream signaling molecules that regulate its expression in OS remain largely unknown. In the present study, we first confirmed that the inhibition of HSP90 with 17 AAG caused significant apoptosis of OS cells via a caspase 3 dependent mechanism, and that inhibition or knockdown of HSP90 by 17 AAG or siRNAs significantly suppressed mRNA and protein expression of Runx2. Furthermore, we provided evidence that Runx2 was transcriptionally regulated by HSP90 when using MG132 and CHX chase assay. We also demonstrated that  catenin was overexpressed in OS tissue, and that knockdown of  catenin induced pronounced apoptosis of OS cells in the presence or absence of 17 AAG. Interestingly, this phenomenon was accompanied with a significant reduction of Runx2 and Cyclin D1 expression, indicating an essential role of Runx2/Cyclin D1 in 17 AAG induced cells apoptosis. Moreover, we demonstrated that the apoptosis of OS cells induced by 17 AAG did require the involvement of the AKT/GSK 3/ catenin signaling pathway by using pharmacological inhibitor GSK 3 (LiCl) or siGSK 3. Our findings reveal a novel mechanism that Runx2 is transcriptionally regulated by HSP90 via the AKT/GSK 3/ catenin signaling pathway, and by which leads to apoptosis of OS cells.
C1 [Liang, Gui Hong; Liang, Zu Jian] Guangzhou Univ Chinese Med, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
   [Liu, Ning; Yang, Jie; Rahhal, Ali Hasan; Zhang, Huan Tian; Zha, Zhen Gang] Jinan Univ, Affiliated Hosp 1, Inst Orthoped Dis, Guangzhou, Guangdong, Peoples R China.
   [Liu, Ning; Yang, Jie; Rahhal, Ali Hasan; Zhang, Huan Tian; Zha, Zhen Gang] Jinan Univ, Affiliated Hosp 1, Ctr Joint Surg & Sports Med, Guangzhou, Guangdong, Peoples R China.
   [He, Ming Tang] Longgang Orthoped Hosp Shenzhen, Shenzhen, Peoples R China.
   [Gao, Xue Juan; He, Qing Yu; Zhang, Huan Tian] Jinan Univ, Coll Life Sci & Technol, Key Lab Funct Prot Res Guangdong Higher Educ Inst, Guangzhou, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Jinan University; Jinan
   University; Jinan University
RP Zhang, HT; Zha, ZG (通讯作者)，Jinan Univ, Affiliated Hosp 1, Inst Orthoped Dis, Guangzhou, Guangdong, Peoples R China.; Zhang, HT; Zha, ZG (通讯作者)，Jinan Univ, Affiliated Hosp 1, Ctr Joint Surg & Sports Med, Guangzhou, Guangdong, Peoples R China.
EM tjnuzht@hotmail.com; zhzgg@vip.163.com
RI He, Qing Yu/H 7078 2014; Rahhal, Ali/LWI 0822 2024
OI He, Qing Yu/0000 0003 0503 9492; Liang, Guihong/0000 0002 7599 2628; 
FU Medical Scientific Research Foundation of Guangdong Province [A2016017];
   Natural Science Foundation of Guangdong Province [2014A030310242]; China
   Postdoctoral Science Foundation [2016M602606]; Macau Foundation for
   Development of Science and Technology [111/2015/A]; National Natural
   Science Foundation of China [81602360, 81672224]
FX Medical Scientific Research Foundation of Guangdong Province, Grant
   number: A2016017; Natural Science Foundation of Guangdong Province,
   Grant number: 2014A030310242; China Postdoctoral Science Foundation,
   Grant number: 2016M602606; Macau Foundation for Development of Science
   and Technology, Grant number: 111/2015/A; National Natural Science
   Foundation of China, Grant numbers: 81602360, 81672224
CR Arioka M, 2014, BIOCHEM PHARMACOL, V90, P397, DOI 10.1016/j.bcp.2014.06.011
   Bahrami A., 2017, J CELL BIOCH
   Behrens J, 2000, ANN NY ACAD SCI, V910, P21
   Cho WH, 2006, J INT MED RES, V34, P676, DOI 10.1177/147323000603400614
   Dai X, 2011, MED SCI MONITOR, V17, pRA177, DOI 10.12659/MSM.881893
   Deng X, 2017, ONCOGENE, V36, P1223, DOI 10.1038/onc.2016.287
   Dickey CA, 2008, P NATL ACAD SCI USA, V105, P3622, DOI 10.1073/pnas.0709180105
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gazitt Y, 2009, INT J ONCOL, V34, P551, DOI 10.3892/ijo_00000181
   Glover J, 2015, PEDIATR BLOOD CANCER, V62, P450, DOI 10.1002/pbc.25346
   Haxaire C, 2016, AM J PATHOL, V186, P1598, DOI 10.1016/j.ajpath.2016.01.016
   Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065 230X(07)99002 8
   Iwaya K, 2003, CLIN EXP METASTAS, V20, P525, DOI 10.1023/A:1025821229013
   Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343
   Kurashina R, 2009, CANCER LETT, V284, P62, DOI 10.1016/j.canlet.2009.04.012
   Kurek KC, 2010, CANCER RES, V70, P5577, DOI 10.1158/0008 5472.CAN 09 4602
   Li N, 2015, ANTI CANCER AGENT ME, V15, P881, DOI 10.2174/1871520615666150304151228
   Li XN, 2008, J CELL BIOL, V181, P959, DOI 10.1083/jcb.200711044
   Lucero CMJ, 2013, J CELL PHYSIOL, V228, P714, DOI 10.1002/jcp.24218
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   McCarthy TL, 2010, MOL ENDOCRINOL, V24, P587, DOI 10.1210/me.2009 0379
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Mori M, 2015, INT J ONCOL, V46, P47, DOI 10.3892/ijo.2014.2727
   Olfa G, 2010, BONE, V46, P901, DOI 10.1016/j.bone.2009.12.027
   OMEARA TR, 2017, TRENDS MICROBIOL, P90
   Pick E, 2007, CANCER RES, V67, P2932, DOI 10.1158/0008 5472.CAN 06 4511
   PosthumaDeBoer J, 2011, CLIN EXP METASTAS, V28, P493, DOI 10.1007/s10585 011 9384 x
   REGARD JB, 2012, COLD SPRING HARB PER, V4, P653
   Schneider JA, 2017, MOL CELL ENDOCRINOL
   Schopf FH, 2017, NAT REV MOL CELL BIO, V18, P345, DOI 10.1038/nrm.2017.20
   Shaikh AB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040506
   Sidera K, 2014, RECENT PAT ANTI CANC, V9, P1
   Solit DB, 2006, CURR TOP MED CHEM, V6, P1205, DOI 10.2174/156802606777812068
   Tian J, 2014, TUMOR BIOL, V35, P9439, DOI 10.1007/s13277 014 2433 8
   Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887
   Uozaki H, 2000, PATHOL RES PRACT, V196, P665, DOI 10.1016/S0344 0338(00)80118 1
   VEGA OA, 2017, J CELL BIOCHEM, P2
   WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324
   Won KY, 2009, TUMORI J, V95, P311
   Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012
   Xu JH, 2015, AM J TRANSL RES, V7, P2527
   Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200
   Zeng H, 2015, ONCOL LETT, V9, P2455, DOI 10.3892/ol.2015.3124
   ZHANG HT, 2017, J CELL BIOCHEM, V1, P9
   Zhang HT, 2017, J CELL BIOCHEM, V118, P2182, DOI 10.1002/jcb.25863
   Zhang HT, 2016, BBA MOL CELL RES, V1863, P335, DOI 10.1016/j.bbamcr.2015.12.001
   Zhang HT, 2014, BBA GENE REGUL MECH, V1839, P1330, DOI 10.1016/j.bbagrm.2014.09.015
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
NR 48
TC 24
Z9 24
U1 1
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN
PY 2018
VL 119
IS 1
BP 948
EP 959
DI 10.1002/jcb.26260
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FN5CO
UT WOS:000416024300092
PM 28681940
DA 2025 08 17
ER

PT J
AU Hu, XY
   Ping, ZC
   Gan, MF
   Tao, YX
   Wang, LL
   Shi, JW
   Wu, XX
   Zhang, W
   Yang, HL
   Xu, YZ
   Wang, ZR
   Geng, DC
AF Hu, Xuanyang
   Ping, Zichuan
   Gan, Minfeng
   Tao, Yunxia
   Wang, Liangliang
   Shi, Jiawei
   Wu, Xiexing
   Zhang, Wen
   Yang, Huilin
   Xu, Yaozeng
   Wang, Zhirong
   Geng, Dechun
TI Theaflavin 3,3′ digallate represses osteoclastogenesis and prevents wear
   debris induced osteolysis via suppression of ERK pathway
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Peri implant osteolysis; Wear debris; Theaflavin 3,3 ' digallate; RANKL;
   ERK pathway
ID PARTICLE INDUCED OSTEOLYSIS; TOTAL HIP ARTHROPLASTY; TITANIUM PARTICLES;
   SIGNALING PATHWAY; BLACK TEA; BISPHOSPHONATE THERAPY; STRONTIUM
   RANELATE; BONE RESORPTION; IN VITRO; POLYETHYLENE
AB Peri implant osteolysis (PIO) and the following aseptic loosening is the leading cause of implant failure. Emerging evidence suggests that receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast formation and osteoclastic bone resorption are responsible for particle stimulated PIO. Here, we explored the effect of theaflavin 3,3' digallate (TF3) on titanium particle induced osteolysis in vivo and in vitro. Twenty eight male C57BL/6 mice were randomly separated into four groups: sham control (sham), titanium particles only (titanium), titanium particles with low TF3 concentration (low TF3, 1 mg/kg TF3), and titanium particles with high TF3 concentration (high TF3, 10 mg/kg TF3). Two weeks later, micro computed tomography and histological analysis were performed. Bone marrow derived macrophages and RAW264.7 murine macrophages were applied to examine osteoclast formation and differentiation. TF3 significantly inhibited titanium particle induced osteolysis and prevented bone destruction compared with titanium group. Interestingly, the number of mature osteoclasts reduced after treatment with TF3 in vivo, suggesting osteoclast formation might be inhibited by TF3. In vitro, TF3 suppressed osteoclast formation, polarization and osteoclastic bone resorption by specifically targeting the RANKL induced ERK signal pathway. Collectively, these results suggest that TF3, a natural active compound derived from black tea, is a promising candidate for the treatment of osteoclast related osteolytic diseases, such as wear debris induced PIO.
   Statement of Significance
   Total joint arthroplasty is widely accepted for the treatment of end stage joint diseases. However, it is reported that aseptic loosening, initiated by peri implant osteolysis, is the major reason for prosthesis failure. Although the pathophysiology of PIO remains unclear, increasing evidence indicates that osteoclasts are excessively activated at the implant site by wear debris from materials. Here, we demonstrated that theaflavin 3,3' digallate, a natural active compound derived from black tea, inhibited osteoclast formation and osteoclastic bone resorption mainly via suppressing the ERK pathway. Moreover, the findings of this study have confirmed for the first time that theaflavin 3,3' digallate has a protective effect on particle induced osteolysis in a mouse calvarial model, thus preventing bone loss. These results indicate that theaflavin 3,3' digallate may be a suitable therapeutic agent to treat wear debris induced periimplant osteolysis. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Hu, Xuanyang; Ping, Zichuan; Gan, Minfeng; Tao, Yunxia; Wang, Liangliang; Shi, Jiawei; Wu, Xiexing; Yang, Huilin; Xu, Yaozeng; Geng, Dechun] Soochow Univ, Affiliated Hosp 1, Dept Orthoped, Suzhou, Peoples R China.
   [Zhang, Wen] Soochow Univ, Inst Orthoped, Suzhou, Peoples R China.
   [Wang, Zhirong] Zhangjiagang Hosp Tradit Chinese Med, Dept Orthoped, Suzhou, Peoples R China.
C3 Soochow University   China; Soochow University   China
RP Xu, YZ; Geng, DC (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthoped, Suzhou, Peoples R China.; Wang, ZR (通讯作者)，Zhangjiagang Hosp Tradit Chinese Med, Dept Orthoped, Suzhou, Peoples R China.
EM xuyaozeng@163.com; wangzzr@126.com; szgengdc@163.com
RI ; Geng, Dechun/LMO 1733 2024; Zhang, Wen/CAA 2126 2022; Shi,
   Jiawei/KDU 6911 2024; Zhirong, Wang/AAR 5563 2021; xiexing,
   wu/ABF 5431 2021
OI /0000 0003 1013 8495; Zhirong, Wang/0000 0002 6163 2138; ping,
   zichuan/0009 0000 9342 8193; GENG, Dechun/0000 0003 4375 2803
FU National High Technology Research and Development Program of China
   [2015AA020316]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD); Nature Science Foundation of Jiangsu
   Province [BK2011303]; National Nature Science Foundation of China
   [81101399, 81272018, 81372018, 81472077, 81672238]
FX We thank Prof. An Qin for technical help and advice. This research was
   supported by the National High Technology Research and Development
   Program of China (2015AA020316), the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD), the Nature
   Science Foundation of Jiangsu Province (BK2011303) and the National
   Nature Science Foundation of China (81101399, 81272018, 81372018,
   81472077 and 81672238).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Dorr LD, 2005, J BONE JOINT SURG AM, V87A, P1816, DOI 10.2106/JBJS.D.01915
   Gannon SC, 2013, J CELL PHYSIOL, V228, P1098, DOI 10.1002/jcp.24259
   Gao Y, 2016, INT J ONCOL, V48, P281, DOI 10.3892/ijo.2015.3257
   Geng DC, 2011, CHINESE MED J PEKING, V124, P586, DOI 10.3760/cma.j.issn.0366 6999.2011.04.019
   Geng DC, 2015, BIOMATERIALS, V69, P12, DOI 10.1016/j.biomaterials.2015.07.061
   Geng DC, 2010, BIOMATERIALS, V31, P1996, DOI 10.1016/j.biomaterials.2009.11.069
   Holt G, 2007, CLIN ORTHOP RELAT R, P240, DOI 10.1097/BLO.0b013e31804b4147
   Kauther MD, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 186
   Keener JD, 2003, J BONE JOINT SURG AM, V85A, P1066, DOI 10.2106/00004623 200306000 00013
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kundu T, 2005, CANCER LETT, V230, P111, DOI 10.1016/j.canlet.2004.12.035
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Leung LK, 2001, J NUTR, V131, P2248, DOI 10.1093/jn/131.9.2248
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Liang YC, 1999, CARCINOGENESIS, V20, P733, DOI 10.1093/carcin/20.4.733
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Lu YC, 2015, ACTA BIOMATER, V20, P147, DOI 10.1016/j.actbio.2015.03.034
   Mandal CC, 2009, ENDOCRINOLOGY, V150, P4989, DOI 10.1210/en.2009 0026
   Masui T, 2005, BIOMATERIALS, V26, P1695, DOI 10.1016/j.biomaterials.2004.05.017
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Muratoglu OK, 2002, BIOMATERIALS, V23, P717, DOI 10.1016/S0142 9612(01)00176 4
   Mutimer J, 2010, CLIN ORTHOP RELAT R, V468, P3228, DOI 10.1007/s11999 010 1379 4
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Oka Y, 2012, J PHARMACOL SCI, V118, P55, DOI 10.1254/jphs.11082FP
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   QIN XY, 1986, J ANTIMICROB CHEMOTH, V18, P747, DOI 10.1093/jac/18.6.747
   Qu SX, 2013, J BIOMED MATER RES A, V101, P394, DOI 10.1002/jbm.a.34327
   Ragab AA, 1999, J ORTHOPAED RES, V17, P803, DOI 10.1002/jor.1100170603
   Reginster JY, 2004, EXPERT OPIN INV DRUG, V13, P857, DOI 10.1517/13543784.13.7.857
   Saleh KJ, 2004, CLIN ORTHOP RELAT R, P138, DOI 10.1097/01.blo.0000142288.66246.4d
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Suda T, 2001, Novartis Found Symp, V232, P235
   SUDA T, 2001, NOVART FDN SYMP, V232, P247
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Taki N, 2005, J ORTHOP RES, V23, P376, DOI 10.1016/j.orthres.2004.08.023
   Urban RM, 2012, J BONE JOINT SURG AM, V94A, P1877, DOI 10.2106/JBJS.J.01507
   Verron E, 2014, DRUG DISCOV TODAY, V19, P312, DOI 10.1016/j.drudis.2013.08.010
   Vives V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7218
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wooley PH, 2004, GENE THER, V11, P402, DOI 10.1038/sj.gt.3302202
   Yamashita Junro, 2012, J Evid Based Dent Pract, V12, P233, DOI 10.1016/S1532 3382(12)70046 5
   Yang CS, 2000, J NUTR, V130, P2409, DOI 10.1093/jn/130.10.2409
   Yang HL, 2016, BIOMATERIALS, V80, P1, DOI 10.1016/j.biomaterials.2015.11.046
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
NR 50
TC 56
Z9 56
U1 0
U2 33
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JAN 15
PY 2017
VL 48
BP 479
EP 488
DI 10.1016/j.actbio.2016.11.022
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA EJ5GY
UT WOS:000393247000041
PM 27838465
DA 2025 08 17
ER

PT J
AU Jerome, CP
   Boyce, R
AF Jerome, Christopher P.
   Boyce, Rogely
TI Bone Therapeutics: Safety Considerations, Session Summary
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE musculoskeletal system; preclinical safety; risk assessment; toxicity
ID OSTEOGENESIS IMPERFECTA; RATS; OSTEOPOROSIS; PAMIDRONATE; PERSPECTIVE;
   OSTEOCLASTS; RESORPTION; PHENOTYPE; WEIGHT
AB This session was a series of presentations focused on safety considerations for late stage or currently marketed bone therapeutic agents. The first presentation was an overview of a major regulatory requirement in the nonclinical filing package for bone therapeutics, studies designed to assess the impact of an agent on bone quality. Two presentations focused on safety issues associated with drugs whose primary mechanism of action is inhibition of bone resorption. Typical findings associated with this class of agents in general and reproductive toxicology studies were reviewed, highlighting INHAND (International Harmonization of Nomenclature and Diagnostic Criteria) nomenclature. This was followed by an overview of safety issues that have been identified largely through clinical experience. Similar presentations followed emphasizing safety and regulatory issues associated with classes of drugs whose primary mechanism of action is stimulation of bone formation known broadly as bone anabolic agents. The major focus of these discussions was carcinogenicity risk assessment. The final presentation was an introduction to a rapidly evolving area in bone therapeutics, treatment of rare genetic bone diseases, and the developmental challenges associated with these indications and novel therapeutic modalities.
C1 [Jerome, Christopher P.] Wake Forest Innovat, Winston Salem, NC USA.
   [Boyce, Rogely] Beechy Ridge ToxPath LLC, POB 536, Clay, WV 25043 USA.
C3 Wake Forest University; Wake Forest Baptist Medical Center
RP Boyce, R (通讯作者)，Beechy Ridge ToxPath LLC, POB 536, Clay, WV 25043 USA.
EM rogely.w.boyce@gmail.com
CR [Anonymous], 2015, GUID IND PROD DEV UN
   Boyce BF, 2009, CRIT REV EUKAR GENE, V19, P171, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.10
   Boyce RW, 2014, BONE, V64, P314, DOI 10.1016/j.bone.2014.04.002
   Bussiere JL, 2012, J BONE MINER RES  S1, V27, pS466
   Chouinard L, 2016, REGUL TOXICOL PHARM, V81, P212, DOI 10.1016/j.yrtph.2016.08.010
   Colman EG, 2003, J BONE MINER RES, V18, P1125, DOI 10.1359/jbmr.2003.18.6.1125
   EMA (European Medicines Agency CHMP), 2006, GUID EV MED PROD TRE
   Glorieux FH, 2017, J BONE MINER RES, V32, P1496, DOI 10.1002/jbmr.3143
   Hernandez CJ, 2006, BONE, V39, P1173, DOI 10.1016/j.bone.2006.06.001
   Jain N, 2009, NAT REV RHEUMATOL, V5, P341, DOI 10.1038/nrrheum.2009.87
   Jolette J, 2017, REGUL TOXICOL PHARM, V86, P356, DOI 10.1016/j.yrtph.2017.04.001
   Montpetit K, 2015, ARCH PHYS MED REHAB, V96, P1834, DOI 10.1016/j.apmr.2015.06.006
   MOSEKILDE L, 1987, CALCIFIED TISSUE INT, V40, P318, DOI 10.1007/BF02556693
   Odgren PR, 2003, CRIT REV EUKAR GENE, V13, P181, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.110
   Palomo T, 2016, CALCIFIED TISSUE INT, V98, P42, DOI 10.1007/s00223 015 0061 y
   Pataki A, 1997, ANAT REC, V249, P458, DOI 10.1002/(SICI)1097 0185(199712)249:4<458::AID AR5>3.0.CO;2 N
   Rauch F, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf4628
   RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203
   Sato A, 2016, BONE, V86, P53, DOI 10.1016/j.bone.2016.02.018
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   US Food and Drug Administration, 2016, OST NONCL EV DRUGS I
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
NR 22
TC 1
Z9 1
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192 6233
EI 1533 1601
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD OCT
PY 2017
VL 45
IS 7
BP 855
EP 858
DI 10.1177/0192623317737231
PG 4
WC Pathology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology; Toxicology
GA FN4YJ
UT WOS:000416012600007
PM 29108483
OA Bronze
DA 2025 08 17
ER

PT J
AU Bullock, WA
   Hoggatt, AM
   Horan, DJ
   Elmendorf, AJ
   Sato, AY
   Bellido, T
   Loots, GG
   Pavalko, FM
   Robling, AG
AF Bullock, Whitney A.
   Hoggatt, April M.
   Horan, Daniel J.
   Elmendorf, Andrew J.
   Sato, Amy Y.
   Bellido, Teresita
   Loots, Gabriela G.
   Pavalko, Fredrick M.
   Robling, Alexander G.
TI Lrp4 Mediates Bone Homeostasis and Mechanotransduction through
   Interaction with Sclerostin In Vivo
SO ISCIENCE
LA English
DT Article
ID GENE; MUTATIONS; SOST; DELETION; DENSITY; AGRIN; MASS
AB Wnt signaling plays a key role in regulating bone remodeling. In vitro studies suggest that sclerostin's inhibitory action on Lrp5 is facilitated by the membrane associated receptor Lrp4. We generated an Lrp4 R1170W knockin mouse model (Lrp4(KI)), based on a published mutation in patients with high bone mass (HBM). Lrp4(KI) mice have an HBM phenotype (assessed radiographically), including increased bone strength and formation. Overexpression of a Sost transgene had osteopenic effects in Lrp4 WT but not Lrp4(KI) mice. Conversely, sclerostin inhibition had blunted osteoanabolic effects in Lrp4(KI) mice. In a disuse induced bone wasting model, Lrp4(KI) mice exhibit significantly less bone loss than wild type (WT) mice. In summary, mice harboring the Lrp4 R1170W missense mutation recapitulate the human HBM phenotype, are less sensitive to altered sclerostin levels, and are protected from disuse induced bone loss. Lrp4 is an attractive target for pharmacological targeting aimed at increasing bone mass and preventing bone loss due to disuse.
C1 [Bullock, Whitney A.; Hoggatt, April M.; Horan, Daniel J.; Elmendorf, Andrew J.; Sato, Amy Y.; Bellido, Teresita; Robling, Alexander G.] Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
   [Loots, Gabriela G.] Lawrence Livermore Natl Lab, Phys & Life Sci, Livermore, CA 94550 USA.
   [Pavalko, Fredrick M.] Indiana Univ Sch Med, Dept Integrat & Cellular Physiol, Indianapolis, IN 46202 USA.
   [Pavalko, Fredrick M.; Robling, Alexander G.] Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
   [Robling, Alexander G.] Richard L Roudebush VA Med Ctr, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; United States
   Department of Energy (DOE); Lawrence Livermore National Laboratory;
   Indiana University System; Indiana University Bloomington; US Department
   of Veterans Affairs; Veterans Health Administration (VHA); Richard L.
   Roudebush VA Medical Center
RP Robling, AG (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.; Robling, AG (通讯作者)，Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.; Robling, AG (通讯作者)，Richard L Roudebush VA Med Ctr, Indianapolis, IN 46202 USA.
EM arobling@iupui.edu
RI ; Loots, Gabriela/AGA 4868 2022
OI Bullock, Whitney/0000 0001 9008 8314; Bellido,
   Teresita/0000 0002 8203 7004; Loots, Gabriela/0000 0001 9546 5561; Sato,
   Amy/0000 0001 5061 1369
FU NIH [AR070624, AR065971, AR069029, DK075730, AR053237]; VA [BX001478,
   BX003783]; U.S. Department of Energy by Lawrence Livermore National
   Laboratory [DE AC52 07NA27344]; Indiana Clinical and Translational
   Sciences Institute   National Institutes of Health, National Center for
   Advancing Translational Sciences, Clinical and Translational Sciences
   Award [UL1TR002529]
FX Thanks to Emily Pemberton for assistance with colony maintenance. Thank
   you to Amgen/UCB Pharma for providing sclerostin antibody. This work was
   supported by NIH grants AR070624 (toW.A.B.), AR065971 (to W.A.B.),
   AR069029 (to F. M.P.), DK075730 (to G.G.L.) and AR053237 (to A.G.R.);
   and by VA grants BX001478 and BX003783 (to A.G. R.). G.G.L. performed
   work under the auspices of the U.S. Department of Energy by Lawrence
   Livermore National Laboratory under Contract DE AC52 07NA27344. This
   publication was made possible, in part, with support from the Indiana
   Clinical and Translational Sciences Institute funded, in part by Award
   Number UL1TR002529 from the National Institutes of Health, National
   Center for Advancing Translational Sciences, Clinical and Translational
   Sciences Award. The content is solely the responsibility of the authors
   and does not necessarily represent the official views of the National
   Institutes of Health.
CR Ahn Y, 2017, DEVELOPMENT, V144, P2824, DOI 10.1242/dev.150680
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Barik A, 2014, DEV NEUROBIOL, V74, P828, DOI 10.1002/dneu.22190
   Boudin E, 2017, J BONE MINER RES, V32, P1739, DOI 10.1002/jbmr.3160
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Bullock WA, 2019, J BONE MINER RES, V34, P1964, DOI 10.1002/jbmr.3812
   Chang MK, 2014, P NATL ACAD SCI USA, V111, pE5187, DOI 10.1073/pnas.1413828111
   Costantini A, 2017, EUR J MED GENET, V60, P675, DOI 10.1016/j.ejmg.2017.09.001
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Fijalkowski I, 2016, J BONE MINER RES, V31, P874, DOI 10.1002/jbmr.2782
   Goel S, 2012, J BIOL CHEM, V287, P16454, DOI 10.1074/jbc.M112.362137
   Holdsworth G, 2018, BONE, V107, P93, DOI 10.1016/j.bone.2017.11.003
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Niziolek PJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140775
   Ohkawara B, 2014, HUM MOL GENET, V23, P1856, DOI 10.1093/hmg/ddt578
   Robling AG, 2016, BONE, V92, P180, DOI 10.1016/j.bone.2016.09.001
   Shen CY, 2015, BONE, V80, P101, DOI 10.1016/j.bone.2015.05.012
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   Taylor Scott, 2018, Bone Rep, V8, P95, DOI 10.1016/j.bonr.2018.03.002
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Warner SE, 2006, BONE, V38, P257, DOI 10.1016/j.bone.2005.08.009
   Witcher PC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98673
   Xiong L, 2015, P NATL ACAD SCI USA, V112, P3487, DOI 10.1073/pnas.1419714112
NR 27
TC 28
Z9 33
U1 0
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2589 0042
J9 ISCIENCE
JI iScience
PD OCT 25
PY 2019
VL 20
BP 205
EP +
DI 10.1016/j.isci.2019.09.023
PG 24
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA JI3SL
UT WOS:000493388000016
PM 31585407
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ji, CJ
   Dong, QY
   Liu, HH
   Yang, XD
   Han, YG
   Zhu, BR
   Xing, HX
AF Ji, Changjiao
   Dong, Qiaoyan
   Liu, Huihui
   Yang, Xiaodeng
   Han, Yingguang
   Zhu, Bingrui
   Xing, Huaixin
TI Acyl protein thioesterase1 alleviates senile osteoporosis by promoting
   osteoblast differentiation via depalmitoylation of BMPR1a
SO REGENERATIVE THERAPY
LA English
DT Article
DE Senile osteoporosis; APT1; BMPR1a; BMP/Smad; Osteoblast differentiation;
   Palmitoylation; Protein modi fication; Bone mineral density
ID PHENOTYPE
AB Objective: Senile osteoporosis (SOP) is an aging related disease. The depalmitoylating enzyme Acyl protein thiesterase1 (APT1) is involved in disease regulation. This study explored the mechanism of APT1 in SOP. Methods: Eight week old SAMP6 mice were selected as SOP models and SAMR1 mice were controls, while osteoblasts were isolated from the femoral surface soft tissues of SOP and control mice as in vitro models. Mouse femur morphological, bone mineral density (BMD), femur maximum elastic stress and maximum load, and APT1 expression were detected by HE staining, X ray bone densitometer, material testing machine, and RT qPCR and Western blot (WB). Osteoprotegrin (OPG) labeled osteoblasts and APT1 localization in bone tissues were detected by immunohistochemical staining. APT1 expression was promoted in SOP mice by tail vein injection of APT1 lentivirus or promoted/silenced in osteoblasts by transfection of pcDNA3.1 APT1 overexpression or si APT1 plasmids. SOP mouse osteoblast differentiation (OD), OD related protein levels, osteoblast proliferation, BMPR1a palmitoylation level, and BMP/Smad pathway were detected by alizarin red staining, ALP activity detection, WB, CCK 8, and IP ABE method. The effects of the pathway inhibitor LDN 193189 on OD were detected. Results: APT1 was under expressed in osteoblasts of bone tissue in SOP mice and mainly localized in osteoblasts. SOP mice manifested increased bone marrow cavity and bone trabecular space, thinned trabecular bone, decreased BMD, maximum elastic stress, maximum load, and reduced OPG positive osteoblasts in bone tissues, which were averted by APT1 overexpression, thus alleviating SOP. APT1 overexpression increased osteoblast calcium nodules, ALP activity, OD related protein levels, and cell proliferation. In mechanism, APT1 overexpression inhibited BMPR1a palmitoylation in SOP mouse osteoblasts and activated the BMP/Smad pathway, thus promoting OD.Conclusion: APT1 activated the BMP/Smad pathway and promoted OD by regulating BMPR1a depalmitoylation, thus alleviating mouse SOP.& COPY; 2023, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/ 4.0/).
C1 [Ji, Changjiao; Han, Yingguang; Zhu, Bingrui] Shandong Univ Tradit Chinese Med, Dept Minimally Invas Orthoped, Affiliated Hosp, Jinan 250353, Peoples R China.
   [Dong, Qiaoyan] Shandong Univ, Med Coll, Dept Pathophysiol, Jinan 250000, Peoples R China.
   [Liu, Huihui] Wendeng Orthopaed & Traumatol Hosp Shandong Prov, Weihai 264499, Peoples R China.
   [Yang, Xiaodeng] Qilu Univ Technol, Shandong Acad Sci, Sch Chem & Chem Engn, Jinan 250353, Peoples R China.
   [Xing, Huaixin] Shandong First Med Univ & Shandong Acad Med Sci, Dept Anesthesiol, Shandong Canc Hosp & Inst, Jinan 250117, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong
   University; Qilu University of Technology; Shandong First Medical
   University & Shandong Academy of Medical Sciences
RP Xing, HX (通讯作者)，Shandong First Med Univ & Shandong Acad Med Sci, Dept Anesthesiol, Shandong Canc Hosp & Inst, Jinan 250117, Shandong, Peoples R China.
EM HuaixinX0920@163.com
RI Liu, Huihui/E 5283 2013
CR Aspray Terry J, 2019, Subcell Biochem, V91, P453, DOI 10.1007/978 981 13 3681 2_16
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen J, 2020, BIOMATER SCI UK, V8, P3430, DOI 10.1039/c9bm01761e
   Chen L, 2016, BMB REP, V49, P122, DOI 10.5483/BMBRep.2016.49.2.228
   Choi LY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.643482
   Guo YY, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101915
   Huang RL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0126 0
   Islam MJ, 2019, COMPUT BIOL CHEM, V80, P31, DOI 10.1016/j.compbiolchem.2019.03.004
   Jin SL, 2020, EUR REV MED PHARMACO, V24, P4095, DOI 10.26355/eurrev_202004_20987
   Kerschan Schindl K, 2016, WIEN MED WOCHENSCHR, V166, P22, DOI 10.1007/s10354 015 0417 y
   Ko SY, 2021, J DENT RES, V100, P1178, DOI 10.1177/00220345211023724
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Liu HC, 2019, CURR MOL MED, V19, P364, DOI 10.2174/1566524019666190325143412
   Lu XH, 2021, J CELL MOL MED, V25, P2069, DOI 10.1111/jcmm.16139
   Mang T, 2020, J CELL SCI, V133, DOI 10.1242/jcs.246934
   Maruyama T, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb4416
   Milano F, 2007, GASTROENTEROLOGY, V132, P2412, DOI 10.1053/j.gastro.2007.03.026
   Niimi K, 2009, COMPARATIVE MED, V59, P431
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Qu MY, 2021, J CELL PHYSIOL, V236, P4738, DOI 10.1002/jcp.30195
   Ren LR, 2021, MOL MED, V27, DOI 10.1186/s10020 021 00303 5
   RESNICK NM, 1989, JAMA J AM MED ASSOC, V261, P1025, DOI 10.1001/jama.261.7.1025
   Sadeghi RS, 2018, ELIFE, V7, DOI 10.7554/eLife.34362
   Saleem AN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000985
   Shi C, 2017, J CELL BIOCHEM, V118, P605, DOI 10.1002/jcb.25746
   Song IW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092194
   Tsukamoto T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075831
   Walker Bone K, 2012, NAT REV RHEUMATOL, V8, P480, DOI 10.1038/nrrheum.2012.93
   Wang LY, 2022, LASER MED SCI, V37, P941, DOI 10.1007/s10103 021 03338 6
   Wang S, 2022, CHEM BIOL DRUG DES, V99, P46, DOI 10.1111/cbdd.13904
   Wawrzyniak Anna, 2008, Pol Arch Med Wewn, V118 Suppl, P59
   Wegleiter T, 2019, P NATL ACAD SCI USA, V116, P25688, DOI 10.1073/pnas.1912671116
   Zhong D, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03586 y
NR 33
TC 3
Z9 4
U1 2
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD DEC
PY 2023
VL 24
BP 351
EP 360
DI 10.1016/j.reth.2023.05.004
EA AUG 2023
PG 10
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA S0SU4
UT WOS:001068361500001
PM 37674692
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Voskaridou, E
   Christoulas, D
   Plata, E
   Bratengeier, C
   Anastasilakis, AD
   Komninaka, V
   Kaliontzi, D
   Gkotzamanidou, M
   Polyzos, SA
   Dimopoulou, M
   Terpos, E
AF Voskaridou, E.
   Christoulas, D.
   Plata, E.
   Bratengeier, C.
   Anastasilakis, A. D.
   Komninaka, V.
   Kaliontzi, D.
   Gkotzamanidou, M.
   Polyzos, S. A.
   Dimopoulou, M.
   Terpos, E.
TI High Circulating Sclerostin is Present in Patients with
   Thalassemia associated Osteoporosis and Correlates with Bone Mineral
   Density
SO HORMONE AND METABOLIC RESEARCH
LA English
DT Article
DE thalassemia; osteoporosis; sclerostin; dickkopf 1; osteoblasts
ID ZOLEDRONIC ACID
AB Osteoporosis is a severe complication of thalassemia. Sclerostin is a Wnt signaling inhibitor, which is produced by osteocytes and inhibits osteoblast function. Sclerostin is implicated in the pathogenesis of osteoporosis of different etiology. The aim of the study was to evaluate circulating sclerostin in 66 patients (median age 42 years) with thalassemia and osteoporosis who participated in a phase 2, randomized study (zoledronic acid vs. placebo) and the results were compared with those of 30 healthy controls (median age 44 years) without osteopenia/osteoporosis and 62 women with postmenopausal osteoporosis (median age 63 years). At baseline, thalassemic patients with osteoporosis had elevated circulating levels of sclerostin (median: 605 pg/ml, range: 22 1227 pg/ml) compared to healthy controls without osteopenia/osteoporosis (250 pg/ml, 0 720 pg/ml, p < 0.001) and reduced levels of sclerostin compared with postmenopausal women with osteoporosis (840 pg/ml, 181 1704 pg/ml, p < 0.001). Thalassemia patients had also increased serum dickkopf 1 (Dkk 1) and high bone turnover. Circulating sclerostin levels correlated with bone mineral density in lumbar spine (r = 0.619, p < 0.001), distal radius (r = 0.401, p = 0.001) and femoral neck (r = 0.301, p = 0.021). Zoledronic acid did not alter sclerostin levels after 12 months of therapy, although it reduced circulating Dkk 1. We conclude that circulating sclerostin is elevated in thalassemia patients with osteoporosis and correlated with their BMD, but it was not reduced post zoledronic acid administration. These findings suggest that high sclerostin may serve as a marker of increased osteocyte activity in thalassemia patients. Drugs targeting sclerostin may also be used in this difficult to treat disorder associated with bone loss.
C1 [Christoulas, D.; Gkotzamanidou, M.; Terpos, E.] Univ Athens, Sch Med, Dept Clin Therapeut, Athens 11528, Greece.
   [Voskaridou, E.; Plata, E.; Komninaka, V.; Kaliontzi, D.; Dimopoulou, M.] Laikon Gen Hosp, Thalassemia Ctr, Athens, Greece.
   [Bratengeier, C.] Biomarker Design Forsch GmbH, Vienna, Austria.
   [Anastasilakis, A. D.] 424 Gen Mil Hosp, Dept Endocrinol, Thessaloniki, Greece.
   [Polyzos, S. A.] Aristotle Univ Thessaloniki, Sch Med, Ippokrat Hosp, Med Clin 2, GR 54006 Thessaloniki, Greece.
C3 National & Kapodistrian University of Athens; Laiko General Hospital;
   Aristotle University of Thessaloniki
RP Terpos, E (通讯作者)，Univ Athens, Sch Med, Dept Clin Therapeut, Alexandra Hosp, 80 Vas Sofi Ave, Athens 11528, Greece.
EM eterpos@med.uoa.gr
RI ; Polyzos, Stergios/H 2844 2019; Anastasilakis,
   Athanasios/AAF 7669 2020; Terpos, Evangelos/AAD 3667 2019; Dimopoulou,
   Maria/KYR 5661 2024; komninaka, veroniki/KVX 8081 2024
OI Polyzos, Stergios/0000 0001 9232 4042; komninaka,
   veroniki/0009 0004 1935 9205; Terpos, Evangelos/0000 0001 5133 1422;
   Anastasilakis, Athanasios/0000 0002 9624 6296; Bratengeier,
   Cornelia/0000 0001 9302 0710
CR Amrein K, 2012, J CLIN ENDOCR METAB, V97, P148, DOI 10.1210/jc.2011 2152
   Cejka D, 2012, NEPHROL DIAL TRANSPL, V27, P226, DOI 10.1093/ndt/gfr270
   Cejka D, 2011, CLIN J AM SOC NEPHRO, V6, P877, DOI 10.2215/CJN.06550810
   Chung YE, 2012, OSTEOPOROSIS INT, V23, P1235, DOI 10.1007/s00198 011 1675 1
   D'Amelio P, 2011, OSTEOPOROSIS INT, V22, P2869, DOI 10.1007/s00198 010 1496 7
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Hadjidakis D, 1997, EUR J CLIN INVEST, V27, P219, DOI 10.1046/j.1365 2362.1997.980636.x
   Kaji H, 2011, EXP CLIN ENDOCR DIAB, V119, P440, DOI 10.1055/s 0031 1275661
   Lewiecki EM, 2011, EXPERT OPIN BIOL TH, V11, P117, DOI 10.1517/14712598.2011.540565
   Mahachoklertwattana P, 2003, J CLIN ENDOCR METAB, V88, P3966, DOI 10.1210/jc.2002 021548
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Patsch JM, 2011, J BONE MINER RES, V26, P1584, DOI 10.1002/jbmr.344
   Polyzos SA, 2012, OSTEOPOROSIS INT, V23, P1171, DOI 10.1007/s00198 010 1525 6
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Scacchi M, 2008, CLIN ENDOCRINOL, V69, P202, DOI 10.1111/j.1365 2265.2008.03191.x
   Sheng ZF, 2012, CLIN ENDOCRINOL, V76, P797, DOI 10.1111/j.1365 2265.2011.04315.x
   Terpos E, 2011, CLIN EXP RHEUMATOL, V29, P921
   Terpos E, 2010, ANN NY ACAD SCI, V1202, P237, DOI 10.1111/j.1749 6632.2010.05542.x
   Voskaridou E, 2003, BRIT J HAEMATOL, V123, P730, DOI 10.1046/j.1365 2141.2003.04657.x
   Voskaridou E, 2012, ANN HEMATOL IN PRESS
   Voskaridou E, 2008, ACTA HAEMATOL BASEL, V119, P40, DOI 10.1159/000114869
   Voskaridou E, 2006, HAEMATOLOGICA, V91, P1193
   Voskaridou E, 2009, HAEMATOL HEMATOL J, V94, P725, DOI [10.3324/haematol.2008.000893, 10.3324/haema tol.2008.000893]
NR 26
TC 44
Z9 47
U1 0
U2 2
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D 70469 STUTTGART, GERMANY
SN 0018 5043
EI 1439 4286
J9 HORM METAB RES
JI Horm. Metab. Res.
PD NOV
PY 2012
VL 44
IS 12
BP 909
EP 913
DI 10.1055/s 0032 1312618
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 037XC
UT WOS:000311138800008
PM 22581647
DA 2025 08 17
ER

PT J
AU Liu, X
   Diao, L
   Zhang, YD
   Yang, X
   Zhou, JN
   Mao, YH
   Shi, XT
   Zhao, FL
   Liu, M
AF Liu, Xuan
   Diao, Li
   Zhang, Yudie
   Yang, Xue
   Zhou, Junnan
   Mao, Yuhang
   Shi, Xiaotian
   Zhao, Fuli
   Liu, Mei
TI Piperlongumine Inhibits Titanium Particles Induced Osteolysis,
   Osteoclast Formation, and RANKL Induced Signaling Pathways
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE piperlongumine; osteoclast formation; bone resorption; RANKL induced
   signaling pathways; osteolysis
ID ZOLEDRONIC ACID; DIFFERENTIATION; OSTEOPOROSIS; ACTIVATION
AB Wear particle induced aseptic loosening is the most common complication of total joint arthroplasty (TJA). Excessive osteoclast formation and bone resorptive activation have been considered to be responsible for extensive bone destruction and prosthesis failure. Therefore, identification of anti osteoclastogenesis agents is a potential therapy strategy for the treatment of aseptic loosening and other osteoclast related osteolysis diseases. In the present study, we reported, for the first time, that piperlongumine (PL), a key alkaloid compound from Piper longum fruits, could significantly suppress the formation and activation of osteoclasts. Furthermore, PL effectively decreased the mRNA expressions of osteoclastic marker genes such as tartrate resistant acid phosphatase (TRAP), calcitonin receptor (CTR), and cathepsin K (CTSK). In addition, PL suppressed the receptor activator of nuclear factor kappa B ligand (RANKL) induced activations of MAPKs (ERK, JNK and p38) and NF kappa B, which down regulated the protein expression of nuclear factor of activated T cells cytoplasmic 1 (NFATc1). Using a titanium (Ti) particle induced calvarial osteolysis model, we demonstrated that PL could ameliorate Ti particle induced bone loss in vivo. These data provide strong evidence that PL has the potential to treat osteoclast related diseases including periprosthetic osteolysis (PPO) and aseptic loosening.
C1 [Liu, Xuan; Diao, Li; Zhang, Yudie; Yang, Xue; Zhou, Junnan; Mao, Yuhang; Shi, Xiaotian; Zhao, Fuli; Liu, Mei] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing 210023, Peoples R China.
C3 Nanjing Normal University
RP Liu, M (通讯作者)，Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing 210023, Peoples R China.
EM liuxuan9751@163.com; diaoli1125@163.com; zyd9909119@163.com;
   yangxue9264983129@163.com; zhoujunnannnu@163.com;
   sky maoyuhang@nnu.edu.cn; shixiaotian2022@163.com;
   zfl18761689227@163.com; liumei@njnu.edu.cn
FU National Natural Science Foundation of China [32071165, 31870895]
FX FundingThis study was funded by National Natural Science Foundation of
   China (Grant No. 32071165; 31870895).
CR Cardemil C, 2013, BIOMATERIALS, V34, P1546, DOI 10.1016/j.biomaterials.2012.11.003
   Conde J, 2021, ACS CENTRAL SCI, V7, P868, DOI 10.1021/acscentsci.1c00070
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Henrique T, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 78220 6
   Hu B, 2019, J CELL MOL MED, V23, P5762, DOI 10.1111/jcmm.14492
   Iwashita M, 2007, EUR J PHARMACOL, V570, P38, DOI 10.1016/j.ejphar.2007.05.073
   Jin Z, 2009, PHYTOTHER RES, V23, P1194, DOI 10.1002/ptr.2630
   Kim KS, 2006, PIGM CELL RES, V19, P90, DOI 10.1111/j.1600 0749.2005.00281.x
   Kurotaki D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115471
   Kwak SC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103164
   Lee SW, 2002, J BIOCHEM MOL BIOL, V35, P371
   Li C, 2019, BIOCHEM BIOPH RES CO, V514, P1244, DOI 10.1016/j.bbrc.2019.05.054
   Li H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113698
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Li YX, 2021, J CELL PHYSIOL, V236, P1950, DOI 10.1002/jcp.29978
   Liu M, 2015, AM J PATHOL, V185, P2653, DOI 10.1016/j.ajpath.2015.06.017
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Miao WH, 2019, CONNECT TISSUE RES, V60, P487, DOI 10.1080/03008207.2019.1593392
   Nagy V, 2015, GERONTOLOGY, V61, P534, DOI 10.1159/000371845
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park JH, 2017, MOL CELLS, V40, P706
   Park JA, 2019, MOL CELLS, V42, P884, DOI 10.14348/molcells.2019.0088
   Park SY, 2015, BBA MOL BASIS DIS, V1852, P2137, DOI 10.1016/j.bbadis.2015.07.007
   Shi JW, 2021, INT IMMUNOPHARMACOL, V94, DOI 10.1016/j.intimp.2021.107459
   Soysa NS, 2009, J BONE MINER METAB, V27, P131, DOI 10.1007/s00774 008 0026 6
   Sun J, 2015, MOL MED REP, V11, P2689, DOI 10.3892/mmr.2014.3001
   Takooree H, 2019, CRIT REV FOOD SCI, V59, pS210, DOI 10.1080/10408398.2019.1565489
   Tang WK, 2020, J CELL MOL MED, V24, P11972, DOI 10.1111/jcmm.15821
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Thatikonda S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 019 2212 y
   Tripathi SK, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104772
   Wang J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01188
   Wang P, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04458 4
   Wang Q, 2020, BIOMATER SCI UK, V8, P5157, DOI 10.1039/d0bm00718h
   Wu XH, 2021, DRUG DES DEV THER, V15, P4741, DOI 10.2147/DDDT.S334421
   Xu SQ, 2018, INFLAMM RES, V67, P233, DOI 10.1007/s00011 017 1112 9
   Yamazaki T, 2012, BONE, V51, P882, DOI 10.1016/j.bone.2012.08.115
   Yao L, 2014, IMMUNOL LETT, V161, P76, DOI 10.1016/j.imlet.2014.05.001
   Yao Y, 2016, ONCOTARGET, V7, P73497, DOI 10.18632/oncotarget.11988
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Zhang L, 2019, BEHAV PHARMACOL, V30, P721, DOI 10.1097/FBP.0000000000000498
NR 42
TC 11
Z9 12
U1 2
U2 21
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2022
VL 23
IS 5
AR 2868
DI 10.3390/ijms23052868
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA ZS8KT
UT WOS:000768709700001
PM 35270008
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jin, WJ
   Lin, XF
   Pan, HH
   Zhao, CC
   Qiu, PC
   Zhao, RB
   Hu, ZH
   Zhou, YY
   Wu, HY
   Chen, X
   Ouyang, HW
   Xie, ZJ
   Tang, RK
AF Jin, Wenjing
   Lin, Xianfeng
   Pan, Haihua
   Zhao, Chenchen
   Qiu, Pengcheng
   Zhao, Ruibo
   Hu, Zihe
   Zhou, Yanyan
   Wu, Haiyan
   Chen, Xiao
   Ouyang, Hongwei
   Xie, Zhijian
   Tang, Ruikang
TI Engineered osteoclasts as living treatment materials for heterotopic
   ossification therapy
SO NATURE COMMUNICATIONS
LA English
DT Article
ID BONE RESORPTION; TETRACYCLINE; INHIBITION; CELLS; ANTIBIOTICS;
   OSTEOBLAST
AB Heterotopic ossification (HO) is the formation of pathological mature bone within extraskeletal soft tissues, and there are currently no reliable methods for removing these calcified plaques. Here, the authors demonstrate that chemically engineered osteoclasts coated with tetracycline can improve their targeting capacity to ectopic calcifications, which extends their bone resorption functions for the treatment of HO.
   Osteoclasts (OCs), the only cells capable of remodeling bone, can demineralize calcium minerals biologically. Naive OCs have limitations for the removal of ectopic calcification, such as in heterotopic ossification (HO), due to their restricted activity, migration and poor adhesion to sites of ectopic calcification. HO is the formation of pathological mature bone within extraskeletal soft tissues, and there are currently no reliable methods for removing these unexpected calcified plaques. In the present study, we develop a chemical approach to modify OCs with tetracycline (TC) to produce engineered OCs (TC OCs) with an enhanced capacity for targeting and adhering to ectopic calcified tissue due to a broad affinity for calcium minerals. Unlike naive OCs, TC OCs are able to effectively remove HO both in vitro and in vivo. This achievement indicates that HO can be reversed using modified OCs and holds promise for engineering cells as "living treatment agents" for cell therapy.
C1 [Jin, Wenjing; Tang, Ruikang] Zhejiang Univ, Dept Chem, Hangzhou 310027, Zhejiang, Peoples R China.
   [Jin, Wenjing; Hu, Zihe; Zhou, Yanyan; Wu, Haiyan; Xie, Zhijian] Zhejiang Univ, Key Lab Oral Biomed Res Zhejiang Prov, Clin Res Ctr Oral Dis Zhejiang Prov, Stomatol Hosp,Sch Stomatol,Canc Ctr,Sch Med, Hangzhou 310006, Zhejiang, Peoples R China.
   [Lin, Xianfeng; Zhao, Chenchen; Qiu, Pengcheng] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Med Coll, Hangzhou 310016, Zhejiang, Peoples R China.
   [Lin, Xianfeng; Zhao, Chenchen; Qiu, Pengcheng] Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou 310016, Zhejiang, Peoples R China.
   [Pan, Haihua; Tang, Ruikang] Zhejiang Univ, Qiushi Acad Adv Studies, Hangzhou 310027, Zhejiang, Peoples R China.
   [Zhao, Ruibo] Zhejiang Sci Tech Univ, Sch Mat Sci & Engn, Hangzhou 310018, Zhejiang, Peoples R China.
   [Chen, Xiao; Ouyang, Hongwei] Zhejiang Univ, Key Lab Tissue Engn & Regenerat Med Zhejiang Prov, Sch Med, Hangzhou, Peoples R China.
   [Chen, Xiao; Ouyang, Hongwei] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dr Li Dak Sum & Yip Yio Chin Ctr Stem Cells & Reg, Hangzhou, Zhejiang, Peoples R China.
   [Chen, Xiao; Ouyang, Hongwei] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Orthoped Surg, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang
   University; Zhejiang Sci Tech University; Zhejiang University; Zhejiang
   University; Zhejiang University
RP Tang, RK (通讯作者)，Zhejiang Univ, Dept Chem, Hangzhou 310027, Zhejiang, Peoples R China.; Xie, ZJ (通讯作者)，Zhejiang Univ, Key Lab Oral Biomed Res Zhejiang Prov, Clin Res Ctr Oral Dis Zhejiang Prov, Stomatol Hosp,Sch Stomatol,Canc Ctr,Sch Med, Hangzhou 310006, Zhejiang, Peoples R China.; Tang, RK (通讯作者)，Zhejiang Univ, Qiushi Acad Adv Studies, Hangzhou 310027, Zhejiang, Peoples R China.
EM xzj66@zju.edu.cn; rtang@zju.edu.cn
RI Chen, Xiao/A 4384 2009; wu, haiyan/KHX 9321 2024; Lin,
   Xianfeng/ABA 2917 2020; Jin, Wenjing/LWH 5997 2024; Zhao,
   Chenchen/AAE 6716 2021; Chen, Xiao/JAC 8548 2023; Ouyang, hong
   wei/ISS 2757 2023; Pan, Haihua/O 7512 2018; Zhao, Ruibo/AHE 3475 2022
OI Chen, Xiao/0000 0002 4438 5286; Jin, Wenjing/0000 0002 9256 4676; Pan,
   Haihua/0000 0003 0327 7622; 
FU National Natural Science Foundation of China [21625105]; National Key RD
   Program [2018YFC1105103]
FX We thank Xiaoyu Wang, and Biao Jin for constructive discussions. We
   thank Shuangshuang Liu and Wei Yin for the assistance with CLSM data
   analysis, Jingyao Chen for their help with histological analysis, and
   Yanhong Chen for assisting with the animal model. This work was
   supported by The National Natural Science Foundation of China (21625105)
   and National Key R&D Program (2018YFC1105103).
CR Agarwal S, 2016, P NATL ACAD SCI USA, V113, pE338, DOI 10.1073/pnas.1515397113
   BASSETT EJ, 1980, SCIENCE, V209, P1532, DOI 10.1126/science.7001623
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   BLAIR HC, 1991, AM J PHYSIOL, V260, pC1315, DOI 10.1152/ajpcell.1991.260.6.C1315
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brady RD, 2018, BONE, V109, P35, DOI 10.1016/j.bone.2017.05.015
   Cackowski FC, 2007, ANN NY ACAD SCI, V1117, P12, DOI 10.1196/annals.1402.073
   Cao ZP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13727 9
   Chen SJ, 2013, J AM CHEM SOC, V135, P4926, DOI 10.1021/ja400337p
   Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232 260.2001
   Dey D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1090
   Doherty TM, 2002, FASEB J, V16, DOI 10.1096/fj.01 0898hyp
   Edwards DS, 2016, J ORTHOP TRAUMA, V30, pS27, DOI 10.1097/BOT.0000000000000666
   Feng YF, 2019, ADV MATER, V31, DOI 10.1002/adma.201805148
   Gao T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10845 2
   Legosz P, 2018, CLIN EXP PHARMACOL P, V45, P1229, DOI 10.1111/1440 1681.13025
   Li CX, 2019, ADV MATER, V31, DOI 10.1002/adma.201807211
   Li YW, 2011, J AGR FOOD CHEM, V59, P7268, DOI 10.1021/jf1047578
   Lin L, 2010, BONE, V46, P425, DOI 10.1016/j.bone.2009.08.057
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Liu ZM, 2016, ADV FUNCT MATER, V26, P1862, DOI 10.1002/adfm.201504480
   Losina E, 2012, J BONE JOINT SURG AM, V94A, P201, DOI [10.2106/JBJS.J.101958, 10.2106/JBJS.J.01958, 10.2106/JBJS.K.00009]
   Massy ZA, 2008, DIABETES METAB, V34, pS16, DOI 10.1016/S1262 3636(08)70098 3
   Matsumoto A, 2009, J AM CHEM SOC, V131, P12022, DOI 10.1021/ja902964m
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   McCarthy EF, 2005, SKELETAL RADIOL, V34, P609, DOI 10.1007/s00256 005 0958 z
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   Pacifici R, 2010, ARCH BIOCHEM BIOPHYS, V503, P41, DOI 10.1016/j.abb.2010.05.027
   Park JH, 2014, ADV MATER, V26, P2001, DOI 10.1002/adma.201304568
   Pavey GJ, 2016, BONE, V90, P159, DOI 10.1016/j.bone.2016.06.014
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Regard JB, 2013, NAT MED, V19, P1505, DOI 10.1038/nm.3314
   Ren XY, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw4991
   Saxon E, 2000, SCIENCE, V287, P2007, DOI 10.1126/science.287.5460.2007
   Shi P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10231 y
   Shimono K, 2011, NAT MED, V17, P454, DOI 10.1038/nm.2334
   Shin J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5380
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Suzuki H, 2016, P NATL ACAD SCI USA, V113, P7840, DOI 10.1073/pnas.1522054113
   Takahata M, 2007, BONE, V41, P77, DOI 10.1016/j.bone.2007.03.016
   Tang L, 2018, NAT BIOTECHNOL, V36, P707, DOI 10.1038/nbt.4181
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   van de Merbel AF, 2018, METHODS MOL BIOL, V1786, P67, DOI 10.1007/978 1 4939 7845 8_4
   Wang B, 2008, ANGEW CHEM INT EDIT, V47, P3560, DOI 10.1002/anie.200704718
   Wang GC, 2012, ANGEW CHEM INT EDIT, V51, P10576, DOI 10.1002/anie.201206154
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Xu RS, 2018, BONE, V109, P134, DOI 10.1016/j.bone.2017.08.025
   Yao SS, 2017, ADV MATER, V29, DOI 10.1002/adma.201605903
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
   Zhao RB, 2016, ANGEW CHEM INT EDIT, V55, P5225, DOI 10.1002/anie.201601364
   Zhao YQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaw9679
   Zhu W, 2019, ADV MATER, V31, DOI 10.1002/adma.201900545
NR 55
TC 28
Z9 30
U1 7
U2 101
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD NOV 3
PY 2021
VL 12
IS 1
AR 6327
DI 10.1038/s41467 021 26593 1
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA WR4DA
UT WOS:000714451200007
PM 34732696
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU McCabe, IC
   Fedorko, A
   Myers, MG
   Leinninger, G
   Scheller, E
   McCabe, LR
AF McCabe, Ian C.
   Fedorko, Alyssa
   Myers, Martin G., Jr.
   Leinninger, Gina
   Scheller, Erica
   McCabe, Laura R.
TI Novel leptin receptor signaling mutants identify location and
   sex dependent modulation of bone density, adiposity, and growth
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE adipocytes; bone density; bone volume; female; leptin receptor; male;
   marrow adiposity; obesity; osteoporosis
ID MESENCHYMAL STROMAL CELLS; MARROW ADIPOSITY; GENE THERAPY; LONG FORM;
   DIFFERENTIATION; ABNORMALITIES; OSTEOBLASTS; DEFICIENCY; APOPTOSIS;
   SYSTEM
AB Leptin, a hormone primarily produced by adipocytes, contributes to the regulation of bone health by modulating bone density, growth and adiposity. Upon leptin binding, multiple sites of the long form of the leptin receptor (LepRb) are phosphorylated to trigger activation of downstream signaling pathways. To address the role of LepRb signaling pathways in bone health, we compared the effects of three LepRb mutations on bone density, adiposity, and growth in male and female mice. The increment 65 mutation, which lacks the known tyrosine phosphorylation sites, caused obesity and the most dramatic bone phenotype marked by excessive bone adiposity, osteoporosis, and decreased growth, consistent with the phenotype of db/db and ob/ob mice that fully lack leptin receptor signaling. Mutation of LepRb Tyr(1138), which results in an inability to recruit and phosphorylate signal transducer and activator of transcription 3, also caused obesity, but bone loss and adiposity were more dominant in male mice and no growth defect was observed. In contrast, mutation of LepRb Tyr(985), which blocks SHP2/SOCS3 recruitment to LepRb and contributes to leptin hypersensitivity, promoted increased femur bone density only in male mice, while marrow adiposity and bone growth were not affected. Additional analyses of vertebral trabecular bone volume indicate that only the Tyr(1138) mutant mice exhibit bone loss in vertebrae. Together, our findings suggest that the phosphorylation status of specific sites of the LepRb contribute to the sex  and location dependent bone responses to leptin. Unraveling the mechanisms by which leptin responses are sex  and location dependent can contribute to the development of uniquely targeted osteoporosis therapies.
C1 [McCabe, Ian C.; Fedorko, Alyssa; Leinninger, Gina; McCabe, Laura R.] Michigan State Univ, Dept Physiol, 2201 Biomed Phys Sci Bldg, E Lansing, MI 48824 USA.
   [McCabe, Laura R.] Michigan State Univ, Dept Radiol, E Lansing, MI 48824 USA.
   [McCabe, Laura R.] Michigan State Univ, Biomed Imaging Res Ctr, E Lansing, MI 48824 USA.
   [Myers, Martin G., Jr.] Univ Michigan, Dept Mol & Integrat Physiol, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA.
   [Myers, Martin G., Jr.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Scheller, Erica] Washington Univ, Dept Med, Div Bone & Mineral Dis, St Louis, MO USA.
C3 Michigan State University; Michigan State University; Michigan State
   University; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan; Washington
   University (WUSTL)
RP McCabe, LR (通讯作者)，Michigan State Univ, Dept Physiol, 2201 Biomed Phys Sci Bldg, E Lansing, MI 48824 USA.
EM mccabel@msu.edu
RI ; McCabe, Laura/AGS 5131 2022; Scheller, Erica/H 6993 2019
OI Scheller, Erica/0000 0002 1551 3816; McCabe, Laura/0000 0001 5407 162X; 
FU National Institute of Diabetes and Digestive and Kidney Diseases [RO1
   DK101050, DK056731]; National Center for Complementary and Integrative
   Health [RO1 AT007695]; National Institute of Dental and Craniofacial
   Research [R00 DE024178]; National Institute of Diabetes and Digestive
   and Kidney Diseases [R01DK056731, P30DK020572] Funding Source: NIH
   RePORTER
FX National Institute of Diabetes and Digestive and Kidney Diseases,
   Grant/Award Numbers: RO1 DK101050, DK056731; National Center for
   Complementary and Integrative Health, Grant/Award Number: RO1 AT007695;
   National Institute of Dental and Craniofacial Research, Grant/Award
   Number: R00 DE024178
CR Abella V, 2017, NAT REV RHEUMATOL, V13, P100, DOI 10.1038/nrrheum.2016.209
   Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563
   Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388
   Björnholm M, 2007, J CLIN INVEST, V117, P1354, DOI 10.1172/JCI30688
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   Devlin MJ, 2010, J BONE MINER RES, V25, P2078, DOI 10.1002/jbmr.82
   Ealey KN, 2006, REGUL PEPTIDES, V136, P9, DOI 10.1016/j.regpep.2006.04.013
   Ecklund K, 2010, J BONE MINER RES, V25, P298, DOI 10.1359/jbmr.090805
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Gat Yablonski G, 2008, CURR OPIN CLIN NUTR, V11, P303, DOI 10.1097/MCO.0b013e3282f795cf
   Gong Y, 2007, J BIOL CHEM, V282, P31019, DOI 10.1074/jbc.M702838200
   Hamrick MW, 2007, CELL TISSUE RES, V327, P133, DOI 10.1007/s00441 006 0312 3
   Hamrick MW, 2005, J BONE MINER RES, V20, P994, DOI 10.1359/JBMR.050103
   Hamrick MW, 2004, J BONE MINER RES, V19, P1607, DOI 10.1359/JBMR.040712
   Hamrick MW, 2004, BONE, V34, P376, DOI 10.1016/j.bone.2003.11.020
   He HB, 2004, ENDOCRINOLOGY, V145, P447, DOI 10.1210/en.2003 1239
   Iwaniec UT, 2007, PEPTIDES, V28, P1012, DOI 10.1016/j.peptides.2007.02.001
   Iwaniec UT, 2011, J BONE MINER RES, V26, P1506, DOI 10.1002/jbmr.365
   Karsenty G, 2006, CELL METAB, V4, P341, DOI 10.1016/j.cmet.2006.10.008
   Kishida Y, 2005, BONE, V37, P607, DOI 10.1016/j.bone.2005.05.009
   Lindenmaier LB, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00110
   Motyl KJ, 2012, BIOCHIMIE, V94, P2089, DOI 10.1016/j.biochi.2012.04.015
   Motyl KJ, 2009, J CELL PHYSIOL, V218, P376, DOI 10.1002/jcp.21608
   Münzberg H, 2003, ENDOCRINOLOGY, V144, P2121, DOI 10.1210/en.2002 221037
   Philbrick KA, 2018, J ENDOCRINOL, V236, P57, DOI 10.1530/JOE 17 0524
   Ramos ES, 2017, J BONE MINER RES, V32, P974, DOI 10.1002/jbmr.3072
   Reid IR, 2004, BONE, V34, P369, DOI 10.1016/j.bone.2003.11.007
   Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426
   Robertson S, 2010, DIABETES, V59, P782, DOI 10.2337/db09 1556
   Scheller EL, 2010, STEM CELLS, V28, P1071, DOI 10.1002/stem.432
   Steppan CM, 2000, REGUL PEPTIDES, V92, P73, DOI 10.1016/S0167 0115(00)00152 X
   Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630
   Turner RT, 2013, J BONE MINER RES, V28, P22, DOI 10.1002/jbmr.1734
   Villanueva EC, 2008, INT J OBESITY, V32, pS8, DOI 10.1038/ijo.2008.232
   Williams GA, 2011, J BONE MINER RES, V26, P1698, DOI 10.1002/jbmr.367
   Yue R, 2016, CELL STEM CELL, V18, P782, DOI 10.1016/j.stem.2016.02.015
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 37
TC 10
Z9 11
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAR
PY 2019
VL 120
IS 3
BP 4398
EP 4408
DI 10.1002/jcb.27726
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HL1LP
UT WOS:000458459600170
PM 30269370
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Chen, XJ
   Zhang, S
   Chen, XT
   Hu, Y
   Wu, J
   Chen, SY
   Chang, J
   Wang, GF
   Gao, YH
AF Chen, Xiaojing
   Zhang, Shuang
   Chen, Xiaoting
   Hu, Yan
   Wu, Jin
   Chen, Shuyan
   Chang, Jing
   Wang, Genfa
   Gao, Yanhong
TI Emodin promotes the osteogenesis of MC3T3 E1 cells via BMP 9/Smad
   pathway and exerts a preventive effect in ovariectomized rats
SO ACTA BIOCHIMICA ET BIOPHYSICA SINICA
LA English
DT Article
DE emodin; estrogen; osteoblast; osteoporosis; BMP 9/Smad pathway
ID MESENCHYMAL STEM CELLS; ESTROGEN PLUS PROGESTIN; OSTEOBLAST
   DIFFERENTIATION; GENE EXPRESSION; BONE; RISKS; RECEPTORS; BENEFITS;
   THERAPY; P38
AB Emodin, a natural anthraquinone extracted from the Chinese herbs rhubarb and giant knotweed rhizome, has been reported to enhance osteoblast differentiation. However, the mechanisms underlying its ability to regulate osteogenesis are unclear. The objective of this study was to determine the role of emodin in osteoblast function in vitro and its osteoprotective effect in vivo. Emodin enhanced the differentiation and mineralization of MC3T3 E1 cells, as evidenced by elevated alkaline phosphatase activity and increased number of mineralized nodules. In cultured osteoblasts, emodin significantly induced the mRNA expression of BMP 9 which is one of the least studied but most osteogenic bone morphogenetic proteins (BMPs). Furthermore, the bone morphogenetic protein receptor Smad (BMPR Smad) signaling axis and p38 mitogen activated protein kinase (p38 MAPK) were activated. The in vivo function of emodin were evaluated by assessing bone histomorphology, trabecular bone microarchitecture, mechanical properties of the skeleton, and serum parameters of bone turnover in ovariectomized (OVX) rats. Emodin combined with low dose of estrogen improved trabecular bone microarchitecture in the fourth lumbar vertebra compared with low dose estrogen alone and enhanced vertebral body strength. Moreover, emodin suppressed the OVX induced elevation of serum osteocalcin (OC). In addition, there were fewer side effects on uterine hypertrophy with the combination therapy than with high dose estrogen alone. However, emodin alone did not exert any osteoprotective effect. These results suggest that emodin may be a promising alternative agent for osteoporosis in combination therapy.
C1 [Chen, Xiaojing; Zhang, Shuang; Chen, Xiaoting; Hu, Yan; Chen, Shuyan; Chang, Jing; Wang, Genfa; Gao, Yanhong] Shanghai Jiao Tong Univ, Sch Med, Dept Geriatr, Xinhua Hosp, Shanghai 200092, Peoples R China.
   [Wu, Jin] Shanghai Jiao Tong Univ, Shanghai Inst Pediat Res, Sch Med, Shanghai 200092, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Wang, GF; Gao, YH (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Geriatr, Xinhua Hosp, Shanghai 200092, Peoples R China.
EM genfa_wang@163.com; yhgao2010@yahoo.com
FU National Natural Science Foundation of China [81101360, 81471399,
   81270205]; Natural Science Foundation of Shanghai [16ZR1422000];
   Medicine Engineering Cross Project of Shanghai Jiao Tong University
   [YG2015MS67]; Scientific Research Foundation for the Returned Overseas
   Chinese Scholars, State Education Ministry [20134701]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81101360), Natural Science Foundation of
   Shanghai (No. 16ZR1422000), the Medicine Engineering Cross Project of
   Shanghai Jiao Tong University (No. YG2015MS67), the Scientific Research
   Foundation for the Returned Overseas Chinese Scholars, State Education
   Ministry (No. 20134701) to Dr. Gao Y. This work was also supported by
   grants from the National Natural Science Foundation of China (Nos.
   81471399 and 81270205) to Dr. Chen S.
CR Bhadauria M, 2009, HEPATOL RES, V39, P290, DOI 10.1111/j.1872 034X.2008.00380.x
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Bragdon B, 2011, CELL SIGNAL, V23, P609, DOI 10.1016/j.cellsig.2010.10.003
   Brown MA, 2005, J BIOL CHEM, V280, P25111, DOI 10.1074/jbc.M503328200
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   [陈小静 Chen Xiaojing], 2014, [上海交通大学学报. 医学版, Journal of Shanghai Jiaotong University .Medical Science], V34, P781
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Gao YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082436
   Hazni H, 2008, PLANTA MED, V74, P1802, DOI 10.1055/s 0028 1088340
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032428
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lee SU, 2008, INT IMMUNOPHARMACOL, V8, P741, DOI 10.1016/j.intimp.2008.01.027
   Lepola VT, 1996, J BONE MINER RES, V11, P1508
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Nishimura R, 2008, J BONE MINER METAB, V26, P203, DOI 10.1007/s00774 007 0824 2
   Ok HM, 2015, CALCIFIED TISSUE INT, V97, P624, DOI 10.1007/s00223 015 0057 7
   Persson I, 1999, CANCER CAUSE CONTROL, V10, P253, DOI 10.1023/A:1008909128110
   Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P108, DOI 10.1007/s00223 007 9091 4
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Schneider DL, 1997, JAMA J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang XJ, 2005, CELL RES, V15, P511, DOI 10.1038/sj.cr.7290321
   Xu DJ, 2012, BMB REP, V45, P247, DOI 10.5483/BMBRep.2012.45.4.247
   Yang F, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 74
   Ye G, 2014, INT J MED SCI, V11, P1065, DOI 10.7150/ijms.8473
   Zhang S, 2016, MOL CELL ENDOCRINOL, V422, P243, DOI 10.1016/j.mce.2015.12.018
   Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917
   Zhao C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092908
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhao YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043383
NR 36
TC 29
Z9 30
U1 2
U2 23
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1672 9145
EI 1745 7270
J9 ACTA BIOCH BIOPH SIN
JI Acta Biochim. Biophys. Sin.
PD OCT
PY 2017
VL 49
IS 10
BP 867
EP 878
DI 10.1093/abbs/gmx087
PG 12
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FI8ZL
UT WOS:000412292300002
PM 28981600
DA 2025 08 17
ER

PT J
AU de Nigris, F
   Ruosi, C
   Napoli, C
AF de Nigris, Filomena
   Ruosi, Carlo
   Napoli, Claudio
TI Clinical efficiency of epigenetic drugs therapy in bone malignancies
SO BONE
LA English
DT Article
DE Osteosarcoma; Ewing sarcoma; Epigenetic drugs; HDACs inhibitors;
   Immunotherapy; Bisphosphonates
ID REFRACTORY MULTIPLE MYELOMA; I HISTONE DEACETYLASES; POOR PROGNOSIS;
   OSTEOSARCOMA CELLS; TUMOR SUPPRESSOR; GENE EXPRESSION; EWING SARCOMA;
   ZOLEDRONIC ACID; DOUBLE BLIND; METHYLATION
AB A great interest in the scientific community is focused on the improvement of the cure rate in patients with bone malignancies that have a poor response to the first line of therapies. Novel treatments currently include epigenetic compounds or molecules targeting epigenetic sensitive pathways. Here, we offer an exhaustive review of such agents in these clinical settings. Carefully designed preclinical studies selected several epigenetic drugs, including inhibitors of DNA methyltransferase (DNMTIs), such as Decitabine, histone deacetylase classes I II (HDACIs), as Entinostat, Belinostat, lysine specific histone demethylase (LSD1), as INCB059872 or FT 2102 (Olutasidenib), inhibitors of isocitrate dehydrogenases, and enhancer of zeste homolog 2 (EZH2), such as EPZ6438 (Tazemetostat) To enhance the therapeutic effect, the prevalent approach in phase II trial is the association of these epigenetic drug inhibitors, with targeted therapy or immune checkpoint blockade. Optimization of drug dosing and regimens of Phase II trials may improve the clinical efficiency of such novel therapeutic approaches against these devastating cancers.
C1 [de Nigris, Filomena] Univ Campania Luigi Vanvitelli, Dept Precis Med, I 80138 Naples, Italy.
   [Ruosi, Carlo] Univ Naples Federico II, Dept Publ Hlth, I 80132 Naples, Italy.
   [Napoli, Claudio] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, I 80138 Naples, Italy.
   [Napoli, Claudio] IRCCS SDN, I 80134 Naples, IT, Italy.
C3 Universita della Campania Vanvitelli; University of Naples Federico II;
   Universita della Campania Vanvitelli; IRCCS Istituto di Ricerca
   Diagnostica e Nucleare (SDN)
RP de Nigris, F (通讯作者)，Univ Campania Luigi Vanvitelli, Sch Med, Dept Precis Med, Via Crecchio 7, I 80138 Naples, Italy.
EM filomena.denigris@unicampania.it
FU Italian Ministry of Health, Programma Valere [RF 2011 02349443,
   RRC 2017]
FX This work was supported in part by "Ricerca Finalizzata 2011 12 Grant"
   (project code RF 2011 02349443, PI Pofessor Napoli), "Ricerca Corrente
   2017" (project code RRC 2017, PI Professor Napoli) from the Italian
   Ministry of Health, Programma Valere (UniCampania L. Vanvitelli 2019 to
   FdN).
CR Afifi S, 2015, PHARMACOTHERAPY, V35, P1173, DOI 10.1002/phar.1671
   Ahuja N, 2014, J CLIN INVEST, V124, P56, DOI 10.1172/JCI69736
   Asp J, 2000, INT J CANCER, V85, P782, DOI 10.1002/(SICI)1097 0215(20000315)85:6<782::AID IJC7>3.0.CO;2 O
   Avet Loiseau H, 2007, BLOOD, V109, P3489, DOI 10.1182/blood 2006 08 040410
   Bendinelli P., 2017, CELL DEATH DIS, V20, pE2520
   Bui C, 2010, FASEB J, V24, P436, DOI 10.1096/fj.09 136291
   Cao C, 2017, ONCOGENE, V36, P133, DOI 10.1038/onc.2016.186
   Chaiyawat P, 2018, MODERN PATHOL, V31, P264, DOI 10.1038/modpathol.2017.125
   Cheng Y, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392 019 0095 0
   Chow WA, 2007, CURR OPIN ONCOL, V19, P371, DOI 10.1097/CCO.0b013e32812143d9
   Colella G, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020615
   de Nigris F, 2016, BBA GENE REGUL MECH, V1859, P697, DOI 10.1016/j.bbagrm.2016.03.005
   de Nigris F, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 472
   de Nigris F, 2008, CANCER RES, V68, P1797, DOI 10.1158/0008 5472.CAN 07 5582
   Dimopoulos M, 2013, LANCET ONCOL, V14, P1129, DOI 10.1016/S1470 2045(13)70398 X
   Dimopoulos MA, 2015, NAT REV CLIN ONCOL, V12, P42, DOI 10.1038/nrclinonc.2014.200
   El Naggar AM, 2019, EMBO REP, V20, DOI 10.15252/embr.201948375
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1093/carcin/bgp220
   Fan H, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/371087
   Fanale D, 2016, ONCOTARGET, V7, P29321, DOI 10.18632/oncotarget.8722
   Fang Y, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0811 9
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Garnock Jones KP, 2015, DRUGS, V75, P695, DOI 10.1007/s40265 015 0388 8
   Gharanei S, 2013, EPIGENETICS US, V8, P893, DOI 10.4161/epi.25617
   Guilhamon P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3166
   Hamm CA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008340
   Harada T, 2017, LEUKEMIA, V31, P2670, DOI 10.1038/leu.2017.144
   He Y, 2014, CELL PHYSIOL BIOCHEM, V34, P1485, DOI 10.1159/000366353
   Hicks KC, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1466018
   Hill KE, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 017 0465 4
   Huan SW, 2020, CANCER MANAG RES, V12, P4429, DOI 10.2147/CMAR.S254412
   Huertas Martínez J, 2017, CANCER LETT, V386, P196, DOI 10.1016/j.canlet.2016.11.020
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Italiano A, 2018, LANCET ONCOL, V19, P649, DOI 10.1016/S1470 2045(18)30145 1
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Jin Z, 2013, J MOL HISTOL, V44, P645, DOI 10.1007/s10735 013 9511 x
   Karlic H, 2015, CANCER GENET NY, V208, P241, DOI 10.1016/j.cancergen.2015.03.008
   Kiany S, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1333214
   Lamoureux F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4511
   Landgraf M, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0072 9
   Li GQ, 2019, ONCOTARGETS THER, V12, P4153, DOI 10.2147/OTT.S195675
   Li Q, 2017, INT J BIOL SCI, V13, P1038, DOI 10.7150/ijbs.19476
   Lim SL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232068
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Liu ZD, 2017, BIOCHEM BIOPH RES CO, V486, P211, DOI 10.1016/j.bbrc.2017.02.045
   López Iglesias AA, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045 017 0495 y
   Lu B, 2020, MOL CANCER RES, V18, P57, DOI 10.1158/1541 7786.MCR 19 0470
   Lu JC, 2015, J CLIN INVEST, V125, P1839, DOI 10.1172/JCI78437
   Lu N, 2015, TUMOR BIOL, V36, P3843, DOI 10.1007/s13277 014 3026 2
   Ma AQ, 2020, NAT CHEM BIOL, V16, P214, DOI 10.1038/s41589 019 0421 4
   Ma Y, 2019, J MOL MED, V97, P957, DOI 10.1007/s00109 019 01782 0
   Marango J, 2008, BLOOD, V111, P3145, DOI 10.1182/blood 2007 06 092122
   Maroni P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010075
   Martinez Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood 2010 07 298349
   Min DJ, 2013, LEUKEMIA, V27, P686, DOI 10.1038/leu.2012.269
   Mithraprabhu S, 2014, EPIGENETICS US, V9, P1511, DOI 10.4161/15592294.2014.983367
   Moran S, 2017, NAT REV CLIN ONCOL, V14, P682, DOI 10.1038/nrclinonc.2017.97
   Moritz LE, 2018, J BIOL CHEM, V293, P13805, DOI 10.1074/jbc.R117.800367
   Morrow James J., 2015, Critical Reviews in Oncogenesis, V20, P173, DOI 10.1615/CritRevOncog.2015013713
   Murahari S, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3046 6
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Parrish JK, 2015, ONCOGENE, V34, P257, DOI 10.1038/onc.2013.541
   Pawlyn C, 2016, CLIN CANCER RES, V22, P5783, DOI 10.1158/1078 0432.CCR 15 1790
   Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078 0432.CCR 03 0561
   Pettke A, 2016, ANTI CANCER DRUG, V27, P1001, DOI 10.1097/CAD.0000000000000418
   Pinkerneil M, 2016, TARGET ONCOL, V11, P783, DOI 10.1007/s11523 016 0444 7
   Pishas KI, 2018, MOL CANCER THER, V17, P1902, DOI 10.1158/1535 7163.MCT 18 0373
   Popovic R, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004566
   Pore SK, 2020, MOL CANCER THER, V19, P420, DOI 10.1158/1535 7163.MCT 19 0611
   Przybycinski J, 2019, EXPERT OPIN THER TAR, V23, P773, DOI 10.1080/14728222.2019.1654458
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Ramalingam SS, 2010, J CLIN ONCOL, V28, P56, DOI 10.1200/JCO.2009.24.9094
   Redondo A, 2017, CANCER CHEMOTH PHARM, V80, P1113, DOI 10.1007/s00280 017 3436 0
   Rizk M, 2019, CANCER SCI, V110, P3695, DOI 10.1111/cas.14207
   Romo Morales A, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27888
   Roodman GD, 2010, J CELL BIOCHEM, V109, P283, DOI 10.1002/jcb.22403
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosenblum JM, 2015, EPIGENETICS US, V10, P31, DOI 10.4161/15592294.2014.989084
   Sáinz Jaspeado M, 2010, MOL CANCER RES, V8, P1489, DOI 10.1158/1541 7786.MCR 10 0060
   Sakimura R, 2005, INT J CANCER, V116, P784, DOI 10.1002/ijc.21069
   Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood 2011 10 387365
   Schiano C, 2019, CANCERS, V11, DOI 10.3390/cancers11101444
   Schiano C, 2019, EXPERT REV CLIN IMMU, V15, P289, DOI 10.1080/1744666X.2019.1561283
   Scognamiglio G, 2019, BRIT J CANCER, V121, P979, DOI 10.1038/s41416 019 0616 1
   Scotlandi K, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040968
   Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064
   Shah MY, 2016, ONCOGENE, V35, P5905, DOI 10.1038/onc.2016.116
   Shi CC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2022 2
   Silverman EK, 2020, WIRES SYST BIOL MED, V12, DOI 10.1002/wsbm.1489
   Suh E, 2020, LANCET ONCOL, V21, P421, DOI 10.1016/S1470 2045(19)30800 9
   Sun XJ, 2015, MOL CANCER RES, V13, P1347, DOI 10.1158/1541 7786.MCR 14 0697
   Svoboda LK, 2014, EPIGENETICS US, V9, P1613, DOI 10.4161/15592294.2014.988048
   Tap WD, 2020, J CLIN ONCOL, V38, P1693, DOI 10.1200/JCO.19.02492
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   Welch D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222228
   Xiong XF, 2020, CANCER BIOL THER, V21, P213, DOI 10.1080/15384047.2019.1680061
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yardley DA, 2011, J CLIN ONCOL, V29
   Yee AJ, 2016, LANCET ONCOL, V17, P1569, DOI 10.1016/S1470 2045(16)30375 8
   Younes A, 2016, LANCET ONCOL, V17, P622, DOI 10.1016/S1470 2045(15)00584 7
   Zhang WP, 2017, ONCOL REP, V37, P1175, DOI 10.3892/or.2016.5324
   Zhang XH, 2018, LEUKEMIA, V32, P2224, DOI 10.1038/s41375 018 0044 x
   Zhu LC, 2015, PATHOL ONCOL RES, V21, P1259, DOI 10.1007/s12253 015 9960 5
   Zoni E, 2016, J BONE ONCOL, V5, P104, DOI 10.1016/j.jbo.2016.04.002
   Zou PZ, 2017, PATHOL RES PRACT, V213, P194, DOI 10.1016/j.prp.2016.12.020
   Zwergel C, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148 019 0663 8
NR 106
TC 35
Z9 35
U1 1
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2021
VL 143
AR 115605
DI 10.1016/j.bone.2020.115605
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PN8OY
UT WOS:000604733200003
PM 32829036
DA 2025 08 17
ER

PT J
AU Tinhofer, I
   Biedermann, R
   Krismer, M
   Crazzolara, R
   Greil, R
AF Tinhofer, I
   Biedermann, R
   Krismer, M
   Crazzolara, R
   Greil, R
TI A role of TRAIL in killing osteoblasts by myeloma cells
SO FASEB JOURNAL
LA English
DT Article
ID MALIGNANT PLASMA CELLS; FAS LIGAND GENE; MULTIPLE MYELOMA; BONE DISEASE;
   INDUCED APOPTOSIS; UP REGULATION; TNF FAMILY; KAPPA B; RECEPTOR;
   EXPRESSION
AB In multiple myeloma (MM), neoplastic plasma cells accumulate in the bone marrow where their survival, proliferation, and apoptosis are controlled at multiple levels by interaction with the bone marrow microenvironment. Myeloma cells actively control these interactions by activating stromal and endothelial cells for production of survival factors, such as interleukin 6, and suppressing other cell types such as erythroblasts, normal B cell progenitors, and T cells. In the present study, we identified primary osteoblasts as additional potential targets for myeloma cell mediated suppression which was partly dependent on the death receptor ligand TRAIL. Besides killing of osteoblasts, myeloma cell lines sensitized osteoblasts to cell death mediated by recombinant TRAIL, whereas primary osteoblasts protected myeloma cells from TRAIL mediated apoptosis that was mediated by osteoprotegerin (OPG). Besides increase of osteoclastogenesis and osteoclast activity, suppression of bone forming cells by myeloma cells might contribute to bone loss in MM patients. In addition, clinical development of recombinant TRAIL as anti myeloma therapy should include evaluation of potential side effects on viability of normal bone cells.
C1 Salzburg Gen Hosp, Med Dept Hematol Oncol Hemostaseol Rheumatol & In, Lab Immunol & Mol Canc Res, Salzburg, Austria.
   Private Paracelsus Med Univ, Salzburg, Austria.
   Univ Innsbruck, Tyrolean Canc Res Inst, A 6020 Innsbruck, Austria.
   Univ Innsbruck Hosp, Dept Orthoped Surg, A 6020 Innsbruck, Austria.
   Univ Innsbruck Hosp, Dept Pediat, A 6020 Innsbruck, Austria.
C3 Paracelsus Private Medical University; University of Innsbruck; Medical
   University of Innsbruck; University of Innsbruck Hospital; Medical
   University of Innsbruck; University of Innsbruck Hospital
RP Univ Hosp, Med Dept Hematol Oncol Hemostaseol Rheumatol & In, Lab Immunol & Mol Canc Res, Salzburg, Austria.
EM i.tinhofer@salk.at
RI Greil, Richard/C 7673 2017; Biedermann, Rainer/AAF 2636 2020
OI Tinhofer Keilholz, Ingeborg/0000 0002 0512 549X; 
CR Atkins GJ, 2002, BONE, V31, P448, DOI 10.1016/S8756 3282(02)00858 X
   Bureau F, 2002, BLOOD, V99, P3683, DOI 10.1182/blood.V99.10.3683
   Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234
   Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356
   Drexler HG, 2000, LEUKEMIA RES, V24, P681, DOI 10.1016/S0145 2126(99)00195 2
   DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097 0142(197509)36:3<842::AID CNCR2820360303>3.0.CO;2 U
   Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097 4652(200001)182:1<41::AID JCP5>3.0.CO;2 7
   Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501
   Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200
   Hjorth Hansen H, 1999, J BONE MINER RES, V14, P256, DOI 10.1359/jbmr.1999.14.2.256
   Kagawa S, 2001, CANCER RES, V61, P3330
   Katavic V, 2003, J IMMUNOL, V170, P1540, DOI 10.4049/jimmunol.170.3.1540
   LEITHAUSER F, 1993, LAB INVEST, V69, P415
   Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251
   LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074 7613(94)90106 6
   Meyer MA, 2004, NEW ENGL J MED, V350, P1464
   Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795
   Munshi A, 2002, CANCER CHEMOTH PHARM, V50, P46, DOI 10.1007/s00280 002 0465 z
   O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167 5699(98)01382 6
   OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0
   Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111
   Roodman GD, 1997, CANCER, V80, P1557, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1557::AID CNCR5>3.3.CO;2 K
   Schulze Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432 1327.1998.2540439.x
   Shipman CM, 2003, CANCER RES, V63, P912
   Silvestris F, 2004, BRIT J HAEMATOL, V126, P475, DOI 10.1111/j.1365 2141.2004.05084.x
   Silvestris F, 2003, BRIT J HAEMATOL, V122, P39, DOI 10.1046/j.1365 2141.2003.04374.x
   Silvestris F, 2002, BLOOD, V99, P1305, DOI 10.1182/blood.V99.4.1305
   Silvestris F, 2001, BLOOD, V97, P1155, DOI 10.1182/blood.V97.5.1155
   Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074 7613(02)00502 2
   SOBEL ES, 1993, INT IMMUNOL, V5, P1275, DOI 10.1093/intimm/5.10.1275
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tinhofer I, 2000, BLOOD, V95, P610, DOI 10.1182/blood.V95.2.610
   Ursini Siegel J, 2002, J IMMUNOL, V169, P5505, DOI 10.4049/jimmunol.169.10.5505
   Villunger A, 1997, BLOOD, V90, P12
   Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386
   Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074 7613(95)90057 8
NR 36
TC 38
Z9 40
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JAN
PY 2006
VL 20
IS 1
BP 759
EP +
DI 10.1096/fj.05 4329fje
PG 19
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA 021PU
UT WOS:000235996000004
PM 16436464
DA 2025 08 17
ER

PT J
AU Jung, SR
   Song, NJ
   Yang, DK
   Cho, YJ
   Kim, BJ
   Hong, JW
   Yun, UJ
   Jo, DG
   Lee, YM
   Choi, SY
   Park, KW
AF Jung, So Ra
   Song, No Joon
   Yang, Dong Kwon
   Cho, Yong Jun
   Kim, Byung Joon
   Hong, Joung Woo
   Yun, Ui Jeong
   Jo, Dong Gyu
   Lee, Young Min
   Choi, Soo Young
   Park, Kye Won
TI Silk proteins stimulate osteoblast differentiation by suppressing the
   Notch signaling pathway in mesenchymal stem cells
SO NUTRITION RESEARCH
LA English
DT Article
DE Osteoblast differentiation; Multipotent cells; Silk protein; Notch; Bone
ID FIBROIN 3D SCAFFOLDS; BONE MARROW; ADIPOCYTE DIFFERENTIATION; PEPTIDES;
   FAT; PROLIFERATION; PREADIPOCYTES; PROGENITORS; EXPRESSION; RESORPTION
AB Silk fibroins are biomaterials that have been applied to surgical sutures, drug delivery systems, food supplements, and tissue engineering. Studies have shown the antiadipogenic effects of silk proteins in 3T3 L1 cells and obese mice. Furthermore, other studies have shown that silk proteins increase osteogenic marker expression in osteoblast like cells. Because osteogenic and adipogenic differentiation from common mesenchymal progenitor cells are often regulated reciprocally, we hypothesized that silk proteins would stimulate osteoblast differentiation. The objective of this study was to evaluate the effects of silk proteins on promoting osteoblast differentiation and identify the underlying mechanism. We showed that silk proteins dose dependently stimulated alkaline phosphatase (ALP) activity, osteoblast differentiation, and induced expression of osteoblast markers in C3H10T1/2 and M2 10B4 multipotent cells. In addition, silk proteins also induced the expression of osteoblast markers in primary rat bone marrow cells isolated from tibiae. Molecular studies showed that silk proteins suppressed the expression of Notch activated genes and blocked activation of the Notch specific reporter. Similarly, inhibiting Notch signaling with pharmacologic inhibitors and by small interfering RNA mediated Notch1 silencing also induced ALP activity and messenger RNA expression. Finally, induction of ALP activity and messenger RNA expression by silk proteins was blunted in Notch1 knock downed cells, further demonstrating Notch signaling as an important mediator for the pro osteogenic effects of silk proteins. Taken together, our data suggest that silk proteins may serve as functional foods to promote bone healing and therapeutic interventions for bone fractures and osteoporosis. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Jung, So Ra; Song, No Joon; Park, Kye Won] Sungkyunkwan Univ, Dept Food Sci & Biotechnol, Suwon, South Korea.
   [Yang, Dong Kwon] Gwangju Inst Sci & Technol, Sch Life Sci, Kwangju, South Korea.
   [Cho, Yong Jun] Hallym Univ, Coll Med, Dept Neurosurg, Chunchon, South Korea.
   [Kim, Byung Joon] Konyang Univ, Dept Internal Med, Div Endocrinol & Metab, Taejon, South Korea.
   [Hong, Joung Woo] Kyung Hee Univ, Grad Sch East West Med Sci, Yongin, South Korea.
   [Yun, Ui Jeong; Jo, Dong Gyu] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea.
   [Lee, Young Min] Natl Acad Agr Sci, Dept Agrofood Resources, RDA, Suwon, South Korea.
   [Choi, Soo Young] Hallym Univ, Dept Biomed Sci, Chunchon, South Korea.
   [Choi, Soo Young] Hallym Univ, Res Inst Biosci & Biotechnol, Chunchon, South Korea.
C3 Sungkyunkwan University (SKKU); Gwangju Institute of Science &
   Technology (GIST); Hallym University; Konyang University; Konyang
   University Hospital; Kyung Hee University; Sungkyunkwan University
   (SKKU); Rural Development Administration (RDA), Republic of Korea;
   Hallym University; Hallym University
RP Choi, SY (通讯作者)，Hallym Univ, Dept Biomed Sci, Chuchon 200702, South Korea.
EM sychoi@hallym.ac.kr; kwpark@skku.edu
RI Hong, Joung Woo/AAG 1173 2021; Jo, Dong Gyu/AAN 9278 2021
OI Jo, Dong Gyu/0000 0003 2271 1076; Park, Kye Won/0000 0003 2771 249X;
   Hong, Joung Woo/0000 0001 6511 7881
FU Korea Healthcare Technology R&D Project, Ministry for Health, Welfare,
   and Family Affairs, Republic of Korea [A101711]; "Cooperative Research
   Program for Agricultural Science & Technology Development" Rural
   Development Administration, Republic of Korea [PJ008447]
FX This study was supported by a grant from the Korea Healthcare Technology
   R&D Project, Ministry for Health, Welfare, and Family Affairs, Republic
   of Korea (A101711). This study was also conducted with the support of
   "Cooperative Research Program for Agricultural Science & Technology
   Development (Project No. PJ008447)" Rural Development Administration,
   Republic of Korea.
CR Altman GH, 2003, BIOMATERIALS, V24, P401, DOI 10.1016/S0142 9612(02)00353 8
   Bayçin D, 2007, J AGR FOOD CHEM, V55, P1227, DOI 10.1021/jf062829o
   Chen JP, 2012, NANOSCALE RES LETT, V7, P1, DOI 10.1186/1556 276X 7 170
   Corral DA, 1998, P NATL ACAD SCI USA, V95, P13835, DOI 10.1073/pnas.95.23.13835
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   File SE, 1999, J CLIN PSYCHOPHARM, V19, P506, DOI 10.1097/00004714 199912000 00004
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hong JW, EXP MOL MED, V42, P12
   Huang G, 2010, CELL PROLIFERAT, V43, P515, DOI 10.1111/j.1365 2184.2010.00701.x
   Jung SR, 2011, NUTR RES, V31, P723, DOI 10.1016/j.nutres.2011.08.010
   KASAI K, 1978, METABOLISM, V27, P201, DOI 10.1016/0026 0495(78)90165 8
   Kim JY, 2010, BMB REP, V43, P52, DOI 10.5483/BMBRep.2010.43.1.052
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Lee SH, 2012, EUR J NUTR, V51, P1011, DOI 10.1007/s00394 011 0280 6
   LUCAS F, 1960, J MOL BIOL, V2, P339, DOI 10.1016/S0022 2836(60)80045 9
   Mandal BB, 2009, BIOMATERIALS, V30, P2956, DOI 10.1016/j.biomaterials.2009.02.006
   Manolagas SC, 1998, AGING CLIN EXP RES, V10, P182, DOI 10.1007/BF03339652
   Mauney JR, 2007, BIOMATERIALS, V28, P5280, DOI 10.1016/j.biomaterials.2007.08.017
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   NADIGER HA, 1985, NEUROCHEM INT, V7, P243, DOI 10.1016/0197 0186(85)90111 1
   Numata K, 2010, ADV DRUG DELIVER REV, V62, P1497, DOI 10.1016/j.addr.2010.03.009
   Pajvani UB, 2011, NAT MED, V17, P961, DOI 10.1038/nm.2378
   Park KW, 2008, MOL ENDOCRINOL, V22, P2038, DOI 10.1210/me.2007 0454
   Park KW, 2010, J LIPID RES, V51, P2775, DOI 10.1194/jlr.M008490
   Park KW, 2009, MOL CELL BIOL, V29, P3905, DOI 10.1128/MCB.00002 09
   Park KW, 2008, CELL METAB, V8, P454, DOI 10.1016/j.cmet.2008.11.001
   Park SH, 2010, BIOMATERIALS, V31, P6162, DOI 10.1016/j.biomaterials.2010.04.028
   Seo CW, 2011, J AGR FOOD CHEM, V59, P4192, DOI 10.1021/jf104812g
   Shahidi F, 2008, J AOAC INT, V91, P914
   Simpson MA, 2011, NAT GENET, V43, P303, DOI 10.1038/ng.779
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Tien LW, 2012, MACROMOL BIOSCI
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092 8674(85)90308 3
   Wongputtaraksa T, 2012, J BIOMED MATER RES B, V100B, P2307, DOI 10.1002/jbm.b.32802
   Zhou CZ, 2001, PROTEINS, V44, P119, DOI 10.1002/prot.1078
NR 36
TC 55
Z9 62
U1 2
U2 48
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271 5317
J9 NUTR RES
JI Nutr. Res.
PD FEB
PY 2013
VL 33
IS 2
BP 162
EP 170
DI 10.1016/j.nutres.2012.11.006
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 101AO
UT WOS:000315747700010
PM 23399667
DA 2025 08 17
ER

PT J
AU Peng, RP
   Dong, YM
   Zheng, M
   Kang, HL
   Wang, PJ
   Zhu, MP
   Song, KH
   Wu, W
   Li, F
AF Peng, Renpeng
   Dong, Yimin
   Zheng, Meng
   Kang, Honglei
   Wang, Pengju
   Zhu, Meipeng
   Song, Kehan
   Wu, Wei
   Li, Feng
TI IL 17 promotes osteoclast induced bone loss by regulating
   glutamine dependent energy metabolism
SO CELL DEATH & DISEASE
LA English
DT Article
ID DIFFERENTIATION
AB Osteoclasts consume an amount of adenosine triphosphate (ATP) to perform their bone resorption function in the development of osteoporosis. However, the mechanism underlying osteoclast energy metabolism has not been fully elucidated. In addition to glucose, glutamine (Glu) is another major energy carrier to produce ATP. However, the role of Glu metabolism in osteoclasts and the related molecular mechanisms has been poorly elucidated. Here we show that Glu is required for osteoclast differentiation and function, and that Glu deprivation or pharmacological inhibition of Glu transporter ASCT2 by V9302 suppresses osteoclast differentiation and their bone resorptive function. In vivo treatment with V9302 improved OVX induced bone loss. Mechanistically, RNA seq combined with in vitro and in vivo experiments suggested that Glu mediates the role of IL 17 in promoting osteoclast differentiation and in regulating energy metabolism. In vivo IL 17 treatment exacerbated OVX induced bone loss, and this effect requires the participation of Glu or its downstream metabolite alpha KG. Taken together, this study revealed a previously unappreciated regulation of IL 17 on energy metabolism, and this regulation is Glu dependent. Targeting the IL 17 Glu energy metabolism axis may be a potential therapeutic strategy for the treatment of osteoporosis and other IL 17 related diseases.
C1 [Peng, Renpeng; Dong, Yimin; Zheng, Meng; Kang, Honglei; Wang, Pengju; Zhu, Meipeng; Song, Kehan; Wu, Wei; Li, Feng] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthoped Surg, Wuhan, Peoples R China.
C3 Huazhong University of Science & Technology
RP Song, KH; Wu, W; Li, F (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthoped Surg, Wuhan, Peoples R China.
EM kehansong@tjh.tjmu.edu.cn; wuweisheit@hotmail.com; lifengmd@hust.edu.cn
RI zheng, mengzhu/MHP 9728 2025; pengju, wang/AAB 9642 2021
OI Song, Kehan/0000 0003 3587 1511
FU National Natural Science Foundation of China (National Science
   Foundation of China)
FX No Statement Available
CR Berry SPDG, 2022, INT IMMUNOPHARMACOL, V102, DOI 10.1016/j.intimp.2021.108402
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cruzat V, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111564
   Dong YM, 2023, CLIN ORTHOP RELAT R, V481, P1209, DOI 10.1097/CORR.0000000000002465
   Dong YM, 2022, PHARMACOL RES, V185, DOI 10.1016/j.phrs.2022.106513
   Dong YM, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.870905
   Dong YM, 2022, SPINE J, V22, P857, DOI 10.1016/j.spinee.2021.12.007
   Gkini V, 2023, NEUROSCIENTIST, V29, P177, DOI 10.1177/10738584211069060
   Gu CF, 2013, CYTOKINE, V64, P477, DOI 10.1016/j.cyto.2013.07.022
   Guo Q, 2021, J BONE MINER RES, V36, P2065, DOI 10.1002/jbmr.4399
   Huang TL, 2021, BRIT J PHARMACOL, V178, P4352, DOI 10.1111/bph.15614
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Koeken VACM, 2019, J INFECT DIS, V219, P1662, DOI 10.1093/infdis/jiy709
   Li GH, 2021, TISSUE CELL, V71, DOI 10.1016/j.tice.2021.101569
   Liu HD, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adg0731
   Liu PS, 2023, NAT IMMUNOL, V24, P452, DOI 10.1038/s41590 023 01430 3
   Liu PS, 2017, NAT IMMUNOL, V18, P985, DOI 10.1038/ni.3796
   Liu SJ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3408467
   Massari F, 2016, CANCER TREAT REV, V45, P46, DOI 10.1016/j.ctrv.2016.03.005
   Min HK, 2021, J TRANSL MED, V19, DOI 10.1186/s12967 021 03071 2
   Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Seales EC, 2006, J CELL BIOCHEM, V97, P45, DOI 10.1002/jcb.20659
   Shen LY, 2022, CURR OSTEOPOROS REP, V20, P53, DOI 10.1007/s11914 022 00721 2
   Song WX, 2020, ACTA PHARMACOL SIN B, V10, P61, DOI 10.1016/j.apsb.2019.12.006
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Xiao DF, 2016, AMINO ACIDS, V48, P2067, DOI 10.1007/s00726 016 2254 8
   Xu YX, 2021, J BONE MINER METAB, V39, P914, DOI 10.1007/s00774 021 01249 8
   Zaidi N, 2012, CANCER RES, V72, P3709, DOI 10.1158/0008 5472.CAN 11 4112
   Zhu MP, 2023, FASEB J, V37, DOI 10.1096/fj.202200911R
NR 31
TC 19
Z9 19
U1 5
U2 21
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB 5
PY 2024
VL 15
IS 2
AR 111
DI 10.1038/s41419 024 06475 2
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HA9Q7
UT WOS:001156888100001
PM 38316760
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Agnusdei, D
   Silvestri, S
AF Agnusdei, Donato
   Silvestri, Sandra
TI Current strategies for the treatment of osteoporosis
SO AGRO FOOD INDUSTRY HI TECH
LA English
DT Article
ID BONE MINERAL DENSITY; RANDOMIZED CLINICAL TRIAL; VERTEBRAL FRACTURE
   RISK; POSTMENOPAUSAL WOMEN; NONVERTEBRAL FRACTURES; PARATHYROID HORMONE;
   CALCIUM SUPPLEMENTATION; STRONTIUM RANELATE; BREAST CANCER;
   ELDERLY WOMEN
AB Calcium and vitamin D supplements should be used, as adjunct, with any osteoporosis treatment HT should be used primarily for the relief of menopausal symptoms, with diminishing long term use of standard doses for the prevention and treatment of osteoporosis. The balance between risks and benefits of such therapy is essentially unknown. Raloxifene therapy reduces vertebral fracture risk but there was no reduction in the risk of nonvertebral fractures. Raloxifene has clinically meaningful effects outside of the skeleton, such as a decrease in the risk of invasive breast cancer BPs determine robust fracture protection, at different skeletal sites. Weekly oral administration produces the same BMD improvement as does daily therapy. No fracture reduction has been shown with this regimen. Strontium Ranelate, by reducing fracture incidence in post menopausal women should be considered a treatment option, although its mechanism of action is not well understood. Teriparatide increases BMD more than does antiresorptive therapy, and reduces both vertebral and nonvertebral fracture risk. Teriparatide treatment should be limited to patients with severe osteoporosis and in patients with inadequate clinical response to antiresorptives.
C1 Eli Lilly & Co, Eli Lilly Italia SpA, Florence, Italy.
C3 Eli Lilly
RP Agnusdei, D (通讯作者)，Eli Lilly & Co, Eli Lilly Italia SpA, Florence, Italy.
CR Barrett Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Brown JP, 2002, CALCIFIED TISSUE INT, V71, P103, DOI 10.1007/s00223 002 2011 8
   Caro JJ, 2004, OSTEOPOROSIS INT, V15, P1003, DOI 10.1007/s00198 004 1652 z
   CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001 9002
   Cummings SR, 2000, AM J MED, V109, P330, DOI 10.1016/S0002 9343(00)00539 8
   Cummings SR, 1999, JAMA J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305
   Delmas PD, 2003, BONE, V33, P522, DOI 10.1016/S8756 3282(03)00241 2
   Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
   ETTINGER B, 1992, AM J OBSTET GYNECOL, V166, P479, DOI 10.1016/0002 9378(92)91653 R
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003 4819 106 1 40
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Johnell O, 2002, J CLIN ENDOCR METAB, V87, P985, DOI 10.1210/jc.87.3.985
   Kanis JA, 2002, OSTEOPOROSIS INT, V13, P443, DOI 10.1007/s001980200052
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   LINDSAY R, 1980, LANCET, V2, P1151
   LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003 4819 117 1 1
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Miller PD, 2005, J BONE MINER RES, V20, P1315, DOI 10.1359/JBMR.050313
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nieves JW, 1998, AM J CLIN NUTR, V67, P18, DOI 10.1093/ajcn/67.1.18
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   RIGGS BL, 1982, NEW ENGL J MED, V306, P446, DOI 10.1056/NEJM198202253060802
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Sambrook PN, 2004, J INTERN MED, V255, P503, DOI 10.1111/j.1365 2796.2004.01317.x
   Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1
   Shea B, 2002, ENDOCR REV, V23, P552, DOI 10.1210/er.2001 7002
   Siris ES, 2005, J BONE MINER RES, V20, P1514, DOI 10.1359/JBMR.050509
   Sorensen OH, 2003, BONE, V32, P120, DOI 10.1016/S8756 3282(02)00946 8
   Torgerson DJ, 2001, JAMA J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891
   Tosteson ANA, 2003, AM J MED, V115, P209, DOI 10.1016/S0002 9343(03)00362 0
   Xu LZ, 2004, BRIT J NUTR, V91, P625, DOI 10.1079/BJN20031085
NR 48
TC 0
Z9 0
U1 0
U2 2
PU TEKNOSCIENZE PUBL
PI MILANO
PA VIALE BRIANZA 22, 20127 MILANO, ITALY
SN 1722 6996
EI 2035 4606
J9 AGRO FOOD IND HI TEC
JI Agro Food Ind. Hi Tech
PD JUL AUG
PY 2007
VL 18
IS 4
BP 54
EP 56
PG 3
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 216HY
UT WOS:000249870300022
DA 2025 08 17
ER

PT J
AU Manoukian, GE
   Tannir, NM
   Jonasch, E
   Qiao, W
   Haygood, TM
   Tu, SM
AF Manoukian, George E.
   Tannir, Nizar M.
   Jonasch, Eric
   Qiao, Wei
   Haygood, Tamara M.
   Tu, Shi Ming
TI Pilot Trial of Bone Targeted Therapy Combining Zoledronate With
   Fluvastatin or Atorvastatin for Patients With Metastatic Renal Cell
   Carcinoma
SO CLINICAL GENITOURINARY CANCER
LA English
DT Article
DE Bisphosphonate; Bone metastasis; Renal cell carcinoma; Statin
ID COA REDUCTASE INHIBITORS; IN VITRO; OSSEOUS METASTASES; SURVIVAL; RISK
AB Bone targeted therapy may improve the clinical outcome of patients with renal cell carcinoma (RCC) and bone metastases. This phase II study was designed to test potential synergistic action and clinical benefit of 2 bone targeted agents: statins and bisphosphonate. Although our treatment provided bone response in some patients, we could not demonstrate a statistically significant delay in time to skeletal events.
   Background: The biological rationale for this study came from the observation that bisphosphonates and statins affect bone metastasis in different ways and thus combination therapy may provide synergistic benefit. This pilot trial evaluated the efficacy and safety of combining a bisphosphonate and a statin in patients with RCC metastatic to bone. Methods: Patients with RCC and bone metastasis received zoledronate and fluvastatin or atorvastatin. Patients were monitored clinically and by imaging for skeletal events. Concentrations of the bone resorption markers deoxypyridinoline (DPD) and N telopeptide (NTX) and the bone formation marker bone specific alkaline phosphatase (BSAP) were monitored for changes during treatment. Results: Eleven patients were enrolled and followed for a median of 6 months. The median time to first skeletal related event for all patients was 9.0 months. Seven (63%) patients experienced skeletal events with a median time to first skeletal related event of 4.0 months (range, 3 18 months); 4 patients (36%) experiences no skeletal events for a median of 12 months of follow up (range, 2 28 months); 4 patients (36%) demonstrated treatment responses with development of sclerosis in lytic bone lesions. Differences in the median changes in biomarker levels between patients who had skeletal events and those who did not were statistically significant for DPD and NTX (P = .03 and .01, respectively) but not for BSAP (P = .4). The regimen was well tolerated, with few adverse reactions related to the study drugs. Conclusion: Although the use of bone targeting therapy combining zoledronate and fluvastatin or atorvastatin affected certain bone biomarkers and provided bone response in several patients with RCC and bone metastasis, we could not demonstrate a statistically significant improvement in time to skeletal events.
C1 [Tu, Shi Ming] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, Houston, TX 77230 USA.
   [Qiao, Wei] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77230 USA.
   [Haygood, Tamara M.] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77230 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center
RP Tu, SM (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, 1155 Pressler St,POB 304139, Houston, TX 77230 USA.
EM stu@mdanderson.org
FU National Institutes of Health through MD Anderson's Cancer Center
   [CA016672]; Novartis Pharmaceuticals Corporation, East Hanover, New
   Jersey; Novartis Pharmaceuticals Corporation
FX This work was supported in part by the National Institutes of Health
   through MD Anderson's Cancer Center Support Grant, CA016672. The authors
   thank Karen Phillips, ELS, for editorial assistance. This work was
   supported in part by a grant from Novartis Pharmaceuticals Corporation,
   East Hanover, New Jersey. Shi Ming Tu served on an Advisory Board
   sponsored by the Novartis Pharmaceuticals Corporation. The other authors
   report they have no relevant relationships to disclose.
CR [Anonymous], NAT MED
   Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   Demers Laurence M., 2000, Cancer, V88, P2919, DOI 10.1002/1097 0142(20000615)88:12+<2919::AID CNCR7>3.0.CO;2 Z
   Dürr HR, 1999, CLIN ORTHOP RELAT R, P283
   Eble J., 2004, WHO CLASSIFICATION T
   Fuchs B, 2005, CLIN ORTHOP RELAT R, P187, DOI 10.1097/01.blo.0000149820.65137.b4
   Horiguchi A, 2004, CLIN CANCER RES, V10, P8648, DOI 10.1158/1078 0432.CCR 04 1568
   Izumi M, 2001, CANCER, V91, P1487, DOI 10.1002/1097 0142(20010415)91:8<1487::AID CNCR1156>3.0.CO;2 2
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jung ST, 2003, CLIN ORTHOP RELAT R, P223, DOI 10.1097/01.blo.0000059580.08469.3e
   Lin PP, 2007, J BONE JOINT SURG AM, V89A, P1794, DOI 10.2106/JBJS.F.00603
   Lipton A, 2003, CANCER, V98, P962, DOI 10.1002/cncr.11571
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Motzer RJ, 2004, CLIN CANCER RES, V10, p6302S, DOI 10.1158/1078 0432.CCR 040031
   Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.2002.20.1.289
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   NIELSEN OS, 1991, J CLIN ONCOL, V9, P509, DOI 10.1200/JCO.1991.9.3.509
   Savage A. D., 1996, Blood, V88, p105A
   Shipman CM, 1998, CANCER RES, V58, P5294
   SWANSON DA, 1981, UROLOGY, V18, P556, DOI 10.1016/0090 4295(81)90455 6
   Tannir N, 2006, CANCER AM CANCER SOC, V107, P497, DOI 10.1002/cncr.22038
   Wang PS, 2000, JAMA J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   YAGODA A, 1995, SEMIN ONCOL, V22, P42
   Zekri J, 2001, INT J ONCOL, V19, P379
NR 24
TC 19
Z9 20
U1 0
U2 2
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 1558 7673
EI 1938 0682
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD DEC
PY 2011
VL 9
IS 2
BP 81
EP 88
DI 10.1016/j.clgc.2011.07.001
PG 8
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Urology & Nephrology
GA 847TC
UT WOS:000296994400002
PM 21958521
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Veerappan, SG
   Healy, M
   Walsh, BJ
   O'Morain, CA
   Daly, JS
   Ryan, BM
AF Veerappan, Sundaram G.
   Healy, Martin
   Walsh, Bernard J.
   O'Morain, Colm A.
   Daly, Jacqueline S.
   Ryan, Barbara M.
TI Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in
   Patients with Crohn's Disease
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Adalimumab; Crohn's disease; Osteoporosis; Bone metabolism
ID INFLAMMATORY BOWEL DISEASE; NECROSIS FACTOR ALPHA; MINERAL DENSITY;
   INFLIXIMAB THERAPY; RHEUMATOID ARTHRITIS; TNF ALPHA; IN VITRO; SERUM;
   IMPROVEMENT; DIAGNOSIS
AB Infliximab has been shown to have beneficial effects on bone metabolism in patients with Crohn's disease (CD) although as yet the exact mechanisms have not been fully elucidated.
   To evaluate the impact of adalimumab therapy on bone metabolism using a combined in vivo and in vitro model.
   Parathyroid hormone, vitamin D, bone formation markers, bone resorption marker, pro inflammatory cytokines, anti inflammatory cytokines, osteoprotegerin, and sRANKL were measured in control patients and pre  and post treatment with adalimumab in CD patients. The effect of control patients' and pre  and post treatment CD patients' sera on human osteoblasts (hFOB 1.19) in vitro cell viability and differentiation was also analyzed.
   There was a significant increase in bone formation markers osteocalcin (P < 0.05) and procollagen type 1 N terminal propeptide (P < 0.01) at 1 and 3 months post treatment. Moreover, there was a sustained but not significant fall in serum CTx, a bone resorption marker. No significant change was seen over time with other parameters measured. Serum from CD patients pre treated with adalimumab showed increased osteoblast viability compared with that of post treated patients at 6 months (P = 0.002) and controls. However, post adalimumab treatment sera at 6 months appeared to increase osteoblast differentiation (P = 0.001), which is likely to be important in new bone formation.
   This first study evaluating the role of adalimumab as a possible bone protector in Crohn's disease patients has shown that similar to infliximab, adalimumab has complex and potentially beneficial effects on bone metabolism.
C1 [Veerappan, Sundaram G.; Daly, Jacqueline S.] Royal Coll Surgeons Ireland, Dept Anat, Div Biol, Dublin 2, Ireland.
   [Veerappan, Sundaram G.; O'Morain, Colm A.; Ryan, Barbara M.] Adelaide & Meath Hosp, Dept Gastroenterol, Dublin 24, Ireland.
   [Healy, Martin] St James Hosp, Dept Biochem, Dublin 8, Ireland.
   [Walsh, Bernard J.] St James Hosp, Dept Gerontol, Dublin 8, Ireland.
C3 Royal College of Surgeons   Ireland; Trinity College Dublin; Trinity
   College Dublin; Trinity College Dublin
RP Veerappan, SG (通讯作者)，Royal Coll Surgeons Ireland, Dept Anat, Div Biol, Dublin 2, Ireland.
EM sveerappan78@gmail.com; mhealy@stjames.ie; jbwalsh@tcd.ie;
   gastroenterology@amnch.ie; jdaly@rcsi.ie; barbara.ryan2@amnch.ie
RI ; Ryan, Brid/AAS 4854 2020
OI Ryan, Barbara/0000 0001 8400 9202; 
CR Abreu MT, 2006, J CLIN GASTROENTEROL, V40, P55, DOI 10.1097/01.mcg.0000190762.80615.d4
   Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333
   Bernstein CN, 2005, INFLAMM BOWEL DIS, V11, P325, DOI 10.1097/01.MIB.0000164015.60795.ca
   Bernstein M, 2005, AM J GASTROENTEROL, V100, P2031, DOI 10.1111/j.1572 0241.2005.50219.x
   Bjarnason I, 1997, GUT, V40, P228, DOI 10.1136/gut.40.2.228
   Card T, 2004, GUT, V53, P251, DOI 10.1136/gut.2003.026799
   Franchimont N, 2004, ALIMENT PHARM THER, V20, P607, DOI 10.1111/j.1365 2036.2004.02152.x
   GENANT HK, 1976, INVEST RADIOL, V11, P541, DOI 10.1097/00004424 197611000 00007
   GHOSH S, 1994, GASTROENTEROLOGY, V107, P1031, DOI 10.1016/0016 5085(94)90227 5
   Haderslev KV, 2000, GASTROENTEROLOGY, V119, P639, DOI 10.1053/gast.2000.16518
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Hyams JS, 1997, J PEDIATR GASTR NUTR, V24, P289, DOI 10.1097/00005176 199703000 00011
   Komatsu M, 2001, CLIN CHEM, V47, P1297
   Krieckaert CLM, 2013, RHEUMATOLOGY, V52, P547, DOI 10.1093/rheumatology/kes320
   Kumar S, 2001, J CELL PHYSIOL, V187, P294, DOI 10.1002/jcp.1082
   Lamb EJ, 2002, ALIMENT PHARM THER, V16, P1895, DOI 10.1046/j.1365 2036.2002.01363.x
   Lancaster MV, 1996, U.S. Patent, Patent No. [5 501 959, 5501959, 5,501,959]
   LANFRANCHI GA, 1992, LANCET, V339, P1053, DOI 10.1016/0140 6736(92)90573 L
   Lin CL, 1996, GASTROENTEROLOGY, V111, P1263, DOI 10.1053/gast.1996.v111.pm8898640
   Mauro M, 2007, CAN J GASTROENTEROL, V21, P637, DOI 10.1155/2007/216162
   Miheller P, 2007, INFLAMM BOWEL DIS, V13, P1379, DOI 10.1002/ibd.20234
   Miheller P, 2006, DIGEST DIS, V24, P201, DOI 10.1159/000091299
   MURCH SH, 1991, GUT, V32, P913, DOI 10.1136/gut.32.8.913
   Oelzner P, 1999, RHEUMATOLOGY, V38, P841, DOI 10.1093/rheumatology/38.9.841
   Pazianas M, 2006, ANN NY ACAD SCI, V1068, P543, DOI 10.1196/annals.1346.055
   Plevy SE, 1997, J IMMUNOL, V159, P6276
   Pollak RD, 1998, AM J GASTROENTEROL, V93, P1483
   Ryan BM, 2004, ALIMENT PHARM THER, V20, P851, DOI 10.1111/j.1365 2036.2004.02097.x
   SILVENNOINEN JA, 1995, GUT, V37, P71, DOI 10.1136/gut.37.1.71
   Sylvester FA, 2002, J BONE MINER RES, V17, P695, DOI 10.1359/jbmr.2002.17.4.695
NR 30
TC 15
Z9 15
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163 2116
EI 1573 2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD JUL
PY 2015
VL 60
IS 7
BP 2119
EP 2129
DI 10.1007/s10620 015 3606 z
PG 11
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA CK2DT
UT WOS:000356021500033
PM 25732718
DA 2025 08 17
ER

PT J
AU Yan, SY
   Zhang, M
   Yang, GM
   Sun, YM
   Ai, DM
AF Yan, Shuyun
   Zhang, Meng
   Yang, Guimei
   Sun, Yumei
   Ai, Dongmei
TI CTGF Promotes the Osteoblast Differentiation of Human Periodontal
   Ligament Stem Cells by Positively Regulating BMP2/Smad Signal
   Transduction
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID TISSUE GROWTH FACTOR; OSTEOGENIC DIFFERENTIATION; FACTOR CTGF/CCN2;
   BONE MARROW; REGENERATION; CCN2; EXPRESSION; PROTEINS; THERAPY
AB Objective. This work is aimed at revealing the role and the molecular mechanism of connective tissue growth factor 2 (CTGF) in the osteoblast differentiation of periodontal ligament stem cells (PDLSCs). Methods. The osteogenic differentiation of PDLSCs was induced by osteogenic induction medium (OM), and the expression level of osteogenic related proteins ALP, RUNX2, OCN, and CTGF was estimated using quantitative real time polymerase chain reaction (qRT PCR) and Western blotting analysis. We constructed cell lines with CTGF overexpression or knockdown to verify the role of CTGF in the osteoblast differentiation of PDLSCs. Alkaline phosphatase (ALP) staining was introduced to measure the osteoblasts activity, and alizarin red S (ARS) staining was employed to test matrix mineralization. The interaction between CTGF and bone morphogenetic protein 2 (BMP 2) was determined by endogenous coimmunoprecipitation (Co IP). Results. The expression level of CTGF was increased during the osteogenic induction of PDLSCs. Additionally, CTGF overexpression effectively maintained the stemness and facilitated the osteoblast differentiation in PDLSCs, and CTGF knockdown exerted opposite effects. Moreover, at molecular mechanism, CTGF increased the activity of BMP 2/Smad signaling pathway. Conclusion. This investigation verified that CTGF promotes the osteoblast differentiation in PDLSCs at least partly by activating BMP 2/Smad cascade signal.
C1 [Yan, Shuyun; Zhang, Meng; Yang, Guimei; Sun, Yumei; Ai, Dongmei] Shandong Univ Tradit Chinese Med, Dept Stomatol, Affiliated Hosp 2, Jinan, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine
RP Yang, GM (通讯作者)，Shandong Univ Tradit Chinese Med, Dept Stomatol, Affiliated Hosp 2, Jinan, Peoples R China.
EM yanshuyun@zydey.org.cn; zhangmeng@zydey.org.cn; yangguimei@zydey.org.cn;
   sunyumei@zydey.org.cn; aidongmei@zydey.org.cn
RI zhang, meng/JMB 0951 2023; SUN, Yumei/HGT 8766 2022
CR Arnott JA, 2011, CRIT REV EUKAR GENE, V21, P43, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.40
   Asano Masahiro, 2005, Cell Commun Signal, V3, P11, DOI 10.1186/1478 811X 3 11
   Beertsen W, 1997, PERIODONTOL 2000, V13, P20, DOI 10.1111/j.1600 0757.1997.tb00094.x
   Branchetti E, 2013, CARDIOVASC RES, V100, P316, DOI 10.1093/cvr/cvt205
   Bright R, 2015, J PERIODONTAL RES, V50, P160, DOI 10.1111/jre.12205
   Cao FD, 2017, MOL MED REP, V16, P9301, DOI 10.3892/mmr.2017.7821
   Chen FM, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0288 1
   Cui Q, 2021, ARCH ORAL BIOL, V124, DOI 10.1016/j.archoralbio.2021.105057
   Ding G, 2010, STEM CELLS, V28, P1829, DOI 10.1002/stem.512
   Ding G, 2010, J CELL PHYSIOL, V223, P415, DOI 10.1002/jcp.22050
   Djordjevic A, 2004, J Matern Fetal Neonatal Med, V16, P367
   Etienne I, 2019, BRAIN RES BULL, V150, P196, DOI 10.1016/j.brainresbull.2019.06.001
   Feissner RF, 2009, FRONT BIOSCI LANDMRK, V14, P1197, DOI 10.2741/3303
   García EV, 2014, THERIOGENOLOGY, V81, P1032, DOI 10.1016/j.theriogenology.2014.01.025
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   GRENIER D, 1987, INFECT IMMUN, V55, P111, DOI 10.1128/IAI.55.1.111 117.1987
   Gu K, 2020, J CELL BIOCHEM, V121, P1101, DOI 10.1002/jcb.29346
   Hasegawa D, 2018, J CELL PHYSIOL, V233, P1752, DOI 10.1002/jcp.26086
   Heng ECK, 2006, J CELL BIOCHEM, V98, P409, DOI 10.1002/jcb.20810
   Izadpanah R, 2006, J CELL BIOCHEM, V99, P1285, DOI 10.1002/jcb.20904
   Kanaan RA, 2006, MED SCI MONITOR, V12, pRA277
   Kikuchi T, 2008, TISSUE ENG PT A, V14, P1089, DOI [10.1089/ten.tea.2007.0167, 10.1089/tea.2007.0167]
   Kim HY, 2018, EUR J PHARMACOL, V834, P84, DOI 10.1016/j.ejphar.2018.07.012
   Lee CH, 2015, J CLIN INVEST, V125, P2690, DOI [10.1172/JCI84508, 10.1172/JCI81589]
   Lee CH, 2010, J CLIN INVEST, V120, P3340, DOI 10.1172/JCI43230
   Lee JS, 2018, J CELL COMMUN SIGNAL, V12, P661, DOI 10.1007/s12079 018 0468 0
   Li XB, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0976 0
   Lin CC, 2015, BIOELECTROMAGNETICS, V36, P494, DOI 10.1002/bem.21933
   Liu JY, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1409 4
   Liu L, 2013, WORLD J GASTROENTERO, V19, P9439, DOI 10.3748/wjg.v19.i48.9439
   Liu Y, 2019, AGING US, V11, P5334, DOI 10.18632/aging.102105
   Maeda A, 2009, J BIOCHEM, V145, P207, DOI 10.1093/jb/mvn159
   Mundy C, 2014, J CELL PHYSIOL, V229, P672, DOI 10.1002/jcp.24491
   Needleman IG, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001724.pub2
   Ono M, 2007, BIOCHEM BIOPH RES CO, V357, P20, DOI 10.1016/j.bbrc.2007.03.052
   Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140 6736(03)15172 0
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Qu Q, 2016, J PERIODONTOL, V87, pE127, DOI 10.1902/jop.2016.150592
   Romuk E, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7156038
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shi Wen X, 2008, CYTOKINE GROWTH F R, V19, P133, DOI 10.1016/j.cytogfr.2008.01.002
   Shimono M, 2003, MICROSC RES TECHNIQ, V60, P491, DOI 10.1002/jemt.10290
   Takigawa M, 2013, J CELL COMMUN SIGNAL, V7, P191, DOI 10.1007/s12079 013 0204 8
   Tassi SA, 2017, J PERIODONTAL RES, V52, P793, DOI 10.1111/jre.12455
   Tsumanuma Y, 2011, BIOMATERIALS, V32, P5819, DOI 10.1016/j.biomaterials.2011.04.071
   Wang JJ, 2009, J ZHEJIANG UNIV SC B, V10, P355, DOI 10.1631/jzus.B0820252
   Wang LY, 2022, LASER MED SCI, V37, P941, DOI 10.1007/s10103 021 03338 6
   Wang MH, 2020, DIFFERENTIATION, V111, P1, DOI 10.1016/j.diff.2019.10.003
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Yamaai T, 2005, J BONE MINER METAB, V23, P280, DOI 10.1007/s00774 004 0600 5
   Yuda A, 2015, J CELL PHYSIOL, V230, P150, DOI 10.1002/jcp.24693
   Zhang L, 2021, J PERIODONTOL, V92, P103, DOI 10.1002/JPER.20 0869
   Zhang Y, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00784
   Zhao B, 2020, J MOL HISTOL, V51, P161, DOI 10.1007/s10735 020 09866 9
   Zheng JJ, 2021, ANN NY ACAD SCI, V1485, P56, DOI 10.1111/nyas.14483
NR 55
TC 8
Z9 8
U1 2
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD SEP 15
PY 2022
VL 2022
AR 2938015
DI 10.1155/2022/2938015
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 5C7XA
UT WOS:000864467500004
PM 36158888
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Li, XY
   Lou, Y
   Hu, WJ
   Wang, KL
   Zhang, YF
   Xu, RJ
   Zhang, T
   Yang, WL
   Qian, Y
AF Li, Xinyu
   Lou, Yun
   Hu, Wenjun
   Wang, Kelei
   Zhang, Yufeng
   Xu, Rongjian
   Zhang, Tan
   Yang, Wanlei
   Qian, Yu
TI Activation of TAZ by XMU MP 1 inhibits osteoclastogenesis and attenuates
   ovariectomy induced cancellous bone loss
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoporosis; Osteoclast; Transcriptional co activator with PDZ Binding;
   motif; Ovariectomy; XMU MP 1
ID CATHEPSIN K; YAP; COACTIVATOR; PATHWAY; MEDIATE
AB Osteoporosis is a metabolic bone loss disorder usually accompanied by overactivated osteoclast formation and increased bone resorption. Transcriptional co activator with PDZ binding motif (TAZ) is an emerging potential target for the treatment of osteoporosis. Our previous research showed that TAZ overexpression inhibited osteoclast formation while TAZ silencing had the opposite effect. In addition, TAZ knockout in mouse osteoclasts induced osteoporosis in animal experiments. XMU MP 1 (XMU) is a selective MST1/2 inhibitor that can theo retically activate TAZ; however, its effect on osteoporosis remains unknown. In this study, we found that XMU treatment significantly increased TAZ expression in osteoclasts and inhibited osteoclast formation in vitro; however, this inhibitory effect was eliminated after the deletion of TAZ. Furthermore, XMU treatment upregu lated TAZ expression in osteoclasts and alleviated ovariectomy (OVX) induced osteoporosis in bilateral OVX mouse models. These findings suggest that XMU can effectively activate TAZ and that pharmacological activation of TAZ may be a promising option for the treatment of osteoporosis.
C1 [Li, Xinyu; Lou, Yun; Hu, Wenjun; Wang, Kelei; Zhang, Yufeng; Xu, Rongjian; Zhang, Tan] Zhejiang Univ, Sch Med, Shaoxing Hosp, Dept Orthoped, Shaoxing 312000, Zhejiang, Peoples R China.
   [Li, Xinyu] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthopaed, Hangzhou 310000, Zhejiang, Peoples R China.
   [Yang, Wanlei; Qian, Yu] Zhejiang Chinese Med Univ, Zhejiang Prov Hosp Chinese Med, Dept Orthopaed, Affiliated Hosp 1, Hangzhou 310006, Zhejiang, Peoples R China.
   [Yang, Wanlei; Qian, Yu] Zhejiang Chinese Med Univ, Zhejiang Prov Hosp Chinese Med, Dept Orthoped Surg, Affiliated Hosp 1, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang Chinese Medical
   University; Zhejiang Chinese Medical University
RP Yang, WL; Qian, Y (通讯作者)，Zhejiang Chinese Med Univ, Zhejiang Prov Hosp Chinese Med, Dept Orthoped Surg, Affiliated Hosp 1, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
EM doctoryangwanlei@aliyun.com; doctor120@hotmail.com
RI Zhang, Yufeng/A 7168 2009; Wang, Kelei/HNQ 2430 2023; Li,
   Xinyu/AAP 3162 2021
OI zhang, yufeng/0009 0009 3418 0381; 
FU National Natural Science Founda tion of China [U22A20281, 82072467,
   82002329]; Natural Science Foundation of Zhejiang Province, China
   [LY23H060001, LQ21H060001]
FX <B>Funding</B> This study was supported by the National Natural Science
   Founda tion of China (grant numbers: U22A20281, 82072467, and 82002329)
   and the Natural Science Foundation of Zhejiang Province, China (grant
   numbers: LY23H060001 and LQ21H060001) .
CR Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200
   Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004 1013.2003
   Dey A, 2020, NAT REV DRUG DISCOV, V19, P480, DOI 10.1038/s41573 020 0070 z
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Fan FQ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2304
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002
   Hao X, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.998077
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874 07
   Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Murakami M, 2006, BIOCHEM BIOPH RES CO, V339, P533, DOI 10.1016/j.bbrc.2005.10.214
   Murakami M, 2005, P NATL ACAD SCI USA, V102, P18034, DOI 10.1073/pnas.0509109102
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Reggiani F, 2021, TRENDS BIOCHEM SCI, V46, P154, DOI 10.1016/j.tibs.2020.08.012
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Tanvetyanon T, 2006, ANN ONCOL, V17, P897, DOI 10.1093/annonc/mdj105
   Triastuti E, 2019, BRIT J PHARMACOL, V176, P3956, DOI 10.1111/bph.14795
   Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748
   Wang KN, 2009, BIOCHEM CELL BIOL, V87, P77, DOI 10.1139/O08 114
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xu XX, 2021, AGING CELL, V20, DOI 10.1111/acel.13465
   Yang WL, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00151 3
   Yang WL, 2018, J CELL PHYSIOL, V233, P4606, DOI 10.1002/jcp.26372
   Yarom N, 2018, OR SURG OR MED OR PA, V125, P27, DOI 10.1016/j.oooo.2017.09.014
   Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhao LM, 2018, BONE, V110, P177, DOI 10.1016/j.bone.2018.01.035
NR 38
TC 1
Z9 1
U1 2
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 15
PY 2024
VL 692
AR 149323
DI 10.1016/j.bbrc.2023.149323
EA DEC 2023
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CW9T6
UT WOS:001128396000001
PM 38043154
DA 2025 08 17
ER

PT J
AU Park, KR
   Kim, S
   Cho, M
   Kang, SW
   Yun, HM
AF Park, Kyung Ran
   Kim, SooHyun
   Cho, MyoungLae
   Kang, Sang Wook
   Yun, Hyung Mun
TI Effects of PIN on Osteoblast Differentiation and Matrix Mineralization
   through Runt Related Transcription Factor
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Styrax Japonica Sieb; et Zucc; PIN; osteoblast; migration;
   differentiation; mineralization
ID BONE MORPHOGENETIC PROTEIN 2; STYRAX JAPONICA SIEB.; STEM BARK;
   NATURAL PRODUCTS; EXPRESSION; OSTEOPOROSIS; MECHANISMS; LIGNANS;
   OSTERIX; CELLS
AB Styrax Japonica Sieb. et Zucc. has been used as traditional medicine in inflammatory diseases, and isolated compounds have shown pharmacological activities. Pinoresinol glucoside (PIN) belonging to lignins was isolated from the stem bark of S. Japonica. This study aimed to investigate the biological function and mechanisms of PIN on cell migration, osteoblast differentiation, and matrix mineralization. Herein, we investigated the effects of PIN in MC3T3 E1 pre osteoblasts, which are widely used for studying osteoblast behavior in in vitro cell systems. At concentrations ranging from 0.1 to 100 mu M, PIN had no cell toxicity in pre osteoblasts. Pre osteoblasts induced osteoblast differentiation, and the treatment of PIN (10 and 30 mu M) promoted the cell migration rate in a dose dependent manner. At concentrations of 10 and 30 mu M, PIN elevated early osteoblast differentiation in a dose dependent manner, as indicated by increases in alkaline phosphatase (ALP) staining and activity. Subsequently, PIN also increased the formation of mineralized nodules in a dose dependent manner, as indicated by alizarin red S (ARS) staining, demonstrating positive effects of PIN on late osteoblast differentiation. In addition, PIN induced the mRNA level of BMP2, ALP, and osteocalcin (OCN). PIN also upregulated the protein level of BMP2 and increased canonical BMP2 signaling molecules, the phosphorylation of Smad1/5/8, and the protein level of Runt related transcription factor 2 (RUNX2). Furthermore, PIN activated non canonical BMP2 signaling molecules, activated MAP kinases, and increased beta catenin signaling. The findings of this study indicate that PIN has biological roles in osteoblast differentiation and matrix mineralization, and suggest that PIN might have anabolic effects in bone diseases such as osteoporosis and periodontitis.
C1 [Park, Kyung Ran; Kang, Sang Wook; Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
   [Kim, SooHyun; Cho, MyoungLae] Natl Inst Korean Med Dev, Gyongsan 38540, South Korea.
C3 Kyung Hee University
RP Kang, SW; Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
EM rudfks282@khu.ac.kr; beluga81@nikom.or.kr; meanglae@nikom.or.kr;
   pathemis@khu.ac.kr; yunhm@khu.ac.kr
RI Kang, Sang/AAY 5970 2021
FU National Research Foundation of Korea [NRF]   Korea government (MSIP)
   [NRF 2018R1D1A1B07043282]
FX We appreciate Bioevaluation Center (Korea Research Institute of
   Bioscience and Biotechnology, Republic of Korea) for experimental
   assistance. This work was supported by the National Research Foundation
   of Korea [NRF] grant funded by the Korea government (MSIP)
   (NRF 2018R1D1A1B07043282).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Artigas N, 2014, J BIOL CHEM, V289, P27105, DOI 10.1074/jbc.M114.576793
   Bikkavilli Rama Kamesh, 2009, Commun Integr Biol, V2, P46
   Chang YM, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep131
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Chen YY, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/378415
   Costa A.F., 1975, ELEMENTOS FLORA AROM, P295
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Do KH, 2009, PHYTOMEDICINE, V16, P530, DOI 10.1016/j.phymed.2008.12.002
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Fukuda T, 2010, DIFFERENTIATION, V80, P46, DOI 10.1016/j.diff.2010.05.002
   Guiglia R, 2013, MED ORAL PATOL ORAL, V18, pE93, DOI 10.4317/medoral.18298
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Histing T, 2012, J SURG RES, V175, P271, DOI 10.1016/j.jss.2011.03.052
   Hung TM, 2009, J KOREAN SOC APPL BI, V52, P560, DOI 10.3839/jksabc.2009.094
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200
   Kim AR, 2015, ARCH PHARM RES, V38, P1059, DOI 10.1007/s12272 014 0543 x
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Liao XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042709
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Min BS, 2004, PLANTA MED, V70, P1210, DOI 10.1055/s 2004 835853
   Moon HI, 2005, BIOL PHARM BULL, V28, P2003, DOI 10.1248/bpb.28.2003
   Nishimura R, 2012, J BIOL CHEM, V287, P33179, DOI 10.1074/jbc.M111.337063
   Ouyang MA, 2007, J AGR FOOD CHEM, V55, P6460, DOI 10.1021/jf0709808
   Owen R, 2020, BIOENGINEERING BASEL, V7, DOI 10.3390/bioengineering7010012
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103700
   Park KR, 2020, INT J BIOL SCI, V16, P330, DOI 10.7150/ijbs.37781
   Park KR, 2019, TOXICOLOGY, V422, P95, DOI 10.1016/j.tox.2019.05.010
   Park KR, 2018, THERANOSTICS, V8, P3087, DOI 10.7150/thno.24426
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Russow G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010083
   Sato MM, 2009, GENES CELLS, V14, P141, DOI 10.1111/j.1365 2443.2008.01258.x
   Soelaiman IN, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/764701
   Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113 8133.2004
   Whelan AM, 2006, ANN PHARMACOTHER, V40, P836, DOI 10.1345/aph.1G226
   Yoshikawa K, 2000, CHEM PHARM BULL, V48, P1093
   Yun KJ, 2007, BIOL PHARM BULL, V30, P139, DOI 10.1248/bpb.30.139
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zheng XG, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20187574, 10.1590/1414 431x20187574]
NR 49
TC 17
Z9 17
U1 0
U2 19
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2020
VL 21
IS 24
AR 9579
DI 10.3390/ijms21249579
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PK9JQ
UT WOS:000602752200001
PM 33339165
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Mazurkiewicz, T
   Matuszewski, L
   Matuszewska, A
   Jaszek, M
AF Mazurkiewicz, Tomasz
   Matuszewski, Lukasz
   Matuszewska, Anna
   Jaszek, Magdalena
TI Implanted bisphosphonates in bone cement affect bone markers in rat
   serum
SO INTERNATIONAL ORTHOPAEDICS
LA English
DT Article
ID NECROSIS FACTOR ALPHA; OSTEOCLAST DIFFERENTIATION; GENE EXPRESSION;
   IN VITRO; OSTEOPROTEGERIN; CELLS; RECEPTOR; ACTIVATION; PRECURSORS;
   RESORPTION
AB Bisphosphonates (BPs) are antiresorptive drugs that provide important effects on bone turnover. The key to the high efficiency of BPs is their affinity for bone tissue, and their chemical structure provides their molecular mechanism of action. BPs are widely used to treat a variety of diseases that cause excess bone resorption, such as bone metastasis, hypercalcaemia due to malignancy and Paget's disease. The goal of this study was to assess whether the bisphosphonate (PamifosA (R)) present in bone cement has any effect on bone turnover. In this paper, we present changes in cytokine levels in the serum of rats treated surgically.
   Research was performed on 40 adult male Wistar rats. The rats were divided into four groups: two control groups (A, B) and two experimental groups (C, D). Bone in rats in the experimental groups was implanted with BP enriched cement, whereas bone in control groups rats was implanted with clean cement (without BPs).
   We found a higher concentration of tumour necrosis factor alpha (TNF alpha) three weeks after surgery in rats implanted with BP enriched cement compared with rats implanted with clean cement. After six weeks of treatment, TNF alpha levels decreased significantly in rats treated with BP enriched cement, whereas the control group experienced an increase in TNF alpha. The concentration of osteoprotegerin ligand (OPG) was higher in rats with BP implants. We found high levels of receptor activator of nuclear factor kappa B ligand (RANKL) in rats after implantation of cement without BP in both groups.
   We conclude that use of bisphosphonate (PamifosA (R)), which is present in bone cement, has an effect on bone turnover in that BPs stimulate an increase in OPG and a decrease in RANKL in the bone microenvironment and thus may be an important component of mechanisms that reduce bone resorption. Therefore, the use of BP enriched cement implants appears to be justified.
C1 [Matuszewski, Lukasz] Med Univ Lublin, Pediat Orthoped & Rehabil Clin, Lublin, Poland.
   [Matuszewska, Anna; Jaszek, Magdalena] Maria Curie Sklodowska Univ Lublin, Dept Biochem, Lublin, Poland.
   [Mazurkiewicz, Tomasz] Med Univ Lublin, Orthoped & Traumatol Dept, Lublin, Poland.
C3 Medical University of Lublin; Maria Curie Sklodowska University; Medical
   University of Lublin
RP Matuszewski, L (通讯作者)，Med Univ Lublin, Pediat Orthoped & Rehabil Clin, Lublin, Poland.
EM lukasz.matuszewski@am.lublin.pl
RI Matuszewski, Łukasz/M 8281 2014; Jaszek, Magdalena/N 3258 2018
OI Matuszewska, Anna/0000 0002 5586 5568; Matuszewski,
   Lukasz/0000 0002 7733 0329; Jaszek, Magdalena/0000 0003 2609 1820
CR Ambroszkiewicz Jadwiga, 2008, Pol Merkur Lekarski, V25, P57
   AMIN D, 1992, J LIPID RES, V33, P1657
   Aspenberg P, 2002, ACTA ORTHOP SCAND, V73, P20, DOI 10.1080/000164702317281350
   Åstrand J, 2002, ACTA ORTHOP SCAND, V73, P24, DOI 10.1080/000164702317281369
   Balga R, 2006, BONE, V39, P325, DOI 10.1016/j.bone.2006.02.056
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   DOUGLAS DL, 1980, LANCET, V1, P1043
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Gupta S., 2001, Current Molecular Medicine (Hilversum), V1, P317, DOI 10.2174/1566524013363780
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jeppsson C, 2003, ACTA ORTHOP SCAND, V74, P483, DOI 10.1080/00016470310017839
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838
   Klein BY, 1998, J CELL BIOCHEM, V68, P186, DOI 10.1002/(SICI)1097 4644(19980201)68:2<186::AID JCB5>3.0.CO;2 R
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Makkonen N, 1996, J PHARMACOL EXP THER, V277, P1097
   Mundy GR, 1998, NEW ENGL J MED, V339, P398, DOI 10.1056/NEJM199808063390609
   Nishikawa M, 1996, BONE, V18, P9, DOI 10.1016/8756 3282(95)00426 2
   O'Brien EA, 2000, BIOCHEM BIOPH RES CO, V274, P281, DOI 10.1006/bbrc.2000.3129
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Screaton G, 2000, CURR OPIN IMMUNOL, V12, P316, DOI 10.1016/S0952 7915(00)00093 5
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stenzl A, 2009, EUR UROL SUPPL, V8, P823, DOI 10.1016/j.eursup.2009.09.001
   SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756 3282(95)00185 G
   Teitelbaum SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1857
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
   WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Wilkinson JM, 2011, BONE, V49, P95, DOI 10.1016/j.bone.2011.01.009
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 38
TC 6
Z9 6
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341 2695
EI 1432 5195
J9 INT ORTHOP
JI Int. Orthop.
PD MAY
PY 2013
VL 37
IS 5
BP 969
EP 974
DI 10.1007/s00264 013 1816 6
PG 6
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 128DW
UT WOS:000317750300029
PM 23404413
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Uskokovic, V
   Desai, TA
AF Uskokovic, Vuk
   Desai, Tejal A.
TI Simultaneous bactericidal and osteogenic effect of nanoparticulate
   calcium phosphate powders loaded with clindamycin on osteoblasts
   infected with Staphylococcus aureus
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Calcium phosphate; Controlled drug delivery; Nanopartides; Osteogenesis;
   Osteomyelitis; Staphylococcus aureus
ID PHASE COMPOSITION CONTROL; DRUG DELIVERY KINETICS; HYDROXYAPATITE;
   OSTEOPONTIN; INTERNALIZATION; MECHANISMS; APOPTOSIS; PROLIFERATION;
   CYTOKINE; PROTEINS
AB Staphylococcus aureus internalized by bone cells and shielded from the immune system provides a reservoir of bacteria in recurring osteomyelitis. Its targeting by the antibiotic therapy may thus be more relevant for treating chronic bone infection than eliminating only the pathogens colonizing the bone matrix. Assessed was the combined osteogenic and antibacterial effect of clindamycin loaded calcium phosphate nanoparticles of different monophasic compositions on co cultures comprising osteoblasts infected with S. aureus. Antibiotic carrying particles were internalized by osteoblasts and minimized the concentration of intracellular bacteria. In vitro treatments of the infected cells, however, could not prevent cell necrosis due to the formation of toxic byproducts of the degradation of the bacterium. Antibiotic loaded particles had a positive morphological effect on osteoblasts per se, without reducing their viability, alongside stimulating the upregulation of expression of different bone growth markers in infected osteoblasts to a higher degree than achieved during the treatment with antibiotic only. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Uskokovic, Vuk; Desai, Tejal A.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, Therapeut Micro & Nanotechnol Lab, San Francisco, CA 94143 USA.
   [Uskokovic, Vuk] Univ Illinois, Dept Bioengn, Chicago, IL USA.
C3 University of California System; University of California San Francisco;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Uskokovic, V (通讯作者)，Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, Therapeut Micro & Nanotechnol Lab, San Francisco, CA 94143 USA.
EM vuk21@yahoo.com
RI Uskokovic, Vuk/S 7986 2018; Desai, Tejal/AAN 7626 2021
OI Uskokovic, Vuk/0000 0003 3256 1606; 
FU NIH/NIDCR [K99 DE021416]
FX Presented were the results of a study supported by the NIH/NIDCR grant
   K99 DE021416. The authors would like to thank Zoran Stojanovic of the
   Institute of Technical Sciences of the Serbian Academy of Sciences and
   Arts for the synthesis of cobalt substituted hydroxyapatite and Nikon
   Imaging Center at UCSF at which confocal microscopy data for this study
   were acquired.
CR Ahmed S, 2001, INFECT IMMUN, V69, P2872, DOI 10.1128/IAI.69.5.2872 2877.2001
   Alexander EH, 2003, BMC MICROBIOL, V3, DOI 10.1186/1471 2180 3 5
   Almeida RA, 1996, J DAIRY SCI, V79, P1021, DOI 10.3168/jds.S0022 0302(96)76454 8
   [Anonymous], ENCY SURFACE COLLOID
   [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
   Baig AA, 1999, CALCIFIED TISSUE INT, V64, P437, DOI 10.1007/PL00005826
   Balasundaram G, 2006, BIOMATERIALS, V27, P2798, DOI 10.1016/j.biomaterials.2005.12.008
   Bayles KW, 1998, INFECT IMMUN, V66, P336, DOI 10.1128/IAI.66.1.336 342.1998
   Bisht S, 2005, INT J PHARMACEUT, V288, P157, DOI 10.1016/j.ijpharm.2004.07.035
   Bisland SK, 2006, PHOTOCH PHOTOBIO SCI, V5, P31, DOI 10.1039/b507082a
   Bost KL, 1999, J INFECT DIS, V180, P1912, DOI 10.1086/315138
   Breithaupt H., 2010, SEPTIC BONE JOINT SU, P72
   Celetti A, 2005, CLIN CANCER RES, V11, P8019, DOI 10.1158/1078 0432.CCR 05 0641
   Chambers AF, 1996, LUNG CANCER J IASLC, V15, P311, DOI 10.1016/0169 5002(95)00595 1
   Chow EK, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001713
   Claro T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018748
   Comett J.B., 1978, J BACTERIOL, V135, P153
   Coppola D, 2004, CLIN CANCER RES, V10, P184, DOI 10.1158/1078 0432.CCR 1405 2
   Cunha BA, 2002, CLIN INFECT DIS, V35, P287, DOI 10.1086/341417
   de Bruyn JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056764
   Del Pozo JL, 2009, NEW ENGL J MED, V361, P787, DOI 10.1056/NEJMcp0905029
   Dingeldein E, 1976, UNFALLCHIRURGIE, V1, P8
   Dorozhkin SV, 2007, J MATER SCI MATER M, V18, P363, DOI 10.1007/s10856 006 0701 x
   Dorozhkin SV, 2013, J FUNCT BIOMATER, V4, P209, DOI 10.3390/jfb4040209
   Ellington JK, 1999, MICROB PATHOGENESIS, V26, P317, DOI 10.1006/mpat.1999.0272
   Ellington JK, 2003, J BONE JOINT SURG BR, V85B, P918, DOI 10.1302/0301 620X.85B6.13509
   Epple M, 2010, J MATER CHEM, V20, P18, DOI 10.1039/b910885h
   Fleet Michael E, 2013, Front Biosci (Elite Ed), V5, P643
   GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042 6822(73)90341 3
   Hanses F, 2011, ENDOCRINOLOGY, V152, P4148, DOI 10.1210/en.2011 0103
   HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990
   Henry Stanley MJ, 2003, J SURG RES, V113, P42, DOI 10.1016/S0022 4804(03)00156 2
   Huang WB, 2004, BONE, V34, P799, DOI 10.1016/j.bone.2003.11.027
   Hudson MC, 1995, MICROB PATHOGENESIS, V19, P409, DOI 10.1006/mpat.1995.0075
   Ignjatovic N, 2013, J MATER SCI MATER M, V24, P343, DOI 10.1007/s10856 012 4793 1
   Itokazu M, 1998, BIOMATERIALS, V19, P817, DOI 10.1016/S0142 9612(97)00237 8
   Jevon M, 1999, INFECT IMMUN, V67, P2677, DOI 10.1128/IAI.67.5.2677 2681.1999
   Kaarbo M, 2011, MITOCHONDRION, V11, P935, DOI 10.1016/j.mito.2011.08.008
   Kahl BC, 2000, INFECT IMMUN, V68, P5385, DOI 10.1128/IAI.68.9.5385 5392.2000
   Kakizawa Y, 2004, ADV MATER, V16, P699, DOI 10.1002/adma.200305782
   Kim SW, 2005, BONE, V37, P359, DOI 10.1016/j.bone.2005.04.020
   King R.W., 2011, OSTEOMYELITIS EMEDIC
   Klemm K., 1981, LOCAL ANTIBIOTIC TRE
   Koziel J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005210
   Kraus R., 2010, SEPTIC BONE JOINT SU, P126
   Krut O, 2003, INFECT IMMUN, V71, P2716, DOI 10.1128/IAI.71.5.2716 2723.2003
   Kubica M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001409
   LEGEROS RZ, 1983, CARIES RES, V17, P419, DOI 10.1159/000260696
   Li Chi, 2009, J Cell Death, V2, P41
   Li DS, 2012, SCIENCE, V336, P1014, DOI 10.1126/science.1219643
   Liebert G., 2011, J VIROL, V85, P3881
   Markovic S, 2011, BIOMED MATER, V6, DOI 10.1088/1748 6041/6/4/045005
   Mayo Foundation for Medical Education and Research, OST
   Mempel M, 2002, BRIT J DERMATOL, V146, P943, DOI 10.1046/j.1365 2133.2002.04752.x
   Menzies BE, 1998, INFECT IMMUN, V66, P5994, DOI 10.1128/IAI.66.12.5994 5998.1998
   Motskin M, 2009, BIOMATERIALS, V30, P3307, DOI 10.1016/j.biomaterials.2009.02.044
   Mouzopoulos G, 2011, INJURY, V42, pS18, DOI 10.1016/S0020 1383(11)70128 0
   Murai M, 1999, MICROBIOL IMMUNOL, V43, P653, DOI 10.1111/j.1348 0421.1999.tb02453.x
   O'Regan A, 2000, INT J EXP PATHOL, V81, P373, DOI 10.1046/j.1365 2613.2000.00163.x
   OELSCHLAEGER TA, 1993, P NATL ACAD SCI USA, V90, P6884, DOI 10.1073/pnas.90.14.6884
   Okada M, 2011, J COLLOID INTERF SCI, V360, P457, DOI 10.1016/j.jcis.2011.04.068
   Onuma K, 1998, CHEM MATER, V10, P3346, DOI 10.1021/cm980062c
   Paluska SA., 2004, CLIN FAM PRACT, V6, P127
   Petrone C, 2008, ACTA BIOMATER, V4, P403, DOI 10.1016/j.actbio.2007.09.007
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Qureshi A.T., 2014, J TISSUE EN IN PRESS, DOI DOI 10.1002/TERM.1532(IN
   Radovic Moreno AF, 2012, ACS NANO, V6, P4279, DOI 10.1021/nn3008383
   Rauschmann MA, 2005, BIOMATERIALS, V26, P2677, DOI 10.1016/j.biomaterials.2004.06.045
   Rousseau M, 2008, J BIOMED MATER RES A, V85A, P487, DOI 10.1002/jbm.a.31553
   SCHRAMM N, 1995, INFECT IMMUN, V63, P324, DOI 10.1128/IAI.63.1.324 332.1995
   Spízek J, 2004, ADV APPL MICROBIOL, V56, P121
   Tang RK, 2003, J CRYST GROWTH, V249, P614, DOI 10.1016/S0022 0248(02)02332 1
   Tunholi Alves VM, 2012, EXP PARASITOL, V131, P143, DOI 10.1016/j.exppara.2012.03.003
   Uehira M, 2013, APPL SURF SCI, V287, P195, DOI 10.1016/j.apsusc.2013.09.117
   Uskokovic V, 2013, MAT SCI ENG C MATER, V33, P3362, DOI 10.1016/j.msec.2013.04.023
   Uskokovic V, 2013, J BIOMED MATER RES A, V101, P1416, DOI 10.1002/jbm.a.34426
   Uskokovic V, 2013, J BIOMED MATER RES A, V101, P1427, DOI 10.1002/jbm.a.34437
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   Wang KW, 2010, J MATER CHEM, V20, P1161, DOI 10.1039/b917441a
   Webster TJ, 2000, BIOMATERIALS, V21, P1803, DOI 10.1016/S0142 9612(00)00075 2
   Webster TJ, 2000, J BIOMED MATER RES, V51, P475, DOI 10.1002/1097 4636(20000905)51:3<475::AID JBM23>3.0.CO;2 9
   Yan Y, 2010, ACS NANO, V4, P2928, DOI 10.1021/nn100173h
   Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955 0674(00)00228 3
   Zhang MZ, 2009, NANO TODAY, V4, P508, DOI 10.1016/j.nantod.2009.10.009
   Zhang XQ, 2009, ACS NANO, V3, P2609, DOI 10.1021/nn900865g
   ZIERDT CH, 1982, J CLIN MICROBIOL, V15, P172, DOI 10.1128/JCM.15.1.172 174.1982
NR 86
TC 50
Z9 55
U1 2
U2 38
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD APR 1
PY 2014
VL 37
BP 210
EP 222
DI 10.1016/j.msec.2014.01.008
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA AE2HZ
UT WOS:000333795200028
PM 24582242
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Perrien, DS
   Achenbach, SJ
   Bledsoe, SE
   Walser, B
   Suva, LJ
   Khosla, S
   Gaddy, D
AF Perrien, DS
   Achenbach, SJ
   Bledsoe, SE
   Walser, B
   Suva, LJ
   Khosla, S
   Gaddy, D
TI Bone turnover across the menopause transition: Correlations with
   inhibins and follicle stimulating hormone
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID OSTEOCLAST FORMATION; DIMERIC INHIBIN; MARROW CULTURES; ACTIVIN A;
   WOMEN; FSH; OSTEOPOROSIS; MECHANISMS; OSTEOBLAST; ESTROGEN
AB Context: Longitudinal clinical studies demonstrate that increases in bone turnover that occur in perimenopausal women correlate better with elevated serum FSH than with changes in serum estradiol (E2). This perimenopausal rise in FSH is due to a selective decrease in ovarian inhibin B (InhB). Our previous demonstration that inhibins suppress both osteoblast and osteoclast development suggests that changes in serum inhibins may regulate osteoblast and osteoclast differentiation and thereby bone turnover, independent of changes in sex steroids.
   Objective: The objective of this study was to determine whether decreased serum inhibin A (InhA) and InhB levels correlate with increases in markers of bone turnover in women across the menopause transition and to evaluate serum inhibins as better predictors of bone turnover markers across the menopause transition than FSH or bioavailable E2.
   Design: We studied a cross sectional age stratified population sample of 188 pre  and postmenopausal women not using oral contraceptives or hormone replacement therapy (age, 21   85 yr).
   Results: Serum InhA and InhB levels significantly correlated inversely with markers of bone formation and bone resorption in pre  and perimenopausal women and with markers of bone formation in postmenopausal women (InhA only). FSH was not significantly correlated with bone turnover in either pre  or postmenopausal women; however, FSH was significantly correlated with bone resorption (C terminal collagen I cross link) in perimenopausal women (age, 45   54 yr). Using multivariate analyses, serum InhA better predicted bone formation and resorption markers in premenopausal women than either FSH or bioavailable E2.
   Conclusions: Decreases in inhibin levels across the menopause transition are associated with increasing bone turnover, regardless of changes in sex steroids or FSH.
C1 Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA.
   Univ Arkansas Med Sci, Ctr Orthopaed Res, Little Rock, AR 72205 USA.
   Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   Mayo Clinic
RP Gaddy, D (通讯作者)，Univ Arkansas Med Sci, Dept Physiol & Biophys, 4301 W Markham,Slot 505, Little Rock, AR 72205 USA.
EM gaddydana@uams.edu
RI ; Khosla, Sundeep/AAE 6170 2020; Perrien, Daniel/ISV 0029 2023
OI Suva, Larry/0000 0002 2892 9757; Perrien, Daniel/0000 0002 5488 3932;
   Khosla, Sundeep/0000 0002 2936 4372; 
FU NIDDK NIH HHS [R01 DK054044] Funding Source: Medline
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Akel NS, 2005, J BONE MINER RES, V20, pS247
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   BROXMEYER HE, 1988, P NATL ACAD SCI USA, V85, P9052, DOI 10.1073/pnas.85.23.9052
   Burger HG, 1999, J STEROID BIOCHEM, V69, P31, DOI 10.1016/S0960 0760(98)00145 9
   CITRON JT, 1995, OSTEOPOROSIS INT, V5, P228, DOI 10.1007/BF01774011
   Danforth DR, 1998, FERTIL STERIL, V70, P119, DOI 10.1016/S0015 0282(98)00127 7
   Ebeling PR, 1996, J CLIN ENDOCR METAB, V81, P3366, DOI 10.1210/jc.81.9.3366
   FUJIMOTO K, 1991, BIOCHEM BIOPH RES CO, V174, P1163, DOI 10.1016/0006 291X(91)91543 L
   Funaba M, 1996, ENDOCRINOLOGY, V137, P4250, DOI 10.1210/en.137.10.4250
   Gaddy Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74
   GGS BL, 2005, J BONE MINER RES, V20, pS4
   Guthrie JR, 1998, OSTEOPOROSIS INT, V8, P282, DOI 10.1007/s001980050066
   INOUE S, 1994, CALCIFIED TISSUE INT, V55, P395, DOI 10.1007/BF00299321
   Khosla S, 1996, J BONE MINER RES, V11, P857
   Khosla S, 1997, J CLIN ENDOCR METAB, V82, P1522, DOI 10.1210/jc.82.5.1522
   Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266
   Klein NA, 1996, J CLIN ENDOCR METAB, V81, P2742, DOI 10.1210/jc.81.7.2742
   Klein NA, 1998, CLIN OBSTET GYNECOL, V41, P912, DOI 10.1097/00003081 199812000 00017
   Klein NA, 1996, J CLIN ENDOCR METAB, V81, P1946, DOI 10.1210/jc.81.5.1946
   KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081 54
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312
   Martin TJ, 2005, J CLIN INVEST, V115, P2322, DOI 10.1172/JCI26239
   MEUNIER H, 1988, P NATL ACAD SCI USA, V85, P247, DOI 10.1073/pnas.85.1.247
   OUE Y, 1994, BONE, V15, P361, DOI 10.1016/8756 3282(94)90301 8
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rosen CJ, 2005, NEW ENGL J MED, V353, P595, DOI 10.1056/NEJMcp043801
   Vale Wylie, 1994, P1861
   Welt CK, 1999, J CLIN ENDOCR METAB, V84, P105, DOI 10.1210/jc.84.1.105
   YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0
   Zhang Z, 2005, J BONE MINER RES, V20, pS26
NR 33
TC 82
Z9 95
U1 0
U2 5
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815 5817 USA
SN 0021 972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAY
PY 2006
VL 91
IS 5
BP 1848
EP 1854
DI 10.1210/jc.2005 2423
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 039TL
UT WOS:000237330000035
PM 16449331
OA Bronze
DA 2025 08 17
ER

PT J
AU Yi, SQ
   Yu, M
   Yang, S
   Miron, RJ
   Zhang, YF
AF Yi, Siqi
   Yu, Miao
   Yang, Shuang
   Miron, Richard J.
   Zhang, Yufeng
TI Tcf12, A Member of Basic Helix Loop Helix Transcription Factors,
   Mediates Bone Marrow Mesenchymal Stem Cell Osteogenic Differentiation In
   Vitro and In Vivo
SO STEM CELLS
LA English
DT Article
DE Tcf12; Bone mesenchymal stem cells; Bone morphogenetic protein
   signaling; Extracellular signal regulated kinase 1/2 signaling;
   Osteogenesis; Bone regeneration
ID FACTOR KAPPA B; OSTEOBLASTIC DIFFERENTIATION; REGENERATIVE MEDICINE;
   COLORECTAL CANCER; BETA CATENIN; MUSCLE CELLS; E CADHERIN; HEB; PROTEIN;
   OSTEOPOROSIS
AB Several basic Helix Loop Helix transcription factors have recently been identified to regulate mesenchymal stem cell (MSC) differentiation. In the present study, Tcf12 was investigated for its involvement in the osteoblastic cell commitment of MSCs. Tcf12 was found highly expressed in undifferentiated MSCs whereas its expression decreased following osteogenic culture differentiation. Interestingly, Tcf12 endogenous silencing using shRNA lentivirus significantly promoted the differentiation ability of MSCs evaluated by alkaline phosphatase staining, alizarin red staining and expression of osteoblast specific markers by real time PCR. Conversely, overexpression of Tcf12 in MSCs suppressed osteoblast differentiation. It was further found that silencing of Tcf12 activated bone morphogenetic protein (BMP) signaling and extracellular signal regulated kinase (Erk)1/2 signaling pathway activity and upregulated the expression of phospho SMAD1 and phospho Erk1/2. A BMP inhibitor (LDN 193189) and Erk1/2 signaling pathway inhibitor (U0126) reduced these findings in the Tcf12 silencing group. Following these in vitro results, a poly L lactic acid/Hydroxyappatite scaffold carrying Tcf12 silencing lentivirus was utilized to investigate the repair of bone defects in vivo. The use of Tcf12 silencing lentivirus significantly promoted new bone formation in 3 mm mouse calvarial defects as assessed by micro CT and histological examination whereas overexpression of Tcf12 inhibited new bone formation. Collectively, these data indicate that Tcf12 is a transcription factor highly expressed in the nuclei of stem cells and its downregulation plays an essential role in osteoblast differentiation partially via BMP and Erk1/2 signaling pathways.
C1 [Yi, Siqi; Yu, Miao; Yang, Shuang; Miron, Richard J.; Zhang, Yufeng] Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Sch & Hosp Stomatol, Minist Educ, Wuhan, Hubei, Peoples R China.
   [Yi, Siqi; Yu, Miao; Yang, Shuang; Miron, Richard J.; Zhang, Yufeng] Wuhan Univ, Key Lab Oral Biomed, Sch & Hosp Stomatol, Minist Educ, Wuhan, Peoples R China.
   [Yi, Siqi; Zhang, Yufeng] Wuhan Univ, Med Res Inst, Wuhan, Peoples R China.
   [Miron, Richard J.] Nova Southeastern Univ, Coll Dent Med, Dept Periodontol, Ft Lauderdale, FL USA.
   [Miron, Richard J.] Univ Bern, Sch Dent Med, Dept Prevent Restorat & Pediat Dent, Bern, Switzerland.
C3 Wuhan University; Wuhan University; Wuhan University; Nova Southeastern
   University; University of Bern
RP Zhang, YF (通讯作者)，Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Sch & Hosp Stomatol, Minist Educ, Wuhan, Hubei, Peoples R China.; Zhang, YF (通讯作者)，Wuhan Univ, Key Lab Oral Biomed, Sch & Hosp Stomatol, Minist Educ, Wuhan, Peoples R China.
EM zyf@whu.edu.cn
RI ; Zhang, Yufeng/GZL 1973 2022; Miron, Richard/J 4995 2012
OI Zhang, Yufeng/0000 0001 8702 5291; 
FU National Natural Science Foundation of China [81271108, 81570954];
   Fundamental Research Funds for the Central Universities [410500041]
FX This work was supported by the funds of the National Natural Science
   Foundation of China (81271108 and 81570954 to Yufeng Zhang), and the
   Fundamental Research Funds for the Central Universities (410500041).
CR Barndt R, 1999, J IMMUNOL, V163, P3331
   Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677 6685.2000
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Cao YN, 2015, J CLIN INVEST, V125, P1679, DOI 10.1172/JCI73780
   Cao Y, 2010, DEV CELL, V18, P662, DOI 10.1016/j.devcel.2010.02.014
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chen WS, 2013, J BIOL CHEM, V288, P9001, DOI 10.1074/jbc.M112.437897
   D'Cruz LM, 2012, EUR J IMMUNOL, V42, P2031, DOI 10.1002/eji.201242497
   FitzPatrick DR, 2013, NAT GENET, V45, P231, DOI 10.1038/ng.2557
   Galán Díez M, 2016, BBA MOL CELL RES, V1863, P490, DOI 10.1016/j.bbamcr.2015.11.037
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Goodnough LH, 2012, DEVELOPMENT, V139, P4428, DOI 10.1242/dev.081679
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Han DY, 2015, INT J CLIN EXP MED, V8, P1411
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hayashi M, 2007, J CELL SCI, V120, P1350, DOI 10.1242/jcs.000067
   Hayrapetyan A, 2015, TISSUE ENG PART B RE, V21, P75, DOI [10.1089/ten.teb.2014.0119, 10.1089/ten.TEB.2014.0119]
   Hebrok M, 1997, EXP CELL RES, V232, P295, DOI 10.1006/excr.1997.3541
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Imayoshi I, 2014, NEURON, V82, P9, DOI 10.1016/j.neuron.2014.03.018
   Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181
   Jeong J, 2013, MOL CELLS, V35, P371, DOI 10.1007/s10059 013 0135 5
   Jones ME, 2011, IMMUNOL RES, V49, P202, DOI 10.1007/s12026 010 8182 x
   Jones Mason ME, 2012, IMMUNITY, V36, P348, DOI 10.1016/j.immuni.2012.02.010
   Kanis JA, 2009, NAT REV RHEUMATOL, V5, P425, DOI 10.1038/nrrheum.2009.139
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kozlik M, 2014, ADV CLIN EXP MED, V23, P1011, DOI 10.17219/acem/37360
   Kumar R, 2008, J BIOL CHEM, V283, P19026, DOI 10.1074/jbc.M709136200
   Langerak AW, 2001, BLOOD, V98, P2456, DOI 10.1182/blood.V98.8.2456
   Lee CC, 2012, J BIOL CHEM, V287, P2798, DOI 10.1074/jbc.M111.258947
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Manokawinchoke J, 2014, J PERIODONTAL RES, V49, P777, DOI 10.1111/jre.12162
   Miraoui H, 2010, J CELL BIOCHEM, V110, P1147, DOI 10.1002/jcb.22628
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Carreira ACO, 2015, VITAM HORM, V99, P293, DOI 10.1016/bs.vh.2015.06.002
   Parker MH, 2006, MOL CELL BIOL, V26, P5771, DOI 10.1128/MCB.02404 05
   Paumard Hernández B, 2015, EUR J HUM GENET, V23, P907, DOI 10.1038/ejhg.2014.205
   Quarto N, 2015, STEM CELLS, V33, P833, DOI 10.1002/stem.1907
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rice DPC, 2000, DEVELOPMENT, V127, P1845
   Sánchez Duffhues G, 2015, BONE, V80, P43, DOI 10.1016/j.bone.2015.05.025
   Sharma VP, 2013, NAT GENET, V45, P304, DOI 10.1038/ng.2531
   Tamura M, 1999, J CELL BIOCHEM, V72, P167, DOI 10.1002/(SICI)1097 4644(19990201)72:2<167::AID JCB1>3.0.CO;2 3
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Uittenbogaard M., 2002, Gene Expression Patterns, V1, P115, DOI 10.1016/S1567 133X(01)00022 9
   Wojciechowski J, 2007, J IMMUNOL, V178, P5717, DOI 10.4049/jimmunol.178.9.5717
   Wu K, 2012, NEUROBIOL LEARN MEM, V97, P69, DOI 10.1016/j.nlm.2011.09.006
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yoon SJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7546
   Yoon SJ, 2011, GENE DEV, V25, P1654, DOI 10.1101/gad.16800511
   Zhang Y, 2008, J CELL BIOCHEM, V105, P487, DOI 10.1002/jcb.21844
   Zhu DX, 2015, J CELL MOL MED, V19, P165, DOI 10.1111/jcmm.12373
NR 54
TC 43
Z9 51
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD FEB
PY 2017
VL 35
IS 2
BP 386
EP 397
DI 10.1002/stem.2491
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA EJ9UT
UT WOS:000393573300011
PM 27574032
DA 2025 08 17
ER

PT J
AU Qu, F
   Wang, JL
   Xu, NR
   Liu, C
   Li, SY
   Wang, N
   Qi, W
   Li, HF
   Li, CB
   Geng, ZY
   Liu, YJ
AF Qu, Feng
   Wang, Junliang
   Xu, Ningru
   Liu, Chang
   Li, Shuyuan
   Wang, Ning
   Qi, Wei
   Li, Haifeng
   Li, Chunbao
   Geng, Zhenying
   Liu, Yujie
TI WNT3A modulates chondrogenesis via canonical and non canonical Wnt
   pathways in MSCs
SO FRONTIERS IN BIOSCIENCE LANDMARK
LA English
DT Article
DE Wnt3A; Mesenchymal; Stem Cells; Induced; Pluripotent; Adult; Human;
   Articular; Chondrocytes
ID MESENCHYMAL STEM CELLS; BETA CATENIN; OSTEOGENIC DIFFERENTIATION;
   ARTICULAR CARTILAGE; SIGNALING PATHWAY; STROMAL CELLS; GENE THERAPY;
   ADULT STEM; EXPRESSION; REPAIR
AB The multilineage commitment of mesenchymal stem cells (MSCs) is controlled via unknown mechanisms. In this study, we investigated the regulation of the differentiation of MSCs into chondrocytes via the Wnt signaling pathway. Overexpression of WNT3A in MSCs activated both the canonical and non canonical Wnt pathways, which were responsible for different WNT3A induced outcomes. WNT3A promoted MSC proliferation via the beta catenin mediated canonical Wnt pathway, and inhibited chondrogenesis of MSCs via the calcium/calmodulin dependent kinase II (CaMKII) mediated non canonical Wnt pathway. Interestingly, blockade of the canonical Wnt pathway by Dickkopf related protein 1 exerted a synergistic effect on the inhibition of chondrogenesis of MSCs, while blockade of the non canonical Wnt pathway by KN93 also exerted a synergistic effect on MSCs proliferation. These results suggest that the WNT3A activated canonical and non canonical pathways counteract each other in the setting of MSCs. This study provides evidence for the delicate regulation of the Wnt signaling cascade during chondrogenesis of MSCs, and suggests that genetic manipulation of the Wnt pathway may offer a powerful vehicle for modulating MSC differentiation in stem cell based cartilage repair.
C1 [Qu, Feng; Xu, Ningru; Geng, Zhenying] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.
   [Qu, Feng; Wang, Junliang; Liu, Chang; Li, Shuyuan; Wang, Ning; Qi, Wei; Li, Haifeng; Li, Chunbao; Liu, Yujie] Chinese Peoples Liberat Army Gen Hosp, Dept Orthoped, Beijing, Peoples R China.
C3 Nankai University; Chinese People's Liberation Army General Hospital
RP Liu, YJ (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Orthoped, 28 Fuxing Rd, Beijing, Peoples R China.
EM liuyj301yy@163.com
RI liu, chang/HCI 5413 2022
FU National Key Technology RD Program [2007BA104B09]
FX This project was financially supported by the National Key Technology
   R&D Program (No: 2007BA104B09)
CR Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104
   ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294
   Baksh D, 2007, J CELL BIOCHEM, V101, P1109, DOI 10.1002/jcb.21097
   Barrilleaux B, 2006, TISSUE ENG, V12, P3007, DOI 10.1089/ten.2006.12.3007
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Chanda D, 2010, J CELL BIOCHEM, V111, P249, DOI 10.1002/jcb.22701
   Chen M, 2008, J CELL SCI, V121, P1455, DOI 10.1242/jcs.020362
   Christoforou N, 2007, PROG CARDIOVASC DIS, V49, P396, DOI 10.1016/j.pcad.2007.02.006
   Church V, 2002, J CELL SCI, V115, P4809, DOI 10.1242/jcs.00152
   Da Forno PD, 2008, CLIN CANCER RES, V14, P5825, DOI 10.1158/1078 0432.CCR 07 5104
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   DU SJ, 1995, MOL CELL BIOL, V15, P2625
   Endo Y, 2005, J BIOL CHEM, V280, P777, DOI 10.1074/jbc.M406391200
   Endo Y, 2008, MOL CELL BIOL, V28, P2368, DOI 10.1128/MCB.01780 07
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Gelse K, 2003, ARTHRITIS RHEUM US, V48, P430, DOI 10.1002/art.10759
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Kühl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/S0168 9525(00)02028 X
   Le Blanc K, 2006, CURR OPIN IMMUNOL, V18, P586, DOI 10.1016/j.coi.2006.07.004
   Liao YHT, 2007, CAN J SURG, V50, P137
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lories RJU, 2007, ARTHRITIS RHEUM US, V56, P4095, DOI 10.1002/art.23137
   MacDonald B. T., 2007, CELL, V131
   Mason JM, 1998, GENE THER, V5, P1098, DOI 10.1038/sj.gt.3300703
   Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245
   Mimeault M, 2007, CLIN PHARMACOL THER, V82, P252, DOI 10.1038/sj.clpt.6100301
   Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427
   Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100
   Nalesso G, 2011, J CELL BIOL, V193, P551, DOI 10.1083/jcb.201011051
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Palmer GD, 2005, MOL THER, V12, P219, DOI 10.1016/j.ymthe.2005.03.024
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Richter W, 2007, CURR OPIN RHEUMATOL, V19, P451
   Samarzija I, 2009, BIOCHEM BIOPH RES CO, V386, P449, DOI 10.1016/j.bbrc.2009.06.033
   Selvaraj V, 2010, TRENDS BIOTECHNOL, V28, P214, DOI 10.1016/j.tibtech.2010.01.002
   Semenov MV, 2007, CELL, V131, DOI 10.1016/j.cell.2007.12.011
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Taschner MJ, 2008, DEV BIOL, V317, P132, DOI 10.1016/j.ydbio.2008.02.007
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Vinatier C, 2009, J BIOMED MATER RES A, V89A, P176, DOI 10.1002/jbm.a.31988
   Yamamoto H, 2010, ONCOGENE, V29, P2036, DOI 10.1038/onc.2009.496
   Zhao XY, 2009, NATURE, V461, P86, DOI 10.1038/nature08267
NR 49
TC 35
Z9 40
U1 1
U2 19
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093 9946
EI 1093 4715
J9 FRONT BIOSCI LANDMRK
JI Front. Biosci.
PD JAN 1
PY 2013
VL 18
BP 493
EP 503
DI 10.2741/4116
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 173RR
UT WOS:000321097100007
PM 23276938
OA Bronze
DA 2025 08 17
ER

PT J
AU Hoehn, D
   Medeiros, LJ
   Kantarjian, HM
   Cortes, JE
   Wang, XM
   Bueso Ramos, CE
AF Hoehn, Daniela
   Medeiros, L. Jeffrey
   Kantarjian, Hagop M.
   Cortes, Jorge E.
   Wang, Xuemei
   Bueso Ramos, Carlos E.
TI Digital image analysis as a tool to assess the effects of imatinib on
   trabecular bone in patients with chronic myelogenous leukemia
SO HUMAN PATHOLOGY
LA English
DT Article
DE Imatinib; Bone homeostasis; Digital image analysis; Bone marrow;
   Trabecular bone
ID ALTERED BONE; C FMS; THERAPY; MESYLATE; INHIBITION; CML
AB Skeletal integrity is sustained by osteoblast osteoclast interactions, controlled by several signaling pathways that include tyrosine kinases. Imatinib is a tyrosine kinase inhibitor with an extended therapeutic range based on its ability to differentially bind to receptor and nonreceptor tyrosine kinases. In this study, we used digital image analysis to assess changes in trabecular bone surface area within bone marrow biopsy specimens of 34 patients with chronic phase chronic myelogenous leukemia treated with single agent imatinib. These patients were 25 men and 9 women with a median age of 59 years. We selected representative areas of paired bone marrow biopsy specimens obtained at baseline and within the subsequent 48 months. Computer assisted analysis was performed to calculate trabecular bone area (TBA) within the sample by using the equation TBA% = sum of trabecular area/total biopsy specimen area. Percentage changes were defined as Delta TBA% and were arbitrarily subdivided into marked (>50%), moderate (10% 50%), and mild (<10%). During the study interval, TBA% increased in 24 patients (71%) and decreased in 10 patients (29%). Overall, there was a significant increase in TBA% (P = .02). No correlation was found between changes in trabecular bone area and either clinical or cytogenetic response (P = .25). The results show that imatinib therapy can alter trabecular bone in bone marrow biopsy specimens of chronic myelogenous leukemia patients, most often resulting in an increase in TBA%. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Hoehn, Daniela; Medeiros, L. Jeffrey; Bueso Ramos, Carlos E.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA.
   [Kantarjian, Hagop M.; Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   [Wang, Xuemei] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center
RP Hoehn, D (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA.
EM dhoehn@mdanderson.org; cbuesora@mdanderson.org
RI ; Cortes, Jorge/ABA 0627 2022; Kantarjian, Hagop/B 4264 2015; Medeiros,
   L Jeffrey/AAB 1018 2019
OI Medeiros, L. Jeffrey/0000 0001 6577 8006; Cortes,
   Jorge/0000 0002 8636 1071
FU NCI NIH HHS [P30 CA016672] Funding Source: Medline
CR BECK JS, 1960, J PATHOL BACTERIOL, V80, P391, DOI 10.1002/path.1700800223
   Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140
   Bueso Ramos CE, 2004, CANCER AM CANCER SOC, V101, P332, DOI 10.1002/cncr.20380
   Dewar AL, 2005, CELL CYCLE, V4, P851, DOI 10.4161/cc.4.7.1788
   Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood 2004 10 3967
   Dewar AL, 2005, IMMUNOL CELL BIOL, V83, P48, DOI 10.1111/j.1440 1711.2004.01296.x
   Dewar AL, 2003, LEUKEMIA, V17, P1713, DOI 10.1038/sj.leu.2403071
   Dewar AL, 2006, BLOOD, V107, P4334, DOI 10.1182/blood 2005 09 3568
   Fitter S, 2008, BLOOD, V111, P2538, DOI 10.1182/blood 2007 07 104281
   FRYDECKA I, 1984, Folia Haematologica (Leipzig), V111, P610
   GARNER A, 1966, J PATHOL BACTERIOL, V91, P545, DOI 10.1002/path.1700910231
   Grey A, 2006, NEW ENGL J MED, V355, P2494, DOI 10.1056/NEJMc062388
   Joensuu H, 2006, NEW ENGL J MED, V355, P628
   MELSEN F, 1978, ACTA PATH MICRO IM A, V86, P70
   MOORE RJ, 1989, J CLIN PATHOL, V42, P814, DOI 10.1136/jcp.42.8.814
   Nurmio M, 2011, TOXICOL APPL PHARM, V254, P267, DOI 10.1016/j.taap.2011.04.019
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   OPPERMANN HC, 1979, PEDIATR RADIOL, V8, P254, DOI 10.1007/BF00974045
   Owen S, 2006, NEW ENGL J MED, V355, P627
   Solís Herruzo JA, 2000, J HEPATOL, V33, P812, DOI 10.1016/S0168 8278(00)80314 1
   Teman CJ, 2010, LEUKEMIA RES, V34, P871, DOI 10.1016/j.leukres.2010.01.005
   Tibullo D, 2009, EXP HEMATOL, V37, P461, DOI 10.1016/j.exphem.2008.12.008
   Tournis S, 2006, NEW ENGL J MED, V355, P627
   Vandyke K, 2010, BLOOD, V115, P766, DOI 10.1182/blood 2009 08 237404
   Yang KH, 2010, J BONE MINER METAB, V28, P713, DOI 10.1007/s00774 010 0203 2
NR 25
TC 4
Z9 5
U1 0
U2 4
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0046 8177
EI 1532 8392
J9 HUM PATHOL
JI Hum. Pathol.
PD DEC
PY 2012
VL 43
IS 12
BP 2354
EP 2359
DI 10.1016/j.humpath.2012.04.012
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA 046JY
UT WOS:000311762500031
PM 22939577
DA 2025 08 17
ER

PT J
AU Mirsaidi, A
   Tiaden, AN
   Richards, PJ
AF Mirsaidi, Ali
   Tiaden, Andre N.
   Richards, Peter J.
TI Prostaglandin E2 inhibits matrix mineralization by human bone
   marrow stromal cell derived osteoblasts via Epac dependent cAMP
   signaling
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   SERINE PROTEASE HTRA1; EP4 RECEPTOR; CANCELLOUS BONE; ADIPOGENIC
   DIFFERENTIATION; REGULATES OSTEOGENESIS; OLDER WOMEN; DENSITY; PGE(2)
AB The osteoinductive properties of prostaglandin E 2 (PGE(2)) and its signaling pathways have led to suggestions that it may serve as a potential therapeutic strategy for bone loss. However, the prominence of PGE(2) as an inducer of bone formation is attributed primarily to findings from studies using rodent models. In the current study, we investigated the effects of PGE(2) on human bone marrow stromal cell (hBMSC) lineage commitment and determined its mode of action. We demonstrated that PGE(2) treatment of hBMSCs significantly altered the expression profile of several genes associated with osteoblast differentiation (RUNX2 and ALP) and maturation (BGLAP and MGP). This was attributed to the activation of specific PGE(2) receptors, and was associated with increases in cAMP production and sustained AKT phosphorylation. Pharmacological inhibition of exchange protein directly activated by cAMP (Epac), but not protein kinase A (PKA), recovered the mineralization functions of hBMSC derived osteoblasts treated with PGE(2) and restored AKT phosphorylation, along with the expression levels of RUNX2, ALP, BGLAP and MGP. Our findings therefore provide insights into how PGE(2) influences hBMSC mediated matrix mineralization, and should be taken into account when evaluating the role of PGE(2) in human bone metabolism.
C1 [Mirsaidi, Ali; Tiaden, Andre N.; Richards, Peter J.] Univ Zurich, Bone & Stem Cell Res Grp, CABMM, CH 8057 Zurich, Switzerland.
   [Richards, Peter J.] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, CH 8057 Zurich, Switzerland.
C3 University of Zurich; University of Zurich; Zurich Center Integrative
   Human Physiology (ZIHP)
RP Richards, PJ (通讯作者)，Univ Zurich, Bone & Stem Cell Res Grp, CABMM, CH 8057 Zurich, Switzerland.; Richards, PJ (通讯作者)，Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, CH 8057 Zurich, Switzerland.
EM peter.richards@cabmm.uzh.ch
FU CABMM; SNSF [31003A_156313]; Swiss National Science Foundation (SNF)
   [31003A_156313] Funding Source: Swiss National Science Foundation (SNF)
FX This study was supported in part by the CABMM Start up grant. A.M. was
   partly supported by SNSF grant 31003A_156313.
CR Akhter MP, 2001, BONE, V29, P121, DOI 10.1016/S8756 3282(01)00486 0
   Alander CB, 2006, PROSTAG OTH LIPID M, V81, P178, DOI 10.1016/j.prostaglandins.2006.09.005
   Bauer DC, 1996, J BONE MINER RES, V11, P29
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Breyer MD, 1996, J AM SOC NEPHROL, V7, P8
   Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661
   Carbone LD, 2003, J BONE MINER RES, V18, P1795, DOI 10.1359/jbmr.2003.18.10.1795
   Choi YH, 2014, FEBS J, V281, P3656, DOI 10.1111/febs.12887
   Dean David D, 2008, J Oral Implantol, V34, P303, DOI 10.1563/1548 1336 34.6.303
   EVANS DB, 1990, BIOCHEM BIOPH RES CO, V167, P194, DOI 10.1016/0006 291X(90)91750 M
   Fujimori K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044698
   HAKEDA Y, 1986, J CELL PHYSIOL, V128, P155, DOI 10.1002/jcp.1041280204
   Inazumi T, 2011, J LIPID RES, V52, P1500, DOI 10.1194/jlr.M013615
   ITO H, 1993, BONE MINER, V21, P219, DOI 10.1016/S0169 6009(08)80232 2
   JEE WSS, 1991, BONE MINER, V15, P33, DOI 10.1016/0169 6009(91)90109 D
   KATOH H, 1995, BBA GEN SUBJECTS, V1244, P41, DOI 10.1016/0304 4165(94)00182 W
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Ke HZ, 2006, J BONE MINER RES, V21, P565, DOI 10.1359/JBMR.051110
   Keila S, 2001, J ENDOCRINOL, V168, P131, DOI 10.1677/joe.0.1680131
   Knippenberg M, 2007, TISSUE ENG, V13, P2495, DOI 10.1089/ten.2006.0420
   Li M, 2005, BONE, V37, P46, DOI 10.1016/j.bone.2005.03.016
   Lindtner RA, 2014, OSTEOPOROSIS INT, V25, P1151, DOI 10.1007/s00198 013 2494 3
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0
   Maiuri T, 2010, J BIOL CHEM, V285, P15038, DOI 10.1074/jbc.M110.121434
   Miller SB, 2006, SEMIN ARTHRITIS RHEU, V36, P37, DOI 10.1016/j.semarthrit.2006.03.005
   MORI S, 1990, BONE, V11, P103, DOI 10.1016/8756 3282(90)90057 6
   Morton DJ, 1998, J BONE MINER RES, V13, P1924, DOI 10.1359/jbmr.1998.13.12.1924
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Naik AA, 2009, J BONE MINER RES, V24, P251, DOI [10.1359/jbmr.081002, 10.1359/JBMR.081002]
   Noack C, 2015, PROSTAG LEUKOTR ESS, V94, P91, DOI 10.1016/j.plefa.2014.11.008
   OGISO B, 1991, J CELL PHYSIOL, V146, P442, DOI 10.1002/jcp.1041460315
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Penke LRK, 2014, J BIOL CHEM, V289, P17151, DOI 10.1074/jbc.M114.558130
   Pino AM, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00139
   Pountos I, 2012, THESCIENTIFICWORLDJO, V2012
   Richards JB, 2006, OSTEOPOROSIS INT, V17, P1410, DOI 10.1007/s00198 006 0142 x
   Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3
   Su B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101411
   Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200
   Tang ZH, 2012, INT J BIOCHEM CELL B, V44, P1106, DOI 10.1016/j.biocel.2012.03.019
   Tiaden AN, 2016, STEM CELLS, V34, P1601, DOI 10.1002/stem.2297
   Tiaden AN, 2012, STEM CELLS, V30, P2271, DOI 10.1002/stem.1190
   Tian XY, 2008, BONE, V42, P914, DOI 10.1016/j.bone.2007.12.228
   Tsuboi H, 2004, BIOCHEM BIOPH RES CO, V322, P1066, DOI 10.1016/j.bbrc.2004.08.018
   Weinreb M, 2006, PROSTAG LEUKOTR ESS, V75, P81, DOI 10.1016/j.plefa.2006.06.004
   Weinreb M, 1999, AM J PHYSIOL ENDOC M, V276, pE376, DOI 10.1152/ajpendo.1999.276.2.E376
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Whittier X, 2016, RHEUM DIS CLIN N AM, V42, P177, DOI 10.1016/j.rdc.2015.08.005
   Wolfe Margaret, 2008, V449, P3, DOI 10.1007/978 1 60327 169 1_1
   Yamakawa K, 2008, ARTHRITIS RHEUM US, V58, P172, DOI 10.1002/art.23158
   Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Zhu YM, 2015, SCI REP UK, V5, DOI 10.1038/srep09344
NR 56
TC 25
Z9 29
U1 0
U2 12
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAY 22
PY 2017
VL 7
AR 2243
DI 10.1038/s41598 017 02650 y
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EV4TE
UT WOS:000401754200030
PM 28533546
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Martin, C
   Lafosse, JM
   Malavaud, B
   Cuvillier, O
AF Martin, Claire
   Lafosse, Jean Michel
   Malavaud, Bernard
   Cuvillier, Olivier
TI Sphingosine kinase 1 mediates androgen induced osteoblast cell growth
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoblasts; Androgens; Sphingosine kinase 1; ERK1/2; PI3K
ID LEUKEMIA CELLS; ACTIVATION; SPHINGOSINE 1 PHOSPHATE; RECEPTORS;
   ESTROGEN; PATHWAY; EXPRESSION; APOPTOSIS; RELEASE
AB Herein we report that the lipid kinase sphingosine kinase 1 (SphK1) is instrumental in mediating androgen induced cell proliferation in osteoblasts Dihydrotestosterone (DHT) triggered cell growth in steroid deprived MC3T3 cells, which was associated with a rapid stimulation of SphK1 and activation of both Akt and ERK signaling pathways This mechanism relied on functional androgen receptoj/PI3K/Akt nongenotropic signaling as pharmacological antagonists could block SphK1 stimulation by DHT and its consequences Finally, SphK1 inhibition not only abrogated DHT induced ERK activation but also blocked cell proliferation, while ERK inhibition had no impact, Suggesting that SphK1 was critical for DHT signaling yet independently of the ERK. (C) 2009 Elsevier Inc All rights reserved
C1 [Martin, Claire; Malavaud, Bernard; Cuvillier, Olivier] CNRS, Inst Pharmacol & Biol Struct, F 31000 Toulouse, France.
   [Martin, Claire; Malavaud, Bernard; Cuvillier, Olivier] Univ Toulouse, UPS, IPBS, F 31000 Toulouse, France.
   [Lafosse, Jean Michel] Hop Rangueil, CHU Toulouse, Serv Orthopedie & Traumatol, F 31000 Toulouse, France.
   [Malavaud, Bernard] Hop Rangueil, CHU Toulouse, Serv Urol & Transplantat Renale, F 31000 Toulouse, France.
C3 Universite de Toulouse; Universite Toulouse III   Paul Sabatier; Centre
   National de la Recherche Scientifique (CNRS); Universite de Toulouse;
   Universite Toulouse III   Paul Sabatier; Universite de Toulouse;
   Universite Toulouse III   Paul Sabatier; CHU de Toulouse; Universite de
   Toulouse; Universite Toulouse III   Paul Sabatier; CHU de Toulouse
RP Cuvillier, O (通讯作者)，CNRS, UMR 5089, BP84225, F 31077 Toulouse, France.
RI CUVILLIER, Olivier/S 1631 2019; CUVILLIER, Olivier/B 2567 2009;
   Malavaud, Bernard/AHA 0480 2022
OI CUVILLIER, Olivier/0000 0003 3346 375X; 
FU Inserm; Ministere de la Sante (Interface Program); CNRS, Fondation pour
   la Recherche Medicale and La Ligue Nationale contre le Cancer; Ministere
   de la Sante; CNRS; Fondation pour la Recherche Medicale and La Ligue
   Nationale contre le Cancer; Ministere de l'Education Nationale, de la
   Recherche et de la Technologie
FX This work was supported by Inserm and Ministere de la Sante (Interface
   Program), CNRS, Fondation pour la Recherche Medicale and La Ligue
   Nationale contre le Cancer (to O.C). C.M. is recipient of the Ministere
   de l'Education Nationale, de la Recherche et de la Technologie.
CR ADEI I, 2008, CANCER RES, V68, P8635
   Baron S, 2004, J BIOL CHEM, V279, P14579, DOI 10.1074/jbc.M306143200
   Bonhoure E, 2006, LEUKEMIA, V20, P95, DOI 10.1038/sj.leu.2404023
   CAIPIO LC, 1999, PROSTAGLANDINS LEUKO, V61, P267
   Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0
   Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828
   Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910
   Dayon A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008048
   Dziak R, 2003, PROSTAG LEUKOTR ESS, V68, P239, DOI 10.1016/S0952 3278(02)00277 6
   Engelbrecht Y, 2003, ENDOCRINOLOGY, V144, P412, DOI 10.1210/en.2002 220769
   French KJ, 2003, CANCER RES, V63, P5962
   Grey A, 2004, CALCIFIED TISSUE INT, V74, P542, DOI 10.1007/s00223 003 0155 9
   Gruber R, 1999, BONE, V24, P465, DOI 10.1016/S8756 3282(99)00017 4
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Kang HY, 2004, J BONE MINER RES, V19, P1181, DOI 10.1359/JBMR.040306
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kozawa O, 1999, J BONE MINER RES, V14, P1761, DOI 10.1359/jbmr.1999.14.10.1761
   LIU RT, 1995, BIOCHEM BIOPH RES CO, V214, P676, DOI 10.1006/bbrc.1995.2339
   Lyons JM, 2001, J BONE MINER RES, V16, P2035, DOI 10.1359/jbmr.2001.16.11.2035
   MASUYAMA A, 1992, CALCIFIED TISSUE INT, V51, P376, DOI 10.1007/BF00316883
   NAKANO Y, 1994, BONE MINER, V26, P245, DOI 10.1016/S0169 6009(08)80173 0
   Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545
   Pchejetski D, 2005, CANCER RES, V65, P11667, DOI 10.1158/0008 5472.CAN 05 2702
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Spiegel S, 1998, BIOCHEMISTRY MOSCOW+, V63, P69
   Sukocheva OA, 2003, MOL ENDOCRINOL, V17, P2002, DOI 10.1210/me.2003 0119
   Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200
   Wiren KM, 2005, CURR OPIN PHARMACOL, V5, P626, DOI 10.1016/j.coph.2005.06.003
   Wiren KM, 2004, J MOL ENDOCRINOL, V32, P209, DOI 10.1677/jme.0.0320209
NR 30
TC 6
Z9 8
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 1
PY 2010
VL 391
IS 1
BP 669
EP 673
DI 10.1016/j.bbrc.2009.11.118
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 544AV
UT WOS:000273624500117
PM 19932089
DA 2025 08 17
ER

PT J
AU Ofotokun, I
   McIntosh, E
   Weitzmann, MN
AF Ofotokun, Ighovwerha
   McIntosh, Emily
   Weitzmann, M. Neale
TI HIV: Inflammation and Bone
SO CURRENT HIV/AIDS REPORTS
LA English
DT Article
DE HIV; AIDS; Osteoporosis; Inflammation; Immuno skeletal interface
ID TUMOR NECROSIS FACTOR; LOSS IN VIVO; OSTEOCLAST DIFFERENTIATION FACTOR;
   ACTIVE ANTIRETROVIRAL THERAPY; HUMAN OSTEOBLASTIC CELLS; MINERAL DENSITY
   CHANGES; MARROW STROMAL CELLS; KAPPA B LIGAND; T CELLS; ESTROGEN
   DEFICIENCY
AB HIV infection and antiretroviral therapy (ART) are now established independent risk factors for osteoporosis. With a spate of recent studies reporting significant elevations in fracture prevalence in HIV patients, and a rapidly aging demographic, defining the mechanisms underlying HIV/ARTinduced skeletal decline has become imperative. The recent emergence of the field of "osteoimmunology" has provided a conceptual framework to explain how the immune and skeletal systems interact. Furthermore, it is becoming clear that inflammatory states leading to perturbations in the immuno skeletal interface, a convergence of common cells and cytokine mediators that regulate both immune and skeletal systems, conspire to imbalance bone turnover and induce osteoporosis. In this review we examine the role of inflammation in the bone loss associated with diverse inflammatory conditions and new concepts into how the underlying mechanisms by which inflammation and immune dysregulation impact bone turnover may be pertinent to the mechanisms involved in HIV/ART induced bone
C1 [Ofotokun, Ighovwerha; McIntosh, Emily] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30303 USA.
   [Weitzmann, M. Neale] Emory Univ, Sch Med, Dept Med, Div Endocrinol & Metab & Lipids, Atlanta, GA 30322 USA.
   [Weitzmann, M. Neale] Vet Affairs Med Ctr, Atlanta Dept, Atlanta, GA 30033 USA.
C3 Emory University; Emory University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Atlanta VA Health Care System
RP Ofotokun, I (通讯作者)，Emory Univ, Sch Med, Dept Med, Div Infect Dis, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA.
EM iofotok@emory.edu; mweitzm@emory.edu
RI Ofotokun, Ighovwerha/L 6545 2015
FU NIAMS [AR059364, AR056090, AR053607]; NIA grant [AG040013]; Biomedical
   Laboratory Research and Development Service of the VA Office of Research
   and Development [5I01BX000105]; NIAID [K23 A1073119]; Atlanta Clinical
   and Translational Science Institute (ACTSI), NIH [MO1RR00039]; Emory
   Center for AIDS Research CFAR, NIH [P30 AI050409]
FX IO and MNW research is supported by NIAMS grant AR059364 and NIA grant
   AG040013. MNW is also supported by the Biomedical Laboratory Research
   and Development Service of the VA Office of Research and Development
   (5I01BX000105) and by NIAMS grants AR056090 and AR053607. IO is also
   supported in part by K23 A1073119 from NIAID. Authors' translational
   research activities are also supported in part by the Emory Center for
   AIDS Research CFAR, NIH Grant P30 AI050409, and the Atlanta Clinical and
   Translational Science Institute (ACTSI), NIH Grant MO1RR00039.
CR ABITBOL V, 1995, GASTROENTEROLOGY, V108, P417, DOI 10.1016/0016 5085(95)90068 3
   Almeida A, 2005, BRIT J HAEMATOL, V129, P482, DOI 10.1111/j.1365 2141.2005.05476.x
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Bolland MJ., 2011, IBMS BONEKEY, V8, P7
   Bonjoch A, 2010, AIDS, V24, P2827, DOI 10.1097/QAD.0b013e328340a28d
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   Brown TT, 2009, JAIDS J ACQ IMM DEF, V51, P554, DOI 10.1097/QAI.0b013e3181adce44
   Bruera D, 2003, AIDS, V17, P1917, DOI 10.1097/00002030 200309050 00010
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   De Milito A, 2004, CURR HIV RES, V2, P11, DOI 10.2174/1570162043485068
   Deeks Steven G, 2009, Top HIV Med, V17, P118
   Desai Seema, 2010, Curr HIV/AIDS Rep, V7, P4, DOI 10.1007/s11904 009 0038 4
   Duvivier C, 2009, AIDS, V23, P817, DOI 10.1097/QAD.0b013e328328f789
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Franco JM, 2002, BLOOD, V99, P3702, DOI 10.1182/blood.V99.10.3702
   Fry TJ, 2001, TRENDS IMMUNOL, V22, P564, DOI 10.1016/S1471 4906(01)02028 2
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Gallant JE, 2004, JAMA J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191
   Gao YH, 2004, P NATL ACAD SCI USA, V101, P16618, DOI 10.1073/pnas.0404888101
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Han XZ, 2006, J IMMUNOL, V176, P625, DOI 10.4049/jimmunol.176.1.625
   Hansen AB, 2011, HIV MED, V12, P157, DOI 10.1111/j.1468 1293.2010.00864.x
   Hashizume M, 2008, RHEUMATOLOGY, V47, P1635, DOI 10.1093/rheumatology/ken363
   Hofbauer LC, 1996, EUR J ENDOCRINOL, V134, P425, DOI 10.1530/eje.0.1340425
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Kalayjian RC, 2005, J INFECT DIS, V192, P1577, DOI 10.1086/466527
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Keating SM, 2011, AIDS
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   KIMBLE RB, 1994, J CLIN INVEST, V93, P1959, DOI 10.1172/JCI117187
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Lopez Granados E, 2007, P NATL ACAD SCI USA, V104, P5056, DOI 10.1073/pnas.0605715104
   MANOLAGAS SC, 1995, INT J IMMUNOPHARMACO, V17, P109, DOI 10.1016/0192 0561(94)00089 7
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   McComsey GA, 2010, CLIN INFECT DIS, V51, P937, DOI 10.1086/656412
   Merlotti D, 2010, NUTR METAB CARDIOVAS, V20, P683, DOI 10.1016/j.numecd.2010.07.008
   Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683
   Mondy K, 2003, CLIN INFECT DIS, V36, P482, DOI 10.1086/367569
   More Judy, 2008, J Fam Health Care, V18, P22
   Morrow M, 2008, AIDS RES HUM RETROV, V24, P621, DOI 10.1089/aid.2007.0186
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   Noël D, 2007, LEUKEMIA LYMPHOMA, V48, P1283, DOI 10.1080/10428190701361869
   Ofotokun I, 2011, DISCOV MED, V11, P385
   Ofotokun I, 2010, CURR OPIN ENDOCRINOL, V17, P523, DOI 10.1097/MED.0b013e32833f48d6
   PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134
   PASSERI G, 1993, ENDOCRINOLOGY, V133, P822, DOI 10.1210/en.133.2.822
   Prior J, 2007, OSTEOPOROSIS INT, V18, P1345, DOI 10.1007/s00198 007 0428 7
   Reid W, 2001, P NATL ACAD SCI USA, V98, P9271, DOI 10.1073/pnas.161290298
   Rifas L, 2003, J CELL BIOCHEM, V88, P650, DOI 10.1002/jcb.10436
   Rifas L, 2009, ARTHRITIS RHEUM US, V60, P3324, DOI 10.1002/art.24877
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Ryan MR, 2005, P NATL ACAD SCI USA, V102, P16735, DOI 10.1073/pnas.0505168102
   Schett G, 2010, NAT REV ENDOCRINOL, V6, P698, DOI 10.1038/nrendo.2010.190
   Sharma A, 2010, AIDS, V24, P2337, DOI 10.1097/QAD.0b013e32833d7da7
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stellbrink HJ, 2010, CLIN INFECT DIS, V51, P963, DOI 10.1086/656417
   Stone B, 2010, ARCH BIOCHEM BIOPHYS, V503, P66, DOI 10.1016/j.abb.2010.07.029
   Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Taylor A, 2010, BONE, V46, pS56, DOI 10.1016/j.bone.2010.01.131
   Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030 200003100 00005
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thirunavukkarasu K, 2001, J BIOL CHEM, V276, P36241, DOI 10.1074/jbc.M104319200
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482
   Triant VA, 2008, J CLIN ENDOCR METAB, V93, P3499, DOI 10.1210/jc.2008 0828
   van Grevenynghe J, 2008, SEMIN IMMUNOL, V20, P196, DOI 10.1016/j.smim.2008.07.008
   Vikulina T, 2010, P NATL ACAD SCI USA, V107, P13848, DOI 10.1073/pnas.1003020107
   Wang MWH, 2004, J CLIN INVEST, V114, P206, DOI 10.1172/JCI200415797
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Weitzmann MN, 2007, ANN NY ACAD SCI, V1116, P360, DOI 10.1196/annals.1402.068
   Weitzmann MN, 2000, BLOOD, V96, P1873, DOI 10.1182/blood.V96.5.1873.h8001873_1873_1878
   Weitzmann MN, 2000, J CELL BIOCHEM, V78, P318, DOI 10.1002/(SICI)1097 4644(20000801)78:2<318::AID JCB13>3.0.CO;2 N
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328
   Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687
   Womack JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017217
   Wong PKK, 2006, ARTHRITIS RHEUM US, V54, P158, DOI 10.1002/art.21537
   Yadav A, 2009, VIROLOGY, V385, P126, DOI 10.1016/j.virol.2008.11.039
   Yamaguchi T, 2011, ENDOCR J
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yin MT, 2011, J INFECT DIS, V203, P1705, DOI 10.1093/infdis/jir184
   Young B, 2011, CLIN INFECT DIS, V52, P1061, DOI 10.1093/cid/ciq242
   Yun TJ, 1998, J IMMUNOL, V161, P6113
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211
NR 106
TC 69
Z9 74
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1548 3568
EI 1548 3576
J9 CURR HIV AIDS REP
JI Curr. Hiv/Aids Rep.
PD MAR
PY 2012
VL 9
IS 1
BP 16
EP 25
DI 10.1007/s11904 011 0099 z
PG 10
WC Infectious Diseases
WE Science Citation Index Expanded (SCI EXPANDED)
SC Infectious Diseases
GA V32TS
UT WOS:000208974100003
PM 22179898
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Hassan, MG
   Vargas, R
   Zhang, B
   Marcel, N
   Cox, TC
   Jheon, AH
AF Hassan, Mohamed G.
   Vargas, Ricardo
   Zhang, Bin
   Marcel, Noah
   Cox, Timothy C.
   Jheon, Andrew H.
TI Altering osteoclast numbers using CTSK models in utero affects mice
   offspring craniofacial morphology
SO ORTHODONTICS & CRANIOFACIAL RESEARCH
LA English
DT Article
DE bone; craniofacial abnormalities; craniofacial development; geometric
   morphometrics; malocclusion; mouse; osteoclast; skeletal
ID CATHEPSIN K; BONE RESORPTION; DIFFERENTIATION; OSTEOPOROSIS; DEFICIENCY;
   COMPONENTS
AB Background Bone remodelling during development and growth is important for craniofacial integrity of offspring. The aim of this study was to investigate the changes in offspring adult skull morphology when the osteoclasts number was altered in utero, using three dimensional (3D) geometric morphometric analysis (GMA). Materials and Methods We altered osteoclasts number in utero via two approaches. First, we generated heterozygous Ctsk(Cre);DTA(fl/+) (diphtheria toxin A) mice. Second, we altered Ctsk expression in vivo by injecting pregnant wild type dams at embryonic day (E) 12.5 with in vivo siRNA specific for Ctsk. Mice were collected at 6 weeks and analysed using geometric morphometric analysis via computed tomography, histomorphometry and gene expression analysis. Results Altering osteoclasts number in utero affected the offspring adult skull morphology. Decreased Ctsk and osteoclast numbers were associated with a decrease in cranial vault height and an increase in mandibular body length. Changes in size and shape were observed with an increased number of osteoclasts in Ctsk(Cre);DTA(fl/+) mice, including an increase in cranial vault height, as well as a shortening of mandibular body length and ramus height. Conclusion The findings of this study suggest that modulation of osteoclast numbers during pre  and post natal development may be a previously unknown factor in the aetiology of skeletal malocclusions. An improved understanding of the factors affecting bone homeostasis during development and growth may help in the development of future therapies that would target the early intervention of skeletal malocclusion.
C1 [Hassan, Mohamed G.] Assiut Univ, Fac Dent, Dept Orthodont, Assiut, Egypt.
   [Hassan, Mohamed G.; Zhang, Bin; Marcel, Noah; Jheon, Andrew H.] UCSF, Program Craniofacial Biol, San Francisco, CA USA.
   [Hassan, Mohamed G.] Washington Univ, Sch Med, Dept Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA.
   [Vargas, Ricardo; Jheon, Andrew H.] UCSF, Div Orthodont, San Francisco, CA USA.
   [Zhang, Bin] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Dept Oral & Maxillofacial Surg, Guangzhou, Guangdong, Peoples R China.
   [Zhang, Bin] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guangzhou, Guangdong, Peoples R China.
   [Cox, Timothy C.] Seattle Childrens Res Inst, Ctr Dev Biol & Regenerat Med, Seattle, WA USA.
   [Jheon, Andrew H.] UCSF, Div Craniofacial Anomalies, San Francisco, CA USA.
   [Cox, Timothy C.] Univ Missouri, Sch Dent, Dept Oral & Craniofacial Sci, Kansas City, MO USA.
C3 Egyptian Knowledge Bank (EKB); Assiut University; University of
   California System; University of California San Francisco; Washington
   University (WUSTL); University of California System; University of
   California San Francisco; Sun Yat Sen University; Sun Yat Sen
   University; Seattle Children's Hospital; University of California
   System; University of California San Francisco; University of Missouri
   System; University of Missouri Kansas City
RP Hassan, MG (通讯作者)，Washington Univ, Sch Med, Musculoskeletal Res Ctr, Div Bone & Mineral Dis,Dept Internal Med, St Louis, MO 63110 USA.
EM hmohamed@wustl.edu
RI Cox, Timothy/HRA 2573 2023; Zhang, Bin/AFA 2751 2022; Vargas,
   Ricardo/KVB 3842 2024; Hassan, Mohamed/AAL 9419 2020
OI Hassan, Mohamed/0000 0001 9208 3381; 
FU Fulbright Program; AMIDEAST; WUSTL Center of Regenerative Medicine; UCSF
   Clinical and Translational Science Institute (CTSI) Pilot Fund program
   [RAS A127552]
FX MGH was supported by the Fulbright Program and AMIDEAST. MGH is
   supported by the Rita Levi Montalcini Postdoctoral Fellowship award from
   WUSTL Center of Regenerative Medicine. AHJ was supported in part by the
   UCSF Clinical and Translational Science Institute (CTSI) Pilot Fund
   program (RAS A127552).
CR Alfaqeeh S, 2015, J DENT RES, V94, P1724, DOI 10.1177/0022034515608828
   Carlson DS, 2015, AM J ORTHOD DENTOFAC, V148, P922, DOI 10.1016/j.ajodo.2015.09.012
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Cheng JW, 2018, J CELL PHYSIOL, V233, P2502, DOI 10.1002/jcp.26126
   Chiu WSM, 2004, GENESIS, V39, P178, DOI 10.1002/gene.20041
   Dallas SL, 2018, CURR OSTEOPOROS REP, V16, P466, DOI 10.1007/s11914 018 0455 7
   DARROCH JN, 1985, BIOMETRIKA, V72, P241, DOI 10.2307/2336077
   Dash S, 2021, J DENT RES, V100, P406, DOI 10.1177/0022034520969109
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Dou C, 2016, J CELL PHYSIOL, V231, P558, DOI 10.1002/jcp.24916
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Ealba EL, 2015, DEV BIOL, V408, P151, DOI 10.1016/j.ydbio.2015.10.001
   FALSETTI AB, 1993, INT J PRIMATOL, V14, P551, DOI 10.1007/BF02215447
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   Hassan MG, 2022, AM J ORTHOD DENTOFAC, V161, pE446, DOI 10.1016/j.ajodo.2021.12.015
   Hassan MG, 2019, ORTHOD CRANIOFAC RES, V22, P113, DOI 10.1111/ocr.12269
   Hoy J.A., 2011, Wildlife Biology in Practice, V7, P15
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Jobke B, 2014, BONE, V59, P37, DOI 10.1016/j.bone.2013.10.024
   Kawasoko S, 2000, J CRAN GENET DEV BIO, V20, P76
   Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797
   Kiviranta R, 2005, BONE, V36, P159, DOI 10.1016/j.bone.2004.09.020
   Kiviranta R, 2001, J BONE MINER RES, V16, P1444, DOI 10.1359/jbmr.2001.16.8.1444
   Klingenberg CP, 2011, MOL ECOL RESOUR, V11, P353, DOI 10.1111/j.1755 0998.2010.02924.x
   Limaye A, 2012, PROC SPIE, V8506, DOI 10.1117/12.935640
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   MARKS SC, 1987, J ORAL PATHOL MED, V16, P164
   Moriwaki S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097177
   NAKASIMA A, 1982, AM J ORTHOD DENTOFAC, V82, P150, DOI 10.1016/0002 9416(82)90493 6
   Park KH, 2015, J DENT RES, V94, P1676, DOI 10.1177/0022034515604620
   Rohlf FJ, 1996, NATO ADV SCI INST SE, V284, P117
   Roth DM, 2021, HEAD NECK PATHOL, V15, P1, DOI 10.1007/s12105 021 01301 z
   Rowe P., 2022, StatPearls
   Schneider RA, 2003, SCIENCE, V299, P565, DOI 10.1126/science.1077827
   Slice DE, 2005, DEV PRIMATOL PROG PR, P1, DOI 10.1007/0 387 27614 9_1
   SMITS B, 1990, J WILDLIFE DIS, V26, P567, DOI 10.7589/0090 3558 26.4.567
   Troen BR, 2006, ANN NY ACAD SCI, V1068, P165, DOI 10.1196/annals.1346.018
   Tsukasaki M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 31592 x
   van Gijn DR, 2013, BRIT J ORAL MAX SURG, V51, P384, DOI 10.1016/j.bjoms.2012.09.008
   Wiley DF, 2005, IEEE VISUALIZATION 2005, PROCEEDINGS, P431
   Wu S, 2006, DEVELOPMENT, V133, P581, DOI 10.1242/dev.02236
NR 43
TC 3
Z9 4
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1601 6335
EI 1601 6343
J9 ORTHOD CRANIOFAC RES
JI Orthod. Craniofac. Res.
PD AUG
PY 2023
VL 26
IS 3
BP 338
EP 348
DI 10.1111/ocr.12614
EA OCT 2022
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA L2ET2
UT WOS:000875834200001
PM 36245435
DA 2025 08 17
ER

PT J
AU Wang, MW
   Yang, Z
   Chen, X
   Zhou, SH
   Huang, GL
   Sun, JN
   Jiang, H
   Xu, WM
   Lin, HC
   Yu, X
   Sun, JP
AF Wang, Ming Wei
   Yang, Zhao
   Chen, Xu
   Zhou, Shu Hua
   Huang, Ge Lin
   Sun, Jian Ning
   Jiang, Hui
   Xu, Wen Ming
   Lin, Hao Cheng
   Yu, Xiao
   Sun, Jin Peng
TI Activation of PTH1R alleviates epididymitis and orchitis through Gq and
   β arrestin 1 pathways
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE PTH1R; epididymitis; orchitis; mumps virus; abaloparatide
ID PROTEIN COUPLED RECEPTORS; STRESS RESPONSE PATHWAY; ANTIVIRAL RESPONSES;
   MALE INFERTILITY; ZIKA VIRUS; INSIGHTS; INHIBITION; MECHANISMS;
   INFECTION; DYNAMICS
AB Inflammation in the epididymis and testis contributes significantly to male infertility. Alternative therapeutic avenues treating epididymitis and orchitis are expected since current therapies using antibiotics have limitations associated to side effects and are commonly ineffective for inflammation due to nonbacterial causes. Here, we demonstrated that type 1 parathyroid hormone receptor (PTH1R) and its endogenous agonists, parathyroid hormone (PTH) and PTH related protein (PTHrP), were mainly expressed in the Leydig cells of testis as well as epididymal epithelial cells. Screening the secretin family G protein coupled receptor identified that PTH1R in the epididymis and testis was down regulated in mumps virus (MuV)  or lipopolysaccharide (LPS) induced inflammation. Remarkably, activation of PTH1R by abaloparatide (ABL), a Food and Drug Administration approved treatment for postmenopausal osteoporosis, alleviated MuV  or LPS induced inflammatory responses in both testis and epididymis and significantly improved sperm functions in both mouse model and human samples. The anti inflammatory effects of ABL were shown to be regulated mainly through the Gq and beta arrestin 1 pathway downstream of PTH1R as supported by the application of ABL in Gnaq(+/ ) and Arrb(1 / ) mouse models. Taken together, our results identified an important immunoregulatory role for PTH1R signaling in the epididymis and testis. Targeting to PTH1R might have a therapeutic effect for the treatment of epididymitis and orchitis or other inflammatory disease in the male reproductive system.
C1 [Wang, Ming Wei; Yang, Zhao; Sun, Jin Peng] Shandong Univ, Key Lab Expt Teratol Minist Educ, Sch Basic Med Sci, Cheeloo Coll Med, Jinan 250012, Shandong, Peoples R China.
   [Wang, Ming Wei; Yang, Zhao; Chen, Xu; Zhou, Shu Hua; Sun, Jian Ning; Jiang, Hui; Yu, Xiao; Sun, Jin Peng] Shandong Univ, Dept Biochem & Mol Biol, Sch Basic Med Sci, Cheeloo Coll Med, Jinan 250012, Shandong, Peoples R China.
   [Chen, Xu; Zhou, Shu Hua; Sun, Jian Ning; Jiang, Hui; Yu, Xiao] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Physiol, Jinan 250012, Shandong, Peoples R China.
   [Huang, Ge Lin; Xu, Wen Ming] Sichuan Univ, Dept Obstet Gynecol, Joint Lab Reprod Med,West China Univ Hosp 2, Key Lab Obstetr Gynecol & Pediat Dis & Birth Defe, Chengdu 610041, Peoples R China.
   [Lin, Hao Cheng] Peking Univ, Dept Urol, Hosp 3, Beijing 100191, Peoples R China.
   [Sun, Jin Peng] Peking Univ, Key Lab Mol Cardiovasc Sci, Minist Educ, Beijing 100091, Peoples R China.
C3 Shandong University; Shandong University; Shandong University; Sichuan
   University; Peking University; Peking University
RP Sun, JP (通讯作者)，Shandong Univ, Key Lab Expt Teratol Minist Educ, Sch Basic Med Sci, Cheeloo Coll Med, Jinan 250012, Shandong, Peoples R China.; Yu, X; Sun, JP (通讯作者)，Shandong Univ, Dept Biochem & Mol Biol, Sch Basic Med Sci, Cheeloo Coll Med, Jinan 250012, Shandong, Peoples R China.; Yu, X (通讯作者)，Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Physiol, Jinan 250012, Shandong, Peoples R China.; Xu, WM (通讯作者)，Sichuan Univ, Dept Obstet Gynecol, Joint Lab Reprod Med,West China Univ Hosp 2, Key Lab Obstetr Gynecol & Pediat Dis & Birth Defe, Chengdu 610041, Peoples R China.; Lin, HC (通讯作者)，Peking Univ, Dept Urol, Hosp 3, Beijing 100191, Peoples R China.; Sun, JP (通讯作者)，Peking Univ, Key Lab Mol Cardiovasc Sci, Minist Educ, Beijing 100091, Peoples R China.
EM xuwenming@scu.edu.cn; haochenglin292@163.com; yuxiao@sdu.edu.cn;
   sunjinpeng@sdu.edu.cn
RI Yang, Xiaofan/L 6472 2015; sun, Jinpeng/AAR 9196 2020; jiang,
   hui/KYP 5273 2024; wang, shuqi/D 4751 2019
OI Wang, Mingwei/0000 0001 6022 6683; Huang, Gelin/0000 0002 0990 1900;
   chen, xu/0000 0002 5620 7612; Yang, Zhao/0000 0001 6948 1912; Sun,
   Jian Ning/0000 0001 8214 3002
FU National Key Basic Research Program of China [2018YFC1003600]; National
   Natural Science Foundation of China [32130055, 31701230, 81873614,
   81601272]; National Key Research and Development Program of China
   [2019YFA0904200]; Major Fundamental Research Program of the Natural
   Science Foundation of Shandong Province, China [ZR2020ZD39]; Key
   Research Project of the Natural Science Foundation of Beijing, China
   [Z20J00129]; National Science Fund for Distinguished Young Scholars
   Grant [81825022]; National Science Fund for Excellent Young Scholars
   Grant [81822008]; COVID 19 Emergency Tackling Research Program of
   Shandong University [2020XGB02]; Clinical Medicine PlusX Young Scholars
   Project of Peking University [2102018237]; Shandong Provincial Natural
   Science Foundation [ZR2019MH041]; Shandong Provincial Natural Science
   Foundation Youth Fund of China [ZR2020QH057]
FX We thank Ying Guan and Jun Yan Wang for assistance in data analysis and
   interpretation. We thank Hui Lin, Wen Tao An, and Chuan Shun Ma for
   technical assistance in the treatment of testis and epididymis with
   siRNA in mice. We acknowledge support from the National Key Basic
   Research Program of China Grant 2018YFC1003600 (to J. P.S., X.Y.,
   H. C.L., and W. M.X), the National Natural Science Foundation of China
   (32130055 to J. P.S., 31701230 to Z.Y., 81873614 to Z. Y.W., and
   81601272 to H. C.L.), the National Key Research and Development Program
   of China (2019YFA0904200 to J. P.S.), the Major Fundamental Research
   Program of the Natural Science Foundation of Shandong Province, China
   (ZR2020ZD39 to J. P.S.), the Key Research Project of the Natural Science
   Foundation of Beijing, China (Z20J00129 to J. P.S.), the National
   Science Fund for Distinguished Young Scholars Grant 81825022 (to
   J. P.S.), the National Science Fund for Excellent Young Scholars Grant
   81822008 (to X.Y.), the COVID 19 Emergency Tackling Research Program of
   Shandong University (2020XGB02 to J. P.S.), Clinical Medicine
   PlusX Young Scholars Project of Peking University (2102018237 to
   H. C.L.), Shandong Provincial Natural Science Foundation (ZR2019MH041 to
   Z. Y.W), and Shandong Provincial Natural Science Foundation Youth Fund
   of China Grant (ZR2020QH057 to Wen Tao An.).
CR Archbold JK, 2011, TRENDS PHARMACOL SCI, V32, P591, DOI 10.1016/j.tips.2011.05.007
   Ardura JA, 2019, TRENDS ENDOCRIN MET, V30, P756, DOI 10.1016/j.tem.2019.07.014
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cheloha RW, 2015, NAT REV ENDOCRINOL, V11, P712, DOI 10.1038/nrendo.2015.139
   Dong JH, 2017, BIOL PSYCHIAT, V81, P654, DOI 10.1016/j.biopsych.2016.09.025
   Fang W, 2018, J AM SOC NEPHROL, V29, P1475, DOI 10.1681/ASN.2017080932
   Fijak M, 2018, HUM REPROD UPDATE, V24, P416, DOI 10.1093/humupd/dmy009
   Flegel C, 2016, SCI REP UK, V6, DOI 10.1038/srep32255
   Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256
   Gardella TJ, 2015, PHARMACOL REV, V67, P310, DOI 10.1124/pr.114.009464
   Hambleton M, 2006, CIRCULATION, V114, P574, DOI 10.1161/CIRCULATIONAHA.105.592550
   Han Z, 2000, CELL DEATH DIFFER, V7, P521, DOI 10.1038/sj.cdd.4400681
   Hohenegger M, 1998, P NATL ACAD SCI USA, V95, P346, DOI 10.1073/pnas.95.1.346
   Hollenstein K, 2014, TRENDS PHARMACOL SCI, V35, P12, DOI 10.1016/j.tips.2013.11.001
   Kir S, 2014, NATURE, V513, P100, DOI 10.1038/nature13528
   Krausz C, 2018, NAT REV UROL, V15, P369, DOI 10.1038/s41585 018 0003 3
   Lagerström MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   Le Tortorec A, 2008, HUM REPROD, V23, P2095, DOI 10.1093/humrep/den207
   Liu CH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14335
   Ma WQ, 2016, CELL, V167, P1511, DOI 10.1016/j.cell.2016.11.016
   Machlus KR, 2016, BLOOD, V127, P1468, DOI [10.1182/blood 2015 08663146, 10.1182/blood 2015 08 663146]
   Meinhardt A, 2017, NAT REV UROL, V14, P135, DOI 10.1038/nrurol.2016.265
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Nagai S, 2011, J BIOL CHEM, V286, P1618, DOI 10.1074/jbc.M110.198416
   Olesen IA, 2017, FERTIL STERIL, V107, P74, DOI 10.1016/j.fertnstert.2016.09.015
   Ping YQ, 2021, NATURE, V589, P620, DOI 10.1038/s41586 020 03083 w
   Punab M, 2017, HUM REPROD, V32, P18, DOI 10.1093/humrep/dew284
   Sampson ER, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002214
   Shiota M, 2014, CLIN CANCER RES, V20, P951, DOI 10.1158/1078 0432.CCR 13 1809
   Simpson E, 2006, IMMUNOL REV, V213, P12, DOI 10.1111/j.1600 065X.2006.00434.x
   Siuda ER, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9480
   Sokolova O, 2013, GUT, V62, P358, DOI 10.1136/gutjnl 2012 302103
   Spehr M, 2003, SCIENCE, V299, P2054, DOI 10.1126/science.1080376
   Srivastava A, 2015, TRENDS ENDOCRIN MET, V26, P628, DOI 10.1016/j.tem.2015.09.001
   Wang HM, 2014, DIABETOLOGIA, V57, P1899, DOI 10.1007/s00125 014 3290 0
   Watkins HA, 2012, DRUG DISCOV TODAY, V17, P1006, DOI 10.1016/j.drudis.2012.05.005
   Weinman EJ, 2011, AM J PHYSIOL RENAL, V300, pF231, DOI 10.1152/ajprenal.00532.2010
   Wootten D, 2018, NAT REV MOL CELL BIO, V19, P638, DOI 10.1038/s41580 018 0049 3
   Wu H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00117
   Wu H, 2016, SCI REP UK, V6, DOI 10.1038/srep19507
   Xiong XF, 2016, NAT CHEM, V8, P1035, DOI [10.1038/NCHEM.2577, 10.1038/nchem.2577]
   Yang D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
   Yang F, 2018, NAT CHEM BIOL, V14, P876, DOI 10.1038/s41589 018 0115 3
   Yang F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9202
   Yang YM, 2019, BIOCHEM BIOPH RES CO, V509, P960, DOI 10.1016/j.bbrc.2019.01.049
   Zhang DL, 2018, ELIFE, V7, DOI 10.7554/eLife.33432
   Zhang DL, 2020, BRIT J PHARMACOL, V177, P5489, DOI 10.1111/bph.15252
   Zhang H, 2020, MED RES REV, V40, P135, DOI 10.1002/med.21598
   Zhao LH, 2019, SCIENCE, V364, P148, DOI 10.1126/science.aav7942
   Zhao S, 2020, BIOORG CHEM, V96, DOI 10.1016/j.bioorg.2020.103596
   Zhao ST, 2014, CELL MOL IMMUNOL, V11, P428, DOI 10.1038/cmi.2014.38
   Zhu WW, 2015, J IMMUNOL, V194, P4825, DOI 10.4049/jimmunol.1402706
NR 53
TC 14
Z9 14
U1 3
U2 39
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 9
PY 2021
VL 118
IS 45
AR e2107363118
DI 10.1073/pnas.2107363118
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA XA8ZI
UT WOS:000720928400013
PM 34740971
DA 2025 08 17
ER

PT J
AU Kondo, T
   Aoki, H
   Otsuka, Y
   Kawaguchi, Y
   Waguri Nagaya, Y
   Aoyama, M
AF Kondo, Takao
   Aoki, Hiromasa
   Otsuka, Yuto
   Kawaguchi, Yohei
   Waguri Nagaya, Yuko
   Aoyama, Mineyoshi
TI Insulin like growth factor 2 promotes osteoclastogenesis increasing
   inflammatory cytokine levels under hypoxia
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Osteoclast; Hypoxia; IGF2; Akt; NF kappa B
ID NF KAPPA B; BONE RESORPTION; FACTOR RECEPTOR; DIFFERENTIATION; PATHWAY;
   IGF2; AKT; PROLIFERATION; MODULATION; EXPRESSION
AB Osteoporosis is caused by an imbalance in bone remodeling due to abnormal osteoclast (OC) formation and activation. Hypoxia at the site of inflammation promotes OC formation and activation in various species, including humans. We previously reported that insulin like growth factor 2 (IGF2) plays an important role in osteoclastogenesis under hypoxia. In our present study, we focused on the mechanism of osteoclastogenesis in regard to IGF2 signaling under hypoxia. We confirmed that the addition of IGF2 promoted osteoclastogenesis under normoxic conditions. Conversely, IGF2 neutralizing antibodies inhibited osteoclastogenesis under both normoxic and hypoxic conditions. IGF2 addition increased levels of phosphorylated Akt (Thr308 and Ser473) and NF kappa B (Ser536), indicating activation of the Akt NF kappa B pathway. IGF2 also increased the expression of inducible nitric oxide synthase, which promotes osteoclastogenesis via nitric oxide production. Expression levels of genes encoding inflammatory cytokines, such as tumor necrosis factor alpha, interleukin (IL) 1 beta, and IL 6, were upregulated, indicating that IGF2 promotes osteoclastogenesis by increasing the expression of inflammatory cytokines via activation of the Akt NF kappa B pathway. These results suggest that IGF2 is a promising therapeutic target for osteoporosis and rheumatoid arthritis. (C) 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
C1 [Kondo, Takao; Aoki, Hiromasa; Otsuka, Yuto; Aoyama, Mineyoshi] Nagoya City Univ, Dept Pathobiol, Grad Sch Pharmaceut Sci, Nagoya, Aichi 4678603, Japan.
   [Kawaguchi, Yohei] Nagoya City Univ, Dept Glial Cell Biol, Grad Sch Med Sci, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.
   [Kawaguchi, Yohei; Waguri Nagaya, Yuko] Nagoya City Univ, Dept Orthopaed Surg, Grad Sch Med Sci, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.
C3 Nagoya City University; Nagoya City University; Nagoya City University
RP Aoyama, M (通讯作者)，Nagoya City Univ, Dept Pathobiol, Grad Sch Pharmaceut Sci, 3 1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.
EM aomine@phar.nagoya cu.ac.jp
OI Aoyama, Mineyoshi/0000 0002 9976 6465
FU Grants in Aid for Scientific Research [20K22715, 20K09465, 20K08211,
   21K16403] Funding Source: KAKEN
CR Abeyrathna P, 2015, VASC PHARMACOL, V74, P38, DOI 10.1016/j.vph.2015.05.008
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Bergman D, 2013, GERONTOLOGY, V59, P240, DOI 10.1159/000343995
   Boone David N., 2012, Critical Reviews in Oncogenesis, V17, P161
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen HX, 2013, CHIN J CANCER, V32, P242, DOI 10.5732/cjc.012.10263
   Eshak ES, 2019, J EPIDEMIOL, V29, P104, DOI 10.2188/jea.JE20170123
   Fukuoka H, 2005, BIOCHEM BIOPH RES CO, V328, P885, DOI 10.1016/j.bbrc.2005.01.042
   Gaber T, 2005, ANN RHEUM DIS, V64, P971, DOI 10.1136/ard.2004.031641
   Goto Y, 2016, STEM CELLS, V34, P2733, DOI 10.1002/stem.2440
   Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004
   Jeong DH, 2020, J NAT PROD, V83, P1174, DOI 10.1021/acs.jnatprod.9b01212
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Knowles HJ, 2015, HYPOXIA, V3, P73, DOI 10.2147/HP.S95960
   Knowles HJ, 2009, J PATHOL, V218, P256, DOI 10.1002/path.2534
   Kodama J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165685
   Kondo T, 2021, AM J PATHOL, V191, P2072, DOI 10.1016/j.ajpath.2021.08.014
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Liu W, 2005, J BIOL CHEM, V280, P43064, DOI 10.1074/jbc.M509006200
   Livingstone C, 2013, ENDOCR RELAT CANCER, V20, pR321, DOI 10.1530/ERC 13 0231
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Maridas DE, 2018, JOVE J VIS EXP, DOI 10.3791/56750
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007
   Muzylak M, 2006, CALCIFIED TISSUE INT, V79, P301, DOI 10.1007/s00223 006 0082 7
   Nakao K, 2009, BIOCHEM BIOPH RES CO, V378, P462, DOI 10.1016/j.bbrc.2008.11.083
   Nomura T, 2014, EXP CELL RES, V321, P167, DOI 10.1016/j.yexcr.2013.11.020
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Oussaief L, 2011, J VIROL, V85, P6502, DOI 10.1128/JVI.02560 10
   Rajpathak SN, 2009, DIABETES METAB RES, V25, P3, DOI 10.1002/dmrr.919
   Shiratori T, 2018, J IMMUNOL, V200, P218, DOI 10.4049/jimmunol.1602035
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Yokota K, 2014, ARTHRITIS RHEUMATOL, V66, P121, DOI 10.1002/art.38218
   Yu JSL, 2016, DEVELOPMENT, V143, P3050, DOI 10.1242/dev.137075
   Zhang F, 2020, J HARD TISSUE BIOL, V29, P99, DOI 10.2485/jhtb.29.99
NR 41
TC 10
Z9 11
U1 0
U2 10
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD JUL
PY 2022
VL 149
IS 3
BP 93
EP 99
DI 10.1016/j.jphs.2022.03.007
EA MAY 2022
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 1W4ZK
UT WOS:000806783300004
PM 35641033
OA gold
DA 2025 08 17
ER

PT J
AU Brommage, R
   Liu, J
   Hansen, GM
   Kirkpatrick, LL
   Potter, DG
   Sands, AT
   Zambrowicz, B
   Powell, DR
   Vogel, P
AF Brommage, Robert
   Liu, Jeff
   Hansen, Gwenn M.
   Kirkpatrick, Laura L.
   Potter, David G.
   Sands, Arthur T.
   Zambrowicz, Brian
   Powell, David R.
   Vogel, Peter
TI High throughput screening of mouse gene knockouts identifies established
   and novel skeletal phenotypes
SO BONE RESEARCH
LA English
DT Article
ID FRIZZLED RELATED PROTEIN 1; TRYPTOPHAN HYDROXYLASE INHIBITORS; CONTROLS
   CHONDROCYTE HYPERTROPHY; SPHINGOSINE 1 PHOSPHATE LYASE; GENETICALLY
   MANIPULATED MICE; CONTROLS BONE FORMATION; ZINC TRANSPORTER GENE;
   VITAMIN D RECEPTOR; PARATHYROID HORMONE; TARGETED DISRUPTION
AB Screening gene function in vivo is a powerful approach to discover novel drug targets. We present high throughput screening (HTS) data for 3762 distinct global gene knockout (KO) mouse lines with viable adult homozygous mice generated using either gene trap or homologous recombination technologies. Bone mass was determined from DEXA scans of male and female mice at 14 weeks of age and by microCT analyses of bones from male mice at 16 weeks of age. Wild type (WT) cagemates/littermates were examined for each gene KO. Lethality was observed in an additional 850 KO lines. Since primary HTS are susceptible to false positive findings, additional cohorts of mice from KO lines with intriguing HTS bone data were examined. Aging, ovariectomy, histomorphometry and bone strength studies were performed and possible non skeletal phenotypes were explored. Together, these screens identified multiple genes affecting bone mass: 23 previously reported genes (Calcr, Cebpb, Crtap, Dcstamp, Dkk1, Duoxa2, Enpp1, Fgf23, Kiss1/Kiss1r, Kl (Klotho), Lrp5, Mstn, Neo1, Npr2, Ostm1, Postn, Sfrp4, Slc30a5, Slc39a13, Sost, Sumf1, Src, Wnt10b), five novel genes extensively characterized (Cldn18, Fam20c, Lrrk1, Sgpl1, Wnt16), five novel genes with preliminary characterization (Agpat2, Rassf5, Slc10a7, Slc26a7, Slc30a10) and three novel undisclosed genes coding for potential osteoporosis drug targets.
C1 [Brommage, Robert; Liu, Jeff; Hansen, Gwenn M.; Kirkpatrick, Laura L.; Potter, David G.; Sands, Arthur T.; Zambrowicz, Brian; Powell, David R.; Vogel, Peter] Lexicon Pharmaceut, The Woodlands, TX 77381 USA.
C3 Lexicon Pharmaceuticals
RP Brommage, R (通讯作者)，Lexicon Pharmaceut, The Woodlands, TX 77381 USA.
EM brommage@outlook.com
RI Brommage, Robert/J 5670 2019; Vogel, Peter/N 2490 2018
OI Hansen, Gwenn/0000 0003 2504 5849; Vogel, Peter/0000 0002 7535 0545
CR Abuin A, 2007, Handb Exp Pharmacol, P129
   Adams D, 2013, DIS MODEL MECH, V6, P571, DOI 10.1242/dmm.011833
   Adissu HA, 2014, DIS MODEL MECH, V7, P515, DOI 10.1242/dmm.015263
   Agalliu D, 2009, NEURON, V61, P708, DOI 10.1016/j.neuron.2008.12.026
   Ahn Y, 2010, DEVELOPMENT, V137, P3221, DOI 10.1242/dev.054668
   Akhter S, 2007, ARCH BIOCHEM BIOPHYS, V460, P227, DOI 10.1016/j.abb.2006.12.005
   Alam I, 2014, BONE, V59, P66, DOI 10.1016/j.bone.2013.10.021
   ALDOURI SMJ, 1987, J ANAT, V153, P139
   Alshbool FZ, 2014, PHYSIOL REP, V2, DOI 10.1002/phy2.200
   Anderson JM, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002584
   [Anonymous], 2012, G3 GENES GENOM GENET, V2, P1415, DOI DOI 10.1534/G3.112.003830
   Arantes HP, 2011, J BONE MINER RES, V26, P2823, DOI 10.1002/jbmr.530
   Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004
   Atasoy D, 2007, P NATL ACAD SCI USA, V104, P2525, DOI 10.1073/pnas.0611003104
   Austin CP, 2004, NAT GENET, V36, P921, DOI 10.1038/ng0904 921
   Ayadi A, 2012, MAMM GENOME, V23, P600, DOI 10.1007/s00335 012 9418 y
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Babij P, 2009, J BONE MINER RES, V24, P1552, DOI [10.1359/jbmr.090417, 10.1359/JBMR.090417]
   Bagdanoff JT, 2010, J MED CHEM, V53, P8650, DOI 10.1021/jm101183p
   Bagdanoff JT, 2009, J MED CHEM, V52, P3941, DOI 10.1021/jm900278w
   Baker Lepain Julie C, 2012, Arthritis Rheum, V64, P1457, DOI 10.1002/art.34526
   Baldridge D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010560
   Baptista MAS, 2013, DIS MODEL MECH, V6, P1316, DOI 10.1242/dmm.011940
   Barbaric Ivana, 2007, Briefings in Functional Genomics & Proteomics, V6, P91, DOI 10.1093/bfgp/elm008
   Barrantes ID, 2006, MOL CELL BIOL, V26, P2317, DOI 10.1128/MCB.26.6.2317 2326.2006
   Barros NMT, 2013, J BONE MINER RES, V28, P688, DOI 10.1002/jbmr.1766
   Bartels CF, 2004, AM J HUM GENET, V75, P27, DOI 10.1086/422013
   Bassett JHD, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002858
   Beamer WG, 2000, BONE, V27, P619, DOI 10.1016/S8756 3282(00)00369 0
   Beckers J, 2009, NAT REV GENET, V10, P371, DOI 10.1038/nrg2578
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bhattacharyya N, 2012, TRENDS ENDOCRIN MET, V23, P610, DOI 10.1016/j.tem.2012.07.002
   Blangy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045909
   Bodine PVN, 2007, J CELL PHYSIOL, V210, P352, DOI 10.1002/jcp.20834
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Bonnet N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078347
   Bonnet N, 2009, J BIOL CHEM, V284, P35939, DOI 10.1074/jbc.M109.060335
   Booth FW, 2009, J PHYSIOL LONDON, V587, P5527, DOI 10.1113/jphysiol.2009.179507
   Boskey AL, 2003, J BONE MINER RES, V18, P1005, DOI 10.1359/jbmr.2003.18.6.1005
   Boskey AL, 2003, J ORTHOPAED RES, V21, P1, DOI 10.1016/S0736 0266(02)00102 X
   Boskey AL, 2002, CALCIFIED TISSUE INT, V71, P145, DOI 10.1007/s00223 001 1121 z
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Bradley A, 2012, MAMM GENOME, V23, P580, DOI 10.1007/s00335 012 9422 2
   Bradshaw AD, 2003, P NATL ACAD SCI USA, V100, P6045, DOI 10.1073/pnas.1030790100
   BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960 9822(95)00127 8
   Brommage R, 2007, BONE, V40, pS187
   Brommage R, 2004, J BONE MINER RES, V19, pS92
   Brommage R, 2003, AM J PHYSIOL ENDOC M, V285, pE454, DOI 10.1152/ajpendo.00470.2002
   Brommage R, 2014, F1000POSTERS, V5, P1029
   Brommage R, 2013, J BONE MINER RES  S1, V28, pS347
   Brommage R., 2006, J MUSCULOSKELET NEUR, V6, P392
   Brommage R, 2010, J BONE MINER RES S1, V25, pS81
   Brommage R, 2009, J BONE MINER RES  S1, V24, pS82
   Brommage R, 2008, OBESITY, V16, P2362, DOI 10.1038/oby.2008.361
   Brown MJ, 2006, ILAR J, V47, P118, DOI 10.1093/ilar.47.2.118
   Brown PM, 2011, GASTROENTEROLOGY, V141, P507, DOI 10.1053/j.gastro.2011.05.005
   Brown SDM, 2012, MAMM GENOME, V23, P632, DOI 10.1007/s00335 012 9427 x
   Canalis E, 2012, J CELL PHYSIOL, V227, P269, DOI 10.1002/jcp.22730
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842
   Chen JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085161, 10.1371/journal.pone.0101277]
   Cheung CL, 2013, J CLIN ENDOCR METAB, V98, pE1557, DOI 10.1210/jc.2013 1983
   Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098
   Cianchetta Giovanni, 2010, Curr Chem Genomics, V4, P19, DOI 10.2174/1875397301004010019
   Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003
   Colledge WH, 2009, PEPTIDES, V30, P34, DOI 10.1016/j.peptides.2008.05.006
   Collette NM, 2013, DEV BIOL, V383, P90, DOI 10.1016/j.ydbio.2013.08.015
   Collins FS, 2007, CELL, V129, P235, DOI 10.1016/j.cell.2007.04.007
   Collins FS, 2007, CELL, V128, P9, DOI 10.1016/j.cell.2006.12.018
   Collins FS, 2014, NATURE, V505, P612, DOI 10.1038/505612a
   Contié S, 2010, CALCIFIED TISSUE INT, V87, P341, DOI 10.1007/s00223 010 9391 y
   Cortés VA, 2009, CELL METAB, V9, P165, DOI 10.1016/j.cmet.2009.01.002
   Cox S, 2006, MOL REPROD DEV, V73, P1008, DOI 10.1002/mrd.20507
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Dacquin R, 2004, J CELL BIOL, V164, P509, DOI 10.1083/jcb.200312135
   Dai JL, 2000, J CLIN INVEST, V106, P887, DOI 10.1172/JCI10483
   Dauphinee SM, 2013, G3 GENES GENOM GENET, V3, P1753, DOI 10.1534/g3.113.007310
   Davey RA, 2008, J BONE MINER RES, V23, P1182, DOI [10.1359/jbmr.080310, 10.1359/JBMR.080310]
   Del Fattore A, 2014, OSTEOPOROSIS INT, V25, P681, DOI 10.1007/s00198 013 2479 2
   Del Fattore A, 2008, J BONE MINER RES, V23, P380, DOI 10.1359/JBMR.071107
   Delany AM, 2000, J CLIN INVEST, V105, P1325, DOI 10.1172/JCI7039C1
   Demay MB, 2007, J STEROID BIOCHEM, V103, P344, DOI 10.1016/j.jsbmb.2006.12.036
   DeWitt MR, 2013, BIOCHEM BIOPH RES CO, V432, P1, DOI 10.1016/j.bbrc.2013.01.058
   Doetschman Thomas, 2009, V530, P423, DOI 10.1007/978 1 59745 471 1_23
   Donahue LR, 2012, MAMM GENOME, V23, P559, DOI 10.1007/s00335 012 9420 4
   Donkó A, 2010, FREE RADICAL BIO MED, V49, P2040, DOI 10.1016/j.freeradbiomed.2010.09.027
   DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482
   Elkasrawy MN, 2010, J MUSCULOSKEL NEURON, V10, P56
   Ellies DL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096257
   Ellwanger K, 2008, MOL CELL BIOL, V28, P4875, DOI 10.1128/MCB.00222 08
   Everett LA, 2001, HUM MOL GENET, V10, P153, DOI 10.1093/hmg/10.2.153
   Fan W, 2011, J BONE MINER RES  S1, V26, pS117
   Feldmann HM, 2009, CELL METAB, V9, P203, DOI 10.1016/j.cmet.2008.12.014
   Foster BL, 2014, J DENT RES, V93, P7, DOI 10.1177/0022034514529150
   Freeman HC, 2006, DIABETES, V55, P2153, DOI 10.2337/db06 0358
   Friddle CJ, 2003, COLD SPRING HARB SYM, V68, P311, DOI 10.1101/sqb.2003.68.311
   Fuchs H., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P13
   Fuchs H, 2012, MAMM GENOME, V23, P611, DOI 10.1007/s00335 012 9415 1
   Fukada T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003642
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gabbay KH, 2010, J BIOL CHEM, V285, P19510, DOI 10.1074/jbc.M110.110247
   Gage PJ, 2008, DEV BIOL, V317, P310, DOI 10.1016/j.ydbio.2008.02.030
   Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101
   Gauger KJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078320
   Gazzerro E, 2007, J BIOL CHEM, V282, P31549, DOI 10.1074/jbc.M701317200
   Gelfman CM, 2007, INVEST OPHTH VIS SCI, V48, P5221, DOI 10.1167/iovs.07 0452
   Georgi B, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003484
   Giaever G, 2014, GENETICS, V197, P451, DOI 10.1534/genetics.114.161620
   Gilmour DT, 1998, EMBO J, V17, P1860, DOI 10.1093/emboj/17.7.1860
   Giunta C, 2008, AM J HUM GENET, V82, P1290, DOI 10.1016/j.ajhg.2008.05.001
   Glantschnig H, 2011, J PHARMACOL EXP THER, V338, P568, DOI 10.1124/jpet.111.181404
   Glantschnig H, 2010, J BIOL CHEM, V285, P40135, DOI 10.1074/jbc.M110.166892
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Grasberger H, 2012, MOL ENDOCRINOL, V26, P481, DOI 10.1210/me.2011 1320
   Grey A, 1999, ENDOCRINOLOGY, V140, P4683, DOI 10.1210/en.140.10.4683
   Grimm D, 2006, SCIENCE, V312, P1862, DOI 10.1126/science.312.5782.1862
   Gruber HE, 2005, J HISTOCHEM CYTOCHEM, V53, P1131, DOI 10.1369/jhc.5A6687.2005
   Hamrick MW, 2006, J BONE MINER RES, V21, P477, DOI 10.1359/JBMR.051203
   Hansen GM, 2008, GENOME RES, V18, P1670, DOI 10.1101/gr.078352.108
   Harmey D, 2006, J BONE MINER RES, V21, P1377, DOI 10.1359/JBMR.060619
   Hayashi D, 2012, GASTROENTEROLOGY, V142, P292, DOI 10.1053/j.gastro.2011.10.040
   Heffner CS, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2186
   Hla T, 2012, CELL METAB, V16, P420, DOI 10.1016/j.cmet.2012.06.017
   Hofmann WE, 2001, J BIOL CHEM, V276, P12460, DOI 10.1074/jbc.M100466200
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   Inoue K, 2002, HUM MOL GENET, V11, P1775, DOI 10.1093/hmg/11.15.1775
   Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399
   Ishikawa HO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042988
   Iwaniec UT, 2007, J BONE MINER RES, V22, P394, DOI 10.1359/JBMR.061118
   Jansen IDC, 2009, FASEB J, V23, P3470, DOI 10.1096/fj.08 122598
   Jeon J, 2011, J BIOL CHEM, V286, P27206, DOI 10.1074/jbc.M111.218065
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Jin HH, 2009, BIOORG MED CHEM LETT, V19, P5229, DOI 10.1016/j.bmcl.2009.07.005
   Joesting MS, 2008, DEV BIOL, V317, P161, DOI 10.1016/j.ydbio.2008.02.021
   Johnson KR, 2007, MOL ENDOCRINOL, V21, P1593, DOI 10.1210/me.2007 0085
   Justice MJ, 2008, DIS MODEL MECH, V1, P109, DOI 10.1242/dmm.001057
   Kambe T, 2008, AM J PHYSIOL REG I, V294, pR1474, DOI 10.1152/ajpregu.00130.2008
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kao R, 2010, J BONE MINER RES  S1, V25, pS425
   Kassai Y, 2005, SCIENCE, V309, P2067, DOI 10.1126/science.1116848
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   KAWAI T, 1992, J BIOL CHEM, V267, P21973
   Kawano T, 2013, BONE, V52, P70, DOI 10.1016/j.bone.2012.09.024
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Ke JY, 2013, GENE DEV, V27, P2305, DOI 10.1101/gad.228544.113
   Keane TM, 2011, NATURE, V477, P289, DOI 10.1038/nature10413
   Kesavan C, 2013, J BONE MINER RES  S1, V28, pS100
   Kettleborough RNW, 2013, NATURE, V496, P494, DOI 10.1038/nature11992
   Khadeer MA, 2005, BONE, V37, P296, DOI 10.1016/j.bone.2005.04.035
   Kim BJ, 2012, J CLIN ENDOCR METAB, V97, P3807, DOI 10.1210/jc.2012 2346
   Kim JS, 2007, J BIOL CHEM, V282, P29359, DOI 10.1074/jbc.M700965200
   Kim KX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097191
   Kimble RB, 1997, J BONE MINER RES, V12, P935, DOI 10.1359/jbmr.1997.12.6.935
   Kitsios GD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013782
   Kollmann K, 2013, EMBO MOL MED, V5, P1871, DOI 10.1002/emmm.201302979
   Kondo E, 2012, CALCIFIED TISSUE INT, V90, P307, DOI 10.1007/s00223 011 9567 0
   Kondo Y, 2006, P NATL ACAD SCI USA, V103, P5723, DOI 10.1073/pnas.0511225103
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Koscielny G, 2014, NUCLEIC ACIDS RES, V42, pD802, DOI 10.1093/nar/gkt977
   Koshizuka Y, 2001, CYTOGENET CELL GENET, V94, P163, DOI 10.1159/000048809
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Kubota T, 2008, J BONE MINER RES, V23, P1661, DOI 10.1359/JBMR.080512
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Kutuzova GD, 2006, P NATL ACAD SCI USA, V103, P12377, DOI 10.1073/pnas.0605252103
   Kutuzova GD, 2008, P NATL ACAD SCI USA, V105, P19655, DOI 10.1073/pnas.0810761105
   Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535
   Laulederkind SJF, 2013, BRIEF BIOINFORM, V14, P520, DOI 10.1093/bib/bbt007
   Lee GS, 2007, J BONE MINER RES, V22, P1968, DOI 10.1359/JBMR.070801
   Lemko HMD, 2012, ENDOCRINOLOGY, V153, P5119, DOI 10.1210/en.2012 1494
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Li QL, 2013, DIS MODEL MECH, V6, P1227, DOI 10.1242/dmm.012765
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2011, J BONE MINER RES, V26, P2610, DOI 10.1002/jbmr.472
   Lim ET, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004494
   Lin MK, 2011, DEV DYNAM, V240, P432, DOI 10.1002/dvdy.22550
   Linares GR, 2012, J BONE MINER RES, V27, P1553, DOI 10.1002/jbmr.1600
   Liu QY, 2008, J PHARMACOL EXP THER, V325, P47, DOI 10.1124/jpet.107.132670
   Liu YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071318
   Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   Lories RJU, 2007, ARTHRITIS RHEUM US, V56, P4095, DOI 10.1002/art.23137
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Ma DD, 2011, J BIOL CHEM, V286, P4302, DOI 10.1074/jbc.M110.140202
   MacArthur DG, 2012, SCIENCE, V335, P823, DOI 10.1126/science.1215040
   MacDonald BT, 2007, BONE, V41, P331, DOI 10.1016/j.bone.2007.05.009
   Mackenzie NCW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032177
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Maeda N, 2000, P NATL ACAD SCI USA, V97, P841, DOI 10.1073/pnas.97.2.841
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Malaval L, 2008, J EXP MED, V205, P1145, DOI 10.1084/jem.20071294
   Malloy PJ, 2011, MOL CELL ENDOCRINOL, V347, P90, DOI 10.1016/j.mce.2011.05.045
   Mani A, 2007, SCIENCE, V315, P1278, DOI 10.1126/science.1136370
   Manolagas SC, 2014, J BONE MINER RES, V29, P2131, DOI 10.1002/jbmr.2293
   Mansergh FC, 2007, PHYSIOL GENOMICS, V32, P64, DOI 10.1152/physiolgenomics.00151.2007
   Marín I, 2006, MOL BIOL EVOL, V23, P2423, DOI 10.1093/molbev/msl114
   Martin A, 2012, PHYSIOL REV, V92, P131, DOI 10.1152/physrev.00002.2011
   Matthaei KI, 2007, J PHYSIOL LONDON, V582, P481, DOI 10.1113/jphysiol.2007.134908
   Matthaei KI, 2009, PHARMACOL THERAPEUT, V123, P32, DOI 10.1016/j.pharmthera.2009.03.016
   Maurin AC, 2005, CELL METAB, V1, P273, DOI 10.1016/j.cmet.2005.03.004
   McDonald M, 2010, J BONE MINER RES  S1, V25, pS23
   McKean DM, 2012, BIOL OPEN, V1, P874, DOI 10.1242/bio.20121982
   Medina Gomez C, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002718
   Meng YH, 2002, NEURON, V35, P121, DOI 10.1016/S0896 6273(02)00758 4
   Mitchell AD, 2007, GROWTH DEVELOP AGING, V70, P25
   Miura K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042180
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Miyata A, 2007, ARCH HISTOL CYTOL, V70, P63, DOI 10.1679/aohc.70.63
   Mizuno K, 2013, CELL SIGNAL, V25, P457, DOI 10.1016/j.cellsig.2012.11.001
   Moffatt P, 2007, J BIOL CHEM, V282, P36454, DOI 10.1074/jbc.M708596200
   Mohan S, 2005, J BONE MINER RES, V20, P1597, DOI 10.1359/JBMR.050406
   Mohun T, 2013, DIS MODEL MECH, V6, P562, DOI 10.1242/dmm.011957
   Moore MW, 2005, E SCHERING RES FDN W, V50, P27
   Morello R, 2008, J CELL PHYSIOL, V217, P127, DOI 10.1002/jcp.21483
   Morello R, 2006, CELL, V127, P291, DOI 10.1016/j.cell.2006.08.039
   Mori H, 2012, J CLIN INVEST, V122, P2405, DOI 10.1172/JCI63604
   Morse A, 2014, P ORTH RES SOC ANN M
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Motyl KJ, 2011, AM J PHYSIOL REG I, V300, pR1250, DOI 10.1152/ajpregu.00764.2010
   Mukhopadhyay M, 2006, DEVELOPMENT, V133, P2149, DOI 10.1242/dev.02381
   Murray KA, 2002, LAB ANIMAL, V31, P25
   NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621
   Neutzsky Wulff AV, 2008, CALCIFIED TISSUE INT, V83, P425, DOI 10.1007/s00223 008 9185 7
   Nieman BJ, 2012, PHYSIOL GENOMICS, V44, P992, DOI 10.1152/physiolgenomics.00093.2012
   Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092 8674(01)00638 9
   Norose K, 1998, INVEST OPHTH VIS SCI, V39, P2674
   Novack DV, 2011, AGEING RES REV, V10, P54, DOI 10.1016/j.arr.2009.09.005
   O'Brien CA, 2005, AM J PHYSIOL ENDOC M, V289, pE784, DOI 10.1152/ajpendo.00029.2005
   Ono N, 2008, J BIOL CHEM, V283, P19400, DOI 10.1074/jbc.M800005200
   Ouchi N, 2010, SCIENCE, V329, P454, DOI 10.1126/science.1188280
   Paes KT, 2011, INVEST OPHTH VIS SCI, V52, P6452, DOI 10.1167/iovs.10 7146
   Park J, 2010, J BIOL CHEM, V285, P35029, DOI 10.1074/jbc.M110.165506
   Pata M, 2008, J BIOL CHEM, V283, P30522, DOI 10.1074/jbc.M805242200
   Paternoster L, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003247
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Person AD, 2010, DEV DYNAM, V239, P327, DOI 10.1002/dvdy.22156
   Pike JW, 2008, ENDOCRINOLOGY, V149, P3656, DOI 10.1210/en.2008 0042
   Plewczynski D, 2009, J MOL MODEL, V15, P695, DOI 10.1007/s00894 008 0353 5
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Pozzi S, 2013, BONE, V53, P487, DOI 10.1016/j.bone.2013.01.012
   Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439 c1
   Qiu J, 2001, ENDOCRINOLOGY, V142, P3421, DOI 10.1210/en.142.8.3421
   Rajan I, 2011, VET PATHOL, V48, P663, DOI 10.1177/0300985810370164
   Rajan I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006612
   Ramírez Solis R, 2012, WIRES SYST BIOL MED, V4, P547, DOI 10.1002/wsbm.1183
   Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131 11144.2005
   Rissanen JP, 2008, CALCIFIED TISSUE INT, V82, P155, DOI 10.1007/s00223 007 9101 6
   Russ AP, 2005, DRUG DISCOV TODAY, V10, P1607, DOI 10.1016/S1359 6446(05)03666 4
   Safadi FF, 1999, J CLIN INVEST, V103, P239, DOI 10.1172/JCI5244
   Saito H, 2008, J BONE MINER RES, V23, pS3
   Saito H, 2011, J BONE MINER RES  S1, V26, pS50
   SAKAI D, 1995, BONE, V17, P111, DOI 10.1016/S8756 3282(95)00152 2
   Satoh W, 2006, DEVELOPMENT, V133, P989, DOI 10.1242/dev.02274
   Savelieva KV, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003301
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Schaniel C, 2011, BLOOD, V118, P2420, DOI 10.1182/blood 2010 09 305664
   Schofield PN, 2012, HUM MUTAT, V33, P826, DOI 10.1002/humu.22077
   Schofield PN, 2012, DIS MODEL MECH, V5, P19, DOI 10.1242/dmm.008334
   Schofield PN, 2011, TOXICOL PATHOL, V39, P559, DOI 10.1177/0192623311399789
   Schulze J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010309
   Scudamore CL, 2014, DIS MODEL MECH, V7, P495, DOI 10.1242/dmm.016394
   Settembre C, 2008, GENE DEV, V22, P2645, DOI 10.1101/gad.1711308
   Settembre C, 2007, P NATL ACAD SCI USA, V104, P4506, DOI 10.1073/pnas.0700382104
   Shi ZC, 2008, J MED CHEM, V51, P3684, DOI 10.1021/jm800338j
   Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081
   Shuang F, 2013, EUR J APPL PHYSIOL, V113, P403, DOI 10.1007/s00421 012 2451 4
   Simpson MA, 2007, AM J HUM GENET, V81, P906, DOI 10.1086/522240
   Skrtic SM, 2013, J BONE MINER RES  S1, V28, pS39
   Smith CM, 2014, DEV DYNAM, V243, P1176, DOI [10.1002/DVDY.24155, 10.1002/dvdy.24155]
   Sogawa C, 2007, J HERED, V98, P575, DOI 10.1093/jhered/esm065
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Spitzweg C, 2010, MOL CELL ENDOCRINOL, V322, P56, DOI 10.1016/j.mce.2010.02.007
   Staiger J, 2009, CARCINOGENESIS, V30, P832, DOI 10.1093/carcin/bgn273
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Tagliabracci VS, 2014, P NATL ACAD SCI USA, V111, P5520, DOI 10.1073/pnas.1402218111
   Tagliabracci VS, 2013, TRENDS BIOCHEM SCI, V38, P121, DOI 10.1016/j.tibs.2012.11.008
   Tagliabracci VS, 2012, SCIENCE, V336, P1150, DOI 10.1126/science.1217817
   Tang T, 2010, NAT BIOTECHNOL, V28, P749, DOI 10.1038/nbt.1644
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Thurner PJ, 2010, BONE, V46, P1564, DOI 10.1016/j.bone.2010.02.014
   Tominaga H, 2008, MOL BIOL CELL, V19, P5373, DOI 10.1091/mbc.E08 03 0329
   Toye AA, 2005, DIABETOLOGIA, V48, P675, DOI 10.1007/s00125 005 1680 z
   Tsuji T, 2005, J BIOL CHEM, V280, P14288, DOI 10.1074/jbc.C500024200
   Turgeon B, 2009, PHYSIOL REV, V89, P1, DOI 10.1152/physrev.00040.2007
   Ueda Y, 2007, J BIOL CHEM, V282, P30373, DOI 10.1074/jbc.M705601200
   Van Wesenbeeck L, 2007, J CLIN INVEST, V117, P919, DOI 10.1172/JCI30328
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Vital SO, 2012, BONE, V50, P989, DOI 10.1016/j.bone.2012.01.010
   Vogel P, 2012, VET PATHOL, V49, P998, DOI 10.1177/0300985812453177
   Vogel P, 2012, VET PATHOL, V49, P166, DOI 10.1177/0300985811415708
   Vogel P, 2011, VET PATHOL, V48, P642, DOI 10.1177/0300985810383870
   Vogel P, 2009, VET PATHOL, V46, P313, DOI 10.1354/vp.46 2 313
   Vogel P, 2014, VET PATHOL
   Vogel P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004112
   Walke DW, 2001, CURR OPIN BIOTECH, V12, P626, DOI 10.1016/S0958 1669(01)00271 3
   Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197
   Wang XF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002708
   Ward PP, 2003, MOL CELL BIOL, V23, P178, DOI 10.1128/MCB.23.1.178 185.2003
   Wattler S, 1999, BIOTECHNIQUES, V26, P1150, DOI 10.2144/99266rr02
   Weber G, 2013, J ENDOCRINOL INVEST, V36, P261, DOI 10.3275/8847
   Wend P, 2012, ACTA PHYSIOL, V204, P34, DOI 10.1111/j.1748 1716.2011.02296.x
   White JK, 2013, CELL, V154, P452, DOI 10.1016/j.cell.2013.06.022
   Wongdee K, 2008, HISTOCHEM CELL BIOL, V130, P79, DOI 10.1007/s00418 008 0419 6
   Wu J, 2008, P NATL ACAD SCI USA, V105, P16934, DOI 10.1073/pnas.0808763105
   Xia CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011676
   Xing WR, 2013, J BONE MINER RES, V28, P1962, DOI 10.1002/jbmr.1935
   Xing WR, 2012, J BONE MINER RES, V27, P1067, DOI 10.1002/jbmr.1551
   Xu J, 2009, J BIOL CHEM, V284, P29470, DOI 10.1074/jbc.M109.044396
   Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092 8674(04)00216 8
   Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211
   Yamashita T, 2000, ENDOCRINOLOGY, V141, P438, DOI 10.1210/en.141.1.438
   Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324
   Yao W, 2010, J BONE MINER RES, V25, P190, DOI 10.1359/jbmr.090719
   Ye QR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103298
   Yngvadottir B, 2009, AM J HUM GENET, V84, P224, DOI 10.1016/j.ajhg.2009.01.008
   Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156
   Yuan Q, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002726
   Zambrowicz BP, 2003, CURR OPIN PHARMACOL, V3, P563, DOI 10.1016/j.coph.2003.04.002
   Zambrowicz BP, 2003, NAT REV DRUG DISCOV, V2, P38, DOI 10.1038/nrd987
   Zambrowicz Brian P., 2007, P3, DOI 10.1016/B978 012369393 8/50002 X
   Zanotti S, 2009, J ENDOCRINOL, V201, P263, DOI 10.1677/JOE 08 0514
   Zeiss CJ, 2012, VET PATHOL, V49, P24, DOI 10.1177/0300985811417247
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
   Zhou FL, 2013, BLOOD REV, V27, P261, DOI 10.1016/j.blre.2013.08.002
   Zhou Z, 2010, DEV CELL, V19, P90, DOI 10.1016/j.devcel.2010.06.016
   Zuniga E, 2011, DEVELOPMENT, V138, P5147, DOI 10.1242/dev.067785
NR 331
TC 103
Z9 122
U1 0
U2 30
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD OCT 28
PY 2014
VL 2
AR 14034
DI 10.1038/boneres.2014.34
PG 30
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AT5RK
UT WOS:000344999400001
PM 26273529
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Choi, LY
   Kim, MH
   Yang, WM
AF Choi, La Yoon
   Kim, Mi Hye
   Yang, Woong Mo
TI Promotion of osteogenesis by Sweroside via BMP2 involved
   signaling in postmenopausal osteoporosis
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE bone formation; osteoblasts; postmenopausal osteoporosis; Sweroside
ID MESENCHYMAL STEM CELLS; BONE FORMATION; OSTEOBLAST DIFFERENTIATION;
   SODIUM FLUORIDE; PATHOGENESIS; REPLACEMENT; FRACTURE
AB Phlomis umbrosa has been traditionally used for bone diseases in traditional Korean Medicine. Sweroside (SOS), marker compounds of P. umbrosa, has been known to promote osteoblast differentiation. In this study, ameliorative effects of SOS on osteoporosis and potential target pathway were investigated. Ovariectomized mice were administered three doses of SOS three times a week for 4 weeks after inducing osteoporosis. Bone mineral content (BMC) and bone mineral density (BMD) were analyzed by dual energy X ray absorptiometry. A human osteosarcoma cell line (SaOS 2) was differentiated to clarify the promoting effects of SOS on osteoblast differentiation and bone formation. Osteoblastic bone forming markers were evaluated in lumbar vertebrae (LV) and mineralized SaOS 2 cells. SOS markedly elevated BMC and BMD levels and attenuated the bone marrow adipocytes in the femoral shaft. SOS increased the formation of bone matrix in SaOS 2 cells. Bone morphogenetic protein 2 (BMP2) and runt related transcription factor 2 (CBFA1) in LV and SaOS 2 cells were up regulated by SOS. SOS increased alkaline phosphatase (ALPL), osteopontin (SPP1), and bone sialoprotein 1 (BSPH1). In conclusion, SOS induced the formation of mineralized bone matrix by regulating BMP2/CBFA1 mediated molecules. Therefore, SOS could be a therapeutic compound of treatment for osteoporosis by producing the new bone matrix.
C1 [Choi, La Yoon; Kim, Mi Hye; Yang, Woong Mo] Kyung Hee Univ, Coll Korean Med, Dept Convergence Korean Med Sci, 26 Kyungheedae Ro, Seoul 02447, South Korea.
C3 Kyung Hee University
RP Yang, WM (通讯作者)，Kyung Hee Univ, Coll Korean Med, Dept Convergence Korean Med Sci, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM wmyang@khu.ac.kr
RI ; Yang, Woong/AAH 9185 2020
OI Yang, Woong Mo/0000 0001 5308 2386; Choi, La Yoon/0000 0002 3817 1310
FU National Research Foundation of Korea [NRF 2019R1I1A2A01063598]
FX National Research Foundation of Korea, Grant/Award Number:
   NRF 2019R1I1A2A01063598
CR ARNAUD CD, 1990, ANNU REV NUTR, V10, P397, DOI 10.1146/annurev.nu.10.070190.002145
   Bartolozzi E, 2015, CLIN CASES MINER BON, V12, P111, DOI 10.11138/ccmbm/2015.12.2.111
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Brown JP, 2014, CAN FAM PHYSICIAN, V60, P324
   Chun JM, 2021, PHYTOMEDICINE, V81, DOI 10.1016/j.phymed.2020.153429
   DELMAS PD, 1993, OSTEOPOROSIS INT, V3, pS81
   Ding Y, 2019, J CELL BIOCHEM, V120, P16025, DOI 10.1002/jcb.28882
   Dirckx N, 2013, BIRTH DEFECTS RES C, V99, P170, DOI 10.1002/bdrc.21047
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   ELKHOURY GY, 1982, AM J ROENTGENOL, V139, P39, DOI 10.2214/ajr.139.1.39
   Gambacciani M, 2014, MENOPAUSE REV, V13, P213, DOI 10.5114/pm.2014.44996
   Go GY, 2021, J FOOD BIOCHEM, V45, DOI 10.1111/jfbc.13705
   Goldstein SR, 2002, AM J OBSTET GYNECOL, V187, P521, DOI 10.1067/mob.2002.123938
   HALL BK, 1987, BONE, V8, P111, DOI 10.1016/8756 3282(87)90079 2
   Jang SA, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7280342
   Jeong YT, 2015, CHEM BIOL INTERACT, V238, P33, DOI 10.1016/j.cbi.2015.05.022
   Kawai M, 2012, J INTERN MED, V272, P317, DOI 10.1111/j.1365 2796.2012.02564.x
   KESHAWARZ NM, 1984, METAB BONE DIS RELAT, V5, P223, DOI 10.1016/0221 8747(84)90063 8
   Kim Sung Jin, 2019, International Journal of Oral Biology, V44, P1
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Langdahl Bente Lomholt, 2018, J Bone Metab, V25, P133, DOI 10.11005/jbm.2018.25.3.133
   Lee D, 2016, MOLECULES, V21, DOI 10.3390/molecules21040461
   Lee JE, 2019, BIOMED REP, V10, P17, DOI 10.3892/br.2018.1172
   Li J, 2016, INT J MOL MED, V37, P901, DOI 10.3892/ijmm.2016.2490
   Li YT, 2020, AGING US, V12, P2226, DOI 10.18632/aging.102742
   Lips P, 2005, OSTEOPOROSIS INT, V16, P447, DOI 10.1007/s00198 004 1762 7
   Lips P, 2011, BEST PRACT RES CL EN, V25, P585, DOI 10.1016/j.beem.2011.05.002
   Liu DB, 2018, MED SCI MONITOR, V24, P4363, DOI 10.12659/MSM.905958
   Lyu HC, 2020, ANN INTERN MED, V173, P516, DOI 10.7326/M20 0882
   신다솜, 2016, [Journal of Korean Medicine, 대한한의학회지], V37, P39
   Machann J, 2008, EUR J RADIOL, V67, P275, DOI 10.1016/j.ejrad.2008.02.032
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   MCQUILLAN DJ, 1995, BONE, V16, P415
   Ministry of Food and Drug Safety, 2016, KOR PHARM, V11
   Muruganandan S, 2018, CURR OSTEOPOROS REP, V16, P434, DOI 10.1007/s11914 018 0451 y
   Nordin BEC, 1996, J BONE MINER RES, V11, P849
   PARFITT AM, 1995, J BONE MINER RES, V10, P466
   du Sert NP, 2020, J PHYSIOL LONDON, V598, P3793, DOI 10.1113/JP280389
   Piao CD, 2019, BIOMED ENG BIOMED TE, V64, P721, DOI 10.1515/bmt 2018 0087
   Seeman E, 2009, CRIT REV EUKAR GENE, V19, P219, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.40
   Shin Y, 2021, PLANTS BASEL, V10, DOI 10.3390/plants10061132
   Silverman Stuart L, 2010, Curr Osteoporos Rep, V8, P151, DOI 10.1007/s11914 010 0025 0
   Sun H, 2013, FITOTERAPIA, V84, P174, DOI 10.1016/j.fitote.2012.11.010
   Veldhuis Vlug AG, 2018, J INTERN MED, V283, P121, DOI 10.1111/joim.12718
   Villareal DT, 2001, JAMA J AM MED ASSOC, V286, P815, DOI 10.1001/jama.286.7.815
   Vinogradova Y, 2019, BMJ BRIT MED J, V364, DOI 10.1136/bmj.k4810
   Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925 4773(97)00203 7
   Wade Gueye NM, 2010, ENDOCRINOLOGY, V151, P5103, DOI 10.1210/en.2010 0091
   Wang CC, 2020, MOLECULES, V25, DOI 10.3390/molecules25020287
   Wang L, 2016, OSTEOPOROSIS INT, V27, P153, DOI 10.1007/s00198 015 3225 8
   Wu QC, 2020, PHYTOMEDICINE, V68, DOI 10.1016/j.phymed.2019.153146
   Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543
   Yang G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082790
   Yang N, 2014, J BONE MINER METAB, V32, P252, DOI 10.1007/s00774 013 0496 z
   Zajdel A, 2017, ACTA BIOCHIM POL, V64, P365, DOI 10.18388/abp.2016_1488
   Zhang Q, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 02895 7
   Zhang W, 2018, AM J CLIN EXP IMMUNO, V7, P40
   Zhou SH, 2003, MOL ENDOCRINOL, V17, P56, DOI 10.1210/me.2002 0210
NR 61
TC 12
Z9 12
U1 5
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD DEC
PY 2021
VL 35
IS 12
BP 7050
EP 7063
DI 10.1002/ptr.7336
EA NOV 2021
PG 14
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XS4FK
UT WOS:000721945800001
PM 34818696
DA 2025 08 17
ER

PT J
AU Qiu, L
   Yang, QW
   Feng, J
   Wang, Y
   Huang, M
AF Qiu, Ling
   Yang, Quan wei
   Feng, Jing
   Wang, Ying
   Huang, Mi
TI Epimedin C prevents glucocorticoid induced osteoporosis via balancing
   EphB4/EphrinB2 axis in a rodent model
SO TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
LA English
DT Article
DE Epimedin C; glucocorticoid induced osteoporosis (GIOP); EphB4; EphrinB2;
   Traditional Chinese medicine; Mouse model
ID HERBA EPIMEDII; ICARIIN; DIFFERENTIATION; PROLIFERATION
AB Purpose: To study the effect of Epimedin C on glucocorticoid (GC) induced osteoporosis in a rodent model as well as its mechanism of action via balancing EphB4/EphrinB2 axis.Methods: Forty eight C57BL/6 male mice were divided randomly into control, dexamethasone injection (DI), Epimedin C gavage (EG), and DI + EG groups. Micro computed and hematoxylin eosin staining was used to examine bone structure. The relationship between EphB4/EphrinB2 and osteoporosis was preliminarily verified by immunohistochemistry. Evidence of Epimedin C preventing the formation of GC  induced osteoclasts was determined by trap staining. Western blot analysis was conducted to determine the levels of EphrinB2, EphB4, Runx2, and LGR4 in mouse bone tissues.Results: In the DI group, morphological examination showed bone loss. The use of immunohistochemistry and Western blot studies showed that EphB4 levels decreased and EphrinB2 levels increased in DI group mice (p < 0.05). The morphological parameters of osteoporosis improved in mice of DI + EG group compared to that in DI group mice, while EphB4 levels were elevated and EphrinB2 levels decreased in comparison with the values in the DI group mice (p < 0.05).Conclusion: Epimedin C prevents bone loss by balancing the process of bone formation and remodeling bidirectionally. It affects bone metabolism by regulating protein levels of Runx2 and LGR4. However, the specific regulatory processes and targets of the anti osteoporotic effect of Epimedin C regarding the EphB4/EphrinB2 signaling pathway still need to be confirmed.
C1 [Qiu, Ling; Yang, Quan wei; Feng, Jing; Huang, Mi] Wuhan Hosp Tradit Chinese & Western Med, 215 Zhong Shan Rd, Wuhan 430022, Peoples R China.
   [Qiu, Ling] Hubei Univ Chinese Med, 188 Tan Hua Lin Rd, Wuhan 430065, Peoples R China.
   [Wang, Ying] Chinese Acad Sci, Key Lab South China Agr Plant Mol Anal & Genet Imp, South China Bot Garden, 723 Xingke Rd, Guangzhou 510650, Peoples R China.
C3 Hubei University of Chinese Medicine; Chinese Academy of Sciences; South
   China Botanical Garden, CAS
RP Huang, M (通讯作者)，Wuhan Hosp Tradit Chinese & Western Med, 215 Zhong Shan Rd, Wuhan 430022, Peoples R China.
EM 303001@hbtcm.edu.cn
RI huang, mi/GVT 4152 2022; Yang, Quanwei/LGX 9980 2024
FU Natural Science Foundation of Hubei Province, Opening Foundation of Key
   Laboratory of South China Agricultural Plant Molecular Analysis and
   Genetic Improvement, South China Botanical Garden, Chinese Academy of
   Sciences [KF202002]; Natural Science Foundation of Hubei Province;
   Opening Foundation of Key Laboratory of South China Agricultural Plant
   Molecular Analysis and Genetic Improvement; South China Botanical
   Garden; Chinese Academy of Sciences [KF202002]; Wuhan Municipal Health
   Commission [WZ21A01]
FX The present study was supported by grants from the Natural Science
   Foundation of Hubei Province, Opening Foundation of Key Laboratory of
   South China Agricultural Plant Molecular Analysis and Genetic
   Improvement, South China Botanical Garden, Chinese Academy of Sciences
   (grant no. KF202002), Wuhan Municipal Health Commission (grant no.
   WZ21A01).
CR Alfaro D, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0912 3
   Chen GM, 2016, EXP THER MED, V12, P279, DOI 10.3892/etm.2016.3333
   Dung HTQ, 2021, PHARMACIA, V68, P365, DOI 10.3897/pharmacia.68.e63801
   Hu K, 2019, EXPERT REV ENDOCRINO, V14, P259, DOI 10.1080/17446651.2019.1617131
   Huang M, 2017, CHIN HERB MED, V9, P69, DOI 10.1016/S1674 6384(17)60078 9
   Huang Mi Huang Mi, 2016, Chinese Journal of Integrated Traditional and Western Medicine, V36, P986
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Kim Y, 2005, J BIOL CHEM, V280, P32905, DOI 10.1074/jbc.M505820200
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Lekamwasam S, 2012, OSTEOPOROSIS INT, V23, P2257, DOI 10.1007/s00198 012 1958 1
   Lin J, 2017, BIOSCI TRENDS, V11, P496, DOI 10.5582/bst.2017.01216
   Pham CV, 2021, J FISH BIOL, V98, P1039, DOI 10.1111/jfb.14241
   Sun P, 2019, J CELL PHYSIOL, V234, P10855, DOI 10.1002/jcp.27927
   Tazaki Y, 2018, COMP BIOCHEM PHYS A, V225, P46, DOI 10.1016/j.cbpa.2018.06.011
   Xu YX, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2021.153485
   Zhang DW, 2008, PHYTOMEDICINE, V15, P55, DOI 10.1016/j.phymed.2007.04.002
   Zhang F, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7241829
   Zhang HF, 2008, ULTRASON SONOCHEM, V15, P376, DOI 10.1016/j.ultsonch.2007.09.002
NR 18
TC 0
Z9 0
U1 2
U2 17
PU PHARMACOTHERAPY GROUP
PI BENIN CITY
PA UNIV BENIN, FACULTY PHARMACY, BENIN CITY, 00000, NIGERIA
SN 1596 5996
J9 TROP J PHARM RES
JI Trop. J. Pharm. Res.
PD JUN
PY 2023
VL 22
IS 6
BP 1197
EP 1204
DI 10.4314/tjpr.v22i6.8
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA L8IJ3
UT WOS:001025640200008
DA 2025 08 17
ER

PT J
AU Luo, N
   Zhang, L
   Xiu, CM
   Luo, X
   Hu, SY
   Ji, KZ
   Liu, QB
   Chen, JQ
AF Luo, Na
   Zhang, Lei
   Xiu, Chunmei
   Luo, Xi
   Hu, Siyuan
   Ji, Kaizhong
   Liu, Qingbai
   Chen, Jianquan
TI Piperlongumine, a Piper longum derived amide alkaloid, protects
   mice from ovariectomy induced osteoporosis by inhibiting
   osteoclastogenesis via suppression of p38 and JNK signaling
SO FOOD & FUNCTION
LA English
DT Article
ID BONE; ACTIVATION; DIFFERENTIATION; FUTURE
AB Postmenopausal osteoporosis (PMOP) is a metabolic bone disease that results from overproduction and hyperactivation of osteoclasts caused by insufficient estrogen in women after menopause. Current therapeutic strategies are mainly focused on treating PMOP patients who have already developed severe bone loss or even osteoporotic fractures. Obviously, a better strategy is to prevent PMOP from occurring in the first place. However, such reagents are largely lacking. Piperlongumine (PLM), an amide alkaloid extracted from long pepper Piper longum, exhibits the anti osteoclastogenic effect in normal bone marrow macrophages (BMMs) and the protective effect against osteolysis induced by titanium particles in mice. This study examined the preventive effect of PLM on PMOP and explored the potential mechanism of this effect using both ovariectomized mice and their primary cells. The result showed that PLM (5 and 10 mg kg( 1)) administered daily for 6 weeks ameliorated ovariectomy induced bone loss and osteoclast formation in mice. Further cell experiments showed that PLM directly suppressed osteoclast formation, F actin ring formation, and osteoclastic resorption pit formation in BMMs derived from osteoporotic mice, but did not obviously affect osteogenic differentiation of bone marrow stromal cells (BMSCs) from these mice. Western blot analysis revealed that PLM attenuated maximal activation of p38 and JNK pathways by RANKL stimulation without affecting acute activation of NF kappa B, AKT, and ERK signaling. Furthermore, PLM inhibited expression of key osteoclastogenic transcription factors NFATc1/c Fos and their target genes (Dcstamp, Atp6v0d2, Acp5, and Oscar). Taken together, our findings suggest that PLM inhibits osteoclast formation and function by suppressing RANKL induced activation of the p38/JNK cFos/NFATc1 signaling cascade, thereby preventing ovariectomy induced osteoporosis in mice. Thus, PLM can potentially be used as an anti resorption drug or dietary supplement for the prevention of PMOP.
C1 [Luo, Na; Xiu, Chunmei; Ji, Kaizhong; Chen, Jianquan] Hangzhou City Univ, Sch Med, Key Lab Novel Targets & Drug Study Neural Repair Z, 51 Huzhou St, Hangzhou 310015, Zhejiang, Peoples R China.
   [Luo, Na; Zhang, Lei; Luo, Xi; Hu, Siyuan; Chen, Jianquan] Soochow Univ, Orthoped Inst, Suzhou Med Coll, Suzhou, Jiangsu, Peoples R China.
   [Liu, Qingbai] Nanjing Med Univ, Lianshui Cty Peoples Hosp, Dept Orthopaed, Affiliated Lianshui Cty Peoples Hosp,Kangda Coll, Huaian, Jiangsu, Peoples R China.
C3 Hangzhou City University; Soochow University   China; Nanjing Medical
   University
RP Chen, JQ (通讯作者)，Hangzhou City Univ, Sch Med, Key Lab Novel Targets & Drug Study Neural Repair Z, 51 Huzhou St, Hangzhou 310015, Zhejiang, Peoples R China.; Chen, JQ (通讯作者)，Soochow Univ, Orthoped Inst, Suzhou Med Coll, Suzhou, Jiangsu, Peoples R China.; Liu, QB (通讯作者)，Nanjing Med Univ, Lianshui Cty Peoples Hosp, Dept Orthopaed, Affiliated Lianshui Cty Peoples Hosp,Kangda Coll, Huaian, Jiangsu, Peoples R China.
EM liu678vip@163.com; chenjq@zucc.edu.cn
RI luo, na/KOC 3893 2024; Zhang, Lei/JLM 4641 2023; Xiu,
   Chunmei/NKO 8377 2025
FU National Natural Science Foundation of China [82272543, 81974344];
   National Natural Science Foundation of China [Z2022042]; Scientific
   Research Project of Jiangsu Commission of Health [J 202327]; Scientific
   Research Foundation of Hangzhou City University
FX This study was supported in part by the National Natural Science
   Foundation of China (82272543, 81974344), the Scientific Research
   Project of Jiangsu Commission of Health (Z2022042), and the Scientific
   Research Foundation of Hangzhou City University (no. J 202327).
CR Basak D, 2016, INT J ONCOL, V48, P1426, DOI 10.3892/ijo.2016.3372
   Bezerra DP, 2013, EUR J PHARM SCI, V48, P453, DOI 10.1016/j.ejps.2012.12.003
   Blangy A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.244798
   Chen JQ, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0004 5
   Duan XH, 2018, THERANOSTICS, V8, P5379, DOI 10.7150/thno.28391
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Go J, 2018, INT J MOL MED, V42, P1875, DOI 10.3892/ijmm.2018.3782
   Gu J, 2021, PHYTOMEDICINE, V82, DOI 10.1016/j.phymed.2021.153461
   Gu JM, 2023, J ORTHOP TRANSL, V38, P117, DOI 10.1016/j.jot.2022.06.007
   Gu XH, 2018, J CELL BIOCHEM, V119, P1041, DOI 10.1002/jcb.26272
   Huang JR, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.586885
   KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Langdahl BL, 2021, BRIT J PHARMACOL, V178, P1891, DOI 10.1111/bph.15024
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Liu J, 2018, AUTOPHAGY, V14, P845, DOI 10.1080/15548627.2017.1390636
   Liu MJ, 2023, J ORTHOP TRANSL, V38, P23, DOI 10.1016/j.jot.2022.07.007
   Liu X, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052868
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Lu C, 2019, INT J MOL MED, V44, P1855, DOI 10.3892/ijmm.2019.4322
   Ma LH, 2023, J ORTHOP TRANSL, V42, P1, DOI 10.1016/j.jot.2023.06.002
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Nedeva IR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641162
   Park JH, 2017, MOL CELLS, V40, P706
   Park Min KH, 2018, CELL MOL LIFE SCI, V75, P2519, DOI 10.1007/s00018 018 2817 9
   Pei J, 2023, CELL CHEM BIOL, V30, P203, DOI 10.1016/j.chembiol.2023.01.004
   Prasad S, 2016, CURR PHARM DESIGN, V22, P4151, DOI 10.2174/1381612822666160601103027
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Qiu ZC, 2022, J ORTHOP TRANSL, V33, P55, DOI 10.1016/j.jot.2022.01.003
   Sun SX, 2022, EUR J PHARMACOL, V927, DOI 10.1016/j.ejphar.2022.175073
   Thatikonda S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 019 2212 y
   Tripathi SK, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104772
   Wang O, 2015, OSTEOPOROSIS INT, V26, P2631, DOI 10.1007/s00198 015 3162 6
   Wang YY, 2016, AGING US, V8, P2915, DOI 10.18632/aging.101100
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Xu SQ, 2018, INFLAMM RES, V67, P233, DOI 10.1007/s00011 017 1112 9
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yao L, 2014, IMMUNOL LETT, V161, P76, DOI 10.1016/j.imlet.2014.05.001
   Zhang LW, 2022, J BONE MINER RES, V37, P559, DOI 10.1002/jbmr.4485
   Zhang LW, 2020, THERANOSTICS, V10, P6638, DOI 10.7150/thno.44793
   Zhang YX, 2022, FOOD FUNCT, V13, P8850, DOI [10.1039/D2FO00780K, 10.1039/d2fo00780k]
   Zhu P, 2021, EUR J MED CHEM, V220, DOI 10.1016/j.ejmech.2021.113471
NR 43
TC 3
Z9 3
U1 2
U2 18
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042 6496
EI 2042 650X
J9 FOOD FUNCT
JI Food Funct.
PD FEB 19
PY 2024
VL 15
IS 4
BP 2154
EP 2169
DI 10.1039/d3fo03830k
EA JAN 2024
PG 16
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA IC8S9
UT WOS:001156903100001
PM 38311970
DA 2025 08 17
ER

PT J
AU Bhattacharyya, S
   Pal, S
   Chattopadhyay, N
AF Bhattacharyya, Sharmistha
   Pal, Subhashis
   Chattopadhyay, Naibedya
TI Abaloparatide, the second generation osteoanabolic drug: Molecular
   mechanisms underlying its advantages over the first in class
   teriparatide
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Abaloparatide; Parathyroid hormone/teriparatide (PTH/TPTD); Parathyroid
   hormone related peptide (PTHrP); PTH 1 receptor (PTH1R); R G and R 0
   conformations of PTH1R; cAMP signaling
ID PARATHYROID HORMONE PTH; BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN;
   JUXTAMEMBRANE REGION; PROTEIN PTHRP; RECEPTOR; PEPTIDE; BINDING;
   STRENGTH; LIGAND
AB Abaloparatide is an analog of human parathyroid hormone related protein (PTHrP) that has recently been approved for the treatment of post menopausal osteoporosis. Abaloparatide is a stimulator of bone formation similar to teriparatide (1 34 PTH/TPTD), the first in class osteoanabolic drug. Both PTH and PTHrP signal via the type 1 PTH receptor (PTH1R) however, the downstream signaling varies between the two ligands. Both ligands have a similar affinity for the R G (GTP gamma S sensitive) state of PTH1R, but, TPTD has a four fold higher affinity for R 0 (GTP gamma S insensitive) than PTHrP that results in a prolonged cAMP signaling. Consequently, a greater production from osteoblastic cells of a potent resorption inducer, receptor activator of nuclear factor kappa B ligand (RANKL) is caused by TPTD than PTHrP. TPTD causes an excess formation over resorption early on producing an anabolic "window" which is lost with time due to increased RANKL production causing resorption to catch up with the formation. Although highly labile, PTHrP has an osteogenic effect accompanied by lesser resorptive and hypercalcemic effects than TPTD because of faster PTHrP PTH1R dissociation than PTH PTH1R complex. Engineered from PTHrP (1 34), abaloparatide was made stable and overcame the loss of the anabolic window and hypercalcemia associated with TPTD. The receptor activating domain (1 21 amino acids) of both ligands is same but multiple substitutions between amino acids 22 34 of PTHrP were made to enhance the peptide's stability. In, women with osteoporosis, abaloparatide increased BMD faster than TPTD and decreased fracture risk at both vertebral and non vertebral sites but unlike TPTD/PTH did not increase resorption or hypercalcemia.
C1 [Bhattacharyya, Sharmistha; Pal, Subhashis; Chattopadhyay, Naibedya] CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226021, Uttar Pradesh, India.
   [Bhattacharyya, Sharmistha] CSIR Cent Drug Res Inst, Div Endocrinol, DBT BIO Care, Lucknow 226021, Uttar Pradesh, India.
   [Chattopadhyay, Naibedya] CSIR Cent Drug Res Inst, AcSIR, Lucknow 226021, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Council of Scientific & Industrial Research (CSIR)  
   India; CSIR   Central Drug Research Institute (CDRI); Academy of
   Scientific & Innovative Research (AcSIR)
RP Chattopadhyay, N (通讯作者)，CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226021, Uttar Pradesh, India.
EM n_chattopadhyay@cdri.res.in
RI Chattopadhyay, Naibedya/AAF 2058 2019; Pal, Subhashis/IXD 3635 2023
OI Pal, Subhashis/0000 0002 3916 5545; Chattopadhyay,
   Naibedya/0000 0003 2473 0246
FU Council of Scientific and Industrial Research, Government of India;
   Department of Bio Technology
FX Funding from the Council of Scientific and Industrial Research,
   Government of India to N.C., S.P., and Department of Bio Technology to
   S. B. is acknowledged.
CR Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931
   Bilezikian JP, 2018, OSTEOPOROSIS INT, V29, P323, DOI 10.1007/s00198 017 4304 9
   Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Bone HG, 2018, J CLIN ENDOCR METAB, V103, P2949, DOI 10.1210/jc.2018 00163
   Boyce EG, 2018, ANN PHARMACOTHER, V52, P462, DOI 10.1177/1060028017748649
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   BURTIS WJ, 1992, CLIN CHEM, V38, P2171
   Cheloha RW, 2015, NAT REV ENDOCRINOL, V11, P712, DOI 10.1038/nrendo.2015.139
   Cosman F, 2017, J BONE MINER RES, V32, P17, DOI 10.1002/jbmr.2991
   Cupp ME, 2013, J PHARMACOL EXP THER, V345, P404, DOI 10.1124/jpet.112.199752
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   Dean T, 2006, MOL ENDOCRINOL, V20, P931, DOI 10.1210/me.2005 0349
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Dean T, 2006, J BIOL CHEM, V281, P32485, DOI 10.1074/JBC.M606179200
   Doyle N, 2018, OSTEOPOROSIS INT, V29, P685, DOI 10.1007/s00198 017 4323 6
   Ebina K, 2017, J BONE MINER METAB, V35, P91, DOI 10.1007/s00774 015 0731 x
   Feinstein TN, 2011, NAT CHEM BIOL, V7, P278, DOI 10.1038/nchembio.545
   Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206
   Finkelstein JS, 2009, J CLIN ENDOCR METAB, V94, P2495, DOI 10.1210/jc.2009 0154
   Fischer J, 2014, STEM CELLS DEV, V23, P2513, DOI 10.1089/scd.2014.0101
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069
   Gensure RC, 2001, J BIOL CHEM, V276, P28650, DOI 10.1074/jbc.M100717200
   Gesty Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Hansen S, 2013, J BONE MINER RES, V28, P736, DOI 10.1002/jbmr.1784
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Hiligsmann M, 2019, SEMIN ARTHRITIS RHEU, V49, P184, DOI 10.1016/j.semarthrit.2019.01.006
   HIRANO T, CALCIF TISSUE INT, V66, P456
   Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893
   Horwitz MJ, 2013, J BONE MINER RES, V28, P2266, DOI 10.1002/jbmr.1978
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kim YJ, 2008, BIOCHEM BIOPH RES CO, V373, P104, DOI 10.1016/j.bbrc.2008.05.183
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Kurland ES, 2004, OSTEOPOROSIS INT, V15, P992, DOI 10.1007/s00198 004 1636 z
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Maeda A, 2013, P NATL ACAD SCI USA, V110, P5864, DOI 10.1073/pnas.1301674110
   Makino A, 2018, CALCIFIED TISSUE INT, V103, P289, DOI 10.1007/s00223 018 0422 4
   MANGIN M, 1989, P NATL ACAD SCI USA, V86, P2408, DOI 10.1073/pnas.86.7.2408
   Martin TJ, 2017, J BONE MINER RES, V32, P11, DOI 10.1002/jbmr.3042
   Martin TJ, 2016, PHYSIOL REV, V96, P831, DOI 10.1152/physrev.00031.2015
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo 124 3 1247
   McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617
   McCloskey EV, 2017, J BONE MINER RES, V32, P1625, DOI 10.1002/jbmr.3163
   McClung MR, 2018, MENOPAUSE, V25, P767, DOI 10.1097/GME.0000000000001080
   MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V118, P824, DOI 10.1210/endo 118 2 824
   Miller PD, 2019, BONE, V120, P137, DOI 10.1016/j.bone.2018.10.015
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Moreira CA, 2017, BONE, V97, P314, DOI 10.1016/j.bone.2016.11.004
   Nussey S., 2001, ENDOCRINOL INTEGR AP
   O'Hanlon CE, 2017, CLIN THER, V39, P1276, DOI 10.1016/j.clinthera.2017.05.348
   Okazaki M, 2008, P NATL ACAD SCI USA, V105, P16525, DOI 10.1073/pnas.0808750105
   Pioszak AA, 2009, J BIOL CHEM, V284, P28382, DOI 10.1074/jbc.M109.022905
   Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129
   Schievano E, 2000, BIOPOLYMERS, V54, P429, DOI 10.1002/1097 0282(200011)54:6<429::AID BIP70>3.3.CO;2 N
   Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199
   Shimizu M, 2000, J BIOL CHEM, V275, P19456, DOI 10.1074/jbc.M001596200
   Shimizu M, 2002, BIOCHEMISTRY US, V41, P13224, DOI 10.1021/bi026162k
   Shimizu N, 2001, J BIOL CHEM, V276, P49003, DOI 10.1074/jbc.M106827200
   Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748
   Takakura A, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.2
   Trivedi R, 2010, EXPERT OPIN INV DRUG, V19, P995, DOI 10.1517/13543784.2010.501077
   UZAWA T, 1995, BONE, V16, P477
   Varela A, 2017, BONE, V95, P143, DOI 10.1016/j.bone.2016.11.027
   Vilardaga JP, 2011, CELL MOL LIFE SCI, V68, P1, DOI 10.1007/s00018 010 0465 9
   Wehbi VL, 2013, P NATL ACAD SCI USA, V110, P1530, DOI 10.1073/pnas.1205756110
   Weidler M, 1999, FEBS LETT, V444, P239, DOI 10.1016/S0014 5793(98)01658 5
   Yamane H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175329
NR 71
TC 36
Z9 40
U1 1
U2 15
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD AUG
PY 2019
VL 166
BP 185
EP 191
DI 10.1016/j.bcp.2019.05.024
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA IH4YU
UT WOS:000474498800017
PM 31136739
DA 2025 08 17
ER

PT J
AU Su, XD
   Yang, SY
   Shrestha, SK
   Soh, Y
AF Su, Xiang Dong
   Yang, Seo Y.
   Shrestha, Saroj K.
   Soh, Yunjo
TI Aster saponin A2 inhibits osteoclastogenesis through mitogen 
   activated protein kinase c Fos NFATc1 signaling pathway
SO JOURNAL OF VETERINARY SCIENCE
LA English
DT Article
DE Saponins; osteoclasts; tartrate resistant acid phosphatase; macrophage
   colony stimulating factor; RANK ligand
ID C FOS; DIFFERENTIATION; RAW264.7; RANK; ASSOCIATION; MECHANISMS; CELLS;
   MAPK
AB Background: In lipopolysaccharide induced RAW264.7 cells, Aster tataricus (AT) inhibits the nuclear factor kappa light chain enhancer of activated B cells and MAPKs pathways and critical pathways of osteoclast development and bone resorption. Objectives: This study examined how aster saponin A2 (AS A2) isolated from AT affects the processes and function of osteoclastogenesis induced by receptor activator of nuclear factor kappa B ligand (RANKL) in RAW264.7 cells and bone marrow macrophages (BMMs). Methods: The cell viability, tartrate resistant acid phosphatase staining, pit formation assay, polymerase chain reaction, and western blot were carried out to determine the effects of AS A2 on osteoclastogenesis. Results: In RAW264.7 and BMMs, AS A2 decreased RANKL initiated osteoclast differentiation in a concentration dependent manner. In AS A2 treated cells, the phosphorylation of ERK1/2, JNK, and p38 protein expression were reduced considerably compared to the control cells. In RAW264.7 cells, AS A2 suppressed the RANKL induced activation of osteoclast related genes. During osteoclast differentiation, AS A2 suppressed the transcriptional and translational expression of NFATc1 and c Fos. AS A2 inhibited osteoclast development, reducing the size of the bone resorption pit area. Conclusion: AS A2 isolated from AT appears to be a viable therapeutic therapy for osteolytic illnesses, such as osteoporosis, Paget's disease, and osteogenesis imperfecta.
C1 [Su, Xiang Dong] Sun Yat Sen Univ, Sch Pharmaceut Sci Shenzhen, Guangzhou 510275, Peoples R China.
   [Yang, Seo Y.] Sangji Univ, Dept Pharmaceut Engn, Wonju 26339, South Korea.
   [Shrestha, Saroj K.; Soh, Yunjo] Jeonbuk Natl Univ, Sch Dent, Dept Dent Pharmacol, Jeonju 54896, South Korea.
   [Soh, Yunjo] Jeonbuk Natl Univ, Sch Pharm, Dept Pharmacol, 567 Baekje Daero, Jeonju 54896, South Korea.
C3 Sun Yat Sen University; Sangji University; Jeonbuk National University;
   Jeonbuk National University
RP Soh, Y (通讯作者)，Jeonbuk Natl Univ, Sch Pharm, Dept Pharmacol, 567 Baekje Daero, Jeonju 54896, South Korea.
EM ysoh@jbnu.ac.kr
RI ; Shrestha, Saroj Kumar/HSG 6009 2023
OI Yang, Seo Young/0000 0002 5248 1374; Shrestha, Saroj
   K/0000 0002 8932 3468
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [NRF 2021R1I1A3055927]; Research
   Base Construction Fund Support Program   Jeonbuk National University;
   Ministry of Education, Science and Technology [NRF 2018R1A6A3A11047338]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) , funded by the Ministry
   of Education (NRF 2021R1I1A3055927 to Soh Y) , Research Base
   Construction Fund Support Program funded by Jeonbuk National University
   in 2021 (Soh Y) and the Ministry of Education, Science and Technology
   (NRF 2018R1A6A3A11047338 to Yang SY) .
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Baykan EK, 2014, OSTEOPOROSIS INT, V25, P2221, DOI 10.1007/s00198 014 2752 z
   Boeyens JCA, 2014, NUTRIENTS, V6, P2584, DOI 10.3390/nu6072584
   CHENG DL, 1994, PHYTOCHEMISTRY, V35, P173
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Guo RH, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2737 8
   Ha H, 2003, EXP MOL MED, V35, P279, DOI 10.1038/emm.2003.38
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kuroda Y, 2012, WORLD J ORTHOP, V3, P167, DOI 10.5312/wjo.v3.i11.167
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Li L, 2017, EUR J PHARMACOL, V815, P202, DOI 10.1016/j.ejphar.2017.09.015
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Liu W, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10771
   Ma CH, 2011, J AGR FOOD CHEM, V59, P9645, DOI 10.1021/jf202028y
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park JH, 2017, MOL CELLS, V40, P706
   Sapkota M, 2018, FOOD CHEM TOXICOL, V120, P418, DOI 10.1016/j.fct.2018.07.032
   Silbermann R, 2014, LEUKEMIA, V28, P951, DOI 10.1038/leu.2013.385
   Su Lei, 2016, Zhongguo Zhong Yao Za Zhi, V41, P2943, DOI 10.4268/cjcmm20161601
   Su XD, 2019, BIOORG CHEM, V92, DOI 10.1016/j.bioorg.2019.103208
   Su XD, 2019, J NAT PROD, V82, P1139, DOI 10.1021/acs.jnatprod.8b00856
   TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092 8674(89)90438 8
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wang XD, 2015, CELL METAB, V22, P811, DOI 10.1016/j.cmet.2015.09.010
   Wu M, 2017, NAT COMMUN, V8, P1
   Wu SH, 2012, INT J MED SCI, V9, P801, DOI 10.7150/ijms.4838
   Yu P, 2015, J ETHNOPHARMACOL, V164, P328, DOI 10.1016/j.jep.2015.02.036
   Zarei A, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.30
   Zou W, 2008, MOL CELL, V31, P422, DOI 10.1016/j.molcel.2008.06.023
NR 35
TC 5
Z9 5
U1 0
U2 5
PU KOREAN SOC VETERINARY SCIENCE
PI SEOUL
PA 401 1, Bldg 85, SEOUL NATL UNIV,  COLLEGE VETERINARY MEDICINE, SEOUL,
   08826, SOUTH KOREA
SN 1229 845X
EI 1976 555X
J9 J VET SCI
JI J. Vet. Sci.
PD JUL
PY 2022
VL 23
IS 4
DI 10.4142/jvs.21246
EA APR 2022
PG 11
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA 3U1NP
UT WOS:000812148200001
PM 35698806
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Alfaro, MP
   Vincent, A
   Saraswati, S
   Thorne, CA
   Hong, CC
   Lee, E
   Young, PP
AF Alfaro, Maria P.
   Vincent, Alicia
   Saraswati, Sarika
   Thorne, Curtis A.
   Hong, Charles C.
   Lee, Ethan
   Young, Pampee P.
TI sFRP2 Suppression of Bone Morphogenic Protein (BMP) and Wnt Signaling
   Mediates Mesenchymal Stem Cell (MSC) Self renewal Promoting Engraftment
   and Myocardial Repair
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DIFFERENTIATION; DISRUPTION; ANTAGONIST; INDUCTION; APOPTOSIS; TARGETS;
   FAMILY; CBFA1
AB Transplantation of mesenchymal stem cells (MSCs) is a promising therapy for ischemic injury; however, inadequate survival of implanted cells in host tissue is a substantial impediment in the progress of cellular therapy. Secreted Frizzled related protein 2 (sFRP2) has recently been highlighted as a key mediator of MSC driven myocardial and wound repair. Notably, sFRP2 mediates significant enhancement of MSC engraftment in vivo. We hypothesized that sFRP2 improves MSC engraftment by modulating self renewal through increasing stem cell survival and by inhibiting differentiation. In previous studies we demonstrated that sFRP2 expressing MSCs exhibited an increased proliferation rate. In the current study, we show that sFRP2 also decreased MSC apoptosis and inhibited both osteogenic and chondrogenic lineage commitment. sFRP2 activity occurred through the inhibition of both Wnt and bone morphogenic protein (BMP) signaling pathways. sFRP2 mediated inhibition of BMP signaling, as assessed by levels of pSMAD 1/5/8, was independent of its effects on the Wnt pathway. We further hypothesized that sFRP2 inhibition of MSC lineage commitment may reduce heterotopic osteogenic differentiation within the injured myocardium, a reported adverse side effect. Indeed, we found that sFRP2 MSC treated hearts and wound tissue had less ectopic calcification. This work provides important new insight into the mechanisms by which sFRP2 increases MSC self renewal leading to superior tissue engraftment and enhanced wound healing.
C1 [Young, Pampee P.] Vanderbilt Univ, Med Ctr, Dept Pathol, Sch Med, Nashville, TN 37232 USA.
   [Thorne, Curtis A.; Lee, Ethan] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA.
   [Hong, Charles C.; Young, Pampee P.] Vanderbilt Univ, Med Ctr, Dept Internal Med, Nashville, TN 37232 USA.
   [Hong, Charles C.; Young, Pampee P.] Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Tennessee Valley Healthcare System
RP Young, PP (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Pathol, Sch Med, 1161 21st Ave S,C2217A MCN, Nashville, TN 37232 USA.
EM pampee.young@vanderbilt.edu
RI ; Hong, Charles/C 9989 2010
OI Hong, Charles/0000 0002 0424 8252; 
FU National Institutes of Health [R01 HL088424, HL08842402S1,
   R01 GM081635]; Veterans Affairs merit award; National Cancer Institute
   [GI SPORE P50CA95103]; American Heart Association [09PRE2010035]; NIDDK,
   National Institutes of Health [U24 DK 59637]; American Heart Association
   (AHA) [09PRE2010035] Funding Source: American Heart Association (AHA)
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants R01 HL088424, HL08842402S1, and R01 GM081635; Veterans
   Affairs merit award (to P. P. Y.); National Cancer Institute GI SPORE
   P50CA95103 (to E. L.); and American Heart Association Grant 09PRE2010035
   (to M. P. A.).MI surgeries were performed in the Cardiovascular
   Pathophysiology and Complications Core of the Vanderbilt Mouse Metabolic
   Phenotyping Center, supported by NIDDK, National Institutes of Health
   Grant U24 DK 59637.
CR Alfaro MP, 2008, P NATL ACAD SCI USA, V105, P18366, DOI 10.1073/pnas.0803437105
   Breitbach M, 2007, BLOOD, V110, P1362, DOI 10.1182/blood 2006 12 063412
   Collavin L, 2003, DEVELOPMENT, V130, P805, DOI 10.1242/dev.00306
   De Robertis EM, 2004, ANNU REV CELL DEV BI, V20, P285, DOI 10.1146/annurev.cellbio.20.011403.154124
   Denker AE, 1999, DIFFERENTIATION, V64, P67, DOI 10.1046/j.1432 0436.1999.6420067.x
   Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1074>3.0.CO;2 C
   Ezan J, 2004, CARDIOVASC RES, V63, P731, DOI 10.1016/j.cardiores.2004.05.006
   Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770
   Gaur T, 2006, J CELL PHYSIOL, V208, P87, DOI 10.1002/jcp.20637
   Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652
   Gregory KE, 2005, J BIOL CHEM, V280, P27970, DOI 10.1074/jbc.M504270200
   Hao JJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002904
   Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131
   Iso Y, 2007, BIOCHEM BIOPH RES CO, V354, P700, DOI 10.1016/j.bbrc.2007.01.045
   Jorgensen C, 2004, CURR OPIN BIOTECH, V15, P406, DOI 10.1016/j.copbio.2004.08.003
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lee HX, 2006, CELL, V124, P147, DOI 10.1016/j.cell.2005.12.018
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Manton KJ, 2007, STEM CELLS, V25, P2845, DOI 10.1634/stemcells.2007 0065
   McReynolds LJ, 2007, BLOOD, V110, P3881, DOI 10.1182/blood 2007 04 085753
   Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636
   Mirotsou M, 2007, P NATL ACAD SCI USA, V104, P1643, DOI 10.1073/pnas.0610024104
   Misra K, 2010, DEV BIOL, V337, P74, DOI 10.1016/j.ydbio.2009.10.015
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092 8674(94)90068 X
   Satija NK, 2007, STEM CELLS DEV, V16, P7, DOI 10.1089/scd.2006.9998
   SCHOFIELD R, 1983, BIOMED PHARMACOTHER, V37, P375
   Suzuki T, 2005, INT J HEMATOL, V82, P285, DOI 10.1532/IJH97.05115
   Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
   Zhang ZY, 2009, J MOL CELL CARDIOL, V46, P370, DOI 10.1016/j.yjmcc.2008.11.016
   Zilberberg L, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 41
NR 34
TC 102
Z9 117
U1 1
U2 16
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
SN 0021 9258
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 12
PY 2010
VL 285
IS 46
BP 35645
EP 35653
DI 10.1074/jbc.M110.135335
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 675QK
UT WOS:000283845300043
PM 20826809
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Tao, ZS
   Zhou, WS
   Zhang, RT
   Li, Y
   Xu, HG
   Wei, S
   Wang, ZY
   Yang, M
AF Tao, Zhou Shan
   Zhou, Wan Shu
   Zhang, Rou Tian
   Li, Yang
   Xu, Hong Guang
   Wei, Shan
   Wang, Zheng Yu
   Yang, Min
TI Co modification of calcium phosphate cement to achieve rapid bone
   regeneration in osteoporotic femoral condyle defect with lithium and
   aspirin
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Calcium phosphate cement; lithium; aspirin; inflammation; osteoporotic
   bone defect
ID BETA TRICALCIUM PHOSPHATE; PARATHYROID HORMONE 1 34; OSTEOGENIC
   DIFFERENTIATION; DISTAL FEMUR; PROMOTES; PROLIFERATION; TERIPARATIDE;
   SCAFFOLDS; REPAIR; DRUGS
AB Local application of lithium or aspirin with biological scaffold has been identified as a potent means to improve bone formation. In this study, lithium and aspirin modified calcium phosphate cement (Asp Li/CPC) was prepared, and the feasibility of this biological scaffold in the treatment of osteoporotic bone defect was observed in vivo and in vitro. In vitro experiments confirmed that Asp Li/CPC had better ability to promote MC3T3 E1 cells differentiation into osteoblasts, osteoblast mineralization and viability, and promote cell expression of ALP, OP, RUNX 2, OC and COL 1 protein than simple CPC or lithium modified CPC by MTT, Alizarin red staining and Western blot evaluation. In vivo experiments confirmed that Asp Li/CPC presented the strongest effect on bone regeneration and bone mineralization through the comparison with CPC group and Li/CPC group with X ray images, Micro CT and Histological evaluation. RT qPCR analysis showed that Asp Li/CPC, Li/CPC group and CPC group demonstrated increased BMP2, Smad1, OPG than the OVX group (P<0.05), while Asp Li/CPC exhibited decreased TNF alpha, IFN gamma and RANKL than the OVX group (P<0.05). Experiments in vivo and in vitro show that Asp Li/CPC is a scheme for rapid repair of femoral condylar defects, and these effects may be achieved by inhibiting local inflammation and through BMP 2/Smad1 and OPG/RANKL signaling pathway.
C1 [Tao, Zhou Shan; Zhang, Rou Tian; Li, Yang; Wang, Zheng Yu; Yang, Min] Wannan Med Coll, Yijishan Hosp, Dept Trauma Orthoped, Affiliated Hosp 1, 2 Zhe Shan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
   [Zhou, Wan Shu] Wannan Med Coll, Dept Geriatr, Affiliated Hosp 2, Wuhu 241000, Anhui, Peoples R China.
   [Xu, Hong Guang] Wannan Med Coll, Key Lab Noncoding RNA Transformat Res Anhui Highe, Spine Res Ctr, Dept Spine Surg,Yijishan Hosp,Affiliated Hosp 1, Wuhu 241001, Anhui, Peoples R China.
   [Wei, Shan] Minist Educ, Key Lab Adv Percept & Intelligent Control High En, Wuhu 241000, Anhui, Peoples R China.
   [Wei, Shan] Anhui Polytech Univ, Addit Mfg Inst, Wuhu 241000, Anhui, Peoples R China.
   [Wei, Shan] Anhui Key Lab Adv Numer Control & Servo Technol, Wuhu 241000, Anhui, Peoples R China.
C3 Wannan Medical College; Wannan Medical College; Wannan Medical College;
   Anhui Polytechnic University
RP Wang, ZY; Yang, M (通讯作者)，Wannan Med Coll, Yijishan Hosp, Dept Trauma Orthoped, Affiliated Hosp 1, 2 Zhe Shan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
EM tzs19900327@yeah.net; zhmm58 66@126.com
RI Xu, Hong Guang/F 1731 2010
FU University Natural Science Research Project of Anhui Province
   [KJ2017A266, KJ2017A117]; "Panfeng" Innovation Team Project for
   Scientific Research of Yijishan Hospital, Wannan Medical College
   [GF2019G04, PF2019005, GF2019T02, PF2019007]; National Natural Science
   Foundation of China [82002322]; Wannan Medical College [YR201917]; Young
   and Middle aged Key Project of Wannan Medical College [WK2020ZF16];
   Additive Manufacturing Institute of Anhui Polytechnic University Open
   Project [2020ybxm06]; Wuhu Science and Technology Plan Project
   [2020ms3 1]
FX This study was supported by a grant from the University Natural Science
   Research Project of Anhui Province (CN) (grant no. KJ2017A266,
   KJ2017A117), Funding of "Peak" Training Program and "Panfeng" Innovation
   Team Project for Scientific Research of Yijishan Hospital, Wannan
   Medical College (grant no. GF2019G04, PF2019005, GF2019T02 and
   PF2019007), National Natural Science Foundation of China (82002322),
   Talented Scholars of Wannan Medical College (YR201917), Young and
   Middle aged Key Project of Wannan Medical College (WK2020ZF16), Additive
   Manufacturing Institute of Anhui Polytechnic University Open Project
   (Grant No. 2020ybxm06), Wuhu Science and Technology Plan Project (Grant
   No. 2020ms3 1).
CR Arioka M, 2014, BIOCHEM PHARMACOL, V90, P397, DOI 10.1016/j.bcp.2014.06.011
   de Oliveira JCD, 2017, ORAL MAXILLOFAC SURG, V21, P247, DOI 10.1007/s10006 017 0624 3
   Du J, 2018, J PERIODONTAL RES, V53, P47, DOI 10.1111/jre.12485
   Fu J, 2019, HORM METAB RES, V51, P511, DOI 10.1055/a 0963 0054
   García García P, 2020, MAT SCI ENG C MATER, V115, DOI 10.1016/j.msec.2020.111009
   Ge YW, 2020, J CELL MOL MED, V24, P3203, DOI 10.1111/jcmm.14995
   Ghamor Amegavi EP, 2020, J BIOMED MATER RES B, V108, P377, DOI 10.1002/jbm.b.34396
   Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917
   Kazemi M, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110071
   Khan PK, 2016, SCI REP UK, V6, DOI 10.1038/srep32964
   Lei L, 2019, J MATER CHEM B, V7, P2722, DOI 10.1039/c9tb00025a
   Li L, 2017, SCI REP UK, V7, DOI 10.1038/srep45204
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Liu Y, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201165
   Luo Y, 2018, BIO MED MATER ENG, V29, P699, DOI 10.3233/BME 181018
   Pan J, 2017, ORTHOD CRANIOFAC RES, V20, P146, DOI 10.1111/ocr.12190
   Ren C, 2019, CHIN J NAT MEDICINES, V17, P756, DOI 10.1016/S1875 5364(19)30092 5
   Tang CY, 2020, BIOCHEM J, V477, P2421, DOI 10.1042/BCJ20200036
   Tao ZS, 2019, J BIOMATER APPL, V34, P664, DOI 10.1177/0885328219863290
   Tao ZS, 2019, J BONE MINER METAB, V37, P1026, DOI 10.1007/s00774 019 01008 w
   Tao ZS, 2019, Z GERONTOL GERIATR, V52, P139, DOI 10.1007/s00391 018 1376 x
   Tao ZS, 2019, J BONE MINER METAB, V37, P28, DOI 10.1007/s00774 018 0906 3
   Tao ZS, 2016, MED BIOL ENG COMPUT, V54, P1959, DOI 10.1007/s11517 016 1494 9
   Tao ZS, 2016, Z GERONTOL GERIATR, V49, P423, DOI 10.1007/s00391 015 0949 1
   Tao ZS, 2016, MED BIOL ENG COMPUT, V54, P1353, DOI 10.1007/s11517 015 1402 8
   Tao ZS, 2015, J CRANIO MAXILL SURG, V43, P2136, DOI 10.1016/j.jcms.2015.09.004
   Tao ZS, 2015, J BIOMATER APPL, V30, P484, DOI 10.1177/0885328215592854
   Tao ZS, 2015, INJURY, V46, P2134, DOI 10.1016/j.injury.2015.07.042
   Tao ZS, 2020, J BIOMATER APPL, V34, P1009, DOI 10.1177/0885328219889630
   Vachhani K, 2018, J ORTHOP RES, V36, P1783, DOI 10.1002/jor.23799
   Wang YM, 2018, BIOCHEM BIOPH RES CO, V498, P981, DOI 10.1016/j.bbrc.2018.03.093
   Wu S, 2019, ARTIF CELL NANOMED B, V47, P1570, DOI 10.1080/21691401.2019.1604534
   Xie Y, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578 019 0369 9
   Xu ZM, 2019, MOLECULES, V24, DOI 10.3390/molecules24234397
   Yuan MT, 2018, INT J MOL MED, V42, P1967, DOI 10.3892/ijmm.2018.3801
   Zhang J, 2018, COLLOID SURFACE B, V170, P563, DOI 10.1016/j.colsurfb.2018.06.038
   Zhao Y, 2020, ACTA BIOMATER, V113, P614, DOI 10.1016/j.actbio.2020.06.024
NR 37
TC 9
Z9 11
U1 1
U2 17
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2021
VL 13
IS 3
BP 952
EP 966
PG 15
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA RB1JE
UT WOS:000631871900009
PM 33841632
DA 2025 08 17
ER

PT S
AU Cook, D
   Genever, P
AF Cook, David
   Genever, Paul
BE Hime, G
   Abud, H
TI Regulation of Mesenchymal Stem Cell Differentiation
SO TRANSCRIPTIONAL AND TRANSLATIONAL REGULATION OF STEM CELLS
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Mesenchymal stem cells; Osteogenesis; Chondrogenesis; Adipogenesis;
   Transcriptional control
ID BONE MORPHOGENETIC PROTEIN 2; MARROW STROMAL CELLS; RECEPTOR RELATED
   PROTEIN 5; OSTEOBLAST DIFFERENTIATION; GENE EXPRESSION; PPAR GAMMA;
   TRANSCRIPTION FACTORS; IN VITRO; CHONDROCYTE DIFFERENTIATION; OSTEOGENIC
   DIFFERENTIATION
AB A population of multipotent stromal cells exists within bone marrow and other adult tissues, which is able to differentiate into different skeletal tissues such as bone, cartilage and fat. These cells are frequently referred to as mesenchymal stem cells (MSCs) and offer significant therapeutic potential, particularly in orthopaedic applications, but may also have broader roles in regenerative medicine, cancer treatment, as anti inflammatories, immunosuppressives and vehicles for gene/protein therapy. Much attention has focused on understanding MSC biology and the regulation of differentiation to help realise these clinical aspirations. Here we review some of the key molecular determinants of MSC function, with an emphasis on transcription factor control and the cell cell signalling pathways that regulate MSC differentiation. The source information comes from a range of different models, including isolated human MSC cultures, animal derived MSC like cell lines, animal models and skeletal developmental processes to provide a wide angled overview of the important players in MSC biology and tri lineage specification.
C1 [Cook, David; Genever, Paul] Univ York, Dept Biol, Area 9, York YO10 5DD, N Yorkshire, England.
C3 University of York   UK
RP Genever, P (通讯作者)，Univ York, Dept Biol, Area 9, Wentworth Way, York YO10 5DD, N Yorkshire, England.
EM paul.genever@york.ac.uk
OI Genever, Paul/0000 0002 5730 8976
CR Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Baksh D, 2007, J CELL BIOCHEM, V101, P1109, DOI 10.1002/jcb.21097
   Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026
   Benfey PN, 2003, NATURE, V425, P244, DOI 10.1038/425244a
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Chen XW, 1996, ANN NY ACAD SCI, V785, P38, DOI 10.1111/j.1749 6632.1996.tb56242.x
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   da Silva ML, 2006, J CELL SCI, V119, P2204, DOI DOI 10.1242/JCS.02932
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   De Luca F, 2001, ENDOCRINOLOGY, V142, P430, DOI 10.1210/en.142.1.430
   Depew MJ, 1999, DEVELOPMENT, V126, P3831
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dong YF, 2006, J CELL PHYSIOL, V208, P77, DOI 10.1002/jcp.20656
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eijken M, 2008, J CELL BIOCHEM, V104, P568, DOI 10.1002/jcb.21651
   Enomoto Iwamoto M, 2001, OSTEOARTHR CARTILAGE, V9, pS76, DOI 10.1053/joca.2001.0448
   Fajas L, 1999, MOL CELL BIOL, V19, P5495
   FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654
   FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   Frith J, 2008, TRANSFUS MED HEMOTH, V35, P216, DOI [10.1159/000127448, 000127448]
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   GITELMAN SE, 1995, CELL GROWTH DIFFER, V6, P827
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248 9261.2004
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Ikeda T, 2004, ARTHRITIS RHEUM US, V50, P3561, DOI 10.1002/art.20611
   Im GI, 2011, BIOTECHNOL LETT, V33, P1061, DOI 10.1007/s10529 010 0514 3
   Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kahler RA, 2006, J CELL BIOCHEM, V97, P969, DOI 10.1002/jcb.20702
   Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925 4773(98)00210 X
   Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Kurata H, 2007, TISSUE ENG, V13, P1513, DOI 10.1089/ten.2006.0374
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447
   Lengner CJ, 2005, J BIOL CHEM, V280, P15872, DOI 10.1074/jbc.M411144200
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Lutz M, 2002, CELL SIGNAL, V14, P977, DOI 10.1016/S0898 6568(02)00058 X
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   McMahon LA, 2008, ANN BIOMED ENG, V36, P185, DOI 10.1007/s10439 007 9416 5
   Moldes M, 1999, BIOCHEM J, V344, P873, DOI 10.1042/0264 6021:3440873
   Mueller E, 2002, J BIOL CHEM, V277, P41925, DOI 10.1074/jbc.M206950200
   Murtaugh LC, 2001, DEV CELL, V1, P411, DOI 10.1016/S1534 5807(01)00039 9
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Okamura M, 2009, P NATL ACAD SCI USA, V106, P5819, DOI 10.1073/pnas.0901676106
   Pelttari K, 2008, INJURY, V39, pS58, DOI 10.1016/j.injury.2008.01.038
   Phillips JE, 2006, J CELL SCI, V119, P581, DOI 10.1242/jcs.02758
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prestwich TC, 2007, CURR OPIN CELL BIOL, V19, P612, DOI 10.1016/j.ceb.2007.09.014
   Quarto N, 2010, TISSUE ENG PT A, V16, P3185, DOI 10.1089/ten.tea.2010.0133
   Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402
   Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097 2765(00)80211 7
   Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702
   Saito T, 2007, EMBO REP, V8, P504, DOI 10.1038/sj.embor.7400934
   SAMPATH TK, 1992, J BIOL CHEM, V267, P20352
   Samulin J, 2008, COMP BIOCHEM PHYS B, V151, P147, DOI 10.1016/j.cbpb.2008.06.010
   Semba I, 2000, DEV DYNAM, V217, P401, DOI 10.1002/(SICI)1097 0177(200004)217:4<401::AID DVDY7>3.0.CO;2 D
   Shimoyama A, 2007, MOL BIOL CELL, V18, P2411, DOI 10.1091/mbc.E06 08 0743
   Shui CX, 2003, J BONE MINER RES, V18, P213, DOI 10.1359/jbmr.2003.18.2.213
   Sim WY, 2007, LAB CHIP, V7, P1775, DOI 10.1039/b712361m
   Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534 5807(01)00003 X
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Tadic T, 2002, J BONE MINER RES, V17, P1008, DOI 10.1359/jbmr.2002.17.6.1008
   Tang QQ, 2000, P NATL ACAD SCI USA, V97, P12446, DOI 10.1073/pnas.220425597
   Tong Q, 2005, MOL CELL BIOL, V25, P706, DOI 10.1128/MCB.25.2.706 715.2005
   Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134
   TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224
   Tu QS, 2006, BIOCHEM BIOPH RES CO, V341, P1257, DOI 10.1016/j.bbrc.2006.01.092
   Valcourt U., 2005, Eur. J. Trauma, V31, P464, DOI DOI 10.1007/S00068 005 2049 1
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Wu L, 2007, MOL CELL BIOCHEM, V301, P83, DOI 10.1007/s11010 006 9399 9
   Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097 2765(00)80306 8
   Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378 1119(98)00227 3
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168
   Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499
   Zeng L, 2002, GENE DEV, V16, P1990, DOI 10.1101/gad.1008002
   Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097 0177(199708)209:4<377::AID AJA5>3.0.CO;2 F
   Zheng H, 2004, CALCIFIED TISSUE INT, V74, P194, DOI 10.1007/s00223 003 0004 x
NR 104
TC 70
Z9 85
U1 0
U2 42
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0065 2598
BN 978 94 007 6621 1; 978 94 007 6620 4
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2013
VL 786
BP 213
EP 229
DI 10.1007/978 94 007 6621 1_12
D2 10.1007/978 94 007 6621 1
PG 17
WC Cell Biology; Developmental Biology; Medicine, Research & Experimental
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology; Research & Experimental Medicine
GA BA2AW
UT WOS:000333215400012
PM 23696359
DA 2025 08 17
ER

PT J
AU Xu, WL
   Ong, HS
   Zhu, Y
   Liu, SW
   Liu, LM
   Zhou, KH
   Xu, ZQ
   Gao, J
   Zhang, Y
   Ye, JH
   Yang, WJ
AF Xu, Wan Lin
   Ong, Hui Shan
   Zhu, Yun
   Liu, Sheng Wen
   Liu, Li Min
   Zhou, Kai Hua
   Xu, Zeng Qi
   Gao, Jun
   Zhang, Yan
   Ye, Jin Hai
   Yang, Wen Jun
TI In Situ Release of VEGF Enhances Osteogenesis in 3D Porous
   Scaffolds Engineered with Osterix Modified Adipose Derived Stem Cells
SO TISSUE ENGINEERING PART A
LA English
DT Article
DE Osterix; ADSCs; VEGF; PCL scaffolds; control release; osteogenesis
ID TRANSCRIPTION FACTOR OSTERIX; GROWTH FACTOR RELEASE; MARROW STROMAL
   CELLS; CALVARIAL BONE; OSTEOBLAST DIFFERENTIATION; TISSUE; DEFECTS;
   EXPRESSION; PROMOTE; VIVO
AB Adipose derived stem cells (ADSCs) can differentiate into various cell types and thus have great potential for regenerative medicine. Herein, rat ADSCs were isolated; transduced with lentiviruses expressing Osterix (Osx), a transcriptional factor essential for osteogenesis. Osx overexpression upregulated key osteogenesis related genes, such as special AT rich binding protein 2, alkaline phosphatase, osteocalcin, and osteopontin, at both mRNA and protein levels. In addition, mineral nodule formation and alkaline phosphatase activity were enhanced in Osx overexpressing ADSCs. The expression of dickkopf related protein 1, a potent Wnt signaling pathway inhibitor, was also increased, whereas that of beta catenin, an intracellular signal transducer in the Wnt pathway, was decreased. beta catenin expression was partially recovered by treatment with lithium chloride, a canonical Wnt pathway activator. The Osx expressing ADSCs were then combined with 3D gelatin coated porous poly(e caprolactone) scaffolds with a unique release prolife of entrapped recombinant human vascular endothelial growth factor (VEGF). The controlled release of VEGF promoted osteogenic differentiation capacity in vitro. When the scaffold ADSC complexes were transplanted into rat calvarial critical sized defects, more bone formed on the gelatin/VEGF coated scaffolds than on other scaffold types. Taken together, the results indicate that, Osx overexpression promotes ADSCs' osteogenesis both in vitro and in vivo, which could be enhanced by release of VEGF.
C1 [Xu, Wan Lin; Ong, Hui Shan; Zhu, Yun; Liu, Sheng Wen; Liu, Li Min; Zhou, Kai Hua; Yang, Wen Jun] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, Shanghai 200011, Peoples R China.
   [Xu, Wan Lin; Ong, Hui Shan; Zhu, Yun; Liu, Sheng Wen; Liu, Li Min; Zhou, Kai Hua; Yang, Wen Jun] Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
   [Xu, Wan Lin; Ong, Hui Shan; Zhu, Yun; Liu, Sheng Wen; Liu, Li Min; Zhou, Kai Hua; Yang, Wen Jun] Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
   [Xu, Wan Lin; Xu, Zeng Qi; Ye, Jin Hai] Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Oral & Maxillofacial Surg, Jiangsu Key Lab Oral Dis, Nanjing 210029, Jiangsu, Peoples R China.
   [Gao, Jun] Nanjing Med Univ, Dept Neurobiol, Key Lab Human Funct Genom Jiangsu, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Yan] East China Univ Sci & Technol, Shanghai Key Lab Adv Polymer Mat, Sch Mat Sci & Engn, Key Lab Ultrafine Mat,Minist Educ, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Nanjing Medical University; Nanjing
   Medical University; East China University of Science & Technology
RP Yang, WJ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Oral & Maxillofacial Head & Neck Oncol, Shanghai 200011, Peoples R China.; Ye, JH (通讯作者)，Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Oral & Maxillofacial Surg, Jiangsu Key Lab Oral Dis, Nanjing 210029, Jiangsu, Peoples R China.
EM yejinhai@njmu.edu.cn; ywjdoctor@hotmail.com
FU National Natural Science Foundation of China [81371123, 81302359,
   81222013]; Jiangsu Natural Science Foundation [BK2012844]; Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD) [2014 37]; Qing Lan Project; Science and Technology Commission of
   Shanghai Municipality [15411950300]
FX This study was supported by the National Natural Science Foundation of
   China (81371123 and 81302359), the Jiangsu Natural Science Foundation
   (BK2012844), the Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD, 2014 37), and the Qing Lan Project through
   grants awarded to J.H Ye. This work was also partially supported by the
   National Natural Science Foundations of China (No. 81222013) with a
   grant awarded to J Gao and the Research Grants (15411950300) from
   Science and Technology Commission of Shanghai Municipality.
CR Alam MI, 2001, PLAST RECONSTR SURG, V108, P952, DOI 10.1097/00006534 200109150 00020
   Bigalke C, 2014, ACTA BIOMATER, V10, P5081, DOI 10.1016/j.actbio.2014.09.002
   Cao ZG, 2015, INT J BIOL SCI, V11, P335, DOI 10.7150/ijbs.10874
   Chen L, 2010, J MATER SCI MATER M, V21, P309, DOI 10.1007/s10856 009 3827 9
   Chen QA, 2010, CYTOTHERAPY, V12, P831, DOI 10.3109/14653249.2010.495980
   Clark D, 2015, J BIOMED MATER RES A, V103, P639, DOI 10.1002/jbm.a.35215
   Deng Y, 2013, BIOMATERIALS, V34, P6717, DOI 10.1016/j.biomaterials.2013.05.042
   Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003
   Etulain J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096402
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603 669
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gnavi S, 2017, J TISSUE ENG REGEN M, V11, P459, DOI 10.1002/term.1936
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Holy CE, 2003, J BIOMED MATER RES A, V65A, P447, DOI 10.1002/jbm.a.10453
   Holzapfel BM, 2013, ADV DRUG DELIVER REV, V65, P581, DOI 10.1016/j.addr.2012.07.009
   Kim KI, 2014, BIOMATERIALS, V35, P4792, DOI 10.1016/j.biomaterials.2014.02.048
   Ko E, 2013, BIOMACROMOLECULES, V14, P3202, DOI 10.1021/bm4008343
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Lee JS, 2011, BIOMATERIALS, V32, P760, DOI 10.1016/j.biomaterials.2010.09.042
   Lin CY, 2013, BIOMATERIALS, V34, P9401, DOI 10.1016/j.biomaterials.2013.08.051
   Lin J, 2007, J TISSUE ENG REGEN M, V1, P211, DOI 10.1002/term.27
   Lin L, 2006, ACTA PHARMACOL SIN, V27, P1608, DOI 10.1111/j.1745 7254.2006.00449.x
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Poldervaart MT, 2014, J CONTROL RELEASE, V184, P58, DOI 10.1016/j.jconrel.2014.04.007
   REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473
   Singh S, 2011, BIOMATERIALS, V32, P2059, DOI 10.1016/j.biomaterials.2010.11.038
   Suárez González D, 2012, BIOMATERIALS, V33, P713, DOI 10.1016/j.biomaterials.2011.09.095
   Tang WJ, 2011, J BIOL CHEM, V286, P32995, DOI 10.1074/jbc.M111.244236
   Tu Q, 2007, TISSUE ENG, V13, P2431, DOI 10.1089/ten.2006.0406
   Tu QS, 2006, BIOCHEM BIOPH RES CO, V341, P1257, DOI 10.1016/j.bbrc.2006.01.092
   Wang SN, 2012, STEM CELL RES, V8, P346, DOI 10.1016/j.scr.2011.12.005
   Wu W, 2015, TISSUE ENG PT A, V21, P1621, DOI [10.1089/ten.tea.2014.0115, 10.1089/ten.TEA.2014.0115]
   Xia LG, 2014, BIOMATERIALS, V35, P8514, DOI 10.1016/j.biomaterials.2014.06.028
   Xia YP, 2003, BLOOD, V102, P161, DOI 10.1182/blood 2002 12 3793
   Xu B, 2009, J DENT RES, V88, P1003, DOI 10.1177/0022034509346928
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Ye JH, 2011, BIOMATERIALS, V32, P5065, DOI 10.1016/j.biomaterials.2011.03.053
   Young S, 2005, J CONTROL RELEASE, V109, P256, DOI 10.1016/j.jconrel.2005.09.023
   Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105
   Zhang C, 2012, BIOCHEM BIOPH RES CO, V420, P782, DOI 10.1016/j.bbrc.2012.03.073
   Zhang QC, 2014, BIOMACROMOLECULES, V15, P84, DOI 10.1021/bm401309u
   Zhang QC, 2013, MAT SCI ENG C MATER, V33, P2094, DOI 10.1016/j.msec.2013.01.025
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 44
TC 23
Z9 27
U1 0
U2 38
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD MAY
PY 2017
VL 23
IS 9 10
BP 445
EP 457
DI 10.1089/ten.tea.2016.0315
PG 13
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA EU9FB
UT WOS:000401342400008
PM 28107808
DA 2025 08 17
ER

PT J
AU Kim, J
   Lyu, HZ
   Jung, C
   Lee, KM
   Han, SH
   Lee, JH
   Cha, M
AF Kim, Jungju
   Lyu, Hao Zhen
   Jung, Chisung
   Lee, Kyung Mee
   Han, Shi Huan
   Lee, Jae Hyup
   Cha, Misun
TI Osteogenic Response of MC3T3 E1 and Raw264.7 in the 3D Encapsulated
   Co Culture Environment
SO TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE 3D culture system; Co culture; Encapsulation; Osteoblast; Osteoclast
ID EXTRACELLULAR MATRIX; CELLS; MODEL; DIFFERENTIATION; CULTURE; MECHANISM
AB BACKGROUND: Three dimensional (3D) in vitro cultures recapitulate the physiological microenvironment and exhibit high concordance with in vivo conditions. Improving co culture models with different kind of cell types cultured on a 3D scaffold can closely mimic the in vivo environment. In this study, we examined the osteogenic response of pre osteoblast MC3T3 E1 cells and Raw264.7 mouse monocytes in a 3D encapsulated co culture environment composed of the Cellrix(R) 3D culture system, which provides a physiologically relevant environment.
   METHODS: The Cellrix(R) 3D Bio Gel scaffolds were used to individually culture or co culture two type cells in 3D microenvironment. Under 3D culture conditions, osteoblastic behavior was evaluated with an ALP assay and staining. ACP assay and TRAP staining were used as osteoclastic behavior indicator.
   RESULTS: Treatment with osteoblastic induction factors (+3F) and RANKL had on positively effect on alkaline phosphatase activity but significantly inhibited to acid phosphatase activity during osteoclastic differentiation in 3D co culture. Interestingly, alkaline phosphatase activity or acid phosphatase activity in 3D co culture was stimulated with opposite differentiation factors at an early stage of differentiation. We guess that these effects may be related to RANK RANKL signaling, which is important in osteoblast regulation of osteoclasts.
   CONCLUSION: In this study, the osteogenic response of 3D encapsulated pre osteoblast MC3T3 E1 cells and mouse monocyte Raw264.7 cells was successfully demonstrated. Our 3D culture conditions will be able to provide a foundation for developing a high throughput in vitro bone model to study the effects of various drugs and other agents on molecular pathways.
C1 [Kim, Jungju; Jung, Chisung; Cha, Misun] Medifab Co Ltd, Res Inst Biotechnol, 70 Dusan Ro, Seoul 08584, South Korea.
   [Lyu, Hao Zhen; Lee, Kyung Mee; Han, Shi Huan; Lee, Jae Hyup] Seoul Natl Univ, Coll Med, Dept Orthoped Surg, Daehak Ro 103, Seoul 03080, South Korea.
   [Lee, Jae Hyup] SMG SNU Boramae Med Ctr, Dept Orthoped Surg, Boramae Ro 5 Gil 20, Seoul 07061, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital
RP Cha, M (通讯作者)，Medifab Co Ltd, Res Inst Biotechnol, 70 Dusan Ro, Seoul 08584, South Korea.; Lee, JH (通讯作者)，Seoul Natl Univ, Coll Med, Dept Orthoped Surg, Daehak Ro 103, Seoul 03080, South Korea.; Lee, JH (通讯作者)，SMG SNU Boramae Med Ctr, Dept Orthoped Surg, Boramae Ro 5 Gil 20, Seoul 07061, South Korea.
EM spinelee@snu.ac.kr; cmsbest@imedifab.com
RI Han, Shihuan/GLU 7577 2022
OI Han, Shi Huan/0000 0001 5400 761X
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education, Science and Technology
   [NRF 2018R1D1A1B07040482, 03 2016 0190]; SNUH Research Fund
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF), funded by the
   Ministry of Education, Science and Technology (NRF 2018R1D1A1B07040482)
   and by Grant No. 03 2016 0190 from the SNUH Research Fund.
CR Bokhari M, 2007, J ANAT, V211, P567, DOI 10.1111/j.1469 7580.2007.00778.x
   Chinta MS, 2020, PRS GLOB OPEN, V8, DOI 10.1097/GOX.0000000000002787
   Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Davidenko N, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 016 5763 9
   Elliott NT, 2011, J PHARM SCI US, V100, P59, DOI 10.1002/jps.22257
   Gevaert M, 2012, BRIDGE, V42, P48
   Han SH, 2021, BIOMED MATER, V16, DOI 10.1088/1748 605X/aba879
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Huang GY, 2017, CHEM REV, V117, P12764, DOI 10.1021/acs.chemrev.7b00094
   Iwamoto Y, 2016, MOL CELL BIOL, V36, P1610, DOI 10.1128/MCB.01028 15
   Jones GL, 2009, BIOMATERIALS, V30, P5376, DOI 10.1016/j.biomaterials.2009.07.028
   Kang YK, 2014, GENET MOL RES, V13, P4673, DOI 10.4238/2014.June.18.10
   Koo S, 2019, ACS APPL BIO MATER, V2, P4648, DOI 10.1021/acsabm.9b00722
   LaBarbera DV, 2012, EXPERT OPIN DRUG DIS, V7, P819, DOI 10.1517/17460441.2012.708334
   Mercatali L, 2017, J VIS EXP, V127, P56311
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   ORLANDINI SZ, 1995, CELL TISSUE RES, V281, P33, DOI 10.1007/BF00307956
   Penolazzi L, 2016, LIFE SCI, V152, P82, DOI 10.1016/j.lfs.2016.03.035
   Prestwich GD, 2008, ACCOUNTS CHEM RES, V41, P139, DOI 10.1021/ar7000827
   Prestwich GD, 2007, J CELL BIOCHEM, V101, P1370, DOI 10.1002/jcb.21386
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rijal G, 2017, INT J BIOMATER, V2017, DOI 10.1155/2017/8074890
   Roeder I, 2011, BLOOD CELL MOL DIS, V46, P308, DOI 10.1016/j.bcmd.2011.03.001
   Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511
   Sharma A, 2019, J AM CHEM SOC, V141, P15611, DOI 10.1021/jacs.9b07171
   Sieni E, 2020, CANCERS, V12, DOI 10.3390/cancers12041043
   Song HK, 2019, ARCH ORAL BIOL, V108, DOI 10.1016/j.archoralbio.2019.104530
   Tevlek A, 2017, MAT SCI ENG C MATER, V72, P316, DOI 10.1016/j.msec.2016.11.082
   Torricelli P, 2004, INT J ARTIF ORGANS, V27, P658, DOI 10.1177/039139880402700803
   Weigelt B, 2010, BREAST CANCER RES TR, V122, P35, DOI 10.1007/s10549 009 0502 2
   Yao ZQ, 2008, J BIOL CHEM, V283, P9917, DOI 10.1074/jbc.M706415200
NR 32
TC 8
Z9 8
U1 3
U2 34
PU KOREAN TISSUE ENGINEERING REGENERATIVE MEDICINE SOC
PI SEOCHO GU
PA 1414 SEOCHO WORLD OFFICETEL 19, SEOUN RO, SEOCHO GU, SEOUL 06732, SOUTH
   KOREA
SN 1738 2696
EI 2212 5469
J9 TISSUE ENG REGEN MED
JI Tissue Eng. Regen. Med.
PD JUN
PY 2021
VL 18
IS 3
BP 387
EP 397
DI 10.1007/s13770 020 00321 0
EA JAN 2021
PG 11
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA SL4XJ
UT WOS:000605945000004
PM 33415675
OA Green Published
DA 2025 08 17
ER

PT J
AU Bandow, K
   Nishikawa, Y
   Ohnishi, T
   Kakimoto, K
   Soejima, K
   Iwabuchi, S
   Kuroe, K
   Matsuguchi, T
AF Bandow, Kenjiro
   Nishikawa, Yoshiaki
   Ohnishi, Tomokazu
   Kakimoto, Kyoko
   Soejima, Kazuhisa
   Iwabuchi, Sadahiro
   Kuroe, Kazuto
   Matsuguchi, Tetsuya
TI Low intensity pulsed ultrasound (LIPUS) induces RANKL, MCP 1, and MIP 1β
   expression in osteoblasts through the angiotensin II type 1 receptor
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN 1; FOCAL ADHESION KINASE;
   MECHANICAL STRESS; IFN GAMMA; BONE RESORPTION; CELLS;
   OSTEOCLASTOGENESIS; ACCELERATION; ACTIVATION; OSTEOLYSIS
AB Constant mechanical stress is essential for the maintenance of bone mass and strength, which is achieved through the cooperative functions of osteoblasts and osteoclasts. However, it has not been fully elucidated how these cell types mediate mechanical signals. Low intensity pulsed ultrasound (LIPUS) therapy is a recently developed method for application of mechanical stress, and is used clinically to promote bone fracture healing. In the present study, we applied LIPUS to osteoblasts at different stages of maturation and analyzed their chemokine and cytokine expression. In comparison with their immature counterparts, mature osteoblasts expressed significantly higher levels of mRNAs for the receptor activator of nuclear factor kappa B ligand (RANKL), monocyte chemoattractant protein (MCP) 1, and macrophage inflammatory protein (MIP) 1 beta after a few hours of LIPUS treatment. Intriguingly, protein and mRNA expression of angiotensin II type 1 receptor (AT1), a known mechanoreceptor in cardiomyocytes, was detected in osteoblasts, and the level of expression increased significantly during cell maturation. Furthermore, LIPUS induced extracellular signal regulated kinase (ERK) phosphorylation and RANKL/chemokine expression was abrogated by a specific AT1 inhibitor. Thus, AT1 may play one of the essential roles in bone metabolism as a mechanoreceptor of osteoblasts.
C1 Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Dent, Kagoshima 8908544, Japan.
   Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Orthodont, Kagoshima 890, Japan.
   Teijin Pharma Ltd, Biomed Engn Labs, Tokyo, Japan.
C3 Kagoshima University; Kagoshima University; Teijin Pharma Limited
RP Matsuguchi, T (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Dent, 8 35 1 Sakuragaoka, Kagoshima 8908544, Japan.
EM tmatsugu@denta.hal.kagoshima u.ac.jp
RI Matsuguchi, Tetsuya/HGU 0412 2022; Iwabuchi, Sadahiro/AAD 4455 2022
OI Bandow, Kenjiro/0000 0002 1362 3034
CR Aguila HL, 2005, IMMUNOL REV, V208, P7, DOI 10.1111/j.0105 2896.2005.00333.x
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Bandow K, 2004, J CELL PHYSIOL, V201, P236, DOI 10.1002/jcp.20056
   Bendre M, 2003, CLIN ORTHOP RELAT R, pS39, DOI 10.1097/01.blo.0000093844.72468.f4
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Boutahar N, 2004, J BIOL CHEM, V279, P30588, DOI 10.1074/jbc.M313244200
   Carey RM, 2003, ENDOCR REV, V24, P261, DOI 10.1210/er.2003 0001
   Chou YF, 2005, J BIOMED MATER RES B, V75B, P81, DOI 10.1002/jbm.b.30261
   Cook SD, 1997, CLIN ORTHOP RELAT R, P198
   Flick LM, 2003, J ORTHOP RES, V21, P676, DOI 10.1016/S0736 0266(03)00011 1
   Iwabuchi S, 2005, BIOMATERIALS, V26, P7104, DOI 10.1016/j.biomaterials.2005.05.004
   Knöll R, 2002, CELL, V111, P943, DOI 10.1016/S0092 8674(02)01226 6
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Lisignoli G, 2002, CYTOKINE, V20, P231, DOI 10.1006/cyto.2002.2006
   Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218
   Marriott I, 2005, BONE, V37, P504, DOI 10.1016/j.bone.2005.05.011
   MikuniTakagaki Y, 1996, ENDOCRINOLOGY, V137, P2028, DOI 10.1210/en.137.5.2028
   MIZUNO K, 1992, LIFE SCI, V51, pPL183, DOI 10.1016/0024 3205(92)90627 2
   Nakamura M, 2003, ENDOCRINOLOGY, V144, P5441, DOI 10.1210/en.2003 0717
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   Nomura S, 2000, MATRIX BIOL, V19, P91, DOI 10.1016/S0945 053X(00)00050 0
   Saito M, 2004, BONE, V35, P644, DOI 10.1016/j.bone.2004.04.024
   Sowa H, 2003, J BIOL CHEM, V278, P21058, DOI 10.1074/jbc.M302044200
   STARNAUD R, 1995, J CELL BIOL, V131, P1351, DOI 10.1083/jcb.131.5.1351
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2005, IMMUNOL REV, V208, P181, DOI 10.1111/j.0105 2896.2005.00337.x
   Valente AJ, 1998, J IMMUNOL, V161, P3719
   Wang JG, 2001, BIOCHEM BIOPH RES CO, V288, P356, DOI 10.1006/bbrc.2001.5775
   WANG SJ, 1994, J ORTHOP RES, V12, P40, DOI 10.1002/jor.1100120106
   Warden SJ, 2000, CALCIFIED TISSUE INT, V66, P157, DOI 10.1007/s002230010031
   Yoshikawa H., 2000, J. Photochem. Photobiol. C, V1, P57
   Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137
NR 33
TC 90
Z9 105
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2007
VL 211
IS 2
BP 392
EP 398
DI 10.1002/jcp.20944
PG 7
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 152ET
UT WOS:000245344500014
PM 17167786
DA 2025 08 17
ER

PT J
AU Hagh, MF
   Noruzinia, M
   Mortazavi, Y
   Soleimani, M
   Kaviani, S
   Maymand, MM
AF Hagh, Majid Farshdousti
   Noruzinia, Mehrdad
   Mortazavi, Yousef
   Soleimani, Masoud
   Kaviani, Saeid
   Maymand, Maryam Mahmodinia
TI Zoledrinic Acid Induces Steoblastic Differentiation of Mesenchymal Stem
   Cells without Change in Hypomethylation Status of OSTERIX Promoter
SO CELL JOURNAL
LA English
DT Article
DE Zoledronic Acid; Osteoblastic Differentiation; Mesenchymal Stem Cells;
   Methylation; OSX
ID BONE MINERAL DENSITY; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTORS;
   ZOLEDRONIC ACID; IN VITRO; BISPHOSPHONATES; CBFA1; GENE; ALENDRONATE;
   EXPRESSION
AB Objective: Mechanism of zoledronic acid on osteoblastic differentiation of mesenchymal stem cells (MSCs) has not fully understood. With the knowledge of some drugs mechanism that alter methylation pattern of some genes, the present research sets out to evaluate osterix (OSX) promoter methylation pattern during zoledronic acid induced osteoblastic differentiation of MSCs.
   Materials and Methods: In this experimental study, MSCs were isolated from human bone marrow. For osteogenic differentiation, MSCs were pulse treated with 5 mu M Zoledronic acid for 3 hours and incubated after a medium change in osteogenic differentiation medium for 3 weeks. DNA and RNA were extracted on days 0, 7, 14 and 21 of MSCs differentiating to osteoblast. After cDNA synthesis, OSX expression was evaluated by RT PCR and quantitative Real Time PCR. After multiplicity of infection (MOI) treatment, gene specific methylation of OSX was analyzed by methylation specific PCR (MSP).
   Results: The mRNA expression of OSX was increased in osteoblast differentiated cells induced by zoledronic acid, especially on days 14 and 21 of differentiation (p<0.05), but expression of OSX didn't change in undifferentiated MSCs. MSP revealed that, on day 0, undifferentiated MSCs are totally methylated. But, on day 7 of differentiation, MSCs treated by zoledronic acid were totally unmethylated. OSX promoter remained unmethylated, afterwards.
   Conclusion: MSP revealed that OSX had a dynamic pattern in methylation, while MSCs gradually differentiated to osteoblasts. Our finding showed that promoter region of OSX is hypomethylated independently from zoledronic acid treatment during osteoblastic differentiation. This knowledge is important to understand drug mechanisms and can be useful for developing new therapies to combat against bone diseases.
C1 [Hagh, Majid Farshdousti; Noruzinia, Mehrdad; Soleimani, Masoud; Kaviani, Saeid] Tarbiat Modares Univ, Dept Hematol, Tehran, Iran.
   [Mortazavi, Yousef] Zanjan Univ Med Sci, Dept Hematol, Zanjan, Iran.
   [Maymand, Maryam Mahmodinia] Sarem Womens Hosp, SCRC, Tehran, Iran.
C3 Tarbiat Modares University
RP Noruzinia, M (通讯作者)，Tarbiat Modares Univ, Dept Hematol, POB 14155 111, Tehran, Iran.
EM noruzinia@modares.ac.ir
RI Hagh, Majid/D 9689 2017; Mortazavi, Yousef/J 2218 2016
OI noruzinia, mehrdad/0000 0002 1325 3758; Mortazavi,
   Yousef/0000 0002 4003 9618
FU Tarbiat Modares University, Faculty of the Medical Science
FX This manuscript is a part of Ph.D. thesis Supported by a grant from the
   Tarbiat Modares University, Faculty of the Medical Science. The authors
   are grateful to all who helped in conducting the present study. The
   authors declare no conflict of interest in this article.
CR Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111
   Boissier S, 2000, CANCER RES, V60, P2949
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   Eun SH, 2010, CURR OPIN CELL BIOL, V22, P737, DOI 10.1016/j.ceb.2010.09.004
   Fan H, 2007, CHINESE MED J PEKING, V120, P1626, DOI 10.1097/00029330 200709020 00015
   Farthing CR, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000116
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022 2836(87)90689 9
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Göllner H, 2001, MECH DEVELOP, V106, P77, DOI 10.1016/S0925 4773(01)00420 8
   Green JR, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.24154
   Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972
   Khazamipour N, 2009, HUM REPROD, V24, P2361, DOI 10.1093/humrep/dep194
   Klein BY, 1998, J CELL BIOCHEM, V68, P186, DOI 10.1002/(SICI)1097 4644(19980201)68:2<186::AID JCB5>3.0.CO;2 R
   Kolell KJ, 2002, MOL BIOL EVOL, V19, P216, DOI 10.1093/oxfordjournals.molbev.a004074
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Liu F, 2008, J BONE MINER METAB, V26, P312, DOI 10.1007/s00774 007 0842 0
   LOOKER AC, 1995, J BONE MINER RES, V10, P796
   Maricic M, 2010, CLIN RHEUMATOL, V29, P1079, DOI 10.1007/s10067 010 1486 3
   Milutinovic S, 2007, CARCINOGENESIS, V28, P560, DOI 10.1093/carcin/bgl167
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991
   Ponader S, 2008, COLLOID SURFACE B, V64, P275, DOI 10.1016/j.colsurfb.2008.02.002
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Siris ES, 2001, JAMA J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815
   Tarfiei G, 2011, CELL J, V13, P11
   Xi RW, 2005, SCIENCE, V310, P1487, DOI 10.1126/science.1120140
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
NR 38
TC 9
Z9 9
U1 0
U2 1
PU ROYAN INST
PI TEHRAN
PA PO BOX 19395 4644, TEHRAN, 00000, IRAN
SN 2228 5806
EI 2228 5814
J9 CELL J
JI Cell J.
PD SUM
PY 2012
VL 14
IS 2
BP 90
EP 97
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 016GF
UT WOS:000309504800003
PM 23508196
DA 2025 08 17
ER

PT J
AU Pérez Castrillón, JL
   Zarrabeitia, MT
   Abad, L
   Vega, G
   Ruiz Mambrilla, M
   Gonzalez Sagredo, M
   Dueñas Laita, A
   Riancho, JA
AF Perez Castrillon, Jose L.
   Zarrabeitia, Maria T.
   Abad, Laura
   Vega, Gemma
   Ruiz Mambrilla, Marta
   Gonzalez Sagredo, Manuel
   Duenas Laita, Antonio
   Riancho, Jose A.
TI Polymorphisms of the farnesyl diphosphate synthase gene modulate bone
   changes in response to atorvastatin
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE Statins; Atorvastatin; Mevalonate; Polymorphisms; FDPS; Osteoporosis;
   Bone mineral density; Bisphosphonates
ID ELEMENT BINDING PROTEIN; POSTMENOPAUSAL WOMEN; STATINS; OSTEOPOROSIS;
   EXPRESSION; ATHEROSCLEROSIS; METABOLISM; MECHANISMS; PROMOTER; DISEASE
AB Although their primary therapeutic indications are different, aminobisphosphonates and statins target enzymes in the mevalonate pathway, which is critical for bone homeostasis. Previous studies have shown that some polymorphisms of the gene encoding farnesyl diphosphate synthase (FDPS), the main target of aminobisphosphonates, modulate the response to these drugs. In this study, we explored whether those single nucleotide polymorphisms (SNPs) also influence the changes in bone mineral density (BMD) following therapy with statins. Sixty six patients with coronary heart disease were studied at baseline and after 1 year therapy with atorvastatin. BMD was measured by DXA. Three SNPs of the FDPS gene (rs2297480, rs11264359 and rs17367421) were analyzed by using Taqman assays. The results showed that there was no association between the SNPs and basal BMD. However, rs2297480 and rs11264359 alleles, which are in linkage disequilibrium, were associated with changes in hip BMD following atorvastatin therapy. Thus, patients with AA genotype at the rs2297480 locus had a 0.8 +/  0.8 % increase in BMD at the femoral neck, whereas in patients with AC/CC genotypes, BMD showed a 2.3 +/  0.8 % decrease (p = 0.02). Similar results were obtained regarding changes of BMD at the femoral trochanter and when alleles at the rs11264359 locus were analyzed. However, there was no association between BMD and rs17367421 alleles. In conclusion, these results suggest that polymorphisms of the FDPS gene may influence the bone response to various drugs targeting the mevalonate pathway, including not only aminobisphosphonates but also statins.
C1 [Perez Castrillon, Jose L.; Abad, Laura; Vega, Gemma] Univ Valladolid, Hosp Univ Rio Hortega, Dept Internal Med, Valladolid 47010, Spain.
   [Zarrabeitia, Maria T.] Univ Cantabria, Unit Legal Med, E 39005 Santander, Spain.
   [Ruiz Mambrilla, Marta] Ctr Med Rehabil & Lenguaje, Valladolid, Spain.
   [Gonzalez Sagredo, Manuel] Hosp Univ Rio Hortega, Unit Invest, Valladolid, Spain.
   [Duenas Laita, Antonio] Univ Valladolid, Hosp Univ Rio Hortega, Dept Clin Pharmacol, Valladolid 47010, Spain.
   [Riancho, Jose A.] Univ Cantabria, Dept Internal Med, Hosp UM, IFIMAV,RETICEF, E 39005 Santander, Spain.
C3 Hospital del Rio Hortega; Universidad de Valladolid; University Hospital
   of Valladolid; Universidad de Cantabria; Hospital del Rio Hortega;
   Hospital del Rio Hortega; Universidad de Valladolid; Universidad de
   Cantabria
RP Pérez Castrillón, JL (通讯作者)，Univ Valladolid, Hosp Univ Rio Hortega, Dept Internal Med, C Dulzaina 2, Valladolid 47010, Spain.
EM castrv@terra.com
RI Perez Castrillon, Jose Luis/AGI 1029 2022
OI Zarrabeitia, Maria T./0000 0002 2836 7766
CR Bagger YZ, 2007, OSTEOPOROSIS INT, V18, P505, DOI 10.1007/s00198 006 0255 2
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Charlton Menys V, 2008, EXP PHYSIOL, V93, P27, DOI 10.1113/expphysiol.2007.035147
   Conde L, 2006, NUCLEIC ACIDS RES, V34, pW621, DOI 10.1093/nar/gkl071
   Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945
   Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Hofbauer LC, 2007, OSTEOPOROSIS INT, V18, P251, DOI 10.1007/s00198 006 0282 z
   Horiuchi N, 2006, ORAL DIS, V12, P85, DOI 10.1111/j.1601 0825.2005.01172.x
   Ishimoto K, 2010, BIOCHEM J, V429, P347, DOI 10.1042/BJ20091511
   Kim JY, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4018
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   O'Brien CA, 2010, BONE, V46, P911, DOI 10.1016/j.bone.2009.08.050
   Olmos JM, 2012, PHARMACOGENOMICS J, V12, P227, DOI 10.1038/tpj.2010.88
   Perez Castrillon J L, 2008, Minerva Med, V99, P45
   Pérez Castrillón JL, 2006, CURR PHARM ANAL, V2, P161, DOI 10.2174/157341206776819337
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   Ruan F, 2012, BIOSCIENCE REP, V32, P511, DOI 10.1042/BSR20110118
   Sato R, 2010, ARCH BIOCHEM BIOPHYS, V501, P177, DOI 10.1016/j.abb.2010.06.004
   Yue JR, 2010, MENOPAUSE, V17, P1071, DOI 10.1097/gme.0b013e3181d3e036
NR 21
TC 3
Z9 3
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0172 8172
EI 1437 160X
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD AUG
PY 2014
VL 34
IS 8
BP 1073
EP 1077
DI 10.1007/s00296 013 2914 x
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA AM3BF
UT WOS:000339725500006
PM 24311107
DA 2025 08 17
ER

PT J
AU Guo, W
   Li, HJ
   Lou, Y
   Zhang, Y
   Wang, J
   Qian, M
   Wei, HF
   Xiao, JR
   Xu, YJ
AF Guo, Wen
   Li, Haijun
   Lou, Yan
   Zhang, Yue
   Wang, Jia
   Qian, Ming
   Wei, Haifeng
   Xiao, Jianru
   Xu, Youjia
TI Tyloxapol inhibits RANKL stimulated osteoclastogenesis and
   ovariectomized induced bone loss by restraining NF κB and MAPK
   activation
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Tyloxapol; Osteoporosis; Osteoclast; Osteoblast; Mitogen activated
   protein kinase (MAPK); Nuclear factor kappa B (NF kappa B)
ID MODELS
AB Objective: Tyloxapol is a non ionic surfactant with diverse pharmacological effects including anti inflammatory, anti malignant tumor and antioxidant activities. However, the effect of tyloxapol on osteoclastogenesis has not been elucidated. In this study, we intended to clarify the effect of tyloxapol on RANKL stimulated osteoclastogenesis and the molecular mechanism both ex vivo and in vivo.
   Methods: In vitro osteoclastogenesis assay was performed in BMMs and Raw 264.7 cells. The mature osteoclasts were visualized by TRAP staining. The osteoblsats were visualized by alkaline phosphatase (ALP) staining and Von Kossa staining. To assess whether tyloxapol inhibited the function of mature osteoclasts, F actin belts and pit formation assays were carried out in BMMs. To evaluate the effect of tyloxapol on post menopausal osteoporosis, the OVX mouse model were utilized. The bone tissue TRAP staining was used to evaluate the osteoclast activity in vivo. The von kossa staining and micro computed tomography were used to evaluate the histomorphometric parameters. The Goldner's staining was used to evaluate the osteoblast activity. The expression of osteoclastogenesis associated markers were evaluated by Real time PCR. The NF kappa B and NFATc1 transcriptional activities were illustrated utilizing the assay of luciferase reporter. The effect of tyloxapol pretreatment on I kappa Ba degradation and p65 phosphorylation was evaluated using Western bloting assay. The effect of tyloxapol pretreatment on p65 nuclear translocation was evaluated utilizing immunofluorescence. The effect of tyloxapol pretreatment on the phosphorylatio of ERK, p38 and JNK was examined utilizing Western bloting assay.
   Results: In our research, we found that tyloxapol suppresses RANKL stimulated osteoclastogenesis in a dose dependent manner and in the initial stage of osteoclastogenesis. Through F actin belts and pit formation assays, we found that tyloxapol had the ability to inhibit the function of mature osteoclasts in vitro. The results of animal experiments demonstrated that tyloxapol inhibits OVX induced bone mass loss by inhibiting the activity of osteoclasts but had a limited effect on osteoblastic differentiation and mineralization. Molecularly, we found that tyloxapol suppresses RANKL stimulated NF kappa B activation through suppressing degradation of I kappa B alpha, phosphorylation and nuclear translocation of p65. At last, MAPK signaling pathway was also suppressed by tyloxapol in dose and time dependent manners.
   Conclusion: Our research illustrated that tyloxapol was able to suppress osteoclastogenesis in vitro and ovariectomized induced bone loss in vivo by restraining NF kappa B and MAPK activation. This is pioneer research could pave the way for the development of tyloxapol as a potential therapeutic treatment for osteoporosis. The translational potential of this article: This study explores that tyloxapol, also known as Triton WR 1339, may be a drug candidate for osteoclastogenic sicknesses like osteoporosis. Our study may also extend the clinical therapeutic spectrum of tyloxapol.
C1 [Guo, Wen; Xu, Youjia] Soochow Univ, Affiliated Hosp 2, Dept Orthoped, 1055 Sanxiang Rd, Suzhou 215004, Peoples R China.
   [Guo, Wen; Li, Haijun] Taizhou Peoples Hosp, Dept Orthoped, Taizhou 225300, Jiangsu, Peoples R China.
   [Lou, Yan; Zhang, Yue; Qian, Ming; Wei, Haifeng; Xiao, Jianru] Second Mil Med Univ, Changzheng Hosp, Orthopaed Oncol Ctr, Dept Orthopaed, Fengyang Rd 415, Shanghai 200000, Peoples R China.
   [Wang, Jia] Shandong First Med Univ & Shandong Acad Med Sci, Sch Publ Hlth, Tai An 271016, Shandong, Peoples R China.
   [Xu, Youjia] Soochow Univ, Osteoporosis Inst, Suzhou 215004, Peoples R China.
C3 Soochow University   China; Naval Medical University; Shandong First
   Medical University & Shandong Academy of Medical Sciences; Soochow
   University   China
RP Xu, YJ (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Orthoped, 1055 Sanxiang Rd, Suzhou 215004, Peoples R China.; Qian, M; Wei, HF; Xiao, JR (通讯作者)，Second Mil Med Univ, Changzheng Hosp, Orthopaed Oncol Ctr, Dept Orthopaed, Fengyang Rd 415, Shanghai 200000, Peoples R China.
EM qian_ming_qm@163.com; wei_haifeng@163.com; xiao_jianru@163.com;
   xuyoujia@suda.edu.cn
OI xiao, jianru/0000 0003 1547 851X
FU National Key Research and Development Program of China, China
   [2019YFC1316000]; National Natural Science Foundation of China, China
   [81874018]; Science and Technology Commission of Shanghai Municipality,
   China [20ZR1457500, 17ZR1439000]; Social Development Clinical Frontier
   Technology Key Project of Jiangsu province [BE2019661]; Gusu Health
   Talent Program [GSWS2019004]; Mingsheng science and technology project
   of Suzhou City [SS201814]
FX This work was supported by grants from the National Key Research and
   Development Program of China, China (2019YFC1316000), the National
   Natural Science Foundation of China, China (81874018), the Science and
   Technology Commission of Shanghai Municipality, China (20ZR1457500,
   17ZR1439000), Social Development Clinical Frontier Technology Key
   Project of Jiangsu province (BE2019661), Gusu Health Talent Program
   (GSWS2019004), Mingsheng science and technology project of Suzhou
   City(SS201814).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Aspray Terry J, 2019, Subcell Biochem, V91, P453, DOI 10.1007/978 981 13 3681 2_16
   Chen K, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110067
   Ensrud KE, 2018, ANN INTERN MED, V168, P306, DOI 10.7326/L17 0587
   Ghio AJ, 1996, AM J RESP CRIT CARE, V154, P783, DOI 10.1164/ajrccm.154.3.8810619
   Han JK, 2018, J CELL BIOCHEM, V119, P7310, DOI 10.1002/jcb.27028
   Heck SO, 2020, TOXICOL MECH METHOD, V30, P73, DOI 10.1080/15376516.2019.1669240
   Ishii M, 2008, MOD RHEUMATOL, V18, P220, DOI 10.1007/s10165 008 0051 2
   Iwaniec UT, 2006, J BONE MINER RES, V21, P1068, DOI 10.1359/JBMR.060402
   Jin HM, 2019, FOOD FUNCT, V10, P6556, DOI 10.1039/c9fo00206e
   Klinck J, 2008, CALCIFIED TISSUE INT, V83, P70, DOI 10.1007/s00223 008 9150 5
   Kong LB, 2020, J CELL MOL MED, V24, P3271, DOI 10.1111/jcmm.15052
   Krum SA, 2008, CELL CYCLE, V7, P1348, DOI 10.4161/cc.7.10.5892
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li ZX, 2019, J BONE MINER RES, V34, P765, DOI 10.1002/jbmr.3652
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Luo J, 2009, DEVELOPMENT, V136, P2747, DOI 10.1242/dev.033571
   Miron RJ, 2016, ACTA BIOMATER, V46, P15, DOI 10.1016/j.actbio.2016.09.029
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park JH, 2017, MOL CELLS, V40, P706
   Rissanen JP, 2010, EXPERT OPIN DRUG DIS, V5, P1163, DOI 10.1517/17460441.2010.532484
   Russell LA, 2018, BEST PRACT RES CL RH, V32, P835, DOI 10.1016/j.berh.2019.04.002
   Sakaida H, 2017, AURIS NASUS LARYNX, V44, P762, DOI 10.1016/j.anl.2016.11.002
   Serikov Vladimir B., 2003, Inflammation, V27, P175, DOI 10.1023/A:1025108207661
   Sun L, 2008, P NATL ACAD SCI USA, V105, P4289, DOI 10.1073/pnas.0712395105
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Wang Q, 2019, MOL BIOL REP, V46, P3073, DOI 10.1007/s11033 019 04745 3
   Yoon KH, 2012, J KOREAN NEUROSURG S, V51, P323, DOI 10.3340/jkns.2012.51.6.323
   You TM, 2015, OR SURG OR MED OR PA, V120, P548, DOI 10.1016/j.oooo.2015.07.017
   Zebic L, 2019, BMJ BRIT MED J, V365, DOI 10.1136/bmj.l1733
   Zhu MP, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109769
NR 34
TC 21
Z9 21
U1 0
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD MAY
PY 2021
VL 28
BP 148
EP 158
DI 10.1016/j.jot.2021.01.005
EA APR 2021
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA SO0TG
UT WOS:000658693500003
PM 33981577
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Viereck, V
   Gründker, C
   Blaschke, S
   Frosch, KH
   Schoppet, M
   Emons, G
   Hofbauer, LC
AF Viereck, V
   Gründker, C
   Blaschke, S
   Frosch, KH
   Schoppet, M
   Emons, G
   Hofbauer, LC
TI Atorvastatin stimulates the production of osteoprotegerin by human
   osteoblasts
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE atorvastatin; mevalonate; osteoblast; osteoprotegerin; RANK ligand
ID COA REDUCTASE INHIBITORS; BONE MORPHOGENETIC PROTEIN 2; HUMAN TRABECULAR
   OSTEOBLASTS; LINEAGE CELLS; OSTEOCLAST FORMATION; MINERAL DENSITY;
   STATIN THERAPY; IN VITRO; DIFFERENTIATION; SIMVASTATIN
AB Recently, HMG CoA reductase inhibitors (statins), potent inhibitors of cholesterol biosynthesis, have been linked to protective effects on bone metabolism. Because of their widespread use, prevention of bone loss and fractures would be a desirable side effect. However, the mechanisms how statins may affect bone metabolism are poorly defined. Here, we evaluated the effect of atorvastatin on osteoblastic production of receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG), cytokines that are essential for osteoclast cell biology. While RANKL enhances osteoclast formation and activation, thereby; promoting bone loss, OPG acts as a soluble decoy receptor and antagonizes the effects of RANKL. In primary human osteoblasts (hOB), atorvastatin increased OPG mRNA levels and protein secretion by hOB by up to three fold in a dose dependent manner with a maximum effect at 10( 6) M (p < 0.001). Time course experiments indicated a time dependent stimulatory effect of atorvastatin on OPG mRNA levels after 24 h and on OPG protein secretion after 48 72 h (P < 0.001). Treatment of hOB with substrates of cholesterol biosynthesis that are downstream of the HMG CoA reductase reaction (mevalonate, geranylgeranyl pyrophosphate) reversed atorvastatin induced enhancement of OPG production. Of note, atorvastatin abrogated the inhibitory effect of glucocorticoids on OPG production. Treatment of hOB with atorvastatin enhanced the expression of osteoblastic differentiation markers, alkaline phosphatase and osteocalcin. In summary, our data suggest that atorvastatin enhances osteoblastic differentiation and production of OPG. This may contribute to the bone sparing effects of statins. J. Cell. Biochem. 96: 1244 1253, 2005. (c) 2005 Wiley Liss, Inc.
C1 Univ Gottingen, Dept Obstet & Gynecol, D 37075 Gottingen, Germany.
   Univ Gottingen, Div Nephrol & Rheumatol, D 37075 Gottingen, Germany.
   Univ Gottingen, Dept Trauma Surg Plast & Reconstruct Surg, D 3400 Gottingen, Germany.
   Univ Marburg, Dept Med, Marburg, Germany.
C3 University of Gottingen; University of Gottingen; University of
   Gottingen; Philipps University Marburg
RP Viereck, V (通讯作者)，Univ Gottingen, Dept Obstet & Gynecol, Robert Koch Str 40, D 37075 Gottingen, Germany.
EM viereck@med.uni goettingen.de
RI Hofbauer, Lorenz/G 2490 2010; Blaschke, Steffen/J 1775 2019; Hofbauer,
   Lorenz C./G 2490 2010
OI Grundker, Carsten/0000 0001 8828 7955; Hofbauer, Lorenz
   C./0000 0002 8691 8423
CR Almog Y, 2004, CIRCULATION, V110, P880, DOI 10.1161/01.CIR.0000138932.17956.F1
   Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289
   Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140 6736(00)02400 4
   Chan MHM, 2001, J CLIN ENDOCR METAB, V86, P4556
   Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152
   Edwards CJ, 2000, LANCET, V355, P2218, DOI 10.1016/S0140 6736(00)02408 9
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Gomberg Maitland M, 2003, J CARDIOVASC RISK, V10, P161, DOI 10.1097/00043798 200306000 00003
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Hatano Hiroshi, 2003, J Orthop Sci, V8, P842, DOI 10.1007/s00776 003 0724 9
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 1998, BIOCHEM BIOPH RES CO, V250, P776, DOI 10.1006/bbrc.1998.9394
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Ireland DC, 2002, J CELL BIOCHEM, V86, P251, DOI 10.1002/jcb.10228
   Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219
   Li XD, 2003, BONE, V33, P652, DOI 10.1016/S8756 3282(03)00239 4
   Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913
   Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002 220682
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Maritz FJ, 2001, ARTERIOSCL THROM VAS, V21, P1636, DOI 10.1161/hq1001.097781
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Oxlund H, 2004, BONE, V34, P609, DOI 10.1016/j.bone.2003.12.014
   Phillips BW, 2001, BIOCHEM BIOPH RES CO, V284, P478, DOI 10.1006/bbrc.2001.4987
   Schoofs MWCJ, 2004, J BONE MINER RES, V19, P1525, DOI 10.1359/JBMR.040607
   Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097 4644(19991001)75:1<22::AID JCB3>3.3.CO;2 Y
   Skaletz Rorowski A, 2003, CURR OPIN LIPIDOL, V14, P599, DOI 10.1097/00041433 200312000 00008
   Skoglund B, 2002, J BONE MINER RES, V17, P2004, DOI 10.1359/jbmr.2002.17.11.2004
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Thunyakitpisal PD, 2004, J PHARMACOL SCI, V94, P403, DOI 10.1254/jphs.94.403
   Viereck V, 2003, J CLIN ENDOCR METAB, V88, P4206, DOI 10.1210/jc.2002 021877
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Viereck V, 2002, J CELL BIOCHEM, V84, P725, DOI 10.1002/jcb.10087
   Wang PS, 2000, JAMA J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
NR 39
TC 62
Z9 65
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD DEC 15
PY 2005
VL 96
IS 6
BP 1244
EP 1253
DI 10.1002/jcb.20598
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 985CF
UT WOS:000233353000014
PM 16152630
DA 2025 08 17
ER

PT J
AU Rangaswami, H
   Schwappacher, R
   Marathe, N
   Zhuang, SH
   Casteel, DE
   Haas, B
   Chen, Y
   Pfeifer, A
   Kato, H
   Shattil, S
   Boss, GR
   Pilz, RB
AF Rangaswami, Hema
   Schwappacher, Raphaela
   Marathe, Nisha
   Zhuang, Shunhui
   Casteel, Darren E.
   Haas, Bodo
   Chen, Yong
   Pfeifer, Alexander
   Kato, Hisashi
   Shattil, Sanford
   Boss, Gerry R.
   Pilz, Renate B.
TI Cyclic GMP and Protein Kinase G Control a Src Containing Mechanosome in
   Osteoblasts
SO SCIENCE SIGNALING
LA English
DT Article
ID FLUID SHEAR STRESS; GROWTH FACTOR I; INDUCED BONE FORMATION; FOCAL
   ADHESION KINASE; NITRIC OXIDE SYNTHASE; SMOOTH MUSCLE CELLS; INDUCED
   MECHANOTRANSDUCTION; TYROSINE PHOSPHATASES; EXTRACELLULAR MATRIX;
   ANABOLIC RESPONSE
AB Mechanical stimulation is crucial for bone growth and remodeling, and fluid shear stress promotes anabolic responses in osteoblasts through multiple second messengers, including nitric oxide (NO). NO triggers production of cyclic guanosine 3', 5' monophosphate (cGMP), which in turn activates protein kinase G (PKG). We found that the NO cGMP PKG signaling pathway activates Src in mechanically stimulated osteoblasts to initiate a proliferative response. PKGII was necessary for Src activation, a process that also required the interaction of Src with beta(3) integrins and dephosphorylation of Src by a complex containing the phosphatases SHP 1 (Src homology 2 domain containing tyrosine phosphatase 1) and SHP 2. PKGII directly phosphorylated and stimulated SHP 1 activity, and fluid shear stress triggered the recruitment of PKGII, Src, SHP 1, and SHP 2 to a mechanosome containing beta(3) integrins. PKGII null mice showed defective Src and ERK (extracellular signal regulated kinase) signaling in osteoblasts and decreased ERK dependent gene expression in bone. Our findings reveal a convergence of NO cGMP PKG and integrin signaling and establish a previously unknown mechanism of Src activation. These results support the use of PKG activating drugs to mimic the anabolic effects of mechanical stimulation of bone in the treatment of osteoporosis.
C1 [Rangaswami, Hema; Schwappacher, Raphaela; Marathe, Nisha; Zhuang, Shunhui; Casteel, Darren E.; Kato, Hisashi; Shattil, Sanford; Boss, Gerry R.; Pilz, Renate B.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Haas, Bodo; Chen, Yong; Pfeifer, Alexander] Univ Bonn, Inst Pharmacol & Toxicol, D 53105 Bonn, Germany.
   [Haas, Bodo; Chen, Yong; Pfeifer, Alexander] Univ Bonn, Biomed Ctr, D 53105 Bonn, Germany.
C3 University of California System; University of California San Diego;
   University of Bonn; University of Bonn
RP Pilz, RB (通讯作者)，Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
EM rpilz@ucsd.edu
RI ; Haas, Bodo/LTC 8833 2024
OI Boss, Gerry/0000 0002 9758 8714; Haas, Bodo/0000 0002 1213 3527
FU NIH [R01AR051300, T32HL007261, P30NS047101]
FX This work was supported by NIH grants R01AR051300 (to R.B.P.),
   T32HL007261 (to N.M.), and P30NS047101 (UCSD Neuroscience Microscopy
   Shared Facility).
CR Aoki K, 1999, BONE, V25, P261, DOI 10.1016/S8756 3282(99)00174 X
   Arias Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Bergula AP, 2004, BONE, V34, P562, DOI 10.1016/j.bone.2003.11.025
   Bikle DD, 2008, OSTEOPOROSIS INT, V19, P1237, DOI 10.1007/s00198 008 0597 z
   Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393
   Chow JWM, 1998, J BONE MINER RES, V13, P1039, DOI 10.1359/jbmr.1998.13.6.1039
   Clancy RM, 1997, J CLIN INVEST, V100, P1789, DOI 10.1172/JCI119706
   Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021
   Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593
   Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143
   Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092 8674(03)00196 X
   Hofmann Franz, 2009, V191, P137, DOI 10.1007/978 3 540 68964 5_8
   Jiang GL, 2002, AM J PHYSIOL ENDOC M, V283, pE383, DOI 10.1152/ajpendo.00547.2001
   Kapur S, 2005, J BIOL CHEM, V280, P20163, DOI 10.1074/jbc.M501460200
   Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756 3282(02)00979 1
   Krejci P, 2005, J CELL SCI, V118, P5089, DOI 10.1242/jcs.02618
   Lau KHW, 2006, J BIOL CHEM, V281, P9576, DOI 10.1074/jbc.M509205200
   Lee DY, 2008, J BONE MINER RES, V23, P1140, DOI 10.1359/JBMR.080302
   Leung EL, 2010, MOL CANCER RES, V8, P578, DOI 10.1158/1541 7786.MCR 09 0178
   Lieskovska J, 2006, J BIOL CHEM, V281, P25041, DOI 10.1074/jbc.M602866200
   Ling Y, 2005, J BIOL CHEM, V280, P3151, DOI 10.1074/jbc.M411035200
   Mancini L, 2000, BIOCHEM BIOPH RES CO, V274, P477, DOI 10.1006/bbrc.2000.3164
   McAllister TN, 1999, J BONE MINER RES, V14, P930, DOI 10.1359/jbmr.1999.14.6.930
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Pavalko FM, 1998, AM J PHYSIOL CELL PH, V275, pC1591
   Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284
   Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082
   Plotkin LI, 2005, AM J PHYSIOL CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004
   Poole AW, 2005, CELL SIGNAL, V17, P1323, DOI 10.1016/j.cellsig.2005.05.016
   Rangaswami H, 2009, J BIOL CHEM, V284, P14796, DOI 10.1074/jbc.M806486200
   Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097 2765(01)00432 4
   Schwartz MA, 2009, SCIENCE, V323, P588, DOI 10.1126/science.1169414
   Shattil SJ, 2005, TRENDS CELL BIOL, V15, P399, DOI 10.1016/j.tcb.2005.06.005
   Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199
   Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113
   Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200
   Turner CH, 1996, AM J PHYSIOL ENDOC M, V270, pE634, DOI 10.1152/ajpendo.1996.270.4.E634
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang N, 2006, J BIOL CHEM, V281, P21878, DOI 10.1074/jbc.M605018200
   Wang YL, 2007, P NATL ACAD SCI USA, V104, P15941, DOI 10.1073/pnas.0707246104
   Watanuki M, 2002, J BONE MINER RES, V17, P1015, DOI 10.1359/jbmr.2002.17.6.1015
   Wimalawansa SJ, 2007, ANN NY ACAD SCI, V1117, P283, DOI 10.1196/annals.1402.066
   Young SRL, 2009, J BONE MINER RES, V24, P411, DOI 10.1359/JBMR.081102
   Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097 2765(04)00050 4
NR 46
TC 79
Z9 91
U1 0
U2 16
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945 0877
EI 1937 9145
J9 SCI SIGNAL
JI Sci. Signal.
PD DEC 21
PY 2010
VL 3
IS 153
AR ra91
DI 10.1126/scisignal.2001423
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 697KA
UT WOS:000285511300002
PM 21177494
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wu, XN
   Ma, YY
   Su, NC
   Shen, JF
   Zhang, H
   Wang, H
AF Wu, Xiangnan
   Ma, Yuanyuan
   Su, Naichuan
   Shen, Jiefei
   Zhang, Hai
   Wang, Hang
TI Lysophosphatidic acid: Its role in bone cell biology and potential for
   use in bone regeneration
SO PROSTAGLANDINS & OTHER LIPID MEDIATORS
LA English
DT Article
DE Lysophosphatidic acid (LPA); LPA receptors; Bone cells; Bone
   regeneration
ID MESENCHYMAL STEM CELLS; G(I) PROTEINS; 2 PATHWAYS; RECEPTORS;
   FIBRONECTIN; OSTEOBLASTS; DIFFERENTIATION; LYSOPHOSPHOLIPIDS;
   ACTIVATION; CHEMOTAXIS
AB Lysophosphatidic acid (LPA) is a simple phospholipid that exerts pleiotropic effects on numerous cell types by activating its family of cognate G protein coupled receptors (GPCRs) and participates in many biological processes, including organismal development, wound healing, and carcinogenesis. Bone cells, such as bone marrow mesenchymal stromal (stem) cells (BMSCs), osteoblasts, osteocytes and osteoclasts play essential roles in bone homeostasis and repair. Previous studies have identified the presence of specific LPA receptors in these bone cells. In recent years, an increasing number of cellular effects of LPA, such as the induction of cell proliferation, survival, migration, differentiation and cytokine secretion, have been found in different bone cells. Moreover, some biomaterials containing LPA have shown the ability to enhance osteogenesis. This review will focus on findings associated with LPA functions in these bone cells and present current studies related to the application of LPA in bone regenerative medicine. Further understanding this information will help us develop better strategies for bone healing.
C1 [Wu, Xiangnan; Su, Naichuan; Shen, Jiefei; Wang, Hang] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Wu, Xiangnan; Su, Naichuan; Shen, Jiefei; Wang, Hang] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Wu, Xiangnan; Su, Naichuan; Shen, Jiefei; Wang, Hang] Sichuan Univ, West China Hosp Stomatol, Dept Prosthodont, Chengdu 610041, Sichuan, Peoples R China.
   [Ma, Yuanyuan] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangdong Prov Key Lab Stomatol, Guangzhou 510055, Guangdong, Peoples R China.
   [Zhang, Hai] Univ Washington, Sch Dent, Dept Restorat Dent, Seattle, WA 98195 USA.
C3 Sichuan University; Sichuan University; Sichuan University; Sun Yat Sen
   University; University of Washington; University of Washington Seattle
RP Wang, H (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China.; Wang, H (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.; Wang, H (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Prosthodont, Chengdu 610041, Sichuan, Peoples R China.
EM wanghang@scu.edu.cn
RI shen, jie/JJF 0994 2023; Su, Naichuan/HLX 7494 2023
OI Su, Naichuan/0000 0001 8034 9410
FU National Natural Science Foundation of China [81170941]
FX The authors would like to acknowledge financial support from the
   National Natural Science Foundation of China (No. 81170941).
CR Aki Y, 2008, ARCH ORAL BIOL, V53, P207, DOI 10.1016/j.archoralbio.2007.08.006
   Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001
   Aoki J, 2008, BBA MOL CELL BIOL L, V1781, P513, DOI 10.1016/j.bbalip.2008.06.005
   Ayre WN, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 015 5644 7
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Binder BYK, 2015, TISSUE ENG PART B RE, V21, P531, DOI [10.1089/ten.teb.2015.0107, 10.1089/ten.TEB.2015.0107]
   Bosetti M, 2017, TISSUE ENG PT A, V23, P1413, DOI [10.1089/ten.tea.2016.0554, 10.1089/ten.TEA.2016.0554]
   Brindley DN, 2009, J LIPID RES, V50, pS225, DOI 10.1194/jlr.R800055 JLR200
   Caverzasio J, 2000, J BONE MINER RES, V15, P1697, DOI 10.1359/jbmr.2000.15.9.1697
   CHECOVICH WJ, 1993, ARTERIOSCLER THROMB, V13, P1662, DOI 10.1161/01.ATV.13.11.1662
   Chen JH, 2008, STEM CELLS, V26, P135, DOI 10.1634/stemcells.2007 0098
   Chen XQ, 2017, FEBS J, V284, P1738, DOI 10.1111/febs.14082
   Chen Z, 2016, SCI REP UK, V6, DOI 10.1038/srep30322
   Chen Z, 2015, BIOCHEM BIOPH RES CO, V468, P21, DOI 10.1016/j.bbrc.2015.11.006
   Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753
   David M, 2014, J BIOL CHEM, V289, P6551, DOI 10.1074/jbc.M113.533232
   David M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009741
   Gidley J, 2006, PROSTAG OTH LIPID M, V80, P46, DOI 10.1016/j.prostaglandins.2006.04.001
   Grey A, 2002, ENDOCRINOLOGY, V143, P4755, DOI 10.1210/en.2002 220347
   Grey A, 2001, ENDOCRINOLOGY, V142, P1098, DOI 10.1210/en.142.3.1098
   Hausman MR, 2001, BONE, V29, P560, DOI 10.1016/S8756 3282(01)00608 1
   Hwang YS, 2014, J BONE MINER METAB, V32, P110, DOI 10.1007/s00774 013 0470 9
   Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060
   Jaganathan BG, 2007, STEM CELLS, V25, P1966, DOI 10.1634/stemcells.2007 0167
   Kanehira M, 2017, STEM CELLS, V35, P739, DOI 10.1002/stem.2499
   Karagiosis SA, 2007, BIOCHEM BIOPH RES CO, V357, P194, DOI 10.1016/j.bbrc.2007.03.121
   Karagiosis SA, 2009, J CELL PHYSIOL, V219, P716, DOI 10.1002/jcp.21720
   Kihara Y, 2015, EXP CELL RES, V333, P171, DOI 10.1016/j.yexcr.2014.11.020
   Kok BPC, 2012, CHEM REV, V112, P5121, DOI 10.1021/cr200433m
   Lancaster ST, 2014, STEROIDS, V83, P52, DOI 10.1016/j.steroids.2014.01.010
   Lapierre DM, 2010, J BIOL CHEM, V285, P25792, DOI 10.1074/jbc.M110.109322
   Lee BH, 2016, BIOL PHARM BULL, V39, P156, DOI 10.1248/bpb.b15 00575
   Lenselink EA, 2015, INT WOUND J, V12, P313, DOI 10.1111/iwj.12109
   Li ZW, 2010, J CELL BIOCHEM, V111, P811, DOI 10.1002/jcb.22731
   Liu YB, 2010, J CELL BIOCHEM, V109, P794, DOI 10.1002/jcb.22471
   Llona Minguez S, 2015, PROG LIPID RES, V58, P51, DOI 10.1016/j.plipres.2015.01.004
   Mansell JP, 2016, BIOCHIMIE, V128, P193, DOI 10.1016/j.biochi.2016.08.011
   Mansell JP, 2011, PROSTAG OTH LIPID M, V95, P45, DOI [10.1016/j.prostaglandins.2011.05.002, 10.1016/j.prostaglandins.2011.05.003]
   Mansell JP, 2010, BIOMATERIALS, V31, P199, DOI 10.1016/j.biomaterials.2009.09.035
   Mansell JP, 2009, MOL CELL ENDOCRINOL, V305, P38, DOI 10.1016/j.mce.2009.02.032
   Masiello LM, 2006, BONE, V39, P72, DOI 10.1016/j.bone.2005.12.013
   McMichael BK, 2010, J BIOL CHEM, V285, P26641, DOI 10.1074/jbc.M110.119909
   Might KR, 2016, VET COMP ORTHOPAED, V29, P306, DOI 10.3415/VCOT 15 08 0137
   Neary G, 2018, J MATER SCI MATER M, V29, DOI 10.1007/s10856 018 6130 9
   Nishimasu H, 2012, TRENDS PHARMACOL SCI, V33, P138, DOI 10.1016/j.tips.2011.12.004
   Orosa B, 2014, ANN RHEUM DIS, V73, P298, DOI 10.1136/annrheumdis 2012 202832
   Pagès C, 2001, PROSTAG OTH LIPID M, V64, P1, DOI 10.1016/S0090 6980(01)00110 1
   Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037
   Panupinthu N, 2007, J BIOL CHEM, V282, P3403, DOI 10.1074/jbc.M605620200
   Peyruchaud O, 2013, BBA MOL CELL BIOL L, V1831, P99, DOI 10.1016/j.bbalip.2012.06.004
   Saba JD, 2004, J CELL BIOCHEM, V92, P967, DOI 10.1002/jcb.20128
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Sheng XY, 2015, DEVELOPMENT, V142, P1390, DOI 10.1242/dev.121723
   Skindersoe ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143509
   Song HY, 2010, BBA MOL CELL BIOL L, V1801, P23, DOI 10.1016/j.bbalip.2009.08.011
   Takeuchi K, 2016, 2016 International Conference on Electronics Packaging (ICEP), P298, DOI 10.1109/ICEP.2016.7486833
   Tanaka M, 2006, J BIOL CHEM, V281, P25822, DOI 10.1074/jbc.M605142200
   Taniguchi R, 2017, NATURE, V548, P356, DOI 10.1038/nature23448
   Teo ST, 2009, IUBMB LIFE, V61, P791, DOI 10.1002/iub.220
   Tomlinson RE, 2013, BONE, V52, P212, DOI 10.1016/j.bone.2012.09.035
   van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419 05
   Wang XY, 2015, APOPTOSIS, V20, P273, DOI 10.1007/s10495 014 1074 0
   Waters KM, 2007, BONE, V41, P833, DOI 10.1016/j.bone.2007.06.029
   Waters KM, 2011, BONE, V48, P1328, DOI 10.1016/j.bone.2011.02.020
   Windischhofer W, 2012, BIOCHIMIE, V94, P1997, DOI 10.1016/j.biochi.2012.05.023
   Xu Y, 2005, J MED CHEM, V48, P3319, DOI 10.1021/jm049186t
   Xu Y, 2003, J ORG CHEM, V68, P5320, DOI 10.1021/jo020729l
   Yao SC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050730
   Yu ZL, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7537630
   Yu ZL, 2016, INT J MOL MED, V37, P468, DOI 10.3892/ijmm.2016.2450
   Yung YC, 2014, J LIPID RES, V55, P1192, DOI 10.1194/jlr.R046458
   Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415
   ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447
NR 74
TC 16
Z9 16
U1 0
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1098 8823
EI 2212 196X
J9 PROSTAG OTH LIPID M
JI Prostaglandins Other Lipid Mediat.
PD AUG
PY 2019
VL 143
AR 106335
DI 10.1016/j.prostaglandins.2019.106335
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA IJ6FG
UT WOS:000475996900001
PM 31054330
DA 2025 08 17
ER

PT J
AU Kim, JA
   Choi, HK
   Kim, TM
   Leem, SH
   Oh, IH
AF Kim, Jin A
   Choi, Hyun Kyung
   Kim, Tae Min
   Leem, Sun Hee
   Oh, Il Hoan
TI Regulation of mesenchymal stromal cells through fine tuning of canonical
   Wnt signaling
SO STEM CELL RESEARCH
LA English
DT Article
ID HEMATOPOIETIC STEM CELLS; BONE MARROW NICHE; SELF RENEWAL; BETA CATENIN;
   REGENERATIVE MEDICINE; PPAR GAMMA; MICROENVIRONMENT; DIFFERENTIATION;
   IDENTIFICATION; ADIPOGENESIS
AB Mesenchymal stromal cells (MSCs) have been extensively utilized for various cell therapeutic trials, but the signals regulating their stromal function remain largely unclear. Here, we show that canonical Wnt signals distinctively regulate MSCs in a biphasic manner depending on signal intensity, i.e., MSCs exhibit proliferation and progenitor self renewal under low Wnt/beta catenin signaling, whereas they exhibit enhanced osteogenic differentiation with priming to osteoblast like lineages under high Wnt/beta catenin signaling. Moreover, low or high levels of beta catenin in MSCs distinctly regulated the hematopoietic support of MSCs to promote proliferation or the undifferentiated state of hematopoietic progenitors, respectively. A gene expression study demonstrated that different intracellular levels of beta catenin in MSCs induce distinct transcriptomic changes in subsets of genes belonging to different gene function categories. Different beta catenin levels also induced differences in intracellular levels of the beta catenin co factors, Tcf 1 and Lef 1. Moreover, nano scale mass spectrometry of proteins that co precipitated with beta catenin revealed distinctive spectra of proteins selectively interacting with beta catenin at specific expression levels. Together, these results show that Wnt/beta catenin signals can coax distinct transcription milieu to induce different transcription profiles in MSCs depending on the signal intensity and that fine tuning of the canonical Wnt signaling intensity can regulate the phase specific functionality of MSCs. (C) 2015 The Authors. Published by Elsevier B.V.
C1 [Kim, Jin A; Choi, Hyun Kyung; Oh, Il Hoan] Catholic High Performance Cell Therapy, Seoul, South Korea.
   [Kim, Jin A; Choi, Hyun Kyung; Oh, Il Hoan] Dept Med Life Sci, Seoul, South Korea.
   [Kim, Tae Min] Catholic Univ Korea, Ctr Canc Evolut, Med Res Ctr, Seoul 137701, South Korea.
   [Leem, Sun Hee] Dong A Univ, Dept Biol Sci, Busan, South Korea.
C3 Catholic University of Korea; Dong A University
RP Oh, IH (通讯作者)，Catholic Univ Korea, Catholic High Performance Cell Therapy, 505 Banpo Dong, Seoul 137701, South Korea.
EM iho@catholic.ac.kr
RI Kim, Jin/O 7928 2019
FU National Research Foundation of Korea (NRF)   Ministry of Science, ICT &
   Future Planning [2011 0019352]; Korea Health Technology R&D Project,
   Ministry of Health & Welfare, Republic of Korea [A120262]
FX The proteomics analysis using nano liquid chromatography/mass
   spectrometry (Nano LC MS/MS) was performed by the Yonsei Proteome
   Research Center (www.proteomix.org), Korea. This research was supported
   by the National Research Foundation of Korea (NRF) funded by the
   Ministry of Science, ICT & Future Planning (No. 2011 0019352) and a
   grant of the Korea Health Technology R&D Project, Ministry of Health &
   Welfare, Republic of Korea (A120262).
CR Ahn JY, 2010, EXP MOL MED, V42, P122, DOI 10.3858/emm.2010.42.2.014
   Antrobus R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018218
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Bilechele Travis L., 2008, V468, P99, DOI 10.1007/978 1 59745 249 6_8
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Boyd NL, 2009, TISSUE ENG PT A, V15, P1897, DOI 10.1089/ten.tea.2008.0351
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008
   Chan CKF, 2009, NATURE, V457, P490, DOI 10.1038/nature07547
   Chen YS, 2012, STEM CELL TRANSL MED, V1, P83, DOI 10.5966/sctm.2011 0022
   Choong ML, 2003, FEBS LETT, V550, P155, DOI 10.1016/S0014 5793(03)00844 5
   Cook DA, 2014, STEM CELL RES, V12, P415, DOI 10.1016/j.scr.2013.10.002
   Frenette PS, 2013, ANNU REV IMMUNOL, V31, P285, DOI 10.1146/annurev immunol 032712 095919
   Gan XQ, 2008, J CELL BIOL, V180, P1087, DOI 10.1083/jcb.200710050
   Gaspari M, 2011, METHODS MOL BIOL, V790, P115, DOI 10.1007/978 1 61779 319 6_9
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Greco SJ, 2007, STEM CELLS, V25, P3143, DOI 10.1634/stemcells.2007 0351
   Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926
   Guillot PV, 2007, STEM CELLS, V25, P646, DOI 10.1634/stemcells.20060208
   Hong SH, 2014, STEM CELLS, V32, P1313, DOI 10.1002/stem.1631
   Jung J, 2009, STEM CELLS DEV, V18, P559, DOI 10.1089/scd.2008.0105
   Kawai M, 2007, BIOCHEM BIOPH RES CO, V363, P276, DOI 10.1016/j.bbrc.2007.08.088
   Keating A, 2006, CURR OPIN HEMATOL, V13, P419, DOI 10.1097/01.moh.0000245697.54887.6f
   Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045
   Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1
   Kim JA, 2009, STEM CELLS, V27, P1318, DOI 10.1002/stem.52
   Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94
   Naveiras O, 2009, NATURE, V460, P259, DOI 10.1038/nature08099
   Nemeth MJ, 2009, STEM CELLS, V27, P1109, DOI 10.1002/stem.32
   Oh IH, 2012, STEM CELLS, V30, P82, DOI 10.1002/stem.776
   Oh IH, 2010, EXPERT OPIN BIOL TH, V10, P1315, DOI 10.1517/14712598.2010.504705
   Oh IH, 2010, STEM CELLS, V28, P1243, DOI 10.1002/stem.453
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Satija NK, 2009, J CELL MOL MED, V13, P4385, DOI 10.1111/j.1582 4934.2009.00857.x
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Tsai CC, 2012, MOL CELL, V47, P169, DOI 10.1016/j.molcel.2012.06.020
   Vacanti V, 2005, J CELL PHYSIOL, V205, P194, DOI 10.1002/jcp.20376
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhang ZY, 2009, STEM CELLS, V27, P126, DOI 10.1634/stemcells.2008 0456
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 45
TC 47
Z9 54
U1 3
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1873 5061
EI 1876 7753
J9 STEM CELL RES
JI Stem Cell Res.
PD MAY
PY 2015
VL 14
IS 3
BP 356
EP 368
DI 10.1016/j.scr.2015.02.007
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP6JR
UT WOS:000359993400010
PM 25863444
OA gold
DA 2025 08 17
ER

PT J
AU Tan, NX
   Wang, Y
   Ren, LCC
   Tie, FF
   Hu, N
   Wang, HL
   Dong, Q
AF Tan, Nixia
   Wang, Yue
   Ren, Lichengcheng
   Tie, Fangfang
   Hu, Na
   Wang, Honglun
   Dong, Qi
TI Network Pharmacology and Molecular Dynamics Simulations Reveal the
   Mechanism of Total Alkaloid Components in Anisodus Tanguticus
   (Maxim.) Pascher in Treating Inflammation and Pain.
SO CHEMISTRY & BIODIVERSITY
LA English
DT Article; Early Access
DE Anisodus tanguticus (Maxim.) Pascher; Network pharmacology; Molecular
   dynamics simulations; Anti inflammatory and analgesic effects; Mechanism
   of action
ID NF KAPPA B; RANKL INDUCED OSTEOCLAST; NLRP3 INFLAMMASOME; ACTIVATION;
   CELLS; EXPRESSION; EFFICACY; DOCKING; GROWTH
AB This study aimed to elucidate the mechanism that total alkaloids in Anisodus tanguticus (AT)(Maxim.) Pascher played anti inflammatory and analgesic effects. In this paper, the anti inflammatory effect in the total alkaloids of AT was confirmed via lipopolysaccharide (LPS) induced inflammation model in RAW 264.7 cells and the main components of AT were immediately analyzed by UPLC/MS. Disease targets were obtained in GeneCards and DisGeNET. Targets of major compounds were searched in ETCM, TCMSP and other databases. The protein protein interaction (PPI) network was constructed using STRING database, and Cytoscape was used for core targets screening. GO and KEGG enrichment analysis were performed using Daivid database. Sailvina was used for molecular docking. Molecular dynamics simulation analysis was performed using the Amber 20 program. The results showed that the main components in AT were anisodamine, atropine, fabiatrin, scopolamine, scopoletin and scopolin, possibly exerting anti inflammatory and analgesic effects through pathways such as EGFR tyrosine kinase inhibitor resistance and IL 17 signaling pathway. Fabiatrin and scopolin could be potential drugs with good anti inflammatory and analgesic effects.
C1 [Tan, Nixia; Tie, Fangfang; Hu, Na; Wang, Honglun; Dong, Qi] Northwest Inst Plateau Biol, CAS Key Lab Tibetan Med Res, Xining 810008, Peoples R China.
   [Tan, Nixia; Wang, Yue; Ren, Lichengcheng] Qinghai Univ, Med Coll, Xining 810016, Peoples R China.
C3 Qinghai University
RP Dong, Q (通讯作者)，Northwest Inst Plateau Biol, CAS Key Lab Tibetan Med Res, Xining 810008, Peoples R China.
EM qdong@nwipb.cas.cn
OI Dong, Qi/0000 0002 6192 1597
FU CAS "Light of West China" Program
FX No Statement Available
CR Adams JD, 2020, CURR MED CHEM, V27, P1444, DOI 10.2174/092986732709200327092413
   Barros CH, 2021, J ETHNOPHARMACOL, V280, DOI 10.1016/j.jep.2021.114460
   Bisht A, 2024, MOL DIVERS, V28, P1743, DOI 10.1007/s11030 023 10684 w
   Cashman JN, 1996, DRUGS, V52, P13, DOI 10.2165/00003495 199600525 00004
   Chen C, 2022, FRONT PLANT SCI, V13, DOI 10.3389/fpls.2022.927336
   Chen L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184129
   Committee F. O. C. E., Pacific Flyway Study Committee
   Coste O, 2012, BEHAV BRAIN RES, V234, P121, DOI 10.1016/j.bbr.2012.06.017
   Cronstein BN, 2002, CLEV CLIN J MED, V69, P13, DOI 10.3949/ccjm.69.Suppl_1.SI13
   Ding HL, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974 020 1704 0
   Ding Jin T. F., 2023, Natural Products Res. Dev, V35, P73
   Du NN, 2019, J SEP SCI, V42, P1163, DOI 10.1002/jssc.201801201
   Ferreira LG, 2015, MOLECULES, V20, P13384, DOI 10.3390/molecules200713384
   Hartono SP, 2022, MAYO CLIN PROC, V97, P154, DOI 10.1016/j.mayocp.2021.08.018
   Hwang JH, 2016, CHEM BIOL INTERACT, V248, P1, DOI 10.1016/j.cbi.2016.01.020
   Imbe H, 2005, BRAIN RES, V1063, P151, DOI 10.1016/j.brainres.2005.09.057
   Jiang YB, 2017, TROP J PHARM RES, V16, P379, DOI 10.4314/tjpr.v16i2.17
   Kawabata A, 2011, BIOL PHARM BULL, V34, P1170, DOI 10.1248/bpb.34.1170
   Li LA, 2023, J CARDIOVASC MED, V24, P232, DOI 10.2459/JCM.0000000000001453
   Li P, 2020, DRUG DES DEV THER, V14, P1609, DOI 10.2147/DDDT.S243383
   Li X, 2023, CHIN J NAT MEDICINES, V21, P323, DOI 10.1016/S1875 5364(23)60429 7
   Li Z, 2020, J RECEPT SIG TRANSD, V40, P58, DOI 10.1080/10799893.2020.1713808
   Liao ST, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13078 5
   Ma LJ, 2015, TOXINS, V7, P138, DOI 10.3390/toxins7010138
   Martin LJ, 2017, J CLIN INVEST, V127, P3359, DOI 10.1172/JCI87406
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   N.l. O.P. Biology, 1991, Tibetan Medicine Chronicle
   Nalamachu S, 2013, AM J MANAG CARE, V19, pS261
   Odira HO, 2022, J EVID BASED INTEGR, V27, DOI 10.1177/2515690X221082986
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Q.I. o. T.M. Qinghai institute for Drug Control, 1996, Tibetan Medicine in China, V1
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Ruan QR, 2001, J VASC RES, V38, P13, DOI 10.1159/000051025
   Santos LHS, 2019, METHODS MOL BIOL, V2053, P13, DOI 10.1007/978 1 4939 9752 7_2
   Seifert O, 2021, Z RHEUMATOL, V80, P205, DOI 10.1007/s00393 020 00951 8
   Sherman BT, 2022, NUCLEIC ACIDS RES, V50, pW216, DOI 10.1093/nar/gkac194
   Simon LS., 1999, AM J MED, V106, p37S, DOI [DOI 10.1016/S0002 9343(99)00115 1, 10.1016/S0002 9343(99)00115 1]
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tang J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7039802
   Tang YP, 2022, CHIN J NAT MEDICINES, V20, P481, DOI 10.1016/S1875 5364(22)60206 1
   Ueda T, 2023, NEUROREPORT, V34, P238, DOI 10.1097/WNR.0000000000001885
   Wan DS, 2016, ECOL EVOL, V6, P1977, DOI 10.1002/ece3.2019
   Xu C, 2022, J PAIN RES, V15, P2067, DOI 10.2147/JPR.S364972
   Xu HY, 2019, NUCLEIC ACIDS RES, V47, pD976, DOI 10.1093/nar/gky987
   Yu HC, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2240894
   Yuan Zhang, 2020, Zhongguo Zhong Yao Za Zhi, V45, P4071, DOI 10.19540/j.cnki.cjcmm.20200706.201
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhang DD, 2022, NEUROTOX RES, DOI 10.1007/s12640 022 00531 5
   Zhang ZH, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm 22 4815
   Zhou MT, 2021, EUR J PHARMACOL, V899, DOI 10.1016/j.ejphar.2021.174043
   Zhou WG, 2024, MOL DIVERS, V28, P2947, DOI 10.1007/s11030 023 10725 4
NR 52
TC 3
Z9 3
U1 13
U2 20
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1612 1872
EI 1612 1880
J9 CHEM BIODIVERS
JI Chem. Biodivers.
PD 2024 NOV 9
PY 2024
DI 10.1002/cbdv.202401199
EA NOV 2024
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA M0H8J
UT WOS:001354450700001
PM 39313870
DA 2025 08 17
ER

PT J
AU Saltel, F
   Chabadel, A
   Zhao, YS
   Lafage Proust, MH
   Clézardin, P
   Jurdic, P
   Bonnelye, E
AF Saltel, Frederic
   Chabadel, Anne
   Zhao, Yingshe
   Lafage Proust, Marie Helene
   Clezardin, Philippe
   Jurdic, Pierre
   Bonnelye, Edith
TI Transmigration:: A new property of mature multinucleated osteoclasts
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE osteoclast; transmigration; podosome; c src; matrix metalloproteinase;
   bisphosphonate
ID MATRIX METALLOPROTEINASES MMP; MOLECULAR MECHANISMS; BONE; BREAST;
   DIFFERENTIATION; PODOSOMES; INTEGRIN; GROWTH; CELLS;
   MATRIX METALLOPROTEINASE 9
AB Even though it is assumed that multinucleated osteoclasts are migrating cells on the bone surface to be resorbed, we show that they can also selectively transmigrate through layers of cells usually found in the bone microenvironment. This activity is associated with c src and MMPs and can be stimulated by bone metastatic breast cancer cells, a process blocked by bisphosphonate treatment.
   Introduction: Osteoclasts have an hematopoietic origin and are bone resorbing cells. Monocytic precursors migrate to the bone surface where they fuse to form multinucleated osteoclasts able to migrate over the bone surface. We studied whether multinucleated osteoclasts were also able to transmigrate through tissues.
   Materials and Methods: Murine spleen derived and green fluorescent protein (GFP) Raw derived osteoclasts were seeded on osteoblasts and several other cell types. The cells were fixed for 20 minutes, 4 or 12 h after osteoclast seeding, and stained with phalloidin to visualize actin using confocal microscopy. Drugs such as PP2 and GM6001, inhibitors of c src and matrix metalloproteinases (MMPs), respectively, and risedronate were used to determine osteoclast transmigration regulating factors.
   Results: We observed by confocal microscopy that multinucleated osteoclasts specifically transmigrate through confluent layers of various cell types present in the bone microenvironment in vitro. This is an efficient process associated with c src and MMPs but is independent of podosomes. Moreover, conditioned medium from bone metastatic breast cancer cells stimulates osteoclast transmigration in vitro, a process inhibited by bisphosphonate treatment.
   Conclusions: Our data describe a new property of mature multinucleated osteoclasts to transmigrate through various cell types. The ability to control this highly regulated osteoclast transmigration process may offer new therapeutic strategies for bone diseases associated with an imbalance in bone remodeling caused by excessive osteoclast resorption.
C1 Ecole Normale Super Lyon, Mol & Cellular Biol Lab, UMR 5161 CNRS, IFR 128 Biosci, F 69364 Lyon, France.
   Fac Med Laennec, INSERM UMR 664, Lyon 08, France.
   Fac Biol, Lab Biol Tissu Osseux, E INSERM 366, St Etienne 2, France.
C3 Ecole Normale Superieure de Lyon (ENS de LYON); Universite Claude
   Bernard Lyon 1; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Institut National de la Sante et de la Recherche
   Medicale (Inserm)
RP Jurdic, P (通讯作者)，Ecole Normale Super Lyon, Mol & Cellular Biol Lab, UMR 5161 CNRS, IFR 128 Biosci, 46 Allee Italie, F 69364 Lyon, France.
EM pjurdic@ens lyon.fr
RI Clezardin, Philippe/M 8071 2014; Bonnelye, Edith/AAT 9134 2021
OI Clezardin, Philippe/0000 0003 0149 4463; Lafage Proust,
   Marie Helene/0000 0002 2091 3961; saltel, frederic/0000 0002 0724 9680
CR Boissier S, 2000, CANCER RES, V60, P2949
   Bonnelye E, 2001, J CELL BIOL, V153, P971, DOI 10.1083/jcb.153.5.971
   Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123
   Boyce BF, 2005, CANCER TREAT REV, V31, pS17
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BURKHARDT R, 1984, BONE CIRCULATION, P1
   Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159, DOI 10.1615/CritRevEukarGeneExpr.v10.i2.50
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Delaissé JM, 2000, CLIN CHIM ACTA, V291, P223, DOI 10.1016/S0009 8981(99)00230 2
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Domon T, 2002, TISSUE CELL, V34, P326, DOI 10.1016/S0040816602000137
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Fleisch H., 2002, PRINCIPLES BONE BIOL, V2nd, P1361
   Fukuda A, 2005, J BONE MINER RES, V20, P2245, DOI 10.1359/JBMR.050816
   FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733
   Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Laing JG, 2005, J CELL SCI, V118, P2167, DOI 10.1242/jcs.02329
   Linder S, 2005, J CELL SCI, V118, P2079, DOI 10.1242/jcs.02390
   Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962 8924(03)00128 4
   Lipton Allan, 2003, Expert Opin Emerg Drugs, V8, P469, DOI 10.1517/eoed.8.2.469.21140
   Liu Y, 2004, J IMMUNOL, V172, P7, DOI 10.4049/jimmunol.172.1.7
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013
   Matter K, 2005, CURR OPIN CELL BIOL, V17, P453, DOI 10.1016/j.ceb.2005.08.003
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Nemeth JA, 2002, J NATL CANCER I, V94, P17
   Nisato RE, 2005, CANCER RES, V65, P9377, DOI 10.1158/0008 5472.CAN 05 1512
   Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235
   Parfitt AM, 2001, J BONE MINER RES, V16, P1583, DOI 10.1359/jbmr.2001.16.9.1583
   Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01 0911fje
   Pilkington MF, 1998, J BONE MINER RES, V13, P688, DOI 10.1359/jbmr.1998.13.4.688
   Prêle CM, 2003, EXP CELL RES, V282, P24, DOI 10.1006/excr.2002.5668
   RASMUSSEN H, 1973, NEW ENGL J MED, V289, P25, DOI 10.1056/NEJM197307052890107
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04 06 0522
   Sato H, 1997, THROMB HAEMOSTASIS, V78, P497
   Sato T, 1998, J BONE MINER RES, V13, P59, DOI 10.1359/jbmr.1998.13.1.59
   Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006
   Shibutani T, 2000, J BIOMED MATER RES, V50, P153, DOI 10.1002/(SICI)1097 4636(200005)50:2<153::AID JBM9>3.0.CO;2 R
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Stains JP, 2005, BIOCHEM BIOPH RES CO, V328, P721, DOI 10.1016/j.bbrc.2004.11.078
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Vaananen K., 2002, Principles of Bone Biology, Vsecond, P127
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092 8674(00)81169 1
   Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595
   Winding B, 2002, CLIN CANCER RES, V8, P1932
   Wozniak MA, 2005, MOL BIOL CELL, V16, P84, DOI 10.1091/mbc.E04 04 0277
   Yu XF, 2003, CONNECT TISSUE RES, V44, P79, DOI 10.1080/03008200390152133
   Zhao HP, 2006, RHEUMATOL INT, V26, P732, DOI 10.1007/s00296 005 0061 8
NR 55
TC 31
Z9 33
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2006
VL 21
IS 12
BP 1913
EP 1923
DI 10.1359/JBMR.060821
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 108ZY
UT WOS:000242278900013
PM 17002556
OA Bronze
DA 2025 08 17
ER

PT J
AU Tu, YB
   Tan, LH
   Lu, T
   Wang, K
   Wang, HY
   Han, B
   Zhao, YX
   Chen, HB
   Li, YF
   Chen, HX
   Chen, MW
   He, CW
AF Tu, Yanbei
   Tan, Lihua
   Lu, Tao
   Wang, Kai
   Wang, Haiyong
   Han, Bing
   Zhao, Yuxin
   Chen, Hanbin
   Li, Yanfang
   Chen, Haixia
   Chen, Meiwan
   He, Chengwei
TI Glytabastan B, a coumestan isolated from Glycine tabacina,
   alleviated synovial inflammation, osteoclastogenesis and
   collagen induced arthritis through inhibiting MAPK and PI3K/AKT pathways
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Glycine tabacina; Glytabastan B; Rheumatoid arthritis; Inflammation;
   Osteoclast; Network pharmacology
ID THERAPEUTIC TARGETS; PHOSPHORYLATION; IDENTIFICATION; PHARMACOLOGY;
   MODELS
AB The roots of Glycine tabacina are used to treat rheumatoid arthritis (RA) and joint infection in folk medicine. Glytabastan B (GlyB), a newly reported coumestan isolated from this species, was found to significantly attenuate IL 1 beta induced inflammation in SW982 human synovial cells at 3 and 6 jiM, as evidenced by the decreased levels of pro inflammatory mediators and matrix metalloproteinases (MMPs). GlyB also suppressed RANKL induced osteoclastogenesis, decreased the expression of osteoclastogenic markers (NFATc1, CTSK, MMP 9) and osteoclast mediated bone resorption. Further, GlyB administration (12.5 and 25 mg/kg) significantly inhibited inflammation, osteoclast formation and disease progression in collagen induced arthritis (CIA) mice. Integration of network pharmacology, quantitative phosphoproteomic and experimental pharmacology results revealed that these beneficial actions were closely associated with the blockade of GlyB on the activation of MAPK, PI3K/AKT and their downstream signals including NF xB and GSK3 beta/NFATc1. Drug affinity responsive target stability (DARTS) assay, cellular thermal shift (CETSA) assay and molecular docking analysis confirmed that there were direct interactions between GlyB and its target proteins ERK2, JNK1 and class I PI3K catalytic subunit p110 (alpha, beta, delta and gamma), which significantly contributed to the inhibition of activation of MAPK and PI3K/AKT pathways. In conclusion, these results strongly suggest GlyB is a promising multiple target candidate for the development of agents for the prevention and treatment of RA.
C1 [Tu, Yanbei; Tan, Lihua; Wang, Kai; Wang, Haiyong; Han, Bing; Zhao, Yuxin; Chen, Hanbin; Chen, Meiwan; He, Chengwei] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Guangdong Hong Kong Macau Joint Lab Chinese Med &, Taipa 999078, Macau, Peoples R China.
   [Tu, Yanbei] Jiangsu Univ, Sch Pharm, Zhenjiang 212013, Jiangsu, Peoples R China.
   [Lu, Tao; Li, Yanfang] Sichuan Univ, Sch Chem Engn, Chengdu 610065, Peoples R China.
   [Chen, Haixia] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin Key Lab Modern Drug Delivery & High Effic, Tianjin 300072, Peoples R China.
C3 University of Macau; Jiangsu University; Sichuan University; Tianjin
   University
RP He, CW (通讯作者)，Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Guangdong Hong Kong Macau Joint Lab Chinese Med &, Taipa 999078, Macau, Peoples R China.
EM chengweihe@um.edu.mo
RI ; Zhao, Yuxin/HNS 3187 2023; He, Chengwei/J 7090 2015; Wang,
   Kai/AIE 2501 2022; wang, pengcheng/N 1680 2017; Chen, Haixia/K 1661 2015
OI yanfang, Li/0000 0002 9675 4864; He, Chengwei/0000 0003 4701 2984; Chen,
   Haixia/0000 0002 2596 9622; Tu, Yanbei/0000 0002 0877 0427; chen, han
   bin/0000 0003 2271 7769; 
FU Macao Science and Technology Development Fund, Macao SAR [070/2017/A2,
   0024/2020/A1]; Research Fund of the University of Macau
   [MYRG2018 00176 ICMS]; 2020 Guangdong Provincial Science and Technology
   Innovation Strategy Special Fund (Guangdong Hong Kong Macau Joint Lab)
   [2020B1212030006]; West China School of Pharmacy, Sichuan University
FX This work was supported by the Macao Science and Technology Development
   Fund, Macao SAR (070/2017/A2, 0024/2020/A1) and the Research Fund of the
   University of Macau (MYRG2018 00176 ICMS) and the 2020 Guangdong
   Provincial Science and Technology Innovation Strategy Special Fund
   (Guangdong Hong Kong Macau Joint Lab) (2020B1212030006). The authors
   thank for the support of Schrodinger software from the West China School
   of Pharmacy, Sichuan University. The authors thank the Shanghai Applied
   Protein Technology Co. Ltd for technology support.
CR Abbasi M, 2019, J CELL PHYSIOL, V234, P10018, DOI 10.1002/jcp.27860
   Alghasham A, 2014, AUTOIMMUNITY, V47, P77, DOI 10.3109/08916934.2013.873413
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284
   Chaikuad A, 2014, NAT CHEM BIOL, V10, P853, DOI [10.1038/NCHEMBIO.1629, 10.1038/nchembio.1629]
   Chen X, 2016, BRIEF BIOINFORM, V17, P696, DOI 10.1093/bib/bbv066
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Dinesh P, 2018, PHARMACOL RES, V134, P31, DOI 10.1016/j.phrs.2018.05.016
   Facciola S, 1990, CORNUCOPIA SOURCE BO
   Falconer J, 2018, ARTHRITIS RHEUMATOL, V70, P984, DOI 10.1002/art.40504
   Franken H, 2015, NAT PROTOC, V10, P1567, DOI 10.1038/nprot.2015.101
   Ghigo A, 2010, BIOESSAYS, V32, P185, DOI 10.1002/bies.200900150
   Graves JD, 1999, PHARMACOL THERAPEUT, V82, P111, DOI 10.1016/S0163 7258(98)00056 4
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007 1110
   Hoshino Negishi K, 2019, ARTHRITIS RHEUMATOL, V71, P222, DOI 10.1002/art.40688
   Invergo BM, 2018, ESSAYS BIOCHEM, V62, P525, DOI 10.1042/EBC20180019
   Jabbour E, 2014, HAEMATOLOGICA, V99, P7, DOI 10.3324/haematol.2013.087171
   Kibble M, 2015, NAT PROD REP, V32, P1249, DOI 10.1039/c5np00005j
   Kim J, 2020, BIOMOL THER, V28, P172
   Krishnan H, 2019, DRUG DISCOV TODAY, V24, P241, DOI 10.1016/j.drudis.2018.07.009
   Lefèvre S, 2015, CURR PHARM DESIGN, V21, P130
   Li T.S. C., 2006, TAIW NAT MED PLANTS
   Lü SW, 2015, J ETHNOPHARMACOL, V176, P177, DOI 10.1016/j.jep.2015.10.010
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Miles JA, 2021, ACS CHEM NEUROSCI, V12, P30, DOI 10.1021/acschemneuro.0c00627
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159 8290.CD 13 0070
   Nehybová T, 2014, ANTI CANCER AGENT ME, V14, P1351, DOI 10.2174/1871520614666140713172949
   Neumann E, 2010, TRENDS MOL MED, V16, P458, DOI 10.1016/j.molmed.2010.07.004
   Pai MY, 2015, METHODS MOL BIOL, V1263, P287, DOI 10.1007/978 1 4939 2269 7_22
   Peng YH, 2019, BRAIN BEHAV IMMUN, V82, P432, DOI 10.1016/j.bbi.2019.09.013
   Rengasamy KRR, 2019, PHARMACOL THERAPEUT, V194, P107, DOI 10.1016/j.pharmthera.2018.09.009
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Soares Silva M, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00183
   Sun W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07626 8
   Tas SW, 2005, CURR PHARM DESIGN, V11, P581, DOI 10.2174/1381612053381918
   Tu YB, 2021, PHARMACOL RES, V169, DOI 10.1016/j.phrs.2021.105615
   Tu YB, 2020, J AGR FOOD CHEM, V68, P10664, DOI 10.1021/acs.jafc.0c00878
   Tu YB, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112855
   Tu YB, 2019, J FUNCT FOODS, V62, DOI 10.1016/j.jff.2019.103528
   Tu YB, 2019, J ETHNOPHARMACOL, V237, P20, DOI 10.1016/j.jep.2019.03.035
   Wang DD, 2019, J CELL PHYSIOL, V234, P14460, DOI 10.1002/jcp.28215
   Wang X, 2017, NUCLEIC ACIDS RES, V45, pW356, DOI 10.1093/nar/gkx374
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zampeli E, 2015, J AUTOIMMUN, V65, P1, DOI 10.1016/j.jaut.2015.10.003
   Zhang RZ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00123
NR 49
TC 20
Z9 21
U1 2
U2 75
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAR
PY 2022
VL 197
AR 114912
DI 10.1016/j.bcp.2022.114912
EA JAN 2022
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 0G0WA
UT WOS:000777774000004
PM 35032460
DA 2025 08 17
ER

PT J
AU Carrasco, ME
   Thaler, R
   Nardocci, G
   Dudakovic, A
   van Wijnen, AJ
AF Carrasco, Margarita E.
   Thaler, Roman
   Nardocci, Gino
   Dudakovic, Amel
   van Wijnen, Andre J.
TI Inhibition of Ezh2 redistributes bivalent domains within transcriptional
   regulators associated with WNT and Hedgehog pathways in osteoblasts
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ZESTE HOMOLOG 2; BONE FORMATION; PRC2 COMPLEX; OSTEOGENIC
   DIFFERENTIATION; CELL DIFFERENTIATION; EPIGENETIC CONTROL; SIGNALING
   PATHWAY; METHYLATION; FATE; REPRESSOR
AB Bivalent epigenomic regulatory domains containing both activating histone 3 lysine 4 (H3K4me3) and repressive lysine 27 (H3K27me3) trimethylation are associated with key developmental genes. These bivalent domains repress transcription in the absence of differentiation signals but maintain regulatory genes in a poised state to allow for timely activation. Previous studies demonstrated that enhancer of zeste homolog 2 (Ezh2), a histone 3 lysine 27 (H3K27) methyltransferase, suppresses osteogenic differentiation and that inhibition of Ezh2 enhances commitment of osteoblast progenitors in vitro and bone formation in vivo. Here, we examined the mechanistic effects of Tazemetostat (EPZ6438), an Food and Drug Administration approved Ezh2 inhibitor for epithelioid sarcoma treatment, because this drug could potentially be repurposed to stimulate osteogenesis for clinical indications. We find that Tazemetostat reduces H3K27me3 marks in bivalent domains in enhancers required for bone formation and stimulates maturation of MC3T3 preosteoblasts. Furthermore, Tazemetostat activates bivalent genes associated with the Wingless/integrated (WNT), adenylyl cyclase (cAMP), and Hedgehog (Hh) signaling pathways based on transcriptomic (RNA seq) and epigenomic (chromatin immunoprecipitation [ChIP] seq) data. Functional analyses using selective pathway inhibitors and silencing RNAs demonstrate that the WNT and Hh pathways modulate osteogenic differentiation after Ezh2 inhibition. Strikingly, we show that loss of the Hh responsive transcriptional regulator Gli1, but not Gli2, synergizes with Tazemetostat to accelerate osteoblast differentiation. These studies establish epigenetic cooperativity of Ezh2, Hh Gli1 signaling, and bivalent regulatory genes in suppressing osteogenesis. Our findings may have important translational ramifications for anabolic applications requiring bone mass accrual and/or reversal of bone loss.
C1 [Carrasco, Margarita E.; Thaler, Roman; Dudakovic, Amel] Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.
   [Nardocci, Gino] Univ Andes, Fac Med, Ctr Biomed Res & Innovat CIIB, Program Mol Biol & Bioinformat, Santiago, Chile.
   [Nardocci, Gino] Ctr Intervent Med Precis & Adv Cellular Therapy, IMPACT, Santiago, Chile.
   [Dudakovic, Amel] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
   [van Wijnen, Andre J.] Univ Vermont, Dept Biochem, Burlington, VT 05405 USA.
C3 Mayo Clinic; Universidad de los Andes   Chile; Mayo Clinic; University
   of Vermont
RP Dudakovic, A (通讯作者)，Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.; Dudakovic, A (通讯作者)，Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.; van Wijnen, AJ (通讯作者)，Univ Vermont, Dept Biochem, Burlington, VT 05405 USA.
EM Dudakovic.Amel@mayo.edu; andre.vanwijnen@uvm.edu
RI ; Nardocci, Gino/GLQ 7690 2022; van Wijnen, Andre/AAG 3578 2019
OI Nardocci, Gino/0000 0002 2342 6480; van Wijnen, Andre
   J./0000 0002 4458 0946; 
FU National Institutes of Health [R01 AR049069]; ANID/CONICYT   FONDECYT
   [11190998]; ANID   Basal funding for Scientific and Technological Center
   of Excellence, IMPACT [FB210024]
FX This work was supported by National Institutes of Health grants R01
   AR049069 (A. J. v. W.) and Career Development Award in Orthopedics
   Research (A. D.), and ANID/CONICYT   FONDECYT 11190998 and ANID   Basal
   funding for Scientific and Technological Center of Excellence, IMPACT,
   FB210024 (G. N.). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Adema V, 2022, CANCER RES, V82, P359, DOI 10.1158/0008 5472.CAN 21 4311
   Aguilar R, 2016, BBA GENE REGUL MECH, V1859, P1043, DOI 10.1016/j.bbagrm.2016.05.009
   Aljazi MB, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101646
   Alman BA, 2015, NAT REV RHEUMATOL, V11, P552, DOI 10.1038/nrrheum.2015.84
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Atlasi Y, 2017, NAT REV GENET, V18, DOI 10.1038/nrg.2017.57
   Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Blanco E, 2020, TRENDS GENET, V36, P118, DOI 10.1016/j.tig.2019.11.004
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Brand M, 2019, CELL STEM CELL, V24, P518, DOI 10.1016/j.stem.2019.03.005
   Camilleri ET, 2018, J BIOL CHEM, V293, P19001, DOI 10.1074/jbc.RA118.003909
   Cao XK, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02670 6
   Chamberlain SJ, 2008, STEM CELLS, V26, P1496, DOI 10.1634/stemcells.2008 0102
   Chen YH, 2016, STEM CELLS, V34, P2183, DOI 10.1002/stem.2400
   Cui Peng, 2012, Genomics Proteomics & Bioinformatics, V10, P82, DOI 10.1016/j.gpb.2012.05.007
   Cyrus S, 2019, AM J MED GENET C, V181, P519, DOI 10.1002/ajmg.c.31754
   Cyrus SS, 2019, AM J MED GENET C, V181, P532, DOI 10.1002/ajmg.c.31748
   de Nigris F, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115605
   Diederichs S, 2019, CELL MOL LIFE SCI, V76, P3875, DOI 10.1007/s00018 019 03099 0
   Dudakovic, 2017, CURRENT MOL BIOL REP, V3, P94, DOI [DOI 10.1007/S40610 017 0064 8, DOI 10.1007/s40610 017 0064 8]
   Dudakovic A, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 17579 0
   Dudakovic A, 2020, J BIOL CHEM, V295, P7877, DOI 10.1074/jbc.RA119.011685
   Dudakovic A, 2018, J BIOL CHEM, V293, P12894, DOI 10.1074/jbc.RA118.002983
   Dudakovic A, 2016, J BIOL CHEM, V291, P24594, DOI 10.1074/jbc.M116.740571
   Dudakovic A, 2015, J BIOL CHEM, V290, P27604, DOI 10.1074/jbc.M115.672345
   Elsherbiny A, 2021, CURR OPIN CELL BIOL, V69, P80, DOI 10.1016/j.ceb.2020.12.014
   Fang C, 2016, J IMMUNOL, V196, P4452, DOI 10.4049/jimmunol.1501466
   Galea Gabriel L, 2020, Gene X, V5, P100027, DOI 10.1016/j.gene.2020.100027
   Galea GL, 2015, J BONE MINER RES, V30, P411, DOI 10.1002/jbmr.2377
   Galvan ML, 2021, BONE, V150, DOI 10.1016/j.bone.2021.115993
   Gordon JAR, 2015, BONE, V81, P739, DOI 10.1016/j.bone.2015.03.011
   Grandy RA, 2016, MOL CELL BIOL, V36, P615, DOI 10.1128/MCB.00877 15
   Griffiths S, 2019, AM J MED GENET A, V179, P588, DOI 10.1002/ajmg.a.61066
   Gustafson CT, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00285
   Haraguchi R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235840
   He AB, 2012, CIRC RES, V110, P406, DOI 10.1161/CIRCRESAHA.111.252205
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hemming S, 2017, FASEB J, V31, P1011, DOI 10.1096/fj.201600748R
   Hemming S, 2014, STEM CELLS, V32, P802, DOI 10.1002/stem.1573
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang Y, 2022, J MED CHEM, V65, P5317, DOI 10.1021/acs.jmedchem.1c02148
   Jadhav U, 2016, CELL, V165, P1389, DOI 10.1016/j.cell.2016.04.031
   Jing H, 2016, MOL THER, V24, P217, DOI 10.1038/mt.2015.152
   Khademi Shirvan Maliheh, 2020, Adv Exp Med Biol, V1288, P87, DOI 10.1007/5584_2020_489
   Khattak MNK, 2010, CANCER INVEST, V28, P797, DOI 10.3109/07357907.2010.494318
   Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036
   Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535 7163.MCT 13 0773
   Kobayashi Y, 2021, BIOCHEM BIOPH RES CO, V567, P72, DOI 10.1016/j.bbrc.2021.06.003
   Lavarone E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09624 w
   Li CC, 2016, P NATL ACAD SCI USA, V113, P5946, DOI 10.1073/pnas.1601918113
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Liu L, 2016, ONCOTARGET, V7, P47145, DOI 10.18632/oncotarget.9975
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Lui H, 2021, TISSUE ENG PT A, V27, P1084, DOI [10.1089/ten.tea.2020.0218, 10.1089/ten.TEA.2020.0218]
   Lui JC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13685
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Montecino M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.611197
   Montecino M, 2015, BONE, V81, P733, DOI 10.1016/j.bone.2015.03.013
   Ohba S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186665
   Pal D, 2021, STEM CELLS DEV, V30, P601, DOI 10.1089/scd.2020.0209
   Paradise CR, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116234
   Paradise CR, 2020, J CELL PHYSIOL, V235, P5293, DOI 10.1002/jcp.29415
   Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432 06
   Plotkin LI, 2019, ADV PROTEIN CHEM STR, V116, P237, DOI 10.1016/bs.apcsb.2019.01.002
   Ramírez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257
   Ross Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Sanulli S, 2015, MOL CELL, V57, P769, DOI 10.1016/j.molcel.2014.12.020
   Schupbach D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115491
   Schwarz D, 2014, DEVELOPMENT, V141, P867, DOI 10.1242/dev.094342
   Sellers WR, 2002, CANCER CELL, V2, P349, DOI 10.1016/S1535 6108(02)00187 3
   Sen B, 2020, J BONE MINER RES, V35, P1149, DOI 10.1002/jbmr.3975
   Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016
   Shi XM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6425
   Shi Y, 2017, ACTA PHARMACOL SIN, V38, P963, DOI 10.1038/aps.2017.7
   Thaler R, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 32915 8
   van Wijnen AJ, 2019, J ORTHOP RES, V37, P1465, DOI 10.1002/jor.24305
   Varet H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157022
   Voigt P, 2013, GENE DEV, V27, P1318, DOI 10.1101/gad.219626.113
   Wang HR, 2016, SCI REP UK, V6, DOI 10.1038/srep36988
   Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139
   Weikert S, 2005, INT J MOL MED, V16, P349
   Wyngaarden LA, 2011, DEVELOPMENT, V138, P3759, DOI 10.1242/dev.063180
   Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540
   Yang J, 2015, INT J ORAL SCI, V7, P73, DOI 10.1038/ijos.2015.14
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 9 r137
   Zhu XX, 2016, ONCOTARGET, V7, P63561, DOI 10.18632/oncotarget.11538
NR 88
TC 11
Z9 11
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP
PY 2023
VL 299
IS 9
AR 105155
DI 10.1016/j.jbc.2023.105155
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA IK6K1
UT WOS:001166255600001
PM 37572850
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Santo, AIE
   Ersek, A
   Freidin, A
   Feldmann, M
   Stoop, AA
   Horwood, NJ
AF Santo, A. I. Espirito
   Ersek, A.
   Freidin, A.
   Feldmann, M.
   Stoop, A. A.
   Horwood, N. J.
TI Selective inhibition of TNFR1 reduces osteoclast numbers and is
   differentiated from anti TNF in a LPS driven model of inflammatory bone
   loss
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE TNF receptor 1; p55; Lipopolysaccharide; Calvaria; Bone
ID TUMOR NECROSIS FACTOR; RHEUMATOID ARTHRITIS; ALPHA; RESORPTION;
   INTERLEUKIN 1; CYTOKINE; BLOCKADE; THERAPY; DISEASE; UPDATE
AB The treatment of autoimmune disorders has been revolutionised by the introduction of biologics such as anti tumour necrosis factor (anti TNF). Although in rheumatoid arthritis patients a bone sparing effect of anti TNF has been shown, the mechanism is not fully understood. Anti TNF molecules block tumour necrosis factor (TNF) and prevent signalling via both TNF receptor I (TNFR1; p55) and TNF receptor 2 (TNFR2; p75). However, signalling via TNFR2 is reported to have protective effects in a number of cell and organ systems. Hence we set out to investigate if pharmacological inhibition of TNFR1 had differential effects compared to pan TNF inhibition in both an in vitro cell based model of human osteoclast activity and an in vivo mouse model of lipopolysaccharide (LPS) induced osteolysis. For the in vitro experiments the anti human TNFR1 domain antibody (dAb) DMS5541 was used, whereas for the in vivo mouse experiments the anti mouse TNFR1 dAb DMS5540 was used. We show that selective blocking of TNFR1 signalling reduced osteoclast formation in the presence of TNF. Subcutaneous LPS injection over the calvaria leads to the development of osteolytic lesions within days due to inflammation driven osteoclast formation. In this model, murine TNFR2 genetically fused with mouse IgG1 Fc domain (mTNFR2.Fc), an anti TNF, did not protect from bone loss in contrast to anti TNFR1, which significantly reduced lesion development, inflammatory infiltrate, and osteoclast number and size. These results support further exploring the use of TNFR1 selective inhibition in inflammatory bone loss disorders such as osteomyelitis and pen prosthetic aseptic loosening. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Santo, A. I. Espirito; Ersek, A.; Freidin, A.; Feldmann, M.; Horwood, N. J.] Univ Oxford, Kennedy Inst Rheumatol, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7FY, England.
   [Stoop, A. A.] GlaxoSmithKline, Biopharm R&D, Stevenage, Herts, England.
C3 University of Oxford; Kennedy Institute for Rheumatology;
   GlaxoSmithKline; Glaxosmithkline United Kingdom
RP Horwood, NJ (通讯作者)，Univ Oxford, Kennedy Inst Rheumatol, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Roosevelt Dr, Oxford OX3 7FY, England.
EM nicole.horwood@kennedy.ox.ac.uk
RI ; Horwood, Nicole/B 4351 2009
OI Stoop, Allart/0000 0001 6931 5682; Horwood, Nicole/0000 0002 6344 1677;
   Ersek, Adel/0000 0001 7963 2980
FU GlaxoSmithKline; Versus Arthritis [20372] Funding Source: researchfish
FX The authors would like to thank Laura Goodall and Andrew Sanderson from
   GlaxoSmithkline for technical expertise with dAb production,
   purification and quality control. This study was funded by
   GlaxoSmithKline.
CR Abu Amer Y, 2000, J BIOL CHEM, V275, P27307
   Binder NB, 2013, ARTHRITIS RHEUM US, V65, P608, DOI 10.1002/art.37797
   BRENNAN FM, 1992, BRIT J RHEUMATOL, V31, P293
   Chiang CY, 1999, INFECT IMMUN, V67, P4231, DOI 10.1128/IAI.67.8.4231 4236.1999
   CORNISH J, 1993, ENDOCRINOLOGY, V132, P1359, DOI 10.1210/en.132.3.1359
   Costa Reis P, 2013, J CLIN IMMUNOL, V33, P1043, DOI 10.1007/s10875 013 9902 5
   Danks L, 2011, J BONE MINER RES, V26, P182, DOI 10.1002/jbmr.210
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Emery P., 2009, J RHEUMATOL RHEUM
   Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939
   Goldring SR, 2013, ANN RHEUM DIS, V72, P52, DOI 10.1136/annrheumdis 2012 202199
   Guo HH, 2013, INT J MOL MED, V32, P296, DOI 10.3892/ijmm.2013.1416
   Horwood NJ, 2003, J EXP MED, V197, P1603, DOI 10.1084/jem.20021845
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lymperi S, 2008, BLOOD, V111, P1173, DOI 10.1182/blood 2007 03 082800
   Lymperi S, 2011, BLOOD, V117, P1540, DOI 10.1182/blood 2010 05 282855
   McCann FE, 2014, ARTHRITIS RHEUMATOL, V66, P2728, DOI 10.1002/art.38755
   Mian AH, 2008, J BONE MINER METAB, V26, P469, DOI 10.1007/s00774 007 0834 0
   Nagano K, 2011, J BONE MINER METAB, V29, P671, DOI 10.1007/s00774 011 0270 z
   Nam JL, 2014, ANN RHEUM DIS, V73, P516, DOI 10.1136/annrheumdis 2013 204577
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116
   Puimège L, 2014, CYTOKINE GROWTH F R, V25, P285, DOI 10.1016/j.cytogfr.2014.03.004
   Schmidt EM, 2013, ARTHRITIS RHEUM US, V65, P2262, DOI 10.1002/art.38055
   Taylor PC, 2009, NAT REV RHEUMATOL, V5, P578, DOI 10.1038/nrrheum.2009.181
   Vasudevan A, 2012, ARTHRITIS RHEUM US, V64, P1005, DOI 10.1002/art.33459
   Vattakuzhi Y, 2012, ARTHRITIS RHEUM US, V64, P2201, DOI 10.1002/art.34403
   Wythe SE, 2014, CALCIFIED TISSUE INT, V94, P98, DOI 10.1007/s00223 013 9764 0
NR 29
TC 19
Z9 21
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 4
PY 2015
VL 464
IS 4
BP 1145
EP 1150
DI 10.1016/j.bbrc.2015.07.094
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CP4UJ
UT WOS:000359877800029
PM 26208457
DA 2025 08 17
ER

PT J
AU Trang, NM
   Kim, EN
   Pham, TH
   Jeong, GS
AF Trang, Nguyen Minh
   Kim, Eun Nam
   Pham, Thi Hoa
   Jeong, Gil Saeng
TI Citropten Ameliorates Osteoclastogenesis Related to MAPK and
   PLCγ/Ca<SUP>2+</SUP> Signaling Pathways through the Regulation of
   Amyloid Beta
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE citropten; osteoclast; amyloid beta; PLC gamma/Ca2+ signaling; molecular
   docking
ID THERAPEUTIC TARGETS; DIFFERENTIATION; 5,7 DIMETHOXYCOUMARIN;
   OSTEOGENESIS; INDUCTION; DEMENTIA; PEPTIDE; RISK
AB Osteoporosis and Alzheimer's disease are typical types of dementia in seniors, which share common risk factors. Previous studies have shown that citizens with osteoporosis are more likely than healthy individuals to be at risk of Alzheimer's disease. Citropten, found in Citrus aurantifolia, has been reported to have several pharmacological activities; however, its antiosteoclastogenic activity remains unknown. Here, receptor activator nuclear factor.B ligand (RANKL) induced osteoclast differentiation, formation, and function in the presence of amyloid beta (A ss) were attenuated by citropten in the RAW 264.7 cell line. The expression of osteoclast specific genes and proteins indicated that citropten pretreatment lowers the MAPK and PLC gamma/Ca2+ signaling pathways. Molecular docking simulations revealed that citropten interacts with the active sites of proteins in the calcium signaling pathway, which have negative binding affinities. These findings indicate that, through A ss regulation, the RANKLinduced osteoclast can be suppressed by citropten, suggesting that citropten is a potential candidate for treating osteoclastogenesisrelated diseases.
C1 [Trang, Nguyen Minh; Kim, Eun Nam; Pham, Thi Hoa; Jeong, Gil Saeng] Chungnam Natl Univ, Coll Pharm, Daejeon 26715, South Korea.
C3 Chungnam National University
RP Jeong, GS (通讯作者)，Chungnam Natl Univ, Coll Pharm, Daejeon 26715, South Korea.
EM gsjeong@cnu.ac.kr
RI Nguyen, Minh Trang/HLX 0330 2023
OI Nguyen, Minh Trang/0000 0002 5619 812X
FU National Research Foundation of Korea (NRF)   Korea government (MSIT)
   [2022R1A5A7085156]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT) (2022R1A5A7085156).
CR Ajoolabady A, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 05153 5
   Al Bari AA, 2020, FASEB BIOADV, V2, P668, DOI 10.1096/fba.2020 00058
   Alagiakrishnan K, 2003, J GERONTOL A BIOL, V58, P362
   Alesiani D, 2008, INT J ONCOL, V32, P425
   Bliuc D, 2013, J BONE MINER RES, V28, P2317, DOI 10.1002/jbmr.1968
   Cao HL, 2010, J CLIN INVEST, V120, P2755, DOI 10.1172/JCI42106
   Chaweewannakorn W, 2019, J CELL PHYSIOL, V234, P1745, DOI 10.1002/jcp.27045
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chen YH, 2017, TZU CHI MED J, V29, P138, DOI 10.4103/tcmj.tcmj_54_17
   Chung PL, 2014, J CELL BIOCHEM, V115, P1412, DOI 10.1002/jcb.24792
   de Menezes HD, 2014, J PHOTOCH PHOTOBIO B, V131, P74, DOI 10.1016/j.jphotobiol.2014.01.008
   Downey CL, 2017, WORLD J ORTHOP, V8, P412, DOI 10.5312/wjo.v8.i5.412
   Galovicová L, 2022, AGRONOMY BASEL, V12, DOI 10.3390/agronomy12030735
   Hampel H, 2021, MOL PSYCHIATR, V26, P5481, DOI 10.1038/s41380 021 01249 0
   Harrison RS, 2007, REV PHYSIOL BIOCH P, V159, P1, DOI 10.1007/112_2007_0701
   He XF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03072 x
   Hong GJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.392
   JONES AR, 1995, J ORTHOP RES, V13, P553, DOI 10.1002/jor.1100130410
   Kajiya H, 2012, ADV EXP MED BIOL, V740, P917, DOI 10.1007/978 94 007 2888 2_41
   Kang JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103646
   Kerekes D, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e10453
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Kim JH, 2018, J IMMUNOL, V200, P1661, DOI 10.4049/jimmunol.1701036
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Koistinen H, 2006, MUSCLE NERVE, V34, P444, DOI 10.1002/mus.20612
   Lee HS, 2022, MOLECULES, V27, DOI 10.3390/molecules27144633
   Lee HS, 2020, MOLECULES, V25, DOI 10.3390/molecules25194590
   Li SF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101683
   Li SF, 2014, BONE, V61, P164, DOI 10.1016/j.bone.2014.01.010
   Lin Y, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 21 6427
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169 409X(96)00423 1
   Ma MJ, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102791
   Nantapong N, 2019, APPL MICROBIOL BIOT, V103, P5355, DOI 10.1007/s00253 019 09848 2
   Narang Nithithep, 2016, Pharmacogn Rev, V10, P118, DOI 10.4103/0973 7847.194043
   Phong NV, 2022, NAT PROD RES, V36, P6336, DOI 10.1080/14786419.2022.2025801
   Palmqvist S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01150 x
   Park JH, 2017, MOL CELLS, V40, P706
   Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007
   Pujadas L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4443
   Shaw K, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 23508 y
   Song BW, 2022, EXP THER MED, V23, DOI 10.3892/etm.2021.10943
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tan ZS, 2005, ARCH NEUROL CHICAGO, V62, P107, DOI 10.1001/archneur.62.1.107
   Trang NM, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12020256
   Truhlar DG, 2007, J COMPUT CHEM, V28, P73, DOI 10.1002/jcc.20529
   VILLANUEVA JE, 1990, J BONE MINER RES, V5, P733
   Wolny D, 2014, ACTA POL PHARM, V71, P1056
   Xia YH, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 31475 1
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Yoon SS, 2012, BIOMOL THER, V20, P245, DOI 10.4062/biomolther.2012.20.3.245
   Zhang H, 2022, BIOORG CHEM, V129, DOI 10.1016/j.bioorg.2022.106114
   Zhang Y, 2012, DIABETES, V61, P1434, DOI 10.2337/db11 0499
   Zhuang JS, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04441 w
NR 54
TC 11
Z9 13
U1 2
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021 8561
EI 1520 5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD JUN 1
PY 2023
VL 71
IS 26
BP 10037
EP 10049
DI 10.1021/acs.jafc.3c00368
EA JUN 2023
PG 13
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA K8DQ3
UT WOS:001012039400001
PM 37260315
DA 2025 08 17
ER

PT J
AU Pánczél, A
   Nagy, SP
   Farkas, J
   Jakus, Z
   Gyori, DS
   Mócsai, A
AF Panczel, Aron
   Nagy, Simon P.
   Farkas, Janos
   Jakus, Zoltan
   Gyori, David S.
   Mocsai, Attila
TI Fluorescence Based Real Time Analysis of Osteoclast Development
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE osteoclasts; cell fusion; fluorescence microscopy; Cre recombinase;
   myeloid cell differentiation; fluorescent Cre reporter
ID BONE HOMEOSTASIS; PROGENITORS; RESORPTION; FUSION; LIGAND
AB Osteoclasts are multinucleated cells of hematopoietic origin which are critically involved in physiological and pathological bone resorption. They develop from myeloid progenitors through characteristic gene expression changes and intercellular fusion. This process is directed by M CSF and RANKL which are also able to trigger osteoclast development from bone marrow cells in vitro. Osteoclasts are conventionally visualized by histochemical staining followed by manual counting, which hinders kinetic studies and automated quantification. Here we describe two fluorescence based assays for the real time analysis of myeloid cell to osteoclast development (FRAMCO) in primary mouse bone marrow cell cultures. Both assays rely on red to green fluorescence conversion of the membrane targeted tdTomato/membrane targeted eGFP (mTmG) transgene by Cre recombinase driven by the osteoclast specific cathepsin K promoter (Ctsk Cre). In the first assay (FRAMCO1.1), osteoclast specific gene expression triggers red to green color conversion of cells carrying both the Ctsk Cre and mTmG transgenes. In the second assay (FRAMCO1.2), red to green fluorescence conversion is triggered by fusion of neighboring co cultured bone marrow cells separately carrying either the Ctsk Cre or the mTmG transgenes. The two assays were tested using a high content confocal fluorescence imaging system, followed by automated quantification. The FRAMCO1.1 assay showed robust red to green fluorescence conversion of more than 50% of the culture (including mononuclear cells) within 3 days under osteoclastogenic conditions. The FRAMCO1.2 assay showed a less robust but still readily measurable red to green color conversion in multinuclear cells within 5 days of differentiation. The assays required both the Ctsk Cre and the mTmG transgenes and gave no signals in parallel macrophage cultures. The proper functioning of the two assays was also confirmed at the DNA, mRNA and bulk protein level. The assay systems were validated using lisophosphatidylcholine, a previously reported inhibitor of preosteoclast fusion. Taken together, our assays allow high throughput automated real time analysis of two critical aspects of osteoclast development, facilitating the screening for novel drug candidates for the pharmacological control of osteoclast mediated bone resorption.
C1 [Panczel, Aron; Nagy, Simon P.; Farkas, Janos; Jakus, Zoltan; Gyori, David S.; Mocsai, Attila] Semmelweis Univ, Sch Med, Dept Physiol, Budapest, Hungary.
C3 Semmelweis University
RP Mócsai, A (通讯作者)，Semmelweis Univ, Sch Med, Dept Physiol, Budapest, Hungary.
EM mocsai.attila@med.semmelweis univ.hu
RI Gyori, David S./F 6276 2019; Mocsai, Attila/B 2792 2008; Győri,
   Dávid/F 6276 2019; Jakus, Zoltán/O 1762 2015
OI Gyori, David S./0000 0002 2048 6752; Mocsai, Attila/0000 0002 0512 1157
FU Hungarian National Scientific Research Fund (NKFIH OTKA Grant) [K119653,
   FK132971, NVKP_16 1 2016 0039]
FX This work was supported by the Hungarian National Scientific Research
   Fund (NKFIH OTKA Grant Nos. K119653 to AM and FK132971 to DG; and
   NVKP_16 1 2016 0039 to AM).
CR Csete D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00937
   Duong LT, 2016, CALCIFIED TISSUE INT, V98, P381, DOI 10.1007/s00223 015 0051 0
   Gyori D, 2014, ARTHRITIS RHEUMATOL, V66, P2210, DOI 10.1002/art.38660
   Gyori DS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00507
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Kertész Z, 2012, EUR J CLIN INVEST, V42, P49, DOI 10.1111/j.1365 2362.2011.02556.x
   Kikuta J, 2013, J CLIN INVEST, V123, P866, DOI 10.1172/JCI65054
   Kitazawa R, 2018, HISTOCHEM CELL BIOL, V149, P405, DOI 10.1007/s00418 018 1639 z
   Kondo T, 2004, BONE, V35, P1120, DOI 10.1016/j.bone.2004.06.011
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Levaot N, 2015, BONE, V79, P21, DOI 10.1016/j.bone.2015.05.021
   Li BE, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 28205 3
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Peng TY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14836
   Purschke M, 2010, PHOTOCH PHOTOBIO SCI, V9, P1634, DOI 10.1039/c0pp00234h
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Shim JH, 2018, CALCIFIED TISSUE INT, V102, P533, DOI 10.1007/s00223 017 0373 1
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Takegahara N, 2016, J BIOL CHEM, V291, P3439, DOI 10.1074/jbc.M115.677427
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Verma SK, 2018, J BIOL CHEM, V293, P254, DOI 10.1074/jbc.M117.809681
   Yahara Y, 2020, NAT CELL BIOL, V22, P49, DOI 10.1038/s41556 019 0437 8
NR 26
TC 5
Z9 7
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JUL 13
PY 2021
VL 9
AR 657935
DI 10.3389/fcell.2021.657935
PG 18
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA TQ2KK
UT WOS:000678114100001
PM 34327196
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Mourskaia, AA
   Amir, E
   Dong, ZF
   Tiedemann, K
   Cory, S
   Omeroglu, A
   Bertos, N
   Ouellet, V
   Clemons, M
   Scheffer, GL
   Park, M
   Hallett, M
   Komarova, SV
   Siegel, PM
AF Mourskaia, Anna A.
   Amir, Eitan
   Dong, Zhifeng
   Tiedemann, Kerstin
   Cory, Sean
   Omeroglu, Atilla
   Bertos, Nicholas
   Ouellet, Veronique
   Clemons, Mark
   Scheffer, George L.
   Park, Morag
   Hallett, Michael
   Komarova, Svetlana V.
   Siegel, Peter M.
TI ABCC5 supports osteoclast formation and promotes breast cancer
   metastasis to bone
SO BREAST CANCER RESEARCH
LA English
DT Article
ID MIGRATION INHIBITORY FACTOR; NITRIC OXIDE; CELL LINES; FACTOR MIF;
   DRUG RESISTANCE; IN VITRO; EXPRESSION; TUMOR; CGMP; ANGIOGENESIS
AB Introduction: Bone is the most common site of breast cancer metastasis and complications associated with bone metastases can lead to a significantly decreased patient quality of life. Thus, it is essential to gain a better understanding of the molecular mechanisms that underlie the emergence and growth of breast cancer skeletal metastases.
   Methods: To search for novel molecular mediators that influence breast cancer bone metastasis, we generated gene expression profiles from laser capture microdissected trephine biopsies of both breast cancer bone metastases and independent primary breast tumours that metastasized to bone. Bioinformatics analysis identified genes that are differentially expressed in breast cancer bone metastases compared to primary, bone metastatic breast tumours.
   Results: ABCC5, an ATP dependent transporter, was found to be overexpressed in breast cancer osseous metastases relative to primary breast tumours. In addition, ABCC5 was significantly up regulated in human and mouse breast cancer cell lines with high bone metastatic potential. Stable knockdown of ABCC5 substantially reduced bone metastatic burden and osteolytic bone destruction in mice. The decrease in osteolysis was further associated with diminished osteoclast numbers in vivo. Finally, conditioned media from breast cancer cells with reduced ABCC5 expression failed to induce in vitro osteoclastogenesis to the same extent as conditioned media from breast cancer cells expressing ABCC5.
   Conclusions: Our data suggests that ABCC5 functions as a mediator of breast cancer skeletal metastasis. ABCC5 expression in breast cancer cells is important for efficient osteoclast mediated bone resorption. Hence, ABCC5 may be a potential therapeutic target for breast cancer bone metastasis.
C1 [Mourskaia, Anna A.; Dong, Zhifeng; Ouellet, Veronique; Park, Morag; Siegel, Peter M.] McGill Univ, Dept Med, Montreal, PQ H3A 1A3, Canada.
   [Tiedemann, Kerstin; Komarova, Svetlana V.] McGill Univ, Fac Dent, Montreal, PQ H3A 0C7, Canada.
   [Tiedemann, Kerstin; Komarova, Svetlana V.] Shriners Hosp Children, Montreal, PQ H3G 1A6, Canada.
   [Cory, Sean; Hallett, Michael] McGill Univ, Ctr Bioinformat, Montreal, PQ H3G 0B1, Canada.
   [Omeroglu, Atilla] McGill Univ, Dept Pathol, Montreal, PQ H3A 2B4, Canada.
   [Bertos, Nicholas] McGill Univ, Breast Canc Funct Genom Grp, Montreal, PQ H3A 1A3, Canada.
   [Park, Morag; Siegel, Peter M.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.
   [Siegel, Peter M.] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada.
   [Mourskaia, Anna A.; Dong, Zhifeng; Cory, Sean; Bertos, Nicholas; Ouellet, Veronique; Park, Morag; Hallett, Michael; Siegel, Peter M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.
   [Amir, Eitan] Princess Margaret Hosp, Div Med Oncol, Toronto, ON M5T 2M9, Canada.
   [Clemons, Mark] Ottawa Hosp Canc Ctr, Div Med Oncol, Ottawa, ON K1H 8L6, Canada.
   [Scheffer, George L.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL 70571007 Amsterdam, MB, Netherlands.
C3 McGill University; McGill University; McGill University; McGill
   University; McGill University; McGill University; McGill University;
   McGill University; University of Toronto; University Health Network
   Toronto; Princess Margaret Cancer Centre; University of Ottawa; Ottawa
   Hospital Research Institute; Vrije Universiteit Amsterdam; VU UNIVERSITY
   MEDICAL CENTER
RP Siegel, PM (通讯作者)，McGill Univ, Dept Med, 1110 Pine Ave West, Montreal, PQ H3A 1A3, Canada.
EM peter.siegel@mcgill.ca
RI Komarova, Svetlana/MTR 5042 2025; Amir, Eitan/L 6052 2019
OI Amir, Eitan/0000 0002 3706 525X; Komarova, Svetlana/0000 0003 3570 3147;
   Hallett, Michael/0000 0001 6738 6786
FU CIHR [CIHR CTP 79857, MOP 119401]; Genome Quebec; FRSQ; CIHR; Terry Fox
   Foundation; Database and Tissue Bank Axis of the Reseau de recherche en
   cancer of the Fonds de recherche du Quebec   Sante (FRQS); Canadian
   Institutes of Health Research [CIHR CTP 79857]
FX This work was funded by grants from the CIHR (CIHR CTP 79857) and Genome
   Quebec. AAM was supported by a studentship from the FRSQ, VO by a
   fellowship from the CIHR and PMS received support as a Research Scholar
   (Junior II) of the FRSQ. We thank Dr. Ursini Siegel and members of the
   Siegel laboratory for helpful discussions and their critical comments on
   the manuscript. We acknowledge infrastructure support and technical
   assistance for the LCM experiments from the Breast Cancer Functional
   Genomics Group (McGill University), which is supported by funds from the
   Terry Fox Foundation. The primary breast material collection was
   supported by the Database and Tissue Bank Axis of the Reseau de
   recherche en cancer of the Fonds de recherche du Quebec   Sante (FRQS).
   The routine histology was provided by the Centre for Bone and
   Periodontal Research (McGill University) and the Goodman Cancer Research
   Centre (McGill University). A. A. M. acknowledges studentship support
   from FRQS. P. M. S. acknowledges previous support as a Research Scholar
   (Junior II) of the FRQS. This work was supported by a team grant from
   the Canadian Institutes of Health Research (CIHR CTP 79857) and a CIHR
   operating grant to P. M. S. (MOP 119401).
CR Akool ES, 2003, MOL CELL BIOL, V23, P4901, DOI 10.1128/MCB.23.14.4901 4916.2003
   Albig AR, 2008, MICROVASC RES, V76, P7, DOI 10.1016/j.mvr.2008.01.001
   Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016
   Amir E, 2012, J CLIN ONCOL, V30, P587, DOI 10.1200/JCO.2010.33.5232
   Armstrong S, 2009, J CELL SCI, V122, P136, DOI 10.1242/jcs.031534
   Arslan C, 2011, EXPERT OPIN THER TAR, V15, P21, DOI 10.1517/14656566.2011.537260
   ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Babykutty S, 2012, CLIN EXP METASTAS, V29, P471, DOI 10.1007/s10585 012 9464 6
   Bando H, 2002, JPN J CANCER RES, V93, P389, DOI 10.1111/j.1349 7006.2002.tb01269.x
   Casimiro S, 2009, MOL CELL ENDOCRINOL, V310, P71, DOI 10.1016/j.mce.2009.07.004
   Chan AS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007955
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Courtwright A, 2009, CANCER RES, V69, P4621, DOI 10.1158/0008 5472.CAN 08 3402
   Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911 009 9109 9
   Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651
   Ding XW, 2010, LIFE SCI, V86, P631, DOI 10.1016/j.lfs.2010.02.012
   Dong SS, 1999, J CELL BIOCHEM, V73, P478, DOI 10.1002/(SICI)1097 4644(19990615)73:4<478::AID JCB6>3.3.CO;2 K
   Fallahian F, 2011, FEBS J, V278, P3360, DOI 10.1111/j.1742 4658.2011.08260.x
   Farke C, 2008, J DAIRY RES, V75, P406, DOI 10.1017/S002202990800335X
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 10 r80
   Gupta GP, 2005, COLD SH Q B, V70, P149, DOI 10.1101/sqb.2005.70.018
   Hilton JF, 2011, BREAST CANCER RES TR, V129, P761, DOI 10.1007/s10549 010 1264 6
   Jacquin C, 2009, BONE, V45, P640, DOI 10.1016/j.bone.2009.06.028
   Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kaplan RN, 2006, CANCER METAST REV, V25, P521, DOI 10.1007/s10555 006 9036 9
   Kaufmann T, 2012, CELL DEATH DIFFER, V19, P42, DOI 10.1038/cdd.2011.121
   Kelly PN, 2011, CELL DEATH DIFFER, V18, P1414, DOI 10.1038/cdd.2011.17
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Kutuzov MA, 2010, INT J BIOCHEM CELL B, V42, P1816, DOI 10.1016/j.biocel.2010.07.014
   Labelle Côté M, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 443
   LaLonde DP, 2005, J BIOL CHEM, V280, P21680, DOI 10.1074/jbc.m500752200
   Lim S, 2009, J PROTEOME RES, V8, P4062, DOI 10.1021/pr900430n
   Liu CR, 2004, CHINESE MED J PEKING, V117, P213
   Lubbe WJ, 2009, CANCER RES, V69, P3529, DOI 10.1158/0008 5472.CAN 09 0067
   Lue H, 2007, ONCOGENE, V26, P5046, DOI 10.1038/sj.onc.1210318
   Mannello F, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 95
   McConnell BV, 2011, MOL CANCER, V10, DOI 10.1186/1476 4598 10 75
   McMahon G, 2000, Oncologist, V5 Suppl 1, P3
   Micali N, 2009, MOL CELL BIOL, V29, P1143, DOI 10.1128/MCB.01273 08
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Mochizuki S, 2007, CANCER SCI, V98, P621, DOI 10.1111/j.1349 7006.2007.00434.x
   Mourskaia AA, 2009, ONCOGENE, V28, P1005, DOI 10.1038/onc.2008.454
   Mujoo K, 2010, NITRIC OXIDE BIOL CH, V22, P43, DOI 10.1016/j.niox.2009.11.007
   Nakayama S, 1999, BRIT J HAEMATOL, V105, P50, DOI 10.1111/j.1365 2141.1999.01311.x
   Natarajan K, 2012, BIOCHEM PHARMACOL, V83, P1084, DOI 10.1016/j.bcp.2012.01.002
   Ouellet V, 2011, AM J PATHOL, V178, P2377, DOI 10.1016/j.ajpath.2011.01.033
   Park S, 2006, BREAST CANCER RES TR, V99, P9, DOI 10.1007/s10549 006 9175 2
   Pratt S, 2005, MOL CANCER THER, V4, P855, DOI 10.1158/1535 7163.MCT 04 0291
   Ridnour LA, 2007, P NATL ACAD SCI USA, V104, P16898, DOI 10.1073/pnas.0702761104
   Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541 7786.MCR 07 0119
   Rose AAN, 2006, B CANCER, V93, P931
   Saravani R, 2012, CELL PROLIFERAT, V45, P199, DOI 10.1111/j.1365 2184.2012.00819.x
   Schulz R, 2012, J EXP MED, V209, P275, DOI 10.1084/jem.20111117
   Shao R, 2009, ONCOGENE, V28, P4456, DOI 10.1038/onc.2009.292
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149
   Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802
   St Romain P, 2012, HUM PATHOL, V43, P398, DOI 10.1016/j.humpath.2011.05.009
   Steenport M, 2009, J IMMUNOL, V183, P8119, DOI 10.4049/jimmunol.0901925
   Suh HC, 2009, BLOOD, V114, P1186, DOI 10.1182/blood 2008 09 179788
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Szigeti A, 2006, FEBS LETT, V580, P6447, DOI 10.1016/j.febslet.2006.10.067
   Teixeira CC, 2008, DEV BIOL, V319, P171, DOI 10.1016/j.ydbio.2008.04.031
   van Herwaarden AE, 2007, MOL CELL BIOL, V27, P1247, DOI 10.1128/MCB.01621 06
   Vasiliou Vasilis, 2009, Human Genomics, V3, P281
   Verjans E, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 230
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xu AJ, 2010, CHINESE MED J PEKING, V123, P3247, DOI 10.3760/cma.j.issn.0366 6999.2010.22.014
   Xu XD, 2008, CANCER LETT, V261, P147, DOI 10.1016/j.canlet.2007.11.028
   Yaroslavskiy BB, 2005, J CELL SCI, V118, P5479, DOI 10.1242/jcs.02655
   Yaroslavskiy BB, 2004, J CELL BIOCHEM, V91, P962, DOI 10.1002/jcb.20009
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
NR 75
TC 41
Z9 46
U1 0
U2 23
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465 542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2012
VL 14
IS 6
AR R149
DI 10.1186/bcr3361
PG 59
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 160YO
UT WOS:000320156600020
PM 23174366
OA Green Published, gold
DA 2025 08 17
ER

PT S
AU Jimenez Andrade, JM
   Mantyh, WG
   Bloom, AP
   Ferng, AS
   Geffre, CP
   Mantyh, PW
AF Jimenez Andrade, Juan Miguel
   Mantyh, William G.
   Bloom, Aaron P.
   Ferng, Alice S.
   Geffre, Christopher P.
   Mantyh, Patrick W.
BE ZiiskindConhaim, L
   Fetcho, JR
   Hochman, S
   MacDermott, AB
   Stein, PSG
TI Bone cancer pain
SO NEURONS AND NETWORKS IN THE SPINAL CORD
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Cellular and Network Functions in the Spinal Cord
CY JUN 23 26, 2009
CL Univ Wisconsin, Pyle Ctr, Madison, WI
HO Univ Wisconsin, Pyle Ctr
DE osteosarcoma; prostate; therapies
ID MURINE MODEL; SKELETAL DESTRUCTION; METASTASIS; NERVE; BISPHOSPHONATES;
   REORGANIZATION; GROWTH; INJURY
AB In the United States, cancer is the second most common cause of death and it is expected that about 562,340 Americans will have died of cancer in 2009. Bone cancer pain is common in patients with advanced breast, prostate, and lung cancer as these tumors have a remarkable affinity to metastasize to bone. Once tumors metastasize to bone, they are a major cause of morbidity and mortality as the tumor induces significant skeletal remodeling, fractures, pain, and anemia. Currently, the factors that drive cancer pain are poorly understood. However, several recently introduced models of bone cancer pain, which closely mirror the human condition, are providing insight into the mechanisms that drive bone cancer pain and guide the development of mechanism based therapies to treat the cancer pain. Several of these mechanism based therapies have now entered human clinical trials. If successful, these therapies have the potential to significantly enlarge the repertoire of modalities that can be used to treat bone cancer pain and improve the quality of life, functional status, and survival of patients with bone cancer.
C1 [Mantyh, Patrick W.] Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA.
C3 University of Arizona
RP Mantyh, PW (通讯作者)，Univ Arizona, Coll Med, Dept Pharmacol, 1656 E Mabel,Rm 119,POB 245215, Tucson, AZ 85724 USA.
EM pmantyh@email.arizona.edu
RI ; ANDRADE, JUAN/C 1416 2016
OI Ferng, Alice/0000 0003 3211 6764; Jimenez Andrade, Juan
   Miguel/0000 0002 2703 9736; Mantyh, William/0000 0003 2096 2461; 
FU NINDS NIH HHS [R01 NS023970] Funding Source: Medline
CR ARGUELLO F, 1988, CANCER RES, V48, P6876
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Delaisse Jean Marie, 1992, P289
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815 04.2005
   GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326
   Halvorson KG, 2005, CANCER RES, V65, P9426, DOI 10.1158/0008 5472.CAN 05 0826
   Halvorson KG, 2006, CLIN J PAIN, V22, P587, DOI 10.1097/01.ajp.0000210902.67849.e6
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019
   Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008
   Lipton A, 2006, CLIN CANCER RES, V12, p6305S, DOI 10.1158/1078 0432.CCR 06 1157
   Lipton Allan, 2008, Curr Opin Support Palliat Care, V2, P197, DOI 10.1097/SPC.0b013e32830baac2
   Mantyh PW, 2006, NAT REV NEUROSCI, V7, P797, DOI 10.1038/nrn1914
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Niiyama Y, 2009, BRIT J ANAESTH, V102, P251, DOI 10.1093/bja/aen347
   Obata K, 2003, PAIN, V101, P65, DOI 10.1016/S0304 3959(02)00296 8
   Peters CM, 2005, EXP NEUROL, V193, P85, DOI 10.1016/j.expneurol.2004.11.028
   Pezet S, 2006, ANNU REV NEUROSCI, V29, P507, DOI 10.1146/annurev.neuro.29.051605.112929
   Rubert CK, 2000, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, P305
   Sabino MAC, 2003, INT J CANCER, V104, P550, DOI 10.1002/ijc.10999
   SCHNITZER TJ, 2008, 12 WORLD C PAIN PT 2
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   von Moos R, 2008, SUPPORT CARE CANCER, V16, P1105, DOI 10.1007/s00520 008 0487 0
   YONEDA T, 1994, BREAST CANCER RES TR, V32, P73, DOI 10.1007/BF00666208
   Zeppetella Giovambattista, 2009, Curr Opin Support Palliat Care, V3, P1, DOI 10.1097/SPC.0b013e3283260658
   NCT00556374
   NCT00381095
   NCT00545129
NR 34
TC 212
Z9 249
U1 0
U2 15
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077 8923
BN 978 1 57331 778 8
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2010
VL 1198
BP 173
EP 181
DI 10.1111/j.1749 6632.2009.05429.x
PG 9
WC Multidisciplinary Sciences; Neurosciences
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Neurosciences & Neurology
GA BQO12
UT WOS:000281413900018
PM 20536932
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Dai, HH
   Yu, YL
   Han, JY
   Luo, J
   Song, C
   Deng, ZB
   Wu, YJ
   Ke, DS
   Xu, J
AF Dai, Hanhao
   Yu, Yunlong
   Han, Junyong
   Luo, Jun
   Song, Chao
   Deng, Zhibo
   Wu, Yijing
   Ke, Dianshan
   Xu, Jie
TI A novel biologically hierarchical hydrogel with osteoblast
   precursor targeting extracellular vesicles ameliorates bone loss in vivo
   via the sequential action of antagomiR 200b 3p and antagomiR 130b 3p
SO CELL PROLIFERATION
LA English
DT Article
ID PARATHYROID HORMONE; META REGRESSION; FRACTURE RISK; DELIVERY;
   DIFFERENTIATION; PROLIFERATION; OSTEOPOROSIS; REDUCTION; EXOSOMES;
   THERAPY
AB Osteoporotic fracture is a major health problem plaguing the ageing society, and improving its treatment is an urgent challenge. How to ameliorate bone loss determines the recovery of such fractures. Extracellular vesicle (EV) loaded hydrogel has the capacity to treat osteoporotic fractures due to its pro osteogenic property. And balancing proliferation and maturation of osteoblast precursors (OBPs) is of great significance to avoid OBP depletion, which is lacking in current treatment. Based on osteoblastogenic miRNAs, this study aimed to explore the efficacies of the combination of hierarchical hydrogel and EVs altering functional miRNAs level in bone loss. Through bioinformatics analyses, we screened out proliferative gene targeting miR 200b 3p and osteogenic gene targeting miR 130b 3p. And antagomiR 200b 3p (ant 200b) enhanced OBP proliferation, and antagomiR 130b 3p (ant 130b) promoted OBP differentiation. After confirming the directional effect of Fibronectin (Fn1) on OBPs, we prepared OBP targeting EVs. Furthermore, encapsulation of two antagomiRNAs in EVs enhanced the respective effect of ant 200b and ant 130b. Notably, hierarchically injectable hydrogel exerted an effective function in promoting the sequential delivery of EVs 200b and EVs 130b. Importantly, hierarchical hydrogel containing dual EVs effectively ameliorated bone loss. Overall, hierarchical hydrogel based on two antagomiRNAs effectively improves bone loss in vivo due to its role in promoting OBP proliferation and maturation sequentially.
C1 [Dai, Hanhao; Yu, Yunlong; Song, Chao; Deng, Zhibo; Wu, Yijing; Ke, Dianshan; Xu, Jie] Shengli Clin Med Coll Fujian Med Univ, Fuzhou, Peoples R China.
   [Yu, Yunlong; Luo, Jun; Ke, Dianshan; Xu, Jie] Fujian Med Univ, Fujian Prov Hosp, Dept Orthoped, Fuzhou, Peoples R China.
   [Han, Junyong] Fujian Acad Med Sci, Inst Immunol, Fuzhou, Peoples R China.
   [Ke, Dianshan; Xu, Jie] Shengli Clin Med Coll Fujian Med Univ, East Rd 134, Fuzhou 350000, Peoples R China.
C3 Fujian Provincial Hospital; Fujian Medical University
RP Ke, DS; Xu, J (通讯作者)，Shengli Clin Med Coll Fujian Med Univ, East Rd 134, Fuzhou 350000, Peoples R China.
EM kds8810@fjmu.edu.cn; jiexud@fjmu.edu.cn
RI ; Dai, Hanhao/GZM 0440 2022; Han, Junyong/JKJ 0839 2023
OI Song, Chao/0000 0002 0828 3426; Ke, Dianshan/0000 0003 0260 7191; Dai,
   Hanhao/0000 0002 8197 3183; 
FU Fujian Provincial Natural Science Foundation Projects [2020J011079];
   Health Research Personnel Training Project of Fujian Provincial Health
   Commission [2019 CX 1]; Joint Project for Health and Education of Fujian
   Province [2021Y9023]; Joint Fund Project for Science and Technology
   Innovation [2019 WJ 01]; Major Scientific Research Project of Fujian
   Province [2021ZD01003]; Postdoctoral Science Foundation of China
   [2022M710702]; Fujian Provincial Hospital [0080132201]; Science and
   Technology Planning Project of Fujian Province [2019J01173]; Startup
   Fund for Scientific Research of Fujian Medical University [2020QH2050]
FX Fujian Provincial Natural Science Foundation Projects, Grant/Award
   Number: 2020J011079; Health Research Personnel Training Project of
   Fujian Provincial Health Commission, Grant/Award Number: 2019 CX 1;
   Joint Fund Project for Science and Technology Innovation, Grant/Award
   Number: 2021Y9023; Joint Project for Health and Education of Fujian
   Province, Grant/Award Number: 2019 WJ 01; Major Scientific Research
   Project of Fujian Province, Grant/Award Number: 2021ZD01003;
   Postdoctoral Science Foundation of China, Grant/Award Number:
   2022M710702; Postdoctoral start up fund of Fujian Provincial Hospital,
   Grant/Award Number: 0080132201; Science and Technology Planning Project
   of Fujian Province, Grant/Award Number: 2019J01173; Startup Fund for
   Scientific Research of Fujian Medical University, Grant/Award Number:
   2020QH2050
CR Alarkawi D, 2020, OSTEOPOROSIS INT, V31, P119, DOI 10.1007/s00198 019 05174 5
   Balani DH, 2017, J CLIN INVEST, V127, P3333, DOI 10.1172/JCI91699
   Basu Roy U, 2010, CELL DEATH DIFFER, V17, P1345, DOI 10.1038/cdd.2010.57
   Bergmann PJM, 2019, J BONE MINER RES, V34, P1976, DOI [10.1002/jbmr.3835, 10.1002/jbmr.3641]
   Black DM, 2020, LANCET DIABETES ENDO, V8, P672, DOI 10.1016/S2213 8587(20)30159 5
   Bouvard B, 2021, JOINT BONE SPINE, V88, DOI 10.1016/j.jbspin.2021.105135
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen L, 2020, FASEB J, V34, P5208, DOI 10.1096/fj.201901864RR
   Cui YZ, 2022, BIOACT MATER, V10, P207, DOI 10.1016/j.bioactmat.2021.09.015
   Esbrit P, 2013, BIOCHEM PHARMACOL, V85, P1417, DOI 10.1016/j.bcp.2013.03.002
   Fu Y, 2021, BIOENGINEERED, V12, P7714, DOI 10.1080/21655979.2021.1982323
   Gonzalez Quevedo D, 2020, OSTEOPOROSIS INT, V31, P77, DOI 10.1007/s00198 019 05153 w
   Grey A, 2013, OSTEOPOROSIS INT, V24, P1, DOI 10.1007/s00198 012 2176 6
   Harvey NC, 2021, OSTEOPOROSIS INT, V32, P1973, DOI 10.1007/s00198 021 05917 3
   He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hu Y, 2021, BIOACT MATER, V6, P2905, DOI 10.1016/j.bioactmat.2021.02.014
   Jiang SF, 2022, BMC GENOMICS, V23, DOI 10.1186/s12864 022 08910 0
   Jilka RL, 2009, BONE, V44, P275, DOI 10.1016/j.bone.2008.10.037
   Jing X, 2022, ACS APPL MATER INTER, V14, P16082, DOI 10.1021/acsami.2c02278
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   Kim DK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22754 4
   Lee SS, 2020, BIOMATERIALS, V257, DOI 10.1016/j.biomaterials.2020.120223
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li X, 2020, BIOMATERIALS, V257, DOI 10.1016/j.biomaterials.2020.120253
   Liang YJ, 2021, THERANOSTICS, V11, P3183, DOI 10.7150/thno.52570
   Luhmann T, 2012, J CONTROL RELEASE, V161, P198, DOI 10.1016/j.jconrel.2011.10.001
   Narayanan A, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116676
   Ogita M, 2008, ENDOCRINOLOGY, V149, P5713, DOI 10.1210/en.2008 0369
   Ohnishi H, 2010, SCI TECHNOL ADV MAT, V11, DOI 10.1088/1468 6996/11/1/014110
   Ouyang T, 2021, ENVIRON TOXICOL, V36, P1817, DOI 10.1002/tox.23302
   Palmer SC, 2020, AM J KIDNEY DIS, V76, P321, DOI 10.1053/j.ajkd.2020.02.439
   Perez RA, 2015, ACTA BIOMATER, V23, P295, DOI 10.1016/j.actbio.2015.06.002
   PITKIN RM, 1983, CLIN PERINATOL, V10, P575, DOI 10.1016/S0095 5108(18)30952 7
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Schaefer T, 2020, ONCOGENE, V39, P278, DOI 10.1038/s41388 019 0997 x
   Shao JT, 2020, INT J NANOMED, V15, P9355, DOI 10.2147/IJN.S281890
   Shen MY, 2019, BIOMATERIALS, V197, P86, DOI 10.1016/j.biomaterials.2019.01.019
   Sordi MB, 2021, CLIN ORAL INVEST, V25, P3441, DOI 10.1007/s00784 020 03666 x
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Sun ZY, 2015, BONE, V76, P121, DOI 10.1016/j.bone.2015.04.006
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang L, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.564731
   Wang ZR, 2021, ANGEW CHEM INT EDIT, V60, P2594, DOI 10.1002/anie.202009842
   Wu D, 2022, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.829136
   Yoshida W, 2019, J CLIN PERIODONTOL, V46, P1030, DOI 10.1111/jcpe.13170
   Yu C, 2018, CARDIOVASC RES, V114, P168, DOI 10.1093/cvr/cvx180
   Zhang BK, 2021, MAT SCI ENG C MATER, V123, DOI 10.1016/j.msec.2020.111782
   Zhang KY, 2018, ACS APPL MATER INTER, V10, P30081, DOI 10.1021/acsami.8b08449
   Zhang S, 2019, ACS BIOMATER SCI ENG, V5, P1944, DOI 10.1021/acsbiomaterials.8b01490
   Zhang YT, 2021, ACS APPL MATER INTER, V13, P18472, DOI 10.1021/acsami.0c22671
   Zheng YY, 2022, BIOACT MATER, V14, P364, DOI 10.1016/j.bioactmat.2022.01.042
   Zou ZY, 2021, BIOACT MATER, V6, P1839, DOI 10.1016/j.bioactmat.2020.11.021
NR 55
TC 2
Z9 2
U1 6
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0960 7722
EI 1365 2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD AUG
PY 2023
VL 56
IS 8
DI 10.1111/cpr.13426
EA FEB 2023
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA N5XS9
UT WOS:000934379700001
PM 36786008
OA gold
DA 2025 08 17
ER

PT J
AU Lu, Q
   Qin, H
   Tan, HT
   Wei, CS
   Yang, XN
   He, JQ
   Liang, WB
   Li, J
AF Lu, Qing
   Qin, Hao
   Tan, Haitao
   Wei, Cansen
   Yang, Xinni
   He, Jinqiao
   Liang, Weibing
   Li, Jing
TI Senescence Osteoblast Derived Exosome Mediated miR 139 5p Regulates
   Endothelial Cell Functions
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID MICRORNAS; ANGIOGENESIS; VESICLES; SURVIVAL; GROWTH
AB The pathogenesis of osteoporosis is considered extremely intricate. Osteoblast differentiation and angiogenesis can greatly affect bone development and formation, given their coupling role in these processes. Exosome mediated miRNA regulates cellular senescence, proliferation, and differentiation. However, whether senescent osteoblasts can regulate the senescence of vascular endothelial cell by miRNA through exosomal pathway remains unclear. In this study, senescent osteoblasts could regulate endothelial cell function, promote cell senescence and apoptosis, and decrease cell proliferation via exosomal pathway. miR 139 5p showed high expression in senescent osteoblasts and their exosomes. After senescent osteoblast derived exosome treatment, miR 139 5p was also upregulated in endothelial cells. Furthermore, transfection of miR 139 5p mimic promoted the senescence and apoptosis of vascular endothelial cells and inhibited their proliferation and migration, whereas transfection of miR 139 5p inhibitor rescued the effect of D galactose. Using double luciferase assay, TBX1 was confirmed to be a direct target gene of miR 139 5p. In conclusion, senescent osteoblast derived exosome mediated miR 139 5p regulated endothelial cell function via exosomal pathway. Our study revealed the role of osteoblast derived exosomes in the bone environment during aging, providing a clue for inventing a new target therapy.
C1 [Lu, Qing; Yang, Xinni; Li, Jing] Guangxi Med Univ, Dept Physiol, Nanning, Peoples R China.
   [Lu, Qing] Guangzhou Kangda Vocat Tech Coll, Guangzhou, Peoples R China.
   [Qin, Hao; Tan, Haitao; He, Jinqiao; Liang, Weibing] Guangxi Med Univ, Affiliated Hosp 8, Dept Orthoped, Guigang, Peoples R China.
   [Wei, Cansen; Li, Jing] Minist Educ, Key Lab Longev & Aging Related Dis, Nanning, Guangxi, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University
RP Li, J (通讯作者)，Guangxi Med Univ, Dept Physiol, Nanning, Peoples R China.; Li, J (通讯作者)，Minist Educ, Key Lab Longev & Aging Related Dis, Nanning, Guangxi, Peoples R China.
EM lijing@gxmu.edu.cn
FU National Natural Science Foundation of China [81760401]; Guangxi Natural
   Science Foundation [2018GXNSFAA281039, 2020GXNSFAA159148]; Guangxi
   First Class Discipline Construction Project in Basic Medical Sciences
   [GXMUBMSTCF G29, GXMUBMSTCF G30]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81760401), the Guangxi Natural Science Foundation (Nos.
   2018GXNSFAA281039 and 2020GXNSFAA159148), and the Guangxi First Class
   Discipline Construction Project in Basic Medical Sciences
   (GXMUBMSTCF G29 and GXMUBMSTCF G30).
CR Agosta C, 2018, INT J CANCER, V143, P944, DOI 10.1002/ijc.31363
   Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Chen L, 2010, J CELL BIOL, V189, P417, DOI 10.1083/jcb.200912037
   Cioffi S, 2014, HUM MOL GENET, V23, P78, DOI 10.1093/hmg/ddt400
   Gallo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030679
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574
   Harvey S, 2015, GEN COMP ENDOCR, V220, P103, DOI 10.1016/j.ygcen.2014.11.004
   Hu ZB, 2010, J CLIN ONCOL, V28, P1721, DOI 10.1200/JCO.2009.24.9342
   Hua SN, 2018, ONCOGENE, V37, P1624, DOI 10.1038/s41388 017 0057 3
   Huang N, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01103
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Kuroiwa T, 1999, J IMMUNOL, V163, P2168
   Li P, 2019, J CELL MOL MED, V23, P2475, DOI 10.1111/jcmm.14121
   Lv LL, 2013, INT J BIOL SCI, V9, P1021, DOI 10.7150/ijbs.6100
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   Portal Núñez S, 2012, HISTOL HISTOPATHOL, V27, P559, DOI 10.14670/HH 27.559
   Sato Kuwabara Y, 2015, INT J ONCOL, V46, P17, DOI 10.3892/ijo.2014.2712
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   Tabet F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4292
   Tan J, 2015, MED SCI MONITOR, V21, P1428, DOI 10.12659/MSM.892247
   Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210
   Yang F, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201600699
   Zelzer E, 2004, DEVELOPMENT, V131, P2161, DOI 10.1242/dev.01053
   Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001
   Zhang M, 2018, EXP THER MED, V15, P447, DOI 10.3892/etm.2017.5362
   Zhang YT, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12570
   Zheng B, 2017, MOL THER, V25, P1279, DOI 10.1016/j.ymthe.2017.03.031
   Zhong X, 2019, MOL MED REP, V20, P5315, DOI 10.3892/mmr.2019.10749
   Zhou Q, 2012, INT J BIOL SCI, V8, P118, DOI 10.7150/ijbs.8.118
NR 31
TC 31
Z9 35
U1 0
U2 26
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD APR 16
PY 2021
VL 2021
DI 10.1155/2021/5576023
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA TP4AC
UT WOS:000677535600002
PM 33954179
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Yu, W
   Xie, CR
   Chen, FC
   Cheng, P
   Yang, L
   Pan, XY
AF Yu, Wei
   Xie, Chao Ran
   Chen, Fan Cheng
   Cheng, Pei
   Yang, Lei
   Pan, Xiao Yun
TI LGR5 enhances the osteoblastic differentiation of MC3T3 E1 cells through
   the Wnt/β catenin pathway
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE leucine rich repeat containing G protein coupled receptor 5;
   osteoblastic differentiation; Wnt; beta catenin pathway; osteoporosis
ID STEM CELLS; RECEPTOR; MECHANISMS; SURVIVAL; INSIGHTS; DISEASE; MARKER
AB Leucine rich repeat containing G protein coupled receptor 5 (LGR5) is a Wnt associated gene that contributes to cell proliferation and self renewal in various organs. LGR5 is expressed in Ewing sarcoma, and LGR5 overexpressing mesenchymal stem cells promote fracture healing. However, the effects of LGR5 on osteoblastic differentiation remain unclear. The aim of the present study was to explore the function of LGR5 in osteoblastic differentiation. LGR5 was overexpressed or knocked down in the MC3T3 E1 pre osteoblastic cell line via lentiviral transfection and its function in osteoblastic differentiation was investigated. The mRNA expression levels of the osteoblast differentiation markers alkaline phosphatase (ALP), osteocalcin and collagen type I a1 were determined, and ALP and Alizarin red staining were performed. In addition, the effects of LGR5 modulation on beta catenin and the expression of target genes in the Wnt pathway were investigated. The results revealed that the overexpression of LGR5 promoted osteoblastic differentiation. This was associated with enhancement of the stability of beta catenin and its levels in the cell nucleus, which enabled it to activate Wnt signaling. By contrast, the inhibition of LGR5 decreased the osteogenic capacity of MC3T3 E1 cells. These results indicate that LGR5 is a positive regulator of osteoblastic differentiation, whose effects are mediated through the Wnt/beta catenin signaling pathway. This suggests suggesting that the regulation of LGR5/Wnt/beta catenin signaling has potential as a therapy for osteoporosis.
C1 [Yu, Wei; Yang, Lei; Pan, Xiao Yun] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped Surg, 109 Xue Yuan Xi Rd, Wenzhou 325000, Zhejiang, Peoples R China.
   [Xie, Chao Ran; Cheng, Pei] Wenzhou Med Univ, Inst Adv Mat Nano Bioapplicat, Sch Ophthalmol & Optometry, Wenzhou 325000, Zhejiang, Peoples R China.
   [Chen, Fan Cheng] Fudan Univ, Zhongshan Hosp, Dept Orthoped Surg, Shanghai 200433, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Fudan University
RP Pan, XY (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped Surg, 109 Xue Yuan Xi Rd, Wenzhou 325000, Zhejiang, Peoples R China.
EM wzfeygk@163.com
FU Zhejiang Province Technology Project [2015C33209]; Wenzhou Technology
   Project [Y20150243]
FX This study was supported by the Zhejiang Province Technology Project
   (grant no. 2015C33209) and Wenzhou Technology Project (grant no.
   Y20150243).
CR Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Barker N, 2010, GASTROENTEROLOGY, V138, P1681, DOI 10.1053/j.gastro.2010.03.002
   Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Canalis E, 2018, EUR J ENDOCRINOL, V178, pR33, DOI 10.1530/EJE 17 0920
   Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108
   de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337
   Friedman MS, 2009, J BIOL CHEM, V284, P14117, DOI 10.1074/jbc.M808337200
   Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175
   Gong X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037137
   Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239
   Jiang M, 2019, J BONE MINER RES, V34, P361, DOI 10.1002/jbmr.3604
   Kemper K, 2012, STEM CELLS, V30, P2378, DOI 10.1002/stem.1233
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Leucht P, 2008, SEMIN CELL DEV BIOL, V19, P434, DOI 10.1016/j.semcdb.2008.09.002
   Lin WP, 2019, FASEB J, V33, P8565, DOI 10.1096/fj.201900082RR
   Liu DH, 2014, J BIOL CHEM, V289, P23809, DOI 10.1074/jbc.M114.568170
   Liu SL, 2019, BIOCHEM BIOPH RES CO, V519, P1, DOI 10.1016/j.bbrc.2019.08.122
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Luo J, 2009, DEVELOPMENT, V136, P2747, DOI 10.1242/dev.033571
   Morita H, 2004, MOL CELL BIOL, V24, P9736, DOI 10.1128/MCB.24.22.9736 9743.2004
   Nakata S, 2013, BRAIN PATHOL, V23, P60, DOI 10.1111/j.1750 3639.2012.00618.x
   Plaks V, 2013, CELL REP, V3, P70, DOI 10.1016/j.celrep.2012.12.017
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Scannell CA, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00081
   Tanese K, 2008, AM J PATHOL, V173, P835, DOI 10.2353/ajpath.2008.071091
   Vieira GC, 2015, ONCOTARGET, V6, P40053, DOI 10.18632/oncotarget.5548
   Xu JG, 2015, J BIOL CHEM, V290, P2455, DOI 10.1074/jbc.M114.599134
   Xu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1288 8
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yamada W, 2009, BIOCHEM BIOPH RES CO, V381, P453, DOI 10.1016/j.bbrc.2009.02.066
   Yoon JK, 2012, CELL SIGNAL, V24, P369, DOI 10.1016/j.cellsig.2011.09.023
   Zhang HB, 2019, J CELL BIOCHEM, V120, P5813, DOI 10.1002/jcb.27867
   Zhu C, 2016, CELL SIGNAL, V28, P989, DOI 10.1016/j.cellsig.2016.04.010
NR 37
TC 7
Z9 9
U1 1
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD AUG
PY 2021
VL 22
IS 2
AR 889
DI 10.3892/etm.2021.10321
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA TB1WK
UT WOS:000667735400001
PM 34194567
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Camacho, A
   Jerez, S
AF Camacho, Ariel
   Jerez, Silvia
TI Bone metastasis treatment modeling via optimal control
SO JOURNAL OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Bone metastasis; Mathematical modeling; Radiotherapy; Denosumab; Optimal
   control
ID MATHEMATICAL MODEL; MICROENVIRONMENT; RADIATION; OSTEOBLAST; THERAPY
AB Metastatic disease is a lethal stage of cancer progression. It is characterized by the spread of aberrant cells from a primary tumor to distant tissues like the bone. Several treatments are used to deal with bone metastases formation, but they are palliative since the disease is considered incurable. Computational and mathematical models are used to understand the underlying mechanisms of how bone metastasis evolves. In this way, new therapies aiming to reduce or eliminate the metastatic burden in the bone tissue may be proposed. We present an optimal control approach to analyze some common treatments for bone metastasis. In particular, we focus on denosumab treatment, an anti resorptive therapy, and radiotherapy treatment which has a cell killing action. We base our work in a variant of an existing model introduced by Komarova. The new model incorporates a logistic equation in order to describe the bone metastasis evolution. We provide proofs of existence and uniqueness of solutions to the corresponding optimal control problems for each treatment. Moreover, we present some numerical simulations to analyze the effectiveness of both treatments when different interactions between cancer and bone cells occur. A discussion of the obtained results is provided.
C1 [Camacho, Ariel; Jerez, Silvia] CIMAT, Guanajuato 36000, Gto, Mexico.
C3 CIMAT   Centro de Investigacion en Matematicas
RP Jerez, S (通讯作者)，CIMAT, Guanajuato 36000, Gto, Mexico.
EM jose.camacho@cimat.mx; jerez@cimat.mx
RI Camacho Gutierrez, Jose Ariel/IAP 6316 2023
OI Camacho Gutierrez, Jose Ariel/0000 0001 8083 9532
FU CONACyT [412803]; Mexico CONACyT [CB2016 286437]
FX The authors are grateful to the anonymous reviewers, whose careful
   observations and helpful suggestions improved considerably the quality
   of this work. Moreover, AC thanks CONACyT for the Graduate Fellowship
   Grant 412803. Finally, this work was partially supported by Mexico
   CONACyT Project CB2016 286437.
CR Garzón Alvarado DA, 2012, COMPUT METHOD BIOMEC, V15, P333, DOI 10.1080/10255842.2010.535522
   [Anonymous], 2007, Optimal Control Applied to Biological Models, DOI DOI 10.1201/9781420011418
   [Anonymous], 2018, The collective Forest tenure reform, DOI DOI 10.1038/S41419 018 0946 6
   Araujo A, 2014, CANCER RES, V74, P2391, DOI 10.1158/0008 5472.CAN 13 2652
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Bara O, 2017, MATH BIOSCI, V290, P9, DOI 10.1016/j.mbs.2017.05.010
   Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958
   Brenner DJ, 2008, SEMIN RADIAT ONCOL, V18, P234, DOI 10.1016/j.semradonc.2008.04.004
   Chow E, 2014, LANCET ONCOL, V15, P164, DOI 10.1016/S1470 2045(13)70556 4
   Coelho RM, 2016, J THEOR BIOL, V391, P1, DOI 10.1016/j.jtbi.2015.11.024
   De Pillis LG, 2003, MATH COMPUT MODEL, V37, P1221, DOI 10.1016/S0895 7177(03)00133 X
   Dingli D, 2009, BRIT J CANCER, V101, P1130, DOI 10.1038/sj.bjc.6605288
   Farhat A, 2017, MATH BIOSCI, V294, P1, DOI 10.1016/j.mbs.2017.09.005
   Fisters KR, 1998, ELECTRON J DIFFERENT, V32, P1
   Fleming W. H., 2012, Deterministic and Stochastic Optimal Control
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Ganesh V, 2017, RADIOTHER ONCOL, V124, P38, DOI 10.1016/j.radonc.2017.06.002
   Graham JM, 2012, MATH BIOSCI ENG, V9, P281, DOI 10.3934/mbe.2012.9.281
   Jerez S, 2018, MATH BIOSCI, V299, P153, DOI 10.1016/j.mbs.2018.03.006
   Jerez S, 2015, MATH BIOSCI, V264, P29, DOI 10.1016/j.mbs.2015.03.003
   Jerez S, 2018, J COMPUT APPL MATH, V330, P866, DOI 10.1016/j.cam.2016.12.026
   Juárez P, 2017, ONCOTARGET, V8, P86447, DOI 10.18632/oncotarget.21200
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kwakwa KA, 2017, CURR OSTEOPOROS REP, V15, P247, DOI 10.1007/s11914 017 0385 9
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lemos JM, 2016, BIOMED SIGNAL PROCES, V24, P128, DOI 10.1016/j.bspc.2015.10.004
   Lipton A, 2016, EUR J CANCER, V53, P75, DOI 10.1016/j.ejca.2015.09.011
   Lukes DL, 1982, Differential Equations: Classical to Control
   Lutz S, 2017, PRACT RADIAT ONCOL, V7, P4, DOI 10.1016/j.prro.2016.08.001
   Massagué J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038
   McAsey M, 2012, COMPUT OPTIM APPL, V53, P207, DOI 10.1007/s10589 011 9454 7
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Oest ME, 2015, J ORTHOP RES, V33, P334, DOI 10.1002/jor.22761
   Ottewell PD, 2016, J BONE ONCOL, V5, P124, DOI 10.1016/j.jbo.2016.03.007
   Paget S., LANCET, V1, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Penninger CL, 2008, MECH RES COMMUN, V35, P32, DOI 10.1016/j.mechrescom.2007.10.007
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pontryagin LS, 1962, Mathematical theory of optimal processes
   Ross DS, 2017, B MATH BIOL, V79, P117, DOI 10.1007/s11538 016 0229 2
   Ryser MD, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002703
   SAVAGEAU MA, 1988, MATH COMPUT MODEL, V11, P546, DOI 10.1016/0895 7177(88)90553 5
   Stephenson B, 2017, J MATH BIOL, V75, P1693, DOI 10.1007/s00285 017 1133 6
   SWAN GW, 1990, MATH BIOSCI, V101, P237, DOI 10.1016/0025 5564(90)90021 P
   Theriault RL, 2012, CANCER CONTROL, V19, P92, DOI 10.1177/107327481201900203
   Tovar A., 2004, THESIS
   Vakaet LAML, 2004, INT J DEV BIOL, V48, P599, DOI 10.1387/ijdb.041817lv
   Van Scoy GK, 2017, MATH BIOSCI, V286, P58, DOI 10.1016/j.mbs.2017.02.001
   Wang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027494
   Warman P.I., 2018, GAMES BASEL, V9, P19
NR 49
TC 20
Z9 21
U1 2
U2 20
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0303 6812
EI 1432 1416
J9 J MATH BIOL
JI J. Math. Biol.
PD JAN
PY 2019
VL 78
IS 1 2
BP 497
EP 526
DI 10.1007/s00285 018 1281 3
PG 30
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Mathematical & Computational
   Biology
GA HS5QT
UT WOS:000463926800017
PM 30132065
DA 2025 08 17
ER

PT J
AU Yuan, H
   Xiao, LY
   Min, W
   Yuan, WC
   Lu, SF
   Huang, GC
AF Yuan, Han
   Xiao, Linyan
   Min, Wen
   Yuan, Wenchao
   Lu, Shengfeng
   Huang, Guicheng
TI Bu Shen Tong Luo decoction prevents bone loss via inhibition of bone
   resorption and enhancement of angiogenesis in ovariectomy induced
   osteoporosis of rats
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Bu Shen Tong Luo decoction; Ovariectomy; Angiogenesis; Bone resorption;
   Blood vessel
ID POSTMENOPAUSAL OSTEOPOROSIS; BREAST CANCER; LIKELY CAUSES; EXPRESSION;
   ICARIIN; RECEPTOR; HYPOXIA; CELLS; DIFFERENTIATION; OSTEOBLASTS
AB Ethnopharmacological relevance: Gathering three ancient formulas, traditional Chinese medicine Bu Shen Tong Luo decoction (BSTLD) has been used to treat postmenopausal osteoporosis (PMO) at the Jiangsu Province Hospital of Chinese Medicine for decades. However, the effect of BSTLD on angiogenesis and bone resorption as well as its possible mechanism are still unknown.
   Aim of the study: This study was aimed to evaluate the preventive effect of BSTLD on ovariectomy induced bone loss and vasculature disorder, and to investigate the possible bone protection mechanism of BSTLD in inhibiting bone resorption by enhancing angiogenesis signaling in ovariectomy induced osteoporosis of rats.
   Materials and methods: The animal experiment was divided into five groups. Rats underwent either sham surgery with intact ovaries (SHAM, n = 10) or bilateral ovariectomy (OVX, n = 40). OVX rats were randomly divided into four groups and gavaged by water (vehicle, 12 mL/kg, n = 10), BSTLD (6 g/kg, n = 10), BSTLD (12 g/kg, n = 10) and 17 beta estradiol (E2, 100 mu g/kg, n = 10) daily for 12 weeks, respectively. The bone loss and microstructure of the distal femur were observed using micro computed tomography (pCT). The biomechanical parameters of the femur were detected using three point bending tests. The distribution of osteoclasts and endothelial cells were analyzed by immunohistochemistry. The mRNA and protein levels of angiogenesis related hypoxia inducible factor 1 alpha (HIF 1 alpha) and vascular endothelial growth factor (VEGF), as well as osteoclast activation related signaling calcitonin receptor (CALCR), cathepsin K (CTSK), receptor activator of NE kappa B ligand (RANKL), osteoprotegerin (OPG), and beta catenin were assayed by RT PCR or Western blot.
   Results: BSTLD protected trabecular bone mass density and trabecular bone microstructure from ovariectomy induced osteoporosis in rats. BSTLD significantly reduced mRNA and protein levels of calcitonin receptor and CTSK in femoral metaphysis and inhibited bone resorption in ovariectomized rats. Furthermore, BSTLD stabilized HIF 1 alpha activity and subsequently increased VEGF expression to enhance angiogenesis and modulated RANKL/OPG signaling in this animal model.
   Conclusions: These results demonstrated that BSTLD reduced osteoclasts activation and bone resorption in ovariectomy induced osteoporosis. Bone protection by BSTLD may be associated with its stimulation of HIF 1 alpha/VEGF angiogenesis signaling and suppression of RANKL/OPG ratio. This study may provide evidence that BSTLD treats postmenopausal osteoporosis, especially with micro circulation complication.
C1 [Yuan, Han; Min, Wen; Yuan, Wenchao; Huang, Guicheng] Nanjing Univ Chinese Med, Sch Clin Med 1, Nanjing 210023, Jiangsu, Peoples R China.
   [Xiao, Linyan] Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210023, Jiangsu, Peoples R China.
   [Lu, Shengfeng] Nanjing Univ Chinese Med, Minist Educ, Key Lab Acupuncture & Med Res, Nanjing 210023, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine
RP Huang, GC (通讯作者)，Nanjing Univ Chinese Med, 138 Xianlin Ave, Nanjing 210023, Jiangsu, Peoples R China.
EM guichenghuang@njucm.edu.cn
FU National Natural Science Foundation of China [81573997, 81473692];
   Research Innovation Program for College Graduates of Jiangsu Province
   [KYZZ16_0409]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Nos. 81573997 and 81473692). Support was also
   obtained from the Research Innovation Program for College Graduates of
   Jiangsu Province (No. KYZZ16_0409).
CR Appelman Dijkstra NM, 2015, DRUGS, V75, P1049, DOI 10.1007/s40265 015 0417 7
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Ding WG, 2011, CONNECT TISSUE RES, V52, P25, DOI 10.3109/03008201003783011
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Griffith JF, 2010, RADIOLOGY, V254, P739, DOI 10.1148/radiol.09090608
   Huang N., 2002, HEBEI J TRADIT CHIN, V24, P10
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Knowles HJ, 2010, FASEB J, V24, P4648, DOI 10.1096/fj.10 162230
   Le AW, 2015, GENET MOL RES, V14, P11250, DOI 10.4238/2015.September.22.19
   Leger AJ, 2010, J BONE MINER METAB, V28, P510, DOI 10.1007/s00774 010 0171 6
   Lemieux C, 2005, J NUTR, V135, P2225, DOI 10.1093/jn/135.9.2225
   Liu DZ, 2005, BRIT J PHARMACOL, V146, P604, DOI 10.1038/sj.bjp.0706335
   Liu J., 2006, CHIN J OSTEOPOROSIS, V4, P46
   Marsden J, 2002, J STEROID BIOCHEM, V83, P123, DOI 10.1016/S0960 0760(02)00258 3
   McNamara LM, 2010, J R SOC INTERFACE, V7, P353, DOI 10.1098/rsif.2009.0282
   Mekraldi S, 2003, BONE, V32, P630, DOI 10.1016/S8756 3282(03)00099 1
   闵文, 2010, [南京中医药大学学报, Journal of Nanjing University of Traditional Chinese Medicine], V26, P344
   Min W., 2013, CHIN J EXP TRADIT ME, V19, P258
   Min W., 2010, CHIN J EXP TRADIT ME, V16, P189
   Peng J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112744
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603 677
   Qiang YW, 2010, BRIT J HAEMATOL, V148, P726, DOI 10.1111/j.1365 2141.2009.08009.x
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Recker RR, 2007, BONE, V40, P843, DOI 10.1016/j.bone.2006.11.001
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Song N, 2017, CHEM BIOL INTERACT, V261, P11, DOI 10.1016/j.cbi.2016.10.020
   Suzuki A, 2006, J HYPERTENS, V24, P1065, DOI 10.1097/01.hjh.0000226196.67052.c0
   Tang YB, 2015, STEM CELLS, V33, P1863, DOI 10.1002/stem.2005
   Tang ZN, 2011, BIOCHEM BIOPH RES CO, V408, P411, DOI 10.1016/j.bbrc.2011.04.035
   Tiosano D, 2014, REPROD BIOL ENDOCRIN, V12, DOI 10.1186/1477 7827 12 97
   Vogt MT, 1997, J BONE MINER RES, V12, P283, DOI 10.1359/jbmr.1997.12.2.283
   Wang LN, 2012, Zhong Guo Shi Yan Fang Ji Xue Za Zhi, V18, P192
   Wang Y, 2017, CHIN J INTEGR MED
   Wei ZS, 2016, AM J TRANSL RES, V8, P1910
   Yun SP, 2009, AM J PHYSIOL CELL PH, V296, pC317, DOI 10.1152/ajpcell.00415.2008
   Zhao H., 2015, INT J PHARMA SCI RES, V6, P15
   Zhao Q, 2012, BONE, V50, P763, DOI 10.1016/j.bone.2011.12.003
   Zhou RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166751
   Zhou W, 2014, NAT REV CANCER, V14, P26, DOI 10.1038/nrc3622
   Zhu BT, 2009, J STEROID BIOCHEM, V113, P65, DOI 10.1016/j.jsbmb.2008.11.011
   Zhu HR, 2010, NEUROPHARMACOLOGY, V59, P70, DOI 10.1016/j.neuropharm.2010.03.017
   Zhu JQ, 2017, RADIOLOGY, V282, P369, DOI 10.1148/radiol.2016152006
NR 42
TC 21
Z9 29
U1 2
U2 53
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUN 28
PY 2018
VL 220
BP 228
EP 238
DI 10.1016/j.jep.2018.01.007
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA GJ1YD
UT WOS:000435062900022
PM 29317302
DA 2025 08 17
ER

PT J
AU Ghadakzadeh, S
   Kannu, P
   Whetstone, H
   Howard, A
   Alman, BA
AF Ghadakzadeh, Saber
   Kannu, Peter
   Whetstone, Heather
   Howard, Andrew
   Alman, Benjamin A.
TI β Catenin modulation in neurofibromatosis type 1 bone repair:
   therapeutic implications
SO FASEB JOURNAL
LA English
DT Article
DE neurofibromin; Wnt signaling; tibial congenital pseudarthrosis;
   osteoblast differentiation; fracture nonunion
ID EMBRYONIC STEM CELLS; CONGENITAL PSEUDOARTHROSIS; TGF BETA; OSTEOBLAST
   DIFFERENTIATION; MURINE MODEL; FRACTURE REPAIR; MINERAL DENSITY; MOUSE
   MODEL; NF1; WNT
AB Tibial pseudarthrosis causes substantial morbidity in patients with neurofibromatosis type 1 (NF1). We studied tibial pseudarthrosis tissue from patients with NF1 and found elevated levels of  catenin compared to unaffected bone. To elucidate the role of  catenin in fracture healing, we used a surgically induced tibial fracture model in conditional knockout (KO) Nfl (Nf1(flox/flox)) mice. When treated with a Cre expressing adenovirus (Ad Cre), there was a localized knockdown of Nf1 in the healing fracture and a subsequent development of a fibrous pseudarthrosis. Consistent with human data, elevated  catenin levels were found in the murine fracture sites. The increased fibrous tissue at the fracture site was rescued by local treatment with a Wingless type MMTV integration site (Wnt) antagonist, Dickkopf 1 (Dkk1). The murine pseudarthrosis phenotype was also rescued by conditional  catenin gene inactivation. The number of colony forming unit osteoblasts (CFU Os), a surrogate marker of undifferentiated mesenchymal cells able to differentiate to osteoblasts, correlated with the capacity to form bone at the fracture site. Our findings indicate that the protein level of  catenin must be precisely regulated for normal osteoblast differentiation. An up regulation of  catenin in NF1 causes a shift away from osteoblastic differentiation resulting in a pseudarthrosis in vivo. These results support the notion that pharmacological modulation of  catenin can be used to treat pseudarthrosis in patients with NF1.Ghadakzadeh, S., Kannu, P., Whetstone, H., Howard A., Alman, B. A.  catenin modulation in neurofibromatosis type 1 bone repair: therapeutic implications.
C1 [Ghadakzadeh, Saber; Kannu, Peter; Whetstone, Heather; Alman, Benjamin A.] Univ Toronto, Div Dev & Stem Cell Biol, Toronto, ON, Canada.
   [Ghadakzadeh, Saber; Kannu, Peter; Alman, Benjamin A.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
   [Kannu, Peter; Howard, Andrew] Hosp Sick Children, Bone Hlth Ctr, Toronto, ON, Canada.
   [Howard, Andrew] Hosp Sick Children, Div Orthopaed Surg, Toronto, ON, Canada.
   [Alman, Benjamin A.] Duke Univ, Dept Orthopaed Surg, Durham, NC 27710 USA.
C3 University of Toronto; University of Toronto; University of Toronto;
   Hospital for Sick Children (SickKids); University of Toronto; Hospital
   for Sick Children (SickKids); Duke University
RP Alman, BA (通讯作者)，Duke Univ, Dept Orthopaed Surg, Durham, NC 27710 USA.
EM ben.alman@duke.edu
RI ; Howard, Andrew/C 7163 2009
OI Howard, Andrew/0000 0001 7226 6471; Kannu, Peter/0000 0001 9479 4232
FU U.S. Army Medical Research Acquisition Activity [W81XWH 13 1 0113]
FX The authors thank the families involved in this study and the NF Society
   of Ontario (NFSO) for their kind contribution and participation. This
   study was funded by Grant W81XWH 13 1 0113 from the U.S. Army Medical
   Research Acquisition Activity. Author contributions: S. Ghadakzadeh and
   B. A. Alman designed the study; S. Ghadakzadeh and H. Whetstone
   performed the research; and S. Ghadakzadeh, P. Kannu, A. Howard, and B.
   A. Alman analyzed the data and wrote the paper. The authors declare no
   conflicts of interest.
CR Anton R, 2007, FEBS LETT, V581, P5247, DOI 10.1016/j.febslet.2007.10.012
   Birke O, 2010, J CHILD ORTHOP, V4, P507, DOI 10.1007/s11832 010 0293 3
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Cheon SS, 2006, FASEB J, V20, P692, DOI 10.1096/fj.05 4759com
   Cho TJ, 2008, J BONE JOINT SURG AM, V90A, P2735, DOI 10.2106/JBJS.H.00014
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Dulai S, 2007, J PEDIATR ORTHOPED, V27, P472, DOI 10.1097/01.bpb.0000271310.87997.ae
   El Khassawna T, 2012, BONE, V51, P651, DOI 10.1016/j.bone.2012.07.011
   El Hoss J, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.00862
   El Hoss J, 2012, J BONE MINER RES, V27, P68, DOI 10.1002/jbmr.528
   Elefteriou F, 2009, AM J MED GENET A, V149A, P2327, DOI 10.1002/ajmg.a.33045
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931
   Heervä E, 2012, BONE, V50, P798, DOI 10.1016/j.bone.2011.12.011
   Heervä E, 2010, BONE, V47, P583, DOI 10.1016/j.bone.2010.06.001
   Ippolito E, 2000, J PEDIATR ORTHOP B, V9, P3, DOI 10.1097/01202412 200001000 00002
   Jang HD, 2011, J BIOL CHEM, V286, P39043, DOI 10.1074/jbc.M111.256768
   Johnston CE, 2002, J BONE JOINT SURG AM, V84A, P1799, DOI 10.2106/00004623 200210000 00010
   Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100
   Kuorilehto T, 2004, J BONE MINER RES, V19, P983, DOI 10.1359/JBMR.040130
   Kuorilehto T, 2005, OSTEOPOROSIS INT, V16, P928, DOI 10.1007/s00198 004 1801 4
   Lammert M, 2005, ARCH DERMATOL, V141, P71, DOI 10.1001/archderm.141.1.71
   Le LQ, 2007, ONCOGENE, V26, P4609, DOI 10.1038/sj.onc.1210261
   Lee DY, 2011, CLIN ORTHOP SURG, V3, P230, DOI 10.4055/cios.2011.3.3.230
   Lee SM, 2012, J ORTHOP RES, V30, P1535, DOI 10.1002/jor.22121
   Lemieux E, 2015, ONCOGENE, V34, P4914, DOI 10.1038/onc.2014.416
   Leskelä HV, 2009, BONE, V44, P243, DOI 10.1016/j.bone.2008.10.050
   Li HM, 2009, PEDIATR RES, V65, P613, DOI 10.1203/PDR.0b013e3181a1c607
   Liu RJ, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 288
   McCarthy TL, 2010, MOL ENDOCRINOL, V24, P587, DOI 10.1210/me.2009 0379
   PARFITT AM, 1988, BONE MINER, V4, P1
   Paria N, 2014, J BONE MINER RES, V29, P2636, DOI 10.1002/jbmr.2298
   Rhodes SD, 2013, J BONE MINER RES, V28, P2476, DOI 10.1002/jbmr.1992
   Rosa Adalberto Luiz, 2005, Braz. Dent. J., V16, P225, DOI 10.1590/S0103 64402005000300010
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Schindeler A, 2011, J BONE JOINT SURG BR, V93B, P1134, DOI 10.1302/0301 620X.93B8.25940
   Schindeler A, 2008, BONE, V42, P616, DOI 10.1016/j.bone.2007.11.006
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200
   Sharma R, 2013, HUM MOL GENET, V22, P4818, DOI 10.1093/hmg/ddt333
   Sokol SY, 2011, DEVELOPMENT, V138, P4341, DOI 10.1242/dev.066209
   Srivastava AK, 1998, MOL CELL BIOCHEM, V182, P135, DOI 10.1023/A:1006857527588
   Stevenson DA, 2011, CLIN GENET, V80, P566, DOI 10.1111/j.1399 0004.2010.01619.x
   Theos A, 2006, ANN INTERN MED, V144, P842, DOI 10.7326/0003 4819 144 11 200606060 00010
   van den Bosch MH, 2014, CELL SIGNAL, V26, P951, DOI 10.1016/j.cellsig.2014.01.021
   Wang WX, 2010, J BONE MINER RES, V25, P1658, DOI 10.1002/jbmr.42
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Wu XH, 2006, HUM MOL GENET, V15, P2837, DOI 10.1093/hmg/ddl208
   Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052
   Yan JC, 2008, HUM MOL GENET, V17, P936, DOI 10.1093/hmg/ddm366
   Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092
   Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101
NR 59
TC 11
Z9 13
U1 0
U2 5
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD SEP
PY 2016
VL 30
IS 9
BP 3227
EP 3237
DI 10.1096/fj.201500190RR
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA DV3JD
UT WOS:000382816300022
PM 27306335
DA 2025 08 17
ER

PT J
AU Sasaki, Y
   Kijima, K
   Yoshioka, K
AF Sasaki, Yamato
   Kijima, Kei
   Yoshioka, Keiji
TI Validity evaluation of a rat model of monoiodoacetate induced
   osteoarthritis with clinically effective drugs
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Osteoarthritis; Pain; Monoiodoacetate; Diclofenac; Clodronate;
   Cartilage; Synovium; Osteoclast
ID KNEE OSTEOARTHRITIS; INTRAARTICULAR CLODRONATE; ARTICULAR CARTILAGE;
   SUBCHONDRAL BONE; PAIN; DICLOFENAC
AB BackgroundKnee osteoarthritis (KOA) is the most common type of joint disease in elderly people and is characterized by pain and dysfunction. Although the monoiodoacetate (MIA) induced model is widely used as a rodent KOA model, it is important to acknowledge the inherent limitations of this model, as the MIA model develops complex pathological phases on a daily basis. An accurate understanding of this model and the selection of an appropriate time point according to the target for drug candidates can lead to the development of clinically effective drugs.MethodsChanges in the pathological state of the MIA model were assessed via histopathological evaluation. Clodronate, a bisphosphonate, and diclofenac, a nonsteroidal anti inflammatory drug (NSAID), were selected as models of clinically effective drugs due to their different mechanisms of action. The analgesic effects of both drugs on the MIA model were evaluated. The long term effect of clodronate on subchondral bone osteoclasts was also evaluated.ResultsHistopathological evaluation revealed that MIA induced symptomatic behavior occurred in the early and late phases and was accompanied by synovial inflammation and osteoclast related joint degeneration, respectively. Although clodronate inhibited symptomatic behavior and prevented cartilage degeneration from the early to late phases, diclofenac inhibited symptomatic behavior only in the early phase. Clodronate acted locally and inhibited the activation of subchondral osteoclasts.ConclusionsPathological changes, such as synovial changes in the early phase and knee joint degeneration in the late phase, in the MIA model are similar to those in human KOA. Our results indicate that the early phase in the MIA model is appropriate for evaluating the effects of anti inflammatory agents such as NSAIDs and corticosteroids. The late phase in the MIA model is appropriate for evaluating the effects of drugs that act on cartilage and subchondral bone.
C1 [Sasaki, Yamato; Kijima, Kei; Yoshioka, Keiji] Seikagaku Corp, Cent Res Lab, Res & Dev Div, Tateno 3 1253, Higashiyamato, Tokyo 2070021, Japan.
C3 Seikagaku Corporation
RP Sasaki, Y (通讯作者)，Seikagaku Corp, Cent Res Lab, Res & Dev Div, Tateno 3 1253, Higashiyamato, Tokyo 2070021, Japan.
EM yamato.sasaki@seikagaku.co.jp
OI Yoshioka, Keiji/0000 0002 6856 8538
CR Alves Simoes M, 2022, OSTEOARTHR CARTILAGE, V30, P802, DOI 10.1016/j.joca.2022.01.010
   Angeby Moller Kristina, 2019, Neurobiol Pain, V6, P100036, DOI 10.1016/j.ynpai.2019.100036
   [Anonymous], 2023, A Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee (BESPOKE), DOI DOI 10.58398/0001.000002
   Revel FB, 2020, RHEUMATOL THER, V7, P217, DOI 10.1007/s40744 020 00196 6
   Blot L, 2000, BRIT J PHARMACOL, V131, P1413, DOI 10.1038/sj.bjp.0703710
   Bove SE, 2006, OSTEOARTHR CARTILAGE, V14, P1041, DOI 10.1016/j.joca.2006.05.001
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Conaghan PG, 2020, ANN INTERN MED, V172, P86, DOI 10.7326/M19 0675
   Conaghan PG, 2015, RHEUMATOLOGY, V54, P270, DOI 10.1093/rheumatology/keu332
   Deere K, 2021, LANCET RHEUMATOL, V3, pE438, DOI 10.1016/S2665 9913(21)00079 5
   Deshmukh V, 2019, OSTEOARTHR CARTILAGE, V27, P1347, DOI 10.1016/j.joca.2019.05.006
   Ferreira Gomes J, 2012, PHARMACOL BIOCHEM BE, V101, P617, DOI 10.1016/j.pbb.2012.03.003
   Gerwin N, 2010, OSTEOARTHR CARTILAGE, V18, pS24, DOI 10.1016/j.joca.2010.05.030
   Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917
   Gupta S, 2005, RHEUMATOLOGY, V44, P1531, DOI 10.1093/rheumatology/kei049
   Guyot P, 2017, SCAND J PAIN, V16, P74, DOI 10.1016/j.sjpain.2017.03.006
   Guzman RE, 2003, TOXICOL PATHOL, V31, P619, DOI 10.1080/01926230390241800
   Hu Y, 2023, OSTEOARTHR CARTILAGE, V31, P199, DOI 10.1016/j.joca.2022.10.003
   Kee CC, 1998, GERIATR NURS, V19, P19, DOI 10.1016/S0197 4572(98)90023 4
   Kim WK, 2016, CHIN MED UK, V11, DOI 10.1186/s13020 016 0089 6
   Leifer VP, 2022, OSTEOARTHR CARTILAGE, V30, P10, DOI 10.1016/j.joca.2021.05.007
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Löfvall H, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1564 5
   Moriyama Y, 2018, TRENDS PHARMACOL SCI, V39, P13, DOI 10.1016/j.tips.2017.10.007
   Mussawy H, 2022, ARCH ORTHOP TRAUM SU, V142, P2991, DOI 10.1007/s00402 021 03889 x
   Nwosu LN, 2017, OSTEOARTHR CARTILAGE, V25, P858, DOI 10.1016/j.joca.2017.01.002
   Nwosu LN, 2018, PAIN REP, V3, DOI 10.1097/PR9.0000000000000685
   Park DR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18208 y
   Pearson RG, 2011, OSTEOARTHR CARTILAGE, V19, P324, DOI 10.1016/j.joca.2010.12.005
   Prieto Potin I, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0664 5
   Richards PJ, 1999, RHEUMATOLOGY, V38, P818, DOI 10.1093/rheumatology/38.9.818
   Rosa RG, 2014, OSTEOARTHR CARTILAGE, V22, P1327, DOI 10.1016/j.joca.2014.07.009
   Rossini M, 2015, RHEUMATOL INT, V35, P255, DOI 10.1007/s00296 014 3100 5
   Rossini M, 2009, RHEUMATOLOGY, V48, P773, DOI 10.1093/rheumatology/kep084
   Sagar DR, 2014, ANN RHEUM DIS, V73, P1558, DOI 10.1136/annrheumdis 2013 203260
   Sakurai Y, 2019, PAIN, V160, P895, DOI 10.1097/j.pain.0000000000001466
   Sanchez Lopez E, 2022, NAT REV RHEUMATOL, V18, P258, DOI 10.1038/s41584 022 00749 9
   Saviola G, 2023, Clin Ter, V174, P245, DOI 10.7417/CT.2023.2528
   Shah A, 2019, CAN ASSOC RADIOL J, V70, P29, DOI 10.1016/j.carj.2018.11.002
   Sinusas K, 2012, AM FAM PHYSICIAN, V85, P49
   Strassle BW, 2010, OSTEOARTHR CARTILAGE, V18, P1319, DOI 10.1016/j.joca.2010.06.007
   Su WP, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135446
   Takahashi I, 2024, SCI REP UK, V14, DOI 10.1038/s41598 024 61502 8
   Tat SK, 2010, BEST PRACT RES CL RH, V24, P51, DOI 10.1016/j.berh.2009.08.004
   Valente JD, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00974
   Yazici Y, 2022, A Phase 3, 28 Week, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (OA 10) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects, P2022
   Yuan XL, 2014, OSTEOARTHR CARTILAGE, V22, P1077, DOI 10.1016/j.joca.2014.05.023
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
NR 48
TC 0
Z9 0
U1 2
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD NOV 29
PY 2024
VL 25
IS 1
AR 975
DI 10.1186/s12891 024 08083 9
PG 12
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA N9E3J
UT WOS:001367276600003
PM 39609755
OA gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Mitra, N
   Liu, YT
   Liu, J
   Serebryany, E
   Mooney, V
   DeVree, BT
   Sunahara, RK
   Yan, ECY
AF Mitra, Nivedita
   Liu, Yuting
   Liu, Jian
   Serebryany, Eugene
   Mooney, Victoria
   DeVree, Brian T.
   Sunahara, Roger K.
   Yan, Elsa C. Y.
TI Calcium Dependent Ligand Binding and G protein Signaling of Family B
   GPCR Parathyroid Hormone 1 Receptor Purified in Nanodiscs
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID LARGE SCALE PURIFICATION; HIGH LEVEL EXPRESSION; MEMBRANE PROTEINS;
   MONOMERIC RHODOPSIN; BIOPHYSICAL CHARACTERIZATION; COUPLED RECEPTORS;
   IN VITRO; RECONSTITUTION; ACTIVATION; TRANSDUCIN
AB GPCRs mediate intracellular signaling upon external stimuli, making them ideal drug targets. However, little is known about their activation mechanisms due to the difficulty in purification. Here, we introduce a method to purify GPCRs in nanodiscs, which incorporates GPCRs into lipid bilayers immediately after membrane solubilization, followed by single step purification. Using this approach, we purified a family B GPCR, parathyroid hormone 1 receptor (PTH1R), which regulates calcium and phosphate homeostasis and is a drug target for osteoporosis. We demonstrated that the purified PTH1R in nanodiscs can bind to PTH(1 34) and activate G protein. We also observed that Ca2+ is a weak agonist of PTH1R, and Ca2+ in millimolar concentration can switch PTH(1 34) from an inverse agonist to an agonist. Hence, our results show that nanodiscs are a viable vehicle for GPCR purification, enabling studies of GPCRs under precise experimental conditions without interference from other cellular or membrane components.
C1 [Mitra, Nivedita; Liu, Yuting; Liu, Jian; Serebryany, Eugene; Mooney, Victoria; Yan, Elsa C. Y.] Yale Univ, Dept Chem, New Haven, CT 06520 USA.
   [DeVree, Brian T.; Sunahara, Roger K.] Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.
C3 Yale University; University of Michigan System; University of Michigan
RP Yan, ECY (通讯作者)，Yale Univ, Dept Chem, 225 Prospect St, New Haven, CT 06520 USA.
EM elsa.yan@yale.edu
RI ; Mitra, Nivedita/JGE 4512 2023; Serebryany, Eugene/E 4595 2017;
   Sunahara, Roger/AAJ 8667 2020; DeVree, Brian/F 6205 2011
OI DeVree, Brian/0000 0003 0582 8125; Sunahara, Roger
   K./0000 0003 1702 8619; Mitra, Nivedita/0000 0003 3799 5681; Yan,
   Elsa/0000 0002 3583 1627; 
FU Seessel Postdoctoral Fellowship; Anderson Postdoctoral Fellowship;
   National Science Foundation fellowship [DGE 0644492]; Yale HHMI Future
   Scientist Fellowship; Sackler Undergraduate Fellowship; NSF CAREER
   Award; Yale Setup Fund; Div Of Molecular and Cellular Bioscience; Direct
   For Biological Sciences [0955407] Funding Source: National Science
   Foundation
FX The authors would like to thank J. Wysolmerski, C. Crews, V. Batista, I.
   Riyalta, Y. Guo, and L. Fu (Yale University) for useful discussions and
   X. Li for assistance in the experiments. We thank H. Wang (Yale
   University), currently at Tsinghua University (PR China), for the help
   with electron microscopy imaging. We thank P. Reeves (University of
   Essex) for providing the pACMV tetO vector and HEK293S GnTI<SUP> </SUP>
   cells. N.M. acknowledges support from the Seessel Postdoctoral
   Fellowship, and J.L. acknowledges the support from the Anderson
   Postdoctoral Fellowship. V.M. is the recipient of the National Science
   Foundation fellowship (DGE 0644492), and E.S. was the recipient of the
   Yale HHMI Future Scientist Fellowship and the Sackler Undergraduate
   Fellowship. E.Y. is the recipient of the NSF CAREER Award. This work was
   supported by the Yale Setup Fund.
CR Altenbach C, 2008, P NATL ACAD SCI USA, V105, P7439, DOI 10.1073/pnas.0802515105
   Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697
   Banerjee S, 2008, J MOL BIOL, V377, P1067, DOI 10.1016/j.jmb.2008.01.066
   Bayburt TH, 2003, PROTEIN SCI, V12, P2476, DOI 10.1110/ps.03267503
   Bayburt TH, 2002, NANO LETT, V2, P853, DOI 10.1021/nl025623k
   Bayburt TH, 2007, J BIOL CHEM, V282, P14875, DOI 10.1074/jbc.M701433200
   Bayburt TH, 2011, J BIOL CHEM, V286, P1420, DOI 10.1074/jbc.M110.151043
   Boldog T, 2006, P NATL ACAD SCI USA, V103, P11509, DOI 10.1073/pnas.0604988103
   Civjan NR, 2003, BIOTECHNIQUES, V35, P556, DOI 10.2144/03353rr02
   Denisov IG, 2004, J AM CHEM SOC, V126, P3477, DOI 10.1021/ja0393574
   Denisov IG, 2007, J BIOL CHEM, V282, P7066, DOI 10.1074/jbc.M609589200
   Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256
   Gan L, 2006, PROTEIN EXPRES PURIF, V47, P296, DOI 10.1016/j.pep.2005.11.004
   Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198
   Grisshammer R, 2009, METHOD ENZYMOL, V463, P631, DOI 10.1016/S0076 6879(09)63036 6
   Hofmann KP, 2009, TRENDS BIOCHEM SCI, V34, P540, DOI 10.1016/j.tibs.2009.07.005
   Inagaki S, 2012, J MOL BIOL, V417, P95, DOI 10.1016/j.jmb.2012.01.023
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jin L, 2000, J BIOL CHEM, V275, P27238
   Klammt C, 2011, PROTEIN SCI, V20, P1030, DOI 10.1002/pro.636
   Knepp AM, 2011, BIOCHEMISTRY US, V50, P502, DOI 10.1021/bi101059w
   Kronenberg HM, 2006, ANN NY ACAD SCI, V1068, P1, DOI 10.1196/annals.1346.002
   Kuszak AJ, 2009, J BIOL CHEM, V284, P26732, DOI 10.1074/jbc.M109.026922
   Lagerström MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518
   Li MS, 2011, P NATL ACAD SCI USA, V108, P9390, DOI 10.1073/pnas.1104824108
   Mannstadt M, 1999, AM J PHYSIOL RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665
   Marx UC, 2000, BIOCHEM BIOPH RES CO, V267, P213, DOI 10.1006/bbrc.1999.1958
   Michalke K, 2010, ANAL BIOCHEM, V401, P74, DOI 10.1016/j.ab.2010.02.017
   Muller DJ, 2008, PHARMACOL REV, V60, P43, DOI 10.1124/pr.107.07111
   Ohtaki T, 1998, J BIOL CHEM, V273, P15464, DOI 10.1074/jbc.273.25.15464
   OHTAKI T, 1993, J BIOL CHEM, V268, P26650
   Orwick MC, 2012, ANGEW CHEM INT EDIT, V51, P4653, DOI 10.1002/anie.201201355
   Parthier C, 2009, TRENDS BIOCHEM SCI, V34, P303, DOI 10.1016/j.tibs.2009.02.004
   Pioszak AA, 2008, P NATL ACAD SCI USA, V105, P5034, DOI 10.1073/pnas.0801027105
   Pioszak AA, 2010, J BIOL CHEM, V285, P12435, DOI 10.1074/jbc.M109.093138
   Ranaghan MJ, 2011, J AM CHEM SOC, V133, P18318, DOI 10.1021/ja2070957
   Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361
   Rasmussen SGF, 2011, NATURE, V469, P175, DOI 10.1038/nature09648
   Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13413, DOI 10.1073/pnas.212519199
   Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299
   Ritchie TK, 2009, METHOD ENZYMOL, V464, P211, DOI 10.1016/S0076 6879(09)64011 8
   Schröder Tittmann K, 2010, BIOCHEMISTRY US, V49, P7956, DOI 10.1021/bi101159s
   Serebryany E, 2012, BBA BIOMEMBRANES, V1818, P225, DOI 10.1016/j.bbamem.2011.07.047
   Shi L, 2012, SCIENCE, V335, P1355, DOI 10.1126/science.1214984
   Shimada M, 2002, J BIOL CHEM, V277, P31774, DOI 10.1074/jbc.M204166200
   SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014 4827(88)90191 7
   Standfuss J, 2011, NATURE, V471, P656, DOI 10.1038/nature09795
   Talmage D. W., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P108
   Tsang C, 2006, ABSTRACTS OF PAPERS
   Tsukamoto H, 2010, J MOL BIOL, V399, P501, DOI 10.1016/j.jmb.2010.04.029
   Whorton MR, 2008, J BIOL CHEM, V283, P4387, DOI 10.1074/jbc.M703346200
   Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104
   Wysolmerski JJ, 1998, DEVELOPMENT, V125, P1285
   Yan R, 2011, BIOCHEMISTRY US, V50, P10598, DOI 10.1021/bi201351d
   Yao XJ, 2006, NAT CHEM BIOL, V2, P417, DOI 10.1038/nchembio801
NR 55
TC 33
Z9 41
U1 0
U2 34
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554 8929
EI 1554 8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD MAR
PY 2013
VL 8
IS 3
BP 617
EP 625
DI 10.1021/cb300466n
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 109NO
UT WOS:000316375500018
PM 23237450
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sarkar, K
   Joedicke, L
   Westwood, M
   Burnley, R
   Wright, M
   McMillan, D
   Byrne, B
AF Sarkar, Kaushik
   Joedicke, Lisa
   Westwood, Marta
   Burnley, Rebecca
   Wright, Michael
   McMillan, David
   Byrne, Bernadette
TI Modulation of PTH1R signaling by an ECD binding antibody results in
   inhibition of β arrestin 2 coupling
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PARATHYROID HORMONE RECEPTOR; C ACTIVATION DOMAIN; MEMBRANE PROTEINS;
   INTERMITTENT TREATMENT; PEPTIDE; DIFFERENTIATION; FRAGMENT; AGONIST;
   INTACT
AB Parathyroid hormone receptor 1 (PTH1R) belongs to the secretin class of G protein coupled receptors (GPCRs) and natively binds parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP). Ligand binding to PTH1R involves binding to the large extracellular domain (ECD) and the orthosteric pocket, inducing conformational changes in the transmembrane domain and receptor activation. PTH1R regulates bone metabolism, signaling mainly through G(s) and G(q/11) G proteins. Here, we used phage display to generate PTH1R ECD specific antibodies with the aim of modulating receptor functionality. We identified ECD scFvhFc, which exhibited high affinity binding to both the isolated ECD and to the full length receptor in styrene maleic acid (SMA) lipid particles. Epitope mapping using hydrogen deuterium exchange mass spectrometry (HDX MS) indicates that the alpha 1 helix of the ECD is ECD scFvhFc's epitope which may partially overlap with the known PTH (1 34) binding site. However, PTH (1 34) mediated G(s) activation is Undisturbed by ECD scFvhFc binding. In contrast, ECD scFvhFc potently inhibits beta arrestin 2 recruitment after PTH (1 34) driven receptor activation and thus represents the first monoclonal antibody to selectively inhibit distinct PTH1R signaling pathways. Given the complexity of PTH1R signaling and the emerging importance of biased GPCR activation in drug development, ECD scFvhFc could be a valuable tool to study PTH1R signaling bias.
C1 [Sarkar, Kaushik; Byrne, Bernadette] Imperial Coll, Dept Life Sci, London SW7 2AZ, England.
   [Sarkar, Kaushik; Joedicke, Lisa; Westwood, Marta; Burnley, Rebecca; Wright, Michael; McMillan, David] UCB Pharma, 208 Bath Rd, Slough SL1 3WE, Berks, England.
   [Burnley, Rebecca] M3, Western Ave,Milton Pk, Abingdon OX14 4SH, Oxon, England.
   [Wright, Michael] Vertex Pharmaceut, 86 88 Jubilee Ave,Milton Pk, Abingdon OX14 4RW, Oxon, England.
C3 Imperial College London; UCB Pharma SA; Vertex Pharmaceuticals
RP Byrne, B (通讯作者)，Imperial Coll, Dept Life Sci, London SW7 2AZ, England.
EM b.byrne@imperial.ac.uk
RI ; McMillan, David/AAJ 7471 2020
OI Byrne, Bernadette/0000 0001 9598 9832; 
CR Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200
   Bodenner D, 2007, CLIN INTERV AGING, V2, P499
   Carter PH, 2007, P NATL ACAD SCI USA, V104, P6846, DOI 10.1073/pnas.0605125104
   Carter PH, 2015, MOL ENDOCRINOL, V29, P307, DOI 10.1210/me.2014 1129
   Clargo AM, 2014, MABS AUSTIN, V6, P143, DOI 10.4161/mabs.27044
   DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Dominik PK, 2016, STRUCTURE, V24, P300, DOI 10.1016/j.str.2015.11.014
   Ehrenmann J, 2018, NAT STRUCT MOL BIOL, V25, P1086, DOI 10.1038/s41594 018 0151 4
   Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206
   Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256
   Gesty Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200
   Gesty Palmer D, 2011, BRIT J PHARMACOL, V164, P59, DOI 10.1111/j.1476 5381.2011.01450.x
   Grauschopf U, 2000, BIOCHEMISTRY US, V39, P8878, DOI 10.1021/bi0001426
   Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669
   Hauser AS, 2018, CELL, V172, P41, DOI 10.1016/j.cell.2017.11.033
   Hoare SRJ, 2005, DRUG DISCOV TODAY, V10, P417, DOI 10.1016/S1359 6446(05)03370 2
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151
   Hutchings CJ, 2017, NAT REV DRUG DISCOV, V16, P661, DOI 10.1038/nrd.2017.173
   Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491
   Jamshad M, 2011, BIOCHEM SOC T, V39, P813, DOI 10.1042/BST0390813
   Jobert AS, 1998, J CLIN INVEST, V102, P34, DOI 10.1172/JCI2918
   JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53
   JOUISHOMME H, 1994, J BONE MINER RES, V9, P943
   KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277
   Lanske B, 1999, J CLIN INVEST, V104, P399, DOI 10.1172/JCI6629
   Latorraca NR, 2017, CHEM REV, V117, P139, DOI 10.1021/acs.chemrev.6b00177
   Lee SC, 2016, NAT PROTOC, V11, P1149, DOI 10.1038/nprot.2016.070
   Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670
   Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248
   Parfitt AM, 1996, J CLIN ENDOCR METAB, V81, P3584, DOI 10.1210/jc.81.10.3584
   Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908
   Pioszak AA, 2008, P NATL ACAD SCI USA, V105, P5034, DOI 10.1073/pnas.0801027105
   Pioszak AA, 2009, J BIOL CHEM, V284, P28382, DOI 10.1074/jbc.M109.022905
   Rankovic Z, 2016, BIOORG MED CHEM LETT, V26, P241, DOI 10.1016/j.bmcl.2015.12.024
   Rickard DJ, 2006, BONE, V39, P1361, DOI 10.1016/j.bone.2006.06.010
   SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349
   Shi LC, 2016, J PHARMACOL EXP THER, V356, P223, DOI 10.1124/jpet.115.227793
   Tamura T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13384
   Trivett MK, 2005, DEV GENES EVOL, V215, P553, DOI 10.1007/s00427 005 0015 x
   Wehbi VL, 2013, P NATL ACAD SCI USA, V110, P1530, DOI 10.1073/pnas.1205756110
   Wysolmerski JJ, 1998, DEVELOPMENT, V125, P1285
NR 43
TC 25
Z9 27
U1 0
U2 7
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD OCT 8
PY 2019
VL 9
AR 14432
DI 10.1038/s41598 019 51016 z
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA JC2IB
UT WOS:000489099500028
PM 31594997
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jiang, YF
   Wang, GY
   Mu, HR
   Ma, XJ
   Wang, ZY
   Lv, Y
   Zhang, T
   Xu, J
   Wang, JZ
   Li, YQ
   Han, J
   Yang, MK
   Wang, ZY
   Zeng, K
   Jin, XM
   Xue, S
   Yin, MZ
   Sun, W
   Hua, YQ
   Cai, ZD
AF Jiang, Yafei
   Wang, Gangyang
   Mu, Haoran
   Ma, Xiaojun
   Wang, Zhuoying
   Lv, Yu
   Zhang, Tao
   Xu, Jing
   Wang, Jinzeng
   Li, Yunqi
   Han, Jing
   Yang, Mengkai
   Wang, Zongyi
   Zeng, Ke
   Jin, Xinmeng
   Xue, Song
   Yin, Mingzhu
   Sun, Wei
   Hua, Yingqi
   Cai, Zhengdong
TI Bromodomain Inhibition Attenuates the Progression and Sensitizes the
   Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE osteosarcoma; BRD4; NHWD 870; chemosensitivity; PDX 3
ID PROSTATE CANCER; BET; RESISTANCE; STAT3; STABILIZATION; EXPRESSION;
   OSTEOLYSIS; APOPTOSIS; RANKL
AB Osteosarcoma is the most common primary malignant bone tumor, and there are few ideal clinically available drugs. The bromodomain and extraterminal domain (BET) protein is an emerging target for aggressive cancer, but therapies targeting the BET in osteosarcoma have been unsuccessful in clinical trials to date, and further exploration of specific BET inhibitors is of great significance. In our study, we demonstrated that NHWD 870, a potent BET inhibitor in a phase I clinical trial, significantly inhibited tumor proliferation and promoted cell apoptosis by reversing the oncogenic signature in osteosarcoma. More importantly, we identified NHWD 870 impeded binding of BRD4 to the promoter of GP130 leading to diminished activation of JAK/STAT3 signaling pathway. Furthermore, GP130 knockdown significantly sensitizes the chemosensitivity in vitro. In OS cell derived xenografts, NHWD 870 effectively inhibited the growth of osteosarcoma. Beyond that, NHWD 870 effectively inhibited the differentiation and maturation of precursor osteoclasts in vitro and attenuated osteoclast mediated bone loss in vivo. Finally, we confirmed the efficacy of synthetic lethal effects of NHWD 870 and cisplatin in antagonizing osteosarcoma in a preclinical PDX model. Taken together, these findings demonstrate that NHWD 870, as an effective BET inhibitor, may be a potential candidate for osteosarcoma intervention linked to its STAT3 signaling inhibitory activity. In addition, NHWD 870 appears to be a promising therapeutic strategy for bone associated tumors, as it interferes with the vicious cycle of tumor progression and bone destruction.
C1 [Jiang, Yafei; Wang, Gangyang; Mu, Haoran; Ma, Xiaojun; Wang, Zhuoying; Lv, Yu; Zhang, Tao; Xu, Jing; Han, Jing; Yang, Mengkai; Wang, Zongyi; Zeng, Ke; Jin, Xinmeng; Xue, Song; Sun, Wei; Hua, Yingqi; Cai, Zhengdong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Orthopaed, Shanghai, Peoples R China.
   [Jiang, Yafei; Wang, Gangyang; Mu, Haoran; Ma, Xiaojun; Wang, Zhuoying; Zhang, Tao; Xu, Jing; Han, Jing; Yang, Mengkai; Wang, Zongyi; Zeng, Ke; Jin, Xinmeng; Xue, Song; Sun, Wei; Hua, Yingqi; Cai, Zhengdong] Shanghai Bone Tumor Inst, Shanghai, Peoples R China.
   [Wang, Jinzeng; Li, Yunqi] Shanghai Jiao Tong Univ SJTU, Ruijin Hosp, Sch Med, Natl Res Ctr Translat Med, Shanghai, Peoples R China.
   [Yin, Mingzhu] Cent South Univ, Hunan Engn Res Ctr Skin Hlth & Dis, Hunan Key Lab Skin Canc & Psoriasis, Dept Dermatol,Xiangya Hosp, Changsha, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Central
   South University
RP Sun, W; Hua, YQ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Orthopaed, Shanghai, Peoples R China.; Sun, W; Hua, YQ (通讯作者)，Shanghai Bone Tumor Inst, Shanghai, Peoples R China.
EM viv sun@163.com; hua_yingqi@163.com
RI ma, xiaojun/MFH 4215 2025; Yin, Mingzhu/JXN 7646 2024; Jiang,
   Yafei/NZO 2042 2025; Sun, Weijie/GLU 8735 2022; Mu,
   Haoran/AFM 0882 2022; Xue, Song/GSM 9259 2022
OI Yin, Mingzhu/0000 0002 6964 7131; MU, HAORAN/0000 0003 4763 1363; Sun,
   Weijie/0000 0003 0112 0461; 
FU National Natural Science Foundation of China [81972512, 81872177,
   81772859, 82072969, 82072968]; Shanghai Science and Technology
   Commission [14140904000]; Shanghai Sailing Program [19YF1440200];
   Shanghai Jiaotong University Translation Medicine Cross Research Fund
   [ZH2018QNA17]; Shanghai Hospital Development Center [SHDC2020CR2037B]
FX This study was supported by National Natural Science Foundation of China
   (81972512, 81872177, 81772859, 82072969 and 82072968). the Shanghai
   Science and Technology Commission (14140904000), Shanghai Sailing
   Program (NO.19YF1440200) and Shanghai Jiaotong University Translation
   Medicine Cross Research Fund (ZH2018QNA17), and the Shanghai Hospital
   Development Center (SHDC2020CR2037B).
CR Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535 7163.MCT 08 0530
   Ashrafizadeh M, 2020, BIOLOGY BASEL, V9, DOI 10.3390/biology9060126
   Biazzo A, 2016, ACTA ORTHOP BELG, V82, P690
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Cao J, 2003, J BONE MINER RES, V18, P270, DOI 10.1359/jbmr.2003.18.2.270
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Carbognin E, 2016, EMBO J, V35, P618, DOI 10.15252/embj.201592629
   Dai XP, 2017, NAT MED, V23, DOI 10.1038/nm.4378
   Deng GT, 2020, THERANOSTICS, V10, P11428, DOI 10.7150/thno.47432
   Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0915 9
   Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888
   Gao LF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17109 4
   Genta S, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912 019 0762 x
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Jiang YF, 2018, J CELL MOL MED, V22, P3941, DOI 10.1111/jcmm.13674
   Jin W, 2020, CELLS BASEL, V9, DOI 10.3390/cells9010217
   Jou Jennifer, 2019, Curr Protoc Bioinformatics, V68, pe89, DOI 10.1002/cpbi.89
   Kelleher FC, 2017, J ADOLESC YOUNG ADUL, V6, P396, DOI 10.1089/jayao.2016.0078
   Liu KS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.422
   Loh AHP, 2019, CANCER LETT, V442, P262, DOI 10.1016/j.canlet.2018.10.033
   Meazza C, 2016, EXPERT REV ANTICANC, V16, P543, DOI 10.1586/14737140.2016.1168697
   Ohba T, 2014, J BONE MINER RES, V29, P1431, DOI 10.1002/jbmr.2182
   Pelish HE, 2015, NATURE, V526, P273, DOI 10.1038/nature14904
   Rokita JL, 2019, CELL REP, V29, P1675, DOI 10.1016/j.celrep.2019.09.071
   Rousseau J, 2011, J BONE MINER RES, V26, P2452, DOI 10.1002/jbmr.455
   Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958
   Sayles LC, 2019, CANCER DISCOV, V9, P46, DOI 10.1158/2159 8290.CD 17 1152
   Shu SK, 2020, MOL CELL, V78, P1096, DOI 10.1016/j.molcel.2020.04.027
   Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159 8290.CD 17 0605
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wakchaure P, 2019, J BIOMOL STRUCT DYN, V37, P3048, DOI 10.1080/07391102.2018.1507838
   Wang GY, 2019, INT J CANCER, V145, P979, DOI 10.1002/ijc.32180
   Wang ZY, 2019, INT J BIOL SCI, V15, P668, DOI 10.7150/ijbs.30168
   Yuan J, 2009, CANCER INVEST, V27, P435, DOI 10.1080/07357900802491477
   Zhang PZ, 2017, NAT MED, V23, P1055, DOI 10.1038/nm.4379
   Zhang T, 2017, ONCOGENE, V36, P6627, DOI 10.1038/onc.2017.270
   Zhang Y, 2019, J CELL PHYSIOL, V234, P1044, DOI 10.1002/jcp.27241
   Zuo DQ, 2017, J CELL MOL MED, V21, P208, DOI 10.1111/jcmm.12957
NR 38
TC 13
Z9 15
U1 4
U2 27
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2234 943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUN 8
PY 2021
VL 11
AR 642134
DI 10.3389/fonc.2021.642134
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA SV8RS
UT WOS:000664085700001
PM 34168981
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wan, XH
   Li, ZG
   Yingling, JM
   Yang, J
   Starbuck, MW
   Ravoori, MK
   Kundra, V
   Vazquez, E
   Navone, NM
AF Wan, Xinhai
   Li, Zhi Gang
   Yingling, Jonathan M.
   Yang, Jun
   Starbuck, Michael W.
   Ravoori, Murali K.
   Kundra, Vikas
   Vazquez, Elba
   Navone, Nora M.
TI Effect of transforming growth factor beta (TGF β) receptor I kinase
   inhibitor on prostate cancer bone growth
SO BONE
LA English
DT Article
DE Prostate cancer; Bone metastases; TGF beta; TGF beta receptor type I
   kinase inhibitor
ID PLASMA LEVELS; CELLS; PROGRESSION; METASTASES; PATHWAYS; BLOCKADE;
   BREAST; SMAD
AB Transforming growth factor beta 1 (TGF beta 1) has been implicated in the pathogenesis of prostate cancer (PCa) bone metastasis. In this study, we tested the antitumor efficacy of a selective TGF beta receptor I kinase inhibitor, LY2109761, in preclinical models. The effect of LY2109761 on the growth of MDA PCa 2b and PC 3 human PCa cells and primary mouse osteoblasts (PMOs) was assessed in vitro by measuring radiolabeled thymidine incorporation into DNA. In vivo, the right femurs of male SCID mice were injected with PCa cells. We monitored the tumor burden in control  and LY2109761 treated mice with MRI analysis and the PCa induced bone response with X ray and micro CT analyses. Histologic changes in bone were studied by performing bone histomorphometric evaluations. PCa cells and PMOs expressed TGF beta receptor I. TGF beta 1 induced pathway activation (as assessed by induced expression of p Smad2) and inhibited cell growth in PC 3 cells and PMOs but not in MDA PCa 2b cells. LY2109761 had no effect on PCa cells but induced PMO proliferation in vitro. As expected, LY2109761 reversed the TGF beta 1 induced pathway activation and growth inhibition in PC 3 cells and PMOs. In vivo, LY2109761 treatment for 6 weeks resulted in increased volume in normal bone and increased osteoblast and osteoclast parameters. In addition, LY2109761 treatment significantly inhibited the growth of MDA PCa 2b and PC 3 in the bone of SCID mice (p<0.05): moreover, it resulted in significantly less bone loss and change in osteoclast associated parameters in the PC 3 tumor bearing bones than in the untreated mice. In summary, we report for the first time that targeting TGF beta receptors with LY2109761 can control PCa bone growth while increasing the mass of normal bone. This increased bone mass in nontumorous bone may be a desirable side effect of LY2109761 treatment for men with osteopenia or osteoporosis secondary to androgen ablation therapy, reinforcing the benefit of effectively controlling PCa growth in bone. Thus, targeting TGF beta receptor I is a valuable intervention in men with advanced PCa. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Wan, Xinhai; Li, Zhi Gang; Yang, Jun; Starbuck, Michael W.; Navone, Nora M.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol Res, Unit 18 6, Houston, TX 77030 USA.
   [Yingling, Jonathan M.] Eli Lilly & Co, Div Oncol, Lilly Res Labs, Angiogenesis & Tumor Microenvironm Biol, Indianapolis, IN 46285 USA.
   [Ravoori, Murali K.] Univ Texas MD Anderson Canc Ctr, Unit 368, Dept Expt Diagnost Imaging, Houston, TX 77030 USA.
   [Kundra, Vikas] Univ Texas MD Anderson Canc Ctr, Unit 1473, Dept Diagnost Radiol, Houston, TX 77030 USA.
   [Vazquez, Elba] Univ Buenos Aires, Dept Biol Chem, Buenos Aires, DF, Argentina.
   [Vazquez, Elba] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.
C3 University of Texas System; UTMD Anderson Cancer Center; Eli Lilly;
   Lilly Research Laboratories; University of Texas System; UTMD Anderson
   Cancer Center; University of Texas System; UTMD Anderson Cancer Center;
   University of Buenos Aires; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
RP Navone, NM (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol Res, Unit 18 6, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM nnavone@mdanderson.org
RI Yao, Jun/JAC 5608 2023; Vazquez, Elba/D 5134 2019
OI Vazquez, Elba/0000 0002 0460 0236
FU National Institutes of Health through MD Anderson's Cancer Center
   [CA016672]; Lilly Research Laboratories; Prostate Cancer Foundation;
   Rolanette and Berdon Lawrence Bone Disease Program of Texas
FX This research was supported in part by the National Institutes of Health
   through MD Anderson's Cancer Center Support Grant, CA016672, and by
   Lilly Research Laboratories, the Prostate Cancer Foundation, and the
   Rolanette and Berdon Lawrence Bone Disease Program of Texas.
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Alliston Tamara, 2008, P667
   Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008 5472.CAN 06 3946
   Balooch G, 2005, P NATL ACAD SCI USA, V102, P18813, DOI 10.1073/pnas.0507417102
   Baron R., 1983, Bone histomorphometry: Techniques and interpretation, P13
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Freshney RI., 1994, Culture of animal cells : A manual of basic technique, V3rd
   Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Juárez P, 2011, BONE, V48, P23, DOI 10.1016/j.bone.2010.08.004
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Kundra V, 2007, PROSTATE, V67, P50, DOI 10.1002/pros.20494
   Li HY, 2008, J MED CHEM, V51, P2302, DOI 10.1021/jm701199p
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Mishra S, 2011, PROSTATE, V71, P1441, DOI 10.1002/pros.21361
   Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275
   Navone NM, 1997, CLIN CANCER RES, V3, P2493
   O'Brien PJ, 2008, BIOL TARGETS THER, V2, P563
   Ravoori M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009854
   Saad F, 2008, J CLIN ONCOL, V26, P5465, DOI 10.1200/JCO.2008.18.4184
   Shariat SF, 2004, CLIN CANCER RES, V10, P1992, DOI 10.1158/1078 0432.CCR 0768 03
   Shariat SF, 2001, J CLIN ONCOL, V19, P2856, DOI 10.1200/JCO.2001.19.11.2856
   Shariat SF, 2008, J UROLOGY, V179, P1593, DOI 10.1016/j.juro.2007.11.044
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959 437X(01)00259 3
   Yang J, 2001, CANCER RES, V61, P5652
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580
NR 30
TC 55
Z9 68
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2012
VL 50
IS 3
BP 695
EP 703
DI 10.1016/j.bone.2011.11.022
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 897KR
UT WOS:000300650100015
PM 22173053
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Kim, HJ
   Yoon, KA
   Lee, MK
   Kim, SH
   Lee, IK
   Kim, SY
AF Kim, Hyun Ju
   Yoon, Kyung Ae
   Lee, Mi Kyung
   Kim, Soon Ha
   Lee, In Kyu
   Kim, Shin Yoon
TI A novel small molecule, NecroX 7, inhibits osteoclast differentiation by
   suppressing NF κB activity and c Fos expression
SO LIFE SCIENCES
LA English
DT Article
DE Osteoclast; NecroX 7; NF kappa B; c Fos; NFATc1
ID TUMOR NECROSIS FACTOR; TOLL LIKE RECEPTORS; BONE RESORPTION; T CELLS;
   SIGNALING PATHWAY; NUCLEAR FACTOR; LIGAND RANKL; ACTIVATION; SURVIVAL;
   NFATC1
AB Aims: Osteoclasts, the unique bone resorbing polykaryons, are responsible for many bone destructive diseases, such as osteoporosis and rheumatoid arthritis. Hence, the regulation of osteoclast formation is considered a potential therapeutic approach for these diseases. In this study, we investigated the effect of a novel small compound, C25H32N4O4S2 (NecroX 7) on osteoclast formation.
   Main methods: We analyzed the effects of NecoX 7 on receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation in vitro and LPS induced bone loss in vivo.
   Key findings: We observed that NecroX 7 suppressed osteoclast formation from primary bone marrow macrophages (BMMs) in a dose dependent manner. NecroX 7 significantly inhibited the NF kappa B signaling pathway without affecting the activation of the mitogen activated protein kinases (MAPKs) JNK, p38, and ERK in response to RANKL In addition, NecroX 7 strongly attenuated the induction of c Fos and nuclear factor of activated T cells c1 (NFATc1), which are crucial transcription factors for osteoclast differentiation. Mirroring the down regulation of c Fos and NFATc1, the expression of osteoclastogenic markers, such as tartrate resistant acid phosphatase (TRAP) and cathepsin K, was also reduced by the addition of NecroX 7. Furthermore, confirming the in vitro anti osteoclastogenic effect, NecroX 7 inhibited lipopolysaccharide (LPS) induced bone loss in vivo.
   Significance: Our data imply that NecroX 7 is useful as a therapeutic drug for the treatment of bone resorption associated diseases. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Kim, Hyun Ju; Yoon, Kyung Ae; Lee, Mi Kyung; Kim, Shin Yoon] Kyungpook Natl Univ & Hosp, Skeletal Dis Genome Res Ctr, Taegu 700412, South Korea.
   [Kim, Soon Ha] LG Life Sci Ltd, Taejon 305380, South Korea.
   [Lee, In Kyu] Kyungpook Natl Univ, Dept Internal Med, WCU Program, Sch Med, Taegu 700422, South Korea.
   [Kim, Shin Yoon] Kyungpook Natl Univ, Dept Orthoped Surg, Sch Med, Skeletal Dis Genome Res Ctr, Taegu 700422, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   Hospital (KNUH); LG Corporation; LG Life Sciences Ltd; Kyungpook
   National University (KNU); Kyungpook National University (KNU)
RP Kim, HJ (通讯作者)，Kyungpook Natl Univ & Hosp, Skeletal Dis Genome Res Ctr, 44 2 Samduk 2 Ga, Taegu 700412, South Korea.
EM biohjk@hanmail.net; syukim@knu.ac.kr
RI Lee, In Kyu/AAR 6374 2021; Kim, Soo/J 5411 2012
FU Ministry of Health & Welfare, Republic of Korea [A111345]; WCU (World
   Class University) through the National Research Foundation of Korea;
   Ministry of Education, Science and Technology [R32 10064]
FX This study was supported by grants from the Korea Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (A111345) and
   the WCU (World Class University) program through the National Research
   Foundation of Korea funded by the Ministry of Education, Science and
   Technology (R32 10064).
CR Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choi JM, 2010, TRANSPL P, V42, P3414, DOI 10.1016/j.transproceed.2010.08.050
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Hong JM, 2011, J BONE MINER RES, V26, P657, DOI 10.1002/jbmr.241
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ikeda F, 2006, J IMMUNOL, V177, P2384, DOI 10.4049/jimmunol.177.4.2384
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200
   JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092 8674(92)90592 Z
   Kim HJ, 2010, ARCH PHARM RES, V33, P1813, DOI 10.1007/s12272 010 1114 4
   Kim HJ, 2009, P NATL ACAD SCI USA, V106, P2325, DOI 10.1073/pnas.0806963106
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   Park J, 2012, TOXICOL APPL PHARM, V263, P1, DOI 10.1016/j.taap.2012.05.014
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Thu VT, 2012, CARDIOVASC RES, V94, P342, DOI 10.1093/cvr/cvs122
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211
NR 37
TC 16
Z9 19
U1 0
U2 7
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
J9 LIFE SCI
JI Life Sci.
PD NOV 2
PY 2012
VL 91
IS 19 20
BP 928
EP 934
DI 10.1016/j.lfs.2012.09.009
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 031TF
UT WOS:000310664500005
PM 23000100
DA 2025 08 17
ER

PT J
AU Balagangadharan, K
   Trivedi, R
   Vairamani, M
   Selvamurugan, N
AF Balagangadharan, Kalimuthu
   Trivedi, Ritu
   Vairamani, Mariappanadar
   Selvamurugan, Nagarajan
TI Sinapic acid loaded chitosan nanoparticles in polycaprolactone
   electrospun fibers for bone regeneration in vitro and
   in vivo
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Sinapic acid; Chitosan; Polycaprolactone; Bone; Runx2
ID OSTEOBLAST DIFFERENTIATION; COMPOSITE SCAFFOLD; FERULIC ACID; TISSUE;
   RUNX2; EXPRESSION; NANOFIBERS; FABRICATION; PARTICLES; MATRIX
AB Sinapic acid (SA) is a plant derived phenolic compound known for its multiple biological properties, but its role in the promotion of bone formation is not yet well studied. Moreover, the delivery of SA is hindered by its complex hydrophobic nature, limiting its bioavailability. In this study, we fabricated a drug delivery system using chitosan nanoparticles (nCS) loaded with SA at different concentrations. These were incorporated into polycaprolactone (PCL) fibers via an electrospinning method. nCS loaded with 50 mu M SA in PCL fibers promoted osteoblast differentiation. Furthermore, SA treatment activated the osteogenesis signaling pathways in mouse mesenchymal stem cells. A critical sized rat calvarial bone defect model system identified that the inclusion of SA into PCL/nCS fibers accelerated bone formation. Collectively, these data suggest that SA promoted osteoblast differentiation in vitro and bone formation in vivo, possibly by activating the TGF beta 1/BMP/Smads/Runx2 signaling pathways, suggesting SA might have therapeutic benefits in bone regeneration.
C1 [Balagangadharan, Kalimuthu; Vairamani, Mariappanadar; Selvamurugan, Nagarajan] SRM Inst Sci & Technol, Sch Bioengn, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
   [Trivedi, Ritu] CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
C3 SRM Institute of Science & Technology Chennai; Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI)
RP Selvamurugan, N (通讯作者)，SRM Inst Sci & Technol, Sch Bioengn, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
EM selvamurugan.n@ktr.srmuniv.ac.in
RI Selvamurugan, Nagarajan/P 7894 2016
OI Selvamurugan, Nagarajan/0000 0003 3713 1920
FU Department of Biotechnology, Ministry of Science and Technology, India
   [BT/PR7792/MED/30/950/2013, BT/PR15014/BRB/10/1481/2016]
FX This work was supported in part by the Department of Biotechnology,
   Ministry of Science and Technology, India (Grant Nos.
   BT/PR7792/MED/30/950/2013 and BT/PR15014/BRB/10/1481/2016 to N. S).
CR Alhosseini SN, 2012, INT J NANOMED, V7, P25, DOI 10.2147/IJN.S25376
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Andreasen MF, 2001, J AGR FOOD CHEM, V49, P4090, DOI 10.1021/jf0101758
   Arumugam B, 2018, J CELL PHYSIOL, V233, P1082, DOI 10.1002/jcp.25964
   Asadian M, 2015, J IRAN CHEM SOC, V12, P1089, DOI 10.1007/s13738 014 0569 5
   Aytimur A, 2015, INT J POLYM MATER PO, V64, P111, DOI 10.1080/00914037.2014.891118
   Bhardwaj N, 2010, BIOTECHNOL ADV, V28, P325, DOI 10.1016/j.biotechadv.2010.01.004
   Chen C., 2016, OXIDATIVE MED CELLUL, V2016
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen RM, 2010, J BONE MINER RES, V25, P2193, DOI 10.1002/jbmr.121
   Cohen MM, 2009, AM J MED GENET A, V149A, P2629, DOI 10.1002/ajmg.a.33021
   Cui WG, 2010, SCI TECHNOL ADV MAT, V11, DOI 10.1088/1468 6996/11/1/014108
   Dhivya S, 2015, J NANOBIOTECHNOL, V13, DOI 10.1186/s12951 015 0099 z
   Dhivya S., 2017, HDB COMPOSITES RENEW, V5, P439
   Ding Y, 2010, BIOSENS BIOELECTRON, V25, P2009, DOI 10.1016/j.bios.2010.01.024
   Domingos M, 2017, P I MECH ENG H, V231, P555, DOI 10.1177/0954411916680236
   Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097 4652(200009)184:3<341::AID JCP8>3.3.CO;2 Q
   Fei YR, 2011, J BIOL CHEM, V286, P40575, DOI 10.1074/jbc.M111.274910
   Frohbergh ME, 2015, TISSUE ENG PT A, V21, P970, DOI [10.1089/ten.TEA.2013.0789, 10.1089/ten.tea.2013.0789]
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Glowacki J, 2008, BIOPOLYMERS, V89, P338, DOI 10.1002/bip.20871
   Goonoo N, 2013, POLYM INT, V62, P523, DOI 10.1002/pi.4474
   Goyal R, 2016, J CONTROL RELEASE, V240, P77, DOI 10.1016/j.jconrel.2015.10.049
   Groppo MF, 2017, ARCH ORAL BIOL, V82, P209, DOI 10.1016/j.archoralbio.2017.06.018
   Guntur AR, 2013, BONEKEY REPORTS, V2
   Guo F, 2011, COLLOID SURFACE B, V86, P140, DOI 10.1016/j.colsurfb.2011.03.032
   Guo ST, 2014, BIOTECHNOL ADV, V32, P778, DOI 10.1016/j.biotechadv.2013.10.002
   Hameed H., 2016, FABAD J PHARM SCI, V41, P39
   Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023
   Hayrapetyan A, 2015, TISSUE ENG PART B RE, V21, P75, DOI [10.1089/ten.teb.2014.0119, 10.1089/ten.TEB.2014.0119]
   Hu X, 2018, ACS APPL MATER INTER, V10, P28372, DOI 10.1021/acsami.8b09421
   Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Jang JH, 2009, ADV DRUG DELIVER REV, V61, P1065, DOI 10.1016/j.addr.2009.07.008
   Joseph CS, 2011, FOOD BIOPROCESS TECH, V4, P1179, DOI 10.1007/s11947 009 0203 1
   Jung SM, 2013, IN VITRO CELL DEV AN, V49, P27, DOI 10.1007/s11626 012 9568 y
   Kanchana G., 2011, Glob. J. Pharmacol, V5, P33, DOI 10.1016/j.fshw.2016.11.002
   Kikuzaki H, 2002, J AGR FOOD CHEM, V50, P2161, DOI 10.1021/jf011348w
   Kim BR, 2014, TISSUE ENG PT A, V20, P3279, DOI [10.1089/ten.tea.2014.0081, 10.1089/ten.TEA.2014.0081]
   Kim DH, 2010, NEUROPHARMACOLOGY, V59, P20, DOI 10.1016/j.neuropharm.2010.03.012
   Kim H, 2014, MAT SCI ENG C MATER, V40, P324, DOI 10.1016/j.msec.2014.04.012
   Kim JI, 2014, MAT SCI ENG C MATER, V44, P52, DOI 10.1016/j.msec.2014.07.062
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   Kumar JP, 2014, J BIOMED NANOTECHNOL, V10, P970, DOI 10.1166/jbn.2014.1808
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Kuttappan S, 2018, ACTA BIOMATER, V78, P36, DOI 10.1016/j.actbio.2018.07.050
   Lai YL, 2006, MOL CELL BIOCHEM, V292, P45, DOI 10.1007/s11010 006 9175 x
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee YJ, 2013, BIOMATERIALS, V34, P5059, DOI 10.1016/j.biomaterials.2013.03.051
   Leena RS, 2017, COLLOID SURFACE B, V158, P308, DOI 10.1016/j.colsurfb.2017.06.048
   Li YL, 2017, CHEM REV, V117, P4376, DOI 10.1021/acs.chemrev.6b00654
   Liu HH, 2013, BIOMATERIALS, V34, P4404, DOI 10.1016/j.biomaterials.2013.02.048
   Liverani L, 2018, BIOACT MATER, V3, P55, DOI 10.1016/j.bioactmat.2017.05.003
   Lord MS, 2010, NANO TODAY, V5, P66, DOI 10.1016/j.nantod.2010.01.001
   Maietta S, 2018, MATERIALS, V11, DOI 10.3390/ma11020312
   Makadia HK, 2011, POLYMERS BASEL, V3, P1377, DOI 10.3390/polym3031377
   Maxhimer JB, 2015, GENES DIS, V2, P57, DOI 10.1016/j.gendis.2014.12.004
   Mishra B, 2010, NANOMED NANOTECHNOL, V6, P9, DOI 10.1016/j.nano.2009.04.008
   Mohamed AM, 2008, MALAYS J MED SCI, V15, P4
   Moreno Cortez IE, 2015, MAT SCI ENG C MATER, V52, P306, DOI 10.1016/j.msec.2015.03.049
   Nagarajan E., 2015, J Appl Pharm Sci, P020, DOI [10.7324/JAPS.2015.50404, DOI 10.7324/JAPS.2015.50404]
   Naseri N, 2014, CARBOHYD POLYM, V109, P7, DOI 10.1016/j.carbpol.2014.03.031
   Linh NTB, 2013, J BIOMED MATER RES A, V101, P2412, DOI 10.1002/jbm.a.34533
   Niciforovic N, 2014, COMPR REV FOOD SCI F, V13, P34, DOI 10.1111/1541 4337.12041
   Pan JF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112885
   Pattnaik S, 2011, INT J BIOL MACROMOL, V49, P1167, DOI 10.1016/j.ijbiomac.2011.09.016
   Pelipenko J, 2015, INT J PHARMACEUT, V484, P57, DOI 10.1016/j.ijpharm.2015.02.043
   Pighinelli L, 2013, CARBOHYD POLYM, V93, P256, DOI 10.1016/j.carbpol.2012.06.004
   Pina S, 2015, ADV MATER, V27, P1143, DOI 10.1002/adma.201403354
   Pratt AB, 2004, BIOTECHNOL BIOENG, V86, P27, DOI 10.1002/bit.10897
   Saravanan S, 2015, J BIOMED NANOTECHNOL, V11, P1124, DOI 10.1166/jbn.2015.2057
   Saravanan S, 2011, INT J BIOL MACROMOL, V49, P188, DOI 10.1016/j.ijbiomac.2011.04.010
   Schofer MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025462
   Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200
   Selvamurugan N., 2004, J BIOL CHEM
   Selvamurugan N, 2006, J CELL BIOCHEM, V99, P545, DOI 10.1002/jcb.20878
   SHAHIDI F, 2004, PHENOLICS FOOD NUTRA
   Shahrezaee M, 2018, NANOMED NANOTECHNOL, V14, P2061, DOI 10.1016/j.nano.2018.06.007
   Shi YZ, 2015, MAT SCI ENG C MATER, V51, P346, DOI 10.1016/j.msec.2015.03.010
   Sobhani Z, 2017, ADV PHARM BULL, V7, P427, DOI 10.15171/apb.2017.051
   Sun L, 2017, ASIAN J PHARM SCI, V12, P418, DOI 10.1016/j.ajps.2017.04.002
   Tan EPS, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1862337
   Trzeciakiewicz A, 2009, NUTR RES REV, V22, P68, DOI 10.1017/S095442240926402X
   Venkatesan J, 2010, MAR DRUGS, V8, P2252, DOI 10.3390/md8082252
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Vimalraj S, 2014, J CELL PHYSIOL, V229, P1236, DOI 10.1002/jcp.24557
   Wang Liang, 2015, Chinese Medical Sciences Journal, V30, P108
   Woo JT, 2010, J ORAL BIOSCI, V52, P15
   Xiang AS, 2011, J MEMBRANE SCI, V371, P211, DOI 10.1016/j.memsci.2011.01.050
   Yang XC, 2009, BIOMACROMOLECULES, V10, P2772, DOI 10.1021/bm900623j
   Ye P, 2006, BIOMATERIALS, V27, P4169, DOI 10.1016/j.biomaterials.2006.03.027
   Yoo HS, 2009, ADV DRUG DELIVER REV, V61, P1033, DOI 10.1016/j.addr.2009.07.007
   Yoon BH, 2007, LIFE SCI, V81, P234, DOI 10.1016/j.lfs.2007.05.007
   Yun KJ, 2008, J AGR FOOD CHEM, V56, P10265, DOI 10.1021/jf802095g
   Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499
   Zang S., 2017, ONCO TARGET, V8
   Zhang CY, 2014, CRYSTENGCOMM, V16, P9513, DOI 10.1039/c4ce01287a
   Zhang XH, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/507154
   Zhao HG, 2009, J BIOMED MATER RES B, V88B, P240, DOI 10.1002/jbm.b.31174
   Zhao ZR, 2005, MOL THER, V12, P247, DOI 10.1016/j.ymthe.2005.03.009
   Zou YN, 2002, J AGR FOOD CHEM, V50, P5884, DOI 10.1021/jf020496z
NR 101
TC 81
Z9 83
U1 2
U2 81
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144 8617
EI 1879 1344
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD JUL 15
PY 2019
VL 216
BP 1
EP 16
DI 10.1016/j.carbpol.2019.04.002
PG 16
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Polymer Science
GA HW0EI
UT WOS:000466353300001
PM 31047045
DA 2025 08 17
ER

PT J
AU Heidari, N
   Vosough, M
   Bagherifard, A
   Sami, SH
   Sarabi, PA
   Behmanesh, A
   Shams, R
AF Heidari, Negar
   Vosough, Massoud
   Bagherifard, Abolfazl
   Sami, Sam Hajialilo
   Sarabi, Pedram Asadi
   Behmanesh, Ali
   Shams, Roshanak
TI Exploring circulating MiRNA signature for osteosarcoma detection:
   Bioinformatics based analyzing and validation
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Article
DE Micro RNA; Circulating miRNA; Osteosarcoma; Early Detection; Wnt
   signaling; P53 signaling
ID MELANOMA CELLS; PROLIFERATION; MICRORNA; IDENTIFICATION; CARCINOMA;
   APOPTOSIS; MIGRATION; PROTEINS; INVASION; PROMOTES
AB Early detection followed by efficient treatment still remain a considerable challenge for osteosarcoma (OS), indicating the importance of emerging innovative diagnostic methods. Circulating miRNAs offer a promising and non invasive approach to assess the OS molecular landscapes. This study utilized RNAseq data from OS plasma miRNA expression profiles (PRJEB30542) and PCR Array data (GSE65071) from GEO and ENA databases. In total, 43 miRNAs demonstrated significant differential expression in OS samples of training dataset. A diagnostic model, including hsa miR 30a 5p, hsa miR 556 3p, hsa miR 200a 3p, and hsa miR 582 5p was identified through multivariate logistic regression analysis and demonstrated significant efficacy in differentiating OS patients from healthy controls in the validation group (AUC: 0.917, sensitivity: 1, specificity: 0.85). The result of target gene prediction and functional enrichment analyses revealed significant associations with terms such as epithelial morphogenesis, P53 and Wnt signaling pathways, and neoplasm metastasis. Further bioinformaticsbased evaluations showed that the down regulation of these miRNAs significantly correlates with poor prognosis and lower survival rate in OS patients and propose their tumor suppressor function in pathogenesis of OS. Furthermore, the study developed a miRNA mRNA subnetwork that connects these miRNAs to the P53 and Wnt signaling pathways, which are critical pathways with oncogenic effects on OS progression. This comprehensive approach not only presents a promising diagnostic model but also proposes potential molecular markers for OS early diagnosis, making prognosis, and targeted therapy. The identified miRNA mRNA functional axis holds promise as a valuable resource for further research in understanding OS pathogenesis and establishing therapeutic modalities.
C1 [Heidari, Negar] Univ Sci & Culture, Fac Sci & Adv Technol Biol, Dept Cellular & Mol Biol, Tehran, Iran.
   [Vosough, Massoud; Sarabi, Pedram Asadi] ACECR, Dept Regenerat Med, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Tehran, Iran.
   [Vosough, Massoud] Karolinska Inst, Inst Lab Med, Expt Canc Med, Stockholm, Sweden.
   [Bagherifard, Abolfazl; Sami, Sam Hajialilo; Behmanesh, Ali; Shams, Roshanak] Iran Univ Med Sci, Bone & Joint Reconstruct Res Ctr, Sch Med, Dept Orthoped, Tehran, Iran.
C3 Academic Center for Education, Culture & Research (ACECR); Academic
   Center for Education, Culture & Research (ACECR); Karolinska Institutet;
   Iran University of Medical Sciences
RP Vosough, M (通讯作者)，ACECR, Dept Regenerat Med, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Tehran, Iran.; Shams, R (通讯作者)，Iran Univ Med Sci, Bone & Joint Reconstruct Res Ctr, Sch Med, Dept Orthoped, Tehran, Iran.
EM negaaarh78@gmail.com; massoud.vosough@gmail.com;
   bagherifard.a@iums.ac.ir; saamhaji@gmail.com; pedramasadi21@gmail.com;
   shams.rosha.86@gmail.com
RI ; Behmanesh, Ali/AAV 4101 2020; Shams, Roshanak/ABA 3080 2020;
   bagherifard, abolfazl/ABH 8559 2020; Vosough, Massoud/AAR 8970 2021
OI Shams, Roshanak/0000 0002 7141 5735; Vosough,
   Massoud/0000 0001 5924 4366
FU Iran University of Medical Sciences [IR.IUMS.REC.1401.216]
FX <B>Acknowledgments</B> This study was financially supported by Iran
   University of Medical Sciences (Grant Ethics No. IR.IUMS.REC.1401.216) .
CR Allen Rhoades W, 2015, CANCER MED US, V4, P977, DOI 10.1002/cam4.438
   Alvarez ML, 2014, METHODS MOL BIOL, V1182, P321, DOI 10.1007/978 1 4939 1062 5_27
   Aran V, 2021, CRIT REV ONCOL HEMAT, V162, DOI 10.1016/j.critrevonc.2021.103340
   Bombaci M, 2019, METHODS MOL BIOL, V1959, P247, DOI 10.1007/978 1 4939 9164 8_16
   de Azevedo JWV, 2020, ONCOL LETT, V19, P1099, DOI 10.3892/ol.2019.11229
   Dean DC, 2018, CANCER METAST REV, V37, P719, DOI 10.1007/s10555 018 9763 8
   Fathi M, 2022, MOL BIOL REP, V49, P6475, DOI 10.1007/s11033 022 07476 0
   Floyd DH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096239
   Gao SS, 2020, J BONE ONCOL, V23, DOI 10.1016/j.jbo.2020.100307
   Gao XZ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1002742
   Guo X, 2023, DRUG RESIST UPDATE, V67, DOI 10.1016/j.drup.2023.100937
   Gyorffy B, 2023, GEROSCIENCE, V45, P1889, DOI 10.1007/s11357 023 00742 4
   He JY, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935 021 02013 8
   Huang JM, 2023, INT J MED SCI, V20, P493, DOI 10.7150/ijms.81990
   Kosela Paterczyk H, 2020, J CANCER, V11, P874, DOI 10.7150/jca.34723
   Kozomara A, 2019, NUCLEIC ACIDS RES, V47, pD155, DOI 10.1093/nar/gky1141
   Li SL, 2021, J CELL PHYSIOL, V236, P3354, DOI 10.1002/jcp.30101
   Li YC, 2018, MOL CELL TOXICOL, V14, P73, DOI 10.1007/s13273 018 0009 1
   Li YS, 2016, ONCOTARGETS THER, V9, P3101, DOI 10.2147/OTT.S96561
   Liu GZ, 2021, J CELL MOL MED, V25, P7395, DOI 10.1111/jcmm.16767
   Llobat L, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9050463
   Lu F, 2021, AM J TRANSL RES, V13, P12588
   Luo H., 2021, Clin. Lab, V4
   Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735
   Matsuoka K, 2020, CELL RES, V30, P885, DOI 10.1038/s41422 020 0370 1
   Mazzara S, 2017, SCI REP UK, V7, DOI 10.1038/srep45477
   Min X, 2018, ONCOL LETT, V15, P2459, DOI 10.3892/ol.2017.7610
   Nepal P, 2021, ANTICANCER RES, V41, P4821, DOI 10.21873/anticanres.15297
   Ohmura S, 2021, MOL CANCER, V20, DOI 10.1186/s12943 021 01393 9
   Plygawko AT, 2020, PHILOS T R SOC B, V375, DOI 10.1098/rstb.2020.0087
   Sadoughi F, 2022, J HEALTHC ENG, V2022, DOI 10.1155/2022/3226440
   Seifi Alan M, 2018, INT J CANCER MANAG, V11, DOI 10.5812/ijcm.69554
   Salehi AS, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/8040419
   Shams R, 2023, ACS BIOMATER SCI ENG, V9, P5186, DOI 10.1021/acsbiomaterials.3c00178
   Shamsi R, 2017, CELL MOL BIOL, V63, P99, DOI 10.14715/cmb/2017.63.10.16
   Sherman BT, 2022, NUCLEIC ACIDS RES, V50, pW216, DOI 10.1093/nar/gkac194
   Sinnberg T, 2010, CANCER RES, V70, P6999, DOI 10.1158/0008 5472.CAN 10 0645
   Smrke A, 2021, CELLS BASEL, V10, DOI 10.3390/cells10010172
   Soghli N, 2022, BIOCHEM PHARMACOL, V201, DOI 10.1016/j.bcp.2022.115094
   Su Gang, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi0813s47
   Sun YF, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 03961 7
   Synoradzki KJ, 2021, CANCERS, V13, DOI 10.3390/cancers13174284
   Tao J, 2018, BIOCHEM BIOPH RES CO, V503, P1092, DOI 10.1016/j.bbrc.2018.06.121
   Tao KY, 2021, CARCINOGENESIS, V42, P1056, DOI 10.1093/carcin/bgab051
   Tokar T, 2018, NUCLEIC ACIDS RES, V46, pD360, DOI 10.1093/nar/gkx1144
   Ueno K, 2013, INT J CANCER, V132, P1731, DOI 10.1002/ijc.27746
   Wenzel J, 2020, ONCOGENE, V39, P3893, DOI 10.1038/s41388 020 1259 7
   Xu H, 2022, BIOENGINEERED, V13, P12876, DOI 10.1080/21655979.2022.2078026
   Xu WL, 2020, ONCOL REP, V44, P1895, DOI 10.3892/or.2020.7760
   Xue YL, 2022, BIOENGINEERED, V13, P9135, DOI 10.1080/21655979.2021.2003942
   Yang XR, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018 015 0275 8
   Ye CY, 2020, EUR REV MED PHARMACO, V24, P11026, DOI 10.26355/eurrev_202011_23587
   Yong L, 2020, J BONE ONCOL, V25, DOI 10.1016/j.jbo.2020.100322
   Yoshimoto S, 2021, LAB INVEST, V101, P38, DOI 10.1038/s41374 020 00486 1
   Zhang RY, 2016, TUMOR BIOL, V37, P3479, DOI 10.1007/s13277 015 4086 7
   Zheng A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1315 8
   Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240
NR 57
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0344 0338
EI 1618 0631
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PD NOV
PY 2024
VL 263
AR 155615
DI 10.1016/j.prp.2024.155615
EA OCT 2024
PG 13
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA I7O0X
UT WOS:001332104200001
PM 39378797
DA 2025 08 17
ER

PT J
AU Liang, X
   Li, BS
   Huang, Q
   Liu, D
   Ma, HX
AF Liang, Xiao
   Li, Baoshan
   Huang, Qian
   Liu, Dan
   Ma, Houxun
TI Klotho prevents DEX induced apoptosis in MC3T3 E1 osteoblasts through
   the NF κB signaling pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Klotho; Dexamethasone; Osteoblast; NF kappa B; Caspase 3
ID BONE; ACTIVATION; GROWTH; REGULATOR; CELLS
AB Dexamethasone (DEX) is a commonly used anti inflammatory drug and an immunosuppressive drug used in clinical practice to treat a variety of diseases. Glucocorticoid induced osteoporosis (GIOP) is a consequence of high dose, or a long term low dose use of glucocorticoids (GCs). These treatment regimens can cause a variety of bone related adverse effects, leading to increased osteoblast and bone cell apoptosis. Evidence suggests that klotho (KL) can inhibit GIOP. It is unknown whether KL attenuates DEX induced apoptosis in MC3T3 E1 cells or the underlying mechanisms involved. In the present study, we found that MC3T3 E1 cells pretreated with DEX led to the up regulation of cleaved caspase 3, and down regulation of caspase 3, which were inhibited by la transfection. Furthermore, flow cytometry and western blot analysis revealed that the NF kappa B inhibitor pyrrolidine dithiocarbamate (PDTC) could restore the DEX induced caspase 3 decrease and inhibit the DEX induced cleaved caspase 3 increase. We observed that DEX stimulated the degradation of I kappa B alpha(NF kappa B inhibitor alpha) and the translocation of NF kappa B, which were suppressed by la transfection. These findings therefore, indicate a protective role for KL against osteoblastic cell apoptosis induced by DEX, via the NF kappa B signaling pathway. (C) 2018 Elsevier Inc. All rights reserved.
RP Ma, HX (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Geriatr, Chongqing 400016, Peoples R China.
EM 540346440@qq.com; 107380728@qq.com; mahouxun1966@163.com
OI Liang, Xiao/0000 0002 1967 1117; Li, Baoshan/0000 0002 6136 2449
FU General Program of National Natural Science Foundation of China
   [30672212]; Medical Science Research Project of Chongqing Health and
   Family Planning Commission, China [2016MSXM080]; Science and Technology
   Planning Project of Yuzhong District of Chongqing, China [20150139]
FX This work was supported by the General Program of National Natural
   Science Foundation of China (Grant No. 30672212)/Medical Science
   Research Project of Chongqing Health and Family Planning Commission,
   China (NO. 2016MSXM080)/Science and Technology Planning Project of
   Yuzhong District of Chongqing, China (NO. 20150139).
CR Buendía P, 2016, VITAM HORM, V101, P119, DOI 10.1016/bs.vh.2016.02.005
   Chalhoub D, 2016, J AM GERIATR SOC, V64, pE304, DOI 10.1111/jgs.14661
   Chua CC, 2003, BBA MOL CELL RES, V1642, P79, DOI 10.1016/S0167 4889(03)00100 9
   den Uyl D, 2011, CURR RHEUMATOL REP, V13, P233, DOI 10.1007/s11926 011 0173 y
   Gu JW, 2009, CANCER BIOL THER, V8, P514, DOI 10.4161/cbt.8.6.7689
   Hachemi Y, 2018, J MOL ENDOCRINOL, V61, pR75, DOI 10.1530/JME 18 0024
   Jiao L., 2018, VASCULAR
   Kalak R, 2009, BONE, V45, P61, DOI 10.1016/j.bone.2009.03.673
   Kawaguchi H, 2006, REV ENDOCR METAB DIS, V7, P17, DOI 10.1007/s11154 006 9011 3
   Komori T, 2016, HORM METAB RES, V48, P755, DOI 10.1055/s 0042 110571
   Kuro o M, 2006, CURR OPIN NEPHROL HY, V15, P437, DOI 10.1097/01.mnh.0000232885.81142.83
   Li H., 2012, US CHIN INT J TRAUMA, V7, P1
   Li SB, 2018, EXP THER MED, V16, P643, DOI 10.3892/etm.2018.6199
   Lin H, 2015, BIOCHEM BIOPH RES CO, V460, P422, DOI 10.1016/j.bbrc.2015.03.049
   Lin H, 2014, DRUG DES DEV THER, V8, P973, DOI 10.2147/DDDT.S65410
   Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242
   Rashidi M, 2018, CELL DEATH DIFFER, V25, P392, DOI 10.1038/cdd.2017.173
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Richter B., 2018, FRONT ENDOCRINOL, V9
   Rosa M. A. D. L., 2012, IUBMB LIFE, V64, P499
   Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177
   [王艳娇 Wang Yan Jiao], 2012, [基础医学与临床, Basic & Clinical Medicine], V32, P487
   Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309
   Weinstein R. S., 2010, J BONE MINER RES OFF, V15, P754
   Yamashita T, 1998, J ENDOCRINOL, V159, P1, DOI 10.1677/joe.0.1590001
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774 008 0019 5
   Zheng SB, 2018, EUR J MED RES, V23, DOI 10.1186/s40001 018 0315 z
   Zhong X, 2011, INT J MOL MED, V28, P535, DOI 10.3892/ijmm.2011.722
   Zhou DA, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 239
   Zhou F., 2018, BIOCH BIOPHYS RES CO, V499
NR 30
TC 7
Z9 8
U1 0
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 9
PY 2018
VL 507
IS 1 4
BP 355
EP 361
DI 10.1016/j.bbrc.2018.11.040
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HD8OM
UT WOS:000452816400055
PM 30442365
DA 2025 08 17
ER

PT J
AU Lin, BR
   Zhou, H
   Leaman, DW
   Goel, VK
   Agarwal, AK
   Bhaduri, SB
AF Lin, Boren
   Zhou, Huan
   Leaman, Douglas W.
   Goel, Vijay K.
   Agarwal, Anand K.
   Bhaduri, Sarit B.
TI Sustained release of small molecules from carbon nanotube reinforced
   monetite calcium phosphate cement
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Calcium phosphate cement; Carbon nanotubes; Drug delivery; Osteoclastic
   inhibition; Bone regeneration
ID NF KAPPA B; UBIQUITIN PROTEASOME PATHWAY; NECROSIS FACTOR ALPHA;
   OSTEOCLAST DIFFERENTIATION; ORTHOPEDIC APPLICATIONS; RECEPTOR ACTIVATOR;
   DRUG DELIVERY; CELLS; INHIBITOR; LIGAND
AB The interest in developing calcium phosphate cement (CPC) as a drug delivery system has risen because of its capability to achieve local and controlled treatment to the site of the bone disease. The purpose of this study was to investigate the release pattern of drug carrying carboxylic acid functionalized multi walled carbon nanotube (MWCNT) reinforced monetite (DCPA, CaHPO4) based CPC. Z Leu Leu Leu al (MG132), a small peptide molecule inhibiting NF kappa B mediated osteoclastic resorption, was used as a model drug. MG132 was added into the cement during setting and released into the medium used to culture indicator cells. Significant cell death was observed in osteoblast MC3T3 E1 cells cultured in the medium incubated with MG132 loaded CPC; however, with the presence of MWCNTs in the cement, the toxic effect was not detectable. NF kappa B activation was quantified using a NF kappa B promoter driving luciferase reporter in human embryonic kidney 293 cells. The medium collected after incubation with drug incorporated CPC with or without MWCNT inhibited TNF alpha induced NF kappa B activation indicating that the effective amount of MG132 was released. CPC/drug complex showed a rapid release within 24 h whereas incorporation of MWCNTs attenuated this burst release effect. In addition, suppression of TNF alpha induced osteoclast differentiation in RAW 264.7 cell culture also confirmed the sustained release of MWCNT/CPC/drug. Our data demonstrated the drug delivery capability of this cement composite, which can potentially be used to carry therapeutic molecules to improve bone regeneration in conjunction with its fracture stabilizing function. Furthermore, it suggested a novel approach to lessen the burst release effect of the CPC based drug delivery system by incorporating functionalized MWCNTs. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Lin, Boren; Goel, Vijay K.; Agarwal, Anand K.] Univ Toledo, Dept Bioengn, Toledo, OH 43606 USA.
   [Zhou, Huan; Bhaduri, Sarit B.] Univ Toledo, Dept Mech Ind & Mfg Engn, Toledo, OH 43606 USA.
   [Leaman, Douglas W.] Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA.
C3 University System of Ohio; University of Toledo; University System of
   Ohio; University of Toledo; University System of Ohio; University of
   Toledo
RP Lin, BR (通讯作者)，Univ Toledo, Dept Bioengn, 2801 W Bancroft St, Toledo, OH 43606 USA.
EM boren.lin@utoledo.edu
RI Lin, Boren/W 8461 2019; zhou, huan/GYJ 4398 2022
OI Lin, Boren/0000 0002 0590 7731
FU State of Ohio Third Frontier Program; NIH [R01 AI068133]
FX The financial supports of the present work by the State of Ohio Third
   Frontier Program (to Bhaduri) and the NIH R01 AI068133 (to Leaman) are
   appreciated.
CR Ang E, 2009, J CELL PHYSIOL, V220, P450, DOI 10.1002/jcp.21787
   [Anonymous], IN SITU SYNTHESIS PO
   Boroujeni NM, 2013, MAT SCI ENG C MATER, V33, P4323, DOI 10.1016/j.msec.2013.06.029
   Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen BD, 2013, CURR APPL PHYS, V13, P1001, DOI 10.1016/j.cap.2013.02.004
   Chen RJ, 2001, J AM CHEM SOC, V123, P3838, DOI 10.1021/ja010172b
   CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586
   Dorozhkin SV, 2008, J MATER SCI, V43, P3028, DOI 10.1007/s10853 008 2527 z
   Elhissi AMA, 2012, J DRUG DELIV, V2012, DOI 10.1155/2012/837327
   Fujisaki K, 2007, LIFE SCI, V80, P1311, DOI 10.1016/j.lfs.2006.12.037
   Ginebra MP, 2006, J CONTROL RELEASE, V113, P102, DOI 10.1016/j.jconrel.2006.04.007
   Guo N, 2013, ASIA PAC J CLIN ONCO, V9, P6, DOI 10.1111/j.1743 7563.2012.01535.x
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Ortiz Lazareno PC, 2008, IMMUNOLOGY, V124, P534, DOI 10.1111/j.1365 2567.2008.02806.x
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092 8674(94)90482 0
   Saito N, 2008, CURR MED CHEM, V15, P523, DOI 10.2174/092986708783503140
   Skjot Arkil H, 2012, ASSAY DRUG DEV TECHN, V10, P69, DOI 10.1089/adt.2010.0366
   Son SJ, 2007, DRUG DISCOV TODAY, V12, P650, DOI 10.1016/j.drudis.2007.06.002
   Su ZD, 2011, J AM CHEM SOC, V133, P6874, DOI 10.1021/ja1084282
   TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460 2075.1994.tb06878.x
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhou H, 2013, MAT SCI ENG C MATER, V33, P4288, DOI 10.1016/j.msec.2013.06.034
NR 24
TC 12
Z9 13
U1 0
U2 49
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD OCT 1
PY 2014
VL 43
BP 92
EP 96
DI 10.1016/j.msec.2014.06.027
PG 5
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA AQ1GD
UT WOS:000342529000012
PM 25175192
OA Bronze
DA 2025 08 17
ER

PT J
AU Ghorbani, A
   Naderi Meshkin, H
AF Ghorbani, Ahmad
   Naderi Meshkin, Hojjat
TI The Endocrine Regulation of Stem Cells: Physiological Importance and
   Pharmacological Potentials for Cell Based Therapy
SO CURRENT STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Differentiation; endocrine; hormone; proliferation; stem cell
ID GLUCAGON LIKE PEPTIDE 1; NEURAL PROGENITOR CELLS; INTESTINAL EPITHELIAL
   PROLIFERATION; CENTRAL NERVOUS SYSTEM; GROWTH HORMONE; THYROID HORMONE;
   PARATHYROID HORMONE; ADIPOSE TISSUE; OSTEOGENIC DIFFERENTIATION;
   SIGNALING PATHWAYS
AB Throughout life, different types of stem cells participate in tissue generation, maintenance, plasticity, and repair. Their abilities to secrete growth factors, to proliferate and differentiate into several cell lineages, and to migrate and home into the damaged tissues have made them attractive candidates for cell therapy and tissue engineering applications. Normal stem cell function is tied to the cell intrinsic mechanisms and extrinsic signals derived from the surrounding microenvironment or circulation. Understanding the regulatory signals that govern stem cell functions is essential in order to have full knowledge about organogenesis, tissue maintenance and tissue plasticity in the physiological condition. It is also important for optimizing tissue engineering and improving the therapeutic efficiency of stem cells in regenerative medicine. A growing body of evidence indicates that hormonal signals can critically influence stem cell functions in fetal, postnatal, and adult tissues. This review focuses on recent studies revealing how growth hormone, insulin, thyroid hormone, parathormone, adrenocorticotropin, glucocorticoids, erythropoietin, and gastrointestinal hormones control stem cell behavior through influencing survival, proliferation, migration, homing, and differentiation of these cells. Moreover, how environmental factors such as exercise, hypoxia, and nutrition might affect stem cell functions through influencing the endocrine system is discussed. Some of the current limitations of cell therapy and how hormones can help overcoming these limitations are briefly outlined.
C1 [Ghorbani, Ahmad] Mashhad Univ Med Sci, Sch Med, Pharmacol Res Ctr Med Plants, Mashhad, Iran.
   [Naderi Meshkin, Hojjat] Iranian Acad Ctr Educ Culture & Res ACECR, Khorasan Razavi Branch, Stem Cell & Regenerat Med Res Dept, Mashhad, Iran.
C3 Mashhad University of Medical Sciences; Academic Center for Education,
   Culture & Research (ACECR)
RP Ghorbani, A (通讯作者)，Mashhad Univ Med Sci, Sch Med, Mashhad, Iran.
EM ghorbania@mums.ac.ir
RI ; Ghorbani, Ahmad/S 8164 2016; naderi, hojjat/AAG 2329 2019
OI Naderi Meshkin, Hojjat/0000 0003 3988 3229; naseri,
   shahrokh/0000 0001 8974 2120; 
CR Ables ET, 2012, WIRES DEV BIOL, V1, P657, DOI 10.1002/wdev.48
   Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281
   Agathocleous M, 2013, TRENDS CELL BIOL, V23, P484, DOI 10.1016/j.tcb.2013.05.004
   Ajo R, 2003, ENDOCRINOLOGY, V144, P1086, DOI 10.1210/en.2002 220667
   Alinejad B, INT J DIABE IN PRESS
   Alinejad B, 2015, DARU, V23, DOI 10.1186/s40199 015 0100 2
   Anacker C, 2013, NEUROPSYCHOPHARMACOL, V38, P872, DOI 10.1038/npp.2012.253
   Androutsellis Theotokis A, 2008, COLD SH Q B, V73, P403, DOI 10.1101/sqb.2008.73.018
   Anthony BA, 2014, TRENDS IMMUNOL, V35, P32, DOI 10.1016/j.it.2013.10.002
   Asselin Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Aubin JE, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P85, DOI 10.1016/B978 0 12 373884 4.00026 4
   Ballen KK, 2007, BIOL BLOOD MARROW TR, V13, P838, DOI 10.1016/j.bbmt.2007.03.007
   Barkho BZ, 2011, CURR STEM CELL RES T, V6, P327
   BEZIN GI, 1975, BLOOD, V46, P79
   Bhaskar B, 2014, CURR STEM CELL RES T, V9, P508, DOI 10.2174/1574888X09666140812112002
   Booth C, 2004, CELL PROLIFERAT, V37, P385, DOI 10.1111/j.1365 2184.2004.00320.x
   Brent G A., 2011, Williams textbook of endocrinology, V12th, P406
   Brunner S, 2007, AM J PHYSIOL ENDOC M, V293, pE1670, DOI 10.1152/ajpendo.00287.2007
   Burgess RJ, 2014, J INTERN MED, V276, P12, DOI 10.1111/joim.12247
   Bylund M, 2003, NAT NEUROSCI, V6, P1162, DOI 10.1038/nn1131
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Calza L, 2002, P NATL ACAD SCI USA, V99, P3258, DOI 10.1073/pnas.052704499
   Calzà L, 2010, J MOL ENDOCRINOL, V44, P13, DOI 10.1677/JME 09 0067
   Chadipiralla K, 2010, CELL TISSUE RES, V340, P323, DOI 10.1007/s00441 010 0953 0
   Chell JM, 2010, CELL, V143, P1161, DOI 10.1016/j.cell.2010.12.007
   Chen ZY, 2007, J BIOL CHEM, V282, P25875, DOI 10.1074/jbc.M701988200
   Christophidis LJ, 2009, GROWTH HORM IGF RES, V19, P497, DOI 10.1016/j.ghir.2009.05.001
   Cianfarani F, 2013, WOUND REPAIR REGEN, V21, P545, DOI 10.1111/wrr.12051
   Cimadamore F, 2011, CELL STEM CELL, V8, P538, DOI 10.1016/j.stem.2011.03.011
   Crews FT, 2004, ALCOHOL, V33, P63, DOI 10.1016/j.alcohol.2004.04.005
   David DJ, 2009, NEURON, V62, P479, DOI 10.1016/j.neuron.2009.04.017
   de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955 0674(00)00276 3
   Derfoul A, 2006, STEM CELLS, V24, P1487, DOI 10.1634/stemcells.2005 0415
   DESIMONE M, 1995, INT J OBESITY, V19, P851
   Dias CC, 2015, J CELL BIOCHEM, V116, P1334, DOI 10.1002/jcb.25090
   Domenice S, 2001, J CLIN ENDOCR METAB, V86, P4068, DOI 10.1210/jc.86.9.4068
   Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911
   Dubovsky AN, 2012, PSYCHOSOMATICS, V53, P103, DOI 10.1016/j.psym.2011.12.007
   During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919
   Dygai A., 2014, THEORY HEMATOPOIESIS
   EISSELE R, 1991, GASTROENTEROLOGY, V101, P70, DOI 10.1016/0016 5085(91)90461 S
   Elias LLK, 2000, CLIN ENDOCRINOL, V53, P423, DOI 10.1046/j.1365 2265.2000.01122.x
   Ercan E, 2014, ACTA HISTOCHEM, V116, P117, DOI 10.1016/j.acthis.2013.06.007
   Evans JF, 2004, BONE, V35, P96, DOI 10.1016/j.bone.2004.03.015
   Evans JF, 2013, CELL TISSUE RES, V352, P413, DOI 10.1007/s00441 013 1561 6
   Feizpour A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108974
   Feldman BJ, 2006, P NATL ACAD SCI USA, V103, P15675, DOI 10.1073/pnas.0607501103
   Fernandez M, 2004, EUR J NEUROSCI, V20, P2059, DOI 10.1111/j.1460 9568.2004.03664.x
   Freund C, 2008, STEM CELLS, V26, P724, DOI 10.1634/stemcells.2007 0617
   Gagnon J, 2015, DIABETES, V64, P1513, DOI 10.2337/db14 1176
   Gago N, 2003, MOL CELL NEUROSCI, V22, P162, DOI 10.1016/S1044 7431(02)00030 1
   Gao MJ, 2012, PEPTIDES, V34, P373, DOI 10.1016/j.peptides.2012.02.006
   Gargett CE, 2008, MOL CELL ENDOCRINOL, V288, P22, DOI 10.1016/j.mce.2008.02.026
   Garrett RW, 2008, MOL CELL ENDOCRINOL, V288, P6, DOI 10.1016/j.mce.2008.02.022
   Garrison AP, 2009, AM J PHYSIOL GASTR L, V296, pG643, DOI 10.1152/ajpgi.90588.2008
   Gattazzo F, 2014, BBA GEN SUBJECTS, V1840, P2506, DOI 10.1016/j.bbagen.2014.01.010
   Ge RL, 2002, J APPL PHYSIOL, V92, P2361, DOI 10.1152/japplphysiol.00684.2001
   Ghasroldasht MM, 2014, CELL BIOL INT, V38, P1081, DOI 10.1002/cbin.10293
   Ghatei MA, 2001, DIGEST DIS SCI, V46, P1255, DOI 10.1023/A:1010615429639
   Ghorbani A, 2013, HORM METAB RES, V45, P221, DOI 10.1055/s 0032 1323764
   Ghorbani A, 2011, EXP CLIN ENDOCR DIAB, V119, P343, DOI 10.1055/s 0031 1275662
   Ghorbani A, 2014, DARU, V22, DOI 10.1186/2008 2231 22 26
   Ghorbani A, 2014, TISSUE CELL, V46, P54, DOI 10.1016/j.tice.2013.11.002
   Ghorbani Ahmad, 2014, Pak J Biol Sci, V17, P523, DOI 10.3923/pjbs.2014.523.528
   GONG JK, 1978, SCIENCE, V199, P1443, DOI 10.1126/science.75570
   Gopalakrishnan V, 2006, BIOCHEM CELL BIOL, V84, P93, DOI 10.1139/O05 163
   Gordan LN, 2003, LEUKEMIA LYMPHOMA, V44, P815, DOI 10.1080/1042819031000067585
   Gosney E., 2012, The Open Endocrinology Journal, V6, P34, DOI DOI 10.2174/1874216501206010034
   Hale LP, 2004, J IMMUNOL, V172, P617, DOI 10.4049/jimmunol.172.1.617
   Han J, 2008, MOL CELL NEUROSCI, V39, P118, DOI 10.1016/j.mcn.2008.06.003
   HAVU N, 1986, DIGESTION, V35, P42, DOI 10.1159/000199381
   Hayakawa Y, 2015, GUT, V64, P544, DOI 10.1136/gutjnl 2014 307190
   Heeschen C, 2003, BLOOD, V102, P1340, DOI 10.1182/blood 2003 01 0223
   Heile AMB, 2009, NEUROSCI LETT, V463, P176, DOI 10.1016/j.neulet.2009.07.071
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Ho VT, 1996, BIOCHEM BIOPH RES CO, V223, P175, DOI 10.1006/bbrc.1996.0865
   Holst JJ, 2004, AM J PHYSIOL ENDOC M, V287, pE199, DOI 10.1152/ajpendo.00545.2003
   Hopkins DFC, 1997, DIABETIC MED, V14, P1044, DOI 10.1002/(SICI)1096 9136(199712)14:12<1044::AID DIA508>3.0.CO;2 F
   Hu XY, 2014, STEM CELLS, V32, P2702, DOI 10.1002/stem.1784
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huber BC, 2010, AM J PHYSIOL HEART C, V298, pH1466, DOI 10.1152/ajpheart.00033.2010
   Hui HX, 2010, PANCREAS, V39, P315, DOI 10.1097/MPA.0b013e3181bc30dd
   Imamine H, 2005, TOHOKU J EXP MED, V205, P123, DOI 10.1620/tjem.205.123
   Isales CM, 2010, ANN NY ACAD SCI, V1192, P110, DOI 10.1111/j.1749 6632.2009.05231.x
   Ishizuya Oka A, 2008, MOL CELL ENDOCRINOL, V288, P71, DOI 10.1016/j.mce.2008.02.020
   Ishizuya Oka A, 2009, FASEB J, V23, P2568, DOI 10.1096/fj.08 128124
   Ito S, 2007, BONE, V40, P84, DOI 10.1016/j.bone.2006.07.012
   Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702 010 0495 3
   Jeon YK, 2014, ENDOCRINOL METAB, V29, P567, DOI 10.3803/EnM.2014.29.4.567
   Jiang Yuling, 2008, Sheng Wu Gong Cheng Xue Bao, V24, P1216
   Joddar B, 2013, J BIOTECHNOL, V168, P218, DOI 10.1016/j.jbiotec.2013.04.021
   Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003
   KASSEM M, 1993, CALCIFIED TISSUE INT, V52, P222, DOI 10.1007/BF00298723
   Khairallah M I, 2014, Pak J Biol Sci, V17, P9
   KHAITOV RM, 1975, BLOOD, V46, P73
   Kim AC, 2007, MOL CELL ENDOCRINOL, V265, P10, DOI 10.1016/j.mce.2006.12.028
   Kim H, 2008, FEBS LETT, V582, P3509, DOI 10.1016/j.febslet.2008.09.021
   Kim YS, 2006, J ORTHOP RES, V24, P1756, DOI 10.1002/jor.20197
   Klinge PM, 2011, NEUROSCI LETT, V497, P6, DOI 10.1016/j.neulet.2011.03.092
   Klopsch C, 2009, J CELL MOL MED, V13, P664, DOI 10.1111/j.1582 4934.2008.00546.x
   Knippenberg S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036857
   KOLDOVSKY O, 1985, PEDIATRICS, V75, P199
   Lang BT, 2009, BRAIN RES, V1258, P25, DOI 10.1016/j.brainres.2008.12.026
   Lavoie JR, 2013, BIOCHIMIE, V95, P2212, DOI 10.1016/j.biochi.2013.06.017
   Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209
   LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644
   Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99
   Lee MJ, 2014, BBA MOL BASIS DIS, V1842, P473, DOI 10.1016/j.bbadis.2013.05.029
   Lemkine GF, 2005, FASEB J, V19, P863, DOI 10.1096/fj.04 2916fje
   Li YM, 2007, BIOCHEM BIOPH RES CO, V363, P209, DOI 10.1016/j.bbrc.2007.08.161
   Lian XJ, 2013, STEM CELLS, V31, P447, DOI 10.1002/stem.1289
   Liu NM, 2013, EXP CELL RES, V319, P2019, DOI 10.1016/j.yexcr.2013.04.008
   Liu NM, 2011, EXP BIOL MED, V236, P1093, DOI 10.1258/ebm.2011.011001
   Lodish H, 2010, IUBMB LIFE, V62, P492, DOI 10.1002/iub.322
   López Juárez A, 2012, CELL STEM CELL, V10, P531, DOI 10.1016/j.stem.2012.04.008
   Luchetti F, 2014, J PINEAL RES, V56, P382, DOI 10.1111/jpi.12133
   Malafaya PB, 2010, TISSUE ENG PT A, V16, P735, DOI [10.1089/ten.tea.2008.0679, 10.1089/ten.TEA.2008.0679]
   Malaterre J, 2003, J NEUROBIOL, V56, P387, DOI 10.1002/neu.10244
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   MAOR G, 1989, ENDOCRINOLOGY, V125, P1239, DOI 10.1210/endo 125 3 1239
   Mazzocca AD, 2011, ARTHROSCOPY, V27, P1459, DOI 10.1016/j.arthro.2011.06.029
   McDevitt TC, 2005, J MOL CELL CARDIOL, V39, P865, DOI 10.1016/j.yjmcc.2005.09.007
   McLenachan S, 2009, GROWTH HORM IGF RES, V19, P212, DOI 10.1016/j.ghir.2008.09.003
   McLeod CJ, 2010, CURR BIOL, V20, P2100, DOI 10.1016/j.cub.2010.10.038
   Melmed S., 2011, Williams Textbook of Endocrinology, V12th, P175
   Messenger AG, 2000, BRIT J DERMATOL, V142, P633, DOI 10.1046/j.1365 2133.2000.03521.x
   MICKLEM H. S., 1966, TRANSPLANTATION, V4, P732
   Mihaylova MM, 2014, CELL STEM CELL, V14, P292, DOI 10.1016/j.stem.2014.02.008
   Naderi Meshkin H, 2015, KNOWLEDGE HLTH, V9, P38
   Naderi Meshkin H, 2015, CELL BIOL INT
   Naderi Meshkin H, 2015, CELL BIOL INT, V39, P23, DOI 10.1002/cbin.10378
   Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825
   Nair AM, 2013, BIOMATERIALS, V34, P7364, DOI 10.1016/j.biomaterials.2013.06.031
   Ogueta S, 2002, MOL CELL ENDOCRINOL, V190, P51, DOI 10.1016/S0303 7207(02)00013 8
   Ohyama M, 2006, J CLIN INVEST, V116, P249, DOI 10.1172/JCI26043
   Orbay H, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/461718
   Otaegi G, 2006, J CELL SCI, V119, P2739, DOI 10.1242/jcs.03012
   Ou CY, 2014, J BIOL CHEM, V289, P17078, DOI 10.1074/jbc.M114.548081
   Pan WH, 2005, ENDOCRINOLOGY, V146, P4898, DOI 10.1210/en.2005 0587
   Pathipati P, 2011, NEUROSCIENCE, V190, P409, DOI 10.1016/j.neuroscience.2011.05.029
   Pavlica S, 2012, BRAIN RES, V1452, P18, DOI 10.1016/j.brainres.2012.02.043
   Pena Bello L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121087
   Pignatelli D, 2002, ENDOCR RES, V28, P683, DOI 10.1081/ERC 120016987
   Pilhatsch M, 2010, BEHAV BRAIN RES, V214, P187, DOI 10.1016/j.bbr.2010.05.016
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   Quesenberry PJ, 2014, STEM CELLS DEV, V23, P1429, DOI 10.1089/scd.2013.0594
   Rafalski VA, 2011, PROG NEUROBIOL, V93, P182, DOI 10.1016/j.pneurobio.2010.10.007
   Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1
   Rölfing JHD, 2014, STEM CELL REV REP, V10, P69, DOI 10.1007/s12015 013 9476 x
   Sammons J, 2004, STEM CELLS DEV, V13, P273, DOI 10.1089/154732804323099208
   Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328
   Sanz C, 2010, AM J PHYSIOL ENDOC M, V298, pE634, DOI 10.1152/ajpendo.00460.2009
   Sato K, 1998, ARCH HISTOL CYTOL, V61, P75, DOI 10.1679/aohc.61.75
   Shi WZ, 2014, BIOCHEM BIOPH RES CO, V447, P95, DOI 10.1016/j.bbrc.2014.03.112
   Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21 24 09733.2001
   STARKMAN MN, 1992, BIOL PSYCHIAT, V32, P756, DOI 10.1016/0006 3223(92)90079 F
   Stewart P M e., 2011, Williams Textbook of Endocrinology, V12th, P479
   Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992
   Strader AD, 2005, GASTROENTEROLOGY, V128, P175, DOI 10.1053/j.gastro.2004.10.043
   Sundberg M, 2006, J NEUROSCI, V26, P5402, DOI 10.1523/JNEUROSCI.4906 05.2006
   Takaya K, 2000, J CLIN ENDOCR METAB, V85, P4908, DOI 10.1210/jc.85.12.4908
   Tang QQ, 2012, ANNU REV BIOCHEM, V81, P715, DOI 10.1146/annurev biochem 052110 115718
   Thomas GA, 2013, SPORTS MED, V43, P839, DOI 10.1007/s40279 013 0064 7
   Thomas RP, 2003, ENDOCR REV, V24, P571, DOI 10.1210/er.2002 0028
   Tiede S, 2010, EUR J CELL BIOL, V89, P769, DOI 10.1016/j.ejcb.2010.06.002
   Tiede S, 2009, STEM CELLS, V27, P2793, DOI 10.1002/stem.213
   Tofighi R, 2011, METHODS MOL BIOL, V758, P67, DOI 10.1007/978 1 61779 170 3_5
   Tsukazaki T, 1994, Osteoarthritis Cartilage, V2, P259, DOI 10.1016/S1063 4584(05)80078 0
   Um S, 2011, ORAL DIS, V17, P662, DOI 10.1111/j.1601 0825.2011.01820.x
   van Beek N, 2008, J CLIN ENDOCR METAB, V93, P4381, DOI 10.1210/jc.2008 0283
   Venero C, 2005, GENE DEV, V19, P2152, DOI 10.1101/gad.346105
   Vicennati V, 2002, J CLIN ENDOCR METAB, V87, P3984, DOI 10.1210/jc.87.8.3984
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Wagers AJ, 2012, CELL STEM CELL, V10, P362, DOI 10.1016/j.stem.2012.02.018
   Wang L, 2007, BLOOD, V110, P4111, DOI 10.1182/blood 2007 03 082586
   Wang SN, 2012, STEM CELL RES, V8, P346, DOI 10.1016/j.scr.2011.12.005
   Wang Y, 2010, NEUROSCIENCE, V167, P750, DOI 10.1016/j.neuroscience.2010.02.007
   Wang Ya Nan, 2014, Sichuan Da Xue Xue Bao Yi Xue Ban, V45, P552
   Waseem T, 2014, PEPTIDES, V52, P113, DOI 10.1016/j.peptides.2013.11.021
   Watanabe J, 2015, PEPTIDES, V69, P40, DOI 10.1016/j.peptides.2015.03.014
   Weil BR, 2009, AM J PHYSIOL REG I, V296, pR1735, DOI 10.1152/ajpregu.90876.2008
   Wright EJ, 2012, STEM CELL TRANSL MED, V1, P759, DOI 10.5966/sctm.2012 0064
   Wu TY, 2014, CURR STEM CELL RES T, V9, P424, DOI 10.2174/1574888X09666140616125446
   Xu XQ, 2008, DIFFERENTIATION, V76, P958, DOI 10.1111/j.1432 0436.2008.00284.x
   Yan JL, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.002238
   Ye N, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896 015 0176 2
   Yeung TM, 2011, CELL MOL LIFE SCI, V68, P2513, DOI 10.1007/s00018 011 0687 5
   Yue FM, 2006, TISSUE ENG, V12, P2105, DOI 10.1089/ten.2006.12.2105
   Zaidi M, 2010, P NATL ACAD SCI USA, V107, P8782, DOI 10.1073/pnas.0912176107
   Zhang Y, 2012, SCI WORLD J, DOI 10.1100/2012/793823
   Zhao YH, 2007, NEUROSCI LETT, V429, P49, DOI 10.1016/j.neulet.2007.09.076
   Zhong Q, 2005, BONE, V36, P820, DOI 10.1016/j.bone.2005.01.020
   Zhou JG, 2005, STEROIDS, V70, P407, DOI 10.1016/j.steroids.2005.02.006
   Zhou Z, 2012, NUTR METAB, V9, DOI 10.1186/1743 7075 9 109
NR 194
TC 10
Z9 11
U1 0
U2 23
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574 888X
EI 2212 3946
J9 CURR STEM CELL RES T
JI Curr. Stem Cell Res. Ther.
PY 2016
VL 11
IS 1
BP 19
EP 34
DI 10.2174/1574888X10666150904113625
PG 16
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DB1UV
UT WOS:000368295400003
PM 26337380
DA 2025 08 17
ER

PT J
AU Boucharaba, A
   Serre, CM
   Guglielmi, J
   Bordet, JC
   Clézardin, P
   Peyruchaud, O
AF Boucharaba, Ahmed
   Serre, Claire Marie
   Guglielmi, Julien
   Bordet, Jean Claude
   Clezardin, Philippe
   Peyruchaud, Olivier
TI The type 1 lysophosphatidic acid receptor is a target for therapy in
   bone metastases
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE breast cancer; platelet; treatment
ID PROTEIN COUPLED RECEPTOR; HORMONE RELATED PROTEIN; BREAST CANCER CELLS;
   MOLECULAR CLONING; EXPRESSION; SUBTYPE; ANTAGONIST; RESORPTION
AB Platelet derived lysophosphatidic acid (LPA) supports the progression of breast and ovarian cancer metastasis to bone. The mechanisms through which LPA promotes bone metastasis formation are, however, unknown. Here we report that silencing of the type 1 LPA receptor (LPA(1)) in cancer cells blocks the production of tumor derived cytokines that are potent activators of osteoclast mediated bone destruction and significantly reduces the progression of osteolytic bone metastases. Moreover, functional blockade of LPA action on its cognate receptor LPA(1) using a pharmacological antagonist mimics the effects of silencing LPA(1) in tumor cells in vitro and substantially reduces bone metastasis progression in animals. Overall, these results suggest that inhibition of platelet derived LPA action on LPA, expressed by tumor cells may be a promising therapeutic target for patients with bone metastases.
C1 INSERM, U664, F 69372 Lyon, France.
   Univ Lyon 1, F 69008 Lyon, France.
   Fac med Laennec, EA 3735, Lab Hemobiol, F 69008 Lyon, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; Universite Claude Bernard Lyon 1
RP Peyruchaud, O (通讯作者)，INSERM, U664, F 69372 Lyon, France.
EM peyruchaud@lyon.inserm.fr
RI ; Clezardin, Philippe/M 8071 2014
OI BORDET, Jean Claude/0000 0003 1498 703X; Peyruchaud,
   Olivier/0000 0002 5393 4945; Clezardin, Philippe/0000 0003 0149 4463
CR An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906
   An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150
   Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200
   Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200
   Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776
   Bendre MS, 2002, CANCER RES, V62, P5571
   Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123
   DELAMATA J, 1995, J CLIN INVEST, V95, P2846, DOI 10.1172/JCI117990
   Falanga A, 2004, J THROMB HAEMOST, V2, P1263, DOI 10.1111/j.1538 7836.2004.00868.x
   Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200
   Fang XJ, 2002, BBA MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388 1981(02)00179 8
   Fischer DJ, 2001, MOL PHARMACOL, V60, P776
   Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200
   Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   Kitayama J, 2004, BREAST CANCER RES, V6, pR640, DOI 10.1186/bcr935
   Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nash GF, 2002, LANCET ONCOL, V3, P425, DOI 10.1016/S1470 2045(02)00789 1
   Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994
   Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01 0911fje
   Peyruchaud O, 2003, J BIOL CHEM, V278, P45826, DOI 10.1074/jbc.M309024200
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Sardar VM, 2002, BBA MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388 1981(02)00185 3
   Schulte KM, 2001, INT J CANCER, V92, P249, DOI 10.1002/1097 0215(200102)9999:9999<::AID IJC1166>3.0.CO;2 D
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Varki NM, 2002, SEMIN THROMB HEMOST, V28, P53, DOI 10.1055/s 2002 20564
   Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102
NR 28
TC 172
Z9 215
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 20
PY 2006
VL 103
IS 25
BP 9643
EP 9648
DI 10.1073/pnas.0600979103
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 058JD
UT WOS:000238660400047
PM 16769891
OA Green Published
DA 2025 08 17
ER

PT J
AU Huang, JB
   Zhou, L
   Wu, HF
   Pavlos, N
   Chim, SM
   Liu, Q
   Zhao, JM
   Xue, W
   Tan, RX
   Ye, JM
   Xu, J
   Ang, ES
   Feng, HT
   Tickner, J
   Xu, JK
   Ding, Y
AF Huang, Jianbin
   Zhou, Lin
   Wu, Huafei
   Pavlos, Nathan
   Chim, Shek Man
   Liu, Qian
   Zhao, Jinmin
   Xue, Wei
   Tan, Ren Xiang
   Ye, Jiming
   Xu, Jun
   Ang, Estabelle S.
   Feng, Haotian
   Tickner, Jennifer
   Xu, Jiake
   Ding, Yue
TI Triptolide inhibits osteoclast formation, bone resorption,
   RANKL mediated NF κB activation and titanium particle induced osteolysis
   in a mouse model
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Triptolide; Osteoclastogenesis; RANKL; NF kappa B; Osteolysis; Titanium
   particle
ID WILFORDII HOOK F; RECEPTOR ACTIVATOR; RHEUMATOID ARTHRITIS;
   EPITHELIAL CELLS; CHINESE HERB; EXPRESSION; LIGAND; DIFFERENTIATION;
   APOPTOSIS; EXTRACT
AB The RANKL induced NF kappa B signaling pathway is required for osteoclast formation and function. By screening for compounds that inhibit RANKL induced NF kappa B activation using a luciferase reporter gene assay in RAW264.7 cells, we identified triptolide (PG490), as a candidate compound targeting osteoclast differentiation and osteoclast mediated osteolysis. Triptolide (PG490) is an active compound of the medicinal herb Tripterygium wilfordii Hook F (TWHF) or Lei Gong Teng with known anti inflammatory properties. We found that triptolide inhibited osteoclastogenesis and bone resorption, as well as RANKL induced NF kappa B activities as monitored by luciferase reporter gene assays and the nuclear translocation of p65. In vivo studies showed that triptolide attenuates titanium induced osteolysis and osteoclast formation in a mouse calvarial model. Considering that drugs which protect against localized bone loss are critically needed for the effective treatment of particle induced osteolysis, our data suggest that triptolide might have therapeutic potential for the treatment of bone lytic diseases caused by prosthetic wear particles. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Huang, Jianbin; Ding, Yue] Sun Yat Sen Univ, Mem Hosp, Dept Orthopaed, Guangzhou 510275, Guangdong, Peoples R China.
   [Zhou, Lin; Wu, Huafei; Chim, Shek Man; Liu, Qian; Feng, Haotian; Tickner, Jennifer; Xu, Jiake] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia.
   [Wu, Huafei; Pavlos, Nathan] Univ Western Australia, Sch Surg, Ctr Orthopaed Res, Perth, WA 6009, Australia.
   [Liu, Qian; Zhao, Jinmin] Guangxi Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Res Ctr Regenerat Med, Guangxi 530021, Peoples R China.
   [Xue, Wei] Jinan Univ, Dept Biomed Engn, Guangdong Higher Educ Inst, Key Lab Biomat, Guangzhou 510632, Guangdong, Peoples R China.
   [Tan, Ren Xiang] Nanjing Univ, Sch Med, Inst Funct Biomol, Nanjing 210093, Jiangsu, Peoples R China.
   [Ye, Jiming] RMIT Univ, Hlth Innovat Res Inst, Melbourne, Vic 3083, Australia.
   [Ye, Jiming] RMIT Univ, Sch Hlth Sci, Melbourne, Vic 3083, Australia.
   [Xu, Jun] Sun Yat Sen Univ, Sch Pharmaceut Sci, Res Ctr Drug Discovery, Guangzhou 510006, Guangdong, Peoples R China.
   [Ang, Estabelle S.] Univ Western Australia, Sch Dent, Perth, WA 6009, Australia.
   [Feng, Haotian] Nestle R&D China Ltd, Program Nutr & Bone & Joint Hlth, Beijing 100095, Peoples R China.
C3 Sun Yat Sen University; University of Western Australia; University of
   Western Australia; Guangxi Medical University; Jinan University; Nanjing
   University; Royal Melbourne Institute of Technology (RMIT); Royal
   Melbourne Institute of Technology (RMIT); Sun Yat Sen University;
   University of Western Australia
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Pathol & Lab Med, Nedlands, WA 6009, Australia.
EM jiake.xu@uwa.edu.au; dingyue36@126.com
RI zhao, jin/LBH 0351 2024; Xu, Jun/A 3865 2010; Tickner,
   Jennifer/H 5965 2014; Chim, Shek/AAK 6809 2020
OI Xu, Jiake/0000 0003 2021 8309; Tickner, Jennifer/0000 0002 5020 0671;
   Pavlos, Nathan/0000 0001 7003 188X; Zhao, Jinmin/0000 0002 1047 8820;
   Yue, Ding/0000 0002 7781 1667
FU National Health and Medical Research Council of Australia [1010420];
   Arthritis Foundation of Western Australia; University of Western
   Australia Research Collaboration Awards; National Natural Science
   Foundation of China [81272020, 81228013]
FX This study was supported in part by the National Health and Medical
   Research Council of Australia (No. 1010420), Arthritis Foundation of
   Western Australia (2013), and University of Western Australia Research
   Collaboration Awards (2014). This work was also supported by funding
   from the National Natural Science Foundation of China (No. 81272020 and
   No. 81228013). Dr. Qian Liu has been a Visiting Scholar to the
   University of Western Australia. Prof. Jiake Xu was a visiting Professor
   to the Research Centre for Regenerative Medicine, Guangxi Medical
   University in 2013. The authors also acknowledge technical suggestions
   from Dr. An Qin, Jay Steer, Jacob Kenny, Dian Teguh and Prof. Ming
   Zheng, and equipment operation assistance from the Centre for
   Microscopy, Characterisation and Analysis (CMCA) of The University of
   Western Australia.
CR Ang E, 2009, J CELL PHYSIOL, V220, P450, DOI 10.1002/jcp.21787
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Brage M, 2004, BONE, V34, P412, DOI 10.1016/j.bone.2003.11.018
   Chen BJ, 2001, LEUKEMIA LYMPHOMA, V42, P253, DOI 10.3109/10428190109064582
   Dai YQ, 2006, NEUROSCI RES, V55, P154, DOI 10.1016/j.neures.2006.02.013
   Fidler JM, 2003, MOL CANCER THER, V2, P855
   Goodman SB, 2006, BIOMATERIALS, V27, P6096, DOI 10.1016/j.biomaterials.2006.08.023
   Hu Yonghong, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P344
   Jones DH, 2002, ANN RHEUM DIS, V61, P32, DOI 10.1136/ard.61.suppl_2.ii32
   Kiviharju TM, 2002, CLIN CANCER RES, V8, P2666
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kusunoki Natsuko, 2004, BMC Pharmacology, V4, P2, DOI 10.1186/1471 2210 4 2
   Lou YJ, 2005, LEUKEMIA RES, V29, P99, DOI 10.1016/j.leukres.2004.05.014
   Matta R, 2009, AM J TRANSL RES, V1, P267
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Pavlos NJ, 2011, MOL CELL BIOL, V31, P1551, DOI 10.1128/MCB.00834 10
   Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Tao XL, 2002, ARTHRITIS RHEUM, V46, P1735, DOI 10.1002/art.10411
   Tao XL, 2000, RHEUM DIS CLIN N AM, V26, P29, DOI 10.1016/S0889 857X(05)70118 6
   Tao XL, 2001, J RHEUMATOL, V28, P2160
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wang ML, 2004, J ARTHROPLASTY, V19, P1028, DOI 10.1016/j.arth.2004.03.024
   Wang X, 2008, NEUROCHEM RES, V33, P1956, DOI 10.1007/s11064 008 9691 z
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
   Xiao Cheng, 2009, Chin Med, V4, P13, DOI 10.1186/1749 8546 4 13
   Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yang SM, 2003, MOL CANCER THER, V2, P65
   Yao Gen Hong, 2008, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V16, P506
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yip KHM, 2006, AM J PATHOL, V169, P503, DOI 10.2353/ajpath.2006.050960
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Zhao GH, 2000, AM J PHYSIOL LUNG C, V279, pL958, DOI 10.1152/ajplung.2000.279.5.L958
   Zhu WB, 2009, MOL PHARMACOL, V75, P812, DOI 10.1124/mol.108.052605
NR 37
TC 38
Z9 43
U1 2
U2 52
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JAN 5
PY 2015
VL 399
IS C
BP 346
EP 353
DI 10.1016/j.mce.2014.10.016
PG 8
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA CA4MI
UT WOS:000348877700037
PM 25448849
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Shoaib, Z
   Fan, TM
   Irudayaraj, JMK
AF Shoaib, Zunaira
   Fan, Timothy M.
   Irudayaraj, Joseph M. K.
TI Osteosarcoma mechanobiology and therapeutic targets
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE 3D cell culture; bisphosphonates; bone remodelling; bone sarcoma;
   mechanobiology; mechanotransduction; osteosarcoma; pharmacology; therapy
ID HISTONE DEACETYLASE INHIBITOR; NF KAPPA B; C TERMINAL TELOPEPTIDE;
   PAGETS DISEASE; RECEPTOR ACTIVATOR; LUNG METASTASIS; COLLAGEN MATRIX;
   DOWN REGULATION; FOCAL ADHESION; BREAST CANCER
AB Osteosarcoma is one of the most common primary tumours of the bone, with a 5 year survival rate of less than 20% after the development of metastases. Osteosarcoma is highly predisposed in Paget's disease of the bone, and both have common characteristic skeletal features due to rapid bone remodelling. Osteosarcoma prognosis is location dependent, which further emphasizes the likely contribution of the bone microenvironment in its pathogenesis. Mechanobiology describes the processes involved when mechanical cues from the changing physical microenvironment of the bone are transduced to biological pathways through mechanosensitive cellular components. Mechanobiology driven therapies have been used to curb tumour progression by direct alteration of the physical microenvironment or inhibition of metastasis associated mechanosensitive proteins. This review emphasizes the contribution of mechanobiology to the progression of osteosarcoma and sheds light on current mechanobiology based therapies and potential new targets for improving disease management. Additionally, the many different 3D models currently used to study osteosarcoma mechanobiology are summarized.
C1 [Shoaib, Zunaira] Univ Illinois, Dept Pathobiol, Urbana, IL USA.
   [Fan, Timothy M.] Univ Illinois, Dept Vet Clin Med, Urbana, IL USA.
   [Fan, Timothy M.; Irudayaraj, Joseph M. K.] Univ Illinois, Canc Ctr Illinois, Urbana, IL 61820 USA.
   [Irudayaraj, Joseph M. K.] Univ Illinois, Dept Bioengn, Nick Holonyak Micro & Nanotechnol Lab, Urbana, IL USA.
   [Irudayaraj, Joseph M. K.] Carle Fdn Hosp, Biomed Res Ctr, Urbana, IL USA.
C3 University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign
RP Fan, TM; Irudayaraj, JMK (通讯作者)，Univ Illinois, Canc Ctr Illinois, Urbana, IL 61820 USA.
EM t fan@illinois.edu; jirudaya@illinois.edu
OI Fan, Timothy/0000 0003 2510 7050; Irudayaraj, Joseph/0000 0002 0630 1520
CR Alexander SPH, 2021, BRIT J PHARMACOL, V178, pS313, DOI 10.1111/bph.15542
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS1, DOI 10.1111/bph.14747
   Anderson ME, 2016, ORTHOP CLIN N AM, V47, P283, DOI 10.1016/j.ocl.2015.08.022
   Bai X, 2018, BIOACT MATER, V3, P401, DOI 10.1016/j.bioactmat.2018.05.006
   Bandyopadhyay O, 2019, J DIGIT IMAGING, V32, P300, DOI 10.1007/s10278 018 0145 0
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Boerman I, 2012, BMC VET RES, V8, DOI 10.1186/1746 6148 8 56
   Brown HK, 2017, CANCER LETT, V386, P189, DOI 10.1016/j.canlet.2016.11.019
   Bulut G, 2012, ONCOGENE, V31, P269, DOI 10.1038/onc.2011.245
   Cai Y, 2014, J CELL BIOCHEM, V115, P625, DOI 10.1002/jcb.24708
   Capobianco E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095596
   Çelik H, 2016, J BIOL CHEM, V291, P13257, DOI 10.1074/jbc.M116.718189
   Chaddad H, 2017, EXP CELL RES, V360, P138, DOI 10.1016/j.yexcr.2017.08.035
   Chaiyawat P, 2020, J BONE ONCOL, V25, DOI 10.1016/j.jbo.2020.100321
   Charras G, 2014, NAT REV MOL CELL BIO, V15, P813, DOI 10.1038/nrm3897
   Chen Y, 2013, P NATL ACAD SCI USA, V110, pE2352, DOI 10.1073/pnas.1221637110
   Codelia VA, 2014, CURR BIOL, V24, P2012, DOI 10.1016/j.cub.2014.07.034
   Cole HA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097381
   Cook MR, 2022, VET COMP ONCOL, V20, P82, DOI 10.1111/vco.12741
   Cooper DML, 2016, CURR OSTEOPOROS REP, V14, P187, DOI 10.1007/s11914 016 0319 y
   Cui Y, 2017, WIRES NANOMED NANOBI, V9, DOI 10.1002/wnan.1443
   Cui Y, 2015, NUCLEIC ACIDS RES, V43, P3046, DOI 10.1093/nar/gkv098
   Damayanti NP, 2017, ACS SENSORS, V2, P1225, DOI 10.1021/acssensors.7b00359
   Danieau G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153751
   Daroszewska A, 2004, J BONE MINER RES, V19, P1506, DOI 10.1359/JBMR.040602
   Deng ZT, 2016, INT J BIOL SCI, V12, P1298, DOI 10.7150/ijbs.16569
   Di Cristofano C, 2010, MODERN PATHOL, V23, P1012, DOI 10.1038/modpathol.2010.77
   Dickerson ME, 2001, J VET INTERN MED, V15, P120, DOI 10.1892/0891 6640(2001)015<0120:RAOASO>2.3.CO;2
   Domingues C, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00678
   Dong CJ, 2016, POLYMERS BASEL, V8, DOI 10.3390/polym8020042
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Du XL, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 450
   Elosegui Artola A, 2017, CELL, V171, P1397, DOI 10.1016/j.cell.2017.10.008
   Endo Munoz L, 2012, BBA REV CANCER, V1826, P434, DOI 10.1016/j.bbcan.2012.07.003
   Endo Munoz L, 2010, CANCER RES, V70, P7063, DOI 10.1158/0008 5472.CAN 09 4291
   Fan TMM, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00013
   Fang Fang, 2018, Oncotarget, V9, P36780, DOI 10.18632/oncotarget.26377
   Feng Helin, 2018, Oncotarget, V9, P27087, DOI 10.18632/oncotarget.25484
   Ferguson JL, 2018, AM FAM PHYSICIAN, V98, P205
   Fledelius C, 1997, J BIOL CHEM, V272, P9755
   Garnero P, 1997, J BONE MINER RES, V12, P1407, DOI 10.1359/jbmr.1997.12.9.1407
   Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300
   Gennari L, 2019, CALCIFIED TISSUE INT, V104, P483, DOI 10.1007/s00223 019 00522 3
   Gong T, 2017, ONCOL LETT, V14, P6744, DOI 10.3892/ol.2017.6972
   Good DA, 2002, AM J HUM GENET, V70, P517, DOI 10.1086/338658
   Greco MR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042162
   Grier WK, 2017, EUR CELLS MATER, V33, P227, DOI 10.22203/eCM.v033a17
   Habas Raymond, 2005, J Biol, V4, P2, DOI 10.1186/jbiol22
   Hansen MF, 2006, J BONE MINER RES, V21, pP58, DOI 10.1359/JBMR.06S211
   He C, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148 018 0605 x
   HEYMAN SJ, 1992, VET SURG, V21, P304, DOI 10.1111/j.1532 950X.1992.tb00069.x
   Heymann D, 2012, J BONE ONCOL, V1, P2, DOI 10.1016/j.jbo.2012.03.001
   Hocking LJ, 2001, AM J HUM GENET, V69, P1055, DOI 10.1086/323798
   Holaska JM, 2006, ANAT REC PART A, V288A, P676, DOI 10.1002/ar.a.20334
   Hoskín V, 2015, MOL BIOL CELL, V26, P3464, DOI 10.1091/mbc.E14 12 1584
   Hou CH, 2018, BIOCHEM PHARMACOL, V155, P71, DOI 10.1016/j.bcp.2018.06.015
   Howlader N., 2019, SEER cancer statistics review, 1975 2016, P1423
   Hsieh YH, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14030260
   Huang YJ, 2016, MOL MED REP, V13, P1888, DOI 10.3892/mmr.2015.4701
   Husari A, 2019, CELL SIGNAL, V63, DOI 10.1016/j.cellsig.2019.109382
   Le HQ, 2016, NAT CELL BIOL, V18, P864, DOI 10.1038/ncb3387
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674
   Jabbari E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132377
   Jana A, 2019, FASEB J, V33, P10618, DOI 10.1096/fj.201900131R
   Jiang YH, 2021, THERANOSTICS, V11, P3868, DOI 10.7150/thno.53347
   Juriga D, 2016, ACS APPL MATER INTER, V8, P23463, DOI 10.1021/acsami.6b06489
   Kim DH, 2015, BIOMATERIALS, V48, P161, DOI 10.1016/j.biomaterials.2015.01.023
   Kim DH, 2012, SCI REP UK, V2, DOI 10.1038/srep00555
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Lagoudakis M.G, 2008, EUROPEAN S BIOMEDICA, V1
   Leeming DJ, 2006, CANCER EPIDEM BIOMAR, V15, P1392, DOI 10.1158/1055 9965.EPI 05 0909
   Lewis DM, 2016, P NATL ACAD SCI USA, V113, P9292, DOI 10.1073/pnas.1605317113
   Li R, 2019, INT J BIOL MACROMOL, V123, P1035, DOI 10.1016/j.ijbiomac.2018.11.003
   Liao SS, 2004, J BIOMED MATER RES B, V69B, P158, DOI 10.1002/jbm.b.20035
   Lin JX, 2020, TISSUE ENG PART B RE, V26, P116, DOI [10.1089/ten.teb.2019.0243, 10.1089/ten.TEB.2019.0243]
   Liu WJ, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148 019 0620 6
   Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006 3495(00)76279 5
   Lucas GJA, 2006, J BONE MINER RES, V21, pP31, DOI 10.1359/JBMR.06S206
   Luu AK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207595
   Lv YF, 2015, SCI REP UK, V5, DOI 10.1038/srep12999
   Marchandet L, 2021, CANCERS, V13, DOI 10.3390/cancers13040683
   Marley K, 2015, EXP CELL RES, V338, P32, DOI 10.1016/j.yexcr.2015.08.001
   Martin Jeff W, 2012, Sarcoma, V2012, P627254, DOI 10.1155/2012/627254
   Mason DE, 2019, J CELL BIOL, V218, P1369, DOI 10.1083/jcb.201806065
   McGuire JJ, 2020, INT J CANCER, V147, P2811, DOI 10.1002/ijc.33046
   McNairn JDK, 2001, J MOL DIAGN, V3, P171, DOI 10.1016/S1525 1578(10)60669 1
   McQueen P, 2011, EXPERT REV ANTICANC, V11, P1223, DOI [10.1586/era.11.94, 10.1586/ERA.11.94]
   Michou L, 2011, JOINT BONE SPINE, V78, P252, DOI 10.1016/j.jbspin.2010.07.010
   Misaghi A, 2018, SICOT J, V4, DOI 10.1051/sicotj/2017028
   Misu S, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00027
   Monteiro MV, 2020, BIOMATER SCI UK, V8, P1855, DOI 10.1039/c9bm02075f
   Mori K, 2009, HISTOL HISTOPATHOL, V24, P235, DOI 10.14670/HH 24.235
   Morice S, 2020, CANCERS, V12, DOI 10.3390/cancers12123847
   Moya IM, 2019, NAT REV MOL CELL BIO, V20, P211, DOI 10.1038/s41580 018 0086 y
   Mozdzen LC, 2017, J MECH BEHAV BIOMED, V66, P28, DOI 10.1016/j.jmbbm.2016.10.017
   Mu XD, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/290368
   Müller DA, 2019, INT J DEV BIOL, V63, P1, DOI 10.1387/ijdb.190019us
   Nakai Y, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0036 5
   Nakatsuka K, 2003, J BONE MINER RES, V18, P1381, DOI 10.1359/jbmr.2003.18.8.1381
   Oh JH, 2006, CLIN ORTHOP RELAT R, P216, DOI 10.1097/01.blo.0000188063.56091.69
   Ohba T, 2014, J BONE MINER RES, V29, P1431, DOI 10.1002/jbmr.2182
   Osuna MAL, 2019, CANCER RES, V79, P1054, DOI 10.1158/0008 5472.CAN 18 1255
   Panciera T, 2017, NAT REV MOL CELL BIO, V18, P758, DOI 10.1038/nrm.2017.87
   Pettke A, 2016, ANTI CANCER DRUG, V27, P1001, DOI 10.1097/CAD.0000000000000418
   Piperno Neumann S, 2016, LANCET ONCOL, V17, P1070, DOI 10.1016/S1470 2045(16)30096 1
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Pobbati AV, 2020, THERANOSTICS, V10, P3622, DOI 10.7150/thno.40889
   Poudel B, 2014, ONCOL LETT, V7, P215, DOI 10.3892/ol.2013.1655
   Punzo Francesca, 2020, Oncotarget, V11, P2763, DOI 10.18632/oncotarget.27669
   R?dini, 2009, RECEPTOR ACTIVATOR N
   Rao Bindal K, 2013, CURR CANCER DRUG TAR, V13, P411, DOI 10.2174/1568009611313040005
   Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437
   Ren XY, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw4991
   Rothzerg E, 2021, J CELL PHYSIOL, V236, P1606, DOI 10.1002/jcp.29967
   Rousseau J, 2011, J BONE MINER RES, V26, P2452, DOI 10.1002/jbmr.455
   Rubio R, 2014, STEM CELLS, V32, P1136, DOI 10.1002/stem.1647
   Sekita A, 2017, BONE, V97, P83, DOI 10.1016/j.bone.2017.01.004
   Sekita A, 2016, MATER TRANS, V57, P2077, DOI 10.2320/matertrans.M2016341
   Sen B, 2015, STEM CELLS, V33, P3065, DOI 10.1002/stem.2090
   Shao XW, 2015, P NATL ACAD SCI USA, V112, pE2595, DOI 10.1073/pnas.1504837112
   Singer FR, 2016, CURR OSTEOPOROS REP, V14, P39, DOI 10.1007/s11914 016 0303 6
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Sparks AB, 2001, CALCIFIED TISSUE INT, V68, P151, DOI 10.1007/s002230001211
   Sun RR, 2016, ONCOTARGET, V7, P38333, DOI 10.18632/oncotarget.9518
   Tanaka T, 2013, CLIN EXP METASTAS, V30, P369, DOI 10.1007/s10585 012 9543 8
   Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361
   Tiffany AS, 2020, RSC ADV, V10, P26982, DOI 10.1039/d0ra03872e
   Tiffany AS, 2019, ACTA BIOMATER, V93, P86, DOI 10.1016/j.actbio.2019.05.031
   Torres HM, 2020, CANCER RES, V80, DOI 10.1158/1538 7445.AM2020 2917
   Tovazzi V, 2019, FUTURE ONCOL, V15, P2319, DOI 10.2217/fon 2019 0170
   Trinidad EM, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.12.10
   Tumaneng K, 2012, NAT CELL BIOL, V14, P1322, DOI 10.1038/ncb2615
   Turner CH, 1999, J BIOMECH, V32, P437, DOI 10.1016/S0021 9290(98)00177 8
   Viguet Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198 005 2035 9
   Wan X, 2009, ONCOGENE, V28, P3401, DOI 10.1038/onc.2009.206
   Warshaw J, 2017, ANAT REC, V300, P1189, DOI 10.1002/ar.23571
   Wei M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay6515
   Weitzman, 2020, IMPACT CELL GEOMETRY
   Xiao LW, 2011, CELL PHYSIOL BIOCHEM, V28, P297, DOI 10.1159/000331743
   Xie CH, 2016, ONCOTARGETS THER, V9, P4005, DOI 10.2147/OTT.S105418
   Yin Q, 2016, P NATL ACAD SCI USA, V113, pE4601, DOI 10.1073/pnas.1603316113
   Yu L, 2020, ACS APPL MATER INTER, V12, P18235, DOI 10.1021/acsami.0c00275
   Yuan Y, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 72552 z
   Yue S, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10081511
   Zanconato F, 2018, NAT MED, V24, P1599, DOI 10.1038/s41591 018 0158 8
   Zhou Q, 2021, MACROMOL BIOSCI, V21, DOI 10.1002/mabi.202000370
   Zimmermann EA, 2015, J BONE MINER RES, V30, P264, DOI 10.1002/jbmr.2340
   Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179
NR 149
TC 130
Z9 137
U1 10
U2 36
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD JAN
PY 2022
VL 179
IS 2
BP 201
EP 217
DI 10.1111/bph.15713
EA DEC 2021
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XW2QT
UT WOS:000732482100001
PM 34679192
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Park, SH
   Kim, JY
   Cheon, YH
   Baek, JM
   Ahn, SJ
   Yoon, KH
   Lee, MS
   Oh, J
AF Park, Sun Hyang
   Kim, Ju Young
   Cheon, Yoon Hee
   Baek, Jong Min
   Ahn, Sung Jun
   Yoon, Kwon Ha
   Lee, Myeung Su
   Oh, Jaemin
TI Protocatechuic Acid Attenuates Osteoclastogenesis by Downregulating
   JNK/c Fos/NFATc1 Signaling and Prevents Inflammatory Bone Loss in Mice
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE osteoclast; protocatechuic acid; RANKL; NFATc1; JNK; LPS
ID NF KAPPA B; C FOS; RECEPTOR ACTIVATOR; DIFFERENTIATION; DEGRADATION;
   CYANIDIN; PROTEIN; RICE
AB Protocatechuic acid (PCA) plays a critical role in nutritional metabolism; it is a major metabolite of anthocyanins, which are flavonoids with a range of health benefits. PCA has a variety of biological activities including anti oxidant, antiinflammatory, anti apoptosis, and anti microbial activities. However, the pharmacological effect of PCA, especially on osteoclastogenesis, remains unknown. We examined the effect of PCA on receptor activator of NF B ligand (RANKL) induced osteoclast differentiation and bone resorption. PCA dose dependently inhibited RANKL induced osteoclast differentiation in mouse bone marrow macrophages (BMMs) and suppressed the bone resorbing activity of mature osteoclasts. At the molecular level, PCA suppressed RANKL induced phosphorylation of JNK among MAPKs only, without significantly affecting the early signaling pathway. PCA also suppressed RANKL stimulated expression of c Fos and nuclear factor of activated T cells c1 (NFATc1) at the mRNA and protein levels, without altering c Fos mRNA expression. Additionally, PCA down regulated the expression of downstream osteoclastogenesis related genes including 3 integrin, DC STAMP, OC STAMP, Atp6v0d2, CTR, and CtsK. Mice treated with PCA efficiently recovered from lipopolysaccharide induced bone loss in vivo. Thus, PCA inhibits RANKL induced osteoclast differentiation and function by suppressing JNK signaling, c Fos stability, and expression of osteoclastic marker genes. These results suggest that PCA could be useful in treatment of inflammatory bone disorders. Copyright (c) 2016 John Wiley & Sons, Ltd.
C1 [Park, Sun Hyang; Baek, Jong Min; Ahn, Sung Jun; Oh, Jaemin] Wonkwang Univ, Sch Med, Dept Anat, 344 2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea.
   [Kim, Ju Young; Yoon, Kwon Ha; Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Cheon, Yoon Hee] Wonkwang Univ, Ctr Metab Funct Regulat, Iksan 570749, Jeonbuk, South Korea.
   [Yoon, Kwon Ha] Wonkwang Univ, Sch Med, Dept Radiol, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su] Wonkwang Univ, Dept Internal Med, Div Rheumatol, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University; Wonkwang University
RP Oh, J (通讯作者)，Wonkwang Univ, Sch Med, Dept Anat, 344 2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea.; Lee, MS (通讯作者)，Wonkwang Univ, Div Rheumatol, Dept Internal Med, Sch Med, 344 2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea.
EM ckhlms@wku.ac.kr; jmoh@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
FU grant of Korean Health Technology R&D Project, Ministry of Health &
   Welfare, Republic of Korea [HI12C0110]
FX This study was supported by a grant of the Korean Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (HI12C0110).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Baek JM, 2015, BIOCHEM BIOPH RES CO, V461, P334, DOI 10.1016/j.bbrc.2015.04.034
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092 8674(00)00116 1
   de Pascual Teresa S, 2010, INT J MOL SCI, V11, P1679, DOI 10.3390/ijms11041679
   Fabricant DS, 2001, ENVIRON HEALTH PERSP, V109, P69, DOI 10.2307/3434847
   Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Hudson EA, 2000, CANCER EPIDEM BIOMAR, V9, P1163
   Ito Y, 2005, BONE, V37, P842, DOI 10.1016/j.bone.2005.04.030
   Kim JY, 2014, INT IMMUNOPHARMACOL, V20, P213, DOI 10.1016/j.intimp.2014.03.001
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Lee CH, 2014, J PHARMACOL SCI, V124, P344, DOI 10.1254/jphs.13174FP
   Li Ping, 1993, Biomedical and Environmental Sciences, V6, P389
   Masella R, 1999, REDOX REP, V4, P113, DOI 10.1179/135100099101534792
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mawatari T, 1999, J Orthop Sci, V4, P431, DOI 10.1007/s007760050126
   MCLEOD JF, 1993, ALLERGY PROC, V14, P363, DOI 10.2500/108854193778773967
   Min SW, 2010, INT IMMUNOPHARMACOL, V10, P959, DOI 10.1016/j.intimp.2010.05.009
   Nunes S, 2015, CRIT REV FOOD SCI NU, V26, P0
   Oikawa T, 2013, CELL MOL LIFE SCI, V70, P3341, DOI 10.1007/s00018 012 1238 4
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Semaming Y, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/593902
   STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tsuda T, 1999, FEBS LETT, V449, P179, DOI 10.1016/S0014 5793(99)00407 X
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Vitaglione P, 2007, J NUTR, V137, P2043, DOI 10.1093/jn/137.9.2043
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
NR 31
TC 30
Z9 31
U1 2
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD APR
PY 2016
VL 30
IS 4
BP 604
EP 612
DI 10.1002/ptr.5565
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DJ1VQ
UT WOS:000373993500009
PM 26792397
DA 2025 08 17
ER

PT J
AU Kim, S
   Lee, H
   Hong, J
   Kim, SHL
   Kwon, E
   Park, TH
   Hwang, NS
AF Kim, Seoyeon
   Lee, Haein
   Hong, Jiyeon
   Kim, Seung Hyun L.
   Kwon, Euntaek
   Park, Tai Hyun
   Hwang, Nathaniel S.
TI Bone Targeted Delivery of Cell Penetrating RUNX2 Fusion Protein in
   Osteoporosis Model
SO ADVANCED SCIENCE
LA English
DT Article
DE bone targeting; cell penetrating protein; hydroxyapatite; osteogenic
   differentiation; osteoporosis; poly(aspartic acid)
ID 30KC19 PROTEIN; DIFFERENTIATION; MINERALIZATION; NANOPARTICLES;
   MECHANISMS; CARRIER; CELLS; RUNX2
AB The onset of osteoporosis leads to a gradual decrease in bone density due to an imbalance between bone formation and resorption. To achieve optimal drug efficacy with minimal side effects, targeted drug delivery to the bone is necessary. Previous studies have utilized peptides that bind to hydroxyapatite, a mineral component of bone, for bone targeted drug delivery. In this study, a hydroxyapatite binding (HAB) tag is fused to 30Kc19 & alpha; Runt related transcription factor 2 (RUNX2) for bone targeting. This recombinant protein can penetrate the nucleus of human mesenchymal stem cells (hMSCs) and act as a master transcription factor for osteogenesis. The HAB tag increases the binding affinity of 30Kc19 & alpha; RUNX2 to mineral deposition in mature osteoblasts and bone tissue, without affecting its osteogenic induction capability. In the osteoporosis mouse model, intravenous injection of HAB 30Kc19 & alpha; RUNX2 results in preferential accumulation in the femur and promotes bone formation while reducing toxicity in the spleen. These findings suggest that HAB 30Kc19 & alpha; RUNX2 may be a promising candidate for bone targeted therapy in osteoporosis.
C1 [Kim, Seoyeon; Lee, Haein; Hong, Jiyeon; Park, Tai Hyun; Hwang, Nathaniel S.] Seoul Natl Univ, Inst Chem Proc, Sch Chem & Biol Engn, 1 Gwanak Ro, Seoul 08826, South Korea.
   [Kim, Seoyeon; Kwon, Euntaek; Park, Tai Hyun; Hwang, Nathaniel S.] Seoul Natl Univ, Interdisciplinary Program Bioengn, 1 Gwanak Ro, Seoul 08826, South Korea.
   [Park, Tai Hyun; Hwang, Nathaniel S.] Seoul Natl Univ, BioMAX N Bio Inst, Inst BioEngn, 1 Gwanakro, Seoul 08826, South Korea.
   [Park, Tai Hyun] Ewha Womans Univ, Dept Nutr Sci & Food Management, 52 Ewhayeodae Gil, Seoul 03760, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Ewha Womans University
RP Park, TH; Hwang, NS (通讯作者)，Seoul Natl Univ, Inst Chem Proc, Sch Chem & Biol Engn, 1 Gwanak Ro, Seoul 08826, South Korea.; Park, TH; Hwang, NS (通讯作者)，Seoul Natl Univ, Interdisciplinary Program Bioengn, 1 Gwanak Ro, Seoul 08826, South Korea.; Park, TH; Hwang, NS (通讯作者)，Seoul Natl Univ, BioMAX N Bio Inst, Inst BioEngn, 1 Gwanakro, Seoul 08826, South Korea.; Park, TH (通讯作者)，Ewha Womans Univ, Dept Nutr Sci & Food Management, 52 Ewhayeodae Gil, Seoul 03760, South Korea.
EM thpark@ewha.ac.kr; nshwang@snu.ac.kr
RI Hwang, Nathaniel/AAI 3333 2020; Park, Tai/C 6529 2013
OI Hwang, Nathaniel/0000 0003 3735 7727; Kim, Seoyeon/0000 0003 2132 5245
FU Ministry of Science and ICT [NRF 2021R1A2C2008821]
FX This work was financially supported by the Ministry of Science and ICT
   (NRF 2021R1A2C2008821). The Institute of Engineering Research at Seoul
   National University provided the infrastructure required for this work.
   Renny Franceschi (University of Michigan Medical School) provided the
   BSP promoter reporter plasmid. Figure 1 and Figure for TOC are created
   with BioRender.com.
CR Adelnia H, 2021, ACS BIOMATER SCI ENG, V7, P2083, DOI 10.1021/acsbiomaterials.1c00150
   Benson MD, 1999, J BONE MINER RES, V14, P396, DOI 10.1359/jbmr.1999.14.3.396
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Chandran T, 2019, SINGAP MED J, V60, P364, DOI 10.11622/smedj.2019028
   Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976 500X.119726
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Curtis N. C., 2018, CRC PRESS, V1, P1
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Gavali S, 2019, BBA MOL CELL RES, V1866, P1498, DOI 10.1016/j.bbamcr.2019.06.014
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Huang Y, 2011, PAIN RES TREAT, V2011, DOI 10.1155/2011/968218
   Jeong J, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 018 0149 3
   Ji Meng Xia, 2015, Chronic Dis Transl Med, V1, P9, DOI 10.1016/j.cdtm.2015.02.006
   Jiang T, 2014, INT J PHARMACEUT, V475, P547, DOI 10.1016/j.ijpharm.2014.08.067
   Kaur M, 2020, CURR DRUG TARGETS, V21, P1640, DOI 10.2174/1389450121666200731173522
   Kawane T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31853 0
   Khadilkar SS, 2019, J OBSTET GYN INDIA, V69, P99, DOI 10.1007/s13224 019 01213 7
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim HD, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100070
   Kim JW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094854
   Kim S, 2021, ACS BIOMATER SCI ENG, V7, P1134, DOI 10.1021/acsbiomaterials.0c01349
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Langdahl BL, 2021, BRIT J PHARMACOL, V178, P1891, DOI 10.1111/bph.15024
   Lasota A, 2004, Rocz Akad Med Bialymst, V49 Suppl 1, P129
   Lee H, 2021, ADV BIOL GER, V5, DOI 10.1002/adbi.202000176
   Lee H, 2020, ACS BIOMATER SCI ENG, V6, P5202, DOI 10.1021/acsbiomaterials.0c00827
   Lee HJ, 2014, BIOMATERIALS, V35, P1696, DOI 10.1016/j.biomaterials.2013.11.001
   Lee S, 2017, CIRC RES, V120, P848, DOI 10.1161/CIRCRESAHA.116.309833
   Li LY, 2018, ADV EXP MED BIOL, V1086, P199, DOI 10.1007/978 981 13 1117 8_13
   Liu JS, 2017, INT J NANOMED, V12, P3561, DOI 10.2147/IJN.S133787
   Liu XL, 2015, CLIN ORAL IMPLAN RES, V26, P392, DOI 10.1111/clr.12360
   Liu Y., 2019, J CONTROL RELEASE, V304, P242
   Miller SC, 2008, PHARM RES DORDR, V25, P2889, DOI 10.1007/s11095 008 9706 0
   Monnery BD, 2021, BIOMACROMOLECULES, V22, P4060, DOI 10.1021/acs.biomac.1c00697
   Nayerossadat Nouri, 2012, Adv Biomed Res, V1, P27, DOI 10.4103/2277 9175.98152
   Niger C, 2011, BONE, V49, P683, DOI 10.1016/j.bone.2011.07.027
   Noirrit Esclassan E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041568
   Park HH, 2014, BIOTECHNOL J, V9, P1582, DOI 10.1002/biot.201400253
   Park HH, 2014, PROCESS BIOCHEM, V49, P1516, DOI 10.1016/j.procbio.2014.05.008
   Park JH, 2012, BIOMATERIALS, V33, P9127, DOI 10.1016/j.biomaterials.2012.08.063
   Park JH, 2012, PROCESS BIOCHEM, V47, P164, DOI 10.1016/j.procbio.2011.10.022
   Park SJ, 2010, BONE, V46, P1498, DOI 10.1016/j.bone.2010.02.027
   Ramamoorth M, 2015, J CLIN DIAGN RES, V9, pGE1, DOI 10.7860/JCDR/2015/10443.5394
   Roca H, 2005, J BIOL CHEM, V280, P30845, DOI 10.1074/jbc.M503942200
   Rouaux C, 2010, NAT NEUROSCI, V13, P1345, DOI 10.1038/nn.2658
   Ruseska I, 2020, BEILSTEIN J NANOTECH, V11, P101, DOI 10.3762/bjnano.11.10
   Ryu J, 2020, INT J BIOCHEM CELL B, V121, DOI 10.1016/j.biocel.2020.105717
   Ryu J, 2016, BIOTECHNOL J, V11, P1443, DOI 10.1002/biot.201600040
   Sánchez AR, 2004, INT J DERMATOL, V43, P709, DOI 10.1111/j.1365 4632.2004.02108.x
   Sophocleous Antonia, 2014, Bonekey Rep, V3, P614, DOI 10.1038/bonekey.2014.109
   Sorrentino A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094939
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Tu Kristie N, 2018, P T, V43, P92
   Wu H, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e12288
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
   Xu JH, 2015, AM J TRANSL RES, V7, P2527
   Yamashita S, 2018, BIOMATERIALS, V154, P74, DOI 10.1016/j.biomaterials.2017.10.053
   Zhao C, 2017, GENES DIS, V4, P229, DOI 10.1016/j.gendis.2017.10.004
NR 60
TC 14
Z9 14
U1 5
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD OCT
PY 2023
VL 10
IS 28
DI 10.1002/advs.202301570
EA AUG 2023
PG 13
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA JN8O8
UT WOS:001047346600001
PM 37574255
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, YN
   Jia, TT
   Feng, Y
   Liu, SY
   Zhang, WJ
   Zhang, DJ
   Xu, X
AF Wang, Y. N.
   Jia, T. T.
   Feng, Y.
   Liu, S. Y.
   Zhang, W. J.
   Zhang, D. J.
   Xu, X.
TI Hyperlipidemia Impairs Osseointegration via the ROS/Wnt/β Catenin
   Pathway
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE dental implants; oxidative stress; osteoblast; osteogenesis; signal
   transduction; animal disease model
ID INDUCED LIPOTOXICITY; IMPLANT; SURFACE
AB The influence of hyperlipidemia on titanium implant osseointegration and the underlying mechanisms is not well understood. This study investigates the changes in osseointegration and explores the potential mechanisms in hyperlipidemia conditions. In vivo, specialized titanium implants were implanted in the femurs of diet induced or genetic hyperlipidemia mice. In vitro, primary murine osteoblasts were cultured on the titanium surface in high fat medium. Results showed that hyperlipidemia led to poor osseointegration in both types of mice in vivo, and high fat medium impaired the osteogenic differentiation of primary osteoblasts on the titanium surface in vitro. In addition, high fat medium caused significant overproduction of reactive oxygen species (ROS) and inhibition of the Wnt/beta catenin pathway in osteoblasts. Both N acetyl L cysteine (NAC, an ROS antagonist) and Wnt3a (an activator of the Wnt/beta catenin pathway) attenuated the poor osteogenic ability of osteoblasts. In addition, NAC reactivated the Wnt/beta catenin pathway in osteoblasts under high fat stimulation. These results demonstrate that hyperlipidemia impairs osseointegration via the ROS/Wnt/beta catenin pathway and provide support for the ROS or Wnt/beta catenin pathway as a promising therapeutic target for the development of novel drugs or implant materials to improve the osseointegration of implants in hyperlipidemic patients.
C1 [Wang, Y. N.; Jia, T. T.; Feng, Y.; Zhang, W. J.; Zhang, D. J.; Xu, X.] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Implantol, 44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
   [Wang, Y. N.; Jia, T. T.; Feng, Y.; Liu, S. Y.; Zhang, W. J.; Zhang, D. J.; Xu, X.] Shandong Key Lab Oral Tissue Regenerat, Jinan, Shandong, Peoples R China.
   [Wang, Y. N.; Jia, T. T.; Feng, Y.; Liu, S. Y.; Zhang, W. J.; Zhang, D. J.; Xu, X.] Shandong Engn Lab Dent Mat & Oral Tissue Regenera, Jinan, Shandong, Peoples R China.
   [Liu, S. Y.] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Periodontol, Jinan, Shandong, Peoples R China.
C3 Shandong University; Shandong University
RP Zhang, DJ; Xu, X (通讯作者)，Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Implantol, 44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
EM djzhang1109@163.com; xinxu@sdu.edu.cn
FU National Natural Science Foundation of China [82071148, 82001055];
   Construction Engineering Special Fund of Taishan Scholars [TS201511106];
   Key Project of Chinese National Programs for Research and Development
   [2016YFC1102705]; Fundamental Research Funds of Shandong University
   [2018GN024]; China Postdoctoral Science Foundation [2019M662371]; Youth
   scientific research funds of School of Stomatology, Shandong University
   [2019QNJJ03]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the National Natural Science Foundation of China (No.
   82071148; No. 82001055), the Construction Engineering Special Fund of
   Taishan Scholars (TS201511106), the Key Project of Chinese National
   Programs for Research and Development (2016YFC1102705), the Fundamental
   Research Funds of Shandong University (2018GN024), the China
   Postdoctoral Science Foundation (2019M662371), and the Youth scientific
   research funds of School of Stomatology, Shandong University
   (2019QNJJ03).
CR Al Saedi A, 2019, BONE, V127, P353, DOI 10.1016/j.bone.2019.06.016
   Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Dalla Valle A, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00726
   Dong XF, 2018, INT J ORAL MAX IMPL, V33, P351, DOI 10.11607/jomi.6015
   Dündar S, 2016, J KOR ASSOC ORAL MAX, V42, P187, DOI 10.5125/jkaoms.2016.42.4.187
   Elbatreek MH, 2019, TRENDS ENDOCRIN MET, V30, P312, DOI 10.1016/j.tem.2019.02.006
   Galli C, 2011, J DENT RES, V90, P360, DOI 10.1177/0022034510386488
   González R, 2018, ANTIOXID REDOX SIGN, V29, P1312, DOI 10.1089/ars.2017.7072
   Guglielmotti MB, 2019, PERIODONTOL 2000, V79, P178, DOI 10.1111/prd.12254
   Gunaratnam K, 2014, ENDOCRINOLOGY, V155, P108, DOI 10.1210/en.2013 1712
   Hoogeboom D, 2009, BBA REV CANCER, V1796, P63, DOI 10.1016/j.bbcan.2009.02.002
   Hu XF, 2018, ACTA BIOMATER, V73, P470, DOI 10.1016/j.actbio.2018.04.008
   Keuroghlian A, 2015, J ORAL IMPLANTOL, V41, pE7, DOI 10.1563/AAID JOI D 13 00105
   Klueh U, 2006, DIABETES TECHNOL THE, V8, P402, DOI 10.1089/dia.2006.8.402
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kuklina E. V., 2011, Morbidity and Mortality Weekly Report, V60, P109
   Marinho HS, 2014, REDOX BIOL, V2, P535, DOI 10.1016/j.redox.2014.02.006
   Mayta Tovalino F, 2019, INT J DENT, V2019, DOI 10.1155/2019/3527872
   Mendonça G, 2008, BIOMATERIALS, V29, P3822, DOI 10.1016/j.biomaterials.2008.05.012
   Morinaga K, 2019, BIOMATERIALS, V192, P62, DOI 10.1016/j.biomaterials.2018.11.003
   Mouthuy PA, 2016, BIOMATERIALS, V109, P55, DOI 10.1016/j.biomaterials.2016.09.010
   Nishi H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071664
   Ren H, 2020, J DENT RES, V99, P938, DOI 10.1177/0022034520916400
   Schaffer JE, 2003, CURR OPIN LIPIDOL, V14, P281, DOI 10.1097/00041433 200306000 00008
   Schwarz F, 2018, J CLIN PERIODONTOL, V45, pS246, DOI 10.1111/jcpe.12954
   Shin SY, 2006, CELL SIGNAL, V18, P601, DOI 10.1016/j.cellsig.2005.06.001
   Tekin MB, 2019, INT J IMPLANT DENT, V5, DOI 10.1186/s40729 019 0170 x
   Tirone F, 2016, EUR J ORAL IMPLANTOL, V9, P77
   Xiao MQ, 2017, FREE RADICAL BIO MED, V111, P316, DOI 10.1016/j.freeradbiomed.2017.04.363
NR 31
TC 41
Z9 46
U1 3
U2 38
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD JUN
PY 2021
VL 100
IS 6
BP 658
EP 665
DI 10.1177/0022034520983245
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA SF2WJ
UT WOS:000652621200013
PM 33402029
DA 2025 08 17
ER

PT J
AU Chang, JK
   Wu, SC
   Wang, GJ
   Cho, MH
   Ho, ML
AF Chang, Je Ken
   Wu, Shun Cheng
   Wang, Gwo Jaw
   Cho, Ming Hsuang
   Ho, Mei Ling
TI Effects of non steroidal anti inflammatory drugs on cell proliferation
   and death in cultured epiphyseal articular chondrocytes of fetal rats
SO TOXICOLOGY
LA English
DT Article
DE non steroidal anti inflammatory drugs; cyclooxygenase 2 inhibitors;
   chondrocyte; proliferation; apoptosis; necrosis
ID METAPHYSEAL HARD TISSUE; RAPIDLY GROWING RATS; BONE REPAIR; FRACTURE
   REPAIR; PHARMACOKINETIC PROPERTIES; RHEUMATOID ARTHRITIS; SUSPENSION
   CULTURE; UP REGULATION; IN VITRO; PROSTAGLANDIN E2
AB Previous reports indicated that non steroidal anti inflammatory drugs (NSAIDs) suppress bone repair. Our previous study further found that ketorolac delayed the endochondral bone formation, and the critical effective timing was at the early stage of repair. Furthermore, we found that NSAIDs suppressed proliferation and induced cell death of cultured osteoblasts. In this study, we hypothesized that chondrocytic proliferation and death, which plays an important role at the early stage of endochondral bone formation, might be affected by NSAIDs. Non selective NSAIDs, indomethacin, ketorolac, diclofenac and piroxicam; cyclooxygenase 2 (COX 2) selective NSAIDs, celecoxib and DFU (an analog of rofecoxib); prostaglandins (PGs), PGE1, PGE2 and PGF2 alpha; and each NSAID plus each PG were tested. The effects of NSAIDs on proliferation, cell cycle kinetics, cytotoxicity and cell death of epiphyseal articular chondrocytes of fetal rats were examined. The results showed that all the tested NSAIDs, except DFU, inhibited thymidine incorporation of chondrocytes at a concentration range (10( 8) to 10( 4) M) covering the theoretic therapeutic concentrations. Cell cycle was arrested by NSAIDs at the G(0)/G(1) phase. Upon a 24 h treatment, LDH leakage and cell death (both apoptosis and necrosis) were significantly induced by the four non selective NSAIDs in chondrocyte cultures. However, COX 2 inhibitors revealed non significant effects on cytotoxicity of chondrocytes except higher concentration of celecoxib (10 4 M). Replenishments of PGE1 PGE2 or PGF2 alpha could not reverse the effects of NSAIDs on chondrocytic proliferation and cytotoxicity. In this study, we found that therapeutic concentrations of non selective NSAIDs caused proliferation suppression and cell death of chondrocytes, suggesting these adverse effects may be one of the reasons that NSAIDs delay the endochondral ossification during bone repair found in previous studies. Furthermore, these effects of NSAIDs may act via PG independent mechanisms. COX 2 selective NSAIDs showed less deleterious effects on chondrocytic proliferation and death. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Kaohsiung Med Univ, Sch Med, Dept Physiol, Kaohsiung 807, Taiwan.
   Kaohsiung Med Univ, Sch Med, Dept Orthopaed, Kaohsiung 807, Taiwan.
   Kaohsiung Med Univ, Orthopaed Res Ctr, Kaohsiung 807, Taiwan.
   Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthopaed, Kaohsiung 807, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University Hospital
RP Ho, ML (通讯作者)，Kaohsiung Med Univ, Sch Med, Dept Physiol, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
EM homelin@cc.kmu.edu.tw
RI ; Ho, Mei Ling/D 5515 2009; Chang, Je Ken/A 1315 2010; Wu,
   Shun Cheng/E 2989 2010
OI Wu, Shun Cheng/0000 0003 4219 3413; Ho, Mei Ling/0000 0001 8064 8488; 
CR ALLEN HL, 1980, ACTA ORTHOP SCAND, V51, P595, DOI 10.3109/17453678008990848
   BLOCKA KLN, 1988, J RHEUMATOL, V15, P757
   Brideau C, 2001, AM J VET RES, V62, P1755, DOI 10.2460/ajvr.2001.62.1755
   Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623 200401000 00017
   BUCKLEY MMT, 1990, DRUGS, V39, P86, DOI 10.2165/00003495 199039010 00008
   CAPLAN AI, 1994, CLIN PLAST SURG, V21, P429
   CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611
   Chang Je Ken, 2002, Kaohsiung J Med Sci, V18, P106
   Chang Je Ken, 2003, Kaohsiung Journal of Medical Sciences, V19, P278
   Chang JK, 2005, CONNECT TISSUE RES, V46, P200, DOI 10.1080/03008200500344025
   Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495 200059040 00017
   Crowston JG, 1998, INVEST OPHTH VIS SCI, V39, P449
   Depré M, 2000, EUR J CLIN PHARMACOL, V56, P167, DOI 10.1007/s002280050736
   DESHMUKH K, 1977, P NATL ACAD SCI USA, V74, P3864, DOI 10.1073/pnas.74.9.3864
   Di Massa A, 2000, Minerva Anestesiol, V66, P749
   Einhorn TA, 2003, ARTHRITIS RES THER, V5, P5, DOI 10.1186/ar607
   Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925 4773(99)00142 2
   FURUTA Y, 1986, ANAT RECORD, V215, P305, DOI 10.1002/ar.1092150313
   Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006 2952(96)00181 5
   HO ML, 1995, CLIN ORTHOP RELAT R, P270
   Ho ML, 1999, BIOCHEM PHARMACOL, V58, P983, DOI 10.1016/S0006 2952(99)00186 0
   Ho ML, 1998, PHARMACOLOGY, V57, P148, DOI 10.1159/000028236
   HORWITZ AL, 1970, J CELL BIOL, V45, P434, DOI 10.1083/jcb.45.2.434
   JEE WSS, 1987, BONE, V8, P171, DOI 10.1016/8756 3282(87)90017 2
   JEE WSS, 1985, CALCIFIED TISSUE INT, V37, P148, DOI 10.1007/BF02554834
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   Kazanov D, 2004, CLIN CANCER RES, V10, P267, DOI 10.1158/1078 0432.CCR 0412 3
   KELLER J, 1987, ACTA ORTHOP SCAND, V58, P379, DOI 10.3109/17453678709146360
   Kucab JE, 2005, BREAST CANCER RES, V7, pR796, DOI 10.1186/bcr1294
   Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124
   Mesner P W Jr, 1997, Adv Pharmacol, V41, P57, DOI 10.1016/S1054 3589(08)61054 6
   MORI S, 1990, BONE, V11, P103, DOI 10.1016/8756 3282(90)90057 6
   NEVO Z, 1972, DEV BIOL, V28, P219, DOI 10.1016/0012 1606(72)90139 X
   NILSSON OS, 1986, CLIN ORTHOP RELAT R, P239
   NORRDIN RW, 1990, PROSTAG LEUKOTR ESS, V41, P139, DOI 10.1016/0952 3278(90)90081 U
   OBERBAUER R, 1993, CLIN PHARMACOKINET, V24, P428, DOI 10.2165/00003088 199324050 00007
   Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558
   SHIH MS, 1987, BONE MINER, V3, P27
   SHIH MS, 1986, BONE MINER, V1, P227
   SHIH MS, 1986, AM J VET RES, V47, P1561
   TODD PA, 1988, DRUGS, V35, P244, DOI 10.2165/00003495 198835030 00004
   TORNKVIST H, 1985, CLIN ORTHOP RELAT R, P264
   TORNKVIST H, 1980, SCAND J RHEUMATOL, V9, P167
   Tsai WC, 2004, J ORTHOP RES, V22, P586, DOI 10.1016/j.orthres.2003.10.014
   UENO K, 1985, BONE, V6, P79, DOI 10.1016/8756 3282(85)90311 4
   Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925 4773(97)00203 7
   YAMAGUCHI DT, 1989, AM J PHYSIOL, V257, pF755, DOI 10.1152/ajprenal.1989.257.5.F755
NR 47
TC 35
Z9 41
U1 1
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300 483X
J9 TOXICOLOGY
JI Toxicology
PD DEC 7
PY 2006
VL 228
IS 2 3
BP 111
EP 123
DI 10.1016/j.tox.2006.08.028
PG 13
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 114AO
UT WOS:000242639300001
PM 17045721
DA 2025 08 17
ER

PT J
AU Wang, YF
   Chang, YY
   Zhang, XM
   Gao, MT
   Zhang, QL
   Li, X
   Zhang, L
   Yao, WF
AF Wang, Yi Fei
   Chang, Yue yue
   Zhang, Xue meng
   Gao, Meng Ting
   Zhang, Qiu lan
   Li, Xin
   Zhang, Li
   Yao, Wei Feng
TI Salidroside protects against osteoporosis in ovariectomized rats by
   inhibiting oxidative stress and promoting osteogenesis via Nrf2
   activation
SO PHYTOMEDICINE
LA English
DT Article
DE Osteoporosis; Osteoblast; Salidroside; Oxidative stress; Ovariectomized
   rats; Nrf2
ID ESTROGEN REPLACEMENT THERAPY; LIGUSTRI LUCIDI; ADIPOGENIC
   DIFFERENTIATION; PEROXIDATION; LIPOPROTEIN; EXPRESSION; PRODUCTS;
   NECROSIS; PATHWAY; FRUCTUS
AB Background: Osteoporosis (OP) is characterized as low bone mass, bone microarchitecture breakdown and bone fragility. The increase of oxidative stress could lead to breakdown in the balance of bone formation and resorption which gives rise to OP. Nrf2 is a transcription factor which takes part in oxidative stress and recently was reported that it can regulate the occurrence of OP. Salidroside (SAL) with the efficacies of anti oxidation, anti aging and bone protection is one of the active ingredients in Ligustri Lucidi Fructus, a traditional Chinese medicinal herb. Nevertheless, few studies have explored the potential mechanism of SAL preventing OP development from the perspective of oxidative stress intervention. Purpose: This study aimed to investigate the pharmacological effect and molecular mechanisms of SAL on OP. Study designs and methods: A tert butyl hydroperoxide (t BHP) induced oxidative stress model was applied for investigating the effects of SAL in vitro, and an ovariectomized (OVX) model was used for in vivo study on the effect of SAL for OP. Related pharmacodynamic actions and molecular mechanisms of SAL were explored in both rat osteoblasts (ROBs) and OVX rats. Network biology and cell metabolomics were performed for further investigating the correlation and association among potential biomarkers, targets and pathways. Results: SAL reduced levels of ROS and lipid peroxidation (LPO), increased activities of antioxidant enzymes like GPx and SOD, and enhanced osteogenic differentiation in t BHP induced ROBs and OVX rats. Mechanistic studies showed SAL prevented OP development and reduced oxidative damage in ROBs and OVX rats through up regulating Nrf2 expression and facilitating its nuclear translocation. The joint analysis of network biology and cell metabolomics revealed that galactose metabolism and fatty acid metabolism could be the major influenced pathways following treatment with SAL. Conclusion: SAL could protect against OP by inhibiting oxidative stress, promoting osteogenesis through the up  regulation of Nrf2 and intervening galactose metabolism and fatty acid metabolism. Our study implied that SAL may be a potential drug to treat OP.
C1 [Wang, Yi Fei; Chang, Yue yue; Zhang, Xue meng; Gao, Meng Ting; Zhang, Qiu lan; Li, Xin; Zhang, Li; Yao, Wei Feng] Nanjing Univ Chinese Med, Sch Pharm, 138 Xianlin Rd, Nanjing 210023, Jiangsu, Peoples R China.
   [Zhang, Li; Yao, Wei Feng] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Natl & Local Collaborat Engn Ctr Chinese Med Reso, Nanjing 210023, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine
RP Yao, WF (通讯作者)，Nanjing Univ Chinese Med, Sch Pharm, 138 Xianlin Rd, Nanjing 210023, Jiangsu, Peoples R China.
EM yaowf@njucm.edu.cn
RI Yifei, Wang/JGM 5589 2023; Yao, Weifeng/I 7394 2013
FU National Natural Science Foundation of China [81973445, 81573554];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD) [2016 YY 026]; Qing Lan Project of Jiangsu Province
   [KYCX21_1806]; Six Talent Peaks Project in Jiangsu Province;
   Postgraduate Research and Practice Innovation Program of Jiangsu
   Province
FX Funding This work was financially supported by National Natural Science
   Foundation of China (Grant No. 81973445 and 81573554) , and A Project
   Funded by the Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD) . This research was also supported by A
   Project Funded by the Qing Lan Project of Jiangsu Province and Six
   Talent Peaks Project in Jiangsu Province (2016 YY 026) , Postgraduate
   Research and Practice Innovation Program of Jiangsu Province (No.
   KYCX21_1806) .
CR Alnahdi A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11091979
   Aoki S, 2012, CHEM PHARM BULL, V60, P251, DOI 10.1248/cpb.60.251
   BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006 291X(05)80311 0
   Chen JJ, 2013, FOOD CHEM TOXICOL, V62, P499, DOI 10.1016/j.fct.2013.09.019
   Feng CC, 2016, CELL CYCLE, V15, P1674, DOI 10.1080/15384101.2016.1152433
   Feng L, 2021, J CHROMATOGR B, V1178, DOI 10.1016/j.jchromb.2021.122857
   Gao LL, 2017, CHEM NAT COMPD+, V53, P553, DOI 10.1007/s10600 017 2046 8
   Ge CX, 2016, J CELL PHYSIOL, V231, P587, DOI 10.1002/jcp.25102
   Ge DW, 2017, EUR REV MED PHARMACO, V21, P4784
   Gegotek A, 2019, CHEM PHYS LIPIDS, V221, P46, DOI 10.1016/j.chemphyslip.2019.03.011
   Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224
   Ghodsi R, 2018, AMINO ACIDS, V50, P1177, DOI 10.1007/s00726 018 2592 9
   Girotti A W, 1985, J Free Radic Biol Med, V1, P87
   Guo QY, 2020, EUR J PHARMACOL, V884, DOI 10.1016/j.ejphar.2020.173394
   Guo XQ, 2017, CELL TISSUE RES, V367, P197, DOI 10.1007/s00441 016 2535 2
   Haeiwa H, 2014, MOL CELL BIOCHEM, V386, P73, DOI 10.1007/s11010 013 1846 9
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   He FW, 2018, MOLECULES, V23, DOI 10.3390/molecules23123353
   Hidalgo Lanussa O, 2018, MOL NEUROBIOL, V55, P5462, DOI 10.1007/s12035 017 0777 y
   Hsu WH, 2020, AGING US, V12, P10556, DOI 10.18632/aging.103279
   Ibáñez L, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/726590
   Jacob RF, 2005, J BIOL CHEM, V280, P39380, DOI 10.1074/jbc.M507587200
   Jagger CJ, 2005, ENDOCRINOLOGY, V146, P113, DOI 10.1210/en.2004 1058
   Ji HJ, 2011, BIOMED PHARMACOTHER, V65, P369, DOI 10.1016/j.biopha.2011.04.020
   Kumar Anil, 2011, Int J Alzheimers Dis, V2011, P347569, DOI 10.4061/2011/347569
   Kumar H, 2014, NAT PROD REP, V31, P109, DOI 10.1039/c3np70065h
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Li HT, 2018, MED SCI MONITOR, V24, P5071, DOI 10.12659/MSM.908699
   Li H, 2017, MOLECULES, V22, DOI 10.3390/molecules22050689
   Li XH, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02598 w
   Liau PR, 2019, MOLECULES, V24, DOI 10.3390/molecules24112143
   Lin X, 2015, CLIN INTERV AGING, V10, P1017, DOI 10.2147/CIA.S54613
   Liu GT, 2000, REPROD TOXICOL, V14, P377, DOI 10.1016/S0890 6238(00)00096 4
   Liu YY, 2013, NEUROCHEM INT, V62, P603, DOI 10.1016/j.neuint.2012.12.010
   Mao GX, 2010, BIOMED ENVIRON SCI, V23, P161, DOI 10.1016/S0895 3988(10)60047 5
   MARTENSSON J, 1991, P NATL ACAD SCI USA, V88, P9360, DOI 10.1073/pnas.88.20.9360
   Medina Gomez G, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030064
   PARFITT AM, 1995, J BONE MINER RES, V10, P466
   Spiteller G, 2003, MED HYPOTHESES, V60, P69, DOI 10.1016/S0306 9877(02)00333 X
   Spiteller G, 1998, CHEM PHYS LIPIDS, V95, P105, DOI 10.1016/S0009 3084(98)00091 7
   STEINBERG KK, 1991, JAMA J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985
   Strehlow K, 2003, CIRC RES, V93, P170, DOI 10.1161/01.RES.0000082334.17947.11
   Su LJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5080843
   Tang X, 2020, J AGR FOOD CHEM, V68, P6588, DOI 10.1021/acs.jafc.0c01820
   THOMPSON W, 1995, AM J OBSTET GYNECOL, V173, P990, DOI 10.1016/0002 9378(95)90248 1
   Tsimikas S, 1998, CURR OPIN LIPIDOL, V9, P301, DOI 10.1097/00041433 199808000 00003
   Wang J, 2017, MOL MED REP, V17, P1125
   Xie DJ, 2020, BMC PLANT BIOL, V20, DOI 10.1186/s12870 020 02685 w
   Xu J, 2019, J PHARMACEUT BIOMED, V171, P171, DOI 10.1016/j.jpba.2019.04.022
   Xu LL, 2020, EXP THER MED, V19, P1084, DOI 10.3892/etm.2019.8313
   Xue XH, 2018, MOL MED REP, V17, P3751, DOI 10.3892/mmr.2017.8349
   Yao WF, 2015, J SEP SCI, V38, P1822, DOI 10.1002/jssc.201500094
   Yildirim D, 2021, LIFE SCI, V280, DOI 10.1016/j.lfs.2021.119671
   Yoo JH, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050283
   Yu XN, 2017, BREAST CANCER TOKYO, V24, P643, DOI 10.1007/s12282 017 0789 5
   Zhai Yuan yuan, 2020, Yaoxue Xuebao, V55, P1222, DOI 10.16438/j.0513 4870.2020 0027
   Zhang DJ, 2021, J SEP SCI, V44, P4343, DOI 10.1002/jssc.202100484
   Zhang HY, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00187
   Zhang JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057251
   Zhao XY, 2020, NAT PROD COMMUN, V15, DOI 10.1177/1934578X20922338
   Zheng HX, 2018, MOLECULES, V23, DOI 10.3390/molecules23092398
NR 61
TC 44
Z9 53
U1 3
U2 46
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD MAY
PY 2022
VL 99
AR 154020
DI 10.1016/j.phymed.2022.154020
EA MAR 2022
PG 18
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 1B2CL
UT WOS:000792248700004
PM 35278902
DA 2025 08 17
ER

PT J
AU Ghorab, MM
   Alsaid, MS
   Nissan, YM
AF Ghorab, Mostafa M.
   Alsaid, Mansour S.
   Nissan, Yassin M.
TI SYNTHESIS AND MOLECULAR DOCKING OF SOME NOVEL ANTICANCER SULFONAMIDES
   CARRYING A BIOLOGICALLY ACTIVE PYRROLE AND PYRROLOPYRIMIDINE MOIETIES
SO ACTA POLONIAE PHARMACEUTICA
LA English
DT Article
DE sulfonamide derivatives; anticancer activity
ID BONE RESORPTION; SRC; TOYOCAMYCIN; INHIBITORS; OSTEOCLAST; ANALOGS;
   TRANCE
AB A novel series of pyrroles and pyrrolopyrimdines carrying a biologically active sulfonamide moiety have been synthesized. The structures were confirmed by elemental analyses and spectral data. All the target compounds were subjected to in vitro cytotoxic screening on breast cancer cell line (MCF 7). Most of the synthesized compounds showed good activity as cytotoxic agents with better IC50 than doxorubicin as a reference drug. In order to suggest a mechanism of action for their activity, molecular docking on the active site of human c Src was performed for all synthesized compounds.
C1 [Ghorab, Mostafa M.; Alsaid, Mansour S.] King Saud Univ, Pharmacognosy Dept, Coll Pharm, Riyadh 11451, Saudi Arabia.
   [Nissan, Yassin M.] Cairo Univ, Fac Pharm, Pharmaceut Chem Dept, Cairo 11562, Egypt.
C3 King Saud University; Egyptian Knowledge Bank (EKB); Cairo University
RP Ghorab, MM (通讯作者)，King Saud Univ, Pharmacognosy Dept, Coll Pharm, POB 2457, Riyadh 11451, Saudi Arabia.
EM mmsghorab@yahoo.com
RI Nissan, Yassin/L 1204 2017
OI Nissan, Yassin/0000 0002 6470 3392
FU Deanship of Scientific Research at King Saud University [RGP VPP 302]
FX The authors would like to extend their sincere appreciation to the
   Deanship of Scientific Research at King Saud University for its funding
   of this research through the Research Group Project no. RGP VPP 302.
CR Danchev N, 2006, ARCH PHARM, V339, P670, DOI 10.1002/ardp.200600116
   Dang Q, 2002, J ORG CHEM, V67, P8703, DOI 10.1021/jo026309d
   DECLERCQ E, 1987, J MED CHEM, V30, P481, DOI 10.1021/jm00386a007
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Finch RA, 1997, ANTI CANCER DRUG DES, V12, P205
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Gangjee A, 2005, BIOORG MED CHEM LETT, V15, P2225, DOI 10.1016/j.bmcl.2005.03.029
   Hall ED, 1997, J PHARMACOL EXP THER, V281, P895
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Jarvis MF, 2002, PAIN, V96, P107, DOI 10.1016/S0304 3959(01)00435 3
   KRAWCZYK SH, 1995, J MED CHEM, V38, P4106, DOI 10.1021/jm00020a026
   Leaf DE, 2007, J APPL PHYSIOL, V102, P1313, DOI 10.1152/japplphysiol.01572.2005
   Missbach M, 2000, BIOORG MED CHEM LETT, V10, P945, DOI 10.1016/S0960 894X(00)00131 1
   Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756 3282(99)00020 4
   SKEHAN P, 1990, JNCI J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Sundaramoorthi R, 2003, BIOORG MED CHEM LETT, V13, P3063, DOI 10.1016/S0960 894X(03)00647 4
   Susa M, 2000, PROTEIN EXPRES PURIF, V19, P99, DOI 10.1006/prep.2000.1221
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715
NR 19
TC 10
Z9 11
U1 0
U2 5
PU POLSKIE TOWARZYSTWO FARMACEUTYCZNE
PI WARSAW
PA DLUGA 16, 00 238 WARSAW, POLAND
SN 0001 6837
EI 2353 5288
J9 ACTA POL PHARM
JI ACTA POL. PHARM.
PD JUL AUG
PY 2014
VL 71
IS 4
BP 603
EP 614
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AP0ID
UT WOS:000341743800010
PM 25272886
DA 2025 08 17
ER

PT J
AU Yaroslavskiy, BB
   Sharrow, AC
   Wells, A
   Robinson, LJ
   Blair, HC
AF Yaroslavskiy, Beatrice B.
   Sharrow, Allison C.
   Wells, Alan
   Robinson, Lisa J.
   Blair, Harry C.
TI Necessity of inositol (1,4,5) trisphosphate receptor 1 and μ calpain in
   NO induced osteoclast motility
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE cyclic GMP; cGMP dependent protein kinase 1; inositol
   (1,4,5) trisphosphate; nitric oxide; CAPN1; VASP
ID NITRIC OXIDE SYNTHASE; DEPENDENT PROTEIN KINASE; BONE RESORPTION;
   RYANODINE RECEPTOR; PLASMA MEMBRANE; CELL ATTACHMENT; CALCIUM RELEASE;
   SMOOTH MUSCLE; IN VIVO; ACTIVATION
AB In skeletal remodeling, osteoclasts degrade bone, detach and move to new locations. Mechanical stretch and estrogen regulate osteoclast motility via nitric oxide ( NO). We have found previously that NO stimulates guanylyl cyclase, activating the cGMP dependent protein kinase 1 (PKG1), reversibly terminating osteoclast matrix degradation and attachment, and initiating motility. The PKG1 substrate vasodilator stimulated protein (VASP), a membrane attachment related protein found in complexes with the integrin alpha v beta 3 in adherent osteoclasts, was also required for motility. Here, we studied downstream mechanisms by which the NO dependent pathway mediates osteoclast relocation. We found that NO stimulated motility is dependent on activation of the Ca2+ activated proteinase mu calpain. RNA interference (RNAi) showed that NO dependent activation of mu calpain also requires PKG1 and VASP. Inhibition of Src kinases, which are involved in the regulation of adhesion complexes, also abolished NO stimulated calpain activity. Pharmacological inhibition and RNAi showed that calpain activation in this process is mediated by the inositol ( 1,4,5) trisphosphate receptor 1 [Ins( 1,4,5) P(3)R1] Ca2+ channel. We conclude that NO induced motility in osteoclasts requires regulated Ca2+ release, which activates mu calpain. This occurs via the Ins( 1,4,5) P(3)R1.
C1 Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15243 USA.
   Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15243 USA.
   Vet Affairs Med Ctr, Pittsburgh, PA 15243 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; US Department of Veterans Affairs;
   Veterans Health Administration (VHA)
RP Blair, HC (通讯作者)，Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15243 USA.
EM hcblair@imap.pitt.edu
OI Sharrow, Allison/0000 0002 4611 6020; Wells, Alan/0000 0002 1637 8150
FU NIAMS NIH HHS [AR053566, R01 AR053976, AR053976, K08 AR053566] Funding
   Source: Medline; NIGMS NIH HHS [R01 GM069668, GM069668] Funding Source:
   Medline
CR Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Armour KJ, 2001, ARTHRITIS RHEUM, V44, P2185, DOI 10.1002/1529 0131(200109)44:9<2185::AID ART372>3.0.CO;2 3
   Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897
   Balla T, 2006, J ENDOCRINOL, V188, P135, DOI 10.1677/joe.1.06595
   BEKKER PJ, 1990, J BONE MINER RES, V5, P557
   Calle Y, 2006, J CELL SCI, V119, P2375, DOI 10.1242/jcs.02939
   Cui J, 2004, J BIOL CHEM, V279, P16311, DOI 10.1074/jbc.M400206200
   Dedieu S, 2004, EXP CELL RES, V292, P187, DOI 10.1016/j.yexcr.2003.08.014
   Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082
   FALSAFI R, 1991, CALCIFIED TISSUE INT, V49, P333, DOI 10.1007/BF02556256
   FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0
   Fritsch RM, 2004, J BIOL CHEM, V279, P12551, DOI 10.1074/jbc.M313365200
   Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390
   Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499 2512.2004
   Golden LH, 2004, BONE, V34, P3, DOI 10.1016/j.bone.2003.09.005
   Grey A, 2000, ENDOCRINOLOGY, V141, P2129, DOI 10.1210/en.141.6.2129
   Guihard G, 1996, BIOCHEM J, V318, P849, DOI 10.1042/bj3180849
   Hayashi M, 2005, J BIOCHEM, V137, P331, DOI 10.1093/jb/mvi036
   Hsu AL, 2000, J BIOL CHEM, V275, P16242, DOI 10.1074/jbc.M002077200
   KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Lee FYI, 2005, J BIOL CHEM, V280, P29929, DOI 10.1074/jbc.M414600200
   Marcantoni A, 2006, J CELL PHYSIOL, V206, P329, DOI 10.1002/jcp.20467
   Marzia M, 2006, J BIOL CHEM, V281, P9745, DOI 10.1074/jbc.M513516200
   MAYER B, 1993, ADV SEC MESS PHOSPH, V28, P111
   Moonga BS, 2002, AM J PHYSIOL RENAL, V282, pF921, DOI 10.1152/ajprenal.00045.2000
   Murthy KS, 2003, AM J PHYSIOL GASTR L, V284, pG221, DOI 10.1152/ajpgi.00401.2002
   Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361
   Nomura S, 2000, MATRIX BIOL, V19, P91, DOI 10.1016/S0945 053X(00)00050 0
   O'Shaughnessy MC, 2000, BIOCHEM BIOPH RES CO, V277, P604, DOI 10.1006/bbrc.2000.3714
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647
   RADDING W, 1994, J CELL PHYSIOL, V160, P17, DOI 10.1002/jcp.1041600104
   Radding W, 1999, EXP CELL RES, V253, P689, DOI 10.1006/excr.1999.4714
   Rooney TA, 1996, J BIOL CHEM, V271, P19817, DOI 10.1074/jbc.271.33.19817
   ROSSER BG, 1993, J BIOL CHEM, V268, P23593
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   Satish L, 2005, MOL CELL BIOL, V25, P1922, DOI 10.1128/MCB.25.5.1922 1941.2005
   Sun L, 2003, FASEB J, V17, P369, DOI 10.1096/fj.02 0205com
   Sunyer T, 1996, J CELL BIOCHEM, V60, P469, DOI 10.1002/(SICI)1097 4644(19960315)60:4<469::AID JCB4>3.0.CO;2 Q
   Tian W, 2004, J PHARM PHARMACOL, V56, P565, DOI 10.1211/0022357023466
   Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537 1891(03)00007 7
   Ueno M, 1998, CALCIFIED TISSUE INT, V63, P22, DOI 10.1007/s002239900484
   Williams JP, 1996, J CELL PHYSIOL, V169, P411, DOI 10.1002/(SICI)1097 4652(199612)169:3<411::AID JCP1>3.3.CO;2 1
   Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234
   Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200
   Yaroslavskiy BB, 2005, J CELL SCI, V118, P5479, DOI 10.1242/jcs.02655
   Yaroslavskiy BB, 2004, J CELL BIOCHEM, V91, P962, DOI 10.1002/jcb.20009
   Zaman G, 1999, J BONE MINER RES, V14, P1123, DOI 10.1359/jbmr.1999.14.7.1123
NR 50
TC 26
Z9 28
U1 0
U2 0
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021 9533
J9 J CELL SCI
JI J. Cell Sci.
PD AUG 15
PY 2007
VL 120
IS 16
BP 2884
EP 2894
DI 10.1242/jcs.004184
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 199KF
UT WOS:000248694000013
PM 17690304
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Song, J
   Jiang, N
   Gan, XQ
   Zhi, W
   Zhu, ZL
AF Song, Jian
   Jiang, Nan
   Gan, Xueqi
   Zhi, Wei
   Zhu, Zhuoli
TI Thrombin inhibitor argatroban modulates bone marrow stromal cells
   behaviors and promotes osteogenesis through canonical Wnt signaling
SO LIFE SCIENCES
LA English
DT Article
DE Argatroban; Osteogenesis; Bone regeneration; Wnt/beta catenin signaling
AB Aims: Coagulation is a common event that play a double edged role in physiological and pathological process. Anti coagulation methods were applied in joint surgery or scaffolds implantation to encourage new vascular formation and avoid coagulation block. However, whether anti coagulation drug perform regulatory roles in bone structure is unknown. This study aims to explore a direct thrombin inhibitor, argatroban, effects on bone marrow stromal cells (BMSCs) and decipher the underlying mechanisms.
   Materials and methods: Argatroban effects on BMSCs were investigated in vivo and in vitro. The drug was applied in periodontal disease model mice and bone loss was evaluated by mu CT and histology. BMSCs were treated with different doses argatroban or vehicle. Cellular reactions were analyzed using wound healing assay, qRT PCR, Alizarin Red S staining and western blotting.
   Key findings: We demonstrated that local injection of argatroban can rescue bone loss in periodontal disease in vivo. To explore the underlying mechanism, we examined that cell proliferation and differentiation capability. Proliferation and migration of BMSCs were both inhibited by applying lower dose of argatroban. Interestingly, without affecting osteoclastogenesis, osteogenic differentiation was significantly induced by argatroban, which were shown by extracellular mineralization and upregulation of early osteoblastic differentiation markers, alkaline phosphatase, Osteocalcin, transcription factors RUNX2 and Osterix. In addition, molecular analysis revealed that argatroban promoted beta catenin nuclear translocation and led to an increase of osteogenesis through activating canonical Wnt signaling.
   Significance: Taken together, our results show the novel application of the anti coagulation compound argatroban in the commitment of BMSCs based alveolar bone regeneration and remodeling.
C1 [Song, Jian; Gan, Xueqi; Zhu, Zhuoli] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, 14,3rd Sect Renmin Nan Rd, Chengdu 610041, Sichuan, Peoples R China.
   [Jiang, Nan] Peking Univ Sch & Hosp Stomatol, Cent Lab, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.
   [Zhi, Wei] Southwest Jiaotong Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Adv Technol Mat, 111,1 North Erhuan Rd, Chengdu 610031, Sichuan, Peoples R China.
C3 Sichuan University; Southwest Jiaotong University
RP Zhu, ZL (通讯作者)，14,3rd Sect Renmin Nan Rd, Chengdu 610041, Sichuan, Peoples R China.
EM zhuzhuoli@scu.edu.cn
FU National Natural Science Foundation of China [81800948, 81970901]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81800948, 81970901).
CR Abraham LA, 1999, J BONE MINER RES, V14, P1320, DOI 10.1359/jbmr.1999.14.8.1320
   Aronovich A, 2013, BLOOD, V122, P2562, DOI 10.1182/blood 2012 08 447458
   Asanuma K, 2013, BREAST CANCER TOKYO, V20, P241, DOI 10.1007/s12282 012 0334 5
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bianco P, 2011, BLOOD, V117, P5281, DOI 10.1182/blood 2011 01 315069
   Cossy J, 2001, BIOORG MED CHEM LETT, V11, P1989, DOI 10.1016/S0960 894X(01)00351 1
   Escolar G, 2006, DRUG TODAY, V42, P223, DOI 10.1358/dot.2006.42.4.953588
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gionis MN, 2013, THROMB RES, V132, P685, DOI 10.1016/j.thromres.2013.09.037
   GUSTAFSON GT, 1983, BIOSCIENCE REP, V3, P255, DOI 10.1007/BF01122457
   Hamano K, 2002, ANN THORAC SURG, V73, P1210, DOI 10.1016/S0003 4975(02)03373 8
   Hantgan RR, 1998, BLOOD, V92, P2064, DOI 10.1182/blood.V92.6.2064.418k07_2064_2074
   Jiang N, 2014, BIOMATERIALS, V35, P2172, DOI 10.1016/j.biomaterials.2013.11.061
   Kawasumi M, 2008, J BONE JOINT SURG BR, V90B, P966, DOI 10.1302/0301 620X.90B7.20235
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Li XX, 2001, LIFE SCI, V68, P1343, DOI 10.1016/S0024 3205(00)01036 5
   Lyden P, 2014, STROKE, V45, P896, DOI 10.1161/STROKEAHA.113.004488
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Macfarlane SR, 2001, PHARMACOL REV, V53, P245
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Narayanan Varsha BA, 2019, INT J RES ORTHOPAEDI, V5, P5
   Pagel CN, 2009, BONE, V44, P813, DOI 10.1016/j.bone.2008.12.031
   Rocha AL, 2020, THROMB RES, V186, P45, DOI 10.1016/j.thromres.2019.12.014
   Rudulier CD, 2015, J ALLERGY CLIN IMMUN, V135, pAB83, DOI 10.1016/j.jaci.2014.12.1202
   Schliephake H, 2002, INT J ORAL MAX SURG, V31, P469, DOI 10.1054/ijom.2002.0244
   Shaughnessy AF, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.d741
   Shi J, 2017, J PERIODONTAL RES, V52, P725, DOI 10.1111/jre.12439
   Simman R, 2008, ANN PLAS SURG, V61, P337, DOI 10.1097/SAP.0b013e318157a185
   Song SJ, 2005, INT J BIOCHEM CELL B, V37, P206, DOI 10.1016/j.biocel.2004.04.026
   Strukova SM, 2001, BIOCHEMISTRY MOSCOW+, V66, P8, DOI 10.1023/A:1002869310180
   Tarzami ST, 2006, J THROMB HAEMOST, V4, P656, DOI 10.1111/j.1538 7836.2006.01788.x
   Xu JL, 2019, MED ORAL PATOL ORAL, V24, pE704, DOI 10.4317/medoral.23015
   Zhang P, 2012, CIRCULATION, V126, P83, DOI 10.1161/CIRCULATIONAHA.112.091918
NR 34
TC 3
Z9 3
U1 0
U2 15
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD MAR 15
PY 2021
VL 269
AR 119073
DI 10.1016/j.lfs.2021.119073
EA JAN 2021
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA QE4SC
UT WOS:000616196300039
PM 33460666
DA 2025 08 17
ER

PT J
AU Bagi, CM
   Volberg, M
   Moalli, M
   Shen, V
   Olson, E
   Hanson, N
   Berryman, E
   Andresen, CJ
AF Bagi, Cedo M.
   Volberg, Marlo
   Moalli, Maria
   Shen, Victor
   Olson, Ellen
   Hanson, Nels
   Berryman, Edwin
   Andresen, Catharine J.
TI Age related changes in marmoset trabecular and cortical bone and
   response to alendronate therapy resemble human bone physiology and
   architecture
SO ANATOMICAL RECORD ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY
   BIOLOGY
LA English
DT Article
DE marmoset; osteoporosis; bone remodeling; bone structure; micro CT;
   histomorphometry
ID BIOMEDICAL RESEARCH; CALLITHRIX JACCHUS; WORLD MONKEY; BISPHOSPHONATES;
   MECHANISMS; MODELS; RATS; 1 ALPHA,25 DIHYDROXYVITAMIN D3; RESORPTION;
   STRENGTH
AB In older humans, bone elongation ceases, periosteal expansion continues, and bone remodeling remains a dominant metabolic process. An appropriate animal model of type I and type II osteoporosis would be a species with sealed growth plates and persistence of bone remodeling. The rat is commonly used as a primary model, but due to delayed epiphyseal closure with continuous modeling and lack of Haversian remodeling, Food and Drug Administration guidelines recommend assessment of bone quality in an additional, nonrodent, remodeling species. This study investigated the skeletal characteristics of senescent marmosets to evaluate their suitability as an osteoporosis model. Animals were randomized across three experimental groups; controls for both sexes and marmosets receiving alendronate for either 30 or 60 days (28 mu g/kg, sc, twice per week). Outcome measures included serum chemistry and bone biomarkers, DEXA, histomorphometry, micro computed tomography, and histopathology. Results showed that the adult marmoset skeleton has similar anatomical characteristics to the adult human, including the absence of growth plates, presence of Haversian system, and true remodeling of cancellous and cortical bone. Structural analyses of senescent marmoset cancellous bone demonstrated loss of trabecular mass and architecture similar to skeletal changes described for elderly men and women. Treatment with alendronate improved trabecular volume and number by reducing bone resorption, although bone formation was also reduced through coupling of bone remodeling. The common marmoset may provide a valuable model for research paradigms targeting human bone pathology and osteoporosis due to skeletal features that are similar to age related changes and response to bisphosphonate therapy reported for humans.
C1 Pfizer Inc, Comparat Med, PGRD, Groton, CT 06340 USA.
   SkeleTech Inc, Bothell, WA USA.
C3 Pfizer; Pfizer USA
RP Bagi, CM (通讯作者)，Pfizer Inc, Comparat Med, PGRD, Eastern Point Rd 8118W 207, Groton, CT 06340 USA.
EM cedo.bagi@pfizer.com
CR Abbott DH, 2003, COMPARATIVE MED, V53, P339
   ABE T, 1992, BONE MINER, V19, P21, DOI 10.1016/0169 6009(92)90841 Z
   Bagi CM, 2006, BONE, V38, P136, DOI 10.1016/j.bone.2005.07.028
   BARON R, 1984, ANAT RECORD, V208, P137, DOI 10.1002/ar.1092080114
   Berkovitz BKB, 2000, ARCH ORAL BIOL, V45, P987, DOI 10.1016/S0003 9969(00)00067 4
   BONJOUR JP, 1980, MINER ELECTROL METAB, V3, P261
   CAPEN CC, 1989, CLIN BIOCH DOMESTIC, P687
   CHOW JWM, 1993, BONE, V14, P355, DOI 10.1016/8756 3282(93)90164 6
   COLMAN RJ, 1997, J BONE MINER RES  S1, V12, pS342
   *FDA, 1994, GUID PRECL CLIN EV A
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   GUELA C, 2002, ACTA NEUROLPATHOL BE, V103, P48
   Hanson NA, 2004, BONE, V35, P326, DOI 10.1016/j.bone.2004.02.019
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   HUNT RD, 1969, AM J CLIN NUTR, V22, P358
   Jerome CP, 1997, CALCIFIED TISSUE INT, V60, P265, DOI 10.1007/s002239900227
   Jerome CP, 2001, BONE, V29, P1, DOI 10.1016/S8756 3282(01)00477 X
   Kaspareit J, 2006, EXP TOXICOL PATHOL, V57, P405, DOI 10.1016/j.etp.2006.02.013
   Layne DG, 2003, COMPARATIVE MED, V53, P351
   LIBERMAN UA, 1985, FEBS LETT, V182, P385, DOI 10.1016/0014 5793(85)80338 0
   Ludlage E, 2003, COMPARATIVE MED, V53, P369
   Mansfield K, 2003, COMPARATIVE MED, V53, P383
   PARFITT AM, 1982, METAB BONE DIS RELAT, V4, P1, DOI 10.1016/0221 8747(82)90002 9
   PETLOMAKI T, 2002, J ORAL MAXILLOFACIAL, V60, P1307
   PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201
   PRYCE C, 1997, HDB MARMOSETS TAMARI
   ROBINSON PD, 1994, J CRAN GENET DEV BIO, V14, P245
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   RODGERS JB, 1993, BONE, V14, P369, DOI 10.1016/8756 3282(93)90166 8
   Rosenthal U., 1993, Journal of Contingencies and Crisis Management, V1, P1, DOI DOI 10.1111/j.1468 5973.1993.tb00001.x
   SHINKI T, 1983, BIOCHEM BIOPH RES CO, V114, P452, DOI 10.1016/0006 291X(83)90801 X
   TURNER CH, 1991, BONE, V12, P203, DOI 10.1016/8756 3282(91)90043 I
   WRONSKI TJ, 1988, CALCIFIED TISSUE INT, V43, P179, DOI 10.1007/BF02571317
   ZIMOLO Z, 1995, J CLIN INVEST, V96, P2277, DOI 10.1172/JCI118283
NR 35
TC 17
Z9 18
U1 0
U2 2
PU WILEY LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1932 8486
J9 ANAT REC
JI Anat. Rec.
PD AUG
PY 2007
VL 290
IS 8
BP 1005
EP 1016
DI 10.1002/ar.20561
PG 12
WC Anatomy & Morphology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology
GA 194FX
UT WOS:000248331000006
PM 17610276
DA 2025 08 17
ER

PT J
AU Wang, YF
   Hao, ZC
   Lu, DX
   Naseem, A
   Sun, Y
   Sun, Y
   Li, JZ
   Kuang, HX
   Liu, Y
   Yang, BY
AF Wang, Yanfu
   Hao, Zhichao
   Lu, Dongxu
   Naseem, Anam
   Sun, Ye
   Sun, Yan
   Li, Jianzhe
   Kuang, Haixue
   Liu, Yan
   Yang, Bingyou
TI Effects of Viscum coloratum (Kom.) Nakai on collagen induced rheumatoid
   arthritis
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Viscum coloratum (Kom.) Nakai; Traditional Chinese medicine; Rheumatoid
   arthritis; Inflammation; Cytokine antibody microarray
AB Ethnopharmacological relevance: Viscum coloratum (Kom.) Nakai has been traditionally used in China for nearly a thousand years to treat rheumatic diseases. However, its efficacy and mechanisms in treating rheumatoid arthritis (RA) have not been demonstrated. Aim of the study: To investigate the anti arthritic effects and molecular mechanisms of Viscum coloratum (Kom.) Nakai on collagen induced arthritic mice through network pharmacology technology and experimental validation. Materials and methods: First, the main ingredients of the extract of Viscum coloratum (Kom.) Nakai (EVC) were identified through chemical composition characterization using Ultra Performance Liquid Chromatography Tandem Mass Spectrometry (UPLC MS). Then, the collagen induced arthritis (CIA) model was established in DBA/1 J mice and the ameliorative effects of EVC on the progression of CIA mice were evaluated by oral treatment with different doses of the EVC for 28 days. After that, cytokine antibody microarray assay was used to detect the levels of multiple inflammation related cytokines and chemokines in each group, and performed Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genome (KEGG) enrichment analysis. Subsequently, the potential target for the effective chemical components of EVC in treating RA was identified using various databases. Additionally, a drug disease target protein protein interaction network (PPI) was conducted using Cytoscape for visualization and clustering, while GO and KEGG enrichment analyses were performed with the Metascape database. Finally, identified phenotypes and targets by network pharmacology analysis were experimentally validated in vivo. Results: Treatment with EVC significantly suppressed the severity of CIA with a dramatic reduction of paw swelling, arthritis index, levels of IgGs (IgG, IgG1, IgG2a, and IgG2b), multi inflammation related cytokines and chemokines on the progression of CIA. Histopathological examinations showed EVC could markedly inhibit inflammatory cell infiltration, tartrate resistant acid phosphatase (TRAP) activity of osteoclast, and bone destruction. Furthermore, GO and KEGG enrichment analyses revealed that EVC could ameliorate RA by inhibiting osteoclast differentiation and regulating multiple signaling pathways including Osteoclast differentiation, IL 17, and TNF. PPI network analysis demonstrated that AKT1, MMP9, MAPK3, and other genes were highly related to EVC in treating RA. Finally, we proved that EVC could inhibit the expression of NFTAc1, MMP9, Cathepsin K, and AKT which were closely related to osteoclast activity. Conclusions: EVC could treat RA through multiple components, multiple targets, and multiple pathways. The present study demonstrated the therapeutic efficacy of EVC and its molecular mechanisms in treating RA, indicating that it would be a potent candidate as a novel botanical drug for further investigation.
C1 [Wang, Yanfu; Hao, Zhichao; Lu, Dongxu; Naseem, Anam; Sun, Ye; Sun, Yan; Li, Jianzhe; Kuang, Haixue; Liu, Yan; Yang, Bingyou] Heilongjiang Univ Chinese Med, Key Lab Basic & Applicat Res Beiyao, Minist Educ, Harbin 150040, Peoples R China.
C3 Heilongjiang University of Chinese Medicine
RP Liu, Y; Yang, BY (通讯作者)，Heilongjiang Univ Chinese Med, Key Lab Basic & Applicat Res Beiyao, Minist Educ, Harbin 150040, Peoples R China.
EM lifeliuyan@163.com; ybywater@163.com
OI Yang, Bingyou/0000 0002 2310 2750; Naseem, Anam/0000 0002 9889 5046
FU National Natural Science Foundation of China (NSFC) [U22A20370];
   Heilongjiang Touyan Innovation Team Program [[2019]5]; Heilongjiang
   Province "Double First Class" Discipline Collaborative Innovation
   Achievement Construction Project [LJGXCG2022 096]; Key Research and
   Development Plan of Heilongjiang Province [GA21D008]
FX This study was financially supported by the National Natural Science
   Foundation of China (NSFC) (U22A20370), Heilongjiang Touyan Innovation
   Team Program ([2019]5), Heilongjiang Province "Double First Class"
   Discipline Collaborative Innovation Achievement Construction Project
   (LJGXCG2022 096), Key Research and Development Plan of Heilongjiang
   Province (GA21D008).
CR Achudhan D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.790925
   Chen L, 2014, ONCOL REP, V31, P737, DOI 10.3892/or.2013.2879
   CHEN YF, 1995, PLANTA MED, V61, P2, DOI 10.1055/s 2006 957987
   Choi JK, 2016, TOXICOL APPL PHARM, V290, P1, DOI 10.1016/j.taap.2015.11.005
   Grötsch B, 2019, J BONE MINER RES, V34, P1352, DOI 10.1002/jbmr.3705
   Guo X, 2021, PHYTOMEDICINE, V93, DOI 10.1016/j.phymed.2021.153801
   Han N, 2011, CHEM BIODIVERS, V8, P1682, DOI 10.1002/cbdv.201000289
   Hwang TL, 2006, FREE RADICAL BIO MED, V41, P1433, DOI 10.1016/j.freeradbiomed.2006.08.001
   Inglis JJ, 2008, NAT PROTOC, V3, P612, DOI 10.1038/nprot.2008.19
   KOSUGE T, 1985, CHEM PHARM BULL, V33, P5351
   Li L, 2021, MOLECULES, V26, DOI 10.3390/molecules26247681
   Li N, 2023, PHYTOMEDICINE, V109, DOI 10.1016/j.phymed.2022.154562
   Li YQ, 2022, J ETHNOPHARMACOL, V282, DOI 10.1016/j.jep.2021.114602
   Mezzetti A, 2005, LUPUS, V14, P769, DOI 10.1191/0961203305lu2218oa
   Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046
   Shang LR, 2023, J ETHNOPHARMACOL, V302, DOI 10.1016/j.jep.2022.115876
   Shen Y, 2022, J ETHNOPHARMACOL, V284, DOI 10.1016/j.jep.2021.114791
   Simirgiotis MJ, 2016, MOLECULES, V21, DOI 10.3390/molecules21030245
   Singh VK, 2024, J BIOMOL STRUCT DYN, V42, P3906, DOI 10.1080/07391102.2023.2216299
   Song XQ, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106179
   Sul OJ, 2021, MOLECULES, V26, DOI 10.3390/molecules26226949
   Tsai SW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051351
   Wang WY, 2018, EUR J MED CHEM, V158, P502, DOI 10.1016/j.ejmech.2018.09.027
   Xie BP, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109045
   Yang WZ, 2017, ACTA PHARM SIN B, V7, P439, DOI 10.1016/j.apsb.2017.04.012
   Yoo JM, 2017, MOLECULES, V22, DOI 10.3390/molecules22010037
   Zeng QO, 2010, BIOMATERIALS, V31, P5772, DOI 10.1016/j.biomaterials.2010.04.022
   Zhang RZ, 2022, J PHARM ANAL, V12, P243, DOI 10.1016/j.jpha.2021.04.003
NR 28
TC 7
Z9 7
U1 3
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUN 12
PY 2024
VL 327
AR 118026
DI 10.1016/j.jep.2024.118026
EA MAR 2024
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA QV8G6
UT WOS:001223730700001
PM 38490288
DA 2025 08 17
ER

PT J
AU Ma, XY
   Wen, XX
   Yang, XJ
   Zhou, DP
   Wu, Q
   Feng, YF
   Ding, HJ
   Lei, W
   Yu, HL
   Liu, B
   Xiang, LB
   Wang, TS
AF Ma, Xiang Yu
   Wen, Xin Xin
   Yang, Xiao Jiang
   Zhou, Da Peng
   Wu, Qiong
   Feng, Ya Fei
   Ding, Hai Jiao
   Lei, Wei
   Yu, Hai Long
   Liu, Bing
   Xiang, Liang Bi
   Wang, Tian Sheng
TI Ophiopogonin D improves osteointegration of titanium alloy implants
   under diabetic conditions by inhibition of ROS overproduction via
   Wnt/β catenin signaling pathway
SO BIOCHIMIE
LA English
DT Article
DE Titanium; Diabetes; Ophiopogonin D; Antioxidant; Wnt/beta catenin
ID OXIDATIVE STRESS; IN VIVO; INDUCED APOPTOSIS; AQUEOUS EXTRACT; 2
   CONSTITUENTS; BONE; CELLS; DIFFERENTIATION; MELLITUS; PROLIFERATION
AB A high failure rate of titanium implants in diabetic patients has been indicated in clinical evidences. Excessive oxidative stress at the bone implant interface plays an important role in the impaired osteointegration under diabetic conditions. While the underlying mechanisms remain unknown and the targeted treatments are urgently needed. Ophiopogonin D (OP D), isolated from Chinese herbal Radix Ophiopogon japonicas, is generally reported to be a potent antioxidant agent. In the present study, we hypothesized that OP D exerted promotive effects on osteointegration against oxidative stress, and investigated the underlying mechanisms associated with alteration of Wnt/beta catenin signaling pathway. Rabbit osteoblasts incubated on titanium alloy implant were co cultured with normal serum (NS), diabetic serum (DS), DS + OP D, DS + NAC (a potent ROS inhibitor) and DS + OP D + Dkk1 (a Wnt inhibitor) for examinations of osteoblast behaviors. For in vivo study, titanium alloy implants were implanted into the femoral condyle defects on diabetic rabbits. Results demonstrated that diabetes induced oxidative stress resulted in osteoblast dysfunctions and apoptotic injury at the bone implant interface, concomitant with the inactivation of Wnt/beta catenin signaling. Importantly, OP D administration attenuated oxidative stress, directly reactivating Wnt/beta catenin signaling. Osteoblast dysfunctions were thus reversed as evidenced by improved osteoblast adhesion, proliferation and differentiation, and ameliorated apoptotic injury, exerting similar effects to NAC treatment. In addition, the positive effects afforded by OP D were confirmed by improved osteointegration and oetogenesis within the titanium alloy implants in vivo by Micro CT and histological analyses. Furthermore, the pro osteogenic effects of OP D were almost completely abolished by the Wnt inhibitor Dkk1. These results demonstrated, for the first time, OP D administration alleviated the damaged osteointegration of titanium alloy implants under diabetic conditions by means of inhibiting oxidative stress via a Wnt/beta catenin dependent mechanism. The OP D administration would become a reliable treatment strategy for implant failure therapy in diabetics due to the optimal anti oxidative and pro osteogenic properties. (C) 2018 Published by Elsevier B.V.
C1 [Ma, Xiang Yu; Zhou, Da Peng; Yu, Hai Long; Liu, Bing; Xiang, Liang Bi] Shenyang Mil Area Command Chinese PLA, Gen Hosp, Dept Orthoped, Shenyang 110016, Liaoning, Peoples R China.
   [Ma, Xiang Yu; Wen, Xin Xin; Ding, Hai Jiao; Wang, Tian Sheng] 463 Hosp PLA, Dept Orthoped, Shenyang 110042, Liaoning, Peoples R China.
   [Yang, Xiao Jiang; Feng, Ya Fei; Lei, Wei] Air Force Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Shaanxi, Peoples R China.
   [Wu, Qiong] Shenyang Pharmaceut Univ, Sch Pharm, Dept Pharmaceut, Shenyang 110164, Peoples R China.
C3 Air Force Medical University; Shenyang Pharmaceutical University
RP Xiang, LB (通讯作者)，Shenyang Mil Area Command Chinese PLA, Gen Hosp, Dept Orthoped, Shenyang 110016, Liaoning, Peoples R China.; Wang, TS (通讯作者)，463 Hosp PLA, Dept Orthoped, Shenyang 110042, Liaoning, Peoples R China.
EM cliffmjx@163.com; xiangliangbi1963@sina.com; Tianshengwangmr@163.com
RI Liu, Lu/AAM 4152 2020; yu, hailong/F 7716 2011; MA,
   XIANGYU/AAS 6485 2021
OI Dapeng, Zhou/0000 0001 7455 5699; 
FU Research Fund for the National Natural Science Foundation of China
   [81702131]; Liao Ning Province Natural Science Foundation of China
   [201601411, 20170540924]
FX This work was supported by the grant from the Research Fund for the
   National Natural Science Foundation of China (No. 81702131) to Xiang Yu
   Ma, Liao Ning Province Natural Science Foundation of China (No.
   201601411) to Xiang Yu Ma, and Liao Ning Province Natural Science
   Foundation of China (No. 20170540924) to Xin Xin Wen.
CR Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   [Anonymous], EVID BASED COMPL ALT
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Bai YJ, 2016, MAT SCI ENG C MATER, V59, P565, DOI 10.1016/j.msec.2015.10.062
   Declercq H, 2004, BIOMATERIALS, V25, P757, DOI 10.1016/S0142 9612(03)00580 5
   Feng YF, 2013, BIOMATERIALS, V34, P2234, DOI 10.1016/j.biomaterials.2012.12.023
   Gali NK, 2016, J APPL TOXICOL, V36, P1355, DOI 10.1002/jat.3341
   Galli C, 2011, J DENT RES, V90, P360, DOI 10.1177/0022034510386488
   Hou CJ, 2012, INT J ORAL MAX SURG, V41, P400, DOI 10.1016/j.ijom.2011.10.004
   Huang Q, 2015, BONE, V74, P18, DOI 10.1016/j.bone.2015.01.002
   Isomura H, 2004, TOXICOLOGY, V197, P93, DOI 10.1016/j.tox.2003.12.006
   Kou JP, 2005, BIOL PHARM BULL, V28, P1234, DOI 10.1248/bpb.28.1234
   Kou J, 2006, BIOL PHARM BULL, V29, P1267, DOI 10.1248/bpb.29.1267
   Kurra S, 2011, DIABETES METAB RES, V27, P430, DOI 10.1002/dmrr.1197
   Li X, 2015, BIOMATERIALS, V36, P44, DOI 10.1016/j.biomaterials.2014.09.012
   Ma XY, 2014, BIOMATERIALS, V35, P7259, DOI 10.1016/j.biomaterials.2014.05.028
   Morris H F, 2000, Ann Periodontol, V5, P157, DOI 10.1902/annals.2000.5.1.157
   Niinomi M, 2008, J MECH BEHAV BIOMED, V1, P30, DOI 10.1016/j.jmbbm.2007.07.001
   Oates TW, 2009, J DENT RES, V88, P367, DOI 10.1177/0022034509334203
   Parthasarathy J, 2010, J MECH BEHAV BIOMED, V3, P249, DOI 10.1016/j.jmbbm.2009.10.006
   Portal Núñez S, 2010, FEBS LETT, V584, P3095, DOI 10.1016/j.febslet.2010.05.047
   Qi HH, 2016, BIOORG MED CHEM LETT, V26, P4720, DOI 10.1016/j.bmcl.2016.08.043
   Qian JC, 2010, J ETHNOPHARMACOL, V128, P438, DOI 10.1016/j.jep.2010.01.031
   Retzepi M, 2010, CLIN ORAL IMPLAN RES, V21, P673, DOI 10.1111/j.1600 0501.2010.01923.x
   Shirakawa J, 2016, FOOD FUNCT, V7, P2508, DOI [10.1039/C5FO01618E, 10.1039/c5fo01618e]
   Simmons JH, 2011, INT J PEDIATR ENDOCR, DOI 10.1186/1687 9856 2011 13
   Tai TW, 2017, SCI REP UK, V7, DOI 10.1038/srep44245
   Tsaryk R, 2007, BIOMATERIALS, V28, P806, DOI 10.1016/j.biomaterials.2006.09.033
   Wang L, 2015, CHEM BIOL INTERACT, V242, P255, DOI 10.1016/j.cbi.2015.10.010
   Wang L, 2016, COLLOID SURFACE B, V148, P440, DOI 10.1016/j.colsurfb.2016.09.018
   Wang X, 2012, BIOCHIMIE, V94, P1705, DOI 10.1016/j.biochi.2012.03.024
   Wu JC, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.7.FOCUS11125
   Yan Jian Yun, 2015, Nan Fang Yi Ke Da Xue Xue Bao, V35, P29
   Yu M, 2011, BONE, V49, P387, DOI 10.1016/j.bone.2011.05.025
   Zancan I, 2015, HUM MOL GENET, V24, P1280, DOI 10.1093/hmg/ddu538
   Zhang WY, 2016, MOL MED REP, V13, P4981, DOI 10.3892/mmr.2016.5198
   Zhang YY, 2015, J PHARMACOL EXP THER, V352, P166, DOI 10.1124/jpet.114.219261
NR 37
TC 25
Z9 28
U1 3
U2 44
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0300 9084
EI 1638 6183
J9 BIOCHIMIE
JI Biochimie
PD SEP
PY 2018
VL 152
BP 31
EP 42
DI 10.1016/j.biochi.2018.04.022
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA GS4RT
UT WOS:000443637700004
PM 29705132
DA 2025 08 17
ER

PT J
AU Jia, YW
   Jiang, JW
   Lu, XY
   Zhang, T
   Zhao, KX
   Han, WQ
   Yang, WL
   Qian, Y
AF Jia, Yewei
   Jiang, Jiawei
   Lu, Xuanyuan
   Zhang, Tan
   Zhao, Kangxian
   Han, Weiqi
   Yang, Wanlei
   Qian, Yu
TI Garcinol suppresses RANKL induced osteoclastogenesis and its underlying
   mechanism
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE AKT; garcinol; mitogen associated protein kinases (MAPK); nuclear
   factor kappa B (NF kappa B); osteoclast (OCs); osteoclastogenesis;
   therapeutics
ID DOWN REGULATION; DIFFERENTIATION; EPIDEMIOLOGY; OSTEOPOROSIS;
   ACTIVATION; INHIBITOR; APOPTOSIS; ERK
AB Osteoclasts (OCs) are multinuclear giant cells responsible for bone resorption, and an excessive bone resorption by OCs plays an important role in osteoporosis. Commonly used drugs for the treatment of osteoporosis have severe side effects. As such, identification of alternative treatments is essential. Garcinol, a polyisoprenylated benzophenone extracted from the fruit of Garcinia indica, has shown a strong antitumor effect through the nuclear factor kappa B (NF kappa B) and mitogen associated protein kinases (MAPK) signaling pathways. However, the role of garcinol in the osteoclastogenesis is still unclear. Here, we demonstrated that garcinol can inhibit the receptor activator of NF kappa B ligand (RANKL) induced osteoclastogenesis, osteoclastogenesis related gene expression, the f actin ring, and resorption pit formation. In addition, garcinol abrogated RANKL induced osteoclastogenesis by attenuating the degradation of the MAPK, NF kappa B, and PI3K AKT signaling pathway as well as downstream factors c jun, c fos, and NFATC1. In vivo, suppression of osteoclastogenesis by garcinol was evidenced by marked inhibition of lipopolysaccharide induced bone resorption. In conclusion, our data demonstrated that garcinol inhibited the RANKL induced osteoclastogenesis by suppressing the MAPK, NF kappa B, and PI3K AKT signaling pathways and thus has potential as a novel therapeutic option for osteolytic bone diseases.
C1 [Jia, Yewei; Jiang, Jiawei; Lu, Xuanyuan; Zhang, Tan; Zhao, Kangxian; Han, Weiqi; Yang, Wanlei; Qian, Yu] Zhejiang Univ, Shaoxing Peoples Hosp, Dept Orthopaed, Sch Med, 568 North ZhongXing Rd, Shaoxing 312000, Zhejiang, Peoples R China.
   [Zhang, Tan; Zhao, Kangxian] Wenzhou Med Univ, Dept Orthopaed, Affiliated Hosp 2, Wenzhou, Zhejiang, Peoples R China.
   [Zhang, Tan; Zhao, Kangxian] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China.
C3 Zhejiang University; Wenzhou Medical University; Wenzhou Medical
   University
RP Qian, Y (通讯作者)，Zhejiang Univ, Shaoxing Peoples Hosp, Dept Orthopaed, Sch Med, 568 North ZhongXing Rd, Shaoxing 312000, Zhejiang, Peoples R China.
EM doctor120@hotmail.com
OI Jia, Yewei/0000 0001 5447 973X
FU National Natural Science Foundation of China [81572126]; Natural Science
   Foundation of Zhejiang Province [LQ16H160013]; Zhejiang Basic Public
   Welfare Research Project [LGF18H060010]
FX National Natural Science Foundation of China, Grant/Award Number:
   81572126; Natural Science Foundation of Zhejiang Province, Grant/Award
   Number: LQ16H160013; Zhejiang Basic Public Welfare Research Project,
   Grant/Award Number: LGF18H060010
CR Balasubramanyam K, 2004, J BIOL CHEM, V279, P33716, DOI 10.1074/jbc.M402839200
   Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chaisson ML, 2004, J BIOL CHEM, V279, P54841, DOI 10.1074/jbc.M406392200
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237
   Kim J, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201600540
   Kim K, 2010, J IMMUNOL, V185, P7460, DOI 10.4049/jimmunol.1000885
   Liao CH, 2005, J CELL BIOCHEM, V96, P155, DOI 10.1002/jcb.20540
   Lin X, 2015, CLIN INTERV AGING, V10, P1017, DOI 10.2147/CIA.S54613
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Nason R, 2009, JARO J ASSOC RES OTO, V10, P151, DOI 10.1007/s10162 008 0153 8
   Qiao H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.11
   Ryu YK, 2018, J NEURAL TRANSM, V125, P1319, DOI 10.1007/s00702 018 1902 4
   Sattui SE, 2014, NAT REV ENDOCRINOL, V10, P592, DOI 10.1038/nrendo.2014.125
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Wang Y, 2015, J AGR FOOD CHEM, V63, P9047, DOI 10.1021/acs.jafc.5b03851
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Yu SY, 2014, J AGR FOOD CHEM, V62, P2085, DOI 10.1021/jf4037722
   Zhang Y, 2016, BIOL PHARM BULL, V39, P2028, DOI 10.1248/bpb.b16 00522
NR 22
TC 17
Z9 17
U1 0
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2019
VL 234
IS 5
BP 7498
EP 7509
DI 10.1002/jcp.27511
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HK7AQ
UT WOS:000458138600187
PM 30471112
DA 2025 08 17
ER

PT J
AU Xing, ZQ
   Lu, CY
   Hu, D
   Yu, YY
   Wang, XD
   Colnot, C
   Nakamura, M
   Wu, YL
   Miclau, T
   Marcucio, RS
AF Xing, Zhiqing
   Lu, Chuanyong
   Hu, Diane
   Yu, Yan yiu
   Wang, Xiaodong
   Colnot, Celine
   Nakamura, Mary
   Wu, Yalei
   Miclau, Theodore
   Marcucio, Ralph S.
TI Multiple roles for CCR2 during fracture healing
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
ID BONE MARROW; ANTIINFLAMMATORY DRUGS; MONOCYTE RECRUITMENT;
   SKELETAL MUSCLE; MICE; INHIBITION; DIFFERENTIATION; ANGIOGENESIS;
   INFLAMMATION; OSTEOCLAST
AB Bone injury induces an inflammatory response that involves neutrophils, macrophages and other inflammatory cells. The recruitment of inflammatory cells to sites of injury occurs in response to specific signaling pathways. The CC chemokine receptor type 2 (CCR2) is crucial for recruiting macrophages, as well as regulating osteoclast function. In this study, we examined fracture healing in Ccr2 /  mice. We first demonstrated that the expression of Ccr2 transcripts and the filtration of macrophages into fracture calluses were most robust during the early phases of fracture healing. We then determined that the number of macrophages at the fracture site was significantly lower in Ccr2 /  mice compared with wild type controls at 3 days after injury. As a result, impaired vascularization, decreased formation of callus, and delayed maturation of cartilage were observed at 7 days after injury in mutant mice. At day 14, Ccr2 /  mice had less bone in their calluses. At day 21, Ccr2 /  mice had larger calluses and more bone compared with wild type mice, suggesting a delayed remodeling. In addition, we examined the effect of Ccr2 mutation on osteoclasts. We found that a lack of Ccr2 did not affect the number of osteoclasts within fracture calluses at 21 days after injury. However, Ccr2 /  osteoclasts exhibited a decreased ability to resorb bone compared with wild type cells, which could contribute to the delayed remodeling of fracture calluses observed in Ccr2 /  mice. Collectively, these results indicate that a deficiency of Ccr2 reduces the infiltration of macrophages and impairs the function of osteoclasts, leading to delayed fracture healing.
C1 [Xing, Zhiqing; Lu, Chuanyong; Hu, Diane; Yu, Yan yiu; Wang, Xiaodong; Colnot, Celine; Miclau, Theodore; Marcucio, Ralph S.] Univ Calif San Francisco, San Francisco Gen Hosp, Orthopaed Trauma Inst, Lab Skeletal Regenerat, San Francisco, CA 94110 USA.
   [Xing, Zhiqing; Lu, Chuanyong; Hu, Diane; Yu, Yan yiu; Wang, Xiaodong; Colnot, Celine; Miclau, Theodore; Marcucio, Ralph S.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Orthopaed Surg, San Francisco, CA 94110 USA.
   [Nakamura, Mary; Wu, Yalei] Univ Calif San Francisco, Affairs Med Ctr, Arthrit Sect, San Francisco, CA 94121 USA.
C3 San Francisco General Hospital Medical Center; University of California
   System; University of California San Francisco; University of California
   System; University of California San Francisco; San Francisco General
   Hospital Medical Center; University of California System; University of
   California San Francisco
RP Marcucio, RS (通讯作者)，Univ Calif San Francisco, San Francisco Gen Hosp, Orthopaed Trauma Inst, Lab Skeletal Regenerat, San Francisco, CA 94110 USA.
EM Ralph.Marcucio@ucsf.edu
RI Nakamura, Mary/ABI 2887 2020; Colnot, Celine/D 4997 2017
OI Marcucio, Ralph/0000 0002 0537 818X; colnot, celine/0000 0001 8423 8718;
   Nakamura, Mary C./0000 0001 8127 9426; 
FU NIH [R01 5R01AR053645]; Synthes; Hellman Family Foundation
FX This work was funded by the NIH (R01 5R01AR053645 to T. M.). Z.X. was
   supported by a fellowship from Synthes and the Hellman Family
   Foundation. We thank the members of the Skeletal Regeneration laboratory
   in the Orthopaedic Trauma Institute at San Francisco General Hospital,
   especially Dr Xiaodong Wang, for discussions of this work and technical
   help. Deposited in PMC for release after 12 months.
CR ALTMAN RD, 1995, J ORTHOP TRAUMA, V9, P392, DOI 10.1097/00005131 199505000 00006
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798
   Capoccia BJ, 2008, J LEUKOCYTE BIOL, V84, P760, DOI 10.1189/jlb.1107756
   Champagne CM, 2002, BONE, V30, P26, DOI 10.1016/S8756 3282(01)00638 X
   Chang JK, 2007, BIOCHEM PHARMACOL, V74, P1371, DOI 10.1016/j.bcp.2007.06.047
   Contreras Shannon V, 2007, AM J PHYSIOL CELL PH, V292, pC953, DOI 10.1152/ajpcell.00154.2006
   Dimmen S, 2008, ACTA ORTHOP, V79, P438, DOI 10.1080/17453670710015373
   ENGESAETER LB, 1992, ACTA ORTHOP SCAND, V63, P330, DOI 10.3109/17453679209154794
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Gonzalez Francisco J., 2007, Cancer Biomarkers, V3, P325
   Ito S, 2007, BONE, V40, P84, DOI 10.1016/j.bone.2006.07.012
   Kalfas I H, 2001, Neurosurg Focus, V10, pE1
   Kellinsalmi M, 2007, EUR J PHARMACOL, V572, P102, DOI 10.1016/j.ejphar.2007.06.030
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   Lloberas J, 2002, EXP GERONTOL, V37, P1325, DOI 10.1016/S0531 5565(02)00125 0
   Lu CY, 2008, J ORTHOP RES, V26, P1384, DOI 10.1002/jor.20667
   Lu CY, 2005, J ORTHOP RES, V23, P1300, DOI 10.1016/j.orthres.2005.04.003
   Ma MH, 2002, J NEUROSCI RES, V68, P691, DOI 10.1002/jnr.10269
   MARKS SC, 1978, CLIN ORTHOP RELAT R, P259
   Mazibrada J, 2008, GYNECOL ONCOL, V108, P112, DOI 10.1016/j.ygyno.2007.08.095
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Ochoa O, 2007, AM J PHYSIOL REG I, V293, pR651, DOI 10.1152/ajpregu.00069.2007
   Ohta M, 2002, INT J CANCER, V102, P220, DOI 10.1002/ijc.10705
   Oshina H, 2007, BONE, V41, P575, DOI 10.1016/j.bone.2007.06.022
   Pountos I, 2008, INJURY, V39, P384, DOI 10.1016/j.injury.2007.10.035
   Rodríguez MDC, 2004, BLOOD, V103, P3349, DOI 10.1182/blood 2003 10 3438
   SCHMIDT CJ, 1977, RADIOLOGY, V122, P517, DOI 10.1148/122.2.517
   Schober A, 2004, CIRC RES, V95, P1125, DOI 10.1161/01.RES.0000149518.86865.3e
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   SUDMANN E, 1979, EUR J CLIN INVEST, V9, P333, DOI 10.1111/j.1365 2362.1979.tb00893.x
   Thompson Z, 2002, J ORTHOPAED RES, V20, P1091, DOI 10.1016/S0736 0266(02)00017 7
   Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919
   Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835
NR 35
TC 151
Z9 172
U1 1
U2 22
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754 8403
EI 1754 8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD JUL AUG
PY 2010
VL 3
IS 7 8
BP 451
EP 458
DI 10.1242/dmm.003186
PG 8
WC Cell Biology; Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Pathology
GA 622YD
UT WOS:000279702000012
PM 20354109
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Zhou, L
   Song, HY
   Zhang, YQ
   Ren, ZZ
   Li, MH
   Fu, Q
AF Zhou, Long
   Song, Hanyi
   Zhang, Yiqi
   Ren, Zhaozhou
   Li, Minghe
   Fu, Qin
TI Polyphyllin VII attenuated RANKL induced osteoclast differentiation via
   inhibiting of TRAF6/c Src/PI3K pathway and ROS production
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Polyphyllin VII; Bone marrow macrophages; Differentiation; osteoclast;
   ROS
ID OXIDATIVE STRESS; ACTIVATION; PREVENTION; RECEPTOR; CELLS
AB Background Osteoporosis is a worldwide severe bone disease. This study aimed to evaluate the effect of polyphyllin VII on the genesis of osteoclasts from bone marrow macrophages (BMMs) and its potentiality as a therapeutic drug for osteoporosis. Methods BMMs were induced to differentiate into osteoclasts by RANKL and M CSF. The cells were then treated with various concentrations of polyphyllin VII. Intracellular reactive oxygen species (ROS) measurement assay, resorption pit formation assay, tartrate resistant acid phosphatase (TRAP) staining and TRAP activity assessment, cell viability assay, active GTPase pull down assay, immunofluorescent staining, immunoblotting, and RT PCR were performed. Results RANKL + M CSF significantly increased TRAP activity, number of osteoclasts, number and area of lacunae, intracellular content of ROS, protein levels of Nox1, TRAF6, c Src and p PI3K, as well as the content of activated GTP Rac1, which were significantly blocked by polyphyllin VII in a concentration dependent manner. Conclusion These findings suggested that polyphyllin VII inhibited differentiation of BMMs into osteoclasts through suppressing ROS synthesis, which was modulated by TRAF6 cSrc PI3k signal transduction pathway including GTP Rac1 and Nox1. Polyphyllin VII could be a therapeutic drug for osteoporosis.
C1 [Zhou, Long; Zhang, Yiqi; Ren, Zhaozhou; Fu, Qin] China Med Univ, Dept Orthoped, Shengjing Hosp, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China.
   [Song, Hanyi] China Med Univ, Dept Gastroenterol, Shengjing Hosp, Shenyang, Peoples R China.
   [Li, Minghe] China Med Univ, Dept Clin Oncol, Shengjing Hosp, Shenyang, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University
RP Fu, Q (通讯作者)，China Med Univ, Dept Orthoped, Shengjing Hosp, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China.
EM fuqin_fq@163.com
RI Ren, Zhaozhou/ADI 5080 2022
CR Anastasilakis AD, 2012, THER CLIN RISK MANAG, V8, P295, DOI 10.2147/TCRM.S24239
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boudot C, 2010, BONE, V46, P1416, DOI 10.1016/j.bone.2010.01.383
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Chen Jun, 2015, Zhonghua Yi Xue Za Zhi, V95, P2393
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dawson Hughes B, 2012, OSTEOPOROSIS INT, V23, P811, DOI 10.1007/s00198 011 1694 y
   Finaud J, 2006, SPORTS MED, V36, P327, DOI 10.2165/00007256 200636040 00004
   He DX, 2016, ONCOTARGET, V7, P31814, DOI 10.18632/oncotarget.6674
   Hernlund E., 2013, ARCH OSTEOPOROS, V8, P1, DOI DOI 10.1007/S11657 013 0136 1
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jin H, 2010, J PHARMACOL EXP THER, V332, P738, DOI 10.1124/jpet.109.162297
   Kim MH, 2009, J CELL PHYSIOL, V221, P618, DOI 10.1002/jcp.21892
   Kong XY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0440 1
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SH, 2015, EXP CELL RES, V331, P267, DOI 10.1016/j.yexcr.2014.12.018
   Lee SH, 2014, INT J MOL SCI, V15, P10605, DOI 10.3390/ijms150610605
   Li ZH, 2013, PARASITOLOGY, V140, P952, DOI 10.1017/S0031182013000139
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384 4394.2004
   Sakai E, 2013, J PHARMACOL SCI, V121, P288, DOI 10.1254/jphs.12243FP
   Sasaki H, 2009, J MED INVESTIG, V56, P33, DOI 10.2152/jmi.56.33
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tan EM, 2017, J BONE MINER RES, V32, P846, DOI 10.1002/jbmr.3031
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Yao N, 2017, AM J CHINESE MED, V45, P575, DOI [10.1142/S0192415X17500343, 10.1142/s0192415x17500343]
   Zhang C, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1036 x
   Zhang C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147405
NR 29
TC 21
Z9 24
U1 2
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD FEB 19
PY 2020
VL 21
IS 1
AR 112
DI 10.1186/s12891 020 3077 z
PG 10
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA KQ9GO
UT WOS:000517229200003
PM 32075617
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Coleman, RE
   Gregory, W
   Marshall, H
   Wilson, C
   Holen, I
AF Coleman, R. E.
   Gregory, W.
   Marshall, H.
   Wilson, C.
   Holen, I.
TI The metastatic microenvironment of breast cancer: Clinical implications
SO BREAST
LA English
DT Article
DE Bisphosphonates; Adjuvant therapy; Bone marrow microenvironment;
   Metastasis
ID DIRECT ANTITUMOR ACTIVITY; ZOLEDRONIC ACID; TUMOR CELLS; NEOADJUVANT
   CHEMOTHERAPY; ADJUVANT TREATMENT; BONE METASTASIS; ORAL CLODRONATE;
   BISPHOSPHONATES; SURVIVAL; GROWTH
AB Metastasis to bone, and indeed potentially to other sites, results from the numerous interactions between cancer cells, haematopoietic stem cells and normal bone cells within the bone marrow microenvironment. These interactions are in turn influenced by multiple endocrine, paracrine and physical factors. Bone targeted treatments may modify the course of the disease via both direct and indirect inhibitory effects on this "vicious cycle" of growth factor and cytokine signalling between tumour and bone cells.
   Improvements in both disease free (DFS) and overall survival in women with early breast cancer have been demonstrated in several large randomised adjuvant trials of oral clodronate and intravenous zoledronic acid. The evidence for a beneficial impact on disease outcome is particularly strong in patients with low levels of reproductive hormones, including pre menopausal women receiving ovarian suppression therapy and those who have passed through menopause at the time of diagnosis. A recent metaanalysis of postmenopausal women treated with adjuvant bisphosphonates showed an 18% improvement in DFS (hazard ratio [HR] = 0.82; 95%CI 0.74 0.92, 2P = <0.001), with reductions in relapse rates not only in bone but also at extra skeletal and loco regional sites. These exciting findings are beginning to change clinical practice. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Coleman, R. E.; Wilson, C.; Holen, I.] Weston Pk Hosp, Acad Unit Clin Oncol, CR UK YCR Sheffield Canc Res Ctr, Sheffield S10 2SJ, S Yorkshire, England.
   [Gregory, W.; Marshall, H.] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England.
C3 Weston Park Hospital; University of Leeds
RP Coleman, RE (通讯作者)，Weston Pk Hosp, Acad Unit Clin Oncol, CR UK YCR Sheffield Canc Res Ctr, Witham Rd, Sheffield S10 2SJ, S Yorkshire, England.
EM r.e.coleman@sheffield.ac.uk
OI Marshall, Helen/0000 0003 0944 0152; Holen, Ingunn/0000 0002 8759 6913
CR Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   Bosch Barrera J, 2011, CLIN TRANSL ONCOL, V13, P148, DOI 10.1007/s12094 011 0634 9
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Brown JE, 2007, CLIN CANCER RES, V13, P5406, DOI 10.1158/1078 0432.CCR 07 0247
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman RE, 2010, BRIT J CANCER, V102, P1099, DOI 10.1038/sj.bjc.6605604
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   Comen EA, 2012, DISCOV MED, V14, P97
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Demicheli R, 1998, BREAST CANCER RES TR, V51, P133, DOI 10.1023/A:1005887422022
   Gnant M, 2011, CANCER RES, V71, DOI 10.1158/0008 5472.SABCS1151 2
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gregory W, 2012, J CLIN ONCOL, V30
   Hadji P, 2012, ANN ONCOL, V23, P2782, DOI 10.1093/annonc/mds169
   Holen I, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2769
   Horak CE, 2008, APMIS, V116, P586, DOI 10.1111/j.1600 0463.2008.01213.x
   Hu M, 2008, CURR OPIN GENET DEV, V18, P27, DOI 10.1016/j.gde.2007.12.006
   Käkönen SM, 2003, CANCER AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132
   Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025
   Martinez AS, 2012, J INTERN MED, DOI DOI 10.1111/J0IM.12024.[EPUB
   Massague Joan, 2003, Clin Adv Hematol Oncol, V1, P576
   Mocellin S, 2006, TRENDS MOL MED, V12, P130, DOI 10.1016/j.molmed.2006.01.006
   Möbus V, 2011, CANCER RES, V71, DOI 10.1158/0008 5472.SABCS11 52 4
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Ottewell PD, 2010, INT J CANCER, V126, P522, DOI 10.1002/ijc.24756
   Páez D, 2012, CLIN CANCER RES, V18, P645, DOI 10.1158/1078 0432.CCR 11 2186
   Paget S., 1889, Cancer and Metastasis Reviews, V8, P98
   Paterson AHG, 2012, LANCET ONCOL, V13, P734, DOI 10.1016/S1470 2045(12)70226 7
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Rack B, 2010, ANTICANCER RES, V30, P1807
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rogers TL, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 177
   Saidak Z, 2009, EXP CELL RES, V315, P2072, DOI 10.1016/j.yexcr.2009.03.003
   Shimamura T, 2005, BIOMED RES TOKYO, V26, P159, DOI 10.2220/biomedres.26.159
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Solomayer EF, 2012, ANN ONCOL, V23, P2271, DOI 10.1093/annonc/mdr612
   Stresing V, 2011, BONE, V48, P259, DOI 10.1016/j.bone.2010.09.035
   Taylor J, 2008, CANCER METAST REV, V27, P67, DOI 10.1007/s10555 007 9106 7
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wilson C, 2012, CANCER TREAT REV, V38, P877, DOI 10.1016/j.ctrv.2012.02.007
   Winter MC, 2013, CLIN CANCER RES, V19, P2755, DOI 10.1158/1078 0432.CCR 12 3235
NR 44
TC 57
Z9 68
U1 0
U2 15
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960 9776
EI 1532 3080
J9 BREAST
JI Breast
PD AUG 1
PY 2013
VL 22
SU 2
BP S50
EP S56
DI 10.1016/j.breast.2013.07.010
PG 7
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA 243JG
UT WOS:000326312100012
PM 24074793
OA hybrid
DA 2025 08 17
ER

PT J
AU Antoinette, AY
   Ziemian, SN
   Brown, AR
   Hudson, EB
   Chlebek, C
   Wright, TM
   Goldring, SR
   Goldring, MB
   Otero, M
   van der Meulen, MCH
AF Antoinette, Adrien Y.
   Ziemian, Sophia N.
   Brown, Allison R.
   Hudson, Erin B.
   Chlebek, Carolyn
   Wright, Timothy M.
   Goldring, Steven R.
   Goldring, Mary B.
   Otero, Miguel
   van der Meulen, Marjolein C. H.
TI PTH treatment before cyclic joint loading improves cartilage health and
   attenuates load induced osteoarthritis development in mice
SO SCIENCE ADVANCES
LA English
DT Article
ID CRUCIATE LIGAMENT TRANSECTION; SUBCHONDRAL BONE CHANGES;
   PARATHYROID HORMONE; ARTICULAR CARTILAGE; RNA SEQ; REDUCES PROGRESSION;
   EXPRESSION PROFILES; CHONDROCYTES; ALENDRONATE; MODEL
AB Osteoarthritis (OA) treatment is limited by the lack of effective nonsurgical interventions to slow disease progression. Here, we examined the contributions of the subchondral bone properties to OA development. We used parathyroid hormone (PTH) to modulate bone mass before OA initiation and alendronate (ALN) to inhibit bone remodeling during OA progression. We examined the spatiotemporal progression of joint damage by combining histopathological and transcriptomic analyses across joint tissues. The additive effect of PTH pretreatment before OA initiation and ALN treatment during OA progression most effectively attenuated load induced OA pathology. Individually, PTH directly improved cartilage health and slowed the development of cartilage damage, whereas ALN primarily attenuated subchondral bone changes associated with OA progression. Joint damage reflected early transcriptomic changes. With both treatments, the structural changes were associated with early modulation of immunoregulation and immunoresponse pathways that may contribute to disease mechanisms. Overall, our results demonstrate the potential of subchondral bone modifying therapies to slow the progression of OA.
C1 [Antoinette, Adrien Y.; Ziemian, Sophia N.; Brown, Allison R.; Hudson, Erin B.; Chlebek, Carolyn; van der Meulen, Marjolein C. H.] Cornell Univ, Ithaca, NY 14850 USA.
   [Wright, Timothy M.; Goldring, Steven R.; Goldring, Mary B.; Otero, Miguel; van der Meulen, Marjolein C. H.] Hosp Special Surg, New York, NY 10021 USA.
   [Otero, Miguel] Weill Cornell Med, New York, NY USA.
C3 Cornell University; Cornell University; Weill Cornell Medicine
RP van der Meulen, MCH (通讯作者)，Cornell Univ, Ithaca, NY 14850 USA.; van der Meulen, MCH (通讯作者)，Hosp Special Surg, New York, NY 10021 USA.
EM mcv3@cornell.edu
RI van der Meulen, Marjolein Christine Hermance/D 1549 2010; van der
   Meulen, Marjolein/D 1549 2010; Wright, Timothy/C 7617 2015
OI van der Meulen, Marjolein Christine Hermance/0000 0001 6637 9808;
   Antoinette, Adrien/0000 0001 8579 3377; Ziemian,
   Sophia/0000 0003 0086 2156; Wright, Timothy/0000 0001 7139 1908;
   Goldring, Mary/0000 0001 5407 9293
FU DOD PRMRP [W81XWH 17 1 0540]; NIH [T32 AR007281]; Clark Foundation
FX This work was funded by DOD PRMRP (W81XWH 17 1 0540), NIH (T32 AR007281)
   (S.N.Z. and M.C.H.v.d.M.), and the Clark Foundation.
CR Abramson SB, 2004, J RHEUMATOL, V31, P70, DOI 10.1097/BOR.0b013e328349c2b1
   Adebayo OO, 2017, OSTEOARTHR CARTILAGE, V25, P2108, DOI 10.1016/j.joca.2017.08.016
   Becher C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 28
   Bellido M, 2011, OSTEOARTHR CARTILAGE, V19, P1228, DOI 10.1016/j.joca.2011.07.003
   Bellido M, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3103
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bingham CO, 2006, ARTHRITIS RHEUM US, V54, P3494, DOI 10.1002/art.22160
   Botter SM, 2008, OSTEOARTHR CARTILAGE, V16, P506, DOI 10.1016/j.joca.2007.08.005
   Bouaziz W, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0540 6
   Burket JC, 2013, BONE, V52, P326, DOI 10.1016/j.bone.2012.10.018
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Casetti R, 2008, CELL MOL IMMUNOL, V5, P161, DOI 10.1038/cmi.2008.20
   Chang JC, 2017, J ORTHOP RES, V35, P474, DOI 10.1002/jor.23263
   Chen ZY, 2017, SCI REP UK, V7, DOI 10.1038/srep40508
   Chlebek C, 2022, J BONE MINER RES, V37, P2277, DOI 10.1002/jbmr.4686
   Chou CH, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 67730 y
   Chu LY, 2020, J BONE MINER RES, V35, P505, DOI 10.1002/jbmr.3909
   Culley KL, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 45334 5
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   Dequeker J, 2003, AGING CLIN EXP RES, V15, P426, DOI 10.1007/BF03327364
   Ding M, 2008, CALCIFIED TISSUE INT, V82, P77, DOI 10.1007/s00223 007 9093 2
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Doyran B, 2017, OSTEOARTHR CARTILAGE, V25, P108, DOI 10.1016/j.joca.2016.08.008
   du Sert NP, 2020, J CEREBR BLOOD F MET, V40, P1769, DOI [10.1186/s12917 020 02451 y, 10.1371/journal.pbio.3000410, 10.1177/0271678X20943823]
   Fisch KM, 2018, OSTEOARTHR CARTILAGE, V26, P1531, DOI 10.1016/j.joca.2018.07.012
   Fukui N, 2008, ARTHRITIS RHEUM US, V58, P154, DOI 10.1002/art.23175
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749 6632.2009.05240.x
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Goldring SR, 2012, THER ADV MUSCULOSKEL, V4, P249, DOI 10.1177/1759720X12437353
   Hartley A, 2020, OSTEOARTHR CARTILAGE, V28, P1180, DOI 10.1016/j.joca.2020.03.020
   Hayami T, 2006, BONE, V38, P234, DOI 10.1016/j.bone.2005.08.007
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   Holyoak DT, 2018, J ORTHOP RES, V36, P711, DOI 10.1002/jor.23731
   Hu QC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041742
   Hu Y, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00147 z
   Ji QB, 2019, ANN RHEUM DIS, V78, P100, DOI 10.1136/annrheumdis 2017 212863
   Kang X, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1099287
   Kelly NH, 2016, BONE, V86, P22, DOI 10.1016/j.bone.2016.02.007
   Khorasani MS, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0546 0
   Ko FC, 2013, ARTHRITIS RHEUM US, V65, P1569, DOI 10.1002/art.37906
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lewallen EA, 2016, GENE, V591, P456, DOI 10.1016/j.gene.2016.06.063
   Liao LF, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02490 w
   Little CB, 2009, ARTHRITIS RHEUM US, V60, P3723, DOI 10.1002/art.25002
   Lohan P, 2016, OSTEOARTHR CARTILAGE, V24, P521, DOI 10.1016/j.joca.2015.10.005
   Lopes EBP, 2017, CURR OSTEOPOROS REP, V15, P593, DOI 10.1007/s11914 017 0411 y
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Main RP, 2020, J ORTHOP RES, V38, P233, DOI 10.1002/jor.24466
   Melville KM, 2014, J BONE MINER RES, V29, P370, DOI 10.1002/jbmr.2082
   Nagata K, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33744 5
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Orth P, 2013, OSTEOARTHR CARTILAGE, V21, P614, DOI 10.1016/j.joca.2013.01.008
   RADIN EL, 1986, CLIN ORTHOP RELAT R, P34
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sanchez Lopez E, 2022, NAT REV RHEUMATOL, V18, P258, DOI 10.1038/s41584 022 00749 9
   Sebastian A, 2021, CELLS BASEL, V10, DOI 10.3390/cells10061462
   Sebastian A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010364
   Shao L, 2020, BONE JOINT RES, V9, P675, DOI 10.1302/2046 3758.910.BJR 2020 0018.R1
   Singh P, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 00269 8
   Singh P, 2019, ANN NY ACAD SCI, V1442, P17, DOI 10.1111/nyas.13930
   Soul J, 2018, ANN RHEUM DIS, V77, P423, DOI 10.1136/annrheumdis 2017 212603
   Steinberg J, 2021, ANN RHEUM DIS, V80, P1070, DOI 10.1136/annrheumdis 2020 219760
   Takimoto R, 2021, IMMUNOLOGY, V162, P306, DOI 10.1111/imm.13283
   Tandonnet S, 2017, GENOM DATA, V11, P9, DOI 10.1016/j.gdata.2016.11.002
   Tesche F, 2005, HISTOL HISTOPATHOL, V20, P329, DOI 10.14670/HH 20.329
   van der Kraan PM, 2007, OSTEOARTHR CARTILAGE, V15, P237, DOI 10.1016/j.joca.2006.11.006
   van Meurs JBJ, 2017, OSTEOARTHR CARTILAGE, V25, P181, DOI 10.1016/j.joca.2016.11.011
   Wang P, 2004, J BIOL CHEM, V279, P15434, DOI 10.1074/jbc.M312797200
   Wheeler TA, 2024, OSTEOARTHR CARTILAGE, V32, P287, DOI 10.1016/j.joca.2023.11.021
   Woodell May JE, 2020, J ORTHOP RES, V38, P253, DOI 10.1002/jor.24457
   Yang X, 2015, J BONE JOINT SURG AM, V97A, P1074, DOI 10.2106/JBJS.N.01052
   Yuan XL, 2014, OSTEOARTHR CARTILAGE, V22, P1077, DOI 10.1016/j.joca.2014.05.023
   Zhang L, 2011, CLIN EXP MED, V11, P235, DOI 10.1007/s10238 011 0131 z
   Zhu SS, 2013, BONE, V53, P340, DOI 10.1016/j.bone.2012.12.044
   Ziemian SN, 2021, BONE, V152, DOI 10.1016/j.bone.2021.116071
   Ziemian SN, 2021, J BONE MINER RES, V36, P2027, DOI 10.1002/jbmr.4397
NR 79
TC 5
Z9 6
U1 1
U2 12
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375 2548
J9 SCI ADV
JI Sci. Adv.
PD APR 19
PY 2024
VL 10
IS 16
AR eadk8402
DI 10.1126/sciadv.adk8402
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA OM3O3
UT WOS:001207652800004
PM 38640238
OA gold
DA 2025 08 17
ER

PT J
AU Zhang, ZG
   Chen, YJ
   Xiang, LH
   Pan, JH
   Wang, Z
   Xiao, GG
   Ju, DH
AF Zhang, Zhi Guo
   Chen, Yan Jing
   Xiang, Li Hua
   Pan, Jing Hua
   Wang, Zhen
   Xiao, Gary Guishan
   Ju, Da Hong
TI Protective effect of Rhizoma Dioscoreae extract against alveolar
   bone loss in ovariectomized rats via regulation of IL 6/STAT3 signaling
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE alveolar bone loss; interleukin 6/signal transducer and activator of
   transcription 3 signaling pathway; herbal medicine; ovariectomized rats;
   Rhizoma Dioscoreae
ID KAPPA B LIGAND; POSTMENOPAUSAL WOMEN; ONCOSTATIN M; OSTEOBLAST
   DIFFERENTIATION; REPLACEMENT THERAPY; PERIODONTAL DISEASE; RECEPTOR
   ACTIVATOR; CYTOKINES; RESORPTION; DENSITY
AB The aim of the present study was to assess the effectiveness of Rhizoma Dioscoreae extract (RDE) on preventing rat alveolar bone loss induced by ovariectomy (OVX), and to determine the role of interleukin 6 (IL 6)/signal transducer and activator of transcription 3 (STAT3) signaling pathway in this effect. Female Wistar rats were subjected to OVX or sham surgery. The rats that had undergone OVX were treated with RDE (RDE group), vehicle (OVX group) or 17 beta estradiol subcutaneous injection (E2 group). Subsequently, bone metabolic activity was assessed by analyzing 3 D alveolar bone construction, bone mineral density, as well as the plasma biomarkers of bone turnover. The gene expression of alveolar bone in the OVX and RDE groups was evaluated by IL 6/STAT3 signaling pathway polymerase chain reaction (PCR) arrays, and differentially expressed genes were determined through reverse transcription quantitative PCR. The inhibitory effect of RDE on alveolar bone loss in the OVX group was demonstrated in the study. In comparison with the OVX group, the RDE group exhibited 19 downregulated genes and 1 upregulated gene associated with the IL 6/STAT3 signaling pathway in alveolar bone. Thus, RDE was shown to relieve OVX induced alveolar bone loss in rats, an effect which was likely associated with decreased abnormal bone remodeling via regulation of the IL 6/STAT3 signaling pathway.
C1 [Zhang, Zhi Guo; Chen, Yan Jing; Xiang, Li Hua; Pan, Jing Hua; Wang, Zhen; Ju, Da Hong] China Acad Chinese Med Sci, Inst Basic Theory, 16 Nanxiaojie, Beijing 100700, Peoples R China.
   [Xiao, Gary Guishan] Dalian Univ Technol, Sch Pharmaceut Sci, 2 Linggong Rd, Dalian 116024, Liaoning, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Basic Theory for
   Chinese Medicine, CACMS; Dalian University of Technology
RP Ju, DH (通讯作者)，China Acad Chinese Med Sci, Inst Basic Theory, 16 Nanxiaojie, Beijing 100700, Peoples R China.; Xiao, GG (通讯作者)，Dalian Univ Technol, Sch Pharmaceut Sci, 2 Linggong Rd, Dalian 116024, Liaoning, Peoples R China.
EM gxiao@dlut.edu.cn; judahong@sohu.com
RI Xiao, Gary/LRU 9536 2024
FU National Natural Science Foundation of China [81473450]; Fundamental
   Research Funds for the Beijing Administration of Traditional Chinese
   Medicine [JJ2015 54]
FX The present study was supported by the National Natural Science
   Foundation of China (grant no. 81473450) and the Fundamental Research
   Funds for the Beijing Administration of Traditional Chinese Medicine
   (grant no. JJ2015 54).
CR Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137
   Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666
   Blanchard F, 2009, CYTOKINE GROWTH F R, V20, P19, DOI 10.1016/j.cytogfr.2008.11.004
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Civitelli R, 2002, ARCH INTERN MED, V162, P1409, DOI 10.1001/archinte.162.12.1409
   Clemett D, 2000, DRUGS, V60, P379, DOI 10.2165/00003495 200060020 00013
   Do Lee B, 2005, ORAL SURG ORAL MED O, V100, P92, DOI 10.1016/j.tripleo.2004.11.020
   Feng Xue Feng, 2008, Zhongguo Zhong Yao Za Zhi, V33, P859
   Gallagher JC, 2011, MENOPAUSE, V18, P109, DOI 10.1097/gme.0b013e3181e324a6
   Garbers C, 2012, CYTOKINE GROWTH F R, V23, P85, DOI 10.1016/j.cytogfr.2012.04.001
   Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357 4310(99)01540 3
   Guimaraes MV, 2016, J PERIODONTOL, V87, P706, DOI 10.1902/jop.2016.150411
   Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407
   Hidaka S, 1999, PHYTOTHER RES, V13, P14, DOI 10.1002/(SICI)1099 1573(199902)13:1<14::AID PTR375>3.0.CO;2 V
   Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Kim S, 2007, MOL ENDOCRINOL, V21, P197, DOI 10.1210/me.2006 0315
   Lindberg RA, 1998, MOL CELL BIOL, V18, P3357, DOI 10.1128/MCB.18.6.3357
   Liu JB, 2009, MED HYPOTHESES, V72, P294, DOI 10.1016/j.mehy.2008.10.015
   Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   Palomo L, 2005, MENOPAUSE, V12, P685, DOI 10.1097/01.gme.0000184421.50696.34
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Rossing MA, 2007, CANCER EPIDEM BIOMAR, V16, P2548, DOI 10.1158/1055 9965.EPI 07 0550
   Saglam M, 2015, J APPL ORAL SCI, V23, P33, DOI 10.1590/1678 775720140288
   Sims NA, 2010, BMB REP, V43, P513, DOI 10.5483/BMBRep.2010.43.8.513
   Streckfus CF, 1997, J GERONTOL A BIOL, V52, pM343, DOI 10.1093/gerona/52A.6.M343
   Strom BL, 2006, AM J EPIDEMIOL, V164, P775, DOI 10.1093/aje/kwj316
   Sugimoto H, 2015, PHYTOTHER RES, V29, P251, DOI 10.1002/ptr.5245
   Sultan N, 2011, MED ORAL PATOL ORAL, V16, pE440, DOI 10.4317/medoral.16.e440
   Tezal M, 2005, J PERIODONTOL, V76, P1123, DOI 10.1902/jop.2005.76.7.1123
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yang J, 2003, ACAD RADIOL, V10, P1153, DOI 10.1016/S1076 6332(03)00109 0
   Zhang Z., 2014, SCI WORLD J, V2014, DOI DOI 10.1155/2014/645975
   Zhang ZG, 2015, NUTRIENTS, V7, P1333, DOI 10.3390/nu7021333
   Zhang ZG, 2014, NUTRIENTS, V6, P5853, DOI 10.3390/nu6125853
NR 36
TC 4
Z9 4
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD NOV
PY 2017
VL 40
IS 5
BP 1602
EP 1610
DI 10.3892/ijmm.2017.3130
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FK3PS
UT WOS:000413398800032
PM 28901385
OA Bronze
DA 2025 08 17
ER

PT J
AU Yuan, BS
   Shi, KX
   Zha, JM
   Cai, YJ
   Gu, Y
   Huang, K
   Yue, WC
   Zhai, QC
   Ding, N
   Ren, WY
   He, WQ
   Xu, Y
   Wang, T
AF Yuan, Baoshi
   Shi, Kexin
   Zha, Juanmin
   Cai, Yujia
   Gu, Yue
   Huang, Kai
   Yue, Wenchang
   Zhai, Qiaocheng
   Ding, Ning
   Ren, Wenyan
   He, Weiqi
   Xu, Ying
   Wang, Tao
TI Nuclear receptor modulators inhibit osteosarcoma cell proliferation and
   tumour growth by regulating the mTOR signaling pathway
SO CELL DEATH & DISEASE
LA English
DT Article
ID PROSTATE CANCER CELLS; PPAR GAMMA; RETINOIC ACID; METABOLISM;
   IDENTIFICATION; ACTIVATION; VULNERABILITY; PROGRESSION; APOPTOSIS;
   MELANOMA
AB Osteosarcoma is the most common primary malignant bone tumour in children and adolescents. Chemoresistance leads to poor responses to conventional therapy in patients with osteosarcoma. The discovery of novel effective therapeutic targets and drugs is still the main focus of osteosarcoma research. Nuclear receptors (NRs) have shown substantial promise as novel therapeutic targets for various cancers. In the present study, we performed a drug screen using 29 chemicals that specifically target 17 NRs in several different human osteosarcoma and osteoblast cell lines. The retinoic acid receptor beta (RARb) antagonist LE135, peroxisome proliferator activated receptor gamma (PPARg) antagonist T0070907, liver X receptor (LXR) agonist T0901317 and Rev Erba agonist SR9011 significantly inhibited the proliferation of malignant osteosarcoma cells (U2OS, HOS MNNG and Saos 2 cells) but did not inhibit the growth of normal osteoblasts. The effects of these NR modulators on osteosarcoma cells occurred in a dose dependent manner and were not observed in NR knockout osteosarcoma cells. These NR modulators also significantly inhibited osteosarcoma growth in vivo and enhanced the antitumour effect of doxorubicin (DOX). Transcriptomic and immunoblotting results showed that these NR modulators may inhibit the growth of osteosarcoma cells by regulating the PI3K/AKT/mTOR and ERK/mTOR pathways. DDIT4, which blocks mTOR activation, was identified as one of the common downstream target genes of these NRs. DDIT4 knockout significantly attenuated the inhibitory effects of these NR modulators on osteosarcoma cell growth. Together, our results revealed that modulators of RARb, PPARg, LXRs and Rev Erba inhibit osteosarcoma growth both in vitro and in vivo through the mTOR signaling pathway, suggesting that treatment with these NR modulators is a novel potential therapeutic strategy.
C1 [Yuan, Baoshi; Shi, Kexin; Cai, Yujia; Gu, Yue; Huang, Kai; Ding, Ning; Ren, Wenyan; He, Weiqi; Xu, Ying; Wang, Tao] Soochow Univ, Cambridge Su Genom Resource Ctr, Suzhou Med Coll, Suzhou 215123, Jiangsu, Peoples R China.
   [Shi, Kexin] Zhejiang Univ, Life Sci Inst, Innovat Ctr Cell Signaling Network, Minist Educ Key,Lab Biosyst Homeostasis & Protect, Hangzhou 310030, Zhejiang, Peoples R China.
   [Zha, Juanmin] Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou 215006, Jiangsu, Peoples R China.
   [Yue, Wenchang] Soochow Univ, Affiliated Hosp 1, Dept Urol, Suzhou 215006, Jiangsu, Peoples R China.
   [Zhai, Qiaocheng] Soochow Univ, Affiliated Hosp 2, Dept Orthopaed, Suzhou 215004, Jiangsu, Peoples R China.
C3 Soochow University   China; Zhejiang University; Soochow University  
   China; Soochow University   China; Soochow University   China
RP Xu, Y; Wang, T (通讯作者)，Soochow Univ, Cambridge Su Genom Resource Ctr, Suzhou Med Coll, Suzhou 215123, Jiangsu, Peoples R China.
EM yingxu@suda.edu.cn; wangtao36@suda.edu.cn
RI Yue, Wenchang/IAQ 2792 2023; ren, wenyan/NNG 7426 2025; Zhai,
   Qiaocheng/GPK 2200 2022; Gu, Yue/JUF 7294 2023; Huang,
   Kai/JRX 9528 2023; Xu, Ying/A 3009 2013; He, Weiqi/I 7935 2013
OI Xu, Ying/0000 0002 6689 7768; Zha, Juanmin/0000 0002 1653 0845; ,
   Yue/0009 0009 4233 896X; He, Weiqi/0000 0003 3137 8420
FU National Natural Science Foundation of China [31601022]; National Key
   R&D Program of China [2018YFA0801104]; Livelihood and Technology Program
   of Suzhou City [N324560122]
FX We are very grateful to Dr. Eric Zhang for providing the U2OS cells.
   This work was supported by the grants from National Natural Science
   Foundation of China (31601022), National Key R & D Program of China
   (2018YFA0801104), and The Livelihood and Technology Program of Suzhou
   City (N324560122).
CR Adamopoulos C, 2016, EXP BIOL MED, V241, P1296, DOI 10.1177/1535370216648806
   Barroca V, 2022, LEUKEMIA, V36, P2140, DOI 10.1038/s41375 022 01609 x
   Brufsky AM, 2018, ONCOLOGIST, V23, P528, DOI 10.1634/theoncologist.2017 0423
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Carbó JM, 2021, CANCER RES, V81, P968, DOI 10.1158/0008 5472.CAN 19 3360
   Casali PG, 2018, ANN ONCOL, V29, P79, DOI 10.1093/annonc/mdy310
   Chandhanayingyong Chandhanarat, 2012, Sarcoma, V2012, P404810, DOI 10.1155/2012/404810
   Chang YW, 2013, CELL PHYSIOL BIOCHEM, V32, P180, DOI 10.1159/000350134
   Chuu CP, 2006, CANCER RES, V66, P6482, DOI 10.1158/0008 5472.CAN 06 0632
   Dahl C, 2019, METHODS MOL BIOL, V2019, P171, DOI 10.1007/978 1 4939 9585 1_12
   Derangère V, 2014, CELL DEATH DIFFER, V21, P1914, DOI 10.1038/cdd.2014.117
   Dong Z, 2016, CELL DEATH DIFFER, V23, P1602, DOI 10.1038/cdd.2016.47
   Dong Z, 2019, CANCER DISCOV, V9, P1556, DOI 10.1158/2159 8290.CD 19 0215
   Forootan FS, 2016, ONCOTARGET, V7, P9323, DOI 10.18632/oncotarget.6975
   Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072
   Fukuchi J, 2004, CANCER RES, V64, P7686, DOI 10.1158/0008 5472.CAN 04 2332
   Geng SJ, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04965 9
   Gill J, 2021, NAT REV CLIN ONCOL, V18, P609, DOI 10.1038/s41571 021 00519 8
   Gong BC, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.686898
   Gupte A, 2015, CLIN CANCER RES, V21, P3216, DOI 10.1158/1078 0432.CCR 14 3026
   Hobbs RM, 2010, CELL, V142, P468, DOI 10.1016/j.cell.2010.06.041
   Horak P, 2010, P NATL ACAD SCI USA, V107, P4675, DOI 10.1073/pnas.0907705107
   Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008 5472.CAN 11 2001
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Jimi S, 1998, ONCOL RES, V10, P7
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kesanakurti D, 2017, ONCOGENE, V36, P5309, DOI 10.1038/onc.2016.261
   Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982
   Kon N, 2021, GENE DEV, V35, DOI 10.1101/gad.348236.121
   Kourtidis A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2240
   Kresse SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048262
   Kuijjer ML, 2012, GENE CHROMOSOME CANC, V51, P696, DOI 10.1002/gcc.21956
   Lee JJ, 2012, ONCOGENE, V31, P3818, DOI 10.1038/onc.2011.543
   León NY, 2021, HUM GENET, V140, P1625, DOI 10.1007/s00439 021 02361 5
   Li Y, 1999, J BIOL CHEM, V274, P15360, DOI 10.1074/jbc.274.22.15360
   Li Y, 2020, HEPATOLOGY, V72, P1682, DOI 10.1002/hep.31196
   Luo P, 2010, ONCOGENE, V29, P2772, DOI 10.1038/onc.2010.50
   Miao ZF, 2021, GASTROENTEROLOGY, V160, P260, DOI 10.1053/j.gastro.2020.09.016
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293
   Overholtzer M, 2003, P NATL ACAD SCI USA, V100, P11547, DOI 10.1073/pnas.1934852100
   Pan Z, 2022, ONCOGENESIS, V11, DOI 10.1038/s41389 022 00390 x
   Patitucci C, 2017, J CLIN INVEST, V127, P1873, DOI 10.1172/JCI90327
   Pencheva N, 2014, CELL, V156, P986, DOI 10.1016/j.cell.2014.01.038
   Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111
   Pommier AJC, 2010, ONCOGENE, V29, P2712, DOI 10.1038/onc.2010.30
   Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092 8674(02)00825 5
   Qiao SX, 2020, GENE DEV, V34, P751, DOI 10.1101/gad.335166.119
   Rathore R, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108678
   REV ERB, 2018, CANCER DISCOV, V8, P261
   Sadikovic B, 2009, HUM MOL GENET, V18, P1962, DOI 10.1093/hmg/ddp117
   Schaefer KL, 2005, CANCER RES, V65, P2251, DOI 10.1158/0008 5472.CAN 04 3037
   Scheiermann C, 2013, NAT REV IMMUNOL, V13, P190, DOI 10.1038/nri3386
   Shorning BY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124507
   Sobecki M, 2017, CANCER RES, V77, P2722, DOI 10.1158/0008 5472.CAN 16 0707
   Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030
   Sulli G, 2018, NATURE, V553, P351, DOI 10.1038/nature25170
   Tsai HC, 2019, AGING US, V11, P9767, DOI 10.18632/aging.102423
   Wang T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.9
   Wang X, 2013, ONCOGENE, V32, P5512, DOI 10.1038/onc.2013.217
   Wenes M, 2016, CELL METAB, V24, P701, DOI 10.1016/j.cmet.2016.09.008
   Yang ZN, 2021, TRENDS CANCER, V7, P541, DOI 10.1016/j.trecan.2020.11.007
   Youssef J, 2011, BRIT J PHARMACOL, V164, P68, DOI 10.1111/j.1476 5381.2011.01383.x
   Yun SH, 2018, PPAR RES, V2018, DOI 10.1155/2018/6727421
   Zeyen L, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23063322
   Zhang J, 2015, CLIN CHIM ACTA, V444, P182, DOI 10.1016/j.cca.2014.12.041
   Zhao LJ, 2019, ENDOCR REV, V40, P1207, DOI 10.1210/er.2018 00222
   Zhao X, 2014, EMBO REP, V15, P518, DOI 10.1002/embr.201338271
   Zou YK, 2019, CANCER DISCOV, V9, P1720, DOI 10.1158/2159 8290.CD 19 0270
NR 69
TC 13
Z9 13
U1 2
U2 18
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JAN 21
PY 2023
VL 14
IS 1
AR 51
DI 10.1038/s41419 022 05545 7
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 8H8DG
UT WOS:000921258600001
PM 36681687
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Gámez, B
   Rodríguez Carballo, E
   Graupera, M
   Rosa, JL
   Ventura, F
AF Gamez, Beatriz
   Rodriguez Carballo, Edgardo
   Graupera, Mariona
   Rosa, Jose Luis
   Ventura, Francesc
TI Class I PI 3 Kinase Signaling Is Critical for Bone Formation Through
   Regulation of SMAD1 Activity in Osteoblasts
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOBLAST; BONE DEVELOPMENT; SMAD; PI3K; BMP
ID PHOSPHOINOSITIDE 3 KINASE ISOFORMS; CELL MIGRATION; PTEN; EXPRESSION;
   GROWTH; LEADS; RUNX2; PI3K; DIFFERENTIATION; METABOLISM
AB Bone formation and homeostasis is carried out by osteoblasts, whose differentiation and activity are regulated by osteogenic signaling networks. A central mediator of these inputs is the lipid kinase phosphatidylinositol 3 kinase (PI3K). However, at present, there are no data on the specific role of distinct class IA PI3K isoforms in bone biology. Here, we performed osteoblast specific deletion in mice to show that both p110 alpha and p110 beta isoforms are required for survival and differentiation and function of osteoblasts and thereby control bone formation and postnatal homeostasis. Impaired osteogenesis arises from increased GSK3 activity and a depletion of SMAD1 protein levels in PI3K deficient osteoblasts. Accordingly, pharmacological inhibition of GSK3 activity or ectopic expression of SMAD1 or SMAD5 normalizes bone morphogenetic protein (BMP) transduction and osteoblast differentiation. Together, these results identify the PI3K GSK3 SMAD1 axis as a central node integrating multiple signaling networks that govern bone formation and homeostasis. (C 2016 American Society for Bone and Mineral Research.
C1 [Gamez, Beatriz; Rodriguez Carballo, Edgardo; Rosa, Jose Luis; Ventura, Francesc] Univ Barcelona, IDIBELL, Dept Ciencies Fisiol 2, Barcelona, Spain.
   [Graupera, Mariona] IDIBELL, Catalan Inst Oncol, Vasc Signaling Lab, Barcelona, Spain.
C3 University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de
   Bellvitge (IDIBELL); Institut Catala d'Oncologia
RP Ventura, F (通讯作者)，Univ Barcelona, IDIBELL, Dept Ciencies Fisiol 2, C Feixa Llarga S N, Lhospitalet De Llobregat 08907, Spain.
EM fventura@ub.edu
RI Rosa, Jose/K 6685 2014; Rosa, Jose Luis/K 6685 2014; Graupera,
   Mariona/J 1122 2017; Ventura, Francesc/K 9700 2014
OI Rosa, Jose Luis/0000 0002 6161 5688; Graupera,
   Mariona/0000 0003 4608 4185; Ventura, Francesc/0000 0001 9673 9405
FU MEC [BFU2011 24254, BFU 2014 56313]; Fundacio La Marato de TV3; ISCIII
   [RETIC RD06/0020]
FX The authors thank Dr B. Vanhaesebroeck for floxed p110 alpha and p110
   beta mice and E Adanero, A Angelo, E Castano, C Saldarriaga, E
   Sanchez Garcia, and B Torrejon for technical assistance. We also
   acknowledge B Gamarra and A Gimeno for assistance in animal handling.
   This work was supported by grants from the MEC (BFU2011 24254 and BFU
   2014 56313), Fundacio La Marato de TV3, and ISCIII (RETIC RD06/0020).
CR Burgers TA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063857
   Burke JE, 2015, TRENDS BIOCHEM SCI, V40, P88, DOI 10.1016/j.tibs.2014.12.003
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chong PA, 2010, P NATL ACAD SCI USA, V107, P18404, DOI 10.1073/pnas.1003023107
   Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Davey RA, 2012, TRANSGENIC RES, V21, P885, DOI 10.1007/s11248 011 9581 z
   Fang F, 2015, J BONE MINER RES, V30, P1195, DOI 10.1002/jbmr.2447
   Ford Hutchinson AF, 2007, J BONE MINER RES, V22, P1245, DOI 10.1359/JBMR.070420
   Foukas LC, 2010, P NATL ACAD SCI USA, V107, P11381, DOI 10.1073/pnas.0906461107
   Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031
   Fuentealba LC, 2007, CELL, V131, P980, DOI 10.1016/j.cell.2007.09.027
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gamell C, 2008, J CELL SCI, V121, P3960, DOI 10.1242/jcs.031286
   Gillespie JR, 2013, ENDOCRINOLOGY, V154, P3702, DOI 10.1210/en.2013 1155
   Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892
   Grey A, 2010, BIOCHEM BIOPH RES CO, V391, P564, DOI 10.1016/j.bbrc.2009.11.099
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Guntur AR, 2011, DEVELOPMENT, V138, P1433, DOI 10.1242/dev.058016
   Iyer S, 2013, J CLIN INVEST, V123, P3409, DOI 10.1172/JCI68049
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104
   Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   McGonnell Imelda M, 2012, Front Endocrinol (Lausanne), V3, P88, DOI 10.3389/fendo.2012.00088
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   Miller LM, 2007, J BONE MINER RES, V22, P1037, DOI 10.1359/JBMR.070402
   Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02 07 0441
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Regard JB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007997
   Riddle RC, 2014, MOL CELL BIOL, V34, P1850, DOI 10.1128/MCB.00075 14
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rodríguez Carballo E, 2011, J BONE MINER RES, V26, P718, DOI 10.1002/jbmr.260
   Sapkota G, 2007, MOL CELL, V25, P441, DOI 10.1016/j.molcel.2007.01.006
   Schwartz S, 2015, CANCER CELL, V27, P109, DOI 10.1016/j.ccell.2014.11.008
   Seibel Markus J, 2005, Clin Biochem Rev, V26, P97
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Smith GC, 2013, FEBS J, V280, P5337, DOI 10.1111/febs.12428
   Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860
   Vanhaesebroeck B, 2011, CURR TOP MICROBIOL, V347, P1, DOI 10.1007/82_2010_65
   Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Yang SY, 2011, J BIOL CHEM, V286, P19149, DOI 10.1074/jbc.M110.197905
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 49
TC 24
Z9 26
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2016
VL 31
IS 8
BP 1617
EP 1630
DI 10.1002/jbmr.2819
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DW5WC
UT WOS:000383717200018
PM 26896753
DA 2025 08 17
ER

PT J
AU Tian, JQ
   Bao, XT
   Yang, F
   Tang, XZ
   Jiang, Q
   Li, YY
   Yao, K
   Yin, YL
AF Tian, Junquan
   Bao, Xuetai
   Yang, Fan
   Tang, Xiongzhuo
   Jiang, Qian
   Li, Yuying
   Yao, Kang
   Yin, Yulong
TI Elevation of Intracellular Alpha Ketoglutarate Levels Inhibits
   Osteoclastogenesis by Suppressing the NF κB Signaling Pathway in a
   PHD1 Dependent Manner
SO NUTRIENTS
LA English
DT Article
DE alpha ketoglutarate; osteoclast; PHD1; NF kappa B
ID SODIUM SALT; LIFE SPAN; BONE; DIFFERENTIATION; ACTIVATION; PROTEIN
AB Age related osteoporosis, a high prevalence disease in the aged population, is generally attributed to the excessive activity of osteoclasts. Most approved drugs treat osteoporosis by inhibition of osteoclasts. Although in vivo studies have shown that alpha ketoglutarate (AKG), an intermediate in the TCA cycle, can ameliorate age related osteoporosis, the effects of AKG on osteoclastogenesis and the underlying mechanism of its action have not been studied yet. Here, we showed that the elevation of intracellular AKG levels by supplementing dimethyl AKG (DM AKG, a cell permeable derivative of AKG) inhibits the receptor activator of NF kappa B ligand (RANKL) induced osteoclasts differentiation from primary bone marrow derived macrophages (BMMs) and RAW264.7 cells in vitro. We further found that DM AKG treatment suppresses NF kappa B signaling and oxidative phosphorylation (OXPHOS) during RANKL induced osteoclastogenesis in RAW264.7 cells. Interestingly, dimethyl oxalylglycine (DMOG), an AKG competitive inhibitor of AKG dependent prolyl hydroxylases (PHDs), antagonizes the suppression of the RANKL activated NF kappa B signaling pathway caused by DM AKG treatment. Furthermore, blocked PHD1 expression (also known as EglN2), instead of PHD2 or PHD3, was confirmed to reverse the DM AKG treatment induced suppression of the RANKL activated NF kappa B signaling pathway. Accordingly, blocked PHD1 expression antagonized the inhibitory effects of DM AKG on osteoclastogenesis. Together, our finding suggests that the elevation of intracellular AKG levels inhibits osteoclastogenesis by suppressing RANKL activated NF kappa B signaling in a PHD1 dependent manner, which may provide a novel nutritional strategy for osteoporosis treatment.
C1 [Tian, Junquan; Bao, Xuetai; Yang, Fan; Jiang, Qian; Yao, Kang; Yin, Yulong] Inst Subtrop Agr, Chinese Acad Sci, Lab Anim Nutr Physiol & Metab Proc, Key Lab Agro Ecol Proc Subtrop Reg,Natl Engn Lab P, Changsha 410125, Peoples R China.
   [Tian, Junquan; Bao, Xuetai; Yang, Fan; Yao, Kang; Yin, Yulong] Univ Chinese Acad Sci, Beijing 100008, Peoples R China.
   [Tang, Xiongzhuo; Jiang, Qian; Yin, Yulong] Hunan Agr Univ, Coll Anim Sci & Technol, Changsha 410000, Peoples R China.
   [Li, Yuying] Chinese Acad Agr Sci, Inst Bast Fiber Crops, Changsha 410205, Peoples R China.
C3 Chinese Academy of Sciences; Institute of Subtropical Agriculture, CAS;
   Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS; Hunan Agricultural University; Chinese Academy of Agricultural
   Sciences; Institute of Bast Fiber Crops, CAAS
RP Jiang, Q; Yao, K (通讯作者)，Inst Subtrop Agr, Chinese Acad Sci, Lab Anim Nutr Physiol & Metab Proc, Key Lab Agro Ecol Proc Subtrop Reg,Natl Engn Lab P, Changsha 410125, Peoples R China.; Yao, K (通讯作者)，Univ Chinese Acad Sci, Beijing 100008, Peoples R China.; Jiang, Q (通讯作者)，Hunan Agr Univ, Coll Anim Sci & Technol, Changsha 410000, Peoples R China.
EM jiangqian@hunau.edu.cn; yaokang@isa.ac.cn
RI li, yuying/JDW 4642 2023; Tian, Junquan/LWH 5801 2024; YANG,
   FAN/MVU 2673 2025; Jiang, Qian/N 7347 2019
OI Li, Yuying/0000 0003 0165 8018; Tian, Junquan/0000 0001 5324 2546; 
FU National Natural Science Foundation of China [32130099]; Key Programs of
   Frontier Scientific Research of the Chinese Academy of Sciences
   [QYZDY SSW SMC008]; TaiShan Industrial Experts Program [tscy20190121]
FX This work was supported by the National Natural Science Foundation of
   China (32130099), Key Programs of Frontier Scientific Research of the
   Chinese Academy of Sciences (QYZDY SSW SMC008), and the TaiShan
   Industrial Experts Program (tscy20190121).
CR Boskey AL, 2010, J DENT RES, V89, P1333, DOI 10.1177/0022034510377791
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buddington RK, 2004, COMP BIOCHEM PHYS A, V138, P215, DOI 10.1016/j.cbpb.2004.03.007
   Carey BW, 2015, NATURE, V518, P413, DOI 10.1038/nature13981
   Cedeno Veloz BA, 2022, J NUTR HEALTH AGING, V26, P778, DOI 10.1007/s12603 022 1825 5
   Cherif H, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2003619
   Chin RM, 2014, NATURE, V510, P397, DOI 10.1038/nature13264
   Chisolm DA, 2018, CURR OPIN IMMUNOL, V51, P62, DOI 10.1016/j.coi.2018.01.005
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cui JR, 2022, AGEING RES REV, V77, DOI 10.1016/j.arr.2022.101608
   Cummins E.P., P NATL ACAD SCI USA
   Demidenko O, 2021, AGING US, V13, P24485, DOI 10.18632/aging.203736
   Dobrowolski PJ, 2008, SCAND J GASTROENTERO, V43, P551, DOI 10.1080/00365520701824951
   Fan JZ, 2021, METABOLITES, V11, DOI 10.3390/metabo11070434
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Filip RS, 2007, INT J VITAM NUTR RES, V77, P89, DOI 10.1024/0300 9831.77.2.89
   Fraisl P, 2009, NAT REV DRUG DISCOV, V8, P139, DOI 10.1038/nrd2761
   Galluzzi L, 2019, AGING US, V11, P3412, DOI 10.18632/aging.102028
   Harrison AP, 2008, J PHYSIOL PHARMACOL, V59, P91
   He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Jiang Q, 2019, J AGR FOOD CHEM, V67, P6019, DOI 10.1021/acs.jafc.9b02180
   Liu PS, 2017, NAT IMMUNOL, V18, P985, DOI 10.1038/ni.3796
   Qi M, 2022, J CACHEXIA SARCOPENI, V13, P677, DOI 10.1002/jcsm.12858
   Radzki RP, 2016, J NUTR HEALTH AGING, V20, P628, DOI 10.1007/s12603 015 0654 1
   Radzki RP, 2012, J BONE MINER METAB, V30, P651, DOI 10.1007/s00774 012 0377 x
   Shahmirzadi AA, 2020, CELL METAB, V32, P447, DOI 10.1016/j.cmet.2020.08.004
   Soysa NS, 2009, J BONE MINER METAB, V27, P131, DOI 10.1007/s00774 008 0026 6
   Su Y, 2019, AGING US, V11, P4183, DOI 10.18632/aging.102045
   Takeda Y, 2011, NATURE, V479, P122, DOI 10.1038/nature10507
   Tang YL, 2015, FREE RADICAL BIO MED, V89, P944, DOI 10.1016/j.freeradbiomed.2015.09.012
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   TeSlaa T, 2016, CELL METAB, V24, P485, DOI 10.1016/j.cmet.2016.07.002
   Tian QY, 2020, AGING CELL, V19, DOI 10.1111/acel.13059
   Vitaca T, 2022, LANCET DIABETES ENDO, V10, P273, DOI 10.1016/S2213 8587(22)00012 2
   Wang Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19360 1
   WOLFFRAM S, 1992, COMP BIOCHEM PHYS A, V101, P759, DOI 10.1016/0300 9629(92)90355 T
   Wright S.H., 2015, NADC 1 A 20 SC 23539
   Xu C, 2022, LIFE METAB, V1, P67, DOI 10.1093/lifemeta/loac012
   Yang F, 2022, J COSMET DERMATOL US, V21, P1736, DOI 10.1111/jocd.14635
   Yuan YX, 2020, EMBO J, V39, DOI 10.15252/embj.2019103304
   Zdzisinska B, 2017, ARCH IMMUNOL THER EX, V65, P21, DOI 10.1007/s00005 016 0406 x
NR 43
TC 7
Z9 8
U1 6
U2 20
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD FEB
PY 2023
VL 15
IS 3
AR 701
DI 10.3390/nu15030701
PG 18
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 8U9AA
UT WOS:000930234400001
PM 36771407
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Singha, UK
   Jiang, Y
   Yu, SB
   Luo, M
   Lu, Y
   Zhang, J
   Xiao, GZ
AF Singha, Ujjal K.
   Jiang, Yu
   Yu, Shibing
   Luo, Min
   Lu, Yi
   Zhang, Jian
   Xiao, Guozhi
TI Rapamycin inhibits osteoblast proliferation and differentiation in
   MC3T3 E1 cells and primary mouse bone marrow stromal cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE rapamycin; mammalian target of rapamycin; osteoblast; proliferation;
   differentiation; osteocalcin; Runx2
ID TRANSCRIPTION FACTOR; CYCLIN D1; OSTEOCALCIN GENE; MESSENGER RNA; CANCER
   CELLS; S6 KINASE; IN VITRO; GROWTH; EXPRESSION; TRANSLATION
AB While the roles of the mammalian target of rapamycin (mTOR) signaling in regulation of cell growth, proliferation, and survival have been well documented in various cell types, its actions in osteoblasts are poorly understood. In this study, we determined the effects of rapamycin, a specific inhibitor of mTOR, on osteoblast proliferation and differentiation using MC3T3 E1 preosteoblastic cells (MC 4) and primary mouse bone marrow stromal cells (BMSCs). Rapamycin significantly inhibited proliferation in both MC 4 cells and BMSCs at a concentration as low as 0.1 nM. Western blot analysis shows that rapamycin treatment markedly reduced levels of cyclin A and D1 protein in both cell types. In differentiating osteoblasts, rapamycin dramatically reduced osteoblast specific osteocalcin (Ocn), bone sialoprotein (Bsp), and osterix (Osx) mRNA expression, ALP activity, and mineralization capacity. However, the drug treatment had no effect on osteoblast differentiation parameters when the cells were completely differentiated. Importantly, rapamycin markedly reduced levels of Runx2 protein in both proliferating and differentiating but not differentiated osteoblasts. Finally, overexpression of S6K in COS 7 cells significantly increased levels of Runx2 protein and Runx2 activity. Taken together, our studies demonstrate that mTOR signaling affects osteoblast functions by targeting osteoblast proliferation and the early stage of osteoblast differentiation.
C1 [Singha, Ujjal K.; Yu, Shibing; Luo, Min; Lu, Yi; Zhang, Jian; Xiao, Guozhi] Univ Pittsburgh, VA Pittsburgh Healthcare Syst Res & dev, Dept Med, Div Heamatol Oncol, Pittsburgh, PA 15240 USA.
   Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15240 USA.
   [Lu, Yi] Tianjin Med Univ, Dept Immunol, Tianjin 300070, Peoples R China.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Tianjin Medical University
RP Xiao, GZ (通讯作者)，Univ Pittsburgh, VA Pittsburgh Healthcare Syst Res & dev, Dept Med, Div Heamatol Oncol, 151C U,Rm 2W 111,Univ Dr C, Pittsburgh, PA 15240 USA.
EM xiaog@upme.edu
RI YU, SHIBING/B 7648 2012; ZHANG, JIAN/Q 6334 2018; Lu, Yi/J 6746 2018;
   luo, min/LDE 6513 2024
CR Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483
   ALBERS MW, 1993, J BIOL CHEM, V268, P22825
   BANERJEE U, 1997, LOOP TR RESTRUCT COM, V3, P1
   BORTELL R, 1993, P NATL ACAD SCI USA, V90, P2300, DOI 10.1073/pnas.90.6.2300
   Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood 2002 01 0189
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   DUEY P, 1997, CELL, V89, P747
   Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062
   Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802
   Freilinger A, 2006, ONCOGENE, V25, P6467, DOI 10.1038/sj.onc.1209660
   Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847
   García Morales P, 2006, MOL CANCER THER, V5, P2172, DOI 10.1158/1535 7163.MCT 05 0363
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201
   Grewe M, 1999, CANCER RES, V59, P3581
   Hurley MM, 1999, J BONE MINER RES, V14, P776, DOI 10.1359/jbmr.1999.14.5.776
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092 8674(03)00929 2
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kozawa O, 2001, J CELL BIOCHEM, V81, P430, DOI 10.1002/1097 4644(20010601)81:3<430::AID JCB1056>3.0.CO;2 G
   Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002 0225
   Law M, 2006, CANCER RES, V66, P1070, DOI 10.1158/0008 5472.CAN 05 1672
   Lian J. B., 2003, Current Pharmaceutical Design, V9, P2677, DOI 10.2174/1381612033453659
   Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126
   Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200
   Ogawa T, 1998, BIOCHEM BIOPH RES CO, V249, P226, DOI 10.1006/bbrc.1998.9118
   Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200
   Shoba LNN, 2003, J CELL BIOCHEM, V88, P1247, DOI 10.1002/jcb.10474
   Stein Gary S., 1996, P69
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wang J, 2004, CANCER RES, V64, P1861, DOI 10.1158/0008 5472.CAN 03 2968
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
   Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000
   Zhang X, 2002, BIOCHEM BIOPH RES CO, V290, P526, DOI 10.1006/bbrc.2001.6217
NR 44
TC 162
Z9 176
U1 0
U2 25
PU WILEY LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0730 2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD FEB 1
PY 2008
VL 103
IS 2
BP 434
EP 446
DI 10.1002/jcb.21411
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 257UC
UT WOS:000252823100009
PM 17516572
DA 2025 08 17
ER

PT J
AU Wang, YP
   Feng, ZJ
   Liu, X
   Yang, CF
   Gao, R
   Liu, WS
   Ou Yang, WB
   Dong, AJ
   Zhang, CN
   Huang, PS
   Wang, WW
AF Wang, Yaping
   Feng, Zujian
   Liu, Xiang
   Yang, Chunfang
   Gao, Rui
   Liu, Wenshuai
   Ou Yang, Wenbin
   Dong, Anjie
   Zhang, Chuangnian
   Huang, Pingsheng
   Wang, Weiwei
TI Titanium alloy composited with dual cytokine releasing polysaccharide
   hydrogel to enhance osseointegration via osteogenic and macrophage
   polarization signaling pathways
SO REGENERATIVE BIOMATERIALS
LA English
DT Article
DE hydrogel; composite scaffold; bone regeneration; cytokine delivery;
   macrophage polarization
ID BONE REGENERATION; BMP 2 DELIVERY; SCAFFOLD; ACTIVATION; RHBMP 2; FUSION
AB Titanium alloy has been widely used in orthopedic surgeries as bone defect filling. However, the regeneration of high quality new bones is limited due to the pro inflammatory microenvironment around implants, resulting in a high occurrence rate of implant loosening or failure in osteological therapy. In this study, extracellular matrix mimetic polysaccharide hydrogel co delivering BMP 2 and interleukin (IL) 4 was composited with 3D printed titanium alloy to promote the osseointegration and regulate macrophage response to create a pro healing microenvironment in bone defect. Notably, it is discovered from the bioinformatics data that IL 4 and BMP 2 could affect each other through multiple signal pathways to achieve a synergistic effect toward osteogenesis. The composite scaffold significantly promoted the osteoblast differentiation and proliferation of human bone marrow mesenchyme stem cells (hBMSCs). The repair of large scale femur defect in rat indicated that the dual cytokine delivered composite scaffold could manipulate a lower inflammatory level in situ by polarizing macrophages to M2 phenotype, resulting in superior efficacy of mature new bone regeneration over the treatment of native titanium alloy or that with an individual cytokine. Collectively, this work highlights the importance of M2 type macrophages enriched immune environment in bone healing. The biomimetic hydrogel metal implant composite is a versatile and advanced scaffold for accelerating in vivo bone regeneration, holding great promise in treating orthopedic diseases.
C1 [Wang, Yaping; Liu, Xiang; Dong, Anjie] Tianjin Univ, Sch Chem Engn & Technol, Minist Educ, Dept Polymer Sci & Engn,Key Lab Syst Bioengn, Tianjin 300072, Peoples R China.
   [Wang, Yaping; Feng, Zujian; Liu, Xiang; Yang, Chunfang; Gao, Rui; Liu, Wenshuai; Ou Yang, Wenbin; Zhang, Chuangnian; Huang, Pingsheng; Wang, Weiwei] Chinese Acad Med Sci, Key Lab Innovat Cardiovasc Devices, Beijing 100037, Peoples R China.
   [Feng, Zujian; Yang, Chunfang; Gao, Rui; Zhang, Chuangnian; Huang, Pingsheng; Wang, Weiwei] Chinese Acad Med Sci & Peking Union Med Coll, Inst Biomed Engn, Tianjin Key Lab Biomat Res, Tianjin 300192, Peoples R China.
   [Ou Yang, Wenbin] Chinese Acad Med Sci & Peking Union Med Coll, China & Fuwai Hosp, Struct Heart Dis Ctr, Natl Ctr Cardiovasc Dis, Beijing 100037, Peoples R China.
C3 Tianjin University; Chinese Academy of Medical Sciences   Peking Union
   Medical College; Chinese Academy of Medical Sciences   Peking Union
   Medical College; Institute of BioMedical Engineering   CAMS; Peking
   Union Medical College; Chinese Academy of Medical Sciences   Peking
   Union Medical College; Peking Union Medical College; Fu Wai Hospital  
   CAMS
RP Dong, AJ (通讯作者)，Tianjin Univ, Sch Chem Engn & Technol, Minist Educ, Dept Polymer Sci & Engn,Key Lab Syst Bioengn, Tianjin 300072, Peoples R China.; Ou Yang, WB; Wang, WW (通讯作者)，Chinese Acad Med Sci, Key Lab Innovat Cardiovasc Devices, Beijing 100037, Peoples R China.; Wang, WW (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Biomed Engn, Tianjin Key Lab Biomat Res, Tianjin 300192, Peoples R China.; Ou Yang, WB (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, China & Fuwai Hosp, Struct Heart Dis Ctr, Natl Ctr Cardiovasc Dis, Beijing 100037, Peoples R China.
EM droywb31@163.com; ajdong@tju.edu.cn; wangww@bme.pumc.edu.cn
RI Liu, Xiang/LIC 9906 2024; Wang, Weiwei/GRF 3625 2022; Feng,
   Zujian/JXL 3416 2024
OI Feng, Zujian/0000 0002 2267 7122; LIU, XIANG/0009 0004 3069 5648; Wang,
   Weiwei/0000 0003 0333 0868
FU National Natural Science Foundation of China [32171380, 31971306];
   Natural Science Fund for Distinguished Young Scholars of Tianjin
   [21JCJQJC00020]; CAMS Innovation Fund for Medical Sciences
   [2021 I2M 1 065, 2021 I2M 1 058]; Non profit Central Research Institute
   Fund of Chinese Academy of Medical Sciences [2019 F40 SYS]; Tianjin
   Innovation and Promotion Plan Key Innovation Team of Implantable and
   Interventional Biomedical Materials
FX This work was financially supported by the National Natural Science
   Foundation of China (32171380, 31971306), Natural Science Fund for
   Distinguished Young Scholars of Tianjin (21JCJQJC00020), CAMS Innovation
   Fund for Medical Sciences (No. 2021 I2M 1 065, 2021 I2M 1 058),
   Non profit Central Research Institute Fund of Chinese Academy of Medical
   Sciences (NO. 2019 F40 SYS) and Tianjin Innovation and Promotion Plan
   Key Innovation Team of Implantable and Interventional Biomedical
   Materials.
CR Armiento AR, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909874
   Bai L, 2018, BIOMATERIALS, V162, P154, DOI 10.1016/j.biomaterials.2018.02.010
   Burdick JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3003997
   Burkus JK, 2002, J SPINAL DISORD TECH, V15, P337, DOI 10.1097/00024720 200210000 00001
   Burla F, 2019, NAT REV PHYS, V1, P249, DOI 10.1038/s42254 019 0036 4
   Cha BH, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700289
   Chaudhuri O, 2020, NATURE, V584, P535, DOI 10.1038/s41586 020 2612 2
   Chen WCW, 2015, BIOMATERIALS, V72, P138, DOI 10.1016/j.biomaterials.2015.08.050
   Chen X, 2021, BIOMATERIALS, V274, DOI 10.1016/j.biomaterials.2021.120895
   Cheng H, 2017, ACS APPL MATER INTER, V9, P11428, DOI 10.1021/acsami.6b16779
   Choi H, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202001446
   David L, 2009, CYTOKINE GROWTH F R, V20, P203, DOI 10.1016/j.cytogfr.2009.05.001
   Eldridge SE, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax9086
   Fang K, 2020, ACS APPL MATER INTER, V12, P52307, DOI 10.1021/acsami.0c13009
   Feng ZJ, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202006454
   Fiedler J, 2002, J CELL BIOCHEM, V87, P305, DOI 10.1002/jcb.10309
   Gaharwar AK, 2020, NAT REV MATER, V5, P686, DOI 10.1038/s41578 020 0209 x
   Gaihre B, 2017, J FUNCT BIOMATER, V8, DOI 10.3390/jfb8040049
   Gan MF, 2021, ACTA BIOMATER, V135, P289, DOI 10.1016/j.actbio.2021.08.041
   Ghiasi Mohammad S, 2017, Bone Rep, V6, P87, DOI 10.1016/j.bonr.2017.03.002
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Green JJ, 2016, NATURE, V540, P386, DOI 10.1038/nature21005
   Gretzer C, 2006, J BIOMAT SCI POLYM E, V17, P669, DOI 10.1163/156856206777346340
   Hollister SJ, 2005, NAT MATER, V4, P518, DOI 10.1038/nmat1421
   Huang KQ, 2019, ACS APPL MATER INTER, V11, P2908, DOI 10.1021/acsami.8b21179
   Huang WJ, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202009189
   Jiang LB, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201901314
   Johnson CT, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw1228
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Liu DH, 2019, CHEM ENG J, V362, P269, DOI 10.1016/j.cej.2019.01.015
   Liu HM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay7608
   Liu J, 2013, BIOMATERIALS, V34, P7862, DOI 10.1016/j.biomaterials.2013.07.029
   Liu WS, 2020, ACS NANO, V14, P12905, DOI 10.1021/acsnano.0c03855
   Luttikhuizen DT, 2006, TISSUE ENG, V12, P1955, DOI 10.1089/ten.2006.12.1955
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Ou QM, 2020, CHEM ENG J, V382, DOI 10.1016/j.cej.2019.123019
   Pajarinen J, 2021, J BIOMED MATER RES A, V109, P1512, DOI 10.1002/jbm.a.37142
   Rifai A, 2019, ACS APPL MATER INTER, V11, P24588, DOI 10.1021/acsami.9b07064
   Rostam HM, 2016, IMMUNOBIOLOGY, V221, P1237, DOI 10.1016/j.imbio.2016.06.010
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Seeherman HJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar4953
   Shanley LC, 2021, ACTA BIOMATER, V133, P208, DOI 10.1016/j.actbio.2021.02.023
   Shekaran A, 2014, BIOMATERIALS, V35, P5453, DOI 10.1016/j.biomaterials.2014.03.055
   Shen HZ, 2021, DENT MATER J, V40, P191, DOI 10.4012/dmj.2019 437
   Shen HZ, 2021, MAT SCI ENG C MATER, V118, DOI 10.1016/j.msec.2020.111471
   Shi LY, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201700591
   Singh G, 2020, MICROMACHINES BASEL, V11, DOI 10.3390/mi11090850
   Tan BW, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 021 00113 9
   Tan JL, 2019, ACS NANO, V13, P5616, DOI 10.1021/acsnano.9b00788
   Tayalia P, 2009, ADV MATER, V21, P3269, DOI 10.1002/adma.200900241
   Tong XM, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701065
   Tong ZR, 2021, BIOACT MATER, V6, P1375, DOI 10.1016/j.bioactmat.2020.10.029
   Wang C, 2021, BIOACT MATER, V6, P137, DOI 10.1016/j.bioactmat.2020.07.007
   Wang Q, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202008906
   Yuan B, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc4704
   Zhang T, 2020, BIOMATER SCI UK, V8, P1279, DOI 10.1039/c9bm01655d
   Zhang W, 2020, BIOMATER SCI UK, V8, P4147, DOI 10.1039/d0bm00361a
   Zhang WJ, 2011, BIOMATERIALS, V32, P9415, DOI 10.1016/j.biomaterials.2011.08.047
   Zhao Y, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201807860
   Zhu YL, 2020, BIOMATERIALS, V256, DOI 10.1016/j.biomaterials.2020.120216
   Zhu YZ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf6654
NR 61
TC 39
Z9 40
U1 3
U2 74
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2056 3418
EI 2056 3426
J9 REGEN BIOMATER
JI Regen. Biomater.
PD APR 8
PY 2022
VL 9
AR rbac003
DI 10.1093/rb/rbac003
EA MAY 2022
PG 17
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 1T6UM
UT WOS:000804865500002
PM 35668921
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Qu, B
   Zeng, ZM
   Yang, HS
   He, J
   Jiang, T
   Xu, XP
   Liu, JW
   Li, YG
   Xiang, D
   Pan, XM
AF Qu, Bo
   Zeng, Zhimou
   Yang, Hongsheng
   He, Jun
   Jiang, Tao
   Xu, Xiaoping
   Liu, Jinwang
   Li, Yugang
   Xiang, Deng
   Pan, Xianming
TI Resveratrol reversed rosiglitazone administration induced bone loss in
   rats with type 2 diabetes mellitus
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Rosiglitazone; Resveratrol; Type 2 diabetes mellitus; Bone loss;
   Osteogenesis; Adiopogenesis; Osteoclast formation
ID FRACTURE RISK; OSTEOPOROSIS; METABOLISM; SIRT1
AB Rosiglitazone (RSG), as an insulin sensitizing drug to treat type 2 diabetes mellitus (T2DM) is reported to decrease bone quality and increase bone fracture risk. The multiple off target effects of Resveratrol (RSV), a natural specific agonist of Sirtuin1 (Sirt1) with pro osteoblastogenesis and anti adipogenesis effects, on bone loss in T2DM are still under discussion. In this study, successfully ovariectomized rats were fed with high fat diet and STZ (HFD/STZ) to induced T2DM mice. RSV alone, RSG alone or co administration of RSV and RSG were given orally to T2DM rats for 8 weeks to determine whether RSV administration had any prevention effect on T2DM osteoporosis. Bone mesenchymal stem cells (BMSCs) and bone marrow derived macrophages (BMMs) were cultured under high glucose condition and were induced to osteoblasts or adipocytes and osteoclasts, respectively. mu CT and HE staining showed that in T2DM osteoporotic rats, RSV co administration prevents RSG induced bone loss. ELISA results confirmed that RSV suppressed osteoclast activity and promoted osteoblast activity in diabetic osteoporosis rats and RSG administrated diabetic osteoporosis rats. In vitro study showed that RSV significantly reversed RSG induced inhibition on osteogenesis and promotion on adiopogenesis of BMSC under high glucose (HG). Moreover, RSV significantly reverse RSG induced osteoclast formation and mature under HG. Taken together, these findings uncover a previously unappreciated anti osteoporosis effect of concomitant treatment with RSV in RSG administrated diabetic rats, suggesting the clinical use of RSV as an adjuvant in the treatment of T2DM for preventing or reversing RSG administration associated bone loss.
C1 [Qu, Bo; Zeng, Zhimou; Yang, Hongsheng; He, Jun; Jiang, Tao; Xu, Xiaoping; Liu, Jinwang; Li, Yugang; Xiang, Deng; Pan, Xianming] Chengdu Med Coll, Affiliated Hosp 1, Dept Orthopaed, 278 Baoguang Ave, Chengdu 610500, Sichuan, Peoples R China.
C3 Chengdu Medical College
RP Pan, XM (通讯作者)，Chengdu Med Coll, Affiliated Hosp 1, Dept Orthopaed, 278 Baoguang Ave, Chengdu 610500, Sichuan, Peoples R China.
EM xianmingpanxj@163.com
FU Science and Technology Project of Health Commission of Sichuan Province
   [23LCYJ032]; Clinical Scientific Research Fund Project of Chengdu
   Medical College; Third Affiliated Hospital of Chengdu Medical College
   [23LHPDZYB20]; Research Fund Project of Chengdu Medical College; Chengdu
   Seventh People's Hospital [2022LHJYZD 03]; Sichuan Province medical
   research project plan [S23035]; Sichuan medical youth innovation
   research project [Q23058]; Sichuan Administration of Traditional Chinese
   Medicine [2024MS026]
FX This work was supported by the Science and Technology Project of Health
   Commission of Sichuan Province (23LCYJ032) ; the Clinical Scientific
   Research Fund Project of Chengdu Medical College and the Third
   Affiliated Hospital of Chengdu Medical College (23LHPDZYB20) ; the
   Research Fund Project of Chengdu Medical College and the Chengdu Seventh
   People's Hospital (2022LHJYZD 03) ; Sichuan Province medical research
   project plan (S23035) ; Sichuan medical youth innovation research
   project (Q23058) ; and the Sichuan Administration of Traditional Chinese
   Medicine (2024MS026) .
CR Ala M, 2020, CURR DIABETES REV, V16, P984, DOI 10.2174/1573399816666200324152517
   Aubert RE, 2010, DIABETES OBES METAB, V12, P716, DOI 10.1111/j.1463 1326.2010.01225.x
   Breuss JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071523
   Chen HD, 2018, BONE, V114, P189, DOI 10.1016/j.bone.2018.06.014
   Chen L, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02178 z
   Chen XH, 2019, EUR REV MED PHARMACO, V23, P6352, DOI 10.26355/eurrev_201907_18459
   Compston J, 2018, J INTERN MED, V283, P140, DOI 10.1111/joim.12725
   Deeks ED, 2007, DRUGS, V67, P2747, DOI 10.2165/00003495 200767180 00008
   El Batran SA, 2006, PHARMACOL RES, V53, P69, DOI 10.1016/j.phrs.2005.08.008
   Gao YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158182
   Hecker A, 2022, INT WOUND J, V19, P9, DOI 10.1111/iwj.13601
   Hou CY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030535
   Jia WP, 2019, DIABETES METAB RES, V35, DOI 10.1002/dmrr.3158
   Kalaitzoglou E, 2016, CURR OSTEOPOROS REP, V14, P310, DOI 10.1007/s11914 016 0329 9
   Kanazawa I, 2018, OSTEOPOROSIS INT, V29, P2527, DOI 10.1007/s00198 018 4638 y
   Karbasforooshan H, 2017, BIOMED PHARMACOTHER, V90, P386, DOI 10.1016/j.biopha.2017.03.056
   Kumar S, 2013, J BONE MINER RES, V28, P1653, DOI 10.1002/jbmr.1918
   Kurra S, 2014, ENDOCRIN METAB CLIN, V43, P233, DOI 10.1016/j.ecl.2013.09.004
   Lee S H, 2022, Insulin resistance: from mechanisms to therapeutic strategies, V46, P15
   Lin ZY, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12688
   Lou ZK, 2019, J BONE MINER METAB, V37, P815, DOI 10.1007/s00774 019 00997 y
   Lv YJ, 2018, THERANOSTICS, V8, P2387, DOI 10.7150/thno.23620
   Mengozzi A, 2022, CIRC RES, V131, P476, DOI 10.1161/CIRCRESAHA.122.320888
   Pardo PS, 2020, MECH AGEING DEV, V188, DOI 10.1016/j.mad.2020.111249
   Puspitasari M, 2017, J ASEAN FED ENDOCR S, V32, P90, DOI 10.15605/jafes.032.02.14
   Rathinavelu S, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/6354787
   Rayalam S, 2008, PHYTOTHER RES, V22, P1367, DOI 10.1002/ptr.2503
   Ren BX, 2021, CANCER LETT, V515, P63, DOI 10.1016/j.canlet.2021.05.001
   Richter B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006063
   Sanches CP, 2017, DIABETOL METAB SYNDR, V9, DOI 10.1186/s13098 017 0278 1
   Sardone LD, 2011, DIABETES, V60, P3271, DOI 10.2337/db10 1672
   Sewing L, 2022, J BONE MINER RES, V37, P837, DOI 10.1002/jbmr.4517
   Singh V, 2020, INFLAMMATION, V43, P1589, DOI 10.1007/s10753 020 01242 9
   Song CY, 2022, CALCIFIED TISSUE INT, V110, P117, DOI 10.1007/s00223 021 00892 7
   Wang YH, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/8124085
   Wong RHX, 2020, J BONE MINER RES, V35, P2121, DOI 10.1002/jbmr.4115
   Wu YY, 2015, INT J ORAL SCI, V7, P63, DOI 10.1038/ijos.2015.2
   Xu LN, 2018, PHARMACOL RES, V130, P451, DOI 10.1016/j.phrs.2018.01.015
   Yang YS, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.831168
   Yu SY, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1474 8
   Zhang YS, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.735824
   Zhou DD, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/9932218
NR 42
TC 1
Z9 1
U1 8
U2 14
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD SEP
PY 2024
VL 178
AR 117208
DI 10.1016/j.biopha.2024.117208
EA JUL 2024
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA A9S3Y
UT WOS:001285861700001
PM 39088966
OA gold
DA 2025 08 17
ER

PT J
AU Banerjee, P
   Dutta, S
   Pal, R
AF Banerjee, Poulomi
   Dutta, Sunit
   Pal, Rajarshi
TI Dysregulation of Wnt Signaling and a Candidate Set of miRNAs Underlie
   the Effect of Metformin on Neural Crest Cell Development
SO STEM CELLS
LA English
DT Article
DE Embryonic stem cells; Neural crest; Epithelial to mesenchymal
   transition; Metformin; Wnt signaling; miRNA deregulation
ID EMBRYONIC STEM CELLS; N CADHERIN SWITCH; MICRORNA REGULATION; MIGRATION;
   GENE; DIFFERENTIATION; INDUCTION; SPECIFICATION; DELAMINATION;
   DEFICIENCY
AB Neural crest cells (NCC) are a population of epithelial cells that arise from the dorsal tube and undergo epithelial mesenchymal transition (EMT) eventually generating tissues from peripheral nervous system, melanocytes, craniofacial cartilage, and bone. The antidiabetic drug metformin reportedly inhibits EMT in physiological conditions like cancer and fibrosis. We hypothesize that perturbation of EMT may also contribute to developmental disabilities associated with neural crest (NC) development. To understand the molecular network underlying metformin action during NC formation, we first differentiated murine embryonic stem (ES) cells into NCC and characterized them by demonstrating spatiotemporal regulation of key markers. Metformin treatment prompted a delay in delamination of NCC by inhibiting key markers like Sox 1, Sox 9, HNK 1, and p 75. We then revealed that metformin impedes Wnt axis, a major signaling pathway active during NC formation via DVL 3 inhibition and impairment in nuclear translocation of beta catenin. Concomitantly we identified and tested a candidate set of miRNAs that play a crucial role in NC cell fate determination. Further studies involving loss and gain of function confirmed that NCC specifiers like Sox 1 and Sox 9 are direct targets of miR 200 and miR 145, respectively and that they are essentially modulated by metformin. Our in vitro findings were strongly supported by in vivo studies in zebrafish. Given that metformin is a widely used drug, for the first time we demonstrate that it can induce a delayed onset of developmental EMT during NC formation by interfering with canonical Wnt signaling and mysregulation of miR 145 and miR 200.
C1 [Banerjee, Poulomi; Pal, Rajarshi] Manipal Univ, Sch Regenerat Med, Bangalore 560065, Karnataka, India.
   [Dutta, Sunit] NEI, Ophthalm Genet & Visual Funct Branch, NIH, Bethesda, MD 20892 USA.
C3 Manipal Academy of Higher Education (MAHE); National Institutes of
   Health (NIH)   USA; NIH National Eye Institute (NEI)
RP Pal, R (通讯作者)，Manipal Univ, Sch Regenerat Med, Bangalore 560065, Karnataka, India.
EM rajarshi.pal@manipal.edu
OI banerjee, poulomi/0000 0002 0987 6442; Pal, Rajarshi/0000 0001 6334 4562
FU Manipal University (MU), Manipal; NEI intramural research program;
   Department of Biotechnology, Ministry of Science and Technology, Govt.
   of India [BT/PR8394/MED/31/227/2013]
FX We thank Dr. Mahendra S. Rao, New York Stem Cell Research Foundation, NY
   for critical comments and useful suggestions, Dr. Brian Brooks for
   support, and Dr. Valeria Zarelli for the reagents for in vivo work; Drs.
   Sanjeev Galande and P. Chandrashekar for lending DVL 3 and TCF 4
   antibodies, respectively. We thank Qiagen for the free trial of
   Ingenuity Pathway Analysis software. We also thank Lithin K. Louis and
   Harshini Surendran for helping during manuscript preparation. Manipal
   University (MU), Manipal is gratefully acknowledged for the support in
   form of infrastructure and graduate fellowship to P.B.; R.P. is a
   faculty member with MU and S.D. is supported by the NEI intramural
   research program. This work was partially supported by a grant from the
   Department of Biotechnology, Ministry of Science and Technology, Govt.
   of India (# BT/PR8394/MED/31/227/2013).
CR Aihara Y, 2010, INT J DEV BIOL, V54, P1287, DOI 10.1387/ijdb.103173ya
   [Anonymous], 2014, PLOS ONE
   Bao B, 2012, CANCER PREV RES, V5, P355, DOI 10.1158/1940 6207.CAPR 11 0299
   Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870
   Barrallo Gimeno A, 2004, DEVELOPMENT, V131, P1463, DOI 10.1242/dev.01033
   Bell DSH, 2010, SOUTH MED J, V103, P265, DOI 10.1097/SMJ.0b013e3181ce0e4d
   Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Carney TJ, 2006, DEVELOPMENT, V133, P4619, DOI 10.1242/dev.02668
   Chambers SM, 2016, METHODS MOL BIOL, V1307, P329, DOI 10.1007/7651_2013_59
   Cheung M, 2003, DEVELOPMENT, V130, P5681, DOI 10.1242/dev.00808
   Clay MR, 2014, DEVELOPMENT, V141, P2506, DOI 10.1242/dev.105551
   Clouthier DE, 2010, AM J MED GENET A, V152A, P2962, DOI 10.1002/ajmg.a.33568
   Cufí S, 2010, CELL CYCLE, V9, P4461, DOI 10.4161/cc.9.22.14048
   Cui SY, 2014, J CELL MOL MED, V18, P1913, DOI 10.1111/jcmm.12358
   Dady A, 2012, DEV DYNAM, V241, P1333, DOI 10.1002/dvdy.23813
   Deardorff MA, 2001, DEVELOPMENT, V128, P3655
   Du ZW, 2013, DEVELOPMENT, V140, P2611, DOI 10.1242/dev.092809
   Duband JL, 2006, ADV EXP MED BIOL, V589, P45
   Dvash T, 2004, BEST PRACT RES CL OB, V18, P929, DOI 10.1016/j.bpobgyn.2004.06.005
   Fineberg SK, 2009, NEURON, V64, P303, DOI 10.1016/j.neuron.2009.10.020
   Ghassibe Sabbagh M, 2011, AM J HUM GENET, V88, P150, DOI 10.1016/j.ajhg.2011.01.003
   Goljanek Whysall K, 2011, P NATL ACAD SCI USA, V108, P11936, DOI 10.1073/pnas.1105362108
   Gray RS, 2009, DEV DYNAM, V238, P2044, DOI 10.1002/dvdy.22028
   Ho NY, 2013, ENVIRON SCI TECHNOL, V47, P3316, DOI 10.1021/es3050967
   Hu JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045965
   Jiang XM, 2015, ONCOTARGET, V6, P3178, DOI 10.18632/oncotarget.3063
   Knight RD, 2006, ADV EXP MED BIOL, V589, P120
   LEDOUARIN NM, 1999, NEURAL CREST
   Lee RTH, 2013, DEVELOPMENT, V140, P4890, DOI 10.1242/dev.094680
   Lewis JL, 2004, DEVELOPMENT, V131, P1299, DOI 10.1242/dev.01007
   Li D, 2009, AQUAT TOXICOL, V91, P229, DOI 10.1016/j.aquatox.2008.11.007
   Liu JP, 1998, DEVELOPMENT, V125, P5055
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Makris SL, 2009, ENVIRON HEALTH PERSP, V117, P17, DOI 10.1289/ehp.11447
   Menendez L, 2013, NAT PROTOC, V8, P203, DOI 10.1038/nprot.2012.156
   Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219
   Monsoro Burq AH, 2003, DEVELOPMENT, V130, P3111, DOI 10.1242/dev.00531
   Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008
   NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443
   Oba Shigeyoshi, 2013, BMC Res Notes, V6, P470, DOI 10.1186/1756 0500 6 470
   Orsulic S, 1999, J CELL SCI, V112, P1237
   Perez Alcala S, 2004, DEVELOPMENT, V131, P4455, DOI 10.1242/dev.01329
   Peterson SM, 2011, ENVIRON HEALTH PERSP, V119, P615, DOI 10.1289/ehp.1002590
   Rani SB, 2013, NEURO ONCOLOGY, V15, P1302, DOI 10.1093/neuonc/not090
   Rogers CD, 2013, J CELL BIOL, V203, P835, DOI 10.1083/jcb.201305050
   Rooryck C, 2011, NAT GENET, V43, P197, DOI 10.1038/ng.757
   ROSENQUIST GC, 1981, DEV BIOL, V87, P201, DOI 10.1016/0012 1606(81)90143 3
   Sen C, 2015, MICRORNA REGENERATIV
   Shi YH, 2010, J NEUROSCI, V30, P14931, DOI 10.1523/JNEUROSCI.4280 10.2010
   Singh AK, 2013, J POSTGRAD MED, V59, P253, DOI 10.4103/0022 3859.123143
   Svoboda KR, 2002, J NEUROSCI, V22, P10731
   Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514
   Tobin JL, 2008, P NATL ACAD SCI USA, V105, P6714, DOI 10.1073/pnas.0707057105
   Trainor PA, 2010, AM J MED GENET A, V152A, P2984, DOI 10.1002/ajmg.a.33454
   Villanueva S, 2002, DEV BIOL, V241, P289, DOI 10.1006/dbio.2001.0485
   Westerfield M, 2004, ZEBRAFISH BOOK GUIDE
   Williams T, 2011, P NATL ACAD SCI USA, V108, P5849, DOI 10.1073/pnas.1013660108
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 276
   Zimmer B, 2012, ENVIRON HEALTH PERSP, V120, P1116, DOI 10.1289/ehp.1104489
NR 60
TC 30
Z9 34
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD FEB
PY 2016
VL 34
IS 2
BP 334
EP 345
DI 10.1002/stem.2245
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA DE0ZA
UT WOS:000370353200008
PM 26529121
OA hybrid
DA 2025 08 17
ER

PT J
AU Kouketsu, A
   Matsui, K
   Kawai, T
   Ezoe, Y
   Takahashi, T
   Kamakura, S
AF Kouketsu, Atsumu
   Matsui, Keiko
   Kawai, Tadashi
   Ezoe, Yushi
   Takahashi, Tetsu
   Kamakura, Shinji
TI Teriparatide with Octacalcium Phosphate Collagen Composite Stimulates
   Osteogenic Factors
SO TISSUE ENGINEERING PART A
LA English
DT Article
DE bone matrix; octacalcium phosphate; osteogenesis; teriparatide
ID BETA TRICALCIUM PHOSPHATE; PARATHYROID HORMONE 1 34; LOCAL
   BONE FORMATION; DEFECT; RECONSTRUCTION; AUGMENTATION; IMPLANTATION;
   EXPRESSION; THERAPY
AB Impact statementOur study suggests that octacalcium phosphate and collagen (OCPcol) together with a TPTD enhances bone regeneration in rodents with calvarial bone defects. Furthermore, we believe that composite of OCPcol and teriparatide (OCPcolTPTD) could be developed into novel clinical technique for the regeneration or repair of bone.
   Octacalcium phosphate and collagen composite (OCPcol) promotes osteogenic differentiation and angiogenesis, thereby enhancing bone regeneration. Although a newly developed freeze dried composite of OCPcol and teriparatide (OCPcolTPTD) reinforced bone regeneration more than OCPcol, the mechanism of bone regeneration remains unresolved. In this study, disks containing OCPcolTPTD, OCPcol, or beta tricalcium phosphate (beta TCP) col were inserted into rodents with calvarial bone defects, before euthanasia 4 weeks later. Immunohistochemical and histochemical analyses were performed on bone samples to evaluate bone matrix development, angiogenesis, and osteoclast and osteoblast localization. In the OCPcolTPTD and OCPcol groups, bone regeneration was observed at the surface of calvarial dura mater and around acidophilic granular cells with abundant collagenous fiber containing cells. Furthermore, the newly formed bone in the OCPcolTPTD group showed a larger total area and individual separated area than the other groups. Various osteogenic proteins were detected in the regenerated bone and peri bone tissues by histochemistry and immunohistochemistry. Although the expression of several osteogenic biomarkers in the OCPcolTPTD group after 4 weeks of implantation was significantly lower than that in the OCPcol group, new bone formation by OCPcolTPTD in the center of the defect, where bone regeneration is difficult, tended to be superior to that by OCPcol. These results suggest that OCPcolTPTD enhanced bone regeneration more evenly and homogenously than OCPcol.
C1 [Kouketsu, Atsumu; Matsui, Keiko; Kawai, Tadashi; Ezoe, Yushi; Takahashi, Tetsu] Tohoku Univ, Grad Sch Dent, Dept Oral Med & Surg, Div Oral & Maxillofacial Surg, Sendai, Miyagi, Japan.
   [Kouketsu, Atsumu] Univ Miyazaki, Fac Med, Dept Med Sensory & Motor Organs, Div Oral & Maxillofacial Surg, Miyazaki, Japan.
   [Kawai, Tadashi] Iwate Med Univ, Sch Dent, Dept Oral & Maxillofacial Reconstruct Surg, Div Oral & Maxillofacial Surg, Morioka, Iwate, Japan.
   [Kamakura, Shinji] Tohoku Univ, Grad Sch Biomed Engn, Bone Regenerat Engn Lab, Sendai, Miyagi, Japan.
C3 Tohoku University; University of Miyazaki; Iwate Medical University;
   Tohoku University
RP Kouketsu, A (通讯作者)，Tohoku Univ, Grad Sch Dent, Dept Oral Med & Surg, Div Oral & Maxillofacial Surg,Aoba Ku, 4 1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM kouketsu_atsumu@dent.tohoku.ac.jp
RI Kamakura, Shinji/A 5385 2013; KAWAI, TADASHI/AAV 6947 2020
OI Kawai, Tadashi/0000 0002 2712 1895
FU Ministry of Education, Science, Sports and Culture of Japan [16H03159,
   16K11741, 18K19891]; Grants in Aid for Scientific Research [18K19891,
   16H03159, 16K11741] Funding Source: KAKEN
FX This study was partially supported by Grants in aid (Nos.16H03159,
   16K11741, and 18K19891) from the Ministry of Education, Science, Sports
   and Culture of Japan
CR Auersvald CM, 2017, ARCH ORAL BIOL, V79, P14, DOI 10.1016/j.archoralbio.2017.02.016
   BROWN WE, 1981, PROG CRYST GROWTH CH, V4, P59, DOI 10.1016/0146 3535(81)90048 4
   Buser D, 2004, INT J ORAL MAX IMPL, V19, P43
   Chan HL, 2013, J DENT RES, V92, P18, DOI 10.1177/0022034512464779
   Habraken W, 2016, MATER TODAY, V19, P69, DOI 10.1016/j.mattod.2015.10.008
   Hawthorne AC, 2013, CLIN ORAL IMPLAN RES, V24, P1164, DOI 10.1111/j.1600 0501.2012.02528.x
   Iwai A, 2018, ORAL DIS, V24, P1514, DOI 10.1111/odi.12923
   Jacobson JA, 2011, TISSUE ENG PT A, V17, P389, DOI [10.1089/ten.tea.2010.0115, 10.1089/ten.TEA.2010.0115]
   Jensen SS, 2009, INT J ORAL MAX IMPL, V24, P218
   Kajii F, 2018, J BIOMED MATER RES B, V106, P1851, DOI 10.1002/jbm.b.33993
   Kamakura S, 1997, J ELECTRON MICROSC, V46, P397, DOI 10.1093/oxfordjournals.jmicro.a023535
   Kamakura S, 2002, J BIOMED MATER RES, V59, P29, DOI 10.1002/jbm.1213
   Kamakura S, 2007, J BIOMED MATER RES A, V83A, P725, DOI 10.1002/jbm.a.31332
   Kamakura S, 2006, J BIOMED MATER RES B, V79B, P210, DOI 10.1002/jbm.b.30531
   Kamakura S, 2020, WOODH PUBL SER BIOM, P289, DOI 10.1016/B978 0 08 102511 6.00012 1
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kawai T, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731419896449
   Kawai T, 2017, J TISSUE ENG REGEN M, V11, P1641, DOI 10.1002/term.2110
   Kawai T, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416670770
   Kawai T, 2014, TISSUE ENG PT A, V20, P1336, DOI [10.1089/ten.TEA.2013.0508, 10.1089/ten.tea.2013.0508]
   Kawai T, 2011, CLIN IMPLANT DENT R, V13, P112, DOI 10.1111/j.1708 8208.2009.00192.x
   Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200
   Kokubo T, 2003, BIOMATERIALS, V24, P2161, DOI 10.1016/S0142 9612(03)00044 9
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kouketsu A, 2020, J TISSUE ENG REGEN M, V14, P99, DOI 10.1002/term.2969
   Matsui A, 2014, CLEFT PALATE CRAN J, V51, P420, DOI 10.1597/12 096
   Matsui A, 2010, TISSUE ENG PT A, V16, P139, DOI [10.1089/ten.tea.2009.0284, 10.1089/ten.TEA.2009.0284]
   Miura KI, 2020, J BIOMED MATER RES B, V108, P243, DOI 10.1002/jbm.b.34384
   Morimoto T, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01097
   NIALL HD, 1974, P NATL ACAD SCI USA, V71, P384, DOI 10.1073/pnas.71.2.384
   Oryan A, 2019, J BIOMED MATER RES B, V107, P50, DOI 10.1002/jbm.b.34094
   Pensak M, 2015, J ORTHOP RES, V33, P1242, DOI 10.1002/jor.22896
   Pereira RS, 2017, INT J ORAL MAX SURG, V46, P503, DOI 10.1016/j.ijom.2017.01.002
   Rowshan HH, 2010, J ORAL MAXIL SURG, V68, P260, DOI 10.1016/j.joms.2009.09.045
   Sibai T, 2011, CLIN ORTHOP RELAT R, V469, P2215, DOI 10.1007/s11999 010 1722 9
   Soini Y, 2001, HISTOPATHOLOGY, V39, P179, DOI 10.1046/j.1365 2559.2001.01211.x
   Stancoven BW, 2013, J PERIODONTAL RES, V48, P243, DOI 10.1111/jre.12001
   SUZUKI O, 1991, TOHOKU J EXP MED, V164, P37, DOI 10.1620/tjem.164.37
   Tallgren A, 2003, J PROSTHET DENT, V89, P427, DOI 10.1016/S0022 3913(03)00158 6
   Tanuma Y, 2013, OR SURG OR MED OR PA, V115, P9, DOI 10.1016/j.oooo.2011.12.029
   Wang DM, 2019, ARCH ORAL BIOL, V98, P17, DOI 10.1016/j.archoralbio.2018.11.002
   Yun JI, 2010, J CLIN PERIODONTOL, V37, P419, DOI 10.1111/j.1600 051X.2010.01547.x
NR 42
TC 3
Z9 3
U1 1
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD FEB 1
PY 2022
VL 28
IS 3 4
BP 125
EP 135
DI 10.1089/ten.tea.2021.0067
EA JAN 2022
PG 11
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA W4NH5
UT WOS:000745243300001
PM 34278819
DA 2025 08 17
ER

PT J
AU Ma, ZP
   Zhang, ZF
   Yang, YF
   Yang, Y
AF Ma, Zhong ping
   Zhang, Zhi feng
   Yang, Yi feng
   Yang, Yun
TI Sesamin Promotes Osteoblastic Differentiation and Protects Rats from
   Osteoporosis
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Bone Marrow Cells; Cell Dedifferentiation; Osteoblasts; Osteoporosis;
   Sesame Oil; Wnt Signaling Pathway
ID BONE MINERAL DENSITY; RUNX2; EXPRESSION; TURNOVER
AB Background: Osteoporosis is a common osteopathy, resulting in fractures, especially in elder people. Sesamin has many pharmacological effects, including supplying calcium. However, how sesamin might prevent osteoporosis is still under study.
   Material/Methods: Bone marrow stromal cells (BMSCs) extracted from rat femur were induced for osteoblastic differentiation. Cell proliferation, alkaline phosphatase (ALP), osterix (OSX), SRY box 9 (SOX9), runt related transcription factor 2 (RUNX2), osteocalcin (OCN), beta catenin, low density lipoprotein receptor related protein 5 (LRP5), and glycogen synthase kinase 3 beta (GSK 3 beta) levels in BMSCs were detected in the presence or absence of sesamin (1 mu M or 10 mu M). In addition, FH535 (1 mu M) was used to silence Wnt/beta catenin in vitro. Ovariectomized (OVX) rats were established and intragastrically administrated sesamin (80 mg/kg), and then the rat bones were analyzed by micro computed tomography. Osteocalcin and collagen type I were measured in the rat femurs.
   Results: Sesamin had no influence on BMSC proliferation. Higher sesamin concentration promoted Wnt/beta catenin activity and enhanced more expressions of ALP, OSX, SOX9, RUNX2, and OCN, gradually and significantly (P<0.05). Silencing Wnt/beta catenin weakened the enhancement on RUNX2 and OCN expression. Sesamin (80 mg/kg) promoted bone structure in ovariectomized rats, and significantly enhanced osteocalcin and collage type I expression (P<0.05).
   Conclusions: Sesamin promoted osteoblastic differentiation of rat BMSCs by regulating the Wnt/beta catenin pathway, and improved rat bone structure. Sesamin could have therapeutic and preventive effects on osteoporosis.
C1 [Ma, Zhong ping; Zhang, Zhi feng; Yang, Yi feng; Yang, Yun] Inner Mongolia Med Univ, Affiliated Hosp 2, Dept Orthoped, Hohhot, Inner Mongolia, Peoples R China.
C3 Inner Mongolia Medical University
RP Yang, Y (通讯作者)，Inner Mongolia Med Univ, Affiliated Hosp 2, Dept Orthoped, Hohhot, Inner Mongolia, Peoples R China.
EM 1461079459@qq.com
CR Annicchiarico R, 2016, STUD HLTH TECHNOL IN, V180, P14
   [Anonymous], HAND HLTH OST
   Arber DA, 2010, AM J SURG PATHOL, V34, P445
   Aversa A, 2012, AGING MALE, V15, P96, DOI 10.3109/13685538.2011.631230
   Birbrair A, 2016, ANN NY ACAD SCI, V1370, P82, DOI 10.1111/nyas.13016
   Boulbaroud S, 2008, Pak J Biol Sci, V11, P1696, DOI 10.3923/pjbs.2008.1696.1701
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Burgers TA, 2013, BONE, V54, P244, DOI 10.1016/j.bone.2013.02.022
   Cho SW, 2011, J BONE MINER RES, V26, P1939, DOI 10.1002/jbmr.366
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Gaudio A, 2012, J CLIN ENDOCR METAB, V97, P3744, DOI 10.1210/jc.2012 1901
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Handschin AE, 2006, CLIN APPL THROMB HEM, V12, P465, DOI 10.1177/1076029606293433
   Henry YM, 2000, OSTEOPOROSIS INT, V11, P512, DOI 10.1007/s001980070094
   Heo JS, 2010, MOL CELLS, V30, P449, DOI 10.1007/s10059 010 0139 3
   Horiuchi K, 2009, J IMMUNOL, V182, P2093, DOI 10.4049/jimmunol.0802491
   Iba K, 2004, J BONE MINER METAB, V22, P594, DOI 10.1007/s00774 004 0528 9
   Kaback LA, 2010, J CELL BIOCHEM, V105, P219
   Kamal Eldin Afaf, 2011, Recent Pat Food Nutr Agric, V3, P17
   Khalid O, 2008, ENDOCRINOLOGY, V149, P5984, DOI 10.1210/en.2008 0680
   Khatib J, 2018, J INVEST MED, V66, P298, DOI 10.1136/jim 2017 000557
   Kovach AE, 2008, AM J SURG PATHOL, V32, P1376
   Loscalzo J., 2012, Harrison's principles of internal medicine
   Majumdar S, 1996, OSTEOPOROSIS INT, V6, P376, DOI 10.1007/BF01623011
   Majundar S, 2010, J BONE MINER RES, V12, P111
   Mithal Ambrish, 2014, Indian J Endocrinol Metab, V18, P449, DOI 10.4103/2230 8210.137485
   Pluijm SMF, 2001, J BONE MINER RES, V16, P2142, DOI 10.1359/jbmr.2001.16.11.2142
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Saidak Z, 2015, J BIOL CHEM, V290, P6903, DOI 10.1074/jbc.M114.621219
   Sirato Yasumoto S, 2001, J AGR FOOD CHEM, V49, P2647, DOI 10.1021/jf001362t
   Smeets Goevaers CG, 1998, OSTEOPOROSIS INT, V8, P404, DOI 10.1007/s001980050083
   STEIGER P, 1992, J BONE MINER RES, V7, P625
   Wade SW, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 014 0182 3
   Wanachewin O, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 71
   Wells G, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004523.pub3
   Wells GA, 2008, ETIDRONATE PRIMARY S
   Wells GA, 2008, COCHRANE DB SYST REV, V119
   Zhou J, 2012, ARCH MED RES, V43, P274, DOI 10.1016/j.arcmed.2012.06.002
NR 40
TC 22
Z9 26
U1 0
U2 15
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD JUL 17
PY 2019
VL 25
BP 5312
EP 5320
DI 10.12659/MSM.915529
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA IK9LE
UT WOS:000476915700003
PM 31314750
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Chang, JK
   Li, CJ
   Liao, HJ
   Wang, CK
   Wang, GJ
   Ho, ML
AF Chang, Je Ken
   Li, Ching Ju
   Liao, Hsiu Jun
   Wang, Chih Kuang
   Wang, Gwo Jaw
   Ho, Mei Ling
TI Anti inflammatory drugs suppress proliferation and induce apoptosis
   through altering expressions of cell cycle regulators and pro apoptotic
   factors in cultured human osteoblasts
SO TOXICOLOGY
LA English
DT Article
DE Anti inflammatory drugs; Human osteoblasts; Proliferation; Apoptosis;
   Cell cycle regulator
ID BONE MINERAL DENSITY; COLON CANCER CELLS; RHEUMATOID ARTHRITIS;
   CYCLOOXYGENASE 2 INHIBITORS; PHARMACOKINETIC PROPERTIES;
   CORTICOSTEROID THERAPY; OLDER WOMEN; FRACTURE; PROSTAGLANDINS;
   GLUCOCORTICOIDS
AB It has been reported that anti inflammatory drugs (AIDs) inhibited bone repair in animal studies, and suppressed proliferation and induced cell death in rat osteoblast cultures. In this study, we further investigated the molecular mechanisms of AID effects on proliferation and cell death in human osteoblasts (hOBs). We examined the effects of dexamethasone (10( 7) and 10( 6) M), non selective non steroidal anti inflammatory drugs (NSAIDs): indomethacin, ketorolac, piroxicam and diclofenac (10( 5) and 10( 1) M), and COX 2 inhibitor: celecoxib (10( 6) and 10( 5) M) on proliferation, cytotoxicity, cell death, and mRNA and protein levels of cell cycle and apoptosis related regulators in hOBs. All the tested AIDs significantly inhibited proliferation and arrested cell cycle at G0/G1 phase in hOBs. Celecoxib and dexamethasone. but not non selective NSAIDs, were found to have cytotoxic effects on hOB, and further demonstrated to induce apoptosis and necrosis (at higher concentration) in hOBs. We further found that indomethacin, celecoxib and dexamethasone increased the mRNA and protein expressions of p27(kip1) and decreased those of cyclin D2 and p cdk2 in hOBs. Bak expression was increased by celecoxib and dexamethasone, while Bcl XL level was declined only by dexamethasone. Furthermore, the replenishment of PGE1, PGE2 or PGF2 alpha did not reverse the effects of AIDs on proliferation and expressions of p27(kip1) and cyclin D2 in hOBs. We conclude that the changes in expressions of regulators of cell cycle (p27(kip1) and cyclin D2) and/or apoptosis (Bak and Bcl XL) by AIDs may contribute to AIDs caused proliferation suppression and apoptosis in hOBs. This effect might not relate to the blockage of prostaglandin synthesis by AIDs. (c) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Li, Ching Ju; Liao, Hsiu Jun; Ho, Mei Ling] Kaohsiung Med Univ, Dept Physiol, Coll Med, Kaohsiung 807, Taiwan.
   [Chang, Je Ken; Wang, Gwo Jaw] Kaohsiung Med Univ, Dept Orthopaed, Coll Med, Kaohsiung 807, Taiwan.
   [Chang, Je Ken; Li, Ching Ju; Liao, Hsiu Jun; Wang, Chih Kuang; Wang, Gwo Jaw; Ho, Mei Ling] Kaohsiung Med Univ, Orthopaed Res Ctr, Coll Med, Kaohsiung 807, Taiwan.
   [Li, Ching Ju; Ho, Mei Ling] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 807, Taiwan.
   [Wang, Chih Kuang] Kaohsiung Med Univ, Coll Life Sci, Fac Med & Appl Chem, Kaohsiung 807, Taiwan.
   [Wang, Gwo Jaw] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthopaed, Kaohsiung 807, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University; Kaohsiung Medical University; Kaohsiung Medical University
   Hospital
RP Ho, ML (通讯作者)，Kaohsiung Med Univ, Dept Physiol, Coll Med, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
EM homelin@cc.kmu.edu.tw
RI ; Wang, Chih Kuang/D 4440 2009; Ho, Mei Ling/D 5515 2009; Chang,
   Je Ken/A 1315 2010
OI Ho, Mei Ling/0000 0001 8064 8488; Wang, Chih Kuang/0000 0002 4398 6979; 
FU National Health Research Institute in Taiwan [NHRI EX97 9615EP];
   Technology Development Program for Academia in Taiwan
   [97 EC 17 A 17 SI 041]
FX This study was supported by a grant from the National Health Research
   Institute in Taiwan (NHRI EX97 9615EP) and the Technology Development
   Program for Academia in Taiwan (97 EC 17 A 17 SI 041).
CR Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357 2725(96)00178 1
   Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099
   Bauer DC, 1996, J BONE MINER RES, V11, P29
   BLOCKA KLN, 1988, J RHEUMATOL, V15, P757
   BUCKLEY MMT, 1990, DRUGS, V39, P86, DOI 10.2165/00003495 199039010 00008
   Carbone LD, 2003, J BONE MINER RES, V18, P1795, DOI 10.1359/jbmr.2003.18.10.1795
   Chang JK, 2007, BIOCHEM PHARMACOL, V74, P1371, DOI 10.1016/j.bcp.2007.06.047
   Chang JK, 2006, TOXICOLOGY, V228, P111, DOI 10.1016/j.tox.2006.08.028
   Chang JK, 2006, CLIN ORTHOP RELAT R, P286, DOI 10.1097/01.blo.0000238869.99980.b2
   Chang JK, 2005, CONNECT TISSUE RES, V46, P200, DOI 10.1080/03008200500344025
   Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495 200059040 00017
   COOPER C, 1995, ANN RHEUM DIS, V54, P49, DOI 10.1136/ard.54.1.49
   Corroyer S, 2002, PEDIATR RES, V51, P169, DOI 10.1203/00006450 200202000 00008
   Fernandes D, 1999, AM J RESP CELL MOL, V21, P77, DOI 10.1165/ajrcmb.21.1.3396
   Gerstenfeld LC, 2007, J BONE JOINT SURG AM, V89A, P114, DOI 10.2106/JBJS.F.00495
   Gerstenfeld Louis C, 2004, Expert Opin Drug Saf, V3, P131, DOI 10.1517/14740338.3.2.131
   Goldberg Y, 1996, ONCOGENE, V12, P893
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Grösch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01 0299fje
   HAKEDA Y, 1986, J CELL PHYSIOL, V128, P155, DOI 10.1002/jcp.1041280204
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9
   HO ML, 1995, CLIN ORTHOP RELAT R, P270
   Ho ML, 1999, BIOCHEM PHARMACOL, V58, P983, DOI 10.1016/S0006 2952(99)00186 0
   Ho ML, 1998, PHARMACOLOGY, V57, P148, DOI 10.1159/000028236
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   Kovarik JM, 1998, PHARMACOTHERAPY, V18, P1230
   Krischak GD, 2007, ARCH ORTHOP TRAUM SU, V127, P453, DOI 10.1007/s00402 007 0288 9
   Lane NE, 1997, J RHEUMATOL, V24, P1132
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Morton DJ, 1998, J BONE MINER RES, V13, P1924, DOI 10.1359/jbmr.1998.13.12.1924
   Niculescu AB III, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629
   OBERBAUER R, 1993, CLIN PHARMACOKINET, V24, P428, DOI 10.2165/00003088 199324050 00007
   Piazza GA, 1997, CANCER RES, V57, P2452
   PILBEAM CC, 1995, J BONE MINER RES, V10, P406
   Radi ZA, 2005, INFLAMM RES, V54, P358, DOI 10.1007/s00011 005 1367 4
   Raisz LG, 1999, OSTEOARTHR CARTILAGE, V7, P419, DOI 10.1053/joca.1998.0230
   Richards JB, 2006, OSTEOPOROSIS INT, V17, P1410, DOI 10.1007/s00198 006 0142 x
   SAAG KG, 1994, AM J MED, V96, P115, DOI 10.1016/0002 9343(94)90131 7
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Suzuki N, 2003, LIFE SCI, V73, P2237, DOI 10.1016/S0024 3205(03)00603 9
   TODD PA, 1988, DRUGS, V35, P244, DOI 10.2165/00003495 198835030 00004
   VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852
   Viereck V, 2003, J CLIN ENDOCR METAB, V88, P4206, DOI 10.1210/jc.2002 021877
   Vrotsos Y, 2003, CRIT REV EUKAR GENE, V13, P255, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.170
   Vuolteenaho K, 2008, BASIC CLIN PHARMACOL, V102, P10, DOI 10.1111/j.1742 7843.2007.00149.x
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Zhang GS, 2000, LEUKEMIA RES, V24, P385, DOI 10.1016/S0145 2126(99)00198 8
NR 51
TC 96
Z9 104
U1 0
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300 483X
J9 TOXICOLOGY
JI Toxicology
PD APR 28
PY 2009
VL 258
IS 2 3
BP 148
EP 156
DI 10.1016/j.tox.2009.01.016
PG 9
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 426BK
UT WOS:000264682200009
PM 19428934
DA 2025 08 17
ER

PT J
AU De Robertis, A
   Mennillo, F
   Rossi, M
   Valensin, S
   Tunici, P
   Mori, E
   Caradonna, N
   Varrone, M
   Salerno, M
AF De Robertis, Alessandra
   Mennillo, Federica
   Rossi, Marco
   Valensin, Silvia
   Tunici, Patrizia
   Mori, Elisa
   Caradonna, Nicola
   Varrone, Maurizio
   Salerno, Massimiliano
TI Human Sarcoma Growth Is Sensitive to Small Molecule Mediated AXIN
   Stabilization
SO PLOS ONE
LA English
DT Article
ID BETA CATENIN; SCAFFOLD PROTEIN; WNT ACTIVATION; HIGH FREQUENCY; COMPLEX;
   INHIBITION; OSTEOSARCOMA; DEGRADATION; SUPPRESSION; EXPRESSION
AB Sarcomas are mesenchymal tumors showing high molecular heterogeneity, reflected at the histological level by the existence of more than fifty different subtypes. Genetic and epigenetic evidences link aberrant activation of the Wnt signaling to growth and progression of human sarcomas. This phenomenon, mainly accomplished by autocrine loop activity, is sustained by gene amplification, over expression of Wnt ligands and co receptors or epigenetic silencing of endogenous Wnt antagonists. We previously showed that pharmacological inhibition of Wnt signaling mediated by Axin stabilization produced in vitro and in vivo antitumor activity in glioblastoma tumors. Here, we report that targeting different sarcoma cell lines with the Wnt inhibitor/Axin stabilizer SEN461 produces a less transformed phenotype, as supported by modulation of anchorage independent growth in vitro. At the molecular level, SEN461 treatment enhanced the stability of the scaffold protein Axin1, a key negative regulator of the Wnt signaling with tumor suppressor function, resulting in downstream effects coherent with inhibition of canonical Wnt signaling. Genetic phenocopy of small molecule Axin stabilization, through Axin1 over expression, coherently resulted in strong impairment of soft agar growth. Importantly, sarcoma growth inhibition through pharmacological Axin stabilization was also observed in a xenograft model in vivo in female CD 1 nude mice. Our findings suggest the usefulness of Wnt inhibitors with Axin stabilization activity as a potentialyl clinical relevant strategy for certain types of sarcomas.
C1 [De Robertis, Alessandra; Mennillo, Federica; Valensin, Silvia; Salerno, Massimiliano] Siena Biotech Med Res Ctr, Mol Oncol Unit, Siena, Italy.
   [De Robertis, Alessandra; Mennillo, Federica; Rossi, Marco; Valensin, Silvia; Tunici, Patrizia; Mori, Elisa; Salerno, Massimiliano] Siena Biotech Med Res Ctr, Dept Pharmacol, Siena, Italy.
   [Rossi, Marco; Tunici, Patrizia] Siena Biotech Med Res Ctr, In Vivo Pharmacol Unit, Siena, Italy.
   [Mori, Elisa] Siena Biotech Med Res Ctr, Data Anal Unit, Siena, Italy.
   [Caradonna, Nicola] Siena Biotech Med Res Ctr, MET Profiling Unit, Siena, Italy.
   [Varrone, Maurizio] Siena Biotech Med Res Ctr, Dept Med Chem, Siena, Italy.
C3 Siena Biotech; Siena Biotech; Siena Biotech; Siena Biotech; Siena
   Biotech; Siena Biotech
RP Salerno, M (通讯作者)，Siena Biotech Med Res Ctr, Mol Oncol Unit, Siena, Italy.
EM massisal67@gmail.com
OI SALERNO, Massimiliano/0000 0002 1093 5454; Rossi,
   Marco/0009 0009 9016 8547
FU Monte Dei Paschi Foundation
FX The study was funded by Monte Dei Paschi Foundation. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82
   Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279
   Bishop E T, 1999, Angiogenesis, V3, P335, DOI 10.1023/A:1026546219962
   Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Chen YC, 2010, MOL THER, V18, P828, DOI 10.1038/mt.2009.291
   Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310
   Clark MA, 2005, NEW ENGL J MED, V353, P701, DOI 10.1056/NEJMra041866
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   De Robertis A, 2013, MOL CANCER THER, V12, P1180, DOI 10.1158/1535 7163.MCT 12 1176 T
   Detwiller KY, 2005, CANCER RES, V65, P5881, DOI 10.1158/0008 5472.CAN 04 4078
   Dieudonné FX, 2010, CANCER RES, V70, P5399, DOI 10.1158/0008 5472.CAN 10 0090
   Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV 100102557
   Finch AJ, 2009, MOL CELL BIOL, V29, P5306, DOI 10.1128/MCB.01745 08
   Gehrke I, 2009, EUR J CANCER, V45, P2759, DOI 10.1016/j.ejca.2009.08.003
   Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653
   Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446
   Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165
   Guo Y, 2008, CANCER RES, V68, P3350, DOI 10.1158/0008 5472.CAN 07 3220
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371
   Iwao K, 1999, JPN J CANCER RES, V90, P205, DOI 10.1111/j.1349 7006.1999.tb00734.x
   James RG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050457
   Karlsson Å, 2003, BLOOD, V101, P2797, DOI 10.1182/blood 2002 10 3091
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kim SE, 2013, SCIENCE, V340, P867, DOI 10.1126/science.1232389
   Leow PC, 2010, INVEST NEW DRUG, V28, P766, DOI 10.1007/s10637 009 9311 z
   LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502
   Liu W, 2006, EMBO J, V25, P1646, DOI 10.1038/sj.emboj.7601057
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Marklein D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052898
   Misra RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050153
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092 8674(92)90630 U
   Rubin EM, 2010, MOL CANCER THER, V9, P731, DOI 10.1158/1535 7163.MCT 09 0147
   Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475
   Saito T, 2002, J PATHOL, V196, P445, DOI 10.1002/path.1066
   Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Stratford EW, 2014, CANCER MED US, V3, P36, DOI 10.1002/cam4.170
   TABONE MD, 1994, J CLIN ONCOL, V12, P2614, DOI 10.1200/JCO.1994.12.12.2614
   Tarkkanen M, 2006, EUR J CANCER, V42, P1172, DOI 10.1016/j.ejca.2006.01.035
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092 8674(02)01014 0
   Vijayakumar S, 2011, CANCER CELL, V19, P601, DOI 10.1016/j.ccr.2011.03.010
   Wan XL, 2007, ONCOLOGIST, V12, P1007, DOI 10.1634/theoncologist.12 8 1007
   Watson AL, 2013, CANCER DISCOV, V3, P674, DOI 10.1158/2159 8290.CD 13 0081
   Wunder JS, 2007, LANCET ONCOL, V8, P513, DOI 10.1016/S1470 2045(07)70169 9
NR 51
TC 7
Z9 9
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 19
PY 2014
VL 9
IS 5
AR e97847
DI 10.1371/journal.pone.0097847
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AN9SK
UT WOS:000340948600082
PM 24842792
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Wang, HF
   Chen, S
   He, ZH
   Chen, JY
   Zhu, Z
   Wan, QB
   Wang, J
   Pei, XB
AF Wang, Hengfei
   Chen, Song
   He, Zihan
   Chen, Junyu
   Zhu, Zhou
   Wan, Qianbing
   Wang, Jian
   Pei, Xibo
TI Synthesis and potential osteogenic applications of Wnt3a loaded ZIF 8
   nanoparticles
SO CHINESE CHEMICAL LETTERS
LA English
DT Article
DE Metal organic frameworks; Nanoparticle; Drug release; Osteogenesis; Bone
   defects
ID DRUG DELIVERY
AB The Wnt signaling pathway plays a critical role in bone homeostasis, and the related protein therapy strategies have been reported to have great potential in osseointegration; however, they face formidable challenges such as complex external environments and unavoidable protein denaturation. In this work, we report a novel approach combining the synthesis of metal organic frameworks (MOFs) and protein encapsulation in a one pot process based on zeolitic imidazolate framework 8 (ZIF 8) and Wnt3a protein, with improved biomechanical behavior and enhanced protein biological response. This combination was designed to enhance the Wnt3a protein function through the improved chemical stability provided by the ZIF 8 crystals. Additionally, the zinc ions contained in the ZIF 8 crystals induced bone homeostasis, further favoring the osteogenesis. The results showed that the Wnt3a protein loaded ZIF 8 crystals served as efficient drug delivery vehicles to promote osteogenesis, preventing protein denaturation. In particular, Wnt3a loaded ZIF 8 nanoparticles (Wnt3a@ZIF 8 NPs) had higher efficacy on bone marrow mesenchymal stem cells (BMSCs) than ZIF 8 NPs or Wnt3a proteins, contributing to the osteogenesis through ZIF 8 crystals and intracellular Wnt3a proteins released from Wnt3a@ZIF 8 NPs. Furthermore, polymerase chain reaction (PCR) analysis showed that the osteogenic pathways were upregulated. Overall, the present onepot process can open up new avenues to develop signaling protein delivery systems for applications in protein therapy strategies. (c) 2024 Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.
C1 [Wang, Hengfei; Chen, Song; He, Zihan; Chen, Junyu; Zhu, Zhou; Wan, Qianbing; Wang, Jian; Pei, Xibo] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis,Dept Prosthodont, Chengdu 610041, Peoples R China.
   [Chen, Song] Chongqing Med Univ, Stomatol Hosp, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing Municipal Key Lab Oral Biomed Engn Highe, Chongqing 401147, Peoples R China.
C3 Sichuan University; Chongqing Medical University
RP Wang, J; Pei, XB (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis,Dept Prosthodont, Chengdu 610041, Peoples R China.
EM ferowang@hotmail.com; xbpei@hotmail.com
RI Pei, Xibo/JGD 3532 2023; Zhu, Zhou/JUF 7436 2023; Wang,
   Jian/JWO 7247 2024
OI Zhu, Zhou/0000 0003 3324 483X; Wang, Jian/0000 0002 5137 0330
FU National Nature Sci ence Foundations of China [82271016, 82271034,
   82270961, 82071164, 8197032972, 81901060]; Key research program of
   Sichuan Science and technology Department [2021YFS0052]; Research and
   Development Program (West China Hospital of Stom atology, Sichuan
   University) [RD 03 202107, RD 03 202310]
FX This work was financially supported by National Nature Sci ence
   Foundations of China (Nos. 82271016, 82271034, 82270961, 82071164,
   8197032972, 81901060) , Key research program of Sichuan Science and
   technology Department (No. 2021YFS0052) , Research and Development
   Program (West China Hospital of Stom atology, Sichuan University) (Nos.
   RD 03 202107, RD 03 202310) .
CR Ballabio A, 2020, NAT REV MOL CELL BIO, V21, P101, DOI 10.1038/s41580 019 0185 4
   Botor M, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11101493
   Chen NX, 2022, BIOMATERIALS, V286, DOI 10.1016/j.biomaterials.2022.121567
   Chen YH, 2021, ACTA BIOMATER, V120, P224, DOI 10.1016/j.actbio.2020.10.011
   Crovador R, 2021, ACS APPL BIO MATER, V4, P6338, DOI 10.1021/acsabm.1c00581
   Eivazzadeh Keihan R, 2020, J TISSUE ENG REGEN M, V14, P1687, DOI 10.1002/term.3131
   Feng H, 2022, CHEM ENG J, V430, DOI 10.1016/j.cej.2021.132867
   Gao XM, 2021, ACS APPL MATER INTER, V13, P97, DOI 10.1021/acsami.0c15945
   Griffin BT, 2016, ADV DRUG DELIVER REV, V106, P367, DOI 10.1016/j.addr.2016.06.006
   Jakubiak GK, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11010079
   Juan CA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094642
   Kim JM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16038 6
   Korkut C, 2009, CELL, V139, P393, DOI 10.1016/j.cell.2009.07.051
   Lee CH, 2011, B KOREAN CHEM SOC, V32, P768, DOI 10.5012/bkcs.2011.32.3.768
   Lee LR, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116378
   Liu B., 2023, Small, V19
   Oh JH, 2014, BMB REP, V47, P110, DOI 10.5483/BMBRep.2014.47.2.156
   Okuchi Y, 2021, NAT MATER, V20, P108, DOI 10.1038/s41563 020 0786 5
   Oosterlaken BM, 2021, ADV MATER, V33, DOI 10.1002/adma.202004418
   Ou ZH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18363 2
   Pan PP, 2021, CHINESE CHEM LETT, V32, P2159, DOI 10.1016/j.cclet.2020.12.001
   Pang XC, 2019, PHARMACOL RES, V144, P235, DOI 10.1016/j.phrs.2019.04.030
   Peng SJ, 2019, ACS APPL MATER INTER, V11, P35604, DOI 10.1021/acsami.9b15037
   Peng SJ, 2019, J COLLOID INTERF SCI, V539, P19, DOI 10.1016/j.jcis.2018.12.035
   Ping H, 2022, SCIENCE, V376, P188, DOI 10.1126/science.abm2664
   Popelut A, 2010, BIOMATERIALS, V31, P9173, DOI 10.1016/j.biomaterials.2010.08.045
   Ran JS, 2018, DRUG DES DEV THER, V12, P1195, DOI 10.2147/DDDT.S162014
   Rico Llanos GA, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13040599
   Shen GY, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102626
   Song YX, 2017, J MATER CHEM B, V5, P6008, DOI 10.1039/c7tb01092c
   Su YY, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/9837035
   Velásquez Hernández MD, 2020, CHEM SCI, V11, P10835, DOI 10.1039/d0sc01204a
   Volleman TNE, 2020, NEUROSPINE, V17, P19
   Wang JM, 2019, J AGR FOOD CHEM, V67, P10285, DOI 10.1021/acs.jafc.9b03835
   Wang YF, 2021, DRUG DES DEV THER, V15, P1531, DOI 10.2147/DDDT.S299479
   Xu C, 2023, CHINESE CHEM LETT, V34, DOI 10.1016/j.cclet.2022.05.042
   Yang LL, 2020, BIOMATER SCI UK, V8, P2638, DOI 10.1039/d0bm00264j
   Yu L, 2023, BIOACT MATER, V20, P598, DOI 10.1016/j.bioactmat.2022.06.017
   Zhang KY, 2018, ADV SCI, V5, DOI 10.1002/advs.201800875
   Zhang QH, 2021, ACS NANO, V15, P8001, DOI 10.1021/acsnano.1c00476
   Zhang ZC, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120905
   Zheng HQ, 2016, J AM CHEM SOC, V138, P962, DOI 10.1021/jacs.5b11720
   Zhuang J, 2014, ACS NANO, V8, P2812, DOI 10.1021/nn406590q
   Zhuang Y, 2021, BIOACT MATER, V6, P1791, DOI 10.1016/j.bioactmat.2020.11.028
NR 44
TC 6
Z9 7
U1 11
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1001 8417
EI 1878 5964
J9 CHINESE CHEM LETT
JI Chin. Chem. Lett.
PD MAR
PY 2024
VL 35
IS 3
AR 108597
DI 10.1016/j.cclet.2023.108597
EA DEC 2023
PG 7
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA IG1O7
UT WOS:001165087200001
DA 2025 08 17
ER

PT J
AU Yin, C
   Tian, Y
   Yu, Y
   Wang, HY
   Wu, ZX
   Huang, ZZ
   Zhang, Y
   Li, DJ
   Yang, CF
   Wang, X
   Li, Y
   Qian, AR
AF Yin, Chong
   Tian, Ye
   Yu, Yang
   Wang, Haoyu
   Wu, Zhixiang
   Huang, Zizhan
   Zhang, Yan
   Li, Dijie
   Yang, Chaofei
   Wang, Xue
   Li, Yu
   Qian, Airong
TI A novel long noncoding RNA AK016739 inhibits osteoblast differentiation
   and bone formation
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE AK016739; bone formation; lncRNA; osteoblast differentiation;
   postmenopausal osteoporosis; transcript factor
ID MESENCHYMAL STEM CELLS; SURFACES
AB The incidence of postmenopausal osteoporosis research 50% in middle aged and older women, however, effects of existing therapy are not ideal. Emerging evidence have proved that long noncoding RNAs (lncRNAs) was correlated with multiple physiological and pathology processes including development, carcinogenesis, and osteogenesis. However, reports on lncRNAs regulating bone formation were relatively limited. In this study, we screened osteogenic lncRNAs through mRNA/lncRNA microarray combined with gene coexpression analysis. The biological function of the screened lncRNA was assessed both in vitro and in vivo. The effects of the lncRNA on osteogenic transcription factors were also evaluated. We identified AK016739, which was correlated with osteogenic differentiation and enriched in skeletal tissues of mice. The expression levels of AK016739 in bone derived mesenchymal stem cells were increased with age and negatively correlated with osteogenic differentiation marker genes. Experiments showed that AK016739 inhibited osteoblast differentiation, and in vivo inhibition of AK016739 by its small interfering RNA would rescue bone formation in ovariectomized osteoporosis mice model. In addition, AK016739 suppressed both expression levels and activities of osteogenic transcription factors. This newly identified lncRNA AK016739 has revealed a new mechanism of osteogenic differentiation and provided new targets for treatment of skeletal disorders.
C1 [Yin, Chong; Tian, Ye; Wu, Zhixiang; Huang, Zizhan; Zhang, Yan; Li, Dijie; Yang, Chaofei; Wang, Xue; Li, Yu; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, Key Lab Space Biosci & Biotechnol, Lab Bone Metab, Xian, Shaanxi, Peoples R China.
   [Yin, Chong; Tian, Ye; Wu, Zhixiang; Huang, Zizhan; Zhang, Yan; Li, Dijie; Yang, Chaofei; Wang, Xue; Li, Yu; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, Res Ctr Special Med & Hlth Syst Engn, Xian, Shaanxi, Peoples R China.
   [Yin, Chong; Tian, Ye; Wu, Zhixiang; Huang, Zizhan; Zhang, Yan; Li, Dijie; Yang, Chaofei; Wang, Xue; Li, Yu; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, NPU UAB Joint Lab Bone Metab, 127 West Youyi Rd, Xian 710072, Shaanxi, Peoples R China.
   [Yu, Yang] Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin, Peoples R China.
   [Wang, Haoyu] Peking Univ, Sch Software & Microelect, Dept Software Technol & Serv Engn, Beijing, Peoples R China.
C3 Northwestern Polytechnical University; Northwestern Polytechnical
   University; Northwestern Polytechnical University; Tianjin Medical
   University; Peking University
RP Li, Y; Qian, AR (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, NPU UAB Joint Lab Bone Metab, 127 West Youyi Rd, Xian 710072, Shaanxi, Peoples R China.
EM liyu@nwpu.edu.cn; qianair@nwpu.edu.cn
RI ; Li, Mengyuan/ISR 9246 2023; Zhang, Yan/MTF 5312 2025; Li,
   Dijie/KVB 3667 2024; Yu, Yang/AAI 2652 2020
OI , Chong/0000 0002 8113 8911; Zhang, Yan/0000 0001 6213 4416; 
FU National Natural Science Foundation of China [31570940, 81772017]; China
   Postdoctoral Science Foundation [2017M613210, 2017M610653]; Fundamental
   Research Funds for the Central Universities [3102018zy053,
   3102016ZY037]; Shaanxi Provincial Key RD Program [2018KWZ 10]; Shenzhen
   Science and Technology Project [JCYJ20160229174320053]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   31570940, 81772017; China Postdoctoral Science Foundation, Grant/Award
   Numbers: 2017M613210, 2017M610653; Fundamental Research Funds for the
   Central Universities, Grant/Award Numbers: 3102018zy053, 3102016ZY037;
   Shaanxi Provincial Key R&D Program, Grant/Award Number: 2018KWZ 10;
   Shenzhen Science and Technology Project, Grant/Award Number:
   JCYJ20160229174320053
CR Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Cao Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097098
   Fassett JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073887
   Gao XR, 2018, CELL BIOSCI, V8, DOI 10.1186/s13578 018 0216 4
   Gennari L, 2016, EXPERT OPIN PHARMACO, V17, P1141, DOI 10.1080/14656566.2016.1176147
   Hu LF, 2018, J CELL PHYSIOL, V233, P1574, DOI 10.1002/jcp.26059
   Hu LF, 2016, BMB REP, V49, P37, DOI 10.5483/BMBRep.2016.49.1.185
   Hu LF, 2015, BMB REP, V48, P583, DOI 10.5483/BMBRep.2015.48.10.098
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Jabbar S, 2011, J CLIN PATHOL, V64, P354, DOI 10.1136/jcp.2010.086595
   Jiao K, 2015, SCI REP UK, V5, DOI 10.1038/srep12593
   Kodama A, 2003, CELL, V115, P343, DOI 10.1016/S0092 8674(03)00813 4
   Li B, 2018, BONE, V111, P82, DOI 10.1016/j.bone.2018.03.017
   Li B, 2017, ORTHOP SURG, V9, P319, DOI 10.1111/os.12321
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Liao JY, 2017, ONCOTARGET, V8, P53581, DOI 10.18632/oncotarget.18655
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Shang GW, 2018, J CELL PHYSIOL, V233, P6041, DOI 10.1002/jcp.26424
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shao AW, 2016, MOL NEUROBIOL, V53, P18, DOI 10.1007/s12035 014 8986 0
   Ushiku C, 2010, J ORTHOP RES, V28, P1338, DOI 10.1002/jor.21105
   Wang QJ, 2017, BIOMED PHARMACOTHER, V89, P1178, DOI 10.1016/j.biopha.2017.02.090
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Wu JJ, 2018, BONE, V108, P62, DOI 10.1016/j.bone.2017.12.013
   Yin C, 2018, J CELL PHYSIOL, V233, P5405, DOI 10.1002/jcp.26374
   Yue JP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11692
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang Y, 2018, HUM GENE THER, V29, P259, DOI 10.1089/hum.2017.153
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
NR 36
TC 35
Z9 36
U1 0
U2 56
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2019
VL 234
IS 7
BP 11524
EP 11536
DI 10.1002/jcp.27815
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HQ8AL
UT WOS:000462645700148
PM 30656695
DA 2025 08 17
ER

PT J
AU Kim, JY
   Cheon, YH
   Ahn, SJ
   Kwak, SC
   Chung, CH
   Lee, CH
   Lee, MS
AF Kim, Ju Young
   Cheon, Yoon Hee
   Ahn, Sung Jun
   Kwak, Sung Chul
   Chung, Chong Hyuk
   Lee, Chang Hoon
   Lee, Myeung Su
TI Harpagoside attenuates local bone Erosion and systemic osteoporosis in
   collagen induced arthritis in mice
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Collagen induced arthritis model; Harpagoside; Inflammation;
   Osteoclasts; Rheumatoid arthritis
ID RHEUMATOID ARTHRITIS; MECHANISMS; DAMAGE; INFLAMMATION; EXPRESSION;
   DEVILS; INTERLEUKIN 6; ANTIBODY; THERAPY; PATHWAY
AB Background Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that causes local bone erosion and systemic osteoporosis. Harpagoside (HAR), an iridoid glycoside, has various pharmacological effects on pain, arthritis, and inflammation. Our previous study suggests that HAR is more deeply involved in the mechanism of bone loss caused by inflammatory stimuli than hormonal changes. Here, we identified the local and systemic bone loss inhibitory effects of HAR on RA and its intracellular mechanisms using a type 2 collagen induced arthritis (CIA) mouse model. Methods The anti osteoporosis and anti arthritic effects of HAR were evaluated on bone marrow macrophage in vitro and CIA in mice in vivo by obtaining clinical scores, measuring hind paw thickness and inflammatory cytokine levels, micro CT and histopathological assessments, and cell based assay. Results HAR markedly reduced the clinical score and incidence rate of CIA in both the prevention and therapy groups. Histological analysis demonstrated that HAR locally ameliorated the destruction of bone and cartilage and the formation of pannus. In this process, HAR decreased the expression of inflammatory cytokines, such as tumor necrosis factor alpha, interleukin (IL) 6, and IL 1 beta in the serum of CIA mice. Additionally, HAR downregulated the expression of receptor activator of nuclear factor kappa B ligand and upregulated that of osteoprotegerin. HAR suppressed systemic bone loss by inhibiting osteoclast differentiation and osteoclast marker gene expression in a CIA mouse model. Conclusions Taken together, these findings show the beneficial effect of HAR on local symptoms and systemic bone erosion triggered by inflammatory arthritis.
C1 [Kim, Ju Young; Cheon, Yoon Hee; Ahn, Sung Jun; Kwak, Sung Chul; Chung, Chong Hyuk; Lee, Chang Hoon; Lee, Myeung Su] Wonkwang Univ, Musculoskeletal & Immune Dis Res Inst, Sch Med, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea.
   [Chung, Chong Hyuk; Lee, Chang Hoon; Lee, Myeung Su] Wonkwang Univ Hosp, Div Rheumatol, Dept Internal Med, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University
RP Lee, MS (通讯作者)，Wonkwang Univ, Musculoskeletal & Immune Dis Res Inst, Sch Med, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea.; Lee, MS (通讯作者)，Wonkwang Univ Hosp, Div Rheumatol, Dept Internal Med, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea.
EM ckhlms@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
FU Wonkwnag University
FX This study was supported by the Wonkwnag University in 2020.
CR Aletaha D, 2006, ARTHRITIS RHEUM US, V54, P2784, DOI 10.1002/art.22052
   Antoni C, 2002, CLIN EXP RHEUMATOL, V20, pS152
   Boe A, 1999, CYTOKINE, V11, P1057, DOI 10.1006/cyto.1999.0502
   Bongartz T, 2006, JAMA J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Braun T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3380
   Butler DM, 1995, EUR CYTOKINE NETW, V6, P225
   Cheon YH, 2021, BIOMED PHARMACOTHER, V139, DOI 10.1016/j.biopha.2021.111697
   Chiu YG, 2017, EXPERT OPIN BIOL TH, V17, P119, DOI 10.1080/14712598.2017.1263614
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   De Benedetti F, 2006, ARTHRITIS RHEUM, V54, P3551, DOI 10.1002/art.22175
   Ethgen O, 2013, CURR MED RES OPIN, V29, P1147, DOI 10.1185/03007995.2013.818531
   Fujita T, 2013, J GASTROENTEROL, V48, P559, DOI 10.1007/s00535 013 0771 8
   Haseeb A, 2017, J ORTHOP RES, V35, P311, DOI 10.1002/jor.23262
   Hayer S, 2016, DIS MODEL MECH, V9, P1329, DOI 10.1242/dmm.025460
   Hermann M, 2006, INTERN MED J, V36, P308, DOI 10.1111/j.1445 5994.2006.01056.x
   Jung SM, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/263625
   Kim JY, 2015, J NAT PROD, V78, P2167, DOI 10.1021/acs.jnatprod.5b00233
   Kumar G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205154
   Lee MK, 2007, J SEP SCI, V30, P2345, DOI 10.1002/jssc.200700117
   McNamee K, 2015, EUR J PHARMACOL, V759, P278, DOI 10.1016/j.ejphar.2015.03.047
   Mncwangi N, 2012, J ETHNOPHARMACOL, V143, P755, DOI 10.1016/j.jep.2012.08.013
   Nakamura Y, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0371 y
   Niki Y, 2001, J CLIN INVEST, V107, P1127, DOI 10.1172/JCI11530
   Okamoto H, 1997, ARTHRITIS RHEUM, V40, P1096, DOI 10.1002/art.1780400614
   Qi J, 2006, PHYTOCHEMISTRY, V67, P1372, DOI 10.1016/j.phytochem.2006.05.029
   Quan LD, 2008, EXPERT OPIN THER PAT, V18, P723, DOI 10.1517/13543776.18.7.723
   Robinson WH, 2001, ARTHRITIS RHEUM US, V44, P1977, DOI 10.1002/1529 0131(200109)44:9<1977::AID ART345>3.0.CO;2 6
   Romas E, 2000, ARTHRITIS RHEUM, V43, P821, DOI 10.1002/1529 0131(200004)43:4<821::AID ANR12>3.0.CO;2 T
   Schett G, 2017, MOD RHEUMATOL, V27, P193, DOI 10.1080/14397595.2016.1265907
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Stewart KM, 2005, J ETHNOPHARMACOL, V100, P225, DOI 10.1016/j.jep.2005.07.004
   Tanaka S, 2018, J ORTHOP SCI, V23, P717, DOI 10.1016/j.jos.2018.06.001
   Tanaka Y, 2018, CURR OPIN PHARMACOL, V40, P110, DOI 10.1016/j.coph.2018.03.006
   Tian JF, 2012, J SEP SCI, V35, P2659, DOI 10.1002/jssc.201200337
   Zwerina J, 2007, P NATL ACAD SCI USA, V104, P11742, DOI 10.1073/pnas.0610812104
NR 36
TC 2
Z9 4
U1 2
U2 17
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2662 7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD AUG 10
PY 2022
VL 22
IS 1
AR 214
DI 10.1186/s12906 022 03694 y
PG 13
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 3R1MI
UT WOS:000838683000001
PM 35948905
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Pang, TT
   Liu, C
   Yao, JJ
   Li, JH
   Li, ZX
   Lou, HJ
   Lei, SY
   Zhang, JC
   Dong, L
   Wang, YF
AF Pang, Tingting
   Liu, Chang
   Yao, Junjie
   Li, Jiahui
   Li, Zhongxu
   Lou, Huijuan
   Lei, Siyuan
   Zhang, Jiangchun
   Dong, Li
   Wang, Yufeng
TI Mechanisms of the Bushen Huoxue formula in the treatment of
   osteoarthritis based on network pharmacology molecular targets
SO MEDICINE
LA English
DT Article
DE mechanisms; network pharmacology molecular targets; osteoarthritis; the
   Bushen Huoxue formula
ID DEGRADATION
AB Background: Osteoarthritis is a common degenerative disease with a high incidence, high disability rate, and poor prognosis. Clinical studies have shown that Bushen Huoxue formula can relieve joint swelling and pain and improve limb function and joint mobility, but there is a lack of high quality scientific basis. Using network pharmacology and molecular docking technology to study the mechanism of Bushen Huoxue formula in the treatment of osteoarthritis.
   Methods: First, the active ingredients and corresponding target predictions of the formula were obtained through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and the China National Knowledge Infrastructure. Meanwhile, the osteoarthritis disease targets were obtained through the genome annotation database platform (GeneCards) and the DrugBank database, and the target proteins obtained above were standardized using the Uniprot (https://www.uniprot.org ) database standardization of names. Then, the Venn diagram was created by taking the intersection of the active ingredient and the target of the disease, and the "active ingredient target" network was constructed and analyzed using Cytoscape 3,7.2 software. At the same time, the intersecting targets were imported into the Search Tool for the Retrieval of Interaction Gene/ Proteins database to build a protein protein interaction network and to screen the core targets; the intersecting targets were visualized by using the Database for Annotation, Visualization and Integrated Discovery 6.8 database for gene ontology functional analysis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and construct the "active ingredient target pathway" network. Finally, the main active ingredients of the formula for tonifying the kidney and invigorating the blood were validated by molecular docking with the core targets.
   Results: A total of 194 active ingredients and 365 targets of the Bushen Huoxue formula were collected, 776 targets for osteoarthritis diseases and 96 targets for the intersection of active ingredients and diseases. The Kyoto Encyclopedia of Genes and Genomes enrichment analysis yielded 104 relevant pathways, including tumor necrosis factor signaling pathways, cancer signaling pathways, nucleotide binding oligomerization domain like receptor signaling pathways, Toll like receptors signaling pathways, and osteoclast differentiation, apoptosis, T cell receptor signaling pathway, and other related pathways. The molecular docking results showed good binding of the main active ingredients to the core targets.
   Conclusion: This study shows that the treatment of osteoarthritis involves multicomponent, multitarget, and multipathway processes. The mechanism of anti inflammatory, antioxidant, inhibition of cartilage matrix degradation, and reduction of subchondral bone destruction may be an important mechanism for the therapeutic effect.
C1 [Pang, Tingting; Liu, Chang; Yao, Junjie; Li, Jiahui; Lou, Huijuan; Lei, Siyuan; Zhang, Jiangchun; Wang, Yufeng] Changchun Univ Chinese Med, Dept Acupuncture & Tuina, Changchun, Peoples R China.
   [Li, Zhongxu] Changchun Univ Chinese Med, Dept Tuina, Affiliated Hosp, Changchun, Peoples R China.
   [Dong, Li] Changchun Univ Chinese Med, Dept Rehabil, Med Coll, Changchun, Peoples R China.
C3 Changchun University of Chinese Medicine; Changchun University of
   Chinese Medicine; Changchun University of Chinese Medicine
RP Wang, YF (通讯作者)，Tradit Chinese Med Hosp Jinlin Prov, Dept Tuina, Changchun 130000, Peoples R China.
EM wangchn@126.com
RI Yao, Junjie/JNS 3182 2023; Lei, Siyuan/JPK 7748 2023; Wang,
   Yufeng/N 9531 2019; Li, Jizhou/JQJ 2189 2023
OI Yao, Junjie/0000 0002 7278 9325; 
CR Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Cai J., 2018, CHIN J TRADIT MED TR, V26, P33
   Chen WP, 2012, ACTA BIOCHIM POL, V59, P537
   Dieleman JL, 2020, JAMA J AM MED ASSOC, V323, P863, DOI 10.1001/jama.2020.0734
   Feng K, 2019, J CELL PHYSIOL, V234, P18192, DOI 10.1002/jcp.28452
   Fukai A, 2010, ARTHRITIS RHEUM US, V62, P826, DOI 10.1002/art.27296
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Huang XJ, 2018, MOL MED REP, V18, P2697, DOI 10.3892/mmr.2018.9280
   Jurgensmeier K, 2021, J ARTHROPLASTY, V36, P416, DOI 10.1016/j.arth.2020.08.036
   Karsdal MA, 2014, ANN RHEUM DIS, V73, P336, DOI 10.1136/annrheumdis 2013 204111
   Li C., 2016, J SICHUAN TRADIT CHI, V34, P101
   Li Jia Shang, 2021, Zhongguo Zhong Yao Za Zhi, V46, P2371, DOI 10.19540/j.cnki.cjcmm.20201126.401
   Li Ling, 2020, Zhongguo Zhong Yao Za Zhi, V45, P1816, DOI 10.19540/j.cnki.cjcmm.20190929.401
   Liang Y., 2016, J CHIN MED MAT, V56, P36
   Lin Jian Guo, 2021, Zhongguo Zhong Yao Za Zhi, V46, P885, DOI 10.19540/j.cnki.cjcmm.20201106.402
   Liu J., 2018, J CLIN EXP MED, V17, P685
   Mok SW, 2020, CARTILAGE, V11, P490, DOI 10.1177/1947603518796550
   Moulharat N, 2004, OSTEOARTHR CARTILAGE, V12, P296, DOI 10.1016/j.joca.2003.11.009
   Nelson AE, 2018, OSTEOARTHR CARTILAGE, V26, P319, DOI 10.1016/j.joca.2017.11.014
   Nishida Y, 2021, ARTHRITIS RHEUMATOL, V73, P1646, DOI 10.1002/art.41725
   Qu D., 2021, J LIAONING U TRADIT, V23, P37
   Safiri S, 2020, ANN RHEUM DIS, V79, P819, DOI 10.1136/annrheumdis 2019 216515
   Sneider EB, 2013, GASTROENTEROL CLIN N, V42, P773, DOI 10.1016/j.gtc.2013.08.003
   Sun Z., 2017, CHIN J TISSUE ENG RE, V21, P2484
   Talbert Paul B, 2004, J Biol, V3, P18, DOI 10.1186/jbiol11
   Wang B., 2015, J SE U MEDICAL SCI E, V34, P47
   Xiao Z., 2016, CHIN J TRADIT MED TR, V24, P1
   Xing L., 2022, CHIN TRADIT PATENT M, V44, P582
   Xue JL, 2019, CELL MOL BIOL, V65, P91, DOI 10.14715/cmb/2019.65.6.15
   Yan H., 2020, J CHIN MED MAT, V43, P3059
   Yang Y., 2020, CHINESE ARCH TRADIT, V38, P206
   [叶大林 Ye Dalin], 2018, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V24, P1606
   Yuan R, 2020, CHINESE MASTERS THES
   [曾莉萍 Zeng Liping], 2012, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V23, P1051
   Zhang J, 2019, J INT MED RES, DOI 10.1177/0300060519873461
   Zhang Xiao Wen, 2021, Zhongguo Zhong Yao Za Zhi, V46, P894, DOI 10.19540/j.cnki.cjcmm.20201117.401
   Zhuang ZL, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.902491
NR 37
TC 6
Z9 7
U1 1
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG 12
PY 2022
VL 101
IS 32
AR e29345
DI 10.1097/MD.0000000000029345
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 3S6WE
UT WOS:000839733700083
PM 35960090
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Dong, KJ
   Lu, LY
   He, M
   Ouyang, YG
   Xue, Y
   Li, CL
   Wu, SY
   Wang, XG
   Shen, HT
   Gao, JJ
   Wang, W
   Chen, DF
   Xing, YG
   Yuan, J
   Jiang, S
AF Dong Kejun
   Lu Liyan
   He Ming
   Ouyang Yinggen
   Xue Yan
   Li Chaoli
   Wu Shaoyong
   Wang Xianggao
   Shen Hongtao
   Gao Jianjun
   Wang Wei
   Chen Dafu
   Xing Yonggang
   Yuan Jian
   Jiang Shan
TI Study on bone resorption behavior of osteoclast under drug effect using
   <SUP>41</SUP>Ca tracing
SO NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION B BEAM
   INTERACTIONS WITH MATERIALS AND ATOMS
LA English
DT Article; Proceedings Paper
CT 12th International Conference on Accelerator Mass Spectrometry (AMS)
CY MAR 20 25, 2011
CL GNS Sci, Wellington, NEW ZEALAND
SP GNS Sci, Natl Isotope Ctr, Australian Nucl Sci & Technol Org, High Voltage Engn, Natl Electrostat Corp
HO GNS Sci
DE Ca 41; Accelerator mass spectrometry; Biological tracing
ID AMS MEASUREMENT; OSTEOBLAST; TRACER; CIAE
AB The mechanisms governing calcium fluxes during bone remodeling processes in Osteoporosis (OP) patients are poorly known. Understanding the changes of Osteoclasts (OC) during this dynamic transition is important to prevent and cure OP. The exploration of long lived Ca 41 (T 1/2=1.04 x 10(5) years) tracer combined with AMS measurements leads to the possibility of monitoring the bone resorption behavior of OC in OP patients. In this work, the behavior of OC with the administration of Strontium Ranelate (SR), a drug for OP, was studied by using Ca 41 labeled hydroxyapatite (HAP) to simulate the bone. AMS on the HI 13 tandem accelerator at CIAE was used to determine trace amounts of Ca 41. The results show that the technique of Ca 41 tracing with AMS can be used to quantitatively monitor the behavior of OC in bone resorption under the effects of drugs. Experimental details and preliminary results will be presented. (C) 2012 Published by Elsevier B.V.
C1 [Dong Kejun; Lu Liyan; He Ming; Ouyang Yinggen; Xue Yan; Li Chaoli; Wu Shaoyong; Wang Wei; Yuan Jian; Jiang Shan] China Inst Atom Energy, Beijing 102413, Peoples R China.
   [Wang Xianggao] Guangxi Univ, Coll Phys Sci & Technol, Nanning 530004, Peoples R China.
   [Shen Hongtao] Guangxi Normal Univ, Coll Phys & Technol, Guilin 541004, Peoples R China.
   [Gao Jianjun] Fudan Univ, Inst Radiat Med, Shanghai 200032, Peoples R China.
   [Wang Wei] China Natl Nucl Corp, Beijing 100822, Peoples R China.
   [Lu Liyan] CNNC Third Qinshan Nucl Power Co Ltd, Haiyan 314300, Peoples R China.
   [Chen Dafu; Xing Yonggang] Beijing Res Inst Traumatol & Orthopaed, Beijing 100035, Peoples R China.
C3 China Institute of Atomic Energy; Guangxi University; Guangxi Normal
   University; Fudan University; China National Nuclear Corporation; China
   National Nuclear Corporation
RP Jiang, S (通讯作者)，China Inst Atom Energy, POB 275 50, Beijing 102413, Peoples R China.
EM jiangs@ciae.ac.cn
RI he, ming/HZM 5794 2023
CR Balkan W, 2005, J AM GERIATR SOC, V53, pS162
   Büchter A, 2005, CLIN ORAL IMPLAN RES, V16, P1, DOI 10.1111/j.1600 0501.2004.01081.x
   Chen CJ, 2004, J PEDIAT HEMATOL ONC, V26, P5, DOI 10.1097/00043426 200401000 00003
   Dong KJ, 2004, CHINESE PHYS LETT, V21, P51, DOI 10.1088/0256 307X/21/1/015
   Draenert KD, 2005, CLIN ORTHOP RELAT R, P12, DOI 10.1097/01.blo.0000150424.59854.7b
   Drouet C, 2008, MAT SCI ENG C BIO S, V28, P1544, DOI 10.1016/j.msec.2008.04.011
   He M, 2010, NUCL INSTRUM METH B, V268, P804, DOI 10.1016/j.nimb.2009.10.035
   Hui SK, 2007, NUCL INSTRUM METH B, V259, P796, DOI 10.1016/j.nimb.2007.02.003
   Jiang S, 2004, NUCL INSTRUM METH B, V223, P750, DOI 10.1016/j.nimb.2004.04.139
   Jiang S., 2010, BONE, V47, pS356
   Jiang S, 2008, BONE, V43, pS98, DOI 10.1016/j.bone.2008.07.196
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Nishiizumi K, 2000, NUCL INSTRUM METH B, V172, P399, DOI 10.1016/S0168 583X(00)00150 6
   Radding W, 1999, EXP CELL RES, V253, P689, DOI 10.1006/excr.1999.4714
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Shen H, 2009, BONE, V44, pS60, DOI 10.1016/j.bone.2009.01.023
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
NR 17
TC 2
Z9 2
U1 1
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168 583X
J9 NUCL INSTRUM METH B
JI Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. Atoms
PD JAN
PY 2013
VL 294
BP 671
EP 674
DI 10.1016/j.nimb.2012.08.051
PG 4
WC Instruments & Instrumentation; Nuclear Science & Technology; Physics,
   Atomic, Molecular & Chemical; Physics, Nuclear
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Instruments & Instrumentation; Nuclear Science & Technology; Physics
GA 066QC
UT WOS:000313234300130
DA 2025 08 17
ER

PT J
AU Kim, S
   Lee, JC
   Cho, ES
   Kwon, J
AF Kim, Sokho
   Lee, Jeong Chae
   Cho, Eui Sic
   Kwon, Jungkee
TI COMP Ang1 Promotes Chondrogenic and Osteogenic Differentiation of
   Multipotent Mesenchymal Stem Cells Through the Ang1/Tie2 Signaling
   Pathway
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE COMP Ang1; MSCs; differentiation; Tie2; MAPK
ID RAT BONE MARROW; GROWTH FACTOR; ENDOTHELIAL CELL; ANGIOPOIETIN 1; P38
AB Mesenchymal stem cells (MSCs) are pleiotrophic cells that differentiate to chondrocytes, osteoblasts, or adipocytes, as a result of crosstalk by specific signaling pathways including MAPK pathway. Recently cartilage oligomeric matrix protein angiopoietin1 (COMP Ang1), an Ang1 variant which is more potent than native Ang1 in phosphorylating Tie2 receptor was developed. The Ang1/Tie2 signaling system not only plays a pivotal role in vessel growth, remodeling, and maturation, but also protective and recruit effect on MSCs. Thus, the aim of the present study was to investigate the differentiate effect of Ang1/Tie2 signaling on MSCs in the presence of chondrogenic, osteogenic and adipogenic induction medium, and to determine the possible mechanisms. Our results clearly demonstrated that MSCs cultured in each induction medium with COMP Ang1 revealed strongly chondrogenic and osteogenic morphological change (3.5  and 2 fold, respectively) as well as up regulate each gene, except for adipogenic differentiation. Accordingly, we found that phosphorylation of Tie2 expression lead to phosphorylation of p38 and AKT and then accelerating each differentiation of MSCs to chondrocytes and osteoblasts. Therefore, our findings suggest that COMP Ang1 present a portal to promote MSCs differentiation to chondrocytes and osteoblasts through Ang1/Tie2 signaling pathway and provide insights into novel therapies for bone diseases. (c) 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 31:1920 1928, 2013
C1 [Kim, Sokho; Kwon, Jungkee] Coll Vet Med, Dept Lab Anim Med, Jeonju 561156, South Korea.
   [Lee, Jeong Chae] Res Ctr Bioact Mat, Jeonju 561156, South Korea.
   [Cho, Eui Sic] Chonbuk Natl Univ, Lab Craniofacial Biol, Inst Oral Biosci, Jeonju 561156, South Korea.
   [Cho, Eui Sic] Chonbuk Natl Univ, Program BK21, Jeonju 561156, South Korea.
C3 Jeonbuk National University; Jeonbuk National University
RP Kwon, J (通讯作者)，Coll Vet Med, Dept Lab Anim Med, Jeonju 561156, South Korea.
EM jkwon@jbnu.ac.kr
FU National Research Foundation of Korea (NRF) [2009 0084511]
FX Grant sponsor: National Research Foundation of Korea (NRF); Grant
   number: 2009 0084511.
CR Agata H, 2009, BIOCHEM BIOPH RES CO, V382, P353, DOI 10.1016/j.bbrc.2009.03.023
   Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Çelebi B, 2010, J PROTEOME RES, V9, P5217, DOI 10.1021/pr100506u
   Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101
   Ho JH, 2010, J ORTHOP RES, V28, P131, DOI 10.1002/jor.20956
   Hong D, 2009, J STEROID BIOCHEM, V116, P86, DOI 10.1016/j.jsbmb.2009.05.007
   Javazon EH, 2007, WOUND REPAIR REGEN, V15, P350, DOI 10.1111/j.1524 475X.2007.00237.x
   Jeong BC, 2010, BONE, V46, P479, DOI 10.1016/j.bone.2009.09.019
   Joo HJ, 2011, BLOOD, V118, P2094, DOI 10.1182/blood 2010 12 323907
   Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24
   Krampera M, 2005, BLOOD, V106, P59, DOI 10.1182/blood 2004 09 3645
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Kuhl PR, 1996, NAT MED, V2, P1022, DOI 10.1038/nm0996 1022
   Lewinson D, 2001, HISTOCHEM CELL BIOL, V116, P381, DOI 10.1007/s004180100331
   Liu XB, 2008, ACTA PHARMACOL SIN, V29, P815, DOI 10.1111/j.1745 7254.2008.00811.x
   Park BH, 2010, BONE, V46, P1442, DOI 10.1016/j.bone.2010.02.004
   Platt MO, 2009, STEM CELLS, V27, P2804, DOI 10.1002/stem.215
   Schliemann C, 2006, HAEMATOLOGICA, V91, P1203
   Sibilia M, 2003, DEVELOPMENT, V130, P4515, DOI 10.1242/dev.00664
   Walenda T, 2011, EXP HEMATOL, V39, P617, DOI 10.1016/j.exphem.2011.02.011
   Wang Y, 2009, AM J PHYSIOL CELL PH, V297, pC1284, DOI 10.1152/ajpcell.00183.2009
   Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960 9822(99)80192 4
   Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007 0226
   Xu J, 2010, CELL TRANSPLANT, V19, P43, DOI 10.3727/096368909X474339
   Xue P, 2013, BIOCHEM BIOPH RES CO, V433, P226, DOI 10.1016/j.bbrc.2013.02.088
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Zhang HS, 2005, PHARMACOLOGY, V74, P57, DOI 10.1159/000083684
   Zhang Jun, 2011, Nan Fang Yi Ke Da Xue Xue Bao, V31, P1697
   Zou ZM, 2010, EXPERT OPIN BIOL TH, V10, P215, DOI 10.1517/14712590903456011
NR 30
TC 13
Z9 15
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD DEC
PY 2013
VL 31
IS 12
BP 1920
EP 1928
DI 10.1002/jor.22453
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 238ZG
UT WOS:000325990300009
PM 23893855
DA 2025 08 17
ER

PT J
AU Ye, SX
   Wang, XP
   Chen, RC
AF Ye, Shuxi
   Wang, Xiaopeng
   Chen, Rongchun
TI A novel classification predicts prognosis and drug sensitivity in
   osteosarcoma based on alterations in gene sets
SO AGING US
LA English
DT Article
DE osteosarcoma; pathways; tumor microenvironment; drug sensitivity
ID CELLS
AB Osteosarcoma is a cancer originating in the bone cells, specifically in the osteoblasts. Previous studies mainly focused on particular molecules but the whole pathway network. We comprehensively analyzed the enrichment score of each signal pathway and identified a novel classification by 20 machine learning algorithms. Furthermore, differences in tumor immune infiltration cells and drug sensitivity were compared in low and high groups. We identified a model consisting of four signaling pathways that predict the prognosis and the immune status of the tumor microenvironment and drug sensitivity in osteosarcoma patients. The novel classification may be used in clinical applications to predict prognosis and drug sensitivity.
C1 [Ye, Shuxi; Wang, Xiaopeng; Chen, Rongchun] Ganzhou Peoples Hosp, Dept Spine Surg, Ganzhou, Jiangxi, Peoples R China.
RP Chen, RC (通讯作者)，Ganzhou Peoples Hosp, Dept Spine Surg, Ganzhou, Jiangxi, Peoples R China.
EM chenrc_6901@126.com
RI Chen, Rongchun/LWJ 8961 2024
CR Agustina Hasrayati, 2018, Patholog Res Int, V2018, P6346409, DOI 10.1155/2018/6346409
   Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059 017 1349 1
   Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108
   Bednarz Misa I, 2021, ADV EXP MED BIOL, V1290, P9, DOI 10.1007/978 3 030 55617 4_2
   Bertrand F., 2022, Partial Least Squares Regression for Generalized Linear Models
   Biazzo A, 2016, ACTA ORTHOP BELG, V82, P690
   Binder H., 2013, CoxBoost: Cox models by likelihood based boosting for a single survival endpoint or competing risks
   Buddingh EP, 2011, CLIN CANCER RES, V17, P2110, DOI 10.1158/1078 0432.CCR 10 2047
   Chiabotto G, 2020, CANCERS, V12, DOI 10.3390/cancers12061519
   Chipoy C, 2007, ONCOGENE, V26, P6653, DOI 10.1038/sj.onc.1210492
   Cole S, 2022, CANCER AM CANCER SOC, V128, P2107, DOI 10.1002/cncr.34163
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Fu YC, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010741
   Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16
   Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587 020 0546 8
   Guo ZH, 2019, PATHOL RES PRACT, V215, P519, DOI 10.1016/j.prp.2019.01.008
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 7
   Hansen MF, 2006, J BONE MINER RES, V21, pP58, DOI 10.1359/JBMR.06S211
   Hao H, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12536
   Ishwaran H., 2023, Fast unified random forests for survival, regression, and classification (RF SRC)
   Kittipatarin C, 2007, CYTOKINE, V39, P75, DOI 10.1016/j.cyto.2007.07.183
   Li M, 2020, MOL CELL TOXICOL, V16, P377, DOI 10.1007/s13273 020 00093 7
   Li MH, 2019, J BONE ONCOL, V16, DOI 10.1016/j.jbo.2019.100236
   Marais LC, 2015, J BONE ONCOL, V4, P80, DOI 10.1016/j.jbo.2015.09.002
   Matsuoka K, 2020, CELL RES, V30, P885, DOI 10.1038/s41422 020 0370 1
   Meltzer PS, 2021, NEW ENGL J MED, V385, P2066, DOI 10.1056/NEJMra2103423
   Mu HR, 2022, CANCER BIOL MED, V19, P1397, DOI 10.20892/j.issn.2095 3941.2022.0279
   Pridgeon MG, 2017, CURR OSTEOPOROS REP, V15, P239, DOI 10.1007/s11914 017 0377 9
   Qin Y, 2020, EUR REV MED PHARMACO, V24, P9265, DOI 10.26355/eurrev_202009_23008
   Ridgeway Greg, 2024, CRAN
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Sadykova LR, 2020, CANCER INVEST, V38, P259, DOI 10.1080/07357907.2020.1768401
   Savage Sharon A., 2011, Sarcoma, V2011, P548151, DOI 10.1155/2011/548151
   Savino AM, 2017, EXPERT REV HEMATOL, V10, P183, DOI 10.1080/17474086.2017.1292121
   Shulman DS, 2020, ADV EXP MED BIOL, V1257, P95, DOI 10.1007/978 3 030 43032 0_9
   Simpson E, 2018, JAAPA J AM ACAD PHYS, V31, P15, DOI 10.1097/01.JAA.0000541477.24116.8d
   Subramaniam D, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2335 1
   Therneau Terry M, 2024, CRAN
   Winer H, 2022, CYTOKINE, V160, DOI 10.1016/j.cyto.2022.156049
   Zeng DQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687975
NR 40
TC 0
Z9 0
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD MAR 15
PY 2024
VL 16
IS 5
PG 12
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA LQ1Y0
UT WOS:001188188200037
DA 2025 08 17
ER

PT J
AU Spreafico, A
   Frediani, B
   Capperucci, C
   Leonini, A
   Gambera, D
   Ferrata, P
   Rosini, S
   Di Stefano, A
   Galeazzi, M
   Marcolongo, R
AF Spreafico, Adriano
   Frediani, Bruno
   Capperucci, Caterina
   Leonini, Alessandra
   Gambera, Dario
   Ferrata, Paolo
   Rosini, Sergio
   Di Stefano, Anna
   Galeazzi, Mauro
   Marcolongo, Roberto
TI Osteogenic growth peptide effects on primary human osteoblast cultures:
   Potential relevance for the treatment of glucocorticoid induced
   osteoporosis
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE osteogenic growth peptide; osteoblasts; glucocorticoids; osteoporosis;
   bone formation; osteoprotegerin; osteoblast apoptosis
ID C TERMINAL PENTAPEPTIDE; APOPTOSIS; BONE; CELLS; OSTEOPROTEGERIN;
   PROLIFERATION; MECHANISMS; BISPHOSPHONATES; MATURATION; OSTEOCYTES
AB The osteogenic growth peptide (OGP) is a naturally Occurring tetradecapepticle that has attracted considerable clinical interest as a bone anabolic agent and hematopoietic stimulator. in vivo studies on animals have demonstrated that the synthetic peptide OGP (10 14), reproducing the OGP C terminal active portion [H Tyr Gly Phe Gly Gly OH] increases bone formation, trabecular bone density and fracture healing. In vitro studies performed on cellular systems based on osteoblastic like cell lines or Mouse stromal cells, have demonstrated that OGP (10 14) increases osteoblast proliferation, alkaline phosphatase (ALKP) activity and matrix synthesis and mineralization. In view of a potential application of OGP (10 14) in clinical therapy, we have tested different concentrations of OGP (10 14) on primary human osteoblast (hOB) Cultures. We have observed significant increases of hOB proliferation (+35%), ALKP activity (+60%), osteocalcin secretion (+50%), and mineralized nodules formation (+49%). Our experimental model based on mature hOBs was used to investigate if OGP (10 14) Could prevent the effects on bone loss induced by sustained glucocorticoid (GC) treatments. A strong decrease in bone formation has been attributed to the effects of GCs on osteoblastogenesis and osteocyte apoptosis, while an increase in bone resorption was due to a transient osteoblastic stimulation, mediated by the OPG/RANKL/RANK system, of osteoclasts recruitment and activation. Moreover, GCs act on hOBs decreasing the release of osteoprotegerin (OPG) a regulator of the RANKL/RANK interaction. Here, we provide evidences that OGP (10 14) inhibits hOB apoptosis induced by an excess of dexamethasone ( 48% of apoptotic cells). Furthermore, we show that OGP (10 14) can increase OPG secretion (+20%) and can restore the altered expression of OPG induced by GCs to physiological levels. Our results Support the employment of OGP (10 14) in clinical trials addressed to the treatment of different bone remodeling alterations including the GC induced osteoporosis. J. Cell. Biochem. 98: 1007 1020, 2006. (c) 2006 Wiley Liss, Inc.
C1 Univ Siena, Policlin Le Scotte, Dept Clin Med & Immunol Sci, Rheumatol Unit, I 53100 Siena, Italy.
   Univ Siena, Dept Mol Biol, I 53100 Siena, Italy.
   Dept Orthoped Rehabilit Sci, I 53100 Siena, Italy.
   Abiogen Pharma, Pisa, Italy.
C3 University of Siena; University of Siena
RP Spreafico, A (通讯作者)，Univ Siena, Policlin Le Scotte, Dept Clin Med & Immunol Sci, Rheumatol Unit, Via Laterina 8, I 53100 Siena, Italy.
EM spreafico@dunisi.it
RI Spreafico, Adriano/K 2397 2018; spreafico, adriano/AAL 6492 2020;
   Benetti, Elisa/AAI 6682 2021
OI Spreafico, Adriano/0000 0002 8047 8666; 
CR Bab I, 1999, J BIOL CHEM, V274, P14474, DOI 10.1074/jbc.274.20.14474
   Bab I, 2002, BIOPOLYMERS, V66, P33, DOI 10.1002/bip.10202
   BAB I, 1992, EMBO J, V11, P1867, DOI 10.1002/j.1460 2075.1992.tb05238.x
   Brager MA, 2000, J ORTHOP RES, V18, P133, DOI 10.1002/jor.1100180119
   CASCIO VL, 1990, BONE MINER, V8, P39
   Chen YC, 2000, J PEPT RES, V56, P147, DOI 10.1034/j.1399 3011.2000.00763.x
   DELANY AM, 1994, J CELL BIOCHEM, V56, P295, DOI 10.1002/jcb.240560304
   Eberhardt AW, 2001, ENDOCRINOLOGY, V142, P1333, DOI 10.1210/en.142.3.1333
   Fazzi R, 2002, LEUKEMIA RES, V26, P839, DOI 10.1016/S0145 2126(02)00008 5
   Frediani B, 2004, BONE, V35, P859, DOI 10.1016/j.bone.2004.06.001
   Gabarin N, 2001, J CELL BIOCHEM, V81, P594, DOI 10.1002/jcb.1083
   Gabet Y, 2004, BONE, V35, P65, DOI 10.1016/j.bone.2004.03.025
   GALLAGHER JA, 1996, HUMAN CELL CULTURE P, P233
   Gavish H, 1997, BIOCHEMISTRY US, V36, P14883, DOI 10.1021/bi971670t
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   Gohel A, 1999, ENDOCRINOLOGY, V140, P5339, DOI 10.1210/en.140.11.5339
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Greenberg Z, 1997, J CELL BIOCHEM, V65, P359, DOI 10.1002/(SICI)1097 4644(19970601)65:3<359::AID JCB6>3.3.CO;2 T
   Gurevitch O, 1996, BLOOD, V88, P4719, DOI 10.1182/blood.V88.12.4719.bloodjournal88124719
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Leclerc N, 2005, ARTHRITIS RHEUM US, V52, P929, DOI 10.1002/art.20872
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022 1759(91)90198 O
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Rattner A, 1997, IN VITRO CELL DEV AN, V33, P757
   ROBINSON D, 1995, J BONE MINER RES, V10, P690
   Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097 4644(19991001)75:1<22::AID JCB3>3.3.CO;2 Y
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   TESTI R, 1995, LEUKEMIA RES, V19, P257, DOI 10.1016/0145 2126(94)00157 6
   Vidal NOA, 1998, J ENDOCRINOL, V159, P191, DOI 10.1677/joe.0.1590191
   Viereck V, 2003, J CLIN ENDOCR METAB, V88, P4206, DOI 10.1210/jc.2002 021877
   Walsh S, 2001, RHEUMATOLOGY, V40, P74, DOI 10.1093/rheumatology/40.1.74
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Xing LP, 2005, BIOCHEM BIOPH RES CO, V328, P709, DOI 10.1016/j.bbrc.2004.11.072
   Zalavras C, 2003, CRIT REV EUKAR GENE, V13, P221, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.140
NR 42
TC 43
Z9 55
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUL 1
PY 2006
VL 98
IS 4
BP 1007
EP 1020
DI 10.1002/jcb.20836
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 056KJ
UT WOS:000238521400026
PM 16795077
DA 2025 08 17
ER

PT J
AU Boraschi Diaz, I
   Komarova, SV
AF Boraschi Diaz, Iris
   Komarova, Svetlana V.
TI The protocol for the isolation and cryopreservation of osteoclast
   precursors from mouse bone marrow and spleen
SO CYTOTECHNOLOGY
LA English
DT Article
DE Osteoclastogenesis; Spleen; Bone marrow; Cryopreservation; Protocol
ID KAPPA B LIGAND; RECEPTOR ACTIVATOR; OSTEOBLASTIC CELLS; INBRED STRAINS;
   STEM CELLS; KNOCKOUT; QUANTIFICATION; EXPRESSION; REGULATOR
AB Osteoclasts are responsible for physiological bone remodeling as well as pathological bone destruction in osteoporosis, periodontitis and rheumatoid arthritis, and thus represent a pharmacological target for drug development. We aimed to characterize and compare the cytokine induced osteoclastogenesis of bone marrow and spleen precursors. Established protocols used to generate osteoclasts from bone marrow were modified to examine osteoclastogenesis of the spleen cells of healthy mice. Osteoclast formation was successfully induced from spleen precursors using receptor activator of nuclear factor kappa B ligand (50 ng/ml) and macrophage colony stimulating factor (50 ng/ml). Compared to bone marrow cultures, differentiation from spleen required a longer cultivation time (9 days for spleen, as compared to 5 days for marrow cultures) and a higher plating density of non adherent cells (75,000/cm(2) for spleen, as compared to 50,000/cm(2) for bone marrow). Osteoclasts generated from spleen precursors expressed osteoclast marker genes calcitonin receptor, cathepsin K and matrix metalloproteinase 9 and were capable of resorbing hydroxyapatite. The differentiation capacity of spleen and bone marrow precursors was comparable for BALB/c, C57BL/6 and FVB mice. We also developed and tested a cryopreservation protocol for the osteoclast precursors. While 70 80 % of cells were lost during the first week of freezing, during the subsequent 5 weeks the losses were within 2 5 % per week. Osteoclastogenesis from the recovered bone marrow precursors was successful up to 5 weeks after freezing. Spleen precursors retained their osteoclastogenic capacity for 1 week after freezing, but not thereafter. The described protocol is useful for the studies of genetically modified animals as well as for screening new osteoclast targeting therapeutics.
C1 [Boraschi Diaz, Iris; Komarova, Svetlana V.] McGill Univ, Shriners Hosp Children Canada, Fac Dent, Montreal, PQ H3G 1A6, Canada.
C3 McGill University
RP Komarova, SV (通讯作者)，McGill Univ, Shriners Hosp Children Canada, Fac Dent, 1529 Cedar Ave,Room 300, Montreal, PQ H3G 1A6, Canada.
EM svetlana.komarova@mcgill.ca
RI ; Komarova, Svetlana/MTR 5042 2025
OI Komarova, Svetlana/0000 0003 3570 3147; 
FU Canadian Institutes of Health Research; Faculty of Dentistry, McGill
   University
FX We are grateful to Dr. Morris F. Manolson, University of Toronto, for
   providing GST RANKL clones. This work was supported by the Canadian
   Institutes of Health Research. IBD is supported by the Faculty of
   Dentistry, McGill University. SVK holds a Canada Research Chair in
   Osteoclast Biology.
CR Beamer WG, 1996, BONE, V18, P397, DOI 10.1016/8756 3282(96)00047 6
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buie HR, 2008, J BONE MINER RES, V23, P2048, DOI 10.1359/JBMR.080808
   Chen F, 2014, J BONE MINER RES, V29, P1412, DOI 10.1002/jbmr.2177
   Chen H, 2011, J BONE MINER RES, V26, P2537, DOI 10.1002/jbmr.456
   De Boer F, 2002, J HEMATOTH STEM CELL, V11, P951, DOI 10.1089/152581602321080619
   Deng WW, 2004, STEM CELLS, V22, P1279, DOI 10.1634/stemcells.2004 0032
   Dimitroulas T, 2013, AUTOIMMUN REV, V12, P958, DOI 10.1016/j.autrev.2013.03.015
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Feng X, 2005, CURRENT TOPICS IN BONE BIOLOGY, P71, DOI 10.1142/9789812701176_0004
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Hayashi S, 1997, J CELL PHYSIOL, V170, P241, DOI 10.1002/(SICI)1097 4652(199703)170:3<241::AID JCP4>3.0.CO;2 O
   Hayashi SI, 2003, J IMMUNOL, V171, P5130, DOI 10.4049/jimmunol.171.10.5130
   Heng BC, 2006, J BIOMED SCI, V13, P433, DOI 10.1007/s11373 005 9051 9
   Holguin N, 2013, CALCIFIED TISSUE INT, V93, P211, DOI 10.1007/s00223 013 9744 4
   Holloway WR, 2002, J BONE MINER RES, V17, P200, DOI 10.1359/jbmr.2002.17.2.200
   Huh YJ, 2006, CELL DEATH DIFFER, V13, P1138, DOI 10.1038/sj.cdd.4401793
   Hunt CJ, 2011, TRANSFUS MED HEMOTH, V38, P107, DOI 10.1159/000326623
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lee SK, 2002, J IMMUNOL, V169, P2374, DOI 10.4049/jimmunol.169.5.2374
   Li X, 2002, BONE, V30, P567, DOI 10.1016/S8756 3282(02)00683 X
   Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054
   LIEGLER TJ, 1995, CLIN DIAGN LAB IMMUN, V2, P369, DOI 10.1128/CDLI.2.3.369 376.1995
   Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613
   Maria SM, 2014, J BIOMED MATER RES B, V102, P903, DOI 10.1002/jbm.b.33071
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   Pagliaro LC, 1998, CLIN CANCER RES, V4, P1971
   Park SJ, 2013, J MOL HISTOL, V44, P65, DOI 10.1007/s10735 012 9465 4
   Risom L, 1999, MUTAT RES GEN TOX EN, V440, P131, DOI 10.1016/S1383 5718(99)00019 4
   Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Tiedemann K, 2013, J CELL SCI, V126, P4187, DOI 10.1242/jcs.127571
   Tiedemann K, 2009, J BIOL CHEM, V284, P33662, DOI 10.1074/jbc.M109.010785
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Xu X, 2010, BIOTECHNOL PROGR, V26, P827, DOI 10.1002/btpr.368
   Zehnder AF, 2006, LARYNGOSCOPE, V116, P201, DOI 10.1097/01.mlg.0000191466.09210.9a
NR 39
TC 30
Z9 35
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920 9069
EI 1573 0778
J9 CYTOTECHNOLOGY
JI Cytotechnology
PD JAN
PY 2016
VL 68
IS 1
BP 105
EP 114
DI 10.1007/s10616 014 9759 3
PG 10
WC Biotechnology & Applied Microbiology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Cell Biology
GA DA1ZF
UT WOS:000367594200011
PM 25245056
OA Green Published
DA 2025 08 17
ER

PT J
AU Zhu, XY
   Gao, QQ
   Zhao, GH
   Wang, H
   Liu, L
   Chen, ZP
   Chen, YJ
   Wu, L
   Xu, ZS
   Li, WD
AF Zhu, Xingyu
   Gao, Qianqian
   Zhao, Genhua
   Wang, Heng
   Liu, Ling
   Chen, Zhipeng
   Chen, Yijun
   Wu, Li
   Xu, Zisheng
   Li, Weidong
TI Comparison Study of Bone Defect Healing Effect of Raw and Processed
   Pyritum in Rats
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Raw pyritum; Processed pyritum; Bone healing; Rat tibia defect; TGF beta
   1/Smad signaling pathway
ID OSTEOBLAST DIFFERENTIATION; TRANSFORMING GROWTH FACTOR BETA 1;
   MECHANISMS; EXPRESSION; MINERALIZATION; MEDICINES; RELEASE; MATRIX;
   CELLS
AB To evaluate and compare the effect of raw and processed pyritum on tibial defect healing, 32 male Sprague Dawley rats were randomly divided into four groups. After tibial defect, animals were produced and grouped: sham and control group were orally administrated with distilled water (1 mL/100 g), while treatment groups were given aqueous extracts of raw and processed pyritum (1.5 g/kg) for successive 42 days. Radiographic examination showed that bone defect healing effect of the treatment groups was obviously superior compared to that of the control group. Bone mineral density of whole tibia was increased significantly after treating with pyritum. Inductively coupled plasma optical emission spectrometry showed that the contents of Ca, P, and Mg in callus significantly increased in the treatment groups comparing with the control. Moreover, serological analysis showed that the concentration of serum phosphorus of the treatment groups significantly increased compared with that of the control group. By in vitro study, we have evaluated the effects of drug containing serum of raw and processed pyritum on osteoblasts. It was manifested that both the drug containing sera of raw and processed pyritum significantly increased the mRNA levels of alkaline phosphatase and collagen type I. Protein levels of phosphorylated Smad2/3 also increased. The mRNA levels of osteocalcin and transforming growth factor beta (TGF beta) type I and II receptors, as well as the protein levels of TGF beta 1 in the processed groups, were higher than those in the control. In summary, both raw and processed pyritum containing sera exhibited positive effects on osteoblasts, which maybe via the TGF beta 1/Smad signaling pathway. Notably, the tibia defect healing effect of pyritum was significantly enhanced after processing.
C1 [Zhu, Xingyu; Gao, Qianqian; Zhao, Genhua; Wang, Heng; Liu, Ling; Chen, Zhipeng; Wu, Li; Li, Weidong] Nanjing Univ Chinese Med, Coll Pharm, 138 Xianlin Ave, Nanjing 210023, Jiangsu, Peoples R China.
   [Chen, Zhipeng; Li, Weidong] Nanjing Univ Chinese Med, Engn Ctr, State Minist Educ Standardizat Chinese Med Proc, Nanjing, Peoples R China.
   [Chen, Yijun] Nanjing Univ, Modern Anal Ctr, Nanjing, Jiangsu, Peoples R China.
   [Xu, Zisheng] Wuhu Pure Sunshine Nat Med Co Ltd, Wuhu, Anhui, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University
RP Li, WD (通讯作者)，Nanjing Univ Chinese Med, Coll Pharm, 138 Xianlin Ave, Nanjing 210023, Jiangsu, Peoples R China.; Xu, ZS (通讯作者)，Wuhu Pure Sunshine Nat Med Co Ltd, Wuhu, Anhui, Peoples R China.
EM 351711422@qq.com; liweidong0801@163.com
RI Xu, Zisheng/AAM 8076 2021; Chen, Zhipeng/M 1879 2018; Gao,
   Qianqian/AAW 1689 2020; Zhu, Xing Yu/KWU 5790 2024
FU National Natural Science Foundation of China [81373970]; Jiangsu Qinglan
   Project
FX This work was supported by grants from the National Natural Science
   Foundation of China (81373970) and Jiangsu Qinglan Project (2014).
CR Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   BASSETT CAL, 1962, J BONE JOINT SURG AM, V44, P1217, DOI 10.2106/00004623 196244060 00020
   Chen M, 2011, IMMUNOLOGY, V132, P376, DOI 10.1111/j.1365 2567.2010.03392.x
   Corrarino JE, 2015, JNP J NURSE PRACT, V11, P960, DOI 10.1016/j.nurpra.2015.07.009
   Cui C, 2014, BONE, V59, P127, DOI 10.1016/j.bone.2013.11.006
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Foster LJ, 2005, STEM CELLS, V23, P1367, DOI 10.1634/stemcells.2004 0372
   Franceschi RT, 2009, CELLS TISSUES ORGANS, V189, P144, DOI 10.1159/000151747
   Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201
   FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235
   Hu YC, 2012, BONE, V50, P1406, DOI 10.1016/j.bone.2012.03.012
   Hwang J, 2004, AM J CHINESE MED, V32, P907, DOI 10.1142/S0192415X0400251X
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Kim J, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201600540
   Kristensen HB, 2014, AM J PATHOL, V184, P778, DOI 10.1016/j.ajpath.2013.11.022
   Laurent P, 2012, INT ENDOD J, V45, P439, DOI 10.1111/j.1365 2591.2011.01995.x
   Liu L, 2017, RSC ADV, V7, P28373, DOI 10.1039/c7ra03970k
   Mackenzie EL, 2008, ANTIOXID REDOX SIGN, V10, P997, DOI 10.1089/ars.2007.1893
   Majeed SA, 2015, OSTEOPOROSIS INT, V26, pS421
   Mao B, 2009, THESIS
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   Messer JG, 2009, BONE, V45, P972, DOI 10.1016/j.bone.2009.07.073
   Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441 011 1201 y
   Nagata M, 2011, J NUTR BIOCHEM, V22, P172, DOI 10.1016/j.jnutbio.2010.01.003
   Ochiai H, 2012, J BIOL CHEM, V287, P22654, DOI 10.1074/jbc.M111.279091
   Oryan A, 2017, INJURY, V48, P1466, DOI 10.1016/j.injury.2017.04.044
   Pang Rj, 2007, THESIS
   Peng LH, 2010, J ETHNOPHARMACOL, V131, P282, DOI 10.1016/j.jep.2010.06.039
   Qiao YQ, 2014, BIOMATERIALS, V35, P6882, DOI 10.1016/j.biomaterials.2014.04.101
   Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190
   Wang JMX y, 2015, PROG MOD BIOMED, V15, P2836
   Wildemann B, 2004, CALCIF TISSUE INT, V74
   Wong RWK, 2006, J ORAL MAXIL SURG, V64, P828, DOI 10.1016/j.joms.2006.01.017
   Wu HH, 2012, PROCESSING CHINESE M
   Yoshikawa Y, 2011, J BONE MINER RES, V26, P2012, DOI 10.1002/jbmr.417
   Yusa K, 2011, BIOCHEM BIOPH RES CO, V412, P273, DOI 10.1016/j.bbrc.2011.07.082
   [赵根华 Zhao Genhua], 2015, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V26, P481
NR 37
TC 9
Z9 12
U1 2
U2 17
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163 4984
EI 1559 0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD JUL
PY 2018
VL 184
IS 1
BP 136
EP 147
DI 10.1007/s12011 017 1166 0
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA GI7ZM
UT WOS:000434723900016
PM 28980123
DA 2025 08 17
ER

PT J
AU Wang, RR
   Feng, YH
   Huang, SN
   Zhang, YJ
   Liu, MJ
   Wang, YY
   Liu, HT
   Chen, MG
   Xu, GY
   Han, B
AF Wang, Ruran
   Feng, Yanhua
   Huang, Shengnan
   Zhang, Yujie
   Liu, Meijie
   Wang, Yuanyuan
   Liu, Haitao
   Chen, Mingguo
   Xu, Guoying
   Han, Bing
TI The Mechanisms of Action of Zuogui Pill on Osteoporosis in
   Ovariectomized Rats
SO CURRENT TOPICS IN NUTRACEUTICAL RESEARCH
LA English
DT Article
DE Bone mineral density; Osteoprotegerin; Postmenopausal osteoporosis;
   Receptor activator of NF kappa B ligand; Zuogui pill
ID OSTEOCLAST DIFFERENTIATION FACTOR; BONE LOSS; OSTEOPROTEGERIN; LIGAND;
   FORMULA
AB Traditional Chinese medicine recommends kidney tonifying treatment for osteoporosis. Zuogui pill is one such treatment composed of eight well characterized Chinese medicinal herbs (Radix rehmanniae preparata, Fructus lycii, Rhizoma dioscoreae, F. corni, Semen cuscutae, Colla cornus cervi, C. carapacis et Plastri testudinis, and R. achyranthis bidentatae). The aim of the study is to evaluate the effects of the Zuogui pill on osteoporosis in ovariectomized rats and to identify the signaling pathways that mediate its action on the bones. A total of 46 6 month old female Sprague Dawley rats were divided into four groups: sham operated control, bilaterally ovariectomized, ovariectomized rats receiving diethylstilbestrol (the positive control group), and ovariectomized rats receiving the Zuogui pill. By the end of 8 week treatments, the following parameters were assessed: (a) bone mineral density and trabecular histomorphology, (b) the expression levels of receptor activator of nuclear factor kappa B ligand and osteoprotegerin in rat tibial osteoblasts and (c) bone marrow stromal cells. The Zuogui pill treatment elevated the trabecular bone area and trabecular thickness and reduced the trabecular spacing in rats with ovariectomy induced osteoporosis. Compared to the ovariectomized group, the Zuogui pill treatment significantly increased the levels of bone mineral density and osteoprotegerin and suppressed the level of receptor activator of the nuclear factor kappa B ligand. These data led us to conclude that the Zuogui pill regulates bone metabolism and improves osteoporosis symptoms possibly through the osteoprotegerin/receptor activator of the nuclear factor kappa B ligand/receptor activator of the nuclear factor kappa B signaling pathway.
C1 [Wang, Ruran; Zhang, Yujie; Chen, Mingguo; Xu, Guoying; Han, Bing] China Acad Chinese Med Sci, South Guanganmen Hosp, Dept Surg, Beijing, Peoples R China.
   [Feng, Yanhua] China Acad Chinese Med Sci, Dept Hosp Infect Control, South Guanganmen Hosp, Beijing 102618, Peoples R China.
   [Huang, Shengnan] China Acad Chinese Med Sci, South Guanganmen Hosp, Dept Pharm, Beijing, Peoples R China.
   [Liu, Meijie] China Acad Chinese Med Sci, Expt Res Ctr, Beijing, Peoples R China.
   [Wang, Yuanyuan] Tsinghua Univ, Dept Encephalopathy, Chuiyangliu Hosp, Beijing, Peoples R China.
   [Liu, Haitao] China Acad Chinese Med Sci, South Guanganmen Hosp, Dept Radiol, Beijing, Peoples R China.
C3 China Academy of Chinese Medical Sciences; China Academy of Chinese
   Medical Sciences; China Academy of Chinese Medical Sciences; China
   Academy of Chinese Medical Sciences; Experimental Research Center,
   CACMS; Tsinghua University; China Academy of Chinese Medical Sciences
RP Feng, YH (通讯作者)，China Acad Chinese Med Sci, Dept Hosp Infect Control, South Guanganmen Hosp, Beijing 102618, Peoples R China.
EM panran1026@126.com
FU Beijing TCM science and technology development [JJ2018 59]; Construction
   Project of Famous Doctor Studio in Beijing Daxing District
FX The study is supported by Beijing TCM science and technology
   development, grant No. JJ2018 59, and the Construction Project of Famous
   Doctor Studio in Beijing Daxing District [No. DXMY 02 WRR].
CR BENNETT AE, 1984, J CLIN ENDOCR METAB, V59, P701, DOI 10.1210/jcem 59 4 701
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   CANALIS E, 1988, J CLIN INVEST, V81, P277, DOI 10.1172/JCI113318
   Dai Y, 2018, J TRADIT CHIN MED, V38, P879
   Garnero P., 2002, PRINCIPLES BONE BIOL, V2, P1291
   GENANT HK, 1989, AM J OBSTET GYNECOL, V161, P1842, DOI 10.1016/S0002 9378(89)80004 3
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hofbauer LC, 2000, J CLIN ENDOCR METAB, V85, P2355, DOI 10.1210/jc.85.7.2355
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lai NN, 2015, J ETHNOPHARMACOL, V166, P228, DOI 10.1016/j.jep.2015.03.011
   Li JY, 2021, PHYTOTHER RES, V35, P1754, DOI 10.1002/ptr.6908
   Li L, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0099222, 10.1371/journal.pone.0112845]
   Liu MJ, 2011, J TRADIT CHIN MED, V31, P98, DOI 10.1016/S0254 6272(11)60020 4
   [吕海波 Lv Haibo], 2010, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V16, P847
   Mitchner Natasha A, 2009, J Fam Pract, V58, pS45
   OMI N, 1995, BONE, V17, pS163, DOI 10.1016/8756 3282(95)00329 C
   Parveen B, 2018, BONE, V113, P57, DOI 10.1016/j.bone.2018.05.011
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Regan MM, 2001, J WOMEN HEALTH GEN B, V10, P343, DOI 10.1089/152460901750269661
   RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   RUDMAN D, 1981, J CLIN INVEST, V67, P1361, DOI 10.1172/JCI110164
   Schmitz D, 2021, J CLIN ENDOCR METAB, V106, pE4471, DOI 10.1210/clinem/dgab507
   Scholz Ahrens KE, 2002, BRIT J NUTR, V88, P365, DOI 10.1079/BJN2002661
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Waynforth H, 1992, EXPT SURG TECHNIQUE, P274
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yin H, 2018, BIOMED PHARMACOTHER, V97, P995, DOI 10.1016/j.biopha.2017.11.029
NR 31
TC 1
Z9 1
U1 2
U2 23
PU NEW CENTURY HEALTH PUBLISHERS, LLC
PI COPPELL
PA PO BOX 175, COPPELL, TX 75019 USA
SN 1540 7535
EI 2641 452X
J9 CURR TOP NUTRACEUT R
JI Curr. Top. Nutraceutical Res.
PD MAY
PY 2022
VL 20
IS 2
BP 247
EP 252
AR 5
DI 10.37290/ctnr2641 452X.20:247 252
PG 6
WC Nutrition & Dietetics; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics; Pharmacology & Pharmacy
GA 1A6QY
UT WOS:000791880100003
DA 2025 08 17
ER

PT J
AU Shockley, KR
   Lazarenko, OP
   Czernik, PJ
   Rosen, CJ
   Churchill, GA
   Lecka Czemik, B
AF Shockley, Keith R.
   Lazarenko, Oxana P.
   Czernik, Piotr J.
   Rosen, Clifford J.
   Churchill, Gary A.
   Lecka Czemik, Beata
TI PPARγ2 Nuclear Receptor Controls Multiple Regulatory Pathways of
   Osteoblast Differentiation From Marrow Mesenchymal Stem Cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE PPAR GAMMA; THIAZOLIDINEDIONES; OSTEOBLAST; BONE MARROW MESENCHYMAL STEM
   CELLS; GENE EXPRESSION
ID BONE MINERAL DENSITY; GAMMA PPAR GAMMA; GENE EXPRESSION; TARGET GENES;
   IN VITRO; ROSIGLITAZONE; MICE; GROWTH; METABOLISM; ACTIVATION
AB Rosiglitazone (Rosi), a member of the thiazolidinedione class of drugs used to treat type 2 diabetes, activates the adipocyte specific transcription factor peroxisome proliferator activated receptor gamma (PPAR gamma). This activation causes bone loss in animals and humans, at least in part due to suppression of osteoblast differentiation from marrow mesenchymal stem cells (MSC). In order to identify mechanisms by which PPAR gamma 2 suppresses osteoblastogenesis and promotes adipogenesis in MSC, we have analyzed the PPAR gamma 2 transcriptome in response to Rosi. A total of 4,252 transcriptional changes resulted when Rosi (1 mu M) was applied to the U 33 marrow stromal cell line stably transfected with PPAR gamma 2 (U 33/gamma 2) as compared to non induced U 33/gamma 2 cells. Differences between U 33/gamma 2 and U 33 cells stably transfected with empty vector (U 33/c) comprised 7,928 transcriptional changes, independent of Rosi. Cell type , time  and treatment specific gene clustering uncovered distinct patterns of PPAR gamma 2 transcriptional control of MSC lineage commitment. The earliest changes accompanying Rosi activation of PPAR gamma 2 included effects on Writ, TGF beta/BMP and G protein signaling activities, as well as sustained induction of adipocyte specific gene expression and lipid metabolism. While suppression of osteoblast phenotype is initiated by a diminished expression of osteoblast specific signaling pathways, induction of the adipocyte phenotype is initiated by adipocyte specific transcriptional regulators. This indicates that distinct mechanisms govern the repression of osteogenesis and the stimulation of adipogenesis. The co expression patterns found here indicate that PPAR gamma 2 has a dominant role in controlling osteoblast differentiation and suggests numerous gene gene interactions that could lead to the identification of a "master" regulatory scheme directing this process. J. Cell. Biochem. 106: 232 246, 2009. (C) 2008 Wiley Liss, Inc.
C1 [Czernik, Piotr J.; Lecka Czemik, Beata] Univ Toledo, Med Ctr, Dept Orthopaed Surg, Toledo, OH 43614 USA.
   [Czernik, Piotr J.; Lecka Czemik, Beata] Univ Toledo, Med Ctr, Dept Physiol, Toledo, OH 43614 USA.
   [Czernik, Piotr J.; Lecka Czemik, Beata] Univ Toledo, Med Ctr, Dept Pharmacol, Ctr Diabet & Endocrine Res, Toledo, OH 43614 USA.
   [Lazarenko, Oxana P.] Arkansas Childrens Hosp, Res Inst, Little Rock, AR 72202 USA.
   [Shockley, Keith R.; Rosen, Clifford J.; Churchill, Gary A.] Jackson Lab, Bar Harbor, ME 04609 USA.
C3 University System of Ohio; University of Toledo; University System of
   Ohio; University of Toledo; University System of Ohio; University of
   Toledo; Arkansas Children's Hospital; Jackson Laboratory
RP Lecka Czemik, B (通讯作者)，Univ Toledo, Med Ctr, Dept Orthopaed Surg, Mail Stop 1095,3000 Arlington Ave, Toledo, OH 43614 USA.
EM Beata.LeckaCzernik@utoledo.edu
RI Churchill, Gary/AAY 7496 2020; rosen, clifford/JOZ 3228 2023
FU NIH/NIA/NIAMS [AG17482, AG028935]; American Diabetes Association
   [1 03 RA 46]; NIH/NHGRI [HG003968]
FX This study was supported by grant NIH/NIA/NIAMS (AG17482 and AG028935 to
   B.L.C.), American Diabetes Association (1 03 RA 46 to B.L.C.), and
   NIH/NHGRI Ruth L. Kirchstein Postdoctoral Fellowship (HG003968 to
   K.R.S.).
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Ackert Bicknell CL, 2008, J BONE MINER RES, V23, P1398, DOI [10.1359/jbmr.080419, 10.1359/JBMR.080419]
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Churchill GA, 2004, BIOTECHNIQUES, V37, P173, DOI 10.2144/04372TE01
   Cock TA, 2004, EMBO REP, V5, P1007, DOI 10.1038/sj.embor.7400254
   Cui XG, 2005, BIOSTATISTICS, V6, P59, DOI 10.1093/biostatistics/kxh018
   DAVIES SS, 2001, J BIOL CHEM, V26, P26
   Escalante Alcalde D, 2003, DEVELOPMENT, V130, P4623, DOI 10.1242/dev.00635
   Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567
   French DM, 2004, AM J PATHOL, V165, P855, DOI 10.1016/S0002 9440(10)63348 2
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006 2646
   Hallmann D, 2003, J BIOL CHEM, V278, P5099, DOI 10.1074/jbc.M208451200
   Heinäniemi M, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 7 r147
   Hsiao EC, 2008, P NATL ACAD SCI USA, V105, P1209, DOI 10.1073/pnas.0707457105
   Ihaka R., 1996, J Comput Graph Statist, V5, P299, DOI [10.2307/1390807, DOI 10.2307/1390807, DOI 10.1080/10618600.1996.10474713]
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Javed A, 2000, J CELL SCI, V113, P2221
   Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224
   Kahn SE, 2008, DIABETES CARE, V31, P845, DOI 10.2337/dc07 2270
   Kanoh H, 1999, CHEM PHYS LIPIDS, V98, P119, DOI 10.1016/S0009 3084(99)00024 9
   Kerr MK, 2001, P NATL ACAD SCI USA, V98, P8961, DOI 10.1073/pnas.161273698
   Kerr MK, 2000, J COMPUT BIOL, V7, P819, DOI 10.1089/10665270050514954
   Lazarenko OP, 2006, BONE, V38, P74, DOI 10.1016/j.bone.2005.07.008
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006 1587
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Lecka Czernik B, 2007, ENDOCRINOLOGY, V148, P903, DOI 10.1210/en.2006 1121
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Lecka Czernik B, 2006, PPAR RES, V2006, DOI 10.1155/PPAR/2006/27489
   Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Lorentzon M, 2005, PEDIATR RES, V57, P223, DOI 10.1203/01.PDR.0000148735.21084.D3
   Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936 6943.2003
   McCauley LK, 2001, ENDOCRINOLOGY, V142, P1975, DOI 10.1210/en.142.5.1975
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   O'Shea JJ, 2008, IMMUNITY, V28, P477, DOI 10.1016/j.immuni.2008.03.002
   Peng J, 2008, ENDOCRINOLOGY, V149, P1329, DOI 10.1210/en.2007 0235
   Rhee EJ, 2005, AM J OBSTET GYNECOL, V192, P1087, DOI 10.1016/j.ajog.2004.09.033
   Ricote M, 2007, BBA MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013
   Rieusset J, 2004, MOL ENDOCRINOL, V18, P2363, DOI 10.1210/me.2003 0325
   Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349
   Schwartz AV, 2006, J CLIN ENDOCR METAB, V91, P3349, DOI 10.1210/jc.2005 2226
   Sharma AM, 2007, J CLIN ENDOCR METAB, V92, P386, DOI 10.1210/jc.2006 1268
   Shockley KR, 2007, PPAR RES, V2007, P81219, DOI DOI 10.1155/2007/81219
   Sorocéanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723
   Sosinsky A, 2003, NUCLEIC ACIDS RES, V31, P3589, DOI 10.1093/nar/gkg544
   Sottile V, 2004, CALCIFIED TISSUE INT, V75, P329, DOI 10.1007/s00223 004 0224 8
   Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467 9868.00346
   Strom TM, 2008, CURR OPIN NEPHROL HY, V17, P357, DOI 10.1097/MNH.0b013e3282fd6e5b
   Teplyuk NM, 2008, J BIOL CHEM, V283, P27585, DOI 10.1074/jbc.M802453200
   Villesen P, 2007, MOL ECOL NOTES, V7, P965, DOI 10.1111/j.1471 8286.2007.01821.x
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Yang HU, 2007, BIOINFORMATICS, V23, P38, DOI 10.1093/bioinformatics/btl548
   Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092 8674(00)00211 7
   Zandbergen F, 2005, BIOCHEM J, V392, P313, DOI 10.1042/BJ20050636
NR 61
TC 142
Z9 161
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD FEB 1
PY 2009
VL 106
IS 2
BP 232
EP 246
DI 10.1002/jcb.21994
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 401EG
UT WOS:000262921600006
PM 19115254
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yue, C
   Jin, HT
   Zhang, X
   Li, WY
   Wang, DL
   Tong, PJ
   Liu, YW
   Tan, Z
AF Yue, Chen
   Jin, Hongting
   Zhang, Xue
   Li, Wuyin
   Wang, Deli
   Tong, Peijian
   Liu, Youwen
   Tan, Zhen
TI Aucubin prevents steroid induced osteoblast apoptosis by enhancing
   autophagy via AMPK activation
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE apoptosis; aucubin; autophagy; osteoblast; SONFH; steroid
ID PROTECTS OSTEOBLASTS; EUCOMMIA ULMOIDES; FEMORAL HEAD; GLUCOCORTICOIDS;
   OSTEONECROSIS; MAINTAINS; PATHWAY; KINASE
AB Steroid induced osteoblast apoptosis is a crucial pathological process in steroid induced osteonecrosis of the femoral head (SONFH). Autophagy can resist apoptosis and AMPK plays an important role in autophagy regulation. Aucubin from the small tree Eucommia ulmoides Oliv., which has a long history of use in orthopaedics and traumatology in Asian medicine, can promote bone formation, but whether it can slow or prevent steroid osteoblast apoptosis is unclear. Therefore, we investigated the pathogenesis of SONFH and how the osteoblast responds to aucubin under the dexamethasone stimulation. In human femoral head osteonecrosis specimens, we found that the autophage and apoptosis level were increased, and the AMPK signalling was crucial to autophagy. We observed that aucubin could prevent dexamethasone induced apoptosis in osteoblasts by enhancing the level of autophagy. Further, we confirmed that the regulatory effect of aucubin on autophagy and apoptosis was achieved by activating AMPK signalling. We have demonstrated a mechanism of disease progression and shown that aucubin could enhance autophagy through AMPK signalling to prevent osteoblast apoptosis. These findings provide a basis for the further investigation of the potential therapeutic role of aucubin in the SONFH.
C1 [Yue, Chen; Zhang, Xue; Li, Wuyin; Liu, Youwen] Luoyang Orthoped Hosp Henan Prov, Dept Orthoped, Luoyang, Henan, Peoples R China.
   [Yue, Chen; Jin, Hongting; Tong, Peijian] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Inst Orthopaed & Traumatol, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Deli; Tan, Zhen] Peking Univ, Shenzhen Hosp, Dept Bone & Joint Surg, Shenzhen, Guangdong, Peoples R China.
C3 Zhejiang Chinese Medical University; Peking University
RP Liu, YW (通讯作者)，Luoyang Orthoped Hosp Henan Prov, Dept Orthoped, Luoyang, Henan, Peoples R China.; Tong, PJ (通讯作者)，Zhejiang Chinese Med Univ, Affiliated Hosp 1, Inst Orthopaed & Traumatol, Hangzhou, Zhejiang, Peoples R China.; Tan, Z (通讯作者)，Peking Univ, Shenzhen Hosp, Dept Bone & Joint Surg, Shenzhen, Guangdong, Peoples R China.
EM chinapeijian@126.com; liuyouwen543@sina.com; tanzeric@bjmu.edu.cn
RI Yue, Chen/IAP 6501 2023; Wang, Deli/G 3379 2010; Liu,
   Youwen/AAE 7833 2019
OI Tan, Zhen/0000 0003 1032 2882; 
FU National Natural Science Foundation of China [81804126, 82004396,
   82074472, 82102574]; Project of science and technology of the Henan
   province [202102310179]; Shenzhen Science and Technology Innovation
   Committee Projects [JCYJ20190809152409606]; Key Medical Subject Project
   in Shenzhen [SZXK023]
FX National Natural Science Foundation of China, Grant/Award Number:
   81804126, 82004396, 82074472 and 82102574; Project of science and
   technology of the Henan province, Grant/Award Number: 202102310179;
   Shenzhen Science and Technology Innovation Committee Projects,
   Grant/Award Number: JCYJ20190809152409606; Key Medical Subject Project
   in Shenzhen, Grant/Award Number: SZXK023
CR Bai X, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.689625
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556 018 0201 5
   Ha J, 2015, MOL ASPECTS MED, V46, P46, DOI 10.1016/j.mam.2015.08.002
   Han YD, 2018, INT J MOL MED, V41, P800, DOI 10.3892/ijmm.2017.3270
   Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   He XR, 2014, J ETHNOPHARMACOL, V151, P78, DOI 10.1016/j.jep.2013.11.023
   Ho TT, 2017, NATURE, V543, P205, DOI 10.1038/nature21388
   Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007
   Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35
   Li X, 2021, BIOMED PHARMACOTHER, V142, DOI 10.1016/j.biopha.2021.111979
   Li YJ, 2019, ADV EXP MED BIOL, V1206, P85, DOI 10.1007/978 981 15 0602 4_4
   Li YT, 2020, AGING US, V12, P2226, DOI 10.18632/aging.102742
   Lin W, 2019, OPHTHALMIC RES, V61, P65, DOI 10.1159/000487486
   Luo Z, 2019, AM J PHYSIOL CELL PH, V316, pC198, DOI 10.1152/ajpcell.00256.2018
   Manai F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020635
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Mizushima N, 2020, NEW ENGL J MED, V383, P1564, DOI 10.1056/NEJMra2022774
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Musumeci G, 2015, INT J MOL SCI, V16, P20560, DOI 10.3390/ijms160920560
   Nie ZG, 2019, BIOCHEM BIOPH RES CO, V511, P693, DOI 10.1016/j.bbrc.2019.02.118
   Peng PJ, 2021, FEBS OPEN BIO, V11, P312, DOI 10.1002/2211 5463.13037
   Saha S, 2018, BIOMED PHARMACOTHER, V104, P485, DOI 10.1016/j.biopha.2018.05.007
   She C, 2014, CELL SIGNAL, V26, P1, DOI 10.1016/j.cellsig.2013.08.046
   Timmermans S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01545
   Tu YY, 2016, ANGEW CHEM INT EDIT, V55, P10210, DOI 10.1002/anie.201601967
   Ugarte A, 2018, CURR OPIN RHEUMATOL, V30, P482, DOI 10.1097/BOR.0000000000000527
   Wang BW, 2019, DRUG DES DEV THER, V13, P3529, DOI 10.2147/DDDT.S210220
   Wang H, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974 020 01863 9
   Wang J, 2017, AM J CHINESE MED, V45, P557, DOI 10.1142/S0192415X17500331
   Wang L, 2015, MOL MED REP, V11, P2711, DOI 10.3892/mmr.2014.3099
   Xiao Y, 2018, PLANTA MED, V84, P91, DOI [10.1055/s 0043 122577, 10.1055/s 0043 118663]
   Xu DW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162694
   Xu YY, 2018, BIOCHEM BIOPH RES CO, V495, P1014, DOI 10.1016/j.bbrc.2017.11.132
   Yoon BH, 2019, J ARTHROPLASTY, V34, P163, DOI 10.1016/j.arth.2018.09.005
   Zhang, 2020, J ORTHOP TRANSL, V31, P92
   Zhou M, 2020, JOINT DIS RELAT SURG, V31, P411, DOI 10.5606/ehc.2020.73036
   Zhou Y, 2017, INFLAMMATION, V40, P2062, DOI 10.1007/s10753 017 0646 x
   Zhu YL, 2014, INT J MOL SCI, V15, P11190, DOI 10.3390/ijms150611190
NR 39
TC 27
Z9 30
U1 1
U2 36
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD NOV
PY 2021
VL 25
IS 21
BP 10175
EP 10184
DI 10.1111/jcmm.16954
EA OCT 2021
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA WS3VU
UT WOS:000703940900001
PM 34612603
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, XZ
   Wang, GK
   Wang, WD
   Ran, CX
   Piao, FY
   Ma, ZJ
   Zhang, ZD
   Zheng, GS
   Cao, F
   Xie, H
   Cui, DP
   Okoye, CS
   Yu, XM
   Wang, ZM
   Zhao, DW
AF Zhang, Xiuzhi
   Wang, Guangkuo
   Wang, Weidan
   Ran, Chunxiao
   Piao, Fengyuan
   Ma, Zhijie
   Zhang, Zhaodong
   Zheng, Guoshuang
   Cao, Fang
   Xie, Hui
   Cui, Daping
   Okoye, Chukwuemeka Samuel
   Yu, Xiaoming
   Wang, Ziming
   Zhao, Dewei
TI Bone marrow mesenchymal stem cells paracrine TGF 81 to mediate the
   biological activity of osteoblasts in bone repair
SO CYTOKINE
LA English
DT Article
DE BMSCs; Paracrine; Bone regeneration; Osteoblasts; TGF 81
ID TARGETING RUNX2; DIFFERENTIATION; BETA; OSTEONECROSIS; IMPLANTATION;
   MAINTENANCE
AB Background: Bone marrow mesenchymal stem cells (BMSCs) are an important source of seed cells for regenerative medicine and tissue engineering therapy. BMSCs have multiple differentiation potentials and can release para crine factors to facilitate tissue repair. Although the role of the osteogenic differentiation of BMSCs has been fully confirmed, the function and mechanism of BMSC paracrine factors in bone repair are still largely unclear. This study aimed to determine the roles of transforming growth factor beta 1 (TGF 81) produced by BMSCs in bone tissue repair.Methods: To confirm our hypothesis, we used a Transwell system to coculture hBMSCs and human osteoblast like cells without contact, which could not only avoid the interference of the osteogenic differentiation of hBMSCs but also establish the cell cell relationship between hBMSCs and human osteoblast like cells and provide stable paracrine substances. In the transwell coculture system, alkaline phosphatase activity, mineralized nodule for mation, cell migration and chemotaxis analysis assays were conducted.Results: Osteogenesis, migration and chemotaxis of osteoblast like cells were regulated by BMSCs in a paracrine manner via the upregulation of osteogenic and migration associated genes. A TGF 8 receptor I inhibitor (LY3200882) significantly antagonized BMSC induced biological activity and related gene expression in osteoblast like cells. Interestingly, coculture with osteoblast like cells significantly increased the production of TGF 81 by BMSCs, and there was potential intercellular communication between BMSCs and osteoblast like cells.Conclusions: Our findings provide evidence that the biological mechanism of BMSC produced TGF 81 promotes bone regeneration and repair, providing a theoretical basis and new directions for the application of BMSC transplantation in the treatment of osteonecrosis and bone injury.
C1 [Zhang, Xiuzhi; Wang, Weidan; Ran, Chunxiao; Piao, Fengyuan; Ma, Zhijie; Zheng, Guoshuang; Cao, Fang; Xie, Hui; Cui, Daping; Okoye, Chukwuemeka Samuel; Wang, Ziming; Zhao, Dewei] Dalian Univ, Affiliated Zhongshan Hosp, Dept Orthoped, Dalian 116001, Liaoning, Peoples R China.
   [Wang, Guangkuo; Zhang, Zhaodong] Henan Univ, Huaihe Hosp, Dept Orthopaed, Kaifeng 475000, Henan, Peoples R China.
   [Yu, Xiaoming] Shenyang Ligong Univ, Sch Mat Sci & Engn, Shenyang 110159, Peoples R China.
C3 Dalian University; Henan University; Shenyang Ligong University
RP Wang, WD; Zhao, DW (通讯作者)，Dalian Univ, Affiliated Zhongshan Hosp, Dept Orthoped, Dalian 116001, Liaoning, Peoples R China.
EM wangweidan@dlu.edu.cn; zhaodewei2016@163.com
RI Zhao, Dewei/G 8369 2016; Ma, Zhijie/LXV 3631 2024
FU Scientific Research Fund Project of Liaoning Provincial Education
   Department [L2019605]; Class General Financial Grant from the China
   Postdoctoral Science Foundation [2017M620099, 2021M690494]; Scientific
   Study Project of Ministry of Education, Liaoning Province
   [LJKQZ2021169]; Dalian Key Medical Specialties "Peak Climbing" Program
   [2021 (243)]; National Natural Science Foundation of China [82172398]
FX This study was supported by the Scientific Research Fund Project of
   Liaoning Provincial Education Department (Grant no. L2019605) , the
   Class General Financial Grant from the China Postdoctoral Science
   Foundation (Grant no. 2017M620099, 2021M690494) , Scientific Study
   Project of Ministry of Education, Liaoning Province (No. LJKQZ2021169) ,
   Dalian Key Medical Specialties "Peak Climbing" Program (No. 2021 (243) )
   , National Natural Science Foundation of China (No. 82172398) .
CR Abdallah BM, 2019, BIOL PROCED ONLINE, V21, DOI 10.1186/s12575 019 0091 3
   Abdallah BM, 2015, BONE, V70, P28, DOI 10.1016/j.bone.2014.07.028
   Bagno L, 2018, MOL THER, V26, P1610, DOI 10.1016/j.ymthe.2018.05.009
   Baksh D, 2007, J CELL PHYSIOL, V212, P817, DOI 10.1002/jcp.21080
   Bianco P, 2015, DEVELOPMENT, V142, P1023, DOI 10.1242/dev.102210
   Brun J, 2013, BONE, V53, P6, DOI 10.1016/j.bone.2012.11.020
   Chen G, 2015, J CLIN INVEST, V125, P3226, DOI 10.1172/JCI80883
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Creff G, 2016, INORG CHEM, V55, P29, DOI 10.1021/acs.inorgchem.5b02349
   Dirckx N, 2013, BIRTH DEFECTS RES C, V99, P170, DOI 10.1002/bdrc.21047
   Dong QZ, 2017, ONCOTARGET, V8, P17059, DOI 10.18632/oncotarget.15001
   Duan XH, 2016, THERANOSTICS, V6, P2183, DOI 10.7150/thno.17140
   Folestad E, 2018, MOL ASPECTS MED, V62, P1, DOI 10.1016/j.mam.2018.01.005
   Fu XR, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080784
   Gersbach CA, 2004, EXP CELL RES, V300, P406, DOI 10.1016/j.yexcr.2004.07.031
   Jiang W, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 82246 9
   Kanaan RA, 2006, MED SCI MONITOR, V12, pRA164
   Ko FC, 2021, DEV DYNAM, V250, P377, DOI 10.1002/dvdy.240
   Kumar Y, 2019, J BIOL CHEM, V294, P68, DOI 10.1074/jbc.W118.007037
   Kumar Y, 2015, J BIOL CHEM, V290, P30975, DOI 10.1074/jbc.M115.669531
   Lebouvier A., STEM CELL RES THER
   Lind M, 1998, ACTA ORTHOP SCAND, V69, P2
   Luo Qing, 2012, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V29, P999
   Majumdar R, 2014, CURR OPIN CELL BIOL, V30, P33, DOI 10.1016/j.ceb.2014.05.010
   MARCELLI C, 1990, J BONE MINER RES, V5, P1087
   Nakano N, 2010, NEUROSCI LETT, V483, P57, DOI 10.1016/j.neulet.2010.07.062
   Ning K., 2022, INT J MOL SCI, V23
   Petrie RJ, 2009, NAT REV MOL CELL BIO, V10, P538, DOI 10.1038/nrm2729
   Polymeri A, 2016, HORM METAB RES, V48, P700, DOI 10.1055/s 0042 118458
   Renn J, 2014, MATRIX BIOL, V34, P193, DOI 10.1016/j.matbio.2013.12.008
   Thiel A, 2018, BIOL REV, V93, P350, DOI 10.1111/brv.12345
   Wan Y, 2013, BONE, V55, P258, DOI 10.1016/j.bone.2012.12.052
   Wang GZ, 2021, AM J TRANSL RES, V13, P967
   Zhang SJ, 2016, EUR REV MED PHARMACO, V20, P899
   Zhang X., Acta Biomater
   Zhang ZD, 2019, MOL MED REP, V19, P3505, DOI 10.3892/mmr.2019.10051
   Zhao DW, 2012, BONE, V50, P325, DOI 10.1016/j.bone.2011.11.002
   Zheng L, 2020, ADV SCI, V7, DOI 10.1002/advs.202000588
NR 38
TC 10
Z9 10
U1 1
U2 12
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 4666
EI 1096 0023
J9 CYTOKINE
JI Cytokine
PD APR
PY 2023
VL 164
AR 156139
DI 10.1016/j.cyto.2023.156139
EA FEB 2023
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 8W1NK
UT WOS:000931086900001
PM 36738525
DA 2025 08 17
ER

PT J
AU Kode, A
   Manavalan, JS
   Mosialou, I
   Bhagat, G
   Rathinam, CV
   Luo, N
   Khiabanian, H
   Lee, A
   Murty, VV
   Friedman, R
   Brum, A
   Park, D
   Galili, N
   Mukherjee, S
   Teruya Feldstein, J
   Raza, A
   Rabadan, R
   Berman, E
   Kousteni, S
AF Kode, Aruna
   Manavalan, John S.
   Mosialou, Ioanna
   Bhagat, Govind
   Rathinam, Chozha V.
   Luo, Na
   Khiabanian, Hossein
   Lee, Albert
   Murty, Vundavalli V.
   Friedman, Richard
   Brum, Andrea
   Park, David
   Galili, Naomi
   Mukherjee, Siddhartha
   Teruya Feldstein, Julie
   Raza, Azra
   Rabadan, Raul
   Berman, Ellin
   Kousteni, Stavroula
TI Leukaemogenesis induced by an activating β catenin mutation in
   osteoblasts
SO NATURE
LA English
DT Article
ID BONE MARROW NICHE; STEM CELL NICHE; PROGENITOR CELLS; NOTCH ACTIVATION;
   EXPRESSION; PATHWAY; IDENTIFICATION; RESISTANCE; PROMOTER; GENE
AB Cells of the osteoblast lineage affect the homing(1,2) and the number of long term repopulating haematopoietic stem cells(3,4), haematopoietic stem cell mobilization and lineage determination and B cell lymphopoiesis(5 7). Osteoblasts were recently implicated in pre leukaemic conditions in mice(8,9). However, a single genetic change in osteoblasts that can induce leukaemogenesis has not been shown. Here we show that an activating mutation of beta catenin in mouse osteoblasts alters the differentiation potential of myeloid and lymphoid progenitors leading to development of acute myeloid leukaemia with common chromosomal aberrations and cell autonomous progression. Activated beta catenin stimulates expression of the Notch ligand jagged 1 in osteoblasts. Subsequent activation of Notch signalling in haematopoietic stem cell progenitors induces the malignant changes. Genetic or pharmacological inhibition of Notch signalling ameliorates acute myeloid leukaemia and demonstrates the pathogenic role of the Notch pathway. In 38% of patients with myelodysplastic syndromes or acute myeloid leukaemia, increased beta catenin signalling and nuclear accumulation was identified in osteoblasts and these patients showed increased Notch signalling in haematopoietic cells. These findings demonstrate that genetic alterations in osteoblasts can induce acute myeloid leukaemia, identify molecular signals leading to this transformation and suggest a potential novel pharmacotherapeutic approach to acute myeloid leukaemia.
C1 [Kode, Aruna; Manavalan, John S.; Mosialou, Ioanna; Luo, Na; Brum, Andrea; Kousteni, Stavroula] Columbia Univ, Coll Phys & Surg, Dept Med, Div Endocrinol, New York, NY 10032 USA.
   [Bhagat, Govind] Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY 10032 USA.
   [Rathinam, Chozha V.] Columbia Univ, Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA.
   [Khiabanian, Hossein; Lee, Albert; Rabadan, Raul] Columbia Univ, Dept Biomed Informat, New York, NY 10032 USA.
   [Khiabanian, Hossein; Lee, Albert; Rabadan, Raul] Columbia Univ, Ctr Computat Biol & Bioinformat, New York, NY 10032 USA.
   [Murty, Vundavalli V.] Columbia Univ, Dept Pathol, New York, NY 10032 USA.
   [Murty, Vundavalli V.] Columbia Univ, Inst Canc Genet, Irving Canc Res Ctr, New York, NY 10032 USA.
   [Friedman, Richard] Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Biomed Informat Shared Resource, New York, NY 10032 USA.
   [Friedman, Richard] Columbia Univ, Coll Phys & Surg, Dept Biomed Informat, New York, NY 10032 USA.
   [Brum, Andrea] Erasmus MC, Dept Internal Med, NL 3015 GE Rotterdam, Netherlands.
   [Park, David; Teruya Feldstein, Julie] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
   [Galili, Naomi; Raza, Azra] Columbia Univ, Myelodysplast Syndromes Ctr, New York, NY 10032 USA.
   [Mukherjee, Siddhartha] Columbia Univ, Dept Med Hematol, New York, NY 10032 USA.
   [Mukherjee, Siddhartha] Columbia Univ, Dept Oncol, New York, NY 10032 USA.
   [Berman, Ellin] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA.
   [Kousteni, Stavroula] Columbia Univ, Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University; Columbia University; Columbia University; Columbia
   University; Columbia University; Columbia University; Erasmus University
   Rotterdam; Erasmus MC; Memorial Sloan Kettering Cancer Center; Columbia
   University; Columbia University; Columbia University; Memorial Sloan
   Kettering Cancer Center; Columbia University
RP Kousteni, S (通讯作者)，Columbia Univ, Coll Phys & Surg, Dept Med, Div Endocrinol, New York, NY 10032 USA.
EM sk2836@columbia.edu
RI Rabadan, Raul/AAZ 7367 2020; Bhagat, Govind/AAE 9493 2021; luo,
   na/KOC 3893 2024; Khiabanian, Hossein/N 7207 2019
OI Bhagat, Govind/0000 0001 6250 048X; Brum, Andrea/0000 0001 6881 1123;
   Rabadan, Raul/0000 0001 7946 9255; Khiabanian,
   Hossein/0000 0003 1446 4394
FU National Institutes of Health [R01 AR054447, P01 AG032959, R01
   AR055931]; Division of Hematologic Oncology, Memorial Sloan Kettering
   Cancer Center, New York; European Union
   [INTERBONE FP7 PEOPLE 2011 IRSES 295181]
FX The authors are grateful to M. Taketo for providing the
   Catnb<SUP>+/lox(ex3)</SUP> mice; R. Dalla Favera and G. Karsenty for
   helpful discussions and critical reading of the manuscript; M. Van Den
   Brink for providing funding support; D. McMahon and C. A. Zhang for help
   with statistical analysis; and J. Sha, F. N. Emmons, I. Linkov and J.
   Pichard for technical assistance. The histology and metabolic unit
   facility of the Diabetes and Endocrinology Research Center (DERC, NIDDK
   DK063608 07), the Molecular Pathology facility of the Herbert Irving
   Cancer Center of Columbia University Medical Center provided help with
   histological analysis and W. Fantl and G. Nolan for provided flow
   cytometry conditions for the nuclear beta catenin antibody. This work
   was supported by the National Institutes of Health (R01 AR054447, and
   P01 AG032959 and R01 AR055931 to S. K.) and by the Division of
   Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York
   (to E. B.) and by a European Union Marie Curie Fellowship
   INTERBONE FP7 PEOPLE 2011 IRSES 295181 (to A.B.).
CR Baia G, 2008, NEOPLASIA, V10, P604, DOI 10.1593/neo.08356
   Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chan CKF, 2009, NATURE, V457, P490, DOI 10.1038/nature07547
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Delaney C, 2010, NAT MED, V16, P232, DOI 10.1038/nm.2080
   Eghbali Fatourechi GZ, 2005, NEW ENGL J MED, V352, P1959, DOI 10.1056/NEJMoa044264
   Estrach S, 2006, DEVELOPMENT, V133, P4427, DOI 10.1242/dev.02644
   Ghosh Choudhury Nandini, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P345
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880
   Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931
   Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092 8674(02)00754 7
   Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585
   Kannan S, 2013, J EXP MED, V210, P321, DOI 10.1084/jem.20121527
   Kiernan AE, 2006, PLOS GENET, V2, P27, DOI 10.1371/journal.pgen.0020004
   Klinakis A, 2011, NATURE, V473, P230, DOI 10.1038/nature09999
   Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238
   Krebs LT, 2000, GENE DEV, V14, P1343
   Kumano K, 2003, IMMUNITY, V18, P699, DOI 10.1016/S1074 7613(03)00117 1
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698
   Lobry C, 2013, J EXP MED, V210, P301, DOI 10.1084/jem.20121484
   Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Manavalan JS, 2012, J CLIN ENDOCR METAB, V97, P3240, DOI 10.1210/jc.2012 1546
   Mancini SJC, 2005, BLOOD, V105, P2340, DOI 10.1182/blood 2004 08 3207
   Mercher T, 2009, J CLIN INVEST, V119, P852, DOI 10.1172/JCI35901
   Parfitt A.M., 1983, Bone Histomorphometry: Techniques and Interpretation, P143
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Rached MT, 2010, J CLIN INVEST, V120, P357, DOI 10.1172/JCI39901
   Raza A, 2012, NAT REV CANCER, V12, P849, DOI 10.1038/nrc3321
   Real PJ, 2009, NAT MED, V15, P50, DOI 10.1038/nm.1900
   Recker RR, 2011, BONE, V49, P955, DOI 10.1016/j.bone.2011.07.017
   ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421
   Rubin MR, 2011, J CLIN ENDOCR METAB, V96, P176, DOI 10.1210/jc.2009 2682
   Schepers K, 2013, CELL STEM CELL, V13, P285, DOI 10.1016/j.stem.2013.06.009
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Simon R. M., 2003, DESIGN ANAL DNA MICR, P65
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   Sternberg A, 2005, BLOOD, V106, P2982, DOI 10.1182/blood 2005 04 1543
   Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209
   Trifonov V, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752 0509 7 S2 S2
   van de Loosdrecht AA, 2008, BLOOD, V111, P1067, DOI 10.1182/blood 2007 07 098764
   van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659
   Walkley CR, 2007, CELL, V129, P1097, DOI 10.1016/j.cell.2007.05.014
   Wu JY, 2008, P NATL ACAD SCI USA, V105, P16976, DOI 10.1073/pnas.0802898105
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
NR 51
TC 425
Z9 481
U1 2
U2 50
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028 0836
EI 1476 4687
J9 NATURE
JI Nature
PD FEB 13
PY 2014
VL 506
IS 7487
BP 240
EP +
DI 10.1038/nature12883
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AA5AK
UT WOS:000331107700042
PM 24429522
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Mei, WH
   Song, D
   Wu, ZD
   Li, Y
   Wang, PP
   Zhang, RH
   Zhu, XF
AF Mei, Wenhui
   Song, Dan
   Wu, Zhidi
   Li Yang
   Wang, Panpan
   Zhang, Ronghua
   Zhu, Xiaofeng
TI Resveratrol protects MC3T3 E1 cells against cadmium induced suppression
   of osteogenic differentiation by modulating the ERK1/2 and JNK pathways
SO ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY
LA English
DT Article
DE Resveratrol; Cadmium; Osteogenic differentiation; Osteoblast;
   Mitogen activated protein kinases
ID INDUCED APOPTOSIS; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION;
   BONE RESORPTION; MAPK PATHWAY; STEM CELLS; ACTIVATION; KINASE;
   OSTEOPOROSIS; PROLIFERATION
AB Resveratrol (RES) is a natural polyphenolic compound with a broad range of physiological and pharmacological properties. Previous studies have shown that RES also plays an important role in protecting and promoting early bone metabolism and differentiation. The accumulation of cadmium (Cd), one of the world?s most poisonous substances, can inhibit skeletal growth and bone maturation, thus causing osteoporosis. However, whether RES can prevent the Cd induced inhibition of osteogenic differentiation remains unknown. In this study, we found that RES promoted the early maturity of osteoblastic MC3T3 E1 cells, as demonstrated by the significantly increased mRNA and protein expression of a range of differentiation markers, including alkaline phosphatase (ALP), collagen 1 (COL1), bone morphogenetic protein 2 (BMP 2), and runt related transcription factor 2 (RUNX2). In contrast, we found that cadmium chloride (CdCl2) inhibited the viability and osteogenic maturity of MC3T3 E1 cells. We also demonstrated that RES pretreatment for 30 min provided significant protection against Cd induced apoptosis and attenuated the inhibition of osteogenic differentiation induced by Cd by modulating ERK1/2 and JNK signaling. In conclusion, our results indicate that RES is a potential femoral protectant that not only enhance the viability and early differentiation of osteoblasts, but also protect osteoblasts from cadmium damage.
C1 [Wang, Panpan; Zhang, Ronghua; Zhu, Xiaofeng] Jinan Univ, Dept Chinese Med, Affiliated Hosp 1, Guangzhou 510630, Guangdong, Peoples R China.
   [Mei, Wenhui; Zhang, Ronghua; Zhu, Xiaofeng] Jinan Univ, Sch Tradit Chinese Med, Guangzhou 510630, Guangdong, Peoples R China.
   [Song, Dan; Wu, Zhidi; Li Yang; Zhang, Ronghua] Jinan Univ, Dept Chinese Med, Coll Pharm, Guangzhou 510630, Guangdong, Peoples R China.
C3 Jinan University; Jinan University; Jinan University
RP Zhang, RH; Zhu, XF (通讯作者)，Jinan Univ, Dept Chinese Med, Affiliated Hosp 1, Guangzhou 510630, Guangdong, Peoples R China.
EM tzrh@jnu.edu.cn; tzhuxf@foxmail.com
RI Zhu, Xiaofeng/ABH 5003 2020; Li, Yang/AAM 5383 2020
FU National Natural Science Foundation of China [81673837, 81973717,
   81873202]; Science and Technology Planning Project of Guangdong Province
   [2016A020226039]; National Key Research and Development Program of China
   [2018YFC2002500]
FX This work was supported by the National Natural Science Foundation of
   China (Reference: 81673837, 81973717, 81873202) , Science and Technology
   Planning Project of Guangdong Province (Reference: 2016A020226039) and
   National Key Research and Development Program of China (2018YFC2002500)
   .
CR Arbon KS, 2012, FOOD CHEM TOXICOL, V50, P198, DOI 10.1016/j.fct.2011.10.031
   Bjorklund G, 2020, CURR MED CHEM, V27, P6837, DOI 10.2174/0929867326666190722153305
   Bodo M, 2010, TOXICOL IN VITRO, V24, P1670, DOI 10.1016/j.tiv.2010.05.020
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Brzóska MM, 2012, J APPL TOXICOL, V32, P34, DOI 10.1002/jat.1632
   Buha A, 2019, ENVIRON RES, V176, DOI 10.1016/j.envres.2019.108539
   Chen CY, 2005, BIOCHEM BIOPH RES CO, V331, P993, DOI 10.1016/j.bbrc.2005.03.237
   Chen X, 2019, J EXPO SCI ENV EPID, V29, P435, DOI 10.1038/s41370 018 0057 6
   Chen X, 2009, ENVIRON TOXICOL PHAR, V28, P232, DOI 10.1016/j.etap.2009.04.010
   Chen ZM, 2016, CHEM BIOL INTERACT, V243, P35, DOI 10.1016/j.cbi.2015.11.016
   Cheng CK, 2020, BRIT J PHARMACOL, V177, P1258, DOI 10.1111/bph.14801
   Dai Z, 2007, PHYTOMEDICINE, V14, P806, DOI 10.1016/j.phymed.2007.04.003
   Oliveira ALD, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121306
   El Mowafy AM, 2009, INT J CARDIOL, V136, P263, DOI 10.1016/j.ijcard.2008.04.094
   Fang LQ, 2015, INT J CLIN EXP MED, V8, P3219
   Feng YL, 2018, INT J MOL MED, V41, P202, DOI 10.3892/ijmm.2017.3208
   Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418
   Gallagher CM, 2008, ENVIRON HEALTH PERSP, V116, P1338, DOI 10.1289/ehp.11452
   Ha TT, 2016, TOXICOL LETT, V260, P18, DOI 10.1016/j.toxlet.2016.08.020
   Hu KH, 2015, CELL PHYSIOL BIOCHEM, V36, P642, DOI 10.1159/000430127
   Hu YN, 2016, ENVIRON INT, V92 93, P515, DOI 10.1016/j.envint.2016.04.042
   Huff MO, 2016, TOXICOL SCI, V152, P62, DOI 10.1093/toxsci/kfw064
   Huminiecki L, 2018, BIOTECHNOL ADV, V36, P1699, DOI 10.1016/j.biotechadv.2018.02.011
   Hunter PM, 2017, NAT REV ENDOCRINOL, V13, P278, DOI 10.1038/nrendo.2016.210
   Jahan S, 2018, MOL NEUROBIOL, V55, P8278, DOI 10.1007/s12035 018 0986 z
   Kawada T, 2020, BIOL TRACE ELEM RES, V194, P1, DOI 10.1007/s12011 019 01764 w
   Kim JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081803
   Ko JH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122589
   Låg M, 2005, TOXICOLOGY, V211, P253, DOI 10.1016/j.tox.2005.03.012
   Liu W, 2016, SCI REP UK, V6, DOI 10.1038/srep20404
   Luciano AM, 2010, REPROD TOXICOL, V30, P81, DOI 10.1016/j.reprotox.2010.01.015
   Luo JM, 2019, ENVIRON SCI POLLUT R, V26, P5913, DOI 10.1007/s11356 018 04087 w
   Lv YJ, 2017, J BONE MINER RES, V32, P1990, DOI 10.1002/jbmr.3151
   Ma J, 2018, MED SCI MONITOR, V24, P2045, DOI 10.12659/MSM.905703
   Martin P, 2006, BIOCHEM BIOPH RES CO, V350, P803, DOI 10.1016/j.bbrc.2006.09.126
   Okoye CN, 2019, AQUAT TOXICOL, V214, DOI 10.1016/j.aquatox.2019.105264
   Ornstrup MJ, 2018, CALCIFIED TISSUE INT, V102, P337, DOI 10.1007/s00223 017 0344 6
   Ou L., 2020, ECOTOX ENVIRON SAFE, V15
   Raut N, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104350
   Rodríguez J, 2016, EXP TOXICOL PATHOL, V68, P391, DOI 10.1016/j.etp.2016.06.001
   Santos SDM, 2007, NAT CELL BIOL, V9, P324, DOI 10.1038/ncb1543
   Satarug S, 2019, CLIN KIDNEY J, V12, P468, DOI 10.1093/ckj/sfy113
   Schutte R, 2008, ENVIRON HEALTH PERSP, V116, P777, DOI 10.1289/ehp.11167
   Shakibaei M, 2008, BIOCHEM PHARMACOL, V76, P1426, DOI 10.1016/j.bcp.2008.05.029
   Stephan LS, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111190
   Sughis M, 2011, ENVIRON HEALTH GLOB, V10, DOI 10.1186/1476 069X 10 104
   Sun KH, 2019, CHEM BIOL INTERACT, V303, P7, DOI 10.1016/j.cbi.2019.01.039
   Taha MM, 2018, INT J OCCUP ENV HEAL, V24, P101, DOI 10.1080/10773525.2018.1518745
   Wang H, 2017, TOXICOLOGY, V380, P30, DOI 10.1016/j.tox.2017.01.013
   Xu C, 2016, NEUROPHARMACOLOGY, V105, P270, DOI 10.1016/j.neuropharm.2016.01.030
   Zhang RX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0959 1
   Zhao HY, 2015, J VET SCI, V16, P297, DOI 10.4142/jvs.2015.16.3.297
NR 52
TC 24
Z9 26
U1 1
U2 67
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0147 6513
EI 1090 2414
J9 ECOTOX ENVIRON SAFE
JI Ecotox. Environ. Safe.
PD MAY
PY 2021
VL 214
AR 112080
DI 10.1016/j.ecoenv.2021.112080
EA MAR 2021
PG 11
WC Environmental Sciences; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Toxicology
GA RF0EK
UT WOS:000634521300001
PM 33677380
OA gold
DA 2025 08 17
ER

PT J
AU Silva, BC
   Cusano, NE
   Bilezikian, JP
AF Silva, Barbara C.
   Cusano, Natalie E.
   Bilezikian, John P.
TI Primary hyperparathyroidism
SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE primary hyperparathyroidism; normocalcemic primary hyperparathyroidism;
   parathyroidectomy; vitamin D; bisphosphonates; calcimimetics
ID ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; BONE MINERAL DENSITY;
   NORMOCALCEMIC PRIMARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY;
   POSTMENOPAUSAL WOMEN; SURGICAL MANAGEMENT; PARATHYROID SURGERY;
   VERTEBRAL FRACTURES; ORAL ALENDRONATE; PREVALENCE
AB Primary hyperparathyroidism (PHPT), the most common cause of hypercalcemia, is most often identified in postmenopausal women with hypercalcemia and parathyroid hormone (PTH) levels that are either frankly elevated or inappropriately normal. The clinical presentation of PHPT includes three phenotypes: target organ involvement of the renal and skeletal systems; mild asymptomatic hypercalcemia; and more recently, high PTH levels in the context of persistently normal albumin corrected and ionized serum calcium values. The factors that determine which of these three clinical presentations is more likely to predominate in a given country include the extent to which biochemical screening is employed, the prevalence of vitamin D deficiency, and whether a medical center or practitioner tends to routinely measure PTH levels in the evaluation of low bone density or frank osteoporosis. When biochemical screening is common, asymptomatic primary hyperparathyroidism is the most likely form of the disease. In countries where vitamin D deficiency is prevalent and biochemical screening is not a feature of the health care system, symptomatic disease with skeletal abnormalities is likely to predominate. Finally, when PTH levels are part of the evaluation for low bone mass, the normocalcemic variant is seen. Guidelines for surgical removal of hyperfunctioning parathyroid tissue apply to all three clinical forms of the disease. If guidelines for surgery are not met, parathyroidectomy can also be an appropriate option if there are no medical contraindications to surgery. In settings where either the serum calcium or bone mineral density is of concern, and surgery is not an option, pharmacological approaches are available and effective. Referencing in this article the most current published articles, we review the different presentations of PHPT, with particular emphasis on recent advances in our understanding of target organ involvement and management. (C) 2018 Published by Elsevier Ltd.
C1 [Silva, Barbara C.] Felicia Rocho & Santa Casa Hosp, Div Endocrinol, Med, Belo Horizonte, MG, Brazil.
   [Cusano, Natalie E.] Lenox Hill Hosp, Div Endocrinol, Med, New York, NY 10021 USA.
   [Cusano, Natalie E.] Lenox Hill Hosp, Div Endocrinol, Bone Metab Program, New York, NY 10021 USA.
   [Bilezikian, John P.] Columbia Univ, Coll Phys & Surg, Div Endocrinol, Med, New York, NY USA.
   [Bilezikian, John P.] Columbia Univ, Coll Phys & Surg, Div Endocrinol, Pharmacol, New York, NY USA.
   [Bilezikian, John P.] Columbia Univ, Coll Phys & Surg, Div Endocrinol, Dept Med Int Educ, New York, NY USA.
   [Bilezikian, John P.] Columbia Univ, Coll Phys & Surg, Div Endocrinol, Metab Bone Dis Program, New York, NY USA.
   [Bilezikian, John P.] Columbia Univ, Coll Phys & Surg, Div Endocrinol, Med Ctr, New York, NY USA.
   [Silva, Barbara C.] Ctr Univ Belo Horizonte UNIBH, Dept Med, Med, Belo Horizonte, MG, Brazil.
C3 Northwell Health; Northwell Health; Columbia University; Columbia
   University; Columbia University; Columbia University; Columbia
   University; Centro Universitario de Belo Horizonte
RP Bilezikian, JP (通讯作者)，Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.
EM jpb2@columbia.edu
FU NIH [DK 32333]
FX This work was supported, in part, by NIH grant DK 32333.
CR Abood A, 2013, DAN MED J, V60
   Amaral LM, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/128352
   Ambrogini E, 2007, J CLIN ENDOCR METAB, V92, P3114, DOI 10.1210/jc.2007 0219
   [Anonymous], 2002, J BONE MINER RES S2
   Bandeira Francisco, 2006, Arq Bras Endocrinol Metab, V50, P657, DOI 10.1590/S0004 27302006000400011
   Bandeira F, 2014, ARQ BRAS ENDOCRINOL, V58, P553
   Battista C, 2017, ENDOCRINE, V55, P275, DOI 10.1007/s12020 016 0974 x
   Bilezikian J.P., 2000, Endotext
   Bilezikian JP, 2018, LANCET, V391, P168, DOI 10.1016/S0140 6736(17)31430 7
   Bilezikian JP, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.33
   Bilezikian JP, 2014, J CLIN ENDOCR METAB, V99, P3561, DOI 10.1210/jc.2014 1413
   Bilezikian John P., 1994, P457
   Boehm BO, 2011, NEW ENGL J MED, V365, P676, DOI 10.1056/NEJMc1104982
   Bollerslev J, 2007, J CLIN ENDOCR METAB, V92, P1687, DOI 10.1210/jc.2006 1836
   Cassibba S, 2014, ENDOCR PRACT, V20, P1137, DOI 10.4158/EP14074.OR
   Castellano E, 2017, J CLIN ENDOCR METAB, V102, P4148, DOI 10.1210/jc.2017 01080
   Castellano E, 2016, J CLIN ENDOCR METAB, V101, P2728, DOI 10.1210/jc.2016 1513
   Cesareo R, 2015, OSTEOPOROSIS INT, V26, P1295, DOI 10.1007/s00198 014 3000 2
   Cetani F, 2012, J ENDOCRINOL INVEST, V35, P655, DOI 10.3275/7970
   Chow CC, 2003, J CLIN ENDOCR METAB, V88, P581, DOI 10.1210/jc.2002 020890
   Cipriani C, 2017, ENDOCRINE, V55, P591, DOI 10.1007/s12020 016 1101 8
   Cipriani C, 2015, J CLIN ENDOCR METAB, V100, P1309, DOI 10.1210/jc.2014 3708
   COHEN J, 1990, JAMA J AM MED ASSOC, V264, P581
   Collier A, 2017, ENDOCR RES, V42, P31, DOI 10.3109/07435800.2016.1169545
   Cusano N, 2015, PARATHYROIDS
   Cusano NE, 2018, J CLIN ENDOCR METAB, V103, P196, DOI 10.1210/jc.2017 01932
   Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P2734, DOI 10.1210/jc.2013 1300
   Eastell R, 2014, J CLIN ENDOCR METAB, V99, P3570, DOI 10.1210/jc.2014 1414
   Eufrazino C, 2013, CLIN MED INSIGHTS EN, V6, P69, DOI [10.4137/CMED.S13147, 10.4137/CMEDED.S13147]
   Faggiano A, 2011, ENDOCRINE, V39, P283, DOI 10.1007/s12020 011 9459 0
   García Martín A, 2012, ENDOCRINE, V42, P764, DOI 10.1007/s12020 012 9694 z
   Griebeler ML, 2016, J CLIN ENDOCR METAB, V101, P1166, DOI 10.1210/jc.2015 3964
   Hansen S, 2012, J BONE MINER RES, V27, P1150, DOI 10.1002/jbmr.1540
   Hansen S, 2010, J BONE MINER RES, V25, P1941, DOI 10.1002/jbmr.98
   Keutgen XM, 2012, ANN SURG, V255, P981, DOI 10.1097/SLA.0b013e31824c5252
   Khan AA, 2017, OSTEOPOROSIS INT, V28, P1, DOI 10.1007/s00198 016 3716 2
   Khan AA, 2004, J CLIN ENDOCR METAB, V89, P3319, DOI 10.1210/jc.2003 030908
   Khan AA, 2009, ENDOCR PRACT, V15, P705, DOI 10.4158/EP08178.ORR
   Khosla S, 1999, J BONE MINER RES, V14, P1700, DOI 10.1359/jbmr.1999.14.10.1700
   Kontogeorgos G, 2015, CLIN ENDOCRINOL, V83, P277, DOI 10.1111/cen.12819
   Koumakis E, 2014, OSTEOPOROSIS INT, V25, P1963, DOI 10.1007/s00198 014 2689 2
   Koumakis E, 2013, J CLIN ENDOCR METAB, V98, P3213, DOI 10.1210/jc.2013 1518
   Lavryk OA, 2017, WORLD J SURG, V41, P122, DOI 10.1007/s00268 016 3716 6
   Lee JH, 2017, OSTEOPOROSIS INT, V28, P1667, DOI 10.1007/s00198 017 3918 2
   Lee PK, 2007, CANCER AM CANCER SOC, V109, P1736, DOI 10.1002/cncr.22599
   Liu JM, 2013, BONE RES, V1, DOI 10.4248/BR201302005
   Lowe H, 2007, J CLIN ENDOCR METAB, V92, P3001, DOI 10.1210/jc.2006 2802
   Lundstam K, 2017, J BONE MINER RES, V32, P1907, DOI 10.1002/jbmr.3177
   Luque Fernández I, 2013, THER ADV ENDOCRINOL, V4, P77, DOI 10.1177/2042018813482344
   Marcocci C, 2014, J CLIN ENDOCR METAB, V99, P3607, DOI 10.1210/jc.2014 1417
   Marques TF, 2011, ARQ BRAS ENDOCRINOL, V55, P314, DOI 10.1590/S0004 27302011000500003
   Maruani G, 2003, J CLIN ENDOCR METAB, V88, P4641, DOI 10.1210/jc.2002 021404
   Misiorowski W, 2017, ENDOCRINE, V58, P380, DOI 10.1007/s12020 017 1414 2
   Nevo Shor A, 2016, BONE, V89, P59, DOI 10.1016/j.bone.2016.05.012
   Ospina NS, 2016, OSTEOPOROSIS INT, V27, P3395, DOI 10.1007/s00198 016 3715 3
   Paik JM, 2012, BMJ BRIT MED J, V345, DOI 10.1136/bmj.e6390
   Pardi E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186485
   Parker CR, 2002, J CLIN ENDOCR METAB, V87, P4482, DOI 10.1210/jc.2001 010385
   Pawlowska M, 2015, CURR OPIN ENDOCRINOL, V22, P413, DOI 10.1097/MED.0000000000000198
   Peacock M, 2005, J CLIN ENDOCR METAB, V90, P135, DOI 10.1210/jc.2004 0842
   Peacock M, 2009, J CLIN ENDOCR METAB, V94, P4860, DOI 10.1210/jc.2009 1472
   Piketty ML, 2017, CLIN CHEM LAB MED, V55, P817, DOI 10.1515/cclm 2016 1183
   Pradeep PV, 2011, INT J ENDOCRINOL, V2011, DOI 10.1155/2011/921814
   Prasarttong Osoth P, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/952426
   Press DM, 2013, SURGERY, V154, P1232, DOI 10.1016/j.surg.2013.06.051
   Press DM, 2013, SURGERY, V154
   Rao DS, 2004, J CLIN ENDOCR METAB, V89, P5415, DOI 10.1210/jc.2004 0028
   Rolighed L, 2014, J CLIN ENDOCR METAB, V99, P1072, DOI 10.1210/jc.2013 3978
   Rosário PW, 2017, WORLD J SURG, V41, P1649, DOI 10.1007/s00268 017 3888 8
   Rosen CJ, 2011, J CLIN DENSITOM, V14, P79, DOI 10.1016/j.jocd.2011.03.004
   Rossini M, 2001, J BONE MINER RES, V16, P113, DOI 10.1359/jbmr.2001.16.1.113
   Rubin MR, 2008, J CLIN ENDOCR METAB, V93, P3462, DOI 10.1210/jc.2007 1215
   Silva BC, 2013, J CLIN ENDOCR METAB, V98, P1963, DOI 10.1210/jc.2012 4255
   Silverberg SJ, 2014, J CLIN ENDOCR METAB, V99, P3580, DOI 10.1210/jc.2014 1415
   SILVERBERG SJ, 1989, J BONE MINER RES, V4, P283, DOI 10.1002/jbmr.5650040302
   Spivacow FR, 2010, MEDICINA BUENOS AIRE, V70, P408
   Stein EM, 2013, J BONE MINER RES, V28, P1029, DOI 10.1002/jbmr.1841
   Stephen AE, 2017, JAMA SURG, V152, P878, DOI 10.1001/jamasurg.2017.1721
   Stokes VJ, 2017, J BONE MINER RES, V32, P2157, DOI 10.1002/jbmr.3296
   Sun B, 2018, OSTEOPOROSIS INT, V29, P635, DOI 10.1007/s00198 017 4322 7
   Szalat A, 2009, EUR J ENDOCRINOL, V160, P317, DOI 10.1530/EJE 08 0620
   Thakker RV, 2016, J INTERN MED, V280, P574, DOI 10.1111/joim.12523
   Thomas MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201
   Tordjman KN, 2004, AM J MED, V117, P861, DOI 10.1016/j.amjmed.2004.06.037
   Tournis S, 2014, J BONE MINER METAB, V32, P151, DOI 10.1007/s00774 013 0473 6
   Tuna MM, 2016, J BONE MINER METAB, V34, P331, DOI 10.1007/s00774 015 0673 3
   TURKEN SA, 1989, AM J MED, V87, P553
   Udelsman R, 2014, J CLIN ENDOCR METAB, V99, P3595, DOI 10.1210/jc.2014 2000
   Vaidya A, 2017, J BONE MINER RES, V32, P1900, DOI 10.1002/jbmr.3168
   Vaidya A, 2016, J CLIN ENDOCR METAB, V101, P1590, DOI 10.1210/jc.2015 3836
   Vaidya A, 2015, J CLIN ENDOCR METAB, V100, P2396, DOI 10.1210/jc.2015 1619
   Verdelli C, 2017, EUR J ENDOCRINOL, V176, pR39, DOI 10.1530/EJE 16 0430
   Vestergaard P, 2004, J INTERN MED, V255, P108, DOI 10.1046/j.0954 6820.2003.01237.x
   Vignali E, 2015, ENDOCR CONNECT, V4, P172, DOI 10.1530/EC 15 0030
   Vignali E, 2009, J CLIN ENDOCR METAB, V94, P2306, DOI 10.1210/jc.2008 2006
   Vu TDT, 2013, BONE, V55, P57, DOI 10.1016/j.bone.2013.03.009
   Walker MD, 2016, OSTEOPOROSIS INT, V27, P3063, DOI 10.1007/s00198 016 3637 0
   Walker MD, 2015, OSTEOPOROSIS INT, V26, P2837, DOI 10.1007/s00198 015 3199 6
   Walker MD, 2017, ENDOCRINE, V55, P3, DOI 10.1007/s12020 016 1169 1
   Walker MD, 2016, J CLIN ENDOCR METAB, V101, P905, DOI 10.1210/jc.2015 4218
   Walker MD, 2009, J CLIN ENDOCR METAB, V94, P1951, DOI 10.1210/jc.2008 2574
   Walker MD, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P469, DOI 10.1016/B978 0 12 397166 1.00032 1
   Wermers RA, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P297, DOI 10.1016/B978 0 12 397166 1.00019 9
   Wilhelm SM, 2016, JAMA SURG, V151, P959, DOI 10.1001/jamasurg.2016.2310
   Yeh MW, 2016, ANN INTERN MED, V164, P715, DOI 10.7326/M15 1232
   Yeh MW, 2013, J CLIN ENDOCR METAB, V98, P1122, DOI 10.1210/jc.2012 4022
   Yu N, 2009, CLIN ENDOCRINOL, V71, P485, DOI 10.1111/j.1365 2265.2008.03520.x
NR 107
TC 83
Z9 92
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521 690X
EI 1532 1908
J9 BEST PRACT RES CL EN
JI Best Pract. Res. Clin. Endoc. Metab.
PD OCT
PY 2018
VL 32
IS 5
BP 593
EP 607
DI 10.1016/j.beem.2018.09.004
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HC0NP
UT WOS:000451495400001
PM 30449543
DA 2025 08 17
ER

PT J
AU Zhai, X
   Yan, ZJ
   Zhao, J
   Chen, K
   Yang, YL
   Cai, MX
   He, C
   Huang, CY
   Li, B
   Yang, MY
   Zhou, XY
   Zhao, YC
   Wei, XZ
   Bai, YS
   Li, M
AF Zhai, Xiao
   Yan, Zijun
   Zhao, Jian
   Chen, Kai
   Yang, Yilin
   Cai, Mengxi
   He, Chen
   Huang, Chunyou
   Li, Bo
   Yang, Mingyuan
   Zhou, Xiaoyi
   Zhao, Yingchuan
   Wei, Xiaozhao
   Bai, Yushu
   Li, Ming
TI Muscone Ameliorates Ovariectomy Induced Bone Loss and Receptor Activator
   of Nuclear Factor κb Ligand Induced Osteoclastogenesis by Suppressing
   TNF Receptor Associated Factor 6 Mediated Signaling Pathways
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE muscone; postmenopausal osteoporosis; osteoclasts; RANK; TRAF6
ID NFATC1; OSTEOPOROSIS; MICE
AB Postmenopausal osteoporosis is caused by the deficiency of estrogen, which breaks bone homeostasis and induces levels of pro inflammatory cytokines. Muscone is a potent anti inflammatory agent and is used to treat bone fracture in traditional Chinese medicine. However, its anti osteoclastogenic effects remain unclear. For in vitro study, morphology tests of osteoclastogenesis were firstly performed. And then, factors in RANK induced NF kappa B and MAPK pathways were examined by RT PCR and Western blot, and the binding of TNF receptor associated factor (TRAF)6 to RANK was inspected by coimmunoprecipitation and immunofluorescence staining. For in vivo experiments, C57BL/6 ovariectomized (OVX) mice were used for detection, including H&E staining, TRAP staining, and micro CT. As a result, muscone reduced OVX induced bone loss in mice and osteoclast differentiation in vitro, by inhibiting TRAF6 binding to RANK, and then suppressed NF kappa B and MAPK signaling pathways. The expression of the downstream biomarkers was finally inhibited, including NFATc1, CTR, TRAP, cathepsin K, and MMP 9. The inflammatory factors, TNF a and IL 6, were also reduced by muscone. Taken together, muscone inhibited the binding of TRAF6 to RANK induced by RANKL, thus blocking NF kB and MAPK pathways, and down regulating related gene expression. Finally, muscone inhibited osteoclastogenesis and osteoclast function by blocking RANK TRAF6 binding, as well as downstream signaling pathways in vitro. Muscone also reduced ovariectomy induced bone loss in vivo.
C1 [Zhai, Xiao; Zhao, Jian; Chen, Kai; Yang, Yilin; Li, Bo; Yang, Mingyuan; Zhou, Xiaoyi; Zhao, Yingchuan; Wei, Xiaozhao; Bai, Yushu; Li, Ming] Navy Med Univ, Shanghai Changhai Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Yan, Zijun; Cai, Mengxi; He, Chen; Huang, Chunyou] Navy Med Univ, Shanghai Changhai Hosp, Grad Management Unit, Shanghai, Peoples R China.
C3 Naval Medical University; Naval Medical University
RP Wei, XZ; Bai, YS; Li, M (通讯作者)，Navy Med Univ, Shanghai Changhai Hosp, Dept Orthoped, Shanghai, Peoples R China.
EM weixianzhao@126.com; spinebaiys@163.com; limingchspine@126.com
RI li, bo/LXV 4038 2024; Yang, Mingyuan/LVS 2769 2024; Yan,
   Zijun/JBR 8593 2023; He, Chen/JLM 5059 2023; Li, Ming/ACU 5300 2022
OI CHEN, KAI/0000 0001 6588 5725
FU National Natural Science Foundation of China [81701199]; Pilot Project
   Clinical Collaboration of Traditional Chinese Medicine and Western
   Medicine for Major and Difficult Diseases [ZY[2018 2020] FWTX 2005];
   Shanghai Science and Technology Commission Fund [17441900500,
   16DZ0504000]; Foundation of Changhai Hospital [CH201717]
FX This study was supported by National Natural Science Foundation of China
   (81701199); Pilot Project Clinical Collaboration of Traditional Chinese
   Medicine and Western Medicine for Major and Difficult Diseases
   (ZY[2018 2020] FWTX 2005); Shanghai Science and Technology Commission
   Fund (17441900500, 16DZ0504000); Foundation of Changhai Hospital
   (CH201717).
CR Callejo R, 2016, CHEM EUR J, V22, P8137, DOI 10.1002/chem.201600519
   Cao X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0040 9
   Chen K., 2018, Bioresour. Technol. Rep., V1, P9, DOI [10.1016/j.biteb.2018.01.004, DOI 10.1016/J.BITEB.2018.01.004]
   Chen K, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01046
   Chen Xiao, 2018, Cell Physiol Biochem, V51, P2858, DOI 10.1159/000496039
   Chen X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0035 6
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.394
   Choe JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/597512
   Cianferotti L, 2015, ENDOCRINE, V50, P12, DOI 10.1007/s12020 015 0606 x
   Du YQ, 2018, MED SCI MONITOR, V24, P8870, DOI 10.12659/MSM.912051
   Gao MH, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0039 2
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Grössinger EM, 2018, J IMMUNOL, V200, P749, DOI 10.4049/jimmunol.1701170
   Guo YJ, 2018, BIOMED PHARMACOTHER, V97, P825, DOI 10.1016/j.biopha.2017.11.025
   Hamam D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.462
   Hu B, 2019, FASEB J, V33, P2574, DOI 10.1096/fj.201800920R
   Kim KJ, 2018, J CLIN MED, V7, DOI 10.3390/jcm7060154
   Koide M, 2009, J BONE MINER RES, V24, P1469, DOI [10.1359/jbmr.090302, 10.1359/JBMR.090302]
   Kumar RA, 2018, INT IMMUNOPHARMACOL, V65, P348, DOI 10.1016/j.intimp.2018.10.016
   Kushwaha P, 2019, J CELL PHYSIOL, V234, P23719, DOI 10.1002/jcp.28940
   Lee JW, 2010, BIOCHEM PHARMACOL, V80, P352, DOI 10.1016/j.bcp.2010.04.014
   Lee W, 2018, J NAT PROD, V81, P1343, DOI 10.1021/acs.jnatprod.7b00927
   Leng XH, 2005, CIRC RES, V97, P415, DOI 10.1161/01.RES.0000181025.43762.cf
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li XJ, 2016, INT J MOL MED, V38, P1661, DOI 10.3892/ijmm.2016.2794
   Liu JJ, 2018, PHYTOMEDICINE, V42, P43, DOI 10.1016/j.phymed.2018.03.020
   Liu PF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097123
   Mediero A, 2018, FASEB J, V32, P3487, DOI 10.1096/fj.201700217R
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Qiu YY, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0534 5
   Santhosh S, 2019, J MICROENCAPSUL, V36, P338, DOI 10.1080/02652048.2019.1631401
   Sapir Koren R, 2017, BONE, V103, P102, DOI 10.1016/j.bone.2017.06.020
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Sun XX, 2019, INFLAMMOPHARMACOLOGY, V27, P503, DOI 10.1007/s10787 018 0541 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Thummuri D, 2017, J MOL MED, V95, P1065, DOI 10.1007/s00109 017 1553 1
   Wakchoure S, 2009, PROSTATE, V69, P652, DOI 10.1002/pros.20913
   Wang CD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.238
   Wang XY, 2014, INT J MOL MED, V34, P103, DOI 10.3892/ijmm.2014.1766
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Wu MR, 2012, INT J BIOL SCI, V8, P1398, DOI 10.7150/ijbs.5079
   Yang LL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122974
   Zaiss MM, 2019, ACR OPEN RHEUMATOL, V1, P382, DOI 10.1002/acr2.11060
NR 43
TC 19
Z9 23
U1 1
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 20
PY 2020
VL 11
AR 348
DI 10.3389/fphar.2020.00348
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA KZ7TT
UT WOS:000523462800001
PM 32265718
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Niu, YB
   Li, YH
   Huang, HT
   Kong, XH
   Zhang, R
   Liu, L
   Sun, Y
   Wang, TM
   Mei, QB
AF Niu, Yinbo
   Li, Yuhua
   Huang, Haitao
   Kong, Xianghe
   Zhang, Rong
   Liu, Li
   Sun, Yang
   Wang, Tingmei
   Mei, Qibing
TI Asperosaponin VI, A Saponin Component from Dipsacus asper Wall,
   induces Osteoblast Differentiation through Bone Morphogenetic
   Protein 2/p38 and Extracellular Signal regulated Kinase 1/2 Pathway
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE osteoporosis; asperosaponin VI; bone morphogenetic protein; p38; ERK
ID ALKALINE PHOSPHATASE ACTIVITY; CELL DIFFERENTIATION; IN VITRO;
   ACTIVATION; EXPRESSION; P38; GROWTH; ENHANCEMENT; DERIVATIVES; RECEPTORS
AB Osteoporosis is a reduction in skeletal mass because of the loss of osteoblastic activity or an increase in osteoclastic activity. The survival of osteoblast cells plays a crucial role in the development of osteoporosis. Asperosaponin VI (ASAVI) is a kind of saponin in the medicinal herb Dipsacus asper Wall which has long been used as an antiosteoporosis drug. The assay of cell proliferation, alkaline phosphatase ( ALP) activity and measurement of mineralized matrix, showed that ASA VI exhibited a significant induction of proliferation, differentiation and mineralization in MC3T3 E1 and primary osteoblastic cells. Induction of differentiation by ASA VI was associated with increased bone morphogenetic protein 2 (BMP 2), indicating that BMP 2 is essential in ASA VI to mediate osteoblast maturation and differentiation. In addition, ASA VI may induce differentiation by increasing the activity of p38 and ERK1/2. In conclusion, ASA VI may induce osteoblast maturation and differentiation, and then increase bone formation via increasing BMP 2 synthesis, and activating p38 and ERK1/2. Copyright (C) 2011 John Wiley & Sons, Ltd.
C1 [Niu, Yinbo; Kong, Xianghe; Wang, Tingmei; Mei, Qibing] NW Polytech Univ, Fac Life Sci, Xian, Shaanxi, Peoples R China.
   [Li, Yuhua; Huang, Haitao; Zhang, Rong; Liu, Li; Sun, Yang; Mei, Qibing] Fourth Mil Med Univ, Sch Pharm, Dept Pharmacol, Xian, Shaanxi, Peoples R China.
C3 Northwestern Polytechnical University; Air Force Medical University
RP Mei, QB (通讯作者)，NW Polytech Univ, Fac Life Sci, Xian, Shaanxi, Peoples R China.
EM qbmei@nwpu.edu.cn
RI liu, jie/B 4901 2011
FU National Natural Science Foundation of China [81073037]
FX This work was supported by the National Natural Science Foundation of
   China (Grant no. 81073037).
CR Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   CANALIS E, 2007, NEW ENGL J MED, V357, P2410
   Cortizo AM, 2003, MOL CELL BIOCHEM, V250, P1, DOI 10.1023/A:1024934008982
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Hung TM, 2006, J ETHNOPHARMACOL, V108, P188, DOI 10.1016/j.jep.2006.04.029
   Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jia TL, 2003, BIOCHEM PHARMACOL, V65, P709, DOI 10.1016/S0006 2952(02)01585 X
   Kapur S, 2004, BONE, V35, P525, DOI 10.1016/j.bone.2004.04.007
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Li CM, 2010, EUR J PHARMACOL, V627, P235, DOI 10.1016/j.ejphar.2009.11.004
   Li YH, 2009, CANCER SCI, V100, P2451, DOI 10.1111/j.1349 7006.2009.01335.x
   Liu ZG, 2009, J ETHNOPHARMACOL, V123, P74, DOI 10.1016/j.jep.2009.02.025
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Peng LH, 2010, J ETHNOPHARMACOL, V131, P282, DOI 10.1016/j.jep.2010.06.039
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Schelonka EP, 2001, JAMA J AM MED ASSOC, V286, P1836, DOI 10.1001/jama.286.15.1836
   Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177
   Sykaras Nikitas, 2003, J Oral Sci, V45, P57
   TAKUWA Y, 1991, BIOCHEM BIOPH RES CO, V174, P96, DOI 10.1016/0006 291X(91)90490 X
   Tang CH, 2003, J BONE MINER RES, V18, P502, DOI 10.1359/jbmr.2003.18.3.502
   Tang CH, 2008, EUR J PHARMACOL, V579, P40, DOI 10.1016/j.ejphar.2007.10.013
   Tomita H, 1996, PHYTOCHEMISTRY, V42, P239, DOI 10.1016/0031 9422(95)00904 3
   Wong RWK, 2007, PHYTOTHER RES, V21, P596, DOI 10.1002/ptr.2126
   Xiao Y, 2004, CELL TRANSPLANT, V13, P15, DOI 10.3727/000000004772664851
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
   Zhang X, 2010, CHINESE MED J PEKING, V123, P2231, DOI 10.3760/cma.j.issn.0366 6999.2010.16.014
NR 30
TC 80
Z9 99
U1 0
U2 34
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0951 418X
J9 PHYTOTHER RES
JI Phytother. Res.
PD NOV
PY 2011
VL 25
IS 11
BP 1700
EP 1706
DI 10.1002/ptr.3414
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 851XY
UT WOS:000297307000019
PM 21452371
DA 2025 08 17
ER

PT J
AU Zhang, JH
   Jiang, T
   Zhang, YX
   Yang, K
   Zhao, YC
   Zhou, Q
   Yang, Z
   Yang, RH
   Ning, RA
   Liu, T
   Deng, LF
   Xi, XB
   Xu, X
   Jiang, M
AF Zhang, Jiahui
   Jiang, Tao
   Zhang, Yuxin
   Yang, Kai
   Zhao, Yichen
   Zhou, Qi
   Yang, Zhuo
   Yang, Renhao
   Ning, Ruonan
   Liu, Tao
   Deng, Lianfu
   Xi, Xiaobing
   Xu, Xing
   Jiang, Min
TI Phillygenin prevents osteoclast differentiation and bone loss by
   targeting RhoA
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE bone loss; Forsythia suspensa; osteoclastogenesis; osteoporosis;
   Phillygenin; RhoA
ID PERFORMANCE LIQUID CHROMATOGRAPHY; RAT PLASMA; RESORPTION; RECEPTOR;
   GTPASES; BORDER; LIGAND
AB Forsythia suspensa tea is a popular traditional Chinese medicine decoction for its healthy and therapeutic benefits. However, its effects in bone metabolism were not clear. In recent study, we uncovered anti osteoclastogenesis property of Phillygenin (Phi), a compound abundant in Forsythia suspensa leaves, and aimed to investigate the effect and mechanism of Phi on bone metabolism in vivo and in vitro. Lipopolysaccharides induced murine calvaria osteolysis and ovariectomy induced bone loss animal models were used to identify the bone protective effect of Phi in vivo and micro CT, pQCT, and TRAP staining were applied. We used CCK8, TUNEL, BrdU, and TRAP staining to evaluate the efficacy of Phi on the proliferation and formation of OCs in primary mBMMs. RNA sequence, activity based protein profiling, molecular docking, G LISA, and WB were used to inspect the target and underlying mechanism of Phi's actions in mBMMs. We found Phi significantly inhibited bone resorption in vivo and inhibited mBMMs osteoclastogenesis in vitro. Ras homolog gene family member A (RhoA) was identified as the direct target of Phi. It counteracted the effects of RhoA activator and acted as a RhoA inhibitor. By targeting RhoA, Phi modulated Rho associated coiled coil containing protein kinase 1 (ROCK1) activity and regulated its downstream NF kappa B/NFATc1/c fos pathway. Furthermore, Phi depressed the disassembling of F actin ring through cofilin and myosin1a. Our findings provided Phi as a potential option for treating bone loss diseases by targeting RhoA and highlighted the importance of F. suspensa as a preventive approach in bone disorders.
   The diagram illustrates that Phi prevents bone loss in vivo and binds to RhoA to inhibit its downstream pathways, including regulating osteoclast differentiation, F actin formation, and bone resorption in vitro. image
C1 [Zhang, Jiahui; Jiang, Tao; Zhang, Yuxin; Yang, Kai; Zhao, Yichen; Zhou, Qi; Yang, Renhao; Ning, Ruonan; Liu, Tao; Deng, Lianfu; Xi, Xiaobing; Xu, Xing; Jiang, Min] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, Dept Orthopaed,Sch Med,Shanghai Key Lab Prevent &, Shanghai, Peoples R China.
   [Jiang, Tao] Shanghai Jiao Tong Univ, Dept Endocrine & Metab Dis, Ruijin Hosp, Sch Med, Shanghai, Peoples R China.
   [Yang, Zhuo] Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Ctr Excellence Mol Cell Sci,Chem Biol Core Facil, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese
   Academy of Sciences; Center for Excellence in Molecular Cell Science,
   CAS; University of Chinese Academy of Sciences, CAS
RP Xi, XB; Xu, X; Jiang, M (通讯作者)，Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, Dept Orthopaed,Sch Med,Shanghai Key Lab Prevent &, Shanghai, Peoples R China.
EM skxixiaobing@163.com; xuxing0510315@126.com; jiangm263@163.com
RI Zhao, Yichen/AEU 1578 2022; Yang, Kai/JQW 2039 2023; jiahui,
   zhang/JAN 5506 2023; Zhou, Qi/JGM 4026 2023; yangyang,
   yang/GRO 2293 2022
FU National Natural Science Foundation of China; Shanghai Jiaotong
   University School of Medicine High level Local University Construction
   of Integrated Traditional Chinese and Western Medicine Research Platform
   Construction Project [2022zxy002]; Shanghai Municipal Commission of
   Health and Family Planning [(2021 2023) 0208]; Three year action plan
   project for Shanghai to further accelerate the inheritance, innovation,
   and development of traditional Chinese medicine [(2021 2023) 0209 03];
   Shanghai Integrated Traditional Chinese and Western Medicine Flagship
   Hospital Construction Project [(2021 2023) 0205 01]; Shanghai Sailing
   Program [21YF1441900];  [22277076]
FX This work was supported by the National Natural Science Foundation of
   China (NO. 22277076), Shanghai Jiaotong University School of Medicine
   High level Local University Construction of Integrated Traditional
   Chinese and Western Medicine Research Platform Construction Project (NO.
   2022zxy002), Shanghai Municipal Commission of Health and Family Planning
   (NO. ZY(2021 2023) 0208), Three year action plan project for Shanghai to
   further accelerate the inheritance, innovation, and development of
   traditional Chinese medicine (NO. ZY (2021 2023) 0209 03), Shanghai
   Integrated Traditional Chinese and Western Medicine Flagship Hospital
   Construction Project (NO. ZY (2021 2023) 0205 01), Shanghai Sailing
   Program (NO. 21YF1441900).
CR Andersen TL, 2009, AM J PATHOL, V174, P239, DOI 10.2353/ajpath.2009.080627
   Aubin JE, 2000, OSTEOPOROSIS INT, V11, P905, DOI 10.1007/s001980070028
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200
   Crosas Molist E, 2022, PHYSIOL REV, V102, DOI 10.1152/physrev.00045.2020
   Diaz Valencia JD, 2022, CELL ADHES MIGR, V16, P1, DOI 10.1080/19336918.2021.2020705
   Fu LS, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419 023 05726 y
   Hwang YH, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081831
   Jiang M, 2019, J BONE MINER RES, V34, P361, DOI 10.1002/jbmr.3604
   Kim H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222313117
   Li J, 2022, MOLECULES, V27, DOI 10.3390/molecules27207055
   Li XC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03181 7
   Li YX, 2008, BIOMED CHROMATOGR, V22, P361, DOI 10.1002/bmc.940
   Li YX, 2006, J PHARMACEUT BIOMED, V41, P628, DOI 10.1016/j.jpba.2005.12.006
   Liu LD, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0269915
   McCall PM, 2019, P NATL ACAD SCI USA, V116, P12629, DOI 10.1073/pnas.1818808116
   Mizoguchi F, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4282
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Nakano S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 40974 z
   Pan LL, 2021, ACTA PHARMACOL SIN, V42, P311, DOI 10.1038/s41401 020 0481 8
   Park KR, 2018, THERANOSTICS, V8, P3087, DOI 10.7150/thno.24426
   Rodríguez Trillo A, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.858069
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Song W, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7964318
   Stenbeck G, 2002, SEMIN CELL DEV BIOL, V13, P285, DOI 10.1016/S1084952102000587
   Strzelecka Kiliszek A, 2017, BBA GEN SUBJECTS, V1861, P1009, DOI 10.1016/j.bbagen.2017.02.005
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Tyska Matthew J., 2010, Communicative & Integrative Biology, V3, P64
   Tyska MJ, 2005, MOL BIOL CELL, V16, P2443, DOI 10.1091/mbc.E04 12 1116
   VANDEWIJNGAERT FP, 1986, J HISTOCHEM CYTOCHEM, V34, P1317, DOI 10.1177/34.10.3745910
   Wang DH, 2021, FOOD SCI BIOTECHNOL, V30, P305, DOI 10.1007/s10068 020 00855 y
   Wang J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01188
   Wang JR, 2023, MOL MED, V29, DOI 10.1186/s10020 023 00638 1
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   WUCHERPFENNIG AL, 1994, J BONE MINER RES, V9, P549
   Zhu PY, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046 020 01618 7
   Zhu X, 2016, J BONE MINER RES, V31, P560, DOI 10.1002/jbmr.2710
NR 38
TC 5
Z9 5
U1 3
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD APR
PY 2024
VL 38
IS 4
BP 1863
EP 1881
DI 10.1002/ptr.8074
EA FEB 2024
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA NE8R6
UT WOS:001162675900001
PM 38358766
OA hybrid
DA 2025 08 17
ER

PT J
AU Mekhail, GM
   Kamel, AO
   Awad, GAS
   Mortada, ND
   Rodrigo, RL
   Spagnuolo, PA
   Wettig, SD
AF Mekhail, George M.
   Kamel, Amany O.
   Awad, Gehanne A. S.
   Mortada, Nahed D.
   Rodrigo, Rowena L.
   Spagnuolo, Paul A.
   Wettig, Shawn D.
TI Synthesis and evaluation of alendronate modified gelatin biopolymer as a
   novel osteotropic nanocarrier for gene therapy
SO NANOMEDICINE
LA English
DT Article
DE alendronate; biopolymer; gelatin; gene therapy; nanoparticles;
   osteotropic
ID TO MICELLE TRANSITION; GEMINI SURFACTANTS; CROSS LINKING; SODIUM
   ALENDRONATE; DELIVERY SYSTEMS; NANOPARTICLES; DRUG; PH; ACID;
   BISPHOSPHONATES
AB Aim: To synthesize an osteotropic alendronate functionalized gelatin (ALN gelatin) biopolymer for nanoparticle preparation and targeted delivery of DNA to osteoblasts for gene therapy applications. Materials & methods: Alendronate coupling to gelatin was confirmed using Fourier transform IR, (PNMR) P 31, x ray diffraction (XRD) and differential scanning calorimetry. ALN gelatin biopolymers prepared at various alendronate/gelatin ratios were utilized to prepare nanoparticles and were optimized in combination with DNA and gemini surfactant for transfecting both HEK 293 and MG 63 cell lines. Results: Gelatin functionalization was confirmed using the above methods. Uniform nanoparticles were obtained from a nanoprecipitation technique. ALN gelatin/gemini/DNA complexes exhibited higher transfection efficiency in MG 63 osteosarcoma cell line compared with the positive control. Conclusion: ALN gelatin is a promising biopolymer for bone targeting of either small molecules or gene therapy applications.
C1 [Mekhail, George M.; Kamel, Amany O.; Rodrigo, Rowena L.; Spagnuolo, Paul A.; Wettig, Shawn D.] Univ Waterloo, Sch Pharm, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
   [Wettig, Shawn D.] Univ Waterloo, Waterloo Inst Nanotechnol, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
   [Mekhail, George M.; Kamel, Amany O.; Awad, Gehanne A. S.; Mortada, Nahed D.] Ain Shams Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Khalifa El Maamon St,Abbasiya Sq, Cairo 11566, Egypt.
C3 University of Waterloo; University of Waterloo; Egyptian Knowledge Bank
   (EKB); Ain Shams University
RP Wettig, SD (通讯作者)，Univ Waterloo, Sch Pharm, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.; Wettig, SD (通讯作者)，Univ Waterloo, Waterloo Inst Nanotechnol, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
EM wettig@uwaterloo.ca
RI ; Wettig, Shawn/ABE 5382 2020
OI Spagnuolo, Paul/0000 0002 2431 4368; Kamel, Amany/0000 0002 7449 3210;
   Mortada, Nahed/0000 0003 2017 4676; Awad, Gehanne A/0000 0003 0357 3114;
   
FU Egyptian Ministry of Higher Education; Natural Sciences and Engineering
   Research Council of Canada (NSERC) [335626 2011]
FX GM Mekhail and SD Wettig would like to acknowledge the Egyptian Ministry
   of Higher Education for providing support in the form of student funding
   (GM Mekhail) and bench fee funding (SD Wettig). The Ministry of Higher
   Education had no involvement in this study. SD Wettig is supported by
   the Natural Sciences and Engineering Research Council of Canada (NSERC
   Discovery grant #335626 2011). The authors have no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Abdel Hafez SM, 2014, INT J BIOL MACROMOL, V64, P334, DOI 10.1016/j.ijbiomac.2013.11.041
   Aft R, 2012, CRIT REV ONCOL HEMAT, V82, P233, DOI 10.1016/j.critrevonc.2011.05.009
   Ahmed T, 2016, NANOMEDICINE UK, V11, P289, DOI 10.2217/nnm.15.203
   Al Dosari MS, 2009, AAPS J, V11, P671, DOI 10.1208/s12248 009 9143 y
   Al Warhi TI, 2012, J SAUDI CHEM SOC, V16, P97, DOI 10.1016/j.jscs.2010.12.006
   AMES WM, 1952, J SCI FOOD AGR, V3, P579, DOI 10.1002/jsfa.2740031204
   Anindyajati A, 2011, INT C INSTR COMM INF
   Ao MQ, 2011, SOFT MATTER, V7, P1199, DOI 10.1039/c0sm00556h
   Aramwit P, 2015, MATER EXPRESS, V5, P241, DOI 10.1166/mex.2015.1233
   Asnani M, 2009, J PHARM SCI US, V98, P2113, DOI 10.1002/jps.21561
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Benyettou F, 2011, J MATER CHEM, V21, P4813, DOI [10.1039/c1jm00060h, 10.1039/cljm00060h]
   Neto JRB, 2014, J RAMAN SPECTROSC, V45, P801, DOI 10.1002/jrs.4559
   Bombelli C, 2009, CURR MED CHEM, V16, P171, DOI 10.2174/092986709787002808
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517 6161.1964.tb00553.x
   Cammarata CR, 2015, MOL PHARMACEUT, V12, P783, DOI 10.1021/mp5006118
   Chen F, 2010, PHARM RES DORDR, V27, P2356, DOI 10.1007/s11095 010 0119 5
   Chen F, 2009, ANTIMICROB AGENTS CH, V53, P4898, DOI 10.1128/AAC.00387 09
   Chen HY, 2012, BIOCONJUGATE CHEM, V23, P1915, DOI 10.1021/bc3003088
   Dearnaley DP, 2009, LANCET ONCOL, V10, P872, DOI 10.1016/S1470 2045(09)70201 3
   Donkuru M, 2012, J MATER CHEM, V22, P6232, DOI 10.1039/c2jm15719e
   Elzoghby AO, 2013, J CONTROL RELEASE, V172, P1075, DOI 10.1016/j.jconrel.2013.09.019
   Farris S, 2010, J AGR FOOD CHEM, V58, P998, DOI 10.1021/jf9031603
   Fielden ML, 2001, EUR J BIOCHEM, V268, P1269, DOI 10.1046/j.1432 1327.2001.01995.x
   Gallo M, 2010, CANC RES S8, V70, P565
   Gashti MP, 2014, J COLLOID INTERF SCI, V431, P149, DOI 10.1016/j.jcis.2014.06.010
   Hiwale P, 2011, BIOMACROMOLECULES, V12, P3186, DOI 10.1021/bm200679w
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Johnsson M, 2003, LANGMUIR, V19, P4609, DOI 10.1021/la0343270
   Katrien C, 2009, PREPARATION CHARACTE
   KENCHINGTON AW, 1954, BIOCHEM J, V58, P202, DOI 10.1042/bj0580202
   Kühbeck D, 2013, BEILSTEIN J ORG CHEM, V9, P1111, DOI 10.3762/bjoc.9.123
   Kuijpers AJ, 2000, J BIOMAT SCI POLYM E, V11, P225, DOI 10.1163/156856200743670
   Kushibiki T, 2006, J BIOMAT SCI POLYM E, V17, P645, DOI 10.1163/156856206777346278
   Lecouvey M, 1999, NUCLEOS NUCLEOT NUCL, V18, P2109, DOI 10.1080/07328319908044867
   Lee EJ, 2011, J BIOMAT SCI POLYM E, V22, P753, DOI 10.1163/092050610X492093
   Lee EJ, 2012, BIOPROC BIOSYST ENG, V35, P297, DOI 10.1007/s00449 011 0591 2
   Leite NB, 2015, BIOPHYS J, V109, P936, DOI 10.1016/j.bpj.2015.07.033
   Lequeux I, 2015, J APPL POLYM SCI, V132, DOI 10.1002/app.41825
   Lezcano V, 2014, EXP CELL RES, V324, P30, DOI 10.1016/j.yexcr.2014.03.016
   Li NY, 2016, COLLOID SURFACE B, V142, P344, DOI 10.1016/j.colsurfb.2016.03.015
   Li WJ, 2014, J MATER CHEM B, V2, P4901, DOI 10.1039/c4tb00502c
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lin YC, 2009, J COLLOID INTERF SCI, V340, P126, DOI 10.1016/j.jcis.2009.08.014
   Liu P, 2015, SCI REP UK, V5, DOI 10.1038/srep17387
   Liu XM, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/6/065008
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Lu Z, 2004, CLIN CANCER RES, V10, P7677, DOI 10.1158/1078 0432.CCR 04 1443
   Mair L, 2009, J BIOMED NANOTECHNOL, V5, P182, DOI 10.1166/jbn.2009.1024
   Mastrobattista E, 2012, NAT MATER, V11, P10, DOI 10.1038/nmat3209
   Mehanny M, 2016, J MOL LIQ, V214, P162, DOI 10.1016/j.molliq.2015.12.007
   Meloun M, 2011, J CHEM ENG DATA, V56, P3848, DOI 10.1021/je200512e
   Meskinfam M., 2011, WORLD ACAD SCI ENG T, V52, P395
   Miller T., 2010, Practical Assessment Research and Evaluation, V15, P1, DOI DOI 10.7275/QBPC GK17
   Mohapatra S, 2012, GLOBAL J PHARM, V6, P23
   Mojarradi H, 2011, COUPLING SUBSTANCES, V44
   Mukherjee I, 2013, J THERM ANAL CALORIM, V114, P1161, DOI 10.1007/s10973 013 3166 4
   Nayerossadat Nouri, 2012, Adv Biomed Res, V1, P27, DOI 10.4103/2277 9175.98152
   Ochiuz L, 2008, MATER PLAST, V45, P372
   Pignatello R, 2009, NANOMEDICINE UK, V4, P161, DOI 10.2217/17435889.4.2.161
   Quintanar Guerrero D, 1998, DRUG DEV IND PHARM, V24, P1113, DOI 10.3109/03639049809108571
   Rahman MS, 2010, THERMOCHIM ACTA, V509, P111, DOI 10.1016/j.tca.2010.06.011
   Rao JP, 2011, PROG POLYM SCI, V36, P887, DOI 10.1016/j.progpolymsci.2011.01.001
   Ratanavaraporn J, 2010, INT J BIOL MACROMOL, V47, P431, DOI 10.1016/j.ijbiomac.2010.06.008
   Reid IR, 2011, BONE, V49, P89, DOI 10.1016/j.bone.2010.09.002
   Salgin S, 2012, INT J ELECTROCHEM SC, V7, P12404
   Samal SK, 2012, CHEM SOC REV, V41, P7147, DOI 10.1039/c2cs35094g
   Saxena A, 2005, COLLOID SURFACE B, V45, P42, DOI 10.1016/j.colsurfb.2005.07.005
   Shao XH, 2012, APPL MECH MATER, V140, P53, DOI 10.4028/www.scientific.net/AMM.140.53
   Shrestha RG, 2012, LANGMUIR, V28, P15472, DOI 10.1021/la3022358
   Singh J, 2015, NANOMEDICINE UK, V10, P405, DOI 10.2217/nnm.14.123
   Singh J, 2011, CURR DRUG DELIV, V8, P299, DOI 10.2174/156720111795256200
   Skorey K, 1997, J BIOL CHEM, V272, P22472, DOI 10.1074/jbc.272.36.22472
   Spizzirri UG, 2009, BIOMACROMOLECULES, V10, P1923, DOI 10.1021/bm900325t
   Sum CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142875
   Szabó T, 2014, PROG ORG COAT, V77, P1226, DOI 10.1016/j.porgcoat.2014.02.007
   Thakor D, 2007, MOL THER, V15, P2124, DOI 10.1038/sj.mt.6300256
   Thoke S.B., 2013, J. Drug Delivery Therap., V3, P65, DOI [10.22270/jddt.v3i5.623, DOI 10.22270/JDDT.V3I5.623]
   Uhríková D, 2005, COLLOID SURFACE B, V42, P59, DOI 10.1016/j.colsurfb.2005.02.002
   Vallapragada V. V., 2011, AM J ANAL CHEM, V2, P718, DOI [10.4236/ajac.2011.26082, DOI 10.4236/AJAC.2011.26082]
   Vandervoort J, 2004, EUR J PHARM BIOPHARM, V57, P251, DOI 10.1016/s0939 6411(03)00187 5
   Wang Feng., 2010, ADV BIOSCIENCE BIOTE, V2010, P185, DOI DOI 10.4236/ABB.2010.13026
   Wasungu L, 2006, BBA BIOMEMBRANES, V1758, P1677, DOI 10.1016/j.bbamem.2006.06.019
   Wasungu L, 2006, J MOL MED JMM, V84, P774, DOI 10.1007/s00109 006 0067 z
   Wettig SD, 2008, CURR GENE THER, V8, P9, DOI 10.2174/156652308783688491
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   Wu D, 2007, INT J BIOL MACROMOL, V40, P345, DOI 10.1016/j.ijbiomac.2006.09.004
   Wu D, 2007, BIOMACROMOLECULES, V8, P708, DOI 10.1021/bm061033v
   Xiong Y, 2009, J INT MED RES, V37, P407, DOI 10.1177/147323000903700216
   Yang P, 2010, EUR J PHARM BIOPHARM, V75, P311, DOI 10.1016/j.ejpb.2010.04.007
   Yao Y, 2015, INT J NANOMED, V10, P6185, DOI 10.2147/IJN.S90524
   Yoshimura T, 2005, LANGMUIR, V21, P10409, DOI 10.1021/la051614q
   Zhao F, 2004, PHARM RES, V21, P144, DOI 10.1023/B:PHAM.0000012162.52419.b3
   Zhou JB, 2012, NAT MATER, V11, P82, DOI [10.1038/NMAT3187, 10.1038/nmat3187]
NR 95
TC 24
Z9 25
U1 2
U2 65
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743 5889
EI 1748 6963
J9 NANOMEDICINE UK
JI Nanomedicine
PD SEP
PY 2016
VL 11
IS 17
BP 2251
EP 2273
DI 10.2217/nnm 2016 0151
PG 23
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA DU7ZC
UT WOS:000382432100005
PM 27527003
DA 2025 08 17
ER

PT J
AU Yoon, H
   Kim, HJ
   Shin, HR
   Kim, BS
   Kim, WJ
   Cho, YD
   Ryoo, HM
AF Yoon, H.
   Kim, H. J.
   Shin, H. R.
   Kim, B. S.
   Kim, W. J.
   Cho, Y. D.
   Ryoo, H. M.
TI Nicotinamide Improves Delayed Tooth Eruption in
   Runx2<SUP>+/ </SUP> Mice
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE osteoblast; osteoclast; bone remodeling; regeneration; bone biology;
   mineralized tissue; development; posttranslational modifications
AB Patients with cleidocranial dysplasia (CCD) caused by mutations in RUNX2 have severe dental anomalies, including delayed or absent eruption of permanent teeth. This requires painful and expensive surgical/orthodontic intervention because of the absence of medicine for this condition. Here, we demonstrate that nicotinamide, a vitamin B3 and class III histone deacetylase inhibitor, significantly improves delayed tooth eruption in Runx2(+/ ) mice, a well known CCD animal model, through the restoration of decreased osteoclastogenesis. We also found that Csf1 mRNA and protein levels were significantly reduced in Runx2(+/ ) osteoblasts as compared with wild type whereas RANKL and OPG levels had no significant difference between wild type and Runx2(+/ ) osteoblasts. The nicotinamide induced restoration of osteoclastogenesis of bone marrow derived macrophages in Runx2(+/ ) mice was due to the increased expression of RUNX2 and CSF1 and increased RANKL/OPG ratio. RUNX2 directly regulated Csf1 mRNA expression via binding to the promoter region of the Csf1 gene. In addition, nicotinamide enhanced the RUNX2 protein level and transacting activity posttranslationally with Sirt2 inhibition. Taken together, our study shows the potential and underlying molecular mechanism of nicotinamide for the treatment of delayed tooth eruption by using the Runx2(+/ ) murine model, suggesting nicotinamide as a candidate therapeutic drug for dental abnormalities in patients with CCD.
C1 [Yoon, H.; Kim, H. J.; Shin, H. R.; Kim, B. S.; Kim, W. J.; Ryoo, H. M.] Seoul Natl Univ, Sch Dent, Dept Mol Genet & Pharmacol, 1 Gwanak Ro, Seoul 08826, South Korea.
   [Yoon, H.; Kim, H. J.; Shin, H. R.; Kim, B. S.; Kim, W. J.; Cho, Y. D.; Ryoo, H. M.] Seoul Natl Univ, Dent Res Inst, BK21 Program, 1 Gwanak Ro, Seoul 08826, South Korea.
   [Cho, Y. D.] Seoul Natl Univ, Dept Periodontol, Sch Dent, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU)
RP Ryoo, HM (通讯作者)，Seoul Natl Univ, Sch Dent, Dept Mol Genet & Pharmacol, 1 Gwanak Ro, Seoul 08826, South Korea.; Ryoo, HM (通讯作者)，Seoul Natl Univ, Dent Res Inst, BK21 Program, 1 Gwanak Ro, Seoul 08826, South Korea.
EM hmryoo@snu.ac.kr
RI Cho, Young Dan/AAR 4573 2021; Ryoo, Hyun Mo/D 5839 2012
OI Ryoo, Hyun Mo/0000 0001 6769 8341; 
FU National Research Foundation of Korea   Korean government (Ministry of
   Science and ICT) [NRF 2020R1A4A101942311, NRF 2020R1A2 B5B0200265811,
   NRF 2017R1A2B3011778, NRF 2017R1A 4A1014584]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the National Research Foundation of Korea, funded by the
   Korean government (Ministry of Science and ICT; grants
   NRF 2020R1A4A101942311, NRF 2020R1A2 B5B0200265811,
   NRF 2017R1A2B3011778, and NRF 2017R1A 4A1014584).
CR Avalos JL, 2005, MOL CELL, V17, P855, DOI 10.1016/j.molcel.2005.02.022
   Bae HS, 2017, J BONE MINER RES, V32, P951, DOI 10.1002/jbmr.3076
   Camilleri S, 2006, EUR J ORAL SCI, V114, P361, DOI 10.1111/j.1600 0722.2006.00399.x
   Cho YD, 2016, J CELL PHYSIOL, V231, P1484, DOI 10.1002/jcp.25183
   Damian DL, 2017, AUSTRALAS J DERMATOL, V58, P174, DOI 10.1111/ajd.12631
   Enomoto H, 2003, J BIOL CHEM, V278, P23971, DOI 10.1074/jbc.M302457200
   Farrow E, 2018, J CRANIOFAC SURG, V29, P382, DOI 10.1097/SCS.0000000000004200
   Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001
   Heinrich J, 2005, ARCH ORAL BIOL, V50, P897, DOI 10.1016/j.archoralbio.2005.02.007
   Ida Yonemochi H, 2002, J ORAL PATHOL MED, V31, P361, DOI 10.1034/j.1600 0714.2002.00087.x
   Islam R, 2018, J CELL PHYSIOL, V233, P9390, DOI 10.1002/jcp.26774
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Kim B, 2020, J DENT RES, V99, P223, DOI 10.1177/0022034519893656
   Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200
   Kim HJ, 2020, MOL CELLS, V43, P160, DOI 10.14348/molcells.2019.0247
   Kim WJ, 2020, EXP MOL MED, V52, P1178, DOI 10.1038/s12276 020 0471 4
   Kim WJ, 2011, J UROLOGY, V185, P2366, DOI 10.1016/j.juro.2011.02.017
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043
   Park SY, 2012, J CELL PHYSIOL, V227, P899, DOI 10.1002/jcp.22799
   Roberts T, 2013, OR SURG OR MED OR PA, V115, P46, DOI 10.1016/j.oooo.2012.07.435
   Rolfe HM, 2014, J COSMET DERMATOL US, V13, P324, DOI 10.1111/jocd.12119
   Shin HR, 2018, HUM MOL GENET, V27, P3827, DOI 10.1093/hmg/ddy252
   Tai PWL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188056
   Wang XZ, 2016, SCI REP UK, V6, DOI 10.1038/srep24225
   Wise GE, 2008, J DENT RES, V87, P414, DOI 10.1177/154405910808700509
   Wise GE, 2005, J DENT RES, V84, P837, DOI 10.1177/154405910508400911
   Wise GE, 2002, CRIT REV ORAL BIOL M, V13, P323, DOI 10.1177/154411130201300403
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 3 r52
   Yoda S, 2004, ARCH ORAL BIOL, V49, P435, DOI 10.1016/j.archoralbio.2004.01.010
NR 31
TC 7
Z9 10
U1 1
U2 17
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD APR
PY 2021
VL 100
IS 4
BP 423
EP 431
DI 10.1177/0022034520970471
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA RA6TV
UT WOS:000631550200011
PM 33143523
DA 2025 08 17
ER

PT J
AU Zhang, YY
   Zou, BH
   Tan, YH
   Su, JB
   Wang, YY
   Xu, JL
   Tao, L
   Zhou, H
   Liu, L
   Li, XJ
AF Zhang, Yueyang
   Zou, Binhua
   Tan, Yanhui
   Su, Jianbing
   Wang, Yiyuan
   Xu, Jialan
   Tao, Lei
   Zhou, Hua
   Liu, Liang
   Li, Xiaojuan
TI Sinomenine inhibits osteolysis in breast cancer by reducing IL 8/CXCR1
   and c Fos/NFATc1 signaling
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Sinomenine; Osteoclast; Breast cancer; IL 8; NFATc1; CXCR1
ID RANKL INDUCED OSTEOCLASTOGENESIS; INDUCED BONE LOSS; ZOLEDRONIC ACID;
   IN VITRO; INTERLEUKIN 8 LEVELS; OPEN LABEL; DIFFERENTIATION; METASTASIS;
   RESORPTION; DENOSUMAB
AB Sinomenine (SIN) is an anti inflammatory and antiarthritic alkaloid derived from Sinomenium acutum, and the product Zhengqing Fengtongning produced from SIN has been marketed in China for treating rheumatoid arthritis (RA). Interestingly, we recently found that SIN could significantly ameliorate bone destruction induced by breast cancer cells in mice. Micro CT examination showed that bone loss of the trabecular bones in tumor bearing mice was markedly decreased by i.p. treatment of SIN at 150 mg/kg body weight. A mechanistic study demonstrated that SIN could suppress osteoclast formation and bone absorption induced by both MDA MB 231 cells and MDA MB 231 cell conditioned medium (MDA MB 231 CM) in preosteoclastic RAW264.7 cells. The MDA MB 231 CM induced osteoclast related genes TRAP and OSCAR were obviously downregulated by SIN. In addition, mRNA expression of c Fos and NFATc1 and nuclear translocation of c Fos and NFATcl protein were inhibited by SIN during MDA MB 231 CM induced osteoclastogenesis, while NF kappa B signaling was not impacted by SIN. More interestingly, SIN was demonstrated to decrease hIL 8 mRNA expression in cultured MDA MB 231 cells and to inhibit hIL 8 protein expression in MDA MB 231 cells cocultured with preosteoclastic RAW264.7 cells while simultaneously downregulating CXCR1, the ligand of IL 8 related to bone destruction, during MDA MB 231 CM induced osteoclastogenesis. Previously, IL 8/CXCR1 was reported to be associated with the pathogenesis and progression of RA, and SIN was observed to markedly ameliorate bone erosion of RA patients. Our current findings may extend the utilization of SIN to preventing osteoclastogenesis and bone destruction in breast cancer patients and may enable IL 8/CXCR1 to serve as new targets for both anticancer and antiarthritic drug discovery.
C1 [Zhang, Yueyang; Zou, Binhua; Tan, Yanhui; Su, Jianbing; Wang, Yiyuan; Xu, Jialan; Tao, Lei; Li, Xiaojuan] Southern Med Univ, Sch Pharmaceut Sci, Lab Antiinflammatory & Immunomodulatory Pharmacol, Guangzhou 510515, Guangdong, Peoples R China.
   [Zhang, Yueyang; Zou, Binhua; Tan, Yanhui; Su, Jianbing; Wang, Yiyuan; Xu, Jialan; Tao, Lei; Li, Xiaojuan] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Guangdong, Peoples R China.
   [Zhou, Hua; Liu, Liang] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Ave Wai Long, Taipa, Macao, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Macau University of Science & Technology
RP Liu, L; Li, XJ (通讯作者)，Southern Med Univ, 1838 Guangzhou Ave North, Guangzhou 510515, Guangdong, Peoples R China.
EM lliu@must.edu.mo; lixiaoj@smu.edu.cn
RI Zhou, Hua/IQS 0555 2023; Zhou, Hua/E 7315 2010; 邹, 斌华/CAG 5540 2022;
   tao, lei/KHW 7900 2024
OI Zhou, Hua/0000 0002 7025 3690; Zou, Binhua/0000 0003 0731 1525; Li,
   Xiaojuan/0000 0002 2668 3044
FU National Natural Science Foundation of China [81773740, 81073119,
   81611130078]; Natural Science Foundation of Guangdong Province [2015
   A030313287]
FX This work was supported by the National Natural Science Foundation of
   China (81773740, 81073119, 81611130078), the Natural Science Foundation
   of Guangdong Province (2015 A030313287) to Xiao juan Li.
CR Adamopoulos IE, 2015, NAT REV RHEUMATOL, V11, P189, DOI 10.1038/nrrheum.2014.198
   Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brook N., 2018, INT J BIOCH CELL BIO
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Cheon YH, 2016, J BONE MINER RES, V31, P403, DOI 10.1002/jbmr.2612
   Clézardin P, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2835
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Finoti LS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006932
   Geng H, 2017, NANOSCALE, V9, P12516, DOI 10.1039/c7nr04365a
   He LG, 2014, ACTA PHARMACOL SIN, V35, P203, DOI 10.1038/aps.2013.139
   He LG, 2016, EUR J PHARMACOL, V779, P66, DOI 10.1016/j.ejphar.2016.03.014
   Herrero AB, 2016, AM J PATHOL, V186, P2171, DOI 10.1016/j.ajpath.2016.04.003
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Huang LF, 2017, PHARMACOL RES, V125, P150, DOI 10.1016/j.phrs.2017.08.014
   Iranikhah M, 2012, PHARMACOTHERAPY, V32, P274, DOI 10.1002/j.1875 9114.2011.01092.x
   Jiang SL, 2016, ONCOL LETT, V12, P1380, DOI 10.3892/ol.2016.4768
   Kamalakar A, 2014, BONE, V61, P176, DOI 10.1016/j.bone.2014.01.015
   Kaneko S, 2000, CYTOKINES CELL MOL T, V6, P71, DOI 10.1080/13684730050515796
   Krishnamurthy A, 2016, ANN RHEUM DIS, V75, P721, DOI 10.1136/annrheumdis 2015 208093
   Lau YS, 2007, BREAST CANCER RES TR, V105, P7, DOI 10.1007/s10549 006 9438 y
   Lee JY, 2017, NEUROSCIENCE, V358, P28, DOI 10.1016/j.neuroscience.2017.06.024
   Li XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074274
   Mancino AT, 2001, J SURG RES, V100, P18, DOI 10.1006/jsre.2001.6204
   Menshawy A, 2018, SUPPORT CARE CANCER, V26, P1029, DOI 10.1007/s00520 018 4060 1
   Nanki T, 2001, J IMMUNOL, V167, P5381, DOI 10.4049/jimmunol.167.9.5381
   Park JH, 2017, MOL CELLS, V40, P706
   Pederson L, 1999, CANCER RES, V59, P5849
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Rothe L, 1998, ENDOCRINOLOGY, V139, P4353, DOI 10.1210/en.139.10.4353
   Sabokbar A, 2016, CLIN REV ALLERG IMMU, V51, P16, DOI 10.1007/s12016 015 8523 6
   Shapiro CL, 2017, J CLIN ONCOL, V35, P3949, DOI 10.1200/JCO.2017.73.7437
   SIMONET WS, 1994, J CLIN INVEST, V94, P1310, DOI 10.1172/JCI117450
   Simos D, 2013, J CLIN MED, V2, P67, DOI 10.3390/jcm2030067
   Song LQ, 2015, BIOCHEM BIOPH RES CO, V464, P705, DOI 10.1016/j.bbrc.2015.07.004
   Sun Y, 2014, INT IMMUNOPHARMACOL, V18, P135, DOI 10.1016/j.intimp.2013.11.014
   Sun Yue, 2012, Zhongguo Zhong Xi Yi Jie He Za Zhi, V32, P1107
   Sung B, 2012, MOL CANCER THER, V11, P350, DOI 10.1158/1535 7163.MCT 11 0731
   Svejda B, 2016, WIEN MED WOCHENSCHR, V166, P68, DOI 10.1007/s10354 016 0437 2
   Tan EM, 2017, J BONE MINER RES, V32, P846, DOI 10.1002/jbmr.3031
   Taubenberger AV, 2014, ADV DRUG DELIVER REV, V79 80, P135, DOI 10.1016/j.addr.2014.10.014
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   van der Woude D, 2015, BEST PRACT RES CL RH, V29, P692, DOI 10.1016/j.berh.2016.02.006
   Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078 0432.CCR 07 4843
   Wei C.J., 2017, J ASIAN NAT PROD RES, P1
   Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91
   Westbrook JA, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djv360
   Wigerblad G, 2016, ANN RHEUM DIS, V75, P730, DOI 10.1136/annrheumdis 2015 208094
   Wright HL, 2009, CURR REV MUSCULOSKE, V2, P56, DOI 10.1007/s12178 009 9046 7
   Yan W, 2014, ACTA PHARMACOL SIN, V35, P124, DOI 10.1038/aps.2013.152
   Yoo JH, 2017, BIOMOL THER, V25, P586, DOI 10.4062/biomolther.2017.157
   Zeng XZ, 2017, BIOCHEM PHARMACOL, V124, P57, DOI 10.1016/j.bcp.2016.10.007
   Zhao B, 2017, BIOMED PHARMACOTHER, V96, P1036, DOI 10.1016/j.biopha.2017.11.123
   Zhou B, 2017, BIOMED PHARMACOTHER, V90, P835, DOI 10.1016/j.biopha.2017.03.084
   Zhou H, 2017, BIOCHEM PHARMACOL, V142, P133, DOI 10.1016/j.bcp.2017.07.010
   Zhu Q, 2014, SCI REP UK, V4, DOI 10.1038/srep07270
   Zhu X, 2016, BIOCHEM PHARMACOL, V104, P118, DOI 10.1016/j.bcp.2016.02.013
NR 60
TC 35
Z9 43
U1 3
U2 60
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD APR
PY 2019
VL 142
BP 140
EP 150
DI 10.1016/j.phrs.2019.02.015
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HT3TU
UT WOS:000464486900014
PM 30797069
DA 2025 08 17
ER

PT J
AU Silva, BC
   Cusano, NE
   Bilezikian, JP
AF Silva, Barbara C.
   Cusano, Natalie E.
   Bilezikian, John P.
TI Primary hyperparathyroidism
SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE primary hyperparathyroidism; normocalcemic primary; hyperparathyroidism;
   parathyroidectomy; vitamin D; bisphosphonates; calcimimetics
ID ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; BONE MINERAL DENSITY;
   NORMOCALCEMIC PRIMARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY;
   POSTMENOPAUSAL WOMEN; SURGICAL MANAGEMENT; PARATHYROID SURGERY;
   VERTEBRAL FRACTURES; ORAL ALENDRONATE; PREVALENCE
AB Primary hyperparathyroidism (PHPT), the most common cause of hypercalcemia, is most often identified in postmenopausal women with hypercalcemia and parathyroid hormone (PTH) levels that are either frankly elevated or inappropriately normal. The clinical presentation of PHPT includes three phenotypes: target organ involvement of the renal and skeletal systems; mild asymptomatic hypercalcemia; and more recently, high PTH levels in the context of persistently normal albumin corrected and ionized serum calcium values. The factors that determine which of these three clinical presentations is more likely to predominate in a given country include the extent to which biochemical screening is employed, the prevalence of vitamin D deficiency, and whether a medical center or practitioner tends to routinely measure PTH levels in the evaluation of low bone density or frank osteoporosis. When biochemical screening is common, asymptomatic primary hyperparathyroidism is the most likely form of the disease. In countries where vitamin D deficiency is prevalent and biochemical screening is not a feature of the health care system, symptomatic disease with skeletal abnormalities is likely to predominate. Finally, when PTH levels are part of the evaluation for low bone mass, the normocalcemic variant is seen. Guidelines for surgical removal of hyperfunctioning parathyroid tissue apply to all three clinical forms of the disease. If guidelines for surgery are not met, parathyroidectomy can also be an appropriate option if there are no medical contraindications to surgery. In settings where either the serum calcium or bone mineral density is of concern, and surgery is not an option, pharmacological approaches are available and effective. Referencing in this article the most current published articles, we review the different presentations of PHPT, with particular emphasis on recent advances in our understanding of target organ involvement and management. (c) 2018 Published by Elsevier Ltd.
C1 [Silva, Barbara C.] Felicio Rocho & Santa Casa Hosp, Div Endocrinol, Belo Horizonte, Brazil.
   [Cusano, Natalie E.] Lenox Hill Hosp, Div Endocrinol, New York, NY USA.
   [Bilezikian, John P.] Columbia Univ, Coll Phys & Surg, Div Endocrinol, New York, NY USA.
   [Bilezikian, John P.] Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.
C3 Northwell Health; Columbia University
RP Bilezikian, JP (通讯作者)，Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.
EM jpb2@columbia.edu
FU NIH [DK 32333]
FX This work was supported, in part, by NIH grant DK 32333.
CR Abood A, 2013, DAN MED J, V60
   Adami S, 2002, J BONE MINER RES, V17, pN18
   Amaral LM, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/128352
   Ambrogini E, 2007, J CLIN ENDOCR METAB, V92, P3114, DOI 10.1210/jc.2007 0219
   Bandeira Francisco, 2006, Arq Bras Endocrinol Metab, V50, P657, DOI 10.1590/S0004 27302006000400011
   Bandeira F, 2014, ARQ BRAS ENDOCRINOL, V58, P553
   Battista C, 2017, ENDOCRINE, V55, P275, DOI 10.1007/s12020 016 0974 x
   Bilezikian J.P., 2000, Endotext
   Bilezikian JP, 2018, LANCET, V391, P168, DOI 10.1016/S0140 6736(17)31430 7
   Bilezikian JP, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.33
   Bilezikian JP, 2014, J CLIN ENDOCR METAB, V99, P3561, DOI 10.1210/jc.2014 1413
   Bilezikian John P., 1994, P457
   Boehm BO, 2011, NEW ENGL J MED, V365, P676, DOI 10.1056/NEJMc1104982
   Bollerslev J, 2007, J CLIN ENDOCR METAB, V92, P1687, DOI 10.1210/jc.2006 1836
   Cassibba S, 2014, ENDOCR PRACT, V20, P1137, DOI 10.4158/EP14074.OR
   Castellano E, 2017, J CLIN ENDOCR METAB, V102, P4148, DOI 10.1210/jc.2017 01080
   Castellano E, 2016, J CLIN ENDOCR METAB, V101, P2728, DOI 10.1210/jc.2016 1513
   Cesareo R, 2015, OSTEOPOROSIS INT, V26, P1295, DOI 10.1007/s00198 014 3000 2
   Cetani F, 2012, J ENDOCRINOL INVEST, V35, P655, DOI 10.3275/7970
   Chow CC, 2003, J CLIN ENDOCR METAB, V88, P581, DOI 10.1210/jc.2002 020890
   Cipriani C, 2017, ENDOCRINE, V55, P591, DOI 10.1007/s12020 016 1101 8
   Cipriani C, 2015, J CLIN ENDOCR METAB, V100, P1309, DOI 10.1210/jc.2014 3708
   COHEN J, 1990, JAMA J AM MED ASSOC, V264, P581
   Collier A, 2017, ENDOCR RES, V42, P31, DOI 10.3109/07435800.2016.1169545
   Cusano NE, 2018, J CLIN ENDOCR METAB, V103, P196, DOI 10.1210/jc.2017 01932
   Cusano NE, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P331, DOI 10.1016/B978 0 12 397166 1.00022 9
   Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P2734, DOI 10.1210/jc.2013 1300
   Eastell R, 2014, J CLIN ENDOCR METAB, V99, P3570, DOI 10.1210/jc.2014 1414
   Eufrazino C, 2013, CLIN MED INSIGHTS EN, V6, P69, DOI [10.4137/CMED.S13147, 10.4137/CMEDED.S13147]
   Faggiano A, 2011, ENDOCRINE, V39, P283, DOI 10.1007/s12020 011 9459 0
   García Martín A, 2012, ENDOCRINE, V42, P764, DOI 10.1007/s12020 012 9694 z
   Griebeler ML, 2016, J CLIN ENDOCR METAB, V101, P1166, DOI 10.1210/jc.2015 3964
   Hansen S, 2012, J BONE MINER RES, V27, P1150, DOI 10.1002/jbmr.1540
   Hansen S, 2010, J BONE MINER RES, V25, P1941, DOI 10.1002/jbmr.98
   Keutgen XM, 2012, ANN SURG, V255, P981, DOI 10.1097/SLA.0b013e31824c5252
   Khan AA, 2017, OSTEOPOROSIS INT, V28, P1, DOI 10.1007/s00198 016 3716 2
   Khan AA, 2004, J CLIN ENDOCR METAB, V89, P3319, DOI 10.1210/jc.2003 030908
   Khan AA, 2009, ENDOCR PRACT, V15, P705, DOI 10.4158/EP08178.ORR
   Khosla S, 1999, J BONE MINER RES, V14, P1700, DOI 10.1359/jbmr.1999.14.10.1700
   Kontogeorgos G, 2015, CLIN ENDOCRINOL, V83, P277, DOI 10.1111/cen.12819
   Koumakis E, 2014, OSTEOPOROSIS INT, V25, P1963, DOI 10.1007/s00198 014 2689 2
   Koumakis E, 2013, J CLIN ENDOCR METAB, V98, P3213, DOI 10.1210/jc.2013 1518
   Lavryk OA, 2017, WORLD J SURG, V41, P122, DOI 10.1007/s00268 016 3716 6
   Lee JH, 2017, OSTEOPOROSIS INT, V28, P1667, DOI 10.1007/s00198 017 3918 2
   Lee PK, 2007, CANCER AM CANCER SOC, V109, P1736, DOI 10.1002/cncr.22599
   Liu JM, 2013, BONE RES, V1, DOI 10.4248/BR201302005
   Lowe H, 2007, J CLIN ENDOCR METAB, V92, P3001, DOI 10.1210/jc.2006 2802
   Lundstam K, 2017, J BONE MINER RES, V32, P1907, DOI 10.1002/jbmr.3177
   Luque Fernández I, 2013, THER ADV ENDOCRINOL, V4, P77, DOI 10.1177/2042018813482344
   Marcocci C, 2014, J CLIN ENDOCR METAB, V99, P3607, DOI 10.1210/jc.2014 1417
   Marques TF, 2011, ARQ BRAS ENDOCRINOL, V55, P314, DOI 10.1590/S0004 27302011000500003
   Maruani G, 2003, J CLIN ENDOCR METAB, V88, P4641, DOI 10.1210/jc.2002 021404
   Misiorowski W, 2017, ENDOCRINE, V58, P380, DOI 10.1007/s12020 017 1414 2
   Nevo Shor A, 2016, BONE, V89, P59, DOI 10.1016/j.bone.2016.05.012
   Ospina NS, 2016, OSTEOPOROSIS INT, V27, P3395, DOI 10.1007/s00198 016 3715 3
   Paik JM, 2012, BMJ BRIT MED J, V345, DOI 10.1136/bmj.e6390
   Pardi E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186485
   Parker CR, 2002, J CLIN ENDOCR METAB, V87, P4482, DOI 10.1210/jc.2001 010385
   Pawlowska M, 2015, CURR OPIN ENDOCRINOL, V22, P413, DOI 10.1097/MED.0000000000000198
   Peacock M, 2005, J CLIN ENDOCR METAB, V90, P135, DOI 10.1210/jc.2004 0842
   Peacock M, 2009, J CLIN ENDOCR METAB, V94, P4860, DOI 10.1210/jc.2009 1472
   Piketty ML, 2017, CLIN CHEM LAB MED, V55, P817, DOI 10.1515/cclm 2016 1183
   Pradeep PV, 2011, INT J ENDOCRINOL, V2011, DOI 10.1155/2011/921814
   Prasarttong Osoth P, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/952426
   Press DM, 2013, SURGERY, V154, P1232, DOI 10.1016/j.surg.2013.06.051
   Rao DS, 2004, J CLIN ENDOCR METAB, V89, P5415, DOI 10.1210/jc.2004 0028
   Rolighed L, 2014, J CLIN ENDOCR METAB, V99, P1072, DOI 10.1210/jc.2013 3978
   Rosário PW, 2017, WORLD J SURG, V41, P1649, DOI 10.1007/s00268 017 3888 8
   Rosen CJ, 2011, J CLIN DENSITOM, V14, P79, DOI 10.1016/j.jocd.2011.03.004
   Rossini M, 2001, J BONE MINER RES, V16, P113, DOI 10.1359/jbmr.2001.16.1.113
   Rubin MR, 2008, J CLIN ENDOCR METAB, V93, P3462, DOI 10.1210/jc.2007 1215
   Silva BC, 2013, J CLIN ENDOCR METAB, V98, P1963, DOI 10.1210/jc.2012 4255
   Silverberg SJ, 2014, J CLIN ENDOCR METAB, V99, P3580, DOI 10.1210/jc.2014 1415
   SILVERBERG SJ, 1989, J BONE MINER RES, V4, P283, DOI 10.1002/jbmr.5650040302
   Spivacow FR, 2010, MEDICINA BUENOS AIRE, V70, P408
   Stein EM, 2013, J BONE MINER RES, V28, P1029, DOI 10.1002/jbmr.1841
   Stephen AE, 2017, JAMA SURG, V152, P878, DOI 10.1001/jamasurg.2017.1721
   Stokes VJ, 2017, J BONE MINER RES, V32, P2157, DOI 10.1002/jbmr.3296
   Sun B, 2018, OSTEOPOROSIS INT, V29, P635, DOI 10.1007/s00198 017 4322 7
   Szalat A, 2009, EUR J ENDOCRINOL, V160, P317, DOI 10.1530/EJE 08 0620
   Thakker RV, 2016, J INTERN MED, V280, P574, DOI 10.1111/joim.12523
   Thomas MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201
   Tordjman KN, 2004, AM J MED, V117, P861, DOI 10.1016/j.amjmed.2004.06.037
   Tournis S, 2014, J BONE MINER METAB, V32, P151, DOI 10.1007/s00774 013 0473 6
   Tuna MM, 2016, J BONE MINER METAB, V34, P331, DOI 10.1007/s00774 015 0673 3
   TURKEN SA, 1989, AM J MED, V87, P553
   Udelsman R, 2014, J CLIN ENDOCR METAB, V99, P3595, DOI 10.1210/jc.2014 2000
   Vaidya A, 2017, J BONE MINER RES, V32, P1900, DOI 10.1002/jbmr.3168
   Vaidya A, 2016, J CLIN ENDOCR METAB, V101, P1590, DOI 10.1210/jc.2015 3836
   Vaidya A, 2015, J CLIN ENDOCR METAB, V100, P2396, DOI 10.1210/jc.2015 1619
   Verdelli C, 2017, EUR J ENDOCRINOL, V176, pR39, DOI 10.1530/EJE 16 0430
   Vestergaard P, 2004, J INTERN MED, V255, P108, DOI 10.1046/j.0954 6820.2003.01237.x
   Vignali E, 2015, ENDOCR CONNECT, V4, P172, DOI 10.1530/EC 15 0030
   Vignali E, 2009, J CLIN ENDOCR METAB, V94, P2306, DOI 10.1210/jc.2008 2006
   Vu TDT, 2013, BONE, V55, P57, DOI 10.1016/j.bone.2013.03.009
   Walker MD, 2016, OSTEOPOROSIS INT, V27, P3063, DOI 10.1007/s00198 016 3637 0
   Walker MD, 2015, OSTEOPOROSIS INT, V26, P2837, DOI 10.1007/s00198 015 3199 6
   Walker MD, 2017, ENDOCRINE, V55, P3, DOI 10.1007/s12020 016 1169 1
   Walker MD, 2016, J CLIN ENDOCR METAB, V101, P905, DOI 10.1210/jc.2015 4218
   Walker MD, 2009, J CLIN ENDOCR METAB, V94, P1951, DOI 10.1210/jc.2008 2574
   Walker MD, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P469, DOI 10.1016/B978 0 12 397166 1.00032 1
   Wermers RA, 2015, PARATHYROIDS: BASIC AND CLINICAL CONCEPTS, 3RD EDITION, P297, DOI 10.1016/B978 0 12 397166 1.00019 9
   Wilhelm SM, 2016, JAMA SURG, V151, P959, DOI 10.1001/jamasurg.2016.2310
   Yeh MW, 2016, ANN INTERN MED, V164, P715, DOI 10.7326/M15 1232
   Yeh MW, 2013, J CLIN ENDOCR METAB, V98, P1122, DOI 10.1210/jc.2012 4022
   Yu N, 2009, CLIN ENDOCRINOL, V71, P485, DOI 10.1111/j.1365 2265.2008.03520.x
NR 106
TC 23
Z9 23
U1 6
U2 20
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1521 690X
EI 1532 1908
J9 BEST PRACT RES CL EN
JI Best Pract. Res. Clin. Endoc. Metab.
PD JAN
PY 2024
VL 38
IS 1
AR 101247
DI 10.1016/j.beem.2018.09.013
EA JAN 2024
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IM9T9
UT WOS:001166869000001
PM 30477754
DA 2025 08 17
ER

PT J
AU Cho, E
   Chen, Z
   Ding, M
   Seong, J
   Lee, S
   Min, SH
   Choi, DK
   Lee, TH
AF Cho, Eunjin
   Chen, Zhihao
   Ding, Mina
   Seong, Jihyoun
   Lee, Sunwoo
   Min, Sang Hyun
   Choi, Dong Kyu
   Lee, Tae Hoon
TI PMSA prevents osteoclastogenesis and estrogen dependent bone loss in
   mice
SO BONE
LA English
DT Article
DE N phenyl methylsulfonamido acetamide (PMSA); Osteoporosis; Osteoclast;
   Nuclear factor of activated T cell cytoplasmic 1 (NFATc1); Bone
   resorption; Ovariectomized (OVX) mouse
ID DIFFERENTIATION; RESORPTION; RANK
AB Excessive bone resorption mediated by mature osteoclasts can cause osteoporosis, leading to fragility fractures. Therefore, an effective therapeutic strategy for anti osteoporosis drugs is the reduction of osteoclast activity. In this study, the osteoclast inhibitory activity of a novel compound, N phenyl methylsulfonamido acetamide (PMSA), was examined. PMSA treatment inhibited receptor activator of nuclear factor kappa B ligand (RNAKL) induced osteoclast differentiation in bone marrow derived macrophage cells (BMMs). We investigated two PMSAs, N 2 (3 acetylphenyl) N 2 (methylsulfonyl) N 1 [2 (phenylthio)phenyl] glycinamide (PMSA 3 Ac), and N 2 (5 chloro 2 methoxyphenyl) N 2 (methylsulfonyl) N 1 [2 (phenylthio)phenyl]glycinamide (PMSA 5 Cl), to determine their effects on osteoclast differentiation. PMSAs inhibited the signaling pathways at the early stage. PMSA 3 Ac inhibited tumor necrosis factor receptor associated factor 6 (TRAF6) expression, whereas PMSA 5 Cl suppressed the mitogen activated protein kinase (MAPK) signaling pathways. However, both PMSAs inhibited the master transcription factor, nuclear factor of activated T cell cytoplasmic 1 (NFATc1), by blocking nuclear localization. An in vivo study of PMSAs was performed in an ovariectomized (OVX) mouse model, and PMSA 5 Cl prevented bone loss in OVX mice. Therefore, our results suggested that PMSAs, specifically PMSA 5 Cl, may serve as a potential therapeutic agent for postmenopausal osteoporosis.
C1 [Cho, Eunjin; Seong, Jihyoun; Lee, Tae Hoon] Chonnam Natl Univ, Dent Sci Res Inst, Sch Dent, Dept Oral Biochem, Gwangju 61186, South Korea.
   [Chen, Zhihao; Ding, Mina; Lee, Tae Hoon] Chonnam Natl Univ, Dept Mol Med BK21plus, Grad Sch, Gwangju 61186, South Korea.
   [Lee, Sunwoo] Chonnam Natl Univ, Dept Chem, Gwangju 61186, South Korea.
   [Min, Sang Hyun; Choi, Dong Kyu] DGMIF, New Drug Dev Ctr, 80 Chumbok Ro, Daegu 41061, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University
RP Lee, TH (通讯作者)，Chonnam Natl Univ, Dent Sci Res Inst, Sch Dent, Dept Oral Biochem, Gwangju 61186, South Korea.
EM sunwoo@chonnam.ac.kr; shmin03@dgmif.re.kr; donkyu@dgmif.re.kr;
   thlee83@jnu.ac.kr
RI Choi, dongKyu/LKL 2959 2024; Lee, Tae Hoon/AAR 3708 2021; Lee,
   Jae Won/HJP 9840 2023
OI Ding, Mina/0000 0002 7114 738X; Lee, Tae Hoon/0000 0003 0105 1750
FU Bio & Medical Technology Development Program of the National Research
   Foundation (NRF)   Ministry of Science, ICT and Future Planning,
   Republic of Korea [NRF 2016M3A9B6903087]
FX This work was supported by the Bio & Medical Technology Development
   Program of the National Research Foundation (NRF) funded by the Ministry
   of Science, ICT and Future Planning, Republic of Korea
   (NRF 2016M3A9B6903087). We thank KBSI for micro CT measurement.
CR Ahn SH, 2018, MOLECULES, V23, DOI 10.3390/molecules23123139
   Cao C, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03040
   Cho E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113436
   Cho E, 2019, MOLECULES, V24, DOI 10.3390/molecules24183346
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092 8674(00)00126 4
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Guan HF, 2015, CELL SIGNAL, V27, P969, DOI 10.1016/j.cellsig.2015.02.006
   Huynh H, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003 018 0028 4
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Ko FC, 2017, J BONE MINER RES, V32, P814, DOI 10.1002/jbmr.3052
   Kwon TK, 2019, MATERIALS, V12, DOI 10.3390/ma12071187
   Lin FT, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2015.48
   Lomaga M.A., 1999, GENES DEV, V13
   Lopes D, 2018, BIOMATERIALS, V185, P240, DOI 10.1016/j.biomaterials.2018.09.028
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Panda S, 2015, IMMUNITY, V43, P647, DOI 10.1016/j.immuni.2015.09.010
   Park JH, 2017, MOL CELLS, V40, P706
   Pereira M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216267
   Russo R, 2019, CELLS BASEL, V8, DOI 10.3390/cells8020131
   Shin B, 2020, J BONE MINER RES, V35, P130, DOI 10.1002/jbmr.3861
   Simon D, 2017, BONE, V105, P35, DOI 10.1016/j.bone.2017.08.013
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tomomura M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130174
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Weivoda MM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14003 6
   Zhang HW, 2013, J BIOL CHEM, V288, P22359, DOI 10.1074/jbc.M112.442459
   Zhang WJ, 2019, LIFE SCI, V235, DOI 10.1016/j.lfs.2019.116820
   Zhao T, 2016, J CELL BIOCHEM, V117, P2138, DOI 10.1002/jcb.25520
NR 31
TC 13
Z9 14
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2021
VL 142
AR 115707
DI 10.1016/j.bone.2020.115707
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PI8LQ
UT WOS:000601336000003
PM 33141068
DA 2025 08 17
ER

PT J
AU Kim, BS
   Kang, HJ
   Park, JY
   Lee, J
AF Kim, Beom Su
   Kang, Hyo Jin
   Park, Ji Yun
   Lee, Jun
TI Fucoidan promotes osteoblast differentiation via JNK  and ERK dependent
   BMP2 Smad 1/5/8 signaling in human mesenchymal stem cells
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID P38 MAP KINASE; BROWN SEAWEED; OSTEOGENIC DIFFERENTIATION; GROWTH;
   OSTEOCALCIN; ACTIVATION; PATHWAYS; HEPARAN; RUNX2
AB Fucoidan has attracted attention as a potential drug because of its biological activities, which include osteogenesis. However, the molecular mechanisms involved in the osteogenic activity of fucoidan in human alveolar bone marrow derived mesenchymal stem cells (hABM MSCs) remain largely unknown. We investigated the action of fucoidan on osteoblast differentiation in hABM MSCs and its impact on signaling pathways. Its effect on proliferation was determined using the crystal violet staining assay. Osteoblast differentiation was evaluated based on alkaline phosphatase (ALP) activity and the mRNA expression of multiple osteoblast markers. Calcium accumulation was determined by Alizarin red S staining. We found that fucoidan induced hABM MSC proliferation. It also significantly increased ALP activity, calcium accumulation and the expression of osteoblast specific genes, such as ALP, runt related transcription factor 2, type I collagen a 1 and osteocalcin. Moreover, fucoidan induced the expression of bone morphogenetic protein 2 (BMP2) and stimulated the activation of extracellular signal related kinase (ERK), c Jun N terminal kinase (JNK) and p38 mitogen activated protein kinase by increasing phosphorylation. However, the effect of fucoidan on osteogenic differentiation was inhibited by specific inhibitors of ERK (PD98059) and JNK (SP600125) but not p38 (SB203580). Fucoidan enhanced BMP2 expression and Smad 1/5/8, ERK and JNK phosphorylation. Moreover, the effect of fucoidan on osteoblast differentiation was diminished by BMP2 knockdown. These results indicate that fucoidan induces osteoblast differentiation through BMP2 Smad 1/5/8 signaling by activating ERK and JNK, elucidating the molecular basis of the osteogenic effects of fucoidan in hABM MSCs.
C1 [Kim, Beom Su; Kang, Hyo Jin; Lee, Jun] Wonkwang Univ, Wonkwang Bone Regenerat Res Inst, Iksan 570749, South Korea.
   [Kim, Beom Su; Park, Ji Yun; Lee, Jun] Bonecell Biotech Inc, Dept Res & Dev, Taejon, South Korea.
C3 Wonkwang University
RP Lee, J (通讯作者)，Wonkwang Univ, Wonkwang Bone Regenerat Res Inst, Iksan 570749, South Korea.
EM omslee@wku.ac.kr
OI Kim, Beom Su/0000 0001 6562 4373
FU Basic Science Research Program through National Research Foundation of
   Korea (NRF)   Ministry of Education, Science and Technology
   [NRF 2012R1A1A2040526]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, Science and Technology (NRF 2012R1A1A2040526).
CR ANGSTWURM K, 1995, NEUROSCI LETT, V191, P1, DOI 10.1016/0304 3940(95)11541 4
   Bilan MI, 2002, CARBOHYD RES, V337, P719, DOI 10.1016/S0008 6215(02)00053 8
   Boo HJ, 2011, PHYTOTHER RES, V25, P1082, DOI 10.1002/ptr.3489
   Changotade SIT, 2008, J BIOMED MATER RES A, V87A, P666, DOI 10.1002/jbm.a.31819
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chizhov AO, 1999, CARBOHYD RES, V320, P108, DOI 10.1016/S0008 6215(99)00148 2
   Cho YS, 2009, FOOD CHEM, V116, P990, DOI 10.1016/j.foodchem.2009.03.051
   Epker B N, 1968, Parodontol Acad Rev, V2, P125
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Fukahori S, 2008, MOL MED REP, V1, P537
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Giraux JL, 1998, EUR J CELL BIOL, V77, P352, DOI 10.1016/S0171 9335(98)80094 0
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Hata K, 2007, J BIOMED MATER RES A, V81A, P446, DOI 10.1002/jbm.a.31086
   HOSODA K, 1993, J BONE MINER RES, V8, P553
   Hughes FJ, 2006, PERIODONTOL 2000, V41, P48, DOI 10.1111/j.1600 0757.2006.00161.x
   Jang HO, 2007, NAT PROD RES, V21, P787, DOI 10.1080/14786410601133475
   Jiao XY, 2007, J BIOL CHEM, V282, P1080, DOI 10.1074/jbc.M513414200
   Kakita A, 2004, PROSTAG LEUKOTR ESS, V70, P469, DOI 10.1016/j.plefa.2003.09.003
   Kim BS, 2013, J BIOMED MATER RES A, V101, P1550, DOI 10.1002/jbm.a.34456
   Kim BS, 2011, BIOSCI BIOTECH BIOCH, V75, P13, DOI 10.1271/bbb.100379
   Kondo A, 2014, LIFE SCI, V96, P18, DOI 10.1016/j.lfs.2013.12.017
   Kook SH, 2014, J PERIODONTOL, V85, P645, DOI 10.1902/jop.2013.130252
   Manton KJ, 2007, STEM CELLS, V25, P2845, DOI 10.1634/stemcells.2007 0065
   Mourao PAS, 2004, CURR PHARM DESIGN, V10, P967, DOI 10.2174/1381612043452730
   Nagamine T, 2009, NUTR CANCER, V61, P340, DOI 10.1080/01635580802567133
   Panetta NJ, 2010, CURR STEM CELL RES T, V5, P122
   Park SJ, 2012, STEM CELLS DEV, V21, P2204, DOI 10.1089/scd.2011.0521
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036
   Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177
   Wang XY, 2011, J BONE MINER RES, V26, P1964, DOI 10.1002/jbmr.394
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Yasuda E, 2005, BIOCHEM BIOPH RES CO, V328, P137, DOI 10.1016/j.bbrc.2004.12.163
   Yu SF, 2013, J BONE MINER METAB, V31, P351, DOI 10.1007/s00774 013 0424 2
NR 35
TC 129
Z9 135
U1 3
U2 39
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD JAN
PY 2015
VL 47
AR e128
DI 10.1038/emm.2014.95
PG 9
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA CN7CQ
UT WOS:000358591800001
PM 25572360
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chen, ZG
   Xue, JQ
   Shen, T
   Ba, G
   Yu, DD
   Fu, Q
AF Chen, Zhiguang
   Xue, Jinqi
   Shen, Tao
   Ba, Gen
   Yu, Dongdong
   Fu, Qin
TI Curcumin alleviates glucocorticoid induced osteoporosis by protecting
   osteoblasts from apoptosis invivo and invitro
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article
DE apoptosis; curcumin; extracellular signal regulated kinase (ERK);
   glucocorticoid induced osteoporosis (GIO); osteoblast
ID INDUCED BONE LOSS; OVARIECTOMIZED RAT; VERTEBRAL FRACTURE; MINERAL
   DENSITY; FEMALE MICE; CELL DEATH; KAPPA B; OSTEOCYTES; THERAPY;
   OSTEOCLASTOGENESIS
AB Curcumin, an active component of the rhizomes of Curcumin longa L., possesses broad anti inflammation and anti cancer properties. Curcumin was previously reported to be capable of protecting ovariectomized rats against osteoporosis. However, the effect of curcumin on glucocorticoid induced osteoporosis (GIO) is not yet clear. The present study investigated the effects of curcumin on dexamethasone (Dex) induced osteoporosis invivo and Dex induced osteoblast apoptosis invivo and invitro. The GIO rat model was induced by subcutaneous injection of Dex for 60days and verified to be successful as evidenced by the significantly decreased bone mineral density (BMD) determined using dual X ray absorptiometry. Subsequently, curcumin administration (100mg/kg) for 60days obviously increased BMD and bone alkaline phosphatase, decreased carboxy terminal collagen cross links, enhanced bone mechanical strength, and improved trabecular microstructure, thereby alleviating Dex induced osteoporosis. Mechanically, curcumin remarkably reversed Dex induced femoral osteoblast apoptosis invivo. In cultured primary osteoblasts, pretreatment with curcumin concentration dependently decreased the number of Dex induced apoptotic osteoblasts by down regulating the ratio of Bax/Bcl 2 as well as the levels of cleaved caspase 3 and cleaved poly ADP ribose polymerase (PARP). Moreover, curcumin pretreatment activated extracellular signal regulated kinase (ERK) signalling in Dex induced osteoblasts by up regulating the expression level of p ERK1/2. Taken together, our study demonstrated that curcumin could ameliorate GIO by protecting osteoblasts from apoptosis, which was possibly related to the activation of the ERK pathway. The results suggest that curcumin may be a promising drug for prevention and treatment of GIO.
C1 [Chen, Zhiguang; Shen, Tao; Ba, Gen; Yu, Dongdong; Fu, Qin] China Med Univ, Shengjing Hosp, Dept Spine & Joint Surg, 36 Sanhao St, Shenyang 110004, Peoples R China.
   [Xue, Jinqi] China Med Univ, Shengjing Hosp, Dept Gen Surg 7, Shenyang 110001, Peoples R China.
C3 China Medical University; China Medical University
RP Fu, Q (通讯作者)，China Med Univ, Shengjing Hosp, Dept Spine & Joint Surg, 36 Sanhao St, Shenyang 110004, Peoples R China.
EM fuq_cmu_sjhospital@163.com
OI Chen, Zhiguang/0009 0005 9674 4796
FU National Nature Science Foundation of China [81370981, 31201053];
   Outstanding Scientific Fund of Shengjing Hospital
FX This study was supported by grants from the National Nature Science
   Foundation of China (No.: 81370981 and No.: 31201053) and Outstanding
   Scientific Fund of Shengjing Hospital.
CR Aktas C, 2012, TOXICOL IND HEALTH, V28, P122, DOI 10.1177/0748233711407242
   Angeli A, 2006, BONE, V39, P253, DOI 10.1016/j.bone.2006.02.005
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Bivik CA, 2006, J INVEST DERMATOL, V126, P1119, DOI 10.1038/sj.jid.5700124
   Cho DC, 2013, J KOREAN NEUROSURG S, V54, P461, DOI 10.3340/jkns.2013.54.6.461
   Cho DC, 2012, ACTA NEUROCHIR, V154, P2215, DOI 10.1007/s00701 012 1516 9
   Conradie MM, 2007, J ENDOCRINOL, V195, P229, DOI 10.1677/JOE 07 0217
   Danial NN, 2007, CLIN CANCER RES, V13, P7254, DOI 10.1158/1078 0432.CCR 07 1598
   de Vries F, 2007, J INTERN MED, V261, P170, DOI 10.1111/j.1365 2796.2006.01754.x
   Feng RJ, 2013, CELL BIOCHEM BIOPHYS, V67, P189, DOI 10.1007/s12013 013 9533 8
   French DL, 2008, PHYTOMEDICINE, V15, P1069, DOI 10.1016/j.phymed.2008.06.007
   Frenkel B, 2015, ADV EXP MED BIOL, V872, P179, DOI 10.1007/978 1 4939 2895 8_8
   Giusti A, 2010, BONE, V47, P169, DOI 10.1016/j.bone.2010.05.019
   Green DR, 2006, CANCER CELL, V9, P328, DOI 10.1016/j.ccr.2006.05.004
   Gu G, 2005, APOPTOSIS, V10, P583, DOI 10.1007/s10495 005 1893 0
   Guañabens N, 2014, CURR OSTEOPOROS REP, V12, P90, DOI 10.1007/s11914 014 0197 0
   Hartojo W, 2010, TRANSL ONCOL, V3, P99, DOI 10.1593/tlo.09235
   Hussan F, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/174916
   Kaji H, 2006, ENDOCR J, V53, P27, DOI 10.1507/endocrj.53.27
   Kim WK, 2011, J CELL BIOCHEM, V112, P3159, DOI 10.1002/jcb.23242
   Lane NE, 1998, ENDOCRIN METAB CLIN, V27, P465, DOI 10.1016/S0889 8529(05)70017 7
   Li G, 2013, WORLD J GASTROENTERO, V19, P7440, DOI 10.3748/wjg.v19.i42.7440
   Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242
   LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169 6009(91)90139 Q
   Mawani Y, 2014, J INORG BIOCHEM, V132, P52, DOI 10.1016/j.jinorgbio.2013.12.004
   Moon HJ, 2012, BIOCHEM BIOPH RES CO, V418, P247, DOI 10.1016/j.bbrc.2012.01.005
   Moriishi Takeshi, 2014, Clin Calcium, V24, P1329, DOI CliCa140913291336
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Ozaki K, 2000, BIOCHEM PHARMACOL, V59, P1577, DOI 10.1016/S0006 2952(00)00277 X
   Pantschenko AG, 2005, J BONE MINER RES, V20, P1414, DOI 10.1359/JBMR.050315
   Rippo MR, 2010, INT J IMMUNOPATH PH, V23, P1153, DOI 10.1177/039463201002300419
   Sato AY, 2015, BONE, V73, P60, DOI 10.1016/j.bone.2014.12.012
   Subramaniam D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030590
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   von Metzler I, 2009, J CANCER RES CLIN, V135, P173, DOI 10.1007/s00432 008 0461 8
   Wang FS, 2011, BONE, V49, P1080, DOI 10.1016/j.bone.2011.08.006
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Xu MX, 2013, INT J ONCOL, V43, P1951, DOI 10.3892/ijo.2013.2107
   Yang MW, 2011, PHYTOMEDICINE, V18, P205, DOI 10.1016/j.phymed.2010.05.011
   Zhang L, 2012, BEHAV BRAIN RES, V235, P67, DOI 10.1016/j.bbr.2012.07.019
   Zheng KM, 2015, ACTA PHARMACOL SIN, V36, P544, DOI 10.1038/aps.2014.166
   Zhou T, 2013, ACTA ODONTOL SCAND, V71, P349, DOI 10.3109/00016357.2012.682092
NR 44
TC 58
Z9 66
U1 1
U2 30
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1440 1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD FEB
PY 2016
VL 43
IS 2
BP 268
EP 276
DI 10.1111/1440 1681.12513
PG 9
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA DC6CN
UT WOS:000369307500016
PM 26515751
OA Bronze
DA 2025 08 17
ER

PT J
AU Yang, XW
   Lai, Q
   Guo, JC
   Yang, XM
   Zhu, WF
   Zhou, S
   Liu, MY
   Zhang, XY
   Zhang, B
   Wei, Y
AF Yang, Xiaowei
   Lai, Qi
   Guo, Jingchong
   Yang, Xinmin
   Zhu, Weifeng
   Zhou, Song
   Liu, Meiying
   Zhang, Xiaoyong
   Zhang, Bin
   Wei, Yen
TI Facile fabrication of phosphazene quercetin alendronate composites as
   pH responsive bone targeted nanomedicine for osteoporosis treatment
SO MATERIALS & DESIGN
LA English
DT Article
DE Osteoporosis treatment; Bone targeted nanomedicine; Quercetin;
   Alendronate; Hexachlorocyclotriphosphazene
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC
   DIFFERENTIATION; NANOPARTICLES; DELIVERY; ACID; MSC
AB Osteoporosis, closely related to age, is characterized by impaired bone mass and bone strength, damage of bone microstructure, resulting in a higher risk of fractures with minimal trauma, especially in the hip and spine. Quercetin (Que), a natural compound, has previously demonstrated its potential anti osteoporosis effects via promoting bone formation and anti bone resorption. However, Que is poor water solubility, lack of bone targeting, and requires high concentration to exert its therapeutic effects. In this work, a pH responsive and bonetargeted nanomedicine HCCP Que PEG ALN (HQPA) was developed via using hexachlorocyclotriphosphazene (HCCP) as the cross linkage, Que, alendronate (ALN), and amino polyethylene glycol (NH2 PEG) as other building blocks. We demonstrated that HQPA can form spherical nanoparticles in aqueous solution with average size of 158.3 +/  59.8 nm with high drug loading capacity of Que (31.4 w/w%) and obvious bone targeting capability. in vitro experimental results indicated that HQPA NPs have dual anti osteoporosis effects of promoting osteoblasts and inhibiting osteoclasts. Furthermore, HQPA NPs can effectively reduce the bone loss in OVX mice with low toxicity to major organs. We believe that this method should be a general and useful route for fabrication of bone targeted natural compounds based nanomedicines for treatment different bone related diseases.
C1 [Yang, Xiaowei; Lai, Qi; Guo, Jingchong; Yang, Xinmin; Zhou, Song; Zhang, Bin] Nanchang Univ, Orthopaed Hosp, Affiliated Hosp 1, Jiangxi Med Coll,Dept Sports Med, 17 Yong Wai Zheng St, Nanchang 330006, Jiangxi, Peoples R China.
   [Zhu, Weifeng; Liu, Meiying] Jiangxi Univ Tradit Chinese Med, Key Lab Modern Chinese Med Preparat, Minist Educ, Nanchang 330004, Jiangxi, Peoples R China.
   [Yang, Xiaowei; Guo, Jingchong; Zhang, Xiaoyong] Nanchang Univ, Dept Chem, 999 Xuefu Ave, Nanchang 330031, Peoples R China.
   [Wei, Yen] Tsinghua Univ, Dept Chem, Beijing 100084, Peoples R China.
   [Wei, Yen] Tsinghua Univ, Tsinghua Ctr Frontier Polymer Res, Beijing 100084, Peoples R China.
C3 Nanchang University; Jiangxi University of Traditional Chinese Medicine;
   Nanchang University; Tsinghua University; Tsinghua University
RP Zhang, B (通讯作者)，Nanchang Univ, Orthopaed Hosp, Affiliated Hosp 1, Jiangxi Med Coll,Dept Sports Med, 17 Yong Wai Zheng St, Nanchang 330006, Jiangxi, Peoples R China.; Liu, MY (通讯作者)，Jiangxi Univ Tradit Chinese Med, Key Lab Modern Chinese Med Preparat, Minist Educ, Nanchang 330004, Jiangxi, Peoples R China.; Zhang, XY (通讯作者)，Nanchang Univ, Dept Chem, 999 Xuefu Ave, Nanchang 330031, Peoples R China.
EM lmy5305@iccas.ac.cn; zhangxiaoyong@ncu.edu.cn; yxwzb11@126.com
RI liu, meiying/H 7762 2013; zhang, xiaoyong/ABD 5797 2021; yang,
   xiaowei/AAI 7847 2020; Wei, Yen/H 5329 2012
FU National Natural Science oundation of China [81860405, 218650165,
   21788102, 21967016, 22261035, 22265019]; Natural Science Foundation
FX This research was supported by the National Natural Science oundation of
   China (Nos. 81860405, 218650165, 21788102, 21967016, 22261035, 22265019)
   and Natural Science Foundation of Jiangxi lo.
CR AbuMoussa S, 2018, J ORTHOP RES, V36, P3294, DOI 10.1002/jor.24125
   Agirrezabal I, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115125
   Akal ZÜ, 2016, CERAM INT, V42, P9065, DOI 10.1016/j.ceramint.2016.02.166
   Aleidi SM, 2021, METABOLITES, V11, DOI 10.3390/metabo11090628
   AlQranei MS, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 59363 y
   Aytac Z, 2016, FOOD CHEM, V197, P864, DOI 10.1016/j.foodchem.2015.11.051
   Casado Díaz A, 2016, J NUTR BIOCHEM, V32, P151, DOI 10.1016/j.jnutbio.2016.03.005
   Genazzani AR, 2021, HUM REPROD UPDATE, V27, P1115, DOI 10.1093/humupd/dmab026
   Ghosh S, 2020, ADV COMPOS HYBRID MA, V3, P303, DOI 10.1007/s42114 020 00154 4
   Gong L, 2020, ORTHOP SURG, V12, P1074, DOI 10.1111/os.12696
   Gu FL, 2019, AM J TRANSL RES, V11, P6032
   Hou QK, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864 018 5155 2
   Hou SL, 2018, ACS APPL MATER INTER, V10, P25983, DOI 10.1021/acsami.8b06114
   Kim DK, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010113
   Kim H.M., 2016, Molecules (Basel, Switzerland), V22
   Kishikawa A, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00157
   Kuang TR, 2022, ADV COMPOS HYBRID MA, V5, P1376, DOI 10.1007/s42114 022 00418 1
   Kwak SC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103164
   Lee JH, 2015, SCI REP UK, V5, DOI 10.1038/srep18833
   Li X, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01498 3
   Li Y, 2015, EXP THER MED, V9, P2072, DOI 10.3892/etm.2015.2388
   Li YY, 2019, J BONE MINER RES, V34, P1938, DOI 10.1002/jbmr.3810
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Long W, 2020, J MOL LIQ, V307, DOI 10.1016/j.molliq.2020.112962
   Mehmood S, 2022, INT J POLYM MATER PO, V71, P139, DOI 10.1080/00914037.2020.1809407
   Muhammad SI, 2013, CLIN INTERV AGING, V8, P1421, DOI 10.2147/CIA.S49704
   Niu YB, 2020, ACTA PHARMACOL SIN, V41, P1476, DOI 10.1038/s41401 020 00509 z
   Obaid R, 2015, CELL REP, V13, P1096, DOI 10.1016/j.celrep.2015.09.071
   Pan PP, 2023, ADV COMPOS HYBRID MA, V6, DOI 10.1007/s42114 022 00593 1
   Papaioannou G, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.314
   Pelusi L, 2022, NUTRIENTS, V14, DOI 10.3390/nu14153209
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Pinheiro RGR, 2020, PHARM RES DORDR, V37, DOI 10.1007/s11095 020 02865 1
   Qin LL, 2023, ADV COMPOS HYBRID MA, V6, DOI 10.1007/s42114 022 00576 2
   Qu XZ, 2021, PEERJ, V9, DOI 10.7717/peerj.12510
   Sarkar A, 2016, BBA GEN SUBJECTS, V1860, P2065, DOI 10.1016/j.bbagen.2016.07.001
   Sfiridaki K, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/867576
   Shang K, 2022, BIOMATER SCI UK, V10, P1373, DOI 10.1039/d1bm02010b
   Srivastava S, 2013, PHYTOMEDICINE, V20, P683, DOI 10.1016/j.phymed.2013.03.001
   Sunogrot S, 2019, J DRUG DELIV SCI TEC, V52, P670, DOI 10.1016/j.jddst.2019.05.035
   Torres Costoso A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173874
   Ulrich C, 2013, STEM CELLS DEV, V22, P2859, DOI 10.1089/scd.2012.0693
   Ural A, 2021, J MECH BEHAV BIOMED, V124, DOI 10.1016/j.jmbbm.2021.104803
   Veronese N, 2022, AGING CLIN EXP RES, V34, P2441, DOI 10.1007/s40520 022 02214 9
   Wang BZ, 2021, J BIOMED NANOTECHNOL, V17, P1392, DOI 10.1166/jbn.2021.3115
   Wang L, 2019, J CELL MOL MED, V23, P4808, DOI 10.1111/jcmm.14371
   Wang ZF, 2022, ADV COMPOS HYBRID MA, V5, P2921, DOI 10.1007/s42114 022 00493 4
   Wei W, 2015, J MATER CHEM A, V3, P4604, DOI 10.1039/c4ta06828a
   Xu Q, 2021, J CELL MOL MED, V25, P10126, DOI 10.1111/jcmm.16949
   Xu YC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081863
   Yang K, 2022, J MED CHEM, V65, P10992, DOI 10.1021/acs.jmedchem.2c00081
   Yang SJ, 2022, DRUG DELIV, V29, P2685, DOI 10.1080/10717544.2022.2111479
   Yang TY, 2018, MOL MED REP, V18, P2599, DOI 10.3892/mmr.2018.9249
   Yasuda Hisataka, 2019, Nihon Yakurigaku Zasshi, V153, P11, DOI 10.1254/fpj.153.11
   Yu MH, 2022, J KOREAN MED SCI, V37, DOI 10.3346/jkms.2022.37.e249
   Zhang YX, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.693079
   Zhang ZH, 2020, J CELL MOL MED, V24, P4233, DOI 10.1111/jcmm.15084
   Zhou YN, 2017, J MATER CHEM B, V5, P612, DOI 10.1039/c6tb02312f
NR 58
TC 4
Z9 4
U1 9
U2 20
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0264 1275
EI 1873 4197
J9 MATER DESIGN
JI Mater. Des.
PD MAY
PY 2024
VL 241
AR 112968
DI 10.1016/j.matdes.2024.112968
EA APR 2024
PG 11
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA SR6I8
UT WOS:001236213100001
OA gold
DA 2025 08 17
ER

PT J
AU Wang, Y
   Hu, BC
   Peng, YS
   Xiong, X
   Jing, WH
   Wang, J
   Gao, HY
AF Wang, Ying
   Hu, Baichun
   Peng, Yusheng
   Xiong, Xin
   Jing, Wenhua
   Wang, Jian
   Gao, Huiyuan
TI In Silico Exploration of the Molecular Mechanism of Cassane Diterpenoids
   on Anti inflammatory and Immunomodulatory Activity
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID TOLL LIKE RECEPTORS; CAESALPINIA MINAX; RHEUMATOID ARTHRITIS; TARGET
   PREDICTION; INFLAMMATION; SEEDS; FURANODITERPENES; NETWORKS; DISEASES;
   TNF
AB Cassane diterpenoids (CAs), recognized as main constituents of many medical plants of the genus Caesalpinia, exhibit diverse bioactivities, including anti inflammatory and immunomodulatory activity, and also showed a therapeutic effect on rheumatoid arthritis (RA) according to previous work, including ours. In this study, 102 CA compounds were selected to explore the possible molecular mechanism of this class of natural products on anti inflammatory and immunomodulatory activity using RA as a disease model through a series of in silico methods: chemical similarity based target prediction, molecular docking, and molecular dynamics (MD) simulation. As a consequence, four signaling pathways (TCR signaling pathway, TLR signaling pathway, VEGF signaling pathway, and osteoclast differentiation pathway) by which CAs exert their effect on inflammation and immunomodulation were identified. Furthermore, the binding modes of CAs complexing with several crucial targets, which were picked out by credible docking results and took part in these signaling pathways, were explored by MD simulations. This is the first time that the molecular mechanism of the anti RA activity of natural CAs has been investigated with in silico methods, and these findings might explain the activity of CAs on anti inflammation and immunomodulation, which could supply a valuable reference for drug design research on CAs.
C1 [Wang, Ying; Hu, Baichun; Xiong, Xin; Jing, Wenhua; Wang, Jian; Gao, Huiyuan] Shenyang Pharmaceut Univ, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Peoples R China.
   [Wang, Ying; Peng, Yusheng; Xiong, Xin; Jing, Wenhua; Gao, Huiyuan] Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Shenyang 110016, Peoples R China.
   [Hu, Baichun; Wang, Jian] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Shenyang 110016, Peoples R China.
C3 Shenyang Pharmaceutical University; Shenyang Pharmaceutical University;
   Shenyang Pharmaceutical University
RP Wang, J; Gao, HY (通讯作者)，Shenyang Pharmaceut Univ, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Peoples R China.; Gao, HY (通讯作者)，Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Shenyang 110016, Peoples R China.; Wang, J (通讯作者)，Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Shenyang 110016, Peoples R China.
EM jianwang@syphu.edu.cn; sypugaohy@163.com
RI wang, jian/GVS 0711 2022
OI Wang, Jian/0000 0002 9589 4056
FU National Natural Science Foundation of China [31670359]; Program for
   Liaoning Innovative Talents [LR2017041]; Natural Science Foundation of
   Liaoning Province [20170540854]; Long Term Training of Young Teachers in
   Shenyang Pharmaceutical University [ZQN2015002]; University Students
   Innovation and Entrepreneurship Training Program [201810163]
FX Authors Y.W., X.X., W.J., and H.G. acknowledge the support from the
   National Natural Science Foundation of China (31670359) and the Program
   for Liaoning Innovative Talents (LR2017041). B.H. and J.W. acknowledge
   the Natural Science Foundation of Liaoning Province (20170540854) and
   Long Term Training of Young Teachers in Shenyang Pharmaceutical
   University (ZQN2015002). Y.P. acknowledges the University Students
   Innovation and Entrepreneurship Training Program (201810163).
CR AbdulHameed MDM, 2012, J CHEM INF MODEL, V52, P492, DOI 10.1021/ci2003544
   Annunziato F, 2009, NAT REV RHEUMATOL, V5, P325, DOI 10.1038/nrrheum.2009.80
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI [10.1093/nar/gkh131, 10.1093/nar/gkw1099]
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Bao H, 2016, MOLECULES, V21, DOI 10.3390/molecules21060791
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bindea G, 2013, BIOINFORMATICS, V29, P661, DOI 10.1093/bioinformatics/btt019
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Bowers KJ, 2006, P 2006 ACM IEEE C SU, P84, DOI [10.1109/SC.2006.54, DOI 10.1109/SC.2006.54]
   Broadhead ML, 2011, EXPERT OPIN THER TAR, V15, P169, DOI 10.1517/14728222.2011.546351
   BYRD RH, 1994, MATH PROGRAM, V63, P129, DOI 10.1007/BF01582063
   Doerks T, 2002, GENOME RES, V12, P47, DOI 10.1101/gr.203201
   Dong RJ, 2015, PHYTOCHEMISTRY, V117, P325, DOI 10.1016/j.phytochem.2015.06.025
   Eichmann A, 2012, CURR OPIN CELL BIOL, V24, P188, DOI 10.1016/j.ceb.2012.02.002
   Fennen M, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1187 7
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007 1110
   Kay E, 2014, BIOFACTORS, V40, P284, DOI 10.1002/biof.1156
   KITAGAWA I, 1994, CHEM PHARM BULL, V42, P1798, DOI 10.1248/cpb.42.1798
   Kondo T, 2012, TRENDS IMMUNOL, V33, P449, DOI 10.1016/j.it.2012.05.002
   Lo YC, 2016, ACS CHEM BIOL, V11, P2244, DOI 10.1021/acschembio.6b00253
   Ma GX, 2012, PLANTA MED, V78, P1363, DOI 10.1055/s 0032 1314976
   Ma GX, 2015, J NAT PROD, V78, P2364, DOI 10.1021/acs.jnatprod.5b00317
   Meng QL, 2017, APOPTOSIS, V22, P1138, DOI 10.1007/s10495 017 1387 x
   Mitra A, 2012, CYTOKINE, V60, P38, DOI 10.1016/j.cyto.2012.06.316
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nicotra L, 2012, EXP NEUROL, V234, P316, DOI 10.1016/j.expneurol.2011.09.038
   Pranithanchai W, 2009, PHYTOCHEMISTRY, V70, P300, DOI 10.1016/j.phytochem.2008.12.006
   Reynolds G, 2014, HUM VACC IMMUNOTHER, V10, P822, DOI 10.4161/hv.27910
   Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036
   Shibuya H, 2015, MOD RHEUMATOL, V25, P72, DOI 10.3109/14397595.2014.900847
   Soltani A, 2018, J CELL PHYSIOL, V233, P4783, DOI 10.1002/jcp.26276
   Sumitomo S, 2018, J AUTOIMMUN, V89, P21, DOI 10.1016/j.jaut.2017.11.001
   Tanaka Sakae, 2005, Mod Rheumatol, V15, P19, DOI 10.1007/s10165 004 0358 6
   Tong ZW, 2018, J ETHNOPHARMACOL, V226, P90, DOI 10.1016/j.jep.2018.08.011
   Truhlar DG, 2007, J COMPUT CHEM, V28, P73, DOI 10.1002/jcc.20529
   Van Hauwermeiren F, 2011, CYTOKINE GROWTH F R, V22, P311, DOI 10.1016/j.cytogfr.2011.09.004
   Vazgiourakis V, 2007, LUPUS, V16, P867, DOI 10.1177/0961203307083179
   Waldner MJ, 2012, EXPERT OPIN THER TAR, V16, P5, DOI 10.1517/14728222.2011.641951
   Wu JM, 2014, FITOTERAPIA, V92, P168, DOI 10.1016/j.fitote.2013.11.002
   Xiang G, 2018, BIOCHEM PHARMACOL, V150, P150, DOI 10.1016/j.bcp.2018.02.003
   Yadav PP, 2009, PHYTOCHEMISTRY, V70, P256, DOI 10.1016/j.phytochem.2008.12.008
   Ylilauri M, 2013, J CHEM INF MODEL, V53, P2626, DOI 10.1021/ci4002475
   Yodsaoue O, 2008, PHYTOCHEMISTRY, V69, P1242, DOI 10.1016/j.phytochem.2007.11.013
   Yodsaoue O, 2010, PHYTOCHEMISTRY, V71, P1756, DOI 10.1016/j.phytochem.2010.06.016
   Zeisbrich M, 2018, ANN RHEUM DIS, V77, P1053, DOI 10.1136/annrheumdis 2017 212647
   Zhang GB, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/621423
NR 48
TC 14
Z9 14
U1 1
U2 39
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549 9596
EI 1549 960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD MAY
PY 2019
VL 59
IS 5
SI SI
BP 2309
EP 2323
DI 10.1021/acs.jcim.8b00862
PG 15
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA IA9NW
UT WOS:000469884900056
PM 30801189
DA 2025 08 17
ER

PT J
AU Wu, JJ
   Cai, PA
   Lu, ZH
   Zhang, Z
   He, XX
   Zhu, BK
   Zheng, L
   Zhao, JM
AF Wu, Jianjun
   Cai, Peian
   Lu, Zhenhui
   Zhang, Zhi
   He, Xixi
   Zhu, Bikang
   Zheng, Li
   Zhao, Jinmin
TI Identification of potential specific biomarkers and key signaling
   pathways between osteogenic and adipogenic differentiation of hBMSCs for
   osteoporosis therapy
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Osteoporosis; Osteogenesis; Adipogenesis; Bone marrow mesenchymal stem
   cells; Microarray analyses
ID MESENCHYMAL STEM CELLS; BONE MARROW; OXIDATIVE STRESS; POSTMENOPAUSAL
   WOMEN; TRANSCRIPTION FACTOR; MANAGEMENT; ACTIVATION; GROWTH; FATE;
   OSTEOBLAST
AB Background The differentiation of bone mesenchymal stem cells (BMSCs) into adipogenesis (AD) rather than osteogenesis (OS) is an important pathological feature of osteoporosis. Illuminating the detailed mechanisms of the differentiation of BMSCs into OS and AD would contribute to the interpretation of osteoporosis pathology. Methods To identify the regulated mechanism in lineage commitment of the BMSCs into OS and AD in the early stages, the gene expression profiles with temporal series were downloaded to reveal the distinct fates when BMSCs adopt a committed lineage. For both OS and AD lineages, the profiles of days 2 4 were compared with day 0 to screen the differentially expressed genes (DEGs), respectively. Next, the functional enrichment analysis was utilized to find out the biological function, and protein protein interaction network to predict the central genes. Finally, experiments were performed to verify our finding. Results FoxO signaling pathway with central genes like FoxO3, IL6, and CAT is the crucial mechanism of OS, while Rap1 signaling pathway of VEGFA and FGF2 enrichment is more significant for AD. Besides, PI3K Akt signaling pathway might serve as the latent mechanism about the initiation of differentiation of BMSCs into multiple lineages. Conclusion Above hub genes and early responder signaling pathways control osteogenic and adipogenic fates of BMSCs, which maybe mechanistic models clarifying the changes of bone metabolism in the clinical progress of osteoporosis. The findings provide a crucial reference for the prevention and therapy of osteoporosis.
C1 [Wu, Jianjun; Cai, Peian; Lu, Zhenhui; Zhang, Zhi; He, Xixi; Zhu, Bikang; Zheng, Li; Zhao, Jinmin] Guangxi Med Univ, Affiliated Hosp 1, Guangxi Engn Ctr Biomed Mat Tissue & Organ Regene, Nanning 530021, Peoples R China.
   [Wu, Jianjun; Cai, Peian; Lu, Zhenhui; Zhang, Zhi; He, Xixi; Zhu, Bikang; Zheng, Li; Zhao, Jinmin] Guangxi Med Univ, Affiliated Hosp 1, Guangxi Collaborat Innovat Ctr Biomed, Nanning 530021, Peoples R China.
   [Wu, Jianjun; Cai, Peian; Zhang, Zhi; He, Xixi; Zhao, Jinmin] Guangxi Med Univ, Affiliated Hosp 1, Dept Orthopaed Trauma & Hand Surg, Nanning 530021, Peoples R China.
   [Zhao, Jinmin] Guangxi Med Univ, Affiliated Hosp 1, Guangxi Key Lab Regenerat Med, Nanning 530021, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University
RP Zheng, L; Zhao, JM (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Guangxi Engn Ctr Biomed Mat Tissue & Organ Regene, Nanning 530021, Peoples R China.
EM zhengli224@163.com; zhaojinmin@126.com
RI Cai, Peian/P 8020 2019; zhao, jin/LBH 0351 2024
FU Guangxi Key Research and Development Plan [GuikeAD19254003]; Guangxi
   Science and Technology Base and Talent Special Project [GuikeAD17129012]
FX This study was financially supported by the Guangxi Key Research and
   Development Plan (Grant No.GuikeAD19254003) and the Guangxi Science and
   Technology Base and Talent Special Project (Grant No. GuikeAD17129012).
CR Andreopoulou P, 2015, ANNU REV MED, V66, P329, DOI 10.1146/annurev med 070313 022841
   Attaix D, 2007, CELL METAB, V6, P425, DOI 10.1016/j.cmet.2007.11.005
   Berendsen AD, 2014, J HISTOCHEM CYTOCHEM, V62, P103, DOI 10.1369/0022155413516347
   Bian HJ, 2016, MOL METAB, V5, P970, DOI 10.1016/j.molmet.2016.08.012
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boquete Castro A, 2016, CLIN ORAL IMPLAN RES, V27, P367, DOI 10.1111/clr.12556
   Cai PA, 2019, CELL BIOCHEM FUNCT, V37, P31, DOI 10.1002/cbf.3370
   Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108
   Chang PY, 2019, J BONE MINER RES, V34, P59, DOI 10.1002/jbmr.3576
   Chapurlat R, 2018, JOINT BONE SPINE, V85, P515, DOI 10.1016/j.jbspin.2017.12.013
   Chen DJ, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12540
   Chung HW, 2003, J HUM GENET, V48, P243, DOI 10.1007/s10038 003 0020 8
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Dumas J, 2016, BIOINFORMATICS, V32, P3679, DOI 10.1093/bioinformatics/btw519
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Fu K, 2018, EPIGENETICS US, V13, P1013, DOI 10.1080/15592294.2018.1526029
   Fu Y, 2014, CELL PROLIFERAT, V47, P604, DOI 10.1111/cpr.12131
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gaspari E, 2018, STEM CELL RES, V32, P1, DOI 10.1016/j.scr.2018.07.025
   Gómez Puerto MC, 2016, AUTOPHAGY, V12, P1804, DOI 10.1080/15548627.2016.1203484
   Gu QG, 2018, CELL PHYSIOL BIOCHEM, V48, P215, DOI 10.1159/000491721
   Han XP, 2018, GENOME BIOL, V19, DOI 10.1186/s13059 018 1426 0
   Hanna H, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0942 x
   Hegner B, 2009, ARTERIOSCL THROM VAS, V29, P232, DOI 10.1161/ATVBAHA.108.179457
   Horowitz MC, 2018, CELL STEM CELL, V23, P151, DOI 10.1016/j.stem.2018.07.010
   Hu P, 2008, DEV CELL, V15, P534, DOI 10.1016/j.devcel.2008.08.018
   Huang TL, 2017, STEM CELLS, V35, P411, DOI 10.1002/stem.2470
   Hung SC, 2004, GENE, V340, P141, DOI 10.1016/j.gene.2004.06.028
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kim S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120073
   Kokabu S, 2013, BIOCHEM BIOPH RES CO, V438, P205, DOI 10.1016/j.bbrc.2013.07.054
   Kusuyama J, 2018, J CELL PHYSIOL, V233, P2549, DOI 10.1002/jcp.26130
   Lamy O, 2019, CURR OSTEOPOROS REP, V17, P8, DOI 10.1007/s11914 019 00502 4
   Li M, 2018, J CELL BIOCHEM, V119, P4928, DOI 10.1002/jcb.26730
   Li YM, 2019, J TRACE ELEM MED BIO, V55, P64, DOI 10.1016/j.jtemb.2019.06.002
   Lu S, 2015, CELL PHYSIOL BIOCHEM, V37, P233, DOI 10.1159/000430348
   Meng JR, 2016, STEM CELL REP, V6, P579, DOI 10.1016/j.stemcr.2016.02.002
   Miller PD, 2016, EXPERT OPIN PHARMACO, V17, P473, DOI 10.1517/14656566.2016.1124856
   Moriishi T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086629
   Ng F, 2008, BLOOD, V112, P295, DOI 10.1182/blood 2007 07 103697
   Ota N, 2001, J HUM GENET, V46, P267, DOI 10.1007/s100380170077
   Piek E, 2010, BONE, V46, P613, DOI 10.1016/j.bone.2009.10.024
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Saito R, 2012, NAT METHODS, V9, P1069, DOI [10.1038/NMETH.2212, 10.1038/nmeth.2212]
   Sanchez AMJ, 2014, CELL MOL LIFE SCI, V71, P1657, DOI 10.1007/s00018 013 1513 z
   Shen GY, 2018, CELL PHYSIOL BIOCHEM, V47, P2307, DOI 10.1159/000491541
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sui BD, 2016, J DENT RES, V95, P1333, DOI 10.1177/0022034516653589
   Sun W, 2018, METABOLISM, V88, P61, DOI 10.1016/j.metabol.2018.06.006
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Tawa H, 2010, CIRC RES, V106, P1731, DOI 10.1161/CIRCRESAHA.110.216747
   Thomas PD, 2019, NAT GENET, V51, P1429, DOI 10.1038/s41588 019 0500 1
   van de Peppel J, 2017, STEM CELL REP, V8, P947, DOI 10.1016/j.stemcr.2017.02.018
   Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300
   Wang C, 2013, BIOMATERIALS, V34, P64, DOI 10.1016/j.biomaterials.2012.09.021
   Wang LJ, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006522
   Wang QL, 2019, EUR REV MED PHARMACO, V23, P7224, DOI 10.26355/eurrev_201909_18825
   Wang XL, 2018, BIOCHEM BIOPH RES CO, V506, P976, DOI 10.1016/j.bbrc.2018.10.197
   Wang YX, 2013, STEM CELLS DEV, V22, P2954, DOI 10.1089/scd.2013.0044
   Wilcock A, 2018, J PAIN SYMPTOM MANAG, V56, P295, DOI 10.1016/j.jpainsymman.2018.05.021
   Wu RY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1082 z
   Xiao LP, 2010, BONE, V47, P360, DOI 10.1016/j.bone.2010.05.021
   Xie ZY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 017 0766 0
   Xu RY, 2018, AGING CELL, V17, DOI 10.1111/acel.12794
   Yang FY, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016225
   Yeung F, 2013, CELL REP, V3, P1847, DOI 10.1016/j.celrep.2013.05.032
   Zhang MJ, 2019, STEM CELL REV REP, V15, P126, DOI 10.1007/s12015 018 9841 x
   Zhang W, 2017, J RECEPT SIG TRANSD, V37, P217, DOI 10.1080/10799893.2016.1212375
   Zhang YY, 2018, MOL CELL, V72, P1021, DOI 10.1016/j.molcel.2018.10.029
NR 74
TC 12
Z9 14
U1 1
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD SEP 23
PY 2020
VL 15
IS 1
AR 437
DI 10.1186/s13018 020 01965 3
PG 14
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA NV9QC
UT WOS:000574645400002
PM 32967719
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Zhong, J
   Wang, L
AF Zhong, Jiao
   Wang, Lu
TI Gypenoside XVII Inhibits High Glucose Induced Apoptosis and Facilitates
   Osteogenic Differentiation in MC3T3 E1 Cells
SO CURRENT TOPICS IN NUTRACEUTICAL RESEARCH
LA English
DT Article
DE Apoptosis; Gypenoside XVII; Osteoporosis; P13K/AKT pathway
ID ACTIVATION; OSTEOBLASTS; AUTOPHAGY; RECEPTOR; INSULIN; DEATH
AB Osteoporosis is a systemic bone disease characterized by compromised bone strength, which predisposes the individual to an increased risk of fractures of the hip, spine, and other skeletal sites. Gynostemma pentaphyllum (of the family Cucurbitaceae) is known to reduce blood lipid, prevent arteriosclerosis, inhibit oxidation, reduce blood glucose, and regulate immunity. Gypenoside XVII is one of the bioactives in G. pentaphyllum, which inhibits receptor activator of nuclear factor kappa B ligand induced osteoclast production. Herein, we show that Gypenoside XVII improves the survival of MC3T3 E1 under high glucose environment. It also inhibits the apoptosis of MC3T3 E1 cells in high glucose environment. In addition, Gypenoside XVII promotes osteogenic differentiation of MC3T3 E1 cells in high glucose environment. Mechanically, we found that Gypenoside XVII inhibited high glucose induced apoptosis and facilitated osteogenic differentiation via activating the PI3K/AKT pathway. These data suggest that Gypenoside XVII might be a potential therapeutic drug in the treatment of osteoporosis.
C1 [Zhong, Jiao; Wang, Lu] Sichuan Univ, West China Hosp 4, Dept Osteoporosis & Ostealgia, 18,Sect 3,Renmin South Rd, Chengdu 610400, Sichuan, Peoples R China.
C3 Sichuan University
RP Wang, L (通讯作者)，Sichuan Univ, West China Hosp 4, Dept Osteoporosis & Ostealgia, 18,Sect 3,Renmin South Rd, Chengdu 610400, Sichuan, Peoples R China.
EM wanglu062101@163.com
CR Chang LP, 2020, BIOFACTORS, V46, P432, DOI 10.1002/biof.1601
   CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191
   Curhan SG, 2021, J AM GERIATR SOC, V69, P3103, DOI 10.1111/jgs.17275
   Dance M, 2006, J BIOL CHEM, V281, P23285, DOI 10.1074/jbc.M600987200
   Gallagher Sean, 2008, J Vis Exp, DOI 10.3791/759
   García Hernández A, 2012, BONE, V50, P276, DOI 10.1016/j.bone.2011.10.032
   Gonzalez Y, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471 2172 13 19
   Gopalakrishnan V, 2006, BIOCHEM CELL BIOL, V84, P93, DOI 10.1139/O05 163
   Han JK, 2018, J CELL BIOCHEM, V119, P7310, DOI 10.1002/jcb.27028
   Huang THW, 2007, TOXICOL APPL PHARM, V218, P30, DOI 10.1016/j.taap.2006.10.013
   Lechleitner M, 2000, J INTERN MED, V248, P67, DOI 10.1046/j.1365 2796.2000.00705.x
   Lee JH, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101426
   Luo Y, 2021, EUR J PHARMACOL, V895, DOI 10.1016/j.ejphar.2021.173893
   Meng XB, 2016, J ALZHEIMERS DIS, V52, P1135, DOI 10.3233/JAD 160096
   Meng XB, 2014, TOXICOL APPL PHARM, V279, P63, DOI 10.1016/j.taap.2014.03.026
   Ogawa N, 2007, HORM METAB RES, V39, P871, DOI 10.1055/s 2007 991157
   Song N, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2819658
   Wang NN, 2021, FREE RADICAL BIO MED, V171, P112, DOI 10.1016/j.freeradbiomed.2021.05.014
   Wu YY, 2012, J STEROID BIOCHEM, V132, P112, DOI 10.1016/j.jsbmb.2012.05.002
   Yang K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020077
   Yang Q, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2021.153541
   Yu HJ, 2016, CELL PHYSIOL BIOCHEM, V39, P123, DOI 10.1159/000445611
   Zavatta G, 2021, ENDOCRIN METAB CLIN, V50, P251, DOI 10.1016/j.ecl.2021.03.002
   Zhang P., 2020, ARCH MED SCI, DOI [10.5114/ aoms.2020.10130, DOI 10.5114/AOMS.2020.10130]
   Zhang P, 2021, J ETHNOPHARMACOL, V276, DOI 10.1016/j.jep.2021.114198
   Zheng K, 2017, J AGR FOOD CHEM, V65, P6625, DOI 10.1021/acs.jafc.7b02296
NR 26
TC 0
Z9 0
U1 0
U2 17
PU NEW CENTURY HEALTH PUBLISHERS, LLC
PI COPPELL
PA PO BOX 175, COPPELL, TX 75019 USA
SN 1540 7535
EI 2641 452X
J9 CURR TOP NUTRACEUT R
JI Curr. Top. Nutraceutical Res.
PD FEB
PY 2022
VL 20
IS 1
BP 129
EP 134
AR 18
DI 10.37290/ctnr2641 452X.20:129 134
PG 6
WC Nutrition & Dietetics; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics; Pharmacology & Pharmacy
GA YP1CQ
UT WOS:000748366700015
DA 2025 08 17
ER

PT J
AU Rementer, CW
   Wu, MT
   Buranaphatthana, W
   Yang, HYL
   Scatena, M
   Giachelli, CM
AF Rementer, Cameron W.
   Wu, Meiting
   Buranaphatthana, Worakanya
   Yang, Hsueh Ying L.
   Scatena, Marta
   Giachelli, Cecilia M.
TI An Inducible, Ligand Independent Receptor Activator of NF κB Gene to
   Control Osteoclast Differentiation from Monocytic Precursors
SO PLOS ONE
LA English
DT Article
ID SIGNAL TRANSDUCTION; CELL THERAPY; CALCIFICATION; PROLIFERATION;
   INHIBITION; GROWTH
AB Osteoclasts are bone resorbing cells that are critical for the normal formation and maintenance of teeth and skeleton. Osteoclast deficiency can contribute to heterotopic ossification (HO), a pathology that is particularly detrimental to the mechanical functions of joints, valves and blood vessels. On the other hand, osteoclast over activity is a major cause of osteoporosis. A reliable method for controlled generation of osteoclasts would be useful as a potential autologous cell therapy for HO, as well as high throughput drug screening for anti osteoporotic drugs. In this report, we describe the development of a cell engineering approach to control monocytic precursor cell differentiation to osteoclasts. Oligomerization of receptor activator of nuclear factor kappa B (RANK) is known to be essential for osteoclast differentiation from monocyte/macrophage precursors. We engineered a murine monocytic cell line, RAW264.7 to express a fusion protein comprising the intracellular RANK signaling domain and FK506 derived dimerization domains that bind to a small molecule chemical inducer of dimerization (CID). Virally infected cells expressing this fusion protein were treated with CID and dose dependent induction of tartrate resistant acid phosphatase activity, as well as multinucleated osteoclast formation were observed. Furthermore, NF kappa B signaling was upregulated in a CID dependent fashion, demonstrating effective RANK intracellular signaling. Functionally CID induced osteoclasts had robust mineral resorptive activity in both two dimensional and three dimensional in vitro resorption assays. In addition, the CID induced osteoclasts have the same life span as native RANKL induced osteoclasts. Most importantly and crucially, the engineered cells differentiated into osteoclasts that were resistant to the potent osteoclast inhibitor, osteoprotegerin. Taken together, these studies are the first to describe a method for inducible control of monocytic precursor differentiation to osteoclasts that may be useful for future development of an engineered autologous cell therapy as well as high throughput drug testing systems to treat diseases of osteoclast over activity that are independent of osteoprotegerin.
C1 [Rementer, Cameron W.; Wu, Meiting; Yang, Hsueh Ying L.; Scatena, Marta; Giachelli, Cecilia M.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Buranaphatthana, Worakanya] Univ Washington, Dept Oral Hlth Sci, Seattle, WA 98195 USA.
C3 University of Washington; University of Washington Seattle; University
   of Washington; University of Washington Seattle
RP Giachelli, CM (通讯作者)，Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
EM ceci@uw.edu
OI Giachelli, Cecilia/0000 0002 6387 5993
FU Life Sciences Discovery Fund [2361524]; NIH [R01HL114611 01,
   T32EB001650]
FX This work is supported by Life Sciences Discovery Fund 2361524, NIH
   grant R01HL114611 01 and NIH training grant T32EB001650. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Blair HC, 2005, BIOCHEM BIOPH RES CO, V328, P728, DOI 10.1016/j.bbrc.2004.11.077
   Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076
   BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Courter DL, 2005, J BIOL CHEM, V280, P12145, DOI 10.1074/jbc.M412555200
   Dismuke AD, 2009, BIOL PROCED ONLINE, V11, P130, DOI 10.1007/s12575 009 9014 z
   Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463 8471.1998
   Forsberg Jonathan Agner, 2010, J Surg Orthop Adv, V19, P54
   Giachelli CM, 1999, AM J PATHOL, V154, P671, DOI 10.1016/S0002 9440(10)65313 8
   Hashem R, 2011, CANCER RADIOTHER, V15, P261, DOI 10.1016/j.canrad.2010.10.003
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Iwamoto K, 2004, BIOCHEM BIOPH RES CO, V325, P229, DOI 10.1016/j.bbrc.2004.10.024
   Janckila AJ, 2001, J BONE MINER RES, V16, P788, DOI 10.1359/jbmr.2001.16.4.788
   Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897
   Simpson CL, 2007, CARDIOVASC PATHOL, V16, P29, DOI 10.1016/j.carpath.2006.07.001
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Lippuner K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13624
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522
   Neff T, 2001, BLOOD, V97, P2535, DOI 10.1182/blood.V97.9.2535
   Ollivere B, 2012, J BONE JOINT SURG BR, V94B, P10, DOI 10.1302/0301 620X.94B1.28047
   Osathanon T, 2008, BIOMATERIALS, V29, P4091, DOI 10.1016/j.biomaterials.2008.06.030
   Paparodis R., 2013, ENDOCR PRACT, V21, P1
   Pichardo SE, 2012, J CRANIOMAXILLOFAC S, V41, pe65
   Pohjolainen V, 2008, HUM PATHOL, V39, P1695, DOI 10.1016/j.humpath.2008.04.015
   ROBERTS JB, 1979, J BONE JOINT SURG AM, V61, P760, DOI 10.2106/00004623 197961050 00018
   Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083
   Shehab D, 2002, J NUCL MED, V43, P346
   SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365
   Susa Mira, 2004, J Transl Med, V2, P6, DOI 10.1186/1479 5876 2 6
   Tey SK, 2007, BIOL BLOOD MARROW TR, V13, P913, DOI 10.1016/j.bbmt.2007.04.005
   Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37
   Van den Wyngaert T, 2011, SUPPORT CARE CANCER, V19, P2035, DOI 10.1007/s00520 010 1061 0
   Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166
   Weinreich MA, 2006, BLOOD, V108, P3713, DOI 10.1182/blood 2006 01 012278
   Whitney ML, 2001, J BIOL CHEM, V276, P41191, DOI 10.1074/jbc.M103191200
   Zeng H, 2001, BLOOD, V98, P328, DOI 10.1182/blood.V98.2.328
NR 39
TC 16
Z9 21
U1 1
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2013
VL 8
IS 12
AR e84465
DI 10.1371/journal.pone.0084465
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 281RE
UT WOS:000329117900097
PM 24386387
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Halvorson, KG
   Sevcik, MA
   Ghilardi, JR
   Sullivan, LJ
   Koewler, NJ
   Bauss, F
   Mantyh, PW
AF Halvorson, Kyle G.
   Sevcik, Molly A.
   Ghilardi, Joseph R.
   Sullivan, Lucy J.
   Koewler, Nathan J.
   Bauss, Frieder
   Mantyh, Patrick W.
TI Intravenous ibandronate rapidly reduces pain, neurochemical indices of
   central sensitization, tumor burden, and skeletal destruction in a mouse
   model of bone cancer
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE tumor bone pain; skeletal malignancies; bisphosphonates; ibandronate;
   nociception
ID CELLS IN VITRO; SPINAL CORD; BISPHOSPHONATES INHIBIT; MEVALONATE
   PATHWAY; SYSTEMIC MORPHINE; BREAKTHROUGH PAIN; ZOLEDRONIC ACID;
   DYNORPHIN A; ION CHANNEL; ALENDRONATE
AB Over half of all chronic cancer pain arises front metastases to bone and bone cancer pain is one of the most difficult of all persistent pain states to fully control. Currently, bone pain is treated primarily by opioid based therapies, which are frequently accompanied by significant unwanted side effects. In an effort, to develop nonopioid based therapies that could rapidly attenuate tumor induced bone pain, we examined the effect, of intravenous administration of the bisphosphonate, ibandronate, in a mouse model of bone cancer pain. Following injection. and confinement of green fluorescent Protein transfected murine osteolytic 2472 sarcoma cells into the marrow space of the femur of male C3H/HeJ mice, ibandronate was ad,administered either as a single dose (300 mu g/kg), at Day 7 post tumor injection, when tumor induced bone destruction and Pain were first evident, or in three consecutive doses (100 mu g/kg/day) at Days 7, 8, and 9 post tumor injection. Intravenous ibandronate administered once or in Three consecutive doses reduced ongoing and movement evoked bone cancer pain related behaviors, neurochemical markers of central sensitization, tumor burden, and tumor induced bone destruction. These results support limited, clinical trials that suggest the potential of ibandronate to rapidly attenuate bone pain and illuminate the mechanisms that. may be responsible fir limiting pain and disease progression.
C1 [Mantyh, Patrick W.] Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA.
   [Halvorson, Kyle G.; Sevcik, Molly A.; Sullivan, Lucy J.; Koewler, Nathan J.] Univ Minnesota, Neurosyst Ctr, Minneapolis, MN 55455 USA.
   [Halvorson, Kyle G.; Sevcik, Molly A.; Sullivan, Lucy J.; Koewler, Nathan J.] Univ Minnesota, Dept Diagnost & Biol Sci, Minneapolis, MN 55455 USA.
   [Halvorson, Kyle G.; Sevcik, Molly A.; Sullivan, Lucy J.; Koewler, Nathan J.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
   [Halvorson, Kyle G.; Sevcik, Molly A.; Sullivan, Lucy J.; Koewler, Nathan J.] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA.
   [Ghilardi, Joseph R.; Mantyh, Patrick W.] VA Med Ctr, Res Serv, Minneapolis, MN USA.
   [Bauss, Frieder] Roche Diagnost GmbH, Pharma Res Penzberg, Penzberg, Germany.
C3 University of Arizona; University of Minnesota System; University of
   Minnesota Twin Cities; University of Minnesota System; University of
   Minnesota Twin Cities; University of Minnesota System; University of
   Minnesota Twin Cities; University of Minnesota System; University of
   Minnesota Twin Cities; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Minneapolis VA Health Care System; Roche
   Holding; Roche Holding Germany
RP Mantyh, PW (通讯作者)，Univ Arizona, Coll Med, Dept Pharmacol, 1501 Campbell Ave, Tucson, AZ 85724 USA.
EM pmantyh@email.arizona.edu
FU National Institutes of Health [NS23970, NS048021]; Hoffman La Roche Inc
FX This work was supported by the National Institutes of Health grants
   NS23970 and NS048021, a Merit Review from the Veterans Administration,
   and a research grant from Hoffman La Roche Inc.
CR Alakangas A, 2002, CALCIFIED TISSUE INT, V70, P40, DOI 10.1007/s002230010047
   Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594
   Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819
   Bauss F, 2002, J RHEUMATOL, V29, P2200
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Body JJ, 2006, SUPPORT CARE CANCER, V14, P408, DOI 10.1007/s00520 005 0913 5
   Boissier S, 2000, CANCER RES, V60, P2949
   Breuil V, 1998, J BONE MINER RES, V13, P1721, DOI 10.1359/jbmr.1998.13.11.1721
   Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807
   Delaisse Jean Marie, 1992, P289
   Edoff K, 2000, CELL TISSUE RES, V299, P193, DOI 10.1007/s004419900142
   Fournier P, 2002, CANCER RES, V62, P6538
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Glüer CC, 2007, BONE, V40, P645, DOI 10.1016/j.bone.2006.10.019
   Hasselstrom J, 1996, PHARMACOL TOXICOL, V79, P40, DOI 10.1111/j.1600 0773.1996.tb00239.x
   Heidenreich A, 2004, SEMIN ONCOL, V31, P67, DOI 10.1053/j.seminoncol.2004.07.026
   Hiraga T, 2001, CANCER RES, V61, P4418
   Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306 4522(00)00110 X
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Honore P, 2000, Prog Brain Res, V129, P389
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0
   IADAROLA MJ, 1988, BRAIN RES, V455, P205, DOI 10.1016/0006 8993(88)90078 9
   Lai J, 2006, NAT NEUROSCI, V9, P1534, DOI 10.1038/nn1804
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luger NM, 2001, CANCER RES, V61, P4038
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304 3959(02)00102 1
   Mach DB, 2002, NEUROSCIENCE, V113, P155, DOI 10.1016/S0306 4522(02)00165 3
   Malan TP, 2000, PAIN, V86, P185, DOI 10.1016/S0304 3959(00)00243 8
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   MCBRIDE WH, 1986, BIOCHIM BIOPHYS ACTA, V865, P27, DOI 10.1016/0304 419X(86)90011 9
   MCCARTHY BG, 1995, NEUROLOGY, V45, P1848, DOI 10.1212/WNL.45.10.1848
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305 7372(98)90005 6
   MOLANDER C, 1987, J COMP NEUROL, V260, P246, DOI 10.1002/cne.902600208
   Monier Faugere MC, 1999, J BONE MINER RES, V14, P1768, DOI 10.1359/jbmr.1999.14.10.1768
   MUHLBAUER RC, 1991, J BONE MINER RES, V6, P1003
   Neudert M, 2003, INT J CANCER, V107, P468, DOI 10.1002/ijc.11397
   Neville Webbe HL, 2003, PALLIATIVE MED, V17, P539, DOI 10.1191/0269216303pm800ra
   NOGUCHI K, 1991, MOL BRAIN RES, V10, P227, DOI 10.1016/0169 328X(91)90065 6
   Olson TH, 1998, NEUROREPORT, V9, P1109, DOI 10.1097/00001756 199804200 00028
   ORR FW, 1995, CLIN ORTHOP RELAT R, P19
   Ossipov MH, 2000, ANN NY ACAD SCI, V909, P12
   PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304 3959(90)90004 W
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140 6736(99)01310 0
   Portenoy RK, 1999, ONCOLOGY NY, V13, P25
   Puigdellívol Sánchez A, 1998, NEUROSCI LETT, V251, P169, DOI 10.1016/S0304 3940(98)00518 7
   Puigdellívol Sánchez A, 2000, ANAT REC, V260, P180, DOI 10.1002/1097 0185(20001001)260:2<180::AID AR70>3.0.CO;2 E
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Sabino MAC, 2003, INT J CANCER, V104, P550, DOI 10.1002/ijc.10999
   Sabino MAC, 2002, CANCER RES, V62, P7343
   SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107
   SATO M, 1991, J CLIN INVEST, V16, P235
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Sevcik MA, 2004, PAIN, V111, P169, DOI 10.1016/j.pain.2004.06.015
   Shipman CM, 1998, CANCER RES, V58, P5294
   Smith SY, 2003, BONE, V32, P45, DOI 10.1016/S8756 3282(02)00923 7
   Tomishige K, 1998, CATAL SURV JPN, V2, P3, DOI 10.1023/A:1019001702796
   Töyräs A, 2003, EUR J PHARM SCI, V19, P223, DOI 10.1016/S0928 0987(03)00108 8
   Vanderah TW, 1996, PAIN, V68, P275, DOI 10.1016/S0304 3959(96)03225 3
   Vanderah TW, 2001, PAIN, V92, P5, DOI 10.1016/S0304 3959(01)00311 6
   Vasikaran SD, 2001, ANN CLIN BIOCHEM, V38, P608, DOI 10.1258/0004563011901037
   Virtanen SS, 2002, CANCER RES, V62, P2708
   Wakchoure S, 2006, CLIN CANCER RES, V12, P2862, DOI 10.1158/1078 0432.CCR 05 2766
   Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0
   Walker K, 2002, PAIN, V100, P219, DOI 10.1016/S0304 3959(02)00040 4
   Wang ZJ, 2001, J NEUROSCI, V21, P1779, DOI 10.1523/JNEUROSCI.21 05 01779.2001
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 71
TC 14
Z9 18
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885 3924
EI 1873 6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD SEP
PY 2008
VL 36
IS 3
BP 289
EP 303
DI 10.1016/j.jpainsymman.2007.10.005
PG 15
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
   Neurology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine;
   Neurosciences & Neurology
GA 348LD
UT WOS:000259211100008
PM 18411018
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Laghezza, A
   Piemontese, L
   Brunetti, L
   Caradonna, A
   Agamennone, M
   Di Pizio, A
   Pochetti, G
   Montanari, R
   Capelli, D
   Tauro, M
   Loiodice, F
   Tortorella, P
AF Laghezza, Antonio
   Piemontese, Luca
   Brunetti, Leonardo
   Caradonna, Alessia
   Agamennone, Mariangela
   Di Pizio, Antonella
   Pochetti, Giorgio
   Montanari, Roberta
   Capelli, Davide
   Tauro, Marilena
   Loiodice, Fulvio
   Tortorella, Paolo
TI Bone Seeking Matrix Metalloproteinase Inhibitors for the Treatment of
   Skeletal Malignancy
SO PHARMACEUTICALS
LA English
DT Article
DE bisphosphonates; matrix metalloproteinase inhibitors; antitumor agent;
   bone targeting; skeletal malignancies
ID ZINC BINDING GROUP; CANCER
AB Matrix metalloproteinases (MMPs) are a family of enzymes involved at different stages of cancer progression and metastasis. We previously identified a novel class of bisphosphonic inhibitors, selective for MMPs crucial for bone remodeling, such as MMP 2. Due to the increasing relevance of specific MMPs at various stages of tumor malignancy, we focused on improving potency towards certain isoforms. Here, we tackled MMP 9 because of its confirmed role in tumor invasion, metastasis, angiogenesis, and immuno response, making it an ideal target for cancer therapy. Using a computational analysis, we designed and characterized potent MMP 2/MMP 9 inhibitors. This is a promising approach to develop and clinically translate inhibitors that could be used in combination with standard care therapy for the treatment of skeletal malignancies.
C1 [Laghezza, Antonio; Piemontese, Luca; Brunetti, Leonardo; Caradonna, Alessia; Loiodice, Fulvio; Tortorella, Paolo] Univ Bari A Moro, Dept Pharm & Pharmaceut Sci, Via E Orabona 4, I 70125 Bari, Italy.
   [Agamennone, Mariangela] Univ G dAnnunzio, Dept Pharm, Via Dei Vestini 31, I 66100 Chieti, Italy.
   [Di Pizio, Antonella] Tech Univ Munich, Leibniz Inst Food Syst Biol, Lise Meitner Str 34, D 85354 Freising Weihenstephan, Germany.
   [Pochetti, Giorgio; Montanari, Roberta; Capelli, Davide] CNR, Ist Cristallog, Monterotondo Stn, I 00015 Rome, Italy.
   [Tauro, Marilena] H Lee Moffitt Canc Ctr & Res Inst, Tumor Biol Dept, Tampa, FL 33612 USA.
C3 Universita degli Studi di Bari Aldo Moro; G d'Annunzio University of
   Chieti Pescara; Technical University of Munich; Leibniz Association;
   Leibniz Institute for Food Systems Biology at the Technical University
   of Munich; Consiglio Nazionale delle Ricerche (CNR); Istituto Di
   Cristallografia (IC CNR); H Lee Moffitt Cancer Center & Research
   Institute
RP Loiodice, F; Tortorella, P (通讯作者)，Univ Bari A Moro, Dept Pharm & Pharmaceut Sci, Via E Orabona 4, I 70125 Bari, Italy.
EM antonio.laghezza@uniba.it; luca.piemontese@uniba.it;
   l.brunetti2@studenti.uniba.it; a.caradonna@hotmail.it;
   magamennone@unich.it; antonelladipizio@gmail.com;
   giorgio.pochetti@ic.cnr.it; roberta.montanari@ic.cnr.it;
   davide.capelli@ic.cnr.it; marilena.tauro@moffitt.org;
   fulvio.loiodice@uniba.it; paolo.tortorella@uniba.it
RI Brunetti, Leonardo/JHT 7634 2023; Agamennone, Mariangela/J 2916 2012;
   montanari, roberta/AAX 6393 2020; Laghezza, Antonio/F 7420 2014; Di
   Pizio, Antonella/ABC 6792 2020; Capelli, Davide/ABF 3964 2020;
   Piemontese, Luca/L 6259 2017
OI Di Pizio, Antonella/0000 0002 8520 5165; Agamennone,
   Mariangela/0000 0001 5198 0051; Laghezza, Antonio/0000 0001 6221 6155;
   pochetti, giorgio/0000 0002 3980 3180; Brunetti,
   Leonardo/0000 0002 7787 6639; Capelli, Davide/0000 0002 6716 3854;
   Piemontese, Luca/0000 0002 7980 5818; Tauro,
   Marilena/0000 0003 2361 7364
CR Alaseem A, 2019, SEMIN CANCER BIOL, V56, P100, DOI 10.1016/j.semcancer.2017.11.008
   Ammazzalorso A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101768
   Azevedo A, 2018, CURR PHARM DESIGN, V24, P1801, DOI 10.2174/1381612824666180604112925
   Campestre C, 2006, BIOORG MED CHEM LETT, V16, P20, DOI 10.1016/j.bmcl.2005.09.057
   Campestre C, 2015, CURR DRUG TARGETS, V16, P1634, DOI 10.2174/1389450116666150113121733
   Cerofolini L, 2019, CURR MED CHEM, V26, P2609, DOI 10.2174/0929867325666180326163523
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Di Pizio A, 2018, MONATSH CHEM, V149, P1293, DOI 10.1007/s00706 018 2237 4
   Dive V, 2005, INT J CANCER, V113, P775, DOI 10.1002/ijc.20459
   Dufour A, 2013, TRENDS PHARMACOL SCI, V34, P233, DOI 10.1016/j.tips.2013.02.004
   Fabre B, 2014, J MED CHEM, V57, P10205, DOI 10.1021/jm500505f
   Fields GB, 2019, CELLS BASEL, V8, DOI 10.3390/cells8090984
   Fowler JA, 2009, DIS MODEL MECH, V2, P604, DOI 10.1242/dmm.003160
   Guise TA, 2003, CLIN ORTHOP RELAT R, pS32, DOI 10.1097/01.blo.0000093055.96273.69
   Lynch CC, 2011, BONE, V48, P44, DOI 10.1016/j.bone.2010.06.007
   Malemud CJ., 2008, Future Rheumatol, V3, P253
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Onken JS, 2019, CLIN EXP METASTAS, V36, P493, DOI 10.1007/s10585 019 09987 w
   Owyong M, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201800226
   Pochetti G, 2006, J MED CHEM, V49, P923, DOI 10.1021/jm050787+
   Pochetti G, 2009, J MED CHEM, V52, P1040, DOI 10.1021/jm801166j
   Purushothaman A, 2008, J BIOL CHEM, V283, P32628, DOI 10.1074/jbc.M806266200
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rubino MT, 2011, CHEMMEDCHEM, V6, P1258, DOI 10.1002/cmdc.201000540
   Schrodinger LLC, 2018, SCHROD SUIT 2018 3 M
   Shay G, 2017, ONCOTARGET, V8, P41827, DOI 10.18632/oncotarget.18103
   Southall NT, 2002, J PHYS CHEM B, V106, P521, DOI 10.1021/jp015514e
   Tauro M, 2018, CANCERS, V10, DOI 10.3390/cancers10060185
   Tauro M, 2017, MOL CANCER THER, V16, P494, DOI 10.1158/1535 7163.MCT 16 0315 T
   Tauro M, 2016, J ENZYM INHIB MED CH, V31, P25, DOI 10.1080/14756366.2016.1217853
   Tauro M, 2014, CANCER METAST REV, V33, P1043, DOI 10.1007/s10555 014 9530 4
   Tauro M, 2014, BIOORG MED CHEM LETT, V24, P2617, DOI 10.1016/j.bmcl.2014.04.077
   Tauro M, 2014, BIOORG MED CHEM LETT, V24, P1941, DOI 10.1016/j.bmcl.2014.03.001
   Tauro M, 2013, BIOORGAN MED CHEM, V21, P6456, DOI 10.1016/j.bmc.2013.08.054
NR 36
TC 3
Z9 4
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1424 8247
J9 PHARMACEUTICALS BASE
JI Pharmaceuticals
PD JUN
PY 2020
VL 13
IS 6
AR 113
DI 10.3390/ph13060113
PG 16
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA MO0TH
UT WOS:000551249100020
PM 32492898
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Diao, XY
   Wang, LW
   Zhou, YT
   Bi, YA
   Zhou, K
   Song, L
AF Diao, Xinyue
   Wang, Liwen
   Zhou, Yating
   Bi, Yanan
   Zhou, Kun
   Song, Lei
TI The mechanism of Epimedin B in treating osteoporosis as revealed by RNA
   sequencing based analysis
SO BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
LA English
DT Article
DE Epimedin B; osteoporosis; RNA sequencing; signalling pathway
ID BONE MINERAL DENSITY; OVARIECTOMIZED RATS; ATTENUATES OSTEOPOROSIS;
   HERBAL MEDICINE; DIFFERENTIATION; ARCHITECTURE; OSTEOBLAST; DXA
AB With the ageing of populations, the management of osteoporosis is a priority of society in general. Epimedin B, a major ingredient of Herba Epimedii, which has the advantages of high content and hypotoxicity has been proved to be effective in preventing osteoporosis in vitro. However, the efficacy and mechanism of Epimedin B on osteoporosis in vivo have not been well elucidated yet. This study aimed to investigate the effects and the potential mechanisms of 8 week repeated oral administration of Epimedin B (10 and 20 mg/kg/day) on a mouse osteoporosis model. Effects of Epimedin B were evaluated by examinations of serum bone turnover markers, bone mineral density, bone microstructure parameters and histopathological section. Epimedin B significantly rose N terminal propeptide of type I procollagen (P1NP) and dropped C telopeptide of type I collagen (CTX1). Connectivity density (Conn.D) increased significantly while structure model index (DA) decreased significantly after treated by Epimedin B. Meanwhile, Epimedin B administration significantly increased the number of trabecular bones while significantly decreased the gap between them. Overall, Epimedin B showed beneficial effects on osteoporosis. Furthermore, RNA sequencing based analysis revealed 5 significantly down regulated transcripts and 107 significantly up regulated transcripts between the Epimedin B administration group and the model group. These transcripts were mapped to 15 pathways by KEGG enrichment analysis, of which PI3K Akt signalling pathway, MAPK signalling pathway and PPAR signalling pathway were most connected to osteoporosis. To conclude, Epimedin B is effective in treating osteoporosis in mice via regulating PI3K Akt, MAPK and PPAR signalling pathway.
C1 [Diao, Xinyue; Wang, Liwen; Zhou, Yating; Bi, Yanan; Zhou, Kun; Song, Lei] Tianjin Univ Tradit Chinese Med, Inst Tradit Chinese Med, Beihua South Rd, Tianjin 301617, Peoples R China.
   [Zhou, Kun; Song, Lei] Tianjin Univ Tradit Chinese Med, Tianjin Key Lab Chinese Med Pharmacol, Tianjin, Peoples R China.
   [Zhou, Kun; Song, Lei] Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, Tianjin, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University
   of Traditional Chinese Medicine; Tianjin University of Traditional
   Chinese Medicine
RP Zhou, K; Song, L (通讯作者)，Tianjin Univ Tradit Chinese Med, Inst Tradit Chinese Med, Beihua South Rd, Tianjin 301617, Peoples R China.
EM z.k.ken@263.net; songlei007123@163.com
RI 周, 亚亭/E 6633 2011; zhou, kun/KRP 1631 2024
FU National Natural Science Foundation of China [81803797]; Natural Science
   Foundation of Tianjin City [18JCYBJC28700]
FX National Natural Science Foundation of China, Grant/Award Number:
   81803797; Natural Science Foundation of Tianjin City, Grant/Award
   Number: 18JCYBJC28700
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Audran M, 2001, CALCIFIED TISSUE INT, V69, P214, DOI 10.1007/s00223 001 1058 2
   Borsy A, 2009, MOL GENET GENOMICS, V281, P301, DOI 10.1007/s00438 008 0413 7
   Burden AM, 2021, OSTEOPOROSIS INT, V32, P817, DOI 10.1007/s00198 020 05756 8
   Chan BY, 2007, BONE, V40, P149, DOI 10.1016/j.bone.2006.07.029
   Chen YH, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/1596951
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Dragojevic J, 2013, J BONE MINER METAB, V31, P512, DOI 10.1007/s00774 013 0445 x
   Ebeling PR, 2010, CURR OPIN ENDOCRINOL, V17, P284, DOI 10.1097/MED.0b013e328339658c
   Guo YN, 2018, CHEM BIODIVERS, V15, DOI 10.1002/cbdv.201700578
   He JB, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 016 0301 4
   Huang H, 2007, J SEP SCI, V30, P3207, DOI 10.1002/jssc.200700262
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Jain S, 2018, CURR OPIN ENDOCRINOL, V25, P366, DOI 10.1097/MED.0000000000000446
   Jiang HX, 2005, J BONE MINER RES, V20, P494, DOI 10.1359/JBMR.041133
   Kasonga A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071798
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim YH, 2019, BIOCHEM BIOPH RES CO, V520, P459, DOI 10.1016/j.bbrc.2019.10.048
   Laib A, 2001, OSTEOPOROSIS INT, V12, P936, DOI 10.1007/s001980170022
   Lau CBS, 2019, J TRADIT COMPL MED, V9, P179, DOI 10.1016/j.jtcme.2018.09.003
   Libouban H, 2002, OSTEOPOROSIS INT, V13, P422, DOI 10.1007/s001980200049
   Lin WL, 2020, AM J CHINESE MED, V48, P1749, DOI 10.1142/S0192415X20500871
   Ma HP, 2011, J ETHNOPHARMACOL, V134, P519, DOI 10.1016/j.jep.2011.01.001
   Ma J, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12955
   Perilli E, 2012, BONE, V50, P1416, DOI 10.1016/j.bone.2012.03.002
   Plotkin LI, 2019, ADV PROTEIN CHEM STR, V116, P237, DOI 10.1016/bs.apcsb.2019.01.002
   Poulsen RC, 2007, EXP BIOL MED, V232, P1275, DOI 10.3181/0704 MR 100
   Qin H, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.581049
   Qin WP, 2013, J BIOL CHEM, V288, P13511, DOI 10.1074/jbc.M113.454892
   Shan SK, 2019, CURR PHARM DESIGN, V25, P4536, DOI 10.2174/1381612825666191127114054
   Shao M, 2017, COMPUT MATH METHOD M, V2017, DOI 10.1155/2017/9426280
   Song C, 2018, FASEB J, V32, P3215, DOI 10.1096/fj.201600825RRR
   Song L, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8417814
   Sun X, 2019, INT J BIOL MACROMOL, V129, P579, DOI 10.1016/j.ijbiomac.2019.02.022
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Takada J, 2020, J BONE MINER METAB, V38, P310, DOI 10.1007/s00774 019 01057 1
   Tang X, 2020, J AGR FOOD CHEM, V68, P6588, DOI 10.1021/acs.jafc.0c01820
   Tveden Nyborg P, 2021, BASIC CLIN PHARMACOL, V128, P4, DOI 10.1111/bcpt.13492
   Valverde Franco G, 2004, HUM MOL GENET, V13, P271, DOI 10.1093/hmg/ddh034
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wang LL, 2016, CURR PHARM DESIGN, V22, P328, DOI 10.2174/1381612822666151112145907
   Wu L, 2017, CURR TOP MED CHEM, V17, P1670, DOI 10.2174/1568026617666161116141033
   Xia WB, 2019, AGING CLIN EXP RES, V31, P1351, DOI 10.1007/s40520 019 01282 8
   Xie WG, 2015, MED SCI MONITOR, V21, P1333, DOI 10.12659/MSM.894111
   Xing LZ, 2017, BIOMED PHARMACOTHER, V89, P1136, DOI 10.1016/j.biopha.2017.02.073
   Xu N, 2017, BIOMED CHROMATOGR, V31, DOI 10.1002/bmc.3871
   Yang CG, 2019, MOL MED REP, V19, P1065, DOI 10.3892/mmr.2018.9752
   [詹扬 Zhan Yang], 2014, [中国药学杂志, Chinese Pharmaceutical Journal], V49, P30
   Zhang Y, 2021, LIFE SCI, V272, DOI 10.1016/j.lfs.2021.119204
   Zhong RL, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/3745051
NR 52
TC 10
Z9 10
U1 2
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1742 7835
EI 1742 7843
J9 BASIC CLIN PHARMACOL
JI Basic Clin. Pharmacol. Toxicol.
PD DEC
PY 2021
VL 129
IS 6
BP 450
EP 461
DI 10.1111/bcpt.13657
EA OCT 2021
PG 12
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA XC1DL
UT WOS:000704322400001
PM 34491615
DA 2025 08 17
ER

PT J
AU Bow, AJ
   Rifkin, RE
   Priester, C
   Christopher, CJ
   Grzeskowiak, RM
   Hecht, S
   Adair, SH
   Mulon, PY
   Castro, HF
   Campagna, SR
   Anderson, DE
AF Bow, Austin J. J.
   Rifkin, Rebecca E. E.
   Priester, Caitlin
   Christopher, Courtney J. J.
   Grzeskowiak, Remigiusz M. M.
   Hecht, Silke
   Adair, Steve H. H.
   Mulon, Pierre Yves
   Castro, Hector F. F.
   Campagna, Shawn R. R.
   Anderson, David E. E.
TI Temporal metabolic profiling of bone healing in a caprine tibia
   segmental defect model
SO FRONTIERS IN VETERINARY SCIENCE
LA English
DT Article
DE bone tissue engineering; metabolomics; large animal model; biomarkers;
   bone remodeling; caprine; regenerative medicine; veterinary research
ID OSTEOBLAST DIFFERENTIATION; ANIMAL MODELS; TISSUE; BIOMATERIALS;
   REGENERATION; SCAFFOLDS; DATABASE; CITRATE
AB Bone tissue engineering is an emerging field of regenerative medicine, with a wide array of biomaterial technologies and therapeutics employed. However, it is difficult to objectively compare these various treatments during various stages of tissue response. Metabolomics is rapidly emerging as a powerful analytical tool to establish broad spectrum metabolic signatures for a target biological system. Developing an effective biomarker panel for bone repair from small molecule data would provide an objective metric to readily assess the efficacy of novel therapeutics in relation to natural healing mechanisms. In this study we utilized a large segmental bone defect in goats to reflect trauma resulting in substantial volumetric bone loss. Characterization of the native repair capacity was then conducted over a period of 12 months through the combination of standard (radiography, computed tomography, histology, biomechanics) data and ultra high performance liquid chromatography high resolution mass spectrometry (UHPLC HRMS) metabolic profiling. Standard metrics demonstrated that samples formed soft callus structures that later mineralized. Small molecule profiles showed distinct temporal patterns associated with the bone tissue repair process. Specifically, increased lactate and amino acid levels at early time points indicated an environment conducive to osteoblast differentiation and extracellular matrix formation. Citrate and pyruvate abundances increased at later time points indicating increasing mineral content within the defect region. Taurine, shikimate, and pantothenate distribution profiles appeared to represent a shift toward a more homeostatic remodeling environment with the differentiation and activity of osteoclasts offsetting the earlier deposition phases of bone repair. The generation of a comprehensive metabolic reference portfolio offers a potent mechanism for examining novel biomaterials and can serve as guide for the development of new targeted therapeutics to improve the rate, magnitude, and quality of bone regeneration.
C1 [Bow, Austin J. J.; Rifkin, Rebecca E. E.; Adair, Steve H. H.; Mulon, Pierre Yves] Univ Tennessee, Dept Large Anim Clin Sci, Coll Vet Med, Knoxville, TN 37996 USA.
   [Priester, Caitlin] Univ Tennessee, Dept Anim Sci, Knoxville, TN USA.
   [Christopher, Courtney J. J.; Castro, Hector F. F.] Univ Tennessee, Dept Chem, Knoxville, TN USA.
   [Hecht, Silke] Univ Tennessee, Dept Small Anim Clin Sci, Coll Vet Med, Knoxville, TN USA.
   [Castro, Hector F. F.] Univ Tennessee, Biol & Small Mol Mass Spectrometry Core & Dept Che, Knoxville, TN USA.
   [Castro, Hector F. F.; Campagna, Shawn R. R.] Univ Tennessee, Dept Chem, Knoxville, TN USA.
   [Anderson, David E. E.] Univ Tennessee, Coll Vet Med, Knoxville, TN 37996 USA.
C3 University of Tennessee System; University of Tennessee Knoxville; UT
   Institute of Agriculture; University of Tennessee System; University of
   Tennessee Knoxville; UT Institute of Agriculture; University of
   Tennessee System; University of Tennessee Knoxville; University of
   Tennessee System; University of Tennessee Knoxville; UT Institute of
   Agriculture; University of Tennessee System; University of Tennessee
   Knoxville; University of Tennessee System; University of Tennessee
   Knoxville; University of Tennessee System; University of Tennessee
   Knoxville; UT Institute of Agriculture
RP Bow, AJ (通讯作者)，Univ Tennessee, Dept Large Anim Clin Sci, Coll Vet Med, Knoxville, TN 37996 USA.; Anderson, DE (通讯作者)，Univ Tennessee, Coll Vet Med, Knoxville, TN 37996 USA.
EM bow.austin@yahoo.com; dander48@utk.edu
RI ; Anderson, David/K 3673 2015; Bow, Austin/AAP 2609 2021
OI Grzeskowiak, Remigiusz/0000 0002 8656 5162; Christopher,
   Courtney/0000 0002 8387 4779; Castro, Hector/0000 0001 7323 1123;
   Anderson, David/0000 0003 0745 7591; Bow, Austin/0000 0003 1975 7364
FU U.S. Army Medical Research and Materiel Command (USAMRMC)
   [W81XWH 15 1 0666]
FX The authors acknowledge partial financial support by the U.S. Army
   Medical Research and Materiel Command (USAMRMC) grant W81XWH 15 1 0666.
CR Barbul A, 2008, J NUTR, V138, p2021S, DOI 10.1093/jn/138.10.2021S
   Bellissimo MP, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103161
   Bergh C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244291
   Bow A, 2019, DRUG METAB REV, V51, P533, DOI 10.1080/03602532.2019.1671860
   Cambiaghi A, 2017, BRIEF BIOINFORM, V18, P498, DOI 10.1093/bib/bbw031
   Chen HD, 2018, BONE, V114, P189, DOI 10.1016/j.bone.2018.06.014
   Costello Leslie C, 2012, Open Bone J, V4, DOI 10.2174/1876525401204010027
   de Grado GF, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418776819
   Ekegren CL, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15122845
   El Rashidy AA, 2017, ACTA BIOMATER, V62, P1, DOI 10.1016/j.actbio.2017.08.030
   Erngren I, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.662659
   Esen E, 2014, CURR OSTEOPOROS REP, V12, P433, DOI 10.1007/s11914 014 0235 y
   Fan JZ, 2021, METABOLITES, V11, DOI 10.3390/metabo11070434
   Fillingham Y, 2016, BONE JOINT J, V98B, P6, DOI [10.1302/0301 620X.98B1.36350, 10.1302/0301 620X.98B.36350]
   Gahoual R., 2020, 4 EMERGING BIOTECHNO, P83
   Goonoo N, 2019, RSC ADV, V9, P18124, DOI 10.1039/c9ra02765c
   Granchi D, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112576
   Greene E, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00458
   Hackam DG, 2006, JAMA J AM MED ASSOC, V296, P1731, DOI 10.1001/jama.296.14.1731
   Hansen SH, 2010, J BIOMED SCI, V17, DOI 10.1186/1423 0127 17 S1 S23
   Hebels DGAJ, 2017, BIOMATERIALS, V149, P88, DOI 10.1016/j.biomaterials.2017.10.008
   Jin ZX, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI138935
   Karner CM, 2018, BONE, V115, P2, DOI 10.1016/j.bone.2017.08.008
   Kozakiewicz M, 2020, MATERIALS, V13, DOI 10.3390/ma13132935
   Lammens J, 2017, TISSUE ENG PART C ME, V23, P694, DOI [10.1089/ten.TEC.2017.0147, 10.1089/ten.tec.2017.0147]
   Lee WC, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108108
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Liu HM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay7608
   Lobb DC, 2019, J HAND SURG AM, V44, P497, DOI 10.1016/j.jhsa.2018.10.032
   Loeffler J, 2018, TRENDS ENDOCRIN MET, V29, P99, DOI 10.1016/j.tem.2017.11.008
   Lu WY, 2010, ANAL CHEM, V82, P3212, DOI 10.1021/ac902837x
   Ma QY, 2019, AM J TRANSL RES, V11, P5008
   Martens L, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.R110.000133
   McGonigle P, 2014, BIOCHEM PHARMACOL, V87, P162, DOI 10.1016/j.bcp.2013.08.006
   Melamud E, 2010, ANAL CHEM, V82, P9818, DOI 10.1021/ac1021166
   Moghadam ET, 2021, J MATER RES TECHNOL, V13, P2078, DOI 10.1016/j.jmrt.2021.05.089
   Oumghar IA, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.584198
   Pang ZQ, 2021, NUCLEIC ACIDS RES, V49, pW388, DOI 10.1093/nar/gkab382
   Park M, 2019, IRAN J PUBLIC HEALTH, V48, P1960
   Pearce AI, 2007, EUR CELLS MATER, V13, P1
   Pivonka Peter, 2012, Bonekey Rep, V1, P221, DOI 10.1038/bonekey.2012.221
   Prideaux M, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115374
   Qu HW, 2019, RSC ADV, V9, P26252, DOI 10.1039/c9ra05214c
   Rabelo TK, 2016, INT IMMUNOPHARMACOL, V39, P97, DOI 10.1016/j.intimp.2016.07.016
   Rabinowitz JD, 2007, ANAL CHEM, V79, P6167, DOI 10.1021/ac070470c
   Reichert JC, 2009, BIOMATERIALS, V30, P2149, DOI 10.1016/j.biomaterials.2008.12.050
   Ruiz P, 2016, SCI REP UK, V6, DOI 10.1038/srep36201
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sinha S, 2009, INDIAN J ORTHOP, V43, P328, DOI 10.4103/0019 5413.55972
   Swank KR, 2020, METABOLITES, V10, DOI 10.3390/metabo10060223
   Tran RT, 2015, ANNU REV MATER RES, V45, P277, DOI 10.1146/annurev matsci 070214 020815
   van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245
   Hernandes VV, 2017, ELECTROPHORESIS, V38, P2232, DOI 10.1002/elps.201700086
   Villasenor A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 38154 6
   Wijnands KAP, 2012, AM J CLIN NUTR, V95, P1270, DOI 10.3945/ajcn.110.009209
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089
   Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065
   Woodruff MA, 2012, MATER TODAY, V15, P430, DOI 10.1016/S1369 7021(12)70194 3
   Wu Y, 2017, MOL CELL ENDOCRINOL, V452, P84, DOI 10.1016/j.mce.2017.05.017
NR 59
TC 2
Z9 2
U1 3
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 2297 1769
J9 FRONT VET SCI
JI Front. Vet. Sci.
PD JAN 17
PY 2023
VL 9
AR 1023650
DI 10.3389/fvets.2022.1023650
PG 14
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA 8I7RU
UT WOS:000921928500001
PM 36733424
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, LB
   Yan, Y
   Ma, R
   Li, DX
   Yin, WF
   Tao, QW
   Xu, Y
AF Zhang, Liu  Bo
   Yan, Yu
   Ma, Ru
   Li, Dong Xu
   Yin, Wei Feng
   Tao, Qing Wen
   Xu, Yuan
TI Integrated phytochemistry and network pharmacology analysis to reveal
   effective substances and mechanisms of Bushen Quhan Zhiwang decoction in
   the treatment of rheumatoid arthritis
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Bushen Quhan Zhiwang decoction (BQZD); Rheumatoid arthritis; UHPLC
   Q Exactive orbitrap mass spectrometry; Network pharmacology;
   TRAF6/p38/JNK MAPK pathway
ID SIGNALING PATHWAYS; INFLAMMATION; BONE; TOXICITY; TARGETS
AB Ethnopharmacological relevance: Bushen Quhan Zhiwang decoction (BQZD), a formula in traditional Chinese medicine (TCM), effectively delays bone destruction in rheumatoid arthritis (RA) patients. However, its chemical constituents, absorbed components, and metabolites remain unrevealed, and its mechanism in treating bone destruction in RA needs further investigation. Aim of the study: Our objective is to identify the chemical constituents, absorbed components, and metabolites of BQZD and explore the potential mechanisms of BQZD in treating bone destruction in RA. Materials and methods: This study systematically identified the chemical constituents, absorbed components, and metabolites of BQZD using ultra  performance liquid chromatography with Q Exactive Orbitrap mass spectrometry combined with parallel reaction monitoring. The absorbed components and metabolites were subjected to network pharmacology analysis to predict the potential mechanisms of BQZD in treating bone destruction in RA. The in vivo anti osteoclastogenic and underlying mechanism were further verified in collagen  induced arthritis (CIA) rats. Results: A total of 182 compounds were identified in BQZD, 27 of which were absorbed into plasma and organs and 42 metabolites were identified in plasma and organs. The KEGG analysis revealed that MAPK signaling pathway was highly prioritized. BQZD treatment attenuated paw swelling and the arthritis index; suppressed synovial hyperplasia, bone destruction, and osteoclast differentiation; and inhibited the levels of TNF alpha, IL 1 beta, and IL  6 in CIA rats. Mechanically, BQZD significantly decreased the protein expression levels of TRAF6, NFATc1, p JNK, and p  p38, which might be related to 9 absorbed components and 1 metabolite. Conclusion: This study revealed the key active components and metabolites of BQZD. BQZD exhibits boneprotective effects via TRAF6/p38/JNK MAPK pathway, which may be associated with 9 absorbed components and 1 metabolite.
C1 [Zhang, Liu  Bo; Yin, Wei Feng] Beijing Univ Chinese Med, Beijing 100029, Peoples R China.
   [Yan, Yu; Tao, Qing Wen; Xu, Yuan] China Japan Friendship Hosp, Dept TCM Rheumatism, Dept Pharm, Beijing 100029, Peoples R China.
   [Ma, Ru] Clin Pharm Dept, Xian 710200, Peoples R China.
   [Ma, Ru] Xian Publ Hlth Ctr, Xian 710200, Peoples R China.
   [Li, Dong Xu] Shenyang Pharmaceut Univ, Shenyang, Peoples R China.
C3 Beijing University of Chinese Medicine; China Japan Friendship Hospital;
   Shenyang Pharmaceutical University
RP Tao, QW; Xu, Y (通讯作者)，China Japan Friendship Hosp, Dept TCM Rheumatism, Dept Pharm, Beijing 100029, Peoples R China.
EM taoqg1@sina.com; xuyuan2004020@163.com
RI ; Qingwen, Tao/HHC 4235 2022
OI YAN, Yu/0000 0002 5478 1733; 
FU National High Level Hospital Clinical Research Funding
   [2022 NHLHCRF LX 02 02, 2022 NHLHCRF LX 02 0105, 2022 
   NHLHCRF LX 02 0103]; Beijing Natural Science Foundation [7232319]; Elite
   Medical Professionals Project of China  Japan Friendship Hospital
   [ZRJY2023 QM28]; National Natural Science Foundation of China for Youth
   [82204901]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This study was
   funded by National High Level Hospital Clinical Research Funding
   (2022 NHLHCRF LX 02 02; 2022 NHLHCRF LX 02 0105; 2022 
   NHLHCRF LX 02 0103) , the Beijing Natural Science Foundation (7232319) ,
   Elite Medical Professionals Project of China  Japan Friendship Hospital
   (NO. ZRJY2023 QM28) and National Natural Science Foundation of China for
   Youth (82204901).
CR Aletaha D, 2018, JAMA J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103
   Auréal M, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11010048
   Binder NB, 2013, ARTHRITIS RHEUM US, V65, P608, DOI 10.1002/art.37797
   Coutant F, 2020, CURR OPIN RHEUMATOL, V32, P57, DOI 10.1097/BOR.0000000000000664
   Crofford LJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4174
   de Hair MJH, 2018, RHEUMATOLOGY, V57, P1135, DOI 10.1093/rheumatology/kex349
   Ding Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01331 9
   Dong W, 2018, BIOCHEM BIOPH RES CO, V505, P1195, DOI 10.1016/j.bbrc.2018.10.059
   [顿珠次仁 Dunzhu Ciren], 2022, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V33, P105
   Fang Y, 2015, New Chin. Med, V47, P113
   Feng D, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.775745
   Forien M, 2017, JOINT BONE SPINE, V84, P531, DOI 10.1016/j.jbspin.2016.08.003
   He JL, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/973930
   Hu L, 2022, INT IMMUNOPHARMACOL, V111, DOI 10.1016/j.intimp.2022.109095
   Jin X, 2016, INFLAMMATION, V39, P434, DOI 10.1007/s10753 015 0265 3
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim SS, 2022, MOLECULES, V27, DOI 10.3390/molecules27020501
   Kwon SH, 2011, NEUROCHEM INT, V58, P533, DOI 10.1016/j.neuint.2011.01.012
   Lan T., 2023, Beijing Univ. Trad. Chin. Med., V46, P4
   Langbour C, 2023, INFLAMM RES, V72, P1121, DOI 10.1007/s00011 023 01717 z
   Li XH, 2022, MOLECULES, V27, DOI 10.3390/molecules27103099
   Lin YJ, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040880
   Miyoshi M, 2018, METHODS MOL BIOL, V1868, P3, DOI 10.1007/978 1 4939 8802 0_1
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Nogales C, 2022, TRENDS PHARMACOL SCI, V43, P136, DOI 10.1016/j.tips.2021.11.004
   Oh SH, 2021, KOREAN J PAIN, V34, P405, DOI 10.3344/kjp.2021.34.4.405
   Qin SH, 2022, J ANAL METHODS CHEM, V2022, DOI 10.1155/2022/8000126
   Shen WT, 2022, IMETA, V1, DOI 10.1002/imt2.36
   Shi SL, 2022, BIOMED PHARMACOTHER, V149, DOI 10.1016/j.biopha.2022.112828
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Sokka T, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2951
   Sun Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.788680
   van Ede AE, 2001, ARTHRITIS RHEUM US, V44, P1515, DOI 10.1002/1529 0131(200107)44:7<1515::AID ART273>3.0.CO;2 7
   van Tuyl LHD, 2010, ANN RHEUM DIS, V69, P1623, DOI 10.1136/ard.2009.121764
   [王钢 Wang Gang], 2021, [中国中医基础医学杂志, Chinese Journal of Basic Medicine in Traditional Chinese Medicine], V27, P1298
   Wang JW, 2022, EUR J PHARMACOL, V935, DOI 10.1016/j.ejphar.2022.175331
   Wang LF, 2021, CELL SIGNAL, V78, DOI 10.1016/j.cellsig.2020.109847
   Wang W, 2019, INT IMMUNOPHARMACOL, V69, P118, DOI 10.1016/j.intimp.2019.01.033
   Wang XH, 2023, IRAN J BASIC MED SCI, V26, P48, DOI 10.22038/IJBMS.2022.66678.14624
   Wang Y, 2021, J ETHNOPHARMACOL, V279, DOI 10.1016/j.jep.2021.114368
   Wei JX, 2022, FRONT CHEM, V10, DOI 10.3389/fchem.2022.869972
   Wu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1500 x
   [徐愿 Xu Yuan], 2020, [北京中医药大学学报, Journal of Beijing University of Traditional Chinese Medicine], V43, P289
   Yan Y., 2023, Phytomedicine, V124
   Yan Y, 2018, Henan Trad. Chin. Med., V38, P762
   Yang WW, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/4557532
   Yin Y, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.882924
   [钟惠娴 Zhong Huixian], 2022, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V33, P242
   Zhu X, 2023, Journal of Chinese Medicinal Materials, V46, P73
   Zhuang JM, 2023, CHIN MED UK, V18, DOI 10.1186/s13020 023 00818 5
NR 50
TC 4
Z9 4
U1 6
U2 17
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAY 10
PY 2024
VL 325
AR 117897
DI 10.1016/j.jep.2024.117897
EA FEB 2024
PG 23
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA KZ7D3
UT WOS:001183847500001
PM 38336180
OA hybrid
DA 2025 08 17
ER

PT J
AU Jin, ZX
   Kho, J
   Dawson, B
   Jiang, MM
   Chen, YQ
   Ali, S
   Burrage, LC
   Grover, M
   Palmer, DJ
   Turner, DL
   Ng, P
   Nagamani, SCS
   Lee, B
AF Jin, Zixue
   Kho, Jordan
   Dawson, Brian
   Jiang, Ming Ming
   Chen, Yuqing
   Ali, Saima
   Burrage, Lindsay C.
   Grover, Monica
   Palmer, Donna J.
   Turner, Dustin L.
   Ng, Philip
   Nagamani, Sandesh C. S.
   Lee, Brendan
TI Nitric oxide modulates bone anabolism through regulation of osteoblast
   glycolysis and differentiation
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID PROTEIN S NITROSYLATION; GLUCOSE UPTAKE; IN VIVO; MITOCHONDRIAL
   BIOGENESIS; ARGININOSUCCINATE LYASE; NITROGLYCERIN THERAPY; SYNTHASE
   EXPRESSION; ORGANIC NITRATES; CAVEOLIN 1; MICE
AB Previous studies have shown that nitric oxide (NO) supplements may prevent bone loss and fractures in preclinical models of estrogen deficiency. However, the mechanisms by which NO modulates bone anabolism remain largely unclear. Argininosuccinate lyase (ASL) is the only mammalian enzyme capable of synthesizing arginine, the sole precursor for nitric oxide synthase dependent (NOS dependent) NO synthesis. Moreover, ASL is also required for channeling extracellular arginine to NOS for NO production. ASL deficiency (ASLD) is thus a model to study cell autonomous, NOS dependent NO deficiency. Here, we report that loss of ASL led to decreased NO production and impairment of osteoblast differentiation. Mechanistically, the bone phenotype was at least in part driven by the loss of NO mediated activation of the glycolysis pathway in osteoblasts that led to decreased osteoblast differentiation and function. Heterozygous deletion of caveolin 1, a negative regulator of NO synthesis, restored NO production, osteoblast differentiation, glycolysis, and bone mass in a hypomorphic mouse model of ASLD. The translational significance of these preclinical studies was further reiterated by studies conducted in induced pluripotent stem cells from an individual with ASLD. Taken together, our findings suggest that ASLD is a unique genetic model for studying NO dependent osteoblast function and that the NO/glycolysis pathway may be a new target to modulate bone anabolism.
C1 [Jin, Zixue; Kho, Jordan; Dawson, Brian; Jiang, Ming Ming; Chen, Yuqing; Ali, Saima; Burrage, Lindsay C.; Palmer, Donna J.; Turner, Dustin L.; Ng, Philip; Nagamani, Sandesh C. S.; Lee, Brendan] Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,MS225, Houston, TX 77030 USA.
   [Burrage, Lindsay C.; Nagamani, Sandesh C. S.; Lee, Brendan] Texas Childrens Hosp, Houston, TX 77030 USA.
   [Grover, Monica] Stanford Sch Med, Dept Pediat Endocrinol, Stanford, CA 94305 USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College
   Medical Hospital; Stanford University
RP Lee, B (通讯作者)，Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,MS225, Houston, TX 77030 USA.
EM blee@bcm.edu
RI ; Ng, Kin Cheung/HIR 5882 2022; Chen, Yuqing/GWU 7343 2022; Jin,
   Zixue/E 4473 2014
OI Kho, Jordan/0000 0003 4860 1721; Ali, Saima/0000 0002 2196 6360; Jin,
   Zixue/0000 0002 7857 398X; 
FU BCM Intellectual and Developmental Disabilities Research Center from the
   National Institute of Child Health & Human Development [P30 HD024064,
   U54 HD083092, P50 HD103555]; BCM Advanced Technology Cores; NIH [R01
   DK114356, UM1 HG006348, K08 DK106453, P30 CA125123, S10 OD028591, R01
   DK102641, R01 AR071741]; Rolanette and Berdon Lawrence Bone Disease
   Program of Texas; BCM Center for Skeletal Medicine and Biology; BCM
   Human Stem Cell Core; Burroughs Wellcome Fund
FX We would like to thank Megan Bagos and Carrie Jiang for assistance with
   mu CT analyses. This work was supported by the BCM Intellectual and
   Developmental Disabilities Research Center (P30 HD024064, U54 HD083092,
   and P50 HD103555) from the National Institute of Child Health & Human
   Development, the BCM Advanced Technology Cores with funding from the NIH
   (R01 DK114356 and UM1 HG006348) , the Rolanette and Berdon Lawrence Bone
   Disease Program of Texas, and the BCM Center for Skeletal Medicine and
   Biology. This project was also supported by the BCM Human Stem Cell
   Core, which is funded in part by the institution and the NIH (P30
   CA125123 and S10 OD028591) and NIH grants R01 DK102641 and R01 AR071741.
   LCB holds a Career Award for Medical Scientists from the Burroughs
   Wellcome Fund and was supported by NIH K08 DK106453.
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Barruet E, 2016, METHODS MOL BIOL, V1353, P101, DOI 10.1007/7651_2014_171
   Basso N, 2006, BONE, V39, P807, DOI 10.1016/j.bone.2006.04.014
   Bolaños JP, 2008, BBA BIOENERGETICS, V1777, P789, DOI 10.1016/j.bbabio.2008.04.011
   Brown GC, 2001, BBA BIOENERGETICS, V1504, P46, DOI 10.1016/S0005 2728(00)00238 3
   Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176
   Chen H, 2019, FASEB J, V33, P7810, DOI 10.1096/fj.201900201RR
   Dirckx N, 2018, J CLIN INVEST, V128, P1087, DOI 10.1172/JCI97794
   Doulias PT, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003252
   Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688
   Erez A, 2011, NAT MED, V17, P1619, DOI 10.1038/nm.2544
   Erez A, 2011, AM J MED GENET C, V157C, P45, DOI 10.1002/ajmg.c.30289
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Etgen GJ, 1997, DIABETES, V46, P1915, DOI 10.2337/diabetes.46.11.1915
   Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810
   GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237
   Gladwin MT, 2011, NAT MED, V17, P1556, DOI 10.1038/nm.2591
   Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17
   Guntur AR, 2018, J BONE MINER RES, V33, P1052, DOI 10.1002/jbmr.3390
   Gyurko R, 2005, BONE, V36, P472, DOI 10.1016/j.bone.2004.12.002
   Helfrich MH, 1997, J BONE MINER RES, V12, P1108, DOI 10.1359/jbmr.1997.12.7.1108
   Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569
   Hukkanen M, 2003, BONE, V32, P142, DOI 10.1016/S8756 3282(02)00955 9
   Hukkanen MVJ, 1999, J BONE MINER RES, V14, P868, DOI 10.1359/jbmr.1999.14.6.868
   Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104
   Jin ZX, 2014, CELL METAB, V20, P483, DOI 10.1016/j.cmet.2014.07.011
   Kalyanaraman H, 2017, J BONE MINER RES, V32, P46, DOI 10.1002/jbmr.2909
   Karner CM, 2018, BONE, V115, P2, DOI 10.1016/j.bone.2017.08.008
   Kellogg DL, 2017, FREE RADICAL BIO MED, V110, P261, DOI 10.1016/j.freeradbiomed.2017.06.018
   Kho J, 2018, AM J HUM GENET, V103, P276, DOI 10.1016/j.ajhg.2018.07.008
   Lee WC, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108108
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Lerner S, 2019, CELL REP, V29, P2144, DOI 10.1016/j.celrep.2019.10.043
   Lira VA, 2007, AM J PHYSIOL ENDOC M, V293, pE1062, DOI 10.1152/ajpendo.00045.2007
   Litvinova L, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00020
   Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200
   McConell GK, 2012, AM J PHYSIOL ENDOC M, V303, pE301, DOI 10.1152/ajpendo.00667.2011
   Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583
   Mineo C, 2006, CARDIOVASC RES, V70, P31, DOI 10.1016/j.cardiores.2006.01.025
   Nagamani SCS, 2012, AM J HUM GENET, V90, P836, DOI 10.1016/j.ajhg.2012.03.018
   Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368
   Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101
   Palmer DJ, 2016, MOL THER NUCL ACIDS, V5, DOI 10.1038/mtna.2016.83
   Pouwels S, 2010, J CLIN ENDOCR METAB, V95, P1924, DOI 10.1210/jc.2009 2342
   Qiu C, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 54077 2
   Razani B, 2001, J BIOL CHEM, V276, P38121
   Rejnmark L, 2006, J BONE MINER RES, V21, P1811, DOI 10.1359/JBMR.060804
   ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092 8674(92)90143 Z
   Roy D, 1998, AM J PHYSIOL ENDOC M, V274, pE692, DOI 10.1152/ajpendo.1998.274.4.E692
   Sabanai K, 2008, J BONE MINER RES, V23, P633, DOI 10.1359/JBMR.080107
   Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131
   Shum LC, 2016, STEM CELLS DEV, V25, P114, DOI 10.1089/scd.2015.0193
   Shyh Chang N, 2013, DEVELOPMENT, V140, P2535, DOI 10.1242/dev.091777
   Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092 8674(01)00495 0
   Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209
   Stan RV, 2005, BBA MOL CELL RES, V1746, P334, DOI 10.1016/j.bbamcr.2005.08.008
   Stettner N, 2018, CELL REP, V23, P1962, DOI 10.1016/j.celrep.2018.04.053
   Tan CC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2144 6
   Tanaka T, 2003, EUR J ENDOCRINOL, V149, P61, DOI 10.1530/eje.0.1490061
   Trane AE, 2014, J BIOL CHEM, V289, P13273, DOI 10.1074/jbc.M113.528695
   van't Hof RJ, 2004, ENDOCRINOLOGY, V145, P5068, DOI 10.1210/en.2004 0205
   Watanuki M, 2002, J BONE MINER RES, V17, P1015, DOI 10.1359/jbmr.2002.17.6.1015
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 3 214
   Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240
   Wimalawansa SJ, 1996, BONE, V18, P301, DOI 10.1016/8756 3282(96)00005 1
   Wimalawansa SJ, 2009, J CLIN ENDOCR METAB, V94, P3356, DOI 10.1210/jc.2008 2225
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhao YY, 2009, J CLIN INVEST, V119, P2009, DOI 10.1172/JCI33338
NR 71
TC 58
Z9 62
U1 3
U2 29
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAR 1
PY 2021
VL 131
IS 5
AR e138935
DI 10.1172/JCI138935
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA QR6RQ
UT WOS:000625344000004
PM 33373331
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Zhang, XY
   Liu, QB
   Zhang, TT
   Gao, P
   Wang, H
   Yao, L
   Huang, JW
   Jiang, SL
AF Zhang, Xiangyu
   Liu, Qingbin
   Zhang, Tingting
   Gao, Pei
   Wang, Hui
   Yao, Lu
   Huang, Jingwen
   Jiang, Shulong
TI Bone targeted nanoplatform enables efficient modulation of bone tumor
   microenvironment for prostate cancer bone metastasis treatment
SO DRUG DELIVERY
LA English
DT Article
DE Prostate cancer; bone metastasis; calcium phosphate nanoparticle; bone
   microenvironment; sonic hedgehog (SHH) protein
ID CALCIUM PHOSPHATE NANOPARTICLES; SIRNA; DELIVERY; PEG; PACLITAXEL;
   THERAPY; PLAYERS; MAOA
AB As there is currently no effective therapy for patients with prostate cancer (PCa) bone metastasis, it was stringent to explore the relevant treatment strategies. Actually, the interaction between cancer cells and bone microenvironment plays important role in prostate cancer bone metastasis, especially the Sonic hedgehog protein (SHH) signaling in the bone microenvironment. The SHH promotes osteoblast maturation and osteoblast then secretes RANKL to induce osteoclastogenesis. Herein, this study develops bone targeting calcium phosphate lipid hybrid nanoparticles (NPs) loaded with docetaxel (DTXL) and SHH siRNA for PCa bone metastasis treatment. For bone targeting purposes, the nanoplatform was modified with alendronate (ALN). (DTXL + siRNA)@NPs ALN NPs effectively change the bone microenvironment by inhibiting the SHH paracrine and autocrine signaling, enhancing the anti tumor effects of DTXL. Besides showing good in vitro cellular uptake, the NPs ALN also inhibited tumor growth both in vitro and in vivo by inducing apoptosis, cell cycle arrest, and autophagy. This DDS comprised of (DTXL + siRNA) loaded NPs provides an excellent strategy to treat PCa bone metastasis.
C1 [Zhang, Xiangyu] Shandong Univ Tradit Chinese Med, Jinan, Peoples R China.
   [Zhang, Xiangyu] Jining Med Univ, Jining 1 Peoples Hosp, Dept Pathol, Jining, Peoples R China.
   [Liu, Qingbin; Jiang, Shulong] Jining Med Univ, Jining 1 Peoples Hosp, Clin Med Lab Ctr, Jining 272000, Peoples R China.
   [Zhang, Tingting; Gao, Pei; Wang, Hui; Yao, Lu] Jining Med Univ, Jining 1 Peoples Hosp, Jining, Peoples R China.
   [Huang, Jingwen] Bengbu Med Coll, Tumor Hosp, Affiliated Hosp 1, Bengbu 233004, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Jining Medical
   University; Jining Medical University; Jining Medical University; Bengbu
   Medical University
RP Jiang, SL (通讯作者)，Jining Med Univ, Jining 1 Peoples Hosp, Clin Med Lab Ctr, Jining 272000, Peoples R China.; Huang, JW (通讯作者)，Bengbu Med Coll, Tumor Hosp, Affiliated Hosp 1, Bengbu 233004, Peoples R China.
EM byyfyhjw@163.com; jnsljiang@163.com
FU National Natural Science Foundation of China [81803097, 81873249,
   82074360]; Natural Science Foundation of Shandong Province
   [ZR2017QH005]; Young Taishan Scholars Program of Shandong Province
   [tsqn201909200]; University Natural Science Research Project of Anhui
   Province [KJ2019A0313]
FX This research was supported through grants from the National Natural
   Science Foundation of China (Grant Nos. 81803097, 81873249, and
   82074360), the Natural Science Foundation of Shandong Province (No.
   ZR2017QH005), the Young Taishan Scholars Program of Shandong Province
   (Grant No. tsqn201909200), and University Natural Science Research
   Project of Anhui Province (No. KJ2019A0313).
CR Abe K, 2015, COLLOID SURFACE A, V474, P63, DOI 10.1016/j.colsurfa.2015.03.006
   Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Berish RB, 2018, NAT REV UROL, V15, P403, DOI 10.1038/s41585 018 0020 2
   Bialas N, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121013
   Bisso S, 2019, EUR J PHARM BIOPHARM, V142, P142, DOI 10.1016/j.ejpb.2019.06.013
   Bushman W, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4040030
   Chen JH, 2016, ACS NANO, V10, P11548, DOI 10.1021/acsnano.6b06182
   Chen SH, 2020, J MATER CHEM B, V8, P3789, DOI 10.1039/d0tb00046a
   Chu WJ, 2017, INT J PHARMACEUT, V516, P352, DOI 10.1016/j.ijpharm.2016.11.051
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Cook LM, 2019, ONCOGENE, V38, P6959, DOI 10.1038/s41388 019 0913 4
   Cummings SR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115411
   Dai JL, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.4
   Furesi G, 2021, TRENDS CANCER, V7, P112, DOI 10.1016/j.trecan.2020.09.006
   He YF, 2017, J CONTROL RELEASE, V264, P76, DOI 10.1016/j.jconrel.2017.08.024
   Huang D, 2019, BIOMATER SCI UK, V7, P3942, DOI 10.1039/c9bm00831d
   Ihle CL, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425 019 0753 3
   Ishii A, 2020, ANTICANCER RES, V40, P5107, DOI 10.21873/anticanres.14514
   Jacob K, 1999, CANCER RES, V59, P4453
   Kara G, 2020, COLLOID SURFACE B, V196, DOI 10.1016/j.colsurfb.2020.111340
   Khalifehzadeh R, 2020, ADV COLLOID INTERFAC, V279, DOI 10.1016/j.cis.2020.102157
   Kingston Robert E, 2003, Curr Protoc Mol Biol, VChapter 9, DOI 10.1002/0471142727.mb0901s63
   Li J, 2012, J CONTROL RELEASE, V158, P108, DOI 10.1016/j.jconrel.2011.10.020
   Long MM, 2021, J CONTROL RELEASE, V334, P303, DOI 10.1016/j.jconrel.2021.04.035
   Lv WT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163981
   Perrot CY, 2013, PHARMACOL THERAPEUT, V137, P183, DOI 10.1016/j.pharmthera.2012.10.002
   Pina S, 2015, ADV MATER, V27, P1143, DOI 10.1002/adma.201403354
   Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101
   Siegel RL, 2021, CA CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
   Tang J, 2018, NANOSCALE, V10, P4258, DOI 10.1039/c7nr08644j
   Urch H, 2006, MATERIALWISS WERKST, V37, P422, DOI 10.1002/mawe.200600008
   Wei J, 2021, CANCER RES, V81, P4275, DOI 10.1158/0008 5472.CAN 21 0198
   Wissing MD, 2015, INT J CANCER, V136, pE760, DOI 10.1002/ijc.29231
   Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003
   Yang RN, 2017, NANOMED NANOTECHNOL, V13, P391, DOI 10.1016/j.nano.2016.07.017
   Zhang XY, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880 019 0425 1
   Zhang XY, 2019, DRUG DES DEV THER, V13, P1357, DOI 10.2147/DDDT.S198400
   Zhou ZL, 2017, NANOMED NANOTECHNOL, V13, P403, DOI 10.1016/j.nano.2016.07.016
NR 38
TC 10
Z9 11
U1 7
U2 88
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071 7544
EI 1521 0464
J9 DRUG DELIV
JI Drug Deliv.
PD DEC 31
PY 2022
VL 29
IS 1
BP 889
EP 905
DI 10.1080/10717544.2022.2050845
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 0D4EG
UT WOS:000775949700001
PM 35285760
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Rafat, A
   Bahmanzadeh, M
   Asl, SS
   Roushandeh, AM
   Golipoor, Z
AF Rafat, Ali
   Bahmanzadeh, Maryam
   Asl, Sara Soleimani
   Roushandeh, Amaneh Mohammadi
   Golipoor, Zoleikha
TI The Role of Melatonin Preconditioning on Survival of Bone Marrow Derived
   Mesenchymal Stem Cells in Differentiation to Osteoblasts
SO IRANIAN RED CRESCENT MEDICAL JOURNAL
LA English
DT Article
DE Antioxidant; Bone Marrow; Mesenchymal Stem Cell; Melatonin Osteoblast;
   Osteogenesis; Preconditioning
ID SIGNALING PATHWAY; INFARCTED HEART; LIVER FIBROSIS; ISCHEMIC HEART;
   TRANSPLANTATION; THERAPY; MECHANISMS; REPAIR
AB Background: Preconditioning has become an increasingly promising strategy and applied in cell therapy and shows multiple therapeutic benefits in several diseases. Some bioactive agents, such as hormones, are utilized to a develop cell therapy outcome. Melatonin is secreted from the pineal gland and is famous for its antioxidant capability and cytoprotection potential. Evidence suggest that melatonin may play an important role in the regulation of mesenchymal stem cells (MSCs) differentiation to osteoblasts.
   Objectives: The aim of this study was to evaluate the influence of melatonin preconditioning on the differentiation of bone marrow derived mesenchymal stem cells (BM MSCs) to osteoblasts.
   Methods: This experimental study was performed at molecular genetic and embryology laboratories of Hamadan University of Medical Sciences, Hamadan, Iran, from October 2015 to April 2017. The bone marrow stem cells (BMSCs) were obtained, cultured, expanded, and preconditioned with 5 mu M melatonin and analyzed for their multi potency and immunophenotypic potential at passage five. There were three groups composed of the control group BMSCs + osteogenic medium group, and melatonin bone marrow stem cells (MT BMSCs) group. The BMSCs and MT BMSCs were cultivated in an osteogenic medium. After three weeks of cell survival, osteogenic capability and apoptosis were assessed in three groups.
   Results: Bone marrow derived mesenchymal stem cells expressed CD44 and CD90, yet not CD45 and showed differentiation to adipocytes and osteoblast. The BMSCs were preconditioned with MT expressed metallothionein 1(MT1) and metallothionein 2 (MT2) (P < 0.05). Group three showed lower expression of Bax gene yet higher expression of Bcl2 (P < 0.05). Group three had a high ability of osteogenic differentiation capability and reduced apoptosis.
   Conclusions: The current study detected that melatonin pretreatment promotes MSC survival, reduce apoptosis, and has a positive effect on osteogenic factors in vitro. The preconditioning strategy may represent a safe approach to improve the beneficial effects of stem cell therapy in bone regenerative medicine.
C1 [Rafat, Ali; Asl, Sara Soleimani] Hamadan Univ Med Sci, Sch Med, Dept Anat Sci, Hamadan, Iran.
   [Bahmanzadeh, Maryam] Hamadan Univ Med Sci, Endometrium & Endometriosis Res Ctr, Hamadan, Iran.
   [Roushandeh, Amaneh Mohammadi] Guilan Univ Med Sci, Paramed Fac, Med Biotechnol Res Ctr, Rasht, Iran.
   [Golipoor, Zoleikha] Guilan Univ Med Sci, Fac Med, Cellular & Mol Res Ctr, Rasht, Iran.
C3 Hamadan University of Medical Sciences; Hamadan University of Medical
   Sciences; Guilan University of Medical Sciences; Guilan University of
   Medical Sciences
RP Golipoor, Z (通讯作者)，Guilan Univ Med Sci, Sch Med, Dept Anat Sci, Rasht, Iran.
EM masoomeh_golipoor@yahoo.com
RI Mohammadi Roushandeh, Amaneh/F 3423 2017; Asl, Sara/O 9292 2017
OI Mohammadi Roushandeh, Amaneh/0000 0002 3639 2291
FU Hamadan University of Medical Sciences, Hamadan, Iran [9411136350]
FX This study was supported by a grant from Hamadan University of Medical
   Sciences, Hamadan, Iran, with code number 9411136350.
CR Abo Aziza Faten A M, 2017, Int J Hematol Oncol Stem Cell Res, V11, P121
   Arthur A, 2009, J CELL PHYSIOL, V218, P237, DOI 10.1002/jcp.21592
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   Golipoor Z, 2016, CELL J, V17, P639
   Golipoor Z, 2010, IRAN J BASIC MED SCI, V13, P76
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Haider KH, 2012, PROG MOL BIOL TRANSL, V111, P323, DOI 10.1016/B978 0 12 398459 3.00015 0
   Han D, 2016, J PINEAL RES, V60, P178, DOI 10.1111/jpi.12299
   Jeong YM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14219 w
   Khatibi S, 2016, ENTOMOL APPL SCI LET, V3, P89
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Lee S, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/632902
   Liu XB, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt499
   Liu XB, 2009, J CELL BIOCHEM, V106, P903, DOI 10.1002/jcb.22064
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Luchetti F, 2014, J PINEAL RES, V56, P382, DOI 10.1111/jpi.12133
   Luchetti F, 2010, FASEB J, V24, P3603, DOI 10.1096/fj.10 154450
   Mehrzadi S, 2017, CAN J PHYSIOL PHARM, V95, P773, DOI 10.1139/cjpp 2016 0409
   Mias C, 2008, STEM CELLS, V26, P1749, DOI 10.1634/stemcells.2007 1000
   Mortezaee K, 2017, CELL TISSUE RES, V369, P303, DOI 10.1007/s00441 017 2604 1
   Mortezaee Keywan, 2016, Iranian Biomedical Journal, V20, P207, DOI 10.7508/ibj.2016.04.004
   Patschan D, 2012, AM J PHYSIOL RENAL, V302, pF1305, DOI 10.1152/ajprenal.00445.2011
   Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1007/BF02253360
   Reiter RJ, 2003, ACTA BIOCHIM POL, V50, P1129
   Roushandeh AM, 2017, ARCH MED RES, V48, P133, DOI 10.1016/j.arcmed.2017.03.007
   Tang YH, 2014, CELL TRANSPLANT, V23, P1279, DOI [10.3727/096368913x667510, 10.3727/096368913X667510]
   Tang YL, 2005, J AM COLL CARDIOL, V46, P1339, DOI 10.1016/j.jacc.2005.05.079
   Wisel S, 2009, J PHARMACOL EXP THER, V329, P543, DOI 10.1124/jpet.109.150839
   Yang Y, 2015, J PINEAL RES, V58, P61, DOI 10.1111/jpi.12193
   Yu SP, 2013, TRANSL STROKE RES, V4, P76, DOI 10.1007/s12975 012 0251 0
   Zaminy Arash, 2008, Iran Biomed J, V12, P133
   Zhang LM, 2013, J PINEAL RES, V54, P24, DOI 10.1111/j.1600 079X.2012.01016.x
NR 32
TC 1
Z9 1
U1 0
U2 13
PU KOWSAR PUBL
PI HOENSBROEK
PA PATERSWEG 22,, HOENSBROEK, LIMBURG 6431 GC, NETHERLANDS
SN 2074 1804
EI 2074 1812
J9 IRAN RED CRESCENT ME
JI Iran. Red Crescent Med. J.
PD NOV
PY 2018
VL 20
IS 11
AR e60886
DI 10.5812/ircmj.60886
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA GZ8EW
UT WOS:000449720700002
OA gold
DA 2025 08 17
ER

PT J
AU Jayakumar, P
   Di Silvio, L
AF Jayakumar, P.
   Di Silvio, L.
TI Osteoblasts in bone tissue engineering
SO PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART H JOURNAL OF
   ENGINEERING IN MEDICINE
LA English
DT Article
DE Osteoblast; bone; tissue; engineering; regeneration
ID MESENCHYMAL STEM CELLS; HUMAN OSTEOGENIC PROTEIN 1; IN VITRO;
   MORPHOGENETIC PROTEINS; GROWTH FACTORS; FRACTURE REPAIR; MARROW;
   DIFFERENTIATION; BIOLOGY; HYDROXYAPATITE
AB Osteoblasts are integral to the development, growth, function, repair and maintenance of bone. The osteoblast forms organic, non mineralized bone matrix and is involved in complex interactions with a variety of factors, mediators and cell types. Degeneration, pathology, and trauma cause disruption and destruction of the normal skeletal environment and may lead to bone loss.
   There is a rise in active populations involved in trauma, elderly patients with fragility fractures and an overall increase in primary, revision and reconstructive bone and joint surgery. Despite the rapid evolution of implant technologies and bone grafting techniques, there is still a great demand for novel bone replacement strategies.
   Bone tissue engineering is the state of the art science with the potential to regenerate bone with natural form and function. This review presents the biology of osteoblasts and their current applications in bone tissue engineering biotechnologies and role in stem cell, bioactive factor, recombinant signalling molecule and gene therapy research.
C1 [Jayakumar, P.; Di Silvio, L.] Kings Coll London, Dept Biomat, London SE1 9RT, England.
C3 University of London; King's College London
RP Jayakumar, P (通讯作者)，Kings Coll London, Dept Biomat, London SE1 9RT, England.
EM Lucy.Di_silvio@kcl.ac.uk
RI ; Jayakumar, Prakash/ABC 4542 2021
OI Di Silvio, Lucy/0000 0003 2554 2052; Jayakumar,
   Prakash/0000 0003 2598 2509; 
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   ALBREKTSSON T, 1981, ACTA ORTHOP SCAND, V52, P155, DOI 10.3109/17453678108991776
   Albrektsson T, 1998, CLIN ORTHOP RELAT R, P81
   Albrektsson T, 2001, EUR SPINE J, V10, pS96, DOI 10.1007/s005860100282
   ALBREKTSSON T, 1980, J BONE JOINT SURG BR, V62, P403, DOI 10.1302/0301 620X.62B3.6997321
   ALBREKTSSON T, 2000, APPL OSSEOINTEGRATIO, V1, P21
   ALBREKTSSON T, 1995, DENT MAXILLOFACIAL I, P1
   ALBREKTSSON T, 1993, SUPPL, V7, P15
   [Anonymous], 2007, The care of patients with fragility fracture (Blue Book)
   [Anonymous], 2007, DORLANDS ILLUSTRATED, V31st
   [Anonymous], ROBBINS PATHOLOGICAL
   Arinzeh Treena Livingston, 2005, Foot Ankle Clin, V10, P651, DOI 10.1016/j.fcl.2005.06.004
   ARKIN AM, 1956, J BONE JOINT SURG AM, V38, P1056, DOI 10.2106/00004623 195638050 00009
   ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294
   Bahamonde ME, 2001, J BONE JOINT SURG AM, V83A, pS56
   Bajada S, 2008, J TISSUE ENG REGEN M, V2, P169, DOI 10.1002/term.83
   Balasch J, 2003, HUM REPROD UPDATE, V9, P207, DOI 10.1093/humupd/dmg017
   BASSETT CAL, 1968, CALC TISS RES, V1, P252
   Bauer TW, 2007, SKELETAL RADIOL, V36, P1105, DOI 10.1007/s00256 007 0377 4
   Bauer TW., 2000, CLIN ORTHOP RELAT R, V371, P10
   Bernstein P, 2009, ORTHOPADE, V38, P1029, DOI 10.1007/s00132 009 1493 8
   Bianco P, 1999, CRIT REV EUKAR GENE, V9, P159, DOI 10.1615/CritRevEukarGeneExpr.v9.i2.30
   Boden SD, 1999, CLIN ORTHOP RELAT R, pS84
   BONFIGLIO M, 1972, CLIN ORTHOP RELAT R, P19
   BOVAN BD, 2006, J AM ACAD ORTHOP SUR, V14, pS157
   Branemark P I, 1977, Scand J Plast Reconstr Surg Suppl, V16, P1
   Bruder SP, 1999, CLIN ORTHOP RELAT R, pS68
   BUCH F, 1985, THESIS U GOTHENBURG, P1
   BURCHARDT H, 1983, CLIN ORTHOP RELAT R, P28
   BURWELL RG, 1963, J BONE JOINT SURG BR, V45, P386, DOI 10.1302/0301 620X.45B2.386
   Buttery LDK, 2001, TISSUE ENG, V7, P89, DOI 10.1089/107632700300003323
   CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27
   Chang SCN, 2003, PLAST RECONSTR SURG, V112, P1841, DOI 10.1097/01.PRS.0000091168.73462.1A
   Chapman MW, 1997, J BONE JOINT SURG AM, V79A, P495, DOI 10.2106/00004623 199704000 00004
   Chen JH, 2010, J BIOMECH, V43, P108, DOI 10.1016/j.jbiomech.2009.09.016
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Chim H, 2008, PLAST RECONSTR SURG, V122, P755, DOI 10.1097/PRS.0b013e31818236b7
   Clines GA, 2010, CURR OPIN ORGAN TRAN, V15, P73, DOI 10.1097/MOT.0b013e328333d52c
   CONNOLLY J, 1989, J BONE JOINT SURG AM, V71A, P684, DOI 10.2106/00004623 198971050 00007
   CONRAD EU, 1995, J BONE JOINT SURG AM, V77A, P214, DOI 10.2106/00004623 199502000 00007
   Cuomo AV, 2009, J BONE JOINT SURG AM, V91A, P1073, DOI 10.2106/JBJS.H.00303
   DEALLER SF, 1981, J MED ENG TECHNOL, V5, P73, DOI 10.3109/03091908109042442
   Di Silvio L., 2001, HUMAN CELL CULTURE, P221
   Di Silvio L., 2004, ENCY BIOMATERIALS BI, V1, P1500
   DISILVIO L, 2008, J BONE JOINT SURG S1, V90, P13
   DiSilvio L, 2006, INJURY, V37, pS33, DOI 10.1016/j.injury.2006.08.022
   DOI K, 1977, J BONE JOINT SURG AM, V59, P809, DOI 10.2106/00004623 197759060 00015
   DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795
   Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095
   Einhorn T A, 1997, Instr Course Lect, V46, P483
   EINHORN TA, 1984, J BONE JOINT SURG AM, V66A, P274, DOI 10.2106/00004623 198466020 00015
   El Tamer MK, 2009, J TISSUE ENG REGEN M, V3, P327, DOI 10.1002/term.173
   ENNEKING WF, 1991, J BONE JOINT SURG AM, V73A, P1123, DOI 10.2106/00004623 199173080 00002
   Frankenburg EP, 1998, J BONE JOINT SURG AM, V80A, P1112, DOI 10.2106/00004623 199808000 00004
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   FRIEDLAENDER GE, 1983, CLIN ORTHOP RELAT R, P58
   Fröhlich M, 2008, CURR STEM CELL RES T, V3, P254, DOI 10.2174/157488808786733962
   FROST HM, 1989, CLIN ORTHOP RELAT R, P283
   FROST HM, 1989, CLIN ORTHOP RELAT R, P294
   Gentleman E, 2009, NAT MATER, V8, P763, DOI [10.1038/NMAT2505, 10.1038/nmat2505]
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Glantz P.O., 1987, PROGR BIOMEDICAL ENG, V4, P24
   GOLDBERG VM, 1991, BONE AND CARTILAGE ALLOGRAFTS : BIOLOGY AND CLINICAL APPLICATIONS, P3
   Gordeladze JO, 2010, ILAR J, V51, P42, DOI 10.1093/ilar.51.1.42
   GOTTLANDER M, 1994, THESIS U GOTEBORG SW, P1
   Handschel J, 2009, J BIOMATER APPL, V23, P549, DOI 10.1177/0885328208094305
   HAUSCHKA PV, 1988, CIBA F SYMP, V136, P207
   HAYNESWORTH SE, 1987, J BIOL CHEM, V262, P10574
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   HEALEY JH, 1990, CLIN ORTHOP RELAT R, P280
   Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Hernigou P, 2005, J BONE JOINT SURG AM, V87A, P1430, DOI 10.2106/JBJS.D.02215
   Hing KA, 2004, PHILOS T R SOC A, V362, P2821, DOI 10.1098/rsta.2004.1466
   HOROWITZ MC, 1991, J BONE JOINT SURG AM, V73A, P1157, DOI 10.2106/00004623 199173080 00004
   Israel DI, 1996, GROWTH FACTORS, V13, P291, DOI 10.3109/08977199609003229
   Jäger M, 2009, CURR STEM CELL RES T, V4, P34, DOI 10.2174/157488809787169039
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   JOHANSSON C, 1992, EUR J EXP MUSCULOSKE, V1, P51
   Johansson CB, 1998, INT J ORAL MAX IMPL, V13, P315
   Jukes JM, 2008, P NATL ACAD SCI USA, V105, P6840, DOI 10.1073/pnas.0711662105
   Jukes JM, 2010, J TISSUE ENG REGEN M, V4, P165, DOI 10.1002/term.234
   Kaigler D, 2010, TISSUE ENG PT A, V16, P2809, DOI [10.1089/ten.tea.2010.0079, 10.1089/ten.TEA.2010.0079]
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Keating JF, 2001, J BONE JOINT SURG BR, V83B, P3, DOI 10.1302/0301 620X.83B1.11952
   KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955 0674(95)80071 9
   Khan Y, 2008, J BONE JOINT SURG AM, V90A, P138, DOI 10.2106/JBJS.G.01218
   Kobayashi Y, 2009, CRIT REV EUKAR GENE, V19, P61, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.30
   Korda M, 2006, TISSUE ENG, V12, P625, DOI 10.1089/ten.2006.12.625
   Kuehnle I, 2002, BMJ BRIT MED J, V325, P372, DOI 10.1136/bmj.325.7360.372
   LANYON LE, 1992, J BONE MINER RES, V7, pS369, DOI 10.1002/jbmr.5650071403
   Larsson S, 2002, CLIN ORTHOP RELAT R, P23
   Leach JK, 2004, EXPERT OPIN BIOL TH, V4, P1015, DOI 10.1517/14712598.4.7.1015
   Lee K, 2009, J BIOMED MATER RES B, V89B, P252, DOI 10.1002/jbm.b.31199
   LEE MY, 1997, CLIN ORTHOP RELAT R, V340, P15
   Levander G., 1938, Surgery Gynecology and Obstetrics, V67, P705
   Lind M, 1996, ACTA ORTHOP SCAND, V67, P407, DOI 10.3109/17453679609002342
   Majors AK, 1997, J ORTHOPAED RES, V15, P546, DOI 10.1002/jor.1100150410
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Matthews SJE, 2005, INJURY, V36, P34, DOI 10.1016/j.injury.2005.07.032
   Mayer H, 1996, CALCIFIED TISSUE INT, V58, P249
   McLaren A, 2001, NATURE, V414, P129, DOI 10.1038/35102194
   Meijer GJ, 2008, BIOMATERIALS, V29, P3053, DOI 10.1016/j.biomaterials.2008.03.012
   Muschler GE, 2004, J BONE JOINT SURG AM, V86A, P1541, DOI 10.2106/00004623 200407000 00029
   Muschler GF, 2001, J ORTHOP RES, V19, P117, DOI 10.1016/S0736 0266(00)00010 3
   *NAT JOINT REG ENG, 2010, 6 NAT JOINT REG ENGL
   National Audit Office, 2010, Major trauma care in England
   Ng AMH, 2005, J ORTHOP SCI, V10, P192, DOI 10.1007/s00776 004 0884 2
   Ng M H Angela, 2004, Med J Malaysia, V59 Suppl B, P41
   NILSSON LP, 1988, INT J ORAL MAXILLOF, V3, P43
   Oreffo ROC, 1999, BONE, V25, p5S, DOI 10.1016/S8756 3282(99)00124 6
   Panetta NJ, 2009, PANMINERVA MED, V51, P25
   Phillips AM, 2005, INJURY, V36, P5, DOI 10.1016/j.injury.2005.07.027
   Pioletti Dominique P, 2007, Swiss Med Wkly, V137 Suppl 155, p86S
   PITTENGER MF, 2001, MESENCHYMAL STEM CEL, V9, P189
   Ragni P, 1987, Ital J Orthop Traumatol, V13, P241
   Reddi AH, 2001, J BONE JOINT SURG AM, V83A, pS1, DOI 10.2106/00004623 200100001 00001
   Ripamonti U, 2001, PLAST RECONSTR SURG, V107, P977, DOI 10.1097/00006534 200104010 00012
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Rose FRAJ, 2002, BIOCHEM BIOPH RES CO, V292, P1, DOI 10.1006/bbrc.2002.6519
   Röser K, 2000, J BIOMED MATER RES, V51, P280
   SAJITA NK, 2009, J CELL MOL MED, V13, P4385
   SIMONDS RJ, 1992, NEW ENGL J MED, V326, P726, DOI 10.1056/NEJM199203123261102
   Solheim E, 1998, INT ORTHOP, V22, P410, DOI 10.1007/s002640050290
   Standring Susan., 2005, GRAYS ANATOMY ANATOM, V39th
   STEVENSON S, 1987, J BONE JOINT SURG AM, V69A, P573, DOI 10.2106/00004623 198769040 00015
   STEVENSON S, 1996, CLIN ORTHOP RELAT R, V326, P86
   SUMMERS BN, 1989, J BONE JOINT SURG BR, V71, P677, DOI 10.1302/0301 620X.71B4.2768321
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   TJELLSTROM A, 1981, LARYNGOSCOPE, V91, P811
   TJELLSTROM A, 1981, AM J OTOL, V2, P303
   Tohma Y, 2008, J TISSUE ENG REGEN M, V2, P61, DOI 10.1002/term.67
   TRANCIK TM, 1986, J BONE JOINT SURG AM, V68A, P527, DOI 10.2106/00004623 198668040 00007
   Tremoleda FL, 2008, CLONING STEM CELLS, V10, P119, DOI [10.1089/clo.2007.0R36, 10.1089/clo.2007.OR36]
   Trippel SB, 1996, J BONE JOINT SURG AM, V78A, P1272, DOI 10.2106/00004623 199608000 00020
   Tsiridis E, 2007, J ORTHOP RES, V25, P1425, DOI 10.1002/jor.20387
   Tsiridis E, 2006, INJURY, V37, pS25, DOI 10.1016/j.injury.2006.08.021
   Tsiridis E, 2006, INJURY, V37, pS13, DOI 10.1016/j.injury.2006.02.036
   Tsiridis E, 2009, EXPERT OPIN BIOL TH, V9, P9, DOI [10.1517/14712590802622473, 10.1517/14712590802622473 ]
   TSUBOI N, 1996, P 3 INT C TISS INT O, P84
   Tsunoda Masaya, 2003, Clin Calcium, V13, P1293
   Turner CH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.268pt3
   URIST MARSHALL R., 1967, CLIN ORTHOP RELATED RESIN COMPLICATIONS OF ORTHOPAEDIC SURGERY, V53, P243
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   URIST MR, 1979, P NATL ACAD SCI USA, V76, P1828, DOI 10.1073/pnas.76.4.1828
   Urist MR., 1981, CLIN ORTHOP RELAT R, V154, P97
   VACANTI CA, 1999, CLIN ORTHOP S, V367, pS375
   Vats A, 2002, CLIN OTOLARYNGOL, V27, P227, DOI 10.1046/j.1365 2273.2002.00579.x
   VIROLAINEN P, 1995, CLIN ORTHOP RELAT R, P263
   Wagner DO, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3107mr1
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   WEISS RE, 1980, P NATL ACAD SCI BIOL, V77, P2074, DOI 10.1073/pnas.77.4.2074
   Wennerberg A., 1996, PhD thesis, P1
   WILKINS RM, 1994, INT ORTHOP, V2, P71
   Wilson Hench J., 1987, PROGR BIOMEDICAL ENG, V4, P29
   WOLFF J, 1901, WECHSELBEZIEHUNGEN Z
   Wozney JM, 2002, SPINE, V27, pS2, DOI 10.1097/00007632 200208151 00002
   XIAOJUN Y, 2004, P NATL ACAD SCI USA, V101, P11203
   Yasuda I., 1953, J. Kyoto. Pref .Univ. Med, V4, P395
   You LD, 2008, BONE, V42, P172, DOI 10.1016/j.bone.2007.09.047
   YOUNG R W, 1963, Clin Orthop Relat Res, V26, P147
   Younger E M, 1989, J Orthop Trauma, V3, P192, DOI 10.1097/00005131 198909000 00002
   Zarb G.e., 1991, INT J PERIODONTICS R, V11, P88
   Zhang HB, 1996, DEVELOPMENT, V122, P2977
NR 164
TC 73
Z9 100
U1 0
U2 54
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0954 4119
EI 2041 3033
J9 P I MECH ENG H
JI Proc. Inst. Mech. Eng. Part H J. Eng. Med.
PY 2010
VL 224
IS H12
SI SI
BP 1415
EP 1440
DI 10.1243/09544119JEIM821
PG 26
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA 687CS
UT WOS:000284752600008
PM 21287829
DA 2025 08 17
ER

PT J
AU Zhao, JL
   Liang, GH
   Yang, JZ
   Huang, HT
   Dou, YX
   Gu, ZX
   Liu, J
   Zeng, LF
   Yang, WY
AF Zhao, Jinlong
   Liang, Guihong
   Yang, Junzheng
   Huang, Hetao
   Dou, Yaoxing
   Gu, Zhuoxu
   Liu, Jun
   Zeng, Lingfeng
   Yang, Weiyi
TI Liuwei Dihuang Pills Enhance Osteogenic Differentiation in MC3T3 E1
   Cells through the Activation of the Wnt/β Catenin Signaling Pathway
SO PHARMACEUTICALS
LA English
DT Article
DE Liuwei Dihuang pills; osteogenic; osteoporosis; Wnt/beta catenin
   signaling pathway
ID OSTEOPOROSIS
AB Objective: The therapeutic efficacy and molecular mechanisms of traditional Chinese medicines (TCMs), such as Liuwei Dihuang pills (LWDH pills), in treating osteoporosis (OP) remain an area of active research and interest in modern medicine. This study investigated the mechanistic underpinnings of LWDH pills in the treatment of OP based on network pharmacology, bioinformatics, and in vitro experiments. Methods: The active ingredients and targets of LWDH pills were retrieved through the TCMSP database. OP related targets were identified using the CTD, GeneCards, and DisGeNET databases. The STRING platform was employed to construct a protein protein interaction (PPI) network, and core targets for LWDH pills in treating OP were identified. The GO functional and KEGG pathway enrichment analyses for potential targets were performed using the R package "clusterProfiler". A "drug target" network diagram was created using Cytoscape 3.7.1 software. The viability of MC3T3 E1 cells was evaluated using the CCK 8 method after treatment with various concentrations (1.25%, 2.5%, 5%, and 10%) of LWDH pill medicated serum for 24, 48, and 72 h. Following a 48 h treatment of MC3T3 E1 cells with LWDH pill medicated serum, the protein levels of collagen I, RUNX2, Wnt3, and beta catenin were quantified using the Western blot analysis, and the activity of alkaline phosphatase (ALP) was measured. Results: A total of 197 putative targets for LWDH pills for OP treatment were pinpointed, from which 20 core targets were singled out, including TP53, JUN, TNF, CTNNB1 (beta catenin), and GSK3B. The putative targets were predominantly involved in signaling pathways such as the Wnt signaling pathway, the MAPK signaling pathway, and the PI3K Akt signaling pathway. The intervention with LWDH pill medicated serum for 24, 48, and 72 h did not result in any notable alterations in the cell viability of MC3T3 E1 cells relative to the control group (all p > 0.05). Significant upregulation in protein levels of collagen I, RUNX2, Wnt3, and beta catenin in MC3T3 E1 cells was observed in response to the treatment with 2.5%, 5%, and 10% of LWDH pill medicated serum in comparison to that with the 10% rabbit serum group (all p < 0.05). Furthermore, the intervention with LWDH pill medicated serum resulted in the formation of red calcified nodules in MC3T3 E1 cells, as indicated by ARS staining. Conclusions: LWDH pills may upregulate the Wnt/beta catenin signaling pathway to elevate the expression of osteogenic differentiation proteins, including collagen I and RUNX2, and to increase the ALP activity in MC3T3 E1 cells for the treatment of OP.
C1 [Zhao, Jinlong; Liang, Guihong; Dou, Yaoxing; Gu, Zhuoxu; Zeng, Lingfeng] Guangzhou Univ Chinese Med, Clin Coll 2, State Key Lab Tradit Chinese Med Syndrome, Guangzhou 510405, Peoples R China.
   [Zhao, Jinlong; Liang, Guihong; Huang, Hetao; Dou, Yaoxing; Zeng, Lingfeng; Yang, Weiyi] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Guangdong Prov Key Lab Chinese Med Prevent & Treat, Affiliated Hosp 2, Guangzhou 510120, Peoples R China.
   [Zhao, Jinlong; Liang, Guihong; Dou, Yaoxing; Liu, Jun; Zeng, Lingfeng] Guangdong Prov Acad Chinese Med Sci, Res Team Bone & Joint Degenerat & Injury, Guangzhou 510120, Peoples R China.
   [Yang, Junzheng; Liu, Jun] Guangzhou Univ Chinese Med, Clin Coll 5, Guangzhou 510405, Peoples R China.
   [Liu, Jun] Guangdong Second Chinese Med Hosp, Guangdong Prov Engn Technol Res Inst Tradit Chines, Guangzhou 510095, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou
   University of Chinese Medicine
RP Zeng, LF (通讯作者)，Guangzhou Univ Chinese Med, Clin Coll 2, State Key Lab Tradit Chinese Med Syndrome, Guangzhou 510405, Peoples R China.; Zeng, LF; Yang, WY (通讯作者)，Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Guangdong Prov Key Lab Chinese Med Prevent & Treat, Affiliated Hosp 2, Guangzhou 510120, Peoples R China.; Zeng, LF (通讯作者)，Guangdong Prov Acad Chinese Med Sci, Res Team Bone & Joint Degenerat & Injury, Guangzhou 510120, Peoples R China.
EM 20222110142@stu.gzucm.edu.cn; liangguihong@gzucm.edu.cn;
   20201110029@stu.gzucm.edu.cn; ynhtsmile@126.com; yaoxingdou@126.com;
   20231110746@stu.gzucm.edu.cn; gjtb@gzucm.edu.cn;
   lingfengzeng@gzucm.edu.cn; czyangwy@gzucm.edu.cn
RI Liu, Jun/KJL 2351 2024; zhong, feng/G 4623 2015; Yang,
   Junzheng/AFC 7121 2022; huang, hetao/MGW 3219 2025; yang,
   junzheng/AFC 7121 2022
OI Yang, Junzheng/0000 0001 9992 3179; 
FU National Natural Science Foundation of China
FX No Statement Available
CR Ahire JJ, 2024, PROBIOTICS ANTIMICRO, V16, P875, DOI 10.1007/s12602 023 10185 0
   Appelman Dijkstra NM, 2022, BEST PRACT RES CL EN, V36, DOI 10.1016/j.beem.2022.101623
   Arafa EA, 2023, BIOMED PHARMACOTHER, V161, DOI 10.1016/j.biopha.2023.114461
   Bodine PVN, 2008, CELL RES, V18, P248, DOI 10.1038/cr.2008.13
   Bouvard B, 2021, JOINT BONE SPINE, V88, DOI 10.1016/j.jbspin.2021.105135
   Cai YQ, 2023, AGING US, V15, P11471, DOI 10.18632/aging.205136
   Catalano A, 2018, BONE, V116, P42, DOI 10.1016/j.bone.2018.07.010
   Chen JC, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1236893
   Foessl I, 2023, NAT REV ENDOCRINOL, V19, P520, DOI 10.1038/s41574 023 00866 9
   Ge JR, 2018, CHIN J INTEGR MED, V24, P415, DOI 10.1007/s11655 016 2744 2
   Huang K, 2024, CELL PROLIFERAT, V57, DOI 10.1111/cpr.13522
   Kim S, 2023, ADV SCI, V10, DOI 10.1002/advs.202301570
   Lewis SR, 2022, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013405.pub2
   Li B, 2015, CELL BIOL INT, V39, P192, DOI 10.1002/cbin.10359
   Liu F, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 023 03656 1
   Liu Y, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015282
   Lu XM, 2013, MOL MED REP, V7, P1203, DOI 10.3892/mmr.2013.1297
   Ma QM, 2023, BIOCHIMIE, V211, P57, DOI 10.1016/j.biochi.2023.03.001
   Niznik JD, 2022, J AM MED DIR ASSOC, V23, P1928, DOI 10.1016/j.jamda.2022.09.013
   Ohta H, 2023, CALCIFIED TISSUE INT, V112, P430, DOI 10.1007/s00223 023 01060 9
   Raiyan S, 2021, J BIOMED MATER RES A, V109, P1113, DOI 10.1002/jbm.a.37103
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Shen YY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.882241
   Takebe H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020677
   Wang J, 2023, INT J BIOL MACROMOL, V248, DOI 10.1016/j.ijbiomac.2023.125879
   Wang YW, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964 022 01002 2
   Xia BJ, 2014, J ETHNOPHARMACOL, V153, P133, DOI 10.1016/j.jep.2014.01.040
   Xiao PL, 2022, OSTEOPOROSIS INT, V33, P2137, DOI 10.1007/s00198 022 06454 3
   Xie YQ, 2022, EUR J MED CHEM, V230, DOI 10.1016/j.ejmech.2022.114119
   Zhang N, 2023, FRONT MED LAUSANNE, V10, DOI 10.3389/fmed.2023.1164656
   Zhang YN, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232416045
   Zheng HL, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03784 8
   Zhu FP, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 022 03470 1
NR 34
TC 0
Z9 0
U1 1
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1424 8247
J9 PHARMACEUTICALS BASE
JI Pharmaceuticals
PD JAN
PY 2024
VL 17
IS 1
AR 99
DI 10.3390/ph17010099
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GM1Z9
UT WOS:001153006400001
PM 38256932
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, LL
   Bao, JQ
   Yang, YT
   Wang, ZX
   Xia, MJ
   Tan, JY
   Zhou, LL
   Wu, YM
   Sun, WL
AF Chen, Lili
   Bao, Jiaqi
   Yang, Yuting
   Wang, Zhongxiu
   Xia, Mengjiao
   Tan, Jingyi
   Zhou, Lili
   Wu, Yanmin
   Sun, Weilian
TI Autophagy was involved in tumor necrosis factor α inhibited osteogenic
   differentiation of murine calvarial osteoblasts through Wnt/β catenin
   pathway
SO TISSUE & CELL
LA English
DT Article
DE TNF alpha; Osteoblasts; Autophagy; Wnt/beta catenin pathway
ID EMBRYONIC STEM CELLS; TNF ALPHA; GENE EXPRESSION; BONE; PROLIFERATION;
   APOPTOSIS; PROMOTES; CULTURE; STIMULATION; METABOLISM
AB Periodontitis is an inflammatory disease with a high incidence characterized by irreversible destruction of alveolar bone. This study aimed to investigate the effect of tumor necrosis factor alpha (TNF alpha) on osteogenic differentiation and its molecular mechanism. TNF alpha inhibited osteogenic differentiation as revealed by the lower accumulation of osteoblastic genes like runt related transcription factor (Runx2), alkaline phosphatase (ALP), osteoprotegerin (OPG), and osteocalcin (OCN). Moreover, TNF alpha down regulated the expressions of LC3II, ATG7, and beclin 1 (BECN1); suggesting that autophagy was inhibited during the process of osteogenic differentiation. Consistently, Wnt/beta catenin signaling pathway members such as low density lipoprotein receptorrelated protein 5 (LAPS), beta catenin, and phosphorylated beta catenin (p beta catenin) were reduced by TNF alpha. Furthermore, the inhibitory effect of TNF alpha on osteogenic differentiation and the Wnt/beta catenin signaling pathway could be abated by autophagy inducers but exacerbated by autophagy inhibitors. The most intriguing finding of all was that TNF alpha inhibited osteoblastic differentiation and the Wnt/beta catenin signaling pathway by down regulating autophagy, and autophagy positively regulated the Wnt/beta catenin pathway and thus influenced osteoblastic differentiation. Our study provides a theoretical basis for autophagy inducer therapy for the alveolar bone loss caused by periodontitis.
C1 [Chen, Lili; Bao, Jiaqi; Yang, Yuting; Wang, Zhongxiu; Xia, Mengjiao; Tan, Jingyi; Zhou, Lili; Wu, Yanmin; Sun, Weilian] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Periodontol, 88 Jiafang St, Hangzhou 310009, Peoples R China.
   [Bao, Jiaqi] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Canc Inst, Hangzhou 310009, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Sun, WL (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Periodontol, 88 Jiafang St, Hangzhou 310009, Peoples R China.
EM weiliansun@zju.edu.cn
RI WANG, Zhongxiu/GQR 0573 2022; Yang, Yuting/C 8527 2014
OI Yang, Yuting/0000 0001 6896 7603; Sun, Weilian/0000 0002 3376 2584
FU Scientific Research Fund of Zhejiang Provincial Education Department
   [Y201942090]; Natural Science Foundation of Zhejiang Province
   [LY16H140002, LQ19H140003]; National Natural Science Foundation of China
   [81771072, 81800972]; Science and Technology Department of Zhejiang
   Province [LGF18H140003]
FX This work was supported by grant of A Project Supported by Scientific
   Research Fund of Zhejiang Provincial Education Department (Y201942090),
   Natural Science Foundation of Zhejiang Province (grant number
   LY16H140002, LQ19H140003), National Natural Science Foundation of China
   (grant number 81771072, 81800972) and the Science and Technology
   Department of Zhejiang Province (grant number LGF18H140003).
CR Abbas S, 2003, CYTOKINE, V22, P33, DOI 10.1016/S1043 4666(03)00106 6
   Algate K, 2016, J PERIODONTAL RES, V51, P549, DOI 10.1111/jre.12339
   An Y, 2016, J CLIN PERIODONTOL, V43, P618, DOI 10.1111/jcpe.12549
   Ba S, 2017, CELL PHYSIOL BIOCHEM, V42, P1920, DOI 10.1159/000479610
   Cavagis A., 2013, ORAL DIS, DOI DOI 10.1111/ODI.12202.N/A N/A.
   Chen JQ, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0004 5
   Choi HK, 2018, J BONE MINER RES, V33, P2021, DOI 10.1002/jbmr.3530
   Chou YT, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.558432
   Evans ND, 2012, EUR CELLS MATER, V24, P211, DOI 10.22203/eCM.v024a15
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gilbert LC, 2013, BONE, V56, P174, DOI 10.1016/j.bone.2013.06.002
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Han YD, 2018, INT J MOL MED, V41, P800, DOI 10.3892/ijmm.2017.3270
   Hocking LJ, 2012, J BONE MINER RES, V27, P1439, DOI 10.1002/jbmr.1668
   Igarashi M, 2004, J MOL HISTOL, V35, P3, DOI 10.1023/B:HIJO.0000020883.33256.fe
   Ishida Y, 1997, OSTEOPOROSIS INT, V7, P323, DOI 10.1007/BF01623772
   Jeong BC, 2018, BIOCHEM BIOPH RES CO, V499, P696, DOI 10.1016/j.bbrc.2018.03.214
   Jia ZQ, 2014, CELL SIGNAL, V26, P2299, DOI 10.1016/j.cellsig.2014.07.028
   Jonason JH, 2014, METHODS MOL BIOL, V1130, P295, DOI 10.1007/978 1 62703 989 5_22
   Kaemmerer E, 2019, CANCERS, V11, DOI 10.3390/cancers11040555
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kim HJ, 2020, BIOCHEM BIOPH RES CO, V524, P1044, DOI 10.1016/j.bbrc.2020.02.054
   Kim HJ, 2020, MOL CELLS, V43, P160, DOI 10.14348/molcells.2019.0247
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Kobayashi Y, 2016, J BIOCHEM, V159, P387, DOI 10.1093/jb/mvv124
   Komori T, 2020, MOL CELLS, V43, P168, DOI 10.14348/molcells.2019.0244
   Kotake S, 2014, BBA GEN SUBJECTS, V1840, P1209, DOI 10.1016/j.bbagen.2013.12.013
   Kühl SJ, 2013, BBA GEN SUBJECTS, V1830, P2297, DOI 10.1016/j.bbagen.2012.08.010
   Kushwaha P, 2020, J CELL PHYSIOL, V235, P6673, DOI 10.1002/jcp.29563
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Li DW, 2018, INT J NANOMED, V13, P7167, DOI 10.2147/IJN.S174553
   Li LQ, 2018, EUR REV MED PHARMACO, V22, P3402, DOI 10.26355/eurrev_201806_15162
   Liang C, 2020, J HAZARD MATER, V391, DOI 10.1016/j.jhazmat.2020.122227
   Liao Y, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 32003 2
   Liu J., 2020, CELL CHEM BIOL, DOI [10.1016/j.chembiol.2020.02.005., DOI 10.1016/J.CHEMBIOL.2020.02.005.]
   Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964
   Ma ZZ, 2019, J MOL HISTOL, V50, P75, DOI 10.1007/s10735 018 9808 x
   Mayer Y, 2013, J PERIODONTOL, V84, P136, DOI 10.1902/jop.2012.120009
   Nava P, 2010, IMMUNITY, V32, P392, DOI 10.1016/j.immuni.2010.03.001
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Sabharwal A, 2018, PERIODONTOL 2000, V78, P212, DOI 10.1111/prd.12226
   Shen DW, 2020, NAT BIOMED ENG, V4, P298, DOI 10.1038/s41551 020 0528 7
   Sidney LE, 2014, STEM CELLS DEV, V23, P605, DOI 10.1089/scd.2013.0336
   Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097 4644(19991001)75:1<22::AID JCB3>3.3.CO;2 Y
   Tang XL, 2009, ARCH ORAL BIOL, V54, P625, DOI 10.1016/j.archoralbio.2009.04.009
   Tang Y, 2014, J DENT RES, V93, P175, DOI 10.1177/0022034513512507
   Tian R, 2016, INFLAMMATION, V39, P1387, DOI 10.1007/s10753 016 0370 y
   Wang LM, 2018, J PERIODONTAL RES, V53, P66, DOI 10.1111/jre.12488
   Wang N, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.150258
   Wang YJ, 2018, CELL PHYSIOL BIOCHEM, V50, P2046, DOI 10.1159/000495050
   Whitehouse CA, 2010, P NATL ACAD SCI USA, V107, P12913, DOI 10.1073/pnas.0913058107
   Xu AH, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 0512 6
   Xu JH, 2015, AM J TRANSL RES, V7, P2527
   Xu XQ, 2020, FASEB J, V34, P8402, DOI 10.1096/fj.201902528RRR
   Yamamoto N, 2002, BIOL PHARM BULL, V25, P509, DOI 10.1248/bpb.25.509
   Yin ZY, 2017, EUR REV MED PHARMACO, V21, P4989
   Zhao BH, 2017, CURR OSTEOPOROS REP, V15, P126, DOI 10.1007/s11914 017 0358 z
NR 59
TC 13
Z9 15
U1 0
U2 16
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0040 8166
J9 TISSUE CELL
JI Tissue Cell
PD DEC
PY 2020
VL 67
AR 101401
DI 10.1016/j.tice.2020.101401
PG 8
WC Anatomy & Morphology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Cell Biology
GA OV1LE
UT WOS:000591979600002
PM 32835949
DA 2025 08 17
ER

PT J
AU Milone, MR
   Pucci, B
   Bruzzese, F
   Carbone, C
   Piro, G
   Costantini, S
   Capone, F
   Leone, A
   Di Gennaro, E
   Caraglia, M
   Budillon, A
AF Milone, M. R.
   Pucci, B.
   Bruzzese, F.
   Carbone, C.
   Piro, G.
   Costantini, S.
   Capone, F.
   Leone, A.
   Di Gennaro, E.
   Caraglia, M.
   Budillon, A.
TI Acquired resistance to zoledronic acid and the parallel acquisition of
   an aggressive phenotype are mediated by p38 MAP kinase activation in
   prostate cancer cells
SO CELL DEATH & DISEASE
LA English
DT Article
DE P38 MAPK; drug resistance; zoledronic acid; prostate cancer
ID MESENCHYMAL TRANSITION; MEVALONATE PATHWAY; DNA DAMAGE; INHIBITION;
   BISPHOSPHONATES; EXPRESSION; OSTEOSARCOMA; METASTASIS; VORINOSTAT;
   MECHANISMS
AB The nitrogen containing bisphosphonates (N BP) zoledronic acid (ZOL) inhibits osteoclast mediated bone resorption, and it is used to prevent skeletal complications from bone metastases. ZOL has also demonstrated anticancer activities in preclinical models and, recently, in cancer patients, highlighting the interest in determining eventual mechanisms of resistance against this agent. In our study, we selected and characterised a resistant subline of prostate cancer (PCa) cells to better understand the mechanisms, by which tumour cells can escape the antitumour effect of ZOL. DU145R80 resistant cells were selected in about 5 months using stepwise increasing concentrations of ZOL from DU145 parental cells. DU145R80 cells showed a resistance index value of 5.5 and cross resistance to another N BP, pamidronate, but not to the non nitrogen containing BP clodronate. Notably, compared with DU145 parental cells, DU145R80 developed resistance to apoptosis and anoikis, as well as overexpressed the anti apoptotic protein Bcl 2 and oncoprotein c Myc. Moreover, DU145R80 cells underwent epithelial to mesenchymal transition (EMT) and showed increased expression of the metalloproteases MMP 2/ 9, as well as increased invading capability. Interestingly, compared with DU145, DU145R80 cells also increased the gene expression and protein secretion of VEGF and the cytokines Eotaxin 1 and IL 12. At the molecular level, DU145R80 cells showed strong activation of the p38 MAPK dependent survival pathway compared with parental sensitive cells. Moreover, using the p38 inhibitor SB203580, we completely reversed the resistance to ZOL, as well as EMT marker expression and invasion. Furthermore, SB203580 treatment reduced the expression of VEGF, Eotaxin 1, IL 12, MMP 9, Bcl 2 and c Myc. Thus, for the first time, we demonstrate that the p38 MAPK pathway can be activated under continuous extensive exposure to ZOL in PCa cells and that the p38 MAPK pathway has a critical role in the induction of resistance, as well as in the acquisition of a more aggressive and invasive phenotype.
C1 [Milone, M. R.; Pucci, B.; Piro, G.; Costantini, S.; Capone, F.; Budillon, A.] CROM, Mercogliano, Av, Italy.
   [Bruzzese, F.; Carbone, C.; Leone, A.; Di Gennaro, E.; Budillon, A.] IRCCS Ist Nazl Tumori G Pascale, Dept Res, Expt Pharmacol Unit, I 80131 Naples, Italy.
   [Caraglia, M.] Univ Naples 2, Dept Biochem & Biophys, Naples, Italy.
C3 Universita della Campania Vanvitelli
RP Budillon, A (通讯作者)，IRCCS Ist Nazl Tumori G Pascale, Natl Canc Inst Naples, Expt Pharmacol Unit, Via M Semmola, I 80131 Naples, Italy.
EM a.budillon@istitutotumori.na.it
RI ; Piro, Geny/R 5563 2019; Carbone, Carmine/L 1009 2016; Leone,
   Alessandra/K 3989 2016; Capone, Francesca/AAS 7458 2021; Caraglia,
   Michele/AFY 9729 2022; Budillon, Alfredo/K 4763 2016; Costantini,
   Susan/J 9914 2018; Caraglia, Michele/N 5670 2015; pucci,
   biagio/AAA 9268 2020; Bruzzese, Francesca/ABI 1665 2020; Di+Gennaro,
   Elena/ABG 1579 2021
OI Milone, Maria Rita/0000 0001 6807 3677; Carbone,
   Carmine/0000 0001 5168 747X; Leone, Alessandra/0000 0002 1051 2937;
   Costantini, Susan/0000 0002 7538 4657; Piro, Geny/0000 0003 3708 5397;
   Caraglia, Michele/0000 0003 2408 6091; Budillon,
   Alfredo/0000 0002 6330 6053; Di Gennaro, Elena/0000 0001 6223 7845;
   Capone, Francesca/0000 0002 5402 6228
FU nonprofit 'Associazione Italiana per la Ricerca sul Cancro' [AIRC IG
   9332]; Italian Ministry of Health (FSN); Novartis Pharmaceuticals
   (Basel, Switzerland); Italian Ministry of Education, Research and
   University (PRIN 2009) [2009EHW394]
FX This work was partially supported by research grants to AB from the
   nonprofit 'Associazione Italiana per la Ricerca sul Cancro' (AIRC IG
   9332), the Italian Ministry of Health (FSN) and Novartis Pharmaceuticals
   (Basel, Switzerland). MC was supported by the Italian Ministry of
   Education, Research and University (PRIN 2009, grant number:
   2009EHW394). The authors are beholden to Dr. Alessandra Trocino from the
   National Cancer Institute of Naples, for providing excellent
   bibliographic service and assistance.
CR Agarwal M, 2013, PROSTATE, V73, P573, DOI 10.1002/pros.22597
   Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009
   Brehmer B, 2003, PROSTATE CANCER P D, V6, P217, DOI 10.1038/sj.pcan.4500657
   Bruzzese F, 2011, J CELL PHYSIOL, V226, P2378, DOI 10.1002/jcp.22574
   Bruzzese F, 2009, MOL CANCER THER, V8, P3075, DOI 10.1158/1535 7163.MCT 09 0254
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Caraglia M, 2004, ONCOGENE, V23, P6900, DOI 10.1038/sj.onc.1207814
   Caraglia M, 2007, J CELL PHYSIOL, V211, P533, DOI 10.1002/jcp.20960
   Chuan YC, 2010, ONCOGENE, V29, P1531, DOI 10.1038/onc.2009.442
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Cuenda A, 2007, BBA MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017
   Facchini G, 2010, CANCER BIOL THER, V10, P543, DOI 10.4161/cbt.10.6.12611
   Fleischmann A, 2012, PROSTATE, V72, P991, DOI 10.1002/pros.21504
   Gonzalez Moreno O, 2010, EXP CELL RES, V316, P554, DOI 10.1016/j.yexcr.2009.11.020
   Haas GP, 2008, CAN J UROL, V15, P3866
   Hanna M, 2009, J BIOL CHEM, V284, P23125, DOI 10.1074/jbc.M109.019059
   Juric V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031303
   Kars MD, 2007, ANTICANCER RES, V27, P4031
   Kim L, 2005, J IMMUNOL, V174, P4178, DOI 10.4049/jimmunol.174.7.4178
   Klinke DJ II, 2013, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00202
   Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132
   Kubo T, 2008, CANCER CHEMOTH PHARM, V62, P111, DOI 10.1007/s00280 007 0580 y
   Ma XK, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 27
   Mahon KL, 2011, ENDOCR RELAT CANCER, V18, pR103, DOI 10.1530/ERC 10 0343
   Marra M, 2009, INT J CANCER, V125, P2004, DOI 10.1002/ijc.24648
   Merrell MA, 2007, EUR J PHARMACOL, V570, P27, DOI 10.1016/j.ejphar.2007.05.075
   Morii T, 2010, ANTICANCER RES, V30, P3565
   Nauseef JT, 2011, NAT REV UROL, V8, P428, DOI 10.1038/nrurol.2011.85
   Ory B, 2008, J CELL MOL MED, V12, P928, DOI 10.1111/j.1582 4934.2008.00141.x
   Phong MS, 2010, MOL CELL BIOL, V30, P3816, DOI 10.1128/MCB.00949 09
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   Rokudai A, 2006, BIOL PHARM BULL, V29, P1102, DOI 10.1248/bpb.29.1102
   Santini D, 2006, NAT CLIN PRACT ONCOL, V3, P325, DOI 10.1038/ncponc0520
   Saylor PJ, 2011, J CLIN ONCOL, V29, P3705, DOI 10.1200/JCO.2010.34.4994
   Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078 0432.CCR 12 0489
   Vindrieux D, 2009, ENDOCR RELAT CANCER, V16, P663, DOI 10.1677/ERC 09 0109
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008 5472.CAN 10 3776
   Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337
NR 41
TC 53
Z9 54
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY
PY 2013
VL 4
AR e641
DI 10.1038/cddis.2013.165
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 156LR
UT WOS:000319824100030
PM 23703386
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ali, T
   Jay, RH
AF Ali, Tamir
   Jay, Roger H.
TI Spontaneous femoral shaft fracture after long term alendronate
SO AGE AND AGEING
LA English
DT Article
DE alendronate; femur; fracture; spontaneous; elderly
ID SUPPRESSED BONE TURNOVER; BISPHOSPHONATES; WOMEN; THERAPY
AB Alendronate is used as first line treatment for osteoporosis in postmenopausal women worldwide. The evidence supporting its benefit in reducing the risk of fragility fracture among this high risk group is well established. Due to its mechanism of action, there were concerns about potential reduction in bone turnover, repair of microdamage and hence reduced bone toughness and increased risk of fractures with long term use. A number of cases have been reported from other countries describing a pattern of atraumatic mid femoral fractures in women on long term alendronate therapy. We present a case of an atraumatic femoral shaft fracture in an elderly woman on long term alendronate therapy admitted to a UK Hospital.
C1 [Ali, Tamir; Jay, Roger H.] Freeman Rd Hosp, Dept Ear Nose & Throat, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.
C3 Newcastle Freeman Hospital; Newcastle University   UK
RP Jay, RH (通讯作者)，Freeman Rd Hosp, Dept Ear Nose & Throat, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.
EM Roger.Jay@nuth.nhs.uk
CR Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Cheung Ralph K. H., 2007, Hong Kong Medical Journal, V13, P485
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P1897, DOI 10.1210/jc.2005 0057
   Schneider JP, 2006, GERIATRICS, V61, P31
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
NR 10
TC 19
Z9 24
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002 0729
EI 1468 2834
J9 AGE AGEING
JI Age Ageing
PD SEP
PY 2009
VL 38
IS 5
BP 625
EP 626
DI 10.1093/ageing/afp106
PG 2
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA 486KB
UT WOS:000269193800029
PM 19556326
OA Bronze
DA 2025 08 17
ER

PT J
AU Sun, ZZ
   Jin, HT
   Zhou, HF
   Yu, L
   Wan, HT
   He, Y
AF Sun, Zhizhen
   Jin, Hongting
   Zhou, Huifen
   Yu, Li
   Wan, Haitong
   He, Yu
TI Guhong Injection promotes fracture healing by activating
   Wnt/beta catenin signaling pathway in vivo and in vitro
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Guhong Injection; Fracture; Wnt/beta catenin signaling pathway; Rat;
   Osteoblast
ID BONE
AB Guhong Injection (GHI), composed of aceglutamide and safflower aqueous extract, has been applied to the clinical treatment of orthopedic diseases, but the relevant mechanism by which GHI exerts effects on bone remodeling has not been reported. In the present study, we investigated the effects of various concentrations of GHI (2.5, 5 and 10 ml/kg) in accelerating rat tibia healing progress by observing haematoxylin and eosin (HE) stained sections, detecting the activity of bone metabolism biochemical markers such as bone morphogenetic protein 2 (BMP 2), transforming growth factor beta (TGF beta), osteocalcin (OC) and C terminal crosslinking telopeptide of type. collagen (CTX 1) in rat serum, as well as measuring the expressions of collagen I (COL 1) and collagen II (COL 2) in rat tibia. Also, we investigated the effects of different concentrations of GHI (30, 60 and 90 mu l/ml) on the proliferation and differentiation of osteoblasts (OBs) through proliferating cell nuclear antigen (PCNA), alkaline phosphatase (ALP) and type I collagen (COL 1). At the same time, the expression of important factors of Wnt/beta catenin signaling pathway including Wnt 3a, beta catenin, disheveled 1 (Dvl 1), glycogen synthase kinases 3beta (GSK 3beta), lymphoid enhancing factor 1 (LEF 1) and axis inhibition protein 2 (Axin 2) after GHI intervention was detected by quantitative real time PCR (q PCR), immunohistochemistry and Western blotting. In vivo, rats of tibia fracture model treated with intraperitoneal injection (ip) of GHI had more mature fibroblasts, as well as shorter period formation of new bone. The levels of BMP 2, TGF beta and OC in rat serum were significantly up regulated, while the level of CTX was down regulated. After 4 weeks of drug treatment, the level of COL 1 in the rat tibia increased, but there was no significant change in the level of COL 2. In vitro, after drug intervention, the number of OBs increased significantly, the activities of PCNA, ALP and COL1 were enhanced. Treatment with GHI increased the mRNA and protein expression of Wnt 3a, beta catenin, Dvl 1 and LEF 1, and decreased the expression of mRNA of Axin 2 and GSK 3beta. All results demonstrate that GHI accelerates the proliferation of OBs and shortens the recovery time of bone structure, and the Wnt/beta catenin signaling pathway is involved in the regulation process.
C1 [Sun, Zhizhen; Jin, Hongting; Zhou, Huifen; Yu, Li; Wan, Haitong; He, Yu] Zhejiang Chinese Med Univ, Hangzhou 310053, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University
RP Wan, HT; He, Y (通讯作者)，Zhejiang Chinese Med Univ, Hangzhou 310053, Zhejiang, Peoples R China.
EM heyu0923@hotmail.com
RI wan, hai/GSM 9077 2022; Yu, Li/C 7448 2017
FU Zhejiang Provincial Natural Science Foundation [LZ18H270001]; National
   Natural Science Foundation of China [81873226]; Zhejiang Provincial
   Program for the Cultivation of High level Innovative Health Talents
   [2014 108 24]
FX This work was supported by the Zhejiang Provincial Natural Science
   Foundation (No. LZ18H270001), National Natural Science Foundation of
   China (No. 81873226), and Zhejiang Provincial Program for the
   Cultivation of High level Innovative Health Talents (No. 2014 108 24).
CR Ablat N, 2016, MOLECULES, V21, DOI 10.3390/molecules21091107
   Ahmadzadeh A., 2015, CELL TISSUE RES, V363, P1
   Bao QW, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02705 0
   Ben Shoham A, 2016, DEVELOPMENT, V143, P3933, DOI 10.1242/dev.139253
   Chen EM, 2015, FEBS LETT, V589, P4088, DOI 10.1016/j.febslet.2015.11.021
   Chen SX, 2015, J BONE MINER RES, V30, P1184, DOI 10.1002/jbmr.2453
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Deng L, 2018, EUR J PHARMACOL, V825, P119, DOI 10.1016/j.ejphar.2018.02.011
   Filip RS, 2007, INT J VITAM NUTR RES, V77, P89, DOI 10.1024/0300 9831.77.2.89
   Geng DC, 2015, BIOMATERIALS, V69, P12, DOI 10.1016/j.biomaterials.2015.07.061
   He Y, 2015, CHIN J PHARM ANAL, V35, P954
   HILTUNEN A, 1993, J ORTHOP RES, V11, P305, DOI 10.1002/jor.1100110219
   James W., 2018, J PHARMACOL EXP THER, V366
   Jin HT, 2015, BONE, V71, P63, DOI 10.1016/j.bone.2014.07.039
   Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359 6101(97)00036 1
   Kostenuik P, 2017, J ORTHOP RES, V35, P213, DOI 10.1002/jor.23460
   Lee DW, 2012, BONE, V50, P974, DOI 10.1016/j.bone.2012.01.007
   Lee SY, 2018, MOL CELLS, V41, P476, DOI 10.14348/molcells.2018.0056
   Liu X.M., 2001, J RADIOIMMUNOL, V14, P290
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo X.Z., 2006, J CLIN RES, V23, P48
   Meling T, 2009, INJURY, V40, P1212, DOI 10.1016/j.injury.2009.06.003
   Niu Kai, 2014, Yaoxue Xuebao, V49, P1136
   Pan Qiu Hui, 2007, Zhongguo Shengwu Huaxue yu Fenzi Shengwu Xuebao, V23, P921
   Park H, 2010, FEBS LETT, V584, P173, DOI 10.1016/j.febslet.2009.11.043
   Sahni V, 2001, J BONE JOINT SURG BR, V83B, P1083, DOI 10.1302/0301 620X.83B7.0831083
   Cabral HWS, 2016, REV ASSOC MED BRAS, V62, P368, DOI 10.1590/1806 9282.62.04.368
   Suh HJ, 2016, NUTR RES PRACT, V10, P569, DOI 10.4162/nrp.2016.10.6.569
   Sun Z.Z., 2018, CHIN J PHARM, V53, P31
   Sun Z.Z., 2018, CHIN J CLIN PHARM, V34, P33
   Wang CL, 2017, J CELL BIOCHEM, V118, P286, DOI 10.1002/jcb.25635
   Wang CJ, 2009, NITRIC OXIDE BIOL CH, V20, P298, DOI 10.1016/j.niox.2009.02.006
   Wu M., 2014, FUJIAN J TRADIT CHIN
   Xia L., 2010, CHIN J ETHNOMED ETHN, V21, P45
   [许兵 XU Bing], 2011, [生命科学, Chinese Bulletin of Life Sciences], V23, P477
   Xu ML, 2017, J BIOL CHEM, V292, P12667, DOI 10.1074/jbc.M117.777581
   [袁本祥 Yuan Benxiang], 2002, [中国中医骨伤科杂志, Chinese Journal of Traditional Medicine Traumatology and Orthopedics], V10, P13
   Zhang Y., 2011, Patent No. [CN1843393B, 1843393]
   Zhen GH, 2014, TRENDS PHARMACOL SCI, V35, P227, DOI 10.1016/j.tips.2014.03.005
   Zhou CK, 2005, J STRAIT PHARM, V17, P15
   Zhou X.Y., 2015, ORTHOP J CHIN, V23, P2075
   [周燕 Zhou Yan], 2012, [免疫学杂志, Immunological Journal], V28, P353
NR 42
TC 9
Z9 10
U1 0
U2 14
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2019
VL 120
AR 109436
DI 10.1016/j.biopha.2019.109436
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA JR4VY
UT WOS:000499625900036
PM 31561068
OA gold
DA 2025 08 17
ER

PT J
AU Wu, CY
   Sun, ZP
   Guo, BF
   Ye, YY
   Han, XH
   Qin, YN
   Liu, S
AF Wu, Chunyu
   Sun, Zhenping
   Guo, Baofeng
   Ye, Yiyi
   Han, Xianghui
   Qin, Yuenong
   Liu, Sheng
TI Osthole inhibits bone metastasis of breast cancer
SO ONCOTARGET
LA English
DT Article
DE osthole; Cnidium monnieri (L.) Cusson; coumarin; breast cancer; bone
   metastasis
ID CELL CYCLE ARREST; NF KAPPA B; CNIDIUM MONNIERI; IN VITRO;
   ADENOCARCINOMA CELLS; TGF BETA; COUMARINS; MICE; DIFFERENTIATION;
   PROLIFERATION
AB Bone is one of the most common sites for breast cancer metastasis, which greatly contributes to patient morbidity and mortality. Osthole, a major extract from Cnidium monnieri (L.), exhibits many biological and pharmacological activities, however, its potential as a therapeutic agent in the treatment of breast cancer bone metastases remain poorly understood. In this study, we set out to investigate whether osthole could inhibit breast cancer metastasis to bone in mice and clarified the potential mechanism of this inhibition. In the murine model of breast cancer osseous metastasis, mice that received osthole developed significantly less bone metastases and displayed decreased tumor burden when compared with mice in the control group. Osthole inhibited breast cancer cell growth, migration, and invasion, and induced apoptosis of breast cancer cells. Additionally, it also regulated OPG/RANKL signals in the interactions between bone cells (osteoblasts and osteoclasts) and cancer cells. Besides, it also inhibited TGF beta/Smads signaling in breast cancer metastasis to bone in MDA 231BO cells. The results of this study suggest that osthole has real potential as a therapeutic candidate in the treatment of breast cancer patients with bone metastases.
C1 [Wu, Chunyu; Sun, Zhenping; Guo, Baofeng; Qin, Yuenong; Liu, Sheng] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Breast Surg Integrated Tradit & Western Med, Shanghai 200032, Peoples R China.
   [Ye, Yiyi; Han, Xianghui; Liu, Sheng] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Pharmacol Lab Tradit Chinese Med, Shanghai 200032, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine
RP Qin, YN; Liu, S (通讯作者)，Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Breast Surg Integrated Tradit & Western Med, Shanghai 200032, Peoples R China.; Liu, S (通讯作者)，Shanghai Univ Tradit Chinese Med, Longhua Hosp, Pharmacol Lab Tradit Chinese Med, Shanghai 200032, Peoples R China.
EM frank_yching@aliyun.com; sliu_tcm@163.com
RI Wu, Chunyu/LBI 5378 2024; WU, CHUNYU/LBI 5378 2024; j, z/JPX 2698 2023
OI Wu, Chunyu/0009 0006 8834 3359; 
FU National Natural Science Foundation of China [81603629]; Natural Science
   Foundation of Shanghai [17ZR1430700, 17ZR1430900]; Shanghai Municipal
   Commission of Health and Family Planning [20164Y0064]
FX This research was supported by The National Natural Science Foundation
   of China (No. 81603629), Natural Science Foundation of Shanghai (No.
   17ZR1430700 and 17ZR1430900), and Shanghai Municipal Commission of
   Health and Family Planning (No. 20164Y0064).
CR Buijs JT., 2012, BoneKEy Reports, V1, P1
   Chen J, 2000, J UROLOGY, V163, P1975, DOI 10.1016/S0022 5347(05)67613 6
   Chen XH, 2010, EUR J PHARMACOL, V629, P40, DOI 10.1016/j.ejphar.2009.12.008
   Chou SY, 2007, PHYTOTHER RES, V21, P226, DOI 10.1002/ptr.2044
   Han XH, 2015, J ETHNOPHARMACOL, V162, P39, DOI 10.1016/j.jep.2014.12.036
   Ji HJ, 2010, EUR J PHARMACOL, V636, P96, DOI 10.1016/j.ejphar.2010.03.038
   Juárez P, 2011, BONE, V48, P23, DOI 10.1016/j.bone.2010.08.004
   Kao SJ, 2012, TOXICOL APPL PHARM, V261, P105, DOI 10.1016/j.taap.2012.03.020
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Liang HJ, 2009, CHEM BIOL INTERACT, V181, P309, DOI 10.1016/j.cbi.2009.08.003
   Liao PC, 2010, J AGR FOOD CHEM, V58, P10445, DOI 10.1021/jf102812t
   Liu LY, 2014, CHEM BIOL INTERACT, V217, P1, DOI 10.1016/j.cbi.2014.04.002
   Liu WB, 2010, NEUROCHEM INT, V57, P206, DOI 10.1016/j.neuint.2010.05.011
   Matsuda H, 2002, BIOL PHARM BULL, V25, P809, DOI 10.1248/bpb.25.809
   Meng F, 2004, PHARMAZIE, V59, P643
   Okamoto Toshihiro, 2005, Current Medicinal Chemistry   Anti Cancer Agents, V5, P47, DOI 10.2174/1568011053352622
   Qin LP, 2003, ACTA PHARMACOL SIN, V24, P181
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sheng Liu, 2011, Zhongguo Zhong Xi Yi Jie He Za Zhi, V31, P684
   Sun F, 2009, DIGEST LIVER DIS, V41, P127, DOI 10.1016/j.dld.2008.01.011
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Thakur VS, 2012, CARCINOGENESIS, V33, P377, DOI 10.1093/carcin/bgr277
   Wang LT, 2015, J BIOMED RES, V29, P132, DOI 10.7555/JBR.27.20120115
   Wu CY, 2014, PATHOL ONCOL RES, V20, P747, DOI 10.1007/s12253 014 9756 z
   Wu CY, 2013, FITOTERAPIA, V91, P205, DOI 10.1016/j.fitote.2013.09.005
   Yang DP, 2010, BIOSCI BIOTECH BIOCH, V74, P1430, DOI 10.1271/bbb.100110
   Yang LL, 2003, PLANTA MED, V69, P1091, DOI 10.1055/s 2003 45188
   Ye YY, 2013, ENVIRON TOXICOL PHAR, V36, P115, DOI 10.1016/j.etap.2013.03.012
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
   Zhai YK, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/921954
   Zhang QY, 2007, PLANTA MED, V73, P13, DOI 10.1055/s 2006 951724
   Zhen GH, 2014, TRENDS PHARMACOL SCI, V35, P227, DOI 10.1016/j.tips.2014.03.005
   Zhou P, 2000, PHYTOCHEMISTRY, V53, P689, DOI 10.1016/S0031 9422(99)00554 3
NR 33
TC 33
Z9 36
U1 1
U2 23
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 29
PY 2017
VL 8
IS 35
BP 58480
EP 58493
DI 10.18632/oncotarget.17024
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FF4RD
UT WOS:000408941900047
PM 28938572
OA Green Published, gold
DA 2025 08 17
ER

PT S
AU Uchihashi, K
   Nakatani, T
   Goetz, R
   Mohammadi, M
   He, X
   Razzaque, MS
AF Uchihashi, Kazuyoshi
   Nakatani, Teruyo
   Goetz, Regina
   Mohammadi, Moosa
   He, Xi
   Razzaque, Mohammed S.
BE Razzaque, MS
TI FGF23 Induced Hypophosphatemia Persists in Hyp Mice Deficient in
   the WNT Coreceptor Lrp6
SO PHOSPHATE AND VITAMIN D IN CHRONIC KIDNEY DISEASE
SE Contributions to Nephrology
LA English
DT Article; Book Chapter
ID PHOSPHATE HOMEOSTASIS; RENAL REGULATION; FGF23; KLOTHO; DICKKOPF 1;
   TOXICITY; RECEPTOR; METABOLISM; MUTATIONS; INSIGHTS
AB Deregulated phosphate homeostasis can lead to a wide range of disorders, including myopathy, cardiac dysfunction, and skeletal abnormalities. Therefore, characterization of the molecular regulation of phosphate metabolism is of pathophysiological and clinical significance. Hyp mouse is the model for human X linked hypophosphatemia which is due to mutations that inactivate the endopeptidases of the X chromosome (PHEX). PHEX inactivation leads to increased serum levels of fibroblast growth factor 23 (FGF23), a phosphaturic hormone that induces excessive renal phosphate excretion and severe hypophosphatemia. The expression of WNT signaling components is increased in Hyp mice. To determine the potential role of WNT signaling in FGF23 mediated hypophosphatemia, we cross bred Hyp mice with mice deficient in the WNT coreceptor low density lipoprotein receptor related protein 6 (Lrp6) to generate Hyp and Lrp6 double mutant mice (Hyp/Lrp6). Like Hyp mice, Hyp/Lrp6 double mutants maintained high serum levels of FGF23, and accordingly exhibited hypophosphatemia to the same degree as the Hyp mice did, indicating that genetically reducing WNT signaling does not impact FGF23 induced phosphaturia. Moreover, similar to Hyp mice, the Hyp/Lrp6 double mutants also exhibited reduced mineralization of the bone, further supporting that reduced WNT signaling does not affect the chronic phosphate wasting caused by excess FGF23 in these mice. In further support of our finding, injection of bioactive FGF23 protein into Lrp6 mutant mice reduced serum phosphate levels to a similar degree as FGF23 injection into wild type mice. Our in vivo studies provide genetic and pharmacological evidence for a WNT independent function of FGF23 in the regulation of phosphate homeostasis. Copyright (C) 2013 S. Karger AG, Basel
C1 [Uchihashi, Kazuyoshi; Nakatani, Teruyo; Razzaque, Mohammed S.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
   [He, Xi] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.
   [Goetz, Regina; Mohammadi, Moosa] NYU, Sch Med, Dept Pharmacol, New York, NY USA.
C3 Harvard University; Harvard School of Dental Medicine; Harvard
   University; Harvard Medical School; New York University
RP Razzaque, MS (通讯作者)，Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Res & Educ Bldg,Room 304,190 Longwood Ave, Boston, MA 02115 USA.
EM mrazzaque@hms.harvard.edu
RI Goetz, Regina/M 2411 2019; Razzaque, Mohammed/K 4282 2019; Mohammadi,
   Moosa/ABA 6745 2020
OI Mohammadi, Moosa/0000 0003 2434 9437; Goetz, Regina/0000 0003 3681 4703
FU NIDCR NIH HHS [R01 DE013686, R01 DE13686] Funding Source: Medline; NIDDK
   NIH HHS [R01 DK077276, R01 DK077276] Funding Source: Medline;
   Grants in Aid for Scientific Research [24791553] Funding Source: KAKEN
CR Andersson E, 2010, DEV DYNAM, V239, P237, DOI 10.1002/dvdy.22101
   Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081
   Baum M, 2005, AM J PHYSIOL RENAL, V288, pF363, DOI 10.1152/ajprenal.00217.2004
   Baum M, 2006, PEDIATR NEPHROL, V21, P1067, DOI 10.1007/s00467 006 0126 2
   Drezner MK, 2003, ENDOCRIN DEV, V6, P126
   Farrow EG, 2010, J ENDOCRINOL, V207, P67, DOI 10.1677/JOE 10 0181
   Gaasbeek A, 2005, AM J MED, V118, P1094, DOI 10.1016/j.amjmed.2005.02.014
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Goetz R, 2007, MOL CELL BIOL, V27, P3417, DOI 10.1128/MCB.02249 06
   Goetz R, 2010, P NATL ACAD SCI USA, V107, P407, DOI 10.1073/pnas.0902006107
   Hartman ML, 2013, CONTRIB NEPHROL, V180, P138, DOI 10.1159/000346793
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Kokubu C, 2004, DEVELOPMENT, V131, P5469, DOI 10.1242/dev.01405
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   Lindvall C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005813
   Liu SG, 2006, AM J PHYSIOL ENDOC M, V291, pE38, DOI 10.1152/ajpendo.00008.2006
   Liu SG, 2009, MOL ENDOCRINOL, V23, P1505, DOI 10.1210/me.2009 0085
   Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097 2765(01)00224 6
   MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092 8674(90)90385 R
   Medici D, 2008, J CELL BIOL, V182, P459, DOI 10.1083/jcb.200803024
   Murer H, 2000, PHYSIOL REV, V80, P1373, DOI 10.1152/physrev.2000.80.4.1373
   Nakatani T, 2009, FASEB J, V23, P3702, DOI 10.1096/fj.08 123992
   Nakatani T, 2009, FASEB J, V23, P433, DOI 10.1096/fj.08 114397
   Ohnishi M, 2013, CONTRIB NEPHROL, V180, P1, DOI 10.1159/000346774
   Ohnishi M, 2010, FASEB J, V24, P3562, DOI 10.1096/fj.09 152488
   Onishi T, 2008, ARCH ORAL BIOL, V53, P99, DOI 10.1016/j.archoralbio.2007.08.009
   Osuka S, 2012, J BONE MINER METAB, V30, P10, DOI 10.1007/s00774 011 0343 z
   PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0
   Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124
   Razzaque MS, 2007, NAT CLIN PRACT ENDOC, V3, P788, DOI 10.1038/ncpendmet0667
   Razzaque MS, 2011, CLIN SCI, V120, P91, DOI 10.1042/CS20100377
   Razzaque MS, 2009, NAT REV ENDOCRINOL, V5, P611, DOI 10.1038/nrendo.2009.196
   Razzaque MS, 2009, AM J PHYSIOL RENAL, V296, pF470, DOI 10.1152/ajprenal.90538.2008
   Razzaque MS, 2007, J ENDOCRINOL, V194, P1, DOI 10.1677/JOE 07 0095
   Razzaque MS, 2013, CONTRIB NEPHROL, V180, P74, DOI 10.1159/000346784
   Razzaque MS, 2010, EXPERT OPIN THER PAT, V20, P981, DOI 10.1517/13543771003774100
   Razzaque MS, 2011, IUBMB LIFE, V63, P240, DOI 10.1002/iub.437
   Razzaque MS, 2009, NEPHROL DIAL TRANSPL, V24, P4, DOI 10.1093/ndt/gfn620
   Razzaque MS, 2006, FASEB J, V20, P720, DOI 10.1096/fj.05 5432fje
   Razzaque MS, 2003, INVEST OPHTH VIS SCI, V44, P1616, DOI 10.1167/iovs.02 0644
   Semënov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960 9822(01)00290 1
   TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Xia WB, 2007, CALCIFIED TISSUE INT, V81, P415, DOI 10.1007/s00223 007 9067 4
   Zhou CJ, 2008, DEV DYNAM, V237, P3681, DOI 10.1002/dvdy.21770
NR 45
TC 10
Z9 11
U1 0
U2 5
PU KARGER
PI BASEL
PA POSTFACH, CH 4009 BASEL, SWITZERLAND
SN 0302 5144
BN 978 3 318 02369 5
J9 CONTRIB NEPHROL
JI Contrib.Nephrol.
PY 2013
VL 180
BP 124
EP 137
DI 10.1159/000346792
PG 14
WC Urology & Nephrology
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA BFV89
UT WOS:000321592100011
PM 23652555
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Karpf, DB
   Pihl, S
   Mourya, S
   Mortensen, E
   Kovoor, E
   Markova, D
   Leff, JA
AF Karpf, David B.
   Pihl, Susanne
   Mourya, Sanchita
   Mortensen, Eva
   Kovoor, Eshwari
   Markova, Denka
   Leff, Jonathan A.
TI A Randomized Double Blind Placebo Controlled First In Human Phase 1
   Trial of TransCon PTH in Healthy Adults
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE CLINICAL TRIALS; HYPOPARATHYROIDISM; DISORDERS OF CALCIUM; PHOSPHATE
   METABOLISM; PTH; LONG ACTING PTH; THERAPEUTICS
ID PARATHYROID HORMONE 1 34; BONE FORMATION; HYPOPARATHYROIDISM; THERAPY;
   PARATHYROID HORMONE 1 34; REABSORPTION; CALCITRIOL; MANAGEMENT;
   PTH(1 84); CHILDREN
AB TransCon PTH is a sustained release, essentially inactive prodrug transiently bound to an inert carrier, designed to release PTH(1 34), and in development for hypoparathyroidism (HP). This phase 1, randomized, placebo controlled, single and multiple ascending dose (SAD and MAD, respectively) trial evaluated safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of TransCon PTH in healthy adults. SAD and MAD cohorts consisted of 10 subjects (eight active, two placebo) who received up to seven single or six multiple ascending doses of TransCon PTH, respectively. TransCon PTH doses ranged from 3.5 to 124 mu g PTH(1 34) for the SAD cohorts and 3.5 to 24 mu g PTH(1 34)/day for the MAD cohorts. The primary PK endpoint was Free PTH. The PD endpoints included albumin adjusted serum calcium (sCa), fractional excretion of calcium (FECa), intact endogenous PTH(1 84), bone turnover markers, renal tubular maximum reabsorption of phosphate/glomerular filtration rate (TMP/GFR), serum phosphate (sP) and magnesium, and 1,25 dihydroxyvitamin D. TransCon PTH was generally well tolerated; there were no drug related serious adverse events (SAEs), and all AEs were transient in nature. Free PTH demonstrated an effective half life of approximately 60 hours and a dose dependent, sustained exposure with an infusion like profile within the calculated physiologic range for active PTH at steady state. Albumin adjusted sCa demonstrated a dose dependent, sustained response with complete control of FECa despite modest hypercalcemia at higher doses. Renal tubular maximum reabsorption of phosphate/glomerular filtration rate (TMP/GFR) showed a dose dependent decrease, resulting in a dose dependent decrease in sP. TransCon PTH administered daily for 10 days showed no increase in the osteoblastic bone formation markers, serum bone specific alkaline phosphatase (BSAP) or P1NP, or the osteoclastic bone resorption marker, urine NTx, but modestly and transiently increased the osteoclast marker, serum CTx. These phase 1 data support TransCon PTH as a daily replacement therapy for HP providing physiological levels of PTH 24 hours per day and advancement into phase 2 clinical development. (c) 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
C1 [Karpf, David B.; Mourya, Sanchita; Mortensen, Eva; Kovoor, Eshwari; Markova, Denka; Leff, Jonathan A.] Ascendis Pharma Inc, 500 Emerson St, Palo Alto, CA 94301 USA.
   [Pihl, Susanne] Ascendis Pharma AS, Hellerup, Denmark.
RP Karpf, DB (通讯作者)，Ascendis Pharma Inc, 500 Emerson St, Palo Alto, CA 94301 USA.
CR Almquist M, 2018, BRIT J SURG, V105, P1313, DOI 10.1002/bjs.10843
   Bilezikian JP, 2016, J CLIN ENDOCR METAB, V101, P2313, DOI 10.1210/jc.2015 3910
   Brandi ML, 2016, J CLIN ENDOCR METAB, V101, P2273, DOI 10.1210/jc.2015 3907
   Clarke BL, 2016, J CLIN ENDOCR METAB, V101, P2284, DOI 10.1210/jc.2015 3908
   Eli Lilly and Co, 2012, FORT HIGHL PRESCR IN
   Horwitz MJ, 2011, J BONE MINER RES, V26, P2287, DOI 10.1002/jbmr.415
   Khurana M, 2019, CLIN PHARMACOL THER, V105, P710, DOI 10.1002/cpt.1200
   Mannstadt M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.55
   Mohan S, 2000, BONE, V27, P471, DOI 10.1016/S8756 3282(00)00355 0
   Payne RB, 1998, ANN CLIN BIOCHEM, V35, P201, DOI 10.1177/000456329803500203
   Rejnmark L, 2018, ENDOCRINE, V59, P237, DOI 10.1007/s12020 017 1479 y
   Rubin MR, 2016, J CLIN ENDOCR METAB, V101, P2742, DOI 10.1210/jc.2015 4135
   Shire NPS Pharmaceuticals Inc. Highlights of prescribing information, HIGHL PRESCR INF
   Sikjaer T, 2011, J BONE MINER RES, V26, P2358, DOI 10.1002/jbmr.470
   Sprogoe K, 2017, ENDOCR CONNECT, V6, pR171, DOI 10.1530/EC 17 0203
   Syed MA, 2001, J CLIN ENDOCR METAB, V86, P1525, DOI 10.1210/jc.86.4.1525
   Underbjerg L, 2013, J BONE MINER RES, V28, P2277, DOI 10.1002/jbmr.1979
   US Food and Drug Administration, 2014, CLIN PHARM BIOPH REV
   Winer KK, 2008, J CLIN ENDOCR METAB, V93, P3389, DOI 10.1210/jc.2007 2552
   Winer KK, 2014, J PEDIATR US, V165, P556, DOI 10.1016/j.jpeds.2014.04.060
   Winer KK, 2012, J CLIN ENDOCR METAB, V97, P391, DOI 10.1210/jc.2011 1908
   Winer KK, 2003, J CLIN ENDOCR METAB, V88, P4214, DOI 10.1210/jc.2002 021736
   Winer KK, 1998, J CLIN ENDOCR METAB, V83, P3480, DOI 10.1210/jc.83.10.3480
   Winer KK, 1996, JAMA J AM MED ASSOC, V276, P631, DOI 10.1001/jama.276.8.631
NR 24
TC 29
Z9 35
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2020
VL 35
IS 8
BP 1430
EP 1440
DI 10.1002/jbmr.4016
EA APR 2020
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA MZ1FZ
UT WOS:000526161900001
PM 32212275
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Hyun, JJ
   Chun, HJ
   Keum, B
   Seo, YS
   Kim, YS
   Jeen, YT
   Lee, HS
   Um, SH
   Kim, CD
   Ryu, HS
   Kim, SG
   Jung, WW
AF Hyun, Jong Jin
   Chun, Hoon Jai
   Keum, Bora
   Seo, Yeon Seok
   Kim, Yong Sik
   Jeen, Yoon Tae
   Lee, Hong Sik
   Um, Soon Ho
   Kim, Chang Duck
   Ryu, Ho Sang
   Kim, Sin Gon
   Jung, Woon Won
TI Effect of omeprazole on the expression of transcription factors in
   osteoclasts and osteoblasts
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE proton pump inhibitor; omeprazole; osteoclast; osteoblast
ID PROTON PUMP INHIBITORS; RISK; ACID; ABSORPTION; MEDICATIONS; GUIDELINES;
   MANAGEMENT; FRACTURE; THERAPY; DISEASE
AB The use of proton pump inhibitors (PPIs) seems to be related to increased fracture risk but the mechanism is unclear. In an effort to clarify the mechanism, we evaluated the effect of omeprazole, a representative of the PPIs, on the expression of transcription factors in osteoclasts and osteoblasts. Murine RAW264.7 and MC3T3 E1 cells were used for osteoclast and osteoblast analysis, to which various concentrations of omeprazole were added. RAW264.7 cells with >= 3 nuclei were considered tartrate resistant acid phosphatase (TRAP) positive, i.e. activated osteoclasts. Expressions of the calcitonin receptor (CTR), c fos, nuclear factor of activated T cells, cytoplasmic 1 (NFATc1), and matrix metalloproteinase (MMP) 9 mRNA in osteoclasts were evaluated. Gene expression of osteocalcin and of the osteoprotegerin/receptor activator of NF kappa B ligand (OPG/RANKL) ratio in osteoblasts was examined and Western blotting of NFATc1 was performed. Treating the osteoclasts with increasing doses of omeprazole did not affect TRAP positivity, but significantly decreased the expressions of CTR, c fos, NFATc1, and MMP 9 regardless of the omeprazole concentration. The expression of osteocalein and of the OPG/RANKL ratio in osteoblasts was augmented with increasing omeprazole concentrations. The result of the Western blot analysis with NFATc1 was similar to that of the expression of NFATc1 mRNA. Omeprazole decreased the activation of osteoclasts but increased that of osteoblasts in vitro, in part causing an osteopetrosis like effect. Together with the effect of omeprazole on calcium homeostasis, increased fracture risk may be due to the osteopetrorickets like effect of omeprazole.
C1 [Kim, Sin Gon] Korea Univ, Div Endocrinol & Metab, Dept Internal Med, Anam Hosp, Seoul 136705, South Korea.
   [Hyun, Jong Jin; Chun, Hoon Jai; Keum, Bora; Seo, Yeon Seok; Kim, Yong Sik; Jeen, Yoon Tae; Lee, Hong Sik; Um, Soon Ho; Kim, Chang Duck; Ryu, Ho Sang] Korea Univ, Div Gastroenterol & Hepatol, Dept Internal Med, Anam Hosp, Seoul 136705, South Korea.
   [Jung, Woon Won] Korea Univ, Coll Hlth Sci, Seoul 136705, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine); Korea University
RP Chun, HJ (通讯作者)，Korea Univ, Div Gastroenterol & Hepatol, Dept Internal Med, Anam Hosp, 126 1,Anamdong 5 Ga, Seoul 136705, South Korea.
EM drchunhj@chol.com
RI ; Kim, Sin Gon/KQU 7757 2024; Kim, Eun Young/JCE 3602 2023; Kim,
   Yongsik/NJS 8538 2025; Lee, Hyo Suk/J 5618 2012
OI Kim, Sin Gon/0000 0002 7430 3675; Lee, Hong Sik/0000 0001 9726 5416;
   Hyun, Jong Jin/0000 0002 5632 7091; 
FU Yuhan Corporation, Korea
FX This study was financially supported by Yuhan Corporation, Korea.
CR Bak YT, 2004, J GASTROEN HEPATOL, V19, pS49, DOI 10.1111/j.1440 1746.2004.03587.x
   Chonan O, 1998, J NUTR SCI VITAMINOL, V44, P473, DOI 10.3177/jnsv.44.473
   Corley DA, 2010, GASTROENTEROLOGY, V139, P93, DOI 10.1053/j.gastro.2010.03.055
   DeVault KR, 2005, AM J GASTROENTEROL, V100, P190, DOI 10.1111/j.1572 0241.2005.41217.x
   Dial S, 2005, JAMA J AM MED ASSOC, V294, P2989, DOI 10.1001/jama.294.23.2989
   Farina C, 2002, CURR PHARM DESIGN, V8, P2033, DOI 10.2174/1381612023393369
   GagnemoPersson R, 1997, CALCIFIED TISSUE INT, V61, P210, DOI 10.1007/s002239900325
   Gray SL, 2010, ARCH INTERN MED, V170, P765, DOI 10.1001/archinternmed.2010.94
   IVANOVIC.P, 1967, ANN INTERN MED, V66, P917, DOI 10.7326/0003 4819 66 5 917
   Jefferies KC, 2008, ARCH BIOCHEM BIOPHYS, V476, P33, DOI 10.1016/j.abb.2008.03.025
   Laheij RJF, 2004, JAMA J AM MED ASSOC, V292, P1955, DOI 10.1001/jama.292.16.1955
   MIZUNASHI K, 1993, CALCIFIED TISSUE INT, V53, P21, DOI 10.1007/BF01352010
   O'Connell MB, 2005, AM J MED, V118, P778, DOI 10.1016/j.amjmed.2005.02.007
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Schinke T, 2009, NAT MED, V15, P674, DOI 10.1038/nm.1963
   Soll AH, 1996, JAMA J AM MED ASSOC, V275, P622
   Suh KS, 2009, BIOL PHARM BULL, V32, P746, DOI 10.1248/bpb.32.746
   Talley NJ, 2005, AM J GASTROENTEROL, V100, P2324, DOI 10.1111/j.1572 0241.2005.00225.x
   Targownik LE, 2008, CAN MED ASSOC J, V179, P319, DOI 10.1503/cmaj.071330
   Targownik LE, 2010, GASTROENTEROLOGY, V138, P896, DOI 10.1053/j.gastro.2009.11.014
   Tintut Y, 2002, J BIOL CHEM, V277, P14221, DOI 10.1074/jbc.M111551200
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Vestergaard P, 2006, CALCIFIED TISSUE INT, V79, P76, DOI 10.1007/s00223 006 0021 7
   Xu J, 2007, HISTOL HISTOPATHOL, V22, P443, DOI 10.14670/HH 22.443
   Yang YX, 2008, CURR DRUG SAF, V3, P204, DOI 10.2174/157488608785699414
   Yang YX, 2006, JAMA J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947
   Yu EW, 2008, CALCIFIED TISSUE INT, V83, P251, DOI 10.1007/s00223 008 9170 1
NR 27
TC 26
Z9 32
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD DEC
PY 2010
VL 26
IS 6
BP 877
EP 883
DI 10.3892/ijmm_00000537
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 690VD
UT WOS:000285035800014
PM 21042782
OA Bronze
DA 2025 08 17
ER

PT J
AU Cui, YT
   Wang, ZH
   Li, ZH
   Ji, X
   Yuan, BM
   Sun, Y
   Peng, CG
   Leng, Y
   Dou, MH
   Wang, JC
   Liu, H
   Wu, DK
AF Cui, Yutao
   Wang, Zhonghan
   Li, Zuhao
   Ji, Xuan
   Yuan, Baoming
   Sun, Yu
   Peng, Chuangang
   Leng, Yi
   Dou, Minghan
   Wang, Jincheng
   Liu, He
   Wu, Dankai
TI Functionalized anti osteoporosis drug delivery system enhances
   osseointegration of an inorganic organic bioactive interface in
   osteoporotic microenvironment
SO MATERIALS & DESIGN
LA English
DT Article
DE Drug delivery system; Inorganic organic bioactive interface; Interface
   osseointegration; OPG; RANKL signaling pathway; Osteoporotic
   microenvironment
ID IN VITRO; HYDROXYAPATITE NANOCRYSTALS; METHYLENE DIPHOSPHONATE;
   MAGNESIUM ALLOY; BONE FORMATION; ALENDRONATE; DIFFERENTIATION; FRACTURE;
   IMPLANTS; CELLS
AB Osteoporosis leads to various complications, such as prosthesis loosening and periprosthetic fracture, after joint replacement. This is mainly due to the impaired osteogenesis and excessive osteoclastic activity in osteoporotic microenvironment, which leads to insufficient osseointegration between prostheses and host bone. In this study, a functional drug releasing inorganic organic bioactive interface was constructed, comprising inorganic three dimensional (3D) printed porous titanium alloy interface and organic poloxamer 407 temperature sensitive hydrogel loaded with a novel anti osteoporosis drug (technetium methylenediphosphonate, 99Tc MDP). The inorganic organic bioactive interface showed good biocompatibility and exhibited a sustained release profile. This performance enhanced osteogenic differentiation, inhibited the expression of osteoclast related genes and inhibited the osteoclastogenesis, as compared with traditional bisphosphonates (alendronate) in vitro. When implanted into the distal femoral defect using an osteoporotic rabbit model, the 99Tc MDP loaded bioactive interface exhibited the most stable osseointegration with native bone. Furthermore, the drug delivery system inhibited osteoclastic activity via regulation of the osteoprotegerin/receptor activator of NF jB ligand (OPG/ RANKL) signaling pathway, which significantly ameliorated the osteoporosis status to effectively prevent continuous bone destruction around the interface. This study has clinical significance, as it demonstrates that the 99Tc MDP modified inorganic organic interface serve as a novel artificial prosthetic interface for patients with poor osteogenesis. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
   <comment>Superscript/Subscript Available</comment
C1 [Cui, Yutao; Wang, Zhonghan; Li, Zuhao; Yuan, Baoming; Sun, Yu; Peng, Chuangang; Leng, Yi; Dou, Minghan; Wang, Jincheng; Liu, He; Wu, Dankai] Second Hosp Jilin Univ, Orthopaed Med Ctr, Changchun 130041, Peoples R China.
   [Ji, Xuan] Second Hosp Jilin Univ, Dept Stomatol, Changchun 130041, Peoples R China.
C3 Jilin University; Jilin University
RP Wang, JC; Liu, H; Wu, DK (通讯作者)，Second Hosp Jilin Univ, Orthopaed Med Ctr, Changchun 130041, Peoples R China.
EM wangjinc@jlu.edu.cn; heliu@jlu.edu.cn; wudk@jlu.edu.cn
RI Wang, Jincheng/AAZ 3503 2021; Wu, Dankai/JFJ 8040 2023; sun,
   yu/HMO 8286 2023
OI Wang, Jincheng/0000 0002 1217 5962; sun, yu/0000 0002 2963 052X; Wu,
   Dankai/0000 0001 7859 6631
FU National Natural Science Foundation of China [82001971]; National Key
   RAMP;D Program of China [2018YFB1105100]; Scientific Development Program
   of Jilin Province [20200403088SF, 20200802008GH, 20200404202YY,
   20200404140YY, 20190304123YY, 20200404190YY, 20180201041SF,
   20180623050TC]; Program of Jilin Provincial Health Department
   [2019SCZT001, 2019SCZT014, 2019SRCJ001]; Youth Talents Promotion Project
   of Jilin Province [192004]
FX This study was supported by the National Natural Science Foundation of
   China (82001971); National Key R&D Program of China (2018YFB1105100);
   Scientific Development Program of Jilin Province (20200403088SF,
   20200802008GH, 20200404202YY, 20200404140YY, 20190304123YY,
   20200404190YY, 20180201041SF, and 20180623050TC); Program of Jilin
   Provincial Health Department (2019SCZT001, 2019SCZT014, and
   2019SRCJ001); and Youth Talents Promotion Project of Jilin Province
   (192004).
CR Al Daghri NM, 2017, MEDICINE, V96, P5780
   Apostu D, 2018, J INT MED RES, V46, P2104, DOI 10.1177/0300060517732697
   Bai HT, 2020, THERANOSTICS, V10, P4779, DOI 10.7150/thno.43736
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Bosco R, 2015, APPL SURF SCI, V328, P516, DOI 10.1016/j.apsusc.2014.12.072
   Brandi ML, 2013, EXPERT OPIN PHARMACO, V14, P1441, DOI 10.1517/14656566.2013.801959
   Brunello G, 2016, BIOTECHNOL ADV, V34, P740, DOI 10.1016/j.biotechadv.2016.03.009
   Chai Y, 2019, ONCOL LETT, V17, P468, DOI 10.3892/ol.2018.9508
   Chen J, 2017, MOL MED REP, V16, P1801, DOI 10.3892/mmr.2017.6839
   Chikarakara E, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/1/015007
   Cui YT, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201901073
   Dolci LS, 2019, INT J PHARMACEUT, V554, P245, DOI 10.1016/j.ijpharm.2018.11.023
   Fakhari A, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00390
   Fernandez Rebollo E, 2018, J BONE MINER RES, V33, P356, DOI 10.1002/jbmr.3298
   Figueroa Pizano MD, 2018, CARBOHYD POLYM, V195, P476, DOI 10.1016/j.carbpol.2018.05.004
   Gao CH, 2018, RSC ADV, V8, P25210, DOI 10.1039/c8ra04815k
   Gao P, 2020, BIOACT MATER, V5, P680, DOI 10.1016/j.bioactmat.2020.04.019
   Gao Y, 2011, ACS NANO, V5, P9788, DOI 10.1021/nn2033105
   Ghouse S, 2018, ADDIT MANUF, V22, P290, DOI 10.1016/j.addma.2018.05.024
   Heinemann C, 2008, BIOMACROMOLECULES, V9, P2913, DOI 10.1021/bm800693d
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Manzano Moreno FJ, 2019, CLIN ORAL INVEST, V23, P813, DOI 10.1007/s00784 018 2505 z
   Kim SE, 2016, BIOMED MATER, V11, DOI 10.1088/1748 6041/11/5/055005
   Kuzyk PRT, 2017, J AM ACAD ORTHOP SUR, V25, P624, DOI 10.5435/JAAOS D 15 00680
   Le Cann S, 2014, MED ENG PHYS, V36, P1185, DOI 10.1016/j.medengphy.2014.07.003
   Lee JY, 2017, J IND ENG CHEM, V52, P277, DOI 10.1016/j.jiec.2017.03.057
   Li CX, 2014, INT J PHARMACEUT, V474, P123, DOI 10.1016/j.ijpharm.2014.08.023
   Li GY, 2018, ACTA BIOMATER, V65, P486, DOI 10.1016/j.actbio.2017.10.033
   Li ZH, 2018, RAPID PROTOTYPING J, V24, P1365, DOI 10.1108/RPJ 10 2017 0205
   Liu H., 2020, MATER DESIGN, V189, P11
   Liu H, 2016, BIOFABRICATION, V8, DOI 10.1088/1758 5090/8/4/045012
   Liu H, 2015, TISSUE ENG PT A, V21, P2733, DOI [10.1089/ten.tea.2014.0666, 10.1089/ten.TEA.2014.0666]
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Loureiro A, 2018, MOL PHARMACEUT, V15, P527, DOI 10.1021/acs.molpharmaceut.7b00893
   Park CG, 2017, MACROMOL RES, V25, P756, DOI 10.1007/s13233 017 5073 1
   Ravichandran R, 2012, BIOMATERIALS, V33, P846, DOI 10.1016/j.biomaterials.2011.10.030
   Rhee Seung Joon, 2018, Knee Surg Relat Res, V30, P284, DOI 10.5792/ksrr.17.036
   Shu Xun Y, 2011, NUCL MED COMMUN, V32, P142, DOI 10.1097/MNM.0b013e32834121cb
   Sipos W, 2009, WIEN MED WOCHENSCHR, V159, P230, DOI 10.1007/s10354 009 0647 y
   Song RL, 2015, MOL MED REP, V11, P1153, DOI 10.3892/mmr.2014.2817
   Terrier CSP, 2017, J INFECTION, V75, P281, DOI 10.1016/j.jinf.2017.07.007
   Wang CZ, 2010, BIOMATERIALS, V31, P8674, DOI 10.1016/j.biomaterials.2010.07.096
   Wang LM, 2008, CLIN EXP PHARMACOL P, V35, P23, DOI 10.1111/j.1440 1681.2007.04738.x
   Wang TT, 2019, CURR DRUG TARGETS, V20, P354, DOI 10.2174/1389450119666180626120852
   Wang ZH, 2017, J ALLOY COMPD, V717, P271, DOI 10.1016/j.jallcom.2017.05.079
   Wang ZQ, 2020, ACS BIOMATER SCI ENG, V6, P4247, DOI 10.1021/acsbiomaterials.0c00386
   Wei PB, 2017, SURF COAT TECH, V313, P381, DOI 10.1016/j.surfcoat.2017.01.108
   Wu HW, 2014, J MATER SCI MATER M, V25, P2649, DOI 10.1007/s10856 014 5289 y
   Xie Z, 2018, DRUG DELIV, V25, P187, DOI 10.1080/10717544.2017.1422295
   Xu F, 2016, MOL MED REP, V14, P2289, DOI 10.3892/mmr.2016.5515
   Yamaguchi M, 2017, EXP THER MED, V14, P1769, DOI 10.3892/etm.2017.4695
   Yan CY, 2019, CARBOHYD POLYM, V210, P110, DOI 10.1016/j.carbpol.2019.01.026
   Yang WK, 2015, J IND ENG CHEM, V27, P391, DOI 10.1016/j.jiec.2015.01.019
   Zhao Y., 2019, ADV FUNCT MATER, V29
   Zhao YH, 2012, CALCIFIED TISSUE INT, V91, P400, DOI 10.1007/s00223 012 9649 7
NR 55
TC 22
Z9 22
U1 11
U2 245
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264 1275
EI 1873 4197
J9 MATER DESIGN
JI Mater. Des.
PD AUG
PY 2021
VL 206
AR 109753
DI 10.1016/j.matdes.2021.109753
EA MAY 2021
PG 15
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA SX9EE
UT WOS:000665498700033
OA gold
DA 2025 08 17
ER

PT J
AU Thummuri, D
   Guntuku, L
   Challa, VS
   Ramavat, RN
   Naidu, VGM
AF Thummuri, Dinesh
   Guntuku, Lalita
   Challa, Veerabhadra Swamy
   Ramavat, Ravinder Naik
   Naidu, Vegi Ganga Modi
TI Abietic acid attenuates RANKL induced osteoclastogenesis and
   inflammation associated osteolysis by inhibiting the NF KB and MAPK
   signaling
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE abietic acid; NF kappa B; osteoclastogenesis; osteoporosis; RANKL
ID BONE; ACTIVATION; DIFFERENTIATION; EXPRESSION; ERK; PHOSPHORYLATION;
   APOPTOSIS; SURVIVAL
AB Osteoporosis is a major debilitating cause of fractures and decreases the quality of life in elderly patients. Bone homeostasis is maintained by bone forming osteoblasts and bone resorpting osteoclasts. Substantial evidences have shown that targeting osteoclasts using natural products is a promising strategy for the treatment of osteoporosis. In the current study, we investigated the osteoprotective effect of Abietic acid (AA) in in vitro and in vivo models of osteolysis. In vitro experiments demonstrated that, AA suppressed receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis and F actin ring formation in a concentration dependent manner. Mechanistically, AA abrogated RANKL induced phosphorylation of IKK alpha/beta (ser 176/180), IkB alpha (ser 32), and inhibited the nuclear translocation of NF kappa B. We also found that, AA attenuated the RANKL induced phosphorylation of MAPKs and decreased the expression of osteoclast specific genes such as TRAP, DC STAMP, c Fos, and NFATc1. Consistent with in vitro results, in vivo Lipoploysaccharide (LPS) induced osteolysis model showed that AA inhibited the LPS induced serum surge in cytokines TNF alpha and IL 6. mu CT analysis showed that AA prevented the LPS induced osteolysis. Furthermore, histopathology and TRAP staining results suggested that AA decreased the number of osteoclasts in LPS injected mice. Taken together, we demonstrated that the osteoprotective action of AA is coupled with the inhibition of NF kappa B and MAPK signaling and subsequent inhibition of NFATc1 and c Fos activities. Hence, AA may be considered as a promising drug candidate for the treatment of osteoporosis.
C1 [Thummuri, Dinesh; Guntuku, Lalita; Challa, Veerabhadra Swamy] Natl Inst Pharmaceut Educ & Res Hyderabad, Dept Pharmacol & Toxicol, Hyderabad, Andhra Pradesh, India.
   [Ramavat, Ravinder Naik] Natl Ctr Lab Anim Sci, Natl Inst Nutr, Hyderabad, Telangana, India.
   [Naidu, Vegi Ganga Modi] Natl Inst Pharmaceut Educ & Res Guwahati, Dept Pharmacol & Toxicol, Gauhati 781032, Assam, India.
C3 National Institute of Pharmaceutical Education & Research, Hyderabad;
   Indian Council of Medical Research (ICMR); ICMR   National Animal
   Resource Facility for Biomedical Research (NARFBR); ICMR   National
   Institute of Nutrition (NIN); National Institute of Pharmaceutical
   Education & Research, S.A.S. Nagar (Mohali)
RP Naidu, VGM (通讯作者)，Natl Inst Pharmaceut Educ & Res Guwahati, Dept Pharmacol & Toxicol, Gauhati 781032, Assam, India.
EM vgmnaidu@gmail.com
RI Thummuri, Dinesh/Q 2252 2019
OI challa, veerabhadra swamy/0000 0001 9425 894X; Naidu,
   VGM/0000 0003 1520 2177
FU Department of Biotechnology (DBT) [BT/SBIRI 1188/SBIRI 23/13]
FX Department of Biotechnology (DBT), Grant number: Sanction order number:
   BT/SBIRI 1188/SBIRI 23/13
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Dannemann C, 2007, BONE, V40, P828, DOI 10.1016/j.bone.2006.11.023
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Fernández MA, 2001, J PHARM PHARMACOL, V53, P867, DOI 10.1211/0022357011776027
   Garbe AI, 2012, J BONE MINER RES, V27, P2085, DOI 10.1002/jbmr.1670
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Huang Qi Quan, 2009, Curr Rheumatol Rep, V11, P357
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jeon Y, 2015, EXP DERMATOL, V24, P140, DOI 10.1111/exd.12616
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim MH, 2009, J CELL PHYSIOL, V221, P618, DOI 10.1002/jcp.21892
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Morley P, 2001, CURR PHARM DESIGN, V7, P671, DOI 10.2174/1381612013397780
   Mundy GR, 2002, ANNU REV MED, V53, P337, DOI 10.1146/annurev.med.53.082901.104047
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Nakamura I, 1996, J BONE MINER RES, V11, P1873
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201
   Song FM, 2016, J CELL PHYSIOL, V231, P1983, DOI 10.1002/jcp.25304
   Takahashi N, 2003, FEBS LETT, V550, P190, DOI 10.1016/S0014 5793(03)00859 7
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thummuri D, 2015, PHARMACOL RES, V99, P63, DOI 10.1016/j.phrs.2015.05.006
   Thummuri D, 2014, ENVIRON TOXICOL PHAR, V38, P58, DOI 10.1016/j.etap.2014.05.002
   Ulusu NN, 2002, PHYTOTHER RES, V16, P88, DOI 10.1002/ptr.983
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Yi G, 2016, INT IMMUNOPHARMACOL, V38, P261, DOI 10.1016/j.intimp.2016.05.029
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
NR 39
TC 39
Z9 40
U1 2
U2 48
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JAN
PY 2019
VL 234
IS 1
BP 443
EP 453
DI 10.1002/jcp.26575
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HC1BG
UT WOS:000451533300035
PM 29932225
DA 2025 08 17
ER

PT J
AU Zhang, Q
   Cuartas, E
   Mehta, N
   Gilligan, J
   Ke, HZ
   Saltzman, WM
   Kotas, M
   Ma, M
   Rajan, S
   Chalouni, C
   Carlson, J
   Vignery, A
AF Zhang, Qing
   Cuartas, Esteban
   Mehta, Nozer
   Gilligan, James
   Ke, Hua Zhu
   Saltzman, W. Mark
   Kotas, Maya
   Ma, Mandy
   Rajan, Sonali
   Chalouni, Cecile
   Carlson, Jodi
   Vignery, Agnes
TI Replacement of bone marrow by bone in rat femurs: The bone bioreactor
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID HUMAN PARATHYROID HORMONE; TRABECULAR BONE; POSTMENOPAUSAL OSTEOPOROSIS;
   DYNAMIC HISTOMORPHOMETRY; MORPHOGENETIC PROTEIN; GENE EXPRESSION;
   ANABOLIC AGENT; ABLATION; MICE; REGENERATION
AB During development and repair of bone, two distinct yet complementary mechanisms, intramembranous and endochondral, mediate new bone formation via osteoblasts. Because mechanical bone marrow ablation leads to the rapid and transient formation of new bone in the marrow cavity, we postulated that parathyroid hormone (PTH), which is a bone anabolic hormone, enhances the formation of new bone that forms after marrow ablation. We subjected the left femur of rats to mechanical marrow ablation, or sham operation, and injected the animals daily with PTH or vehicle for 1, 2, or 3 weeks in a first experiment, then with PTH, parathyroid hormone related peptide (PTHrP), or vehicle for 3 weeks in a second experiment. We subjected both femurs from each rat to soft X ray, peripheral quantitative computed tomography, computed tomography on a microscale, and histological analysis, and determined the concentration of serum osteocalcin. In addition, in the second experiment, we determined the serum concentration of calcium, tartrate resistant acid phosphatase (TRAP), and receptor activator of NF kappa B ligand (RANKL) at 3 weeks, and subjected femurs to biomechanical testing. Following treatment with PTH or PTHrP for 3 weeks, bone filled the marrow cavity of the shafts whose marrow had been ablated. PTH increased trabecular density in the right femur, but failed to induce bone formation in the medullary region of the right unoperated femoral shafts. The newly formed bone endowed left femoral shafts with improved biomechanical properties when compared to those of right femurs and left femurs from control, shamoperated, and vehicle treated rats. PTHrP, like PTH, increased serum osteocalcin, but neither increased serum calcium, TRAP, or RANKL at 3 weeks. Our results reveal that the newly formed bone that follows marrow ablation is responsive to PTH, expand the role of PTH in bone, and might open new avenues of investigations to the field of regenerative medicine and tissue engineering. Local bone marrow removal in conjunction with pharmacologic intervention with an anabolic agent might provide a technique for rapid preferential site directed bone growth in areas of high bone loss.
C1 [Zhang, Qing; Cuartas, Esteban; Vignery, Agnes] Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06510 USA.
   [Mehta, Nozer; Gilligan, James] Unigene Labs Inc, Fairfield, NJ USA.
   [Ke, Hua Zhu] Yale Univ, Dept Biomed Engn, New Haven, CT 06510 USA.
   [Saltzman, W. Mark; Kotas, Maya; Ma, Mandy; Rajan, Sonali] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA.
   [Carlson, Jodi] Yale Univ, Sch Med, Dept Comparat Med, New Haven, CT 06510 USA.
C3 Yale University; Yale University; Yale University; Yale University
RP Vignery, A (通讯作者)，Yale Univ, Sch Med, Dept Orthopaed & Rehabil, 330 Cedar St, New Haven, CT 06510 USA.
EM agnes.vignery@yale.edu
OI Scholz, Jodi/0000 0002 9571 5599
FU NIDCR NIH HHS [DE14097, DE12110] Funding Source: Medline
CR AMSEL S, 1969, ANAT RECORD, V164, P101, DOI 10.1002/ar.1091640107
   BAB I, 1988, ENDOCRINOLOGY, V123, P345, DOI 10.1210/endo 123 1 345
   BAB I, 1991, ENDOCRINOLOGY, V128, P2638
   Ballica R, 1999, J BONE MINER RES, V14, P1067, DOI 10.1359/jbmr.1999.14.7.1067
   BARON R, 1984, ANAT RECORD, V208, P137, DOI 10.1002/ar.1092080114
   Chen XD, 2003, CALCIFIED TISSUE INT, V72, P577, DOI 10.1007/s00223 002 1101 y
   Gabet Y, 2006, BONE, V39, P276, DOI 10.1016/j.bone.2006.02.004
   GUNDBERG CM, 1984, METHOD ENZYMOL, V107, P516
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Kieslinger M, 2005, DEV CELL, V9, P757, DOI 10.1016/j.devcel.2005.10.009
   Koh AJ, 2005, ENDOCRINOLOGY, V146, P4584, DOI 10.1210/en.2005 0333
   Kuroda S, 2005, CALCIFIED TISSUE INT, V77, P212, DOI 10.1007/s00223 004 0267 x
   Li HM, 2005, J EXP MED, V201, P1169, DOI 10.1084/jem.20041444
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Morinobu M, 2005, J EXP MED, V201, P961, DOI 10.1084/jem.20041097
   MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048
   PATT HM, 1975, EXP HEMATOL, V3, P135
   REEVE J, 1976, LANCET, V1, P1035
   REEVE J, 1980, BMJ BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340
   Shimizu T, 1998, BONE, V23, P127, DOI 10.1016/S8756 3282(98)00086 6
   STEWART AF, 1987, BIOCHEM BIOPH RES CO, V146, P672, DOI 10.1016/0006 291X(87)90581 X
   STEWLER GJ, 1987, J CLIN INVEST, V80, P1803
   SUVA LJ, 1993, J BONE MINER RES, V8, P379
   Tanaka H, 2001, BIOCHEM BIOPH RES CO, V287, P1157, DOI 10.1006/bbrc.2001.5711
   Tsuji K, 2004, J BONE MINER RES, V19, P1481, DOI 10.1359/JBMR.040601
   VIGNERY A, 1980, ANAT RECORD, V196, P191, DOI 10.1002/ar.1091960210
   Yamashita T, 2000, ENDOCRINOLOGY, V141, P438, DOI 10.1210/en.141.1.438
NR 28
TC 16
Z9 16
U1 0
U2 0
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD FEB
PY 2008
VL 14
IS 2
BP 237
EP 246
DI 10.1089/tea.2007.0261
PG 10
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 273VY
UT WOS:000253961200003
PM 18333776
DA 2025 08 17
ER

PT J
AU Verron, E
   Masson, M
   Khoshniat, S
   Duplomb, L
   Wittrant, Y
   Baud'huin, M
   Badran, Z
   Bujoli, B
   Janvier, P
   Scimeca, JC
   Bouler, JM
   Guicheux, J
AF Verron, Elise
   Masson, Martial
   Khoshniat, Solmaz
   Duplomb, Laurence
   Wittrant, Yohann
   Baud'huin, Marc
   Badran, Zahi
   Bujoli, Bruno
   Janvier, Pascal
   Scimeca, Jean Claude
   Bouler, Jean Michel
   Guicheux, Jerome
TI Gallium modulates osteoclastic bone resorption in vitro without
   affecting osteoblasts
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE gallium; osteoclast; bone resorption; osteoporosis; osteoblast
ID CANCER RELATED HYPERCALCEMIA; KAPPA B LIGAND; BISPHOSPHONATE THERAPY;
   RECEPTOR ACTIVATOR; MESSENGER RNA; NITRATE; FRACTURE; PROTEIN;
   OSTEOPOROSIS; PERSISTENCE
AB Background and purpose:
   Gallium (Ga) has been shown to be effective in the treatment of disorders associated with accelerated bone loss, including cancer related hypercalcemia and Paget's disease. These clinical applications suggest that Ga could reduce bone resorption. However, few studies have studied the effects of Ga on osteoclastic resorption. Here, we have explored the effects of Ga on bone cells in vitro.
   Experimental approach:
   In different osteoclastic models [osteoclasts isolated from long bones of neonatal rabbits (RBC), murine RAW 264.7 cells and human CD14 positive cells], we have performed resorption activity tests, staining for tartrate resistant acid phosphatase (TRAP), real time polymerase chain reaction analysis, viability and apoptotic assays. We also evaluated the effect of Ga on osteoblasts in terms of proliferation, viability and activity by using an osteoblastic cell line (MC3T3 E1) and primary mouse osteoblasts.
   Key results:
   Gallium dose dependently (0 100 mu M) inhibited the in vitro resorption activity of RBC and induced a significant decrease in the expression level of transcripts coding for osteoclastic markers in RAW 264.7 cells. Ga also dramatically reduced the formation of TRAP positive multinucleated cells. Ga down regulated in a dose dependant manner the expression of the transcription factor NFATc1. However, Ga did not affect the viability or activity of primary and MC3T3 E1 osteoblasts.
   Conclusions and implications:
   Gallium exhibits a dose dependent anti osteoclastic effect by reducing in vitro osteoclastic resorption, differentiation and formation without negatively affecting osteoblasts. We provide evidence that this inhibitory mechanism involves down regulation of NFATc1 expression, a master regulator of RANK induced osteoclastic differentiation.
C1 [Verron, Elise; Masson, Martial; Khoshniat, Solmaz; Wittrant, Yohann; Badran, Zahi; Bouler, Jean Michel; Guicheux, Jerome] INSERM, U791, F 75654 Paris 13, France.
   [Verron, Elise; Masson, Martial; Khoshniat, Solmaz; Duplomb, Laurence; Wittrant, Yohann; Baud'huin, Marc; Bujoli, Bruno; Janvier, Pascal; Bouler, Jean Michel; Guicheux, Jerome] Nantes Atlantic Univ, Nantes, France.
   [Verron, Elise] Graftys SARL, Aix En Provence, France.
   [Duplomb, Laurence; Baud'huin, Marc] INSERM, U 957, LPRO, F 75654 Paris 13, France.
   [Bujoli, Bruno; Janvier, Pascal] CNRS, UMR 6230, CEISAM, F 75700 Paris, France.
   [Scimeca, Jean Claude] Univ Nice, CNRS UNSA, UMR 6235, F 06108 Nice 2, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Nantes Universite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS);
   CNRS   Institute of Chemistry (INC); Universite Cote d'Azur
RP Guicheux, J (通讯作者)，INSERM, U791, F 75654 Paris 13, France.
EM jerome.guicheux@inserm.fr
RI Verron, Elise/P 2645 2014; Scimeca, Jean Claude/P 3830 2016; BUJOLI,
   Bruno/E 4924 2019; BADRAN, Zahi/A 4307 2015; guicheux,
   Jerome/F 7767 2013; Baud'huin, Marc/K 8519 2015; Guicheux,
   Jerome/F 7767 2013; Badran, Zahi/A 4307 2015; BOULER,
   Jean Michel/C 2099 2011
OI Verron, Elise/0000 0003 4276 5127; Scimeca,
   Jean Claude/0000 0003 3773 6110; BUJOLI, Bruno/0000 0002 2256 0792;
   BOULER, Jean Michel/0000 0001 9784 5584; Guicheux,
   Jerome/0000 0003 2754 3024; Duplomb, Laurence/0000 0002 5715 3759;
   Baud'huin, Marc/0000 0002 3357 329X; Badran, Zahi/0000 0003 2592 4333; 
FU INSERM; Fondation de l'Avenir pour la Recherche Medicale Appliquee
   (FARMA); Societe francaise de rhumatologie (SFR); Arthritis Courtin
   Foundation; Gabiphoce Project [ANR 08 BIOT 008]
FX The authors wish to thank Danielle Quincey, Dominique Heymann, Assem
   Soueidan, Gael Grimandi, Pierre Weiss, Paul Pilet and the Graftys
   company. The authors acknowledge the financial support of the INSERM,
   the Fondation de l'Avenir pour la Recherche Medicale Appliquee (FARMA),
   the Societe francaise de rhumatologie (SFR), the Arthritis Courtin
   Foundation and the Gabiphoce Project (ANR BioTECS ANR 08 BIOT 008).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Benezeth P, 1997, GEOCHIM COSMOCHIM AC, V61, P1345, DOI 10.1016/S0016 7037(97)00012 4
   Blair HC, 1998, BIOESSAYS, V20, P837, DOI 10.1002/(SICI)1521 1878(199810)20:10<837::AID BIES9>3.0.CO;2 D
   BLAIR HC, 1992, J CELL BIOCHEM, V48, P401, DOI 10.1002/jcb.240480409
   BOCKMAN RS, 1993, J CELL BIOCHEM, V52, P396, DOI 10.1002/jcb.240520404
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   DONNELLY R, 1991, BONE MINER, V12, P167, DOI 10.1016/0169 6009(91)90030 4
   Duplomb L, 2008, ENDOCRINOLOGY, V149, P3688, DOI 10.1210/en.2007 1719
   Emkey RD, 2006, AM J MED, V119, p18S, DOI 10.1016/j.amjmed.2005.12.019
   Ensrud KE, 2000, J AM GERIATR SOC, V48, P241, DOI 10.1111/j.1532 5415.2000.tb02641.x
   Faucheux C, 2009, J BIOMED MATER RES A, V89A, P46, DOI 10.1002/jbm.a.31989
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Gallagher AM, 2008, J BONE MINER RES, V23, P1569, DOI 10.1359/JBMR.080510
   Grimandi G, 2006, MICROSC RES TECHNIQ, V69, P606, DOI 10.1002/jemt.20326
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Guicheux J, 1998, BONE, V22, P25, DOI 10.1016/S8756 3282(97)00224 X
   GUIDON PT, 1993, J BONE MINER RES, V8, P103
   HALL TJ, 1990, BONE MINER, V8, P211, DOI 10.1016/0169 6009(90)90106 P
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Huybrechts KF, 2006, BONE, V38, P922, DOI 10.1016/j.bone.2005.10.022
   JENIS LG, 1993, J CELL BIOCHEM, V52, P330, DOI 10.1002/jcb.240520309
   Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721
   Lindsay R, 2001, JAMA J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320
   Ma ZJ, 2010, BIOL TRACE ELEM RES, V133, P342, DOI 10.1007/s12011 009 8445 3
   Magne D, 2003, J BONE MINER RES, V18, P1430, DOI 10.1359/jbmr.2003.18.8.1430
   MATKOVIC V, 1990, LANCET, V335, P72, DOI 10.1016/0140 6736(90)90540 L
   McClung M R, 2000, Expert Opin Pharmacother, V1, P225, DOI 10.1517/14656566.1.2.225
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Niesvizky R, 2003, SEMIN ONCOL, V30, P20, DOI 10.1016/S0093 7754(03)00172 6
   Orcel P, 2005, JOINT BONE SPINE, V72, P461, DOI 10.1016/j.jbspin.2005.09.002
   Papapoulos SE, 2005, OSTEOPOROSIS INT, V16, P468, DOI 10.1007/s00198 004 1725 z
   PECK WA, 1993, AM J MED, V94, P646
   Rabenda V, 2008, OSTEOPOROSIS INT, V19, P811, DOI 10.1007/s00198 007 0506 x
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Suzuki A, 2006, J BONE MINER RES, V21, P674, DOI 10.1359/JBMR.020603
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   van Balen R, 2001, CLIN ORTHOP RELAT R, P232
   Vinatier C, 2005, BIOMATERIALS, V26, P6643, DOI 10.1016/j.biomaterials.2005.04.057
   WARRELL RP, 1988, ANN INTERN MED, V108, P669, DOI 10.7326/0003 4819 108 5 669
   WARRELL RP, 1986, CANCER RES, V46, P4208
   WARRELL RP, 1984, J CLIN INVEST, V73, P1487, DOI 10.1172/JCI111353
   WARRELL RP, 1990, ANN INTERN MED, V113, P847, DOI 10.7326/0003 4819 113 11 847
   Wittrant Y, 2004, EXP CELL RES, V293, P292, DOI 10.1016/j.yexcr.2003.10.016
NR 49
TC 72
Z9 78
U1 0
U2 48
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD APR
PY 2010
VL 159
IS 8
BP 1681
EP 1692
DI 10.1111/j.1476 5381.2010.00665.x
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 576EL
UT WOS:000276127000013
PM 20397300
OA Green Published
DA 2025 08 17
ER

PT J
AU Zhang, QS
   Major, MB
   Takanashi, S
   Camp, ND
   Nishiya, N
   Peters, EC
   Ginsberg, MH
   Schultz, PG
   Moon, RT
   Ding, S
AF Zhang, Qisheng
   Major, Michael B.
   Takanashi, Shinichi
   Camp, Nathan D.
   Nishiya, Naoyuki
   Peters, Eric C.
   Ginsberg, Mark H.
   Schultz, Peter G.
   Moon, Randall T.
   Ding, Sheng
TI Small molecule synergist of the Wnt/β catenin signaling pathway
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE ARFGAP inhibitor; small molecule screen; Wnt signaling; regenerative
   medicine
ID ADP RIBOSYLATION FACTOR; WNT; INHIBITOR; ACTIVATION; PROTEIN; CANCER;
   EXPRESSION; XENOPUS; COMPLEX; SCREEN
AB The Wnt/beta catenin signaling pathway regulates cell fate and behavior during embryogenesis, adult tissue homeostasis, and regeneration. When inappropriately activated, the pathway has been linked to colorectal cancer and melanoma, and when attenuated it may contribute to Alzheimer's disease and osteoporosis. Small molecules that modulate Writ signaling will likely provide new insights into the regulation of this key developmental pathway and ultimately provide pharmacological agents to control Writ signaling in vivo. To this end, we screened a library of 100,000 small molecules for activity in a cell based assay of Wnt/beta catemn signaling and discovered a purine derivative, QS11, that synergizes with Wnt 3a ligand in the activation of Wnt/beta catenin signal transduction. Through affinity chromatography and subsequent functional assays, we showed that QS11 binds and inhibits the GTPase activating protein of ADP ribosylation factor 1 (ARFGAP1), suggesting that QS11 modulates Wnt/beta catenin signaling through an effect on protein trafficking. Consistent with its function as an ARFGAP inhibitor, QS11 inhibits migration of ARFGAP overexpressing breast cancer cells.
C1 Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Pharmacol, Seattle, WA 98195 USA.
   Univ Washington, Sch Med, Inst Stem Cell & Regenerat Med, Seattle, WA 98195 USA.
   Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   Genom Inst Novartis Res Fdn, San Diego, CA 92121 USA.
C3 Scripps Research Institute; Scripps Research Institute; University of
   Washington; University of Washington Seattle; Howard Hughes Medical
   Institute; University of Washington; University of Washington Seattle;
   University of California System; University of California San Diego;
   Novartis; Novartis USA
RP Schultz, PG (通讯作者)，Scripps Res Inst, Dept Chem, 10550 N Torrey Rd, La Jolla, CA 92037 USA.
EM schultz@scripps.edu; rtmoon@u.washington.edu; sding@scripps.edu
RI ; Peters, Eric/W 2739 2019; Moon, Randall/B 1743 2014
OI Nishiya, Naoyuki/0000 0003 1575 9944; Moon, Randall/0000 0002 9352 1408;
   Major, Michael/0000 0002 6753 8513; Zhang, Qisheng/0000 0001 9808 5038
FU NIGMS NIH HHS [T32 GM 07270, T32 GM007270] Funding Source: Medline
CR Bejsovec A, 2005, CELL, V120, P11, DOI 10.1016/S0092 8674(04)01246 2
   Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003
   CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045
   DasGupta R, 2005, SCIENCE, V308, P826, DOI 10.1126/science.1109374
   Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81
   Ding S, 2002, J AM CHEM SOC, V124, P1594, DOI 10.1021/ja0170302
   Dove A, 2003, NAT BIOTECHNOL, V21, P859, DOI 10.1038/nbt0803 859
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Hung DT, 2005, SCIENCE, V310, P670, DOI 10.1126/science.1116739
   Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421
   KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Kwok TCY, 2006, NATURE, V441, P91, DOI 10.1038/nature04657
   Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535 6108(03)00334 9
   Liu J, 2005, ANGEW CHEM INT EDIT, V44, P1987, DOI 10.1002/anie.200462552
   MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232
   MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092 8674(89)90506 0
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521 1878(199807)20:7<536::AID BIES4>3.0.CO;2 I
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092 8674(82)90409 3
   Onodera Y, 2005, EMBO J, V24, P963, DOI 10.1038/sj.emboj.7600588
   Pai R, 2004, MOL BIOL CELL, V15, P2156, DOI 10.1091/mbc.E03 12 0894
   Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881
   Park CH, 2005, BIOCHEM BIOPH RES CO, V328, P227, DOI 10.1016/j.bbrc.2004.12.151
   Polakis P, 2000, GENE DEV, V14, P1837
   Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Shan JF, 2005, BIOCHEMISTRY US, V44, P15495, DOI 10.1021/bi0512602
   Tanaka M, 2005, PLOS BIOL, V3, P764, DOI 10.1371/journal.pbio.0030128
   Tsai SC, 1998, J BIOL CHEM, V273, P20697, DOI 10.1074/jbc.273.33.20697
NR 30
TC 106
Z9 174
U1 0
U2 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 1
PY 2007
VL 104
IS 18
BP 7444
EP 7448
DI 10.1073/pnas.0702136104
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 164MY
UT WOS:000246239400027
PM 17460038
OA Green Published
DA 2025 08 17
ER

PT J
AU Clifton, KB
   Conover, CA
AF Clifton, Kari B.
   Conover, Cheryl A.
TI Pregnancy associated plasma protein A modulates the anabolic effects of
   parathyroid hormone in mouse bone
SO BONE
LA English
DT Article
DE Pregnancy associated plasma protein A; Parathyroid hormone; Insulin like
   growth factor; Insulin like growth factor binding proteins
ID GROWTH FACTOR I; IGF I; BINDING PROTEIN; MICE; RESISTANCE; DELETION;
   RECEPTOR
AB Intermittent parathyroid hormone (PTH) is a potent anabolic therapy for bone, and several studies have implicated local insulin like growth factor (IGF) signaling in mediating this effect The IGF system is complex and includes ligands and receptors, as well as IGF binding proteins (IGFBPs) and IGFBP proteases. Pregnancy associated plasma protein A (PAPP A) is a metalloprotease expressed by osteoblasts in vitro that has been shown to enhance local IGF action through cleavage of inhibitory IGFBP 4. This study was set up to test two specific hypotheses: 1) Intermittent PTH treatment increases the expression of IGF I, IGFBP 4 and PAPP A in bone in vivo, thereby increasing local IGF activity. 2) In the absence of PAPP A, local IGF activity and the anabolic effects of PTH on bone are reduced. Wild type (WT) and PAPP A knock out (KO) mice were treated with 80 mu g/kg human PTH 1 34 or vehicle by subcutaneous injection five days per week for six weeks. IGF I, IGFBP 4 and PAPP A mRNA expression in bone were significantly increased in response to PTH treatment PTH treatment of WT mice, but not PAPP A KO mice, significantly increased expression of an IGF responsive gene. Bone mineral density (BMD), as measured by DEXA, was significantly decreased in femurs of PAPP A KO compared to WT mice with PTH treatment. Volumetric BMD, as measured by pQCT, was significantly decreased in femoral midshaft (primarily cortical bone), but not metaphysis (primarily trabecular bone), of PAPP A KO compared to WT mice with PTH treatment These data suggest that stimulation of PAPP A expression by intermittent PTH treatment contributes to PTH bone anabolism in mice. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Clifton, Kari B.; Conover, Cheryl A.] Mayo Clin, Div Endocrinol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Conover, CA (通讯作者)，Mayo Clin, Div Endocrinol, Endocrine Res Unit, 200 First St SW,5 194 Joseph, Rochester, MN 55905 USA.
EM Conover.Cheryl@mayo.edu
FU NIH [T32 DK07352]
FX This work was supported, in part, by NIH grant T32 DK07352 to KBC.
CR Adamo ML, 2006, ENDOCRINOLOGY, V147, P2944, DOI 10.1210/en.2005 0742
   Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885
   Conover CA, 2004, BONE, V34, P297, DOI 10.1016/j.bone.2003.10.011
   Conover CA, 2012, TRENDS ENDOCRIN MET, V23, P242, DOI 10.1016/j.tem.2012.02.008
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Harrington SC, 2007, CIRC RES, V100, P1696, DOI 10.1161/CIRCRESAHA.106.146183
   Holly J, 2006, NEUROENDOCRINOLOGY, V83, P154, DOI 10.1159/000095523
   LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend 4 12 1806
   Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P2641, DOI 10.1210/endo.142.6.8192
   Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P4349, DOI 10.1210/en.142.10.4349
   MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338
   Phang D, 2010, GROWTH HORM IGF RES, V20, P192, DOI 10.1016/j.ghir.2010.01.001
   Qin XZ, 2006, ENDOCRINOLOGY, V147, P5653, DOI 10.1210/en.2006 1055
   Resch ZT, 2006, ENDOCRINOLOGY, V147, P5634, DOI 10.1210/en.2006 0493
   Tanner SJ, 2008, J BONE MINER RES, V23, P655, DOI 10.1359/JBMR.071210
   Wang YM, 2007, J BONE MINER RES, V22, P1329, DOI 10.1359/JBMR.070517
   Yamaguchi M, 2005, ENDOCRINOLOGY, V146, P2620, DOI 10.1210/en.2004 1511
   Zhou R, 2003, J ENDOCRINOL, V178, P177, DOI 10.1677/joe.0.1780177
NR 21
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2015
VL 81
BP 413
EP 416
DI 10.1016/j.bone.2015.08.015
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CX0FR
UT WOS:000365372800050
PM 26297833
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Badran, SA
   Atia tul Wahab
   Fayyaz, S
   Taj, B
   Choudhary, MI
AF Badran, Serene A.
   Atia tul Wahab
   Fayyaz, Sharmeen
   Taj, Bushra
   Choudhary, M. Iqbal
TI Megestrol acetate induced proliferation and differentiation of
   osteoblastic MC3T3 E1 cells: A drug repurposing approach
SO STEROIDS
LA English
DT Article
DE Megestrol acetate; Osteoblast cells; MC3T3 E1; Alkaline phosphatase
   (ALP); Bone morphogenic proteins (BMPs); Drug repurposing
ID OSTEOGENIC DIFFERENTIATION; BONE METABOLISM; OSTEOPOROSIS;
   MINERALIZATION; THERAPY; PATHWAY
AB Aims: Drug repurposing or repositioning i.e.; identifying new indications for existing drugs have recently accelerated the process of drug discovery and development. Megestrol acetate (1) is a well known progestin. It is commonly used as an appetite stimulant, and also in the treatment of breast, and endometrial cancers. The aim of this study is to investigate the effect of megestrol acetate (1) in osteoblast differentiation, and to determine the possible mechanism involved in megestrol acetate (1) induced osteoblast differentiation.
   Main methods: Cytotoxicity of different steroidal drugs was evaluated using MTT assay. Alkaline phosphatase (ALP) activity was also determined, and alizarin red S (ARS) staining was performed to measure extracellular mineralization. Osteogenic protein levels were determined using Western blot analysis.
   Key findings: Results of the current study indicated that the megestrol acetate (1) enhanced the proliferation and differentiation of osteoblast cells at 1, 0.2, and 0.04 mu M. This stimulatory effect of the megestrol acetate (1) was more prominent at 0.2 mu M for cell proliferation, while the maximum cell differentiation (ALPase activity, and calcification) was observed at 0.04 mu M. Western blot analysis also showed that megestrol acetate (1) altered the expression of bone morphogenic protein 2 (BMP2), p38, and pJNK proteins. Hence, only moderate doses of MGA (1) can enhance osteoblast proliferation and differentiation.
   Significance: Our results identified that megestrol acetate (1) could be a potential lead for further research towards bone fragility related disorders.
C1 [Badran, Serene A.] Univ Jordan, Fac Dent, Dept Pediat Dent & Orthodont, Amman 11942, Jordan.
   [Atia tul Wahab; Taj, Bushra; Choudhary, M. Iqbal] Univ Karachi, Int Ctr Chem & Biol Sci, Dr Panjwani Ctr Mol Med & Drug Res, Karachi 75270, Pakistan.
   [Fayyaz, Sharmeen; Choudhary, M. Iqbal] Univ Karachi, Int Ctr Chem & Biol Sci, HEJ Res Inst Chem, Karachi 75270, Pakistan.
   [Choudhary, M. Iqbal] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah 21589, Saudi Arabia.
C3 University of Jordan; University of Karachi; University of Karachi; King
   Abdulaziz University
RP Atia tul Wahab (通讯作者)，Univ Karachi, Int Ctr Chem & Biol Sci, Dr Panjwani Ctr Mol Med & Drug Res, Karachi 75270, Pakistan.; Choudhary, MI (通讯作者)，Univ Karachi, Int Ctr Chem & Biol Sci, HEJ Res Inst Chem, Karachi 75270, Pakistan.
EM tulwahab@yahoo.com; iqbal.choudhary@iccs.edu
RI ; Choudhary, M./C 8633 2012; Badran, Serene/AAI 2458 2021; fayyaz,
   sharmeen/AAP 5124 2021; Wahab, Atia tul /KCL 2242 2024; ,
   Atia tul Wahab/C 5839 2018
OI Badran, Serene/0000 0002 8528 7607; , Atia tul Wahab/0000 0002 2730 5547
CR [Anonymous], CLIN NUTR
   [Anonymous], REHABILITATION OLDER
   [Anonymous], ICARIIN INDICES MC3T
   [Anonymous], SCI WORLD J
   Cavalla D, 2013, DRUG DISCOV TODAY, V18, P523, DOI 10.1016/j.drudis.2012.12.009
   Crockett JC, 2016, ADVANCES IN PATHOBIOLOGY AND MANAGEMENT OF PAGET'S DISEASE OF BONE, P71, DOI 10.1016/B978 0 12 805083 5.00006 3
   Cuenda A, 2007, BBA MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010
   Dumont AS, 2000, J PHARMACOL TOX MET, V43, P31, DOI 10.1016/S1056 8719(00)00077 0
   ERLIK Y, 1981, MATURITAS, V3, P167, DOI 10.1016/0378 5122(81)90008 6
   Farish E, 2000, Climacteric, V3, P125, DOI 10.3109/13697130009167614
   Fournier A, 2008, BREAST CANCER RES TR, V107, P103, DOI 10.1007/s10549 007 9523 x
   Fracon Ricardo N, 2008, J Oral Sci, V50, P247, DOI 10.2334/josnusd.50.247
   Fu C, 2017, RSC ADV, V7, P8886, DOI 10.1039/c6ra26020a
   Hosseini S, 2019, COLLOID SURFACE B, V173, P662, DOI 10.1016/j.colsurfb.2018.10.035
   Huang ZF, 2018, EXP THER MED, V15, P5159, DOI 10.3892/etm.2018.6127
   Khajuria DK, 2011, REV BRAS REUMATOL, V51, P365
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Kim M, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21601 9
   Kwak EJ, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/829650
   Langedijk J, 2015, DRUG DISCOV TODAY, V20, P1027, DOI 10.1016/j.drudis.2015.05.001
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Liu M, 2018, INT J BIOL MACROMOL, V107, P137, DOI 10.1016/j.ijbiomac.2017.08.151
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602
   Lorentzon M, 2015, J INTERN MED, V277, P650, DOI 10.1111/joim.12369
   Majumdar SR, 2017, OSTEOPOROSIS INT, V28, P1965, DOI 10.1007/s00198 017 3986 3
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Prior JC, 2018, CLIMACTERIC, V21, P366, DOI 10.1080/13697137.2018.1467400
   Rao GG, 2006, EXPERT REV ANTICANC, V6, P43, DOI 10.1586/14737140.6.1.43
   Riedel T, 2018, MOL PHARMACEUT, V15, P116, DOI 10.1021/acs.molpharmaceut.7b00764
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Ruiz García V, 2018, J CACHEXIA SARCOPENI, V9, P444, DOI 10.1002/jcsm.12292
   Seifert Klauss V, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/845180
   Suh KS, 2018, CYTOTECHNOLOGY, V70, P215, DOI 10.1007/s10616 017 0135 y
   Thu HE, 2017, IRAN J BASIC MED SCI, V20, P894, DOI 10.22038/IJBMS.2017.9111
   Tsukune N, 2017, BIOCHEM BIOPH RES CO, V488, P664, DOI 10.1016/j.bbrc.2017.02.110
   Tu Kristie N, 2018, P T, V43, P92
   Ulivieri FM, 2018, CURR RHEUMATOL REV, V14, P53, DOI 10.2174/1573397112666161201162322
   Nguyen VT, 2018, PROCESS BIOCHEM, V67, P127, DOI 10.1016/j.procbio.2018.01.025
   Wermers RA, 2004, MAYO CLIN PROC, V79, P1557, DOI 10.4065/79.12.1557
   Yazid MD, 2010, CANCER CELL INT, V10, DOI 10.1186/1475 2867 10 42
   Zhao M, 2003, J DENT RES, V82, P23, DOI 10.1177/154405910308200106
NR 42
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039 128X
EI 1878 5867
J9 STEROIDS
JI Steroids
PD MAY
PY 2020
VL 157
AR 108607
DI 10.1016/j.steroids.2020.108607
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA LF4BM
UT WOS:000527364000008
PM 32084501
DA 2025 08 17
ER

PT J
AU Wu, JD
   Wang, AF
   Wang, X
   Li, GF
   Jia, P
   Shen, GS
   Chen, B
   Yuan, Y
   Zhang, H
   Yang, F
   Xu, YJ
AF Wu, Jiadong
   Wang, Aifei
   Wang, Xiao
   Li, Guangfei
   Jia, Peng
   Shen, Guangsi
   Chen, Bin
   Yuan, Ye
   Zhang, Hui
   Yang, Fan
   Xu, Youjia
TI Rapamycin improves bone mass in high turnover osteoporosis with iron
   accumulation through positive effects on osteogenesis and angiogenesis
SO BONE
LA English
DT Article
DE Osteoporosis; Rapamycin; Iron accumulation; Osteogenesis; Angiogenesis
ID MESENCHYMAL STEM CELLS; OSTEOCLAST DIFFERENTIATION; POSTMENOPAUSAL
   WOMEN; SIGNALING PATHWAY; MTORC1; ACTIVATION; PREVENTION; INDUCTION;
   PROMOTES; TARGET
AB Iron accumulation is an independent risk factor for type I osteoporosis, but the molecular mechanisms of the phenomenon are not well defined, and effective therapy has not been reported. Here, we found that the level of mTOR was increased both in wild type mouse models with iron accumulation and transgenic mouse models (Hepc( / )) of high turnover osteoporosis with iron accumulation. We show that an increased level of mTOR can depress osteogenesis and angiogenesis by Cxcl9 both in bone and in vitro. Suppression of mTOR in mouse models by rapamycin and in vitro by siRNA transfection recovered both osteogenesis and angiogenesis. These findings revealed the role of mTOR in osteogenesis and angiogenesis in high turnover osteoporosis with iron accumulation and showed that rapamycin targeting of mTOR ameliorates osteogenesis and angiogenesis to improve bone mass.
C1 [Wu, Jiadong; Wang, Aifei; Wang, Xiao; Li, Guangfei; Jia, Peng; Shen, Guangsi; Chen, Bin; Yuan, Ye; Zhang, Hui; Yang, Fan; Xu, Youjia] Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou 215004, Peoples R China.
   [Wu, Jiadong] Southeast Univ, Coll Med, Affiliated Yancheng Hosp, Dept Orthoped, Yancheng 224005, Peoples R China.
   [Yang, Fan; Xu, Youjia] Soochow Univ, Osteoporosis Inst, Suzhou 215004, Peoples R China.
C3 Soochow University   China; Southeast University   China; Soochow
   University   China
RP Xu, YJ (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou 215004, Peoples R China.
EM xuyoujia@suda.edu.cn
RI Li, Guangfei/AAA 2948 2020; Wang, Aifei/GRR 8071 2022
OI Yuan, Ye/0009 0001 8184 7451; Li, Guangfei/0000 0002 5527 8996; 
FU National Natural Science Foundation of China [81874018, 81803242];
   Pre Research Fund of the National Natural Science Foundation of China
   [SDFEYGJ1601]; Postgraduate Research & Practice Innovation Program of
   Jiangsu Province [KYCX17_1996]; Jiangsu Provincial Young Medical Talents
   Program [QNRC2016880]; Suzhou Grant [SZZXJ201504, SS201634]; Hospital
   preponderant academic subjects group [XKQ2015001]; Jiangsu Natural
   Science Foundation (Youth Foundation) [BK2017095]; Suzhou Peoples
   Livelihood Science and Technology Project [sys 2018053]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81874018 and 81803242), Pre Research Fund of
   the National Natural Science Foundation of China (No. SDFEYGJ1601),
   Postgraduate Research & Practice Innovation Program of Jiangsu Province
   (No. KYCX17_1996), Jiangsu Provincial Young Medical Talents Program (No.
   QNRC2016880), Suzhou Grant (No. SZZXJ201504 and SS201634), and Hospital
   preponderant academic subjects group (No. XKQ2015001), Jiangsu Natural
   Science Foundation (Youth Foundation) (No. BK2017095), Suzhou Peoples
   Livelihood Science and Technology Project (No. sys 2018053).
CR Akhter MP, 2001, BONE, V29, P121, DOI 10.1016/S8756 3282(01)00486 0
   Balogh E, 2016, BBA MOL BASIS DIS, V1862, P1640, DOI 10.1016/j.bbadis.2016.06.003
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Bonnick SL, 2010, MENOPAUSE, V17, P25, DOI [10.1097/gme.0b013e3181c617e6, 10.1097/gme.0b013e3181e617e6]
   Briggs AM, 2016, GERONTOLOGIST, V56, pS243, DOI 10.1093/geront/gnw002
   Browne AJ, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058 017 0885 7
   Bruneau S, 2013, BLOOD, V122, P1833, DOI 10.1182/blood 2013 03 488486
   Camaschella C, 2015, NEW ENGL J MED, V373, P485, DOI 10.1056/NEJMc1507104
   Chen B, 2015, EXP THER MED, V10, P7, DOI 10.3892/etm.2015.2484
   Chen CT, 2012, MOL CANCER THER, V11, P2212, DOI 10.1158/1535 7163.MCT 12 0180
   Chen JQ, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0004 5
   Chen J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004688
   Dai QG, 2017, J BIOL CHEM, V292, P196, DOI 10.1074/jbc.M116.764761
   DeShields SC, 2018, J ENDOCRINOL INVEST, V41, P1051, DOI 10.1007/s40618 018 0828 x
   Drager J, 2016, ACTA BIOMATER, V42, P411, DOI 10.1016/j.actbio.2016.07.037
   Drager J, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.4
   EASTELL R, 1993, OSTEOPOROSIS INT, V3, P255, DOI 10.1007/BF01623829
   Gambacciani M, 2014, MENOPAUSE REV, V13, P213, DOI 10.5114/pm.2014.44996
   GRANICK S, 1954, B NEW YORK ACAD MED, V30, P81
   Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068
   Gupta A, 2016, AUST PRESCR, V39, P40, DOI 10.18773/austprescr.2016.028
   Hadji P, 2013, CRIT REV ONCOL HEMAT, V87, P101, DOI 10.1016/j.critrevonc.2013.05.015
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Huynh H, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003 018 0028 4
   Houghton PJ, 2010, CLIN CANCER RES, V16, P1368, DOI 10.1158/1078 0432.CCR 09 1314
   Hsiao EC, 2008, P NATL ACAD SCI USA, V105, P1209, DOI 10.1073/pnas.0707457105
   Huang B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13885
   Jeney V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00077
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Kamer C. M., 2017, MOT CELL BIOL, V37, DOI [10.1128/MCB.00253 16(e00253 00216), DOI 10.1128/MCB.00253 16(E00253 00216)]
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Kim BJ, 2013, OSTEOPOROSIS INT, V24, P2627, DOI 10.1007/s00198 013 2363 0
   Kim BJ, 2012, J BONE MINER RES, V27, P2279, DOI 10.1002/jbmr.1692
   Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lamming DW, 2012, SCIENCE, V335, P1638, DOI 10.1126/science.1215135
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Li GW, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1403 x
   Marx J, 2004, SCIENCE, V305, P1420, DOI 10.1126/science.305.5689.1420
   Messer JG, 2009, BONE, V45, P972, DOI 10.1016/j.bone.2009.07.073
   Mukhopadhyay S, 2016, MOL CANCER THER, V15, P347, DOI 10.1158/1535 7163.MCT 15 0720
   Paddenberg R, 2007, RESP RES, V8, DOI 10.1186/1465 9921 8 15
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Sahin H, 2012, HEPATOLOGY, V55, P1610, DOI 10.1002/hep.25545
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721
   Wang L, 2017, MOL MED REP, V16, P6642, DOI 10.3892/mmr.2017.7451
   Wang L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.36
   Wang X, 2018, METABOLISM, V83, P167, DOI 10.1016/j.metabol.2018.01.005
   Watson A, 2016, CELL SIGNAL, V28, P412, DOI 10.1016/j.cellsig.2016.01.014
   Weinberg Eugene D, 2008, Pediatr Endocrinol Rev, V6 Suppl 1, P81
   Xiao F, 2018, CELL PHYSIOL BIOCHEM, V45, P1927, DOI 10.1159/000487969
   Xu S, 2016, J BONE MINER RES, V31, P1320, DOI 10.1002/jbmr.2800
   Zhang Y, 2017, J BONE MINER RES, V32, P1829, DOI 10.1002/jbmr.3172
NR 55
TC 34
Z9 47
U1 2
U2 34
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2019
VL 121
BP 16
EP 28
DI 10.1016/j.bone.2018.12.019
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HN9CE
UT WOS:000460495000003
PM 30610968
DA 2025 08 17
ER

PT J
AU Domazetovic, V
   Marcucci, G
   Falsetti, I
   Bilia, AR
   Vincenzini, MT
   Brandi, ML
   Iantomasi, T
AF Domazetovic, Vladana
   Marcucci, Gemma
   Falsetti, Irene
   Bilia, Anna Rita
   Vincenzini, Maria Teresa
   Brandi, Maria Luisa
   Iantomasi, Teresa
TI Blueberry Juice Antioxidants Protect Osteogenic Activity against
   Oxidative Stress and Improve Long Term Activation of the Mineralization
   Process in Human Osteoblast Like SaOS 2 Cells: Involvement of SIRT1
SO ANTIOXIDANTS
LA English
DT Article
DE blueberry juice (BJ); total soluble polyphenols (TSP); osteoporosis;
   dietary antioxidants; oxidative stress; osteoblast osteogenic
   differentiation; alkaline phosphatase (ALP); Runt related transcription
   factor 2 (RUNX 2); sirtuin type 1 deacetylase (SIRT1)
ID STARVATION INDUCED APOPTOSIS; BONE LOSS; HYDROGEN PEROXIDE;
   PHENOLIC ACIDS; OSTEOCLAST FORMATION; N ACETYLCYSTEINE; POLYPHENOLS;
   DIFFERENTIATION; ANTHOCYANINS; OSTEOPOROSIS
AB Diets rich in fruits and vegetables with many antioxidants can be very important in the prevention and treatment of osteoporosis. Studies show that oxidative stress, often due to lack of antioxidants, is involved in alteration of bone remodeling and reduction in bone density. This study demonstrates in human osteoblast like SaOS 2 cells that blueberry juice (BJ), containing 7.5 or 15 mu g center dot mL( 1) total soluble polyphenols (TSP), is able to prevent the inhibition of osteogenic differentiation and the mineralization process due to oxidative stress induced by glutathione depletion. This situation mimics a metabolic condition of oxidative stress that may occur during estrogen deficiency. The effect of BJ phytochemicals occurs through redox  and non redox regulated mechanisms. BJ protects from oxidative damage factors related to bone remodeling and bone formation, such as alkaline phosphatase and Runt related transcription factor 2. It upregulates these factors by activation of sirtuin type 1 deacetylase expression, a possible molecular target for anti osteoporotic drugs. Quantitative analysis of TSP in BJ shows high levels of anthocyanins with high antioxidant capacity and bioavailability. These novel data may be important to elucidate the molecular and cellular beneficial effects of blueberry polyphenols on bone regeneration, and they suggest their use as a dietary supplement for osteoporosis prevention and therapies.
C1 [Domazetovic, Vladana; Marcucci, Gemma; Falsetti, Irene; Vincenzini, Maria Teresa; Brandi, Maria Luisa; Iantomasi, Teresa] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Viale Morgagni 50, I 50134 Florence, Italy.
   [Bilia, Anna Rita] Ugo Schiff Univ Florence, Dept Chem, Via U Schiff,6, I 50019 Sesto Fiorentino, Italy.
C3 University of Florence
RP Domazetovic, V; Vincenzini, MT (通讯作者)，Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Viale Morgagni 50, I 50134 Florence, Italy.
EM vladana.domazetovic@unifi.it; gemma.marcucci@unifi.it;
   irene.falsetti@stud.unifi.it; annarita.bilia@unifi.it;
   vincenzini@unifi.it; marialuisa.brandi@unifi.it; tiantomasi@unifi.it
RI ; Bilia, Anna/AAL 2963 2020; Marcucci, Gemma/K 5205 2016
OI brandi, maria luisa/0000 0002 8741 0592; 
FU Fondazione Cassa di Risparmio di Pistoia e Pescia [IANTCRPP15];
   Ministero dell'Istruzione, dell'Universita e della Ricerca [RICATEN18]
FX This study was supported by grants from Fondazione Cassa di Risparmio di
   Pistoia e Pescia (IANTCRPP15) and Ministero dell'Istruzione,
   dell'Universita e della Ricerca (RICATEN18) to T.I. and M.L.B.
CR Almeida M, 2010, J BONE MINER RES, V25, P769, DOI 10.1359/jbmr.091017
   Ancillotti C, 2016, FOOD CHEM, V204, P176, DOI 10.1016/j.foodchem.2016.02.106
   Artsi H, 2014, ENDOCRINOLOGY, V155, P3508, DOI 10.1210/en.2014 1334
   Austermann K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040871
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Banfi G, 2008, CLIN CHEM LAB MED, V46, P1550, DOI 10.1515/CCLM.2008.302
   Boskey AL, 2008, CHEM REV, V108, P4716, DOI 10.1021/cr0782473
   Bu SY, 2009, J NUTR BIOCHEM, V20, P35, DOI 10.1016/j.jnutbio.2007.11.012
   Cao GH, 2001, AM J CLIN NUTR, V73, P920
   Chen JR, 2014, J BONE MINER RES, V29, P1043, DOI 10.1002/jbmr.2034
   Chen JR, 2010, J BONE MINER RES, V25, P2399, DOI 10.1002/jbmr.137
   Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065 6995(03)00018 0
   Cohen Kfir E, 2011, ENDOCRINOLOGY, V152, P4514, DOI 10.1210/en.2011 1128
   Devareddy L, 2008, J NUTR BIOCHEM, V19, P694, DOI 10.1016/j.jnutbio.2007.09.004
   Díaz García MC, 2013, FOOD CHEM, V138, P938, DOI 10.1016/j.foodchem.2012.11.061
   Domazetovic V, 2019, FEBS OPEN BIO, V9, P1082, DOI 10.1002/2211 5463.12634
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Domazetovic V, 2017, CHEM BIOL INTERACT, V275, P13, DOI 10.1016/j.cbi.2017.07.015
   Domazetovic V, 2017, FEBS OPEN BIO, V7, P705, DOI 10.1002/2211 5463.12216
   Doshi Sejal B, 2013, J Midlife Health, V4, P140, DOI 10.4103/0976 7800.118990
   Fontani F, 2015, CALCIFIED TISSUE INT, V96, P335, DOI 10.1007/s00223 015 9961 0
   Gilsanz V, 2007, PEDIATRICS, V119, pS145, DOI 10.1542/peds.2006 2023G
   GUNDLE R, 1995, CALCIFIED TISSUE INT, V56, pS8, DOI 10.1007/BF03354640
   Gurt I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134391
   Hausser HJ, 2005, BIOCHEM BIOPH RES CO, V333, P216, DOI 10.1016/j.bbrc.2005.05.097
   Higgs J, 2017, EFORT OPEN REV, V2, P300, DOI 10.1302/2058 5241.2.160079
   Hubert PA, 2014, ANTIOXIDANTS BASEL, V3, P144, DOI 10.3390/antiox3010144
   Islam MA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5137431
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kotobuki N, 2008, CELL TISSUE RES, V332, P279, DOI 10.1007/s00441 008 0580 1
   Kuntz S, 2015, BRIT J NUTR, V113, P1044, DOI 10.1017/S0007114515000161
   Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004 1021
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Li AN, 2014, NUTRIENTS, V6, P6020, DOI 10.3390/nu6126020
   Li T, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/s13018 014 0056 9
   Liu JP, 2016, MOL MED REP, V14, P1643, DOI 10.3892/mmr.2016.5417
   Lohachoompol V, 2004, J BIOMED BIOTECHNOL, P248
   Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002 021496
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Marcucci G, 2015, CLIN CASES MINER BON, V12, P151, DOI 10.11138/ccmbm/2015.12.2.151
   Matsumoto H, 2001, J AGR FOOD CHEM, V49, P1546, DOI 10.1021/jf001246q
   MCQUILLAN DJ, 1995, BONE, V16, P415
   Michalska A, 2015, INT J MOL SCI, V16, P18642, DOI 10.3390/ijms160818642
   Novotny R, 2004, PREV MED, V39, P355, DOI 10.1016/j.ypmed.2004.01.031
   Ohyama Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191192
   Oka Y, 2012, J PHARMACOL SCI, V118, P55, DOI 10.1254/jphs.11082FP
   Östman B, 2009, FREE RADICAL BIO MED, V47, P668, DOI 10.1016/j.freeradbiomed.2009.05.031
   Prencipe FP, 2014, J PHARMACEUT BIOMED, V89, P257, DOI 10.1016/j.jpba.2013.11.016
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ren TT, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/469059
   RODAN SB, 1987, CANCER RES, V47, P4961
   Romagnoli C, 2013, FEBS J, V280, P867, DOI 10.1111/febs.12075
   Sanders KM, 2007, TRANSL RES, V150, P215, DOI 10.1016/j.trsl.2007.03.012
   Sendur OF, 2009, JOINT BONE SPINE, V76, P514, DOI 10.1016/j.jbspin.2009.02.005
   Tarantino U, 2017, J ORTHOP TRAUMATOL, V18, pS3, DOI 10.1007/s10195 017 0474 7
   Tou JC, 2015, BBA MOL BASIS DIS, V1852, P1186, DOI 10.1016/j.bbadis.2014.10.003
   Tylavsky FA, 2004, AM J CLIN NUTR, V79, P311
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Weaver Connie M., 2012, Journal of Nutrition in Gerontology and Geriatrics, V31, P239, DOI 10.1080/21551197.2012.698220
   Yagi H, 2013, J CELL BIOCHEM, V114, P1163, DOI 10.1002/jcb.24459
   Zainabadi K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178520
   Zhang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070438
   Zhang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024486
   Zhong SQ, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201700405
   Zhou L, 2017, MOL MED REP, V16, P2969, DOI 10.3892/mmr.2017.6917
NR 65
TC 41
Z9 44
U1 0
U2 19
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2076 3921
J9 ANTIOXIDANTS BASEL
JI Antioxidants
PD FEB
PY 2020
VL 9
IS 2
AR 125
DI 10.3390/antiox9020125
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA KU7ET
UT WOS:000519877100029
PM 32024159
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, ZQ
   Zhu, ZZ
   Luo, C
   Zhu, CC
   Zhang, CL
   Guo, ZJ
   Wang, XY
AF Zhang, Zhenqin
   Zhu, Zhenzhu
   Luo, Cheng
   Zhu, Chengcheng
   Zhang, Changli
   Guo, Zijian
   Wang, Xiaoyong
TI A Potential Bone Targeting Hypotoxic Platinum(II) Complex with an
   Unusual Cytostatic Mechanism toward Osteosarcoma Cells
SO INORGANIC CHEMISTRY
LA English
DT Article
ID CONTAINING BISPHOSPHONATES; MOLECULAR MECHANISMS; MEVALONATE PATHWAY;
   ANTICANCER AGENTS; CANCER CELLS; IN VIVO; X RAY; INHIBITORS;
   BIOSYNTHESIS; DELIVERY
AB Osteosarcoma (OS) is the most common primary pediatric bone tumor lethal to children and adolescents. Chemotherapeutic agents such as cisplatin are not effective for OS because of their poor accessibility to this cancer and severe systemic toxicity. In this study, a lipophilic platinum(II) complex bearing a bisphosphonate bone targeting moiety, cis [PtL(NH3)(2)Cl]NO3 {BPP; L = tetraethyl [2 (pyridin 2 yl)ethane 1,1 diyl]bisphosphonatel, was prepared and characterized by NMR, electrospray ionization mass spectrometry, and single crystal X ray crystallography. The cytotoxicity of BPP toward OS cell lines U2OS and MG 63 was tested by 3 (4,S dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide (MTT) assay. BPP exhibits moderate inhibition against U2OS cells through a mechanism involving both DNA binding and a mevalonate pathway. The acute toxicity of BPP to mice is 7 fold lower than that of cisplatin. The relative low systemic toxicity may result from the steric hindrance of the ligand, which blocks BPP approaching the bases of DNA. The results suggest that incorporating bisphosphonates into a platinum complex not only enhances its bone targeting property but also minimizes its reactivity toward DNA and thereby lowers the systematic toxicity of the complex. The diminished cytotoxicity of BPP could be compensated for by increasing the therapeutic dose with marginal harm. This strategy provides a new possibility for overcoming the ineffectiveness and systemic toxicity of platinum drugs in the treatment of OS.
C1 [Zhang, Zhenqin; Luo, Cheng; Zhu, Chengcheng; Zhang, Changli; Guo, Zijian] Nanjing Univ, Sch Chem & Chem Engn, State Key Lab Coordinat Chem, Nanjing 210023, Peoples R China.
   [Zhu, Zhenzhu; Wang, Xiaoyong] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Jiangsu, Peoples R China.
   [Zhang, Zhenqin] Nanjing Med Univ, Sch Pharm, Nanjing 211166, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University; Nanjing Medical University
RP Guo, ZJ (通讯作者)，Nanjing Univ, Sch Chem & Chem Engn, State Key Lab Coordinat Chem, Nanjing 210023, Peoples R China.; Wang, XY (通讯作者)，Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Jiangsu, Peoples R China.
EM zguo@nju.edu.cn; boxwxy@nju.edu.cn
RI Zhu, Zhenzhu/T 1413 2019; Zhang, Changli/AFH 4995 2022; Zhang,
   Zhenqin/KYQ 5345 2024
OI Zhu, Zhenzhu/0000 0002 1329 2618; zhenqin, ZHANG/0000 0003 1796 2743
FU National Natural Science Foundation of China [31570809, 91213305,
   31700714]; National Basic Research Program of China [2015CB856300,
   2011CB935800]; Natural Science Foundation of Jiangsu Province
   [BK20150054]; Scientific Research Funds of Nanjing Medical University
   [KY109NJMUZD15024]
FX We thank the National Natural Science Foundation of China (Grants
   31570809, 91213305, and 31700714), National Basic Research Program of
   China (Grants 2015CB856300 and 2011CB935800), Natural Science Foundation
   of Jiangsu Province (Grant BK20150054), and Scientific Research Funds of
   Nanjing Medical University (Grant KY109NJMUZD15024).
CR ALLEY MC, 1988, CANCER RES, V48, P589
   [Anonymous], 2000, WLR
   [Anonymous], 2009, NRD
   [Anonymous], 2000, SHELXTL VERSION 6 10
   Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105
   BERNERSPRICE SJ, 1990, J INORG BIOCHEM, V38, P305, DOI 10.1016/0162 0134(90)80005 I
   Bose RN, 2008, P NATL ACAD SCI USA, V105, P18314, DOI 10.1073/pnas.0803094105
   Cheng LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025433
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   CRICK DC, 1995, BIOCHEM BIOPH RES CO, V211, P590, DOI 10.1006/bbrc.1995.1854
   Fournier PGJ, 2008, CANCER RES, V68, P8945, DOI 10.1158/0008 5472.CAN 08 2195
   Galanski M, 2003, J MED CHEM, V46, P4946, DOI 10.1021/jm0308040
   HORMI OEO, 1990, SYNTHETIC COMMUN, V20, P1865, DOI 10.1080/00397919008053112
   Journe F, 2008, BREAST CANCER RES TR, V107, P49, DOI 10.1007/s10549 007 9535 6
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Lin YS, 2012, J MED CHEM, V55, P3201, DOI 10.1021/jm201657x
   Lovejoy KS, 2008, P NATL ACAD SCI USA, V105, P8902, DOI 10.1073/pnas.0803441105
   Manallack DT, 2013, CHEM SOC REV, V42, P485, DOI 10.1039/c2cs35348b
   Margiotta N, 2011, J INORG BIOCHEM, V105, P548, DOI 10.1016/j.jinorgbio.2010.12.011
   Margiotta N, 2009, DALTON T, P10904, DOI 10.1039/b919721d
   Margiotta N, 2008, J INORG BIOCHEM, V102, P2078, DOI 10.1016/j.jinorgbio.2008.07.008
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Oldfield SP, 2007, J MED CHEM, V50, P5227, DOI 10.1021/jm0708275
   Poynton FE, 2017, CHEM SOC REV, V46, P7706, DOI 10.1039/c7cs00680b
   Puckett CA, 2010, DALTON T, V39, P1159, DOI 10.1039/b922209j
   Qiu L, 2017, EUR J PHARMACOL, V810, P120, DOI 10.1016/j.ejphar.2017.06.035
   Qiu L, 2015, J BIOL INORG CHEM, V20, P1263, DOI 10.1007/s00775 015 1305 z
   Raveendran R, 2016, CHEM SCI, V7, P2381, DOI 10.1039/c5sc04205d
   Reed DE, 2014, P NATL ACAD SCI USA, V111, P18100, DOI 10.1073/pnas.1420596111
   Reithofer MR, 2011, J INORG BIOCHEM, V105, P46, DOI 10.1016/j.jinorgbio.2010.09.006
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Siegel R, 2013, CA CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Stiller CA, 2013, EUR J CANCER, V49, P684, DOI 10.1016/j.ejca.2012.09.011
   Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078 0432.CCR 12 0489
   Tusek Bozic L, 2010, POLYHEDRON, V29, P2527, DOI 10.1016/j.poly.2010.05.022
   Wang C, 2011, PROCESS BIOCHEM, V46, P1221, DOI 10.1016/j.procbio.2011.02.020
   Wang D, 2010, P NATL ACAD SCI USA, V107, P9584, DOI 10.1073/pnas.1002565107
   Wang X. Y, 2015, ACCOUNTS CHEM RES, V48, P2622
   Wang XY, 2013, CHEM SOC REV, V42, P202, DOI 10.1039/c2cs35259a
   Xue ZQ, 2010, CHEM COMMUN, V46, P1212, DOI 10.1039/b922222g
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
   Zhang ZQ, 2017, CHEM ASIAN J, V12, P1659, DOI 10.1002/asia.201700577
NR 45
TC 16
Z9 17
U1 1
U2 77
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0020 1669
EI 1520 510X
J9 INORG CHEM
JI Inorg. Chem.
PD MAR 19
PY 2018
VL 57
IS 6
BP 3315
EP 3322
DI 10.1021/acs.inorgchem.7b03261
PG 8
WC Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA GA3HQ
UT WOS:000428219500043
PM 29513007
DA 2025 08 17
ER

PT J
AU Tan, YH
   Deng, WD
   Zhang, YY
   Ke, MH
   Zou, BH
   Luo, XW
   Su, JB
   Wang, YY
   Xu, JL
   Nandakumar, KS
   Liu, YH
   Zhou, XF
   Li, XJ
AF Tan, Yanhui
   Deng, Wende
   Zhang, Yueyang
   Ke, Minhong
   Zou, Binhua
   Luo, Xiaowei
   Su, Jianbin
   Wang, Yiyuan
   Xu, Jialan
   Nandakumar, Kutty Selva
   Liu, Yonghong
   Zhou, Xuefeng
   Li, Xiaojuan
TI A marine fungus derived nitrobenzoyl sesquiterpenoid suppresses receptor
   activator of NF κB ligand induced osteoclastogenesis and inflammatory
   bone destruction
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE DC STAMP; NF kappa B; NFATc1; nitrobenzoyl sesquiterpenoids; osteoclast;
   osteolysis
ID RANKL INDUCED OSTEOCLASTOGENESIS; NUCLEAR FACTOR; TRANSCRIPTIONAL
   ACTIVITY; DC STAMP; C FOS; DIFFERENTIATION; DRUG; OSTEOPOROSIS;
   PATHOGENESIS; INHIBITORS
AB Background and Purpose: Osteoclasts are unique cells to absorb bone. Targeting osteoclast differentiation is a therapeutic strategy for osteolytic diseases. Natural marine products have already become important sources of new drugs. The naturally occurring nitrobenzoyl sesquiterpenoids first identified from marine fungi in 1998 are bioactive compounds with a special structure, but their pharmacological functions are largely unknown. Here, we investigated six marine fungus derived nitrobenzoyl sesquiterpenoids on osteoclastogenesis and elucidated the mechanisms.
   Experimental Approach: Compounds were first tested by RANKL induced NF kappa B luciferase activity and osteoclastic TRAP assay, followed by molecular docking to characterize the structure activity relationship. The effects and mechanisms of the most potent nitrobenzoyl sesquiterpenoid on RANKL induced osteoclastogenesis and bone resorption were further evaluated in vitro. Micro CT and histology analysis were used to assess the prevention of bone destruction by nitrobenzoyl sesquiterpenoids in vivo.
   Key Results: Nitrobenzoyl sesquiterpenoid 4, with a nitrobenzoyl moiety at C 14 and a hydroxyl group at C 9, was the most active compound on NF kappa B activity and osteoclastogenesis. Consequently, nitrobenzoyl sesquiterpenoid 4 exhibited suppression of RANKL induced osteoclastogenesis and bone resorption from 0.5 mu M. It blocked RANKL induced I kappa Ba phosphorylation, NF kappa B p65 and RelB nuclear translocation, NFATc1 activation, reduced DC STAMP but not c Fos expression during osteoclastogenesis in vitro. Nitrobenzoyl sesquiterpenoid 4 also ameliorated LPS induced osteolysis in vivo.
   Conclusion and Implications: These results highlighted nitrobenzoyl sesquiterpenoid 4 as a novel inhibitor of osteoclast differentiation. This marine derived sesquiterpenoid is a promising lead compound for the treatment of osteolytic diseases.
C1 [Tan, Yanhui; Deng, Wende; Zhang, Yueyang; Ke, Minhong; Zou, Binhua; Su, Jianbin; Wang, Yiyuan; Xu, Jialan; Li, Xiaojuan] Southern Med Univ, Sch Pharmaceut Sci, Lab Antiinflammatory & Immunomodulatory Pharmacol, Guangzhou, Peoples R China.
   [Tan, Yanhui; Deng, Wende; Zhang, Yueyang; Ke, Minhong; Zou, Binhua; Su, Jianbin; Wang, Yiyuan; Xu, Jialan; Nandakumar, Kutty Selva; Li, Xiaojuan] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China.
   [Luo, Xiaowei; Liu, Yonghong; Zhou, Xuefeng] Chinese Acad Sci, Guangdong Key Lab Marine Mat Med, CAS Key Lab Trop Marine Bioresources & Ecol, South China Sea Inst Oceanol, Guangzhou 510301, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Chinese Academy of Sciences; South China Sea Institute of
   Oceanology, CAS
RP Zhou, XF (通讯作者)，Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China.; Li, XJ (通讯作者)，Chinese Acad Sci, Guangdong Key Lab Marine Mat Med, CAS Key Lab Trop Marine Bioresources & Ecol, South China Sea Inst Oceanol, Guangzhou 510301, Peoples R China.
EM xfzhou@scsio.ac.cn; lixiaoj@smu.edu.cn
RI Nandakumar, Kutty Selva/D 5438 2011; 邹, 斌华/CAG 5540 2022; Liu,
   Yonghong/E 3118 2014; Su, Jianbin/L 6647 2019
OI Nandakumar, Kutty Selva/0000 0001 7790 8197; Li,
   Xiaojuan/0000 0002 2668 3044; Zou, Binhua/0000 0003 0731 1525
FU National Natural Science Foundation of China [81773740, 81741154,
   81073119]; Guangzhou Science and Technology Plan Project [201804010027];
   Pearl River S&T Nova Program of Guangzhou Scientific Research Project
   [201610010017]
FX We are grateful to Dr. Dong Jie, Xiangya School of Pharmaceutical
   Sciences, Central South University, for his efforts on molecular docking
   analysis. This work was supported by grants from the National Natural
   Science Foundation of China (81773740, 81741154, and 81073119),
   Guangzhou Science and Technology Plan Project (201804010027), and Pearl
   River S&T Nova Program of Guangzhou Scientific Research Project
   (201610010017).
CR Abou El Kassem LT, 2018, Z NATURFORSCH C, V73, P9, DOI 10.1515/znc 2017 0037
   Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Abu Amer Y, 2008, AUTOIMMUNITY, V41, P204, DOI 10.1080/08916930701694543
   Alexander SPH, 2018, BRIT J PHARMACOL, V175, P407, DOI 10.1111/bph.14112
   Belofsky GN, 1998, TETRAHEDRON, V54, P1715, DOI 10.1016/S0040 4020(97)10396 9
   BISKOBING DM, 1995, J BONE MINER RES, V10, P1025
   Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756 3282(99)00105 2
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Broadhead ML, 2011, EXPERT OPIN THER TAR, V15, P169, DOI 10.1517/14728222.2011.546351
   Cheung RCF, 2016, APPL MICROBIOL BIOT, V100, P1645, DOI 10.1007/s00253 015 7244 3
   Chiu YH, 2016, J CELL PHYSIOL, V231, P2402, DOI 10.1002/jcp.25389
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   De Vlam K, 2014, ACTA DERM VENEREOL, V94, P627, DOI 10.2340/00015555 1833
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Fang W, 2014, MEDCHEMCOMM, V5, P701, DOI 10.1039/c3md00371j
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982
   Grabowski P, 2009, ENDOCR DEV, V16, P32, DOI 10.1159/000223687
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092 8674(00)81698 0
   Jakob F, 2015, UNFALLCHIRURG, V118, P925, DOI 10.1007/s00113 015 0085 9
   Durán Peña MJ, 2015, NAT PROD REP, V32, P1236, DOI 10.1039/c5np00024f
   Jimi E, 2005, IMMUNOL REV, V208, P80, DOI 10.1111/j.0105 2896.2005.00329.x
   Kang HK, 2015, INT J MOL SCI, V16, P6018, DOI 10.3390/ijms16036018
   Kilkenny C, 2010, J GENE MED, V12, P561, DOI [10.1002/jgm.1473, 10.1113/jphysiol.2010.192278, 10.1111/j.1476 5381.2010.00872.x]
   Lai Y, 2018, ORG LETT, V20, P4298, DOI 10.1021/acs.orglett.8b01733
   Li N, 2018, EUR J MED CHEM, V155, P531, DOI 10.1016/j.ejmech.2018.06.027
   Malve H, 2016, J PHARM BIOALLIED SC, V8, P83, DOI 10.4103/0975 7406.171700
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Menshawy A, 2018, SUPPORT CARE CANCER, V26, P1029, DOI 10.1007/s00520 018 4060 1
   Conesa Buendía FM, 2019, J BONE MINER RES, V34, P923, DOI 10.1002/jbmr.3665
   Napetschnig J, 2013, ANNU REV BIOPHYS, V42, P443, DOI 10.1146/annurev biophys 083012 130338
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Panagopoulos PK, 2018, J MUSCULOSKEL NEURON, V18, P304
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Qin JJ, 2017, CHIN J NAT MEDICINES, V15, P401, DOI 10.1016/S1875 5364(17)30062 6
   Rahbaek L, 1997, J NAT PROD, V60, P811, DOI 10.1021/np970142f
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tan YH, 2018, J NAT PROD, V81, P92, DOI 10.1021/acs.jnatprod.7b00698
   Tateiwa D, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080818
   Vitaku E., 2013, TOP 2000 PHARM PRODU
   Wang XY, 2020, FITOTERAPIA, V142, DOI 10.1016/j.fitote.2020.104482
   Wu QX, 2012, PHYTOCHEM LETT, V5, P114, DOI 10.1016/j.phytol.2011.11.005
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Yagi M, 2006, J BONE MINER METAB, V24, P355, DOI 10.1007/s00774 006 0697 9
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhao HY, 2016, CURR PHARM BIOTECHNO, V17, P271, DOI 10.2174/1389201017666151223123424
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092 8674(00)80222 6
   Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097 2765(00)80066 0
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 61
TC 31
Z9 33
U1 2
U2 50
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD SEP
PY 2020
VL 177
IS 18
BP 4242
EP 4260
DI 10.1111/bph.15179
EA AUG 2020
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ND7VF
UT WOS:000557909400001
PM 32608081
OA Green Published, Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Midha, S
   Chawla, S
   Chakraborty, J
   Chameettachal, S
   Ghosh, S
AF Midha, Swati
   Chawla, Shikha
   Chakraborty, Juhi
   Chameettachal, Shibu
   Ghosh, Sourabh
TI Differential Regulation of Hedgehog and Parathyroid Signaling in
   Mulberry and Nonmulberry Silk Fibroin Textile Braids
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE mulberry and nonmulberry silk; hedgehog/parathyroid signaling;
   osteogenesis; in vitro model
ID MESENCHYMAL STEM CELLS; HORMONE RELATED PEPTIDE; BONE MARROW CELLS;
   OSTEOBLAST DIFFERENTIATION; GENE EXPRESSION; IN VITRO; OSTEOGENIC
   DIFFERENTIATION; MECHANICAL PROPERTIES; SKELETAL DEVELOPMENT; MATRIX
   STIFFNESS
AB Even after several decades of research, the most optimal source of silk for promoting osteogenesis in situ is still a subject of debate. A major gap in existing knowledge is role of underlying signaling mechanisms in both the mulberry and nonmulberry silk species that leads to the development of differential levels of osteogenesis. In our previous study, we elucidated the role of Wnt/beta catenin signaling for promoting superior osteogenic differentiation in nonmulberry silk braids in the presence of TGF beta and pro osteogenic supplements. Here, we provide a comparative osteogenic analysis of the two most popular silk species (mulberry and nonmulberry silk), in the form of silk braids prepared from natively spun fibers, by conducting detailed gene expression profiling using 25 different osteogenic markers, followed by further validation by immunohistochemistry. Our study provides novel insights into the direct regulatory role of nonmulberry silk fibroin braids on hedgehog and parathyroid signaling pathways in controlling osteogenic differentiation of cultured human fetal osteoblasts (hFOBs), a phenomenon not very evident in the mulberry silk textile braids. Although both silk braids enabled adequate cellular attachment, proliferation, and extracellular collagen matrix formation, superior expression of osteogenic markers (ALP, VDR, Runx2), matrix proteins (Co11A2, OPN), and signaling molecules (GLI1, GLI2, Shh) with characteristic terminal osteocytic phenotype could only be observed in nonmulberry silk. Therefore, our study provided detailed insights into the development of engineered bone to be a prospective tissue equivalent with potential to provide the essential instructive elements for activating physiological pathways of bone differentiation. Such engineered constructs have potential for use as an in vitro model for drug testing and as scaffolds for bone regeneration strategies.
C1 [Midha, Swati; Chawla, Shikha; Chakraborty, Juhi; Chameettachal, Shibu; Ghosh, Sourabh] Indian Inst Technol Delhi, Dept Text Technol, Regenerat Engn Lab, New Delhi 110016, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Delhi
RP Ghosh, S (通讯作者)，Indian Inst Technol Delhi, Dept Text Technol, Regenerat Engn Lab, New Delhi 110016, India.
EM sghosh08@textile.iitd.ac.in
RI Shikha, Chawla/AAX 3684 2021; Midha, Swati/S 6796 2019
OI /0000 0003 0295 5356; Chawla, Shikha/0000 0001 6088 4985; CHAKRABORTY,
   JUHI/0000 0002 1567 2147; Chameettachal, Dr Shibu/0000 0003 3862 7282
FU Department of Biotechnology, India [BT/PR8038/MED/32/303/2013,
   BT/PR15451/MED/32/539/2016]
FX We are thankful to Department of Biotechnology, India
   (BT/PR8038/MED/32/303/2013 and BT/PR15451/MED/32/539/2016).
CR Abdallah BM, 2006, BONE, V39, P181, DOI 10.1016/j.bone.2005.12.082
   Altman GH, 2003, BIOMATERIALS, V24, P401, DOI 10.1016/S0142 9612(02)00353 8
   Andiappan M, 2016, PROG BIOMATER, V5, P81, DOI 10.1007/s40204 016 0047 5
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Bellis SL, 2011, BIOMATERIALS, V32, P4205, DOI 10.1016/j.biomaterials.2011.02.029
   Bhattacharjee M, 2013, BIOMATERIALS, V34, P8161, DOI 10.1016/j.biomaterials.2013.07.018
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Cai HC, 2016, P NATL ACAD SCI USA, V113, P14751, DOI 10.1073/pnas.1612520114
   Chameettachal S, 2016, ACS BIOMATER SCI ENG, V2, P1450, DOI 10.1021/acsbiomaterials.6b00152
   Chawla S, 2018, J CELL PHYSIOL, V233, P3817, DOI 10.1002/jcp.26071
   Chawla Shikha, 2017, Bioprinting, V7, P1, DOI 10.1016/j.bprint.2017.05.001
   Chen HL, 2002, J BIOL CHEM, V277, P19374, DOI 10.1074/jbc.M108913200
   Cheung HY, 2009, J COMPOS MATER, V43, P2521, DOI 10.1177/0021998309345347
   Choi MH, 2011, J PERIODONTAL IMPLAN, V41, P167, DOI 10.5051/jpis.2011.41.4.167
   Dalcq J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050140
   Damoulis PD, 2007, ANN NY ACAD SCI, V1117, P367, DOI 10.1196/annals.1402.038
   Das RK, 2014, BIOMATERIALS, V35, P5278, DOI 10.1016/j.biomaterials.2014.03.044
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   Datta NS, 2005, J BONE MINER RES, V20, P1051, DOI 10.1359/JBMR.050106
   Davies JA, 2016, BIOCHEM SOC T, V44, P696, DOI 10.1042/BST20150289
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   FERMOR B, 1995, J BONE MINER RES, V10, P1935
   Gao GF, 2015, BIOTECHNOL LETT, V37, P2349, DOI 10.1007/s10529 015 1921 2
   HOLMES RE, 1979, PLAST RECONSTR SURG, V63, P626, DOI 10.1097/00006534 197905000 00004
   Hon MP, 2012, COMPOS PART B ENG, V43, P2801, DOI 10.1016/j.compositesb.2012.04.042
   Hulsart Billstrom G, 2016, EUR CELLS MATER, V31, P312, DOI 10.22203/eCM.v031a20
   Jiang P, 2006, MATER LETT, V60, P919, DOI 10.1016/j.matlet.2005.10.056
   Khatiwala CB, 2006, AM J PHYSIOL CELL PH, V290, pC1640, DOI 10.1152/ajpcell.00455.2005
   Ko E, 2018, ACS APPL MATER INTER, V10, P7614, DOI 10.1021/acsami.7b03328
   Lim JY, 2005, TISSUE ENG, V11, P19, DOI 10.1089/ten.2005.11.19
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Liu XM, 2007, BIOMATERIALS, V28, P4535, DOI 10.1016/j.biomaterials.2007.06.016
   Lv HW, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0083 4
   Mandal BB, 2009, BIOMATERIALS, V30, P5019, DOI 10.1016/j.biomaterials.2009.05.064
   Martin TJ, 2005, J CLIN INVEST, V115, P2322, DOI 10.1172/JCI26239
   Melke J, 2016, ACTA BIOMATER, V31, P1, DOI 10.1016/j.actbio.2015.09.005
   Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200
   Midha S, 2017, ACS BIOMATER SCI ENG, V3, P1062, DOI 10.1021/acsbiomaterials.7b00006
   Midha S, 2016, MAT SCI ENG C MATER, V68, P663, DOI 10.1016/j.msec.2016.06.041
   Midha S, 2016, BIOMATERIALS, V97, P133, DOI 10.1016/j.biomaterials.2016.04.020
   Mitic Z, 2017, MAT SCI ENG C MATER, V79, P930, DOI 10.1016/j.msec.2017.05.127
   Morgan AW, 2008, BIOMATERIALS, V29, P2556, DOI 10.1016/j.biomaterials.2008.02.007
   Mullen CA, 2013, J MECH BEHAV BIOMED, V28, P183, DOI 10.1016/j.jmbbm.2013.06.013
   Murab S, 2016, LAB INVEST, V96, P1311, DOI 10.1038/labinvest.2016.102
   Naskar D, 2014, SCI REP UK, V4, DOI 10.1038/srep04745
   Okazaki K, 2003, J ORTHOPAED RES, V21, P511, DOI 10.1016/S0736 0266(02)00161 4
   Park KW, 2009, MOL CELL BIOL, V29, P3905, DOI 10.1128/MCB.00002 09
   Rauh J, 2015, TISSUE ENG PART C ME, V21, P192, DOI [10.1089/ten.tec.2014.0230, 10.1089/ten.TEC.2014.0230]
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Sahu N, 2015, ADV HEALTHC MATER, V4, P1709, DOI 10.1002/adhm.201500283
   Setzer B, 2009, BIOMATERIALS, V30, P979, DOI 10.1016/j.biomaterials.2008.10.054
   Shimoyama A, 2007, MOL BIOL CELL, V18, P2411, DOI 10.1091/mbc.E06 08 0743
   Silva SS, 2013, ACTA BIOMATER, V9, P8972, DOI 10.1016/j.actbio.2013.06.044
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Sun JW, 2015, MOL MED REP, V12, P5211, DOI 10.3892/mmr.2015.4048
   Theodoris CV, 2015, CELL, V160, P1072, DOI 10.1016/j.cell.2015.02.035
   Tigli RS, 2009, J TISSUE ENG REGEN M, V3, P348, DOI 10.1002/term.169
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xu JH, 2015, AM J TRANSL RES, V7, P2527
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yang J, 2015, INT J ORAL SCI, V7, P73, DOI 10.1038/ijos.2015.14
   Yang RJ, 1996, J BIOL CHEM, V271, P29839, DOI 10.1074/jbc.271.47.29839
   Yen ML, 2007, STEM CELLS, V25, P125, DOI 10.1634/stemcells.2006 0295
   Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200
   Zhang C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026504
   Zhang M, 2014, MOL ENDOCRINOL, V28, P295, DOI 10.1210/me.2013 1152
   Zhang S, 2012, HORM METAB RES, V44, P724, DOI 10.1055/s 0032 1321845
NR 67
TC 17
Z9 19
U1 1
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD FEB
PY 2018
VL 4
IS 2
SI SI
BP 595
EP 607
DI 10.1021/acsbiomaterials.7b00874
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA FW3GJ
UT WOS:000425194500032
PM 33418748
DA 2025 08 17
ER

PT J
AU Saito, MT
   Mofatto, LS
   Albiero, ML
   Casati, MZ
   Sallum, EA
   Nociti, FH
   Silvério, KG
AF Saito, Miki Taketomi
   Mofatto, Luciana Souto
   Albiero, Mayra Laino
   Casati, Marcio Zafallon
   Sallum, Enilson Antonio
   Nociti Junior, Francisco Humberto, Jr.
   Silverio, Karina Gonzales
TI Transcriptome profile of highly osteoblastic/cementoblastic periodontal
   ligament cell clones
SO JOURNAL OF APPLIED ORAL SCIENCE
LA English
DT Article
DE Cell differentiation; Clone cells; Sequence Analysis, RNA; Periodontal
   ligament; Osteoblasts
ID DIFFERENTIAL EXPRESSION ANALYSIS; OSTEOBLAST DIFFERENTIATION; GENE;
   ACTIVATION; BMP
AB Heterogeneous cell populations of osteo/cementoblastic (O/C) or fibroblastic phenotypes constitute the periodontal dental ligament (PDL). A better understanding of these PDL cell subpopulations is essential to propose regenerative approaches based on a sound biological rationale. Objective: Our study aimed to clarify the differential transcriptome profile of PDL cells poised to differentiate into the O/C cell lineage. Methodology: To characterize periodontal derived cells with distinct differentiation capacities, single cellderived clones were isolated from adult human PDL progenitor cells and their potential to differentiate into osteo/cementoblastic (O/C) phenotype (C O clones) or fibroblastic phenotype (C F clones) was assessed in vitro. The transcriptome profile of the clonal cell lines in standard medium cultivation was evaluated using next generation sequencing technology (RNA seq). Over 230 differentially expressed genes (DEG) were identified, in which C O clones showed a higher number of upregulated genes (193) and 42 downregulated genes. Results: The upregulated genes were associated with the Cadherin and Wnt signaling pathways as well as annotated biological processes, including "anatomical structure development" and "cell adhesion." Both transcriptome and RT qPCR showed up regulation of WNT2, WNT16, and WIF1 in C O clones. Conclusions: This comprehensive transcriptomic assessment of human PDL progenitor cells revealed that expression of transcripts related to the biological process "anatomical structure development," Cadherin signaling, and Wnt signaling can identify PDL cells with a higher potential to commit to the O/C phenotype. A better understanding of these pathways and their function in O/C differentiation will help to improve protocols for periodontal regenerative therapies.
C1 [Saito, Miki Taketomi] Univ Fed Para, Inst Ciencias Saude, Dept Saude Publ, Belem, Para, Brazil.
   [Mofatto, Luciana Souto] Univ Estadual Campinas, Inst Biol UNICAMP, Dept Genet & Evolucao Microbiol & Imunol, Lab Genon & Expressao, Campinas, SP, Brazil.
   [Albiero, Mayra Laino] Univ Sorocaba, Dept Periodontia, UNISO, Sorocaba, SP, Brazil.
   [Casati, Marcio Zafallon; Sallum, Enilson Antonio; Nociti Junior, Francisco Humberto, Jr.; Silverio, Karina Gonzales] Univ Estadual Campinas UNICAMP, Fac Odontol Piracicaba, Dept Protese & Periodontia, Div Periodontia, Piracicaba, SP, Brazil.
C3 Universidade Federal do Para; Universidade Estadual de Campinas;
   Universidade de Sorocaba; Universidade Estadual de Campinas
RP Silvério, KG (通讯作者)，Univ Estadual Campinas, Dept Protese & Periodontia, Div Periodontia, Av Limeira 901, BR 13401903 Piracicaba, SP, Brazil.
EM kgsilverio@fop.unicamp.br
RI Saito, Miki/D 7178 2011; Silvério, Karina/JXL 9271 2024; casati,
   marcio/G 7475 2012; SALLUM, ENILSON/B 8103 2012; Mofatto,
   Luciana/A 8914 2011; Nociti, Francisco/G 4907 2015
OI Mofatto, Luciana/0000 0002 2087 7251; 
FU Sao Paulo Research Foundation   FAPESP [2013/08919 3]; Coordination for
   the Improvement of Higher Education Personnel (CAPES) [001]
FX This study was financed by Sao Paulo Research Foundation   FAPESP (grant
   #2013/08919 3) and Coordination for the Improvement of Higher Education
   Personnel (CAPES)   finance code 001. We also thank the Department of
   Pathology, Piracicaba Dental School, University of Campinas, for
   providing their flow cytometer and for the assistance of Dr. Fabio Haach
   Theo.
CR Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099
   Ayturk UM, 2013, J BONE MINER RES, V28, P2081, DOI 10.1002/jbmr.1946
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Fujii S, 2008, J CELL PHYSIOL, V215, P743, DOI 10.1002/jcp.21359
   Gori F, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.36
   Han PP, 2015, J BONE MINER RES, V30, P1160, DOI 10.1002/jbmr.2445
   Haÿ E, 2014, J CELL PHYSIOL, V229, P1765, DOI 10.1002/jcp.24629
   Jacobsen CM, 2014, J BONE MINER RES, V29, P2297, DOI 10.1002/jbmr.2198
   Jääger K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038833
   Jia SH, 2016, DEV BIOL, V420, P110, DOI 10.1016/j.ydbio.2016.10.001
   Jia SH, 2013, DEVELOPMENT, V140, P423, DOI 10.1242/dev.081927
   Kebschull M, 2017, METHODS MOL BIOL, V1537, P327, DOI 10.1007/978 1 4939 6685 1_19
   Kobayashi Y, 2016, J BIOCHEM, V159, P387, DOI 10.1093/jb/mvv124
   Kook SH, 2016, MOL CELL BIOCHEM, V411, P83, DOI 10.1007/s11010 015 2570 4
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 323
   Lim WH, 2015, J PERIODONTOL, V86, P319, DOI 10.1902/jop.2014.140286
   Lin Z, 2015, J PERIODONTOL, V86, pS134, DOI 10.1902/jop.2015.130689
   Marie PJ, 2014, TRENDS ENDOCRIN MET, V25, P567, DOI 10.1016/j.tem.2014.06.009
   Martin M., 2011, EMBNET J, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   Matthews BG, 2016, J PERIODONTAL RES, V51, P304, DOI 10.1111/jre.12309
   Mourao Leila Cristina, 2015, J Indian Soc Periodontol, V19, P155, DOI 10.4103/0972 124X.149935
   Nuñez J, 2019, PERIODONTOL 2000, V79, P107, DOI 10.1111/prd.12250
   Park SJ, 2015, J MOL HISTOL, V46, P93, DOI 10.1007/s10735 014 9604 1
   Regard JB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007997
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Romanos GE, 2016, INT J ORAL MAX IMPL, V31, P939, DOI 10.11607/jomi.4384
   Saito MT, 2014, J PERIODONTOL, V85, pE205, DOI 10.1902/jop.2014.130461
   Sharan R, 2003, BIOINFORMATICS, V19, P1787, DOI 10.1093/bioinformatics/btg232
   Silvério KG, 2012, J PERIODONTAL RES, V47, P309, DOI 10.1111/j.1600 0765.2011.01433.x
   Silvério KG, 2010, J PERIODONTOL, V81, P1207, DOI 10.1902/jop.2010.090729
   Tomokiyo A, 2008, DIFFERENTIATION, V76, P337, DOI 10.1111/j.1432 0436.2007.00233.x
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Trubiani O, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20204987
   Trubiani O, 2019, STEM CELLS DEV, V28, P995, DOI 10.1089/scd.2019.0025
   Twine NA, 2014, BONE, V67, P23, DOI 10.1016/j.bone.2014.06.027
   Marques IDV, 2016, BIOINTERPHASES, V11, DOI 10.1116/1.4960654
   Yamada S, 2016, J DENT RES, V95, P1026, DOI 10.1177/0022034516645796
   Yamaguchi A, 2008, JPN DENT SCI REV, V44, P48, DOI 10.1016/j.jdsr.2007.11.003
   Zhao N, 2016, J BONE MINER RES, V31, P430, DOI 10.1002/jbmr.2690
NR 39
TC 4
Z9 5
U1 0
U2 8
PU UNIV SAO PAULO FAC ODONTOLOGIA BAURU
PI BAURU SP
PA AL DR OCTAVIO PINHEIRO BRISOLLA, 9 75, BAURU SP, 17012 901, BRAZIL
SN 1678 7757
EI 1678 7765
J9 J APPL ORAL SCI
JI J. Appl. Oral Sci.
PY 2020
VL 28
AR e20200242
DI 10.1590/1678 7757 2020 0242
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA ON5SK
UT WOS:000586760300001
PM 33111882
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hu, Y
   Li, XQ
   Zhang, Q
   Gu, ZR
   Luo, Y
   Guo, JW
   Wang, XH
   Jing, YY
   Chen, X
   Su, JC
AF Hu, Yan
   Li, Xiaoqun
   Zhang, Qin
   Gu, Zhengrong
   Luo, Ying
   Guo, Jiawei
   Wang, Xiuhui
   Jing, Yingying
   Chen, Xiao
   Su, Jiacan
TI Exosome guided bone targeted delivery of Antagomir 188 as an anabolic
   therapy for bone loss
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Exosomes; Bone targeting; miR 188; CXCR4; Osteoporosis
ID CORTICAL BONE; IN VITRO; CELL; MARROW; KRAS; MICROARCHITECTURE;
   OSTEOGENESIS; TERIPARATIDE; OSTEOBLAST; DENOSUMAB
AB The differentiation shift from osteogenesis to adipogenesis of bone marrow mesenchymal stem cells (BMSCs) characterizes many pathological bone loss conditions. Stromal cell derived factor 1 (SDF1) is highly enriched in the bone marrow for C X C motif chemokine receptor 4 (CXCR4) positive hematopoietic stem cell (HSC) homing and tumor bone metastasis. In this study, we displayed CXCR4 on the surface of exosomes derived from genetically engineered NIH 3T3 cells. CXCR4(+) exosomes selectively accumulated in the bone marrow. Then, we fused CXCR4(+) exosomes with liposomes carrying antagomir 188 to produce hybrid nanoparticles (NPs). The hybrid NPs specifically gathered in the bone marrow and released antagomir 188, which promoted osteogenesis and inhibited adipogenesis of BMSCs and thereby reversed age related trabecular bone loss and decreased cortical bone porosity in mice. Taken together, this study presents a novel way to obtain bone targeted exosomes via surface display of CXCR4 and a promising anabolic therapeutic approach for age related bone loss.
C1 [Hu, Yan; Li, Xiaoqun; Guo, Jiawei; Chen, Xiao; Su, Jiacan] Naval Med Univ, Changhai Hosp, Dept Trauma Orthoped, Shanghai 200433, Peoples R China.
   [Zhang, Qin; Wang, Xiuhui; Jing, Yingying] Shanghai Univ, Inst Translat Med, Shanghai 200444, Peoples R China.
   [Gu, Zhengrong] Shanghai Baoshan Luodian Hosp, Dept Orthoped, Shanghai 201908, Peoples R China.
   [Luo, Ying] Naval Med Univ, Changhai Hosp, Ctr Lab, Shanghai 200433, Peoples R China.
   [Chen, Xiao] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
C3 Naval Medical University; Shanghai University; Naval Medical University;
   Fudan University
RP Chen, X; Su, JC (通讯作者)，Naval Med Univ, Changhai Hosp, Dept Trauma Orthoped, Shanghai 200433, Peoples R China.; Jing, YY (通讯作者)，Shanghai Univ, Inst Translat Med, Shanghai 200444, Peoples R China.; Chen, X (通讯作者)，Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
EM jingy4172@shu.edu.cn; sirchenxiao@126.com; drsujiacan@163.com
RI ; Chen, Xiao/G 2310 2018; luo, ying/HJP 8548 2023; Hu,
   Yan/AFZ 8800 2022; Wang, Xiuhui/O 5616 2019; Su, Jiacan/N 7068 2019; Gu,
   Jimmy/N 4439 2019; Guo, Jiawei/JMH 1084 2023
OI Guo, Jiawei/0000 0002 7613 932X; Hu, Yan/0000 0002 9484 6546; Su,
   Jiacan/0000 0001 7080 263X
FU National Key R&D Program of China [2018YFC2001500]; National Natural
   Science Foundation of China [91749204, 81771491, 81871099]
FX This work was supported by grants from National Key R&D Program of China
   (No.2018YFC2001500) and National Natural Science Foundation of China
   (No.91749204, 81771491 to J. Su, and 81871099 to X. Chen).
CR Ambrosi TH, 2017, CELL STEM CELL, V20, P771, DOI 10.1016/j.stem.2017.02.009
   Bala Y, 2015, CURR OPIN RHEUMATOL, V27, P406, DOI 10.1097/BOR.0000000000000183
   Chen X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0035 6
   Conley LaComb MK, 2016, MOL CANCER, V15, DOI 10.1186/s12943 016 0552 0
   Cooper DML, 2016, CURR OSTEOPOROS REP, V14, P187, DOI 10.1007/s11914 016 0319 y
   de Lima MCP, 2001, ADV DRUG DELIVER REV, V47, P277, DOI 10.1016/S0169 409X(01)00110 7
   El Andaloussi S, 2012, NAT PROTOC, V7, P2112, DOI 10.1038/nprot.2012.131
   Elsharkasy OM, 2020, ADV DRUG DELIVER REV, V159, P332, DOI 10.1016/j.addr.2020.04.004
   Frith JE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02486 0
   Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747
   Huang XX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05178 5
   Itaka K, 2007, MOL THER, V15, P1655, DOI 10.1038/sj.mt.6300218
   Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li H, 2015, CELL DEATH DIFFER, V22, P1935, DOI 10.1038/cdd.2015.99
   Li XQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb7135
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Lin Y, 2018, ADV SCI, V5, DOI 10.1002/advs.201700611
   Lv QJ, 2020, ADV SCI, V7, DOI 10.1002/advs.202000515
   Metavarayuth K, 2019, NANO LETT, V19, P8372, DOI 10.1021/acs.nanolett.9b02001
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Nie WD, 2020, ANGEW CHEM INT EDIT, V59, P2018, DOI 10.1002/anie.201912524
   Pecot CV, 2014, MOL CANCER THER, V13, P2876, DOI 10.1158/1535 7163.MCT 14 0074
   Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845
   Perets N, 2019, NANO LETT, V19, P3422, DOI 10.1021/acs.nanolett.8b04148
   Piffoux M, 2018, ACS NANO, V12, P6830, DOI 10.1021/acsnano.8b02053
   Quinn Z, 2021, BIOACT MATER, V6, P749, DOI 10.1016/j.bioactmat.2020.09.016
   Shang FQ, 2021, BIOACT MATER, V6, P666, DOI 10.1016/j.bioactmat.2020.08.014
   Smit M.J., 2020, ANNU REV PHARMACOL, V61, P541
   Song H, 2019, NANO LETT, V19, P3040, DOI 10.1021/acs.nanolett.9b00287
   Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874
   Stewart MP, 2016, NATURE, V538, P183, DOI 10.1038/nature19764
   Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078 0432.CCR 09 2329
   Tsai JN, 2016, J CLIN ENDOCR METAB, V101, P2023, DOI 10.1210/jc.2016 1160
   Tsai JN, 2017, J BONE MINER RES, V32, P2001, DOI 10.1002/jbmr.3198
   Wang L., 2020, DRUG DISCOV TODAY, V20, P30340
   Wang QF, 2016, MATER TODAY, V19, P451, DOI 10.1016/j.mattod.2015.12.003
   Wu T, 2020, BIOACT MATER, V5, P348, DOI 10.1016/j.bioactmat.2020.03.004
   Xue W, 2014, P NATL ACAD SCI USA, V111, pE3553, DOI 10.1073/pnas.1412686111
   Yang ZG, 2020, NAT BIOMED ENG, V4, P69, DOI 10.1038/s41551 019 0485 1
   Yuan TL, 2014, CANCER DISCOV, V4, P1182, DOI 10.1158/2159 8290.CD 13 0900
   Zehentmeier S, 2019, IMMUNOL REV, V289, P142, DOI 10.1111/imr.12749
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang LH, 2019, NANO LETT, V19, P4237, DOI 10.1021/acs.nanolett.9b00030
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zou W, 2020, CELL METAB, V32, P801, DOI 10.1016/j.cmet.2020.09.011
NR 49
TC 179
Z9 192
U1 6
U2 177
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING, DONGHENG DISTRICT 100717,
   PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD SEP
PY 2021
VL 6
IS 9
BP 2905
EP 2913
DI 10.1016/j.bioactmat.2021.02.014
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA ST1ZI
UT WOS:000662249100022
PM 33718671
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gallagher, JC
AF Gallagher, J. Christopher
TI Advances in osteoporosis from 1970 to 2018
SO MENOPAUSE THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article; Proceedings Paper
CT 29th Annual Meeting of the North American Menopause Society (NAMS)
CY OCT 03 06, 2018
CL San Diego, CA
SP N Amer Menopause Soc
DE Bone density; Bone remodeling; Clinical trials; Osteoporosis
ID BONE MINERAL DENSITY; PARATHYROID HORMONE FRAGMENT;
   DUAL PHOTON ABSORPTIOMETRY; VERTEBRAL FRACTURE RISK; POSTMENOPAUSAL
   WOMEN; OSTEOCLAST DIFFERENTIATION; SALMON CALCITONIN; RANDOMIZED TRIAL;
   TRABECULAR BONE; DOUBLE BLIND
AB In 1970, there were no drugs under study for osteoporosis. Estrogen was used, but little was known about the correct dose for preventing bone loss. At that time, fractures were not even recognized as a disease, but regarded as part of normal aging. From 1970 to this year (2018), there have been extensive advances in the osteoporosis field ranging from fracture epidemiology to the remarkable invention of bone density measurements, There have been major advances in therapeutic options available for patients for prevention and treatment of osteoporosis. In parallel, the advances in the laboratory helped elucidate the process of bone remodeling, not only at the macroscopic level but also at the cellular level. This led to rapid advances in translational research from cellular biology to new therapies exemplified by the development of monoclonal antibodies for osteoporosis. Further understanding of the signaling pathways in bone cells will lead to new small molecules made for osteoporosis treatment, perhaps causing less adverse events. University based research throughout the world has been a leader in most of these advances, and Pharma support for phase 1 to 4 studies helped bring these discoveries to patients. In the osteoporosis field alone, one sees the tremendous value of grant support for university research by National funding agencies such as the National Institute of Health in this country and similar agencies in other countries, There are clinical challenges that have to be solved with long term compliance with osteoporosis medication if we want to reduce fracture incidence in the long term.
C1 [Gallagher, J. Christopher] Creighton Univ, Dept Endocrinol, 2400 Burt St,Criss Bldg,Suite 281, Omaha, NE 68131 USA.
C3 Creighton University
RP Gallagher, JC (通讯作者)，Creighton Univ, Dept Endocrinol, 2400 Burt St,Criss Bldg,Suite 281, Omaha, NE 68131 USA.
EM jcg@creighton.edu
CR ALBRIGHT FULLER, 1940, TRANS ASSOC AMER PHYSICIANS, V55, P298
   ALOIA JF, 1988, AM J MED, V84, P401, DOI 10.1016/0002 9343(88)90259 8
   [Anonymous], 1994, GUID PRECL CLIN EV A
   [Anonymous], 2011, I MED US COMM REV DI
   [Anonymous], 1984, GUID CLIN EV DRUGS U
   [Anonymous], 1979, GUID CLIN EV DRUGS U
   [Anonymous], 1974, PHYS DESK REFERENCE
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2015, J BONE MINER RES, V30, P934, DOI 10.1002/jbmr.2442
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Bush TL, 1996, JAMA J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389
   CAMERONJR, 1963, SCIENCE, V142, P230, DOI 10.1126/science.142.3589.230
   CANN CE, 1980, J COMPUT ASSIST TOMO, V4, P493, DOI 10.1097/00004728 198008000 00018
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   COPP DH, 1962, ENDOCRINOLOGY, V70, P638, DOI 10.1210/endo 70 5 638
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman Felicia, 2014, Bonekey Rep, V3, P518, DOI 10.1038/bonekey.2014.13
   Cummings SR, 2000, AM J MED, V109, P330, DOI 10.1016/S0002 9343(00)00539 8
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140 6736(93)92555 8
   Cummings SR, 2008, NEW ENGL J MED, V359, P697, DOI 10.1056/NEJMoa0800743
   Cummings SR, 2011, J BONE MINER RES, V26, P397, DOI 10.1002/jbmr.191
   Cummings SR, 2010, NEW ENGL J MED, V362, P686, DOI 10.1056/NEJMoa0808692
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dell RM, 2012, J BONE MINER RES, V27, P2544, DOI 10.1002/jbmr.1719
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   FDA approval of calcitonin Summary Basis of Approval, 1984, FDA APPR CALC SUMM B
   FLEISCH H, 1962, J PHYSIOL PARIS, V54, P340
   FOSTER GV, 1966, LANCET, V1, P107
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   Frost HM, 1996, ANAT RECORD, V244, P139, DOI 10.1002/(SICI)1097 0185(199602)244:2<139::AID AR1>3.0.CO;2 X
   GALANTE L, 1973, CLIN SCI, V44, P605, DOI 10.1042/cs0440605
   Gallagher J C, 1973, Clin Endocrinol Metab, V2, P293, DOI 10.1016/S0300 595X(73)80045 3
   Gallagher JC, 2001, J CLIN ENDOCR METAB, V86, P4717, DOI 10.1210/jc.86.10.4717
   GALLAGHER JC, 1988, BONE MINER, V4, P189
   GALLAGHER JC, 1982, P NATL ACAD SCI BIOL, V79, P3325, DOI 10.1073/pnas.79.10.3325
   Gallagher JC, 2002, J CLIN ENDOCR METAB, V87, P4914, DOI 10.1210/jc.2002 020727
   GALLAGHER JC, 1979, J CLIN INVEST, V64, P729, DOI 10.1172/JCI109516
   GALLAGHER JC, 1990, ANN INTERN MED, V113, P649, DOI 10.7326/0003 4819 113 9 649
   GALLAGHER JC, 1989, P SOC EXP BIOL MED, V191, P287
   GALLAGHER JC, 1991, AM J MED, V90, P171
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003 4819 97 5 699
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gong YQ, 1996, AM J HUM GENET, V59, P146
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   HADDAD JG, 1970, NEW ENGL J MED, V283, P549, DOI 10.1056/NEJM197009102831101
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   HEDLUND LR, 1988, BONE MINER, V5, P59, DOI 10.1016/0169 6009(88)90006 2
   Henriksen K, 2016, BONE, V91, P122, DOI 10.1016/j.bone.2016.07.019
   HOLICK MF, 1971, P NATL ACAD SCI USA, V68, P803, DOI 10.1073/pnas.68.4.803
   HORSMAN A, 1977, BRIT MED J, V2, P789, DOI 10.1136/bmj.2.6090.789
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523
   HUTCHINSON TA, 1979, LANCET, V2, P705
   Jackson RD, 2006, J BONE MINER RES, V21, P817, DOI 10.1359/JBMR.060312
   Jha S, 2015, J BONE MINER RES, V30, P2179, DOI 10.1002/jbmr.2565
   Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198 007 0543 5
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kobayashi Y, 2016, J BIOCHEM, V159, P387, DOI 10.1093/jb/mvv124
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lindsay R, 2002, JAMA J AM MED ASSOC, V287, P2668, DOI 10.1001/jama.287.20.2668
   Lindsay R, 2009, FERTIL STERIL, V92, P1045, DOI 10.1016/j.fertnstert.2009.02.093
   Mazess R, 1987, CALCIFIED TISSUE INT, V51, P14
   MAZESS RB, 1981, CALCIFIED TISSUE INT, V33, P365, DOI 10.1007/BF02409457
   McClung MR, 2017, OSTEOPOROSIS INT, V28, P1723, DOI 10.1007/s00198 017 3919 1
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V119, P1654, DOI 10.1210/endo 119 4 1654
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   MULLER R, 1994, PHYS MED BIOL, V39, P145, DOI 10.1088/0031 9155/39/1/009
   NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277
   Nakamura T, 2013, J BONE MINER METAB, V31, P417, DOI 10.1007/s00774 012 0418 5
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   OTT SM, 1990, J BONE MINER RES, V5, P745
   PODBESEK R, 1983, ENDOCRINOLOGY, V112, P1000, DOI 10.1210/endo 112 3 1000
   Prentice RL, 2013, OSTEOPOROSIS INT, V24, P567, DOI 10.1007/s00198 012 2224 2
   REEVE J, 1980, BMJ BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   REIFENSTEIN EC, 1947, J CLIN INVEST, V26, P24, DOI 10.1172/JCI101787
   RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Selye H, 1932, ENDOCRINOLOGY, V16, P547, DOI 10.1210/endo 16 5 547
   Shiraki M, 1996, ENDOCR J, V43, P211, DOI 10.1507/endocrj.43.211
   Silverman SL, 2008, J BONE MINER RES, V23, P1923, DOI 10.1359/JBMR.080710
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SMITH R, 1970, P ROY SOC MED, V63, P931, DOI 10.1177/003591577006300930
   Speroff L, 1996, JAMA J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601
   VEER JVDS, 1970, CALC TISS RES, V4, P88
   WAHNER HW, 1988, MAYO CLIN PROC, V63, P1075, DOI 10.1016/S0025 6196(12)65502 5
   Watts NB, 1993, AM J MED, V95, P557
   Wilson RA., 1968, Feminine forever
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   ZAGZEBSKI JA, 1991, CALCIFIED TISSUE INT, V49, P107, DOI 10.1007/BF02565130
NR 109
TC 12
Z9 13
U1 1
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1072 3714
EI 1530 0374
J9 MENOPAUSE
JI Menopause J. N. Am. Menopause Soc.
PD DEC
PY 2018
VL 25
IS 12
BP 1403
EP 1417
DI 10.1097/GME.0000000000001263
PG 15
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Obstetrics & Gynecology
GA HK3CW
UT WOS:000457791300004
PM 30489459
DA 2025 08 17
ER

PT J
AU Li, L
   Liu, F
   Huang, W
   Wang, J
   Wan, YP
   Li, M
   Pang, YQ
   Yin, ZS
AF Li, Lei
   Liu, Fuen
   Huang, Wei
   Wang, Jun
   Wan, Yunpeng
   Li, Meng
   Pang, Yiqun
   Yin, Zongsheng
TI Ricolinostat (ACY 1215) inhibits VEGF expression via PI3K/AKT
   pathway and promotes apoptosis in osteoarthritic osteoblasts
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Osteoarthritis; HDAC6; ACY 1215; PI3K/AKT; Osteoblasts
ID MESENCHYMAL STEM CELLS; SUBCHONDRAL BONE; CARTILAGE; MIGRATION;
   ANGIOGENESIS; BORTEZOMIB; SURVIVAL
AB Osteoarthritis (OA) is involved in these pathophysiological changes of articular cartilage, subchondral bone and synovium. As a selective HDAC6 inhibitor, Ricolinostat (ACY 1215) has demonstrated chondroprotective effects in OA. However, its efficacy remains unclear in subchondral bone. In this study, we found that the mRNA and protein levels of HDAC6 were elevated in human OA osteoblasts in vitro. PI3K/AKT signaling pathway was suppressed with downregulation of VEGF expression in osteoblasts after ACY 1215 treatment. ACY 1215 promoted apoptosis of OA osteoblast in a concentration dependent manner, and the expression of apoptosis related proteins was also changed by activating caspase pathway. Moreover, western blotting showed decreased expression of MMP9 and MMP13 in IL 1 beta induced chondrocytes after co culture with ACY 1215 stimulated osteoblasts. These data of immunohistochemistry and micro CT from OA model mice also demonstrated the weak staining of MMPs in cartilage and prevention of aberrant subchondral bone formation after ACY 1215 injection. Therefore, high expression of HDAC6 in osteoblasts also contributed to the OA progression, and our study provided a new evidence that HDAC6 inhibitor may be a potential therapeutic drug for OA.
C1 [Li, Lei; Liu, Fuen; Huang, Wei; Wang, Jun; Wan, Yunpeng; Yin, Zongsheng] Anhui Med Univ, Dept Orthopaed, Affiliated Hosp 1, 269 Jixi Rd, Hefei, Anhui, Peoples R China.
   [Li, Meng] Univ Sci & Technol China, Dept Orthopaed, Affiliated Hosp 1, 17 Lujiang Raod, Hefei, Anhui, Peoples R China.
   [Pang, Yiqun] Univ Sci & Technol China, Dept Radiol, Affiliated Hosp 1, 17 Lujiang Raod, Hefei, Anhui, Peoples R China.
C3 Anhui Medical University; Chinese Academy of Sciences; University of
   Science & Technology of China, CAS; Chinese Academy of Sciences;
   University of Science & Technology of China, CAS
RP Yin, ZS (通讯作者)，Anhui Med Univ, Dept Orthopaed, Affiliated Hosp 1, 269 Jixi Rd, Hefei, Anhui, Peoples R China.
EM zsahmu1961@sina.com
FU National Natural Science Foundation of China [81672161]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81672161).
CR ALTMAN RD, 1991, J RHEUMATOL, V18, P10
   Amin AK, 2009, J BONE JOINT SURG BR, V91B, P691, DOI 10.1302/0301 620X.91B5.21544
   Benoy V, 2017, NEUROTHERAPEUTICS, V14, P417, DOI 10.1007/s13311 016 0501 z
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Bruyere O., 2019, SEMIN ARTHRITIS RHEU, P1
   Cao JL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0788 2
   Castañeda S, 2012, BIOCHEM PHARMACOL, V83, P315, DOI 10.1016/j.bcp.2011.09.018
   Cheng AWM, 2011, OSTEOARTHR CARTILAGE, V19, P118, DOI 10.1016/j.joca.2010.10.019
   Cheng C, 2019, BIOMED PHARMACOTHER, V109, P2464, DOI 10.1016/j.biopha.2018.11.017
   Clark IA, 2008, INT J BIOCHEM CELL B, V40, P1362, DOI 10.1016/j.biocel.2007.12.006
   Corti F, 2019, CANCER TREAT REV, V72, P45, DOI 10.1016/j.ctrv.2018.11.001
   Danchuk S., 2017, PLOS ONE, V12
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   De Vreese R, 2017, EUR J MED CHEM, V135, P174, DOI 10.1016/j.ejmech.2017.04.013
   du Souich P, 2014, PHARMACOL THERAPEUT, V142, P362, DOI 10.1016/j.pharmthera.2014.01.002
   Findlay DM, 2014, CURR OSTEOPOROS REP, V12, P127, DOI 10.1007/s11914 014 0192 5
   Franses RE, 2010, OSTEOARTHR CARTILAGE, V18, P563, DOI 10.1016/j.joca.2009.11.015
   Fu S, 2019, OSTEOARTHR CARTILAGE, V27, P1064, DOI 10.1016/j.joca.2019.03.003
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Gradilone SA, 2013, CANCER RES, V73, P2259, DOI 10.1158/0008 5472.CAN 12 2938
   Henrotin Y, 2012, OSTEOPOROSIS INT, V23, pS847, DOI 10.1007/s00198 012 2162 z
   Hochberg MC, 2010, OSTEOARTHR CARTILAGE, V18, pS28, DOI 10.1016/j.joca.2010.02.016
   HOWELL DS, 1986, AM J MED, V80, P24, DOI 10.1016/0002 9343(86)90075 6
   Imhof H, 2000, INVEST RADIOL, V35, P581, DOI 10.1097/00004424 200010000 00004
   Kaluza D, 2011, EMBO J, V30, P4142, DOI 10.1038/emboj.2011.298
   KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494
   Kim KS, 2011, RHEUMATOL INT, V31, P543, DOI 10.1007/s00296 010 1592 1
   Lafeber FPJG, 2013, OSTEOARTHR CARTILAGE, V21, P1452, DOI 10.1016/j.joca.2013.08.012
   Lee DH, 2019, MOL CARCINOGEN, V58, P944, DOI 10.1002/mc.22983
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Lu JS, 2018, J BONE MINER RES, V33, P909, DOI 10.1002/jbmr.3388
   Martel Pelletier J, 2015, MOLECULES, V20, P4277, DOI 10.3390/molecules20034277
   Massicotte F, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2087
   Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008 5472.CAN 05 2961
   Pan J, 2012, BONE, V51, P212, DOI 10.1016/j.bone.2011.11.030
   Pufe T, 2004, J PATHOL, V202, P367, DOI 10.1002/path.1527
   Ryu CH, 2010, BIOCHEM BIOPH RES CO, V398, P105, DOI 10.1016/j.bbrc.2010.06.043
   Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood 2011 10 387365
   Schulz R, 2012, J EXP MED, V209, P275, DOI 10.1084/jem.20111117
   Tsuchida AI, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0441 0
   Vrtacnik P, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34255 4
   Xie LQ, 2012, ARTHRITIS RHEUM US, V64, P1899, DOI 10.1002/art.34370
   Yuan XL, 2014, OSTEOARTHR CARTILAGE, V22, P1077, DOI 10.1016/j.joca.2014.05.023
   Zhang WB, 2018, BIOMED PHARMACOTHER, V97, P818, DOI 10.1016/j.biopha.2017.10.103
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 45
TC 24
Z9 27
U1 0
U2 9
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2019
VL 118
AR 109357
DI 10.1016/j.biopha.2019.109357
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA IY4WZ
UT WOS:000486395000132
PM 31548177
OA gold
DA 2025 08 17
ER

PT J
AU Pham, L
   Beyer, K
   Jensen, ED
   Rodriguez, JS
   Davydova, J
   Yamamoto, M
   Petryk, A
   Gopalakrishnan, R
   Mansky, KC
AF Pham, Lan
   Beyer, Kayla
   Jensen, Eric D.
   Rodriguez, Julio Sotillo
   Davydova, Julia
   Yamamoto, Masato
   Petryk, Anna
   Gopalakrishnan, Rajaram
   Mansky, Kim C.
TI Bone Morphogenetic Protein 2 Signaling in Osteoclasts Is Negatively
   Regulated by the BMP Antagonist, Twisted Gastrulation
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE OSTEOCLAST; BONE MORPHOGENETIC PROTEIN 2; TWISTED GASTRULATION; BONE
ID RECEPTOR ACTIVATOR; DIFFERENTIATION; CELLS; EXPRESSION; APOPTOSIS;
   LINEAGE; CHORDIN; LIGAND
AB Bone morphogenetic proteins (BMPs) have been shown to regulate both osteoblasts and ostcoclasts. We previously reported that BMP2 could directly enhance RANKL mediated osteoclast differentiation by increasing the size and number of osteoclasts. Similarly, genetic deletion of the BMP antagonist Twisted gastrulation (TWSG1) in mice, resulted in an enhancement of osteoclast formation, activity and osteopenia. This was accompanied by increased levels of phosphorylated Smad (pSmad) 1/5/8 in Twsg1( / ) osteoclasts in vitro. The purpose of this study was to develop an adenoviral vector overexpressing Twsg1 as a means of inhibiting osteoclast activity. We demonstrate that overexpressing TWSG1 in primary osteoclasts decreased the size and number of multinuclear TRAP positive osteoclasts, expression of osteoclast genes, and resorption ability. Overexpression of TWSG1 did not affect osteoclast proliferation or apoptosis. However, overexpression of TWSG1 decreased the levels of pSmad 1/5/8 in osteoclasts. Addition of exogenous BMP2 to osteoclasts overexpressing TWSG1 rescued the size and levels of pSmad 1/5/8 compared to cultures infected with a control virus. Finally, TWSG1 overexpression in ostcoclasts isolated from the Twsg1( / ) mice rescued size of the osteoclasts while further addition of exogenous BMP2 reversed the effect of TWSG1 overexpression and increased the size of the osteoclasts similar to control virus infected cells. Taken together, we demonstrate that overexpressing TWSG1 in osteoclasts via an adenoviral vector results in inhibition of osteoclastogenesis and may provide a potential therapy for inhibiting osteoclast activity in a localized manner. J. Cell. Biochem. 112: 793 803, 2011. (C) 2010 Wiley Liss, Inc.
C1 [Pham, Lan; Beyer, Kayla; Jensen, Eric D.; Rodriguez, Julio Sotillo; Gopalakrishnan, Rajaram] Univ Minnesota, Sch Dent, Dept Diagnost & Biol Sci, Minneapolis, MN 55455 USA.
   [Davydova, Julia] Univ Minnesota, Sch Med, Dept Surg, Minneapolis, MN 55455 USA.
   [Yamamoto, Masato; Petryk, Anna] Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
   [Yamamoto, Masato; Petryk, Anna] Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA.
   [Mansky, Kim C.] Univ Minnesota, Sch Dent, Dept Dev & Surg Sci, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Gopalakrishnan, R (通讯作者)，Univ Minnesota, Sch Dent, Dept Diagnost & Biol Sci, 16 108A Moos Tower,515 Delaware St SE, Minneapolis, MN 55455 USA.
EM gopal007@umn.edu; kmansky@umn.edu
RI ; Jensen, Eric/HJI 9245 2023; Mansky, Kim/AAB 3592 2022; Davydova,
   Julia/HJH 9028 2023
OI Mansky, Kim/0000 0002 2826 5030; Davydova, Julia/0000 0001 5766 5722; 
FU National Institute of Dental and Craniofacial Research [MinnCResT T32,
   DE007288, R01 DE016601, R01CA094084, R03 DE020117, R01 AR056642]
FX Grant sponsor: National Institute of Dental and Craniofacial Research;
   Grant numbers: MinnCResT T32, DE007288, R01 DE016601, R01CA094084, R03
   DE020117, R01 AR056642.
CR Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Davydova J, 2004, CANCER RES, V64, P4319, DOI 10.1158/0008 5472.CAN 04 0064
   Giannoudis PV, 2007, OSTEOPOROSIS INT, V18, P1565, DOI 10.1007/s00198 007 0441 x
   Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656
   Jensen ED, 2010, J CELL BIOCHEM, V109, P672, DOI 10.1002/jcb.22462
   KANATANI M, 1995, J BONE MINER RES, V10, P1681, DOI 10.1002/jbmr.5650101110
   Kaneko H, 2000, BONE, V27, P479, DOI 10.1016/S8756 3282(00)00358 6
   Kirker Head CA, 2007, JAVMA J AM VET MED A, V231, P1039, DOI 10.2460/javma.231.7.1039
   Larraín J, 2001, DEVELOPMENT, V128, P4439
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   MacKenzie B, 2009, DEV BIOL, V328, P13, DOI 10.1016/j.ydbio.2008.12.041
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Nosaka T, 2003, MOL CELL BIOL, V23, P2969, DOI 10.1128/MCB.23.8.2969 2980.2003
   Oelgeschläger M, 2003, DEVELOPMENT, V130, P4047, DOI 10.1242/dev.00633
   Okamoto M, 2006, J BONE MINER RES, V21, P1022, DOI 10.1359/JBMR.060411
   Petryk A, 2005, BONE, V36, P617, DOI 10.1016/j.bone.2005.01.018
   Petryk A, 2004, DEV BIOL, V267, P374, DOI 10.1016/j.ydbio.2003.11.015
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rodriguez JES, 2009, J BONE MINER RES, V24, P1917, DOI [10.1359/JBMR.090507, 10.1359/jbmr.090507]
   Ross JJ, 2001, NATURE, V410, P479, DOI 10.1038/35068578
   Toth JM, 2009, SPINE, V34, P539, DOI 10.1097/BRS.0b013e3181952695
   Väänänen HK, 2008, ARCH BIOCHEM BIOPHYS, V473, P132, DOI 10.1016/j.abb.2008.03.037
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
NR 26
TC 30
Z9 42
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAR
PY 2011
VL 112
IS 3
BP 793
EP 803
DI 10.1002/jcb.23003
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 728YK
UT WOS:000287910200008
PM 21328453
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Rajakumar, SA
   Papp, E
   Lee, KK
   Grandal, I
   Merico, D
   Liu, CC
   Allo, B
   Zhang, L
   Grynpas, MD
   Minden, MD
   Hitzler, JK
   Guidos, CJ
   Danska, JS
AF Rajakumar, Sujeetha A.
   Papp, Eniko
   Lee, Kathy K.
   Grandal, Ildiko
   Merico, Daniele
   Liu, Careesa C.
   Allo, Bedilu
   Zhang, Lucia
   Grynpas, Marc D.
   Minden, Mark D.
   Hitzler, Johann K.
   Guidos, Cynthia J.
   Danska, Jayne S.
TI B cell acute lymphoblastic leukemia cells mediate RANK RANKL dependent
   bone destruction
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID HUMAN MONOCLONAL ANTIBODY; MULTIPLE MYELOMA; OSTEOCLAST DIFFERENTIATION;
   RECEPTOR ACTIVATOR; OSTEOPROTEGERIN LIGAND; CHILDHOOD LEUKEMIA;
   ZOLEDRONIC ACID; BREAST CANCER; EXPRESSION; DENOSUMAB
AB Although most children survive B cell acute lymphoblastic leukemia (B ALL), they frequently experience longterm, treatment related health problems, including osteopenia and osteonecrosis. Because some children present with fractures at ALL diagnosis, we considered the possibility that leukemic B cells contribute directly to bone pathology. To identify potential mechanisms of B ALL driven bone destruction, we examined the p53( / ); Rag2( / ); Prkdc(scid/scid) triple mutant (TM) mice and p53( / ); Prkdc(scid/scid) double mutant (DM) mouse models of spontaneous B ALL. In contrast to DM animals, leukemic TM mice displayed brittle bones, and the TM leukemic cells over expressed Rankl, encoding receptor activator of nuclear factor kappa B ligand. RANKL is a key regulator of osteoclast differentiation and bone loss. Transfer of TM leukemic cells into immunodeficient recipient mice caused trabecular bone loss. To determine whether human B ALL can exert similar effects, we evaluated primary human B ALL blasts isolated at diagnosis for RANKL expression and their impact on bone pathology after their transplantation into NOD.Prkdc(scid/scid)Il2rg(tm1Wjl)/SzJ (NSG) recipient mice. Primary B ALL cells conferred bone destruction evident in increased multinucleated osteoclasts, trabecular bone loss, destruction of the metaphyseal growth plate, and reduction in adipocyte mass in these patient derived xenografts (PDXs). Treating PDX mice with the RANKL antagonist recombinant osteoprotegerin Fc (rOPG Fc) protected the bone from B ALL induced destruction even under conditions of heavy tumor burden. Our data demonstrate a critical role of the RANK RANKL axis in causing B ALL mediated bone pathology and provide preclinical support for RANKL targeted therapy trials to reduce acute and long term bone destruction in these patients.
C1 [Rajakumar, Sujeetha A.; Danska, Jayne S.] Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 0A4, Canada.
   [Rajakumar, Sujeetha A.; Papp, Eniko; Minden, Mark D.; Danska, Jayne S.] Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada.
   [Papp, Eniko; Grandal, Ildiko; Hitzler, Johann K.; Guidos, Cynthia J.] Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 0A4, Canada.
   [Lee, Kathy K.; Liu, Careesa C.; Allo, Bedilu; Zhang, Lucia; Grynpas, Marc D.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5T 3H7, Canada.
   [Lee, Kathy K.; Zhang, Lucia] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON M5S 1A8, Canada.
   [Merico, Daniele] Hosp Sick Children, Ctr Appl Genom, Toronto, ON M5G 0A4, Canada.
   [Liu, Careesa C.; Grynpas, Marc D.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON M5S 1A8, Canada.
   [Minden, Mark D.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada.
   [Hitzler, Johann K.] Hosp Sick Children, Dept Pediat, Div Hematol & Oncol, Toronto, ON M5G 1X8, Canada.
   [Guidos, Cynthia J.; Danska, Jayne S.] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada.
C3 University of Toronto; Hospital for Sick Children (SickKids); University
   of Toronto; University of Toronto; Hospital for Sick Children
   (SickKids); University of Toronto; Sinai Health System Toronto;
   Lunenfeld Tanenbaum Research Institute; University of Toronto;
   University of Toronto; Hospital for Sick Children (SickKids); University
   of Toronto; University of Toronto; University Health Network Toronto;
   Princess Margaret Cancer Centre; University of Toronto; Hospital for
   Sick Children (SickKids); University of Toronto
RP Danska, JS (通讯作者)，Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 0A4, Canada.; Danska, JS (通讯作者)，Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada.; Danska, JS (通讯作者)，Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada.
EM jayne.danska@sickkids.ca
RI Grynpas, Marc/ABG 7096 2020; Mullighan, Charles/H 3253 2011; Merico,
   Daniele/MEK 7718 2025; ZHANG, LUCIA/JXX 1102 2024
OI Allo, Bedilu/0000 0002 6496 0671; Lee, Kathy
   Kyungeun/0000 0003 4207 289X; Rajakumar, Sujeetha/0000 0001 9340 5979;
   Merico, Daniele/0000 0002 3728 4401; 
FU Leukemia and Lymphoma Society of Canada [524579]; Ontario Institute of
   Cancer Research (AL TRI FR HSK); SickKids Foundation
FX This work was supported by grants to J.S.D. from the Leukemia and
   Lymphoma Society of Canada (524579) and to J.S.D. and C.J.G. from the
   Ontario Institute of Cancer Research (AL TRI FR HSK). J.S.D. and C.J.G.
   receive support from the SickKids Foundation.
CR Alos N., 2012, SCI TRANSL MED, V30, P2760
   Angsubhakorn N., 2018, BMJ Case Rep, V2018
   Bankhead P, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17204 5
   Barcala V, 2003, EUR J HAEMATOL, V70, P417, DOI 10.1034/j.1600 0609.2003.00067.x
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Capparelli C, 2003, J BONE MINER RES, V18, P852, DOI 10.1359/jbmr.2003.18.5.852
   CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   Cummings EA, 2015, J CLIN ENDOCR METAB, V100, P3408, DOI 10.1210/JC.2015 2176
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Gasparini C, 2014, CELL MOL LIFE SCI, V71, P2083, DOI 10.1007/s00018 013 1545 4
   Gladdy RA, 2003, CANCER CELL, V3, P37, DOI 10.1016/S1535 6108(02)00236 2
   Granacher NCP, 2017, EXP HEMATOL ONCOL, V6, DOI 10.1186/s40164 017 0071 8
   Green JR, 1997, PHARMACOL TOXICOL, V80, P225, DOI 10.1111/j.1600 0773.1997.tb01964.x
   Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038
   Halton J, 2009, J BONE MINER RES, V24, P1326, DOI [10.1359/JBMR.090202, 10.1359/jbmr.090202]
   Halton JM, 1996, J BONE MINER RES, V11, P1774
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Henderson RC, 1998, J PEDIAT HEMATOL ONC, V20, P322, DOI 10.1097/00043426 199807000 00008
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Horowitz MC, 2010, BONE, V47, P472, DOI 10.1016/j.bone.2010.06.011
   Hunger SP, 2015, NEW ENGL J MED, V373, P1541, DOI 10.1056/NEJMra1400972
   Hunger SP, 2012, J CLIN ONCOL, V30, P1663, DOI 10.1200/JCO.2011.37.8018
   Johnson RM, 2014, GENE DEV, V28, P1179, DOI 10.1101/gad.240820.114
   Jones DP, 2008, PEDIATR BLOOD CANCER, V51, P724, DOI 10.1002/pbc.21695
   Kaiafa G, 2015, HIPPOKRATIA, V19, P78
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kozhemyakina E, 2015, DEVELOPMENT, V142, P817, DOI 10.1242/dev.105536
   Kurata T, 2012, JPN J CLIN ONCOL, V42, P663, DOI 10.1093/jjco/hys088
   Kusumbe AP, 2016, NATURE, V532, P380, DOI 10.1038/nature17638
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Mahmood K, 2017, CASE REP MED, V2017, DOI 10.1155/2017/2347810
   Manilay JO, 2014, TRENDS MOL MED, V20, P405, DOI 10.1016/j.molmed.2014.03.003
   Mazurier F, 2003, NAT MED, V9, P959, DOI 10.1038/nm886
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   McDermott SP, 2010, BLOOD, V116, P193, DOI 10.1182/blood 2010 02 271841
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Mostoufi Moab S, 2014, CURR OSTEOPOROS REP, V12, P300, DOI 10.1007/s11914 014 0222 3
   Munker R, 1998, HAEMATOLOGICA, V83, P416
   Nagasawa T, 2006, NAT REV IMMUNOL, V6, P107, DOI 10.1038/nri1780
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Notta F, 2010, BLOOD, V115, P3704, DOI 10.1182/blood 2009 10 249326
   Pacifici R, 2010, ARCH BIOCHEM BIOPHYS, V503, P41, DOI 10.1016/j.abb.2010.05.027
   Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Perova T, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008661
   Rajakumar, 2020, SCI TRANSL MED, V12
   Raje NS, 2019, CLIN CANCER RES, V25, P12, DOI 10.1158/1078 0432.CCR 18 1537
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Roodman GD, 2008, CANCER TREAT REV, V34, P92, DOI 10.1016/j.ctrv.2007.09.002
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rubin J, 1998, ENDOCRINOLOGY, V139, P1006, DOI 10.1210/en.139.3.1006
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Schmiedel BJ, 2013, CANCER RES, V73, P683, DOI 10.1158/0008 5472.CAN 12 2280
   Schmiedel BJ, 2013, J IMMUNOL, V190, P821, DOI 10.4049/jimmunol.1201792
   Schubert A, 2008, GYNECOL ENDOCRINOL, V24, P331, DOI 10.1080/09513590802095845
   Secchiero P, 2006, J CELL PHYSIOL, V207, P158, DOI 10.1002/jcp.20547
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2012, NAT REV RHEUMATOL, V8, P684, DOI 10.1038/nrrheum.2012.167
   Terpos E, 2009, EXPERT OPIN BIOL TH, V9, P465, DOI [10.1517/14712590902845610, 10.1517/14712590902845610 ]
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   VANDONGEN JJM, 1988, BLOOD, V71, P603
   Verma SP, 2014, INDIAN J HEMATOL BLO, V30, pS24, DOI 10.1007/s12288 012 0221 4
   WILLSON JKV, 1959, RADIOLOGY, V72, P672, DOI 10.1148/72.5.672
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
NR 81
TC 24
Z9 26
U1 0
U2 12
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD SEP 16
PY 2020
VL 12
IS 561
AR eaba5942
DI 10.1126/scitranslmed.aba5942
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA NQ6HM
UT WOS:000570971200005
PM 32938796
DA 2025 08 17
ER

PT J
AU Lewington, VJ
AF Lewington, VJ
TI Bone seeking radionuclides for therapy
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE bone pain palliation; metastasis; targeted radionuclide therapy;
   dosimetry
ID EXTERNAL BEAM RADIOTHERAPY; PROSTATE CANCER PATIENTS; DOUBLE BLIND
   CROSSOVER; SR 89 THERAPY; HYDROXYETHYLIDENE DIPHOSPHONATE; RADIOACTIVE
   PHOSPHORUS; SKELETAL METASTASES; TARGETED THERAPY; DOSE ESCALATION; PAIN
   PALLIATION
AB Systemic therapy using bone seeking radiopharmaceuticals has clear advantages for the treatment of multisite metastatic pain. Evidence supporting the use of beta particle, electron, and alpha particle emitting radiopharmaceuticals is reviewed here. Appropriate patient selection relies on correlating clinical symptoms with focal abnormalities on conventional bone scintigraphy. Time to symptom relief and response duration vary with the physical half life and dose rate of the radionuclide used, offering the opportunity to tailor radiopharmaceutical choice to individual patient circumstances. Toxicity is limited to temporary myelosuppression, governed by the administered activity and underlying bone marrow reserve. Optimal responses are achieved in patients with a modest skeletal tumor burden, suggesting that targeted therapy should be considered early in the management of bone metastases. The development of reliable dosimetric models will facilitate patient specific prescribing to deliver enhanced symptom response within acceptable toxicity limits. It is likely that targeted therapy will be most effective in the context of multimodality tumor management. Further research is required to examine the potential of radionuclides in combination with external beam irradiation, bisphosphonates, or chemotherapy. This approach might allow targeted therapy to progress beyond symptom palliation to early intervention for survival gain.
C1 Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England.
C3 Royal Marsden NHS Foundation Trust
RP Royal Marsden Hosp, Downs Rd, Sutton SM2 5PT, Surrey, England.
EM val.lewington@rmh.nthames.nhs.uk
OI Lewington, Val/0000 0002 8521 5478
CR Ahonen A, 1994, J Nucl Biol Med, V38, P123
   Akerley W, 2002, CANCER, V94, P1654, DOI 10.1002/cncr.10437
   ANDERSON OM, 2002, J CLIN ONCOL, V20, P1953
   [Anonymous], 1990, Cancer pain relief and palliative care: report of a WHO expert committee [meeting held in Geneva from 3 to 10 July 1989]
   ARIEL IM, 1985, INT SURG, V70, P63
   ATKINS HL, 1993, RADIOLOGY, V186, P279, DOI 10.1148/radiology.186.1.7677974
   Bishayee A, 2000, J NUCL MED, V41, P2043
   BLAKE GM, 1988, J NUCL MED, V29, P549
   BLAKE GM, 1986, EUR J NUCL MED, V12, P447, DOI 10.1007/BF00254749
   Body JJ, 2003, CANCER, V97, P859, DOI 10.1002/cncr.11139
   BREEN SL, 1992, J NUCL MED, V33, P1316
   Buffa FM, 2003, EUR J NUCL MED MOL I, V30, P1114, DOI 10.1007/s00259 003 1197 y
   Burnet N G, 1990, Clin Oncol (R Coll Radiol), V2, P220, DOI 10.1016/S0936 6555(05)80172 4
   Bushnell D. L., 1996, Journal of Nuclear Medicine, V37, p31P
   Cameron PJ, 1999, NUCL MED COMMUN, V20, P609, DOI 10.1097/00006231 199907000 00003
   CHEUNG A, 1980, RADIOLOGY, V134, P209, DOI 10.1148/radiology.134.1.6153129
   Coleman R E, 2000, Breast Cancer, V7, P361, DOI 10.1007/BF02966406
   COLLINS C, 1993, J NUCL MED, V34, P1839
   de Klerk JMH, 1999, NUCL MED COMMUN, V20, P833, DOI 10.1097/00006231 199909000 00009
   DEKLERK JMH, 1992, J NUCL MED, V33, P646
   DEKLERK JMH, 1994, EUR J NUCL MED, V21, P1114, DOI 10.1007/BF00181067
   DEKLERK JMH, 1994, THESIS U UTRECHT, P81
   FARHANGHI M, 1992, J NUCL MED, V33, P1451
   Fuster D, 2000, Rev Esp Med Nucl, V19, P270
   Hamdy NAT, 2001, SEMIN NUCL MED, V31, P62, DOI 10.1053/snuc.2001.18767
   Han SH, 1999, J NUCL MED, V40, P639
   Han SH, 2002, J NUCL MED, V43, P1150
   Henriksen G, 2003, J NUCL MED, V44, P252
   Hoskin P J, 1989, Clin Oncol (R Coll Radiol), V1, P67, DOI 10.1016/S0936 6555(89)80037 8
   KIM EE, 1991, J NUCL MED, V32, P1233
   Kossman SE, 2000, CANCER, V88, P620, DOI 10.1002/(SICI)1097 0142(20000201)88:3<620::AID CNCR19>3.0.CO;2 #
   Krishnamurthy GT, 1997, J NUCL MED, V38, P230
   LAING AH, 1991, BRIT J RADIOL, V64, P816, DOI 10.1259/0007 1285 64 765 816
   LEWINGTON VJ, 1991, EUR J CANCER, V27, P954, DOI 10.1016/0277 5379(91)90257 E
   Liepe K, 2003, BRIT J CANCER, V89, P625, DOI 10.1038/sj.bjc.6601158
   Liepe K, 2003, J NUCL MED, V44, P953
   Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065
   MAXFIELD J R Jr, 1958, South Med J, V51, P320
   MAXON HR, 1991, J NUCL MED, V32, P1877
   MAXON HR, 1988, RADIOLOGY, V166, P501, DOI 10.1148/radiology.166.2.3122267
   MCEWAN AJB, 1998, NUCL MED CLIN DIAGNO, P1083
   Nair N, 1999, J NUCL MED, V40, P256
   O'Sullivan JM, 2002, BRIT J CANCER, V86, P1715, DOI 10.1038/sj.bjc.6600348
   Palmedo H, 2003, J CLIN ONCOL, V21, P2869, DOI 10.1200/JCO.2003.12.060
   Palmedo H, 2000, EUR J NUCL MED, V27, P123, DOI 10.1007/s002590050017
   Papatheofanis FJ, 1997, BRIT J RADIOL, V70, P594, DOI 10.1259/bjr.70.834.9227252
   Papatheofanis FJ, 1997, J NUCL MED, V38, P1175
   Papatheofanis FJ, 2000, J NUCL MED, V41, P1021
   Paszkowski AL, 1999, CLIN NUCL MED, V24, P852, DOI 10.1097/00003072 199911000 00006
   PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360 3016(93)90309 J
   POTSAID M, 1976, J NUCL MED, V17, P548
   PRENEN JAC, 1991, J NUCL MED, V32, P2057
   QUILTY PM, 1994, RADIOTHER ONCOL, V31, P33, DOI 10.1016/0167 8140(94)90411 1
   Quirijnen JMSP, 1996, J NUCL MED, V37, P1511
   Resche I, 1997, EUR J CANCER, V33, P1583, DOI 10.1016/S0959 8049(97)00155 X
   SAMARATUNGA RC, 1995, J NUCL MED, V36, P336
   Sciuto R, 2002, J NUCL MED, V43, P79
   Serafini AN, 1998, J CLIN ONCOL, V16, P1574, DOI 10.1200/JCO.1998.16.4.1574
   Serafini AN, 2001, J NUCL MED, V42, P895
   SILBERSTEIN EB, 1993, SEMIN ONCOL, V20, P10
   SILBERSTEIN EB, 1992, SEMIN NUCL MED, V22, P17, DOI 10.1016/S0001 2998(05)80153 9
   Silberstein EB, 2000, SEMIN RADIAT ONCOL, V10, P240, DOI 10.1053/srao.2000.6592
   SINGH A, 1989, J NUCL MED, V30, P1814
   Smeland S, 2003, INT J RADIAT ONCOL, V56, P1397, DOI 10.1016/S0360 3016(03)00274 8
   SPIERS FW, 1976, BRIT J RADIOL, V49, P133, DOI 10.1259/0007 1285 49 578 133
   SRIVASTAVA SC, 1985, INT J NUCL MED BIOL, V12, P167, DOI 10.1016/0047 0740(85)90023 3
   Srivastava SC, 1998, CLIN CANCER RES, V4, P61
   Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140 6736(00)03639 4
   TURNER JH, 1991, EUR J CANCER, V27, P1084, DOI 10.1016/0277 5379(91)90297 Q
   TURNER JH, 1989, J CLIN ONCOL, V7, P1926, DOI 10.1200/JCO.1989.7.12.1926
   TURNER JH, 1989, EUR J NUCL MED, V15, P784
   TWYCROSS RG, 1982, PAIN, V14, P303, DOI 10.1016/0304 3959(82)90137 3
   van Rensburg AJ, 1998, J NUCL MED, V39, P2110
   WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360 3016(94)90539 8
NR 74
TC 166
Z9 183
U1 0
U2 1
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190 5316 USA
SN 0161 5505
EI 1535 5667
J9 J NUCL MED
JI J. Nucl. Med.
PD JAN
PY 2005
VL 46
SU 1
BP 38S
EP 47S
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 887JG
UT WOS:000226301300006
PM 15653650
DA 2025 08 17
ER

PT J
AU Zhang, XL
   Pang, R
   Zhang, K
   Xu, Q
   Xu, CL
   Shi, W
   Liang, XY
   Li, D
   Cui, WH
   Bai, SC
   Li, ZJ
   Li, H
   Zhang, HF
AF Zhang, Xinglong
   Pang, Ran
   Zhang, Kai
   Xu, Qian
   Xu, Chunlei
   Shi, Wei
   Liang, Xinyu
   Li, Dong
   Cui, Wenhao
   Bai, Shucai
   Li, Zhijun
   Li, Hui
   Zhang, Huafeng
TI Apocynin exerts cytoprotective effects on dexamethasone induced
   osteoblasts by inhibiting oxidative stress through the Nrf2 signalling
   pathway
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE apocynin; femoral head necrosis; Nrf2 pathway; osteoblast apoptosis;
   oxidative stress
ID FEMORAL HEAD; OSTEONECROSIS; APOPTOSIS; NECROSIS; INJURY; DAMAGE; DEATH;
   CELLS
AB Steroid induced femoral head necrosis (SIFHN) is a serious clinical complication that is caused by prolonged or excessive use of glucocorticoids (GCs). Osteoblast apoptosis and osteogenic differentiation dysfunction caused by GC induced oxidative stress and mitochondrial impairment are strongly implicated in SIFHN. Apocynin (APO) is a kind of acetophenone extracted from an herb. In recent years, APO has received much attention for its antiapoptotic and antioxidant properties. This study aimed to investigate whether APO could protect against SIFHN and explore the mechanism. In our study, low dose APO had no toxic effects on osteoblasts and restored dexamethasone (Dex) treated osteoblasts by improving survival, inhibiting OS and restoring mitochondrial dysfunction. Mechanistically, APO alleviated Dex induced osteoblast injury by activating the Nrf2 pathway, and the use of ML385 to block Nrf2 significantly eliminated the protective effect of APO. In addition, APO could reduce the formation of empty lacunae, restore bone mass and promote the expression of Nrf2 in SIFHN rats. In conclusion, APO protects osteoblasts from Dex induced oxidative stress and mitochondrial dysfunction through activation of the Nrf2 pathway and may be a beneficial drug for the treatment of SIFHN.
C1 [Zhang, Xinglong; Li, Hui] TianjinNankai Hosp, Dept Orthopaed, Tianjin, Peoples R China.
   [Xu, Chunlei; Shi, Wei; Liang, Xinyu; Li, Dong; Li, Zhijun; Zhang, Huafeng] Tianjin Med Univ, Dept Orthopaed, Gen Hosp, Tianjin, Peoples R China.
   [Xu, Qian] Tianjin Univ Tradit Chinese Med, Sch Integrat Med, Tianjin, Peoples R China.
   [Cui, Wenhao] Kyoto Prefectural Univ Med, Dept Pharmacol, Kyoto, Japan.
   [Cui, Wenhao] Youjia Hangzhou Biomed Technol Co Ltd, R&D Ctr, Hangzhou, Peoples R China.
   [Bai, Shucai] Tianjin Hosp, Dept Orthopaed, Tianjin, Peoples R China.
   [Li, Zhijun; Zhang, Huafeng] TianjinNankai Hosp, Dept Orthopaed, Tianjin 300052, Peoples R China.
   [Li, Hui] Tianjin Nankai Hosp, Dept Orthopaed, Tianjin 300052, Peoples R China.
C3 Tianjin Medical University; Tianjin University of Traditional Chinese
   Medicine; Kyoto Prefectural University of Medicine
RP Li, ZJ; Zhang, HF (通讯作者)，TianjinNankai Hosp, Dept Orthopaed, Tianjin 300052, Peoples R China.; Li, H (通讯作者)，Tianjin Nankai Hosp, Dept Orthopaed, Tianjin 300052, Peoples R China.
EM hansontijmu@163.com; ortholivea@126.com; tijmuhua516@163.com
RI zhang, hua/AAQ 3108 2021
CR Bai SC, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9192413
   Beier EE, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.13
   Calder JDF, 2004, J BONE JOINT SURG BR, V86B, P1209, DOI 10.1302/0301 620X.86B8.14834
   Camus SM, 2015, BLOOD, V125, P3805, DOI 10.1182/blood 2014 07 589283
   Chang C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2020.102460
   Chen L, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9102012
   Cho RL, 2018, BRIT J PHARMACOL, V175, P3928, DOI 10.1111/bph.14465
   Choi EM, 2012, J APPL TOXICOL, V32, P714, DOI 10.1002/jat.1689
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Cruz Alvarez S, 2017, NEUROSCIENCE, V350, P65, DOI 10.1016/j.neuroscience.2017.03.011
   French D, 2008, BLOOD, V111, P4496, DOI 10.1182/blood 2007 11 123885
   Hwang YJ., 2019, PLOS ONE, V14
   Kirindage KGIS, 2022, FOODS, V11, DOI 10.3390/foods11030420
   Kubo Y, 2021, ANTIOXID REDOX SIGN, V35, P357, DOI 10.1089/ars.2020.8163
   Levaot N, 2011, J CLIN INVEST, V121, P3244, DOI 10.1172/JCI45843
   Lin CC, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010226
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018 016 2223 0
   Mahmood A, 2021, MOL CELL BIOCHEM, V476, P2047, DOI 10.1007/s11010 020 04039 4
   Mishra P, 2022, J BIOMOL STRUCT DYN, V40, P12316, DOI 10.1080/07391102.2021.1970624
   Mishra P, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 43320 5
   Moore VD, 2008, BLOOD, V111, P2300, DOI 10.1182/blood 2007 06 098012
   MUSSO ES, 1986, CLIN ORTHOP RELAT R, P209
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Picard M, 2014, NAT REV ENDOCRINOL, V10, P303, DOI 10.1038/nrendo.2014.22
   Soares MPR, 2019, CELL BIOL INT, V43, P466, DOI 10.1002/cbin.11110
   Savla SR, 2021, DRUG METAB REV, V53, P542, DOI 10.1080/03602532.2021.1895203
   Schulz E, 2008, CIRCULATION, V118, P1347, DOI 10.1161/CIRCULATIONAHA.108.784298
   SHIMIZU K, 1994, J BONE JOINT SURG AM, V76A, P215, DOI 10.2106/00004623 199402000 00007
   Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev biochem 061516 045037
   Sung YJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0730 7
   Varoga D, 2009, CLIN ORTHOP RELAT R, V467, P3273, DOI 10.1007/s11999 009 1076 3
   Wang ZJ, 2019, INT IMMUNOPHARMACOL, V77, DOI 10.1016/j.intimp.2019.105952
   Weinstein RS, 2017, ENDOCRINOLOGY, V158, P3817, DOI 10.1210/en.2017 00662
   Xu YE, 2019, LIFE SCI, V224, P58, DOI 10.1016/j.lfs.2019.03.051
   Yan WJ, 2017, CIRCULATION, V136, P2162, DOI 10.1161/CIRCULATIONAHA.117.029557
   Yang N, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.447
   Zhang L, 2006, MED HYPOTHESES, V66, P1205, DOI 10.1016/j.mehy.2005.11.041
   Zhang PX, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0084 5
   Zhang X, 2020, CELL DEATH DIFFER, V27, P540, DOI 10.1038/s41418 019 0372 z
   Zhang YL, 2018, NAT CELL BIOL, V20, P1181, DOI 10.1038/s41556 018 0178 0
   Zhen YF, 2014, J CELL PHYSIOL, V229, P1475, DOI 10.1002/jcp.24589
   Zheng LZ, 2018, J ORTHOP TRANSL, V13, P13, DOI 10.1016/j.jot.2018.01.003
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 43
TC 2
Z9 3
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD DEC
PY 2023
VL 27
IS 23
BP 3911
EP 3927
DI 10.1111/jcmm.17974
EA SEP 2023
PG 17
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GJ8D5
UT WOS:001071557400001
PM 37749949
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Selvarajah, GT
   Kirpensteijn, J
   van Wolferen, ME
   Rao, NAS
   Fieten, H
   Mol, JA
AF Selvarajah, Gayathri T.
   Kirpensteijn, Jolle
   van Wolferen, Monique E.
   Rao, Nagesha A. S.
   Fieten, Hille
   Mol, Jan A.
TI Gene expression profiling of canine osteosarcoma reveals genes
   associated with short and long survival times
SO MOLECULAR CANCER
LA English
DT Article
ID APPENDICULAR OSTEOSARCOMA; OSTEOGENIC SARCOMA; RESISTANCE; CANCER; DOGS;
   CHEMOTHERAPY; TUMORS; P53; IDENTIFICATION; DOXORUBICIN
AB Background: Gene expression profiling of spontaneous tumors in the dog offers a unique translational opportunity to identify prognostic biomarkers and signaling pathways that are common to both canine and human. Osteosarcoma (OS) accounts for approximately 80% of all malignant bone tumors in the dog. Canine OS are highly comparable with their human counterpart with respect to histology, high metastatic rate and poor long term survival. This study investigates the prognostic gene profile among thirty two primary canine OS using canine specific cDNA microarrays representing 20,313 genes to identify genes and cellular signaling pathways associated with survival. This, the first report of its kind in dogs with OS, also demonstrates the advantages of cross species comparison with human OS.
   Results: The 32 tumors were classified into two prognostic groups based on survival time (ST). They were defined as short survivors (dogs with poor prognosis: surviving fewer than 6 months) and long survivors (dogs with better prognosis: surviving 6 months or longer). Fifty one transcripts were found to be differentially expressed, with common upregulation of these genes in the short survivors. The overexpressed genes in short survivors are associated with possible roles in proliferation, drug resistance or metastasis. Several deregulated pathways identified in the present study, including Wnt signaling, Integrin signaling and Chemokine/cytokine signaling are comparable to the pathway analysis conducted on human OS gene profiles, emphasizing the value of the dog as an excellent model for humans.
   Conclusion: A molecular based method for discrimination of outcome for short and long survivors is useful for future prognostic stratification at initial diagnosis, where genes and pathways associated with cell cycle/proliferation, drug resistance and metastasis could be potential targets for diagnosis and therapy. The similarities between human and canine OS makes the dog a suitable pre clinical model for future 'novel' therapeutic approaches where the current research has provided new insights on prognostic genes, molecular pathways and mechanisms involved in OS pathogenesis and disease progression.
C1 [Selvarajah, Gayathri T.; Kirpensteijn, Jolle; van Wolferen, Monique E.; Rao, Nagesha A. S.; Fieten, Hille; Mol, Jan A.] Univ Utrecht, Dept Clin Sci Compan Anim, NL 3584 CM Utrecht, Netherlands.
   [Selvarajah, Gayathri T.] Univ Putra Malaysia, Dept Vet Clin Studies, Serdang 43400, Malaysia.
C3 Utrecht University; Universiti Putra Malaysia
RP Selvarajah, GT (通讯作者)，Univ Utrecht, Dept Clin Sci Compan Anim, Yalelaan 108, NL 3584 CM Utrecht, Netherlands.
EM G.T.Selvarajah@uu.nl; J.Kirpensteijn@uu.nl; M.E.vanWolferen@uu.nl;
   nagesha_nrao@yahoo.com; H.Fieten@uu.nl; J.A.Mol@uu.nl
RI Kirpensteijn, Jolle/K 1773 2019
OI Mol, Jan/0000 0002 0843 8088; Selvarajah, Gayathri
   Thevi/0000 0001 7240 9882
FU Ministry of Higher Education (MOHE) of (Malaysia); University Putra
   Malaysia
FX The authors are grateful to the Ministry of Higher Education (MOHE) of
   (Malaysia) and University Putra Malaysia for providing financial support
   for the PhD candidate working on this project. The statistical advice by
   Dr. Erik Teske, graphical assistance by I. C. M. Lavrijsen and QPCR
   assistance by Frank Riemers is greatly appreciated. We thank Ms Linda
   McPhee http://www.write research.com for her contribution in preparation
   of the manuscript.
CR Bacon NJ, 2008, JAVMA J AM VET MED A, V232, P1504, DOI 10.2460/javma.232.10.1504
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   BRODEY RS, 1976, J AM VET MED ASSOC, V168, P1032
   BRODEY RS, 1979, YALE J BIOL MED, V52, P345
   BRODEY RS, 1969, CLIN ORTHOP RELAT R, P54
   Chen K, 2008, PEDIATR BLOOD CANCER, V51, P349, DOI 10.1002/pbc.21595
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Dickerson ME, 2001, J VET INTERN MED, V15, P120, DOI 10.1892/0891 6640(2001)015<0120:RAOASO>2.3.CO;2
   Dundas SR, 2005, J PATHOL, V205, P74, DOI 10.1002/path.1672
   Fan TM, 2008, J VET INTERN MED, V22, P602, DOI 10.1111/j.1939 1676.2008.0089.x
   Fang H, 2007, OMICS, V11, P14, DOI 10.1089/omi.2006.0002
   Garge NR, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471 2105 6 S2 S10
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008 5472.CAN 03 1952
   Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677
   Imamura T, 2001, J BIOL CHEM, V276, P7534, DOI 10.1074/jbc.M008143200
   Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462
   Johansson K, 2007, CARCINOGENESIS, V28, P465, DOI 10.1093/carcin/bgl148
   Kaul SC, 2005, J BIOL CHEM, V280, P39373, DOI 10.1074/jbc.M500022200
   Kaul Z, 2006, ANN NY ACAD SCI, V1067, P469, DOI 10.1196/annals.1354.067
   Khanna C, 2001, CANCER RES, V61, P3750
   Khanna C, 2006, NAT BIOTECHNOL, V24, P1065, DOI 10.1038/nbt0906 1065b
   Kirpensteijn J, 2002, MOL CELL ENDOCRINOL, V197, P179, DOI 10.1016/S0303 7207(02)00269 1
   Kirpensteijn J, 2002, ANTICANCER RES, V22, P2765
   Kirpensteijn J, 2002, VET PATHOL, V39, P240, DOI 10.1354/vp.39 2 240
   Kirpensteijn J, 2008, VET SURG, V37, P454, DOI 10.1111/j.1532 950X.2008.00407.x
   KRAEGEL SA, 1991, J AM VET MED ASSOC, V199, P1057
   Krynetskaia N, 2008, MOL PHARMACOL, V73, P260, DOI 10.1124/mol.107.041764
   LARUE SM, 1989, CLIN VET ONCOLOGY, P234
   Leek JT, 2006, BIOINFORMATICS, V22, P507, DOI 10.1093/bioinformatics/btk005
   Lindblad Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338
   LING GV, 1974, J AM VET MED ASSOC, V165, P55
   LIU SK, 1977, J SMALL ANIM PRACT, V18, P313, DOI 10.1111/j.1748 5827.1977.tb05890.x
   Loukopoulos P, 2007, J COMP PATHOL, V136, P65, DOI 10.1016/j.jcpa.2006.11.005
   MACEWEN EG, 1990, CANCER METAST REV, V9, P125, DOI 10.1007/BF00046339
   MADEWELL BR, 1978, EUR J CANCER, V14, P287, DOI 10.1016/0014 2964(78)90192 5
   Man TK, 2005, CANCER RES, V65, P8142, DOI 10.1158/0008 5472.CAN 05 0985
   Maraqa L, 2006, SURG ONCOL, V15, P205, DOI 10.1016/j.suronc.2006.12.003
   MCCLEESE JK, 2009, INT J CANC IN PRESS
   Mendoza S, 1998, ANTICANCER RES, V18, P4449
   Meyer B, 2004, ANTICANCER RES, V24, P707
   Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008 5472.CAN 04 2463
   Morey JS, 2006, BIOL PROCED ONLINE, V8, P175, DOI 10.1251/bpo126
   Perissinotto E, 2005, CLIN CANCER RES, V11, P490
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   PIRKEYEHRHART N, 1995, J AM ANIM HOSP ASSOC, V31, P65, DOI 10.5326/15473317 31 1 65
   Ptitsyn AA, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471 2105 9 S9 S8
   Rajkumar T, 2008, ANTI CANCER DRUG, V19, P257, DOI 10.1097/CAD.0b013e3282f435b6
   Rao NAS, 2008, ANIM GENET, V39, P333, DOI 10.1111/j.1365 2052.2008.01733.x
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Schaefer KL, 2008, EUR J CANCER, V44, P699, DOI 10.1016/j.ejca.2008.01.020
   Sennoune SR, 2004, AM J PHYSIOL CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003
   SHAPIRO W, 1988, J AM VET MED ASSOC, V192, P507
   Shoieb AM, 1998, IN VIVO, V12, P455
   Slonim DK, 2002, NAT GENET, V32, P502, DOI 10.1038/ng1033
   SPODNICK GJ, 1992, J AM VET MED ASSOC, V200, P995
   Srivastava A, 2006, CLIN CANCER RES, V12, P4237, DOI 10.1158/1078 0432.CCR 05 2307
   TJALMA RA, 1966, JNCI J NATL CANCER I, V36, P1137
   Trieb K, 2000, IMMUNOBIOLOGY, V201, P368, DOI 10.1016/S0171 2985(00)80091 1
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Uozaki H, 2000, PATHOL RES PRACT, V196, P665, DOI 10.1016/S0344 0338(00)80118 1
   Uozaki H, 1997, CANCER AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097 0142(19970615)79:12<2336::AID CNCR7>3.0.CO;2 J
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Walters DK, 2008, ANTICANCER RES, V28, P673
   Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148
   WITHROW SJ, 1991, CLIN ORTHOP RELAT R, P159
   Wolf M, 2000, CANCER GENET CYTOGEN, V123, P128, DOI 10.1016/S0165 4608(00)00319 8
   Yan TQ, 2007, CANCER, V109, P1870, DOI 10.1002/cncr.22595
   Yang R, 2007, INT J CANCER, V121, P943, DOI 10.1002/ijc.22749
   Zhang J, 2009, MOL CANCER RES, V7, P67, DOI 10.1158/1541 7786.MCR 08 0347
NR 69
TC 69
Z9 87
U1 1
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476 4598
J9 MOL CANCER
JI Mol. Cancer
PD SEP 7
PY 2009
VL 8
AR 72
DI 10.1186/1476 4598 8 72
PG 18
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 496EE
UT WOS:000269951300001
PM 19735553
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Britton, RA
   Irwin, R
   Quach, D
   Schaefer, L
   Zhang, J
   Lee, T
   Parameswaran, N
   McCabe, LR
AF Britton, Robert A.
   Irwin, Regina
   Quach, Darin
   Schaefer, Laura
   Zhang, Jing
   Lee, Taehyung
   Parameswaran, Narayanan
   McCabe, Laura R.
TI Probiotic L. reuteri Treatment Prevents Bone Loss in a
   Menopausal Ovariectomized Mouse Model
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID INULIN TYPE FRUCTANS; INTESTINAL MICROBIOTA; LACTOBACILLUS REUTERI;
   OSTEOCLAST FORMATION; T CELLS; BACTERIAL; DIFFERENTIATION; INFLAMMATION;
   ABSORPTION; OSTEOBLAST
AB Estrogen deficiency is a major risk factor for osteoporosis that is associated with bone inflammation and resorption. Half of women over the age of 50 will experience an osteoporosis related fracture in their lifetime, thus novel therapies are needed to combat post menopausal bone loss. Recent studies suggest an important role for gut bone signaling pathways and the microbiota in regulating bone health. Given that the bacterium Lactobacillus reuteri ATCC PTA 6475 (L. reuteri) secretes beneficial immunomodulatory factors, we examined if this candidate probiotic could reduce bone loss associated with estrogen deficiency in an ovariectomized (Ovx) mouse menopausal model. Strikingly, L. reuteri treatment significantly protected Ovx mice from bone loss. Osteoclast bone resorption markers and activators (Trap5 and RANKL) as well as osteoclastogenesis are significantly decreased in L. reuteri treated mice. Consistent with this, L. reuteri suppressed Ovx induced increases in bone marrow CD4+ T lymphocytes (which promote osteoclastogenesis) and directly suppressed osteoclastogenesis in vitro. We also identified that L. reuteri treatment modifies microbial communities in the Ovx mouse gut. Together, our studies demonstrate that L. reuteri treatment suppresses bone resorption and loss associated with estrogen deficiency. Thus, L. reuteri treatment may be a straightforward and cost effective approach to reduce post menopausal bone loss. (C) 2014 Wiley Periodicals, Inc.
C1 [Britton, Robert A.; Quach, Darin; Schaefer, Laura] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.
   [Irwin, Regina; Zhang, Jing; Lee, Taehyung; Parameswaran, Narayanan; McCabe, Laura R.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.
   [McCabe, Laura R.] Michigan State Univ, Dept Radiol, E Lansing, MI 48824 USA.
   [McCabe, Laura R.] Michigan State Univ, Biomed Imaging Res Ctr, E Lansing, MI 48824 USA.
C3 Michigan State University; Michigan State University; Michigan State
   University; Michigan State University
RP Britton, RA (通讯作者)，Michigan State Univ, Dept Microbiol & Mol Genet, 6175 Biomed Phys Sci Bldg, E Lansing, MI 48824 USA.
EM rbritton@msu.edu; mccabel@msu.edu
RI ; McCabe, Laura/AGS 5131 2022; Zhang, Jing/E 4844 2013; Parameswaran,
   Narayanan/V 1969 2019
OI Quach, Darin/0000 0002 3244 5376; Parameswaran,
   Narayanan/0000 0002 8894 5564; McCabe, Laura/0000 0001 5407 162X; Zhang,
   Jing/0000 0003 0391 7298; Schaefer, Laura/0000 0003 1628 2893; 
FU NIH NCAAM [AT005472, 1RO1AT007695]; MSU; Biogia
FX Contract grant sponsor: NIH NCAAM; Contract grant number: AT005472.
   Contract grant sponsor: MSU and Biogia. Contract grant sponsor: NIH
   NCAAM; Contract grant number: 1RO1AT007695.
CR Abrams SA, 2005, AM J CLIN NUTR, V82, P471
   Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469
   Bäckhed F, 2012, CELL HOST MICROBE, V12, P611, DOI 10.1016/j.chom.2012.10.012
   Barlow DH, 2010, HUM REPROD UPDATE, V16, P761, DOI 10.1093/humupd/dmq008
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   CHAO A, 1984, SCAND J STAT, V11, P265
   CHAO A, 1992, J AM STAT ASSOC, V87, P210, DOI 10.2307/2290471
   Coxam V, 2007, J NUTR, V137, p2527S, DOI 10.1093/jn/137.11.2527S
   Fukata M, 2008, J IMMUNOL, V180, P1886, DOI 10.4049/jimmunol.180.3.1886
   Harris L, 2009, AM J PHYSIOL GASTR L, V296, pG1020, DOI 10.1152/ajpgi.90696.2008
   Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200
   Jilka RL, 1998, J CLIN INVEST, V101, P1942, DOI 10.1172/JCI1039
   Jolliff JS, 2012, J ANIM SCI, V90, P3012, DOI 10.2527/jas.2011 4424
   Kimoto Nira H, 2007, BRIT J NUTR, V98, P1178, DOI 10.1017/S0007114507787469
   Kühbacher T, 2006, GUT, V55, P833, DOI 10.1136/gut.2005.078303
   Lee T, 2013, AM J PATHOL, V182, P1114, DOI 10.1016/j.ajpath.2012.12.025
   Lemon KP, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004183
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mccabe LR, 2013, J CELL PHYSIOL, V228, P1793, DOI 10.1002/jcp.24340
   McNamara LM, 2010, J R SOC INTERFACE, V7, P353, DOI 10.1098/rsif.2009.0282
   Motyl K., 2009, BIOL PROCED ONLINE
   Mutus R, 2006, POULTRY SCI, V85, P1621, DOI 10.1093/ps/85.9.1621
   Oakley BB, 2008, APPL ENVIRON MICROB, V74, P4898, DOI 10.1128/AEM.02884 07
   Pacifici R, 2012, J BONE MINER RES, V27, P231, DOI 10.1002/jbmr.1500
   Patial S, 2011, J CELL PHYSIOL, V226, P1323, DOI 10.1002/jcp.22460
   Reuter G, 2001, Curr Issues Intest Microbiol, V2, P43
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Roberfroid MB, 2002, J NUTR, V132, P3599, DOI 10.1093/jn/132.12.3599
   Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059
   Schaefer L, 2010, MICROBIOL SGM, V156, P1589, DOI 10.1099/mic.0.035642 0
   Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541 09
   Scholz Ahrens KE, 2007, J NUTR, V137, p2513S, DOI 10.1093/jn/137.11.2513S
   Shornikova AV, 1997, J PEDIATR GASTR NUTR, V24, P399, DOI 10.1097/00005176 199704000 00008
   Sjögren K, 2012, J BONE MINER RES, V27, P1357, DOI 10.1002/jbmr.1588
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Thomas CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031951
   Thomas DW, 2010, PEDIATRICS, V126, P1217, DOI 10.1542/peds.2010 2548
   Tubelius Py, 2005, Environ Health, V4, P25, DOI 10.1186/1476 069X 4 25
   Vaarala O, 2008, DIABETES, V57, P2555, DOI 10.2337/db08 0331
   Valeur N, 2004, APPL ENVIRON MICROB, V70, P1176, DOI 10.1128/AEM.70.2.1176 1181.2004
   Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062 07
   Weaver CM, 2011, J AGR FOOD CHEM, V59, P6501, DOI 10.1021/jf2009777
   Weizman Z, 2005, PEDIATRICS, V115, P5, DOI 10.1542/peds.2004 1815
   Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336
   Whelan K, 2013, CURR OPIN GASTROEN, V29, P184, DOI 10.1097/MOG.0b013e32835d7bba
   Yan F, 2011, CURR OPIN GASTROEN, V27, P496, DOI 10.1097/MOG.0b013e32834baa4d
   Yang L, 2012, J POLYM RES, V19, P1
   Yoo Jennifer, 2007, Proc Am Thorac Soc, V4, P277, DOI 10.1513/pats.200702 033AW
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
NR 50
TC 387
Z9 450
U1 3
U2 120
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD NOV
PY 2014
VL 229
IS 11
BP 1822
EP 1830
DI 10.1002/jcp.24636
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA AO8ZX
UT WOS:000341646000027
PM 24677054
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Shen, CY
   Deng, MX
   Wang, XB
   Li, XY
   Chen, XB
   Gao, Z
   Li, CC
   Liu, YC
AF Shen, Chongyang
   Deng, Mingxing
   Wang, Xiaobao
   Li, Xiaoyu
   Chen, Xiongbin
   Gao, Zhi
   Li, Chuncai
   Liu, Yincong
TI Zuogui Wan modulates macrophage polarization and promotes osteogenic
   differentiation through regulation of CD51 positive bone marrow
   mesenchymal stem cells
SO SCIENTIFIC REPORTS
LA English
DT Article
DE Zuogui Wan (ZGW); Postmenopausal osteoporosis (PMOP); Bone marrow
   mesenchymal stem cells (BMSCs); Macrophage polarization; CD51
ID GENES; OSTEOPOROSIS; ESTROGEN
AB Background Zuogui Wan (ZGW) is a traditional herbal formula used to treat chronic kidney and bone diseases. Previous research has shown that ZGW slows down the aging process of bone marrow mesenchymal stem cells (BMSCs) and improves bone metabolism. However, its role in treating postmenopausal osteoporosis (PMOP) has not yet been fully investigated. Therefore, we investigated the therapeutic effects of ZGW and its potential mechanisms in an ovariectomy (OVX) induced osteoporosis rat model. Results We observed significant improvements in bone loss and the osteoporotic phenotype in OVX rats treated with ZGW. These findings were confirmed with micro computed tomography (micro CT) and histomorphological analysis. We also discovered that ZGW reversed the macrophage imbalance, which in turn inhibited osteoclast differentiation and bone resorption. Furthermore, RNA Seq results revealed the active expression of CD51 in BMSCs before and after ZGW therapy, which is associated with macrophage polarization and osteoblastic differentiation. The results also showed that ZGW decreased CD51 + BMSCs levels, which is closely related to the inhibition of osteoblast differentiation and promotion of osteoclast resorption. Conclusions Our study demonstrated that ZGW may improve postmenopausal osteoporosis by restoring macrophage polarization and down regulating CD51 + BMSCs. In addition, ZGW promoted osteoblast formation and inhibited osteoclast resorption.
C1 [Shen, Chongyang; Deng, Mingxing; Li, Xiaoyu; Chen, Xiongbin; Liu, Yincong] Chengdu Univ Tradit Chinese Med, Basic Med Sch, Chengdu, Peoples R China.
   [Wang, Xiaobao; Li, Chuncai] Chengdu Univ Tradit Chinese Med, Sch Clin Med, Chengdu, Peoples R China.
   [Gao, Zhi] Sichuan Orthoped Hosp, Chengdu, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine
RP Liu, YC (通讯作者)，Chengdu Univ Tradit Chinese Med, Basic Med Sch, Chengdu, Peoples R China.; Li, CC (通讯作者)，Chengdu Univ Tradit Chinese Med, Sch Clin Med, Chengdu, Peoples R China.
EM lccymx@126.com; 18155579730@163.com
RI Shen, Chongyang/W 8463 2019
FU National Natural Science Foundation of China
FX We would like to thank LetPub for its linguistic assistance during the
   preparation of this manuscript.
CR Bolego C, 2013, ARTERIOSCL THROM VAS, V33, P1127, DOI 10.1161/ATVBAHA.113.301328
   Chen GM, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000013936
   Chen PP, 2019, MOL CELL ENDOCRINOL, V493, DOI 10.1016/j.mce.2019.110449
   Choi JY, 2020, EXP MOL MED, V52, P1165, DOI 10.1038/s12276 020 0472 3
   Columbo M, 2001, J ALLERGY CLIN IMMUN, V107, P554, DOI 10.1067/mai.2001.113238
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Härkönen PL, 2006, ANN NY ACAD SCI, V1089, P218, DOI 10.1196/annals.1386.045
   Kadomoto S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010144
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kim HK, 2009, LIFE SCI, V84, P290, DOI 10.1016/j.lfs.2008.12.017
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Li JY, 2021, PHYTOTHER RES, V35, P1754, DOI 10.1002/ptr.6908
   Li SY, 2012, EUR J PHARMACOL, V674, P65, DOI 10.1016/j.ejphar.2011.06.033
   Liu H, 2021, NEUROIMMUNOMODULAT, DOI 10.1159/000519010
   Liu JL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.733808
   Lv FX, 2024, J ETHNOPHARMACOL, V318, DOI 10.1016/j.jep.2023.116884
   Maggiani F, 2011, J CLIN PATHOL, V64, P701, DOI 10.1136/jcp.2011.090852
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Pierce JL, 2019, BONE, V118, P2, DOI 10.1016/j.bone.2018.05.019
   Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252
   Qiu JW, 2023, INT J ANAL CHEM, V2023, DOI 10.1155/2023/1473878
   Qiu YY, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0534 5
   Schacht E., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P174
   Shi T, 2023, MEDICINA LITHUANIA, V59, DOI 10.3390/medicina59081414
   Taylor R, 2011, J PATHOL, V225, P151, DOI 10.1002/path.2937
   Taylor RM, 2012, LAB INVEST, V92, P600, DOI 10.1038/labinvest.2012.5
   Tianqi Wang, 2023, J Tradit Chin Med, V43, P474, DOI 10.19852/j.cnki.jtcm.20220507.001
   Wei Q, 2024, EUR J PHARMACOL, V977, DOI 10.1016/j.ejphar.2024.176666
   Xiao JRMT, 2023, PHARMACEUTICALS BASE, V16, DOI 10.3390/ph16101438
   Xie ZY, 2022, EXP MOL MED, V54, P483, DOI 10.1038/s12276 022 00749 5
   Yan CP, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.883228
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   Yin H, 2018, BIOMED PHARMACOTHER, V97, P995, DOI 10.1016/j.biopha.2017.11.029
   Zhao JL, 2021, COMPLEMENT THER CLIN, V44, DOI 10.1016/j.ctcp.2021.101419
   Zhu BB, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.991976
   Zhu HP, 2018, BMC ENDOCR DISORD, V18, DOI 10.1186/s12902 018 0230 x
   Zhu XN, 2022, BMC WOMENS HEALTH, V22, DOI 10.1186/s12905 022 02034 z
NR 37
TC 1
Z9 1
U1 4
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD OCT 30
PY 2024
VL 14
IS 1
AR 26130
DI 10.1038/s41598 024 77590 5
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA K8F7T
UT WOS:001346203600082
PM 39478130
OA gold
DA 2025 08 17
ER

PT J
AU Zhang, WJ
   Xu, JJ
   Qiu, JH
   Xing, CC
   Li, XM
   Leng, B
   Su, Y
   Lin, JM
   Lin, JF
   Mei, XQ
   Huang, YQ
   Pan, YT
   Xue, Y
AF Zhang, Wenjuan
   Xu, Jingjin
   Qiu, Juhui
   Xing, Cencan
   Li, Xiumin
   Leng, Bo
   Su, Yi
   Lin, Jinmei
   Lin, Jiaofen
   Mei, Xuqiao
   Huang, Yiqun
   Pan, Yutian
   Xue, Yu
TI Novel and rapid osteoporosis model established in zebrafish using high
   iron stress
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Zebrafish; High iron; Osteoporosis; Bone calcification; Cartilage
   development
ID COLLAGEN EXPRESSION; BONE; INHIBITION; CARTILAGE; OVERLOAD
AB Osteoporosis is a global public health concern and, it can result from numerous pathogenic mechanisms, many of which are closely related with age, nutritional disorders, endocrine imbalance, or adverse drug side effects presented by glucocorticoids, heparin, and anti epileptics. Given its wide range etiologies, it is crucial to establish an animal model of osteoporosis for use in screening potential drugs quickly and effectively. Previous research has reported that an accumulation of elevated iron in the body is an independent risk factor for osteoporosis. As such, we sought to use both zebrafish larvae and adults to model an osteoporosis phenotype using high iron stress (FAC, ferric ammonium citrate). Skeletal staining results suggested that iron overload caused a significant decrease in bone calcification as well as severe developmental cartilage defects. In addition, osteoblast and cartilage specific mRNA expression levels were downregulated after exposure to a high iron environment. Most importantly, we demonstrated in both larval and adult fish that high iron induced osteogenic defects were significantly rescued using alendronate (AL), a drug known to be effective against to human osteoporosis. Even more, the repair effect of AL was achieved by facilitating osteoblast differentiation and targeting Bmp signaling. Taken together, our findings propose an rapid and effective osteoporosis model, which could be used widely for future osteoporosis drug screening. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Zhang, Wenjuan; Xu, Jingjin; Li, Xiumin; Leng, Bo; Su, Yi; Lin, Jinmei; Lin, Jiaofen; Pan, Yutian; Xue, Yu] Minnan Normal Univ, Engn Technol Ctr Mushroom Ind, Zhangzhou 363000, Fujian, Peoples R China.
   [Qiu, Juhui; Xing, Cencan; Xue, Yu] State Key Lab Membrane Biol, Beijing 100101, Peoples R China.
   [Xing, Cencan] Chinese Acad Agr Sci, Inst Agroprod Proc Sci & Technol, Beijing 100193, Peoples R China.
   [Mei, Xuqiao; Huang, Yiqun] Zhangzhou Municipal Hosp, Zhangzhou 363000, Fujian, Peoples R China.
C3 MinNan Normal University; Chinese Academy of Agricultural Sciences
RP Pan, YT; Xue, Y (通讯作者)，Minnan Normal Univ, Engn Technol Ctr Mushroom Ind, Zhangzhou 363000, Fujian, Peoples R China.
EM pytmnnu@163.com; xueyu0614@163.com
OI Pan, Yu Tian/0000 0001 9842 9320; Li, Xiumin/0000 0002 5296 2960
FU State Key Laboratory of Membrane Biology [2017kf10]; National Natural
   Science Foundation of China [31501174]; Fujian provincial university for
   outstanding youth scientific research personnel training program;
   Natural Scinece Foundation of Fujian Province [2015J05070, 2015J05071,
   2016J05195, 2016J01651]; Minnan Normal University [MJ14007, MJ14003];
   project of the education Department in Fujian Province [JA52969]; Key
   Science and Technology Project of Fujian Province [2013Y0081]
FX We are grateful to the members of Pan Laboratory from MNNU and Meng
   Laboratory from THU for discussion and technical assistance, This study
   was supported by State Key Laboratory of Membrane Biology(grant number
   2017kf10). This work was financially supported by grants from the
   National Natural Science Foundation of China (grant number 31501174),
   and Fujian provincial university for outstanding youth scientific
   research personnel training program of 2017, and from Natural Scinece
   Foundation of Fujian Province(grant number 2015J05070, 2015J05071,
   2016J05195 and 2016J01651), and from Outstanding Youth Research
   Personnel Training Program of Minnan Normal University (grant number
   MJ14007 and MJ14003), and from project of the education Department in
   Fujian Province(grant number JA52969), and Key Science and Technology
   Project of Fujian Province (grant number 2013Y0081).
CR BARLET JP, 1994, REPROD NUTR DEV, V34, P221, DOI 10.1051/rnd:19940305
   Chen B, 2014, CALCIFIED TISSUE INT, V94, P353, DOI 10.1007/s00223 013 9817 4
   Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596
   Du SJ, 2001, DEV BIOL, V238, P239, DOI 10.1006/dbio.2001.0390
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Gavaia PJ, 2006, GENE EXPR PATTERNS, V6, P637, DOI 10.1016/j.modgep.2005.11.010
   Javidan Y, 2004, METHOD CELL BIOL, V76, P415
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Kato M, 2007, P NATL ACAD SCI USA, V104, P3432, DOI 10.1073/pnas.0611192104
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302
   M. Publications World Health Organization (Group), 1994, WHO TECHN REP SER
   [毛文晴 Mao Wenqing], 2011, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V17, P937
   Nieto N, 2000, J BIOL CHEM, V275, P20136, DOI 10.1074/jbc.M001422200
   Pasqualetti S, 2015, INT J EXP PATHOL, V96, P11, DOI 10.1111/iep.12106
   Schartl M, 2014, DIS MODEL MECH, V7, P181, DOI 10.1242/dmm.012245
   Seeman E, 2003, J APPL PHYSIOL, V95, P2142, DOI 10.1152/japplphysiol.00564.2003
   Singh SP, 2012, DEV CELL, V22, P879, DOI 10.1016/j.devcel.2012.03.006
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   Voskaridou E, 2004, BRIT J HAEMATOL, V127, P127, DOI 10.1111/j.1365 2141.2004.05143.x
   Walker MB, 2007, BIOTECH HISTOCHEM, V82, P23, DOI 10.1080/10520290701333558
   Woolf AD, 2006, CLIN RHEUMATOL, V25, P613, DOI 10.1007/s10067 006 0265 7
   Zhu XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044405
NR 22
TC 38
Z9 47
U1 0
U2 43
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 5
PY 2018
VL 496
IS 2
BP 654
EP 660
DI 10.1016/j.bbrc.2017.12.172
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FV1IA
UT WOS:000424313500062
PM 29305866
DA 2025 08 17
ER

PT J
AU Bishop, RT
   Marino, S
   Carrasco, G
   Li, BY
   Allen, RJ
   Sparatore, A
   Ottewell, PD
   Mollat, P
   Sims, AH
   Capulli, M
   Wang, N
   Idris, AI
AF Bishop, Ryan T.
   Marino, Silvia
   Carrasco, Giovana
   Li, Boya
   Allen, Richard J.
   Sparatore, Anna
   Ottewell, Penelope D.
   Mollat, Patrick
   Sims, Andrew H.
   Capulli, Mattia
   Wang, Ning
   Idris, Aymen I.
TI Combined administration of a small molecule inhibitor of TRAF6 and
   Docetaxel reduces breast cancer skeletal metastasis and osteolysis
SO CANCER LETTERS
LA English
DT Article
DE 6877002; NF kappa B; RANKL; CD40L; Combination therapy
ID NF KAPPA B; NECROSIS FACTOR RECEPTOR; BONE METASTASIS; OSTEOCLAST
   DIFFERENTIATION; TAMOXIFEN RESISTANCE; SIGNAL TRANSDUCTION;
   UP REGULATION; T CELLS; RANK; EXPRESSION
AB Tumour necrosis factor receptor associated factor 6 (TRAF6) has been implicated in breast cancer and osteoclastic bone destruction. Here, we report that 6877002, a verified small molecule inhibitor of TRAF6, reduced metastasis, osteolysis and osteoclastogenesis in models of osteotropic human and mouse breast cancer. First, we observed that TRAF6 is highly expressed in osteotropic breast cancer cells and its level of expression was higher in patients with bone metastasis. Pre exposure of osteoclasts and osteoblasts to non cytotoxic concentrations of 6877002 inhibited cytokine induced NF kappa B activation and osteoclastogenesis, and reduced the ability of osteotropic human MDA MB 231 and mouse 4T1 breast cancer cells to support bone cell activity. 6877002 inhibited human MDA MB 231 induced osteolysis in the mouse calvaria organ system, and reduced soft tissue and bone metastases in immuno competent mice following intra cardiac injection of mouse 4T1 Luc2 cells. Of clinical relevance, combined administration of 6877002 with Docetaxel reduced metastasis and inhibited osteolytic bone damage in mice bearing 4T1 Luc2 cells. Thus, TRAF6 inhibitors such as 6877002   alone or in combination with conventional chemotherapy   show promise for the treatment of metastatic breast cancer.
C1 [Bishop, Ryan T.; Marino, Silvia; Carrasco, Giovana; Li, Boya; Allen, Richard J.; Ottewell, Penelope D.; Wang, Ning; Idris, Aymen I.] Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
   [Bishop, Ryan T.] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, 12902 Magnolia Dr, Tampa, FL 33612 USA.
   [Marino, Silvia; Idris, Aymen I.] Univ Edinburgh, Western Gen Hosp, Edinburgh Canc Res Ctr, Bone & Canc Grp, Crewe Rd, Edinburgh EH4 2XR, Midlothian, Scotland.
   [Marino, Silvia] Indiana Univ, Div Hematol Oncol, IU Sch Med, Indianapolis, IN 46204 USA.
   [Sparatore, Anna] Univ Milan, Dept Pharmaceut Sci, Milan, Italy.
   [Mollat, Patrick] Galapagos SASU, 102 Ave Gaston Roussel, F 93230 Romainville, France.
   [Sims, Andrew H.] Univ Edinburgh, Western Gen Hosp, MRC Inst Genet & Mol Med, Appl Bioinformat Canc, Edinburgh, Midlothian, Scotland.
   [Capulli, Mattia] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy.
C3 H Lee Moffitt Cancer Center & Research Institute; University of
   Edinburgh; Indiana University System; Indiana University Bloomington;
   Indiana University Indianapolis; University of Milan; Galapagos NV;
   University of Edinburgh; University of L'Aquila
RP Idris, AI (通讯作者)，Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM aymen.idris@sheffield.ac.uk
RI ; Sparatore, Anna/J 8634 2015; Idris, Aymen/AAX 1138 2020; Sims,
   Andrew/E 4819 2012; Wang, Ning/HKO 8446 2023
OI Allen, Richard/0000 0003 2448 7987; Sparatore, Anna/0000 0003 2135 2649;
   Bishop, Ryan/0000 0002 1332 4798; Carrasco Gonzalez, Denise
   Giovana/0000 0002 0382 4334; WANG, NING/0000 0002 2663 7515; Marino,
   Silvia/0000 0003 3695 0908
FU Cancer Research UK Development Fund (University of Edinburgh); Breast
   Cancer Now (University of Sheffield)
FX These studies were supported in part by Cancer Research UK Development
   Fund (University of Edinburgh) and funding from Breast Cancer Now
   (University of Sheffield).
CR Aarts SABM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974 017 0875 9
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Bilir C, 2015, ONCOL LETT, V9, P2819, DOI 10.3892/ol.2015.3094
   Bishop RT, 2019, CANCER LETT, V450, P76, DOI 10.1016/j.canlet.2019.02.032
   Blake ML, 2014, CLIN EXP METASTAS, V31, P233, DOI 10.1007/s10585 013 9624 3
   Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788
   Bussard KM, 2010, J CELL BIOCHEM, V111, P1138, DOI 10.1002/jcb.22799
   Campbell Graeme M, 2014, Bonekey Rep, V3, P564, DOI 10.1038/bonekey.2014.59
   Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934
   Capulli M, 2012, J BONE MINER RES, V27, P2387, DOI 10.1002/jbmr.1686
   Chung JY, 2002, J CELL SCI, V115, P679
   Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   Das Roy L, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2345
   Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092 8674(00)00126 4
   Eyre R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12807 0
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Goldstein RH, 2010, CANCER RES, V70, P10044, DOI 10.1158/0008 5472.CAN 10 1254
   Guédat P, 2007, BMC BIOCHEM, V8, DOI 10.1186/1471 2091 8 S1 S14
   Guo JP, 2010, J BIOL CHEM, V285, P3676, DOI 10.1074/jbc.M109.078212
   Hemingway F, 2011, BONE, V48, P938, DOI 10.1016/j.bone.2010.12.023
   Holen I, 2016, ONCOTARGET, V7, P75571, DOI 10.18632/oncotarget.12289
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Idris AI, 2009, EUR J PHARMACOL, V602, P215, DOI 10.1016/j.ejphar.2008.11.023
   Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kadono Y, 2005, EMBO REP, V6, P171, DOI 10.1038/sj.embor.7400345
   Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797
   Kim NS, 2006, MOL CELL BIOL, V26, P1002, DOI 10.1128/MCB.26.3.1002 1013.2006
   Kishida S, 2005, GENES CELLS, V10, P447, DOI 10.1111/j.1365 2443.2005.00852.x
   Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Lerebours F, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 41
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   Li Q, 2006, J BIOL CHEM, V281, P37566, DOI 10.1074/jbc.M603643200
   Li Z, 2012, CURR MOL MED, V12, P967, DOI 10.2174/156652412802480871
   Lin YY, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju012
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Manders K, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 179
   Marino S, 2019, METHODS MOL BIOL, V1914, P71, DOI 10.1007/978 1 4939 8997 3_5
   Marino S, 2019, METHODS MOL BIOL, V1914, P131, DOI 10.1007/978 1 4939 8997 3_7
   Marino Silvia, 2018, Oncotarget, V9, P16134, DOI 10.18632/oncotarget.24743
   Marino S, 2017, CANCER LETT, V410, P180, DOI 10.1016/j.canlet.2017.09.034
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakai Y, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0036 5
   Nutter F, 2014, ENDOCR RELAT CANCER, V21, P327, DOI 10.1530/ERC 13 0158
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Park HH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01999
   Peramuhendige P, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18327 5
   Pullen SS, 1999, BIOCHEMISTRY US, V38, P10168, DOI 10.1021/bi9909905
   Rezaeian AH, 2017, NAT CELL BIOL, V19, P38, DOI 10.1038/ncb3445
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rucci N, 2010, CANCER RES, V70, P6150, DOI 10.1158/0008 5472.CAN 09 2758
   Santini D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019234
   Seijkens TTP, 2018, J AM COLL CARDIOL, V71, P527, DOI 10.1016/j.jacc.2017.11.055
   Shen HY, 2017, MOL MED REP, V16, P2269, DOI 10.3892/mmr.2017.6782
   Shi D, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2187 8
   Shi JB, 2019, CANCER SCI, V110, P1909, DOI 10.1111/cas.14012
   Shibata A, 2002, BREAST CANCER RES TR, V73, P237, DOI 10.1023/A:1015872531675
   Siclari VA, 2006, CANCER METAST REV, V25, P621, DOI 10.1007/s10555 006 9023 1
   Sophocleous A., 2015, J BIOL CHEM
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Tang Z.N., 2011, ONCOL REP
   Tapia MA, 2007, CELL CYCLE, V6, P2284, DOI 10.4161/cc.6.18.4721
   Teitelbaum SL, 1997, J LEUKOCYTE BIOL, V61, P381, DOI 10.1002/jlb.61.4.381
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Tulotta C, 2019, CLIN CANCER RES, V25, P2769, DOI 10.1158/1078 0432.CCR 18 2202
   van den Berg SM, 2015, INT J OBESITY, V39, P782, DOI 10.1038/ijo.2014.198
   Wang B, 2017, CANCER LETT, V408, P60, DOI 10.1016/j.canlet.2017.08.021
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wei CW, 2014, P NATL ACAD SCI USA, V111, pE601, DOI 10.1073/pnas.1316255111
   Welte T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/804347
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Xu J, 2015, CANCER CELL, V27, P177, DOI 10.1016/j.ccell.2014.11.025
   Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065
   Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888
   Zarzycka B, 2015, J CHEM INF MODEL, V55, P294, DOI 10.1021/ci500631e
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
NR 88
TC 24
Z9 27
U1 0
U2 36
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD SEP 28
PY 2020
VL 488
BP 27
EP 39
DI 10.1016/j.canlet.2020.05.021
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA LY7OG
UT WOS:000540716200003
PM 32474152
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Bellon, M
   Ko, NL
   Lee, MJ
   Yao, Y
   Waldmann, TA
   Trepel, JB
   Nicot, C
AF Bellon, Marcia
   Ko, Nga Ling
   Lee, Min Jung
   Yao, Yuan
   Waldmann, Thomas A.
   Trepel, Jane B.
   Nicot, Christophe
TI Adult T cell leukemia cells overexpress Wnt5a and promote osteoclast
   differentiation
SO BLOOD
LA English
DT Article
ID ACUTE MYELOID LEUKEMIA; BETA CATENIN; SIGNALING PATHWAY; CONSTITUTIVE
   ACTIVATION; IN VIVO; HYPERCALCEMIA; CANCER; PROLIFERATION; EXPRESSION;
   TARGET
AB Adult T cell leukemia/lymphoma (ATL) is etiologically linked to infection with the human T cell leukemia/lymphoma virus type 1 (HTLV I). ATL is classified into 4 distinct clinical diseases: acute, lymphoma, chronic, and smoldering. Acute ATL is the most aggressive form, representing 60% of cases and has a 4 year survival of <5%. A frequent complication and cause of death in acute ATL patients is the presence of lytic bone lesions and hypercalcemia. We analyzed the Wnt/beta catenin pathway because of its common role in cancer and bone remodeling. Our study demonstrated that ATL cells do not express high levels of beta catenin but displayed high levels of LEF 1/TCF genes along with elevated levels of beta catenin (LEF 1/TCF target genes) responsive genes. By profiling Wnt gene expression, we discovered that ATL patient leukemia cells shifted expression toward the noncanonical Wnt pathway. Interestingly, ATL cells overexpressed the osteolytic associated genes Wnt5a, PTHLH, and RANKL. We further show that Wnt5a secreted by ATL cells favors osteoclast differentiation and expression of RANK. Our results suggest that Wnt5a is a major contributing factor to the increase in osteolytic bone lesions and hypercalcemia found in ATL patients. Anti Wnt5a therapy may prevent or reduce osteolytic lesions found in ATL patients and improve therapy outcome.
C1 [Bellon, Marcia; Ko, Nga Ling; Yao, Yuan; Nicot, Christophe] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Ctr Viral Oncol, Kansas City, KS 66103 USA.
   [Lee, Min Jung; Trepel, Jane B.] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Waldmann, Thomas A.] NIH, Metab Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
C3 University of Kansas; University of Kansas Medical Center; National
   Institutes of Health (NIH)   USA; NIH National Cancer Institute (NCI);
   National Institutes of Health (NIH)   USA; NIH National Cancer Institute
   (NCI)
RP Nicot, C (通讯作者)，Ctr Viral Oncol, 3901 Rainbow Blvd,3025 Wahl Hall West, Kansas City, KS 66160 USA.
EM cnicot@kumc.edu
RI ; Ko, Nga/S 1191 2019; Waldmann, Thomas/AAT 5972 2021
OI Ko, Nga Ling/0000 0003 2140 5202; 
FU National Institutes of Health [AI 058944, CA106258]; National Cancer
   Institute; Biomedical Research Training Program
FX This work was supported by the National Institutes of Health (AI 058944,
   CA106258) (C.N.), the Intramural Research Program of the National Cancer
   Institute (T.A.W., J.B.T.), and the Biomedical Research Training Program
   (M.B.).
CR Bellon M, 2008, BLOOD, V112, P2946, DOI 10.1182/blood 2008 01 134692
   Camilli TC, 2010, BIOCHEM PHARMACOL, V80, P702, DOI 10.1016/j.bcp.2010.03.002
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106
   Chim CS, 2007, LEUKEMIA, V21, P2527, DOI 10.1038/sj.leu.2404939
   Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Datta A, 2006, J BIOL CHEM, V281, P23414, DOI 10.1074/jbc.M600684200
   FUJIHIRA T, 1985, JPN J CLIN ONCOL, V15, P385
   Gelebart P, 2008, BLOOD, V112, P5171, DOI 10.1182/blood 2008 02 139212
   Guo W, 2008, NATURE, V453, P529, DOI 10.1038/nature06933
   Hanaki H, 2012, MOL CANCER THER, V11, P298, DOI 10.1158/1535 7163.MCT 11 0682
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hino M, 2001, ANN HEMATOL, V80, P426, DOI 10.1007/s002770100305
   Ho HYH, 2012, P NATL ACAD SCI USA, V109, P4044, DOI 10.1073/pnas.1200421109
   Jeong SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.1208825
   Jesse S, 2010, INT J CANCER, V126, P1109, DOI 10.1002/ijc.24802
   Katagiri T, 1997, EXP CELL RES, V230, P342, DOI 10.1006/excr.1996.3432
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kieslinger M, 2005, DEV CELL, V9, P757, DOI 10.1016/j.devcel.2005.10.009
   Kikuchi A, 2012, ACTA PHYSIOL, V204, P17, DOI 10.1111/j.1748 1716.2011.02294.x
   Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509
   KIYOKAWA T, 1987, CANCER AM CANCER SOC, V59, P1187, DOI 10.1002/1097 0142(19870315)59:6<1187::AID CNCR2820590626>3.0.CO;2 8
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Ma G, 2012, ONCOGENE
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Martín V, 2010, CANCER SCI, V101, P425, DOI 10.1111/j.1349 7006.2009.01413.x
   McDonald SL, 2009, BRIT J CANCER, V101, P209, DOI 10.1038/sj.bjc.6605174
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Nosaka K, 2002, BLOOD, V99, P634, DOI 10.1182/blood.V99.2.634
   Okada Y, 2004, J BONE MINER RES, V19, P1105, DOI 10.1359/JBMR.040314
   Pise Masison CA, 2009, BLOOD, V113, P4016, DOI 10.1182/blood 2008 08 175901
   Richard V, 2001, AM J PATHOL, V158, P2219, DOI 10.1016/S0002 9440(10)64694 9
   Roman Gomez J, 2007, EUR J CANCER, V43, P2736, DOI 10.1016/j.ejca.2007.10.004
   Simon M, 2005, ONCOGENE, V24, P2410, DOI 10.1038/sj.onc.1208431
   Skokowa J, 2006, NAT MED, V12, P1191, DOI 10.1038/nm1484
   Takaori Kondo A, 1998, BLOOD, V91, P4747, DOI 10.1182/blood.V91.12.4747.412k41_4747_4751
   Tsukasaki K, 2009, J CLIN ONCOL, V27, P453, DOI 10.1200/JCO.2008.18.2428
   Valencia A, 2009, LEUKEMIA, V23, P1658, DOI 10.1038/leu.2009.86
   Veeck J, 2012, BBA REV CANCER, V1825, P18, DOI 10.1016/j.bbcan.2011.09.003
   Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003
NR 42
TC 32
Z9 35
U1 0
U2 16
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
J9 BLOOD
JI Blood
PD JUN 20
PY 2013
VL 121
IS 25
BP 5045
EP 5054
DI 10.1182/blood 2012 07 439109
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 184NR
UT WOS:000321898500013
PM 23660959
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Sujitha, S
   Rasool, M
AF Sujitha, Sali
   Rasool, Mahaboobkhan
TI Berberine coated mannosylated liposomes curtail RANKL stimulated
   osteoclastogenesis through the modulation of GSK3β pathway via
   upregulating miR 23a
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Rheumatoid arthritis; ML BBR; miR 23a; GSK3 beta/p GSK3 beta;
   Osteoclastogenesis
ID RHEUMATOID ARTHRITIS; GSK 3 BETA INHIBITION; DOWN REGULATION;
   BONE FORMATION; OSTEOBLAST; DIFFERENTIATION; EXPRESSION; INFLAMMATION;
   MACROPHAGES; MECHANISMS
AB Drug induced microRNAs manifest significant therapeutic approaches; however, such progress in the treatment of osteopathic disorders including osteoporosis and rheumatoid arthritis still remains obscure. Contrarily, nonspecific drug delivery, at high doses, increases the risk of side effects and reduces drug therapeutic efficacy. Accordingly, the present study was designed to examine the therapeutic effect of berberine coated mannosylated liposomes (ML BBR) on RANKL (100 ng/ml) stimulated bone marrow derived monocytes/macrophages (BMMs) via altering miR 23a expression. Initial studies using confocal microscopy showed successful internalization of ML BBR in RANKL stimulated BMMs. Treatment with ML BBR abrogated the increased osteoclast formation in BMM cells via inhibiting phosphorylated glutathione synthase kinase beta (p GSK3 beta) mediated NFATc1 activation. Consequently, ML BBR also attenuated the expression of bone degrading enzymes (TRAP, cathepsin K and MMP 9) thereby inhibiting the bone resorptive activity of osteoclasts. Moreover, ML BBR induced the expression levels of miR 23a at the gene level, which in turn attenuated GSK3 beta/p GSK3 beta expression as confirmed via blotting analysis. Further miR 23a inhibition of the GSK3 beta phosphorylation was confirmed using luciferase reporter assay. Comparatively, LY2090314 (GSK3 beta inhibitor) treatment inhibited the protein level expression of GSK3 beta/p GSK3 beta. However, LY2090314 treatment induced a basal level expression of miR 23a owing to the suggestion that ML BBR has an influential role in upregulating miR 23a level to inhibit GSK 3 beta phosphorylation. Cumulatively, our findings endorsed that preferential internalization of ML BBR by BMMs effectively modulated the RANKL/p GSK3 beta pathway and curtailed the osteoclast mediated bone erosion possibly through post transcriptional gene silencing via miR 23a.
C1 [Sujitha, Sali; Rasool, Mahaboobkhan] VIT, Immunopathol Lab, Sch Bio Sci & Technol, SMV 240, Vellore 632014, Tamil Nadu, India.
C3 Vellore Institute of Technology (VIT); VIT Vellore
RP Rasool, M (通讯作者)，VIT, Immunopathol Lab, Sch Bio Sci & Technol, SMV 240, Vellore 632014, Tamil Nadu, India.
EM rasool.m@vit.ac.in
RI Rasool, Mahaboobkhan/KOC 4395 2024
OI Rasool, Mahaboobkhan/0000 0003 4980 5355
FU University Grants Commission Maulana Azad National Fellowship (UGC MANF)
   [MANF 2017 18 KER 82149]
FX Sall Sujitha would like to thank University Grants Commission Maulana
   Azad National Fellowship (UGC MANF) for providing financial assistance
   in the form of Junior Research Fellowship (JRF) [ID no:
   MANF 2017 18 KER 82149].
CR Allijn IE, 2017, J CONTROL RELEASE, V247, P127, DOI 10.1016/j.jconrel.2016.12.042
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Amirhosseini M, 2018, J CELL PHYSIOL, V233, P2398, DOI 10.1002/jcp.26111
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Antika LD, 2017, J NUTR BIOCHEM, V49, P42, DOI 10.1016/j.jnutbio.2017.07.014
   Aslani S, 2019, J CELL PHYSIOL, V234, P8082, DOI 10.1002/jcp.27582
   Bernhardt A, 2017, EUR CELLS MATER, V33, P28, DOI 10.22203/eCM.v033a03
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chen GP, 2019, BIOCHEM BIOPH RES CO, V509, P329, DOI 10.1016/j.bbrc.2018.12.112
   Dou C, 2014, BBA GENE REGUL MECH, V1839, P1084, DOI 10.1016/j.bbagrm.2014.08.002
   Fu FS, 2019, J CELL PHYSIOL, V234, P11951, DOI 10.1002/jcp.27888
   Ganova P., 2016, IMMUNOME RES S, V12, P3
   Ghosh S, 2018, AAPS PHARMSCITECH, V19, P1320, DOI 10.1208/s12249 017 0939 2
   Gindin Y, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00233
   Gu QL, 2017, J ORTHOP TRANSL, V10, P86, DOI 10.1016/j.jot.2017.05.002
   Guo Q, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.22
   Hagert C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00114
   Hase H, 2008, ARTHRITIS RHEUM US, V58, P3356, DOI 10.1002/art.23971
   Hu JZ, 2017, INT IMMUNOPHARMACOL, V43, P1, DOI 10.1016/j.intimp.2016.11.031
   Huynh H., MTORC1 IMPEDES OSTEO, DOI [10.1038/s42003 018 0028 4, DOI 10.1038/S42003 018 0028 4]
   Jang HD, 2013, BONE, V55, P126, DOI 10.1016/j.bone.2013.02.005
   Jang HD, 2011, J BIOL CHEM, V286, P39043, DOI 10.1074/jbc.M111.256768
   Jia MD, 2018, INT J PHARMACEUT, V540, P57, DOI 10.1016/j.ijpharm.2018.02.001
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kwok SK, 2012, ARTHRITIS RHEUM US, V64, P740, DOI 10.1002/art.33390
   Lee Y, 2013, BONE, V56, P383, DOI 10.1016/j.bone.2013.07.007
   Li YB, 2016, MOL CELL BIOCHEM, V420, P161, DOI 10.1007/s11010 016 2783 1
   Liu HX, 2018, PHYTOTHER RES, V32, P2487, DOI 10.1002/ptr.6188
   Liu Y, 2019, J CELL PHYSIOL, V234, P13832, DOI 10.1002/jcp.28063
   Luo HN, 2019, GENE, V686, P250, DOI 10.1016/j.gene.2018.11.025
   Marchand B, 2015, J BIOL CHEM, V290, P5592, DOI 10.1074/jbc.M114.616714
   Matzelle MM, 2012, ARTHRITIS RHEUM US, V64, P1540, DOI 10.1002/art.33504
   Medunjanin S., 2016, GSK 3 BETA CIBTRIKS, P1, DOI [10.1038/srep38553, DOI 10.1038/SREP38553]
   Miao CG, 2013, CELL SIGNAL, V25, P2069, DOI 10.1016/j.cellsig.2013.04.002
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Morishima S, 2003, J ENDOCRINOL, V176, P285, DOI 10.1677/joe.0.1760285
   Neog MK, 2018, EUR J PHARM BIOPHARM, V133, P162, DOI 10.1016/j.ejpb.2018.10.010
   Ng AY, 2018, JBMR PLUS, V2, P328, DOI 10.1002/jbm4.10058
   Niwa Y, 2019, J TRANSL MED, V17, DOI 10.1186/s12967 018 1762 6
   Park J, 2015, PHYSIOL RES, V64, P711, DOI 10.33549/physiolres.932901
   Schett G, 2008, NAT CLIN PRACT RHEUM, V4, P473, DOI 10.1038/ncprheum0881
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Shi CG, 2014, BONE, V68, P67, DOI 10.1016/j.bone.2014.08.004
   Shin J, 2014, MOL CELLS, V37, P747, DOI 10.14348/molcells.2014.0220
   Sujitha S, 2018, TOXICOL APPL PHARM, V359, P34, DOI 10.1016/j.taap.2018.09.017
   Sultana F, 2017, COLLOID SURFACE B, V155, P349, DOI 10.1016/j.colsurfb.2017.04.046
   Sultana F, 2017, EUR J PHARM BIOPHARM, V115, P229, DOI 10.1016/j.ejpb.2017.03.009
   Tanaka S, 2018, J ORTHOP SCI, V23, P717, DOI 10.1016/j.jos.2018.06.001
   Van Lent PLEM, 1998, ANN RHEUM DIS, V57, P408, DOI 10.1136/ard.57.7.408
   Vishal M, 2017, J CELL PHYSIOL, V232, P371, DOI 10.1002/jcp.25434
   Wan S, 2018, CURR DRUG TARGETS, V19, P191, DOI 10.2174/1389450118666171117125319
   Wang N, 2014, BBA GENE REGUL MECH, V1839, P849, DOI 10.1016/j.bbagrm.2014.05.027
   Wang X, 2017, BIOMED PHARMACOTHER, V89, P887, DOI 10.1016/j.biopha.2017.02.099
   Wang ZG, 2014, INFLAMMATION, V37, P1789, DOI 10.1007/s10753 014 9909 y
   Wimalawansa SJ, 2000, J CLIN DENSITOM, V3, P187, DOI 10.1385/JCD:3:2:187
   Xiao Y, 2019, J CELL PHYSIOL, V234, P13959, DOI 10.1002/jcp.28079
   Xie X, 2011, ENDOCR J, V58, P761, DOI 10.1507/endocrj.K11E 024
   Yachi K, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392 018 0033 6
   Yu FY, 2018, LIFE SCI, V202, P11, DOI 10.1016/j.lfs.2018.03.042
   Zaheer S, 2015, EXPERT OPIN DRUG MET, V11, P461, DOI 10.1517/17425255.2015.1000860
   Zeng HC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15000
   Zhou YX, 2016, EXP THER MED, V11, P2495, DOI 10.3892/etm.2016.3184
NR 62
TC 20
Z9 23
U1 0
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD SEP
PY 2019
VL 74
AR 105703
DI 10.1016/j.intimp.2019.105703
PG 15
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA IY0OQ
UT WOS:000486093000054
PM 31261037
DA 2025 08 17
ER

PT J
AU Liu, HN
   Webster, TJ
AF Liu, Huinan
   Webster, Thomas J.
TI Ceramic/polymer nanocomposites with tunable drug delivery capability at
   specific disease sites
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE nanocomposite; controlled drug delivery; peptide delivery; protein
   delivery; prolonged drug release; hydroxyapatite; biodegradable polymer;
   PLGA; orthopedic/dental applications; bone diseases
ID RECOMBINANT HUMAN BONE; INCREASED OSTEOBLAST FUNCTIONS; MORPHOGENETIC
   PROTEIN 2; POROUS HYDROXYAPATITE; CLINICAL APPLICATIONS; CARRIERS;
   MICROSPHERES; MATURATION; COMPOSITE; SCAFFOLDS
AB Pharmaceutical agents are often used to stimulate new bone formation for the treatment of bone injuries or diseases (such as osteoporosis). However, there are several problems associated with current orthopedic drug delivery methods. First, conventional systemic administration of pharmaceutical agents may not effectively reach targeted sites and, thus, they can cause nonspecific bone formation in areas not affected by injury or disease. Second, even if intentionally delivered or implanted locally to the damaged bone tissue, these agents tend to rapidly diffuse into adjacent tissues due to weak physical bonding to their drug carriers, which limits their potential to promote prolonged bone formation in targeted areas of bone disease. Therefore, in this study, biodegradable ceramic/polymer nanocomposites were explored as novel drug carriers for orthopedic applications to prolong local drug release and, thus, improve drug effectiveness at bone disease sites. Specifically, a bone morphogenetic protein (BMP 7) derived peptide (DIF 7c) was used as a model drug in this study and was first loaded onto nanocrystalline hydroxyapatite (nano HA) by either covalent chemical attachment or physical adsorption. These drug carrying nano HA particles were then dispersed into a degradable polymer (poly lactide co glycolide or PLGA) matrix to create an implantable system capable of long term drug release. The aminophase silane covalent chemical immobilization process was utilized in this study. These nanocomposite based drug delivery systems were then characterized for drug loading efficiency and in vitro drug release. Results demonstrated that DIF 7c was successfully immobilized onto nano HA placed in PLGA. Moreover, a greater prolonged two phase release profile (of more than 3 months) was achieved when using aminophase silane chemical immobilization to nano HA particles. Since previous studies have demonstrated greater in vivo bone growth on nano compared with micron HA particles placed in rat calvaria, this study continued to demonstrate that ceramic/polymer nanocomposites are promising candidates as novel orthopedic materials to promote bone regeneration. (C) 2009 Wiley Periodicals, Inc. J Biomed Mater Res 93A: 1180 1192, 2010
C1 [Liu, Huinan; Webster, Thomas J.] Brown Univ, Div Engn, Providence, RI 02912 USA.
C3 Brown University
RP Webster, TJ (通讯作者)，Brown Univ, Div Engn, 182 Hope St, Providence, RI 02912 USA.
EM Thomas_Webster@Brown.edu
RI webster, thomas/D 1523 2013; Liu, Huinan/N 2891 2015
OI Liu, Huinan/0000 0001 9366 6204
FU NSF
FX Contract grant sponsor: NSF [Nanoscale Exploratory Research (NER) grant]
CR Aebli N, 2005, J BIOMED MATER RES A, V73A, P295, DOI 10.1002/jbm.a.30299
   Alam MI, 2001, BIOMATERIALS, V22, P1643
   [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
   Balasundaram G, 2006, BIOMATERIALS, V27, P2798, DOI 10.1016/j.biomaterials.2005.12.008
   Balasundaram G, 2006, NANOMEDICINE UK, V1, P169, DOI 10.2217/17435889.1.2.169
   Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264 007 0424 8
   Chao EYS, 1998, CLIN ORTHOP RELAT R, pS163
   Chen YP, 2009, J BIOMED MATER RES A, V91A, P296, DOI 10.1002/jbm.a.32246
   Chubinskaya S, 2007, INT ORTHOP, V31, P773, DOI 10.1007/s00264 007 0423 9
   Cosijns A, 2007, EUR J PHARM BIOPHARM, V67, P498, DOI 10.1016/j.ejpb.2007.02.018
   DASH AK, 1992, PHARMACEUT RES, V9, P993, DOI 10.1023/A:1015842108772
   Dellinger JG, 2006, J BIOMED MATER RES A, V76A, P366, DOI 10.1002/jbm.a.30523
   Ergun C, 2007, J BIOMED MATER RES A, V80A, P990, DOI 10.1002/jbm.a.30923
   Ferraz MP, 2007, J BIOMED MATER RES A, V81A, P994, DOI 10.1002/jbm.a.31151
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445 2197.2007.04175.x
   Genin F. Y., 2004, United States Patent, Patent No. 6767550
   GERHART TN, 1993, CLIN ORTHOP RELAT R, P317
   Hollander AP, 2006, TISSUE ENG, V12, P1787, DOI 10.1089/ten.2006.12.1787
   HONG HG, 1994, LANGMUIR, V10, P153, DOI 10.1021/la00013a023
   Ioku K., 1991, Phosphorus Research Bulletin, V1, P15
   Kaito T, 2005, BIOMATERIALS, V26, P73, DOI 10.1016/j.biomaterials.2004.02.010
   Khang G, 2003, MACROMOL RES, V11, P207, DOI 10.1007/BF03218355
   Kim HW, 2004, BIOMATERIALS, V25, P1279, DOI 10.1016/j.biomaterials.2003.07.003
   Koempel JA, 1998, J BIOMED MATER RES, V41, P359, DOI 10.1002/(SICI)1097 4636(19980905)41:3<359::AID JBM3>3.0.CO;2 B
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Li PJ, 2003, J BIOMED MATER RES A, V66A, P79, DOI 10.1002/jbm.a.10519
   LIU H, 2008, THESIS BROWN U PROVI
   Liu H, 2006, INT J NANOMED, V1, P541, DOI 10.2147/nano.2006.1.4.541
   Liu H, 2007, BIOMATERIALS, V28, P354, DOI 10.1016/j.biomaterials.2006.08.049
   Liu H, 2006, J BIOMED MATER RES A, V78A, P798, DOI 10.1002/jbm.a.30734
   LIU JP, 1991, ANAL CHEM, V63, P413, DOI 10.1021/ac00005a005
   Liu TY, 2005, J CONTROL RELEASE, V107, P112, DOI 10.1016/j.jconrel.2005.05.025
   MILLER TA, 1991, PLAST RECONSTR SURG, V87, P87, DOI 10.1097/00006534 199101000 00014
   Minamide A, 2001, SPINE, V26, P933, DOI 10.1097/00007632 200104150 00017
   Miyai T, 2008, BIOMATERIALS, V29, P350, DOI 10.1016/j.biomaterials.2007.09.040
   Pecina M, 2001, INT ORTHOP, V25, P203, DOI 10.1007/s002640100262
   Pham Hai H, 2002, AAPS PharmSciTech, V3, pE1
   *PIERC, INSTR MICR PROT ASS
   Ribeiro CC, 2004, BIOMATERIALS, V25, P4363, DOI 10.1016/j.biomaterials.2003.11.028
   Sato M, 2006, BIOMATERIALS, V27, P2358, DOI 10.1016/j.biomaterials.2005.10.041
   SOMIYA S, 1988, MATER SCI FORUM, V34, P371
   TORIUMI DM, 1991, ARCH OTOLARYNGOL, V117, P1101
   WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220
   Webster TJ, 2000, BIOMATERIALS, V21, P1803, DOI 10.1016/S0142 9612(00)00075 2
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
   YASKO AW, 1992, J BONE JOINT SURG AM, V74A, P659, DOI 10.2106/00004623 199274050 00005
   Zhang R., 2000, Polymer Preprints, V41, P1618
NR 49
TC 38
Z9 43
U1 0
U2 50
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD JUN 1
PY 2010
VL 93A
IS 3
BP 1180
EP 1192
DI 10.1002/jbm.a.32614
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 586NF
UT WOS:000276916200038
PM 19777574
DA 2025 08 17
ER

PT J
AU Zheng, ZA
   Johansson, H
   Harvey, NC
   Lorentzon, M
   Vandenput, L
   Liu, EW
   Kanis, JA
   McCloskey, E
AF Zheng, Zhangan
   Johansson, Helena
   Harvey, Nicholas C.
   Lorentzon, Mattias
   Vandenput, Liesbeth
   Liu, Enwu
   Kanis, John A.
   McCloskey, Eugene, V
TI Potential Adverse Effect of Nonsteroidal Anti Inflammatory Drugs
   (NSAIDs) on Bisphosphonate Efficacy: An Exploratory Post Hoc Analysis
   From a Randomized Controlled Trial of Clodronate
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE NSAID; fracture; BMD; bisphosphonate; clodronate
ID SELECTIVE CYCLOOXYGENASE 2 INHIBITOR; BONE MINERAL DENSITY;
   DOUBLE BLIND; FRACTURE RISK; WOMEN; THERAPY; BIOAVAILABILITY;
   OSTEOPOROSIS; RISEDRONATE; MEDICATION
AB Nonsteroidal anti inflammatory drugs (NSAIDs) have been reported to have weak but beneficial effects on bone health, including fracture risk, but many epidemiological studies are likely confounded. We explored the relationship between NSAIDs and fracture risk in a post hoc analysis of a well documented, randomized, placebo controlled study of the bisphosphonate, clodronate, in which treatment reduced osteoporotic fracture risk by 23%. Concurrent medication use at baseline was used to identify those prescribed oral NSAIDs. Only verified, incident fractures were included in the analysis. A total of 1082 (20.8%) women reported use of NSAIDs at baseline. They were slightly, but significantly, younger (mean 79 versus 80 years, p = 0.004), heavier (mean 66.7 versus 64.7 kg, p < 0.001) than nonusers, with slightly higher femoral neck bone mineral density (FN BMD, 0.66 versus 0.64 g/cm(2), p < 0.001). In an adjusted model, NSAID use was associated with a significant increase in osteoporotic fracture risk over the 3 year study period (hazard ratio [HR] 1.27; 95% confidence interval [CI], 1.01 1.62; p = 0.039). However, this increase in risk was not statistically significant in the placebo group (HR 1.11; 95% CI, 0.81 1.52). In women receiving clodronate, the effect of the bisphosphonate to reduce osteoporotic fracture risk was not observed in those receiving NSAIDs (HR 0.95; 95% CI, 0.65 1.41; p = 0.81) in contrast to those not using NSAIDs (HR 0.71; 95% CI, 0.58 0.89; p = 0.002). In a subset with hip BMD repeated at 3 years, BMD loss during clodronate therapy was greater in those women receiving NSAIDs than in nonusers (eg, total hip  2.75% versus  1.27%, p = 0.078; femoral neck  3.06% versus  1.12%, p = 0.028), and was not significantly different from that observed in women receiving placebo. The efficacy of the bisphosphonate, clodronate, to reduce fracture risk was largely negated in those receiving NSAIDs. Although the mechanism is unclear, this clinically significant observation requires exploration in studies of commonly used bisphosphonates. (c) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
C1 [Zheng, Zhangan; McCloskey, Eugene, V] Univ Sheffield, Dept Oncol & Metab, Mellanby Ctr Musculoskeletal Res, Med Res Council MRC Versus Arthrit Ctr Integrated, Sheffield, S Yorkshire, England.
   [Zheng, Zhangan] Second Peoples Hosp Wuhu, Dept Trauma & Spine Surg, Wuhu, Peoples R China.
   [Johansson, Helena; Lorentzon, Mattias; Vandenput, Liesbeth] Univ Gothenburg, Sahlgrenska Acad, Sahlgrenska Osteoporosis Ctr, Dept Internal Med & Clin Nutr,Inst Med, Gothenburg, Sweden.
   [Johansson, Helena; Lorentzon, Mattias; Vandenput, Liesbeth; Liu, Enwu; Kanis, John A.] Australian Catholic Univ, Mary McKillop Inst Hlth Res, Melbourne, Vic, Australia.
   [Harvey, Nicholas C.] Univ Southampton, MRC Lifecourse Epidemiol Ctr, Southampton, Hants, England.
   [Kanis, John A.; McCloskey, Eugene, V] Univ Sheffield, Ctr Metab Bone Dis, Sheffield, S Yorkshire, England.
C3 University of Sheffield; University of Gothenburg; Australian Catholic
   University; University of Southampton; University of Sheffield
RP McCloskey, E (通讯作者)，Northern Gen Hosp, Metab Bone Ctr, Herries Rd, Sheffield SS 7AU, S Yorkshire, England.
RI ; Vandenput, Liesbeth/AAP 3655 2020; Liu, Enwu/AGC 4748 2022; Harvey,
   Nicholas/JWO 4341 2024; Lorentzon, Mattias/W 7878 2019; McCloskey,
   Eugene/T 5197 2019
OI Harvey, Nicholas/0000 0002 8194 2512; Vandenput,
   Liesbeth/0000 0002 1712 6131; Lorentzon, Mattias/0000 0003 0749 1431;
   Liu, Enwu/0000 0003 2580 3523; 
FU MRC [MC_PC_21003, MR/P020941/1, MC_PC_21022] Funding Source: UKRI;
   Medical Research Council [MR/P020941/1] Funding Source: researchfish;
   Novo Nordisk Fonden [NNF17OC0026882] Funding Source: researchfish
CR Abrahamsen B, 2011, ARCH INTERN MED, V171, P998, DOI 10.1001/archinternmed.2011.20
   Bauer DC, 1996, J BONE MINER RES, V11, P29
   Bleicher K, 2011, OSTEOPOROSIS INT, V22, P2421, DOI 10.1007/s00198 010 1478 9
   CHAMBERS TJ, 1985, ENDOCRINOLOGY, V116, P234, DOI 10.1210/endo 116 1 234
   Chuang PY, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1047 2
   Cohen DB, 2006, AM J SPORT MED, V34, P362, DOI 10.1177/0363546505280428
   Cryer B, 2016, AM J MED SCI, V352, P472, DOI 10.1016/j.amjms.2016.08.028
   de Vries F, 2009, OSTEOPOROSIS INT, V20, P1989, DOI 10.1007/s00198 009 0891 4
   GERTZ BJ, 1995, CLIN PHARMACOL THER, V58, P288, DOI 10.1016/0009 9236(95)90245 7
   Huang KC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001566
   Igarashi K, 2002, BIOCHEM PHARMACOL, V63, P523, DOI 10.1016/S0006 2952(01)00861 9
   Jones Roger, 2001, American Journal of Medicine, V110, p4S, DOI 10.1016/S0002 9343(00)00627 6
   Kanis JA, 1996, BONE, V19, P663, DOI 10.1016/S8756 3282(96)00285 2
   Kanis JA, 2001, OSTEOPOROSIS INT, V12, P417, DOI 10.1007/s001980170112
   Kayan K, 2009, OSTEOPOROSIS INT, V20, P2055, DOI 10.1007/s00198 009 0942 x
   McCloskey E, 2004, J BONE MINER RES, V19, P728, DOI 10.1359/JBMR.040116
   McCloskey EV, 2009, OSTEOPOROSIS INT, V20, P811, DOI 10.1007/s00198 008 0786 9
   McCloskey E, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115715
   McCloskey E, 2010, EUR J CANCER, V46, P558, DOI 10.1016/j.ejca.2009.12.003
   McCloskey EV, 2008, J BONE MINER RES, V23, P1561, DOI [10.1359/jbmr.080515, 10.1359/JBMR.080515]
   McCloskey EV, 2007, J BONE MINER RES, V22, P135, DOI 10.1359/JBMR.061008
   McCloskey EV, 2001, BRIT J HAEMATOL, V113, P1035, DOI 10.1046/j.1365 2141.2001.02851.x
   McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317
   Muñoz Ortego J, 2014, J BONE MINER RES, V29, P1770, DOI 10.1002/jbmr.2217
   Nakatsu Y, 2018, PHARMACOL REP, V70, P29, DOI 10.1016/j.pharep.2017.07.006
   NELL A, 1989, ARCH ORAL BIOL, V34, P187, DOI 10.1016/0003 9969(89)90006 X
   Ohlin A, 1999, INFLAMM RES, V48, P181, DOI 10.1007/s000110050444
   PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59
   Pilotto A, 2003, DRUG AGING, V20, P701, DOI 10.2165/00002512 200320090 00006
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Rossini M, 2014, DRUG AGING, V31, P547, DOI 10.1007/s40266 014 0184 2
   Roux C, 2012, OSTEOPOROSIS INT, V23, P1083, DOI 10.1007/s00198 011 1800 1
   Roux C, 2012, OSTEOPOROSIS INT, V23, P277, DOI 10.1007/s00198 011 1574 5
   Stitham J, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00024
   Su B, 2013, J APPL PHYSIOL, V115, P892, DOI 10.1152/japplphysiol.00053.2013
   Taketa T, 2008, J BONE MINER METAB, V26, P143, DOI 10.1007/s00774 007 0808 2
   van Staa TP, 2002, BONE, V31, P508, DOI 10.1016/S8756 3282(02)00848 7
   Van Staa TP, 2000, BONE, V27, P563, DOI 10.1016/S8756 3282(00)00361 6
   Vestergaard P, 2012, OSTEOPOROSIS INT, V23, P1255, DOI 10.1007/s00198 011 1692 0
   Villikka K, 2002, BONE, V31, P418, DOI 10.1016/S8756 3282(02)00841 4
   Vosse D, 2009, ANN RHEUM DIS, V68, P1839, DOI 10.1136/ard.2008.100503
NR 41
TC 4
Z9 6
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2022
VL 37
IS 6
BP 1117
EP 1124
DI 10.1002/jbmr.4548
EA APR 2022
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 1X3LJ
UT WOS:000783733700001
PM 35441396
OA hybrid, Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Chen, Y
   Di Grappa, MA
   Molyneux, SD
   McKee, TD
   Waterhouse, P
   Penninger, JM
   Khokha, R
AF Chen, Yan
   Di Grappa, Marco A.
   Molyneux, Sam D.
   McKee, Trevor D.
   Waterhouse, Paul
   Penninger, Josef M.
   Khokha, Rama
TI RANKL blockade prevents and treats aggressive osteosarcomas
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID FACTOR KAPPA B; MCCUNE ALBRIGHT SYNDROME; STIMULATORY G PROTEIN; MARROW
   STROMAL CELLS; RECEPTOR ACTIVATOR; ZOLEDRONIC ACID; FIBROUS DYSPLASIA;
   CARNEY COMPLEX; OSTEOCLAST FORMATION; IN VITRO
AB Osteosarcoma (OS) is the most common primary bone cancer, which occurs primarily in children and adolescents, severely affecting survivors' quality of life. Despite its chemosensitivity and treatment advances, long term survival rates for OS patients have stagnated over the last 20 years. Thus, it is necessary to develop new molecularly targeted therapies for this metastatic bone cancer. Mutations in TP53 and RB are linked to OS predisposition and to the evolution of spontaneous OS. We established receptor activator of nuclear factor kappa B ligand (RANKL) as a therapeutic target for suppression and prevention of OS. Combined conditional osteoblast specific deletions of Rb, p53, and the protein kinase A (PKA) regulatory subunit Prkar1 alpha genes in genetically engineered mouse models (GEMMs) generate aggressive osteosarcomas, characterized by PKA, RANKL, and osteoclast hyperactivity. Whole body Rankl deletion completely abrogates tumorigenesis. Although osteoblastic Rank deletion has little effect, osteoclastic Rank deletion delays tumorigenesis and prolongs life span. The latter is associated with inactivation of osteoclastogenesis and up regulation of the tumor suppressor phosphatase and tensin homolog (PTEN). Further, we use these GEMMs as preclinical platforms to show that RANKL blockade with RANK Fc arrests tumor progression and improves survival and also inhibits lung metastasis. Moreover, preemptive administration of RANK Fc completely prevents tumorigenesis in mice highly predisposed to this aggressive cancer. Denosumab, a fully human monoclonal antibody against RANKL, is currently used to treat patients with osteoporosis or bone metastases. Our studies provide a strong rationale to consider RANKL blockade for the treatment and prevention of aggressive RANKL overexpressing OS in humans.
C1 [Chen, Yan; Di Grappa, Marco A.; Molyneux, Sam D.; Waterhouse, Paul; Khokha, Rama] Univ Hlth Network, Ontario Canc Inst, Princess Margaret Canc Ctr, Toronto, ON M5G 1L7, Canada.
   [McKee, Trevor D.] Univ Hlth Network, Spatiotemporal Targeting & Amplificat Radiat Resp, Toronto, ON M5G 1L7, Canada.
   [Penninger, Josef M.] Austrian Acad Sci IMBA, Inst Mol Biotechnol, A 1030 Vienna, Austria.
C3 University of Toronto; University Health Network Toronto; Princess
   Margaret Cancer Centre; University of Toronto; University Health Network
   Toronto; Vienna Biocenter (VBC); Institute of Molecular Biotechnology
   (IMBA); Austrian Academy of Sciences
RP Khokha, R (通讯作者)，Univ Hlth Network, Ontario Canc Inst, Princess Margaret Canc Ctr, 101 Coll St, Toronto, ON M5G 1L7, Canada.
EM rkhokha@uhnresearch.ca
RI ; Penninger, Josef/I 6860 2013; McKee, Trevor/N 4992 2016
OI Waterhouse, Paul/0000 0001 8745 5224; Khokha, Rama/0000 0002 6028 1524;
   Penninger, Josef/0000 0002 8194 3777; McKee, Trevor/0000 0002 2195 6146;
   
FU Canadian Institutes of Health Research (CIHR); Ontario Institute for
   Cancer Research (OICR); Global Leadership Round in Genomics and Life
   Sciences (GL2)
FX This study is supported by funding from the Canadian Institutes of
   Health Research (CIHR), Ontario Institute for Cancer Research (OICR),
   and Global Leadership Round in Genomics and Life Sciences (GL2) to R.K.
CR Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Barrett Lee P, 2014, LANCET ONCOL, V15, P114, DOI 10.1016/S1470 2045(13)70539 4
   Beristain AG, 2012, J CELL SCI, V125, P943, DOI 10.1242/jcs.094029
   Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Boyce AM, 2012, J BONE MINER RES, V27, P1462, DOI 10.1002/jbmr.1603
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Carney JA, 2001, AM J SURG PATHOL, V25, P164, DOI 10.1097/00000478 200102000 00004
   Cathonnas R, 2015, ONCOLOGY BASEL, V88, P257, DOI 10.1159/000369975
   Chalhoub N, 2009, ANNU REV PATHOL MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432 007 0330 x
   Diel IJ, 2015, EUR J CANCER, V51, P1467, DOI 10.1016/j.ejca.2015.04.017
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Dougall William C, 2007, Curr Opin Support Palliat Care, V1, P317, DOI 10.1097/SPC.0b013e3282f335be
   Egan KP, 2012, HISTOPATHOLOGY, V61, P1168, DOI 10.1111/j.1365 2559.2012.04333.x
   Endo Munoz L, 2010, CANCER RES, V70, P7063, DOI 10.1158/0008 5472.CAN 09 4291
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Ganda K, 2014, OSTEOPOROSIS INT, V25, P777, DOI 10.1007/s00198 013 2585 1
   Grimaud E, 2003, AM J PATHOL, V163, P2021, DOI 10.1016/S0002 9440(10)63560 2
   Hanada R, 2009, NATURE, V462, P505, DOI 10.1038/nature08596
   Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105 2896.2006.00375.x
   Kalariti N, 2004, ANTICANCER RES, V24, P3923
   Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kirschner LS, 2000, HUM MOL GENET, V9, P3037, DOI 10.1093/hmg/9.20.3037
   Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238
   Kirschner LS, 2005, CANCER RES, V65, P4506, DOI 10.1158/0008 5472.CAN 05 0580
   Kondo H, 2002, J BONE MINER RES, V17, P1667, DOI 10.1359/jbmr.2002.17.9.1667
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lee JA, 2011, PEDIATR BLOOD CANCER, V56, P738, DOI 10.1002/pbc.22720
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Liu BY, 1998, ENDOCRINOLOGY, V139, P1952, DOI 10.1210/en.139.4.1952
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Marino S, 2000, GENE DEV, V14, P994
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Meyers PA, 2011, CANCER AM CANCER SOC, V117, P1736, DOI 10.1002/cncr.25744
   Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391
   Mori K, 2007, J PATHOL, V211, P555, DOI 10.1002/path.2140
   Mori K, 2007, ONCOL REP, V18, P1365
   Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Odri GA, 2010, CANCER RES, V70, P7610, DOI 10.1158/0008 5472.CAN 09 4272
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Piersanti S, 2010, J BONE MINER RES, V25, P1103, DOI 10.1359/jbmr.091036
   Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259 003 1441 5
   Savage SA, 2013, NAT GENET, V45, P799, DOI 10.1038/ng.2645
   SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007 1021.2004
   Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808
   WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yu MJ, 2011, J IMMUNOL, V187, P1797, DOI 10.4049/jimmunol.1002628
NR 55
TC 78
Z9 84
U1 0
U2 22
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD DEC 9
PY 2015
VL 7
IS 317
AR 317ra197
DI 10.1126/scitranslmed.aad0295
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA CY0ZW
UT WOS:000366136800005
PM 26659571
DA 2025 08 17
ER

PT J
AU Shim, KS
   Hwang, YH
   Jang, SA
   Kim, T
   Ha, H
AF Shim, Ki Shuk
   Hwang, Youn Hwan
   Jang, Seon A
   Kim, Taesoo
   Ha, Hyunil
TI Water Extract ofLysimachia christinaeInhibits Trabecular Bone
   Loss and Fat Accumulation in Ovariectomized Mice
SO NUTRIENTS
LA English
DT Article
DE Lysimachia christinae; osteoporosis; ovariectomy; osteoclast
   differentiation
ID LYSIMACHIA CHRISTINAE; OSTEOCLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN;
   BODY COMPOSITION; C FOS; ESTROGEN; MARROW; CELLS; PATHOGENESIS;
   INDUCTION
AB In Asia, extracts ofLysimachia christinaehave been used for liver or urinogenital system related diseases in traditional medicine. In this study, we investigated the effects of the water extract ofL. christinae(WELC) on receptor activator of nuclear factor kappa Beta ligand (RANKL) induced osteoclastic differentiation of bone marrow macrophages, and on osteoporosis and obesity in ovariectomy mice. RANK signaling pathways related to osteoclast differentiation were examined by real time polymerase chain reaction (PCR) and western blot analysis. Additionally, we performed micro computed tomography to assess trabecular bone loss, histological analysis for fat accumulation in adipose, liver, and bone tissues, and phytochemical profiling for WELC characterization. WELC significantly inhibited osteoclast differentiation by downregulating RANKL induced mitogen activated protein kinase (MAPK)/c Fos/nuclear factor of activated T cells (NFAT) signaling in osteoclast precursors and ovariectomy induced trabecular loss by suppressing osteolcastic bone resorption. WELC markedly decreased ovariectomy induced body weight gain and fat accumulation in adipose, liver, and bone tissues. Furthermore, ultra high performance liquid chromatography tandem mass spectrometry (UHPLC MS/MS) identified 16 phytochemicals in WELC when compared with the mass fragmentation of standard chemicals. Collectively, these results suggest that WELC might possess beneficial effects on postmenopausal osteoporosis by inhibiting osteoclast differentiation and obesity by suppressing fat accumulation.
C1 [Shim, Ki Shuk; Hwang, Youn Hwan; Jang, Seon A; Kim, Taesoo; Ha, Hyunil] Korea Inst Oriental Med, Herbal Med Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
   [Hwang, Youn Hwan] Univ Sci & Technol UST, Korean Convergence Med Major KIOM, 1672 Yuseongdae Ro, Daejeon 34054, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); University of Science &
   Technology (UST)
RP Ha, H (通讯作者)，Korea Inst Oriental Med, Herbal Med Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
EM angeloshim@kiom.re.kr; hyhhwang@kiom.re.kr; white7068@kiom.re.kr;
   xotn91@kiom.re.kr; hyunil74@kiom.re.kr
RI Hwang, Youn Hwan/AAU 9373 2021
OI Hwang, Youn Hwan/0000 0002 4959 2436
FU Korea Institute of Oriental Medicine, Ministry of Education, Science and
   Technology, Korea [KSN 2012330]
FX This research was funded by the Korea Institute of Oriental Medicine,
   Ministry of Education, Science and Technology, Korea [grant number KSN
   2012330].
CR Ambrosi TH, 2017, CELL STEM CELL, V20, P771, DOI 10.1016/j.stem.2017.02.009
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Asarian L, 2002, HORM BEHAV, V42, P461, DOI 10.1006/hbeh.2002.1835
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen J, 1998, Zhong Yao Cai, V21, P388
   Clegg DJ, 2006, DIABETES, V55, P978, DOI 10.2337/diabetes.55.04.06.db05 1339
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   De Franciscis P, 2019, MEDICINA LITHUANIA, V55, DOI 10.3390/medicina55090544
   Deng J, 2015, J ETHNOPHARMACOL, V166, P102, DOI 10.1016/j.jep.2015.03.031
   Gao FF, 2013, HELV CHIM ACTA, V96, P985, DOI 10.1002/hlca.201200328
   Gavin KM, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00276
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Ha H, 2014, MOLECULES, V19, P3940, DOI 10.3390/molecules19043940
   Hawkes CP, 2019, BONE, V119, P57, DOI 10.1016/j.bone.2018.03.012
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Huang XA, 2007, MOLECULES, V12, P43, DOI 10.3390/12010043
   Hwang YH, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081831
   Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890
   Ko CH, 2009, J AGR FOOD CHEM, V57, P7293, DOI 10.1021/jf901545u
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li J., 2014, J ANHUI SCI TECHNOL, V2, P55
   Lizcano F, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/757461
   Lundholm L, 2008, FERTIL STERIL, V90, P44, DOI 10.1016/j.fertnstert.2007.06.011
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mo H, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431X20198754, 10.1590/1414 431x20198754]
   Most W, 1997, BONE, V20, P27, DOI 10.1016/S8756 3282(96)00309 2
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Palmisano BT, 2017, ADV EXP MED BIOL, V1043, P227, DOI 10.1007/978 3 319 70178 3_12
   Peng B., 2011, J CLIN MED PRACT, V11, P71
   Peng JM, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201900082
   Poehlman ET, 2002, ACTA OBSTET GYN SCAN, V81, P603, DOI 10.1034/j.1600 0412.2002.810705.x
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Sakai A, 1998, BONE, V23, P443, DOI 10.1016/S8756 3282(98)00121 5
   Shimoda H., 2006, BMC COMPLEM ALTERN M, V6, P9, DOI [10.1186/1472 6882 6 9, DOI 10.1186/1472 6882 6 9]
   Sowers M, 2007, J CLIN ENDOCR METAB, V92, P895, DOI 10.1210/jc.2006 1393
   Syed FA, 2008, OSTEOPOROSIS INT, V19, P1323, DOI 10.1007/s00198 008 0574 6
   Tian LJ, 2008, J ASIAN NAT PROD RES, V10, P265, DOI 10.1080/10286020701605265
   Wang JM, 2012, BIOSCI TRENDS, V6, P89, DOI 10.5582/bst.2012.v6.2.89
   Wu YC, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00080
   YADAV RNS, 1988, CELL BIOCHEM FUNCT, V6, P197, DOI 10.1002/cbf.290060308
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang X, 2011, J ETHNOPHARMACOL, V137, P57, DOI 10.1016/j.jep.2011.04.029
   Zhang CC, 2014, J CELL PHYSIOL, V229, P1330, DOI 10.1002/jcp.24553
   Zhou RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166751
NR 47
TC 8
Z9 9
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD JUL
PY 2020
VL 12
IS 7
AR 1927
DI 10.3390/nu12071927
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA MS2SV
UT WOS:000554133600001
PM 32610585
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zheng, T
   Wang, X
   Yim, MJ
AF Zheng, Ting
   Wang, Xin
   Yim, Mijung
TI Miconazole inhibits receptor activator of nuclear factor κB
   ligand mediated osteoclast formation and function
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Miconazole; Osteoclast; RANKL; NFATc1; Bone loss
ID NECROSIS FACTOR RECEPTOR; CAPACITATIVE CA2+ ENTRY; C JUN; BONE;
   DIFFERENTIATION; RANKL; EXPRESSION; CELLS; METABOLISM; MECHANISMS
AB Osteoclasts are responsible for bone erosion in diseases as diverse as osteoporosis, periodontitis, and rheumatoid arthritis. Antifungal products have received recent attention as potential therapeutic and preventative drugs in human disease. Since little is known about the action of miconazole, an antifungal imidazole, on bone metabolism, we investigated the effects of miconazole on osteoclast formation using mouse bone marrow macrophages (BMMs). Miconazole inhibited RANKL induced osteoclast formation in a dose dependent manner without cytotoxicity. Furthermore, miconazole inhibited the bone resorptive activity of osteoclasts. Miconazole suppressed RANKL induced expression of c Fos and NFATcl, two essential transcription factors for osteoclast differentiation. Miconazole seemed to inhibit osteoclast formation MAPK pathways as well as Blimpl through MafB expression. Miconazole also inhibited RANKL induced expression of the pro inflammatory cytokines, COX 2 and iNOS. In accordance with the in vitro study, miconazole reduced lipopolysaccharide incluced osteoclast formation in vivo. Therefore, miconazole exerted an inhibitory effect on osteoclast formation in vitro and in vivo. It could be useful for the treatment of bone diseases associated with excessive bone resorption. (C) 2014 Elsevier B.V. All rights reserved
C1 [Zheng, Ting; Wang, Xin; Yim, Mijung] Sookmyung Womens Univ, Coll Pharm, Seoul 140742, South Korea.
C3 Sookmyung Women's University
RP Yim, MJ (通讯作者)，53 12 Chungpa Dong 2 Ka,Yongsan Ku, Seoul 140742, South Korea.
EM myim@sm.ac.kr
RI Zheng, Ting/ITR 8293 2023
OI Zheng, Ting/0000 0001 7723 7653
FU Sookmyung Women's University Research Grants
FX This work was supported by the Sookmyung Women's University Research
   Grants 2012,
CR Axmann R, 2009, ARTHRITIS RHEUM US, V60, P2747, DOI 10.1002/art.24781
   Battaglino R, 2004, J BONE MINER RES, V19, P1420, DOI 10.1359/JBMR.040606
   Belenky P, 2013, CELL REP, V3, P350, DOI 10.1016/j.celrep.2012.12.021
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   Coley KC, 1997, PHARMACOTHERAPY, V17, P379
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Debeljak N, 2003, ARCH BIOCHEM BIOPHYS, V409, P159, DOI 10.1016/S0003 9861(02)00418 6
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Duret C, 2006, MOL PHARMACOL, V70, P329, DOI 10.1124/mol.105.022046
   Ferron M, 2011, CELL METAB, V14, P466, DOI 10.1016/j.cmet.2011.08.013
   Ha H, 2006, J IMMUNOL, V176, P111, DOI 10.4049/jimmunol.176.1.111
   Han SY, 2005, BLOOD, V106, P1240, DOI 10.1182/blood 2004 12 4975
   Harper JL, 2000, LIFE SCI, V67, P651, DOI 10.1016/S0024 3205(00)00659 7
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Jang HD, 2011, J BIOL CHEM, V286, P39043, DOI 10.1074/jbc.M111.256768
   Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799
   Ju YJ, 2003, CELL SIGNAL, V15, P197, DOI 10.1016/S0898 6568(02)00079 7
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kunzelmann Marche C, 2001, J BIOL CHEM, V276, P5134, DOI 10.1074/jbc.M007924200
   Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Lloyd SAJ, 2008, CALCIFIED TISSUE INT, V82, P361, DOI 10.1007/s00223 008 9133 6
   Lomax RB, 1998, CELL CALCIUM, V23, P229, DOI 10.1016/S0143 4160(98)90121 X
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Nishikaw K, 2010, P NATL ACAD SCI USA, V107, P3117, DOI 10.1073/pnas.0912779107
   Ostrosky Zeichner L, 2010, NAT REV DRUG DISCOV, V9, P719, DOI 10.1038/nrd3074
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   VANDEN BOSSCHE H, 1995, PHARMACOL THERAPEUT, V67, P79
   Venkatakrishnan K, 2000, CLIN PHARMACOKINET, V38, P111, DOI 10.2165/00003088 200038020 00002
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhou W, 2006, PROSTAG OTH LIPID M, V80, P28, DOI 10.1016/j.prostaglandins.2006.03.005
   Zou W, 2005, J CELL PHYSIOL, V202, P371, DOI 10.1002/jcp.20127
NR 48
TC 8
Z9 8
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD AUG 15
PY 2014
VL 737
BP 185
EP 193
DI 10.1016/j.ejphar.2014.04.047
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AK8VH
UT WOS:000338706200022
PM 24842191
DA 2025 08 17
ER

PT J
AU Nishioku, T
   Kubo, T
   Kamada, T
   Okamoto, K
   Tsukuba, T
   Uto, T
   Shoyama, Y
AF Nishioku, Tsuyoshi
   Kubo, Toshiki
   Kamada, Tsukushi
   Okamoto, Kuniaki
   Tsukuba, Takayuki
   Uto, Takuhiro
   Shoyama, Yukihiro
TI ( ) Epigallocatechin 3 gallate inhibits RANKL induced osteoclastogenesis
   via downregulation of NFATc1 and suppression of HO 1 HMGB1 RAGE pathway
SO BIOMEDICAL RESEARCH TOKYO
LA English
DT Article
ID HEME OXYGENASE 1; GREEN TEA; TRANSCRIPTION FACTOR; BONE RESORPTION;
   UP REGULATION; DIFFERENTIATION; CANCER; CELLS; EGCG; EXPRESSION
AB Osteoporosis disturbs the balance of bone metabolism, and excessive bone resorption causes a decrease in bone density, thus increasing the risk of fracture. ( ) Epigallocatechin 3 gallate (EGCG) is the most abundant catechin contained in green tea. EGCG has a variety of pharmacological activities. Recently, it was reported that EGCG inhibits osteoclast differentiation, but the details of the mechanism underlying the EGCG mediated suppression of osteoclastogenesis are unknown. In this study, we investigated the effects of EGCG on several signaling pathways in osteoclastogenesis. EGCG suppressed the expression of the nuclear factor of activated T cells cytoplasmic 1 (NFATc1), the master regulator of osteoclastogenesis. EGCG decreased the expression of cathepsin K, c Src, and ATP6V0d2 and suppressed bone resorption. We also found that EGCG upregulated heme oxygenase 1 (HO 1) and suppressed the extracellular release of high mobility group box 1 (HMGB1). In addition, EGCG decreased the expression of the receptor for advanced glycation end products (RAGE), which is the receptor of HMGB I, in osteoclastogenesis. In summary, our study showed that EGCG could inhibit osteoclast differentiation through the downregulation of NFATc1 and the suppression of the HO 1 HMGB1 RAGE pathway. EGCG might have the potential to be a lead compound that suppresses bone resorption in the treatment of osteoporosis.
C1 [Nishioku, Tsuyoshi; Kubo, Toshiki; Kamada, Tsukushi] Nagasaki Int Univ, Fac Pharmaceut Sci, Dept Pharmacol, 2825 7 Huis Ten Bosch, Nagasaki 8593298, Japan.
   [Okamoto, Kuniaki] Okayama Univ, Dept Dent Pharmacol, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2 5 1 Shikata Cho, Okayama 7008525, Japan.
   [Tsukuba, Takayuki] Nagasaki Univ, Div Oral Pharmacol, Grad Sch Biomed Sci, 1 7 1 Sakamoto, Nagasaki 8528588, Japan.
   [Uto, Takuhiro; Shoyama, Yukihiro] Nagasaki Int Univ, Dept Pharmacognosy, Fac Pharmaceut Sci, 2825 7 Huis Ten Bosch, Nagasaki 8593298, Japan.
C3 Nagasaki International University; Okayama University; Nagasaki
   University; Nagasaki International University
RP Nishioku, T (通讯作者)，Nagasaki Int Univ, 2825 7 Huis Ten Bosch, Nagasaki 8593298, Japan.
EM nishiokut@niu.ac.jp
RI ; Uto, Takuhiro/ISS 5698 2023; Tsukuba, Takayuki/I 9542 2018
OI Uto, Takuhiro/0000 0003 0450 2123; 
FU Japan Society for the Promotion of Science [16K08567]; Grants in Aid for
   Scientific Research [16K08567, 20H03860] Funding Source: KAKEN
FX This work was supported in part by Grants in Aid for Scientific Research
   from the Japan Society for the Promotion of Science [to T. N. (C)
   16K08567].
CR Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   Chen ST, 2019, MOLECULES, V24, DOI 10.3390/molecules24010156
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kuo CL, 2014, IMMUNOPHARM IMMUNOT, V36, P364, DOI 10.3109/08923973.2014.953637
   Kweon MH, 2006, J BIOL CHEM, V281, P33761, DOI 10.1074/jbc.M604748200
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li YZ, 2019, BIOCHEM BIOPH RES CO, V513, P898, DOI 10.1016/j.bbrc.2019.03.165
   Lin RW, 2009, BIOCHEM BIOPH RES CO, V379, P1033, DOI 10.1016/j.bbrc.2009.01.007
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   MILLIN DJ, 1969, J AGR FOOD CHEM, V17, P717, DOI 10.1021/jf60164a026
   Nakachi K, 2000, BIOFACTORS, V13, P49, DOI 10.1002/biof.5520130109
   Nishioku T, 2016, BIOCHEM BIOPH RES CO, V473, P620, DOI 10.1016/j.bbrc.2016.03.147
   Pei JR, 2014, ENVIRON TOXICOL, V29, P588, DOI 10.1002/tox.21784
   Potenza MA, 2007, AM J PHYSIOL ENDOC M, V292, pE1378, DOI 10.1152/ajpendo.00698.2006
   Rivera Pérez J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103716
   Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372
   Shimizu M, 2008, CANCER EPIDEM BIOMAR, V17, P3020, DOI 10.1158/1055 9965.EPI 08 0528
   Shin CM, 2018, CLIN NUTR, V37, P452, DOI 10.1016/j.clnu.2017.01.014
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Stingl JC, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 360
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Yamaguchi Y, 2014, J APPL TOXICOL, V34, P49, DOI 10.1002/jat.2827
   Yu CX, 2017, INT J BIOL SCI, V13, P1560, DOI 10.7150/ijbs.18830
   Zaveri NT, 2006, LIFE SCI, V78, P2073, DOI 10.1016/j.lfs.2005.12.006
   Zhou Z, 2008, J BONE MINER RES, V23, P1084, DOI 10.1359/JBMR.080234
   Zwerina J, 2005, FASEB J, V19, P2011, DOI 10.1096/fj.05 4278fje
NR 35
TC 12
Z9 12
U1 0
U2 7
PU BIOMEDICAL RESEARCH PRESS LTD
PI SAPPORO
PA HOKKAIDO UNIV, LAB HISTOLOGY & CYTOLOGY, C/O TOSHIHIKO IWANAGA, KITA
   15 NISHI 7, SAPPORO, 060 8638, JAPAN
SN 0388 6107
EI 1880 313X
J9 BIOMED RES TOKYO
JI Biomed. Res.
PY 2020
VL 41
IS 6
BP 269
EP 277
DI 10.2220/biomedres.41.269
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA OZ7AO
UT WOS:000595074600002
PM 33268671
OA gold
DA 2025 08 17
ER

PT J
AU Kim, SS
   Jeong, SP
   Park, BS
   Kim, IR
AF Kim, Seong Sik
   Jeong, Soon Pill
   Park, Bong Soo
   Kim, In Ryoung
TI Melatonin Attenuates RANKL Induced Osteoclastogenesis via Inhibition of
   Atp6v0d2 and DC STAMP through MAPK and NFATc1 Signaling Pathways
SO MOLECULES
LA English
DT Article
DE melatonin; bone remodeling; osteoporosis; V ATPase; osteoclastogenesis
ID BONE RESORPTION; PROTON PUMP; FUSION; CELLS; DIFFERENTIATION;
   OSTEOPOROSIS; ACTIVATION; MECHANISMS; PRECURSORS; PREVENTION
AB Melatonin is a hormone secreted by the pineal gland that is involved in the biorhythm of reproductive activities. The present study investigated the inhibitory effects of melatonin on osteoclastogenesis in RAW 264.7 cells according to changes in V ATPase and the corresponding inhibition of the MAPK and NFATc1 signaling processes. Methods: the cytotoxic effect of melatonin was investigated by MTT assay. Osteoclast differentiation and gene expression of osteoclast related factors were confirmed via TRAP staining, pit formation assay, immunofluorescence imaging, western blot, and real time PCR. Results: melatonin was found to inactivate the p38 and JNK of MAP kinase in RAW264.7 cells treated with RANKL and treated with a combination RANKL and melatonin for 1, 3, and 5 days. The melatonin treatment group showed a reduction in osteoclastogenesis transcription factors and ATP6v0d2 gene expression. Conclusions: melatonin inhibits osteoclast differentiation and cell fusion by inhibiting the expression of Atp6v0d2 through the inactivation of MAPK and NFATc1 signaling in RANKL stimulated RAW264.7 macrophages. The findings of the present study suggest that melatonin could be a suitable therapy for bone loss and imply a potential role of melatonin in bone health.
C1 [Kim, Seong Sik; Jeong, Soon Pill] Pusan Natl Univ, Dent Res Inst, Dept Orthodont, Dent Hosp, Yangsan 50612, South Korea.
   [Park, Bong Soo; Kim, In Ryoung] Pusan Natl Univ, Sch Dent, Dept Oral Anat, Yangsan 50612, South Korea.
   [Park, Bong Soo; Kim, In Ryoung] Pusan Natl Univ, Dent & Life Sci Inst, Sch Dent, Yangsan 50612, South Korea.
C3 Pusan National University; Pusan National University; Pusan National
   University
RP Kim, IR (通讯作者)，Pusan Natl Univ, Sch Dent, Dept Oral Anat, Yangsan 50612, South Korea.; Kim, IR (通讯作者)，Pusan Natl Univ, Dent & Life Sci Inst, Sch Dent, Yangsan 50612, South Korea.
EM softid@pusan.ac.kr; spjeong@gmail.com; parkbs@pusan.ac.kr;
   biowool@pusan.ac.kr
RI kim, Inryoung/AGF 2385 2022; Kim, In Ryoung/AGF 2385 2022
OI kim, Inryoung/0000 0003 0232 0385; 
FU National Research Foundation of Korea (NRF)   Korea government
   [NRF 2018R1D1A1B07047739, NRF 2019R1A2C108405712]
FX FundingThis study was financially supported by a National Research
   Foundation of Korea (NRF) grant funded by the Korea government (No.
   NRF 2018R1D1A1B07047739 and NRF 2019R1A2C108405712).
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bae WJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061742
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Boyce BF, 2018, GENETICS OF BONE BIOLOGY AND SKELETAL DISEASE, 2ND EDITION, P173, DOI 10.1016/B978 0 12 804182 6.00011 3
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   CANALIS E, 1988, J CLIN INVEST, V81, P277, DOI 10.1172/JCI113318
   Cardinali DP, 2003, J PINEAL RES, V34, P81, DOI 10.1034/j.1600 079X.2003.00028.x
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Ghareghani M, 2018, FUND CLIN PHARMACOL, V32, P181, DOI 10.1111/fcp.12337
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Kim HJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061142
   Kim SH, 2018, J BONE MINER METAB, V36, P537, DOI 10.1007/s00774 017 0871 2
   Kotlarczyk MP, 2012, J PINEAL RES, V52, P414, DOI 10.1111/j.1600 079X.2011.00956.x
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Ladizesky MG, 2001, LIFE SCI, V70, P557, DOI 10.1016/S0024 3205(01)01431 X
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   LERNER AB, 1958, J AM CHEM SOC, V80, P2587, DOI 10.1021/ja01543a060
   Liu PI, 2021, ONCOGENE, V40, P1503, DOI 10.1038/s41388 020 01613 4
   Lu L, 2017, J CELL MOL MED, V21, P1361, DOI 10.1111/jcmm.13066
   Maria S, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12465
   Maria S, 2014, J PINEAL RES, V56, P115, DOI 10.1111/jpi.12116
   Martin TJ, 2015, REV ENDOCR METAB DIS, V16, P131, DOI 10.1007/s11154 014 9308 6
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Munmun F.A., 2021, ROLE MEK1 2 MEK5 MEL
   O'Brien CA, 2013, BONE, V54, P258, DOI 10.1016/j.bone.2012.08.121
   Oh JH, 2015, MOL CELLS, V38, P279, DOI 10.14348/molcells.2015.2340
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Ping ZC, 2017, ACTA BIOMATER, V51, P513, DOI 10.1016/j.actbio.2017.01.034
   Raisz LG, 1999, CLIN CHEM, V45, P1353
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Rody WJ, 2001, AM J ORTHOD DENTOFAC, V120, P477, DOI 10.1067/mod.2001.118623
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Sanchez Barcelo J, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/830231
   Satué M, 2015, J CELL BIOCHEM, V116, P551, DOI 10.1002/jcb.25005
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Wu QY, 2019, J MOL MED, V97, P19, DOI 10.1007/s00109 018 1723 9
   Xu J, 2003, J CELL BIOCHEM, V88, P1256, DOI 10.1002/jcb.10477
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
NR 47
TC 17
Z9 21
U1 2
U2 9
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD JAN
PY 2022
VL 27
IS 2
AR 501
DI 10.3390/molecules27020501
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA ZB6UI
UT WOS:000756974400001
PM 35056817
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xu, C
   Wang, ZD
   Liu, YJ
   Wei, BG
   Liu, XY
   Duan, KY
   Zhou, PH
   Xie, Z
   Wu, M
   Guan, JZ
AF Xu, Chen
   Wang, Zhaodong
   Liu, Yajun
   Wei, Bangguo
   Liu, Xiangyu
   Duan, Keyou
   Zhou, Pinghui
   Xie, Zhao
   Wu, Min
   Guan, Jianzhong
TI Extracellular vesicles derived from bone marrow mesenchymal stem cells
   loaded on magnetic nanoparticles delay the progression of diabetic
   osteoporosis via delivery of miR 150 5p
SO CELL BIOLOGY AND TOXICOLOGY
LA English
DT Article
DE Diabetic osteoporosis; Bone marrow mesenchymal stem cells; Magnetic
   nanoparticles; Extracellular vesicles; MicroRNA 150 5p; MMP14;
   Wnt/beta catenin pathway; Osteogenesis
ID EXOSOMES
AB Extracellular vesicles derived from bone marrow mesenchymal stem cells (BMSC EVs) are emerged as carriers of therapeutic targets against bone disorders, yet its isolation and purification are limited with recent techniques. Magnetic nanoparticles (MNPs) can load EVs with a unique targeted drug delivery system. We constructed gold coated magnetic nanoparticles (GMNPs) by decorating the surface of the Fe3O4@SiO2 core and a silica shell with poly(ethylene glycol) (PEG) aldehyde (CHO) and examined the role of BMSC EVs loaded on GMNPs in diabetic osteoporosis (DO). The osteoporosis related differentially expressed miR 150 5p was singled out by microarray analysis. DO models were then established in Sprague Dawley rats by streptozotocin injection, where poor expression of miR 150 5p was validated in the bone tissues. Next, GMNP(E) was prepared by combining GMNPs with anti CD63, after which osteoblasts were co cultured with the GMNP(E) BMSC EVs. The re expression of miR 150 5p facilitated osteogenesis in osteoblasts. GMNP(E) could promote the enrichment of EVs in the bone tissues of DO rats. BMSC EVs delivered miR 150 5p to osteoblasts, where miR 150 5p targeted MMP14 and consequently activated Wnt/beta catenin pathway. This effect contributed to the enhancement of osteoblast proliferation and maturation. Furthermore, GMNP(E) enhanced the EV based delivery of miR 150 5p to regulate the MMP14/Wnt/beta catenin axis, resulting in promotion of osteogenesis. Overall, our findings suggest the potential of GMNP BMSCEVs to strengthen osteoblast proliferation and maturation in DO, showing promise as an appealing drug delivery strategy against DO.
C1 [Xu, Chen; Wang, Zhaodong; Liu, Yajun; Wei, Bangguo; Liu, Xiangyu; Duan, Keyou; Zhou, Pinghui; Wu, Min; Guan, Jianzhong] Bengbu Med Coll, Dept Orthoped, Affiliated Hosp 1, 287 Changhuai Rd, Bengbu 233000, Anhui, Peoples R China.
   [Xu, Chen; Zhou, Pinghui; Guan, Jianzhong] Bengbu Med Coll, Anhui Prov Key Lab Tissue Transplantat, Bengbu 233000, Peoples R China.
   [Xu, Chen; Guan, Jianzhong] Jinan Univ, Guangzhou 510000, Guangdong, Peoples R China.
   [Xie, Zhao] Third Mil Med Univ Chinese PLA, Chongqing 400038, Peoples R China.
C3 Bengbu Medical University; Bengbu Medical University; Jinan University;
   Army Medical University
RP Wu, M; Guan, JZ (通讯作者)，Bengbu Med Coll, Dept Orthoped, Affiliated Hosp 1, 287 Changhuai Rd, Bengbu 233000, Anhui, Peoples R China.
EM minwu2021@126.com; jianzhongguan2021@126.com
RI Wu, Min/AAK 8627 2020
OI Guan, Jianzhong/0009 0006 5601 7276
FU Key Project of Natural Science of Bengbu Medical College [2020byzd178];
   Key Project of Natural Science Research of Anhui Province [KJ2020ZD51]
FX This work was supported by Key Project of Natural Science of Bengbu
   Medical College (2020byzd178) and Key Project of Natural Science
   Research of Anhui Province (KJ2020ZD51).
CR An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Cao Y, 2021, EUR REV MED PHARMACO, V25, P636, DOI 10.26355/eurrev_202101_24625
   Chen Z, 2018, J IMMUNOL, V201, P2472, DOI 10.4049/jimmunol.1800304
   Cortet B, 2019, JOINT BONE SPINE, V86, P315, DOI 10.1016/j.jbspin.2018.08.002
   Crous A, 2021, STEM CELL REV REP, V17, P1570, DOI 10.1007/s12015 021 10142 w
   Delgado Calle J, 2018, FASEB J, V32, P2878, DOI 10.1096/fj.201700919RRR
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dong CL, 2015, J CELL BIOCHEM, V116, P2970, DOI 10.1002/jcb.25245
   Duan SR, 2020, DRUG DES DEV THER, V14, P3143, DOI [10.2147/DDDT.S255828, 10.2147/DDDT.S255628]
   Ge J, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5120275
   Guan H, 2020, EXP CELL RES, V392, DOI 10.1016/j.yexcr.2020.112007
   Huang YJ, 2021, J CELL MOL MED, V25, P7734, DOI 10.1111/jcmm.16654
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Jauregui R, 2018, ACS APPL MATER INTER, V10, P33847, DOI 10.1021/acsami.8b09751
   Kooijmans SAA, 2013, J CONTROL RELEASE, V172, P229, DOI 10.1016/j.jconrel.2013.08.014
   Li SY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.675470
   Li T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115577
   Liao ZW, 2019, THERANOSTICS, V9, P4084, DOI 10.7150/thno.33638
   Liu BH, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd0914
   Liu SY, 2020, NAT BIOMED ENG, V4, P1063, DOI 10.1038/s41551 020 00637 1
   Liu TJ, 2020, ARCH ORAL BIOL, V113, DOI 10.1016/j.archoralbio.2020.104713
   Liu Z, 2021, BMC CANCER, V21, DOI 10.1186/s12885 021 08185 w
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu H, 2014, ONCOGENE, V33, P2909, DOI 10.1038/onc.2013.247
   Mohsin S, 2019, EXPERT OPIN BIOL TH, V19, P937, DOI 10.1080/14712598.2019.1618266
   Mori MA, 2019, CELL METAB, V30, P656, DOI 10.1016/j.cmet.2019.07.011
   Tran N, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957 4484/24/18/185102
   Tran N, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957 4484/23/45/455104
   Oliveira Rodríguez M, 2017, BIOSENS BIOELECTRON, V87, P38, DOI 10.1016/j.bios.2016.08.001
   Paiva KBS, 2017, PROG MOL BIOL TRANSL, V148, P203, DOI 10.1016/bs.pmbts.2017.05.001
   Pang XL, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 02949 1
   Qin YH, 2016, SCI REP UK, V6, DOI 10.1038/srep21961
   Qiu M, 2021, HUM GENE THER, V32, P717, DOI 10.1089/hum.2020.005
   Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44
   Rehling T, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/6324348
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Schacter GI, 2017, ENDOCRIN METAB CLIN, V46, P63, DOI 10.1016/j.ecl.2016.09.010
   Sharma AR, 2019, J NUTR BIOCHEM, V74, DOI 10.1016/j.jnutbio.2019.108228
   Tang CY, 2020, BIOCHEM J, V477, P2421, DOI 10.1042/BCJ20200036
   Wang Q, 2020, MOL CELL BIOCHEM, V463, P91, DOI 10.1007/s11010 019 03632 6
   Wang YY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03899 z
   Wang Fischer Y, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/8054073
   Wu K, 2019, NANOTECHNOLOGY, V30, DOI 10.1088/1361 6528/ab4241
   Xu YX, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2021.153485
   Yang CL, 2020, LAB INVEST, V100, P1494, DOI 10.1038/s41374 020 0451 2
   Yuan ZY, 2016, CURR STEM CELL RES T, V11, P216, DOI 10.2174/1574888X10666150519093429
   Zhao CY, 2010, OSTEOPOROSIS INT, V21, P129, DOI 10.1007/s00198 009 0928 8
   Zhou JR, 2018, CANCER IMMUNOL RES, V6, P1578, DOI 10.1158/2326 6066.CIR 17 0479
   Zhu JM, 2019, THERANOSTICS, V9, P6901, DOI 10.7150/thno.37357
   Zuo RT, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1426 3
NR 50
TC 18
Z9 18
U1 3
U2 38
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0742 2091
EI 1573 6822
J9 CELL BIOL TOXICOL
JI Cell Biol. Toxicol.
PD AUG
PY 2023
VL 39
IS 4
BP 1257
EP 1274
DI 10.1007/s10565 022 09744 y
EA SEP 2022
PG 18
WC Cell Biology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Toxicology
GA P2ZA7
UT WOS:000854415100003
PM 36112264
OA hybrid
DA 2025 08 17
ER

PT J
AU Wu, R
   Tang, Y
   Zang, WQ
   Wang, YY
   Li, M
   Du, YW
   Zhao, GQ
   Xu, YM
AF Wu, Rui
   Tang, Yue
   Zang, Wenqiao
   Wang, Yuanyuan
   Li, Min
   Du, Yuwen
   Zhao, Guoqiang
   Xu, Yuming
TI MicroRNA 128 regulates the differentiation of rat bone mesenchymal stem
   cells into neuron like cells by Wnt signaling
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE BMSCs; Neuron; Micror 128; Differentiation; Wnt3a
ID MARROW STROMAL CELLS
AB Bone marrow mesenchymal stem cells (BMSCs) are a source of multipotent stem cells ideally suited for various cell based therapies. BMSCs can differentiate into neuron like cells under the appropriate conditions. MicroRNAs are members of a family of noncoding small RNAs that regulate gene expression at the posttranscriptional level, either by inhibiting mRNA translation or by promoting mRNA degradation. MicroRNAs play an important role in the differentiation of BMSCs into neurons. MicroRNA 128, a brain enriched microRNA, was recently found to be necessary in the neural differentiation of BMSCs. Studies have shown that Wnt signaling pathway is involved in regulating MSC differentiation. Our goal here was to investigate whether microRNA 128 can regulate the differentiation of BMSCs through modulation of Wnt3a, a key component of the Wnt signaling pathway. By means of dual luciferase reporter assay, we describe for the first time that by binding to a specific site in the 3' UTR of Wnt3a in BMSCs, downregulated microRNA 128 may lead to the neural differentiation of mesenchymal stem cells. Transfection of microRNA 128 mimic decreased the nerve cell markers and Wnt3a expression levels. On the other hand, the inhibition of microRNA 128 significantly elevated the nerve cell markers as well as the Wnt3a expression levels. This suggests that microRNA 128 acts as an endogenous attenuator of BMSCs differentiation into neurons.
C1 [Wu, Rui; Xu, Yuming] Zhengzhou Univ, Dept Neurol, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China.
   [Wu, Rui] Zhengzhou Univ, Dept Neurol Rehabil, Affiliated Hosp 2, Zhengzhou 450014, Peoples R China.
   [Tang, Yue; Zang, Wenqiao; Wang, Yuanyuan; Li, Min; Du, Yuwen; Zhao, Guoqiang] Zhengzhou Univ, Coll Basic Med Sci, Zhengzhou 450001, Peoples R China.
C3 Zhengzhou University; Zhengzhou University; Zhengzhou University
RP Xu, YM (通讯作者)，Zhengzhou Univ, Dept Neurol, Affiliated Hosp 1, 1 Jianshe Rd, Zhengzhou 450052, Peoples R China.
EM zhaogq@zzu.edu.cn; ymxuzzu@gmail.com
RI xu, yuming/KRP 2493 2024
CR Clements WK, 2009, DEV DYNAM, V238, P1788, DOI 10.1002/dvdy.21977
   Collino F, 2011, VITAM HORM, V87, P291, DOI 10.1016/B978 0 12 386015 6.00033 0
   De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753
   Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570
   Foshay Kara M, 2007, Curr Stem Cell Res Ther, V2, P264, DOI 10.2174/157488807782793781
   Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008 5472.CAN 08 2629
   Guo L, 2011, EXP HEMATOL, V39, P608, DOI 10.1016/j.exphem.2011.01.011
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kim BJ, 2002, NEUROREPORT, V13, P1185, DOI 10.1097/00001756 200207020 00023
   Klein JD, 2011, METHODS MOL BIOL, V698, P75, DOI 10.1007/978 1 60761 999 4_7
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sanchez Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389
   Steward O, 2003, NEURON, V40, P347, DOI 10.1016/S0896 6273(03)00635 4
   Tiedge H, 1999, SCIENCE, V283, P186, DOI 10.1126/science.283.5399.186
   Torrente Y, 2008, CELL TRANSPLANT, V17, P1103, DOI 10.3727/096368908787236576
   Wang JJ, 2010, CHIN J HISTOCHEM CYT, V19, P222
   Wang YL, 2009, CURR OPIN MOL THER, V11, P292
   Wislet Gendebien S, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/601560
   Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097 4547(20000815)61:4<364::AID JNR2>3.0.CO;2 C
   Yang Q, 2008, BIOCHEM BIOPH RES CO, V372, P520, DOI 10.1016/j.bbrc.2008.05.039
   Yanjie J., 2007, NEUROREPORT, V18, P1443
   Ye Y, 2011, CELL BIOCHEM BIOPHYS, V59, P179, DOI 10.1007/s12013 010 9130 z
   Yi R, 2011, J CELL SCI, V124, P1775, DOI 10.1242/jcs.069104
   [曾荣 Zeng Rong], 2012, [广东医学, Guangdong Medical Journal], V33, P3031
   Zhang XM, 2005, ONCOGENE, V24, P4220, DOI 10.1038/sj.onc.1208597
   Zhang Y, 2009, J MOL MED, V87, P43, DOI 10.1007/s00109 008 0403 6
NR 26
TC 29
Z9 37
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD FEB
PY 2014
VL 387
IS 1 2
BP 151
EP 158
DI 10.1007/s11010 013 1880 7
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AA1AN
UT WOS:000330828600016
PM 24307102
DA 2025 08 17
ER

PT J
AU Hu, WH
   Cai, CH
   Li, YH
   Kang, F
   Chu, TW
   Dong, SW
AF Hu, Wenhui
   Cai, Chenhui
   Li, Yuheng
   Kang, Fei
   Chu, Tongwei
   Dong, Shiwu
TI Farnesoid X receptor agonist attenuates subchondral bone osteoclast
   fusion and osteochondral pathologies of osteoarthritis via suppressing
   JNK1/2/NFATc1 pathway
SO FASEB JOURNAL
LA English
DT Article
DE farnesoid X receptor; JNK1; 2; NFATc1 pathway; osteoarthritis;
   osteoclastogenesis; subchondral bone
ID CRUCIATE LIGAMENT TRANSECTION; MESENCHYMAL STEM CELLS; CARTILAGE
   DEGRADATION; ARTICULAR CARTILAGE; BILE ACID; INHIBITION; KNEE; MODELS;
   INJURY; PAIN
AB Osteoarthritis (OA) is a prevalent degenerative disease of the joint, featured by articular cartilage destruction and subchondral bone marrow lesions. Articular cartilage and subchondral bone constitute an osteochondral unit that guarantees joint homeostasis. During OA initiation, activated osteoclasts in subchondral bone ultimately result in impaired capacities of the subchondral bone in response to mechanical stress, followed by the degradation of overlying articular cartilage. Thus, targeting osteoclasts could be a potential therapeutic option for treating OA. Here, we observed that farnesoid X receptor (FXR) expression and osteoclast fusion and activity in subchondral bone were concomitantly changed during early stage OA in the OA mouse model established by anterior cruciate ligament transection (ACLT). Then, we explored the therapeutic effects of FXR agonist GW4064 on the osteochondral pathologies in ACLT mice. We showed that GW4064 obviously ameliorated subchondral bone deterioration, associated with reduction in tartrate resistant acid phosphatase (TRAP) positive multinuclear osteoclast number, as well as articular cartilage degradation, which were blocked by the treatment with FXR antagonist Guggulsterone. Mechanistically, GW4064 impeded osteoclastogenesis through inhibiting subchondral bone osteoclast fusion via suppressing c Jun N terminal kinase (JNK) 1/2/nuclear factor of activated T cells 1 (NFATc1) pathway. Taken together, our results present evidence for the protective effects of GW4064 against OA by blunting osteoclast mediated aberrant subchondral bone loss and subsequent cartilage deterioration. Therefore, GW4064 demonstrates the potential as an alternative therapeutic option against OA for further drug development.
C1 [Hu, Wenhui; Li, Yuheng; Kang, Fei; Dong, Shiwu] Third Mil Med Univ, Army Med Univ, Coll Biomed Engn, Dept Biomed Mat Sci, Chongqing, Peoples R China.
   [Cai, Chenhui; Chu, Tongwei] Third Mil Med Univ, Army Med Univ, Xinqiao Hosp, Dept Orthoped, Chongqing, Peoples R China.
   [Dong, Shiwu] Third Mil Med Univ, Army Med Univ, State Key Lab Trauma Burns & Combined Injury, Chongqing, Peoples R China.
C3 Army Medical University; Army Medical University; Army Medical
   University
RP Dong, SW (通讯作者)，Third Mil Med Univ, Dept Biomed Mat Sci, Chongqing 400038, Peoples R China.; Chu, TW (通讯作者)，Third Mil Med Univ, Xinqiao Hosp, Dept Orthoped, Chongqing 400037, Peoples R China.
EM chtw@sina.com; dongshiwu@163.com
RI ; li, yuheng/LPQ 3255 2024
OI Hu, Wenhui/0000 0002 8886 7260; 
FU Key Program of Natural Science Foundation of China [81930067]; Project
   of Nature Science Foundation of China [31870962]; Medical Innovation of
   Graduate Students in Chongqing [CYS20372]; General Program of Natural
   Science Foundation of Chongqing [cstc2019jcyj  msxmX0176]
FX This work was supported by grants from the Key Program of Natural
   Science Foundation of China (81930067), the Project of Nature Science
   Foundation of China (31870962), the Medical Innovation of Graduate
   Students in Chongqing (CYS20372), and the General Program of Natural
   Science Foundation of Chongqing (cstc2019jcyj  msxmX0176).
CR Andriacchi TP, 2020, OSTEOARTHRITIS CARTI, V2, DOI 10.1016/j.ocarto.2020.100026
   Bingham CO, 2006, ARTHRITIS RHEUM US, V54, P3494, DOI 10.1002/art.22160
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Cariou B, 2006, J BIOL CHEM, V281, P11039, DOI 10.1074/jbc.M510258200
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Chang Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082904
   Chatziravdeli V, 2019, CURR GENOMICS, V20, P184, DOI 10.2174/1389202920666190422142053
   Chen D, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.44
   Cho SW, 2013, J BONE MINER RES, V28, P2109, DOI 10.1002/jbmr.1961
   Conaghan PG, 2019, NAT REV RHEUMATOL, V15, P355, DOI 10.1038/s41584 019 0221 y
   Contartese D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103696
   Cosenza S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15376 8
   Coughlin TR, 2016, ANN NY ACAD SCI, V1383, P58, DOI 10.1111/nyas.13261
   Cui Z, 2016, ANN RHEUM DIS, V75, P1714, DOI 10.1136/annrheumdis 2015 207923
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092 8674(00)00116 1
   Deng JZ, 2021, FASEB J, V35, DOI 10.1096/fj.202100135R
   Dong YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060943
   Edd SN, 2018, OSTEOARTHR CARTILAGE, V26, P1425, DOI 10.1016/j.joca.2018.06.017
   Fang C, 2022, ACTA PHARMACOL SIN, V43, P1299, DOI 10.1038/s41401 021 00747 9
   Fang H, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21184 5
   Gao XL, 2018, CARDIOVASC RES, V114, P737, DOI 10.1093/cvr/cvy011
   Gianotti SM, 2009, J SCI MED SPORT, V12, P622, DOI 10.1016/j.jsams.2008.07.005
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Goldring SR, 2012, THER ADV MUSCULOSKEL, V4, P249, DOI 10.1177/1759720X12437353
   Han CY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072069
   Hayami T, 2006, BONE, V38, P234, DOI 10.1016/j.bone.2005.08.007
   Hayami T, 2012, BONE, V50, P1250, DOI 10.1016/j.bone.2012.03.025
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Hu Y, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00147 z
   Huang XJ, 2018, BIOMED PHARMACOTHER, V107, P433, DOI 10.1016/j.biopha.2018.07.161
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Kitagawa F, 2013, TISSUE ENG PART C ME, V19, P438, DOI [10.1089/ten.TEC.2012.0166, 10.1089/ten.tec.2012.0166]
   Krenn V, 2006, HISTOPATHOLOGY, V49, P358, DOI 10.1111/j.1365 2559.2006.02508.x
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Lu ZY, 2017, CHEM BIOL INTERACT, V277, P62, DOI 10.1016/j.cbi.2017.08.011
   Ma HL, 2007, OSTEOARTHR CARTILAGE, V15, P695, DOI 10.1016/j.joca.2006.11.005
   Ma K, 2006, J CLIN INVEST, V116, P1102, DOI 10.1172/JCI25604
   Ma L, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4855
   Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032
   Meyer EG, 2008, AM J SPORT MED, V36, P1966, DOI 10.1177/0363546508318046
   Park DR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18208 y
   Pastoureau PC, 2010, OSTEOARTHR CARTILAGE, V18, pS106, DOI 10.1016/j.joca.2010.05.024
   Prodromos CC, 2007, ARTHROSCOPY, V23, P1320, DOI 10.1016/j.arthro.2007.07.003
   Qin HJ, 2019, BONE, V125, P140, DOI 10.1016/j.bone.2019.05.010
   Sekiguchi Y, 2017, MOL MED REP, V16, P1328, DOI 10.3892/mmr.2017.6752
   Shaktivesh, 2019, J MECH BEHAV BIOMED, V90, P388, DOI 10.1016/j.jmbbm.2018.10.023
   Sharma AR, 2013, INT J MOL SCI, V14, P19805, DOI 10.3390/ijms141019805
   Siebelt M, 2014, BONE, V66, P163, DOI 10.1016/j.bone.2014.06.009
   Tavares SJS, 2021, FITOTERAPIA, V150, DOI 10.1016/j.fitote.2021.104842
   Srikanth VK, 2005, OSTEOARTHR CARTILAGE, V13, P769, DOI 10.1016/j.joca.2005.04.014
   Strassle BW, 2010, OSTEOARTHR CARTILAGE, V18, P1319, DOI 10.1016/j.joca.2010.06.007
   Tamimi I, 2020, BONE, V140, DOI 10.1016/j.bone.2020.115558
   Tateiwa D, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080818
   Temp J, 2020, OSTEOARTHR CARTILAGE, V28, P475, DOI 10.1016/j.joca.2019.11.003
   Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200
   van Meer BL, 2015, BRIT J SPORT MED, V49, P975, DOI 10.1136/bjsports 2013 093258
   Vincent TL, 2019, SEMIN ARTHRITIS RHEU, V49, pS36, DOI 10.1016/j.semarthrit.2019.09.018
   Wang TT, 2018, CYTOKINE GROWTH F R, V44, P38, DOI 10.1016/j.cytogfr.2018.10.002
   Yahara Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.622035
   Zeng C, 2015, OSTEOARTHR CARTILAGE, V23, P189, DOI 10.1016/j.joca.2014.11.014
   Zeng QY, 2020, CHEM BIOL INTERACT, V327, DOI 10.1016/j.cbi.2020.109179
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zheng Ting, 2017, J Bone Metab, V24, P207, DOI 10.11005/jbm.2017.24.4.207
   Zheng T, 2017, ONCOTARGET, V8, P76558, DOI 10.18632/oncotarget.20576
   Zhou F, 2019, ACTA PHARM SIN B, V9, P973, DOI 10.1016/j.apsb.2019.01.015
   Zhu M, 2013, FASEB J, V27, P3344, DOI 10.1096/fj.12 220228
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
   Zhu XB, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.607764
NR 68
TC 7
Z9 7
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2022
VL 36
IS 4
AR e22243
DI 10.1096/fj.202101717R
PG 17
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA ZZ0CU
UT WOS:000772945800001
PM 35224782
DA 2025 08 17
ER

PT J
AU Zhu, J
   Tang, Y
   Wu, Q
   Ji, YC
   Feng, ZF
   Kang, FW
AF Zhu, Jie
   Tang, Yi
   Wu, Qing
   Ji, Ying Chen
   Feng, Zi Fan
   Kang, Fei Wu
TI HIF 1α facilitates osteocyte mediated osteoclastogenesis by activating
   JAK2/STAT3 pathway in vitro
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE hypoxia inducible factor 1 alpha; JAK2; STAT3 pathway;
   osteoclastogenesis; osteocyte; receptor activator of nuclear
   factor kappa B
ID RANKL EXPRESSION; HYPOXIA; CELLS; DIFFERENTIATION; IL 6; OSTEOBLASTS;
   HIF1 ALPHA; BINDING; PROTEIN; OXYGEN
AB Osteocytes, entrapped within the mineralized bone matrix, has been found to have numerous functions such as acting as an orchestrator of bone remodeling through regulation of both osteoclast and osteoblast activity and also functioning as an endocrine cell. Due to a specialized morphology and surrounding structure, osteocytes are more tolerant to hypoxia during osteoporosis, fracture, osteoarthritis, and orthodontic orthognathic combination therapy. Hypoxia inducible factor 1 alpha (HIF 1 alpha) is one of the master regulators of hypoxia reactions, playing an important role in bone modeling, remodeling, and homeostasis. This study aimed to investigate the pivotal functional role of HIF 1 alpha in osteocytes initiating of bone remodeling under hypoxia. In the present study, the osteoclasts formation induced by RAW264.7 was significantly promoted in conditioned media (CM) from osteocytic MLO Y4 exposed to hypoxia in vitro. Therefore, hypoxic MLO Y4 cells simulated by 100 mu mol/L CoCl2 or 2% O 2 stably expressed HIF 1 alpha proteins and upregulated the expression of receptor activator of nuclear factor kappa B ligand (RANKL) at both the messenger RNA (mRNA) and protein level. Furthermore, with the Knockdown of HIF 1 alpha, the expression of RANKL mRNA and protein decreased after transient transfection. In addition, the phosphorylation of Janus kinase 2 (JAK2) and signal transducer and activator of transcription (STAT3) was also correlated with HIF 1 alpha and RANKL levels under hypoxia. Then AG490, a JAK2 inhibitor, inhibited p JAK2, p STAT3 and RANKL expression. It was possible that AG490 disturbed the contact of HIF 1 alpha and RANKL by JAK2/STAT3 pathway, influencing osteoclastogenesis. Our findings suggested that HIF 1 alpha promoted the expression of RANKL by activating JAK2/STAT3 pathway in MLO Y4 cells, and enhanced osteocyte mediated osteoclastic differentiation in vitro.
C1 [Zhu, Jie; Tang, Yi; Wu, Qing; Ji, Ying Chen; Feng, Zi Fan; Kang, Fei Wu] Tongji Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Shanghai, Peoples R China.
   [Zhu, Jie; Tang, Yi; Wu, Qing; Ji, Ying Chen; Feng, Zi Fan; Kang, Fei Wu] Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Shanghai, Peoples R China.
C3 Tongji University
RP Kang, FW (通讯作者)，Tongji Univ, Hosp Stomatol, Dept Oral & Maxillofacial Surg, 399,Middle Yan Chang Rd, Shanghai 200072, Peoples R China.
EM kfw@tongji.edu.cn
RI Zhu, Jie/L 7165 2019
FU Technology Committee Foundation of Shanghai [16411961100]; National
   Natural Science Foundation of China [81670961]
FX Technology Committee Foundation of Shanghai, Grant/Award Number:
   16411961100; National Natural Science Foundation of China, Grant/Award
   Number: 81670961
CR Al Dujaili SA, 2011, J CELL BIOCHEM, V112, P2412, DOI 10.1002/jcb.23164
   Arnett TR, 2010, ARCH BIOCHEM BIOPHYS, V503, P103, DOI 10.1016/j.abb.2010.07.021
   Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223 013 9774 y
   Bhaskara VK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105555
   Bonewald LF., 2010, ANN NY ACAD SCI, V1116, P281
   Bonewald Lynda F, 2006, Bonekey Osteovision, V3, P7
   Choe JY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4162
   Dodd JS, 1999, AM J PHYSIOL CELL PH, V277, pC598, DOI 10.1152/ajpcell.1999.277.3.C598
   FranzOdendaal T. A., 2010, DEV DYNAM, V235, P176
   Greer SN, 2012, EMBO J, V31, P2448, DOI 10.1038/emboj.2012.125
   Hagberg H, 1996, PEDIATR RES, V40, P603, DOI 10.1203/00006450 199610000 00015
   Harada D., 2014, BONE DRUGS PEDIAT, P335, DOI [10.1007/978 1 4899 7436 5_8, DOI 10.1007/978 1 4899 7436 5_8]
   Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394
   Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771
   Johnson RW, 2015, PHARMACOL THERAPEUT, V150, P169, DOI 10.1016/j.pharmthera.2015.02.002
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim HJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061467
   Klein Nulend J, 2013, BONE, V54, P182, DOI 10.1016/j.bone.2012.10.013
   Knowles HJ, 2009, BONE, V44, pS132, DOI 10.1016/j.bone.2009.01.287
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Letechipia JE, 2010, MED HYPOTHESES, V75, P196, DOI 10.1016/j.mehy.2010.02.021
   Li CH, 2016, INFLAMM RES, V65, P193, DOI 10.1007/s00011 015 0905 y
   Li CH, 2013, BIOCHEM BIOPH RES CO, V435, P533, DOI 10.1016/j.bbrc.2013.04.084
   Li J., 2013, ECS ELECTROCHEMISTY, V2, pA25, DOI DOI 10.4161/JKST.23930
   Liu T, 2012, INT J BIOCHEM CELL B, V44, P1337, DOI 10.1016/j.biocel.2012.04.017
   Lovibond AC, 2003, BIOCHEM BIOPH RES CO, V309, P762, DOI 10.1016/j.bbrc.2003.08.068
   Lu CY, 2013, BONE, V52, P220, DOI 10.1016/j.bone.2012.09.037
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Park HJ, 2011, MOL CELLS, V31, P573, DOI 10.1007/s10059 011 1055 x
   PEAD MJ, 1988, CALCIFIED TISSUE INT, V43, P92, DOI 10.1007/BF02555153
   Perez Amodio S, 2004, J BONE MINER RES, V19, P1722, DOI 10.1359/JBMR.040509
   Rochefort GY, 2010, OSTEOPOROSIS INT, V21, P1457, DOI 10.1007/s00198 010 1194 5
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447
   Shaw AT, 2016, SEMIN CELL DEV BIOL, V49, P2, DOI 10.1016/j.semcdb.2015.10.013
   Sun KT, 2015, BONE, V73, P145, DOI 10.1016/j.bone.2014.11.026
   Tamama K., 2015, J CELL BIOCHEM, V112, P804
   Tan SD, 2007, BONE, V41, P745, DOI 10.1016/j.bone.2007.07.019
   Tando T, 2016, BIOCHEM BIOPH RES CO, V470, P391, DOI 10.1016/j.bbrc.2016.01.033
   Tang ZN, 2011, BIOCHEM BIOPH RES CO, V408, P411, DOI 10.1016/j.bbrc.2011.04.035
   Tate MLK, 1998, BONE, V22, P107
   Tseng WP, 2010, J CELL PHYSIOL, V223, P810, DOI 10.1002/jcp.22104
   Utting JC, 2006, EXP CELL RES, V312, P1693, DOI 10.1016/j.yexcr.2006.02.007
   Utting JC, 2010, CELL BIOCHEM FUNCT, V28, P374, DOI 10.1002/cbf.1660
   Wan C, 2010, ANN NY ACAD SCI, V1192, P322, DOI 10.1111/j.1749 6632.2009.05238.x
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xu CF, 2017, MED SCI MONITOR, V23, P4909, DOI 10.12659/MSM.905418
   Xu NR, 2013, EXP MOL PATHOL, V94, P33, DOI 10.1016/j.yexmp.2012.08.003
   YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463
   Yang YZ, 2009, CRIT REV EUKAR GENE, V19, P197, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.30
   Yu X, 2018, BIOL CHEM, V399, P1313, DOI 10.1515/hsz 2018 0253
NR 55
TC 83
Z9 98
U1 1
U2 68
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD NOV
PY 2019
VL 234
IS 11
BP 21182
EP 21192
DI 10.1002/jcp.28721
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA IM5EX
UT WOS:000478018200178
PM 31032948
DA 2025 08 17
ER

PT J
AU Barnes, VM
   Xu, T
   Shimizu, E
   Nakatani, T
   Jefcoat, S
   Vasilov, A
   Qin, L
   Partridge, NC
AF Barnes, Virginia Monsul
   Xu, Tao
   Shimizu, Emi
   Nakatani, Teruyo
   Jefcoat, Steven
   Vasilov, Anatoliy
   Qin, Ling
   Partridge, Nicola C.
TI Triclosan Blocks MMP 13 Expression in Hormone Stimulated
   Osteoblasts
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE Matrix metalloproteinase 13; osteoblasts; periodontal diseases;
   triclosan
ID BONE DEVELOPMENT; HYPERTROPHIC CHONDROCYTES; COLLAGENASE 3 MMP 13;
   CELLS; GROWTH; ROLES; MMP13; MOUSE
AB Background: Matrix metalloproteinase 13 (MMP 13) is an important enzyme for the modulation of bone turnover and gingival recession. Elevated levels of MMP 13 are associated with alveolar bone resorption, periodontal ligament breakdown, and gingival attachment loss, which are the clinical symptoms of periodontal disease. Evidence continues to suggest that periodontal disease contributes to oral tissue breakdown and is linked to numerous systemic conditions. Triclosan (TCN) is a long standing, proven antibacterial and anti inflammatory agent found in the only Food and Drug Administration approved dentifrice for the treatment of plaque and gingivitis.
   Methods: This study examines the inhibitory effects of TCN on lipopolysaccharide , parathyroid hormone (PTH) , and prostaglandin E 2 (PGE(2)) induced expression of MMP 13 in UMR 106 01 cells, an osteoblastic osteosarcoma cell line. The cells were stimulated with PTH or PGE2 to induce MMP 13 mRNA expression, and real time reverse transcription polymerase chain reaction was performed to determine gene expression levels. Western blot analysis assessed the presence or absence of protein degradation or inhibition of protein synthesis. MMP 13 promoter reporter assay was used to explore possible direct effects of TCN on the MMP 13 promoter.
   Results: TCN significantly reduced PTH or PGE(2) elevated expression of MMP 13 in osteoblastic cells without affecting basal levels of the mRNA. Surprisingly, TCN enhanced the expression of c fos and amphiregulin mRNA. A promoter assay indicated that TCN directly inhibits the activation of the PTH responsive minimal promoter of MMP 13.
   Conclusion: The present study appears to have identified a nuclear mechanism of action of TCN that accounts for the ability of TCN to inhibit PTH  or PGE(2) induced MMP 13 expression in osteoblastic cells.
C1 [Barnes, Virginia Monsul] Colgate Palmol Co Technol Ctr, Piscataway, NJ USA.
   [Xu, Tao] Colgate Palmol Co Technol Ctr, Clin Res, Piscataway, NJ USA.
   [Shimizu, Emi; Nakatani, Teruyo; Partridge, Nicola C.] NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, New York, NY 10010 USA.
   [Jefcoat, Steven; Vasilov, Anatoliy; Qin, Ling] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA.
C3 New York University; Rutgers University System; Rutgers University New
   Brunswick; Rutgers University Biomedical & Health Sciences
RP Partridge, NC (通讯作者)，NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, 345 E 24th St, New York, NY 10010 USA.
EM ncp234@nyu.edu
OI Partridge, Nicola/0000 0002 5406 4814
FU Colgate Palmolive Company
FX This research was funded by the Colgate Palmolive Company. The authors
   thank Rose Richter (Colgate Palmolive Company Technology Center,
   Piscataway, NJ) for assistance with formatting of the figures and
   statistics and Harsh Trivedi (Colgate Palmolive Company Technology
   Center) for his valuable critique. This work is based on a thesis
   submitted by Virginia Monsul Barnes to the graduate faculty of the
   University of Medicine and Dentistry of New Jersey/Robert Wood Johnson
   Medical School in partial fulfillment of the requirements for the MS
   degree. Drs. Barnes and Xu were full time employees of the Colgate
   Palmolive Company at the time of the research. Dr. Barnes is currently
   the Associate Director of Clinical Research at the Colgate Palmolive
   Company Technology Center. Drs. Shimizu, Nakatani, Jefcoat, Vasilov,
   Qin, and Partridge had no financial interest in the company beyond the
   funding provided for this work.
CR Baron R., 2003, GEN PRINCIPLES BONE, P1
   Caton JG, 2000, J PERIODONTOL, V71, P521, DOI 10.1902/jop.2000.71.4.521
   D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200
   Davis BA, 1998, CALCIFIED TISSUE INT, V63, P416, DOI 10.1007/s002239900550
   Delaissé JM, 2000, CLIN CHIM ACTA, V291, P223, DOI 10.1016/S0009 8981(99)00230 2
   GACK S, 1995, CELL GROWTH DIFFER, V6, P759
   Gaffar Abdul, 2004, Compend Contin Educ Dent, V25, P4
   GOLUB LM, 1994, J AM DENT ASSOC, V125, P163, DOI 10.14219/jada.archive.1994.0261
   Golub LM, 1994, J AM DENT ASSOC, V125, P169
   Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200
   Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101
   Jeffcoat M, 2005, J PERIODONTOL, V76, P2125, DOI 10.1902/jop.2005.76.11 S.2125
   Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097 0177(199703)208:3<387::AID AJA9>3.0.CO;2 E
   MEYER RB, 1974, LIFE SCI, V14, P1019, DOI 10.1016/0024 3205(74)90228 8
   Mustafa M, 2003, J PHARM SCI, V92, P1648, DOI 10.1002/jps.10429
   PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo 120 5 1956
   PARTRIDGE NC, 1993, FRONTIERS OF OSTEOSARCOMA RESEARCH, P269
   Qin L, 2005, J BIOL CHEM, V280, P3974, DOI 10.1074/jbc.M409807200
   Scannapieco Frank A, 2004, Compend Contin Educ Dent, V25, P16
   SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378 1119(88)90403 9
   Socransky S S., 2003, Clinical Periodontology and Implant Dentistry, V4, P106
   Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461
   Tuckermann JP, 2000, J BONE MINER RES, V15, P1257, DOI 10.1359/jbmr.2000.15.7.1257
   Volpe Anthony R., 1996, Journal of Clinical Dentistry, V7, pS1
   Xu Tao, 2004, Compend Contin Educ Dent, V25, P46
NR 25
TC 7
Z9 9
U1 0
U2 7
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611 2690 USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD NOV
PY 2013
VL 84
IS 11
BP 1683
EP 1689
DI 10.1902/jop.2013.120154
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 275OG
UT WOS:000328686100020
PM 23368947
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sun, J
   Zhou, HF
   Deng, Y
   Zhang, YD
   Gu, P
   Ge, SF
   Fan, XQ
AF Sun, Jing
   Zhou, Huifang
   Deng, Yuan
   Zhang, Yidan
   Gu, Ping
   Ge, Shengfang
   Fan, Xianqun
TI Conditioned Medium from Bone Marrow Mesenchymal Stem Cells Transiently
   Retards Osteoblast Differentiation by Downregulating Runx2
SO CELLS TISSUES ORGANS
LA English
DT Article
DE Bone marrow mesenchymal stem cell; Osteoblast differentiation;
   Osteogenesis; Conditioned medium
ID NECROSIS FACTOR ALPHA; OSTEOGENIC DIFFERENTIATION; REGENERATIVE
   MEDICINE; STROMAL CELLS; TNF ALPHA; IN VITRO; INHIBIT; ADULT; MSC;
   PROLIFERATION
AB Mesenchymal stem cells (MSCs) are attractive candidates for cell therapy and regenerative medicine because of their potential for proliferation and multilineage differentiation. MSCs secrete various cytokines, acting as trophic mediators to regulate neighboring cells. Osteoblasts are the cells directly responsible for forming new bone, and they are the final target of many osteogenic regulators. However, the induction effect of MSCs on osteoblasts is still unknown. In this study, we isolated osteoblasts from rat calvariae and investigated their proliferation and differentiation under induction of varied concentrations of MSC conditioned medium (MSC CM). Cells in the MSC CM groups showed a reduction in cell proliferation at 3 6 days, and a decrease in the expression of osteocalcin and osteopontin at 3 days, with low levels of alkaline phosphatase activity. The expression of osteogenic markers went back to normal at 7 days. In order to evaluate the molecular mechanisms underlying this suppression, levels of two osteoblastic transcription factors, runt related transcription factor 2 (Runx2) and osterix (Osx), were detected at both mRNA and protein levels. The results indicated that MSC CM significantly inhibited Runx2 expression in a concentration dependent manner. However, the effect was not due to the inhibition of Osx, for Osx was not significantly altered. This work demonstrates that MSCs may suppress osteoblast proliferation and transiently retard osteoblast differentiation by downregulating Runx2. These results highlight the need to take into account the paracrine effect of MSCs when using them in regenerative medicine for the repair of bone defects. Copyright (C) 2012 S. Karger AG, Basel
C1 [Sun, Jing; Zhou, Huifang; Deng, Yuan; Zhang, Yidan; Gu, Ping; Ge, Shengfang; Fan, Xianqun] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Ophthalmol, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University
RP Fan, XQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Ophthalmol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM fanxq@sh163.net
RI Deng, Yuan/Y 8081 2019; Ping, Gu/JXM 1659 2024
OI Deng, Yuan/0000 0001 8585 1178; 
FU Shanghai Leading Academic Discipline Project [S30205]; National Natural
   Science Foundation of China [81000404, 81100696]; Shanghai Health Bureau
   [XYQ2011053]
FX The research was supported by the Shanghai Leading Academic Discipline
   Project (S30205), the National Natural Science Foundation of China
   (81000404 and 81100696), and the Young Talents Training Program of the
   Shanghai Health Bureau (XYQ2011053).
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   Chen HY, 2011, CELLS TISSUES ORGANS, V194, P161, DOI 10.1159/000324743
   Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301 472X(00)00482 3
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365 2141.2000.01986.x
   Fei YR, 2011, J BIOL CHEM, V286, P40575, DOI 10.1074/jbc.M111.274910
   Feng ZY, 2011, INT J MOL SCI, V12, P2543, DOI 10.3390/ijms12042543
   Franchimont N, 1997, ENDOCRINOLOGY, V138, P5248, DOI 10.1210/en.138.12.5248
   Frank O, 2002, J CELL BIOCHEM, V85, P737, DOI 10.1002/jcb.10174
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gronthos S, 2001, J CELL PHYSIOL, V189, P54, DOI 10.1002/jcp.1138
   Guo J, 2007, INFLAMMATION, V30, P97, DOI 10.1007/s10753 007 9025 3
   Guo ZX, 2009, EUR J IMMUNOL, V39, P2840, DOI 10.1002/eji.200839070
   Han CM, 2007, DIFFERENTIATION, V75, P292, DOI 10.1111/j.1432 0436.2006.00140.x
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 12
   Horwitz EM, 2006, CYTOTHERAPY, V8, P194, DOI 10.1080/14653240600758562
   Javed A, 2009, CELLS TISSUES ORGANS, V189, P133, DOI 10.1159/000151719
   Kadow Romacker A, 2009, CELLS TISSUES ORGANS, V190, P61, DOI 10.1159/000178022
   Kasten P, 2006, CELLS TISSUES ORGANS, V183, P68, DOI 10.1159/000095511
   Kitajima I, 1996, BONE, V19, P263, DOI 10.1016/8756 3282(96)00181 0
   KUNO H, 1994, ENDOCRINOLOGY, V134, P2524, DOI 10.1210/en.134.6.2524
   Lee HL, 2010, EXP MOL MED, V42, P437, DOI 10.3858/emm.2010.42.6.045
   Majumdar MK, 2003, J BIOMED SCI, V10, P228, DOI 10.1159/000068710
   Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pratap J, 2003, CANCER RES, V63, P5357
   Ramasamy R, 2007, TRANSPLANTATION, V83, P71, DOI 10.1097/01.tp.0000244572.24780.54
   Spaggiari GM, 2009, BLOOD, V113, P6576, DOI 10.1182/blood 2009 02 203943
   Sun HL, 2006, BIOMATERIALS, V27, P5651, DOI 10.1016/j.biomaterials.2006.07.027
   Taguchi Y, 1998, P ASSOC AM PHYSICIAN, V110, P559
   Xiao CW, 2011, BIOMED MATER, V6, DOI 10.1088/1748 6041/6/1/015013
   Yeh LCC, 2002, J CELL PHYSIOL, V190, P322, DOI 10.1002/jcp.10064
   Zhang H, 2011, J CELL BIOL, V193, P475, DOI 10.1083/jcb.201101021
   Zhang JJ, 2010, INT J CANCER, V126, P2229, DOI 10.1002/ijc.24821
   Zhou HF, 2011, INVEST OPHTH VIS SCI, V52, P1735, DOI 10.1167/iovs.10 5988
NR 37
TC 35
Z9 36
U1 0
U2 14
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1422 6405
EI 1422 6421
J9 CELLS TISSUES ORGANS
JI Cells Tissues Organs
PY 2012
VL 196
IS 6
BP 510
EP 522
DI 10.1159/000339245
PG 13
WC Anatomy & Morphology; Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Cell Biology; Developmental Biology
GA 042KS
UT WOS:000311470700004
PM 22906827
DA 2025 08 17
ER

PT J
AU Jorgensen, NR
   Syberg, S
   Ellegaard, M
AF Jorgensen, N. R.
   Syberg, S.
   Ellegaard, M.
TI The Role of P2X Receptors in Bone Biology
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Bone biology; bone formation; bone resorption; bone turnover; P2X
   receptor; osteoblast; osteoclast; osteocyte; osteoporosis; single
   nucleotide polymorphism
ID NUCLEOTIDE RECEPTORS; OF FUNCTION; EXTRACELLULAR NUCLEOTIDES;
   RHEUMATOID ARTHRITIS; OSTEOCLAST FORMATION; POLYMORPHISM LEADS; ALA
   POLYMORPHISM; MINERAL DENSITY; IN VITRO; ATP
AB Bone is a highly dynamic organ, being constantly modeled and remodeled in order to adapt to the changing need throughout life. Bone turnover involves the coordinated actions of bone formation and bone degradation. Over the past decade great effort has been put into the examination of how P2X receptors regulate bone metabolism and especially for the P2X7 receptor an impressive amount of evidence has now documented its expression in osteoblasts, osteoclasts, and osteocytes as well as important functional roles in proliferation, differentiation, and function of the cells of bone. Key evidence has come from studies on murine knockout models and from pharmacologic studies on cells and animals. More recently, the role of P2X receptors in human bone diseases has been documented. Loss of functions polymorphisms in the P2X7 receptorare associated with bone loss and increased fracture risk. Very recently a report from a genetic study in multiple myeloma demonstrated that decreased P2X7 receptor function was associated with increased risk of developing multiple myeloma. In contrast, the risk of developing myeloma bone disease and subsequent vertebral fractures was increased in subjects carrying P2X7 receptor gain of function alleles as compared to subjects only carrying loss of function or normal functioning alleles. It is evident that P2X receptors are important in regulating bone turnover and maintaining bone mass, and thereby holding great potential as novel drug targets for treatment of bone diseases. However, further research is needed before we fully understand the roles and effects of P2X receptors in bone.
C1 [Jorgensen, N. R.; Syberg, S.; Ellegaard, M.] Glostrup Cty Hosp, Res Ctr Ageing & Osteoporosis, Dept Diagnost, DK 2600 Glostrup, Denmark.
   [Jorgensen, N. R.; Syberg, S.; Ellegaard, M.] Glostrup Cty Hosp, Dept Med, DK 2600 Glostrup, Denmark.
   [Jorgensen, N. R.] Univ Copenhagen, Inst Clin Med, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen; University of
   Copenhagen
RP Jorgensen, NR (通讯作者)，Glostrup Cty Hosp, Dept Diagnost, Ndr Ringvej 57, DK 2600 Glostrup, Denmark.
EM niklas@dadlnet.dk
RI ; Jørgensen, Niklas/B 6003 2012
OI Jorgensen, Niklas Rye/0000 0001 9624 5210; Syberg,
   Susanne/0000 0003 4999 4950; 
CR Adinolfi Elena, 2005, Purinergic Signal, V1, P219, DOI 10.1007/s11302 005 6322 x
   Alqallaf SM, 2009, BRIT J PHARMACOL, V156, P1124, DOI 10.1111/j.1476 5381.2009.00119.x
   Aspden RM, 2001, LANCET, V357, P1118, DOI 10.1016/S0140 6736(00)04264 1
   Brandao Burch Andrea, 2012, Front Endocrinol (Lausanne), V3, P41, DOI 10.3389/fendo.2012.00041
   Buckley KA, 2002, BONE, V31, P582, DOI 10.1016/S8756 3282(02)00877 3
   Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460 9568.1996.tb00745.x
   Cabrini G, 2005, J IMMUNOL, V175, P82, DOI 10.4049/jimmunol.175.1.82
   Chen LF, 2006, J IMMUNOL, V176, P3115, DOI 10.4049/jimmunol.176.5.3115
   CHENG SL, 1994, CALCIFIED TISSUE INT, V55, P356, DOI 10.1007/BF00299315
   Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002
   Dao Ung LP, 2004, BRIT J HAEMATOL, V125, P815, DOI 10.1111/j.1365 2141.2004.04976.x
   Di Virgilio F, 2007, TRENDS PHARMACOL SCI, V28, P465, DOI 10.1016/j.tips.2007.07.002
   Gartland A, 2003, CRIT REV EUKAR GENE, V13, P243, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.160
   Gartland A, 2003, CALCIFIED TISSUE INT, V73, P361, DOI 10.1007/s00223 002 2098 y
   Gartland A, 2001, J BONE MINER RES, V16, P846, DOI 10.1359/jbmr.2001.16.5.846
   Gartland A, 2012, EUR J HUM GENET, V20, P559, DOI 10.1038/ejhg.2011.245
   Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028
   Gu BJ, 2004, J BIOL CHEM, V279, P31287, DOI 10.1074/jbc.M313902200
   Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200
   Guile SD, 2009, J MED CHEM, V52, P3123, DOI 10.1021/jm801528x
   Gum RJ, 2012, PURINERG SIGNAL, V8, pS41, DOI 10.1007/s11302 011 9272 5
   Hansen RR, 2011, PAIN, V152, P1766, DOI 10.1016/j.pain.2011.03.024
   Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE 08 0568
   Hazama R, 2009, GENES CELLS, V14, P871, DOI 10.1111/j.1365 2443.2009.01317.x
   Henriksen Z, 2006, CELL CALCIUM, V39, P435, DOI 10.1016/j.ceca.2006.01.012
   Henriksen Z, 2006, J BONE MINER RES, P14
   Hiken JF, 2004, AM J PHYSIOL CELL PH, V287, pC403, DOI 10.1152/ajpcell.00361.2003
   Hoebertz A, 2000, BONE, V27, P503, DOI 10.1016/S8756 3282(00)00351 3
   Ihara H, 2005, BIOCHEM BIOPH RES CO, V326, P329, DOI 10.1016/j.bbrc.2004.11.037
   Jacobson KA, 2002, J MED CHEM, V45, P4057, DOI 10.1021/jm020046y
   Jelassi B, 2013, CARCINOGENESIS, V34, P1487, DOI 10.1093/carcin/bgt099
   Jilka RL, 1998, BONE, V23, P75, DOI 10.1016/S8756 3282(98)00077 5
   Jorgensen NR, 2012, EUR J HUM GENET, V20, P675, DOI 10.1038/ejhg.2011.253
   Jorgensen NR, 2002, J BIOL CHEM, V277, P7574, DOI 10.1074/jbc.M104608200
   Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497
   Jorgensen NR, 2000, J BONE MINER RES, V15, P1024, DOI 10.1359/jbmr.2000.15.6.1024
   Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003 0021
   Keystone EC, 2012, ANN RHEUM DIS, V71, P1630, DOI 10.1136/annrheumdis 2011 143578
   Korcok J, 2004, J BONE MINER RES, V19, pS418
   Kringelbach TM, 2014, PURINERG SIGNAL, V10, P337, DOI 10.1007/s11302 013 9404 1
   Kringelbach TM., 2014, BONE IN PRESS
   Kvist TM., 2014, THESCIENTIFICWORLDJO, V2014
   Le Stunff H, 2004, J BIOL CHEM, V279, P16918, DOI 10.1074/jbc.M313064200
   Lemaire I, 2006, J IMMUNOL, V177, P7257, DOI 10.4049/jimmunol.177.10.7257
   Li JL, 2009, CALCIFIED TISSUE INT, V84, P405, DOI 10.1007/s00223 009 9237 7
   Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200
   Ling G, 2009, AM J CARDIOVASC DRUG, V9, P197, DOI 10.2165/00129784 200909030 00006
   Liu LJ, 2010, EUR J PHARMACOL, V640, P15, DOI 10.1016/j.ejphar.2010.04.036
   Liu PS, 2010, TOXICOL APPL PHARM, V244, P308, DOI 10.1016/j.taap.2010.01.007
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   MODDERMAN WE, 1994, CALCIFIED TISSUE INT, V55, P141, DOI 10.1007/BF00297190
   Morrison MS, 1998, J PHYSIOL LONDON, V511, P495, DOI 10.1111/j.1469 7793.1998.495bh.x
   Mrazek F, 2010, HUM IMMUNOL, V71, P201, DOI 10.1016/j.humimm.2009.10.013
   Naemsch LN, 1999, J CELL SCI, V112, P4425
   Naemsch LN, 2001, DRUG DEVELOP RES, V53, P130, DOI 10.1002/ddr.1180
   Naemsch LN, 2001, J BIOL CHEM, V276, P39107, DOI 10.1074/jbc.M105881200
   Nakamura E, 2000, AM J PHYSIOL CELL PH, V279, pC510, DOI 10.1152/ajpcell.2000.279.2.C510
   Nakano Y, 2007, BONE, V41, P549, DOI 10.1016/j.bone.2007.06.011
   Nicke A, 2009, J BIOL CHEM, V284, P25813, DOI 10.1074/jbc.M109.033134
   Nishii N, 2009, BIOL PHARM BULL, V32, P18, DOI 10.1248/bpb.32.18
   Nissen N, 2009, CALCIFIED TISSUE INT, V84, P276, DOI 10.1007/s00223 009 9219 9
   Ohlendorff SD, 2007, PHARMACOGENET GENOM, V17, P555, DOI 10.1097/FPC.0b013e3280951625
   Orriss Isabel, 2011, Front Biosci (Schol Ed), V3, P1038
   Orriss IR, 2007, ENDOCRINOLOGY, V148, P4208, DOI 10.1210/en.2007 0066
   Orriss IR, 2006, BONE, V39, P300, DOI 10.1016/j.bone.2006.02.063
   Orriss IR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069057
   Orriss IR, 2012, BONE, V51, P389, DOI 10.1016/j.bone.2012.06.013
   Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037
   Panupinthu N, 2007, J BIOL CHEM, V282, P3403, DOI 10.1074/jbc.M605620200
   Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05 03 0222
   Pellegatti P, 2011, FASEB J, V25, P1264, DOI 10.1096/fj.10 169854
   Qi J, 2007, J APPL PHYSIOL, V102, P1152, DOI 10.1152/japplphysiol.00535.2006
   Ralevic V, 1998, PHARMACOL REV, V50, P413
   Ralston SH, 2006, GENE DEV, V20, P2492, DOI 10.1101/gad.1449506
   Roger S, 2010, J PSYCHI RES
   Schett G, 2010, NAT REV ENDOCRINOL, V6, P698, DOI 10.1038/nrendo.2010.190
   Shemon AN, 2006, J BIOL CHEM, V281, P2079, DOI 10.1074/jbc.M507816200
   Skarratt KK, 2005, FEBS LETT, V579, P2675, DOI 10.1016/j.febslet.2005.03.091
   Sluyter R, 2004, GENES IMMUN, V5, P588, DOI 10.1038/sj.gene.6364127
   Sluyter R, 2004, J IMMUNOL, V172, P3399, DOI 10.4049/jimmunol.172.6.3399
   Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200
   Steinberg TH, 2007, PURINERG SIGNAL, V3, P53, DOI 10.1007/s11302 006 9036 9
   Stock TC, 2012, J RHEUMATOL, V39, P720, DOI 10.3899/jrheum.110874
   Stokes L., 2010, FASEB J
   Stokes L, 2011, HYPERTENSION, V58, P1086, DOI 10.1161/HYPERTENSIONAHA.111.176180
   Sun C., 2010, PURINERG SIGNAL
   Syberg S, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/637986
   Syberg S, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/391097
   Taylor SRJ, 2009, J LEUKOCYTE BIOL, V85, P978, DOI 10.1189/jlb.0408251
   Vangsted A., 2014, EUR J HAEMATOL
   Viecilli RF, 2009, AM J ORTHOD DENTOFAC, V135, P694, DOI 10.1016/j.ajodo.2009.02.013
   Wesselius A, 2013, OSTEOPOROSIS INT, V24, P1235, DOI 10.1007/s00198 012 2059 x
   Wesselius A, 2013, PURINERG SIGNAL, V9, P123, DOI 10.1007/s11302 012 9337 0
   Wildman SS, 1998, BRIT J PHARMACOL, V123, P1214, DOI 10.1038/sj.bjp.0701717
   Wiley JS, 2003, J BIOL CHEM, V278, P17108, DOI 10.1074/jbc.M212759200
   Wiley JS, 2002, LANCET, V359, P1114, DOI 10.1016/S0140 6736(02)08156 4
   Zippel N, 2012, STEM CELLS DEV, V21, P884, DOI 10.1089/scd.2010.0576
NR 97
TC 24
Z9 24
U1 0
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929 8673
EI 1875 533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2015
VL 22
IS 7
BP 902
EP 914
DI 10.2174/0929867321666141215094749
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA CB1LM
UT WOS:000349389000011
PM 25515517
DA 2025 08 17
ER

PT J
AU Virk, MS
   Petrigliano, FA
   Liu, NQ
   Chatziioannou, AF
   Stout, D
   Kang, CO
   Dougall, WC
   Lieberman, JR
AF Virk, Mandeep S.
   Petrigliano, Frank A.
   Liu, Nancy Q.
   Chatziioannou, Arion F.
   Stout, David
   Kang, Christine O.
   Dougall, William C.
   Lieberman, Jay R.
TI Influence of simultaneous targeting of the bone morphogenetic protein
   pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone
SO BONE
LA English
DT Article
DE Bone metastasis; Bone morphogenetic protein (BMP); Receptor activator of
   nuclear factor kappa B ligand (RANKL); Receptor activator of nuclear
   factor kappa B Fc protein (RANK:Fc protein); Prostate cancer
ID KAPPA B; OSTEOCLAST DIFFERENTIATION; METASTATIC PROSTATE; RECEPTOR
   ACTIVATOR; ANIMAL MODELS; TUMOR; GROWTH; MECHANISMS; RANKL;
   OVEREXPRESSION
AB Metastasis to bone is the leading cause of morbidity and mortality in advanced prostate cancer patients. Considering the complex reciprocal interactions between the tumor cells and the bone microenvironment, there is increasing interest in developing combination therapies targeting both the tumor growth and the bone microenvironment. In this Study, we investigated the effect of simultaneous blockade of BMP pathway and RANK/RANKL axis in an osteolytic prostate cancer lesion in bone. We used a retroviral vector encoding noggin (RetroNoggin) to antagonize the effect of BMPs and RANK:Fc, which is a recombinant RANKL antagonist was used to inhibit RANK/RANKL axis. The tumor growth and bone loss were evaluated using plain radiographs, hind limb tumor measurements, micro PET/CT ((18)FDG and F 18 fluoride tracer), and histology. Tibias implanted with PC 3 cells developed pure osteolytic lesions at 2 weeks with progressive increase in cortical bone destruction at successive time points. Tibias implanted with PC 3 cells over expressing noggin (RetroNoggin) resulted in reduced tumor size and decreased bone loss compared to the implanted tibias in untreated control animals. RANK: Fc administration inhibited the formation of osteoclasts, delayed the development of osteolytic lesions, decreased bone loss and reduced tumor size in tibias implanted with PC 3 cells. The combination therapy with RANK:Fc and noggin over expression effectively delayed the radiographic development of osteolytic lesions, and decreased the bone loss and tumor burden compared to implanted tibias treated with noggin over expression alone. Furthermore, the animals treated with the combination strategy exhibited decreased bone loss (micro CT) and lower tumor burden (FDG micro PET) compared to animals treated with RANK:Fc alone. Combined blockade of RANK/RANKL axis and BMP pathway resulted in reduced tumor burden and decreased bone loss compared to inhibition of either individual pathway alone in osteolytic prostate cancer lesion in bone. These results suggest that simultaneous targeting of tumor cells and osteoclasts may be the most effective method of inhibiting the progression of established osteolytic metastatic lesions in vivo. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Virk, Mandeep S.; Lieberman, Jay R.] Univ Connecticut, Ctr Hlth, New England Musculoskeletal Inst, Dept Orthopaed Surg, Farmington, CT 06030 USA.
   [Petrigliano, Frank A.; Liu, Nancy Q.; Kang, Christine O.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci 76 134, Dept Orthopaed Surg, Los Angeles, CA 90095 USA.
   [Chatziioannou, Arion F.; Stout, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA.
   [Dougall, William C.] Amgen Inc, Dept Hematol & Oncol Res, Seattle, WA USA.
C3 University of Connecticut; University of California System; University
   of California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; Amgen
RP Lieberman, JR (通讯作者)，Univ Connecticut, Ctr Hlth, New England Musculoskeletal Inst, Dept Orthopaed Surg, 263 Farmington Ave, Farmington, CT 06030 USA.
EM jlieberman@uchc.edu
RI ; Virk, Mandeep/AAW 9319 2020
OI Virk, Mandeep/0000 0001 6294 2771; Dougall, William/0000 0001 9487 251X
FU National Institute of Health [RO1 CA103039]
FX Funding source. This work was supported by a research grant from the
   National Institute of Health (RO1 CA103039 to JRL).
CR Bagi CM, 2005, ADV DRUG DELIVER REV, V57, P995, DOI 10.1016/j.addr.2004.12.014
   Banerjee S, 2007, CANCER RES, V67, P3818, DOI 10.1158/0008 5472.CAN 06 3879
   Berger F, 2002, EUR J NUCL MED MOL I, V29, P1225, DOI 10.1007/s00259 002 0850 1
   Bobinac D, 2005, CROAT MED J, V46, P389
   Boyce BF, 1999, ENDOCR RELAT CANCER, V6, P333, DOI 10.1677/erc.0.0060333
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown Julie M, 2004, Cancer Treat Res, V118, P149
   Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679
   Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097 0142(20000615)88:12+<2989::AID CNCR14>3.0.CO;2 Q
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Coleman R E, 2000, Oncologist, V5, P463, DOI 10.1634/theoncologist.5 6 463
   Cooper CR, 2003, CANCER AM CANCER SOC, V97, P739, DOI 10.1002/cncr.11181
   Deng HY, 2007, EXP CELL RES, V313, P1033, DOI 10.1016/j.yexcr.2006.12.020
   Duivenvoorden WCM, 2007, BRIT J CANCER, V96, P1526, DOI 10.1038/sj.bjc.6603740
   Feeley BT, 2006, J BONE MINER RES, V21, P1571, DOI 10.1359/JBMR.060706
   Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015
   Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802
   Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   HAWKINS RA, 1992, J NUCL MED, V33, P633
   Herschman HR, 2003, CURR OPIN IMMUNOL, V15, P378, DOI 10.1016/S0952 7915(03)00066 9
   Hsu WK, 2008, J NUCL MED, V49, P414, DOI 10.2967/jnumed.107.045666
   Ignatoski KMW, 2008, PROSTATE, V68, P820, DOI 10.1002/pros.20744
   Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100
   Lee Y, 2003, J ORTHOP RES, V21, P62, DOI 10.1016/S0736 0266(02)00095 5
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Lipton A, 2006, CLIN CANCER RES, V12, p6305S, DOI 10.1158/1078 0432.CCR 06 1157
   Michigami T, 2001, CANCER RES, V61, P1637
   Myers R, 2002, EUR NEUROPSYCHOPHARM, V12, P545, DOI 10.1016/S0924 977X(02)00103 7
   NARITA N, 1990, CALCIFIED TISSUE INT, V46, P200, DOI 10.1007/BF02555045
   Ohshiba T, 2003, BRIT J CANCER, V88, P1318, DOI 10.1038/sj.bjc.6600858
   Roodman GD, 2006, ANN NY ACAD SCI, V1068, P100, DOI 10.1196/annals.1346.013
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Saad F, 2006, EUR UROL, V49, P429, DOI 10.1016/j.eururo.2005.12.045
   Schwalbe M, 2003, INT J ONCOL, V23, P89
   Storey JA, 2007, CURR OPIN ONCOL, V19, P254, DOI 10.1097/CCO.0b013e32805e8787
   Vessella RL, 2006, CLIN CANCER RES, V12, p6285S, DOI 10.1158/1078 0432.CCR 06 0813
   Virk MS, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2169
   Whang PG, 2005, J ORTHOP RES, V23, P1475, DOI 10.1016/j.orthres.2005.05.004
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Yang SX, 2005, CANCER RES, V65, P5769, DOI 10.1158/0008 5472.CAN 05 0289
   Ye L, 2007, HISTOL HISTOPATHOL, V22, P1129, DOI 10.14670/HH 22.1129
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Zhang J, 2003, CANCER RES, V63, P7883
NR 48
TC 35
Z9 39
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2009
VL 44
IS 1
BP 160
EP 167
DI 10.1016/j.bone.2008.09.009
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 395TV
UT WOS:000262547300020
PM 18929692
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Huang, HBA
   Xu, L
   Ding, YY
   Qin, J
   Huang, CC
   Li, X
   Tang, YJ
   Qian, GH
   Lv, HT
AF Huang, Hongbiao
   Xu, Lei
   Ding, Yueyue
   Qin, Jie
   Huang, Chengcheng
   Li, Xuan
   Tang, Yunjia
   Qian, Guanghui
   Lv, Haitao
TI Bioinformatics identification of hub genes and signaling pathways
   regulated by intravenous immunoglobulin treatment in acute Kawasaki
   disease
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE Kawasaki disease; mechanism of action; intravenous immunoglobulin;
   bioinformatics analysis
ID GAMMA GLOBULIN; DIAGNOSIS
AB Kawasaki disease (KD) is an acute, self limiting form of vasculitis commonly encountered in infants and young children. Intravenous immunoglobulin (IVIG) is the primary drug used for the treatment of KD, which may significantly reduce the occurrence of coronary artery lesions. However, the specific molecular profile changes of KD caused by IVIG treatment have remained elusive and require further research. The present study was designed to identify key genes, pathways and immune cells affected by IVIG treatment using multiple bioinformatics analysis methods. The results suggested that myeloid cells and neutrophils were affected by IVIG treatment. Kyoto Encyclopedia of Genes and Genomes pathway analysis identified that hematopoietic cell lineages and osteoclast differentiation may have an important role in the mechanism of action of IVIG treatment. Immune cell analysis indicated that the levels of monocytes, M1 macrophages, neutrophils and platelets were markedly changed in patients with KD after vs. prior to IVIG treatment. The key upregulated genes, including ZW10 interacting kinetochore protein, GINS complex subunit 1 and microRNA 30b 3p in whole blood cells of patients with KD following treatment with IVIG indicated that these IVIG targeted molecules may have important roles in KD. In addition, these genes were further examined by literature review and indicated to be involved in cell proliferation, apoptosis and virus related immune response in patients with KD. Therefore, the present results may provide novel insight into the mechanisms of action of IVIG treatment for KD.
C1 [Huang, Hongbiao; Xu, Lei; Ding, Yueyue; Qin, Jie; Huang, Chengcheng; Li, Xuan; Tang, Yunjia; Qian, Guanghui; Lv, Haitao] Soochow Univ, Childrens Hosp, Inst Pediat Res, 92 Zhongnan St, Suzhou 215025, Jiangsu, Peoples R China.
C3 Soochow University   China
RP Qian, GH; Lv, HT (通讯作者)，Soochow Univ, Childrens Hosp, Inst Pediat Res, 92 Zhongnan St, Suzhou 215025, Jiangsu, Peoples R China.
EM ghqian@suda.edu.cn; lvhaitao@suda.edu.cn
RI Tang, Yunjia/CAA 0812 2022; huang, chengcheng/GRX 5340 2022; Huang,
   Hongbiao/LLM 2445 2024
OI Huang, Hongbiao/0000 0002 5420 3415
FU National Natural Science Foundation of China [81971477, 81870365,
   82070512, 81970436]; Jiangsu Provincial Medical Young Talents
   [QNRC2016756]; Applied Foundational Research of Medical and Health Care
   of Suzhou City [SYS2019086]; Suzhou Medical Key Discipline Pediatric
   Cardiology [Szxk201507]; Key Medical Talents in Jiangsu Province
   [ZDRCA2016049]; Second cycle key subjects of maternal and child health
   in Jiangsu Province [FXK201740]; Introduction Project of Clinical
   Medical Expert Team in Suzhou City [SZYJTD201805]
FX The present study was supported by grants from the National Natural
   Science Foundation of China (grant nos. 81971477, 81870365, 82070512 and
   81970436), Jiangsu Provincial Medical Young Talents (grant no.
   QNRC2016756), the Applied Foundational Research of Medical and Health
   Care of Suzhou City (grant no. SYS2019086), Suzhou Medical Key
   Discipline Pediatric Cardiology (grant no. Szxk201507), Key Medical
   Talents in Jiangsu Province (grant no. ZDRCA2016049), Second cycle key
   subjects of maternal and child health in Jiangsu Province (grant no.
   FXK201740) and Introduction Project of Clinical Medical Expert Team in
   Suzhou City (grant no. SZYJTD201805).
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Andreozzi L, 2017, IMMUNOL LETT, V184, P112, DOI 10.1016/j.imlet.2017.02.011
   Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059 017 1349 1
   Armaroli G, 2019, ARTHRITIS RHEUMATOL, V71, P792, DOI 10.1002/art.40784
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Chang DQ, 2019, J CELL BIOCHEM, V120, P13001, DOI 10.1002/jcb.28571
   Chen SJ, 2016, JAMA PEDIATR, V170, P1156, DOI 10.1001/jamapediatrics.2016.2055
   Cottineau J, 2017, J CLIN INVEST, V127, P1991, DOI 10.1172/JCI90727
   de Graeff N, 2019, RHEUMATOLOGY, V58, P672, DOI 10.1093/rheumatology/key344
   Dou Z, 2019, CELLS BASEL, V8, DOI 10.3390/cells8030278
   Fu Y, 2019, MED SCI MONITOR, V25, P8873, DOI 10.12659/MSM.919046
   FURUSHO K, 1984, LANCET, V2, P1055
   Guo Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01299
   Han JW, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007583
   Ikeda K, 2010, CLIN EXP IMMUNOL, V160, P246, DOI 10.1111/j.1365 2249.2009.04073.x
   Inagaki Minoru, 1991, Acta Paediatrica Japonica, V33, P791
   INAMO Y, 1987, Acta Paediatrica Japonica, V29, P202
   Jian Y, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182226
   Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020 0123
   Kaneko K, 2012, PEDIATR CARDIOL, V33, P1086, DOI 10.1007/s00246 012 0229 4
   Kato Kumiko, 2007, Allergol Int, V56, P439, DOI 10.2332/allergolint.O 06 462
   Koizumi K, 2019, THER APHER DIAL, V23, P92, DOI 10.1111/1744 9987.12754
   Kumar B, 2016, ONCOTARGET, V7, P72593, DOI 10.18632/oncotarget.12241
   Lau AC, 2009, ARTHRITIS RHEUM US, V60, P2131, DOI 10.1002/art.24660
   LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835
   Li Y, 2020, BIOL RES, V53, DOI 10.1186/s40659 020 00277 4
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo MS, 2018, INT J RHEUM DIS, V21, P64, DOI 10.1111/1756 185X.13220
   Maruyama K, 2012, IMMUNITY, V37, P1024, DOI 10.1016/j.immuni.2012.08.022
   McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484
   NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305
   Ogihara Y, 2014, PEDIATR RES, V76, P287, DOI 10.1038/pr.2014.92
   Rodriguez MM, 2017, PEDIATR ANN, V46, pE19, DOI 10.3928/19382359 20161214 01
   Ronconi G, 2020, J BIOL REG HOMEOS AG, V34, P767
   Rowley AH, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00374
   Shao MT, 2020, TRANSL CANCER RES, V9, P187, DOI 10.21037/tcr.2019.12.66
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   Sosa T, 2019, JAMA PEDIATR, V173, P278, DOI 10.1001/jamapediatrics.2018.3307
   Sugitani Yuichiro, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr 2017 223584
   Sun L, 2018, CARDIOLOGY, V141, P25, DOI 10.1159/000493420
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tang L, 2019, CLIN TRANSL ONCOL, V21, P1624, DOI 10.1007/s12094 019 02090 2
   Tsujimoto H, 2001, CLIN EXP IMMUNOL, V126, P355, DOI 10.1046/j.1365 2249.2001.01675.x
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Uthman L, 2021, CARDIOVASC DRUG THER, V35, P1083, DOI 10.1007/s10557 020 07083 w
   Vargas Rondón N, 2018, CANCERS, V10, DOI 10.3390/cancers10010004
   von Gunten S, 2006, BLOOD, V108, P4255, DOI 10.1182/blood 2006 05 021568
   Wu G, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018535
   Yang L, 2020, ONCOL REP, V43, P1831, DOI 10.3892/or.2020.7573
   Yi XH, 2020, J CELL MOL MED, V24, P2866, DOI 10.1111/jcmm.14856
   Zhang GY, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00192
   Zhang X, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/8919534
   Zhu ZB, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879 019 4720 x
NR 53
TC 2
Z9 2
U1 1
U2 17
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JUL
PY 2021
VL 22
IS 1
AR 784
DI 10.3892/etm.2021.10216
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA SH5NR
UT WOS:000654183200001
PM 34055083
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shi, Y
   Liao, XY
   Long, JY
   Yao, LT
   Chen, JQ
   Yin, B
   Lou, F
   He, GX
   Ye, L
   Qin, L
   Long, FX
AF Shi, Yu
   Liao, Xueyang
   Long, James Y.
   Yao, Lutian
   Chen, Jianquan
   Yin, Bei
   Lou, Feng
   He, Guangxu
   Ye, Ling
   Qin, Ling
   Long, Fanxin
TI Gli1<SUP>+</SUP> progenitors mediate bone anabolic function of
   teriparatide via Hh and Igf signaling
SO CELL REPORTS
LA English
DT Article
ID MESENCHYMAL PROGENITORS; CELLS; DISTINCT; CHONDROCYTES; OSTEOBLASTS;
   REVEALS; MICE
AB Teriparatide is the most widely prescribed bone anabolic drug in the world, but its cellular targets remain incompletely defined. The Gli1(+) metaphyseal mesenchymal progenitors (MMPs) are a main source for osteoblasts in postnatal growing mice, but their potential response to teriparatide is unknown. Here, by lineage tracing, we show that teriparatide stimulates both proliferation and osteoblast differentiation of MMPs. Single cell RNA sequencing reveals heterogeneity among MMPs, including an unexpected chondrocyte like osteoprogenitor (COP). COP expresses the highest level of Hedgehog (Hh) target genes and the insulin like growth factor 1 receptor (Igf1r) among all cell clusters. COP also expresses Pth1r and further upregulates Igf1r upon teriparatide treatment. Inhibition of Hh signaling or deletion of Igf1r fromMMPs diminishes the proliferative and osteogenic effects of teriparatide. The study therefore identifies COP as a teriparatide target wherein Hh and insulin like growth factor (Igf) signaling are critical for the osteoanabolic response in growing mice.
C1 [Shi, Yu; Liao, Xueyang; Yin, Bei; Ye, Ling] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Shi, Yu; Liao, Xueyang; Yin, Bei; Ye, Ling] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.
   [Shi, Yu; Liao, Xueyang; Yao, Lutian; Long, Fanxin] Childrens Hosp Philadelphia, Dept Surg, Translat Res Program Pediat Orthoped, Philadelphia, PA 19104 USA.
   [Long, James Y.] NYU, Courant Inst Math Sci, New York, NY USA.
   [Chen, Jianquan] Soochow Univ, Med Coll, Orthoped Inst, Suzhou, Peoples R China.
   [Lou, Feng] Sichuan Univ, West China Hosp Stomatol, Chengdu, Peoples R China.
   [He, Guangxu] Cent South Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Peoples R China.
   [Qin, Ling; Long, Fanxin] Univ Penn, Dept Orthoped Surg, Philadelphia, PA 19104 USA.
C3 Sichuan University; Sichuan University; University of Pennsylvania;
   Pennsylvania Medicine; Childrens Hospital of Philadelphia; New York
   University; Soochow University   China; Sichuan University; Central
   South University; University of Pennsylvania
RP Long, FX (通讯作者)，Childrens Hosp Philadelphia, Dept Surg, Translat Res Program Pediat Orthoped, Philadelphia, PA 19104 USA.; Long, FX (通讯作者)，Univ Penn, Dept Orthoped Surg, Philadelphia, PA 19104 USA.
EM longf1@chop.edu
RI ye, ling/AFP 0048 2022; yao, lutian/JPK 8105 2023
OI yao, lutian/0000 0002 0652 2075; Liao, Xueyang/0000 0001 7876 3129
FU NIH [P30 AR069619, DK111212]
FX The work is partially supported by NIH grant DK111212 (to F. Long). mCT
   analysis was conducted at the Penn Center for Musculoskeletal Disorders
   (PCMD), supported by NIH P30 AR069619.
CR Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023
   Balani DH, 2017, J CLIN INVEST, V127, P3333, DOI 10.1172/JCI91699
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cao JY, 2019, NATURE, V566, P496, DOI 10.1038/s41586 019 0969 x
   Capriani C, 2012, J BONE MINER RES, V27, P2419, DOI 10.1002/jbmr.1800
   Dietrich P, 2000, MAMM GENOME, V11, P196, DOI 10.1007/s003350010037
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Henry SP, 2009, GENESIS, V47, P805, DOI 10.1002/dvg.20564
   Hilton MJ, 2007, DEV BIOL, V308, P93, DOI 10.1016/j.ydbio.2007.05.011
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Joeng KS, 2009, DEVELOPMENT, V136, P4177, DOI 10.1242/dev.041624
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Long FX, 2001, DEVELOPMENT, V128, P5099
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Mizoguchi T, 2014, DEV CELL, V29, P340, DOI 10.1016/j.devcel.2014.03.013
   Mukohira H, 2019, INT IMMUNOL, V31, P729, DOI 10.1093/intimm/dxz042
   Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067
   Qin X, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009169
   Riobó NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103
   ROULEAU MF, 1990, J BONE MINER RES, V5, P1043
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02171 2
   Shi Y, 2015, P NATL ACAD SCI USA, V112, P4678, DOI 10.1073/pnas.1502301112
   Siclari VA, 2013, BONE, V53, P575, DOI 10.1016/j.bone.2012.12.013
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Zhong LL, 2020, ELIFE, V9, DOI 10.7554/eLife.54695
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhou X, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004820
NR 32
TC 26
Z9 29
U1 1
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211 1247
J9 CELL REP
JI Cell Reports
PD AUG 17
PY 2021
VL 36
IS 7
AR 109542
DI 10.1016/j.celrep.2021.109542
EA AUG 2021
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA UC2IS
UT WOS:000686356500011
PM 34407400
OA gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Yang, B
   Li, XF
AF Yang, Bing
   Li, Xiaofeng
TI Unveiling the Mechanisms of Bone Marrow Toxicity Induced by Lead Acetate
   Exposure
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Pb; Bone marrow toxicity; Gene; Signaling pathway
ID STEM CELLS
AB Lead (Pb), a widespread heavy metal, causes severe toxicity in human and animal organs (e.g., bone marrow), whereas the mechanisms of the bone marrow toxicity induced by Pb exposure are unclear. Hence, this study was designed to reveal the hub genes involved in Pb induced bone marrow toxicity. GSE59894 dataset obtained from Gene Expression Omnibus (GEO) was composed of lead acetate (PbAc2) treated and control bone marrow samples. Totally 120 and 85 differentially expressed genes (DEGs) were identified on the 1st day, while 153 and 157 DEGs on the 3rd day in the bone marrow treated with 200 and 600 mg/kg of PbAc2, respectively. Notably, a total of 28 and 32 overlapping DEGs were identified in the bone marrow on the 1st and 3rd day treated with PbAc2, respectively. Biological process analysis suggested that the common DEGs were primarily participated in cell differentiation, the response to drug, xenobiotic stimulus, and organic cyclic compound. Pathway analysis demonstrated that the overlapping DEGs were primarily linked to PI3K Akt, TGF & beta;, MAPK, and osteoclast differentiation signaling pathways. Moreover, the hub genes, including PLD2, DAPK1, ALB, TNF, FOS, CDKN1A, and TGFB3, might contribute to PbAc2 induced bone marrow toxicity. Overall, our study offers an important insight into the molecular mechanisms of Pb induced bone marrow toxicity.
C1 [Yang, Bing; Li, Xiaofeng] Anhui Sci & Technol Univ, Coll Anim Sci, Fengyang 233100, Peoples R China.
C3 Anhui Science & Technology University
RP Li, XF (通讯作者)，Anhui Sci & Technol Univ, Coll Anim Sci, Fengyang 233100, Peoples R China.
EM lixf@ahstu.edu.cn
RI Yang, Bing/JYP 6657 2024
FU Open Project of Anhui Province Key Laboratory of Embryo Development and
   Reproductive Regulation [FSKFKT011]; Talent Introduction Program of
   Anhui Science and Technology University [DKYJ202003]; Open Project of
   Anhui Province Key Laboratory of Wetland Ecosystem Protection and
   Restoration [AHZDSYS2019 01]; Natural Science Foundation of Anhui
   Provincial Education Department [KJ2020A0083]; Open Project of Longyan
   University; Fujian Provincial Key Laboratory for Prevention and Control
   of Animal Infectious Diseases and Biotechnology [ZDSYS2020004]
FX & nbsp;This study was supported by The Open Project of Anhui Province
   Key Laboratory of Embryo Development and Reproductive Regulation (No.
   FSKFKT011), Talent Introduction Program of Anhui Science and Technology
   University (No. DKYJ202003), The Open Project of Anhui Province Key
   Laboratory of Wetland Ecosystem Protection and Restoration (No.
   AHZDSYS2019 01), Natural Science Foundation of Anhui Provincial
   Education Department (No. KJ2020A0083) and The Open Project of Longyan
   University & Fujian Provincial Key Laboratory for Prevention and Control
   of Animal Infectious Diseases and Biotechnology (No. ZDSYS2020004).
CR Abou Ezzi G, 2019, STEM CELL REP, V13, P48, DOI 10.1016/j.stemcr.2019.05.017
   Aguilar G, 2021, AM J PHYSIOL HEART C, V321, pH1083, DOI 10.1152/ajpheart.00065.2021
   Bao WR, 2021, INT J BIOL MACROMOL, V183, P1715, DOI 10.1016/j.ijbiomac.2021.05.120
   Bataller A, 2019, LEUKEMIA, V33, P1076, DOI 10.1038/s41375 019 0420 1
   Beier EE, 2016, TOXICOL SCI, V149, P277, DOI 10.1093/toxsci/kfv234
   Chen KM, 2022, J BIOMATER TISS ENG, V12, P1314, DOI 10.1166/jbt.2022.3031
   Du GF, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.759596
   Fan P, 2022, EXP GERONTOL, V164, DOI 10.1016/j.exger.2022.111829
   Fiorim J, 2020, TOXICOLOGY, V443, DOI 10.1016/j.tox.2020.152557
   Ganesan R, 2018, J LEUKOCYTE BIOL, V103, P867, DOI 10.1002/JLB.2A1017 407RR
   Ganter B, 2005, J BIOTECHNOL, V119, P219, DOI 10.1016/j.jbiotec.2005.03.022
   Hiew VV, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/2116367
   Jafarzadeh E, 2022, TOXICOL IND HEALTH, V38, P655, DOI 10.1177/07482337221115514
   Jeong S, 2021, FEBS LETT, V595, P58, DOI 10.1002/1873 3468.13963
   Jiang YX, 2022, CELL TRANSPLANT, V31, DOI 10.1177/09636897221107636
   Juran CM, 2021, STEM CELL RES, V56, DOI 10.1016/j.scr.2021.102513
   Li L, 2022, INT J STEM CELLS, V15, P405, DOI 10.15283/ijsc21152
   Liang XY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.702916
   Lu HK, 2014, INT J CLIN EXP PATHO, V7, P640
   Luo Y, 2020, CELL BIOL INT, V44, P1373, DOI 10.1002/cbin.11331
   Ma YG, 2021, J HAZARD MATER, V405, DOI 10.1016/j.jhazmat.2020.124251
   Manso BA, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2020.101994
   Morris EV, 2020, J BONE MINER RES, V35, P942, DOI 10.1002/jbmr.3951
   Okesola MA, 2019, TOXICOL MECH METHOD, V29, P255, DOI 10.1080/15376516.2018.1558321
   Qi SS, 2019, BIOL TRACE ELEM RES, V187, P172, DOI 10.1007/s12011 018 1362 6
   Rafiei H, 2018, REP BIOCHEM MOL BIOL, V6, P131
   Samsonraj RM, 2018, STEM CELL TRANSL MED, V7, P197, DOI 10.1002/sctm.17 0086
   Shabestari M, 2020, INT J RHEUM DIS, V23, P788, DOI 10.1111/1756 185X.13843
   Sheng ZJ, 2020, BIOL TRACE ELEM RES, V195, P491, DOI 10.1007/s12011 019 01864 7
   Song YM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22189964
   Suljevic D, 2021, BIOL TRACE ELEM RES, V199, P1574, DOI 10.1007/s12011 020 02272 y
   Bich VNT, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 24512 x
   Wang B, 2022, CLIN INTERV AGING, V17, P777, DOI 10.2147/CIA.S361008
   Wang N, 2020, LEUKEMIA LYMPHOMA, V61, P641, DOI 10.1080/10428194.2019.1686499
   Wang S, 2022, STEM CELLS, V40, P508, DOI 10.1093/stmcls/sxac013
   Wang S, 2020, J INT MED RES, V48, DOI 10.1177/0300060520933453
   Wu LZ, 2020, BIOCHEM BIOPH RES CO, V521, P98, DOI 10.1016/j.bbrc.2019.10.083
   Wu XL, 2022, NUTRIENTS, V14, DOI 10.3390/nu14153014
   Yang FH, 2020, EXP THER MED, V20, P309, DOI 10.3892/etm.2020.8689
   Yang ZY, 2020, J TISSUE ENG REGEN M, V14, P588, DOI 10.1002/term.3023
   Zhang JH, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 18287 5
   Zhang J, 2021, CELL REPROGRAM, V23, P127, DOI 10.1089/cell.2020.0093
   Zhang YL, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9121926
   Zhang YF, 2022, CELL BIOSCI, V12, DOI 10.1186/s13578 022 00813 7
   Zhao ZH, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.648261
   ZHOU GX, 2016, MEDIAT INFLAMM, V2016, DOI DOI 10.1155/2016/2543070
   Zhu XJ, 2023, COMP BIOCHEM PHYS C, V263, DOI 10.1016/j.cbpc.2022.109489
NR 47
TC 1
Z9 3
U1 3
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0163 4984
EI 1559 0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD MAR
PY 2024
VL 202
IS 3
BP 1041
EP 1066
DI 10.1007/s12011 023 03733 w
EA JUN 2023
PG 26
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA GE5Y3
UT WOS:001018126300001
PM 37378799
DA 2025 08 17
ER

PT J
AU Palmqvist, P
   Lundberg, P
   Persson, E
   Johansson, A
   Lundgren, I
   Lie, A
   Conaway, HH
   Lerner, UH
AF Palmqvist, P
   Lundberg, P
   Persson, E
   Johansson, A
   Lundgren, I
   Lie, A
   Conaway, HH
   Lerner, UH
TI Inhibition of hormone and cytokine stimulated osteoclastogenesis and
   bone resorption by interleukin 4 and interleukin 13 is associated with
   increased osteoprotegerin and decreased RANKL and RANK in a
   STAT6 dependent pathway
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NF KAPPA B; PROINFLAMMATORY CYTOKINES; MATURE OSTEOCLASTS; RECEPTOR
   ACTIVATOR; RESORBING ACTIVITY; MOUSE CALVARIAE; NUCLEAR FACTOR;
   GENE THERAPY; LIGAND; CELLS
AB Interleukin (IL) 4 and IL 13 are cytokines that inhibit bone resorption. Data showing an inhibitory effect of IL 4 and IL 13 on RANK mRNA in mouse calvariae were first reported at the 22nd American Society for Bone and Mineral Research Meeting (Lerner, U. H., and Conaway, H. H. 2000) J. Bone Min. Res. 15, Suppl. 1, Abstr. SU 230). In the present study, release of Ca 45 from cultured mouse calvarial bones stimulated by different cytokines, peptides, and steroid hormones was inhibited by IL 4 and IL 13. IL 4 and IL  13 decreased receptor activator of nuclear factor kappa B ligand (RANKL) and RANK mRNA and increased osteoprotegerin (OPG) mRNA in calvariae. Additionally, the cytokines decreased RANKL protein and increased OPG protein in calvarial bones. In osteoblasts isolated from calvariae, both an increase in RANKL mRNA and a decrease in OPG mRNA and protein elicited by vitamin D 3 were reversed by IL 4 and IL 13. IL 4 and IL 13 decreased the number of tartrate resistant acid phosphatase positive multinucleated cells and the mRNA expression of calcitonin receptor, tartrate resistant acid phosphatase, and cathepsin K in mouse spleen cells and bone marrow macrophages (BMM) treated with macrophage colony stimulating factor and RANKL. Inhibition of mRNA for RANK and the transcription factor NFAT2 was also noted in spleen cell and BMM cultures treated with IL 4 and IL 13. In addition, RANK mRNA and RANK protein were decreased by IL 4 and IL 13 in RAW 264.7 cells. Osteoblasts, spleen cells, and BMM expressed mRNA for the four proteins making up the IL 4 and IL  13 receptors. No effects by IL 4 on bone resorption and osteoclast formation or on RANKL and RANK mRNA expression were seen in Stat6( / ) mice. The data indicate that IL 4 and IL 13, via a STAT6 dependent pathway, inhibit osteoclast differentiation and bone resorption by activating receptors on osteoblasts and osteoclasts that affect the RANKL/RANK/OPG system.
C1 Umea Univ, Dept Oral Cell Biol, S 90187 Umea, Sweden.
   Umea Univ, Dept Periodont, S 90187 Umea, Sweden.
   Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA.
C3 Umea University; Umea University; University of Arkansas System;
   University of Arkansas Medical Sciences
RP Umea Univ, Dept Oral Cell Biol, S 90187 Umea, Sweden.
EM ulf.lerner@odont.umu.se
RI ; Johansson, Anders/KIL 2757 2024
OI Lerner, Ulf/0000 0002 3579 1960; Johansson, Anders/0000 0002 3847 6827
CR Abu Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530
   Ahlen J, 2002, BONE, V31, P242, DOI 10.1016/S8756 3282(02)00784 6
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Bendixen AC, 2001, P NATL ACAD SCI USA, V98, P2443, DOI 10.1073/pnas.041493198
   BOONEKAMP PM, 1984, P K NED AKAD B PHYS, V87, P371
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   DEWHIRST FE, 1985, J IMMUNOL, V135, P2562
   Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   HOROWITZ J, 2002, PRINCIPLES BONE BIOL, P961
   HORTON JE, 1972, SCIENCE, V177, P793, DOI 10.1126/science.177.4051.793
   Joosten LAB, 1999, ARTHRITIS RES, V1, P81, DOI 10.1186/ar14
   KASONO K, 1993, BONE MINER, V21, P179, DOI 10.1016/S0169 6009(08)80229 2
   Kawaguchi H, 1996, J BONE MINER RES, V11, P358
   Kelly Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458
   Kim YJ, 2005, J BIOL CHEM, V280, P21515, DOI 10.1074/jbc.M502230200
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lee CK, 2004, ARTHRITIS RHEUM US, V50, P3831, DOI 10.1002/art.20637
   Lerner UH, 2000, MATRIX BIOL, V19, P107, DOI 10.1016/S0945 053X(00)00052 4
   Lerner UH, 2004, CRIT REV ORAL BIOL M, V15, P64, DOI 10.1177/154411130401500202
   LERNER UH, 1987, J BONE MINER RES, V2, P375
   LERNER UH, 2002, PRINCIPLES BONE BIOL, P961
   Lerner UH, 1997, KININ SYSTEM, P219
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   LJUNGGREN O, 1991, J BONE MINER RES, V6, P543
   Lubberts E, 2000, J CLIN INVEST, V105, P1697, DOI 10.1172/JCI7739
   Mangashetti LS, 2005, J IMMUNOL, V175, P917, DOI 10.4049/jimmunol.175.2.917
   Martin TJ, 1998, CRIT REV EUKAR GENE, V8, P107, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.10
   MIOSSEC P, 1994, ARTHRITIS RHEUM, V37, P1715, DOI 10.1002/art.1780371202
   Mirosavljevic D, 2003, J BONE MINER RES, V18, P984, DOI 10.1359/jbmr.2003.18.6.984
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Mohamed SGK, 2005, BIOCHEM BIOPH RES CO, V329, P839, DOI 10.1016/j.bbrc.2005.02.049
   Moreno JL, 2003, BLOOD, V102, P1078, DOI 10.1182/blood 2002 11 3437
   NAGASAKI K, 1991, BIOCHEM BIOPH RES CO, V178, P694, DOI 10.1016/0006 291X(91)90163 2
   NAKANO Y, 1994, J BONE MINER RES, V9, P1533, DOI 10.1002/jbmr.5650091005
   Okada Y, 1998, BONE, V22, P361, DOI 10.1016/S8756 3282(97)00296 2
   Onoe Y, 1996, J IMMUNOL, V156, P758
   Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353
   RIANCHO JA, 1993, J BONE MINER RES, V8, P1337
   SHIOI A, 1991, J CELL BIOCHEM, V47, P272, DOI 10.1002/jcb.240470313
   Takahashi N, 2002, PRINCIPLES BONE BIOL, P109
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   WATANABE K, 1990, BIOCHEM BIOPH RES CO, V172, P1035, DOI 10.1016/0006 291X(90)91550 C
   Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200
   Woods JM, 2001, J IMMUNOL, V166, P1214, DOI 10.4049/jimmunol.166.2.1214
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
NR 53
TC 116
Z9 136
U1 1
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 3
PY 2006
VL 281
IS 5
BP 2414
EP 2429
DI 10.1074/jbc.M510160200
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 006XT
UT WOS:000234931800004
PM 16251181
OA hybrid
DA 2025 08 17
ER

PT J
AU Kiyono, K
   Mabuchi, S
   Otaka, A
   Iwasaki, Y
AF Kiyono, Kenjiro
   Mabuchi, Shun
   Otaka, Akihisa
   Iwasaki, Yasuhiko
TI Bone targeting polyphosphodiesters that promote osteoblastic
   differentiation
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE bone targeting; osteoblast; osteoblastic differentiation;
   polyphosphoester
ID POLYPHOSPHOESTER IONOMERS; PHOSPHORIC ACID; OSTEOPOROSIS; POLYESTERS;
   PHOSPHATE
AB Polymers for pharmaceutical use have been attractive in medical treatments because of the conjugation of multifunctional components and their long circulation time in the blood stream. Bone targeted drug delivery systems are also no exceptional, and several polymers have been proposed for the treatment of bone diseases, such as cancer metastasis and osteoporosis. Herein, we report that polyphosphodiesters (PPDEs) have a potential to enhance osteoblastic differentiation, and they have a targeting ability to bone tissues in vivo. Two types of PPDEs, poly (ethylene sodium phosphate) (PEP center dot Na) and poly (propylene sodium phosphate) (PPP center dot Na), have been synthesized. Regardless of the alkylene structure in the main chain of PPDEs, the gene expression of osteoblast specific transcription factors and differentiation markers of mouse osteoblastic like cells (MC3T3 E1 cells) cultured in a differentiation medium was significantly upregulated by the addition of PPDEs. Moreover, it was also clarified that the signaling pathway related to cytoplasmic calcium ions was activated by PPDEs. The mineralization of MC3T3 E1 cells has a similar trend with its gene expression and is synergistically enhanced by PPDEs with beta glycerophosphate. The biodistribution of fluorescence labeled PPDEs was also determined after intravenous injection in mice. PPDEs accumulated well in the bone through the blood stream, whereas polyphosphotriesters (PPTEs) tended to be excreted from the kidneys. Hydrophilic PEP center dot Na showed a superior bone affinity as compared with PPP center dot Na. PPDEs could be candidate polymers for the restoration of bone remodeling and bone targeting drug delivery platforms.
C1 [Kiyono, Kenjiro; Mabuchi, Shun; Iwasaki, Yasuhiko] Kansai Univ, Dept Chem & Mat Engn, Suita, Osaka, Japan.
   [Otaka, Akihisa] Natl Cerebral & Cardiovasc Ctr, Res Inst, Dept Biomed Engn, Suita, Osaka, Japan.
   [Otaka, Akihisa; Iwasaki, Yasuhiko] Kansai Univ, ORDIST, Suita, Osaka, Japan.
C3 Kansai University; National Cerebral & Cardiovascular Center   Japan;
   Kansai University
RP Iwasaki, Y (通讯作者)，Kansai Univ, Dept Chem & Mat Engn, Suita, Osaka, Japan.; Iwasaki, Y (通讯作者)，Kansai Univ, Dept Chem & Mat Engn, 3 3 35 Yamate Cho, Osaka, Suita 5648680, Japan.
EM yasu.bmt@kansai u.ac.jp
RI Iwasaki, Yasuhiko/D 6870 2011
FU Japan Society for the Promotion of Science [19H04474]
FX Japan Society for the Promotion of Science, Grant/Award Number:
   #19H04474
CR Al Bari AA, 2020, FASEB BIOADV, V2, P668, DOI 10.1096/fba.2020 00058
   BARAN J, 1995, MACROMOLECULES, V28, P5167, DOI 10.1021/ma00119a002
   Bauer KN, 2018, EUR POLYM J, V108, P286, DOI 10.1016/j.eurpolymj.2018.08.058
   Bauer KN, 2017, PROG POLYM SCI, V73, P61, DOI 10.1016/j.progpolymsci.2017.05.004
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Cosman F, 2021, CURR OSTEOPOROS REP, V19, P189, DOI 10.1007/s11914 021 00663 1
   Dera R, 2020, MACROMOL CHEM PHYS, V221, DOI 10.1002/macp.201900466
   Fixen C, 2021, CURR OSTEOPOROS REP, V19, P15, DOI 10.1007/s11914 020 00652 w
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Ikeuchi R, 2013, J BIOMED MATER RES A, V101, P318, DOI 10.1002/jbm.a.34321
   Ishibashi Hideaki, 2018, Osteoporos Sarcopenia, V4, P86, DOI 10.1016/j.afos.2018.09.004
   Iwasaki Y, 2020, MOLECULES, V25, DOI 10.3390/molecules25030758
   Iwasaki Y, 2017, BIOMATER SCI UK, V6, P91, DOI 10.1039/c7bm00930e
   Iwasaki Y, 2013, J BIOMAT SCI POLYM E, V24, P882, DOI 10.1080/09205063.2012.710823
   Iwasaki Y, 2010, MACROMOLECULES, V43, P2664, DOI 10.1021/ma100242s
   Iwasaki Y, 2009, CHEM LETT, V38, P1054, DOI 10.1246/cl.2009.1054
   Jensen PR, 2021, BONE, V145, DOI 10.1016/j.bone.2021.115850
   KALUZYNSKI K, 1976, MACROMOLECULES, V9, P365, DOI 10.1021/ma60050a039
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kootala S, 2015, MACROMOL BIOSCI, V15, P1634, DOI 10.1002/mabi.201500166
   Langdahl BL, 2021, BRIT J PHARMACOL, V178, P1891, DOI 10.1111/bph.15024
   Liu L, 2020, ACS BIOMATER SCI ENG, V6, P1500, DOI 10.1021/acsbiomaterials.9b01374
   Liu ZG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17120 8
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Miron RJ, 2012, J DENT RES, V91, P736, DOI 10.1177/0022034511435260
   Monge S, 2011, BIOMACROMOLECULES, V12, P1973, DOI 10.1021/bm2004803
   Otaka A, 2021, MATERIALIA, V15, DOI 10.1016/j.mtla.2020.100977
   Otaka A, 2020, J BIOMED MATER RES A, V108, P2090, DOI 10.1002/jbm.a.36968
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Pelosi C, 2020, EUR POLYM J, V141, DOI 10.1016/j.eurpolymj.2020.110079
   Penczek S., 1990, Model of Biopolymer by Ring Opening Polymerization, P291
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rossi M, 2021, J ENDOCRINOL, V248, pR29, DOI 10.1530/JOE 20 0285
   Seeman E, 2013, J GERONTOL A BIOL, V68, P1218, DOI 10.1093/gerona/glt071
   Sivakumar PM, 2022, CARBOHYD POLYM, V283, DOI 10.1016/j.carbpol.2022.119142
   Steinbach T, 2015, ANGEW CHEM INT EDIT, V54, P6098, DOI 10.1002/anie.201500147
   Tanaka S, 2019, EFORT OPEN REV, V4, P158, DOI 10.1302/2058 5241.4.180018
   Toda H, 2016, ACTA BIOMATER, V29, P215, DOI 10.1016/j.actbio.2015.10.036
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang L, 2020, ACS APPL MATER INTER, V12, P32312, DOI 10.1021/acsami.0c07016
   Yang JY, 2014, J CONTROL RELEASE, V190, P288, DOI 10.1016/j.jconrel.2014.04.013
   Zhang SY, 2013, MACROMOLECULES, V46, P5141, DOI 10.1021/ma400675m
   Zhou X, 2021, NANO LETT, V21, P7998, DOI 10.1021/acs.nanolett.1c02150
NR 48
TC 5
Z9 5
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD MAY
PY 2023
VL 111
IS 5
BP 714
EP 724
DI 10.1002/jbm.a.37499
EA JAN 2023
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 9V5IW
UT WOS:000911172300001
PM 36622032
DA 2025 08 17
ER

PT J
AU Ramasubramanian, A
   Jeeawoody, S
   Yang, F
AF Ramasubramanian, Anusuya
   Jeeawoody, Shaheen
   Yang, Fan
TI Gene delivery of osteoinductive signals to a human fetal osteoblast cell
   line induces cell death in a dose dependent manner
SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH
LA English
DT Article
DE Gene delivery; Osteoblast; BMP2; GNAS; Noggin; Apoptosis
ID BONE MORPHOGENETIC PROTEIN 2; STEM CELLS; STROMAL CELLS; IN VIVO;
   APOPTOSIS; THERAPY; OSTEOGENESIS; INDUCTION; DIFFERENTIATION;
   TRANSPLANTATION
AB Gene delivery provides a powerful tool for regulating tissue regeneration by activating or inhibiting specific genes associated with targeted signaling pathways. Up regulating bone morphogenetic protein 2 (BMP 2) or silencing GNAS and Noggin gene expression in stem cells has been shown to enhance osteogenic differentiation and bone tissue formation. However, few studies have examined how such gene delivery would influence other differentiated cell types residing in the bone. In this study, we examined the effects of DNA delivery of BMP 2 and siRNA delivery of GNAS or Noggin on a widely used human fetal osteoblast cell line (hFOB1.19) using biomaterials mediated gene delivery. Our results showed that both GNAS and Noggin siRNA delivery increased cell death in hFOB1.19 in a dose dependent manner. In particular, groups treated with the highest doses of BMP 2, siGNAS or siNoggin showed a more than 50 % decline in cell proliferation and a 90 % decline in cell viability compared to untransfected and sham DNA/siRNA transfected controls. TUNEL staining showed that BMP 2, siGNAS or siNoggin induced cell apoptosis in hFOBs. In contrast, cells transfected using sham DNA or siRNA showed no noticeable cell death or apoptosis. These results elucidate the nuanced responses of progenitor and immortalized cell populations to the delivery of exogenous osteoinductive genes. In particular, they highlight the differences between immortalized and primary cell lines and underscore the importance of targeted gene delivery mechanisms in the regeneration of injured bone tissue.
C1 [Ramasubramanian, Anusuya] Stanford Univ, Program Biomech Engn, Stanford, CA 94305 USA.
   [Jeeawoody, Shaheen; Yang, Fan] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.
   [Yang, Fan] Stanford Univ, Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University; Stanford University
RP Yang, F (通讯作者)，Stanford Univ, Sch Med, Dept Orthopaed Surg, 300 Pasteur Dr,Edwards R105, Stanford, CA 94305 USA.
EM fanyang@stanford.edu
RI Yang, Fan/GYU 4249 2022
OI Jeeawoody, Shaheen/0000 0002 1554 6810
FU Stanford Undergraduate Advising and Research Office; Stanford School of
   Engineering
FX A.R. and S.J. would like to thank the Stanford Undergraduate Advising
   and Research Office for funding. S.J. would also like to thank the
   Stanford School of Engineering for funding.
CR Almonte Becerril M, 2010, APOPTOSIS, V15, P631, DOI 10.1007/s10495 010 0458 z
   Cheema SK, 2007, WOUND REPAIR REGEN, V15, P286, DOI 10.1111/j.1524 475X.2007.00228.x
   Cho SW, 2009, ADV FUNCT MATER, V19, P3112, DOI 10.1002/adfm.200900519
   Clines GA, 2010, CURR OPIN ORGAN TRAN, V15, P73, DOI 10.1097/MOT.0b013e328333d52c
   Dragoo JL, 2003, J ORTHOP RES, V21, P622, DOI 10.1016/S0736 0266(02)00238 3
   Evans CH, 2004, GENE THER, V11, P379, DOI 10.1038/sj.gt.3302196
   Gardlík R, 2005, MED SCI MONITOR, V11, pRA110
   Gautschi OP, 2009, J MUSCULOSKEL NEURON, V9, P53
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Haÿ E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200
   Hughes SM, 2002, MOL THER, V5, P16, DOI 10.1006/mthe.2001.0512
   Hyzy SL, 2012, J CELL BIOCHEM, V113, P3236, DOI 10.1002/jcb.24201
   Jabbarzadeh E, 2008, P NATL ACAD SCI USA, V105, P11099, DOI 10.1073/pnas.0800069105
   Jeon O, 2008, TISSUE ENG PT A, V14, P1285, DOI 10.1089/ten.tea.2007.0253
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Lee SJ, 2010, BIOMATERIALS, V31, P5652, DOI 10.1016/j.biomaterials.2010.03.019
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602
   Mikami Y, 2010, J CELL PHYSIOL, V223, P123, DOI 10.1002/jcp.22017
   Ramasubramanian A, 2011, PHARM RES DORDR, V28, P1328, DOI 10.1007/s11095 011 0406 9
   SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980
   Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593
   Strulovici Y, 2007, MOL THER, V15, P850, DOI 10.1038/mt.sj.6300125
   Subramaniam M, 2002, J CELL BIOCHEM, V87, P9, DOI 10.1002/jcb.10259
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Wan DC, 2007, J BIOL CHEM, V282, P26450, DOI 10.1074/jbc.M703282200
   Wang XX, 2011, PLAST RECONSTR SURG, V128, P395, DOI 10.1097/PRS.0b013e31821e6e10
   Wang XL, 2011, GROWTH FACTORS, V29, P36, DOI 10.3109/08977194.2010.544656
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yang F, 2005, BIOMATERIALS, V26, P5991, DOI 10.1016/j.biomaterials.2005.03.018
   Yang F, 2009, GENE THER, V16, P533, DOI 10.1038/gt.2008.182
   Yang F, 2010, P NATL ACAD SCI USA, V107, P3317, DOI 10.1073/pnas.0905432106
   Youm YS, 2010, CLIN ORTHOP SURG, V2, P250, DOI 10.4055/cios.2010.2.4.250
   Zachos T, 2007, MOL THER, V15, P1543, DOI 10.1038/sj.mt.6300192
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhao YX, 2007, P NATL ACAD SCI USA, V104, P9673, DOI 10.1073/pnas.0703407104
NR 38
TC 3
Z9 4
U1 0
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 2190 393X
EI 2190 3948
J9 DRUG DELIV TRANSL RE
JI Drug Deliv. Transl. Res.
PD APR
PY 2015
VL 5
IS 2
BP 160
EP 167
DI 10.1007/s13346 013 0163 x
PG 8
WC Instruments & Instrumentation; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Instruments & Instrumentation; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA CM0MD
UT WOS:000357371200008
PM 25787741
DA 2025 08 17
ER

PT J
AU Gao, F
   Liu, YH
   Liu, MF
   Zhu, LX
AF Gao, Feng
   Liu, Yuanhang
   Liu, Mingfa
   Zhu, Lixin
TI Zoledronic acid regulates osteoblast differentiation via the mTORC1
   signaling pathway
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Zoledronic acid; bone disease; osteoblast; mTOR
ID BISPHOSPHONATE RELATED OSTEONECROSIS; PROMOTES OSTEOGENIC
   DIFFERENTIATION; BONE FORMATION; CELLS; INHIBITION; PROLIFERATION;
   PRENYLATION; GROWTH; MODEL; JAW
AB Zoledronic acid (ZA) exerts an important role in regulating bone metabolism. The purpose of this study was to investigate mechanisms of ZA in terms of their effect on bone formation in vitro. Human osteoblasts (MG63 cell line) were treated with serial concentrations of ZA 0, 10( 3), 10( 6), 10( 9) and 10( 12) M). Cell viability, cell apoptosis, alkaline phosphatase (ALP) activity, and expression levels of the marker genes and proteins associated with osteogenic differentiation were evaluated. Signaling from mechanistic target of rapamycin complex 1 (mTORC1) of MG63 cells was detected after ZA treatment, combined with or without rapamycin (mTORC1 inhibitor). Data were statistically analyzed by one way analysis, with a significance level of 5%. An MTT assay and a flow cytometric Annexin V/propidium iodide assay revealed that exposure of MG63 cells to ZA exhibited a significant inhibition of cell viability and induction of apoptosis at concentrations of 10( 3) and 10( 6) M, but no changes at concentrations of 10( 9) and 10( 12) M (short time treatment), compared to no drug. In addition, ZA caused an increased expression level of marker genes and proteins associated with osteogenic differentiation and ALP activity at concentrations of 10( 9) and 10( 12) M, but inhibited osteogenic differentiation at concentrations of 10( 3) and 10( 6) M, compared to no drug. Furthermore, research into the mechanism responsible showed that low concentrations of ZA induced osteogenic differentiation through preventing mTORC1 activity. In contrast, high concentrations of ZA reduced osteogenic differentiation through promoting mTORC1 activity. Rapamycin, an mTORC1 specific inhibitor, could rescue the defect of osteogenic differentiation caused by exposure to high concentrations of ZA. This in vitro study indicates that ZA mediated osteoblastic differentiation is mTORC1 dependent. Low concentrations of ZA are better for regulating bone formation via inhibiting mTORC1 activity.
C1 [Gao, Feng; Zhu, Lixin] Southern Med Univ, Zhujiang Hosp, Dept Orthoped Surg, Guangzhou 510282, Guangdong, Peoples R China.
   [Gao, Feng] Inner Mongolia Autonomous Reg Hosp Tradit Chin, Dept Orthoped Surg, Hohhot, Peoples R China.
   [Liu, Yuanhang; Liu, Mingfa] Inner Mongolia Hohhot 1 Hosp, Dept Emergency Med, Hohhot, Peoples R China.
C3 Southern Medical University   China
RP Zhu, LX (通讯作者)，Southern Med Univ, Zhujiang Hosp, Dept Orthoped Surg, Guangzhou 510282, Guangdong, Peoples R China.
EM zhulix in1966@163.com
CR Basso FG, 2013, GERONTOLOGY, V59, P534, DOI 10.1159/000351194
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Bobyn J, 2014, J ORTHOP RES, V32, P1090, DOI 10.1002/jor.22628
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Brandi ML, 2010, DISCOV MED, V10, P209
   Chen JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116549
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Gokosmanoglu F, 2016, J RES MED SCI, V21, DOI 10.4103/1735 1995.193503
   Hoefert S, 2015, CLIN ORAL INVEST, V19, P1307, DOI 10.1007/s00784 014 1358 3
   Hu LW, 2016, MOL MED REP, V14, P3535, DOI 10.3892/mmr.2016.5669
   Huang B, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005426
   Huang X, 2016, MOL MED REP, V13, P613, DOI 10.3892/mmr.2015.4627
   Kaiser T, 2013, BREAST CANCER RES TR, V140, P35, DOI 10.1007/s10549 013 2613 z
   Kauffmann P, 2017, OR SURG OR MED OR PA, V123, P20, DOI 10.1016/j.oooo.2016.08.010
   Lan YC, 2013, ANTICANCER RES, V33, P3807
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Martin SK, 2010, J BONE MINER RES, V25, P2126, DOI 10.1002/jbmr.114
   Moriceau G, 2010, CANCER RES, V70, P10329, DOI 10.1158/0008 5472.CAN 10 0578
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Panaroni C, 2015, J BONE MINER RES, V30, P2273, DOI 10.1002/jbmr.2581
   Pettway GJ, 2008, BONE, V42, P806, DOI 10.1016/j.bone.2007.11.017
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Ruggiero SL, 2011, ANN NY ACAD SCI, V1218, P38, DOI 10.1111/j.1749 6632.2010.05768.x
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Shapiro JR, 2017, BONE, V99, P1, DOI 10.1016/j.bone.2017.03.040
   Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757
   Tenta R, 2006, ANTICANCER RES, V26, P283
   Wang Y, 2017, MOL BIOL REP, V44, P129, DOI 10.1007/s11033 016 4089 5
   Yang XM, 2013, INTRACTABLE RARE DIS, V2, P18, DOI 10.5582/irdr.2013.v2.1.18
   Yeh LCC, 2013, J CELL BIOCHEM, V114, P1760, DOI 10.1002/jcb.24519
   Yu M, 2017, J PERIODONTOL, P1
   Zhu ED, 2014, ENDOCRINOLOGY, V155, P1188, DOI 10.1210/en.2013 1993
NR 35
TC 2
Z9 2
U1 0
U2 5
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2018
VL 11
IS 5
BP 4585
EP 4594
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GI0AJ
UT WOS:000434031300024
DA 2025 08 17
ER

PT J
AU He, YQ
   Zhang, Q
   Shen, Y
   Han, T
   Zhang, QL
   Zhang, JH
   Lin, B
   Song, HT
   Hsu, HY
   Qin, LP
   Xin, HL
   Zhang, QY
AF He, Yu Qiong
   Zhang, Qi
   Shen, Yi
   Han, Ting
   Zhang, Quan Long
   Zhang, Jian Hua
   Lin, Bing
   Song, Hong Tao
   Hsu, Hsien Yeh
   Qin, Lu Ping
   Xin, Hai Liang
   Zhang, Qiao Yan
TI Rubiadin 1 methyl ether from Morinda officinalis How. Inhibits
   osteoclastogenesis through blocking RANKL induced NF κB pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Morinda officinalis How; Rubiadin 1 methyl ether; Osteoclast; RANKL;
   NF kappa B pathway
ID INDUCED BONE LOSS; DIFFERENTIATION; ANTHRAQUINONES; CELLS; ACID
AB Rubiadin 1 methyl ether (RBM) is a natural anthraquinone compound isolated from the root of Morinda officinalis How. In our previous study, RBM was found to have inhibitory effects on the TRAP activity of osteoclasts, which means that RBM may be a candidate for therapy of bone diseases characterized by enhanced bone resorption. However, the further effect of RBM on osteoclasts and the underlying mechanism remain unclear. In the present study, we investigated the effects of RBM isolated from Morinda officinalis How. on osteoclasts derived from bone marrow macrophages (BMMs) and the underlying mechanism in vitro. RBM at the dose that did not affect the viability of cells significantly inhibited RANKL induced osteoclastogenesis and actin ring formation of osteoclast, while RBM performed a stronger effect at the early stage. In addition, RBM downregulated the expression of osteoclast related proteins, including nuclear factor of activated T cells cytoplasmic 1 (NFATc1), cellular oncogene Fos (c Fos), matrix metallopeptidase 9 (MMP 9) and cathepsin K (CtsK) as shown by Western blot. Furthermore, RBM inhibited the phosphorylation of NF kappa B p65 and the degradation of lact as well as decreased the nuclear translocation of p65. Collectively, the results suggest that RBM inhibit osteoclastic bone resorption through blocking NF kappa B pathway and may be a promising agent for the prevention and treatment of bone diseases characterized by excessive bone resorption. (C) 2018 Elsevier Inc. All rights reserved.
C1 [He, Yu Qiong; Han, Ting; Zhang, Jian Hua; Qin, Lu Ping; Xin, Hai Liang; Zhang, Qiao Yan] Second Mil Med Univ, Dept Pharmacognosy, Sch Pharm, Shanghai 200433, Peoples R China.
   [He, Yu Qiong; Zhang, Quan Long; Qin, Lu Ping; Zhang, Qiao Yan] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 311402, Zhejiang, Peoples R China.
   [Zhang, Qi; Shen, Yi] Fujian Univ Tradit Chinese Med, Sch Pharm, Fuzhou 350108, Fujian, Peoples R China.
   [Lin, Bing; Song, Hong Tao] Fuzhou Gen Hosp Nanjing Mil Reg, Fuzhou 350025, Fujian, Peoples R China.
   [Hsu, Hsien Yeh] Natl Yang Ming Univ, Dept Biotechnol & Lab Sci Med, Taipei, Taiwan.
C3 Naval Medical University; Zhejiang Chinese Medical University; Fujian
   University of Traditional Chinese Medicine; National Yang Ming Chiao
   Tung University
RP Xin, HL (通讯作者)，Second Mil Med Univ, Dept Pharmacognosy, Sch Pharm, Shanghai 200433, Peoples R China.; Qin, LP; Zhang, QY (通讯作者)，Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 311402, Zhejiang, Peoples R China.
EM qinluping@126.com; hailiangxin@163.com; zqy1965@163.com
RI HAN, TINGTING/GQZ 8692 2022
FU National Natural Science Foundation of China [U1505226]; Shanghai
   Municipal Science and Technology Commission [14401902700]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. U1505226) and Shanghai Municipal Science and Technology
   Commission (Grant No. 14401902700).
CR Arnett TR, 2018, BONE, V115, P25, DOI 10.1016/j.bone.2017.12.021
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bao LL, 2011, CHEM BIOL INTERACT, V194, P97, DOI 10.1016/j.cbi.2011.08.013
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Comini LR, 2011, PHYTOMEDICINE, V18, P1093, DOI 10.1016/j.phymed.2011.05.008
   Doss HM, 2018, LIFE SCI, V207, P284, DOI 10.1016/j.lfs.2018.06.013
   Edwards JR, 2012, DISCOV MED, V13, P201
   Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900
   Honma M, 2014, CURR OSTEOPOROS REP, V12, P115, DOI 10.1007/s11914 014 0189 0
   Kanokmedhakul K, 2005, J ETHNOPHARMACOL, V100, P284, DOI 10.1016/j.jep.2005.03.018
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li N, 2009, MOLECULES, V14, P2049, DOI 10.3390/molecules14062049
   Noguchi T, 2018, BIOCHEM BIOPH RES CO, V503, P644, DOI 10.1016/j.bbrc.2018.06.055
   Park JH, 2017, MOL CELLS, V40, P706
   Pengjam Y, 2016, BIOMOL THER, V24, P123, DOI 10.4062/biomolther.2015.106
   Sapkota M, 2018, FOOD CHEM TOXICOL, V120, P418, DOI 10.1016/j.fct.2018.07.032
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105
   Wang B., 2018, INHIBITION EFFECTS N
   Wang JS, 2018, BIOCHEM BIOPH RES CO, V495, P2133, DOI 10.1016/j.bbrc.2017.12.091
   Wijekoon HMS, 2018, BMC VET RES, V14, DOI 10.1186/s12917 018 1466 4
   Wu YB, 2009, MOLECULES, V14, P573, DOI 10.3390/molecules14010573
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Xu X, 2016, EUR J MED CHEM, V123, P769, DOI 10.1016/j.ejmech.2016.08.004
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Zhang JH, 2018, J ETHNOPHARMACOL, V213, P230, DOI 10.1016/j.jep.2017.10.028
   Zhang K, 2018, INT IMMUNOPHARMACOL, V61, P150, DOI 10.1016/j.intimp.2018.05.030
   Zhang YG, 2017, MOL MED REP, V16, P8223, DOI 10.3892/mmr.2017.7670
   Zhao QX, 2007, FRONT BIOSCI LANDMRK, V12, P2519, DOI 10.2741/2252
NR 32
TC 26
Z9 30
U1 0
U2 33
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 2
PY 2018
VL 506
IS 4
BP 927
EP 931
DI 10.1016/j.bbrc.2018.10.100
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HD1DK
UT WOS:000452249100025
PM 30392907
DA 2025 08 17
ER

PT J
AU Choi, SW
   Yeon, JT
   Ryu, BJ
   Kim, KJ
   Moon, SH
   Lee, H
   Lee, MS
   Lee, SY
   Heo, JC
   Park, SJ
   Kim, SH
AF Choi, Sik Won
   Yeon, Jeong Tae
   Ryu, Byung Jun
   Kim, Kwang Jin
   Moon, Seong Hee
   Lee, Hyuk
   Lee, Myeung Su
   Lee, Sam Youn
   Heo, Jin Chul
   Park, Sang Joon
   Kim, Seong Hwan
TI Repositioning Potential of PAK4 to Osteoclastic Bone Resorption
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOCLAST; PAK4 INHIBITOR; DRUG REPOSITION; PODOSOME; OSTEOCLAST FUSION
ID FACTOR RECEPTOR; TNF ALPHA; MIGRATION; DIFFERENTIATION; NFATC1; FUSION;
   INTEGRIN; LIPOPOLYSACCHARIDE; MODULATION; INDUCTION
AB Drug repositioning is a rational approach for expanding the use of existing drugs or candidate drugs to treat additional disorders. Here we investigated the possibility of using the anticancer p21 activated kinase 4 (PAK4) targeted inhibitor PF 3758309 to treat osteoclast mediated disorders. PAK4 was highly expressed in bone marrow cells and was phosphorylated during their differentiation into osteoclasts, and osteoclast differentiation was significantly inhibited by the dominant negative form of PAK4 and by PF 3758309. Specifically, PF 3758309 significantly inhibited the fusion of preosteoclasts, the podosome formation, and the migration of preosteoclasts. PF 3758309 also had in vivo antiresorptive activity in a lipopolysaccharide induced bone erosion model and in vitro antiosteoclastogenic activity in the differentiation of human bone marrow derived cells and peripheral blood mononuclear cells into osteoclasts. These data demonstrate the relevance of PAK4 in osteoclast differentiation and the potential of PAK4 inhibitors for treating osteoclast related disorders. (c) 2015 American Society for Bone and Mineral Research (c) 2015 American Society for Bone and Mineral Research.
C1 [Choi, Sik Won; Ryu, Byung Jun; Moon, Seong Hee; Kim, Seong Hwan] Korea Res Inst Chem Technol, Drug Discovery Div, Pharmacol Res Ctr, Lab Translat Therapeut, Taejon 305600, South Korea.
   [Yeon, Jeong Tae; Kim, Kwang Jin] Sunchon Natl Univ, Dept Pharm, Sunchon, South Korea.
   [Lee, Hyuk] Korea Res Inst Chem Technol, Med Chem Res Ctr, Taejon 305600, South Korea.
   [Lee, Myeung Su] Wonkwang Univ, Div Rheumatol, Dept Internal Med, Iksan, Jeonbuk, South Korea.
   [Lee, Sam Youn] Wonkwang Univ, Dept Cardiac & Thorac Surg, Iksan, Jeonbuk, South Korea.
   [Heo, Jin Chul] Korea Res Inst Chem Technol, Drug Discovery Div, Pharmacol Res Ctr, Taejon 305600, South Korea.
   [Park, Sang Joon] Kyungpook Natl Univ, Dept Histol, Coll Vet Med, Daegu, South Korea.
C3 Korea Research Institute of Chemical Technology (KRICT); Sunchon
   National University; Korea Research Institute of Chemical Technology
   (KRICT); Wonkwang University; Wonkwang University; Korea Research
   Institute of Chemical Technology (KRICT); Kyungpook National University
   (KNU)
RP Kim, SH (通讯作者)，Korea Res Inst Chem Technol, Drug Discovery Div, Pharmacol Res Ctr, Lab Translat Therapeut, POB 107, Taejon 305600, South Korea.
EM hwan@krict.re.kr
RI Kim, Seong/AAA 6086 2021; Lee, Sang Hoon/ABH 6210 2020
OI Choi, Sik Won/0000 0003 1726 2536; 
FU Korea Research Institute of Chemical Technology [SI 1404]
FX This work was supported by the project grant (SI 1404) of Korea Research
   Institute of Chemical Technology.
CR Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Blangy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045909
   Boissy P, 1998, J CELL SCI, V111, P2563
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200
   Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993
   Choi SW, 2012, FEBS LETT, V586, P263, DOI 10.1016/j.febslet.2011.12.033
   Cirelli JA, 2009, GENE THER, V16, P426, DOI 10.1038/gt.2008.174
   Coles LD, 2012, CLIN PHARMACOL THER, V92, P193, DOI 10.1038/clpt.2012.83
   Croke M, 2011, J CELL SCI, V124, P3811, DOI 10.1242/jcs.086280
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   D'Amelio P, 2004, FASEB J, V18, P410, DOI 10.1096/fj.04 2214fje
   Daroszewska A, 2006, NAT CLIN PRACT RHEUM, V2, P270, DOI 10.1038/ncprheum0172
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Eswaran J, 2008, TRENDS BIOCHEM SCI, V33, P394, DOI 10.1016/j.tibs.2008.06.002
   Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194
   Gringel A, 2006, J CELL PHYSIOL, V209, P568, DOI 10.1002/jcp.20777
   Gupta SC, 2013, TRENDS PHARMACOL SCI, V34, P508, DOI 10.1016/j.tips.2013.06.005
   Ha J, 2011, CYTOKINE, V55, P48, DOI 10.1016/j.cyto.2011.03.026
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Hu SQ, 2011, MOL BIOL CELL, V22, P3120, DOI 10.1091/mbc.E11 01 0086
   Ito Y, 2010, J CLIN INVEST, V120, P1981, DOI 10.1172/JCI39650
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kitaura H, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/181849
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li YY, 2012, GENOME MED, V4, DOI 10.1186/gm326
   Linder S, 2005, J CELL SCI, V118, P2079, DOI 10.1242/jcs.02390
   Lu YB, 2003, J BIOL CHEM, V278, P10374, DOI 10.1074/jbc.M205875200
   Miyamoto Takeshi, 2006, Mod Rheumatol, V16, P341
   Mörmann M, 2008, MOL IMMUNOL, V45, P3330, DOI 10.1016/j.molimm.2008.04.022
   Nakamura I, 1999, J CELL SCI, V112, P3985
   ORCEL P, 1993, AM J PHYSIOL, V264, pE391, DOI 10.1152/ajpendo.1993.264.3.E391
   Paliouras GN, 2009, MOL CELL BIOL, V29, P3018, DOI 10.1128/MCB.01286 08
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Park MH, 2013, ONCOGENE, V32, P2475, DOI 10.1038/onc.2012.255
   Ryu BJ, 2014, CANCER LETT, V349, P45, DOI 10.1016/j.canlet.2014.03.024
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Tehrani S, 2006, MOL BIOL CELL, V17, P2882, DOI 10.1091/mbc.E06 03 0187
   Tumber A, 2001, INT J CANCER, V91, P665
   van Helden SFG, 2006, J IMMUNOL, V177, P1567, DOI 10.4049/jimmunol.177.3.1567
   Wong LE, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.13
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014 4827(89)90266 8
   Zhang HJ, 2011, CARCINOGENESIS, V32, P765, DOI 10.1093/carcin/bgr033
   Zhao HB, 2005, J BONE MINER RES, V20, P2116, DOI 10.1359/JBMR.050724
NR 55
TC 7
Z9 7
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2015
VL 30
IS 8
BP 1494
EP 1507
DI 10.1002/jbmr.2468
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CN1JL
UT WOS:000358175500017
PM 25640698
DA 2025 08 17
ER

PT J
AU Hamidouche, Z
   Fromigué, O
   Ringe, J
   Häupl, T
   Marie, PJ
AF Hamidouche, Zahia
   Fromigue, Olivia
   Ringe, Jochen
   Haeupl, Thomas
   Marie, Pierre J.
TI Crosstalks between integrin alpha 5 and IGF2/IGFBP2 signalling trigger
   human bone marrow derived mesenchymal stromal osteogenic differentiation
SO BMC CELL BIOLOGY
LA English
DT Article
ID IGF BINDING PROTEIN 2; STEM CELLS; EXTRACELLULAR MATRIX; MINERAL
   DENSITY; GENE EXPRESSION; IN VITRO; GROWTH; CULTURE; MODEL
AB Background: The potential of mesenchymal stromal cells (MSCs) to differentiate into functional bone forming cells provides an important tool for bone regeneration. The identification of factors that trigger osteoblast differentiation in MSCs is therefore critical to promote the osteogenic potential of human MSCs. In this study, we used microarray analysis to identify signalling molecules that promote osteogenic differentiation in human bone marrow stroma derived MSCs.
   Results: Microarray analysis and validation experiments showed that the expression of IGF2 and IGFBP2 was increased together with integrin alpha5 (ITGA5) during dexamethasone induced osteoblast differentiation in human MSCs. This effect was functional since we found that IGF2 and IGFBP2 enhanced the expression of osteoblast phenotypic markers and in vitro osteogenic capacity of hMSCs. Interestingly, we showed that downregulation of endogenous ITGA5 using specific shRNA decreased IGF2 and IGFBP2 expression in hMSCs. Conversely, ITGA5 overexpression upregulated IGF2 and IGFBP2 expression in hMSCs, which indicates tight crosstalks between these molecules. Consistent with this concept, activation of endogenous ITGA5 using a specific antibody that primes the integrin, or a peptide that specifically activates ITGA5 increased IGF2 and IGFBP2 expression in hMSCs. Finally, we showed that pharmacological inhibition of FAK/ERK1/2 MAPKs or PI3K signalling pathways that are enhanced by ITGA5 activation, blunted IGF2 and IGFBP2 expression in hMSCs.
   Conclusion: The results show that ITGA5 is a key mediator of IGF2 and IGFBP2 expression that promotes osteoblast differentiation in human MSCs, and reveal that crosstalks between ITGA5 and IGF2/IGFBP2 signalling are important mechanisms that trigger osteogenic differentiation in human bone marrow derived mesenchymal stromal cells.
C1 [Hamidouche, Zahia; Fromigue, Olivia; Marie, Pierre J.] INSERM, Lab Osteoblast Biol & Pathol, U606, F 75475 Paris, France.
   [Hamidouche, Zahia; Fromigue, Olivia; Marie, Pierre J.] Univ Paris Diderot, UMR606, F 75475 Paris, France.
   [Ringe, Jochen; Haeupl, Thomas] Charite, D 13353 Berlin, Germany.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris Cite; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin
RP Marie, PJ (通讯作者)，INSERM, Lab Osteoblast Biol & Pathol, U606, F 75475 Paris, France.
EM pierre.marie@inserm.fr
RI Fromigue, Olivia/B 8225 2013
OI Fromigue, Olivia/0000 0002 3050 6155
FU Etablissement Francais du Sang (EFS, Scientific Council), France
   [2004 08, 2005.11]; European Commission [LSHB CT 2003 503161 Genostem]
FX The authors thank Biopredic (Rennes, France) for providing hMSCs, Dr. S.
   Kuwada (University of Utah, USA) for the ITGA5 plasmid, Dr. M.J.
   Humphries (University of Manchester, UK) for the SNAKA51 antibody and
   CRRETAWAC peptide, and Drs. P. Vaudin and J.C. Pages (University of
   Tours, France) for the ITGA5 constructs. This work was supported by
   grants from the Etablissement Francais du Sang (EFS, Scientific Council
   No 2004 08 and 2005.11, France) and the Integrated Project of the
   European Commission FP6 research funding programme (Contract
   LSHB CT 2003 503161 Genostem).
CR AMARNANI S, 1993, J BONE MINER RES, V8, P157
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Canalis E, 2003, CURR OPIN RHEUMATOL, V15, P454, DOI 10.1097/00002281 200307000 00013
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Clark K, 2005, J CELL SCI, V118, P291, DOI 10.1242/jcs.01623
   Conover CA, 2002, GROWTH HORM IGF RES, V12, P178, DOI 10.1016/S1096 6374(02)00044 8
   Conover CA, 2003, GROWTH HORM IGF RES, V13, P328, DOI 10.1016/S1096 6374(03)00092 3
   Delorme Bruno, 2007, V140, P67
   DeMambro VE, 2008, ENDOCRINOLOGY, V149, P2051, DOI 10.1210/en.2007 1068
   Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201
   Fromigué O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873
   Fromigue O, 1997, CYTOKINE, V9, P613, DOI 10.1006/cyto.1997.0209
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Häupl T, 2007, J BIOMOL SCREEN, V12, P328, DOI 10.1177/1087057107299261
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   KANZAKI S, 1995, J BONE MINER RES, V10, P854
   Karasik D, 2002, CALCIFIED TISSUE INT, V71, P323, DOI 10.1007/s00223 002 1002 0
   Kassem M, 2004, CLONING STEM CELLS, V6, P369, DOI 10.1089/clo.2004.6.369
   Khosla S, 1998, J CLIN INVEST, V101, P2165, DOI 10.1172/JCI1111
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011
   MORSCZECK C, 2009, CLIN ORAL I IN PRESS
   Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200
   Palermo C, 2004, AM J PHYSIOL ENDOC M, V286, pE648, DOI 10.1152/ajpendo.00049.2003
   Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008 5472.CAN 03 3056
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   SAUGSPIER MFO, 2010, STEM CELLS IN PRESS
   THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527
   Wang GK, 2006, J BIOL CHEM, V281, P14085, DOI 10.1074/jbc.M513686200
NR 32
TC 75
Z9 89
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2121
J9 BMC CELL BIOL
JI BMC Cell Biol.
PD JUN 23
PY 2010
VL 11
AR 44
DI 10.1186/1471 2121 11 44
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 624IZ
UT WOS:000279812200001
PM 20573191
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wille, A
   Weske, S
   Lipinski, KV
   Wollnitzke, P
   Schröder, NH
   Thomas, N
   Nowak, MK
   Deister Jonas, J
   Behr, B
   Keul, P
   Levkau, B
AF Wille, Annalena
   Weske, Sarah
   Lipinski, Karin von Wnuck
   Wollnitzke, Philipp
   Schroeder, Nathalie H.
   Thomas, Nadine
   Nowak, Melissa K.
   Deister Jonas, Jennifer
   Behr, Bjoern
   Keul, Petra
   Levkau, Bodo
TI Sphingosine 1 phosphate promotes osteogenesis by stimulating osteoblast
   growth and neovascularization in a vascular endothelial growth
   factor dependent manner
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE analysis/quantification of bone bone mu CT; animal models genetic animal
   models; bone modeling and remodeling molecular pathways remodeling;
   cells of bone osteoblasts; systems biology   bone
   interactors bone endothelial cell interaction
ID SPHINGOSINE 1 PHOSPHATE LEVELS; BONE MINERAL DENSITY; SPROUTING
   ANGIOGENESIS; CIRCULATING LEVELS; CELLS; VEGF; DIFFERENTIATION;
   PROLIFERATION; ACTIVATION; EXPRESSION
AB Sphingosine 1 phosphate (S1P) plays multiple roles in bone metabolism and regeneration. Here, we have identified a novel S1P regulated osteoanabolic mechanism functionally connecting osteoblasts (OBs) to the highly specialized bone vasculature. We demonstrate that S1P/S1PR3 signaling in OBs stimulates vascular endothelial growth factor a (VEGFa) expression and secretion to promote bone growth in an autocrine and boost osteogenic H type differentiation of bone marrow endothelial cells in a paracrine manner. VEGFa neutralizing antibodies and VEGF receptor inhibition by axitinib abrogated OB growth in vitro and bone formation in male C57BL/6J in vivo following S1P stimulation and S1P lyase inhibition, respectively. Pharmacological S1PR3 inhibition and genetic S1PR3 deficiency suppressed VEGFa production, OB growth in vitro, and inhibited H type angiogenesis and bone growth in male mice in vivo. Together with previous work on the osteoanabolic functions of S1PR2 and S1PR3, our data suggest that S1P dependent bone regeneration employs several nonredundant positive feedback loops between OBs and the bone vasculature. The identification of this yet unappreciated aspect of osteoanabolic S1P signaling may have implications for regular bone homeostasis as well as diseases where the bone microvasculature is affected such as age related osteopenia and posttraumatic bone regeneration.
C1 [Wille, Annalena; Weske, Sarah; Lipinski, Karin von Wnuck; Wollnitzke, Philipp; Schroeder, Nathalie H.; Thomas, Nadine; Nowak, Melissa K.; Deister Jonas, Jennifer; Keul, Petra; Levkau, Bodo] Heinrich Heine Univ Dusseldorf, Inst Mol Med 3, Univ Str 1, D 40225 Dusseldorf, Germany.
   [Behr, Bjoern] Univ Hosp BG Bergmannsheil, Dept Plast Surg, D 44789 Bochum, Germany.
C3 Heinrich Heine University Dusseldorf; Ruhr University Bochum
RP Levkau, B (通讯作者)，Heinrich Heine Univ Dusseldorf, Inst Mol Med 3, Univ Str 1, D 40225 Dusseldorf, Germany.
EM annalena.wille@hhu.de; Sarah.Weske@med.uni duesseldorf.de;
   Karin.WnuckLipinski@med.uni duesseldorf.de;
   Philipp.Wollnitzke@med.uni duesseldorf.de;
   NathalieHannelore.Schroeder@med.uni duesseldorf.de;
   Nadine.Thomas@hhu.de; Melissa.Nowak@med.uni duesseldorf.de;
   Jennifer.Deister Jonas@med.uni duesseldorf.de; bjorn.behr@rub.de;
   Petra.Keul@med.uni duesseldorf.de; bodo.levkau@med.uni duesseldorf.de
RI ; Behr, Björn/AAS 1877 2021
OI Wille, Annalena/0000 0002 9454 0483; 
FU Deutsche Forschungsgesellschaft [DFG  INST 208/746 1 FUGG];
   ElseKroener Fresenius Stiftung (OSTEOPROTECT, Sphingolipid basedtherapy
   of bone diseases) [GRK2098, 11]; Deutsche Forschungsgemeinschaft DFG [LE
   940/8 2, BE 4169/8 2]
FX This instrument was funded by the Deutsche Forschungsgesellschaft (DFG 
   INST 208/746 1 FUGG). This work was funded by the
   ElseKroener Fresenius Stiftung (OSTEOPROTECT, Sphingolipid basedtherapy
   of bone diseases) to B.L., Deutsche Forschungsgemeinschaft (GRK2098,
   project 11) to B.L., and Deutsche Forschungsgemeinschaft DFG (LE 940/8 2
   and BE 4169/8 2) to B.L. and B.B.
CR Ahn Seong Hee, 2013, J Bone Metab, V20, P61, DOI 10.11005/jbm.2013.20.2.61
   Ardawi Mohammed Salleh M, 2018, J Bone Metab, V25, P87, DOI 10.11005/jbm.2018.25.2.87
   Bae SJ, 2016, OSTEOPOROSIS INT, V27, P2533, DOI 10.1007/s00198 016 3565 z
   Ben Shoham A, 2012, DEVELOPMENT, V139, P3859, DOI 10.1242/dev.078550
   Billich A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059630
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brizuela L, 2014, MOL ONCOL, V8, P1181, DOI 10.1016/j.molonc.2014.04.001
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chellaiah MA, 2003, CALCIFIED TISSUE INT, V72, P197, DOI 10.1007/s00223 002 1025 6
   Declercq H, 2004, BIOMATERIALS, V25, P757, DOI 10.1016/S0142 9612(03)00580 5
   Del Galdo S, 2013, CELL SIGNAL, V25, P2478, DOI 10.1016/j.cellsig.2013.08.017
   Delany AM, 2000, J CLIN INVEST, V105, P915, DOI 10.1172/JCI7039
   Eghbali Fatourechi GZ, 2005, NEW ENGL J MED, V352, P1959, DOI 10.1056/NEJMoa044264
   Gaengel K, 2012, DEV CELL, V23, P587, DOI 10.1016/j.devcel.2012.08.005
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI200112450
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Hashimoto Y, 2015, MOL CELL BIOCHEM, V401, P39, DOI 10.1007/s11010 014 2290 1
   Heo K, 2009, BMB REP, V42, P685, DOI 10.5483/BMBRep.2009.42.10.685
   HLA T, 1990, J BIOL CHEM, V265, P9308
   Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090 6980(01)00109 5
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huang B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13885
   Huang CC, 2021, CELLS BASEL, V10, DOI 10.3390/cells10082168
   Ishii M, 2010, J EXP MED, V207, P2793, DOI 10.1084/jem.20101474
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Jacobsen KA, 2008, J BONE MINER RES, V23, P596, DOI 10.1359/JBMR.080103
   Jung B, 2012, DEV CELL, V23, P600, DOI 10.1016/j.devcel.2012.07.015
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Kikuta J, 2013, P NATL ACAD SCI USA, V110, P7009, DOI 10.1073/pnas.1218799110
   Kim BJ, 2016, J ENDOCRINOL INVEST, V39, P297, DOI 10.1007/s40618 015 0364 x
   Kim BJ, 2012, J CLIN ENDOCR METAB, V97, P3807, DOI 10.1210/jc.2012 2346
   Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200
   Kusumbe AP, 2015, NAT PROTOC, V10, P1904, DOI 10.1038/nprot.2015.125
   Kusumbe AP, 2014, NAT MED, V20, P1238, DOI 10.1038/nm.3747
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Langen UH, 2017, NAT CELL BIOL, V19, P189, DOI 10.1038/ncb3476
   Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092 8674(00)81661 X
   Lee SH, 2021, J CLIN DENSITOM, V24, P414, DOI 10.1016/j.jocd.2021.03.005
   Lee SH, 2012, J CLIN ENDOCR METAB, V97, pE1421, DOI 10.1210/jc.2012 1044
   Liu Jingjing, 2011, World J Biol Chem, V2, P1, DOI 10.4331/wjbc.v2.i1.1
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Lu L, 2015, J NEURO ONCOL, V121, P91, DOI 10.1007/s11060 014 1612 1
   Marenzana M, 2013, BONE RES, V1, P203, DOI 10.4248/BR201303001
   Masuko K, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 29
   Matsuzaki E, 2013, BONE, V55, P315, DOI 10.1016/j.bone.2013.04.008
   Meriane M, 2006, STEM CELLS, V24, P2557, DOI 10.1634/stemcells.2006 0209
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Pugsley MK, 2000, J PHARMACOL TOX MET, V44, P333, DOI 10.1016/S1056 8719(00)00125 8
   Quint P, 2013, J BIOL CHEM, V288, P5398, DOI 10.1074/jbc.M112.413583
   Rabie ABM, 2002, AM J ORTHOD DENTOFAC, V122, P202, DOI 10.1067/mod.2002.125991
   Ramasamy SK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13601
   Ramasamy SK, 2016, ANNU REV CELL DEV BI, V32, P649, DOI 10.1146/annurev cellbio 111315 124936
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640
   SODEK J, 1995, ANN NY ACAD SCI, V760, P223, DOI 10.1111/j.1749 6632.1995.tb44633.x
   Song HE, 2020, J INVEST MED, V68, P1295, DOI 10.1136/jim 2020 001322
   Stradner MH, 2008, OSTEOARTHR CARTILAGE, V16, P305, DOI 10.1016/j.joca.2007.06.018
   Tantikanlayaporn D, 2018, JBMR PLUS, V2, P217, DOI 10.1002/jbm4.10037
   TRUETA J, 1960, J BONE JOINT SURG BR, V42, P97, DOI 10.1302/0301 620X.42B1.97
   Venkataraman K, 2008, CIRC RES, V102, P669, DOI 10.1161/CIRCRESAHA.107.165845
   Wang H, 2018, CELL BIOL INT, V42, P1492, DOI 10.1002/cbin.10991
   Wang H, 2015, CELL MOL BIOL LETT, V20, P597, DOI 10.1515/cmble 2015 0035
   Wang L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.36
   Weske S, 2019, BONE, V125, P1, DOI 10.1016/j.bone.2019.04.015
   Weske S, 2018, NAT MED, V24, P667, DOI 10.1038/s41591 018 0005 y
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Xu C, 2022, ELIFE, V11, DOI [10.7554/eLife.60183, 10.7554/eLife.60183.sa0, 10.7554/eLife.60183.sa1, 10.7554/eLife.60183.sa2]
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Zelzer E, 2002, DEVELOPMENT, V129, P1893
   Zhang JK, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12874
NR 74
TC 4
Z9 4
U1 3
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR 19
PY 2024
VL 39
IS 3
BP 357
EP 372
DI 10.1093/jbmr/zjae006
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OF0Z1
UT WOS:001205746200001
PM 38477738
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Ruppender, NS
   Merkel, AR
   Martin, TJ
   Mundy, GR
   Sterling, JA
   Guelcher, SA
AF Ruppender, Nazanin S.
   Merkel, Alyssa R.
   Martin, T. John
   Mundy, Gregory R.
   Sterling, Julie A.
   Guelcher, Scott A.
TI Matrix Rigidity Induces Osteolytic Gene Expression of Metastatic Breast
   Cancer Cells
SO PLOS ONE
LA English
DT Article
ID HORMONE RELATED PROTEIN; GROWTH FACTOR; PEPTIDE GENE; IN VIVO; BONE;
   HEDGEHOG; KINASE; ACTIVATION; MIGRATION; STIFFNESS
AB Nearly 70% of breast cancer patients with advanced disease will develop bone metastases. Once established in bone, tumor cells produce factors that cause changes in normal bone remodeling, such as parathyroid hormone related protein (PTHrP). While enhanced expression of PTHrP is known to stimulate osteoclasts to resorb bone, the environmental factors driving tumor cells to express PTHrP in the early stages of development of metastatic bone disease are unknown. In this study, we have shown that tumor cells known to metastasize to bone respond to 2D substrates with rigidities comparable to that of the bone microenvironment by increasing expression and production of PTHrP. The cellular response is regulated by Rhodependent actomyosin contractility mediated by TGF beta signaling. Inhibition of Rho associated kinase (ROCK) using both pharmacological and genetic approaches decreased PTHrP expression. Furthermore, cells expressing a dominant negative form of the TGF beta receptor did not respond to substrate rigidity, and inhibition of ROCK decreased PTHrP expression induced by exogenous TGF beta. These observations suggest a role for the differential rigidity of the mineralized bone microenvironment in early stages of tumor induced osteolysis, which is especially important in metastatic cancer since many cancers (such as those of the breast and lung) preferentially metastasize to bone.
C1 [Ruppender, Nazanin S.; Guelcher, Scott A.] Vanderbilt Univ, Dept Chem & Biomol Engn, Nashville, TN 37235 USA.
   [Ruppender, Nazanin S.; Merkel, Alyssa R.; Martin, T. John; Mundy, Gregory R.; Sterling, Julie A.; Guelcher, Scott A.] Vanderbilt Univ, Med Ctr, Ctr Bone Biol, Nashville, TN USA.
   [Merkel, Alyssa R.; Mundy, Gregory R.] Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN USA.
   [Mundy, Gregory R.; Sterling, Julie A.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA.
   [Sterling, Julie A.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA.
   [Martin, T. John] St Vincents Inst, Melbourne, Vic, Australia.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Tennessee Valley Healthcare System; Vanderbilt University; St. Vincent's
   Institute of Medical Research
RP Ruppender, NS (通讯作者)，Vanderbilt Univ, Dept Chem & Biomol Engn, Nashville, TN 37235 USA.
EM scott.guelcher@vanderbilt.edu
OI Merkel, Alyssa/0000 0001 6498 4211
FU National Institutes of Health Breast Cancer SPORE [P50 CA098131, P01
   CA040035]; Tumor Microenvironment Network (TMEN) [U54 CA126505]
FX The authors acknowledge financial support from the National Institutes
   of Health Breast Cancer SPORE (P50 CA098131), P01 CA040035, and Tumor
   Microenvironment Network (TMEN) (U54 CA126505) grants. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alexander NR, 2008, CURR BIOL, V18, P1295, DOI 10.1016/j.cub.2008.07.090
   Baker AB, 2008, CIRC RES, V103, P289, DOI 10.1161/CIRCRESAHA.108.179465
   Barman SA, 2009, VASC HEALTH RISK MAN, V5, P663, DOI 10.2147/VHRM.S4711
   Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544
   Candiello J, 2007, FEBS J, V274, P2897, DOI 10.1111/j.1742 4658.2007.05823.x
   Cuppone M, 2004, CALCIFIED TISSUE INT, V74, P302, DOI 10.1007/s00223 002 2123 1
   DAIFOTIS AG, 1992, J BIOL CHEM, V267, P23455
   Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995
   Eichberger T, 2008, J BIOL CHEM, V283, P12426, DOI 10.1074/jbc.M707117200
   Enderling H, 2008, BIOPHYS J, V95, P2203, DOI 10.1529/biophysj.108.133199
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   GUELCHER S, 2008, TISSUE ENG IN PRESS
   Guelcher SA, 2008, BIOMATERIALS, V29, P1762, DOI 10.1016/j.biomaterials.2007.12.046
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   GUISE TA, 1993, J CLIN ENDOCR METAB, V77, P40, DOI 10.1210/jc.77.1.40
   Hafeman AE, 2008, PHARM RES DORDR, V25, P2387, DOI 10.1007/s11095 008 9618 z
   Hotte SJ, 2002, CANCER AM CANCER SOC, V95, P506, DOI 10.1002/cncr.10709
   Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587
   Javelaud D, 2007, CANCER RES, V67, P2317, DOI 10.1158/0008 5472.CAN 06 3950
   JOHNSON RW, CANC RES UNPUB
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   KHATIWALA CB, 2006, J CELLULAR PHYSL, V211, P661
   Kostic A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006361
   Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008 5472.CAN 09 1541
   Miao DS, 2004, EXP CELL RES, V294, P210, DOI 10.1016/j.yexcr.2003.10.021
   Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103
   Moore SW, 2010, DEV CELL, V19, P194, DOI 10.1016/j.devcel.2010.07.018
   Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555 008 9170 7
   Nowlan NC, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000250
   OHNO M, 1995, J CLIN INVEST, V95, P1363, DOI 10.1172/JCI117787
   Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911 004 1404 x
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127
   PIROLA CJ, 1994, ENDOCRINOLOGY, V134, P2230, DOI 10.1210/en.134.5.2230
   POWELL GJ, 1991, CANCER RES, V51
   Raeber GP, 2005, BIOPHYS J, V89, P1374, DOI 10.1529/biophysj.104.050682
   Sakata R, 2004, EUR J CLIN INVEST, V34, P129, DOI 10.1111/j.1365 2362.2004.01302.x
   SOUTHBY J, 1990, CANCER RES, V50, P7710
   Sperling L.H., 2001, INTRO PHYS POLYM SCI, V3rd
   Sterling JA, 2006, CANCER RES, V66, P7548, DOI 10.1158/0008 5472.CAN 06 0452
   Tang GH, 2004, J DENT RES, V83, P434, DOI 10.1177/154405910408300516
   THIEDE MA, 1990, P NATL ACAD SCI USA, V87, P6969, DOI 10.1073/pnas.87.18.6969
   THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653
   VanderVeldeZimmermann D, 1997, EXP CELL RES, V230, P111, DOI 10.1006/excr.1996.3405
   Wells RG, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.110pe13
   Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042
   YAMAMOTO M, 1992, P NATL ACAD SCI USA, V89, P5326, DOI 10.1073/pnas.89.12.5326
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zaman MH, 2005, BIOPHYS J, V89, P1389, DOI 10.1529/biophysj.105.060723
   Zaman MH, 2006, P NATL ACAD SCI USA, V103, P10889, DOI 10.1073/pnas.0604460103
NR 51
TC 63
Z9 78
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD NOV 15
PY 2010
VL 5
IS 11
AR e15451
DI 10.1371/journal.pone.0015451
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 680KW
UT WOS:000284231800033
PM 21085597
OA Green Published, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Liu, ZM
   Zuo, XM
   Cai, YS
   Zuo, YY
   Ma, KQ
   Wu, S
   Qu, XC
   Chen, XD
AF Liu, Zimeng
   Zuo, Xuemei
   Cai, Yisheng
   Zuo, Yuyang
   Ma, Keqiang
   Wu, Shuang
   Qu, Xiaochao
   Chen, Xiangding
TI Flavonoids in Astragali Radix Functions as Regulators of CDK2,
   VEGFA and MYC in Osteoporosis and Type 1 Diabetes Mellitus
SO LETTERS IN DRUG DESIGN & DISCOVERY
LA English
DT Article
DE Osteoporosis; type 1 diabetes mellitus; Astragali Radix; WGCNA;
   molecular docking; network pharmacology
ID MESENCHYMAL STEM CELLS; SMOOTH MUSCLE CELLS; MOLECULAR DOCKING; BONE;
   PROLIFERATION; ANGIOGENESIS; PREDICTION; IV; PROGRESSION; METABOLISM
AB Background People with type 1 diabetes mellitus (T1DM) are significantly more likely to have osteoporosis (OP). Astragali Radix is a Chinese herbal medicine containing various active ingredients, and several clinical trials have been reported to use it to treat OP and T1DM, respectively. Objective To evaluate the targets and potential mechanisms of Astragali Radix administration on OP and T1DM. Methods The targets of Astragali Radix were identified using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. The OP and T1DM datasets were downloaded from the Gene Expression Omnibus (GEO) database. The weighted gene correlation network analysis (WGCNA) method was used to identify the co expression genes associated with OP and T1DM. In addition, the common gene targets of OP and T1DM were screened using two public databases. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using the R tool. After the validation of key genes, molecular docking was performed to visualize small molecule protein interactions. Results The compound target network mainly contained 17 compounds and 147 corresponding targets. There were 561 GO items and 154 signaling pathways in KEGG, mainly including the AGE RAGE signaling pathway in diabetic complications and osteoclast differentiation. The results of molecular docking showed that flavonoids were the top compound of Astragali Radix, which had a high affinity with CDK2, VEGFA, and MYC. Conclusion Flavonoids in Astragali Radix may regulate multiple signaling pathways through MYC, CDK2, and VEGFA, which may play a therapeutic role in OP and T1DM.
C1 [Liu, Zimeng; Zuo, Xuemei; Cai, Yisheng; Zuo, Yuyang; Ma, Keqiang; Wu, Shuang; Qu, Xiaochao; Chen, Xiangding] Hunan Normal Univ, Coll Life Sci, Lab Mol & Stat Genet, Changsha, Peoples R China.
   [Liu, Zimeng; Zuo, Xuemei; Cai, Yisheng; Zuo, Yuyang; Ma, Keqiang; Wu, Shuang; Qu, Xiaochao; Chen, Xiangding] Hunan Normal Univ, Coll Life Sci, Hunan Prov Key Lab Anim Intestinal Funct & Regulat, Changsha, Peoples R China.
C3 Hunan Normal University; Hunan Normal University
RP Qu, XC; Chen, XD (通讯作者)，Hunan Normal Univ, Coll Life Sci, Lab Mol & Stat Genet, Changsha, Peoples R China.; Qu, XC; Chen, XD (通讯作者)，Hunan Normal Univ, Coll Life Sci, Hunan Prov Key Lab Anim Intestinal Funct & Regulat, Changsha, Peoples R China.
EM quxc@hunnu.edu.cn; xdchen@hunnu.edu.cn
RI Chen, Xiang Ding/HTO 7355 2023; ZUO, YUYANG/JPL 6375 2023
FU Scientific Research Projects of the Provincial Education Department of
   Hunan [22C0009]; National Students' Platform for Innovation and
   Entrepreneurship Training Program [202210542035]; The 2021 Hunan
   Provincial Excellent Graduate Demonstration Course, "Bioinformatics,"
   Department of Education of Hunan Province, Xiang Jiao Tong [116]
FX This work was funded by Scientific Research Projects of the Provincial
   Education Department of Hunan (22C0009), the National Students' Platform
   for Innovation and Entrepreneurship Training Program (202210542035) and
   the 2021 Hunan Provincial Excellent Graduate Demonstration Course,
   "Bioinformatics," Department of Education of Hunan Province, Xiang Jiao
   Tong [2022] No.116).
CR Anthamatten A, 2019, J MIDWIFERY WOM HEAL, V64, P265, DOI 10.1111/jmwh.12954
   Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935
   Costa SMB, 2020, MOL CELL ENDOCRINOL, V518, DOI 10.1016/j.mce.2020.111027
   Behl T, 2017, J PHARM PHARMACOL, V69, P223, DOI 10.1111/jphp.12683
   Bessette L, 2008, OSTEOPOROSIS INT, V19, P79, DOI 10.1007/s00198 007 0426 9
   Bian Q, 2011, PHARMAZIE, V66, P63, DOI 10.1691/ph.2011.0219
   Boschitsch EP, 2017, CLIMACTERIC, V20, P157, DOI 10.1080/13697137.2017.1282452
   Cao Yi, 2019, Biomed Res Int, V2019, P7023950, DOI 10.1155/2019/7023950
   Casagrande F, 2001, BIOCHEM PHARMACOL, V61, P1205, DOI 10.1016/S0006 2952(01)00583 4
   Cazarolli LH, 2008, MINI REV MED CHEM, V8, P1429, DOI 10.2174/138955708786369564
   Chai YH, 2021, BIOENGINEERED, V12, P4464, DOI 10.1080/21655979.2021.1946633
   Chen ML, 2001, PHARMACEUT RES, V18, P1645, DOI 10.1023/A:1013319408893
   Chen ZJ, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112895
   COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Fei QM, 2010, ACTA BIOCH BIOPH SIN, V42, P801, DOI 10.1093/abbs/gmq086
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006 291X(89)92678 8
   Ferreira LG, 2015, MOLECULES, V20, P13384, DOI 10.3390/molecules200713384
   Fulzele K, 2012, BONE, V50, P452, DOI 10.1016/j.bone.2011.06.018
   Gallagher JC, 2007, MENOPAUSE, V14, P567, DOI 10.1097/gme.0b013e31804c793d
   Gebe JA, 2002, TISSUE ANTIGENS, V59, P78, DOI 10.1034/j.1399 0039.2002.590202.x
   Gong Z, 2022, OSTEOPOROSIS INT, V33, P453, DOI 10.1007/s00198 021 06061 8
   Granlund L, 2021, BMJ OPEN DIAB RES CA, V9, DOI 10.1136/bmjdrc 2020 002076
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030
   Huang XP, 2022, BMC ENDOCR DISORD, V22, DOI 10.1186/s12902 022 01103 6
   Ishizuka T, 2011, J ENDOCRINOL, V208, P147, DOI 10.1677/JOE 10 0305
   Jin P, 2010, TRANSPL P, V42, P2745, DOI 10.1016/j.transproceed.2010.05.145
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Kang WQ, 2022, ACTA CIR BRAS, V37, DOI 10.1590/acb371101
   Khan TS, 2015, J OSTEOPOROS, V2015, DOI 10.1155/2015/174186
   Kim DY, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201800302
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Lai Patrick Kwok Kin, 2014, J Tradit Complement Med, V4, P239, DOI 10.4103/2225 4110.139109
   Landis Piwowar K R, 2008, Curr Mol Pharmacol, V1, P233
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471 2105 9 559
   Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744
   Lindquist O, 1977, Scand J Soc Med Suppl, V14, P80
   Liu M, 2013, BMC COMPLEM ALTERN M, V13, DOI [10.1186/1472 6882 13 11, 10.1186/1472 6882 13 141]
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Miao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep39398
   Mills CD, 2012, CRIT REV IMMUNOL, V32, P463, DOI 10.1615/CritRevImmunol.v32.i6.10
   Misra S, 2023, EUR J CLIN PHARMACOL, V79, P609, DOI 10.1007/s00228 023 03474 8
   Montagnani A, 2013, DIABETES OBES METAB, V15, P784, DOI 10.1111/dom.12077
   NIHPanel, 2001, JAMA J AM MED ASSOC, V285, P785, DOI DOI 10.1001/JAMA.285.6.785
   Niknam Z, 2022, J CARDIOVASC THORAC, V14, P34, DOI 10.34172/jcvtr.2021.54
   Ning K, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7573904
   Nogales C, 2022, TRENDS PHARMACOL SCI, V43, P136, DOI 10.1016/j.tips.2021.11.004
   Parvez MSA, 2020, INT J BIOL MACROMOL, V163, P1787, DOI 10.1016/j.ijbiomac.2020.09.098
   Peng J, 2016, CONNECT TISSUE RES, V57, P277, DOI 10.3109/03008207.2016.1171858
   Pezzotti G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174080
   Phu HT, 2020, CURR VASC PHARMACOL, V18, P369, DOI 10.2174/1570161117666190715121939
   Pinzi L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184331
   PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460 2075.1989.tb08557.x
   Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727
   Rahimi R, 2010, CYTOKINE, V49, P123, DOI 10.1016/j.cyto.2009.11.005
   Raina R, 2021, EUR REV MED PHARMACO, V25, P2206, DOI 10.26355/eurrev_202103_25253
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 77
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Sang Z, 2010, AM J CHINESE MED, V38, P1027, DOI 10.1142/S0192415X10008445
   SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Sheikpranbabu S, 2010, BIOCHIMIE, V92, P1040, DOI 10.1016/j.biochi.2010.05.004
   Shoback D, 2020, J CLIN ENDOCR METAB, V105, DOI DOI 10.1210/CLINEM/DGAA048
   Song WJ, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 35791 9
   Stolzing A, 2010, CELLS TISSUES ORGANS, V191, P453, DOI 10.1159/000281826
   Tao WY, 2013, J ETHNOPHARMACOL, V145, P1, DOI 10.1016/j.jep.2012.09.051
   Tse HYG, 2012, J ETHNOPHARMACOL, V139, P447, DOI 10.1016/j.jep.2011.11.031
   Wan C., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P323
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Wei XX, 2022, BRIEF BIOINFORM, V23, DOI 10.1093/bib/bbab425
   Xia QD, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12949
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Yang F, 2016, CELL PHYSIOL BIOCHEM, V39, P1369, DOI 10.1159/000447841
   Yu T, 2020, AGING US, V12, P9500, DOI 10.18632/aging.103223
   Yuan W, 2008, PLANTA MED, V74, P1259, DOI 10.1055/s 2008 1081290
   Zhang DQ, 2018, LIFE SCI, V200, P105, DOI 10.1016/j.lfs.2018.03.036
   Zhang HX, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.756550
   Zhang M, 2020, COMPUT BIOL CHEM, V86, DOI 10.1016/j.compbiolchem.2020.107248
   Zheng JH, 2018, CANCERS, V10, DOI 10.3390/cancers10110461
   Zhou W, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 69708 2
   Ziegler AG, 2013, JAMA J AM MED ASSOC, V309, P2473, DOI 10.1001/jama.2013.6285
NR 82
TC 0
Z9 0
U1 10
U2 21
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570 1808
EI 1875 628X
J9 LETT DRUG DES DISCOV
JI Lett. Drug Des. Discov.
PY 2024
VL 21
IS 14
BP 2967
EP 2980
DI 10.2174/1570180820666230811150017
EA OCT 2023
PG 14
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA K5R2S
UT WOS:001183230800001
DA 2025 08 17
ER

PT J
AU Nagase, Y
   Nagashima, M
   Shimane, K
   Nishikawa, T
   Naito, M
   Tanaka, S
AF Nagase, Yuichi
   Nagashima, Masakazu
   Shimane, Kenichi
   Nishikawa, Takuji
   Naito, Masashi
   Tanaka, Sakae
TI Effect of TNF inhibitors with bisphosphonates vs bisphosphonates alone
   on bone mineral density and bone and cartilage biomarkers at 1 year in
   patients with rheumatoid arthritis: A prospective study
SO MODERN RHEUMATOLOGY
LA English
DT Article
DE Rheumatoid arthritis; TNF inhibitors; bisphosphonates; bone mineral
   density; bone resorption and formation markers
ID NECROSIS FACTOR ALPHA; RECEPTOR ACTIVATOR; TURNOVER MARKERS;
   SERUM LEVELS; OSTEOCLASTS; LIGAND; OSTEOPROTEGERIN; INFLIXIMAB; PATHWAY;
   WOMEN
AB Background The present study aimed prospectively to investigate the effect of a combination of tumour necrosis factor inhibitors and bisphosphonates (TNFi with BP) on bone mineral density (BMD) and bone and cartilage biomarkers compared to that of BP alone at 1 year in patients with rheumatoid arthritis (RA). Methods Two groups of patients with RA and osteoporosis were enrolled. One group (37 patients) had already received BP, while the other group (37 patients) had already received TNFi with BP. The serum bone resorption and formation markers, cartilage markers, BMD in the lumbar spine, femoral neck, and distal radius were prospectively investigated at the beginning of the study and at 6 and 12 months. Results The percentages of change recorded for the various assessment categories were as follows in the TNFi with BP group: (1) tartrate resistant acid phosphatase 5b had significantly decreased and osteocalcin had increased; (2) matrix metalloproteinase 3 and cartilage oligomeric matrix protein had significantly decreased; and (3) each BMD did not differ significantly between the groups. Conclusion Our data suggested that TNFi with BP therapy not only suppressed cartilage degradation and bone resorption but also increased bone formation; however, this treatment did not affect the BMD at 1 year.
C1 [Nagase, Yuichi] Tokyo Metropolitan Tama Med Ctr, Dept Rheumat Surg, 2 8 29 Musashidai, Fuchu, Tokyo 1838524, Japan.
   [Nagashima, Masakazu] Katsushika Rehabil Hosp, Dept Rheumatol, Katsushika Ku, Tokyo, Japan.
   [Shimane, Kenichi; Nishikawa, Takuji] Tokyo Metropolitan Bokutoh Hosp, Dept Rheumatol, Sumida Ku, Tokyo, Japan.
   [Naito, Masashi] Sagamihara Natl Hosp, Dept Orthopaed Surg, Sagamihara, Kanagawa, Japan.
   [Tanaka, Sakae] Univ Tokyo Hosp, Dept Orthopaed Surg, Bunkyo Ku, Tokyo, Japan.
C3 Sagamihara National Hospital; University of Tokyo
RP Nagase, Y (通讯作者)，Tokyo Metropolitan Tama Med Ctr, Dept Rheumat Surg, 2 8 29 Musashidai, Fuchu, Tokyo 1838524, Japan.
EM nagaseyuichi17@gmail.com
RI Tanaka, Sakae/Y 3061 2019
CR Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Chopin F, 2008, ANN RHEUM DIS, V67, P353, DOI 10.1136/ard.2007.076604
   den Broeder AA, 2002, ANN RHEUM DIS, V61, P311, DOI 10.1136/ard.61.4.311
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140 6736(94)91049 9
   Gulyas K, 2020, CLIN RHEUMATOL, V39, P167, DOI 10.1007/s10067 019 04771 3
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Janckila AJ, 2002, CLIN CHIM ACTA, V320, P49, DOI 10.1016/S0009 8981(02)00026 8
   Janckila AJ, 2008, J BONE MINER RES, V23, P1287, DOI 10.1359/JBMR.080329
   Kanai T, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01595 9
   Krieckaert CLM, 2013, RHEUMATOLOGY, V52, P547, DOI 10.1093/rheumatology/kes320
   Lange U, 2005, RHEUMATOLOGY, V44, P1546, DOI 10.1093/rheumatology/kei082
   LARSEN A, 1977, ACTA RADIOL DIAGN, V18, P481, DOI 10.1177/028418517701800415
   Lee JS, 2020, RHEUMATOL INT, V40, P481, DOI 10.1007/s00296 019 04418 1
   Lee SE, 2001, J BIOL CHEM, V276, P49343, DOI 10.1074/jbc.M103642200
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Matsumoto T, 2011, ARTHRITIS RHEUM US, V63, P3908, DOI 10.1002/art.30646
   O'Gradaigh D, 2004, ANN RHEUM DIS, V63, P354, DOI 10.1136/ard.2003.008458
   Posthumus MD, 1999, RHEUMATOLOGY, V38, P1081, DOI 10.1093/rheumatology/38.11.1081
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   RIARIOSFORZA GG, 1995, ANN RHEUM DIS, V54, P807, DOI 10.1136/ard.54.10.807
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis 2019 216655
   Szentpetery A, 2013, J RHEUMATOL, V40, P653, DOI 10.3899/jrheum.120397
   Tada M, 2017, RHEUMATOL INT, V37, P999, DOI 10.1007/s00296 017 3720 7
   Terpos E, 2011, CLIN EXP RHEUMATOL, V29, P921
   van Staa TP, 2006, ARTHRITIS RHEUM US, V54, P3104, DOI 10.1002/art.22117
   Vis M, 2006, ANN RHEUM DIS, V65, P1495, DOI 10.1136/ard.2005.044198
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yasunori K, 2008, CLIN RHEUMATOL, V27, P1093, DOI 10.1007/s10067 008 0870 8
NR 31
TC 2
Z9 2
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1439 7595
EI 1439 7609
J9 MOD RHEUMATOL
JI Mod. Rheumatol.
PD APR 18
PY 2022
VL 32
IS 3
BP 517
EP 521
DI 10.1093/mr/roab037
EA OCT 2021
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 0O1NV
UT WOS:000783296700006
PM 34910195
OA Bronze
DA 2025 08 17
ER

PT J
AU Duan, YB
   Yu, J
   Liu, S
   Ji, M
AF Duan, Yanbing
   Yu, Jia
   Liu, Shi
   Ji, Min
TI Synthesis of Anthraquinone Ibuprofen Prodrugs with Hydroxyapatite
   Affinity and Anti Inflammatory Activity Characteristics
SO MEDICINAL CHEMISTRY
LA English
DT Article
DE Bone targeting; prodrug; hydrolysis; hydroxyapatite; bone affinity;
   anti inflammatory
ID TOXICOLOGICAL PROPERTIES; DIACEREIN; BONE; ESTER; RHEIN; ARTHRITIS;
   NAPROXEN; NSAIDS
AB The synthesis and pharmacological activities of anthraquinone ibuprofen prodrugs for finding new anti inflammatory drugs specifically targeting osseous tissues were studied. Two hydrolytically activated anti inflammatory prodrugs containing anthraquinone moiety and ibuprofen moiety were designed and synthesized. Rhein was chosen as bone targeting agent and potentially active drug, which was linked chemically with ibuprofen through glycol ester as bone targeting anti inflammatory prodrugs. The chemical structures of the new compounds were confirmed by IR, H 1 NMR, C 13 NMR, MS and elemental analysis. The studies of bioactivities demonstrated that both prodrugs showed significant binding capability to hydroxyapatite (HAP), the major component of bone, and were hydrolytically activated under physiological conditions in vitro and better anti inflammatory activity in vivo.
C1 [Duan, Yanbing; Ji, Min] Southeast Univ, Sch Chem & Chem Engn, Nanjing 210096, Peoples R China.
   [Yu, Jia] Southeast Univ, Coll Chengxian, Nanjing 210088, Peoples R China.
   [Liu, Shi] Nanjing Hailing Pharmaceut Co Ltd, Yangtze River Pharm Grp, Nanjing 210049, Peoples R China.
C3 Southeast University   China; Southeast University   China
RP Ji, M (通讯作者)，Southeast Univ, Sch Chem & Chem Engn, Nanjing 210096, Peoples R China.
EM dybwell@gmail.com; jimin@seu.edu.cn
CR BECCERICA E, 1990, PHARM RES, V22, P227
   Cocco MT, 2003, EUR J MED CHEM, V38, P513, DOI 10.1016/S0223 5234(03)00074 6
   DEBORD P, 1994, EUR J DRUG METAB PH, V19, P13, DOI 10.1007/BF03188817
   Dharap SS, 2005, P NATL ACAD SCI USA, V102, P12962, DOI 10.1073/pnas.0504274102
   DUAN Y, 2009, J SE U ENG EDIT, V25, P128
   Duan YB, 2009, LETT DRUG DES DISCOV, V6, P393, DOI 10.2174/1570180810906050393
   Erez R, 2008, BIOORG MED CHEM LETT, V18, P816, DOI 10.1016/j.bmcl.2007.11.029
   Fonteneau N, 2001, TETRAHEDRON, V57, P9131, DOI 10.1016/S0040 4020(01)00918 8
   GIAMMONA G, 1989, INT J PHARMACEUT, V57, P55, DOI 10.1016/0378 5173(89)90263 9
   Heyneman CA, 2000, DRUGS, V60, P555, DOI 10.2165/00003495 200060030 00004
   Itokawa H, 2008, J NAT MED TOKYO, V62, P263, DOI 10.1007/s11418 008 0246 z
   Khan MSY, 2005, EUR J MED CHEM, V40, P371, DOI 10.1016/j.ejmech.2004.11.009
   Lombardino G.J., 1985, NONSTEROIDAL ANTIINF
   Mahfouz NM, 1999, EUR J MED CHEM, V34, P551, DOI 10.1016/S0223 5234(00)80025 2
   MIAN M, 1987, J PHARM PHARMACOL, V39, P845, DOI 10.1111/j.2042 7158.1987.tb05131.x
   MOLLER NL, 1989, EUR J MED CHEM, V24, P463, DOI 10.1016/0223 5234(89)90048 2
   Moore AR, 1998, OSTEOARTHR CARTILAGE, V6, P19, DOI 10.1053/joca.1997.0088
   Pelletier JP, 2001, J RHEUMATOL, V28, P814
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   POVOROZNYUK V, 2008, REGION ANESTH PAIN M, V33, pE213
   SAARI WS, 1978, J MED CHEM, V21, P746, DOI 10.1021/jm00206a006
   SHANBHAG VR, 1992, J PHARM SCI, V81, P149, DOI 10.1002/jps.2600810210
   Spencer CM, 1997, DRUGS, V53, P98, DOI 10.2165/00003495 199753010 00007
   TAMMARA VK, 1993, PHARM RES DORDR, V10, P1191, DOI 10.1023/A:1018976520391
   Tamura T, 2002, EUR J PHARMACOL, V448, P81, DOI 10.1016/S0014 2999(02)01898 8
   Tamura T, 2001, OSTEOARTHR CARTILAGE, V9, P257, DOI 10.1053/joca.2000.0383
   Tamura T, 2001, EUR J PHARMACOL, V419, P269, DOI 10.1016/S0014 2999(01)00990 6
NR 27
TC 10
Z9 12
U1 0
U2 19
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573 4064
EI 1875 6638
J9 MED CHEM
JI Med. Chem.
PD NOV
PY 2009
VL 5
IS 6
BP 577
EP 582
DI 10.2174/157340609790170498
PG 6
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 549OI
UT WOS:000274062600011
PM 19673691
DA 2025 08 17
ER

PT J
AU Xiao, ZS
   Cao, L
   Smith, MD
   Li, HX
   Li, W
   Smith, JC
   Quarles, LD
AF Xiao, Zhousheng
   Cao, Li
   Smith, Micholas Dean
   Li, Hanxuan
   Li, Wei
   Smith, Jeremy C.
   Quarles, Leigh Darryl
TI Genetic interactions between polycystin 1 and Wwtr1 in osteoblasts
   define a novel mechanosensing mechanism regulating bone formation in
   mice
SO BONE RESEARCH
LA English
DT Article
ID YAP/TAZ; MARROW; TAZ; SKELETOGENESIS; INACTIVATION; GROWTH; CELLS; PKD1;
   YAP
AB Molecular mechanisms transducing physical forces in the bone microenvironment to regulate bone mass are poorly understood. Here, we used mouse genetics, mechanical loading, and pharmacological approaches to test the possibility that polycystin 1 and Wwtr1 have interdependent mechanosensing functions in osteoblasts. We created and compared the skeletal phenotypes of control Pkd1flox/+;Wwtr1flox/+, Pkd1Oc cKO, Wwtr1Oc cKO, and Pkd1/Wwtr1Oc cKO mice to investigate genetic interactions. Consistent with an interaction between polycystins and Wwtr1 in bone in vivo, Pkd1/Wwtr1Oc cKO mice exhibited greater reductions of BMD and periosteal MAR than either Wwtr1Oc cKO or Pkd1Oc cKO mice. Micro CT 3D image analysis indicated that the reduction in bone mass was due to greater loss in both trabecular bone volume and cortical bone thickness in Pkd1/Wwtr1Oc cKO mice compared to either Pkd1Oc cKO or Wwtr1Oc cKO mice. Pkd1/Wwtr1Oc cKO mice also displayed additive reductions in mechanosensing and osteogenic gene expression profiles in bone compared to Pkd1Oc cKO or Wwtr1Oc cKO mice. Moreover, we found that Pkd1/Wwtr1Oc cKO mice exhibited impaired responses to tibia mechanical loading in vivo and attenuation of load induced mechanosensing gene expression compared to control mice. Finally, control mice treated with a small molecule mechanomimetic, MS2 that activates the polycystin complex resulted in marked increases in femoral BMD and periosteal MAR compared to vehicle control. In contrast, Pkd1/Wwtr1Oc cKO mice were resistant to the anabolic effects of MS2. These findings suggest that PC1 and Wwtr1 form an anabolic mechanotransduction signaling complex that mediates mechanical loading responses and serves as a potential novel therapeutic target for treating osteoporosis.
C1 [Xiao, Zhousheng; Cao, Li; Quarles, Leigh Darryl] Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38163 USA.
   [Smith, Micholas Dean; Smith, Jeremy C.] Oak Ridge Natl Lab, UT ORNL Ctr Mol Biophys, Oak Ridge, TN 37830 USA.
   [Smith, Micholas Dean; Smith, Jeremy C.] Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA.
   [Li, Hanxuan; Li, Wei] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN 38163 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee
   Knoxville; United States Department of Energy (DOE); Oak Ridge National
   Laboratory; University of Tennessee System; University of Tennessee
   Knoxville; University of Tennessee System; University of Tennessee
   Health Science Center
RP Xiao, ZS (通讯作者)，Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38163 USA.
EM zxiao2@uthsc.edu
RI Smith, Micholas/H 5267 2019; Li, Wei/A 2671 2011; smith,
   jeremy/B 7287 2012
OI Quarles, L. Darryl/0000 0002 5082 7896; xiao,
   zhousheng/0000 0002 3363 5673; Li, Wei/0000 0002 9522 4474; Smith,
   Micholas/0000 0002 0777 7539; 
FU This work was supported by National Institutes of Health (NIH), National
   Institute of Arthritis and Musculoskeletal and Skin Diseases (Grant RO1
    AR071930) and National Institute of Diabetes and Digestive and Kidney
   Diseases (Grant RO1 DK121132). This rese [RO1  AR071930]; National
   Institutes of Health (NIH), National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [RO1 DK121132]; National Institute of
   Diabetes and Digestive and Kidney Diseases [DE AC05 00OR22725]; Office
   of Science of the U.S. Department of Energy
FX This work was supported by National Institutes of Health (NIH), National
   Institute of Arthritis and Musculoskeletal and Skin Diseases (Grant RO1
    AR071930) and National Institute of Diabetes and Digestive and Kidney
   Diseases (Grant RO1 DK121132). This research also used resources of the
   Compute and Data Environment for Science (CADES) at the Oak Ridge
   National Laboratory, which is supported by the Office of Science of the
   U.S. Department of Energy under Contract No. DE AC05 00OR22725.
CR Al Saedi A, 2020, CALCIFIED TISSUE INT, V107, P126, DOI 10.1007/s00223 020 00700 8
   Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042
   Chen Z, 2016, SCI REP UK, V6, DOI 10.1038/srep30322
   Chen Z, 2015, BIOCHEM BIOPH RES CO, V468, P21, DOI 10.1016/j.bbrc.2015.11.006
   Clabaut A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245014
   De Rechter S, 2017, J CLIN ENDOCR METAB, V102, P4210, DOI 10.1210/jc.2017 01157
   Dupont S, 2016, EXP CELL RES, V343, P42, DOI 10.1016/j.yexcr.2015.10.034
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Evenepoel P, 2019, KIDNEY INT, V95, P412, DOI 10.1016/j.kint.2018.09.018
   Furuya Y, 2011, J BIOL CHEM, V286, P37023, DOI 10.1074/jbc.M111.246280
   Gao L, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10312
   GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456
   Gitomer B, 2021, KIDNEY INT, V99, P977, DOI 10.1016/j.kint.2020.07.041
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Hossain Z, 2007, P NATL ACAD SCI USA, V104, P1631, DOI 10.1073/pnas.0605266104
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kegelman CD, 2020, CURR OSTEOPOROS REP, V18, P526, DOI 10.1007/s11914 020 00605 3
   Kegelman CD, 2018, FASEB J, V32, P2706, DOI 10.1096/fj.201700872R
   Kim HN, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138815
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim KM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092427
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li XH, 2019, ELIFE, V8, DOI 10.7554/eLife.49631
   Lin FM, 2003, P NATL ACAD SCI USA, V100, P5286, DOI 10.1073/pnas.0836980100
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Merrick D, 2019, HUM MOL GENET, V28, P16, DOI 10.1093/hmg/ddy322
   Naïm M, 2007, J CHEM INF MODEL, V47, P122, DOI 10.1021/ci600406v
   Palhinha L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00841
   Panciera T, 2017, NAT REV MOL CELL BIO, V18, P758, DOI 10.1038/nrm.2017.87
   Piontek KB, 2004, J AM SOC NEPHROL, V15, P3035, DOI 10.1097/01.ASN.0000144204.01352.86
   Piontek K, 2007, NAT MED, V13, P1490, DOI 10.1038/nm1675
   Qin L, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0099 y
   Qiu N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046038
   Qiu N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015240
   Reginensi A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003380
   Salmi A, 2022, GENOMICS, V114, DOI 10.1016/j.ygeno.2022.110422
   Suchacki KJ, 2016, CURR OPIN PHARMACOL, V28, P50, DOI 10.1016/j.coph.2016.03.001
   Tian Y, 2007, MOL CELL BIOL, V27, P6383, DOI 10.1128/MCB.00254 07
   Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376
   Xiao ZS, 2008, J BIOL CHEM, V283, P12624, DOI 10.1074/jbc.M710407200
   Xiao ZS, 2006, J BIOL CHEM, V281, P30884, DOI 10.1074/jbc.M604772200
   Xiao ZS, 2018, J CLIN INVEST, V128, P157, DOI 10.1172/JCI93725
   Xiao ZS, 2015, REV ENDOCR METAB DIS, V16, P115, DOI 10.1007/s11154 015 9313 4
   Xiao ZS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114198
   Xiao ZS, 2011, FASEB J, V25, P2418, DOI 10.1096/fj.10 180299
   Xiao ZS, 2010, J BIOL CHEM, V285, P1177, DOI 10.1074/jbc.M109.050906
   Xiong JH, 2018, BONE, V112, P1, DOI 10.1016/j.bone.2018.04.001
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Yang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056585
   Yang WL, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00151 3
   Yeung DKW, 2005, J MAGN RESON IMAGING, V22, P279, DOI 10.1002/jmri.20367
   Yue R, 2016, CELL STEM CELL, V18, P782, DOI 10.1016/j.stem.2016.02.015
   Zarka M, 2021, LAB INVEST, V101, P1597, DOI 10.1038/s41374 021 00668 5
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zubidat D, 2023, BONE REP, V18, DOI 10.1016/j.bonr.2023.101655
NR 55
TC 9
Z9 10
U1 0
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD OCT 26
PY 2023
VL 11
IS 1
AR 57
DI 10.1038/s41413 023 00295 4
PG 12
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA U9QD7
UT WOS:001088071200003
PM 37884491
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Araujo, JC
   Poblenz, A
   Corn, PG
   Parikh, NU
   Starbuck, MW
   Thompson, JT
   Lee, F
   Logothetis, CJ
   Darnay, BG
AF Araujo, John C.
   Poblenz, Ann
   Corn, Paul G.
   Parikh, Nila U.
   Starbuck, Michael W.
   Thompson, Jerry T.
   Lee, Francis
   Logothetis, Christopher J.
   Darnay, Bryant G.
TI Dasatinib inhibits both osteoclast activation and prostate cancer PC 3
   cell induced osteoclast formation
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE osteoclast; Src; prostate cancer; dasatinib; PC 3
ID ALPHA(V)BETA(3) INTEGRIN; BONE RESORPTION; KINASE ACTIVITY; C SRC;
   OSTEOPROTEGERIN; EXPRESSION; METASTASES; CARCINOMA; ADHESION; PYK2
AB Purpose;Therapies to target prostate cancer bone metastases have only limited effects. New treatments are focused on the interaction between cancer cells, bone marrow cells and the bone matrix. Osteoclasts play an important role in the development of bone tumors caused by prostate cancer. Since Src kinase has been shown to be necessary for osteoclast function, we hypothesized that dasatinib, a SIT family kinase inhibitor, would reduce osteoclast activity and prostate cancer (PC 3) cell induced osteoclast formation.
   Results: Dasatinib inhibited RANKL induced osteoclast differentiation of bone marrow derived monocytes with an EC50 of 7.5 nM. PC 3 cells, a human prostate cancer cell line, were able to differentiate RAW 264.7 cells, a murine monocytic cell line, into osteoclasts and dasatinib inhibited this differentiation. In addition, conditioned medium from PC 3 cell cultures was able to differentiate RAW 264.7 cells into osteoclasts and this too, was inhibited by dasatinib. Even the lowest concentration of dasatinib, 1.25 nmol, inhibited osteoclast differentiation by 29%. Moreover, dasatinib inhibited osteoclast activity by 58% as measured by collagen I release.
   Experimental design: We performed in vitro experiments utilizing the Src family kinase inhibitor dasatinib to target osteoclast activation as a means of inhibiting prostate cancer bone metastases.
   Conclusion: Dasatinib inhibits osteoclast differentiation of mouse primary bone marrow derived monocytes and PC 3 cell induced osteoclast differentiation. Dasatinib also inhibits osteoclast degradation activity. Inhibiting osteoclast differentiation and activity may be an effective targeted therapy in patients with prostate cancer bone metastases.
C1 [Araujo, John C.; Corn, Paul G.; Parikh, Nila U.; Starbuck, Michael W.; Logothetis, Christopher J.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Poblenz, Ann; Darnay, Bryant G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Thompson, Jerry T.] Penn State Univ, Dept Vet & Biomed Sci, Ctr Mol Toxicol, Philadelphia, PA USA.
   [Thompson, Jerry T.] Penn State Univ, Dept Vet & Biomed Sci, Ctr Carcinogenesis, Philadelphia, PA USA.
   [Lee, Francis] Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); Pennsylvania State University;
   Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Bristol Myers Squibb
RP Araujo, JC (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
EM johna@mdanderson.org
OI Corn, Paul/0000 0002 4106 6335
FU University of Texas SPORE in Prostate Cancer [P50 CA90270, T32 CA009666]
FX This work supported in part by The University of Texas SPORE in Prostate
   Cancer P50 CA90270 and T32 CA009666 Training Grant.
CR BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102
   CHARHON SA, 1983, CANCER AM CANCER SOC, V51, P918, DOI 10.1002/1097 0142(19830301)51:5<918::AID CNCR2820510526>3.0.CO;2 J
   CLARKE NW, 1992, BRIT J UROL, V69, P64, DOI 10.1111/j.1464 410X.1992.tb15461.x
   Corey E, 2005, CANCER RES, V65, P1710, DOI 10.1158/0008 5472.CAN 04 2033
   Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200
   LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817
   Loberg RD, 2005, J CLIN ONCOL, V23, P8232, DOI 10.1200/JCO.2005.03.0841
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Michaelson MD, 2004, CLIN CANCER RES, V10, P2705, DOI 10.1158/1078 0432.CCR 03 0735
   Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008 5472.CAN 05 1731
   Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008 5472.CAN 07 2997
   PERCIVAL RC, 1987, EUR J SURG ONCOL, V13, P41
   Pienta KJ, 2005, CA CANCER J CLIN, V55, P300, DOI 10.3322/canjclin.55.5.300
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   SAWYERS CL, 2004, ASH ANN M ABSTR, V104, P1
   Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004 1211
   Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835
   Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   TETI A, 1991, AM J PHYSIOL, V261, pC1, DOI 10.1152/ajpcell.1991.261.1.C1
   TOKARSKI JS, 2004, ASH ANN M, V104, P553
   URWIN GH, 1985, BRIT J UROL, V57, P721, DOI 10.1111/j.1464 410X.1985.tb07040.x
   Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036
   Yonou H, 2003, CANCER RES, V63, P2096
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 29
TC 34
Z9 39
U1 0
U2 24
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538 4047
EI 1555 8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD NOV 15
PY 2009
VL 8
IS 22
BP 2153
EP 2159
DI 10.4161/cbt.8.22.9770
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 645PZ
UT WOS:000281477800019
PM 19855158
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Liang, C
   Yu, XJ
   Xiong, NP
   Zhang, ZC
   Sun, ZY
   Dong, Y
AF Liang, Chao
   Yu, Xijiao
   Xiong, Naping
   Zhang, Zhichang
   Sun, Zhenyu
   Dong, Yang
TI Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents
   Tumor Mediated Bone Destruction by Blockade of PI3K/AKT Pathway
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE pictilisib; osteosarcoma; osteoclasts; targeted therapy; PI3K inhibitor
AB Despite advances in neoadjuvant chemotherapy, outcomes for patients with osteosarcoma resistant to first line chemotherapy have been dismal for decades. There is thus an urgent need to develop novel targeted drugs to effectively treat refractory osteosarcoma. Dysregulation in the PI3K/AKT pathway has been observed during the development of osteosarcoma. Herein, we first evaluated p AKT (Ser473) expression levels in osteosarcoma tissue using high throughput tissue microarrays. Then, we demonstrated the role of pictilisib, a novel potent PI3K inhibitor, in osteosarcoma and related osteolysis. Functional studies of pictilisib in osteosarcoma cell lines and bone marrow derived macrophages were performed in vitro. Patient derived xenografts and orthotopic mouse models were used to assess the effects of pictilisib in vivo. The results showed that positive p AKT expression levels after neoadjuvant chemotherapy were significantly associated with tumor cell necrosis rate. Pictilisib effectively inhibited the proliferation of osteosarcoma through G0/G1 S phase cell cycle arrest, and enhanced the sensitivity of osteosarcoma to doxorubicin, although it failed to induce cell apoptosis alone. In addition, pictilisib inhibited differentiation of osteoclasts and bone resorption in vitro and tumor related osteolysis in vivo via inhibition of the PI3K/AKT/GSK3 beta and NF kappa B pathways. Pictilisib combined with conventional chemotherapy drugs represents a potential treatment strategy to suppress tumor growth and bone destruction in p AKT positive patients.
C1 [Liang, Chao; Zhang, Zhichang; Sun, Zhenyu; Dong, Yang] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthoped, Shanghai, Peoples R China.
   [Yu, Xijiao] Jinan Stomatol Hosp, Dept Endodont, Jinan, Peoples R China.
   [Xiong, Naping] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; ShanghaiTech University
RP Sun, ZY; Dong, Y (通讯作者)，Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthoped, Shanghai, Peoples R China.
EM AaronSun616@163.com; dongyang6405@163.com
RI YU, XIJIAO/KFA 3924 2024; Zhang, Zhichang/MTF 0132 2025
OI yang, dong/0000 0003 3773 9346
FU Interdisciplinary Research Fund of Translational Medicine from Shanghai
   Jiao Tong University [ZH2018QNB06]
FX This research was supported by grants from the Interdisciplinary
   Research Fund of Translational Medicine from Shanghai Jiao Tong
   University (ZH2018QNB06).
CR Alfranca A, 2015, CELL MOL LIFE SCI, V72, P3097, DOI 10.1007/s00018 015 1918 y
   Avnet S, 2008, INT J ONCOL, V33, P1231, DOI 10.3892/ijo_00000113
   Chawla S, 2019, LANCET ONCOL, V20, P1719, DOI 10.1016/S1470 2045(19)30663 1
   Chou Alexander J, 2008, Paediatr Drugs, V10, P315, DOI 10.2165/00148581 200810050 00005
   Edgar KA, 2010, CANCER RES, V70, P1164, DOI 10.1158/0008 5472.CAN 09 2525
   Endo Munoz L, 2012, BBA REV CANCER, V1826, P434, DOI 10.1016/j.bbcan.2012.07.003
   Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d
   Foukas LC, 2006, NATURE, V441, P366, DOI 10.1038/nature04694
   Gao Y, 2020, ONCOL LETT, V20, P1001, DOI 10.3892/ol.2020.11685
   Gobin B, 2014, CANCER LETT, V344, P291, DOI 10.1016/j.canlet.2013.11.017
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Heymann Dominique, 2013, Bonekey Rep, V2, P378, DOI 10.1038/bonekey.2013.112
   Ji F, 2017, ONCOL LETT, V14, P6749, DOI 10.3892/ol.2017.7005
   Kelleher FC, 2017, J ADOLESC YOUNG ADUL, V6, P396, DOI 10.1089/jayao.2016.0078
   Kuijjer ML, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755 8794 7 4
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Lee YT, 2018, EUR J PHARMACOL, V834, P188, DOI 10.1016/j.ejphar.2018.07.034
   Lilienthal I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186885
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Moriceau G, 2010, CURR PHARM DESIGN, V16, P2981, DOI 10.2174/138161210793563554
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111
   Sarker D, 2015, CLIN CANCER RES, V21, P77, DOI 10.1158/1078 0432.CCR 14 0947
   Schöffski P, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058 018 1015 x
   Sharma A, 2021, CURR DRUG TARGETS, V22, P77, DOI 10.2174/1389450121666200910160404
   Sun ZY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00389
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Wang D, 2019, CANCER RES, V79, P7, DOI 10.1158/0008 5472.CAN 18 1086
   Wang YJ, 2019, EPIGENOMICS UK, V11, P1693, DOI 10.2217/epi 2019 0262
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Zeng SX, 2017, CLIN CANCER RES, V23, P6580, DOI 10.1158/1078 0432.CCR 17 0033
   Zhang J, 2015, CLIN CHIM ACTA, V444, P182, DOI 10.1016/j.cca.2014.12.041
   Zhu YR, 2015, CANCER BIOL THER, V16, P602, DOI 10.1080/15384047.2015.1017155
NR 35
TC 10
Z9 11
U1 1
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2234 943X
J9 FRONT ONCOL
JI Front. Oncol.
PD FEB 15
PY 2021
VL 10
AR 615146
DI 10.3389/fonc.2020.615146
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA QO6CL
UT WOS:000623228200001
PM 33659212
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Rekhi, B
   Verma, V
   Gulia, A
   Jambhekar, NA
   Desai, S
   Juvekar, SL
   Bajpai, J
   Puri, A
AF Rekhi, Bharat
   Verma, Vivek
   Gulia, Ashish
   Jambhekar, Nirmala A.
   Desai, Subhash
   Juvekar, Shashikant L.
   Bajpai, Jyoti
   Puri, Ajay
TI Clinicopathological Features of a Series of 27 Cases of Post Denosumab
   Treated Giant Cell Tumors of Bones: A Single Institutional Experience at
   a Tertiary Cancer Referral Centre, India
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Giant cell tumor of bone; Denosumab; Targeted therapy; Bone tumor
ID OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; RECEPTOR ACTIVATOR;
   KAPPA B
AB Giant cell tumor of bone (GCTB) is mostly a benign tumor, but associated with recurrences and metastasis. Lately, denosumab is being utilized in the treatment of certain GCTBs. Twenty seven tumors, analyzed in the present study, occurred in 16 males and 11 females (M: F = 1.45:1), in the age range of 16 to 47 years (mean = 29.5, median = 29). Most tumors were identified in the tibia(6) and femur(6), followed by the humerus(3), radius(3), pelvis(3), fibula(3), sacrum(1), metacarpal(1) and metatarsal(1) bones. There were 18(66.6 %) primary and 9(33.3 %) recurrent tumors. Exact tumor size (19 cases) varied from 3.7 to 15 cm (mean = 7.8, median = 6.4). Eight of the 19 tumors (42.1 %) had size more than or equal to 8 cm. On histopathologic examination of post denosumab treated specimens, more than half cases (15)(55.5 %) revealed complete absence of osteoclast like giant cells (OCLGs) and 12 cases revealed residual OCLGCs. In addition, there was replacement by fibro osseous tissue, including reactive woven bone or osteoid in most cases, followed by variable amount of spindle cells, hyalinisation, fibrosis and chronic inflammatory cells, including lymphocytes, macrophages and plasma cells. Post treatment follow up (25 cases, 92.5 %), over 7 27 months duration (median = 18), revealed 20 cases continuously disease free. Five patients developed recurrences at 9, 12, 13, 14 and 18 months, respectively. Out of these, who underwent repeat surgical intervention, 4 patients are alive with no evidence of disease and a single patient, planned for a second surgery, is alive with disease. Denosumab was mostly offered to patients with large sized, borderline salvageable tumors, in order to decrease the morbidity of index surgical procedure, that led to disappearance of OCLGCs in most cases. Post denosumab treated GCT cases appear as low grade osteosarcomas on histopathologic examination, but lack the clinical behaviour of an osteosarcoma, therefore may be considered as pseudo malignant bony lesions.
C1 [Rekhi, Bharat; Jambhekar, Nirmala A.] Tata Mem Hosp, Dept Surg Pathol, 8th Floor,Annex Bldg,Dr EB Rd, Bombay 400012, Maharashtra, India.
   [Verma, Vivek; Gulia, Ashish; Puri, Ajay] Tata Mem Hosp, Dept Surg Oncol Bone & Soft Tissues, Bombay 400012, Maharashtra, India.
   [Desai, Subhash; Juvekar, Shashikant L.] Tata Mem Hosp, Dept Radiodiag, Bombay 400012, Maharashtra, India.
   [Bajpai, Jyoti] Tata Mem Hosp, Dept Med Oncol, Bombay 400012, Maharashtra, India.
C3 Tata Memorial Centre (TMC); Tata Memorial Hospital; Tata Memorial Centre
   (TMC); Tata Memorial Hospital; Tata Memorial Centre (TMC); Tata Memorial
   Hospital; Tata Memorial Centre (TMC); Tata Memorial Hospital
RP Rekhi, B (通讯作者)，Tata Mem Hosp, Dept Surg Pathol, 8th Floor,Annex Bldg,Dr EB Rd, Bombay 400012, Maharashtra, India.
EM rekhi.bharat@gmail.com
RI Puri, Ajay/AAD 3769 2019; Bajpai, Jyoti/ABG 6370 2020; Rekhi,
   Bharat/AAB 5893 2020; Gulia, Ashish/AAM 8129 2021; Verma,
   Vivek/M 8760 2019
OI Rekhi, Bharat/0000 0002 3509 4794; Puri, Ajay/0000 0002 4323 753X; 
CR [Anonymous], J CLIN ONCOL, DOI DOI 10.1016/S1470 2045(13)70277 8
   Aponte Tinao LA, 2015, CLIN ORTHOP RELAT R, V473, P3050, DOI 10.1007/s11999 015 4249 2
   Athanasou NABM., 2013, CLASSIFICATION TUMOR, V4th ed., P321
   Balke M, 2010, LANCET ONCOL, V11, P218, DOI 10.1016/S1470 2045(10)70027 9
   Beebe Dimmer JL, 2009, RARE TUMORS, V1, DOI 10.4081/rt.2009.e52
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Demirsoy U, 2014, J PEDIAT HEMATOL ONC, V36, P156, DOI 10.1097/MPH.0000000000000034
   Desai SS, 2011, GROSSING SURG ONCOLO, P70
   Girolami I, 2016, J CLIN PATHOL, V69, P240, DOI 10.1136/jclinpath 2015 203248
   Gupta R, 2008, ANN DIAGN PATHOL, V12, P239, DOI 10.1016/j.anndiagpath.2007.09.002
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Lipton Allan, 2011, Curr Opin Support Palliat Care, V5, P258, DOI 10.1097/SPC.0b013e328349731c
   Morgan T, 2005, AM J PATHOL, V167, P117, DOI 10.1016/S0002 9440(10)62959 8
   Stadler N, 2015, CLINICS PRACT, V5, DOI 10.4081/cp.2015.697
   Szendröi M, 2004, J BONE JOINT SURG BR, V86B, P5, DOI 10.1302/0301 620X.86B1.14053
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Wojcik J, 2016, AM J SURG PATHOL, V40, P72, DOI 10.1097/PAS.0000000000000506
   Won KY, 2011, PATHOLOGY, V43, P318, DOI 10.1097/PAT.0b013e3283463536
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 21
TC 31
Z9 32
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219 4956
EI 1532 2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD JAN
PY 2017
VL 23
IS 1
BP 157
EP 164
DI 10.1007/s12253 016 0123 0
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA EI2HN
UT WOS:000392307600021
PM 27722984
DA 2025 08 17
ER

PT J
AU Molfetta, L
   Seriolo, B
AF Molfetta, L.
   Seriolo, B.
TI ARTHRITIS AND OSTEOPOROSIS: PATHOGENETIC CORRELATIONS IN FUNCTION OF
   ARTHROPLASTY
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE arthritis; inflammation; subchondral bone; bone edema; clodronate
ID BONE MINERAL DENSITY; HIP ARTHROPLASTY; SYNOVIAL FLUID; OSTEOARTHRITIS;
   CARTILAGE; KNEE; IMPLANTATION; SERUM; DEXA; STEM
AB Osteoarthritis is being increasingly characterised as an inflammatory incoming and recurrent disease, with the specific symptoms of inflammation at every stage of the disease. With regard to the pathogenesis over time, the degenerative and inflammatory components are combined and lead to osteocartilaginous degeneration. Such deterioration involves other joint tissues as well as the subchondral bone tissue, the suffering of which is the key event of the beginning and progression of OA; its involvement concerns the same pathogenetic mechanisms and the same chemical mediators of the chondropathy. The increase in joint inflammatory events leads to suspect the onset or the worsening of the osteometabolic disorder, which is documented by the MR as "bone edema" or as algodystrophic syndrome. The pain appears both while moving and resting and with signs of inflammation. The treatment of OA requires drugs, such as paracetamol, selective and nonselective NSAIDs and opiates, for pain control. Treatment should ensure the pharmacological control of the pain related to the osteometabolic juxta articular alteration, through bisphosphonates, favouring those which can control bone loss, inflammation and pain.
C1 [Molfetta, L.; Seriolo, B.] Univ Genoa, Sch Med & Pharmaceut Sci, Res Ctr Osteoporosis & Osteoarticular Dis CROPO, Genoa, Italy.
C3 University of Genoa
RP Molfetta, L (通讯作者)，Res Ctr Osteoporosis & Osteoarticular Dis, Sch Med & Pharmaceut Sci, Via LB Alberti 4, I 16132 Genoa, Italy.
EM Prof.molfetta@gmail.com
CR Adami S., 2001, Reumatismo, V53, P18
   ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   BENDELE AM, 1988, ARTHRITIS RHEUM US, V31, P561, DOI 10.1002/art.1780310416
   Bettica P, 2002, ARTHRITIS RHEUM, V46, P3178, DOI 10.1002/art.10630
   Bhandari M, 2005, J BONE JOINT SURG AM, V87A, P293, DOI 10.2106/JBJS.D.01772
   Breedveld FC, 1989, CELL IMMUNOL, V21, P1
   Burger H, 1996, ARTHRITIS RHEUM, V39, P81, DOI 10.1002/art.1780390111
   CAMPION GV, 1989, BRIT J RHEUMATOL, V28, P393
   Chang CY, 2015, SEMIN MUSCULOSKEL R, V19, P12, DOI 10.1055/s 0034 1396763
   Creamer P, 1997, LANCET, V350, P503, DOI 10.1016/S0140 6736(97)07226 7
   Dieppe P, 1999, BMJ BRIT MED J, V318, P1299, DOI 10.1136/bmj.318.7194.1299
   FAZZALARI NL, 1993, CALCIFIED TISSUE INT, V53, pS143, DOI 10.1007/BF01673424
   GRAY ML, 1988, J ORTHOP RES, V6, P777, DOI 10.1002/jor.1100060602
   Grochola LF, 2008, ARCH ORTHOP TRAUM SU, V128, P383, DOI 10.1007/s00402 007 0507 4
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Leichtle UG, 2011, HIP INT, V21, P706, DOI 10.5301/HIP.2011.8841
   Molfetta L, 2003, REUMATOLOGO, V56, P29
   Molfetta L, 2000, J ORTHOP TRAUMATOL, V1, P17
   MURPHY G, 1990, BIOCHEM SOC T, V18, P812, DOI 10.1042/bst0180812
   Parfitt A. M., 1996, P315
   Petersson IF, 1998, OSTEOARTHR CARTILAGE, V6, P33, DOI 10.1053/joca.1997.0090
   RADIN EL, 1970, ARTHRITIS RHEUM, V13, P139, DOI 10.1002/art.1780130206
   Roemer FW, 2014, BEST PRACT RES CL RH, V28, P31, DOI 10.1016/j.berh.2014.02.002
   Salaffi F, 2001, SCALE VALUTAZIONE MA
   Smolders JMH, 2013, J ARTHROPLASTY, V28, P1177, DOI 10.1016/j.arth.2012.08.025
   Tat SK, 2010, BEST PRACT RES CL RH, V24, P51, DOI 10.1016/j.berh.2009.08.004
   Viapiana O, 2009, GIBIS, V10, P5
   Vidovic D, 2013, INJURY, V44, pS62, DOI 10.1016/S0020 1383(13)70201 8
   Westacott CI, 1997, ARTHRITIS RHEUM, V40, P1282, DOI 10.1002/1529 0131(199707)40:7<1282::AID ART13>3.0.CO;2 E
   Yuan GH, 2003, ARTHRITIS RHEUM US, V48, P602, DOI 10.1002/art.10768
   Zeng Y, 2011, ORTHOPEDICS, V34
NR 31
TC 1
Z9 2
U1 0
U2 5
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393 974X
EI 1724 6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD OCT DEC
PY 2015
VL 29
IS 4
BP 985
EP 990
PG 6
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA DB0UD
UT WOS:000368222100032
PM 26753665
DA 2025 08 17
ER

PT J
AU Pollock, E
   Klotsas, AE
   Compston, J
   Gkrania Klotsas, E
AF Pollock, Emily
   Klotsas, Angelos Emmanouil
   Compston, Juliet
   Gkrania Klotsas, Effrossyni
TI Bone health in HIV infection
SO BRITISH MEDICAL BULLETIN
LA English
DT Article
DE HIV; AIDS; osteoporosis; fracture; vitamin D; bisphosphonates; bone
   mineral density; antiretroviral
ID ACTIVE ANTIRETROVIRAL THERAPY; RANDOMIZED CONTROLLED TRIAL; VITAMIN D
   DEFICIENCY; MINERAL DENSITY; HIV 1 INFECTED PATIENTS; PROTEASE
   INHIBITORS; TENOFOVIR DF; OSTEOPOROSIS; OSTEOPENIA; MEN
AB Osteoporosis is among the chronic problems emerging as the human immunodeficiency virus (HIV) positive population ages.
   We reviewed the English language bibliography using Pubmed 2.0, Web of Science and Embase for relevant abstracts and articles.
   The prevalence of low bone mineral density (BMD) and fracture is increased in the HIV positive population.
   The pathogenesis is multifactorial; there is some evidence that HIV infection is an independent risk factor and that highly active antiretroviral therapy has adverse skeletal effects.
   Physicians should routinely review the bone health of all HIV patients.
   More studies of the mechanisms of bone loss, the skeletal effects of antiretroviral therapy and the therapeutic outcome of bone protective therapy in HIV positive individuals are needed.
C1 [Gkrania Klotsas, Effrossyni] Addenbrookes Hosp, Dept Infect Dis, Cambridge CB2 2QQ, England.
   [Pollock, Emily] Univ Cambridge, Sch Clin Med, Cambridge, England.
   [Klotsas, Angelos Emmanouil] Luton & Dunstable Hosp, Dept Endocrinol & Diabet, Luton, Beds, England.
C3 Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's
   Hospital; University of Cambridge; University of Cambridge
RP Gkrania Klotsas, E (通讯作者)，Addenbrookes Hosp, Dept Infect Dis, Box 153,Hills Rd, Cambridge CB2 2QQ, England.
EM eg318@cam.ac.uk
RI ; Gkrania Klotsas, effrossyni/AAT 8424 2021
OI Gkrania Klotsas, Effrossyni/0000 0002 0930 8330; 
FU Medical Research Council [G0701652] Funding Source: researchfish; MRC
   [G0701652] Funding Source: UKRI; Medical Research Council [G0701652]
   Funding Source: Medline
CR Amorosa V, 2006, CLIN INFECT DIS, V42, P108, DOI 10.1086/498511
   Arnsten JH, 2006, CLIN INFECT DIS, V42, P1014, DOI 10.1086/501015
   Arnsten JH, 2007, AIDS, V21, P617, DOI 10.1097/QAD.0b013e3280148c05
   Bolland MJ, 2007, J CLIN ENDOCR METAB, V92, P4522, DOI 10.1210/jc.2007 1660
   Bolland MJ, 2007, J CLIN ENDOCR METAB, V92, P1283, DOI 10.1210/jc.2006 2216
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   Brown TT, 2009, JAIDS J ACQ IMM DEF, V51, P554, DOI 10.1097/QAI.0b013e3181adce44
   Carr A, 2001, AIDS, V15, P703, DOI 10.1097/00002030 200104130 00005
   Cassetti I, 2007, HIV CLIN TRIALS, V8, P164, DOI 10.1310/hct0803 164
   Cazanave C, 2008, AIDS, V22, P395, DOI 10.1097/QAD.0b013e3282f423dd
   Chirch LM, 2006, CLIN INFECT DIS, V43, P1084, DOI 10.1086/507901
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Dolan SE, 2006, J CLIN ENDOCR METAB, V91, P2938, DOI 10.1210/jc.2006 0127
   Duvivier C, 2009, AIDS, V23, P817, DOI 10.1097/QAD.0b013e328328f789
   Fairfield WP, 2001, J CLIN ENDOCR METAB, V86, P2020, DOI 10.1210/jc.86.5.2020
   Gallant JE, 2004, JAMA J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191
   Gibellini D, 2008, J MED VIROL, V80, P1507, DOI 10.1002/jmv.21266
   Gibellini D, 2007, J MED VIROL, V79, P1446, DOI 10.1002/jmv.20938
   Grund B, 2009, AIDS, V23, P1519, DOI 10.1097/QAD.0b013e32832c1792
   Gyllensten K, 2006, AIDS, V20, P1906, DOI 10.1097/01.aids.0000244216.08327.39
   *HPA, 2008, HIV UK
   Huang J, 2009, AIDS, V23, P51, DOI 10.1097/QAD.0b013e32831c8adc
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Jones S, 2008, OSTEOPOROSIS INT, V19, P913, DOI 10.1007/s00198 007 0524 8
   Lin D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.cd005645.pub2
   Malizia AP, 2007, ANTIVIR RES, V74, P72, DOI 10.1016/j.antiviral.2006.12.003
   McComsey GA, 2008, CLIN INFECT DIS, V46, P1290, DOI 10.1086/529384
   McComsey GA, 2007, AIDS, V21, P2473, DOI 10.1097/QAD.0b013e3282ef961d
   Morse CG, 2006, JAMA J AM MED ASSOC, V296, P844, DOI 10.1001/jama.296.7.844
   Negredo E, 2007, AIDS, V21, P657, DOI 10.1097/QAD.0b013e3280142191
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   *NICE NIFHACE, 2005, TA87 OST 2 PREV GUID
   Pan G, 2006, ANN NY ACAD SCI, V1068, P297, DOI 10.1196/annals.1346.057
   Poole KES, 2006, BMJ BRIT MED J, V333, P1251, DOI 10.1136/bmj.39050.597350.47
   Prior J, 2007, OSTEOPOROSIS INT, V18, P1345, DOI 10.1007/s00198 007 0428 7
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Recker RR, 2009, AM J MED, V122, P22, DOI 10.1016/j.amjmed.2008.12.004
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Rivas P, 2008, HIV MED, V9, P89, DOI 10.1111/j.1468 1293.2007.00525.x
   Rodríguez M, 2009, AIDS RES HUM RETROV, V25, P9, DOI 10.1089/aid.2008.0183
   Seeman E, 2009, OSTEOPOROSIS INT, V20, P187, DOI 10.1007/s00198 008 0813 x
   SERRANO S, 1995, BONE, V16, P185, DOI 10.1016/8756 3282(94)00028 X
   Silverman SL, 2009, AM J MED, V122, P33, DOI 10.1016/j.amjmed.2008.12.005
   SINGH K, 2006, AIDS READ, V16, P413
   Singh Kasha, 2006, AIDS Read, V16, P407
   Tran H, 2003, J LIPID RES, V44, P1859, DOI 10.1194/jlr.M200487 JLR200
   Triant VA, 2008, J CLIN ENDOCR METAB, V93, P3499, DOI 10.1210/jc.2008 0828
   van den Bout van den Beukel CJP, 2008, HIV MED, V9, P771, DOI 10.1111/j.1468 1293.2008.00630.x
   Villamor E, 2006, NUTR REV, V64, P226, DOI 10.1111/j.1753 4887.2006.tb00205.x
NR 49
TC 14
Z9 14
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007 1420
EI 1471 8391
J9 BRIT MED BULL
JI Br. Med. Bull.
PD DEC
PY 2009
VL 92
IS 1
BP 123
EP 133
DI 10.1093/bmb/ldp037
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 531RD
UT WOS:000272684600007
PM 19875393
OA Bronze
DA 2025 08 17
ER

PT J
AU Guo, XQ
   Qi, L
   Yang, J
   Wang, Y
   Wang, C
   Li, ZM
   Li, L
   Qu, Y
   Wang, D
   Han, ZM
AF Guo, Xiao Qin
   Qi, Lin
   Yang, Jing
   Wang, Yue
   Wang, Chuan
   Li, Zong Min
   Li, Ling
   Qu, Ye
   Wang, Dan
   Han, Ze Min
TI Salidroside accelerates fracture healing through cell autonomous and
   non autonomous effects on osteoblasts
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE Salidroside; Osteoblast; Hypoxia inducible factor 1 alpha (HIF 1 alpha);
   Vascular endothelial growth factor (VEGF); Fracture
ID HYPOXIA INDUCIBLE FACTOR; HIPPEL LINDAU PROTEIN; BONE FORMATION;
   FUTURE DIRECTIONS; NONUNION MODEL; DIFFERENTIATION; ANGIOGENESIS;
   EXPRESSION; OSTERIX; FACTOR 1 ALPHA
AB Salidroside (SAL), a major active component of Rhodiola rosea L., exhibits diverse pharmacological effects. However, the direct roles of SAL in fracture healing remain largely unknown. Here, we demonstrate that SAL significantly promotes proliferation by altering the cell cycle distribution of osteoblastic cells. SAL also greatly stimulates osteoblast differentiation and mineralization by inducing the expression of Runx2 and Osterix. In addition to its osteoblast autonomous effects, SAL can activate the HIF 1 alpha pathway coupling of angiogenesis and osteogenesis through cell non autonomous effects. Our in vitro results suggest that SAL significantly up regulates HIF 1 alpha expression at the mRNA and protein levels. Furthermore, the nuclear translocation and transcriptional activity of HIF 1 alpha and the HIF responsive gene VEGF increase following SAL treatment. Our mechanistic study revealed that the regulation of osteoblastic proliferation and HIF 1 alpha expression partly involves MAPK/ERK and PI3K/Akt signaling. Our in vivo analysis also demonstrated that SAL can promote angiogenesis within the callus and accelerate fracture healing. Thus, SAL promotes skeletal regeneration in cell autonomous and cell non autonomous ways and might be a potential therapy for accelerating fracture healing.
C1 [Guo, Xiao Qin; Wang, Yue] Tianjin Key Lab Prevent & Control Occupat & Envir, Tianjin, Peoples R China.
   [Guo, Xiao Qin; Qi, Lin; Yang, Jing; Wang, Yue; Li, Zong Min; Qu, Ye; Wang, Dan] Logist Coll Chinese Peoples Armed Police Forces, Dept Pathogen Biol & Immunol, Huizhi Ring Rd 1, Tianjin 300309, Peoples R China.
   [Wang, Chuan; Han, Ze Min] Logist Coll Chinese Peoples Armed Police Forces, Dept Stomatol, Affiliated Hosp, Tianjin, Peoples R China.
   [Li, Ling] Logist Coll Chinese Peoples Armed Police Forces, Dept Pharmacol, Tianjin, Peoples R China.
RP Wang, Y (通讯作者)，Tianjin Key Lab Prevent & Control Occupat & Envir, Tianjin, Peoples R China.; Wang, Y (通讯作者)，Logist Coll Chinese Peoples Armed Police Forces, Dept Pathogen Biol & Immunol, Huizhi Ring Rd 1, Tianjin 300309, Peoples R China.; Han, ZM (通讯作者)，Logist Coll Chinese Peoples Armed Police Forces, Dept Stomatol, Affiliated Hosp, Tianjin, Peoples R China.
EM wangyue6808@126.com; 6666665901@sina.com
FU National Natural Science Foundation of China [81273520, 81572852,
   81502256]; Great Program of the Science Foundation of Tianjin
   [12JCZDJC26300, 15JCYBJC28900]; Great Program for Science and Technology
   in Logistics College of Chinese People's Armed Police Forces [WHZ201202,
   WHB201404, WHB201405, WHB201406]
FX This work was supported by grants from the National Natural Science
   Foundation of China (nos. 81273520, 81572852, and 81502256), the Great
   Program of the Science Foundation of Tianjin (nos. 12JCZDJC26300 and
   15JCYBJC28900) and the Great Program for Science and Technology in
   Logistics College of Chinese People's Armed Police Forces (nos.
   WHZ201202, WHB201404, WHB201405 and WHB201406).
CR Artigas N, 2014, J BIOL CHEM, V289, P27105, DOI 10.1074/jbc.M114.576793
   Blouin CC, 2004, BLOOD, V103, P1124, DOI 10.1182/blood 2003 07 2427
   Carragee EJ, 2011, SPINE J, V11, P695, DOI 10.1016/j.spinee.2011.08.418
   Chen JJ, 2013, FOOD CHEM TOXICOL, V62, P499, DOI 10.1016/j.fct.2013.09.019
   Choi IH, 2000, J ORTHOP RES, V18, P698, DOI 10.1002/jor.1100180504
   Choi P, 2004, J ORTHOP RES, V22, P1100, DOI 10.1016/j.orthres.2004.03.008
   Colnot CI, 2001, MECH DEVELOP, V100, P245, DOI 10.1016/S0925 4773(00)00532 3
   Coulibaly MO, 2010, CRIT REV EUKAR GENE, V20, P105, DOI 10.1615/CritRevEukarGeneExpr.v20.i2.20
   Court Brown CM, 2008, J TRAUMA, V64, P1517, DOI 10.1097/TA.0b013e3181469840
   Déry MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Donneys A, 2013, PLAST RECONSTR SURG, V131, p711E, DOI 10.1097/PRS.0b013e3182865c57
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eckardt H, 2005, J BONE JOINT SURG BR, V87B, P1434, DOI 10.1302/0301 620X.87B10
   Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200
   Geiger F, 2005, J BONE MINER RES, V20, P2028, DOI 10.1359/JBMR.050701
   Hagiwara H, 1996, AM J PHYSIOL CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311
   HILTUNEN A, 1993, CLIN ORTHOP RELAT R, P23
   Ortuño MJ, 2013, BONE, V52, P548, DOI 10.1016/j.bone.2012.11.007
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Komatsu DE, 2004, BONE, V34, P680, DOI 10.1016/j.bone.2003.12.024
   Krane SM, 2005, J EXP MED, V201, P841, DOI 10.1084/jem.20050354
   Lee SH, 2012, J BIOL CHEM, V287, P14760, DOI 10.1074/jbc.M112.340232
   Li HZ, 2008, MOL CANCER RES, V6, P917, DOI 10.1158/1541 7786.MCR 08 0093
   Li LH, 2014, AM J TRANSL RES, V6, P377
   Mangiavini L, 2014, DEV BIOL, V393, P124, DOI 10.1016/j.ydbio.2014.06.013
   Mao GX, 2010, BIOMED ENVIRON SCI, V23, P161, DOI 10.1016/S0895 3988(10)60047 5
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nishimura R, 2012, J BIOL CHEM, V287, P33179, DOI 10.1074/jbc.M111.337063
   Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054
   Pagé EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200
   Parker MJ, 2007, CLIN ORTHOP RELAT R, P175, DOI 10.1097/BLO.0b013e3180325a42
   Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642
   Stains JP, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 7 222
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Yu PZ, 2007, CHEM BIODIVERS, V4, P508, DOI 10.1002/cbdv.200790043
   Zhang JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057251
   Zhang JP, 2009, EUR J PHARMACOL, V607, P6, DOI 10.1016/j.ejphar.2009.01.046
NR 42
TC 20
Z9 25
U1 2
U2 25
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0302 766X
EI 1432 0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD FEB
PY 2017
VL 367
IS 2
BP 197
EP 211
DI 10.1007/s00441 016 2535 2
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA EK0TZ
UT WOS:000393641300004
PM 27942852
DA 2025 08 17
ER

PT J
AU Huang, JM
   Wang, CZ
   Lu, SY
   Wang, Z
   Yan, ZQ
AF Huang, Jun ming
   Wang, Chen zhong
   Lu, Shun yi
   Wang, Zhe
   Yan, Zuo qin
TI Oroxin B Attenuates Ovariectomy Induced Bone Loss by Suppressing
   Osteoclast Formation and Activity
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE osteoclast; Oroxin B; MAPK; NF kappa B; RANKL; osteoporosis
ID T CELLS C1; NUCLEAR FACTOR; ACTIVATION; DIFFERENTIATION; RECEPTOR;
   PATHWAY; ICARIIN
AB Background: Osteoclasts are the major players in bone resorption and have always been studied in the prevention and treatment of osteoporosis. Previous studies have confirmed that a variety of flavonoids inhibit osteoporosis and improve bone health mainly through inhibiting osteoclastogenesis. Oroxin B (OB) is a flavonoid compound extracted from traditional Chinese herbal medicine Oroxylum indicum (L.) Vent, exerts potent antitumor and anti inflammation effect, but its effect on osteoclastogensis remains unknown.
   Methods: We comprehensively evaluated the effect of OB on the formation and function of osteoclasts and the underling mechanism by bone marrow derived macrophage in vitro. In vivo, we used mice ovariectomized model to verify the protective effect of OB.
   Results: OB was found to inhibit osteoclast formation and bone resorption function in vitro, in a dose dependent manner and the increased osteoclastic related genes induced by RANKL (NFATc1, c fos, cathepsin K, RANK, MMP9 and TRAP) were also attenuated following OB treatment. Mechanistical investigation showed OB abrogated the increased phosphorylation level of MAPK and NF kappa B pathway, and diminished the expression of the vital transcription factors for osteoclastogenesis. OB also prevented ovariectomy (OVX) induced bone loss by inhibiting osteoclast formation and activity in mice.
   Conclusion: Our study demonstrated that OB may act as an anti osteoporosis agent by inhibiting osteoclast maturation and attenuating bone resorption.
C1 [Huang, Jun ming; Wang, Chen zhong; Lu, Shun yi; Wang, Zhe; Yan, Zuo qin] Fudan Univ, Zhongshan Hosp, Dept Orthopaed, Shanghai 200032, Peoples R China.
C3 Fudan University
RP Yan, ZQ (通讯作者)，180 Feng Lin Rd, Shanghai 200032, Peoples R China.
EM yan.zuoqin@zs hospital.sh.cn
RI ; lu, shunyi/IUP 2257 2023; Wang, Chenzhong/ACB 1204 2022
OI Huang, Jun ming/0000 0002 6800 2788; Lu, ShunYi/0009 0007 8045 5855
FU National Natural Science Foundation of China [81871742]
FX This work was supported by the National Natural Science Foundation of
   China (81871742).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Doshi Krunal, 2012, J Ayurveda Integr Med, V3, P194, DOI 10.4103/0975 9476.104434
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   El Kholy K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01300
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Huang JM, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/8085325
   Jeong E, 2018, CELL DEATH DIFFER, V25, P1364, DOI 10.1038/s41418 017 0048 5
   Jiang L, 2015, MOLECULES, V20, P11257, DOI 10.3390/molecules200611257
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim Y, 2005, J BIOL CHEM, V280, P32905, DOI 10.1074/jbc.M505820200
   Krum SA, 2011, J CELL BIOCHEM, V112, P401, DOI 10.1002/jcb.22970
   Lalrinzuali K, 2018, J ETHNOPHARMACOL, V227, P290, DOI 10.1016/j.jep.2018.08.018
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee J, 2015, EXP CELL RES, V339, P380, DOI 10.1016/j.yexcr.2015.10.001
   Lee MS, 2009, J IMMUNOL, V183, P3390, DOI 10.4049/jimmunol.0804314
   Lee SE, 2001, J BIOL CHEM, V276, P49343, DOI 10.1074/jbc.M103642200
   Li NN, 2018, PHARMACOGN MAG, V14, P207, DOI 10.4103/pm.pm_119_17
   Li NN, 2019, MOLECULES, V24, DOI 10.3390/molecules24234384
   Lu L, 2017, J CELL MOL MED, V21, P1361, DOI 10.1111/jcmm.13066
   Mori T, 1970, Seikei Geka, V21, P618
   Mun SH, 2020, EXP MOL MED, V52, P1239
   Nijveldt RJ, 2001, AM J CLIN NUTR, V74, P418
   Salleh NNHN, 2020, MOLECULES, V25, DOI 10.3390/molecules25235677
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Qiu JZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080197
   Sakai A, 2001, J BONE MINER METAB, V19, P277, DOI 10.1007/s007740170011
   Siriwatanametanon N, 2010, J ETHNOPHARMACOL, V130, P196, DOI 10.1016/j.jep.2010.04.036
   Svedbom A, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0137 0
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Wang T, 2015, INT J MOL SCI, V16, P27470, DOI 10.3390/ijms161126039
   Wang Z, 2018, OSTEOPOROSIS INT, V29, P535, DOI 10.1007/s00198 017 4255 1
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Xu HH, 2021, INT IMMUNOPHARMACOL, V95, DOI 10.1016/j.intimp.2021.107464
   Yang P, 2015, TOXICOL APPL PHARM, V288, P269, DOI 10.1016/j.taap.2015.07.026
   Zaveri Maitreyi, 2006, J Immunotoxicol, V3, P83, DOI 10.1080/15476910600725942
   Zhan YF, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01587
   Zhang X, 2014, PHYTOTHER RES, V28, P498, DOI 10.1002/ptr.5027
   Zhu W, 2019, BIOCHEM BIOPH RES CO, V509, P294, DOI 10.1016/j.bbrc.2018.12.125
NR 40
TC 5
Z9 6
U1 0
U2 15
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177 8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2021
VL 15
BP 4811
EP 4825
DI 10.2147/DDDT.S328238
PG 15
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XH5WY
UT WOS:000725505700002
PM 34876805
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tonti, E
   de Oya, NJ
   Galliverti, G
   Moseman, EA
   Di Lucia, P
   Amabile, A
   Sammicheli, S
   De Giovanni, M
   Sironi, L
   Chevrier, N
   Sitia, G
   Gennari, L
   Guidotti, LG
   von Andrian, UH
   Iannacone, M
AF Tonti, Elena
   de Oya, Nereida Jimenez
   Galliverti, Gabriele
   Moseman, E. Ashley
   Di Lucia, Pietro
   Amabile, Angelo
   Sammicheli, Stefano
   De Giovanni, Marco
   Sironi, Laura
   Chevrier, Nicolas
   Sitia, Giovanni
   Gennari, Luigi
   Guidotti, Luca G.
   von Andrian, Ulrich H.
   Iannacone, Matteo
TI Bisphosphonates Target B Cells to Enhance Humoral Immune Responses
SO CELL REPORTS
LA English
DT Article
ID SUBCAPSULAR SINUS MACROPHAGES; GERMINAL CENTER FORMATION; T CELL;
   ACTIVATION; INFECTION; RECEPTOR; ANTIGEN; ANTIBODY; ABSENCE; MICE
AB Bisphosphonates are a class of drugs that are widely used to inhibit loss of bone mass in patients. We show here that the administration of clinically relevant doses of bisphosphonates in mice increases antibody responses to live and inactive viruses, proteins, haptens, and existing commercial vaccine formulations. Bisphosphonates exert this adjuvant like activity in the absence of CD4(+) and gamma delta T cells, neutrophils, or dendritic cells, and their effect does not rely on local macrophage depletion, Toll like receptor signaling, or the inflammasome. Rather, bisphosphonates target directly B cells and enhance B cell expansion and antibody production upon antigen encounter. These data establish bisphosphonates as an additional class of adjuvants that boost humoral immune responses.
C1 [Tonti, Elena; de Oya, Nereida Jimenez; Galliverti, Gabriele; Di Lucia, Pietro; Amabile, Angelo; Sammicheli, Stefano; De Giovanni, Marco; Sironi, Laura; Sitia, Giovanni; Guidotti, Luca G.; Iannacone, Matteo] Ist Sci San Raffaele, Div Immunol Transplantat & Infect Dis, I 20132 Milan, Italy.
   [Tonti, Elena; Moseman, E. Ashley; von Andrian, Ulrich H.; Iannacone, Matteo] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
   [Chevrier, Nicolas] Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA.
   [Sironi, Laura] Univ Milano Bicocca, Dept Phys, I 20126 Milan, Italy.
   [Gennari, Luigi] Univ Siena, Dept Med Surg & Neurosci, I 53100 Siena, Italy.
   [Guidotti, Luca G.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Iannacone, Matteo] Univ Vita Salute San Raffaele, I 20132 Milan, Italy.
C3 Vita Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Harvard University; Harvard Medical School; Harvard University;
   University of Milano Bicocca; University of Siena; Scripps Research
   Institute; Vita Salute San Raffaele University
RP von Andrian, UH (通讯作者)，Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
EM uva@hms.harvard.edu; matteo.iannacone@hsr.it
RI Sitia, Giovanni/K 1036 2016; Iannacone, Matteo/I 8507 2018; Jimenez de
   Oya, Nereida/K 8470 2016; Jiménez de Oya, Nereida/ABZ 4365 2022; De
   Giovanni, Marco/KFB 0251 2024; Guidotti, Luca/I 8542 2018; Sironi,
   Laura/AAA 5384 2022; von Andrian, Ulrich/A 5775 2008; Guidotti, Luca
   G./I 8542 2018; Gennari, Luigi/J 7013 2016
OI Sitia, Giovanni/0000 0003 1024 9128; Jimenez de Oya,
   Nereida/0000 0003 3129 813X; Iannacone, Matteo/0000 0002 9370 2671;
   Tonti, Elena/0000 0001 5002 7613; De Giovanni,
   Marco/0000 0001 7521 3092; SIRONI, LAURA/0000 0002 6638 7709; von
   Andrian, Ulrich/0000 0003 4231 2283; Guidotti, Luca
   G./0000 0002 0205 2678; Di Lucia, Pietro/0000 0002 0726 1532
FU ERC [281648, 250219]; NIH [AI40696, AI078897, AI069259]; Italian
   Association for Cancer Research (AIRC) [9965]; Giovanni Armenise Harvard
   Foundation; European Research Council (ERC) [250219, 281648] Funding
   Source: European Research Council (ERC)
FX We thank T. Cataudella, A. Fiocchi, B. Fiore, D. Covarello, and M.
   Mainetti for technical support; R. Serra for secretarial assistance; P.
   Dellabona (San Raffaele Scientific Institute) for providing
   MHC II<SUP> / </SUP> mice; W. Havran (The Scripps Research Institute)
   for providing TCR delta<SUP> / </SUP> mice; B. Beutler (The Scripps
   Research Institute) for providing
   MyD88<SUP> / </SUP>/Trif<SUP>Lps2/Lps2</SUP> mice; S. Whelan (Harvard
   Medical School) for providing VSV and VSVeGFP; N. van Rooijen for
   providing clodronate liposomes; F. Benvenuti (International Centre for
   Genetic Engineering and Biotechnology) for providing
   Flt3 ligand secreting B16 tumor cells; S. Cenci, C. Scielzo, P. Ghia,
   and the members of the Iannacone, Guidotti and von Andrian laboratories
   for helpful discussions; and F.V. Chisari, A. Mondino, P. Dellabona, R.
   Pardi, and Z.M. Ruggeri for critical reading of the manuscript. This
   work was supported by ERC grants 281648 (to M.I.) and 250219 (to
   L.G.G.); NIH grants AI40696 (to L.G.G.) and AI078897 and AI069259 (to
   U.H.v.A.); Italian Association for Cancer Research (AIRC) grant 9965 (to
   M.I.); and a career development award from the Giovanni Armenise Harvard
   Foundation (to M.I.).
CR BACHMANN MF, 1993, J VIROL, V67, P3917, DOI 10.1128/JVI.67.7.3917 3922.1993
   Blasius AL, 2006, BLOOD, V107, P2474, DOI 10.1182/blood 2005 09 3746
   Carrasco YR, 2007, IMMUNITY, V27, P160, DOI 10.1016/j.immuni.2007.06.007
   Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036
   Cavanagh LL, 2005, NAT IMMUNOL, V6, P1029, DOI 10.1038/ni1249
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Favus MJ, 2010, NEW ENGL J MED, V363, P2027, DOI 10.1056/NEJMct1004903
   Galli G, 2007, P NATL ACAD SCI USA, V104, P3984, DOI 10.1073/pnas.0700191104
   Gonzalez SF, 2010, NAT IMMUNOL, V11, P427, DOI 10.1038/ni.1856
   Hangartner L, 2006, NAT REV IMMUNOL, V6, P231, DOI 10.1038/nri1783
   Hangartner L, 2003, P NATL ACAD SCI USA, V100, P12883, DOI 10.1073/pnas.2135542100
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Iannacone M, 2010, NATURE, V465, P1079, DOI 10.1038/nature09118
   ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092 8674(93)90112 4
   Junt T, 2007, NATURE, V450, P110, DOI 10.1038/nature06287
   Lauterslager TGM, 2001, VACCINE, V19, P2749, DOI 10.1016/S0264 410X(00)00513 2
   Moseman EA, 2012, IMMUNITY, V36, P415, DOI 10.1016/j.immuni.2012.01.013
   Norton JT, 2012, J IMMUNOL, V188, P2977, DOI 10.4049/jimmunol.1100830
   Norton JT, 2011, P NATL ACAD SCI USA, V108, P11163, DOI 10.1073/pnas.1107899108
   Pao W, 1996, CURR BIOL, V6, P1317, DOI 10.1016/S0960 9822(02)70718 5
   Phan TG, 2007, NAT IMMUNOL, V8, P992, DOI 10.1038/ni1494
   PIERRE P, 1992, EUR J IMMUNOL, V22, P3179, DOI 10.1002/eji.1830221223
   Qi H, 2006, SCIENCE, V312, P1672, DOI 10.1126/science.1125703
   RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889
   Scandella E, 2007, J IMMUNOL, V178, P1468, DOI 10.4049/jimmunol.178.3.1468
   Schilbach K, 2001, BLOOD, V97, P2917, DOI 10.1182/blood.V97.9.2917
   SCOTT DW, 1970, CLIN EXP IMMUNOL, V6, P313
   Thompson K, 2010, ADV EXP MED BIOL, V658, P11, DOI 10.1007/978 1 4419 1050 9_2
   Tonti E, 2012, J IMMUNOL, V188, P3217, DOI 10.4049/jimmunol.1103501
   VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83
   Wen L, 1996, J EXP MED, V183, P2271, DOI 10.1084/jem.183.5.2271
NR 31
TC 35
Z9 40
U1 0
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211 1247
J9 CELL REP
JI Cell Reports
PD OCT
PY 2013
VL 5
IS 2
BP 323
EP 330
DI 10.1016/j.celrep.2013.09.004
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 269SU
UT WOS:000328263000005
PM 24120862
OA gold, Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Nishikawa, K
   Nakashima, T
   Takeda, S
   Isogai, M
   Hamada, M
   Kimura, A
   Kodama, T
   Yamaguchi, A
   Owen, MJ
   Takahashi, S
   Takayanagi, H
AF Nishikawa, Keizo
   Nakashima, Tomoki
   Takeda, Shu
   Isogai, Masashi
   Hamada, Michito
   Kimura, Ayako
   Kodama, Tatsuhiko
   Yamaguchi, Akira
   Owen, Michael J.
   Takahashi, Satoru
   Takayanagi, Hiroshi
TI Maf promotes osteoblast differentiation in mice by mediating the
   age related switch in mesenchymal cell differentiation
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID BONE MARROW ADIPOCYTES; FACTOR C MAF; OSTEOCLAST DIFFERENTIATION;
   TERMINAL DIFFERENTIATION; INSULIN SENSITIVITY; NEGATIVE REGULATORS;
   BINDING PROTEIN; GENE EXPRESSION; STROMAL CELLS; PPAR GAMMA
AB Aging leads to the disruption of the homeostatic balance of multiple biological systems. In bone marrow multipotent mesenchymal cells undergo differentiation into various anchorage dependent cell types, including osteoblasts and adipocytes. With age as well as with treatment of antidiabetic drugs such as thiazolidinediones, mesenchymal cells favor differentiation into adipocytes, resulting in an increased number of adipocytes and a decreased number of osteoblasts, causing osteoporosis. The mechanism behind this differentiation switch is unknown. Here we show an age related decrease in the expression of Maf in mouse mesenchymal cells, which regulated mesenchymal cell bifurcation into osteoblasts and adipocytes by cooperating with the osteogenic transcription factor Runx2 and inhibiting the expression of the adipogenic transcription factor Pparg. The crucial role of Maf in both osteogenesis and adipogenesis was underscored by in vivo observations of delayed bone formation in perinatal Maf( / ) mice and an accelerated formation of fatty marrow associated with bone loss in aged Maf(+/ ) mice. This study identifies a transcriptional mechanism for an age related switch in cell fate determination and may provide a molecular basis for novel therapeutic strategies against age related bone diseases.
C1 [Takayanagi, Hiroshi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Cell Signaling, Bunkyo Ku, Tokyo 1138549, Japan.
   [Nishikawa, Keizo; Nakashima, Tomoki; Takayanagi, Hiroshi] Int Res Ctr Mol Sci Tooth & Bone Dis, Global Ctr Excellence Program, Tokyo, Japan.
   [Nakashima, Tomoki; Takayanagi, Hiroshi] Takayanagi Osteonetwork Project, ERATO, Japan Sci & Technol Agcy, Tokyo, Japan.
   [Takeda, Shu; Kimura, Ayako] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Orthopaed Surg, Tokyo 1138549, Japan.
   [Isogai, Masashi; Hamada, Michito; Takahashi, Satoru] Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan.
   [Isogai, Masashi; Hamada, Michito; Takahashi, Satoru] Univ Tsukuba, Lab Anim Resource Ctr, Tsukuba, Ibaraki 305, Japan.
   [Kodama, Tatsuhiko] Univ Tokyo, Adv Sci & Technol Res Ctr, Dept Mol Biol & Med, Tokyo, Japan.
   [Yamaguchi, Akira] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Pathol, Tokyo 1138549, Japan.
   [Owen, Michael J.] GlaxoSmithKline Inc, Stevenage, Herts, England.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Japan Science & Technology Agency (JST); Institute of Science Tokyo;
   Tokyo Medical & Dental University (TMDU); University of Tsukuba;
   University of Tsukuba; University of Tokyo; Institute of Science Tokyo;
   Tokyo Medical & Dental University (TMDU); GlaxoSmithKline;
   Glaxosmithkline United Kingdom
RP Takayanagi, H (通讯作者)，Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Cell Signaling, Bunkyo Ku, Yushima 1 5 45, Tokyo 1138549, Japan.
EM taka.csi@tmd.ac.jp
RI Yamaguchi, Akira/AAX 9286 2020; takeda, shu/B 5195 2012
FU Japan Science and Technology Agency; Japan Society for the Promotion of
   Science (JSPS); Ministry of Education, Culture, Sports, Science and
   Technology of Japan; Tokyo Biochemical Research Foundation; Life Science
   Foundation of Japan; Yokoyama Foundation for Clinical Pharmacology;
   Takeda Science Foundation; Grants in Aid for Scientific Research
   [21659427] Funding Source: KAKEN
FX We thank H.R. Ueda, M. Asagiri, T. Ando, Y. Kunisawa, T. Honda, Y.
   Suzuki, T. Kudo, A. Izumi, A. Suematsu, and A. Hirota for discussion and
   assistance. This work was supported in part by a grant for ERATO from
   the Takayanagi Osteonetwork Project from the Japan Science and
   Technology Agency; Grant in Aids for Creative Scientific Research and
   Young Scientist (A and Start up) from the Japan Society for the
   Promotion of Science (JSPS); Grant in Aid for Challenging Exploratory
   Research JSPS; grants for the Genome Network Project and Global Center
   of Excellence Program from the Ministry of Education, Culture, Sports,
   Science and Technology of Japan; and grants from Tokyo Biochemical
   Research Foundation, Life Science Foundation of Japan, Yokoyama
   Foundation for Clinical Pharmacology, and Takeda Science Foundation.
CR Adler AS, 2007, GENE DEV, V21, P3244, DOI 10.1101/gad.1588507
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Belaid Choucair Z, 2008, STEM CELLS, V26, P1556, DOI 10.1634/stemcells.2008 0068
   Chen JH, 2007, NUCLEIC ACIDS RES, V35, P7417, DOI 10.1093/nar/gkm681
   Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003
   Corre J, 2004, BRIT J HAEMATOL, V127, P344, DOI 10.1111/j.1365 2141.2004.05198.x
   Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Ho IC, 2002, CELL, V109, pS109, DOI 10.1016/S0092 8674(02)00705 5
   Holmes C, 2007, J BONE MINER RES, V22, P1373, DOI 10.1359/JBMR.070604
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500
   Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Kovács KA, 2003, J BIOL CHEM, V278, P36959, DOI 10.1074/jbc.M303147200
   Kudo M, 2004, ENDOCRINOLOGY, V145, P4948, DOI 10.1210/en.2004 0180
   Lamberts SWJ, 1997, SCIENCE, V278, P419, DOI 10.1126/science.278.5337.419
   Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003 0288
   MacLean HE, 2003, DEV BIOL, V262, P51, DOI 10.1016/S0012 1606(03)00324 5
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Maurin AC, 2000, BONE, V26, P485, DOI 10.1016/S8756 3282(00)00252 0
   McDonough AK, 2008, NAT CLIN PRACT ENDOC, V4, P507, DOI 10.1038/ncpendmet0920
   Meunier P, 1971, CLIN ORTHOP RELAT R, V80, P147, DOI DOI 10.1097/00003086 197110000 00021
   Meyre D, 2009, NAT GENET, V41, P157, DOI 10.1038/ng.301
   Montecino M, 1996, BIOCHEMISTRY US, V35, P5093, DOI 10.1021/bi952489s
   Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206
   Nakanishi R, 2006, J BONE MINER RES, V21, P1713, DOI 10.1359/JBMR.060719
   Naveiras O, 2009, NATURE, V460, P259, DOI 10.1038/nature08099
   Nishikaw K, 2010, P NATL ACAD SCI USA, V107, P3117, DOI 10.1073/pnas.0912779107
   Nishikawa K, 2003, MOL CELL BIOL, V23, P8295, DOI 10.1128/MCB.23.22.8295 8305.2003
   NISHIYORI A, 1994, J BIOL CHEM, V269, P1323
   Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   ROSEN CJ, 1994, J CELL BIOCHEM, V56, P348, DOI 10.1002/jcb.240560311
   Rowe GC, 2009, ENDOCRINOLOGY, V150, P135, DOI 10.1210/en.2008 0678
   Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Serria MS, 2003, BIOCHEM BIOPH RES CO, V310, P318, DOI 10.1016/j.bbrc.2003.08.144
   Shi XM, 2000, J CELL BIOCHEM, V76, P518, DOI 10.1002/(SICI)1097 4644(20000301)76:3<518::AID JCB18>3.0.CO;2 M
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101
   Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   TSUKADA T, 1993, ONCOGENE, V8, P3313
   Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097 2765(00)80306 8
   Xiao Y, 2007, BONE, V40, P700, DOI 10.1016/j.bone.2006.10.021
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Zhang XS, 2004, J GENE MED, V6, P4, DOI 10.1002/jgm.477
NR 60
TC 147
Z9 168
U1 0
U2 9
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD OCT
PY 2010
VL 120
IS 10
BP 3455
EP 3465
DI 10.1172/JCI42528
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 657DN
UT WOS:000282393200010
PM 20877012
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Tanaka, M
   Mori, H
   Kayasuga, R
   Kawabata, K
AF Tanaka, Makoto
   Mori, Hiroshi
   Kayasuga, Ryoji
   Kawabata, Kazuhito
TI Induction of creatine kinase release from cultured osteoclasts via the
   pharmacological action of aminobisphosphonates
SO SPRINGERPLUS
LA English
DT Article
DE Osteoclast; Bisphosphonate; Creatine kinase; Minodronic acid;
   Alendronate; Risedronate
ID RANDOMIZED TRIAL; BONE RESORPTION; BRAIN ISOENZYME; IN VITRO;
   RISEDRONATE; BISPHOSPHONATES; INHIBITION; ALENDRONATE; APOPTOSIS; WOMEN
AB An increase of serum creatine kinase (CK) has been observed in clinical studies of nitrogen containing aminobisphosphonates (N BPs). Osteoclasts are thought to be the source of the CK, but there is no clear evidence for the hypothesis. In this study, CK release from rabbit osteoclasts induced by N BPs was examined in an in vitro culture system. Rabbit bone derived cells were cultured for 3 days on the N BPs pretreated cortical bone slices. CK activity in the culture medium was measured at 3 days of culture. The CK activity was increased with all N BPs at concentrations at which showed antiresorptive activity over 60% inhibition of C terminal cross linking telopeptide of type I collagen (CTX 1) release. The maximum induction of CK activity was 2.6 times the control level. The lowest N BP concentration inducing CK release was 3 times lower than that required to decrease the osteoclast number. Bafilomycin A1, an inhibitor of vacuolar H+ ATPase, abrogated all N BP actions, including CK release. Bone derived cells except osteoclasts were insensitive to bafilomycin A1, suggesting that osteoclasts were the source of CK. Regarding the time course, CK release occurred after a 1 day lag time and increased steadily until day 3 of culture. These results show that CK release is induced by N BPs from osteoclasts at concentrations at which N BPs show antiresorptive activity over 60% inhibition of CTX 1 release in vitro. These findings explain the mechanism of the CK increase induced by clinical use of N BPs.
C1 [Tanaka, Makoto] Ono Pharmaceut Co Ltd, Res Promot, Shimamoto, Osaka 6188585, Japan.
   [Mori, Hiroshi; Kayasuga, Ryoji; Kawabata, Kazuhito] Ono Pharmaceut Co Ltd, Discovery Res Labs, Shimamoto, Osaka 6188585, Japan.
C3 Ono Pharmaceutical Co Ltd; Ono Pharmaceutical Co Ltd
RP Tanaka, M (通讯作者)，Ono Pharmaceut Co Ltd, Res Promot, 3 1 1 Sakurai, Shimamoto, Osaka 6188585, Japan.
EM mak.tanaka@ono.co.jp
RI TANAKA, MAKOTO/I 1679 2012
FU Ono Pharmaceutical Co., Ltd.
FX All authors are employees of Ono Pharmaceutical Co., Ltd., the sponsor
   of the study.
CR Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Burnstock G, 2013, PURINERG SIGNAL, V9, P541, DOI 10.1007/s11302 013 9381 4
   Chang EJ, 2008, NAT MED, V14, P966, DOI 10.1038/nm.1860
   Chen JF, 2010, J BIOL CHEM, V285, P36315, DOI 10.1074/jbc.M110.157743
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   EPPENBERGER HM, 1967, J BIOL CHEM, V242, P204
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Hazama R, 2009, GENES CELLS, V14, P871, DOI 10.1111/j.1365 2443.2009.01317.x
   Ito M, 1998, CALCIFIED TISSUE INT, V63, P143, DOI 10.1007/s002239900505
   Ito M, 1999, BONE, V25, P447, DOI 10.1016/S8756 3282(99)00197 0
   JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251
   Kakudo S, 1996, J BONE MINER METAB, V14, P129, DOI [10.1007/BF02239480, DOI 10.1007/BF02239480]
   Kuiper JWP, 2008, PLOS BIOL, V6, P568, DOI 10.1371/journal.pbio.0060051
   Matsumoto T, 2009, OSTEOPOROSIS INT, V20, P1429, DOI 10.1007/s00198 008 0816 7
   Matsumoto T, 2011, ARTHRITIS RHEUM US, V63, P3908, DOI 10.1002/art.30646
   Miyazaki T, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.385369
   Nishida S, 2003, BIOL PHARM BULL, V26, P96, DOI 10.1248/bpb.26.96
   Nozaki K, 2008, CLIN PHARMACOL THER, V18, pS7
   Ogura Y, 2004, J BONE MINER METAB, V22, P111, DOI 10.1007/s00774 003 0458 y
   Ohno K, 2011, CURR MED CHEM, V18, P220, DOI 10.2174/092986711794088335
   Orriss IR, 2012, BONE, V51, P389, DOI 10.1016/j.bone.2012.06.013
   Pellegatti P, 2011, FASEB J, V25, P1264, DOI 10.1096/fj.10 169854
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   SAKAI D, 1995, BONE, V17, P111, DOI 10.1016/S8756 3282(95)00152 2
   SISTERMANS EA, 1995, CELL TISSUE RES, V280, P435, DOI 10.1007/BF00307817
   Takami M, 2003, BONE, V32, P341, DOI 10.1016/S8756 3282(03)00024 3
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Tsubaki M, 2013, BIOCHEM PHARMACOL, V85, P163, DOI 10.1016/j.bcp.2012.10.009
   Waguespack SG, 2002, J CLIN ENDOCR METAB, V87, P2212, DOI 10.1210/jc.87.5.2212
   WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Whyte MP, 1996, J BONE MINER RES, V11, P1438, DOI 10.1002/jbmr.5650111010
   YONEYAMA T, 1989, NEW ENGL J MED, V320, P1284
NR 37
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH 6330, SWITZERLAND
SN 2193 1801
J9 SPRINGERPLUS
JI SpringerPlus
PD FEB 3
PY 2015
VL 4
AR 59
DI 10.1186/s40064 015 0848 3
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CO4UO
UT WOS:000359156400007
PM 25664231
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Feng, ZP
   Deng, HC
   Du, J
   Chen, DY
   Jiang, R
   Liang, XY
AF Feng, Zhengping
   Deng, Huacong
   Du, Jia
   Chen, Danyan
   Jiang, Rong
   Liang, Xiaoyan
TI Lentiviral mediated RNAi targeting p38MAPK ameliorates high
   glucose induced apoptosis in osteoblast MC3T3 E1 cell line
SO INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY
LA English
DT Article
DE Apoptosis; High glucose; Lentivirus; p38MAPK; MC3T3 E1 cell line; RNA
   interference
ID ACTIVATED PROTEIN KINASE; GLYCATION END PRODUCTS; BONE MINERAL DENSITY;
   P38 MAPK; PHOSPHORYLATION; OSTEOPOROSIS; INVOLVEMENT; INHIBITION;
   FRACTURES; PATHWAYS
AB The p38 mitogen activated protein kinase (p38MAPK) pathway is an important signaling cascade involved in cell growth, differentiation and apoptosis. High glucose activates p38MAPK pathway in different cells, including osteoblasts. In the present study, role of p38MAPK in high glucose induced osteoblast apoptosis and potential of RNA interference (RNAi) targeting p38MAPK as a therapy strategy have been reported. Lentiviral mediated RNAi effectively reduced p38MAPK and p p38MAPK expressions in osteoblastic cell line (MC3T3 E1) following high glucose (22 mM) induction. Inhibition of p38MAPK activity significantly suppressed high glucose induced apoptosis of MC3T3 E1 cell and was confirmed by flow cytometry and ultra structural examination by transmission electronic microscope. Inhibition of p38MAPK also significantly attenuates caspase 3 and bax protein expressions, but increased significantly bcl 2 expression as determined by Western blot analysis. The results suggested that p38MAPK mediates high glucose induced osteoblast apoptosis, partly through modulating the expressions of caspase 3, bax and bcl 2. Inhibition of p38MAPK with lentiviral mediated RNAi or its specific inhibitor provides a new strategy to treat high glucose induced osteoblast apoptosis.
C1 [Feng, Zhengping; Deng, Huacong; Chen, Danyan] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrinol, Chongqing 400016, Peoples R China.
   [Du, Jia; Jiang, Rong; Liang, Xiaoyan] Chongqing Med Univ, Lab Stem Cell & Tissue Engn, Chongqin 400016, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University
RP Deng, HC (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrinol, Chongqing 400016, Peoples R China.
EM deng_huacong@yahoo.com.cn
RI liang, yan/JCE 5297 2023
FU National Natural Science Foundation of China [30570744, 30771038]
FX Financial assistance (NO: 30570744, 30771038) from National Natural
   Science Foundation of China is gratefully acknowledged.
CR Alikhani M, 2007, BONE, V40, P345, DOI 10.1016/j.bone.2006.09.011
   ANGELA M, 2004, REV ENDOCR METAB DIS, V5, P261
   [Anonymous], 2001, SOUTH MED J, V94, P569, DOI DOI 10.1097/00007611 200106000 00005
   Brixen KT, 2004, BASIC CLIN PHARMACOL, V94, P260
   Busik JV, 2002, INVEST OPHTH VIS SCI, V43, P2356
   Chae HJ, 2001, IMMUNOPHARM IMMUNOT, V23, P133, DOI 10.1081/IPH 100103855
   Chou CT, 2007, TOXICOL APPL PHARM, V218, P265, DOI 10.1016/j.taap.2006.11.012
   Du YP, 2010, INVEST OPHTH VIS SCI, V51, P2158, DOI 10.1167/iovs.09 3674
   Dufour C, 2008, AM J PHYSIOL ENDOC M, V294, pE794, DOI 10.1152/ajpendo.00791.2007
   Gronowicz GA, 2004, BONE, V35, P621, DOI 10.1016/j.bone.2004.05.005
   Haÿ E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200
   He HB, 2004, ENDOCRINOLOGY, V145, P447, DOI 10.1210/en.2003 1239
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Hsu SS, 2007, TOXICOLOGY, V231, P21, DOI 10.1016/j.tox.2006.11.005
   Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326
   Kanazawa I, 2009, CALCIFIED TISSUE INT, V85, P228, DOI 10.1007/s00223 009 9272 4
   Kuki S, 2006, CIRC J, V70, P1076, DOI 10.1253/circj.70.1076
   Larsen KI, 2002, J CELL BIOCHEM, V87, P75, DOI 10.1002/jcb.10252
   Li YM, 2007, BIOCHEM BIOPH RES CO, V363, P209, DOI 10.1016/j.bbrc.2007.08.161
   Nakagami H, 2001, DIABETES, V50, P1472, DOI 10.2337/diabetes.50.6.1472
   Nicodemus KK, 2001, DIABETES CARE, V24, P1192, DOI 10.2337/diacare.24.7.1192
   Qi JS, 2008, J ENDOCRINOL INVEST, V31, P314, DOI 10.1007/BF03346364
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rane MJ, 2010, AM J PHYSIOL RENAL, V298, pF49, DOI 10.1152/ajprenal.00032.2009
   Riad A, 2007, EUR J PHARMACOL, V554, P40, DOI 10.1016/j.ejphar.2006.08.065
   Schwartz AV, 2001, J CLIN ENDOCR METAB, V86, P32, DOI 10.1210/jc.86.1.32
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   SUE AB, 2004, CLIN DIABETES, V22
   Turner B., 2009, US Pharmacist, V34, P14
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Gangoiti MV, 2008, EUR J PHARMACOL, V600, P140, DOI 10.1016/j.ejphar.2008.10.031
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Wiren KM, 2006, BONE, V38, P637, DOI 10.1016/j.bone.2005.10.029
   YOON JH, 2003, KOREAN J ORTHOD, V33, P169
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774 008 0019 5
   Zayzafoon M, 2002, J BIOL CHEM, V277, P37212, DOI 10.1074/jbc.M200129200
   Zhen DH, 2010, J DIABETES COMPLICAT, V24, P334, DOI 10.1016/j.jdiacomp.2009.05.002
NR 37
TC 8
Z9 14
U1 0
U2 9
PU NATL INST SCIENCE COMMUNICATION NISCAIR
PI NEW DELHI
PA DR K S KRISHNAN MARG, PUSA CAMPUS, NEW DELHI 110 012, INDIA
SN 0019 5189
EI 0975 1009
J9 INDIAN J EXP BIOL
JI Indian J. Exp. Biol.
PD FEB
PY 2011
VL 49
IS 2
BP 94
EP 104
PG 11
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA 719RK
UT WOS:000287226400002
PM 21428210
DA 2025 08 17
ER

PT J
AU Morita, T
   Shima, Y
   Fujimoto, K
   Tsuboi, H
   Saeki, Y
   Narazaki, M
   Ogata, A
   Kumanogoh, A
AF Morita, Takayoshi
   Shima, Yoshihito
   Fujimoto, Kosuke
   Tsuboi, Hideki
   Saeki, Yukihiko
   Narazaki, Masashi
   Ogata, Atsushi
   Kumanogoh, Atsushi
TI Anti receptor activator of nuclear factor κB ligand antibody treatment
   increases osteoclastogenesis promoting IL 8 in patients with rheumatoid
   arthritis
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
DE denosumab; FK506; osteoclast like cells; osteoimmunology RANKL
ID MOLECULAR MECHANISM; INTERLEUKIN 8 GENE; CYTOKINE LEVELS; DOUBLE BLIND;
   BONE; TACROLIMUS; PREVENTION; OSTEOLYSIS; DENOSUMAB; THERAPY
AB The receptor activator of nuclear factor kappa B ligand (RANKL) is an important factor for osteoclastogenesis and contributes to the pathology of rheumatoid arthritis (RA); thus, the anti RANKL antibody (Ab) has been expected to protect joint destruction in RA patients. IL 8 also has osteoclastogenic activity; however, the role of IL 8 in the bone pathology of RA as well as the relation between IL 8 and RANKL remain unclear. In the present study, clinical observation revealed serum IL 8 levels of 611 pg ml( 1) in RA patients with anti RANKL Ab and 266 pg ml( 1) in the same patients without anti RANKL Ab. In vitro assay showed that anti RANKL Ab induced production of IL 8 from pre osteoclast like cells (OCLs), and IL 8 promoted the formation of OCLs from peripheral monocytes even without RANKL activity. We further showed that treatment with FK506 (tacrolimus) possibly inhibits the increase in IL 8 levels in RA patients with anti RANKL Ab, and in vitro assay confirmed that FK506 suppressed IL 8 production in pre OCLs. These results suggest that inhibition of RANKL induces the change in osteoclastogenesis promoting factor from RANKL to IL 8, and FK506 may be a valuable combination drug to support the use of anti RANKL Ab in treatment of RA.
C1 [Morita, Takayoshi; Shima, Yoshihito; Fujimoto, Kosuke; Narazaki, Masashi; Ogata, Atsushi; Kumanogoh, Atsushi] Osaka Univ, Dept Resp Med & Clin Immunol, Grad Sch Med, 2 2 Yamadaoka, Suita, Osaka 5650871, Japan.
   [Morita, Takayoshi; Kumanogoh, Atsushi] World Premier Int Immunol Frontier Res Ctr, Lab Lmmunopathol, Suita, Osaka 5650871, Japan.
   [Fujimoto, Kosuke] Osaka City Univ, Dept Immunol & Genom, Grad Sch Med, Suita, Osaka 5450051, Japan.
   [Fujimoto, Kosuke] Univ Tokyo, Int Res & Dev Ctr Mucosal Vaccines, Inst Med Sci, Div Innate Immune Regulat,Minato Ku, Tokyo 1080071, Japan.
   [Tsuboi, Hideki] Osaka Rosai Hosp, Dept Orthoped Surg, Sakai, Osaka 5918025, Japan.
   [Tsuboi, Hideki; Saeki, Yukihiko] Natl Hosp Org Osaka Minami Med Ctr, Dept Clin Res, Kawachi Nagano, Osaka 5868521, Japan.
   [Ogata, Atsushi] NTT West Osaka Hosp, Div Allergy Rheumatol & Connect Tissue Dis, Osaka, Osaka 5438922, Japan.
C3 University of Osaka; Osaka Metropolitan University; University of Tokyo;
   Osaka Rosai Hospital
RP Shima, Y (通讯作者)，Osaka Univ, Dept Resp Med & Clin Immunol, Grad Sch Med, 2 2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM ryanjin@imed3.med.osaka u.ac.jp
RI Kumanogoh, Atsushi/C 7354 2009; Morita, Takayoshi/AAW 2706 2021
OI Ogata, Atsushi/0000 0003 3944 3442; 
FU Japan Society for the Promotion of Science (JSPS) KAKENHI [JP18H05282];
   Japan Agency for Medical Research and Development (AMED) [JP18cm016335,
   JP18cm059042]
FX This work was supported by the Japan Society for the Promotion of
   Science (JSPS) KAKENHI (JP18H05282 to AK), the Japan Agency for Medical
   Research and Development (AMED) (JP18cm016335 and JP18cm059042 to AK).
CR ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   de Ciriza CP., 2015, BIOCH PHYSL, V4, P179, DOI DOI 10.4172/2168 9652.1000179
   Dutta S, 2011, THER ADV MUSCULOSKEL, V3, P283, DOI 10.1177/1759720X11419038
   Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802
   Hidaka T, 2001, J CLIN APHERESIS, V16, P74, DOI 10.1002/jca.1016
   Kamalakar A, 2014, BONE, V61, P176, DOI 10.1016/j.bone.2014.01.015
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Kawai S, 2006, J RHEUMATOL, V33, P2153
   Klimiuk PA, 2011, RHEUMATOL INT, V31, P457, DOI 10.1007/s00296 009 1299 3
   Klintmalm G., 1994, TRANSPLANT REV, V8, P53, DOI 10.1016/S0955 470X(05)80015 1
   Krishnamurthy A, 2016, ANN RHEUM DIS, V75, P721, DOI 10.1136/annrheumdis 2015 208093
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Miyasaka N, 2011, INFLAMM REGEN, V31, P25
   Miyazaki M, 2007, CLIN RHEUMATOL, V26, P231, DOI 10.1007/s10067 006 0287 1
   MUKAIDA N, 1990, J BIOL CHEM, V265, P21128
   Mukaida N, 2003, AM J PHYSIOL LUNG C, V284, pL566, DOI 10.1152/ajplung.00233.2002
   MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Namba S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182923
   Nishimoto N, 2000, ANN RHEUM DIS, V59, P21, DOI 10.1136/ard.59.suppl_1.i21
   Okamoto K, 2011, INT IMMUNOPHARMACOL, V11, P543, DOI 10.1016/j.intimp.2010.11.010
   Osiri M, 2016, CLIN RHEUMATOL, V35, P1673, DOI 10.1007/s10067 016 3306 x
   Russo RC, 2014, EXPERT REV CLIN IMMU, V10, P593, DOI 10.1586/1744666X.2014.894886
   Secchiero P, 2006, J CELL PHYSIOL, V207, P158, DOI 10.1002/jcp.20547
   Shimamura M, 2014, P NATL ACAD SCI USA, V111, P8191, DOI 10.1073/pnas.1400544111
   Steger Guenther G, 2011, Ther Adv Med Oncol, V3, P233, DOI 10.1177/1758834011412656
   Tanaka S, 2013, WORLD J ORTHOP, V4, P1, DOI 10.5312/wjo.v4.i1.1
   Tanaka Y, 2013, MOD RHEUMATOL, V23, P1045, DOI [10.3109/s10165 012 0817 4, 10.1007/s10165 012 0817 4]
   Trevino JG, 2005, CANCER RES, V65, P7214, DOI 10.1158/0008 5472.CAN 04 3858
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233
NR 35
TC 14
Z9 14
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0953 8178
EI 1460 2377
J9 INT IMMUNOL
JI Int. Immunol.
PD MAY
PY 2019
VL 31
IS 5
BP 277
EP 285
DI 10.1093/intimm/dxz009
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA JE1TD
UT WOS:000490477700001
PM 30753461
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Zhang, BS
   Zhao, JZ
   Yan, HJ
   Zhao, YF
   Tian, H
   Wang, C
   Wang, RQ
   Jin, JM
   Chen, Y
   Yang, CF
   Li, CF
   Jiao, YW
   Zheng, KP
   Zhu, FX
   Tian, WM
AF Zhang, Bongsong
   Zhao, Juzhi
   Yan, Hongji
   Zhao, Yufang
   Tian, Hui
   Wang, Cao
   Wang, Ruiqi
   Jin, Jiaming
   Chen, Yue
   Yang, Chaofan
   Li, Chunfeng
   Jiao, Yanwen
   Zheng, Kaipeng
   Zhu, Fuxing
   Tian, Weiming
TI A novel nano delivery system targeting different stages of osteoclasts
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID BONE RESORPTION; CALCITONIN RECEPTOR; HYALURONAN; OSTEOPOROSIS;
   NANOPARTICLE; PEPTIDE; EXPRESSION; FRACTURES; PROTEIN; CELLS
AB Osteoclast (OC) abnormalities represent osteoporosis's critical mechanism (OP). OCs undergo multiple processes that range from monocytic to functional. Different drugs target OCs at different developmental stages; however, almost no Suitable drug targeted delivery systems exist. Therefore, we designed two dual targeting nanoparticles to target OCs at different functional stages. Using the calcitonin gene related peptide receptor (CGRPR), which OC precursors highly express, and specific TRAPpeptides screened in the bone resorption lacuna, where mature OCs function, respectively, two types of dual targeted nanoparticles were constructed. Afterwards, nanoparticles were grafted with hyaluronic acid (HA), which specifically binds to CD44 on the surface of the OCs. In vivo and in vitro experiments show that both nanoparticles have noticeable targeting effects on OCs. This suggests that dual targeting nanoparticles designed for different functional periods of OC can be well targeted to the corresponding OC, and further promote the more precise delivery of drugs used to treat OP.
C1 [Zhang, Bongsong; Zhao, Juzhi; Zhao, Yufang; Tian, Hui; Wang, Cao; Wang, Ruiqi; Jin, Jiaming; Chen, Yue; Yang, Chaofan; Li, Chunfeng; Jiao, Yanwen; Zheng, Kaipeng; Zhu, Fuxing; Tian, Weiming] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150080, Peoples R China.
   [Yan, Hongji] AlbaNova Univ Ctr, Sch Engn Sci Chem Biotechnol & Hlth, Royal Inst Technol, Div Glycosci,Dept Chem,ETH, S 10691 Stockholm, Sweden.
   [Yan, Hongji] Karolinska Inst, AIMES Ctr Adv Integrated Med & Engn Sci, Stockholm, Sweden.
   [Yan, Hongji] KTH Royal Inst Technol, Stockholm, Sweden.
   [Yan, Hongji] Karolinska Inst, Dept Neurosci, SE 17177 Stockholm, Sweden.
   [Zhao, Yufang] Harbin Inst Technol, Lab Space Environm & Phys Sci, Harbin 150080, Peoples R China.
C3 Harbin Institute of Technology; Royal Institute of Technology;
   Karolinska Institutet; Royal Institute of Technology; Karolinska
   Institutet; Harbin Institute of Technology
RP Tian, WM (通讯作者)，Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150080, Peoples R China.
EM tianweiming@hit.edu.cn
RI Li, Chunfeng/ABD 8502 2020; Tian, Weiming/AGY 1338 2022; Yan,
   Hongji/GWC 1169 2022; Yang, Chaofan/AAY 4503 2021
OI Wang, Ruiqi/0000 0002 8025 7089; /0000 0001 7257 5522; Tian,
   Weiming/0000 0003 4958 4118; Zhang, Bosong/0000 0001 8712 6906
FU National Natural Science Foundation of China [51773050, 81770923]
FX This research is supported by the National Natural Science Foundation of
   China (grants 51773050 and 81770923). English language editing of this
   Article was provided by Journal Prep.
CR Ariyoshi W, 2014, OSTEOARTHR CARTILAGE, V22, P111, DOI 10.1016/j.joca.2013.10.013
   Bilecen DS, 2017, J BIOMAT SCI POLYM E, V28, P1859, DOI 10.1080/09205063.2017.1354675
   Boll H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025692
   Bono P, 2001, MOL BIOL CELL, V12, P891, DOI 10.1091/mbc.12.4.891
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cai MX, 2017, INT J NANOMED, V12, P7469, DOI 10.2147/IJN.S139775
   Chen C, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0605 5
   Chen Q, 2016, ADV COLLOID INTERFAC, V233, P94, DOI 10.1016/j.cis.2015.10.004
   Collin Osdoby P, 2003, METH MOLEC MED, V80, P153
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   de la Rosa JMR, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601012
   Dong W., 2005, ADV DRUG DELIVER REV, V57, P1049
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   ERIKSEN EF, 1984, METAB BONE DIS RELAT, V5, P235, DOI 10.1016/0221 8747(84)90065 1
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Fatisson J, 2011, BIOSENS BIOELECTRON, V26, P3207, DOI 10.1016/j.bios.2010.12.027
   Gramoun A, 2007, J CELL BIOCHEM, V102, P341, DOI 10.1002/jcb.21296
   Granholm S, 2008, J CELL BIOCHEM, V104, P920, DOI 10.1002/jcb.21674
   Granholm S, 2011, J CELL BIOCHEM, V112, P3300, DOI 10.1002/jcb.23256
   Guzmán E, 2011, ACS APPL MATER INTER, V3, P3181, DOI 10.1021/am200671m
   Huang L, 2000, J BIOL CHEM, V275, P29829, DOI 10.1074/jbc.M002737200
   Huang L, 2018, BIOMATERIALS, V182, P58, DOI 10.1016/j.biomaterials.2018.07.046
   Husheem M, 2005, CALCIFIED TISSUE INT, V76, P222, DOI 10.1007/s00223 004 0123 z
   Kanis JA, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0144 1
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Le Pape F, 2016, J BONE ONCOL, V5, P93, DOI 10.1016/j.jbo.2016.02.008
   Lee CW, 2014, BIOCHEM BIOPH RES CO, V449, P438, DOI 10.1016/j.bbrc.2014.05.050
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   MARKS SC, 1981, AM J ANAT, V161, P1, DOI 10.1002/aja.1001610102
   Matsubara T, 2017, BIOCHEM BIOPH RES CO, V489, P472, DOI 10.1016/j.bbrc.2017.05.174
   Peruzzi B, 2012, CLIN REV BONE MINER, V10, P71, DOI 10.1007/s12018 011 9086 6
   Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Ruggiero SL, 2009, AUST ENDOD J, V35, P119, DOI 10.1111/j.1747 4477.2009.00213.x
   Sheu T.J., 2010, J BONE MINER RES, V17, P922
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Suzuki K, 2005, J HISTOCHEM CYTOCHEM, V53, P1525, DOI 10.1369/jhc.5A6630.2005
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teitelbaum SL, 1997, J LEUKOCYTE BIOL, V61, P381, DOI 10.1002/jlb.61.4.381
   Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858
   Wang YT, 2017, BIOMATERIALS, V114, P97, DOI 10.1016/j.biomaterials.2016.11.010
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Xu HX, 2020, EXP HEMATOL ONCOL, V9, DOI 10.1186/s40164 020 00192 0
   Xu XY, 2012, MOL MED REP, V6, P409, DOI 10.3892/mmr.2012.908
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200
NR 48
TC 13
Z9 15
U1 2
U2 45
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PD MAR 29
PY 2022
VL 10
IS 7
BP 1821
EP 1830
DI 10.1039/d2bm00076h
EA FEB 2022
PG 10
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 0A6JS
UT WOS:000764257000001
PM 35244664
DA 2025 08 17
ER

PT J
AU Marzinzik, AL
   Amstutz, R
   Bold, G
   Bourgier, E
   Cotesta, S
   Glickman, JF
   Götte, M
   Henry, C
   Lehmann, S
   Hartwieg, JCD
   Ofner, S
   Pellé, X
   Roddy, TP
   Rondeau, JM
   Stauffer, F
   Stout, SJ
   Widmer, A
   Zimmermann, J
   Zoller, T
   Jahnke, W
AF Marzinzik, Andreas L.
   Amstutz, Rene
   Bold, Guido
   Bourgier, Emmanuelle
   Cotesta, Simona
   Glickman, J. Fraser
   Goette, Marjo
   Henry, Christelle
   Lehmann, Sylvie
   Hartwieg, J. Constanze D.
   Ofner, Silvio
   Pelle, Xavier
   Roddy, Thomas P.
   Rondeau, Jean Michel
   Stauffer, Frederic
   Stout, Steven J.
   Widmer, Armin
   Zimmermann, Johann
   Zoller, Thomas
   Jahnke, Wolfgang
TI Discovery of Novel Allosteric Non Bisphosphonate Inhibitors of Farnesyl
   Pyrophosphate Synthase by Integrated Lead Finding
SO CHEMMEDCHEM
LA English
DT Article
DE allosteric inhibitors; antitumor agents; anti infective drug discovery;
   FPPS; immunomodulation; immunotherapy
ID NITROGEN CONTAINING BISPHOSPHONATES; ZOLEDRONIC ACID; FPPS INHIBITORS;
   STATINS; DRUGS; AMINOBISPHOSPHONATES; DERIVATIVES; MECHANISMS; EFFICACY;
   ANALOGS
AB Farnesyl pyrophosphate synthase (FPPS) is an established target for the treatment of bone diseases, but also shows promise as an anticancer and anti infective drug target. Currently available anti FPPS drugs are active site directed bisphosphonate inhibitors, the peculiar pharmacological profile of which is inadequate for therapeutic indications beyond bone diseases. The recent discovery of an allosteric binding site has paved the way toward the development of novel non bisphosphonate FPPS inhibitors with broader therapeutic potential, notably as immunomodulators in oncology. Herein we report the discovery, by an integrated lead finding approach, of two new chemical classes of allosteric FPPS inhibitors that belong to the salicylic acid and quinoline chemotypes. We present their synthesis, biochemical and cellular activities, structure activity relationships, and provide X ray structures of several representative FPPS complexes. These novel allosteric FPPS inhibitors are devoid of any affinity for bone mineral and could serve as leads to evaluate their potential in none bone diseases.
C1 [Marzinzik, Andreas L.; Amstutz, Rene; Bold, Guido; Bourgier, Emmanuelle; Cotesta, Simona; Glickman, J. Fraser; Goette, Marjo; Henry, Christelle; Lehmann, Sylvie; Hartwieg, J. Constanze D.; Ofner, Silvio; Pelle, Xavier; Roddy, Thomas P.; Rondeau, Jean Michel; Stauffer, Frederic; Stout, Steven J.; Widmer, Armin; Zimmermann, Johann; Zoller, Thomas; Jahnke, Wolfgang] Novartis Inst BioMed Res, CH 4002 Basel, Switzerland.
C3 Novartis
RP Marzinzik, AL (通讯作者)，Novartis Inst BioMed Res, CH 4002 Basel, Switzerland.
EM andreas.marzinzik@novartis.com; wolfgang.jahnke@novartis.com
RI Glickman, Joseph/H 3021 2013
OI Glickman, Joseph/0000 0002 6706 4039
CR Ballatore C, 2013, CHEMMEDCHEM, V8, P385, DOI 10.1002/cmdc.201200585
   Berenson James R, 2011, Curr Opin Support Palliat Care, V5, P233, DOI 10.1097/SPC.0b013e328349dc17
   Cottet F, 2003, EUR J ORG CHEM, V2003, P1559
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   De Schutter JW, 2014, J MED CHEM, V57, P5764, DOI 10.1021/jm500629e
   Docampo Roberto, 2001, Current Drug Targets   Infectious Disorders, V1, P51, DOI 10.2174/1568005013343191
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Glickman JF, 2007, ASSAY DRUG DEV TECHN, V5, P205, DOI 10.1089/adt.2007.057
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Harada H, 2001, BIOORGAN MED CHEM, V9, P2709, DOI 10.1016/S0968 0896(01)00201 2
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   Jahnke W., 2015, ANGEW CHEM, V127, P14783, DOI DOI 10.1002/ANGE.201507064
   Jahnke W, 2015, ANGEW CHEM INT EDIT, V54, P14575, DOI 10.1002/anie.201507064
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kesselheim AS, 2013, NAT REV DRUG DISCOV, V12, P425, DOI 10.1038/nrd3977
   Koul HK, 2012, PROSTATE CANCER P D, V15, P111, DOI 10.1038/pcan.2011.41
   LECLERC G, 1986, J MED CHEM, V29, P2433, DOI 10.1021/jm00162a003
   Lin YS, 2012, J MED CHEM, V55, P3201, DOI 10.1021/jm201657x
   Lindert S, 2013, CHEM BIOL DRUG DES, V81, P742, DOI 10.1111/cbdd.12121
   Liu JG, 2014, BBA GEN SUBJECTS, V1840, P1051, DOI 10.1016/j.bbagen.2013.11.006
   Liu YL, 2015, ACS MED CHEM LETT, V6, P349, DOI 10.1021/ml500528x
   Maag H, 2007, BIOTECHNOL PHARM ASP, V5, P3
   Marma MS, 2007, J MED CHEM, V50, P5967, DOI 10.1021/jm0702884
   Morgan G, 2010, SEMIN ONCOL, V37, pS30, DOI 10.1053/j.seminoncol.2010.10.005
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Santini D, 2010, CURR CANCER DRUG TAR, V10, P46, DOI 10.2174/156800910790980223
   Schmidberger JW, 2015, ACTA CRYSTALLOGR D, V71, P721, DOI 10.1107/S1399004715001121
   Simonen M, 2008, J BIOMOL SCREEN, V13, P456, DOI 10.1177/1087057108318757
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   Varela I, 2008, NAT MED, V14, P767, DOI 10.1038/nm1786
   Wang XY, 2007, CELL HOST MICROBE, V2, P96, DOI 10.1016/j.chom.2007.06.009
   Zhang Y., 2010, ANGEW CHEM, V122, P1154
   Zhang YH, 2010, ANGEW CHEM INT EDIT, V49, P1136, DOI 10.1002/anie.200905933
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 39
TC 24
Z9 28
U1 0
U2 20
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860 7179
EI 1860 7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD NOV
PY 2015
VL 10
IS 11
BP 1884
EP 1891
DI 10.1002/cmdc.201500338
PG 8
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA CU8FS
UT WOS:000363777500011
PM 26381451
DA 2025 08 17
ER

PT J
AU Zhang, FX
   Tang, ZL
   Qiu, ZC
AF Zhang, Feng xiang
   Tang, Zi ling
   Qiu, Zuo cheng
TI A novel strategy for exploring food originated anti adipogenesis
   substances and mechanism by structural similarity evaluation, ADME
   prediction, network pharmacology and experimental validation
SO FOOD & FUNCTION
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; BONE LOSS; GENISTEIN; PHYTOESTROGENS;
   DATABASE; ALLICIN; CELLS
AB Screening potential functional substances based on active compounds is still a challenge faced by researchers since hundreds and thousands of possible compounds exist in natural products (food, herb, etc.). In this study, an integrated strategy by a combination of structural similarity evaluation, ADME (absorption, distribution, metabolism, excretion) prediction, network pharmacology and experimental validation (SANE strategy) was proposed and applied to explore anti adipogenesis substances. This strategy was divided into four parts: first, potential compounds were screened based on representative active compounds by similarity evaluation and ADME prediction. Second, the activity of targeted compounds was evaluated in vitro based on the molecular biology method. Third, network pharmacology was used to explore potential targets and pathways. Last, the core pharmacological mechanism was confirmed by modern pharmacology methods. As a result, 8 prenylgenistein (8PG) was screened with chemical structure similarity with genistein and improved ADME propriety. Meanwhile, 8PG was found to present significant anti adipogenesis effects in pre adipocyte 3T3 L1 cells and primary human bone marrow stromal cells (hBMSC). Through using methods including: chemical staining, functional assays, and Real time PCR, 8PG was found to present more potency than genistein in suppressing the adipocyte differentiation. Further, the potential pharmacological mechanism was predicted, and significant effects of 8PG on activating the Wnt/beta catenin pathway in 3T3 L1 cells and hBMSC were confirmed by immunoblotting in the absence/presence of signaling pathway blocker and immunofluorescence staining. A new insight for exploring more potent compounds based on accurate effect compounds is provided in our work. Moreover, a potential compound (8PG), suppressing adipogenesis, was also supplied.
C1 [Zhang, Feng xiang; Tang, Zi ling; Qiu, Zuo cheng] Jinan Univ, Guangzhou Key Lab Formula Pattern Tradit Chinese, Formula Pattern Res Ctr, Sch Tradit Chinese Med, Guangzhou 510632, Peoples R China.
   [Zhang, Feng xiang] Jinan Univ, Affiliated Hosp 1, Dept Gynaecol & Obstet, Guangzhou 510632, Peoples R China.
C3 Jinan University; Jinan University
RP Qiu, ZC (通讯作者)，Jinan Univ, Guangzhou Key Lab Formula Pattern Tradit Chinese, Formula Pattern Res Ctr, Sch Tradit Chinese Med, Guangzhou 510632, Peoples R China.
EM zcqiu@jnu.edu.cn
RI ; zhang, fengxiang/AAA 3869 2021
OI zhang, fengxiang/0000 0003 1255 4222; Qiu,
   Zuo cheng/0000 0002 9161 5435; Tang, Ziling/0000 0002 0635 1931
FU National Natural Science Foundation of China [81903618]; Guangzhou Basic
   and Applied Basic Research Foundation [202102021160]; Huang Zhendong
   Research Fund for Traditional Chinese Medicine of Jinan University
FX This work was supported by National Natural Science Foundation of China
   (81903618), Guangzhou Basic and Applied Basic Research Foundation
   (202102021160), and Huang Zhendong Research Fund for Traditional Chinese
   Medicine of Jinan University.
CR Al Maharik N, 2003, TETRAHEDRON, V59, P4177, DOI 10.1016/S0040 4020(03)00579 9
   Ashley EA, 2018, LANCET, V391, P1608, DOI 10.1016/S0140 6736(18)30324 6
   Atmaca A, 2008, MENOPAUSE, V15, P748, DOI 10.1097/gme.0b013e31815c1e7f
   Dai JJ, 2020, GENE, V762, DOI 10.1016/j.gene.2020.145042
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Fanti P, 1998, OSTEOPOROSIS INT, V8, P274, DOI 10.1007/s001980050065
   Heim M, 2004, ENDOCRINOLOGY, V145, P848, DOI 10.1210/en.2003 1014
   Hellman K, 2020, ACS CHEM NEUROSCI, V11, P173, DOI 10.1021/acschemneuro.9b00524
   Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415
   Jenkins J. L., 2006, Drug Discov. Today Technol, V3, P413, DOI [10.1016/j.ddtec.2006.12.008. 5.2, DOI 10.1016/J.DDTEC.2006.12.008.5.2, 10.1016/j.ddtec.2006.12.008, DOI 10.1016/J.DDTEC.2006.12.008]
   Kanno S, 2004, TOXICOLOGY, V196, P137, DOI 10.1016/j.tox.2003.12.002
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lucas AJ, 2019, EXPERT OPIN DRUG DIS, V14, P1313, DOI 10.1080/17460441.2019.1660642
   MELTON LJ, 1995, J BONE MINER RES, V10, P175
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Narod SA, 2011, NAT REV CLIN ONCOL, V8, P669, DOI 10.1038/nrclinonc.2011.110
   Pinzi L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184331
   Poulsen RC, 2008, NUTR REV, V66, P359, DOI 10.1111/j.1753 4887.2008.00046.x
   ROSS SE, 2000, SCIENCE, V289, P950, DOI DOI 10.1126/SCIENCE.289.5481.950
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sidders B, 2018, J MOL BIOL, V430, P3005, DOI 10.1016/j.jmb.2018.07.016
   Sisask G, 2013, BONE, V54, P126, DOI 10.1016/j.bone.2013.01.019
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Szkudelska K, 2000, J STEROID BIOCHEM, V75, P265, DOI 10.1016/S0960 0760(00)00172 2
   Yu F, 2015, GENE, V573, P273, DOI 10.1016/j.gene.2015.07.054
   Zainal M, 2021, SAUDI DENT J, V33, P105, DOI 10.1016/j.sdentj.2020.01.008
   Zhang FX, 2020, RSC ADV, V10, P34847, DOI 10.1039/d0ra06382g
   Zhang M, 2009, PHYTOTHER RES, V23, P713, DOI 10.1002/ptr.2724
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhang Y., 2018, ONCOTARGET, V9
   Zhang Y, 2008, ARCH PHARM RES, V31, P1534, DOI 10.1007/s12272 001 2147 5
   Zhang Y, 2007, J ETHNOPHARMACOL, V109, P165, DOI 10.1016/j.jep.2006.07.005
   Zoete V, 2016, J CHEM INF MODEL, V56, P1399, DOI 10.1021/acs.jcim.6b00174
NR 38
TC 10
Z9 10
U1 3
U2 38
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042 6496
EI 2042 650X
J9 FOOD FUNCT
JI Food Funct.
PD AUG 7
PY 2021
VL 12
IS 15
BP 7081
EP 7091
DI 10.1039/d1fo01124c
EA MAY 2021
PG 11
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA TX5GO
UT WOS:000664238800001
PM 34156051
DA 2025 08 17
ER

PT J
AU Hu, JH
   Zhao, W
   Huang, YJ
   Wang, Z
   Jiang, TT
   Wang, L
AF Hu, Jinghui
   Zhao, Wei
   Huang, Yujie
   Wang, Zhe
   Jiang, Tingting
   Wang, Li
TI MiR 1180 from bone marrow MSCs promotes cell proliferation and
   glycolysis in ovarian cancer cells via SFRP1/Wnt pathway
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE miR 1180; Ovarian cancer; Cell proliferation; Glycolysis; SFRP1
ID STEM CELLS; HEPATOCELLULAR CARCINOMA; CISPLATIN RESISTANCE
AB BackgroundThe ovarian cancer microenvironment is responsible for cancer cell growth and disease relapse. Bone marrow mesenchymal stem cells (BM MSCs) play important roles in ovarian cancer, however, the mechanism of BM MSCs inducing cell proliferation and glycolysis needs further research.MethodsmiRNA array was used to analyze the significant miRNAs. RT qPCR was used to examine the level of miR 1180 and SFRP1. The western blotting was used to detect the protein level of SFRP1 and Wnt signal pathway. We utilized luciferase reporter assay to confirm the direct interaction of SFRP1 with miR 1180. MTT assay were employed to investigate the proliferation of ovarian cancer cells. ECAR, ATP assay were used to measure the glycolysis state of ovarian cancer cells.ResultsIt was demonstrated that BM MSCs promoted ovarian cancer cell proliferation and glycolysis. The miRNA profile from the BM MSCs indicated that miR 1180 was up regulated in the conditioned medium of BM MSCs. MiR 1180 could accelerate ovarian cancer cell proliferation and glycolysis. We also found that up regulation of miR 1180 activated Wnt signaling by targeting SFRP1 in ovarian cancer cells.ConclusionThe study demonstrated that miR 1180 was a critical miRNA mediating BM MSCs induced cell proliferation and glycolysis and could be a new target in ovarian cancer therapy.
C1 [Hu, Jinghui; Zhao, Wei; Huang, Yujie; Wang, Zhe; Jiang, Tingting] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Gynaecol, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
   [Wang, Li] Nanjing Med Univ, Changzhou Maternal & Child Hlth Care Hosp, Dept Obstet & Gynaecol, Changzhou, Peoples R China.
C3 Zhejiang University; Nanjing Medical University
RP Hu, JH (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Gynaecol, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM jinghui_hu@sohu.com
RI Huang, Yujie/HPB 5204 2023; Jiang, Tingting/MCK 2463 2025
FU First Affiliated Hospital, School of medicine, Zhejiang University,
   Hangzhou, China
FX The research was supported by The First Affiliated Hospital, School of
   medicine, Zhejiang University, Hangzhou, China.
CR [Anonymous], ONCOTARGET
   Castells M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.384
   Coffman LG, 2016, ONCOTARGET, V7, P6916, DOI 10.18632/oncotarget.6870
   Cooper SJ, 2012, MOL CANCER THER, V11, P2105, DOI 10.1158/1535 7163.MCT 11 0873
   Fang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9640
   Gauger KJ, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471 213X 12 25
   Ge QQ, 2017, HISTOL HISTOPATHOL, V32, P77, DOI 10.14670/HH 11 772
   Huang GL, 2017, CELL CYCLE, V16, P685, DOI 10.1080/15384101.2017.1295180
   Huang MX, 2017, CANCER LETT, V398, P12, DOI 10.1016/j.canlet.2017.03.038
   Huang RX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112209
   Lis R, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 59
   Lis R, 2011, INT J CANCER, V128, P715, DOI 10.1002/ijc.25619
   Mader EK, 2009, CLIN CANCER RES, V15, P7246, DOI 10.1158/1078 0432.CCR 09 1292
   McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273
   Pfankuchen DB, 2017, ONCOTARGET, V8, P67553, DOI 10.18632/oncotarget.18738
   Ridge SM, 2017, MOL CANCER, V16, DOI 10.1186/s12943 017 0597 8
   Sherwood V, 2014, CARCINOGENESIS, V35, P784, DOI 10.1093/carcin/bgt390
   Shikata Y, 2017, CANCER SCI, V108, P772, DOI 10.1111/cas.13172
   Tahir SA, 2013, CANCER RES, V73, P1900, DOI 10.1158/0008 5472.CAN 12 3040
   Tan GS, 2016, SCI REP UK, V6, DOI 10.1038/srep22328
   Touboul C, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 28
   Tyciakova S, 2015, J GENE MED, V17, P54, DOI 10.1002/jgm.2823
   Vallabhaneni KC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166027
   Vallée A, 2018, REV NEUROSCIENCE, V29, P71, DOI 10.1515/revneuro 2017 0032
   Wang WW, 2015, ONCOTARGET, V6, P42276, DOI 10.18632/oncotarget.5514
   Watts TL, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 1091 6
   Yang YY, 2015, STEM CELLS DEV, V24, P1205, DOI 10.1089/scd.2014.0413
   Zhou W, 2015, ONCOTARGET, V6, P37566
   Zhou X, 2016, BIOMED PHARMACOTHER, V79, P315, DOI 10.1016/j.biopha.2016.02.025
   Zhuang ZH, 2017, ONCOL REP, V38, P2051, DOI 10.3892/or.2017.5899
NR 30
TC 27
Z9 29
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475 2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD MAR 20
PY 2019
VL 19
AR 66
DI 10.1186/s12935 019 0751 z
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HQ3VT
UT WOS:000462339300005
PM 30936781
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sehring, I
   Mohammadi, HF
   Haffner Luntzer, M
   Ignatius, A
   Huber Lang, M
   Weidinger, G
AF Sehring, Ivonne
   Mohammadi, Hossein Falah
   Haffner Luntzer, Melanie
   Ignatius, Anita
   Huber Lang, Markus
   Weidinger, Gilbert
TI Zebrafish fin regeneration involves generic and regeneration specific
   osteoblast injury responses
SO ELIFE
LA English
DT Article
ID COMPLEMENT SYSTEM; C5A RECEPTOR; SKELETAL MINERALIZATION; 3RD COMPONENT;
   BONE; DEDIFFERENTIATION; HOMEOSTASIS; ACTIVATION; BLASTEMA; TISSUE
AB Successful regeneration requires the coordinated execution of multiple cellular responses to injury. In amputated zebrafish fins, mature osteoblasts dedifferentiate, migrate towards the injury, and form proliferative osteogenic blastema cells. We show that osteoblast migration is preceded by cell elongation and alignment along the proximodistal axis, which require actomyosin, but not microtubule (MT) turnover. Surprisingly, osteoblast dedifferentiation and migration can be uncoupled. Using pharmacological and genetic interventions, we found that NF kappa B and retinoic acid signalling regulate dedifferentiation without affecting migration, while the complement system and actomyosin dynamics affect migration but not dedifferentiation. Furthermore, by removing bone at two locations within a fin ray, we established an injury model containing two injury sites. We found that osteoblasts dedifferentiate at and migrate towards both sites, while accumulation of osteogenic progenitor cells and regenerative bone formation only occur at the distal facing injury. Together, these data indicate that osteoblast dedifferentiation and migration represent generic injury responses that are differentially regulated and can occur independently of each other and of regenerative growth. We conclude that successful fin bone regeneration appears to involve the coordinated execution of generic and regeneration specific responses of osteoblasts to injury.
C1 [Sehring, Ivonne; Mohammadi, Hossein Falah; Weidinger, Gilbert] Univ Ulm, Inst Biochem & Mol Biol, Ulm, Germany.
   [Haffner Luntzer, Melanie; Ignatius, Anita] Univ Hosp Ulm, Inst Orthopaed Res & Biomech, Ulm, Germany.
   [Huber Lang, Markus] Univ Hosp Ulm, Inst Clin & Expt Trauma Immunol ITI, Ulm, Germany.
C3 Ulm University; Ulm University; Ulm University
RP Sehring, I; Weidinger, G (通讯作者)，Univ Ulm, Inst Biochem & Mol Biol, Ulm, Germany.
EM Ivonne.sehring@uni ulm.de; gilbert.weidinger@uni ulm.de
RI Haffner Luntzer, Melanie/L 3562 2019; Ignatius, Anita/M 6012 2013;
   Huber Lang, Markus/AAJ 2209 2020; Weidinger, Gilbert/A 8342 2010
OI Ignatius, Anita/0000 0002 4782 1979; Sehring,
   Ivonne/0000 0002 7812 0278; Haffner Luntzer,
   Melanie/0000 0002 3333 2613; Weidinger, Gilbert/0000 0003 3599 6760
FU Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
   [251293561   SFB 1149, 316249678   SFB 1279, 450627322   SFB 1506];
   Deutsche Forschungsgemeinschaft [251293561   SFB 1149, 316249678   SFB
   1279, 450627322   SFB 1506]; Medical Faculty, Ulm University
FX Deutsche Forschungsgemeinschaft Project ID 251293561   SFB 1149 Gilbert
   WeidingerDeutsche Forschungsgemeinschaft project ID 316249678   SFB 1279
   Gilbert WeidingerDeutsche Forschungsgemeinschaft project ID 450627322  
   SFB 1506 Gilbert WeidingerMedical Faculty, Ulm University
   Hertha Nathorff Program Ivonne SehringThe funders had no role in study
   design, data collection and interpretation, or the decision to submit
   the work for publication.
CR Aleström P, 2020, LAB ANIM UK, V54, P213, DOI 10.1177/0023677219869037
   Ames RS, 2001, J IMMUNOL, V166, P6341, DOI 10.4049/jimmunol.166.10.6341
   Ando K, 2017, DEV CELL, V43, P643, DOI 10.1016/j.devcel.2017.10.015
   Ando R, 2002, P NATL ACAD SCI USA, V99, P12651, DOI 10.1073/pnas.202320599
   Apschner A, 2014, DIS MODEL MECH, V7, P811, DOI 10.1242/dmm.015693
   Arbore G, 2016, SCIENCE, V352, DOI 10.1126/science.aad1210
   Bensimon Brito A, 2016, BMC DEV BIOL, V16, DOI 10.1186/s12861 016 0102 4
   Blum N, 2015, DEVELOPMENT, V142, P2894, DOI 10.1242/dev.120204
   Boshra H, 2006, FISH SHELLFISH IMMUN, V20, P239, DOI 10.1016/j.fsi.2005.04.004
   BROWN SS, 1981, J CELL BIOL, V88, P487, DOI 10.1083/jcb.88.3.487
   BROWN SS, 1979, J CELL BIOL, V83, P657, DOI 10.1083/jcb.83.3.657
   Cao ZG, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2009539118
   Chablais F, 2010, DEVELOPMENT, V137, P871, DOI 10.1242/dev.043885
   Chen CH, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005437
   Chugh P, 2018, J CELL SCI, V131, DOI 10.1242/jcs.186254
   Daetwyler S, 2020, BIOL OPEN, V9, DOI 10.1242/bio.056200
   Del Rio Tsonis K, 1998, J IMMUNOL, V161, P6819
   Dirckx N, 2013, BIRTH DEFECTS RES C, V99, P170, DOI 10.1002/bdrc.21047
   Ehrnthaller C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081341
   Etienne Manneville S, 2013, ANNU REV CELL DEV BI, V29, P471, DOI 10.1146/annurev cellbio 101011 155711
   Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149
   Florian S, 2016, METHODS MOL BIOL, V1413, P403, DOI 10.1007/978 1 4939 3542 0_25
   Gemberling M, 2013, TRENDS GENET, V29, P611, DOI 10.1016/j.tig.2013.07.003
   Geurtzen K, 2014, DEVELOPMENT, V141, P2225, DOI 10.1242/dev.105817
   Huber Lang M, 2013, SEMIN IMMUNOL, V25, P73, DOI 10.1016/j.smim.2013.05.006
   Huitema LFA, 2012, P NATL ACAD SCI USA, V109, P21372, DOI 10.1073/pnas.1214231110
   Ignatius A, 2011, J TRAUMA, V71, P952, DOI 10.1097/TA.0b013e3181f8aa2d
   Ignatius A, 2011, J CELL BIOCHEM, V112, P2594, DOI 10.1002/jcb.23186
   Jain U, 2013, BRIT J PHARMACOL, V168, P488, DOI 10.1111/j.1476 5381.2012.02183.x
   Kimura Y, 2003, J IMMUNOL, V170, P2331, DOI 10.4049/jimmunol.170.5.2331
   Knopf F, 2011, DEV CELL, V20, P713, DOI 10.1016/j.devcel.2011.04.014
   Kovács M, 2004, J BIOL CHEM, V279, P35557, DOI 10.1074/jbc.M405319200
   Kujawski S, 2014, DEV CELL, V28, P573, DOI 10.1016/j.devcel.2014.01.019
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lee HJ, 2020, GENOME BIOL, V21, DOI 10.1186/s13059 020 1948 0
   Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018
   March DR, 2004, MOL PHARMACOL, V65, P868, DOI 10.1124/mol.65.4.868
   Marí Beffa M, 2010, DEV DYNAM, V239, P2779, DOI 10.1002/dvdy.22444
   Markiewski MM, 2004, J IMMUNOL, V173, P747, DOI 10.4049/jimmunol.173.2.747
   Mastellos D, 2002, TRENDS IMMUNOL, V23, P485, DOI 10.1016/S1471 4906(02)02287 1
   Mastellos D, 2001, J IMMUNOL, V166, P2479, DOI 10.4049/jimmunol.166.4.2479
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Mishra R, 2020, DEV CELL, V52, P167, DOI 10.1016/j.devcel.2019.11.016
   Natarajan N, 2018, CIRCULATION, V137, P2152, DOI 10.1161/CIRCULATIONAHA.117.030801
   Owlarn S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02338 x
   Petrie RJ, 2009, NAT REV MOL CELL BIO, V10, P538, DOI 10.1038/nrm2729
   Pfefferli C, 2015, REGENERATION, V2, P72, DOI 10.1002/reg2.33
   Poss KD, 2004, GENE DEV, V18, P1527, DOI 10.1101/gad.1182604
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Singh SP, 2012, DEV CELL, V22, P879, DOI 10.1016/j.devcel.2012.03.006
   Sousa S, 2011, DEVELOPMENT, V138, P3897, DOI 10.1242/dev.064717
   Stewart S, 2012, DEV BIOL, V365, P339, DOI 10.1016/j.ydbio.2012.02.031
   Sumichika H, 2002, J BIOL CHEM, V277, P49403, DOI 10.1074/jbc.M209672200
   Swaney KF, 2010, ANNU REV BIOPHYS, V39, P265, DOI 10.1146/annurev.biophys.093008.131228
   Thiel A, 2018, BIOL REV, V93, P350, DOI 10.1111/brv.12345
   Thorgersen EB, 2019, HEPATOLOGY, V70, P725, DOI 10.1002/hep.30508
   VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787
   Wurtzel O, 2015, DEV CELL, V35, P632, DOI 10.1016/j.devcel.2015.11.004
   Zhang SC, 2014, DEV COMP IMMUNOL, V46, P3, DOI 10.1016/j.dci.2014.01.010
NR 59
TC 12
Z9 15
U1 0
U2 10
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD JUN 24
PY 2022
VL 11
AR e77614
DI 10.7554/eLife.77614
PG 28
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA 3B7AX
UT WOS:000828090300001
PM 35748539
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Poon, M
   Zeng, L
   Zhang, LY
   Popovic, M
   Chow, R
   Lam, H
   Bedard, G
   Emmenegger, U
   Simmons, C
   Chow, E
AF Poon, Michael
   Zeng, Liang
   Zhang, Liying
   Popovic, Marko
   Chow, Ronald
   Lam, Henry
   Bedard, Gillian
   Emmenegger, Urban
   Simmons, Christine
   Chow, Edward
TI Skeletal morbidity rates over time in patients with bone metastases from
   solid tumors reported in bone modifying agents randomised trials
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Bisphosphonates; Bone metastases; Skeletal related events; Skeletal
   morbidity rates time trend
AB Objective: Skeletal related events (SREs) are common in patients with bone metastases and lead to decreased quality of life and functional status. The definition of an SRE has evolved over the years and now excludes hypercalcemia of malignancy due to its low incidence. The purpose of this review was to investigate if advances in bone targeted therapies have decreased skeletal morbidity rates (SMR) over time.
   Methods: A literature search was conducted in several databases to identify phase III results from bone targeted therapy trials from 1980 through September 2011. Graphs were created to document the trends of the natural log of SMR over the mean time of enrolment for all placebo and intervention arms. Statistical hypothesis testing was employed to account for confounding factors.
   Results: A total of 14 studies were identified which reported the SMR from phase III trials from 1990 to 2007. A statistically significant downward trend was observed in the placebo arms of trials over time; a similar trend was seen in all intervention arms. In a direct comparison of intervention against placebo arms, it was found that there was a significant decreasing time trend (p < 0.0001) and a significant departure in SMR from placebo to intervention arms (p = 0.0348). These results were seen even after accounting for the confounding factors of histology and differences in drugs.
   Conclusion: The decrease in SMR over time may not only be a result of advancements with bone targeted agents, but also due to better management and awareness of events associated with bone metastases. (C) 2012 Elsevier GmbH. All rights reserved.
C1 [Poon, Michael; Zeng, Liang; Zhang, Liying; Popovic, Marko; Chow, Ronald; Lam, Henry; Bedard, Gillian; Emmenegger, Urban; Chow, Edward] Univ Toronto, Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada.
   [Simmons, Christine] Univ Toronto, St Michaels Hosp, Toronto, ON M4N 3M5, Canada.
C3 University of Toronto; Sunnybrook Research Institute; Sunnybrook Health
   Science Center; University of Toronto; Saint Michaels Hospital Toronto
RP Chow, E (通讯作者)，Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Dept Radiat Oncol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM edward.chow@sunnybrook.ca
RI Chow, Ronald/V 3117 2019
OI Popovic, Marko/0000 0002 0370 5968
FU Bratty Family Fund; Michael and Karyn Goldstein Cancer Research Fund;
   Joseph and Silvana Melara Cancer Research Fund; Ofelia Cancer Research
   Fund
FX We thank the generous support of Bratty Family Fund, Michael and Karyn
   Goldstein Cancer Research Fund, Joseph and Silvana Melara Cancer
   Research Fund, and Ofelia Cancer Research Fund. We thank Dr. Kris Dennis
   for his comments.
CR Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   Bundred NJ, 2008, CANCER AM CANCER SOC, V112, P1001, DOI 10.1002/cncr.23259
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Dearnaley DP, 2003, J NATL CANCER I, V95, P1300, DOI 10.1093/jnci/djg038
   Delea T, 2004, ONCOLOGY BASEL, V67, P390, DOI 10.1159/000082923
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Higginson IJ, 2002, J PAIN SYMPTOM MANAG, V23, P96, DOI 10.1016/S0885 3924(01)00406 7
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Jagdev SP, 2001, ANN ONCOL, V12, P1433, DOI 10.1023/A:1012506426440
   Khan L, 2012, SUPPORT CARE CANCER, V20, P549, DOI 10.1007/s00520 011 1120 1
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Lagman R, 2005, SEMIN ONCOL, V32, P134, DOI 10.1053/j.seminoncol.2004.11.015
   Langer C, 2010, LUNG CANCER, V67, P4, DOI 10.1016/j.lungcan.2009.08.020
   Lipton A, 2004, CLIN CANCER RES, V10, p6397S, DOI 10.1158/1078 0432.CCR 040030
   Lipton A, 2003, CANCER, V98, P962, DOI 10.1002/cncr.11571
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Ristevski B, 2009, CAN J SURG, V52, P302
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Saad F, 2006, BJU INT, V97, P1351, DOI 10.1111/j.1464 410X.2006.06279_7.x
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2007, CLIN GENITOURIN CANC, V5, P390, DOI 10.3816/CGC.2007.n.022
   Saad F, 2010, UROLOGY, V76, P1175, DOI 10.1016/j.urology.2010.05.026
   Saad Fred, 2005, Clin Prostate Cancer, V4, P31, DOI 10.3816/CGC.2005.n.009
   Shiue K, 2010, EXPERT REV ANTICANC, V10, P697, DOI 10.1586/ERA.10.47
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Tripathy D, 2004, ANN ONCOL, V15, P743, DOI 10.1093/annonc/mdh173
   Zaghloul MS, 2010, INT J CLIN ONCOL, V15, P382, DOI 10.1007/s10147 010 0074 5
NR 36
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD DEC
PY 2012
VL 1
IS 3
BP 74
EP 80
DI 10.1016/j.jbo.2012.10.001
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA V37LL
UT WOS:000209277200003
PM 26909260
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wehrhan, F
   Moebius, P
   Amann, K
   Ries, J
   Preidl, R
   Neukam, FW
   Weber, M
AF Wehrhan, Falk
   Moebius, Patrick
   Amann, Kerstin
   Ries, Jutta
   Preidl, Raimund
   Neukam, Friedrich W.
   Weber, Manuel
TI Macrophage and osteoclast polarization in bisphosphonate associated
   necrosis and osteoradionecrosis
SO JOURNAL OF CRANIO MAXILLOFACIAL SURGERY
LA English
DT Article
DE Bisphosphonate associated osteonecrosis of the jaw; BRONJ;
   Osteoradionecrosis; ORN; Macrophage polarization; Osteoclast
   polarization
ID SQUAMOUS CELL CARCINOMAS; TUMOR ASSOCIATED MACROPHAGES; STAGE
   BREAST CANCER; ADIPOSE TISSUE; IN VIVO; OSTEONECROSIS; JAW; BONE;
   EXPRESSION; M2
AB Purpose: Bisphosphonate related osteonecrosis of the jaw (BRONJ) is a complication of antiresorptive therapy with nitrogen containing bisphosphonates (BP). With various suggestions as to pathogenesis, the etiology of BRONJ is not sufficiently understood. Osteoclasts and their precursors, that is, macrophages, are the main target cells of BP. BP can repolarize regeneration  and healing associated M2 macrophages towards the tissue destructive M1 type. The current study aims to elucidate differences in macrophage and osteoclast polarization in BRONJ, osteoradionecrosis (ORN) and healthy control specimens.
   Materials and methods: A total of 39 jaw bone samples (18 BRONJ, 8 ORN and 13 healthy controls) were processed for immunohistochemistry to detect CD68 , CD11c  and CD163 positive cells. Macrophages and osteoclasts were distinguished on the basis of morphological differences. Samples were digitized, and the macrophage and osteoclast cell counts were quantitatively analyzed.
   Results: In jaw bone affected by BRONJ, a significantly increased macrophage infiltration and Ml polarization of macrophages can be seen. The density of CD68 expressing osteoclasts is significantly increased in BRONJ specimens compared to ORN and to healthy controls.
   Conclusions: A bisphosphonate derived shift of macrophage polarization towards Ml polarized macrophages might impair bone tissue homeostasis and thus contribute to the pathogenesis of BRONJ. The observed increase in osteoclast density might be caused by BP induced prolonged osteoclast survival. (C) 2017 European Association for Cranio Maxillo Facial Surgery. Published by Elsevier Ltd. All rights reserved.
C1 [Wehrhan, Falk; Moebius, Patrick; Ries, Jutta; Preidl, Raimund; Neukam, Friedrich W.; Weber, Manuel] Friedrich Alexander Univ Erlangen Nurnberg, Dept Oral & Maxillofacial Surg, Glueckstr 11, D 91054 Erlangen, Germany.
   [Amann, Kerstin] Friedrich Alexander Univ Erlangen Nurnberg, Dept Nephropathol, Inst Pathol, Erlangen, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg
RP Weber, M (通讯作者)，Friedrich Alexander Univ Erlangen Nurnberg, Dept Oral & Maxillofacial Surg, Glueckstr 11, D 91054 Erlangen, Germany.
EM manuel.weber@uk erlangen.de
RI ; Weber, Manuel/K 5458 2019
OI Weber, Manuel/0000 0002 8649 5977; 
FU foundation "Wissenschaftsfonds der DGZMK"
FX This study was financially supported by the foundation
   "Wissenschaftsfonds der DGZMK" (grant to Falk Wehrhan in 2012).
CR Allavena P, 2012, CLIN EXP IMMUNOL, V167, P195, DOI 10.1111/j.1365 2249.2011.04515.x
   Aron Wisnewsky J, 2009, J CLIN ENDOCR METAB, V94, P4619, DOI 10.1210/jc.2009 0925
   Assaf AT, 2013, ANTICANCER RES, V33, P3917
   Ben Aharon I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070044
   Benoit M, 2008, J IMMUNOL, V181, P3733, DOI 10.4049/jimmunol.181.6.3733
   Bonomi M, 2010, MED ONCOL, V27, P224, DOI 10.1007/s12032 009 9195 y
   Braga TT, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00602
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440 1827.2011.02695.x
   Cho KY, 2013, J STROKE CEREBROVASC, V22, P910, DOI 10.1016/j.jstrokecerebrovasdis.2012.11.020
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Coscia M, 2010, J CELL MOL MED, V14, P2803, DOI 10.1111/j.1582 4934.2009.00926.x
   Fernández M, 2010, J CELL BIOCHEM, V111, P130, DOI 10.1002/jcb.22676
   Fischer Posovszky P, 2011, ENDOCRINOLOGY, V152, P3074, DOI 10.1210/en.2011 1031
   Froehner M, 2014, UROL INT, V93, P249, DOI 10.1159/000365788
   Groetz K. A., 2012, BISPHOSPHONAT ASSOZI
   Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108
   Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098
   Hasan D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742 2094 9 222
   He MF, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756 8722 6 80
   Hirata Y, 2011, J AM COLL CARDIOL, V58, P248, DOI 10.1016/j.jacc.2011.01.048
   Hoefert S, 2016, CLIN ORAL INVEST, V20, P1043, DOI 10.1007/s00784 015 1584 3
   Hoefert S, 2015, CLIN ORAL INVEST, V19, P1307, DOI 10.1007/s00784 014 1358 3
   Hoefert S, 2015, CLIN ORAL INVEST, V19, P497, DOI 10.1007/s00784 014 1273 7
   Jacobs C, 2015, J BONE ONCOL, V4, P54, DOI 10.1016/j.jbo.2015.06.001
   Kawamura K, 2009, PATHOL INT, V59, P300, DOI 10.1111/j.1440 1827.2009.02369.x
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026
   Lan CY, 2013, TECHNOL CANCER RES T, V12, P259, DOI 10.7785/tcrt.2012.500312
   Locati M, 2013, ADV IMMUNOL, V120, P163, DOI 10.1016/B978 0 12 417028 5.00006 5
   Lu CF, 2010, HEAD NECK J SCI SPEC, V32, P18, DOI 10.1002/hed.21138
   Mantovani A, 2007, EUR J IMMUNOL, V37, P14, DOI 10.1002/eji.200636910
   Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133
   Marx RE, 2012, INT J ORAL MAX SURG, V41, P283, DOI 10.1016/j.ijom.2011.12.016
   Marx Robert E, 2014, Int J Oral Maxillofac Implants, V29, pe247, DOI 10.11607/jomi.te61
   Mitsimponas KT, 2014, INT J CLIN EXP PATHO, V7, P496
   Mountzios G, 2010, TRANSL RES, V155, P247, DOI 10.1016/j.trsl.2010.01.002
   Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409
   Novak ML, 2013, J LEUKOCYTE BIOL, V93, P875, DOI 10.1189/jlb.1012512
   Pejnovic NN, 2013, DIABETES, V62, P1932, DOI 10.2337/db12 0222
   Pollard JW, 2009, NAT REV IMMUNOL, V9, P259, DOI 10.1038/nri2528
   Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rogers TL, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 177
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Sindrilaru A, 2011, J CLIN INVEST, V121, P985, DOI 10.1172/JCI44490
   Stockmann P, 2014, CLIN ORAL INVEST, V18, P1299, DOI 10.1007/s00784 013 1092 2
   Stockmann P, 2010, SUPPORT CARE CANCER, V18, P449, DOI 10.1007/s00520 009 0688 1
   Tseng HC, 2015, ONCOTARGET, V6, P20002, DOI 10.18632/oncotarget.4755
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Veltman JD, 2010, BRIT J CANCER, V103, P629, DOI 10.1038/sj.bjc.6605814
   Webb SL, 2014, BRIT J PHARMACOL, V171, P3765, DOI 10.1111/bph.12742
   Weber M, 2015, BRIT J CANCER, V113, P510, DOI 10.1038/bjc.2015.212
   Weber M, 2016, ORAL ONCOL, V52, P75, DOI 10.1016/j.oraloncology.2015.11.001
   Weber M, 2014, J CRANIO MAXILL SURG, V42, P1087, DOI 10.1016/j.jcms.2014.01.035
   Wehrhan F, 2015, CLIN ORAL INVEST, V19, P1289, DOI 10.1007/s00784 014 1354 7
   Wehrhan F, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 522
   Wehrhan F, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 102
   Wehrhan F, 2011, ORAL SURG ORAL MED O, V112, P216, DOI 10.1016/j.tripleo.2011.02.028
   Wehrhan F, 2010, J TRANSL MED, V8, DOI 10.1186/1479 5876 8 96
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Yamaguchi T, 2016, INFECT IMMUN, V84, P2802, DOI 10.1128/IAI.00461 16
   Zhang QZ, 2013, CLIN CANCER RES, V19, P3176, DOI 10.1158/1078 0432.CCR 13 0042
NR 65
TC 19
Z9 23
U1 2
U2 30
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1010 5182
EI 1878 4119
J9 J CRANIO MAXILL SURG
JI J. Cranio MaxilloFac. Surg.
PD JUN
PY 2017
VL 45
IS 6
BP 944
EP 953
DI 10.1016/j.jcms.2017.02.023
PG 10
WC Dentistry, Oral Surgery & Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Surgery
GA EY0BW
UT WOS:000403624200020
PM 28365078
DA 2025 08 17
ER

PT J
AU Tanaka, S
   Mizutani, H
   Tsuruya, E
   Fukuda, R
   Kuge, K
   Okubo, N
AF Tanaka, Sakae
   Mizutani, Hideki
   Tsuruya, Eri
   Fukuda, Ryoko
   Kuge, Kiyoka
   Okubo, Naoki
TI Long term safety and effectiveness of denosumab in Japanese patients
   with osteoporosis: 3 year post marketing surveillance study
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Denosumab; Hypocalcaemia; Japanese; Osteoporosis; Real world survey
ID SURGEONS POSITION PAPER; POSTMENOPAUSAL WOMEN; AMERICAN ASSOCIATION;
   FRACTURE; OSTEONECROSIS; RANKL; RISK; MEN
AB Introduction Denosumab is a humanized IgG2 monoclonal antibody that was approved for the treatment of osteoporosis in Japan in 2013. This study aimed to investigate the long term safety and effectiveness of denosumab in Japanese patients with osteoporosis in daily clinical practice. Materials and methods This 3 year, prospective, observational, post marketing study included patients who initiated treatment with denosumab (60 mg/6 months) for osteoporosis. Data were assessed at baseline, 3, 6, 12, 24 and 36 months. Key endpoints were adverse events (AEs), adverse drug reactions (ADRs), occurrence of osteoporotic fractures, bone mineral density (BMD), and bone turnover markers. Multivariate analyses were conducted to identify predictors of hypocalcaemia and percent change in BMD. Results Overall, 3534 patients were assessed (mean 75.7 years; 89.8% women). In total, 298 patients (8.4%) developed ADRs; the most common was hypocalcaemia (3.9%). Hypocalcaemia risk was significantly increased in patients with creatinine clearance < 30 mL/min, no prior use of bisphosphonates, prior use of calcium and vitamin D preparations, baseline serum calcium < 8.5 mg/dL, and no concomitant use of calcium or vitamin D preparations. Six patients had adjudicated osteonecrosis of the jaw. Lumbar spine BMD increased significantly from baseline (mean percent change: 11.4% at 36 months). All bone turnover markers decreased significantly from baseline. Over 3 years, 3.3% of patients developed a new osteoporotic fracture. Conclusions This study confirmed the long term safety and effectiveness of denosumab in Japanese patients with osteoporosis in daily clinical practice. No new safety signals were identified.
C1 [Tanaka, Sakae] Univ Tokyo, Grad Sch Med, Dept Orthopaed Surg, Bunkyo Ku, 7 3 1 Hongo, Tokyo 1138655, Japan.
   [Mizutani, Hideki; Tsuruya, Eri; Fukuda, Ryoko; Kuge, Kiyoka] Daiichi Sankyo Co Ltd, Post Mkt Study Dept, Chuo Ku, 3 5 1 Nihonbashi Honcho, Tokyo 1038426, Japan.
   [Okubo, Naoki] Daiichi Sankyo Co Ltd, Biostatist & Data Management Dept, Tokyo, Japan.
C3 University of Tokyo; Daiichi Sankyo Company Limited; Daiichi Sankyo
   Company Limited
RP Mizutani, H (通讯作者)，Daiichi Sankyo Co Ltd, Post Mkt Study Dept, Chuo Ku, 3 5 1 Nihonbashi Honcho, Tokyo 1038426, Japan.
EM mizutani.hideki.m5@daiichisankyo.co.jp
RI Tanaka, Sakae/Y 3061 2019
OI Tanaka, Sakae/0000 0001 9210 9414
FU Daiichi Sankyo Co., Ltd. (Tokyo, Japan); Daiichi Sankyo Co., Ltd.
FX We are deeply grateful to the investigators and participants of the
   survey. This study was sponsored by Daiichi Sankyo Co., Ltd. (Tokyo,
   Japan). In addition, the authors would like to thank Go Kuratomi, PhD,
   and Catherine Rees, of Springer Healthcare Communications, who wrote the
   outline and the subsequent drafts of this manuscript, respectively, and
   Sarah Greig, PhD, of Springer Healthcare Communications who assisted
   with manuscript revisions post submission. This medical writing
   assistance was funded by Daiichi Sankyo Co., Ltd. This study was
   sponsored by Daiichi Sankyo Co., Ltd. (Tokyo, Japan).
CR [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   [Anonymous], 2009, The Asian Audit: Epidemiology, costs and burden of osteoporosis in Asia
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.1093/biomet/26.4.404
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Iidaka T, 2016, OSTEOARTHR CARTILAGE, V24, P117, DOI 10.1016/j.joca.2015.07.017
   Iki Masayuki, 2012, Clin Calcium, V22, P797, DOI CliCa1206797803
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kamatari M, 2007, J BONE MINER METAB, V25, P302, DOI 10.1007/s00774 007 0768 6
   Kitamura S, 1998, CLIN ORTHOP RELAT R, P29
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   McClung Michael R, 2006, Curr Osteoporos Rep, V4, P28, DOI 10.1007/s11914 006 0012 7
   McClung MR, 2012, J BONE MINER RES, V27, P211, DOI 10.1002/jbmr.536
   Nakamura T, 2014, J CLIN ENDOCR METAB, V99, P2599, DOI 10.1210/jc.2013 4175
   Orimo Hajime, 2012, Arch Osteoporos, V7, P3
   Price David, 2014, Ann Am Thorac Soc, V11 Suppl 2, pS92, DOI 10.1513/AnnalsATS.201308 276RM
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Sugimoto T, 2015, OSTEOPOROSIS INT, V26, P765, DOI 10.1007/s00198 014 2964 2
   Tanaka S, 2018, THER RES, V39, P453
NR 22
TC 12
Z9 13
U1 1
U2 5
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAY
PY 2021
VL 39
IS 3
BP 463
EP 473
DI 10.1007/s00774 020 01180 4
EA JAN 2021
PG 11
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA RU3VD
UT WOS:000604236200003
PM 33387064
DA 2025 08 17
ER

PT J
AU Lloyd, SAJ
   Travis, ND
   Lu, T
   Bateman, TA
AF Lloyd, Shane A. J.
   Travis, Neil D.
   Lu, Teng
   Bateman, Ted A.
TI Development of a low dose anti resorptive drug regimen reveals
   synergistic suppression of bone formation when coupled with disuse
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE osteoprotegerin; zoledronic acid; osteoporosis; bone loss; microcomputed
   tomography
ID SUSPENSION INDUCED OSTEOPENIA; MOUSE LONG BONES; PARATHYROID HORMONE;
   POSTMENOPAUSAL WOMEN; DURATION SPACEFLIGHT; CALCIUM METABOLISM; MINERAL
   DENSITY; OSTEOPOROSIS; BISPHOSPHONATES; ALENDRONATE
AB Safe and effective countermeasures to spaceflight induced osteoporosis are required to mitigate the potential for mission critical fractures and ensure long term bone health in astronauts. Two anti resorptive drugs, the bisphosphonate zoledronic acid (ZOL) and the anti receptor activator of NF kappa B ligand protein osteoprotegerin (OPG), were investigated to find the minimum, comparable doses that yield a maximal increase in bone quality, while minimizing deleterious effects on turnover and mineralization. Through a series of five trials in normally loaded female mice (n = 56/trial), analysis of trabecular volume fraction and connectivity using microcomputed tomography, along with biomechanical testing, quantitative histomorphometry, and compositional analysis, was used to select 45 mu g/kg ZOL and 500 mu g/kg OPG as doses that satisfy these criteria. These doses were then examined for their ability to mitigate bone loss following short term unloading through hindlimb suspension (HLS). Seventy two mice were prophylactically administered ZOL, OPG, or PBS and assigned to loaded control or 2 wk HLS groups (n = 12 for each of 6 groups). Both anti resorptives were able to preserve trabecular microarchitecture and femoral elastic and maximum force in HLS mice (+ 30 40% ZOL/OPG vs. PBS). In HLS mice, anti resorptive dosing reduced resorption perimeter at the femoral endocortical surface by 30% vs. PBS. In loaded control mice, anti resorptives produced no change in bone formation rate; however, reductions in bone formation rate brought about by HLS were exacerbated by anti resorptive treatment, suggesting synergistic inhibition of osteoblasts during disuse. Refined anti resorptive dosing will tend to target countermeasures to the period of disuse, resulting in faster recovery and less adverse effects for astronauts.
C1 [Lloyd, Shane A. J.; Travis, Neil D.; Lu, Teng; Bateman, Ted A.] Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA.
   [Lloyd, Shane A. J.] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada.
C3 Clemson University; University of British Columbia
RP Bateman, TA (通讯作者)，Clemson Univ, Dept Bioengn, 501 Rhodes Engn Res Ctr, Clemson, SC 29634 USA.
EM bateman@clemson.edu
CR Bateman TA, 2000, BONE, V26, P443, DOI 10.1016/S8756 3282(00)00256 8
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Body JJ, 1999, J BONE MINER RES, V14, P1557, DOI 10.1359/jbmr.1999.14.9.1557
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BROZ JJ, 1993, J BIOMECH ENG T ASME, V115, P447, DOI 10.1115/1.2895510
   Cryer Byron, 2005, Am J Geriatr Pharmacother, V3, P127, DOI 10.1016/S1543 5946(05)80019 4
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Ding M, 2003, CALCIFIED TISSUE INT, V72, P737, DOI 10.1007/s00223 002 2066 6
   Finkelstein JS, 2006, J CLIN ENDOCR METAB, V91, P2882, DOI 10.1210/jc.2006 0190
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fleisch HA, 1997, ANN MED, V29, P55, DOI 10.3109/07853899708998743
   Gallagher JC, 2001, RHEUM DIS CLIN N AM, V27, P143, DOI 10.1016/S0889 857X(05)70191 5
   GLOBUS RK, 1986, ENDOCRINOLOGY, V118, P733, DOI 10.1210/endo 118 2 733
   Greenspan SL, 2000, AM FAM PHYSICIAN, V61, P2731
   HOWARD GA, 1981, P NATL ACAD SCI BIOL, V78, P3204, DOI 10.1073/pnas.78.5.3204
   Judex Stefan, 2003, Curr Osteoporos Rep, V1, P11, DOI 10.1007/s11914 003 0003 x
   Lane H W, 1999, Life Support Biosph Sci, V6, P13
   Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307
   Lang TF, 2006, J BONE MINER RES, V21, P1224, DOI 10.1359/JBMR.060509
   Lawler A, 2004, SCIENCE, V303, P444, DOI 10.1126/science.303.5657.444
   LeBlanc A. D., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P335
   Markin A A, 2005, Aviakosm Ekolog Med, V39, P36
   MARTINEZ E, 1993, DIFFER GEOM APPL, V3, P1, DOI 10.1016/0926 2245(93)90020 2
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Midura R. J., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P327
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   SIMSKE SJ, 1992, J BIOMECH, V25, P489, DOI 10.1016/0021 9290(92)90089 J
   SIMSKE SJ, 1991, J MATER SCI MATER M, V2, P43, DOI 10.1007/BF00701686
   Smith SM, 2005, J BONE MINER RES, V20, P208, DOI 10.1359/JBMR.041105
   Smith SM, 1999, AM J PHYSIOL REG I, V277, pR1
   Tesch PA, 2005, EUR J APPL PHYSIOL, V93, P463, DOI 10.1007/s00421 004 1236 9
   TILTON FE, 1980, AVIAT SPACE ENVIR MD, V51, P1209
   Tommasini SM, 2005, J BONE MINER RES, V20, P1372, DOI 10.1359/JBMR.050326
   Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140 6736(00)02217 0
   Zayzafoon M, 2005, IMMUNOL REV, V208, P267, DOI 10.1111/j.0105 2896.2005.00330.x
NR 39
TC 17
Z9 26
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750 7587
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD MAR
PY 2008
VL 104
IS 3
BP 729
EP 738
DI 10.1152/japplphysiol.00632.2007
PG 10
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Sport Sciences
GA 271XV
UT WOS:000253822900022
PM 18174391
DA 2025 08 17
ER

PT J
AU Lai, S
   Liu, C
   Liu, C
   Fan, LY
   Li, XL
   Yang, YL
   Zhu, YS
   Deng, L
   Xiao, L
   Mu, YD
AF Lai, Shuang
   Liu, Chang
   Liu, Cong
   Fan, Liyuan
   Li, Xinlun
   Yang, Yiling
   Zhu, Yushu
   Deng, Li
   Xiao, Li
   Mu, Yandong
TI Lycium barbarum polysaccharide glycoprotein promotes osteogenesis
   in hPDLSCs via ERK activation
SO ORAL DISEASES
LA English
DT Article
DE bone remodeling; ERK1; 2 signaling pathway; hPDLSCs; Lycium barbarum
   polysaccharide glycoprotein
ID STRUCTURAL CHARACTERIZATION; MICROBIOTA; MECHANISM; UPDATE; HEALTH;
   CELLS
AB Objective A lack of relevant research on Lycium barbarum polysaccharide glycoprotein (LBP) application in oral diseases. Here, we focused on the effect of LBP on osteogenic differentiation of human periodontal ligament stem cells (hPDLSCs) and periodontitis bone loss. Methods Human periodontal ligament stem cells (hPDLSCs) were isolated and identified by flow cytometry. Alkaline phosphatase (ALP) activity, Alizarin Red staining, and combined qPCR and Western blot analyses were performed to elucidate the effects of LBP on the osteogenic potential of hPDLSCs. In vivo experiments were performed with the treatment of LBP in rat periodontal model. MicroCT scanning and histological analysis were conducted to evaluate osteogenesis in situ. Results Human periodontal ligament stem cells (hPDLSCs) were successfully isolated and identified with CD90, CD29, and CD45. LBP enhanced hPDLSCs proliferation and migration and promoted RUNX2, ALP, Collagen I, and Osteocalcin expression through activating the ERK1/2 signaling pathway in vitro. The inflammatory factors, including interleukin 6 (IL 6) and interleukin 8 (IL 8) were reduced after LBP treatment. Alveolar bone resorption was significantly decreased in the LBP treated groups in vivo, and osteoclast was markedly decreased by LBP application. Conclusion LBP promoted hPDLSC osteogenesis by targeting the ERK1/2 signaling pathway and reverse bone loss by reducing inflammation. These findings provided latent hope for LBP application in periodontal therapy.
C1 [Lai, Shuang; Liu, Chang; Li, Xinlun; Yang, Yiling; Zhu, Yushu; Xiao, Li; Mu, Yandong] Univ Elect Sci & Technol China, Dept Stomatol, Sichuan Prov Peoples Hosp, Chengdu 611731, Sichuan, Peoples R China.
   [Lai, Shuang; Liu, Cong; Fan, Liyuan; Deng, Li] Univ Elect & Technol China, Sch Med, Chengdu, Peoples R China.
C3 University of Electronic Science & Technology of China; Sichuan
   Provincial People's Hospital
RP Xiao, L; Mu, YD (通讯作者)，Univ Elect Sci & Technol China, Dept Stomatol, Sichuan Prov Peoples Hosp, Chengdu 611731, Sichuan, Peoples R China.
EM xiao1985621@163.com; muyd@uestc.edu.cn
RI Lai, Shuang/HCG 9992 2022; Deng, Li/A 7233 2015; Mu,
   Yandong/JWO 2699 2024
FU Department of Science and Technology of Sichuan Province [2021YFS0009];
   National Natural Science Foundation of China [82071168]
FX Department of Science and Technology of Sichuan Province, Grant/Award
   Number: 2021YFS0009; National Natural Science Foundation of China,
   Grant/Award Number: 82071168
CR Amagase H, 2011, FOOD RES INT, V44, P1702, DOI 10.1016/j.foodres.2011.03.027
   Anand PS, 2014, J PERIODONTOL, V85, P765, DOI 10.1902/jop.2014.130543
   Brusca MI, 2010, J PERIODONTOL, V81, P1010, DOI 10.1902/jop.2010.090575
   Butera A, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9010069
   Chan HHL, 2019, J ETHNOPHARMACOL, V236, P336, DOI 10.1016/j.jep.2019.03.023
   Chapple ILC, 2015, J CLIN PERIODONTOL, V42, pS71, DOI 10.1111/jcpe.12366
   Cheng J, 2015, DRUG DES DEV THER, V9, P33, DOI [10.2147/DDDT.572892, 10.2147/DDDT.S72892]
   Curtis MA, 2020, PERIODONTOL 2000, V83, P14, DOI 10.1111/prd.12296
   Ding Y, 2019, FOOD FUNCT, V10, P3671, DOI [10.1039/c9fo00638a, 10.1039/C9FO00638A]
   Feng L, 2020, MOLECULES, V25, DOI 10.3390/molecules25061351
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hernández Vigueras S, 2016, J PERIODONTOL, V87, P124, DOI 10.1902/jop.2015.150365
   Jing L, 2020, FOOD NUTR RES, V64, DOI 10.29219/fnr.v64.4208
   Jing L, 2018, MOL MED REP, V17, P2415, DOI 10.3892/mmr.2017.8128
   Kim JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081803
   Kukolj T, 2018, J CELL PHYSIOL, V233, P447, DOI 10.1002/jcp.25904
   Kulczynski B, 2016, POL J FOOD NUTR SCI, V66, P67, DOI 10.1515/pjfns 2015 0040
   Liu L, 2015, INT J OPHTHALMOL CHI, V8, P11, DOI 10.3980/j.issn.2222 3959.2015.01.02
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Sanz JL, 2022, INT ENDOD J, V55, P1066, DOI 10.1111/iej.13805
   Masci A, 2018, FOOD CHEM, V254, P377, DOI 10.1016/j.foodchem.2018.01.176
   Mazgaeen L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020379
   Nan Y, 2012, AFR J MICROBIOL RES, V6, P4757, DOI 10.5897/AJMR12.363
   Papapanou PN, 2018, J CLIN PERIODONTOL, V45, pS162, DOI 10.1111/jcpe.12946
   Puhl Ana C, 2015, Nucl Recept Signal, V13, pe004, DOI 10.1621/nrs.13004
   Shao Q, 2023, ORAL DIS, V29, P1137, DOI 10.1111/odi.14066
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Tian XJ, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090389
   Tonetti MS, 2018, J CLIN PERIODONTOL, V45, pS149, DOI [10.1002/JPER.18 0006, 10.1111/jcpe.12945]
   Trubiani O, 2019, STEM CELLS DEV, V28, P995, DOI 10.1089/scd.2019.0025
   Wu DT, 2018, TRENDS FOOD SCI TECH, V79, P171, DOI 10.1016/j.tifs.2018.07.016
   Xiao J, 2014, SCI REP UK, V4, DOI 10.1038/srep05587
   Yang RF, 2015, J FUNCT FOODS, V17, P903, DOI 10.1016/j.jff.2015.06.045
   Yin IX, 2020, INT J NANOMED, V15, P2555, DOI 10.2147/IJN.S246764
   Zhang HY, 2019, J CELL BIOCHEM, V120, P5018, DOI 10.1002/jcb.27777
   Zhang Wenjing, 2018, Artif Cells Nanomed Biotechnol, V46, P1463, DOI 10.1080/21691401.2017.1373657
   Zhao B, 2020, J MOL HISTOL, V51, P161, DOI 10.1007/s10735 020 09866 9
   Zhao QH, 2016, LIFE SCI, V157, P82, DOI 10.1016/j.lfs.2016.05.045
   Zhao QS, 2015, CARBOHYD POLYM, V127, P176, DOI 10.1016/j.carbpol.2015.03.041
   Zhao ZK, 2016, NEURAL REGEN RES, V11, P1312, DOI 10.4103/1673 5374.189197
NR 40
TC 8
Z9 9
U1 4
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1354 523X
EI 1601 0825
J9 ORAL DIS
JI Oral Dis.
PD NOV
PY 2023
VL 29
IS 8
BP 3503
EP 3513
DI 10.1111/odi.14409
EA NOV 2022
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CH7R3
UT WOS:000877936600001
PM 36250230
DA 2025 08 17
ER

PT J
AU Yao, QQ
   Liang, HX
   Huang, B
   Xiang, L
   Wang, TL
   Xiong, Y
   Yang, B
   Guo, YJ
   Gong, P
AF Yao, Qianqian
   Liang, Hengxing
   Huang, Bo
   Xiang, Lin
   Wang, Tianlu
   Xiong, Yi
   Yang, Bo
   Guo, Yanjun
   Gong, Ping
TI Beta adrenergic signaling affect osteoclastogenesis via osteocytic
   MLO Y4 cells' RANKL production
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE beta adrenoceptor; Sympathetic nervous system; Osteocytes;
   Osteoclastogenesis
ID SYMPATHETIC NERVOUS SYSTEM; OSTEOGENIC SARCOMA CELLS; BONE RESORPTION;
   IN VITRO; HUMAN OSTEOBLASTS; RECEPTOR; EXPRESSION; DIFFERENTIATION;
   COMMUNICATION; OVARIECTOMY
AB The sympathetic nervous system play a pivotal role in bone remodeling through beta adrenoceptor (beta AR). However, it is not well documented whether the beta adrenoceptor pathway has the potential to influence osteocytes. In this study, cell viability, the expression of beta AR subtypes, enzymes of catecholamine synthesis or degradation, bone related gene and protein in osteocytic MLO Y4 cells were investigated by beta adrenergic stimulation. Isoproterenol (ISO) promoted RANKL to OPG expression in osteocytes, as well as osteoclasts formation in osteocytes RAW264.7 cell co cultures but not RAW264.7 cell monoculture. The ISO stimulated effect was enhanced in beta 1 AR antagonist pretreatment, but was rescued by blocking beta 2 AR. The results indicate that (beta 1  and beta 2  AR play reciprocal roles on MLO Y4 cells in the regulation of osteoclastogenesis, and osteocyte beta adrenergic signaling might be a new valuable therapy for bone disease. (C) 2016 Published by Elsevier Inc.
C1 [Yao, Qianqian] Cent S Univ, Oral Med Ctr, Xiangya Hosp 2, Changsha, Hunan, Peoples R China.
   [Liang, Hengxing] Cent S Univ, Xiangya Hosp 2, Dept Thorac Surg, Changsha, Hunan, Peoples R China.
   [Huang, Bo; Xiang, Lin; Wang, Tianlu; Xiong, Yi; Yang, Bo; Guo, Yanjun; Gong, Ping] Sichuan Univ, West China Hosp Stomatol, Dent Implant Ctr, 14 Third Sect,Renmin Nan Rd, Chengdu 610041, Sichuan, Peoples R China.
   [Huang, Bo; Xiang, Lin; Wang, Tianlu; Xiong, Yi; Yang, Bo; Guo, Yanjun; Gong, Ping] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
C3 Central South University; Central South University; Sichuan University;
   Sichuan University
RP Gong, P (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dent Implant Ctr, 14 Third Sect,Renmin Nan Rd, Chengdu 610041, Sichuan, Peoples R China.
EM dentistgong@hotmail.com
RI XIONG, Yi/HGU 1217 2022; Yang, Bo/F 9554 2013; Wang,
   Tianlu/GQA 3126 2022; Huang, Bo/JBJ 7315 2023
OI Xiang, Lin/0000 0002 7938 5112; 
FU National Natural Science Foundation of China [NSFC 81170995]; Doctoral
   Specialty Foundation of High School [20110181130005]
FX Authors thank the generous gift from Prof. Lynda F. Bonewald's Lab of
   the Department of Oral Biology, University (Kansas City, Missouri, USA)
   for MLO Y4 cells. This work was supported by the National Natural
   Science Foundation of China (NSFC 81170995) and Doctoral Specialty
   Foundation of High School (20110181130005).
CR Aitken SJ, 2009, ARCH BIOCHEM BIOPHYS, V482, P96, DOI 10.1016/j.abb.2008.11.012
   Arai M, 2003, BBA MOL CELL RES, V1640, P137, DOI 10.1016/S0167 4889(03)00042 9
   Asada N, 2013, CELL STEM CELL, V12, P737, DOI 10.1016/j.stem.2013.05.001
   Bliziotes M, 2006, BONE, V39, P1313, DOI 10.1016/j.bone.2006.06.009
   Bonewald Lynda F, 2006, Bonekey Osteovision, V3, P7
   Bonnet N, 2008, J CELL PHYSIOL, V217, P819, DOI 10.1002/jcp.21564
   Bonnet N, 2007, J APPL PHYSIOL, V102, P1502, DOI 10.1152/japplphysiol.00815.2006
   Bonnet N, 2005, BONE, V37, P622, DOI 10.1016/j.bone.2005.07.012
   Bouxsein ML, 2009, ENDOCRINOLOGY, V150, P144, DOI 10.1210/en.2008 0843
   Dénes A, 2005, NEUROSCIENCE, V134, P947, DOI 10.1016/j.neuroscience.2005.03.060
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Elefteriou F, 2014, CALCIFIED TISSUE INT, V94, P140, DOI 10.1007/s00223 013 9752 4
   Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028
   HILL EL, 1991, CELL TISSUE RES, V264, P469, DOI 10.1007/BF00319037
   Irie K, 2002, MICROSC RES TECHNIQ, V58, P85, DOI 10.1002/jemt.10122
   Komoto S, 2012, CHRONOBIOL INT, V29, P66, DOI 10.3109/07420528.2011.636496
   Kondo A, 2001, BIOCHEM PHARMACOL, V61, P319, DOI 10.1016/S0006 2952(00)00544 X
   Kondo H, 2011, CALCIFIED TISSUE INT, V88, P23, DOI 10.1007/s00223 010 9421 9
   Nagatsu T, 2009, CLIN CHEM, V55, P193, DOI 10.1373/clinchem.2008.109215
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nicolas B., 2007, J BONE MINER RES, V22, P578
   Obata K, 2007, FEBS LETT, V581, P5917, DOI 10.1016/j.febslet.2007.11.065
   Parsian A, 2004, GENOMICS, V83, P454, DOI 10.1016/j.ygeno.2003.09.002
   Pierroz DD, 2012, J BONE MINER RES, V27, P1252, DOI 10.1002/jbmr.1594
   Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756 3282(99)00215 X
   Shu T., 2009, INT J BIOCHEM CELL B, V41, P455
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Suga S, 2010, J PHARMACOL SCI, V112, P184, DOI 10.1254/jphs.09283FP
   Swift JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106904
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Togari A, 1997, NEUROSCI LETT, V233, P125, DOI 10.1016/S0304 3940(97)00649 6
   Togari A, 2008, J PHARMACOL SCI, V106, P542, DOI 10.1254/jphs.FM0070227
   Xiong JH, 2014, BONE, V66, P146, DOI 10.1016/j.bone.2014.06.006
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
NR 34
TC 19
Z9 26
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 8
PY 2017
VL 488
IS 4
BP 634
EP 640
DI 10.1016/j.bbrc.2016.11.011
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA EY4VB
UT WOS:000403974600011
PM 27823934
DA 2025 08 17
ER

PT J
AU Xu, WX
   Liu, Y
   Liu, SZ
   Zhang, Y
   Qiao, GF
   Yan, JL
AF Xu, Wen Xiao
   Liu, Yang
   Liu, Sheng Zhi
   Zhang, Yu
   Qiao, Guo Fen
   Yan, Jinglong
TI Arsenic trioxide exerts a double effect on osteoblast growth in vitro
SO ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
LA English
DT Article
DE Arsenic trioxide; Osteoblast; Proliferation; Apoptosis; Collagen; Double
   effect
ID ACUTE PROMYELOCYTIC LEUKEMIA; INDUCED CELL PROLIFERATION;
   MULTIPLE MYELOMA; COMBINATION THERAPY; HUMAN KERATINOCYTES; APOPTOSIS;
   BONE; ACTIVATION; PATHWAY; MITOCHONDRIA
AB Arsenic trioxide (ATO) is a promising antitumor agent used to treat acute promyelocytic leukemia (APL) and, recently solid tumor. The present study was designed to evaluate the effect of ATO proliferation of osteoblast that plays very important roles in maintaining the structure integrity and function of bone.
   Cell survives, apoptosis, collagen, and molecular targets were identified by multiple detecting techniques, including MTT assay, electron microscopy, collagen detecting kit, TUNEL kit, and western blot in hFOB1.19 human osteoblasts cell line. The results showed that low dose of ATO (0.25, 0.5, and 1 mu M) remarkably enhanced the viability of cultured osteoblasts in a concentration  and time dependent manner. Intriguingly, a dual effect of high dose of ATO (5, 10, and 20 mu M) was also observed showing significant reduction in viability of culture osteoblasts at concentration  and time dependent fashion. Moreover, low dose of ATO promoted secretion and synthesis of collagen, whereas high dose of ATO induced typical morphological characteristics of apoptosis in osteoblasts. Mechanically, western blot results demonstrated that low dose of ATO dramatically up regulated TGF beta 1 protein and activated p AKT proliferative signaling. And, high dose of ATO increased Bax/Bcl 2 ratio in a time dependent fashion and activated caspase 3 apoptotic signaling. These results demonstrate at the first time that ATO exerts a double effect on osteoblast function depending upon the concentration and provide a clue to rationally use ATO for clinicians to pay more attention to protect bone from the adverse effects of therapeutic dose of ATO during tumor therapy. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Xu, Wen Xiao; Yan, Jinglong] Harbin Med Univ, Affiliated Hosp 2, Dept Orthoped, Harbin, Peoples R China.
   [Xu, Wen Xiao; Liu, Yang; Liu, Sheng Zhi; Zhang, Yu; Qiao, Guo Fen] Harbin Med Univ, Dept Pharmacol, State Prov Key Labs Biomed Pharmaceut China, Key Lab Cardiovasc Res,Minist Educ, Harbin, Peoples R China.
C3 Harbin Medical University; Harbin Medical University
RP Yan, JL (通讯作者)，23 Youzheng St, Harbin 150001, Peoples R China.
EM yjlg4@hotmail.com
FU National Natural Science Foundation of China [81173051]
FX This study was supported by the National Natural Science Foundation of
   China grant (81173051).
CR Beezhold K, 2011, TOXICOL SCI, V123, P411, DOI 10.1093/toxsci/kfr188
   Berenson JR, 2007, CLIN CANCER RES, V13, P1762, DOI 10.1158/1078 0432.CCR 06 1812
   Bi X, 2010, SKIN PHARMACOL PHYS, V23, P68, DOI 10.1159/000265677
   Brunner M, 2013, INT REV CEL MOL BIO, V305, P1, DOI 10.1016/B978 0 12 407695 2.00001 9
   Chang ST, 2012, BONE, V51, P524, DOI 10.1016/j.bone.2012.05.010
   Chen Yuan zhong, 2003, Zhonghua Xue Ye Xue Za Zhi, V24, P231
   Chu WF, 2012, CARDIOVASC RES, V96, P90, DOI 10.1093/cvr/cvs230
   Chu WF, 2011, J CELL PHYSIOL, V226, P2586, DOI 10.1002/jcp.22604
   Escobar García DM, 2012, ARCH TOXICOL, V86, P857, DOI 10.1007/s00204 012 0802 x
   Ferreccio C, 2013, EPIDEMIOLOGY, V24, P898, DOI 10.1097/EDE.0b013e31829e3e03
   Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170
   Hamann I, 2013, REDOX BIOL, V1, P104, DOI 10.1016/j.redox.2012.11.010
   HAROUSSEAU JL, 2004, AM SOC HEMATOL ED PR, P237
   Held LA, 2013, CANCER INVEST, V31, P172, DOI 10.3109/07357907.2012.756109
   Hu YC, 2013, BIOCHEM PHARMACOL, V85, P1018, DOI 10.1016/j.bcp.2013.01.008
   Hu YC, 2012, BONE, V50, P1406, DOI 10.1016/j.bone.2012.03.012
   Insinga A, 2005, CELL CYCLE, V4, P67, DOI 10.4161/cc.4.1.1400
   Kato M, 2006, J AM SOC NEPHROL, V17, P3325, DOI 10.1681/ASN.2006070754
   Kumar P, 2008, MOL CANCER THER, V7, P2060, DOI 10.1158/1535 7163.MCT 08 0287
   Li C, 2013, TOXICOL LETT, V219, P223, DOI 10.1016/j.toxlet.2013.03.024
   Liu YH, 2010, J CELL BIOCHEM, V111, P1546, DOI 10.1002/jcb.22886
   Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723
   Ozkan K, 2007, GROWTH FACTORS, V25, P101, DOI 10.1080/08977190701352594
   Pinton P, 2011, CELL DEATH DIFFER, V18, P1450, DOI 10.1038/cdd.2011.31
   Sanz MA, 2011, J CLIN ONCOL, V29, P495, DOI 10.1200/JCO.2010.32.1067
   Shen Y, 2001, LEUKEMIA, V15, P735, DOI 10.1038/sj.leu.2402106
   Shi Jian Jun, 2008, Shanghai Kou Qiang Yi Xue, V17, P335
   Siu CW, 2006, BLOOD, V108, P103, DOI 10.1182/blood 2006 01 0054
   Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014 5793(98)00061 1
   Tang CH, 2009, TOXICOL APPL PHARM, V241, P173, DOI 10.1016/j.taap.2009.08.011
   Wang L, 2013, ONCOL REP, V30, P2427, DOI 10.3892/or.2013.2729
   Yavuz MS, 2008, INT ENDOD J, V41, P633, DOI 10.1111/j.1365 2591.2008.01406.x
   Yen YP, 2012, ARCH TOXICOL, V86, P923, DOI 10.1007/s00204 012 0864 9
   Zhang TC, 2003, CARCINOGENESIS, V24, P1811, DOI 10.1093/carcin/bgg141
   Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424
   Zhao H, 2012, ARCH ORTHOP TRAUM SU, V132, P1669, DOI 10.1007/s00402 012 1589 1
   Zhou J, 2012, CHINESE MED J PEKING, V125, P3556, DOI 10.3760/cma.j.issn.0366 6999.2012.19.035
NR 37
TC 16
Z9 17
U1 0
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1382 6689
EI 1872 7077
J9 ENVIRON TOXICOL PHAR
JI Environ. Toxicol. Pharmacol.
PD SEP
PY 2014
VL 38
IS 2
BP 412
EP 419
DI 10.1016/j.etap.2014.07.010
PG 8
WC Environmental Sciences; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Pharmacology & Pharmacy; Toxicology
GA AR8PY
UT WOS:000343838300009
PM 25128771
DA 2025 08 17
ER

PT J
AU Zhang, B
   Li, YL
   Yu, Y
   Zhao, JL
   Ou, YZ
   Chao, Y
   Yang, BH
   Yu, XR
AF Zhang, Bo
   Li, Yali
   Yu, Yang
   Zhao, Jinlong
   Ou, Yangzhen
   Chao, Yu
   Yang, Binhui
   Yu, Xiaorui
TI MicroRNA 378 Promotes Osteogenesis Angiogenesis Coupling in BMMSCs for
   Potential Bone Regeneration
SO ANALYTICAL CELLULAR PATHOLOGY
LA English
DT Article
ID SIGNALING PATHWAY; GROWTH FACTOR; STEM CELLS; DIFFERENTIATION; WNT
AB Bone tissue regeneration was closely associated with osteogenesis and angiogenesis. The harmonious regulation of osteogenetic and angiogenic growth factors would enhance bone regeneration, while the imbalance of that would lead to local excessive bone formation or vascular mass due to exogenous delivery. Therefore, microRNA is believed to regulate multiple metabolism progress through endogenous signaling pathways on the gene level. In this work, we identified microRNA 378 as a positive regulator of osteogenesis and angiogenesis simultaneously and also observed an increase of microRNA 378 than control in human bone marrow mesenchymal stem cells (hBMMSCs) after osteoblast induction. Besides, osteogenetic and angiogenic gene expression increased simultaneously after overexpression of microRNA 378. Moreover, alizarin red staining and alkaline phosphatase (ALP) staining enhanced, and secretion of vascular endothelial growth factor (VEGF) increased. In this way, we believed miR378 was an ideal target to osteogenesis angiogenesis coupling for bone regeneration, which provides a potential tool for the gene therapy of bone regeneration.
C1 [Zhang, Bo; Chao, Yu; Yu, Xiaorui] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Biochem & Mol Biol, Xian 710061, Shaanxi, Peoples R China.
   [Zhang, Bo; Li, Yali; Yu, Yang; Zhao, Jinlong; Ou, Yangzhen; Yang, Binhui] Xi An Jiao Tong Univ, Hosp 3201, Hanzhong 723000, Shaanxi, Peoples R China.
   [Yu, Xiaorui] Xi An Jiao Tong Univ, Minist Educ, Key Lab Environm & Genes Related Dis, Xian 710061, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University
RP Yu, XR (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Biochem & Mol Biol, Xian 710061, Shaanxi, Peoples R China.; Yang, BH (通讯作者)，Xi An Jiao Tong Univ, Hosp 3201, Hanzhong 723000, Shaanxi, Peoples R China.; Yu, XR (通讯作者)，Xi An Jiao Tong Univ, Minist Educ, Key Lab Environm & Genes Related Dis, Xian 710061, Shaanxi, Peoples R China.
EM ybh3201@sina.com; xiaoruiy@mail.xjtu.edu.cn
RI bo, zhang/KBB 8283 2024
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406
   Cancedda R, 2007, BIOMATERIALS, V28, P4240, DOI 10.1016/j.biomaterials.2007.06.023
   Chen JY, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0377 1
   Chen J, 2013, TISSUE ENG PART B RE, V19, P516, DOI [10.1089/ten.teb.2012.0672, 10.1089/ten.TEB.2012.0672]
   Dicarlo M, 2015, CELLS TISSUES ORGANS, V201, P333, DOI 10.1159/000445346
   Fang T, 2016, EXP CELL RES, V347, P74, DOI 10.1016/j.yexcr.2016.07.010
   Fei YR, 2011, J BIOL CHEM, V286, P40575, DOI 10.1074/jbc.M111.274910
   Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050 1738(00)00074 8
   Hayashi H, 2016, J CELL SCI, V129, P1210, DOI 10.1242/jcs.181883
   Icli B, 2013, CIRC RES, V113, P1231, DOI 10.1161/CIRCRESAHA.113.301780
   Jin Y, 2015, MOL CELL BIOCHEM, V402, P111, DOI 10.1007/s11010 014 2319 5
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104
   Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Liu J, 2010, J BIOL CHEM, V285, P26599, DOI 10.1074/jbc.M110.115824
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Rossi M, 2013, J CELL PHYSIOL, V228, P1506, DOI 10.1002/jcp.24306
   Rouwkema J, 2008, TRENDS BIOTECHNOL, V26, P434, DOI 10.1016/j.tibtech.2008.04.009
   Shi CG, 2014, BONE, V68, P67, DOI 10.1016/j.bone.2014.08.004
   Shi KK, 2013, BONE, V55, P487, DOI 10.1016/j.bone.2013.04.002
   Towler DA, 2003, OSTEOPOROSIS INT, V14, pS46, DOI 10.1007/s00198 003 1473 5
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Wang Z, 2015, SCI REP UK, V5, DOI 10.1038/srep15280
   Wildemann B, 2004, J CONTROL RELEASE, V95, P249, DOI 10.1016/j.jconrel.2003.11.014
   Xiao B, 2016, MOL MED REP, V13, P379, DOI 10.3892/mmr.2015.4537
   You L, 2014, INT J CLIN EXP PATHO, V7, P7249
   Zheng LL, 2017, J CELL PHYSIOL, V232, P182, DOI 10.1002/jcp.25406
NR 30
TC 20
Z9 22
U1 1
U2 22
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2210 7177
EI 2210 7185
J9 ANAL CELL PATHOL
JI Anal. Cell. Pathol.
PY 2018
VL 2018
AR 8402390
DI 10.1155/2018/8402390
PG 9
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology; Pathology
GA FZ1AG
UT WOS:000427306700001
PM 29686962
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Stains, JP
   Civitelli, R
AF Stains, JP
   Civitelli, R
TI Gap junctions regulate extracellular signal regulated kinase signaling
   to affect gene transcription
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; HUMAN OSTEOBLASTIC CELLS; INTERCELLULAR
   COMMUNICATION; IN VITRO; CONNEXIN 43 PHOSPHORYLATION; SP1
   PHOSPHORYLATION; PARATHYROID HORMONE; C SRC; EXPRESSION; GROWTH
AB Osteoblasts are highly coupled by gap junctions formed by connexin43. Overexpression of connexin45 in osteoblasts results in decreased chemical and electrical coupling and reduces gene transcription from connexin response elements (CxREs) in the osteocalcin and collagen Ialpha1 promoters. Here, we demonstrate that transcription from the gap junction dependent osteocalcin CxRE is regulated by extracellular signal regulated protein kinase (ERK) and phosphatidylinositol 3 kinase (PI3K) cascades. Overexpression of a constitutively active mitogen activated protein kinase kinase (MEK), Raf, or Ras can increase transcription more than twofold of the CxRE, whereas inhibition of MEK or PI3K can decrease transcription threefold from the osteocalcin CxRE. Importantly, disruption of gap junctional communication by overexpression of connexin45 or treatment with pharmacological inhibitors of gap junctions results in reduced Raf, ERK, and Akt activation. The consequence of attenuated gap junction dependent signal cascade activation is a decrease in Sp1 phosphorylation by ERK, resulting in decreased Sp1 recruitment to the CxRE and inhibited gene transcription. These data establish that ERK/PI3K signaling is required for the optimal elaboration of transcription from the osteocalcin CxRE, and that disruption of gap junctional communication attenuates the ability of cells to respond to an extracellular cue, presumably by limiting the propagation of second messengers among adjacent cells by connexin43 gap junctions.
C1 Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA.
   Barnes Jewish Hosp, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Barnes Jewish Hospital; Washington
   University (WUSTL)
RP Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA.
EM rcivitel@im.wustl.edu
RI Civitelli, Roberto/AAA 8260 2019
OI Civitelli, Roberto/0000 0003 4076 4315
FU NIAMS NIH HHS [T32 AR007033, R01 AR041255, R01 AR41255, T32 AR07033]
   Funding Source: Medline
CR BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101
   BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526
   Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508
   Bowling N, 2001, J MOL CELL CARDIOL, V33, P789, DOI 10.1006/jmcc.2000.1349
   Cesen Cummings K, 1998, CARCINOGENESIS, V19, P61, DOI 10.1093/carcin/19.1.61
   Cruciani V, 2002, BIOL CELL, V94, P433, DOI 10.1016/S0248 4900(02)00014 X
   Doble BW, 2000, CIRC RES, V86, P293, DOI 10.1161/01.RES.86.3.293
   Flachon V, 2002, EUR J CELL BIOL, V81, P243, DOI 10.1078/0171 9335 00245
   Fritz S, 2002, J CLIN ENDOCR METAB, V87, P1362, DOI 10.1210/jc.87.3.1362
   Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200
   Goldberg GS, 1998, EXP CELL RES, V239, P82, DOI 10.1006/excr.1997.3872
   Hervé JC, 2004, BBA BIOMEMBRANES, V1662, P22, DOI 10.1016/j.bbamem.2003.10.022
   Huang RC, 2002, CANCER RES, V62, P2806
   Kam Y, 1998, BBA BIOMEMBRANES, V1372, P384, DOI 10.1016/S0005 2736(98)00075 3
   KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049
   Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0
   Kjaer AW, 2004, AM J MED GENET A, V127A, P152, DOI 10.1002/ajmg.a.20614
   Kojima T, 2002, EXP CELL RES, V276, P40, DOI 10.1006/excr.2002.5511
   KOVAL M, 1995, J CELL BIOL, V130, P987, DOI 10.1083/jcb.130.4.987
   Krutovskikh VA, 2002, ONCOGENE, V21, P1989, DOI 10.1038/sj.onc.1205187
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357 2725(03)00264 4
   Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131
   Lecanda F, 1998, MOL BIOL CELL, V9, P2249, DOI 10.1091/mbc.9.8.2249
   Lecanda F, 2000, J CELL BIOL, V151, P931, DOI 10.1083/jcb.151.4.931
   Li Z, 1999, BONE, V25, P661, DOI 10.1016/S8756 3282(99)00227 6
   Lin GC, 2004, J CELL SCI, V117, P881, DOI 10.1242/jcs.00942
   Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210
   Martinez AD, 2002, CIRC RES, V90, P1100, DOI 10.1161/01.RES.0000019580.64013.31
   Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964
   Milanini Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200
   Nicholson SM, 2001, J NEUROSCI RES, V66, P23, DOI 10.1002/jnr.1194
   Niessen H, 2000, J CELL SCI, V113, P1365
   Parrizas M, 1997, J BIOL CHEM, V272, P154
   Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090
   PHILIPPE J, 1994, DIABETES, V43, P523, DOI 10.2337/diabetes.43.4.523
   PITTS JD, 1988, BRIT J CANCER, V58, P52
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200
   Ransjö M, 2003, BIOCHEM BIOPH RES CO, V303, P1179, DOI 10.1016/S0006 291X(03)00502 3
   Richardson RR, 2004, J MED GENET, V41, P60, DOI 10.1136/jmg.2003.012005
   Schiller PC, 2001, J BIOL CHEM, V276, P14133, DOI 10.1074/jbc.M011055200
   Schiller PC, 2001, BONE, V28, P362, DOI 10.1016/S8756 3282(00)00458 0
   Schiller PC, 2001, BONE, V28, P38, DOI 10.1016/S8756 3282(00)00412 9
   Schulz R, 2003, FASEB J, V17, P1355, DOI 10.1096/fj.02 0975fje
   SHANG Y, 2002, CELL, V103, P843
   Stains JP, 2003, J BIOL CHEM, V278, P24377, DOI 10.1074/jbc.M212554200
   STAINS JP, 2004, BIOCH J         0910
   STEINBERG TH, 1994, EMBO J, V13, P744, DOI 10.1002/j.1460 2075.1994.tb06316.x
   Subauste MC, 2001, J BIOL CHEM, V276, P49164, DOI 10.1074/jbc.M105700200
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200
   VanderMolen MA, 1996, J BIOL CHEM, V271, P12165, DOI 10.1074/jbc.271.21.12165
   VOZZI C, 1995, J CELL BIOL, V131, P1561, DOI 10.1083/jcb.131.6.1561
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Zhang W, 2002, J CELL PHYSIOL, V193, P233, DOI 10.1002/jcp.10168
   Zhao M, 2002, J BONE MINER RES, V17, P1441, DOI 10.1359/jbmr.2002.17.8.1441
NR 58
TC 101
Z9 114
U1 0
U2 7
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814 2755 USA
SN 1059 1524
EI 1939 4586
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD JAN
PY 2005
VL 16
IS 1
BP 64
EP 72
DI 10.1091/mbc.E04 04 0339
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 882QW
UT WOS:000225954400009
PM 15525679
OA Green Published
DA 2025 08 17
ER

PT J
AU Richard, MJ
   Driban, JB
   McAlindon, TE
AF Richard, M. J.
   Driban, J. B.
   McAlindon, T. E.
TI Pharmaceutical treatment of osteoarthritis
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Pharmaceutical; Pharmacological; Osteoarthritis; Pain management;
   Practice guideline
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ALL CAUSE MORTALITY;
   HYALURONIC ACID; INTRAARTICULAR INJECTIONS; CLINICAL PHARMACOKINETICS;
   MOLECULAR MECHANISMS; KNEE OSTEOARTHRITIS; TRAMADOL; MANAGEMENT; PAIN
AB Objective: To review the current state of pharmaceutical treatment recommendations for the manage ment of osteoarthritis.Method: A narrative review was drafted to describe treatment guidelines, mechanism of action, phar macokinetics, and toxicity for nine classes of pharmaceuticals: 1) oral nonsteroidal anti inflammatory drugs (NSAIDs), 2) topical NSAIDs, 3) COX 2 inhibitors, 4) duloxetine, 5) intra articular corticosteroids, 6) intra articular hyaluronic acid, 7) acetaminophen (paracetamol), 8) tramadol, and 9) capsaicin.Results: In general, oral and topical NSAIDs, including COX 2 inhibitors, are strongly recommended first  line treatments for osteoarthritis due to their ability to improve pain and function but are associated with increased risks in patients with certain comorbidities (e.g., heightened cardiovascular risks). Intra articular corticosteroid injections are generally recommended for osteoarthritis management and have relatively minor adverse effects. Other treatments, such as capsaicin, tramadol, and acetaminophen, are more controversial, and many updated guidelines offer differing recommendations.Conclusion: The pharmaceutical management of osteoarthritis is a constantly evolving field. Promising treatments are emerging, and medicines that were once considered conventional (e.g., acetaminophen) are gradually becoming less acceptable based on concerns with efficacy and safety. Clinicians need to consider the latest evidence and recommendations to make an informed decision with their patients about how to optimize treatment plans for patients with knee, hip, polyarticular, or hand osteoarthritis.(c) 2022 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Richard, M. J.; Driban, J. B.; McAlindon, T. E.] Tufts Med Ctr, Div Rheumatol Immunol & Allergy, 800 Washington St,Box 406, Boston, MA 02111 USA.
C3 Tufts Medical Center
RP McAlindon, TE (通讯作者)，Tufts Med Ctr, Div Rheumatol Immunol & Allergy, 800 Washington St,Box 406, Boston, MA 02111 USA.
EM mrichard1@tuftsmedicalcenter.org; jdriban@tuftsmedicalcenter.org;
   tmcalindon@tuftsmedicalcenter.org
RI Driban, Jeffrey/H 3486 2019
OI Richard, Michael/0000 0001 9617 9989; McAlindon,
   Timothy/0000 0002 5031 1021
CR American Academy of Orthopaedic Surgeons, 2021, MAN OST KNEE NON ART
   American Academy of Orthopaedic Surgeons, 2017, MAN OST HIP EV BAS C
   Anand P, 2011, BRIT J ANAESTH, V107, P490, DOI 10.1093/bja/aer260
   Anderson BJ, 2008, PEDIATR ANESTH, V18, P915, DOI 10.1111/j.1460 9592.2008.02764.x
   [Anonymous], 2015, AC LAB
   [Anonymous], 2003, ULTR TRAM HYDR LAB
   [Anonymous], 2004, CYMB LAB
   Ayhan E, 2014, WORLD J ORTHOP, V5, P351, DOI 10.5312/wjo.v5.i3.351
   Babbar S, 2009, THER DRUG MONIT, V31, P502, DOI 10.1097/FTD.0b013e3181a8b200
   Bahrami MH, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03577 8
   Balogh L, 2008, J AGR FOOD CHEM, V56, P10582, DOI 10.1021/jf8017029
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Barakat A, 2019, CNS DRUGS, V33, P481, DOI 10.1007/s40263 019 00623 5
   Beakley BD, 2015, PAIN PHYSICIAN, V18, P395
   Bondy PK, 1980, METABOLIC CONTROL DI, V8th, P1427
   Bravo L, 2017, EXPERT OPIN DRUG DIS, V12, P1281, DOI 10.1080/17460441.2017.1377697
   Brown S, 2019, ACTA BIOMATER, V93, P239, DOI 10.1016/j.actbio.2019.03.010
   Bruyère O, 2019, SEMIN ARTHRITIS RHEU, V49, P337, DOI 10.1016/j.semarthrit.2019.04.008
   Cooper C, 2019, DRUG AGING, V36, P15, DOI 10.1007/s40266 019 00660 1
   Creamer P, 1997, ANN RHEUM DIS, V56, P634, DOI 10.1136/ard.56.11.634
   Dajani EZ, 2008, J PHYSIOL PHARMACOL, V59, P117
   Dayer P, 1997, DRUGS, V53, P18, DOI 10.2165/00003495 199700532 00006
   Dominkus M, 1996, ARZNEIMITTEL FORSCH, V46, P1138
   Fallacara A, 2018, POLYMERS BASEL, V10, DOI 10.3390/polym10070701
   Fitzpatrick FA, 2004, CURR PHARM DESIGN, V10, P577, DOI 10.2174/1381612043453144
   FORREST JAH, 1982, CLIN PHARMACOKINET, V7, P93, DOI 10.2165/00003088 198207020 00001
   Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264 6021:3390607
   Gigis I, 2016, HIPPOKRATIA, V20, P26
   Gong L, 2014, PHARMACOGENET GENOM, V24, P374, DOI 10.1097/FPC.0000000000000057
   Gong L, 2012, PHARMACOGENET GENOM, V22, P310, DOI 10.1097/FPC.0b013e32834f94cb
   Gupta RC, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00192
   Habib GS, 2009, CLIN RHEUMATOL, V28, P749, DOI 10.1007/s10067 009 1135 x
   Haeseler G, 2006, PAIN, V126, P234, DOI 10.1016/j.pain.2006.07.003
   Hamilton S.R., 2009, Open Drug Metab J, V3, P43, DOI DOI 10.2174/1874073100903010043
   Hara K, 2005, ANESTH ANALG, V100, P1400, DOI 10.1213/01.ANE.0000150961.24747.98
   Haroutiunian S, 2010, PAIN MED, V11, P535, DOI 10.1111/j.1526 4637.2010.00809.x
   Harris RC, 2006, CLIN J AM SOC NEPHRO, V1, P236, DOI 10.2215/CJN.00890805
   Hummer CD, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03729 w
   Hunter LJ, 2011, OPEN ACCESS EMERG M, V3, P39, DOI 10.2147/OAEM.S22795
   Ioannidis JPA, 2001, JAMA J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821
   Józwiak Bebenista M, 2014, ACTA POL PHARM, V71, P11
   Kijowski R, 2019, RADIOLOGY, V293, P664, DOI 10.1148/radiol.2019192034
   Kloppenburg M, 2019, ANN RHEUM DIS, V78, P16, DOI 10.1136/annrheumdis 2018 213826
   Knadler MP, 2011, CLIN PHARMACOKINET, V50, P281, DOI 10.2165/11539240 000000000 00000
   Kolasinski SL, 2020, ARTHRIT CARE RES, V72, P149, DOI [10.1002/art.41142, 10.1002/acr.24131]
   Kraus VB, 2018, OSTEOARTHR CARTILAGE, V26, P34, DOI 10.1016/j.joca.2017.10.003
   Li LY, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02764 3
   Makris UE, 2010, J RHEUMATOL, V37, P1236, DOI 10.3899/jrheum.090935
   McAlindon TE, 2017, JAMA J AM MED ASSOC, V317, P1967, DOI 10.1001/jama.2017.5283
   McCormack PL, 2010, DRUGS, V70, P1831, DOI 10.2165/11206050 000000000 00000
   Nakhaee S, 2021, FORENSIC TOXICOL, V39, P293, DOI 10.1007/s11419 020 00569 0
   Newton R, 2000, THORAX, V55, P603, DOI 10.1136/thorax.55.7.603
   Onutu Adela Hilda, 2015, Rom J Anaesth Intensive Care, V22, P123
   Osani MC, 2019, KOREAN J INTERN MED, V34, P966, DOI 10.3904/kjim.2018.460
   Paik J, 2019, DRUGS, V79, P455, DOI 10.1007/s40265 019 01083 3
   Paulson SK, 2000, DRUG METAB DISPOS, V28, P308
   Peck J, 2021, ORTHOP REV, V13, DOI 10.52965/001c.25549
   Pergolizzi JV, 2013, PAIN PRACT, V13, P239, DOI 10.1111/j.1533 2500.2012.00578.x
   Rahimi HR, 2014, J RES MED SCI, V19, P855
   Rutjes AWS, 2012, ANN INTERN MED, V157, P180, DOI 10.7326/0003 4819 157 3 201208070 00473
   Schjerning AM, 2020, NAT REV CARDIOL, V17, P574, DOI 10.1038/s41569 020 0366 z
   Scott PA, 2007, ANN RHEUM DIS, V66, P1296, DOI 10.1136/ard.2006.068650
   Sharma SK, 2013, EUR J PHARMACOL, V720, P55, DOI 10.1016/j.ejphar.2013.10.053
   Solomon DH, 2021, NSAID PHARMACOLOGY M
   Stout A, 2019, PM&R, V11, P409, DOI 10.1002/pmrj.12042
   Tashiro Y, 2001, BIOL PHARM BULL, V24, P278, DOI 10.1248/bpb.24.278
   Trelle S, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.c7086
   Vane JR, 1998, INFLAMM RES, V47, pS78
   Varga Z, 2017, CUREUS J MED SCIENCE, V9, DOI 10.7759/cureus.1144
   VERBEECK RK, 1983, CLIN PHARMACOKINET, V8, P297, DOI 10.2165/00003088 198308040 00003
   Walker K, 2022, STATPEARLS
   Whelton A., 1999, Am J Med, V106, p13S, DOI [10.1016/S0002 9343(99)00113 8, DOI 10.1016/S0002 9343(99)00113 8]
   Williams DM, 2018, RESP CARE, V63, P655, DOI 10.4187/respcare.06314
   Woessner KM, 2013, IMMUNOL ALLERGY CLIN, V33, P237, DOI 10.1016/j.iac.2012.12.002
   Wu YZ, 2021, CARTILAGE, V13, p169S, DOI 10.1177/19476035211021903
   Zeng C, 2019, JAMA J AM MED ASSOC, V321, P969, DOI 10.1001/jama.2019.1347
   Zeng C, 2018, BRIT J SPORT MED, V52, P642, DOI 10.1136/bjsports 2017 098043
NR 77
TC 138
Z9 145
U1 41
U2 228
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD APR
PY 2023
VL 31
IS 4
BP 458
EP 466
DI 10.1016/j.joca.2022.11.005
EA MAR 2023
PG 9
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA A7YX9
UT WOS:000957249700001
PM 36414224
OA Bronze
DA 2025 08 17
ER

PT J
AU Ma, SQ
   Xu, SD
   Li, MT
   Du, YQ
   Tian, GJ
   Deng, JY
   Zhang, WY
   Wei, PF
   Zhao, B
   Zhang, XS
   Liu, ZH
   Wang, YL
AF Ma, Shiqing
   Xu, Shendan
   Li, Minting
   Du, Yaqi
   Tian, Guangjie
   Deng, Jiayin
   Zhang, Wenyi
   Wei, Pengfei
   Zhao, Bo
   Zhang, Xuesong
   Liu, Zihao
   Wang, Yonglan
TI A Bone Targeting Nanoparticle Loaded OGP to Restore Bone Homeostasis for
   Osteoporosis Therapy
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE bones; nanoparticles; osteoporosis; PLGA; targets
ID OSTEOGENIC GROWTH PEPTIDE; MODIFIED PLGA NANOPARTICLES; DRUG DELIVERY
   SYSTEMS; BIOACTIVE MOLECULES; REGENERATION; CHITOSAN
AB Restoring bone homeostasis is the key to the treatment of osteoporosis. How to increase osteogenic ability or inhibit osteoclast activity has always been a topic of great concern. In recent years, short peptides with biological activity have received great attention in bone repair. However, the application of short peptides is still limited due to the lack of a stable and targeted delivery system. Poly(lactic co glycolic acid) (PLGA) nanoparticles modified by alendronate (AL) to transport osteogenic peptides (OGP) (AL PLGA@P NPs) are designed. Benefiting from the high affinity of AL for hydroxyapatite, AL PLGA@P NPs have the ability to target bone. In this delivery system, OGP that promotes osteogenesis synergizes with AL, which inhibits osteoclasts, to regulate bone homeostasis, which gives them more advantages in the treatment of osteoporosis. The data shows that nanoparticles can selectively deliver peptides to the bone surface without systemic toxicity. Moreover, nanoparticles can upregulate osteogenesis related factors (ALP, Runx 2, and BMP2) and downregulate osteoclast related factors (TRAP and CTSK) in vitro. With AL PLGA@P NPs, bone microarchitecture and bone mass are improved in ovariectomized osteoporosis rats. Therefore, this study proposes a novel osteoporosis based drug system that effectively improves bone density.
C1 [Ma, Shiqing] Tianjin Med Univ, Dept Stomatol, Hosp 2, Tianjin 300211, Peoples R China.
   [Xu, Shendan; Li, Minting; Du, Yaqi; Deng, Jiayin; Zhang, Wenyi; Liu, Zihao; Wang, Yonglan] Tianjin Med Univ, Sch & Hosp Stomatol, Tianjin 30070, Peoples R China.
   [Wei, Pengfei; Zhao, Bo] Beijing Biosis Healing Biol Technol Co Ltd, Beijing 102600, Peoples R China.
   [Zhang, Xuesong] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 4, Dept Orthopaed, Beijing 100048, Peoples R China.
C3 Tianjin Medical University; Chinese People's Liberation Army General
   Hospital
RP Liu, ZH; Wang, YL (通讯作者)，Tianjin Med Univ, Sch & Hosp Stomatol, Tianjin 30070, Peoples R China.; Zhang, XS (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Med Ctr 4, Dept Orthopaed, Beijing 100048, Peoples R China.
EM zhangxuesong301@126.com; liuzihao@tmu.edu.cn; Wangyonglan@tmu.edu.cn
RI DU, YAQI/MFJ 7170 2025; Li, Minting/KYQ 0564 2024
OI Xu, Shendan/0000 0002 0475 1456; 
FU National Natural Science Foundation of China [81972128]; Clinical
   Research Special Fund of Wu Jieping Medical Foundation
   [320.6750.2021 07 21]; Scientific Foundation of Tianjin Education
   Commission [2019KJ173]; Science and Technology Project of Tianjin Health
   Committee [QN20026]; Natural Science Foundation of Tianjin
   [21JCYBJC01150]; Scientific Foundation of Hospital of Stomatology,
   Tianjin Medical University [2020YKY05]
FX S.M. and S.X. contributed equally to this work. This work was supported
   by the National Natural Science Foundation of China (Grant No.
   81972128), the Clinical Research Special Fund of Wu Jieping Medical
   Foundation (320.6750.2021 07 21), the Scientific Foundation of Tianjin
   Education Commission (No. 2019KJ173), the Science and Technology Project
   of Tianjin Health Committee (No. QN20026), the Natural Science
   Foundation of Tianjin (No. 21JCYBJC01150), and the Scientific Foundation
   of Hospital of Stomatology, Tianjin Medical University (No. 2020YKY05).
   The authors thank Xinying Yu, Lining Wang, and Kai Zhang for their
   technical support.
CR Ahn GY, 2021, BIOMATER RES, V25, DOI 10.1186/s40824 021 00231 9
   Aoki K, 2012, ADV DRUG DELIVER REV, V64, P1220, DOI 10.1016/j.addr.2012.05.017
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Axelsson KF, 2017, JAMA J AM MED ASSOC, V318, P146, DOI 10.1001/jama.2017.8040
   Bab I, 2002, BIOPOLYMERS, V66, P33, DOI 10.1002/bip.10202
   Blasi Paolo, 2019, Journal of Pharmaceutical Investigation, V49, P337
   Borandeh S, 2021, ADV DRUG DELIVER REV, V173, P349, DOI 10.1016/j.addr.2021.03.022
   Chandra A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073553
   Czerwinski Edward, 2007, Ortop Traumatol Rehabil, V9, P337
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Ding DW, 2018, MAT SCI ENG C MATER, V92, P1041, DOI 10.1016/j.msec.2017.12.036
   Ding N, 2018, J CELL PHYSIOL, V233, P7415, DOI 10.1002/jcp.26587
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Figliomeni A, 2018, CLIN EXP RHEUMATOL, V36, P948
   Ho Shui Ling A, 2018, BIOMATERIALS, V180, P143, DOI 10.1016/j.biomaterials.2018.07.017
   Hu XC, 2020, INT J BIOL MACROMOL, V162, P262, DOI 10.1016/j.ijbiomac.2020.06.154
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim SM, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13203471
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee D, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 80608 3
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Liu Q, 2021, ACS NANO, V15, P1608, DOI 10.1021/acsnano.0c09206
   Lorentzon M, 2019, J INTERN MED, V285, P381, DOI 10.1111/joim.12873
   Lukert B. P., 2020, J CLIN ENDOCR METAB, V105, P879
   Ma QY, 2019, J BIOL CHEM, V294, P11240, DOI 10.1074/jbc.RA119.007625
   Ma SQ, 2022, BIOMATER SCI UK, V10, P4773, DOI 10.1039/d2bm00725h
   Ma SQ, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13196
   Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042
   Martin T John, 2014, J Bone Metab, V21, P8, DOI 10.11005/jbm.2014.21.1.8
   Mu YZ, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202101452
   Naot D, 2019, PHYSIOL REV, V99, P781, DOI 10.1152/physrev.00066.2017
   Ortega Oller I, 2017, COLLOID SURFACE B, V159, P586, DOI 10.1016/j.colsurfb.2017.08.027
   Pigossi SC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111885
   Policastro GM, 2016, WIRES NANOMED NANOBI, V8, P449, DOI 10.1002/wnan.1376
   PRESTWOOD KM, 1995, ANNU REV MED, V46, P249
   Rashki S, 2021, CARBOHYD POLYM, V251, DOI 10.1016/j.carbpol.2020.117108
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   ROBINSON D, 1995, J BONE MINER RES, V10, P690
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Safari B, 2021, INT J BIOL MACROMOL, V175, P544, DOI 10.1016/j.ijbiomac.2021.02.052
   Shi C, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2020.107473
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Tesauro D, 2019, MOLECULES, V24, DOI 10.3390/molecules24020351
   Vanella L, 2010, BONE, V46, P236, DOI 10.1016/j.bone.2009.10.012
   Victor RD, 2020, MATERIALS, V13, DOI 10.3390/ma13214995
   Wang YC, 2013, AAPS PHARMSCITECH, V14, P585, DOI 10.1208/s12249 013 9943 3
   Wusiman A, 2019, INT J NANOMED, V14, P3221, DOI 10.2147/IJN.S203072
   Zhang BJ, 2018, J BIOMED MATER RES A, V106, P95, DOI 10.1002/jbm.a.36210
   Zhang CG, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.607017
   Zhou DY, 2021, ANNU REV FOOD SCI T, V12, P407, DOI 10.1146/annurev food 070720 112725
   Zou ML, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.593310
   Zuo YP, 2022, INT J BIOL MACROMOL, V195, P558, DOI 10.1016/j.ijbiomac.2021.12.028
NR 54
TC 10
Z9 10
U1 4
U2 69
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD OCT 6
PY 2023
VL 12
IS 25
DI 10.1002/adhm.202300560
EA AUG 2023
PG 15
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA IT7I6
UT WOS:001050207900001
PM 37562069
DA 2025 08 17
ER

PT J
AU Eguchi, K
   Akiba, Y
   Akiba, N
   Nagasawa, M
   Cooper, LF
   Uoshima, K
AF Eguchi, Kaori
   Akiba, Yosuke
   Akiba, Nami
   Nagasawa, Masako
   Cooper, Lyndon F.
   Uoshima, Katsumi
TI Insulin like growth factor binding Protein 3 suppresses osteoblast
   differentiation via bone morphogenetic protein 2
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Insulin like growth factor binding protein 3 (IGFBP 3); Bone marrow
   stromal cells; Osteoblast differentiation; Osteogenesis; Bone
   morphogenesis protein 2 (BMP 2) Insulin like growth factor (IGF 1)
ID FACTOR I; TRANSFORMING GROWTH FACTOR BETA 1; MATRIX
AB Bone augmentation therapy is used in dental implantation. While techniques to induce bone formation are generally successful, the maintenance of bone mass is more difficult. Therefore, it is important to understand the mechanisms that regulate this process. Insulin like growth factor 1 (IGF 1) is one of the most abundant growth factors that regulate bone mass, promote osteoblast differentiation, and accelerate bone formation. The activity of IGF 1 is regulated by IGF binding proteins (IGFBPs). IGFBP 3 forms a ternary complex with IGF 1, extending its half life in the circulating system. Therefore, IGFBP 3 acts as a stabilizer and transporter of IGF 1. Recent studies reported new IGF 1 independent functions of IGFBP 3 related with bone metabolism. In this study, we investigated the function of IGFBP 3 in osteoblast differentiation. Our results showed that IGFBP 3 decreases the expression of osteoblast differentiation markers, whose expression is enhanced by bone morphogenetic protein 2 (BMP 2). IGFBP 3 also reduced BMP 2 effect on ALP activity and mineral nodule formation. In addition, IGFBP 3 suppresses the activity of the Smad Binding Element (SBE) reporter, induced by BMP 2 signaling. These results suggest that IGFBP 3 inhibits osteoblast differentiation through the BMP 2 signal pathway, and that IGFBP 3 might play a role in bone mass maintenance in an IGF 1 dependent and  independent manner. (C) 2018 The Authors. Published by Elsevier Inc.
C1 [Eguchi, Kaori; Akiba, Yosuke; Akiba, Nami; Nagasawa, Masako; Uoshima, Katsumi] Niigata Univ, Grad Sch Med & Dent Sci, Div Bioprosthodont, Niigata, Japan.
   [Cooper, Lyndon F.] Univ Illinois, Coll Dent, Chicago, IL USA.
C3 Niigata University; University of Illinois System; University of
   Illinois Chicago; University of Illinois Chicago Hospital
RP Akiba, Y (通讯作者)，Niigata Univ, Grad Sch Med & Dent Sci, Div Bioprosthodont, Niigata, Japan.
EM kaori mic@dent.niigata u.ac.jp; yoakiba@dent.niigata u.ac.jp;
   namiaki@dent.niigata u.ac.jp; nagasawa@dent.niigata u.ac.jp;
   cooperlf@uic.edu; fish@dent.niigata u.ac.jp
FU JSPS KAKENHI [JP26462915, JP25462988]; Japan Public Private Partnership
   Student Study Abroad Program (TOBITATE! Young Ambassador Program)
FX This work was supported by the JSPS KAKENHI Grants in Aid for Scientific
   Research (C) [grant numbers JP26462915 and JP25462988], and a
   scholarship from the Japan Public Private Partnership Student Study
   Abroad Program (TOBITATE! Young Ambassador Program).
CR BAUTISTA CM, 1990, METABOLISM, V39, P96, DOI 10.1016/0026 0495(90)90154 5
   BAXTER RC, 1990, J CLIN ENDOCR METAB, V70, P1347, DOI 10.1210/jcem 70 5 1347
   Bikle D.D., 2011, IBMS BoneKEy, V8, P328, DOI DOI 10.1138/20110521
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Buckway CK, 2001, J CLIN ENDOCR METAB, V86, P4943, DOI 10.1210/jc.86.10.4943
   CANALIS E, 1993, ENDOCRINOLOGY, V133, P33, DOI 10.1210/en.133.1.33
   Chen Jiani, 2005, Journal of Medical and Dental Sciences, V52, P27
   Fanayan S, 2002, J BIOL CHEM, V277, P7255, DOI 10.1074/jbc.M108038200
   Garten A, 2012, ENDOCRIN METAB CLIN, V41, P283, DOI 10.1016/j.ecl.2012.04.011
   Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337
   Jogie Brahim S, 2009, ENDOCR REV, V30, P417, DOI 10.1210/er.2008 0028
   JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3
   Kawai M, 2012, ENDOCRIN METAB CLIN, V41, P323, DOI 10.1016/j.ecl.2012.04.013
   Niu TH, 2005, GENE, V361, P38, DOI 10.1016/j.gene.2005.07.016
   Ohlsson C, 2009, ENDOCR REV, V30, P494, DOI 10.1210/er.2009 0010
   PFEILSCHIFTER J, 1995, J CLIN INVEST, V96, P767, DOI 10.1172/JCI118121
   Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092 8674(00)80132 4
   Seck T, 1998, J CLIN ENDOCR METAB, V83, P2331, DOI 10.1210/jc.83.7.2331
   Tahimic Candice G T, 2013, Front Endocrinol (Lausanne), V4, P6, DOI 10.3389/fendo.2013.00006
   Vasylyeva TL, 2007, DIABETES RES CLIN PR, V76, P177, DOI 10.1016/j.diabres.2006.09.012
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Yamada PM, 2009, AM J PHYSIOL CELL PH, V296, pC954, DOI 10.1152/ajpcell.00598.2008
   Zhong YB, 2011, J CELL SCI, V124, P1925, DOI 10.1242/jcs.082644
   Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092 8674(00)80133 6
   Zimmermann EM, 2000, AM J PHYSIOL GASTR L, V278, pG447, DOI 10.1152/ajpgi.2000.278.3.G447
NR 25
TC 38
Z9 40
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 9
PY 2018
VL 507
IS 1 4
BP 465
EP 470
DI 10.1016/j.bbrc.2018.11.065
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HD8OM
UT WOS:000452816400072
PM 30454898
OA hybrid
DA 2025 08 17
ER

PT J
AU Salvadori, L
   Belladonna, ML
   Castiglioni, B
   Paiella, M
   Panfili, E
   Manenti, T
   Ercolani, C
   Cornioli, L
   Chiappalupi, S
   Gentili, G
   Leigheb, M
   Sorci, G
   Bosetti, M
   Filigheddu, N
   Riuzzi, F
AF Salvadori, Laura
   Belladonna, Maria Laura
   Castiglioni, Beatrice
   Paiella, Martina
   Panfili, Eleonora
   Manenti, Tommaso
   Ercolani, Catia
   Cornioli, Luca
   Chiappalupi, Sara
   Gentili, Giulia
   Leigheb, Massimiliano
   Sorci, Guglielmo
   Bosetti, Michela
   Filigheddu, Nicoletta
   Riuzzi, Francesca
TI KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves
   Osteoblast Activity by Modulating Src and p38 MAPK
SO NUTRIENTS
LA English
DT Article
DE osteoclast; RANKL; osteoblast; signaling pathways; natural product;
   age related diseases
ID NF KAPPA B; BONE MECHANICAL PROPERTIES; TRIGONELLA FOENUM GRAECUM;
   C SRC; DIFFERENTIATION; ACTIVATION; FENUGREEK; OSTEOPOROSIS;
   PATHOGENESIS; RESORPTION
AB The imbalance in osteoblast (OB) dependent bone formation in favor of osteoclast (OC) dependent bone resorption is the main cause of loss of tissue mineral mass during bone remodeling leading to osteoporosis conditions. Thus, the suppression of OC activity together with the improvement in the OB activity has been proposed as an effective therapy for maintaining bone mass during aging. We tested the new dietary product, KYMASIN UP containing standardized Withania somnifera, Silybum marianum and Trigonella foenum graecum herbal extracts or the single extracts in in vitro models mimicking osteoclastogenesis (i.e., RAW 264.7 cells treated with RANKL, receptor activator of nuclear factor kappa Beta ligand) and OB differentiation (i.e., C2C12 myoblasts treated with BMP2, bone morphogenetic protein 2). We found that the dietary product reduces RANKL dependent TRAP (tartrate resistant acid phosphatase) positive cells (i.e., OCs) formation and TRAP activity, and down regulates osteoclastogenic markers by reducing Src (non receptor tyrosine kinase) and p38 MAPK (mitogen activated protein kinase) activation. Withania somnifera appears as the main extract responsible for the anti osteoclastogenic effect of the product. Moreover, KYMASIN UP maintains a physiological release of the soluble decoy receptor for RANKL, OPG (osteoprotegerin), in osteoporotic conditions and increases calcium mineralization in C2C12 derived OBs. Interestingly, KYMASIN UP induces differentiation in human primary OB like cells derived from osteoporotic subjects. Based on our results, KYMASIN UP or Withania somnifera based dietary supplements might be suggested to reverse the age related functional decline of bone tissue by re balancing the activity of OBs and OCs, thus improving the quality of life in the elderly and reducing social and health care costs.
C1 [Salvadori, Laura; Paiella, Martina; Filigheddu, Nicoletta] Univ Piemonte Orientale, Dept Translat Med, I 28100 Novara, Italy.
   [Salvadori, Laura; Chiappalupi, Sara; Gentili, Giulia; Sorci, Guglielmo; Filigheddu, Nicoletta; Riuzzi, Francesca] Interuniv Inst Myol IIM, I 06132 Perugia, Italy.
   [Belladonna, Maria Laura; Panfili, Eleonora; Chiappalupi, Sara; Gentili, Giulia; Sorci, Guglielmo; Riuzzi, Francesca] Univ Perugia, Dept Med & Surg, I 06132 Perugia, Italy.
   [Castiglioni, Beatrice; Bosetti, Michela] Univ Piemonte Orientale, Dept Pharmaceut Sci, I 28100 Novara, Italy.
   [Manenti, Tommaso; Ercolani, Catia; Cornioli, Luca] Lab Biokyma Srl, I 52031 Anghiari, Italy.
   [Leigheb, Massimiliano] Univ Piemonte Orientale, Dept Hlth Sci, I 28100 Novara, Italy.
   [Leigheb, Massimiliano] Maggiore della Carita Hosp, Dept Orthopaed & Traumatol, I 28100 Novara, Italy.
C3 University of Eastern Piedmont Amedeo Avogadro; University of Perugia;
   University of Eastern Piedmont Amedeo Avogadro; University of Eastern
   Piedmont Amedeo Avogadro
RP Riuzzi, F (通讯作者)，Interuniv Inst Myol IIM, I 06132 Perugia, Italy.; Riuzzi, F (通讯作者)，Univ Perugia, Dept Med & Surg, I 06132 Perugia, Italy.
EM laurasalvadori1988@gmail.com; marialaura.belladonna@unipg.it;
   beatrice.castiglioni@uniupo.it; martina.paiella@uniupo.it;
   eleonora.panfili@unipg.it; tmanenti@biokyma.com;
   catia.ercolani@biokyma.com; lcornioli@biokyma.com;
   sara.chiappalupi@unipg.it; giulia.gentili@studenti.unipg.it;
   massimiliano.leigheb@uniupo.it; guglielmo.sorci@unipg.it;
   michela.bosetti@uniupo.it; nicoletta.filigheddu@uniupo.it;
   francesca.riuzzi@unipg.it
RI ; Bosetti, Michela/AAR 9556 2021; Belladonna, Maria Laura/LZG 9042 2025;
   Filigheddu, Nicoletta/N 7219 2015; Castiglioni, Beatrice/HGU 3251 2022;
   Donato, Rosario/I 3943 2019; Panfili, Eleonora/KGL 1654 2024; Leigheb,
   Massimiliano/AAK 8135 2021; chiappalupi, Sara/AAI 9096 2021
OI Belladonna, Maria Laura/0000 0001 6522 0870; Chiappalupi,
   Sara/0000 0001 8377 0665; Paiella, Martina/0000 0002 7116 493X; Bosetti,
   Michela/0000 0002 3682 8702; Panfili, Eleonora/0000 0003 2466 2933;
   Filigheddu, Nicoletta/0000 0002 3848 611X; Riuzzi,
   Francesca/0000 0001 7908 3379; Sorci, Guglielmo/0000 0002 1973 9679;
   Leigheb, Massimiliano/0000 0002 7818 2209
FU Fondazione Cassa di Risparmio di Perugia [2019.0321.026]; AGING Project
   "Departments of Excellence [2018 2022]
FX The authors were supported by Fondazione Cassa di Risparmio di Perugia
   (Project 2019.0321.026 to G.S.) and by the AGING Project "Departments of
   Excellence 2018 2022", DIMET (L.S. and N.F.).
CR Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Anjaneyulu K, 2018, ETHIOP J HEALTH SCI, V28, P787, DOI 10.4314/ejhs.v28i6.14
   Azam Z, 2020, FRONT BIOSCI LANDMRK, V25, P1259, DOI 10.2741/4855
   Azizieh FY, 2019, BIOMARK INSIGHTS, V14, DOI 10.1177/1177271919843825
   Bosetti M, 2014, J BIOMED MATER RES A, V102, P3531, DOI 10.1002/jbm.a.35016
   Bosetti M, 2007, BIOMOL ENG, V24, P613, DOI 10.1016/j.bioeng.2007.08.019
   Bosetti M, 2017, TISSUE ENG PT A, V23, P1413, DOI [10.1089/ten.tea.2016.0554, 10.1089/ten.TEA.2016.0554]
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chiappalupi S, 2020, J CACHEXIA SARCOPENI, V11, P929, DOI 10.1002/jcsm.12561
   Choi MH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248020
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   Corrado A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103679
   de Sire A, 2021, WORLD J ORTHOP, V12, P456, DOI 10.5312/wjo.v12.i7.456
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Folwarczna J, 2014, EUR REV MED PHARMACO, V18, P1937
   Folwarczna J, 2014, MOL NUTR FOOD RES, V58, P1457, DOI 10.1002/mnfr.201300936
   Gao YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158182
   Georges S, 2009, CYTOKINE GROWTH F R, V20, P29, DOI 10.1016/j.cytogfr.2008.11.005
   Gigliotti CL, 2016, J IMMUNOL, V197, P3905, DOI 10.4049/jimmunol.1600424
   Halloran D, 2020, J DEV BIOL, V8, DOI 10.3390/jdb8030019
   He C, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.585644
   Hidaka Y, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030218
   Hwang JS, 2020, J DIABETES INVEST, V11, P287, DOI 10.1111/jdi.13165
   Ichikawa H, 2006, MOL CANCER THER, V5, P1434, DOI 10.1158/1535 7163.MCT 06 0096
   Ji L, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04298 y
   Jilka RL, 2013, J GERONTOL A BIOL, V68, P1209, DOI 10.1093/gerona/glt046
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kavitha CV, 2014, MOL CARCINOGEN, V53, P169, DOI 10.1002/mc.21959
   Kim JH, 2009, MOL CELLS, V28, P201, DOI 10.1007/s10059 009 0123 y
   Kim JL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/919374
   Kim JL, 2012, EXP BIOL MED, V237, P417, DOI 10.1258/ebm.2011.011376
   Kim JL, 2012, J CELL BIOCHEM, V113, P247, DOI 10.1002/jcb.23351
   Kim S, 2019, J MICROBIOL BIOTECHN, V29, P11, DOI 10.4014/jmb.1810.10005
   Kirk B, 2020, J CACHEXIA SARCOPENI, V11, P609, DOI 10.1002/jcsm.12567
   LI H, 1994, J CELL BIOL, V124, P827, DOI 10.1083/jcb.124.5.827
   Li H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113698
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   Nagareddy PR, 2006, J PHARM PHARMACOL, V58, P513, DOI 10.1211/jpp.58.4.0011
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Orecchini E, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.593829
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rathi A, 2020, DRUG RES, V70, P257, DOI 10.1055/a 1147 5724
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Salvadori L, 2021, NUTRIENTS, V13, DOI 10.3390/nu13010049
   SCHIAFFINO S, 1994, J APPL PHYSIOL, V77, P493, DOI 10.1152/jappl.1994.77.2.493
   Shishodia S, 2006, ONCOGENE, V25, P1463, DOI 10.1038/sj.onc.1209194
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Wang J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01188
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Zhang ZG, 2014, INT J MOL SCI, V15, P17130, DOI 10.3390/ijms150917130
   Zhi X, 2020, J CELL MOL MED, V24, P5122, DOI 10.1111/jcmm.15153
   Zinnia MA, 2021, INT J BIOL MACROMOL, V186, P351, DOI 10.1016/j.ijbiomac.2021.06.197
NR 54
TC 4
Z9 5
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD AUG
PY 2022
VL 14
IS 15
AR 3053
DI 10.3390/nu14153053
PG 19
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 3S9OF
UT WOS:000839915800001
PM 35893905
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, JY
   Niu, CC
   Jiang, ZC
   Zhang, Z
   Pan, YX
   Xing, QQ
   Guo, Q
   An, SB
   Hu, YH
   Wang, L
AF Li, Jingyi
   Niu, Chengcheng
   Jiang, Zichao
   Zhang, Zhen
   Pan, Yixiao
   Xing, Qiqi
   Guo, Qi
   An, Senbo
   Hu, Yihe
   Wang, Long
TI Targeted Delivery of Curcumin to Polyethylene Induced Osteolysis by
   Magnetically Guided Zoledronate Anchored Poly Lactic Co Glycolic Acid
   Nanoparticles via Repressing NF κB Signaling
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE polyethylene induced osteolysis; magnetically guided;
   zoledronate anchored; curcumin; targeted delivery
ID PERIPROSTHETIC OSTEOLYSIS; METASTASIS; INFLAMMATION; SYSTEM
AB Aseptic loosening induced by periprosthetic osteolysis (PPO) is the leading complication of total joint arthroplasty (TJA) and results in patients having to receive revision surgery. However, there is still no efficient drug to prevent or even slow the pathological process. Herein, we report novel dual targeted, curcumin loaded Poly lactic co glycolic acid nanoparticles (ZSCNPs) to inhibit polyethylene induced osteolysis. These ZSCNPs have good biocompatibility and excellent bone binding affinity. Under external magnetic field guidance, the ZSCNPs can specifically target osteolytic sites with sustained curcumin release, efficiently suppress the effect of I kappa B kinase, subsequently inhibit activation of the nuclear factor kappa B (NF kappa B) signaling pathway, and ultimately prevent osteoclast formation and particle induced osteolysis. Therefore, these novel dual targeted, drug loaded nanoparticles could be applied as a useful strategy for targeted treatment of PPO after TJA.
C1 [Li, Jingyi; Jiang, Zichao; Zhang, Zhen; Pan, Yixiao; Xing, Qiqi; Guo, Qi; An, Senbo; Hu, Yihe; Wang, Long] Cent South Univ, Xiangya Hosp, Dept Orthoped, Changsha, Peoples R China.
   [Li, Jingyi; Jiang, Zichao; Zhang, Zhen; Pan, Yixiao; Xing, Qiqi; Guo, Qi; An, Senbo; Hu, Yihe; Wang, Long] Cent South Univ, Xiangya Hosp, Hunan Engn Res Ctr Biomed Met & Ceram Implants, Dept Orthoped, Changsha, Peoples R China.
   [Niu, Chengcheng] Cent South Univ, Xiangya Hosp 2, Dept Ultrasound Diag, Changsha, Peoples R China.
   [Niu, Chengcheng] Cent South Univ, Xiangya Hosp 2, Res Ctr Ultrasonog, Changsha, Peoples R China.
C3 Central South University; Central South University; Central South
   University; Central South University
RP Wang, L (通讯作者)，Cent South Univ, Xiangya Hosp, Dept Orthoped, Changsha, Peoples R China.; Wang, L (通讯作者)，Cent South Univ, Xiangya Hosp, Hunan Engn Res Ctr Biomed Met & Ceram Implants, Dept Orthoped, Changsha, Peoples R China.
EM dr_wanglong@csu.edu.cn
RI ; niu, chengcheng/S 8269 2017
OI Wang, Long/0000 0002 2733 7370; 
FU National Natural Science Foundation of China [81601883, 81974267]; Hunan
   Provincial Natural Science Foundation of China [2018JJ3861]; Hunan
   Provincial Health Commission Research Foundation Project [B2019166];
   Fundamental Research Funds for the Central Universities of Central South
   University
FX This project was funded by the National Natural Science Foundation of
   China (Grant No. 81601883 and 81974267), Hunan Provincial Natural
   Science Foundation of China (Grant 2018JJ3861) and Hunan Provincial
   Health Commission Research Foundation Project (B2019166) and the
   Fundamental Research Funds for the Central Universities of Central South
   University.
CR An SB, 2018, CELL PHYSIOL BIOCHEM, V50, P1100, DOI 10.1159/000494537
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Beck RT, 2012, J ORTHOP RES, V30, P541, DOI 10.1002/jor.21554
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Chin KY, 2016, DRUG DES DEV THER, V10, P3029, DOI 10.2147/DDDT.S117432
   Desai MA, 2008, ORTHOPEDICS, V31, P518, DOI 10.3928/01477447 20080601 07
   Fiume G, 2015, SCI REP UK, V5, DOI 10.1038/srep13864
   Gautam SC, 2007, ADV EXP MED BIOL, V595, P321
   Goodship AE, 2008, J ORTHOP RES, V26, P693, DOI 10.1002/jor.20533
   Jiang JH, 2016, AM J PATHOL, V186, P57, DOI 10.1016/j.ajpath.2015.09.006
   Kunwar A, 2016, ADV EXP MED BIOL, V928, P1, DOI 10.1007/978 3 319 41334 1_1
   Li B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00055
   Huynh NCN, 2017, BONE, V95, P76, DOI 10.1016/j.bone.2016.11.017
   Niu CC, 2013, BIOMATERIALS, V34, P2307, DOI 10.1016/j.biomaterials.2012.12.003
   Ouyang ZX, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00584
   Panmekiate S, 2015, DENTOMAXILLOFAC RAD, V44, DOI 10.1259/dmfr.20140322
   Park KR, 2018, THERANOSTICS, V8, P3087, DOI 10.7150/thno.24426
   Pontoriero M, 2019, J MOL MED, V97, P675, DOI 10.1007/s00109 019 01777 x
   Singh T, 2015, J DRUG TARGET, V23, P1, DOI 10.3109/1061186X.2014.950668
   Tang K, 2018, RSC ADV, V8, P5407, DOI 10.1039/c7ra13091k
   Termaat MF, 2005, J BONE JOINT SURG AM, V87A, P1367, DOI 10.2106/JBJS.D.02585
   Wang L, 2020, J MATER CHEM B, V8, P4132, DOI 10.1039/d0tb00364f
   Wang L, 2018, ACS APPL MATER INTER, V10, P42102, DOI 10.1021/acsami.8b16323
   Wang L, 2016, INFLAMMATION, V39, P218, DOI 10.1007/s10753 015 0241 y
   Wilken R, 2011, MOL CANCER, V10, DOI 10.1186/1476 4598 10 12
NR 26
TC 6
Z9 6
U1 1
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD DEC 4
PY 2020
VL 11
AR 600156
DI 10.3389/fphar.2020.600156
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PG7PI
UT WOS:000599922700001
PM 33343370
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Deng, XH
   Xiao, WL
   Lin, BF
   Wang, F
   Song, L
   Wang, NN
AF Deng, Xuehui
   Xiao, Wenlong
   Lin, Bingfeng
   Wang, Fang
   Song, Li
   Wang, Nani
TI Synergistic anti osteoporosis effects of Anemarrhena
   asphodeloides bunge Phellodendron chinense CK Schneid herb pair via
   ferroptosis suppression in ovariectomized mice
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Anemarrhena asphodeloides bunge;
   Phellodendron chinense CK Schneid; herb pair;
   osteoporosis; ferroptosis
ID INDUCED OSTEOCLAST DIFFERENTIATION; LIPID PEROXIDATION; KAPPA B;
   ACTIVATION; CELLS; ACSL4
AB Introduction Ferroptosis plays a crucial role in the progression of postmenopausal osteoporosis. Anemarrhena asphodeloides Bunge/Phellodendron chinense C.K. Schneid (AA/PC) is the core herb pair in traditional Chinese medicines formulae for postmenopausal osteoporosis treatment. However, the synergistic effects, and mechanisms, of AA/PC on alleviating ferroptosis and postmenopausal osteoporosis remain unclear.Methods The goal herein was to analyze the effective ingredients and molecular mechanisms of AA/PC in the treatment of osteoporosis through serum pharmacochemistry, network pharmacology, metabolomics analysis, and pharmacodynamics evaluation. A bilateral ovariectomized (OVX) mouse model was established.Results and Discussion Micron scale computed tomography analysis showed that AA/PC increased bone mineral density in OVX mice. The effects of AA/PC were better than AA or PC alone on inhibiting the bone resorption marker nuclear factor of activated T cells 1. Furthermore, five absorbable compounds were detected in serum: mangiferin, magnoflorine, berberine, timosaponin BIII, and timosaponin AIII. Network pharmacology showed these compounds had close relationship with seven ferroptosis targets. Importantly, compared with AA or PC alone, the AA/PC herb pair exerted better effects on regulating crucial ferroptosis pathways, including the system xc /glutathione/glutathione peroxidase 4, transferrin receptor/ferritin, and acyl CoA synthetase long chain family member 4/polyunsaturated fatty acids signaling pathways. These results indicate that AA/PC exerts synergistic effects on regulating glutathione synthesis, iron homeostasis, and lipid metabolism in ferroptosis. This work lays the foundation for further development and use of AA/PC herb pair for preventing and treating postmenopausal osteoporosis.
C1 [Deng, Xuehui; Wang, Nani] Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou, Peoples R China.
   [Deng, Xuehui; Xiao, Wenlong; Lin, Bingfeng; Wang, Fang; Song, Li; Wang, Nani] Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou, Peoples R China.
   [Xiao, Wenlong; Wang, Nani] Hangzhou Med Coll, Sch Pharm, Hangzhou, Peoples R China.
C3 Zhejiang Chinese Medical University; Hangzhou Medical College
RP Wang, NN (通讯作者)，Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou, Peoples R China.; Wang, NN (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou, Peoples R China.; Wang, NN (通讯作者)，Hangzhou Med Coll, Sch Pharm, Hangzhou, Peoples R China.
EM wnn8511@163.com
FU National Natural Science Foundation of China [82374012, 81973447];
   Zhejiang Provincial Natural Science Foundation of China [TGC24H280004];
   Zhejiang Provincial Medicine Foundation [2024ZR007, 2024ZR001,
   2024KY867, 2022ZX002, GZY ZJ KJ 23006, GZY ZJ SY 2402]
FX The author(s) declare that financial support was received for the
   research, authorship, and/or publication of this article. This work was
   supported by the National Natural Science Foundation of China [grant
   number 82374012, 81973447]; Zhejiang Provincial Natural Science
   Foundation of China [grant number TGC24H280004]; Zhejiang Provincial
   Medicine Foundation [grant number 2024ZR007, 2024ZR001, 2024KY867,
   2022ZX002, GZY ZJ KJ 23006]; State Administration of Traditional Chinese
   Medicine Science and Technology Department Zhejiang Provincial
   Administration of Traditional Chinese Medicine Co construction of Key
   Laboratory of Research on Prevention and Treatment for depression
   syndrome [grant number GZY ZJ SY 2402].
CR Aihaiti Y, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.672054
   Ali D, 2022, AGING CELL, V21, DOI 10.1111/acel.13726
   Blain H, 2008, BONE, V43, P862, DOI 10.1016/j.bone.2008.07.236
   Chen QC, 2021, J BONE MINER METAB, V39, P748, DOI 10.1007/s00774 021 01225 2
   Chen Xinlei, 2020, AUTOPHAGY, DOI DOI 10.1080/15548627.2020.1810918
   Cui Y, 2021, BRAIN BEHAV IMMUN, V93, P312, DOI 10.1016/j.bbi.2021.01.003
   Deng XH, 2024, PHYTOMEDICINE, V124, DOI 10.1016/j.phymed.2023.155282
   Gao ZH, 2022, EXP GERONTOL, V165, DOI 10.1016/j.exger.2022.111836
   Han SY, 2019, AM J CHINESE MED, V47, P439, DOI [10.1142/S0192415X19500228, 10.1142/s0192415x19500228]
   Hu CX, 2020, J PROTEOME RES, V19, P455, DOI 10.1021/acs.jproteome.9b00637
   Hu XQ, 2022, PHYTOMEDICINE, V105, DOI 10.1016/j.phymed.2022.154384
   Hu YX, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.986384
   Huang CQ, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 05362 y
   Ke ZB, 2019, J CELL PHYSIOL, V234, P19942, DOI 10.1002/jcp.28592
   Kim BJ, 2012, J BONE MINER RES, V27, P2279, DOI 10.1002/jbmr.1692
   Kim C, 2012, J WOMENS HEALTH, V21, P872, DOI 10.1089/jwh.2012.3549
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Li Bo, 2022, Phytomedicine, V102, P154198, DOI 10.1016/j.phymed.2022.154198
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Li J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2298 2
   Li P, 2024, BIOMED REP, V20, DOI 10.3892/br.2023.1715
   Lin BF, 2023, INT J BIOL MACROMOL, V231, DOI 10.1016/j.ijbiomac.2023.123324
   Liu J, 2022, FEBS J, V289, P7038, DOI 10.1111/febs.16059
   Liu J, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420 022 00902 z
   Ma GX, 2021, FOOD FUNCT, V12, P5539, DOI [10.1039/d0fo02567d, 10.1039/D0FO02567D]
   Mahana A, 2023, J ETHNOPHARMACOL, V300, DOI 10.1016/j.jep.2022.115750
   Michopoulos F, 2009, J PROTEOME RES, V8, P2114, DOI 10.1021/pr801045q
   O'Boyle NM, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758 2946 4 22
   Park E, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2064 5
   Perez MA, 2020, DEV CELL, V54, P447, DOI 10.1016/j.devcel.2020.06.019
   Shen XB, 2022, BIOORG CHEM, V119, DOI 10.1016/j.bioorg.2021.105546
   Shi JW, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.898360
   Song CZ, 2023, FOOD FUNCT, V14, P1087, DOI [10.1039/d2fo03331c, 10.1039/D2FO03331C]
   Sun ZY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00389
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Tang DL, 2021, CELL RES, V31, P107, DOI 10.1038/s41422 020 00441 1
   Tao HQ, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105967
   Ursini F, 2020, FREE RADICAL BIO MED, V152, P175, DOI 10.1016/j.freeradbiomed.2020.02.027
   Wang L, 2021, J ETHNOPHARMACOL, V273, DOI 10.1016/j.jep.2021.113988
   Wang NN, 2021, FREE RADICAL BIO MED, V171, P112, DOI 10.1016/j.freeradbiomed.2021.05.014
   Wang NN, 2020, PHYTOMEDICINE, V75, DOI 10.1016/j.phymed.2020.153247
   Wu YH, 2019, BIOMED PHARMACOTHER, V109, P2252, DOI 10.1016/j.biopha.2018.11.095
   Xia CJ, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110170
   Xiang ZJ, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11060799
   Xu PC, 2022, FREE RADICAL BIO MED, V193, P720, DOI 10.1016/j.freeradbiomed.2022.11.013
   Xu PC, 2022, J ETHNOPHARMACOL, V293, DOI 10.1016/j.jep.2022.115269
   Xue CC, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1234563
   Yan CL, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.910675
   Yang RZ, 2021, J CELL PHYSIOL, V236, P6691, DOI 10.1002/jcp.30331
   Yang YQ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00198 w
   Yi JZ, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420 021 00768 7
   Yuan SY, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13158
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhang FZ, 2018, J CELL PHYSIOL, V233, P4626, DOI 10.1002/jcp.26187
   Zhang HL, 2022, NAT CELL BIOL, V24, P88, DOI 10.1038/s41556 021 00818 3
   Zhang XJ, 2024, MOL MED REP, V30, DOI 10.3892/mmr.2024.13257
   Zhang ZW, 2022, CELLS BASEL, V11, DOI 10.3390/cells11162560
   Zhao XN, 2018, BIOMED CHROMATOGR, V32, DOI 10.1002/bmc.4296
   Zhou C, 2023, INT J BIOL SCI, V19, P1471, DOI 10.7150/ijbs.77979
   Zhu HH, 2021, RESP RES, V22, DOI 10.1186/s12931 021 01781 1
NR 60
TC 0
Z9 0
U1 6
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 24
PY 2024
VL 15
AR 1378634
DI 10.3389/fphar.2024.1378634
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA L1U5J
UT WOS:001348642500001
PM 39512823
OA gold
DA 2025 08 17
ER

PT J
AU Fantasia, JE
AF Fantasia, John E.
TI The Role of Antiangiogenic Therapy in the Development of Osteonecrosis
   of the Jaw
SO ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Antiangiogenic therapy; Vascular endothelial growth factor inhibitors;
   Tyrosine kinase inhibitors; Mammalian target of rapamycin inhibitors;
   Nitrogen containing bisphosphonates; Receptor activator of nuclear
   factor kappa B ligand inhibitors; Denosumab
ID BISPHOSPHONATE RELATED OSTEONECROSIS; MULTIPLE MYELOMA PATIENTS;
   ZOLEDRONIC ACID; CLINICAL FEATURES; CANCER PATIENTS; IN VIVO;
   BEVACIZUMAB; PATIENT; SUNITINIB; COMBINATION
AB There is an increasing use of established and newer medications that have antiangiogenic properties. Inhibition of angiogenesis likely has either a primary or secondary role in the development of osteonecrosis of the jaw (ONJ). These medications are being used in the treatment of various cancers and in the treatment of several non oncologic conditions. Antiangiogenic medications, when used in combination with antiresorptive medications such as nitrogen containing bisphosphonates or denosumab, seem to increase the likelihood of osteonecrosis of the jaw. This review highlights the role of inhibitors of angiogenesis and their role in the development of osteonecrosis of the jaws.
C1 [Fantasia, John E.] Hofstra North Shore LIJ Sch Med, Div Oral & Maxillofacial Pathol, Dept Dent Med, New Hyde Pk, NY 11040 USA.
C3 Hofstra University; Northwell Health
RP Fantasia, JE (通讯作者)，Hofstra North Shore LIJ Sch Med, Div Oral & Maxillofacial Pathol, Dept Dent Med, 270 05 76th Ave, New Hyde Pk, NY 11040 USA.
EM fantasia@lij.edu
CR Agrillo A, 2012, EUR REV MED PHARMACO, V16, P952
   Arduino PG, 2011, J ORAL PATHOL MED, V40, P510, DOI 10.1111/j.1600 0714.2010.01004.x
   Ayllon J, 2009, ANN ONCOL, V20, P600, DOI 10.1093/annonc/mdn788
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Balmor GR, 2012, ISR MED ASSOC J, V14, P193
   Bettini G, 2012, BMJ Case Rep
   Beuselinck B, 2012, BRIT J CANCER, V107, P1665, DOI 10.1038/bjc.2012.385
   Binello PB, 2012, INT J IMMUNOPATH PH, V25, P789, DOI 10.1177/039463201202500328
   Bozas G, 2010, ONKOLOGIE, V33, P321, DOI 10.1159/000313680
   Brunello A, 2009, BONE, V44, P173, DOI 10.1016/j.bone.2008.08.132
   Christodoulou C, 2009, ONCOLOGY BASEL, V76, P209, DOI 10.1159/000201931
   Disel U, 2012, ORAL ONCOL, V48, pE2, DOI 10.1016/j.oraloncology.2011.07.030
   Estilo CL, 2008, J CLIN ONCOL, V26, P4037, DOI 10.1200/JCO.2007.15.5424
   Fakih MG, 2006, ONCOLOGIST, V11, P85, DOI 10.1634/theoncologist.11 1 85
   Fangusaro J, 2013, J CLIN ONCOL, V31, pE24, DOI 10.1200/JCO.2012.43.6733
   Fleissig Y, 2012, OR SURG OR MED OR PA, V113, pE1, DOI 10.1016/j.tripleo.2011.06.023
   Francini F, 2011, J AM DENT ASSOC, V142, P506, DOI 10.14219/jada.archive.2011.0220
   Greuter S, 2008, ANN ONCOL, V19, P2091, DOI 10.1093/annonc/mdn653
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549 010 0866 3
   Guillet M, 2010, J CLIN ONCOL, V28, pE14, DOI 10.1200/JCO.2009.23.4252
   Hoefert S, 2010, ORAL SURG ORAL MED O, V110, P463, DOI 10.1016/j.tripleo.2010.04.049
   Hopp RN, 2012, J ORAL MAXIL SURG, V70, P632, DOI 10.1016/j.joms.2011.02.104
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Katsenos S, 2012, ARCH BRONCONEUMOL, V48, P218, DOI [10.1016/j.arbr.2012.03.004, 10.1016/j.arbres.2012.01.007]
   Koch FP, 2011, ORAL MAXILLOFAC SURG, V15, P63, DOI 10.1007/s10006 010 0224 y
   Koczywas M, 2011, J THORAC ONCOL, V6, P1960, DOI 10.1097/JTO.0b013e31822e726f
   Kyrgidis A, 2011, OSTEOPOROSIS INT, V22, P369, DOI 10.1007/s00198 010 1177 6
   Lane HA, 2009, CLIN CANCER RES, V15, P1612, DOI 10.1158/1078 0432.CCR 08 2057
   Lescaille G, 2014, BONE, V58, P103, DOI 10.1016/j.bone.2013.10.002
   Magremanne M, 2013, J ORAL MAXIL SURG, V71, P53, DOI 10.1016/j.joms.2012.03.022
   Misso G, 2012, CANCER BIOL THER, V13, P1491, DOI 10.4161/cbt.22274
   Ngamphaiboon N, 2011, CLIN BREAST CANCER, V11, P252, DOI 10.1016/j.clbc.2011.02.001
   Nicolatou Galitis O, 2012, OR SURG OR MED OR PA, V113, P234, DOI 10.1016/j.tripleo.2011.08.024
   Otto S, 2012, J CRANIO MAXILL SURG, V40, P303, DOI 10.1016/j.jcms.2011.05.003
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Santos Silva AR, 2013, OR SURG OR MED OR PA, V115, pE32, DOI 10.1016/j.oooo.2013.02.001
   Sato Manabu, 2013, Nihon Shokakibyo Gakkai Zasshi, V110, P655
   Serra E, 2009, INT J IMMUNOPATH PH, V22, P1121, DOI 10.1177/039463200902200429
   Shim K, 2008, DRUG SAFETY, V31, P359, DOI 10.2165/00002018 200831050 00001
   Sivolella S, 2013, ANTICANCER RES, V33, P1793
   Smidt Hansen T, 2013, J ORAL MAXIL SURG, V71, P1532, DOI 10.1016/j.joms.2013.03.019
   Stresing V, 2011, BONE, V48, P259, DOI 10.1016/j.bone.2010.09.035
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   Tosi P, 2006, BLOOD, V108, P3951, DOI 10.1182/blood 2006 07 033571
   Traina TA, 2006, ONCOLOGIST, V11, P1070, DOI 10.1634/theoncologist.11 10 1070
   Vincenzi B, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 56
   Yabu T, 2005, BLOOD, V106, P125, DOI 10.1182/blood 2004 09 3679
NR 47
TC 23
Z9 25
U1 1
U2 5
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 1042 3699
EI 1558 1365
J9 ORAL MAXIL SURG CLIN
JI Oral Maxillofac. Surg. Clin. N. Am.
PD NOV
PY 2015
VL 27
IS 4
BP 547
EP +
DI 10.1016/j.coms.2015.06.004
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CX1OV
UT WOS:000365466400009
PM 26515736
DA 2025 08 17
ER

PT J
AU Yang, X
   Liang, JM
   Wang, ZY
   Su, YG
   Zhan, YF
   Wu, ZX
   Li, J
   Li, XD
   Chen, RF
   Zhao, JM
   Xu, JK
   Liu, Q
   Zhou, B
AF Yang, Xue
   Liang, Jiamin
   Wang, Ziyi
   Su, Yuangang
   Zhan, Yunfei
   Wu, Zuoxing
   Li, Jing
   Li, Xuedong
   Chen, Runfeng
   Zhao, Jinmin
   Xu, Jiake
   Liu, Qian
   Zhou, Bo
TI Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting
   Osteoclastogenesis and RANKL Mediated NF κB and MAPK Signaling Pathways
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE sesamolin; NF kappa B; MAPK; osteoclast; postmenopausal osteoporosis
ID RECEPTOR ACTIVATOR; NUCLEAR FACTOR; CANCER CELLS; DIFFERENTIATION;
   OSTEOPOROSIS; NFATC1; PREVALENCE; ESTROGEN
AB This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology. Postmenopausal osteoporosis (PMOP), which increases the risk of fracture, is the most common bone disease in women. PMOP not only increases the risk of death but also imposes a financial burden on countless families. At present, most of the drugs used to treat osteoporosis have significant side effects, so it is important to find effective anti osteoporosis medications without major side effects. Sesamolin (Ses) is a kind of natural lignan extracted from sesame oil. Many researches have shown that Ses has anti inflammatory, antioxidative, and anticancer effects, however it is still unknown whether it has any effect on osteoporosis. In this research, we explored the therapeutic effect of Ses in the process of osteoclast formation and bone resorption and found that Ses effectively inhibited osteoclast formation in vitro through TRAcP staining and hydroxyapatite resorption assays. Through Western blot analysis of the NF kappa B pathway, MAPK pathway, c Fos and NFATc1, it was found that Ses not only effectively inhibited the activation of NF kappa B and MAPK signaling pathways induced by RANKL but also significantly reduced the protein expression of c Fos and NFATc1. Several genes specifically expressed in osteoclasts were determined by qPCR, and Ses was also found to play a significant inhibitory role on the expression of these genes. Besides, an osteoporosis model induced in ovariectomized (OVX) mice was employed to verify that Ses could effectively reduce bone loss caused by estrogen deficiency in vivo. In conclusion, Ses showed promise as a new treatment for postmenopausal osteoporosis.
C1 [Yang, Xue; Liang, Jiamin; Su, Yuangang; Li, Jing; Li, Xuedong; Chen, Runfeng; Zhao, Jinmin; Zhou, Bo] Guangxi Med Univ, Guangxi ASEAN Collaborat Innovat Ctr Major Dis Pr, Guangxi Key Lab Regenerat Med, Guangxi, Peoples R China.
   [Wang, Ziyi; Xu, Jiake] Univ WA, Sch Biomed Sci, Perth, WA, Australia.
   [Zhan, Yunfei] Jiu Jiang 1 Peoples Hosp, Jiujiang, Jiangxi, Peoples R China.
   [Wu, Zuoxing] Xiamen Univ, Sch Med, Zhongshan Hosp, Dept Nucl Med, Fujian, Peoples R China.
   [Zhao, Jinmin; Xu, Jiake; Liu, Qian] Guangxi Med Univ, Dept Orthopaed, Res Ctr Regenerat Med, Affiliated Hosp 1, Guangxi, Peoples R China.
C3 Guangxi Medical University; University of Western Australia; Xiamen
   University; Guangxi Medical University
RP Zhou, B (通讯作者)，Guangxi Med Univ, Guangxi ASEAN Collaborat Innovat Ctr Major Dis Pr, Guangxi Key Lab Regenerat Med, Guangxi, Peoples R China.; Liu, Q (通讯作者)，Guangxi Med Univ, Dept Orthopaed, Res Ctr Regenerat Med, Affiliated Hosp 1, Guangxi, Peoples R China.
EM liuqian@gxmu.edu.cn; zhoubo@gxmu.edu.cn
RI Su, Yuangang/KKU 6952 2024; zhao, jin/LBH 0351 2024; li,
   xuedong/JYP 4367 2024
OI Wang, Ziyi/0000 0002 1334 7287; Xu, Jiake/0000 0003 2021 8309; 
FU National Science Foundation of China [81860655, 81960405]; Natural
   Science Foundation of Guangxi Province [2018GXNSFAA050092]
FX This research was supported by National Science Foundation of China
   (Nos. 81860655 and 81960405) and Natural Science Foundation of Guangxi
   Province (No. 2018GXNSFAA050092).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Baek SH, 2020, CURR PHARM BIOTECHNO, V21, P169, DOI 10.2174/1389201020666191011151123
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Cheng H, 2009, OSTEOPOROSIS INT, V20, P1507, DOI 10.1007/s00198 009 0835 z
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Honma M, 2021, PHARMACOL THERAPEUT, V218, DOI 10.1016/j.pharmthera.2020.107682
   Hou RCW, 2005, ANN NY ACAD SCI, V1042, P279, DOI 10.1196/annals.1338.050
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kim JG, 2007, MENOPAUSE, V14, P913, DOI 10.1097/gme.0b013e31802d976f
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Lee SE, 2018, INT IMMUNOPHARMACOL, V64, P16, DOI 10.1016/j.intimp.2018.08.027
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mediero A, 2013, BRIT J PHARMACOL, V169, P1372, DOI 10.1111/bph.12227
   Michailidis D, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00723
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Noel SE, 2018, J BONE MINER RES, V33, P396, DOI 10.1002/jbmr.3315
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Pathak Niti, 2014, Pharmacogn Rev, V8, P147, DOI 10.4103/0973 7847.134249
   PECK WA, 1993, AM J MED, V94, P646
   Piri F, 2016, J CLIN DIAGN RES, V10, pAF1, DOI 10.7860/JCDR/2016/18648.8433
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Shinohara Masahiro, 2007, Curr Osteoporos Rep, V5, P67
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Soysa Niroshani Surangika, 2012, J Med Dent Sci, V59, P65
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Svedbom A, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0137 0
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tatangelo G, 2019, J BONE MINER RES, V34, P616, DOI 10.1002/jbmr.3640
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wu D, 2019, CELL MOL BIOL, V65, P96, DOI 10.14715/cmb/2019.65.6.16
   Wu MS, 2019, MOLECULES, V24, DOI 10.3390/molecules24244426
   Xing LP, 2013, BONE RES, V1, P336, DOI 10.4248/BR201304004
   Xiong Q, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/596789
NR 44
TC 31
Z9 31
U1 2
U2 32
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 14
PY 2021
VL 12
AR 664697
DI 10.3389/fphar.2021.664697
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA TA4AF
UT WOS:000667190900001
PM 34194327
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yeon, JT
   Kim, KJ
   Chun, SW
   Lee, HI
   Lim, JY
   Son, YJ
   Kim, SH
   Choi, SW
AF Yeon, Jeong Tae
   Kim, Kwang Jin
   Chun, Sang Woo
   Lee, Hae In
   Lim, Ji Yeon
   Son, Young Jin
   Kim, Seong Hwan
   Choi, Sik Won
TI KCNK1 inhibits osteoclastogenesis by blocking the Ca<SUP>2+</SUP>
   oscillation and JNK NFATc1 signaling axis
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE K+ channel; KCNK1; Osteoclast; Ca2+; JNK; NFATc1
ID NF KAPPA B; C JUN; K+ CHANNEL; RECEPTOR ACTIVATOR; BONE RESORPTION;
   DIFFERENTIATION; TWIK 1; EXPRESSION; CELL; MECHANISM
AB KCNK1 (K+ channel, subfamily K, member 1) is a member of the inwardly rectifying K+ channel family, which drives the membrane potential towards the K+ balance potential. Here, we investigated its functional relevance during osteoclast differentiation. KCNK1 was significantly induced during osteoclast differentiation, but its functional overexpression significantly inhibited osteoclast differentiation induced by RANKL (also known as TNFSF11), which was accompanied by the attenuation of the RANKL induced Ca2+ oscillation, JNK activation and NFATc1 expression. In contrast, KCNK1 knockdown enhanced the RANKL induced osteoclast differentiation, JNK activation and NFATc1 expression. In conclusion, we suggest that KCNK1 is a negative regulator of osteoclast differentiation; the increase of K+ influx by its functional blockade might inhibit osteoclast differentiation by inhibiting Ca2+ oscillation and the JNK NFATc1 signaling axis. Together with the increased attention on the pharmacological possibilities of using channel inhibition in the treatment of osteoclast related disorders, further understanding of the functional roles and mechanisms of K+ channels underlying osteoclast related diseases could be helpful in developing relevant therapeutic strategies.
C1 [Yeon, Jeong Tae] Sunchon Natl Univ, Res Inst Basic Sci, Sunchon 540742, South Korea.
   [Kim, Kwang Jin; Son, Young Jin] Sunchon Natl Univ, Dept Pharm, Sunchon 540742, South Korea.
   [Chun, Sang Woo; Lee, Hae In] Wonkwang Univ, Inst Wonkwang Biomaterial & Implant, Coll Dent, Dept Oral Physiol, Iksan 570749, South Korea.
   [Lim, Ji Yeon; Kim, Seong Hwan; Choi, Sik Won] Korea Res Inst Chem Technol, Drug Discovery Div, Pharmacol Res Ctr, Lab Translat Therapeut, Taejon 305600, South Korea.
C3 Sunchon National University; Sunchon National University; Wonkwang
   University; Korea Research Institute of Chemical Technology (KRICT)
RP Kim, SH (通讯作者)，Korea Res Inst Chem Technol, Drug Discovery Div, Pharmacol Res Ctr, Lab Translat Therapeut, Taejon 305600, South Korea.
EM hwan@krict.re.kr; superwon@krict.re.kr
RI Kim, Seong/AAA 6086 2021; Jin Ho, Seo/B 3621 2014
OI Choi, Sik Won/0000 0003 1726 2536; 
FU Korea Research Institute of Chemical Technology [SI 1404]
FX This work was supported by a project grant [grant number SI 1404] from
   the Korea Research Institute of Chemical Technology.
CR ARKETT SA, 1992, J PHYSIOL LONDON, V458, P633, DOI 10.1113/jphysiol.1992.sp019438
   Arrighi I, 1998, FEBS LETT, V425, P310, DOI 10.1016/S0014 5793(98)00260 9
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Choi SW, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 35
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Enyedi P, 2010, PHYSIOL REV, V90, P559, DOI 10.1152/physrev.00029.2009
   Espinosa L, 2002, J CELL SCI, V115, P3837, DOI 10.1242/jcs.00062
   Jimi E, 1999, J IMMUNOL, V163, P434
   Kajiya H, 2003, AM J PHYSIOL CELL PH, V285, pC457, DOI 10.1152/ajpcell.00033.2003
   KELLY MEM, 1992, J MEMBRANE BIOL, V126, P171
   Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014 5793(98)01731 1
   Lesage F, 1997, FEBS LETT, V402, P28, DOI 10.1016/S0014 5793(96)01491 3
   Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460 2075.1996.tb00437.x
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Nie X, 2005, PFLUG ARCH EUR J PHY, V451, P479, DOI 10.1007/s00424 005 1480 9
   Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Shibata Toshiya, 1996, Osaka City Medical Journal, V42, P93
   SIMS SM, 1989, AM J PHYSIOL, V256, pC1277, DOI 10.1152/ajpcell.1989.256.6.C1277
   Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Valverde P, 2005, J DENT RES, V84, P488, DOI 10.1177/154405910508400603
   Valverde P, 2004, J BONE MINER RES, V19, P155, DOI 10.1359/JBMR.0301213
   Vicente R, 2003, J BIOL CHEM, V278, P46307, DOI 10.1074/jbc.M304388200
   Yang SY, 2007, GENE DEV, V21, P1803, DOI 10.1101/gad.1544107
   Zhou M, 2009, J NEUROSCI, V29, P8551, DOI 10.1523/JNEUROSCI.5784 08.2009
NR 33
TC 13
Z9 16
U1 0
U2 3
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0021 9533
EI 1477 9137
J9 J CELL SCI
JI J. Cell Sci.
PD SEP 15
PY 2015
VL 128
IS 18
BP 3411
EP 3419
DI 10.1242/jcs.170738
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CS6IQ
UT WOS:000362182400006
PM 26208638
OA Bronze
DA 2025 08 17
ER

PT J
AU Putnam, NE
   Fulbright, LE
   Curry, JM
   Ford, CA
   Petronglo, JR
   Hendrix, AS
   Cassat, JE
AF Putnam, Nicole E.
   Fulbright, Laura E.
   Curry, Jacob M.
   Ford, Caleb A.
   Petronglo, Jenna R.
   Hendrix, Andrew S.
   Cassat, James E.
TI MyD88 and IL 1R signaling drive antibacterial immunity and
   osteoclast driven bone loss during Staphylococcus aureus osteomyelitis
SO PLOS PATHOGENS
LA English
DT Article
ID RESORBING ACTIVITY; NEUTROPHIL RECRUITMENT; BACTERIAL INFECTIONS;
   ACTIVATING FACTOR; MICE DEFICIENT; INTERLEUKIN 1; IL 1 BETA;
   DIFFERENTIATION; MACROPHAGE; RECEPTOR
AB Staphylococcus aureus is able to infect virtually all organ systems and is a frequently isolated etiologic agent of osteomyelitis, a common and debilitating invasive infection of bone. Treatment of osteomyelitis requires invasive surgical procedures and prolonged antibiotic therapy, yet is frequently unsuccessful due to extensive pathogen induced bone damage that can limit antibiotic penetration and immune cell influx to the infectious focus. We previously established that S. aureus triggers profound alterations in bone remodeling in a murine model of osteomyelitis, in part through the production of osteolytic toxins. However, staphylococcal strains lacking osteolytic toxins still incite significant bone destruction, suggesting that host immune responses are also major drivers of pathologic bone remodeling during osteomyelitis. The objective of this study was to identify host immune pathways that contribute to antibacterial immunity during S. aureus osteomyelitis, and to define how these immune responses alter bone homeostasis and contribute to bone destruction. We specifically focused on the interleukin 1 receptor (IL 1R) and downstream adapter protein MyD88 given the prominent role of this signaling pathway in both antibacterial immunity and osteo immunologic crosstalk. We discovered that while IL 1R signaling is necessary for local control of bacterial replication during osteomyelitis, it also contributes to bone loss during infection. Mechanistically, we demonstrate that S. aureus enhances osteoclastogenesis of myeloid precursors in vitro, and increases the abundance of osteoclasts residing on bone surfaces in vivo. This enhanced osteoclast abundance translates to trabecular bone loss, and is dependent on intact IL 1R signaling. Collectively, these data define IL 1R signaling as a critical component of the host response to S. aureus osteomyelitis, but also demonstrate that IL 1R dependent immune responses trigger collateral bone damage through activation of osteoclast mediated bone resorption.
   Author summary Osteomyelitis is a common, debilitating infection of bone that rarely resolves without prolonged antibiotics and invasive surgical procedures. This study explores the role of host inflammation during osteomyelitis. Our findings highlight innate immune responses that are critical for control of S. aureus burdens in bone, prevention of bacterial dissemination, and death. Conversely, these same immune pathways were found to contribute to disease pathogenesis by activating infection associated bone loss. Such bone loss is associated with detrimental outcomes during osteomyelitis, including pathologic fractures and irreversible changes in bone growth plates. Alterations in bone remodeling that occur during S. aureus osteomyelitis are multifaceted, driven by bacterial toxins and inflammation mediated changes. We found that inflammation incited by S. aureus in bone contributes to pathologic bone loss. We highlight a mechanism by which S. aureus stimulates formation of bone resorbing osteoclasts both in vitro and in vivo. Our data illustrate connections between innate immune signaling pathways and bone homeostasis. These connections may be relevant to other autoinflammatory bone and joint conditions characterized by bone loss, such as rheumatoid arthritis. Collectively, this work outlines the fine balance between promotion of bacterial clearance and protection from collateral tissue damage.
C1 [Putnam, Nicole E.; Petronglo, Jenna R.; Cassat, James E.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.
   [Fulbright, Laura E.; Curry, Jacob M.; Hendrix, Andrew S.; Cassat, James E.] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pediat Infect Dis, Nashville, TN 37232 USA.
   [Ford, Caleb A.; Cassat, James E.] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA.
   [Cassat, James E.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Infect Immunol & Inflammat VI4, Nashville, TN 37232 USA.
   [Cassat, James E.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Bone Biol, Nashville, TN 37232 USA.
   [Hendrix, Andrew S.] Univ Toledo, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Vanderbilt University; Vanderbilt University; University System of Ohio;
   University of Toledo
RP Cassat, JE (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Cassat, JE (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pediat Infect Dis, Nashville, TN 37232 USA.; Cassat, JE (通讯作者)，Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA.; Cassat, JE (通讯作者)，Vanderbilt Univ, Med Ctr, Vanderbilt Inst Infect Immunol & Inflammat VI4, Nashville, TN 37232 USA.; Cassat, JE (通讯作者)，Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Bone Biol, Nashville, TN 37232 USA.
EM jim.cassat@vanderbilt.edu
RI ; Ford, Caleb/ABI 1793 2020; Putnam, Nicole/AAV 4297 2020; Cassat,
   James/KWU 8809 2024; Curry, Jacob/NRB 4759 2025
OI Putnam, Nicole/0000 0002 7975 0503; Petronglo,
   Jenna/0000 0001 9969 6607; Ford, Caleb/0000 0002 3710 8037; Curry,
   Jacob/0000 0002 9242 0461; 
FU National Institute of Allergy and Infectious Diseases [1F30AI138424,
   1R01AI132560, 5K08AI113107, 1F31AI133926]; Burroughs Wellcome Fund;
   National Institute of General Medical Sciences [T32GM007347]; National
   Institute of Arthritis and Musculoskeletal and Skin Diseases
   Interdisciplinary Training in Rheumatic Diseases grant [5T32AR059039];
   National Institutes of Health [S10RR027631]
FX JEC is supported by National Institute of Allergy and Infectious
   Diseases (https://www.niaid.nih.gov) grants 1R01AI132560 and
   5K08AI113107 and a Career Award for Medical Scientists from the
   Burroughs Wellcome Fund (https://www.bwfund.org). NEP is supported by
   the National Institute of Allergy and Infectious Diseases
   (https://www.niaid.nih.gov) grant 1F31AI133926. CAF was supported
   through the National Institute of General Medical Sciences
   (https://www.nigms.nih.gov) Medical Scientist Training Program grant
   T32GM007347 and is currently supported by the National Institute of
   Allergy and Infectious Diseases (https://www.niaid.nih.gov) grant
   1F30AI138424. JRP is supported by the National Institute of Arthritis
   and Musculoskeletal and Skin Diseases (https://www.niams.nih.gov)
   Interdisciplinary Training in Rheumatic Diseases grant 5T32AR059039. The
   research support for the mu CT50 and computer cluster is maintained by
   National Institutes of Health (https://www.nih.gov) grant S10RR027631.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR [Anonymous], 2014, MEDIATORS INFLAMM, V22, pS40
   Asensi V, 2003, AM J MED GENET A, V119A, P132, DOI 10.1002/ajmg.a.20137
   ASMBS Clinical Issues Committee, 2012, PLOS PATHOG, V8, pe21
   Bajayo A, 2005, P NATL ACAD SCI USA, V102, P12956, DOI 10.1073/pnas.0502562102
   Bar Shavit Z, 2008, AUTOIMMUNITY, V41, P195, DOI 10.1080/08916930701694469
   Beaulieu LM, 2014, ARTERIOSCL THROM VAS, V34, P552, DOI 10.1161/ATVBAHA.113.302700
   Berendt T, 2004, CLIN MED, V4, P510, DOI 10.7861/clinmedicine.4 6 510
   Bernthal NM, 2011, J ORTHOP RES, V29, P1621, DOI 10.1002/jor.21414
   Birt MC, 2017, J ORTHOP, V14, P45, DOI 10.1016/j.jor.2016.10.004
   Boles BR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010146
   Bost KL, 2001, J INTERF CYTOK RES, V21, P297, DOI 10.1089/107999001300177484
   Brandt SL, 2018, J IMMUNOL, V200, P3871, DOI 10.4049/jimmunol.1701574
   Braun T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3380
   Cain DW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019957
   Cassat JE, 2013, CELL HOST MICROBE, V13, P759, DOI 10.1016/j.chom.2013.05.003
   Craven RR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007446
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   DEWHIRST FE, 1985, J IMMUNOL, V135, P2562
   Feuerstein R, 2015, J IMMUNOL, V194, P2735, DOI 10.4049/jimmunol.1402566
   Frantz AL, 2012, MUCOSAL IMMUNOL, V5, P501, DOI 10.1038/mi.2012.23
   GILLASPY AF, 1995, INFECT IMMUN, V63, P3373, DOI 10.1128/IAI.63.9.3373 3380.1995
   Haas DW, 1996, AM J MED, V101, P550, DOI 10.1016/S0002 9343(96)00260 4
   Hanke ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042476
   Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253
   Hol J, 2010, J LEUKOCYTE BIOL, V87, P501, DOI 10.1189/jlb.0809532
   Holzinger D, 2012, J LEUKOCYTE BIOL, V92, P1069, DOI 10.1189/jlb.0112014
   Horai R, 1998, J EXP MED, V187, P1463, DOI 10.1084/jem.187.9.1463
   HORTON JE, 1972, SCIENCE, V177, P793, DOI 10.1126/science.177.4051.793
   Hultgren OH, 2002, J IMMUNOL, V168, P5207, DOI 10.4049/jimmunol.168.10.5207
   JANDINSKI JJ, 1988, J ORAL PATHOL MED, V17, P145, DOI 10.1111/j.1600 0714.1988.tb01515.x
   Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320
   JIMI E, 1995, ENDOCRINOLOGY, V136, P808, DOI 10.1210/en.136.2.808
   Kaito C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001267
   Kielian T, 2005, INFECT IMMUN, V73, P7428, DOI 10.1128/IAI.73.11.7428 7435.2005
   Kielian T, 2004, J NEUROPATH EXP NEUR, V63, P381, DOI 10.1093/jnen/63.4.381
   Kielian T, 2007, J IMMUNOL, V178, P4528, DOI 10.4049/jimmunol.178.7.4528
   Kim J, 2013, J BONE MINER RES, V28, P2381, DOI 10.1002/jbmr.1973
   Kim JH, 2009, J IMMUNOL, V183, P1862, DOI 10.4049/jimmunol.0803007
   Kini U., 2012, Radionuclide and hybrid bone imaging
   Knight Julian, 2001, Curr Infect Dis Rep, V3, P427, DOI 10.1007/BF03160478
   Krisher T, 2014, J CELL BIOCHEM, V115, P2146, DOI 10.1002/jcb.24891
   Kubatzky KF, 2018, CYTOKINE, V112, P102, DOI 10.1016/j.cyto.2018.06.013
   Kumar V., 2014, Robbins and Cotran Pathologic Basis of Disease, Professional Edition E Book
   Kuwabara T, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3908061
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SK, 2006, BONE, V38, P678, DOI 10.1016/j.bone.2005.10.011
   Lee YM, 2010, INT IMMUNOL, V22, P805, DOI 10.1093/intimm/dxq431
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Li JY, 2016, J CLIN INVEST, V126, P2049, DOI 10.1172/JCI86062
   Lukens JR, 2014, P NATL ACAD SCI USA, V111, P1066, DOI 10.1073/pnas.1318688111
   Martino MM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11051
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   MCDOWELL TL, 1995, ARTHRITIS RHEUM, V38, P221, DOI 10.1002/art.1780380210
   Bertelli AM, 2016, BBA MOL BASIS DIS, V1862, P1975, DOI 10.1016/j.bbadis.2016.07.016
   Miller LS, 2007, J IMMUNOL, V179, P6933, DOI 10.4049/jimmunol.179.10.6933
   Miller LS, 2006, IMMUNITY, V24, P79, DOI 10.1016/j.immuni.2005.11.011
   Muñoz Planillo R, 2009, J IMMUNOL, V183, P3942, DOI 10.4049/jimmunol.0900729
   Na YY, 2017, ONCOTARGET, V8, P4228, DOI 10.18632/oncotarget.13935
   NAKAI S, 1989, LIFE SCI, V45, P585, DOI 10.1016/0024 3205(89)90043 X
   Novince CM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06126 x
   Prabhakara R, 2011, INFECT IMMUN, V79, P1789, DOI 10.1128/IAI.01386 10
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Sato N, 2004, J EXP MED, V200, P601, DOI 10.1084/jem.20040689
   Shiratori T, 2018, J IMMUNOL, V200, P218, DOI 10.4049/jimmunol.1602035
   Simsa Maziel S, 2013, AM J PHYSIOL ENDOC M, V305, pE15, DOI 10.1152/ajpendo.00335.2012
   Sjogren K, 2012, BONE, V50, pS91, DOI [10.1016/j.bone.2012.02.272, 10.1002/jbmr.1588]
   STORK LC, 1988, EXP HEMATOL, V16, P163
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392
   Thurlow LR, 2011, J IMMUNOL, V186, P6585, DOI 10.4049/jimmunol.1002794
   Trouillet Assant S, 2015, J INFECT DIS, V211, P571, DOI 10.1093/infdis/jiu386
   Tsezou A, 2008, CLIN VACCINE IMMUNOL, V15, P1888, DOI 10.1128/CVI.00209 08
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Ueda Y, 2009, J IMMUNOL, V182, P6477, DOI 10.4049/jimmunol.0803961
   Vargas SJ, 1996, J BONE MINER RES, V11, P1736, DOI 10.1002/jbmr.5650111117
   Villano JS, 2014, COMPARATIVE MED, V64, P110
   von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang QL, 2001, INFECT IMMUN, V69, P2270, DOI 10.1128/IAI.69.4.2270 2276.2001
   Wang Y, 2017, J CELL PHYSIOL, V232, P2396, DOI 10.1002/jcp.25774
   Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm2
   Wengner AM, 2008, BLOOD, V111, P42, DOI 10.1182/blood 2007 07 099648
   Wilde AD, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005341
   Xiong J, 2012, ASN NEURO, V4, DOI 10.1042/AN20120008
   Yan J, 2016, P NATL ACAD SCI USA, V113, pE7554, DOI 10.1073/pnas.1607235113
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshii T, 2002, CYTOKINE, V19, P59, DOI 10.1006/cyto.2002.1039
NR 88
TC 61
Z9 71
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553 7366
EI 1553 7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2019
VL 15
IS 4
AR e1007744
DI 10.1371/journal.ppat.1007744
PG 31
WC Microbiology; Parasitology; Virology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology; Parasitology; Virology
GA HW5PY
UT WOS:000466742700056
PM 30978245
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Zhang, JL
   Zhang, Y
   Chen, JF
   Gong, WM
   Tu, XL
AF Zhang, Jinling
   Zhang, Ying
   Chen, Jiafeng
   Gong, Weimin
   Tu, Xiaolin
TI The Osteocyte with SB216763 Activated Canonical Wnt Signaling Constructs
   a Multifunctional 4D Intelligent Osteogenic Module
SO BIOMOLECULES
LA English
DT Article
DE osteocyte; SB216763; DOME; Wnt signaling; osteogenesis; 4D intelligent
   osteogenic module
ID SMALL MOLECULE INHIBITORS; BONE; ANGIOGENESIS; REGENERATION
AB The enhancement of bioactivity in materials has become an important focus within the field of bone tissue engineering. Four dimensional intelligent osteogenic module, an innovative fusion of 3D printing with the time axis, shows immense potential in augmenting the bioactivity of these materials, thereby facilitating autologous bone regeneration efficiently. This study focuses on novel bone repair materials, particularly bioactive scaffolds with a developmental osteogenic microenvironment prepared through 3D bioprinting technology. This research mainly creates a developmental osteogenic microenvironment named "DOME". This is primed by the application of a small amount of the small molecule drug SB216763, which activates canonical Wnt signaling in osteocytes, promoting osteogenesis and mineralization nodule formation in bone marrow stromal cells and inhibiting the formation of adipocytes. Moreover, DOME enhances endothelial cell migration and angiogenesis, which is integral to bone repair. More importantly, the DOME PCI3D system, a 4D intelligent osteogenic module constructed through 3D bioprinting, stably supports cell growth (91.2% survival rate after 7 days) and significantly increases the expression of osteogenic transcription factors in bone marrow stromal cells and induces osteogenic differentiation and mineralization for 28 days. This study presents a novel approach for bone repair, employing 3D bioprinting to create a multifunctional 4D intelligent osteogenic module. This innovative method not only resolves challenges related to shape matching and biological activity but also demonstrates the vast potential for applications in bone repair.
C1 [Zhang, Jinling; Zhang, Ying; Chen, Jiafeng; Gong, Weimin; Tu, Xiaolin] Chongqing Med Univ, Inst Life Sci, Lab Skeletal Dev & Regenerat, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University
RP Tu, XL (通讯作者)，Chongqing Med Univ, Inst Life Sci, Lab Skeletal Dev & Regenerat, Chongqing 400016, Peoples R China.
EM 2021110818@stu.cqmu.edu.cn; 2021130118@stu.cqmu.edu.cn;
   2023130462@stu.cqmu.edu.cn; 2020111811@stu.cqmu.edu.cn; xtu@cqmu.edu.cn
RI ; gong, weimin/HTL 9563 2023
OI Zhang, Ying/0009 0007 1174 7256; chen, jiafeng/0000 0001 6551 8757
FU National Natural Science Foundation of China
FX No Statement Available
CR Ahmad B, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00076
   Ahmadi A, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03204 4
   Awale GM, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2219756120
   Azbazdar Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.631623
   Billiet T, 2014, BIOMATERIALS, V35, P49, DOI 10.1016/j.biomaterials.2013.09.078
   Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074 5521(00)00025 9
   Ding L, 2019, CLIN CANCER RES, V25, P6452, DOI 10.1158/1078 0432.CCR 19 0799
   Gaharwar AK, 2020, NAT REV MATER, V5, P686, DOI 10.1038/s41578 020 0209 x
   Gao B, 2016, TRENDS BIOTECHNOL, V34, P746, DOI 10.1016/j.tibtech.2016.03.004
   Gonsalves FC, 2011, P NATL ACAD SCI USA, V108, P5954, DOI 10.1073/pnas.1017496108
   Gwak J, 2012, CELL RES, V22, P237, DOI 10.1038/cr.2011.127
   Henriksen EJ, 2003, AM J PHYSIOL ENDOC M, V284, pE892, DOI 10.1152/ajpendo.00346.2002
   James AW, 2016, TISSUE ENG PART B RE, V22, P284, DOI [10.1089/ten.TEB.2015.0357, 10.1089/ten.teb.2015.0357]
   Kang X, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1036375
   Koons GL, 2020, NAT REV MATER, V5, P584, DOI 10.1038/s41578 020 0204 2
   Liu JQ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 021 00762 6
   Liu XZ, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.120998
   Liu YX, 2022, CELLS BASEL, V11, DOI 10.3390/cells11050831
   Luo GL, 2016, J MED CHEM, V59, P1041, DOI 10.1021/acs.jmedchem.5b01550
   Malhotra A, 2016, TRENDS BIOTECHNOL, V34, P983, DOI 10.1016/j.tibtech.2016.07.005
   Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053
   Moseti D, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010124
   Narcisi R, 2016, TISSUE ENG PT A, V22, P1264, DOI 10.1089/ten.tea.2016.0081
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Rodriguez Jimenez FJ, 2021, NEUROTHERAPEUTICS, V18, P515, DOI 10.1007/s13311 020 00928 0
   Saran U, 2014, ARCH BIOCHEM BIOPHYS, V561, P109, DOI 10.1016/j.abb.2014.07.006
   Seo BB, 2017, BIOMATERIALS, V122, P91, DOI 10.1016/j.biomaterials.2017.01.016
   Tibbits S, 2014, ARCHIT DESIGN, V84, P116, DOI 10.1002/ad.1710
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   Wan ZQ, 2020, ACTA BIOMATER, V101, P26, DOI 10.1016/j.actbio.2019.10.038
   Wang B, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.926622
   Wang PT, 2022, BIO DES MANUF, V5, P497, DOI 10.1007/s42242 022 00196 1
   You DQ, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202103920
   Zhang J, 2021, NEURAL REGEN RES, V16, P394, DOI 10.4103/1673 5374.290913
   Zhang MR, 2023, INFLAMM REGEN, V43, DOI 10.1186/s41232 023 00285 3
   Zhang YL, 2020, TRANSL CANCER RES, V9, P1246, DOI 10.21037/tcr.2019.12.50
   Zhang YN, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232416045
   Zhu GY, 2021, BIOACT MATER, V6, P4110, DOI 10.1016/j.bioactmat.2021.03.043
   Zisch AH, 2003, CARDIOVASC PATHOL, V12, P295, DOI 10.1016/S1054 8807(03)00089 9
NR 41
TC 2
Z9 2
U1 2
U2 12
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2218 273X
J9 BIOMOLECULES
JI Biomolecules
PD MAR
PY 2024
VL 14
IS 3
AR 354
DI 10.3390/biom14030354
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA MD6Q6
UT WOS:001191731600001
PM 38540772
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Paramasivam, S
   Perumal, SS
AF Paramasivam, Sivasakthi
   Perumal, Senthamil Selvan
TI Methanolic extract of O.umbellata L. exhibits anti osteoporotic
   effect via promoting osteoblast proliferation in MG 63 cells and
   inhibiting osteoclastogenesis in RANKL stimulated RAW 264.7 cells
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Oldenlandia umbellata; Anti osteoporotic; Osteoblast; Osteoclast; MG 63;
   RAW 264.7 cells
ID DIFFERENTIATION; PATHWAYS; AUCUBIN
AB Ethnopharmacological relevance: Oldenlandia umbellata L., belonging to the Rubiaceae family, is an annual plant possessing anti inflammatory and antipyretic, anti nociceptive, anti bacterial, anti helminthic, antioxidant and hepatoprotective activities and used in traditional medicine to treat inflammation and respiratory diseases.
   Aim of the study: The present study aims to evaluate the anti osteoporotic effect of Methanolic extract of O. umbellata in MG 63 cells and RANKL stimulated RAW 264.7 cells.
   Materials and methods: The methanolic extract from the aerial parts of O.umbellata was subjected to metabolite profiling. The anti osteoporotic effect of MOU was assessed in MG 63 cells and RANKL stimulated RAW 264.7 cells. In MG 63 cells, the proliferative effect of MOU was evaluated using MTT assay, ALP assay, Alizarin red staining, ELISA and western blot. Similarly, the anti osteoclastogenic effect of MOU was assessed in RANKLstimulated RAW 264.7 cells via MTT, TRAP staining and western blot.
   Results: LC MS metabolite profiling showed the presence of 59 phytoconstituents including scandoside, scandoside methyl ester, deacetylasperuloside, asperulosidic acid, and cedrelopsin in MOU. In MG 63 cells, MOU has increased the proliferation of osteoblast cells and ALP activity, thereby increasing bone mineralization. ELISA results showed increased levels of osteogenic markers such as osteocalcin and osteopontin in the culture media. Western blot analysis showed inhibition of GSK3 beta protein expression and increased the expression levels of beta catenin, Runx 2, col 1 and osterix, promoting osteoblast differentiation. In RANKL stimulated RAW 264.7 cells, MOU did not elicit any significant cytotoxicity; instead, it suppressed the osteoclastogenesis reducing the osteoclast number. MOU has reduced TRAP activity in a dose dependent manner. MOU inhibited the TRAF6, NFATc1, c Jun, C fos and cathepsin K expression, thereby inhibiting osteoclast formation.
   Conclusion: In conclusion, MOU promoted osteoblast differentiation via inhibiting GSK3 beta and activating Wnt/beta catenin signalling and its transcription factors, including beta catenin, Runx2 and Osterix. Similarly, MOU inhibited osteoclast formation by inhibiting the expression of TRAF6, NFATc1, c Jun, C fos and cathepsin K in RANKRANKL signalling. Finally, it can be emphasised that O.umbellata is a potential source of therapeutic leads for the treatment of osteoporosis.
C1 [Paramasivam, Sivasakthi; Perumal, Senthamil Selvan] Anna Univ, Univ Coll Engn, Dept Pharmaceut Technol, BIT Campus, Trichy 620024, Tamil Nadu, India.
C3 Anna University; Anna University of Technology Tiruchirappalli
RP Perumal, SS (通讯作者)，Anna Univ, Univ Coll Engn, Dept Pharmaceut Technol, BIT Campus, Trichy 620024, Tamil Nadu, India.
EM senthamil77@gmail.com
RI ; Paramasivam, Sivasakthi/JBS 2575 2023
OI Paramasivam, Sivasakthi/0000 0001 5676 2950; Perumal, Senthamil
   Selvan/0000 0003 1747 490X; 
CR Amirhosseini M, 2018, J CELL PHYSIOL, V233, P2398, DOI 10.1002/jcp.26111
   Amjadi Moheb F, 2019, J CELL PHYSIOL, V234, P14641, DOI 10.1002/jcp.28207
   Arun P., 2010, J Pharm Sci Technol, V2, P198
   Bandeira F, 2020, ARCH ENDOCRIN METAB, V64, P331, DOI 10.20945/2359 3997000000275
   Binkley Neil, 2005, Curr Osteoporos Rep, V3, P150
   Chau JFL, 2009, HISTOL HISTOPATHOL, V24, P1593, DOI 10.14670/HH 24.1593
   Chen ML, 2014, EXPERT OPIN THER TAR, V18, P817, DOI 10.1517/14728222.2014.912632
   Cheng Y, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.950122
   Fan JZ, 2015, BRAZ J MED BIOL RES, V48, P637, DOI [10.1590/1414 431X20154494, 10.1590/1414 431x20154494]
   Ge YL, 2021, CYTOTECHNOLOGY, V73, P169, DOI 10.1007/s10616 021 00454 7
   Hattori K, 2023, MOD RHEUMATOL, V33, P217, DOI 10.1093/mr/roab129
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Jeong DW, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/3231784
   Jiang WX, 2012, BIOMED CHROMATOGR, V26, P863, DOI 10.1002/bmc.1743
   Khatami N, 2019, J CELL BIOCHEM, V120, P15069, DOI 10.1002/jcb.28768
   Kim EN, 2019, PHYTOTHER RES, V33, P2948, DOI 10.1002/ptr.6468
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Lee KY, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2611 8
   Li YT, 2020, AGING US, V12, P2226, DOI 10.18632/aging.102742
   Li YT, 2018, CHEM BIOL INTERACT, V283, P51, DOI 10.1016/j.cbi.2018.02.005
   Liao HJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1353 3
   Lim SY, 2017, DRUG DES DEV THER, V11, P1221, DOI 10.2147/DDDT.S127568
   Liu LL, 2021, PHARMACOGN MAG, V17, P38, DOI 10.4103/pm.pm_186_20
   Lv YD, 2015, EXP THER MED, V9, P143, DOI 10.3892/etm.2014.2071
   Mahibalan S., 2008, NPAIJ, V4, P184
   Mahibalan S, 2016, MED CHEM RES, V25, P466, DOI 10.1007/s00044 015 1500 z
   Manchanda R., 2022, BJOG INT J OBSTET GY, V129, P16, DOI 10
   Modi PK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222240
   Molagoda IMN, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110711
   Mustofa F.I., 2021, J TUMBUH OBAT INDONE, V14, P36
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Nugroho A., 2012, KOREAN J PHARMACOGN, V43, P302
   Padhy I., 2014, INT J PHARM HEAL RES, V2, P12
   Pang Y, 2021, SAUDI J BIOL SCI, V28, P4916, DOI 10.1016/j.sjbs.2021.06.070
   Ranatunga S, 2023, BONE, V169, DOI 10.1016/j.bone.2023.116686
   Reid IR, 2016, INTERN MED J, V46, P767, DOI 10.1111/imj.13131
   Saraswathy G., 2008, PHARMACOLOGYONLINE, V3, P253
   Shi HL, 2017, TROP J PHARM RES, V16, P1595, DOI 10.4314/tjpr.v16i7.18
   Sivapraksam S.S.K., 2014, INT J PHARM SCI REV, V26, P320
   Somnath D.E., 2014, INT J PHARM PHARM SC, V6, P94
   Sun H, 2013, FITOTERAPIA, V84, P174, DOI 10.1016/j.fitote.2012.11.010
   Suvarna V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00981
   Takegahara N, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116353
   Tan MRA, 2020, 3 BIOTECH, V10, DOI 10.1007/s13205 020 2145 2
   Tsao YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010159
   Wang XD, 2019, MOL MED, V25, DOI 10.1186/s10020 019 0107 0
   WFO, 2022, OLD UMB L
   Wu D., 2021, OSTEOPOROSIS RECENT, DOI [10.5772/intechopen.97549, DOI 10.5772/INTECHOPEN.97549]
   Yoganarasimhan S N., 2000, Medicinal plants of India Tamilnadu
   Zhang Y, 2022, APPL BIOCHEM BIOTECH, DOI 10.1007/s12010 022 03927 3
NR 52
TC 11
Z9 12
U1 1
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD OCT 28
PY 2023
VL 315
AR 116641
DI 10.1016/j.jep.2023.116641
EA MAY 2023
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA K7OY5
UT WOS:001018308100001
PM 37236379
DA 2025 08 17
ER

PT J
AU Saito, A
   Ooki, A
   Nakamura, T
   Onodera, S
   Hayashi, K
   Hasegawa, D
   Okudaira, T
   Watanabe, K
   Kato, H
   Onda, T
   Watanabe, A
   Kosaki, K
   Nishimura, K
   Ohtaka, M
   Nakanishi, M
   Sakamoto, T
   Yamaguchi, A
   Sueishi, K
   Azuma, T
AF Saito, Akiko
   Ooki, Akio
   Nakamura, Takashi
   Onodera, Shoko
   Hayashi, Kamichika
   Hasegawa, Daigo
   Okudaira, Takahito
   Watanabe, Katsuhito
   Kato, Hiroshi
   Onda, Takeshi
   Watanabe, Akira
   Kosaki, Kenjiro
   Nishimura, Ken
   Ohtaka, Manami
   Nakanishi, Mahito
   Sakamoto, Teruo
   Yamaguchi, Akira
   Sueishi, Kenji
   Azuma, Toshifumi
TI Targeted reversion of induced pluripotent stem cells from patients with
   human cleidocranial dysplasia improves bone regeneration in a rat
   calvarial bone defect model
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Cleidocranial dysplasia; RUNX2; iPSCs; Osteoblasts; Osteogenesis;
   CRISPR/Cas
ID TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; GENETIC CORRECTION;
   DNA BINDING; RUNX2; MUTATIONS; CBFA1; RUNX2/CBFA1; EXPRESSION; ALLELES
AB Background: Runt related transcription factor 2 (RUNX2) haploinsufficiency causes cleidocranial dysplasia (CCD) which is characterized by supernumerary teeth, short stature, clavicular dysplasia, and osteoporosis. At present, as a therapeutic strategy for osteoporosis, mesenchymal stem cell (MSC) transplantation therapy is performed in addition to drug therapy. However, MSC based therapy for osteoporosis in CCD patients is difficult due to a reduction in the ability of MSCs to differentiate into osteoblasts resulting from impaired RUNX2 function. Here, we investigated whether induced pluripotent stem cells (iPSCs) properly differentiate into osteoblasts after repairing the RUNX2 mutation in iPSCs derived from CCD patients to establish normal iPSCs, and whether engraftment of osteoblasts derived from properly reverted iPSCs results in better regeneration in immunodeficient rat calvarial bone defect models.
   Methods: Two cases of CCD patient derived induced pluripotent stem cells (CCD iPSCs) were generated using retroviral vectors (OCT3/ 4, SOX2, KLF4, and c MYC) or a Sendai virus SeVdp vector (KOSM302L). Reverted iPSCs were established using programmable nucleases, clustered regularly interspaced short palindromic repeats (CRISPR)/ Casderived RNA guided endonucleases, to correct mutations in CCD iPSCs. The mRNA expressions of osteoblast specific markers were analyzed using quantitative reverse transcriptase polymerase chain reaction. iPSCs derived osteoblasts were transplanted into rat calvarial bone defects, and bone regeneration was evaluated using microcomputed tomography analysis and histological analysis.
   Results: Mutation analysis showed that both contained nonsense mutations: one at the very beginning of exon 1 and the other at the initial position of the nuclear matrix targeting signal. The osteoblasts derived from CCD iPSCs (CCD OBs) expressed low levels of several osteoblast differentiation markers, and transplantation of these osteoblasts into calvarial bone defects created in rats with severe combined immunodeficiency showed poor regeneration. However, reverted iPSCs improved the abnormal osteoblast differentiation which resulted in much better engraftment into the rat calvarial bone defect.
   Conclusions: Taken together, these results demonstrate that patient specific iPSC technology can not only provide a useful disease model to elucidate the role of RUNX2 in osteoblastic differentiation but also raises the tantalizing prospect that reverted iPSCs might provide a practical medical treatment for CCD.
C1 [Saito, Akiko; Nakamura, Takashi; Onodera, Shoko; Azuma, Toshifumi] Tokyo Dent Coll, Dept Biochem, Tokyo, Japan.
   [Ooki, Akio; Sueishi, Kenji] Tokyo Dent Coll, Dept Orthodont, Tokyo, Japan.
   [Hayashi, Kamichika; Hasegawa, Daigo; Okudaira, Takahito; Watanabe, Katsuhito; Kato, Hiroshi; Onda, Takeshi; Watanabe, Akira] Tokyo Dent Coll, Dept Oral & Maxillofacial Surg, Tokyo, Japan.
   [Yamaguchi, Akira; Azuma, Toshifumi] Tokyo Dent Coll, Oral Hlth Sci Ctr, Tokyo, Japan.
   [Kosaki, Kenjiro] Keio Univ Sch Med, Ctr Med Genet, Tokyo, Japan.
   [Nishimura, Ken] Univ Tsukuba, Fac Med, Lab Gene Regulat, Ibaraki, Japan.
   [Ohtaka, Manami; Nakanishi, Mahito] Natl Inst Adv Ind Sci & Technol, Biotechnol Res Inst Drug Discovery, Tsukuba, Ibaraki, Japan.
C3 Tokyo Dental College; Tokyo Dental College; Tokyo Dental College; Tokyo
   Dental College; Keio University; University of Tsukuba; National
   Institute of Advanced Industrial Science & Technology (AIST)
RP Saito, A (通讯作者)，Tokyo Dent Coll, Dept Biochem, Tokyo, Japan.
EM ayokoyama@tdc.ac.jp
RI Nishimura, KEN/JBJ 7405 2023; Yamaguchi, Akira/AAX 9286 2020; Onda,
   Takeshi/V 7114 2019; AZUMA, TOSHIFUMI/HTQ 4727 2023; NAKAMURA,
   Takashi/I 3248 2014; Nakanishi, Mahito/I 9888 2018
OI Onodera, Shoko/0000 0003 0673 3400; Onda, Takeshi/0000 0003 4722 1954;
   Nakamura, Takashi/0000 0002 6124 061X; Nakanishi,
   Mahito/0000 0002 7068 7587
FU JSPS KAKENHI [25462900, 26861686, 26861560, 16 K20427, 16 K20428];
   Grants in Aid for Scientific Research [16K20427, 26861686, 25462900,
   16K15791, 26861560, 16K20619] Funding Source: KAKEN
FX This work was supported by JSPS KAKENHI (C) (grant no. 25462900) and by
   JSPS KAKENHI for young scientists (B) (grant nos. 26861686, 26861560, 16
   K20427, and 16 K20428).
CR Antebi B, 2014, CURR OSTEOPOROS REP, V12, P41, DOI 10.1007/s11914 013 0184 x
   Doecke JD, 2006, J BONE MINER RES, V21, P265, DOI 10.1359/JBMR
   Glotzer DJ, 2008, DEV BIOL, V315, P459, DOI 10.1016/j.ydbio.2008.01.005
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hayashi Kamichika, 2016, BDJ Open, V2, P15007, DOI 10.1038/bdjopen.2015.7
   Hojo H, 2016, DEV CELL, V37, P238, DOI 10.1016/j.devcel.2016.04.002
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Koo T, 2015, MOL CELLS, V38, P475, DOI 10.14348/molcells.2015.0103
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797 307
   LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519
   Li HL, 2016, METHODS, V101, P27, DOI 10.1016/j.ymeth.2015.10.015
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Liu TJ, 2007, J CELL PHYSIOL, V211, P728, DOI 10.1002/jcp.20988
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Ma N, 2013, J BIOL CHEM, V288, P34671, DOI 10.1074/jbc.M113.496174
   Maeder ML, 2016, MOL THER, V24, P430, DOI 10.1038/mt.2016.10
   Mastushita M, 2015, MOL SYNDROMOL, V6, P50, DOI 10.1159/000370337
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Mendoza Londono R, 1993, GENEREVIEWS
   Mundlos S, 1999, J MED GENET, V36, P177
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Nishimura K, 2011, J BIOL CHEM, V286, P4760, DOI 10.1074/jbc.M110.183780
   NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0
   Ochiai Shino H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099534
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129
   Rouhani F, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004432
   Saito A, 2013, FASEB J, V27, P2165, DOI 10.1096/fj.12 221432
   Sebastiano V, 2011, STEM CELLS, V29, P1717, DOI 10.1002/stem.718
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Trounson A, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 52
   Tsuji K, 2004, J BONE MINER RES, V19, P1481, DOI 10.1359/JBMR.040601
   Vaughan T, 2004, BONE, V34, P1029, DOI 10.1016/j.bone.2004.02.004
   Vaughan T, 2002, J BONE MINER RES, V17, P1527, DOI 10.1359/jbmr.2002.17.8.1527
   VILLANUEVA AR, 1977, AM J MED TECHNOL, V43, P536
   Wang YX, 2012, CELL RES, V22, P637, DOI 10.1038/cr.2012.23
   Yamasaki S, 2016, IN VITRO CELL DEV AN, V52, P252, DOI 10.1007/s11626 015 9968 x
   Yousfi M, 2002, BIOCHEM BIOPH RES CO, V297, P641, DOI 10.1016/S0006 291X(02)02260 X
   Zaidi SK, 2006, J CELL PHYSIOL, V209, P935, DOI 10.1002/jcp.20791
   Zaidi SK, 2001, J CELL SCI, V114, P3093
   Zhang YW, 2000, GENE, V244, P21, DOI 10.1016/S0378 1119(99)00558 2
NR 42
TC 28
Z9 29
U1 1
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD JAN 22
PY 2018
VL 9
AR 12
DI 10.1186/s13287 017 0754 4
PG 10
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA FT2NK
UT WOS:000422980300001
PM 29357927
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Costa, AG
   Bilezikian, JP
AF Costa, Aline G.
   Bilezikian, John P.
TI Bone Turnover Markers in Primary Hyperparathyroidism
SO JOURNAL OF CLINICAL DENSITOMETRY
LA English
DT Article
DE Bone turnover markers; primary hyperparathyroidism; PTH
ID ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; MILD PRIMARY
   HYPERPARATHYROIDISM; HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN;
   MINERAL DENSITY; BIOCHEMICAL MARKERS; SERUM CALCIUM; CIRCULATING
   SCLEROSTIN; ORAL ALENDRONATE; ELDERLY PATIENTS
AB Primary hyperparathyroidism is an endocrine disorder characterized by elevated or inappropriate normal levels of parathyroid hormone in a setting of hypercalcemia. The inclusion of calcium on the basic metabolic bone panel has allowed this disorder to be diagnosed even in the absence of symptoms. Nevertheless, the skeleton can be a target of excess parathyroid hormone activity even during its asymptomatic presentation. Bone turnover markers a surrogate index of the process of the remodeling process at the level of bone, and thus can be useful to monitor skeleton involvement in primary hyperparathyroidism.
C1 [Costa, Aline G.; Bilezikian, John P.] Columbia Univ, Metab Bone Dis Unit, Coll Phys & Surg, Div Endocrinol,Dept Med, New York, NY 10032 USA.
   [Costa, Aline G.] Univ Fed Sao Paulo, Div Endocrinol, Dept Med, Sao Paulo, Brazil.
C3 Columbia University; Universidade Federal de Sao Paulo (UNIFESP)
RP Bilezikian, JP (通讯作者)，Columbia Univ, Metab Bone Dis Unit, Coll Phys & Surg, Div Endocrinol,Dept Med, 630 W 168th St,PH 8 W,Room 864, New York, NY 10032 USA.
EM jpb2@columbia.edu
RI Costa, Aline/JDM 2967 2023
FU NIDDK NIH HHS [R01 DK032333] Funding Source: Medline
CR Alatalo SL, 2004, CLIN CHEM, V50, P883, DOI 10.1373/clinchem.2003.029355
   Alonso S, 2012, J ENDOCRINOL INVEST, V35, P640, DOI 10.3275/7923
   Ardawi MSM, 2012, OSTEOPOROSIS INT, V23, P1789, DOI 10.1007/s00198 011 1806 8
   Bilezikian JP, 2009, J CLIN ENDOCR METAB, V94, P335, DOI 10.1210/jc.2008 1763
   Bilezikian JP, 2005, J INTERN MED, V257, P6, DOI 10.1111/j.1365 2796.2004.01422.x
   Boudou P, 2009, J BONE MINER METAB, V27, P240, DOI 10.1007/s00774 008 0033 7
   Brixen K., 2006, Dynamics of bone and cartilage metabolism, P583
   Chow CC, 2003, J CLIN ENDOCR METAB, V88, P581, DOI 10.1210/jc.2002 020890
   Christiansen P, 1999, BONE, V25, P237, DOI 10.1016/S8756 3282(99)00150 7
   Christiansen P, 1997, BONE, V21, P93, DOI 10.1016/S8756 3282(97)00078 1
   Costa AG, 2011, J CLIN ENDOCR METAB, V96, P3804, DOI 10.1210/jc.2011 0566
   Diamond T, 1996, OSTEOPOROSIS INT, V6, P329, DOI 10.1007/BF01623394
   Faggiano A, 2011, ENDOCRINE, V39, P283, DOI 10.1007/s12020 011 9459 0
   GALLAGHER JC, 1972, LANCET, V1, P503
   GARTON M, 1995, CLIN ENDOCRINOL, V42, P493, DOI 10.1111/j.1365 2265.1995.tb02668.x
   Grey A, 1996, J CLIN ENDOCR METAB, V81, P3450, DOI 10.1210/jc.81.10.3450
   Grey AB, 1996, ANN INTERN MED, V125, P360, DOI 10.7326/0003 4819 125 5 199609010 00002
   Guo CY, 2000, EUR J ENDOCRINOL, V142, P451, DOI 10.1530/eje.0.1420451
   Guo CY, 1996, J CLIN ENDOCR METAB, V81, P3487, DOI 10.1210/jc.81.10.3487
   Iglesias P, 2008, AM J MED SCI, V335, P111, DOI 10.1097/MAJ.0b013e3181379f3e
   KAPLAN RA, 1977, J CLIN PHARMACOL, V17, P410, DOI 10.1002/j.1552 4604.1977.tb04624.x
   Khan AA, 2004, J CLIN ENDOCR METAB, V89, P3319, DOI 10.1210/jc.2003 030908
   Khan AA, 2009, ENDOCR PRACT, V15, P705, DOI 10.4158/EP08178.ORR
   Krause C, 2010, J BIOL CHEM, V285, P41614, DOI 10.1074/jbc.M110.153890
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Marcocci C, 2009, J CLIN ENDOCR METAB, V94, P2766, DOI 10.1210/jc.2008 2640
   MARCUS R, 1984, ANN INTERN MED, V100, P633, DOI 10.7326/0003 4819 100 5 633
   Mosekilde L, 2008, CLIN ENDOCRINOL, V69, P1, DOI 10.1111/j.1365 2265.2007.03162.x
   MUNDY GR, 1980, LANCET, V1, P1317, DOI 10.1016/S0140 6736(80)91783 3
   Orr Walker BJ, 2000, ARCH INTERN MED, V160, P2161, DOI 10.1001/archinte.160.14.2161
   PARISIEN M, 1995, J BONE MINER RES, V10, P1393
   Parker CR, 2002, J CLIN ENDOCR METAB, V87, P4482, DOI 10.1210/jc.2001 010385
   Peacock M, 2005, J CLIN ENDOCR METAB, V90, P135, DOI 10.1210/jc.2004 0842
   Peacock M, 2011, J CLIN ENDOCR METAB, V96, pE9, DOI 10.1210/jc.2010 1221
   REASNER CA, 1993, J CLIN ENDOCR METAB, V77, P1067, DOI 10.1210/jc.77.4.1067
   Rossini M, 2001, J BONE MINER RES, V16, P113, DOI 10.1359/jbmr.2001.16.1.113
   Rubin MR, 2008, J CLIN ENDOCR METAB, V93, P3462, DOI 10.1210/jc.2007 1215
   Rubin MR, 2003, J CLIN ENDOCR METAB, V88, P1174, DOI 10.1210/jc.2002 020667
   Sajid Crockett S, 2008, METABOLISM, V57, P517, DOI 10.1016/j.metabol.2007.11.014
   Seibel MJ, 2001, PARATHYROIDS BASIC C, V1, P399
   SELBY PL, 1986, NEW ENGL J MED, V314, P1481, DOI 10.1056/NEJM198606053142304
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   SHANE E, 1981, ANN INTERN MED, V95, P23, DOI 10.7326/0003 4819 95 1 23
   Shoback DM, 2003, J CLIN ENDOCR METAB, V88, P5644, DOI 10.1210/jc.2002 021597
   SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P723, DOI 10.1210/jc.80.3.723
   Steiniche T, 2000, BONE, V26, P535, DOI 10.1016/S8756 3282(00)00260 X
   Stilgren LS, 2003, CALCIFIED TISSUE INT, V73, P210, DOI 10.1007/s00223 002 2100 8
   Tamura Y, 2007, J BONE MINER METAB, V25, P226, DOI 10.1007/s00774 007 0754 z
   Thorsen K, 1997, SURGERY, V122, P882, DOI 10.1016/S0039 6060(97)90328 7
   Valdemarsson S, 1998, J INTERN MED, V243, P115
   van Bezooijen RL, 2007, J BONE MINER RES, V22, P19, DOI 10.1359/JBMR.061002
   van Lierop AH, 2010, EUR J ENDOCRINOL, V163, P833, DOI 10.1530/EJE 10 0699
   Woitge HW, 1999, J BONE MINER RES, V14, P792, DOI 10.1359/jbmr.1999.14.5.792
   Zanchetta JR, 2001, J BONE MINER RES, V16, P189, DOI 10.1359/jbmr.2001.16.1.189
NR 54
TC 32
Z9 33
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1094 6950
J9 J CLIN DENSITOM
JI J. Clin. Densitom.
PD JAN MAR
PY 2013
VL 16
IS 1
BP 22
EP 27
DI 10.1016/j.jocd.2012.11.004
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 093GA
UT WOS:000315178500007
PM 23374737
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Bhandari, KH
   Asghar, W
   Newa, M
   Jamali, F
   Doschak, MR
AF Bhandari, Krishna H.
   Asghar, Waheed
   Newa, Madhuri
   Jamali, Fakhreddin
   Doschak, Michael R.
TI Evaluation of Bone Targeting Salmon Calcitonin Analogues in Rats
   Developing Osteoporosis and Adjuvant Arthritis
SO CURRENT DRUG DELIVERY
LA English
DT Article
DE Bisphosphonate; bone mineral density (BMD); bone targeting; bone volume;
   adjuvant arthritis; calcitonin; polyethylene glycol (PEG); micro CT;
   osteoporosis
ID DELIVERY SYSTEM; OSTEOCLAST; OSTEOARTHRITIS; PATHOGENESIS; PEGYLATION;
   BEHAVIOR
AB Synthetic analogues of the peptide hormone calcitonin have been used in medicine as biologic drug therapies for decades, to treat pathological conditions of excessive bone turnover, such as osteoporosis, where more bones are removed than replaced during bone remodeling. Osteoporosis and other chronic skeletal diseases, including inflammatory arthritis, exact a substantial and growing toll on aging populations worldwide however they respond poor to synthetic biologic drug therapy, due in part to the rapid half life of elimination, which for calcitonin is 43 minutes. To address those shortcomings, we have developed and synthesized bone targeting variants of calcitonin as a targeted drug delivery strategy, by conjugation to bisphosphonate drug bone seeking functional groups in highly specific reaction conditions. To evaluate their in vivo efficacy, bisphosphonate mediated bone targeting with PEGylated (polyethylene glycol conjugated) and non PEGylated salmon calcitonin analogues were synthesized and dose escalation was performed in female rats developing Osteoporosis. The bone targeting calcitonin analogues were also tested in a separate cohort of male rats developing adjuvant induced arthritis. Ovariectomized female rats developing Osteoporosis were administered daily sub cutaneous injection of analogues equivalent to 5, 10 and 20 IU/kg of calcitonin for 3 months. Adjuvant arthritis was developed in male rats by administering Mycobacterium butyricum through tail base injection. Daily sub cutaneous injection of analogues equivalent to 20 IU/kg of calcitonin was administered and the rats were measured for visible signs of inflammation to a 21 day endpoint. In both studies, the effect of drug intervention upon bone volume and bone mineral density (BMD) was assessed by measuring the trabecular bone volume percentage and BMD at the proximal tibial metaphysis using in vivo micro computed tomography. With dose escalation studies, only bone targeting analogue dosed groups showed a trend towards increased BMD and bone volume at 4, 8 and 12 weeks. Significant preservation of bone volume and BMD as evidenced by nonsignificant (P>0.05) loss of bone volume and BMD at the end of 3 month study endpoint was seen in animals dosed with 20 IU/kg of calcitonin compounds. Similarly, in case of adjuvant induced arthritis rats, there was a significant increase (P<0.05) in bone volume and BMD in calcitonin bisphosphonate and calcitonin PEG bisphosphonate treated groups at 21 days compared to the baseline values. Improved efficacy in terms of preserving bone volume and BMD in Osteoporosis, and in rats developing adjuvant induced arthritis, by these analogues suggests their potential as new drug candidates for further evaluation to determine their usefulness in bone diseases characterized by excessive bone resorption.
C1 [Bhandari, Krishna H.; Asghar, Waheed; Newa, Madhuri; Jamali, Fakhreddin; Doschak, Michael R.] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
C3 University of Alberta
RP Doschak, MR (通讯作者)，Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
EM mdoschak@ualberta.ca
RI ; Asghar, Waheed/KLY 9181 2024
OI Doschak, Michael/0000 0002 0293 6596; Asghar, Dr.
   Waheed/0000 0003 1669 1662
FU Canadian Institutes for Health Research (CIHR) Proof of Principle (POP1)
   grant; Osteoarthritis (OA) Alberta Team Grant, from the Alberta
   Innovates   Health Solutions (AIHS) Interdisciplinary program
FX This research was funded by the Canadian Institutes for Health Research
   (CIHR) Proof of Principle (POP1) grant, and by the Osteoarthritis (OA)
   Alberta Team Grant, from the Alberta Innovates   Health Solutions (AIHS)
   Interdisciplinary program.
CR AIDA S, 1994, ANN RHEUM DIS, V53, P247, DOI 10.1136/ard.53.4.247
   Andersson MK, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2127
   [Anonymous], UCM341779 FDA
   [Anonymous], 2013, MED LETT DRUGS THER, V55, P29
   Berry PA, 2010, J RHEUMATOL, V37, P1252, DOI 10.3899/jrheum.091055
   Bhandari KH, 2012, J CONTROL RELEASE, V158, P44, DOI 10.1016/j.jconrel.2011.09.096
   Bhandari KH, 2010, INT J PHARMACEUT, V394, P26, DOI 10.1016/j.ijpharm.2010.04.015
   Boron WF, 2004, ADV PHYSIOL EDUC, V28, P160, DOI 10.1152/advan.00045.2004
   Bouyer P, 2004, J PHYSIOL LONDON, V559, P85, DOI 10.1113/jphysiol.2004.067793
   CARE AD, 1970, J ENDOCRINOL, V48, P1, DOI 10.1677/joe.0.0480001
   CHAMBERS TJ, 1985, PRESSE MED, V14, P2061
   CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104
   CHAMBERS TJ, 1982, J CELL SCI, V57, P247
   Cheng WQ, 2007, PHARM RES, V24, P99, DOI 10.1007/s11095 006 9128 9
   Doschak MR, 2009, MOL PHARMACEUT, V6, P634, DOI 10.1021/mp8002368
   Farley J, 2000, CALCIFIED TISSUE INT, V67, P247, DOI 10.1007/s002230001112
   Fujisaki J, 1997, BIOL PHARM BULL, V20, P1183
   GOLTZMAN D, 1985, SCIENCE, V227, P1343, DOI 10.1126/science.2983422
   Hamidi M, 2006, DRUG DELIV, V13, P399, DOI 10.1080/10717540600814402
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   HORTON MA, 1985, CANCER RES, V45, P5663
   Ide M, 2001, Clin Calcium, V11, P638
   Kang JS, 2009, EXPERT OPIN EMERG DR, V14, P363, DOI 10.1517/14728210902907847
   Kotaniemi A, 1996, J RHEUMATOL, V23, P1875
   Lacey JV, 2002, JAMA J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334
   Lamb HM, 1997, DRUG AGING, V11, P413, DOI 10.2165/00002512 199711050 00007
   MURAD F, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P446, DOI 10.1073/pnas.65.2.446
   Okubo Y, 2000, BIOCHEM BIOPH RES CO, V269, P317, DOI 10.1006/bbrc.2000.2294
   Overman RA, 2013, ANN PHARMACOTHER, V47, P1675, DOI 10.1177/1060028013509233
   Pappalardo A, 1994, Clin Ter, V144, P99
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Raisz LG, 2005, NEW ENGL J MED, V353, P164, DOI 10.1056/NEJMcp042092
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Ryan SM, 2011, J CONTROL RELEASE, V149, P126, DOI 10.1016/j.jconrel.2010.10.004
   Sexton PM, 1999, CURR MED CHEM, V6, P1067
   Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359 6446(05)03575 0
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Youn YS, 2006, J CONTROL RELEASE, V114, P334, DOI 10.1016/j.jconrel.2006.06.007
   Zaidi M, 2002, BONE, V30, P655, DOI 10.1016/S8756 3282(02)00688 9
NR 43
TC 12
Z9 12
U1 0
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567 2018
EI 1875 5704
J9 CURR DRUG DELIV
JI Curr. Drug Deliv.
PY 2015
VL 12
IS 1
BP 98
EP 107
DI 10.2174/156720181201150310154026
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CD3TW
UT WOS:000351006000013
PM 25860966
DA 2025 08 17
ER

PT J
AU Hu, S
   Liu, CC
   Chen, G
   Willett, T
   Young, RN
   Grynpas, MD
AF Hu, S.
   Liu, C. C.
   Chen, G.
   Willett, T.
   Young, R. N.
   Grynpas, M. D.
TI In vivo effects of two novel ALN EP4a conjugate drugs on bone in the
   ovariectomized rat model for reversing postmenopausal bone loss
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Anabolic drug; Biomechanical testing; Bisphosphonates; Bone
   histomorphometry; Conjugate drug; Osteoporosis
ID FRACTURE INTERVENTION TRIAL; PROSTAGLANDIN EP4 RECEPTOR; HUMAN
   PARATHYROID HORMONE; CANCELLOUS BONE; BIOMECHANICAL PROPERTIES;
   OSTEOCLAST FORMATION; MICRODAMAGE ACCUMULATION; VERTEBRAL FRACTURES;
   ANABOLIC ACTIONS; FEMALE RATS
AB A Summary Two alendronate EP4 agonist (ALN EP4a) conjugate drugs, C1 and C2, which differ in structure by a short linker molecule, were evaluated in ovariectomized (OVX) rats for their anabolic effects. We showed that C1 led to significant anabolic effects on cortical and trabecular bone while anabolic effects associated with C2 were minimal.
   Introduction EP4as were covalently linked to ALN to create ALN EP4a conjugate anabolic bone drugs, C1 and C2, which differ in structure by a short linker molecule in C1. When administered systemically, C1 and C2 are delivered to bone through targeted binding of ALN, where local hydrolytic enzymes liberate EP4a from ALN to exert anabolic effects. Here, we compare effects of C1 to C2 in a curative in vivo study.
   Methods Three month old female Sprague Dawley rats were OVX or sham operated and allowed to lose bone for 3 months. Animals were then treated via tail vein injections for 3 months and sacrificed. Treatment groups were as follows: C1L (5 mg/kg biweekly), C1H (5 mg/kg weekly), C2L (15 mg/kg monthly), C2H (15 mg/kg biweekly), OVX and sham control (phosphate buffered saline (PBS) biweekly), and ALN/EP4a unconjugated mixture (0.75 mg/kg each biweekly).
   Results MicroCT analysis showed that C1H treatment significantly increased vertebral bone mineral density (vBMD) and trabecular bone volume versus OVX controls while C2 treatments did not. Biomechanical testing showed that C1H treatment but not C2 treatments led to significant improvement in the load bearing abilities of the vertebrae compared to OVX controls. C1 stimulated endocortical bone formation and increased load bearing in femurs, while C2 did not.
   Conclusions We showed that C1 led to significant anabolic effects on cortical and trabecular bone while anabolic effects associated with C2 were minimal. These results led us to hypothesize a mode of action by which presence of a linker is crucial in facilitating the anabolic effects of EP4a when dosed as a prodrug with ALN.
C1 [Hu, S.; Grynpas, M. D.] Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5S 1A8, Canada.
   [Hu, S.; Liu, C. C.; Willett, T.; Grynpas, M. D.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.
   [Liu, C. C.; Willett, T.; Grynpas, M. D.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON M5S 3G9, Canada.
   [Chen, G.; Young, R. N.] Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada.
   [Grynpas, M. D.] 25 Orde St,Suite 417, Toronto, ON M5T 3H7, Canada.
C3 University of Toronto; University of Toronto; Sinai Health System
   Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto;
   Simon Fraser University
RP Grynpas, MD (通讯作者)，Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5S 1A8, Canada.; Grynpas, MD (通讯作者)，Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.; Grynpas, MD (通讯作者)，Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON M5S 3G9, Canada.; Grynpas, MD (通讯作者)，25 Orde St,Suite 417, Toronto, ON M5T 3H7, Canada.
EM grynpas@mshri.on.ca
RI ; Grynpas, Marc/E 4576 2013
OI Willett, Thomas/0000 0002 6220 4557; Young, Robert/0000 0002 8235 6080
FU Natural Sciences and Engineering Research Council of Canada [CHRPJ
   351731 08]; Canadian Institutes of Health Research (Institute of
   Musculoskeletal Health and Arthritis) [CHRPJ 351731 08]; University of
   Toronto
FX We thank the following individuals for their assistance in this study:
   Adeline Ng, Ariana Dela Cruz, Elise Post, and Richard Cheung for general
   experimental techniques and technical assistance; Kate Banks for animal
   care; Douglas Holmyard for BSE; and Richard Renlund for animal
   pathology. This work was supported by a Collaborative Health Research
   Grant from the Natural Sciences and Engineering Research Council of
   Canada and the Canadian Institutes of Health Research (Institute of
   Musculoskeletal Health and Arthritis), awarded to RNY and MDG, Grant
   number CHRPJ 351731 08. SH was supported by a research fellowship from
   the University of Toronto.
CR Allen MR, 2006, BONE, V39, P872, DOI 10.1016/j.bone.2006.04.028
   Arns S, 2012, BIOORGAN MED CHEM, V20, P2131, DOI 10.1016/j.bmc.2012.01.024
   Billot X, 2003, BIOORG MED CHEM LETT, V13, P1129, DOI 10.1016/S0960 894X(03)00042 8
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Chen G, 2015, BIOCONJUGATE CHEM, V26, P1095, DOI 10.1021/acs.bioconjchem.5b00160
   COLLINS DA, 1992, J BONE MINER RES, V7, P555
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   FLANAGAN AM, 1992, ENDOCRINOLOGY, V130, P443, DOI 10.1210/en.130.1.443
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Green JR, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.24154
   JEE WSS, 1990, BONE, V11, P253, DOI 10.1016/8756 3282(90)90078 D
   Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756 3282(97)00147 6
   Jolette J, 2006, TOXICOL PATHOL, V34, P929, DOI 10.1080/01926230601072301
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kaneki H, 1999, J CELL BIOCHEM, V73, P36, DOI 10.1002/(SICI)1097 4644(19990401)73:1<36::AID JCB5>3.3.CO;2 6
   KE HZ, 1993, BONE MINER, V21, P189, DOI 10.1016/S0169 6009(08)80230 9
   Ke HZ, 2006, J BONE MINER RES, V21, P565, DOI 10.1359/JBMR.051110
   KE HZ, 1993, BONE, V14, P481, DOI 10.1016/8756 3282(93)90183 B
   KE HZ, 1992, BONE MINER, V19, P45, DOI 10.1016/0169 6009(92)90843 3
   LAURITZEN DB, 1993, J BONE MINER RES, V8, P871
   Li M, 2007, INT ORTHOP, V31, P767, DOI 10.1007/s00264 007 0406 x
   Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054
   Liu CC, 2015, J BONE MINER RES, V30, P670, DOI 10.1002/jbmr.2382
   Mano M, 2000, CALCIFIED TISSUE INT, V67, P85, DOI 10.1007/s00223001102
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Meng XW, 1996, J BONE MINER RES, V11, P421
   Miyaura C, 2000, J BIOL CHEM, V275, P19819, DOI 10.1074/jbc.M002079200
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   PAPADOPOULOS G, 1991, J AM OIL CHEM SOC, V68, P669, DOI 10.1007/BF02662292
   RODAN GA, 1993, OSTEOPOROSIS INT, V3, pS7
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sakuma Y, 2000, J BONE MINER RES, V15, P218, DOI 10.1359/jbmr.2000.15.2.218
   SCUTT A, 1995, J BONE MINER RES, V10, P474
   Suponitzky I, 1998, J ENDOCRINOL, V156, P51, DOI 10.1677/joe.0.1560051
   Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023
   Tian XY, 2008, BONE, V42, P914, DOI 10.1016/j.bone.2007.12.228
   Tomita M, 2002, BONE, V30, P159, DOI 10.1016/S8756 3282(01)00688 3
   Tsuchie H, 2013, TOHOKU J EXP MED, V229, P19, DOI 10.1620/tjem.229.19
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   WRONSKI TJ, 1988, CALCIFIED TISSUE INT, V43, P179, DOI 10.1007/BF02571317
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
NR 45
TC 10
Z9 12
U1 0
U2 10
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD FEB
PY 2016
VL 27
IS 2
BP 797
EP 808
DI 10.1007/s00198 015 3284 x
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DD6PN
UT WOS:000370046200040
PM 26272313
DA 2025 08 17
ER

PT J
AU Li, YY
   Cao, SQ
   Li, QW
   Li, HW
   Yu, LX
   Shao, B
   Yuan, Q
   Zou, SJ
   Zhou, CC
AF Li, Yuyu
   Cao, Shuqin
   Li, Qiwen
   Li, Hanwen
   Yu, Leixiao
   Shao, Bin
   Yuan, Quan
   Zou, Shujuan
   Zhou, Chenchen
TI Engineered Plant Virus Complexes with a RANK Motif Modulator and Bone
   Targeting for Osteoporosis Treatment
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article; Early Access
DE osteoporosis; engineered plant virus; bone targeting; RANK Motif2/3;
   osteoclastogenesis
ID OSTEOCLASTS
AB Osteoporosis is a systemic skeletal disorder characterized by excessive osteoclastic bone resorption and impaired osteoblastic bone formation. Traditional delivery of antiresorptive drugs lacks a specific biodistribution in the body and may cause adverse effects to the patients. In this study, the peptide BTRM is first synthesized consisting of the bone targeting peptide Asp8 (BT) and the peptide derived from the amino acid sequences of RANK Motif2/3 (RM), two cytoplasmic RANK motifs (PVQEET560 565 and PVQEQG604 609) that have been reported to play an important role in osteoclastogenesis. Then, BTRM is conjugated on the plant virus like nanoparticles (VNPs) obtained from cowpea chlorotic mottle viruses (CCMVs), forming the engineered plant viruses BTRM  VNPs. In vitro experiments demonstrate that BTRM VNPs can effectively and safely inhibit osteoclast differentiation and function. Moreover, after injection into ovariectomized mice, BTRM VNPs show excellent capability to target bone tissue and improve osteoporotic bone loss. Collectively, the findings may provide a novel and promising strategy in the treatment of osteoporotic defects via targeting bone tissue and regulating the function of RANK Motif2/3.
C1 [Li, Yuyu; Li, Qiwen; Li, Hanwen; Yu, Leixiao; Shao, Bin; Yuan, Quan; Zou, Shujuan; Zhou, Chenchen] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Cao, Shuqin] Stomatol Univ, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, West China Hosp, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University
RP Zou, SJ; Zhou, CC (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
EM drzsj@scu.edu.cn; chenchenzhou5510@scu.edu.cn
RI Shao, Bin/AAE 5957 2019; Yu, Leixiao/ABC 4827 2021; Li,
   Qiwen/J 9130 2019; Zhou, Chenchen/LKJ 8704 2024; Li, Yuyu/S 8628 2019;
   Li, Hanwen/ABF 7174 2020
OI Yu, Leixiao/0000 0001 8804 948X; Cao, Shuqin/0000 0002 1143 8919; 
FU National Natural Science Foundation of China [82071150, 82271017,
   82171001, 82222015]; Sichuan Science & Technology Program [2021YFH0015];
   Sichuan University Postdoctoral Interdisciplinary Innovation Fund;
   Sichuan University; West China Hospital of Stomatology [RD 03 202010,
   RD 02 202004, RD 02 202207, RCDWJS2021 9, RCDWJS2021 15]
FX The authors acknowledge financial support from the National Natural
   Science Foundation of China (82071150, 82271017, 82171001, and 82222015)
   , the Sichuan Science & Technology Program (2021YFH0015) , the Sichuan
   University Postdoctoral Interdisciplinary Innovation Fund, the Postdoc
   Research Funding from Sichuan University, and the West China Hospital of
   Stomatology (RD 03 202010, RD 02 202004, RD 02 202207, RCDWJS2021 9, and
   RCDWJS2021 15) .
CR Ali A, 2007, J VIROL METHODS, V141, P84, DOI 10.1016/j.jviromet.2006.11.038
   Almendárez Rodriguez C, 2022, INT J BIOL MACROMOL, V213, P1007, DOI 10.1016/j.ijbiomac.2022.06.021
   An JM, 2021, ACS APPL MATER INTER, V13, P23314, DOI 10.1021/acsami.0c22170
   Balke I, 2019, ADV DRUG DELIVER REV, V145, P119, DOI 10.1016/j.addr.2018.08.007
   Brisse M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583077
   Brown C, 2017, NATURE, V550, pS15, DOI 10.1038/550S15a
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Camara A, 2019, IMMUNITY, V50, P1467, DOI 10.1016/j.immuni.2019.05.008
   Chen Q., ADV FUNCT MATER
   Chen YL, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.909408
   Chung YH, 2022, NAT REV MATER, V7, P372, DOI 10.1038/s41578 021 00399 5
   Deeks ED, 2018, DRUG AGING, V35, P163, DOI 10.1007/s40266 018 0525 7
   Everts Graber J, 2022, J BONE MINER RES, V37, P340, DOI 10.1002/jbmr.4472
   Gao X, 2021, BIOMATERIALS, V265, DOI 10.1016/j.biomaterials.2020.120404
   Gilarska A, 2021, ACS APPL MATER INTER, V13, P49762, DOI 10.1021/acsami.1c17472
   Gómez Aleza C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 20138 8
   Hasegawa T, 2019, NAT IMMUNOL, V20, P1631, DOI 10.1038/s41590 019 0526 7
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P1, DOI 10.1007/s00198 019 05176 3
   Kendler DL, 2022, ADV THER, V39, P58, DOI 10.1007/s12325 021 01936 y
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Li QW, 2020, J BONE MINER RES, V35, P1597, DOI 10.1002/jbmr.4015
   Li YY, 2019, J BONE MINER RES, V34, P1938, DOI 10.1002/jbmr.3810
   Li ZM, 2022, ADV MATER, V34, DOI 10.1002/adma.202200449
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Mitchell MJ, 2021, NAT REV DRUG DISCOV, V20, P101, DOI 10.1038/s41573 020 0090 8
   Mullard A, 2019, NAT REV DRUG DISCOV, V18, P411, DOI 10.1038/d41573 019 00083 y
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Ostrovsky V, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9010076
   Pattipeiluhu R, 2022, ADV MATER, V34, DOI 10.1002/adma.202201095
   Piotrowski Daspit AS, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abo0522
   Pretto C, 2021, MACROMOL BIOSCI, V21, DOI 10.1002/mabi.202100095
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   Taniguchi N, 2020, J PERIODONTOL, V91, P947, DOI 10.1002/JPER.19 0385
   Vallet Regí M, 2022, CHEM SOC REV, V51, P5365, DOI 10.1039/d1cs00659b
   Wang YC, 2022, SMALL, V18, DOI 10.1002/smll.202202544
   Wu YS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06898 4
   Xu RS, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368 020 0080 z
   Xu XQ, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14051109
   Xue F, 2023, CHINESE CHEM LETT, V34, DOI 10.1016/j.cclet.2022.04.046
   Yahara Y, 2020, NAT CELL BIOL, V22, P49, DOI 10.1038/s41556 019 0437 8
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   Zhang Y, 2018, MOLECULES, V23, DOI 10.3390/molecules23092311
   Zhu Z, 2021, ANTIMICROB AGENTS CH, V65
NR 46
TC 1
Z9 1
U1 2
U2 35
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD 2023 FEB 23
PY 2023
DI 10.1021/acsami.2c19632
EA FEB 2023
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA 9F0HO
UT WOS:000937157900001
PM 36821292
DA 2025 08 17
ER

PT J
AU Shen, YC
   Jiang, B
   Lu, W
   Luo, B
   Zhou, Y
   Qian, GY
AF Shen, Yingchao
   Jiang, Bo
   Lu, Wei
   Luo, Bin
   Zhou, Yuan
   Qian, Guiying
TI Dexamethasone induced mitochondrial ROS mediated inhibition of AMPK
   activity facilitates osteoblast necroptosis
SO TOXICOLOGY RESEARCH
LA English
DT Article
DE osteoblasts death; dexamethasone; necroptosis; AMPK; mitochondrial ROS
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; ACTIVATED PROTEIN KINASE; OXIDATIVE
   STRESS; CELL DEATH; NECROSTATIN 1; MECHANISMS
AB Long term or high dose glucocorticoid use can lead to serious orthopedic complications, including femoral head necrosis. Both basic and clinical studies have shown that high doses dexamethasone (Dex) can directly induce osteoblasts death. This study investigated the mechanism underlying Dex induced osteoblast death. In this study, we showed that Dex induces osteoblast necroptosis, rather than apoptosis, through the inhibition of AMP activated protein kinase (AMPK) activity. We also demonstrated that inactivation of AMPK mediated necroptosis is through receptor interacting protein kinase 3 (RIP3), but not RIP1. Furthermore, we found that Dex induced necroptosis is dependent on mitochondrial reactive oxygen species (ROS) following with directly activation of RIP1 and inactivation of AMPK. These findings provide new insights into the mechanism of Dex induced osteoblast death and may have implications for the development of new therapies for osteoporosis and other bone related diseases.
C1 [Shen, Yingchao; Lu, Wei; Luo, Bin; Zhou, Yuan; Qian, Guiying] Nanjing Univ Chinese Med, Changshu Hosp, Dept Orthopaed, 6 Huanghe Rd, Changshu 215500, Jiangsu, Peoples R China.
   [Jiang, Bo] Soochow Univ, Dept Hand & Foot Surg, Affiliated Hosp 2, 1055 Sanxiang Rd, Suzhou 215004, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Soochow University   China
RP Qian, GY (通讯作者)，Nanjing Univ Chinese Med, Changshu Hosp, Dept Orthopaed, 6 Huanghe Rd, Changshu 215500, Jiangsu, Peoples R China.
EM csfy045@njucm.edu.cn; jiangbo082611@163.com; Csfy016@njucm.edu.cn;
   fsyy01031@njucm.edu.cn; 86274458@qq.com; csfy044@njucm.edu.cn
RI jiang, bo/KCY 7118 2024
FU Science and Technology Program of Changshu Municipal Health Commission
   [csws202004]; Natural Science Foundation of Nanjing University of
   Chinese Medicine [XZR2020064]; Changshu Municipal Science and Technology
   Bureau Grant Funded Research Project [CS202131]
FX This work was supported by the Science and Technology Program of
   Changshu Municipal Health Commission (csws202004),the Natural Science
   Foundation of Nanjing University of Chinese Medicine (XZR2020064), and
   Changshu Municipal Science and Technology Bureau Grant Funded Research
   Project (CS202131).
CR Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Choi ME, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128834
   Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003
   Deng S, 2019, BIOMED PHARMACOTHER, V110, P602, DOI 10.1016/j.biopha.2018.11.103
   Ding HY, 2015, BIOCHEM BIOPH RES CO, V460, P157, DOI 10.1016/j.bbrc.2015.02.161
   Fan JB, 2018, CELL PHYSIOL BIOCHEM, V51, P31, DOI 10.1159/000495159
   Feng M, 2018, INT J CLIN EXP PATHO, V11, P675
   Feng M, 2014, J STEROID BIOCHEM, V144, P455, DOI 10.1016/j.jsbmb.2014.09.005
   Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300 9084(02)01369 X
   Galluzzi L, 2017, ANNU REV PATHOL MECH, V12, P103, DOI 10.1146/annurev pathol 052016 100247
   Galluzzi L, 2008, CELL, V135, P1161, DOI 10.1016/j.cell.2008.12.004
   Guo M, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/3027954
   Guo SG, 2017, BIOCHEM BIOPH RES CO, V487, P660, DOI 10.1016/j.bbrc.2017.04.111
   Guo SG, 2016, BIOCHEM BIOPH RES CO, V471, P545, DOI 10.1016/j.bbrc.2016.02.036
   Ma L, 2020, FEBS OPEN BIO, V10, P211, DOI 10.1002/2211 5463.12771
   Nie ZG, 2019, MOL MED REP, V20, P401, DOI 10.3892/mmr.2019.10267
   Quinn JMW, 2010, FASEB J, V24, P275, DOI 10.1096/fj.09 137158
   Rosenberg N, 2012, RAMBAM MAIMONIDES ME, V3, DOI 10.5041/RMMJ.10080
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Souttou B, 2001, J CELL PHYSIOL, V187, P59, DOI 10.1002/1097 4652(2001)9999:9999<00::AID JCP1051>3.0.CO;2 F
   Sun WX, 2015, MOL CELL BIOCHEM, V409, P51, DOI 10.1007/s11010 015 2511 2
   Wang L, 2020, DRUG DES DEV THER, V14, P4451, DOI 10.2147/DDDT.S266502
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Wu XJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7126982
   Xu YY, 2018, BIOCHEM BIOPH RES CO, V495, P1014, DOI 10.1016/j.bbrc.2017.11.132
   Zhang YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14329
   Zhao S, 2017, ONCOTARGET, V8, P104867, DOI 10.18632/oncotarget.20452
NR 28
TC 3
Z9 4
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2045 452X
EI 2045 4538
J9 TOXICOL RES UK
JI Toxicol. Res.
PD OCT 29
PY 2023
VL 12
IS 5
BP 922
EP 929
DI 10.1093/toxres/tfad080
EA SEP 2023
PG 8
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA X3WK4
UT WOS:001071322300001
PM 37915480
OA Green Published
DA 2025 08 17
ER

PT J
AU Iu, MF
   Kaji, H
   Naito, J
   Sowa, H
   Sugimoto, T
   Chihara, K
AF Iu, MF
   Kaji, H
   Naito, J
   Sowa, H
   Sugimoto, T
   Chihara, K
TI Low dose parathyroid hormone and estrogen reverse alkaline phosphatase
   activity suppressed by dexamethasone in mouse osteoblastic cells
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE osteoblast; parathyroid hormone; estrogen; glucocorticoid; alkaline
   phosphatase
ID CORTICOSTEROID INDUCED OSTEOPOROSIS; 11 BETA HYDROXYSTEROID
   DEHYDROGENASE TYPE 1; GLUCOCORTICOID INDUCED OSTEOPOROSIS;
   PROTEIN KINASE; BONE; APOPTOSIS; PROLIFERATION; PATHOGENESIS;
   MECHANISMS; PREVENTION
AB Glucocorticoid (GC) induced osteoporosis (GIO) is frequently seen in patients with excessive GC. Numerous questions remain to be clarified about the pathogenesis and treatment of GIO, and the mechanism of GC inhibited bone formation is not well known. Several studies suggest that parathyroid hormone (PTH) and hormone replacement therapy are effective for GIO. We therefore investigated whether PTH and estrogen would affect cell proliferation and alkaline phosphatase ( ALP) activity inhibited by dexamethasone (Dex) in mouse osteoblastic cell line MC3T3 E1 cells. Low dose (10( 11) M) PTH as well as 10( 8) M 17 beta estradiol (17 beta E 2) significantly attenuated Dex inhibited ALP activity, although 10( 8) M PTH did not affect it. ICI 182780 (10( 8) M) antagonized the effects of 17 beta E 2 on Dex suppressed ALP activity. Neutralizing anti IGF I antibody (3 mu g/ml) blocked the reverse effects of 17 beta E 2 on ALP activity suppressed by Dex. PTH (10( 11) M), but not 17 beta  E 2, significantly attenuated [H 3] thymidine incorporation inhibited by Dex. On the other hand, PTH and estrogen did not affect the level of 11 beta hydrosteroid dehydrogenase type I mRNA increased by Dex. In conclusion, the present study demonstrated that low dose PTH and estrogen reversed Dex inhibited ALP activity in the mouse osteoblastic cell line.
C1 Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Endocrinol Metab Neurol & Hematol Oncol,Chuo, Kobe, Hyogo 6500017, Japan.
   Shimane Univ, Sch Med, Div Endocrinol Metab & Hematol Oncol, Izumo, Shimane, Japan.
C3 Kobe University; Shimane University
RP Kaji, H (通讯作者)，Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Endocrinol Metab Neurol & Hematol Oncol,Chuo, 7 5 2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM hiroshik@med.kobe u.ac.jp
RI Kaji, Hiroshi/AAI 5628 2020
CR ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502
   BRESSOT C, 1979, METAB BONE DIS RELAT, V1, P303, DOI 10.1016/0221 8747(79)90024 9
   Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159
   Cole JA, 1999, ENDOCRINOLOGY, V140, P5771, DOI 10.1210/en.140.12.5771
   Cooper MS, 2002, J BONE MINER RES, V17, P979, DOI 10.1359/jbmr.2002.17.6.979
   DEMPSTER DW, 1983, CALCIFIED TISSUE INT, V35, P410, DOI 10.1007/BF02405069
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   DYKMAN TR, 1985, ARTHRITIS RHEUM US, V28, P361, DOI 10.1002/art.1780280402
   ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo 125 2 825
   Gohel A, 1999, ENDOCRINOLOGY, V140, P5339, DOI 10.1210/en.140.11.5339
   GOHEL A, 1996, ORTHOP RES SOC, V22, P183
   GRAY TK, 1989, BIOCHEM BIOPH RES CO, V158, P407, DOI 10.1016/S0006 291X(89)80062 2
   HALL GM, 1994, ARTHRITIS RHEUM, V37, P1499, DOI 10.1002/art.1780371014
   Hochberg MC, 1996, ARTHRITIS RHEUM US, V39, P1791
   Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   LOWRY OH, 1954, J BIOL CHEM, V207, P19
   Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061
   Nasu M, 1997, FEBS LETT, V409, P63, DOI 10.1016/S0014 5793(97)00484 5
   OPPERMANN UCT, 1995, EUR J BIOCHEM, V227, P202, DOI 10.1111/j.1432 1033.1995.tb20377.x
   RAISZ LG, 1988, NEW ENGL J MED, V318, P818
   ROSS EJ, 1982, LANCET, V2, P646
   Sambrook PN, 2000, J BONE MINER RES, V15, P1645, DOI 10.1359/jbmr.2000.15.9.1645
   Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
NR 29
TC 9
Z9 9
U1 0
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD NOV
PY 2005
VL 23
IS 6
BP 450
EP 455
DI 10.1007/s00774 005 0627 2
PG 6
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 980BB
UT WOS:000232987800006
PM 16261451
DA 2025 08 17
ER

PT J
AU Kwong, LM
   Tong, LM
AF Kwong, Louis M.
   Tong, Lisa M.
TI Drug Interactions with Rivaroxaban Following Total Joint Replacement
   Surgery
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE arthroplasty; drug interactions; rivaroxaban; total hip replacement;
   total knee replacement
ID FACTOR XA INHIBITOR; TOTAL HIP; KNEE REPLACEMENT; DOUBLE BLIND; BAY
   59 7939; ENOXAPARIN; THROMBOPROPHYLAXIS; PHARMACODYNAMICS;
   PHARMACOKINETICS; PREVENTION
AB OBJECTIVE: To evaluate potential drug drug interactions with rivaroxaban in patients undergoing total hip replacement (THR) and total knee replacement (TKR) surgeries.
   DATA SOURCES: PubMed; January 2009 April 2012 abstract databases of major congresses for hematology and cardiovascular medicine.
   STUDY SELECTION AND DATA EXTRACTION: Searches were performed using the key words rivaroxaban and drug interaction. Studies were included if they evaluated interactions with drugs that are commonly used in patients undergoing THR or TKR, based on our clinical experience.
   DATA SYNTHESIS: A Phase 1 study found that coadministration of rivaroxaban and the nonsteroidal antiinflammatory drug (NSAID) naproxen significantly increased bleeding time. However, in a retrospective analysis of 4 large trials evaluating rivaroxaban in patients undergoing THR or TKR, the difference between major and clinically relevant nonmajor bleeding was not significantly different between NSAID users and nonusers. In addition, proton pump inhibitors, which are frequently coadministered with NSAIDs to prevent gastrointestinal toxicity, have not been demonstrated to cause any appreciable changes in rivaroxaban pharmacokinetics or pharmacodynamics. A Phase 2 study that evaluated several doses and administration intervals of rivaroxaban in combination with aspirin or both aspirin and clopidogrel in patients with acute coronary syndrome found that clinically significant bleeding events occurred in patients receiving rivaroxaban 10 mg daily (the dose approved for the orthopedic indication). However, this risk was not great enough to end the trial early.
   CONCLUSIONS: Phase 1 drug drug interaction studies in healthy humans provided little insight into the pharmacodynamic drug interactions between rivaroxaban and NSAIDs or antiplatelet agents. A pooled analysis of the RECORD (Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism) trials and data from other large trials provides clinical evidence that these agents can be coadministered with rivaroxaban, as long as proper monitoring is instituted.
C1 [Kwong, Louis M.] LABiomed TRIAL Group, Thrombosis Res Inst, Torrance, CA USA.
   [Tong, Lisa M.] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA.
   [Tong, Lisa M.] Univ Pacific, Sch Pharm, Stockton, CA 95211 USA.
   [Tong, Lisa M.] Dept Vet Affairs Med Ctr, San Francisco, CA USA.
C3 University of California System; University of California San Francisco;
   University of the Pacific
EM lmkwongmd@hotmail.com
FU Janssen Scientific Affairs, LLC.; Astellas; Bayer; Takeda;
   GlaxoSmithKline; Pfizer
FX We acknowledge Matthew Romo PharmD, who provided editorial support with
   funding from Janssen Scientific Affairs, LLC. Dr. Kwong has served as a
   consultant for Zimmer Orthopaedics and has received grants from
   Astellas, Bayer, Takeda, GlaxoSmithKline, and Pfizer. He has served as a
   paid speaker for Zimmer Orthopaedics, Bayer, Janssen, and ConvaTec. He
   has received royalties from Zimmer Orthpaedics for product development
   and has received payment for the development of an educational
   presentation by Joint Commission Resources.
CR [Anonymous], EUR SOC CARDIOL
   [Anonymous], PACK INS NEX ES
   [Anonymous], PACK INS PRIL OM
   [Anonymous], REC MED MAN OST HIP
   [Anonymous], 2011, PREV VEN THROMB DIS
   [Anonymous], INT SOC THROMB HAEM
   [Anonymous], PACK INS XAR RIV
   Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08 0670
   Colwell CW, 2005, ORTHOPEDICS, V28, P143
   Eriksson BI, 2008, NEW ENGL J MED, V358, P2765, DOI 10.1056/NEJMoa0800374
   Friedman Richard J, 2010, Am J Orthop (Belle Mead NJ), V39, P14
   Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08 0656
   Gnoth MJ, 2011, J PHARMACOL EXP THER, V338, P372, DOI 10.1124/jpet.111.180240
   Iorio R, 2008, J BONE JOINT SURG AM, V90A, P1598, DOI 10.2106/JBJS.H.00067
   Kakkar AK, 2008, LANCET, V372, P31, DOI 10.1016/S0140 6736(08)60880 6
   Knudsen JE, 2008, PHARMACOTHERAPY, V28, P540, DOI 10.1592/phco.28.4.540
   Kubitza D, 2006, J CLIN PHARMACOL, V46, P549, DOI 10.1177/0091270006286904
   Kubitza D, 2007, EUR HEART J, V28, P189
   Kubitza D, 2007, BRIT J CLIN PHARMACO, V63, P469, DOI 10.1111/j.1365 2125.2006.02776.x
   Kubitza D, 2006, J CLIN PHARMACOL, V46, P981, DOI 10.1177/0091270006292127
   Kubitza D, 2010, BRIT J CLIN PHARMACO, V70, P703, DOI 10.1111/j.1365 2125.2010.03753.x
   Lanza FL, 2009, AM J GASTROENTEROL, V104, P728, DOI 10.1038/ajg.2009.115
   Lassen MR, 2008, NEW ENGL J MED, V358, P2776, DOI 10.1056/NEJMoa076016
   Mega JL, 2009, LANCET, V374, P29, DOI 10.1016/S0140 6736(09)60738 8
   Mega JL, 2012, NEW ENGL J MED, V366, P9, DOI 10.1056/NEJMoa1112277
   Moore KT, 2011, J CARDIOVASC PHARM, V58, P581, DOI 10.1097/FJC.0b013e31822f6c2b
   Rat AC, 2010, ARTHRIT CARE RES, V62, P54, DOI 10.1002/acr.20014
   Turpie AGG, 2009, LANCET, V373, P1673, DOI 10.1016/S0140 6736(09)60734 0
   Wilkinson GR, 2005, NEW ENGL J MED, V352, P2211, DOI 10.1056/NEJMra032424
NR 29
TC 4
Z9 4
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1060 0280
EI 1542 6270
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD SEP
PY 2012
VL 46
IS 9
BP 1232
EP 1238
DI 10.1345/aph.1R055
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 005XS
UT WOS:000308784000012
PM 22932305
DA 2025 08 17
ER

PT J
AU Huang, AR
   Li, L
   Liu, XX
   Lian, QT
   Guo, GY
   Xu, TH
   Lu, XM
   Ma, L
   Ma, HY
   Yu, YQ
   Yao, L
AF Huang, Aoran
   Li, Lu
   Liu, Xiaoxu
   Lian, Qiuting
   Guo, Guangying
   Xu, Tianhua
   Lu, Xiaomei
   Ma, Ling
   Ma, Haiying
   Yu, Yanqiu
   Yao, Li
TI Hedgehog signaling is a potential therapeutic target for vascular
   calcification
SO GENE
LA English
DT Article
DE Vascular smooth muscle cells; RNA sequencing; Vascular calcification;
   Osteogenic differentiation; Hedgehog pathway
ID SMOOTH MUSCLE CELLS; GROWTH FACTOR; ACTIVATION; ATHEROSCLEROSIS;
   DIFFERENTIATION; INHIBITION; MECHANISMS; INDUCTION; PLATFORM; PACKAGE
AB Background: Patients with chronic kidney disease (CKD) suffered from vascular calcification (VC), one major contributor for their increased mortality rate. Hedgehog (Hh) signaling plays a crucial role in physiological bone mineralization and is associated with several cardiovascular diseases. However, the molecular changes underlying VC is ill defined and it remains unclear whether Hh signaling intervention affects VC.Methods: We constructed human primary vascular smooth muscle cell (VSMC) calcification model and performed RNA sequencing. Alizarin red staining and calcium content assay were conducted to identify the occurrence of VC. Three different R packages were applied to determine differentially expressed genes (DEGs). Enrichment analysis and protein protein interaction (PPI) network analysis were carried out to explore the biological roles of DEGs. qRT PCR assay was then applied to validate the expression of key genes. By using Connectivity Map (CMAP) analysis, several small molecular drugs targeting these key genes were obtained, including SAG (Hedgehog signaling activator) and cyclopamine (CPN) (Hedgehog signaling inhibitor), which were subsequently used to treat VSMC.Results: Obvious Alizarin red staining and increased calcium content identified the occurrence of VC. By integrating results from three R packages, we totally obtained 166 DEGs (86 up regulated and 80 down regulated), which were significantly enriched in ossification, osteoblast differentiation, and Hh signaling. PPI network analysis identified 10 key genes and CMAP analysis predicted several small molecular drugs targeting these key genes including chlorphenamine, isoeugenol, CPN and phenazopyridine. Notably, our in vitro experiment showed that SAG markedly alleviated VSMC calcification, whereas CPN significantly exacerbated VC.Conclusions: Our research provided deeper insight to the pathogenesis of VC and indicated that targeting Hh signaling pathway may represent a potential and effective therapy for VC.
C1 [Huang, Aoran; Li, Lu; Liu, Xiaoxu; Lian, Qiuting; Guo, Guangying; Xu, Tianhua; Yao, Li] China Med Univ, Dept Nephrol, Hosp 1, Shenyang 110000, Peoples R China.
   [Lu, Xiaomei; Ma, Ling; Ma, Haiying; Yu, Yanqiu] China Med Univ, Coll Basic Med Sci, Dept Pathophysiol, Shenyang 110013, Peoples R China.
   [Yu, Yanqiu] Shenyang Engn Technol R&D Ctr Cell Therapy Co LTD, Shenyang 110169, Peoples R China.
C3 China Medical University; China Medical University
RP Yao, L (通讯作者)，China Med Univ, Dept Nephrol, Hosp 1, Shenyang 110000, Peoples R China.; Yu, YQ (通讯作者)，China Med Univ, Coll Basic Med Sci, Dept Pathophysiol, Shenyang 110013, Peoples R China.
EM yqyu@cmu.edu.cn; yaolicmu@163.com
RI yu, ye/KVB 7532 2024; LI, XIAO/IQV 9318 2023
FU National Natural Science Foundations of China [82070763]; Natural
   Science Foundations of Shenyang [22 321 33 05]
FX This study was funded by the National Natural Science Foundations of
   China (grant number 82070763) and Natural Science Foundations of
   Shenyang (No. 22 321 33 05) .
CR Chen NX, 2015, CURR OSTEOPOROS REP, V13, P372, DOI 10.1007/s11914 015 0293 9
   Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200
   Demer LL, 2019, TRENDS ENDOCRIN MET, V30, P646, DOI 10.1016/j.tem.2019.06.001
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   El Maadidi S, 2014, J IMMUNOL, V192, P1171, DOI 10.4049/jimmunol.1300842
   El Deeb OS, 2019, J CELL BIOCHEM, V120, P14476, DOI 10.1002/jcb.28707
   Gupta Sachin, 2010, Ther Adv Med Oncol, V2, P237, DOI 10.1177/1758834010366430
   Hu W, 2018, EXP THER MED, V15, P1994, DOI 10.3892/etm.2017.5623
   Huang AR, 2021, J MOL MED, V99, P75, DOI 10.1007/s00109 020 02014 6
   Huang DL, 2018, ONCOL LETT, V15, P6077, DOI 10.3892/ol.2018.8142
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Kawaguchi M, 2011, CIRCULATION, V123, P594, DOI 10.1161/CIRCULATIONAHA.110.982777
   Kramann R, 2016, CELL STEM CELL, V19, P628, DOI 10.1016/j.stem.2016.08.001
   Kramann R, 2015, J CLIN INVEST, V125, P2935, DOI 10.1172/JCI74929
   Lanzer P, 2014, EUR HEART J, V35, P1515, DOI 10.1093/eurheartj/ehu163
   Leopold JA, 2015, TRENDS CARDIOVAS MED, V25, P267, DOI 10.1016/j.tcm.2014.10.021
   Li FH, 2010, ARTERIOSCL THROM VAS, V30, P1787, DOI 10.1161/ATVBAHA.110.208520
   Li HJ, 2012, AM J PHYSIOL HEART C, V303, pH1319, DOI 10.1152/ajpheart.00160.2012
   Li WX, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI150051
   Li YL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00661
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Nyholt DR, 2014, BIOINFORMATICS, V30, P2086, DOI 10.1093/bioinformatics/btu171
   Piccolo E, 2013, J MOL MED, V91, P83, DOI 10.1007/s00109 012 0936 6
   Rennenberg RJMW, 2009, VASC HEALTH RISK MAN, V5, P185
   Richards JB, 2008, LANCET, V371, P1505, DOI 10.1016/S0140 6736(08)60599 1
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen JY, 2020, TOXICOL APPL PHARM, V387, DOI 10.1016/j.taap.2019.114853
   Shih MF, 2018, REGUL TOXICOL PHARM, V92, P333, DOI 10.1016/j.yrtph.2017.12.021
   Shimizu T, 2009, ARTERIOSCL THROM VAS, V29, P1104, DOI 10.1161/ATVBAHA.109.187856
   Sigafoos AN, 2021, CANCERS, V13, DOI 10.3390/cancers13143410
   Su BF, 2018, LIFE SCI, V208, P26, DOI 10.1016/j.lfs.2018.07.009
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224
   Wu KL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/306964
   Yaker L, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.823450
   Yang L, 2022, CIRC RES, V130, P213, DOI 10.1161/CIRCRESAHA.121.319745
   Yao YC, 2010, CIRC RES, V107, P485, DOI 10.1161/CIRCRESAHA.110.219071
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang M, 2009, J CELL SCI, V122, P1382, DOI 10.1242/jcs.040709
   Zhang WQ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059 015 0694 1
   Zhang XX, 2019, CELL SIGNAL, V63, DOI 10.1016/j.cellsig.2019.109359
   Zhou H, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13162
   Zhou JC, 2016, CANCER LETT, V370, P313, DOI 10.1016/j.canlet.2015.11.006
NR 47
TC 3
Z9 3
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 1119
EI 1879 0038
J9 GENE
JI Gene
PD JUL 1
PY 2023
VL 872
AR 147457
DI 10.1016/j.gene.2023.147457
EA MAY 2023
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA M6NC2
UT WOS:001031353200001
PM 37141952
DA 2025 08 17
ER

PT J
AU Brazier, H
   Pawlak, G
   Vives, V
   Blangy, A
AF Brazier, Helene
   Pawlak, Geraldine
   Vives, Virginie
   Blangy, Anne
TI The Rho GTPase Wrch1 regulates osteoclast precursor adhesion and
   migration
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Osteoclast; Podosome; Wrch1; Pyk2; Integrin
ID COLONY STIMULATING FACTOR; SRC KINASE ACTIVITY; CELL MIGRATION; FAMILY
   GTPASE; C SRC; ALPHA V BETA 3 INTEGRIN; MULTINUCLEATED CELLS;
   BONE RESORPTION; ACTIN DYNAMICS; PROTEIN
AB An excess of osteoclastic bone resorption relative to osteoblastic bone formation results in progressive bone loss, characteristic of osteoporosis. Understanding the mechanisms of osteoclast differentiation is essential to develop novel therapeutic approaches to prevent and treat osteoporosis. We showed previously that Wrch1/RhoU is the only RhoGTPase whose expression is induced by RANKL during osteoclastogenesis. It associates with podosomes and the suppression of Wrch1 in osteoclast precursors leads to defective multinucleated cell formation. Here we further explore the functions of this RhoGTPase in osteoclasts, using RAW264.7 cells and bone marrow macrophages as osteoclast precursors. Suppression of Wrch1 did not prevent induction of classical osteoclastic markers such as NFATc1, Src, TRAP (Tartrate Resistant Acid Phosphatase) or cathepsin K. ATP6v0d2 and DC STAMP, which are essential for fusion, were also expressed normally. Similar to the effect of RANKL, we observed that Wrch1 expression increased osteoclast precursor aggregation and reduced their adhesion onto vitronectin but not onto fibronectin. We further found that Wrch1 could bind integrin 93 cytoplasmic domain and interfered with adhesion induced Pyk2 and paxillin phosphorylation. Wrch1 also acted as an inhibitor of M CSF induced prefusion osteoclast migration. In mature osteoclasts, high Wrch1 activity inhibited podosome belt formation. Nevertheless, it had no effect on mineralized matrix resorption. Our observations suggest that during osteoclastogenesis, Wrch1 potentially acts through the modulation of alpha v beta 3 signaling to regulate osteoclast precursor adhesion and migration and allow fusion. As an essential actor of osteoclast differentiation, the atypical RhoGTPase Wrch1/RhoU could be an interesting target for the development of novel antiresorptive drugs. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Brazier, Helene; Pawlak, Geraldine; Vives, Virginie; Blangy, Anne] Univ Montpellier, Ctr Rech Biochim Macromol, CNRS, UMR 5237, F 34293 Montpellier 5, France.
   [Pawlak, Geraldine] Univ Grenoble 1, INSERM,Equipe DySAD, U823,Inst Albert Bonniot, CNRS,ERL3148, F 38042 Grenoble 9, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS   National
   Institute for Biology (INSB); Universite de Montpellier; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Centre
   National de la Recherche Scientifique (CNRS); Communaute Universite
   Grenoble Alpes; Universite Grenoble Alpes (UGA)
RP Blangy, A (通讯作者)，Univ Montpellier, Ctr Rech Biochim Macromol, CNRS, UMR 5237, 1919 Route Mende, F 34293 Montpellier 5, France.
EM anne.blangy@crbm.cnrs.fr
RI VIVES, Virginie/JVZ 4304 2024
OI BLANGY, Anne/0000 0001 7043 0784
FU Association pour la Recherche sur le Cancer [3476, 3897]; Association de
   Recherche Sur la Polyarthrite
FX We are very grateful to Corinne Albiges Rizo for sharing reagents and
   for fruitful scientific discussion. This work was funded by
   institutional grants (French National Center for Scientific Research:
   CNRS and Montpellier I and II Universities), by the Association pour la
   Recherche sur le Cancer (grants 3476 and 3897) and by the Association de
   Recherche Sur la Polyarthrite. H.B. and V.V. are recipients of
   fellowships from the Association pour la Recherche Sur le Cancer.
CR Badowski C, 2008, MOL BIOL CELL, V19, P633, DOI 10.1091/mbc.E06 01 0088
   Berzat AC, 2005, J BIOL CHEM, V280, P33055, DOI 10.1074/jbc.M507362200
   Block M.R., 2008, EUR J CELL BIOL
   Boissy P, 1998, J CELL SCI, V111, P2563
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brazier H, 2006, J BONE MINER RES, V21, P1387, DOI 10.1359/JBMR.060613
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092 8674(04)00003 0
   Caswell P, 2008, TRENDS CELL BIOL, V18, P257, DOI 10.1016/j.tcb.2008.03.004
   Cernuda Morollón E, 2006, CIRC RES, V98, P757, DOI 10.1161/01.RES.0000210579.35304.d3
   Chuang YY, 2007, J CELL SCI, V120, P1927, DOI 10.1242/jcs.03456
   Contractor T, 2005, IN VIVO, V19, P335
   Deakin NO, 2008, J CELL SCI, V121, P2435, DOI 10.1242/jcs.018044
   Dennison E, 2005, CURR OPIN RHEUMATOL, V17, P456, DOI 10.1097/01.bor.0000166384.80777.0d
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Humphries JD, 2007, J CELL BIOL, V179, P1043, DOI 10.1083/jcb.200703036
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kim JM, 2007, INT J MOL MED, V19, P393
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Krits I, 2002, CALCIFIED TISSUE INT, V71, P530, DOI 10.1007/s00223 001 1112 0
   Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Luxenburg C, 2006, EUR J CELL BIOL, V85, P203, DOI 10.1016/j.ejcb.2005.11.002
   Luxenburg C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000179
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Miyamoto T, 2000, BLOOD, V96, P4335, DOI 10.1182/blood.V96.13.4335.h8004335_4335_4343
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361
   Ogasawara T, 2004, J BONE MINER RES, V19, P1128, DOI 10.1359/jbmr.2004.19.7.1128
   Ory S, 2000, J CELL SCI, V113, P1177
   Ory S, 2008, EUR J CELL BIOL, V87, P469, DOI 10.1016/j.ejcb.2008.03.002
   Ory S, 2007, BIOL CELL, V99, P701, DOI 10.1042/BC20070058
   Roodman GD, 2006, ANN NY ACAD SCI, V1068, P100, DOI 10.1196/annals.1346.013
   Russell R.G., 2008, OSTEOPOROS INT
   Ruusala A, 2008, MOL CELL BIOL, V28, P1802, DOI 10.1128/MCB.00201 07
   Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04 06 0522
   SALTEL F, 2008, EUR J CELL BIOL
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   Saras J, 2004, EXP CELL RES, V299, P356, DOI 10.1016/j.yexcr.2004.05.029
   Shutes A, 2004, CURR BIOL, V14, P2052, DOI 10.1016/j.cub.2004.11.011
   Shyu JF, 2007, BONE, V40, P1329, DOI 10.1016/j.bone.2007.01.014
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wang YQ, 2008, J BONE MINER RES, V23, P260, DOI 10.1359/JBMR.071013
   Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402 e97
   Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094
   Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
NR 51
TC 47
Z9 50
U1 0
U2 9
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357 2725
EI 1878 5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD JUN
PY 2009
VL 41
IS 6
BP 1391
EP 1401
DI 10.1016/j.biocel.2008.12.007
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 425WU
UT WOS:000264669300022
PM 19135548
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Lin, SC
   Tsou, SH
   Kuo, CY
   Chen, WL
   Wu, KW
   Lin, CL
   Huang, CN
AF Lin, Sheng Chieh
   Tsou, Sing Hua
   Kuo, Chien Yin
   Chen, Wei Liang
   Wu, Kuan Wen
   Lin, Chih Li
   Huang, Chien Ning
TI Denosumab Attenuates Glucolipotoxicity Induced β Cell Dysfunction and
   Apoptosis by Attenuating RANK/RANKL Signals
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE denosumab; glucolipotoxicity; pancreatic beta cell; RANK/RANKL pathway;
   type 2 diabetes
ID PROLIFERATION
AB Obesity is strongly associated with insulin sensitivity in type 2 diabetes (T2D), mainly because free fatty acids (FFAs) are released from excess fat tissue. Long term exposure to high levels of FFAs and glucose leads to glucolipotoxicity, causing damage to pancreatic beta cells, thus accelerating the progression of T2D. Therefore, the prevention of beta cell dysfunction and apoptosis is essential to prevent the development of T2D. Unfortunately, there are currently no specific clinical strategies for protecting beta cells, highlighting the need for effective therapies or preventive approaches to improve the survival of beta cells in T2D. Interestingly, recent studies have shown that the monoclonal antibody denosumab (DMB), used in osteoporosis, displays a positive effect on blood glucose regulation in patients with T2D. DMB acts as an osteoprotegerin (OPG) by inhibiting the receptor activator of the NF kappa B ligand (RANKL), preventing the maturation and function of osteoclasts. However, the exact mechanism by which the RANK/RANKL signal affects glucose homeostasis has not been fully explained. The present study used human 1.4 x 10(7) beta cells to simulate the T2D metabolic condition of high glucose and free fatty acids (FFAs), and it investigated the ability of DMB to protect beta cells from glucolipotoxicity. Our results show that DMB effectively attenuated the cell dysfunction and apoptosis caused by high glucose and FFAs in beta cells. This may be caused by blocking the RANK/RANKL pathway that reduced mammalian sterile 20 like kinase 1 (MST1) activation and indirectly increased pancreatic and duodenal homeobox 1 (PDX 1) expression. Furthermore, the increase in inflammatory cytokines and ROS caused by the RANK/RANKL signal also played an important role in glucolipotoxicity induced cytotoxicity, and DMB can also protect beta cells by reducing the mechanisms mentioned above. These findings provide detailed molecular mechanisms for the future development of DMB as a potential protective agent of beta cells.
C1 [Lin, Sheng Chieh; Kuo, Chien Yin; Lin, Chih Li; Huang, Chien Ning] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan.
   [Lin, Sheng Chieh] Chung Shan Med Univ Hosp, Dept Orthopaed, Taichung 402, Taiwan.
   [Tsou, Sing Hua; Lin, Chih Li] Chung Shan Med Univ Hosp, Dept Med Res, Taichung 402, Taiwan.
   [Kuo, Chien Yin] Chung Shan Med Univ Hosp, Dept Surg, Taichung 402, Taiwan.
   [Chen, Wei Liang] Chung Shan Med Univ Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taichung 402, Taiwan.
   [Wu, Kuan Wen] Natl Taiwan Univ Hosp, Dept Orthopaed Surg, Taichung 100, Taiwan.
   [Huang, Chien Ning] Chung Shan Med Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Taichung 402, Taiwan.
C3 Chung Shan Medical University; Chung Shan Medical University; Chung Shan
   Medical University Hospital; Chung Shan Medical University; Chung Shan
   Medical University Hospital; Chung Shan Medical University; Chung Shan
   Medical University Hospital; Chung Shan Medical University; Chung Shan
   Medical University Hospital; National Taiwan University; National Taiwan
   University Hospital; Chung Shan Medical University; Chung Shan Medical
   University Hospital
RP Lin, CL; Huang, CN (通讯作者)，Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan.; Lin, CL (通讯作者)，Chung Shan Med Univ Hosp, Dept Med Res, Taichung 402, Taiwan.; Huang, CN (通讯作者)，Chung Shan Med Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Taichung 402, Taiwan.
EM phoenix33343@gmail.com; zinminid@gmail.com; a9704119@hotmail.com;
   chen.wl0204@gmail.com; wukuanwen@gmail.com; dll@csmu.edu.tw;
   cshy049@csmu.edu.tw
RI ; Lin, Chih Li/H 9515 2019
OI Chen, Wei Liang/0000 0002 0995 2986; WU, KUAN WEN/0000 0001 8170 9879
FU Chung Shan Medical University Hospital [CSH 2021 C 017, CSH 2020 C 009];
   Taiwan National Science and Technology Council [111 2320 B 040 017 MY3,
   111 2314 B 040 029 MY3, 112 2320 B 040 003 MY3]
FX This work was supported by grants from the Chung Shan Medical University
   Hospital (CSH 2021 C 017 for S. C.L. and CSH 2020 C 009 for C. N.H.) and
   from the Taiwan National Science and Technology Council
   (111 2320 B 040 017 MY3 for C. L.L., 111 2314 B 040 029 MY3 for C. N.H.,
   and 112 2320 B 040 003 MY3 for S. H.T.).
CR Abe I, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000018067
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Alcendor RR, 2007, CIRC RES, V100, P1512, DOI 10.1161/01.RES.0000267723.65696.4a
   Ardestani A, 2016, DIABETOLOGIA, V59, P1843, DOI 10.1007/s00125 016 3892 9
   Berbudi A, 2020, CURR DIABETES REV, V16, P442, DOI 10.2174/1573399815666191024085838
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Cerf ME, 2020, METABOLITES, V10, DOI 10.3390/metabo10110452
   Cohrs CM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.033
   Cui JJ, 2019, MOL CANCER RES, V17, P1316, DOI 10.1158/1541 7786.MCR 18 0910
   Ebrahim N, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.1091757
   Eguchi N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041509
   Graves DT, 2020, PERIODONTOL 2000, V82, P214, DOI 10.1111/prd.12318
   Habibi P, 2022, HORM MOL BIOL CLIN I, V43, P345, DOI 10.1515/hmbci 2021 0069
   Henderson GC, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082590
   Kondegowda NG, 2015, CELL METAB, V22, P77, DOI 10.1016/j.cmet.2015.05.021
   Kornelius E, 2019, J CELL MOL MED, V23, P619, DOI 10.1111/jcmm.13967
   Malle EK, 2015, J EXP MED, V212, P1239, DOI 10.1084/jem.20150218
   Napoli N, 2018, DIABETES METAB RES, V34, DOI 10.1002/dmrr.2991
   Orhan C, 2022, J FOOD BIOCHEM, V46, DOI 10.1111/jfbc.14159
   Pacheco Soto BT, 2021, J DRUG ASSESS, V10, P97, DOI 10.1080/21556660.2021.1989194
   Romero Díaz C, 2021, DIABETES THER, V12, P71, DOI 10.1007/s13300 020 00964 1
   Scuto M., FREE RADIC BIOL MED
   Shang HY, 2022, J PHYSIOL BIOCHEM, V78, P709, DOI 10.1007/s13105 022 00904 6
   Takata T, 2022, NUTRIENTS, V14, DOI 10.3390/nu14020332
   Wang LT, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065814
   Weir GC, 2020, DIABETES, V69, P273, DOI 10.2337/db19 0138
   Yamaguchi Y, 2016, J TOXICOL SCI, V41, P105, DOI 10.2131/jts.41.105
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   You SF, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.976465
   Yuan YT, 2021, LIFE SCI, V274, DOI 10.1016/j.lfs.2021.119312
NR 30
TC 8
Z9 11
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2023
VL 24
IS 12
AR 10289
DI 10.3390/ijms241210289
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA K7OS2
UT WOS:001018301700001
PM 37373436
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Gligorov, J
   Lotz, JP
AF Gligorov, Joseph
   Lotz, Jean Pierre
TI Optimal treatment strategies in postmenopausal women with
   hormone receptor positive and HER2 negative metastatic breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Metastatic breast cancer; Strategies; Endocrine therapy; mTOR;
   Chemotherapy; Anthracyclines; Cardioprotectant; Taxanes; Antiangiogenic;
   Bisphosphonates
ID NONSTEROIDAL AROMATASE INHIBITORS; ZOLEDRONIC ACID; PHASE III;
   MTOR INHIBITOR; BONE METASTASES; LIPOSOMAL ANTHRACYCLINES; SKELETAL
   COMPLICATIONS; THERAPEUTIC STRATEGIES; MEGESTROL ACETATE; ENDOCRINE
   THERAPY
AB Metastatic breast cancer (MBC) is unfortunately still considered incurable; treatment aims to prolong progression free and overall survival, relieve disease symptoms, and maintain quality of life. Treatment can include endocrine therapy, radiotherapy, chemotherapy, bisphosphonates, and/or targeted therapy; which is used depends on the characteristics of the disease [e.g., hormone receptor status, disease site(s), and response to previous treatment] and the patient (age, comorbidity, and personal preferences). For most patients with hormone receptor positive tumors. the first choice of treatment is further endocrine therapy, but endocrine resistance is a common problem in advanced disease. Several novel anticancer agents have been developed with the aim of overcoming endocrine resistance, many of which target intracellular signaling pathways implicated in disease progression or resistance. Among these, inhibitors of growth factor receptor tyrosine kinases and of mammalian target of rapamycin have shown the most promise in clinical trials. Chemotherapy is the cornerstone of MBC treatment in most women. Important considerations when choosing chemotherapy include the choice of agents, and whether to use single agent or combination therapy. Anthracyclines are one of the most active cytotoxic agents currently used for the treatment of breast cancer, and for many women, further anthracycline therapy at progression or relapse would be the preferred option. However, lifetime exposure to anthracyclines is limited by cumulative cardiotoxicity, which often prevents rechallenge in later lines of therapy.
C1 [Gligorov, Joseph; Lotz, Jean Pierre] Univ Paris 06, APHP Tenon, Dept Med Oncol, F 75970 Paris 20, France.
C3 Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Tenon   APHP
RP Gligorov, J (通讯作者)，Univ Paris 06, APHP Tenon, Dept Med Oncol, 4 Rue Chine, F 75970 Paris 20, France.
EM joseph.gligorov@tnn.aphp.fr
RI ; Gligorov, Joseph/NUP 2902 2025
OI Gligorov, Joseph/0000 0002 9900 6386; 
CR Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140 6736(05)66544 0
   [Anonymous], P AM SOC CLIN ONCOL
   [Anonymous], 2005, COCHRANE DATABASE SY
   Awada A, 2008, EUR J CANCER, V44, P84, DOI 10.1016/j.ejca.2007.10.003
   Bartsch R, 2009, BREAST CANCER RES TR, V115, P373, DOI 10.1007/s10549 008 0132 0
   Bertelli G, 2005, ONCOLOGY BASEL, V69, P471, DOI 10.1159/000090985
   Beslija S, 2007, ANN ONCOL, V18, P215, DOI 10.1093/annonc/mdl155
   Body JJ, 2006, CLIN CANCER RES, V12, p6258S, DOI 10.1158/1078 0432.CCR 06 0840
   Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097 0142(20011101)92:9<2247::AID CNCR1570>3.0.CO;2 Y
   Boulay A, 2005, CLIN CANCER RES, V11, P5319, DOI 10.1158/1078 0432.CCR 04 2402
   Buzdar AU, 1998, CANCER AM CANCER SOC, V83, P1142, DOI 10.1002/(SICI)1097 0142(19980915)83:6<1142::AID CNCR13>3.3.CO;2 7
   Cardoso F, 2007, BREAST, V16, P9, DOI 10.1016/j.breast.2006.11.002
   Carlini P, 2007, CANCER INVEST, V25, P102, DOI 10.1080/07357900701224789
   Carrick S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003372.pub2
   Chia S, 2008, BREAST, V17, pS16, DOI 10.1016/j.breast.2007.12.004
   Chin YS, 2007, BREAST, V16, P436, DOI 10.1016/j.breast.2007.02.002
   Chu I, 2005, CANCER RES, V65, P18
   Chung CT, 2003, ONCOLOGIST, V8, P514, DOI 10.1634/theoncologist.8 6 514
   Clark AS, 2002, MOL CANCER THER, V1, P707
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman R, 2008, CANCER TREAT REV, V34, P629, DOI 10.1016/j.ctrv.2008.05.001
   Conte P, 2004, ANN ONCOL, V15, P124
   Cvetkokic RS, 2005, DRUGS, V65, P1005, DOI 10.2165/00003495 200565070 00008
   De Placido S, 1998, BREAST CANCER RES TR, V52, P55, DOI 10.1023/A:1006159001039
   DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078 0432.CCR 04 0035
   Demonty G, 2007, EUR J CANCER, V43, P497, DOI 10.1016/j.ejca.2006.10.020
   Di Cosimo S, 2005, J CLIN ONCOL, V23, p219S
   Diel IJ, 2007, CRIT REV ONCOL HEMAT, V64, P198, DOI 10.1016/j.critrevonc.2007.07.005
   Dombernowsky P, 1998, J CLIN ONCOL, V16, P453, DOI 10.1200/JCO.1998.16.2.453
   Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808
   Ershler WB, 2006, ONCOLOGIST, V11, P325, DOI 10.1634/theoncologist.11 4 325
   Fossati R, 1998, J CLIN ONCOL, V16, P3439, DOI 10.1200/JCO.1998.16.10.3439
   Gennari A, 2005, CANCER, V104, P1742, DOI 10.1002/cncr.21359
   Ghersi D, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003366.pub2
   Gligorov J, 2007, ONCOLOGIE, V9, P591, DOI 10.1007/s10269 007 0752 8
   Gligorov J, 2007, CRIT REV ONCOL HEMAT, V64, P115, DOI 10.1016/j.critrevonc.2007.06.010
   Gnant M, 2008, LANCET ONCOL, V9, P840, DOI 10.1016/S1470 2045(08)70204 3
   Gordon David H, 2005, Clin Breast Cancer, V6, P125, DOI 10.3816/CBC.2005.n.014
   Hasinoff BB, 1998, SEMIN ONCOL, V25, P3
   HEI YJ, 2005, BREAST CANC RES TREA, V88
   Hoff AO, 2006, J CLIN ONCOL, V24, p475S
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   Hynes NE, 2006, J MAMMARY GLAND BIOL, V11, P53, DOI 10.1007/s10911 006 9012 6
   Jensen BV, 2006, SEMIN ONCOL, V33, pS15, DOI 10.1053/j.seminoncol.2006.04.022
   Johnston SRD, 2005, CLIN CANCER RES, V11, p889S
   Kataja VV, 2005, ANN ONCOL, V16, P10, DOI 10.1093/annonc/mdi816
   Kaufman B, 2006, ANN ONCOL, V17
   Kaufmann M, 2000, J CLIN ONCOL, V18, P1399, DOI 10.1200/JCO.2000.18.7.1399
   Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002 220620
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   KOLARIC K, 1995, ONCOLOGY, V52, P251
   Lane HA, 2006, SEMIN ONCOL, V33, pS18, DOI 10.1053/j.seminoncol.2006.03.024
   Lane Heidi A., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P184
   Lonning PE, 2000, J CLIN ONCOL, V18, P2234, DOI 10.1200/JCO.2000.18.11.2234
   Mano M, 2006, CANCER TREAT REV, V32, P106, DOI 10.1016/j.ctrv.2005.12.008
   Miles BJ, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.5077
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098
   Mouridsen H, 2001, J CLIN ONCOL, V19, P2596, DOI 10.1200/JCO.2001.19.10.2596
   Myers C, 1998, SEMIN ONCOL, V25, P10
   Ng R, 2006, SEMIN ONCOL, V33, P2, DOI 10.1053/j.seminoncol.2005.11.001
   Nicholson RI, 2001, ENDOCR RELAT CANCER, V8, P175, DOI 10.1677/erc.0.0080175
   Normanno N, 2005, ENDOCR RELAT CANCER, V12, P721, DOI 10.1677/erc.1.00857
   Paridaens R, 2004, J CLIN ONCOL, V22, p6S
   Pavlakis N, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub2
   Pérez Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126
   Rivera E, 2003, ONCOLOGIST, V8, P3
   Robert NJ, 2004, SEMIN ONCOL, V31, P106, DOI 10.1053/j.seminoncol.2004.09.018
   Robertson JFR, 2003, CANCER, V98, P229, DOI 10.1002/cncr.11468
   Ross, 1998, Oncologist, V3, P237
   Safra T, 2003, ONCOLOGIST, V8, P17
   Safra T, 2008, ISR MED ASSOC J, V10, P339
   SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040 8428(94)00144 I
   Santini D, 2006, EXPERT OPIN BIOL TH, V6, P1333, DOI 10.1517/14712598.6.12.1333
   Seymour L, 1999, Cancer Prev Control, V3, P145
   Sherer JT, 2007, PHARMACOTHERAPY, V27, P207, DOI 10.1592/phco.27.2.207
   Sini P, 2005, CLIN CANCER RES, V11, P4521, DOI 10.1158/1078 0432.CCR 04 1954
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Sledge G, 2007, J CLIN ONCOL, V25
   Smith IE, 2006, SEMIN ONCOL, V33, pS19, DOI 10.1053/j.seminoncol.2006.03.020
   Sparano JA, 1999, J CLIN ONCOL, V17, P880, DOI 10.1200/JCO.1999.17.3.880
   SPEYER JL, 1988, NEW ENGL J MED, V319, P745, DOI 10.1056/NEJM198809223191203
   SPEYER JL, 1992, J CLIN ONCOL, V10, P117, DOI 10.1200/JCO.1992.10.1.117
   Steele N, 2006, BREAST, V15, P430, DOI 10.1016/j.breast.2005.08.032
   Swain SM, 1997, J CLIN ONCOL, V15, P1333, DOI 10.1200/JCO.1997.15.4.1333
   Swain SM, 1997, J CLIN ONCOL, V15, P1318, DOI 10.1200/JCO.1997.15.4.1318
   Tabernero J, 2005, J CLIN ONCOL, V23, p193S
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Venturini M, 1996, J CLIN ONCOL, V14, P3112, DOI 10.1200/JCO.1996.14.12.3112
   VILLANI F, 1990, TOXICOL APPL PHARM, V102, P292, DOI 10.1016/0041 008X(90)90028 S
   Wakeling AE, 2005, ENDOCR RELAT CANCER, V12, pS183, DOI 10.1677/erc.1.01014
   Wardley A, 2005, BRIT J CANCER, V92, P1869, DOI 10.1038/sj.bjc.6602551
   Wong R, 2002, Cochrane Database Syst Rev, pCD002068
   Yu K, 2001, ENDOCR RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249
NR 94
TC 17
Z9 20
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167 6806
EI 1573 7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PY 2008
VL 112
SU 1
SI SI
BP 53
EP 66
DI 10.1007/s10549 008 0232 x
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 404QP
UT WOS:000263168400007
PM 19101794
DA 2025 08 17
ER

PT J
AU Hsiao, HB
   Wu, JB
   Lin, WC
AF Hsiao, Hung Bo
   Wu, Jin Bin
   Lin, Wen Chuan
TI ( ) Epicatechin 3 O β D allopyranoside prevent ovariectomy induced bone
   loss in mice by suppressing RANKL induced NF κB and NFATc 1 signaling
   pathways
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE ECAP; Davallia formosana Hayata; Osteoclastogenesis; Osteoporosis;
   Osteoclast; RANKL
ID OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; LIGAND RANKL;
   EXPRESSION; RESORPTION; INFLAMMATION; INDUCTION; ROLES; GENE
AB Background: Davallia formosana Hayata is a herb that has been used in Chinese medicine to treat bone diseases, including arthritis, bone fractures and osteoporosis. The rhizome of D. formosana H. has been found to be rich in ( ) Epicatechin 3 O beta D allopyranoside (ECAP), which is considered to be the active component of the plant in terms of its antiosteoporotic effect. This study investigated the molecular mechanism of the antiosteoporotic property of ECAP isolated from the roots of D. formosana H. using both in vitro and in vivo models.
   Methods: We studied the effects of ECAP on the signaling pathways of the receptor activator of nuclear factor kappa B ligand (RANKL) stimulated osteoclastogenesis and ovariectomy induced osteoporosis. In the in vitro study, the inhibitory action of ECAP on RANKL induced osteoclastogenesis and the expression of osteoclast related marker genes were investigated, and in the in vivo study, the effects of ECAP on bone were evaluated using ovariectomized (OVX) mice orally administered ECAP for 4 weeks.
   Results: We demonstrated that ECAP dose dependently inhibited RANKL  and nuclear factor of activated T cells, and cytoplasmic 1 (NFATc 1) induced osteoclastogenesis by RAW 264.7 cells, and reduced the extent of bone resorption. Furthermore, mu CT images and TRAP staining showed that oral administration of ECAP to OVX mice prevented bone loss. ECAP administration also exerted recovery effects on serum C terminal telopeptide of type I collagen and osteocalcin levels in OVX mice. In addition, we also found that MMP 9 expression was decreased in vivo and in vitro.
   Conclusions: Overall, our findings suggested that ECAP suppresses RANKL induced osteoclastogenesis through NF kappa B and NFATc 1 signaling pathways, and has the potential for use in osteoporosis treatment.
C1 [Hsiao, Hung Bo] Natl Chung Hsing Univ, Dept Life Sci, Taichung, Taiwan.
   [Wu, Jin Bin; Lin, Wen Chuan] China Med Univ, Sch Pharm, 91 Hsueh Shih Rd, Taichung 404, Taiwan.
C3 National Chung Hsing University; China Medical University Taiwan
RP Lin, WC (通讯作者)，China Med Univ, Sch Pharm, 91 Hsueh Shih Rd, Taichung 404, Taiwan.
EM wclin@mail.cmu.edu.tw
FU Chinese Medicine Research Center, China Medical University (the Ministry
   of Education, the Aim for the Top University Plan)
FX Chinese Medicine Research Center, China Medical University (the Ministry
   of Education, the Aim for the Top University Plan).
CR Ang ESM, 2007, J CELL PHYSIOL, V212, P787, DOI 10.1002/jcp.21076
   Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bruzzaniti A, 2006, REV ENDOCR METAB DIS, V7, P123, DOI 10.1007/s11154 006 9009 x
   Delaissé JM, 2000, CLIN CHIM ACTA, V291, P223, DOI 10.1016/S0009 8981(99)00230 2
   Hsiao HB, 2013, OSTEOPOROSIS INT, V24, P1663, DOI 10.1007/s00198 012 2199 z
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Kim HH, 2003, EXP CELL RES, V289, P368, DOI 10.1016/S0014 4827(03)00288 X
   Ko YJ, 2012, J ETHNOPHARMACOL, V139, P558, DOI 10.1016/j.jep.2011.11.050
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lin Tzu Hung, 2013, EVID BASED COMPL ALT, V2013
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Naylor K, 2012, NAT REV RHEUMATOL, V8, P379, DOI 10.1038/nrrheum.2012.86
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Ruocco MG, 2007, ADV EXP MED BIOL, V602, P125
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009
   Walsh NC, 2003, GENE, V307, P111, DOI 10.1016/S0378 1119(03)00449 9
NR 28
TC 14
Z9 14
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD MAY 3
PY 2017
VL 17
AR 245
DI 10.1186/s12906 017 1737 9
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA ET6VT
UT WOS:000400431700001
PM 28468652
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kuznik, A
   Pazdzierniok Holewa, A
   Jewula, P
   Kuznik, N
AF Kuznik, Anna
   Pazdzierniok Holewa, Agnieszka
   Jewula, Pawel
   Kuznik, Nikodem
TI Bisphosphonates much more than only drugs for bone diseases
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Bisphosphonate; Bone disease; Osteoporosis; Paget's disease; Bone
   imaging; Bone metastasis
ID ZOLEDRONIC ACID; PAGETS DISEASE; BREAST CANCER; AMERICAN SOCIETY;
   IN VITRO; INORGANIC PYROPHOSPHATE; CLINICAL FEATURES; MODIFYING AGENTS;
   DOUBLE BLIND; LUNG CANCER
AB alpha,alpha Bisphosphonates (BPs) are well established in the treatment of bone diseases such as osteoporosis and Paget's disease. Their successful application originates from their high affinity to hydroxyapatite. While the initially appreciated features of BPs are already beneficial to many patients, recent developments have further expanded their pleiotropic applications. This review describes the background of the interactions of BPs with bone cells that form the basis of the classical treatment.
   A better understanding of the mechanism behind their interactions allows for the parallel application of BPs against bone cancer and metastases followed by palliative pain relief. Targeted therapy with bone seeking BPs coupled with a diagnostic agent in one particle resulted in theranostics which is also described here. For example, in such a system, BP moieties are bound to contrast agents used in magnetic resonance imaging or radionuclides used in positron emission tomography. In addition, another example of the pleiotropic function of BPs which involves targeting the imaging agents to bone tissues accompanied by pain reduction is presented in this work.
C1 [Kuznik, Anna; Pazdzierniok Holewa, Agnieszka; Kuznik, Nikodem] Silesian Tech Univ, Dept Organ & Bioorgan Chem & Biotechnol, B Krzywoustego 4, PL 44100 Gliwice, Poland.
   [Kuznik, Anna; Pazdzierniok Holewa, Agnieszka] Silesian Tech Univ, Biotechnol Ctr, B Krzywoustego 4, PL 44100 Gliwice, Poland.
   [Jewula, Pawel] Brno Univ Technol, Cent European Inst Technol, Purkynova 656 123, Brno 61200, Czech Republic.
C3 Silesian University of Technology; Silesian University of Technology;
   Brno University of Technology
RP Kuznik, A (通讯作者)，Silesian Tech Univ, Dept Organ & Bioorgan Chem & Biotechnol, B Krzywoustego 4, PL 44100 Gliwice, Poland.
EM Anna.Kuznik@polsl.pl
RI Kuźnik, Nikodem/B 2492 2013; Kuznik, Nikodem/B 2492 2013;
   Pazdzierniok Holewa, Agnieszka/HJZ 4499 2023; Jewula, Pawel/J 5254 2018
OI Kuznik, Nikodem/0000 0001 7760 7511; Pazdzierniok Holewa,
   Agnieszka/0000 0003 2643 6366; Kuznik, Anna/0000 0002 0801 7435; 
FU Ministry of Education, Youth and Sports of the Czech Republic under the
   project CEITEC 2020 [LQ1601]; Silesian University of Technology
   [04/020/RGJ18/0058]
FX This work was financially supported by the Ministry of Education, Youth
   and Sports of the Czech Republic under the project CEITEC 2020
   (LQ1601).NK gratefully acknowledges Silesian University of Technology
   for financial support (grant no. 04/020/RGJ18/0058).
CR Aapro M, 2010, ONCOLOGIST, V15, P1147, DOI 10.1634/theoncologist.2007 0245
   Abdou W.M., 2009, ARKIVOC, V143 182, pix
   Abrahamsen B, 2010, CALCIFIED TISSUE INT, V86, P421, DOI 10.1007/s00223 010 9364 1
   ADAZAMLI IK, 1989, J MED CHEM, V32, P139, DOI 10.1021/jm00121a026
   Aderibigbe B, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9010002
   ADZAMLI IK, 1993, MAGN RESON MED, V29, P505, DOI 10.1002/mrm.1910290412
   Agyin JK, 2013, BIOORG MED CHEM LETT, V23, P6455, DOI 10.1016/j.bmcl.2013.09.043
   Anderson K, 2018, J CLIN ONCOL, V36, P812, DOI 10.1200/JCO.2017.76.6402
   Armamento Villareal R, 2006, NEW ENGL J MED, V355, P2048, DOI 10.1056/NEJMc062268
   Arvelo F, 2016, ECANCERMEDICALSCIENC, V10, DOI 10.3332/ecancer.2016.701
   Aspenberg P, 2010, ACTA ORTHOP, V81, P460, DOI 10.3109/17453674.2010.492766
   Bailly T, 2003, TETRAHEDRON LETT, V44, P189, DOI 10.1016/S0040 4039(02)02442 5
   Benassi MS, 2007, CANCER LETT, V250, P194, DOI 10.1016/j.canlet.2006.10.004
   Beuzeboc P, 2014, J CLIN MED, V3, P521, DOI 10.3390/jcm3020521
   Bhushan K., 2009, P INT SOC MAG RESON, V17, P222
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Blomen Leo J. M. J., 1995, P111
   Bock O., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P144
   Bonnick SL, 2011, J CLIN DENSITOM, V14, P377, DOI 10.1016/j.jocd.2011.07.006
   Bono CM, 2003, EUR SPINE J, V12, pS90, DOI 10.1007/s00586 003 0603 2
   Bosco R, 2015, APPL SURF SCI, V328, P516, DOI 10.1016/j.apsusc.2014.12.072
   Cermak K, 2010, CLIN ORTHOP RELAT R, V468, P1991, DOI 10.1007/s11999 009 1192 0
   Chakraborty S, 2018, CHEM BIOL DRUG DES, V92, P1618, DOI 10.1111/cbdd.13327
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Cheung LC, 2018, LEUKEMIA, V32, P2326, DOI 10.1038/s41375 018 0144 7
   Chuah C, 2005, LEUKEMIA, V19, P1896, DOI 10.1038/sj.leu.2403949
   Clezardin Philippe, 2013, Bonekey Rep, V2, P267, DOI 10.1038/bonekey.2013.1
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Cranney A, 2002, ENDOCR REV, V23, P517, DOI 10.1210/er.2001 3002
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   Cui X, 2015, CHEM COMMUN, V51, P9332, DOI 10.1039/c5cc02259b
   Cundy T, 2012, CLIN BIOCHEM, V45, P43, DOI 10.1016/j.clinbiochem.2011.09.026
   Czyzykowski R, 2017, ONCOL CLIN PRACT, V13, P268, DOI 10.5603/OCP.2017.0040
   Dai XY, 2019, CANCER LETT, V442, P202, DOI 10.1016/j.canlet.2018.10.022
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Davie M, 1999, BONE, V24, p11S, DOI 10.1016/S8756 3282(99)00027 7
   DELMAS PD, 1982, J CLIN ENDOCR METAB, V54, P837, DOI 10.1210/jcem 54 4 837
   Dhesy Thind S, 2017, J CLIN ONCOL, V35, P2062, DOI 10.1200/JCO.2016.70.7257
   Diel IJ, 2010, BREAST CARE, V5, P306, DOI 10.1159/000322043
   Ding N, 2018, J CELL PHYSIOL, V233, P7415, DOI 10.1002/jcp.26587
   Dobbs M B, 1999, Iowa Orthop J, V19, P43
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Ermer MA, 2018, J ORAL MAXIL SURG, V76, P553, DOI 10.1016/j.joms.2017.08.019
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   FLEISCH H, 1962, AM J PHYSIOL, V203, P671, DOI 10.1152/ajplegacy.1962.203.4.671
   Fleisch H., 2000, LAB PATIENT
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   FLEISH H, 1961, AM J PHYSIOL, V200, P1296, DOI 10.1152/ajplegacy.1961.200.6.1296
   Frediani B, 2009, CLIN DRUG INVEST, V29, P359, DOI 10.2165/00044011 200929060 00001
   FRIJLINK WB, 1979, LANCET, V1, P799
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Gdowski AS, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046 017 0578 1
   Ghoneima AA, 2010, ORTHOD CRANIOFAC RES, V13, P1, DOI 10.1111/j.1601 6343.2009.01472.x
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   Glorieux FH, 2007, PEDIATRICS, V119, pS163, DOI 10.1542/peds.2006 2023I
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Golob AL, 2015, MED CLIN N AM, V99, P587, DOI 10.1016/j.mcna.2015.01.010
   Goodchild Jason H, 2018, Gen Dent, V66, P23
   Hao DP, 2012, J MAGN RESON IMAGING, V36, P1060, DOI 10.1002/jmri.23725
   HARINCK HIJ, 1987, BMJ BRIT MED J, V295, P1301, DOI 10.1136/bmj.295.6609.1301
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Hernandez RK, 2018, BMC CANCER, V18, DOI 10.1186/s12885 017 3922 0
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Hosking D, 2007, J BONE MINER RES, V22, P142, DOI 10.1359/JBMR.061001
   Huang M, 2014, TRENDS PHARMACOL SCI, V35, P41, DOI 10.1016/j.tips.2013.11.004
   Iafisco M, 2008, LANGMUIR, V24, P4924, DOI 10.1021/la703381h
   Imerci A, 2015, INT J SURG CASE REP, V9, P127, DOI 10.1016/j.ijscr.2015.02.043
   Kanis JA., 1991, PATHOPHYSIOLOGY TREA
   Kenny GD, 2016, J FLUORINE CHEM, V184, P58, DOI 10.1016/j.jfluchem.2016.02.008
   KHAIRI MRA, 1974, JAMA J AM MED ASSOC, V230, P562, DOI 10.1001/jama.230.4.562
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kubícek V, 2005, J AM CHEM SOC, V127, P16477, DOI 10.1021/ja054905u
   Kubícek V, 2007, EUR J INORG CHEM, P333, DOI 10.1002/ejic.200600615
   Kubícek V, 2010, CONTRAST MEDIA MOL I, V5, P294, DOI 10.1002/cmmi.386
   Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood 2003 01 0305
   Lalatonne Y, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/747852
   Laurent S, 2016, MRI CONTRAST AGENTS
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Li QL, 2016, J INVEST DERMATOL, V136, P275, DOI 10.1038/JID.2015.377
   Loeb JA, 2006, J NEUROL SCI, V243, P77, DOI 10.1016/j.jns.2005.11.033
   Lopez Olivo MA, 2012, SUPPORT CARE CANCER, V20, P2985, DOI 10.1007/s00520 012 1563 z
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Machkour M'Rabet Salima, 2017, CORAL REEFS, P1
   Malwal SR, 2018, J AM CHEM SOC, V140, P7568, DOI 10.1021/jacs.8b02363
   Maricic M, 2010, CLIN RHEUMATOL, V29, P1079, DOI 10.1007/s10067 010 1486 3
   Marmurek J., 2011, P INT SOC MAG RESON, V19, P457
   Maruotti N, 2012, EUR J CLIN PHARMACOL, V68, P1013, DOI 10.1007/s00228 012 1216 7
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Menschutkin N., 1865, ANN CHEM PHARM, V133, P317, DOI [10.1002/jlac.18651330307, DOI 10.1002/JLAC.18651330307]
   Mignot MA, 2017, OSTEOPOROSIS INT, V28, P3431, DOI 10.1007/s00198 017 4215 9
   Miller PD, 1999, AM J MED, V106, P513, DOI 10.1016/S0002 9343(99)00062 5
   Mishiro K, 2019, COORDIN CHEM REV, V383, P104, DOI 10.1016/j.ccr.2018.12.005
   Modi ND, 2012, LEUKEMIA, V26, P589, DOI 10.1038/leu.2011.282
   Morrow JR, 2017, INORG CHEM, V56, P6029, DOI 10.1021/acs.inorgchem.7b01277
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Muschitz C, 2017, WIEN MED WOCHENSCHR, V167, P18, DOI 10.1007/s10354 016 0502 x
   Nadar RA, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601119
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   Ouyang ZX, 2018, CURR DRUG TARGETS, V19, P409, DOI 10.2174/1573399811666150615145409
   Papapoulos SE, 2008, BEST PRACT RES CL EN, V22, P831, DOI 10.1016/j.beem.2008.07.001
   Paterson A H G, 2002, Clin Breast Cancer, V3, P206, DOI 10.3816/CBC.2002.n.025
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Petroianu GA, 2011, PHARMAZIE, V66, P804, DOI 10.1691/ph.2011.1053
   Plotkin LI, 2011, BONE, V49, P122, DOI 10.1016/j.bone.2010.08.011
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Porta Sales J, 2017, PALLIATIVE MED, V31, P5, DOI 10.1177/0269216316639793
   Powles TJ, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.73.6157
   Ramjan KA, 2009, NAT CLIN PRACT ENDOC, V5, P167, DOI 10.1038/ncpendmet1067
   RAYMOND KN, 1984, TOP CURR CHEM, V123, P49
   Reid IR, 2010, J CLIN ENDOCR METAB, V95, P4380, DOI 10.1210/jc.2010 0597
   Reid IR, 2011, BONE, V49, P89, DOI 10.1016/j.bone.2010.09.002
   Reid IR, 1996, AM J MED, V101, P341, DOI 10.1016/S0002 9343(96)00227 6
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   Reinholz MM, 2010, BONE, V47, P12, DOI 10.1016/j.bone.2010.03.006
   Renier JC, 1997, REV RHUM, V64, P35
   Rennert G, 2017, CLIN CANCER RES, V23, P1684, DOI 10.1158/1078 0432.CCR 16 0547
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   RIGGS BL, 1983, AM J MED, V75, P899, DOI 10.1016/0002 9343(83)90860 4
   Rizzoli R, 2008, BONE, V42, P841, DOI 10.1016/j.bone.2008.01.003
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Rogers MJ, 1996, BIOCHEM BIOPH RES CO, V224, P863, DOI 10.1006/bbrc.1996.1113
   ROGERS MJ, 1992, BIOCHEM BIOPH RES CO, V189, P414, DOI 10.1016/0006 291X(92)91574 A
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   ROUX C, 1995, ARTHRITIS RHEUM, V38, P851, DOI 10.1002/art.1780380620
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   RUSSELL RGG, 1971, J CLIN INVEST, V50, P961, DOI 10.1172/JCI106589
   RUSSELL RGG, 1965, LANCET, V2, P461
   Sandiford L, 2013, ACS NANO, V7, P500, DOI 10.1021/nn3046055
   Santangelo A, 2006, ARCH GERONTOL GERIAT, V43, P187, DOI 10.1016/j.archger.2005.10.006
   Santini D, 2006, NAT CLIN PRACT ONCOL, V3, P325, DOI 10.1038/ncponc0520
   Schem C, 2017, J BONE MINER RES, V32, P536, DOI 10.1002/jbmr.3012
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Seitz S, 2009, J BONE MINER RES, V24, P62, DOI 10.1359/JBMR.080907
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   Siris E, 1996, J CLIN ENDOCR METAB, V81, P961, DOI 10.1210/jc.81.3.961
   Soriano R, 2014, BEST PRACT RES CL EN, V28, P885, DOI 10.1016/j.beem.2014.09.004
   Sousa S, 2018, CALCIFIED TISSUE INT, V102, P227, DOI 10.1007/s00223 017 0353 5
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Tanvetyanon T, 2006, ANN ONCOL, V17, P897, DOI 10.1093/annonc/mdj105
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Tu Kristie N, 2018, P T, V43, P92
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Vallet S, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040202
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   Visekruna M, 2008, J CLIN ENDOCR METAB, V93, P2948, DOI 10.1210/jc.2007 2803
   Vitha T, 2009, DALTON T, P3204, DOI 10.1039/b820705d
   Waalen J., 2010, J EXP PHARM, V2, P122
   Wang YXJ, 2011, QUANT IMAG MED SURG, V1, P35, DOI 10.3978/j.issn.2223 4292.2011.08.03
   Waning DL, 2014, CLIN CANCER RES, V20, P3071, DOI 10.1158/1078 0432.CCR 13 1590
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Weinreich J, 2012, ANTICANCER RES, V32, P4299
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Weishaupt D., 2006, How does MRI work? : an introduction to the physics and function of magnetic resonance imaging, V2nd, DOI DOI 10.1007/978 3 540 37845 7_5
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Wu M, 2018, CONTRAST MEDIA MOL I, DOI 10.1155/2018/1382183
   Wysowski DK, 2009, NEW ENGL J MED, V360, P89, DOI 10.1056/NEJMc0808738
   Wysowski DK, 2005, ARCH INTERN MED, V165, P346, DOI 10.1001/archinte.165.3.346 b
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 303
   Zamagni Elena, 2018, Am Soc Clin Oncol Educ Book, V38, P638, DOI 10.1200/EDBK_205583
   Zameer S, 2018, PHARMACOL REP, V70, P900, DOI 10.1016/j.pharep.2018.03.011
   Zekri J, 2014, J BONE ONCOL, V3, P25, DOI 10.1016/j.jbo.2013.12.001
   Zhou ZC, 2005, CANCER AM CANCER SOC, V104, P1713, DOI 10.1002/cncr.21383
   Zinnen S, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2589
NR 188
TC 77
Z9 82
U1 3
U2 32
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JAN 5
PY 2020
VL 866
AR 172773
DI 10.1016/j.ejphar.2019.172773
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA JV7NN
UT WOS:000502548300004
PM 31705903
DA 2025 08 17
ER

PT J
AU Lou, YN
   Zou, LF
   Shen, ZY
   Zheng, JW
   Lin, YQ
   Zhang, Z
   Chen, XK
   Pan, J
   Zhang, XT
AF Lou, Yani
   Zou, Linfang
   Shen, Zhenyu
   Zheng, Jianwei
   Lin, Yuanqu
   Zhang, Zhe
   Chen, Xuankuai
   Pan, Jun
   Zhang, Xutong
TI Protective effect of dexmedetomidine against delayed bone healing caused
   by morphine via PI3K/Akt mediated Nrf2 antioxidant defense system
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE morphine; oxidative stress; dexmedetomidine; calvarial defect;
   PI3K/Akt/Nrf2 pathway
ID OXIDATIVE STRESS; OPIOID USE; FRACTURE; INJURY; DAMAGE; PAIN
AB Background As a class of analgesics, opioids are frequently used to treat both acute and chronic moderate to severe pain. Patients frequently receive opioid painkillers after orthopedic accidents or surgeries. Evidence suggests that opioid drug users have a 55.1% higher risk of fracture and poor bone repair than non users of opioid drugs. The key pathogenic alterations in the incidence and progression of poor bone repair are over apoptosis and aging of osteoblasts due to the stress caused by oxidation. Dexmedetomidine (Dex) has been proven to protect against a variety of degenerative illnesses by reducing oxidative stress. However, nothing is known about how it affects bone repair.Methods PI3K/Akt/Nrf2 pathway was detected by immunofluorescence and Western blot. SOD, CAT, JC 1, dihydroethidium and mitosox were used in the Oxidative Stress. Micro CT, H&E and Masson's staining, immunohistochemically were performed to evaluate the therapeutic effects of DEX on calvarial defects in the morphine induced rat model.Results We found that morphine induced an imbalance in the metabolism and catabolism of primary rat Osteoblasts. However, these conditions could be inhibited by DEX treatment. In the meantime, DEX induced the expression of Nrf2 regulated antioxidant enzymes such as NQO1, HO 1, GCLm, GCLc, and TrxR1. DEX mediated Nrf2 activation is linked to the PI3K/Akt signaling system. Furthermore, it has been established that intravenous DEX enhanced the growth of bone healing in a model of a surgically produced rat cranial lesion.Conclusion This is the first description of the unique DEX mechanism acting as a Nrf2 activator against morphine mediated oxidative harm, raising the possibility that the substance may be used to prevent bone defects.
C1 [Lou, Yani; Zhang, Xutong] Second Affiliated Hosp, Dept Anesthesiol & Perioperat Med, Wenzhou, Peoples R China.
   [Lou, Yani; Zou, Linfang; Shen, Zhenyu; Zheng, Jianwei; Lin, Yuanqu; Zhang, Zhe; Chen, Xuankuai; Pan, Jun; Zhang, Xutong] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
   [Lou, Yani; Zhang, Xutong] Wenzhou Med Univ, Key Lab Anesthesiol Zhejiang Prov, Wenzhou, Peoples R China.
   [Zou, Linfang; Shen, Zhenyu; Zheng, Jianwei; Lin, Yuanqu; Zhang, Zhe; Chen, Xuankuai; Pan, Jun] Second Affiliated Hosp, Dept Orthopaed, Wenzhou, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Zhang, XT (通讯作者)，Second Affiliated Hosp, Dept Anesthesiol & Perioperat Med, Wenzhou, Peoples R China.; Pan, J; Zhang, XT (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.; Zhang, XT (通讯作者)，Wenzhou Med Univ, Key Lab Anesthesiol Zhejiang Prov, Wenzhou, Peoples R China.; Pan, J (通讯作者)，Second Affiliated Hosp, Dept Orthopaed, Wenzhou, Peoples R China.
EM zhangxutong@wmu.edu.cn; panjun@wmu.edu.cn
FU Department of science and Technology of Zhejiang Province [LGD21H310004]
FX We thank XZ (Department of Anesthesiology and Perioperative Medicine,
   The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou
   Medical University) and JP (Department of Orthopaedics, The Second
   Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical
   University) for technical assistance in this study.r The author(s)
   declare that financial support was received for the research,
   authorship, and/or publication of this article. This work was supported
   by Department of science and Technology of Zhejiang Province
   (LGD21H310004).
CR Benggon M, 2012, ANESTH ANALG, V115, P154, DOI 10.1213/ANE.0b013e31824e2b86
   Best SA, 2018, CELL METAB, V27, P935, DOI 10.1016/j.cmet.2018.02.006
   Burlacu CC, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105452
   Cai Y, 2016, J CELL BIOL, V215, P245, DOI 10.1083/jcb.201605065
   Chen QM, 2022, FREE RADICAL BIO MED, V179, P133, DOI 10.1016/j.freeradbiomed.2021.12.001
   Coluzzi F, 2020, CURR OSTEOPOROS REP, V18, P325, DOI 10.1007/s11914 020 00585 4
   Corder G, 2018, ANNU REV NEUROSCI, V41, P453, DOI 10.1146/annurev neuro 080317 061522
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Gao M, 2022, ONCOGENE, V41, P4018, DOI 10.1038/s41388 022 02403 w
   Gao QZ, 2020, CELL DEATH DIFFER, V27, P1086, DOI 10.1038/s41418 019 0399 1
   Jonason JH, 2014, METHODS MOL BIOL, V1130, P295, DOI 10.1007/978 1 62703 989 5_22
   Keating GM, 2015, DRUGS, V75, P1119, DOI 10.1007/s40265 015 0419 5
   King T, 2007, PAIN, V132, P154, DOI 10.1016/j.pain.2007.06.026
   Kobayashi EH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11624
   Lee S, 2019, KOREAN J ANESTHESIOL, V72, P323, DOI 10.4097/kja.19259
   Li WG, 2008, BIOCHEM PHARMACOL, V76, P1485, DOI 10.1016/j.bcp.2008.07.017
   Liu BB, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109895
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev pharmtox 011112 140320
   Oladeji PO, 2021, INJURY, V52, P2469, DOI 10.1016/j.injury.2021.05.011
   Reymond S, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 08712 0
   Ross D, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101950
   Saunders KW, 2010, J GEN INTERN MED, V25, P310, DOI 10.1007/s11606 009 1218 z
   Shi J, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101954
   Su JD, 2012, FREE RADICAL BIO MED, V52, P126, DOI 10.1016/j.freeradbiomed.2011.10.002
   Sun YB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1416 5
   Sverrisdóttir E, 2015, EUR J PHARM SCI, V74, P45, DOI 10.1016/j.ejps.2015.03.020
   Taghavi SF, 2023, BIOMED PHARMACOTHER, V157, DOI 10.1016/j.biopha.2022.114022
   Tang CL, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118004
   TISEO PJ, 1995, PAIN, V61, P47, DOI 10.1016/0304 3959(94)00148 8
   Wang H, 2022, ACTA PHARM SIN B, V12, P1871, DOI 10.1016/j.apsb.2021.10.015
   Wang X, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107725
   Wang Z, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5454210
   Xu ZR, 2022, REDOX BIOL, V54, DOI 10.1016/j.redox.2022.102351
   Yu C, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6635460
   Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003
   Zhang ZW, 2022, CELLS BASEL, V11, DOI 10.3390/cells11162560
   Zhao XJ, 2018, REDOX BIOL, V18, P124, DOI 10.1016/j.redox.2018.07.002
   Zhuang YW, 2022, CELL, V185, P4361, DOI 10.1016/j.cell.2022.09.041
   Zhuang Y, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/7591840
NR 39
TC 3
Z9 4
U1 1
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAY 28
PY 2024
VL 15
AR 1396713
DI 10.3389/fphar.2024.1396713
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA TR1B2
UT WOS:001242883900001
PM 38863982
OA gold, Green Published
DA 2025 08 17
ER

PT S
AU Wimalawansa, SJ
AF Wimalawansa, Sunil J.
BE Zaidi, M
TI Rationale for using nitric oxide donor therapy for prevention of bone
   loss and treatment of osteoporosis in humans
SO SKELETAL BIOLOGY AND MEDICINE, PT B: DISEASE MECHANISMS AND THERAPEUTIC
   CHALLENGES
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT 2nd Conference on Skeletal Biology and Medicine
CY APR 25 28, 2007
CL New York, NY
SP Mt Sinai Sch Med, New York Acad Sci
DE menopause; cGMP; nitric oxide synthase inhibitors; osteopenia;
   nitroglycerine; novel therapies; RANKL; OPG; SERM; estrogen
ID OSTEOBLAST LIKE CELLS; INFLAMMATION INDUCED OSTEOPOROSIS; INHIBITOR
   L NAME; NITRITE/NITRATE LEVELS; NO PRODUCTION; L ARGININE; MALE RATS;
   IN VITRO; SYNTHASE; OSTEOCLAST
AB Nitric oxide (NO) is a ubiquitous molecule involved in most cellular functions. While osteocytes communicate between bone cells, diffusible small molecules H+ and NO are involved in short term regulation of bone metabolism. Studies conducted over the past two decades have demonstrated the regulatory role of NO in bone metabolism. Circulating NO products are significantly lower in postmenopausal women, and estrogen supplementation restores this. Skeletal beneficial effects of estrogen are abolished with NO synthase enzyme inhibitors, suggesting some estrogenic skeletal effects are mediated through NO/cGMP pathway. Since estrogen/hormone replacement therapy (HRT) has potential adverse effects, supplementing NO directly is sensible. NO is also involved with other cellular functions, such as isoprenylation of the Rho GTPase that stimulates Rho PK (the functioning Rho PK in turn inactivates something that would otherwise turn on the BMP 2/Cbfal Runx 2 cycle), and likely to be the final common pathway of other agents including statins. The first human study using nitroglycerine in the prevention of oophorectomy induced bone loss demonstrated an equivalent efficacy to estrogen in the prevention of bone loss. A randomized NIH funded NOVEL clinical study is currently assessing the effectiveness of topically administered nitroglycerine in the prevention of postmenopausal bone loss. If efficacy of nitroglycerine is confirmed, it may become a highly cost effective and safe alternative therapy to treat osteoporosis. Nitroglycerine has beneficial effects in multiple systems, especially the cardiovascular system. If results of this study confirm our hypothesis, it is plausible that nitroglycerine therapy may supplant estrogen replacement and SERMs in preventing and treating postmenopausal osteoporosis.
C1 Univ Med & Dent New Jersey, Div Endocrinol & Metab, New Brunswick, NJ 08903 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences
RP Wimalawansa, SJ (通讯作者)，Univ Med & Dent New Jersey, Div Endocrinol & Metab, 372 MEB, New Brunswick, NJ 08903 USA.
EM wimalasu@umdnj.edu
OI Wimalawansa, Prof. Sunil/0000 0003 1096 8595
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Armour KE, 1998, ENDOCRINOLOGY, V139, P799, DOI 10.1210/en.139.2.799
   Armour KE, 1999, J BONE MINER RES, V14, P2137, DOI 10.1359/jbmr.1999.14.12.2137
   Armour KJ, 2001, ARTHRITIS RHEUM, V44, P2790, DOI 10.1002/1529 0131(200112)44:12<2790::AID ART466>3.0.CO;2 X
   BRANDI ML, 1995, P NATL ACAD SCI USA, V92, P2954, DOI 10.1073/pnas.92.7.2954
   Broulík PD, 2003, PHYSIOL RES, V52, P729, DOI 10.33549/physiolres.930375
   Brunori M, 1999, CELL MOL LIFE SCI, V56, P549, DOI 10.1007/s000180050452
   Burger E H, 1999, Adv Dent Res, V13, P93
   Evans DM, 1996, J BONE MINER RES, V11, P300
   Fini M, 2001, BIOMED PHARMACOTHER, V55, P213, DOI 10.1016/S0753 3322(01)00054 3
   GARRETT IR, 2004, PHARM DESIGN, V7, P715
   GRIMES JP, 2005, NATL OST FDN ANN M A
   Hsia J, 2007, CIRCULATION, V115, P846, DOI 10.1161/CIRCULATIONAHA.106.673491
   HUKKANEN M, 1995, ENDOCRINOLOGY, V136, P5445, DOI 10.1210/en.136.12.5445
   IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265
   Jamal S., 1997, J BONE MINERAL RES, V12, pS229
   KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569
   KAWASE T, 1993, J BONE MINER RES, V8, pS372
   Kikkawa I, 1998, MICROBIOL IMMUNOL, V42, P591, DOI 10.1111/j.1348 0421.1998.tb02329.x
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lee SK, 2004, EXP CELL RES, V298, P359, DOI 10.1016/j.yexcr.2004.04.039
   LOWIK CWGM, 1994, J CLIN INVEST, V93, P1465, DOI 10.1172/JCI117124
   MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   MONCADA S, 1993, NEW ENGL J MED, V329, P2002
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Morimoto LM, 2002, CANCER CAUSE CONTROL, V13, P741, DOI 10.1023/A:1020239211145
   Oelzner P, 1997, MED KLIN, V92, P607, DOI 10.1007/BF03044788
   Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841
   PUNJABI CJ, 1992, J IMMUNOL, V149, P2179
   RALSTON SH, 1994, ENDOCRINOLOGY, V135, P330, DOI 10.1210/en.135.1.330
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   ROSSELLI M, 1995, HYPERTENSION, V25, P848, DOI 10.1161/01.HYP.25.4.848
   ROSSELLI M, 1994, BIOCHEM BIOPH RES CO, V202, P1543, DOI 10.1006/bbrc.1994.2107
   Silverton SF, 1999, BIOCHEM BIOPH RES CO, V259, P73, DOI 10.1006/bbrc.1999.0703
   Stacey E, 1998, J CLIN ENDOCR METAB, V83, P3056, DOI 10.1210/jc.83.9.3056
   Sterck JGH, 1998, AM J PHYSIOL ENDOC M, V274, pE1113, DOI 10.1152/ajpendo.1998.274.6.E1113
   Turner CH, 1996, AM J PHYSIOL ENDOC M, V270, pE634, DOI 10.1152/ajpendo.1996.270.4.E634
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   VISSER JJ, 1994, MED HYPOTHESES, V43, P339, DOI 10.1016/0306 9877(94)90113 9
   WIMALAWANSA DM, IN PRESS CALCIF TISS
   Wimalawansa S, 2000, J BONE MINER RES, V15, P1119, DOI 10.1359/jbmr.2000.15.6.1119
   Wimalawansa SJ, 2000, CALCIFIED TISSUE INT, V66, P56, DOI 10.1007/s002230050011
   Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240
   Wimalawansa SJ, 1997, BONE, V21, P275, DOI 10.1016/S8756 3282(97)00125 7
   Wimalawansa SJ, 1996, BONE, V18, P301, DOI 10.1016/8756 3282(96)00005 1
   WIMALAWANSA SJ, IN PRESS EXP OPIN PH
   WIMALAWANSA SJ, 1998, THESIS U LONDON
   WIMALAWANSA SJ, IN PRESS J MUSCULOSK
   Zofkova I, 1997, Cas Lek Cesk, V136, P459
NR 50
TC 57
Z9 66
U1 0
U2 13
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND
SN 0077 8923
BN 978 1 57331 728 3
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2007
VL 1117
BP 283
EP 297
DI 10.1196/annals.1402.066
PG 15
WC Endocrinology & Metabolism; Multidisciplinary Sciences; Pathology;
   Physiology
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Science & Technology   Other Topics;
   Pathology; Physiology
GA BHD19
UT WOS:000252266600024
PM 18056048
DA 2025 08 17
ER

PT J
AU Rodvold, JJ
   Chiu, KT
   Hiramatsu, N
   Nussbacher, JK
   Galimberti, V
   Mahadevan, NR
   Willert, K
   Lin, JH
   Zanetti, M
AF Rodvold, Jeffrey J.
   Chiu, Kevin T.
   Hiramatsu, Nobuhiko
   Nussbacher, Julia K.
   Galimberti, Valentina
   Mahadevan, Navin R.
   Willert, Karl
   Lin, Jonathan H.
   Zanetti, Maurizio
TI Intercellular transmission of the unfolded protein response promotes
   survival and drug resistance in cancer cells
SO SCIENCE SIGNALING
LA English
DT Article
ID ENDOPLASMIC RETICULUM STRESS; WNT SIGNALING PATHWAY; BETA CATENIN;
   PROSTATE CANCER; TUMOR CELLS; CHAPERONE GRP78/BIP; MITOTIC BLOCK; ER;
   ACTIVATION; PROLIFERATION
AB Increased protein translation in cells and various factors in the tumor microenvironment can induce endoplasmic reticulum (ER) stress, which initiates the unfolded protein response (UPR). We have previously reported that factors released from cancer cells mounting a UPR induce a de novo UPR in bone marrow derived myeloid cells, macrophages, and dendritic cells that facilitates protumorigenic characteristics in culture and tumor growth in vivo. We investigated whether this intercellular signaling, which we have termed transmissible ER stress (TERS), also operates between cancer cells and what its functional consequences were within the tumor. We found that TERS signaling induced a UPR in recipient human prostate cancer cells that included the cell surface expression of the chaperone GRP78. TERS also activated Wnt signaling in recipient cancer cells and enhanced resistance to nutrient starvation and common chemotherapies such as the proteasome inhibitor bortezomib and the microtubule inhibitor paclitaxel. TERS induced activation of Wnt signaling required the UPR kinase and endonuclease IRE1. However, TERS induced enhancement of cell survival was predominantly mediated by the UPR kinase PERK and a reduction in the abundance of the transcription factor ATF4, which prevented the activation of the transcription factor CHOP and, consequently, the induction of apoptosis. When implanted in mice, TERS primed cancer cells gave rise to faster growing tumors than did vehicle primed cancer cells. Collectively, our data demonstrate that TERS is a mechanism of intercellular communication through which tumor cells can adapt to stressful environments.
C1 [Rodvold, Jeffrey J.; Chiu, Kevin T.; Galimberti, Valentina; Mahadevan, Navin R.; Zanetti, Maurizio] Univ Calif San Diego, Dept Med, Lab Immunol, La Jolla, CA 92093 USA.
   [Rodvold, Jeffrey J.; Chiu, Kevin T.; Galimberti, Valentina; Mahadevan, Navin R.; Zanetti, Maurizio] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
   [Hiramatsu, Nobuhiko; Lin, Jonathan H.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.
   [Nussbacher, Julia K.; Willert, Karl] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Zanetti, M (通讯作者)，Univ Calif San Diego, Dept Med, Lab Immunol, La Jolla, CA 92093 USA.; Zanetti, M (通讯作者)，Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
EM mzanetti@ucsd.edu
RI ; Mahadevan, Navin/KLZ 9858 2024
OI Lin, Jonathan/0000 0002 7438 6941; Zanetti,
   Maurizio/0000 0001 6346 8776; 
FU U.S. Department of Defense grant [W81XWH 12 1 0156]; Frank H. and Eva B.
   Buck Foundation; Japan Society for the Promotion of Science Postdoctoral
   Fellowship for Research Abroad;  [NIH R01NS088485];  [NIH U54OD020351]; 
   [VA BX002284]
FX We This work was supported by U.S. Department of Defense grant
   W81XWH 12 1 0156 to M.Z. and NIH R01NS088485, NIH U54OD020351, and VA
   BX002284 to J.H.L. J.J.R. acknowledges the support of the Frank H. and
   Eva B. Buck Foundation. N.H. was supported by a Japan Society for the
   Promotion of Science Postdoctoral Fellowship for Research Abroad.
CR Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018
   Armstrong JL, 2010, J BIOL CHEM, V285, P6091, DOI 10.1074/jbc.M109.014092
   Atilla Gokcumen GE, 2006, CHEMBIOCHEM, V7, P1443, DOI 10.1002/cbic.200600117
   Axten JM, 2013, ACS MED CHEM LETT, V4, P964, DOI 10.1021/ml400228e
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Bell RJA, 2015, SCIENCE, V348, P1036, DOI 10.1126/science.aab0015
   Ben Sahra I, 2016, SCIENCE, V351, P728, DOI 10.1126/science.aad0489
   Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014
   Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777
   Cao W, 2014, J IMMUNOL, V192, P2920, DOI 10.4049/jimmunol.1302801
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Condamine T, 2014, J CLIN INVEST, V124, P2626, DOI 10.1172/JCI74056
   Cross BCS, 2012, P NATL ACAD SCI USA, V109, pE869, DOI 10.1073/pnas.1115623109
   Cubillos Ruiz JR, 2015, CELL, V161, P1527, DOI 10.1016/j.cell.2015.05.025
   Cullen SJ, 2013, AM J CANCER RES, V3, P196
   Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014
   Davidson G, 2010, TRENDS CELL BIOL, V20, P453, DOI 10.1016/j.tcb.2010.05.002
   DiPaola RS, 2002, CLIN CANCER RES, V8, P3311
   Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008 5472.CAN 07 2950
   Du QA, 2006, CANCER RES, V66, P7024, DOI 10.1158/0008 5472.CAN 05 4110
   Fernandez A, 2014, P NATL ACAD SCI USA, V111, P1409, DOI 10.1073/pnas.1323697111
   Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105
   Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370
   Gonzalez Gronow M, 2006, CANCER RES, V66, P11424, DOI 10.1158/0008 5472.CAN 06 1721
   Gonzalez Gronow M, 2009, ANTIOXID REDOX SIGN, V11, P2299, DOI [10.1089/ars.2009.2568, 10.1089/ARS.2009.2568]
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Haendeler J, 2003, MOL CELL BIOL, V23, P4598, DOI 10.1128/MCB.23.13.4598 4610.2003
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097 2765(00)80330 5
   Hayashi MT, 2012, NAT STRUCT MOL BIOL, V19, P387, DOI 10.1038/nsmb.2245
   He B, 2006, CELL DEATH DIFFER, V13, P393, DOI 10.1038/sj.cdd.4401833
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054
   Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370
   Hosoi T, 2014, BIOCHEM BIOPH RES CO, V447, P378, DOI 10.1016/j.bbrc.2014.04.034
   Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371
   Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690
   Jeon YJ, 2015, CANCER CELL, V27, P354, DOI 10.1016/j.ccell.2015.02.006
   JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552
   Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670
   Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100
   Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008 5472.CAN 07 0325
   Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701
   Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523
   Li YH, 2014, CANCER RES, V74, P1639, DOI 10.1158/0008 5472.CAN 13 3568
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Mahadevan NR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051845
   Mahadevan NR, 2011, J IMMUNOL, V187, P4403, DOI 10.4049/jimmunol.1101531
   Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108
   Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556
   Misra UK, 2006, J BIOL CHEM, V281, P13694, DOI 10.1074/jbc.M511694200
   Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917
   Montague TG, 2014, NUCLEIC ACIDS RES, V42, pW401, DOI 10.1093/nar/gku410
   Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569
   Notte A, 2015, INT J BIOCHEM CELL B, V62, P1, DOI 10.1016/j.biocel.2015.02.010
   Nusse R, 2008, COLD SH Q B, V73, P59, DOI 10.1101/sqb.2008.73.035
   Papandreou CN, 2004, J CLIN ONCOL, V22, P2108, DOI 10.1200/JCO.2004.02.106
   Papandreou CN, 2004, CANCER RES, V64, P5036, DOI 10.1158/0008 5472.CAN 03 2707
   Preissler S, 2015, ELIFE, V4, DOI 10.7554/eLife.12621
   Quinones QJ, 2008, HISTOL HISTOPATHOL, V23, P1409, DOI 10.14670/HH 23.1409
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008 5472.CAN 05 3092
   Ray R, 2012, J BIOL CHEM, V287, P32755, DOI 10.1074/jbc.M112.399808
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Rodvold JJ, 2016, CANCER LETT, V380, P227, DOI 10.1016/j.canlet.2015.09.009
   Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374
   Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063
   Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200
   Spiotto MT, 2010, CANCER RES, V70, P78, DOI 10.1158/0008 5472.CAN 09 2747
   Taylor RC, 2013, CELL, V153, P1435, DOI 10.1016/j.cell.2013.05.042
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960 9822(03)00240 9
   Walter F, 2015, CELL DEATH DIFFER, V22, P1502, DOI 10.1038/cdd.2014.241
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959 437X(98)80068 3
   WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588
   Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005
   Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018
   Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81
   Zanetti M, 2016, ONCOGENE, V35, P269, DOI 10.1038/onc.2015.108
   Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080071
   Zhou JZ, 2014, AGING CELL, V13, P197, DOI 10.1111/acel.12161
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
NR 83
TC 88
Z9 94
U1 1
U2 25
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945 0877
EI 1937 9145
J9 SCI SIGNAL
JI Sci. Signal.
PD JUN 6
PY 2017
VL 10
IS 482
AR eaah7177
DI 10.1126/scisignal.aah7177
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA EW9LY
UT WOS:000402842500001
PM 28588081
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, YQ
   Feng, XT
   Li, YW
   Song, QL
   Long, NL
   Fu, XT
   Wang, YF
   He, YJ
   Yan, HY
   Li, C
   Feng, LN
   Fan, CD
   Li, MQ
   Han, Y
   Sun, DD
AF Li, Yuqing
   Feng, Xiaotong
   Li, Yuwei
   Song, Qile
   Long, Naling
   Fu, Xiaoting
   Wang, Yifan
   He, Yingjiao
   Yan, Huiying
   Li, Cong
   Feng, Lina
   Fan, Cundong
   Li, Mingquan
   Han, Yi
   Sun, Dongdong
TI Icariin loaded selenium gold multi shell nanocomposites with NIR II
   response release to relieve post damaged bone microenvironment for
   osteoporosis synergy therapy
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Bone microenvironment; Osteoporosis; Icariin; Inflammatory response and
   oxidative stress; Synergy therapy
ID RESISTANT ACID PHOSPHATASE; CELL ANALYSIS SYSTEM; TIME; NANOPARTICLES;
   NANOMATERIALS; CYTOTOXICITY; OSTEOCLASTS; DELIVERY
AB Imbalance of inflammatory response and oxidative stress in bone microenvironment are the two most important mechanisms leading to the development and progression of osteoporosis. Developing high efficiency and low toxicity nanodrugs to regulate bone microenvironment has been emerging as potential strategy for therapy of human osteoporosis. Herein, functional icariin (ICA) loaded selenium Au multi shell nanocomposites (SAS ICA NPs) were designed. Under near infrared light (NIR) irradiation, Au NPs showed a significant photothermal effect to trigger Se NPs and icariin releases, which synergistically inhibited the release of inflammatory factors and accumulation of reactive oxygen species (ROS). The results showed that SAS ICA did not cause significant cytotoxicity towards macrophage and osteoblast. SAS ICA treatment in vitro effectively induced macrophage phenotypic polarization, and inhibited release of inflammatory factors and ROS in macrophages. Additionally, SAS ICA treatment in vitro significantly promoted alkaline phosphatase activation and the deposition of calcium nodules in osteoblast, implying the activation of osteoblasts. Importantly, SAS ICA administration in vivo effectively improved bone mineral density (BMD) in ovariectomy mice by up regulating type 1 colaggen (Col 1), Nuclear transcription related factor 2 (Runx 2), bone formation protein (BMP2) and osteocalcin (OCN) expression and inhibiting osteoclast activation (TRAP staining). Moreover, SAS ICA in vivo showed no side effects and good biocompatibility. Taken together, our findings validated the rational design that icariin loaded selenium Au multi shell nanocomposites possessed NIR II responsive release for synergetic theray of osteoporosis by regulating the bone microenvironment.
C1 [Li, Yuqing; Li, Yuwei; Long, Naling; He, Yingjiao; Han, Yi; Sun, Dongdong] Anhui Agr Univ, Sch Life Sci, Hefei 230036, Peoples R China.
   [Feng, Xiaotong; Song, Qile; Fu, Xiaoting; Wang, Yifan; Feng, Lina; Fan, Cundong] Shandong First Med Univ, Shandong Key Lab Brain Injury & Funct Rehabil, Affiliated Hosp 2, Tai An 271000, Shandong, Peoples R China.
   [Yan, Huiying; Li, Cong; Li, Mingquan] Changchun Univ Chinese Med, Dept Neurol, Affiliated Clin Hosp 3, Changchun 130117, Jilin, Peoples R China.
C3 Anhui Agricultural University; Shandong First Medical University &
   Shandong Academy of Medical Sciences; Changchun University of Chinese
   Medicine
RP Han, Y; Sun, DD (通讯作者)，Anhui Agr Univ, Sch Life Sci, Hefei 230036, Peoples R China.; Li, MQ (通讯作者)，Changchun Univ Chinese Med, Dept Neurol, Affiliated Clin Hosp 3, Changchun 130117, Jilin, Peoples R China.
EM Limingquan0001@126.com; yi.han@ahau.edu.cn; sunddwj@ahau.edu.cn
RI Fan, Cundong/ABG 5600 2021; Feng, Xiaotong/H 3777 2018; Yan,
   huiying/LFU 0378 2024; Han, Yi/AAV 8691 2021
OI Han, Yi/0000 0002 4424 1485
FU National Natural Science Foundation of China [32471441]; Anhui
   Provincial Natural Science Foundation [2308085MB38, 2208085MC44];
   Science and Technology Development Projects in Jilin Province
   [YDZJ202201ZYTS232]; Key Projects of Youth Talent Fund in Anhui
   Provincial Universities [gxyqZD2020006]; Shandong Provincial Natural
   Science Foundation [ZR2022QH149]; Key R & D Projects in Anhui Province
   [202104f06020028]; The 2021 Fuyang City Science and Technology Major
   Special Project [FK20208005]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 32471441) , Anhui Provincial Natural Science Foundation
   (2308085MB38, 2208085MC44) , Science and Technology Development Projects
   in Jilin Province (YDZJ202201ZYTS232) , Key Projects of Youth Talent
   Fund in Anhui Provincial Universities (gxyqZD2020006) , Shandong
   Provincial Natural Science Foundation (ZR2022QH149) , Key R & D Projects
   in Anhui Province (202104f06020028) and 2021 Fuyang City Science and
   Technology Major Special Project (FK20208005) .
CR Adami G, 2020, J BONE MINER RES, V35, P478, DOI 10.1002/jbmr.3915
   Alekseeva OY, 2019, B EXP BIOL MED+, V168, P125, DOI 10.1007/s10517 019 04662 2
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Bae YJ, 2008, BIOL TRACE ELEM RES, V124, P28, DOI 10.1007/s12011 008 8119 6
   Barrioni BR, 2019, J MATER SCI MATER M, V30, DOI 10.1007/s10856 019 6288 9
   Barrioni BR, 2017, J MATER SCI, V52, P8904, DOI 10.1007/s10853 017 0944 6
   Bi ZY, 2022, BIOMED PHARMACOTHER, V151, DOI 10.1016/j.biopha.2022.113180
   Boehm J, 2012, J CLIN PATHOL, V65, P1013, DOI 10.1136/jclinpath 2012 200854
   Booth M, 2022, BIOTECH HISTOCHEM, V97, P222, DOI 10.1080/10520295.2021.1933179
   Chen GM, 2016, EXP THER MED, V12, P279, DOI 10.3892/etm.2016.3333
   Chen YC, 2021, J CONTROL RELEASE, V330, P438, DOI 10.1016/j.jconrel.2020.12.025
   Chiang WL, 2015, J CONTROL RELEASE, V199, P53, DOI 10.1016/j.jconrel.2014.12.011
   Chistiakov DA, 2017, IMMUNOBIOLOGY, V223, P101, DOI 10.1016/j.imbio.2017.10.005
   Duan SF, 2023, RSC ADV, V13, P14443, DOI 10.1039/d3ra02620e
   Estell EG, 2021, NAT REV ENDOCRINOL, V17, P31, DOI 10.1038/s41574 020 00426 5
   Ethiraj LP, 2022, EUR J HISTOCHEM, V66, DOI 10.4081/ejh.2022.3369
   Foglieni C, 2001, HISTOCHEM CELL BIOL, V115, P223
   Gu QL, 2017, J ORTHOP TRANSL, V10, P86, DOI 10.1016/j.jot.2017.05.002
   Hanga Farcas A, 2023, PLANTS BASEL, V12, DOI 10.3390/plants12102055
   Hao Y, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1188357
   Harvey NC, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 021 01049 7
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Hoefert S, 2006, ORTHOPADE, V35, P204, DOI 10.1007/s00132 005 0901 y
   Hu YR, 2016, INTEGR FERROELECTR, V169, P140, DOI 10.1080/10584587.2016.1165565
   Iantomasi T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043772
   Jasmin, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477 3155 9 4
   Jiang W, 2024, CRIT REV FOOD SCI, V64, P5852, DOI 10.1080/10408398.2022.2159317
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li MZ, 2020, J MATER CHEM B, V8, P1863, DOI 10.1039/c9tb02932j
   Li X, 2021, Nan Fang Yi Ke Da Xue Xue Bao, V41, P1773, DOI 10.12122/j.issn.1673 4254.2021.12.03
   Li ZQ, 2021, ACS APPL BIO MATER, V4, P6758, DOI 10.1021/acsabm.1c00489
   Liang H, 2019, ACS APPL MATER INTER, V11, P41758, DOI 10.1021/acsami.9b16848
   Liang XX, 2019, J CELL BIOCHEM, V120, P13121, DOI 10.1002/jcb.28585
   Lin T, 2023, INT IMMUNOPHARMACOL, V114, DOI 10.1016/j.intimp.2022.109560
   Lindsay BR, 2016, ARCH OSTEOPOROS, V11, DOI 10.1007/s11657 016 0272 5
   Liu HR, 2017, EXP THER MED, V13, P1360, DOI 10.3892/etm.2017.4128
   Liu Xiang Hui, 2020, Zhongguo Gu Shang, V33, P784, DOI 10.12200/j.issn.1003 0034.2020.08.019
   Liu YS, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 020 03896 w
   Livshits G, 2022, LIFE SCI, V306, DOI 10.1016/j.lfs.2022.120847
   Lou SH, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen 2016 012802
   Ma H, 2021, J MATER CHEM A, V9, P17569, DOI 10.1039/d1ta04134g
   Ma MY, 2023, MOLECULES, V28, DOI 10.3390/molecules28186652
   Ma YP, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.739212
   Mendes LS, 2018, BIOMED MATER, V13, DOI 10.1088/1748 605X/aa9085
   Moester MJC, 2014, BIOCHEM BIOPH RES CO, V443, P80, DOI 10.1016/j.bbrc.2013.11.055
   Mohamad NV, 2020, ENDOCR METAB IMMUNE, V20, P1478, DOI 10.2174/1871530320666200604160614
   Muñoz M, 2020, CLIN OBSTET GYNECOL, V63, P770, DOI 10.1097/GRF.0000000000000572
   Murata Y, 2020, TISSUE ENG PART C ME, V26, P244, DOI [10.1089/ten.TEC.2020.0029, 10.1089/ten.tec.2020.0029]
   Nakayama T, 2011, BONE, V49, P1331, DOI 10.1016/j.bone.2011.09.045
   Nie ZL, 2023, ACTA BIOMATER, V157, P625, DOI 10.1016/j.actbio.2022.11.005
   Qian GW, 2021, INT J BIOPRINTING, V7, P92, DOI 10.18063/ijb.v7i2.346
   Reis FS, 2023, ARCH ENDOCRIN METAB, V67, DOI 10.20945/2359 3997000000626
   Ricles LM, 2011, INT J NANOMED, V6, P407, DOI 10.2147/IJN.S16354
   Schmidtke Schrezenmeier G, 2011, CYTOTHERAPY, V13, P962, DOI 10.3109/14653249.2011.571246
   Sener LT, 2017, EXP THER MED, V14, P1866, DOI 10.3892/etm.2017.4781
   Seth A, 2020, ACS APPL MATER INTER, V12, P42499, DOI 10.1021/acsami.0c10781
   Shen MK, 2022, INT J NANOMED, V17, P2593, DOI 10.2147/IJN.S366926
   Spilmont M, 2014, EUR J NUTR, V53, P1155, DOI 10.1007/s00394 013 0615 6
   Stefanowicz Hajduk J, 2020, TOXICOL REP, V7, P335, DOI 10.1016/j.toxrep.2020.02.002
   Tee SY, 2021, NANOSCALE, V13, P14268, DOI 10.1039/d1nr04197e
   Thomas MV, 2011, J DENT RES, V90, P1052, DOI 10.1177/0022034510393967
   Wang M, 2020, BIOMED PHARMACOTHER, V131, DOI [10.1016/j.biopha.2020.110675, 10.1016/J.biopha.2020.110675]
   Wang SQ, 2021, DRUG DES DEV THER, V15, P3619, DOI 10.2147/DDDT.S310686
   Wang YF, 2020, ACS APPL POLYM MATER, V2, P4258, DOI 10.1021/acsapm.0c00680
   Wang Z, 2018, OSTEOPOROSIS INT, V29, P535, DOI 10.1007/s00198 017 4255 1
   Wu YD, 2023, COORDIN CHEM REV, V495, DOI 10.1016/j.ccr.2023.215370
   Xia SL, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 023 03998 w
   Xu YX, 2019, EUR J PHARMACOL, V865, DOI 10.1016/j.ejphar.2019.172794
   Yan GJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23123280
   You CQ, 2018, MAT SCI ENG C MATER, V92, P453, DOI 10.1016/j.msec.2018.06.044
   Yu L, 2017, COLLOID SURFACE B, V152, P376, DOI 10.1016/j.colsurfb.2017.01.047
   Yu SM, 2018, J MATER CHEM B, V6, P5215, DOI 10.1039/c8tb01084f
   Yun HF, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 112
   Zhang Wei, 2014, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V30, P1209
   Zhang YG, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.728066
   Zhou MY, 2020, J BIOMED NANOTECHNOL, V16, P739, DOI 10.1166/jbn.2020.2938
   Zhu CL, 2017, ADV MATER, V29, DOI 10.1002/adma.201703702
   Zinck N, 2021, ANAT REC, V304, P958, DOI 10.1002/ar.24526
NR 78
TC 3
Z9 3
U1 16
U2 30
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD NOV 1
PY 2024
VL 499
AR 156421
DI 10.1016/j.cej.2024.156421
EA OCT 2024
PG 16
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA I7H4A
UT WOS:001331929500001
DA 2025 08 17
ER

PT J
AU Zhang, L
   Meng, S
   Tu, QS
   Yu, LM
   Tang, Y
   Dard, MM
   Kim, SH
   Valverde, P
   Zhou, XD
   Chen, JK
AF Zhang, Lan
   Meng, Shu
   Tu, Qisheng
   Yu, Liming
   Tang, Yin
   Dard, Michel M.
   Kim, Sung Hoon
   Valverde, Paloma
   Zhou, Xuedong
   Chen, Jake
TI Adiponectin Ameliorates Experimental Periodontitis in Diet Induced
   Obesity Mice
SO PLOS ONE
LA English
DT Article
ID MAPK SIGNALING PATHWAY; INSULIN RESISTANCE; OXIDATIVE STRESS;
   PLASMA CONCENTRATIONS; GLOBULAR ADIPONECTIN; METABOLIC SYNDROME; HUMAN
   OSTEOBLASTS; BONE LOSS; EXPRESSION; PROTEIN
AB Adiponectin is an adipokine that sensitizes the body to insulin. Low levels of adiponectin have been reported in obesity, diabetes and periodontitis. In this study we established experimental periodontitis in male adiponectin knockout and diet induced obesity mice, a model of obesity and type 2 diabetes, and aimed at evaluating the therapeutic potential of adiponectin. We found that systemic adiponectin infusion reduced alveolar bone loss, osteoclast activity and infiltration of inflammatory cells in both periodontitis mouse models. Furthermore, adiponectin treatment decreased the levels of pro inflammatory cytokines in white adipose tissue of diet induced obesity mice with experimental periodontitis. Our in vitro studies also revealed that forkhead box O1, a key transcriptional regulator of energy metabolism, played an important role in the direct signaling of adiponectin in osteoclasts. Thus, adiponectin increased forkhead box O1 mRNA expression and its nuclear protein level in osteoclast precursor cells undergoing differentiation. Inhibition of c Jun N terminal kinase signaling decreased nuclear protein levels of forkhead box O1. Furthermore, over expression of forkhead box O1 inhibited osteoclastogenesis and led to decreased nuclear levels of nuclear factor of activated T cells c1. Taken together, this study suggests that systemic adiponectin application may constitute a potential intervention therapy to ameliorate type 2 diabetes associated periodontitis. It also proposes that adiponectin inhibition of osteoclastogenesis involves forkhead box O1.
C1 [Zhang, Lan; Meng, Shu; Tu, Qisheng; Yu, Liming; Tang, Yin; Chen, Jake] Tufts Univ, Sch Dent Med, Div Oral Biol, Boston, MA 02111 USA.
   [Zhang, Lan; Meng, Shu; Tang, Yin; Zhou, Xuedong] Sichuan Univ, West China Hosp Stomatol, Key Lab Oral Dis, Chengdu 610064, Sichuan, Peoples R China.
   [Dard, Michel M.] NYU, Coll Dent, New York, NY USA.
   [Kim, Sung Hoon] Kyung Hee Univ, Coll Oriental Med, Canc Prevent Mat Dev Res Ctr, Seoul, South Korea.
   [Kim, Sung Hoon] Kyung Hee Univ, Coll Oriental Med, Seoul, South Korea.
   [Valverde, Paloma] Wentworth Inst Technol, Dept Sci, Boston, MA USA.
   [Chen, Jake] Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Dept Anat & Cell Biol, Boston, MA 02111 USA.
C3 Tufts University; Sichuan University; New York University; Kyung Hee
   University; Kyung Hee University; Tufts University
RP Tu, QS (通讯作者)，Tufts Univ, Sch Dent Med, Div Oral Biol, Boston, MA 02111 USA.
EM qisheng.tu@tufts.edu; jk.chen@tufts.edu
RI ; Liming, Yu/Y 4291 2019; tang, yin/AAR 2123 2021; Zhou,
   Xuedong/LSL 0410 2024; Chen, Jake/A 2857 2009
OI Zhou, Xuedong/0000 0002 9319 7302; Zhang, Lan/0000 0002 9714 999X; Tu,
   Qisheng/0000 0003 0639 8761; kim, sunghoon/0000 0002 1570 3230
FU National Institutes of Health (NIH) [R01DE16710, R01DE21464];
   International Association of Dental Research (IADR); Academy of
   Osseointegration (AO) Innovation in Implant Science Award; Ministry of
   Education, Science and Technology (MEST) in South Korea [2007 0054931];
   NIH [DK080344]
FX This project was supported by National Institutes of Health (NIH) grants
   R01DE16710 and R01DE21464, and the International Association of Dental
   Research (IADR) and the Academy of Osseointegration (AO) Innovation in
   Implant Science Award (to J.C.); Ministry of Education, Science and
   Technology (MEST) grant 2007 0054931 in South Korea (to S. H. K.); NIH
   grant DK080344 (to L. Q. D.). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amar S, 2007, P NATL ACAD SCI USA, V104, P20466, DOI 10.1073/pnas.0710335105
   Bartell S, 2012, ASBMR 2012 ANN M, P284
   Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4
   Bobbert P, 2008, J MOL CELL CARDIOL, V44, P388, DOI 10.1016/j.yjmcc.2007.10.018
   Bullon P, 2009, J DENT RES, V88, P503, DOI 10.1177/0022034509337479
   Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/en.143.3.998
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Eke PI, 2012, J DENT RES, V91, P914, DOI 10.1177/0022034512457373
   Galli C, 2011, J PERIODONTAL RES, V46, P397, DOI 10.1111/j.1600 0765.2011.01354.x
   Hay N, 2011, BBA MOL CELL RES, V1813, P1965, DOI 10.1016/j.bbamcr.2011.03.013
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595
   Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126
   Kajimura D, 2013, CELL METAB, V17, P901, DOI 10.1016/j.cmet.2013.04.009
   Kang EH, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3218
   Kousteni S, 2012, BONE, V50, P437, DOI 10.1016/j.bone.2011.06.034
   Li CH, 2007, J PERIODONTOL, V78, P1120, DOI 10.1902/jop.2007.060320
   Li H, 2013, STEROIDS, V78, P115, DOI 10.1016/j.steroids.2012.10.015
   Luo E, 2012, ACTA BIOMATER, V8, P734, DOI 10.1016/j.actbio.2011.10.029
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Luo XH, 2006, J BONE MINER RES, V21, P1648, DOI 10.1359/JBMR.060707
   Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007 0259
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mao XM, 2006, NAT CELL BIOL, V8, P516, DOI 10.1038/ncb1404
   Mealey BL, 2006, J AM DENT ASSOC, V137, p26S, DOI 10.14219/jada.archive.2006.0404
   Miyazaki T, 2005, BIOCHEM BIOPH RES CO, V333, P79, DOI 10.1016/j.bbrc.2005.05.076
   Nakanishi S, 2005, METABOLISM, V54, P194, DOI 10.1016/j.metabol.2004.08.012
   Park PH, 2008, J LEUKOCYTE BIOL, V83, P1258, DOI 10.1189/jlb.0907631
   Ren WH, 2006, PROG BIOCHEM BIOPHYS, V33, P846
   Saito T, 2008, J DENT RES, V87, P319, DOI 10.1177/154405910808700416
   Saxena NK, 2010, GASTROENTEROLOGY, V139, P1762, DOI 10.1053/j.gastro.2010.07.001
   Shu RZ, 2009, LAB INVEST, V89, P1043, DOI 10.1038/labinvest.2009.63
   Subedi A, 2013, FEBS LETT, V587, P1556, DOI 10.1016/j.febslet.2013.03.040
   Sun WL, 2011, INTERNAL MED, V50, P1569, DOI 10.2169/internalmedicine.50.5166
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Toker H, 2009, J PERIODONTOL, V80, P672, DOI 10.1902/jop.2009.080509
   Tu Q, 2008, J CELL PHYSIOL, V217, P40, DOI 10.1002/jcp.21472
   Tu QS, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.152405
   Tu QS, 2009, J CELL PHYSIOL, V218, P135, DOI 10.1002/jcp.21576
   Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930
   Wulster Radcliffe MC, 2004, BIOCHEM BIOPH RES CO, V316, P924, DOI 10.1016/j.bbrc.2004.02.130
   Yamaguchi N, 2008, FEBS LETT, V582, P451, DOI 10.1016/j.febslet.2007.12.037
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
   Zimmermann GS, 2013, J PERIODONTOL, V84, P624, DOI 10.1902/jop.2012.120254
NR 47
TC 34
Z9 38
U1 2
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 16
PY 2014
VL 9
IS 5
AR e97824
DI 10.1371/journal.pone.0097824
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AM1NZ
UT WOS:000339614800072
PM 24836538
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, H
   Jiang, WL
   Hong, KH
   Cai, J
   He, YC
   Ma, XM
   Wu, P
   Lang, JZ
   Ma, YG
   Huang, CG
   Yuan, JD
AF Huang, Hao
   Jiang, Wenli
   Hong, Kehua
   Cai, Jie
   He, Yongchao
   Ma, Xuming
   Wu, Peng
   Lang, Junzhe
   Ma, Yuegang
   Huang, Caiguo
   Yuan, Jiandong
TI Protocatechualdehyde inhibits receptor activator of nuclear factor
   kappa B ligand induced osteoclastogenesis and attenuates
   lipopolysaccharide induced inflammatory osteolysis
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE anti&#8208; resorptives; bone resorption; ERK; LPS; osteoclast;
   protocatechualdehyde
ID TUMOR NECROSIS FACTOR; BONE RESORPTION; IN VITRO; GENE EXPRESSION;
   C FOS; PROTEIN KINASE; UP REGULATION; DIFFERENTIATION; RANKL; NFATC1
AB Inflammatory osteolysis as a consequence of chronic bacterial infection underlies several lytic bone conditions, such as otitis media, osteomyelitis, septic arthritis, periodontitis, periprosthetic infection, and aseptic loosening of orthopedic implants. In consideration of the lack of effective preventive or treatments options against infectious osteolysis, the exploitation of novel pharmacological compounds/agents is critically required. The present study assessed the effect of protocatechualdehyde (PCA), a natural occurring polyphenolic compound with diverse biological activities including but not limited to antibacterial and antiinflammatory properties, on nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis in vitro and lipopolysaccharide (LPS) induced bone loss in vivo. In the present study, it was found that PCA potently inhibited RANKL induced osteoclast formation, fusion, and activation toward bone resorption in a dose dependent manner via the suppression of the ERK/c Fos/nuclear factor of activated T cells, cytoplasmic 1 signaling axis. It was further demonstrated that the in vivo administration of PCA could effectively protect mice against the deleterious effects of LPS induced calvarial bone destruction by attenuating osteoclast formation and activity in a dose dependent manner. Collectively, these findings provided evidence for the potential therapeutic application of PCA in the prevention and treatment of infectious osteolytic conditions, and potentially other osteoclast mediated bone diseases.
C1 [Huang, Hao; Ma, Yuegang] Zhejiang Univ, Shaoxing Peoples Hosp, Dept Orthoped, Shaoxing Hosp,Sch Med, Shaoxing, Peoples R China.
   [Jiang, Wenli; Huang, Caiguo] Navy Med Univ, Coll Basic Med, Dept Biochem & Mol Biol, Shanghai, Peoples R China.
   [Hong, Kehua; Cai, Jie; Ma, Xuming; Wu, Peng; Lang, Junzhe; Yuan, Jiandong] Wenzhou Med Univ, Dept Orthoped, Affiliated Hosp 1, Wenzhou 325000, Peoples R China.
   [He, Yongchao] Wenzhou Med Univ, Dept Orthoped, Affiliated Cangnan Hosp, Wenzhou, Peoples R China.
C3 Zhejiang University; Naval Medical University; Wenzhou Medical
   University; Wenzhou Medical University
RP Yuan, JD (通讯作者)，Wenzhou Med Univ, Dept Orthoped, Affiliated Hosp 1, Wenzhou 325000, Peoples R China.
EM yuanjd2000@126.com
RI Yuan, Jiandong/AAU 5777 2020; Wu, Peng/JZD 5184 2024
FU National Key Research and Development Program of China [2028YFC0310904]
FX National Key Research and Development Program of China, Grant/Award
   Number: 2028YFC0310904
CR AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Arizon M, 2012, P NATL ACAD SCI USA, V109, P7043, DOI 10.1073/pnas.1116770109
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chakravarti A, 2009, BLOOD, V114, P1633, DOI 10.1182/blood 2008 09 178301
   Chao CY, 2009, FOODBORNE PATHOG DIS, V6, P201, DOI 10.1089/fpd.2008.0187
   CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952
   Choi J, 2014, J MED FOOD, V17, P842, DOI 10.1089/jmf.2013.0159
   Ciftci O, 2013, TOXICOL IND HEALTH, V29, P806, DOI 10.1177/0748233712442735
   Citak M, 2015, KNEE, V22, P338, DOI 10.1016/j.knee.2015.03.008
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Dressler L.G., 1992, J NATL CANCER INST M, V20, P167, DOI [10.3390/ijms20205154, DOI 10.3390/IJMS20205154]
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Guan S, 2006, EUR J PHARMACOL, V538, P73, DOI 10.1016/j.ejphar.2006.03.065
   Harris WH, 2001, CLIN ORTHOP RELAT R, P66
   HAUSMANN E, 1970, SCIENCE, V168, P862, DOI 10.1126/science.168.3933.862
   Haworth CS, 2004, THORAX, V59, P613, DOI 10.1136/thx.2003.012047
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Heinrich M, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.112230
   Henderson B, 2003, TRENDS MICROBIOL, V11, P570, DOI 10.1016/j.tim.2003.10.005
   Hong CY, 2004, J ORAL PATHOL MED, V33, P162, DOI 10.1111/j.0904 2512.2004.00045.x
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Izzo AA, 2020, BRIT J PHARMACOL, V177, P2169, DOI 10.1111/bph.15054
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kumar G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205154
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee MS, 2009, J IMMUNOL, V183, P3390, DOI 10.4049/jimmunol.0804314
   Lende Amol B., 2011, Inflammopharmacology, V19, P255, DOI 10.1007/s10787 011 0086 4
   Lerner UH, 2000, MATRIX BIOL, V19, P107, DOI 10.1016/S0945 053X(00)00052 4
   Li CM, 2012, PHARM BIOL, V50, P413, DOI 10.3109/13880209.2011.608193
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Liu YR, 2007, J ETHNOPHARMACOL, V111, P573, DOI 10.1016/j.jep.2007.01.005
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   MARKS SC, 1992, BONE, V13, P89, DOI 10.1016/8756 3282(92)90365 4
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mörmann M, 2008, MOL IMMUNOL, V45, P3330, DOI 10.1016/j.molimm.2008.04.022
   Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030 7043.2003
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park JH, 2017, MOL CELLS, V40, P706
   RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892 54
   Scazzocchio B, 2011, DIABETES, V60, P2234, DOI 10.2337/db10 1461
   Seo SW, 2010, BONE, V46, P695, DOI 10.1016/j.bone.2009.10.032
   Shi GF, 2006, NEUROSCI LETT, V403, P206, DOI 10.1016/j.neulet.2006.02.057
   Sobacchi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00629
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanaka T., 2011, Journal of Experimental and Clinical Medicine, V3, P27, DOI 10.1016/j.jecm.2010.12.005
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wei G, 2013, INFLAMMATION, V36, P592, DOI 10.1007/s10753 012 9581 z
   WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106
   WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xu Y, 2012, BASIC CLIN PHARMACOL, V110, P384, DOI 10.1111/j.1742 7843.2011.00827.x
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhou Z, 2007, ANTIVIR RES, V74, P59, DOI 10.1016/j.antiviral.2006.12.005
   Zhu X, 2016, J BONE MINER RES, V31, P560, DOI 10.1002/jbmr.2710
NR 76
TC 7
Z9 8
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD JUL
PY 2021
VL 35
IS 7
BP 3821
EP 3835
DI 10.1002/ptr.7088
EA MAR 2021
PG 15
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA TS8TH
UT WOS:000634006100001
PM 33778997
DA 2025 08 17
ER

PT J
AU Jin, G
   Wang, FF
   Li, T
   Jia, DD
   Shen, Y
   Xu, HC
AF Jin, Gu
   Wang, Fang Fang
   Li, Tao
   Jia, Dong Dong
   Shen, Yong
   Xu, Hai Chao
TI Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB
   Ligand (RANKL) Induced Osteoclastogenesis by Inhibiting the JNK and
   NF κB Pathways in Mouse Bone Marrow Derived Monocyte/Macrophages
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Garcinia; MAP Kinase Signaling System; NF kappa B; Osteoclasts; RANK
   Ligand
ID OSTEOPOROSIS; DIFFERENTIATION; EXPRESSION; CELLS; MAPK
AB Background: Neogambogic acid (NGA) is used in traditional Chinese medicine. The aim of this study was to investigate the effects of NGA on gene signaling pathways involved in osteoclastogenesis in mouse bone marrow derived monocyte/macrophages (BMMs) and on bone resorption in vitro.
   Material/Methods: Primary mouse BMMs were cultured with increasing concentrations of NGA. Real time polymerase chain reaction was used to study the expression of mRNAs corresponding to gene products specific to receptor activator of NF kappa B ligand (RANKL) induced osteoclast differentiation, including tartrate resistant acid phosphatase (TRAP), calcitonin receptor (CTR), cathepsin K (CTSK), and nuclear factor of activated T cells c1 (NFATc1). A cell counting kit 8 assay was used to evaluate cell proliferation. Western blotting and confocal immunofluorescence microscopy were used to investigate the signaling pathways. A bone resorption model was used to quantify bone resorption.
   Results: An NGA dose of <= 0.4 mu g/ml had no significant effect on the proliferation of mouse BMMs in vitro (P>0.05); concentrations of between 0.1 0.4 mu g/ml significantly inhibited RANKL induced osteoclastogenesis (P<0.01) in a dose dependent manner. Compared with the control group, NGA significantly reduced RANKL induced bone resorption in vitro (P<0.01), and downregulated the expression of osteoclast related mRNAs of TRAP, CTR, CTSK, and NFATc1. NGA suppressed the activation of JNK but not the p38 signaling pathway and significantly reduced NF kappa B p65 phosphorylation and the nuclear transport of NF kappa B molecules, which inhibited NFATc1 expression.
   Conclusions: NGA suppressed RANKL induced osteoclastogenesis by inhibiting the JNK and NF kappa B pathways in mouse BMMs in vitro and reduced osteoclastic bone resorption.
C1 [Jin, Gu; Li, Tao; Jia, Dong Dong; Xu, Hai Chao] Zhejiang Canc Hosp, Dept Bone & Soft Tissue Surg, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Fang Fang] Zhejiang Canc Hosp, Dept Gynecol Radiat Oncol, Hangzhou, Zhejiang, Peoples R China.
   [Shen, Yong] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Emergency, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang Cancer Hospital; Zhejiang Cancer Hospital; Hangzhou Medical
   College; Zhejiang Provincial People's Hospital
RP Xu, HC (通讯作者)，Zhejiang Canc Hosp, Dept Bone & Soft Tissue Surg, Hangzhou, Zhejiang, Peoples R China.
EM xuhc@zju.edu.cn
RI Wang, Fang Fang/GPF 6144 2022; Li, Tao/AAC 8501 2022
FU Health Department of Zhejiang Province [2017KY024]
FX This work was supported by the Health Department of Zhejiang Province
   (grant number 2017KY024)
CR [Anonymous], 2016, Math Probl Eng
   Baek JM, 2015, BIOCHEM BIOPH RES CO, V461, P334, DOI 10.1016/j.bbrc.2015.04.034
   Chen RZ, 2017, J CANCER, V8, P839, DOI 10.7150/jca.17657
   Drissi H, 2016, J CELL BIOCHEM, V117, P1753, DOI 10.1002/jcb.25560
   Ikeda Kyoji, 2014, J Bone Metab, V21, P163, DOI 10.11005/jbm.2014.21.3.163
   Kim JH, 2016, INT J MOL MED, V37, P649, DOI 10.3892/ijmm.2016.2477
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Li L, 2017, EUR J PHARMACOL, V815, P202, DOI 10.1016/j.ejphar.2017.09.015
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Liu YJ, 2016, J CHEM NY, V2016, DOI 10.1155/2016/6903524
   Milat F, 2016, MED J AUSTRALIA, V205, P185, DOI 10.5694/mja16.00568
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sigal LH, 2006, JCR J CLIN RHEUMATOL, V12, P207, DOI 10.1097/01.rhu.0000231385.94784.e4
   Thouverey C, 2012, CELL MOL LIFE SCI, V69, P3115, DOI 10.1007/s00018 012 0983 8
   Thummuri D, 2017, J MOL MED, V95, P1065, DOI 10.1007/s00109 017 1553 1
   Vattakuzhi Y, 2012, ARTHRITIS RHEUM US, V64, P2201, DOI 10.1002/art.34403
   Wang C, 2016, MED SCI MONITOR, V22, P226, DOI 10.12659/MSM.897044
   Wu DJ, 2016, J AUTOIMMUN, V73, P73, DOI 10.1016/j.jaut.2016.06.004
   Yao Q, 2014, CELL BIOCHEM BIOPHYS, V69, P229, DOI 10.1007/s12013 013 9787 1
   Yu XJ, 2016, ONCOL REP, V36, P3611, DOI 10.3892/or.2016.5188
   Yu XJ, 2016, ACTA BIOCH BIOPH SIN, V48, P454, DOI 10.1093/abbs/gmw021
   Zhang DW, 2016, MED SCI MONITOR, V22, P2187, DOI 10.12659/MSM.896690
   Zhao XY, 2017, J AGR FOOD CHEM, V65, P9647, DOI 10.1021/acs.jafc.7b03666
NR 23
TC 8
Z9 8
U1 0
U2 28
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
EI 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD APR 26
PY 2018
VL 24
BP 2569
EP 2577
DI 10.12659/MSM.909651
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GE2XT
UT WOS:000431078700003
PM 29698379
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Liu, ZC
   Yang, K
   Yan, XM
   Wang, TQ
   Jiang, T
   Zhou, Q
   Qi, J
   Qian, ND
   Zhou, HB
   Chen, B
   Huang, P
   Guo, L
   Zhang, XK
   Xu, X
   Jiang, M
   Deng, L
AF Liu, Zhuochao
   Yang, Kai
   Yan, Xueming
   Wang, Tianqi
   Jiang, Tao
   Zhou, Qi
   Qi, Jin
   Qian, Niandong
   Zhou, Hanbing
   Chen, Bo
   Huang, Ping
   Guo, Lei
   Zhang, Xingkai
   Xu, Xing
   Jiang, Min
   Deng, Lianfu
TI The effects of tranylcypromine on osteoclastogenesis in vitro and
   in vivo
SO FASEB JOURNAL
LA English
DT Article
DE osteoclasts; monoamine oxidase inhibitor; bone loss
ID DIFFERENTIATION; INHIBITORS; CANCER; DERIVATIVES; ACTIVATION; LSD1;
   EXPRESSION; DENOSUMAB; DRUGS; NFAT2
AB Identification of anti osteoclastogenic agents is important for the treatment of bone loss diseases that feature excessive osteoclast (OC) activity and bone resorption. Tranylcypromine (TCP), an irreversible inhibitor of monoamine oxidase (MAO), has been used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders. TCP has been discovered to exert anabolic effect on osteoblasts, and MAO A has also been verified as an important mediator in prostate cancer cells to accelerate osteoclastogenesis. In current study, we were focused on TCP and MAO A effects on osteoclastogenesis. As illustrated by tartrate resistant acid phosphatase staining, TCP was capable of inhibiting osteoclastogenesis induced by receptor activators of the NF kappa B ligand (RANKL) in bone marrow derived macrophage cells without any cytotoxicity. It was also shown to effectively suppress bone resorption of OCs. The subsequent study revealed that TCP inhibited osteoclastogenesis related genes in a time dependent manner through protein kinase B (AKT) mediated mechanism followed by the nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) c fos pathway. And TCP could overcome the osteoclastogenic effects of AKT activator SC79. In addition, our results indicated that the expression and catalytic activity of MAO A were up regulated by RANKL stimulation and down regulated by TCP in vitro and in vivo. Furthermore, the effects of MAO A knockdown on OC differentiation indicated that MAO A played an important role in osteoclastogenesis in vitro and might contribute to the inhibitory effects of TCP. And AKT, NFATc1, and c fos were involved in the MAO A pathway. Notably, our in vivo study reflected that TCPs were capable of restoring the bone loss in LPS induced calvaria osteolysis and estrogen deficiency induced osteoporosis models. Thus, our current work provided a potential option for the treatment of bone loss diseases and highlighted the important role of MAO A in osteoclastogenesis as well. Liu, Z., Yang, K., Yan, X., Wang, T., Jiang, T., Zhou, Q., Qi, J., Qian, N., Zhou, H., Chen, B., Huang, P., Guo, L., Zhang, X., Xu, X., Jiang, M., Deng, L. The effects of tranylcypromine on osteoclastogenesis in vitro and in vivo.
C1 [Liu, Zhuochao; Yang, Kai; Yan, Xueming; Wang, Tianqi; Jiang, Tao; Zhou, Qi; Qi, Jin; Qian, Niandong; Zhou, Hanbing; Chen, Bo; Huang, Ping; Guo, Lei; Xu, Xing; Jiang, Min; Deng, Lianfu] Shanghai Jiao Tong Univ, Shanghai Key Lab Bone & Joint Dis, Shanghai Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed,Sch Med, Shanghai, Peoples R China.
   [Liu, Zhuochao; Zhang, Xingkai] Shanghai Jiao Tong Univ, Sch Med, Shanghai Ruijin Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Jiang, Tao] Shanghai Jiao Tong Univ, Sch Med, Shanghai Ruijin Hosp, Dept Traumatol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Xu, X; Jiang, M (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
EM xuxing0510315@126.com; jiangm263@163.com
RI Zhou, Han/ISU 2803 2023; Yang, Kai/JQW 2039 2023; guo,
   leixin/HPF 6884 2023; Zhou, Qi/JGM 4026 2023; Wang, Tianqi/KIC 1831 2024
OI Jiang, Min/0000 0003 1530 6830; Yang, Kai/0000 0002 5544 7817; 
FU Natural Science Foundation of China [81703576, 81502902]; Shanghai
   Municipal Health Bureau Young Scientific Research Project [20154Y0005,
   201840185]; Committee of Science and Technology Young Scientific
   Research Foundation of Shanghai [16ZR1431900]; Natural Science
   Foundation of Shanghai [17140901800]; Ruijing Young Talent Program
   [GCQN 2017 A16, GCQN 2017 B22]
FX This work was supported by the Natural Science Foundation of China
   (81703576, 81502902), Shanghai Municipal Health Bureau Young Scientific
   Research Project (20154Y0005, 201840185), Committee of Science and
   Technology Young Scientific Research Foundation of Shanghai
   (16ZR1431900), Natural Science Foundation of Shanghai (17140901800), and
   Ruijing Young Talent Program (GCQN 2017 A16, GCQN 2017 B22). The authors
   declare no conflicts of interest.
CR Altar CA, 2003, BIOL PSYCHIAT, V54, P703, DOI 10.1016/S0006 3223(03)00073 8
   Anagnostis P, 2015, CLIMACTERIC, V18, P32, DOI 10.3109/13697137.2015.1099092
   [Anonymous], CHEM ECOL, DOI DOI 10.3389/FNEUR.2017.00626]
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Battaglino R, 2004, J BONE MINER RES, V19, P1420, DOI 10.1359/JBMR.040606
   Binda C, 2010, J AM CHEM SOC, V132, P6827, DOI 10.1021/ja101557k
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown JP, 2014, CAN FAM PHYSICIAN, V60, P324
   BURGER A, 1948, J AM CHEM SOC, V70, P2198, DOI 10.1021/ja01186a062
   Campas Clara, 2009, Drug News Perspect, V22, P126, DOI 10.1358/dnp.2009.22.2.1334453
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Duan YC, 2017, EUR J MED CHEM, V140, P392, DOI 10.1016/j.ejmech.2017.09.038
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Gokosmanoglu F, 2016, J RES MED SCI, V21, DOI 10.4103/1735 1995.193503
   Halleen JM, 2006, CLIN LAB, V52, P499
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Ivy AS, 2003, PHARMACOL BIOCHEM BE, V75, P81, DOI 10.1016/S0091 3057(03)00044 3
   Jones LH, 2017, NAT REV DRUG DISCOV, V16, P285, DOI 10.1038/nrd.2016.244
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506
   Koide M, 2017, J BONE MINER RES, V32, P2074, DOI 10.1002/jbmr.3175
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Metozzi A, 2015, EXPERT REV ENDOCRINO, V10, P153, DOI 10.1586/17446651.2015.979787
   Mollard E, 2018, INT J WOMENS HEALTH, V10, P1, DOI 10.2147/IJWH.S147006
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Poole L, 2018, J PSYCHOSOM RES, V113, P30, DOI 10.1016/j.jpsychores.2018.07.009
   Sawant A, 2013, CANCER RES, V73, P672, DOI 10.1158/0008 5472.CAN 12 2202
   Schulz Fincke J, 2018, EUR J MED CHEM, V144, P52, DOI 10.1016/j.ejmech.2017.12.001
   Shi CG, 2016, J BONE MINER RES, V31, P1003, DOI 10.1002/jbmr.2770
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Strittmatter SM, 2014, NAT MED, V20, P590, DOI 10.1038/nm.3595
   Sun J, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0015 x
   Sun K, 2017, BIOORG MED CHEM LETT, V27, P5036, DOI 10.1016/j.bmcl.2017.10.003
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Ulrich S, 2017, EUR NEUROPSYCHOPHARM, V27, P697, DOI 10.1016/j.euroneuro.2017.05.007
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Xu X, 2016, EUR J MED CHEM, V123, P769, DOI 10.1016/j.ejmech.2016.08.004
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zheng YC, 2016, CURR TOP MED CHEM, V16, P2179, DOI 10.2174/1568026616666160216154042
NR 49
TC 14
Z9 15
U1 0
U2 21
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD SEP
PY 2019
VL 33
IS 9
BP 9828
EP 9841
DI 10.1096/fj.201802242RR
PG 14
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA IS5TA
UT WOS:000482214200012
PM 31291555
DA 2025 08 17
ER

PT J
AU Chang, XC
   Deng, J
   Zhou, FY
   Geng, ZH
   Li, X
   Wang, S
AF Chang, Xiaochi
   Deng, Jing
   Zhou, Fengyi
   Geng, Zhihao
   Li, Xin
   Wang, Shuai
TI D alanine suppressed osteoclastogenesis derived from bone marrow
   macrophages and downregulated ERK/p38 signalling pathways
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE D alanine; Bone marrow derived macrophages; Osteoclastogenesis; MAPK
   signalling pathways; Sema4D
ID LIPOTEICHOIC ACID; ENTEROCOCCUS FAECALIS; DIFFERENTIATION; EXPRESSION;
   NFATC1; SERINE; CELLS
AB Objectives: D alanine is a residue of the backbone structure of Type I Lipoteichoic acid (LTA), which is a virulence factor in inflammation caused by gram positive bacteria. However, the role of D alanine in infectious bone destruction has not been investigated. We aimed to explore the role of D alanine in the proliferation, apoptosis, and differentiation of osteoclasts. Design: Mouse bone marrow derived macrophages (BMMs) were isolated as osteoclast precursors and stimulated with D alanine. Cell proliferation and apoptosis were detected using CCK 8 and flow cytometry, respectively. The formation of osteoclasts morphologically observed by tartrate resistant acid phosphatase staining (TRAP) and immunofluorescence staining. The expressions of osteoclastogenic genes were measured by real time RT PCR. The protein expressions of osteoclastogenic markers, p38, and ERK1/2 MAPK signalling were measured by western blot. The expression level of soluble Sema4D was detected via enzyme linked immunosorbent assay (ELISA). Results: The cell proliferation of BMMs was significantly inhibited by D alanine in a dose dependent manner. Apoptosis of BMMs was markedly activated with the stimulation of D alanine. The differentiation of BMMs into osteoclasts was significantly inhibited by D alanine, and the gene and protein expressions of NFATc1, c Fos, and Blimp decreased. Western blot showed that D alanine inhibited the phosphorylated p38 and ERK1/2 signalling pathways of BMMs. Moreover, the expression level of soluble Sema4D significantly decreased in the supernatant of BMMs due to the D alanine intervention. Conclusion: D alanine plays a pivotal role in the inhibition of RANKL induced osteoclastogenesis and might become a potential therapeutic drug for bone resorptive diseases.
C1 [Chang, Xiaochi] Peking Univ, Dept Periodontol, Sch & Hosp Stomatol, Beijing, Peoples R China.
   [Chang, Xiaochi; Deng, Jing; Geng, Zhihao; Wang, Shuai] Qingdao Univ, Dept Stomatol, Affiliated Hosp, Qingdao, Peoples R China.
   [Deng, Jing; Zhou, Fengyi; Wang, Shuai] Qingdao Univ, Sch Stomatol, Qingdao, Peoples R China.
   [Zhou, Fengyi] 971 Hosp PLA Navy, Dept Gastroenterol, Qingdao, Peoples R China.
   [Li, Xin] Shenzhen Univ, Clin Med Acad, Dept Stomatol, Gen Hosp, Shenzhen, Guangdong, Peoples R China.
   [Li, Xin] Shenzhen Univ, Inst Stomatol Res, Shenzhen, Peoples R China.
   [Wang, Shuai] Qingdao Univ, Dept Stomatol, Affiliated Hosp, Sch Stomatol, Qingdao 266003, Shandong, Peoples R China.
C3 Peking University; Qingdao University; Qingdao University; Shenzhen
   University; Shenzhen University; Qingdao University
RP Li, X (通讯作者)，Shenzhen Univ, Clin Med Acad, Dept Stomatol, Gen Hosp, Shenzhen, Guangdong, Peoples R China.; Wang, S (通讯作者)，Qingdao Univ, Dept Stomatol, Affiliated Hosp, Sch Stomatol, Qingdao 266003, Shandong, Peoples R China.
EM lizn007@126.com; wangshuai0920@sina.com
RI wang, shuai/AEK 5112 2022
OI Wang, Shuai/0000 0002 2666 5233; Chang, Xiaochi/0000 0002 1760 6856
FU Qingdao Application and Basic Research Fund For Youth [19 6  2 37  cg];
   Science Technology and Innovation Committee of Shenzhen Municipality
   [20220810163811002]; Research Fund for Overseas High level Talents of
   Shenzhen [RC00336]
FX The authors are grateful to Qian Wen (Biomedical Center, Qingdao
   University) for her assistance in flow cytometry. This study was sup 
   ported by Qingdao Application and Basic Research Fund For Youth (Grant
   No.: 19 6  2 37  cg) , the Science Technology and Innovation Committee
   of Shenzhen Municipality (Grant No. 20220810163811002) and the Research
   Fund for Overseas High level Talents of Shenzhen (Grant No.: RC00336) .
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Baik JE, 2008, J ENDODONT, V34, P975, DOI 10.1016/j.joen.2008.05.005
   Belibasakis GN, 2011, APMIS, V119, P167, DOI 10.1111/j.1600 0463.2010.02706.x
   Bharatiya B, 2021, COLLOID SURFACE B, V199, DOI 10.1016/j.colsurfb.2020.111551
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chung JH, 2014, J PERIODONTAL RES, V49, P563, DOI 10.1111/jre.12136
   Ding D, 2022, INT J MOL MED, V49, DOI 10.3892/ijmm.2021.5059
   Fabretti F, 2006, INFECT IMMUN, V74, P4164, DOI 10.1128/IAI.00111 06
   Hasty DL, 2006, J IMMUNOL, V176, P5567, DOI 10.4049/jimmunol.176.9.5567
   Hu CC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155550
   Ishihata K, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232012633
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kwon Y, 2023, J CELL PHYSIOL, V238, P2425, DOI 10.1002/jcp.31099
   Li Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691013
   Liu X, 2017, BIOCHEM BIOPH RES CO, V485, P421, DOI 10.1016/j.bbrc.2017.02.062
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Morath S, 2005, J ENDOTOXIN RES, V11, P348, DOI 10.1179/096805105X67328
   Nardone V, 2014, CLINICS, V69, P438, DOI 10.6061/clinics/2014(06)12
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Nishikaw K, 2010, P NATL ACAD SCI USA, V107, P3117, DOI 10.1073/pnas.0912779107
   Park OJ, 2015, J ENDODONT, V41, P1480, DOI 10.1016/j.joen.2015.04.025
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Stuart CH, 2006, J ENDODONT, V32, P93, DOI 10.1016/j.joen.2005.10.049
   Takarada T, 2012, J CELL PHYSIOL, V227, P3477, DOI 10.1002/jcp.24048
   Tian YG, 2013, J ENDODONT, V39, P632, DOI 10.1016/j.joen.2012.12.019
   Tobeiha M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6910312
   Tominari T, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 92744 5
   Villéger R, 2014, ANTON LEEUW INT J G, V106, P693, DOI 10.1007/s10482 014 0239 8
   Wang S, 2019, INNATE IMMUN LONDON, V25, P13, DOI 10.1177/1753425918812646
   Wang S, 2015, INNATE IMMUN LONDON, V21, P726, DOI 10.1177/1753425915593162
   Yang JY, 2016, J ENDODONT, V42, P570, DOI 10.1016/j.joen.2016.01.012
   Yang LH, 2000, NEUROSCI LETT, V295, P97, DOI 10.1016/S0304 3940(00)01597 4
   Zeng Yanglin, 2023, J Endod, V49, P62, DOI 10.1016/j.joen.2022.10.003
   Zhang C, 2010, INT ENDOD J, V43, P109, DOI 10.1111/j.1365 2591.2009.01649.x
NR 39
TC 2
Z9 2
U1 1
U2 25
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD MAY
PY 2024
VL 161
AR 105912
DI 10.1016/j.archoralbio.2024.105912
EA FEB 2024
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA MX6L8
UT WOS:001196973800001
PM 38382164
DA 2025 08 17
ER

PT J
AU Zhang, S
   Xie, YL
   Yan, FF
   Zhang, YF
   Yang, ZQ
   Chen, Z
   Zhao, Y
   Huang, Z
   Cai, L
   Deng, ZM
AF Zhang, Sheng
   Xie, Yuanlong
   Yan, Feifei
   Zhang, Yufeng
   Yang, Zhiqiang
   Chen, Zhe
   Zhao, Yong
   Huang, Zan
   Cai, Lin
   Deng, Zhouming
TI Negative pressure wound therapy improves bone regeneration by promoting
   osteogenic differentiation via the AMPK ULK1 autophagy axis
SO AUTOPHAGY
LA English
DT Article
DE AMPK; bone nonunion; bone regeneration; macroautophagy; autophagy;
   mesenchymal stem cells; negative pressure wound therapy; osteoblast
   differentiation; ULK1
ID MESENCHYMAL STEM CELLS; NON UNIONS; R PACKAGE; AMPK; PHOSPHORYLATION;
   AUTOPHAGY; SIZE; PROLIFERATION; MECHANISMS; GUIDELINES
AB Deficient bone regeneration causes bone defects or nonunion in a substantial proportion of trauma patients that urges for novel therapies. To develop a reliable therapy, we investigated the effect of negative pressure wound therapy (NPWT) on bone regeneration in vivo in a rat calvarial defect model. Negative pressure (NP) treatment in vitro was mimicked to test its effect on osteoblast differentiation in rat mesenchymal stem cells (MSCs) and MC3T3 E1 cells. Transcriptomic analyses, pharmaceutical interventions, and shRNA knockdowns were conducted to explore the underlying mechanism and their clinical relevance was investigated in samples from patients with nonunion. The potential application of a combined therapy of MSCs in hydrogels with negative pressure was tested in the rat critical size calvarial defect model. We found that NPWT promoted bone regeneration in vivo and NP treatment induced osteoblast differentiation in vitro. NP induced osteogenesis via activating macroautophagy/autophagy by AMPK ULK1 signaling that was impaired in clinical samples from patients with nonunion. More importantly, the combined therapy involving MSCs in hydrogels with negative pressure significantly improved bone regeneration in rat critical size calvarial defect model. Thus, our study identifies a novel AMPK ULK1 autophagy axis by which negative pressure promotes osteoblast differentiation of MSCs and bone regeneration. NPWT treatment can potentially be adopted for therapy of bone defects.
C1 [Zhang, Sheng; Xie, Yuanlong; Yan, Feifei; Zhang, Yufeng; Yang, Zhiqiang; Chen, Zhe; Zhao, Yong; Cai, Lin; Deng, Zhouming] Wuhan Univ, Dept Orthoped, Zhongnan Hosp, 163 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.
   [Huang, Zan] Wuhan Univ, Dept Biochem, Key Lab Cell Hemostasis Hubei Prov, Coll Life Sci, Wuhan, Hubei, Peoples R China.
   [Huang, Zan] Shanghai Childrens Hosp, Nhc Key Lab Med Embryogenesis & Dev Mol Biol, Shanghai Key Lab Embryo & Reprod Engn, Shanghai, Peoples R China.
C3 Wuhan University; Wuhan University; Shanghai Jiao Tong University
RP Cai, L; Deng, ZM (通讯作者)，Wuhan Univ, Dept Orthoped, Zhongnan Hosp, 163 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.; Huang, Z (通讯作者)，Wuhan Univ, Coll Life Sci, Key Lab Cell Hemostasis Hubei Prov, 299 Bayi Rd, Wuhan 430072, Hubei, Peoples R China.
EM z huang@whu.edu.cn; orthopedics@whu.edu.cn; dengzhouming@foxmail.com
RI ; Zhang, shuyuan/IUN 4098 2023; Xie, Yuanlong/V 7190 2019; Yan,
   Feifei/GRX 6364 2022; Zhang, Yufeng/GZL 1973 2022
OI Zhang, Yufeng/0000 0003 3610 5229; Deng, Zhouming/0000 0003 3052 6241; 
FU National Natural Science Foundation of China [81870162, 81870427,
   81702150]
FX This work was supported by the National Natural Science Foundation of
   China [81870162]; National Natural Science Foundation of China
   [81870427]; National Natural Science Foundation of China [81702150].
CR Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159 11
   Baldwin C, 2009, ANN PLAS SURG, V62, P92, DOI 10.1097/SAP.0b013e31817762fd
   Bishop JA, 2012, J AM ACAD ORTHOP SUR, V20, P273, DOI 10.5435/JAAOS 20 05 273
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005
   Carling D, 2011, NAT CHEM BIOL, V7, P512, DOI [10.1038/NCHEMBIO.610, 10.1038/nchembio.610]
   Deng ZM, 2014, ARCH MED SCI, V10, P764, DOI 10.5114/aoms.2013.34411
   Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123
   Garg P, 2017, ORTHOP SURG, V9, P13, DOI 10.1111/os.12304
   Giannoudis PV, 2016, INJURY, V47, pS53, DOI 10.1016/S0020 1383(16)30840 3
   Giannoudis PV, 2015, INJURY, V46, pS48, DOI 10.1016/S0020 1383(15)30055 3
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hadjiargyrou M, 2014, J BONE MINER RES, V29, P2307, DOI 10.1002/jbmr.2373
   Han YJ, 2019, J CLIN INVEST, V129, P1895, DOI 10.1172/JCI124590
   Hardie DG, 2012, CHEM BIOL, V19, P1222, DOI 10.1016/j.chembiol.2012.08.019
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Hsu CC, 2013, J DERMATOL SCI, V70, P196, DOI 10.1016/j.jdermsci.2013.03.007
   Iheozor Ejiofor Z, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012522.pub2
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Ivanovska IL, 2015, TRENDS CELL BIOL, V25, P523, DOI 10.1016/j.tcb.2015.04.003
   Jaber FA, 2019, J CELL PHYSIOL, V234, P12105, DOI 10.1002/jcp.27071
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587 019 0201 4
   Kim J, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.16
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kusumbe AP, 2015, NAT PROTOC, V10, P1904, DOI 10.1038/nprot.2015.125
   Leininger BE, 2006, J TRAUMA, V61, P1207, DOI 10.1097/01.ta.0000241150.15342.da
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp698, 10.1093/bioinformatics/btp352]
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Marsh D, 1998, CLIN ORTHOP RELAT R, pS22
   McNulty AK, 2007, WOUND REPAIR REGEN, V15, P838, DOI 10.1111/j.1524 475X.2007.00287.x
   Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708
   Nauth A, 2018, J ORTHOP TRAUMA, V32, pS7, DOI 10.1097/BOT.0000000000001115
   Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094
   Panteli M, 2015, J CELL MOL MED, V19, P685, DOI 10.1111/jcmm.12532
   Pelaez D, 2012, BIOCHEM BIOPH RES CO, V417, P1286, DOI 10.1016/j.bbrc.2011.12.131
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Schemitsch EH, 2017, J ORTHOP TRAUMA, V31, pS20, DOI 10.1097/BOT.0000000000000978
   Sinclair KL, 2017, CURR STEM CELL RES T, V12, P312, DOI 10.2174/1574888X11666160614104500
   So E, 2018, J FOOT ANKLE SURG, V57, P776, DOI 10.1053/j.jfas.2018.01.002
   Spicer PP, 2012, NAT PROTOC, V7, P1918, DOI 10.1038/nprot.2012.113
   Steward AJ, 2015, J ANAT, V227, P717, DOI 10.1111/joa.12243
   Toosi S, 2020, BIOFACTORS, V46, P326, DOI 10.1002/biof.1598
   Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Xie YL, 2019, INT J BIOL MACROMOL, V133, P137, DOI 10.1016/j.ijbiomac.2019.04.016
   Yang Z, 2014, MOL MED REP, V9, P1331, DOI 10.3892/mmr.2014.1968
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
   Zhu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107339
NR 51
TC 65
Z9 68
U1 9
U2 82
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554 8627
EI 1554 8635
J9 AUTOPHAGY
JI Autophagy
PD SEP 2
PY 2022
VL 18
IS 9
BP 2229
EP 2245
DI 10.1080/15548627.2021.2016231
EA DEC 2021
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 3X3NQ
UT WOS:000735815300001
PM 34964701
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Sun, YY
   Zhao, J
   Ji, ZL
AF Sun, Yanyan
   Zhao, Jian
   Ji, Zhongling
TI Bifunctional Platinum(II) Complexes with Bisphosphonates Substituted
   Diamine Derivatives: Synthesis and In vitro Cytotoxicity
SO CHEMISTRY & BIODIVERSITY
LA English
DT Article
DE Bisphosphonates; Platinum(II) complexes; Cytotoxicity; Hydroxyapatite
   affinity; Apoptosis
ID BIOLOGICAL EVALUATION; ANTICANCER AGENTS; HIGH AFFINITY; HYDROXYAPATITE;
   DRUGS; LIGANDS; BLOCKS; MATRIX; ESTERS; CELLS
AB A series of N,N dibisphosphonate containing 1,3 propanediamine derivatives (L1   L6) and their corresponding dichloridoplatinum(II) complexes (1   6) have been synthesized and characterized by elemental analysis, H 1 NMR, C 13 NMR, P 31 NMR and HR MS spectra. The in vitro antitumor activities of compounds L1   L6 and 1   6 were tested by WST 8 assay with Cell Counting Kit 8, indicating that platinum based complexes 1   6 showed higher cytotoxicity than corresponding ligands L1   L6 against A549 and MG 63, especially complex 2 which displayed comparable cytotoxicity to those of cisplatin and zoledronate after 48 h incubation. In addition, complexes 1   6 were more active in vitro on osteosarcoma cell line MG 63 than normal osteoblast cell line hFOB 1.19. The structure activity relationship has been summarized based on the in vitro cytotoxicity of three series of platinum complexes from this and our previous studies. The in vitro bone affinity of platinum complexes was also tested by hydroxyapatite (HAP) chromatography in terms of capacity factor K. Besides, in this paper, representative complex 2, which has been proved to be a promising antitumor agent with high cytotoxicity and bone HAP binding property, was investigated for its mechanism of action producing cell death against MG 63.
C1 [Sun, Yanyan; Ji, Zhongling] Suzhou Univ Sci & Technol, Sch Chem Biol & Mat Engn, Suzhou 215009, Peoples R China.
   [Zhao, Jian] Southeast Univ, Sch Chem & Chem Engn, Nanjing 211189, Jiangsu, Peoples R China.
C3 Suzhou University of Science & Technology; Southeast University   China
RP Sun, YY (通讯作者)，Suzhou Univ Sci & Technol, Sch Chem Biol & Mat Engn, Suzhou 215009, Peoples R China.; Zhao, J (通讯作者)，Southeast Univ, Sch Chem & Chem Engn, Nanjing 211189, Jiangsu, Peoples R China.
EM sunyy0628@163.com; zhaojianzhaokuan@163.com
RI Zhao, Jian/D 2798 2012
OI Zhao, Jian/0000 0002 9365 7727
FU National Natural Science Foundation of China [21401137, 21601034];
   Science and Technology Project of Suzhou (Agriculture), China
   [SYN201415]; College and Institute's High level Elite Project of Suzhou,
   China
FX This study is supported by National Natural Science Foundation of China
   (No. 21401137, No. 21601034) and Science and Technology Project of
   Suzhou (Agriculture) (SYN201415), China. Sun also appreciates very much
   the financial support from the College and Institute's High level Elite
   Project of Suzhou, China.
CR Bohacek RS, 2001, J MED CHEM, V44, P660, DOI 10.1021/jm0002681
   Bortolini O, 2012, EUR J MED CHEM, V52, P221, DOI 10.1016/j.ejmech.2012.03.020
   Bose RN, 2008, P NATL ACAD SCI USA, V105, P18314, DOI 10.1073/pnas.0803094105
   Galanski M, 2003, J MED CHEM, V46, P4946, DOI 10.1021/jm0308040
   Gao CZ, 2016, MINI REV MED CHEM, V16, P872, DOI 10.2174/1389557516666151120115947
   Guo ZJ, 1999, ANGEW CHEM INT EDIT, V38, P1513
   Hochdörffer K, 2012, J MED CHEM, V55, P7502, DOI 10.1021/jm300493m
   Hoechst F., 1967, FR, Patent No. [1554236, 1967, 1554236]
   Huang KB, 2013, EUR J MED CHEM, V64, P554, DOI 10.1016/j.ejmech.2013.04.024
   Jakupec MA, 2008, DALTON T, P183, DOI 10.1039/b712656p
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   KLENNER T, 1990, CANCER TREAT REV, V17, P253, DOI 10.1016/0305 7372(90)90056 L
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Mao JF, 2009, CHEM COMMUN, P908, DOI 10.1039/b817968a
   Margiotta N, 2007, DALTON T, P3131, DOI 10.1039/b705239a
   Margiotta N, 2011, J INORG BIOCHEM, V105, P548, DOI 10.1016/j.jinorgbio.2010.12.011
   Margiotta N, 2009, DALTON T, P10904, DOI 10.1039/b919721d
   Margiotta N, 2008, J INORG BIOCHEM, V102, P2078, DOI 10.1016/j.jinorgbio.2008.07.008
   Papapoulos SE, 2006, BONE, V38, P613, DOI 10.1016/j.bone.2006.01.141
   Piccinonna S, 2012, DALTON T, V41, P9689, DOI 10.1039/c2dt30712j
   Qiu L, 2016, MOLECULES, V21, DOI 10.3390/molecules21030255
   Qiu L, 2015, J BIOL INORG CHEM, V20, P1263, DOI 10.1007/s00775 015 1305 z
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Sasanelli R, 2007, J MED CHEM, V50, P3434, DOI 10.1021/jm061435l
   Shen CC, 2013, INT J MOL MED, V32, P448, DOI 10.3892/ijmm.2013.1399
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Sun YY, 2017, BIOORG MED CHEM LETT, V27, P1070, DOI 10.1016/j.bmcl.2016.12.050
   Sun YY, 2017, INORG CHIM ACTA, V457, P46, DOI 10.1016/j.ica.2016.12.006
   van Zutphen S, 2005, COORDIN CHEM REV, V249, P2845, DOI 10.1016/j.ccr.2005.03.005
   Wild A, 2012, CHEM COMMUN, V48, P6357, DOI 10.1039/c2cc31275a
   Wilson JJ, 2012, J MED CHEM, V55, P5326, DOI 10.1021/jm3002857
   Xing RM, 2009, DALTON T, P1710, DOI 10.1039/b900256c
   Xue ZQ, 2010, CHEM COMMUN, V46, P1212, DOI 10.1039/b922222g
   Yang H, 2016, TUMOR BIOL, V37, P10981, DOI 10.1007/s13277 016 4977 2
   Yang Z, 2007, CHEM COMMUN, P3453, DOI 10.1039/b705326f
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zhao YM, 2006, DALTON T, P2617, DOI 10.1039/b601739h
NR 37
TC 13
Z9 13
U1 1
U2 18
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1612 1872
EI 1612 1880
J9 CHEM BIODIVERS
JI Chem. Biodivers.
PD DEC
PY 2017
VL 14
IS 12
AR e1700348
DI 10.1002/cbdv.201700348
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FQ5SR
UT WOS:000418421800014
PM 28975737
DA 2025 08 17
ER

PT J
AU Damron, TA
   Zhang, ML
   Pritchard, MR
   Middleton, FA
   Horton, JA
   Margulies, BM
   Strauss, JA
   Farnum, CE
   Spadaro, JA
AF Damron, Timothy A.
   Zhang, Mingliang
   Pritchard, Meredith R.
   Middleton, Frank A.
   Horton, Jason A.
   Margulies, Bryan M.
   Strauss, Judith A.
   Farnum, Cornelia E.
   Spadaro, Joseph A.
TI MICROARRAY CLUSTER ANALYSIS OF IRRADIATED GROWTH PLATE ZONES FOLLOWING
   LASER MICRODISSECTION
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
DE Growth plate; Microarray; Chondrocytes; Rat; Irradiation
ID RADIATION INDUCED DAMAGE; RADIOPROTECTANT DRUGS; CHILDHOOD TUMORS;
   UP REGULATION; THERAPY; PHYSIS; PROLIFERATION; RAT
AB Purpose: Genes and pathways involved in early growth plate chondrocyte recovery after fractionated irradiation were sought as potential targets for selective radiorecovery modulation.
   Materials and Methods: Three groups of six 5 week male Sprague Dawley rats underwent fractionated irradiation to the right tibiae over 5 days, totaling 17.5 Gy, and then were killed at 7, 11, and 16 days after the first radiotherapy fraction. The growth plates were collected from the proximal tibiae bilaterally and subsequently underwent laser microdissection to separate reserve, perichondral, proliferative, and hypertrophic zones. Differential gene expression was analyzed between irradiated right and nonirradiated left tibia using RAE230 2.0 GeneChip microarray, compared between zones and time points and subjected to functional pathway cluster analysis with real time polymerase chain reaction to confirm selected results.
   Results: Each zone had a number of pathways showing enrichment after the pattern of hypothesized importance to growth plate recovery, yet few met the strictest criteria. The proliferative and hypertrophic zones showed both the greatest number of genes with a 10 fold right/left change at 7 days after initiation of irradiation and enrichment of the most functional pathways involved in bone, cartilage, matrix, or skeletal development. Six genes confirmed by real time polymerase chain reaction to have early upregulation included insulin like growth factor 2, procollagen type I alpha 2, matrix metallopeptidase 9, parathyroid hormone receptor 1, fibromodulin, and aggrecan 1.
   Conclusions: Nine overlapping pathways in the proliferative and hypertrophic zones (skeletal development, ossification, bone remodeling, cartilage development, extracellular matrix structural constituent, proteinaceous extracellular matrix, collagen, extracellular matrix, and extracellular matrix part) may play key roles in early growth plate radiorecovery. (C) 2009 Elsevier Inc.
C1 [Damron, Timothy A.] SUNY Upstate Med Univ, Dept Orthoped Surg, Syracuse, NY 13202 USA.
   [Spadaro, Joseph A.] Cornell Univ, Ithaca, NY USA.
C3 State University of New York (SUNY) System; SUNY Upstate Medical
   University; Cornell University
RP Damron, TA (通讯作者)，SUNY Upstate Med Univ, Dept Orthoped Surg, Suite 130,550 Harrison St, Syracuse, NY 13202 USA.
EM damront@upstate.edu
RI Damron, Timothy/AAE 5816 2020
OI Horton, Jason A/0000 0003 3396 5063; Middleton,
   Frank/0000 0002 3107 7188
FU National Institutes of Health (National Cancer Institute) [RO1 CA83892]
FX Supported by National Institutes of Health (National Cancer Institute)
   grant RO1 CA83892 and David G. Murray Endowed Professorship.
CR BUTLER MS, 1990, CLIN ORTHOP RELAT R, P235
   Damron TA, 2006, RADIAT RES, V165, P350, DOI 10.1667/RR3504.1
   Damron TA, 2004, CLIN ORTHOP RELAT R, P233, DOI 10.1097/01.blo.0000129344.28160.9d
   Damron TA, 2004, INT J RADIAT BIOL, V80, P217, DOI 10.1080/09553000410001669524
   Damron TA, 2004, J HISTOCHEM CYTOCHEM, V52, P157, DOI 10.1177/002215540405200203
   Damron TA, 2003, J BONE JOINT SURG AM, V85A, P1302, DOI 10.2106/00004623 200307000 00017
   Damron TA, 2000, INT J CANCER, V90, P73, DOI 10.1002/(SICI)1097 0215(20000420)90:2<73::AID IJC3>3.3.CO;2 5
   GOLDWEIN JW, 1991, CLIN ORTHOP RELAT R, P101
   Horton JA, 2006, J ORTHOP RES, V24, P1945, DOI 10.1002/jor.20251
   Margulies BS, 2006, CALCIFIED TISSUE INT, V78, P302, DOI 10.1007/s00223 005 0135 3
   Margulies Bryan, 2003, Am J Clin Oncol, V26, pe106, DOI 10.1097/00000421 200308000 00032
   ROBERTSON WW, 1991, J PEDIATR ORTHOPED, V11, P284
   Spadaro JA, 2005, INT J RADIAT BIOL, V81, P759, DOI 10.1080/09553000500495710
   Spadaro JA, 2003, J PEDIATR ORTHOPED, V23, P35, DOI 10.1097/00004694 200301000 00007
   Tamurian RM, 1999, J ORTHOPAED RES, V17, P286, DOI 10.1002/jor.1100170219
   Wang Y, 2007, CELLS TISSUES ORGANS, V186, P192, DOI 10.1159/000105673
   Zhang ML, 2008, BONE, V43, P511, DOI 10.1016/j.bone.2008.04.021
   Zhang ML, 2007, CALCIFIED TISSUE INT, V81, P26, DOI 10.1007/s00223 007 9025 1
NR 18
TC 7
Z9 9
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0360 3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUL 1
PY 2009
VL 74
IS 3
BP 949
EP 956
DI 10.1016/j.ijrobp.2008.10.009
PG 8
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 455JJ
UT WOS:000266754800042
PM 19480974
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Conaway, HH
   Henning, P
   Lie, A
   Tuckermann, J
   Lerner, UH
AF Conaway, H. Herschel
   Henning, Petra
   Lie, Anita
   Tuckermann, Jan
   Lerner, Ulf H.
TI Activation of dimeric glucocorticoid receptors in osteoclast progenitors
   potentiates RANKL induced mature osteoclast bone resorbing activity
SO BONE
LA English
DT Article
DE Glucocorticoid; Glucocorticoid receptor; Osteoclast; Bone resorption;
   Osteoporosis
ID MOUSE CALVARIAL BONES; OSTEOBLAST LIKE CELLS; NF KAPPA B; INDUCED
   OSTEOPOROSIS; CORTICOSTEROID THERAPY; VERTEBRAL FRACTURE; RESORPTION;
   OSTEOPROTEGERIN; INHIBITION; DIFFERENTIATION
AB Glucocorticoid (GC) therapy is the greatest risk factor for secondary osteoporosis. Pathogenic mechanisms involve an initial increase in bone resorption followed by decreased bone formation. To gain a better understanding of the resorptive activity of GCs, we have used mouse bone marrow macrophages (BMM) to determine if GCs can directly modulate RANKL stimulated osteoclast formation and/or activity. In agreement with previous studies, experiments performed in plastic wells showed that GCs (dexamethasone, hydrocortisone, and prednisolone) inhibited osteoclast number and size during the initial phases of RANKL stimulated osteoclastogenesis; however, in prolonged cultures, decreased apoptosis was observed and escape from GC induced inhibition occurred with an enhanced number of osteoclasts formed, many with an increased area. When BMM cells were seeded on bone slices, GCs robustly enhanced RANKL stimulated formation of resorption pits and release of CTX without affecting the number or size of osteoclasts formed and with no effect on apoptosis. Stimulation of pit formation was not associated with increased life span of osteoclasts or an effect on mRNA expression of several osteoclastic or osteoclastogenic genes. The potentiation of RANKL induced CTX release by dexamethasone was significantly less in BMM cells from mice with conditional knockout of the osteoclastic glucocorticoid receptor and completely absent in cells from Gem mice, which carry a point mutation in one dimerizing interface of the GC receptor. These data suggest that: 1. Plastic is a poor medium to use for studying direct effects of GCs on osteoclasts 2. GCs can enhance bone resorption without decreasing apoptosis, and 3. A direct enhancement of RANKL mediated resorption is stimulated by the dimeric GC  receptor. (C) 2016 Elsevier Inc All rights reserved.
C1 [Conaway, H. Herschel] Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA.
   [Henning, Petra; Lerner, Ulf H.] Univ Gothenburg, Ctr Bone & Arthrit Res, Dept Internal Med & Clin Nutr, Inst Med,Sahlgrenska Acad, Gothenburg, Sweden.
   [Lie, Anita; Lerner, Ulf H.] Umea Univ, Dept Mol Periodontol, Umea, Sweden.
   [Tuckermann, Jan] Univ Ulm, Inst Comparat Mol Endocrinol, Ulm, Germany.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Gothenburg; Umea University; Ulm University
RP Lerner, UH (通讯作者)，Univ Gothenburg, Ctr Bone & Arthrit Res, Dept Internal Med & Clin Nutr, Inst Med,Sahlgrenska Acad, Gothenburg, Sweden.
EM ulf.lerner@gu.se
RI ; Henning, Petra/KIL 4650 2024
OI Henning, Petra/0000 0002 9330 6265; Lerner, Ulf/0000 0002 3579 1960
FU Swedish Research Council, COMBINE; ALF/LUA research grant in Gothenburg;
   Lundberg Foundation; Swedish Rheumatism Association; Royal 80 Year Fund
   of King Gustav V; Vasterbotten County Council
FX This study was supported by the Swedish Research Council, COMBINE, the
   ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the
   Swedish Rheumatism Association, the Royal 80 Year Fund of King Gustav V,
   and the Vasterbotten County Council. We are grateful for the skillful
   technical assistance by Mrs. Inger Lundgren. We thank Dr. Tim Arnett at
   UCL, London for providing us with the ivory slices.
CR Alatalo SL, 2000, CLIN CHEM, V46, P1751
   Brändström H, 2001, BIOCHEM BIOPH RES CO, V280, P831, DOI 10.1006/bbrc.2000.4223
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   COOPER C, 1995, ANN RHEUM DIS, V54, P49, DOI 10.1136/ard.54.1.49
   DEMPSTER DW, 1989, J BONE MINER RES, V4, P137
   Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397
   Dovio A, 2004, J CLIN ENDOCR METAB, V89, P4923, DOI 10.1210/jc.2004 0164
   Dovio A, 2006, EUR J ENDOCRINOL, V154, P745, DOI 10.1530/eje.1.02147
   Frijters R, 2010, BMC GENOMICS, V11, DOI 10.1186/1471 2164 11 359
   Granholm S, 2007, J ENDOCRINOL, V195, P415, DOI 10.1677/JOE 07 0338
   Granholm S, 2013, BONE, V52, P83, DOI 10.1016/j.bone.2012.09.019
   Hirayama T, 2002, J ENDOCRINOL, V175, P155, DOI 10.1677/joe.0.1750155
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 2009, ARTHRITIS RHEUM, V60, P1427, DOI 10.1002/art.24445
   Hong JM, 2011, J BONE MINER RES, V26, P657, DOI 10.1002/jbmr.241
   Humphrey EL, 2006, BONE, V38, P652, DOI 10.1016/j.bone.2005.10.004
   Jensen PR, 2015, BONE, V73, P16, DOI 10.1016/j.bone.2014.12.004
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Jia JJ, 2011, FASEB J, V25, P3366, DOI 10.1096/fj.11 182519
   JILKA RL, 1986, BONE, V7, P29, DOI 10.1016/8756 3282(86)90149 3
   Kassel O, 2007, MOL CELL ENDOCRINOL, V275, P13, DOI 10.1016/j.mce.2007.07.003
   Kim HJ, 2007, ANN NY ACAD SCI, V1116, P335, DOI 10.1196/annals.1402.057
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kim HJ, 2010, BMB REP, V43, P524, DOI 10.5483/BMBRep.2010.43.8.524
   Lane NE, 2010, ANN NY ACAD SCI, V1192, P81, DOI 10.1111/j.1749 6632.2009.05228.x
   Maresova KB, 2013, CALCIFIED TISSUE INT, V92, P354, DOI 10.1007/s00223 012 9684 4
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Moutsatsou P, 2012, TRENDS MOL MED, V18, P348, DOI 10.1016/j.molmed.2012.04.005
   Naganathan V, 2000, ARCH INTERN MED, V160, P2917, DOI 10.1001/archinte.160.19.2917
   Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007
   Orriss IR, 2012, METHODS MOL BIOL, V816, P103, DOI 10.1007/978 1 61779 415 5_8
   Palmqvist P, 2006, J BIOL CHEM, V281, P2414, DOI 10.1074/jbc.M510160200
   Pasqualetti S, 2015, INT J EXP PATHOL, V96, P11, DOI 10.1111/iep.12106
   PHILIBERT D, 1991, FRONT HORM RES, V19, P1
   Pluijm SMF, 2009, J BONE MINER RES, V24, P768, DOI [10.1359/jbmr.081244, 10.1359/JBMR.081244]
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092 8674(00)81183 6
   Rubin J, 1998, ENDOCRINOLOGY, V139, P1006, DOI 10.1210/en.139.3.1006
   Schwab AM, 2005, ENDOCRINOLOGY, V146, P4349, DOI 10.1210/en.2005 0601
   Shi J, 2015, BONE, V79, P222, DOI 10.1016/j.bone.2015.06.014
   Sivagurunathan S, 2005, J BONE MINER RES, V20, P390, DOI 10.1359/JBMR.041233
   Soares Schanoski A, 2007, J LEUKOCYTE BIOL, V82, P700, DOI 10.1189/jlb.1106673
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Souza PPC, 2013, IMMUNOL INVEST, V42, P555, DOI 10.3109/08820139.2013.822766
   Swanson C, 2006, ENDOCRINOLOGY, V147, P3613, DOI 10.1210/en.2005 0717
   Takayanagi H, 2012, NAT REV RHEUMATOL, V8, P684, DOI 10.1038/nrrheum.2012.167
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teitelbaum SL, 2015, CLIN EXP RHEUMATOL, V33, pS37
   Tuckermann JP, 2007, J CLIN INVEST, V117, P1381, DOI 10.1172/JCI28034
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   Vidal NOA, 1998, J ENDOCRINOL, V159, P191, DOI 10.1677/joe.0.1590191
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang FS, 2013, ARTHRITIS RHEUM US, V65, P1530, DOI 10.1002/art.37948
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
NR 56
TC 48
Z9 51
U1 0
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2016
VL 93
BP 43
EP 54
DI 10.1016/j.bone.2016.08.024
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EA9TL
UT WOS:000386987500005
PM 27596806
DA 2025 08 17
ER

PT J
AU Kumar, S
   Ponnazhagan, S
AF Kumar, Sanjay
   Ponnazhagan, Selvarangan
TI Mobilization of bone marrow mesenchymal stem cells in vivo
   augments bone healing in a mouse model of segmental bone defect
SO BONE
LA English
DT Article
DE Fracture; Stem cells; Osteoinduction; Mobilization
ID GROWTH FACTOR I; COLONY STIMULATING FACTOR; HEMATOPOIETIC STEM;
   PROGENITOR CELLS; PERIPHERAL BLOOD; G CSF; PHOSPHATIDYLINOSITOL
   3 KINASE; INSULIN; AMD3100; REPAIR
AB Although the number of mesenchymal stem cells (MSC) in the bone marrow is sufficient to maintain skeletal homeostasis, in osteopenic pathology, aggravated osteoclast activity or insufficient osteoblast numbers ensue, affecting normal bone remodeling. Most of the currently available therapies are anti resorptive with limited osteogenic potential. Since mobilization of stem/progenitors from the BM is a prerequisite for their participation in tissue repair, amplification of endogenous stem cells may provide an alternative approach in these conditions. The present study determined the potential of MSC mobilization in vivo, using combinations of different growth factors with the CXCR4 antagonist, AMD3100, in a mouse model of segmental bone defect. Results indicated that among several factors tested IGF1 had maximum proliferative ability of MSC in vitro. Results of the in vivo studies indicated that the combination of IGF1 and AMD3100 provided significant augmentation of bone growth as determined by DXA, micro CT and histomorphometry in mice bearing segmental fractures. Further, characterization of MSC isolated from mice treated with IGF1 and AMD3100 indicated Akt/PI3K, MEK1/2 Erk1/2 and smad2/3 as key signaling pathways mediating this effect. These data indicate the potential of in vivo stem cell mobilization as a novel alternative for bone healing. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Kumar, Sanjay; Ponnazhagan, Selvarangan] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Ponnazhagan, S (通讯作者)，Univ Alabama Birmingham, Dept Pathol, LHRB 513,701,19th St S, Birmingham, AL 35294 USA.
EM pons@uab.edu
RI kumar, Sanjay/ITT 3680 2023
FU National Institutes of Health [R01AR50251, R01CA133737, R01AR560948, P30
   AR046031]; U.S. Army Department of Defense [BC101411, BC044440,
   PC050949]
FX Financial support of the National Institutes of Health grants
   R01AR50251, R01CA133737, R01AR560948, P30 AR046031 and the U.S. Army
   Department of Defense grants BC101411, BC044440 and PC050949 is
   gratefully acknowledged.
CR Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF
   Bowie MB, 2006, J CLIN INVEST, V116, P2808, DOI 10.1172/JCI28310
   Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385
   Calandra G, 2008, BONE MARROW TRANSPL, V41, P331, DOI 10.1038/sj.bmt.1705908
   CANALIS E, 1980, J CLIN INVEST, V66, P709, DOI 10.1172/JCI109908
   Capoccia BJ, 2006, BLOOD, V108, P2438, DOI 10.1182/blood 2006 04 013755
   Chavakis E, 2008, J MOL CELL CARDIOL, V45, P514, DOI 10.1016/j.yjmcc.2008.01.004
   Cottler Fox Michele H, 2003, Hematology Am Soc Hematol Educ Program, P419
   De Silvestro G, 2004, HEPATO GASTROENTEROL, V51, P805
   Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661
   FLORINI JR, 1985, J GERONTOL, V40, P2, DOI 10.1093/geronj/40.1.2
   Gallagher KA, 2007, J CLIN INVEST, V117, P1249, DOI 10.1172/JCI29710
   Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856
   GIORGETTI S, 1993, J BIOL CHEM, V268, P7358
   Grey A, 2003, ENDOCRINOLOGY, V144, P4886, DOI 10.1210/en.2003 0350
   HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo 122 1 254
   ISGAARD J, 1986, AM J PHYSIOL, V250, pE367, DOI 10.1152/ajpendo.1986.250.4.E367
   Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150
   Kale S, 2003, J CLIN INVEST, V112, P42, DOI 10.1172/JCI200317856
   Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902
   Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004 0342
   Kumar S, 2007, FASEB J, V21, P3917, DOI 10.1096/fj.07 8275com
   Kumar S, 2010, MOL THER, V18, P1026, DOI 10.1038/mt.2009.315
   Lévesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994
   Levi B, 2010, PLAST RECONSTR SURG, V126, P41, DOI 10.1097/PRS.0b013e3181da8858
   Liu ZJ, 2008, ANTIOXID REDOX SIGN, V10, P1869, DOI 10.1089/ars.2008.2121
   Machalinski B, 2006, FOLIA HISTOCHEM CYTO, V44, P97
   Martin C, 2006, BRIT J HAEMATOL, V134, P326, DOI 10.1111/j.1365 2141.2006.06181.x
   MOCHIZUKI H, 1992, ENDOCRINOLOGY, V131, P1075, DOI 10.1210/en.131.3.1075
   Nolta JA, 2006, GENE THERAPY MESENCH
   Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Pitchford SC, 2009, CELL STEM CELL, V4, P62, DOI 10.1016/j.stem.2008.10.017
   ROBERTS AW, 1995, BLOOD, V86, P1600, DOI 10.1182/blood.V86.4.1600.bloodjournal8641600
   Rojas M, 2005, AM J RESP CELL MOL, V33, P145, DOI 10.1165/rcmb.2004 0330OC
   RUDMAN D, 1981, J CLIN INVEST, V67, P1361, DOI 10.1172/JCI110164
   SCHLECHTER NL, 1986, P NATL ACAD SCI USA, V83, P7932, DOI 10.1073/pnas.83.20.7932
   Shepherd RM, 2006, BLOOD, V108, P3662, DOI 10.1182/blood 2006 06 030577
   Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66
   SPENCER EM, 1991, BONE, V12, P21, DOI 10.1016/8756 3282(91)90050 S
   Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434
   Uchida N, 1997, BLOOD, V89, P465, DOI 10.1182/blood.V89.2.465
   Wengner AM, 2008, BLOOD, V111, P42, DOI 10.1182/blood 2007 07 099648
   Yao R, 1996, ONCOGENE, V13, P343
   Zhang DS, 2008, J MOL CELL CARDIOL, V44, P281, DOI 10.1016/j.yjmcc.2007.11.010
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674
   Zhou YF, 2006, CANCER RES, V66, P10849, DOI 10.1158/0008 5472.CAN 06 2146
NR 48
TC 91
Z9 104
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2012
VL 50
IS 4
BP 1012
EP 1018
DI 10.1016/j.bone.2012.01.027
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 914QU
UT WOS:000301967400026
PM 22342795
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sedghizadeh, PP
   Sun, ST
   Jones, AC
   Sodagar, E
   Cherian, P
   Chen, C
   Junka, AF
   Neighbors, JD
   McKenna, CE
   Russell, RGG
   Ebetino, FH
AF Sedghizadeh, Parish P.
   Sun, Shuting
   Jones, Allan C.
   Sodagar, Esmat
   Cherian, Philip
   Chen, Casey
   Junka, Adam F.
   Neighbors, Jeffrey D.
   McKenna, Charles E.
   Russell, R. Graham G.
   Ebetino, Frank H.
TI Bisphosphonates in dentistry: Historical perspectives, adverse effects,
   and novel applications
SO BONE
LA English
DT Article
DE Bisphosphonate; Pyrophosphate; Dentistry; Bone targeting conjugates
ID MEDICATION RELATED OSTEONECROSIS; NITROGEN CONTAINING BISPHOSPHONATES;
   ORTHODONTIC TOOTH MOVEMENT; MICROBIAL BIOFILMS; RANDOMIZED TRIAL;
   IN VITRO; BONE; JAW; HYDROXYAPATITE; DIPHOSPHONATES
AB Studies of the potential role of bisphosphonates in dentistry date back to physical chemical research in the 1960s, and the genesis of the discovery of bisphosphonate pharmacology in part can be linked to some of this work. Since that time, parallel research on the effects of bisphosphonates on bone metabolism continued, while efforts in the dental field included studies of bisphosphonate effects on dental calculus, caries, and alveolar bone loss. While some utility of this drug class in the dental field was identified, leading to their experimental use in various dentrifice formulations and in some dental applications clinically, adverse effects of bisphosphonates in the jaws have also received attention. Most recently, certain bisphosphonates, particularly those with strong bone targeting properties, but limited biochemical effects (low potency bisphosphonates), are being studied as a local remedy for the concerns of adverse effects associated with other more potent members of this drug class. Additionally, low potency bisphosphonate analogs are under study as vectors to target active drugs to the mineral surfaces of the jawbones. These latter efforts have been devised for the prevention and treatment of oral problems, such as infections associated with oral surgery and implants. Advances in the utility and mechanistic understanding of the bisphosphonate class may enable additional oral therapeutic options for the management of multiple aspects of dental health.
C1 [Sedghizadeh, Parish P.; Sodagar, Esmat; Chen, Casey] Univ Southern Calif, Herman Ostrow Sch Dent, Div Periodontol Diagnost Sci & Dent Hyg, Los Angeles, CA 90007 USA.
   [Sun, Shuting; Cherian, Philip; Neighbors, Jeffrey D.; Ebetino, Frank H.] BioVinc LLC, 2265 E Foothill Blvd, Pasadena, CA 91107 USA.
   [Jones, Allan C.] Gen Dent Practice, Torrance, CA USA.
   [Junka, Adam F.] Med Univ Wroclaw, Dept Pharmaceut Microbiol & Parasitol, Wroclaw, Poland.
   [Junka, Adam F.] Wroclaw Res Ctr EIT, Wroclaw, Poland.
   [Neighbors, Jeffrey D.] Penn State Univ, Coll Med, Dept Pharmacol & Med, Hershey, PA USA.
   [McKenna, Charles E.] Univ Southern Calif, Dept Chem, Los Angeles, CA 90007 USA.
   [Russell, R. Graham G.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford, England.
   [Russell, R. Graham G.] Univ Sheffield, Dept Oncol & Metab, Mellanby Ctr Musculoskeletal Res, Sheffield, S Yorkshire, England.
C3 University of Southern California; Wroclaw Medical University;
   Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; University of Southern
   California; University of Oxford; University of Sheffield
RP Ebetino, FH (通讯作者)，BioVinc LLC, 2265 E Foothill Blvd, Pasadena, CA 91107 USA.; Sedghizadeh, PP (通讯作者)，Univ Southern Calif, Herman Ostrow Sch Dent, 925 West 34th St 4110, Los Angeles, CA 90089 USA.
EM sedghiza@usc.edu; halebetino@biovinc.com
RI ; Russell, R/JEF 5877 2023; Sedghizadeh, Parish/AAI 8453 2020; Russell,
   Robert Graham G/JEF 5877 2023
OI Junka, Adam/0000 0002 7559 8903; Cherian, Philip/0000 0002 1070 6483;
   Russell, Robert Graham G/0000 0002 4136 1828
FU National Institutes of Health, National Institute of Dental and
   Craniofacial Research (NIDCR) [R41 DE025789 01, R42DE025789 02];
   National Institute of Allergy and Infectious Diseases [R44AI125060]
   Funding Source: NIH RePORTER
FX This work was supported by grants (R41 DE025789 01 and R42DE025789 02)
   from the National Institutes of Health, National Institute of Dental and
   Craniofacial Research (NIDCR), to PPS and FHE.
CR Abtahi J, 2016, INT J ORAL MAX SURG, V45, P1564, DOI 10.1016/j.ijom.2016.09.001
   Abtahi J, 2012, BONE, V50, P1148, DOI 10.1016/j.bone.2012.02.001
   Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603
   Akram Z, 2017, BRIT J CLIN PHARMACO, V83, P444, DOI 10.1111/bcp.13147
   [Anonymous], 2005, J AM DENT ASS, V136
   [Anonymous], 2009, NY TIMES
   Arns S, 2012, BIOORGAN MED CHEM, V20, P2131, DOI 10.1016/j.bmc.2012.01.024
   Ballal NV, 2019, INT ENDOD J, V52, P1228, DOI 10.1111/iej.13110
   BASSETT CAL, 1969, LANCET, V2, P845
   BENEDICT JJ, 1986, CALCIFIED TISSUE INT, V38, pS31
   Bentley KLD, 2017, J BONE MINER RES, V32, P985, DOI 10.1002/jbmr.3055
   BRUNSVOLD MA, 1992, J PERIODONTOL, V63, P825, DOI 10.1902/jop.1992.63.10.825
   Cachovan G, 2011, ANTIMICROB AGENTS CH, V55, P1142, DOI 10.1128/AAC.01267 10
   Chen X, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9070569
   Cheong S, 2014, J ORAL MAXIL SURG, V72, P2461, DOI 10.1016/j.joms.2014.07.004
   Cornish J, 2011, BONE, V49, P710, DOI 10.1016/j.bone.2011.07.020
   Daubert DM, 2019, PERIODONTOL 2000, V81, P29, DOI 10.1111/prd.12280
   Deymier AC, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115152
   Dios PD, 2006, ANTIMICROB AGENTS CH, V50, P2996, DOI 10.1128/AAC.01550 05
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Ebetino FH, 2016, J BONE MINER RES, V31, P1783, DOI 10.1002/jbmr.2928
   Eguchi T, 2017, MED ORAL PATOL ORAL, V22, pE788, DOI 10.4317/medoral.22013
   Eick S, 2004, J CLIN PERIODONTOL, V31, P376, DOI 10.1111/j.0303 6979.2004.00490.x
   FLEISCH H, 1981, METAB BONE DIS RELAT, V3, P279, DOI 10.1016/0221 8747(81)90044 8
   FLEISCH H, 1966, P SOC EXP BIOL MED, V122, P317
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   FLEISCH H, 1962, AM J PHYSIOL, V203, P671, DOI 10.1152/ajplegacy.1962.203.4.671
   FLEISCH H, 1972, J DENT RES, V51, P324
   FLEISH H, 1961, AM J PHYSIOL, V200, P1296, DOI 10.1152/ajplegacy.1961.200.6.1296
   FONG IW, 1986, ANTIMICROB AGENTS CH, V29, P405, DOI 10.1128/AAC.29.3.405
   Fraimow Henry S, 2009, Semin Plast Surg, V23, P90, DOI 10.1055/s 0029 1214161
   FRANCIS MD, 1965, ANN NY ACAD SCI, V131, P694, DOI 10.1111/j.1749 6632.1965.tb34834.x
   FRANCIS MD, 1969, CALC TISS RES, V3, P151, DOI 10.1007/BF02058658
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   FRANCIS MD, 1965, J DENT RES, V44, P635, DOI 10.1177/00220345650440040501
   FRANCIS MD, 1966, ARCH ORAL BIOL, V11, P141, DOI 10.1016/0003 9969(66)90183 X
   Fujimura Y, 2009, EUR J ORTHODONT, V31, P572, DOI 10.1093/ejo/cjp068
   GERTZ BJ, 1993, OSTEOPOROSIS INT, V3, pS13
   Hasegawa T, 2019, OSTEOPOROSIS INT, V30, P231, DOI 10.1007/s00198 018 4746 8
   Hasegawa T, 2017, OSTEOPOROSIS INT, V28, P2465, DOI 10.1007/s00198 017 4063 7
   Hayashida S, 2020, J BONE MINER METAB, V38, P126, DOI 10.1007/s00774 019 01035 7
   Helmi M, 2019, BMC ORAL HEALTH, V19, DOI 10.1186/s12903 019 0955 6
   Herczegh P, 2002, J MED CHEM, V45, P2338, DOI 10.1021/jm0105326
   Hohneker John A, 2005, Tex Dent J, V122, P973
   Hokugo A, 2019, BONE, V123, P115, DOI 10.1016/j.bone.2019.03.027
   Houghton TJ, 2008, J MED CHEM, V51, P6955, DOI 10.1021/jm801007z
   Jeffcoat Marjorie K, 2007, J Int Acad Periodontol, V9, P70
   Jung SY, 2019, ORAL DIS, V25, P471, DOI 10.1111/odi.12966
   Junka A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169565
   Junka AF, 2015, J ORAL MAXIL SURG, V73, P451, DOI 10.1016/j.joms.2014.09.019
   Kang SH, 2020, J KOR ASSOC ORAL MAX, V46, P78, DOI [10.5125/jkaoms.2020.46.1.78, 10.5125/jkamos.2020.46.1.78]
   Katsarelis H, 2015, J DENT RES, V94, P534, DOI 10.1177/0022034515572021
   Kempfle JS, 2018, BIOCONJUGATE CHEM, V29, P1240, DOI 10.1021/acs.bioconjchem.8b00022
   Khan AA, 2017, J CLIN DENSITOM, V20, P8, DOI 10.1016/j.jocd.2016.09.005
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   Kim BN, 2014, J ANTIMICROB CHEMOTH, V69, P309, DOI 10.1093/jac/dkt374
   KING WR, 1971, CLIN ORTHOP RELAT R, P251, DOI 10.1097/00003086 197107000 00021
   Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774 009 0128 9
   KOCH G, 1990, CARIES RES, V24, P72, DOI 10.1159/000261242
   Kumar Satish K S, 2010, Curr Osteoporos Rep, V8, P40, DOI 10.1007/s11914 010 0008 1
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Levine RS, 2020, BRIT DENT J, V229, P687, DOI 10.1038/s41415 020 2346 4
   Lidhar T, 2020, BRIT J ORAL MAX SURG, V58, pE75, DOI 10.1016/j.bjoms.2020.06.030
   Liu L, 2004, EUR J ORTHODONT, V26, P469, DOI 10.1093/ejo/26.5.469
   Lu LQ, 2020, J CLIN PHARM THER, V45, P45, DOI 10.1111/jcpt.13056
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Marolt D, 2012, J ORAL MAXIL SURG, V70, P1081, DOI 10.1016/j.joms.2011.05.002
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   MCKAY FS, 1948, AM J PUBLIC HEALTH, V38, P828
   MCKENNA CE, 1977, TETRAHEDRON LETT, P155
   MCKENNA CE, 1979, J CHEM SOC CHEM COMM, P739, DOI 10.1039/c39790000739
   McPherson JC, 2012, EUR J MED CHEM, V47, P615, DOI 10.1016/j.ejmech.2011.10.049
   Meeker DG, 2019, J ARTHROPLASTY, V34, P1458, DOI 10.1016/j.arth.2019.03.008
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   Milazzo I, 2002, INT J ANTIMICROB AG, V20, P451, DOI 10.1016/S0924 8579(02)00190 5
   Morioka M, 2010, BIOORGAN MED CHEM, V18, P1143, DOI 10.1016/j.bmc.2009.12.041
   MULDER H, 1994, BRIT J RHEUMATOL, V33, P348
   Pitts NB, 2017, NAT REV DIS PRIMERS, V3, P1, DOI 10.1038/nrdp.2017.30
   Roelofs AJ, 2012, J BONE MINER RES, V27, P835, DOI 10.1002/jbmr.1543
   Rosin Grget Kata, 2013, Acta Med Acad, V42, P179, DOI 10.5644/ama2006 124.85
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   RUSSELL RGG, 1964, LANCET, V1, P1446
   Schaudinn C, 2012, OR SURG OR MED OR PA, V114, P480, DOI 10.1016/j.oooo.2012.06.006
   Schaudinn C, 2009, J AM DENT ASSOC, V140, P978, DOI 10.14219/jada.archive.2009.0307
   Sedghizadeh P., 2020, BONE REP, V13
   Sedghizadeh P, 2019, J BONE MINER RES, V34, P367
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   Sedghizadeh PP, 2013, OR SURG OR MED OR PA, V115, P224, DOI 10.1016/j.oooo.2012.08.455
   Sedghizadeh PP, 2009, J AM DENT ASSOC, V140, P1259, DOI 10.14219/jada.archive.2009.0049
   Sedghizadeh PP, 2009, J AM DENT ASSOC, V140, P61, DOI 10.14219/jada.archive.2009.0019
   Shah NP, 2017, BRIT DENT J, V222, P727, DOI 10.1038/sj.bdj.2017.412
   Stoodley P, 2011, CURR ORTHOP PRACT, V22, P558, DOI 10.1097/BCO.0b013e318230efcf
   Sun ST, 2021, BRIT J PHARMACOL, V178, P2008, DOI 10.1111/bph.15251
   Tan SY, 2010, SINGAP MED J, V51, P842
   Tartari T, 2015, INT ENDOD J, V48, P399, DOI 10.1111/iej.12329
   ten Cate JM, 2019, J DENT RES, V98, P725, DOI 10.1177/0022034519831604
   Tengvall P, 2004, BIOMATERIALS, V25, P2133, DOI 10.1016/j.biomaterials.2003.08.049
   Wan Jason T, 2020, [Bone Research, 骨研究], V8, P14
   Wang H, 2020, J BONE MINER RES, V35, P343, DOI 10.1002/jbmr.3889
   Xing LP, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115492
   Yahara H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241676
   Zehnder M, 2005, J ENDODONT, V31, P817, DOI 10.1097/01.don.0000158233.59316.fe
   Zhang QZ, 2013, CLIN CANCER RES, V19, P3176, DOI 10.1158/1078 0432.CCR 13 0042
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zuffetti F, 2015, CLIN IMPLANT DENT R, V17, pE168, DOI 10.1111/cid.12151
NR 111
TC 10
Z9 11
U1 1
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2021
VL 147
DI 10.1016/j.bone.2021.115933
EA MAR 2021
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA RS3UL
UT WOS:000643707100001
PM 33757899
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Bai, SB
   Liu, DZ
   Cheng, Y
   Cui, H
   Liu, M
   Cui, MX
   Zhang, BL
   Mei, QB
   Zhou, SY
AF Bai, Shao bo
   Liu, Dao zhou
   Cheng, Ying
   Cui, Han
   Liu, Miao
   Cui, Min xuan
   Zhang, Bang le
   Mei, Qi bing
   Zhou, Si yuan
TI Osteoclasts and tumor cells dual targeting nanoparticle to treat bone
   metastases of lung cancer
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Osteoclasts; Bone metastases of lung cancer; Docetaxel; PAMAM;
   Hyaluronic acid
ID DRUG DELIVERY SYSTEMS; GOLD NANOPARTICLES; PAMAM DENDRIMERS;
   DOXORUBICIN; BISPHOSPHONATE; DOCETAXEL; DIFFERENTIATION;
   BIODISTRIBUTION; CHEMOTHERAPY; PENETRATION
AB Bone is one of the prone metastatic sites of lung cancer. Osteoclast plays an important role in bone resorption and the growth of bone metastases of lung cancer. In order to treat bone metastases of lung cancer, we reported a docetaxel (DTX) loaded nanoparticle, DTX@AHP, which could target dually at osteoclasts and bone metastatic tumor cells. The in vitro drug release from DTX@AHP exhibited pH and redox responsive characteristics. DTX@AHP displayed high binding affinity with bone matrix. In addition, DTX@AHP significantly inhibited the differentiation of RAW264.7 into osteoclast and effectively inhibited the proliferation of osteoclasts and tumor cells in in vitro 3D bone metastases model of lung cancer. DTX@AHP could accumulate in bone metastases sites in vivo. Consequently, DTX@AHP not only markedly inhibited the growth of bone metastases of lung cancer but also reduced osteolysis in tumor bearing mice. DTX@AHP exhibited great potential in the treatment of bone metastases of lung cancer. (C) 2019 (C) Elsevier Inc. All rights reserved.
C1 [Bai, Shao bo; Liu, Dao zhou; Cheng, Ying; Cui, Han; Liu, Miao; Cui, Min xuan; Zhang, Bang le; Zhou, Si yuan] Fourth Mil Med Univ, Sch Pharm, Dept Pharmaceut, Xian, Shaanxi, Peoples R China.
   [Mei, Qi bing; Zhou, Si yuan] Fourth Mil Med Univ, State Adm Tradit Chinese Med, Key Lab Gastrointestinal Pharmacol Chinese Mat Me, Xian, Shaanxi, Peoples R China.
C3 Air Force Medical University; Air Force Medical University
RP Zhou, SY (通讯作者)，Fourth Mil Med Univ, Sch Pharm, Dept Pharmaceut, Xian, Shaanxi, Peoples R China.; Zhou, SY (通讯作者)，Fourth Mil Med Univ, State Adm Tradit Chinese Med, Key Lab Gastrointestinal Pharmacol Chinese Mat Me, Xian, Shaanxi, Peoples R China.
EM zhousy@fmmu.edu.cn
RI liu, miao/KGL 7043 2024; Cui, Han/KPB 7522 2024
OI Zhang, Bang Le/0000 0001 9008 5391
FU National Nature Science Foundation [81872803]
FX This work was supported by the National Nature Science Foundation (No.
   81872803).
CR Abedi Gaballu F, 2018, APPL MATER TODAY, V12, P177, DOI 10.1016/j.apmt.2018.05.002
   Addison WN, 2015, BONE, V71, P244, DOI 10.1016/j.bone.2014.11.003
   Adjei IM, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040205
   Alric C, 2013, NANOSCALE, V5, P5930, DOI 10.1039/c3nr00012e
   Arima H, 2017, THER DELIV, V8, P215, DOI 10.4155/tde 2016 0064
   Chauhan AS, 2018, MOLECULES, V23, DOI 10.3390/molecules23040938
   Chen WQ, 2016, CA CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Deng S, 2018, J BIOMAT SCI POLYM E, V29, P1643, DOI 10.1080/09205063.2018.1481005
   Dobosz M, 2014, NEOPLASIA, V16, P1, DOI 10.1593/neo.131848
   Falcao L, 2018, MOLECULES, V23, DOI 10.3390/molecules23051081
   Fang RH, 2017, BIOMATERIALS, V128, P69, DOI 10.1016/j.biomaterials.2017.02.041
   Fang XB, 2016, INT J PHARMACEUT, V502, P28, DOI 10.1016/j.ijpharm.2016.01.029
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Fox LJ, 2018, ADV COLLOID INTERFAC, V257, P1, DOI 10.1016/j.cis.2018.06.005
   François A, 2011, CHEMMEDCHEM, V6, P2003, DOI 10.1002/cmdc.201100311
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hochdörffer K, 2012, J MED CHEM, V55, P7502, DOI 10.1021/jm300493m
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hu KL, 2015, NANOSCALE, V7, P8607, DOI 10.1039/c5nr01084e
   Huang JB, 2014, BIOMATERIALS, V35, P550, DOI 10.1016/j.biomaterials.2013.09.089
   Jiao ZX, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16853 w
   Kannan RM, 2014, J INTERN MED, V276, P579, DOI 10.1111/joim.12280
   Kesharwani P, 2015, COLLOID SURFACE B, V136, P413, DOI 10.1016/j.colsurfb.2015.09.043
   Kim KM, 2018, ONCOTARGET, V9, P3562, DOI 10.18632/oncotarget.23337
   Kitazawa R, 2018, HISTOCHEM CELL BIOL, V149, P405, DOI 10.1007/s00418 018 1639 z
   Kumar B, 2017, COLLOID SURFACE B, V150, P352, DOI 10.1016/j.colsurfb.2016.10.049
   Lee SY, 2018, DRUG DELIV, V25, P1472, DOI 10.1080/10717544.2018.1480673
   Li CJ, 2016, ORTHOP SURG, V8, P105, DOI 10.1111/os.12238
   Li HJ, 2016, ACS NANO, V10, P6753, DOI 10.1021/acsnano.6b02326
   Li J, 2018, INT J PHARMACEUT, V546, P215, DOI 10.1016/j.ijpharm.2018.05.045
   Li LM, 2015, INT J MOL MED, V36, P113, DOI 10.3892/ijmm.2015.2222
   Li YF, 2018, J CANCER RES CLIN, V144, P1463, DOI 10.1007/s00432 018 2678 5
   Liou YM, 2018, J CELL PHYSIOL, V233, P6888, DOI 10.1002/jcp.26452
   Liu H, 2013, NEOPLASMA, V60, P240, DOI 10.4149/neo_2013_032
   Longmire M, 2008, NANOMEDICINE UK, V3, P703, DOI 10.2217/17435889.3.5.703
   Luo ZY, 2018, THERANOSTICS, V8, P3584, DOI 10.7150/thno.25409
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Pang L, 2017, DRUG DELIV, V24, P83, DOI 10.1080/10717544.2016.1230903
   Rafiei P, 2017, INT J NANOMED, V12, P935, DOI 10.2147/IJN.S121881
   Rezazadeh M, 2018, RES PHARM SCI, V13, P181, DOI 10.4103/1735 5362.228918
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   Sadekar S, 2011, BIOMACROMOLECULES, V12, P88, DOI 10.1021/bm101046d
   Shadrack DM, 2018, MOLECULES, V23, DOI 10.3390/molecules23061419
   Sousa S, 2018, CALCIFIED TISSUE INT, V102, P227, DOI 10.1007/s00223 017 0353 5
   Tavares AJ, 2017, P NATL ACAD SCI USA, V114, pE10871, DOI 10.1073/pnas.1713390114
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Traore MA, 2018, METHODS MOL BIOL, V1831, P25, DOI 10.1007/978 1 4939 8661 3_3
   Ueno M, 2018, PHYTOTHER RES, V32, P452, DOI 10.1002/ptr.5988
   Vermeirsch H, 2004, PHARMACOL BIOCHEM BE, V79, P243, DOI 10.1016/j.pbb.2004.07.011
   Wilhelm S, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.14
   Xu XL, 2016, EUR J PHARM SCI, V88, P178, DOI 10.1016/j.ejps.2016.02.015
   Yang J, 2018, J CANCER RES CLIN, V144, P1835, DOI 10.1007/s00432 018 2702 9
   Ye WL, 2015, SCI REP UK, V5, DOI 10.1038/srep14614
   Ye WL, 2015, J PHARM SCI US, V104, P2293, DOI 10.1002/jps.24476
   Yu MX, 2015, ACS NANO, V9, P6655, DOI 10.1021/acsnano.5b01320
   Zhang F, 2017, J CONTROL RELEASE, V249, P173, DOI 10.1016/j.jconrel.2017.01.032
   Zhao N, 2016, J BONE MINER RES, V31, P430, DOI 10.1002/jbmr.2690
   Zhao YP, 2017, NANOSCALE, V9, P6264, DOI 10.1039/c7nr00962c
NR 63
TC 27
Z9 31
U1 2
U2 71
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD OCT
PY 2019
VL 21
AR 102054
DI 10.1016/j.nano.2019.102054
PG 13
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA JW7XO
UT WOS:000503261200009
PM 31310809
DA 2025 08 17
ER

PT J
AU Wu, XH
   Fang, XX
   Lu, F
   Chen, Q
   Liu, JJ
   Zheng, LP
AF Wu, Xinhui
   Fang, Xiaoxin
   Lu, Feng
   Chen, Qiong
   Liu, Junjian
   Zheng, Longpo
TI An update on the role of ferroptosis in the pathogenesis of osteoporosis
SO EFORT OPEN REVIEWS
LA English
DT Article
DE ferroptosis; osteoporosis; lipid peroxidation; review
ID CELL DEATH; RHEUMATOID ARTHRITIS; LIPID PEROXIDATION; COENZYME Q(10);
   FATTY ACIDS; BONE LOSS; THERAPY; DEFICIENCY; METABOLISM; ACTIVATION
AB center dot Ferroptosis is a novel form of programmed cell death, distinguished from apoptosis, autophagy, and programmed necrosis and has received much attention since it was defined in 2012. center dot Ferroptotic cells physiologically exhibit iron metabolism dysregulation, oxidative stress, and lipid peroxidation. Morphologically, they show plasma membrane disruption, cytoplasmic swelling, and mitochondrial condensation. center dot Osteoporosis is taken more and more seriously as the proportion of the aging population continues to increase globally. Interestingly, ferroptosis has been demonstrated to be involved in the development and progression of osteoporosis in many extant studies. center dot The review summarizes iron metabolism, lipid peroxidation, and the different regulatory signals in ferroptosis. Changes in signaling mechanisms within osteoblasts, osteoclasts, and osteocytes after ferroptosis occur are explained here. center dot Studies showed ferroptosis play an important role in different osteoporosis models (diabetes osteoporosis, postmenopausal osteoporosis, glucocorticoid induced osteoporosis). Inhibitors and EC (Exos) targeting ferroptosis could ameliorate bone loss in osteoporotic mice by protecting cells against lipid peroxidation. Shortly, we hope that more effective and appropriate clinical therapy means will be utilized in the treatment of osteoporosis.
C1 [Wu, Xinhui; Liu, Junjian; Zheng, Longpo] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Orthoped, Shanghai, Peoples R China.
   [Zheng, Longpo] Tongji Univ, Shanghai Peoples Hosp 10, Orthoped Intelligent Minimally Invas Diag & Treatm, Sch Med, Shanghai, Peoples R China.
   [Fang, Xiaoxin] Zhejiang Univ, Affiliated Jinhua Hosp, Sch Med, Dept Endocrinol & Metab, Jinhua, Peoples R China.
   [Lu, Feng] Nanjing Med Univ, Jiangning, Nanjing, Peoples R China.
   [Chen, Qiong] Zhejiang Chinese Med Univ, Jinhua TCM Hosp, Hangzhou, Zhejiang, Peoples R China.
C3 Tongji University; Tongji University; Zhejiang University; Nanjing
   Medical University; Zhejiang Chinese Medical University
RP Liu, JJ; Zheng, LP (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Orthoped, Shanghai, Peoples R China.; Zheng, LP (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Orthoped Intelligent Minimally Invas Diag & Treatm, Sch Med, Shanghai, Peoples R China.
EM jjliu@tongji.edu.cn; dr.zheng@tongji.edu.cn
RI zheng, longpo/GWV 5230 2022
FU National Key R&D Program of China [2022YFC2504300]; National Natural
   Science Foundation of China [82372395]; Special Project for Promoting
   High Quality Development of Industries of Shanghai Municipal Commission
   of Economy and Informatization [2023 GZL RGZN 01037]
FX Funding Statement This work was supported by National Key R&D Program of
   China (grant no. 2022YFC2504300) , National Natural Science Foundation
   of China (grant no. 82372395) and The Special Project for Promoting
   High Quality Development of Industries of Shanghai Municipal Commission
   of Economy and Informatization (grant no. 2023 GZL RGZN 01037) .
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Alehagen U, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178614
   Angeli A, 2006, BONE, V39, P253, DOI 10.1016/j.bone.2006.02.005
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438
   BANNAI S, 1980, J BIOL CHEM, V255, P2372
   Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586 019 1705 2
   Brown CW, 2019, DEV CELL, V51, P575, DOI 10.1016/j.devcel.2019.10.007
   Buckley L, 2017, ARTHRIT CARE RES, V69, P1095, DOI 10.1002/acr.23279
   Chen JJ, 2018, TRENDS CELL BIOL, V28, P77, DOI 10.1016/j.tcb.2017.11.007
   Curtis JR, 2006, ARTHRIT RHEUM ARTHR, V55, P420, DOI 10.1002/art.21984
   D'Amelio P, 2008, BONE, V43, P1010, DOI 10.1016/j.bone.2008.08.107
   DeBose Boyd RA, 2018, SEMIN CELL DEV BIOL, V81, P97, DOI 10.1016/j.semcdb.2017.12.003
   Dixon SJ, 2014, ELIFE, V3, DOI 10.7554/eLife.02523
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586 019 1707 0
   Dolma S, 2003, CANCER CELL, V3, P285, DOI 10.1016/S1535 6108(03)00050 3
   Duan JY, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.701788
   El Hout M, 2018, SEMIN CANCER BIOL, V53, P125, DOI 10.1016/j.semcancer.2018.07.009
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Fardet L, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000647
   Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962 8924(97)01187 2
   Feng H, 2020, CELL REP, V30, P3411, DOI 10.1016/j.celrep.2020.02.049
   Feng HZ, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006203
   Feng Y, 2021, CELL MOL BIOL LETT, V26, DOI 10.1186/s11658 021 00281 w
   Forcina GC, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800311
   Gao ZH, 2022, EXP GERONTOL, V165, DOI 10.1016/j.exger.2022.111836
   Hassannia B, 2019, CANCER CELL, V35, P830, DOI 10.1016/j.ccell.2019.04.002
   Hayano M, 2016, CELL DEATH DIFFER, V23, P270, DOI 10.1038/cdd.2015.93
   Hishikawa D, 2008, P NATL ACAD SCI USA, V105, P2830, DOI 10.1073/pnas.0712245105
   Horikoshi N, 1999, BIOCHEM BIOPH RES CO, V261, P864, DOI 10.1006/bbrc.1999.1123
   Hu Q, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.810327
   Hu YX, 2023, J CLIN MED, V12, DOI 10.3390/jcm12062125
   Jeney V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00077
   Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580 020 00324 8
   Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/nchembio.2238, 10.1038/NCHEMBIO.2238]
   Kang R, 2018, CELL HOST MICROBE, V24, P97, DOI 10.1016/j.chom.2018.05.009
   Kaur J, 2022, CURR OPIN ENDOCRINOL, V29, P310, DOI 10.1097/MED.0000000000000733
   Kim HK, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104827
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kraft VAN, 2020, ACS CENTRAL SCI, V6, P41, DOI 10.1021/acscentsci.9b01063
   Küch EM, 2014, BBA MOL CELL BIOL L, V1841, P227, DOI 10.1016/j.bbalip.2013.10.018
   LAAN RFJM, 1993, ANN INTERN MED, V119, P963, DOI 10.7326/0003 4819 119 10 199311150 00001
   Lane NE, 1998, ENDOCRIN METAB CLIN, V27, P465, DOI 10.1016/S0889 8529(05)70017 7
   Lecka Czernik B, 2017, DIABETOLOGIA, V60, P1163, DOI 10.1007/s00125 017 4269 4
   Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026
   Li Y, 2023, NUTRIENTS, V15, DOI 10.3390/nu15092115
   Liang C, 2019, ADV MATER, V31, DOI 10.1002/adma.201904197
   Lin YF, 2022, FASEB J, V36, DOI 10.1096/fj.202101610R
   Liu J, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008150.pub2
   Liu T, 2019, CANCER RES, V79, P1913, DOI 10.1158/0008 5472.CAN 18 3037
   López LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023
   Lu JS, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52513 x
   Luo C, 2022, FREE RADICAL BIO MED, V188, P337, DOI 10.1016/j.freeradbiomed.2022.06.236
   Ma HD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9067610
   Magtanong L, 2019, CELL CHEM BIOL, V26, P420, DOI 10.1016/j.chembiol.2018.11.016
   Mandal PK, 2010, J BIOL CHEM, V285, P22244, DOI 10.1074/jbc.M110.121327
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   Morré DJ, 2011, BIOFACTORS, V37, P355, DOI 10.1002/biof.156
   Mortensen SA, 2014, JACC HEART FAIL, V2, P641, DOI 10.1016/j.jchf.2014.06.008
   Ni S, 2021, FREE RADICAL BIO MED, V169, P271, DOI 10.1016/j.freeradbiomed.2021.04.027
   Okyay E, 2013, MATURITAS, V76, P320, DOI 10.1016/j.maturitas.2013.07.015
   PORTER NA, 1979, BIOCHEM BIOPH RES CO, V89, P1058, DOI 10.1016/0006 291X(79)92115 6
   Qu XZ, 2021, PEERJ, V9, DOI 10.7717/peerj.12510
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Recalcati S, 2010, ANTIOXID REDOX SIGN, V13, P1593, DOI 10.1089/ars.2009.2983
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Ru Q, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00247 y
   Ryu MS, 2017, J CLIN INVEST, V127, P1786, DOI 10.1172/JCI90519
   SAAG KG, 1994, AM J MED, V96, P115, DOI 10.1016/0002 9343(94)90131 7
   Santoro MM, 2020, CELL METAB, V31, P13, DOI 10.1016/j.cmet.2019.12.007
   Sato H, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 66945 3
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Song H, 2019, NANO LETT, V19, P3040, DOI 10.1021/acs.nanolett.9b00287
   Song XX, 2018, CURR BIOL, V28, P2388, DOI 10.1016/j.cub.2018.05.094
   Stockwell BR, 2020, TRENDS CELL BIOL, V30, P478, DOI 10.1016/j.tcb.2020.02.009
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Tang DL, 2021, CELL RES, V31, P107, DOI 10.1038/s41422 020 00441 1
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Tonelli C, 2018, ANTIOXID REDOX SIGN, V29, P1727, DOI 10.1089/ars.2017.7342
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   Van Belle TL, 2011, PHYSIOL REV, V91, P79, DOI 10.1152/physrev.00003.2010
   Van Staa TP, 2003, J BONE MINER RES, V18, P913, DOI 10.1359/jbmr.2003.18.5.913
   Wang F, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1397 3
   Wang LY, 2020, CELL DEATH DIFFER, V27, P662, DOI 10.1038/s41418 019 0380 z
   Wang XD, 2022, BIOL TRACE ELEM RES, V200, P298, DOI 10.1007/s12011 021 02627 z
   Winterbourn CC, 1995, TOXICOL LETT, V82 3, P969, DOI 10.1016/0378 4274(95)03532 X
   Wong Ekkabut J, 2007, BIOPHYS J, V93, P4225, DOI 10.1529/biophysj.107.112565
   Wu CH, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18935 1
   Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200
   Xu PC, 2022, FREE RADICAL BIO MED, V193, P720, DOI 10.1016/j.freeradbiomed.2022.11.013
   Yan HF, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 020 00428 9
   Yang WS, 2008, CHEM BIOL, V15, P234, DOI 10.1016/j.chembiol.2008.02.010
   Yang WS, 2016, P NATL ACAD SCI USA, V113, pE4966, DOI 10.1073/pnas.1603244113
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
   Yang YQ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00198 w
   Yin HY, 2011, CHEM REV, V111, P5944, DOI 10.1021/cr200084z
   Zhang YL, 2018, NAT CELL BIOL, V20, P1181, DOI 10.1038/s41556 018 0178 0
   Zhong ZY, 2023, REDOX BIOL, V63, DOI 10.1016/j.redox.2023.102711
   Zou Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09277 9
NR 100
TC 7
Z9 8
U1 3
U2 16
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 2396 7544
EI 2058 5241
J9 EFORT OPEN REV
JI EFORT Open Rev.
PD AUG
PY 2024
VL 9
IS 8
DI 10.1530/EOR 23 0148
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA H0U2J
UT WOS:001320675000001
PM 39087516
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chen, YW
   Sun, QY
AF Chen, Yuwei
   Sun, Qiyuan
TI Analysis of Puerarin's Mechanism in Treating Diabetic Osteoporosis by
   using Network Pharmacology
SO INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Network pharmacology; puerarin; diabetic osteoporosis; protein protein
   interactions
AB Puerarin can promote the proliferation of osteoblasts and it can also be used as a scaffold material, but its mechanism is unknown. In this study, we explored the primary molecular mechanism of puerarin in diabetic osteoporosis treatment. We used traditional Chinese medicine systems pharmacology database and analysis platform, PubChem, web based gene set analysis toolkit, cytoscape and so on to screen the drug targets of puerarin and the disease targets of diabetic osteoporosis. We analyzed the puerarin mechanism based on the protein protein interaction co expression network, gene ontology, Kyoto encyclopedia of genes and genomes enrichment, etc., and molecular docking by AutoDock. The main enriched signaling pathways in the Kyoto encyclopedia of genes and genomes were non small cell lung cancer, endocrine resistance and so on. The main enriched biological processes were positive regulation of cell migration, cytokine mediated signaling pathway and so on. The main enriched cell components of the cellular component were the integrin complex, platelet alpha granule membrane and so on. The main cellular functions of the molecular function were C X3 C chemokine binding, nitric oxide synthase regulator activity and so on. The tumor necrosis factor, phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit alpha and prostaglandin endoperoxide synthase 2 with puerarin docking binding energy were all less than  5 kcal/mol( 1). In conclusion puerarin may act through multiple targets and some pathways in diabetic osteoporosis.
C1 [Chen, Yuwei] Soochow Univ, Dept Orthoped, Suzhou Hosp 9, Suzhou 215200, Jiangsu, Peoples R China.
   [Sun, Qiyuan] Soochow Univ, Dept Endocrinol, Suzhou Hosp 9, Suzhou 215200, Jiangsu, Peoples R China.
C3 Soochow University   China; Soochow University   China
RP Sun, QY (通讯作者)，Soochow Univ, Dept Endocrinol, Suzhou Hosp 9, Suzhou 215200, Jiangsu, Peoples R China.
EM sunqiyuan0321@163.com
RI Sun, Qiyuan/AAV 9969 2021
FU Suzhou Ninth People's Hospital [YK202126]
FX This study was supported by the institute level scientific research
   project of Suzhou Ninth People's Hospital (Project number: YK202126).
CR Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   [陈文明 Chen Wenming], 2021, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V27, P73
   [中华医学会糖尿病学分会 Chinese Diabetes Society], 2021, [中华内分泌代谢杂志, Chinese Journal of Endocrinology and Metabolism], V37, P311
   [杜丽坤 Du Likun], 2022, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V28, P296
   Fu SC, 2019, INT J RHEUM DIS, V22, P1619, DOI 10.1111/1756 185X.13647
   He Q, 2021, J ETHNOPHARMACOL, V273, DOI 10.1016/j.jep.2021.113946
   [李建国 Li Jianguo], 2019, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V25, P132
   [连李荣 Lian Lirong], 2022, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V28, P551
   Liang XZ, 2019, Chin Arch Tradit Chin Med, V37, P2628
   Liu BS, 2022, J HEALTHC ENG, V2022, DOI 10.1155/2022/5298892
   Liu LL, 2020, ORTHOP SURG, V12, P1304, DOI 10.1111/os.12750
   Lu ZQ, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 03194 2
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Luo MR, 2022, Chin J Tissue Eng Res, V26, P1888
   Mohsin S, 2019, EXPERT OPIN BIOL TH, V19, P937, DOI 10.1080/14712598.2019.1618266
   Qi SM, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.692574
   Shen YW, 2023, PHYTOMEDICINE, V110, DOI 10.1016/j.phymed.2022.154607
   Shi L, 2022, China Med Her, V19, P20
   Sun X, 2019, INT J BIOL MACROMOL, V129, P579, DOI 10.1016/j.ijbiomac.2019.02.022
   Tang H, 2021, Hebei Med, V27, P395
   Veeriah V, 2019, CALCIFIED TISSUE INT, V104, P344, DOI 10.1007/s00223 018 0496 z
   Wang L, 2020, Cent South Pharm, V18, P15
   [温明韬 Wen Mingtao], 2021, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V27, P1129
   [杨一秋 Yang Yiqiu], 2022, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V28, P347
   [杨占华 Yang Zhanhua], 2021, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V27, P413
   Yin B, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/5273914
   [岳海振 Yue Haizhen], 2021, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V27, P77
   Zhang LL, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20203520
   [赵元 Zhao Yuan], 2021, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V27, P866
   [朱卫丰 Zhu Weifeng], 2022, [中草药, Chinese Traditional and Herbal Drugs], V53, P1004
NR 30
TC 0
Z9 0
U1 0
U2 4
PU INDIAN PHARMACEUTICAL ASSOC
PI MUMBAI
PA KALINA, SANTA CRUZ EAST, MUMBAI, 00000, INDIA
SN 0250 474X
EI 1998 3743
J9 INDIAN J PHARM SCI
JI Indian J. Pharm. Sci.
PY 2023
VL 85
IS 4
SI Sp4
BP 10
EP 19
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EV3U4
UT WOS:001141676600001
DA 2025 08 17
ER

PT J
AU Talmo, CT
   Shanbhag, AS
   Rubash, HE
AF Talmo, Carl T.
   Shanbhag, Arun S.
   Rubash, Harry E.
TI Nonsurgical management of osteolysis
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID TOTAL HIP ARTHROPLASTY; DEBRIS INDUCED OSTEOLYSIS;
   NECROSIS FACTOR ALPHA; BONE MINERAL DENSITY; REVISION TOTAL HIP;
   PERIPROSTHETIC ACETABULAR OSTEOLYSIS; PARTICLE INDUCED
   OSTEOCLASTOGENESIS; VOLUMETRIC COMPUTERIZED TOMOGRAPHY; PERIPHERAL BLOOD
   MONOCYTES; WEAR DEBRIS
AB Osteolysis remains a common mode of total hip arthroplasty failure. In vitro and animal models have been used to determine the pathophysiology of osteolysis by carefully dissecting the biochemical pathways leading to particulate wear debris and periprosthetic bone loss. Numerous cytokines and inflammatory mediators, including TNF alpha and IL 1, are critical participants in this cascade and may represent prime targets for pharmacologic intervention. Osteoclasts, the end effector cells involved in the osteolytic process, also represent potential targets. Cell surface receptors on osteoclast precursors, such as receptor activator of NF kappa B (RANK) (on osteoclasts) and RANK ligand (RANKL) (on stromal cells), provide opportunities to arrest osteoclast maturation. Enhancing the naturally occurring osteoprotegerin is another recent attempt at modulating osteoclast behavior and a possible target for pharmacologic therapies. Other nonoperative strategies include intercepting tumor necrosis factor alpha activity, interfering with the RANK RANKL interaction necessary for osteoclast development and maturation, bisphosphonate therapy, and using viral vectors to deliver genes. Although each of these approaches has potential benefits, there are substantial challenges to effective implementation. Until there is convincing evidence of efficacy in human clinical trials, we recommend vigilant screening and appropriate surgery with component loosening or substantial likelihood of loosening, periprosthetic fracture, or major bone loss.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthoped Surg, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard Medical School
RP Rubash, HE (通讯作者)，Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthoped Surg, 55 Fruit St,YAW 3B, Boston, MA 02114 USA.
EM HRUBASH@partners.org
OI Talmo, Carl/0000 0003 0702 5211; Shanbhag, Arun/0000 0002 9397 9152
CR ABB J, 1983, IMMUNOLOGY, V49, P239
   Antoniou J, 2000, J ORTHOP RES, V18, P64, DOI 10.1002/jor.1100180110
   Aspenberg P., 1998, Clin. Orthop, V352, P75
   Åstrand J, 2003, CLIN ORTHOP RELAT R, P296, DOI 10.1097/01.blo.0000052938.71325.46
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bhandari M, 2005, J BONE JOINT SURG AM, V87A, P293, DOI 10.2106/JBJS.D.01772
   Blaine TA, 1997, J BONE JOINT SURG AM, V79A, P1519, DOI 10.2106/00004623 199710000 00009
   Bragdon CR, 2005, J ARTHROPLASTY, V20, P258, DOI 10.1016/j.arth.2004.03.027
   Bragdon CR, 2003, CLIN ORTHOP RELAT R, P50, DOI 10.1097/01.blo.0000096811.78689.2b
   BRUNELLI MP, 1998, CLIN ORTHOP RELAT R, V348, P15
   Bukata SV, 2004, J ORTHOP RES, V22, P6, DOI 10.1016/S0736 0266(03)00153 0
   Capparelli C, 2003, J BONE MINER RES, V18, P852, DOI 10.1359/jbmr.2003.18.5.852
   CHIBA J, 1994, CLIN ORTHOP RELAT R, V300, P304
   Childs LM, 2002, J BONE MINER RES, V17, P192, DOI 10.1359/jbmr.2002.17.2.192
   Childs LM, 2001, J BONE MINER RES, V16, P338, DOI 10.1359/jbmr.2001.16.2.338
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   Claus AM, 2003, J BONE JOINT SURG AM, V85A, P1519, DOI 10.2106/00004623 200308000 00013
   Clohisy JC, 2004, CLIN ORTHOP RELAT R, P188, DOI 10.1097/01.blo.0000150126.73024.42
   Clohisy JC, 2004, J ORTHOPAED RES, V22, P13, DOI 10.1016/S0736 0266(03)00156 6
   Clohisy JC, 2003, J IMMUNOL, V171, P5547, DOI 10.4049/jimmunol.171.10.5547
   Clohisy JC, 2003, J ORTHOPAED RES, V21, P202, DOI 10.1016/S0736 0266(02)00133 X
   Cundy T, 2005, NEW ENGL J MED, V353, P918, DOI 10.1056/NEJMoa050893
   DORR LD, 1990, CLIN ORTHOP RELAT R, P82
   Dowd JE, 2000, J BONE JOINT SURG AM, V82A, P1102, DOI 10.2106/00004623 200008000 00006
   Frenkel SR, 2001, J BIOMED MATER RES, V58, P645, DOI 10.1002/jbm.1064
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Geesink RGT, 1999, J BONE JOINT SURG BR, V81B, P710, DOI 10.1302/0301 620X.81B4.9311
   GILBERT JL, 1993, J BIOMED MATER RES, V27, P1533, DOI 10.1002/jbm.820271210
   GLANT TT, 1994, J ORTHOPAED RES, V12, P720, DOI 10.1002/jor.1100120515
   GLANT TT, 1993, J BONE MINER RES, V8, P1071
   GOLDRING SR, 1983, J BONE JOINT SURG AM, V65, P575, DOI 10.2106/00004623 198365050 00001
   Goodman SB, 2003, J BIOMED MATER RES A, V65A, P454, DOI 10.1002/jbm.a.3000
   Goodman SB, 1999, J BONE JOINT SURG BR, V81B, P1069, DOI 10.1302/0301 620X.81B6.9638
   GOODMAN SB, 1991, CLIN ORTHOP RELAT R, V271, P300
   GOODMAN SB, 1989, CLIN ORTHOP RELAT R, V244, P182
   GOODMAN SB, 1990, CLIN ORTHOP RELAT R, V257, P305
   Greenfield EM, 2002, J ORTHOPAED RES, V20, P1, DOI 10.1016/S0736 0266(01)00070 5
   HARRIS WH, 1995, CLIN ORTHOP RELAT R, P46
   Haynes DR, 2001, J BONE JOINT SURG BR, V83B, P902, DOI 10.1302/0301 620X.83B6.10905
   HERMAN JH, 1994, J RHEUMATOL, V21, P338
   Hochberg MC, 1999, ARTHRITIS RHEUM US, V42, P1246, DOI 10.1002/1529 0131(199906)42:6<1246::AID ANR22>3.0.CO;2 U
   Horowitz SM, 1996, J BIOMED MATER RES, V31, P91, DOI 10.1002/(SICI)1097 4636(199605)31:1<91::AID JBM11>3.0.CO;2 P
   Huang W, 2003, CALCIFIED TISSUE INT, V73, P584, DOI 10.1007/s00223 003 0059 8
   Huk OL, 2003, J ORTHOP RES, V21, P81, DOI 10.1016/S0736 0266(02)00099 2
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Jacobs JJ, 2001, CLIN ORTHOP RELAT R, P71
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   KIM KJ, 1993, CLIN ORTHOP RELAT R, P142
   Konttinen YT, 1999, ANN RHEUM DIS, V58, P691, DOI 10.1136/ard.58.11.691
   Kurtz S, 2005, J BONE JOINT SURG AM, V87A, P1487, DOI 10.2106/JBJS.D.02441
   Leung S, 2005, J BONE JOINT SURG AM, V87A, P592, DOI 10.2106/JBJS.D.02116
   Lie SA, 2004, J BONE JOINT SURG BR, V86B, P504, DOI 10.1302/0301 620X.86B4.14799
   Lind M, 1998, ACTA ORTHOP SCAND, V69, P2
   Lipton A, 2005, EXPERT OPIN BIOL TH, V5, P817, DOI 10.1517/14712598.5.6.817
   Looney RJ, 2002, ARTHRITIS RES, V4, P59, DOI 10.1186/ar384
   LYONS AR, 1998, T 10 COMB M ORTH ASS, P209
   Mahomed NN, 2003, J BONE JOINT SURG AM, V85A, P27, DOI 10.2106/00004623 200301000 00005
   MALONEY WJ, 1995, J BONE JOINT SURG AM, V77, P1301, DOI 10.2106/00004623 199509000 00002
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Murakami N, 2003, BIOMATERIALS, V24, P2153, DOI 10.1016/S0142 9612(03)00041 3
   Pandey R, 1996, ACTA ORTHOP SCAND, V67, P221, DOI 10.3109/17453679608994677
   Pap T, 1999, J RHEUMATOL, V26, P166
   Pollice PE, 2001, J BONE JOINT SURG AM, V83A, P1057, DOI 10.2106/00004623 200107000 00012
   Potter HG, 2004, J BONE JOINT SURG AM, V86A, P1947, DOI 10.2106/00004623 200409000 00013
   Puri L, 2002, J BONE JOINT SURG AM, V84A, P609, DOI 10.2106/00004623 200204000 00016
   Rubash H E, 1999, Instr Course Lect, V48, P37
   Rubash HE, 2004, T ORTHOP RES SOC, V29, P1888
   Savarino L, 2005, J BONE JOINT SURG BR, V87B, P571, DOI 10.1302/0301 620X.87B4.15316
   Schwarz EM, 2003, J ORTHOPAED RES, V21, P1049, DOI 10.1016/S0736 0266(03)00093 7
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321
   Shanahan JC, 2002, CLIN IMMUNOL, V103, P231, DOI 10.1006/clim.2002.5191
   SHANBHAG AS, 1995, J ARTHROPLASTY, V10, P498, DOI 10.1016/S0883 5403(05)80152 4
   Shanbhag AS, 1997, CLIN ORTHOP RELAT R, P33
   SHANBHAG AS, 1994, J BONE JOINT SURG BR, V76B, P60, DOI 10.1302/0301 620X.76B1.8300684
   SHANBHAG AS, 1999, T ORTHOP RES SOC, V44, P255
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Skoglund B, 2003, J ORTHOPAED RES, V21, P196, DOI 10.1016/S0736 0266(02)00150 X
   SUMNER DR, 1995, J BONE JOINT SURG AM, V77A, P1135, DOI 10.2106/00004623 199508000 00001
   TAKAGI M, 1998, CLIN ORTHOP RELAT R, V352, P35
   Takei I, 2000, J BIOMED MATER RES, V52, P613, DOI 10.1002/1097 4636(20001215)52:4<613::AID JBM5>3.0.CO;2 8
   Tanzer M, 2005, CLIN ORTHOP RELAT R, P30, DOI 10.1097/01.blo.0000194728.62996.2d
   Termaat MF, 2005, J BONE JOINT SURG AM, V87A, P1367, DOI 10.2106/JBJS.D.02585
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   Trnka HJ, 1999, ARCH ORTHOP TRAUM SU, V119, P456, DOI 10.1007/s004020050020
   Ulrich Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623 200208000 00017
   Vermes C, 2004, J BONE JOINT SURG BR, V86B, P759, DOI 10.1302/0301 620X.86B5.14552
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   von Knoch F, 2005, J BIOMED MATER RES A, V75A, P288, DOI 10.1002/jbm.a.30441
   Walde TA, 2005, CLIN ORTHOP RELAT R, P138, DOI 10.1097/01.blo.0000164028.14504.46
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Wei XC, 2005, J BONE MINER RES, V20, P1136, DOI 10.1359/JBMR.050206
   Weiland DE, 2005, J ORTHOP RES, V23, P713, DOI 10.1016/j.orthres.2005.02.007
   Wilkinson JM, 2003, J BONE MINER RES, V18, P1995, DOI 10.1359/jbmr.2003.18.11.1995
   Wilkinson JM, 2003, J ORTHOP RES, V21, P691, DOI 10.1016/S0736 0266(02)00237 1
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Yamaguchi K, 2005, J ORTHOP SCI, V10, P32, DOI 10.1007/s00776 004 0854 8
   Yang SY, 2004, GENE THER, V11, P483, DOI 10.1038/sj.gt.3302192
   Zhang XP, 2001, J BONE MINER RES, V16, P660, DOI 10.1359/jbmr.2001.16.4.660
NR 99
TC 30
Z9 34
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 921X
EI 1528 1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD DEC
PY 2006
IS 453
BP 254
EP 264
DI 10.1097/01.blo.0000246531.59876.a8
PG 11
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 113PU
UT WOS:000242610600042
PM 17016218
DA 2025 08 17
ER

PT J
AU Ang, ESM
   Yang, XH
   Chen, HH
   Liu, Q
   Zheng, MH
   Xu, JK
AF Ang, Estabelle S. M.
   Yang, Xiaohong
   Chen, Honghui
   Liu, Qian
   Zheng, Ming H.
   Xu, Jiake
TI Naringin abrogates osteoclastogenesis and bone resorption via the
   inhibition of RANKL induced NF κB and ERK activation
SO FEBS LETTERS
LA English
DT Article
DE Naringin; Osteoclastogenesis; Bone resorption; RANKL; NF kappa B
ID INDUCED GENOMIC INSTABILITY; RECEPTOR ACTIVATOR; ENDOTOXIN SHOCK;
   PROTEIN KINASE; MICE; DIFFERENTIATION; LIGAND; SUPPRESSION; INVOLVEMENT;
   PATHWAY
AB Osteolytic bone diseases including osteoporosis are commonly accompanied with enhanced osteoclast formation and bone resorption. Naringin, a natural occurring flavonoid has been found to protect against retinoic acid induced osteoporosis and improve bone quality in rats. Here, we showed that naringin perturbs osteoclast formation and bone resorption by inhibiting RANK mediated NF kappa B and ERK signaling. Naringin suppressed gene expression of key osteoclast marker genes. Naringin was found to inhibit RANKL induced activation of NF kappa B by suppressing RANKL mediated I kappa B alpha degradation. In addition, naringin inhibited RANKL induced phosphorylation of ERK. This study identifies naringin as an inhibitor for osteoclast formation and bone resorption, and provides evidence that natural compounds such as naringin might be beneficial as an alternative medicine for the prevention and treatment of osteolysis. (C) 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Xu, Jiake] Univ Western Australia, Sch Pathol & Lab Med, QEII Med Ctr, Nedlands, WA 6009, Australia.
   [Ang, Estabelle S. M.] Univ Western Australia, Sch Dent, Oral Biol Res Lab, Nedlands, WA 6009, Australia.
   [Yang, Xiaohong; Chen, Honghui] Jinan Univ, Guangzhou Inst Traumat Surg, Affiliated Hosp 4, Coll Med, Guangzhou 510220, Guangdong, Peoples R China.
   [Liu, Qian; Zheng, Ming H.] Univ Western Australia, Ctr Orthopaed Res, Sch Surg, Nedlands, WA 6009, Australia.
C3 University of Western Australia; Queen Elizabeth II Medical Centre;
   University of Western Australia; Jinan University; University of Western
   Australia
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Pathol & Lab Med, QEII Med Ctr, 1st Floor M Block, Nedlands, WA 6009, Australia.
EM jiake.xu@uwa.edu.au
RI ; Yan, Xiaohui/T 8783 2019
OI Zheng, Minghao/0000 0003 1185 4768; Xu, Jiake/0000 0003 2021 8309; 
FU National Health and Medical Research Council of Australia; Arthritis
   Foundation of Western Australia; Sir Charles Gairdner Hospital
   Foundation, Western Australia; University of Western Australia; National
   Health and Medical Research Council of Australia/Osteoporosis Australia
   (NHMRC/OA)
FX This work was supported in part by the National Health and Medical
   Research Council of Australia, Arthritis Foundation of Western Australia
   and the Sir Charles Gairdner Hospital Foundation, Western Australia.
   This work is also supported by the University of Western Australia
   research collaboration award and an Endeavour Executive Award, which was
   awarded to Jiake Xu. Estabelle Ang was a recipient of the National
   Health and Medical Research Council of Australia/Osteoporosis Australia
   (NHMRC/OA) Scholarship.
CR Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   Ang ESM, 2007, J CELL PHYSIOL, V212, P787, DOI 10.1002/jcp.21076
   Ang ESM, 2009, J CELL PHYSIOL, V221, P642, DOI 10.1002/jcp.21898
   Attia SM, 2008, MUTAGENESIS, V23, P515, DOI 10.1093/mutage/gen045
   Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756 3282(99)00105 2
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P363, DOI 10.1021/tx00016a015
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jagetia GC, 2003, MUTAGENESIS, V18, P337, DOI 10.1093/mutage/geg001
   Jagetia GC, 2002, MUTAT RES GEN TOX EN, V519, P37, DOI 10.1016/S1383 5718(02)00111 0
   Kanno S, 2006, LIFE SCI, V78, P673, DOI 10.1016/j.lfs.2005.04.051
   Kawaguchi K, 2004, PLANTA MED, V70, P17, DOI 10.1055/s 2004 815449
   Kawaguchi K, 1999, EUR J PHARMACOL, V368, P245, DOI 10.1016/S0014 2999(98)00867 X
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lin JM, 2007, EUR J CLIN INVEST, V37, P407, DOI 10.1111/j.1365 2362.2007.01800.x
   Mandadi K, 2009, PHYTOMEDICINE, V16, P513, DOI 10.1016/j.phymed.2008.09.001
   Matsumoto M, 2000, FEBS LETT, V486, P23, DOI 10.1016/S0014 5793(00)02231 6
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Nam NH, 2006, MINI REV MED CHEM, V6, P945, DOI 10.2174/138955706777934937
   Pavlos NJ, 2005, MOL CELL BIOL, V25, P5253, DOI 10.1128/MCB.25.12.5253 5269.2005
   Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytogfr.2003.10.005
   Tsai SH, 1999, BRIT J PHARMACOL, V126, P673, DOI 10.1038/sj.bjp.0702357
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wei M, 2007, AM J CHINESE MED, V35, P663, DOI 10.1142/S0192415X07005156
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612
   Yip KHM, 2006, AM J PATHOL, V169, P503, DOI 10.2353/ajpath.2006.050960
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 31
TC 94
Z9 119
U1 1
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0014 5793
EI 1873 3468
J9 FEBS LETT
JI FEBS Lett.
PD SEP 2
PY 2011
VL 585
IS 17
BP 2755
EP 2762
DI 10.1016/j.febslet.2011.07.046
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 812LQ
UT WOS:000294295400023
PM 21835177
DA 2025 08 17
ER

PT J
AU Niu, YB
   Kong, XH
   Li, YH
   Fan, L
   Pan, YL
   Li, CR
   Wu, XL
   Lu, TL
   Mei, QB
AF Niu, Yin Bo
   Kong, Xiang He
   Li, Yu Hua
   Fan, Li
   Pan, Ya Lei
   Li, Chen Rui
   Wu, Xiang Long
   Lu, Ting Li
   Mei, Qi Bing
TI Radix Dipsaci total saponins stimulate MC3T3 E1 cell differentiation via
   the bone morphogenetic protein 2/MAPK/Smad dependent Runx2 pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE MC3T3 E1 cells; differentiation
ID ACTIVATED PROTEIN KINASE; GROWTH FACTOR BETA; OSTEOBLAST
   DIFFERENTIATION; SIGNAL TRANSDUCTION; EXPRESSION; BMP 2; OSTEOPOROSIS;
   RECEPTORS; SMAD
AB Radix Dipsaci total saponins (RTS) are primary active components of Radix Dipsaci, which is administered orally for the treatment of osteoporosis according to Chinese Medicine. RTS have also been shown to reduce the risk of bone fractures in rats. However, the detailed molecular mechanisms underlying their action remain elusive. In the present study, the ability of RTS to increase alkaline phosphatase activity, osteocalcin levels and the degree of mineralization was investigated in MC3T3 E1 mouse osteoblast precursor cells. In addition, the associated molecular mechanism was detected. The results revealed that RTS exerted an effect on osteoblastic maturation and differentiation. Induction of differentiation by RTS was associated with an increase in the expression levels of bone morphogenetic protein 2 (BMP 2), phosphorylated (P) Smad1/518, P ERK1/2, P p38 and Runt related transcription factor 2 (Runx2). Blocking BMP 2 expression with noggin significantly reduced the levels of osteoblastic differentiation and subsequently attenuated the expression levels of P Smad1/5/8, P ERK1/2, P p38 and Runx2. This indicated that RTS induced osteoblastic differentiation through BMP 2/mitogen activated protein kinase/Smad1/5/8 dependent Runx2 signaling pathways and that it may be a promising agent for enhancing bone formation.
C1 [Niu, Yin Bo; Fan, Li; Pan, Ya Lei; Li, Chen Rui; Wu, Xiang Long; Lu, Ting Li; Mei, Qi Bing] Northwestern Polytech Univ, Sch Life Sci, Key Lab Space Biosci & Biotechnol, Xian 710072, Shaanxi, Peoples R China.
   [Kong, Xiang He] Changan Univ, Grad Sch, Xian 710064, Shaanxi, Peoples R China.
   [Li, Yu Hua; Mei, Qi Bing] Fourth Mil Med Univ, Sch Pharm, Dept Pharmacol, Xian 710032, Shaanxi, Peoples R China.
C3 Northwestern Polytechnical University; Chang'an University; Air Force
   Medical University
RP Mei, QB (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, Key Lab Space Biosci & Biotechnol, 127 Youyi West Rd, Xian 710072, Shaanxi, Peoples R China.
EM lutinglixinxin@nwpu.edu.cn; qbmei@nwpu.edu.cn
RI Li, Chenrui/D 9013 2011
FU National Natural Science Foundation of China [81202457]; China
   Postdoctoral Science Foundation [2012T50822]; Fundamental Research
   Foundation of Northwestern Polytechnical University [3102014JKY15013]
FX This study was financially supported by grants from the National Natural
   Science Foundation of China (no. 81202457), the China Postdoctoral
   Science Foundation (no. 2012T50822) and the Fundamental Research
   Foundation of Northwestern Polytechnical University (no.
   3102014JKY15013).
CR Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Berg C, 2003, NAT REV DRUG DISCOV, V2, P257, DOI 10.1038/nrd1068
   Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Hsu YL, 2009, MOL NUTR FOOD RES, V53, P1452, DOI 10.1002/mnfr.200800483
   Jia TL, 2003, BIOCHEM PHARMACOL, V65, P709, DOI 10.1016/S0006 2952(02)01585 X
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Niu YB, 2012, OSTEOPOROSIS INT, V23, P2649, DOI 10.1007/s00198 012 1932 y
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959 437X(94)90141 O
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sakai S, 2008, J TISSUE ENG REGEN M, V2, P164, DOI 10.1002/term.72
   Sakou T, 1999, J BONE MINER RES, V14, P1145, DOI 10.1359/jbmr.1999.14.7.1145
   Schelonka EP, 2001, JAMA J AM MED ASSOC, V286, P1836, DOI 10.1001/jama.286.15.1836
   Sumanasinghe RD, 2006, TISSUE ENG, V12, P3459, DOI 10.1089/ten.2006.12.3459
   Sykaras Nikitas, 2003, J Oral Sci, V45, P57
   TAKUWA Y, 1991, BIOCHEM BIOPH RES CO, V174, P96, DOI 10.1016/0006 291X(91)90490 X
   Tang CH, 2004, MOL PHARMACOL, V66, P440
   Weston CR, 2002, SCIENCE, V296, P2345, DOI 10.1126/science.1073344
   Wong RWK, 2007, PHYTOTHER RES, V21, P596, DOI 10.1002/ptr.2126
   Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325
   Yang RS, 2005, BONE, V36, P276, DOI 10.1016/j.bone.2004.10.009
NR 27
TC 30
Z9 34
U1 1
U2 31
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUN
PY 2015
VL 11
IS 6
BP 4468
EP 4472
DI 10.3892/mmr.2015.3249
PG 5
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CJ4ZL
UT WOS:000355497100066
PM 25625570
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhu, JW
   Chen, Q
   Xia, XC
   Mo, PL
   Shen, YM
   Yu, CD
AF Zhu, Jingwei
   Chen, Qiang
   Xia, Xiaochun
   Mo, Pingli
   Shen, Yuemao
   Yu, Chundong
TI Mycoepoxydiene suppresses RANKL induced osteoclast differentiation and
   reduces ovariectomy induced bone loss in mice
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE Mycoepoxydiene; Osteoclast differentiation; NF kappa B; ERK1/2; NFATc1
ID NF KAPPA B; COLONY STIMULATING FACTOR; RECEPTOR ACTIVATOR;
   NUCLEAR FACTOR; SIGNALING PATHWAYS; DOWN REGULATION; KEY REGULATOR;
   EXPRESSION; CELLS; NFATC1
AB Mycoepoxydiene (MED) is a compound isolated from the marine fungal Diaporthe sp. HLY 1 associated with mangroves. MED has various biological effects such as anti microbial, anti cancer, and anti inflammatory activities. However, the effect of MED on the differentiation of osteoclasts, the multinucleated bone resorbing cells which play a crucial role in bone remodeling, is still unknown. In this study, we showed that MED could inhibit receptor activator of NF kappa B ligand (RANKL) induced osteoclast differentiation and the expression of three well known osteoclast markers such as tartrate resistant acid phosphatase, calcitonin receptor, and cathepsin K in bone marrow derived macrophages. Furthermore, we found that MED inhibited the expression of nuclear factor of activated T cells c1, a key transcriptional factor in osteoclast differentiation, via inhibiting the phosphorylation of TAK1 and then blocking the activation of NF kappa B and ERK1/2 pathways. Moreover, MED could prevent bone loss in ovariectomized mice. Taken together, we demonstrate for the first time that MED can suppress RANKL induced osteoclast differentiation in vitro and ovariectomy induced osteoporosis in vivo, suggesting that MED is a potential lead compound for the development of novel drugs for osteoporosis treatment.
C1 [Zhu, Jingwei; Chen, Qiang; Xia, Xiaochun; Mo, Pingli; Yu, Chundong] Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Life Sci, Xiamen, Peoples R China.
   [Shen, Yuemao] Shandong Univ, Sch Pharmaceut Sci, Jinan 250100, Peoples R China.
C3 Xiamen University; Shandong University
RP Yu, CD (通讯作者)，Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Life Sci, Xiamen, Peoples R China.
EM yshen@sdu.edu.cn; cdyu@xmu.edu.cn
RI Zhu, Jingwei/NGR 0326 2025; chen, qiang/GWZ 7308 2022; Yu,
   C/G 4626 2010; Shen, YM/G 4681 2010
OI Yu, Chundong/0000 0002 4141 8345; Shen, Yuemao/0000 0002 3881 0135; 
FU National Basic Research Program of China (973 Program) [2009CB522200,
   2010CB833802]; Natural Science Foundation of Fujian Province of China
   [2010 J06014]; Program for New Century Excellent Talents in University
   of the Ministry of Education [NCET 10 0718]; Natural Science Foundation
   of China [30770455, 31170819]
FX This work was supported by grants from the National Basic Research
   Program of China (973 Program, 2009CB522200 and 2010CB833802), the
   Natural Science Foundation of Fujian Province of China (2010 J06014),
   the Program for New Century Excellent Talents in University of the
   Ministry of Education (NCET 10 0718), and the Natural Science Foundation
   of China (30770455 and 31170819).
CR Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Baron R, 2004, NAT MED, V10, P458, DOI 10.1038/nm0504 458
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen J, 2010, RADIAT PROT DOSIM, V142, P1, DOI 10.1093/rpd/ncq205
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   He YX, 2011, BONE, V48, P1388, DOI 10.1016/j.bone.2011.03.720
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hirata K, 2010, BIOL PHARM BULL, V33, P133, DOI 10.1248/bpb.33.133
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Huber DM, 2001, ENDOCRINOLOGY, V142, P3800, DOI 10.1210/en.142.9.3800
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Jiang J, 2006, J ENDODONT, V32, P742, DOI 10.1016/j.joen.2006.02.003
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lin X, 2005, FEMS MICROBIOL LETT, V251, P53, DOI 10.1016/j.femsle.2005.07.025
   Mellis DJ, 2011, J ENDOCRINOL, V211, P131, DOI 10.1530/JOE 11 0212
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Omata Yasunori, 2011, Clin Calcium, V21, P1175, DOI CliCa110811751180
   Remen KMR, 2011, J BIOL CHEM, V286, P33084, DOI 10.1074/jbc.M111.235937
   Suda T, 2001, Novartis Found Symp, V232, P235
   Takami M, 2005, FEBS LETT, V579, P832, DOI 10.1016/j.febslet.2004.12.066
   Takao K, 2002, ORG LETT, V4, P2941, DOI 10.1021/ol026338a
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600 0765.2005.00814.x
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Uchida R, 2011, J BONE MINER METAB, V29, P404, DOI 10.1007/s00774 010 0234 8
   Wang JF, 2010, BIOORG MED CHEM LETT, V20, P7054, DOI 10.1016/j.bmcl.2010.09.105
   WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828
   Yamashita M, 2010, REGUL PEPTIDES, V162, P99, DOI 10.1016/j.regpep.2010.03.003
NR 36
TC 18
Z9 18
U1 0
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175 7598
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD JAN
PY 2013
VL 97
IS 2
BP 767
EP 774
DI 10.1007/s00253 012 4146 5
PG 8
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA 072EJ
UT WOS:000313651700027
PM 22678021
DA 2025 08 17
ER

PT J
AU Viereck, V
   Gründker, C
   Friess, SC
   Frosch, KH
   Raddatz, D
   Schoppet, M
   Nisslein, T
   Emons, G
   Hofbauer, LC
AF Viereck, V
   Gründker, C
   Friess, SC
   Frosch, KH
   Raddatz, D
   Schoppet, M
   Nisslein, T
   Emons, G
   Hofbauer, LC
TI Isopropanolic extract of black cohosh stimulates osteoprotegerin
   production by human osteoblasts
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE black cohosh; osteoprotegerin; osteoblasts; osteoblastic differentiation
ID CIMICIFUGA RACEMOSA EXTRACT; BONE; EXPRESSION; LIGAND; CELLS;
   PHYTOESTROGENS; LOCALIZATION; CYTOKINE; BNO 1055
AB Introduction: Despite its positive effects on the skeleton, estrogen replacement therapy is no longer recommended as first line therapy for the prevention and treatment of postmenopausal osteoporosis because it increases cardiovascular, thromboembolic, and breast cancer risk. Recently, herbal therapeutics such as an isopropanolic extract (iCR) from the rhizomes of Cimicifuga (=Actaea) racemosa (black cohosh) are gaining interest as an alternative in the treatment of menopausal symptoms. Whereas animal studies in rats suggest positive skeletal effects, the mechanism of its actions on bone cells remain unclear. RANKL is essential for osteoclast formation and activation, while osteoprotegerin (OPG) neutralizes RANKL.
   Materials and Methods: In this study, we assessed the effects of iCR on OPG and RANKL mRNA steady state levels by semiquantitative RT PCR and on protein production by an ELISA system in human osteoblasts (hOBs).
   Results: Under serum free conditions, treatment with iCR increased OPG mRNA levels and protein secretion of hOBs by 2  to 3 fold in a dose dependent manner, with a maximum effect at a 10(6) fold dilution of iCR (p < 0.001) after 24 48 h. Time course experiments indicated a stimulatory effect of iCR on osteoblastic OPG protein secretion by 3  to 5 fold (p < 0.001) as early as 12 h, whereas RANKL expression was very low and was not found to be modulated by iCR. Of note, the stimulatory effect of iCR on OPG production was abrogated by the pure estrogen receptor antagonist ICI 182,780. Moreover, iCR enhanced two osteoblastic differentiation markers, bone specific alkaline phosphatase activity and osteocalcin expression, by up to 4  and 3 fold, respectively (p < 0.001).
   Conclusions: Our data suggest that iCR enhances differentiation and increases the OPG to RANKL ratio of normal human osteoblasts. These effects may contribute to the positive skeletal effects of black cohosh.
C1 Univ Gottingen, Dept Obstet & Gynecol, D 37075 Gottingen, Germany.
   Univ Gottingen, Dept Trauma Surg, D 37075 Gottingen, Germany.
   Univ Gottingen, Dept Gastroenterol & Endocrinol, D 37075 Gottingen, Germany.
   Univ Marburg, Dept Med, Marburg, Germany.
   Schaper & Brummer Co, R&D Dept Vet Med, Saltzgitter, Germany.
C3 University of Gottingen; University of Gottingen; University of
   Gottingen; Philipps University Marburg
RP Viereck, V (通讯作者)，Univ Gottingen, Dept Obstet & Gynecol, Robert Koch St 40, D 37075 Gottingen, Germany.
EM viereck@med.uni goettingen.de
RI ; Hofbauer, Lorenz C./G 2490 2010; Hofbauer, Lorenz/G 2490 2010
OI Grundker, Carsten/0000 0001 8828 7955; Hofbauer, Lorenz
   C./0000 0002 8691 8423; 
CR Anderson JJB, 1998, BAILLIERE CLIN ENDOC, V12, P543, DOI 10.1016/S0950 351X(98)80003 7
   BIERECK V, 2002, BIOCHEM BIOPH RES CO, V291, P680
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   BOYAN BD, 1989, J BIOL CHEM, V264, P11879
   Braidman IP, 2001, J BONE MINER RES, V16, P214, DOI 10.1359/jbmr.2001.16.2.214
   Burdette JE, 2003, J AGR FOOD CHEM, V51, P5661, DOI 10.1021/jf034264r
   Burguera B, 2001, ENDOCRINOLOGY, V142, P3546, DOI 10.1210/en.142.8.3546
   Cheung AM, 2004, CAN MED ASSOC J, V170, P1665, DOI 10.1503/cmaj.1030757
   FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601
   Fitzpatrick LA, 1999, MAYO CLIN PROC, V74, P601, DOI 10.4065/74.6.601
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Hostanska K, 2004, BIOL PHARM BULL, V27, P1970, DOI 10.1248/bpb.27.1970
   Hostanska K, 2004, BREAST CANCER RES TR, V84, P151, DOI 10.1023/B:BREA.0000018413.98636.80
   Jarry H, 2003, MATURITAS, V44, pS31, DOI 10.1016/S0378 5122(02)00346 8
   JARRY H, 1985, PLANTA MED, V51, P316, DOI 10.1055/s 2007 969500
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Nisslein T, 2003, J BONE MINER METAB, V21, P370, DOI 10.1007/s00774 003 0431 9
   OURSLER MJ, 1993, ANN MED, V25, P361, DOI 10.3109/07853899309147298
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Pockaj BA, 2004, CANCER INVEST, V22, P515, DOI 10.1081/CNV 200026394
   Raddatz D, 2004, ALIMENT PHARM THERAP, V19, P47, DOI 10.1046/j.1365 2036.2003.01802.x
   Seidlová Wuttke D, 2003, MATURITAS, V44, pS39, DOI 10.1016/S0378 5122(02)00347 X
   Seldlová Wuttke D, 2005, MATURITAS, V51, P177, DOI 10.1016/j.maturitas.2004.07.007
   Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097 4644(19991001)75:1<22::AID JCB3>3.3.CO;2 Y
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Spelsberg TC, 1999, MOL ENDOCRINOL, V13, P819, DOI 10.1210/me.13.6.819
   STEWART BW, 2003, WORLD CANC REPORT, P188
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Viereck V, 2003, J CLIN ENDOCR METAB, V88, P4206, DOI 10.1210/jc.2002 021877
   Viereck V, 2005, TRENDS ENDOCRIN MET, V16, P214, DOI 10.1016/j.tem.2005.05.002
   Viereck V, 2002, J CELL BIOCHEM, V84, P725, DOI 10.1002/jcb.10087
   Wuttke W, 2003, MATURITAS, V44, pS67, DOI 10.1016/S0378 5122(02)00350 X
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
NR 34
TC 31
Z9 36
U1 0
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2005
VL 20
IS 11
BP 2036
EP 2043
DI 10.1359/JBMR.050716
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 976VO
UT WOS:000232761800017
PM 16234977
DA 2025 08 17
ER

PT J
AU Lu, K
   Wang, HZ
   Wu, XY
   Li, C
   Deng, ZY
AF Lu, Ke
   Wang, Hongzhen
   Wu, Xiaoyang
   Li, Chong
   Deng, Zhiyong
TI miRNA 137 3p targets kruppel like factor 4 gene to inhibit Rap1/p38MAPK
   signaling in osteoporotic rats
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE miRNA 137 3p; KLF4 gene; Rap1/p38MAPK signaling pathway; zoledronic
   acid; osteoporosis
ID BONE MINERAL DENSITY; ZOLEDRONIC ACID; PROTECTS OSTEOBLASTS; CANCER;
   MICRORNA 137; EXPRESSION; MEN; FRACTURES; APOPTOSIS; THERAPY
AB Objective: To investigate the role of miRNA 137 3p and Kruppel like factor 4 (KLF4) in the regulation of osteoblast proliferation and apoptosis in osteoporotic (OP) rats by zoledronic acid (ZA) via the Rap1/p38MAPK signaling pathway. Methods: Sixty rats were randomly and equally divided into control, Sham, OP and OP + ZA treatment groups. The targeting relationship between miRNA 137 3p and KLF4 was validated by Targetscan and double luciferase reporters. qRT PCR and western blot were used to detect the expression of miR 137 3p, KLF4, and Rap1/p38MAPK pathway related factors and markers of osteogenic differentiation in femoral tissue and cell lines of each group. MTT assays and flow cytometry were used to detect cell proliferation and apoptosis, respectively. Results: Compared to the control and Sham groups, the OP model group showed significantly lower levels of blood phosphorus and BMD; both in femoral tissue and cell lines, the OP model group showed significantly increased miRNA 137 3p expression, decreased KLF4 expression, inhibited Rap1/p38MAPK pathway activation and the down regulated expression of osteogenic differentiation markers; leading to the decreased osteoblast proliferation and increased apoptosis rates (all P<0.05). All these indices improved following ZA treatment (all P<0.05). Compared to blank and negative control groups, miRNA 137 3p expression in the miR 137 3p mimic group was upregulated, whilst KLF4, p38 MAPK, Rap1 and p p38 MAPK were down regulated. si KLF4 could reverse the effects of miRNA 137 3p inhibition. Conclusion: Inhibiting miRNA 137 3p up regulates the expression of KLF4, activates Rap1/p38MAPK signaling pathway, and promotes the proliferation of osteoblasts in OP rats treated with ZA, inhibiting osteoblast apoptosis.
C1 [Lu, Ke; Wang, Hongzhen] Jiangsu Univ, Affiliated Kunshan Hosp, Dept Joint Surg, Suzhou, Jiangsu, Peoples R China.
   [Wu, Xiaoyang] Jiangsu Univ, Affiliated Kunshan Hosp, Dept Gastrointestinal Surg, Suzhou, Jiangsu, Peoples R China.
   [Li, Chong] Jiangsu Univ, Affiliated Kunshan Hosp, Dept Orthoped, Suzhou, Jiangsu, Peoples R China.
   [Deng, Zhiyong] Jiangsu Univ, Affiliated Kunshan Hosp, Dept Pathol, 91 Qianjin West Rd, Suzhou 215300, Jiangsu, Peoples R China.
C3 Jiangsu University; Jiangsu University; Jiangsu University; Jiangsu
   University
RP Deng, ZY (通讯作者)，Jiangsu Univ, Affiliated Kunshan Hosp, Dept Pathol, 91 Qianjin West Rd, Suzhou 215300, Jiangsu, Peoples R China.
EM dongqirong15l@163.com
RI Lu, Ke/KBC 3813 2024
FU Beijing Bethune Charitable Foundation [B19337ES]
FX This work was supported by the Beijing Bethune Charitable Foundation
   (B19337ES).
CR Ahn TK, 2018, J ORTHOP RES, V36, P244, DOI 10.1002/jor.23640
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   [Anonymous], 2018, BIOSCI REP
   Bilousova G, 2011, STEM CELLS, V29, P206, DOI 10.1002/stem.566
   Dong J, 2013, J CELL BIOCHEM, V114, P2738, DOI 10.1002/jcb.24622
   Frank E, 2017, ANN INTERN MED, V167, P899, DOI 10.7326/L17 0489
   Ghaleb AM, 2017, GENE, V611, P27, DOI 10.1016/j.gene.2017.02.025
   Griffith JF, 2010, RADIOLOGY, V254, P739, DOI 10.1148/radiol.09090608
   Heaney RP, 2010, AM J CLIN NUTR, V92, P101, DOI 10.3945/ajcn.2009.29085
   Herrmann K, 2018, ATLA ALTERN LAB ANIM, V46, P317, DOI 10.1177/026119291804600606
   Keiler AM, 2012, LAB ANIM UK, V46, P237, DOI 10.1258/la.2012.011154
   Kim JH, 2014, J CELL BIOL, V204, P1063, DOI 10.1083/jcb.201308102
   Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069
   Li XD, 2017, BRIT J CANCER, V116, P66, DOI 10.1038/bjc.2016.379
   Liu JS, 2018, J BIOMED NANOTECHNOL, V14, P1965, DOI 10.1166/jbn.2018.2635
   Liu XJ, 2018, INT J MOL MED, V42, P1026, DOI 10.3892/ijmm.2018.3690
   Liu XD, 2015, BIOL CHEM, V396, P339, DOI 10.1515/hsz 2014 0268
   Majithia N, 2016, SUPPORT CARE CANCER, V24, P1219, DOI 10.1007/s00520 015 2915 2
   Nayak S, 2017, J AM GERIATR SOC, V65, P490, DOI 10.1111/jgs.14668
   Panwar B, 2017, BIOINFORMATICS, V33, P1554, DOI 10.1093/bioinformatics/btx019
   Park SE, 2014, ENDOCR J, V61, P1069, DOI 10.1507/endocrj.EJ14 0119
   Sambandan S, 2017, SCIENCE, V355, P634, DOI 10.1126/science.aaf8995
   Solberg LB, 2014, CALCIFIED TISSUE INT, V94, P510, DOI 10.1007/s00223 013 9834 3
   Telonis AG, 2017, NUCLEIC ACIDS RES, V45, P2973, DOI 10.1093/nar/gkx082
   Tu CW, 2014, J SURG RES, V192, P112, DOI 10.1016/j.jss.2014.05.034
   van Wijnen AJ, 2013, CURR OSTEOPOROS REP, V11, P72, DOI 10.1007/s11914 013 0143 6
   Wang L, 2012, ANN BIOMED ENG, V40, P1884, DOI 10.1007/s10439 012 0548 x
   Wiedemann A, 2019, CALCIFIED TISSUE INT, V104, P355, DOI 10.1007/s00223 018 0505 2
   Wu L, 2013, ENDOCR J, V60, P1047, DOI 10.1507/endocrj.EJ12 0376
   Yishake M, 2018, J ORTHOP RES, V36, P937, DOI 10.1002/jor.23682
   Zhang BC, 2015, INT J BIOL MACROMOL, V74, P111, DOI 10.1016/j.ijbiomac.2014.12.002
   Zhang HM, 2018, J CELL BIOCHEM, V119, P938, DOI 10.1002/jcb.26259
   Zhang SJ, 2018, INT J BIOL MACROMOL, V107, P2094, DOI 10.1016/j.ijbiomac.2017.10.080
   Zhang XG, 2018, J CELL PHYSIOL, V233, P6798, DOI 10.1002/jcp.26430
   Zhang ZQ, 2014, OSTEOPOROSIS INT, V25, P497, DOI 10.1007/s00198 013 2418 2
   Zhao B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202269
NR 36
TC 0
Z9 0
U1 0
U2 4
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2020
VL 13
IS 4
BP 2180
EP 2193
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA LJ3BE
UT WOS:000530042400010
DA 2025 08 17
ER

PT J
AU Wang, SY
   Yang, XY
   Huang, J
   Yang, S
   Wu, Q
   Chen, HH
   Wu, ST
   Dou, CL
   Yang, GP
   Xiang, YX
AF Wang, Siyi
   Yang, Xiaoyan
   Huang, Jie
   Yang, Shuang
   Wu, Qian
   Chen, Honghui
   Wu, Shuting
   Dou, Changlin
   Yang, Guoping
   Xiang, Yuxia
TI Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a
   biosimilar of denosumab (LY06006): a randomized, double blind,
   single dose, parallel controlled clinical study in healthy Chinese
   subjects
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Article
DE Denosumab; biosimilar; pharmacokinetics; pharmacodynamics;
   immunogenicity
ID POSTMENOPAUSAL OSTEOPOROSIS; WOMEN; RANKL; REDUCTION; DIAGNOSIS;
   EXPOSURE
AB Objectives: To compare the pharmacokinetics (PK), pharmacodynamics (PD), safety, and immunogenicity of LY06006 (denosumab biosimilar) and denosumab in healthy Chinese adult male subjects.
   Methods: In this randomized, double blind, parallel controlled, single dose, comparative biosimilar study, a total of 168 subjects received 60 mg of LY06006 or denosumab by subcutaneous (SC) abdominal injections in a 1:1 ratio with a follow up period of 168 days.
   Results: After a single SC abdominal injection of 60 mg LY06006/denosumab, the geometric mean ratio of the main pharmacokinetic parameters, C max and AUC(0 infinity), of the two drugs were 97.57% and 104.27%, respectively; the geometric mean ratio of the main pharmacodynamic parameters AUEC(0 t), and E max, were 101.00% and 99.64%, respectively, and the 90% confidence interval was observed to be within 80 125%. The subjects in the test group (LY06006) and control group (denosumab) were all negative for anti drug antibody (ADA). The incidence and severity of treatment emergent adverse events (TEAEs) were similar for both groups, and no grade 3 or higher TEAEs occurred in either group.
   Conclusions: This study demonstrated that LY06006 and denosumab have similar characteristics and bioequivalence in pharmacokinetics. Moreover, they had similar pharmacodynamic profiles, safety, and immunogenicity.
C1 [Wang, Siyi; Yang, Guoping] Cent South Univ, XiangYa Sch Pharmaceut Sci, Changsha, Peoples R China.
   [Wang, Siyi; Yang, Xiaoyan; Huang, Jie; Yang, Shuang; Wu, Qian; Chen, Honghui; Wu, Shuting; Yang, Guoping; Xiang, Yuxia] Cent South Univ, Xiangya Hosp 3, Ctr Clin Pharmacol, Changsha, Hunan, Peoples R China.
   [Dou, Changlin] Shandong Boan Biotechnol Co Ltd, Res & Dev Ctr, Yantai, Peoples R China.
   [Yang, Guoping] Cent South Univ, Xiangya Hosp 3, Dept Pharm, Changsha, Peoples R China.
   [Yang, Guoping] Cent South Univ, Res Ctr Drug Clin Evaluat, Changsha, Peoples R China.
   [Yang, Guoping] Natl Local Joint Engn Lab Drug Clin Evaluat Techn, Changsha, Peoples R China.
C3 Central South University; Central South University; Central South
   University; Central South University
RP Xiang, YX (通讯作者)，Cent South Univ, Xiangya Hosp 3, Ctr Clin Pharmacol, Changsha, Hunan, Peoples R China.; Yang, GP (通讯作者)，Cent South Univ, Xiangya Hosp 3, Changsha, Peoples R China.
EM ygp9880@126.com; www7592059@163.com
RI Yang, Xiaoyan/P 9080 2014
OI YANG, Guoping/0000 0001 5930 586X
FU National Natural Science Foundation of China [81803639]; Hunan
   Provincial Natural Science Foundation of China [2020JJ5852]; Key
   Research and Development Project of Hunan Province [2020SK2010]
FX This work was supported by the [National Natural Science Foundation of
   China]; under Grant [number 81803639]; [Hunan Provincial Natural Science
   Foundation of China] under Grant [number 2020JJ5852]; and [The Key
   Research and Development Project of Hunan Province] under Grant [number
   2020SK2010].
CR Amgen, AMGEN PROLIA DENOSUM
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bone HG, 2013, J CLIN ENDOCR METAB, V98, P4483, DOI 10.1210/jc.2013 1597
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Chen HJ., 2022, FRONT PHARMACOL, V13, P10
   Chen Q, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197984
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Deeks ED, 2018, DRUG AGING, V35, P163, DOI 10.1007/s40266 018 0525 7
   Delmas PD, 2008, J CLIN DENSITOM, V11, P325, DOI 10.1016/j.jocd.2008.02.002
   Dempster DW, 2012, CLIN THER, V34, P521, DOI 10.1016/j.clinthera.2012.02.002
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Li E, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S75219
   McClung MR, 2014, NEW ENGL J MED, V370, P1664, DOI 10.1056/NEJMc1402396
   Nakamura T, 2014, J CLIN ENDOCR METAB, V99, P2599, DOI 10.1210/jc.2013 4175
   Niu SP., 2022, FRONT PHARMACOL, V13, P11
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   PECK WA, 1993, AM J MED, V94, P646
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
NR 21
TC 2
Z9 2
U1 0
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354 3784
EI 1744 7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD OCT 3
PY 2022
VL 31
IS 10
BP 1133
EP 1142
DI 10.1080/13543784.2022.2120389
EA SEP 2022
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 5I2KN
UT WOS:000850934400001
PM 36045484
DA 2025 08 17
ER

PT J
AU Goldman, SM
   Valerio, MS
   Janakiram, NB
   Dearth, CL
AF Goldman, Stephen M.
   Valerio, Michael S.
   Janakiram, Naveena B.
   Dearth, Christopher L.
TI COX 2 inhibition does not alter wound healing outcomes of a volumetric
   muscle loss injury treated with a biologic scaffold
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE inflammation; myogenesis; NSAIDS; regeneration; skeletal muscle; trauma;
   wounds and injuries
ID SATELLITE CELL PROLIFERATION; SKELETAL MUSCLE; ANTIINFLAMMATORY
   MEDICATION; REGENERATION; MACROPHAGES; TRANSPLANTATION; PHENOTYPE;
   PATHWAY; GROWTH; TISSUE
AB Volumetric muscle loss (VML) injuries are characterized by a heightened immune response that alters canonical wound healing outcomes and results in a chronic reduction of both total myofiber number and functional capacity. Preclinical and clinical investigations aimed at repairing VML injuries have largely utilized biologic scaffolds (BSs) as a potential therapeutic intervention. BSs rely on the recruitment of a myriad of host derived immune, stem, and stromal cells to induce a wound healing response that has been routinely characterized as largely fibrous matrix deposition and limited myofiber regeneration at the site of the defect. While the mechanisms by which this occurs are not fully elucidated, the role of the immune response and modulation thereof is believed to be critical to BS mediated wound healing outcomes. Given the known roles of nonsteroidal anti inflammatory drugs (NSAIDs) on cyclooxygenase (COX) signaling and of COX signaling on macrophage polarization and myogenesis, it is plausible that prescription of NSAIDs could alter BS mediated VML repair. To study the effect of COX 2 inhibition on BS mediated repair of VML, an established rat model of VML was acutely treated with BSs with and without adjunct administration of mavacoxib, a COX 2 specific inhibitor. Evaluation of the function of the affected musculature as well as the tissue level histomorphology, evaluated at 14 and 90 days postoperatively, suggested that COX 2 inhibition does not alter the baseline repair outcomes of the BS therapy. These studies provide useful information to clinicians regarding the postoperative prescription of NSAIDS in concert with a BS therapy in the treatment of VML.
C1 [Goldman, Stephen M.; Valerio, Michael S.; Janakiram, Naveena B.; Dearth, Christopher L.] DoD VA Extrem Trauma & Amputat Ctr Excellence, Res & Surveillance Div, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.
   [Goldman, Stephen M.; Valerio, Michael S.; Janakiram, Naveena B.; Dearth, Christopher L.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA.
   [Goldman, Stephen M.; Valerio, Michael S.; Janakiram, Naveena B.; Dearth, Christopher L.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA.
C3 Uniformed Services University of the Health Sciences   USA; Walter Reed
   National Military Medical Center
RP Dearth, CL (通讯作者)，DoD VA Extrem Trauma & Amputat Ctr Excellence, Res & Surveillance Div, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.
EM christopher.l.dearth.civ@mail.mil
RI ; Valerio, Michael/JKB 7726 2023; Goldman, Stephen/AAT 7318 2020
OI Goldman, Stephen/0000 0002 2244 1443; Valerio,
   Michael/0000 0003 1261 7078; Dearth, Christopher/0000 0003 3701 0950; 
FU National Institute of Biomedical Imaging and Bioengineering
   [5R03EB018889 02]
FX National Institute of Biomedical Imaging and Bioengineering, Grant/Award
   Number: 5R03EB018889 02
CR Aguilar CA, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420 018 0027 8
   Alghnam S, 2017, INJURY PREV, V23, P87, DOI 10.1136/injuryprev 2016 042059
   ALMEKINDERS LC, 1986, AM J SPORT MED, V14, P303, DOI 10.1177/036354658601400411
   Aurora A, 2015, CELLS TISSUES ORGANS, V202, P189, DOI 10.1159/000447582
   Aurora A, 2015, BIOMATERIALS, V67, P393, DOI 10.1016/j.biomaterials.2015.07.040
   Bondesen BA, 2006, AM J PHYSIOL CELL PH, V290, pC1651, DOI 10.1152/ajpcell.00518.2005
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   Chen XYK, 2013, J PLAST RECONSTR AES, V66, P1750, DOI 10.1016/j.bjps.2013.07.037
   Corona B. T., 2017, CLIN TRANSL SCI
   Corona Benjamin T, 2017, J Exp Orthop, V4, P36, DOI 10.1186/s40634 017 0112 6
   Corona BT, 2015, J REHABIL RES DEV, V52, P785, DOI 10.1682/JRRD.2014.07.0165
   Corona BT, 2013, BIOMATERIALS, V34, P3324, DOI 10.1016/j.biomaterials.2013.01.061
   Cox SR, 2010, J VET PHARMACOL THER, V33, P461, DOI 10.1111/j.1365 2885.2010.01165.x
   Dearth CL, 2016, ACTA BIOMATER, V31, P50, DOI 10.1016/j.actbio.2015.11.043
   Dziki J, 2016, NPJ REGEN MED, V1, DOI 10.1038/npjregenmed.2016.8
   Garg K, 2015, J ORTHOP RES, V33, P40, DOI 10.1002/jor.22730
   Gentile NE, 2014, AM J PHYS MED REHAB, V93, pS79, DOI 10.1097/PHM.0000000000000145
   Gessner D. M., 2019, INJURY
   Goldman SM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191245
   Goldman SM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186593
   Goldman SM, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0589 z
   Greising S. M., 2017, SCI REPORTS
   Greising SM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13306 2
   Hurtgen BJ, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1617 y
   Martinez CO, 2010, AM J PHYSIOL REG I, V299, pR832, DOI 10.1152/ajpregu.00797.2009
   Mase Vincent J Jr, 2010, Orthopedics, V33, P511, DOI 10.3928/01477447 20100526 24
   Merly F, 1999, MUSCLE NERVE, V22, P724, DOI 10.1002/(SICI)1097 4598(199906)22:6<724::AID MUS9>3.0.CO;2 O
   MISHRA DK, 1995, J BONE JOINT SURG AM, V77, P1510, DOI 10.2106/00004623 199510000 00005
   Na YR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063451
   Nakanishi Y, 2011, CARCINOGENESIS, V32, P1333, DOI 10.1093/carcin/bgr128
   Nuutila K, 2017, WOUND REPAIR REGEN, V25, P408, DOI 10.1111/wrr.12547
   OBREMSKY WT, 1994, AM J SPORT MED, V22, P558, DOI 10.1177/036354659402200420
   Otis JS, 2005, EXP CELL RES, V310, P417, DOI 10.1016/j.yexcr.2005.08.009
   Sadtler K, 2017, SEMIN IMMUNOL, V29, P14, DOI 10.1016/j.smim.2017.05.002
   Seymour RB, 2017, J BONE JOINT SURG AM, V99, DOI 10.2106/JBJS.17.00066
   Sicari BM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008085
   Thorsson O, 1998, AM J SPORT MED, V26, P172, DOI 10.1177/03635465980260020401
   Tidball JG, 2007, J PHYSIOL LONDON, V578, P327, DOI 10.1113/jphysiol.2006.118265
   Volkow ND, 2011, JAMA J AM MED ASSOC, V305, P1299, DOI 10.1001/jama.2011.401
   Wang HZ, 2014, AM J PATHOL, V184, P1167, DOI 10.1016/j.ajpath.2013.12.020
   Wheatley BM, 2019, J AM ACAD ORTHOP SUR, V27, pE330, DOI 10.5435/JAAOS D 17 00727
   Zhang J, 2014, J IMMUNOL, V193, P5149, DOI 10.4049/jimmunol.1303486
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 43
TC 6
Z9 6
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD DEC
PY 2020
VL 14
IS 12
BP 1929
EP 1938
DI 10.1002/term.3144
EA NOV 2020
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA PF5JX
UT WOS:000590566300001
PM 33049117
OA gold
DA 2025 08 17
ER

PT J
AU Browne, AJ
   Kubasch, ML
   Göbel, A
   Hadji, P
   Chen, D
   Rauner, M
   Stölzel, F
   Hofbauer, LC
   Rachner, TD
AF Browne, Andrew J.
   Kubasch, Marie L.
   Goebel, Andy
   Hadji, Peyman
   Chen, David
   Rauner, Martina
   Stoelzel, Friedrich
   Hofbauer, Lorenz C.
   Rachner, Tilman D.
TI Concurrent antitumor and bone protective effects of everolimus in
   osteotropic breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
DE mTOR inhibition; Breast cancer; Bone metastases; Hormone ablation;
   Antiresorptive
ID MTOR INHIBITOR; OSTEOCLAST DIFFERENTIATION; MAMMALIAN TARGET; RAPAMYCIN;
   PATHWAY; CELLS; THERAPY; RAD001; WOMEN; METASTASIS
AB Background: The mammalian target of rapamycin inhibitor everolimus is approved as an antitumor agent in advanced estrogen receptor positive breast cancer. Surrogate bone marker data from clinical trials suggest effects on bone metabolism, but the mode of action of everolimus in bone biology remains unclear. In this study, we assessed potential bone protective effects of everolimus in the context of osteotropic tumors.
   Methods: The effects of everolimus on cancer cell viability in vitro and on tumor growth in vivo were assessed. Everolimus regulated osteoclastogenesis and osteoblastogenesis were also assessed in vitro before we assessed the bone protective effect of everolimus in a model where bone loss was induced in ovariectomized (OVX) mice. Finally, the role of everolimus in the progression of osteolytic bone disease was assessed in an intracardiac model of breast cancer bone metastases.
   Results: At low concentrations (1 nM) in vitro, everolimus reduced the viability of human and murine cancer cell lines and impaired the osteoclastogenesis of osteoclast progenitors as assessed by quantitative real time polymerase chain reaction and counting tartrate resistant acid phosphatase positive, multinucleated osteoclasts (p < 0.001). Everolimus had little or no deleterious effect on osteoblastogenesis in vitro, with concentrations of 1 and 10 nM increasing the messenger RNA expression of osteoblast marker genes (p <= 0.05) and leaving mineralization in differentiated human mesenchymal stem cells unchanged. Everolimus treatment (1 mg/kg body weight/day) prevented the bone loss observed in OVX mice and concurrently inhibited the metastatic growth of MDA MB 231 cells by 70% (p < 0.002) while preserving bone mass in an intracardiac model of bone metastasis.
   Conclusions: These results underline the antitumor effects of everolimus and highlight its bone protective efficacy, warranting further research on the potential implications on bone health in populations prone to osteoporosis and bone metastases, such as postmenopausal women with breast cancer.
C1 [Browne, Andrew J.; Kubasch, Marie L.; Goebel, Andy; Rauner, Martina; Hofbauer, Lorenz C.; Rachner, Tilman D.] Tech Univ Dresden, Div Endocrinol Diabet & Bone Dis, Dept Med 3, Fetscherstr 74, D 01307 Dresden, Germany.
   [Browne, Andrew J.; Kubasch, Marie L.; Goebel, Andy; Rauner, Martina; Hofbauer, Lorenz C.; Rachner, Tilman D.] Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany.
   [Hadji, Peyman] Philipps Univ Marburg, Marburg, Germany.
   [Chen, David] Novartis Pharmaceut, E Hanover, NJ USA.
   [Stoelzel, Friedrich] Tech Univ Dresden, Div Hematol, Dept Med 1, Dresden, Germany.
   [Hofbauer, Lorenz C.] German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany.
   [Hofbauer, Lorenz C.] German Canc Res Ctr, Heidelberg, Germany.
C3 Technische Universitat Dresden; Technische Universitat Dresden; Philipps
   University Marburg; Novartis; Novartis USA; Technische Universitat
   Dresden; Helmholtz Association; German Cancer Research Center (DKFZ);
   Helmholtz Association; German Cancer Research Center (DKFZ)
RP Rachner, TD (通讯作者)，Tech Univ Dresden, Div Endocrinol Diabet & Bone Dis, Dept Med 3, Fetscherstr 74, D 01307 Dresden, Germany.; Rachner, TD (通讯作者)，Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany.
EM tilman.rachner@uniklinikum dresden.de
RI Stölzel, Friedrich/AAZ 8613 2021; Rauner, Martina/A 1665 2015; Hofbauer,
   Lorenz C./G 2490 2010; Hofbauer, Lorenz/G 2490 2010
OI Rauner, Martina/0000 0002 4067 6799; Hofbauer, Lorenz
   C./0000 0002 8691 8423; 
FU Novartis Pharmaceutical Corp.; DFG [SKELMET Forschergruppe 1586];
   Dresden International Graduate School for Biomedicine and Bioengineering
   (DIGS BB); German Research Foundation (DFG)
FX Novartis Pharmaceutical Corp. and the DFG (SKELMET Forschergruppe 1586)
   provided funding for this study. We thank the Dresden International
   Graduate School for Biomedicine and Bioengineering (DIGS BB) and the
   German Research Foundation (DFG) for their support with paying the
   publication costs in the context of the Excellence Initiative.
CR Alayev A, 2016, ONCOGENE, V35, P3535, DOI 10.1038/onc.2015.414
   Albert JM, 2006, MOL CANCER THER, V5, P1183, DOI 10.1158/1535 7163.MCT 05 0400
   [Anonymous], 2014, BONEKEY REP, DOI [10.1038/bonekey.2014.24, DOI 10.1038/BONEKEY.2014.24]
   [Anonymous], 2016, INT J MOL SCI
   Apelo SIA, 2016, AGING CELL, V15, P28, DOI 10.1111/acel.12405
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Beeram M, 2007, ANN ONCOL, V18, P1323, DOI 10.1093/annonc/mdm170
   Browne AJ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.32
   Brufsky A, 2006, SEMIN ONCOL, V33, pS13, DOI 10.1053/j.seminoncol.2006.03.022
   Brufsky AM, 2007, CLIN BREAST CANCER, V8, pS22, DOI 10.3816/CBC.2007.s.009
   Cejka D, 2010, ARTHRITIS RHEUM US, V62, P2294, DOI 10.1002/art.27504
   CHEN JH, 2015, BIOMED RES INT
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Dronca RS, 2014, AM J CLIN ONCOL CANC, V37, P369, DOI 10.1097/COC.0b013e31827b45d4
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Gnant M, 2013, JNCI J NATL CANCER I, V105, P654, DOI 10.1093/jnci/djt026
   Hadji P, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.60
   Hadji P, 2013, CRIT REV ONCOL HEMAT, V87, P101, DOI 10.1016/j.critrevonc.2013.05.015
   Hainsworth JD, 2010, CANCER AM CANCER SOC, V116, P4122, DOI 10.1002/cncr.25320
   Houghton PJ, 2010, CLIN CANCER RES, V16, P1368, DOI 10.1158/1078 0432.CCR 09 1314
   Huang B, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005426
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Irelli A, 2016, BONE, V87, P169, DOI 10.1016/j.bone.2016.04.006
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Kong Y, 2016, CLIN CANCER RES, V22, P1018, DOI 10.1158/1078 0432.CCR 15 1110
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Liu HY, 2012, ANTICANCER RES, V32, P1627
   LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302
   Lui A, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2490 z
   Martin SK, 2015, STEM CELLS, V33, P1359, DOI 10.1002/stem.1931
   Martin SK, 2010, J BONE MINER RES, V25, P2126, DOI 10.1002/jbmr.114
   Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680
   Mogi M, 2009, BIOCHEM BIOPH RES CO, V384, P82, DOI 10.1016/j.bbrc.2009.04.084
   Monzon JG, 2012, ONCOTARGETS THER, V5, DOI 10.2147/OTT.S21259
   Mukhopadhyay S, 2016, MOL CANCER THER, V15, P347, DOI 10.1158/1535 7163.MCT 15 0720
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Politano A, 2010, CANCER GROWTH METAST, V3, P21
   Rachner TD, 2013, J BONE ONCOL, V2, P110, DOI 10.1016/j.jbo.2013.05.003
   Shui C, 2002, CALCIFIED TISSUE INT, V71, P437, DOI 10.1007/s00223 001 1138 3
   Simone V, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1717 8
   Wright LE, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.31
   Yu YF, 2014, ACTA BIOCH BIOPH SIN, V46, P792, DOI 10.1093/abbs/gmu069
   Yunokawa M, 2012, CANCER SCI, V103, P1665, DOI 10.1111/j.1349 7006.2012.02359.x
   Zhang XB, 2012, EUR J CANCER, V48, P1581, DOI 10.1016/j.ejca.2012.02.053
NR 46
TC 23
Z9 23
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465 5411
EI 1465 542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD AUG 9
PY 2017
VL 19
AR 92
DI 10.1186/s13058 017 0885 7
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FE0VH
UT WOS:000407937300001
PM 28793923
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Agarwal, S
   Loder, S
   Levi, B
AF Agarwal, Shailesh
   Loder, Shawn
   Levi, Benjamin
TI Heterotopic Ossification Following Upper Extremity Injury
SO HAND CLINICS
LA English
DT Article
DE Heterotopic ossification; Burn injury; Elbow; Upper extremity
ID SPINAL CORD INJURY; SELECTIVE COX 2 INHIBITOR; RISK FACTORS;
   RADIATION THERAPY; SURGICAL RESECTION; HIP ARTHROPLASTY; BONY ANKYLOSIS;
   BURN INJURY; ELBOW; PREVENTION
AB Heterotopic ossification (HO) presents a substantial barrier to rehabilitation for patients with severe burns or trauma. Although surgical excision is a mainstay of management for this condition, this is unable to address the chronic sequelae of HO, including chronic pain, joint contractures, nerve dysfunction, and open wounds. Current therapeutic modalities are aimed at excision and the prevention of recurrence using nonsteroidal antiinflammatory drugs (NSAIDs) or radiation therapy. Research is now focused on identifying alternative strategies to prevent the initial occurrence of HO through NSAIDs and novel inhibitors of the bone morphogenetic protein signaling pathway.
C1 [Agarwal, Shailesh; Loder, Shawn; Levi, Benjamin] Univ Michigan, Sect Plast Surg, 1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Levi, B (通讯作者)，1150 West Med Ctr Dr,MSRB2 A574, Ann Arbor, MI 48109 USA.
EM blevi@umich.edu
FU National Institutes of Health/National Institute of General Medical
   Sciences [K08GM109105 0]; Plastic Surgery Foundation; Association for
   Academic Surgery Roslyn Award; American Association for the Surgery of
   Trauma Research & Education Foundation Scholarship; American College of
   Surgeons Clowes Award; Coller Society Research Fellowship; NIH Loan
   Repayment Program; National Institutes of Health [F32AR06649901A1]
FX B. Levi was supported by funding from National Institutes of
   Health/National Institute of General Medical Sciences grant
   K08GM109105 0, Plastic Surgery Foundation, the Association for Academic
   Surgery Roslyn Award, American Association for the Surgery of Trauma
   Research & Education Foundation Scholarship, and American College of
   Surgeons Clowes Award. S. Agarwal was supported by the Coller Society
   Research Fellowship, NIH Loan Repayment Program, National Institutes of
   Health, F32AR06649901A1, and Plastic Surgery Foundation.
CR Adams JE, 2013, TXB HAND UPPER EXTRE
   Agarwal S, 2016, P NATL ACAD SCI USA, V113, pE338, DOI 10.1073/pnas.1515397113
   Amstutz HC, 2004, J BONE JOINT SURG AM, V86A, P28, DOI 10.2106/00004623 200401000 00006
   Back DL, 2007, ANZ J SURG, V77, P642, DOI 10.1111/j.1445 2197.2007.04178.x
   Baldwin K, 2011, J HAND SURG AM, V36A, P798, DOI 10.1016/j.jhsa.2011.01.015
   Bauer AS, 2012, J HAND SURG AM, V37A, P1422, DOI 10.1016/j.jhsa.2012.03.013
   Bauer DC, 1996, J BONE MINER RES, V11, P29
   Beckmann JT, 2014, AM J SPORT MED, V42, P1359, DOI 10.1177/0363546514526361
   Brouwer KM, 2010, J HAND SURG AM, V35A, P1115, DOI 10.1016/j.jhsa.2010.03.040
   Cipriano C, 2009, ORTHOPEDICS, V32
   Citak M, 2016, SPINAL CORD, V54, P303, DOI 10.1038/sc.2015.182
   Citak M, 2012, SPINE, V37, P1953, DOI 10.1097/BRS.0b013e31825ee81b
   Crane NJ, 2013, BONE, V57, P335, DOI 10.1016/j.bone.2013.08.026
   D'Lima DD, 2001, ORTHOPEDICS, V24, P1139
   ELLEDGE ES, 1988, J TRAUMA, V28, P684, DOI 10.1097/00005373 198805000 00023
   EVANS EB, 1959, J BONE JOINT SURG AM, V41, P785, DOI 10.2106/00004623 195941050 00001
   Gaur A, 2003, J BONE JOINT SURG AM, V85A, P1538, DOI 10.2106/00004623 200308000 00016
   Genêt F, 2015, J PATHOL, V236, P229, DOI 10.1002/path.4519
   Grohs JG, 2007, ACTA ORTHOP, V78, P95, DOI 10.1080/17453670610013484
   Harris M, 2015, CONNECT TISSUE RES, V56, P144, DOI 10.3109/03008207.2015.1013190
   Heyd R, 2009, STRAHLENTHER ONKOL, V185, P506, DOI 10.1007/s00066 009 1968 x
   Hong CC, 2015, ORTHOP TRAUMATOL SUR, V101, P209, DOI 10.1016/j.otsr.2014.10.021
   Lee EK, 2013, J SHOULDER ELB SURG, V22, P716, DOI 10.1016/j.jse.2012.11.020
   Levi B, 2015, J TRAUMA ACUTE CARE, V79, P870, DOI 10.1097/TA.0000000000000838
   Lima MC, 2014, ACTA ORTOP BRAS, V22, P12, DOI 10.1590/S1413 78522014000100001
   Lin SH, 2014, J MED ULTRASOUND, V22, P222, DOI 10.1016/j.jmu.2014.10.004
   Lin Y, 2014, CLIN NUCL MED, V39, P62, DOI 10.1097/RLU.0b013e318286824f
   Lindenhovius ALC, 2007, J SHOULDER ELB SURG, V16, P621, DOI 10.1016/j.jse.2007.01.005
   Maender C, 2010, J SHOULDER ELB SURG, V19, P1269, DOI 10.1016/j.jse.2010.05.029
   MALONEY WJ, 1991, J BONE JOINT SURG AM, V73A, P191, DOI 10.2106/00004623 199173020 00006
   Medina A, 2014, J BURN CARE RES, V35, P251, DOI 10.1097/BCR.0b013e3182957768
   Mishra MV, 2011, J MED IMAG RADIAT ON, V55, P333, DOI 10.1111/j.1754 9485.2011.02275.x
   Oni JK, 2014, HIP INT, V24, P256, DOI 10.5301/hipint.5000109
   Orchard GR, 2015, J BURN CARE RES, V36, P465, DOI 10.1097/BCR.0000000000000123
   Pavey GJ, 2015, CLIN ORTHOP RELAT R, V473, P2840, DOI 10.1007/s11999 015 4272 3
   PELLEGRINI VD, 1994, INT J RADIAT ONCOL, V30, P743, DOI 10.1016/0360 3016(92)90967 M
   Peterson JR, 2015, STEM CELLS DEV, V24, P205, DOI 10.1089/scd.2014.0291
   Peterson JR, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008810
   Peterson JR, 2013, BONE, V54, P28, DOI 10.1016/j.bone.2013.01.002
   Podlipská J, 2016, SCI REP UK, V6, DOI 10.1038/srep22365
   Polfer EM, 2015, BONE JOINT J, V97B, P572, DOI 10.1302/0301 620X.97B4.34866
   Pontell ME, 2015, J BURN CARE RES, V36, P57, DOI 10.1097/BCR.0000000000000116
   Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412
   Potter BK, 2010, J BONE JOINT SURG AM, V92A, P74, DOI 10.2106/JBJS.J.00776
   Rath E, 2016, AM J SPORT MED, V44, P677, DOI 10.1177/0363546515618623
   Reznik JE, 2014, J MUSCULOSKEL NEURON, V14, P19
   Ring D, 2003, J BONE JOINT SURG AM, V85A, P849, DOI 10.2106/00004623 200305000 00012
   Ring David, 2004, J Bone Joint Surg Am, V86 A Suppl 1, P2
   Robinson CG, 2010, INT J RADIAT ONCOL, V77, P1493, DOI 10.1016/j.ijrobp.2009.06.072
   Romanò CL, 2004, J ARTHROPLASTY, V19, P14, DOI 10.1016/S0883 5403(03)00279 1
   Salazar D, 2014, CLIN ORTHOP RELAT R, V472, P2269, DOI 10.1007/s11999 014 3591 0
   Schuetz P, 2005, SPINAL CORD, V43, P604, DOI 10.1038/sj.sc.3101761
   Seegenschmiedt MH, 1997, INT J RADIAT ONCOL, V39, P161, DOI 10.1016/S0360 3016(97)00285 X
   Seegenschmiedt MH, 2001, INT J RADIAT ONCOL, V51, P756, DOI 10.1016/S0360 3016(01)01640 6
   SEEGENSCHMIEDT MH, 1993, RADIOLOGY, V188, P257, DOI 10.1148/radiology.188.1.8511308
   Shafer DM, 2008, BURNS, V34, P355, DOI 10.1016/j.burns.2007.04.006
   Shimono K, 2011, NAT MED, V17, P454, DOI 10.1038/nm.2334
   Spiro AS, 2010, J ORTHOP RES, V28, P785, DOI 10.1002/jor.21044
   Stover S L, 1976, Paraplegia, V14, P146
   Sun YB, 2015, J SHOULDER ELB SURG, V24, P1735, DOI 10.1016/j.jse.2015.07.006
   Tozun R, 1992, J Arthroplasty, V7, P57, DOI 10.1016/0883 5403(92)90033 M
   Treacy RBC, 2005, J BONE JOINT SURG BR, V87B, P167, DOI 10.1302/0301 620X.87B2.15030
   Vasileiadis GI, 2011, ORTHOPEDICS, V34, P467, DOI 10.3928/01477447 20110427 23
   Vavken P, 2011, ARCH ORTHOP TRAUM SU, V131, P1309, DOI 10.1007/s00402 011 1280 y
   Vavken P, 2009, CLIN ORTHOP RELAT R, V467, P3283, DOI 10.1007/s11999 009 0924 5
   Veltman ES, 2014, STRATEG TRAUMA LIMB, V9, P65, DOI 10.1007/s11751 014 0192 0
   Virk MS, 2013, TXB HAND EXTREMITY S
   WITTENBERG RH, 1992, J BONE JOINT SURG BR, V74, P215, DOI 10.1302/0301 620X.74B2.1544955
   Xue DT, 2011, INT ORTHOP, V35, P3, DOI 10.1007/s00264 009 0886 y
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
NR 70
TC 18
Z9 19
U1 0
U2 14
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0749 0712
EI 1558 1969
J9 HAND CLIN
JI Hand Clin.
PD MAY
PY 2017
VL 33
IS 2
BP 363
EP +
DI 10.1016/j.hcl.2016.12.013
PG 12
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA ET5IK
UT WOS:000400317200013
PM 28363301
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Young, RN
   Grynpas, MD
AF Young, Robert N.
   Grynpas, Marc D.
TI Targeting therapeutics to bone by conjugation with bisphosphonates
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID METAPHYSEAL HARD TISSUE; RAPIDLY GROWING RATS; OSTEOGENESIS IMPERFECTA;
   IN VIVO; OSTEOTROPIC PRODRUGS; ALENDRONATE; OSTEOPOROSIS; DRUGS;
   PHARMACOKINETICS; PROSTAGLANDIN E2
AB Bisphosphonates target and bind avidly to the mineral (hydroxyapatite) found in bone. This targeting ability has been exploited to design and prepare bisphosphonate conjugate prodrugs to deliver a wide variety of drug molecules selectively to bones. It is important that conjugates be stable in the blood stream and that conjugate that is not taken up by bone is eliminated rapidly. The prodrugs should release active drug at a rate appropriate so as to provide efficacy. Radiolabelling is the best method to quantify and evaluate pharmacokinetics, tissue distribution, bone uptake and release of the active drug(s). Recent reports have described bisphosphonate conjugates derived from the antiresorptive drug, alendronic acid and anabolic prostanoid drugs that effectively deliver prostaglandins and prostaglandin EP4 receptor agonists to bone and show enhanced anabolic efficacy and tolerability compared to the drugs alone. These conjugate drugs can be dosed infrequently (weekly or bimonthly) whereas the free drugs must be dosed daily.
C1 [Young, Robert N.] Simon Fraser Univ, Dept Chem, Burnaby, BC, Canada.
   [Grynpas, Marc D.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.
   [Grynpas, Marc D.] Univ Toronto, Toronto, ON, Canada.
C3 Simon Fraser University; University of Toronto; Sinai Health System
   Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto
RP Young, RN (通讯作者)，Simon Fraser Univ, Dept Chem, Burnaby, BC, Canada.
EM robert_young@sfu.ca
RI Grynpas, Marc/ABG 7096 2020
OI Young, Robert/0000 0002 8235 6080
FU Canadian Institutes of Health Research; Institute for Musculoskelctal
   Health and Arthritis [122069, 139096]; Canada Foundation for Innovation;
   British Columbia Government Leading Edge Endowment Fund
FX The authors acknowledge the financial support of the Canadian Institutes
   of Health Research, Institute for Musculoskelctal Health and Arthritis
   (Grant # 122069 and Grant # 139096), Canada Foundation for Innovation,
   and the British Columbia Government Leading Edge Endowment Fund.
CR Agyin JK, 2013, BIOORG MED CHEM LETT, V23, P6455, DOI 10.1016/j.bmcl.2013.09.043
   Arns S, 2012, BIOORGAN MED CHEM, V20, P2131, DOI 10.1016/j.bmc.2012.01.024
   Billot X., 2003, Patent No. [WO 03/103772, 03103772]
   Byun Ji Hye, 2017, J Bone Metab, V24, P37
   Chen G, 2015, BIOCONJUGATE CHEM, V26, P1095, DOI 10.1021/acs.bioconjchem.5b00160
   Erez R, 2008, BIOORG MED CHEM LETT, V18, P816, DOI 10.1016/j.bmcl.2007.11.029
   Ferreira Diego Dos Santos, 2016, Int J Nanomedicine, V11, P3737, DOI 10.2147/IJN.S109966
   GERTZ BJ, 1995, CLIN PHARMACOL THER, V58, P288, DOI 10.1016/0009 9236(95)90245 7
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Gittens SA, 2005, ADV DRUG DELIVER REV, V57, P1011, DOI 10.1016/j.addr.2004.12.015
   Glorieux FH, 2017, J BONE MINER RES, V32, P1496, DOI 10.1002/jbmr.3143
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   Hochdörffer K, 2012, J MED CHEM, V55, P7502, DOI 10.1021/jm300493m
   Houghton TJ, 2008, J MED CHEM, V51, P6955, DOI 10.1021/jm801007z
   Hu S, 2016, OSTEOPOROSIS INT, V27, P797, DOI 10.1007/s00198 015 3284 x
   Jahnke W, 2015, ANGEW CHEM INT EDIT, V54, P14575, DOI 10.1002/anie.201507064
   JEE WSS, 1987, BONE, V8, P171, DOI 10.1016/8756 3282(87)90017 2
   Karamustafa F., 2006, Fabad J. Pharm. Sci, V31, P31
   Lin JH, 1999, INT J CLIN PRACT, P18
   Liu CC, 2015, J BONE MINER RES, V30, P670, DOI 10.1002/jbmr.2382
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Lv F, 2016, ENDOCR PRACT, V22, P1369, DOI 10.4158/EP161322.OR
   Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36
   Markovic T, 2017, DRUG DISCOV TODAY, V22, P57, DOI 10.1016/j.drudis.2016.08.003
   Miller SC, 2008, PHARM RES
   NORRDIN RW, 1990, PROSTAG LEUKOTR ESS, V41, P139, DOI 10.1016/0952 3278(90)90081 U
   Orwoll ES, 2014, J CLIN INVEST, V124, P491, DOI 10.1172/JCI71101
   Ouyang L, 2011, BIOORGAN MED CHEM, V19, P3750, DOI 10.1016/j.bmc.2011.05.004
   Pan HZ, 2008, MOL PHARMACEUT, V5, P548, DOI 10.1021/mp800003u
   Paolino D, 2015, J MATER CHEM B, P3250
   PIERCE WM, 1987, P SOC EXP BIOL MED, V186, P96
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Reagan MR, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.881.881
   Reddy R, 2008, CHEMMEDCHEM, V3, P1863, DOI 10.1002/cmdc.200800255
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   SVENSSON LA, 1991, AGENT ACTION SUPPL, V34, P71
   Tanaka KSE, 2008, BIOORGAN MED CHEM, V16, P9217, DOI 10.1016/j.bmc.2008.09.010
   UENO K, 1985, BONE, V6, P79, DOI 10.1016/8756 3282(85)90311 4
   Willson TM, 1996, BIOORG MED CHEM LETT, V6, P1043, DOI 10.1016/0960 894X(96)00164 3
   Xie HB, 2017, J MED CHEM, V60, P7012, DOI 10.1021/acs.jmedchem.6b00951
   Young RN, 2004, HETEROCYCLES, V64, P437
NR 41
TC 32
Z9 36
U1 0
U2 25
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471 4892
EI 1471 4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD JUN
PY 2018
VL 40
BP 87
EP 94
DI 10.1016/j.coph.2018.03.010
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GM6YE
UT WOS:000438324100015
PM 29626715
OA Green Submitted
DA 2025 08 17
ER

PT J
AU He, XQ
   Wang, H
   Jin, T
   Xu, YQ
   Mei, LB
   Yang, J
AF He, Xiaoqing
   Wang, Hai
   Jin, Tao
   Xu, Yongqing
   Mei, Liangbin
   Yang, Jun
TI TLR4 Activation Promotes Bone Marrow MSC Proliferation and Osteogenic
   Differentiation via Wnt3a and Wnt5a Signaling
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; TOLL LIKE RECEPTORS; FACTOR KAPPA B;
   ADIPOGENESIS; EXPRESSION; INHIBIT; INNATE
AB Mesenchymal stem cells (MSCs) from adult bone marrow maintain their self renewal ability and the ability to differentiate into osteoblast. Thus, adult bone marrow MSCs play a key role in the regeneration of bone tissue. Previous studies indicated that TLR4 is expressed in MSCs and is critical in regulating the fate decision of MSCs. However, the exact functional role and underlying mechanisms of how TLR4 regulate bone marrow MSC proliferation and differentiation are unclear. Here, we found that activated TLR4 by its ligand LPS promoted the proliferation and osteogenic differentiation of MSCs in vitro. TLR4 activation by LPS also increased cytokine IL 6 and IL 1 beta production in MSCs. In addition, LPS treatment has no effect on inducing cell death of MSCs. Deletion of TLR4 expression in MSCs completely eliminated the effects of LPS on MSC proliferation, osteogenic differentiation and cytokine production. We also found that the mRNA and protein expression of Wnt3a and Wnt5a, two important factors in regulating MSC fate decision, was upregulated in a TLR4 dependent manner. Silencing Wnt3a with specific siRNA remarkably inhibited TLR4 induced MSC proliferation, while Wnt5a specific siRNA treatment significantly antagonized TLR4 induced MSC osteogenic differentiation. These results together suggested that TLR4 regulates bone marrow MSC proliferation and osteogenic differentiation through Wnt3a and Wnt5a signaling. These finding provide new data to understand the role and the molecular mechanisms of TLR4 in regulating bone marrow MSC functions. These data also provide new insight in developing new therapy in bone regeneration using MSCs by modulating TLR4 and Wnt signaling activity.
C1 [He, Xiaoqing; Wang, Hai] Third Mil Med Univ, Chongqing, Peoples R China.
   [He, Xiaoqing; Wang, Hai; Jin, Tao; Xu, Yongqing; Mei, Liangbin; Yang, Jun] Kunming Gen Hosp Chengdu Mil Command, Dept Orthopaed Surg, Kunming, Peoples R China.
C3 Army Medical University; Kunming General Hospital
RP Xu, YQ (通讯作者)，Kunming Gen Hosp Chengdu Mil Command, Dept Orthopaed Surg, Kunming, Peoples R China.
EM yongqingxu97@126.com
RI xiaoqing, he/ABF 8047 2021
FU National Natural Sciences Foundation of China [81472096]
FX This work was funded by the National Natural Sciences Foundation of
   China (Grant No. 81472096). The funder had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Bilkovski R, 2010, J BIOL CHEM, V285, P6170, DOI 10.1074/jbc.M109.054338
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Brewster BD, 2012, J SURG RES, V177, P330, DOI 10.1016/j.jss.2012.04.042
   Bruder SP, 1998, J ORTHOPAED RES, V16, P155, DOI 10.1002/jor.1100160202
   Brun J, 2013, BONE, V53, P6, DOI 10.1016/j.bone.2012.11.020
   Carrero R, 2012, STEM CELL REV REP, V8, P905, DOI 10.1007/s12015 012 9364 9
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Chen CH, 2015, STEM CELLS DEV, V24, P1751, DOI 10.1089/scd.2014.0489
   Chen CH, 2011, NEUROTOX RES, V20, P15, DOI 10.1007/s12640 010 9214 y
   Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567
   Ebert R, 2015, STEM CELL RES, V15, P231, DOI 10.1016/j.scr.2015.06.008
   Fiedler T, 2013, EXP CELL RES, V319, P2883, DOI 10.1016/j.yexcr.2013.08.020
   Fu YC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091581
   Gao S, 2014, EXP BIOL MED, V239, P366, DOI 10.1177/1535370213518169
   Glenn Justin D, 2014, World J Stem Cells, V6, P526, DOI 10.4252/wjsc.v6.i5.526
   Glennie S, 2005, BLOOD, V105, P2821, DOI 10.1182/blood 2004 09 3696
   Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369
   He SD, 2011, P NATL ACAD SCI USA, V108, P20054, DOI 10.1073/pnas.1116302108
   He WX, 2014, J ENDODONT, V40, P69, DOI 10.1016/j.joen.2013.09.011
   Hwang SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101558
   Jones E, 2011, INJURY, V42, P562, DOI 10.1016/j.injury.2011.03.030
   Kondo M, 2015, ARTHRITIS RHEUMATOL, V67, P1250, DOI 10.1002/art.39036
   Levin S, 2014, STEM CELL REV REP, V10, P376, DOI 10.1007/s12015 014 9498 z
   Liotta F, 2008, STEM CELLS, V26, P279, DOI 10.1634/stemcells.2007 0454
   Livingston TL, 2003, J MATER SCI MATER M, V14, P211, DOI 10.1023/A:1022824505404
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   Mo IFY, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 52
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rahmat Z, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt160
   Raicevic G, 2012, TISSUE ENG PT A, V18, P1410, DOI [10.1089/ten.tea.2011.0434, 10.1089/ten.TEA.2011.0434]
   Raicevic G, 2011, CELL IMMUNOL, V270, P207, DOI 10.1016/j.cellimm.2011.05.010
   Raicevic G, 2010, HUM IMMUNOL, V71, P235, DOI 10.1016/j.humimm.2009.12.005
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Romieu Mourez R, 2009, J IMMUNOL, V182, P7963, DOI 10.4049/jimmunol.0803864
   Satija NK, 2007, STEM CELLS DEV, V16, P7, DOI 10.1089/scd.2006.9998
   Shang YC, 2007, ACTA PHARMACOL SIN, V28, P1761, DOI 10.1111/j.1745 7254.2007.00671.x
   Sharifnia T, 2015, AM J PHYSIOL GASTR L, V309, pG270, DOI 10.1152/ajpgi.00304.2014
   Sodhi CP, 2010, GASTROENTEROLOGY, V138, P185, DOI 10.1053/j.gastro.2009.09.045
   Tang J, 2015, CELL PROLIFERAT, V48, P239, DOI 10.1111/cpr.12173
   Wang ZJ, 2009, CELL BIOL INT, V33, P665, DOI 10.1016/j.cellbi.2009.03.006
   Xu NR, 2013, EXP MOL PATHOL, V94, P33, DOI 10.1016/j.yexmp.2012.08.003
   Yu JM, 2006, MOL CELL BIOCHEM, V288, P17, DOI 10.1007/s11010 005 9113 3
NR 44
TC 80
Z9 86
U1 2
U2 30
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 1
PY 2016
VL 11
IS 3
AR e0149876
DI 10.1371/journal.pone.0149876
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DF5ZW
UT WOS:000371434500068
PM 26930594
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Wu, YX
   Sun, Y
   Ye, YP
   Zhang, P
   Guo, JC
   Huang, JM
   Jing, XZ
   Xiang, W
   Yu, SY
   Guo, FJ
AF Wu, Ying Xing
   Sun, Yue
   Ye, Ya Ping
   Zhang, Peng
   Guo, Jia Chao
   Huang, Jun Ming
   Jing, Xing Zhi
   Xiang, Wei
   Yu, Shi Ying
   Guo, Feng Jing
TI Iguratimod prevents ovariectomy induced bone loss and suppresses
   osteoclastogenesis via inhibition of peroxisome proliferator activated
   receptor γ
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE iguratimod; postmenopausal osteoporosis; ovariectomy; RANKL; PPAR gamma
ID FACTOR KAPPA B; ANTIRHEUMATIC DRUG; RHEUMATOID ARTHRITIS; MARROW
   ADIPOGENESIS; CYTOKINE PRODUCTION; SYNOVIAL CELLS; RAW264.7 CELLS;
   RANKL; DIFFERENTIATION; EXPRESSION
AB Iguratimod is known for its anti inflammatory activities and therapeutic effects in patients with rheumatoid arthritis. It has previously been demonstrated that iguratimod attenuates bone destruction and osteoclast formation in the Walker 256 rat mammary gland carcinoma cell induced bone cancer pain model. Therefore, it was hypothesized that iguratimod may additionally exhibit therapeutic effects on benign osteoclast associated diseases including postmenopausal osteoporosis. In the present study, ovariectomized mice were used to investigate the effects of iguratimod in vivo. Bone marrow mononuclear cells were cultured to detect the effects of iguratimod on receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis in vitro and the molecular mechanisms involved. It was demonstrated that iguratimod may prevent ovariectomy induced bone loss by suppressing osteoclast activity in vivo. Consistently, iguratimod may inhibit RANKL induced osteoclastogenesis and bone resorption in primary bone marrow mononuclear cells. At the molecular level, peroxisome proliferator activated receptor gamma (PPAR gamma)/c Fos pathway, which is essential in RANKL induced osteoclast differentiation, was suppressed by iguratimod. Subsequently, iguratimod decreased the expression of nuclear factor of activated T cells c1 and downstream osteoclast marker genes. The results of the present study demonstrated that iguratimod may inhibit ovariectomy induced bone loss and osteoclastogenesis by modulating RANKL signaling. Therefore, iguratimod may act as a novel therapeutic to prevent postmenopausal osteoporosis.
C1 [Wu, Ying Xing; Ye, Ya Ping; Guo, Jia Chao; Huang, Jun Ming; Jing, Xing Zhi; Xiang, Wei; Guo, Feng Jing] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Orthoped, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
   [Sun, Yue; Zhang, Peng; Yu, Shi Ying] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Canc Ctr, Wuhan 430030, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology
RP Guo, FJ (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Orthoped, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
EM guofjdoc@163.com
RI zhan, lin/AAP 5149 2020; yu, shiying/MGB 6671 2025
OI Huang, Jun ming/0000 0002 6800 2788; Guo, Fengjing/0000 0002 5968 4836
FU National Nature Science Foundation of China [81572094, 81371915]
FX This study was supported by grants from the National Nature Science
   Foundation of China (nos. 81572094 and 81371915).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bu SM, 2012, EUR J APPL PHYSIOL, V112, P3295, DOI 10.1007/s00421 011 2306 4
   Chen Y, 2015, INT J CLIN EXP MED, V8, P8608
   Cline Smith A, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88839
   Conaway HH, 2016, BONE, V93, P43, DOI 10.1016/j.bone.2016.08.024
   Du F, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2554
   Fan HL, 2016, MOL MED REP, V13, P2485, DOI 10.3892/mmr.2016.4849
   Gan K, 2016, INT IMMUNOPHARMACOL, V35, P294, DOI 10.1016/j.intimp.2016.03.038
   Gu DR, 2017, BIOCHEM BIOPH RES CO, V482, P1073, DOI 10.1016/j.bbrc.2016.11.160
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   KAKONEN SM, 2003, CANCER, V97, pS834
   Kawakami A, 1999, J LAB CLIN MED, V133, P566, DOI 10.1016/S0022 2143(99)90186 5
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kohno M, 2001, J RHEUMATOL, V28, P2591
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li GW, 2014, MENOPAUSE, V21, P1007, DOI [10.1097/gme.0000000000000201, 10.1097/GME.0000000000000201]
   Luo Q, 2013, J IMMUNOL, V191, P4969, DOI 10.4049/jimmunol.1300832
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Okamura K, 2015, MOD RHEUMATOL, V25, P534, DOI 10.3109/14397595.2014.998361
   Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945
   Ortega N, 2003, ANN NY ACAD SCI, V995, P109, DOI 10.1111/j.1749 6632.2003.tb03214.x
   Roodman GD, 2012, CANCER METAST REV, V31, P569, DOI 10.1007/s10555 012 9372 x
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Sottile V, 2004, CALCIFIED TISSUE INT, V75, P329, DOI 10.1007/s00223 004 0224 8
   Sun Y, 2016, J HUAZHONG U SCI MED, V36, P691, DOI 10.1007/s11596 016 1646 z
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wang XT, 2016, CELL MOL BIOL, V62, P44, DOI 10.14715/cmb/2016.62.12.8
   Wang XD, 2015, MOL MED REP, V11, P3451, DOI 10.3892/mmr.2015.3204
   Zhang Y, 2015, SCI REP UK, V5, DOI 10.1038/srep13575
NR 36
TC 26
Z9 28
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD DEC
PY 2017
VL 16
IS 6
BP 8200
EP 8208
DI 10.3892/mmr.2017.7648
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FQ3AM
UT WOS:000418229200038
PM 28983607
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Wang, SE
   Xu, L
   Wang, DL
   Zhao, SJ
   Li, K
   Ma, F
   Yao, QL
   Zhang, YK
   Wu, ZQ
   Shao, Y
   Song, SL
   Yan, WJ
AF Wang, Shuoer
   Xu, Lun
   Wang, Dongliang
   Zhao, Songjiao
   Li, Kun
   Ma, Fen
   Yao, Qianlan
   Zhang, Yunkui
   Wu, Zhiqiang
   Shao, Yang
   Song, Shaoli
   Yan, Wangjun
TI YTHDF1 promotes the osteolytic bone metastasis of breast cancer via
   inducing EZH2 and CDH11 translation
SO CANCER LETTERS
LA English
DT Article
DE Bone metastatic breast cancer; Osteolytic destruction; m6A; YTHDF1; EZH2
ID MESENCHYMAL TRANSITION; GENE EXPRESSION; TUMOR GROWTH; STATISTICS;
   PATHOGENESIS; MECHANISMS; SUBTYPES; TARGET; SITE; LYN
AB Bone metastasis is common in breast cancer and more effective therapies are required, however, its molecular mechanism is poorly understood. Additionally, the role of the m6A reader YTHDF1 in bone metastasis of breast cancer has not been reported. Here, we reveal that the increased expression of YTHDF1 is clinically correlated with breast cancer bone metastases. YTHDF1 promotes migration, invasion, and osteoblast adhesion and induces osteoclast differentiation of cancer cells in vitro and vivo. Mechanically, RNA seq, MeRIP seq and RIP seq analysis, and molecular biology experiments demonstrate that YTHDF1 translationally enhances EZH2 and CDH11 expression by reading m6A enriched sites of their transcripts. Moreover, adeno associated virus (AAV) was used to deliver shYTHDF1 (shYTHDF1 AAV) in intratibial injection models, eliciting a significant suppressive effect on breast cancer bone metastatic formation and osteolytic destruction. Overall, we uncovered that YTHDF1 promotes osteolytic bone metastases of breast cancer by inducing EZH2 and CDH11 translation.
C1 [Wang, Shuoer; Xu, Lun; Li, Kun; Wu, Zhiqiang; Yan, Wangjun] Fudan Univ, Shanghai Canc Ctr, Dept Musculoskeletal Oncol, Shanghai 200032, Peoples R China.
   [Wang, Shuoer; Wang, Dongliang; Song, Shaoli] Fudan Univ, Canc Inst, Shanghai Canc Ctr, Dept Nucl Med, Shanghai 200032, Peoples R China.
   [Zhao, Songjiao] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Ma, Fen] Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, MOE Key Lab Standardizat Chinese Med, Shanghai Key Lab Cpd Chinese Med, Shanghai, Peoples R China.
   [Ma, Fen] Chinese Acad Sci, Inst Neurosci, CAS Ctr Excellence Brain Sci & Intelligence Techno, Shanghai, Peoples R China.
   [Yao, Qianlan] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China.
   [Zhang, Yunkui] Fudan Univ, Shanghai Canc Ctr, Dept Anesthesiol, Shanghai, Peoples R China.
   [Shao, Yang] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai 200032, Peoples R China.
   [Wang, Shuoer; Xu, Lun; Wang, Dongliang; Li, Kun; Yao, Qianlan; Zhang, Yunkui; Wu, Zhiqiang; Shao, Yang; Song, Shaoli; Yan, Wangjun] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Shanghai Jiao Tong University;
   Shanghai University of Traditional Chinese Medicine; Chinese Academy of
   Sciences; Fudan University; Fudan University; Fudan University; Fudan
   University
RP Yan, WJ (通讯作者)，Fudan Univ, Shanghai Canc Ctr, Dept Musculoskeletal Oncol, Shanghai 200032, Peoples R China.; Song, SL (通讯作者)，Fudan Univ, Canc Inst, Shanghai Canc Ctr, Dept Nucl Med, Shanghai 200032, Peoples R China.; Shao, Y (通讯作者)，Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai 200032, Peoples R China.
EM thierryhenrysy@gmail.com; shaoli song@163.com; yanwj@fudan.edu.cn
RI zhang, yunkui/HSI 2878 2023; , wuzhiqiang/C 7843 2017; wang,
   shuoer/KQW 5045 2024; song, sl/GRS 1884 2022
OI Wang, Shuoer/0000 0003 4315 1776
FU National Natural Science Foundation of China [82072972, 82272035,
   81971648, 82002726]
FX This work was supported by the National Natural Science Foundation of
   China to (No. 82072972,82272035, 81971648, 82002726) . Working models
   were created with Biorender.com .
CR Anita R, 2020, AM J CANCER RES, V10, P2546
   Awolaran O, 2016, BREAST, V30, P156, DOI 10.1016/j.breast.2016.09.017
   Barbieri I, 2020, NAT REV CANCER, V20, P303, DOI 10.1038/s41568 020 0253 2
   BELLAHCENE A, 1995, AM J PATHOL, V146, P95
   Brabletz S, 2021, EMBO J, V40, DOI 10.15252/embj.2021108647
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Chen WQ, 2016, CA CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Choi YL, 2010, CANCER RES, V70, P2296, DOI 10.1158/0008 5472.CAN 09 3141
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Demirkan B, 2013, J CLIN MED, V2, P264, DOI 10.3390/jcm2040264
   Dewan MZ, 2006, BIOMED PHARMACOTHER, V60, P273, DOI 10.1016/j.biopha.2006.06.004
   Ell B, 2012, CELL, V151, DOI 10.1016/j.cell.2012.10.005
   Fang Z, 2022, EXP HEMATOL ONCOL, V11, DOI 10.1186/s40164 022 00298 7
   Fattet L, 2020, DEV CELL, V54, P302, DOI 10.1016/j.devcel.2020.05.031
   Frye M, 2018, SCIENCE, V361, P1346, DOI 10.1126/science.aau1646
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Hanaki S, 2021, J BIOCHEM, V170, P1, DOI 10.1093/jb/mvab007
   Haruehanroengra P, 2020, RNA BIOL, V17, P1560, DOI 10.1080/15476286.2020.1722449
   He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1109 9
   He PC, 2021, EMBO J, V40, DOI 10.15252/embj.2020105977
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Huang JH, 2021, CANCER SCI, V112, P1376, DOI 10.1111/cas.14840
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   LEE YTNM, 1983, J SURG ONCOL, V23, P175, DOI 10.1002/jso.2930230311
   Li JY, 2012, BREAST CANCER RES TR, V131, P837, DOI 10.1007/s10549 011 1502 6
   Li XQ, 2022, CANCER RES, V82, P1560, DOI 10.1158/0008 5472.CAN 21 1331
   Liu NA, 2017, NUCLEIC ACIDS RES, V45, P6051, DOI 10.1093/nar/gkx141
   Liu Q, 2019, NUCLEIC ACIDS RES, V47, pW548, DOI 10.1093/nar/gkz479
   Nombela P, 2021, MOL CANCER, V20, DOI 10.1186/s12943 020 01263 w
   Park M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23126806
   Saad F, 2010, CANCER TREAT REV, V36, P177, DOI 10.1016/j.ctrv.2009.11.005
   Siegel RL, 2023, CA CANCER J CLIN, V73, P17, DOI [10.3322/caac.21763, 10.3322/caac.21820]
   Siegel RL, 2022, CA CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Sikorski Vilbert, 2023, Trends Pharmacol Sci, V44, P335, DOI 10.1016/j.tips.2023.03.004
   Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008 5472.CAN 07 5644
   Soni A, 2015, AM J CLIN PATHOL, V143, P471, DOI 10.1309/AJCPYO5FSV3UPEXS
   Sun Y, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04672 5
   Tahara RK, 2019, ADV EXP MED BIOL, V1152, P105, DOI 10.1007/978 3 030 20301 6_7
   Tamura D, 2008, INT J ONCOL, V33, P17
   Thaper D, 2017, ONCOGENE, V36, P3964, DOI 10.1038/onc.2017.5
   Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007
   Wafai R, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058 020 01366 8
   Wang J, 2022, NAT CELL BIOL, V24, P384, DOI 10.1038/s41556 022 00850 x
   Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014
   Waning DL, 2014, CLIN CANCER RES, V20, P3071, DOI 10.1158/1078 0432.CCR 13 1590
   Yang H, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.934223
   Yang XL, 2017, BREAST CANCER TARGET, V9, P227, DOI 10.2147/BCTT.S126184
   Yao XM, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04711 1
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
   Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580 019 0168 5
   Zhang L, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30105 0
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
NR 54
TC 7
Z9 7
U1 2
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD AUG 10
PY 2024
VL 597
AR 217047
DI 10.1016/j.canlet.2024.217047
EA JUN 2024
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA WS7E4
UT WOS:001256920300001
PM 38871245
DA 2025 08 17
ER

PT J
AU Ruan, YR
   Kato, H
   Taguchi, Y
   Yamauchi, N
   Umeda, M
AF Ruan, Yaru
   Kato, Hirohito
   Taguchi, Yoichiro
   Yamauchi, Nobuhiro
   Umeda, Makoto
TI Irradiation by high intensity red light emitting diode enhances human
   bone marrow mesenchymal stem cells osteogenic differentiation and
   mineralization through Wnt/β catenin signaling pathway
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Bone regeneration; LED; Osteoblasts; Photobiomodulation therapy
ID LOW LEVEL LASER; OSTEOBLAST DIFFERENTIATION; HUMAN ADIPOSE;
   PROLIFERATION; THERAPY; EXPRESSION; GROWTH; PHOTOBIOMODULATION;
   INHIBITION; ACTIVATION
AB Photobiomodulation therapy (PBMT) using a light emitting diode (LED) has been employed for various photomedicine studies. The aim of this study was to determine the effects of a high intensity red LED on the proliferation and osteogenic differentiation of human bone marrow mesenchymal stem cells (BMSCs) and the related mechanism. BMSCs were subjected to high intensity red LED (LZ1 00R205 Deep Red LED) irradiations for 0 to 40 s with energy densities ranging from 0 to 8 J/cm(2). The distance from the LED to the cell layer was 40 mm. The spot size on the target was 4 cm(2). Cell proliferation was measured at 3, 24, 48, and 72 h. The effects of LED irradiation on osteogenic differentiation and mineralization were examined with a particular focus on the Wnt/beta catenin signaling pathway. The high intensity red LED irradiations did not alter BMSC proliferation after 72 h. LED exposure of 6 J/cm(2)(30 s) led to significant enhancements of osteogenic differentiation and mineralization. Additionally, the high intensity LED irradiation induced activation of Wnt/beta catenin. The effects of the high intensity LED irradiation on BMSC osteogenic differentiation and mineralization were suppressed by treatment with the Wnt/beta catenin inhibitor XAV939.P < 0.05 was considered significant. The results indicate that high intensity red LED irradiation increases BMSC osteogenic differentiation and mineralization via Wnt/beta catenin activation. Therefore, short duration irradiation with a portable high intensity LED may be used as a potential approach in hard tissue regeneration therapy.
C1 [Ruan, Yaru; Kato, Hirohito; Taguchi, Yoichiro; Yamauchi, Nobuhiro; Umeda, Makoto] Osaka Dent Univ, Dept Periodontol, 8 1 Kuzuhahanazono Cho, Hirakata, Osaka, Japan.
RP Taguchi, Y (通讯作者)，Osaka Dent Univ, Dept Periodontol, 8 1 Kuzuhahanazono Cho, Hirakata, Osaka, Japan.
EM taguchi@cc.osaka dent.ac.jp
FU Japan Society for the Promotion of Science (Tokyo, Japan) [16K11617,
   17K11818, 18K17080]; Osaka Dental University [19 05]; Grants in Aid for
   Scientific Research [18K17080, 17K11818, 16K11617] Funding Source: KAKEN
FX This work was supported by Grants in Aid for Scientific Research
   (16K11617, 17K11818, and 18K17080) from the Japan Society for the
   Promotion of Science (Tokyo, Japan), and a Research Promotion Grant
   (19 05) from Osaka Dental University.
CR Anders JJ, 2015, PHOTOMED LASER SURG, V33, P183, DOI 10.1089/pho.2015.9848
   AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Baksh D, 2007, J CELL PHYSIOL, V212, P817, DOI 10.1002/jcp.21080
   Bartold PM, 2006, PERIODONTOL 2000, V40, P7, DOI 10.1111/j.1600 0757.2005.00147.x
   Bouvet Gerbettaz S, 2009, LASER SURG MED, V41, P291, DOI 10.1002/lsm.20759
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Cobb CM, 2006, J PERIODONTOL, V77, P545, DOI 10.1902/jop.2006.050417
   Cui GH, 2016, EXP THER MED, V12, P3390, DOI 10.3892/etm.2016.3791
   De Girolamo L., 2016, Orthop. J. Sports Med, V4, DOI [10.1177/2325967116S00128, DOI 10.1177/2325967116S00128]
   ERIKSSON AR, 1983, J PROSTHET DENT, V50, P101, DOI 10.1016/0022 3913(83)90174 9
   Esnouf A, 2007, ACUPUNCTURE ELECTRO, V32, P81, DOI 10.3727/036012907815844165
   Finke B, 2007, BIOMATERIALS, V28, P4521, DOI 10.1016/j.biomaterials.2007.06.028
   Gardner S, 2009, NEUROENDOCRINOLOGY, V89, P241, DOI 10.1159/000165377
   Gough NR, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002806
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   Hamblin MR, 2016, J BIOPHOTONICS, V9, P1122, DOI 10.1002/jbio.201670113
   Han L, 2018, LASER MED SCI, V33, P637, DOI 10.1007/s10103 018 2455 3
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Hou JF, 2008, LASER SURG MED, V40, P726, DOI 10.1002/lsm.20709
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12 10281
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   IKEDA T, 1992, J HISTOCHEM CYTOCHEM, V40, P1079, DOI 10.1177/40.8.1619274
   Karsenty G, 1995, Int Rev Immunol, V12, P177, DOI 10.3109/08830189509056711
   Katayama N, 2014, INT J MOL SCI, V15, P14026, DOI 10.3390/ijms150814026
   Kim HK, 2009, LASER MED SCI, V24, P214, DOI 10.1007/s10103 008 0550 6
   Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341
   Li WT, 2010, PHOTOMED LASER SURG, V28, pS157, DOI 10.1089/pho.2009.2540
   Lin F, 2010, J TRANSL MED, V8, DOI 10.1186/1479 5876 8 16
   Listl S, 2010, J CLIN PERIODONTOL, V37, P920, DOI 10.1111/j.1600 051X.2010.01611.x
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Matys J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2785302
   McCarthy TL, 2000, J BIOL CHEM, V275, P21746, DOI 10.1074/jbc.M002291200
   Mohammadi Z, 2015, IRAN J BASIC MED SCI, V18, P259
   Mombelli A, 2000, PERIODONTOLOGY, V17, P63
   Mvula B, 2008, LASER MED SCI, V23, P277, DOI 10.1007/s10103 007 0479 1
   Opel Daniel R, 2015, J Clin Aesthet Dermatol, V8, P36
   Peng F, 2012, LASER MED SCI, V27, P645, DOI 10.1007/s10103 011 1005 z
   PONTORIERO R, 1994, CLIN ORAL IMPLAN RES, V5, P254, DOI 10.1034/j.1600 0501.1994.050409.x
   Rahiotis Christos, 2010, J Oral Sci, V52, P187
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Tuby H, 2007, LASER SURG MED, V39, P373, DOI 10.1002/lsm.20492
   Umeda M, 2011, J INVESTIG CLIN DENT, V2, P268, DOI 10.1111/j.2041 1626.2011.00071.x
   Yamamoto Y, 2003, J DENT RES, V82, P962, DOI 10.1177/154405910308201205
   Yamauchi N, 2018, J PERIODONTOL, V89, P351, DOI 10.1002/JPER.17 0365
   Yang DZ, 2016, SCI REP UK, V6, DOI 10.1038/srep37370
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   You WL, 2014, MOL CELL BIOCHEM, V386, P125, DOI 10.1007/s11010 013 1851 z
   Yuan Y, 2017, CELL PHYSIOL BIOCHEM, V43, P237, DOI 10.1159/000480344
   Zhang RF, 2018, EUR REV MED PHARMACO, V22, P2860, DOI 10.26355/eurrev_201805_14988
   Zhang TR, 2017, LASER MED SCI, V32, P1189, DOI 10.1007/s10103 017 2224 8
   Zheng CX, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0060 3
NR 51
TC 29
Z9 29
U1 2
U2 20
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD FEB
PY 2021
VL 36
IS 1
BP 55
EP 65
DI 10.1007/s10103 020 03002 5
EA JUN 2020
PG 11
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA PO5TQ
UT WOS:000543323600001
PM 32588268
DA 2025 08 17
ER

PT J
AU Jiang, WL
   Rixiati, Y
   Huang, H
   Shi, YJ
   Huang, CG
   Jiao, BH
AF Jiang, Wenli
   Rixiati, Youlutuziayi
   Huang, Hao
   Shi, YiJun
   Huang, Caiguo
   Jiao, Binghua
TI Asperolide A prevents bone metastatic breast cancer via the
   PI3K/AKT/mTOR/c Fos/NFATc1 signaling pathway
SO CANCER MEDICINE
LA English
DT Article
DE Asperolide A; bone metastases; breast cancer; mTOR; osteoclast
AB Background Breast cancer is the leading cause of death among women with malignant tumors worldwide. Bone metastasis is the main factor affecting the prognosis of breast cancer. Therefore, both antitumor and anti breast cancer induced osteolysis agents are urgently needed. Methods We examined the effect of Asperolide A (AA), a marine derived agent, on osteolysis and RANKL induced phosphoinositide 3 kinase (PI3K)/AKT/mTOR/c FOS/nuclear factor activated T cell 1 (NFATc1) pathway activation, F actin ring formation, and reactive oxygen species (ROS) generation in vitro. We evaluated AA effect on breast cancer MDA MB 231 and MDA MB 436 cells in vitro through CCK8 assay, wound healing assay, transwell assay, Annexin V FITC/PI staining for cell apoptosis, and cell cycle assay. Furthermore, we assessed the effect of AA in vivo using a breast cancer induced bone osteolysis nude mouse model, followed by micro computed tomography, tartrate resistant acid phosphatase staining, and hematoxylin and eosin staining. Results Asperolide A inhibited osteoclast formation and differentiation, bone resorption, F actin belt formation, ROS activity, and osteoclast specific gene and protein expressions and prevented PI3K/AKT/mTOR/c FOS/NFATc1 signaling activation in a dose dependent manner in vitro. AA also inhibited breast cancer growth and breast cancer induced bone osteolysis by reducing osteoclast formation and function and inactivated PI3K/AKT/mTOR signaling in vivo. Conclusions Our study demonstrated that AA suppressed bone metastatic breast cancer. These findings indicate AA as a potential, novel curative drug candidate for patients with bone metastatic breast cancer.
C1 [Jiang, Wenli; Shi, YiJun; Huang, Caiguo; Jiao, Binghua] Navy Med Univ, Dept Biochem & Mol Biol, Coll Basic Med, Shanghai 200433, Peoples R China.
   [Rixiati, Youlutuziayi] Soochow Univ, Dept Pathol, Med Sch, Suzhou, Peoples R China.
   [Huang, Hao] Shaoxing Peoples Hosp, Dept Orthopaed, Shaoxing, Peoples R China.
C3 Naval Medical University; Soochow University   China
RP Huang, CG; Jiao, BH (通讯作者)，Navy Med Univ, Dept Biochem & Mol Biol, Coll Basic Med, Shanghai 200433, Peoples R China.
EM huangcaig@hotmail.com; biojiao@163.com
RI ; Shi, Yijun/AEN 2304 2022
OI Rixiati, Youlutuziayi/0000 0002 7706 8308; 
FU National Natural Science Foundation of China [41576160, 41776140];
   National Key Research and Development Program [2018YFC0310904]
FX National Natural Science Foundation of China, Grant/Award Number:
   41576160 and 41776140; National Key Research and Development Program,
   Grant/Award Number: 2018YFC0310904
CR Aggarwal V, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110735
   Castaneda SA, 2017, SURG ONCOL CLIN N AM, V26, P371, DOI 10.1016/j.soc.2017.01.013
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chen HP, 2018, J AGR FOOD CHEM, V66, P3146, DOI 10.1021/acs.jafc.8b00287
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   DeSantis C, 2014, CA CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Ding YX, 2020, J CELL PHYSIOL, V235, P4407, DOI 10.1002/jcp.29317
   Feng MX, 2016, SCI REP UK, V6, DOI 10.1038/srep19074
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Jiang WL, 2018, ONCOL LETT, V16, P6445, DOI 10.3892/ol.2018.9486
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Lian Z, 2019, CARCINOGENESIS, V40, pE1, DOI 10.1093/carcin/bgy036
   Lv C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.484
   Ma J, 2020, J DRUG TARGET, V28, P176, DOI 10.1080/1061186X.2019.1624969
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nishimura K, 2016, FREE RADICAL BIO MED, V97, P330, DOI 10.1016/j.freeradbiomed.2016.06.021
   Osuala KO, 2019, ADV EXP MED BIOL, V1152, P401, DOI 10.1007/978 3 030 20301 6_21
   Sun HF, 2012, J NAT PROD, V75, P148, DOI 10.1021/np2006742
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tang WZ, 2019, NAT PROD RES, V33, P2970, DOI 10.1080/14786419.2018.1513510
   Ueda S, 2002, BLOOD, V99, P3342, DOI 10.1182/blood.V99.9.3342
   Ungard RG, 2019, MOL PAIN, V15, DOI 10.1177/1744806918822185
   Wu MY, 2018, CELL PHYSIOL BIOCHEM, V46, P1423, DOI 10.1159/000489184
   Yeon JT, 2019, ARCH PHARM RES, V42, P712, DOI 10.1007/s12272 019 01163 8
   Yoon JY, 2018, TISSUE ENG REGEN MED, V15, P333, DOI 10.1007/s13770 018 0116 z
   Yuan GX, 2019, CANCER LETT, V443, P135, DOI 10.1016/j.canlet.2018.11.038
   Zhang Z, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.182
   Zhang ZW, 2012, BIOL PHARM BULL, V35, P1964, DOI 10.1248/bpb.b12 00368
NR 29
TC 21
Z9 22
U1 2
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2045 7634
J9 CANCER MED US
JI Cancer Med.
PD NOV
PY 2020
VL 9
IS 21
BP 8173
EP 8185
DI 10.1002/cam4.3432
EA SEP 2020
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA OL7GY
UT WOS:000572542000001
PM 32976685
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lin, LS
   Guo, ZY
   He, EJ
   Long, XD
   Wang, DF
   Zhang, YT
   Guo, WH
   Wei, Q
   He, W
   Wu, WY
   Li, JC
   Wo, LL
   Hong, DL
   Zheng, JK
   He, M
   Zhao, QH
AF Lin, Longshuai
   Guo, Zengya
   He, Enjun
   Long, Xidai
   Wang, Difei
   Zhang, Yingting
   Guo, Weihong
   Wei, Qian
   He, Wei
   Wu, Wanying
   Li, Jingchi
   Wo, Lulu
   Hong, Dengli
   Zheng, Junke
   He, Ming
   Zhao, Qinghua
TI SIRT2 regulates extracellular vesicle mediated liver bone communication
SO NATURE METABOLISM
LA English
DT Article
ID MINERAL DENSITY; SUPPRESSES OSTEOCLASTOGENESIS; PROMOTES ANGIOGENESIS;
   OSTEOPOROSIS; DIFFERENTIATION; THERAPY; GROWTH; MEN
AB The interplay between liver and bone metabolism remains largely uncharacterized. Here, we uncover a mechanism of liver bone crosstalk regulated by hepatocyte SIRT2. We demonstrate that hepatocyte SIRT2 expression is increased in aged mice and elderly humans. Liver specific SIRT2 deficiency inhibits osteoclastogenesis and alleviates bone loss in mouse models of osteoporosis. We identify leucine rich alpha 2 glycoprotein 1 (LRG1) as a functional cargo in hepatocyte derived small extracellular vesicles (sEVs). In SIRT2 deficient hepatocytes, LRG1 levels in sEVs are upregulated, leading to increased transfer of LRG1 to bone marrow derived monocytes (BMDMs), and in turn, to inhibition of osteoclast differentiation via reduced nuclear translocation of NF kappa B p65. Treatment with sEVs carrying high levels of LRG1 inhibits osteoclast differentiation in human BMDMs and in mice with osteoporosis, resulting in attenuated bone loss in mice. Furthermore, the plasma level of sEVs carrying LRG1 is positively correlated with bone mineral density in humans. Thus, drugs targeting hepatocyte osteoclast communication may constitute a promising therapeutic strategy for primary osteoporosis.
   Lin et al. show that small extracellular vesicles derived from SIRT2 deficient hepatocytes inhibit osteoclast differentiation from mouse and human bone marrow derived monocytes and alleviate bone loss in mouse models of osteoporosis.
C1 [Lin, Longshuai; Wang, Difei; Zhang, Yingting; Wei, Qian; He, Wei; Wu, Wanying; Li, Jingchi; Wo, Lulu; Hong, Dengli; Zheng, Junke; He, Ming] Shanghai Jiao Tong Univ, Dept Pathophysiol, Key Lab Cell Differentiat & Apoptosis, Minist Educ,Shanghai Frontiers Sci Ctr Cellular Ho, Shanghai, Peoples R China.
   [Lin, Longshuai; He, Enjun; Guo, Weihong; Zhao, Qinghua] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, Shanghai, Peoples R China.
   [Lin, Longshuai; Long, Xidai; He, Ming] Youjiang Med Univ Nationalities, Dept Pathol, Affiliated Hosp, Baise, Peoples R China.
   [Guo, Zengya] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gen Surg, Sch Med, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Youjiang
   Medical University for Nationalities; Shanghai Jiao Tong University
RP He, M (通讯作者)，Shanghai Jiao Tong Univ, Dept Pathophysiol, Key Lab Cell Differentiat & Apoptosis, Minist Educ,Shanghai Frontiers Sci Ctr Cellular Ho, Shanghai, Peoples R China.; Zhao, QH (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, Shanghai, Peoples R China.; He, M (通讯作者)，Youjiang Med Univ Nationalities, Dept Pathol, Affiliated Hosp, Baise, Peoples R China.
EM heming@shsmu.edu.cn; qinghua.zhao@shgh.cn
RI Zhang, Yingting/A 9746 2016; Wu, Wanying/GWM 6957 2022; Liu,
   LianXin/D 6712 2013
OI Enjun, He/0009 0002 8451 7623; Wang, Difei/0000 0001 7263 6401; 
FU National Natural Science Foundation of China [92057118, 82070603,
   81825001, 81860489]; Shanghai Science and Technology Commission
   [20JC1410100]; Shanghai Natural Science Foundation [19ZR1428400,
   19ZR1440700]; Shanghai Pujiang Program by Science and Technology
   Commission of Shanghai Municipality [16PJ1405400, 16PJ0004679];
   Fundamental Research Funds for the Central Universities;
   Medical Industrial Interdisciplinary Research Fund of Shanghai Jiao Tong
   University [YG2017MS02]; innovative research team of high level local
   universities in Shanghai [SSMU ZDCX20180800]; Youth Science and
   Technology Innovation Studio of SJTU SM [JYKCGZS15, JYKCGZS8]; practice
   training base for interdisciplinary innovative talents of Shanghai Jiao
   Tong University [SJTUJXCX 28, SJTUJXCX 3]
FX This study was funded by the National Natural Science Foundation of
   China (grant nos. 92057118 and 82070603 to M.H.; grant no. 81825001 to
   J. K.Z.; and grant no. 81860489 to X. D.L.); Shanghai Science and
   Technology Commission (grant no. 20JC1410100 to J. K.Z.); Shanghai
   Natural Science Foundation (grant no. 19ZR1428400 to M.H.; and grant no.
   19ZR1440700 to Q. H.Z.); Shanghai Pujiang Program by Science and
   Technology Commission of Shanghai Municipality (grant no. 16PJ1405400 to
   M.H.; and grant no. 16PJ0004679 to Q. H.Z.); the Fundamental Research
   Funds for the Central Universities; Medical Industrial Interdisciplinary
   Research Fund of Shanghai Jiao Tong University (grant no. YG2017MS02 to
   Q. H.Z.); innovative research team of high level local universities in
   Shanghai (grant no. SSMU ZDCX20180800 to M.H.); Youth Science and
   Technology Innovation Studio of SJTU SM (grant no. JYKCGZS15 to M.H.;
   and grant no. JYKCGZS8 to Q. H.Z.); practice training base for
   interdisciplinary innovative talents of Shanghai Jiao Tong University
   (grant no. SJTUJXCX 3 to Q. H.Z.; and grant no. SJTUJXCX 28 to M.H.). We
   thank B. Wang and X. Tong (SJTU SM) for discussion; staff at the Core
   Facility of Basic Medical Sciences and SJTU SM for protein LC MS
   analysis.
CR Ahn KS, 2007, BLOOD, V110, P2286, DOI 10.1182/blood 2007 04 084996
   Amrhein V, 2019, NATURE, V567, P305, DOI 10.1038/d41586 019 00857 9
   [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boonyayothin W, 2021, FRONT PLANT SCI, V12, DOI 10.3389/fpls.2021.683417
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   DeLuca HF, 2016, VITAM HORM, V100, P1, DOI 10.1016/bs.vh.2015.11.001
   Ehnert S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102555
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Gallego Rojo FJ, 1998, HEPATOLOGY, V28, P695, DOI 10.1002/hep.510280315
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Gu ZT, 2020, J CELL MOL MED, V24, P12619, DOI 10.1111/jcmm.15826
   Guarino M, 2016, OSTEOPOROSIS INT, V27, P1967, DOI 10.1007/s00198 016 3512 z
   Guo ZY, 2020, MOL THER NUCL ACIDS, V22, P179, DOI 10.1016/j.omtn.2020.08.021
   He M, 2020, CELL METAB, V31, P580, DOI 10.1016/j.cmet.2020.01.009
   Huang D, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI138986
   Jann J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207597
   Jing YX, 2019, CELL MOL BIOL, V65, P66, DOI 10.14715/cmb/2019.65.7.12
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim SJ, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115497
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Lin SZ, 2018, AGEING RES REV, V44, P22, DOI 10.1016/j.arr.2018.03.006
   Louvet L, 2020, BONE, V136, DOI 10.1016/j.bone.2020.115361
   Lu K, 2022, CELL METAB, V34, P441, DOI 10.1016/j.cmet.2022.02.006
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Ma J, 2019, NUCLEIC ACIDS RES, V47, pD1211, DOI 10.1093/nar/gky869
   Melis D, 2016, BONE, V86, P79, DOI 10.1016/j.bone.2016.02.012
   Moreno R, 2010, NUCLEIC ACIDS RES, V38, P6029, DOI 10.1093/nar/gkq439
   Nakchbandi IA, 2014, WORLD J GASTROENTERO, V20, P9427, DOI 10.3748/wjg.v20.i28.9427
   Nakchbandi IA, 2009, NAT REV GASTRO HEPAT, V6, P660, DOI 10.1038/nrgastro.2009.166
   Ornstrup MJ, 2014, J CLIN ENDOCR METAB, V99, P4720, DOI 10.1210/jc.2014 2799
   Park JH, 2017, MOL CELLS, V40, P706
   Qin WP, 2019, CURR OSTEOPOROS REP, V17, P548, DOI 10.1007/s11914 019 00537 7
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raney BJ, 2014, BIOINFORMATICS, V30, P1003, DOI 10.1093/bioinformatics/btt637
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   Sun H, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.625287
   Sung S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123715
   Tokunaga T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030800
   Tran PHL, 2020, ADV MATER, V32, DOI 10.1002/adma.201904040
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706
   Wakolbinger R, 2019, OSTEOPOROSIS INT, V30, P1195, DOI 10.1007/s00198 019 04870 6
   Wang RH, 2016, SCI REP UK, V6, DOI 10.1038/srep28633
   Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008 5472.CAN 17 3841
   Wang XM, 2013, NATURE, V499, P306, DOI 10.1038/nature12345
   Wang XD, 2015, CELL METAB, V22, P811, DOI 10.1016/j.cmet.2015.09.010
   Wang Y, 2019, AGEING RES REV, V55, DOI 10.1016/j.arr.2019.100961
   Watt MJ, 2019, ENDOCR REV, V40, P1367, DOI 10.1210/er.2019 00034
   Weske S, 2018, NAT MED, V24, P667, DOI 10.1038/s41591 018 0005 y
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463
   Yin GN, 2022, EXP MOL MED, V54, P626, DOI 10.1038/s12276 022 00773 5
   Yin PB, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00336
   Yu MC, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143137
   Zhang CS, 2022, NAT METAB, V4, P1369, DOI 10.1038/s42255 022 00640 7
   Zhang YT, 2021, CELL DISCOV, V7, DOI 10.1038/s41421 021 00326 6
   Zhang YX, 2020, CELL REP, V30, P1951, DOI 10.1016/j.celrep.2020.01.036
   Zheng RB, 2019, NUCLEIC ACIDS RES, V47, pD729, DOI 10.1093/nar/gky1094
NR 61
TC 47
Z9 53
U1 15
U2 63
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2522 5812
J9 NAT METAB
JI Nat. Metab.
PD MAY
PY 2023
VL 5
IS 5
BP 821
EP +
DI 10.1038/s42255 023 00803 0
EA MAY 2023
PG 37
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA H9EC3
UT WOS:000992787300003
PM 37188819
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Jie, ZW
   Wang, SY
   Ma, QL
   Shen, Y
   Zhao, XD
   Yu, HJ
   Xie, Z
   Jiang, C
AF Jie, Zhiwei
   Wang, Shiyu
   Ma, Qingliang
   Shen, Yang
   Zhao, Xiangde
   Yu, Hejun
   Xie, Ziang
   Jiang, Chao
TI Pexmetinib suppresses osteoclast formation and breast cancer induced
   osteolysis via P38/STAT3 signal pathway
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE P38 mitogen activated protein kinase; Pexmetinib; Osteoclast; Breast
   cancer; Osteolysis
ID CONSTITUTIVE ACTIVATION; DUAL INHIBITOR; STAT3 ACTIVITY; P38 MAPK; BONE;
   METASTASIS; EXPRESSION; CELLS; PATHOGENESIS; INVASION
AB Breast cancer metastases to the bone can lead to a series of bone related events that seriously affect the quality of life. Pexmetinib, a novel p38 mitogen activated protein kinase (p38) inhibitor that has been evaluated in phase I clinical trials for myelodysplastic syndrome, but the effects of Pexmetinib on breast cancer induced osteolysis haven't been explored. Here, we found that Pexmetinib inhibited receptor activator of nuclear factor KB ligandinduced osteoclast formation and bone resorption in vitro. Pexmetinib suppressed p38 mediated signal transducer and activator of transcription 3 (STAT3), which direct regulated transcription of the nuclear factor of activated T cells 1 (NFATc1), leading to reduced osteoclast formation. Moreover, Pexmetinib exerted anti tumor effects in breast cancer cells in vitro via suppressing p38 mediated STAT3 activation and matrix metalloproteinases (MMPs) expression. Furthermore, Pexmetinib suppressed breast cancer associated osteolysis in vivo. These results suggest that Pexmetinib may be a promising drug for the treatment of breast cancer induced osteolysis.
C1 [Jie, Zhiwei; Ma, Qingliang; Shen, Yang; Zhao, Xiangde; Yu, Hejun; Xie, Ziang; Jiang, Chao] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed, Sch Med, Hangzhou, Peoples R China.
   [Jie, Zhiwei; Ma, Qingliang; Shen, Yang; Zhao, Xiangde; Yu, Hejun; Xie, Ziang; Jiang, Chao] Key Lab Musculoskeletal Syst Degenerat & Regenerat, Hangzhou, Peoples R China.
C3 Zhejiang University
RP Xie, Z; Jiang, C (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed, Sch Med, Hangzhou, Peoples R China.; Xie, Z; Jiang, C (通讯作者)，Key Lab Musculoskeletal Syst Degenerat & Regenerat, Hangzhou, Peoples R China.
EM ziang_xie@zju.edu.cn; 3319001@zju.edu.cn
FU National Natural Science Fund of China [81772387, 81472064]
FX This study was sponsored by the National Natural Science Fund of China
   (81772387; 81472064)
CR Alas S, 2001, CANCER RES, V61, P5137
   Bachegowda L, 2016, CANCER RES, V76, P4841, DOI 10.1158/0008 5472.CAN 15 3062
   Banerjee K, 2016, INT J CANCER, V138, P2570, DOI 10.1002/ijc.29923
   Bode JG, 2012, CELL SIGNAL, V24, P1185, DOI 10.1016/j.cellsig.2012.01.018
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031 10
   Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906
   Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101
   Garcia Manero G, 2015, CLIN CANCER RES, V21, P985, DOI 10.1158/1078 0432.CCR 14 1765
   Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078 0432.CCR 04 1752
   Ishiyama K, 2015, ALLERGOL INT, V64, P241, DOI 10.1016/j.alit.2015.01.006
   Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Li CH, 2018, INT IMMUNOPHARMACOL, V58, P136, DOI 10.1016/j.intimp.2018.03.021
   Liu H., 2015, Cancer Cell Microenviron, V2, DOI DOI 10.1007/s11433 015 5705 4
   Liu YP, 2012, CLIN BREAST CANCER, V12, P276, DOI 10.1016/j.clbc.2012.04.003
   Lu D, 2018, J BONE MINER RES, V33, P1773, DOI 10.1002/jbmr.3469
   Min YF, 2010, CANCER RES, V70, P2819, DOI 10.1158/0008 5472.CAN 09 1915
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Tan SHS, 2015, OSTEOPOROSIS INT, V26, P421, DOI 10.1007/s00198 014 2885 0
   Walker SR, 2014, MOL CELL ENDOCRINOL, V382, P616, DOI 10.1016/j.mce.2013.03.010
   Xie TX, 2006, CANCER RES, V66, P3188, DOI 10.1158/0008 5472.CAN 05 2674
   Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Yang J, 2012, LEUKEMIA, V26, P2114, DOI 10.1038/leu.2012.71
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
NR 32
TC 5
Z9 6
U1 2
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD AUG
PY 2022
VL 35
AR 100439
DI 10.1016/j.jbo.2022.100439
EA JUN 2022
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 2X3FI
UT WOS:000825093000002
PM 35800294
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lee, SH
   Park, SY
   Kim, JH
   Kim, N
   Lee, J
AF Lee, Sung Hoon
   Park, Shin Young
   Kim, Jung Ha
   Kim, Nacksung
   Lee, Junwon
TI Ginsenoside Rg2 inhibits osteoclastogenesis by downregulating the
   NFATc1, c Fos, and MAPK pathways
SO BMB REPORTS
LA English
DT Article
ID NF KAPPA B; ACTIVATED PROTEIN KINASE; RECEPTOR ACTIVATOR; KEY REGULATOR;
   BONE; RANKL; DIFFERENTIATION; IMMUNE; OSTEOIMMUNOLOGY; OSTEOPOROSIS
AB Ginsenosides, among the most active components of ginseng, exhibit several therapeutic effects against cancer, diabetes, and other metabolic diseases. However, the molecular mechanism underlying the anti osteoporotic activity of ginsenoside Rg2, a major ginsenoside, has not been clearly elucidated. This study aimed to determine the effects of ginsenoside Rg2 on receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast formation. Results indicate that ginsenoside Rg2 inhibits RANKLinduced osteoclast differentiation of bone marrow macrophages (BMMs) without cytotoxicity. Pretreatment with ginsenoside Rg2 significantly reduced the RANKL induced gene expression of c fos and nuclear factor of activated T cells (Nfatc1), as well as osteoclast specific markers tartrate resistant acid phosphatase (TRAP, Acp5) and osteoclast associated receptor (Oscar). Moreover, RANKL induced phosphorylation of mitogen activated protein kinases (MAPKs) was decreased by ginsenoside Rg2 in BMM. Therefore, we suggest that ginsenoside Rg2 suppresses RANKLinduced osteoclast differentiation through the regulation of MAPK signaling mediated osteoclast markers and could be developed as a therapeutic drug for the prevention and treatment of osteoporosis. [BMB Reports 2023; 56(10): 551 556]
C1 [Lee, Sung Hoon; Lee, Junwon] PaiChai Univ, Grad Sch, Dept Life Sci & Genet Engn, Daejeon 35345, South Korea.
   [Park, Shin Young] PaiChai Univ, Div Software Engn, Daejeon 35345, South Korea.
   [Kim, Jung Ha; Kim, Nacksung] Chonnam Natl Univ Med Sch, Dept Pharmacol, Gwangju 61469, South Korea.
C3 Pai Chai University; Pai Chai University; Chonnam National University
RP Lee, J (通讯作者)，PaiChai Univ, Grad Sch, Dept Life Sci & Genet Engn, Daejeon 35345, South Korea.; Kim, N (通讯作者)，Chonnam Natl Univ Med Sch, Dept Pharmacol, Gwangju 61469, South Korea.
EM naksungkim@jnu.ac.kr; junwon@pcu.ac.kr
RI park, shiny/ABY 8695 2022; Park, Shin Young/ABY 8695 2022
OI Park, Shin Young/0000 0002 6073 4634
FU Ministry of Science and ICT (MSIT) , Korea [IITP 2023 RS 2022 00156334];
   NRF   Korean Government (MSIT) [2021R1A2C1008317]
FX This work was supported by the Ministry of Science and ICT (MSIT) ,
   Korea, under the Innovative Human Resource Development for Local
   Intellectualization Support Program (IITP 2023 RS 2022 00156334)
   supervised by the Institute for Information & Communications Technology
   Planning & Evaluation (IITP) , and by an NRF grant funded by the Korean
   Government (MSIT) (2021R1A2C1008317) .
CR Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang Y, 2008, EUR J PHARMACOL, V578, P28, DOI 10.1016/j.ejphar.2007.09.023
   Chen WF, 2006, BRIT J PHARMACOL, V147, P542, DOI 10.1038/sj.bjp.0706640
   GENANT HK, 1989, AM J OBSTET GYNECOL, V161, P1842, DOI 10.1016/S0002 9378(89)80004 3
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kiefer D, 2003, AM FAM PHYSICIAN, V68, P1539
   Kim H, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2720 4
   Kim HJ, 2007, MOL PHARMACOL, V72, P418, DOI 10.1124/mol.107.034173
   Kim HR, 2008, IMMUNOPHARM IMMUNOT, V30, P333, DOI 10.1080/08923970801949125 
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lau WS, 2008, J STEROID BIOCHEM, V108, P64, DOI 10.1016/j.jsbmb.2007.06.005
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Liu J, 2009, BIOORG MED CHEM LETT, V19, P3320, DOI 10.1016/j.bmcl.2009.04.054
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nedeva IR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641162
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Pan XY, 2012, EUR J PHARMACOL, V683, P27, DOI 10.1016/j.ejphar.2012.02.040
   Reid Ian R, 2002, Expert Opin Drug Saf, V1, P93, DOI 10.1517/14740338.1.1.93
   Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood 2004 01 0041
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Xue QQ, 2023, J GINSENG RES, V47, P237, DOI 10.1016/j.jgr.2022.08.001
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yao F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122951
   Yuan HD, 2012, CHEM BIOL INTERACT, V195, P35, DOI 10.1016/j.cbi.2011.10.006
   Zhang GZ, 2008, J ETHNOPHARMACOL, V115, P441, DOI 10.1016/j.jep.2007.10.026
   Zhou LS, 2016, EMBO REP, V17, P811, DOI 10.15252/embr.201541643
NR 43
TC 8
Z9 9
U1 1
U2 6
PU KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER, # 801,  635 4 , YEOKSAM DONG,
   KANGNAM KU, SEOUL, 135 703, SOUTH KOREA
SN 1976 6696
EI 1976 670X
J9 BMB REP
JI BMB Rep.
PD OCT 31
PY 2023
VL 56
IS 10
BP 551
EP 556
DI 10.5483/BMBRep.2023 0100
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA W9BC8
UT WOS:001094499000004
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fijalkowski, I
   Geets, E
   Steenackers, E
   Van Hoof, V
   Ramos, FJ
   Mortier, G
   Fortuna, AM
   Van Hul, W
   Boudin, E
AF Fijalkowski, Igor
   Geets, Ellen
   Steenackers, Ellen
   Van Hoof, Viviane
   Ramos, Feliciano J.
   Mortier, Geert
   Fortuna, Ana Maria
   Van Hul, Wim
   Boudin, Eveline
TI A Novel Domain Specific Mutation in a Sclerosteosis Patient Suggests a
   Role of LRP4 as an Anchor for Sclerostin in Human Bone
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE WNT;  CATENIN; LRPs; SCLEROSTEOSIS; ANABOLICS
ID VAN BUCHEM DISEASE; CENANI LENZ SYNDROME; SOST GENE;
   NEUROMUSCULAR JUNCTION; CHROMOSOME 17Q12 Q21; POSTMENOPAUSAL WOMEN;
   MYASTHENIA GRAVIS; PROTEIN 4; DELETION; RECEPTOR
AB Mutations in the LRP4 gene, coding for a Wnt signaling coreceptor, have been found to cause several allelic conditions. Among these, two are characterized by a strong skeletal involvement, namely sclerosteosis and Cenani Lenz syndrome. In this work, we evaluated the role of LRP4 in the pathophysiology of these diseases. First, we report a novel LRP4 mutation, leading to the substitution of arginine at position 1170 in glutamine, identified in a patient with sclerosteosis. This mutation is located in the central cavity of the third  propeller domain, which is in line with two other sclerosteosis mutations we previously described. Reporter assays demonstrate that this mutation leads to impaired sclerostin inhibition of Wnt signaling. Moreover, we compared the effect of this novel variant to mutations causing Cenani Lenz syndrome and show that impaired membrane trafficking of the LRP4 protein is the likely mechanism underlying Cenani Lenz syndrome. This is in contrast to sclerosteosis mutations, previously shown to impair the binding between LRP4 and sclerostin. In addition, to better understand the biology of LRP4, we investigated the circulating sclerostin levels in the serum of a patient suffering from sclerosteosis owing to a LRP4 mutation. We demonstrate that impaired sclerostin binding to the mutated LRP4 protein leads to dramatic increase in circulating sclerostin in this patient. With this study, we provide the first evidence suggesting that LRP4 is responsible for the retention of sclerostin in the bone environment in humans. These findings raise potential concerns about the utility of determining circulating sclerostin levels as a marker for other bone related parameters. Although more studies are needed to fully understand the mechanism whereby LRP4 facilitates sclerostin action, it is clear that this protein represents a potent target for future osteoporosis therapies and an interesting alternative for the antisclerostin treatment currently under study. (c) 2016 American Society for Bone and Mineral Research.
C1 [Fijalkowski, Igor; Geets, Ellen; Steenackers, Ellen; Mortier, Geert; Van Hul, Wim; Boudin, Eveline] Univ Antwerp, Dept Med Genet, B 2020 Antwerp, Belgium.
   [Fijalkowski, Igor; Geets, Ellen; Steenackers, Ellen; Mortier, Geert; Van Hul, Wim; Boudin, Eveline] Univ Antwerp Hosp, Antwerp, Belgium.
   [Van Hoof, Viviane] Univ Antwerp Hosp, Dept Clin Chem, Antwerp, Belgium.
   [Ramos, Feliciano J.] Univ Zaragoza, Fac Med, Hosp Clin Univ Lozano Blesa, Unidad Genet,Serv Pediat,GCV CIBERER, Zaragoza, Spain.
   [Fortuna, Ana Maria] Ctr Hosp Porto, Ctr Genet Med, Oporto, Portugal.
   [Fortuna, Ana Maria] ICBAS UP, UMIB, Unit Multidisciplinary Res Biomed, Oporto, Portugal.
C3 University of Antwerp; University of Antwerp; University of Antwerp;
   Lozano Blesa University Clinical Hospital; CIBER   Centro de
   Investigacion Biomedica en Red; CIBERER; University of Zaragoza;
   Universidade do Porto
RP Van Hul, W (通讯作者)，Univ Antwerp, Dept Med Genet, Prins Boudewijnlaan 43, B 2650 Edegem, Belgium.; Van Hul, W (通讯作者)，Univ Antwerp Hosp, Prins Boudewijnlaan 43, B 2650 Edegem, Belgium.
EM wim.vanhul@uantwerpen.be
RI Mortier, Geert/D 2542 2012; BOUDIN, EVELINE/O 3966 2019; Van Hoof,
   Viviane/D 1587 2012; Ramos, Feliciano/ABH 8920 2020
OI Mortier, Geert/0000 0001 9871 4578; Boudin, Eveline/0000 0003 4818 6804;
   Van Hul, Wim/0000 0002 5065 7858; Fortuna, Ana/0000 0002 1296 5366; Van
   Hoof, Viviane/0000 0002 6054 3053; Fijalkowski, Igor/0000 0002 3212 5516
FU Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO grant) [G031915N];
   Systems Biology for the Functional Validation of Genetic Determinants of
   Skeletal Diseases project (SYBIL); Instituut voor de Aanmoediging van
   Innovatie door Wetenschap en Technologie in Vlaanderen (IWT); Fonds voor
   Wetenschappelijk Onderzoek Vlaanderen (FWO) [12A3814N]
FX This research was supported by grants of the Fonds voor Wetenschappelijk
   Onderzoek Vlaanderen (FWO grant G031915N) and Systems Biology for the
   Functional Validation of Genetic Determinants of Skeletal Diseases
   project (SYBIL). IF holds a predoctoral research grant with the
   Instituut voor de Aanmoediging van Innovatie door Wetenschap en
   Technologie in Vlaanderen (IWT). EB holds a postdoctoral grant with the
   Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO personal grant
   12A3814N). The authors thank Dr Michaela Kneissel (Novartis Pharma AG,
   Basel, Switzerland) for providing the LRP4 constructs and Kaatje Toye (
   Department of Endocrinology, Ghent University Hospital, Ghent, Belgium)
   for providing the measurements of serum resorption markers.
CR Balemans W, 1999, AM J HUM GENET, V64, P1661, DOI 10.1086/302416
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Balemans W, 2008, CALCIFIED TISSUE INT, V82, P445, DOI 10.1007/s00223 008 9130 9
   Barik A, 2014, J NEUROSCI, V34, P13892, DOI 10.1523/JNEUROSCI.1733 14.2014
   BEIGHTON P, 1977, CLIN GENET, V11, P1
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   CENANI A, 1967, Z KINDERHEILKD, V101, P181, DOI 10.1007/BF00438491
   Chang MK, 2014, P NATL ACAD SCI USA, V111, pE5187, DOI 10.1073/pnas.1413828111
   Choi HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007930
   Higuchi O, 2011, ANN NEUROL, V69, P418, DOI 10.1002/ana.22312
   Johnson EB, 2005, HUM MOL GENET, V14, P3523, DOI 10.1093/hmg/ddi381
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Li Y, 2010, AM J HUM GENET, V86, P696, DOI 10.1016/j.ajhg.2010.03.004
   Lindy AS, 2014, AM J MED GENET A, V164, P2391, DOI 10.1002/ajmg.a.36647
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   Ohkawara B, 2014, HUM MOL GENET, V23, P1856, DOI 10.1093/hmg/ddt578
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Pangrazio A, 2011, BONE, V49, P568, DOI 10.1016/j.bone.2011.05.006
   Pevzner A, 2012, J NEUROL, V259, P427, DOI 10.1007/s00415 011 6194 7
   Piters E, 2010, HUM MUTAT, V31, pE1526, DOI 10.1002/humu.21274
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   TRUSWELL AS, 1958, J BONE JOINT SURG BR, V40, P208, DOI 10.1302/0301 620X.40B2.208
   Van Hul W, 1998, AM J HUM GENET, V62, P391, DOI 10.1086/301721
   van Lierop AH, 2013, J BONE MINER RES, V28, P848, DOI 10.1002/jbmr.1794
   VANHOOF VO, 1988, CLIN CHEM, V34, P1857
   Weatherbee SD, 2006, DEVELOPMENT, V133, P4993, DOI 10.1242/dev.02696
   Xiong L, 2015, P NATL ACAD SCI USA, V112, P3487, DOI 10.1073/pnas.1419714112
   Zhang B, 2012, ARCH NEUROL CHICAGO, V69, P445, DOI 10.1001/archneurol.2011.2393
NR 33
TC 57
Z9 63
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2016
VL 31
IS 4
BP 874
EP 881
DI 10.1002/jbmr.2782
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DJ2BH
UT WOS:000374008200019
PM 26751728
DA 2025 08 17
ER

PT J
AU Guo, D
   Hong, D
   Wang, P
   Wang, JC
   Chen, LH
   Zhao, WB
   Zhang, LW
   Yao, C
   Chu, BX
   Chen, SN
   Li, ZY
   Chen, HX
AF Guo, Di
   Hong, Dun
   Wang, Peng
   Wang, Jiacheng
   Chen, Lihua
   Zhao, Weibo
   Zhang, Liwei
   Yao, Can
   Chu, Binxiang
   Chen, Shenao
   Li, Zhiyan
   Chen, Haixiao
TI Histone deacetylase inhibitor CI 994 inhibits osteoclastogenesis via
   suppressing NF κB and the downstream c Fos/NFATc1 signaling pathways
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE CI 994; Osteoclast; Osteolysis; NF kappa B signaling pathway; c Fos;
   NFATc1
ID IN VITRO; BONE; DIFFERENTIATION; CELLS; ACETYLATION; COMBINATION; DRUG
AB [4 (acetylamino) N (2 amino phenyl) benzamide] (CI 994) is a histone deacetylase 1 3 specific inhibitor that has been shown to indirectly increase the production of Dickkopf 1, which is an inhibitor of osteoclastic development. However, whether CI 994 has an influence on receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis is still unclear; in our study, this mechanism was investigated. In an in vitro study, using a tartrate resistant acid phosphatase (TRAP) stain, an F actin ring, bone absorption test, quantitative PCR and Western blotting, the role of CI 994 in osteoclastogenesis and the expression of related genes and proteins were investigated. In an in vivo study, the effect of CI 994 on osteolysis was evaluated using a titanium particle induced murine calvarial osteolysis model. Our results indicated that CI 994 inhibited osteoclast differentiation and the function of bone resorption without cytotoxic effects. Moreover, CI 994 inhibited the expression of osteoclast related genes, including ACP5, CTSK, NFATc1, c Fos, DC STAMP and V ATPase d2. Furthermore, CI 994 suppressed the phosphorylation of I kappa B alpha and p65 and the expression of downstream c Fos and NFATc1. Consistent with the in vitro results described above, our in vivo experiment indicated that CI 994 inhibited Ti induced osteolysis. In conclusion, CI 994 inhibited osteoclastogenesis by suppressing NF kappa B and the downstream c Fos/NFATc1 signaling pathway. Thus, this study showed the possibility of using CI 994 for the treatment of exorbitant osteoclastic bone resorption.
C1 [Guo, Di; Hong, Dun; Wang, Peng; Wang, Jiacheng; Zhao, Weibo; Zhang, Liwei; Yao, Can; Chu, Binxiang; Chen, Shenao; Li, Zhiyan; Chen, Haixiao] Wenzhou Med Univ, Orthoped Dept, Taizhou Hosp, Linhai 317000, Peoples R China.
   [Chen, Lihua] Wenzhou Med Univ, Enze Med Res Ctr, Taizhou Hosp, Linhai 317000, Peoples R China.
   [Guo, Di; Hong, Dun; Wang, Peng; Wang, Jiacheng; Chen, Lihua; Zhao, Weibo; Yao, Can; Chu, Binxiang; Chen, Shenao; Li, Zhiyan; Chen, Haixiao] Taizhou Hosp, Bone Dev & Metab Res Ctr, Linhai 317000, Peoples R China.
   [Zhang, Liwei] Soochow Univ Med, Orthoped Inst, Suzhou 215008, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Chen, HX (通讯作者)，Wenzhou Med Univ, Orthoped Dept, Taizhou Hosp, Linhai 317000, Peoples R China.
EM chenhx@enzemed.com
RI Chen, Lihua/AAH 7898 2019; Hong, Dun/IUP 2161 2023
OI Hong, Dun/0000 0002 2094 4987; 
FU Natural Science Foundation of China [81171748, 31501147]; Natural
   Science Foundation of Zhejiang Province [LY17H160068]; Experimental
   Animal Science Project of Zhejiang Province [2018C37123]
FX This study was supported by the Natural Science Foundation of China
   (81171748, 31501147), Natural Science Foundation of Zhejiang Province
   (LY17H160068), Experimental Animal Science Project of Zhejiang Province
   (2018C37123).
CR [Anonymous], 2018, INT J MOL SCI
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Authement ME, 2016, J NEUROPHYSIOL, V116, P1093, DOI 10.1152/jn.00238.2016
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cantley MD, 2011, J CELL PHYSIOL, V226, P3233, DOI 10.1002/jcp.22684
   Chen YH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010138
   Chiu YH, 2016, J CELL PHYSIOL, V231, P2402, DOI 10.1002/jcp.25389
   Chou DHC, 2012, CHEM BIOL, V19, P669, DOI 10.1016/j.chembiol.2012.05.010
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   ELBELTAGI HM, 1993, CANCER RES, V53, P3008
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hubeek I, 2008, ONCOL REP, V19, P1517
   Kim JH, 2011, BIOCHEM J, V436, P253, DOI 10.1042/BJ20110062
   Kraker AJ, 2003, MOL CANCER THER, V2, P401
   Li L, 2016, EUR J PHARMACOL, V777, P17, DOI 10.1016/j.ejphar.2016.02.057
   Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680 000000000 00000
   Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Nakamura T, 2005, J IMMUNOL, V175, P5809, DOI 10.4049/jimmunol.175.9.5809
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Ono T., 2018, Histochem Cell Biol
   Rahman MM, 2003, BLOOD, V101, P3451, DOI 10.1182/blood 2002 08 2622
   Rasheed WK, 2007, EXPERT OPIN INV DRUG, V16, P659, DOI 10.1517/13543784.16.5.659
   Sugatani T, 2015, BONE, V81, P168, DOI 10.1016/j.bone.2015.07.018
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Undevia SD, 2004, ANN ONCOL, V15, P1705, DOI 10.1093/annonc/mdh438
   Wang YJ, 2013, EPIGENETICS US, V8, P756, DOI 10.4161/epi.25202
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Zhang L., 2018, J CELL PHYSL
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 31
TC 9
Z9 11
U1 1
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD APR 5
PY 2019
VL 848
BP 96
EP 104
DI 10.1016/j.ejphar.2019.01.021
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HM4ZF
UT WOS:000459483200012
PM 30682334
DA 2025 08 17
ER

PT J
AU Yonezawa, N
   Murakami, H
   Kato, S
   Takeuchi, A
   Tsuchiya, H
AF Yonezawa, Noritaka
   Murakami, Hideki
   Kato, Satoshi
   Takeuchi, Akihiko
   Tsuchiya, Hiroyuki
TI Giant cell tumor of the thoracic spine completely removed by total
   spondylectomy after neoadjuvant denosumab therapy
SO EUROPEAN SPINE JOURNAL
LA English
DT Article
DE Giant cell tumor; Denosumab; Total spondylectomy; Spine; RANKL
ID OPEN LABEL; BONE; EFFICACY
AB Purpose Denosumab, a novel monoclonal antibody that targets the receptor activator of nuclear factor kappa B (RANK) ligand (RANKL), has recently been used to treat patients with giant cell tumor of bone (GCTB). However, few reports have described the clinical results of denosumab therapy for spinal GCTB and evaluated treatment efficacy with respect to the entirety of the resected vertebra after denosumab therapy.
   Methods We present the case of a 51 year old man with T12 GCTB that was completely removed by a total spondylectomy following 10 courses of neoadjuvant denosumab therapy. Post therapy radiological findings indicated epidural tumor reduction in the spinal canal and sclerotic rim formation. However, the affected vertebra collapsed despite denosumab therapy and a massive bridging callus formation was present between the spinal GCTB and adjacent vertebra.
   Results These morphological changes made the tumor margins unclear and increased the difficulty of dissection of the segmental arteries from the vertebral body and en bloc corpectomy by a posterior approach. Pathological findings indicated increased woven bone at the peripheral lesion of the resected vertebra and RANKL positive stromal cells remained around the woven bone.
   Conclusions These findings support that GCTB stromal cells survived around the newly formed woven bone after long term denosumab treatment and total surgical resection of such primary spinal lesions as the gold standard treatment, even following administration of denosumab. Surgeons should note that prolonged adjuvant denosumab therapy may increase the difficulty of performing a posterior approach total en bloc spondylectomy.
C1 [Yonezawa, Noritaka; Murakami, Hideki; Kato, Satoshi; Takeuchi, Akihiko; Tsuchiya, Hiroyuki] Kanazawa Univ, Sch Med, Dept Orthoped Surg, 13 1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.
C3 Kanazawa University
RP Murakami, H (通讯作者)，Kanazawa Univ, Sch Med, Dept Orthoped Surg, 13 1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.
EM hmuraka@med.kanazawa u.ac.jp
RI TSUCHIYA, HIROYUKI/C 5142 2015; Takeuchi, Akihiko/AAJ 1563 2020
OI Takeuchi, Akihiko/0000 0002 4071 5620; Yonezawa,
   Noritaka/0000 0002 8037 6213; Kato, Satoshi/0000 0003 4762 5932; 
FU Grants in Aid for Scientific Research [16K15658] Funding Source: KAKEN
CR Agarwal A, 2013, CASE REP ONCOL MED, V2013, DOI 10.1155/2013/496351
   Balke Maurice, 2012, Sarcoma, V2012, P410973, DOI 10.1155/2012/410973
   Boriani S, 2012, SPINE, V37, pE37, DOI 10.1097/BRS.0b013e3182233ccd
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Cavalcante RAD, 2016, SPINE, V41, pE178, DOI 10.1097/BRS.0000000000001191
   Gaston CL, 2011, J BONE JOINT SURG BR, V93B, P1665, DOI 10.1302/0301 620X.93B12.27663
   Goldschlager T, 2015, J NEUROSURG SPINE, V22, P526, DOI 10.3171/2014.10.SPINE13937
   Gortzak Y, 2010, J BONE JOINT SURG BR, V92B, P1475, DOI 10.1302/0301 620X.92B10.23495
   Kajiwara D, 2016, ASIAN SPINE J, V10, P553, DOI 10.4184/asj.2016.10.3.553
   Kumar R, 2017, SPINE, V42, pE629, DOI 10.1097/BRS.0000000000001951
   Lau CPY, 2013, CONNECT TISSUE RES, V54, P439, DOI 10.3109/03008207.2013.848202
   Mattei TA, 2014, SPINE J, V14, pE15, DOI 10.1016/j.spinee.2014.02.019
   Randhawa SS, 2016, ASIAN SPINE J, V10, P945, DOI 10.4184/asj.2016.10.5.945
   Roux S, 2002, AM J CLIN PATHOL, V117, P210
   Rutkowski P, 2015, ANN SURG ONCOL, V22, P2860, DOI 10.1245/s10434 015 4634 9
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   van der Heijden L, 2014, ONCOLOGIST, V19, P550, DOI 10.1634/theoncologist.2013 0432
NR 18
TC 22
Z9 25
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0940 6719
EI 1432 0932
J9 EUR SPINE J
JI Eur. Spine J.
PD MAY
PY 2017
VL 26
IS 1
SU S
BP S236
EP S242
DI 10.1007/s00586 017 5086 7
PG 7
WC Clinical Neurology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Orthopedics
GA FA8TF
UT WOS:000405718300043
PM 28396950
DA 2025 08 17
ER

PT J
AU Wang, SF
   Niu, XM
   Bao, X
   Wang, Q
   Zhang, JP
   Lu, S
   Wang, YJ
   Xu, L
   Wang, MW
   Zhang, J
AF Wang, Shengfei
   Niu, Xiaomin
   Bao, Xiao
   Wang, Qin
   Zhang, Jianping
   Lu, Shun
   Wang, Yongjun
   Xu, Ling
   Wang, Mingwei
   Zhang, Jie
TI The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour
   cell growth in bone metastasis of lung cancer, as evidenced by
   multimodality molecular imaging
SO ONCOLOGY REPORTS
LA English
DT Article
DE non small cell lung cancer; bone metastasis; phosphoinositide 3 kinase
   inhibitor; multimodality molecular imaging; multiparametric
   quantification
ID ZOLEDRONIC ACID; DISEASE; EFFICACY; PHOSPHATASE; NVP BKM120; MECHANISMS;
   PREVENTION; SURVIVAL; THERAPY; BREAST
AB Non small cell lung cancer (NSCLC) metastasis commonly occurs in bone, which often results in pathological fractures. Sustained phosphoinositide 3 kinase (PI3K) signalling promotes the growth of PI3K dependent NSCLC and elevates osteoclastogenic potential. The present study investigated the effects of a PI3K inhibitor on NSCLC growth in bone and osteoclast formation, and aimed to determine whether it could control symptoms associated with bone metastasis. A bone metastasis xenograft model was established by implanting NCI H460 luc2 lung cancer cells, which contain a phosphatidylinositol  4,5 bisphosphate 3 kinase catalytic subunit alpha mutation, into the right tibiae of mice. After 1 week, the tumours were challenged with a PI3K inhibitor (buparlisib) or blank control for 3 weeks. Tumour growth and burden were longitudinally assessed in vivo via reporter gene bioluminescence imaging (BLI), small animal positron emission tomography/computed tomography (CT) [F 18 fluorodeoxyglucose (F 18 FDG)] and single photon emission computed tomography/CT [Tc 99m methylene diphosphonate (Tc 99m MDP)] imaging. Tibia sections of intraosseous NCI H460 tumours were analysed by immunohistochemistry (IHC), western blotting and flow cytometry. Dynamic weight bearing (DWB) tests were further performed to examine the improvement of symptoms associated with bone metastasis during the entire study. Administration of buparlisib significantly inhibited the progression of bone metastasis of NSCLC, as evidenced by significantly reduced uptake of F 18 FDG, Tc 99m MDP and BLI signals in the treated lesions. In addition, buparlisib appeared to inhibit the expression of tartrate resistant acid phosphatase and receptor activator of nuclear factor kappa B ligand, as determined by IHC. Buparlisib also resulted in increased cell apoptosis, as determined by a higher percentage of Annexin V staining and increased caspase 3 expression. Furthermore, buparlisib significantly increased weight bearing capacity, as revealed by DWB tests. The PI3K inhibitor, buparlisib, suppressed osteoclast formation in vivo, and exhibited antitumour activity, thus leading to increased weight bearing ability in mice with bone metastasis of lung cancer. Therefore, targeting the PI3K pathway may be a potential therapeutic strategy that prevents the structural skeletal damage associated with bone metastasis of lung cancer.
C1 [Wang, Shengfei; Zhang, Jie] Fudan Univ, Shanghai Canc Ctr, Dept Thorac Surg, 270 Dongan Rd, Shanghai 200032, Peoples R China.
   [Wang, Shengfei; Bao, Xiao; Zhang, Jianping; Wang, Mingwei; Zhang, Jie] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200433, Peoples R China.
   [Niu, Xiaomin; Lu, Shun] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Shanghai Lung Canc Ctr, Shanghai 200030, Peoples R China.
   [Bao, Xiao; Zhang, Jianping; Wang, Mingwei] Fudan Univ, Shanghai Canc Ctr, Dept Nucl Med, 270 Dongan Rd, Shanghai 200032, Peoples R China.
   [Bao, Xiao; Zhang, Jianping; Wang, Mingwei] Fudan Univ, Ctr Biomed Imaging, Shanghai 200433, Peoples R China.
   [Bao, Xiao; Zhang, Jianping; Wang, Mingwei] Shanghai Engn Res Ctr Mol Imaging Probes, Shanghai 200032, Peoples R China.
   [Bao, Xiao] Tongji Univ, Shanghai Pulm Hosp, Dept Radiol, Shanghai 200433, Peoples R China.
   [Wang, Qin; Xu, Ling] Shanghai Univ Tradit Chinese Med, Yueyang Hosp, Dept Oncol, Shanghai 200437, Peoples R China.
   [Wang, Yongjun] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Orthopaed & Traumatol, Shanghai 200000, Peoples R China.
   [Zhang, Jie] Univ Pittsburgh, Med Ctr, Dept Cardiothorac Surg, Pittsburgh, PA 15232 USA.
C3 Fudan University; Fudan University; Shanghai Jiao Tong University; Fudan
   University; Fudan University; Tongji University; Shanghai University of
   Traditional Chinese Medicine; Shanghai University of Traditional Chinese
   Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh
RP Zhang, J (通讯作者)，Fudan Univ, Shanghai Canc Ctr, Dept Thorac Surg, 270 Dongan Rd, Shanghai 200032, Peoples R China.; Wang, MW (通讯作者)，Fudan Univ, Shanghai Canc Ctr, Dept Nucl Med, 270 Dongan Rd, Shanghai 200032, Peoples R China.
EM wang.mingwei88@163.com; zhangjie2289@hotmail.com
RI qianglong, wang/HIK 3742 2022; zheng, zongli/C 7309 2008; Lu,
   Shun/ABF 8341 2021
OI Wang, Ming Wei/0000 0003 0020 4700; 
FU National Natural Science Foundation of China [81302005, 11275050,
   30700188]; Shanghai Municipality Science and Technology Commission
   Foundation Key Project [15411951602, 14JC1401400, 16401970704,
   13ZR1438500]; Ministry of Education Returned Scientific Research
   Foundation; Trans Century Training Programme Foundation for the Talents
   by the State Education Commission; Youth Foundation of Shanghai
   Municipal Public Health Bureau [20124Y114]; Project of Shanghai
   Municipal Public Health Bureau [201840122]; Scientific Research Project
   of Shanghai Municipal Cadre Health Bureau [2017(12)]; Interdisciplinary
   Program of Shanghai Jiao Tong University [YG2017MS80]; 'Shanghai Young
   Physician Development Program' of Shanghai Municipal Public Health
   Bureau; Shanghai Engineering Research Center of Molecular Imaging Probes
   [14DZ2251400];  [2012(105)]
FX This study was supported by the National Natural Science Foundation of
   China (grant nos. 81302005, 11275050 and 30700188), the Shanghai
   Municipality Science and Technology Commission Foundation Key Project
   (grant nos. 15411951602, 14JC1401400, 16401970704 and 13ZR1438500), the
   Ministry of Education Returned Scientific Research Foundation,
   Trans Century Training Programme Foundation for the Talents by the State
   Education Commission (to JZ), the Youth Foundation of Shanghai Municipal
   Public Health Bureau (grant no. 20124Y114), the Project of Shanghai
   Municipal Public Health Bureau (grant no. 201840122), the Scientific
   Research Project of Shanghai Municipal Cadre Health Bureau [2017(12)],
   the Interdisciplinary Program of Shanghai Jiao Tong University (grant
   no. YG2017MS80), the 'Shanghai Young Physician Development Program' of
   Shanghai Municipal Public Health Bureau, the second batch (2012(105))
   (to XMN), and the Shanghai Engineering Research Center of Molecular
   Imaging Probes (grant no. 14DZ2251400).
CR [Anonymous], 2017, National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: non small cell lung cancer
   [Anonymous], RECENT RESULTS CANC
   Bao X, 2016, THERANOSTICS, V6, P2084, DOI 10.7150/thno.13917
   Blazquez R, 2018, GLIA, V66, P2438, DOI 10.1002/glia.23485
   Blüml S, 2015, ANN RHEUM DIS, V74, P227, DOI 10.1136/annrheumdis 2013 203486
   Campone M, 2018, EUR J CANCER, V103, P147, DOI 10.1016/j.ejca.2018.08.002
   Cappuzzo F, 2007, J CLIN ONCOL, V25, P2248, DOI 10.1200/JCO.2006.09.4300
   Chan BA, 2015, TRANSL LUNG CANCER R, V4, P36, DOI 10.3978/j.issn.2218 6751.2014.05.01
   Chen WQ, 2016, CA CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cheung FH, 2014, ORTHOP CLIN N AM, V45, P109, DOI 10.1016/j.ocl.2013.09.003
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Cook GJR, 2011, EJNMMI RES, V1, DOI 10.1186/2191 219X 1 4
   EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853
   Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Gan ZY, 2015, EUR J HAEMATOL, V94, P343, DOI 10.1111/ejh.12436
   Gdowski AS, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046 017 0578 1
   Heudel PE, 2017, BRIT J CANCER, V116, P303, DOI 10.1038/bjc.2016.430
   La Monica S, 2009, BIOCHEM PHARMACOL, V78, P460, DOI 10.1016/j.bcp.2009.04.033
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Lopez Olivo MA, 2012, SUPPORT CARE CANCER, V20, P2985, DOI 10.1007/s00520 012 1563 z
   Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535 7163.MCT 11 0474
   Martín M, 2017, ANN ONCOL, V28, P313, DOI 10.1093/annonc/mdw562
   Mhaskar R, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003188.pub3, 10.1002/14651858.CD003188.pub4]
   Momcilovic M, 2018, BIOMOL THER, V26, P81, DOI 10.4062/biomolther.2017.220
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Peng XB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058361
   Quadros AU, 2015, SCI REP UK, V5, DOI 10.1038/srep14648
   Ratasvuori M, 2014, J SURG ONCOL, V110, P360, DOI 10.1002/jso.23654
   Ren H, 2012, CANCER LETT, V325, P139, DOI 10.1016/j.canlet.2012.06.018
   Riihimäki M, 2014, LUNG CANCER, V86, P78, DOI 10.1016/j.lungcan.2014.07.020
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Siegel RL, 2017, CA CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sos ML, 2009, P NATL ACAD SCI USA, V106, P18351, DOI 10.1073/pnas.0907325106
   Speranza MC, 2016, SCI REP UK, V6, DOI 10.1038/srep20189
   Tsurutani J, 2006, J CLIN ONCOL, V24, P306, DOI 10.1200/JCO.2005.02.4133
   Vansteenkiste JF, 2015, J THORAC ONCOL, V10, P1319, DOI 10.1097/JTO.0000000000000607
   Weber KL, 2006, J BONE JOINT SURG AM, V88A, P11, DOI 10.2106/JBJS.F.00635
   Werbeck JL, 2014, VET PATHOL, V51, P868, DOI 10.1177/0300985813505116
   Wong MHF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub3
   Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097 0215(19980911)77:6<887::AID IJC15>3.0.CO;2 Z
   Xuan WH, 2017, CELL BIOCHEM FUNCT, V35, P171, DOI 10.1002/cbf.3260
   Yao Z, 2018, CURR OPIN CHEM BIOL, V45, P148, DOI 10.1016/j.cbpa.2018.05.009
   Zhang F, 2011, THERANOSTICS, V1, P302, DOI 10.7150/thno/v01p0302
   Zhu M, 2013, PAIN MED, V14, P257, DOI 10.1111/pme.12016
   Zhu WJ, 2015, CELL BIOCHEM BIOPHYS, V72, P171, DOI 10.1007/s12013 014 0433 3
   Zito CR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031331
NR 49
TC 15
Z9 15
U1 0
U2 18
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021 335X
EI 1791 2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2019
VL 41
IS 5
BP 2636
EP 2646
DI 10.3892/or.2019.7080
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HS6XZ
UT WOS:000464015900004
PM 30896825
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Witt Enderby, PA
   Slater, JP
   Johnson, NA
   Bondi, CD
   Dodda, BR
   Kotlarczyk, MP
   Clafshenkel, WP
   Sethi, S
   Higginbotham, S
   Rutkowski, JL
   Gallagher, KM
   Davis, VL
AF Witt Enderby, Paula A.
   Slater, John P.
   Johnson, Nakpangi A.
   Bondi, Corry D.
   Dodda, Balasunder R.
   Kotlarczyk, Mary P.
   Clafshenkel, William P.
   Sethi, Shalini
   Higginbotham, Suzanne
   Rutkowski, James L.
   Gallagher, Katie M.
   Davis, Vicki L.
TI Effects on bone by the light/dark cycle and chronic treatment with
   melatonin and/or hormone replacement therapy in intact female mice
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Article
DE bone density; bone morphogenetic proteins; circadian; hormone
   replacement therapy (HRT); melatonin; menopause; osteoporosis; Per 2;
   retinal degeneration
ID MESENCHYMAL STEM CELLS; ADOLESCENT IDIOPATHIC SCOLIOSIS;
   CIRCADIAN RHYTHM; GENE EXPRESSION; OSTEOBLAST DIFFERENTIATION; SIGNALING
   DYSFUNCTION; OSTEOCLAST FORMATION; URINARY EXCRETION; DIURNAL VARIATION;
   TURNOVER MARKERS
AB In this study, the effects of the light/dark cycle, hormone replacement therapy (HRT), and nocturnal melatonin supplementation on osteogenic markers and serum melatonin levels were examined in a blind mouse model (MMTV Neu transgenic mice). Melatonin levels in this mouse strain (FVB/N) with retinal degeneration (rd / ) fluctuate in a diurnal manner, suggesting that these mice, although blind, still perceive light. Real time RT PCR analyses demonstrated that Runx2, Bmp2, Bmp6, Bglap, and Per2 mRNA levels coincide with melatonin levels. The effect of chronic HRT (0.5 mg 17 beta estradiol + 50 mg progesterone in 1800 kcal of diet) alone and in combination with melatonin (15 mg/L drinking water) on bone quality and density was also assessed by histomorphometry and microcomputed tomography, respectively. Bone density was significantly increased (P < 0.05) after 1 yr of treatment with the individual therapies, HRT (22% increase) and nocturnal melatonin (20% increase) compared to control. Hormone replacement therapy alone also increased surface bone, decreased trabecular space, and decreased the number of osteoclasts without affecting osteoblast numbers compared to the control group (P < 0.05). Chronic HRT + melatonin therapy did not significantly increase bone density, even though this combination significantly increased Bglap mRNA levels. These data suggest that the endogenous melatonin rhythm modulates markers important to bone physiology. Hormone replacement therapy with or without nocturnal melatonin in cycling mice produces unique effects on bone markers and bone density. The effects of these therapies alone and combined may improve bone health in women in perimenopause and with low nocturnal melatonin levels from too little sleep, too much light, or age.
C1 [Witt Enderby, Paula A.; Slater, John P.; Johnson, Nakpangi A.; Bondi, Corry D.; Dodda, Balasunder R.; Kotlarczyk, Mary P.; Clafshenkel, William P.; Sethi, Shalini; Gallagher, Katie M.; Davis, Vicki L.] Duquesne Univ, Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA.
   [Higginbotham, Suzanne] Duquesne Univ, Sch Pharm, Div Clin Social & Adm Sci, Pittsburgh, PA 15282 USA.
   [Rutkowski, James L.] Clarion Res Grp, Clarion, PA USA.
C3 Duquesne University; Duquesne University
RP Witt Enderby, PA (通讯作者)，Duquesne Univ, Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA.
EM wittp@duq.edu
RI ; Clafshenkel, William/HMV 6399 2023; Rutkowski, James/AAY 8652 2020
OI Kotlarczyk, Mary/0000 0002 5846 8461; Clafshenkel,
   William/0000 0003 4902 8154; Higginbotham, Suzanne/0009 0002 9428 9898;
   Witt Enderby, Paula/0000 0002 1844 4457
FU Division of Clinical, Social, and Administrative Sciences, Duquesne
   University; Susan G. Komen for the Cure
FX Funding for this research was provided by the Susan G. Komen for the
   Cure awarded to PAW E and VLD and the Division of Clinical, Social, and
   Administrative Sciences, Duquesne University awarded to PAW E and SH. We
   would like to thank Patricia Lott at the Center for Bone Metabolism and
   Disease, University of Alabama, for her technical assistance with the
   histomorphometry. All authors state that they have no conflict of
   interest.
CR Anisimov VN, 2003, INT J CANCER, V103, P300, DOI 10.1002/ijc.10827
   [Anonymous], 2012, MENOPAUSE, V19, P257, DOI 10.1097/gme.0b013e31824b970a
   [Anonymous], 2011, ANN INT MED
   Azeddine B, 2007, CLIN ORTHOP RELAT R, P45, DOI 10.1097/BLO.0b013e318811f39fa
   Bellipanni G, 2001, EXP GERONTOL, V36, P297, DOI 10.1016/S0531 5565(00)00217 5
   Blask DE, 2005, CANCER RES, V65, P11174, DOI 10.1158/0008 5472.CAN 05 1945
   Cardinali DP, 2003, J PINEAL RES, V34, P81, DOI 10.1034/j.1600 079X.2003.00028.x
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Cutando A, 2008, J PINEAL RES, V45, P174, DOI 10.1111/j.1600 079X.2008.00573.x
   Deif M, 2007, ALEXANDRIA J MED, V43
   Dijk DJ, 2002, J APPL PHYSIOL, V92, P852, DOI 10.1152/japplphysiol.00924.2001
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   EASTELL R, 1992, J CLIN ENDOCR METAB, V74, P487, DOI 10.1210/jc.74.3.487
   Ebeling PR, 1996, J CLIN ENDOCR METAB, V81, P3366, DOI 10.1210/jc.81.9.3366
   Egermann M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 271
   Feskanich D, 2009, OSTEOPOROSIS INT, V20, P537, DOI 10.1007/s00198 008 0729 5
   Fjelldal PG, 2004, J PINEAL RES, V36, P132, DOI 10.1046/j.1600 079X.2003.00109.x
   Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028
   Gery S, 2007, ONCOGENE, V26, P7916, DOI 10.1038/sj.onc.1210585
   Greenspan SL, 1997, CALCIFIED TISSUE INT, V60, P419, DOI 10.1007/s002239900256
   Gu X, 2012, CELL DEATH DIFFER, V19, P397, DOI 10.1038/cdd.2011.103
   GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578
   Hardeland R, 2012, J PINEAL RES, V52, P139, DOI 10.1111/j.1600 079X.2011.00934.x
   HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046 3049.1988
   IGUCHI H, 1982, J CLIN ENDOCR METAB, V55, P27, DOI 10.1210/jcem 55 1 27
   Ireland D, 2003, METH MOLEC MED, V80, P433
   Isobe Y, 2004, BRAIN RES, V1013, P204, DOI 10.1016/j.brainres.2004.04.052
   Isojima Y, 2003, J BIOCHEM, V134, P777, DOI 10.1093/jb/mvg219
   Johnston JD, 2006, ENDOCRINOLOGY, V147, P959, DOI 10.1210/en.2005 1100
   Jung Hynes B, 2010, J PINEAL RES, V49, P60, DOI 10.1111/j.1600 079X.2010.00767.x
   Kennaway DJ, 2002, AM J PHYSIOL REG I, V282, pR358, DOI 10.1152/ajpregu.00360.2001
   Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774 002 0408 0
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Kono H, 2011, J PINEAL RES, V51, P387, DOI 10.1111/j.1600 079X.2011.00901.x
   Kos Kudla B, 2002, NEUROENDOCRINOL LETT, V23, P243
   Kotlarczyk MP, 2012, J PINEAL RES, V52, P414, DOI 10.1111/j.1600 079X.2011.00956.x
   Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219
   Ladizesky MG, 2003, J PINEAL RES, V34, P143, DOI 10.1034/j.1600 079X.2003.00021.x
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lockley SW, 1997, J CLIN ENDOCR METAB, V82, P3763, DOI 10.1210/jc.82.11.3763
   Lucas RJ, 2001, BEHAV BRAIN RES, V125, P97, DOI 10.1016/S0166 4328(01)00274 1
   MACHIDA M, 1995, J BONE JOINT SURG BR, V77B, P134, DOI 10.1302/0301 620X.77B1.7822371
   Maronde E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011527
   Moreau A, 2004, SPINE, V29, P1772, DOI 10.1097/01.BRS.0000134567.52303.1A
   Moriya T, 2007, NEUROSCIENCE, V146, P494, DOI 10.1016/j.neuroscience.2007.02.018
   Nakade O, 1999, J PINEAL RES, V27, P106, DOI 10.1111/j.1600 079X.1999.tb00603.x
   Nakamura A, 2009, TISSUE ENG PART C ME, V15, P169, DOI 10.1089/ten.tec.2007.0334
   Nováková M, 2012, J CLIN ENDOCR METAB, V97, pE312, DOI 10.1210/jc.2011 2750
   Ostrowska Z, 2003, Endocr Regul, V37, P163
   Ostrowska Z, 2003, Endocr Regul, V37, P211
   Ostrowska Z, 2001, NEUROENDOCRINOL LETT, V22, P121
   Oyama J, 2006, J PINEAL RES, V40, P219, DOI 10.1111/j.1600 079X.2005.00302.x
   Park KH, 2011, J PINEAL RES, V51, P187, DOI 10.1111/j.1600 079X.2011.00875.x
   Potocki L, 2000, J MED GENET, V37, P428, DOI 10.1136/jmg.37.6.428
   Prior JC, 2005, ENDOCRINE, V26, P297, DOI 10.1385/ENDO:26:3:297
   Prior JC, 1998, ENDOCR REV, V19, P397, DOI 10.1210/er.19.4.397
   PROVENCIO I, 1994, VISION RES, V34, P1799, DOI 10.1016/0042 6989(94)90304 2
   Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600 079X.2006.00318.x
   Ripperger JA, 2010, CELL CYCLE, V9, P2515, DOI 10.4161/cc.9.13.12075
   Robinson LJ, 2009, EXP CELL RES, V315, P1287, DOI 10.1016/j.yexcr.2009.01.014
   Roth JA, 1999, J BIOL CHEM, V274, P22041, DOI 10.1074/jbc.274.31.22041
   Sadat Ali M, 2000, JOINT BONE SPINE, V67, P62
   Saintier D, 2006, J STEROID BIOCHEM, V99, P165, DOI 10.1016/j.jsbmb.2006.01.009
   Sanchez Barcelo J, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/830231
   SANDYK R, 1992, INT J NEUROSCI, V62, P215
   SCHLEMMER A, 1992, J CLIN ENDOCR METAB, V74, P476, DOI 10.1210/jc.74.3.476
   Seifert Klauss V, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/845180
   Sethi S, 2010, J PINEAL RES, V49, P222, DOI 10.1111/j.1600 079X.2010.00784.x
   Sowers MR, 2003, OSTEOPOROSIS INT, V14, P191, DOI 10.1007/s00198 002 1329 4
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Suzuki N, 2002, J PINEAL RES, V33, P253, DOI 10.1034/j.1600 079X.2002.02953.x
   TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065
   Turgut M, 2005, J PINEAL RES, V39, P392, DOI 10.1111/j.1600 079X.2005.00263.x
   UEBELHART D, 1991, J CLIN ENDOCR METAB, V72, P367, DOI 10.1210/jcem 72 2 367
   Uslu S, 2007, ANAL QUANT CYTOL, V29, P317
   Vakkuri O, 1996, EUR J ENDOCRINOL, V135, P188, DOI 10.1530/eje.0.1350188
   Witt Enderby PA, 2006, J PINEAL RES, V41, P297, DOI 10.1111/j.1600 079X.2006.00369.x
   Zaminy Arash, 2008, Iran Biomed J, V12, P133
   Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600 079X.2010.00803.x
NR 82
TC 51
Z9 58
U1 1
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0742 3098
EI 1600 079X
J9 J PINEAL RES
JI J. Pineal Res.
PD NOV
PY 2012
VL 53
IS 4
BP 374
EP 384
DI 10.1111/j.1600 079X.2012.01007.x
PG 11
WC Endocrinology & Metabolism; Neurosciences; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA 027EV
UT WOS:000310335500006
PM 22639972
DA 2025 08 17
ER

PT J
AU Zambuzzi, WF
   Bruni Cardoso, A
   Granjeiro, JM
   Peppelenbosch, MP
   de Carvalho, HF
   Aoyama, H
   Ferreira, CV
AF Zambuzzi, Willian Fernando
   Bruni Cardoso, Alexandre
   Granjeiro, Jose Mauro
   Peppelenbosch, Maikel Petrus
   de Carvalho, Hernandes Faustino
   Aoyama, Hiroshi
   Ferreira, Carmen Verissima
TI On the Road to Understanding of the Osteoblast Adhesion: Cytoskeleton
   Organization Is Rearranged by Distinct Signaling Pathways
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE PRE OSTEOBLAST; ADHESION; PP2A; MAPKp38; COFILIN; Akt; SIGNAL
   TRANSDUCTION; ACTIN
ID PROTEIN TYROSINE PHOSPHATASE; IN VIVO; PHOSPHORYLATION; DIFFERENTIATION;
   DYNAMICS; GROWTH; CELLS; BONE; MODULATION; ACTIVATION
AB Pre osteoblast adhesion attracts increasing interest in both medicine and dentistry. However, how this physiological event alters osteoblast phenotype is poorly understood. We therefore attempted to address this question by investigating key biochemical mechanism that governs pre osteoblast adhesion on polystyrene surface. Importantly, we found that cofilin activity was strongly modulated by PP2A (Ser/Thr phosphatase), while cell cycle was arrested. Accordingly, we observed that the profile of cofilin phosphorylation (at Ser03) was similar to phospho PP2A (at Tyr307). Also, it is plausible to suggest during pre osteoblast adhesion that PP2A phosphorylation at Y307 was executed by phospho Src (Y416). In addition, it was observed that MAPKp38, but not MAPK erk, played a key role on pre osteoblast adhesion by phosphorylating MAPKAPK 2 and ATF 2 (also called CRE BP1). Also, the up modulation of RhoA reported here suggests its involvement at the beginning of osteoblast attachment, while Akt remained active during all periods. Altogether, our results clearly showed that osteoblast adhesion is under an intricate network of signaling molecules, which are responsible to guide their interaction with substrate mainly via cytoskeleton rearrangement. J. Cell. Biochem. 108: 134 144, 2009. (C) 2009 Wiley Liss, Inc.
C1 [Zambuzzi, Willian Fernando] Univ Estadual Campinas, Div Cell Signaling & Biossays, Inst Biol, Dept Biochem, BR 13083970 Campinas, SP, Brazil.
   [Bruni Cardoso, Alexandre; de Carvalho, Hernandes Faustino] Univ Estadual Campinas, Inst Biol, Dept Cell Biol, BR 13083970 Campinas, SP, Brazil.
   [Granjeiro, Jose Mauro] Univ Fed Fluminense, Inst Biol, Dept Cell & Mol Biol, Niteroi, RJ, Brazil.
   [Peppelenbosch, Maikel Petrus] Univ Groningen, Univ Med Ctr Groningen, Dept Cell Biol, Kinome Profiling Unit, Groningen, Netherlands.
C3 Universidade Estadual de Campinas; Universidade de Sao Paulo;
   Universidade Estadual de Campinas; Universidade de Sao Paulo;
   Universidade Federal Fluminense; University of Groningen
RP Zambuzzi, WF (通讯作者)，Univ Estadual Campinas, Div Cell Signaling & Biossays, Inst Biol, Dept Biochem, BR 13083970 Campinas, SP, Brazil.
EM wzamba@unicamp.br
RI Granjeiro, Jose/D 8289 2012; Carvalho, Hernandes/C 2046 2012;
   Bruni Cardoso, Alexandre/K 6443 2013; Zambuzzi, Willian/ABD 8339 2020;
   Zambuzzi, Willian/F 9519 2012; Peppelenbosch, Maikel/U 5304 2019
OI Granjeiro, Jose/0000 0002 8027 8293; Peppelenbosch,
   Maikel/0000 0001 9112 6028; Zambuzzi, Willian/0000 0002 4149 5965; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Fapesp)
   [08/53003 9]
FX Grant sponsor: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (Fapesp); Grant number: 08/53003 9.
CR ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617
   BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460 2075.1995.tb00280.x
   Bertazzo S, 2009, CLIN ORAL IMPLAN RES, V20, P288, DOI 10.1111/j.1600 0501.2008.01642.x
   BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418
   Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827
   CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671
   Choi MG, 2005, P NATL ACAD SCI USA, V102, P4578, DOI 10.1073/pnas.0500693102
   Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962 8924(01)02008 6
   Ferreira CV, 2006, BIOCHIMIE, V88, P1859, DOI 10.1016/j.biochi.2006.08.007
   Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911
   Hamilton DW, 2007, BIOMATERIALS, V28, P1806, DOI 10.1016/j.biomaterials.2006.11.041
   HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003 2697(72)90094 2
   Kneser U, 2006, J CELL MOL MED, V10, P695, DOI 10.1111/j.1582 4934.2006.tb00429.x
   LAVOIE JN, 1993, J BIOL CHEM, V268, P24210
   Logeart Avramoglou D, 2005, J CELL MOL MED, V9, P72, DOI 10.1111/j.1582 4934.2005.tb00338.x
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Müller P, 2008, J CELL MOL MED, V12, P281, DOI 10.1111/j.1582 4934.2007.00103.x
   Myers KR, 2008, TRENDS CELL BIOL, V18, P184, DOI 10.1016/j.tcb.2008.02.002
   PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092 8674(92)90163 7
   Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380
   Zambuzzi WF, 2009, MOL CELL BIOCHEM, V322, P143, DOI 10.1007/s11010 008 9951 x
   Zambuzzi WF, 2008, CELL PHYSIOL BIOCHEM, V22, P497, DOI 10.1159/000185506
NR 23
TC 44
Z9 49
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP 1
PY 2009
VL 108
IS 1
BP 134
EP 144
DI 10.1002/jcb.22236
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 491JC
UT WOS:000269573700016
PM 19562668
DA 2025 08 17
ER

PT J
AU Zuo, RJ
   Liao, Q
   Ye, ZW
   Ding, CC
   Guo, ZZ
   He, JJ
   Liu, GY
AF Zuo, Renjie
   Liao, Quan
   Ye, Ziwei
   Ding, Chenchun
   Guo, Zhenzhen
   He, Junjie
   Liu, Guoyan
TI Antler blood enhances the ability of stem cell derived exosomes to
   promote bone and vascular regeneration
SO REGENERATIVE THERAPY
LA English
DT Article
DE Antler blood; Exosomes; Bone regeneration; Mesenchymal stem cell;
   Vascular regeneration; miR 21 5p
ID MESSENGER RNA; OSTEOPONTIN; DIFFERENTIATION; EXPRESSION
AB Background: Bone marrow mesenchymal stem cells (BMSC) derived exosomes (Exos) are important in promoting bone and vascular regeneration. Antler blood (ALB) is a valuable traditional Chinese medicine with potent regenerative effects. However, there is still a lack of clarity regarding the relationship between ALB and BMSC Exos. Methods: Primary BMSCs were isolated from SD Rats, and BMSC derived Exos (BMSC Exos) were harvested and identified accordingly. ALB was treated with the solution contained pepsin and hydrochloric acid to simulated gastrointestinal digestion in vitro. Furthermore, the liquid chromatography mass spectrometry (LC MS) was performed to determine the components of digested ALB. Moreover, ALB was utilized to intervene on BMSCs to produce specialized Exos (Exos ALB), of which the angiogenesis functions were detected both in vitro and in vivo. For the potential mechanism, both high throughput sequencing and proteomics were performed. Results: The main components of ALB consist of amino acids and peptides. Both ALB and BMSC Exos exhibited significant promotion of bone and blood vessel formation, respectively. Moreover, ALB and BMSC Exos could increase the expression of BMP 2, RUNX2, and ALP, but reduce the Osteopontin (OPN) expression. Notably, Exos ALB exhibited the strongest performance in these functions, whereas the presence of miR 21 5p inhibitor can partially counteract the effects of Exos ALB. The proteomics reveal differential genes associated with bone minimization, angiogenesis, osteoblast differentiation, vesiclemediated transport, and the Wnt signaling pathway. Conclusion: ALB enhances the ability of BMSCs derived Exos to promote bone and vascular regeneration, which may be related to the up regulation of miR 21 5p. (c) 2024 The Author(s). Published by Elsevier BV on behalf of The Japanese Society for Regenerative Medicine. This is an open access article under the CC BY NC ND license (http://creativecommons.org/ licenses/by nc nd/4.0/).
C1 [Zuo, Renjie; Liao, Quan; Ding, Chenchun; He, Junjie; Liu, Guoyan] Xiamen Univ, Sch Med, Xiamen 361102, Fujian, Peoples R China.
   [Ye, Ziwei; Guo, Zhenzhen; Liu, Guoyan] Xiamen Univ, Sch Pharmaceut Sci, Xiamen 361102, Fujian, Peoples R China.
   [Liu, Guoyan] Xiamen Univ, Zhongshan Hosp, Sch Med, Dept Gastrointestinal Surg, Xiamen 361000, Fujian, Peoples R China.
   [Liu, Guoyan] Xiamen Univ, Dept Gastrointestinal Surg, Zhongshan Hosp, Xiamen 361000, Fujian, Peoples R China.
C3 Xiamen University; Xiamen University; Xiamen University; Xiamen
   University
RP Liu, GY (通讯作者)，Xiamen Univ, Dept Gastrointestinal Surg, Zhongshan Hosp, Xiamen 361000, Fujian, Peoples R China.
EM zuorenjie@stu.xmu.edu.cn; liaoquan@stu.xmu.edu.cn;
   yeziwei@stu.xmu.edu.cn; jsdingdcc@163.com;
   32320221154442@stu.xmu.edu.cn; 24520221154755@stu.xmu.edu.cn;
   liuguoyan@xmu.edu.cn
RI 刘, 国彦/KPA 5019 2024; Zi, Ye/GWM 3932 2022
FU National Natural Science Foundation of China [81870388]; Special Project
   for Marine Economic Development of Xiamen City [17GYY001NF01]
FX The present study was supported by grants from The National Natural
   Science Foundation of China (No. 81870388) , the Special Project for
   Marine Economic Development of Xiamen City (No.17GYY001NF01) .
CR Ablikim M, 2012, PHYS REV D, V86, DOI 10.1103/PhysRevD.86.092009
   Bitencourt TA, 2022, MBIO, V13, DOI 10.1128/mbio.03272 21
   CHEN JK, 1993, MATRIX, V13, P113, DOI 10.1016/S0934 8832(11)80070 3
   Cheng X, 2022, MOL BIOL REP, V49, P2003, DOI 10.1007/s11033 021 07017 1
   Ding CB, 2022, LWT FOOD SCI TECHNOL, V168, DOI 10.1016/j.lwt.2022.113889
   Diomede F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093242
   Feleke M, 2021, J ORTHOP TRANSL, V27, P57, DOI 10.1016/j.jot.2020.10.012
   Gargalionis AN, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092182
   Greening DW, 2015, METHODS MOL BIOL, V1295, P179, DOI 10.1007/978 1 4939 2550 6_15
   Guo N, 2022, TOXICOLOGY, V466, DOI 10.1016/j.tox.2021.153079
   Hao MQ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.913408
   Helwa I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170628
   Ho TJ, 2024, PHARMACEUTICALS BASE, V17, DOI 10.3390/ph17040434
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huang YZ, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100617
   KAJI H, 1995, LIFE SCI, V56, P1903, DOI 10.1016/0024 3205(95)00165 3
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Komori T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105776
   Krylova SV, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24021337
   Li CY, 2023, CELL REGEN, V12, DOI 10.1186/s13619 023 00169 4
   Li S, 2023, J CONTROL RELEASE, V358, P13, DOI 10.1016/j.jconrel.2023.04.014
   Liao W, 2019, CLIN SCI, V133, P1955, DOI 10.1042/CS20181064
   Liu F, 2022, BIOENGINEERED, V13, P3503, DOI 10.1080/21655979.2022.2029108
   Liu L, 2019, BIOMATERIALS, V192, P523, DOI 10.1016/j.biomaterials.2018.11.007
   Liu YY, 2023, J ETHNOPHARMACOL, V304, DOI 10.1016/j.jep.2022.116052
   Ma SX, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2145 y
   Ma S, 2024, BIOMED PHARMACOTHER, V170, DOI 10.1016/j.biopha.2023.116076
   Makris K, 2023, CALCIFIED TISSUE INT, V112, P233, DOI 10.1007/s00223 022 01048 x
   Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200
   Palaniappan P, 2021, PAN AFR MED J, V40, DOI 10.11604/pamj.2021.40.93.28184
   Qian Z, 2020, J BONE MINER RES, V35, P1481, DOI 10.1002/jbmr.4017
   Rodriguez DE, 2014, ACTA BIOMATER, V10, P494, DOI 10.1016/j.actbio.2013.10.010
   Sikora M, 2023, STEM CELL RES THER, V14, DOI 10.1186/s13287 023 03271 1
   Sun H, 2024, N S ARCH PHARMACOL, V397, P15, DOI 10.1007/s00210 023 02642 y
   Tseng SH, 2012, MOLECULES, V17, P10574, DOI 10.3390/molecules170910574
   Wang TT, 2023, J FUNCT FOODS, V102, DOI 10.1016/j.jff.2023.105439
   Wu D, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00958 6
   Wu PY, 2022, PHARM BIOL, V60, P1303, DOI 10.1080/13880209.2022.2093385
   Wu XD, 2022, MATER TODAY BIO, V15, DOI 10.1016/j.mtbio.2022.100319
   Xia YQ, 2020, ADV MATER, V32, DOI 10.1002/adma.202002054
   Yang SS, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115073
   Zhang YT, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12570
NR 42
TC 1
Z9 1
U1 3
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD JUN
PY 2024
VL 26
BP 1168
EP 1180
DI 10.1016/j.reth.2024.11.003
EA NOV 2024
PG 13
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA N3P7D
UT WOS:001363504000001
PM 39640919
OA gold
DA 2025 08 17
ER

PT J
AU Zhou, TY
   Zhou, YL
   Ge, DD
   Xie, YH
   Wang, JY
   Tang, L
   Dong, QW
   Sun, P
AF Zhou, Tianyu
   Zhou, Yilin
   Ge, Dongdong
   Xie, Youhong
   Wang, Jiangyan
   Tang, Lin
   Dong, Qunwei
   Sun, Ping
TI Decoding the mechanism of Eleutheroside E in treating osteoporosis via
   network pharmacological analysis and molecular docking of
   osteoclast related genes and gut microbiota
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE Eleutheroside E (EE); postmenopausal osteoporosis (PMO); network
   pharmacology; molecular docking; gut microbiota
ID INTESTINAL MICROBIOTA; DOUBLE BLIND; BONE LOSS; INFLAMMATION; HEALTH;
   PATHOPHYSIOLOGY; SENTICOSUS; WOMEN; IL 6
AB ObjectiveEleutheroside E (EE) is an anti inflammatory natural compound derived from the edible medicinal herb Acanthopanax senticosus. This study aims to investigate the underlying mechanism of the anti osteoporosis action of EE through network pharmacology, molecular docking and gut microbiota.Materials and methodsNetwork pharmacology was used to explore the potential core targets and main pathways mediated by EE in osteoporosis (OP) treatment. Molecular docking was exploited to investigate the interactions between the active anti OP compounds in EE and the potential downstream targets. Following the multi approach bioinformatics analysis, ovariectomy (OVX) model was also established to investigate the in vivo anti OP effects of EE.ResultsThe top 10 core targets in PPI network were TP53, AKT1, JUN, CTNNB1, STAT3, HIF1A, EP300, CREB1, IL1B and ESR1. Molecular docking results that the binding energy of target proteins and the active compounds was approximately between  5.0 and  7.0 kcal/mol, which EE has the lowest docking binding energy with HIF1A. Enrichment analysis of GO and KEGG pathways of target proteins indicated that EE treatment could potentially alter numerous biological processes and cellular pathways. In vivo experiments demonstrated the protective effect of EE treatment against accelerated bone loss, where reduced serum levels of TRAP, CTX, TNF alpha, LPS, and IL 6 and increased bone volume and serum levels of P1NP were observed in EE treated mice. In addition, changes in gut microbiota were spotted by 16S rRNA gene sequencing, showing that EE treatment increased the relative abundance of Lactobacillus and decreased the relative abundance of Clostridiaceae.ConclusionIn summary, these findings suggested that the characteristics of multi target and multi pathway of EE against OP. In vivo, EE prevents the onset of OP by regulating gut microbiota and inflammatory response and is therefore a potential OP drug.
C1 [Zhou, Tianyu; Zhou, Yilin; Xie, Youhong; Wang, Jiangyan; Tang, Lin; Sun, Ping] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Peoples R China.
   [Ge, Dongdong; Dong, Qunwei] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Orthoped, Guangzhou, Peoples R China.
   [Dong, Qunwei] Yunfu Hosp Tradit Chinese Med, Dept Orthoped, Yunfu, Peoples R China.
C3 Guangdong Pharmaceutical University; Guangdong Pharmaceutical University
RP Sun, P (通讯作者)，Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Peoples R China.; Dong, QW (通讯作者)，Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Orthoped, Guangzhou, Peoples R China.; Dong, QW (通讯作者)，Yunfu Hosp Tradit Chinese Med, Dept Orthoped, Yunfu, Peoples R China.
EM dongqunwei@126.com; sing_ping928@gdpu.edu.cn
RI Ge, Dongdong/P 3745 2019; wang, jiangyan/MFI 8355 2025
FU National Science Foundation for Young Scholars, China [81603641];
   Science and Technology Planning Project of Yunfu, Guangdong Province,
   China [2020A090402]
FX The author(s) declare financial support was received for the research,
   authorship, and/or publication of this article. This work was supported
   by grants from the National Science Foundation for Young Scholars, China
   [No. 81603641], Science and Technology Planning Project of Yunfu,
   Guangdong Province, China [No. 2020A090402].
CR Al Daghri NM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005780
   Aron Wisnewsky J, 2021, GASTROENTEROLOGY, V160, P573, DOI 10.1053/j.gastro.2020.10.057
   Bateman A, 2021, NUCLEIC ACIDS RES, V49, pD480, DOI 10.1093/nar/gkaa1100
   Britton RA, 2014, J CELL PHYSIOL, V229, P1822, DOI 10.1002/jcp.24636
   Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Chen K, 2022, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.898624
   Chen XJ, 2022, AGING US, V14, P5727, DOI 10.18632/aging.204172
   D'Amelio P, 2018, CALCIFIED TISSUE INT, V102, P415, DOI 10.1007/s00223 017 0331 y
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Dong YZ, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 98925 6
   Föger Samwald U, 2020, EXCLI J, V19, P1017, DOI 10.17179/excli2020 2591
   Hasan LK, 2021, J RHEUMATOL, V48, P940, DOI 10.3899/jrheum.200951
   He CY, 2014, INFLAMMATION, V37, P1533, DOI 10.1007/s10753 014 9880 7
   He LL, 2023, NANOMATERIALS BASEL, V13, DOI 10.3390/nano13061083
   He WW, 2022, MOL NUTR FOOD RES, V66, DOI 10.1002/mnfr.202200174
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004
   Hirano T, 2021, INT IMMUNOL, V33, P127, DOI 10.1093/intimm/dxaa078
   Hong GJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.392
   Hsin KY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083922
   Jafarnejad S, 2017, J AM COLL NUTR, V36, P497, DOI 10.1080/07315724.2017.1318724
   Jaghoori MM, 2016, J COMPUT AID MOL DES, V30, P237, DOI 10.1007/s10822 016 9900 9
   Levescot A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI141008
   Li B, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110923
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Nilsson AG, 2018, J INTERN MED, V284, P307, DOI 10.1111/joim.12805
   NISHIBE S, 1990, CHEM PHARM BULL, V38, P1763, DOI 10.1248/cpb.38.1763
   Ohta H, 2015, OSTEOPOROSIS INT, V26, P849, DOI 10.1007/s00198 014 2940 x
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Robrahn L, 2020, CANCER LETT, V490, P186, DOI 10.1016/j.canlet.2020.07.002
   Schmolz MW, 2001, PHYTOTHER RES, V15, P268, DOI 10.1002/ptr.746
   Selby Peter, 2004, Curr Osteoporos Rep, V2, P101, DOI 10.1007/s11914 004 0018 y
   Sjogren K, 2012, BONE, V50, pS91, DOI [10.1016/j.bone.2012.02.272, 10.1002/jbmr.1588]
   Sun JF, 2022, INT J BIOL MACROMOL, V216, P537, DOI 10.1016/j.ijbiomac.2022.07.024
   Suzuki T, 2020, ANIM SCI J, V91, DOI 10.1111/asj.13357
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Takimoto T, 2018, BIOSCI MICROB FOOD H, V37, P87, DOI 10.12938/bmfh.18 006
   Tilg H, 2018, CANCER CELL, V33, P954, DOI 10.1016/j.ccell.2018.03.004
   Tong XS, 2020, DIFFERENTIATION, V114, P58, DOI 10.1016/j.diff.2020.06.002
   Velasco J, 2010, OSTEOPOROSIS INT, V21, P109, DOI 10.1007/s00198 009 0931 0
   Wang Y, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.682862
   Xiao WY, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/7275057
   Xiong ZC, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/5510290
   Yu CY, 2003, TOXICOL IN VITRO, V17, P229, DOI 10.1016/S0887 2333(03)00008 0
   Zhang YL, 2017, DRUG DES DEV THER, V11, P1881, DOI 10.2147/DDDT.S139804
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zhou ZC, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/1646905
   Zhu J, 2019, J CELL PHYSIOL, V234, P21182, DOI 10.1002/jcp.28721
   Zhu TX, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20192139
   Zhuang WT, 2023, FRONT PSYCHIATRY, V14, DOI 10.3389/fpsyt.2023.1143328
NR 52
TC 5
Z9 5
U1 2
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD NOV 7
PY 2023
VL 14
AR 1257298
DI 10.3389/fendo.2023.1257298
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA Y6ZE2
UT WOS:001106715900001
PM 38027135
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, J
   Motyl, KJ
   Irwin, R
   MacDougald, OA
   Britton, RA
   McCabe, LR
AF Zhang, Jing
   Motyl, Katherine J.
   Irwin, Regina
   MacDougald, Ormond A.
   Britton, Robert A.
   McCabe, Laura R.
TI Loss of Bone and Wnt10b Expression in Male Type 1 Diabetic Mice Is
   Blocked by the Probiotic Lactobacillus reuteri
SO ENDOCRINOLOGY
LA English
DT Article
ID ACTIVATED RECEPTOR GAMMA; ELEMENT BINDING PROTEIN; TNF ALPHA THERAPY;
   NF KAPPA B; GENE EXPRESSION; CROHNS DISEASE; YOUNG MICE; ADIPOGENESIS;
   CELLS; METABOLISM
AB Type 1 diabetes (T1D) induced osteoporosis is characterized by a predominant suppression of osteoblast number and activity, as well as increased bone marrow adiposity but no change in osteoclast activity. The fundamental mechanisms and alternative anabolic treatments (with few side effects) for T1D bone loss remain undetermined. Recent studies by our laboratory and others indicate that probiotics can benefit bone health. Here, we demonstrate that Lactobacillus reuteri, a probiotic with anti inflammatory and bone health properties, prevents T1D induced bone loss and marrow adiposity in mice. We further found that L. reuteri treatment prevented the suppression of Wnt10b in T1D bone. Consistent with a role for attenuated bone Wnt10b expression in T1D osteoporosis, we observed that bone specific Wnt10b transgenic mice are protected from T1D bone loss. To examine the mechanisms of this protection, we focused on TNF alpha, a cytokine upregulated in T1D that causes suppression of osteoblast Wnt10b expression in vitro. Addition of L. reuteri prevented TNF alpha mediated suppression of Wnt10b and osteoblast maturation markers. Taken together, our findings reveal a mechanism by which T1D causes bone loss and open new avenues for use of probiotics to benefit the bone.
C1 [Zhang, Jing; Motyl, Katherine J.; Irwin, Regina; McCabe, Laura R.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.
   [MacDougald, Ormond A.] Michigan State Univ, Dept Mol & Integrat Physiol, E Lansing, MI 48824 USA.
   [Britton, Robert A.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.
   [McCabe, Laura R.] Michigan State Univ, Dept Radiol, E Lansing, MI 48824 USA.
   [McCabe, Laura R.] Michigan State Univ, Biomed Imaging Res Ctr, E Lansing, MI 48824 USA.
C3 Michigan State University; Michigan State University; Michigan State
   University; Michigan State University; Michigan State University
RP McCabe, LR (通讯作者)，Michigan State Univ, Dept Physiol, 2201 Biomed Phys Sci Bldg, E Lansing, MI 48824 USA.
EM mccabel@msu.edu
RI MacDougald, Ormond/HTL 2168 2023; Zhang, Jing/E 4844 2013
OI McCabe, Laura/0000 0001 5407 162X; MacDougald,
   Ormond/0000 0001 6907 7960; Zhang, Jing/0000 0003 0391 7298
FU National Institutes of Health [R01 DK101050, R01 AT007695 01, R01
   DK62876]; National Cancer Institute [P30CA046592] Funding Source: NIH
   RePORTER; National Institute of Diabetes and Digestive and Kidney
   Diseases [P30DK020572] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health Grants R01
   DK101050 (to L.R.M.), R01 AT007695 01 (to L.R.M. and R.A.B.), and R01
   DK62876 (to O.A.M.).
CR Alblowi J, 2009, AM J PATHOL, V175, P1574, DOI 10.2353/ajpath.2009.090148
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   Botolin S, 2005, ENDOCRINOLOGY, V146, P3622, DOI 10.1210/en.2004 1677
   Botolin S, 2006, J CELL BIOCHEM, V99, P411, DOI 10.1002/jcb.20842
   Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006 1006
   Boyce Brendan F., 2005, Keio Journal of Medicine, V54, P127, DOI 10.2302/kjm.54.127
   Britton RA, 2014, J CELL PHYSIOL, V229, P1822, DOI 10.1002/jcp.24636
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Coe LM, 2013, J CELL PHYSIOL, V228, P689, DOI 10.1002/jcp.24177
   Coe LM, 2011, J CELL PHYSIOL, V226, P477, DOI 10.1002/jcp.22357
   Danne T, 1997, DIABETES CARE, V20, P281, DOI 10.2337/diacare.20.3.281
   Durnez A, 2013, J RHEUMATOL, V40, P1712, DOI 10.3899/jrheum.121417
   Fox KE, 2008, J BIOL CHEM, V283, P35096, DOI 10.1074/jbc.M806423200
   Frese SA., 2012, Adv Microbiol, V2, P399, DOI [10.4236/aim.2012.23051, DOI 10.4236/AIM.2012.23051]
   Gilbert LC, 2013, BONE, V56, P174, DOI 10.1016/j.bone.2013.06.002
   Graves DT, 2008, FRONT BIOSCI LANDMRK, V13, P1227, DOI 10.2741/2757
   Hinoi E, 2009, ANN NY ACAD SCI, V1173, pE20, DOI 10.1111/j.1749 6632.2009.05061.x
   Holl RW, 1998, EUR J PEDIATR, V157, P972, DOI 10.1007/s004310050980
   Iyer C, 2008, CELL MICROBIOL, V10, P1442, DOI 10.1111/j.1462 5822.2008.01137.x
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kast Woelbern HR, 2004, J BIOL CHEM, V279, P23908, DOI 10.1074/jbc.M403145200
   Kayal RA, 2007, J BONE MINER RES, V22, P560, DOI 10.1359/JBMR.070115
   Kayal RA, 2010, J BONE MINER RES, V25, P1604, DOI 10.1002/jbmr.59
   Kennell JA, 2005, J BIOL CHEM, V280, P24004, DOI 10.1074/jbc.M501080200
   Kimoto Nira H, 2007, BRIT J NUTR, V98, P1178, DOI 10.1017/S0007114507787469
   Ko KI, 2015, DIABETOLOGIA, V58, P633, DOI 10.1007/s00125 014 3470 y
   Kubota T, 2009, J BONE MINER METAB, V27, P265, DOI 10.1007/s00774 009 0064 8
   Li JP, 2003, P NATL ACAD SCI USA, V100, P9476, DOI 10.1073/pnas.1133426100
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Li ZP, 2003, HEPATOLOGY, V37, P343, DOI 10.1053/jhep.2003.50048
   Liu RK, 2006, AM J PATHOL, V168, P757, DOI 10.2353/ajpath.2006.050907
   Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200
   Martin LM, 2007, HISTOCHEM CELL BIOL, V128, P125, DOI 10.1007/s00418 007 0308 4
   McCabe L, CRIT REV EUKARYOT GE, V21, P187
   McCabe LR, 2007, J CELL BIOCHEM, V102, P1343, DOI 10.1002/jcb.21573
   Mccabe LR, 2013, J CELL PHYSIOL, V228, P1793, DOI 10.1002/jcp.24340
   Miheller P, 2006, DIGEST DIS, V24, P201, DOI 10.1159/000091299
   Moon Randall T, 2005, Sci STKE, V2005, pcm1
   Motyl K, 2009, BIOL PROCED ONLINE, V11, P296, DOI 10.1007/s12575 009 9000 5
   Motyl KJ, 2012, J CELL PHYSIOL, V227, P1326, DOI 10.1002/jcp.22844
   Motyl KJ, 2009, J CELL PHYSIOL, V218, P575, DOI 10.1002/jcp.21626
   Motyl KJ, AM J PHYSL REGUL INT, V300, pR1250
   Mutus R, 2006, POULTRY SCI, V85, P1621, DOI 10.1093/ps/85.9.1621
   Oh PL, 2010, ISME J, V4, P377, DOI 10.1038/ismej.2009.123
   Ontiveros C, 2004, J CELL PHYSIOL, V200, P169, DOI 10.1002/jcp.20054
   Ontiveros C, 2003, J CELL BIOCHEM, V88, P427, DOI 10.1002/jcb.10410
   Pacifici R, 2012, J BONE MINER RES, V27, P231, DOI 10.1002/jbmr.1500
   Pazianas M, 2006, ANN NY ACAD SCI, V1068, P543, DOI 10.1196/annals.1346.055
   Resta Lenert S, 2006, GASTROENTEROLOGY, V130, P731, DOI 10.1053/j.gastro.2005.12.015
   Riddle RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063323
   Robinson JW, 2015, J BONE MINER RES, V30, P695, DOI 10.1002/jbmr.2394
   Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989 5999.2002
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Sabin MA, 2009, AUST FAM PHYSICIAN, V38, P695
   Saidenberg Kermanac'h N, 2004, BONE, V35, P1200, DOI 10.1016/j.bone.2004.07.004
   Schaefer L, 2010, MICROBIOL SGM, V156, P1589, DOI 10.1099/mic.0.035642 0
   Schwartz Ann V, 2007, Curr Osteoporos Rep, V5, P105
   Seriolo B, 2006, ANN NY ACAD SCI, V1069, P420, DOI 10.1196/annals.1351.040
   Shornikova AV, 1997, PEDIATR INFECT DIS J, V16, P1103, DOI 10.1097/00006454 199712000 00002
   Shornikova AV, 1997, J PEDIATR GASTR NUTR, V24, P399, DOI 10.1097/00005176 199704000 00008
   Thomas CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031951
   Thomas CM, PLOS ONE, V7
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Vengellur A, 2004, TOXICOL SCI, V82, P638, DOI 10.1093/toxsci/kfh278
   Wright WS, 2007, DIABETES, V56, P295, DOI 10.2337/db06 1339
   Yoshizawa T, 2009, J CLIN INVEST, V119, P2807, DOI 10.1172/JCI39366
   Zhang J, 2012, DIABETES METAB, pS1
   Zhou FH, 2006, J BONE MINER RES, V21, P1075, DOI 10.1359/JBMR.060410
NR 72
TC 117
Z9 143
U1 0
U2 34
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD SEP
PY 2015
VL 156
IS 9
BP 3169
EP 3182
DI 10.1210/EN.2015 1308
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CS6ZV
UT WOS:000362234100014
PM 26135835
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Li, JKJ
   Lin, JCA
   Liu, HC
   Chang, WHS
AF Li, Jimmy Kuan Jung
   Lin, James Cheng An
   Liu, Hwa Chang
   Chang, Walter Hong Shong
TI Cytokine release from osteoblasts in response to different intensities
   of pulsed electromagnetic field stimulation
SO ELECTROMAGNETIC BIOLOGY AND MEDICINE
LA English
DT Article
DE ALP; intensity; osteoblasts; PEMF; PGE(2); TGF beta 1
ID GROWTH FACTOR BETA; RAT CALVARIAL CELLS; BONE RESORPTION; CORTICAL BONE;
   IN VITRO; OSTEOCLAST FORMATION; COLLAGEN SYNTHESIS; ADULT DOGS;
   PROSTAGLANDIN E2; CULTURES
AB We use an in vitro osteoblast cell culture model to investigate the effects of low frequency (7.5Hz) pulsed electromagnetic field ( PEMF) stimulation on osteoblast population, cytokines (prostaglandin E 2 (PGE(2)), transforming growth factor beta 1(TGF beta 1), and alkaline phosphatase ( ALP) activity to find the optimal intensity of PEMF for osteoblast growth. The results demonstrate that PEMF can stimulate osteoblast growth, release of TGF beta 1, and, in addition, an increase of ALP activity. The synthesis and release of PGE(2) in the culture medium are reduced with increasing numbers of cells. Higher intensity does not necessarily mean increased osteoblast growth, and the most efficient intensity is about 2mV/cm in this case. Although the lower intensities of the PEMF are yet to be determined, the results of this study can shed light on the mechanisms of PEMF stimulation on non union fracture therapy and osteoporosis prevention in the future.
C1 Chung Yuan Christian Univ, Dept Biomed Engn, Bone Tissue Engn Res Lab, Chungli 32023, Taiwan.
   Chung Yuan Christian Univ, R&D Ctr Membrane Technol, Chungli, Taiwan.
   Natl Taiwan Univ Hosp, Dept Orthopaed Surg, Taipei, Taiwan.
C3 Chung Yuan Christian University; Chung Yuan Christian University;
   National Taiwan University; National Taiwan University Hospital
RP Chang, WHS (通讯作者)，Chung Yuan Christian Univ, Dept Biomed Engn, Bone Tissue Engn Res Lab, Room 818,Bldg Engn, Chungli 32023, Taiwan.
EM whchang@cycu.edu.tw
RI Chang, Wen Hao/C 4906 2013
OI Chang, Wen Hao/0000 0003 4880 6006; /0000 0003 3636 5506
CR BASSETT CAL, 1981, J BONE JOINT SURG AM, V63, P511, DOI 10.2106/00004623 198163040 00001
   BASSETT CAL, 1977, CLIN ORTHOP RELAT R, V124, P128
   BERG H, 1993, BIOELECTROCH BIOENER, V31, P1
   Bodamyali T, 1998, BIOCHEM BIOPH RES CO, V250, P458, DOI 10.1006/bbrc.1998.9243
   BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261
   BONEWALD LF, 1989, CONNECT TISSUE RES, V23, P201, DOI 10.3109/03008208909002418
   Bostrom MPG, 1998, CLIN ORTHOP RELAT R, pS124, DOI 10.1097/00003086 199810001 00014
   CENTRELLA M, 1987, J BIOL CHEM, V262, P2869
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P431, DOI 10.1002/bem.10118
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P189, DOI 10.1002/bem.10078
   CHANG WH, 2000, J MED BIOL ENG, V20, P225
   CHYUN YS, 1984, PROSTAG OTH LIPID M, V27, P97, DOI 10.1016/0090 6980(84)90223 5
   CLEARY SF, 1993, AM IND HYG ASSOC J, V54, P178, DOI 10.1202/0002 8894(1993)054<0178:AROIVS>2.0.CO;2
   COLLINS DA, 1992, J BONE MINER RES, V7, P555
   COLLINS DA, 1991, J BONE MINER RES, V6, P157
   COSSARIZZA A, 1989, RADIAT RES, V118, P161, DOI 10.2307/3577431
   De Mattei M, 1999, BIOELECTROMAGNETICS, V20, P177, DOI 10.1002/(SICI)1521 186X(1999)20:3<177::AID BEM4>3.0.CO;2 #
   Heermeier K, 1998, BIOELECTROMAGNETICS, V19, P222, DOI 10.1002/(SICI)1521 186X(1998)19:4<222::AID BEM4>3.0.CO;2 3
   HIGH WB, 1987, BONE, V8, P363, DOI 10.1016/8756 3282(87)90068 8
   Ho Mei Ling, 1999, Kaohsiung Journal of Medical Sciences, V15, P248
   JEE WSS, 1990, BONE, V11, P253, DOI 10.1016/8756 3282(90)90078 D
   JEE WSS, 1985, CALCIFIED TISSUE INT, V37, P148, DOI 10.1007/BF02554834
   Kassem M, 2000, EUR J CLIN INVEST, V30, P429
   Kassem M, 1997, APMIS Suppl, V71, P1
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   KHALIL AM, 1991, MUTAT RES, V247, P141, DOI 10.1016/0027 5107(91)90041 L
   KLEIN DC, 1970, ENDOCRINOLOGY, V86, P1436, DOI 10.1210/endo 86 6 1436
   Li J, 2003, ELECTROMAGN BIOL MED, V22, P87, DOI 10.1081/JBC 120024619
   LI XJ, 1990, BONE, V11, P353, DOI 10.1016/8756 3282(90)90091 C
   Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756 3282(96)00138 X
   NAGAI M, 1993, BONE, V14, P655, DOI 10.1016/8756 3282(93)90088 R
   NAGATA T, 1994, CALCIFIED TISSUE INT, V55, P451, DOI 10.1007/BF00298559
   Peter SJ, 2000, J BIOMED MATER RES, V50, P452, DOI 10.1002/(SICI)1097 4636(20000605)50:3<452::AID JBM20>3.0.CO;2 0
   ROSEN DM, 1988, J CELL PHYSIOL, V134, P337, DOI 10.1002/jcp.1041340304
   SAFFAR JL, 1988, BONE, V9, P141, DOI 10.1016/8756 3282(88)90003 8
   Satake T, 1990, Kanagawa Shigaku, V24, P692
   SHIH MS, 1986, CALCIFIED TISSUE INT, V39, P191, DOI 10.1007/BF02555117
   Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097 4644(19991001)75:1<22::AID JCB3>3.3.CO;2 Y
   Sollazzo V, 1997, BIOELECTROMAGNETICS, V18, P541, DOI 10.1002/(SICI)1521 186X(1997)18:8<541::AID BEM2>3.0.CO;2 2
   SPORN MB, 1988, JAMA J AM MED ASSOC, V262, P738
   TASHJIAN AH, 1987, ENDOCRINOLOGY, V120, P2029, DOI 10.1210/endo 120 5 2029
   Tsai C L, 1991, Chin J Physiol, V34, P201
   Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197
   Vander Molen MA, 2000, BONE, V27, P227, DOI 10.1016/S8756 3282(00)00315 X
   VANDERPLAS A, 1992, J BONE MINER RES, V7, P389
   WELCH RD, 1993, J ORTHOPAED RES, V11, P110, DOI 10.1002/jor.1100110113
   WRANA JL, 1988, J CELL BIOL, V106, P915, DOI 10.1083/jcb.106.3.915
   YANG RS, 1994, J JPN BIOELECTR RES, V8, P117
NR 48
TC 33
Z9 45
U1 0
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1536 8378
EI 1536 8386
J9 ELECTROMAGN BIOL MED
JI Electromagn. Biol. Med.
PY 2007
VL 26
IS 3
BP 153
EP 165
DI 10.1080/15368370701572837
PG 13
WC Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Biophysics
GA 215VQ
UT WOS:000249837500001
PM 17886003
DA 2025 08 17
ER

PT J
AU Dou, C
   Ding, N
   Luo, F
   Hou, TY
   Cao, Z
   Bai, Y
   Liu, C
   Xu, JZ
   Dong, SW
AF Dou, Ce
   Ding, Ning
   Luo, Fei
   Hou, Tianyong
   Cao, Zhen
   Bai, Yun
   Liu, Chuan
   Xu, Jianzhong
   Dong, Shiwu
TI Graphene Based MicroRNA Transfection Blocks Preosteoclast Fusion to
   Increase Bone Formation and Vascularization
SO ADVANCED SCIENCE
LA English
DT Article
DE dendritic cell specific transmembrane protein (DC STAMP); graphene
   oxide; miRNA; osteoclasts; vascularization
ID OSTEOCLAST DIFFERENTIATION; GENE DELIVERY; IN VITRO; DC STAMP;
   MECHANISM; LIGAND; OXIDE
AB The objective of this study is to design a graphene based miRNA transfection drug delivery system for antiresorptive therapy. An efficient nonviral gene delivery system is developed using polyethylenimine (PEI) functionalized graphene oxide (GO) complex loaded with miR 7b overexpression plasmid. GO PEI complex exhibits excellent transfection efficiency within the acceptable range of cytotoxicity. The overexpression of miR 7b after GO PEI miR 7b transfection significantly abrogates osteoclast (OC) fusion and bone resorption activity by hampering the expression of an essential fusogenic molecule dendritic cell specific transmembrane protein. However, osteoclastogenesis occurs without cell cell fusion and preosteoclast (POC) is preserved. Through preservation of POC, GO PEI miR 7b transfection promotes mesenchymal stem cell osteogenesis and endothelial progenitor cells angiogenesis in the coculture system. Platelet derived growth factor BB secreted by POC is increased by GO PEI miR 7b both in vitro and in vivo. In treating osteoporotic ovariectomized mice, GO PEI miR 7b significantly enhances bone mineral density, bone volume as well as bone vascularization through increasing CD31(hi)Emcn(hi) cell number. This study provides a cell cell fusion targeted miRNA transfection drug delivery strategy in treating bone disorders with excessive osteoclastic bone resorption.
C1 [Dou, Ce; Ding, Ning; Luo, Fei; Hou, Tianyong; Xu, Jianzhong] Third Mil Med Univ, Southwest Hosp, Dept Orthoped, Chongqing 400038, Peoples R China.
   [Cao, Zhen; Bai, Yun; Liu, Chuan; Dong, Shiwu] Third Mil Med Univ, Dept Biomed Mat Sci, Chongqing 400038, Peoples R China.
C3 Army Medical University; Army Medical University
RP Xu, JZ (通讯作者)，Third Mil Med Univ, Southwest Hosp, Dept Orthoped, Chongqing 400038, Peoples R China.; Dong, SW (通讯作者)，Third Mil Med Univ, Dept Biomed Mat Sci, Chongqing 400038, Peoples R China.
EM xujianzhong1962@163.com; dongshiwu@tmmu.edu.cn
RI Dou, Ce/B 8841 2012
OI Dong, Shiwu/0000 0002 5032 4893
FU National Key Technology Research and Development Program of China
   [2017YFC1103300]; Nature Science Foundation of China [81572164]; China
   Postdoctoral Science Foundation [2017M613315]; TMMU [2017MPRC 04];
   Innovation Project of Southwest Hospital [SWH2016LHYS 10]
FX C.D. and N.D. contributed equally to this work. This work was funded by
   the National Key Technology Research and Development Program of China
   (2017YFC1103300), grant from the Nature Science Foundation of China
   (81572164), first class General Financial Grant from the China
   Postdoctoral Science Foundation (2017M613315), and TMMU funding for
   young investigators (2017MPRC 04) and Innovation Project of Southwest
   Hospital (SWH2016LHYS 10).
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Ding ZJ, 2014, ACS APPL MATER INTER, V6, P19797, DOI 10.1021/am505084s
   Dou C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.69
   Dou C., 2014, J CELL PHYSL, V231, P558
   Dou C, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040231
   Dou C, 2014, BBA GENE REGUL MECH, V1839, P1084, DOI 10.1016/j.bbagrm.2014.08.002
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Feng LZ, 2011, NANOSCALE, V3, P1252, DOI 10.1039/c0nr00680g
   Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504
   Hong X, 2004, CHEM MATER, V16, P4022, DOI 10.1021/cm049422o
   Hu WW, 2007, GENE THER, V14, P891, DOI 10.1038/sj.gt.3302940
   Kim H, 2014, SMALL, V10, P117, DOI 10.1002/smll.201202636
   Kusumbe AP, 2014, NAT MED, V20, P1238, DOI 10.1038/nm.3747
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Le Goff B, 2013, JOINT BONE SPINE, V80, P586, DOI 10.1016/j.jbspin.2013.04.002
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Misof BM, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.1
   Paul A, 2013, SCI REP UK, V3, DOI 10.1038/srep02366
   Paul A, 2012, MOL PHARMACEUT, V9, P2479, DOI 10.1021/mp3000502
   PIERCE AM, 1991, ELECTRON MICROSC REV, V4, P1, DOI 10.1016/0892 0354(91)90015 5
   Putnam D, 2001, P NATL ACAD SCI USA, V98, P1200, DOI 10.1073/pnas.031577698
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Roche B, 2014, J BONE MINER RES, V29, P1608, DOI 10.1002/jbmr.2191
   Russell G, 2001, Novartis Found Symp, V232, P251
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Spangenberg A, 2016, CALCIFIED TISSUE INT, V99, P608, DOI 10.1007/s00223 016 0186 7
   Tang LAL, 2010, J AM CHEM SOC, V132, P10976, DOI 10.1021/ja104017y
   Teti Anna, 2013, Bonekey Rep, V2, P449, DOI 10.1038/bonekey.2013.183
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yin D, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957 4484/24/10/105102
   Yin LC, 2013, ADV MATER, V25, P3063, DOI 10.1002/adma.201205088
NR 36
TC 86
Z9 96
U1 2
U2 68
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD FEB
PY 2018
VL 5
IS 2
AR 1700578
DI 10.1002/advs.201700578
PG 10
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA FX6MR
UT WOS:000426200000023
PM 29619305
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, SZ
   Wu, D
   Sun, X
   Fan, Y
   Zha, RR
   Jalali, A
   Feng, Y
   Li, KX
   Sano, T
   Vike, N
   Li, FJ
   Rispoli, J
   Sudo, A
   Liu, J
   Robling, A
   Nakshatri, H
   Li, BY
   Yokota, H
AF Liu, Shengzhi
   Wu, Di
   Sun, Xun
   Fan, Yao
   Zha, Rongrong
   Jalali, Aydin
   Feng, Yan
   Li, Kexin
   Sano, Tomohiko
   Vike, Nicole
   Li, Fangjia
   Rispoli, Joseph
   Sudo, Akihiro
   Liu, Jing
   Robling, Alexander
   Nakshatri, Harikrishna
   Li, Bai Yan
   Yokota, Hiroki
TI Overexpression of Lrp5 enhanced the anti breast cancer effects of
   osteocytes in bone
SO BONE RESEARCH
LA English
DT Article
ID METASTASIS; PROGRESSION; SCLEROSTIN; CELLS
AB Osteocytes are the most abundant cells in bone, which is a frequent site of breast cancer metastasis. Here, we focused on Wnt signaling and evaluated tumor osteocyte interactions. In animal experiments, mammary tumor cells were inoculated into the mammary fat pad and tibia. The role of Lrp5 mediated Wnt signaling was examined by overexpressing and silencing Lrp5 in osteocytes and establishing a conditional knockout mouse model. The results revealed that administration of osteocytes or their conditioned medium (CM) inhibited tumor progression and osteolysis. Osteocytes overexpressing Lrp5 or beta catenin displayed strikingly elevated tumor suppressive activity, accompanied by downregulation of tumor promoting chemokines and upregulation of apoptosis inducing and tumor suppressing proteins such as p53. The antitumor effect was also observed with osteocyte derived CM that was pretreated with a Wnt activating compound. Notably, silencing Lrp5 in tumors inhibited tumor progression, while silencing Lrp5 in osteocytes in conditional knockout mice promoted tumor progression. Osteocytes exhibited elevated Lrp5 expression in response to tumor cells, implying that osteocytes protect bone through canonical Wnt signaling. Thus, our results suggest that the Lrp5/beta catenin axis activates tumor promoting signaling in tumor cells but tumor suppressive signaling in osteocytes. We envision that osteocytes with Wnt activation potentially offer a novel cell based therapy for breast cancer and osteolytic bone metastasis.
C1 [Liu, Shengzhi; Wu, Di; Sun, Xun; Fan, Yao; Zha, Rongrong; Jalali, Aydin; Feng, Yan; Li, Kexin; Sano, Tomohiko; Yokota, Hiroki] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Wu, Di; Sun, Xun; Fan, Yao; Zha, Rongrong; Feng, Yan; Li, Kexin; Li, Bai Yan; Yokota, Hiroki] Harbin Med Univ, Sch Pharm, Dept Pharmacol, Harbin, Peoples R China.
   [Wu, Di] Dalian Med Univ, Dept Pharm, Affiliated Hosp 2, Dalian, Peoples R China.
   [Sano, Tomohiko; Sudo, Akihiro] Mie Univ, Dept Orthoped Surg, Tsu, Mie, Japan.
   [Vike, Nicole; Rispoli, Joseph] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.
   [Li, Fangjia; Liu, Jing] Indiana Univ Purdue Univ, Dept Phys, Indianapolis, IN 46205 USA.
   [Robling, Alexander; Yokota, Hiroki] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Robling, Alexander; Yokota, Hiroki] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
   [Nakshatri, Harikrishna] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.
   [Nakshatri, Harikrishna; Yokota, Hiroki] Indiana Univ Sch Med, Simon Canc Ctr, Indianapolis, IN 46202 USA.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; Harbin Medical University; Dalian Medical University; Mie
   University; Purdue University System; Purdue University; Purdue
   University System; Purdue University; Purdue University in Indianapolis;
   Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington
RP Liu, SZ; Yokota, H (通讯作者)，Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.; Yokota, H (通讯作者)，Harbin Med Univ, Sch Pharm, Dept Pharmacol, Harbin, Peoples R China.; Yokota, H (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.; Yokota, H (通讯作者)，Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.; Yokota, H (通讯作者)，Indiana Univ Sch Med, Simon Canc Ctr, Indianapolis, IN 46202 USA.
EM 757599061@qq.com; hyokota@iupui.edu
RI Li, Ke Xin/AAG 5874 2021; Yifan, Liu/AHD 1515 2022; Rispoli,
   Joseph/AAB 1655 2019
OI Jalali, Seyedaydin/0009 0008 8529 3629; Li, Fangjia/0000 0002 7446 9106;
   Liu, Jing/0000 0002 4912 4560
FU breast cancer advocacy group; Indiana University Precision Health
   Initiative; NIH [R01AR52144, R03CA238555, R01AR053237]; 100 Voices of
   Hope; National Institute of Arthritis and Musculoskeletal and Skin
   Diseases [R01AR053237] Funding Source: NIH RePORTER
FX The authors appreciate Andy Chen, April Hoggatt, Rahul Prakash, and
   Xinyu Zhao for technical support and Kazunori Hamamura for critical
   reading of the manuscript. This study was supported in part by funds
   from a breast cancer advocacy group, 100 Voices of Hope (H.Y.), and the
   Indiana University Precision Health Initiative (H.N.), as well as NIH
   R01AR52144 (H.Y.), R03CA238555 (H.Y.), and R01AR053237 (A.R.).
CR Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Bonar SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035979
   Buijs JT, 2011, CANCER MICROENVIRON, V4, P261, DOI 10.1007/s12307 011 0075 6
   Buzhor E, 2014, REGEN MED, V9, P649, DOI [10.2217/RME.14.35, 10.2217/rme.14.35]
   Chen A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 23833 1
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   De Craene B, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1521
   Delgado Calle J, 2017, LEUKEMIA, V31, P2686, DOI 10.1038/leu.2017.152
   Eda H, 2016, J BONE MINER RES, V31, P1225, DOI 10.1002/jbmr.2789
   Ewens A, 2005, ANTICANCER RES, V25, P3905
   Ferrari N, 2013, J CELL PHYSIOL, V228, P1137, DOI 10.1002/jcp.24285
   Gao HQ, 2017, MOL MED REP, V16, P317, DOI 10.3892/mmr.2017.6608
   Goldring SR, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2015 000049
   Hamamura K, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 312
   Hsu YL, 2013, ONCOGENE, V32, P4436, DOI 10.1038/onc.2012.444
   Jing D, 2017, INT J ONCOL, V51, P1261, DOI 10.3892/ijo.2017.4119
   Joseph A, 2020, J CELL PHYSIOL, V235, P5555, DOI 10.1002/jcp.29486
   Klein Nulend J, 2013, BONE, V54, P182, DOI 10.1016/j.bone.2012.10.013
   Li FJ, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42132 x
   Liu SZ, 2018, CANCER RES, V78, P3865, DOI 10.1158/0008 5472.CAN 18 0056
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Martin M, 2019, BIOMECH MODEL MECHAN, V18, P1475, DOI 10.1007/s10237 019 01158 w
   Parker TM, 2020, SEMIN CANCER BIOL, V63, P1, DOI 10.1016/j.semcancer.2019.09.003
   Pham PV, 2016, ONCOTARGETS THER, V9, P4441, DOI 10.2147/OTT.S105239
   Prasad M, 2019, MOL CANCER RES, V17, P1556, DOI 10.1158/1541 7786.MCR 19 0165
   Ribot EJ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06258 0
   Sapir Koren R, 2014, OSTEOPOROSIS INT, V25, P2685, DOI 10.1007/s00198 014 2808 0
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Sekita A, 2017, BONE, V97, P83, DOI 10.1016/j.bone.2017.01.004
   Tai S, 2011, PROSTATE, V71, P1668, DOI 10.1002/pros.21383
   Uehara I, 2018, CANCERS, V10, DOI 10.3390/cancers10070219
   Ulsperger E, 2003, ONCOL REP, V10, P1529
   Valencia K, 2012, CLIN CANCER RES, V18, P969, DOI 10.1158/1078 0432.CCR 11 1686
   Wang LF, 2019, HEPATOL INT, V13, P521, DOI 10.1007/s12072 019 09967 y
   Wang N, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0876 3
   Wang WC, 2019, ONCOGENE, V38, P4540, DOI 10.1038/s41388 019 0736 3
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Wu Q, 2017, ONCOTARGET, V8, P27990, DOI 10.18632/oncotarget.15856
   Xiong ZC, 2018, CANCER MANAG RES, V10, P287, DOI 10.2147/CMAR.S155524
   Xu WX, 2015, CELL SIGNAL, V27, P2332, DOI 10.1016/j.cellsig.2015.08.014
   Yousef EM, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 609
   Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008 5472.CAN 05 4579
   Zhao LM, 2013, BONE, V54, P35, DOI 10.1016/j.bone.2013.01.033
   Zhao XH, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935 020 1136 z
NR 45
TC 31
Z9 33
U1 0
U2 11
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD JUL 6
PY 2021
VL 9
IS 1
AR 32
DI 10.1038/s41413 021 00152 2
PG 13
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA TE8VB
UT WOS:000670284000001
PM 34230453
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Long, HL
   Chen, XT
   Nan, XM
   Zheng, HY
AF Long, Hailun
   Chen, Xiaotao
   Nan, Xiaomei
   Zheng, Hongyan
TI Curcumin in the Treatment of Periodontitis based on Gene Expression
   Omnibus Data Mining and Network Pharmacology
SO INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Curcumin; periodontitis; network pharmacology; diabetes; signaling
   pathway; lipopolysaccharide
AB We aimed to develop novel methods for treating periodontitis by identifying the main targets and pathways of curcumin in treating periodontitis. Potential targets of curcumin and differential genes were obtained from multiple drug databases and gene expression omnibus database chip data, respectively. Common targets of curcumin and periodontitis were screened, a protein protein interaction network map of these common targets was constructed, and the critical targets were identified. These targets were subjected to gene ontology and Kyoto encyclopedia of genes and genomes enrichment analysis to construct a "curcumin target  pathway" network. Finally, molecular docking was performed on curcumin and its key targets. We retrieved 115 curcumin related targets from multiple drug databases. We further identified 376 differential genes and 413 curcumin targets. Among the 2587 targets for periodontitis diseases, 72 common curcumin periodontitis targets were identified. Notably, AKT serine/threonine kinase 1, tumor protein P53, signal transducer and activator of transcription 3, matrix metallopeptidase 9, caspase 3, epidermal growth factor receptor, epidermal growth factor, cyclin D1, mitogen activated protein kinase 14, and peroxisome proliferator activated receptor gamma were the key targets of curcumin in periodontitis treatment. Approximately 805 processes, including cellular response to chemical stress, and 39 signaling pathways, including forkhead box O1 signaling pathway, were enriched. All key targets, except tumor protein P53, had a high affinity for curcumin. Curcumin interacts with forkhead box O1, advanced glycosylation end product specific receptor, mitogen activated protein kinase, phosphoinositide 3 kinase protein kinase B, and tumor necrosis factor signaling pathways in diabetic complications via key targets, including AKT serine/threonine kinase 1, mitogen  activated protein kinase 14, epidermal growth factor and epidermal growth factor receptor. Therefore, curcumin may reduce periodontal tissue inflammation and alveolar bone loss by inhibiting inflammatory cytokine expression and promoting osteoclast apoptosis, thereby facilitating periodontitis treatment.
C1 [Chen, Xiaotao; Nan, Xiaomei; Zheng, Hongyan] Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept Stomatol, Urumqi 830001, Xinjiang, Peoples R China.
   [Long, Hailun] Shihezi Univ, Sch Med Univ, Shihezi 832003, Xinjiang, Peoples R China.
C3 Shihezi University
RP Chen, XT (通讯作者)，Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept Stomatol, Urumqi 830001, Xinjiang, Peoples R China.
EM zhushuaijun@fjmu.edu.cn
FU Xinjiang Uygur Autonomous Region Regional Collaborative Innovation
   Special Fund [2021E02071]; National Nature Science Foundation Project
   [82260195]
FX This study was supported by Xinjiang Uygur Autonomous Region Regional
   Collaborative Innovation Special Fund (No. 2021E02071) and National
   Nature Science Foundation Project (No. 82260195).
CR Beklen A, 2007, J DENT RES, V86, P347, DOI 10.1177/154405910708600409
   Burley SK, 2021, NUCLEIC ACIDS RES, V49, pD437, DOI 10.1093/nar/gkaa1038
   Chatterjee Anirban, 2017, J Indian Soc Periodontol, V21, P132, DOI 10.4103/jisp.jisp_136_17
   Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388 018 0171 x
   Devji Tahira, 2017, J Am Dent Assoc, V148, pe124, DOI 10.1016/j.adaj.2017.06.020
   Feng YL, 2018, INT J MOL MED, V41, P202, DOI 10.3892/ijmm.2017.3208
   Guimaraes MR, 2012, INNATE IMMUN LONDON, V18, P155, DOI 10.1177/1753425910392935
   Guru Sanjeela Rakshith, 2017, Indian J Dent Res, V28, P560, DOI 10.4103/ijdr.IJDR_461_16
   Hatamipour M, 2019, J CELL PHYSIOL, V234, P19320, DOI 10.1002/jcp.28626
   Jaiswal S, 2017, NEW ENGL J MED, V377, P111, DOI 10.1056/NEJMoa1701719
   Ji Z, 2019, P NATL ACAD SCI USA, V116, P9453, DOI 10.1073/pnas.1821068116
   Kuo WT, 2019, GASTROENTEROLOGY, V157, P1323, DOI 10.1053/j.gastro.2019.07.058
   Kwon T, 2021, INT DENT J, V71, P462, DOI 10.1111/idj.12630
   Li YL, 2021, J PERIODONTAL RES, V56, P837, DOI 10.1111/jre.12914
   Madkour MM, 2021, EUR J MED CHEM, V213, DOI 10.1016/j.ejmech.2021.113216
   Nonaka K, 2018, J PERIODONTAL RES, V53, P334, DOI 10.1111/jre.12518
   Renaux A, 2018, NUCLEIC ACIDS RES, V46, P2699, DOI 10.1093/nar/gky092
   Reynolds Ian, 2018, Evid Based Dent, V19, P14, DOI 10.1038/sj.ebd.6401287
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Singh A, 2018, J ALTERN COMPLEM MED, V24, P76, DOI 10.1089/acm.2017.0059
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Syriopoulou A, 2021, METHODS MOL BIOL, V2266, P89, DOI 10.1007/978 1 0716 1209 5_5
   Tonetti MS, 2017, J CLIN PERIODONTOL, V44, P456, DOI 10.1111/jcpe.12732
   Wang LP, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00593
   Wu XW, 2023, J CLIN PERIODONTOL, V50, P220, DOI 10.1111/jcpe.13730
   Xiao CJ, 2018, HEAD FACE MED, V14, DOI 10.1186/s13005 018 0169 1
   Xiong YX, 2020, IRAN J BASIC MED SCI, V23, P954, DOI 10.22038/IJBMS.2020.44070.10351
NR 27
TC 0
Z9 0
U1 0
U2 2
PU INDIAN PHARMACEUTICAL ASSOC
PI MUMBAI
PA KALINA, SANTA CRUZ EAST, MUMBAI, 00000, INDIA
SN 0250 474X
EI 1998 3743
J9 INDIAN J PHARM SCI
JI Indian J. Pharm. Sci.
PY 2023
VL 85
SI 5
BP 253
EP 261
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA KE0S4
UT WOS:001178170400036
DA 2025 08 17
ER

PT J
AU Zhang, J
   Zhao, YN
   Hou, XL
   Chen, B
   Xiao, ZF
   Han, J
   Shi, CY
   Liu, JZ
   Miao, Q
   Dai, JW
AF Zhang, Jing
   Zhao, Yannan
   Hou, Xianglin
   Chen, Bing
   Xiao, Zhifeng
   Han, Jin
   Shi, Chunying
   Liu, Jianzhou
   Miao, Qi
   Dai, Jianwu
TI The inhibition effects of insulin on BMP2 induced muscle heterotopic
   ossification
SO BIOMATERIALS
LA English
DT Article
DE BMP2; Heterotopic ossification; Insulin; AICT; Osterix
ID BONE MORPHOGENETIC PROTEINS; SKELETAL MUSCLE; OSTEOBLAST
   DIFFERENTIATION; SIGNALING PATHWAYS; COLLAGEN SYNTHESIS;
   DIABETES MELLITUS; CELL LINE; PROGRESSIVA; BMP; RECEPTOR
AB Bone morphogenetic proteins (BMPs) play an important role in regulating osteoblastic differentiation and bone formation. But the diffuse of BMPs into muscle tissues around bone injury sites often leads to heterotopic ossification, which has been regarded as one of major side effects of BMP implementation in bone defect patients. It raises great demands for exploring effective methods that preventing BMP induced heterotopic ossification while not interrupting the osteoinductive activity of BMPs for in situ bone defect repair. Here we found insulin, a positive regulator for bone regeneration, inhibited BMP2 induced muscle heterotopic ossification by suppressing the expression of bone transcription factor Osterix. By analyzing downstream molecules of insulin pathway, we found AKT/mTOR/GSK3 signaling was responsible for the inhibition of insulin on BMP2 induced ossification, and GSK3 inhibitor SB216763 attenuated BMP2 induced muscle heterotopic ossification. The data might shed light on developing effective clinical therapy for inhibiting muscle heterotopic ossification when BMPs were used bone defect repair. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Zhang, Jing; Zhao, Yannan; Hou, Xianglin; Chen, Bing; Xiao, Zhifeng; Dai, Jianwu] Third Mil Med Univ, Coll Prevent Med, Chongqing Engn Res Ctr Nanomed, Inst Combined Injury,State Key Lab Trauma Burns &, Chongqing 400038, Peoples R China.
   [Zhao, Yannan; Hou, Xianglin; Chen, Bing; Xiao, Zhifeng; Han, Jin; Shi, Chunying; Dai, Jianwu] Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing 100101, Peoples R China.
   [Liu, Jianzhou; Miao, Qi] Beijing Union Med Coll Hosp, Peking Union Med Coll, Dept Cardiac Surg, Beijing, Peoples R China.
C3 Army Medical University; Chinese Academy of Sciences; Institute of
   Genetics & Developmental Biology, CAS; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Peking Union Medical College
   Hospital; Peking Union Medical College
RP Dai, JW (通讯作者)，Third Mil Med Univ, Coll Prevent Med, Chongqing Engn Res Ctr Nanomed, Inst Combined Injury,State Key Lab Trauma Burns &, 30 Gaotanyan Rd, Chongqing 400038, Peoples R China.
EM jwdai@genetics.ac.cn
RI Chen, Bing/HPH 1735 2023; ZHAO, YANNAN/HSD 0288 2023; Zeng,
   Xiao/ABG 5938 2021; Liu, Jianzhou/ADN 7696 2022
FU Ministry of Science and Technology of China [2011CB965001]; "Strategic
   Priority Research Program" of the Chinese Academy of Sciences
   [XDA01030401]; National Natural Science Foundation of China [31100698,
   81100144]; Chongqing Science & techonology commision
   [cstc2013kjrc qnrc10008, cstc2013kjrc ljrccj10001]
FX We thank Professor Hongbin Zhang from Peking Union Medical College for
   kindly providing pLXIN hyg myrAKT1 plasmid. This work was supported by
   grants from the Ministry of Science and Technology of China
   (2011CB965001) and the "Strategic Priority Research Program" of the
   Chinese Academy of Sciences (Grant No. XDA01030401) and the National
   Natural Science Foundation of China (31100698, 81100144) and Chongqing
   Science & techonology commision (cstc2013kjrc qnrc10008 and
   cstc2013kjrc ljrccj10001).
CR Aubin J, 2004, GENE DEV, V18, P1482, DOI 10.1101/gad.1202604
   Bolster DR, 2004, P NUTR SOC, V63, P351, DOI 10.1079/PNS2004355
   Chrastil J, 2013, SPINE, V38, pE1020, DOI 10.1097/BRS.0b013e3182982f8e
   Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097 4652(200101)186:1<82::AID JCP1001>3.0.CO;2 R
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   DELPRATO S, 1987, J CLIN INVEST, V79, P547, DOI 10.1172/JCI112846
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002
   Gandhi A, 2005, BONE, V37, P482, DOI 10.1016/j.bone.2005.04.039
   Gannon FH, 1997, HUM PATHOL, V28, P339, DOI 10.1016/S0046 8177(97)90133 7
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445 2197.2007.04175.x
   Groeneveld EHJ, 2000, EUR J ENDOCRINOL, V142, P9, DOI 10.1530/eje.0.1420009
   ITUARTE EA, 1989, CALCIFIED TISSUE INT, V45, P27, DOI 10.1007/BF02556657
   Jackson WM, 2009, J ORTHOP RES, V27, P1645, DOI 10.1002/jor.20924
   Janghorbani M, 2006, DIABETES CARE, V29, P1573, DOI 10.2337/dc06 0440
   Joseph V, 2007, SPINE, V32, P2885, DOI 10.1097/BRS.0b013e31815b7596
   Kanakaris Nikolaos K, 2008, J Surg Orthop Adv, V17, P133
   Kapadia RA, 2005, DEV BIOL, V285, P496, DOI 10.1016/j.ydbio.2005.07.029
   Kemink SAG, 2000, J ENDOCRINOL INVEST, V23, P295, DOI 10.1007/BF03343726
   Kimball SR, 2002, J APPL PHYSIOL, V93, P1168, DOI 10.1152/japplphysiol.00221.2002
   KREAM BE, 1985, ENDOCRINOLOGY, V116, P296, DOI 10.1210/endo 116 1 296
   Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348
   Lanchoney TF, 1998, CLIN ORTHOP RELAT R, P38
   Leblanc E, 2011, J BONE MINER RES, V26, P1166, DOI 10.1002/jbmr.311
   Levy MM, 2001, BONE, V29, P317, DOI 10.1016/S8756 3282(01)00585 3
   LODER RT, 1988, CLIN ORTHOP RELAT R, P210
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Massagué J, 2012, FEBS LETT, V586, P1833, DOI 10.1016/j.febslet.2012.05.030
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   McCarthy EF, 2005, SKELETAL RADIOL, V34, P609, DOI 10.1007/s00256 005 0958 z
   Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Nesti LJ, 2008, J BONE JOINT SURG AM, V90A, P2390, DOI 10.2106/JBJS.H.00049
   Nicodemus KK, 2001, DIABETES CARE, V24, P1192, DOI 10.2337/diacare.24.7.1192
   Olmsted EA, 2003, CLIN ORTHOP RELAT R, P331, DOI 10.1097/01.blo.0000052934.71325.79
   Poynton AR, 2002, SPINE, V27, pS40, DOI 10.1097/00007632 200208151 00010
   PUN KK, 1989, J BONE MINER RES, V4, P853
   ROSEN DM, 1983, ENDOCRINOLOGY, V112, P992, DOI 10.1210/endo 112 3 992
   Ryder JW, 2001, ACTA PHYSIOL SCAND, V171, P249, DOI 10.1046/j.1365 201x.2001.00827.x
   Seiner JM, 2002, CLIN ORTHOP RELAT R, pS110
   Shafritz AB, 1996, NEW ENGL J MED, V335, P555, DOI 10.1056/NEJM199608223350804
   Shore EM, 2008, BONE, V43, P427, DOI 10.1016/j.bone.2008.05.013
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Su XL, 2011, J MOL CELL CARDIOL, V51, P51, DOI 10.1016/j.yjmcc.2011.03.014
   Thrailkill K M, 2000, Diabetes Technol Ther, V2, P69, DOI 10.1089/152091599316775
   VERHAEGHE J, 1990, DIABETES, V39, P477, DOI 10.2337/diabetes.39.4.477
   Wosczyna MN, 2012, J BONE MINER RES, V27, P1004, DOI 10.1002/jbmr.1562
   YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
NR 49
TC 17
Z9 19
U1 0
U2 60
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 2014
VL 35
IS 34
BP 9322
EP 9331
DI 10.1016/j.biomaterials.2014.07.056
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA AP2KO
UT WOS:000341901300008
PM 25132600
DA 2025 08 17
ER

PT J
AU Shu, B
   Shi, Q
   Wang, YJ
AF Shu Bing
   Shi Qi
   Wang Yong jun
TI Shen (Kidney) tonifying principle for primary osteoporosis: to treat
   both the disease and the Chinese medicine syndrome
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE primary osteoporosis; Chinese medicine; syndrome; Shen (Kidney) essence
   deficiency; Shen (Kidney) tonifying herbs
ID INHIBITS OSTEOCLAST DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; BONE
   LOSS; POSITION STATEMENT; IN VITRO; ACTIVATION; MODEL; MICE; BETA;
   EXPRESSION
AB Primary osteoporosis (POP) is one of the most common diseases in the elderly people resulting in high risk of fracture and poor quality of life. In addition to the pathological changes in bone mass, most of the POP patients also suffer from Chinese medicine (CM) syndromes of Shen (Kidney) essence deficiency. Shen essences are highly related to bone. Shen essence deficiency plays an important part in the development of POP and a better diagnosis of POP could be made by combining CM syndromes with Western medicine risk factors. Treatments of POP should aim at both increasing the bone mass and relieving the syndromes of Shen essence deficiency. Clinical study confirmed that treating POP patients with Shen tonifying herbs could increase the bone mass and relieve the CM syndromes of POP patients. Basic researches clarified the mechanism by which Shen tonifying herbs increased bone mass in animal models. The mechanisms by which Shentonifying herbs relieve the CM syndromes are still in investigation.
C1 [Shu Bing; Shi Qi; Wang Yong jun] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai 200032, Peoples R China.
   [Shu Bing; Shi Qi; Wang Yong jun] Shanghai Univ Tradit Chinese Med, Spine Res Inst, Shanghai 200032, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine
RP Shi, Q (通讯作者)，Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai 200032, Peoples R China.
EM shiqish@hotmail.com; yjwang8888@126.com
RI wang, ying/L 2593 2018
OI Shu, Bing/0000 0002 6009 5377
FU National Basic Research Program of China (973 Program) [2010CB530400];
   Program for Innovative Research Team in University [IRT 1270]; National
   Natural Science Foundation of China [81403239]; Shanghai Natural Science
   Foundation [12ZR1450400]; 085 Project of Shanghai University of
   Traditional Chinese Medicine [085ZY 1204]
FX Supported by the National Basic Research Program of China (973 Program,
   No. 2010CB530400), the Program for Innovative Research Team in
   University (No, IRT 1270), National Natural Science Foundation of China
   (No. 81403239), Shanghai Natural Science Foundation (No. 12ZR1450400),
   and 085 Project of Shanghai University of Traditional Chinese Medicine
   (No. 085ZY 1204)
CR [Anonymous], 2003, WHO TECHNICAL REPORT, V921, P1
   BHATTACHARYYA MH, 1988, P NATL ACAD SCI USA, V85, P8761, DOI 10.1073/pnas.85.22.8761
   Bian Q, 2012, MENOPAUSE, V19, P225, DOI 10.1097/gme.0b013e3182272ef1
   Bian Qin, 2012, Front Biosci (Elite Ed), V4, P1224
   Bian Qin, 2011, Zhong Xi Yi Jie He Xue Bao, V9, P179, DOI 10.3736/jcim20110211
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen HY, 2008, BONE, V43, P494, DOI 10.1016/j.bone.2008.05.004
   Chen KM, 2007, PHARMAZIE, V62, P388, DOI 10.1691/ph.2007.5.6682
   Cheng X., 2009, CHIN J HLTH MANAG, V3, P148
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   How W, 2011, PROGR MODERN BIOMED, V11, P1927
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Ishii T, 2003, J BIOL CHEM, V278, P26970, DOI 10.1074/jbc.M304113200
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kim JY, 2014, BONE, V60, P104, DOI 10.1016/j.bone.2013.12.013
   Lan Y, 2006, DEV DYNAM, V235, P1448, DOI 10.1002/dvdy.20723
   Li JF, 2009, EUR J MED CHEM, V44, P2796, DOI 10.1016/j.ejmech.2008.12.024
   Li XF, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/652317
   Ming Lei guo, 2012, Yaoxue Xuebao, V47, P174
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Rauner M, 2008, AGE, V30, P273, DOI 10.1007/s11357 008 9069 9
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Siris E, 2014, OSTEOPOROSIS INT, V25, P1439, DOI 10.1007/s00198 014 2655 z
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Tang DZ, 2011, BIOCHEM BIOPH RES CO, V405, P256, DOI 10.1016/j.bbrc.2011.01.021
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Tang DZ, 2014, 36 ANN M AM SOC BON
   Tomat A., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P174
   Wang BL, 2014, ARTHRITIS RHEUMATOL, V66, P107, DOI 10.1002/art.38195
   Wu CY, 2013, FITOTERAPIA, V91, P205, DOI 10.1016/j.fitote.2013.09.005
   Xie YM, 2007, WORLD SCI TECHN MODE, V9, P38
   Yan Y, 2009, J CELL SCI, V122, P3566, DOI 10.1242/jcs.051904
   Yang Z, 2012, 19 NAT C ORTH TRAUM
   Yang Z, 2012, MENOPAUSE, V19, P1156, DOI 10.1097/gme.0b013e3182507e18
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhao Y, 2011, MENOPAUSE, V18, P690, DOI 10.1097/gme.0b013e3181fd7f4b
   Zhou W. J., 2007, LAB ANIM COMP MED CH, V27, P242
   Zhou XH, 2012, STAT MED, V31, P628, DOI 10.1002/sim.3980
   Zhou XH, 2012, STAT MED, V31, P643, DOI 10.1002/sim.4382
NR 40
TC 28
Z9 41
U1 0
U2 22
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1672 0415
EI 1993 0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD SEP
PY 2015
VL 21
IS 9
BP 656
EP 661
DI 10.1007/s11655 015 2306 z
PG 6
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA CS7LA
UT WOS:000362263900003
PM 26432789
DA 2025 08 17
ER

PT J
AU Yang, J
   He, J
   Wang, J
   Cao, Y
   Ling, J
   Qian, J
   Lu, Y
   Li, H
   Zheng, Y
   Lan, Y
   Hong, S
   Matthews, J
   Starbuck, MW
   Navone, NM
   Orlowski, RZ
   Lin, P
   Kwak, LW
   Yi, Q
AF Yang, J.
   He, J.
   Wang, J.
   Cao, Y.
   Ling, J.
   Qian, J.
   Lu, Y.
   Li, H.
   Zheng, Y.
   Lan, Y.
   Hong, S.
   Matthews, J.
   Starbuck, M. W.
   Navone, N. M.
   Orlowski, R. Z.
   Lin, P.
   Kwak, L. W.
   Yi, Q.
TI Constitutive activation of p38 MAPK in tumor cells contributes to
   osteolytic bone lesions in multiple myeloma
SO LEUKEMIA
LA English
DT Article
DE Myeloma; p38 MAPK; osteolytic bone lesions; osteoblastogenesis;
   osteoclastogenesis
ID PROTEIN KINASE PREVENTS; MARROW MICROENVIRONMENT; INDUCED CYTOTOXICITY;
   DENDRITIC CELLS; INHIBITING P38; DIFFERENTIATION; GROWTH; INDUCTION;
   P38 ALPHA; PATHOPHYSIOLOGY
AB Bone destruction is a hallmark of multiple myeloma and affects more than 80% of patients. However, current therapy is unable to completely cure and/or prevent bone lesions. Although it is accepted that myeloma cells mediate bone destruction by inhibition of osteoblasts and activation of osteoclasts, the underlying mechanism is still poorly understood. This study demonstrates that constitutive activation of p38 mitogen activated protein kinase in myeloma cells is responsible for myeloma induced osteolysis. Our results show that p38 is constitutively activated in most myeloma cell lines and primary myeloma cells from patients. Myeloma cells with high/detectable p38 activity, but not those with low/undetectable p38 activity, injected into severe combined immunodeficient (SCID) or SCID hu mice caused bone destruction. Inhibition or knockdown of p38 in human myeloma reduced or prevented myeloma induced osteolytic bone lesions without affecting tumor growth, survival, or homing to bone. Mechanistic studies showed that myeloma cell p38 activity inhibited osteoblastogenesis and bone formation and activated osteoclastogenesis and bone resorption in myeloma bearing SCID mice. This study elucidates a novel molecular mechanism activation of p38 signaling in myeloma cells by which myeloma cells induce osteolytic bone lesions, and indicates that targeting myeloma cell p38 may be a viable approach to treating or preventing myeloma bone disease.
C1 [Yang, J.; He, J.; Wang, J.; Cao, Y.; Qian, J.; Lu, Y.; Li, H.; Zheng, Y.; Lan, Y.; Hong, S.; Matthews, J.; Orlowski, R. Z.; Kwak, L. W.; Yi, Q.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Div Canc Med, Houston, TX 77030 USA.
   [Yang, J.; He, J.; Wang, J.; Cao, Y.; Qian, J.; Lu, Y.; Li, H.; Zheng, Y.; Lan, Y.; Hong, S.; Matthews, J.; Orlowski, R. Z.; Kwak, L. W.; Yi, Q.] Univ Texas MD Anderson Canc Ctr, Ctr Canc Immunol Res, Houston, TX 77030 USA.
   [Ling, J.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol Res, Houston, TX 77030 USA.
   [Starbuck, M. W.; Navone, N. M.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol Res, Houston, TX 77030 USA.
   [Lin, P.] Univ Texas MD Anderson Canc Ctr, Div Pathol & Lab Med, Dept Hematopathol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson
   Cancer Center; University of Texas System; UTMD Anderson Cancer Center
RP Yi, Q (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Div Canc Med, 1515 Holcombe Blvd,Unit 0903, Houston, TX 77030 USA.
EM jiyang@mdanderson.org; qyi@mdanderson.org
RI ; Orlowski, Robert/ABX 6428 2022; Lu, Young/E 8451 2014; Zheng,
   Yuhuan/J 8404 2013
OI Orlowski, Robert/0000 0002 5723 4129; Kwak, Larry/0000 0002 1884 5349; 
FU National Cancer Institute [R01 CA138402, R01 CA138398, P50 CA142509, K99
   CA137158, R00 CA137158]; Leukemia and Lymphoma Society Translational
   Research grants; Multiple Myeloma Research Foundation; Commonwealth
   Foundation for Cancer Research; International Myeloma Foundation;
   Lymphoma Research Foundation; American Society of Hematology; University
   Cancer Foundation; Center for Targeted Therapy of The University of
   Texas MD Anderson Cancer Center
FX We thank Brian Dawson for technical support with m CT scanning and
   analysis. We also thank our departmental Myeloma Tissue Bank for patient
   samples. This work was supported by National Cancer Institute R01 Grants
   CA138402 and CA138398 and P50 Grant CA142509 (Q Yi), the Leukemia and
   Lymphoma Society Translational Research grants, the Multiple Myeloma
   Research Foundation (Q Yi), the Commonwealth Foundation for Cancer
   Research (Q Yi), National Cancer Institute K99/R00 Grant CA137158 (J
   Yang), the International Myeloma Foundation (J Yang), the Lymphoma
   Research Foundation (J Yang), the American Society of Hematology (J
   Yang), and by funds from the University Cancer Foundation and the Center
   for Targeted Therapy of The University of Texas MD Anderson Cancer
   Center (Q Yi).
CR Anderson KC, 2005, ONCOLOGY NY, V19, P983
   Awasthi A, 2003, J EXP MED, V197, P1037, DOI 10.1084/jem.20022033
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Böhm C, 2009, J IMMUNOL, V183, P5938, DOI 10.4049/jimmunol.0901026
   Esteve FR, 2007, BEST PRACT RES CL HA, V20, P613, DOI 10.1016/j.beha.2007.08.003
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Hideshima T, 2004, ONCOGENE, V23, P8766, DOI 10.1038/sj.onc.1208118
   Hideshima T, 2003, BLOOD, V101, P703, DOI 10.1182/blood 2002 06 1874
   Hiruma Y, 2009, BLOOD, V113, P4894, DOI 10.1182/blood 2008 08 173948
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ishitsuka K, 2008, BRIT J HAEMATOL, V141, P598, DOI 10.1111/j.1365 2141.2008.07044.x
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Mbalaviele G, 2006, J PHARMACOL EXP THER, V317, P1044, DOI 10.1124/jpet.105.100362
   Navas T, 2008, LEUKEMIA LYMPHOMA, V49, P1963, DOI 10.1080/10428190802322919
   Nguyen AN, 2006, EXP CELL RES, V312, P1909, DOI 10.1016/j.yexcr.2006.02.026
   Roodman GD, 2007, BONE MARROW TRANSPL, V40, P1139, DOI 10.1038/sj.bmt.1705802
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Roodman GD, 2007, NAT MED, V13, P25, DOI 10.1038/nm0107 25
   Suzuki A, 2002, BONE, V30, P91, DOI 10.1016/S8756 3282(01)00660 3
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vanderkerken K, 2007, CANCER RES, V67, P4572, DOI 10.1158/0008 5472.CAN 06 4361
   Viñals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014 5793(01)03236 7
   von Metzler I, 2007, LEUKEMIA, V21, P2025, DOI 10.1038/sj.leu.2404806
   Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200
   Wang SQ, 2006, BLOOD, V108, P4071, DOI 10.1182/blood 2006 04 016980
   Wang SQ, 2006, BLOOD, V107, P2432, DOI 10.1182/blood 2005 06 2486
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Wei S, 2007, ADV ANAT PATHOL, V14, P42, DOI 10.1097/PAP.0b013e31802ef4f2
   Wen J, 1938, LEUKEMIA RES, V34, P85
   Wen JG, 2008, BRIT J HAEMATOL, V140, P169, DOI 10.1111/j.1365 2141.2007.06895.x
   Wen JG, 2010, LEUKEMIA RES, V34, P85, DOI 10.1016/j.leukres.2009.05.024
   Xie J, 2005, EXP HEMATOL, V33, P564, DOI 10.1016/j.exphem.2005.03.001
   Yaccoby S, 1998, BLOOD, V92, P2908, DOI 10.1182/blood.V92.8.2908.420a32_2908_2913
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yan D, 2007, BONE, V41, P1036, DOI 10.1016/j.bone.2007.07.018
   Yang J, 2007, CANCER CELL, V12, P252, DOI 10.1016/j.ccr.2007.08.008
   Yang J, 2006, CANCER CELL, V10, P295, DOI 10.1016/j.ccr.2006.08.025
   Yang J, 2009, CLIN CANCER RES, V15, P951, DOI 10.1158/1078 0432.CCR 08 1823
   Yun HJ, 2009, RHEUMATOL INT, V29, P1161, DOI 10.1007/s00296 008 0832 0
   Zwerina J, 2006, ARTHRITIS RHEUM US, V54, P463, DOI 10.1002/art.21626
NR 45
TC 23
Z9 27
U1 2
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887 6924
EI 1476 5551
J9 LEUKEMIA
JI Leukemia
PD SEP
PY 2012
VL 26
IS 9
BP 2114
EP 2123
DI 10.1038/leu.2012.71
PG 10
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA 999VK
UT WOS:000308342900017
PM 22425892
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, J
   Wei, JJ
   Wu, CH
   Zou, T
   Zhao, H
   Huo, TQ
   Wei, CJ
   Yang, T
AF Li, Jun
   Wei, Jia J.
   Wu, Cen H.
   Zou, Tao
   Zhao, Hong
   Huo, Tian Q.
   Wei, Cheng J.
   Yang, Ting
TI Epimedin A inhibits the PI3K/AKT/NF κB signalling axis and osteoclast
   differentiation by negatively regulating TRAF6 expression
SO MOLECULAR MEDICINE
LA English
DT Article
DE Epimedin A; Osteoporosis; Osteoclastogenesis; TRAF6; PI3K/AKT/NF kappa B
   signalling pathway
ID NF KAPPA B; CHINESE HERBAL MEDICINE; BONE LOSS; PREVENTION
AB BackgroundEpimedin A (EA) has been shown to suppress extensive osteoclastogenesis and bone resorption, but the effects of EA remain incompletely understood. The aim of our study was to investigate the effects of EA on osteoclastogenesis and bone resorption to explore the corresponding signalling pathways.MethodsRats were randomly assigned to the sham operation or ovariectomy group, and alendronate was used for the positive control group. The therapeutic effect of EA on osteoporosis was systematically analysed by measuring bone mineral density and bone biomechanical properties. In vitro, RAW264.7 cells were treated with receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage colony stimulating factor (M CSF) to induce osteoclast differentiation. Cell viability assays, tartrate resistant acid phosphatase (TRAP) staining, and immunofluorescence were used to elucidate the effects of EA on osteoclastogenesis. In addition, the expression of bone differentiation related proteins or genes was evaluated using Western blot analysis or quantitative polymerase chain reaction (PCR), respectively.ResultsAfter 3 months of oral EA intervention, ovariectomized rats exhibited increased bone density, relative bone volume, trabecular thickness, and trabecular number, as well as reduced trabecular separation. EA dose dependently normalized bone density and trabecular microarchitecture in the ovariectomized rats. Additionally, EA inhibited the expression of TRAP and NFATc1 in the ovariectomized rats. Moreover, the in vitro results indicated that EA inhibits osteoclast differentiation by suppressing the TRAF6/PI3K/AKT/NF kappa B pathway. Further studies revealed that the effect on osteoclast differentiation, which was originally inhibited by EA, was reversed when the TRAF6 gene was overexpressed.ConclusionsThe findings indicated that EA can negatively regulate osteoclastogenesis by inhibiting the TRAF6/PI3K/AKT/NF kappa B axis and that ameliorating ovariectomy induced osteoporosis in rats with EA may be a promising potential therapeutic strategy for the treatment of osteoporosis.
C1 [Li, Jun; Wu, Cen H.; Zou, Tao; Zhao, Hong; Huo, Tian Q.] Nanjing Univ Chinese Med, Dept Spine Surg, Changzhou TCM Hosp, Changzhou 213000, Peoples R China.
   [Wei, Jia J.] Yunnan Prov Hosp Tradit Chinese Med, Dept Orthoped, Kunming 650000, Peoples R China.
   [Wei, Cheng J.] Jiangsu Prov Hosp Tradit Chinese Med, Dept Orthoped, Nanjing 210000, Peoples R China.
   [Yang, Ting] Nanjing Univ Chinese Med, Dept Rheumatol, Changzhou TCM Hosp, Changzhou 213000, Peoples R China.
C3 Nanjing University of Chinese Medicine; Yunnan University of Chinese
   Medicine; Nanjing University of Chinese Medicine; Nanjing University of
   Chinese Medicine
RP Li, J (通讯作者)，Nanjing Univ Chinese Med, Dept Spine Surg, Changzhou TCM Hosp, Changzhou 213000, Peoples R China.; Wei, CJ (通讯作者)，Jiangsu Prov Hosp Tradit Chinese Med, Dept Orthoped, Nanjing 210000, Peoples R China.
EM lijun331188@163.com; hongzhao1982@163.com
RI wei, jiajun/KQU 4229 2024; huo, tianqun/GQY 7820 2022
OI jun, li/0009 0004 4092 2365; 
FU Changzhou Municipal Health Commission
FX Not applicable.
CR Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Cheng XG, 2021, J BONE MINER RES, V36, P427, DOI 10.1002/jbmr.4187
   Dou C, 2021, BIOACT MATER, V6, P4697, DOI 10.1016/j.bioactmat.2021.04.038
   Efthimiou P, 2020, ABSOLUTE RHEUMATOLOGY REVIEW, P1, DOI 10.1007/978 3 030 23022 7
   Fink HA, 2019, ANN INTERN MED, V171, P37, DOI 10.7326/M19 0533
   Gyori DS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00507
   Jones AR, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 00713 8
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Leali PT, 2009, CLIN CASES MINER BON, V6, P109
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Liu JJ, 2018, PHYTOMEDICINE, V42, P43, DOI 10.1016/j.phymed.2018.03.020
   Liu Y, 2021, J MATER SCI MATER M, V32, DOI 10.1007/s10856 020 06472 9
   Ma XQ, 2018, LIFE SCI, V209, P140, DOI 10.1016/j.lfs.2018.08.008
   Sukhdeo S, 2020, ANAT REC, V303, P129, DOI 10.1002/ar.24050
   Tosteson ANA, 2003, AM J MED, V115, P209, DOI 10.1016/S0002 9343(03)00362 0
   Wang LL, 2016, CURR PHARM DESIGN, V22, P328, DOI 10.2174/1381612822666151112145907
   Xie XD, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.826023
   Yee AJ, 2012, CLIN INTERV AGING, V7, P331, DOI 10.2147/CIA.S14566
   Yun J, 2019, BIOCHIMIE, V157, P81, DOI 10.1016/j.biochi.2018.11.008
   Zeng XZ, 2020, ACTA PHARMACOL SIN, V41, P229, DOI 10.1038/s41401 019 0289 6
   Zhai YK, 2013, PHARMAZIE, V68, P713, DOI 10.1691/ph.2013.2900
   Zhang HF, 2008, ULTRASON SONOCHEM, V15, P376, DOI 10.1016/j.ultsonch.2007.09.002
   Zhang LB, 2022, FRONT CHEM, V10, DOI 10.3389/fchem.2022.1023779
NR 23
TC 4
Z9 5
U1 3
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1076 1551
EI 1528 3658
J9 MOL MED
JI Mol. Med.
PD AUG 16
PY 2024
VL 30
IS 1
AR 125
DI 10.1186/s10020 024 00893 w
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA C8R6F
UT WOS:001291987200001
PM 39152382
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, CL
   Wang, SY
   Xing, Z
   Lin, AF
   Liang, K
   Song, J
   Hui, QS
   Yao, J
   Chen, ZY
   Park, PK
   Hawke, DH
   Zhou, JW
   Zhou, Y
   Zhang, SX
   Liang, H
   Hung, MC
   Gallick, GE
   Han, L
   Lin, CR
   Yang, LQ
AF Li, Chunlai
   Wang, Shouyu
   Xing, Zhen
   Lin, Aifu
   Liang, Ke
   Song, Jian
   Hui, Qingsong
   Yao, Jun
   Chen, Zhongyuan
   Park, Peter K.
   Hawke, David H.
   Zhou, Jianwei
   Zhou, Yan
   Zhang, Shuxing
   Liang, Han
   Hung, Mien Chie
   Gallick, Gary E.
   Han, Leng
   Lin, Chunru
   Yang, Liuqing
TI A ROR1 HER3 IncRNA signalling axis modulates the Hippo YAP pathway to
   regulate bone metastasis
SO NATURE CELL BIOLOGY
LA English
DT Article
ID RECEPTOR TYROSINE KINASES; BREAST CANCER METASTASIS; NONCODING RNAS;
   LUNG CANCER; EXPRESSION; FAMILY; EGFR; TAZ; ACTIVATION; PHOSPHORYLATION
AB Bone metastases remain a serious health concern because of limited therapeutic options. Here, we report that crosstalk between ROR1 HER3 and the Hippo YAP pathway promotes breast cancer bone metastasis in a long noncoding RNA dependent fashion. Mechanistically, the orphan receptor tyrosine kinase ROR1 phosphorylates HER3 at a previously unidentified site Tyr1307, following neuregulin stimulation, independently of other ErbB family members. p HER3 Tyr1307 recruits the LLGL2 MAYA NSUN6 RNA protein complex to methylate Hippo/MST1 at Lys59. This methylation leads to MST1 inactivation and activation of YAP target genes in tumour cells, which elicits osteoclast differentiation and bone metastasis. Furthermore, increased ROR1, p HER3 Tyr1307 and MAYA levels correlate with tumour metastasis and unfavourable outcomes. Our data provide insights into the mechanistic regulation and linkage of the ROR1 HER3 and Hippo YAP pathway in a cancer specific context, and also imply valuable therapeutic targets for bone metastasis and possible therapy resistant tumours.
C1 [Li, Chunlai; Wang, Shouyu; Xing, Zhen; Lin, Aifu; Liang, Ke; Hui, Qingsong; Yao, Jun; Park, Peter K.; Hung, Mien Chie; Lin, Chunru; Yang, Liuqing] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Song, Jian; Gallick, Gary E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Chen, Zhongyuan; Liang, Han] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
   [Chen, Zhongyuan] Rice Univ, Dept Stat, Houston, TX 77030 USA.
   [Hawke, David H.; Liang, Han] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
   [Zhou, Jianwei] Nanjing Med Univ, Sch Publ Hlth, Dept Mol Cell Biol & Toxicol, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Zhou, Yan] Yixing Peoples Hosp, Dept Oncol, 75 Zhenguan Rd, Yixing 214200, Peoples R China.
   [Zhang, Shuxing] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Hung, Mien Chie; Lin, Chunru; Yang, Liuqing] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA.
   [Hung, Mien Chie] China Med Univ, Ctr Mol Med, Taichung 404, Taiwan.
   [Hung, Mien Chie] China Med Univ, Grad Inst Canc Biol, Taichung 404, Taiwan.
   [Han, Leng] Univ Texas Hlth Sci Ctr Houston, Houston McGovern Med Sch, Dept Biochem & Mol Biol, Houston, TX 77030 USA.
   [Yang, Liuqing] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA.
   [Li, Chunlai; Wang, Shouyu] Nanjing Med Univ, Sch Publ Hlth, Dept Mol Cell Biol & Toxicol, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Lin, Aifu] Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Zhejiang, Peoples R China.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; Rice University; University of Texas
   System; UTMD Anderson Cancer Center; Nanjing Medical University;
   University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; China Medical University
   Taiwan; China Medical University Taiwan; University of Texas System;
   University of Texas Health Science Center Houston; University of Texas
   System; UTMD Anderson Cancer Center; Nanjing Medical University;
   Zhejiang University
RP Lin, CR; Yang, LQ (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.; Lin, CR; Yang, LQ (通讯作者)，Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA.; Yang, LQ (通讯作者)，Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA.
EM clin2@mdanderson.org; lyang7@mdanderson.org
RI ; Yang, Liuqing/HQY 8902 2023; Hung, Mien Chie/ABD 5911 2021; Han,
   Leng/HCH 3491 2022; Zhou, Jianwei/JPW 9256 2023; Li,
   Chunlai/AAI 8839 2021; Yao, Jun/JAC 5608 2023
OI Han, Leng/0000 0002 7380 2640; Liang, Ke/0009 0002 2078 989X; Li,
   Chunlai/0000 0003 1897 9889; Hung, Mien Chie/0000 0003 4317 4740; 
FU National Institutes of Health [R00CA166527, R00DK094981]; Cancer
   Prevention Research Institute of Texas Firsttime Faculty Recruitment
   Award [R1218]
FX We are grateful to J. Massague and X. Zhang for providing the MDA MB 231
   LM2 and BoM 1833 cell lines and to D. Yu for providing the
   MDA MB 231 BRN and BT474 BRN cells. We thank D. Aten for assistance with
   figure presentation. This work was supported by National Institutes of
   Health Pathway to Independence Award (R00CA166527) and Cancer Prevention
   Research Institute of Texas Firsttime Faculty Recruitment Award (R1218)
   grants to L.Q.Y. and National Institutes of Health Pathway to
   Independence Award (R00DK094981) to C.R.L.
CR Bae SY, 2013, BREAST CANCER RES TR, V139, P741, DOI 10.1007/s10549 013 2570 6
   Baskar S, 2008, CLIN CANCER RES, V14, P396, DOI 10.1158/1078 0432.CCR 07 1823
   Bergeron JJM, 2016, ANNU REV BIOCHEM, V85, P573, DOI 10.1146/annurev biochem 060815 014659
   Bicocca VT, 2012, CANCER CELL, V22, P656, DOI 10.1016/j.ccr.2012.08.027
   Bittner N, 2015, PATHOL ONCOL RES, V21, P1217, DOI 10.1007/s12253 015 9955 2
   Borcherding N, 2014, PROTEIN CELL, V5, P496, DOI 10.1007/s13238 014 0059 7
   Castello A, 2012, CELL, V149, P1393, DOI 10.1016/j.cell.2012.04.031
   Chien HP, 2016, VIRCHOWS ARCH, V468, P589, DOI 10.1007/s00428 016 1911 3
   Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048
   Daneshmanesh AH, 2013, LEUKEMIA LYMPHOMA, V54, P843, DOI 10.3109/10428194.2012.731599
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Forrester WC, 2002, CELL MOL LIFE SCI, V59, P83, DOI 10.1007/s00018 002 8407 9
   Gentile A, 2014, INT J CANCER, V135, P2305, DOI 10.1002/ijc.28879
   Gentile A, 2011, CANCER RES, V71, P3132, DOI 10.1158/0008 5472.CAN 10 2662
   Glantschnig H, 2002, J BIOL CHEM, V277, P42987, DOI 10.1074/jbc.M208538200
   Gomez M, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001 1326 3 22
   Green JL, 2008, TRENDS CELL BIOL, V18, P536, DOI 10.1016/j.tcb.2008.08.006
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Haag S, 2015, RNA, V21, P1532, DOI 10.1261/rna.051524.115
   Halder G, 2012, NAT REV MOL CELL BIO, V13, P591, DOI 10.1038/nrm3416
   Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002
   Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458
   Haskins JW, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005770
   Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200
   Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Karachaliou N, 2014, TRANSL LUNG CANCER R, V3, P122, DOI 10.3978/j.issn.2218 6751.2014.03.02
   Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295
   Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901 802
   Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004
   MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181
   Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884
   Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876
   Oishi I, 1999, GENES CELLS, V4, P41, DOI 10.1046/j.1365 2443.1999.00234.x
   Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011
   Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013
   Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014
   Rashid F, 2016, GENOM PROTEOM BIOINF, V14, P73, DOI 10.1016/j.gpb.2016.03.005
   Sapru MK, 2001, LIFE SCI, V69, P2663, DOI 10.1016/S0024 3205(01)01343 1
   Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474
   Shimo T, 2006, J BONE MINER RES, V21, P1045, DOI 10.1359/JBMR.060416
   Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936
   Tao JJ, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005125
   Thompson BJ, 2015, J CELL BIOL, V210, P871, DOI 10.1083/jcb.201507005
   Tichon A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12209
   Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456
   Wang WQ, 2015, NAT CELL BIOL, V17, P490, DOI 10.1038/ncb3113
   Waning DL, 2014, CLIN CANCER RES, V20, P3071, DOI 10.1158/1078 0432.CCR 13 1590
   Willingham AT, 2005, SCIENCE, V309, P1570, DOI 10.1126/science.1115901
   Xing Z, 2014, CELL, V159, P1110, DOI 10.1016/j.cell.2014.10.013
   Xue ZH, 2016, MOL CELL, V64, P37, DOI 10.1016/j.molcel.2016.08.010
   Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759
   Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008
   Yoda A, 2003, J RECEPT SIG TRANSD, V23, P1, DOI 10.1081/RRS 120018757
   Yoon JH, 2013, J MOL BIOL, V425, P3723, DOI 10.1016/j.jmb.2012.11.024
   Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112
   Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037
   Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216
   Zhang CY, 2011, CELL BIOSCI, V1, DOI 10.1186/2045 3701 1 8
   Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993
   Zhang SY, 2013, CANCER RES, V73, P5764, DOI 10.1158/0008 5472.CAN 12 1803
   Zhang SP, 2012, AM J PATHOL, V181, P1903, DOI 10.1016/j.ajpath.2012.08.024
   Zhang SP, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031127, 10.1371/journal.pone.0046853]
   Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303
NR 66
TC 248
Z9 271
U1 1
U2 115
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465 7392
EI 1476 4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD FEB
PY 2017
VL 19
IS 2
BP 106
EP 119
DI 10.1038/ncb3464
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA EJ8BL
UT WOS:000393447200006
PM 28114269
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ha, H
   An, H
   Shim, KS
   Kim, T
   Lee, KJ
   Hwang, YH
   Ma, JY
AF Ha, Hyunil
   An, Hyosun
   Shim, Ki Shuk
   Kim, Taesoo
   Lee, Kwang Jin
   Hwang, Youn Hwan
   Ma, Jin Yeul
TI Ethanol Extract of Atractylodes macrocephala Protects Bone Loss
   by Inhibiting Osteoclast Differentiation
SO MOLECULES
LA English
DT Article
DE Atractylodes macrocephala; osteoporosis; RANKL; osteoclast
ID NF KAPPA B; C FOS; ATRACTYLENOLIDE III; KEY REGULATOR; ANIMAL MODEL;
   RANKL; KOIDZ; ACTIVATION; NFATC1; LIPOPOLYSACCHARIDE
AB The rhizome of Atractylodes macrocephala has been used mainly in Traditional Chinese Medicine for invigorating the functions of the stomach and spleen. In the present study, we investigated the inhibitory effect of the 70% ethanol extract of the rhizome of Atractylodes macrocephala (AMEE) on osteoclast differentiation. We found that AMEE inhibits osteoclast differentiation from its precursors induced by receptor activator of nuclear factor kappa B ligand (RANKL), an essential cytokine required for osteoclast differentiation. AMEE attenuated RANKL induced activation of NF kappa B signaling pathway, subsequently inhibiting the induction of osteoclastogenic transcription factors, c Fos and nuclear factor of activated T cells cytoplasmic 1. Consistent with the in vitro results, administration of AMEE protected RANKL induced bone loss in mice. We also identified atractylenolide I and II as active constituents contributing to the anti osteoclastogenic effect of AMEE. Taken together, our results demonstrate that AMEE has a protective effect on bone loss via inhibiting osteoclast differentiation and suggest that AMEE may be useful in preventing and treating various bone diseases associated with excessive bone resorption.
C1 [Ha, Hyunil; An, Hyosun; Shim, Ki Shuk; Kim, Taesoo; Lee, Kwang Jin; Hwang, Youn Hwan; Ma, Jin Yeul] Korea Inst Oriental Med, KM Based Herbal Drug Res Grp, Taejon 305811, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Ma, JY (通讯作者)，Korea Inst Oriental Med, KM Based Herbal Drug Res Grp, Taejon 305811, South Korea.
EM yjma@kiom.re.kr
RI Hwang, Youn Hwan/AAU 9373 2021
FU Korea Institute of Oriental Medicine, Ministry of Education, Science and
   Technology, Republic of Korea [K13050]
FX This work was supported by a grant (K13050) from the Korea Institute of
   Oriental Medicine, Ministry of Education, Science and Technology,
   Republic of Korea.
CR Banu J, 2012, NUTR REV, V70, P22, DOI 10.1111/j.1753 4887.2011.00451.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Dong HY, 2008, NAT PROD RES, V22, P1418, DOI 10.1080/14786410801931629
   Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200
   Gao Q, 2012, PHYTOTHER RES, V26, P557, DOI 10.1002/ptr.3595
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111
   Hou JosephP., 2005, HEALING POWER CHINES
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jiang H, 2011, MOLECULES, V16, P3146, DOI 10.3390/molecules16043146
   Kim CK, 2011, J ETHNOPHARMACOL, V137, P396, DOI 10.1016/j.jep.2011.05.036
   Kim HJ, 2007, MOL PHARMACOL, V72, P418, DOI 10.1124/mol.107.034173
   Kim SH, 2005, IMMUNOPHARM IMMUNOT, V27, P331, DOI 10.1081/IPH 200067950
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee JC, 2007, PHYTOMEDICINE, V14, P390, DOI 10.1016/j.phymed.2006.09.012
   Lee JH, 2009, J BIOL CHEM, V284, P13725, DOI 10.1074/jbc.M806941200
   Li CQ, 2007, J ETHNOPHARMACOL, V114, P212, DOI 10.1016/j.jep.2007.08.002
   Li CQ, 2007, PHYTOTHER RES, V21, P347, DOI 10.1002/ptr.2040
   Li XC, 2012, MOLECULES, V17, P13457, DOI 10.3390/molecules171113457
   Lim H, 2012, ARCH PHARM RES, V35, P2007, DOI 10.1007/s12272 012 1118 3
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Dan S, 2008, CHIN J CHROMATOGR, V26, P637
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Wang CC, 2002, PLANTA MED, V68, P204, DOI 10.1055/s 2002 23144
   Wang Changhe, 2012, Zhongguo Zhong Yao Za Zhi, V37, P1809
   Wang KT, 2010, J PHARM PHARMACOL, V62, P381, DOI 10.1211/jpp.62.03.0014
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630
NR 34
TC 25
Z9 27
U1 1
U2 19
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1420 3049
J9 MOLECULES
JI Molecules
PD JUL
PY 2013
VL 18
IS 7
BP 7376
EP 7388
DI 10.3390/molecules18077376
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 298CG
UT WOS:000330300900004
PM 23884114
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Wang, N
   Liu, XC
   Tang, Z
   Wei, XH
   Dong, H
   Liu, YC
   Wu, H
   Wu, ZG
   Li, XK
   Ma, X
   Guo, Z
AF Wang, Ning
   Liu, Xuanchen
   Tang, Zhen
   Wei, Xinghui
   Dong, Hui
   Liu, Yichao
   Wu, Hao
   Wu, Zhigang
   Li, Xiaokang
   Ma, Xue
   Guo, Zheng
TI Increased BMSC exosomal miR 140 3p alleviates bone
   degradation and promotes bone restoration by targeting Plxnb1 in
   diabetic rats
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Bone defect; Diabetes mellitus; Exosomes; MiR 140 3p; Plexin B1
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; ADIPOSE TISSUE;
   MICRORNAS; EXPRESSION; INSULIN; MINERALIZATION; RECOGNITION; BIOMARKERS;
   MECHANISM
AB Background: Diabetes mellitus (DM) is considered to be an important factor for bone degeneration disorders such as bone defect nonunion, which is characterized by physical disability and tremendous economy cost to families and society. Exosomal miRNAs of BMSCs have been reported to participate in osteoblastogenesis and modulating bone formation. However, their impacts on the development of bone degeneration in DM are not yet known. The role of miRNAs in BMSCs exosomes on regulating hyperglycemia bone degeneration was investigated in the present study.
   Results: The osteogenic potential in bone defect repair of exosomes derived from diabetes mellitus BMSCs derived exosomes (DM Exos) were revealed to be lower than that in normal BMSCs derived exosomes (N Exos) in vitro and in vivo. Here, we demonstrate that miR 140 3p level was significantly altered in exosomes derived from BMSCs, ADSCs and serum from DM rats. In in vitro experiments, upregulated miR 140 3p exosomes promoted DM BMSCs differentiation into osteoblasts. The effects were exerted by miR 140 3p targeting plxnb1, plexin B1 is the receptor of semaphoring 4D(Sema4D) that inhibited osteocytes differentiation, thereby promoting bone formation. In DM rats with bone defect, miR 140 3p upregulated exosomes were transplanted into injured bone and accelerated bone regeneration. Besides, miR 140 3p in the exosomes was transferred into BMSCs and osteoblasts and promoted bone regeneration by targeting the plexin B1/RohA/ROCK signaling pathway.
   Conclusions: Normal Exos and miR 140 3p overexpressed Exos accelerated diabetic wound healing by promoting the osteoblastogenesis function of BMSCs through inhibition plexin B1 expression which is the receptor of Sema4D and the plexin B1/RhoA/ROCK pathway compared with diabetes mellitus Exos. This offers a new insight and a new therapy for treating diabetic bone unhealing.
C1 [Wang, Ning; Tang, Zhen; Wei, Xinghui; Dong, Hui; Liu, Yichao; Wu, Hao; Li, Xiaokang; Guo, Zheng] Fourth Mil Med Univ, Tangdu Hosp, Dept Orthopaed, Xian 710038, Shaanxi, Peoples R China.
   [Liu, Xuanchen] Fourth Mil Med Univ, Tangdu Hosp, Dept Nutr, Xian 710038, Shaanxi, Peoples R China.
   [Wu, Zhigang] 63750 Hosp Peoples Liberat Army, Dept Orthoped, Xian 710043, Shaanxi, Peoples R China.
   [Ma, Xue] Fourth Mil Med Univ, Sch Pharm, Dept Pharmacol, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University
RP Li, XK; Guo, Z (通讯作者)，Fourth Mil Med Univ, Tangdu Hosp, Dept Orthopaed, Xian 710038, Shaanxi, Peoples R China.; Ma, X (通讯作者)，Fourth Mil Med Univ, Sch Pharm, Dept Pharmacol, Xian 710032, Shaanxi, Peoples R China.
EM lxkfmmu@163.com; maxuel@fmmu.edu.cn; guozheng@fmmu.edu.cn
RI ; dong, hui/JDN 2423 2023; wang, ning/AFX 9397 2022
OI Wang, Ning/0000 0003 1851 6219; 
FU National Key Research and Development Program of China [2017YFC1104900];
   National Natural Science Foundation of China [51871239, 51771227,
   81772328]; Shaanxi Key Research and Development Program [2020SF 088];
   China Postdoctoral Science Foundation [2020M673663]
FX This work was supported by the National Key Research and Development
   Program of China (Grant Number 2017YFC1104900), the National Natural
   Science Foundation of China (Grant Numbers 51871239, 51771227 and
   81772328), the Shaanxi Key Research and Development Program (Grant
   Number 2020SF 088) and China Postdoctoral Science Foundation
   (2020M673663).
CR Alblowi J, 2009, AM J PATHOL, V175, P1574, DOI 10.2353/ajpath.2009.090148
   Ameres SL, 2007, CELL, V130, P101, DOI 10.1016/j.cell.2007.04.037
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bjorge IM, 2017, BIOMATER SCI UK, V6, P60, DOI 10.1039/c7bm00479f
   Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085
   Chen B, 2017, STEM CELL TRANSL MED, V6, P1753, DOI 10.1002/sctm.16 0477
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Compston J, 2018, J INTERN MED, V283, P140, DOI 10.1111/joim.12725
   Cruz NG, 2013, DIABETES RES CLIN PR, V99, P85, DOI 10.1016/j.diabres.2012.09.003
   Donath MY, 2019, NAT REV IMMUNOL, V19, P734, DOI 10.1038/s41577 019 0213 9
   Fu YC, 2019, EUR REV MED PHARMACO, V23, P73, DOI 10.26355/eurrev_201908_18632
   Gandla J, 2017, PAIN, V158, P1765, DOI 10.1097/j.pain.0000000000000971
   García García A, 2015, IMMUNOL LETT, V168, P129, DOI 10.1016/j.imlet.2015.06.020
   Gómez Barrena E, 2019, BIOMATERIALS, V196, P100, DOI 10.1016/j.biomaterials.2018.03.033
   Gopalakrishnan V, 2006, BIOCHEM CELL BIOL, V84, P93, DOI 10.1139/O05 163
   Guo YQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15621
   Hamann C, 2011, AM J PHYSIOL ENDOC M, V301, pE1220, DOI 10.1152/ajpendo.00378.2011
   Hao ZC., 2017, CELL PROLIFERAT, V50, P5
   Hu ZA, 2019, ACTA BIOMATER, V84, P402, DOI 10.1016/j.actbio.2018.11.052
   Jeppesen DK, 2019, CELL, V177, P428, DOI 10.1016/j.cell.2019.02.029
   Jiao HL, 2015, CURR OSTEOPOROS REP, V13, P327, DOI 10.1007/s11914 015 0286 8
   Kishore R, 2017, EUR HEART J, V38, P212, DOI 10.1093/eurheartj/ehw324
   Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev physiol 021014 071641
   Kume S, 2005, J BONE MINER RES, V20, P1647, DOI 10.1359/JBMR.050514
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Liu XL, 2017, NANOSCALE, V9, P4430, DOI 10.1039/c7nr00352h
   Liu XL, 2017, INT J BIOL SCI, V13, P232, DOI 10.7150/ijbs.16951
   Marin C, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00006
   Min ZX, 2015, INT J CLIN EXP MED, V8, P1009
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Notsu M, 2014, ENDOCRINOLOGY, V155, P2402, DOI 10.1210/en.2013 1818
   Pando R, 2012, J NUTR BIOCHEM, V23, P1474, DOI 10.1016/j.jnutbio.2011.09.010
   Panganiban RP, 2016, J ALLERGY CLIN IMMUN, V137, P1423, DOI 10.1016/j.jaci.2016.01.029
   Paschou SA, 2017, J CLIN ENDOCR METAB, V102, P3621, DOI 10.1210/jc.2017 00042
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Qin YH, 2016, SCI REP UK, V6, DOI 10.1038/srep21961
   Rauch A, 2019, NAT GENET, V51, P716, DOI 10.1038/s41588 019 0359 1
   Roy AD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15831
   Sahoo S, 2011, CIRC RES, V109, P724, DOI 10.1161/CIRCRESAHA.111.253286
   Salazar Roa M, 2020, EMBO J, V39, DOI 10.15252/embj.2019104324
   Schaap Oziemlak AM, 2010, STEM CELLS DEV, V19, P877, DOI 10.1089/scd.2009.0112
   Su T, 2019, ACS NANO, V13, P2450, DOI 10.1021/acsnano.8b09375
   Takahara S, 2018, BONE JOINT RES, V7, P139, DOI 10.1302/2046 3758.72.BJR 2017 0082.R1
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 018 0075 6
   Toh WS, 2017, SEMIN CELL DEV BIOL, V67, P56, DOI 10.1016/j.semcdb.2016.11.008
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Waki T, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 0931 0
   Wan N, 2020, BIOMATER SCI UK, V8, P1604, DOI 10.1039/c9bm01426h
   Wu JY, 2019, BIOMATERIALS, V206, P87, DOI 10.1016/j.biomaterials.2019.03.022
   Xie Y, 2017, J CELL MOL MED, V21, P1033, DOI 10.1111/jcmm.13039
   Xu GS, 2012, BLOOD, V119, P4205, DOI 10.1182/blood 2011 05 353300
   Xu RY, 2018, AGING CELL, V17, DOI 10.1111/acel.12794
   Yang K, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475 2840 9 66
   Ying W, 2021, CELL METAB, V33, P781, DOI 10.1016/j.cmet.2020.12.019
   Ying W, 2017, CELL, V171, P372, DOI 10.1016/j.cell.2017.08.035
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zhu Y, 2019, STEM CELL TRANSL MED, V8, P593, DOI 10.1002/sctm.18 0199
NR 59
TC 55
Z9 58
U1 5
U2 58
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD MAR 2
PY 2022
VL 20
IS 1
AR 97
DI 10.1186/s12951 022 01267 2
PG 20
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA ZL1VB
UT WOS:000763468100001
PM 35236339
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Fan, FY
   Deng, R
   Lai, SH
   Wen, Q
   Zeng, YJ
   Gao, L
   Liu, Y
   Kong, PY
   Zhong, JF
   Su, Y
   Zhang, X
AF Fan, Fang Yi
   Deng, Rui
   Lai, Si Han
   Wen, Qin
   Zeng, Yunjing
   Gao, Lei
   Liu, Yao
   Kong, Peiyan
   Zhong, Jiangfan
   Su, Yi
   Zhang, Xi
TI Inhibition of microRNA 221 5p induces osteogenic differentiation by
   directly targeting smad3 in myeloma bone disease mesenchymal stem cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE myeloma bone disease; bone marrow mesenchymal stem cell;
   microRNA 221 5p; smad family member 3; PI3K; AKT; mTOR
ID OSTEOBLAST DIFFERENTIATION; PROMOTES; EXPRESSION
AB Myeloma bone disease (MBD) is one of the clinical features of multiple myeloma, which contributes to the attenuation of osteoblast function. Bone marrow mesenchymal stem cells exhibit a high potential for differentiation into osteoblasts. A number of studies have reported that microRNAs (miRs) serve a vital role in mesenchymal stem cell (MSC) osteogenesis; however, the role of miR 221 5p in the osteogenic differentiation of MBD MSCs remains unclear. The present study revealed that the osteogenic differentiation capacity of MBD MSCs was reduced compared with that of normal (N) MSCs. Further experiments demonstrated that miR 221 5p expression was downregulated in N MSCs following osteoblast induction while no obvious alterations in expression levels were observed in MBD MSCs. The inhibition of miR 221 5p promoted the osteogenic differentiation of MBD MSCs. Bioinformatics, luciferase reporter assays, reverse transcription quantitative PCR and western blotting assays indicated that smad family member 3 (smad3) was a direct target of miR 221 5p in MBD MSCs. A negative association was identified between the expression levels of smad3 and miR 221 5p. Investigations of the molecular mechanism indicated that suppressed miR 221 5p could regulate the osteogenic differentiation of MBD MSCs by upregulating smad3 expression. It was also identified that the PI3K/AKT/mTOR signaling pathway was activated following miR 221 5p inhibition, and this increased the osteogenic differentiation capacity of MBD MSCs. The present study may improve the understanding regarding the role of miR 221 5p in the regulation of osteogenic differentiation, and may contribute to the development of a novel therapy for MBD.
C1 [Fan, Fang Yi; Wen, Qin; Zeng, Yunjing; Gao, Lei; Liu, Yao; Kong, Peiyan; Zhong, Jiangfan; Zhang, Xi] Army Med Univ, Xinqiao Hosp, Dept Hematol, 83 Xinqiao Main St, Chongqing 400037, Sichuan, Peoples R China.
   [Fan, Fang Yi; Deng, Rui; Lai, Si Han; Su, Yi] Gen Hosp Western Theater Command, Dept Hematol, 270 Tianhui Rd, Chengdu 610083, Sichuan, Peoples R China.
   [Fan, Fang Yi; Deng, Rui; Lai, Si Han; Su, Yi] Gen Hosp Western Theater Command, Hematopoet Stem Cell Transplantat Ctr, 270 Tianhui Rd, Chengdu 610083, Sichuan, Peoples R China.
C3 Army Medical University
RP Zhang, X (通讯作者)，Army Med Univ, Xinqiao Hosp, Dept Hematol, 83 Xinqiao Main St, Chongqing 400037, Sichuan, Peoples R China.; Su, Y (通讯作者)，Gen Hosp Western Theater Command, Dept Hematol, 270 Tianhui Rd, Chengdu 610083, Sichuan, Peoples R China.; Su, Y (通讯作者)，Gen Hosp Western Theater Command, Hematopoet Stem Cell Transplantat Ctr, 270 Tianhui Rd, Chengdu 610083, Sichuan, Peoples R China.
EM suhang1234@hotmail.com; zhangxxi@sina.com
RI sihan, lai/GOE 6801 2022; fan, fang/GQY 9173 2022; Yao,
   Liu/LJM 3304 2024
OI Liu, Yao/0000 0003 1782 7322; 
FU National Key Research Program 'Stem Cell and Transformation Research'
   Key Project [2017YFA0105502]
FX The present study was supported by the National Key Research Program
   'Stem Cell and Transformation Research' Key Project (grant. no.
   2017YFA0105502).
CR Anderson KC, 2016, CLIN CANCER RES, V22, P5419, DOI 10.1158/1078 0432.CCR 16 0625
   Arfat Y, 2018, MOL THER NUCL ACIDS, V11, P323, DOI 10.1016/j.omtn.2017.11.009
   Berenson JR, 2005, BEST PRACT RES CL HA, V18, P653, DOI 10.1016/j.beha.2005.03.001
   Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754
   Chen Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058104
   Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092 8674(00)81696 7
   Diao YZ, 2009, J BIOMED MATER RES A, V91A, P123, DOI 10.1002/jbm.a.32186
   Ell Brian, 2014, Bonekey Rep, V3, P549, DOI 10.1038/bonekey.2014.44
   Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008 5472.CAN 05 0298
   Gu YX, 2013, J BIOMED MATER RES A, V101, P748, DOI 10.1002/jbm.a.34377
   Hackinger S, 2017, HUM MOL GENET, V26, P3850, DOI 10.1093/hmg/ddx285
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Heider U, 2005, BIOCHEM BIOPH RES CO, V338, P687, DOI 10.1016/j.bbrc.2005.09.146
   Hu R, 2010, EXPERT OPIN THER TAR, V14, P1109, DOI 10.1517/14728222.2010.512916
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Kyle RA, 2009, LEUKEMIA, V23, P3, DOI 10.1038/leu.2008.291
   Li H, 2015, CELL DEATH DIFFER, V22, P1935, DOI 10.1038/cdd.2015.99
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu Q, 2016, CALCIFIED TISSUE INT, V99, P500, DOI 10.1007/s00223 016 0173 z
   Luo GM, 2017, AM J TRANSL RES, V9, P2077
   Lv Hao, 2015, Med Sci Monit, V21, P1527, DOI 10.12659/MSM.894323
   Meng YB, 2015, J ORTHOP RES, V33, P957, DOI 10.1002/jor.22884
   Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078 0432.CCR 10 1804
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Tong YX, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858 015 0031 z
   Vimalraj S, 2013, CURR ISSUES MOL BIOL, V15, P7
   Xu Z, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14570
   Yaccoby S, 2010, BRIT J HAEMATOL, V149, P311, DOI 10.1111/j.1365 2141.2010.08141.x
   Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35
   You L, 2014, INT J CLIN EXP PATHO, V7, P7249
   Zhang S, 2016, MOL CELL ENDOCRINOL, V422, P243, DOI 10.1016/j.mce.2015.12.018
   Zhang YQ, 2017, AM J TRANSL RES, V9, P126
   Zhou Mingliang, 2012, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V26, P755
NR 33
TC 28
Z9 33
U1 1
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD DEC
PY 2019
VL 18
IS 6
BP 6536
EP 6544
DI 10.3892/ol.2019.10992
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA KA1RN
UT WOS:000505576300099
PM 31788114
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Gan, K
   Yang, LL
   Xu, LX
   Feng, XK
   Zhang, QD
   Wang, F
   Tan, WF
   Zhang, MJ
AF Gan, Ke
   Yang, Leilei
   Xu, Lingxiao
   Feng, Xiaoke
   Zhang, Qiande
   Wang, Fang
   Tan, Wenfeng
   Zhang, Miaojia
TI Iguratimod (T 614) suppresses RANKL induced osteoclast differentiation
   and migration in RAW264.7 cells via NF κB and MAPK pathways
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Iguratimod; Osteoclast; RANKL; Differentiation; Function; Migrations
ID RHEUMATOID ARTHRITIS; NUCLEAR FACTOR; BONE EROSION; ACTIVATION; DAMAGE;
   PRECURSORS; BLOCKING; FAMILY; ROLES
AB Introduction: Iguratimod (T 614) has been confirmed as a highly efficacious and safe novel disease modifying anti rheumatic drug (DMARD) for rheumatoid arthritis therapy in China and Japan due to its potent anti inflammation effect. Here, we investigate the effects of Iguratimod on osteoclast differentiation, migration and function.
   Methods: The effect of Iguratimod on osteoclastogenesis, migration and bone resorption were assessed by TRAP staining, transwell migration assay and osteologic discs, respectively. Relative expressions of osteoclastic related genes, chemokines and transcription factors were assessed by reverse transcription polymerase chain reaction (RT PCR) and signaling pathways were analyzed by western blotting.
   Results: Iguratimod significantly inhibits osteoclast differentiation, migration and bone resorption in RANKL induced RAW264.7 cell in a dose dependent manner. The expressions of osteoclastic related genes including TRAP, CTSK and CTR were increased in RAW264.7 cell upon RANKL stimulation but were obviously suppressed in the presence of Iguratimod. RANKL induced the expression of chemokines including CCL7, CCL4 and CCL12 and osteoclastic related transcription factors of c Fos, c Jun and NFATc1 could be significantly inhibited by Iguratimod in a dose dependent manner. Western blotting indicated Iguratimod could suppress the activation of MAPKs and NF kappa B pathway in RANKL induced osteoclastogenesis in RAW264.7.
   Conclusions: These findings revealed a directly inhibitory role of Iguratimod on osteoclast formation and function, which is distinct from previous report, suggesting Iguratimod provide a unique therapeutic strategy for RA and especially in light of preventing bone destruction. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Gan, Ke; Yang, Leilei; Xu, Lingxiao; Tan, Wenfeng; Zhang, Miaojia] Nanjing Med Univ, Affiliated Hosp 1, Dept Rheumatol, 300 Guanzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Gan, Ke] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China.
   [Feng, Xiaoke; Zhang, Qiande] Nanjing Med Univ, Integrat Med Inst, 300 Guanzhou Rd,138 Xianling Rd, Nanjing, Jiangsu, Peoples R China.
   [Wang, Fang] Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, 300 Guanzhou Rd, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing University of Chinese Medicine;
   Nanjing Medical University; Nanjing Medical University
RP Tan, WF; Zhang, MJ (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Rheumatol, 300 Guanzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM tw2006@njmu.edu.cn; miaojia_zhang@163.com
OI , Gan/0000 0001 6458 3098
FU National Natural Science Foundation of China (NSFC) [30701129, 30901332,
   81172845, 81273294, 81403240, 81401352]; National Natural Science
   Foundation of Jiangsu Province [BK2011851, BK2012875, BK20140956,
   BK20141021]; special project of clinical medicine from Jiangsu Province
   [BL2013034]; Youth Natural Science Foundation of Nanjing University of
   Chinese Medicine [13XZR12]; Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD); Asia Pacific League of
   Associations for Rheumatology (APLAR); International League of
   Associations for Rheumatology (ILAR)
FX Support for this work was obtained from the National Natural Science
   Foundation of China (NSFC): 30701129 (W.T.), 30901332 (F.W.), 81172845
   (W.T.), 81273294(M.Z.), 81403240 (K.G.), 81401352(L.X), National Natural
   Science Foundation of Jiangsu Province: BK2011851 (W.T.),
   BK2012875(M.Z.), BK20140956(K.G.), BK20141021(L.X.), the special project
   of clinical medicine from Jiangsu Province: BL2013034(M.Z.), the Youth
   Natural Science Foundation of Nanjing University of Chinese Medicine,
   13XZR12(K.G.), a project funded by the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD), and
   scholarship from Asia Pacific League of Associations for Rheumatology
   (APLAR) and International League of Associations for Rheumatology (ILAR)
   (W.T.).
CR Aikawa Y, 2002, INFLAMM RES, V51, P188, DOI 10.1007/PL00000291
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Burmester GR, 2014, NAT REV RHEUMATOL, V10, P77, DOI 10.1038/nrrheum.2013.168
   Cohen G, 2007, ANN RHEUM DIS, V66, P358, DOI 10.1136/ard.2006.057497
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Du F, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2554
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kohno M, 2001, J RHEUMATOL, V28, P2591
   Li JT, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/310628
   Luo Q, 2013, J IMMUNOL, V191, P4969, DOI 10.4049/jimmunol.1300832
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Molenaar ETH, 2004, ARTHRITIS RHEUM, V50, P36, DOI 10.1002/art.11481
   Muller Ladner Ulf, 2002, Curr Rheumatol Rep, V4, P201, DOI 10.1007/s11926 002 0066 1
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis 2013 204573
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 1997, BIOCHEM BIOPH RES CO, V240, P279, DOI 10.1006/bbrc.1997.7404
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   TANAKA K, 1992, ARZNEIMITTEL FORSCH, V42 2, P935
   Tanaka K, 2015, EXPERT REV CLIN IMMU, V11, P565, DOI 10.1586/1744666X.2015.1027151
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   VanderHeijde DMFM, 1995, BRIT J RHEUMATOL, V34, P74
   Wei Y, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/214683
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
NR 30
TC 45
Z9 51
U1 0
U2 39
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUN
PY 2016
VL 35
BP 294
EP 300
DI 10.1016/j.intimp.2016.03.038
PG 7
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA DM2XX
UT WOS:000376212500036
PM 27085680
DA 2025 08 17
ER

PT J
AU Sliwinski, L
   Folwarczna, J
   Janiec, W
   Grynkiewicz, G
   Kuzyk, K
AF Sliwinski, L
   Folwarczna, J
   Janiec, W
   Grynkiewicz, G
   Kuzyk, K
TI Differential effects of genistein, estradiol and raloxifene on rat
   osteoclasts in vitro
SO PHARMACOLOGICAL REPORTS
LA English
DT Article
DE osteoclasts; genistein; estradiol; raloxifene; rat
ID ESTROGEN RECEPTOR ALPHA; TYROSINE KINASE INHIBITORS; BONE LOSS; SOY
   ISOFLAVONES; CELL FORMATION; POSTMENOPAUSAL; BETA; OSTEOPROTEGERIN;
   PHYTOESTROGENS; INTERLEUKIN 6
AB Genistein, a major phytoestrogen of soy, is considered a potential drug for prevention and treatment of postmenopausal osteoporosis. It is not clear whether mechanism of action of genistein on bone turnover is distinct from that of estradiol or raloxifene. The aim of the present study was to investigate the effects of genistein on the fort nation of osteoclasts from neonatal rat bone marrow cells in vitro, and compare them with those of estradiol and raloxifene. Formation of osteoclasts was stimulated by 1,25 dihydroxyvitamin D 3, added to the culture media on the second day after plating, together with genistein ( 10( 8) 10( 1) M), estradiol (10( 10) 10( 7) M) or raloxifene (10( 9) 10( 6) M). The bone marrow cell culture lasted 7 or 9 days. Number of osteoclasts and number of osteoclast "ghosts" (necrotic giant cells) were determined.
   Genistein, estradiol and raloxifene, at some concentrations, decreased the number of osteoclasts after 9 day culture of bone marrow cells. Genistein decreased the number at 10( 8) M because of decreasing the viability of osteoclasts, whereas at 10( 5) M due to attenuation of osteoclast formation. Estradiol decreased the osteoclast number at 10( 9) M due to decreasing their viability, whereas at 10( 8) and 10( 7) M it was the effect of both decreasing the viability and inhibition of the formation. Decreases in the number of osteoclasts caused by raloxifene (10( 9), 10( 8) M) were the effect of decreasing the viability of these cells.
C1 Med Univ Silesia, Dept Pharmacol, PL 41200 Sosnowiec, Poland.
   Pharmaceut Res Inst, PL 01793 Warsaw, Poland.
C3 Medical University of Silesia; Pharmaceutical Research Institute  
   Poland
RP Folwarczna, J (通讯作者)，Med Univ Silesia, Dept Pharmacol, Jagiellonska 4, PL 41200 Sosnowiec, Poland.
EM jfolwarczna@slam.katowice.pl
RI Grynkiewicz, Grzegorz/E 6967 2019
OI Folwarczna, Joanna/0000 0002 4376 2748
CR Albertazzi P, 2002, CLIMACTERIC, V5, P190, DOI 10.1080/713605224
   Amano H, 1998, J BONE MINER RES, V13, P846, DOI 10.1359/jbmr.1998.13.5.846
   Anderson JJB, 1998, P SOC EXP BIOL MED, V217, P345, DOI 10.3181/00379727 217 44243
   Arai Y, 2000, J Epidemiol, V10, P127
   Baker VL, 2000, OBSTET GYNECOL SURV, V55, pS21, DOI 10.1097/00006254 200007001 00001
   Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105
   Blair HC, 1996, J CELL BIOCHEM, V61, P629, DOI 10.1002/(SICI)1097 4644(19960616)61:4<629::AID JCB17>3.0.CO;2 A
   Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309
   Chen XW, 2002, BIOCHEM BIOPH RES CO, V295, P417, DOI 10.1016/S0006 291X(02)00667 8
   Fanti P, 1998, OSTEOPOROSIS INT, V8, P274, DOI 10.1007/s001980050065
   Fitzpatrick LA, 2003, MATURITAS, V44, pS21, DOI 10.1016/S0378 5122(02)00345 6
   Gao YH, 1999, BIOCHEM PHARMACOL, V58, P767, DOI 10.1016/S0006 2952(99)00162 8
   Gao YH, 2000, INT J MOL MED, V5, P261
   Ishimi Y, 1999, ENDOCRINOLOGY, V140, P1893, DOI 10.1210/en.140.4.1893
   Kajiya H, 2000, J CELL PHYSIOL, V183, P83, DOI 10.1002/(SICI)1097 4652(200004)183:1<83::AID JCP10>3.0.CO;2 W
   Li BB, 2003, BIOL PHARM BULL, V26, P780, DOI 10.1248/bpb.26.780
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mei J, 2001, J CLIN ENDOCR METAB, V86, P5217, DOI 10.1210/jc.86.11.5217
   Morabito N, 2002, J BONE MINER RES, V17, P1904, DOI 10.1359/jbmr.2002.17.10.1904
   Pacifici R, 1998, ENDOCRINOLOGY, V139, P2659, DOI 10.1210/en.139.6.2659
   Polkowski K, 2000, Acta Pol Pharm, V57, P135
   Ramalho AC, 2002, EUR CYTOKINE NETW, V13, P39
   Rickard DJ, 2003, J CELL BIOCHEM, V89, P633, DOI 10.1002/jcb.10539
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Saintier D, 2004, J CELL PHYSIOL, V198, P269, DOI 10.1002/jcp.10406
   Schiller C, 1997, ENDOCRINOLOGY, V138, P4567, DOI 10.1210/en.138.11.4567
   Setchell KDR, 2003, AM J CLIN NUTR, V78, p593S, DOI 10.1093/ajcn/78.3.593S
   Somjen D, 2002, J ENDOCRINOL, V173, DOI 10.1677/joe.0.1730415
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Teti A, 1999, J BONE MINER RES, V14, P1251, DOI 10.1359/jbmr.1999.14.7.1251
   Viereck V, 2002, J CELL BIOCHEM, V84, P725, DOI 10.1002/jcb.10087
   Vincent A, 2000, MAYO CLIN PROC, V75, P1174, DOI 10.4065/75.11.1174
   Williams JP, 1998, AM J CLIN NUTR, V68, p1369S, DOI 10.1093/ajcn/68.6.1369S
   Wu XJ, 2003, ENDOCRINOLOGY, V144, P5545, DOI 10.1210/en.2003 0296
   Yamagishi T, 2001, ENDOCRINOLOGY, V142, P3632, DOI 10.1210/en.142.8.3632
NR 35
TC 18
Z9 23
U1 0
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1734 1140
EI 2299 5684
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD MAY JUN
PY 2005
VL 57
IS 3
BP 352
EP 359
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 948UO
UT WOS:000230741400006
PM 15985718
DA 2025 08 17
ER

PT J
AU Piva, R
   Penolazzi, L
   Lambertini, E
   Giordano, S
   Gambari, R
AF Piva, R
   Penolazzi, L
   Lambertini, E
   Giordano, S
   Gambari, R
TI Induction of apoptosis of human primary osteoclasts treated with a
   transcription factor decoy mimicking a promoter region of estrogen
   receptor α
SO APOPTOSIS
LA English
DT Article
DE apoptosis; estrogen receptor alpha; osteoclasts; transcription factor
   decoy
ID BREAST CANCER CELLS; CIS ELEMENT DECOY; BONE RESORPTION; SEX STEROIDS;
   GENE THERAPY; IN VIVO; MECHANISMS; EXPRESSION; TRANSFECTION; CULTURES
AB In this paper we investigated how the increase of human estrogen receptor alfa (ER alpha) gene expression may affect breast, osteoblast and osteoclast cells. Increase of ER alpha expression was obtained by interfering with the activity of a negative transcription factor and by removing it with a short and powerful decoy oligonucleotide (RA4 3') mimicking a region of distal promoter C of ER alpha gene. We provide evidence that this decoy was able to induce apoptosis in osteoclasts, but not in osteoblasts and in breast cancer cells, in an estrogen dependent manner. This effect was associated with increase of the levels of Caspase 3 and Fas receptor. Since ER alpha is important in the transcription of different genes and is involved in several pathological processes, including neoplastic and osteopenic diseases, our findings may be of relevance for a possible new therapeutical approach of such diseases.
C1 Univ Ferrara, Dipartmento Biochim & Biol Mol, I 44100 Ferrara, Italy.
   Univ Ferrara, ER GenTech, I 44100 Ferrara, Italy.
   Univ Ferrara, Interdisciplinary Ctr Study Inflammat, I 44100 Ferrara, Italy.
C3 University of Ferrara; University of Ferrara; University of Ferrara
RP Gambari, R (通讯作者)，Univ Ferrara, Dipartmento Biochim & Biol Mol, Via Fossato Mortara 74, I 44100 Ferrara, Italy.
EM gam@unife.it
RI ; Gambari, Roberto/F 9555 2015
OI Piva, Roberta/0000 0003 2663 6210; Penolazzi,
   Letizia/0000 0002 1293 5087; Gambari, Roberto/0000 0001 9205 6033
CR Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Delmas PD, 1997, NEW ENGL J MED, V336, P558, DOI 10.1056/NEJM199702203360807
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022 1759(86)90368 6
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Fibach E, 2003, BLOOD, V102, P1276, DOI 10.1182/blood 2002 10 3096
   Fox SB, 2004, CLIN CANCER RES, V10, P3521, DOI 10.1158/1078 0432.CCR 03 0461
   Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736
   Harada S, 1997, MOL ENDOCRINOL, V11, P1832, DOI 10.1210/me.11.12.1832
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Hurtado J, 2002, Expert Opin Pharmacother, V3, P521
   Igarashi K, 2004, BONE, V35, P47, DOI 10.1016/j.bone.2004.02.009
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057
   Lambertini E, 2002, BIOCHEM BIOPH RES CO, V292, P761, DOI 10.1006/bbrc.2002.6708
   Lee Y, 1998, J STEROID BIOCHEM, V67, P327, DOI 10.1016/S0960 0760(98)00128 9
   LEVENSON AS, 1994, J STEROID BIOCHEM, V51, P229, DOI 10.1016/0960 0760(94)90035 3
   Maeda K, 2002, HUM PATHOL, V33, P386, DOI 10.1053/hupa.2002.124720
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   Matsuzaki K, 1999, ENDOCRINOLOGY, V140, P925, DOI 10.1210/en.140.2.925
   MAURIZI M, 1983, CELL TISSUE RES, V229, P505
   Moreno JL, 2003, BLOOD, V102, P1078, DOI 10.1182/blood 2002 11 3437
   Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897 894
   Morishita R, 2004, J PHARMACOL SCI, V95, P1, DOI 10.1254/jphs.95.1
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   Osipo C, 2003, J NATL CANCER I, V95, P1597, DOI 10.1093/jnci/djg079
   Penolazzi L, 2000, BBA GENE STRUCT EXPR, V1492, P560, DOI 10.1016/S0167 4781(00)00145 7
   Penolazzi L, 2003, BIOCHEM PHARMACOL, V66, P1189, DOI 10.1016/S0006 2952(03)00470 2
   Piva R, 2002, TECHNOL CANCER RES T, V1, P405, DOI 10.1177/153303460200100512
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Schulte CMS, 2004, BLOOD, V103, P3635, DOI 10.1182/blood 2003 09 3081
   Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076
   Song RXD, 2003, APOPTOSIS, V8, P55, DOI 10.1023/A:1021649019025
   Song RXD, 2001, J NATL CANCER I, V93, P1714, DOI 10.1093/jnci/93.22.1714
   Sooy K, 2002, ENDOCRINOLOGY, V143, P3370, DOI 10.1210/en.2001 211441
   Sudhoff H, 2003, ANN OTO RHINOL LARYN, V112, P780, DOI 10.1177/000348940311200907
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Tomita N, 2004, INT J MOL MED, V13, P629
   VAANANEN HK, 1993, ANN MED, V25, P353, DOI 10.3109/07853899309147297
   van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566
   Villanova I, 1999, J BONE MINER RES, V14, P1867, DOI 10.1359/jbmr.1999.14.11.1867
   Voskaridou E, 2001, BRIT J HAEMATOL, V112, P36, DOI 10.1046/j.1365 2141.2001.02549.x
   Walsh NC, 2004, CURR OPIN RHEUMATOL, V16, P419, DOI 10.1097/01.bor.0000127824.42507.68
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Winding B, 2003, BREAST CANCER RES TR, V78, P205, DOI 10.1023/A:1022943127689
   Wu XJ, 2005, J BONE MINER RES, V20, P107, DOI 10.1359/JBMR.041022
   Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471 4914(02)02340 7
   Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193
NR 52
TC 26
Z9 28
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360 8185
EI 1573 675X
J9 APOPTOSIS
JI Apoptosis
PD OCT
PY 2005
VL 10
IS 5
BP 1079
EP 1094
DI 10.1007/s10495 005 0618 8
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 963HU
UT WOS:000231795700014
PM 16151641
DA 2025 08 17
ER

PT J
AU Colvin, L
   Fallon, M
AF Colvin, L.
   Fallon, M.
TI Challenges in cancer pain management bone pain
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE palliative care; cancer induced bone pain; cancer pain
ID DORSAL HORN NEURONS; NERVE GROWTH FACTOR; MURINE MODEL; SPINAL CORD;
   NEUROCHEMICAL CHANGES; SELECTIVE INHIBITION; SUBSTANCE P; RAT MODEL;
   TUMOR; MECHANISMS
AB Whilst not strictly a neuropathic injury, cancer induced bone pain (CIBP) is a unique state with features of neuropathy and inflammation. Recent work has demonstrated that osteoclasts damage peripheral nerves (peptidergic C fibres and SNS) within trabeculated bone leading to deafferentation, In addition, glia cell activation and neuronal hyperexcitability within the dorsal horn, are all similar to a neuropathy. Gabapentin and carbamazepine (both anti convulsants that modulate neuropathy) are effective at attenuating dorsal horn neuronal excitability and normalizing pain like behaviours in a rat model of CIBP. However alterations in neuroreceptors in the dorsal horn do not mimic neuropathy, rather only dynorphin is upregulated, glia cells are active and hypertrophic and c fos expression is increased post noxious behavioural stimulus. CIBP perhaps illustrates best the complexity of cancer pains. Rarely are they purely neuropathic, inflammatory, ischaemic or visceral but rather a combination. Management is multimodal with radiotherapy, analgesics (opioids, NSAIDs), bisphosphonates, radioisotopes and tumouricidal therapies. The difficulty with opioids relates to efficacy on spontaneous pain at rest and movement  related pain. Potential adjuvants to standard analgesic therapies for CIBP are being explored in clinical trials and include inhibitors of glutamate release. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [Colvin, L.; Fallon, M.] Western Gen Hosp, Dept Anaesthesia Crit Care & Pain Med Palliat Med, St Columbas Hosp Chair Palliat Med, Edinburgh Canc Res Ctr,Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland.
C3 University of Edinburgh
RP Fallon, M (通讯作者)，Western Gen Hosp, Dept Anaesthesia Crit Care & Pain Med Palliat Med, St Columbas Hosp Chair Palliat Med, Edinburgh Canc Res Ctr,Inst Genet & Mol Med, Crewe Rd S, Edinburgh EH4 2XU, Midlothian, Scotland.
EM Marie.Fallon@ed.ac.uk
OI Fallon, Marie/0000 0001 9214 0091; Colvin, Lesley/0000 0002 1563 8600
CR Alarmo EL, 2008, ANN ONCOL, V19, P308, DOI 10.1093/annonc/mdm453
   Allen BJ, 1997, J NEUROSCI, V17, P5921
   Berman HH, 1998, NEUROREPORT, V9, P4179, DOI 10.1097/00001756 199812210 00033
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   BOUHASSIRA D, 1995, NEUROSCIENCE, V69, P931, DOI 10.1016/0306 4522(95)00269 O
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buijs JT, 2007, CLIN EXP METASTAS, V24, P609, DOI 10.1007/s10585 007 9118 2
   Cain DM, 2001, J NEUROSCI, V21, P9367, DOI 10.1523/JNEUROSCI.21 23 09367.2001
   CERVERO F, 1980, BRAIN, V103, P717, DOI 10.1093/brain/103.4.717
   Clohisy D. R., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P293
   Davis KD, 2000, NEUROL RES, V22, P313
   de Wit R, 2001, PAIN, V91, P339, DOI 10.1016/S0304 3959(00)00455 3
   DeLeo JA, 1997, BRAIN RES, V759, P50, DOI 10.1016/S0006 8993(97)00209 6
   Dickenson AH, 2002, BRIT J ANAESTH, V88, P755, DOI 10.1093/bja/88.6.755
   Donovan Rodriguez T, 2005, ANESTHESIOLOGY, V102, P132, DOI 10.1097/00000542 200501000 00022
   DUGGAN AW, 1988, BRAIN RES, V451, P261, DOI 10.1016/0006 8993(88)90771 8
   Eccleston C, 2005, PAIN, V113, P7, DOI 10.1016/j.pain.2004.09.006
   ESTAPE J, 1990, J INT MED RES, V18, P298, DOI 10.1177/030006059001800406
   FUCELLA L, 1974, CLIN PHARMACOL THER, V3, P277
   Gramoun A, 2007, J CELL BIOCHEM, V102, P341, DOI 10.1002/jcb.21296
   Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306 4522(00)00110 X
   Honore P, 2000, Prog Brain Res, V129, P389
   Honore P, 2000, PAIN MED, V1, P303, DOI 10.1046/j.1526 4637.2000.00047.x
   Jimenez Andrade JM, 2007, PAIN, V133, P183, DOI 10.1016/j.pain.2007.06.016
   Khasabov SG, 2007, BRAIN RES, V1180, P7, DOI 10.1016/j.brainres.2007.08.075
   Kidd BL, 2001, BRIT J ANAESTH, V87, P3, DOI 10.1093/bja/87.1.3
   Kinder M, 2008, EXP CELL RES, V314, P173, DOI 10.1016/j.yexcr.2007.09.021
   King T, 2007, PAIN, V132, P154, DOI 10.1016/j.pain.2007.06.026
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Kirschstein T, 1999, J NEUROPHYSIOL, V82, P2853, DOI 10.1152/jn.1999.82.6.2853
   KRISHTAL OA, 1988, NEUROSCIENCE, V27, P995, DOI 10.1016/0306 4522(88)90203 5
   Luger NM, 2005, J PAIN SYMPTOM MANAG, V29, pS32, DOI 10.1016/j.jpainsymman.2005.01.008
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304 3959(02)00102 1
   Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747
   Marceau F, 2004, NAT REV DRUG DISCOV, V3, P845, DOI 10.1038/nrd1522
   Martin CD, 2007, NEUROSCI LETT, V427, P148, DOI 10.1016/j.neulet.2007.08.055
   Mcquay H.J., 2013, Cochrane Database Syst Rev., DOI [DOI 10.1002/14651858.CD001793, 10.1002/14651858.CD001793.PUB2]
   Medhurst S., 2001, British Journal of Pharmacology, V134, p156P
   Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249
   Mercadante S, 2002, EUR J CANCER, V38, P1358, DOI 10.1016/S0959 8049(02)00102 8
   Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304 3959(01)00324 4
   MINOTTI V, 1989, PAIN, V36, P177, DOI 10.1016/0304 3959(89)90021 3
   Minotti V, 1998, PHARMACOTHERAPY, V18, P504
   Nelson JB, 2003, J UROLOGY, V170, pS65, DOI 10.1097/01.ju.0000096372.07687.86
   NELSON JB, 2003, J UROLOGY 2, V170, pS6708
   Peters CM, 2005, EXP NEUROL, V193, P85, DOI 10.1016/j.expneurol.2004.11.028
   Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987 7053(00)00227 6
   Porreca F, 2002, TRENDS NEUROSCI, V25, P319, DOI 10.1016/S0166 2236(02)02157 4
   Price MP, 2002, NEURON, V35, P407, DOI 10.1016/S0896 6273(02)00772 9
   Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896 6273(01)00547 5
   Ross JR, 2003, BMJ BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469
   Sabino M. C., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P561
   Sabino MAC, 2003, INT J CANCER, V104, P550, DOI 10.1002/ijc.10999
   Sabino MAC, 2002, CANCER RES, V62, P7343
   Sato S, 2008, CANCER SCI, V99, P316, DOI 10.1111/j.1349 7006.2007.00690.x
   Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992
   Serafini AN, 2001, J NUCL MED, V42, P895
   Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400
   Sluka KA, 2007, PAIN, V129, P102, DOI 10.1016/j.pain.2006.09.038
   Stambaugh J, 1988, J Clin Pharmacol, V28, pS34
   STAMFORD JA, 1995, BRIT J ANAESTH, V75, P217, DOI 10.1093/bja/75.2.217
   STAQUET MJ, 1989, J CLIN PHARMACOL, V29, P1031, DOI 10.1002/j.1552 4604.1989.tb03274.x
   Sumitani H, 2001, J ORAL PATHOL MED, V30, P41, DOI 10.1034/j.1600 0714.2001.300107.x
   Sunshine A, 1988, J Clin Pharmacol, V28, pS47
   SWETT JE, 1985, J COMP NEUROL, V231, P66, DOI 10.1002/cne.902310106
   Tracey I, 2002, J NEUROSCI, V22, P2748, DOI 10.1523/JNEUROSCI.22 07 02748.2002
   Tsubaki M, 2007, MOL CELL BIOCHEM, V304, P53, DOI 10.1007/s11010 007 9485 7
   Urch C, 2004, PALLIATIVE MED, V18, P267, DOI 10.1191/0269216304pm887ra
   Urch CE, 2003, PAIN, V106, P347, DOI 10.1016/j.pain.2003.08.002
   Vanderah TW, 2001, PAIN, V92, P5, DOI 10.1016/S0304 3959(01)00311 6
   VENTAFRIDDA V, 1974, CLIN PHARMACOL THER, V2, P284
   Voilley Nicolas, 2004, Current Drug Targets   Inflammation and Allergy, V3, P71, DOI 10.2174/1568010043483980
   Wagner R, 1996, NEUROSCIENCE, V73, P625, DOI 10.1016/0306 4522(96)00127 3
   Walker K, 2002, PAIN, V100, P219, DOI 10.1016/S0304 3959(02)00040 4
   WALLEY J, 2006, P NCRI C, P62
   Wang HB, 2005, NEURON, V46, P9, DOI 10.1016/j.neuron.2005.03.011
   Willis W.D., 1991, SENSORY MECH SPINAL, V2nd
   Wong R, 2002, Cochrane Database Syst Rev, pCD002068
   Woolf CJ, 1996, J NEUROSCI, V16, P2716
   Woolf CJ, 2007, ANESTHESIOLOGY, V106, P864, DOI 10.1097/01.anes.0000264769.87038.55
   Yamamoto J, 2008, NEUROSCIENCE, V151, P843, DOI 10.1016/j.neuroscience.2007.11.025
   Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2
NR 82
TC 81
Z9 84
U1 2
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD MAY
PY 2008
VL 44
IS 8
BP 1083
EP 1090
DI 10.1016/j.ejca.2008.03.001
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 318LE
UT WOS:000257092400004
PM 18439817
DA 2025 08 17
ER

PT J
AU Li, RB
   Yuan, XY
   Chen, X
   Ou, YL
   Chen, J
AF Li, Ruibo
   Yuan, Xingyue
   Chen, Xi
   Ou, Yili
   Chen, Jin
TI Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis
   based on FDA adverse event reporting system (FAERS)
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE osteoporosis; Denosumab; adverse drug reactions; pharmacovigilance; FDA
   adverse event reporting system
ID POSTMENOPAUSAL WOMEN; PREVENTION; HYPOCALCEMIA; FRACTURES; PATIENT
AB Objective To comprehensively analyze the ADRs associated with Denosumab (Prolia) in the treatment of osteoporosis using data from the FAERS database, and gain a better understanding of the potential risks and side effects of Denosumab (Prolia) therapy.Methods Data of Denosumab (Prolia) were collected from the FAERS database covering the period from first quarter of 2010 to the third quarter of 2023. Disproportionality analysis was performed by calculating the reporting odds ratios (ROR), proportional reporting ratio (PRR), and Bayesian analysis confidence propagation neural network (BCPNN) to detect positive signals.Results Totally, 17,985,365 reports were collected from the FAERS database, 1,97,807 reports of Denosumab (Prolia) were identified as the "primary suspected (PS)" ADRs. Denosumab (Prolia) induced ADRs occurred in 27 organ systems. 38 significant disproportionality PTs satisfying with the three algorithms were retained at the same time. Unexpected significant ADRs such as bone density abnormal and immobile also occur. The majority of the ADRs occurred within the first 30 days after Denosumab (Prolia) initiation.Conclusion Based on the American FAERS database, the high frequency ADRs of Denosumab (Prolia) were hypocalcaemia, bone density abnormal, eczema, rebound effect, spinal deformity, etc. Clinical use of this drug should focus on this part of ADRs. Attention should also be paid to newly discovered ADRs, such as immobile, menopausal symptoms, etc., to avoid more serious consequences. Cohort studies, more detailed and comprehensive case information, and long term clinical investigations are needed to confirm these results and to further understand the safety profile of Denosumab (Prolia).
C1 [Li, Ruibo; Chen, Xi; Ou, Yili; Chen, Jin] Deyang Peoples Hosp, Dept Orthopaed, Deyang, Sichuan, Peoples R China.
   [Yuan, Xingyue] Deyang PeoplesHospital, Dept Pathol, Deyang, Sichuan, Peoples R China.
RP Li, RB (通讯作者)，Deyang Peoples Hosp, Dept Orthopaed, Deyang, Sichuan, Peoples R China.
EM lirb09@163.com
FU Science and Technology Planning Project of Deyang City [2021SZZ063];
   Xinglin Scholars" Hospital Special Project of Chengdu University of
   Traditional Chinese Medicine [YYZX2022027]
FX The author(s) declare that financial support was received for the
   research, authorship, and/or publication of this article. RL was
   supported by Science and Technology Planning Project of Deyang City
   (2021SZZ063) and "Xinglin Scholars" Hospital Special Project of Chengdu
   University of Traditional Chinese Medicine (YYZX2022027).
CR Caldito NG, 2021, MULT SCLER J, V27, P1066, DOI 10.1177/1352458520949986
   Center J R., 2021, MARCUS FELDMANS OSTE, P669, DOI 10.1016/B978 0 12 813073 5.00028 9
   Cirmi S, 2020, CANCERS, V12, DOI 10.3390/cancers12040826
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Daga Natasha, 2021, Drug Ther Bull, V59, P139, DOI 10.1136/dtb.2021.234508rep
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Huang ST, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1182753
   Huynh ALH, 2016, PHARMACOEPIDEM DR S, V25, P1274, DOI 10.1002/pds.4045
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lewiecki EM, 2012, CLIN PHARMACOL THER, V91, P123, DOI 10.1038/clpt.2011.268
   Lyu HC, 2019, J CLIN ENDOCR METAB, V104, P1753, DOI 10.1210/jc.2018 02236
   Miller PD, 2016, J CLIN ENDOCR METAB, V101, P3163, DOI 10.1210/jc.2016 1801
   Nachankar A, 2022, BMJ CASE REP, V15, DOI 10.1136/bcr 2022 250647
   Oteo Alvaro A, 2023, OSTEOPOROSIS INT, V34, P1799, DOI 10.1007/s00198 023 06838 z
   Pang KL, 2020, DRUG DES DEV THER, V14, P4029, DOI 10.2147/DDDT.S270829
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   Sakaeda T, 2013, INT J MED SCI, V10, P796, DOI 10.7150/ijms.6048
   Sarafrazi N, 2021, NCHS data brief. No 405
   Su S, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1225919
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang LH, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.21106
   Woo EJ, 2014, SPINE J, V14, P560, DOI 10.1016/j.spinee.2013.09.056
   Yin YC, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 23834 1
NR 25
TC 3
Z9 3
U1 7
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 10
PY 2024
VL 15
AR 1358592
DI 10.3389/fphar.2024.1358592
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WD1B4
UT WOS:001252829400001
PM 38915470
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, CF
   Xu, Y
   Han, L
   Wu, WQ
   Lu, XH
AF Wang, Chenfeng
   Xu, Yang
   Han, Lin
   Wu, Weiqing
   Lu, Xuhua
TI Drug discovery in spinal cord injury induced osteoporosis: a text
   mining based study
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Drug discovery; spinal cord injury (SCI); osteoporosis (OP); text mining
ID BONE LOSS; OSTEOCLAST DIFFERENTIATION; MONOCLONAL ANTIBODY; SIGNALING
   PATHWAY; CLAZAKIZUMAB; ALENDRONATE; SCLEROSTIN; PREVENTION; CYTOKINE;
   DISEASE
AB Background: Spinal cord injury (SCI) and osteoporosis (OP) are common diseases in spine surgery, and OP could be the complication of SCI. However, SCI induced OP is a complex pathologic process and drug discovery is limited, which restricts the study in the mechanism and treatment of the disease. This study aims to identify the genes and molecular pathways related to SCI induced OP through computational tools and public datasets, and to explore drug targeting therapy, ultimately preventing the occurrence of OP after SCI.
   Methods: In this study, common genes related to SCI and OP were obtained by text mining, then which conducted the functional analysis. Protein protein interaction (PPI) networks were constructed by STRING online and Cytoscape software. Finally, core genes and potential drugs were performed after undergoing drug gene interaction analysis which also completed functional analysis.
   Results: A total of 371 genes common to ''SCI' and 'OP' were identified by text mining. After functional analysis, 207 significant genes were screened out. Subsequently, PPI analysis yielded 23 genes targetable by 13 drugs which were the candidate to treat SCI induced OP.
   Conclusions: Taken together, siltuximab, olokizumab, clazakizumab and BAN2401 were first discovered to become the potential drugs for the treatment of SCI induced OP. Drug discovery using text mining and pathway analysis is a significant way to investigate the pathomechanism of the disease while exploring existing drugs to treat the disease.
C1 [Wang, Chenfeng; Han, Lin; Wu, Weiqing; Lu, Xuhua] Shanghai Changzheng Hosp, Dept Orthopaed, Shanghai, Peoples R China.
   [Xu, Yang] Xiamen Univ, Dept Orthopaed, Xiamen, Peoples R China.
C3 Naval Medical University; Xiamen University
RP Lu, XH (通讯作者)，Naval Med Univ, Shanghai Changzheng Hosp, Dept Orthopaed, 415 Feng Yang St, Shanghai 200003, Peoples R China.
EM xuhualu@hotmail.com
RI Xu, Yang/AFE 0696 2022; Han, Lin/ABC 9111 2021
OI Han, Lin/0000 0002 3492 8822
FU Research Projects of Shanghai Changzheng Hospital [0910, 2020YCXYJ ZD06]
FX This study was supported by the Research Projects of Shanghai Changzheng
   Hospital (No. 0910 and No. 2020YCXYJ ZD06).
CR Battaglino RA, 2012, CURR OSTEOPOROS REP, V10, P278, DOI 10.1007/s11914 012 0117 0
   Rodriguez Merchan EC, 2019, BLOOD REV, V33, P6, DOI 10.1016/j.blre.2018.05.002
   Chisalita SI, 2017, ORTHOP SURG, V9, P380, DOI 10.1111/os.12358
   Cui S, 2011, J BONE MINER RES, V26, P1084, DOI 10.1002/jbmr.299
   Doberer K, 2021, J AM SOC NEPHROL, V32, P708, DOI 10.1681/ASN.2020071106
   Du P, 2021, INT J MED SCI, V18, P1356, DOI 10.7150/ijms.53564
   Edwards WB, 2018, J BONE MINER RES, V33, P1729, DOI 10.1002/jbmr.3525
   Fu S, 2018, SAUDI J BIOL SCI, V25, P259, DOI 10.1016/j.sjbs.2016.10.019
   Garland DE, 2004, J SPINAL CORD MED, V27, P202, DOI 10.1080/10790268.2004.11753748
   Geusens P, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116209
   Gilchrist NL, 2007, J CLIN ENDOCR METAB, V92, P1385, DOI 10.1210/jc.2006 2013
   Grainger DJ, 1999, OSTEOPOROSIS INT, V9, P398, DOI 10.1007/s001980050163
   Gritti G, 2021, LEUKEMIA, V35, P2710, DOI 10.1038/s41375 021 01299 x
   Gunnarsson AK, 2012, SCAND J SURG, V101, P204, DOI 10.1177/145749691210100311
   Haider IT, 2018, OSTEOPOROSIS INT, V29, P2703, DOI 10.1007/s00198 018 4733 0
   Harmer D, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00788
   Invernizzi M, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00204
   Jiang SD, 2007, OSTEOPOROSIS INT, V18, P339, DOI 10.1007/s00198 006 0229 4
   Jiang SD, 2006, CLIN ENDOCRINOL, V65, P555, DOI 10.1111/j.1365 2265.2006.02683.x
   Kim HJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061467
   Kong FX, 2018, HUM GENE THER, V29, P271, DOI 10.1089/hum.2017.091
   Kretsos K, 2014, CLIN PHARM DRUG DEV, V3, P388, DOI 10.1002/cpdd.121
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lau AG, 2014, HAEMOPHILIA, V20, P716, DOI 10.1111/hae.12399
   Lee KH, 2019, J TRANSL MED, V17, DOI 10.1186/s12967 019 2129 3
   Li HT, 2019, INT J BIOL SCI, V15, P277, DOI 10.7150/ijbs.30348
   Li L, 2016, SCI REP UK, V6, DOI 10.1038/srep32131
   Li R, 2021, BRIEF BIOINFORM, V22, P1279, DOI 10.1093/bib/bbaa300
   Li SF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101683
   Li SF, 2014, BONE, V61, P164, DOI 10.1016/j.bone.2014.01.010
   Lin T, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.28
   Logovinsky V, 2016, ALZHEIMERS RES THER, V8, DOI [10.1186/s13195 016 0181 2, 10.1016/j.trci.2016.01.001]
   Mease PJ, 2016, ARTHRITIS RHEUMATOL, V68, P2163, DOI 10.1002/art.39700
   Metzger CE, 2019, BONE, V120, P465, DOI 10.1016/j.bone.2018.12.007
   Molagoda IMN, 2020, MAR DRUGS, V18, DOI 10.3390/md18090472
   Morse L, 2008, OSTEOPOROSIS INT, V19, P645, DOI 10.1007/s00198 007 0494 x
   Morse LR, 2016, OSTEOPOROSIS INT, V27, P3503, DOI 10.1007/s00198 016 3678 4
   Morse LR, 2013, OSTEOPOROSIS INT, V24, P961, DOI 10.1007/s00198 012 2072 0
   Mukherjee S, 2022, BLOOD ADV, V6, P359, DOI 10.1182/bloodadvances.2021004441
   Nasonov E, 2022, ANN RHEUM DIS, V81, P469, DOI 10.1136/annrheumdis 2021 219876
   Pan JM, 2019, J RECEPT SIG TRANSD, V39, P80, DOI 10.1080/10799893.2019.1625061
   Qin WP, 2015, J BONE MINER RES, V30, P1994, DOI 10.1002/jbmr.2549
   Recht M, 2013, HAEMOPHILIA, V19, P908, DOI 10.1111/hae.12195
   Rofo F, 2021, TRANSL NEURODEGENER, V10, DOI 10.1186/s40035 021 00258 x
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Shams R, 2021, BIOCELL, V45, P1453, DOI 10.32604/biocell.2021.017659
   Sharif Pooneh Salari, 2010, Inflammation & Allergy Drug Targets, V9, P393
   Singh P, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18030972
   Soleyman Jahi S, 2018, EUR SPINE J, V27, P1798, DOI 10.1007/s00586 017 5114 7
   Sroga GE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117046
   Sutor TW, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020608
   Tang CY, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859 020 03662 8
   Taves S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50787 9
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Torres L, 2019, OSTEOPOROSIS INT, V30, P441, DOI 10.1007/s00198 018 4721 4
   Toti P, 2013, ARCH ORAL BIOL, V58, P912, DOI 10.1016/j.archoralbio.2013.02.013
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wu Y, 2021, OSTEOPOROSIS INT, V32, P1117, DOI 10.1007/s00198 020 05807 0
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xie LX, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17196993
   Yao HL, 2018, MOL MED REP, V17, P6681, DOI 10.3892/mmr.2018.8657
   Yu RG, 2021, J HEALTHC ENG, V2021, DOI 10.1155/2021/6674744
   Yu T, 2020, AGING US, V12, P9500, DOI 10.18632/aging.103223
   Zehnder Y, 2004, OSTEOPOROSIS INT, V15, P180, DOI 10.1007/s00198 003 1529 6
   Zhao XL, 2018, EUR J PHARMACOL, V834, P30, DOI 10.1016/j.ejphar.2018.07.009
NR 65
TC 1
Z9 1
U1 0
U2 5
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305 5839
EI 2305 5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD JUL
PY 2022
VL 10
IS 13
AR 733
DI 10.21037/atm 21 6900
PG 12
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 5V2IT
UT WOS:000877059000011
PM 35957736
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jia, F
   Ruan, LF
   Du, CC
   Liu, Y
   Cai, XM
   Dou, R
   Zhang, JY
   Liu, XG
   Chen, J
   Zhang, XC
   Chai, ZF
   Hu, Y
AF Jia, Fei
   Ruan, Lifo
   Du, Chuanchao
   Liu, Yu
   Cai, Xiaomeng
   Dou, Rui
   Zhang, Jiayu
   Liu, Xiaoguang
   Chen, Jun
   Zhang, Xingcai
   Chai, Zhifang
   Hu, Yi
TI The nanoformula of zoledronic acid and calcium carbonate targets
   osteoclasts and reverses osteoporosis
SO BIOMATERIALS
LA English
DT Article
DE Osteoporosis; Osteoclast; pH responsive; Zoledronic acid; Nanomedicines
ID ACUTE PHASE RESPONSE; BONE STRENGTH; DIFFERENTIATION; OVARIECTOMY; RISK;
   TERM; MASS
AB Osteoporosis is known as an imbalance in bone catabolism and anabolism. Overactive bone resorption causes bone mass loss and increased incidence of fragility fractures. Antiresorptive drugs are widely used for osteoporosis treatment, and their inhibitory effects on osteoclasts (OCs) have been well established. However, due to the lack of selectivity, their off target and side effects often bring suffering to patients. Herein, an OCs' microenvironment responsive nanoplatform HA MC/CaCO3/ZOL@PBAE SA (HMCZP) is developed, consisting of succinic anhydride (SA) modified poly(beta amino ester) (PBAE) micelle, calcium carbonate shell, minocyclinemodified hyaluronic acid (HA MC) and zoledronic acid (ZOL). Results indicate that HMCZP, as compared with the first line therapy, could more effectively inhibit the activity of mature OCs and significantly reverse the systemic bone mass loss in ovariectomized mice. In addition, the OCs targeted capacity of HMCZP makes it therapeutically efficient at sites of severe bone mass loss and allows it to reduce the adverse effects of ZOL, such as acute phase reaction. High throughput RNA sequencing (RNA seq) reveals that HMCZP could down regulate a critical osteoporotic target, tartrate resistant acid phosphatase (TRAP), as well as other potential therapeutical targets for osteoporosis. These results suggest that an intelligent nanoplatform targeting OCs is a promising strategy for osteoporosis therapy.
C1 [Jia, Fei; Du, Chuanchao; Liu, Yu; Liu, Xiaoguang] Peking Univ Third Hosp, Dept Orthoped, Beijing 100191, Peoples R China.
   [Jia, Fei; Du, Chuanchao; Liu, Yu; Liu, Xiaoguang] Beijing Key Lab Spinal Dis, Beijing 100191, Peoples R China.
   [Jia, Fei; Du, Chuanchao; Liu, Yu; Liu, Xiaoguang] Engn Res Ctr Bone & Joint Precis Med, Beijing 100191, Peoples R China.
   [Ruan, Lifo; Cai, Xiaomeng; Dou, Rui; Zhang, Jiayu; Chen, Jun; Chai, Zhifang; Hu, Yi] Univ Chinese Acad Sci UCAS, Inst High Energy Phys, Chinese Acad Sci CAS, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.
   [Zhang, Xingcai] Harvard Univ, John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
   [Hu, Yi] Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Beijing 100730, Peoples R China.
C3 Peking University; Chinese Academy of Sciences; Key Laboratory for
   Biological Effects of Nanomaterials & Nanosafety, CAS; Institute of High
   Energy Physics, CAS; Harvard University; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Peking Union Medical College
   Hospital
RP Liu, XG (通讯作者)，Peking Univ Third Hosp, Dept Orthoped, Beijing 100191, Peoples R China.; Liu, XG (通讯作者)，Beijing Key Lab Spinal Dis, Beijing 100191, Peoples R China.; Liu, XG (通讯作者)，Engn Res Ctr Bone & Joint Precis Med, Beijing 100191, Peoples R China.; Chen, J; Hu, Y (通讯作者)，Univ Chinese Acad Sci UCAS, Inst High Energy Phys, Chinese Acad Sci CAS, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.
EM xgliudoctor@163.com; chenjun@ihep.ac.cn; pumch.huyi@hotmail.com
RI Chen, Jun/AAC 9248 2022; zhang, xingcai/AAK 8496 2021; HU,
   YI/L 3309 2016
OI Ruan, Lifu/0000 0002 2126 8183; Chen, Jun/0000 0003 1260 1674
FU National Natural Science Foundation of China [81802686, 21574136,
   11875269]; Beijing Municipal Natural Science Foundation [7192226,
   7212212]; National High Level Hospital Clinical Research Funding
   [2022 PUMCH E 004]; Hundred Talents Program of CAS; Medical Research
   Center of Peking Univer sity Third Hospital
FX This work was supported by the National Natural Science Foundation of
   China (81802686, 21574136, 11875269) , Beijing Municipal Natural Science
   Foundation (7192226, 7212212) , National High Level Hospital Clinical
   Research Funding (2022 PUMCH E 004) , and Hundred Talents Program of CAS
   for financial support. The authors would also like to thank the support
   from the Medical Research Center of Peking Univer sity Third Hospital.
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Amaroli A, 2022, J TISSUE ENG, V13, DOI 10.1177/20417314221110192
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cai C, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01286
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Carey JJ, 2017, BONE, V104, P44, DOI 10.1016/j.bone.2017.05.021
   Chen WJ, 2021, INT J CLIN PHARM TH, V59, P721, DOI 10.5414/CP203987
   Chen YJ, 2011, EUR J APPL PHYSIOL, V111, P1759, DOI 10.1007/s00421 010 1820 0
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Czupalla C, 2006, MOL CELL PROTEOMICS, V5, P134, DOI 10.1074/mcp.M500291 MCP200
   Deckard C, 2017, J BIOL PHYS, V43, P139, DOI 10.1007/s10867 016 9439 y
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Fazliana M, 2009, MATURITAS, V62, P91, DOI 10.1016/j.maturitas.2008.10.004
   Fink HA, 2019, ANN INTERN MED, V171, P37, DOI 10.7326/M19 0533
   Huang X, 2016, MOL MED REP, V13, P613, DOI 10.3892/mmr.2015.4627
   Humphrey MB, 2006, J BONE MINER RES, V21, P237, DOI 10.1359/JBMR.051016
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Khajuria DK, 2015, EUR J PHARM SCI, V66, P173, DOI 10.1016/j.ejps.2014.10.015
   Lee NH, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121025
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li ZR, 2021, BIOACT MATER, V6, P4053, DOI 10.1016/j.bioactmat.2021.04.014
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Lynn DM, 2000, J AM CHEM SOC, V122, P10761, DOI 10.1021/ja0015388
   Mazhab Jafari MT, 2016, NATURE, V539, P118, DOI 10.1038/nature19828
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Negishi Koga T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7637
   Okimoto N, 2020, J BONE MINER METAB, V38, P230, DOI 10.1007/s00774 019 01050 8
   Owen HC, 2012, J BONE MINER RES, V27, P1541, DOI 10.1002/jbmr.1612
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155332
   Parkinson IH, 2012, OSTEOPOROSIS INT, V23, P1957, DOI 10.1007/s00198 011 1832 6
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Piers TM, 2020, FASEB J, V34, P2436, DOI 10.1096/fj.201902447R
   Rahmati M, 2021, J TISSUE ENG, V12, DOI 10.1177/20417314211047100
   Reid IR, 2010, J CLIN ENDOCR METAB, V95, P4380, DOI 10.1210/jc.2010 0597
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   RICO H, 1994, MATURITAS, V18, P183, DOI 10.1016/0378 5122(94)90124 4
   Robinson JI, 2010, ANN RHEUM DIS, V69, P1054, DOI 10.1136/ard.2009.110874
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P249, DOI 10.1007/s00223 013 9750 6
   Rossini M, 2012, J BONE MINER RES, V27, P227, DOI 10.1002/jbmr.521
   Sahara T, 2003, ANAT REC PART A, V270A, P152, DOI 10.1002/ar.a.10020
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Sun KQ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.629968
   Sun ST, 2021, BRIT J PHARMACOL, V178, P2008, DOI 10.1111/bph.15251
   Tsukasaki M, 2020, NAT METAB, V2, DOI 10.1038/s42255 020 00318 y
   TURNER RT, 1987, J BONE MINER RES, V2, P115
   Vaisman DN, 2005, BIOL TRACE ELEM RES, V104, P131, DOI 10.1385/BTER:104:2:131
   Wang TT, 2019, J CLIN INVEST, V129, P3492, DOI 10.1172/JCI130029
   Weng YT, 2021, REDOX BIOL, V40, DOI 10.1016/j.redox.2020.101849
   Wu WJ, 2015, FOOD FUNCT, V6, P3351, DOI 10.1039/c5fo00544b
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yang ZY, 2022, BIOMATERIALS, V283, DOI 10.1016/j.biomaterials.2022.121438
   Yao JH, 2014, COMPUT MED IMAG GRAP, V38, P628, DOI 10.1016/j.compmedimag.2014.04.001
   Zhang CG, 2021, J BONE MINER RES, V36, P567, DOI 10.1002/jbmr.4211
   Zhang Y, 2007, BIOL PHARM BULL, V30, P898, DOI 10.1248/bpb.30.898
   Zhou MX, 2019, NANO LETT, V19, P3671, DOI 10.1021/acs.nanolett.9b00737
   Zhou Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abl6432
   Zhu SP, 2016, J CELL BIOCHEM, V117, P1464, DOI 10.1002/jcb.25442
NR 62
TC 28
Z9 29
U1 14
U2 82
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD MAY
PY 2023
VL 296
AR 122059
DI 10.1016/j.biomaterials.2023.122059
EA FEB 2023
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 9V1XF
UT WOS:000948192700001
PM 36848779
DA 2025 08 17
ER

PT J
AU Kim, YG
   Kim, MO
   Kim, SH
   Kim, HJ
   Pokhrel, NK
   Lee, JH
   Lee, HJ
   Kim, JY
   Lee, Y
AF Kim, Yong Gun
   Kim, Myoung Ok
   Kim, Sung Hyun
   Kim, Hyo Jeong
   Pokhrel, Nitin Kumar
   Lee, Ji Hye
   Lee, Heon Jin
   Kim, Jae Young
   Lee, Youngkyun
TI 6 Shogaol, an active ingredient of ginger, inhibits osteoclastogenesis
   and alveolar bone resorption in ligature induced periodontitis in mice
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE bone resorption; calcium; osteoclasts; periodontitis
ID FACTOR KAPPA B; RECEPTOR ACTIVATOR; OXIDATIVE STRESS; MECHANISMS; RANKL;
   DIFFERENTIATION; CONSTITUENT; EXPRESSION; INDUCTION; CYTOKINES
AB Periodontitis is an inflammatory disease of the tissues surrounding teeth that causes destruction of connective tissues. During the progress of periodontitis, osteoclasts are solely accountable for the resorption of alveolar bones that leads to the loss of teeth if not properly treated. Thus, the development of effective anti resorptive therapies will greatly benefit the treatment of periodontitis patients. In the present study, we suggest an inhibitory effect of 6 shogaol, an ingredient of ginger, on osteoclast differentiation and bone resorption. Mouse bone marrow cells were cultured in the presence of macrophage colony stimulating factor and receptor activator of nuclear factor kappa B ligand (RANKL) to investigate the effect of 6 shogaol on osteoclast differentiation and intracellular signaling pathways. 6 shogaol significantly reduced osteoclast differentiation, actin ring formation, and resorption. In the presence of 6 shogaol, osteoclast signaling including the RANKL induced activation of mitogen activated protein kinases, Ca2+ oscillation, generation of reactive oxygen species, and nuclear factor of activated T cells, cytoplasmic 1 nuclear translocation was significantly inhibited in vitro. Furthermore, a ligature induced periodontitis model in mice was used to determine the role of 6 shogaol in vivo. The administration of 6 shogaol prevented osteoclastogenesis and alveolar bone resorption induced by ligature. Furthermore, the ligature induced number of macrophages and neutrophils as well as the expression of interleukin 1 beta and tumor necrosis factor alpha were considerably lower in the periodontal tissues following shogaol injection. These results confirm the anti osteoclastogenic effect of 6 shogaol and suggest the possibility of application as an anti resorptive strategy in periodontitis.
C1 [Kim, Yong Gun] Kyungpook Natl Univ, Sch Dent, Dept Periodontol, Daegu, South Korea.
   [Kim, Myoung Ok] Kyungpook Natl Univ, Coll Ecol & Environm Sci, Dept Anim Biotechnol, Sangju, South Korea.
   [Kim, Sung Hyun] Korea Polytech Coll, Dept Biomed Anal, Chungnam, South Korea.
   [Kim, Hyo Jeong; Pokhrel, Nitin Kumar; Kim, Jae Young; Lee, Youngkyun] Kyungpook Natl Univ, Sch Dent, Dept Biochem, Daegu, South Korea.
   [Lee, Ji Hye] Pusan Natl Univ, Sch Dent, Dept Oral Pathol, Yangsan, South Korea.
   [Lee, Heon Jin] Kyungpook Natl Univ, Sch Dent, Dept Oral Microbiol, Daegu, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   (KNU); Kyungpook National University (KNU); Pusan National University;
   Pusan National University Hospital; Kyungpook National University (KNU)
RP Lee, Y (通讯作者)，Kyungpook Natl Univ, Sch Dent, 2177 Dalgubeol Daero, Daegu 41940, South Korea.
EM ylec@knu.ac.kr
RI ; LEE, JIHYE/ABG 2265 2021
OI Lee, Youngkyun/0000 0001 9049 6908; Lee, Heon Jin/0000 0002 1911 5014; 
FU National Research Foundation of Korea (NRF, Seoul, Korea)   Ministry of
   Science, ICT, and Future Planning [NRF  2017R1A2B4004618,
   NRF 2017R1A5A2015391]
FX This work was supported by grants from the National Research Foundation
   of Korea (NRF, Seoul, Korea) funded by the Ministry of Science, ICT, and
   Future Planning (Y.L., NRF  2017R1A2B4004618 and NRF 2017R1A5A2015391).
   The authors report no conflicts of interest related to this study.
   Yong Gun Kim, Myoung Ok Kim, and Sung Hyun Kim contributed equally to
   this work. Yong Gun Kim, Myoung Ok Kim, Sung Hyun Kim, and Youngkyun Lee
   designed and performed the experiments, analyzed the data, and wrote the
   paper. Hyo Jeong Kim, Nitin Kumar Pokhrel, and Ji Hye Lee performed
   experiments and analyzed data. Heon Jin Lee and Jae Young Kim analyzed
   the data.
CR Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Baliga MS, 2011, CRIT REV FOOD SCI, V51, P499, DOI 10.1080/10408391003698669
   Bartold PM, 2010, PERIODONTOL 2000, V53, P55, DOI 10.1111/j.1600 0757.2010.00347.x
   Bhattarai S, 2001, J PHARM SCI US, V90, P1658, DOI 10.1002/jps.1116
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Bullon P, 2009, J DENT RES, V88, P503, DOI 10.1177/0022034509337479
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dugasani S, 2010, J ETHNOPHARMACOL, V127, P515, DOI 10.1016/j.jep.2009.10.004
   Fernandes T, 2018, INT J PHARMACEUT, V536, P199, DOI 10.1016/j.ijpharm.2017.11.019
   Garlet GP, 2010, J DENT RES, V89, P1349, DOI 10.1177/0022034510376402
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Joshi D, 2016, DRUG DELIV, V23, P363, DOI 10.3109/10717544.2014.935531
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim MO, 2014, CARCINOGENESIS, V35, P683, DOI 10.1093/carcin/bgt365
   Kim YG, 2015, J DENT RES, V94, P1243, DOI 10.1177/0022034515592592
   Kinane DF., 2017, NAT REV DIS PRIM, V3, P1, DOI DOI 10.1038/NRDP.2017.38
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Kou KR, 2018, FOOD FUNCT, V9, P1310, DOI 10.1039/c7fo01354j
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Linden GJ, 2013, J CLIN PERIODONTOL, V40, pS8, DOI [10.1111/jcpe.12064, 10.1902/jop.2013.1340010]
   Ling H, 2010, BRIT J PHARMACOL, V161, P1763, DOI 10.1111/j.1476 5381.2010.00991.x
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Nibali L, 2016, J CLIN PERIODONTOL, V43, P156, DOI 10.1111/jcpe.12497
   Oliver R C, 1993, Periodontol 2000, V2, P117, DOI 10.1111/j.1600 0757.1993.tb00224.x
   Papapanou P N, 1996, Ann Periodontol, V1, P1, DOI 10.1902/annals.1996.1.1.1
   Park G, 2016, TOXICOL APPL PHARM, V310, P51, DOI 10.1016/j.taap.2016.08.019
   Park JH, 2017, MOL CELLS, V40, P706
   Peng SJ, 2015, FOOD FUNCT, V6, P2813, DOI [10.1039/c5fo00214a, 10.1039/C5FO00214A]
   Preshaw PM, 2018, PERIODONTOL 2000, V76, P131, DOI 10.1111/prd.12148
   Semwal RB, 2015, PHYTOCHEMISTRY, V117, P554, DOI 10.1016/j.phytochem.2015.07.012
   Silva N, 2015, J APPL ORAL SCI, V23, P329
   Sohn Y, 2013, IMMUNOPHARM IMMUNOT, V35, P462, DOI 10.3109/08923973.2013.782318
   Svardstrom G, 1996, J CLIN PERIODONTOL, V23, P1093, DOI 10.1111/j.1600 051X.1996.tb01809.x
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Touaitahuata Heiani, 2014, Small GTPases, V5, pe28119, DOI 10.4161/sgtp.28119
   Townsend EA, 2013, AM J RESP CELL MOL, V48, P157, DOI 10.1165/rcmb.2012 0231OC
NR 41
TC 27
Z9 28
U1 1
U2 50
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD JUN
PY 2020
VL 91
IS 6
BP 809
EP 818
DI 10.1002/JPER.19 0228
EA NOV 2019
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA LZ4BG
UT WOS:000496723100001
PM 31675438
DA 2025 08 17
ER

PT J
AU Lian, CJ
   Wu, ZZ
   Gao, B
   Peng, Y
   Liang, AJ
   Xu, CXX
   Liu, L
   Qiu, XJ
   Huang, JJ
   Zhou, H
   Cai, YF
   Su, PQ
   Huang, DS
AF Lian, Chengjie
   Wu, Zizhao
   Gao, Bo
   Peng, Yan
   Liang, Anjing
   Xu, Caixia
   Liu, Lei
   Qiu, Xianjian
   Huang, Junjun
   Zhou, Hang
   Cai, Yifeng
   Su, Peiqiang
   Huang, Dongsheng
TI Melatonin reversed tumor necrosis factor alpha inhibited osteogenesis of
   human mesenchymal stem cells by stabilizing SMAD1 protein
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Article
DE human mesenchymal stem cells; melatonin; osteogenesis; SMAD1; SMURF1;
   tumor necrosis factor alpha
ID OSTEOBLAST DIFFERENTIATION; TNF ALPHA; SIGNALING PATHWAYS; IN VIVO;
   INFLAMMATORY RESPONSE; BONE HOMEOSTASIS; OSTEOPOROSIS; EXPRESSION;
   DEGRADATION; MECHANISMS
AB Tumor necrosis factor alpha (TNF alpha) plays a pivotal role in inflammation related osteoporosis through the promotion of bone resorption and suppression of bone formation. Numerous drugs have been produced to treat osteoporosis by inhibiting bone resorption, but they offer few benefits to bone formation, which is what is needed by patients with severe bone loss. Melatonin, which can exert both anti inflammatory and pro osteogenic effects, shows promise in overcoming TNF alpha inhibited osteogenesis and deserves further research. This study demonstrated that melatonin rescued TNFa inhibited osteogenesis of human mesenchymal stem cells and that the interactions between SMURF1 and SMAD1 mediated the crosstalk between melatonin signaling and TNFa signaling. Additionally, melatonin treatment was found to downregulate TNF alpha induced SMURF1 expression and then decrease SMURF1 mediated ubiquitination and degradation of SMAD1 protein, leading to steady bone morphogenetic protein SMAD1 signaling activity and restoration of TNFa impaired osteogenesis. Thus, melatonin has prospects for treating osteoporosis caused by inflammatory factors due to its multifaceted functions on regulation of bone formation, bone resorption, and inflammation. Further studies will focus on unveiling the specific mechanisms by which melatonin downregulates SMURF1 expression and confirming the clinical therapeutic value of melatonin in the prevention and therapy of bone loss associated with inflammation.
C1 [Lian, Chengjie; Wu, Zizhao; Gao, Bo; Peng, Yan; Liang, Anjing; Qiu, Xianjian; Huang, Junjun; Huang, Dongsheng] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Guangzhou, Guangdong, Peoples R China.
   [Xu, Caixia] Sun Yat Sen Univ, Affiliated Hosp 1, Res Ctr Translat Med, Guangzhou, Guangdong, Peoples R China.
   [Liu, Lei] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou, Guangdong, Peoples R China.
   [Zhou, Hang; Cai, Yifeng; Su, Peiqiang] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Orthoped, Guangzhou, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Sun Yat Sen University
RP Huang, DS (通讯作者)，Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Guangzhou, Guangdong, Peoples R China.; Su, PQ (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Dept Orthoped, Guangzhou, Guangdong, Peoples R China.
EM supq@mail.sysu.edu.cn; huangdongshen18@hotmail.com
RI ; PENG, YANWEN/AAW 3114 2020; Lian, Cheng/HHS 1095 2022; LIU,
   LEI/AAY 2012 2020
OI LIU, LEI/0000 0003 4898 5665; Lian, Cheng/0000 0002 9016 832X; CHENGJIE,
   LIAN/0000 0001 6600 4141; 
FU National Natural Science Foundation of China [81371907, 81572134]
FX This research was supported by the National Natural Science Foundation
   of China (No. 81371907 and 81572134). We thank LetPub (www.letpub.com)
   for its linguistic assistance during the preparation of this manuscript.
CR Amstrup AK, 2015, J PINEAL RES, V59, P221, DOI 10.1111/jpi.12252
   An R, 2016, BASIC RES CARDIOL, V111, DOI 10.1007/s00395 015 0526 1
   Baum R, 2014, CURR OSTEOPOROS REP, V12, P9, DOI 10.1007/s11914 013 0183 y
   Binkley N, 2012, J BONE MINER RES, V27, P1821, DOI 10.1002/jbmr.1602
   Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871
   Chuffa LGA, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1032 4
   Gao WJ, 2014, J PINEAL RES, V56, P62, DOI 10.1111/jpi.12098
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   Huang RL, 2014, STEM CELLS DEV, V23, P277, DOI 10.1089/scd.2013.0345
   Katsuyama T, 2015, PEPTIDES, V73, P88, DOI 10.1016/j.peptides.2015.09.007
   Kotake S, 2014, BBA GEN SUBJECTS, V1840, P1209, DOI 10.1016/j.bbagen.2013.12.013
   Kotlarczyk MP, 2012, J PINEAL RES, V52, P414, DOI 10.1111/j.1600 079X.2011.00956.x
   Lee HL, 2013, J CELL PHYSIOL, V228, P1076, DOI 10.1002/jcp.24256
   Lim SY, 2015, CURR OPIN RHEUMATOL, V27, P216, DOI 10.1097/BOR.0000000000000169
   Liu XZ, 2013, J PINEAL RES, V55, P14, DOI 10.1111/jpi.12045
   Liu YL, 2011, STEM CELLS, V29, P1804, DOI 10.1002/stem.728
   Luchetti F, 2014, J PINEAL RES, V56, P382, DOI 10.1111/jpi.12133
   Maldonado MD, 2016, J CELL BIOCHEM, V9999, P1
   Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267
   Maraka S, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h3783
   Maria S, 2014, J PINEAL RES, V56, P115, DOI 10.1111/jpi.12116
   Mauriz JL, 2013, J PINEAL RES, V54, P1, DOI 10.1111/j.1600 079X.2012.01014.x
   Mi WX, 2016, FEBS LETT, V590, P396, DOI 10.1002/1873 3468.12064
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   Ortiz F, 2015, J PINEAL RES, V58, P34, DOI 10.1111/jpi.12191
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Park KH, 2011, J PINEAL RES, V51, P187, DOI 10.1111/j.1600 079X.2011.00875.x
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Sánchez A, 2015, INT J MOL SCI, V16, P16981, DOI 10.3390/ijms160816981
   Sang CL, 2016, BONE, V84, P78, DOI 10.1016/j.bone.2015.12.012
   Satomura K, 2007, J PINEAL RES, V42, P231, DOI 10.1111/j.1600 079X.2006.00410.x
   Sethi S, 2010, J PINEAL RES, V49, P222, DOI 10.1111/j.1600 079X.2010.00784.x
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Sullivan CB, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt492
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Zhang LM, 2013, J PINEAL RES, V54, P24, DOI 10.1111/j.1600 079X.2012.01016.x
   Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600 079X.2010.00803.x
   Zhao L, 2011, STEM CELLS, V29, P1601, DOI 10.1002/stem.703
   Zhao L, 2010, J BONE MINER RES, V25, P1246, DOI 10.1002/jbmr.28
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
NR 44
TC 53
Z9 59
U1 0
U2 35
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0742 3098
EI 1600 079X
J9 J PINEAL RES
JI J. Pineal Res.
PD OCT
PY 2016
VL 61
IS 3
BP 317
EP 327
DI 10.1111/jpi.12349
PG 11
WC Endocrinology & Metabolism; Neurosciences; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA DW0QK
UT WOS:000383345900005
PM 27265199
DA 2025 08 17
ER

PT J
AU Zhu, FB
   Wang, JY
   Ni, YM
   Yin, W
   Hou, Q
   Zhang, YL
   Yan, SG
   Quan, RF
AF Zhu, Fangbing
   Wang, Jianyue
   Ni, Yueming
   Yin, Wei
   Hou, Qiao
   Zhang, Yingliang
   Yan, Shigui
   Quan, Renfu
TI Curculigoside Protects against Titanium Particle Induced Osteolysis
   through the Enhancement of Osteoblast Differentiation and Reduction of
   Osteoclast Formation
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID NF KAPPA B; PERIPROSTHETIC OSTEOLYSIS; RANKL/RANK/OPG; ACTIVATION;
   REGISTRY; WEAR
AB Wear particle induced periprosthetic osteolysis is mainly responsible for joint replacement failure and revision surgery. Curculigoside is reported to have bone protective potential, but whether curculigoside attenuates wear particle induced osteolysis remains unclear. In this study, titanium particles (Ti) were used to stimulate osteoblastic MC3T3 E1 cells in the presence or absence of curculigoside, to determine their effect on osteoblast differentiation. Rat osteoclastic bone marrow stromal cells (BMSCs) were cocultured with Ti in the presence or absence of curculigoside, to evaluate its effect on osteoclast formation in vitro. Ti was also used to stimulate mouse calvaria to induce an osteolysis model, and curculigoside was administrated to evaluate its effect in the osteolysis model by micro CT imaging and histopathological analyses. As the results indicated, in MC3T3 E1 cells, curculigoside treatment attenuated the Ti induced inhibition on cell differentiation and apoptosis, increased alkaline phosphatase activity (ALP) and cell mineralization, and inhibited TNF alpha, IL 1 beta, and IL 6 production and ROS generation. In BMSCs, curculigoside treatment suppressed the Ti induced cell formation and suppressed the TNF alpha, IL 1 beta, and IL 6 production and F actin ring formation. In vivo, curculigoside attenuated Ti induced bone loss and histological damage in murine calvaria. Curculigoside treatment also reversed the RANK/RANKL/OPG and NF kappa B signaling pathways, by suppressing the RANKL and NF kappa B expression, while activating the OPG expression. Our study demonstrated that curculigoside treatment was able to attenuate wear particle induced periprosthetic osteolysis in in vivo and in vitro experiments, promoted osteoblastic MC3T3 E1 cell differentiation, and inhibited osteoclast BMSC formation. It suggests that curculigoside may be a potential pharmaceutical agent for wear particle stimulated osteolysis therapy.
C1 [Zhu, Fangbing; Yan, Shigui] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Orthopaed Surg, Hangzhou 310009, Zhejiang, Peoples R China.
   [Zhu, Fangbing; Wang, Jianyue; Hou, Qiao; Zhang, Yingliang; Quan, Renfu] Xiaoshan Tradit Chinese Med Hosp, Dept Orthopaed, Hangzhou 311201, Zhejiang, Peoples R China.
   [Wang, Jianyue; Ni, Yueming; Hou, Qiao; Zhang, Yingliang; Quan, Renfu] Zhejiang Chinese Med Univ, Affiliated Jiangnan Hosp, Dept Orthoped, Hangzhou 311201, Zhejiang, Peoples R China.
   [Yin, Wei] Zhejiang Univ, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang Chinese Medical University; Zhejiang
   University
RP Yan, SG (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Orthopaed Surg, Hangzhou 310009, Zhejiang, Peoples R China.; Quan, RF (通讯作者)，Xiaoshan Tradit Chinese Med Hosp, Dept Orthopaed, Hangzhou 311201, Zhejiang, Peoples R China.; Quan, RF (通讯作者)，Zhejiang Chinese Med Univ, Affiliated Jiangnan Hosp, Dept Orthoped, Hangzhou 311201, Zhejiang, Peoples R China.
EM dabing213@126.com; wangjy3399@aliyun.com; 383159302@qq.com;
   yinwei565l@zju.edu.cn; lanse0603@163.com; 39862676@qq.com;
   zrjwsj@zju.edu.cn; quanrenfu@126.com
RI ; Wang, jianyue/NFT 1111 2025
OI quan, ren fu/0000 0002 2591 0700; 
FU Zhejiang Medicine and Health Science and Technology Plan [2019320455];
   Hangzhou Medical and Health Technology Project [0020190358, 0020190844]
FX The work was supported by the Zhejiang Medicine and Health Science and
   Technology Plan (No. 2019320455) and Hangzhou Medical and Health
   Technology Project (Nos. 0020190358 and 0020190844).
CR Athanasou NA, 2016, BONE JOINT RES, V5, P162, DOI 10.1302/2046 3758.55.BJR 2016 0086
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Ding HM, 2016, INT IMMUNOPHARMACOL, V30, P43, DOI 10.1016/j.intimp.2015.11.026
   Dobzyniak M, 2006, CLIN ORTHOP RELAT R, P76, DOI 10.1097/01.blo.0000203484.90711.52
   Evans JT, 2019, LANCET, V393, P655, DOI 10.1016/S0140 6736(18)32531 5
   Evans JT, 2019, LANCET, V393, P647, DOI 10.1016/S0140 6736(18)31665 9
   Fitzgerald SJ, 2018, J ARTHROPLASTY, V33, P2387, DOI 10.1016/j.arth.2018.03.029
   Ge YW, 2018, INT J MOL MED, V42, P2031, DOI 10.3892/ijmm.2018.3780
   Gu Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.275
   Jiang YP, 2013, ACTA BIOMATER, V9, P7564, DOI 10.1016/j.actbio.2013.03.010
   Learmonth ID, 2007, LANCET, V370, P1508, DOI 10.1016/S0140 6736(07)60457 7
   Lin TH, 2014, ACTA BIOMATER, V10, P1, DOI 10.1016/j.actbio.2013.09.034
   López López JA, 2017, BMJ BRIT MED J, V359, DOI 10.1136/bmj.j4651
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Meng BW, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12874
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Nie Y, 2013, J ETHNOPHARMACOL, V147, P547, DOI 10.1016/j.jep.2013.03.066
   O'Neill SC, 2013, BONE JOINT J, V95B, P1022, DOI 10.1302/0301 620X.95B8.31229
   Prkic A, 2017, ARCH ORTHOP TRAUM SU, V137, P761, DOI 10.1007/s00402 017 2687 x
   Schipper ON, 2017, FOOT ANKLE INT, V38, P351, DOI 10.1177/1071100716682333
   Shen QP, 2013, J PHARM PHARMACOL, V65, P1005, DOI 10.1111/jphp.12054
   Takayanagi Hiroshi, 2007, Clin Calcium, V17, P484
   Tan SR, 2019, MOL MED REP, V19, P2057, DOI 10.3892/mmr.2019.9854
   Thorkildsen R, 2017, J HAND SURG EUR VOL, V42, P310, DOI 10.1177/1753193416674161
   Vertullo CJ, 2018, J BONE JOINT SURG AM, V100, P2033, DOI 10.2106/JBJS.17.01639
   Viswanath AI, 2020, J SHOULDER ELB SURG, V29, P838, DOI 10.1016/j.jse.2019.12.021
   Wang L, 2017, FITOTERAPIA, V117, P109, DOI [10.1016/j.fitote.2017.01.009, 10.1016/j.fitot]
   Wang L, 2016, INFLAMMATION, V39, P218, DOI 10.1007/s10753 015 0241 y
   Wang ZH, 2017, ACTA BIOMATER, V48, P489, DOI 10.1016/j.actbio.2016.11.020
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Xiong LB, 2019, THERANOSTICS, V9, P7140, DOI 10.7150/thno.35988
   Xu H, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5410875
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   Yingjun W., 2020, CHIN J MOD APPL PHAR, V37, P2299
   Zhang QL, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9281481
   Zhou CH, 2018, BRIT J PHARMACOL, V175, P859, DOI 10.1111/bph.14092
NR 37
TC 19
Z9 19
U1 0
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 8861
EI 2314 7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PD JUL 5
PY 2021
VL 2021
AR 5707242
DI 10.1155/2021/5707242
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA TP3RG
UT WOS:000677510400001
PM 34285923
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, LH
   Wei, X
   Li, KM
   Gong, H
   Zhu, LG
   Yang, SF
   Wang, SQ
   Gu, JY
   Chen, M
   Yin, XL
   Zhan, JW
   Feng, MS
   Yu, J
   Sun, W
   Chen, X
AF Li, Linghui
   Wei, Xu
   Li, Kaiming
   Gong, Hao
   Zhu, Liguo
   Yang, Shaofeng
   Wang, Shangquan
   Gu, Jinyu
   Chen, Ming
   Yin, Xunlu
   Zhan, Jiawen
   Feng, Minshan
   Yu, Jie
   Sun, Wu
   Chen, Xin
TI Traditional Chinese Medicine formula Bu Shen Huo Xue Fang (BSHXF)
   protects nucleus pulposus cells against the inflammatory and oxidative
   stress induced degenerative changes
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Nucleus pulposus cells (NPCs); Senescence; Intervertebral disc
   degeneration (IDD); Bu Shen Huo Xue Fang (BSHXF); Aucubin; Tanshinol
ID INTERVERTEBRAL DISC DEGENERATION; INDUCED OSTEOPOROSIS; MOLECULAR BASIS;
   DEGRADATION; SENESCENCE; CARTILAGE; ADAMTS 4; EXTRACT; PROLIFERATION;
   EXPRESSION
AB Degeneration of the intervertebral disc is primarily caused by the loss of nucleus pulposus cells (NPCs) and extracellular matrix (ECM) (IDD). Bu Shen Huo Xue Fang (BSHXF), a traditional Chinese medicine decoction, has been used to treat IDD in clinical; nevertheless, the active components and underlying molecular mechanisms remain unknown. BSHXF improved IL 113 and H2O2 stimulation induced injuries on NPCs by promoting cell viability, increasing ECM deposition, inhibiting cell senescence, and decreasing the levels of inflammatory factors. The active ingredients in BSHXF were identified by LC MS/MS analysis; three active ingredients from the principal drugs, Aucubin, Tanshinol, and Tanshinone II A promoted NPC viability; and Aucubin and Tanshinol promoted NPC viability more. Aucubin and Tanshinol, respectively, improved H2O2 stimulation induced injuries on NPCs by promoting cell viability, increasing ECM deposition, inhibiting cell senescence, and decreasing the levels of inflammatory factors. The activator of NF cB and Wnt signaling pathways attenuated Aucubin and Tanshinol's protective effects by promoting ECM degradation and NPC senescence. Aucubin, Tanshinol, and Tanshinone II A were identified as the most potent compounds in BSHXF protection against degenerative changes in NPCs. The NF cB and Wnt signaling pathways might be involved in the protective effects of Aucubin and Tanshinol against H2O2 induced degenerative changes.
C1 [Li, Linghui; Li, Kaiming; Zhu, Liguo; Yang, Shaofeng; Wang, Shangquan; Gu, Jinyu; Chen, Ming; Yin, Xunlu; Zhan, Jiawen; Feng, Minshan; Yu, Jie; Sun, Wu; Chen, Xin] China Acad Chinese Med Sci, Wangjing Hosp, Dept Gen Orthoped, Huajiadi St, Beijing 100102, Peoples R China.
   [Wei, Xu] China Acad Chinese Med Sci, Wangjing Hosp, Dept Acad Dev, Huajiadi St, Beijing 100102, Peoples R China.
   [Gong, Hao] Changping Hosp Integrated Chinese & Western Med, Dept Orthopaed, 219 Huangping St, Beijing 102208, Peoples R China.
   [Yang, Shaofeng] Hunan Univ Chinese Med, Dept Spine, Hosp 1, Changsha 410007, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Wang Jing Hospital, CACMS;
   China Academy of Chinese Medical Sciences; Wang Jing Hospital, CACMS;
   Hunan University of Chinese Medicine
RP Zhu, LG; Yang, SF (通讯作者)，China Acad Chinese Med Sci, Wangjing Hosp, Dept Gen Orthoped, Huajiadi St, Beijing 100102, Peoples R China.; Yang, SF (通讯作者)，Hunan Univ Chinese Med, Dept Spine, Hosp 1, Changsha 410007, Peoples R China.
EM tcmspine@163.com; spineyangshaofeng@163.com
RI Li, Kaiming/HLG 1748 2023
FU National Natural Science Foundation of China [81904230, 81804120,
   81302992, 81674005]
FX The study was financially supported by the National Natural Science
   Foundation of China (Nos. 81904230, 81804120, 81302992, and 81674005) .
CR Adams MA, 2006, SPINE, V31, P2151, DOI 10.1097/01.brs.0000231761.73859.2c
   Arai F, 2012, J ORTHOP RES, V30, P1478, DOI 10.1002/jor.22095
   Brocker Chad N., 2009, Human Genomics, V4, P43
   Burrage PS, 2006, FRONT BIOSCI LANDMRK, V11, P529, DOI 10.2741/1817
   Chen FP, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 91
   Chen GH, 2017, PLANTA MED, V83, P1264, DOI 10.1055/s 0043 108761
   Cheung KSC, 2009, RHEUMATOL INT, V29, P525, DOI 10.1007/s00296 008 0744 z
   Chung SA, 2003, ORTHOP CLIN N AM, V34, P209, DOI 10.1016/S0030 5898(03)00026 9
   Dai SQ, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5556122
   Dai SQ, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6672978
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   DEYO RA, 1990, ANN INTERN MED, V112, P598, DOI 10.7326/0003 4819 112 8 598
   Ding F, 2013, APOPTOSIS, V18, P777, DOI 10.1007/s10495 013 0839 1
   Ding H, 2023, MATER DESIGN, V225, DOI 10.1016/j.matdes.2022.111493
   Dong WG, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12664
   Dowdell J, 2017, NEUROSURGERY, V80, pS46, DOI 10.1093/neuros/nyw078
   Duan JH, 2023, J ETHNOPHARMACOL, V316, DOI 10.1016/j.jep.2023.116692
   Feng CC, 2016, CELL CYCLE, V15, P1674, DOI 10.1080/15384101.2016.1152433
   Fleming JE Jr, 2000, ORTHOP CLIN N AM, V31, P357, DOI 10.1016/S0030 5898(05)70156 5
   Gopal D, 2012, ADV EXP MED BIOL, V760, P114
   Guo YB, 2014, J ETHNOPHARMACOL, V155, P1401, DOI 10.1016/j.jep.2014.07.058
   Han XY, 2022, J ETHNOPHARMACOL, V291, DOI 10.1016/j.jep.2022.115160
   He Y, 2013, MATRIX BIOL, V32, P143, DOI 10.1016/j.matbio.2012.12.001
   Hiyama A, 2013, GLOB SPINE J, V3, P165, DOI 10.1055/s 0033 1345036
   Hiyama A, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4379
   Hiyama A, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3830
   Hiyama A, 2010, ARTHRITIS RHEUM US, V62, P3036, DOI 10.1002/art.27599
   Holguin N, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29352 3
   Kondo N, 2011, SPINE, V36, pE513, DOI 10.1097/BRS.0b013e3181f52cb5
   Kong Jingbo, 2013, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V27, P1523
   Lai JN, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/697893
   Le Maitre CL, 2007, BIOCHEM SOC T, V35, P652, DOI 10.1042/BST0350652
   Le Maitre CL, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2198
   Li F, 2016, PHARM BIOL, V54, P1857, DOI 10.3109/13880209.2015.1133657
   Li W, 2015, INT IMMUNOPHARMACOL, V28, P382, DOI 10.1016/j.intimp.2015.06.032
   Li Zhi bin, 2009, Zhongguo Gu Shang, V22, P773
   Liu H, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0950 9
   Liu ZC, 2018, ACTA PHARMACOL SIN, V39, P912, DOI 10.1038/aps.2018.36
   Lu H, 2013, EXP THER MED, V6, P684, DOI 10.3892/etm.2013.1223
   Lu JR, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/589846
   Pan YL, 2014, AM J CHINESE MED, V42, P143, DOI 10.1142/S0192415X14500104
   Podichetty VK, 2007, CELL MOL BIOL, V53, P4, DOI 10.1170/T814
   Qi SS, 2019, BIOL TRACE ELEM RES, V187, P172, DOI 10.1007/s12011 018 1362 6
   Rannou F, 2004, AM J PATHOL, V164, P915, DOI 10.1016/S0002 9440(10)63179 3
   Roberts S, 2006, EUR SPINE J, V15, pS312, DOI 10.1007/s00586 006 0126 8
   Shi SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089123
   Song RH, 2007, ARTHRITIS RHEUM US, V56, P575, DOI 10.1002/art.22334
   Sun XW, 2018, PAK J PHARM SCI, V31, P1671
   Tan LJ, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/5154290
   Vergroesen PPA, 2015, OSTEOARTHR CARTILAGE, V23, P1057, DOI 10.1016/j.joca.2015.03.028
   Walker Matthew H, 2004, Spine J, V4, p158S, DOI 10.1016/j.spinee.2004.07.010
   Wang JY, 2016, J ETHNOPHARMACOL, V194, P609, DOI 10.1016/j.jep.2016.10.038
   Wang K, 2019, INT IMMUNOPHARMACOL, V69, P398, DOI 10.1016/j.intimp.2019.01.004
   Wang XB, 2020, MECH AGEING DEV, V190, DOI 10.1016/j.mad.2020.111293
   Wen You Liang, 2014, Zhongguo Gu Shang, V27, P153
   Yang SF, 2019, J CELL BIOCHEM, V120, P19318, DOI 10.1002/jcb.26760
   Yang SF, 2019, J CELL PHYSIOL, V234, P13639, DOI 10.1002/jcp.28044
   Yang YJ, 2018, ACTA PHARMACOL SIN, V39, P633, DOI 10.1038/aps.2017.134
   Yang YJ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1092746
   Zhang C, 2022, J ORTHOP SURG HONG K, V30, DOI 10.1177/10225536221135474
   Zhang F, 2016, INT J MOL MED, V37, P1439, DOI 10.3892/ijmm.2016.2573
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhao CQ, 2007, AGEING RES REV, V6, P247, DOI 10.1016/j.arr.2007.08.001
NR 63
TC 5
Z9 8
U1 3
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0731 7085
EI 1873 264X
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD NOV 30
PY 2023
VL 236
AR 115656
DI 10.1016/j.jpba.2023.115656
EA SEP 2023
PG 13
WC Chemistry, Analytical; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA S9UF0
UT WOS:001074536800001
PM 37688906
DA 2025 08 17
ER

PT J
AU Tomblyn, M
AF Tomblyn, Michael
TI The Role of Bone Seeking Radionuclides in the Palliative Treatment of
   Patients With Painful Osteoblastic Skeletal Metastases
SO CANCER CONTROL
LA English
DT Article
ID REFRACTORY PROSTATE CANCER; PHASE II TRIAL; SYMPTOMATIC OSSEOUS
   METASTASES; EXTERNAL BEAM RADIOTHERAPY; REPEATED SM 153 LEXIDRONAM;
   GROWTH FACTOR BETA; SR 89 THERAPY; BREAST CANCER; DOUBLE BLIND; TARGETED
   THERAPY
AB Background: Pain from skeletal metastases represents a major burden of advanced disease from solid tumors. Analgesic medications, bisphosphonates, hormonal agents, cytotoxic chemotherapy, and external beam radiotherapy are all effective treatments. However, patients often suffer from diffuse painful metastases and respond poorly to these standard therapies. Bone seeking radionuclides can specifically target osteoblastic lesions to offer palliation of pain.
   Methods: This article offers a narrative review of bone seeking radionuclides, examines the evidence of safety and efficacy for the treatment of painful skeletal metastases, and presents guidelines for their appropriate use in this patient population.
   Results: Seven bone seeking radionuclides have shown evidence of both safety and efficacy in reducing pain from diffuse skeletal metastases. Sm 153 EDTMP and Sr 89 are most commonly used in the United States and have been safely utilized for both repeat dosing as well as concurrent dosing with cytotoxic chemotherapy.
   Conclusions: Targeted bone seeking radionuclides are underutilized in the treatment of painful diffuse osteoblastic metastases. Several new agents are in active clinical investigation, and the pending approval of the first alpha emitting radionuclide (Ra 223) may offer a new class of agents that provide greater efficacy and less toxicity than those currently available for routine clinical use.
C1 [Tomblyn, Michael] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL 33612 USA.
C3 H Lee Moffitt Cancer Center & Research Institute; State University
   System of Florida; University of South Florida
RP Tomblyn, M (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM Michael.Tomblyn@moffitt.org
CR [Anonymous], EUR MULT CANC C SEPT
   Ashayeri E, 2002, J NATL MED ASSOC, V94, P706
   ATKINS HL, 1995, J NUCL MED, V36, P725
   Baczyk M, 2007, NUCL MED COMMUN, V28, P245
   BLAKE GM, 1988, J NUCL MED, V29, P549
   Bouchet LG, 2000, J NUCL MED, V41, P682
   Chakraborty S, 2008, CANCER BIOTHER RADIO, V23, P202, DOI 10.1089/cbr.2007.374
   Christensen MH, 2012, CANCER TREAT REV, V38, P164, DOI 10.1016/j.ctrv.2011.05.008
   Cleeland CS, 2000, SEMIN RADIAT ONCOL, V10, P175, DOI 10.1053/srao.2000.6590
   COLLINS C, 1993, J NUCL MED, V34, P1839
   Dafermou A, 2001, EUR J NUCL MED, V28, P788, DOI 10.1007/s002590100533
   Das T, 2009, NUCL MED BIOL, V36, P561, DOI 10.1016/j.nucmedbio.2009.02.002
   deKlerk JMH, 1996, J NUCL MED, V37, P244
   deKlerk JMH, 1997, ANTICANCER RES, V17, P1773
   Dolezal J, 2007, UROL INT, V78, P50, DOI 10.1159/000096935
   Dolezal J, 2000, Nucl Med Rev Cent East Eur, V3, P161
   EARY JF, 1993, J NUCL MED, V34, P1031
   ENGLARO EE, 1992, CLIN NUCL MED, V17, P41, DOI 10.1097/00003072 199201000 00012
   Etchebehere Elba Cristina Sá de Camargo, 2004, Sao Paulo Med. J., V122, P208, DOI 10.1590/S1516 31802004000500006
   Finlay OG, 2005, LANCET ONCOL, V6, P392, DOI 10.1016/S1470 2045(05)70206 0
   Fizazi K, 2009, J CLIN ONCOL, V27, P2429, DOI 10.1200/JCO.2008.18.9811
   Fuster D, 2000, NUCL MED COMMUN, V21, P623, DOI 10.1097/00006231 200007000 00004
   GOECKELER WF, 1986, NUCL MED BIOL, V13, P479
   Gunawardana DH, 2004, CLIN NUCL MED, V29, P81, DOI 10.1097/01.rlu.0000109721.58471.44
   Han SH, 2002, J NUCL MED, V43, P1150
   Henriksen G, 2003, J NUCL MED, V44, P252
   Hicsonmez Ayse, 2010, World J Oncol, V1, P158, DOI 10.4021/wjon235w
   Horvat AG, 2009, RADIOL ONCOL, V43, P213, DOI 10.2478/v10019 009 0038 4
   ICRU International Commission on Radiation Units and Measurements, 1984, 37 ICRU
   Kostenuik PJ, 1997, CLIN EXP METASTAS, V15, P41
   Kraeber Bodéré F, 2000, EUR J NUCL MED, V27, P1487, DOI 10.1007/s002590000315
   Krishnamurthy GT, 1997, J NUCL MED, V38, P230
   KUBAN DA, 1989, J UROLOGY, V141, P572, DOI 10.1016/S0022 5347(17)40897 4
   Lam MGEH, 2008, EUR J NUCL MED MOL I, V35, P756, DOI 10.1007/s00259 007 0659 z
   Lewington VJ, 2005, J NUCL MED, V46, p38S
   Liepe K, 2007, NUCL MED COMMUN, V28, P623, DOI 10.1097/MNM.0b013e32825a6adc
   Liu CJ, 2012, NUCL MED COMMUN, V33, P90, DOI 10.1097/MNM.0b013e32834d3c13
   LUDWIG H, 1982, BRIT J RADIOL, V55, P173, DOI 10.1259/0007 1285 55 651 173
   Lutz S, 2011, INT J RADIAT ONCOL, V79, P965, DOI 10.1016/j.ijrobp.2010.11.026
   Máthé D, 2010, NUCL MED BIOL, V37, P215, DOI 10.1016/j.nucmedbio.2009.09.004
   Menda Y, 2000, CLIN NUCL MED, V25, P698, DOI 10.1097/00003072 200009000 00009
   MERTENS WC, 1993, AM J CLIN ONCOL CANC, V16, P238, DOI 10.1097/00000421 199306000 00009
   Morris MJ, 2009, J CLIN ONCOL, V27, P2436, DOI 10.1200/JCO.2008.20.4164
   MUIR GH, 1994, BRIT J CANCER, V69, P130, DOI 10.1038/bjc.1994.21
   Nilsson S, 2005, CLIN CANCER RES, V11, P4451, DOI 10.1158/1078 0432.CCR 04 2244
   Nilsson S, 2007, LANCET ONCOL, V8, P587, DOI 10.1016/S1470 2045(07)70147 X
   Oosterhof GON, 2003, EUR UROL, V44, P519, DOI 10.1016/S0302 2838(03)00364 6
   Paes Fabio M, 2011, J Support Oncol, V9, P197, DOI 10.1016/j.suponc.2011.06.004
   Paes FM, 2010, SEMIN NUCL MED, V40, P89, DOI 10.1053/j.semnuclmed.2009.10.003
   Palmedo H, 2003, J CLIN ONCOL, V21, P2869, DOI 10.1200/JCO.2003.12.060
   Palmedo H, 2000, EUR J NUCL MED, V27, P123, DOI 10.1007/s002590050017
   Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304 3959(99)00006 8
   PORTER AT, 1993, SEMIN ONCOL, V20, P38
   PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360 3016(93)90309 J
   POULTER CA, 1992, INT J RADIAT ONCOL, V23, P207, DOI 10.1016/0360 3016(92)90563 W
   QUILTY PM, 1994, RADIOTHER ONCOL, V31, P33, DOI 10.1016/0167 8140(94)90411 1
   Rajan R, 1996, PROSTATE, V28, P1, DOI 10.1002/(SICI)1097 0045(199601)28:1<1::AID PROS1>3.0.CO;2 L
   Resche I, 1997, EUR J CANCER, V33, P1583, DOI 10.1016/S0959 8049(97)00155 X
   Figuls MRI, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003347.pub2
   Sapienza Marcelo Tatit, 2004, Rev. Hosp. Clin., V59, P321, DOI 10.1590/S0041 87812004000600003
   Sartor O, 2004, UROLOGY, V63, P940, DOI 10.1016/j.urology.2004.01.034
   Sartor O, 2007, CANCER AM CANCER SOC, V109, P637, DOI 10.1002/cncr.22431
   Sciuto R, 1996, NUCL MED COMMUN, V17, P799, DOI 10.1097/00006231 199609000 00011
   Sciuto R, 2002, J NUCL MED, V43, P79
   Sciuto R, 2001, BREAST CANCER RES TR, V66, P101, DOI 10.1023/A:1010658522847
   Serafini AN, 1998, J CLIN ONCOL, V16, P1574, DOI 10.1200/JCO.1998.16.4.1574
   Silberstein EB, 1993, SEMIN ONCOL S2, V20, P0
   SINGH A, 1989, J NUCL MED, V30, P1814
   Smeland S, 2003, INT J RADIAT ONCOL, V56, P1397, DOI 10.1016/S0360 3016(03)00274 8
   SOLOWAY MS, 1988, CANCER AM CANCER SOC, V61, P195, DOI 10.1002/1097 0142(19880101)61:1<195::AID CNCR2820610133>3.0.CO;2 Y
   Srivastava SC, 1998, CLIN CANCER RES, V4, P61
   Stoll BA., 1983, BONE METASTASES, P1
   TAYLOR AJ, 1994, J NUCL MED, V35, P2054
   Tian JH, 1999, EUR J NUCL MED, V26, P2, DOI 10.1007/s002590050351
   TONG D, 1982, CANCER AM CANCER SOC, V50, P893, DOI 10.1002/1097 0142(19820901)50:5<893::AID CNCR2820500515>3.0.CO;2 Y
   Tu SM, 2009, J CLIN ONCOL, V27, P3319, DOI 10.1200/JCO.2008.20.5393
   Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140 6736(00)03639 4
   Turner SL, 2001, BRIT J CANCER, V84, P297, DOI 10.1054/bjoc.2000.1610
NR 78
TC 43
Z9 48
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1073 2748
J9 CANCER CONTROL
JI Cancer Control
PD APR
PY 2012
VL 19
IS 2
BP 137
EP 144
DI 10.1177/107327481201900208
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 994XV
UT WOS:000307969100008
PM 22487976
OA Bronze
DA 2025 08 17
ER

PT J
AU Sibai, T
   Morgan, EF
   Einhorn, TA
AF Sibai, Tarek
   Morgan, Elise F.
   Einhorn, Thomas A.
TI Anabolic Agents and Bone Quality
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID PARATHYROID HORMONE 1 34; STRONTIUM RANELATE TREATMENT; GROWTH FACTOR I;
   MINERAL DENSITY; POSTMENOPAUSAL WOMEN; INTERMITTENT TREATMENT; VERTEBRAL
   FRACTURES; GH DEFICIENCY; DOUBLE BLIND; ADULT RATS
AB The definition of bone quality is evolving particularly from the perspective of anabolic agents that can enhance not only bone mineral density but also bone microarchitecture, composition, morphology, amount of microdamage, and remodeling dynamics.
   This review summarizes the molecular pathways and physiologic effects of current and potential anabolic drugs.
   From a MEDLINE search (1996 2010), articles were identified by the search terms "bone quality" (1851 articles), "anabolic agent" (5044 articles), "PTH or parathyroid hormone" (32,229 articles), "strontium" or "strontium ranelate" (283 articles), "prostaglandin" (77,539 articles), and "statin" or "statins" (14,233 articles). The search strategy included combining each with the phrase "bone quality." Another more limited search aimed at finding more novel potential agents.
   Parathyroid hormone is the only US Food and Drug Administration approved bone anabolic agent in the United States and has been the most extensively studied in in vitro animal and human trials. Strontium ranelate is approved in Europe but has not undergone Food and Drug Administration trials in the United States. All the studies on prostaglandin agonists have used in vivo animal models and there are no human trials examining prostaglandin agonist effects. The advantages of statins include the long established advantages and safety profile, but they are limited by their bioavailability in bone. Other potential pathways include proline rich tyrosine kinase 2 (PYK2) and sclerostin (SOST) inhibition, among others.
   The ongoing research to enhance the anabolic potential of current agents, identify new agents, and develop better delivery systems will greatly enhance the management of bone quality related injuries and diseases in the future.
C1 [Sibai, Tarek; Einhorn, Thomas A.] Boston Univ, Dept Orthopaed Surg, Med Ctr, Boston, MA 02118 USA.
   [Morgan, Elise F.] Boston Univ, Dept Mech Engn, Boston, MA 02118 USA.
C3 Boston University; Boston University
RP Einhorn, TA (通讯作者)，Boston Univ, Dept Orthopaed Surg, Med Ctr, 720 Harrison Ave,Suite 808, Boston, MA 02118 USA.
EM thomas.einhorn@bmc.org
RI ; Morgan, Elise/L 1706 2013
OI Einhorn, Thomas/0000 0002 5075 4885; 
CR Akhter MP, 2001, BONE, V29, P121, DOI 10.1016/S8756 3282(01)00486 0
   Alkhiary YM, 2004, T ORTHOP RES SOC, V29, P328
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Arlot ME, 2008, J BONE MINER RES, V23, P215, DOI 10.1359/JBMR.071012
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Aubin J. E., 2002, PRINCIPLES BONE BIOL, V1, P59, DOI [10.1016/B978 012098652 1.50106 2, DOI 10.1016/B978 012098652 1.50106 2]
   Bain SD, 2009, OSTEOPOROSIS INT, V20, P1417, DOI 10.1007/s00198 008 0815 8
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2002, EUR J PHARMACOL, V450, P11, DOI 10.1016/S0014 2999(02)02040 X
   Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146
   Benoit DSW, 2006, BIOMATERIALS, V27, P6102, DOI 10.1016/j.biomaterials.2006.06.031
   Blake GM, 2007, J CLIN DENSITOM, V10, P259, DOI 10.1016/j.jocd.2007.03.102
   Bouxsein ML, 2009, J BONE JOINT SURG AM, V91A, P1329, DOI 10.2106/JBJS.H.01030
   Bouxsein ML, 2003, OSTEOPOROSIS INT, V14, pS118, DOI 10.1007/s00198 003 1489 x
   Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104
   Buehler J, 2001, BONE, V29, P176, DOI 10.1016/S8756 3282(01)00484 7
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   DEGERBLAD M, 1995, EUR J ENDOCRINOL, V133, P180, DOI 10.1530/eje.0.1330180
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Dobnig H, 2009, J BONE MINER RES, V24, P1998, DOI [10.1359/JBMR.090527, 10.1359/jbmr.090527]
   Edward B, 2006, PRIMER METABOLIC BON, P90
   Edwards CJ, 2000, LANCET, V355, P2218, DOI 10.1016/S0140 6736(00)02408 9
   Finkelstein Joel S., 1996, P993
   Garrett IR, 2007, J ORTHOP RES, V25, P1351, DOI 10.1002/jor.20391
   Gazzerro Elisabetta, 2006, Expert Rev Endocrinol Metab, V1, P47, DOI 10.1586/17446651.1.1.47
   GHIRON LJ, 1995, J BONE MINER RES, V10, P1844
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Gutierrez GE, 2006, OSTEOPOROSIS INT, V17, P1033, DOI 10.1007/s00198 006 0079 0
   Gutierrez GE, 2008, J BONE MINER RES, V23, P1722, DOI 10.1359/JBMR.080603
   Habermann B, 2010, CALCIFIED TISSUE INT, V86, P82, DOI 10.1007/s00223 009 9317 8
   Hock JM, 1999, J CLIN INVEST, V104, P371, DOI 10.1172/JCI7991
   Hodsman AB, 2003, J CLIN ENDOCR METAB, V88, P5212, DOI 10.1210/jc.2003 030768
   Holzer G, 1999, CLIN ORTHOP RELAT R, P258, DOI 10.1097/00003086 199909000 00033
   Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756 3282(97)00147 6
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Juppner H., 2005, ENDOCRINOLOGY, P1377
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Ke HZ, 1998, BONE, V23, P249, DOI 10.1016/S8756 3282(98)00102 1
   Ke HZ, 2006, J BONE MINER RES, V21, P565, DOI 10.1359/JBMR.051110
   Kneissel M, 2001, BONE, V28, P237, DOI 10.1016/S8756 3282(00)00448 8
   Komatsubara S, 2005, BONE, V36, P678, DOI 10.1016/j.bone.2005.02.002
   Langlois JA, 1998, J CLIN ENDOCR METAB, V83, P4257, DOI 10.1210/jc.83.12.4257
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Li M, 2007, INT ORTHOP, V31, P767, DOI 10.1007/s00264 007 0406 x
   Li M, 2003, J BONE MINER RES, V18, P2033, DOI 10.1359/jbmr.2003.18.11.2033
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Ma YF, 1995, BONE, V17, P549, DOI 10.1016/8756 3282(95)00387 8
   Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marie PJ, 2006, BONE, V38, P10, DOI 10.1016/j.bone.2005.07.029
   Mazziotti G, 2006, J BONE MINER RES, V21, P520, DOI 10.1359/JBMR.060112
   Meunier PJ, 2009, OSTEOPOROSIS INT, V20, P1663, DOI 10.1007/s00198 008 0825 6
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Mundy GR, 1987, OSTEOCLAST ONTOGENY
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Oxlund H, 2001, CALCIFIED TISSUE INT, V69, P299, DOI 10.1007/s00223 001 2027 5
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Raisz LG, 2003, PROSTAG OTH LIPID M, V71, P287, DOI 10.1016/S1098 8823(03)00049 2
   Reginster JY, 2008, ARTHRITIS RHEUM US, V58, P1687, DOI 10.1002/art.23461
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Saraf SK, 2007, INDIAN J EXP BIOL, V45, P444
   Sato M, 2004, J BONE MINER RES, V19, P623, DOI 10.1359/JBMR.040112
   Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004 1211
   Skoglund B, 2002, J BONE MINER RES, V17, P2004, DOI 10.1359/jbmr.2002.17.11.2004
   Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023
   UEDA K, 1980, J PEDIATR US, V97, P834, DOI 10.1016/S0022 3476(80)80282 4
   Watts NB, 2002, J BONE MINER RES, V17, P1148, DOI 10.1359/jbmr.2002.17.7.1148
   Weinreb M, 1999, AM J PHYSIOL ENDOC M, V276, pE376, DOI 10.1152/ajpendo.1999.276.2.E376
   Whitfield JF, 1997, J BONE MINER RES, V12, P1246, DOI 10.1359/jbmr.1997.12.8.1246
   Wüster C, 2001, J BONE MINER RES, V16, P398, DOI 10.1359/jbmr.2001.16.2.398
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   YANG RS, 1993, CALCIFIED TISSUE INT, V52, P57, DOI 10.1007/BF00675627
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 83
TC 46
Z9 53
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 921X
EI 1528 1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD AUG
PY 2011
VL 469
IS 8
BP 2215
EP 2224
DI 10.1007/s11999 010 1722 9
PG 10
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 785ZL
UT WOS:000292271700013
PM 21132409
OA Green Published
DA 2025 08 17
ER

PT J
AU Chien, PG
   Xi, HB
   Pyle, AD
AF Chien, Peggie
   Xi, Haibin
   Pyle, April D.
TI Recapitulating human myogenesis ex vivo using human pluripotent
   stem cells
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE human myogenesis; human pluripotent stem cells; muscle stem and
   progenitor cells; development; cell differentiation
ID HEAVY CHAIN EXPRESSION; WNT SIGNALING CONTROLS; SKELETAL MUSCLE;
   VERTEBRATE MYOGENESIS; PROGENITOR CELLS; PARAXIAL MESODERM;
   GENE EXPRESSION; CLONAL ANALYSIS; SONIC HEDGEHOG; IN VITRO
AB Human pluripotent stem cells (hPSCs) provide a human model for developmental myogenesis, disease modeling and development of therapeutics. Differentiation of hPSCs into muscle stem cells has the potential to provide a cell based therapy for many skeletal muscle wasting diseases. This review describes the current state of hPSCs towards recapitulating human myogenesis ex vivo, considerations of stem cell and progenitor cell state as well as function for future use of hPSC derived muscle cells in regenerative medicine.
C1 [Chien, Peggie; Xi, Haibin; Pyle, April D.] Univ Calif Los Angeles, Mol Biol Inst, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles
RP Pyle, AD (通讯作者)，Univ Calif Los Angeles, 615 Charles E Young Dr,257 BSRB, Los Angeles, CA 90095 USA.
EM apyle@mednet.ucla.edu
OI Chien, Peggie/0000 0002 5285 4177; Pyle, April/0000 0001 6122 1649; Xi,
   Haibin/0000 0002 1265 5704
FU CIRM Quest [DISC2 10695]; NIH NIAMS [R01 AR064327]; UCLA BSCRC/JCCC;
   Ablon Scholars Award; George and Nouhad Ayoub Centennial Chair for Life
   Science Innovation; NIH SBIR; NIAMS [R01 AR064327, F31 AR078640]; Center
   for Duchenne Muscular Dystrophy at UCLA Azrieli Graduate Student Award;
   BSCRC pre doctoral training program; NIH [T32 AR065972]; National
   Institute of Arthritis and Musculoskeletal and Skin Diseases
   [R01AR064327, F31AR078640, T32AR065972] Funding Source: NIH RePORTER
FX Acknowledgements We thank the Eli and Edythe Broad Center of
   Regenerative Medicine and Stem Cell Research (BSCRC) at UCLA. A.D.P. is
   funded by CIRM Quest (DISC2 10695) , NIH NIAMS (R01 AR064327) , UCLA
   BSCRC/JCCC, the Ablon Scholars Award, the George and Nouhad Ayoub
   Centennial Chair for Life Science Innovation, and an NIH SBIR to MyoGene
   Bio. P.C. is funded by NIAMS (F31 AR078640) , the Center for Duchenne
   Muscular Dystrophy at UCLA Azrieli Graduate Student Award, the BSCRC
   pre doctoral training program, and an NIH T32 award (T32 AR065972) .
   H.X. is funded by NIAMS (R01 AR064327) . Fig. 1 was created with
   BioRender.com .
CR Abujarour R, 2014, STEM CELL TRANSL MED, V3, P149, DOI 10.5966/sctm.2013 0095
   Albini S, 2013, CELL REP, V3, P661, DOI 10.1016/j.celrep.2013.02.012
   Alexander MS, 2016, CELL STEM CELL, V19, P800, DOI 10.1016/j.stem.2016.08.006
   Amthor H, 1999, DEVELOPMENT, V126, P1041
   Applebaum Mordechai, 2015, Results Probl Cell Differ, V56, P77, DOI 10.1007/978 3 662 44608 9_4
   Atit R, 2006, DEV BIOL, V296, P164, DOI 10.1016/j.ydbio.2006.04.449
   Aulehla A, 2008, NAT CELL BIOL, V10, P186, DOI 10.1038/ncb1679
   Bachman JF, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.167197
   Bardeen CR, 1901, AM J ANAT, V1, P1, DOI 10.1002/aja.1000010102
   Bardeen CR, 1906, AM J ANAT, V6, P259, DOI 10.1002/aja.1000060108
   Bareja A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090398
   Barruet E, 2020, ELIFE, V9, DOI 10.7554/eLife.51576
   Bénazéraf B, 2013, ANNU REV CELL DEV BI, V29, P1, DOI 10.1146/annurev cellbio 101011 155703
   Biressi S, 2007, DEV BIOL, V308, P281, DOI 10.1016/j.ydbio.2007.06.006
   Biressi S, 2007, DEV BIOL, V304, P633, DOI 10.1016/j.ydbio.2007.01.016
   BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0
   Borchin B, 2013, STEM CELL REP, V1, P620, DOI 10.1016/j.stemcr.2013.10.007
   Borello U, 1999, DEVELOPMENT, V126, P4247
   Borello U, 2006, DEVELOPMENT, V133, P3723, DOI 10.1242/dev.02517
   Brent AE, 2002, CURR OPIN GENET DEV, V12, P548, DOI 10.1016/S0959 437X(02)00339 8
   Bröhl D, 2012, DEV CELL, V23, P469, DOI 10.1016/j.devcel.2012.07.014
   Brunelli S, 2007, DEV BIOL, V304, P604, DOI 10.1016/j.ydbio.2007.01.006
   Buckingham M, 2014, DEV CELL, V28, P225, DOI 10.1016/j.devcel.2013.12.020
   Bukys MA, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101346
   Cao JY, 2020, SCIENCE, V370, P808, DOI 10.1126/science.aba7721
   Castiglioni A, 2014, STEM CELL REP, V2, P560, DOI 10.1016/j.stemcr.2014.03.010
   Castiglioni A, 2014, STEM CELL REP, V2, P92, DOI 10.1016/j.stemcr.2013.12.006
   Chakrabarty A, 2013, WIRES SYST BIOL MED, V5, P181, DOI 10.1002/wsbm.1204
   Chal J, 2015, NAT BIOTECHNOL, V33, P962, DOI 10.1038/nbt.3297
   CHO M, 1993, J CELL BIOL, V121, P795, DOI 10.1083/jcb.121.4.795
   Chu LF, 2019, CELL REP, V28, P2247, DOI 10.1016/j.celrep.2019.07.090
   cihak R., 1972, Ontogenesis of the skeleton and intrinsic muscles of the human hand and foot, V59, P158, DOI [10.1007/978 3 662 09081 7_4, DOI 10.1007/978 3 662 09081 7_4]
   Darabi R, 2012, CELL STEM CELL, V10, P610, DOI 10.1016/j.stem.2012.02.015
   Darabi R, 2011, STEM CELL REV REP, V7, P948, DOI 10.1007/s12015 011 9258 2
   De Micheli AJ, 2020, SKELET MUSCLE, V10, DOI 10.1186/s13395 020 00236 3
   Dequéant ML, 2006, SCIENCE, V314, P1595, DOI 10.1126/science.1133141
   Diaz Cuadros M, 2020, NATURE, V580, P113, DOI 10.1038/s41586 019 1885 9
   Domcke S, 2020, SCIENCE, V370, P809, DOI 10.1126/science.aba7612
   DRAEGER A, 1987, J NEUROL SCI, V81, P19, DOI 10.1016/0022 510X(87)90181 X
   ECOBPRINCE M, 1989, J NEUROL SCI, V91, P71, DOI 10.1016/0022 510X(89)90076 2
   Edom Vovard F, 1999, J CELL SCI, V112, P191
   FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092 8674(94)90009 4
   Fan CM, 1997, DEV BIOL, V191, P160, DOI 10.1006/dbio.1997.8713
   FIDZIANSKA A, 1980, J NEUROPATH EXP NEUR, V39, P476, DOI 10.1097/00005072 198007000 00006
   Garcia SM, 2018, STEM CELL REP, V10, P1160, DOI 10.1016/j.stemcr.2018.01.022
   Gattazzo F, 2020, STEM CELL REP, V15, P597, DOI 10.1016/j.stemcr.2020.07.011
   Ghosh S, 1998, J MUSCLE RES CELL M, V19, P431, DOI 10.1023/A:1005305922537
   Goudenege S, 2012, MOL THER, V20, P2153, DOI 10.1038/mt.2012.188
   Gros J, 2005, NATURE, V435, P954, DOI 10.1038/nature03572
   Guo CE, 2019, GENOME BIOL, V20, DOI 10.1186/s13059 019 1699 y
   Han XP, 2020, NATURE, V581, P303, DOI 10.1038/s41586 020 2157 4
   HAUSCHKA SD, 1974, DEV BIOL, V37, P345, DOI 10.1016/0012 1606(74)90154 7
   HAUSCHKA SD, 1974, DEV BIOL, V37, P329, DOI 10.1016/0012 1606(74)90153 5
   He LW, 2003, ANAT EMBRYOL, V207, P29, DOI 10.1007/s00429 003 0327 4
   Hicks MR, 2018, NAT CELL BIOL, V20, P46, DOI 10.1038/s41556 017 0010 2
   Hubaud A, 2014, NAT REV MOL CELL BIO, V15, P709, DOI 10.1038/nrm3891
   Hutcheson DA, 2009, GENE DEV, V23, P997, DOI 10.1101/gad.1769009
   Imboden S, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85905 z
   JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092 8674(94)90008 6
   Judson RN, 2013, FEBS J, V280, P4100, DOI 10.1111/febs.12370
   Kassar Duchossoy L, 2005, GENE DEV, V19, P1426, DOI 10.1101/gad.345505
   Kim E, 2020, BIOMATERIALS, V248, DOI 10.1016/j.biomaterials.2020.119995
   Kim J, 2017, STEM CELL RES, V23, P87, DOI 10.1016/j.scr.2017.07.013
   Kim TW, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00729
   LEINWAND LA, 1983, P NATL ACAD SCI BIOL, V80, P3716, DOI 10.1073/pnas.80.12.3716
   Lewis WH, 1902, AM J ANAT, V1, P145, DOI 10.1002/aja.1000010204
   Lewis WH, 1910, Manual of Human Embryology, P454
   Linker C, 2005, DEVELOPMENT, V132, P3895, DOI 10.1242/dev.01961
   Loh KM, 2016, CELL, V166, P451, DOI 10.1016/j.cell.2016.06.011
   Maffioletti SM, 2018, CELL REP, V23, P899, DOI 10.1016/j.celrep.2018.03.091
   Martins JMF, 2020, CELL STEM CELL, V26, P172, DOI 10.1016/j.stem.2019.12.007
   MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911
   Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008
   ORAHILLY R, 1975, ANAT EMBRYOL, V148, P1, DOI 10.1007/BF00315559
   Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092 8674(00)81291 X
   Rao LJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02636 4
   Rao LJ, 2012, STEM CELL REV REP, V8, P1109, DOI 10.1007/s12015 012 9413 4
   Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594
   Relaix F, 2004, GENE DEV, V18, P1088, DOI 10.1101/gad.301004
   Rios AC, 2011, NATURE, V473, P532, DOI 10.1038/nature09970
   Rubenstein AB, 2020, SCI REP UK, V10, DOI 10.1038/s41598 019 57110 6
   Saga Y, 2012, CURR OPIN GENET DEV, V22, P331, DOI 10.1016/j.gde.2012.05.004
   Sambasivan R, 2007, SEMIN CELL DEV BIOL, V18, P870, DOI 10.1016/j.semcdb.2007.09.013
   Schiaffino S, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395 015 0046 6
   Shelton M, 2014, STEM CELL REP, V3, P516, DOI 10.1016/j.stemcr.2014.07.001
   Shi XZ, 2006, GENE DEV, V20, P1692, DOI 10.1101/gad.1419406
   Sturgeon CM, 2014, NAT BIOTECHNOL, V32, P554, DOI 10.1038/nbt.2915
   Tajbakhsh S, 1997, CURR OPIN GENET DEV, V7, P634, DOI 10.1016/S0959 437X(97)80011 1
   Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155
   Tanaka A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061540
   Tedesco FS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003541
   Tey SR, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00284
   Tierney MT, 2016, CELL REP, V14, P1940, DOI 10.1016/j.celrep.2016.01.072
   Tintignac LA, 2015, PHYSIOL REV, V95, P809, DOI 10.1152/physrev.00033.2014
   Tzouanacou E, 2009, DEV CELL, V17, P365, DOI 10.1016/j.devcel.2009.08.002
   Uezumi A, 2016, STEM CELL REP, V7, P263, DOI 10.1016/j.stemcr.2016.07.004
   Umeda K, 2012, SCI REP UK, V2, DOI 10.1038/srep00455
   von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008
   WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0
   White RB, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471 213X 10 21
   Xi HB, 2020, CELL STEM CELL, V27, P158, DOI [10.1016/j.stem.2020.04.017, 10.1016/j.stem.2020.06.006]
   Xi HB, 2017, CELL REP, V18, P1573, DOI 10.1016/j.celrep.2017.01.040
   Xu C, 2013, CELL, V155, P909, DOI 10.1016/j.cell.2013.10.023
   Xu XT, 2015, STEM CELL REP, V5, P419, DOI 10.1016/j.stemcr.2015.07.016
   Yeo GHT, 2020, CELL STEM CELL, V26, P938, DOI 10.1016/j.stem.2020.04.020
   Young CS, 2016, CELL STEM CELL, V18, P533, DOI 10.1016/j.stem.2016.01.021
   Zhao MM, 2020, STEM CELL REP, V15, P80, DOI 10.1016/j.stemcr.2020.06.004
NR 107
TC 3
Z9 3
U1 0
U2 11
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD FEB 15
PY 2022
VL 411
IS 2
AR 112990
DI 10.1016/j.yexcr.2021.112990
EA JAN 2022
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 0J6DX
UT WOS:000780194500002
PM 34973262
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU D'Souza, S
   Kurihara, N
   Shiozawa, Y
   Joseph, J
   Taichman, R
   Galson, DL
   Roodman, GD
AF D'Souza, Sonia
   Kurihara, Noriyoshi
   Shiozawa, Yusuke
   Joseph, Jeena
   Taichman, Russell
   Galson, Deborah L.
   Roodman, G. David
TI Annexin II interactions with the annexin II receptor enhance multiple
   myeloma cell adhesion and growth in the bone marrow microenvironment
SO BLOOD
LA English
DT Article
ID INCREASES OSTEOCLAST FORMATION; BINDING PROTEINS; EXPRESSION; THERAPY;
   BIOLOGY; CLONING
AB Multiple myeloma (MM) is an incurable B cell malignancy in which the marrow microenvironment plays a critical role in our inability to cure MM. Marrow stromal cells in the microenvironment support homing, lodging, and growth of MM cells through activation of multiple signaling pathways in both MM and stromal cells. Recently, we identified annexin II (AXII) as a previously unknown factor produced by stromal cells and osteoclasts (OCL) that is involved in OCL formation, HSC and prostate cancer (PCa) homing to the BM as well as mobilization of HSC and PCa cells. AXII expressed on stromal cells supports PCa cell lodgment via the AXII receptor (AXIIR) on PCa cells, but the role of AXII and AXIIR in MM is unknown. In this study, we show that MM cells express AXIIR, that stromal/osteoblast derived AXII facilitates adhesion of MM cells to stromal cells via AXIIR, and OCL derived AXII enhances MM cell growth. Finally, we demonstrate that AXII activates the ERK1/2 and AKT pathways in MM cells to enhance MM cell growth. These results demonstrate that AXII and AXIIR play important roles in MM and that targeting the AXII/AXIIR axis may be a novel therapeutic approach for MM. (Blood. 2012; 119(8):1888 1896)
C1 [Roodman, G. David] Univ Pittsburgh, Sch Med, UPMC,Div Hematol Oncol & Bone, VA Healthcare Syst,Univ Dr C,Med Ctr,Dept Med,Bio, Pittsburgh, PA 15240 USA.
   [Shiozawa, Yusuke; Joseph, Jeena; Taichman, Russell] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; University of Michigan System; University of Michigan
RP Roodman, GD (通讯作者)，Univ Pittsburgh, Sch Med, UPMC,Div Hematol Oncol & Bone, VA Healthcare Syst,Univ Dr C,Med Ctr,Dept Med,Bio, R&D 151U, Pittsburgh, PA 15240 USA.
EM roodmangd@upmc.edu
RI ; Taichman, Russell/NOF 9711 2025; Galson, Deborah/E 9370 2010
OI Galson, Deborah L./0000 0002 2045 8807; Taichman, Russell
   S./0000 0002 7890 0020; 
FU National Institutes of Health [R21 CA141426]; National Cancer Institute
   [P01CA093900] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health grant R21
   CA141426.
CR Bao HY, 2009, INT J HEMATOL, V90, P177, DOI 10.1007/s12185 009 0356 8
   Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood 2002 01 0008
   Etienne Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Greenstein S, 2003, EXP HEMATOL, V31, P271, DOI 10.1016/S0301 472X(03)00023 7
   HAJJAR KA, 1994, J BIOL CHEM, V269, P21191
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood 2004 01 0037
   Jung YH, 2007, BLOOD, V110, P82, DOI 10.1182/blood 2006 05 021352
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Li FH, 2005, J BONE MINER RES, V20, P1161, DOI 10.1359/JBMR.050207
   Lu GW, 2006, J BIOL CHEM, V281, P30542, DOI 10.1074/jbc.M607072200
   Menaa C, 1999, J CLIN INVEST, V103, P1605, DOI 10.1172/JCI6374
   Moss SE, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 4 219
   RAYNAL P, 1994, BBA REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304 4157(94)90019 1
   Rescher U, 2004, J CELL SCI, V117, P2631, DOI 10.1242/jcs.01245
   Shiozawa Y, 2008, J CELL BIOCHEM, V105, P370, DOI 10.1002/jcb.21835
   SUAREZ F, 1993, J BONE MINER RES, V8, P1201
   TAKAHASHI S, 1994, J BIOL CHEM, V269, P28696
   WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592
   Zhou JB, 2005, FRONT BIOSCI LANDMRK, V10, P1581, DOI 10.2741/1642
NR 19
TC 63
Z9 64
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006 4971
J9 BLOOD
JI Blood
PD FEB 23
PY 2012
VL 119
IS 8
BP 1888
EP 1896
DI 10.1182/blood 2011 11 393348
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 898CU
UT WOS:000300713800017
PM 22223826
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Infante, A
   Gener, B
   Vázquez, M
   Olivares, N
   Arrieta, A
   Grau, G
   Llano, I
   Madero, L
   Bueno, AM
   Sagastizabal, B
   Gerovska, D
   Araúzo Bravo, MJ
   Astigarraga, I
   Rodríguez, CI
AF Infante, Arantza
   Gener, Blanca
   Vazquez, Miguel
   Olivares, Nerea
   Arrieta, Arantza
   Grau, Gema
   Llano, Isabel
   Madero, Luis
   Bueno, Ana Maria
   Sagastizabal, Belen
   Gerovska, Daniela
   Arauzo Bravo, Marcos J.
   Astigarraga, Itziar
   Rodriguez, Clara I.
TI Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta
   eliciting a pro osteogenic paracrine response: TERCELOI clinical trial
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Article
DE cell therapy; mesenchymal stem cell; paracrine mechanism of action;
   regenerative medicine
ID MESENCHYMAL STEM CELLS; QUALITY OF LIFE; RNA SEQ EXPERIMENTS; TRABECULAR
   BONE; STROMAL CELLS; EXPRESSION ANALYSIS; HELICAL DOMAIN; CHILDREN;
   MARROW; PAIN
AB Background Osteogenesis imperfecta (OI) is a rare genetic disease characterized by bone fragility, with a wide range in the severity of clinical manifestations. The majority of cases are due to mutations in the COL1A1 or COL1A2 genes, which encode type I collagen. Mesenchymal stem cells (MSCs), as the progenitors of the osteoblasts, the main type I collagen secreting cell type in the bone, have been proposed and tested as an innovative therapy for OI with promising but transient outcomes.
   Methods To overcome the short term effect of MSCs therapy, we performed a phase I clinical trial based on reiterative infusions of histocompatible MSCs, administered in a 2.5 year period, in two pediatric patients affected by severe and moderate OI. The aim of this study was to assess the safety and effectiveness of this cell therapy in nonimmunosuppressed OI patients. The host response to MSCs was studied by analyzing the sera from OI patients, collected before, during, and after the cell therapy.
   Results We first demonstrated that the sequential administration of MSCs was safe and improved the bone parameters and quality of life of OI patients along the cell treatment plus 2 year follow up period. Moreover, the study of the mechanism of action indicated that MSCs therapy elicited a pro osteogenic paracrine response in patients, especially noticeable in the patient affected by severe OI.
   Conclusions Our results demonstrate the feasibility and potential of reiterative MSCs infusion for two pediatric OI and highlight the paracrine response shown by patients as a consequence of MSCs treatment.
C1 [Infante, Arantza; Gener, Blanca; Rodriguez, Clara I.] Cruces Univ Hosp, Biocruces Bizkaia Hlth Res Inst, Stem Cells & Cell Therapy Lab, Baracaldo 48903, Spain.
   [Gener, Blanca; Llano, Isabel] Cruces Univ Hosp, Serv Genet, Baracaldo, Spain.
   [Vazquez, Miguel; Grau, Gema; Astigarraga, Itziar] Cruces Univ Hosp, Biocruces Bizkaia Hlth Res Inst, Dept Pediat, Baracaldo, Spain.
   [Olivares, Nerea; Arrieta, Arantza] Cruces Univ Hosp, Dept Biochem, Immunol Unit, Baracaldo, Spain.
   [Madero, Luis] Nino Jesus Univ, Childrents Hosp, Dept Pediat Hematol Oncol & Stem Cells, Madrid, Spain.
   [Bueno, Ana Maria] Getafe Univ Hosp, Dept Orthoped Surg, Madrid, Spain.
   [Sagastizabal, Belen] Getafe Univ Hosp, Dept Endocrinol, Madrid, Spain.
   [Gerovska, Daniela; Arauzo Bravo, Marcos J.] Biodonostia Hlth Res Inst, Computat Biol & Syst Biomed Res Grp, Donostia San Sebastian, Spain.
   [Astigarraga, Itziar] Basque Country Univ UPV EHU, Dept Pediat, Leioa, Spain.
C3 Hospital Universitario Cruces; Hospital Universitario Cruces; Hospital
   Universitario Cruces; Hospital Universitario Cruces; Hospital
   Universitario de Getafe; Hospital Universitario de Getafe; Instituto de
   Investigacion Sanitaria Biogipuzkoa; University of Basque Country
RP Rodríguez, CI (通讯作者)，Cruces Univ Hosp, Biocruces Bizkaia Hlth Res Inst, Stem Cells & Cell Therapy Lab, Baracaldo 48903, Spain.
EM cirodriguez@osakidetza.eus
RI Gerovska, Daniela/B 6931 2018; Rodriguez, Clara I/E 5402 2012; Marcos,
   Arauzo Bravo/A 1706 2011; Astigarraga, Itziar/I 1215 2014; Rodríguez,
   Clara/E 5402 2012; Astigarraga, I/I 1215 2014
OI Gerovska, Daniela/0000 0003 0671 4277; Rodriguez, Clara
   I/0000 0002 6749 6288; Astigarraga, Itziar/0000 0002 5012 0137; Infante,
   Arantza/0000 0002 1625 2865
FU Spanish Ministry of Health [EC10 219]; Instituto de Salud Carlos III
   (European Regional Development Fund; "A way to make Europe")
   [PI15/00820]; Bioef EiTB maratoia [BIO14/TP/007]; AHUCE Foundation
FX We are grateful to the patients affected by OI and their families, and
   to the AHUCE Foundation, especially to its director Ms Julia Piniella,
   for the support during the clinical trial. We also thank Dr ME
   Fernandez Santos (GM Cell Production Unit, IiSGM) for her expertise in
   the cell production, Jose Ignacio Pijoan Zubizarreta (Clinical
   Epidemiology Unit of Cruces University Hospital) for the overall support
   provided to the project, and Natale Imaz (Biocruces Bizkaia Health
   Research Institute) for providing the data and safety monitoring of the
   clinical trial. We are indebted to all the health professionals from
   Cruces University Hospital, especially to the Pediatric Intensive Care
   Unit for their participation. This study was funded by the Spanish
   Ministry of Health through the call for independent clinical trials
   projects "EC10 219," Instituto de Salud Carlos III through the project
   "PI15/00820" (Co funded by European Regional Development Fund; "A way to
   make Europe"), Bioef EiTB maratoia (BIO14/TP/007), and the AHUCE
   Foundation.
CR Alberich Bayarri A, 2014, RADIOLOGIA MADRID, V56, P27, DOI 10.1016/j.rx.2013.06.001
   Alberich Bayarri A, 2008, AM J ROENTGENOL, V191, P721, DOI 10.2214/AJR.07.3528
   Alberich Bayarri A, 2010, MED PHYS, V37, P4930, DOI 10.1118/1.3481509
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Ben Amor IM, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/540178
   Boberg E, 2020, STEM CELL TRANSL MED, V9, P1190, DOI 10.1002/sctm.20 0099
   Cabral WA, 2004, AM J HUM GENET, V74, P752, DOI 10.1086/383252
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   Clines GA, 2011, J BONE MINER RES, V26, P2523, DOI 10.1002/jbmr.450
   DELRIO LD, 1994, PEDIATR RES, V35, P362, DOI 10.1203/00006450 199403000 00018
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Flowers S, 2009, J BIOL CHEM, V284, P10067, DOI 10.1074/jbc.M808782200
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Garganta MD, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 2252 y
   Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002
   Götherström C, 2014, STEM CELL TRANSL MED, V3, P255, DOI 10.5966/sctm.2013 0090
   Gregory P, 2005, BONE, V37, P139, DOI 10.1016/j.bone.2005.04.015
   Guntur AR, 2018, J BONE MINER RES, V33, P1052, DOI 10.1002/jbmr.3390
   Horowitz AM, 2020, SCIENCE, V369, P167, DOI 10.1126/science.aaw2622
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Infante A, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.265
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736
   Jones GN, 2012, STEM CELL TRANSL MED, V1, P70, DOI 10.5966/sctm.2011 0007
   Kang H, 2017, TRANSL RES, V181, P27, DOI 10.1016/j.trsl.2016.11.005
   Kocijan R, 2016, J CLIN ENDOCR METAB, V101, P4125, DOI 10.1210/jc.2016 2365
   Ladang A, 2020, CALCIFIED TISSUE INT, V106, P239, DOI 10.1007/s00223 019 00628 8
   Le Blanc K, 2005, TRANSPLANTATION, V79, P1607, DOI 10.1097/01.TP.0000159029.48678.93
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp100]
   Lindahl K, 2015, EUR J HUM GENET, V23, P1112, DOI 10.1038/ejhg.2015.129
   Liu SY, 2015, CELL METAB, V22, P606, DOI 10.1016/j.cmet.2015.08.018
   Maioli M, 2019, EUR J HUM GENET, V27, P1090, DOI 10.1038/s41431 019 0373 x
   Marini JC, 2007, HUM MUTAT, V28, P209, DOI 10.1002/humu.20429
   Marini JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.52
   Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200
   Martin I, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat2189
   Martin Rufino JD, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0901 6
   McGrath PJ, 2008, J PAIN, V9, P771, DOI 10.1016/j.jpain.2008.04.007
   Moosa S, 2016, CLIN GENET, V89, P517, DOI 10.1111/cge.12678
   Munir S, 2020, EMBO REP, V21, DOI 10.15252/embr.201948777
   O'Keefe RJ, 2020, J BONE MINER RES, V35, P3, DOI 10.1002/jbmr.3839
   Otsuru S, 2018, CYTOTHERAPY, V20, P62, DOI 10.1016/j.jcyt.2017.09.012
   Otsuru S, 2012, BLOOD, V120, P1933, DOI 10.1182/blood 2011 12 400085
   PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857
   Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140 6736(04)16051 0
   Rauch F, 2015, AM J HUM GENET, V96, P425, DOI 10.1016/j.ajhg.2014.12.027
   Rauch F, 2010, EUR J HUM GENET, V18, P642, DOI 10.1038/ejhg.2009.242
   Riordan NH, 2019, STEM CELL TRANSL MED, V8, P1008, DOI 10.1002/sctm.19 0010
   Rossi V, 2019, CURR OPIN PEDIATR, V31, P708, DOI 10.1097/MOP.0000000000000813
   Shoucri BM, 2017, ENDOCRINOLOGY, V158, P3109, DOI 10.1210/en.2017 00348
   Soifer HS, 2007, MOL THER, V15, P2070, DOI 10.1038/sj.mt.6300311
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Tsimicalis A, 2018, EUR J PEDIATR, V177, P891, DOI 10.1007/s00431 018 3127 9
   van de Peppel J, 2017, STEM CELL REP, V8, P947, DOI 10.1016/j.stemcr.2017.02.018
   Vanz AP, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887 018 1077 z
   Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650 200108000 00006
   von Schroeder HP, 2003, BONE, V33, P673, DOI 10.1016/S8756 3282(03)00215 1
   Wang ZQ, 2012, INTRACTABLE RARE DIS, V1, P81, DOI 10.5582/irdr.2012.v1.2.81
   Zack P, 2005, ACTA PAEDIATR, V94, P1238, DOI 10.1080/08035250510028722
   Zarecki P, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115105
NR 65
TC 35
Z9 39
U1 1
U2 11
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2001 1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD JAN
PY 2021
VL 11
IS 1
AR e265
DI 10.1002/ctm2.265
PG 23
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA PV3GH
UT WOS:000609878700003
PM 33463067
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gu, DR
   Yang, H
   Kim, SC
   Hwang, YH
   Ha, H
AF Gu, Dong Ryun
   Yang, Hyun
   Kim, Seong Cheol
   Hwang, Youn Hwan
   Ha, Hyunil
TI Water Extract of Piper longum Linn Ameliorates
   Ovariectomy Induced Bone Loss by Inhibiting Osteoclast Differentiation
SO NUTRIENTS
LA English
DT Article
DE Piper longum Linn; osteoporosis; ovariectomy; osteoclast
ID COLONY STIMULATING FACTOR; RANKL; ALKALOIDS; MICE; ACTIVATION;
   EXPRESSION; INDUCTION; FUSION; LIGAND; INJURY
AB Piper longum linn has traditionally been used for the treatment of respiratory and gastrointestinal disorders in India. Although various pharmacological effects of P. longum have been studied, its effects on bone have not been clearly elucidated. Therefore, this study examined the inhibitory effect of the water extract of P. longum Linn (WEPL) on osteoclast differentiation. WEPL directly affected the osteoclast precursors and suppressed osteoclast differentiation in vitro. In addition, the expression levels of c Fos and nuclear factor of activated T cells 1, a critical transcription factor for osteoclastogenesis, were significantly downregulated by WEPL via the suppression of the receptor activator of nuclear factor (NF) kappa B ligand induced mitogen activated protein kinase and NF kappa B signaling pathways. Consistent with the in vitro results, oral administration of WEPL (100 and 300 mpk) to ovariectomized mice for six weeks relieved the OVX induced bone loss. We also identified phytochemicals in WEPL that are reported to exert inhibitory effects on osteoclastogenesis and/or bone loss. Collectively, the findings of our study indicate that WEPL has an anti osteoporotic effect on OVX induced bone loss by diminishing osteoclast differentiation, suggesting that it may be useful to treat several bone diseases caused by excessive bone resorption.
C1 [Gu, Dong Ryun; Yang, Hyun; Kim, Seong Cheol; Hwang, Youn Hwan; Ha, Hyunil] Korea Inst Oriental Med, KM Convergence Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
   [Hwang, Youn Hwan] Univ Sci & Technol UST, Korean Convergence Med Major KIOM, 1672 Yuseongdae Ro, Daejeon 34054, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); University of Science &
   Technology (UST)
RP Ha, H (通讯作者)，Korea Inst Oriental Med, KM Convergence Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
EM hyunil74@kiom.re.kr
RI Hwang, Youn Hwan/AAU 9373 2021
OI Hwang, Youn Hwan/0000 0002 4959 2436
FU Korea Institute of Oriental Medicine, Ministry of Education, Science,
   and Technology, Republic of Korea [KSN2021330]
FX This work was funded by the Korea Institute of Oriental Medicine,
   Ministry of Education, Science, and Technology, Republic of Korea [grant
   number KSN2021330].
CR Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chanda D, 2009, J TOXICOL SCI, V34, P99, DOI 10.2131/jts.34.99
   Choudhary N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191006
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   Deepak V, 2015, BIOFACTORS, V41, P403, DOI 10.1002/biof.1241
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   He H, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1392 6
   Hiasa M, 2009, BLOOD, V114, P4517, DOI 10.1182/blood 2009 04 215020
   Idris AI, 2010, BONE, V46, P1089, DOI 10.1016/j.bone.2010.01.368
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jiang XY, 1997, BIOCHEM MOL BIOL INT, V42, P325
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kumar S, 2011, J ACUPUNCT MERIDIAN, V4, P134, DOI 10.1016/S2005 2901(11)60020 4
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lee W, 2013, BIOCHEM BIOPH RES CO, V430, P406, DOI 10.1016/j.bbrc.2012.11.030
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Li CR, 2019, J FUNCT FOODS, V58, P138, DOI 10.1016/j.jff.2019.04.048
   Liu HL, 2015, FOOD CHEM, V177, P191, DOI 10.1016/j.foodchem.2015.01.033
   Liu ZH, 2021, EUR J MED CHEM, V210, DOI 10.1016/j.ejmech.2020.112982
   More KN, 2020, B KOREAN CHEM SOC, V41, P488, DOI 10.1002/bkcs.11992
   Nabi SA, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 37
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nishimura H, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2020.100268
   Oláh Z, 2017, PHYTOMEDICINE, V34, P44, DOI 10.1016/j.phymed.2017.06.006
   Raisz LG, 1999, CLIN CHEM, V45, P1353
   Sawangjaroen N, 2004, J ETHNOPHARMACOL, V91, P357, DOI 10.1016/j.jep.2004.01.014
   Shah AH, 1998, PLANT FOOD HUM NUTR, V52, P231, DOI 10.1023/A:1008088323164
   Singh A, 2017, J PHARM ANAL, V7, P77, DOI 10.1016/j.jpha.2016.10.002
   Soelaiman IN, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/764701
   Sun ZY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00389
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tan SD, 2007, BONE, V41, P745, DOI 10.1016/j.bone.2007.07.019
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Verma VC, 2011, J ANTIBIOT, V64, P427, DOI 10.1038/ja.2011.27
   Vezeridis PS, 2006, BIOCHEM BIOPH RES CO, V348, P1082, DOI 10.1016/j.bbrc.2006.07.146
   Wakade AS, 2008, INDIAN J EXP BIOL, V46, P528
   Wang B, 2017, REV BRAS FARMACOGN, V27, P369, DOI 10.1016/j.bjp.2017.02.003
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Xu RR, 2019, FOOD CHEM, V298, DOI 10.1016/j.foodchem.2019.125067
   Yadav V, 2020, J ETHNOPHARMACOL, V247, DOI 10.1016/j.jep.2019.112255
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yan RY, 2013, MOLECULES, V18, P7739, DOI 10.3390/molecules18077739
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
NR 51
TC 10
Z9 10
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD SEP
PY 2022
VL 14
IS 17
AR 3667
DI 10.3390/nu14173667
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 4K0OZ
UT WOS:000851661900001
PM 36079923
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liang, H
   Xu, XM
   Feng, XB
   Ma, L
   Deng, XY
   Wu, SL
   Liu, XM
   Yang, C
AF Liang, Hang
   Xu, Xiaomo
   Feng, Xiaobo
   Ma, Liang
   Deng, Xiangyu
   Wu, Shuilin
   Liu, Xiangmei
   Yang, Cao
TI Gold nanoparticles loaded hydroxyapatite composites guide osteogenic
   differentiation of human mesenchymal stem cells through Wnt/β catenin
   signaling pathway
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE gold nanoparticles; hydroxyapatite; nanocomposites; osteoblast
   differentiation; bone regeneration
ID MARROW STROMAL CELLS; BONE; PROLIFERATION; SIZE; OSTEOBLAST;
   NANOHYDROXYAPATITE; DRUG
AB Background: Precise control and induction of the differentiation of stem cells to osteoblasts by artificial biomaterials are a promising strategy for rapid bone regeneration and reconstruction.
   Purpose: In this study, gold nanoparticles (AuNPs) loaded hydroxyapatite (HA Au) nanocomposites were designed to guide the osteogenic differentiation of human bone marrow derived mesenchymal stem cells (hMSCs) through the synergistic effects of both AuNPs and HA.
   Materials and methods: The HA Au nanoparticles were synthesized and characterized by several analytical techniques. Cell viability and proliferation of hMSCs were characterized by CCK 8 test. Cellular uptake of nanoparticles was observed by transmission electron microscope. For the evaluation of osteogenic differentiation, alkaline phosphatase (ALP) activity and staining, Alizarin red staining, and a quantitative real time polymerase chain reaction (RT PCR) analysis were performed. In order to examine specific signaling pathways, RT PCR and Western blotting assay were performed.
   Results: The results confirmed the successful synthesis of HA Au nanocomposites. The HA Au nanoparticles showed good cytocompatibility and internalized into hMSCs at the studied concentrations. The increased level of ALP production, deposition of calcium mineralization, as well as the expression of typical osteogenic genes, indicated the enhancement of osteogenic differentiation of hMSCs. Moreover, the incorporation of Au could activate the Wnt/beta catenin signaling pathway, which seemed to be the molecular mechanism underlying the osteoinductive capability of HA Au nanoparticles.
   Conclusion: The HA Au nanoparticles exerted a synergistic effect on accelerating osteogenic differentiation of hMSCs, suggesting they may be potential candidates for bone repair and regeneration.
C1 [Liang, Hang; Feng, Xiaobo; Ma, Liang; Deng, Xiangyu; Yang, Cao] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Orthopaed, Union Hosp, Wuhan 430022, Hubei, Peoples R China.
   [Xu, Xiaomo; Wu, Shuilin; Liu, Xiangmei] Hubei Univ, Key Lab Green Preparat & Applicat Funct Mat, Minist Educ, Sch Mat Sci & Engn, Wuhan 430062, Hubei, Peoples R China.
   [Wu, Shuilin] Tianjin Univ, Sch Mat Sci & Engn, Key Lab Adv Ceram & Machining Technol, Minist Educ, Tianjin 300072, Peoples R China.
C3 Huazhong University of Science & Technology; Hubei University; Tianjin
   University
RP Yang, C (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Orthopaed, Union Hosp, Wuhan 430022, Hubei, Peoples R China.; Liu, XM (通讯作者)，Hubei Univ, Key Lab Green Preparat & Applicat Funct Mat, Minist Educ, Sch Mat Sci & Engn, Wuhan 430062, Hubei, Peoples R China.
EM liuxiangmei1978@163.com; yangcao1971@sina.com
RI ; wu, shuilin/LUZ 0692 2024; 梁, 航/JHU 9336 2023; WU,
   Shuilin/F 7897 2010; Xiangmei, Liu/LUZ 0868 2024
OI Yang, Cao/0000 0002 0058 614X; wu, shuilin/0000 0002 1270 1870; Liang,
   Hang/0000 0001 8299 4456; liu, xiangmei/0000 0002 6469 2363; 
FU National Key Research and Development Program of China [2018YFB1105700]
FX This work was supported by National Key Research and Development Program
   of China (2018YFB1105700).
CR Case N, 2008, J BIOL CHEM, V283, P29196, DOI 10.1074/jbc.M801907200
   Chellapandian C, 2019, PROCESS BIOCHEM, V80, P58, DOI 10.1016/j.procbio.2019.02.009
   Choi SY, 2015, INT J NANOMED, V10, P4383, DOI 10.2147/IJN.S78775
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Dhore CR, 2001, ARTERIOSCL THROM VAS, V21, P1998, DOI 10.1161/hq1201.100229
   Frank O, 2002, J CELL BIOCHEM, V85, P737, DOI 10.1002/jcb.10174
   Gao P, 2016, SCI REP UK, V6, DOI 10.1038/srep23367
   Gong T, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.29
   Huebsch N, 2009, NATURE, V462, P426, DOI 10.1038/nature08601
   Hutter E, 2010, ACS NANO, V4, P2595, DOI 10.1021/nn901869f
   Khajuria DK, 2018, ACS APPL MATER INTER, V10, P19373, DOI 10.1021/acsami.8b02792
   Khlebtsov N, 2013, THERANOSTICS, V3, P167, DOI 10.7150/thno.5716
   Ko WK, 2015, J COLLOID INTERF SCI, V438, P68, DOI 10.1016/j.jcis.2014.08.058
   Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774 002 0408 0
   Kumar PSM, 2017, MICROB PATHOGENESIS, V113, P68, DOI 10.1016/j.micpath.2017.10.032
   Lee JH, 2015, SCI REP UK, V5, DOI 10.1038/srep18833
   Lee JH, 2015, NANOSCALE, V7, P11642, DOI 10.1039/c5nr01580d
   Li JC, 2016, NANOSCALE, V8, P7992, DOI 10.1039/c5nr08808a
   Li JC, 2013, ACS APPL MATER INTER, V5, P10357, DOI 10.1021/am4034526
   Liu DD, 2010, ACS NANO, V4, P2185, DOI 10.1021/nn901479w
   Liu XM, 2017, MAT SCI ENG C MATER, V70, P1, DOI 10.1016/j.msec.2016.08.059
   Liu XS, 2013, NANOSCALE, V5, P3982, DOI 10.1039/c3nr00284e
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Marcucio RS, 2016, J ORTHOP TRAUMA, V30, pE74, DOI 10.1097/BOT.0000000000000535
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Naveena N, 2012, J MATER CHEM, V22, P5239, DOI 10.1039/c1jm14401d
   Orza A, 2011, ACS NANO, V5, P4490, DOI 10.1021/nn1035312
   Pan T, 2016, ACS APPL MATER INTER, V8, P19217, DOI 10.1021/acsami.6b02969
   Pissuwan D, 2011, J CONTROL RELEASE, V149, P65, DOI 10.1016/j.jconrel.2009.12.006
   Pugazhendhi A, 2018, INT J PHARMACEUT, V539, P104, DOI 10.1016/j.ijpharm.2018.01.034
   Ravichandran R, 2012, BIOMATERIALS, V33, P846, DOI 10.1016/j.biomaterials.2011.10.030
   Remya KR, 2013, J BIOMED NANOTECHNOL, V9, P1483, DOI 10.1166/jbn.2013.1640
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Sathiyavimal S, 2019, INT J BIOL MACROMOL, V129, P844, DOI 10.1016/j.ijbiomac.2019.02.058
   Sen B, 2008, ENDOCRINOLOGY, V149, P6065, DOI 10.1210/en.2008 0687
   Shanmuganathan R, 2019, INT J BIOL MACROMOL, V130, P727, DOI 10.1016/j.ijbiomac.2019.02.060
   Shi ZL, 2009, ACTA BIOMATER, V5, P338, DOI 10.1016/j.actbio.2008.07.023
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Takahashi Yanaga F, 2007, J PHARMACOL SCI, V104, P293, DOI 10.1254/jphs.CR0070024
   Tautzenberger A, 2012, INT J NANOMED, V7, P4545, DOI 10.2147/IJN.S34127
   Wang Z, 2016, APPL SURF SCI, V378, P496, DOI 10.1016/j.apsusc.2016.03.094
   Xia Y, 2018, NANOMED NANOTECHNOL, V14, P35, DOI 10.1016/j.nano.2017.08.014
   Xu XM, 2018, ACTA BIOMATER, V77, P352, DOI 10.1016/j.actbio.2018.07.030
   Yang KN, 2013, NANOSCALE, V5, P1205, DOI 10.1039/c2nr33575a
   Yao YY, 2014, J NANOSCI NANOTECHNO, V14, P4851, DOI 10.1166/jnn.2014.8717
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Zhang DW, 2014, MAT SCI ENG C MATER, V42, P70, DOI 10.1016/j.msec.2014.04.042
   Zhang YH, 2017, THERANOSTICS, V7, P1214, DOI 10.7150/thno.17252
   Zhou H, 2011, ACTA BIOMATER, V7, P2769, DOI 10.1016/j.actbio.2011.03.019
   Zhou YZ, 2012, ACS APPL MATER INTER, V4, P6900, DOI 10.1021/am302041b
NR 50
TC 52
Z9 53
U1 1
U2 23
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2019
VL 14
BP 6151
EP 6163
DI 10.2147/IJN.S213889
PG 13
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA IN4QP
UT WOS:000478660200002
PM 31447557
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Kang, H
   Kerloc'h, A
   Rotival, M
   Xu, XQ
   Zhang, Q
   D'Souza, Z
   Kim, M
   Scholz, JC
   Ko, JH
   Srivastava, PK
   Genzen, JR
   Cui, WG
   Aitman, TJ
   Game, L
   Melvin, JE
   Hanidu, A
   Dimock, J
   Zheng, J
   Souza, D
   Behera, AK
   Nabozny, G
   Cook, HT
   Bassett, JHD
   Williams, GR
   Li, J
   Vignery, A
   Petretto, E
   Behmoaras, J
AF Kang, Heeseog
   Kerloc'h, Audrey
   Rotival, Maxime
   Xu, Xiaoqing
   Zhang, Qing
   D'Souza, Zelpha
   Kim, Michael
   Scholz, Jodi Carlson
   Ko, Jeong Hun
   Srivastava, Prashant K.
   Genzen, Jonathan R.
   Cui, Weiguo
   Aitman, Timothy J.
   Game, Laurence
   Melvin, James E.
   Hanidu, Adedayo
   Dimock, Janice
   Zheng, Jie
   Souza, Donald
   Behera, Aruna K.
   Nabozny, Gerald
   Cook, H. Terence
   Bassett, J. H. Duncan
   Williams, Graham R.
   Li, Jun
   Vignery, Agnes
   Petretto, Enrico
   Behmoaras, Jacques
TI Kcnn4 Is a Regulator of Macrophage Multinucleation in Bone
   Homeostasis and Inflammatory Disease
SO CELL REPORTS
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; GIANT CELL FORMATION; CRESCENTIC
   GLOMERULONEPHRITIS; OSTEOCLAST DIFFERENTIATION;
   INTERMEDIATE CONDUCTANCE; RAT MODEL; ION CHANNELS; K+ CHANNEL; FUSION;
   ACTIVATION
AB Macrophages can fuse to form osteoclasts in bone or multinucleate giant cells (MGCs) as part of the immune response. We use a systems genetics approach in rat macrophages to unravel their genetic determinants of multinucleation and investigate their role in both bone homeostasis and inflammatory disease. We identify a trans regulated gene network associated with macrophage multinucleation and Kcnn4 as being the most significantly trans regulated gene in the network and induced at the onset of fusion. Kcnn4 is required for osteoclast and MGC formation in rodents and humans. Genetic deletion of Kcnn4 reduces macrophage multinucleation through modulation of Ca2+ signaling, increases bone mass, and improves clinical outcome in arthritis. Pharmacological blockade of Kcnn4 reduces experimental glomerulonephritis. Our data implicate Kcnn4 in macrophage multinucleation, identifying it as a potential therapeutic target for inhibition of bone resorption and chronic inflammation.
C1 [Kang, Heeseog; Xu, Xiaoqing; Zhang, Qing; Kim, Michael; Vignery, Agnes] Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06510 USA.
   [Kang, Heeseog; Xu, Xiaoqing; Zhang, Qing; Kim, Michael; Vignery, Agnes] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA.
   [Kerloc'h, Audrey; Ko, Jeong Hun; Cook, H. Terence; Behmoaras, Jacques] Univ London Imperial Coll Sci Technol & Med, CCIR, London W12 0NN, England.
   [Rotival, Maxime; D'Souza, Zelpha; Srivastava, Prashant K.; Aitman, Timothy J.; Petretto, Enrico] Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, London W12 0NN, England.
   [Scholz, Jodi Carlson] Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06510 USA.
   [Genzen, Jonathan R.] Univ Utah, Dept Pathol, Salt Lake City, UT 84108 USA.
   [Genzen, Jonathan R.] ARUP Labs, Salt Lake City, UT 84108 USA.
   [Cui, Weiguo] Blood Ctr Wisconsin, Milwaukee, WI 53213 USA.
   [Game, Laurence] Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, Genom Lab, London W12 0NN, England.
   [Melvin, James E.] NIDCR, NIH, Bethesda, MD 20892 USA.
   [Hanidu, Adedayo; Dimock, Janice; Zheng, Jie; Souza, Donald; Behera, Aruna K.; Nabozny, Gerald; Li, Jun] Boehringer Ingelheim Pharmaceut Inc, Dept Immunol & Inflammat, Ridgefield, CT 06877 USA.
   [Bassett, J. H. Duncan; Williams, Graham R.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Mol Endocrinol Grp, London W12 0NN, England.
C3 Yale University; Yale University; Imperial College London; Imperial
   College London; Yale University; Utah System of Higher Education;
   University of Utah; Utah System of Higher Education; University of Utah;
   ARUP Laboratories; Versiti Blood Center of Wisconsin; Imperial College
   London; National Institutes of Health (NIH)   USA; NIH National
   Institute of Dental & Craniofacial Research (NIDCR); Boehringer
   Ingelheim; Imperial College London
RP Vignery, A (通讯作者)，Yale Univ, Sch Med, Dept Orthopaed, New Haven, CT 06510 USA.
EM agnes.vignery@yale.edu; enrico.petretto@imperial.ac.uk;
   jacquesb@imperial.ac.uk
RI Srivastava, Prashant/B 3215 2012; Kang, Heeseog/LJL 5469 2024; Zhang,
   Qingtai/NTR 0237 2025
OI Aitman, Timothy/0000 0002 7875 4502; Rotival,
   Maxime/0000 0003 2519 8044; Scholz, Jodi/0000 0002 9571 5599; xu,
   xiaoqing/0000 0002 6959 8667
FU Kidney Research UK [RP9/2013]; Wellcome Trust [WT092523MA]; European
   Community [HEALTH F4  2010 241504]; Medical Research Council; Boehringer
   Ingelheim; Kidney Research UK [RP9/2013] Funding Source: researchfish;
   Medical Research Council [MC_U120097112, MR/M004716/1, MC_U120061454]
   Funding Source: researchfish; MRC [MR/M004716/1, MC_U120061454,
   MC_U120097112] Funding Source: UKRI
FX The authors are grateful to Veterinary Clinical Services at the Yale
   School of Medicine and to the Yale Core Center for Musculoskeletal
   Diseases, in particular, to Nancy Troiano for her assistance in
   processing the mouse bones for histomorphometry analysis. We also thank
   Bolder Biopath (Boulder, CO) for processing the arthritic mouse bones
   for histology, and grading the pathology. We would like to thank
   Jennifer Smith for her excellent technical assistance and Kathrin Saar
   (MDC, Berlin) for genotyping protocols and data analysis. We gratefully
   acknowledge funding from Kidney Research UK (RP9/2013) (J.B.), Wellcome
   Trust (WT092523MA) (J.B.). We also acknowledge funding from the European
   Community's Seventh Framework Programme (FP7/2007 2013) under grant
   agreement no. HEALTH F4  2010 241504 (EURATRANS) (E.P. and M .R.) and
   the Medical Research Council (E.P.). A.H., J.D., J.Z., D.S., A.K.B.,
   G.N., and J.L. are employees of Boehringer Ingelheim. This work was
   supported in part by a grant from Boehringer Ingelheim.
CR Aitman TJ, 2006, NATURE, V439, P851, DOI 10.1038/nature04489
   Ballica R, 1999, J BONE MINER RES, V14, P1067, DOI 10.1359/jbmr.1999.14.7.1067
   BARON R, 1984, ANAT RECORD, V208, P137, DOI 10.1002/ar.1092080114
   Begenisich T, 2004, J BIOL CHEM, V279, P47681, DOI 10.1074/jbc.M409627200
   Behmoaras J, 2010, J AM SOC NEPHROL, V21, P1136, DOI 10.1681/ASN.2009090968
   Bottolo L, 2011, GENETICS, V189, P1449, DOI 10.1534/genetics.111.131425
   Bottolo L, 2011, BIOINFORMATICS, V27, P587, DOI 10.1093/bioinformatics/btq684
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Breitling R, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000232
   Brodbeck WG, 2009, CURR OPIN HEMATOL, V16, P53, DOI 10.1097/MOH.0b013e32831ac52e
   Bühling F, 2001, J PATHOL, V195, P375
   Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958 1669(97)80130 9
   Cella M, 2003, J EXP MED, V198, P645, DOI 10.1084/jem.20022220
   Chen C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017238
   Chen EH, 2005, SCIENCE, V308, P369, DOI 10.1126/science.1104799
   Chen YJ, 2011, J CEREBR BLOOD F MET, V31, P2363, DOI 10.1038/jcbfm.2011.101
   D'Souza Z, 2013, DIS MODEL MECH, V6, P1477, DOI 10.1242/dmm.012328
   da Costa CET, 2005, J EXP MED, V201, P687, DOI 10.1084/jem.20041785
   Deplano S, 2013, J LEUKOCYTE BIOL, V93, P127, DOI 10.1189/jlb.0612284
   Feske S, 2012, NAT REV IMMUNOL, V12, P532, DOI 10.1038/nri3233
   Helming L, 2009, TRENDS CELL BIOL, V19, P514, DOI 10.1016/j.tcb.2009.07.005
   Helming L, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1159665
   Huang C., 2013, DIABETES
   Hubner N, 2005, NAT GENET, V37, P243, DOI 10.1038/ng1522
   Hull RP, 2013, BMC GENOMICS, V14, DOI 10.1186/1471 2164 14 92
   Humphrey MB, 2006, J BONE MINER RES, V21, P237, DOI 10.1359/JBMR.051016
   Humphrey MB, 2004, J BONE MINER RES, V19, P224, DOI 10.1359/JBMR.0301234
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kaneko Y, 2003, J IMMUNOL, V170, P3377, DOI 10.4049/jimmunol.170.6.3377
   Kramnik I, 2000, P NATL ACAD SCI USA, V97, P8560, DOI 10.1073/pnas.150227197
   Lam J, 2011, DRUG DEVELOP RES, V72, P573, DOI 10.1002/ddr.20467
   Lan HY, 1998, KIDNEY INT, V53, P136, DOI 10.1046/j.1523 1755.1998.00748.x
   Langley SR, 2013, CARDIOVASC RES, V97, P653, DOI 10.1093/cvr/cvs329
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lemaire I, 2006, J IMMUNOL, V177, P7257, DOI 10.4049/jimmunol.177.10.7257
   Li HM, 2005, J EXP MED, V201, P1169, DOI 10.1084/jem.20041444
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Lyons PA, 2012, NEW ENGL J MED, V367, P214, DOI 10.1056/NEJMoa1108735
   Margolin AA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471 2105 7 S1 S7
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Otero K, 2012, J IMMUNOL, V188, P2612, DOI 10.4049/jimmunol.1102836
   Page TH, 2012, J BIOL CHEM, V287, P5710, DOI 10.1074/jbc.M111.260695
   Paloneva J, 2002, AM J HUM GENET, V71, P656, DOI 10.1086/342259
   Paloneva J, 2000, NAT GENET, V25, P357, DOI 10.1038/77153
   Peng QS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000500
   Pichugin AV, 2009, AM J PATHOL, V174, P2190, DOI 10.2353/ajpath.2009.081075
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067
   Sims NA, 2004, ARTHRITIS RHEUM US, V50, P2338, DOI 10.1002/art.20382
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takeda Y, 2003, J CELL BIOL, V161, P945, DOI 10.1083/jcb.200212031
   Tam FWK, 1999, NEPHROL DIAL TRANSPL, V14, P1658, DOI 10.1093/ndt/14.7.1658
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Thye T, 2012, NAT GENET, V44, P257, DOI 10.1038/ng.1080
   Toyama K, 2008, J CLIN INVEST, V118, P3025, DOI 10.1172/JCI30836
   Tsai AT, 2005, BIOMATERIALS, V26, P5835, DOI 10.1016/j.biomaterials.2005.03.003
   Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520
   Valverde P, 2005, J DENT RES, V84, P488, DOI 10.1177/154405910508400603
   Vignery A, 2005, J EXP MED, V202, P337, DOI 10.1084/jem.20051123
   Vignery Agnes, 2008, V475, P149, DOI 10.1007/978 1 59745 250 2_9
   Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151
   Wulff H, 2003, J CLIN INVEST, V111, P1703, DOI 10.1172/JCI200316921
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Zhu XW, 2007, J INFECT DIS, V196, P1076, DOI 10.1086/521030
NR 65
TC 49
Z9 52
U1 1
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211 1247
J9 CELL REP
JI Cell Reports
PD AUG 21
PY 2014
VL 8
IS 4
BP 1210
EP 1224
DI 10.1016/j.celrep.2014.07.032
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AO8AD
UT WOS:000341573500027
PM 25131209
OA Green Published
DA 2025 08 17
ER

PT J
AU He, ZC
   Li, XY
   Guo, YL
   Ma, D
   Fang, Q
   Ren, LL
   Zhang, ZY
   Wang, WL
   Yu, ZY
   Zhao, P
   Wang, JS
AF He, Zheng C.
   Li, Xin Y.
   Guo, Yong L.
   Ma, Dan
   Fang, Qin
   Ren, Ling L.
   Zhang, Zhao Y.
   Wang, Weili
   Yu, Zheng Y.
   Zhao, Peng
   Wang, Ji S.
TI Heme oxygenase 1 attenuates the inhibitory effect of bortezomib against
   the APRIL NF κB CCL3 signaling pathways in multiple myeloma cells:
   Corelated with bortezomib tolerance in multiple myeloma
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE April; bortezomib (BTZ); heme oxygenase 1 (HO 1); multiple myeloma (MM);
   NF kappa B (NF kappa B); osteoclast (OCs); targeted therapy
ID INDUCED OSTEOCLAST DIFFERENTIATION; BONE DISEASE; CRUCIAL ROLE; RANKL;
   GROWTH; LENALIDOMIDE; DESTRUCTION; ADHESION; ICAM 1; MODEL
AB Osteoclasts (OCs) play an essential role in bone destruction in patients with multiple myeloma (MM). Bortezomib can ameliorate bone destruction in patients with MM, but advanced MM often resists bortezomib. We studied the molecular mechanisms of bortezomib tolerance in MM. The expression of the MM related genes in newly diagnosed patients with MM and normal donors were studied. C C motif chemokine ligand 3 (CCL3) is a cytokine involved in the differentiation of OCs, and its expression is closely related to APRIL (a proliferation inducing ligand). We found that bortezomib treatment inhibited APRIL and CCL3. But the heme oxygenase 1 (HO 1) activator hemin attenuated the inhibitory effects of bortezomib on APRIL and CCL3. We induced mononuclear cells to differentiate into OCs, and the enzyme linked immunosorbent assay showed that the more OCs differentiated, the higher the levels CCL3 secretions detected. Animal experiments showed that hemin promoted MM cell infiltration in mice. The weight and survival rate of tumor mice were associated with HO 1 expression. Immunohistochemical staining showed that HO 1, APRIL, and CCL3 staining were positively stained in the tumor infiltrating sites. Then, MM cells were transfected with L HO 1/si HO 1 expression vectors and cultured with an nuclear factor (NF) kappa B (kappa B) pathway inhibitor, QNZ. The results showed that HO 1 was the upstream gene of APRIL, NF kappa B, and CCL3. We showed that HO 1 could attenuate the inhibitory effect of bortezomib against the APRIL NF kappa B CCL3 signaling pathways in MM cells, and the tolerance of MM cells to bortezomib and the promotion of bone destruction are related to HO 1.
C1 [He, Zheng C.; Li, Xin Y.; Guo, Yong L.; Ma, Dan; Zhang, Zhao Y.; Wang, Weili; Yu, Zheng Y.; Zhao, Peng; Wang, Ji S.] Med Univ, Dept Hematol, Affiliated Hosp, Guiyang, Guizhou, Peoples R China.
   [He, Zheng C.; Li, Xin Y.; Guo, Yong L.; Ma, Dan; Zhang, Zhao Y.; Wang, Weili; Yu, Zheng Y.; Zhao, Peng; Wang, Ji S.] Guizhou Med Univ, Affiliated Hosp, Hematol Inst Guizhou Prov, Guiyang, Guizhou, Peoples R China.
   [He, Zheng C.; Li, Xin Y.; Guo, Yong L.; Ma, Dan; Zhang, Zhao Y.; Wang, Weili; Yu, Zheng Y.; Zhao, Peng; Wang, Ji S.] Guizhou Med Univ, Guizhou Prov Lab Hematopoiet Stem Cell Transplant, Affiliated Hosp, Guiyang, Guizhou, Peoples R China.
   [Fang, Qin] Guizhou Med Univ, Dept Pharm, Affiliated Hosp, Guiyang, Guizhou, Peoples R China.
   [Ren, Ling L.] North Sichuan Med Coll, Affiliated Hosp, Dept Hematol, Nanchong, Peoples R China.
C3 Guizhou Medical University; Guizhou Medical University; Guizhou Medical
   University; North Sichuan Medical University
RP Wang, JS (通讯作者)，Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Guiyang 550004, Guizhou, Peoples R China.
EM 1014712228@qq.com
RI he, zeying/HCH 3380 2022; fang, qin/GQA 8223 2022; zhao,
   Peng/KYP 4537 2024
FU Provincial Governor Special Fund of Guizhou Province [2010 84];
   International Cooperation Project of Guizhou Province [2011 7010];
   Social Project of Guizhou Province [2011 3012]; National Natural Science
   Foundation of China [81660616, 81470006, 81360501]
FX Provincial Governor Special Fund of Guizhou Province, Grant/Award
   Number: #2010 84; International Cooperation Project of Guizhou Province,
   Grant/Award Number: #2011 7010; Social Project of Guizhou Province,
   Grant/Award Number: #2011 3012; National Natural Science Foundation of
   China, Grant/Award Numbers: #81660616, #81470006, #81360501
CR Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004
   Avet Loiseau H, 2018, LEUKEMIA, V32, P1267, DOI 10.1038/s41375 018 0098 9
   Bak SU, 2017, BMB REP, V50, P103, DOI 10.5483/BMBRep.2017.50.2.220
   Bolzoni M, 2013, EXP HEMATOL, V41, P387, DOI 10.1016/j.exphem.2012.11.005
   Cheung WY, 2012, BONE, V50, P104, DOI 10.1016/j.bone.2011.09.052
   Choi S, 2006, J BIOL CHEM, V281, P12722, DOI 10.1074/jbc.M601018200
   Delgado Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008 5472.CAN 15 1703
   Fujii Y, 2003, FEBS LETT, V539, P45, DOI 10.1016/S0014 5793(03)00182 0
   Giuliani N, 2012, LEUKEMIA, V26, P1391, DOI 10.1038/leu.2011.381
   Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood 2002 04 1121
   GUPTA A, 2012, MOL CANCER, V11
   Hiruma Y, 2009, BLOOD, V113, P4894, DOI 10.1182/blood 2008 08 173948
   Hu JS, 2013, CANCER CELL INT, V13, DOI 10.1186/1475 2867 13 25
   Jakob C, 2009, CLIN LYMPHOMA MYELOM, V9, P430, DOI 10.3816/CLM.2009.n.085
   Ke K, 2015, MOL CELL ENDOCRINOL, V409, P11, DOI 10.1016/j.mce.2015.03.022
   Kim HN, 2015, MOL ENDOCRINOL, V29, P1498, DOI 10.1210/me.2015 1133
   Kim HJ, 2014, MOL CELLS, V37, P598, DOI 10.14348/molcells.2014.0153
   Kovacs E, 2010, LEUKEMIA RES, V34, P912, DOI 10.1016/j.leukres.2009.08.012
   Kuribayashi N, 1998, MED ONCOL, V15, P248, DOI 10.1007/BF02787208
   Labrinidis A, 2009, CLIN CANCER RES, V15, P1998, DOI 10.1158/1078 0432.CCR 08 2444
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   Lee HJ, 2010, J PERIODONTAL RES, V45, P367, DOI 10.1111/j.1600 0765.2009.01247.x
   Lee J, 2015, J BONE MINER RES, V30, P1597, DOI 10.1002/jbmr.2503
   Li Volti G, 2017, ANTIOXID REDOX SIGN, V27, P363, DOI 10.1089/ars.2016.6735
   Longo V, 2012, CANCER TREAT REV, V38, P787, DOI 10.1016/j.ctrv.2012.03.004
   Lu SH, 2015, J NAT PROD, V78, P61, DOI 10.1021/np500663y
   Ma D, 2014, ANTI CANCER DRUG, V25, P406, DOI 10.1097/CAD.0000000000000068
   Masuda H, 2014, BONE, V58, P1, DOI 10.1016/j.bone.2013.09.020
   Mohty M, 2014, CANCER AM CANCER SOC, V120, P618, DOI 10.1002/cncr.28481
   Nemeth Z, 2016, ONCOTARGET, V7, P23919, DOI 10.18632/oncotarget.8081
   Nyman JS, 2016, BONE, V91, P81, DOI 10.1016/j.bone.2016.07.007
   Quinn J, 2011, BLOOD, V117, P890, DOI 10.1182/blood 2010 01 264424
   Sonmez M, 2014, HEMATOLOGY, V19, P213, DOI 10.1179/1607845413Y.0000000114
   Tai YT, 2016, BLOOD, V127, P3225, DOI 10.1182/blood 2016 01 691162
   Tang SS, 2018, EXP CELL RES, V363, P196, DOI 10.1016/j.yexcr.2018.01.005
   Terpos E, 2003, EUR J HAEMATOL, V70, P34, DOI 10.1034/j.1600 0609.2003.02823.x
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   Terpos E, 2013, J CLIN ONCOL, V31, P2347, DOI 10.1200/JCO.2012.47.7901
   Vallet S, 2011, LEUKEMIA, V25, P1174, DOI 10.1038/leu.2011.43
   Vijayan V, 2014, BRIT J PHARMACOL, V171, P107, DOI 10.1111/bph.12434
   Virginie FA, 2011, BMC CANCER, V11, P1
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wu WB, 2016, FEBS J, V283, P834, DOI 10.1111/febs.13633
NR 43
TC 6
Z9 7
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY
PY 2019
VL 120
IS 5
BP 6972
EP 6987
DI 10.1002/jcb.27879
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HO6VK
UT WOS:000461070700018
PM 30368867
DA 2025 08 17
ER

PT J
AU Brunauer, R
   Xia, IG
   Asrar, SN
   Dawson, LA
   Dolan, CP
   Muneoka, K
AF Brunauer, Regina
   Xia, Ian G.
   Asrar, Shabistan N.
   Dawson, Lindsay A.
   Dolan, Connor P.
   Muneoka, Ken
TI Aging Delays Epimorphic Regeneration in Mice
SO JOURNALS OF GERONTOLOGY SERIES A BIOLOGICAL SCIENCES AND MEDICAL
   SCIENCES
LA English
DT Article
DE Cell differentiation; Osteoblasts; Regenerative medicine; Stem cells;
   Wound healing
ID DIGIT TIP; BONE; GROWTH; MECHANISMS; CAPACITY; STRESS; CELLS; MODEL; FIN
AB Epimorphic regeneration is a multitissue regeneration process where amputation does not lead to scarring, but blastema formation and patterned morphogenesis for which cell plasticity and concerted cell cell interactions are pivotal. Tissue regeneration declines with aging, yet if and how aging impairs epimorphic regeneration is unknown. Here, we show for the first time that aging derails the spatiotemporal regulation of epimorphic regeneration in mammals, first, by exacerbating tissue histolysis and delaying wound closure, and second, by impairing blastema differentiation and skeletal regrowth. Surprisingly, aging did not limit stem cell availability in the blastema but reduced osteoblast dependent bone formation. Our data suggest that aging delays regeneration not by stem cell exhaustion, but functional defects of differentiated cells that may be driven by an aged wound environment and alterations in the spatiotemporal regulation of regeneration events. Our findings emphasize the importance of accurate timing of signaling events for regeneration and highlight the need for carefully timed interventions in regenerative medicine.
C1 [Brunauer, Regina; Xia, Ian G.; Asrar, Shabistan N.; Dawson, Lindsay A.; Dolan, Connor P.; Muneoka, Ken] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Physiol & Pharmacol, 660 Raymond Stotzer Pkwy, College Stn, TX 77843 USA.
   [Dolan, Connor P.] DoD VA Extrem Trauma & Amputat Ctr Excellence, Bethesda, MD USA.
   [Dolan, Connor P.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA.
   [Dolan, Connor P.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA.
C3 Texas A&M University System; Texas A&M University College Station;
   Uniformed Services University of the Health Sciences   USA; Walter Reed
   National Military Medical Center
RP Brunauer, R (通讯作者)，Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Physiol & Pharmacol, 660 Raymond Stotzer Pkwy, College Stn, TX 77843 USA.
EM rbrunauer@cvm.tamu.edu
RI Brunauer, Regina/AAA 5101 2022
OI Dawson, Lindsay/0000 0002 4903 6050; Brunauer,
   Regina/0000 0001 9384 5501
FU Texas AM University
FX This work was supported by Texas A&M University.
CR Anchelin M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016955
   Andreasen CM, 2018, J BONE MINER RES, V33, P606, DOI 10.1002/jbmr.3354
   Biteau B, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001159
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090
   Brunauer R, 2018, GERONTOLOGY, V64, P300, DOI 10.1159/000485320
   Brunauer R, 2017, GERONTOLOGY, V63, P84, DOI 10.1159/000449501
   Burri O, BIOP VSI Reader
   Busse E, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52921 z
   Chen JQ, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0004 5
   Davesne D, 2019, BIOL REV, V94, P1338, DOI 10.1111/brv.12505
   Dawson LA, 2021, WOUND REPAIR REGEN, V29, P196, DOI 10.1111/wrr.12856
   Dawson LA, 2019, JOVE J VIS EXP, DOI 10.3791/59749
   Dawson LA, 2018, WOUND REPAIR REGEN, V26, P263, DOI 10.1111/wrr.12666
   Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023
   Fernando WA, 2011, DEV BIOL, V350, P301, DOI 10.1016/j.ydbio.2010.11.035
   Flurkey K., 2007, MOUSE MODELS AGING R
   Gibon E, 2017, J ORTHOP TRANSL, V10, P28, DOI 10.1016/j.jot.2017.04.002
   Gruber R, 2006, EXP GERONTOL, V41, P1080, DOI 10.1016/j.exger.2006.09.008
   Han M, 2008, DEV BIOL, V315, P125, DOI 10.1016/j.ydbio.2007.12.025
   Hayflick L, 2007, PLOS GENET, V3, P2351, DOI 10.1371/journal.pgen.0030220
   He JN, 2006, BONE, V38, P826, DOI 10.1016/j.bone.2005.11.021
   Itou J, 2012, BIOL OPEN, V1, P739, DOI 10.1242/bio.20121057
   Kwak YH, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 45339 0
   Laschober GT, 2011, REJUV RES, V14, P119, DOI 10.1089/rej.2010.1077
   Liu L, 2018, CELL STEM CELL, V23, P544, DOI 10.1016/j.stem.2018.08.019
   López Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   McCusker C, 2015, REGENERATION, V2, P54, DOI 10.1002/reg2.32
   Miller RA, 2000, J GERONTOL A BIOL, V55, pB117, DOI 10.1093/gerona/55.3.B117
   Muneoka K, 2021, J EXP ZOOL PART B, V336, P165, DOI 10.1002/jez.b.22925
   Muneoka Ken, 2008, Birth Defects Research, V84, P265, DOI 10.1002/bdrc.20137
   Navarro A, 2004, AM J PHYSIOL REG I, V286, pR505, DOI 10.1152/ajpregu.00208.2003
   Oviedo NJ, 2009, SEMIN CELL DEV BIOL, V20, P557, DOI 10.1016/j.semcdb.2009.04.005
   Pang WW, 2011, P NATL ACAD SCI USA, V108, P20012, DOI 10.1073/pnas.1116110108
   Piemontese M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93771
   Roy S, 2008, EXP GERONTOL, V43, P968, DOI 10.1016/j.exger.2008.09.003
   Sammarco MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140156
   Sammarco MC, 2014, J BONE MINER RES, V29, P2336, DOI 10.1002/jbmr.2261
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Sehring IM, 2020, WIRES DEV BIOL, V9, DOI 10.1002/wdev.367
   Seifert AW, 2013, BMC BIOL, V11, DOI 10.1186/1741 7007 11 2
   Simkin J, 2017, DEVELOPMENT, V144, P3907, DOI 10.1242/dev.150086
   Simkin J, 2015, REGENERATION, V2, P93, DOI 10.1002/reg2.36
   Simkin J, 2015, REGENERATION, V2, P106, DOI 10.1002/reg2.34
   Slack JMW, 2017, EMBO REP, V18, P1497, DOI 10.15252/embr.201643795
   Takeo M, 2013, NATURE, V499, P228, DOI 10.1038/nature12214
   Tsai SB, 2007, AGING CELL, V6, P209, DOI 10.1111/j.1474 9726.2007.00278.x
   Vieira WA, 2020, GERONTOLOGY, V66, P212, DOI 10.1159/000504294
   Wendler S, 2015, AGING CELL, V14, P857, DOI 10.1111/acel.12367
   Yukata K, 2014, BONE, V62, P79, DOI 10.1016/j.bone.2014.02.002
NR 49
TC 9
Z9 9
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079 5006
EI 1758 535X
J9 J GERONTOL A BIOL
JI J. Gerontol. Ser. A Biol. Sci. Med. Sci.
PD OCT
PY 2021
VL 76
IS 10
BP 1726
EP 1733
DI 10.1093/gerona/glab131
EA MAY 2021
PG 8
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA YL1QF
UT WOS:000745673000016
PM 33970250
DA 2025 08 17
ER

PT J
AU Kim, W
   Tokuda, H
   Tanabe, K
   Yamaguchi, S
   Hioki, T
   Tachi, J
   Matsushima Nishiwaki, R
   Kozawa, O
   Iida, H
AF Kim, Woo
   Tokuda, Haruhiko
   Tanabe, Kumiko
   Yamaguchi, Shinobu
   Hioki, Tomoyuki
   Tachi, Junko
   Matsushima Nishiwaki, Rie
   Kozawa, Osamu
   Iida, Hiroki
TI Acetaminophen reduces osteoprotegerin synthesis stimulated by
   PGE2 and PGF2α in osteoblasts: attenuation of
   SAPK/JNK but not p38 MAPK or p44/p42 MAPK
SO BIOMEDICAL RESEARCH TOKYO
LA English
DT Article
ID BONE; DIFFERENTIATION; RESVERATROL; TRAMADOL
AB Acetaminophen is one of the most widely used analgesic and antipyretic medicines, whose long period use has reportedly been associated with an increased risk of bone fracture. However, the mechanism underlying this undesired effect remains to be investigated. The homeostatic control of bone tissue depends on the interaction between osteoblasts and osteoclasts. Osteoprotegerin produced by osteoblasts is known to play an essential role in suppressing osteoclast induction. We have previously reported that prostaglandin (PG) E 2 and PGF(2 alpha) induce osteoprotegerin synthesis through p38 mitogen activated protein kinase (MAPK), p44/p42 MAPK and stress activated protein kinase/c Jun N terminal kinase (SAPK/JNK) in osteoblast like MC3T3 E1 cells. In the present study, we investigated the effects of acetaminophen on the osteoprotegerin synthesis induced by PGE(2) and PGF(2 alpha) in MC3T3 E1 cells. Acetaminophen significantly suppressed the osteoprotegerin release stimulated by PGE(2) and PGF(2 alpha). The PGE(2) induced expression of osteoprotegerin mRNA was also reduced by acetaminophen. Acetaminophen markedly downregulated the phosphorylation of SAPK/JNK stimulated by PGE(2) and PGF(2 alpha), but not those of p38 MAPK or p44/p42 MAPK. SP600125, an inhibitor of SAPK/JNK, suppressed the levels of PGE(2)  and PGF(2 alpha) upregulated osteoprotegerin mRNA expression. Taken together, these results strongly suggest that acetaminophen reduces the PGE(2)  and PGF(2 alpha) stimulated synthesis of osteoprotegerin in osteoblasts, and that the suppressive effect is exerted via attenuation of SAPK/JNK. These findings provide a molecular basis for the possible effect of acetaminophen on bone tissue metabolism.
C1 [Kim, Woo; Tanabe, Kumiko; Yamaguchi, Shinobu; Hioki, Tomoyuki; Tachi, Junko; Iida, Hiroki] Gifu Univ, Dept Anesthesiol & Pain Med, Grad Sch Med, Gifu 5011194, Japan.
   [Kim, Woo; Tokuda, Haruhiko; Tachi, Junko; Matsushima Nishiwaki, Rie; Kozawa, Osamu] Gifu Univ, Dept Pharmacol, Grad Sch Med, Gifu 5011194, Japan.
   [Tokuda, Haruhiko] Natl Ctr Geriatr & Gerontol, Dept Clin Lab Med Genome Ctr, Obu 4748511, Japan.
   [Hioki, Tomoyuki] Kizawa Mem Hosp, Dept Dermatol, Minokamo 5050034, Japan.
C3 Gifu University; Gifu University; National Center for Geriatrics &
   Gerontology
RP Kozawa, O (通讯作者)，Gifu Univ, Dept Pharmacol, Grad Sch Med, Gifu 5011194, Japan.
EM okkasugai@yahoo.co.jp
RI Takama, Hiroyuki/H 8679 2019
OI Matsushima Nishiwaki, Rie/0009 0003 7496 737X
FU JSPS KAKENHI [19K09370]; National Center for Geriatrics and Gerontology
   (NCGG), Japan [29 12, 19 21];  [24462289]; Grants in Aid for Scientific
   Research [19K09370] Funding Source: KAKEN
FX We appreciate Mrs. Yumiko Kurokawa's skillful technical assistance. This
   investigation was supported in part by JSPS KAKENHI (grant number;
   19K09370 to HI), Grant in Aid for Scientific research (grant number;
   24462289 to HT), and the Research Funding for Longevity Sciences (grant
   numbers; 29 12 and 19 21 to HT) from National Center for Geriatrics and
   Gerontology (NCGG), Japan.
CR Abuknesha RA, 2011, ANAL BIOANAL CHEM, V401, P2195, DOI 10.1007/s00216 011 5272 0
   Agas D, 2013, J CELL PHYSIOL, V228, P25, DOI 10.1002/jcp.24117
   Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Bravo L, 2017, EXPERT OPIN DRUG DIS, V12, P1281, DOI 10.1080/17460441.2017.1377697
   Brune K, 2015, EUR J PAIN, V19, P953, DOI 10.1002/ejp.621
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Ghanem CI, 2016, PHARMACOL RES, V109, P119, DOI 10.1016/j.phrs.2016.02.020
   Hahn TW, 2000, ACTA ANAESTH SCAND, V44, P302, DOI 10.1034/j.1399 6576.2000.440314.x
   Hikiji H, 2008, PROG LIPID RES, V47, P107, DOI 10.1016/j.plipres.2007.12.003
   Iorga A, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100300
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kato K, 1996, J NEUROCHEM, V66, P946
   Kim W., 2020, Heliyon, V6
   Kozawa O, 1997, AM J PHYSIOL ENDOC M, V272, pE208, DOI 10.1152/ajpendo.1997.272.2.E208
   Kuroyanagi G, 2014, ARCH BIOCHEM BIOPHYS, V542, P39, DOI 10.1016/j.abb.2013.12.002
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Nakatsu Y, 2018, PHARMACOL REP, V70, P29, DOI 10.1016/j.pharep.2017.07.006
   Qiu S, 2015, MOL CELL BIOCHEM, V399, P131, DOI 10.1007/s11010 014 2240 y
   Rossi F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081919
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytogfr.2003.10.005
   Subedi M, 2019, BIOMED PHARMACOTHER, V111, P443, DOI 10.1016/j.biopha.2018.12.085
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563
   Wheatley BM, 2019, J AM ACAD ORTHOP SUR, V27, pE330, DOI 10.5435/JAAOS D 17 00727
   Williams LJ, 2011, BONE, V48, P1277, DOI 10.1016/j.bone.2011.03.435
   Yamamoto N, 2014, INT J MOL MED, V34, P1439, DOI 10.3892/ijmm.2014.1934
NR 29
TC 1
Z9 1
U1 0
U2 7
PU BIOMEDICAL RESEARCH PRESS LTD
PI SAPPORO
PA HOKKAIDO UNIV, LAB HISTOLOGY & CYTOLOGY, C/O TOSHIHIKO IWANAGA, KITA
   15 NISHI 7, SAPPORO, 060 8638, JAPAN
SN 0388 6107
EI 1880 313X
J9 BIOMED RES TOKYO
JI Biomed. Res.
PY 2021
VL 42
IS 2
BP 77
EP 84
DI 10.2220/biomedres.42.77
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA RM9ZN
UT WOS:000640015500004
PM 33840687
OA gold
DA 2025 08 17
ER

PT J
AU Zhou, QH
   Chen, X
   Yao, K
   Zhang, YJ
   He, HX
   Huang, H
   Chen, H
   Peng, SM
   Huang, M
   Cheng, L
   Zhang, Q
   Xie, RH
   Li, KW
   Lin, TX
   Huang, H
AF Zhou, Qianghua
   Chen, Xu
   Yao, Kai
   Zhang, Yangjie
   He, Haixia
   Huang, Hao
   Chen, Hao
   Peng, Shengmeng
   Huang, Ming
   Cheng, Liang
   Zhang, Qiang
   Xie, Ruihui
   Li, Kaiwen
   Lin, Tianxin
   Huang, Hai
TI TSPAN18 facilitates bone metastasis of prostate cancer by protecting
   STIM1 from TRIM32 mediated ubiquitination
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Prostate cancer; Bone metastasis; STIM1; TSPAN18; TRIM32
ID OPERATED CA2+ ENTRY; CELL PROLIFERATION; MIGRATION; INVASION; CALCIUM;
   EXPRESSION; METABOLISM; ACTIVATION; SECRETION; DENOSUMAB
AB BackgroundBone metastasis is a principal cause of mortality in patients with prostate cancer (PCa). Increasing evidence indicates that high expression of stromal interaction molecule 1 (STIM1) mediated store operated calcium entry (SOCE) significantly activates the calcium (Ca2+) signaling pathway and is involved in multiple steps of bone metastasis in PCa. However, the regulatory mechanism and target therapy of STIM1 is poorly defined.MethodsLiquid chromatography mass spectrometry analysis was performed to identify tetraspanin 18 (TSPAN18) as a binding protein of STIM1. Co IP assay was carried out to explore the mechanism by which TSPAN18 inhibits STIM1 degradation. The biological function of TSPAN18 in bone metastasis of PCa was further investigated in vitro and in vivo models.ResultWe identified that STIM1 directly interacted with TSPAN18, and TSPAN18 competitively inhibited E3 ligase tripartite motif containing 32 (TRIM32) mediated STIM1 ubiquitination and degradation, leading to increasing STIM1 protein stability. Furthermore, TSPAN18 significantly stimulated Ca2+ influx in an STIM1 dependent manner, and then markedly accelerated PCa cells migration and invasion in vitro and bone metastasis in vivo. Clinically, overexpression of TSPAN18 was positively associated with STIM1 protein expression, bone metastasis and poor prognosis in PCa.ConclusionTaken together, this work discovers a novel STIM1 regulative mechanism that TSPAN18 protects STIM1 from TRIM32 mediated ubiquitination, and enhances bone metastasis of PCa by activating the STIM1 Ca2+ signaling axis, suggesting that TSPAN18 may be an attractive therapeutic target for blocking bone metastasis in PCa.
C1 [Zhou, Qianghua; Chen, Xu; Zhang, Yangjie; Huang, Hao; Chen, Hao; Peng, Shengmeng; Huang, Ming; Cheng, Liang; Zhang, Qiang; Xie, Ruihui; Li, Kaiwen; Lin, Tianxin; Huang, Hai] Sun Yat sen Univ, Sun Yat sen Mem Hosp, Dept Urol, 107th yanjiangxi Rd, Guangzhou 510120, Peoples R China.
   [Zhou, Qianghua; Chen, Xu; Zhang, Yangjie; He, Haixia; Huang, Hao; Chen, Hao; Peng, Shengmeng; Huang, Ming; Cheng, Liang; Zhang, Qiang; Xie, Ruihui; Li, Kaiwen; Lin, Tianxin; Huang, Hai] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China.
   [Zhou, Qianghua; Yao, Kai] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou 510060, Peoples R China.
   [He, Haixia] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Radiat Oncol, Guangzhou 510120, Peoples R China.
   [Lin, Tianxin] Guangdong Prov Clin Res Ctr Urol Dis, Guangzhou 510120, Guangdong, Peoples R China.
   [Huang, Hai] Guangzhou Med Univ, Qingyuan Peoples Hosp, Dept Urol, Affiliated Hosp 6, Qingyuan 511518, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Sun Yat Sen University; Guangzhou Medical University
RP Li, KW; Lin, TX; Huang, H (通讯作者)，Sun Yat sen Univ, Sun Yat sen Mem Hosp, Dept Urol, 107th yanjiangxi Rd, Guangzhou 510120, Peoples R China.; Li, KW; Lin, TX; Huang, H (通讯作者)，Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China.; Lin, TX (通讯作者)，Guangdong Prov Clin Res Ctr Urol Dis, Guangzhou 510120, Guangdong, Peoples R China.; Huang, H (通讯作者)，Guangzhou Med Univ, Qingyuan Peoples Hosp, Dept Urol, Affiliated Hosp 6, Qingyuan 511518, Guangdong, Peoples R China.
EM likw6@mail.sysu.edu.cn; lintx@mail.sysu.edu.cn; Huangh9@mail.sysu.edu.cn
RI Huang, Mingzhe/JJC 9847 2023; zhang, yangjie/HMV 9582 2023; Chen,
   Xu/ISS 8928 2023; Huang, Hai/AFN 6563 2022; Zhang, Yunwei/AAW 8460 2020;
   Zhou, Qianghua/AAQ 1973 2021; zhang, qiang/HZJ 9551 2023
FU Guangdong Science and Technology Department [2017B030314026]
FX AcknowledgementsThis work was supported by grants from Guangdong Science
   and Technology Department (2017B030314026). We sincerely thank Prof.
   Xiaojuan Wang and Tian Qiao from the Bioinformatics and Omics Center,
   SYSMH for their assistance in mass spectrometry analysis. We also would
   like to thank Dr Jian chang Fu and Dr Yuan zhong Yang from Department of
   Pathology, SYSUCC for their assistance in IHC score.
CR Ardura JA, 2020, CANCERS, V12, DOI 10.3390/cancers12051071
   Bekelman JE, 2018, J CLIN ONCOL, V36, P3251, DOI 10.1200/JCO.18.00606
   Cahalan MD, 2009, NAT CELL BIOL, V11, P669, DOI 10.1038/ncb0609 669
   Chen X, 2019, CLIN CANCER RES, V25, P1389, DOI 10.1158/1078 0432.CCR 18 1656
   Derler I, 2016, AM J PHYSIOL CELL PH, V310, pC643, DOI 10.1152/ajpcell.00007.2016
   Fairchild CL, 2013, J CELL SCI, V126, P1464, DOI 10.1242/jcs.120915
   Figiel S, 2019, CANCERS, V11, DOI 10.3390/cancers11111814
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hegemann M, 2017, THER ADV UROL, V9, P81, DOI 10.1177/1756287216686018
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Huang CY, 2018, CELLS BASEL, V7, DOI 10.3390/cells7120262
   Huang QQ, 2023, BMC MED, V21, DOI 10.1186/s12916 023 02763 4
   Jin JK, 2011, INT J CANCER, V128, P2545, DOI 10.1002/ijc.26024
   Kondratskyi A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.156
   Koo CZ, 2020, J BIOL CHEM, V295, P12822, DOI 10.1074/jbc.RA120.012601
   Kutschat AP, 2021, CANCER RES, V81, P2943, DOI 10.1158/0008 5472.CAN 20 2874
   Kyriakopoulos CE, 2018, J CLIN ONCOL, V36, P1080, DOI 10.1200/JCO.2017.75.3657
   Lee SK, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2021.110281
   Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637
   Li ZA, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.191
   Liao JH, 2006, CANCER RES, V66, P9065, DOI 10.1158/0008 5472.CAN 06 0317
   Liu X, 2020, EBIOMEDICINE, V61, DOI 10.1016/j.ebiom.2020.103058
   Matthews AL, 2017, BIOCHEM SOC T, V45, P719, DOI 10.1042/BST20160290
   Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171
   Noy PJ, 2019, HAEMATOLOGICA, V104, P1892, DOI 10.3324/haematol.2018.194241
   Peng SM, 2022, INT J BIOL SCI, V18, P3528, DOI 10.7150/ijbs.72629
   Perrouin Verbe MA, 2019, PROSTATE, V79, P1793, DOI 10.1002/pros.23904
   Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374
   Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019
   Sanders JL, 2001, AM J PHYSIOL ENDOC M, V281, pE1267, DOI 10.1152/ajpendo.2001.281.6.E1267
   Siegel RL, 2019, CA CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Smith MR, 2013, J CLIN ONCOL, V31, P3800, DOI 10.1200/JCO.2012.44.6716
   Xia JL, 2016, CANCER LETT, V381, P31, DOI 10.1016/j.canlet.2016.07.014
   Xie RH, 2021, MOL THER, V29, P291, DOI 10.1016/j.ymthe.2020.08.018
   Yang N, 2013, CANCER LETT, V330, P163, DOI 10.1016/j.canlet.2012.11.040
   Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019
   Yano S, 2004, BONE, V35, P664, DOI 10.1016/j.bone.2004.04.014
   Zhang BZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03716 9
   Zhang Z, 2015, ONCOGENE, V34, P4808, DOI 10.1038/onc.2014.404
   Zhao HK, 2020, THERANOSTICS, V10, P6483, DOI 10.7150/thno.44025
   Zhou QH, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc 2021 002455
   Zhou QH, 2021, THERANOSTICS, V11, P4809, DOI 10.7150/thno.55814
   Zhou YB, 2017, ONCOL REP, V38, P2629, DOI 10.3892/or.2017.5961
   Zhu RX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10739 3
NR 44
TC 17
Z9 17
U1 2
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756 9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD AUG 5
PY 2023
VL 42
IS 1
AR 195
DI 10.1186/s13046 023 02764 4
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA O0PV3
UT WOS:001040936200001
PM 37542345
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Stresing, V
   Fournier, PG
   Bellahcène, A
   Benzaïd, I
   Mönkkönen, H
   Colombel, M
   Ebetino, FH
   Castronovo, V
   Clézardin, P
AF Stresing, Verena
   Fournier, Pierrick G.
   Bellahcene, Akeila
   Benzaid, Ismahene
   Monkkonen, Hannu
   Colombel, Marc
   Ebetino, F. Hal
   Castronovo, Vincent
   Clezardin, Philippe
TI Nitrogen containing bisphosphonates can inhibit angiogenesis in
   vivo without the involvement of farnesyl pyrophosphate synthase
SO BONE
LA English
DT Article
DE Bisphosphonate; Risedronate; Zoledronate; FPPS; Angiogenesis
ID METASTATIC BONE DISEASE; ZOLEDRONIC ACID; ENDOTHELIAL CELLS;
   CANCER PATIENTS; ATP ANALOG; SIGNALING PATHWAYS; ALENDRONATE;
   ACTIVATION; APOPTOSIS; GROWTH
AB Nitrogen containing bisphosphonates (N Bps) are widely used to block bone destruction associated with bone metastasis because they are effective inhibitors of osteoclast mediated bone resorption. More specifically, once internalized by osteoclasts, N BPs block the activity of farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway. In addition to their antiresorptive activity, preclinical evidence shows that N BPs have antiangiogenic properties. However, the exact reasons for which N BPs inhibit angiogenesis remain largely unknown. Using different angiogenesis models, we examined here the effects of zoledronate, risedronate and three structural analogs of risedronate (NE 58025, NE 58051 and NE 10790) with lower potencies to inhibit FPPS activity. Risedronate and zoledronate were much more potent than NE compounds at inhibiting both endothelial cell proliferation in vitro and vessel sprouting in the chicken egg chorioallantoic membrane (CAM) assay. In addition, only risedronate and zoledronate inhibited the revascularization of the prostate gland in testosterone stimulated castrated rats. Moreover, as opposed to NE compounds, risedronate and zoledronate induced intracellular accumulation of isopentenyl pyrophosphate (IPP) in endothelial cells by blocking the activity of the IPP consuming enzyme FPPS. Thus, these results indicated that N BPs inhibited angiogenesis in a FPPS dependent manner. However, drug concentrations used to inhibit angiogenesis, both in vitro and in the CAM and prostate gland assays, were high. In contrast, a low concentration of risedronate (1 mu M) was sufficient to inhibit blood vessel formation in the ex vivo rat aortic ring assay. Moreover, NE 58025 (which had a 7 fold lower potency than risedronate to inhibit FPPS activity) was as effective as risedronate to reduce angiogenesis in the rat aortic ring assay. In conclusion, our results suggest that low concentrations of N BPs inhibit angiogenesis in a FPPS independent manner, whereas higher drug concentrations were required to inhibit FPPS activity in vivo. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Stresing, Verena; Fournier, Pierrick G.; Benzaid, Ismahene; Monkkonen, Hannu; Colombel, Marc; Clezardin, Philippe] Fac Med Alexis Carrel, INSERM, UMR 664, IFR62, F 69372 Lyon, France.
   [Stresing, Verena; Fournier, Pierrick G.; Benzaid, Ismahene; Monkkonen, Hannu; Colombel, Marc; Clezardin, Philippe] Univ Lyon 1, F 69100 Villeurbanne, France.
   [Bellahcene, Akeila; Castronovo, Vincent] Univ Liege, GIGA Canc, Metastasis Res Lab, B 4000 Cointe Ougree, Belgium.
   [Monkkonen, Hannu] Univ Kuopio, Dept Pharmaceut, FI 70211 Kuopio, Finland.
   [Ebetino, F. Hal] Warner Chilcott, Mason, OH USA.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; Universite Claude Bernard Lyon 1;
   University of Liege; University of Eastern Finland
RP Stresing, V (通讯作者)，Fac Med Alexis Carrel, INSERM, U664, UFR Med Lyon Est Domaine Laennec, Rue Guillaume Paradin, F 69372 Lyon, France.
EM philippe.clezardin@inserm.fr
RI ; Clezardin, Philippe/M 8071 2014; Fournier, Pierrick/B 6560 2015
OI BENZAID, ISMAHENE/0000 0001 9935 4236; Clezardin,
   Philippe/0000 0003 0149 4463; colombel, marc/0000 0002 0152 8021;
   Fournier, Pierrick/0000 0001 7633 8129
FU Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; Alliance for Better Bone Health
   (Procter & Gamble Pharmaceuticals and Sanofi Aventis); Novartis; Ligue
   Regionale contre le Cancer; Association pour la Recherche sur le Cancer;
   Inserm (poste vert)
FX P. Clezardin is supported by Institut National de la Sante et de la
   Recherche Medicale (Inserm), Universite Claude Bernard Lyon 1, Alliance
   for Better Bone Health (Procter & Gamble Pharmaceuticals and
   Sanofi Aventis), Novartis and Ligue Regionale contre le Cancer. P.
   Fournier was a recipient of a fellowship from the Association pour la
   Recherche sur le Cancer. Hannu Monkkonen was supported by Inserm (poste
   vert). Akeila Bellahcene is a Senior Research Associate at the National
   Fund for Scientific Research (Belgium).
CR Bellahcène A, 2007, ENDOTHELIUM J ENDOTH, V14, P123, DOI 10.1080/10623320701347187
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Biver E, 2010, BONE, V46, P643, DOI 10.1016/j.bone.2009.10.034
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Deckers MML, 2002, J BONE MINER RES, V17, P998, DOI 10.1359/jbmr.2002.17.6.998
   Dieli F, 2003, BLOOD, V102, P2310, DOI 10.1182/blood 2003 05 1655
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Ebetino FH, 2008, BONE, V42, pS36, DOI 10.1016/j.bone.2007.12.056
   FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495 199142060 00003
   Fournier P, 2002, CANCER RES, V62, P6538
   Fournier PG, 2010, NEOPLASIA, V12, P571, DOI 10.1593/neo.10282
   Hashimoto K, 2007, BIOCHEM BIOPH RES CO, V354, P478, DOI 10.1016/j.bbrc.2007.01.014
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Inoue R, 2005, BRIT J PHARMACOL, V146, P633, DOI 10.1038/sj.bjp.0706373
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   Kunzmann V, 2000, BLOOD, V96, P384
   Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008 5472.CAN 07 1882
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2008, ANTI CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   NICOSIA RF, 1990, LAB INVEST, V63, P115
   Plotkin LI, 2001, CELL COMMUN ADHES, V8, P377, DOI 10.3109/15419060109080757
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Ribatti D, 2007, CLIN RHEUMATOL, V26, P1094, DOI 10.1007/s10067 006 0455 3
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   Skorey K, 1997, J BIOL CHEM, V272, P22472, DOI 10.1074/jbc.272.36.22472
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Tang XD, 2010, INT J CANCER, V126, P90, DOI 10.1002/ijc.24710
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 35
TC 80
Z9 90
U1 0
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD FEB 1
PY 2011
VL 48
IS 2
BP 259
EP 266
DI 10.1016/j.bone.2010.09.035
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 710UY
UT WOS:000286543700012
PM 20920623
DA 2025 08 17
ER

PT J
AU Ali, D
   Chen, L
   Kowal, JM
   Okla, M
   Manikandan, M
   AlShehri, M
   AlMana, Y
   AlObaidan, R
   AlOtaibi, N
   Hamam, R
   Alajez, NM
   Aldahmash, A
   Kassem, M
   Alfayez, M
AF Ali, Dalia
   Chen, Li
   Kowal, Justyna M.
   Okla, Meshail
   Manikandan, Muthurangan
   AlShehri, Moayad
   AlMana, Yousef
   AlObaidan, Reham
   AlOtaibi, Najd
   Hamam, Rimi
   Alajez, Nehad M.
   Aldahmash, Abdullah
   Kassem, Moustapha
   Alfayez, Musaad
TI Resveratrol inhibits adipocyte differentiation and cellular senescence
   of human bone marrow stromal stem cells
SO BONE
LA English
DT Article
DE Bone marrow skeletal stromal cells; Osteogenesis; Adipogenesis; Bone
   marrow adiposity; Antioxidant; Cellular senescence
ID DIET INDUCED OBESITY; ADIPOSE TISSUE; FAT CONTENT; MINERAL DENSITY;
   OSTEOGENIC DIFFERENTIATION; GENE EXPRESSION; MESSENGER RNA;
   SELF RENEWAL; SIRT1; OSTEOPOROSIS
AB Bone marrow adipose tissue (BMAT) is a unique adipose depot originating from bone marrow stromal stem cells (BMSCs) and regulates bone homeostasis and energy metabolism. An increased BMAT volume is observed in several conditions e.g. obesity, type 2 diabetes, osteoporosis and is known to be associated with bone fragility and increased risk for fracture. Therapeutic approaches to decrease the accumulation of BMAT are clinically relevant. In a screening experiment of natural compounds, we identified Resveratrol (RSV), a plant derived antioxidant mediating biological effects via sirtuin related mechanisms, to exert significant effects of BMAT formation. Thus, we examined in details the effects RSV on adipocytic and osteoblastic differentiation of tolermerized human BMSCs (hBMSC TERT). RSV (1.0 mu M) enhanced osteoblastic differentiation and inhibited adipocytic differentiation of hBMSC TERT when compared with control and Sirtinol (Sirtuin inhibitor). Global gene expression profiling and western blot analysis revealed activation of a number of signaling pathways including focal adhesion kinase (FAK). Pharmacological inhibition of FAK using (PF 573228) and AKT inhibitor (LY 294002) (5 mu M), diminished RSV induced osteoblast differentiation. In addition, RSV reduced the levels of senescence associated secretory phenotype (SASP), gene markers associated with senescence (P53, P16, and P21), intracellular ROS levels and increased gene expression of enzymes protecting cells from oxidative damage (HMOX1 and SOD3). In vitro treatment of primary hBMSCs from aged patients characterized with high adipocytic and low osteoblastic differentiation ability with RSV, significantly enhanced osteoblast and decreased adipocyte formation when compared to hBMSCs from young donors. RSV targets hBMSCs and inhibits adipogenic differentiation and senescence associated phenotype and thus a potential agent for treating conditions of increased BMAT formation.
C1 [Manikandan, Muthurangan; AlShehri, Moayad; AlMana, Yousef; AlObaidan, Reham; AlOtaibi, Najd; Hamam, Rimi; Alajez, Nehad M.; Aldahmash, Abdullah; Kassem, Moustapha; Alfayez, Musaad] King Saud Univ, Coll Med, Dept Anat, Stem Cell Unit, Riyadh, Saudi Arabia.
   [Ali, Dalia; Chen, Li; Kowal, Justyna M.; Kassem, Moustapha] Univ Hosp Odense, Dept Endocrinol & Metab, Mol Endocrinol & Stem Cell Res Unit KMEB, Odense, Denmark.
   [Ali, Dalia; Chen, Li; Kowal, Justyna M.; Kassem, Moustapha] Univ Southern Denmark, JB Winslows Vej 25,1, DK 5000 Odense C, Denmark.
   [Okla, Meshail] King Saud Univ, Coll Appl Med Sci, Dept Community Hlth Sci, Riyadh, Saudi Arabia.
   [Aldahmash, Abdullah] King Saud Univ, Prince Naif Hlth Res Ctr, Riyadh, Saudi Arabia.
   [Kassem, Moustapha] Univ Copenhagen, Danish Stem Cell Ctr DanStem, Dept Cellular & Mol Med, DK 2200 Copenhagen, Denmark.
C3 King Saud University; University of Southern Denmark; Odense University
   Hospital; University of Southern Denmark; King Saud University; King
   Saud University; University of Copenhagen
RP Ali, D (通讯作者)，Univ Southern Denmark, JB Winslows Vej 25,1, DK 5000 Odense C, Denmark.; Ali, D (通讯作者)，Odense Univ Hosp, Mol Endocrinol & Stem Cell Res Unit KMEB, JB Winslows Vej 25,1, DK 5000 Odense C, Denmark.
EM dayesh@health.sdu.dk; lchen@health.sdu.dk; jkowal@health.sdu.dk;
   meokla@ksu.edu.sa; coralmani@gmail.com; moayadkhalid@gmail.com;
   yousef.almana@gmail.com; Re.alobaidan@gmail.com; najd.muneef@gmail.com;
   rimih@hotmail.com; nalajez@gmail.com; dahmash@ksu.edu.sa;
   mkassem@health.sdu.dk; alfayez@ksu.edu.sa
RI ; muthurangan, manikandan/GVU 5356 2022; Okla, Meshail/E 9317 2017; Ali,
   Dalia/KEH 0488 2024; Kassem, Moustapha/J 7688 2013; Chen,
   Li/AAN 7309 2020; Aldahmash, Abdullah/D 4693 2015
OI Ali, Dalia/0000 0002 2852 5971; Kowal, Justyna
   Magdalena/0000 0002 8489 4464; Almana, Yousef/0000 0002 3367 4162; Okla,
   Meshail/0000 0003 4855 243X; muthurangan,
   manikandan/0000 0003 3057 1851; Alajez, Nehad/0000 0002 1546 1091
FU Deanship of Scientific Research at King Saud University Research Group
   [RG 1438 033]
FX This work was supported by the Deanship of Scientific Research at King
   Saud University Research Group No. RG 1438 033.
CR Abdallah BM, 2015, BONE, V70, P28, DOI 10.1016/j.bone.2014.07.028
   Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Abed E, 2016, Biomarkers in Bone Disease, P1
   de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156
   Aldahmash A, 2012, ANN SAUDI MED, V32, P68, DOI 10.5144/0256 4947.2012.68
   Amiri F, 2015, CELL STRESS CHAPERON, V20, P237, DOI 10.1007/s12192 014 0560 1
   [Anonymous], J CLIN EXP CARDIOLOG
   Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   Baker N, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0225 8
   Baum T, 2012, J MAGN RESON IMAGING, V35, P117, DOI 10.1002/jmri.22757
   Bhattacharya Semantee, 2011, Pathophysiology, V18, P221, DOI 10.1016/j.pathophys.2011.02.001
   Biggs MJP, 2009, BIOMATERIALS, V30, P5094, DOI 10.1016/j.biomaterials.2009.05.049
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Bornstein S, 2017, ENDOCRINOLOGY, V158, P3369, DOI 10.1210/en.2017 00299
   Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200
   Buhrmann C, 2014, J BIOL CHEM, V289, P22048, DOI 10.1074/jbc.M114.568790
   Camp HS, 2002, TRENDS MOL MED, V8, P442, DOI 10.1016/S1471 4914(02)02396 1
   Cao ZX, 2004, EUR J PHARMACOL, V489, P39, DOI 10.1016/j.ejphar.2004.02.031
   Chen SC, 2019, J CLIN ENDOCR METAB, V104, P3585, DOI 10.1210/jc.2019 00084
   Chen X, 2015, IMMUNOLOGY, V145, P455, DOI 10.1111/imm.12473
   Costa CD, 2011, OBES SURG, V21, P356, DOI 10.1007/s11695 010 0251 7
   Dai Z, 2007, PHYTOMEDICINE, V14, P806, DOI 10.1016/j.phymed.2007.04.003
   Das Samarjit, 2007, Inflammation & Allergy Drug Targets, V6, P168, DOI 10.2174/187152807781696464
   Edwards JR, 2013, J BONE MINER RES, V28, P960, DOI 10.1002/jbmr.1824
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   Gehm BD, 2004, J STEROID BIOCHEM, V88, P223, DOI 10.1016/j.jsbmb.2003.12.002
   Gertz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049761
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Griffith JF, 2006, RADIOLOGY, V241, P831, DOI 10.1148/radiol.2413051858
   Griffith JF, 2005, RADIOLOGY, V236, P945, DOI 10.1148/radiol.2363041425
   Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001
   Hu J, 2016, SCI REP UK, V6, DOI 10.1038/srep20875
   Hung LM, 2000, CARDIOVASC RES, V47, P549, DOI 10.1016/S0008 6363(00)00102 4
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Kao CL, 2010, STEM CELLS DEV, V19, P247, DOI 10.1089/scd.2009.0186
   Khanh VC, 2018, BIOCHEM BIOPH RES CO, V500, P682, DOI 10.1016/j.bbrc.2018.04.136
   Kupisiewicz K, 2010, CALCIFIED TISSUE INT, V87, P437, DOI 10.1007/s00223 010 9399 3
   Li GW, 2014, CLIN RADIOL, V69, P254, DOI 10.1016/j.crad.2013.10.005
   Ling L, 2017, MOL MED REP, V15, P1188, DOI 10.3892/mmr.2017.6143
   Liu XM, 2018, MOL CELL BIOCHEM, V439, P213, DOI 10.1007/s11010 017 3149 z
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lv YJ, 2018, THERANOSTICS, V8, P2387, DOI 10.7150/thno.23620
   Mathieu PS, 2012, TISSUE ENG PART B RE, V18, P436, DOI [10.1089/ten.teb.2012.0014, 10.1089/ten.TEB.2012.0014]
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Andrade JMO, 2014, EUR J NUTR, V53, P1503, DOI 10.1007/s00394 014 0655 6
   Patsch JM, 2013, J BONE MINER RES, V28, P1721, DOI 10.1002/jbmr.1950
   Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rosen ED, 2000, GENE DEV, V14, P1293
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Sato M, 1998, J BONE MINER RES, V13, P1221, DOI 10.1359/jbmr.1998.13.8.1221
   Schilling T, 2014, J STEROID BIOCHEM, V139, P252, DOI 10.1016/j.jsbmb.2012.12.006
   Seo E, 2011, MOL CELL BIOL, V31, P4593, DOI 10.1128/MCB.05798 11
   Shakibaei M, 2011, J BIOL CHEM, V286, P11492, DOI 10.1074/jbc.M110.198713
   Sheu Y, 2017, BONE, V97, P299, DOI 10.1016/j.bone.2017.02.001
   Shirjang S, 2017, CELL IMMUNOL, V315, P1, DOI 10.1016/j.cellimm.2016.12.005
   Simic P, 2013, EMBO MOL MED, V5, P430, DOI 10.1002/emmm.201201606
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Tamori Y, 2002, DIABETES, V51, P2045, DOI 10.2337/diabetes.51.7.2045
   Tencerova M, 2019, CELL REP, V27, P2050, DOI 10.1016/j.celrep.2019.04.066
   Tencerova M, 2018, J BONE MINER RES, V33, P1154, DOI 10.1002/jbmr.3408
   Tencerova M, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00127
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Veldhuis Vlug AG, 2018, J INTERN MED, V283, P121, DOI 10.1111/joim.12718
   Vishnubalaji R, 2012, CELL TISSUE RES, V347, P419, DOI 10.1007/s00441 011 1306 3
   Wang WS, 2016, NAT REV MOL CELL BIO, V17, P691, DOI 10.1038/nrm.2016.96
   Wang YJ, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0109 y
   Wei Shengjuan, 2013, J Genomics, V1, P5, DOI 10.7150/jgen.3769
   Yeung DKW, 2005, J MAGN RESON IMAGING, V22, P279, DOI 10.1002/jmri.20367
   Yoon DS, 2015, BIOCHEM BIOPH RES CO, V467, P1026, DOI 10.1016/j.bbrc.2015.10.017
   Yoon DS, 2014, STEM CELLS, V32, P3219, DOI 10.1002/stem.1811
   Yuan HF, 2013, ONCOTARGETS THER, V6, P1399, DOI 10.2147/OTT.S37750
NR 75
TC 49
Z9 52
U1 2
U2 41
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2020
VL 133
AR 115252
DI 10.1016/j.bone.2020.115252
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA KR1BX
UT WOS:000517355400021
PM 31978617
DA 2025 08 17
ER

PT J
AU Waddell, SJ
   de Andrés, MC
   Tsimbouri, PM
   Alakpa, EV
   Cusack, M
   Dalby, MJ
   Oreffo, ROC
AF Waddell, Shona J.
   de Andres, Maria C.
   Tsimbouri, Penelope M.
   Alakpa, Enateri V.
   Cusack, Maggie
   Dalby, Matthew J.
   Oreffo, Richard O. C.
TI Biomimetic oyster shell replicated topography alters the behaviour of
   human skeletal stem cells
SO JOURNAL OF TISSUE ENGINEERING
LA English
DT Article
DE Nacre; topography; skeletal stem cell; osteogenic differentiation; bone
   regeneration
ID OSTEOBLASTS MAINTAINED INVITRO; BONE TISSUE REGENERATION; SIGNALING
   PATHWAY; NACRE; DIFFERENTIATION; NANOTOPOGRAPHY; METABOLOMICS;
   ACTIVATION; MATRIX; RUNX2
AB The regenerative potential of skeletal stem cells provides an attractive prospect to generate bone tissue needed for musculoskeletal reparation. A central issue remains efficacious, controlled cell differentiation strategies to aid progression of cell therapies to the clinic. The nacre surface from Pinctada maxima shells is known to enhance bone formation. However, to date, there is a paucity of information on the role of the topography of P. maxima surfaces, nacre and prism. To investigate this, nacre and prism topographical features were replicated onto polycaprolactone and skeletal stem cell behaviour on the surfaces studied. Skeletal stem cells on nacre surfaces exhibited an increase in cell area, increase in expression of osteogenic markers ALP (p<0.05) and OCN (p<0.01) and increased metabolite intensity (p<0.05), indicating a role of nacre surface to induce osteogenic differentiation, while on prism surfaces, skeletal stem cells did not show alterations in cell area or osteogenic marker expression and a decrease in metabolite intensity (p<0.05), demonstrating a distinct role for the prism surface, with the potential to maintain the skeletal stem cell phenotype.
C1 [Waddell, Shona J.; de Andres, Maria C.; Oreffo, Richard O. C.] Univ Southampton, Fac Med, Inst Dev Sci, Ctr Human Dev Stem Cells & Regenerat, Southampton SO16 6HW, Hants, England.
   [Tsimbouri, Penelope M.; Dalby, Matthew J.] Univ Glasgow, CMVLS, Inst Mol Cell & Syst Biol, Ctr Cell Engn, Glasgow, Lanark, Scotland.
   [Alakpa, Enateri V.] Umea Univ, Dept Integrat Med Biol, Umea, Sweden.
   [Cusack, Maggie] Univ Stirling, Div Biol & Environm Sci, Stirling, Scotland.
C3 University of Southampton; University of Glasgow; Umea University;
   University of Stirling
RP Oreffo, ROC (通讯作者)，Univ Southampton, Fac Med, Inst Dev Sci, Ctr Human Dev Stem Cells & Regenerat, Southampton SO16 6HW, Hants, England.
EM roco@soton.ac.uk
RI ; Oreffo, Richard/A 4615 2011; Alakpa, Enateri/N 6996 2013; Dalby,
   Matthew/G 2426 2012; de+Andrés, María/AAP 1473 2020; Tsimbouri,
   Penelope/F 4373 2010
OI Tsimbouri, Penelope/0000 0001 5124 7458; Oreffo,
   Richard/0000 0001 5995 6726; Dalby, Matthew/0000 0002 0528 3359; de
   Andres, Maria C./0000 0003 2260 6356; Alakpa,
   Enateri/0000 0003 1530 9177
FU BBSRC [BB/L021072/1, BB/L00609X/1]; UK Regenerative Medicine Platform
   [MR/K026682/1]; University of Southampton; MRC grant [MR/K011278/1];
   Biotechnology and Biological Sciences Research Council [JF20604,
   BB/L021072/1, BB/N018419/1, BB/L00609X/1, BB/G008868/1, BB/E526015/1,
   BB/L023814/1] Funding Source: researchfish; Chief Scientist Office
   [CZB/4/714] Funding Source: researchfish; Engineering and Physical
   Sciences Research Council [EP/K034898/1, EP/G048703/1] Funding Source:
   researchfish; Medical Research Council [MR/K011278/1, MR/K026682/1]
   Funding Source: researchfish; BBSRC [BB/L021072/1, BB/L00609X/1,
   BB/L023814/1, BB/G008868/1, BB/E526015/1, BB/N018419/1] Funding Source:
   UKRI; EPSRC [EP/G048703/1, EP/K034898/1] Funding Source: UKRI; MRC
   [MR/K011278/1, MR/K026682/1] Funding Source: UKRI
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The work
   in the authors' laboratories was supported by grants from the BBSRC
   (BB/L021072/1 and BB/L00609X/1 and UK Regenerative Medicine Platform
   (MR/K026682/1) and University of Southampton to R.O.C.O. M.J.D. and M.C.
   acknowledge MRC grant MR/K011278/1.
CR Abagnale G, 2015, BIOMATERIALS, V61, P316, DOI 10.1016/j.biomaterials.2015.05.030
   Alakpa EV, 2017, ACS NANO, V11, P6717, DOI 10.1021/acsnano.7b01044
   Almeida MJ, 2001, J BIOMED MATER RES, V57, P306, DOI 10.1002/1097 4636(200111)57:2<306::AID JBM1172>3.0.CO;2 H
   Atlan G, 1997, CR ACAD SCI III VIE, V320, P253, DOI 10.1016/S0764 4469(97)86933 8
   Brammer KS, 2011, ACTA BIOMATER, V7, P683, DOI 10.1016/j.actbio.2010.09.022
   Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb 2006 7 10 r100
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Cliff TS, 2017, CURR OPIN GENET DEV, V46, P44, DOI 10.1016/j.gde.2017.06.008
   Creek DJ, 2012, BIOINFORMATICS, V28, P1048, DOI 10.1093/bioinformatics/bts069
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Dalby MJ, 2014, NAT MATER, V13, P558, DOI [10.1038/NMAT3980, 10.1038/nmat3980]
   Dawson JI, 2014, STEM CELLS, V32, P35, DOI 10.1002/stem.1559
   Duplat D, 2007, BIOMATERIALS, V28, P2155, DOI 10.1016/j.biomaterials.2007.01.015
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gothard D, 2014, J TISSUE ENG, V5, DOI 10.1177/2041731414551763
   Green DW, 2015, MOL CELLS, V38, P267, DOI 10.14348/molcells.2015.2315
   Janeczek AA, 2016, STEM CELLS, V34, P418, DOI 10.1002/stem.2241
   Jones EA, 2016, THER ADV MUSCULOSKEL, V8, P57, DOI 10.1177/1759720X16642372
   Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095
   Kanno T, 2007, J CELL BIOCHEM, V101, P1266, DOI 10.1002/jcb.21249
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470
   Kato RB, 2014, J CELL PHYSIOL, V229, P1690, DOI 10.1002/jcp.24614
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Knobloch M, 2017, CELL REP, V20, P2144, DOI 10.1016/j.celrep.2017.08.029
   Kulangara K, 2012, BIOMATERIALS, V33, P4998, DOI 10.1016/j.biomaterials.2012.03.053
   Lamghari M, 2001, BIOMATERIALS, V22, P555, DOI 10.1016/S0142 9612(00)00213 1
   Leal J, 2016, OSTEOPOROSIS INT, V27, P549, DOI 10.1007/s00198 015 3277 9
   Lee N, 2015, STEM CELLS DEV, V24, P983, DOI 10.1089/scd.2014.0130
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   LOPEZ E, 1992, TISSUE CELL, V24, P667, DOI 10.1016/0040 8166(92)90037 8
   Lu QZ, 2015, J TISSUE ENG REGEN M, V9, P1352, DOI 10.1002/term.1747
   Ritz U, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122569
   Rogatzki MJ, 2015, FRONT NEUROSCI SWITZ, V9, DOI 10.3389/fnins.2015.00022
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shen Q, 2005, J BIOL CHEM, V280, P40589, DOI 10.1074/jbc.M504166200
   Shen Y, 2014, ACS APPL MATER INTER, V6, P12177, DOI 10.1021/am501448t
   Shim KS, 2017, J IND ENG CHEM, V55, P101, DOI 10.1016/j.jiec.2017.06.033
   SILVE C, 1992, CALCIFIED TISSUE INT, V51, P363, DOI 10.1007/BF00316881
   Song W, 2011, J NANOMATER, V2011, DOI 10.1155/2011/265251
   Tsimbouri PM, 2012, ACS NANO, V6, P10239, DOI 10.1021/nn304046m
   Weng JJ, 2013, BBA GEN SUBJECTS, V1830, P2839, DOI 10.1016/j.bbagen.2012.12.021
   Westbroek P, 1998, NATURE, V392, P861, DOI 10.1038/31798
   Williams EL, 2013, METHODS MOL BIOL, V1035, P67, DOI 10.1007/978 1 62703 508 8_7
   Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380
   Yamada Y, 2014, HISTOL HISTOPATHOL, V29, P691, DOI 10.14670/HH 29.691
   Yang WL, 2016, MAT SCI ENG C MATER, V60, P45, DOI 10.1016/j.msec.2015.11.012
   Zaidi SK, 2001, J CELL SCI, V114, P3093
   Zhang GG, 2017, J BIOMED MATER RES A, V105, P662, DOI 10.1002/jbm.a.35939
NR 49
TC 22
Z9 22
U1 3
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2041 7314
J9 J TISSUE ENG
JI J. Tissue Eng.
PD SEP 4
PY 2018
VL 9
AR 2041731418794007
DI 10.1177/2041731418794007
PG 13
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GS5TM
UT WOS:000443733700001
PM 30202512
OA Green Accepted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, TY
   Zhou, LL
   Zhou, C
   Liu, ZP
   Chen, C
   Feng, Z
   Zhou, XP
AF Liu Tian yang
   Zhou Ling ling
   Zhou Cong
   Liu Zhang pu
   Chen Chen
   Feng Zhe
   Zhou Xue ping
TI Inhibition mechanism of Qingluo Tongbi Granule
   (ae...c⟫eeEuroecu<SUP>1</SUP>e¢uc<SUP>2</SUP>') on osteoclast
   differentiation induced by synovial fibroblast and monocytes co culture
   in adjuvant induced arthritic rats
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Qingluo Tongbi Granule; rheumatoid arthritis; osteoclast
   differentiation; signaling pathway; regulation of tumor necrosis factor
   receptor associated factor 6/mitogen activated protein kinase pathways;
   Chinese medicine
ID ALPHA
AB To study the mechanism underlying the inhibitory effect of Qingluo Tongbi Granule (ae...c >> eeEuroecu(1)e cent uc(2)', QTG) on osteoclast differentiation in rheumatoid arthritis in rats.
   Fibroblast and monocyte co culture were used to induce osteoclast differentiation in adjuvant induced arthritic (AIA) rats. Serum containing QTG was prepared and added to the osteoclasts, and activation of the tumor necrosis factor receptor associated factor 6/mitogen activated protein kinase/nuclear factor of activated T cells, cytoplasmic1 (TRAF6/MAPK/NFATc1) pathways was examined.
   The induced osteoclasts were multinucleated and stained positive for tartrate resistant acid phosphatase (TRAP) staining. Serum containing QTG at 14.4, 7.2 or 3.6 g/kg inhibited the activation of TRAF6, extracellular regulated protein kinase (ERK)1/2, c Jun N terminal kinase (JNK) and p38 and decreased the percentage of cells with nuclear NFATc1 in a dose dependent manner, the high and middle doses exhibited clear inhibitory activity (P < 0.01 and P < 0.05, respectively). After the addition of MAPK inhibitors, the NFATc1 expression showed no significant difference compared with the control group (P > 0.05).
   Serum containing QTG could generally inhibit the TRAF6/MAPK pathways and possibly inhibit the NFATc1 pathway. In addition, QTG may regulate other signaling pathways that are related to osteoclast differentiation and maturation.
C1 [Liu Tian yang; Zhou Ling ling; Zhou Cong; Liu Zhang pu; Chen Chen; Feng Zhe; Zhou Xue ping] Nanjing Univ Chinese Med, Nanjing 210023, Jiangsu, Peoples R China.
   [Liu Tian yang] Anhui Univ Chinese Med, Dept Rheumatol & Immunol, Affiliated Hosp 1, Hefei 230038, Peoples R China.
C3 Nanjing University of Chinese Medicine; Anhui University of Chinese
   Medicine
RP Zhou, XP (通讯作者)，Nanjing Univ Chinese Med, Nanjing 210023, Jiangsu, Peoples R China.
EM llzhou74@163.com; zxp@njutcm.edu.cn
RI Liu, Tianyang/HOC 6916 2023
FU National Natural Science Foundation of China [81072749]; Ministry of
   Education of Overseas Returnees Research Fund [2006331]; Six Talent
   Peaks Subject of Jiangsu Province [2007]; Priority Academic Program
   Development of Jiangsu Higher Education Institutions [20116]; Jiangsu
   Province Ordinary University Innovative Research Project; Ordinary
   University Innovative Research Project of Jiangsu Province [2011]
FX Supported by the National Natural Science Foundation of China (No.
   81072749), the Ministry of Education of Overseas Returnees Research Fund
   (No. 2006331), Six Talent Peaks Subject of Jiangsu Province (No. 2007),
   a project funded by the Priority Academic Program Development of Jiangsu
   Higher Education Institutions (No. 20116), Jiangsu Province Ordinary
   University Innovative Research Project and Ordinary University
   Innovative Research Project of Jiangsu Province (No. 2011)
CR Boyce BF, 2009, ANN NY ACAD SCI, V1192, P367
   Chen BS, 2009, J HARBIN MED U CHIN, V39, P489
   [陈长华 CHEN Changhua], 2008, [中成药, Chinese Traditional Patent Medicine], V30, P35
   Dong Y, 2008, INTERNAL MED, P712
   Feng ZH, 2007, MED MOL BIOL, P296
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   Han Y, 2007, CHINA PHARM CHIN, V36, P814
   [黄艳 HUANG Yan], 2009, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V20, P510
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   Lu CJ, 2012, CHIN J INTEGR MED, V18, P186, DOI 10.1007/s11655 012 1020 3
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   Park MK, 2011, IMMUNOL LETT, V139, P42, DOI 10.1016/j.imlet.2011.04.013
   Taira H, 2003, CALCIFIED TISSUE INT, V73, P78, DOI 10.1007/s00223 002 2061 y
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Trouvin AP, 2010, CLIN INTERV AGING, V5, P345, DOI 10.2147/CIA.S10153
   Xing LP, 2012, WORLD J ORTHOP, V3, P212, DOI 10.5312/wjo.v3.i12.212
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhou XP, 2003, PHARM CLIN CHIN MAT, V1, P35
   Zhou Xue ping, 2006, Zhongguo Xinyao yu Linchuang Zazhi, V25, P492
   [周学平 Zhou Xueping], 2006, [中国免疫学杂志, Chinese Journal of Immunology], V22, P718
   [周学平 Zhou Xueping], 2003, [中国免疫学杂志, Chinese Journal of Immunology], V19, P545
   Zhou XuePing Zhou XuePing, 2008, Chinese Journal of Immunology, V24, P1088
NR 24
TC 10
Z9 12
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1672 0415
EI 1993 0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD APR
PY 2015
VL 21
IS 4
BP 291
EP 298
DI 10.1007/s11655 014 1839 x
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA CF9XE
UT WOS:000352919700008
PM 25182154
DA 2025 08 17
ER

PT J
AU Budzinska, A
   Galganski, L
   Jarmuszkiewicz, W
AF Budzinska, Adrianna
   Galganski, Lukasz
   Jarmuszkiewicz, Wieslawa
TI The bisphosphonates alendronate and zoledronate induce adaptations of
   aerobic metabolism in permanent human endothelial cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SAFETY; OXYGEN; PHARMACOKINETICS; MITOCHONDRIA; OSTEOPOROSIS;
   FIBROBLASTS; OSTEOBLASTS; MECHANISMS; MIGRATION; HYPOXIA
AB Nitrogen containing bisphosphonates (NBPs), compounds that are widely used in the treatment of bone disorders, may cause side effects related to endothelial dysfunction. The aim of our study was to investigate the effects of chronic 6 day exposure to two common bone preserving drugs, alendronate and zoledronate, on endothelial function and oxidative metabolism of cultured human endothelial cells (EA.hy926). NBPs reduced cell viability, induced oxidative stress and a pro inflammatory state and downregulated the prenylation dependent ERK1/2 signaling pathway in endothelial cells. In addition, NBPs induced increased anaerobic respiration and slightly increased oxidative mitochondrial capacity, affecting mitochondrial turnover through reduced mitochondrial fission. Moreover, by blocking the mevalonate pathway, NBPs caused a significant decrease in the level of coenzyme Q10, thereby depriving endothelial cells of an important antioxidant and mitochondrial electron carrier. This resulted in increased formation of reactive oxygen species (ROS), upregulation of antioxidant enzymes, and impairment of mitochondrial respiratory function. A general decrease in mitochondrial respiration occurred with stronger reducing fuels (pyruvate and glutamate) in NBP treated intact endothelial cells, and significantly reduced phosphorylating respiration was observed during the oxidation of succinate and especially malate in NBP treated permeabilized endothelial cells. The observed changes in oxidative metabolism caused a decrease in ATP levels and an increase in oxygen levels in NBP treated cells. Thus, NBPs modulate the energy metabolism of endothelial cells, leading to alterations in the cellular energy state, coenzyme Q10 redox balance, mitochondrial respiratory function, and mitochondrial turnover.
C1 [Budzinska, Adrianna; Galganski, Lukasz; Jarmuszkiewicz, Wieslawa] Adam Mickiewicz Univ, Coll Biol, Lab Mitochondrial Biochem, Dept Bioenerget, Uniwersytetu Poznanskiego 6, PL 61614 Poznan, Poland.
C3 Adam Mickiewicz University
RP Jarmuszkiewicz, W (通讯作者)，Adam Mickiewicz Univ, Coll Biol, Lab Mitochondrial Biochem, Dept Bioenerget, Uniwersytetu Poznanskiego 6, PL 61614 Poznan, Poland.
EM wieslawa.jarmuszkiewicz@amu.edu.pl
OI Jarmuszkiewicz, Wieslawa/0000 0001 8550 8337; Galganski,
   Lukasz/0000 0002 1064 426X
FU National Science Centre, Poland [OPUS 2020/37/B/NZ1/01188]
FX This research was funded by National Science Centre, Poland, OPUS
   2020/37/B/NZ1/01188.
CR Açil Y, 2018, J CRANIO MAXILL SURG, V46, P538, DOI 10.1016/j.jcms.2017.12.015
   Batie M, 2019, SCIENCE, V363, P1222, DOI 10.1126/science.aau5870
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Broniarek I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041485
   Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016
   Bui TM, 2020, J LEUKOCYTE BIOL, V108, P787, DOI 10.1002/JLB.2MR0220 549R
   Carbonare LD, 2010, DRUG HEALTHC PATIENT, V2, P121, DOI 10.2147/DHPS.S6285
   Chakraborty AA, 2019, SCIENCE, V363, P1217, DOI 10.1126/science.aaw1026
   Cocquyt V, 1999, J CLIN PHARMACOL, V39, P385, DOI 10.1177/00912709922007958
   Cook SJ, 2017, FEBS J, V284, P4177, DOI 10.1111/febs.14122
   Cremers S, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115501
   Cutini PH, 2016, J MOL CELL CARDIOL, V100, P83, DOI 10.1016/j.yjmcc.2016.08.017
   Davidson MH, 2001, DRUGS, V61, P197, DOI 10.2165/00003495 200161020 00005
   Davidson SM, 2007, CIRC RES, V100, P1128, DOI 10.1161/01.RES.0000261970.18328.1d
   Dominiak K, 2018, REDOX BIOL, V18, P256, DOI 10.1016/j.redox.2018.07.018
   Fu PF, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 97006 y
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Jarmuszkiewicz W, 2023, FRONT BIOSCI LANDMRK, V28, DOI 10.31083/j.fbl2803061
   Jarmuszkiewicz W, 2020, FREE RADICAL BIO MED, V161, P163, DOI 10.1016/j.freeradbiomed.2020.10.011
   Kalyan S, 2014, J CLIN ENDOCR METAB, V99, P1307, DOI 10.1210/jc.2013 3648
   Kang SJ, 2021, EXP MOL MED, V53, P1116, DOI 10.1038/s12276 021 00649 0
   Koziel A, 2017, PFLUG ARCH EUR J PHY, V469, P815, DOI 10.1007/s00424 017 1935 9
   Koziel A, 2012, PFLUG ARCH EUR J PHY, V464, P657, DOI 10.1007/s00424 012 1156 1
   Larsen S, 2012, J PHYSIOL LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185
   Maeng YS, 2006, CELL SIGNAL, V18, P994, DOI 10.1016/j.cellsig.2005.08.007
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Qu K, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.1084604
   Rao RM, 2007, CIRC RES, V101, P234, DOI 10.1161/CIRCRESAHA.107.151860b
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Sharma D, 2016, SCI REP UK, V6, DOI 10.1038/srep20580
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Swida Barteczka A, 2009, BIOCHEM J, V424, P297, DOI 10.1042/BJ20091158
   Szewczyk A, 2015, PHARMACOL REP, V67, P704, DOI 10.1016/j.pharep.2015.04.009
   Tang XQ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00175
   Walter C, 2011, ORAL DIS, V17, P194, DOI 10.1111/j.1601 0825.2010.01720.x
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Zapolski T, 2010, CARDIOL J, V17, P335
   Ziebart Thomas, 2011, Clin Oral Investig, V15, P105, DOI 10.1007/s00784 009 0365 2
NR 41
TC 5
Z9 5
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 27
PY 2023
VL 13
IS 1
AR 16205
DI 10.1038/s41598 023 43377 3
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA X7AX4
UT WOS:001099946000055
PM 37758809
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Mosca, MG
   Mangini, M
   Cioffi, S
   Barba, P
   Mariggiò, S
AF Mosca, Maria Giovanna
   Mangini, Maria
   Cioffi, Stefania
   Barba, Pasquale
   Mariggio, Stefania
TI Peptide targeting of lysophosphatidylinositol sensing GPR55 for
   osteoclastogenesis tuning
SO CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE G protein coupled receptor (GPCR); GPR55; Lysophosphatidylinositol
   (LPI); Peptidic binder; Osteoclastogenesis
ID L ALPHA LYSOPHOSPHATIDYLINOSITOL; PROTEIN COUPLED RECEPTORS; CANNABINOID
   RECEPTOR; AGONIST LYSOPHOSPHATIDYLINOSITOL; IDENTIFICATION;
   PHARMACOLOGY; REVEALS; LIGAND; CELLS; PHYSIOLOGY
AB Background: The G protein coupled receptor GPR55 has been implicated in multiple biological activities, which has fuelled interest in its functional targeting. Its controversial pharmacology and often species dependent regulation have impacted upon the potential translation of preclinical data involving GPR55.
   Results: With the aim to identify novel GPR55 regulators, we have investigated lysophosphatidylinositol (LPI) induced GPR55 mediated signal transduction. The expression system for wild type and mutated GPR55 was HeLa cells silenced for their endogenous receptor by stable expression of a short hairpin RNA specific for GPR55 5 ' UTR, which allowed definition of the requirement of GPR55 Lys(80) for LPI induced MAPK activation and receptor internalisation. In RAW264.7 macrophages, GPR55 pathways were investigated by Gpr55 silencing using small interfering RNAs, which demonstrated that LPI increased intracellular Ca2+ levels and induced actin filopodium formation through GPR55 activation. Furthermore, the LPI/GPR55 axis was shown to have an active role in osteoclastogenesis of precursor RAW264.7 cells induced by 'receptor activator of nuclear factor kappa beta ligand' (RANKL). Indeed, this differentiation into mature osteoclasts was associated with a 14 fold increase in Gpr55 mRNA levels. Moreover, GPR55 silencing and antagonism impaired RANKL induced transcription of the osteoclastogenesis markers: 'nuclear factor of activated T cells, cytoplasmic 1 ', matrix metalloproteinase 9, cathepsin K, tartrate resistant acid phosphatase, and the calcitonin receptor, as evaluated by real time PCR. Phage display was previously used to identify peptides that bind to GPR55. Here, the GPR55 specific peptide P1 strongly inhibited osteoclast maturation of RAW264.7 macrophages, confirming its activity as a blocker of GPR55 mediated functions. Although osteoclast syncytium formation was not affected by pharmacological regulation of GPR55, osteoclast activity was dependent on GPR55 signalling, as shown with resorption assays on bone slices, where LPI stimulated and GPR55 antagonists inhibited bone erosion.
   Conclusions: Our data indicate that GPR55 represents a target for development of novel therapeutic approaches for treatment of pathological conditions caused by osteoclast exacerbated bone degradation, such as in osteoporosis or during establishment of bone metastases.
C1 [Mosca, Maria Giovanna; Mangini, Maria; Cioffi, Stefania; Mariggio, Stefania] CNR, Inst Prot Biochem, Naples, Italy.
   [Barba, Pasquale] CNR, Inst Genet & Biophys, Naples, Italy.
   [Mangini, Maria; Cioffi, Stefania; Mariggio, Stefania] CNR, Inst Biochem & Cell Biol, Naples, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle
   Proteine (IBP CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto
   di Genetica e Biofisica "Adriano Buzzati Traverso" (IGB CNR); Consiglio
   Nazionale delle Ricerche (CNR)
RP Mariggiò, S (通讯作者)，CNR, Inst Prot Biochem, Naples, Italy.
EM stefania.mariggio@ibbc.cnr.it
RI ; Mangini, Maria/AAL 9201 2021; Mariggio', Stefania/H 5467 2015
OI MARIGGIO, STEFANIA/0000 0002 6397 3016; Mangini,
   Maria/0000 0002 4524 6317; 
FU P.O.R. FESR Campania SATIN; PRIN Project [2012CK5RPF_05]
FX This work was supported by the P.O.R. FESR Campania SATIN, and PRIN
   Project 2012CK5RPF_05.
CR Alavi MS, 2018, BIOMED PHARMACOTHER, V98, P222, DOI 10.1016/j.biopha.2017.12.056
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS21, DOI 10.1111/bph.14748
   Alhouayek M, 2018, TRENDS PHARMACOL SCI, V39, P586, DOI 10.1016/j.tips.2018.02.011
   AlSuleimani YM, 2015, BRIT J PHARMACOL, V172, P3043, DOI 10.1111/bph.13107
   Andradas C, 2011, ONCOGENE, V30, P245, DOI 10.1038/onc.2010.402
   Andradas C, 2016, ONCOTARGET, V7, P47565, DOI 10.18632/oncotarget.10206
   Apostu D, 2019, DRUG METAB REV, V51, P65, DOI 10.1080/03602532.2019.1574303
   Balenga NA, 2014, BRIT J PHARMACOL, V171, P5387, DOI 10.1111/bph.12850
   Balenga NAB, 2011, CELL RES, V21, P1452, DOI 10.1038/cr.2011.60
   Barnes PJ, 2006, J CLIN INVEST, V116, P1210, DOI 10.1172/JCI28535
   Bondarenko A, 2010, BRIT J PHARMACOL, V161, P308, DOI 10.1111/j.1476 5381.2010.00744.x
   Bondarenko AI, 2017, VASC PHARMACOL, V89, P39, DOI 10.1016/j.vph.2017.01.002
   Chiarini F, 2016, BBA MOL CELL RES, V1863, P449, DOI 10.1016/j.bbamcr.2015.08.015
   Chiurchiù V, 2015, INT IMMUNOL, V27, P153, DOI 10.1093/intimm/dxu097
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Corda D, 2002, BBA MOL CELL BIOL L, V1582, P52, DOI 10.1016/S1388 1981(02)00137 3
   Cuetara BLV, 2006, IN VITRO CELL DEV AN, V42, P182, DOI 10.1290/0510075.1
   Elbegdorj O, 2013, J MOL GRAPH MODEL, V39, P50, DOI 10.1016/j.jmgm.2012.10.005
   Fakhouri L, 2017, BIOORGAN MED CHEM, V25, P4355, DOI 10.1016/j.bmc.2017.06.016
   FALASCA M, 1995, ONCOGENE, V10, P2113
   Ferro R, 2018, ONCOGENE, V37, P6368, DOI 10.1038/s41388 018 0390 1
   Filippi BM, 2008, BBA MOL CELL RES, V1783, P2311, DOI 10.1016/j.bbamcr.2008.07.021
   Firer MA, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 70
   Ford LA, 2010, BRIT J PHARMACOL, V160, P762, DOI 10.1111/j.1476 5381.2010.00743.x
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256
   Gaston TE, 2017, EPILEPSY BEHAV, V70, P313, DOI 10.1016/j.yebeh.2016.11.016
   Guerrero Alba R, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01496
   Guy AT, 2015, SCIENCE, V349, P974, DOI 10.1126/science.aab3516
   Gyori DS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00507
   Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178
   Hayakawa K, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 45742 7
   Henstridge CM, 2011, MOL ENDOCRINOL, V25, P1835, DOI 10.1210/me.2011 1197
   Henstridge CM, 2010, BRIT J PHARMACOL, V160, P604, DOI 10.1111/j.1476 5381.2009.00625.x
   Henstridge CM, 2009, FASEB J, V23, P183, DOI 10.1096/fj.08 108670
   Heynen Genel S., 2010, SCREENING SELECTIVE
   Jones GE, 1998, CELL ADHES COMMUN, V6, P237, DOI 10.3109/15419069809004479
   Kargl J, 2016, BRIT J PHARMACOL, V173, P142, DOI 10.1111/bph.13345
   Kargl J, 2013, J PHARMACOL EXP THER, V346, P54, DOI 10.1124/jpet.113.204180
   Kong LB, 2020, J CELL MOL MED, V24, P3271, DOI 10.1111/jcmm.15052
   Kotsikorou E, 2011, BIOCHEMISTRY US, V50, P5633, DOI 10.1021/bi200010k
   Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105
   Leyva Illades Dinorah, 2013, Cancer Manag Res, V5, P147, DOI 10.2147/CMAR.S35175
   Lingerfelt MA, 2017, BIOCHEMISTRY US, V56, P473, DOI 10.1021/acs.biochem.6b01013
   Mangini M, 2017, ONCOTARGET, V8, P5179, DOI 10.18632/oncotarget.14121
   Marichal Cancino BA, 2017, CURR NEUROPHARMACOL, V15, P771, DOI 10.2174/1570159X14666160729155441
   Masquelier J, 2018, BBA MOL CELL BIOL L, V1863, P1458, DOI 10.1016/j.bbalip.2018.09.003
   Morales P, 2016, CURR MED CHEM, V23, P2087, DOI 10.2174/0929867323666160425113836
   Moreno E, 2014, J BIOL CHEM, V289, P21960, DOI 10.1074/jbc.M114.561761
   Oka S, 2007, BIOCHEM BIOPH RES CO, V362, P928, DOI 10.1016/j.bbrc.2007.08.078
   Oka S, 2009, J BIOCHEM, V145, P13, DOI 10.1093/jb/mvn136
   Park JH, 2017, MOL CELLS, V40, P706
   Perez JJ, 2018, CURR TOP MED CHEM, V18, P566, DOI 10.2174/1568026618666180522075258
   Pietr M, 2009, FEBS LETT, V583, P2071, DOI 10.1016/j.febslet.2009.05.028
   Piñeiro R, 2011, ONCOGENE, V30, P142, DOI 10.1038/onc.2010.417
   Ramírez Orozco RE, 2019, CURR NEUROPHARMACOL, V17, P947, DOI 10.2174/1570159X17666190118143014
   Ross RA, 2011, TRENDS PHARMACOL SCI, V32, P265, DOI 10.1016/j.tips.2011.01.005
   Ross RA, 2009, TRENDS PHARMACOL SCI, V30, P156, DOI 10.1016/j.tips.2008.12.004
   Rossi F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081919
   Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460
   Sawzdargo M, 1999, MOL BRAIN RES, V64, P193, DOI 10.1016/S0169 328X(98)00277 0
   Schuelert N, 2011, NEUROSCI LETT, V500, P72, DOI 10.1016/j.neulet.2011.06.004
   Sioud M, 2019, MOL BIOTECHNOL, V61, P286, DOI 10.1007/s12033 019 00156 8
   Soe K, 2017, J CELL SCI, V130, P2026, DOI 10.1242/jcs.202036
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Stancic A, 2015, NEUROGASTROENT MOTIL, V27, P1432, DOI 10.1111/nmo.12639
   Staton PC, 2008, PAIN, V139, P225, DOI 10.1016/j.pain.2008.04.006
   Thundimadathil Jyothi, 2012, J Amino Acids, V2012, P967347, DOI 10.1155/2012/967347
   Tudurí E, 2017, J MOL ENDOCRINOL, V58, pR191, DOI 10.1530/JME 16 0253
   Turpin A, 2020, TRANSL ONCOL, V13, P308, DOI 10.1016/j.tranon.2019.10.012
   Waldeck Weiermair M, 2008, J CELL SCI, V121, P1704, DOI 10.1242/jcs.020958
   Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106
   Wu CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060314
   Wu V, 2019, J BIOL CHEM, V294, P11062, DOI 10.1074/jbc.REV119.005601
   Wu XN, 2019, PROSTAG OTH LIPID M, V143, DOI 10.1016/j.prostaglandins.2019.106335
   Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200
   Zhou J, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00264
NR 77
TC 6
Z9 7
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1478 811X
J9 CELL COMMUN SIGNAL
JI Cell Commun. Signal.
PD APR 26
PY 2021
VL 19
IS 1
AR 48
DI 10.1186/s12964 021 00727 w
PG 24
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA RT7RM
UT WOS:000644654500001
PM 33902596
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Zhang, QG
   Gong, WY
   Wu, HY
   Wang, J
   Jin, QC
   Lin, C
   Xu, SY
   Bao, WQ
   Wang, Y
   Wu, J
   Feng, SS
   Zhao, CZ
   Chen, B
   Liu, ZQ
AF Zhang, Qiguo
   Gong, Wenyu
   Wu, Hongyan
   Wang, Jing
   Jin, Qichuan
   Lin, Chun
   Xu, Shiyun
   Bao, Wenqiang
   Wang, Yin
   Wu, Jing
   Feng, Shanshan
   Zhao, Changzhi
   Chen, Bing
   Liu, Zhiqiang
TI DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple
   myeloma via regulating GLI2 ubiquitination
SO CARCINOGENESIS
LA English
DT Article
ID CONTRIBUTES; ANTIBODY
AB Bortezomib based chemotherapy represents the most prevalent regimens for multiple myeloma (MM), whereas acquired drug resistance remains a major obstacle. Myeloma cells often produce excessive amount of dickkopf 1 (DKK1), giving rise to myeloma bone disease. However, it remains obscure about the effects and mechanisms of DKK1 in the progression and bortezomib responsiveness of MM cells. In the current study, we found WWP2, an E3 ubiquitin protein ligase, was downregulated in the bortezomib resistant cells along with high expression of DKK1. Further investigation revealed that WWP2 was a direct target of Wnt/beta catenin signaling pathway, and DKK1 suppressed the expression of WWP2 via canonical Wnt signaling. We further identified that WWP2 mediated the ubiquitination and degradation of GLI2, a main transcriptional factor of the Hedgehog (Hh) pathway. Therefore, DKK1 induced WWP2 downregulation improved GLI2 stability and activation of Hh signaling pathway, contributing to the resistance to bortezomib of MM cells. Clinical data also validated that WWP2 expression was associated with the treatment response and clinic outcomes of MM patients. WWP2 overexpression restricted MM progression and enhanced cell sensitivity to bortezomib treatment in vitro and in vivo. Taken together, our findings demonstrate that DKK1 facilitates the generation of bortezomib resistance in MM via downregulating WWP2 and activating Hh pathway. Thus, the manipulation of DKK1 WWP2 GLI2 axis might sensitize myeloma cells to proteasome inhibitors.
C1 [Zhang, Qiguo; Wang, Jing; Chen, Bing] Nanjing Univ, Dept Hematol, Nanjing Drum Tower Hosp, Nanjing 210008, Jiangsu, Peoples R China.
   [Zhang, Qiguo; Gong, Wenyu; Jin, Qichuan; Lin, Chun; Xu, Shiyun; Bao, Wenqiang; Wang, Yin; Wu, Jing; Feng, Shanshan; Zhao, Changzhi] Anhui Med Univ, Dept Hematol, Chuzhou Peoples Hosp 1, Chuzhou, Anhui, Peoples R China.
   [Wu, Hongyan] Nanjing Univ, Dept Pathol, Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China.
   [Liu, Zhiqiang] Tianjin Med Univ, Sch Basic Med Sci, Dept Pathophysiol, Tianjin, Peoples R China.
C3 Nanjing University; Anhui Medical University; Nanjing University;
   Tianjin Medical University
RP Chen, B (通讯作者)，Nanjing Univ, Dept Hematol, Nanjing Drum Tower Hosp, Nanjing 210008, Jiangsu, Peoples R China.; Liu, ZQ (通讯作者)，Tianjin Med Univ, Tianjin Key Lab Cellular Homeostasis & Human Dis, Sch Basic Med Sci, Dept Physiol & Pathophysiol, Tianjin 300070, Peoples R China.
EM chenb211@163.com; zhiqiangliu@tmu.edu.cn
RI Liu, Zhiqiang/E 6950 2014; jing, wang/KCZ 2144 2024; Xu,
   Shiyun/B 2918 2011
OI Liu, Zhiqiang/0000 0002 0677 8097; 
FU Nanjing Key Medical Science and Technology Development Project
   [ZKX18023]; Chuzhou Science and Technology Development Project
   [2018zd004]; National Natural Science Foundation of China [81870161,
   82070221]; Beijing Natural Science Foundation of China [Z200020]
FX This study was supported by Nanjing Key Medical Science and Technology
   Development Project (ZKX18023) and Chuzhou Science and Technology
   Development Project (2018zd004). This work was also supported by the
   National Natural Science Foundation of China (81870161, 82070221), the
   Beijing Natural Science Foundation of China (Z200020).
CR Bazarbachi AH, 2019, LEUKEMIA, V33, P2343, DOI 10.1038/s41375 019 0561 2
   Chen HJ, 2020, J CELL MOL MED, V24, P6070, DOI 10.1111/jcmm.15189
   Chen W, 2014, PATHOL ONCOL RES, V20, P799, DOI 10.1007/s12253 014 9838 y
   Chen XLL, 2014, MOL CELL BIOL, V34, P3855, DOI 10.1128/MCB.00960 14
   Colla S, 2007, BLOOD, V109, P4470, DOI 10.1182/blood 2006 11 056747
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Guerrero Garcia TA, 2018, EXPERT REV PROTEOMIC, V15, P1033, DOI 10.1080/14789450.2018.1543595
   Gulino A, 2012, VITAM HORM, V88, P211, DOI 10.1016/B978 0 12 394622 5.00009 2
   Hirata H, 2011, INT J CANCER, V128, P1793, DOI 10.1002/ijc.25507
   Huang Y, 2018, LIFE SCI, V209, P249, DOI 10.1016/j.lfs.2018.08.019
   Jin YL, 2019, ONCOL RES, V27, P729, DOI 10.3727/096504018X15443011011637
   Korvala J, 2012, BMC MED GENET, V13, DOI 10.1186/1471 2350 13 26
   Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808
   Liu AM, 2019, SEMIN CELL DEV BIOL, V93, P153, DOI 10.1016/j.semcdb.2018.10.009
   Liu H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8949
   Liu J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21386 y
   Liu Z, 2014, ONCOGENE, V33, P65, DOI 10.1038/onc.2012.544
   Liu ZQ, 2014, BLOOD, V124, P2061, DOI 10.1182/blood 2014 03 557298
   Mabille C, 2018, BONE, V113, P114, DOI 10.1016/j.bone.2017.10.004
   Martin Orozco E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02854
   Meyer MA, 2004, NEW ENGL J MED, V350, P1464
   Mund T, 2018, J BIOL CHEM, V293, P5200, DOI 10.1074/jbc.RA117.000934
   Niewiadomski P, 2014, CELL REP, V6, P168, DOI 10.1016/j.celrep.2013.12.003
   Pozzi S, 2013, BONE, V53, P487, DOI 10.1016/j.bone.2013.01.012
   Qian JF, 2007, BLOOD, V110, P1587, DOI 10.1182/blood 2007 03 082529
   Qian JF, 2012, BLOOD, V119, P161, DOI 10.1182/blood 2011 07 368472
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Ri M, 2010, LEUKEMIA, V24, P1506, DOI 10.1038/leu.2010.137
   Robak P, 2018, CANCER TREAT REV, V70, P199, DOI 10.1016/j.ctrv.2018.09.001
   Sabol M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092562
   Siegel RL, 2021, CA CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
   Soond SM, 2011, ONCOGENE, V30, P2451, DOI 10.1038/onc.2010.617
   Stewart DJ, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/djt356
   Terpos E, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12761
   Xie Y, 2020, ONCOGENE, V39, P922, DOI 10.1038/s41388 019 1037 6
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yu ZL, 2016, ONCOTARGET, V7, P15725, DOI 10.18632/oncotarget.7398
   Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood 2005 11 013458
   Zhang R, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392 019 0082 5
   Zhang R, 2019, PATHOL ONCOL RES, V25, P443, DOI 10.1007/s12253 018 0506 5
NR 40
TC 11
Z9 11
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143 3334
EI 1460 2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 2021
VL 42
IS 10
BP 1223
EP 1231
DI 10.1093/carcin/bgab086
EA SEP 2021
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA WS7UX
UT WOS:000715383500002
PM 34546340
DA 2025 08 17
ER

EF